PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	UT	PM	OA	HC	HP	DA	WOS
J	Theeler, BJ; Flynn, FG; Erickson, JC				Theeler, Brett J.; Flynn, Frederick G.; Erickson, Jay C.			Headaches After Concussion in US Soldiers Returning From Iraq or Afghanistan	HEADACHE			English	Article						mild traumatic brain injury; concussion; military; posttraumatic headache	TRAUMATIC BRAIN-INJURY; CHRONIC POSTTRAUMATIC HEADACHES; UNITED-STATES; PREVALENCE; MIGRAINE; HEAD; DISABILITY; INCREASES; VETERANS; IMPACT	Objectives.-To determine the prevalence, characteristics, impact, and treatment patterns of headaches after concussion in US Army soldiers returning from a deployment to Iraq or Afghanistan. Methods.-A cross-sectional study was conducted with a cohort of soldiers undergoing postdeployment evaluation during a 5-month period at the Madigan Traumatic Brain Injury Program at Et. Lewis, WA. All soldiers screening positive for a deployment-related concussion were given a 13-item headache questionnaire. Results.-A total of 1033 (19.6%) of 5270 returning soldiers met criteria for a deployment-related concussion. Among those with a concussion, 957 (97.8%) reported having headaches during the final 3 months of deployment. Posttraumatic headaches, defined as headaches beginning within I week after a concussion, were present in 361 (37%) soldiers. In total, 58% of posttraumatic headaches were classified as migraine. Posttraumatic headaches had a higher attack frequency than nontraumatic headaches, averaging 10 days per month. Chronic daily headache was present in 27% of soldiers with posttraumatic headache compared with 14% of soldiers with nontraumatic headache. Posttraumatic headaches interfered with duty performance in 37% of cases and caused more sick call visits compared with nontraumatic headache. In total, 78% of soldiers with posttraumatic headache used abortive medications, predominantly over-the-counter analgesics, and most perceived medication as effective. Conclusions.-More than 1 in 3 returning military troops who have sustained a deployment-related concussion have headaches that meet criteria for posttraumatic headache. Migraine is the predominant headache phenotype precipitated by a concussion during military deployment. Compared with headaches not directly attributable to head trauma, posttraumatic headaches are associated with a higher frequency of headache attacks and an increased prevalence of chronic daily headache.	[Theeler, Brett J.] USA, Med Corps, Neurol Serv, William Beaumont Army Med Ctr,Dept Med, Ft Bliss, TX USA; [Flynn, Frederick G.] Madigan Traumat Brain Injury Program, Ft Lewis, WA USA; [Erickson, Jay C.] USA, Med Corps, Neurol Serv, Madigan Army Med Ctr,Dept Med, Ft Lewis, WA USA		Theeler, BJ (corresponding author), USA, Med Corps, Neurol Serv, William Beaumont Army Med Ctr,Dept Med, Ft Bliss, TX USA.				Uniformed Services University of the Health Sciences	The Comprehensive National Neuroscience Program at the Uniformed Services University of the Health Sciences.	Afari N, 2009, HEADACHE, V49, P1267, DOI 10.1111/j.1526-4610.2009.01517.x; Armed Forces Health Surveillance Center, 2009, MSMR, V16, P10; Baandrup L, 2005, CEPHALALGIA, V25, P132, DOI 10.1111/j.1468-2982.2004.00818.x; Couch JR, 2009, EUR J NEUROL, V16, DOI 10.1111/j.1468-1331.2008.02362.x; Couch JR, 2007, NEUROLOGY, V69, P1169, DOI 10.1212/01.wnl.0000276985.07981.0a; DUCKRO PN, 1995, HEADACHE, V35, P7, DOI 10.1111/j.1526-4610.1995.hed3501007.x; Erickson JC, 2009, NEUROLOGY, V72, pA494; Evans RW, 2008, HEADACHE, V48, P1216, DOI 10.1111/j.1526-4610.2008.01216.x; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; Formisano R, 2009, J HEADACHE PAIN, V10, P145, DOI 10.1007/s10194-009-0108-4; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; Helseth EK, 2008, HEADACHE, V48, P883, DOI 10.1111/j.1526-4610.2007.00962.x; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Lenaerts ME, 2008, CEPHALALGIA, V28, P12, DOI 10.1111/j.1468-2982.2008.01608.x; Lenaerts Marc E, 2004, Curr Treat Options Neurol, V6, P507, DOI 10.1007/s11940-004-0008-5; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lipton RB, 2001, HEADACHE, V41, P646, DOI 10.1046/j.1526-4610.2001.041007646.x; Marcus DA, 2003, HEADACHE, V43, P117, DOI 10.1046/j.1526-4610.2003.03028.x; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Sheftell FD, 2007, NEUROL SCI, V28, pS203, DOI 10.1007/s10072-007-0777-1; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; STEWART WF, 1992, JAMA-J AM MED ASSOC, V267, P64, DOI 10.1001/jama.267.1.64; STEWART WF, 1991, AM J EPIDEMIOL, V134, P1111, DOI 10.1093/oxfordjournals.aje.a116014; Stovner LJ, 2009, EUR J NEUROL, V16, P112, DOI 10.1111/j.1468-1331.2008.02363.x; Stovner LJ, 2008, NEUROLOGY, V71, P383, DOI 10.1212/01.wnl.0000324088.61277.3f; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Theeler BJ, 2008, HEADACHE, V48, P876, DOI 10.1111/j.1526-4610.2008.01159.x; Theeler BJ, 2010, HEADACHE, V50, P790, DOI 10.1111/j.1526-4610.2009.01571.x; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x	32	84	84	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0017-8748	1526-4610		HEADACHE	Headache	SEP	2010	50	8					1262	1272		10.1111/j.1526-4610.2010.01700.x			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	645RU	WOS:000281483200003	20553333				2022-02-06	
J	Horn, SD; Gassaway, J				Horn, Susan D.; Gassaway, Julie			Practice Based Evidence Incorporating Clinical Heterogeneity and Patient-Reported Outcomes for Comparative Effectiveness Research	MEDICAL CARE			English	Article; Proceedings Paper	Symposium on Clinical and Comparative Effectiveness Research Methods II	JUN 01-02, 2009	Rockville, MD	Agcy Healthcare Res & Qual		practice-based-evidence; comparative effectiveness research; clinical heterogeneity; patient; treatment; outcome heterogeneity; severity of illness	TRAUMATIC BRAIN-INJURY; LONG-TERM-CARE; STROKE REHABILITATION; INPATIENT REHABILITATION; INFANTS; ILLNESS; BRONCHIOLITIS; RELIABILITY; IMPROVEMENT; HOSPITALS	Background: Comparative effectiveness research analyzes groups of patients and looks for associations between medical treatments and patient outcomes. To make meaningful comparisons of medical interventions, one must consider clinical heterogeneity of patient populations, intervention combinations, and outcomes. Objectives: To explain how practice-based evidence (PBE) study methodology measures and controls for heterogeneity of patients, treatments, and outcomes seen in real-world clinical settings. Research Design: Overview of PBE methodology. Conclusions: PBE study designs address comparative effectiveness by creating a comprehensive set of patient, treatment, and outcome variables, and analyzing them to identify treatments associated with better outcomes for specific types of patients. PBE studies are an alternative to randomized controlled trials, well suited to determine what works best for specific patient types, and provide clinicians with a rational basis for treatment recommendations for individual patients. They provide a holistic picture of patients, treatments, and outcomes, with no preset limits to the number of variables that can be included. Such an approach is needed for high quality comparative effectiveness research.	[Horn, Susan D.; Gassaway, Julie] Int Sever Informat Syst Inc, Inst Clin Outcomes Res, Salt Lake City, UT 84102 USA		Horn, SD (corresponding author), Int Sever Informat Syst Inc, Inst Clin Outcomes Res, 699 E South Temple,Suite 300, Salt Lake City, UT 84102 USA.	shorn@isisicor.com					Antonow JA, 2001, J NURS CARE QUAL, V15, P39, DOI 10.1097/00001786-200104000-00007; AVERILL RF, 1992, HEALTH SERV RES, V27, P587; Bergstrom N, 2005, J AM GERIATR SOC, V53, P1721, DOI 10.1111/j.1532-5415.2005.53506.x; Bergstrom N, 2008, J AM GERIATR SOC, V56, P1252, DOI 10.1111/j.1532-5415.2008.01765.x; Berwick DM, 2005, HEALTH SERV RES, V40, P317, DOI 10.1111/j.1475-6773.2005.0n359.x; Chang VT, 2000, CANCER, V88, P2164, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2164::AID-CNCR24>3.0.CO;2-5; Cohen J., 2013, STAT POWER ANAL BEHA; Connor SR, 2005, J PAIN SYMPTOM MANAG, V29, P286, DOI 10.1016/j.jpainsymman.2005.01.003; Conroy B, 2005, ARCH PHYS MED REHAB, V86, pS73, DOI 10.1016/j.apmr.2005.08.129; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; DeJong G, 2009, ARCH PHYS MED REHAB, V90, P1269, DOI 10.1016/j.apmr.2008.11.021; Fielder R, 1996, FUNCTIONAL EVALUATIO, P75; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Garber AM, 2009, NEW ENGL J MED, V360, P1925, DOI 10.1056/NEJMp0901355; Gassaway J, 2005, ARCH PHYS MED REHAB, V86, pS16, DOI 10.1016/j.apmr.2005.08.114; Gassaway J, 2009, J SPINAL CORD MED, V32, P260, DOI 10.1080/10790268.2009.11760780; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; Horn S, 2007, DRUG DISCOV DEV, V10, P30; Horn SD, 2005, ARCH PHYS MED REHAB, V86, pS8, DOI 10.1016/j.apmr.2005.08.116; Horn SD, 2005, ARCH PHYS MED REHAB, V86, pS101, DOI 10.1016/j.apmr.2005.09.016; Horn SD, 2004, J AM GERIATR SOC, V52, P359, DOI 10.1111/j.1532-5415.2004.52106.x; HORN SD, 1991, MED CARE, V29, P305, DOI 10.1097/00005650-199104000-00001; Horn SD, 2007, MED CARE, V45, pS50, DOI 10.1097/MLR.0b013e318070c07b; Horn SD, 2010, ADV SKIN WOUND CARE, V23, P120, DOI 10.1097/01.ASW.0000363516.47512.67; James R, 2005, ARCH PHYS MED REHAB, V86, pS82, DOI 10.1016/j.apmr.2005.07.314; Latham NK, 2005, ARCH PHYS MED REHAB, V86, pS41, DOI 10.1016/j.apmr.2005.08.128; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; Ryser DK, 2005, ARCH PHYS MED REHAB, V86, P1108, DOI 10.1016/j.apmr.2004.11.041; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; UB Foundation Activities Inc., 2004, IRF PAI TRAIN MAN; Westfall JM, 2007, JAMA-J AM MED ASSOC, V297, P403, DOI 10.1001/jama.297.4.403; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Whiteneck GG, 1992, GUIDE USE CHART CRAI; Whitford DL, 2009, DIABETES CARE, V32, P251, DOI 10.2337/dc08-1200; Willson D F, 2000, Pediatr Crit Care Med, V1, P127, DOI 10.1097/00130478-200010000-00007; Willson DF, 2003, J PEDIATR-US, V143, pS142, DOI 10.1067/S0022-3476(03)00514-6; Willson DF, 2001, PEDIATRICS, V108, P851, DOI 10.1542/peds.108.4.851	39	84	84	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0025-7079			MED CARE	Med. Care	JUN	2010	48	6		1			S17	S22		10.1097/MLR.0b013e3181d57473			6	Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Health Care Sciences & Services; Public, Environmental & Occupational Health	603SG	WOS:000278227800005	20421825				2022-02-06	
J	Wakao, S; Hayashi, T; Kitada, M; Kohama, M; Matsue, D; Teramoto, N; Ose, T; Itokazu, Y; Koshino, K; Watabe, H; Iida, H; Takamoto, T; Tabata, Y; Dezawa, M				Wakao, Shohei; Hayashi, Takuya; Kitada, Masaaki; Kohama, Misaki; Matsue, Dai; Teramoto, Noboru; Ose, Takayuki; Itokazu, Yutaka; Koshino, Kazuhiro; Watabe, Hiroshi; Iida, Hidehiro; Takamoto, Tomoaki; Tabata, Yasuhiko; Dezawa, Mari			Long-term observation of auto-cell transplantation in non-human primate reveals safety and efficiency of bone marrow stromal cell-derived Schwann cells in peripheral nerve regeneration	EXPERIMENTAL NEUROLOGY			English	Article						Mesenchymal stem cells; Monkey; Schwann cells; Nerve regeneration; Peripheral nerve; Transdifferentiation	RAT SPINAL-CORD; OLFACTORY ENSHEATHING GLIA; IN-VITRO; STEM-CELLS; AXONAL REGENERATION; FUNCTIONAL RECOVERY; DIFFERENTIATION; MODEL; GRAFT; STRATEGIES	Based on their differentiation ability, bone marrow stromal cells (MSCs) are a good source for cell therapy. Using a cynomolgus monkey peripheral nervous system injury model, we examined the safety and efficacy of Schwann cells induced from MSCs as a source for auto-cell transplantation therapy in nerve injury. Serial treatment of monkey MSCs with reducing agents and cytokines induced their differentiation into cells with Schwann cell properties at a very high ratio. Expression of Schwann cell markers was confirmed by both immunocytochemistry and reverse transcription-polymerase chain reaction. Induced Schwann cells were used for auto-cell transplantation into the median nerve and followed-up for 1 year. No abnormalities were observed in general conditions. Ki67-immunostaining revealed no sign of massive proliferation inside the grafted tube. Furthermore, (18)F-fluorodeoxygluocose-positron emission tomography scanning demonstrated no abnormal accumulation of radioactivity except in regions with expected physiologic accumulation. Restoration of the transplanted nerve was corroborated by behavior analysis, electrophysiology and histological evaluation. Our results suggest that auto-cell transplantation therapy using MSC-derived Schwann cells is safe and effective for accelerating the regeneration of transected axons and for functional recovery of injured nerves. The practical advantages of MSCs are expected to make this system applicable for spinal cord injury and other neurotrauma or myelin disorders where the acceleration of regeneration is expected to enhance functional recovery. (C) 2010 Elsevier Inc. All rights reserved.	[Dezawa, Mari] Tohoku Univ, Grad Sch Med, Dept Stem Cell Biol & Histol, Aoba Ku, Sendai, Miyagi 9808575, Japan; [Hayashi, Takuya; Teramoto, Noboru; Ose, Takayuki; Koshino, Kazuhiro; Watabe, Hiroshi; Iida, Hidehiro] Natl Cardiovasc Ctr, Res Inst, Adv Med Engn Ctr, Dept Invest Radiol, Osaka 5658565, Japan; [Itokazu, Yutaka] Kyoto Univ, Grad Sch Med, Dept Anat & Neurobiol, Kyoto 6068501, Japan; [Takamoto, Tomoaki; Tabata, Yasuhiko] Kyoto Univ, Inst Frontier Med Sci, Field Tissue Engn, Dept Biomat, Kyoto 6068507, Japan		Dezawa, M (corresponding author), Tohoku Univ, Grad Sch Med, Dept Stem Cell Biol & Histol, Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	mdezawa@m.tains.tohoku.ac.jp	Iida, Hidehiro/D-4582-2011; Hayashi, Takuya/A-1634-2011; Kitada, Masaaki/I-1591-2017; Iida, Hidehiro/D-5159-2011	Hayashi, Takuya/0000-0001-7639-0197; Kitada, Masaaki/0000-0002-4103-9767; Iida, Hidehiro/0000-0002-7914-3068	National Institute of Biomedical Innovation (NIBIO)National Institute of Biomedical Innovation [05-6]; Ministry of Health, Labor and WelfareMinistry of Health, Labour and Welfare, Japan; Ministry of Education, Culture, Sports, Science and Technology JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [19390074]	We thank to Dr. J. J. Archelos (Karl-Franzens Universitat, Graz, Austria) for providing us the PO antibody and to Ms. Mori E., Ms. Kotera J. and Ms. Mamiya R. for their technical assistance. This study was supported by the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NIBIO, 05-6) and by the Health and Labor Sciences Research Grants of "Research on Psychiatric and Neurological Diseases and Mental Health" from the Ministry of Health, Labor and Welfare. The study was also supported by Grant-in-Aid for Scientific Research (B) (19390074) from the Ministry of Education, Culture, Sports, Science and Technology Japan.	Ahmed Z, 1999, SCAND J PLAST RECONS, V33, P393; Al-Sugair A, 1998, SEMIN NUCL MED, V28, P303, DOI 10.1016/S0001-2998(98)80035-4; ARCHIBALD SJ, 1995, J NEUROSCI, V15, P4109; Auba C, 2006, J NEUROSURG, V105, P602, DOI 10.3171/jns.2006.105.4.602; Bunge MB, 2008, J SPINAL CORD MED, V31, P262, DOI 10.1080/10790268.2008.11760720; Bunge MB, 2002, PROG BRAIN RES, V137, P275; Dezawa M, 2001, EUR J NEUROSCI, V14, P1771, DOI 10.1046/j.0953-816x.2001.01814.x; Dezawa M, 2000, PROG RETIN EYE RES, V19, P171, DOI 10.1016/S1350-9462(99)00010-5; FAWCETT JW, 1990, ANNU REV NEUROSCI, V13, P43, DOI 10.1146/annurev.neuro.13.1.43; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hall S, 2001, J HAND SURG-BRIT EUR, V26, P129, DOI 10.1054/jhsb.2000.0497; HAMACHER K, 1986, J NUCL MED, V27, P235; Hamada K, 2006, ANN NUCL MED, V20, P671; Hess JR, 2007, PLAST RECONSTR SURG, V119, P246, DOI 10.1097/01.prs.0000245341.71666.97; Hill CE, 2006, GLIA, V53, P338, DOI 10.1002/glia.20287; Hisasue S, 2005, J UROLOGY, V173, P286, DOI 10.1097/01.ju.0000141578.84536.80; Ishikawa N, 2009, J BIOMED MATER RES A, V89A, P1118, DOI 10.1002/jbm.a.32389; Jiang L, 2008, NEUROREPORT, V19, P1015, DOI 10.1097/WNR.0b013e3283040efc; Kamada T, 2005, J NEUROPATH EXP NEUR, V64, P37, DOI 10.1093/jnen/64.1.37; Kingham PJ, 2007, EXP NEUROL, V207, P267, DOI 10.1016/j.expneurol.2007.06.029; Kitada M, 2001, GLIA, V36, P364, DOI 10.1002/glia.1123; Kitada M, 2006, GLIA, V54, P35, DOI 10.1002/glia.20354; Lee SJ, 2008, PLAST RECONSTR SURG, V121, P1188, DOI 10.1097/01.prs.0000305563.77782.35; MCKAY HA, 2002, EXP BRAIN RES, V142, P308; Mimura T, 2004, J NEUROSURG, V101, P806, DOI 10.3171/jns.2004.101.5.0806; Mligiliche Nurru L., 2003, Anatomical Science International, V78, P156, DOI 10.1046/j.0022-7722.2003.00056.x; Nagane K, 2009, TISSUE ENG PT A, V15, P1655, DOI 10.1089/ten.tea.2008.0453; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Plant GW, 1998, CELL TRANSPLANT, V7, P381, DOI 10.1016/S0963-6897(98)00016-5; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Radtke Christine, 2009, Eplasty, V9, pe47; Roth TM, 2007, GLIA, V55, P1123, DOI 10.1002/glia.20534; Shimizu S, 2007, BIOCHEM BIOPH RES CO, V359, P915, DOI 10.1016/j.bbrc.2007.05.212; Someya Y, 2008, J NEUROSURG-SPINE, V9, P600, DOI 10.3171/SPI.2008.9.08135; Torigoe K, 1996, EXP NEUROL, V137, P301, DOI 10.1006/exnr.1996.0030; Vukovic J, 2007, NEURON GLIA BIOL, V3, P105, DOI 10.1017/S1740925X07000671; Xu YF, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-21	37	84	87	1	23	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	JUN	2010	223	2			SI		537	547		10.1016/j.expneurol.2010.01.022			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	597GD	WOS:000277743700034	20153320				2022-02-06	
J	Rosenbaum, AM; Arnett, PA				Rosenbaum, Aaron M.; Arnett, Peter A.			The development of a survey to examine knowledge about and attitudes toward concussion in high-school students	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Concussion survey; Survey validation; High-school athletes; Concussion attitudes; Concussion knowledge	COLLEGIATE FOOTBALL PLAYERS; CLUSTER-ANALYSIS; RECOVERY; RETURN; EPIDEMIOLOGY; ATHLETICS; INJURY; IMPACT	The development of a new measure of concussion knowledge and attitudes that is more comprehensive and psychometrically sound than previous measures is described. A group of high-school students (N = 529) completed the measure. The measure demonstrated fair to satisfactory test-retest reliability (knowledge items, r = .67; attitude items, r = .79). Exploratory factor analysis of the attitude items revealed a four-factor solution (eigenvalues ranged from 1.07-3.35) that displayed adequate internal consistency (Cohen's alpha range = .59-.72). Cluster analysis of the knowledge items resulted in a three-cluster solution distributed according to their level of difficulty. The potential uses for the measure are described.	[Rosenbaum, Aaron M.; Arnett, Peter A.] Penn State Univ, University Pk, PA 16802 USA		Rosenbaum, AM (corresponding author), Penn State Univ, 113 Moore Bldg, University Pk, PA 16802 USA.	amr262@psu.edu			Penn State University College of Liberal Arts Research and Graduate Studies Office; Pennsylvania State Education Association; Penn State University Department of Psychology	This study was part of the first author's doctoral dissertation, which was completed at Penn State University. It was partially funded by the Penn State University College of Liberal Arts Research and Graduate Studies Office, the Pennsylvania State Education Association, and the Penn State University Department of Psychology. The authors wish to thank the high schools and their administrators who participated in the project-especially Cathy Phillips at Peru High School. Finally, we would like to thank each of the undergraduate research assistants at Penn State University and Plattsburgh State University of New York for their dedication to this project.	American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Aukerman DF, 2006, SOUTH MED J, V99, P132, DOI 10.1097/01.smj.0000199749.22741.5e; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Crowne D. P., 1964, APPROVAL MOTIVE STUD; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erdfelder E, 1996, BEHAV RES METH INS C, V28, P1, DOI 10.3758/BF03203630; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P331; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Olympia RP, 2007, PEDIATR EMERG CARE, V23, P703, DOI 10.1097/PEC.0b013e318155adfc; REVELLE W, 1979, MULTIVAR BEHAV RES, V14, P57, DOI 10.1207/s15327906mbr1401_4; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schmelkin L.P., 1991, MEASUREMENT DESIGN A; SILVERSTEIN AB, 1974, MULTIVAR BEHAV RES, V9, P325, DOI 10.1207/s15327906mbr0903_7; Stevens J.P., 2002, APPL MULTIVARIATE ST, V4th ed.; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Tabachnick B.G., 2001, USING MULTIVARIATE S; von Holst H, 2004, J REHABIL MED, V36, P8, DOI 10.1080/16501960410023633; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	43	84	85	0	15	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2010	32	1					44	55		10.1080/13803390902806535			12	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	550YJ	WOS:000274170400005	19381997				2022-02-06	
J	Hunt, TN; Ferrara, MS; Bornstein, RA; Baumgartner, TA				Hunt, Tamerah N.; Ferrara, Michael S.; Bornstein, Robert A.; Baumgartner, Ted A.			The Reliability of the Modified Balance Error Scoring System	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						balance; head injury; concussion; BESS; youth	MILD HEAD-INJURY; POSTURAL STABILITY; CONCUSSION; STATEMENT; SPORT	Objective: Study I investigated the intraclass reliability and percent variance associated with each component within the traditional Balance Error Scoring System (BESS) protocol. Study 2 investigated the reliability of subsequent modifications of the BESS. Design: Prospective cross-sectional examination of the traditional and modified BESS protocols. Setting: Schools participating in Georgia High School Athletics Association. Intervention: The modified BESS consisted of 2 surfaces (firm and foam) and 2 stances (single-leg and tandem-leg stance) repeated for a total of three 20-second trials. Participants: Participants consisted of 2 independent samples of high school athletes aged 13 to 19 years. Main Outcome Measures: Percent variance for each condition of the BESS was obtained using GENOVA 3.1. An intraclass reliability coefficient and repeated measures analysis of variance were calculated using SPSS 13.0. Results: Study 1 obtained an intraclass correlation coefficient (r = 0.60) with stance accounting for 55% of the total variance. Removing the double-leg stance increased the intraclass correlation coefficient (r = 0.71). Study 2 found a statistically significant difference between trials I and 2 (F(1.65 286) = 4.890, P = 0.013) and intraclass reliability coefficient of r = 0.88 for 3 trials of 4 conditions. Conclusions: The variance associated with the double-leg stance was very small, and when removed, the intraclass reliability coefficient of the BESS increased. Removal of the double-leg stance and addition of 3 trials of 4 conditions provided an easily administered, cost-effective, time-efficient tool that provides reliable objective information for clinicians to base clinical decisions upon.	[Hunt, Tamerah N.] Ohio State Univ, Ctr Sports Med, Sch Allied Med Profess, Columbus, OH 43221 USA; [Ferrara, Michael S.; Baumgartner, Ted A.] Univ Georgia, Dept Kinesiol, Athens, GA 30602 USA; [Bornstein, Robert A.] Ohio State Univ, Dept Psychiat, Columbus, OH 43221 USA		Hunt, TN (corresponding author), Ohio State Univ, Ctr Sports Med, Sch Allied Med Profess, 2050 Kenny Rd,Ste 3100, Columbus, OH 43221 USA.	tamerah.hunt@osumc.edu	Hunt, Tamerah/E-3281-2011				Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; BAUMGARTNER TA, 2003, MEASUREMENT EVALUATI, P96; Brennan RL, 1992, ELEMENTS GEN THEORY; CRICK JE, 1982, GENOVA GEN ANAL VARI; EKDAHL C, 1989, SCAND J REHABIL MED, V21, P187; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 1996, J SPORT REHABIL, V5, P45, DOI 10.1123/jsr.5.1.45; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; JANSEN EC, 1982, ACTA NEUROL SCAND, V66, P93; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 1997, J SPORT REHABIL, V6, P283, DOI 10.1123/jsr.6.3.283; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Susco TM, 2004, J ATHL TRAINING, V39, P241; Valovich TC, 2003, J ATHL TRAINING, V38, P51; VALOVICH TC, 2002, THESIS U VIRGINIA CH; Wilkins JC, 2004, J ATHL TRAINING, V39, P156	22	84	84	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	NOV	2009	19	6					471	475		10.1097/JSM.0b013e3181c12c7b			5	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	520NB	WOS:000271850500006	19898074				2022-02-06	
J	Oddo, M; Milby, A; Chen, I; Frangos, S; MacMurtrie, E; Maloney-Wilensky, E; Stiefel, M; Kofke, WA; Levine, JM; Le Roux, PD				Oddo, Mauro; Milby, Andrew; Chen, Isaac; Frangos, Suzanne; MacMurtrie, Eileen; Maloney-Wilensky, Eileen; Stiefel, Michael; Kofke, W. Andrew; Levine, Joshua M.; Le Roux, Peter D.			Hemoglobin Concentration and Cerebral Metabolism in Patients With Aneurysmal Subarachnoid Hemorrhage	STROKE			English	Article						brain oxygen; cerebral microdialysis; hemoglobin; subarachnoid hemorrhage	TRAUMATIC BRAIN-INJURY; BLOOD-TRANSFUSION; CRITICALLY-ILL; MEDICAL COMPLICATIONS; HEMODILUTIONAL ANEMIA; ENERGY-METABOLISM; OXYGEN; MICRODIALYSIS; MORTALITY; ASSOCIATION	Background and Purpose-The optimal hemoglobin (Hgb) target after aneurysmal subarachnoid hemorrhage is not precisely known. We sought to examine the threshold of Hgb concentration associated with an increased risk of cerebral metabolic dysfunction in patients with poor-grade subarachnoid hemorrhage. Methods-Twenty consecutive patients with poor-grade subafachnoid hemorrhage who underwent multimodality neuromonitoring (intracranial pressure, brain tissue oxygen tension, cerebral microdialysis) were studied prospectively. Brain tissue oxygen tension and extracellular lactate/pyruvate ratio were used as markers of cerebral metabolic dysfunction and the relationship between Hgb concentrations and the incidence of brain hypoxia (defined by a brain tissue oxygen tension <20 mm Hg) and cell energy dysfunction (defined by a lactate/pyruvate ratio >40) was analyzed. Results-Compared with higher Hgb concentrations, a Hgb concentration <9 g/dL was associated with lower brain tissue oxygen tension (27.2 [interquartile range, 21.2 to 33.1] versus 19.9 [interquartile range, 7.1 to 33.1] turn Hg, P=0.02), higher lactate/pyruvate ratio (29 [interquartile range, 25 to 38] versus 36 [interquartile range, 26 to 59], P=0.16), and an increased incidence of brain hypoxia (21% versus 52%, P<0.01) and cell energy dysfunction (23% versus 43%, P=0.03). On multivariable analysis, a Hgb concentration <9 g/dL was associated with a higher risk of brain hypoxia (OR, 7.92; 95% CI, 2.32 to 27.09; P<0.01) and cell energy dysfunction (OR, 4.24; 95% Cl, 1.33 to 13.55; P=0.02) after adjusting for cerebral perfusion pressure, central venous pressure, PaO2/FIO2 ratio, and symptomatic vasospasm. Conclusions-A Hgb concentration <9 g/dL is associated with an increased incidence of brain hypoxia and cell energy dysfunction in patients with poor-grade subarachnoid hemorrhage. (Stroke. 2009;40:1275-1281.)	[Le Roux, Peter D.] Univ Penn, Med Ctr, Div Clin Res, Dept Neurosurg, Philadelphia, PA 19104 USA; [Levine, Joshua M.] Univ Penn, Med Ctr, Dept Neurol, Philadelphia, PA 19104 USA; [Kofke, W. Andrew; Levine, Joshua M.] Univ Penn, Med Ctr, Dept Anesthesia & Crit Care, Philadelphia, PA 19104 USA		Le Roux, PD (corresponding author), Univ Penn, Med Ctr, Div Clin Res, Dept Neurosurg, 3rd Floor Silverstein Bldg,3400 Spruce St, Philadelphia, PA 19104 USA.	Peter.LeRoux@uphs.upenn.edu	Oddo, Mauro/R-3370-2016	Oddo, Mauro/0000-0002-6155-2525	SICPA Foundation, Switzerland; Integra Foundation; Mary Elisabeth Groff Surgical and Medical Research Trust	This work was supported by Research Grants from the SICPA Foundation, Switzerland (M.O.), the Integra Foundation (P.D.L.), and the Mary Elisabeth Groff Surgical and Medical Research Trust (P.D.L.).	[Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; BORGSTROM L, 1975, ACTA PHYSIOL SCAND, V93, P505, DOI 10.1111/j.1748-1716.1975.tb05842.x; Corwin HL, 2004, CRIT CARE MED, V32, P39, DOI 10.1097/01.CCM.0000104112.34142.79; Dexter F, 1997, BRIT J ANAESTH, V79, P346, DOI 10.1093/bja/79.3.346; Gajic O, 2007, AM J RESP CRIT CARE, V176, P886, DOI 10.1164/rccm.200702-271OC; George ME, 2008, NEUROCRIT CARE, V8, P337, DOI 10.1007/s12028-008-9066-y; Hare GMT, 2004, ANESTH ANALG, V99, P528, DOI 10.1213/01.ANE.0000136769.65960.D1; Hare GMT, 2003, J APPL PHYSIOL, V94, P2058, DOI 10.1152/japplphysiol.00931.2002; Hare GMT, 2007, J APPL PHYSIOL, V103, P1021, DOI 10.1152/japplphysiol.01315.2006; Hebert PC, 2001, CRIT CARE MED, V29, P227, DOI 10.1097/00003246-200102000-00001; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; JOHANNSSON H, 1975, ACTA PHYSIOL SCAND, V93, P515, DOI 10.1111/j.1748-1716.1975.tb05843.x; Kett-White R, 2002, NEUROSURGERY, V50, P1213, DOI 10.1097/00006123-200206000-00008; Kim JS, 2000, EUR NEUROL, V43, P201, DOI 10.1159/000008176; Koch CG, 2008, NEW ENGL J MED, V358, P1229, DOI 10.1056/NEJMoa070403; Lee EJ, 2001, J NEUROL SCI, V190, P3, DOI 10.1016/S0022-510X(01)00567-6; LEROUX PD, 1995, J NEUROSURG, V83, P394, DOI 10.3171/jns.1995.83.3.0394; LeRoux PD, 1996, J NEUROSURG, V85, P39, DOI 10.3171/jns.1996.85.1.0039; Malone DL, 2003, J TRAUMA, V54, P898, DOI 10.1097/01.TA.0000060261.10597.5C; MAYBERG MR, 1994, STROKE, V25, P2315, DOI 10.1161/01.STR.25.11.2315; McIntyre LA, 2006, NEUROCRIT CARE, V5, P4, DOI 10.1385/NCC:5:1:4; McLaren AT, 2007, AM J PHYSIOL-REG I, V292, pR403, DOI 10.1152/ajpregu.00403.2006; Muench E, 2007, CRIT CARE MED, V35, P1844, DOI 10.1097/01.CCM.0000275392.08410.DD; Naidech AM, 2007, CRIT CARE MED, V35, P2383, DOI 10.1097/01.CCM.0000284516.17580.2C; Naidech AM, 2006, NEUROSURGERY, V59, P775, DOI 10.1227/01.NEU.0000232662.86771.A9; Netzer G, 2007, CHEST, V132, P1116, DOI 10.1378/chest.07-0145; Nortje J, 2006, BRIT J ANAESTH, V97, P95, DOI 10.1093/bja/ael137; Patel MB, 2006, J TRAUMA, V61, P46, DOI 10.1097/01.ta.0000219730.71206.3a; Rigamonti A, 2008, BRIT J ANAESTH, V100, P357, DOI 10.1093/bja/aem401; Samuelsson C, 2007, J CEREBR BLOOD F MET, V27, P1309, DOI 10.1038/sj.jcbfm.9600433; Sarrafzadeh A, 2004, J NEUROSURG, V100, P400, DOI 10.3171/jns.2004.100.3.0400; Smith MJ, 2004, J NEUROSURG, V101, P1, DOI 10.3171/jns.2004.101.1.0001; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vincent JL, 2002, JAMA-J AM MED ASSOC, V288, P1499, DOI 10.1001/jama.288.12.1499; Wartenberg KE, 2006, CURR OPIN CRIT CARE, V12, P78, DOI 10.1097/01.ccx.0000216571.80944.65; Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35	38	84	87	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	APR	2009	40	4					1275	1281		10.1161/STROKEAHA.108.527911			7	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	426LJ	WOS:000264709500039	19265059	Bronze			2022-02-06	
J	Hughes, TF; Ganguli, M				Hughes, Tiffany F.; Ganguli, Mary			Modifiable Midlife Risk Factors for Late-Life Cognitive Impairment and Dementia	CURRENT PSYCHIATRY REVIEWS			English	Article						Lifestyle; cognition; Alzheimer's disease; epidemiology	TRAUMATIC BRAIN-INJURY; INCIDENT ALZHEIMER-DISEASE; WHITE-MATTER LESIONS; BODY-MASS INDEX; HORMONE REPLACEMENT THERAPY; HEALTH INITIATIVE MEMORY; SYSTOLIC BLOOD-PRESSURE; ESTROGEN PLUS PROGESTIN; TOTAL CHOLESTEROL LEVEL; GINKGO-BILOBA EXTRACT	The baby boom generation is approaching the age of greatest risk for cognitive impairment and dementia. There is growing interest in strategies to modify the environment in midlife to increase the probability of maintaining cognitive health in late life. Several potentially modifiable risk factors have been studied in relation to cognitive impairment and dementia in late life, but methodological limitations of observational research have resulted in some inconsistencies across studies. The most promising strategies are maintaining cardiovascular health, engaging in mental, physical, and social activities, using alcohol in moderation, abstaining from tobacco use, and following a heart-healthy diet. Other factors that may influence cognitive health are occupational attainment, depression, personality, exposure to general anes-thesia, head injury, postmenopausal hormone therapy, non-steroidal anti-inflammatory medications, and nutritional supplements such as antioxidants. Some long-term observational studies initiated in midlife or earlier, and some randomized controlled trials, have examined the effects of specific cognitive health promotion behaviors in midlife on the risk of cognitive impairment in late life. Overall, these studies provide limited support for risk reduction at this time. Recommendations and challenges for developing effective strategies to reduce the burden of cognitive impairment and dementia in the future are discussed.	[Hughes, Tiffany F.] Univ Pittsburgh, Sch Med, Dept Psychiat, 3811 OHara St, Pittsburgh, PA 15213 USA; [Ganguli, Mary] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA; [Ganguli, Mary] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA		Hughes, TF (corresponding author), Univ Pittsburgh, Sch Med, Dept Psychiat, 3811 OHara St, Pittsburgh, PA 15213 USA.	hughest2@upmc.edu			National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH019986]; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K24 AG022035]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; United States Department of Health and Human Services; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019986] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K24AG022035] Funding Source: NIH RePORTER	Dr. Hughes is supported by T32 award #MH019986 from the National Institute of Mental Health, and Dr. Ganguli is supported in part by grant # K24 AG022035 from the National Institute on Aging, National Institutes of Health, United States Department of Health and Human Services.	Acevedo A, 2007, J GERIATR PSYCH NEUR, V20, P239, DOI 10.1177/0891988707308808; Adams KF, 2006, NEW ENGL J MED, V355, P763, DOI 10.1056/NEJMoa055643; Addae JI, 2003, J ALZHEIMERS DIS, V5, P91, DOI 10.3233/JAD-2003-5204; Agarwal DP, 2002, ALCOHOL ALCOHOLISM, V37, P409, DOI 10.1093/alcalc/37.5.409; Aisen PS, 2008, JAMA-J AM MED ASSOC, V300, P1774, DOI 10.1001/jama.300.15.1774; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Alcala-Lopez D, 2019, CORTEX, V118, P4, DOI 10.1016/j.cortex.2018.05.006; Aliev G, 2003, NEUROTOX RES, V5, P491, DOI 10.1007/BF03033159; Allen RR, 2008, J NUTR, V138, P725, DOI 10.1093/jn/138.4.725; Andel R, 2005, J GERONTOL B-PSYCHOL, V60, pP251, DOI 10.1093/geronb/60.5.P251; Andel R., 2005, AGING HLTH, V1, P107; Andel R, 2008, J GERONTOL A-BIOL, V63, P62, DOI 10.1093/gerona/63.1.62; Andrieu S, 2008, CURR ALZHEIMER RES, V5, P406, DOI 10.2174/156720508785132271; Anstey KJ, 2007, AM J EPIDEMIOL, V166, P367, DOI 10.1093/aje/kwm116; Anttila T, 2004, BMJ-BRIT MED J, V329, P539, DOI 10.1136/bmj.38181.418958.BE; Anttila T, 2002, NEUROLOGY, V59, P887, DOI 10.1212/WNL.59.6.887; Archer N, 2008, PSYCHOL MED, V12, P1; Arendash GW, 2006, NEUROSCIENCE, V142, P941, DOI 10.1016/j.neuroscience.2006.07.021; Arvanitakis Z, 2008, NEUROLOGY, V70, P1795, DOI 10.1212/01.wnl.0000288181.00826.63; Ashford JW, 2002, J ALZHEIMERS DIS, V4, P169, DOI 10.3233/JAD-2002-4307; Atti AR, 2008, J AM GERIATR SOC, V56, P111, DOI 10.1111/j.1532-5415.2007.01458.x; Balk EM, 2007, ARCH INTERN MED, V167, P21, DOI 10.1001/archinte.167.1.21; Ball K, 2002, JAMA-J AM MED ASSOC, V288, P2271, DOI 10.1001/jama.288.18.2271; Balzer J, 2008, J AM COLL CARDIOL, V51, P2141, DOI 10.1016/j.jacc.2008.01.059; Barberger-Gateau P, 2002, BRIT MED J, V325, P932, DOI 10.1136/bmj.325.7370.932; Barker DJP, 1998, CLIN SCI, V95, P115, DOI 10.1042/CS19980019; Barnes LL, 2004, NEUROLOGY, V63, P2322, DOI 10.1212/01.WNL.0000147473.04043.B3; Bassuk SS, 1999, ANN INTERN MED, V131, P165, DOI 10.7326/0003-4819-131-3-199908030-00002; BAUMBAICKER C, 1985, DRUG ALCOHOL DEPEN, V15, P305, DOI 10.1016/0376-8716(85)90008-0; Beeri MS, 2005, AM J GERIAT PSYCHIAT, V13, P116, DOI 10.1097/00019442-200502000-00005; Beeri MS, 2004, NEUROLOGY, V63, P1902, DOI 10.1212/01.WNL.0000144278.79488.DD; Behl C, 1999, PROG NEUROBIOL, V57, P301, DOI 10.1016/S0301-0082(98)00055-0; Beland F, 2005, J GERONTOL B-PSYCHOL, V60, pP320, DOI 10.1093/geronb/60.6.P320; Ben-Shlomo Y, 2002, INT J EPIDEMIOL, V31, P285, DOI 10.1093/ije/31.2.285; Bennett DA, 2006, LANCET NEUROL, V5, P406, DOI 10.1016/S1474-4422(06)70417-3; BERKMAN LF, 1995, PSYCHOSOM MED, V57, P245, DOI 10.1097/00006842-199505000-00006; Bernstein R, 2008, OLDER MORE DIVERSE N; Bhalla RK, 2006, AM J GERIAT PSYCHIAT, V14, P419, DOI 10.1097/01.JGP.0000203130.45421.69; Birns J, 2006, J HYPERTENS, V24, P1907, DOI 10.1097/01.hjh.0000244934.81180.16; BLACK JE, 1987, NEUROSCI LETT, V83, P351, DOI 10.1016/0304-3940(87)90113-3; Bodovitz S, 1996, J BIOL CHEM, V271, P4436; BOHNEN N, 1994, INT J NEUROSCI, V77, P181, DOI 10.3109/00207459408986029; BOHNEN NILJ, 1994, J AM GERIATR SOC, V42, P198, DOI 10.1111/j.1532-5415.1994.tb04952.x; Bond GE, 2005, INT PSYCHOGERIATR, V17, P653, DOI 10.1017/S1041610205001651; Borenstein AG, 2004, NEUROEPIDEMIOLOGY PR, P102; Borenstein AR, 2006, ALZ DIS ASSOC DIS, V20, P63, DOI 10.1097/01.wad.0000201854.62116.d7; Braak H, 1997, NEUROBIOL AGING, V18, pS85, DOI 10.1016/S0197-4580(97)00062-6; Brayne C, 2007, NAT REV NEUROSCI, V8, P233, DOI 10.1038/nrn2091; Breitner JCS, 2003, LANCET NEUROL, V2, P527, DOI 10.1016/S1474-4422(03)00498-8; Briones TL, 2004, BRAIN RES, V1018, P130, DOI 10.1016/j.brainres.2004.06.001; Broe GA, 1998, AUST NZ J PUBL HEAL, V22, P621, DOI 10.1111/j.1467-842X.1998.tb01449.x; Brookmeyer R, 2007, ALZHEIMERS DEMENT, V3, P186, DOI 10.1016/j.jalz.2007.04.381; Brown J, 2003, EUR J NEUROSCI, V17, P2042, DOI 10.1046/j.1460-9568.2003.02647.x; Butters Meryl A, 2008, Dialogues Clin Neurosci, V10, P345; Cabeza R, 2002, NEUROIMAGE, V17, P1394, DOI 10.1006/nimg.2002.1280; Carlson MC, 2008, ALZHEIMERS DEMENT, V4, P324, DOI 10.1016/j.jalz.2008.07.002; Carmel R, 1997, AM J CLIN NUTR, V66, P750, DOI 10.1093/ajcn/66.4.750; Centers for Disease Control and Prevention Alzheimer's Association, 2007, HLTH BRAIN IN NAT PU; Chen PJ, 1999, ARCH GEN PSYCHIAT, V56, P261, DOI 10.1001/archpsyc.56.3.261; COBB JL, 1995, NEUROLOGY, V45, P1707, DOI 10.1212/WNL.45.9.1707; Coley N, 2008, EPIDEMIOL REV, V30, P35, DOI 10.1093/epirev/mxn010; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Commenges D, 2000, EUR J EPIDEMIOL, V16, P357, DOI 10.1023/A:1007614613771; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Costa DA, 2007, NEUROBIOL AGING, V28, P831, DOI 10.1016/j.neurobiolaging.2006.04.009; Costa MS, 2008, NEUROCHEM INT, V53, P89, DOI 10.1016/j.neuint.2008.06.006; Cracchiolo JR, 2007, NEUROBIOL LEARN MEM, V88, P277, DOI 10.1016/j.nlm.2007.07.007; Cramer C, 2008, NEUROLOGY, V71, P344, DOI 10.1212/01.wnl.0000319647.15752.7b; Crews WD, 2008, AM J CLIN NUTR, V87, P872, DOI 10.1093/ajcn/87.4.872; Crook T, 1986, DEV NEUROPSYCHOL, V2, P261, DOI 10.1080/87565648609540348; Crooks VC, 2008, AM J PUBLIC HEALTH, V98, P1221, DOI 10.2105/AJPH.2007.115923; Crowe M., 2003, Journals of Gerontology. Series B, Psychological Sciences and Social Sciences, V58, P249; Crowe M, 2006, PSYCHOL AGING, V21, P573, DOI 10.1037/0882-7974.21.3.573; CRYSTAL H, 1988, NEUROLOGY, V38, P1682, DOI 10.1212/WNL.38.11.1682; Curb JD, 1999, NEUROLOGY, V52, P971, DOI 10.1212/WNL.52.5.971; Dai Q, 2006, AM J MED, V119, P751, DOI 10.1016/j.amjmed.2006.03.045; Dam R.M.T., 2008, BMJ-BRIT MED J, V337, pA1440, DOI [10.1136/bmj.a1440, DOI 10.1136/bmj.a1440]; de Kloet ER, 2005, NAT REV NEUROSCI, V6, P463, DOI 10.1038/nrn1683; de la Monte SM, 2005, J ALZHEIMERS DIS, V7, P45; DeKosky ST, 2008, JAMA-J AM MED ASSOC, V300, P2253, DOI 10.1001/jama.2008.683; DeKosky ST, 2006, CONTEMP CLIN TRIALS, V27, P238, DOI 10.1016/j.cct.2006.02.007; den Heijer T, 2005, NEUROLOGY, V64, P263, DOI 10.1212/01.WNL.0000149641.55751.2E; di Giuseppe R, 2008, J NUTR, V138, P1939, DOI 10.1093/jn/138.10.1939; Dik MG, 2003, J CLIN EXP NEUROPSYC, V25, P643, DOI 10.1076/jcen.25.5.643.14583; Dodge HH, 2008, NEUROLOGY, V70, P1809, DOI 10.1212/01.wnl.0000303814.13509.db; Dodge HH, 2008, J GERONTOL A-BIOL, V63, P1193, DOI 10.1093/gerona/63.11.1193; Downey DB, 2001, AM PSYCHOL, V56, P497, DOI 10.1037//0003-066X.56.6-7.497; EBLY EM, 1995, ARCH NEUROL-CHICAGO, V52, P612, DOI 10.1001/archneur.1995.00540300086018; Edwards JD, 2005, AGING MENT HEALTH, V9, P262, DOI 10.1080/13607860412331336788; Edwards JD, 2002, GERONTOLOGY, V48, P329, DOI 10.1159/000065259; Engelhart MJ, 2002, JAMA-J AM MED ASSOC, V287, P3223, DOI 10.1001/jama.287.24.3223; Espeland MA, 2004, JAMA-J AM MED ASSOC, V291, P2959, DOI 10.1001/jama.291.24.2959; Evans DA, 1997, ARCH NEUROL-CHICAGO, V54, P1399, DOI 10.1001/archneur.1997.00550230066019; Fewlass DC, 2004, FASEB J, V18, P1870, DOI 10.1096/fj.04-2572com; Fillit HM, 2002, MAYO CLIN PROC, V77, P681, DOI 10.4065/77.7.681; Fratiglioni L, 2000, LANCET, V355, P1315, DOI 10.1016/S0140-6736(00)02113-9; Galanis DJ, 1997, AM J EPIDEMIOL, V145, P507; Ganguli M, 2006, ARCH GEN PSYCHIAT, V63, P153, DOI 10.1001/archpsyc.63.2.153; Ganguli M, 2005, NEUROLOGY, V65, P1210, DOI 10.1212/01.wnl.0000180520.35181.24; Ganguli M, 2005, ARCH NEUROL-CHICAGO, V62, P779, DOI 10.1001/archneur.62.5.779; Gasparini L, 2002, TRENDS PHARMACOL SCI, V23, P288, DOI 10.1016/S0165-6147(02)02037-0; Gasparini M, 2002, NEUROL SCI, V23, P11, DOI 10.1007/s100720200017; Geda YE, 2006, ARCH NEUROL-CHICAGO, V63, P435, DOI 10.1001/archneur.63.3.435; Gillette-Guyonnet S, 2007, J NUTR HEALTH AGING, V11, P132; Grantham-McGregor Sally, 2003, Forum Nutr, V56, P272; Grassi D, 2008, J NUTR, V138, P1671, DOI 10.1093/jn/138.9.1671; Graves AB, 2001, NEUROLOGY, V57, P1453, DOI 10.1212/WNL.57.8.1453; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Guo ZC, 1996, BRIT MED J, V312, P805, DOI 10.1136/bmj.312.7034.805; Gustafson D, 2003, ARCH INTERN MED, V163, P1524, DOI 10.1001/archinte.163.13.1524; Haan MN, 2006, NAT CLIN PRACT NEURO, V2, P159, DOI 10.1038/ncpneuro0124; Hamed MS, 2008, SOUTH MED J; Hanon O, 2005, J NUTR HEALTH AGING, V9, P106; Havlik RJ, 2002, STROKE, V33, P26, DOI 10.1161/hs0102.101890; Hayden KM, 2007, NEUROLOGY, V69, P275, DOI 10.1212/01.wnl.0000265223.25679.2a; Helmer C, 2001, J NEUROL NEUROSUR PS, V71, P303, DOI 10.1136/jnnp.71.3.303; Heo HJ, 2005, J AGR FOOD CHEM, V53, P1445, DOI 10.1021/jf048989m; Hernan MA, 2008, EPIDEMIOLOGY, V19, P448, DOI 10.1097/EDE.0b013e31816bbe14; Heron M. P., 2007, NATL VITAL STAT REPO, V56; Holtzman RE, 2004, J GERONTOL B-PSYCHOL, V59, pP278, DOI 10.1093/geronb/59.6.P278; Hsiung GYR, 2006, DEMENT GERIATR COGN, V22, P413, DOI 10.1159/000095751; Hu FB, 2002, CURR OPIN LIPIDOL, V13, P3, DOI 10.1097/00041433-200202000-00002; Huang TL, 2008, NEUROLOGY, V70, P1818, DOI 10.1212/01.wnl.0000311444.20490.98; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; Hughes TF, MIDLIFE FRUIT VEGETA; Hultsch DF, 1999, PSYCHOL AGING, V14, P245, DOI 10.1037/0882-7974.14.2.245; Jang Y, 2005, J GERONTOL B-PSYCHOL, V60, pP313, DOI 10.1093/geronb/60.6.P313; Jellinger KA, 2001, EUR J NEUROL, V8, P707, DOI 10.1046/j.1468-1331.2001.00322.x; Jeynes B, 2008, CURR ALZHEIMER RES, V5, P432, DOI 10.2174/156720508785908937; Johnson DK, 2006, ARCH NEUROL-CHICAGO, V63, P1312, DOI 10.1001/archneur.63.9.1312; Jorm AF, 2001, AUST NZ J PSYCHIAT, V35, P776, DOI 10.1046/j.1440-1614.2001.00967.x; Jorm AF, 1998, AGE AGEING, V27, P477, DOI 10.1093/ageing/27.4.477; Kalmijn S, 2000, ARTERIOSCL THROM VAS, V20, P2255, DOI 10.1161/01.ATV.20.10.2255; Kant AK, 2004, J AM DIET ASSOC, V104, P615, DOI 10.1016/j.jada.2004.01.010; Karp A, 2006, DEMENT GERIATR COGN, V21, P65, DOI 10.1159/000089919; Karp A, 2004, AM J EPIDEMIOL, V159, P175, DOI 10.1093/aje/kwh018; KATZMAN R, 1995, J AM GERIATR SOC, V43, P583, DOI 10.1111/j.1532-5415.1995.tb06112.x; KATZMAN R, 1993, NEUROLOGY, V43, P13, DOI 10.1212/WNL.43.1_Part_1.13; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kim JM, 2008, INT J GERIATR PSYCH, V23, P41, DOI 10.1002/gps.1833; Kivipelto M, 2002, ANN INTERN MED, V137, P149, DOI 10.7326/0003-4819-137-3-200208060-00006; Kivipelto M, 2005, ARCH NEUROL-CHICAGO, V62, P1556, DOI 10.1001/archneur.62.10.1556; Kivipelto M, 2001, NEUROLOGY, V56, P1683, DOI 10.1212/WNL.56.12.1683; Klegeris Andis, 2005, Current Alzheimer Research, V2, P355, DOI 10.2174/1567205054367883; Kloppenborg RP, 2008, EUR J PHARMACOL, V585, P97, DOI 10.1016/j.ejphar.2008.02.049; Knopman DS, 2007, NEUROLOGY, V69, P739, DOI 10.1212/01.wnl.0000267661.65586.33; Koponen S, 2004, NEUROLOGY, V63, P749, DOI 10.1212/01.WNL.0000134603.57107.2F; Korf ESC, 2004, HYPERTENSION, V44, P29, DOI 10.1161/01.HYP.0000132475.32317.bb; Kramer AF, 2004, J GERONTOL A-BIOL, V59, P940; KRIEGLSTEIN J, 1986, LIFE SCI, V39, P2327, DOI 10.1016/0024-3205(86)90663-6; Kroger E, 2008, AM J EPIDEMIOL, V167, P820, DOI 10.1093/aje/kwm382; Krumholz HM, 1998, CIRCULATION, V97, P958; Kuh D, 2003, J EPIDEMIOL COMMUN H, V57, P778, DOI 10.1136/jech.57.10.778; Kwok T, 2008, ARCH GERONTOL GERIAT, V46, P273, DOI 10.1016/j.archger.2007.05.001; Laitinen MH, 2006, DEMENT GERIATR COGN, V22, P99, DOI 10.1159/000093478; Larson EB, 2006, ANN INTERN MED, V144, P73, DOI 10.7326/0003-4819-144-2-200601170-00004; Launer LJ, 2007, CURR ALZHEIMER RES, V4, P141, DOI 10.2174/156720507780362155; Launer LJ, 2000, NEUROBIOL AGING, V21, P49, DOI 10.1016/S0197-4580(00)00096-8; Launer LJ, 2005, NEUROBIOL AGING, V26, P335, DOI 10.1016/j.neurobiolaging.2004.03.016; Launer LJ, 2001, NEUROLOGY, V57, P1447, DOI 10.1212/WNL.57.8.1447; Laurin D, 2004, AM J EPIDEMIOL, V159, P959, DOI 10.1093/aje/kwh124; Laurin D, 2001, ARCH NEUROL-CHICAGO, V58, P498, DOI 10.1001/archneur.58.3.498; Lautenschlager NT, 2008, JAMA-J AM MED ASSOC, V300, P1027, DOI 10.1001/jama.300.9.1027; Lavery LL, 2008, J AM GERIATR SOC; LeBars PL, 1997, JAMA-J AM MED ASSOC, V278, P1327, DOI 10.1001/jama.278.16.1327; LeBlanc ES, 2001, JAMA-J AM MED ASSOC, V285, P1489, DOI 10.1001/jama.285.11.1489; Letenneur L, 1999, J NEUROL NEUROSUR PS, V66, P177, DOI 10.1136/jnnp.66.2.177; Levine B, 2007, J INT NEUROPSYCH SOC, V13, P143, DOI 10.1017/S1355617707070178; Levy R, 1994, Int Psychogeriatr, V6, P63, DOI 10.1017/S1041610294001626; Li G, 2004, NEUROLOGY, V63, P1624, DOI 10.1212/01.WNL.0000142963.90204.58; Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074; Lopez OL, 2003, ARCH NEUROL-CHICAGO, V60, P1394, DOI 10.1001/archneur.60.10.1394; Lovden M, 2005, PSYCHOL AGING, V20, P423, DOI 10.1037/0882-7974.20.3.423; Luchsinger JA, 2004, LANCET NEUROL, V3, P579, DOI 10.1016/S1474-4422(04)00878-6; Luchsinger JA, 2004, NEUROLOGY, V63, P1187, DOI 10.1212/01.WNL.0000140292.04932.87; Luchsinger JA, 2007, ARCH NEUROL-CHICAGO, V64, P570, DOI 10.1001/archneur.64.4.570; Luo Y, 2002, P NATL ACAD SCI USA, V99, P12197, DOI 10.1073/pnas.182425199; Luo Y, 2006, LIFE SCI, V78, P2066, DOI 10.1016/j.lfs.2005.12.004; Luukinen H, 1999, NEUROLOGY, V52, P557, DOI 10.1212/WNL.52.3.557; Luukinen H, 2005, EUR J NEUROL, V12, P86, DOI 10.1111/j.1468-1331.2004.00953.x; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Lyketsos CG, 2007, NEUROLOGY, V68, P1800; Lytle ME, 2004, ALZ DIS ASSOC DIS, V18, P57, DOI 10.1097/01.wad.0000126614.87955.79; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Maia L, 2002, EUR J NEUROL, V9, P377, DOI 10.1046/j.1468-1331.2002.00421.x; Malouf R., 2004, COCHRANE DB SYST REV, V1, DOI [DOI 10.1002/14651858.CD004394, DOI 10.1002/14651858.CD004326]; Mandal PK, 2008, BBA-BIOMEMBRANES, V1778, P2633, DOI 10.1016/j.bbamem.2008.07.002; Manschot SM, 2007, DIABETOLOGIA, V50, P2388, DOI 10.1007/s00125-007-0792-z; Marambaud P, 2005, J BIOL CHEM, V280, P37377, DOI 10.1074/jbc.M508246200; Martin BK, 2008, ARCH NEUROL-CHICAGO, V65, P896, DOI 10.1001/archneur.2008.65.7.nct70006; Maslow K, 2008, ALZHEIMERS DEMENT, V4, P110, DOI 10.1016/j.jalz.2008.02.005; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McCann SE, 2001, PUBLIC HEALTH NUTR, V4, P989, DOI 10.1079/PHN2001168; MCCRAE RR, 1992, J PERS, V60, P175, DOI 10.1111/j.1467-6494.1992.tb00970.x; MCDOWELL I, 1994, NEUROLOGY, V44, P2073; McIntosh C, 2004, J NEUROL NEUROSUR PS, V75, P16, DOI 10.1136/jnnp.2004.045708; Mehlig K, 2008, AM J EPIDEMIOL, V167, P684, DOI 10.1093/aje/kwm366; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Mielke MM, 2005, NEUROLOGY, V64, P1689, DOI 10.1212/01.WNL.0000161870.78572.A5; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Millen BE, 2005, J AM DIET ASSOC, V105, P1723, DOI 10.1016/j.jada.2005.08.007; Moceri VM, 2000, NEUROLOGY, V54, P415, DOI 10.1212/WNL.54.2.415; Moceri VM, 2001, EPIDEMIOLOGY, V12, P383, DOI 10.1097/00001648-200107000-00007; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; Mookadam F, 2004, ARCH INTERN MED, V164, P1514, DOI 10.1001/archinte.164.14.1514; Morris JC, 2001, ARCH NEUROL-CHICAGO, V58, P397, DOI 10.1001/archneur.58.3.397; Morris MC, 2004, NEUROLOGY, V62, P1573, DOI 10.1212/01.WNL.0000123250.82849.B6; Morris MC, 2002, JAMA-J AM MED ASSOC, V287, P3230, DOI 10.1001/jama.287.24.3230; Morris MC, 2003, ARCH NEUROL-CHICAGO, V60, P940, DOI 10.1001/archneur.60.7.940; Mortimer JA, 1997, GERIATRICS, V52, pS50; Mortimer JA, 2005, J GERIATR PSYCH NEUR, V18, P218, DOI 10.1177/0891988705281869; Mortimer JA, 2003, J CLIN EXP NEUROPSYC, V25, P671, DOI 10.1076/jcen.25.5.671.14584; Mortimer JA, 2006, ALZ DIS ASSOC DIS, V20, pS35, DOI 10.1097/00002093-200607001-00004; Mossello E, 2008, DEMENT GERIATR COGN, V25, P372, DOI 10.1159/000121334; Mukamal KJ, 2003, JAMA-J AM MED ASSOC, V289, P1405, DOI 10.1001/jama.289.11.1405; Nebes RD, 2000, PSYCHOL MED, V30, P679, DOI 10.1017/S0033291799001968; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Newson RS, 2005, J GERONTOL B-PSYCHOL, V60, pP113, DOI 10.1093/geronb/60.3.P113; Notkola IL, 1998, NEUROEPIDEMIOLOGY, V17, P14, DOI 10.1159/000026149; Nourhashemi Fati, 2008, Expert Rev Neurother, V8, P691, DOI 10.1586/14737175.8.5.691; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Oken BS, 1998, ARCH NEUROL-CHICAGO, V55, P1409, DOI 10.1001/archneur.55.11.1409; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Ong KL, 2007, HYPERTENSION, V49, P69, DOI 10.1161/01.HYP.0000252676.46043.18; ORRELL M, 1995, BMJ-BRIT MED J, V310, P951, DOI 10.1136/bmj.310.6985.951; Ownby RL, 2006, ARCH GEN PSYCHIAT, V63, P530, DOI 10.1001/archpsyc.63.5.530; Padwal R, 2001, BMJ-BRIT MED J, V322, P977, DOI 10.1136/bmj.322.7292.977; Panza F, 2006, BRAIN RES REV, V51, P275, DOI 10.1016/j.brainresrev.2005.11.007; Peila R, 2006, ACTA NEUROL SCAND, V114, P102, DOI 10.1111/j.1600-0404.2006.00693.x; Peila R, 2006, STROKE, V37, P1165, DOI 10.1161/01.STR.0000217653.01615.93; Peters R, 2008, AGE AGEING, V37, P505, DOI 10.1093/ageing/afn095; Petersen RC, 2001, ARCH NEUROL-CHICAGO, V58, P1985, DOI 10.1001/archneur.58.12.1985; Petersen RC, 2008, CNS SPECTRUMS, V13, P45, DOI 10.1017/S1092852900016151; Petrovitch H, 2000, NEUROBIOL AGING, V21, P57, DOI 10.1016/S0197-4580(00)82479-3; Pfrieger FW, 2003, CELL MOL LIFE SCI, V60, P1158, DOI 10.1007/s00018-003-3018-7; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Podewils LJ, 2005, AM J EPIDEMIOL, V161, P639, DOI 10.1093/aje/kwi092; Poon IO, 2008, PHARMACOTHERAPY, V28, P366, DOI 10.1592/phco.28.3.366; POSTIGLIONE A, 1989, ATHEROSCLEROSIS, V80, P63, DOI 10.1016/0021-9150(89)90069-5; Potter GG, 2008, NEUROLOGY, V70, P1803, DOI 10.1212/01.wnl.0000295506.58497.7e; Prochaska JO, 1997, AM J HEALTH PROMOT, V12, P38, DOI 10.4278/0890-1171-12.1.38; Qiu CX, 2005, LANCET NEUROL, V4, P487, DOI 10.1016/S1474-4422(05)70141-1; Qiu CX, 2003, AM J IND MED, V43, P204, DOI 10.1002/ajim.10159; Raber J, 2004, NEUROBIOL AGING, V25, P641, DOI 10.1016/j.neurobiolaging.2003.12.023; Racchi M, 1997, BIOCHEM J, V322, P893, DOI 10.1042/bj3220893; Rapp SR, 2003, JAMA-J AM MED ASSOC, V289, P2663, DOI 10.1001/jama.289.20.2663; Ravaglia G, 2008, NEUROLOGY, V70, P1786, DOI 10.1212/01.wnl.0000296276.50595.86; Rea TD, 2005, ARCH NEUROL-CHICAGO, V62, P1047, DOI 10.1001/archneur.62.7.1047; Refolo LM, 2000, NEUROBIOL DIS, V7, P321, DOI 10.1006/nbdi.2000.0304; Reitz C, 2004, ARCH NEUROL-CHICAGO, V61, P705, DOI 10.1001/archneur.61.5.705; Reitz C, 2008, DEMENT GERIATR COGN, V25, P232, DOI 10.1159/000115847; Reynolds MD, 1999, NEUROLOGY, V53, P228, DOI 10.1212/WNL.53.1.228; Rezvani AH, 2001, BIOL PSYCHIAT, V49, P258, DOI 10.1016/S0006-3223(00)01094-5; Richards M, 2001, BRIT MED J, V322, P199, DOI 10.1136/bmj.322.7280.199; Richards M, 2002, PUBLIC HEALTH NUTR, V5, P631, DOI 10.1079/PHN2002338; Richards SS, 2000, J AM GERIATR SOC, V48, P1035, DOI 10.1111/j.1532-5415.2000.tb04777.x; Ritchie K, 2007, NEUROLOGY, V69, P536, DOI 10.1212/01.wnl.0000266670.35219.0c; Ritchie K, 1997, Int Psychogeriatr, V9, P309, DOI 10.1017/S1041610297004468; Roberts BW, 2000, PSYCHOL BULL, V126, P3, DOI 10.1037/0033-2909.126.1.3; Roberts RO, 2008, ARCH NEUROL-CHICAGO, V65, P1066, DOI 10.1001/archneur.65.8.1066; Rockwood K., 2006, ACTA NEUROL SCAND  S, V185, P171; Rodriguez EG, 2002, J AM GERIATR SOC, V50, P1852, DOI 10.1046/j.1532-5415.2002.50515.x; Rolland Y, 2008, J AM MED DIR ASSOC, V9, P390, DOI 10.1016/j.jamda.2008.02.007; Romas SN, 1999, NEUROLOGY, V53, P517, DOI 10.1212/WNL.53.3.517; Ronnemaa E, 2008, NEUROLOGY, V71, P1065, DOI 10.1212/01.wnl.0000310646.32212.3a; Rosengren A, 2005, ARCH INTERN MED, V165, P321, DOI 10.1001/archinte.165.3.321; Rovio S, 2005, LANCET NEUROL, V4, P705, DOI 10.1016/S1474-4422(05)70198-8; Rovio S, 2007, INT J GERIATR PSYCH, V22, P874, DOI 10.1002/gps.1755; Ruitenberg A, 2001, DEMENT GERIATR COGN, V12, P33, DOI 10.1159/000051233; Saczynski JS, 2008, J GERONTOL A-BIOL, V63, P848, DOI 10.1093/gerona/63.8.848; Saczynski JS, 2006, AM J EPIDEMIOL, V163, P433, DOI 10.1093/aje/kwj061; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; Savaskan E, 2003, GERONTOLOGY, V49, P380, DOI 10.1159/000073766; Scarmeas N, 2001, NEUROLOGY, V57, P2236, DOI 10.1212/WNL.57.12.2236; Scarmeas N, 2006, ANN NEUROL, V59, P912, DOI 10.1002/ana.20854; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; Schneider Lon S., 2005, Current Alzheimer Research, V2, P541, DOI 10.2174/156720505774932287; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Schofield PW, 1997, NEUROLOGY, V49, P30, DOI 10.1212/WNL.49.1.30; Seeman TE, 2001, HEALTH PSYCHOL, V20, P243, DOI 10.1037//0278-6133.20.4.243; Sheline YI, 2003, AM J PSYCHIAT, V160, P1516, DOI 10.1176/appi.ajp.160.8.1516; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Silverman W, 1997, NEUROBIOL AGING, V18, P377, DOI 10.1016/S0197-4580(97)00051-1; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Small BJ, 2004, PSYCHOL AGING, V19, P592, DOI 10.1037/0882-7974.19.4.592; Small BJ, 2003, J GERONTOL B-PSYCHOL, V58, pP166, DOI 10.1093/geronb/58.3.P166; SMITH LL, 1991, FREE RADICAL BIO MED, V11, P47, DOI 10.1016/0891-5849(91)90187-8; Smyth KA, 2004, NEUROLOGY, V63, P498, DOI 10.1212/01.WNL.0000133007.87028.09; Snowdon DA, 1996, JAMA-J AM MED ASSOC, V275, P528, DOI 10.1001/jama.275.7.528; Solfrizzi V, 2004, NEUROLOGY, V63, P1882, DOI 10.1212/01.WNL.0000144281.38555.E3; Solfrizzi V, 2006, NEUROBIOL AGING, V27, P1694, DOI 10.1016/j.neurobiolaging.2005.09.026; Solomon A, 2007, NEUROLOGY, V68, P751, DOI 10.1212/01.wnl.0000256368.57375.b7; Sparks DL, 2008, CURR ALZHEIMER RES, V5, P416, DOI 10.2174/156720508785132316; SPARKS DL, 1994, EXP NEUROL, V126, P88, DOI 10.1006/exnr.1994.1044; STERN Y, 1994, JAMA-J AM MED ASSOC, V271, P1004, DOI 10.1001/jama.271.13.1004; STERN Y, 1995, NEUROLOGY, V45, P55, DOI 10.1212/WNL.45.1.55; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Stewart R, 2005, ARCH NEUROL-CHICAGO, V62, P55, DOI 10.1001/archneur.62.1.55; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Sturman MT, 2008, NEUROLOGY, V70, P360, DOI 10.1212/01.wnl.0000285081.04409.bb; Swan GE, 2007, NEUROPSYCHOL REV, V17, P259, DOI 10.1007/s11065-007-9035-9; Szczygielski J, 2005, J NEURAL TRANSM, V112, P1547, DOI 10.1007/s00702-005-0326-0; Szekely CA, 2008, NEUROLOGY, V70, P2291, DOI 10.1212/01.wnl.0000313933.17796.f6; Taaffe DR, 2008, J GERONTOL A-BIOL, V63, P529, DOI 10.1093/gerona/63.5.529; Tan ZS, 2003, ARCH INTERN MED, V163, P1053, DOI 10.1001/archinte.163.9.1053; Tervo S, 2004, DEMENT GERIATR COGN, V17, P196, DOI 10.1159/000076356; TRAVIS R, 1995, J SOC PSYCHOL, V135, P499, DOI 10.1080/00224545.1995.9712218; Tyas SL, 2003, NEUROBIOL AGING, V24, P589, DOI 10.1016/S0197-4580(02)00156-2; Tyas SL, 2007, AM J EPIDEMIOL, V165, P1231, DOI 10.1093/aje/kwm085; UK Prospective Diabetes Study Grp, 1999, DIABETES CARE, V22, P1125; van de Rest O., 2008, NEUROLOGY, V71, P430, DOI DOI 10.1212/01.WNL.0000324268.45138.86; VANDUIJN CM, 1992, AM J EPIDEMIOL, V135, P775, DOI 10.1093/oxfordjournals.aje.a116364; Verghese J, 2006, NEUROLOGY, V66, P821, DOI 10.1212/01.wnl.0000202520.68987.48; Verghese J, 2003, NEW ENGL J MED, V348, P2508, DOI 10.1056/NEJMoa022252; Verghese J, 2003, NEUROLOGY, V61, P1667, DOI 10.1212/01.WNL.0000098934.18300.BE; Vitolo O, 2007, J NEUROBIOL AGING; Vlad SC, 2008, NEUROLOGY, V70, P1672, DOI 10.1212/01.wnl.0000311269.57716.63; Wang HX, 2002, AM J EPIDEMIOL, V155, P1081, DOI 10.1093/aje/155.12.1081; Wang JYJ, 2006, NEUROLOGY, V66, P911, DOI 10.1212/01.wnl.0000192165.99963.2a; Watson GS, 2005, AM J GERIAT PSYCHIAT, V13, P950, DOI 10.1176/appi.ajgp.13.11.950; West SG, 2008, AM J PUBLIC HEALTH, V98, P1359, DOI 10.2105/AJPH.2007.124446; Whalley LJ, 2006, LANCET NEUROL, V5, P87, DOI 10.1016/S1474-4422(05)70286-6; Whitmer RA, 2008, NEUROLOGY, V71, P1057, DOI 10.1212/01.wnl.0000306313.89165.ef; Whitmer RA, 2005, NEUROLOGY, V64, P277, DOI 10.1212/01.WNL.0000149519.47454.F2; Whitmer RA, 2005, BMJ-BRIT MED J, V330, P1360, DOI 10.1136/bmj.38446.466238.E0; Whitmer RA, 2007, CURR ALZHEIMER RES, V4, P103, DOI 10.2174/156720507780362047; Wilson RS, 2007, NEUROLOGY, V69, P1911, DOI 10.1212/01.wnl.0000271087.67782.cb; Wilson RS, 2007, NEUROLOGY, V68, P2085, DOI 10.1212/01.wnl.0000264930.97061.82; Wilson RS, 2007, ARCH GEN PSYCHIAT, V64, P1204, DOI 10.1001/archpsyc.64.10.1204; Wilson RS, 2006, NEUROEPIDEMIOLOGY, V27, P143, DOI 10.1159/000095761; Wilson RS, 2003, NEUROLOGY, V61, P812, DOI 10.1212/01.WNL.0000083989.44027.05; Wilson RS, 2002, NEUROLOGY, V59, P1910, DOI 10.1212/01.WNL.0000036905.59156.A1; Winocur G, 2007, J INT NEUROPSYCH SOC, V13, P153, DOI 10.1017/S135561770707018X; Wolazin B, 2006, ACTA NEUROL SCAND, V114, P63; Wu JH, 2003, ANN EPIDEMIOL, V13, P369, DOI 10.1016/S1047-2797(02)00464-7; Xu W, 2008, DIABETES; Yaffe K, 2002, ARCH NEUROL-CHICAGO, V59, P378, DOI 10.1001/archneur.59.3.378; Yaffe K, 2002, BIOL PSYCHIAT, V51, P677, DOI 10.1016/S0006-3223(01)01289-6; Yamada M, 2003, J AM GERIATR SOC, V51, P410, DOI 10.1046/j.1532-5415.2003.51117.x; Young SE, 2006, DIABETES CARE, V29, P2688, DOI 10.2337/dc06-0915; Zandi PP, 2002, JAMA-J AM MED ASSOC, V288, P2123, DOI 10.1001/jama.288.17.2123; Zandi PP, 2005, ARCH GEN PSYCHIAT, V62, P217, DOI 10.1001/archpsyc.62.2.217; Zandi PP, 2002, NEUROLOGY, V59, P880, DOI 10.1212/WNL.59.6.880; Zandi PP, 2004, ARCH NEUROL-CHICAGO, V61, P82, DOI 10.1001/archneur.61.1.82; ZHANG MY, 1990, ANN NEUROL, V27, P428, DOI 10.1002/ana.410270412; Zunzunegui MV, 2003, J GERONTOL B-PSYCHOL, V58, pS93, DOI 10.1093/geronb/58.2.S93; [No title captured]	348	84	88	0	0	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1573-4005	1875-6441		CURR PSYCHIATRY REV	Curr. Psychiatry Rev.		2009	5	2					73	92		10.2174/157340009788167347			20	Psychiatry	Emerging Sources Citation Index (ESCI)	Psychiatry	V95WG	WOS:000213226100001	19946443	Green Accepted			2022-02-06	
J	Ruff, RL; Ruff, SS; Wang, XF				Ruff, Robert L.; Ruff, Suzanne S.; Wang, Xiao-Feng			Headaches among Operation Iraqi Freedom/Operation Enduring Freedom veterans with mild traumatic brain injury associated with exposures to explosions	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						blast; combat; explosion; headache; migraine; OEF; OIF; pain; sleep; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; EDITION CVLT-II; OLFACTORY DYSFUNCTION; COGNITIVE IMPAIRMENT; SCREENING TOOL; MEMORY; PERFORMANCE; CLASSIFICATION; AFGHANISTAN; DEFICITS	Traumatic brain injury (TBI) is a common injury type among Operation Iraqi Freedom/Operation Enduring Freedom (OIF/OEF) veterans, and headaches are a frequent consequence of TBI. We examined the hypothesis that among veterans who reported mild TBI caused by exposure to an explosion during deployment in OIF/OEF, those with residual neurocognitive deficits would have a higher frequency of headaches and more severe headaches. We evaluated 155 consecutive veterans with neurological examination and neuropsychological testing. We excluded 29 veterans because they did not have mild TBI or they did not complete the evaluation. We analyzed headache pattern, intensity, and frequency. Among the 126 veterans studied, 80 had impairments on neurological examination or neuropsychological testing that were best attributed to TBI. Veterans with impairments had been exposed to more explosions and were more likely to have headache, features of migraine, more severe pain, more frequent headaches, posttraumatic stress disorder, and impaired sleep with nightmares.	[Ruff, Robert L.] Vet Affairs Med Ctr, Louis Stokes Cleveland Dept, Neurol Serv & Polytrauma Syst Care, Cleveland, OH USA; [Ruff, Robert L.] Case Western Reserve Univ, Dept Neurol, Cleveland, OH 44106 USA; [Ruff, Suzanne S.] Louis Stokes Cleveland VAMC, Psychol Serv & Polytrauma Syst Care, Cleveland, OH 44106 USA; [Wang, Xiao-Feng] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA		Ruff, RL (corresponding author), Louis Stokes Cleveland VAMC, Neurol Serv W127, 10701 E Blvd, Cleveland, OH 44106 USA.	Robert.Ruff1@va.gov			Patient Care Services of the LSCVAMC, Cleveland, Ohio	This material is the result of work supported by Patient Care Services of the LSCVAMC, Cleveland, Ohio.	Agresti A, 1996, INTRO CATEGORICAL DA, P16; AGRESTI A, 1996, INTRO CATEGORICAL DA, P71; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BECK AT, 1996, BECK DEPRESSION INVE, P128; Benge JF, 2007, BRAIN INJURY, V21, P395, DOI 10.1080/02699050701311091; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P606, DOI 10.1017/S1355617705050721; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Bowden SC, 1998, NEUROPSYCHOL REHABIL, V8, P243, DOI 10.1080/713755573; Breslau N, 2001, BIOL PSYCHIAT, V50, P699, DOI 10.1016/S0006-3223(01)01167-2; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; Busch RM, 2005, J CLIN EXP NEUROPSYC, V27, P1022, DOI 10.1080/13803390490919263; Callahan CD, 2002, J HEAD TRAUMA REHAB, V17, P251, DOI 10.1097/00001199-200206000-00006; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; de Kruijk JR, 2003, BRAIN INJURY, V17, P73, DOI 10.1080/0269905021000010221; Demakis GJ, 2004, J CLIN EXP NEUROPSYC, V26, P441, DOI 10.1080/13803390490510149; Donders J, 2008, ASSESSMENT, V15, P123, DOI 10.1177/1073191107310926; Doty RL, 2007, AM J RHINOL, V21, P460, DOI 10.2500/ajr.2007.21.3043; Doty RL, 1997, ARCH NEUROL-CHICAGO, V54, P1131, DOI 10.1001/archneur.1997.00550210061014; Doty RL, 2001, ANNU REV PSYCHOL, V52, P423, DOI 10.1146/annurev.psych.52.1.423; Doty RL, 1996, LARYNGOSCOPE, V106, P353, DOI 10.1097/00005537-199603000-00021; DOTY RL, 1989, PERCEPT PSYCHOPHYS, V45, P381, DOI 10.3758/BF03210709; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Fisher D C, 2000, Appl Neuropsychol, V7, P126, DOI 10.1207/S15324826AN0703_2; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; GRAHAM JR, 1999, MMPI 2 ASSESSING PER, P256; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HOCHBERG Y, 1987, MULTIPLE COMPARISON; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Iverson GL, 1999, CLIN NEUROPSYCHOL, V13, P437, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT437; Jacobs ML, 2008, ARCH CLIN NEUROPSYCH, V23, P113, DOI 10.1016/j.acn.2007.09.003; JOHNSTONE B, 1995, BRAIN INJURY, V9, P377, DOI 10.3109/02699059509005777; Kang HK, 2003, AM J EPIDEMIOL, V157, P141, DOI 10.1093/aje/kwf187; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Keane T.M., 1991, PCL M DSM 4; Kern RC, 2000, LARYNGOSCOPE, V110, P2106, DOI 10.1097/00005537-200012000-00025; KERR C, 1995, BRAIN INJURY, V9, P777, DOI 10.3109/02699059509008234; Khasnis A, 2003, J Postgrad Med, V49, P169; Kraus MF, 2007, COGN BEHAV NEUROL, V20, P170, DOI 10.1097/WNN.0b013e318142badb; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; KREMER E, 1981, PAIN, V10, P241, DOI 10.1016/0304-3959(81)90199-8; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Langeluddecke PM, 2003, ARCH CLIN NEUROPSYCH, V18, P181, DOI 10.1016/S0887-6177(01)00195-0; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; LEVIN HS, 1985, BRAIN, V108, P579, DOI 10.1093/brain/108.3.579; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; LICHTENBERGER EO, 2001, ESSENTIALS WMS 3 ASS, P288; Linder Steven L, 2007, Curr Pain Headache Rep, V11, P396, DOI 10.1007/s11916-007-0223-3; Lipsky RH, 2005, J NEUROPSYCH CLIN N, V17, P465, DOI 10.1176/appi.neuropsych.17.4.465; London B, 2008, ANN NEUROL, V63, P159, DOI 10.1002/ana.21293; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; McQueen, 2003, BRAIN IMPAIR, V4, P135, DOI [10.1375/brim.4.2.135.270, DOI 10.1375/BRIM.4.2.135.27024]; Meyers J E, 1996, Appl Neuropsychol, V3, P89, DOI 10.1207/s15324826an0302_8; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Ord JS, 2008, CLIN NEUROPSYCHOL, V22, P689, DOI 10.1080/13854040701425437; Ozakbas S, 2004, MULT SCLER, V10, P686, DOI 10.1191/1352458504ms1111oa; Pickett TC, 2007, J REHABIL RES DEV, V44, P983, DOI 10.1682/JRRD.2007.01.0001; Rinne MB, 2006, J REHABIL MED, V38, P224, DOI 10.1080/16501970600582989; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ryan JJ, 2003, ASSESSMENT, V10, P151, DOI 10.1177/1073191103010002006; SAMUELS MA, 2003, OFFICE PRACTICE NEUR, P1661; SAWYER RN, 1993, NEUROLOGY, V43, P1596, DOI 10.1212/WNL.43.8.1596; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Sherman Kristen Brewer, 2006, Phys Med Rehabil Clin N Am, V17, P473, DOI 10.1016/j.pmr.2005.11.007; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Suchy Y, 2003, CLIN NEUROPSYCHOL, V17, P492, DOI 10.1076/clin.17.4.492.27949; Suh M, 2006, NEUROSCI LETT, V410, P203, DOI 10.1016/j.neulet.2006.10.001; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tombaugh TN, 2006, ARCH CLIN NEUROPSYCH, V21, P753, DOI 10.1016/j.acn.2006.08.009; VANBELLE G, 2004, BIOSTATISTICS METHOD, P345; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Western SL, 1997, ARCH CLIN NEUROPSYCH, V12, P426; Wilde MC, 2007, ARCH PHYS MED REHAB, V88, P1284, DOI 10.1016/j.apmr.2007.07.012; Yousem DM, 1999, ACAD RADIOL, V6, P264, DOI 10.1016/S1076-6332(99)80449-8; Yousem DM, 1996, AM J NEURORADIOL, V17, P1171; ZADIKOFF C, 2007, MOVEMENT DISORD, V23, P297, DOI DOI 10.1002/MDS.21837	85	84	86	0	9	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2008	45	7					941	952		10.1682/JRRD.2008.02.0028			12	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	387WI	WOS:000261981900001	19165684	Bronze			2022-02-06	
J	Baguley, IJ; Slewa-Younan, S; Heriseanu, RE; Nott, MT; Mudaliar, Y; Nayyar, V				Baguley, Ian J.; Slewa-Younan, Shameran; Heriseanu, Roxana E.; Nott, Melissa T.; Mudaliar, Yugan; Nayyar, Vineet			The incidence of dysautonomia and its relationship with autonomic arousal following traumatic brain injury	BRAIN INJURY			English	Article						dysautonomia; traumatic brain injury; incidence; autonomic overactivity; outcome	SEVERE HEAD-INJURY; SCALE; MANAGEMENT; COMA	Primary objective: To determine the incidence of autonomic arousal vs. Dysautonomia following traumatic brain injury ( TBI) in an Intensive Care Unit ( ICU) setting and to prospectively evaluate these groups against injury severity and outcome variables. Research design: Prospective observational group comparison (cohort) study of consecutive ICU admissions to a major trauma hospital over a 2-year period. Main outcomes and results: Eighty-nine of 113 subjects met inclusion and exclusion criteria, with consent gained for 79 subjects ( 61 male, 18 female: 89% of potential subjects). During the first 7 days post-injury, elevated autonomic parameters were almost universal in the sample ( 92%), predominantly hypertension and tachycardia. Nineteen of 79 subjects ( 24%) were autonomically aroused on day 7 ( that is, had elevated heart rate, respiratory rate, blood pressure and temperature). Dysautonomia was diagnosed on day 14 post-injury in six of 79 subjects ( 8%) using previously published criteria. Autonomically aroused subjects had significantly more severe injuries, poorer outcomes and greater estimated costs than non-aroused subjects. Furthermore, Dysautonomic subjects within the autonomically aroused group had significantly worse outcome and, excluding early deaths, a greater period of hospitalization and higher estimated costs. Conclusions: The 8% incidence of Dysautonomia during ICU admission was in broad agreement with previous research. While day 7 autonomic arousal indicated a greater degree of injury, the diagnosis of Dysautonomia provided additional prognostic information. A coordinated multi-centre research effort into this condition appears appropriate.	Westmead Hosp, Intens Care Unit, Westmead, NSW 2145, Australia; Westmead Hosp, Brain Injury Rehabil Serv, Westmead, NSW 2145, Australia		Baguley, IJ (corresponding author), Westmead Hosp, Brain Injury Rehabil Serv, POB 533, Wentworthville, NSW 2145, Australia.	ianb@biru.wsahs.nsw.gov.au	Nott, Melissa T/M-6778-2018; Baguley, Ian J/K-6878-2013; Baguley, Ian/AAM-5828-2021	Nott, Melissa T/0000-0001-7088-5826; Baguley, Ian J/0000-0001-5650-3705; 			Baguley IJ, 2007, J NEUROL NEUROSUR PS, V78, P539, DOI 10.1136/jnnp.2006.096388; Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Baguley IJ, 2004, BRAIN INJURY, V18, P409, DOI 10.1080/02699050310001645775; Baguley IJ, 1999, MAYO CLIN PROC, V74, P105, DOI 10.4065/74.1.105; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Fernandez-Ortega JF, 2006, J TRAUMA, V61, P1129, DOI 10.1097/01.ta.0000197634.83217.80; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1977, LANCET, V1, P878; KISHNER S, 2006, POST HEAD INJURY AUT; Lemke DM, 2007, CRIT CARE NURSE, V27, P30; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x	14	84	87	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2007	21	11					1175	1181		10.1080/02699050701687375			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	222WX	WOS:000250329900009	17952716				2022-02-06	
J	Wilde, MC; Castriotta, RJ; Lai, JM; Atanasov, S; Masel, BE; Kuna, ST				Wilde, Mark C.; Castriotta, Richard J.; Lai, Jenny M.; Atanasov, Strahil; Masel, Brent E.; Kuna, Samuel T.			Cognitive impairment in patients with traumatic brain injury and obstructive sleep apnea	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	34th Annual Meeting of the International-Neuropsychological-Society	FEB 01-04, 2006	Boston, MA	Int Neuropsychol Soc		brain injuries; hypersomnia; neuropsychology; rehabilitation; sleep apnea; obstructive; sleep disorders; trauma	PSYCHOMOTOR VIGILANCE PERFORMANCE; MILD HEAD-INJURY; DAYTIME SLEEPINESS; ADULTS; DISORDERS; RECOVERY; NIGHT	Objective: To examine the impact of comorbid obstructive sleep apnea (OSA) on the cognitive functioning of traumatic brain injury (TBI) patients. Design: A case-control study. Neuropsychologic test performances of TBI patients with OSA were compared with those who did not have OSA. The diagnosis of OSA was based on standard criteria using nocturnal polysomnography. Setting: Three academic medical centers with level I trauma centers, accredited sleep disorders centers, and rehabilitation medicine programs. Participants: Thirty-five TBI patients who were part of a project that assessed the effect of sleep disorders in a larger sample of consecutively recruited TBI patients. There were 19 patients with TBI and OSA. They were compared with 16 TBI patients without OSA who were comparable in terms of age, education, severity of injury (when available), time postinjury, and Glasgow Coma Scale scores (when available). Interventions: Not applicable. Main Outcome Measures: The Psychomotor Vigilance Test, Rey Complex Figure Test, Rey Auditory Verbal Learning Test, digit span test from the Wechsler Memory Scale-Revised, and finger-tapping test. Results: The TBI patients with OSA performed significantly worse than the non-sleep disordered TBI patients on verbal and visual delayed-recall measures. The groups performed comparably on motor, visual construction, and attention tests. The TBI patients with OSA made more attention lapses (reaction times >= 500ms), but showed comparable fastest and slowest reaction times on a measure of sustained attention. Conclusions: OSA is associated with more impairment of sustained attention and memory in TBI patients. It is possible that early identification and treatment of OSA may improve cognitive, and thus potentially functional, outcomes of TBI patients with this disease.	Univ Texas Hlth Ctr, Houston, TX USA; Mem Hermann Hosp Sleep Disorders Ctr, Houston, TX USA; Univ Texas, Med Branch, Galveston, TX USA; Transit Learning Ctr, Galveston, TX USA; Univ Penn, Sch Med, Philadelphia, PA USA; Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA		Castriotta, RJ (corresponding author), Univ Texas, Hlth Sci Ctr, Div Pulm & Crit Care & Sleep Med, 6431 Fannin St, Houston, TX 77030 USA.	Richard.J.Castriotta@uth.tmc.edu	Castriotta, Richard/B-1158-2009; Lang, Steven/AAE-8102-2021; Sanguansri, Luz/B-6630-2011	Lang, Steven/0000-0003-1669-9146; Sanguansri, Luz/0000-0003-1908-7604; Castriotta, Richard/0000-0003-3502-4558			Aloia MS, 2004, J INT NEUROPSYCH SOC, V10, P772, DOI 10.1017/S1355617704105134; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; CARSKADON MA, 1986, SLEEP, V9, P519, DOI 10.1093/sleep/9.4.519; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Chesson AL, 1997, SLEEP, V20, P406; Cohen J., 2013, STAT POWER ANAL BEHA; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dinges DF, 2003, SLEEP MED, V4, P393, DOI 10.1016/S1389-9457(03)00108-4; Dinges DF, 1997, SLEEP, V20, P267; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; Guilleminault C, 2000, NEUROLOGY, V54, P653, DOI 10.1212/WNL.54.3.653; Heaton RK, 1991, COMPREHENSIVE NORMS; High WM, 2006, ARCH PHYS MED REHAB, V87, P334, DOI 10.1016/j.apmr.2005.11.028; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P1162, DOI 10.1164/ajrccm/147.5.1162; LEVIN HS, 1992, J NEUROTRAUM, V9, pS359; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Phipps-Nelson J, 2003, SLEEP, V26, P695, DOI 10.1093/sleep/26.6.695; Rechtschaffen A., 1968, MANUAL STANDARDIZED; Sforza E, 2004, EUR RESPIR J, V24, P279, DOI 10.1183/09031936.04.00091903; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Webster JB, 2001, ARCH PHYS MED REHAB, V82, P316, DOI 10.1053/apmr.2001.20840; Wechsler D., 1989, WECHSLER MEMORY SCAL; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	30	84	86	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2007	88	10					1284	1288		10.1016/j.apmr.2007.07.012			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation; Sport Sciences	220MT	WOS:000250161500009	17908570				2022-02-06	
J	Dusick, JR; Glenn, TC; Lee, WP; Vespa, PM; Kelly, DF; Lee, SM; Hovda, DA; Martin, NA				Dusick, Joshua R.; Glenn, Thomas C.; Lee, Wn Paul; Vespa, Paul M.; Kelly, Daniel F.; Lee, Stefan M.; Hovda, David A.; Martin, Neil A.			Increased pentose phosphate pathway flux after clinical traumatic brain injury: a [1,2-C-13(2)]glucose labeling study in humans	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						glucose; hyperglycolysis; lactate; metabolism; pentose phosphate cycle; traumatic brain injury	ACID CYCLE FLUX; MASS ISOTOPOMER ANALYSIS; CEREBRAL-BLOOD-FLOW; HEAD-INJURY; GLUCOSE-METABOLISM; IN-VIVO; RAT-BRAIN; LIPID-PEROXIDATION; OXIDATIVE STRESS; UP-REGULATION	Patients with traumatic brain injury (TBI) routinely exhibit cerebral glucose uptake in excess of that expected by the low levels of oxygen consumption and lactate production. This brings into question the metabolic fate of glucose. Prior studies have shown increased flux through the pentose phosphate cycle (PPC) during cellular stress. This study assessed the PPC after TBI in humans. [1,2-C-13(2)]glucose was infused for 60 mins in six consented, severe-TBI patients (GCS<9) and six control subjects. Arterial and jugular bulb blood sampled during infusion was analyzed for C-13-labeled isotoporners of lactate by gas chromatography/mass spectroscopy. The product of lactate concentration and fractional abundance of isotoporners was used to determine blood concentration of each isotopomer. The difference of jugular and arterial concentrations determined cerebral contribution. The formula PPC=(m1/m2)/(3+(m1/m2)) was used to calculate PPC flux relative to glycolysis. There was enrichment of [1,2-C-13(2)]glucose in arterial-venous blood (enrichment averaged 16.6% in TBI subjects and 28.2% in controls) and incorporation of C-13- label into lactate, showing metabolism of labeled substrate. The PPC was increased in TBI patients relative to controls (19.6 versus 6.9%, respectively; P= 0.002) and was excellent for distinguishing the groups (AUC=0.944, P<0.0001). No correlations were found between PPC and other clinical parameters, although PPC was highest in patients studied within 48 of injury (averaging 33% versus 13% in others; P= 0.0006). This elevation in the PPC in the acute period after severe TBI likely represents a shunting of substrate into alternative biochemical pathways that may be critical for preventing secondary injury and initiating recovery.	Univ Calif Los Angeles, Med Ctr, Div Neurosurg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Med Ctr, Cerebral Blood Flow Lab, Los Angeles, CA 90095 USA; Harbor UCLA Med Ctr, Div Endocrinol, Torrance, CA 90509 USA; Los Angeles Biomed Res Inst, Torrance, CA 90509 USA; Univ Calif Los Angeles, Div Neurosurg, Los Angeles, CA USA; Univ Calif Los Angeles, Brain Injury Res Ctr, Los Angeles, CA USA		Glenn, TC (corresponding author), Univ Calif Los Angeles, Med Ctr, Div Neurosurg, 10833 Le Conte Ave,Room 18-265 NPI,Mail Code 7039, Los Angeles, CA 90095 USA.	t-lenn@mednet.ucla.edu		Martin, Neil/0000-0002-6565-4131; Glenn, Thomas/0000-0003-4273-3408	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [NINDS 30308] Funding Source: Medline		Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; BAQUER NZ, 1988, CURR TOP CELL REGUL, V29, P265; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; BEACONSFIELD PETER, 1963, LIFE SCI, V7, P459; BENYOSEPH O, 1995, J NEUROCHEM, V64, P1336; BenYoseph O, 1996, J NEUROCHEM, V66, P2329; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Boros LG, 2002, DRUG DISCOV TODAY, V7, P364, DOI 10.1016/S1359-6446(02)02179-7; DIPIETRO DAVID, 1959, ARCH BIOCHEM AND BIOPHYS, V80, P268, DOI 10.1016/0003-9861(59)90251-6; GAITONDE MK, 1983, J NEUROCHEM, V41, P1253, DOI 10.1111/j.1471-4159.1983.tb00819.x; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Gruetter R, 2002, NEUROCHEM INT, V41, P143, DOI 10.1016/S0197-0186(02)00034-7; GUERRA RM, 1967, BIOCHIM BIOPHYS ACTA, V148, P356, DOI 10.1016/0304-4165(67)90131-6; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; HARKONEN MH, 1974, BRAIN RES, V65, P141, DOI 10.1016/0006-8993(74)90341-2; HOSTETLE.KY, 1970, J NEUROCHEM, V17, P33, DOI 10.1111/j.1471-4159.1970.tb00499.x; HOSTETLE.KY, 1967, BIOCHEMISTRY-US, V6, P2961, DOI 10.1021/bi00862a001; HOTHERSALL JS, 1982, J NEUROCHEM, V39, P1325, DOI 10.1111/j.1471-4159.1982.tb12574.x; Hovda D.A., 1996, NEUROTRAUMA, P1459; HOVDA DA, 1992, J NEUROTRAUMA S1, V9, P47; Hyder F, 1996, P NATL ACAD SCI USA, V93, P7612, DOI 10.1073/pnas.93.15.7612; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; Kaibara T, 1999, J NEUROSURG, V90, P339, DOI 10.3171/jns.1999.90.2.0339; KATZ J, 1989, J BIOL CHEM, V264, P12994; KATZ J, 1960, J BIOL CHEM, V235, P2165; KRASS ME, 1967, IOCH BIOPHYS ACTA, V148, P384; LEE WNP, 1991, BIOL MASS SPECTROM, V20, P451, DOI 10.1002/bms.1200200804; Lee WNP, 1996, DEV NEUROSCI-BASEL, V18, P469, DOI 10.1159/000111442; Lee WNP, 1998, AM J PHYSIOL-ENDOC M, V274, pE843, DOI 10.1152/ajpendo.1998.274.5.E843; LEHNINGER AL, 2005, LEHNINGER PRINCIPLES, P549; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Otori T, 2004, J NEUROTRAUM, V21, P707, DOI 10.1089/0897715041269623; Ross B, 2003, NMR BIOMED, V16, P358, DOI 10.1002/nbm.852; Rothman DL, 2003, ANNU REV PHYSIOL, V65, P401, DOI 10.1146/annurev.physiol.65.092101.142131; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Soustiel JF, 2005, J NEUROTRAUM, V22, P955, DOI 10.1089/neu.2005.22.955; TSERNG KY, 1984, ANAL CHEM, V56, P517, DOI 10.1021/ac00267a049; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF	42	84	85	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2007	27	9					1593	1602		10.1038/sj.jcbfm.9600458			10	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	202ZY	WOS:000248946100007	17293841	Bronze			2022-02-06	
J	O'Connor, CA; Cernak, I; Johnson, F; Vink, R				O'Connor, Christine A.; Cernak, Ibolja; Johnson, Felicity; Vink, Robert			Effects of progesterone on neurologic and morphologic outcome following diffuse traumatic brain injury in rats	EXPERIMENTAL NEUROLOGY			English	Article						hormone; neurotrauma; progesterone; traumatic brain injury; gender	AMYLOID PRECURSOR PROTEIN; NEUROTROPHIC FACTOR; SPINAL-CORD; GENDER-DIFFERENCES; SEX-HORMONES; BLOOD-FLOW; ESTROGEN; EDEMA; EPIDEMIOLOGY; CONTUSION	Previous studies have identified that progesterone may be neuroprotective following traumatic brain injury (TBI). However, most of these have utilized models of TBI that produce a focal lesion or a significant ischemic component, neither of which is necessarily present in diffuse TBI. The current study uses a model of diffuse TBI in rats to examine the effects of progesterone on morphological changes and functional outcome following TBI. Male and ovariectomized female rats were subject to severe impact-acceleration injury under halothane anesthesia. After injury, animals were given a physiological, subcutaneous dose of progesterone (1.67 mg/kg) or equal volume of vehicle (sesame oil) daily throughout a 9-day neurologic assessment period where functional outcome was assessed using the rotarod and Barnes maze tests. There was a similar postinjury performance of male and ovariectomized female animals. Post-injury administration of progesterone improved the motor and cognitive performance of ovariectomized and male animals compared to vehicle-treated controls. Morphological differences between these animals, such as dark cell change, caspase-3 and APP immunoreactivity, were also investigated. Progesterone-treated males showed comparatively less dead or dying neurons, and marked attenuation of caspase-3 immunoreactivity. Both ovariectomized female and male animals treated with progesterone showed a profound reduction in axonal injury (seen via diminished APP immunoreactivity) when compared to controls. We conclude that physiological concentrations of progesterone administered after diffuse TBI confers beneficial effects on morphologic and functional outcome in both ovariectomized female and male animals. (C) 2007 Elsevier Inc. All rights reserved.	Univ Adelaide, Discipline Pathol, Adelaide, SA 5005, Australia; Johns Hopkins Univ, Appl Phys Lab, Laurel, MD 20732 USA		Vink, R (corresponding author), Univ Adelaide, Discipline Pathol, Adelaide, SA 5005, Australia.	christine.o'connor@adelaide.edu.au; ibolja.cernak@hjhuapl.edu; felicity.johnson@adelaide.edu.au; Robert.Vink@adelaide.edu.au	Vink, Robert/S-5616-2019; Vink, Robert/J-7351-2012	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Ibolja, Cernak/0000-0003-3214-698X			Asbury ET, 1998, BEHAV BRAIN RES, V97, P99, DOI 10.1016/S0166-4328(98)00031-X; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Ciriza I, 2006, J NEUROBIOL, V66, P916, DOI 10.1002/neu.20293; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Duval P, 1998, J NEUROENDOCRINOL, V10, P823; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Franklin TB, 2006, PSYCHONEUROENDOCRINO, V31, P38, DOI 10.1016/j.psyneuen.2005.05.008; Gibbs RB, 1999, BRAIN RES, V844, P20, DOI 10.1016/S0006-8993(99)01880-6; Gibbs RB, 1998, BRAIN RES, V810, P294; Gonzalez SL, 2005, J STEROID BIOCHEM, V94, P143, DOI 10.1016/j.jsbmb.2005.01.016; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Grossman KJ, 2000, BEHAV BRAIN RES, V116, P141, DOI 10.1016/S0166-4328(00)00275-8; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; Hillier SL, 1997, BRAIN INJURY, V11, P649; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; Kahveci FS, 2001, SURG NEUROL, V56, P206, DOI 10.1016/S0090-3019(01)00555-9; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Lockhart EM, 2002, NEUROSCI LETT, V328, P33, DOI 10.1016/S0304-3940(02)00448-2; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Muneyyirci-Delale O, 1999, FERTIL STERIL, V72, P817, DOI 10.1016/S0015-0282(99)00386-6; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; O'Connor CA, 2003, J NEUROTRAUM, V20, P533, DOI 10.1089/089771503767168465; OGATA T, 1993, NEUROSCIENCE, V55, P445, DOI 10.1016/0306-4522(93)90513-F; PEDAZAR J, 1997, MULTIPLE REGRESSION; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Roof RL, 1999, PHYSIOL BEHAV, V68, P81, DOI 10.1016/S0031-9384(99)00162-6; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Schumacher M, 2004, GROWTH HORM IGF RES, V14, pS18, DOI 10.1016/j.ghir.2004.03.007; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Vink R, 2000, FRONT BIOSCI, V5, pD656, DOI 10.2741/Vink; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656	44	84	86	0	13	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAY	2007	205	1					145	153		10.1016/j.expneurol.2007.01.034			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	166TO	WOS:000246403400017	17362936				2022-02-06	
J	Trivedi, MA; Ward, MA; Hess, TM; Gale, SD; Dempsey, RJ; Rowley, HA; Johnson, SC				Trivedi, Mehul A.; Ward, Michael A.; Hess, Timothy M.; Gale, Shawn D.; Dempsey, Robert J.; Rowley, Howard A.; Johnson, Sterling C.			Longitudinal changes in global brain volume between 79 and 409 days after traumatic brain injury: Relationship with duration of coma	JOURNAL OF NEUROTRAUMA			English	Article						brain volume change; injury severity; SIENA	ACCURATE; ATROPHY; MR	Neuropathological and experimental animal studies indicate that traumatic brain injury (TBI) results in long-term, neurodegenerative changes. Structural image evaluation using normalization of atrophy (SIENA) offers an automated analysis of the subtle changes in percent brain volume change (%BVC) associated with TBI. In the present study, SIENA was used to evaluate %BVC in individuals who had sustained a mild to severe TBI. We obtained three-dimensional (3D) TI-weighted anatomical magnetic resonance imaging (MRI) scans approximately 79 days and again 409 days post-injury. TBI patients (n = 37) displayed significantly greater decline in %BVC (-1.43%) relative to a normal comparison group (+0.1%, n = 30). Greater %BVC was associated with longer duration of post-injury coma. These results confirm previous findings from cross-sectional studies and argue that the brain undergoes continued structural change for several months post-injury.	William S Middleton Mem VA Hosp, GRECC, Madison, WI 53705 USA; Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI USA; Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI USA; Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurosurg, Madison, WI USA; Univ Wisconsin, Sch Med & Publ Hlth, Dept Radiol, Madison, WI USA; Barrow Neurol Inst, Dept Clin Neuropsychol, Phoenix, AZ 85013 USA		Johnson, SC (corresponding author), William S Middleton Mem VA Hosp, GRECC, 2500 Overlook Terrace,11G, Madison, WI 53705 USA.	scj@medicine.wisc.edu	Gale, Shawn/M-3144-2013	Gale, Shawn/0000-0002-8989-0964	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01 MH065723-05, R01 MH065723, R01 MH65723, R01 MH065723-06] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH065723] Funding Source: NIH RePORTER		BARTSCH AJ, BRAIN, V130, P36; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; Bigler E.D., 2005, TXB TRAUMATIC BRAIN, P79, DOI DOI 10.1007/S00417-005-0003-X; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; Enzinger C, 2005, NEUROLOGY, V64, P1704, DOI 10.1212/01.WNL.0000161871.83614.BB; GRAHAM DI, 2002, GREENFIELDS NEUROPAT, V1, P823; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Smith SM, 2002, NEUROIMAGE, V17, P479, DOI 10.1006/nimg.2002.1040; Smith SM, 2001, J COMPUT ASSIST TOMO, V25, P466, DOI 10.1097/00004728-200105000-00022; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046	13	84	85	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2007	24	5					766	771		10.1089/neu.2006.0205			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	167YT	WOS:000246489300002	17518532	Green Accepted			2022-02-06	
J	Tanriverdi, F; Unluhizarci, K; Coksevim, B; Selcuklu, A; Casanueva, FF; Kelestimur, F				Tanriverdi, Fatih; Unluhizarci, Kursad; Coksevim, Bekir; Selcuklu, Ahmed; Casanueva, Felipe F.; Kelestimur, Fahrettin			Kickboxing sport as a new cause of traumatic brain injury-mediated hypopituitarism	CLINICAL ENDOCRINOLOGY			English	Article							GROWTH-HORMONE GH; REPLACEMENT THERAPY; SUBARACHNOID HEMORRHAGE; PITUITARY DYSFUNCTION; DEFICIENT PATIENTS; SHEEHANS-SYNDROME; HIGH-RISK; ADULTS; CONCUSSION; EPIDEMIOLOGY	Objective Traumatic brain injury, which is a frequent and a worldwide important public health problem, may result in pituitary dysfunction. Concussion, a common type of lesion after traumatic brain injury, is an injury associated with sports including boxing and kickboxing. Kickboxing is one of the most popular martial arts and approximately 1-million people around the world participate in kickboxing sport. Head is the most common site of injury in amateur and professional kickboxers. Pituitary consequences of chronic repetitive head trauma in kickboxing have not been investigated until now. Therefore, the present study was designed to investigate the pituitary function in both retired and active amateur kickboxers. Patients and Design Twenty-two amateur kickboxers who have boxed in national and international championships (16 men, 6 women) with a mean age of 27.3 +/- 7.1 years, and 22 age- and sex-matched healthy controls were included in the study. Basal hormone levels were obtained from the participants. To assess GH-IGF-I axis, GHRH + GHRP-6 test and glucagon stimulation tests were used. Hypothalamo-pituitary-adrenal axis was assessed by glucagon stimulation test. Result When mean basal hormone levels were compared between kickboxers and the controls, IGF-I level was significantly lower in kickboxers (P < 0.05). Five (22.7%) and two (9.1%) of the 22 kickboxers had GH deficiency had ACTH deficiency, respectively. There were significant negative correlations between IGF-I levels and age, duration of sports and number of bouts (P < 0.05). Conclusions Present data clearly demonstrate for the first time that amateur kickboxing is a novel cause of hypopituitarism and kickboxers are at a risk for hypopituitarism especially isolated GH deficiency. Therefore, participants of the combative sports who were exposed to chronic repetitive head trauma need to be screened.	Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey; Erciyes Univ, Sch Med, Dept Physiol, Kayseri, Turkey; Erciyes Univ, Sch Med, Dept Neurosurg, Kayseri, Turkey; Dept Med, Div Endocrine, Santiago De Compostela, Galicia, Spain		Kelestimur, F (corresponding author), Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey.	fktimur@erciyes.edu.tr	kelestimur, f/ABE-9873-2021	Coksevim, Bekir/0000-0002-8637-071X			ABSTRACT R, 2005, GROWTH HORM IGF RES, V15, P349; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; AMATO G, 1993, J CLIN ENDOCR METAB, V77, P1671, DOI 10.1210/jc.77.6.1671; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; BIRRER RB, 1996, AM J SPORTS MED, V24, P72; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; BURKE CW, 1992, CLIN ENDOCRINOL, V36, P133, DOI 10.1111/j.1365-2265.1992.tb00946.x; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; CUNEO RC, 1992, CLIN ENDOCRINOL, V37, P387, DOI 10.1111/j.1365-2265.1992.tb02347.x; DEBOER H, 1994, METABOLISM, V43, P199, DOI 10.1016/0026-0495(94)90245-3; DICKSTEIN G, 1991, J CLIN ENDOCR METAB, V72, P773, DOI 10.1210/jcem-72-4-773; Dokmetas HS, 2000, J CLIN ENDOCR METAB, V85, P3713, DOI 10.1210/jc.85.10.3713; Gartland S, 2001, BRIT J SPORT MED, V35, P308, DOI 10.1136/bjsm.35.5.308; Gibney J, 1999, J CLIN ENDOCR METAB, V84, P2596, DOI 10.1210/jc.84.8.2596; Golgeli A, 2004, EUR J ENDOCRINOL, V150, P153, DOI 10.1530/eje.0.1500153; Gomez JM, 2002, CLIN ENDOCRINOL, V56, P329, DOI 10.1046/j.1365-2265.2002.01472.x; Hillier SL, 1997, BRAIN INJURY, V11, P649; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Kelestimur F, 2004, J ENDOCRINOL INVEST, V27, pRC28, DOI 10.1007/BF03345299; Kelestimur Fahrettin, 2005, Pituitary, V8, P259, DOI 10.1007/s11102-006-6051-3; Kelestimur F, 2006, CLIN ENDOCRINOL, V64, P667, DOI 10.1111/j.1365-2265.2006.02525.x; Kelestimur Fahrettin, 2003, Pituitary, V6, P181, DOI 10.1023/B:PITU.0000023425.20854.8e; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Lamberts SWJ, 1998, LANCET, V352, P127; Popovic V, 2000, LANCET, V356, P1137, DOI 10.1016/S0140-6736(00)02755-0; Powell JW, 2001, J ATHL TRAINING, V36, P307; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Servadei F, 2002, NEUROEPIDEMIOLOGY, V21, P297, DOI 10.1159/000065523; Shalet SM, 1998, ENDOCR REV, V19, P203, DOI 10.1210/er.19.2.203; Sonksen PH, 2001, J ENDOCRINOL, V170, P13, DOI 10.1677/joe.0.1700013; Tanriverdi F, 2005, GROWTH HORM IGF RES, V15, P231, DOI 10.1016/j.ghir.2005.03.005; Tanriverdi F, 2005, CLIN ENDOCRINOL, V62, P706, DOI 10.1111/j.1365-2265.2005.02283.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Zazryn TR, 2003, BRIT J SPORT MED, V37, P448, DOI 10.1136/bjsm.37.5.448; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52	39	84	86	0	26	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-0664	1365-2265		CLIN ENDOCRINOL	Clin. Endocrinol.	MAR	2007	66	3					360	366		10.1111/j.1365-2265.2006.02737.x			7	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	134UQ	WOS:000244110100008	17302869				2022-02-06	
J	Maniker, AH; Vaynman, AY; Karimi, RJ; Sabit, AO; Holland, B				Maniker, Allen H.; Vaynman, Artem Y.; Karimi, Reza J.; Sabit, Aria O.; Holland, Bart			Hemorrhagic complications of external ventricular drainage	NEUROSURGERY			English	Article						complications; drain; hematoma; intracerebral; ventricular	INTRACRANIAL-PRESSURE MONITORS; INTRACEREBRAL HEMORRHAGE; INTRAVENTRICULAR HEMORRHAGE; INFECTIOUS COMPLICATIONS; CEREBROSPINAL-FLUID; CONTROLLED-TRIAL; BLOOD-PRESSURE; DOUBLE-BLIND; HYDROCEPHALUS; VENTRICULOSTOMIES	OBJECTIVE: Despite the widespread use of external ventricular drainage (EVD), the frequency of associated hemorrhagic complications remains unclear. This retrospective study examined the frequency of hemorrhagic complications of EVD and attempted to discern associated risk factors. METHODS: Treatment records from 160 patients admitted during a 2.5-year period who required EVD placement were reviewed. Indications for placement of EVD included acute complications of cerebrovascular disease (n = 94), traumatic brain injury (n = 36), primary hydrocephalus (n = 16), and tumor (n =14). Patients received either a 3.0 or 2.5-mm outer diameter ventricular catheter (n = 82 and 78, respectively). Postinsertion computed tomographic scans were obtained within 24 hours on all patients and were analyzed for any new hemorrhage related to the ventricular catheter. Patient age, sex, catheter type, and dimensions of hemorrhage were also analyzed. RESULTS: The incidence of EVD-related hemorrhage was 33 +/- 0.04%. However, the incidence of detectable change in the clinical neurological examination was 2.5%. A significant proportion of EVD-related hemorrhages were small (< 4 CM), punctate, intraparenchymal hematomas. Patients with cerebrovascular exhibited an increased incidence (39%) of hemorrhage. The mean volume of intraparenchymal hemorrhage was larger in patients who received the 2.5-mm ventricular catheter, as well as those admitted for cerebrovascular disease. CONCLUSION: Hemorrhagic complications of EVD, placement are more common than previously suspected. Admitting diagnosis seems to have an effect on the development of an associated hemorrhage and its size. Catheter gauge has. an effect on hematoma volume. Most of the hemorrhages seen on, postinsertion computed tomographic scans do not cause detectable changes in the clinical examination.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Prevent Med & Community Hlth, Newark, NJ 07103 USA		Maniker, AH (corresponding author), Doctors Off Complex,90 Bergen St,8th Floor, Newark, NJ 07103 USA.	maniker@umdnj.edu					Anderson RCE, 2004, J NEUROSURG, V101, P53, DOI 10.3171/ped.2004.101.2.0053; AUCOIN PJ, 1986, AM J MED, V80, P369, DOI 10.1016/0002-9343(86)90708-4; Blaha M, 2003, PEDIATR NEUROSURG, V39, P27, DOI 10.1159/000070877; BLOMSTEDT GC, 1985, J NEUROSURG, V62, P694, DOI 10.3171/jns.1985.62.5.0694; Butcher K, 2003, J CLIN NEUROSCI, V10, P158, DOI 10.1016/S0967-5868(02)00324-7; CHAN KH, 1988, NEUROSURGERY, V23, P436, DOI 10.1227/00006123-198810000-00005; Forbes KP, 2003, NEURORADIOLOGY, V45, P363, DOI 10.1007/s00234-003-0995-z; Guyot LL, 1998, ACT NEUR S, V71, P47; Hader WJ, 2000, NEUROSURGERY, V46, P1149, DOI 10.1097/00006123-200005000-00025; Hoff JT, 2003, ACT NEUR S, V86, P11; KANTER RK, 1985, CRIT CARE MED, V13, P837, DOI 10.1097/00003246-198510000-00012; Khan SH, 1998, ACT NEUR S, V71, P50; KHANNA RK, 1995, J NEUROSURG, V83, P791, DOI 10.3171/jns.1995.83.5.0791; Lane PL, 2000, CAN J SURG, V43, P442; Lozier AP, 2002, NEUROSURGERY, V51, P170, DOI 10.1097/00006123-200207000-00024; Maitinez-Manas RM, 2000, J NEUROL NEUROSUR PS, V69, P82, DOI 10.1136/jnnp.69.1.82; Maruishi M, 2001, NEUROL MED-CHIR, V41, P300, DOI 10.2176/nmc.41.300; MAYFRANK L, 1994, ACTA NEUROCHIR, V126, P201; MAYFRANK L, 1993, ACTA NEUROCHIR, V122, P32, DOI 10.1007/BF01446983; Naff NJ, 2004, NEUROSURGERY, V54, P577, DOI 10.1227/01.NEU.0000108422.10842.60; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NORTH B, 1986, NEUROSURGERY, V18, P730, DOI 10.1227/00006123-198606000-00009; Pfausler B, 2004, ACTA NEUROCHIR, V146, P477, DOI 10.1007/s00701-004-0258-8; PIETS C, 1989, AM J CARDIOL, V63, pC40; Rasool AHG, 2004, J HUM HYPERTENS, V18, P187, DOI 10.1038/sj.jhh.1001647; RHODES TT, 1987, PEDIATR NEUROSCI, V13, P255, DOI 10.1159/000120339; Roitberg BZ, 2001, BRIT J NEUROSURG, V15, P324; Ross IB, 2003, AM J NEURORADIOL, V24, P1528; Rossi S, 1998, ACT NEUR S, V71, P91; Sumer MM, 2002, NEUROL SCI, V23, P29, DOI 10.1007/s100720200020; TOUHO H, 1991, Neurologia Medico-Chirurgica, V31, P396, DOI 10.2176/nmc.31.396; Whitehead WE, 2001, PEDIATR NEUROSURG, V35, P205, DOI 10.1159/000050422; Wiesmann M, 2001, J CLIN NEUROSCI, V8, P126, DOI 10.1054/jocn.2000.0749; WINFIELD JA, 1993, NEUROSURGERY, V33, P424; Zabramski JM, 2003, J NEUROSURG, V98, P725, DOI 10.3171/jns.2003.98.4.0725; Zhong J, 2003, NEUROL RES, V25, P339, DOI 10.1179/016164103101201661	36	84	85	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	OCT	2006	59	4		S			419	424		10.1227/01.NEU.0000222817.99752.E6			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	097AV	WOS:000241419500046					2022-02-06	
J	Yates, PJ; Williams, WH; Harris, A; Round, A; Jenkins, R				Yates, PJ; Williams, WH; Harris, A; Round, A; Jenkins, R			An epidemiological study of head injuries in a UK population attending an emergency department	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; RISK-FACTORS; ASSOCIATIONS; MORTALITY	We aimed to identify the attendance rate for all head injuries, and for moderate to severe head injury (MSHI), in an emergency department (ED), and related risk factors for MSHI, including age, sex, area of residence, and socioeconomic status (SES). This was a retrospective descriptive epidemiological study of an ED database of head injury attendances over 6 years, carried out in an ED that serves both urban and mixed rural and urban areas, with a wide socioeconomic range, and a total population of 344 600. The main outcome measure was rates of attendance for head injury. Head injury presentations accounted for 3.4% of all attendances per year. An overall rate of 453 per 100 000 was found for all head injuries, of which 40 per 100 000 were moderate to severe (10.9%). Urban residents had significantly greater risk of presenting with MSHI compared with residents of mixed/rural areas. Males were more at risk than females, and children and adolescents had higher risk of MSHI. A high attendance rate of MSHI was found in the 5 year old age group in urban areas for both sexes. A gradient, with higher attendance in groups with lower SES, was observed for children in urban areas, while the gradient was reversed in mixed/rural areas. Head injuries are a relatively common cause of attendance at ED. There is significant variation in attendance with MSHI with regard to sex, age, socioeconomic factors, and type of area of residence. The planning and delivery of preventative and management services may be improved by such analyses.	Univ Exeter, Sch Psychol, Ctr Clin Neuropsychol Res, Exeter EX4 4QG, Devon, England; Royal Devon & Exeter Hosp, NHS Fdn, Mardon Neurorehabil Ctr, Exeter EX2 5DW, Devon, England; Royal Devon & Exeter Hosp, NHS Fdn, Emergency Dept, Exeter EX2 5DW, Devon, England; Publ Hlth Directorate, E Devon PCT, Exeter, Devon, England; Publ Hlth Directorate, Mid Devon PCT, Exeter, Devon, England		Williams, WH (corresponding author), Univ Exeter, Sch Psychol, Ctr Clin Neuropsychol Res, Exeter EX4 4QG, Devon, England.	w.h.williams@ex.ac.uk		williams, huw/0000-0003-0670-2620			Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Deb S, 1999, BRAIN INJURY, V13, P369, DOI 10.1080/026990599121557; *DEP ENV TRANSP RE, 2000, IND MULT DEPR 2000 R; Dunn L, 2003, J NEUROL NEUROSUR PS, V74, P1060, DOI 10.1136/jnnp.74.8.1060; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Greenwood E, 2003, NAT REV CANCER, V3, P7, DOI 10.1038/nrc978; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; Lalloo R, 2003, INJURY, V34, P261, DOI 10.1016/S0020-1383(02)00277-2; Lyons RA, 2003, INJ PREV, V9, P33, DOI 10.1136/ip.9.1.33; *NHS CTR COD CLAS, 1996 HLTH SERV GUID; Roberts I, 1996, BRIT MED J, V313, P784; Stella J, 2001, ANZ J SURG, V71, P665, DOI 10.1046/j.1445-1433.2001.02229.x; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; TEASDALE G, 1974, LANCET, V2, P81; Tennant A, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-21; TENNANT A, 1996, TRAUMATIC BRAIN INJU; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Turner-Stokes L, 2005, J NEUROL NEUROSUR PS, V76, P901, DOI 10.1136/jnnp.2005.066472; Wagner AK, 2000, J TRAUMA, V49, P404, DOI 10.1097/00005373-200009000-00004; Wenden FJ, 1998, CLIN REHABIL, V12, P53, DOI 10.1191/026921598675567949; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774	25	84	85	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	2006	77	5					699	701		10.1136/jnnp.2005.081901			3	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	038QM	WOS:000237238000034	16464899	Green Published			2022-02-06	
J	Townend, W; Dibble, C; Abid, K; Vail, A; Sherwood, R; Lecky, F				Townend, W; Dibble, C; Abid, K; Vail, A; Sherwood, R; Lecky, F			Rapid elimination of protein S-100B from serum after minor head trauma	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; blood; clearance; craniocerebral trauma; half-life; mild traumatic brain injury; protein S-100B	BRAIN-INJURY; OUTCOME PREDICTION; CARDIAC-SURGERY; MARKER; S100B; DAMAGE; RELEASE	Protein S-100B is released into the circulation after traumatic brain injury, and its serum concentration relates to measures of injury severity and outcome. These properties have led to interest in its development as a marker for clinical use, particularly in the prediction of adverse outcome for those with apparently trivial injuries. Before it can be used in populations of patients with head injuries, however, more needs to be understood about its release and elimination. This study was designed to estimate the elimination half-life of S-100B from the circulation after minor head trauma. We studied 14 patients with minor head injuries and measured serum S-100B serially after initial assessment in the Emergency Department of an inner city teaching hospital. We used curve-fit analysis to estimate the elimination constant that best fitted our data, and from this estimated the elimination half-life of protein S-100B. We estimated the mean half-life in this setting to be 97 min (95% confidence interval [CI] of 75-136 min). S-100B is cleared rapidly, relative to the time elapsed between injury and initial assessment in the Emergency Department. Variation in the time elapsed between injury and sampling is likely to influence the accuracy of head injury outcome prediction based on S-100B concentrations in serum, and should he considered when designing future studies.	Hull Royal Infirm, Emergency Dept, Kingston Upon Hull HU3 2JZ, N Humberside, England; Hope Hosp, Salford M6 8HD, Lancs, England; Univ Manchester, Med Stat Grp, Manchester, Lancs, England; Kings Coll Hosp London, London, England		Townend, W (corresponding author), Hull Royal Infirm, Emergency Dept, Kingston Upon Hull HU3 2JZ, N Humberside, England.	William.Townend@hey.nhs.uk		Vail, Andy/0000-0001-8274-2726			Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; Blomquist S, 1997, J CARDIOTHOR VASC AN, V11, P699, DOI 10.1016/S1053-0770(97)90160-9; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Jackson RGM, 2000, CLIN CHEM LAB MED, V38, P1165, DOI 10.1515/CCLM.2000.179; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Jonsson H, 1999, ANN THORAC SURG, V68, P2202, DOI 10.1016/S0003-4975(99)00851-6; Li Ning, 2004, Chin J Traumatol, V7, P156; Pelinka LE, 2004, SHOCK, V21, P72, DOI 10.1097/01.shk.0000101672.49265.14; Pelinka LE, 2003, BRIT J ANAESTH, V91, P595, DOI 10.1093/bja/aeg225; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Raabe A, 2000, NEUROSURG REV, V23, P136, DOI 10.1007/PL00011944; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Rothoerl RD, 1999, BRAIN INJURY, V13, P387; Rothoerl RD, 2000, ACT NEUR S, V76, P97; Sapsed-Byrne S, 1997, PERFUSION-UK, V12, P167, DOI 10.1177/026765919701200304; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Stranjalis G, 2004, J NEUROTRAUM, V21, P1070, DOI 10.1089/0897715041651088; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; USUI A, 1989, CLIN CHEM, V35, P1942; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Woertgen C, 2002, BRAIN INJURY, V16, P807, DOI 10.1080/02699050210128933	25	84	85	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2006	23	2					149	155		10.1089/neu.2006.23.149			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	020HX	WOS:000235900600004	16503799				2022-02-06	
J	Ziino, C; Ponsford, J				Ziino, C; Ponsford, J			Measurement and prediction of subjective fatigue following traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						fatigue; closed head injuries; brain injuries; depression; anxiety	OUTCOME FOLLOWING MODERATE; HEAD-INJURY; MULTIPLE-SCLEROSIS; DOUBLE-BLIND; CANCER-PATIENTS; DEPRESSION; SLEEP; SCALE; PREVALENCE; SEVERITY	Numerous outcome studies have found fatigue to be a common problem following traumatic brain injury (TBI). This study examined the magnitude, causes and impact of fatigue following TBI using three subjective fatigue scales, and investigated its relationship with demographic and injury-related factors, and mood. Forty-nine controls and 49 TBI participants (36.2% with GCS score of 13-15, 29.8% with GCS score of 9-12, and 34% with GCS score of 3-8) were seen at a mean of approximately 8 months post injury. All participants completed three subjective fatigue measures, including the Fatigue Severity Scale (FSS), Visual Analogue Scale-Fatigue (VAS-F) and Causes of Fatigue Questionnaire (COF). TBI participants reported a significantly greater impact of fatigue on their lifestyle on the FSS relative to controls, and reported activities requiring physical and mental effort as more frequent causes of fatigue on the COF. There were, however, no significant group differences on subscales of the VAS-F. Greater time since injury and higher education levels were associated with higher fatigue levels, independent of the effects of mood. Injury severity and age were not found to be significant predictors of subjective fatigue severity in TBI participants.	Monash Univ, Dept Psychol, Clayton, Vic 3800, Australia; Monash Epworth Rehabil Res Ctr, Clayton, Vic 3800, Australia		Ziino, C (corresponding author), Monash Univ, Dept Psychol, POB 17, Clayton, Vic 3800, Australia.	Carlo.Ziino@med.monash.edu.au					Aaronson L S, 1999, Image J Nurs Sch, V31, P45; Aaronson LS, 2003, WESTERN J NURS RES, V25, P419, DOI 10.1177/0193945903025004007; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Beenen LFM, 1999, J NEUROL NEUROSUR PS, V67, P474, DOI 10.1136/jnnp.67.4.474; BELZA BL, 1993, NURS RES, V42, P93; Bensing JM, 1999, MED CARE, V37, P1078, DOI 10.1097/00005650-199910000-00011; Bruce IN, 1999, ANN RHEUM DIS, V58, P379, DOI 10.1136/ard.58.6.379; Caci H, 2003, PSYCHIAT RES, V118, P89, DOI 10.1016/S0165-1781(03)00044-1; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; Cooke KM, 1998, J BEHAV MED, V21, P103, DOI 10.1023/A:1018719722614; De Vries J, 2003, OCCUP ENVIRON MED, V60, P10; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Ettinger AB, 1998, J EPILEPSY, V11, P105, DOI 10.1016/S0896-6974(97)00139-4; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Ferraccioli G, 1996, J RHEUMATOL, V23, P1539; Fishbain DA, 2003, PAIN MED, V4, P51, DOI 10.1046/j.1526-4637.2003.03008.x; FISK JD, 1994, CLIN INFECT DIS, V18, pS79, DOI 10.1093/clinids/18.Supplement_1.S79; Fleming J, 1999, BRAIN INJURY, V13, P417; FUHRER R, 1995, PSYCHOL MED, V25, P895, DOI 10.1017/S0033291700037387; Gaudino EA, 1997, ARCH NEUROL-CHICAGO, V54, P1372, DOI 10.1001/archneur.1997.00550230045015; GIBSON H, 1985, SPORTS MED, V2, P120, DOI 10.2165/00007256-198502020-00004; Hann DM, 1998, QUAL LIFE RES, V7, P301, DOI 10.1023/A:1008842517972; Harter M, 2001, DISABIL REHABIL, V23, P737; Hayashi M, 1999, CLIN NEUROPHYSIOL, V110, P272, DOI 10.1016/S1388-2457(98)00003-0; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Herlofson K, 2002, EUR J NEUROL, V9, P595, DOI 10.1046/j.1468-1331.2002.00444.x; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; HILL B, 2001, INN REH C MELB AUSTR; JONES RK, 1974, SURG NEUROL, V2, P101; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; KRUPP LB, 1995, NEUROLOGY, V45, P1956, DOI 10.1212/WNL.45.11.1956; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Lavidor M, 2003, BRIT J HEALTH PSYCH, V8, P95, DOI 10.1348/135910703762879237; LEE KA, 1991, PSYCHIAT RES, V36, P291, DOI 10.1016/0165-1781(91)90027-M; LEWIS G, 1992, J EPIDEMIOL COMMUN H, V46, P92, DOI 10.1136/jech.46.2.92; Lichstein KL, 1997, BEHAV RES THER, V35, P733, DOI 10.1016/S0005-7967(97)00029-6; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; MCNAIR DM, 1981, EDITS MANUAL PROFILE; Meek PM, 2000, NURS RES, V49, P181, DOI 10.1097/00006199-200007000-00001; Mendoza TR, 1999, CANCER-AM CANCER SOC, V85, P1186, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; *MIMS AUSTR, 2004, 2004 MIMS ANN; Morriss RK, 1997, J PSYCHOSOM RES, V42, P597, DOI 10.1016/S0022-3999(97)89895-9; Nelson H.E., 1991, NATL ADULT READING T, V2nd ed.; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PAWLIKOWSKA T, 1994, BRIT MED J, V308, P763, DOI 10.1136/bmj.308.6931.763; Piper B.F., 1989, KEY ASPECTS COMFORT, P199; PIPER BF, 1989, KEY ASPECTS COMFORT, P197; Pollina DA, 1998, J NEUROPSYCH CLIN N, V10, P338, DOI 10.1176/jnp.10.3.338; PONSFORD J, 1995, TRAUMATIC BRAIN INJU, P1; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Rammohan KW, 2002, J NEUROL NEUROSUR PS, V72, P179, DOI 10.1136/jnnp.72.2.179; Ream E, 1996, INT J NURS STUD, V33, P519, DOI 10.1016/0020-7489(96)00004-1; Reyes-Gibby CC, 2003, PAIN MED, V4, P231, DOI 10.1046/j.1526-4637.2003.03033.x; RIDSDALE L, 1993, BMJ-BRIT MED J, V307, P103, DOI 10.1136/bmj.307.6896.103; Salinsky MC, 1996, EPILEPSIA, V37, P181, DOI 10.1111/j.1528-1157.1996.tb00010.x; SCHWARTZ JE, 1993, J PSYCHOSOM RES, V37, P753, DOI 10.1016/0022-3999(93)90104-N; Schwartz TL, 2004, J CLIN PSYCHIAT, V65, P1223, DOI 10.4088/JCP.v65n0910; Schwarz R, 2003, ONKOLOGIE, V26, P140, DOI 10.1159/000069834; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; SMETS EMA, 1993, BRIT J CANCER, V68, P220, DOI 10.1038/bjc.1993.319; Snaith R., 1994, HOSP ANXIETY DEPRESS; Spigset O, 1999, DRUG SAFETY, V20, P277, DOI 10.2165/00002018-199920030-00007; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Tench CM, 2000, RHEUMATOLOGY, V39, P1249, DOI 10.1093/rheumatology/39.11.1249; Tench CM, 2003, RHEUMATOLOGY, V42, P1050, DOI 10.1093/rheumatology/keg289; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1; Wade A, 2003, INT CLIN PSYCHOPHARM, V18, P133, DOI 10.1097/01.yic.0000068045.82050.00; WALKER GC, 1991, ARCH PHYS MED REHAB, V72, P469; WESSELY S, 1995, LANCET, V345, P1333, DOI 10.1016/S0140-6736(95)92537-6; Winstead-Fry P, 1998, J Nurs Meas, V6, P111	82	84	85	0	14	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2005	11	4					416	425		10.1017/S1355617705050472			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	948UY	WOS:000230742400009	16209422				2022-02-06	
J	Fleming, JM; Shum, D; Strong, J; Lightbody, S				Fleming, JM; Shum, D; Strong, J; Lightbody, S			Prospective memory rehabilitation for adults with traumatic brain injury: A compensatory training programme	BRAIN INJURY			English	Article							EVERYDAY MEMORY; SELF-AWARENESS; REMEDIATION	Primary objective: To describe a prospective memory rehabilitation programme based on a compensatory training approach and report the results of three case studies. Research design: Programme evaluation using pre-and post-intervention assessments and telephone follow-up. Methods and procedures: Three participants with traumatic brain injury completed 8 weeks of training with 1 - 2 hour individual sessions. Assessments were formal prospective memory assessment, self-report and measures of diary use. Experimental interventions: Intervention aimed to identify potential barriers, establish self-awareness of memory deficits, introduce a customized compensatory tool, a cueing system and organizational strategies. A significant other was involved in training to assist generalization. Main outcomes and results: All three participants improved on formal prospective memory assessment and demonstrated successful diary use after the programme. Self-report of prospective memory failure fluctuated and may reflect increased self-awareness. Conclusion: A compensatory approach may be useful in improving prospective memory performance following TBI.	Univ Queensland, Sch Hlth & Rehab Sci, Dept Occupat Therapy, Brisbane, Qld 4072, Australia; Princess Alexandra Hosp, Brisbane, Qld 4102, Australia; Griffith Univ, Brisbane, Qld 4111, Australia		Fleming, JM (corresponding author), Univ Queensland, Sch Hlth & Rehab Sci, Dept Occupat Therapy, Brisbane, Qld 4072, Australia.	j.fleming@mailbox.uq.edu.au	Shum, David/A-3914-2008; Fleming, Jennifer M/B-4436-2011; Strong, Jenny/F-1211-2010	Shum, David/0000-0002-4810-9262; Strong, Jenny/0000-0002-9367-8755			BURKE JM, 1994, BRAIN INJURY, V8, P71, DOI 10.3109/02699059409150960; Camp C. J., 1990, AGING COGNITION MENT, P231; Cappa SF, 2003, EUR J NEUROL, V10, P11, DOI 10.1046/j.1468-1331.2003.00537.x; COCKBURN J, 1995, CORTEX, V31, P87, DOI 10.1016/S0010-9452(13)80107-4; Cockburn J., 1996, PROSPECTIVE MEMORY T, P327; EINSTEIN GO, 1996, PROSPECTIVE MEMORY T, P116; Ellis J, 2000, APPL COGNITIVE PSYCH, V14, pS1, DOI 10.1002/acp.767; FLEMING J, IN PRESS CANADIAN J; Fleming JM, 1996, BRAIN INJURY, V10, P1; GLISKY EL, 1996, PROSPECTIVE MEMORY T, P249; Hannon R, 1995, REHABIL PSYCHOL, V40, P289, DOI 10.1037/0090-5550.40.4.289; Hutchinson J, 1997, TOP LANG DISORD, V18, P45, DOI 10.1097/00011363-199711000-00006; KAPUR N, 1995, HDB MEMORY DISORDERS, P533; Kim HJ, 2000, BRAIN INJURY, V14, P187, DOI 10.1080/026990500120844; Kinch J., 2001, BRAIN IMPAIR, V2, P119, DOI [10.1375/brim.2.2.119, DOI 10.1375/BRIM.2.2.119]; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; LYNCH WJ, 1995, J HEAD TRAUMA REHAB, V10, P94, DOI 10.1097/00001199-199502000-00011; Neulinger K., 2002, BRAIN IMPAIR, V3, P1, DOI [10.1375/brim.3.1.1, DOI 10.1375/BRIM.3.1.1]; Ownsworth TL, 2000, CLIN NEUROPSYCHOL, V14, P76, DOI 10.1076/1385-4046(200002)14:1;1-8;FT076; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; Raskin SA, 1996, J HEAD TRAUMA REHAB, V11, P32, DOI 10.1097/00001199-199606000-00007; RASKIN SA, UNPUB MEMORY INTENTI; Raymond MJ, 1996, J COGNITIVE REHABILI, V14, P18; Roche NL, 2002, BRAIN INJURY, V16, P931, DOI 10.1080/02699050210138581; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; SHUM D, 2002, P INT NEUR SOC 13 AN; SOHLBERG M M, 1992, Brain Injury, V6, P129, DOI 10.3109/02699059209029651; SOHLBERG M M, 1992, Brain Injury, V6, P139, DOI 10.3109/02699059209029652; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; Sohlberg MM, 1996, J HEAD TRAUMA REHAB, V11, P65, DOI 10.1097/00001199-199604000-00007; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; Strong J., 1995, BRIT J OCCUPATIONAL, V58, P55; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Toglia JP, 1998, COGNITION AND OCCUPATION IN REHABILITATION, P5; van den Broek MD, 2000, BRAIN INJURY, V14, P455; WAUGH N, 1999, UNPUB SELF REPORT YO; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; WILSON BA, 1995, HDB MEMORY DISORDERS, P451; Winograd E., 1988, PRACTICAL ASPECTS ME, V1, P348; ZENICUS A, 1991, BRAIN INJURY, V5, P369	41	84	92	0	40	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2005	19	1					1	10		10.1080/02699050410001720059			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	875AS	WOS:000225392600001	15762096				2022-02-06	
J	Van Loo, MA; Moseley, AM; Bosman, JM; De Bie, RA; Hassett, L				Van Loo, MA; Moseley, AM; Bosman, JM; De Bie, RA; Hassett, L			Test-re-test reliability of walking speed, step length and step width measurement after traumatic brain injury: a pilot study	BRAIN INJURY			English	Article							INTERRATER RELIABILITY; CONCURRENT VALIDITY; PERFORMANCE; ADULTS; GAIT	Primary objective: Assess the test-re-test reliability of walking speed, step length and step width measurement in people with traumatic brain injury (TBI). Research design: Repeated measures (two test occasions). Methods: Thirteen people with TBI completed four comfortable and four fast-paced walking trials of the 10 m walk test and two trials of the 6-minute walk test (6MWT). Walking speed, step length and step width were measured during the 10 m walk test and walking distance and average speed were measured during the 6MWT. The tests were repeated 1-week later. Main results: Walking speed and distance showed excellent test-re-test reliability, with an intra-class correlation coefficient (ICC) of 0.95-0.96. Reliability was also high for step length and width measurement (ICC 0.91-0.98). Conclusions: This test-re-test reliability means that walking speed and distance and step length and width can be used by physiotherapists to monitor improvements in walking after TBI.	Univ Sydney, Fac Med, Rehabil Studies Unit, Ryde, NSW 1680, Australia; Maastricht Univ, Maastricht, Netherlands; Liverpool Hlth Serv, Brain Injury Rehabil Unit, Sydney, NSW, Australia		Moseley, AM (corresponding author), Univ Sydney, Fac Med, Rehabil Studies Unit, POB 6, Ryde, NSW 1680, Australia.	amoseley@mail.usyd.edu.au		Hassett, Leanne/0000-0002-3546-1822			Bohannon R W, 1992, Int J Rehabil Res, V15, P246, DOI 10.1097/00004356-199209000-00009; Bohannon RW, 1997, AGE AGEING, V26, P15, DOI 10.1093/ageing/26.1.15; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; Dean CM, 2001, CLIN REHABIL, V15, P415, DOI 10.1191/026921501678310216; Evans MD, 1997, ARCH PHYS MED REHAB, V78, P725, DOI 10.1016/S0003-9993(97)90080-0; Fleiss JL, 1986, DESIGN ANAL CLIN EXP, P7; Fransen M, 1997, PHYS THER, V77, P944, DOI 10.1093/ptj/77.9.944; Harada ND, 1999, ARCH PHYS MED REHAB, V80, P837, DOI 10.1016/S0003-9993(99)90236-8; King MB, 2000, PHYS THER, V80, P8, DOI 10.1093/ptj/80.1.8; King S, 1999, J RHEUMATOL, V26, P2233; MAYERSON NH, 1984, ARCH PHYS MED REHAB, V65, P92; MCGAVIN CR, 1976, BMJ-BRIT MED J, V1, P822, DOI 10.1136/bmj.1.6013.822; Montgomery PS, 1998, J AM GERIATR SOC, V46, P706, DOI 10.1111/j.1532-5415.1998.tb03804.x; Stevens D, 1999, AM J RESP CRIT CARE, V160, P1540, DOI 10.1164/ajrccm.160.5.9808139; van Loo M, 2003, CLIN REHABIL, V17, P775, DOI 10.1191/0269215503cr677oa; van Loo MA, 2003, DISABIL REHABIL, V25, P1195, DOI 10.1080/09638280310001599989; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; Wall JC, 2000, J ORTHOP SPORT PHYS, V30, P410, DOI 10.2519/jospt.2000.30.7.410; Watson MJ, 2002, PHYSIOTHERAPY, V88, P386, DOI [10.1016/S0031-9406(05)61264-3, DOI 10.1016/S0031-9406(05)61264-3, 10.1016/S0031_9406(05)61264_3]	19	84	86	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2004	18	10					1041	1048		10.1080/02699050410001672314			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	845LQ	WOS:000223244600007	15370902				2022-02-06	
J	Bull, R; Espy, KA; Senn, TE				Bull, R; Espy, KA; Senn, TE			A comparison of performance on the Towers of London and Hanoi in young children	JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY			English	Article						executive functions; inhibition; shifting; short-term memory; tower tasks; children	LEARNING-DISABLED READERS; EXECUTIVE FUNCTION TASKS; TRAUMATIC BRAIN-INJURY; WORKING-MEMORY; FRONTAL-LOBE; PRESCHOOL-CHILDREN; INDIVIDUAL-DIFFERENCES; PORTEUS MAZE; SYSTEM; INTELLIGENCE	Background: The Towers of London (TOL) and Hanoi (TOH) have been viewed as equivalent measures of planning and/or problem solving, although recent evidence in adults suggests that the underlying measurement characteristics of these two tasks may differ. As tower tasks are one of the few instruments that can be used to assess executive functioning in young children, the cognitive demands for both tasks merit further examination. Methods: The relation among tower tasks and those of shortterm memory, inhibition, and shifting ability were examined in a sample of 118 typically developing young children (M age - 4 years, 9 months, SD = 6 months). Half the children completed TOL and half completed TOH, with groups matched with respect to age, sex, and child vocabulary. Results: Whilst performance on a shifting task uniquely predicted TOH performance, none of the executive function measures were related to TOL performance after statistically controlling for the influence of baseline naming speed. For both tower tasks, performance on a shifting task contributed more strongly on complex trials that required more moves in the counter-intuitive direction relative to the end-state goal, whereas inhibition task performance only predicted performance on complex TOL trials. Conclusions: Successful tower task performance may be determined, at least at higher levels of complexity, by mental flexibility in this age range. However, overall the findings suggest that TOL and TOH are not interchangeable tasks even in young children, and more generally, raise methodological issues regarding the complex nature of executive function tasks.	Univ Aberdeen, Sch Psychol, Dept Psychol, Aberdeen AB24 2UB, Scotland; So Illinois Univ, Sch Med, Dept Family & Community Med, Carbondale, IL 62901 USA		Bull, R (corresponding author), Univ Aberdeen, Sch Psychol, Dept Psychol, William Guild Bldg, Aberdeen AB24 2UB, Scotland.	r.bull@abdn.ac.uk	Bull, Rebecca/A-7895-2008; Bull, Rebecca/AAC-4344-2020	Bull, Rebecca/0000-0003-3273-7202			Anderson M, 2001, J CHILD PSYCHOL PSYC, V42, P287, DOI 10.1017/S0021963001007016; Anderson P, 1996, CLIN NEUROPSYCHOL, V10, P54, DOI 10.1080/13854049608406663; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P319, DOI 10.1080/713755568; Baddeley Alan, 1996, Quarterly Journal of Experimental Psychology Section A Human Experimental Psychology, V49, P5, DOI 10.1080/027249896392784; Baker SC, 1996, NEUROPSYCHOLOGIA, V34, P515, DOI 10.1016/0028-3932(95)00133-6; Bishop DVM, 2001, J CHILD PSYCHOL PSYC, V42, P551, DOI 10.1111/1469-7610.00749; Bull R, 1999, DEV NEUROPSYCHOL, V15, P421, DOI 10.1080/87565649909540759; Bull R, 2001, DEV NEUROPSYCHOL, V19, P273, DOI 10.1207/S15326942DN1903_3; Carlin D, 2000, NEUROPSYCHOLOGIA, V38, P655, DOI 10.1016/S0028-3932(99)00102-5; Chase-Carmichael CA, 1999, CLIN NEUROPSYCHOL, V13, P405, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT405; Duncan J, 1996, COGNITIVE PSYCHOL, V30, P257, DOI 10.1006/cogp.1996.0008; Espy KA, 2002, CHILD NEUROPSYCHOL, V8, P83, DOI 10.1076/chin.8.2.83.8723; Espy KA, 1997, DEV NEUROPSYCHOL, V13, P495, DOI 10.1080/87565649709540690; Espy KA, 2001, CLIN NEUROPSYCHOL, V15, P46, DOI 10.1076/clin.15.1.46.1908; ESPY KA, IN PRESS DEV NEUROPS; Gathercole SE, 2000, BRIT J EDUC PSYCHOL, V70, P177, DOI 10.1348/000709900158047; GILHOOLY KJ, IN PRESS THINKING RE; GNYS JA, 1991, DEV NEUROPSYCHOL, V7, P487, DOI 10.1080/87565649109540507; GOEL V, 1995, NEUROPSYCHOLOGIA, V33, P623, DOI 10.1016/0028-3932(95)90866-P; Goel V, 2001, COGNITIVE SCI, V25, P287; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Humes GE, 1997, ASSESSMENT, V4, P249, DOI 10.1177/107319119700400305; Huttenlocher PR, 1997, J COMP NEUROL, V387, P167, DOI 10.1002/(SICI)1096-9861(19971020)387:2<167::AID-CNE1>3.0.CO;2-Z; Kail, 1977, PERSPECTIVES DEV MEM, V1, P3; Kemp, 1998, NEPSY DEV NEUROPSYCH; KINNEY HC, 1988, J NEUROPATH EXP NEUR, V47, P217, DOI 10.1097/00005072-198805000-00003; KLAHR D, 1994, MAC FDN MEN, P177; KLAHR D, 1981, COGNITIVE PSYCHOL, V13, P113, DOI 10.1016/0010-0285(81)90006-2; Klahr D., 1978, CHILDRENS THINKING W, P181; Krasnegor N.A., 1996, ATTENTION MEMORY EXE; KRIKORIAN R, 1994, J CLIN EXP NEUROPSYC, V16, P840, DOI 10.1080/01688639408402697; Levin HS, 2001, NEUROPSYCHOLOGY, V15, P557, DOI 10.1037//0894-4105.15.4.557; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; MORRIS RG, 1993, NEUROPSYCHOLOGIA, V31, P1367, DOI 10.1016/0028-3932(93)90104-8; Numminen H, 2001, RES DEV DISABIL, V22, P373, DOI 10.1016/S0891-4222(01)00078-6; OWEN AM, 1990, NEUROPSYCHOLOGIA, V28, P1021, DOI 10.1016/0028-3932(90)90137-D; Ozonoff S, 1999, J AUTISM DEV DISORD, V29, P171, DOI 10.1023/A:1023052913110; Pennington B., 1996, ATTENTION MEMORY EXE, P327; Pennington BF, 1997, AM J HUM GENET, V60, P13; Phillips LH, 1999, MEMORY, V7, P209, DOI 10.1080/741944066; Rabbitt P., 1997, METHODOLOGY FRONTAL; Rowe JB, 2001, NEUROPSYCHOLOGIA, V39, P315, DOI 10.1016/S0028-3932(00)00109-3; SENN TE, IN PRESS NEUROPSYCHO; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Shallice T, 1990, NEUROPSYCHOLOGY MENT; Shum D, 2000, BRAIN COGNITION, V44, P59; SIMON HA, 1975, COGNITIVE PSYCHOL, V7, P268, DOI 10.1016/0010-0285(75)90012-2; STUSS DT, 1992, BRAIN COGNITION, V20, P8, DOI 10.1016/0278-2626(92)90059-U; Swanson HL, 1996, J EXP CHILD PSYCHOL, V61, P242, DOI 10.1006/jecp.1996.0016; Swanson HL, 2000, INTELLIGENCE, V28, P1, DOI 10.1016/S0160-2896(99)00025-2; THATCHER RW, 1991, DEV NEUROPSYCHOL, V7, P397, DOI 10.1080/87565649109540500; van den Heuvel OA, 2003, NEUROIMAGE, V18, P367, DOI 10.1016/S1053-8119(02)00010-1; Wechsler, 1990, WECHSLER PRESCHOOL P; WELSH M, 1995, J GEN PSYCHOL, V122, P69, DOI 10.1080/00221309.1995.9921223; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; Welsh MC, 1999, BRAIN COGNITION, V41, P231, DOI 10.1006/brcg.1999.1123; WOODCOCK RW, 1989, WOODCOCK JOHNSON COG; [No title captured]	59	84	88	0	28	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9630	1469-7610		J CHILD PSYCHOL PSYC	J. Child Psychol. Psychiatry	MAY	2004	45	4					743	754		10.1111/j.1469-7610.2004.00268.x			12	Psychology, Developmental; Psychiatry; Psychology	Social Science Citation Index (SSCI)	Psychology; Psychiatry	826CB	WOS:000221805400009	15056306	Green Published			2022-02-06	
J	Whiteneck, G; Brooks, CA; Mellick, D; Harrison-Felix, C; Terrill, MS; Noble, K				Whiteneck, G; Brooks, CA; Mellick, D; Harrison-Felix, C; Terrill, MS; Noble, K			Population-based estimates of outcomes after hospitalization for traumatic brain injury in Colorado	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	State of the Science Conference	APR, 2002	Geroge Washington Univ, Washington, DC	Rehabilitat Res & Training Ctr, NIDRR	Geroge Washington Univ	brain injuries; outcomes research; population surveillance; rehabilitation	HEAD-INJURY; UNITED-STATES; SEVERITY; SYSTEM; REHABILITATION; VARIABLES; WORSE; MILD	Objective: To determine statewide, population-based outcomes of persons hospitalized with traumatic brain injury (TBI) at 1 year postinjury. Design: Follow-up Survey of a representative cohort. Setting: A statewide, population-based registry and follow-up system for persons hospitalized with TBI. Participants: A total of 1591 adult Coloradoans with moderate and severe injury oversampled, but weighted to be representative of persons hospitalized with TBI (1996-1999) who survived their injuries and completed follow-up telephone interviews at 1 year postinjury. Interventions: Not applicable. Main Outcome Measures: Checklists of symptoms and service utilization, the FIM instrument(TM). the Craig Handicap Assessment and Reporting Technique Short Form, a single-item quality of life (QOL) measure, and a needs assessment checklist. Results: Problematic outcomes occurring at 1 year postinjury included one third or more being bothered by fatigue. feeling irritable or grouchy, having headaches, and experiencing trouble sleeping more frequently than preinjury; 37% reported needing the assistance of another person in physical and/or cognitive activities of daily living; substantial participation restrictions were noted in areas of occupation (30%) and social integration (22%); and 29% responded that their QOL was only fair or poor. Negative outcomes were reported more frequently among individuals who were more severely injured, older, or female. Conclusions: Substantial percentages of people hospitalized with TBI in a population-based sample reported a variety of problematic outcomes at 1 year postinjury.	Craig Hosp, Res Dept, Englewood, CO 80113 USA		Brooks, CA (corresponding author), Craig Hosp, Res Dept, 3425 S Clarkson St, Englewood, CO 80113 USA.	cabrooks@craighospital.org					BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; Brooks CA, 1997, ARCH PHYS MED REHAB, V78, pS26, DOI 10.1016/S0003-9993(97)90152-0; Caplan B, 1996, J HEAD TRAUMA REHAB, V11, P1; Cifu DX, 1999, ARCH PHYS MED REHAB, V80, P85, DOI 10.1016/S0003-9993(99)90312-X; *CO DEP PUBL HLTH, 2002, INJ COL; Department of Health and Human Services [DHHS], 1989, FED INT HEAD INJ TAS; Dijkers M., 1991, J AM PARAPLEGIA SOC, V14, P85; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Fiedler RC, 2000, AM J PHYS MED REHAB, V79, P87, DOI 10.1097/00002060-200001000-00017; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Heinemann AW, 2002, ARCH PHYS MED REHAB, V83, P1052, DOI 10.1053/apmr.2002.34283; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MELLICK D, 1999, J REHABIL OUTCOMES, V3, P12; *NAT CTR HLTH STAT, 1998, HLTH US 1998; Rose A, 1993, J ENVIRON DEV, V2, P1; SELMAN U, 1993, ARCH PHYS MED REAHAB, V74, P61; Smith PM, 1996, ARCH PHYS MED REHAB, V77, P431, DOI 10.1016/S0003-9993(96)90029-5; Sosin DM, 1996, BRAIN INJURY, V10, P47; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Svenson JE, 2001, AM J EMERG MED, V19, P19, DOI 10.1053/ajem.2001.18041; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman D, 1999, TRAUMATIC BRAIN INJU, DOI http://www.cdc.gov/ncipc/tbi/tbi_congress/TBI_in_the_US.PDF; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Thurman DJ., 1995, GUIDELINES SURVEILLA; Uniform Data System for Medical Rehabilitation, 1993, GUID UN DAT SET MED; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; Whiteneck G, 2001, COLORADO TRAUMATIC B; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Whiteneck GG, 1992, GUIDE USE CHART CRAI; *WHO, 1986, INT CLASS DIS 9 REV; WILLER B, 1990, EPIDEMIOLOGY DISABIL; World Health Organization, 1993, INT CLASS IMP DIS HA; [No title captured]	38	84	84	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2004	85	4		2			S73	S81		10.1016/j.apmr.2003.08.107			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation; Sport Sciences	812FL	WOS:000220825300010	15083425				2022-02-06	
J	Rios, M; Perianez, JA; Munoz-Cespedes, JM				Rios, M; Perianez, JA; Munoz-Cespedes, JM			Attentional control and slowness of information processing after severe traumatic brain injury	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; CARD-SORTING-TEST; WORKING-MEMORY; REACTION-TIME; FOCUSED ATTENTION; PREFRONTAL CORTEX; TASK-PERFORMANCE; FRONTAL LESIONS; DEFICITS; DISORDERS	Attention is a basic cognitive function and a prerequisite for other cognitive processes and is frequently impaired after traumatic brain injury. In the present study, 29 severe traumatic brain injury patients and 30 control subjects completed a battery of three neuropsychological tests of attention (WCST, TMT, Stroop). The aim was to clarify the attentional mechanisms underlying tests performance and to explore the types of attentional impairment after severe traumatic brain injury. Significant differences were found between the control and clinical groups in almost all measures. However, some of these differences disappeared when the speed of information processing was controlled using covariance analysis. In addition, a factor analysis revealed a four-factor solution explaining 89.6% of the variance in the data, i.e. cognitive flexibility, speed of processing, interference and working memory. This result supports the view of at least four different subprocesses of attentional control underlie test performance and allows one to differentiate between high- and low-level processes. The implications for neuropsychological assessment and rehabilitation are discussed.	Univ Nacl Educ Distancia, Fac Psicol, Dept Psicol Basica 2, E-28040 Madrid, Spain; Univ Illes Balears, Dept Psychol, Palma de Mallorca, Spain; Beata Maria Ana Hosp, Brain Damage Unit, Madrid, Spain; Univ Complutense, Dept Basic Psychol 2, E-28040 Madrid, Spain		Rios, M (corresponding author), Univ Nacl Educ Distancia, Fac Psicol, Dept Psicol Basica 2, C Juan del Rosal 10, E-28040 Madrid, Spain.	mrios@psi.uned.es	Rios-Lago, Marcos/P-6930-2019; Perianez, Jose Antonio/AAI-3988-2021; Rios-Lago, Marcos/C-9568-2012	Rios-Lago, Marcos/0000-0003-0187-5047; Perianez, Jose Antonio/0000-0003-4310-4021; Rios-Lago, Marcos/0000-0003-0187-5047			ALLPORT A, 1993, ATTENTION PERFORM, V14, P182; Andres P, 2001, J CLIN EXP NEUROPSYC, V23, P225; Arbuthnott K, 2000, J CLIN EXP NEUROPSYC, V22, P518, DOI 10.1076/1380-3395(200008)22:4;1-0;FT518; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; AZOUVI P, 1995, J INT NEUROPSYCH SOC, V1, P213; Baddeley A, 2001, J EXP PSYCHOL GEN, V130, P641, DOI 10.1037//0096-3445.130.4.641; Baddeley AD, 2001, AM PSYCHOL, V56, P851, DOI 10.1037/0003-066X.56.11.851; BAKE AJ, 2001, CLIN NEUROPSYCHOL, V15, P405; Barcelo F, 2002, NEUROREPORT, V13, P1887, DOI 10.1097/00001756-200210280-00011; Barcelo F, 2000, NEUROPSYCHOLOGIA, V38, P1342, DOI 10.1016/S0028-3932(00)00046-4; Barcelo F, 1998, NEUROREPORT, V9, P747, DOI 10.1097/00001756-199803090-00034; Ben-Yishay Y., 1987, NEUROPSYCHOLOGICAL R, P165; Berti S, 2003, EUR J NEUROSCI, V17, P1119, DOI 10.1046/j.1460-9568.2003.02527.x; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Boone KB, 1998, ARCH CLIN NEUROPSYCH, V13, P585, DOI 10.1016/S0887-6177(97)00074-7; Fasotti L, 2000, NEUROPSYCHOL REHABIL, V10, P47, DOI 10.1080/096020100389291; Fernandez-Duque D, 2001, J CLIN EXP NEUROPSYC, V23, P74, DOI 10.1076/jcen.23.1.74.1217; Ferraro FR, 1996, BRAIN COGNITION, V32, P429, DOI 10.1006/brcg.1996.0075; Fristoe NM, 1997, NEUROPSYCHOLOGY, V11, P428, DOI 10.1037/0894-4105.11.3.428; Gennarelli, 1998, Semin Clin Neuropsychiatry, V3, P160; Godefroy O, 1996, BRAIN COGNITION, V30, P155, DOI 10.1006/brcg.1996.0010; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Greve KW, 2002, BRAIN INJURY, V16, P29, DOI 10.1080/0269905011008803; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Henik A, 1996, J Int Neuropsychol Soc, V2, P467; Kinsella GJ, 1998, NEUROPSYCHOL REHABIL, V8, P351, DOI 10.1080/713755576; Klenberg L, 2001, DEV NEUROPSYCHOL, V20, P407, DOI 10.1207/S15326942DN2001_6; Konishi S, 1999, CEREB CORTEX, V9, P745, DOI 10.1093/cercor/9.7.745; Koren D, 1998, NEUROPSYCHOLOGY, V12, P289, DOI 10.1037/0894-4105.12.2.289; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; Mateer CA, 1996, J HEAD TRAUMA REHAB, V11, P1; MILLER E, 1981, BRIT J CLIN PSYCHOL, V20, P69, DOI 10.1111/j.2044-8260.1981.tb00498.x; Milner B, 1963, ARCH NEUROL-CHICAGO, V9, P100, DOI DOI 10.1001/ARCHNEUR.1963.00460070100010; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; Monchi O, 2001, J NEUROSCI, V21, P7733, DOI 10.1523/JNEUROSCI.21-19-07733.2001; Munoz-Cespedes JM, 2001, REV NEUROLOGIA, V32, P351, DOI 10.33588/rn.3204.2000456; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; PICANO JJ, 1992, ARCH CLIN NEUROPSYCH, V7, P271, DOI 10.1016/0887-6177(92)90168-M; Pineda DA, 2000, REV NEUROLOGIA, V31, P1112, DOI 10.33588/rn.3112.2000417; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; RIST F, 1991, HDB SCHIZOPHRENIA, V5, P241; Robertson I. R., 1999, COGNITIVE NEUROREHAB, P302; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; Schmitter-Edgecombe M, 1996, J Int Neuropsychol Soc, V2, P111; SCHMITTEREDGECOMBE ME, 1992, J CLIN EXP NEUROPSYC, V14, P717, DOI 10.1080/01688639208402858; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shallice T., 1988, NEUROPSYCHOLOGY MENT; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; Simpson A, 2000, NEUROPSYCHOLOGY, V14, P310, DOI 10.1037//0894-4105.14.2.310; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sohlberg MM, 2001, ANN NY ACAD SCI, V931, P359; Spikman JM, 2001, BRAIN COGNITION, V47, P446, DOI 10.1006/brcg.2001.1320; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spikman JM, 2000, J CLIN EXP NEUROPSYC, V22, P325, DOI 10.1076/1380-3395(200006)22:3;1-V;FT325; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; Stevens J.P., 1992, APPL MULTIVARIATE ST, V2nd; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 2001, NEUROPSYCHOLOGIA, V39, P771, DOI 10.1016/S0028-3932(01)00013-6; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; TREXLER LE, 1988, BRAIN COGNITION, V8, P291, DOI 10.1016/0278-2626(88)90056-5; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; VELTMAN JC, 1996, NEUROPSYCHOLOGY, V10, P1; VILKKI J, 1992, J CLIN EXP NEUROPSYC, V14, P518, DOI 10.1080/01688639208402841; Wang LH, 2001, COGNITIVE BRAIN RES, V12, P19, DOI 10.1016/S0926-6410(01)00022-2; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; YELA M, 1968, REV PSICOLOGIA GEN A, V92, P313; ZAHN TP, 1991, J ABNORM CHILD PSYCH, V19, P233, DOI 10.1007/BF00909980; Zahn TP, 1999, J CLIN EXP NEUROPSYC, V21, P352, DOI 10.1076/jcen.21.3.352.924; Zoccolotti P, 2000, CORTEX, V36, P93, DOI 10.1016/S0010-9452(08)70839-6; [No title captured], DOI DOI 10.1016/S0079-7421(08)60452-1	80	84	85	0	16	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAR	2004	18	3					257	272		10.1080/02699050310001617442			16	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	763NH	WOS:000188091900003	14726285				2022-02-06	
J	Bazarian, JJ; Pope, C; McClung, J; Cheng, YT; Flesher, W				Bazarian, JJ; Pope, C; McClung, J; Cheng, YT; Flesher, W			Ethnic and racial disparities in emergency department care for mild traumatic brain injury	ACADEMIC EMERGENCY MEDICINE			English	Article; Proceedings Paper	5th World Congress on Traumatic Brain Injury	MAY, 2003	STOCKHOLM, SWEDEN			ethnic groups; African Americans; Hispanic Americans; whites; minority groups; brain injuries; brain concussion; emergency services	MINOR HEAD-INJURY; CARDIOVASCULAR PROCEDURES; RACE; HEALTH; SYMPTOMS; SEQUELAE; IMPACT; CHEMOTHERAPY; GENDER; RISK	Objectives: To identify racial, ethnic, and gender disparities in the emergency department (ED) care for mild traumatic brain injury (mTBI). Methods: A secondary analysis of ED visits in the National Hospital Ambulatory Medical Care Survey for the years 1998 through 2000 was performed. Cases of mTBI were identified using ICD-9 codes 800.0, 800.5, 850.9, 801.5, 803.0, 803.5, 804.0, 804.5, 850.0, 850.1, 850.5, 850.9, 854.0, and 959.01. ED care variables related to imaging, procedures, treatments, and disposition were analyzed along racial, ethnic, and gender categories. The relationship between race, ethnicity, and selected ED care variables was analyzed using multivariate logistic regression with control for associated injuries, geographic region, and insurance type. Results: The incidence of mTBI was highest among men (590/100,000), Native Americans/Alaska Natives (1026.2/100,000), and non-Hispanics (391.1/1.00,000). After controlling for important confounders, Hispanics were more likely than non-Hispanics to receive a nasogastric tube (OR, 6.36; 95% CI = 1.2 to 33.6); nonwhites were more likely to receive ED care by a resident (OR, 3.09; 95% CI = 1.9 to 5.0) and less likely to be sent back to the referring physician after ED discharge (OR, 0.47; 95% CI = 0.3 to 0.9). Men and women received equivalent ED care. Conclusions: There are significant racial and ethnic but not gender disparities in ED care for mTBI. The causes of these disparities and the relationship between these disparities and post-mTBI outcome need to be examined.	Univ Rochester, Med Ctr, Dept Emergency Med, Rochester, NY 14642 USA; Univ Rochester, Dept Community & Prevent Med, Rochester, NY 14642 USA; Hosp Max Peralta, San Jose, Costa Rica		Bazarian, JJ (corresponding author), Univ Rochester, Med Ctr, Dept Emergency Med, Box 655,601 Elmwood Ave, Rochester, NY 14642 USA.	jeff_bazarian@urmc.rochester.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1K23 NS4195-02] Funding Source: Medline		Bazarian J, 2000, BRAIN INJURY, V14, P285; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; BIJUR PE, 1990, PEDIATRICS, V86, P337; Blustein J, 1998, J HEALTH CARE POOR U, V9, P153; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; BRAVEMAN P, 1995, AM J PUBLIC HEALTH, V85, P625, DOI 10.2105/AJPH.85.5.625; Carlisle DM, 1997, AM J PUBLIC HEALTH, V87, P263, DOI 10.2105/AJPH.87.2.263; CASEY R, 1986, PEDIATRICS, V78, P497; Choi DMA, 2000, BRIT MED J, V320, P980, DOI 10.1136/bmj.320.7240.980; COONLEYHOGANSON R, 1984, NEUROSURGERY, V14, P315, DOI 10.1227/00006123-198403000-00009; Cooper-Patrick L, 1999, JAMA-J AM MED ASSOC, V282, P583, DOI 10.1001/jama.282.6.583; CORONADO V, 2002, COMMUNICATION; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Earle CC, 2002, J CLIN ONCOL, V20, P1786, DOI 10.1200/JCO.2002.07.142; Earle CC, 2000, CHEST, V117, P1239, DOI 10.1378/chest.117.5.1239; Einbinder LC, 2000, MED CARE RES REV, V57, P162; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Erickson F., 1982, COUNSELOR GATEKEEPER; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; FORD ES, 1995, HEALTH SERV RES, V30, P237; GORNICK ME, 2001, MINORITY HLTH TODAY, V2, P17; GUADAGNOLI E, 1995, NEW ENGL J MED, V333, P573, DOI 10.1056/NEJM199508313330908; Jackson PB, 1998, RES AGING, V20, P298, DOI 10.1177/0164027598203002; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Jay G W, 1996, J Insur Med, V27, P262; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Johnstone B, 2003, BRAIN INJURY, V17, P95, DOI 10.1080/0269905021000010212; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kaplan JB, 2003, JAMA-J AM MED ASSOC, V289, P2709, DOI 10.1001/jama.289.20.2709; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Klassen AC, 2002, AM J PUBLIC HEALTH, V92, P811, DOI 10.2105/AJPH.92.5.811; KRAUS JF, 2003, NEUROSURG FOCUS, V8; LaVeist TA, 2000, MED CARE RES REV, V57, P146, DOI 10.1177/107755800773743637; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; Maly RC, 2003, CANCER, V97, P1517, DOI 10.1002/cncr.11211; McKenzie K, 1999, INT REV PSYCHIATR, V11, P153, DOI 10.1080/09540269974320; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; MIROWSKY J, 1995, AM SOCIOL REV, V60, P449, DOI 10.2307/2096424; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; *NIH, 2002, NIH POL REP RAC ETHN; Oddone EZ, 1999, STROKE, V30, P1350, DOI 10.1161/01.STR.30.7.1350; PARKER RS, 1994, SEMIN NEUROL, V14, P67, DOI 10.1055/s-2008-1041061; PILOTE L, 1995, NEW ENGL J MED, V333, P565, DOI 10.1056/NEJM199508313330907; QUINTANA JM, 1997, INT J QUAL HEALTH C, V9, P101; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RUTHERFORD WH, 1977, LANCET, V1, P1; SAVILLETROIKE M, 1999, ETHNOGRAPHY COMMUNIC; Sehgal AR, 2003, JAMA-J AM MED ASSOC, V289, P996, DOI 10.1001/jama.289.8.996; Smedley BD, 2003, UNEQUAL TREATMENT CO, DOI DOI 10.17226/12875; Snowden LR, 2003, AM J PUBLIC HEALTH, V93, P239, DOI 10.2105/AJPH.93.2.239; STRAKOWSKI SM, 1995, J CLIN PSYCHIAT, V56, P101; THURMAN DJ, 1995, GUIDELINES SURVEILAN; TODD KH, 1993, JAMA-J AM MED ASSOC, V269, P1537, DOI 10.1001/jama.269.12.1537; *US DEP HHS, RESH HLTH MIN COMM U; van Ryn M, 2003, AM J PUBLIC HEALTH, V93, P248, DOI 10.2105/AJPH.93.2.248; Vazquez LA, 1997, HISPANIC J BEHAV SCI, V19, P377, DOI 10.1177/07399863970193009; Warner TD, 2002, J LEARN DISABIL-US, V35, P500; Waxman MA, 2000, ANN EMERG MED, V36, P456, DOI 10.1067/mem.2000.108315; Weech-Maldonado R, 2001, HEALTH SERV RES, V36, P575; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; Young BA, 2003, DIABETES CARE, V26, P495, DOI 10.2337/diacare.26.2.495	64	84	84	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	NOV	2003	10	11					1209	1217		10.1197/S1069-6563(03)00491-3			9	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Emergency Medicine	740WY	WOS:000186426300011	14597497				2022-02-06	
J	Geddes, DM; LaPlaca, MC; Cargill, RS				Geddes, DM; LaPlaca, MC; Cargill, RS			Susceptibility of hippocampal neurons to mechanically induced injury	EXPERIMENTAL NEUROLOGY			English	Article						neuron; selective vulnerability; TBI; stretch; cortex; hippocampus	TRAUMATIC BRAIN-INJURY; IN-VITRO MODEL; LONG-TERM POTENTIATION; D-ASPARTATE RECEPTORS; GLUTAMATE-RECEPTOR; CEREBRAL-ISCHEMIA; CORTICAL-NEURONS; CALCIUM RESPONSE; NEURAL TRAUMA; CA1 NEURONS	Experimental models of traumatic cortical brain injury in rodents reveal that specific regions of the hippocampus (e.g., CA3 and hilar subfields) are severely injured despite their distance from the initial insult. Hippocampal neurons may be intrinsically more vulnerable to mechanical insult than cortical neurons due to increased NMDA receptor densities and lower energy capacities, as evidenced by increased susceptibility to ischemic insults. The selective vulnerability of hippocampal neurons was evaluated using an in vitro model of TBI in which either primary rat cortical or hippocampal neurons (E17) seeded onto silicone substrates were subjected to graded levels of mechanical stretch. Although cortical neurons exhibited significantly longer increases in stretch-induced membrane permeability, injury of hippocampal neurons resulted in larger increases in intracellular free calcium concentration [Ca2+](i) and cell death. [ATP](i) deficits due to stretch were apparent by 60 min after injury in cortical neurons but recovered by 24 h, whereas significant deficits in [ATP](i) were not observed in hippocampal neurons until 24 It after injury. MK801 pretreatment decreased the stretch-induced [Ca2+](i) transients in both hippocampal and cortical cultures, thereby negating the regional specificity. However, MK801 pretreatment did not improve hippocampal viability and paradoxically, significantly increased cell death among cortical neurons. As the hippocampus is the primary brain region responsible for the memory deficits and epileptic seizures associated with TBI, understanding why this region is selectively damaged could lead to the development of more accurate mechanical tolerances as well as effective pharmaceutical agents. (C) 2003 Elsevier Science (USA). All rights reserved.	Exponent Failure Anal Associates Inc, Philadelphia, PA 19104 USA; Georgia Inst Technol, Sch Biomed Engn, Atlanta, GA 30332 USA		Cargill, RS (corresponding author), Exponent Failure Anal Associates Inc, 3401 Market St,Suite 300, Philadelphia, PA 19104 USA.	rcargill@exponent.com					Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.0741951.x; ARAKI T, 1989, ACTA NEUROL SCAND, V80, P548, DOI 10.1111/j.1600-0404.1989.tb03925.x; BENSON DL, 1994, J NEUROCYTOL, V23, P279, DOI 10.1007/BF01188497; Bernaudin M, 1998, EXP NEUROL, V150, P30, DOI 10.1006/exnr.1997.6728; Bi GQ, 1995, J CELL BIOL, V131, P1747, DOI 10.1083/jcb.131.6.1747; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; Cochran SA, 2001, ULTRASOUND MED BIOL, V27, P841, DOI 10.1016/S0301-5629(01)00382-9; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; DeLima AD, 1997, J COMP NEUROL, V388, P526; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; Gillardon F, 1999, NEUROSCIENCE, V93, P1219, DOI 10.1016/S0306-4522(99)00292-4; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guzman HR, 2001, J ACOUST SOC AM, V110, P597, DOI 10.1121/1.1376130; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Kovacs AD, 2001, EXP NEUROL, V168, P47, DOI 10.1006/exnr.2000.7576; Kuroiwa T, 2000, ACTA NEUROPATHOL, V100, P587, DOI 10.1007/s004010000235; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; LaPlaca MC, 1998, J NEUROSCI RES, V52, P220, DOI 10.1002/(SICI)1097-4547(19980415)52:2<220::AID-JNR10>3.0.CO;2-B; Li JH, 1998, EUR J NEUROSCI, V10, P1704, DOI 10.1046/j.1460-9568.1998.00169.x; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Mautes AEM, 2001, J MOL NEUROSCI, V16, P33, DOI 10.1385/JMN:16:1:33; MONAGHAN DT, 1986, P NATL ACAD SCI USA, V83, P7532, DOI 10.1073/pnas.83.19.7532; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Ohmori T, 1996, BRAIN RES, V743, P109, DOI 10.1016/S0006-8993(96)01034-7; Peng TI, 1998, MOL PHARMACOL, V53, P974; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; PYLOVA SI, 1989, BRAIN RES, V490, P170, DOI 10.1016/0006-8993(89)90446-0; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; Ross ST, 2000, J NEUROPHYSIOL, V83, P2916, DOI 10.1152/jn.2000.83.5.2916; Rzigalinski BA, 1997, J NEUROCHEM, V68, P289; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Shi R, 2002, NEUROSCIENCE, V110, P765, DOI 10.1016/S0306-4522(01)00596-6; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; STOJANOVIC T, 1988, METAB BRAIN DIS, V3, P265, DOI 10.1007/BF00999536; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Tang SL, 1997, J CHART INST WATER E, V11, P14; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767, DOI 10.1152/jn.1995.74.6.2767; Terasaki M, 1997, J CELL BIOL, V139, P63, DOI 10.1083/jcb.139.1.63; Togo T, 1999, J CELL SCI, V112, P719; Toth Z, 1997, J NEUROSCI, V17, P8106; Tovar KR, 1999, J NEUROSCI, V19, P4180; Tymianski M, 1996, NEUROSURGERY, V38, P1176; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Wenzel A, 1997, J NEUROCHEM, V68, P469; XIE XY, 1991, J NEUROSCI, V11, P3257; YAWO H, 1985, J NEUROSCI, V5, P1626	52	84	86	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	NOV	2003	184	1					420	427		10.1016/S0014-4886(03)00254-1			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	747KZ	WOS:000186804800043	14637111				2022-02-06	
J	Slomine, BS; Gerring, JP; Grados, MA; Vasa, R; Brady, KD; Christensen, JR; Denckla, MB				Slomine, BS; Gerring, JP; Grados, MA; Vasa, R; Brady, KD; Christensen, JR; Denckla, MB			Performance on measures of 'executive function' following pediatric traumatic brain injury	BRAIN INJURY			English	Article							FRONTAL-LOBE LESIONS; HEAD-INJURY; CHILDREN; ADOLESCENTS; TESTS; COGNITION; AMNESIA; DAMAGE; SCALE; COMA	Objective: To investigate the relationships among age at injury, neuroanatomic lesion location, and measures of executive function (EF) following paediatric traumatic brain injury (TBI). Methods: EF was assessed in 68 children (aged 7-15) with moderate-to-severe TBI 1 year post-injury. EF tests included: (1) Tower of Hanoi (TOH), a measure of problem solving ability, (2) Wisconsin Card Sorting Test (WCST), a measure of categorization and ability to shift cognitive strategies, (3) Letter Fluency (LF), a measure of novel lexical search and rule-governed word generation. EF variables included number of moves needed to achieve a 3-ring solution on the TOH, number of perseverative and non-perseverative errors on the WCST, and number of words generated on LF. Intellectual functioning was also assessed using the Verbal Intellectual Quotient (VIQ) from the Wechsler Intelligence Scale from Children-3rd edn (WISC-III). Data from standardized MRIs, performed at 3-months post-injury, were available for all subjects and were used to determine lesion location, lesion volumes, and total number of lesions. The relationships among EF, lesion variables (frontal lesion volume, extrafrontal lesion volume, total number of lesions) and age at injury were examined. Pre-injury special education services and attention deficit hyperactivity disorder (ADHD) were controlled for. Results: Younger age at injury was associated with more perseverative errors on the WCST and worse performance on LF. Frontal lesion volume was not predictive of performance on any measures of EF. Greater extrafrontal lesion volume and total number of lesions were predictive of worse performance on LF. When controlling for pre-injury special education placement and pre-injury ADHD, there was little change in the results. Conclusions: Younger age at injury places children at greater risk of impairment on measures of EF. Performance on measures of EF depends on brain variables other than frontal lobes including extrafrontal cortical brain areas and total number of lesions. The relationship between extrafrontal brain regions and EF suggests that domain-specific cognitive content (i.e. language or visuospatial analysis), mediated by the parietal or temporal lobes, may disrupt underlying cognitive processes necessary for successful performance on measures of EF. In addition, the association between total number of lesions and EF may be related to disconnections and disruption of frontal/subcortical systems.	Kennedy Inst, Dept Neuropsychol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA		Slomine, BS (corresponding author), Kennedy Inst, Dept Neuropsychol, 707 N Broadway, Baltimore, MD 21205 USA.	slomine@kennedykrieger.org		Grados, Marco/0000-0002-6189-6264	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD024061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20MH000997] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30 HD 24061] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20 MH-00997] Funding Source: Medline		American Psychiatric Association, 1987, DIAGN STAT MAN MENT, V3; Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; Archibald SJ, 1999, CHILD NEUROPSYCHOL, V5, P115, DOI 10.1076/chin.5.2.115.3167; Basso MR, 1999, CLIN NEUROPSYCHOL, V13, P283, DOI 10.1076/clin.13.3.283.1743; Benson D.F., 1986, FRONTAL LOBES; BLASTER DD, 1997, AM J NEURORADIOL, V18, P1; Cripe L., 1996, ECOLOGICAL VALIDITY, P171; Cummings JL, 1992, DEMENTIA CLIN APPROA; Delis DC., 2001, DELIS KAPLAN EXECUTI; Denckla M B, 1994, FRAMES REFERENCE ASS, P117; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; EWINGCOBBS L, 1998, TRAUMATIC BRAIN INJU, P11; Filley CM, 1999, NEUROPSY NEUROPSY BE, V12, P156; GADDES WH, 1975, BRAIN LANG, V2, P257, DOI 10.1016/S0093-934X(75)80070-8; GARTH J, 1997, PEDIAT REHABILITATIO, V2, P99; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Hamster K., 1983, MULTILINGUAL APHASIA; Heaton PDRK., 1993, WISCONSIN CARD SORTI; JANOWSKY JS, 1989, BEHAV NEUROSCI, V103, P548, DOI 10.1037/0735-7044.103.3.548; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; Milner B., 1964, FRONTAL GRANULAR COR, P313; PERRET E, 1974, NEUROPSYCHOLOGIA, V12, P323, DOI 10.1016/0028-3932(74)90047-5; SLIFER KJ, 1993, J APPL BEHAV ANAL, V26, P469, DOI 10.1901/jaba.1993.26-469; Stuss DT, 1998, J INT NEUROPSYCH SOC, V4, P265, DOI 10.1017/S1355617798002653; STUSS DT, 1992, BRAIN COGNITION, V20, P8, DOI 10.1016/0278-2626(92)90059-U; Talairach TM, 1988, COPLANAR STEREOTAXIC; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TAYLOR HG, 1984, EARLY BRAIN DAMAGE R, P325; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; WELNER Z, 1987, J AM ACAD CHILD PSY, V26, P649, DOI 10.1097/00004583-198709000-00007; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; WILSON J T L, 1990, Brain Injury, V4, P349; YLIVASKER M, 1998, TRAUMATIC BRAIN INJU, P159; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012; [No title captured]; [No title captured]; [No title captured]	45	84	85	0	26	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2002	16	9					759	772		10.1080/02699050210127286			14	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	585PD	WOS:000177532800002	12217202				2022-02-06	
J	de Kruijk, JR; Leffers, P; Meerhoff, S; Rutten, J; Twijnstra, A				de Kruijk, JR; Leffers, P; Meerhoff, S; Rutten, J; Twijnstra, A			Effectiveness of bed rest after mild traumatic brain injury: a randomised trial of no versus six days of bed rest	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							MODERATE HEAD-INJURY; HEALTH SURVEY; DOUBLE-BLIND; FOLLOW-UP; SENSITIVITY; MANAGEMENT; SYMPTOMS; SF-36	Background: Outcome after mild traumatic brain injury (MTBI) is determined largely by the appearance of post-traumatic complaints (PTC). The prevalence of PTC after six months is estimated to be between 20 and 80%. Bed rest has been advocated to prevent PTC but its effectiveness has never been established. Objective: To evaluate the effect of bed rest on the severity of PTC after MTBI. Methods: Patients presenting with MTBI to the emergency room were randomly assigned to two intervention strategies. One group was advised not to take bed rest (NO) and the other to take full bed rest (FULL) for six days after the trauma. The primary outcome measures were severity of PTC on a visual analogue scale and physical and mental health on the medical outcomes study 36 item short form health survey (SF-36) at two weeks and three and six months after the trauma. Results: Between October 1996 and July 1999, 107 (54 NO, 53 FULL) patients were enrolled. Outcome variables in both groups clearly improved between two weeks and six months. After adjustment for differences in baseline variables, most PTC tended to be somewhat more severe in the FULL group six months after the trauma, but no significant differences were found. Neither were there any significant differences in the outcome parameters between the two groups after three months. Two weeks after the trauma, most PTC in the FULL group were slightly less severe than those in the NO group, and physical subscores of the SF-36 in the FULL group were slightly better. These differences were not significant. Patients in the FULL group reported significantly less dizziness during the intervention period. Conclusions: As a means of speeding up recovery of patients with PTC after MTBI, bed rest is no more effective than no bed rest at all. Bed rest probably has some palliative effect within the first two weeks after the trauma.	Univ Hosp Maastricht, Dept Neurol, NL-6229 HX Maastricht, Netherlands; Maastricht Univ, Dept Epidemiol, Maastricht, Netherlands; Maastricht Univ, Fac Med, Maastricht, Netherlands		de Kruijk, JR (corresponding author), Univ Hosp Maastricht, Dept Neurol, P Debeylaan 25, NL-6229 HX Maastricht, Netherlands.	jdk@sneu.azm.nl	Leffers, Pieter/B-8642-2009; Rutten, Joost/L-4618-2015	Rutten, Joost/0000-0002-5259-9794			Aaronson NK, 1998, J CLIN EPIDEMIOL, V51, P1055, DOI 10.1016/S0895-4356(98)00097-3; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Allen C, 1999, LANCET, V354, P1229, DOI 10.1016/S0140-6736(98)10063-6; BOHNEN NI, 1993, NEUROLOGY, V43, P103, DOI 10.1212/WNL.43.1_Part_1.103; BOHNEN NJ, 1995, J NEUROL REHABIL, V9, P33; Chapman EH, 1999, J HEAD TRAUMA REHAB, V14, P521, DOI 10.1097/00001199-199912000-00002; COLLINS MW, 1999, JAMA-J AM MED ASSOC, V282, P974; de Kruijk JR, 2001, BRAIN INJURY, V15, P117, DOI 10.1080/026990501458353; Haase J, 1992, Acta Neurochir Suppl (Wien), V55, P75; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Kraus J, 1996, NEUROTRAUMA, P13; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1991, J NEUROL SCI, V103, pS39; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MEERHOFF S, 2000, NED TIJDSCHR GENEES, V144, P915; Merchant RE, 1999, ANN NY ACAD SCI, V890, P42, DOI 10.1111/j.1749-6632.1999.tb07979.x; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Nell V, 2000, ARCH PHYS MED REHAB, V81, P614, DOI 10.1053/mr.2000.3877; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; Paniak C, 2000, BRAIN INJURY, V14, P219; Ruff RM, 1999, BRAIN INJURY, V13, P943; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; VANTHOOFT F, 1973, COMMOTIO CEREBRI AND; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177	28	84	84	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	AUG	2002	73	2					167	172		10.1136/jnnp.73.2.167			6	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	577KK	WOS:000177059900016	12122176	Bronze, Green Published			2022-02-06	
J	Levin, HS; Hanten, G; Chang, CC; Zhang, LF; Schachar, R; Ewing-Cobbs, L; Max, JE				Levin, HS; Hanten, G; Chang, CC; Zhang, LF; Schachar, R; Ewing-Cobbs, L; Max, JE			Working memory after traumatic brain injury in children	ANNALS OF NEUROLOGY			English	Article							CLOSED-HEAD INJURY; SHORT-TERM-MEMORY; PREFRONTAL CORTEX; INFORMATION; INVOLVEMENT; LESIONS	To investigate the effects of traumatic brain injury on working memory in children, we administered semantic (letter identity) and phonological (letter rhyme) N-back tasks to children who were on average 5 years post-mild (n = 54) or -severe (n = 26) traumatic brain injury and 44 typically developing children who were comparable in age. The correct detection of targets and false alarms were measured for each task. Memory load (which varied from 0 to 3 letters back) and age significantly affected the detection of targets and false alarms in both tasks. The severity of traumatic brain injury affected the correct detection of letters on the identity task and false alarms on the rhyme task. Traumatic brain injury severity also interacted with memory load in its effect on false alarms on the rhyme task. Traumatic brain injury results in impaired working memory and diminished inhibition in children. The N-back working memory task is feasible for administration to brain-injured children and potentially could be useful for studying brain activation associated with working memory and effects of drug therapy in this group of patients.	Baylor Coll Med, Cognit Neurosci Lab, Houston, TX 77030 USA; Hosp Sick Children, Dept Psychiat, Toronto, ON M5G 1X8, Canada; Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77225 USA; Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA		Levin, HS (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, 6560 Fannin St,Suite 1144,Box 67, Houston, TX 77030 USA.	hlevin@bcm.tmc.edu		Schachar, Russell/0000-0002-2015-4395	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Bunge SA, 2001, BRAIN, V124, P2074, DOI 10.1093/brain/124.10.2074; Callicott JH, 1999, CEREB CORTEX, V9, P20, DOI 10.1093/cercor/9.1.20; DANEMAN M, 1983, J EXP PSYCHOL LEARN, V9, P561, DOI 10.1037/0278-7393.9.4.561; Fletcher PC, 2001, BRAIN, V124, P849, DOI 10.1093/brain/124.5.849; Gathercole SE, 1997, J EXP CHILD PSYCHOL, V67, P290, DOI 10.1006/jecp.1997.2391; GOLDMAN PS, 1977, NATURE, V267, P613, DOI 10.1038/267613a0; Hanten G, 1999, DEV NEUROPSYCHOL, V16, P393, DOI 10.1207/S15326942DN1603_23; Hanten G, 2000, J MEM LANG, V43, P335, DOI 10.1006/jmla.2000.2731; Harnishfeger KK, 1996, J EXP CHILD PSYCHOL, V62, P292, DOI 10.1006/jecp.1996.0032; Huttenlocher PR, 1997, J COMP NEUROL, V387, P167, DOI 10.1002/(SICI)1096-9861(19971020)387:2<167::AID-CNE1>3.0.CO;2-Z; Jansma JM, 2000, NEUROIMAGE, V12, P688, DOI 10.1006/nimg.2000.0645; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; Luciana M, 1998, NEUROPSYCHOLOGIA, V36, P273, DOI 10.1016/S0028-3932(97)00109-7; Martin R., 1994, NEUROPSYCHOLOGY, V8, P506, DOI [10.1037/0894-4105.8.4.506, DOI 10.1037/0894-4105.8.4.506]; MARTIN RC, 1993, MEM COGNITION, V21, P176, DOI 10.3758/BF03202730; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Mehta MA, 2000, J NEUROSCI, V20; Nystrom LE, 2000, NEUROIMAGE, V11, P424, DOI 10.1006/nimg.2000.0572; PETRIDES M, 1982, NEUROPSYCHOLOGIA, V20, P249, DOI 10.1016/0028-3932(82)90100-2; SAWAGUCHI T, 1991, SCIENCE, V251, P947, DOI 10.1126/science.1825731; Saykin AJ, 1999, BRAIN, V122, P1963, DOI 10.1093/brain/122.10.1963; Swanson HL, 2001, J EXP CHILD PSYCHOL, V79, P294, DOI 10.1006/jecp.2000.2587; Swanson HL, 1999, DEV PSYCHOL, V35, P986, DOI 10.1037/0012-1649.35.4.986; TEASDALE G, 1974, LANCET, V2, P81; Vaidya CJ, 1998, P NATL ACAD SCI USA, V95, P14494, DOI 10.1073/pnas.95.24.14494	32	84	84	1	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	JUL	2002	52	1					82	88		10.1002/ana.10252			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	566WT	WOS:000176451800013	12112051				2022-02-06	
J	Floyd, CL; Golden, KM; Black, RT; Hamm, RJ; Lyeth, BG				Floyd, CL; Golden, KM; Black, RT; Hamm, RJ; Lyeth, BG			Craniectomy position affects Morris water maze performance and hippocampal cell loss after parasagittal fluid percussion	JOURNAL OF NEUROTRAUMA			English	Article						animal models; cell death; glial fibrillary acidic protein (GFAP); reactive astrocytes; traumatic brain injury	TRAUMATIC BRAIN-INJURY; BEHAVIORAL-ANALYSIS; ASTROCYTES; MEMORY; RATS; CONSEQUENCES; DAMAGE	Valid and reliable animal models are essential for mechanistic and therapeutic studies of traumatic brain injury (TBI). Therefore, model characterization is a continual and reciprocal process between the experimental laboratory and the clinic. Several excellent experimental models of TBI, including the lateral fluid percussion rat model, are currently in wide use in many neurotrauma laboratories. However, small differences in the position of lateral fluid percussion craniectomy are reported between labs. Additionally, differences in hippocampal cell death have also been reported. Therefore, we hypothesized that small changes in craniectomy position could affect commonly used outcome measures such as vestibulomotor function, Morris water maze (MWM) performance, hippocampal cell loss, and glial fibrillary acidic protein (GFAP) immunoreactivity. Four placements were systematically manipulated: rostral, caudal, medial and lateral. The medial and caudal placements produced significantly greater impairments in the MWM acquisition task over the lateral and rostral placements. The rostral placement produced diffuse cortical damage but little hippocampal cell loss. In contrast, the medial, lateral, and caudal placements produced more mid-dorsally localized cortical damage and significant cell loss in the CA2/CA3 and hilus ipsilateral to the injury site. Furthermore, reactive astrocytosis was more pronounced in the medial, lateral, and caudal placements than in the rostral placement. All craniectomy position groups had similar durations of traumatic unconsciousness and similar impairment on motor tasks. We conclude that small alterations in craniectomy position produce differences in cognitive performance, hippocampal cell loss, and reactive astrocytosis but not in motor performance nor transient unconsciousness.	Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA; Univ Calif Davis, Ctr Neurosci, Davis, CA 95616 USA; Virginia Commonwealth Univ, Med Coll Virginia, Div Neurol Surg, Richmond, VA 23298 USA		Lyeth, BG (corresponding author), Univ Calif Davis, Dept Neurol Surg, 1 Shields Ave, Davis, CA 95616 USA.	bglyeth@ucdavis.edu		Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029995] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 29995] Funding Source: Medline		ANNETT LE, 1989, BEHAV BRAIN RES, V31, P231, DOI 10.1016/0166-4328(89)90005-3; Baldwin SA, 1996, GLIA, V16, P266; Bedell EA, 1998, J NEUROTRAUM, V15, P985, DOI 10.1089/neu.1998.15.985; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BRANDEIS R, 1989, INT J NEUROSCI, V48, P29, DOI 10.3109/00207458909002151; DEBRUIN JPC, 1994, BRAIN RES, V652, P323, DOI 10.1016/0006-8993(94)90243-7; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCINTOSH TK, 1987, CENTRAL NERV SYST TR, V4, P1987; MEANEY DF, 1988, FRONTIERS HEAD NECK, P169; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Okimura Y, 1996, J NEUROTRAUM, V13, P385, DOI 10.1089/neu.1996.13.385; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SUTHERLAND RJ, 1983, BEHAV BRAIN RES, V7, P133, DOI 10.1016/0166-4328(83)90188-2; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69	23	84	87	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2002	19	3					303	316		10.1089/089771502753594873			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	534BC	WOS:000174563900002	11939498				2022-02-06	
J	Girotto, JA; MacKenzie, E; Fowler, C; Redett, R; Robertson, B; Manson, PN				Girotto, JA; MacKenzie, E; Fowler, C; Redett, R; Robertson, B; Manson, PN			Long-term physical impairment and functional outcomes after complex facial fractures	PLASTIC AND RECONSTRUCTIVE SURGERY			English	Article							TRAUMATIC BRAIN INJURY; HEALTH SURVEY SF-36; MIDFACIAL FRACTURES; HEAD-INJURY; RECOVERY; REHABILITATION; SEVERITY; TESTS	To develop an understanding of the expected functional outcomes after facial trauma, a retrospective cohort study of patients with complex facial fractures was conducted. A cohort of adults aged 18 to 55 years who were admitted to the R. Adams Cowley Shock Trauma Center between July of 1986 and July of 1994 for treatment of a Le Fort midface fracture (resulting from blunt force) was retrospectively identified. Outcomes of interest included measures of general health status and psychosocial well being in addition to self-reported somatic symptoms. General health status was ascertained using the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36). The Body Satisfaction Scale was used to define patient concerns about altered body image and shape. To determine whether complex maxillofacial trauma and facial fractures contributed to altered social interactions, the Social Avoidance and Distress scale was used. In addition, information about a patient, his or her injury, and its treatment were ascertained from the medical records. Using the methods described above, 265 patients with Le Fort fractures were identified. These individuals were matched to a similar group of 242 general injury patients. A total of 190 of the Le Fort patients (72 percent of those eligible for the study) and 144 (60 percent) general injury patients were successfully located, and long-term interview data were acquired. Le Fort fracture patients as a group had similar health status outcomes when compared with the group of general injury patients. However, when outcomes were examined by the complexity of the Le Fort fracture, the authors found that study subjects with severe, comminuted Le Fort injuries (group D) had significantly lower SF-36 scores (worse outcomes) for the two dimensions related to role limitations: role limitations due to physical problems and role limitations due to emotional problems (p < 0.05). SF-36 scores for all other dimensions except physical function were also lower for comminuted versus less complex Le Fort fractures, although differences were not statistically significant. Specifically, there was a direct relationship between severity of facial injury and patients reporting work disability. Of group C and D Le Fort patients (severely comminuted fractures) only 55 and 58 percent, respectively, had returned to work at the time of follow-up interview. These figures are significantly lower than the back-to-work percentage of patients with less severe facial injury (70 percent). When study participants were asked if they were experiencing specific somatic symptoms at the time of the interview that they had not experienced before the injury, a significantly larger percent of the Le Fort fracture patients (compared with the general injury patients) responded in the affirmative. Differences between the Le Fort fracture and general injury groups were statistically significant (p < 0.05) for all 11 symptoms. The percentage of patients reporting complaints increased with increasing complexity of facial fracture in the areas of visual problems, alterations in smell, difficulty with mastication, difficulty with breathing, and epiphora, and these differences reached statistical significance. Patients sustaining comminuted Le Fort facial fractures report poorer health outcomes than patients with less severe facial injury and substantially worse outcomes than population norms. It is also this severely injured population that reports the greatest percentage of injury-related disability, preventing employment at long-term follow-up. The long-term goal of centralized tertiary trauma treatment centers must be to return the patient to a productive, active lifestyle.	Johns Hopkins Univ, Sch Med, Dept Surg, Div Plast & Reconstruct Surg, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Ctr Injury Res & Policy, Baltimore, MD USA; Univ Maryland, Ctr Shock Trauma, Dept Surg, Div Plast & Reconstruct Surg, Baltimore, MD 21201 USA		Girotto, JA (corresponding author), Johns Hopkins Univ Hosp, Div Plast & Reconstruct Surg, JHOC Room 8152,601 N Carolina St, Baltimore, MD 21287 USA.	Girotto@Home.com					AFZELIUS LF, 1980, INT J ORAL MAXILLOF, V9, P25, DOI 10.1016/S0300-9785(80)80003-2; ALQURAINY IA, 1991, BRIT J ORAL MAX SURG, V29, P291; ALQURAINY IA, 1991, BRIT J ORAL MAX SURG, V29, P302; ALQURAINY IA, 1991, BRIT J ORAL MAX SURG, V29, P368, DOI 10.1016/0266-4356(91)90002-M; ASHBURN MA, 1989, MIL MED, V154, P86; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BRAMLEY P, 1972, P ROY SOC MED, V65, P916, DOI 10.1177/003591577206501063; BROOKS DN, 1986, J NEUROL NEUROSUR PS, V49, P549, DOI 10.1136/jnnp.49.5.549; BROOKS DN, 1984, J CLIN NEUROPSYCHOL, V6, P71, DOI 10.1080/01688638408401198; Butcher JL, 1996, J TRAUMA, V41, P4, DOI 10.1097/00005373-199607000-00002; CONVERSE JM, 1967, PLAST RECONSTR SURG, V39, P20, DOI 10.1097/00006534-196701000-00002; DRUDGE OW, 1984, J CLIN PSYCHOL, V40, P259, DOI 10.1002/1097-4679(198401)40:1<259::AID-JCLP2270400149>3.0.CO;2-C; DUTTON GN, 1992, EYE, V6, P86, DOI 10.1038/eye.1992.17; Fingerhut LA., 1997, INJURY CHARTBOOK HLT; GENSEMER IB, 1988, J TRAUMA, V28, P44, DOI 10.1097/00005373-198801000-00006; GLANCY KE, 1992, J TRAUMA, V33, P602, DOI 10.1097/00005373-199210000-00017; Habal M B, 1992, J Craniofac Surg, V3, P175, DOI 10.1097/00001665-199211000-00011; Hakelius L, 1973, J Maxillofac Surg, V1, P150, DOI 10.1016/S0301-0503(73)80031-1; HAUG HZ, 1992, J ORAL MAXIL SURG, V50, P218, DOI 10.1016/0278-2391(92)90315-Q; Hawkins ML, 1996, J TRAUMA, V41, P257, DOI 10.1097/00005373-199608000-00010; HOLT JE, 1983, OPHTHALMOLOGY, V90, P14; Jourard SM., 1953, J CONSULT PSYCHOL, V17, P343, DOI 10.1037/h0060689; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; LEIBSOHN R, 1976, ANN OPHTHALMOL, V8, P1057; LOVIUS BBJ, 1990, J CRANIO MAXILL SURG, V18, P339, DOI 10.1016/S1010-5182(05)80052-6; LUND K, 1971, J ORAL SURG, V29, P557; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MACKENZIE EJ, 1993, J TRAUMA, V34, P528, DOI 10.1097/00005373-199304000-00009; MACKENZIE EJ, 1993, J ORTHOP TRAUMA, V7, P393, DOI 10.1097/00005131-199310000-00001; MCCOY FJ, 1980, LONG TERM RESULTS PL, P485; MCCOY FJ, 1962, PLAST RECONSTR SURG, V29, P381; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; MORGAN B D G, 1972, British Journal of Plastic Surgery, V25, P147, DOI 10.1016/S0007-1226(72)80037-7; PATTERSON R, 1991, CAN J SURG, V34, P183; REYNOLDS JR, 1978, PLAST RECONSTR SURG, V61, P871, DOI 10.1097/00006534-197861060-00007; SCHERZER BP, 1986, ARCH PHYS MED REHAB, V67, P366; Slade PD., 1990, PSYCHOL HEALTH, V4, P213, DOI [DOI 10.1080/08870449008400391, 10.1080/08870449008400391]; SPIESSL B, 1971, THER UMSCH, V28, P881; STEIDLER NE, 1980, J ORAL SURG, V9, P259; Tajima S, 1974, J Maxillofac Surg, V2, P201, DOI 10.1016/S0301-0503(74)80041-X; TESSIER P, 1972, PLAST RECONSTR SURG, V40, P497; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WATSON D, 1969, J CONSULT CLIN PSYCH, V33, P448, DOI 10.1037/h0027806; WILLIAMS JM, 1984, J NEUROSURG, V61, P581, DOI 10.3171/jns.1984.61.3.0581	45	84	91	1	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0032-1052	1529-4242		PLAST RECONSTR SURG	Plast. Reconstr. Surg.	AUG	2001	108	2					312	327		10.1097/00006534-200108000-00005			16	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	456RW	WOS:000170096900005	11496168				2022-02-06	
J	McIntosh, AS; McCrory, P				McIntosh, AS; McCrory, P			Effectiveness of headgear in a pilot study of under 15 rugby union football	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						rugby union; headgear; helmets; concussion; adolescents	ICE-HOCKEY; INJURIES; CHILDREN; IMPACT	Objective-To determine whether protective headgear reduced the incidence of concussion in a pilot study of under 15 rugby union. Methods-Sixteen under 15 rugby union teams were recruited from three interschool competitions in metropolitan Sydney and the adjacent country region. A prospective study was undertaken over a single competitive season. The study had two arms: a headgear arm and a control arm. Headgear wearing rates and injury data were reported to the investigators and verified using spot checks. Results-A total of 294 players participated in the study. There were 1179 player exposures with headgear and 357 without headgear. In the study time frame, there were nine incidences of concussion; seven of the players involved wore headgear and two did not. There was no significant difference between concussion rates between the two study arms. Conclusions-Although there is some controversy about the desirability of wearing protective headgear in football, this pilot study strongly suggests that current headgear does not provide significant protection against concussion in rugby union at a junior level.	Univ New S Wales, Sch Safety Sci, Sydney, NSW 2052, Australia; Univ Melbourne, Ctr Sports Med Res, Parkville, Vic 3052, Australia; Univ Melbourne, Brain Res Inst, Parkville, Vic 3052, Australia		McIntosh, AS (corresponding author), Univ New S Wales, Sch Safety Sci, Sydney, NSW 2052, Australia.		McCrory, Paul/Q-8688-2019				BIASCA N, 1995, UNFALLCHIRURG, V98, P283; Cantu RC, 1997, CLIN J SPORT MED, V7, P83, DOI 10.1097/00042752-199704000-00001; CLARKE KS, 1979, MED SCI SPORT EXER, V11, P138; EDGAR M, 1995, LANCET, V345, P1452, DOI 10.1016/S0140-6736(95)91031-X; FEKETE JF, 1968, CAN MED ASSOC J, V99, P1234; Finch C, 1993, 51 MON U ACC RES CTR; GARRAWAY M, 1995, LANCET, V345, P1485; Gissane C, 1997, Aust J Sci Med Sport, V29, P91; Honey CR, 1998, CLIN J SPORT MED, V8, P43, DOI 10.1097/00042752-199801000-00010; *IRB, 1996, LAWS GAM RUGB FOOTB; McCrory P, 1998, SPORTS NEUROLOGY, P441; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; Mills N J, 1990, Br J Sports Med, V24, P55; Shafi S, 1998, J PEDIATR SURG, V33, P317, DOI 10.1016/S0022-3468(98)90454-7; THOMAS S, 1994, BRIT MED J, V308, P173, DOI 10.1136/bmj.308.6922.173; VIRGIN H, 1980, AM J SPORT MED, V8, P310, DOI 10.1177/036354658000800503; Wekesa M, 1996, BRIT J SPORT MED, V30, P61, DOI 10.1136/bjsm.30.1.61; Wilson BD, 1998, SPORTS MED, V25, P333, DOI 10.2165/00007256-199825050-00005	19	84	85	0	25	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	JUN	2001	35	3					167	169		10.1136/bjsm.35.3.167			3	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	440UV	WOS:000169193700009	11375874	Green Published, Bronze			2022-02-06	
J	Cvek, M; Andreasen, JO; Borum, MK				Cvek, M; Andreasen, JO; Borum, MK			Healing of 208 intraalveolar root fractures in patients aged 7-17 years	DENTAL TRAUMATOLOGY			English	Article						root fractures; pulp heating; splinting	PERMANENT INCISORS; PROGNOSIS; REPLANTATION; MONKEYS; REPAIR; TEETH	This retrospective study consisted of 208 root-fractured, 168 splinted and 40 not splinted incisors in young individuals ja,oed 7-17 years) created in the period 1959-1973 at the Pedodontic Department. Eastman Institute, Stockholm. Clinical and radiographic analyses showed that 69 teeth (33%) had developed hard tissue (fusion) healing of, fragments. Interposition of periodontal ligament (PDL) and bone between the fragments was found in 17 teeth (8%). Interposition of PBL, alone was found in 74 teeth (36%). Finally non-healing with pulp necrosis and inflammatory: changes between fragments was seen in 48 teeth (23%), Various clinical factors were analyzed for their relationship to the healing outcome with respect to healing/no healing and type of healing (hard tissue versus interposition of bone and/or PDL). Immature root and positive pulp sensitivity at time of injury was found to be significantly related to both pulp healing and hard tissue repair of the fracture. The same applied to concussion or subluxation of the coronal fragment compared to luxation with displacement (extrusive or lateral luxation). This relation was also represented by the variable millimeter diastasis between fragments before and after repositioning. Repositioning appeared to enhance the likelihood of both pulp healing and hard tissue repair. A positive effect of splinting, splinting methods (cap splints or orthodontic bands with an arch wire) or splinting periods could not be demonstrated on either pulp healing or type of healing (hard tissue versus interposition of bone and/or PDL). In conclusion, the findings from this retrospective study have cast doubts an the efficacy of long-term splinting and the types of splint used for root fracture healing. It is suggested that the role of splinting and splinting methods be examined in further studies.	Eastman Inst, Dept Pedodont, Stockholm, Sweden; Rigshosp, Dept Oral & Maxillofacial Surg, Taastrup, Denmark; Municipal Dent Serv, Taastrup, Denmark		Cvek, M (corresponding author), Eastman Inst, Dept Pedodont, Stockholm, Sweden.						ANDREASEN FM, 1988, ENDOD DENT TRAUMATOL, V4, P202; ANDREASEN FM, 1989, ENDOD DENT TRAUMATOL, V5, P11; ANDREASEN FM, 1989, ENDOD DENT TRAUMATOL, V5, P111; ANDREASEN FM, 1994, TXB COLOR ATLAS TRAU, P279; ANDREASEN JO, 1967, J ORAL SURG, V25, P414; ANDREASEN JO, 1981, INT J ORAL MAXILLOF, V10, P54, DOI 10.1016/S0300-9785(81)80008-7; ANDREASEN JO, 1975, ACTA ODONTOL SCAND, V33, P313, DOI 10.3109/00016357509004636; Andreasen JO., 1972, TRAUMATIC INJURIES T, P111; Armitage P., 1987, STAT METHODS MED RES; BENATI FW, 1994, OKLA DENT ASS J, V65, P30; Caliskan MK, 1996, ENDOD DENT TRAUMATOL, V12, P129; CHANG SP, 1988, ENDOD DENT TRAUMATOL, V4, P186; Feiglin B, 1995, Dent Clin North Am, V39, P53; FOUNTAIN SB, 1984, PATHWAYS PULP, P502; KRISTERSON L, 1983, INT J ORAL SURG, V10, P54; MANDEL U, 1989, ARCH ORAL BIOL, V34, P209, DOI 10.1016/0003-9969(89)90010-1; MICHANOWICZ AE, 1971, J AM DENT ASSOC, V82, P569, DOI 10.14219/jada.archive.1971.0101; RABIE G, 1988, ENDOD DENT TRAUMATOL, V4, P99; TZIAFAS D, 1993, ENDOD DENT TRAUMATOL, V9, P40; YATES JA, 1992, INT ENDOD J, V25, P150, DOI 10.1111/j.1365-2591.1992.tb00778.x; ZACHRISSON BU, 1975, SCAND J DENT RES, V83, P345	21	84	88	0	11	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	1600-4469			DENT TRAUMATOL	Dent. Traumatol.	APR	2001	17	2					53	62		10.1034/j.1600-9657.2001.017002053.x			10	Dentistry, Oral Surgery & Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Dentistry, Oral Surgery & Medicine	424TN	WOS:000168248700002	11475947				2022-02-06	
J	Greve, KW; Sherwin, E; Stanford, MS; Mathias, C; Love, J; Ramzinski, P				Greve, KW; Sherwin, E; Stanford, MS; Mathias, C; Love, J; Ramzinski, P			Personality and neurocognitive correlates of impulsive aggression in long-term survivors of severe traumatic brain injury	BRAIN INJURY			English	Article							DISTURBANCE; COGNITION; BEHAVIOR; LESIONS; DAMAGE; SCALE	This study addresses a common outcome of severe traumatic brain injury (TBI), disinhibited aggressive behaviour. This behaviour has been classified in aggression literature as `impulsive aggression' (IA). The purpose was to: (1) characterize those TBI patients who are likely to be an aggression risk, and (2) determine if TBI patients with IA demonstrate personality style and neurocognitive performance similar to that seen in other IA groups. Participants were 45 survivors of severe TBI (26 of whom had persisting problems with IA), who were clients of a residential brain injury treatment facility. IA participants had a higher incidence of pre- morbid aggressive behaviour, were younger, had a shorter tenure in the programme, and were more impulsive, irritable, and antisocial than the non- aggressive control participants. Unlike past research, no neurocognitive differences were found. The results are discussed in terms of the conceptualization, identification, and treatment of persisting IA in severe TBI.	Univ New Orleans, Dept Psychol, UNO Lakefront, New Orleans, LA 70148 USA; Georgia So Univ, Statesboro, GA 30460 USA; Tangram Premier, San Marcos, TX USA		Greve, KW (corresponding author), Univ New Orleans, Dept Psychol, UNO Lakefront, New Orleans, LA 70148 USA.			Mathias, Charles/0000-0003-1902-673X			Barratt ES, 1997, BIOL PSYCHIAT, V41, P1045, DOI 10.1016/S0006-3223(96)00175-8; Barratt ES, 1997, J CLIN PSYCHOPHARM, V17, P341, DOI 10.1097/00004714-199710000-00002; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; BONTON AL, 1983, CONTRIBUTIONS NEUROP; BUSS AH, 1992, J PERS SOC PSYCHOL, V63, P452, DOI 10.1037/0022-3514.63.3.452; Cicerone KD, 1997, ARCH CLIN NEUROPSYCH, V12, P173, DOI 10.1016/S0887-6177(96)00022-4; COCCARO EF, 1989, ARCH GEN PSYCHIAT, V46, P587; Coccaro EF, 1997, PSYCHIAT RES, V73, P147, DOI 10.1016/S0165-1781(97)00119-4; Dunn L.M., 1997, PEABODY PICTURE VOCA, V3rd Edition; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; ESLINGER PJ, 1995, NEUROREHABILITATION, V5, P161, DOI 10.3233/NRE-1995-5206; Eysenck H.J., 1975, EYSENCK PERSONALITY; FOSTER HG, 1989, PROG NEURO-PSYCHOPH, V13, P865, DOI 10.1016/0278-5846(89)90038-9; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Grafman J., 1994, HDB PERCEPTION COGNI, P159, DOI 10.1016/b978-0-08-092668-1.50014-4; Grafman J, 1994, HDB NEUROPSYCHOLOGY, P187; Grafman J., 1989, INTEGRATING THEORY P, P93; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Heaton SK, 1993, WISCONSIN CARD SORTI; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; Mathias CW, 1999, PROG NEURO-PSYCHOPH, V23, P1037, DOI 10.1016/S0278-5846(99)00053-6; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; MUNGAS D, 1988, BRIT J PSYCHIAT, V152, P180, DOI 10.1192/bjp.152.2.180; Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1; *PSYCH ASS RES, 1990, WISC CARD SORT TEST; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Stanford MS, 1996, PERS INDIV DIFFER, V21, P1073, DOI 10.1016/S0191-8869(96)00151-1; STANFORD MS, 1995, PERS INDIV DIFFER, V19, P757, DOI 10.1016/0191-8869(95)00144-U; Stanford MS, 1997, PERS INDIV DIFFER, V23, P961, DOI 10.1016/S0191-8869(97)00120-7; *WAR DEP ADJ GEN O, 1944, ARM IND TEST BATTR M	32	84	85	0	8	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAR	2001	15	3					255	262					8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	407ZM	WOS:000167302100005	11260773				2022-02-06	
J	Ono, J; Yamaura, A; Kubota, M; Okimura, Y; Isobe, K				Ono, J; Yamaura, A; Kubota, M; Okimura, Y; Isobe, K			Outcome prediction in severe head injury: analyses of clinical prognostic factors	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						clinical prognostic factor; outcome; severe head injury; CT	EVOKED-POTENTIALS; SCALE; COMA	Retrospective analysis of 272 patients with severe head injury was performed, Patient age, Glasgow Coma Scale (GCS) score, pupillary abnormalities, impaired oculocephalic response, presence of subarachnoid haemorrhage, and multiplicity of parenchymal lesions on computerised tomography (CT) were examined, The CT findings were divided into 2 groups, diffuse brain injury (DBI) and mass lesion, according to the classification of the Traumatic Coma Data Bank. The DBI, basically, has no high or mixed density lesion more than 25 mi on CT. and was classified into 4 subgroups: DBI I includes injuries where there is no visible pathology; DBI II includes all injuries in which the cisterns are present with a midline shift of less than 5 mm; DBI Iii includes injuries with swelling where the cisterns are compressed or absent and the midline shift is less than 5 mm; DBI IV includes injuries with a midline shift of more than 5 mm. The mass lesions were categorised into 3 subgroups: epidural haematoma; acute subdural haematoma: and intracerebral haematoma. Outcomes were determined at 6 months following trauma using the Glasgow Outcome Scale. All DBI I patients recovered well. in the DBI Ii group, age, GCS score and detection of multiple parenchymal lesions on CT were significantly correlated with outcome. For the DBI III and IV groups, the only significant prognostic factor was the GCS score, In patients with a mass lesion, the GCS score was the only significant prognostic factor in the epidural haematoma group, but the GCS score and the presence of subarachnoid haemorrhage were predictive factors in the acute subdural haematoma group. Outcomes were unfavourable in the majority of patients with intracerebral haematoma, GCS score could predict outcome in all groups. The confidence of the outcome prediction ranged from 75.8 to 92.1%, depending on logistic regression analysis. (C) 2001 Harcourt Publishers Ltd.	Chiba Univ, Sch Med, Dept Neurosurg, Chiba 280, Japan		Ono, J (corresponding author), Chiba Cardiovasc Ctr, Dept Neurosurg, Tsurumai 575, Ichihara 2900512, Japan.						ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; CHAN KH, 1993, NEUROSURGERY, V32, P547, DOI 10.1227/00006123-199304000-00009; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GREENBERG RP, 1981, J NEUROSURG, V55, P227, DOI 10.3171/jns.1981.55.2.0227; HOULDEN DA, 1990, NEUROSURGERY, V27, P701, DOI 10.1227/00006123-199011000-00006; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENNETT B, 1975, LANCET, V1, P480; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; TEASDALE G, 1974, LANCET, V2, P81; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; YAMAURA A, 1981, Neurologia Medico-Chirurgica, V21, P685	15	84	92	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	MAR	2001	8	2					120	123		10.1054/jocn.2000.0732			4	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	427WM	WOS:000168428500005	11484659				2022-02-06	
J	Ruppel, RA; Kochanek, PM; Adelson, PD; Rose, ME; Wisniewski, SR; Bell, MJ; Clark, RSB; Marion, DW; Graham, SH				Ruppel, RA; Kochanek, PM; Adelson, PD; Rose, ME; Wisniewski, SR; Bell, MJ; Clark, RSB; Marion, DW; Graham, SH			Excitatory amino acid concentrations in ventricular cerebrospinal fluid after severe traumatic brain injury in infants and children: The role of child abuse	JOURNAL OF PEDIATRICS			English	Article; Proceedings Paper	Annual Congress of the American-Academy-of-Pediatrics	OCT 16-19, 1998	SAN FRANCISCO, CA	Amer Acad Pediat			SHAKEN-BABY SYNDROME; NONACCIDENTAL HEAD-INJURY; CENTRAL-NERVOUS-SYSTEM; DEVELOPING RAT-BRAIN; METHYL-D-ASPARTATE; YOUNG-CHILDREN; NEUROTOXICITY; BLOCKADE; RELEASE; CSF	Background: Excitotoxicity is an important mechanism in secondary neuronal injury after traumatic brain injury (TBI). Excitatory amino acids (EAAs) are increased in cerebrospinal fluid (CSF) in adults after TBI; however, studies in pediatric head trauma are lacking. We hypothesized that CSF glutamate, aspartate, and glycine would be increased after TBI in children and that these increases would be associated with age, child abuse, poor outcome, and cerebral ischemia. Methods: EAAs were measured in 66 CSF samples from 18 children after severe TBI. Control samples were obtained from 19 children who received lumbar punctures to rule out meningitis. Results: Peak and mean CSF glycine and peak CSF glutamate levels were increased versus control values. Subgroups of patients with TBI were compared by using univariate regression analysis. Massive increases in CSF glutamate were found in children <4 years old and in child abuse victims. Increased CSF glutamate and glycine were associated with poor outcome. A trend toward an association between high glutamate concentration and ischemic blood flow was observed. Conclusions: CSF EAAs are increased in infants and children with severe TBI. Young age and child abuse were associated with extremely high CSF glutamate concentrations after TBI. A possible role for excitotoxicity after pediatric TBI is supported.	Univ Pittsburgh, Sch Med,Childrens Hosp Pittsburgh, Dept Anesthesiol & Crit Care Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Safar Ctr Resuscitat Res,Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Safar Ctr Resuscitat Res,Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Safar Ctr Resuscitat Res,Dept Neurol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med,Childrens Hosp Pittsburgh, Dept Epidemiol & Publ Hlth, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; VA Pittsburgh Hlth Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA		Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med,Childrens Hosp Pittsburgh, Safar Ctr Resuscitat Res, 3434 5th Ave,Suite 201, Pittsburgh, PA 15260 USA.		Marion, Donald/AAR-5749-2021; Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860			Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; ALEXANDER R, 1990, AM J DIS CHILD, V144, P58, DOI 10.1001/archpedi.1990.02150250068033; ARAKI K, 1988, ACTA NEUROL SCAND, V78, P473, DOI 10.1111/j.1600-0404.1988.tb03690.x; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; BRUCE DA, 1984, BRIT MED J, V289, P715, DOI 10.1136/bmj.289.6447.715; BRUCE DA, 1989, PEDIATR ANN, V18, P482, DOI 10.3928/0090-4481-19890801-07; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; BURNASHEV N, 1992, SCIENCE, V257, P1415, DOI 10.1126/science.1382314; CAMPAGNE MV, 1994, J CEREBR BLOOD F MET, V14, P1011, DOI 10.1038/jcbfm.1994.133; CHOI DW, 1987, J NEUROSCI, V7, P357; DOPPENBERG EMR, 1997, ANN NY ACAD SCI, V825, P305; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; FADEN AI, 1989, SCIENCE, V244, P789; Gilliland MGF, 1998, J FORENSIC SCI, V43, P723; GUR D, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P68; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; HU B, 1991, J NEUROCHEM, V56, P933, DOI 10.1111/j.1471-4159.1991.tb02011.x; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; IKONOMIDOU C, 1989, J NEUROSCI, V9, P2809; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MCDONALD JW, 1988, BRAIN RES, V459, P200, DOI 10.1016/0006-8993(88)90306-X; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MIES G, 1991, J CEREBR BLOOD F MET, V11, P753, DOI 10.1038/jcbfm.1991.132; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P627; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; Zauner A, 1996, ACT NEUR S, V67, P40	34	84	85	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	JAN	2001	138	1					18	25		10.1067/mpd.2001.110979			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Pediatrics	393PK	WOS:000166478700005	11148507				2022-02-06	
J	Graham, SH; Chen, J; Clark, RSB				Graham, SH; Chen, J; Clark, RSB			Bcl-2 family gene products in cerebral ischemia and traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; bax; bcl-2; bcl-w; bcl-x; bid; cerebral ischemia; programmed cell death; traumatic brain injury	PROGRAMMED CELL-DEATH; PERMEABILITY TRANSITION PORE; CYTOCHROME-C RELEASE; PROTOONCOGENE BCL-2; TRANSGENIC MICE; RAT-BRAIN; ISOLATED-MITOCHONDRIA; SEQUENCE SIMILARITY; GLOBAL-ISCHEMIA; FOCAL ISCHEMIA	The proto-oncogene bcl-2 plays a key role in regulating programmed cell death in neurons, The present review discusses the mechanisms by which bcl-2 family genes regulate programmed cell death, and their role in controlling cell death in cerebral ischemia and traumatic brain, Expression of several bcl-2 family members is altered in brain tissues after ischemia and trauma, suggesting that bcl-2 family genes could play a role in determining the fate of injured neurons. Furthermore, alteration of expression of bcl-2 family genes using transgenic approaches, viral vectors, or anti-sense oligonucleotides modifies neuronal cell death and neurological outcome after injury, These data suggest that the activity of bcl-2 family gene products participates in determining cellular and neurologic outcomes in ischemia and trauma, Strategies that either mimic the death-suppressor effects or inhibit the death-promoter effects of bcl-2 family gene products may improve outcome after ischemia and trauma.	Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15213 USA; Vet Affairs Pittsburgh Hlth Ctr, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA		Graham, SH (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurol, 526 S BST, Pittsburgh, PA 15213 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS035965, K08NS001946] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS3031, K08 NS01946, P01 NS35965] Funding Source: Medline		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Asahi M, 1997, J CEREBR BLOOD F MET, V17, P11, DOI 10.1097/00004647-199701000-00003; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1995, ONCOGENE, V11, P1921; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Chen J, 2000, J CEREBR BLOOD F MET, V20, P1033, DOI 10.1097/00004647-200007000-00002; CHEN J, 1995, NEUROREPORT, V6, P394, DOI 10.1097/00001756-199501000-00040; Chen J, 1996, J NEUROCHEM, V67, P64; Chen J, 1997, J CEREBR BLOOD F MET, V17, P2, DOI 10.1097/00004647-199701000-00002; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHENG TS, 1997, MRS INTERNET J N S R, V2, P1; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHOI SS, 1995, ONCOGENE, V11, P1693; Clark D, 1999, IEEE INTERNET COMPUT, V3, P13; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; D'Agata V, 1998, NEUROSCI LETT, V243, P137, DOI 10.1016/S0304-3940(98)00116-5; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; Gillardon F, 1996, MOL BRAIN RES, V40, P254, DOI 10.1016/0169-328X(96)00059-9; GONZALEZGARCIA M, 1995, P NATL ACAD SCI USA, V92, P4304, DOI 10.1073/pnas.92.10.4304; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hamner S, 1999, NEUROSCIENCE, V91, P673, DOI 10.1016/S0306-4522(98)00642-3; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; Lawrence MS, 1997, J CEREBR BLOOD F MET, V17, P740; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIN EY, 1993, J IMMUNOL, V151, P1979; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; MacManus JP, 2000, J NEUROTRAUM, V17, P899, DOI 10.1089/neu.2000.17.899; MAH SP, 1993, J NEUROCHEM, V60, P1183, DOI 10.1111/j.1471-4159.1993.tb03275.x; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Minami M, 2000, NEUROSCI LETT, V279, P193, DOI 10.1016/S0304-3940(99)00987-8; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; NEILAN JG, 1993, J VIROL, V67, P4391, DOI 10.1128/JVI.67.7.4391-4394.1993; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pan GH, 1998, FEBS LETT, V426, P151, DOI 10.1016/S0014-5793(98)00330-5; Panizzon KL, 1998, NEUROREPORT, V9, P4131, DOI 10.1097/00001756-199812210-00024; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; Print CG, 1998, P NATL ACAD SCI USA, V95, P12424, DOI 10.1073/pnas.95.21.12424; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; REYNOLDS JE, 1994, CANCER RES, V54, P6348; Rickman DW, 1999, DEV BRAIN RES, V115, P41, DOI 10.1016/S0165-3806(99)00046-2; SATO N, 1994, J NEUROBIOL, V25, P1227, DOI 10.1002/neu.480251005; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Urabe T, 1998, NEUROSCI LETT, V247, P159, DOI 10.1016/S0304-3940(98)00311-5; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; VAUX DL, 1992, INT IMMUNOL, V4, P821, DOI 10.1093/intimm/4.7.821; Vekrellis K, 1997, DEVELOPMENT, V124, P1239; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; White MJ, 1997, ANN NEUROL, V42, P580, DOI 10.1002/ana.410420408; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yan CH, 2000, J CEREBR BLOOD F MET, V20, P620, DOI 10.1097/00004647-200003000-00020; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	93	84	118	1	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2000	17	10					831	841		10.1089/neu.2000.17.831			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	364LR	WOS:000089894300004	11063051				2022-02-06	
J	Anderson, VA; Catroppa, C; Rosenfeld, J; Haritou, F; Morse, SA				Anderson, VA; Catroppa, C; Rosenfeld, J; Haritou, F; Morse, SA			Recovery of memory function following traumatic brain injury in pre-school children	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; CHILDHOOD; SKILLS; AGE; ADOLESCENTS; DISCOURSE; DEFICITS; SEQUELAE; MOTOR	Traumatic brain injury (TBI) may have a profound impact on a child's ongoing development. Various risk factors have been found to predict outcome, but considerable variability remains unexplained. This study used a prospective, longitudinal design to examine recovery of memory function following TBI within the pre-school period. Ninety-six children with TBI were divided according to injury severity (mild, moderate, severe), and compared to age and SES matched healthy controls (n = 35). Children were evaluated acutely and at 6,12 and 18 months post-injury using intellectual and memory measures. Results showed a relationship between greater injury severity and poorer intellectual ability. This dose-response relationship was not clearly evident for memory function within the acute phase of recovery, but developed over time, with greater memory impairments evident for children with more severe TBI by 12 months post-injury. Children with mild TBI exhibited few memory problems. Findings are discussed in the context of theories of plasticity and recovery of function.	Univ Melbourne, Dept Psychol, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Res Inst, Melbourne, Vic, Australia		Anderson, VA (corresponding author), Univ Melbourne, Dept Psychol, Parkville, Vic 3052, Australia.	anderson@psych.unimelb.edu.au	Catroppa, Cathy/AAX-9458-2021	Catroppa, Cathy/0000-0002-9750-0436			Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P283; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; ANDERSON V, 1988, P 13 ANN BRAIN IMP C, P223; Anderson V., 1995, NEUROPSYCHOLOGICAL A; ANDERSON V, UNPUB PEDIAT NEUROSU; ANDERSON V, IN PRESS BRIT J CANC; Anderson V A, 1996, Appl Neuropsychol, V3, P128, DOI 10.1207/s15324826an0303&4_5; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; CATROPPA C, IN PRESS CHILD NEURO; CATROPPA C, UNPUB NEUROPSYCHOLOG; CHAPLIN D, 1993, ARCH PHYS MED REHAB, V74, P161; Chapman S.B, 1995, TRAUMATIC HEAD INJUR, P95; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; Ciccetti D., 1984, VINELAND ADAPTIVE BE; Cowan N., 1997, DEV MEMORY CHILDHOOD, P163; Dennis M, 1996, J NEURO-ONCOL, V29, P91, DOI 10.1007/BF00165522; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; DENNIS M, 1985, J CLIN EXP NEUROPSYC, V7, P526, DOI 10.1080/01688638508401283; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Dennis M, 1989, CLIN NEUROPSYCHOLOGY, P85; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; EWINGCOBBS L, 1994, NEUROSURGERY, V35, P225, DOI 10.1227/00006123-199408000-00007; Farmer JE, 1999, DEV NEUROPSYCHOL, V15, P269, DOI 10.1080/87565649909540749; Garth J, 1997, Pediatr Rehabil, V1, P99; GRONWALL D, J INT NEUROPSYCHOLOG, V3, P592; HUDPETH W, 1990, J EDUC PSYCHOL, V82, P881; JORDAN FM, 1994, BRAIN INJURY, V8, P501, DOI 10.3109/02699059409151002; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; Kennard MA, 1936, AM J PHYSIOL, V115, P138, DOI 10.1152/ajplegacy.1936.115.1.138; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; Kraus JF., 1995, TRAUMATIC HEAD INJUR, P117; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; LANGECASSOCK H, NEUROPEDIATRIE, V19, P105; Lenneberg E.H., 1967, BIOL FDN LANGUAGE; Levin H S, 1991, Neurosurg Clin N Am, V2, P457; McCarthy D., 1972, MANUAL MCCARTHY SCAL; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; SMITH A, 1983, J CONSULT CLIN PSYCH, V51, P768, DOI 10.1037/0022-006X.51.5.768; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; TEASDALE G, 1974, LANCET, V2, P81; THATCHER RW, 1991, DEV NEUROPSYCHOL, V7, P397, DOI 10.1080/87565649109540500; Todd JA, 1996, NEUROPSYCHOL REHABIL, V6, P81, DOI 10.1080/713755500; TOMPKINS C, 1990, BRAIN LANG, V40, P86; Walsh K. W., 1978, NEUROPSYCHOLOGY CLIN; Wechsler D., 1989, MANUAL PRESCHOOL PRI; Wechsler D., 1991, MANUAL WECHSLER INTE, V3rd; Wilson BA, 1991, RIVERMEAD BEHAV MEMO; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; [No title captured]	53	84	84	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2000	14	8					679	692					14	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	342XT	WOS:000088672000001	10969886				2022-02-06	
J	Douglas, JM; Spellacy, FJ				Douglas, JM; Spellacy, FJ			Correlates of depression in adults with severe traumatic brain injury and their carers	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; SOCIAL SUPPORT; FAMILY; PATIENT; STRESS; HEALTH; DISABILITY; CAREGIVERS; RELATIVES; SCALE	Although it is generally accepted that social support plays a role in the maintenance of psychological well-bring, there has been relatively little direct investigation of the role that social support may play in affecting post-injury depressive symptoms and mediating the effects of traumatic brain injury (TBI). Consequently, social support was selected as the framework within which to investigate possible indicators of depression in adults with severe TBI and their carers. The authors were interested in the degree of association bt between social support and the criterion variable of depression in the context of demographic and disability-related variables that have been identified as significant correlates of depression. Thirty-five adults with severe TBI (PTA > 7 days) and their primary carts participated in the study. Time post-injury ranged from 3.5-10 years and all the participants were living in the community. Fifty-seven per cent of the adults with TBI and 60% of their carers were classified as showing significant symptoms of depression. As hypothesized, social support contributed significantly to the prediction of depression. In particular, strong-tie support appeared ru be an important indicator of well-being for both dir participants with TBI and their carers.	La Trobe Univ, Sch Human Commun Sci, Bundoora, Vic 3083, Australia; Univ Victoria, Dept Psychol, Victoria, BC V8W 2Y2, Canada		Douglas, JM (corresponding author), La Trobe Univ, Sch Human Commun Sci, Bundoora, Vic 3083, Australia.	J.Douglas@latrobe.edu.au	Douglas, Jacinta M/C-2380-2009	Douglas, Jacinta/0000-0003-0940-6624			ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/0090-5550.39.1.29; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; BLUMENTHAL MD, 1975, ARCH GEN PSYCHIAT, V32, P985; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Caplan R. D., 1979, MENTAL HLTH EC, P89; COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037//0033-2909.98.2.310; Coughlan AK, 1988, CLIN REHABIL, V2, P207, DOI DOI 10.1177/026921558800200305; DEAN A, 1977, J NERV MENT DIS, V165, P403, DOI 10.1097/00005053-197712000-00006; DEROGATIS R, 1983, SCL90R ADM PROCEDURE; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Duncan-Jones P., 1981, NEUROSIS SOCIAL ENV; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; Ensel W., 1986, SOCIAL SUPPORT LIFE, P129; FINLAYJONES RA, 1979, BRIT J PSYCHIAT, V134, P609, DOI 10.1192/bjp.134.6.609; GOVE WR, 1979, AM SOCIOL REV, V44, P126, DOI 10.2307/2094822; House J.S., 1985, SOCIAL SUPPORT HLTH, P83; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kinsella G, 1989, Int Disabil Stud, V11, P9; Kozloff R., 1987, J HEAD TRAUMA REHAB, V2, P14, DOI [DOI 10.1097/00001199-198709000-00004, 10.1097/00001199-198709000-00004]; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; Lin N., 1986, SOCIAL SUPPORT LIFE; Lin N., 1986, SOCIAL SUPPORT LIFE, P17, DOI DOI 10.1016/B978-0-12-450660-2.50008-2; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; Liss M, 1990, Int J Rehabil Res, V13, P309, DOI 10.1097/00004356-199012000-00004; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; MOORE A, 1993, BRAIN INJURY, V7, P247, DOI 10.3109/02699059309029677; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PEARLIN LI, 1981, J HEALTH SOC BEHAV, V22, P337, DOI 10.2307/2136676; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; SARASON IG, 1985, PSYCHOSOM MED, V47, P156, DOI 10.1097/00006842-198503000-00007; SCHAEFER C, 1981, Journal of Behavioral Medicine, V4, P381, DOI 10.1007/BF00846149; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; WILKINSON SM, 1989, CLIN REHABIL, V3, P317; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4; ZUNG WW, 1974, MEASUREMENT DEPRESSI; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008	45	84	86	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2000	14	1					71	88		10.1080/026990500120943			18	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	274CY	WOS:000084747200008	10670663				2022-02-06	
J	Munar, F; Ferrer, AM; de Nadal, M; Poca, MA; Pedraza, S; Sahuquillo, J; Garnacho, A				Munar, F; Ferrer, AM; de Nadal, M; Poca, MA; Pedraza, S; Sahuquillo, J; Garnacho, A			Cerebral hemodynamic effects of 7.2% hypertonic saline in patients with head injury and raised intracranial pressure	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	1998 Annual Meeting of the European-Society-of-Anesthesiology	MAY, 1998	BARCELONA, SPAIN	European Soc Anesthesiol		cerebral blood flow; cerebral perfusion pressure; head injury; hemodynamics; hypertonic saline; intracranial pressure; osmolality	LACTATED RINGERS SOLUTION; SEVERE HEMORRHAGIC-SHOCK; TRAUMATIC BRAIN INJURY; ORGAN BLOOD-FLOW; PORCINE MODEL; WATER-CONTENT; RESUSCITATION; FLUID; HYPERTENSION; MANNITOL	The aim of the present study was to investigate the acute effects of 7.2% hypertonic saline (HS) on intracranial pressure (ICP), cerebral and systemic hemodynamics, serum sodium, and osmolality in 14 patients with moderate and severe traumatic brain injury (Glasgow Coma Scale less than or equal to 13) and raised ICP (>15 mm Hg) within the first 72 h postinjury. After CO2 reactivity and autoregulation were tested, each patient received a 15-min infusion of 7.2% HS (1,232 mEq/L, volume 1.5 mL/kg). ICP, serial hemodynamics, cerebral blood flow (CBF) estimated from cerebral arteriovenous oxygen content difference (AVDO(2)), and laboratory variables, including serum osmolality, electrolytes, urea, and creatinine were collected before infusion (T-0) and at 5, 30, 60, and 120 min after (T-5, T-30, T-60, T-120). Urine output was measured 2 h before infusion and at T-120. While CO2 reactivity was preserved in all patients, autoregulation was preserved in only four. ICP decreased to about 30% of base line (p = 0.0001) during the whole study period. During the first hour after infusion, cerebral perfusion pressure (p less than or equal to 0.04) and cardiac index (CI; p less than or equal to 0.01) increased, while systemic vascular resistance index fell (p less than or equal to 0.05). Heart rate increased (p less than or equal to 0.04) during the first 30 min. Pulmonary artery occlusion pressure (PAOP) increased (p = 0.004) at T-5. There were no significant changes in mean arterial blood pressure (MABP), urine output, and estimated CBF. A significant positive correlation (r = 0.75; p = 0.02) between ICP and serum osmolality was found at T-5. The administration of 7.2% HS in patients with traumatic brain injury significantly reduces ICP without significant changes in relative global CBF (expressed as 1/AVDO(2)), increases CI and transiently increases PAOP, without changing MABP and urine output. The correlation between changes in osmolality and ICP supports the hypothesis that HSS may in part decrease ICP by means of an osmotic mechanism.	Univ Barcelona, Hosp Gen Valle Hebron, Dept Anesthesiol, E-08035 Barcelona, Spain; Univ Barcelona, Hosp Gen Valle Hebron, Dept Neurosurg, E-08035 Barcelona, Spain; Univ Barcelona, Hosp Gen Valle Hebron, Dept Neuroradiol, E-08035 Barcelona, Spain; Univ Barcelona, Hosp Gen Valle Hebron, Neurotraumatol Res Unit, E-08035 Barcelona, Spain		Munar, F (corresponding author), Hosp Gen Valle Hebron, Unidad Neurotraumatol, Hosp Traumatol, Paseo Vall Hebron 119-129, E-08035 Barcelona, Spain.	davaz@i3d.es	de Nadal, Miriam/J-8127-2017; pedraza, salvador/AAC-1728-2019; Garnacho, Angel/A-9309-2013; Sahuquillo, Juan/B-3577-2008; Poca, Maria A./B-8475-2008; Bauza, Francisca Munar/AAB-6682-2019	de Nadal, Miriam/0000-0002-4559-2463; pedraza, salvador/0000-0003-2517-4413; Sahuquillo, Juan/0000-0003-0713-5875; Poca, Maria A./0000-0002-3831-0536; Bauza, Francisca Munar/0000-0003-4579-3027			BAKAY L, 1952, SURG GYNECOL OBSTET, V95, P67; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BINET L, 1949, CR SOC BIOL, V143, P1416; DEFELIPPE J, 1980, LANCET, V2, P1002; DUCEY JP, 1989, J TRAUMA, V29, P1510, DOI 10.1097/00005373-198911000-00010; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; GOETTING MG, 1990, CRIT CARE MED, V18, P1220, DOI 10.1097/00003246-199011000-00006; GUNNAR W, 1988, SURGERY, V103, P398; Hartl R, 1997, ACT NEUR S, V70, P126; Hartl R, 1997, J TRAUMA, V42, pS41, DOI 10.1097/00005373-199705001-00008; HOLCROFT JW, 1987, ANN SURG, V206, P279, DOI 10.1097/00000658-198709000-00006; JENNETT B, 1975, LANCET, V1, P480; KIEN ND, 1991, ANESTH ANALG, V73, P597; KOCH T, 1994, ACTA ANAESTH SCAND, V38, P104, DOI 10.1111/j.1399-6576.1994.tb03849.x; KREIMEIER U, 1990, J SURG RES, V49, P493, DOI 10.1016/0022-4804(90)90174-Z; LASSEN NA, 1959, PHYSIOL REV, V39, P183, DOI 10.1152/physrev.1959.39.2.183; MANINGAS PA, 1987, CRIT CARE MED, V15, P1121, DOI 10.1097/00003246-198712000-00009; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; OLSEN KS, 1993, ANESTHESIOLOGY, V79, P666, DOI 10.1097/00000542-199310000-00006; OMAHONY JB, 1984, J TRAUMA, V24, P869, DOI 10.1097/00005373-198410000-00001; PROUGH DS, 1985, CRIT CARE MED, V13, P407, DOI 10.1097/00003246-198505000-00008; PROUGH DS, 1991, ANESTHESIOLOGY, V75, P319, DOI 10.1097/00000542-199108000-00021; PROUGH DS, 1986, J NEUROSURG, V64, P627, DOI 10.3171/jns.1986.64.4.0627; RAMMING S, 1994, J TRAUMA, V37, P705, DOI 10.1097/00005373-199411000-00003; READ RC, 1960, CIRC RES, V8, P538, DOI 10.1161/01.RES.8.3.538; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROSNER MJ, 1987, NEUROSURGERY, V21, P147, DOI 10.1227/00006123-198708000-00003; Sahuquillo J, 1998, ACT NEUR S, V71, P233; SAHUQUILLO J, 1994, NEUROCHEMICAL MONITO, P180; Schatzmann C, 1998, ACT NEUR S, V71, P31; SCHMIDT JF, 1990, J CARDIOVASC PHARM, V15, P983, DOI 10.1097/00005344-199006000-00017; SCHMOKER JD, 1992, J TRAUMA, V33, P476, DOI 10.1097/00005373-199209000-00024; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; SILVA MRF, 1987, AM J PHYSIOL, V253, pH751, DOI 10.1152/ajpheart.1987.253.4.H751; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; STANFORD GG, 1989, ARCH SURG-CHICAGO, V124, P733; STIFF JL, 1979, ANESTH ANALG, V58, P42; Suarez JI, 1998, CRIT CARE MED, V26, P1118, DOI 10.1097/00003246-199806000-00038; Sztark F, 1997, ANN FR ANESTH, V16, P282, DOI 10.1016/S0750-7658(97)86412-X; Taylor G, 1996, J PEDIATR SURG, V31, P65, DOI 10.1016/S0022-3468(96)90321-8; TODD MM, 1985, J NEUROSURG, V63, P944, DOI 10.3171/jns.1985.63.6.0944; TRAVERSO LW, 1987, J TRAUMA, V27, P32, DOI 10.1097/00005373-198701000-00006; UZZELL BP, 1986, J NEUROSURG, V65, P630, DOI 10.3171/jns.1986.65.5.0630; VASSAR MJ, 1993, ARCH SURG-CHICAGO, V128, P1003; VELASCO IT, 1980, AM J PHYSIOL, V239, pH664, DOI 10.1152/ajpheart.1980.239.5.H664; WALSH JC, 1991, J SURG RES, V50, P284, DOI 10.1016/0022-4804(91)90192-O; WEINSTABL C, 1991, ANESTHESIOLOGY, V75, pA201; WISNER DH, 1990, J TRAUMA, V30, P75, DOI 10.1097/00005373-199001000-00011; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478; ZORNOW MH, 1989, J TRAUMA, V29, P484, DOI 10.1097/00005373-198904000-00011	55	84	87	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2000	17	1					41	51		10.1089/neu.2000.17.41			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Neurosciences & Neurology	278WR	WOS:000085012400004	10674757				2022-02-06	
J	Murakami, N; Yamaki, T; Iwamoto, Y; Sakakibara, T; Kobori, N; Fushiki, S; Ueda, S				Murakami, N; Yamaki, T; Iwamoto, Y; Sakakibara, T; Kobori, N; Fushiki, S; Ueda, S			Experimental brain injury induces expression of amyloid precursor protein, which may be related to neuronal loss in the hippocampus	JOURNAL OF NEUROTRAUMA			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; ALZHEIMERS-DISEASE; BETA-PROTEIN; HEAD-INJURY; NEUROFIBRILLARY TANGLES; DEMENTIA-PUGILISTICA; LEVELS DECREASE; MESSENGER-RNA; RAT; DEPOSITION	Previous reports have demonstrated that some focal brain injuries increase amyloid precursor protein (APP) immunoreactivity in the region surrounding the injury where it was localized, in damaged axons and in pre-alpha 2 cells of the entorhinal cortex. However, to date, APP expession in the hippocampus remote from the impact site has not been comprehensively studied. Therefore, we have evaluated APP expression not only in the locally injured cerebral cortex but also in the hippocampus remote from the impact site, In the present paper, diffuse axonal injury was induced in rats in midline fluid percussion injury, APE expression was examined post injury using Western blot analysis and immunohistochemistry. Western blot analysis demonstrated that the expression of 100-kd APP was increased in both the cerebral cortex and hippocampus 24 h after injury. It then decreased in the hippocampus, but did not change in the cerebral cortex, 7 days after injury, Immunohistochemical studies showed increased immunoreactivity of APP in the neuronal perikarya and reactive astrocytes near the region of injury in the cerebral cortex 24 h to 7 days after injury, In the hippocampus, APP accumulated in the CA3 neurons 24 h and 3 days after injury, although no hemorrhagic lesions were seen at that site, The APP positive neurons in CA3 showed shrunken cell bodies and pyknotic nuclei 3 days after injury, and some of the neurons in CA3 had disappeared by 7 days postinjury, The results of present study suggest that traumatic brain injury induces overexpression and accumulation of APP in neuronal perikarya and that these events are followed by degeneration of CA3 neurons, Further, the decline in APP expression in the hippocampus is thought to be due to neuronal loss in CA3 subsector.	Kyoto Prefectural Univ Med, Dept Neurosurg, Kamigyo Ku, Kyoto 602, Japan; Kyoto Prefectural Univ Med, Dept Dynam Pathol, Res Inst Neurol Dis & Geriatr, Kyoto 602, Japan		Murakami, N (corresponding author), Kyoto Prefectural Univ Med, Dept Neurosurg, Kamigyo Ku, Kawaramachi Hirokoji, Kyoto 602, Japan.						ALLSOP D, 1990, AM J PATHOL, V136, P255; CLINTON J, 1991, NEUROPATH APPL NEURO, V17, P69, DOI 10.1111/j.1365-2990.1991.tb00695.x; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; DOYLE E, 1990, NEUROSCI LETT, V115, P97, DOI 10.1016/0304-3940(90)90524-D; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GABUZDA D, 1994, J BIOL CHEM, V269, P13623; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HAASS C, 1991, J NEUROSCI, V11, P3783; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HILBICH C, 1993, J BIOL CHEM, V268, P26571; HUBER G, 1993, BRAIN RES, V603, P348, DOI 10.1016/0006-8993(93)91261-P; Iwamoto Y, 1997, NEUROSURGERY, V40, P163, DOI 10.1097/00006123-199701000-00036; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBLANC AC, 1992, J NEUROSCI RES, V31, P635, DOI 10.1002/jnr.490310407; Lee RKK, 1996, ANN NY ACAD SCI, V777, P338, DOI 10.1111/j.1749-6632.1996.tb34443.x; LEE RKK, 1995, P NATL ACAD SCI USA, V92, P8083, DOI 10.1073/pnas.92.17.8083; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; LYETH BG, 1993, MOL CHEM NEUROPATHOL, V18, P247, DOI 10.1007/BF03160117; MARUYAMA K, 1990, NATURE, V347, P566, DOI 10.1038/347566a0; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, P28; MURAKAMI N, 1993, ADV NEUROTRAUMA RES, V5, P42; NAKAMURA Y, 1992, NEUROSCI LETT, V136, P95, DOI 10.1016/0304-3940(92)90656-R; Nicoll JAR, 1996, ANN NY ACAD SCI, V777, P271, DOI 10.1111/j.1749-6632.1996.tb34431.x; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; Pierce JES, 1996, J NEUROSCI, V16, P1083; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; RINK A, 1995, AM J PATHOL, V147, P1575; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROBERTS GW, 1988, LANCET, V2, P1456; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SCHUBERT W, 1991, BRAIN RES, V563, P184, DOI 10.1016/0006-8993(91)91532-6; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHIGEMOTO R, 1992, J COMP NEUROL, V322, P121, DOI 10.1002/cne.903220110; SHINVERS BD, 1988, EMBO J, V7, P1365; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEPHENSON DT, 1992, BRAIN RES, V593, P128, DOI 10.1016/0006-8993(92)91274-I; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; WALLACE WC, 1995, J NEUROSCI, V15, P4896; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WILLIAM E, 1992, P NATL ACAD SCI USA, V89, P2551; YAMAKI T, 1994, J NEUROTRAUM, V11, P613, DOI 10.1089/neu.1994.11.613; Yamaki T, 1997, BRAIN RES, V752, P151, DOI 10.1016/S0006-8993(96)01469-2; YOSHIKAWA K, 1992, NATURE, V359, P64, DOI 10.1038/359064a0	69	84	87	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	1998	15	11					993	1003		10.1089/neu.1998.15.993			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	139RN	WOS:000077043400008	9840772				2022-02-06	
J	Buxbaum, LJ; Schwartz, MF; Montgomery, MW				Buxbaum, LJ; Schwartz, MF; Montgomery, MW			Ideational apraxia and naturalistic action	COGNITIVE NEUROPSYCHOLOGY			English	Article							ALZHEIMERS-DISEASE; LEFT-HEMISPHERE; NEGLECT; DAMAGE	It is frequently claimed that ideational apraxia, an impairment of the performance of complex actions with objects, is a left-hemisphere syndrome. We assessed the consequences of left-hemisphere damage for naturalistic action performance in two studies. In Study 1, we compared the action errors of left-hemisphere stroke patients (LCVA) to previously reported patients with right-hemisphere stroke (RCVA) and closed head injury (CHI), and found that LCVA were no more vulnerable to errors of action than the other patient groups once differences in severity were controlled. In Study 2, we compared the naturalistic action performance of a patient with severe ideational apraxia and left-hemisphere damage to that of two RCVA patients of equal clinical severity. There was considerable quantitative and qualitative similarity in the errors of the three patients. From these-and other findings, we argue that deficits in left-hemisphere systems do not compromise complex action in a unique or transparent manner. We offer an alternative account based on nonspecific resource limitations that accommodates the data from all patient groups.	Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Temple Univ, Philadelphia, PA 19122 USA		Buxbaum, LJ (corresponding author), Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.						ALLPORT A, 1993, ATTENTION PERFORMANC, V14; Baddeley A.D., 1994, NEUROPSYCHOLOGY, V8, P485, DOI [10.1037/0894-4105.8.4.485, DOI 10.1037/0894-4105.8.4.485]; Baddeley A.D., 1986, WORKING MEMORY; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; BROWN JW, 1988, AGNOSIA APRAXIA SELE; Buxbaum LJ, 1997, COGNITIVE NEUROPSYCH, V14, P219, DOI 10.1080/026432997381565; Buxbaum LJ, 1996, NEUROPSYCHOLOGIA, V34, P113, DOI 10.1016/0028-3932(95)00088-7; COSLETT HB, 1987, NEUROLOGY, V37, P957, DOI 10.1212/WNL.37.6.957; DERENZI E, 1988, BRAIN, V111, P1173, DOI 10.1093/brain/111.5.1173; DERENZI E, 1968, NEUROPSYCHOLOGIA, V6, P41, DOI 10.1016/0028-3932(68)90037-7; *FIM, 1993, FIM GUID US UN DAT S; HAALAND KY, 1984, BRAIN COGNITION, V3, P370, DOI 10.1016/0278-2626(84)90029-0; HARRINGTON DL, 1991, NEUROPSYCHOLOGIA, V29, P147, DOI 10.1016/0028-3932(91)90017-3; HECAEN H, 1981, HDB CLIN NEUROPSYCHO; HEILMAN KM, 1978, NEUROLOGY, V28, P229, DOI 10.1212/WNL.28.3.229; Howard D, 1992, PYRAMIDS PALM TREES; Kertesz A., 1982, W APHASIA BATTERY; KIMURA D, 1982, PHILOS T ROY SOC B, V298, P135, DOI 10.1098/rstb.1982.0077; KIMURA D, 1974, BRAIN, V97, P337, DOI 10.1093/brain/97.1.337; Kleinbaum D.G., 1978, APPL REGRESSION ANAL; LEHMKUHL G, 1981, CORTEX, V17, P153, DOI 10.1016/S0010-9452(81)80017-2; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; Liepmann H., 1920, ERGEBNISSE GESAMTEN, V27, P516; LUCCHELLI F, 1993, INT J GERIATR PSYCH, V8, P413, DOI 10.1002/gps.930080508; Luria A.R., 1966, HIGHER CORTICAL FUNC; MORLAAS J, 1928, CONTRIBUTION ETUDE A; NORMAN DA, 1986, CONSCIOUSNESS SELF R, V0004; OCHIPA C, 1989, ANN NEUROL, V25, P190, DOI 10.1002/ana.410250214; Pocock, 1983, CLIN TRIALS PRACTICA; POECK K, 1983, J NEUROL, V230, P1, DOI 10.1007/BF00313591; RAPCSAK SZ, 1989, NEUROLOGY, V39, P664, DOI 10.1212/WNL.39.5.664; Reason J., 1990, HUMAN ERROR INTERNET, DOI DOI 10.1017/CBO9781139062367; ROBERTSON I, 1992, INT J NEUROSCI, V62, P45; ROBERTSON IH, 1993, UNILATERAL NEGLECT C, P00257; Schwartz M. F., 1997, APRAXIA NEUROPSYCHOL, P269; SCHWARTZ MF, 1991, COGN NEUROPSYCHOL, V8, P381, DOI 10.1080/02643299108253379; Schwartz MF, 1998, NEUROPSYCHOLOGY, V12, P13, DOI 10.1037/0894-4105.12.1.13; SCHWARTZ MF, 1998, NATURALISTIC ACTION; SHALLICE T, 1989, BRAIN, V112, P1587, DOI 10.1093/brain/112.6.1587; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Warrington E. K., 1991, VISUAL OBJECT SPACE; Wilson B., 1999, BEHAVIOURAL INATTENT BEHAV INATTENTION TE	42	84	84	0	4	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0264-3294			COGNITIVE NEUROPSYCH	Cogn. Neuropsychol.	SEP-DEC	1998	15	6-8					617	643		10.1080/026432998381032			27	Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	156VL	WOS:000078022700006	22448839				2022-02-06	
J	Lee, KR; Drury, I; Vitarbo, E; Hoff, JT				Lee, KR; Drury, I; Vitarbo, E; Hoff, JT			Seizures induced by intracerebral injection of thrombin: A model of intracerebral hemorrhage	JOURNAL OF NEUROSURGERY			English	Article						intracerebral hemorrhage; seizure; brain edema; coagulation cascade; thrombin; rat	POST-TRAUMATIC EPILEPSY; BRAIN EDEMA; INHIBITORS; ACTIVATION; IRON	The coagulation cascade plays an important role in brain edema formation caused by intracerebral blood. In particular, thrombin produces brain injury via direct brain cell toxicity. Seizures and increased cerebral electrical activity are commonly associated with intracerebral blood and are possible effects of thrombin leading to cell injury in the brain. In this study, artificial clots containing concentrations of thrombin found in hematomas were infused intracerebrally in rats. The animals were observed clinically for seizure activity, behavior, and neurological deficits. Several animals underwent video electroencephalographic (EEG) monitoring during intracerebral infusion and for 30 minutes postinfusion. All animals were killed 24 hours after injection, and brain water and ion contents were measured to determine the amount of brain edema. Clinically, thrombin produced focal motor seizures in all animals. None of the control animals or those receiving N alpha-(2-Naphthalenesulfonyl-glycyl)-4-amidino-DL-phenylalanine-piperidide (alpha-NAPAP), a thrombin inhibitor added to the thrombin, showed clinical evidence of seizures. Of the rats undergoing EEG monitoring, all animals receiving thrombin showed electrical evidence of seizure activity, whereas none of the control animals exhibited seizure activity. There was no evidence of seizure activity on EEG monitoring when alpha-NAPAP was injected along with the thrombin. In addition, the artificial clots containing thrombin produced agitation and a circling tendency in the rats, along with brain edema. These results indicate that the coagulation cascade is involved in seizure production and increased brain electrical activity, which contribute to the neurological deficits and brain edema formation that are seen with intracerebral hemorrhage.	UNIV MICHIGAN,DEPT SURG NEUROSURG,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT NEUROL,ANN ARBOR,MI 48109						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS023870, R01NS017760] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-23870, NS-17760] Funding Source: Medline		ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; BERGER AR, 1988, NEUROLOGY, V38, P1363, DOI 10.1212/WNL.38.9.1363; CERVONI L, 1994, NEUROSURG REV, V17, P185, DOI 10.1007/BF00418427; FAUGHT E, 1989, NEUROLOGY, V39, P1089, DOI 10.1212/WNL.39.8.1089; KAPLAN HA, 1961, EPILEPSIA, V2, P111; LANCMAN ME, 1993, EPILEPSIA, V34, P141, DOI 10.1111/j.1528-1157.1993.tb02386.x; Lee KR, 1996, ACTA NEUROCHIR, V138, P396, DOI 10.1007/BF01420301; LEE KR, 1995, J NEUROSURG, V83, P1045, DOI 10.3171/jns.1995.83.6.1045; Lee KR, 1996, J NEUROSURG, V84, P91, DOI 10.3171/jns.1996.84.1.0091; LEE KR, 1994, INTRACRANIAL PRESSUR, V9, P70; LEE KR, 1996, NEUROSURG FOCUS, V1; LEE ST, 1992, J NEUROSURG, V76, P435, DOI 10.3171/jns.1992.76.3.0435; LIPTON RB, 1987, J NEUROL, V234, P86, DOI 10.1007/BF00314107; MAFFRAND JP, 1992, NOUV REV FR HEMATOL, V34, P405; MARKWARDT F, 1988, NOUV REV FR HEMATOL, V30, P161; MIRSHAHI M, 1989, BLOOD, V74, P1025; Paxinos G., 1982, RAT BRAIN STEREOTAXI, V1st ed.; RICHARDSON E P Jr, 1954, Epilepsia, V3, P49, DOI 10.1111/j.1528-1157.1954.tb03153.x; SEEGERS WH, 1962, PROTHROMBIN, P417; SUNG CY, 1989, J NEUROL NEUROSUR PS, V52, P1273, DOI 10.1136/jnnp.52.11.1273; SUZUKI M, 1992, STROKE, V23, P1181, DOI 10.1161/01.STR.23.8.1181; SVENDSEN L, 1984, THROMB RES, V34, P457, DOI 10.1016/0049-3848(84)90250-0; VAUGHAN PJ, 1995, J NEUROSCI, V15, P5389; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006; WILLMORE LJ, 1990, EPILEPSIA, V31, pS67, DOI 10.1111/j.1528-1157.1990.tb05861.x; WILLMORE LJ, 1978, SCIENCE, V200, P1501, DOI 10.1126/science.96527; WILLMORE LJ, 1978, ANN NEUROL, V4, P329, DOI 10.1002/ana.410040408; YANG GY, 1994, J NEUROSURG, V81, P93, DOI 10.3171/jns.1994.81.1.0093	28	84	86	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	JUL	1997	87	1					73	78		10.3171/jns.1997.87.1.0073			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	XF331	WOS:A1997XF33100011	9202268				2022-02-06	
J	Goodman, JC; Valadka, AB; Gopinath, SP; Cormio, M; Robertson, CS				Goodman, JC; Valadka, AB; Gopinath, SP; Cormio, M; Robertson, CS			Lactate and excitatory amino acids measured by microdialysis are decreased by pentobarbital coma in head-injured patients	JOURNAL OF NEUROTRAUMA			English	Article						intracranial pressure; barbiturate coma; pentobarbital; microdialysis; lactic acid; amino acids; glutamate; aspartate; excitotoxicity	IN-VIVO MICRODIALYSIS; CEREBRAL-ARTERY OCCLUSION; CONCUSSIVE BRAIN INJURY; BARBITURATE THERAPY; BLOOD-FLOW; NEURONAL ENVIRONMENT; ISCHEMIA; DAMAGE; TEMPERATURE; PATHOPHYSIOLOGY	Primary traumatic brain injury and secondary ischemic/hypoxic injury are being increasingly characterized at the neurochemical level. Neurochemical monitoring using microdialysis has shown that these forms of tissue damage share many common features. In particular, anaerobic glycolysis with increased lactate production and release of excitatory amino acids into the extracellular space are seen in both conditions. Clinical microdialysis studies have heretofore focused on methodological issues, establishment of basal analyte values, and clinico-neurochemical correlation. Here we report the neurochemical consequences of therapeutic intervention in head injury. Specifically, induction of thiopental coma to manage severe increased intracranial pressure in seven patients was associated with a 37% reduction of lactate, 59% reduction of glutamate, and 66% reduction in aspartate in the extracellular space of the brain.	BAYLOR COLL MED, DEPT NEUROL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT NEUROSURG, HOUSTON, TX 77030 USA		Goodman, JC (corresponding author), BAYLOR COLL MED, DEPT PATHOL, 1 BAYLOR PLAZA, HOUSTON, TX 77030 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27616] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER		Bellec C, 1991, Agressologie, V32, P396; BENVENISTE H, 1990, PROG NEUROBIOL, V35, P195, DOI 10.1016/0301-0082(90)90027-E; BULLOCK R, 1992, NEUROCHEMICAL MONITO, V9, P443; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CHOI DW, 1993, CALCIUM GLUTAMATE IN; CROUGHWELL N, 1992, J THORAC CARDIOV SUR, V103, P549; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DURING MJ, 1991, MICRODIALYSIS NEUROS, V7, P450; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; GINSBERG MD, 1990, PROTECTION BRAIN ISC, P37; HAMBERGER A, 1991, J INTERN MED, V230, P375, DOI 10.1111/j.1365-2796.1991.tb00460.x; HAMBERGER A, 1995, NEUROL RES, V17, P97, DOI 10.1080/01616412.1995.11740295; HAMBERGER A, 1991, MICRODIALYSIS NEUROS, V7, P450; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HILLERED L, 1990, ACTA NEUROCHIR, V102, P91, DOI 10.1007/BF01405420; Hillered L, 1992, Clin Neuropharmacol, V15 Suppl 1 Pt A, p695A; HILLERED L, 1990, NEUROSCI LETT, V113, P328, DOI 10.1016/0304-3940(90)90606-A; HILLERED L, 1991, RES EXP MED, V191, P219, DOI 10.1007/BF02576677; HILLERED L, 1995, NEUROCHEMICAL MONITO, P59; KANTHAN R, 1995, J NEUROL NEUROSUR PS, V59, P326, DOI 10.1136/jnnp.59.3.326; KANTHAN R, 1995, STROKE, V26, P870, DOI 10.1161/01.STR.26.5.870; KATAYAMA Y, 1992, BRAIN RES, V584, P329, DOI 10.1016/0006-8993(92)90916-W; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, NEUROCHEMICAL MONITO, P72; KEHR J, 1993, J NEUROSCI METH, V48, P251, DOI 10.1016/0165-0270(93)90096-A; KRAIG RP, 1988, J CEREB BLOOD FLOW M, V10, P1; LANDOLT H, 1994, ACTA NEUROCHIR, P475; LANGEMANN H, 1995, CLIN NEUROL NEUROSUR, V97, P149, DOI 10.1016/0303-8467(94)00067-G; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; McIntosh TK, 1996, LAB INVEST, V74, P315; MELDRUM BS, 1994, NEUROLOGY, V44, P14; MEYERSON BA, 1990, LIFE SCI, V46, P301, DOI 10.1016/0024-3205(90)90037-R; MICHENFELDER JD, 1976, ARCH NEUROL-CHICAGO, V33, P345, DOI 10.1001/archneur.1976.00500050031006; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; PARSONS LH, 1994, CRIT REV NEUROBIOL, V8, P189; REA GL, 1983, NEUROSURGERY, V12, P401, DOI 10.1227/00006123-198304000-00005; REA GL, 1995, NEUROSURGERY, V3, P410; Robertson C S, 1995, New Horiz, V3, P410; Robertson CS, 1990, J NEUROTRAUM, V7, P1, DOI 10.1089/neu.1990.7.1; Robinson T. E., 1991, MICRODIALYSIS NEUROS; RONNEENGSTROM E, 1992, J CEREBR BLOOD F MET, V12, P873, DOI 10.1038/jcbfm.1992.119; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SCHEYER RD, 1994, NEUROLOGY, V44, P1469, DOI 10.1212/WNL.44.8.1469; SCHEYER RD, 1994, EPILEPSY RES, V18, P227, DOI 10.1016/0920-1211(94)90043-4; SHAPIRO HM, 1985, BRIT J ANAESTH, V57, P82, DOI 10.1093/bja/57.1.82; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; SMITH AL, 1972, ANESTHESIOLOGY, V36, P378, DOI 10.1097/00000542-197204000-00015; SMITH DS, 1980, ACTA PHYSIOL SCAND, P129; SMITH ML, 1986, J CEREBR BLOOD F MET, V6, P574, DOI 10.1038/jcbfm.1986.104; STEEN PA, 1980, ANESTHESIOLOGY, V53, P183; STEEN PA, 1978, J NEUROCHEM, V31, P1317, DOI 10.1111/j.1471-4159.1978.tb06257.x; TSUJI O, 1994, INTRACRANIAL PRESSUR, V9, P268; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; UNGERSTEDT U, 1987, LIFE SCI, V41, P861, DOI 10.1016/0024-3205(87)90181-0; UNGERSTEDT U, 1991, MICRODIALYSIS NEUROS, V7, P450; WEISEND MP, 1994, J NEUROSURG, V80, P120, DOI 10.3171/jns.1994.80.1.0120; [No title captured]	59	84	84	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	1996	13	10					549	556		10.1089/neu.1996.13.549			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	VQ834	WOS:A1996VQ83400001	8915906				2022-02-06	
J	Clark, RSB; Kochanek, PM; Obrist, WD; Wong, HR; Billiar, TR; Wisniewski, SR; Marion, DW				Clark, RSB; Kochanek, PM; Obrist, WD; Wong, HR; Billiar, TR; Wisniewski, SR; Marion, DW			Cerebrospinal fluid and plasma nitrite and nitrate concentrations after head injury in humans	CRITICAL CARE MEDICINE			English	Article; Proceedings Paper	24th Educational and Scientific Symposium of the Society-of-Critical-Care-Medicine	JAN 31-FEB 04, 1995	SAN FRANCISCO, CA	Soc Crit Care Med		cerebrospinal fluid; head injury; nitrate; nitrite; nitric oxide; hypothermia; critical illness; Glasgow Coma Scale; brain; neurologic emergencies	OXIDE SYNTHESIS; BRAIN INJURY; PERITONEAL-MACROPHAGES; MONONUCLEAR PHAGOCYTES; SPINAL-CORD; L-ARGININE; HYPOTHERMIA; INHIBITION; MECHANISM; CYTOKINES	Objectives: To measure cerebrospinal fluid and plasma nitrite and nitrate concentrations as indicators of nitric oxide production in adults after severe closed head injury. To determine if there is an association between cerebrospinal fluid and plasma nitrite and nitrate concentrations, and cerebral blood flow, arterio-jugular oxygen content difference, injury severity, and outcome after severe closed head injury. Design: A prospective, clinical study. Setting: Multidisciplinary intensive care unit. Patients: Fifteen comatose (Glasgow Coma Scale score of less than or equal to 7) adult patients with severe closed-head injury were studied during the prospective, randomized evaluation of the effect of moderate hypothermia (32 degrees C for 24 hrs) on neurologic outcome after closed-head injury. Seven patients were in the hypothermic group and eight patients were in the normothermic treatment group. Interventions: None. Measurements and Main Results: Patients were examined sequentially, every 12 hrs for 2 days. Intraventricular cerebrospinal fluid was assayed for nitrite and nitrate concentrations. Cerebral blood flow was measured by the (133)xenon intravenous method. Simultaneous blood samples were obtained for measurements of arterio-jugular oxygen content difference and plasma nitrite and nitrate concentrations. Cerebral metabolic rate for oxygen was calculated. Cerebrospinal fluid nitrite and nitrate concentrations were highest at 30 to 42 hrs vs. 6 to 18, 18 to 30, and 42 to 54 hrs (26.4 +/- 3.3 vs. 17.3 +/- 2.1, 20.0 +/- 2.2, and 18.8 +/- 2.4 mu M, respectively, p < .05). There was no difference over time in plasma nitrite and nitrate concentrations. Cerebral blood flow was increased and arterio-jugular oxygen content difference was reduced at 18 to 30, 30 to 42, and 42 to 54 hrs vs. 6 to 18 hrs (p < .05). At 30 to 42 hrs, cerebrospinal fluid nitrite and nitrate concentrations were 80% higher in patients who died vs. survivors (36.4 +/- 3.2 vs. 20.2 +/- 3.6, p < .05). Using a generalized, multivariate, linear regression model, both plasma nitrite and nitrate concentrations and Injury Severity Score independently predicted cerebrospinal fluid nitrite and nitrate concentrations (p < .00001 and p = .0053, respectively). Cerebral blood flow and arterio-jugular oxygen content difference were not associated with cerebrospinal fluid or plasma nitrite and nitrate concentrations using this model. Cerebrospinal fluid nitrite and nitrate concentrations were in creased over time in hypothermic vs. normothermic patients. But, where this difference occurred could not be determined by multiple comparisons (p = .03). The hypothermic patients had lower admission Glasgow Coma Scale scores than normothermic patients (p = .04) and tended to have higher Injury Severity Scores (p = .09). Conclusions: Increases in cerebrospinal fluid nitrite and nitrate concentrations peaked at 30 to 42 hrs after severe closed-head injury. This increase in cerebrospinal fluid nitrite and nitrate concentrations was greater in nonsurvivors. Also, cerebrospinal fluid and plasma nitrite and nitrate concentrations were associated with Injury Severity Score, suggesting that increased nitric oxide production in the brain is associated with injury severity and death. Hypothermia did not prevent the increase in cerebrospinal fluid nitrite and nitrate concentrations. Further study is required to determine the source of this increase in cerebrospinal fluid nitrite and nitrate concentrations and to further define the relationship to outcome and the effect of hypothermia on this process.	UNIV PITTSBURGH, SAFAR CTR RESUSCITAT RES, DEPT PEDIAT, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, SAFAR CTR RESUSCITAT RES, DEPT NEUROSURG, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, SAFAR CTR RESUSCITAT RES, DEPT SURG, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, SAFAR CTR RESUSCITAT RES, DEPT EPIDEMIOL, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, BRAIN TRAUMA RES CTR, PITTSBURGH, PA 15260 USA		Clark, RSB (corresponding author), UNIV PITTSBURGH, SAFAR CTR RESUSCITAT RES, DEPT ANESTHESIOL & CRIT CARE MED, 3434 5TH AVE, PITTSBURGH, PA 15260 USA.		Marion, Donald/AAR-5749-2021; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860; Wong, Hector/0000-0001-7989-1173	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2P50 NS30318-04A1, NS 30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, P20NS030318] Funding Source: NIH RePORTER		ALBINA JE, 1993, J IMMUNOL, V150, P5080; ARCHER S, 1993, FASEB J, V7, P349, DOI 10.1096/fasebj.7.2.8440411; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; BERNARD C, 1994, EUR J PHARM-ENVIRON, V270, P115, DOI 10.1016/0926-6917(94)90087-6; CHAO CC, 1992, J IMMUNOL, V149, P2736; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DING AH, 1988, J IMMUNOL, V141, P2407; FARACI FM, 1994, STROKE, V25, P692, DOI 10.1161/01.STR.25.3.692; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GOODMAN JC, 1995, J NEUROTRAUM, V12, P971; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Hewett S. J., 1995, Journal of Neurotrauma, V12, P350; IADECOLA C, 1995, AM J PHYSIOL-REG I, V268, pR286, DOI 10.1152/ajpregu.1995.268.1.R286; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P52, DOI 10.1038/jcbfm.1995.6; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P378, DOI 10.1038/jcbfm.1995.47; IADECOLA C, 1994, J CEREBR BLOOD F MET, V14, P175, DOI 10.1038/jcbfm.1994.25; IALENTI A, 1992, EUR J PHARMACOL, V211, P177, DOI 10.1016/0014-2999(92)90526-A; JACOB TD, 1993, J TRAUMA, V35, P590, DOI 10.1097/00005373-199310000-00015; JENNETT B, 1975, LANCET, V1, P480; KADER A, 1994, NEUROSURGERY, V35, P272, DOI 10.1227/00006123-199408000-00013; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; KUIPER MA, 1994, J NEUROL SCI, V121, P46, DOI 10.1016/0022-510X(94)90155-4; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MASS AIR, 1977, CEREBROSPINAL FLUID, P17; MERRILL JE, 1993, J IMMUNOL, V151, P2132; MILSTIEN S, 1994, J NEUROCHEM, V63, P1178; MONCADA S, 1992, ACTA PHYSIOL SCAND, V145, P201, DOI 10.1111/j.1748-1716.1992.tb09359.x; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1993, J CEREB BLOOD FLO S1, V13, pS571; OCHOA JB, 1991, ANN SURG, V214, P621, DOI 10.1097/00000658-199111000-00013; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; REULEN HJ, 1977, J NEUROSURG, V46, P24, DOI 10.3171/jns.1977.46.1.0024; ROSNER B, 1984, BIOMETRICS, V40, P1025, DOI 10.2307/2531153; STOCLET JC, 1993, CIRCULATION, V87, P77; TEASDALE G, 1974, LANCET, V2, P81; VISSER JJ, 1994, ANN INTERN MED, V120, P345, DOI 10.7326/0003-4819-120-4-199402150-00023; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; WONG HR, 1995, CRIT CARE MED, V23, P835, DOI 10.1097/00003246-199505000-00010; XIE QW, 1994, J LEUKOCYTE BIOL, V56, P576, DOI 10.1002/jlb.56.5.576; XU J, 1990, J NEUROCHEM, V55, P907, DOI 10.1111/j.1471-4159.1990.tb04577.x	50	84	87	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUL	1996	24	7					1243	1251		10.1097/00003246-199607000-00030			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	UX035	WOS:A1996UX03500030	8674343				2022-02-06	
J	SCHMIDT, RH; GRADY, MS				SCHMIDT, RH; GRADY, MS			LOSS OF FOREBRAIN CHOLINERGIC NEURONS FOLLOWING FLUID-PERCUSSION INJURY - IMPLICATIONS FOR COGNITIVE IMPAIRMENT IN CLOSED-HEAD INJURY	JOURNAL OF NEUROSURGERY			English	Article						FLUID-PERCUSSION INJURY; TRAUMATIC BRAIN INJURY; ACETYLCHOLINE; CATECHOLAMINE; NUCLEUS BASALIS; SEPTAL NUCLEUS; RAT	CONCUSSIVE BRAIN INJURY; DIFFUSE AXONAL INJURY; ALZHEIMERS-DISEASE; BASAL FOREBRAIN; TEGMENTAL NUCLEUS; NERVOUS-SYSTEM; RAT-BRAIN; PROJECTIONS; MEMORY; HISTOCHEMISTRY	Disturbances in memory, concentration, and problem solving are common after even mild to moderate traumatic brain injury. Because these functions are mediated in part by forebrain cholinergic and catecholaminergic innervation, in this study the authors sought to determine if experimental concussive injury produces detectable morphological damage to these systems. Fluid-percussion head injury, sufficient to cause a 13- to 14-minute loss of righting reflex, was produced in rats that had been anesthetized with halothane. Injury was delivered either at midline or 2 mm off midline and compared with appropriate sham-injured controls. After 11 to 15 days, the rat brains were stained in serial sections for choline acetyltransferase, tyrosine hydroxylase, dopamine beta-hydroxylase, acetylcholinesterase, and nicotinamide adenine dinucleotide phosphate diaphorase. Cell counts were determined for the entire population of ventrobasal forebrain cholinergic cells. Midline injury produced a bilateral loss of cholinergic neurons averaging 36% in area Chi (medial septal nucleus), 45% in Ch2 (nucleus of the diagonal band of Broca), and 41% in Ch4 (nucleus basalis of Meynart), (p less than or equal to 0.05). Lateralized injury resulted in cholinergic neuron loss of similar magnitude ipsilaterally (p less than or equal to 0.05), but a smaller contralateral loss of between 11% and 28%. No loss of neurons was detected in the pontomesencephalic cholinergic groups Ch5 and Ch6. There was no visible effect of head injury on forebrain dopamine or noradrenergic innervation. A significant and apparently selective loss of ventrobasal forebrain cholinergic neurons following brief concussive injury in rats is demonstrated in this study. This type of injury is known to produce significant disturbance in cognitive tasks linked to neocortical and hippocampal cholinergic function. It remains to be determined how this neuron loss occurs, whether it can be prevented with neuroprotective agents, how it affects innervation in target tissues, and whether it occurs in human victims of traumatic brain injury.	UNIV WASHINGTON, DEPT NEUROL SURG, SEATTLE, WA USA						NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS01371] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001371] Funding Source: NIH RePORTER		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ASTONJONES G, 1991, PROG BRAIN RES, V88, P501; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COYLE JT, 1983, SCIENCE, V219, P1184, DOI 10.1126/science.6338589; DEKKER AJAM, 1991, NEUROSCI BIOBEHAV R, V15, P299, DOI 10.1016/S0149-7634(05)80008-9; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DUBACH M, 1987, NEUROSCI LETT, V75, P205, DOI 10.1016/0304-3940(87)90298-9; FIBIGER HC, 1982, BRAIN RES REV, V4, P327, DOI 10.1016/0165-0173(82)90011-X; FRANCIS PT, 1985, NEW ENGL J MED, V313, P7, DOI 10.1056/NEJM198507043130102; GRAHAM DI, 1993, HEAD INJURY, P91; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Hagg Theo, 1993, P265; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hayes R L, 1986, Cent Nerv Syst Trauma, V3, P163; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HEPLER DJ, 1985, J NEUROSCI, V5, P866; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; Katayama Y, 1988, Brain Inj, V2, P51, DOI 10.3109/02699058809150931; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Katayama Y, 1986, Neurol Med Chir (Tokyo), V26, P1, DOI 10.2176/nmc.26.1; KAYAMA Y, 1992, BRAIN RES, V569, P210, DOI 10.1016/0006-8993(92)90632-J; KITT C A, 1988, Society for Neuroscience Abstracts, V14, P631; Kraus JF, 1993, HEAD INJURY, P1; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; MARTIN LJ, 1993, J NEUROSCI, V13, P2249; Mesulam M, 1988, NEUROTRANSMITTERS CO, P237, DOI [10.1007/978-1-4613-0925-3_15, DOI 10.1007/978-1-4613-0925-3_15]; MESULAM MM, 1987, ANN NEUROL, V22, P683, DOI 10.1002/ana.410220603; MESULAM MM, 1983, NEUROSCIENCE, V10, P1185, DOI 10.1016/0306-4522(83)90108-2; MIYAMOTO M, 1987, BRAIN RES, V419, P19, DOI 10.1016/0006-8993(87)90564-6; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; PALMER AM, 1990, FASEB J, V4, P2745, DOI 10.1096/fasebj.4.10.2165009; Povlishock John T., 1993, P185; RAJKOWSKI J, 1992, NEUR ABST, V18, P538; RAO N, 1985, ARCH PHYS MED REHAB, V66, P30; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; SCHERERSINGLER U, 1983, J NEUROSCI METH, V9, P229, DOI 10.1016/0165-0270(83)90085-7; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SHU SY, 1988, NEUROSCI LETT, V85, P169, DOI 10.1016/0304-3940(88)90346-1; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Steel RGD, 1960, PRINCIPLES PROCEDURE, P99; TAGO H, 1986, J HISTOCHEM CYTOCHEM, V34, P1431, DOI 10.1177/34.11.2430009; WAITE JJ, 1993, NEUR ABST, V19, P1231; WARD A, 1950, J NEUROSURG, V7, P398, DOI 10.3171/jns.1950.7.5.0398; WILCOX KS, 1989, BRAIN RES BULL, V22, P557, DOI 10.1016/0361-9230(89)90111-1; WOOLF NJ, 1986, BRAIN RES BULL, V16, P603, DOI 10.1016/0361-9230(86)90134-6; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	51	84	87	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	1995	83	3					496	502		10.3171/jns.1995.83.3.0496			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	RR001	WOS:A1995RR00100018	7666229				2022-02-06	
J	SBORDONE, RJ; LITER, JC; PETTLERJENNINGS, P				SBORDONE, RJ; LITER, JC; PETTLERJENNINGS, P			RECOVERY OF FUNCTION FOLLOWING SEVERE TRAUMATIC BRAIN INJURY - A RETROSPECTIVE 10-YEAR FOLLOW-UP	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY	It has been widely assumed that most of the recovery following severe traumatic brain injury (TBI) occurs within the first 6 months, and that virtually all of the recovery occurs within the first 1-2 years post-injury. In an effort to evaluate the long-term recovery of patients who had sustained severe TBI, we interviewed the relatives and significant others of 20 patients who had sustained TBI at least 5 years earlier, using a modified version of the Portland Adaptability Inventory. Retrospective ratings were collected to evaluate the patients' psychosocial, cognitive, physical, and emotional status prior to their injury, and at 1, 2, 5, and an average of 10.3 years post-injury. The results indicated that TBI patients exhibit significant improvements in their social, cognitive, physical, and emotional functioning after 2 years post-injury regardless of the severity of their initial brain trauma. These data suggest that patients who sustain severe TBI continue to make gradual improvements in their functioning for at least 10 years post-injury. Our findings contradict the widely held assumption that the recovery process ends after 1 or 2 years post-injury.	UNIV CALIF IRVINE,COLL MED,DEPT NEUROSURG,IRVINE,CA; UNIV CALIF IRVINE,COLL MED,DEPT MED PHYS,IRVINE,CA; UNIV CALIF IRVINE,COLL MED,DEPT REHABIL,IRVINE,CA; UNIV CALIF IRVINE,DEPT COGNIT SCI,IRVINE,CA 92717; UNIV SO CALIF,DEPT PSYCHOL,LOS ANGELES,CA 90089								Bond M R, 1979, Int Rehabil Med, V1, P155; Bond M R, 1975, Ciba Found Symp, P141; BOND MR, 1976, SCAND J REHABIL MED, V8, P127; BROOKS DN, 1987, NEUROBEHAVIORAL RECO, P57; COOPER PR, 1982, HEAD INJURY, P1; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DIKMEN S, 1987, NEUROBEHAVIORAL RECO, P73; Kinsella G, 1989, Int Disabil Stud, V11, P9; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; Lezak M.D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI DOI 10.1097/00001199-198703000-00009; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; MILLER H, 1965, LANCET, V1, P225; Miller JD., 1983, REHABILITATION HEAD, P37; MILTON SB, 1991, J HEAD TRAUMA REHAB, V6, P35; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; RUFF RM, 1991, J NEUROSURG, V75, pS50, DOI 10.3171/sup.1991.75.1s.0s50; SBORDONE RJ, 1984, PROF PSYCHOL-RES PR, V15, P165; SBORDONE RJ, IN PRESS EC VALIDITY; SBORDONE RJ, 1988, J HEAD TRAUMA REHAB, V3, P55; SBORDONE RJ, 1987, REHABILITATION COGNI, P3; Sparadeo F. R., 1990, J HEAD TRAUMA REHAB, V5, P1, DOI DOI 10.1097/00001199-199009000-00004; SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; TERAYAMA Y, 1993, SURG NEUROL, V39, P177, DOI 10.1016/0090-3019(93)90179-5; TERAYAMA Y, 1991, SURG NEUROL, V36, P335, DOI 10.1016/0090-3019(91)90021-Z; THOMSEN I V, 1981, Journal of Clinical Neuropsychology, V3, P43, DOI 10.1080/01688638108403112; Vogenthaler D R, 1989, Brain Inj, V3, P355, DOI 10.3109/02699058909004560; WILSON B, 1991, Brain Injury, V5, P189, DOI 10.3109/02699059109008089; WIRKINGER MS, 1992, BRAIN INJURY, V6, P183	30	84	84	0	3	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	APR	1995	9	3					285	299		10.3109/02699059509008199			15	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	QR499	WOS:A1995QR49900006	7541681				2022-02-06	
J	DHILLON, HS; DONALDSON, D; DEMPSEY, RJ; PRASAD, MR				DHILLON, HS; DONALDSON, D; DEMPSEY, RJ; PRASAD, MR			REGIONAL LEVELS OF FREE FATTY-ACIDS AND EVANS BLUE EXTRAVASATION AFTER EXPERIMENTAL BRAIN INJURY	JOURNAL OF NEUROTRAUMA			English	Article							INCREASED PROSTAGLANDIN SYNTHESIS; CONTROLLED CORTICAL IMPACT; EXPERIMENTAL HEAD-INJURY; ARACHIDONIC-ACID; CEREBRAL-ISCHEMIA; VASCULAR-PERMEABILITY; AMINO-ACIDS; RAT; METABOLISM; LEUKOTRIENE-C4	The recently developed controlled cortical-impact (CCI) model of brain injury in rats serves as an excellent tool to understand some of the neurochemical mechanisms mediating the pathophysiology of traumatic brain injury. In this study, rats were subjected to lateral CCI brain injury of low-grade severity. Their brains were frozen in situ at various times after injury to measure regional levels of free fatty acids. Tissue total free fatty acids at the injury site within the left cortex were increased at 30 min, 2.5 h, and 24 h postinjury. In injured animals, increases in stearic and arachidonic acids were slightly greater than those in palmitic and oleic acids. The levels of total free fatty acids in the cortex adjacent to the injury site were also increased in injured animals at 2.5 h and 24 h after injury (p < 0.05). Only stearic and arachidonic acids were observed to be significantly increased (p < 0.05) in the adjacent cortex of injured animals at all times after injury. Although no significant increases in total free fatty acids were observed in the left hippocampus adjacent to the injury site, stearate and arachidonate concentrations were increased at 30 min and 2.5 h after injury (p < 0.05). Extravasation of Evans blue was found to be significantly increased in the ipsilateral cortex of injured animals at 30 min and 10 h after brain injury. These results indicate the degradation of membrane phospholipids and blood-brain barrier breakdown in the ipsilateral cortex after lateral CCI brain injury. These results also suggest that arachidonic acid and its metabolites may play a role as a mediator in the blood-brain barrier breakdown associated with cortical impact brain injury in rats.	UNIV KENTUCKY, MED CTR, DEPT SURG, DIV NEUROSURG, LEXINGTON, KY 40536 USA						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R55NS031816, R01NS031816] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 31816] Funding Source: Medline		ABE K, 1987, J NEUROCHEM, V48, P503, DOI 10.1111/j.1471-4159.1987.tb04121.x; BABA T, 1991, J CEREBR BLOOD F MET, V11, P638, DOI 10.1038/jcbfm.1991.115; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CAVAZZUTI M, 1987, J CEREBR BLOOD F MET, V7, P806, DOI 10.1038/jcbfm.1987.138; CHAN PH, 1984, FED PROC, V43, P210; COMBS DJ, 1990, STROKE, V21, P936, DOI 10.1161/01.STR.21.6.936; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEMPSEY RJ, 1986, J NEUROSURG, V64, P118, DOI 10.3171/jns.1986.64.1.0118; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fiskum G, 1983, Am J Emerg Med, V1, P147, DOI 10.1016/0735-6757(83)90082-7; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; IKEDA M, 1986, J NEUROCHEM, V47, P123; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATSURA K, 1993, J NEUROCHEM, V61, P1677, DOI 10.1111/j.1471-4159.1993.tb09803.x; KONTOS HA, 1985, CIRC RES, V57, P142, DOI 10.1161/01.RES.57.1.142; KONTOS HA, 1980, SCIENCE, V209, P1242, DOI 10.1126/science.7403881; LYETH BG, 1992, J NEUROTRAUM, V9, pS463; MARCOUX FW, 1988, BRAIN RES, V452, P329, DOI 10.1016/0006-8993(88)90037-6; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MONCADA S, 1978, PHARMACOL REV, V30, P293; MOSKOWITZ MA, 1984, SCIENCE, V224, P886, DOI 10.1126/science.6719118; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; PRASAD MR, 1988, CAN J PHYSIOL PHARM, V66, P1518, DOI 10.1139/y88-248; PRASAD MR, 1994, J NEUROCHEM, V63, P1089; PRASAD MR, 1994, J NEUROTRAUMA, V11, P123; REHNCRONA S, 1979, STROKE, V10, P437, DOI 10.1161/01.STR.10.4.437; SHAPIRA Y, 1992, J NEUROSURG ANESTH, V4, P231, DOI 10.1097/00008506-199210000-00001; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TZIGARET C, 1993, J NEUROCHEM, V60, P827, DOI 10.1111/j.1471-4159.1993.tb03226.x; UNTERBERG A, 1987, ACTA NEUROPATHOL, V73, P209, DOI 10.1007/BF00686613; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; VINK R, 1988, J BIOL CHEM, V263, P757; VISOLI F, 1993, J NEUROCHEM, V61, P1835; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617	52	84	89	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	1994	11	4					405	415		10.1089/neu.1994.11.405			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	PG289	WOS:A1994PG28900006	7837281				2022-02-06	
J	MOONEY, GF; HAAS, LJ				MOONEY, GF; HAAS, LJ			EFFECT OF METHYLPHENIDATE ON BRAIN INJURY-RELATED ANGER	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						ANGER; BRAIN INJURIES; METHYLPHENIDATE	CLOSED HEAD-INJURY; FOLLOW-UP; ADJUSTMENT; BEHAVIOR; TRAUMA		UNIV UTAH, DEPT FAMILY & PREVENTAT MED, SALT LAKE CITY, UT 84132 USA		MOONEY, GF (corresponding author), UNIV UTAH, CTR REHABIL, 50 N MED DR, SALT LAKE CITY, UT 84132 USA.						BARKLEY RA, 1977, J CHILD PSYCHOL PSYC, V18, P137, DOI 10.1111/j.1469-7610.1977.tb00425.x; BRAUN CMJ, 1988, J NEUROLOGICAL REHAB, V2, P109; Brooks D N, 1979, Int Rehabil Med, V1, P160; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; GAULTIERI CT, 1988, BRAIN INJURY, V2, P273; HAAS JF, 1985, ARCH PHYS MED REHAB, V66, P472; HOGARTY GE, 1971, ARCH GEN PSYCHIAT, V25, P470; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; LEZAK M, 1983, NEUROPSYCHOLOGICAL A, P549; LEZAK MD, 1980, 8TH ANN M INT NEUR S; LIPPER S, 1976, J NERV MENT DIS, V162, P366, DOI 10.1097/00005053-197605000-00008; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; McNair D., 1981, MANUAL PROFILE MOOD; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; SPIELBERGER CD, 1983, ADV PERSONALITY ASSE, V175; Spielberger CD, 1980, PRELIMINARY MANUAL S; STERN JM, 1978, SCAND J REHABIL MED, V10, P7; STEVENSON RD, 1989, PEDIATR CLIN N AM, V36, P1183; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WEINSTEIN GS, 1981, J CLIN PSYCHIAT, V42, P120	26	84	86	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	1993	74	2					153	160					8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	KL171	WOS:A1993KL17100008	8431099				2022-02-06	
J	ANDERSEN, BJ; MARMAROU, A				ANDERSEN, BJ; MARMAROU, A			POSTTRAUMATIC SELECTIVE STIMULATION OF GLYCOLYSIS	BRAIN RESEARCH			English	Article						TRAUMA; ACIDOSIS; GLYCOLYSIS; P-13 MRS; BLOOD FLOW	CEREBRAL ENERGY-METABOLISM; NUCLEAR MAGNETIC-RESONANCE; PERCUSSION BRAIN INJURY; HEAD-INJURY; BLOOD-FLOW; FLUID; CAT; POTASSIUM; RAT; PH	Ventilated, chloralose anesthetized cats were subjected to 3.2 atmosphere fluid percussion injury and compared with sham operated controls. In both groups, global cerebral blood flow (CBF), cerebral metabolic rate of oxygen utilization (CMRO2), cerebral metabolic rate of glucose utilization (CMRGl), and P-31 magnetic resonance spectroscopy (MRS) determinations of tissue pH (pH(i)) phosphocreatine (PCr), and inorganic phosphate (Pi) were measured before and 5, 15, 30, and 60 min post-trauma. Following trauma, pH decreased slightly 30 min following trauma and gradually returned to normal. CMRO2, CBF, and arterial pO2 remained at control values throughout the experiment while CMRGl increased 243% at 5 min post-injury then rapidly returned to control values. This combination of acidosis and increased glucose utilization indicates that trauma causes a transient isolated increase in cerebral glycolysis and may be important to consider when investigating the etiology of post traumatic acidosis.	VIRGINIA COMMONWEALTH UNIV,DIV NEUROSURG,RICHMOND,VA 23284		ANDERSEN, BJ (corresponding author), UNIV ARKANSAS MED SCI HOSP,DEPT NEUROSURG,SLOT 507,4301 W MARKHAM ST,LITTLE ROCK,AR 72205, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56NS019235, P01NS012587, R01NS019235, P50NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587, NS19235] Funding Source: Medline		ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; CHAPMAN AG, 1977, J NEUROCHEM, V28, P1025, DOI 10.1111/j.1471-4159.1977.tb10665.x; CISBA L, 1985, BRAIN RES, V336, P167; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; GROOTEGOED JA, 1986, J REPROD FERTIL, V77, P109, DOI 10.1530/jrf.0.0770109; HAYES RL, 1984, SCIENCE, V223, P301, DOI 10.1126/science.6701514; HOWSE DC, 1975, J NEUROCHEM, V24, P935, DOI 10.1111/j.1471-4159.1975.tb03658.x; HOWSE DC, 1974, AM J PHYSIOL, V227, P1444, DOI 10.1152/ajplegacy.1974.227.6.1444; HUBSCHMANN OR, 1985, J NEUROSURG, V62, P698, DOI 10.3171/jns.1985.62.5.0698; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; JENKINS L, 1981, ANAT REC, V199, pA127; JULIAN FJ, 1962, J GEN PHYSIOL, V46, P297, DOI 10.1085/jgp.46.2.297; KING LJ, 1967, J NEUROCHEM, V14, P613, DOI 10.1111/j.1471-4159.1967.tb09564.x; KRIVANEK J, 1961, J NEUROCHEM, V6, P183, DOI 10.1111/j.1471-4159.1961.tb13463.x; LAURITZEN M, 1987, J CEREB BLOOD FLOW M, V7, pS125; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LEWIS DV, 1975, BRAIN RES, V99, P175, DOI 10.1016/0006-8993(75)90623-X; LOTHMAN E, 1975, BRAIN RES, V88, P15, DOI 10.1016/0006-8993(75)90943-9; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; PETROFF OAC, 1985, NEUROLOGY, V35, P781, DOI 10.1212/WNL.35.6.781; SACKTOR B, 1966, J BIOL CHEM, V241, P5071; SHAH KR, 1983, NEUROSCI LETT, V40, P287, DOI 10.1016/0304-3940(83)90053-8; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; SUNAMI K, 1989, Neurosurgical Review, V12, P400, DOI 10.1007/BF01790682; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; WEISS J, 1985, J CLIN INVEST, V75, P436, DOI 10.1172/JCI111718; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOUNG W, 1986, BRAIN RES, V365, P42, DOI 10.1016/0006-8993(86)90720-1; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	32	84	84	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUL 10	1992	585	1-2					184	189		10.1016/0006-8993(92)91205-S			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	JH130	WOS:A1992JH13000022	1511300				2022-02-06	
J	GOWER, DJ; LEE, KS; MCWHORTER, JM				GOWER, DJ; LEE, KS; MCWHORTER, JM			ROLE OF SUBTEMPORAL DECOMPRESSION IN SEVERE CLOSED HEAD-INJURY	NEUROSURGERY			English	Article									WAKE FOREST UNIV, MED CTR,BOWMAN GRAY SCH MED,DEPT SURG, NEUROSURG SECT,300 S HAWTHORNE RD, WINSTON SALEM, NC 27103 USA								ALEXANDER E, 1987, BRIT J NEUROSURG, V1, P421; ANDREWS BT, 1986, NEUROSURGERY, V19, P408, DOI 10.1227/00006123-198609000-00012; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRUCE DA, 1986, ANESTHESIA NEUROSURG, P150; CLARK K, 1968, J NEUROSURG, V29, P367, DOI 10.3171/jns.1968.29.4.0367; Cooper P R, 1976, Surg Neurol, V5, P25; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; CRONE KR, 1985, NEUROSURGERY, V16, P726; FELL DA, 1975, J NEUROSURG, V42, P37, DOI 10.3171/jns.1975.42.1.0037; HATASHITA S, 1987, J NEUROSURG, V67, P573, DOI 10.3171/jns.1987.67.4.0573; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; MOODY RA, 1968, J NEUROSURG, V29, P586, DOI 10.3171/jns.1968.29.6.0586; RANSOHOFF J, 1971, J NEUROSURG, V34, P70, DOI 10.3171/jns.1971.34.1.0070; VENES JL, 1975, J NEUROSURG, V42, P429, DOI 10.3171/jns.1975.42.4.0429; YAMAURA A, 1977, Neurologia Medico-Chirurgica, V17, P43, DOI 10.2176/nmc.17pt1.43; YAMAURA A, 1979, Neurologia Medico-Chirurgica, V19, P717, DOI 10.2176/nmc.19.717; YOUNG PH, 1982, SOUTHERN MED J, V75, P473, DOI 10.1097/00007611-198204000-00025	17	84	86	1	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	OCT	1988	23	4					417	422		10.1227/00006123-198810000-00002			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	Q5611	WOS:A1988Q561100002	3200370				2022-02-06	
J	ELSASS, L; KINSELLA, G				ELSASS, L; KINSELLA, G			SOCIAL-INTERACTION FOLLOWING SEVERE CLOSED HEAD-INJURY	PSYCHOLOGICAL MEDICINE			English	Article									LA TROBE UNIV, DEPT PSYCHOL, BUNDOORA, VIC 3083, AUSTRALIA				Kinsella, Glynda/O-6347-2017	Kinsella, Glynda/0000-0002-5859-0934			BLYTH B, 1981, NEW ZEAL MED J, V93, P267; Bond M R, 1975, Ciba Found Symp, P141; BOND MR, 1976, SCAND J REHABIL MED, V8, P127; BROWN GW, 1975, SOCIOLOGY, V9, P225, DOI 10.1177/003803857500900203; Goldberg DP, 1972, DETECTION PSYCHIATRI; HENDERSON S, 1978, BRIT J PSYCHIAT, V132, P74, DOI 10.1192/S0007125000283001; HENDERSON S, 1978, BRIT J PSYCHIAT, V132, P463, DOI 10.1192/bjp.132.5.463; HENDERSON S, 1977, BRIT J PSYCHIAT, V131, P185, DOI 10.1192/bjp.131.2.185; HENDERSON S, 1977, NEUROSIS SOCIAL ENV; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; MILLER PM, 1976, SOC PSYCHIATR, V11, P51, DOI 10.1007/BF00578738; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; SKEIKH K, 1979, INT REHABILITATION M, V1, P51; TENNANT C, 1977, MED J AUSTRALIA, V2, P392, DOI 10.5694/j.1326-5377.1977.tb114568.x; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; [No title captured]	20	84	84	1	6	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0033-2917	1469-8978		PSYCHOL MED	Psychol. Med.	FEB	1987	17	1					67	78		10.1017/S003329170001299X			12	Psychology, Clinical; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Psychiatry	G6283	WOS:A1987G628300009	3575579				2022-02-06	
J	Engler-Chiurazzi, EB; Brown, CM; Povroznik, JM; Simpkins, JW				Engler-Chiurazzi, E. B.; Brown, C. M.; Povroznik, J. M.; Simpkins, J. W.			Estrogens as neuroprotectants: Estrogenic actions in the context of cognitive aging and brain injury	PROGRESS IN NEUROBIOLOGY			English	Article; Proceedings Paper	International Conference on Aging and Disease (ICAD)	NOV 01-02, 2014	Beijing, PEOPLES R CHINA	Int Soc Aging & Dis, Xuanwu Hosp, Beijing Capital Univ, Wenzhou Med Univ, First Affiliated Hosp		Estrogen; Neuroprotection; Aging; Cognition; Stroke; Traumatic brain injury	CONJUGATED EQUINE ESTROGENS; CEREBRAL-ARTERY OCCLUSION; AGED FEMALE RAT; POSTMENOPAUSAL HORMONE-THERAPY; FOREBRAIN CHOLINERGIC NEURONS; MESSENGER-RIBONUCLEIC-ACID; ESTRADIOL-MEDIATED PROTECTION; SPATIAL REFERENCE MEMORY; DENDRITIC SPINE DENSITY; NITRIC-OXIDE SYNTHASE	There is ample empirical evidence to support the notion that the biological impacts of estrogen extend beyond the gonads to other bodily systems, including the brain and behavior. Converging preclinical findings have indicated a neuroprotective role for estrogen in a variety of experimental models of cognitive function and brain insult. However, the surprising null or even detrimental findings of several large clinical trials evaluating the ability of estrogen-containing hormone treatments to protect against age-related brain changes and insults, including cognitive aging and brain injury, led to hesitation by both clinicians and patients in the use of exogenous estrogenic treatments for nervous system outcomes. That estrogen-containing therapies are used by tens of millions of women for a variety of health-related applications across the lifespan has made identifying conditions under which benefits with estrogen treatment will be realized an important public health issue. Here we provide a summary of the biological actions of estrogen and estrogen-containing formulations in the context of aging, cognition, stroke, and traumatic brain injury. We have devoted special attention to highlighting the notion that estrogen appears to be a conditional neuroprotectant whose efficacy is modulated, by several interacting factors. By developing criteria standards for desired beneficial peripheral and neuroprotective outcomes among unique patient populations, we can optimize estrogen treatments for attenuating the consequences of, and perhaps even preventing, cognitive aging, and brain injury. (C) 2016 Elsevier Ltd. All rights reserved.	[Engler-Chiurazzi, E. B.; Brown, C. M.; Povroznik, J. M.; Simpkins, J. W.] West Virginia Univ, Ctr Basic & Translat Stroke Res, POB 9229, Morgantown, WV 26506 USA; [Engler-Chiurazzi, E. B.; Simpkins, J. W.] West Virginia Univ, Dept Physiol & Pharmacol, Morgantown, WV 26506 USA; [Brown, C. M.] West Virginia Univ, Dept Neurobiol & Anat, Morgantown, WV 26506 USA; [Povroznik, J. M.] West Virginia Univ, Dept Pediat, Morgantown, WV 26506 USA		Engler-Chiurazzi, EB (corresponding author), West Virginia Univ, Ctr Basic & Translat Stroke Res, POB 9229, Morgantown, WV 26506 USA.	elengler@hsc.wvu.edu; cdbrown2@hsc.wvu.edu; jpovrozn@mix.wvu.edu; jwsimpkins@hsc.wvu.edu	Brown, Candice/AAD-4982-2019	Brown, Candice/0000-0001-5845-0221	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P20 GM109098, P01 AG022550, P01 AG027956, K01 NS081015];  [U54 GM109492]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM109098, U54GM104942] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K01NS081014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG022550, P01AG027956] Funding Source: NIH RePORTER	The writing of this review was supported by the National Institutes of Health (JWS = P20 GM109098, P01 AG022550, and P01 AG027956; CMB = K01 NS081015). This work was also supported U54 GM109492. This content is solely the responsibility of the authors.	Acaz-Fonseca E, 2014, MOL CELL ENDOCRINOL, V389, P48, DOI 10.1016/j.mce.2014.01.009; Acosta JI, 2013, BRAIN RES, V1514, P18, DOI 10.1016/j.brainres.2013.01.016; Acosta JI, 2009, HORM BEHAV, V55, P454, DOI 10.1016/j.yhbeh.2008.11.008; Acosta JI, 2010, ENDOCRINOLOGY, V151, P3795, DOI 10.1210/en.2010-0055; Acosta JI, 2009, ENDOCRINOLOGY, V150, P4248, DOI 10.1210/en.2008-1802; Adams MM, 2002, J NEUROSCI, V22, P3608; Aimone JB, 2014, PHYSIOL REV, V94, P991, DOI 10.1152/physrev.00004.2014; Alkayed NJ, 2001, J NEUROSCI, V21, P7543, DOI 10.1523/JNEUROSCI.21-19-07543.2001; Almeida OP, 2005, AM J GERIAT PSYCHIAT, V13, P142, DOI 10.1176/appi.ajgp.13.2.142; Amaral DG, 2007, HIPPOCAMPUS BOOK, P343; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Arevalo MA, 2015, NAT REV NEUROSCI, V16, P17, DOI 10.1038/nrn3856; Arevalo MA, 2010, BBA-GEN SUBJECTS, V1800, P1106, DOI 10.1016/j.bbagen.2009.10.002; Arnold AP, 2009, HORM BEHAV, V55, P570, DOI 10.1016/j.yhbeh.2009.03.011; Asl SZ, 2013, J NEUROSURG, V119, P353, DOI 10.3171/2013.4.JNS121636; Asthana S, 1999, PSYCHONEUROENDOCRINO, V24, P657, DOI 10.1016/S0306-4530(99)00020-7; Ayres S, 1996, J LAB CLIN MED, V128, P367, DOI 10.1016/S0022-2143(96)80008-4; Baba Y, 2010, MENOPAUSE, V17, P506, DOI 10.1097/gme.0b013e3181c7dd41; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; Bagger YZ, 2005, MENOPAUSE, V12, P12, DOI 10.1097/00042192-200512010-00005; Bake S, 2004, ENDOCRINOLOGY, V145, P5471, DOI 10.1210/en.2004-0984; Bake S, 2009, MICROVASC RES, V78, P413, DOI 10.1016/j.mvr.2009.06.009; Barha CK, 2009, J NEUROENDOCRINOL, V21, P155, DOI 10.1111/j.1365-2826.2008.01809.x; Barha CK, 2013, NEUROBIOL AGING, V34, P986, DOI 10.1016/j.neurobiolaging.2012.07.009; Barha CK, 2010, NEUROPSYCHOPHARMACOL, V35, P547, DOI 10.1038/npp.2009.161; Barrett-Connor E, 1999, J AM GERIATR SOC, V47, P1289, DOI 10.1111/j.1532-5415.1999.tb07427.x; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Bechmann I, 2007, TRENDS IMMUNOL, V28, P5, DOI 10.1016/j.it.2006.11.007; Behl C, 1997, MOL PHARMACOL, V51, P535, DOI 10.1124/mol.51.4.535; Berchtold Nicole C., 2009, P1, DOI 10.1007/978-1-59745-422-3_1; Berry B, 1997, BEHAV NEUROSCI, V111, P267, DOI 10.1037/0735-7044.111.2.267; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Berthold A., 1849, TEXTS DOC, P399; Bhavnani BR, 2003, J STEROID BIOCHEM, V85, P473, DOI 10.1016/S0960-0760(03)00220-6; Biernaskie J, 2001, MAGNET RESON MED, V46, P827, DOI 10.1002/mrm.1263; Bimonte HA, 1999, PSYCHONEUROENDOCRINO, V24, P161, DOI 10.1016/S0306-4530(98)00068-7; Bimonte HA, 2003, NEUROBIOL AGING, V24, P37, DOI 10.1016/S0197-4580(02)00015-5; Bimonte-Nelson HA, 2004, NEUROREPORT, V15, P2659, DOI 10.1097/00001756-200412030-00021; Bimonte-Nelson HA, 2004, BEHAV NEUROSCI, V118, P707, DOI 10.1037/0735-7044.118.4.707; Bimonte-Nelson HA, 2003, BEHAV NEUROSCI, V117, P1395, DOI 10.1037/0735-7044.117.6.1395; Bimonte-Nelson HA, 2006, EUR J NEUROSCI, V24, P229, DOI 10.1111/j.1460-9568.2006.04867.x; Bingham D, 2005, J CEREBR BLOOD F MET, V25, P414, DOI 10.1038/sj.jcbfm.9600031; Blaustein JD, 2008, ENDOCRINOLOGY, V149, P2697, DOI 10.1210/en.2008-0396; BLAUSTEIN MP, 1993, AM J PHYSIOL, V264, pC1367, DOI 10.1152/ajpcell.1993.264.6.C1367; BLEECKER ML, 1988, J CLIN PSYCHOL, V44, P403, DOI 10.1002/1097-4679(198805)44:3<403::AID-JCLP2270440315>3.0.CO;2-0; Bottner M, 2014, J STEROID BIOCHEM, V139, P245, DOI 10.1016/j.jsbmb.2013.03.003; Bohacek J, 2009, J NEUROENDOCRINOL, V21, P640, DOI 10.1111/j.1365-2826.2009.01882.x; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Brinton RD, 2000, NEUROBIOL AGING, V21, P475, DOI 10.1016/S0197-4580(00)00109-3; Brinton RD, 1997, EXP NEUROL, V147, P211, DOI 10.1006/exnr.1997.6619; Brinton RD, 2000, MATURITAS, V34, pS35, DOI 10.1016/S0378-5122(00)00107-9; Brinton RD, 2001, LEARN MEMORY, V8, P121, DOI 10.1101/lm.39601; Brinton RD, 2008, TRENDS NEUROSCI, V31, P529, DOI 10.1016/j.tins.2008.07.003; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; Brown CM, 2008, EXP NEUROL, V210, P782, DOI 10.1016/j.expneurol.2007.11.021; Brown CM, 2010, ENDOCRINOLOGY, V151, P4916, DOI 10.1210/en.2010-0371; Brown CM, 2009, SEMIN REPROD MED, V27, P240, DOI 10.1055/s-0029-1216277; Brown TJ, 1996, NEUROENDOCRINOLOGY, V63, P53, DOI 10.1159/000126935; Bruce-Keller AJ, 2007, J NEUROTRAUM, V24, P203, DOI 10.1089/neu.2006.0163; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Burek M, 2010, ARTERIOSCL THROM VAS, V30, P298, DOI 10.1161/ATVBAHA.109.197582; Bushnell C, 2014, ANN INTERN MED, V160, P853, DOI 10.7326/M14-0762; Bushnell C, 2014, STROKE, V45, P1545, DOI 10.1161/01.str.0000442009.06663.48; Bushnell CD, 2006, STROKE, V37, P2387, DOI 10.1161/01.STR.0000236053.37695.15; CAMPBELL S, 1977, CLIN OBSTET GYNAECOL, V4, P31; Carlson LE, 1998, PSYCHONEUROENDOCRINO, V23, P583; Carswell HVO, 2010, CLIN SCI, V118, P375, DOI 10.1042/CS20090018; Carswell HV, 2004, J CEREBR BLOOD F MET, V24, P298, DOI 10.1097/01.WCB.0000112322.75217.FD; Casals JB, 2011, COMPARATIVE MED, V61, P305; Chakrabarti M, 2014, BRAIN RES BULL, V109, P22, DOI 10.1016/j.brainresbull.2014.09.004; Chen SH, 2009, CRIT CARE MED, V37, P3097, DOI 10.1097/CCM.0b013e3181bc7986; Cipolla MJ, 2009, MICROCIRCULATION, V16, P685, DOI 10.3109/10739680903164131; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; Cook DJ, 2012, NEUROTHERAPEUTICS, V9, P371, DOI 10.1007/s13311-012-0115-z; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Daniel JM, 2013, HORM BEHAV, V63, P231, DOI 10.1016/j.yhbeh.2012.05.003; Daniel JM, 1999, PHYSIOL BEHAV, V66, P11, DOI 10.1016/S0031-9384(98)00272-8; Daniel JM, 2006, ENDOCRINOLOGY, V147, P607, DOI 10.1210/en.2005-0998; Daniel JM, 1997, HORM BEHAV, V32, P217, DOI 10.1006/hbeh.1997.1433; Daniel JM, 2001, J NEUROSCI, V21, P6949, DOI 10.1523/JNEUROSCI.21-17-06949.2001; Davies AM, 1996, PHILOS T ROY SOC B, V351, P389, DOI 10.1098/rstb.1996.0033; Day M, 2005, NEUROBIOL LEARN MEM, V83, P13, DOI 10.1016/j.nlm.2004.06.009; Day NL, 2013, J NEUROTRAUM, V30, P1531, DOI 10.1089/neu.2013.2854; Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987; Deutsch ER, 2013, BRAIN RES, V1530, P82, DOI 10.1016/j.brainres.2013.07.014; Dey P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128239; Dubal DB, 1999, J NEUROSCI, V19, P6385; Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253, DOI 10.1097/00004647-199811000-00012; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.98.4.1952; Dubal DB, 2006, ENDOCRINOLOGY, V147, P3076, DOI 10.1210/en.2005-1177; Duckles SP, 2011, ACTA PHYSIOL, V203, P149, DOI 10.1111/j.1748-1716.2010.02184.x; Dumas J, 2008, HORM BEHAV, V53, P159, DOI 10.1016/j.yhbeh.2007.09.011; Durukan A, 2007, PHARMACOL BIOCHEM BE, V87, P179, DOI 10.1016/j.pbb.2007.04.015; Dykens J. A., 1995, OXYGEN PARADOX, P453; Dykens JA, 2003, EXP GERONTOL, V38, P101, DOI 10.1016/S0531-5565(02)00162-6; Eichenbaum H, 2000, NAT REV NEUROSCI, V1, P41, DOI 10.1038/35036213; El-Bakri NK, 2004, J CELL MOL MED, V8, P537, DOI 10.1111/j.1582-4934.2004.tb00478.x; Elkabes S, 2014, EXP NEUROL, V259, P28, DOI 10.1016/j.expneurol.2014.01.008; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Engler E. B., 2007, SOC NEUROSCIENCE; Engler-Chiurazzi E, 2011, NEUROBIOL AGING, V32, P680, DOI 10.1016/j.neurobiolaging.2009.09.005; Engler-Chiurazzi EB, 2012, HORM BEHAV, V62, P1, DOI 10.1016/j.yhbeh.2012.04.004; Ennaceur A, 2010, BEHAV BRAIN RES, V215, P244, DOI 10.1016/j.bbr.2009.12.036; Espeland MA, 2004, JAMA-J AM MED ASSOC, V291, P2959, DOI 10.1001/jama.291.24.2959; Espeland MA, 2013, JAMA INTERN MED, V173, P1429, DOI 10.1001/jamainternmed.2013.7727; Fader AJ, 1999, PHARMACOL BIOCHEM BE, V62, P711, DOI 10.1016/S0091-3057(98)00219-6; Fader AJ, 1998, NEUROBIOL LEARN MEM, V69, P225, DOI 10.1006/nlme.1998.3820; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Farin A, 2003, J NEUROSURG, V98, P32, DOI 10.3171/jns.2003.98.1.0032; Farrag AF, 2002, DEMENT GERIATR COGN, V13, P193, DOI 10.1159/000048652; Feng Z, 2004, J PINEAL RES, V37, P198, DOI 10.1111/j.1600-079X.2004.00158.x; Fester L, 2014, BRAIN RES; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; Foster TC, 2003, NEUROBIOL AGING, V24, P839, DOI 10.1016/S0197-4580(03)00014-9; Foster TC, 2008, MOL THER, V16, P1587, DOI 10.1038/mt.2008.140; Foster TC, 2012, HIPPOCAMPUS, V22, P656, DOI 10.1002/hipo.20935; Foy MR, 1999, J NEUROPHYSIOL, V81, P925, DOI 10.1152/jn.1999.81.2.925; Freedman MA, 2002, J WOMEN HEALTH GEN-B, V11, P703, DOI 10.1089/15409990260363661; Frick KM, 2002, NEUROSCIENCE, V115, P547, DOI 10.1016/S0306-4522(02)00377-9; Frick KM, 2001, BEHAV NEUROSCI, V115, P229, DOI 10.1037//0735-7044.115.1.229; Frye CA, 2007, NEUROBIOL LEARN MEM, V88, P208, DOI 10.1016/j.nlm.2007.04.003; Gabryel B, 2012, PHARMACOL REP, V64, P1; GALEA LAM, 1993, PERS INDIV DIFFER, V14, P53, DOI 10.1016/0191-8869(93)90174-2; Gan BK, 2004, ANN ACAD MED SINGAP, V33, P63; Garry PS, 2015, EXP NEUROL, V263, P235, DOI 10.1016/j.expneurol.2014.10.017; Gatson JW, 2012, J NEUROTRAUM, V29, P2209, DOI 10.1089/neu.2011.2274; Gibbs RB, 2000, NEUROBIOL AGING, V21, P107, DOI 10.1016/S0197-4580(00)00103-2; Gibbs RB, 1999, HORM BEHAV, V36, P222, DOI 10.1006/hbeh.1999.1541; Gibbs RB, 1997, BRAIN RES, V757, P10, DOI 10.1016/S0006-8993(96)01432-1; Gibbs RB, 2002, HORM BEHAV, V42, P245, DOI 10.1006/hbeh.2002.1825; Gibbs RB, 2007, HORM BEHAV, V52, P352, DOI 10.1016/j.yhbeh.2007.05.011; Gibbs RB, 2010, ENDOCR REV, V31, P224, DOI 10.1210/er.2009-0036; Gibson CL, 2013, J CEREBR BLOOD F MET, V33, P1355, DOI 10.1038/jcbfm.2013.102; Gleason CE, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001833; Goldstein LB, 2011, STROKE, V42, P517, DOI 10.1161/STR.0b013e3181fcb238; Good M, 1999, EUR J NEUROSCI, V11, P4476, DOI 10.1046/j.1460-9568.1999.00920.x; Gordon KB, 2005, BRAIN RES, V1036, P155, DOI 10.1016/j.brainres.2004.12.052; Gould E., 2007, HIPPOCAMPUS BOOK, P343; Granholm AC, 2000, EXPERT OPIN INV DRUG, V9, P685, DOI 10.1517/13543784.9.4.685; Green PS, 1998, NEUROSCIENCE, V84, P7, DOI 10.1016/S0306-4522(97)00595-2; Green PS, 1997, J NEUROSCI, V17, P511; Green PS, 2001, ENDOCRINOLOGY, V142, P400, DOI 10.1210/en.142.1.400; Greendale GA, 2010, AM J EPIDEMIOL, V171, P1214, DOI 10.1093/aje/kwq067; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; Gresack JE, 2004, NEUROSCIENCE, V128, P459, DOI 10.1016/j.neuroscience.2004.06.011; Gresack JE, 2007, NEUROBIOL LEARN MEM, V88, P393, DOI 10.1016/j.nlm.2007.07.015; Gridley KE, 1998, MOL PHARMACOL, V54, P874, DOI 10.1124/mol.54.5.874; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Gurman P, 2015, CLIN PHARMACOL THER, V97, P274, DOI 10.1002/cpt.33; Gustafsson JA, 1999, J ENDOCRINOL, V163, P379, DOI 10.1677/joe.0.1630379; Habib P, 2015, J STEROID BIOCHEM, V146, P3, DOI 10.1016/j.jsbmb.2014.02.018; Hall CB, 2000, STAT MED, V19, P1555, DOI 10.1002/(SICI)1097-0258(20000615/30)19:11/12<1555::AID-SIM445>3.0.CO;2-3; Hammond R, 2009, HORM BEHAV, V56, P309, DOI 10.1016/j.yhbeh.2009.06.008; HAMPSON E, 1990, PSYCHONEUROENDOCRINO, V15, P97, DOI 10.1016/0306-4530(90)90018-5; Handa RJ, 2012, J NEUROENDOCRINOL, V24, P160, DOI 10.1111/j.1365-2826.2011.02206.x; Harms C, 2001, J NEUROSCI, V21, P2600, DOI 10.1523/JNEUROSCI.21-08-02600.2001; Hawk T, 1998, BRAIN RES, V796, P296, DOI 10.1016/S0006-8993(98)00327-8; Hawkes K, 2003, AM J HUM BIOL, V15, P380, DOI 10.1002/ajhb.10156; Henderson VW, 2012, CLIMACTERIC, V15, P229, DOI 10.3109/13697137.2012.656254; Henderson VW, 2007, MENOPAUSE, V14, P572, DOI 10.1097/gme.0b013e31803df49c; Henderson VW, 2013, P NATL ACAD SCI USA, V110, P20290, DOI 10.1073/pnas.1312353110; Hendrix SL, 2006, CIRCULATION, V113, P2425, DOI 10.1161/CIRCULATIONAHA.105.594077; Hersh AL, 2004, JAMA-J AM MED ASSOC, V291, P47, DOI 10.1001/jama.291.1.47; Holmes MM, 2002, BEHAV NEUROSCI, V116, P928, DOI 10.1037//0735-7044.116.5.928; Horsburgh K, 2002, J CEREBR BLOOD F MET, V22, P1189, DOI 10.1097/01.wcb.0000037991.07114.4e; Hruska Z, 2007, HORM BEHAV, V52, P297, DOI 10.1016/j.yhbeh.2007.05.010; Inagaki T, 2010, HORM BEHAV, V58, P415, DOI 10.1016/j.yhbeh.2010.05.013; Jacome LF, 2010, NEUROBIOL LEARN MEM, V94, P488, DOI 10.1016/j.nlm.2010.08.016; JARRARD LE, 1984, BEHAV NEUROSCI, V98, P946, DOI 10.1037/0735-7044.98.6.946; JENSEN EV, 1962, RECENT PROG HORM RES, V18, P387; Jones Jo, 2012, Natl Health Stat Report, P1; Jover T., 2002, J NEUROSCI; KASSIS JA, 1981, J BIOL CHEM, V256, P7378; Kesslak JP, 1998, BEHAV NEUROSCI, V112, P1012, DOI 10.1037/0735-7044.112.4.1012; Khaksari M, 2013, CAN J PHYSIOL PHARM, V91, P700, DOI 10.1139/cjpp-2012-0359; Khaksari M, 2011, CAN J PHYSIOL PHARM, V89, P31, DOI [10.1139/Y10-103, 10.1139/y10-103]; Kimura Doreen, 2002, Neuro Endocrinol Lett, V23 Suppl 4, P67; Kittner SJ, 1996, NEW ENGL J MED, V335, P768, DOI 10.1056/NEJM199609123351102; Koellhoffer EC, 2013, TRANSL STROKE RES, V4, P390, DOI 10.1007/s12975-012-0230-5; Kok HS, 2006, MENOPAUSE, V13, P19, DOI 10.1097/01.gme.0000196592.36711.a0; Kritz-Silverstein D, 2002, J AM GERIATR SOC, V50, P55, DOI 10.1046/j.1532-5415.2002.50008.x; Kuhl H, 2005, CLIMACTERIC, V8, P3, DOI 10.1080/13697130500148875; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Laughlin GA, 2000, J CLIN ENDOCR METAB, V85, P645, DOI 10.1210/jc.85.2.645; Lebesgue D, 2006, J NEUROTRAUM, V23, P1814, DOI 10.1089/neu.2006.23.1814; Lebrun CEI, 2005, CLIN ENDOCRINOL, V63, P50, DOI 10.1111/j.1365-2265.2005.02297.x; Leon RL, 2012, ENDOCRINOLOGY, V153, P3386, DOI 10.1210/en.2011-1859; LERNER SP, 1990, BIOL REPROD, V42, P633, DOI 10.1095/biolreprod42.4.633; Levin-Allerhand J A, 2002, J Nutr Health Aging, V6, P315; Lewis DK, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.11.007; Lewis MC, 2008, BEHAV NEUROSCI, V122, P716, DOI 10.1037/0735-7044.122.3.716; Li RN, 2014, MOL CELL ENDOCRINOL, V389, P13, DOI 10.1016/j.mce.2013.12.018; Li XL, 2004, EXP NEUROL, V187, P94, DOI 10.1016/j.expneurol.2004.01.004; Liang Y, 2001, BRAIN RES BULL, V54, P661, DOI 10.1016/S0361-9230(01)00483-X; Lisabeth L, 2012, LANCET NEUROL, V11, P82, DOI 10.1016/S1474-4422(11)70269-1; Littleton-Kearney MT, 2005, J CEREBR BLOOD F MET, V25, P421, DOI 10.1038/sj.jcbfm.9600052; Liu F, 2012, J NEUROENDOCRINOL, V24, P319, DOI 10.1111/j.1365-2826.2011.02248.x; Liu F, 2008, NAT NEUROSCI, V11, P334, DOI 10.1038/nn2057; Liu FD, 2009, STROKE, V40, P1842, DOI 10.1161/STROKEAHA.108.538686; Liu R, 2002, STROKE, V33, P2485, DOI 10.1161/01.STR.0000030317.43597.C8; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; LU KH, 1979, BIOL REPROD, V21, P193, DOI 10.1095/biolreprod21.1.193; LUINE V, 1994, BEHAV NEURAL BIOL, V62, P230, DOI 10.1016/S0163-1047(05)80021-4; LUINE V, 1990, BRAIN RES, V523, P321, DOI 10.1016/0006-8993(90)91507-D; Luine VN, 2014, HORM BEHAV, V66, P602, DOI 10.1016/j.yhbeh.2014.08.011; Luine VN, 2003, ENDOCRINOLOGY, V144, P2836, DOI 10.1210/en.2003-0004; Ma VY, 2014, ARCH PHYS MED REHAB, V95, P986, DOI 10.1016/j.apmr.2013.10.032; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MacLusky NJ, 2005, ENDOCRINOLOGY, V146, P287, DOI 10.1210/en.2004-0730; Macrae IM, 2011, BRIT J PHARMACOL, V164, P1062, DOI 10.1111/j.1476-5381.2011.01398.x; Maghool F, 2013, BRAIN RES, V1497, P61, DOI 10.1016/j.brainres.2012.12.014; Magnotti LJ, 2008, J AM COLL SURGEONS, V206, P984, DOI 10.1016/j.jamcollsurg.2007.12.038; Maki PM, 2012, ENDOCRINOLOGY, V153, P3564, DOI 10.1210/en.2012-1175; Maki PM, 2006, NEUROSCIENCE, V138, P1027, DOI 10.1016/j.neuroscience.2006.01.001; Manson JE, 2013, JAMA-J AM MED ASSOC, V310, P1353, DOI 10.1001/jama.2013.278040; Manwani B, 2011, WOMENS HEALTH, V7, P319, DOI [10.2217/WHE.11.22, 10.2217/whe.11.22]; Maren S, 2001, ANNU REV NEUROSCI, V24, P897, DOI 10.1146/annurev.neuro.24.1.897; Markowska AL, 1999, J NEUROSCI, V19, P8122; Markowska AL, 2002, J NEUROSCI, V22, P10985; Mayer LP, 2005, ARTERIOSCL THROM VAS, V25, P1910, DOI 10.1161/01.ATV.0000175767.46520.6a; Mayer LP, 2002, REPROD TOXICOL, V16, P775, DOI 10.1016/S0890-6238(02)00048-5; McClean J, 2008, EXP NEUROL, V210, P41, DOI 10.1016/j.expneurol.2007.09.027; McClure RES, 2013, HORM BEHAV, V63, P144, DOI 10.1016/j.yhbeh.2012.09.011; McCullough LD, 2001, STROKE, V32, P796, DOI 10.1161/01.STR.32.3.796; McLaughlin KJ, 2008, HORM BEHAV, V54, P386, DOI 10.1016/j.yhbeh.2008.04.010; McMillan PJ, 1996, J NEUROSCI, V16, P1860; Mehra RD, 2005, BRAIN RES, V1056, P22, DOI 10.1016/j.brainres.2005.06.073; Mennenga SE, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00294; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Miller CP, 1996, STEROIDS, V61, P305, DOI 10.1016/0039-128X(95)00234-H; Miller NR, 2005, ENDOCRINOLOGY, V146, P3070, DOI 10.1210/en.2004-1515; Milner TA, 2005, J COMP NEUROL, V491, P81, DOI 10.1002/cne.20724; Milner TA, 2001, J COMP NEUROL, V429, P355; MOORADIAN AD, 1993, J STEROID BIOCHEM, V45, P509, DOI 10.1016/0960-0760(93)90166-T; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152; Nakagami F, 2010, ATHEROSCLEROSIS, V211, P41, DOI 10.1016/j.atherosclerosis.2010.01.016; Nappi RE, 1999, GYNECOL OBSTET INVES, V47, P29, DOI 10.1159/000010058; Neal-Perry G, 2010, MATURITAS, V67, P34, DOI 10.1016/j.maturitas.2010.04.016; Neese SL, 2010, HORM BEHAV, V58, P878, DOI 10.1016/j.yhbeh.2010.08.017; Neves-e-Castro M, 1975, Med Hypotheses, V1, P132, DOI 10.1016/0306-9877(75)90054-7; Nilsen J, 2002, BRAIN RES, V930, P216, DOI 10.1016/S0006-8993(02)02254-0; Nilsen J, 2003, P NATL ACAD SCI USA, V100, P2842, DOI 10.1073/pnas.0438041100; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; Offner H, 2006, ANN NY ACAD SCI, V1089, P343, DOI 10.1196/annals.1386.021; OHKURA T, 1995, DEMENTIA, V6, P99, DOI 10.1159/000106929; OLTON DS, 1979, AM PSYCHOL, V34, P583, DOI 10.1037/0003-066X.34.7.583; Ormerod BK, 2003, J NEUROBIOL, V55, P247, DOI 10.1002/neu.10181; Packard MG, 1996, BEHAV NEUROSCI, V110, P626; Packard MG, 1998, HORM BEHAV, V34, P126, DOI 10.1006/hbeh.1998.1464; Paganini-Hill A, 2001, MATURITAS, V38, P243, DOI 10.1016/S0378-5122(01)00167-0; Pan YL, 1999, P SOC EXP BIOL MED, V221, P118, DOI 10.1046/j.1525-1373.1999.d01-64.x; Park EM, 2006, J CEREBR BLOOD F MET, V26, P392, DOI 10.1038/sj.jcbfm.9600194; PENG MT, 1972, FERTIL STERIL, V23, P535; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; Perez E, 2005, DRUG DEVELOP RES, V66, P78, DOI 10.1002/ddr.20047; Perez E, 2005, BRAIN RES, V1038, P216, DOI 10.1016/j.brainres.2005.01.026; Peterson CM, 2000, J SOC GYNECOL INVEST, V7, pS3, DOI 10.1177/1071557600007001S03; Petrea RE, 2009, STROKE, V40, P1032, DOI 10.1161/STROKEAHA.108.542894; Petrone AB, 2014, MOL CELL ENDOCRINOL, V389, P40, DOI 10.1016/j.mce.2013.12.017; Pike CJ, 1999, J NEUROCHEM, V72, P1552, DOI 10.1046/j.1471-4159.1999.721552.x; Prokai L, 2003, P NATL ACAD SCI USA, V100, P11741, DOI 10.1073/pnas.2032621100; Prokai L, 2003, DRUG METAB DISPOS, V31, P701, DOI 10.1124/dmd.31.6.701; Prokai L, 2007, PHARMACOL THERAPEUT, V114, P1, DOI 10.1016/j.pharmthera.2007.01.006; Prossnitz ER, 2014, MOL CELL ENDOCRINOL, V389, P71, DOI 10.1016/j.mce.2014.02.002; RANNEVIK G, 1995, MATURITAS, V21, P103, DOI 10.1016/0378-5122(94)00869-9; Rapp PR, 2003, J NEUROSCI, V23, P5708; Rau SW, 2003, J NEUROSCI, V23, P11420; Reeves MJ, 2008, LANCET NEUROL, V7, P915, DOI 10.1016/S1474-4422(08)70193-5; Rhodes ME, 2006, NEUROBIOL LEARN MEM, V85, P183, DOI 10.1016/j.nlm.2005.10.003; Rissman EF, 2002, P NATL ACAD SCI USA, V99, P3996, DOI 10.1073/pnas.012032699; Ritzel RM, 2013, HORM BEHAV, V63, P238, DOI 10.1016/j.yhbeh.2012.04.007; Rocca WA, 2007, NEUROLOGY, V69, P1074, DOI 10.1212/01.wnl.0000276984.19542.e6; Rocca WA, 2014, MOL CELL ENDOCRINOL, V389, P7, DOI 10.1016/j.mce.2014.01.020; Rocca WA, 2011, BRAIN RES, V1379, P188, DOI 10.1016/j.brainres.2010.10.031; Rodefer J. S., 2007, BRAIN AGING MODELS M; Rodgers SP, 2010, ENDOCRINOLOGY, V151, P1194, DOI 10.1210/en.2009-1245; Rodriguiz RM., 2006, ANIMAL MODELCOGNIT; Romer W, 1997, STEROIDS, V62, P688, DOI 10.1016/S0039-128X(97)00068-8; Romer W, 1997, STEROIDS, V62, P304, DOI 10.1016/S0039-128X(96)00224-3; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; ROSSER M, 1993, BIOL REPROD, V48, P89, DOI 10.1095/biolreprod48.1.89; Rossouw JE, 2007, JAMA-J AM MED ASSOC, V297, P1465, DOI 10.1001/jama.297.13.1465; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Rouchaud A, 2011, STROKE, V42, P1289, DOI 10.1161/STROKEAHA.110.599399; Ruiz-Palmero I, 2013, MOL CELL ENDOCRINOL, V372, P105, DOI 10.1016/j.mce.2013.03.018; Rusa R, 1999, STROKE, V30, P1665, DOI 10.1161/01.STR.30.8.1665; Sarkar S, 2015, BRAIN RES, V1616, P101, DOI 10.1016/j.brainres.2015.04.059; Sarkar SN, 2008, P NATL ACAD SCI USA, V105, P15148, DOI 10.1073/pnas.0802379105; Sawada H, 1998, J NEUROSCI RES, V54, P707, DOI 10.1002/(SICI)1097-4547(19981201)54:5<707::AID-JNR16>3.0.CO;2-T; Selvamani A, 2010, J NEUROSCI, V30, P6852, DOI 10.1523/JNEUROSCI.0761-10.2010; Selvamani A, 2010, NEUROBIOL AGING, V31, P1618, DOI 10.1016/j.neurobiolaging.2008.08.014; Sherwin BB, 2008, FRONT NEUROENDOCRIN, V29, P88, DOI 10.1016/j.yfrne.2007.08.002; SHERWIN BB, 1988, PSYCHONEUROENDOCRINO, V13, P345, DOI 10.1016/0306-4530(88)90060-1; Shughrue PJ, 1997, J COMP NEUROL, V388, P507, DOI 10.1002/(SICI)1096-9861(19971201)388:4<507::AID-CNE1>3.0.CO;2-6; Shughrue PJ, 2000, NEUROSCIENCE, V96, P41, DOI 10.1016/S0306-4522(99)00520-5; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Shuster LT, 2010, MATURITAS, V65, P161, DOI 10.1016/j.maturitas.2009.08.003; Simpkins J. W., 1997, AM J MED, V103, P19, DOI 10.1016/s0002-9343(97)00260-x; Simpkins JW, 2008, BRAIN RES REV, V57, P421, DOI 10.1016/j.brainresrev.2007.04.007; Simpkins JW, 2008, ALZHEIMERS DEMENT, V4, pS131, DOI 10.1016/j.jalz.2007.10.009; Simpkins JW, 1997, J NEUROSURG, V87, P724, DOI 10.3171/jns.1997.87.5.0724; Singer CA, 1998, NEUROREPORT, V9, P2565, DOI 10.1097/00001756-199808030-00025; SINGH M, 1995, ENDOCRINOLOGY, V136, P2320, DOI 10.1210/en.136.5.2320; SINGH M, 1994, BRAIN RES, V644, P305, DOI 10.1016/0006-8993(94)91694-2; Singh M, 2013, HORM BEHAV, V63, P284, DOI 10.1016/j.yhbeh.2012.06.003; Sitruk-Ware R, 2002, MENOPAUSE, V9, P6, DOI 10.1097/00042192-200201000-00003; Slewa-Younan S, 2004, ARCH PHYS MED REHAB, V85, P376, DOI 10.1016/j.apmr.2003.05.007; Slowik A, 2015, J STEROID BIOCHEM, V153, P135, DOI 10.1016/j.jsbmb.2015.02.013; Smith CC, 2010, P NATL ACAD SCI USA, V107, P19543, DOI 10.1073/pnas.1009307107; Smith KM, 2014, EXP NEUROL, V259, P44, DOI 10.1016/j.expneurol.2014.03.010; SOHRABJI F, 1995, P NATL ACAD SCI USA, V92, P11110, DOI 10.1073/pnas.92.24.11110; Sohrabji F, 2013, J NEUROENDOCRINOL, V25, P1173, DOI 10.1111/jne.12059; Sohrabji F, 2013, NEUROCHEM INT, V63, P291, DOI 10.1016/j.neuint.2013.06.013; Sohrabji F, 2013, HORM BEHAV, V63, P222, DOI 10.1016/j.yhbeh.2012.06.002; Soustiel JF, 2005, J NEUROTRAUM, V22, P345, DOI 10.1089/neu.2005.22.345; Spary EJ, 2009, J CHEM NEUROANAT, V38, P185, DOI 10.1016/j.jchemneu.2009.05.008; Stackman RW, 1997, NEUROBIOL LEARN MEM, V67, P167, DOI 10.1006/nlme.1996.3753; Strom JO, 2013, SCI REP-UK, V3, DOI 10.1038/srep03111; Strom JO, 2011, INT J MOL SCI, V12, P1533, DOI 10.3390/ijms12031533; Suzuki S, 2007, P NATL ACAD SCI USA, V104, P6013, DOI 10.1073/pnas.0610394104; Suzuki S, 2007, J COMP NEUROL, V500, P1064, DOI 10.1002/cne.21240; Suzuki T, 2004, J NEUROTRAUM, V21, P842, DOI 10.1089/0897715041526186; Talboom JS, 2008, NEUROBIOL LEARN MEM, V90, P155, DOI 10.1016/j.nlm.2008.04.002; Talboom JS, 2010, HORM BEHAV, V58, P917, DOI 10.1016/j.yhbeh.2010.09.002; Tanapat P, 1999, J NEUROSCI, V19, P5792, DOI 10.1523/JNEUROSCI.19-14-05792.1999; Tanapat P, 2005, J COMP NEUROL, V481, P252, DOI 10.1002/cne.20385; Tang MY, 1996, METABOLISM, V45, P411, DOI 10.1016/S0026-0495(96)90212-7; Timiras P., 1995, HORMONES AGING; TOFT D, 1966, P NATL ACAD SCI USA, V55, P1574, DOI 10.1073/pnas.55.6.1574; Toran-Allerand CD, 2005, ENDOCRINOLOGY, V146, P3843, DOI 10.1210/en.2004-1616; Toung TJK, 1998, STROKE, V29, P1666, DOI 10.1161/01.STR.29.8.1666; US Census Bureau, 2008, NP2008 T2 US CENS BU; VANDENBERG SG, 1978, PERCEPT MOTOR SKILL, V47, P599, DOI 10.2466/pms.1978.47.2.599; Vedder LC, 2014, NEUROBIOL AGING, V35, P2183, DOI 10.1016/j.neurobiolaging.2014.04.004; Vegeto E, 2008, FRONT NEUROENDOCRIN, V29, P507, DOI 10.1016/j.yfrne.2008.04.001; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Walf AA, 2008, NEUROREPORT, V19, P789, DOI 10.1097/WNR.0b013e3282fe209c; Walf AA, 2006, NEUROBIOL LEARN MEM, V86, P35, DOI 10.1016/j.nlm.2006.01.004; Wallace M, 2006, BRAIN RES, V1126, P176, DOI 10.1016/j.brainres.2006.07.064; Wang J, 2001, J NEUROCHEM, V77, P804, DOI 10.1046/j.1471-4159.2001.00271.x; Wang Q, 1999, STROKE, V30, P630, DOI 10.1161/01.STR.30.3.630; Wang X., 2003, TOX SOC NEUR ABSTR, V29, P635; Wang XF, 2003, INVEST OPHTH VIS SCI, V44, P2067, DOI 10.1167/iovs.02-0841; Wang XF, 2006, MOL PHARMACOL, V70, P395, DOI 10.1124/mol.106.022384; Warren SG, 1997, BEHAV NEUROSCI, V111, P259, DOI 10.1037/0735-7044.111.2.259; Warren SG, 1995, BRAIN RES, V703, P26, DOI 10.1016/0006-8993(95)01059-9; Waters EM, 2011, BRAIN RES, V1379, P86, DOI 10.1016/j.brainres.2010.09.069; Wei J, 2013, ACTA PHARMACOL SIN, V34, P1485, DOI 10.1038/aps.2013.160; WISE PM, 1980, NEUROENDOCRINOLOGY, V30, P15, DOI 10.1159/000122968; Wise PM, 2000, J NEUROCYTOL, V29, P401, DOI 10.1023/A:1007169408561; Witty CF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051385; Wolf OT, 2002, HORM BEHAV, V41, P259, DOI 10.1006/hbeh.2002.1770; Woolley CS, 1997, J NEUROSCI, V17, P1848; WOOLLEY CS, 1992, J NEUROSCI, V12, P2549; WOOLLEY CS, 1994, J NEUROSCI, V14, P7680; WOOLLEY CS, 1990, J NEUROSCI, V10, P4035, DOI 10.1523/JNEUROSCI.10-12-04035.1990; Workman JL, 2012, BEHAV NEUROSCI, V126, P54, DOI 10.1037/a0025538; Yamaguchi-Shima N, 2007, BRAIN RES, V1155, P34, DOI 10.1016/j.brainres.2007.04.016; Yang SH, 2004, P NATL ACAD SCI USA, V101, P4130, DOI 10.1073/pnas.0306948101; Yang SH, 2000, STROKE, V31, P745, DOI 10.1161/01.STR.31.3.745; Yasui T, 1999, J CLIN LAB ANAL, V13, P266, DOI 10.1002/(SICI)1098-2825(1999)13:6<266::AID-JCLA3>3.3.CO;2-R; Yi KD, 2011, BRAIN RES, V1379, P61, DOI 10.1016/j.brainres.2010.11.058; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhang B, 2010, J IMMUNOL, V184, P4087, DOI 10.4049/jimmunol.0902339; Zhang F, 2004, NEUROL RES, V26, P835, DOI 10.1179/016164104X3824; Zhang QG, 2014, MOL CELL ENDOCRINOL, V389, P84, DOI 10.1016/j.mce.2013.12.019; Zhang YQ, 1998, BRAIN RES, V784, P321, DOI 10.1016/S0006-8993(97)00502-7; Zhang YM, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-49; Zhao LQ, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-24; Zhao LQ, 2004, BRAIN RES, V1010, P22, DOI 10.1016/j.brainres.2004.02.066; Zheng JB, 1999, J STEROID BIOCHEM, V68, P65, DOI 10.1016/S0960-0760(98)00161-7; Zheng JB, 1999, EUR J PHARMACOL, V368, P95, DOI 10.1016/S0014-2999(99)00012-6	379	83	86	4	67	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0301-0082	1873-5118		PROG NEUROBIOL	Prog. Neurobiol.	OCT	2017	157				SI		188	211		10.1016/j.pneurobio.2015.12.008			24	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology	FJ7TG	WOS:000412961200011	26891883	Green Submitted, Green Accepted			2022-02-06	
J	Robba, C; Cardim, D; Tajsic, T; Pietersen, J; Bulman, M; Donnelly, J; Lavinio, A; Gupta, A; Menon, DK; Hutchinson, PJA; Czosnyka, M				Robba, Chiara; Cardim, Danilo; Tajsic, Tamara; Pietersen, Justine; Bulman, Michael; Donnelly, Joseph; Lavinio, Andrea; Gupta, Arun; Menon, David K.; Hutchinson, Peter J. A.; Czosnyka, Marek			Ultrasound non-invasive measurement of intracranial pressure in neurointensive care: A prospective observational study	PLOS MEDICINE			English	Article							OPTIC-NERVE SHEATH; TRAUMATIC BRAIN-INJURY; VENTRICULOSTOMY PLACEMENT; HEMORRHAGIC COMPLICATIONS; PULSATILITY INDEX; SINUS THROMBOSIS; DIAMETER; HYPERTENSION; PREDICTION; GUIDELINES	Background The invasive nature of the current methods for monitoring of intracranial pressure (ICP) has prevented their use in many clinical situations. Several attempts have been made to develop methods to monitor ICP non-invasively. The aim of this study is to assess the relationship between ultrasound-based non-invasive ICP (nICP) and invasive ICP measurement in neurocritical care patients. Methods and findings This was a prospective, single-cohort observational study of patients admitted to a tertiary neurocritical care unit. Patients with brain injury requiring invasive ICP monitoring were considered for inclusion. nICP was assessed using optic nerve sheath diameter (ONSD), venous transcranial Doppler (vTCD) of straight sinus systolic flow velocity (FVsv), and methods derived from arterial transcranial Doppler (aTCD) on the middle cerebral artery (MCA): MCA pulsatility index (PIa) and an estimator based on diastolic flow velocity (FVd). A total of 445 ultrasound examinations from 64 patients performed from 1 January to 1 November 2016 were included. The median age of the patients was 53 years (range 37-64). Median Glasgow Coma Scale at admission was 7 (range 3-14), and median Glasgow Outcome Scale was 3 (range 1-5). The mortality rate was 20%. ONSD and FVsv demonstrated the strongest correlation with ICP (R = 0.76 for ONSD versus ICP; R = 0.72 for FVsv versus ICP), whereas PIa and the estimator based on FVd did not correlate with ICP significantly. Combining the 2 strongest nICP predictors (ONSD and FVsv) resulted in an even stronger correlation with ICP (R = 0.80). The ability to detect intracranial hypertension (ICP-20 mm Hg) was highest for ONSD (area under the curve [AUC] 0.91, 95% CI 0.88-0.95). The combination of ONSD and FVsv methods showed a statistically significant improvement of AUC values compared with the ONSD method alone (0.93, 95% CI 0.90-0.97, p = 0.01). Major limitations are the heterogeneity and small number of patients included in this study, the need for specialised training to perform and interpret the ultrasound tests, and the variability in performance among different ultrasound operators. Conclusions Of the studied ultrasound nICP methods, ONSD is the best estimator of ICP. The novel combination of ONSD ultrasonography and vTCD of the straight sinus is a promising and easily available technique for identifying critically ill patients with intracranial hypertension.	[Robba, Chiara; Lavinio, Andrea; Gupta, Arun; Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Neurosci Crit Care Unit, Cambridge, England; [Robba, Chiara] Univ Genoa, Dept Neurosci, Genoa, Italy; [Cardim, Danilo; Donnelly, Joseph; Czosnyka, Marek] Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Brain Phys Lab,Dept Clin Neurosci, Cambridge, England; [Tajsic, Tamara] Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci, Cambridge, England; [Pietersen, Justine; Bulman, Michael] Univ Cambridge, Addenbrookes Hosp, Dept Anaesthesia, Cambridge, England; [Hutchinson, Peter J. A.] Univ Cambridge Hosp, Div Neurosurg, Cambridge, England; [Czosnyka, Marek] Warsaw Univ Technol, Inst Elect Syst, Warsaw, Poland		Robba, C (corresponding author), Univ Cambridge, Addenbrookes Hosp, Neurosci Crit Care Unit, Cambridge, England.; Robba, C (corresponding author), Univ Genoa, Dept Neurosci, Genoa, Italy.	kiarobba@gmail.com	Donnelly, Joseph/N-6803-2019; Donnelly, Joseph/E-9235-2018; Cardim, Danilo Augusto/B-8447-2012; Robba, Chiara/AAS-7421-2020	Donnelly, Joseph/0000-0002-6502-8069; Donnelly, Joseph/0000-0002-6502-8069; Cardim, Danilo Augusto/0000-0002-9261-1321; Pietersen, Justine Mari/0000-0001-8770-3355	NIHR Brain Injury Healthcare Technology Cooperative, Cambridge, UK; Woolf Fisher Scholarship (NZ); National Institute for Health Research Cambridge BRC as a Research Professor of Neurosurgery; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-R3-12-013] Funding Source: researchfish	DC and MC are partially supported by NIHR Brain Injury Healthcare Technology Cooperative, Cambridge, UK. JD is supported by a Woolf Fisher Scholarship (NZ). PJAH is supported by the National Institute for Health Research Cambridge BRC as a Research Professor of Neurosurgery. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amini A, 2013, AM J EMERG MED, V31, P236, DOI 10.1016/j.ajem.2012.06.025; Badri S, 2012, INTENS CARE MED, V38, P1800, DOI 10.1007/s00134-012-2655-4; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Bauer DF, 2011, NEUROSURGERY, V69, P255, DOI 10.1227/NEU.0b013e31821a45ba; Binz DD, 2009, NEUROCRIT CARE, V10, P253, DOI 10.1007/s12028-009-9193-0; Budohoski Karol P, 1800, Acta Neurochir Suppl, V114, P121, DOI 10.1007/978-3-7091-0956-4_22; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cardim D, 2016, J NEUROTRAUM, V33, P792, DOI 10.1089/neu.2015.4134; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839; de Riva N, 2012, NEUROCRIT CARE, V17, P58, DOI 10.1007/s12028-012-9672-6; Dubourg J, 2011, INTENS CARE MED, V37, P1059, DOI 10.1007/s00134-011-2224-2; Geeraerts T, 2008, INTENS CARE MED, V34, P2062, DOI 10.1007/s00134-008-1149-x; Geeraerts T, 2008, CRIT CARE, V12, DOI 10.1186/cc7006; Helmke K, 2000, TRANSPLANTATION, V70, P392, DOI 10.1097/00007890-200007270-00029; Helmke K, 1996, PEDIATR RADIOL, V26, P701, DOI 10.1007/BF01383383; Holloway KL, 1996, J NEUROSURG, V85, P419, DOI 10.3171/jns.1996.85.3.0419; Hosmer D, 1989, APPL LOGISTIC REGRES; Kashif FM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003249; Komut E, 2016, AM J EMERG MED, V34, P963, DOI 10.1016/j.ajem.2016.02.012; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Moretti R, 2009, J NEUROSURG ANESTH, V21, P16, DOI 10.1097/ANA.0b013e318185996a; Ragauskas A, 2012, NEUROLOGY, V78, P1684, DOI 10.1212/WNL.0b013e3182574f50; Ragauskas A, 2014, NEUROL RES, V36, P607, DOI 10.1179/1743132813Y.0000000308; Rajajee V, 2011, NEUROCRIT CARE, V15, P506, DOI 10.1007/s12028-011-9606-8; Robba C, 2016, BRIT J ANAESTH, V117, P783, DOI 10.1093/bja/aew356; Robba C, 2016, ACTA NEUROL SCAND, V134, P4, DOI 10.1111/ane.12527; Robba C, 2017, J NEUROSURG ANESTH, V29, P243, DOI 10.1097/ANA.0000000000000295; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Schmidt B, 1997, STROKE, V28, P2465, DOI 10.1161/01.STR.28.12.2465; Schoser BGH, 1999, J NEUROSURG, V91, P744, DOI 10.3171/jns.1999.91.5.0744; Steiner T, 2013, CEREBROVASC DIS, V35, P93, DOI 10.1159/000346087; Strumwasser A, 2011, J SURG RES, V170, P265, DOI 10.1016/j.jss.2011.03.009; VALDUEZA JM, 1995, STROKE, V26, P1196, DOI 10.1161/01.STR.26.7.1196; WARDLAW JM, 1994, J NEUROSURG, V80, P332, DOI 10.3171/jns.1994.80.2.0332; Zweifel C, 2012, NEUROSURGERY, V71, P853, DOI 10.1227/NEU.0b013e3182675b42	38	83	87	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1549-1277	1549-1676		PLOS MED	PLos Med.	JUL	2017	14	7							e1002356	10.1371/journal.pmed.1002356			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC1QA	WOS:000406611200026	28742869	Green Published, gold, Green Submitted			2022-02-06	
J	Scott, G; Ramlackhansingh, AF; Edison, P; Hellyer, P; Cole, J; Veronese, M; Leech, R; Greenwood, RJ; Turkheimer, FE; Gentleman, SM; Heckemann, RA; Matthews, PM; Brooks, DJ; Sharp, DJ				Scott, Gregory; Ramlackhansingh, Anil F.; Edison, Paul; Hellyer, Peter; Cole, James; Veronese, Mattia; Leech, Rob; Greenwood, Richard J.; Turkheimer, Federico E.; Gentleman, Steve M.; Heckemann, Rolf A.; Matthews, Paul M.; Brooks, David J.; Sharp, David J.			Amyloid pathology and axonal injury after brain trauma	NEUROLOGY			English	Article							ALZHEIMERS-DISEASE; DEMENTIA; NETWORK; REGISTRATION; DYSFUNCTION; PROGRESSION; DEPOSITION; SEVERITY; ANATOMY; ATROPHY	Objective:To image -amyloid (A) plaque burden in long-term survivors of traumatic brain injury (TBI), test whether traumatic axonal injury and A are correlated, and compare the spatial distribution of A to Alzheimer disease (AD).Methods:Patients 11 months to 17 years after moderate-severe TBI underwent C-11-Pittsburgh compound B (C-11-PiB)-PET, structural and diffusion MRI, and neuropsychological examination. Healthy aged controls and patients with AD underwent PET and structural MRI. Binding potential (BPND) images of C-11-PiB, which index A plaque density, were computed using an automatic reference region extraction procedure. Voxelwise and regional differences in BPND were assessed. In TBI, a measure of white matter integrity, fractional anisotropy, was estimated and correlated with C-11-PiB BP(ND.)Results:Twenty-eight participants (9 with TBI, 9 controls, 10 with AD) were assessed. Increased C-11-PiB BPND was found in TBI vs controls in the posterior cingulate cortex and cerebellum. Binding in the posterior cingulate cortex increased with decreasing fractional anisotropy of associated white matter tracts and increased with time since injury. Compared to AD, binding after TBI was lower in neocortical regions but increased in the cerebellum.Conclusions:Increased A burden was observed in TBI. The distribution overlaps with, but is distinct from, that of AD. This suggests a mechanistic link between TBI and the development of neuropathologic features of dementia, which may relate to axonal damage produced by the injury.	[Scott, Gregory; Ramlackhansingh, Anil F.; Edison, Paul; Hellyer, Peter; Cole, James; Leech, Rob; Gentleman, Steve M.; Heckemann, Rolf A.; Matthews, Paul M.; Brooks, David J.; Sharp, David J.] Univ London Imperial Coll Sci Technol & Med, Dept Med, Div Brain Sci, London SW7 2AZ, England; [Hellyer, Peter; Veronese, Mattia; Turkheimer, Federico E.] Kings Coll London, Inst Psychiat Psychol & Neurosci, London WC2R 2LS, England; [Greenwood, Richard J.] UCL, Inst Neurol, London WC1E 6BT, England; [Heckemann, Rolf A.] Gothenburg Univ, Sahlgrenska Univ Hosp, MedTech West, S-41124 Gothenburg, Sweden; [Brooks, David J.] Aarhus Univ, Inst Clin Med, DK-8000 Aarhus C, Denmark		Sharp, DJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Med, Div Brain Sci, London SW7 2AZ, England.	david.sharp@imperial.ac.uk	Veronese, Mattia/S-3114-2019; Hellyer, Peter J/F-7112-2013; Veronese, Mattia/A-6012-2013; Turkheimer, Federico E/B-9485-2012; Heckemann, Rolf Andreas/H-9022-2019; Sharp, David J/A-2119-2013; Leech, Robert/AAE-8254-2019; Cole, James H/I-5197-2019	Hellyer, Peter J/0000-0002-5139-3401; Veronese, Mattia/0000-0003-3562-0683; Turkheimer, Federico E/0000-0002-3766-3815; Heckemann, Rolf Andreas/0000-0003-3582-3683; Leech, Robert/0000-0002-5801-6318; Cole, James H/0000-0003-1908-5588; Scott, Gregory/0000-0001-8063-5871; Edison, Paul/0000-0002-6551-2002; Brooks, David/0000-0003-2602-2518	Wellcome Trust-GlaxoSmithKline Translational Medicine Training Programme; Imperial College Healthcare Trust Biomedical Research Centre; MRC PET programme grantUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G1100809/1]; MS Society of Great Britain; Progressive MS Alliance; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC); GlaxoSmithKlineGlaxoSmithKline; National Institute for Health ResearchNational Institute for Health Research (NIHR); Medical Research Council (UK)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G1100810, MC_U120036861, G0701951, G0900897, MC_U120085814, MR/L022141/1, G1100809] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MC_U120036861, G0900897, MC_U120085814, G0701951, MR/L022141/1, G1100809, G1100810] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0514-10022, NIHR-RP-011-048] Funding Source: researchfish	G. Scott was supported by a clinical research fellowship awarded in the Wellcome Trust-GlaxoSmithKline Translational Medicine Training Programme. This work was supported by the Imperial College Healthcare Trust Biomedical Research Centre. A. Ramlackhansingh, P. Edison, P. Hellyer, and J. Cole report no disclosures relevant to the manuscript. M. Veronese is supported by an MRC PET programme grant (G1100809/1). R. Leech and R. Greenwood report no disclosures relevant to the manuscript. F. Turkheimer is supported by an MRC PET programme grant (G1100809/1). S. Gentleman and R. Heckemann report no disclosures relevant to the manuscript. P. Matthews has consulted or received honoraria for lectures from GlaxoSmithKline, Biogen, IDEC, IXICO, and Novartis, and has research support from the MS Society of Great Britain, the Progressive MS Alliance, the MRC, and GlaxoSmithKline, and personal support from the Edmond J. Safra Foundation and from Lily Safra. Matthews is an NIHR Senior Investigator. D. Brooks has been a consultant and part time employee for GE Healthcare in the past. D. Sharp receives personal and research support from the National Institute for Health Research and the Medical Research Council (UK). Go to Neurology.org for full disclosures.	Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Cole JH, 2015, ANN NEUROL, V77, P571, DOI 10.1002/ana.24367; Crossley NA, 2014, BRAIN, V137, P2382, DOI 10.1093/brain/awu132; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Frisoni GB, 2011, ALZHEIMERS DEMENT, V7, P171, DOI 10.1016/j.jalz.2010.06.007; Harris JA, 2010, NEURON, V68, P428, DOI 10.1016/j.neuron.2010.10.020; Heckemann RA, 2010, NEUROIMAGE, V51, P221, DOI 10.1016/j.neuroimage.2010.01.072; Hong YT, 2014, JAMA NEUROL, V71, P23, DOI 10.1001/jamaneurol.2013.4847; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Ikoma Y, 2013, J CEREBR BLOOD F MET, V33, P1725, DOI 10.1038/jcbfm.2013.133; Ikonomovic MD, 2008, BRAIN, V131, P1630, DOI 10.1093/brain/awn016; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Klein A, 2009, NEUROIMAGE, V46, P786, DOI 10.1016/j.neuroimage.2008.12.037; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Magnoni S, 2015, BRAIN, V138, P2263, DOI 10.1093/brain/awv152; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Polymenidou M, 2012, J EXP MED, V209, P889, DOI 10.1084/jem.20120741; Ponsford J, 2011, J NEUROTRAUM, V28, P1683, DOI 10.1089/neu.2010.1623; Quigley H, 2011, INT J GERIATR PSYCH, V26, P991, DOI 10.1002/gps.2640; Raj A, 2012, NEURON, V73, P1204, DOI 10.1016/j.neuron.2011.12.040; Rowe CC, 2007, NEUROLOGY, V68, P1718, DOI 10.1212/01.wnl.0000261919.22630.ea; Rowe CC, 2011, J NUCL MED, V52, P1733, DOI 10.2967/jnumed.110.076315; Rowe CC, 2010, NEUROBIOL AGING, V31, P1275, DOI 10.1016/j.neurobiolaging.2010.04.007; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Thal DR, 2002, NEUROLOGY, V58, P1791, DOI 10.1212/WNL.58.12.1791; Tosun D, 2011, BRAIN, V134, P1077, DOI 10.1093/brain/awr044; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246	36	83	84	0	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	MAR 1	2016	86	9					821	828		10.1212/WNL.0000000000002413			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DF4TG	WOS:000371343100002	26843562	Green Published, hybrid			2022-02-06	
J	Welch, RD; Ayaz, SI; Lewis, LM; Unden, J; Chen, JY; Mika, VH; Saville, B; Tyndall, JA; Nash, M; Buki, A; Barzo, P; Hack, D; Tortella, FC; Schmid, K; Hayes, RL; Vossough, A; Sweriduk, ST; Bazarian, JJ				Welch, Robert D.; Ayaz, Syed I.; Lewis, Lawrence M.; Unden, Johan; Chen, James Y.; Mika, Valerie H.; Saville, Ben; Tyndall, Joseph A.; Nash, Marshall; Buki, Andras; Barzo, Pal; Hack, Dallas; Tortella, Frank C.; Schmid, Kara; Hayes, Ronald L.; Vossough, Arastoo; Sweriduk, Stephen T.; Bazarian, Jeffrey J.			Ability of Serum Glial Fibrillary Acidic Protein, Ubiquitin C-Terminal Hydrolase-L1, and S100B To Differentiate Normal and Abnormal Head Computed Tomography Findings in Patients with Suspected Mild or Moderate Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article							NEW-ORLEANS CRITERIA; INTRACRANIAL LESIONS; RULE; BIOMARKERS; MANAGEMENT; S100-BETA; DIAGNOSIS; ACCURACY; GFAP	Head computed tomography (CT) imaging is still a commonly obtained diagnostic test for patients with minor head injury despite availability of clinical decision rules to guide imaging use and recommendations to reduce radiation exposure resulting from unnecessary imaging. This prospective multicenter observational study of 251 patients with suspected mild to moderate traumatic brain injury (TBI) evaluated three serum biomarkers' (glial fibrillary acidic protein [GFAP], ubiquitin C-terminal hydrolase-L1 [UCH-L1] and S100B measured within 6h of injury) ability to differentiate CT negative and CT positive findings. Of the 251 patients, 60.2% were male and 225 (89.6%) had a presenting Glasgow Coma Scale score of 15. A positive head CT (intracranial injury) was found in 36 (14.3%). UCH-L1 was 100% sensitive and 39% specific at a cutoff value >40pg/mL. To retain 100% sensitivity, GFAP was 0% specific (cutoff value 0pg/mL) and S100B had a specificity of only 2% (cutoff value 30pg/mL). All three biomarkers had similar values for areas under the receiver operator characteristic curve: 0.79 (95% confidence interval; 0.70-0.88) for GFAP, 0.80 (0.71-0.89) for UCH-L1, and 0.75 (0.65-0.85) for S100B. Neither GFAP nor UCH-L1 curve values differed significantly from S100B (p=0.21 and p=0.77, respectively). In our patient cohort, UCH-L1 outperformed GFAP and S100B when the goal was to reduce CT use without sacrificing sensitivity. UCH-L1 values <40pg/mL could potentially have aided in eliminating 83 of the 215 negative CT scans. These results require replication in other studies before the test is used in actual clinical practice.	[Welch, Robert D.; Ayaz, Syed I.; Mika, Valerie H.] Wayne State Univ, Dept Emergency Med, Detroit, MI 48230 USA; [Lewis, Lawrence M.] Washington Univ, Dept Emergency Med, St Louis, MO USA; [Unden, Johan] Clin Sci Malmo, Dept Anesthesiol & Intens Care, Malmo, Sweden; [Chen, James Y.] Univ Calif San Diego Hlth Syst, Dept Radiol, San Diego, CA USA; [Saville, Ben] Berry Consultants, Austin, TX USA; [Tyndall, Joseph A.] Univ Florida, Dept Emergency Med, Gainesville, FL USA; [Nash, Marshall] Neurostudies Net, Decatur, GA USA; [Buki, Andras] Univ Pecs, Dept Neurosurg, Pecs, Hungary; [Barzo, Pal] Univ Szeged, Dept Neurosurg, Szeged, Hungary; [Hack, Dallas] US Army, Med Res & Mat Command, Ft Detrick, MD USA; [Tortella, Frank C.] Walter Reed Army Inst Res, Appl Neurobiol, Silver Spring, MD USA; [Schmid, Kara] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Silver Spring, MD USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Ctr Innovat Res, Alachua, FL USA; [Vossough, Arastoo] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA; [Sweriduk, Stephen T.] Shields Hlth Care Grp, Dept Radiol, Brockton, MA USA; [Bazarian, Jeffrey J.] Univ Rochester, Sch Med, Dept Emergency Med, Rochester, NY USA		Welch, RD (corresponding author), Wayne State Univ, Dept Emergency Med, Detroit, MI 48230 USA.	rwelch@med.wayne.edu	Mika, Valerie H./AAO-2816-2020		U.S. Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-06-1-0517, W81XWH-10-C-0251]	This work is supported by the U.S. Army Medical Research and Material Command under Contract N. W81XWH-06-1-0517 and Contract N. W81XWH-10-C-0251. The views, opinions and/or findings contained in this report are those of the authors and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.	Barbosa RR, 2012, J TRAUMA ACUTE CARE, V73, pS307, DOI 10.1097/TA.0b013e3182701885; Bazarian JJ, 2013, J NEUROTRAUM, V30, P1747, DOI 10.1089/neu.2013.2853; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Bossuyt PM, 2003, ANN INTERN MED, V138, P40, DOI 10.7326/0003-4819-138-1-200301070-00010; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Egea-Guerrero JJ, 2012, BRAIN INJURY, V26, P76, DOI 10.3109/02699052.2011.635360; Florkowski Christopher M, 2008, Clin Biochem Rev, V29 Suppl 1, pS83; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Korevaar Daniel A, 2014, Evid Based Med, V19, P47, DOI 10.1136/eb-2013-101637; Korley FK, 2013, ACAD EMERG MED, V20, P463, DOI 10.1111/acem.12136; Kou ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080296; McMahon PJ, 2015, J NEUROTRAUM, V32, P527, DOI 10.1089/neu.2014.3635; Melnick ER, 2012, JT COMM J QUAL PATIE, V38, P483, DOI 10.1016/S1553-7250(12)38064-1; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Sauerbrei W, 2014, STAT MED, V33, P5413, DOI 10.1002/sim.6265; Smith-Bindman R, 2009, ARCH INTERN MED, V169, P2078, DOI 10.1001/archinternmed.2009.427; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Stiell IG, 2010, CAN MED ASSOC J, V182, P1527, DOI 10.1503/cmaj.091974; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zongo D, 2012, ANN EMERG MED, V59, P209, DOI 10.1016/j.annemergmed.2011.07.027	33	83	84	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2016	33	2					203	214		10.1089/neu.2015.4149			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	DA7PH	WOS:000367995800006	26467555	Green Accepted, Green Submitted, Green Published, hybrid			2022-02-06	
J	Wagenman, KL; Blake, TP; Sanchez, SM; Schultheis, MT; Radcliffe, J; Berg, RA; Dlugos, DJ; Topjian, AA; Abend, NS				Wagenman, Katherine L.; Blake, Taylor P.; Sanchez, Sarah M.; Schultheis, Maria T.; Radcliffe, Jerilynn; Berg, Robert A.; Dlugos, Dennis J.; Topjian, Alexis A.; Abend, Nicholas S.			Electrographic status epilepticus and long-term outcome in critically ill children	NEUROLOGY			English	Article							NONCONVULSIVE STATUS EPILEPTICUS; TRAUMATIC BRAIN-INJURY; INTENSIVE-CARE-UNIT; CONTINUOUS VIDEO-EEG; COMATOSE CHILDREN; SEIZURES; PREDICTORS; VALIDITY; VERSION; RISK	Objective:Electrographic seizures (ES) and electrographic status epilepticus (ESE) are common in children in the pediatric intensive care unit (PICU) with acute neurologic conditions. We aimed to determine whether ES or ESE was associated with worse long-term outcomes.Methods:Three hundred children with an acute neurologic condition and encephalopathy underwent clinically indicated EEG monitoring and were enrolled in a prospective observational study. We aimed to obtain follow-up data from 137 subjects who were neurodevelopmentally normal before PICU admission.Results:Follow-up data were collected for 60 of 137 subjects (44%) at a median of 2.7 years. Subjects with and without follow-up data were similar in clinical characteristics during the PICU admission. Among subjects with follow-up data, ES occurred in 12 subjects (20%) and ESE occurred in 14 subjects (23%). Multivariable analysis indicated that ESE was associated with an increased risk of unfavorable Glasgow Outcome Scale (Extended Pediatric Version) category (odds ratio 6.36, p = 0.01) and lower Pediatric Quality of Life Inventory scores (23 points lower, p = 0.001). Among subjects without prior epilepsy diagnoses ESE was associated with an increased risk of subsequently diagnosed epilepsy (odds ratio 13.3, p = 0.002). ES were not associated with worse outcomes.Conclusions:Among children with acute neurologic disorders who were reported to be neurodevelopmentally normal before PICU admission, ESE but not ES was associated with an increased risk of unfavorable global outcome, lower health-related quality of life scores, and an increased risk of subsequently diagnosed epilepsy even after adjusting for neurologic disorder category, EEG background category, and age.	[Berg, Robert A.; Topjian, Alexis A.] Univ Penn, Childrens Hosp Philadelphia, Dept Anesthesia & Crit Care Med, Philadelphia, PA 19104 USA; Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Wagenman, Katherine L.; Sanchez, Sarah M.; Dlugos, Dennis J.; Abend, Nicholas S.] Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA; [Dlugos, Dennis J.; Abend, Nicholas S.] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Dlugos, Dennis J.; Abend, Nicholas S.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Blake, Taylor P.; Schultheis, Maria T.] Drexel Univ, Dept Psychol, Philadelphia, PA 19104 USA; [Radcliffe, Jerilynn] Univ Penn, Childrens Hosp Philadelphia, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA		Abend, NS (corresponding author), Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA.	abend@email.chop.edu		Schultheis, Maria/0000-0002-6558-548X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23NS076550]; Clinical & Translational Research Center [UL1RR024134]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD047349] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024134] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL094345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS075363, U01NS045911, U01NS077276, K23NS076550] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM) [R01LM011124] Funding Source: NIH RePORTER	Supported by NIH (K23NS076550) to Dr. Abend and the Clinical & Translational Research Center (grant UL1RR024134).	Abend NS, 2011, NEUROLOGY, V76, P1071, DOI 10.1212/WNL.0b013e318211c19e; Abend NS, 2009, NEUROLOGY, V72, P1931, DOI 10.1212/WNL.0b013e3181a82687; Abend NS, 2007, PEDIATR NEUROL, V37, P165, DOI 10.1016/j.pediatrneurol.2007.05.012; Abend NS, 2013, NEUROLOGY, V81, P383, DOI 10.1212/WNL.0b013e31829c5cfe; Abend NS, 2013, SEIZURE-EUR J EPILEP, V22, P467, DOI 10.1016/j.seizure.2013.03.008; Abend NS, 2011, NEUROCRIT CARE, V15, P70, DOI 10.1007/s12028-010-9380-z; Abend NS, 2010, NEUROCRIT CARE, V12, P382, DOI 10.1007/s12028-010-9337-2; Arango JI, 2012, CHILD NERV SYST, V28, P1925, DOI 10.1007/s00381-012-1863-0; Beers SR, 2012, J NEUROTRAUM, V29, P1126, DOI 10.1089/neu.2011.2272; Brooks DR, 2012, EPILEPSY BEHAV, V23, P57, DOI 10.1016/j.yebeh.2011.11.002; Brophy GM, 2012, NEUROCRIT CARE, V17, P3, DOI 10.1007/s12028-012-9695-z; Carrera E, 2008, ARCH NEUROL-CHICAGO, V65, P1612, DOI 10.1001/archneur.65.12.1612; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; Greiner HM, 2012, PEDIATRICS, V129, pE748, DOI 10.1542/peds.2011-2067; Gutierrez-Colina AM, 2012, PEDIATR NEUROL, V46, P158, DOI 10.1016/j.pediatrneurol.2011.12.009; Gwer S, 2012, ARCH DIS CHILD, V97, P343, DOI 10.1136/archdischild-2011-300935; Hauf M, 2009, AM J NEURORADIOL, V30, P693, DOI 10.3174/ajnr.A1456; Hesdorffer DC, 1998, ANN NEUROL, V44, P908, DOI 10.1002/ana.410440609; Hosain SA, 2005, PEDIATR NEUROL, V32, P162, DOI 10.1016/j.pediatrneurol.2004.09.008; Jette N, 2006, ARCH NEUROL-CHICAGO, V63, P1750, DOI 10.1001/archneur.63.12.1750; Kirkham FJ, 2012, INTENS CARE MED, V38, P853, DOI 10.1007/s00134-012-2529-9; Lambrechtsen FACP, 2008, EPILEPSIA, V49, P615, DOI 10.1111/j.1528-1167.2007.01465.x; Leung H, 2010, EPILEPSIA, V51, P1570, DOI 10.1111/j.1528-1167.2009.02409.x; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McCoy B, 2011, EPILEPSIA, V52, P1973, DOI 10.1111/j.1528-1167.2011.03291.x; Oddo M, 2009, CRIT CARE MED, V37, P2051, DOI 10.1097/CCM.0b013e3181a00604; Sanchez SM, 2013, J CLIN NEUROPHYSIOL, V30, P156, DOI 10.1097/WNP.0b013e31827eda27; Schreiber JM, 2012, NEUROCRIT CARE, V17, P31, DOI 10.1007/s12028-012-9715-z; Shahwan A, 2010, EPILEPSIA, V51, P1198, DOI 10.1111/j.1528-1167.2009.02517.x; Tay SKH, 2006, EPILEPSIA, V47, P1504, DOI 10.1111/j.1528-1167.2006.00623.x; Topjian AA, 2013, CRIT CARE MED, V41, P215, DOI 10.1097/CCM.0b013e3182668035; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Varni JW, 1999, MED CARE, V37, P126, DOI 10.1097/00005650-199902000-00003; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Williams K, 2011, EPILEPSIA, V52, P1130, DOI 10.1111/j.1528-1167.2011.03070.x; Young GB, 1996, NEUROLOGY, V47, P83	37	83	85	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	FEB 4	2014	82	5					396	404		10.1212/WNL.0000000000000082			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AH9WA	WOS:000336494600009	24384638	Green Published			2022-02-06	
J	Covassin, T; Moran, R; Wilhelmy, K				Covassin, Tracey; Moran, Ryan; Wilhelmy, Kristyn			Concussion Symptoms and Neurocognitive Performance of High School and College Athletes Who Incur Multiple Concussions	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						multiple concussions; cognitive testing; symptoms	TEST-RETEST RELIABILITY; BASE-LINE; IMPACT; EPIDEMIOLOGY; RECOVERY	Background: Multiple concussions have been associated with prolonged symptoms, recovery time, and risk for future concussions. However, very few studies have examined the effect of multiple concussions on neurocognitive performance and the recently revised symptom clusters using a large database. Purpose: To examine concussed athletes with a history of 0, 1, 2, or 3 concussions on neurocognitive performance and the recently revised symptom clusters. Study Design: Cohort study (prognosis); Level of evidence, 2. Methods: The independent variables were concussion group (0, 1, 2, and 3 concussions) and time (baseline, 3 days, and 8 days). The dependent variables were neurocognitive test scores as measured by the Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) neurocognitive test battery (verbal and visual memory, processing speed, and reaction time) and 4 concussion symptom clusters (migraine-cognitive-fatigue, affective, somatic, and sleep). All concussed athletes (n = 596) were administered the ImPACT test at a mean 2.67 1.98 and 7.95 4.46 days after injury. A series of 4 (concussion group) x 3 (time) repeated-measures analyses of covariance (age = covariate) were performed on ImPACT composite scores and symptom clusters. Results: Concussed athletes with 3 concussions were still impaired 8 days after a concussion compared with baseline scores on verbal memory (P < .001), reaction time (P < .001), and migraine-cognitive-fatigue symptoms (P < .001). There were no significant findings on the remaining dependent variables. Conclusion: Concussed athletes with a history of 3 concussions take longer to recover than athletes with 1 or no previous concussion. Future research should concentrate on validating the new symptom clusters on multiple concussed athletes, examining longer recovery times (ie, >8 days) among athletes with multiple concussions.	[Covassin, Tracey; Moran, Ryan; Wilhelmy, Kristyn] Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA		Covassin, T (corresponding author), Michigan State Univ, Dept Kinesiol, 308 West Circle Dr,Room 105, E Lansing, MI 48824 USA.	covassin@msu.edu					[Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; Chrisman SP, 2013, BRAIN INJURY, V27, P1, DOI 10.3109/02699052.2012.722251; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2012, REHABIL RES PRACT, V2012; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Sport Injury Prevention Research Centre and Canadian Academy of Sport and Exercise Medicine, 2012, CLIN J SPORT MED, V22, P304; Stephens R, 2010, J NEUROPSYCH CLIN N, V22, P295, DOI 10.1176/appi.neuropsych.22.3.295; Terry DP, 2012, BRAIN INJURY, V26, P1684, DOI 10.3109/02699052.2012.722259; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	24	83	83	2	57	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	DEC	2013	41	12					2885	2889		10.1177/0363546513499230			5	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Sport Sciences	258QH	WOS:000327473300022	23959963				2022-02-06	
J	Saha, B; Peron, S; Murray, K; Jaber, M; Gaillard, A				Saha, Bhaskar; Peron, Sophie; Murray, Kerren; Jaber, Mohamed; Gaillard, Afsaneh			Cortical lesion stimulates adult subventricular zone neural progenitor cell proliferation and migration to the site of injury	STEM CELL RESEARCH			English	Article							TRAUMATIC BRAIN-INJURY; STEM-CELLS; NEURONAL MIGRATION; NEUROBLAST MIGRATION; NEUROTROPHIC FACTOR; DIRECTED MIGRATION; CEREBRAL-CORTEX; VASCULAR NICHE; BLOOD-VESSELS; NEUROGENESIS	The subventricular zone (SVZ) is the principal neurogenic niche present in the adult non-human mammalian brain. Neurons generated in the SVZ migrate along the rostral migratory stream to reach the olfactory bulb. Brain injuries stimulate SVZ neurogenesis and direct migration of new progenitors to the sites of injury. To date, cortical injury-induced adult SVZ neurogenesis in mice remains ambiguous and migration of neural progenitors to the site of injury has not been studied in detail. Here we report that aspiration lesion in the motor cortex induces a transient, but significant increase in the proliferation as well as neurogenesis in the SVZ. New neural progenitors migrate ectopically to the injured area with the assistance of blood vessels and reactive astrocytes. The SVZ origin of these progenitors was further confirmed using lentiviral transduction. In addition, we show that astrocyte-assisted ectopic migration is regulated by CXCR4/SDF-1 signaling pathway. Finally, upon reaching the lesion area, these progenitors differentiate mainly into glial cells and, to a lesser extent, mature neurons. These data provide a detailed account of the changes occurring in the SVZ and the cortex following lesion, and indicate the potential of the endogenous neural progenitors in cortical repair. (C) 2013 Elsevier B.V. All rights reserved.	[Saha, Bhaskar; Peron, Sophie; Jaber, Mohamed; Gaillard, Afsaneh] INSERM, U1084, F-86022 Poitiers, France; [Saha, Bhaskar; Peron, Sophie; Jaber, Mohamed; Gaillard, Afsaneh] Univ Poitiers, F-86022 Poitiers, France; [Murray, Kerren] Inst Pasteur, Migrat & Canc Unit, F-75724 Paris 15, France		Gaillard, A (corresponding author), Univ Poitiers, Expt & Clin Neurosci Lab, INSERM, U1084, Bldg B36,1 Rue Georges Bonnet,BP 633, F-86022 Poitiers, France.	Afsaneh.Gaillard@univ-poitiers.fr		Peron, Sophie/0000-0002-7167-4585; Jaber, Mohamed/0000-0003-2536-1913	Institut de Recherche sur la Moelle epiniere et sur l'Encephale (IRME); Agence Nationale de La RechercheFrench National Research Agency (ANR)European Commission [ANR-09-MNPS-027-01]; FEDEREuropean Commission [33552]; CPER; ANRFrench National Research Agency (ANR)	This work was funded by grants from the Institut de Recherche sur la Moelle epiniere et sur l'Encephale (IRME), and the Agence Nationale de La Recherche ANR-09-MNPS-027-01 (to A.G); FEDER No 33552 and the CPER 5. B.S. is a postdoctoral fellow of ANR. We thank Dr. Andre Goffinet for Reelin antibody, M. Francheteau for technical assistance and staffs of Image'UP platform (University of Poitiers).	ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Amankulor NM, 2009, J NEUROSCI, V29, P10299, DOI 10.1523/JNEUROSCI.2500-09.2009; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Bagri A, 2002, DEVELOPMENT, V129, P4249; Bajetto A, 1999, J NEUROCHEM, V73, P2348, DOI 10.1046/j.1471-4159.1999.0732348.x; Bergmann O, 2012, NEURON, V74, P634, DOI 10.1016/j.neuron.2012.03.030; Blizzard CA, 2011, CEREB CORTEX, V21, P281, DOI 10.1093/cercor/bhq091; Buffo A, 2005, P NATL ACAD SCI USA, V102, P18183, DOI 10.1073/pnas.0506535102; Carbonell WS, 2005, J NEUROSCI, V25, P7040, DOI 10.1523/JNEUROSCI.5171-04.2005; Chazal G, 2000, J NEUROSCI, V20, P1446; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Consiglio A, 2004, P NATL ACAD SCI USA, V101, P14835, DOI 10.1073/pnas.0404180101; Courtes S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020430; Decressac M, 2010, EXP NEUROL, V226, P24, DOI 10.1016/j.expneurol.2010.07.022; Dizon MLV, 2006, NEUROSCIENCE, V142, P717, DOI 10.1016/j.neuroscience.2006.06.050; Doetsch F, 1997, J NEUROSCI, V17, P5046; Faiz M, 2008, MOL CELL NEUROSCI, V38, P170, DOI 10.1016/j.mcn.2008.02.002; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; Gaillard A, 1998, ADV ANAT EMBRYOL CEL, V148, P1; Gaillard A, 2008, M S-MED SCI, V24, P132, DOI 10.1051/medsci/2008242132; Gaillard A, 2007, NAT NEUROSCI, V10, P1294, DOI 10.1038/nn1970; Gaillard A, 2007, CELL ADHES MIGR, V1, P161, DOI 10.4161/cam.1.4.5274; Goings GE, 2002, NEUROSCI LETT, V329, P161, DOI 10.1016/S0304-3940(02)00611-0; GOMEZPINILLA F, 1992, NEUROSCIENCE, V49, P771, DOI 10.1016/0306-4522(92)90355-6; Grubb MS, 2008, J NEUROSCI, V28, P2919, DOI 10.1523/JNEUROSCI.5550-07.2008; Hoglinger GU, 2004, NAT NEUROSCI, V7, P726, DOI 10.1038/nn1265; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Itoh T, 2009, NEUROL RES, V31, P90, DOI 10.1179/174313208X332995; Jablonska B, 2010, NAT NEUROSCI, V13, P541, DOI 10.1038/nn.2536; Jin K, 2003, MOL CELL NEUROSCI, V24, P171, DOI 10.1016/S1044-7431(03)00159-3; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kojima T, 2010, STEM CELLS, V28, P545, DOI 10.1002/stem.306; Kokovay E, 2010, CELL STEM CELL, V7, P163, DOI 10.1016/j.stem.2010.05.019; Lois C, 1996, SCIENCE, V271, P978, DOI 10.1126/science.271.5251.978; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Macas J, 2006, J NEUROSCI, V26, P13114, DOI 10.1523/JNEUROSCI.4667-06.2006; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; Marti-Fabregas J, 2010, NEUROLOGY, V74, P357, DOI 10.1212/WNL.0b013e3181cbccec; Masuda T, 2007, NEUROSCI LETT, V425, P114, DOI 10.1016/j.neulet.2007.08.039; Ohtani Y, 1998, NEUROSCI LETT, V249, P163, DOI 10.1016/S0304-3940(98)00425-X; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Rodriguez JJ, 2009, NEUROREPORT, V20, P907, DOI 10.1097/WNR.0b013e32832be77d; Rubin JB, 2003, P NATL ACAD SCI USA, V100, P13513, DOI 10.1073/pnas.2235846100; SAHA B, 2012, FRONT CELL NEUROSCI, V6; Salman H, 2004, J NEUROTRAUM, V21, P283, DOI 10.1089/089771504322972077; Sanai N, 2011, NATURE, V478, P382, DOI 10.1038/nature10487; Seidenfaden R, 2006, MOL CELL NEUROSCI, V32, P187, DOI 10.1016/j.mcn.2006.04.003; Shen Q, 2008, CELL STEM CELL, V3, P289, DOI 10.1016/j.stem.2008.07.026; Sirko S, 2009, BRAIN, V132, P2252, DOI 10.1093/brain/awp043; Snapyan M, 2009, J NEUROSCI, V29, P4172, DOI 10.1523/JNEUROSCI.4956-08.2009; Stumm R, 2007, J MOL ENDOCRINOL, V38, P377, DOI 10.1677/JME-06-0032; Sundholm-Peters NL, 2005, J NEUROPATH EXP NEUR, V64, P1089, DOI 10.1097/01.jnen.0000190066.13312.8f; Thored P, 2007, STROKE, V38, P3032, DOI 10.1161/STROKEAHA.107.488445; Wang CM, 2011, CELL RES, V21, P1534, DOI 10.1038/cr.2011.83; Whitman MC, 2009, J COMP NEUROL, V516, P94, DOI 10.1002/cne.22093; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; Zheng WM, 2013, J NEUROTRAUM, V30, P1872, DOI 10.1089/neu.2010.1579; Zhu Y, 2009, DEVELOPMENT, V136, P1919, DOI 10.1242/dev.032276	62	83	89	0	13	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1873-5061	1876-7753		STEM CELL RES	Stem Cell Res.	NOV	2013	11	3					965	977		10.1016/j.scr.2013.06.006			13	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Biotechnology & Applied Microbiology	264UA	WOS:000327905300001	23900166	Bronze			2022-02-06	
J	Tate, CM; Wang, KKW; Eonta, S; Zhang, Y; Carr, W; Tortella, FC; Hayes, RL; Kamimori, GH				Tate, Charmaine M.; Wang, Kevin K. W.; Eonta, Stephanie; Zhang, Yang; Carr, Walter; Tortella, Frank C.; Hayes, Ronald L.; Kamimori, Gary H.			Serum Brain Biomarker Level, Neurocognitive Performance, and Self-Reported Symptom Changes in Soldiers Repeatedly Exposed to Low-Level Blast: A Breacher Pilot Study	JOURNAL OF NEUROTRAUMA			English	Article						blast injury; biomarker; military injury; neurocognitive; symptoms	FIBRILLARY ACIDIC PROTEIN; C-TERMINAL HYDROLASE; NEUROPSYCHOLOGICAL ASSESSMENT METRICS; SPECTRIN BREAKDOWN PRODUCTS; INTRACRANIAL LESIONS; INJURY; MILD; S100B; OVERPRESSURE; GFAP	Breachers are a unique military and law enforcement population because they are routinely exposed to low-level blast (LLB) during training and operations. This repeated exposure has been associated with symptoms similar to that of sports concussion. This study examined effects of repeated exposure to LLB during an explosive entry course. Twenty-one members of the New Zealand Defence Force volunteered for this study. Serum samples, neurocognitive performance, and self-reported symptoms were periodically measured before, during, and after a 2-week course. Serum concentrations of three biomarkers, ubiquitin C-terminal hydrolase-L1, II-spectrin breakdown product, and glial fibrillary acidic protein, were determined with sandwich enzyme-linked immunosorbent assays, and rank scores were derived using the area under the curve (relative to baseline) for each subject. Neurocognitive performance was measured with a computer-based test battery, and symptoms were assessed by paper-based inventory. There was a significant relationship (p<0.05) between composite biomarker and neurocognitive performance and between neurocognitive performance and symptoms. The individuals with the five highest (Top 5) and lowest (Bottom 5) composite biomarker scores were identified and compared using Wilcoxon's rank-sum test. The Top 5 had significantly longer reaction times and lower percent correct on neurocognitive performance and an increase in symptom reporting. The difference between individuals expressing the highest biomarker load during breacher training (Top 5) and those with the lowest biomarker load (Bottom 5) is reflected in neurocognitive performance deficits and self-reported symptoms. This suggests a measureable degree of brain perturbation linked to LLB exposure. Follow-up studies are underway to expand upon these results.	[Tate, Charmaine M.] New Zealand Def Force, Auckland, New Zealand; [Wang, Kevin K. W.; Hayes, Ronald L.] Banyan Biomarkers Inc, Banyan Labs, Alachua, FL USA; [Eonta, Stephanie; Carr, Walter] Naval Med Res Ctr, Silver Spring, MD USA; [Zhang, Yang; Kamimori, Gary H.] Walter Reed Army Inst Res, Dept Behav Biol, Silver Spring, MD USA; [Tortella, Frank C.] Walter Reed Army Inst Res, Brain Trauma Neuroprotect Neurorestorat Branch, Silver Spring, MD USA; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat, Ctr Neuroprote & Biomarker Res, Gainesville, FL 32610 USA		Wang, KKW (corresponding author), Univ Florida, Dept Psychiat, Ctr Neuroprote & Biomarker Res, 100 South Newell Dr POB 100256, Gainesville, FL 32610 USA.	kwang@ufl.edu		Wang, Kevin/0000-0002-9343-6473	NZDF; Congressionally Directed Medical Research ProgramUnited States Department of Defense [W81XWH-09-2-0055 of]; RAD III of the U.S. Army Medical Research and Materiel Command	This work was funded by the NZDF, a grant from the Congressionally Directed Medical Research Program (award no.: W81XWH-09-2-0055 of), and RAD III of the U.S. Army Medical Research and Materiel Command. The authors thank Christina R. LaValle for her statistical support, the contributing New Zealand military unit medical staff, and the staff of the Walter Reed Army Institute of Research and Naval Medical Research Center for their assistance in the completion of this study and the preparation of the manuscript for this article. The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the NZDF, the U.S. Army, the U.S. Navy, or of the U.S. DoD.	American Psychiatric Association, 2000, DIAGNOSTIC AND STATI; Arnaoutakis GJ, 2011, J THORAC CARDIOV SUR, V142, P902, DOI 10.1016/j.jtcvs.2011.06.027; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Blennow K, 2011, ACTA NEUROL SCAND, V123, P245, DOI 10.1111/j.1600-0404.2010.01408.x; Britt TW, 2000, J APPL SOC PSYCHOL, V30, P1599, DOI 10.1111/j.1559-1816.2000.tb02457.x; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Crooks Carol Y, 2007, Phys Med Rehabil Clin N Am, V18, P681, DOI 10.1016/j.pmr.2007.06.005; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Dutta S, 2002, BIOL CHEM, V383, P785, DOI 10.1515/BC.2002.082; Eonta SE, 2011, AVIAT SPACE ENVIR MD, V82, P34, DOI 10.3357/ASEM.2799.2011; FEINSTEIN DL, 1992, J NEUROSCI RES, V32, P1, DOI 10.1002/jnr.490320102; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jacobs JE, 1996, AM J ROENTGENOL, V166, P579, DOI 10.2214/ajr.166.3.8623631; Juarez V J, 1995, J Neurosci Nurs, V27, P283; Kane RL, 2007, ARCH CLIN NEUROPSYCH, V22, pS3, DOI 10.1016/j.acn.2006.10.001; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Kobeissy FH, 2008, PROTEOM CLIN APPL, V2, P1467, DOI 10.1002/prca.200800011; Lewis SB, 2010, J NEUROSCI RES, V88, P1475, DOI 10.1002/jnr.22323; Liu MC, 2006, BIOCHEM J, V394, P715, DOI 10.1042/BJ20050905; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MENEGAZZI JJ, 1993, J TRAUMA, V34, P46, DOI 10.1097/00005373-199301000-00008; Mitchener A, 1997, J NEUROL NEUROSUR PS, V62, P633, DOI 10.1136/jnnp.62.6.633; MOKUNO K, 1989, J NEUROSCI RES, V23, P396, DOI 10.1002/jnr.490230405; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Shiang K-D., 2004, SAS CONFERENCE PROCE; Siman R, 2008, BRAIN RES, V1213, P1, DOI 10.1016/j.brainres.2008.03.034; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Tanielian T., 2008, INVISIBLE WOUNDS OF; The Breacher Injury Consortium, 2011, ADVANCED TECH NOLOGY; Vincent AS, 2008, MIL MED, V173, P836, DOI 10.7205/MILMED.173.9.836; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Weinberger S, 2011, NATURE, V477, P390, DOI 10.1038/477390a; Welch W. M., 2005, US TODAY; Wiesmann M, 2010, ACTA NEUROL SCAND, V121, P178, DOI 10.1111/j.1600-0404.2009.01196.x	43	83	85	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2013	30	19					1620	1630		10.1089/neu.2012.2683			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	227WQ	WOS:000325146800002	23687938				2022-02-06	
J	Leigh, R; Oishi, K; Hsu, J; Lindquist, M; Gottesman, RF; Jarso, S; Crainiceanu, C; Mori, S; Hillis, AE				Leigh, Richard; Oishi, Kenichi; Hsu, John; Lindquist, Martin; Gottesman, Rebecca F.; Jarso, Samson; Crainiceanu, Ciprian; Mori, Susumu; Hillis, Argye E.			Acute lesions that impair affective empathy	BRAIN			English	Article						empathy; stroke; emotion perception; magnetic resonance imaging; prosody	VENTROMEDIAL PREFRONTAL CORTEX; TRAUMATIC BRAIN-INJURY; FRONTOTEMPORAL DEMENTIA; EMOTIONAL EMPATHY; COGNITIVE EMPATHY; TEMPOROPARIETAL JUNCTION; AFFECTIVE PROSODY; MIND; DEFICITS; DISSOCIATION	Functional imaging studies of healthy participants and previous lesion studies have provided evidence that empathy involves dissociable cognitive functions that rely on at least partially distinct neural networks that can be individually impaired by brain damage. These studies converge in support of the proposal that affective empathy-making inferences about how another person feels-engages at least the following areas: prefrontal cortex, orbitofrontal gyrus, anterior insula, anterior cingulate cortex, temporal pole, amygdala and temporoparietal junction. We hypothesized that right-sided lesions to any one of these structures, except temporoparietal junction, would cause impaired affective empathy (whereas bilateral damage to temporoparietal junction would be required to disrupt empathy). We studied 27 patients with acute right hemisphere ischaemic stroke and 24 neurologically intact inpatients on a test of affective empathy. Acute impairment of affective empathy was associated with infarcts in the hypothesized network, particularly temporal pole and anterior insula. All patients with impaired affective empathy were also impaired in comprehension of affective prosody, but many patients with impairments in prosodic comprehension had spared affective empathy. Patients with impaired affective empathy were older, but showed no difference in performance on tests of hemispatial neglect, volume of infarct or sex distribution compared with patients with intact affective empathy.	[Leigh, Richard; Gottesman, Rebecca F.; Hillis, Argye E.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Leigh, Richard; Oishi, Kenichi; Hsu, John; Jarso, Samson; Mori, Susumu] Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA; [Lindquist, Martin; Gottesman, Rebecca F.; Crainiceanu, Ciprian] Johns Hopkins Univ, Dept Biostat, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; [Hillis, Argye E.] Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD USA; [Hillis, Argye E.] Johns Hopkins Univ, Dept Cognit Sci, Krieger Sch Arts & Sci, Baltimore, MD 21218 USA		Hillis, AE (corresponding author), Johns Hopkins Univ Hosp, Dept Neurol, Meyer 6-113,600 North Wolfe St, Baltimore, MD 21287 USA.	argye@JHMI.edu	Gottesman, Rebecca/ABA-8468-2020; Oishi, Kenichi/H-1371-2013; Leigh, Richard/K-8401-2013	Oishi, Kenichi/0000-0002-1200-8611; Leigh, Richard/0000-0002-8285-1815	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RO1NS47691]; Yousem Family Research Fund; NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD065955]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD065955] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015909] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047691] Funding Source: NIH RePORTER	This work was supported by: National Institute of Neurological Disorders and Stroke, RO1NS47691 (to A. E. H.), and The Yousem Family Research Fund and NICHD R01 HD065955 (to K.O.).	Balconi M, 2012, APPL PSYCHOPHYS BIOF, V37, P161, DOI 10.1007/s10484-012-9188-z; Bodini B, 2004, CURR OPIN NEUROL, V17, P55, DOI 10.1097/00019052-200402000-00010; Brune M, 2006, NEUROSCI BIOBEHAV R, V30, P437, DOI 10.1016/j.neubiorev.2005.08.001; Brunnlieb C, 2013, BRAIN RES, V1499, P29, DOI 10.1016/j.brainres.2013.01.009; Bzdok D, 2012, BRAIN STRUCT FUNCT, V217, P783, DOI 10.1007/s00429-012-0380-y; Carr L, 2003, P NATL ACAD SCI USA, V100, P5497, DOI 10.1073/pnas.0935845100; Caviness VS, 2002, STROKE, V33, P2549, DOI 10.1161/01.STR.0000036083.90045.08; Corbetta M, 2008, NEURON, V58, P306, DOI 10.1016/j.neuron.2008.04.017; Couto B, 2013, CORTEX, V49, P1420, DOI 10.1016/j.cortex.2012.08.006; Cox CL, 2012, SOC COGN AFFECT NEUR, V7, P727, DOI 10.1093/scan/nsr051; Dara C, 2012, NEUROCASE; DAVIS MH, 1983, J PERS SOC PSYCHOL, V44, P113, DOI 10.1037/0022-3514.44.1.113; de Waal FBM, 2012, SCIENCE, V336, P874, DOI 10.1126/science.1220999; Decety J, 2003, CONSCIOUS COGN, V12, P577, DOI 10.1016/S1053-8100(03)00076-X; Decety J, 2007, NEUROSCIENTIST, V13, P580, DOI 10.1177/1073858407304654; Decety Jean, 2004, Behav Cogn Neurosci Rev, V3, P71, DOI 10.1177/1534582304267187; Dziobek I, 2008, J AUTISM DEV DISORD, V38, P464, DOI 10.1007/s10803-007-0486-x; Eslinger PJ, 2011, J NEUROPSYCH CLIN N, V23, P74, DOI 10.1176/appi.neuropsych.23.1.74; Eslinger PJ, 2005, J NEUROL NEUROSUR PS, V76, P1630, DOI 10.1136/jnnp.2004.053157; Eslinger PJ, 1998, EUR NEUROL, V39, P193, DOI 10.1159/000007933; Fellows LK, 2005, J COGNITIVE NEUROSCI, V17, P850, DOI 10.1162/0898929054021139; Finley A, 2003, STROKE, V34, P259; Gorno-Tempini ML, 2001, NEUROIMAGE, V14, P465, DOI 10.1006/nimg.2001.0811; Gu XS, 2012, BRAIN, V135, P2726, DOI 10.1093/brain/aws199; Hurlemann R, 2010, J NEUROSCI, V30, P4999, DOI 10.1523/JNEUROSCI.5538-09.2010; Hynes CA, 2006, NEUROPSYCHOLOGIA, V44, P374, DOI 10.1016/j.neuropsychologia.2005.06.011; Jimura K, 2010, BRAIN RES, V1328, P104, DOI 10.1016/j.brainres.2010.03.016; Kipps CM, 2006, SOC NEUROSCI-UK, V1, P235, DOI 10.1080/17470910600989847; Lamm C, 2011, NEUROIMAGE, V54, P2492, DOI 10.1016/j.neuroimage.2010.10.014; Lee J, 2011, PSYCHOL MED, V41, P2297, DOI 10.1017/S0033291711000614; Lee SE, 2012, NEUROCASE, V18, P305, DOI 10.1080/13554794.2011.604637; Leopold A, 2012, SOC COGN AFFECT NEUR, V7, P871, DOI 10.1093/scan/nsr071; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; Narvid J, 2009, NEUROCASE, V15, P190, DOI 10.1080/13554790802632967; Neumann D, 2012, ARCH PHYS MED REHAB, V93, P1414, DOI 10.1016/j.apmr.2012.03.009; Oishi K, 2009, NEUROIMAGE, V46, P486, DOI 10.1016/j.neuroimage.2009.01.002; Ota H, 2001, NEUROLOGY, V57, P2064, DOI 10.1212/WNL.57.11.2064; Rankin KP, 2006, BRAIN, V129, P2945, DOI 10.1093/brain/awl254; Rankin KP, 2005, COGN BEHAV NEUROL, V18, P28, DOI 10.1097/01.wnn.0000152225.05377.ab; Roldan Gerschcovich E, 2011, NEUROCASE, V17, P270, DOI 10.1080/13554791003730618; Ross ED, 1997, BRAIN LANG, V56, P27, DOI 10.1006/brln.1997.1731; Ross ED, 2008, BRAIN LANG, V104, P51, DOI 10.1016/j.bandl.2007.04.007; Samson D, 2005, BRAIN, V128, P1102, DOI 10.1093/brain/awh464; Samson D, 2004, NAT NEUROSCI, V7, P499, DOI 10.1038/nn1223; Samson D, 2007, NEUROPSYCHOLOGIA, V45, P2561, DOI 10.1016/j.neuropsychologia.2007.03.013; Saxe R, 2004, ANNU REV PSYCHOL, V55, P87, DOI 10.1146/annurev.psych.55.090902.142044; Saxe R, 2003, NEUROIMAGE, V19, P1835, DOI 10.1016/S1053-8119(03)00230-1; Schnell K, 2011, NEUROIMAGE, V54, P1743, DOI 10.1016/j.neuroimage.2010.08.024; Sebastian CL, 2012, SOC COGN AFFECT NEUR, V7, P53, DOI 10.1093/scan/nsr023; Shamay-Tsoory SG, 2005, COGN BEHAV NEUROL, V18, P55, DOI 10.1097/01.wnn.0000152228.90129.99; Shamay-Tsoory SG, 2003, J COGNITIVE NEUROSCI, V15, P324, DOI 10.1162/089892903321593063; Shamay-Tsoory SG, 2007, NEUROPSYCHOLOGIA, V45, P3054, DOI 10.1016/j.neuropsychologia.2007.05.021; Shamay-Tsoory SG, 2007, SCHIZOPHR RES, V90, P274, DOI 10.1016/j.schres.2006.09.020; Shamay-Tsoory SG, 2011, NEUROSCIENTIST, V17, P18, DOI 10.1177/1073858410379268; Shamay-Tsoory SG, 2009, BRAIN, V132, P617, DOI 10.1093/brain/awn279; Stone VE, 2003, NEUROPSYCHOLOGIA, V41, P209, DOI 10.1016/S0028-3932(02)00151-3; STOTLAND E, 1963, J ABNORM PSYCHOL, V66, P532, DOI 10.1037/h0042891; Stuss DT, 2004, BRAIN COGNITION, V55, P69, DOI 10.1016/s0278-2626(03)00271-9; Thompson-Schill SL, 1998, P NATL ACAD SCI USA, V95, P15855, DOI 10.1073/pnas.95.26.15855; Viskontas IV, 2007, ANN NY ACAD SCI, V1121, P528, DOI 10.1196/annals.1401.025	60	83	85	1	28	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	AUG	2013	136		8				2539	2549		10.1093/brain/awt177			11	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	190KG	WOS:000322338000024	23824490	Green Published, Bronze			2022-02-06	
J	Zuckerman, SL; Lee, YM; Odom, MJ; Solomon, GS; Sills, AK				Zuckerman, Scott L.; Lee, Young M.; Odom, Mitchell J.; Solomon, Gary S.; Sills, Allen K.			Baseline neurocognitive scores in athletes with attention deficit-spectrum disorders and/or learning disability Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						sports-related concussion; age; learning disability; mild traumatic brain injury; attention deficit hyperactivity disorder; trauma; Immediate Post-Concussion Assessment and Cognitive Testing	SPORTS-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURIES; TEST-RETEST RELIABILITY; HIGH-SCHOOL; UNITED-STATES; RECREATION ACTIVITIES; IMPACT; SYMPTOMS; BATTERY; SENSITIVITY	Object. Up to 16% of children in the US between the ages of 3 and 17 years have either attention deficit-spectrum disorder or a learning disability (LD). Sports-related concussions among youth athletes represent a significant public health concern, and neurocognitive testing is a method to evaluate the severity of cognitive impairment and recovery after a sports-related concussion. The goal of this study was to assess baseline neurocognitive differences between athletes with attention deficit hyperactivity disorder (ADHD) and/or LD versus those with neither disorder and to establish normative data for these special populations. Methods. Between August 2007 and March 2012,6636 young athletes underwent baseline neurocognitive testing performed using the Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) battery. Of these participants, 90 had self-reported LD only, 262 had self-reported ADHD only, and 55 reported both. Those with ADHD and/or LD were matched with 407 participants with no history of ADHD or LD by age, sex, and number of prior concussions. The mean scores and SDs were calculated for each group to obtain normative values. A pairwise comparison between each diagnostic group was done to assess whether LD and/or ADHD diagnostic status predicted participants' baseline neurocognitive scores. Results. Participants with ADHD had significantly lower verbal memory, visual memory, and visual motor processing speed scores, along with significantly higher reaction time, impulse control, and symptom scores compared with those without LD or ADHD. Participants with LD had similar results, with significantly lower verbal memory, visual memory, and visual motor processing speed scores, higher reaction time and symptom score, but did not differ in their impulse control score compared with those without LD or ADHD. Participants with both LD and ADHD had a significantly lower visual motor speed score and a significantly higher reaction time and symptom score than those without LD or ADHD, but did not differ with regard to the other composite scores. Conclusions. Athletes with ADHD and/or LD have lower baseline ImPACT neurocognitive scores compared with athletes without ADHD and LD. Preliminary normative neurocognitive data for these special populations are provided.	[Zuckerman, Scott L.; Solomon, Gary S.; Sills, Allen K.] Vanderbilt Sports Concuss Ctr, Dept Neurol Surg, Nashville, TN USA; [Lee, Young M.; Odom, Mitchell J.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA		Zuckerman, SL (corresponding author), 1500 21st Ave South,Suite 4340, Nashville, TN 37212 USA.	scott.zuckerman@vanderbilt.edu	Meijer, Anna/K-5118-2016; Solomon, Gary/K-9011-2019				Akinbami Lara J, 2011, NCHS Data Brief, P1; American Speech-Language-Hearing Association, 1991, LEARN DIS ISS DEF; Aubry Mark, 2002, Phys Sportsmed, V30, P57, DOI 10.3810/psm.2002.02.176; Boyle CA, 2011, PEDIATRICS, V127, P1034, DOI 10.1542/peds.2010-2989; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; ImPACT, 2007, IMPACT 2007 6 0 CLIN; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Kessler RC, 2010, ARCH GEN PSYCHIAT, V67, P1168, DOI 10.1001/archgenpsychiatry.2010.146; LAHEY BB, 1994, AM J PSYCHIAT, V151, P1673; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Ma R, 2012, J BONE JOINT SURG AM, V94A, P1618, DOI 10.2106/JBJS.K.01127; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maruff P, 2009, ARCH CLIN NEUROPSYCH, V24, P165, DOI 10.1093/arclin/acp010; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Pastor Patricia N, 2008, Vital Health Stat 10, P1; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2006, APPL NEUROPSYCHOL, V13, P151, DOI 10.1207/s15324826an1303_2; Schatz P, 2012, J ATHL TRAINING, V47, P289, DOI 10.4085/1062-6050-47.3.14; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Wisniewska B, 2007, Adv Med Sci, V52 Suppl 1, P215	31	83	83	0	38	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	AUG	2013	12	2					103	109		10.3171/2013.5.PEDS12524			7	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Pediatrics; Surgery	187CM	WOS:000322094500002	23790088				2022-02-06	
J	Spikman, JM; Milders, MV; Visser-Keizer, AC; Westerhof-Evers, HJ; Herben-Dekker, M; van der Naalt, J				Spikman, Jacoba M.; Milders, Maarten V.; Visser-Keizer, Annemarie C.; Westerhof-Evers, Herma J.; Herben-Dekker, Meike; van der Naalt, Joukje			Deficits in Facial Emotion Recognition Indicate Behavioral Changes and Impaired Self-Awareness after Moderate to Severe Traumatic Brain Injury	PLOS ONE			English	Article							DYSEXECUTIVE QUESTIONNAIRE; EXECUTIVE DYSFUNCTION; EXPRESSION; IMPAIRMENTS; VALIDITY; ADULTS; METAANALYSIS; ASSOCIATION; RELIABILITY; PERCEPTION	Traumatic brain injury (TBI) is a leading cause of disability, specifically among younger adults. Behavioral changes are common after moderate to severe TBI and have adverse consequences for social and vocational functioning. It is hypothesized that deficits in social cognition, including facial affect recognition, might underlie these behavioral changes. Measurement of behavioral deficits is complicated, because the rating scales used rely on subjective judgement, often lack specificity and many patients provide unrealistically positive reports of their functioning due to impaired self-awareness. Accordingly, it is important to find performance based tests that allow objective and early identification of these problems. In the present study 51 moderate to severe TBI patients in the sub-acute and chronic stage were assessed with a test for emotion recognition (FEEST) and a questionnaire for behavioral problems (DEX) with a self and proxy rated version. Patients performed worse on the total score and on the negative emotion subscores of the FEEST than a matched group of 31 healthy controls. Patients also exhibited significantly more behavioral problems on both the DEX self and proxy rated version, but proxy ratings revealed more severe problems. No significant correlation was found between FEEST scores and DEX self ratings. However, impaired emotion recognition in the patients, and in particular of Sadness and Anger, was significantly correlated with behavioral problems as rated by proxies and with impaired self-awareness. This is the first study to find these associations, strengthening the proposed recognition of social signals as a condition for adequate social functioning. Hence, deficits in emotion recognition can be conceived as markers for behavioral problems and lack of insight in TBI patients. This finding is also of clinical importance since, unlike behavioral problems, emotion recognition can be objectively measured early after injury, allowing for early detection and treatment of these problems.	[Spikman, Jacoba M.; Visser-Keizer, Annemarie C.; Westerhof-Evers, Herma J.] Univ Groningen, Dept Clin & Dev Neuropsychol, Groningen, Netherlands; [Spikman, Jacoba M.; Herben-Dekker, Meike; van der Naalt, Joukje] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Groningen, Netherlands; [Milders, Maarten V.] Heriot Watt Univ, Sch Life Sci, Edinburgh, Midlothian, Scotland; [Visser-Keizer, Annemarie C.] Univ Groningen, Univ Med Ctr Groningen, Ctr Rehabil, Haren, Netherlands; [Herben-Dekker, Meike] Rehabil Ctr Friesland, Beetsterzwaag, Netherlands		Spikman, JM (corresponding author), Univ Groningen, Dept Clin & Dev Neuropsychol, Groningen, Netherlands.	j.m.spikman@rug.nl		van der Naalt, Joukje/0000-0001-9873-2418; Spikman, Jacoba/0000-0002-6477-0763	Dutch Brain Foundation [F2008-1-18]	The study was partly funded by the Dutch Brain Foundation (grant nr F2008-1-18) [https://www.hersenstichting.nl/]. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. No additional external funding received for this study.	Adolphs R, 2002, CURR OPIN NEUROBIOL, V12, P169, DOI 10.1016/S0959-4388(02)00301-X; Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; Babbage DR, 2011, NEUROPSYCHOLOGY, V25, P277, DOI 10.1037/a0021908; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P606, DOI 10.1017/S1355617705050721; Biehl M, 1997, J NONVERBAL BEHAV, V21, P3, DOI 10.1023/A:1024902500935; Blair RJR, 2003, PHILOS T R SOC B, V358, P561, DOI 10.1098/rstb.2002.1220; Bodenburg S, 2008, J NERV MENT DIS, V196, P75, DOI 10.1097/NMD.0b013e31815faa2b; Bornhofen C, 2008, J INT NEUROPSYCH SOC, V14, P511, DOI 10.1017/S1355617708080703; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Burgess P, 1996, BEHAV ASSESSMENT DYS; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Chan RCK, 2008, J NEUROL NEUROSUR PS, V79, P86, DOI 10.1136/jnnp.2007.117184; Chaytor N, 2007, BRAIN INJURY, V21, P615, DOI 10.1080/02699050701426949; Cohen J., 2013, STAT POWER ANAL BEHA; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Diehl-Schmid J, 2007, ARCH CLIN NEUROPSYCH, V22, P459, DOI 10.1016/j.acn.2007.01.024; Ekman P., 1976, PICTURES FACIAL AFFE; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Fujiwara E, 2008, NEUROPSYCHOLOGIA, V46, P461, DOI 10.1016/j.neuropsychologia.2007.08.027; Fusar-Poli P, 2009, J PSYCHIATR NEUROSCI, V34, P418; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; GURDJIAN ES, 1976, J TRAUMA, V16, P35, DOI 10.1097/00005373-197601000-00005; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hart T, 2004, ARCH PHYS MED REHAB, V85, P1450, DOI 10.1016/j.apmr.2004.01.030; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; HOLM S, 1979, SCAND J STAT, V6, P65; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Ietswaart M, 2008, NEUROPSYCHOLOGIA, V46, P148, DOI 10.1016/j.neuropsychologia.2007.08.002; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Knox L, 2009, BRAIN COGNITION, V69, P442, DOI 10.1016/j.bandc.2008.09.009; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marsh AA, 2008, NEUROSCI BIOBEHAV R, V32, P454, DOI 10.1016/j.neubiorev.2007.08.003; Marsh AA, 2011, J CHILD PSYCHOL PSYC, V52, P834, DOI 10.1111/j.1469-7610.2010.02353.x; McDonald S, 2006, DISABIL REHABIL, V28, P1529, DOI 10.1080/09638280600646185; Milders M, 2003, NEUROPSYCHOLOGIA, V41, P1484, DOI 10.1016/S0028-3932(03)00079-4; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; Milders M, 2006, NEUROPSYCHOLOGY, V20, P400, DOI 10.1037/0894-4105.20.4.400; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Radice-Neumann D, 2007, BRAIN INJURY, V21, P807, DOI 10.1080/02699050701504281; Rapcsak SZ, 2000, NEUROLOGY, V54, P575, DOI 10.1212/WNL.54.3.575; Sherer M, 2005, J HEAD TRAUMA REHAB, V20, P287, DOI 10.1097/00001199-200507000-00002; Simblett SK, 2011, NEUROPSYCHOL REHABIL, V21, P1, DOI [10.1080/09602011.2010.531216, 10.1080/09602011.2011.592099]; Spikman JM, 2012, J NEUROTRAUM, V29, P101, DOI 10.1089/neu.2011.2084; Spikman JM, 2010, J NEUROTRAUMA; Sprengelmeyer R, 1998, P ROY SOC B-BIOL SCI, V265, P1927, DOI 10.1098/rspb.1998.0522; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; Stuss D.T., 2011, J INT NEUROPSYCH SOC, V17, P1; Stuss DT, 2011, CURR OPIN NEUROL, V24, P584, DOI 10.1097/WCO.0b013e32834c7eb9; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Wise K, 2005, BRAIN INJURY, V19, P765, DOI 10.1080/0269905050019977; Young A., 2002, FACIAL EXPRESSIONS E; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020	59	83	84	1	48	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 12	2013	8	6							e65581	10.1371/journal.pone.0065581			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	163FW	WOS:000320322400035	23776505	Green Published, Green Submitted, gold			2022-02-06	
J	Kontos, AP; Kotwal, RS; Elbin, RJ; Lutz, RH; Forsten, RD; Benson, PJ; Guskiewicz, KM				Kontos, Anthony P.; Kotwal, Russ S.; Elbin, R. J.; Lutz, Robert H.; Forsten, Robert D.; Benson, Peter J.; Guskiewicz, Kevin M.			Residual Effects of Combat-Related Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						mTBI; PTSD; symptoms; military	MENTAL-HEALTH PROBLEMS; RECURRENT CONCUSSION; FOOTBALL PLAYERS; HISTORY; COLLEGIATE; SERVICE; RISK; IRAQ	Mild traumatic brain injury (mTBI) has gained considerable notoriety during the past decade of conflict in Afghanistan and Iraq. However, the relationship between combat-related mTBI and residual mTBI symptoms, post-traumatic stress disorder (PTSD) symptoms, and neurocognitive deficits remains unclear. The purpose of the study was to compare residual mTBI and PTSD symptoms, and neurocognitive deficits among U.S. Army Special Operations Command (USASOC) personnel with diagnosed blunt, blast, and blast-blunt combination mTBIs. This study involved a retrospective medical records review of 27,169 USASOC personnel who completed a military version of the Immediate Post-Concussion Assessment Cognitive Test (ImPACT), Post-Concussion Symptom Scale (PCSS), and PTSD Checklist (PCL) between November 2009 and December 2011. Of the 22,203 personnel who met criteria for the study, 2,813 (12.7%) had a diagnosis of at least one mTBI. A total of 28% (n = 410) of USASOC personnel with a history of diagnosed mTBI reported clinical levels of PTSD symptoms. Personnel with a history of diagnosed blunt (OR = 3.58), blast (OR = 4.23) or combination (OR = 5.73) mTBI were at significantly (p = 0.001) greater risk of reporting clinical levels of PTSD symptoms than those with no history of mTBI. A dose-response gradient for exposure to blast/combination mTBI on clinical levels of PTSD symptoms was also significant (p = 0.001). Individuals with blast/combination mTBIs scored higher in residual mTBI (p = 0.001) and PTSD symptoms (p = 0.001), and performed worse on tests of visual memory (p = 0.001), and reaction time (p = 0.001) than those with blunt or no mTBI history. Individuals with combination mTBIs scored lower in verbal memory (p = 0.02) than those with blunt mTBIs. Residual PTSD and mTBI symptoms appear to be more prevalent in personnel with blast mTBI. A dose-response gradient for blast mTBI and symptoms suggests that repeated exposures to these injuries may have lingering effects.	[Kontos, Anthony P.; Elbin, R. J.] Univ Pittsburgh, Med Ctr, Sports Med Concuss Program, Pittsburgh, PA 15203 USA; [Kotwal, Russ S.; Lutz, Robert H.; Forsten, Robert D.; Benson, Peter J.] USA, Special Operat Command, Ft Bragg, NC USA; [Guskiewicz, Kevin M.] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC USA		Kontos, AP (corresponding author), Univ Pittsburgh, Sch Med, Dept Orthopaed Surg, UPMC Sports Med Concuss Program, 3200 South Water St, Pittsburgh, PA 15203 USA.	akontos@pitt.edu		Guskiewicz, Kevin/0000-0002-8682-2130; Kontos, Anthony/0000-0002-3749-4310	U.S. Special Operations Command Biomedical Initiatives Steering Committee	This research was funded by the U.S. Special Operations Command Biomedical Initiatives Steering Committee. The views expressed herein are those of the author(s) and do not reflect the official policy of the Department of the Army, Department of Defense, or the U.S. Government. Citations of commercial products or organizations do not constitute an official DoD endorsement or approval of the products or services of these organizations. This report was approved for public release by the U.S. Army Special Operations Command Operational Security Office and Public Affairs Office on March 27, 2012, and the U.S. Army Medical Department Public Affairs Office on March 27, 2012.	Bruce JM, 2009, NEUROSURGERY, V64, P100, DOI 10.1227/01.NEU.0000336310.47513.C8; Cernak I, 1999, WORLD J SURG, V23, P44, DOI 10.1007/s002689900563; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Defense and Veteran Brain Injury Center, DOD WORLDW NUMB TBI; Forsten R. D., 2008, J SPECIAL OPERATIONS, V8, P74; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kontos AP, 2004, J APPL SPORT PSYCHOL, V16, P220, DOI 10.1080/10413200490485568; Kotwal RS, 2011, ARCH SURG-CHICAGO, V146, P1349, DOI 10.1001/archsurg.2011.213; Krainin Benjamin M, 2011, J Spec Oper Med, V11, P38; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Mental Health Advisory Team-IV (MHAT), 2006, OP IR FREED MENT HLT; Murray CK, 2005, MIL MED, V170, P516, DOI 10.7205/MILMED.170.6.516; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Vanderploeg RD, 2004, VETERANS HLTH INITIA; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	31	83	84	0	30	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2013	30	8			SI		680	686		10.1089/neu.2012.2506			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	133PO	WOS:000318151500010	23031200	Green Submitted			2022-02-06	
J	McCrory, P; Meeuwisse, WH; Aubry, M; Cantu, RC; Dvorak, J; Echemendia, RJ; Engebretsen, L; Johnston, KM; Kutcher, JS; Raftery, M; Sills, A; Benson, BW; Davis, GA; Ellenbogen, R; Guskiewicz, KM; Herring, SA; Iverson, GL; Jordan, BD; Kissick, J; McCrea, M; McIntosh, AS; Maddocks, DL; Makdissi, M; Purcell, L; Putukian, M; Schneider, K; Tator, CH; Turner, M				McCrory, Paul; Meeuwisse, Willem H.; Aubry, Mark; Cantu, Robert C.; Dvorak, Jiri; Echemendia, Ruben J.; Engebretsen, Lars; Johnston, Karen M.; Kutcher, Jeffrey S.; Raftery, Martin; Sills, Allen; Benson, Brian W.; Davis, Gavin A.; Ellenbogen, Richard; Guskiewicz, Kevin M.; Herring, Stanley A.; Iverson, Grant L.; Jordan, Barry D.; Kissick, James; McCrea, Michael; McIntosh, Andrew S.; Maddocks, David L.; Makdissi, Michael; Purcell, Laura; Putukian, Margot; Schneider, Kathryn; Tator, Charles H.; Turner, Michael			Consensus Statement on Concussion in Sport-The 4th International Conference on Concussion in Sport Held in Zurich, November 2012	PM&R			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL; POSTURAL CONTROL; HEAD-INJURIES; LONG-TERM; POSTCONCUSSION SYNDROME; PROFESSIONAL FOOTBALL; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION		[McCrory, Paul] Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic, Australia; [Meeuwisse, Willem H.; Schneider, Kathryn] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Meeuwisse, Willem H.] Univ Calgary, Fac Med, Hotchkiss Brain Inst, Calgary, AB, Canada; [Aubry, Mark] Int Ice Hockey Federat, Zurich, Switzerland; [Aubry, Mark; Kissick, James] Ottawa Sport Med Ctr, Ottawa, ON, Canada; [Cantu, Robert C.] Boston Univ, Med Ctr, Ctr Study Traumat Encephalopathy, Boston, MA USA; [Dvorak, Jiri] Univ Zurich, Zurich, Switzerland; [Dvorak, Jiri] Schulthess Clin Zulich, Zurich, Switzerland; [Dvorak, Jiri] FIFA Med Assessment & Res Ctr, Zurich, Switzerland; [Echemendia, Ruben J.] Psychol & Neurobehav Associates Inc, State Coll, PA USA; [Echemendia, Ruben J.] Univ Missouri, Kansas City, MO 64110 USA; [Engebretsen, Lars] Oslo Univ Hosp, Dept Orthopaed Surg, Oslo, Norway; [Engebretsen, Lars] Univ Oslo, Fac Med, N-0316 Oslo, Norway; [Engebretsen, Lars] Oslo Sports Trauma Res Ctr, Oslo, Norway; [Engebretsen, Lars] Int Olymp Comm, Lausanne, Switzerland; [Johnston, Karen M.] Univ Toronto, Div Neurosurg, Toronto, ON, Canada; [Johnston, Karen M.] Athlet Edge Sports Med, Concuss Management Program, Toronto, ON, Canada; [Kutcher, Jeffrey S.] Univ Michigan, Dept Neurol, Michigan NeuroSport, Ann Arbor, MI USA; [Raftery, Martin] Int Rugby Board, Dublin, Ireland; [Sills, Allen] Vanderbilt Univ, Med Ctr, Vanderbilt Sports Concuss Ctr, Nashville, TN USA; [Benson, Brian W.] Univ Calgary, Fac Med, Dept Clin Neurosci, Calgary, AB, Canada; [Benson, Brian W.] Univ Calgary, Dept Family Med, Sport Med Ctr, Fac Kinesiol, Calgary, AB, Canada; [Davis, Gavin A.] Austin Hosp, Dept Neurosurg, Melbourne, Vic 3084, Australia; [Davis, Gavin A.] Cabrini Hosp, Melbourne, Vic, Australia; [Davis, Gavin A.] Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia; [Ellenbogen, Richard] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Guskiewicz, Kevin M.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Guskiewicz, Kevin M.] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC USA; [Herring, Stanley A.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Herring, Stanley A.] Univ Washington, Dept Orthopaed, Seattle, WA 98195 USA; [Herring, Stanley A.] Univ Washington, Dept Sports Med & Neurol Surg, Seattle, WA 98195 USA; [Herring, Stanley A.] Seattle Sports Concuss Program, Seattle, WA USA; [Herring, Stanley A.] Seattle Seahawks, Seattle, WA USA; [Herring, Stanley A.] Seattle Mariners, Seattle, WA USA; [Iverson, Grant L.] Neuropsychol Outcome Assessment Lab, Vancouver, BC, Canada; [Iverson, Grant L.] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; [Jordan, Barry D.] Cornell Univ, Weill Med Coll, New York, NY 10021 USA; [Jordan, Barry D.] Burke Rehabil Hosp, White Plains, NY USA; [Jordan, Barry D.] New York State Athlet Commiss, New York, NY USA; [Kissick, James] Univ Ottawa, Dept Family Med, Ottawa, ON, Canada; [McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI USA; [McIntosh, Andrew S.] Monash Univ, Monash Injury Res Inst, Australian Ctr Res Injury Sports & Its Prevent, Sydney, NSW, Australia; [McIntosh, Andrew S.] Univ New S Wales, Fac Sci, Sydney, NSW, Australia; [McIntosh, Andrew S.] McIntosh Consultancy & Res Pty Ltd, Sydney, NSW, Australia; [Maddocks, David L.] Perry Maddocks Trollope Lawyers, Melbourne, Vic, Australia; [Makdissi, Michael] Melbourne Brain Ctr, Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia; [Makdissi, Michael] Univ Melbourne, Melbourne Physiotherapy Dept, Ctr Hlth Exercise & Sports Med, Melbourne, Vic, Australia; [Purcell, Laura] McMaster Univ, Dept Pediat, Hamilton, ON, Canada; [Purcell, Laura] McMaster Univ, David Braley Sport Med & Rehabil Ctr, Hamilton, ON, Canada; [Putukian, Margot] Princeton Univ, Princeton, NJ 08544 USA; [Putukian, Margot] Univ Med & Dent New Jersey, Newark, NJ 07103 USA; [Tator, Charles H.] Toronto Western Hosp, Toronto, ON, Canada; [Tator, Charles H.] Univ Toronto, Toronto, ON M5S 1A1, Canada; [Tator, Charles H.] Krembil Neurosci Ctr, Toronto, ON, Canada; [Tator, Charles H.] ThinkFirst Canada, Toronto, ON, Canada; [Turner, Michael] British Horseracing Author, London, England		McCrory, P (corresponding author), Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic, Australia.			Guskiewicz, Kevin/0000-0002-8682-2130; Schneider, Kathryn/0000-0002-5951-5899; Iverson, Grant/0000-0001-7348-9570; makdissi, michael/0000-0003-0334-7133; McCrory, Paul/0000-0003-4850-0568			Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bazarian JJ, 2001, CLIN PEDIATR, V40, P207, DOI 10.1177/000992280104000405; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bleiberg Joseph, 2005, Neurosurgery, V56, pE1166; Bloom GA, 2004, BRIT J SPORT MED, V38, P519, DOI 10.1136/bjsm.2004.011999; Boutin D, 2008, NEUROCASE, V14, P239, DOI 10.1080/13554790802247543; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broshek DK, 2005, CLIN SPORT MED, V24, P663, DOI 10.1016/j.csm.2005.04.005; Broshek DK, 2005, CLIN SPORTS MED, V24, px; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chen JK, 2004, CLIN J SPORT MED, V14, P379; Chen JK, 2004, BRIT J SPORT MED, V38, P659; Collie A, 2003, BRIT J SPORT MED, V37, P556, DOI 10.1136/bjsm.37.6.556; Collie A, 2003, BRIT J SPORT MED, V37, P2, DOI 10.1136/bjsm.37.1.2; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Collins MW, 2002, NEUROSURGERY, V51, P80; Curnow WJ, 2008, HEALTH PROMOT J AUST, V19, P10, DOI 10.1071/HE08010; Davidhizar R, 2002, Accid Emerg Nurs, V10, P149, DOI 10.1054/aaen.2002.0365; Davidson JA, 2005, EUR J EMERG MED, V12, P24, DOI 10.1097/00063110-200502000-00007; Lima DPD, 2008, INJURY, V39, P604, DOI 10.1016/j.injury.2007.11.008; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney JS, 2008, BRIT J SPORT MED, V42, P5; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Denke NJ, 2008, J EMERG NURS, V34, P363, DOI 10.1016/j.jen.2008.04.013; Dvorak J, 2007, BRIT J SPORT MED, V41, pI44, DOI 10.1136/bjsm.2007.037960; Dvorak J, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2007.039362; Eckner JT, 2012, PSYCHOL ASSESSMENT, V24, P249, DOI 10.1037/a0025042; Eckner JT, 2011, J ATHL TRAINING, V46, P409; Finch C, 2005, INJURY PREV, V11, P242, DOI 10.1136/ip.2004.006882; Finch C, 2000, SPORT HLTH, V18, P35; Finch C, 1993, 51 MON U ACC RES CTR; Finch CF, 2003, J SCI MED SPORT, V6, P505, DOI 10.1016/S1440-2440(03)80275-X; Finch CF, 2001, BRIT J SPORT MED, V35, P89, DOI 10.1136/bjsm.35.2.89; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Fox ZG, 2008, J ATHL TRAINING, V43, P456, DOI 10.4085/1062-6050-43.5.456; FUKUHARA T, 1994, BRAIN RES, V657, P333, DOI 10.1016/0006-8993(94)90987-3; Gabbe B, 2003, J SCI MED SPORT, V6, P231, DOI 10.1016/S1440-2440(03)80259-1; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gianotti S, 2007, NEUROREHABILITATION, V22, P181; Gioia G, 2004, BRIT J SPORT MED, V38, P657; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Hagel BE, 2005, BRIT MED J, V330, P281, DOI 10.1136/bmj.38314.480035.7C; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Hansen Kari Schroder, 2003, Traffic Inj Prev, V4, P285, DOI 10.1080/714040486; Hayden MG, 2007, CHILD NERV SYST, V23, P431, DOI 10.1007/s00381-006-0277-2; Hewson Paul J, 2005, Traffic Inj Prev, V6, P127, DOI 10.1080/15389580590931590; Hinkle DA, 1997, J NEUROTRAUM, V14, P729, DOI 10.1089/neu.1997.14.729; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; JENNETT B, 1975, LANCET, V1, P480; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Johnston KM, 2001, J AM COLL SURGEONS, V192, P515, DOI 10.1016/S1072-7515(01)00797-9; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Kristman VL, 2008, CLIN J SPORT MED, V18, P322, DOI 10.1097/JSM.0b013e31817e6f3e; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Lee LK, 2007, PEDIATR EMERG CARE, V23, P4; Lee LK, 2007, PEDIATR EMERG CARE, V23, P580, DOI 10.1097/PEC.0b013e31813444ea; Lee Michael A, 2006, Conn Med, V70, P377; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell M, 2004, CLIN SPORTS MED, V23, pix; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P7; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Ma M, 2008, AM J EMERG MED, V26, P763, DOI 10.1016/j.ajem.2007.10.029; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrea, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI [10.1001/jama.290.19.2556, DOI 10.1001/JAMA.290.19.2556]; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrea M, 2000, STANDARDIZED ASSESSM, P22; McCrory P, 2004, CLIN J SPORT MED, V14, P139, DOI 10.1097/00042752-200405000-00006; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2002, BRIT J SPORT MED, V36, P316, DOI 10.1136/bjsm.36.5.316; McCrory P, 2002, BRIT J SPORT MED, V36, P314, DOI 10.1136/bjsm.36.5.314; McCrory P, 2002, BRIT J SPORT MED, V36, P3, DOI 10.1136/bjsm.36.1.3; McCrory P, 2011, CLIN SPORTS MED, V30, pxi; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; McCrory P, 2011, CLIN SPORT MED, V30, P201, DOI 10.1016/j.csm.2010.08.002; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; McIntosh AS, 2003, J SCI MED SPORT, V6, P355, DOI 10.1016/S1440-2440(03)80030-0; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140, DOI 10.1097/JSM.0b013e31803212ae; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Mueller BA, 2008, EPIDEMIOLOGY, V19, P270, DOI 10.1097/EDE.0b013e318163567c; Nandoe RDS, 2002, J ALZHEIMERS DIS, V4, P303, DOI 10.3233/JAD-2002-4405; Nordqvist ACS, 1996, MOL BRAIN RES, V38, P285; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; Peng Rui-yun, 2003, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V15, P213; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Purcell L, 2008, CLIN PEDIATR, V47, P106, DOI 10.1177/0009922807306053; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Rousseff R T, 2006, Electromyogr Clin Neurophysiol, V46, P275; Schnadower D, 2007, CURR OPIN PEDIATR, V19, P258, DOI 10.1097/MOP.0b013e3281084e85; Shaw NH, 2004, CAN MED ASSOC J, V170, P15; Shaw NH, 2004, CMAJ, V170, P8; Shaw NH, 2004, CMAJ, V170, P6; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; STERN MB, 1991, MOVEMENT DISORD, V6, P95, DOI 10.1002/mds.870060202; Sulheim S, 2006, JAMA-J AM MED ASSOC, V295, P919, DOI 10.1001/jama.295.8.919; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Terrell TR, 2008, CLIN J SPORT MED, V18, P10, DOI 10.1097/JSM.0b013e31815c1d4c; Theye Fred, 2004, Clin Med Res, V2, P165; Townend W, 2006, INJURY, V37, P1098, DOI 10.1016/j.injury.2006.07.014; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2; Weiss MR, 2005, RES Q EXERCISE SPORT, V76, pS71, DOI 10.1080/02701367.2005.10599291; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196; YARNELL PR, 1970, LANCET, V1, P863; Yunoki M, 1998, ACT NEUR S, V71, P142	163	83	83	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	APR	2013	5	4					255	279		10.1016/j.pmrj.2013.02.012			25	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	137VI	WOS:000318465900002	23466418	Green Accepted, Green Submitted, Green Published			2022-02-06	
J	Tchantchou, F; Zhang, YM				Tchantchou, Flaubert; Zhang, Yumin			Selective Inhibition of Alpha/Beta-Hydrolase Domain 6 Attenuates Neurodegeneration, Alleviates Blood Brain Barrier Breakdown, and Improves Functional Recovery in a Mouse Model of Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						ABHD6; neuroinflammation; neuroprotection; traumatic brain injury; 2-arachidonylglycerol	CONTROLLED CORTICAL IMPACT; NITRIC-OXIDE SYNTHASE; ACID AMIDE HYDROLASE; MONOACYLGLYCEROL LIPASE; ENDOCANNABINOID SYSTEM; CANNABINOID RECEPTORS; UP-REGULATION; ACTIVATION; EXPRESSION; PROTECTS	2-arachidonylglycerol (2-AG) is the most abundant endocannabinoid in the central nervous system and is elevated after brain injury. Because of its rapid hydrolysis, however, the compensatory and neuroprotective effect of 2-AG is short-lived. Although inhibition of monoacylglycerol lipase, a principal enzyme for 2-AG degradation, causes a robust increase of brain levels of 2-AG, it also leads to cannabinoid receptor desensitization and behavioral tolerance. Alpha/beta hydrolase domain 6 (ABHD6) is a novel 2-AG hydrolytic enzyme that accounts for a small portion of 2-AG hydrolysis, but its inhibition is believed to elevate the levels of 2-AG within the therapeutic window without causing side effect. Using a mouse model of traumatic brain injury (TBI), we found that post-insult chronic treatment with a selective ABHD6 inhibitor WWL70 improved motor coordination and working memory performance. WWL70 treatment reduced lesion volume in the cortex and neurodegeneration in the dendate gyrus. It also suppressed the expression of inducible nitric oxide synthase and cyclooxygenase-2 and enhanced the expression of arginase-1 in the ipsilateral cortex at 3 and 7 days post-TBI, suggesting microglia/macrophages shifted from M1 to M2 phenotypes after treatment. The blood-brain barrier dysfunction at 3 and 7 days post-TBI was dramatically reduced. Furthermore, the beneficial effects of WWL70 involved up-regulation and activation of cannabinoid type 1 and type 2 receptors and were attributable to the phosphorylation of the extracellular signal regulated kinase and the serine/threonine protein kinase AKT. This study indicates that the fine-tuning of 2-AG signaling by modulating ABHD6 activity can exert anti-inflammatory and neuroprotective effects in TBI.	[Tchantchou, Flaubert; Zhang, Yumin] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA		Zhang, YM (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	yumin.zhang@usuhs.edu			Blast Lethality Injury and Research Program [R600-070-00000-00-106109]; Defense Medical Research and Development Program [0130-10-00003-00002]	This work was supported by grants from the Blast Lethality Injury and Research Program (R600-070-00000-00-106109) and the Defense Medical Research and Development Program (0130-10-00003-00002). The authors are grateful to Drs. De-Maw Chuang and Fengshan Yu for careful reading and critical comments on the manuscript. We also acknowledge Ms. Laura Tucker and Dr. Amanda Fu from the Center for Neuroscience and Regenerative Medicine for their help during behavioral tests and CCI surgery.	Ahmad M, 2008, J NEUROSCI RES, V86, P3605, DOI 10.1002/jnr.21809; Arimoto T, 2003, NEUROBIOL DIS, V12, P35, DOI 10.1016/S0969-9961(02)00017-7; Ay I, 2008, BRAIN RES, V1234, P198, DOI 10.1016/j.brainres.2008.07.121; Blankman JL, 2007, CHEM BIOL, V14, P1347, DOI 10.1016/j.chembiol.2007.11.006; Bryan KJ, 2009, FRONT NEUROSCI, P1; Canas PM, 2009, J NEUROSCI, V29, P14741, DOI 10.1523/JNEUROSCI.3728-09.2009; Chanda PK, 2010, MOL PHARMACOL, V78, P996, DOI 10.1124/mol.110.068304; Chauhan NB, 2010, J NEUROSCI METH, V190, P1, DOI 10.1016/j.jneumeth.2010.04.004; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Cohen-Yeshurun A, 2011, J CEREBR BLOOD F MET, V31, P1768, DOI 10.1038/jcbfm.2011.53; Dall'Igna OP, 2007, EXP NEUROL, V203, P241, DOI 10.1016/j.expneurol.2006.08.008; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; Dauge V, 2001, NEUROPSYCHOPHARMACOL, V25, P690, DOI 10.1016/S0893-133X(01)00291-3; Di Filippo C, 2004, J LEUKOCYTE BIOL, V75, P453, DOI 10.1189/jlb.0703303; Di Lorenzo A, 2011, BLOOD, V117, P2284, DOI 10.1182/blood-2010-04-281956; Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495; Diaz-Laviada I, 2005, MINI-REV MED CHEM, V5, P619, DOI 10.2174/1389557054368808; Du HZ, 2011, BRIT J PHARMACOL, V163, P1533, DOI 10.1111/j.1476-5381.2011.01444.x; Elliott MB, 2008, J NEUROSCI METH, V168, P320, DOI 10.1016/j.jneumeth.2007.10.019; Faul M, 2010, TRAUMATIC BRAIN INJU; Frank PG, 2008, AM J PHYSIOL-HEART C, V295, pH926, DOI 10.1152/ajpheart.00779.2008; Galante M, 2009, HUM MOL GENET, V18, P1449, DOI 10.1093/hmg/ddp055; Galve-Roperh I, 2008, CURR PHARM DESIGN, V14, P2279, DOI 10.2174/138161208785740117; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hilton GD, 2008, J CEREBR BLOOD F MET, V28, P1845, DOI 10.1038/jcbfm.2008.75; Horne E. A., 2011, SOC NEUR ANN M; Hughes RN, 2004, NEUROSCI BIOBEHAV R, V28, P497, DOI 10.1016/j.neubiorev.2004.06.006; Hwang J, 2010, LIFE SCI, V86, P615, DOI 10.1016/j.lfs.2009.06.003; Iravani MM, 2002, NEUROSCIENCE, V110, P49, DOI 10.1016/S0306-4522(01)00562-0; Izzo AA, 2001, BRIT J PHARMACOL, V134, P563, DOI 10.1038/sj.bjp.0704293; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Jeong WI, 2008, CELL METAB, V7, P227, DOI 10.1016/j.cmet.2007.12.007; Julien B, 2005, GASTROENTEROLOGY, V128, P742, DOI 10.1053/j.gastro.2004.12.050; Kan WH, 2008, J APPL PHYSIOL, V105, P1076, DOI 10.1152/japplphysiol.90495.2008; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Kunz A, 2007, J NEUROSCI, V27, P7083, DOI 10.1523/JNEUROSCI.1645-07.2007; Kuo HS, 2011, J NEUROSCI, V31, P4137, DOI 10.1523/JNEUROSCI.2592-10.2011; Lee S, 2011, J AM SOC NEPHROL, V22, P317, DOI 10.1681/ASN.2009060615; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Liu Y, 2004, J IMMUNOL, V172, P7, DOI 10.4049/jimmunol.172.1.7; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lourbopoulos A, 2011, BRAIN RES, V1390, P126, DOI 10.1016/j.brainres.2011.03.020; Mackie K, 2006, ANNU REV PHARMACOL, V46, P101, DOI 10.1146/annurev.pharmtox.46.120604.141254; Mangleri RA, 2007, PHARMACOL RES, V56, P360, DOI 10.1016/j.phrs.2007.09.003; Martin-Moreno AM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-8; Marrs WR, 2011, J BIOL CHEM, V286, P28723, DOI 10.1074/jbc.M110.202853; Marrs WR, 2010, NAT NEUROSCI, V13, P951, DOI 10.1038/nn.2601; Mechoulam R, 2002, TRENDS MOL MED, V8, P58, DOI 10.1016/S1471-4914(02)02276-1; Molina-Holgado F, 2007, EUR J NEUROSCI, V25, P629, DOI 10.1111/j.1460-9568.2007.05322.x; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Naidoo V, 2012, NEUROTHERAPEUTICS, V9, P801, DOI 10.1007/s13311-011-0100-y; Nomura DK, 2011, SCIENCE, V334, P809, DOI 10.1126/science.1209200; Oz M, 2006, PHARMACOL THERAPEUT, V111, P114, DOI 10.1016/j.pharmthera.2005.09.009; Panikashvili D, 2006, NEUROBIOL DIS, V22, P257, DOI 10.1016/j.nbd.2005.11.004; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Pitkanen A., 2005, DRUG DISCOV TODAY DI, V2, P409, DOI DOI 10.1016/J.DDMEC.2005.11.011; Rojo AI, 2010, GLIA, V58, P588, DOI 10.1002/glia.20947; Savinainen JR, 2012, ACTA PHYSIOL, V204, P267, DOI 10.1111/j.1748-1716.2011.02280.x; Schlosburg JE, 2010, NAT NEUROSCI, V13, P1113, DOI 10.1038/nn.2616; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schneider C, 2009, J NEUROIMMUNOL, V213, P84, DOI 10.1016/j.jneuroim.2009.05.015; Scotter EL, 2010, BRIT J PHARMACOL, V160, P480, DOI 10.1111/j.1476-5381.2010.00735.x; Sell SL, 2008, ANESTHESIOLOGY, V108, P873, DOI 10.1097/ALN.0b013e31816c8a15; Shohami E, 2011, BRIT J PHARMACOL, V163, P1402, DOI 10.1111/j.1476-5381.2011.01343.x; Soetikno V, 2011, NUTR METAB, V8, DOI 10.1186/1743-7075-8-35; Straiker A, 2009, MOL PHARMACOL, V76, P1220, DOI 10.1124/mol.109.059030; Tanaka K, 2009, NEUROSCI LETT, V462, P235, DOI 10.1016/j.neulet.2009.07.024; Taylor AN, 2008, J NEUROTRAUM, V25, P311, DOI 10.1089/neu.2007.0486; Tchantchou F, 2004, NEUROMOL MED, V6, P93, DOI 10.1385/NMM:6:2-3:093; Tchantchou F, 2007, FASEB J, V21, P2400, DOI 10.1096/fj.06-7649com; Teixeira-Clerc F, 2006, NAT MED, V12, P671, DOI 10.1038/nm1421; Thau-Zuchman O, 2012, J NEUROTRAUM, V29, P375, DOI 10.1089/neu.2010.1673; van der Poorten D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012841; van der Stelt M, 2001, J NEUROSCI, V21, P8765, DOI 10.1523/JNEUROSCI.21-22-08765.2001; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Yu FS, 2012, J NEUROTRAUM, V29, P2342, DOI 10.1089/neu.2012.2449; Yu FS, 2012, J NEUROTRAUM, V29, P362, DOI 10.1089/neu.2011.1942; Zhang J, 2008, J BIOL CHEM, V283, P22601, DOI 10.1074/jbc.M800524200	84	83	84	0	19	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2013	30	7					565	579		10.1089/neu.2012.2647			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	133PD	WOS:000318150300008	23151067	Green Published			2022-02-06	
J	Palacios, EM; Sala-Llonch, R; Junque, C; Fernandez-Espejo, D; Roig, T; Tormos, JM; Bargallo, N; Vendrell, P				Palacios, Eua M.; Sala-Llonch, Roser; Junque, Carme; Fernandez-Espejo, Davinia; Roig, Teresa; Tormos, Jose M.; Bargallo, Nuria; Vendrell, Pere			Long-term declarative memory deficits in diffuse TB!: Correlations with cortical thickness, white matter integrity and hippocampal volume	CORTEX			English	Article						Traumatic brain injury; Declarative memory; Cortical thickness; Diffusion tensor imaging; Hippocampus	TRAUMATIC BRAIN-INJURY; HUMAN CEREBRAL-CORTEX; STRUCTURAL CONNECTIVITY; GEOMETRICALLY ACCURATE; LONGITUDINAL CHANGES; EPISODIC MEMORY; TENSOR; ATROPHY; NETWORK; RECOVERY	We investigated structural brain damage in subjects who had suffered severe and diffuse traumatic brain injury (TBI), and examined its relationship with declarative memory impairment. Cortical thickness, diffusion tensor imaging (DTI), and volumetric and shape data of the hippocampus were assessed in a group of 26 adults with severe TBI in the chronic stage and 22 healthy matched controls. Declarative memory was evaluated by Rey's Auditory Verbal Learning Test (RAVLT). TBI patients performed significantly worse than controls on all RAVLT measures. The group comparison for cortical thickness and DTI revealed a pattern of widespread atrophy in TBI patients. In the TBI group DTI measures correlated with cortical thickness in the prefrontal and parietal regions, including the precuneus. Declarative memory correlated with both cortical thickness and DTI measures. However, although hippocampal volume was significantly decreased in TBI patients, no correlations were found. Multiple regression analysis of all the structural measures revealed that decreases in Fractional anisotropy (FA) and thinning of the left parietal region were the best predictors of memory impairment. In conclusion, cortical thickness reductions in the left hemisphere and a lack of white matter integrity are the main contributors to long-term impairment in declarative memory among patients suffering from severe and diffuse TBI. In this study the hippocampus did not make a significant contribution to memory dysfunctions, suggesting that damage to this structure is compensated for by other regions, with the definitive sequelae being mainly explained by alterations in cortico-subcortical connectivity. (C) 2012 Elsevier Ltd. All rights reserved.	[Palacios, Eua M.; Sala-Llonch, Roser; Junque, Carme; Vendrell, Pere] Univ Barcelona, Dept Psychiat & Clin Psychobiol, E-08036 Barcelona, Spain; [Palacios, Eua M.; Sala-Llonch, Roser; Junque, Carme; Vendrell, Pere] August Pi I Sunyer Biomed Res Inst IDIBAPS, Barcelona, Spain; [Fernandez-Espejo, Davinia] Univ Western Ontario, Ctr Brain & Mind, London, ON, Canada; [Roig, Teresa; Tormos, Jose M.] Inst Univ Neurorehabil Guttmann, Badalona, Spain; [Bargallo, Nuria] Hosp Clin Barcelona, Ctr Diagnost Imatge CDIC, Barcelona, Spain		Junque, C (corresponding author), Univ Barcelona, Dept Psychiat & Clin Psychobiol, C Casanova 143, E-08036 Barcelona, Spain.	cjunque@ub.edu	Vendrell, Pere/B-4392-2011; Fernandez-Espejo, Davinia/AAT-5481-2021; Junque, Carme/B-4400-2011; Sala-Llonch, Roser/L-4135-2015; Bargallo, Nuria/G-6854-2016; Sala-Llonch, Roser/E-7882-2012	Vendrell, Pere/0000-0001-8918-5440; Fernandez-Espejo, Davinia/0000-0001-5941-7546; Junque, Carme/0000-0002-6381-3063; Sala-Llonch, Roser/0000-0003-3576-0475; Bargallo, Nuria/0000-0001-6284-5402; Sala-Llonch, Roser/0000-0003-3576-0475; Tormos Munoz, Jose Maria/0000-0002-8764-2289	MAPFRE Foundation	The authors thank MAPFRE Foundation for the financial support. We also thank Cesar Garrido from the Centre de Diagnostic per la Imatge of the Hospital Clinic (CDIC), for his assistance with data recollection.	Adams JH, 2011, J NEUROTRAUM, V28, P701, DOI 10.1089/neu.2010.1733; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cabeza R, 2008, NAT REV NEUROSCI, V9, P613, DOI 10.1038/nrn2459; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; HUTTENLOCHER PR, 1990, NEUROPSYCHOLOGIA, V28, P517, DOI 10.1016/0028-3932(90)90031-I; Hutton C, 2009, NEUROIMAGE, V48, P371, DOI 10.1016/j.neuroimage.2009.06.043; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lerch JP, 2005, NEUROIMAGE, V24, P163, DOI 10.1016/j.neuroimage.2004.07.045; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McCauley SR, 2010, DEV NEUROPSYCHOL, V35, P318, DOI 10.1080/87565641003696866; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Mori S, 2006, NEURON, V51, P527, DOI 10.1016/j.neuron.2006.08.012; Newcombe V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019214; Palacios EM, 2012, NEUROLOGY, V20, P852; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Segonne F, 2007, IEEE T MED IMAGING, V26, P518, DOI 10.1109/TMI.2006.887364; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shaw P, 2008, J NEUROSCI, V28, P3586, DOI 10.1523/JNEUROSCI.5309-07.2008; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; Smith SM, 2002, NEUROIMAGE, V17, P479, DOI 10.1006/nimg.2002.1040; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Sowell ER, 2004, J NEUROSCI, V24, P8223, DOI 10.1523/JNEUROSCI.1798-04.2004; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Wagner AD, 2005, TRENDS COGN SCI, V9, P445, DOI 10.1016/j.tics.2005.07.001; Wang JY, 2011, NEUROLOGY, V77, P818, DOI 10.1212/WNL.0b013e31822c61d7; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149	46	83	87	1	15	ELSEVIER MASSON, CORPORATION OFFICE	PARIS	65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE	0010-9452	1973-8102		CORTEX	Cortex	MAR	2013	49	3					646	657		10.1016/j.cortex.2012.02.011			12	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	122MT	WOS:000317322900005	22482692				2022-02-06	
J	Wang, YQ; Wang, L; Zhang, MY; Wang, T; Bao, HJ; Liu, WL; Dai, DK; Zhang, L; Chang, P; Dong, WW; Chen, XP; Tao, LY				Wang, Yao-Qi; Wang, Long; Zhang, Ming-Yang; Wang, Tao; Bao, Hai-Jun; Liu, Wei-Li; Dai, Ding-Kun; Zhang, Lu; Chang, Pan; Dong, Wen-Wen; Chen, Xi-Ping; Tao, Lu-Yang			Necrostatin-1 Suppresses Autophagy and Apoptosis in Mice Traumatic Brain Injury Model	NEUROCHEMICAL RESEARCH			English	Article						Traumatic brain injury; Autophagy; Apoptosis; Necrostatin-1; Necroptosis	NECROTIC CELL-DEATH; CONTROLLED CORTICAL IMPACT; TUMOR-NECROSIS-FACTOR; INDUCED NECROPTOSIS; HT-22 CELLS; L929 CELLS; BECLIN 1; KAPPA-B; RECEPTOR; RAT	Traumatic brain injury (TBI) results in neuronal apoptosis, autophagic cell death and necroptosis. Necroptosis is a newly discovered caspases-independent programmed necrosis pathway which can be triggered by activation of death receptor. Previous works identified that necrostatin-1 (NEC-1), a specific necroptosis inhibitor, could reduce tissue damage and functional impairment through inhibiting of necroptosis process following TBI. However, the role of NEC-1 on apoptosis and autophagy after TBI is still not very clear. In this study, the amount of TBI-induced neural cell deaths were counted by PI labeling method as previously described. The expression of autophagic pathway associated proteins (Beclin-1, LC3-II, and P62) and apoptotic pathway associated proteins (Bcl-2 and caspase-3) were also respectively assessed by immunoblotting. The data showed that mice pretreated with NEC-1 reduced the amount of PI-positive cells from 12 to 48 h after TBI. Immunoblotting results showed that NEC-1 suppressed TBI-induced Beclin-1 and LC3-II activation which maintained p62 at high level. NEC-1 pretreatment also reversed TBI-induced Bcl-2 expression and caspase-3 activation, as well as the ratio of Beclin-1/Bcl-2. Both 3-MA and NEC-1 suppressed TBI-induced caspase-3 activation and LC3-II formation, Z-VAD only inhibited caspase-3 activation but increased LC3-II expression at 24 h post-TBI. All these results revealed that multiple cell death pathways participated in the development of TBI, and NEC-1 inhibited apoptosis and autophagy simultaneously. These coactions may further explain how can NEC-1 reduce TBI-induced tissue damage and functional deficits and reflect the interrelationship among necrosis, apoptosis and autophagy.	[Wang, Yao-Qi; Wang, Long; Zhang, Ming-Yang; Wang, Tao; Bao, Hai-Jun; Liu, Wei-Li; Dai, Ding-Kun; Zhang, Lu; Chang, Pan; Dong, Wen-Wen; Chen, Xi-Ping; Tao, Lu-Yang] Soochow Univ, Coll Med, Dept Forens Sci, Suzhou 215123, Jiangsu, Peoples R China; [Wang, Yao-Qi; Wang, Long; Zhang, Ming-Yang; Wang, Tao; Bao, Hai-Jun; Liu, Wei-Li; Dai, Ding-Kun; Zhang, Lu; Chang, Pan; Dong, Wen-Wen; Chen, Xi-Ping; Tao, Lu-Yang] Soochow Univ, Coll Med, Lab Neural Injury, Suzhou 215123, Jiangsu, Peoples R China; [Zhang, Ming-Yang] Nantong Univ, Coll Med, Dept Forens Sci, Nantong 226001, Jiangsu, Peoples R China		Chen, XP (corresponding author), Soochow Univ, Coll Med, Dept Forens Sci, Suzhou 215123, Jiangsu, Peoples R China.	xiping.chen@163.com; luyang.tao@163.com	Mingyang, Zhang/J-7412-2019	Mingyang, Zhang/0000-0001-7084-6237	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30872666, 81172911]; Shanghai Forensic Key Lab Foundation [KF1005]	This work was financially supported by the National Natural Science Foundation of China (30872666 and 81172911) and the Shanghai Forensic Key Lab Foundation (KF1005).	Bell BD, 2008, P NATL ACAD SCI USA, V105, P16677, DOI 10.1073/pnas.0808597105; Ch'en IL, 2008, P NATL ACAD SCI USA, V105, P17463, DOI 10.1073/pnas.0808043105; Cheema ZF, 1999, J NEUROSCI, V19, P1754; Christofferson DE, 2010, CURR OPIN CELL BIOL, V22, P263, DOI 10.1016/j.ceb.2009.12.003; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Declercq W, 2009, CELL, V138, P229, DOI 10.1016/j.cell.2009.07.006; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Denecker G, 2001, CELL MOL LIFE SCI, V58, P356, DOI 10.1007/PL00000863; Denecker G, 2001, CELL DEATH DIFFER, V8, P829, DOI 10.1038/sj.cdd.4400883; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Erlich S, 2006, AUTOPHAGY, V2, P49, DOI 10.4161/auto.2156; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Festjens N, 2007, CELL DEATH DIFFER, V14, P400, DOI 10.1038/sj.cdd.4402085; Graham SH, 2000, J NEUROTRAUM, V17, P831, DOI 10.1089/neu.2000.17.831; Han WD, 2009, APOPTOSIS, V14, P674, DOI 10.1007/s10495-009-0334-x; Itakura E, 2008, MOL BIOL CELL, V19, P5360, DOI 10.1091/mbc.E08-01-0080; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Kim Sunja, 2010, Int J Physiol Pathophysiol Pharmacol, V2, P137; Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Luo CL, 2010, J NEUROSCI RES, V88, P2847, DOI 10.1002/jnr.22453; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Meloni BP, 2011, J NEUROSCI METH, V195, P67, DOI 10.1016/j.jneumeth.2010.11.023; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Pattingre S, 2006, CANCER RES, V66, P2885, DOI 10.1158/0008-5472.CAN-05-4412; Qin ZH, 1999, J NEUROSCI, V19, P4023; Rosenbaum DM, 2010, J NEUROSCI RES, V88, P1569, DOI 10.1002/jnr.22314; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sadasivan S, 2008, BIOCHEM BIOPH RES CO, V373, P478, DOI 10.1016/j.bbrc.2008.05.031; Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4; Vanden Berghe T, 2004, J BIOL CHEM, V279, P7925, DOI 10.1074/jbc.M307807200; Vanden Berghe T, 2003, J BIOL CHEM, V278, P5622, DOI 10.1074/jbc.M208925200; Vanden Berghe Tom, 2004, Methods Mol Med, V98, P101; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Vercammen D, 1997, CYTOKINE, V9, P801, DOI 10.1006/cyto.1997.0252; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Wang Y, 2008, AUTOPHAGY, V4, P214, DOI 10.4161/auto.5369; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xu XS, 2007, J NEUROCHEM, V103, P2004, DOI 10.1111/j.1471-4159.2007.04884.x; Xu XS, 2010, BRAIN RES, V1355, P189, DOI 10.1016/j.brainres.2010.07.080; Xu XS, 2010, BRAIN RES, V1343, P206, DOI 10.1016/j.brainres.2010.04.080; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Zhang N, 2011, AUTOPHAGY, V7, P598, DOI 10.4161/auto.7.6.15103; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhu S, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2010.94; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	51	83	91	1	20	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	SEP	2012	37	9					1849	1858		10.1007/s11064-012-0791-4			10	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	985PP	WOS:000307280100003	22736198				2022-02-06	
J	Katz, E; Wang, J; Privman, M; Halamek, J				Katz, Evgeny; Wang, Joseph; Privman, Marina; Halamek, Jan			Multianalyte Digital Enzyme Biosensors with Built-in Boolean Logic	ANALYTICAL CHEMISTRY			English	Article							TRAUMATIC BRAIN-INJURY; BIOMARKER; SIGNALS; SYSTEMS; PROTEIN; GATES		[Katz, Evgeny; Halamek, Jan] Clarkson Univ, Dept Chem & Biomol Sci, Potsdam, NY 13699 USA; [Wang, Joseph] Univ Calif San Diego, Dept NanoEngn, La Jolla, CA 92093 USA; [Privman, Marina] SUNY Empire State Coll, Ft Drum, NY 13602 USA		Katz, E (corresponding author), Clarkson Univ, Dept Chem & Biomol Sci, Potsdam, NY 13699 USA.	ekatz@clarkson.edu; josephwang@ucsd.edu	Wang, Joseph/C-6175-2011		Office of Naval ResearchOffice of Naval Research [N00014-08-1-1202]; NSFNational Science Foundation (NSF) [CBET-1066397, CBET-1066531]; Directorate For EngineeringNational Science Foundation (NSF)NSF - Directorate for Engineering (ENG) [1066531] Funding Source: National Science Foundation	This work was supported by the Office of Naval Research (Award #N00014-08-1-1202) and NSF (Awards #CBET-1066397 and #CBET-1066531). The authors thank all students, postdoctoral researchers, and collaborators who made this interesting research possible.	Beutler E, 2008, BLOOD, V111, P16, DOI 10.1182/blood-2007-04-077412; Borisov SM, 2008, CHEM REV, V108, P423, DOI 10.1021/cr068105t; Calude C. S., 2009, LECT NOTES COMPUTER, V5715; Chuang MC, 2011, CHEM COMMUN, V47, P3087, DOI 10.1039/c0cc05716a; CLARK LC, 1962, ANN NY ACAD SCI, V102, P29, DOI 10.1111/j.1749-6632.1962.tb13623.x; Crowther J. R., 2010, ELISA GUIDEBOOK; de Silva AP, 2007, NAT NANOTECHNOL, V2, P399, DOI 10.1038/nnano.2007.188; Ehrenkranz JRL, 2002, EPIDEMIOLOGY, V13, pS15, DOI 10.1097/00001648-200205001-00003; Halamek J, 2011, ANAL CHEM, V83, P8383, DOI 10.1021/ac202139m; Halamek J, 2010, MOL BIOSYST, V6, P2554, DOI 10.1039/c0mb00153h; Halamek J, 2010, ANALYST, V135, P2249, DOI 10.1039/c0an00270d; Halamkova L, 2012, ANALYST, V137, P1768, DOI 10.1039/c2an00014h; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Katz, 2012, MOL SUPRAMOLECULAR I; Katz E, 2012, BIOMOLECULAR INFORM; Katz E, 2010, CHEM SOC REV, V39, P1835, DOI 10.1039/b806038j; Khalili H, 2011, CLIN GASTROENT-SER, P47, DOI 10.1007/978-1-60761-866-9_3; Kratz A, 2004, NEW ENGL J MED, V351, P1548, DOI 10.1056/NEJMcpc049016; Kumar V, 2011, ANALYST, V136, P5151, DOI 10.1039/c1an15726d; Lee SY, 2010, J NEUROL, V257, P1708, DOI 10.1007/s00415-010-5608-2; LEECH D, 1994, CHEM SOC REV, V23, P205, DOI 10.1039/cs9942300205; Li ZJ, 2011, CHEM COMMUN, V47, P3060, DOI 10.1039/c0cc05037g; Lusczek E.R., 2011, J BIOANAL BIOMED, V3, P038; Margulies D, 2009, J AM CHEM SOC, V131, P9142, DOI 10.1021/ja900848t; May EE, 2008, IEEE SENS J, V8, P1011, DOI 10.1109/JSEN.2008.923945; Melnikov D, 2010, J PHYS CHEM B, V114, P12166, DOI 10.1021/jp105912e; OLERUD JE, 1976, ARCH INTERN MED, V136, P692, DOI 10.1001/archinte.136.6.692; Privman M, 2011, ACS APPL MATER INTER, V3, P1620, DOI 10.1021/am200165m; Privman V, 2011, ISR J CHEM, V51, P118, DOI 10.1002/ijch.201000066; Privman V, 2010, J PHYS CHEM B, V114, P14103, DOI 10.1021/jp108693m; Rafael SP, 2012, ANAL CHEM, V84, P1076, DOI 10.1021/ac202701c; Renneberg R., 2008, SERIES ADV BIOCH ENG; Ronkainen NJ, 2010, CHEM SOC REV, V39, P1747, DOI 10.1039/b714449k; Sassolas A, 2008, CHEM REV, V108, P109, DOI 10.1021/cr0684467; Schena M., 2002, MICROARRAY ANAL; Steinem C., 2010, SERIES SPRINGER SERI; Stojanovic MN, 2002, J AM CHEM SOC, V124, P3555, DOI 10.1021/ja016756v; Stojanovic MN, 2003, NAT BIOTECHNOL, V21, P1069, DOI 10.1038/nbt862; Strack G, 2010, J PHYS CHEM LETT, V1, P839, DOI 10.1021/jz100070u; Tan KK, 2009, INJURY, V40, P978, DOI 10.1016/j.injury.2009.02.023; Vaidya VS, 2010, BIOMARKERS MED DRUG; van Emon JM, 2006, IMMUNOASSAY OTHER BI; von Maltzahn G, 2007, J AM CHEM SOC, V129, P6064, DOI 10.1021/ja070461l; Wang J, 2008, CHEM REV, V108, P814, DOI 10.1021/cr068123a; Wang J, 2010, ANAL BIOANAL CHEM, V398, P1591, DOI 10.1007/s00216-010-3746-0; Warsinke A, 2009, ANAL BIOANAL CHEM, V393, P1393, DOI 10.1007/s00216-008-2572-0; Willner I, 2000, ANGEW CHEM INT EDIT, V39, P1180, DOI 10.1002/(SICI)1521-3773(20000403)39:7<1180::AID-ANIE1180>3.0.CO;2-E; Win MN, 2008, SCIENCE, V322, P456, DOI 10.1126/science.1160311; Zhou JA, 2011, TALANTA, V83, P955, DOI 10.1016/j.talanta.2010.10.057; Zhou M, 2012, ANGEW CHEM INT EDIT, V51, P2686, DOI 10.1002/anie.201107068; Zhou ND, 2011, ANAL CHIM ACTA, V703, P94, DOI 10.1016/j.aca.2011.07.023; Zourob M, 2010, RECOGNITION RECEPTORS IN BIOSENSORS, P415, DOI 10.1007/978-1-4419-0919-0_11	52	83	83	1	62	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0003-2700	1520-6882		ANAL CHEM	Anal. Chem.	JUL 3	2012	84	13					5463	5469		10.1021/ac3007076			7	Chemistry, Analytical	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry	966XS	WOS:000305871300003	22656194				2022-02-06	
J	Demirtas-Tatlidede, A; Vahabzadeh-Hagh, AM; Bernabeu, M; Tormos, JM; Pascual-Leone, A				Demirtas-Tatlidede, Asli; Vahabzadeh-Hagh, Andrew M.; Bernabeu, Montserrat; Tormos, Jose M.; Pascual-Leone, Alvaro			Noninvasive Brain Stimulation in Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						DAI; diffuse axonal injury; LLLT; low-level laser therapy; rTMS; TBI; TBS; TCD; tDCS; theta burst stimulation; TMS; transcranial direct current stimulation; transcranial Doppler sonography; transcranial magnetic stimulation; traumatic brain injury	TRANSCRANIAL MAGNETIC STIMULATION; DIFFUSE AXONAL INJURY; HUMAN MOTOR CORTEX; SPINAL-CORD-INJURY; DORSOLATERAL PREFRONTAL CORTEX; EMITTING-DIODE IRRADIATION; MAJOR DEPRESSIVE DISORDER; THETA-BURST STIMULATION; EXCITATORY AMINO-ACIDS; ACUTE ISCHEMIC-STROKE	Objective: To review novel techniques of noninvasive brain stimulation (NBS), which may have value in assessment and treatment of traumatic brain injury (TBI). Methods: Review of the following techniques: transcranial magnetic stimulation, transcranial direct current stimulation, low-level laser therapy, and transcranial Doppler sonography. Furthermore, we provide a brief overview of TMS studies to date. Main findings: We describe the rationale for the use of these techniques in TBI, discuss their possible mechanisms of action, and raise a number of considerations relevant to translation of these methods to clinical use. Depending on the stimulation parameters, NBS may enable suppression of the acute glutamatergic hyperexcitability following TBI and/or counter the excessive GABAergic effects in the subacute stage. In the chronic stage, brain stimulation coupled to rehabilitation may enhance behavioral recovery, learning of new skills, and cortical plasticity. Correlative animal models and comprehensive safety trials seem critical to establish the use of these modalities in TBI. Conclusions: Different forms of NBS techniques harbor the promise of diagnostic and therapeutic utility, particularly to guide processes of cortical reorganization and enable functional restoration in TBI. Future lines of safety research and well-designed clinical trials in TBI are warranted to determine the capability of NBS to promote recovery and minimize disability.	[Demirtas-Tatlidede, Asli; Vahabzadeh-Hagh, Andrew M.; Pascual-Leone, Alvaro] Harvard Univ, Sch Med, Berenson Allen Ctr Noninvas Brain Stimulat, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Bernabeu, Montserrat; Tormos, Jose M.; Pascual-Leone, Alvaro] Univ Autonoma Barcelona, Guttmann Univ, Inst Neurorehabil, Badalona, Spain		Pascual-Leone, A (corresponding author), Harvard Univ, Sch Med, Berenson Allen Ctr Noninvas Brain Stimulat, Beth Israel Deaconess Med Ctr, 330 Brookline Ave,KS-158, Boston, MA 02215 USA.	apleone@bidmc.harvard.edu	Pascual-Leone, Alvaro/AAC-5101-2019; Pascual-Leone, Alvaro/G-6566-2011	Pascual-Leone, Alvaro/0000-0001-8975-0382; Tormos Munoz, Jose Maria/0000-0002-8764-2289; Demirtas-Tatlidede, MD, PhD, Asli/0000-0003-2050-5674	BBVA Translational Research Chair in BiomedicineBBVA Foundation; International Brain Research Foundation (IBRF); National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K 24 RR018875]; Instituto de Salud Carlos IIIInstituto de Salud Carlos IIIEuropean Commission [PI082004]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [K24RR018875] Funding Source: NIH RePORTER	Supported in part by a BBVA Translational Research Chair in Biomedicine, a grant from the International Brain Research Foundation (IBRF), and National Institutes of Health grant K 24 RR018875 to A. P. L., and grant PI082004 from the Instituto de Salud Carlos III. A.M.V.-H. is a Howard Hughes Medical Institute medical research training fellow.	Alexandrov AV, 2009, STROKE, V40, pS107, DOI 10.1161/STROKEAHA.108.530931; Bachtold MR, 1998, ULTRASOUND MED BIOL, V24, P557, DOI 10.1016/S0301-5629(98)00014-3; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Barba C, 2006, NEUROCASE, V12, P232, DOI 10.1080/13554790600878879; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Becerra GD, 2007, BEHAV BRAIN RES, V179, P118, DOI 10.1016/j.bbr.2007.01.024; Bellner J, 2004, SURG NEUROL, V62, P45, DOI 10.1016/j.surneu.2003.12.007; Bernabeu M, 2009, J NEUROTRAUM, V26, P2185, DOI 10.1089/neu.2008.0859; Bestmann S, 2008, TRENDS COGN SCI, V12, P81, DOI 10.1016/j.tics.2007.12.002; BLINC A, 1993, BLOOD, V81, P2636; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Boggio PS, 2007, RESTOR NEUROL NEUROS, V25, P123; Boggio PS, 2006, NEUROSCI LETT, V404, P232, DOI 10.1016/j.neulet.2006.05.051; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Brighina F, 2003, NEUROSCI LETT, V336, P131, DOI 10.1016/S0304-3940(02)01283-1; Byrnes KR, 2005, LASER SURG MED, V36, P171, DOI 10.1002/lsm.20143; Calabresi P, 2003, LANCET NEUROL, V2, P622, DOI 10.1016/S1474-4422(03)00532-5; Centonze D, 2007, NEUROLOGY, V68, P1045, DOI 10.1212/01.wnl.0000257818.16952.62; Centonze D, 2005, J PSYCHIATR NEUROSCI, V30, P127; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; Chen R, 1997, ELECTROMYOGR MOTOR C, V105, P415, DOI 10.1016/S0924-980X(97)00036-2; Chew E, 2009, 5 WORLD C ISPRM 13 1; Chistyakov AV, 2001, J NEUROL NEUROSUR PS, V70, P580, DOI 10.1136/jnnp.70.5.580; Chistyakov AV, 1998, ACTA NEUROCHIR, V140, P467, DOI 10.1007/s007010050126; Chistyakov AV, 1999, CLIN NEUROPHYSIOL, V110, P1080, DOI 10.1016/S1388-2457(99)00029-2; Crossley M, 2005, BRAIN INJURY, V19, P729, DOI 10.1080/02699050400013733; Datta A, 2010, NEUROIMAGE, V52, P1268, DOI 10.1016/j.neuroimage.2010.04.252; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Di Lazzaro V, 2005, J PHYSIOL-LONDON, V565, P945, DOI 10.1113/jphysiol.2005.087288; Dockery CA, 2009, J NEUROSCI, V29, P7271, DOI 10.1523/JNEUROSCI.0065-09.2009; Soler MD, 2010, BRAIN, V133, P2565, DOI 10.1093/brain/awq184; Edwards DJ, 2009, RESTOR NEUROL NEUROS, V27, P199, DOI 10.3233/RNN-2009-0470; Eells JT, 2003, P NATL ACAD SCI USA, V100, P3439, DOI 10.1073/pnas.0534746100; Eggers J, 2005, NEUROLOGY, V64, P1052, DOI 10.1212/01.WNL.0000154599.45969.D6; Eggers R, 2009, ULTRASOUND MED BIOL, V35, P523, DOI 10.1016/j.ultrasmedbio.2008.09.009; ERB DE, 1991, EXP BRAIN RES, V83, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fecteau S, 2007, J NEUROSCI, V27, P12500, DOI 10.1523/JNEUROSCI.3283-07.2007; Fecteau S, 2010, SUBST USE MISUSE, V45, P1766, DOI 10.3109/10826084.2010.482434; Ferrucci R, 2008, NEUROLOGY, V71, P493, DOI 10.1212/01.wnl.0000317060.43722.a3; Floel A, 2007, BRAIN RES REV, V53, P250, DOI 10.1016/j.brainresrev.2006.08.006; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Forster C, 1999, ACTA NEUROPATHOL, V97, P215, DOI 10.1007/s004010050977; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; Fregni F, 2005, NEUROREPORT, V16, P1551, DOI 10.1097/01.wnr.0000177010.44602.5e; Fregni F, 2006, COGN BEHAV NEUROL, V19, P21, DOI 10.1097/00146965-200603000-00003; Fregni F, 2007, LANCET NEUROL, V6, P188, DOI 10.1016/S1474-4422(07)70032-7; Fregni F, 2006, MOVEMENT DISORD, V21, P1693, DOI 10.1002/mds.21012; Fregni F, 2006, PAIN, V122, P197, DOI 10.1016/j.pain.2006.02.023; Fujiki M, 2006, NEUROSCI LETT, V405, P226, DOI 10.1016/j.neulet.2006.07.005; Gandiga PC, 2006, CLIN NEUROPHYSIOL, V117, P845, DOI 10.1016/j.clinph.2005.12.003; GARRAGHTY PE, 1991, SOMATOSENS MOT RES, V8, P347, DOI 10.3109/08990229109144757; George MS, 2010, ARCH GEN PSYCHIAT, V67, P507, DOI 10.1001/archgenpsychiatry.2010.46; George MS, 2010, NEUROPSYCHOPHARMACOL, V35, P301, DOI 10.1038/npp.2009.87; Hallett M, 2007, NEURON, V55, P187, DOI 10.1016/j.neuron.2007.06.026; Hesse S, 2007, RESTOR NEUROL NEUROS, V25, P9; Holtz ML, 2001, BRAIN RES, V898, P49, DOI 10.1016/S0006-8993(01)02140-0; Hoskison MM, 2009, NEUROSCIENCE, V159, P483, DOI 10.1016/j.neuroscience.2008.12.050; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Hummel F, 2005, NEUROREHAB NEURAL RE, V19, P14, DOI 10.1177/1545968304272698; Ilic S, 2006, PHOTOMED LASER SURG, V24, P458, DOI 10.1089/pho.2006.24.458; Iyer MB, 2005, NEUROLOGY, V64, P872, DOI 10.1212/01.WNL.0000152986.07469.E9; Jaffres P, 2005, INTENS CARE MED, V31, P785, DOI 10.1007/s00134-005-2630-4; Jang SH, 2005, RESTOR NEUROL NEUROS, V23, P51; Janicak PG, 2008, J CLIN PSYCHIAT, V69, P222, DOI 10.4088/JCP.v69n0208; Jo JM, 2009, AM J PHYS MED REHAB, V88, P404, DOI 10.1097/PHM.0b013e3181a0e4cb; Karu T, 1999, J PHOTOCH PHOTOBIO B, V49, P1, DOI 10.1016/S1011-1344(98)00219-X; Karu TI, 2005, LASER SURG MED, V36, P307, DOI 10.1002/lsm.20148; KATSURA K, 1994, BIOCHEM SOC T, V22, P991, DOI 10.1042/bst0220991; Knoch D, 2006, J NEUROSCI, V26, P6469, DOI 10.1523/JNEUROSCI.0804-06.2006; Knoch D, 2008, CEREB CORTEX, V18, P1987, DOI 10.1093/cercor/bhm237; Kobayashi M, 2003, LANCET NEUROL, V2, P145, DOI 10.1016/S1474-4422(03)00321-1; Kobori N, 2006, J NEUROSCI, V26, P4236, DOI 10.1523/JNEUROSCI.4687-05.2006; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lang N, 2005, EUR J NEUROSCI, V22, P495, DOI 10.1111/j.1460-9568.2005.04233.x; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Leung MCP, 2002, LASER SURG MED, V31, P283, DOI 10.1002/lsm.10096; Liebetanz D, 2002, BRAIN, V125, P2238, DOI 10.1093/brain/awf238; Lim W, 2007, LASER SURG MED, V39, P614, DOI 10.1002/lsm.20533; Litscher G, INTERNET J NEUROMONI; Lo EH, 2008, NAT MED, V14, P497, DOI 10.1038/nm1735; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Machii K, 2006, CLIN NEUROPHYSIOL, V117, P455, DOI 10.1016/j.clinph.2005.10.014; Madhavan S, 2011, EXP BRAIN RES, V209, P9, DOI 10.1007/s00221-010-2511-0; Martin Paula I., 2004, Seminars in Speech and Language, V25, P181; Meairs S, 2007, PROG BIOPHYS MOL BIO, V93, P354, DOI 10.1016/j.pbiomolbio.2006.07.019; Mochizuki-Oda N, 2002, NEUROSCI LETT, V323, P207, DOI 10.1016/S0304-3940(02)00159-3; Monti A, 2008, J NEUROL NEUROSUR PS, V79, P451, DOI 10.1136/jnnp.2007.135277; Moosavi SH, 1999, J NEUROL SCI, V164, P179, DOI 10.1016/S0022-510X(99)00065-9; Mori F, 2010, EUR J NEUROL, V17, P295, DOI 10.1111/j.1468-1331.2009.02806.x; Mori F, 2009, PROG BRAIN RES, V175, P429, DOI 10.1016/S0079-6123(09)17528-3; Naeser MA, 2005, BRAIN LANG, V93, P95, DOI 10.1016/j.bandl.2004.08.004; NAVEH N, 1990, J NEUROSCI RES, V26, P386, DOI 10.1002/jnr.490260316; Nedelmann M, 2008, ULTRASOUND MED BIOL, V34, P2019, DOI 10.1016/j.ultrasmedbio.2008.06.003; Nitsche MA, 2003, SUPPL CLIN NEUROPHYS, V56, P255; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2009, EXP NEUROL, V219, P14, DOI 10.1016/j.expneurol.2009.03.038; Nogawa S, 1997, J NEUROSCI, V17, P2746; O'Dell DM, 2000, BRAIN RES, V861, P325, DOI 10.1016/S0006-8993(00)02055-2; O'Reardon JP, 2007, BIOL PSYCHIAT, V62, P1208, DOI 10.1016/j.biopsych.2007.01.018; Oliveri M, 2001, NEUROLOGY, V57, P1338, DOI 10.1212/WNL.57.7.1338; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; Pape TLB, 2009, BRAIN STIMUL, V2, P22, DOI 10.1016/j.brs.2008.09.004; PARK CK, 1989, J CEREBR BLOOD F MET, V9, P617, DOI 10.1038/jcbfm.1989.88; Pascual JM, 2007, J NEUROTRAUM, V24, P944, DOI 10.1089/neu.2006.0190; Pascual-Leone A, 2005, ANNU REV NEUROSCI, V28, P377, DOI 10.1146/annurev.neuro.27.070203.144216; Pascual-Leone A., 2002, HDB TRANSCRANIAL MAG; PASCUALLEONE A, 1993, ELECTROEN CLIN NEURO, V89, P120, DOI 10.1016/0168-5597(93)90094-6; Paus T, 1997, J NEUROSCI, V17, P3178; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Poreisz C, 2007, BRAIN RES BULL, V72, P208, DOI 10.1016/j.brainresbull.2007.01.004; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Priori A, 2003, CLIN NEUROPHYSIOL, V114, P589, DOI 10.1016/S1388-2457(02)00437-6; PURPURA DP, 1965, J NEUROPHYSIOL, V28, P166, DOI 10.1152/jn.1965.28.1.166; Raymont V, 2006, PROG BRAIN RES, V157, P199, DOI 10.1016/S0079-6123(06)57013-X; Reis J, 2008, J PHYSIOL-LONDON, V586, P325, DOI 10.1113/jphysiol.2007.144824; Ricci Raffaella, 2008, Ther Clin Risk Manag, V4, P1127; Ridding MC, 2007, NAT REV NEUROSCI, V8, P559, DOI 10.1038/nrn2169; RINALDI PC, 1991, BRAIN RES, V558, P36, DOI 10.1016/0006-8993(91)90711-4; Rioult-Pedotti MS, 1998, NAT NEUROSCI, V1, P230, DOI 10.1038/678; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; Ropper AH., 2005, ADAMS VICTORS PRINCI; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Rossini PM, 2007, NEUROLOGY, V68, P484, DOI 10.1212/01.wnl.0000250268.13789.b2; Rotenberg A, 2008, 3 INT C TRANSCR MAGN; Rotenberg A, 2007, CLIN NEUROPHYSIOL, V118, P2536, DOI 10.1016/j.clinph.2007.08.003; Rotenberg A, 2009, CLIN NEUROPHYSIOL, V120, P1417, DOI 10.1016/j.clinph.2009.05.004; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sack AT, 2007, CEREB CORTEX, V17, P2841, DOI 10.1093/cercor/bhm013; Sandrini M, 2008, NEUROPSYCHOLOGIA, V46, P2056, DOI 10.1016/j.neuropsychologia.2008.02.003; Shulga A, 2008, J NEUROSCI, V28, P6996, DOI 10.1523/JNEUROSCI.5268-07.2008; Silvanto J, 2008, BRAIN TOPOGR, V21, P1, DOI 10.1007/s10548-008-0067-0; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; Sorenson SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [10.1097/00001199-199106000-00003, DOI 10.1097/00001199-199106000-00003]; Stern WM, 2007, J NEUROPSYCH CLIN N, V19, P179, DOI 10.1176/appi.neuropsych.19.2.179; STEWARD O, 1989, Journal of Neurotrauma, V6, P99, DOI 10.1089/neu.1989.6.99; STROEMER RP, 1995, STROKE, V26, P2135, DOI 10.1161/01.STR.26.11.2135; Syntichaki P, 2003, NAT REV NEUROSCI, V4, P672, DOI 10.1038/nrn1174; Takeuchi N, 2006, BRAIN INJURY, V20, P991, DOI 10.1080/02699050600909771; Tyler WJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003511; Valero-Cabre A, 2005, IEEE ENG MED BIOL, V24, P29, DOI 10.1109/MEMB.2005.1384097; Valero-Cabre A, 2007, EXP BRAIN RES, V176, P603, DOI 10.1007/s00221-006-0639-8; Vanderhasselt MA, 2006, EXP BRAIN RES, V172, P561, DOI 10.1007/s00221-006-0540-5; Vespa P, 2003, NEUROSURG FOCUS, V15, P1, DOI DOI 10.3171/foc.2003.15.6.4; Vykhodtseva N, 2008, ULTRASONICS, V48, P279, DOI 10.1016/j.ultras.2008.04.004; Wagner T, 2007, NEUROIMAGE, V35, P1113, DOI 10.1016/j.neuroimage.2007.01.027; Wagner T, 2007, ANNU REV BIOMED ENG, V9, P527, DOI 10.1146/annurev.bioeng.9.061206.133100; Wassermann EM, 1996, ELECTROMYOGR MOTOR C, V101, P412; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8; Whelan HT, 2001, J CLIN LASER MED SUR, V19, P305, DOI 10.1089/104454701753342758; Williams JA, 2010, PHYS THER, V90, P398, DOI 10.2522/ptj.20090075; Yasokawa YT, 2007, J NEUROTRAUM, V24, P163, DOI 10.1089/neu.2006.0073; Yurkewicz L, 2005, J NEUROTRAUM, V22, P1428, DOI 10.1089/neu.2005.22.1428; Zhang Q, 2000, J BIOMED OPT, V5, P206, DOI 10.1117/1.429988; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547	160	83	88	2	47	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2012	27	4					274	292		10.1097/HTR.0b013e318217df55			19	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	975PJ	WOS:000306523000005	21691215	Green Accepted			2022-02-06	
J	Len, TK; Neary, JP; Asmundson, GJG; Goodman, DG; Bjornson, B; Bhambhani, YN				Len, Trevor K.; Neary, J. Patrick; Asmundson, Gordon J. G.; Goodman, David G.; Bjornson, Bruce; Bhambhani, Yagesh N.			Cerebrovascular Reactivity Impairment after Sport-Induced Concussion	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						MILD TRAUMATIC BRAIN INJURY; PATHOPHYSIOLOGY; CEREBROVASCULAR REACTIVITY; TRANSCRANIAL DOPPLER; CEREBRAL BLOOD VELOCITY; CONCUSSION	DYNAMIC CEREBRAL AUTOREGULATION; END-TIDAL CO2; BLOOD-FLOW-VELOCITY; TRANSCRANIAL DOPPLER; HEALTHY HUMANS; ARTERIAL; OXYGENATION; DIAMETER; MIDDLE; MECHANISMS	LEN, T. K., J. P. NEARY, G. J. G. ASMUNDSON, D. G. GOODMAN, B. BJORNSON, and Y. N. BHAMBHANI. Cerebrovascular Reactivity Impairment after Sport-Induced Concussion. Med. Sci. Sports Exerc., Vol. 43, No. 12, pp. 2241-2248, 2011. Purpose: This study evaluated cerebrovascular reactivity (CVR) after a sport-induced concussion, also called mild traumatic brain injury (mTBI), by monitoring middle cerebral artery blood velocity (vMCA) with transcranial Doppler ultrasonography and simultaneous end-tidal carbon dioxide (PETCO2) measurements. Methods: Thirty-one athletes (16-25 yr old) participated in this study. The participants were divided into two groups-healthy (n = 21) and mTBI (n = 10). Participants in the mTBI group suffered an mTBI within the last 7 d ((x) over bar = 4.5 +/- 1.1 d). Outcome measures included vMCA and PETCO2 in response to breath holding (5 x 20 s, 40-s rest) and hyperventilation (5 x 20 s, 40-s rest). Results: Resting vMCA values between groups were not significantly different. Percentage change of vMCA was significantly different after the recovery period of the second hyperventilation (P = 0.034). mTBI subjects failed to return to resting levels after each breath hold. PETCO2 changes mirrored the vMCA changes. Conclusions: These data suggest that normal CVR responses may be disrupted in the days immediately after occurrence of mTBI. Transcranial Doppler ultrasonography combined with expired gas measurements provides a useful method for assessing CVR impairment after mTBI. Further research, including serial monitoring after mTBI and analysis of CVR response to exercise, is warranted before any firm conclusions can be drawn.	[Len, Trevor K.; Neary, J. Patrick] Univ Regina, Fac Kinesiol & Hlth Studies, Regina, SK S4S 0A2, Canada; [Asmundson, Gordon J. G.] Univ Regina, Traumat Stress Grp, Regina, SK S4S 0A2, Canada; [Goodman, David G.] Simon Fraser Univ, Dept Biomed Physiol & Kinesiol, Burnaby, BC V5A 1S6, Canada; [Bjornson, Bruce] Univ British Columbia, Fac Med, Dept Pediat, Vancouver, BC, Canada; [Bhambhani, Yagesh N.] Univ Alberta, Dept Occupat Therapy, Edmonton, AB, Canada		Neary, JP (corresponding author), Univ Regina, Fac Kinesiol & Hlth Studies, Regina, SK S4S 0A2, Canada.	patrick.neary@uregina.ca	Bjornson, Bruce Hal/A-8616-2010	Bjornson, Bruce Hal/0000-0002-1465-6196	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Saskatchewan Health Research Foundation	This study was supported by grants from the Canadian Institutes of Health Research (J.P.N.) and the Saskatchewan Health Research Foundation (J.P.N.).	Ainslie PN, 2007, EXP PHYSIOL, V92, P769, DOI 10.1113/expphysiol.2006.036814; Ainslie PN, 2007, J APPL PHYSIOL, V102, P658, DOI 10.1152/japplphysiol.00911.2006; Ainslie PN, 2009, AM J PHYSIOL-REG I, V296, pR1473, DOI 10.1152/ajpregu.91008.2008; Alexandrov AV, 2007, J NEUROIMAGING, V17, P11, DOI 10.1111/j.1552-6569.2006.00088.x; [Anonymous], 2006, MED SCI SPORT EXER, V38, P395, DOI 10.1249/01.mss.0000202025.48774.31; BARTON CW, 1994, ANN EMERG MED, V23, P560, DOI 10.1016/S0196-0644(94)70078-8; Bhambhani Y, 2007, RESP PHYSIOL NEUROBI, V156, P196, DOI 10.1016/j.resp.2006.08.009; Carrera E, 2009, J NEUROL SCI, V285, P191, DOI 10.1016/j.jns.2009.06.041; Cummings KJ, 2007, J APPL PHYSIOL, V102, P1891, DOI 10.1152/japplphysiol.01437.2006; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Dineen NE, 2010, J APPL PHYSIOL, V108, P604, DOI 10.1152/japplphysiol.01157.2009; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Fukushima U, 1999, J VET MED SCI, V61, P1293, DOI 10.1292/jvms.61.1293; Gall B, 2004, BRIT J SPORT MED, V38, P773, DOI 10.1136/bjsm.2003.009530; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Geary GG, 2000, AM J PHYSIOL-HEART C, V279, pH610, DOI 10.1152/ajpheart.2000.279.2.H610; GILLER CA, 1993, NEUROSURGERY, V32, P737, DOI 10.1227/00006123-199305000-00006; Golding EM, 1999, AM J PHYSIOL-HEART C, V277, pH1457, DOI 10.1152/ajpheart.1999.277.4.H1457; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287, DOI 10.1152/ajpregu.1998.275.4.R1287; Gommer ED, 2008, PHYSIOL MEAS, V29, P1293, DOI 10.1088/0967-3334/29/11/005; Ide Kojiro, 2003, Journal of Applied Physiology, V95, P129; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Karadeniz U, 2005, ANN THORAC SURG, V79, P139, DOI 10.1016/j.athoracsur.2004.06.046; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Liu HL, 2002, MAGN RESON IMAGING, V20, P643, DOI 10.1016/S0730-725X(02)00595-7; Low DA, 2008, J APPL PHYSIOL, V104, P976, DOI 10.1152/japplphysiol.01040.2007; MARKUS HS, 1992, STROKE, V23, P668, DOI 10.1161/01.STR.23.5.668; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Ogoh S, 2010, J APPL PHYSIOL, V108, P538, DOI 10.1152/japplphysiol.01235.2009; Palada I, 2007, RESP PHYSIOL NEUROBI, V157, P374, DOI 10.1016/j.resp.2007.02.002; Peebles K, 2007, J PHYSIOL-LONDON, V584, P347, DOI 10.1113/jphysiol.2007.137075; Przybylowski T, 2003, J PHYSIOL-LONDON, V548, P323, DOI 10.1113/jphysiol.2002.029678; RangeL-Castilla L, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E7; RINGELSTEIN EB, 1990, ULTRASOUND MED BIOL, V16, P745, DOI 10.1016/0301-5629(90)90039-F; Schramm P, 2011, J NEUROSURG ANESTH, V23, P41, DOI 10.1097/ANA.0b013e3181f35854; Serrador JM, 2000, STROKE, V31, P1672, DOI 10.1161/01.STR.31.7.1672; Settakis G, 2002, J NEUROIMAGING, V12, P252, DOI 10.1177/10528402012003007; Simmons GH, 2007, J PHYSIOL-LONDON, V583, P1155, DOI 10.1113/jphysiol.2007.137216; Stoll M, 1996, STROKE, V27, P1132; Takano Y, 2003, RESP MED, V97, P476, DOI 10.1053/rmed.2002.1468; Tegeler C, 2004, CEREBROVASC DIS, V17, P1; Totaro R, 1999, CEREBROVASC DIS, V9, P142, DOI 10.1159/000015943; Valdueza JM, 1997, AM J NEURORADIOL, V18, P1929; Wilson LC, 2010, AM J PHYSIOL-REG I, V298, pR1035, DOI 10.1152/ajpregu.00815.2009	44	83	83	1	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	DEC	2011	43	12					2241	2248		10.1249/MSS.0b013e3182249539			8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	851EL	WOS:000297251100004	21606867				2022-02-06	
J	Oddo, M; Levine, JM; Mackenzie, L; Frangos, S; Feihl, F; Kasner, SE; Katsnelson, M; Pukenas, B; Macmurtrie, E; Maloney-Wilensky, E; Kofke, WA; LeRoux, PD				Oddo, Mauro; Levine, Joshua M.; Mackenzie, Larami; Frangos, Suzanne; Feihl, Francois; Kasner, Scott E.; Katsnelson, Michael; Pukenas, Bryan; Macmurtrie, Eileen; Maloney-Wilensky, Eileen; Kofke, W. Andrew; LeRoux, Peter D.			Brain Hypoxia Is Associated With Short-term Outcome After Severe Traumatic Brain Injury Independently of Intracranial Hypertension and Low Cerebral Perfusion Pressure	NEUROSURGERY			English	Article						Brain hypoxia; Brain tissue oxygen pressure; Cerebral perfusion pressure; Indepedent predictor; Intracranial Pressure; Outcome; Traumatic brain injury	SEVERE HEAD-INJURY; TISSUE OXYGEN-TENSION; NEUROCRITICAL CARE; HYPERTONIC SALINE; INTENSIVE-CARE; BLOOD-FLOW; METABOLISM; DELIVERY; CLASSIFICATION; MICRODIALYSIS	BACKGROUND: Brain hypoxia (BH) can aggravate outcome after severe traumatic brain injury (TBI). Whether BH or reduced brain oxygen (Pbto(2)) is an independent outcome predictor or a marker of disease severity is not fully elucidated. OBJECTIVE: To analyze the relationship between Pbto(2), intracranial pressure (ICP), and cerebral perfusion pressure (CPP) and to examine whether BH correlates with worse outcome independently of ICP and CPP. METHODS: We studied 103 patients monitored with ICP and Pbto2 for > 24 hours. Durations of BH (Pbto(2) < 15 mm Hg), ICP > 20 mm Hg, and CPP < 60 mm Hg were calculated with linear interpolation, and their associations with outcome within 30 days were analyzed. RESULTS: Duration of BH was longer in patients with unfavorable (Glasgow Outcome Scale score, 1-3) than in those with favorable (Glasgow Outcome Scale, 4-5) outcome (8.3 +/- 15.9 vs 1.7 +/- 3.7 hours; P < .01). In patients with intracranial hypertension, those with BH had fewer favorable outcomes (46%) than those without (81%; P < .01); similarly, patients with low CPP and BH were less likely to have favorable outcome than those with low CPP but normal Pbto2 (39% vs 83%; P < .01). After ICP, CPP, age, Glasgow Coma Scale score, Marshall computed tomography grade, and Acute Physiology and Chronic Health Evaluation II score were controlled for, BH was independently associated with poor prognosis (adjusted odds ratio for favorable outcome, 0.89 per hour of BH; 95% confidence interval, 0.79-0.99; P = .04). CONCLUSION: Brain hypoxia is associated with poor short-term outcome after severe traumatic brain injury independently of elevated ICP, low CPP, and injury severity. Pbto2 may be an important therapeutic target after severe traumatic brain injury.	[LeRoux, Peter D.] Univ Penn, Med Ctr, Dept Neurosurg, Div Clin Res, Philadelphia, PA 19107 USA; [Levine, Joshua M.; Mackenzie, Larami; Kasner, Scott E.; Katsnelson, Michael] Univ Penn, Med Ctr, Dept Neurol, Philadelphia, PA 19107 USA; [Levine, Joshua M.; Kofke, W. Andrew] Univ Penn, Med Ctr, Dept Anesthesiol & Crit Care, Philadelphia, PA 19107 USA; [Pukenas, Bryan] Univ Penn, Med Ctr, Dept Radiol, Philadelphia, PA 19107 USA; [Oddo, Mauro] Univ Lausanne, Dept Intens Care Med, Med Ctr, Lausanne, Switzerland; [Feihl, Francois] Univ Lausanne, Div Pathophysiol, Med Ctr, Lausanne, Switzerland		LeRoux, PD (corresponding author), Univ Penn, Med Ctr, Dept Neurosurg, Div Clin Res, 330 S 9th St, Philadelphia, PA 19107 USA.	peter.leroux@uphs.upenn.edu	Oddo, Mauro/R-3370-2016	Oddo, Mauro/0000-0002-6155-2525			Adamides AA, 2009, ACTA NEUROCHIR, V151, P1399, DOI 10.1007/s00701-009-0398-y; Bhatia A, 2007, INTENS CARE MED, V33, P1322, DOI 10.1007/s00134-007-0660-9; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS65; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Chang JJJ, 2009, CRIT CARE MED, V37, P283, DOI 10.1097/CCM.0b013e318192fbd7; Coles Jonathan P, 2004, Curr Opin Crit Care, V10, P120, DOI 10.1097/00075198-200404000-00008; Coles JP, 2004, BRAIN, V127, P2479, DOI 10.1093/brain/awh268; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Hemphill JC, 2005, PHYSIOL MEAS, V26, P373, DOI 10.1088/0967-3334/26/4/004; Hemphill JC, 2005, AM J NEURORADIOL, V26, P1095; Jaeger M, 2005, ACTA NEUROCHIR, V147, P51, DOI 10.1007/s00701-004-0408-z; Jaeger M, 2003, J NEUROL NEUROSUR PS, V74, P513, DOI 10.1136/jnnp.74.4.513; Jaeger M, 2006, CRIT CARE MED, V34, P1783, DOI 10.1097/01.CCM.0000218413.51546.9E; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Johnston AJ, 2004, INTENS CARE MED, V30, P791, DOI 10.1007/s00134-003-2155-7; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; LeRoux PD, 1997, J NEUROSURG, V87, P1, DOI 10.3171/jns.1997.87.1.0001; Limaye AP, 2008, JAMA-J AM MED ASSOC, V300, P413, DOI 10.1001/jama.300.4.413; Longhi L, 2007, INTENS CARE MED, V33, P2136, DOI 10.1007/s00134-007-0845-2; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maloney-Wilensky E, 2009, CRIT CARE MED, V37, P2057, DOI 10.1097/CCM.0b013e3181a009f8; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Martini RP, 2009, J NEUROSURG, V111, P644, DOI 10.3171/2009.2.JNS08998; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; Oddo M, 2009, J NEUROL NEUROSUR PS, V80, P916, DOI 10.1136/jnnp.2008.156596; Oddo M, 2010, NEUROSURGERY, V67, P338, DOI 10.1227/01.NEU.0000371979.48809.D9; Oddo M, 2009, STROKE, V40, P1275, DOI 10.1161/STROKEAHA.108.527911; ROBERTSON C, 2004, YOUMANS NEUROLOGICAL, P5103; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Schaller B, 2005, J TRAUMA, V59, P1521, DOI 10.1097/01.ta.0000197402.20180.6b; Scheufler KM, 2002, ANESTH ANALG, V95, P1042, DOI 10.1097/00000539-200210000-00046; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506; Stiefel MF, 2004, J NEUROSURG, V101, P241, DOI 10.3171/jns.2004.101.2.0241; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; Weiner GM, 2010, NEUROSURGERY, V66, P1111, DOI 10.1227/01.NEU.0000369607.71913.3E	49	83	87	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	NOV	2011	69	5					1037	1045		10.1227/NEU.0b013e3182287ca7			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	832UV	WOS:000295835300024	21673608				2022-02-06	
J	Thom, M; Liu, JY; Thompson, P; Phadke, R; Narkiewicz, M; Martinian, L; Marsdon, D; Koepp, M; Caboclo, L; Catarino, CB; Sisodiya, SM				Thom, Maria; Liu, Joan Y. W.; Thompson, Pam; Phadke, Rahul; Narkiewicz, Marta; Martinian, Lillian; Marsdon, Derek; Koepp, Matthias; Caboclo, Luis; Catarino, Claudia B.; Sisodiya, Sanjay M.			Neurofibrillary tangle pathology and Braak staging in chronic epilepsy in relation to traumatic brain injury and hippocampal sclerosis: a post-mortem study	BRAIN			English	Article						Braak stage; epilepsy; head trauma; hippocampal sclerosis	TEMPORAL-LOBE EPILEPSY; ALZHEIMERS-DISEASE; TDP-43 IMMUNOREACTIVITY; ILAE COMMISSION; DEMENTIA; TAU; CLASSIFICATION; DEGENERATION; SEIZURES; ENCEPHALOPATHY	The long-term pathological effects of chronic epilepsy on normal brain ageing are unknown. Previous clinical and epidemiological studies show progressive cognitive decline in subsets of patients and an increased prevalence of Alzheimer's disease in epilepsy. In a post-mortem series of 138 patients with long-term, mainly drug-resistant epilepsy, we carried out Braak staging for Alzheimer's disease neurofibrillary pathology using tau protein immunohistochemistry. The stages were compared with clinicopathological factors, including seizure history and presence of old traumatic brain injury. Overall, 31% of cases were Braak Stage 0, 36% Stage I/II, 31% Stage III/IV and 2% Stage V/VI. The mean age at death was 56.5 years and correlated with Braak stage (P < 0.001). Analysis of Braak stages within age groups showed a significant increase in mid-Braak stages (III/IV), in middle age (40-65 years) compared with data from an ageing non-epilepsy series (P < 0.01). There was no clear relationship between seizure type (generalized or complex partial), seizure frequency, age of onset and duration of epilepsy with Braak stage although higher Braak stages were noted with focal more than with generalized epilepsy syndromes (P < 0.01). In 30% of patients, there was pathological evidence of traumatic brain injury that was significantly associated with higher Braak stages (P < 0.001). Cerebrovascular disease present in 40.3% and cortical malformations in 11.3% were not significantly associated with Braak stage. Astrocytic-tau protein correlated with the presence of both traumatic brain injury (P < 0.01) and high Braak stage (P < 0.001). Hippocampal sclerosis, identified in 40% (bilateral in 48%), was not associated with higher Braak stages, but asymmetrical patterns of tau protein accumulation within the sclerotic hippocampus were noted. In over half of patients with cognitive decline, the Braak stage was low indicating causes other than Alzheimer's disease pathology. In summary, there is evidence of accelerated brain ageing in severe chronic epilepsy although progression to high Braak stages was infrequent. Traumatic brain injury, but not seizures, was associated with tau protein accumulation in this series. It is likely that Alzheimer's disease pathology is not the sole explanation for cognitive decline associated with epilepsy.	[Thom, Maria; Liu, Joan Y. W.; Thompson, Pam; Martinian, Lillian; Koepp, Matthias; Caboclo, Luis; Catarino, Claudia B.; Sisodiya, Sanjay M.] UCL, Inst Neurol, Dept Clin & Expt Epilepsy, London WC1N 3BG, England; [Thom, Maria; Liu, Joan Y. W.; Thompson, Pam; Phadke, Rahul; Narkiewicz, Marta; Martinian, Lillian; Marsdon, Derek; Koepp, Matthias; Caboclo, Luis; Catarino, Claudia B.; Sisodiya, Sanjay M.] Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England; [Thom, Maria; Phadke, Rahul; Narkiewicz, Marta; Martinian, Lillian; Marsdon, Derek] UCL, Inst Neurol, Div Neuropathol, London WC1N 3BG, England; [Thompson, Pam; Koepp, Matthias; Catarino, Claudia B.; Sisodiya, Sanjay M.] Natl Soc Epilepsy, Gerrards Cross SL9 0RJ, Bucks, England; [Koepp, Matthias; Caboclo, Luis; Catarino, Claudia B.; Sisodiya, Sanjay M.] UCL, Inst Neurol, Div Clin Neurol, London WC1N 3BG, England		Thom, M (corresponding author), UCL, Inst Neurol, Dept Clin & Expt Epilepsy, Queen Sq, London WC1N 3BG, England.	m.thom@ion.ucl.ac.uk	Catarino, Claudia Bacanhim/ABC-2316-2021; Caboclo, Luis Otavio S F/G-6880-2012; Catarino, Claudia B/AAD-5165-2021; Phadke, Rahul/U-6960-2019; Catarino, Claudia Bacanhim/A-7719-2010	Catarino, Claudia B/0000-0002-6528-7570; Catarino, Claudia Bacanhim/0000-0002-6528-7570; Liu, Joan/0000-0002-0777-5189	Department of Health's NIHR Biomedical Research CentresNational Institute for Health Research (NIHR); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [0600934]; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0600934] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600934] Funding Source: researchfish	This work was undertaken at UCLH/UCL, which received a proportion of funding from the Department of Health's NIHR Biomedical Research Centres funding scheme; the study was supported by the Medical Research Council (grant 0600934).	Alafuzoff I, 2008, BRAIN PATHOL, V18, P484, DOI 10.1111/j.1750-3639.2008.00147.x; Amador-Ortiz C, 2007, ANN NEUROL, V61, P435, DOI 10.1002/ana.21154; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; Ball M, 1997, NEUROBIOL AGING, V18, pS1, DOI 10.1016/s0197-4580(97)00057-2; Baxendale SA, 1998, EPILEPSIA, V39, P158, DOI 10.1111/j.1528-1157.1998.tb01353.x; Berg AT, 2010, EPILEPSIA, V51, P676, DOI 10.1111/j.1528-1167.2010.02522.x; Bernhardt BC, 2009, NEUROLOGY, V72, P1747, DOI 10.1212/01.wnl.0000345969.57574.f5; Blanc F, 2011, EPILEPSIA, V52, P10, DOI 10.1111/j.1528-1167.2010.02773.x; Blumcke I, 2007, ACTA NEUROPATHOL, V113, P235, DOI 10.1007/s00401-006-0187-0; Blumcke I, 2009, EPILEPSY BEHAV, V15, P34, DOI 10.1016/j.yebeh.2009.02.033; Bothwell M, 2000, CELL, V102, P271, DOI 10.1016/S0092-8674(00)00032-5; Braak H, 1997, NEUROBIOL AGING, V18, P351, DOI 10.1016/S0197-4580(97)00056-0; Braak H, 2006, ACTA NEUROPATHOL, V112, P389, DOI 10.1007/s00401-006-0127-z; Breteler MMB, 1995, AM J EPIDEMIOL, V142, P1300, DOI 10.1093/oxfordjournals.aje.a117597; Bruton C., 1988, NEUROPATHOLOGY TEMPO; Catarino CB, 2011, BRAIN, V134, P2982, DOI 10.1093/brain/awr129; Cormack F, 2005, NEUROIMAGE, V27, P635, DOI 10.1016/j.neuroimage.2005.05.023; CORSELLIS JAN, 1989, BRIT MED J, V298, P105, DOI 10.1136/bmj.298.6666.105; CORSELLIS JAN, 1959, J MENT SCI, V105, P714, DOI 10.1192/bjp.105.440.714; CORSELLIS JAN, 1957, BRAIN, V80, P193, DOI 10.1093/brain/80.2.193; DICKSON DW, 1994, ACTA NEUROPATHOL, V88, P212; Duvernoy HM., 2005, HUMAN HIPPOCAMPUS FU; Duyckaerts C, 1997, ACTA NEUROPATHOL, V93, P501, DOI 10.1007/s004010050645; Duyckaerts C, 2009, ACTA NEUROPATHOL, V118, P5, DOI 10.1007/s00401-009-0532-1; Engel J, 2006, EPILEPSIA, V47, P1558, DOI 10.1111/j.1528-1167.2006.00215.x; French JA, 2007, EPILEPSIA, V48, P3, DOI 10.1111/j.1528-1167.2007.00992.x; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Frost B, 2009, J BIOL CHEM, V284, P12845, DOI 10.1074/jbc.M808759200; Gaitatzis A, 2004, BRAIN, V127, P2427, DOI 10.1093/brain/awh267; Gaitatzis A, 2004, EPILEPSIA, V45, P1613, DOI 10.1111/j.0013-9580.2004.17504.x; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Gouras GK, 1997, ANN NEUROL, V41, P402, DOI 10.1002/ana.410410317; Helmstaedter C, 2009, BRAIN, V132, P2822, DOI 10.1093/brain/awp182; Hermann B, 2008, EPILEPSIA, V49, P731, DOI 10.1111/j.1528-1167.2007.01435.x; Hermann B, 2008, LANCET NEUROL, V7, P151, DOI 10.1016/S1474-4422(08)70018-8; Hermann Bruce, 2007, Epilepsy Curr, V7, P1, DOI 10.1111/j.1535-7511.2007.00151.x; Hermann BP, 2006, ANN NEUROL, V60, P80, DOI 10.1002/ana.20872; HOUSER CR, 1990, J NEUROSCI, V10, P267; Iqbal K, 2008, J CELL MOL MED, V12, P38, DOI 10.1111/j.1582-4934.2008.00225.x; Iqbal K, 2010, BIOCHEM SOC T, V38, P962, DOI 10.1042/BST0380962; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Keller SS, 2008, EPILEPSIA, V49, P741, DOI 10.1111/j.1528-1167.2007.01485.x; Keller SS, 2009, EPILEPSY BEHAV, V15, P186, DOI 10.1016/j.yebeh.2009.03.005; Kwan P, 2010, EPILEPSIA, V51, P1069, DOI 10.1111/j.1528-1167.2009.02397.x; Lace G, 2009, BRAIN, V132, P1324, DOI 10.1093/brain/awp059; Lee EB, 2008, ACTA NEUROPATHOL, V115, P305, DOI 10.1007/s00401-007-0331-5; Lim ACB, 2003, J ALZHEIMERS DIS, V5, P329, DOI 10.3233/JAD-2003-5409; Lin JJ, 2007, CEREB CORTEX, V17, P2007, DOI 10.1093/cercor/bhl109; MACKENZIE IRA, 1994, ACTA NEUROPATHOL, V87, P504; MARGERISON JH, 1966, BRAIN, V89, P499, DOI 10.1093/brain/89.3.499; Marques CM, 2007, EPILEPSY BEHAV, V10, P477, DOI 10.1016/j.yebeh.2007.02.002; Mattsson N, 2010, NEUROSCI RES, V66, P330, DOI 10.1016/j.neures.2009.11.012; McDonald CR, 2008, EPILEPSIA, V49, P794, DOI 10.1111/j.1528-1167.2008.01539.x; McIntosh AM, 2001, EPILEPSIA, V42, P1288, DOI 10.1046/j.1528-1157.2001.02001.x; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meencke H J, 1996, Epilepsy Res Suppl, V12, P335; Mendez M F, 1994, J Geriatr Psychiatry Neurol, V7, P230; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Oyegbile TO, 2004, NEUROLOGY, V62, P1736, DOI 10.1212/01.WNL.0000125186.04867.34; Palop JJ, 2009, ARCH NEUROL-CHICAGO, V66, P435, DOI 10.1001/archneurol.2009.15; Probst A, 2007, ACTA NEUROPATHOL, V114, P335, DOI 10.1007/s00401-007-0262-1; Riederer F, 2008, NEUROLOGY, V71, P419, DOI 10.1212/01.wnl.0000324264.96100.e0; Schultz C, 2004, NEUROBIOL AGING, V25, P397, DOI 10.1016/S0197-4580(03)00113-1; Sen A, 2006, J NEUROPATH EXP NEUR, V65, P55, DOI 10.1097/01.jnen.0000195940.48033.a2; Sen A, 2008, DEV NEUROSCI-BASEL, V30, P96, DOI 10.1159/000109855; Sen A, 2007, NEUROREPORT, V18, P511, DOI 10.1097/WNR.0b013e3280586879; Sen A, 2007, EPILEPSIA, V48, P1447, DOI 10.1111/j.1528-1167.2007.01107.x; Spencer S, 2008, LANCET NEUROL, V7, P525, DOI 10.1016/S1474-4422(08)70109-1; Tellez-Zenteno JF, 2005, EPILEPSIA, V46, P1955, DOI 10.1111/j.1528-1167.2005.00344.x; Thom M, 2005, BRAIN, V128, P1344, DOI 10.1093/brain/awh475; Thom M, 2009, NEUROLOGY, V73, P1033, DOI 10.1212/WNL.0b013e3181b99a07; Thom M, 2010, ANN NEUROL, V68, P424, DOI 10.1002/ana.22142; Thom M, 2010, EPILEPSIA, V51, P1801, DOI 10.1111/j.1528-1167.2010.02681.x; Wang JZ, 2008, PROG NEUROBIOL, V85, P148, DOI 10.1016/j.pneurobio.2008.03.002; Wieser HG, 2004, EPILEPSIA, V45, P32; Zarow C, 2008, CURR NEUROL NEUROSCI, V8, P363, DOI 10.1007/s11910-008-0057-3	76	83	86	0	13	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	OCT	2011	134		10				2969	2981		10.1093/brain/awr209			13	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	830TZ	WOS:000295681400016	21903728	hybrid, Green Submitted, Green Published			2022-02-06	
J	King, NS; Kirwilliam, S				King, Nigel S.; Kirwilliam, Simon			Permanent post-concussion symptoms after mild head injury	BRAIN INJURY			English	Article						Mild head injury; permanent post-concussion symptoms	RANDOMIZED CONTROLLED-TRIAL; ROUTINE FOLLOW-UP; BRAIN-INJURY; QUESTIONNAIRE; RECOVERY	Objective: A small minority of individuals experience long-term or permanent post-concussion symptoms (PCS) after a mild head injury (MHI). There has been no systematic, quantitative research examining a wide range of variables in a representative sample of such patients (i.e. with PCS for more than 18 months). This study explores a broad spectrum of demographic, cognitive, emotional and psychosocial factors (known to be important in the development of early PCS) in a representative sample of patients with permanent PCS. Method: One hundred consecutively referred patients to a Community Head Injury Service in Buckinghamshire, UK for the treatment of persistent PCS, at least 18 months post-MHI, were identified and invited to participate. An exploratory design evaluated a range of demographic, cognitive, emotional and psychosocial variables and their relationship to PCS severity and quality-of-life (QoL). Results: Twenty-four participants, with a mean time post-injury of 6.9 years, responded. They were characterized by: (i) older age compared to those typically presenting with MHI, (ii) very high levels of PCS, (iii) high post-injury unemployment, (iv) pre- or post-morbid factors which might exacerbate post-concussional difficulties, (v) elevated levels of anxiety and depression and (vi) mildly reduced scores on tests of short-term memory and speed of information processing. Post-hoc analysis of the total sample (n = 100) confirmed older age and a high proportion having pre- or post-morbid factors. QoL negatively correlated with PCS severity, and anxiety scores accounted for 45.9% of the variance in PCS severity. Conclusions: Very high levels of PCS, high post-injury unemployment and measurable cognitive deficits can be permanent features of MHI. Quality-of-life is directly related to symptom severity. Age, pre-/post-morbid concomitant factors, neuropsychological deficits and emotional status are key variables in understanding the phenomenon of permanent PCS. Important vulnerability factors in the development of such may therefore be older age and any additional compromise to an individual's emotional or cognitive capacities.	[King, Nigel S.] Camborne Ctr, Community Head Injury Serv, Aylesbury HP21 7ET, Bucks, England; [King, Nigel S.] Univ Oxford, Warneford Hosp, Oxford Doctoral Course Clin Psychol, Oxford, England; [Kirwilliam, Simon] Charing Cross Hosp, Clin Hlth Psychol & Neuropsychol Team, London, England		King, NS (corresponding author), Camborne Ctr, Community Head Injury Serv, Aylesbury HP21 7ET, Bucks, England.	nigel.king@hmc.ox.ac.uk					BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; GRONWALL D, 1975, LANCET, V2, P995; Jakola AS, 2007, ACTA NEUROL SCAND, V115, P398, DOI 10.1111/j.1600-0404.2007.00827.x; Jennett BFrankowskiR, 1990, HDB CLIN NEUROLOGY, V13, P1; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Weiss D, 1997, ASSESSING PSYCHOL TR, P399, DOI DOI 10.1037/T12199-000; World Health Organization, 1993, MNH7PSF939 WHO; World Health Organization, 2001, WHO INT CLASS FUNCT; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	26	83	83	0	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2011	25	5					462	470		10.3109/02699052.2011.558042			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	745KQ	WOS:000289164700004	21401372				2022-02-06	
J	Liesemer, K; Bratton, SL; Zebrack, CM; Brockmeyer, D; Statler, KD				Liesemer, Kate; Bratton, Susan L.; Zebrack, C. Michelle; Brockmeyer, Douglas; Statler, Kimberly D.			Early Post-Traumatic Seizures in Moderate to Severe Pediatric Traumatic Brain Injury: Rates, Risk Factors, and Clinical Features	JOURNAL OF NEUROTRAUMA			English	Article						CT scanning; epilepsy; pediatric brain injury; secondary insult	HEAD-INJURY; CHILDREN; PREDICTORS	We performed a retrospective, observational study at a level I pediatric trauma center of children with moderate-to-severe traumatic brain injury (TBI) from January 2002 to September 2006 to identify clinical and radiographic risk factors for early post-traumatic seizures (EPTS). Two hundred and ninety-nine children ages 0-15 years were evaluated, with 24 excluded because they died before the initial head computed tomography (CT) was obtained (n=20), or because their medical records were missing (n=4). Records were reviewed for accident characteristics, pre-hospital hypoxia or hypotension, initial non-contrast head CT characteristics, seizure occurrence, antiepileptic drug (AED) administration, and outcome. All care was at the discretion of the treating physicians, including the use of AEDs and continuous electroencephalogram (EEG) monitoring in patients receiving neuromuscular blocking agents. The primary outcome was seizure activity during the first 7 days as determined by clinician observation or EEG analysis. Of the 275 patients included in the study, 34 had identified EPTS (12%). Risk factors identified on bivariable analysis included pre-hospital hypoxia, young age, nonaccidental trauma (NAT), severe TBI, impact seizure, and subdural hemorrhage, while receiving an AED was protective. Independent risk factors identified by multivariable analysis were age <2 years (OR 3.0 [95% CI 1.0,8.6]), Glasgow Coma Scale (GCS) score <= 8 (OR 8.7 [95% CI 1.1,67.6]), and NAT as a mechanism of injury (OR 3.4 [95% CI 1.0,11.3]). AED treatment was protective against EPTS (OR 0.2 [95% CI 0.07,0.5]). Twenty-three (68%) patients developed EPTS within the first 12 h post-injury. This early peak in EPTS activity and demonstrated protective effect of AED administration in this cohort suggests that to evaluate the maximal potential benefit among patients at increased risk for EPTS, future research should be randomized and prospective, and should intervene during pre-trauma center care with initiation of continuous EEG monitoring as soon as possible.	[Liesemer, Kate; Bratton, Susan L.] Univ Utah, Sch Med, Salt Lake City, UT 84118 USA; [Liesemer, Kate; Bratton, Susan L.; Statler, Kimberly D.] Primary Childrens Med Ctr, Dept Pediat, Div Crit Care Med, Salt Lake City, UT 84118 USA; [Zebrack, C. Michelle] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; [Zebrack, C. Michelle] Lucile Packard Childrens Hosp, Div Cardiol & Cardiovasc Intens Care Med, Palo Alto, CA USA; [Brockmeyer, Douglas] Primary Childrens Med Ctr, Dept Pediat, Div Neurosurg, Salt Lake City, UT 84118 USA		Liesemer, K (corresponding author), Univ Utah, Sch Med, 295 Chipeta Way,POB 581289, Salt Lake City, UT 84118 USA.	Kate.Liesemer@utah.edu	Bratton, Susan L./O-2353-2013	Bratton, Susan L./0000-0002-4605-8078			Adelson P David, 2003, Pediatr Crit Care Med, V4, pS72; Barlow KM, 2000, DEV MED CHILD NEUROL, V42, P591, DOI 10.1017/S0012162200001110; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS83; Bruce D A, 1990, Curr Probl Pediatr, V20, P61; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Chiaretti A, 2000, CHILD NERV SYST, V16, P862, DOI 10.1007/s003810000368; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Faul M, 2010, TRAUMATIC BRAIN INJU; HAHN YS, 1988, NEUROSURGERY, V22, P864, DOI 10.1227/00006123-198805000-00008; Keenan HT, 2007, PEDIATRICS, V119, pE616, DOI 10.1542/peds.2006-2313; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; King JT, 2005, J NEUROTRAUM, V22, P947, DOI 10.1089/neu.2005.22.947; LEWIS RJ, 1993, ANN EMERG MED, V22, P1114, DOI 10.1016/S0196-0644(05)80974-6; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Ong LC, 1996, J PAEDIATR CHILD H, V32, P173, DOI 10.1111/j.1440-1754.1996.tb00917.x; Ratan SK, 1999, PEDIATR NEUROSURG, V30, P127, DOI 10.1159/000028779; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Young KD, 2004, ANN EMERG MED, V43, P435, DOI 10.1016/j.annemergmed.2003.09.016; Zebrack M, 2009, PEDIATRICS, V124, P56, DOI 10.1542/peds.2008-1006	21	83	91	1	12	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2011	28	5					755	762		10.1089/neu.2010.1518			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	762JI	WOS:000290472100276	21381863				2022-02-06	
J	Cooper, DB; Kennedy, JE; Cullen, MA; Critchfield, EN; Amador, RR; Bowles, AO				Cooper, Douglas B.; Kennedy, Jan E.; Cullen, Maren A.; Critchfield, Eda. N.; Amador, Ricardo R.; Bowles, Amy O.			Association between combat stress and post-concussive symptom reporting in OEF/OIF service members with mild traumatic brain injuries	BRAIN INJURY			English	Article						Mild traumatic brain injury; blast injury; post-traumatic stress disorder; post-concussion syndrome	POSTCONCUSSION SYNDROME; PSYCHOMETRIC PROPERTIES; PTSD CHECKLIST; BASE RATES; DISORDER; IRAQ; AFGHANISTAN; VETERANS; CRITERIA	Objective: The relationship between combat stress and post-concussive symptoms in service members with mild traumatic brain injuries (mTBI) is poorly understood. It was hypothesized that the co-occurrence of combat stress would have a significant effect on the severity of post-concussive complaints, specifically on emotional and cognitive symptoms. Methods: Four hundred and seventy-two combat-deployed service members with mTBI completed self-report inventories of post-traumatic stress and post-concussive symptoms. Two groups were formed based on post-traumatic stress symptoms (High Combat Stress and Low Combat Stress). Results: A 3-8-fold increase in post-concussive symptoms was observed when comparing the High and Low Combat Stress Groups. Elevations in post-concussive symptom reporting were not limited to emotional and/or cognitive symptoms, but rather were inclusive of all measured post-concussive symptoms. Conclusions: The findings of the present study suggest that non-brain injury-related factors, such as high-levels of combat stress, may impact post-concussive symptom reporting in this population, further confounding the accuracy of the post-concussion syndrome (PCS) diagnosis. Considerable caution should be exercised in making the diagnosis of PCS in concussed service members with co-occurring combat-stress disorders.	[Cooper, Douglas B.] Brooke Army Med Ctr, MCHE DOR TBI, Traumat Brain Injury Serv, Dept Orthoped & Rehabil, Ft Sam Houston, TX 78234 USA; [Kennedy, Jan E.; Cullen, Maren A.; Amador, Ricardo R.] Brooke Army Med Ctr, Def & Vet Brain Injury Ctr, Ft Sam Houston, TX 78234 USA		Cooper, DB (corresponding author), Brooke Army Med Ctr, MCHE DOR TBI, Traumat Brain Injury Serv, Dept Orthoped & Rehabil, 3851 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA.	douglas.cooper2@amedd.army.mil					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chemtob CM, 1998, J NERV MENT DIS, V186, P701, DOI 10.1097/00005053-199811000-00007; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; *DEF VET BRAIN INJ, 2008, OP IR FREED OIF OP E; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Hoffer ME, 2010, OTOL NEUROTOL, V31, P232, DOI 10.1097/MAO.0b013e3181c993c3; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Interian A, 2004, PSYCHOSOM MED, V66, P141, DOI 10.1097/01.PSY.0000107883.14385.EC; Keen SM, 2008, J REHABIL RES DEV, V45, P465, DOI 10.1682/JRRD.2007.09.0138; Lange RT, 2008, CLIN NEUROPSYCHOL, V22, P209, DOI 10.1080/13854040701290062; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; McCrea M., 2008, MILD TRAUMATIC BRAIN; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Powell GE, 2008, J NEUROL NEUROSUR PS, V79, P237, DOI 10.1136/jnnp.2007.131722; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; TABER KH, 2009, J NEUROPSYCH CLIN N, V21, pR4; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004	25	83	84	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2011	25	1					1	7		10.3109/02699052.2010.531692			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	731JI	WOS:000288101700001	21117916				2022-02-06	
J	Wade, SL; Cassedy, A; Walz, NC; Taylor, HG; Stancin, T; Yeates, KO				Wade, Shari L.; Cassedy, Amy; Walz, Nicolay C.; Taylor, H. Gerry; Stancin, Terry; Yeates, Keith Owen			The Relationship of Parental Warm Responsiveness and Negativity to Emerging Behavior Problems Following Traumatic Brain Injury in Young Children	DEVELOPMENTAL PSYCHOLOGY			English	Article						brain injury; parent-child interactions; externalizing behavior; responsiveness; negativity	CLOSED-HEAD-INJURY; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; EXTERNALIZING PROBLEMS; EARLY-CHILDHOOD; PSYCHIATRIC-DISORDERS; CONDUCT PROBLEMS; SHORT-TERM; PERSONALITY-CHANGE; OUTCOMES; ADOLESCENTS	Parenting behaviors play a critical role in the child's behavioral development, particularly for children with neurological deficits. This study examined the relationship of parental warm responsiveness and negativity to changes in behavior following traumatic brain injury (TBI) in young children relative to an age-matched cohort of children with orthopedic injuries (OI). It was hypothesized that responsive parenting would buffer the adverse effects of TBI on child behavior, whereas parental negativity would exacerbate these effects. Children, ages 3-7 years, hospitalized for TBI (n = 80) or 01(n = 113), were seen acutely and again 6 months later. Parent-child dyads were videotaped during free play. Parents completed behavior ratings (Child Behavior Checklist; T. M. Achenbach & L. A. Rescorla, 2001) at both visits, with baseline ratings reflecting preinjury behavior. Hypotheses were tested using multiple regression, with preinjury behavior ratings, race, income, child IQ, family functioning, and acute parental distress serving as covariates. Parental responsiveness and negativity had stronger associations with emerging externalizing behaviors and attention-deficit/hyperactivity disorder symptoms among children with severe TBI. Findings suggest that parenting quality may facilitate or impede behavioral recovery following early TBI. Interventions that increase positive parenting may partially ameliorate emerging behavior problems.	[Wade, Shari L.] Cincinnati Childrens Hosp, Med Ctr, Div Pediat Phys Med & Rehabil, Dept Pediat, Cincinnati, OH 45229 USA; [Wade, Shari L.; Cassedy, Amy; Walz, Nicolay C.] Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA; [Taylor, H. Gerry] Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry; Stancin, Terry] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Stancin, Terry] Metrohlth Med Ctr, Dept Pediat, Cleveland, OH USA; [Stancin, Terry] Metrohlth Med Ctr, Dept Psychiat, Cleveland, OH USA; [Yeates, Keith Owen] Nationwide Childrens Hosp, Dept Pediat, Columbus, OH USA; [Yeates, Keith Owen] Nationwide Childrens Hosp, Dept Psychol, Columbus, OH USA; [Yeates, Keith Owen] Nationwide Childrens Hosp, Dept Psychiat, Columbus, OH USA; [Yeates, Keith Owen] Ohio State Univ, Columbus, OH 43210 USA		Wade, SL (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Pediat Phys Med & Rehabil, Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org	Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Yeates, Keith/0000-0001-7680-2892	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR008084] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD042729] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR008084] Funding Source: NIH RePORTER		Achenbach T. M., 2001, MANUAL ASEBA SCH AGE; Ackerman BP, 2003, CHILD DEV, V74, P694, DOI 10.1111/1467-8624.00563; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; BAKEMAN R, 1980, CHILD DEV, V51, P437, DOI 10.2307/1129277; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Bradley RH, 2001, CHILD DEV, V72, P1868, DOI 10.1111/1467-8624.t01-1-00383; Bradley RH, 2007, DEV PSYCHOL, V43, P1390, DOI 10.1037/0012-1649.43.6.1390; Chronis AM, 2007, DEV PSYCHOL, V43, P70, DOI 10.1037/0012-1649.43.1.70; Davidov M, 2006, CHILD DEV, V77, P44, DOI 10.1111/j.1467-8624.2006.00855.x; Deater-Deckard K, 1998, DEV PSYCHOPATHOL, V10, P469, DOI 10.1017/S0954579498001709; Deater-Deckard K, 2006, PARENT-SCI PRACT, V6, P59, DOI 10.1207/s15327922par0601_3; Derogatis LR, 1982, BRIEF SYMPTOM INVENT; DODGE KA, 1994, CHILD DEV, V65, P649, DOI 10.1111/j.1467-8624.1994.tb00774.x; Eisenberg N, 2005, CHILD DEV, V76, P1055, DOI 10.1111/j.1467-8624.2005.00897.x; Elliott C. D., 1990, DIFFERENTIAL ABILITY; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; Eyberg S., 1988, CHILD FAMILY BEHAV T, V10, P33, DOI [10.1300/J019v10n01_04, DOI 10.1300/J019V10N01_04]; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Goldstrohm SL, 2005, ARCH CLIN NEUROPSYCH, V20, P675, DOI 10.1016/j.acn.2005.02.005; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Landry SH, 1997, DEV PSYCHOL, V33, P1040, DOI 10.1037/0012-1649.33.6.1040; Landry SH, 2006, DEV PSYCHOL, V42, P627, DOI 10.1037/0012-1649.42.4.627; Landry SH, 2002, DEV NEUROPSYCHOL, V21, P15, DOI 10.1207/S15326942DN2101_2; Landry SH, 2001, DEV PSYCHOL, V37, P387, DOI 10.1037//0012-1649.37.3.387; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1032, DOI 10.1097/01.chi.0000173293.05817.b1; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; MCCLELLAND GH, 1993, PSYCHOL BULL, V114, P376, DOI 10.1037/0033-2909.114.2.376; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Nowak C, 2008, CLIN CHILD FAM PSYCH, V11, P114, DOI 10.1007/s10567-008-0033-0; Patterson, 1982, SOCIAL LEARNING APPR, V3; ROTHBAUM F, 1994, PSYCHOL BULL, V116, P55, DOI 10.1037/0033-2909.116.1.55; Rubin KH, 2003, DEV PSYCHOL, V39, P164, DOI 10.1037//0012-1649.39.1.164; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Shaw DS, 1998, J ABNORM CHILD PSYCH, V26, P95, DOI 10.1023/A:1022665704584; Shaw DS, 2003, DEV PSYCHOL, V39, P189, DOI 10.1037/0012-1649.39.2.189; Statistical Solutions, 2001, SOLAS MISS DAT AN; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TAYLOR HG, 1997, J INT NEUROPSYCH SOC, V3, P1; TEASDALE G, 1974, LANCET, V2, P81; Vasa RA, 2002, J AM ACAD CHILD PSY, V41, P148, DOI 10.1097/00004583-200202000-00008; Verger K, 2000, BRAIN INJURY, V14, P495; Wade SL, 2008, REHABIL PSYCHOL, V53, P180, DOI 10.1037/0090-5550.53.2.180; Wade SL, 2003, J HEAD TRAUMA REHAB, V18, P164, DOI 10.1097/00001199-200303000-00007; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; Yeates KO, 2010, PEDIAT NEUROPSYCHOLO, P112; [No title captured]	63	83	83	1	30	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0012-1649	1939-0599		DEV PSYCHOL	Dev. Psychol.	JAN	2011	47	1					119	133		10.1037/a0021028			15	Psychology, Developmental	Social Science Citation Index (SSCI)	Psychology	710BS	WOS:000286486500012	21244154	Green Accepted			2022-02-06	
J	Casson, IR; Viano, DC; Powell, JW; Pellman, EJ				Casson, Ira R.; Viano, David C.; Powell, John W.; Pellman, Elliot J.			Twelve Years of National Football League Concussion Data	SPORTS HEALTH-A MULTIDISCIPLINARY APPROACH			English	Article						concussion; traumatic brain injury; injury epidemiology; sport injury prevention		Background: Concussion in the National Football League (NFL) remains an important issue. An initial description of the injury epidemiology involved 6 years from 1996 to 2001. Hypothesis: The increased attention to concussions may have resulted in team physicians being more conservative in treating players in recent years. Study Design: Two consecutive 6-year periods (1996-2001 and 2002-2007) were compared to determine changes in the circumstances associated with the injury, the patterns of signs and symptoms, and the players' time loss from participation in the NFL. Methods: During 2002-2007, concussions were recorded by NFL team physicians and athletic trainers using the same standardized reporting form used from 1996 to 2001. Player position, type of play, concussion signs and symptoms, loss of consciousness, and medical action taken were recorded. Results: There were 0.38 documented concussions per NFL game in 2002-2007-7.6% lower than the 0.42 in the earlier period (1996-2001). The injury rate was lower in quarterbacks and wide receivers but significantly higher in tight ends during the second 6 years. The most frequent symptoms were headaches and dizziness; the most common signs were problems with information processing and immediate recall. During 2002-2007, a significantly lower fraction of concussed players returned to the same game, and more were removed from play. Most concussed players (83.5%) returned to play in < 7 days; the percentage decreased to 57.4% with loss of consciousness. The number of players returning in < 7 days was 8% lower during 2002-2007 and 25% lower for those with loss of consciousness. Conclusion: The most recent 6 years of NFL concussion data show a remarkable similarity to the earlier period. However, there was a significant decrease in the percentage of players returning to the same game, and players were held out of play longer. Clinical Relevance: There was a more conservative management of concussion in NFL players from 2002 to 2007 even though the clinical signs and symptoms remained similar to the earlier 6-year period.	[Casson, Ira R.] Long Isl Jewish Med Ctr, Dept Neurol, New Hyde Pk, NY 11040 USA; [Casson, Ira R.] Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10461 USA; [Viano, David C.] ProBiomech LLC, 265 Warrington Rd, Bloomfield Hills, MI 48304 USA; [Powell, John W.] Michigan State Univ, Dept Kinesiol, Lansing, MI 48824 USA; [Powell, John W.] Michigan State Univ, Dept Radiol, Lansing, MI 48824 USA; [Pellman, Elliot J.] ProHLTH Care Assoc LLP, New York, NY 11042 USA; [Pellman, Elliot J.] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; [Pellman, Elliot J.] Mt Sinai Sch Med, Dept Orthoped, New York, NY 10029 USA		Viano, DC (corresponding author), ProBiomech LLC, 265 Warrington Rd, Bloomfield Hills, MI 48304 USA.	dviano@comcast.net			National Football League; NFL Charities; National Football League Players Association	The authors were members of the National Football League's Mild Traumatic Brain Injury Committee during the conduct of this research. Funding for the research was provided by the National Football League and NFL Charities, the latter of which is funded by the National Football League Players Association and the league. Their support and encouragement to conduct research on concussion are greatly appreciated.	Casson IR, 2008, NEUROL CLIN, V26, P217, DOI 10.1016/j.ncl.2007.11.005; Casson IR, 2008, NEUROSURGERY, V62, P204, DOI 10.1227/01.NEU.0000311079.65895.3E; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Pellman EJ, 2005, NEUROSURGERY, V56, P79, DOI 10.1227/01.NEU.0000150180.16552.8D; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman Elliot J, 2006, Neurosurg Focus, V21, pE12	7	83	84	0	13	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1941-7381	1941-0921		SPORTS HEALTH	Sports Health	NOV-DEC	2010	2	6					471	483		10.1177/1941738110383963			13	Sport Sciences	Emerging Sources Citation Index (ESCI)	Sport Sciences	V19RK	WOS:000214835900004	23015977	Green Published			2022-02-06	
J	Koike, MA; Green, KN; Blurton-Jones, M; LaFerla, FM				Koike, Maya A.; Green, Kim N.; Blurton-Jones, Mathew; LaFerla, Frank M.			Oligemic Hypoperfusion Differentially Affects Tau and Amyloid-beta	AMERICAN JOURNAL OF PATHOLOGY			English	Article							MIDDLE CEREBRAL-ARTERY; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; COGNITIVE DECLINE; VASCULAR-LESIONS; A-BETA; DEMENTIA; ISCHEMIA; RISK	Decreased blood flow to the brain in humans is associated with altered Alzheimer's disease (AD)-related pathology, although the underlying mechanisms by which hypoperfusion influences AD neuropathology remains unknown. To try to address this question, we developed an oligemic model of cerebral hypoperfusion in the 3xTg-AD mouse model of AD. We bilaterally and transiently occluded the common carotid artery and then examined the molecular and cellular pathways by which hypoperfusion influenced tau and amyloid-beta proteins. We report the novel finding that a single, mild, transient hypoperfusion insult acutely increases A beta levels by enhancing beta-secretase protein expression. In contrast, transient hypoperfusion markedly decreases total tau levels, coincident with activation of macroautophagy and ubiquitin-proteosome pathways. Furthermore, we find that oligemia results in a significant increase specifically in tau phosphorylated at serine(212) and threonine(214), a tau epitope associated with paired helical filaments in AD patients. Despite the mild and transient nature of this hypoperfusion injury, the pattern of decreased total tau, altered phosphorylated tau, and increased amyloid-beta persisted for several weeks postoligemia. Our study indicates that a single, mild, cerebral hypoperfusion event produces profound and long lasting effects on both tau and amyloid-beta. This finding may have implications for the pathogenesis of AD, as it indicates for the first time that total tau and amyloid-beta are differentially impacted by mild hypoperfusion. (Am J Pathol 2010, 177:300-310; DOI: 10.2353/ajpath.2010.090750)	[Koike, Maya A.; Green, Kim N.; Blurton-Jones, Mathew; LaFerla, Frank M.] Univ Calif Irvine, Inst Memory Impairments & Neurol Disorders, Dept Neurobiol & Behav, Irvine, CA 92697 USA		LaFerla, FM (corresponding author), Univ Calif Irvine, Inst Memory Impairments & Neurol Disorders, Dept Neurobiol & Behav, 3212 Biol Sci 3, Irvine, CA 92697 USA.	laferla@uci.edu		Blurton-Jones, Mathew/0000-0002-7770-7157	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG-021982, 1F31NS063650-01A1, AG-029378]; Southern California ARCS; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS063650] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K01AG029378, R01AG021982] Funding Source: NIH RePORTER	Supported in part by grants from the National Institute of Health AG-021982 to F.M.L. and National Institute of Health 1F31NS063650-01A1 and Southern California ARCS award to M.A.K., and National Institute of Health AG-029378 to M.B.J.	Anders A, 2001, FASEB J, V15, P1837, DOI 10.1096/fj.01-0007fje; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; CLINTON J, 1991, NEUROPATH APPL NEURO, V17, P69, DOI 10.1111/j.1365-2990.1991.tb00695.x; de Leon MJ, 2001, P NATL ACAD SCI USA, V98, P10966, DOI 10.1073/pnas.191044198; Gordon-Krajcer W, 2007, NEUROCHEM RES, V32, P729, DOI 10.1007/s11064-006-9199-3; Goulding JMR, 1999, J NEUROL NEUROSUR PS, V67, P654, DOI 10.1136/jnnp.67.5.654; Green KN, 2002, J PHYSIOL-LONDON, V541, P1013, DOI 10.1113/jphysiol.2002.017582; Green KN, 2001, J NEUROCHEM, V77, P953, DOI 10.1046/j.1471-4159.2001.00338.x; Hamano T, 2008, EUR J NEUROSCI, V27, P1119, DOI 10.1111/j.1460-9568.2008.06084.x; Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; Honig LS, 2003, ARCH NEUROL-CHICAGO, V60, P1707, DOI 10.1001/archneur.60.12.1707; Ikeda K, 2000, NEUROSCI LETT, V284, P187, DOI 10.1016/S0304-3940(00)01009-0; Jellinger KA, 2001, EUR J NEUROL, V8, P707, DOI 10.1046/j.1468-1331.2001.00322.x; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kalaria RN, 2003, INT PSYCHOGERIATR, V15, P47, DOI 10.1017/S1041610203008950; Kalaria RN, 2000, NEUROBIOL AGING, V21, P321, DOI 10.1016/S0197-4580(00)00125-1; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Ksiezak-Reding H, 2000, CELL MOTIL CYTOSKEL, V47, P236, DOI 10.1002/1097-0169(200011)47:3<236::AID-CM6>3.0.CO;2-K; Lee JH, 2000, ARCH NEUROL-CHICAGO, V57, P1474, DOI 10.1001/archneur.57.10.1474; Lee PH, 2006, NEUROCHEM RES, V31, P821, DOI 10.1007/s11064-006-9086-y; Li L, 2009, NEUROBIOL AGING, V30, P1091, DOI 10.1016/j.neurobiolaging.2007.10.011; LOEB C, 1992, STROKE, V23, P1225, DOI 10.1161/01.STR.23.9.1225; Makinen S, 2008, J CEREBR BLOOD F MET, V28, P263, DOI 10.1038/sj.jcbfm.9600529; Moroney JT, 1996, STROKE, V27, P1283, DOI 10.1161/01.STR.27.8.1283; Mosconi L, 2008, ANN NY ACAD SCI, V1147, P180, DOI 10.1196/annals.1427.007; Nihashi T, 2001, ACTA NEUROCHIR, V143, P287, DOI 10.1007/s007010170109; O'Rourke MF, 2007, J AM COLL CARDIOL, V50, P1, DOI 10.1016/j.jacc.2006.12.050; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Riekse RG, 2004, J AM GERIATR SOC, V52, P1442, DOI 10.1111/j.1532-5415.2004.52405.x; Schneider JA, 2007, ANN NEUROL, V62, P59, DOI 10.1002/ana.21142; Sun X, 2006, P NATL ACAD SCI USA, V103, P18727, DOI 10.1073/pnas.0606298103; TATEMICHI TK, 1994, NEUROLOGY, V44, P1885, DOI 10.1212/WNL.44.10.1885; Tesco G, 2007, NEURON, V54, P721, DOI 10.1016/j.neuron.2007.05.012; Tseng BP, 2008, NEUROBIOL AGING, V29, P1607, DOI 10.1016/j.neurobiolaging.2007.04.014; van Groen T, 2005, STROKE, V36, P1551, DOI 10.1161/01.STR.0000169933.88903.cf; Vermeer SE, 2003, NEW ENGL J MED, V348, P1215, DOI 10.1056/NEJMoa022066; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Webster CM, 2009, NEUROBIOL DIS, V33, P301, DOI 10.1016/j.nbd.2008.11.001; Wen Y, 2004, BRAIN RES, V1022, P30, DOI 10.1016/j.brainres.2004.05.106; Wen Y, 2007, BBA-MOL BASIS DIS, V1772, P473, DOI 10.1016/j.bbadis.2006.10.011; Zhang X, 2007, J BIOL CHEM, V282, P10873, DOI 10.1074/jbc.M608856200; Zheng-Fischhofer QY, 1998, EUR J BIOCHEM, V252, P542, DOI 10.1046/j.1432-1327.1998.2520542.x; ZHIYOU C, 2009, NEUROCHEM RES, V7, P1226	45	83	85	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUL	2010	177	1					300	310		10.2353/ajpath.2010.090750			11	Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Pathology	624GM	WOS:000279805100032	20472896	Green Published, Bronze			2022-02-06	
J	Schmidt, S; Kwee, LC; Allen, KD; Oddone, EZ				Schmidt, Silke; Kwee, Lydia Coulter; Allen, Kelli D.; Oddone, Eugene Z.			Association of ALS with head injury, cigarette smoking and APOE genotypes	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Case-control study; US veterans; Candidate gene; Gene-environment interaction; Neurodegeneration	AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON-DISEASE; TRAUMATIC BRAIN-INJURY; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; APOLIPOPROTEIN-E GENOTYPES; WESTERN WASHINGTON-STATE; GULF-WAR VETERANS; E EPSILON 4; ALZHEIMERS-DISEASE; PARKINSON-DISEASE	Objective: An increased risk of ALS has been reported for US veterans, but the cause is unknown. Since head injury and cigarette smoking are two previously implicated environmental risk factors that are more common in military than civilian study populations, we tested their association with ALS in a US veteran study population. Methods: We used logistic regression to examine the association of ALS with head injury and cigarette smoking in 241 incident cases and 597 controls. Since APOE is a plausible ALS candidate gene, we also tested its main effect and its statistical interaction with these environmental exposures. Results: Cigarette smoking was not associated with ALS in this predominantly male and Caucasian population. Veterans who had experienced head injuries during the last 15 years before the reference date had an adjusted odds ratio of 2.33 (95% confidence interval 1.18-4.61), relative to veterans without any head injuries. This association was strongest in APOE-4 carriers. Conclusions: Our results add to the body of evidence suggesting that head injuries may be a risk factor for multiple neurodegenerative diseases, including ALS. We hypothesize that the strength of association between head injuries and ALS may depend upon APOE genotype. (C) 2010 Elsevier B.V. All rights reserved.	[Schmidt, Silke; Kwee, Lydia Coulter] Duke Univ, Med Ctr, Dept Med, Ctr Human Genet, Durham, NC 27710 USA; [Schmidt, Silke; Kwee, Lydia Coulter; Allen, Kelli D.; Oddone, Eugene Z.] Durham VAMC, Epidemiol Res & Informat Ctr, Durham, NC 27705 USA; [Schmidt, Silke; Kwee, Lydia Coulter; Allen, Kelli D.; Oddone, Eugene Z.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA		Schmidt, S (corresponding author), Duke Univ, Med Ctr, Dept Med, Ctr Human Genet, Box 3445, Durham, NC 27710 USA.	silke.schmidt@duke.edu			National Institutes of Health/National Institute of Environmental Health SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01 ES 013244]; ALS Association [ALSA 1230]; Department of Veterans AffairsUS Department of Veterans Affairs [CSP 500A, CSP 478]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01ES013244] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health/National Institute of Environmental Health Sciences [R01 ES 013244] and the ALS Association [ALSA 1230]. The National Registry of Veterans with ALS and its DNA bank were supported by the Office of Research and Development, Cooperative Studies Program, Department of Veterans Affairs [CSP #500A and CSP #478].	AlChalabi A, 1996, LANCET, V347, P159, DOI 10.1016/S0140-6736(96)90343-8; Allen KD, 2008, NEUROEPIDEMIOLOGY, V30, P180, DOI 10.1159/000126910; ARMON C, 1991, NEUROLOGY, V41, P1077, DOI 10.1212/WNL.41.7.1077; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Belli S, 2005, EUR J EPIDEMIOL, V20, P237, DOI 10.1007/s10654-004-6879-7; Bennet AM, 2007, JAMA-J AM MED ASSOC, V298, P1300, DOI 10.1001/jama.298.11.1300; BINAZZI A, 2008, AMYOTROPH LATERAL SC, V16, P1; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; BROOKS BR, 1994, J NEUROL SCI, V124, P96, DOI 10.1016/0022-510X(94)90191-0; CAMPBELL AM, 1970, J NEUROL NEUROSUR PS, V33, P877, DOI 10.1136/jnnp.33.6.877; Cedarbaum JM, 1999, J NEUROL SCI, V169, P13, DOI 10.1016/S0022-510X(99)00210-5; CHANCELLOR AM, 1993, J NEUROL NEUROSUR PS, V56, P1200, DOI 10.1136/jnnp.56.11.1200; Chen HL, 2003, ARCH NEUROL-CHICAGO, V60, P1059, DOI 10.1001/archneur.60.8.1059; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; Chio A, 2005, BRAIN, V128, P472, DOI 10.1093/brain/awh373; Chio A, 2002, NEUROLOGY, V59, P99, DOI 10.1212/WNL.59.1.99; Chio A, 2008, J NEUROL SCI, V269, P187, DOI 10.1016/j.jns.2007.10.005; CORDELL HJ, 2009, NAT REV GENET   0512; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Crawford F, 2009, NEUROSCIENCE, V159, P1349, DOI 10.1016/j.neuroscience.2009.01.033; DEAPEN DM, 1986, AM J EPIDEMIOL, V123, P790, DOI 10.1093/oxfordjournals.aje.a114308; del Aguila MA, 2003, NEUROLOGY, V60, P813, DOI 10.1212/01.WNL.0000049472.47709.3B; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; FELMUS MT, 1976, NEUROLOGY, V26, P167, DOI 10.1212/WNL.26.2.167; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Frantseva M, 2002, PROG BRAIN RES, V137, P171; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; GRESHAM L S, 1986, Neuroepidemiology, V5, P29, DOI 10.1159/000110810; Haasdijk ED, 2002, NEUROSCI LETT, V335, P29, DOI 10.1016/S0304-3940(02)01159-X; Haley RW, 2003, NEUROLOGY, V61, P750, DOI 10.1212/WNL.61.6.750; Horner RD, 2003, NEUROLOGY, V61, P742, DOI 10.1212/01.WNL.0000069922.32557.CA; Kamel F, 1999, NEUROEPIDEMIOLOGY, V18, P194, DOI 10.1159/000026211; Kamel F, 2002, EPIDEMIOLOGY, V13, P311, DOI 10.1097/00001648-200205000-00012; Kamel F, 2008, ENVIRON HEALTH PERSP, V116, P943, DOI 10.1289/ehp.11193; Katzman R, 1996, NEUROLOGY, V46, P889; KONDO K, 1981, ARCH NEUROL-CHICAGO, V38, P220, DOI 10.1001/archneur.1981.00510040046007; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Lemeshow S, 2000, APPL LOGISTIC REGRES; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Li YJ, 2004, NEUROGENETICS, V5, P209, DOI 10.1007/s10048-004-0193-0; Li YJ, 2004, NEUROLOGY, V62, P2005, DOI 10.1212/01.WNL.0000128089.53030.AC; Longstreth WT, 1998, ARCH NEUROL-CHICAGO, V55, P201, DOI 10.1001/archneur.55.2.201; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McCulloch CC, 2008, HUM GENET, V123, P257, DOI 10.1007/s00439-008-0466-z; McGuire V, 1996, NEUROLOGY, V47, P571, DOI 10.1212/WNL.47.2.571; McGuire V, 1997, AM J EPIDEMIOL, V145, P1076, DOI 10.1093/oxfordjournals.aje.a009070; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Migliore L, 2009, MUTAT RES-FUND MOL M, V667, P82, DOI 10.1016/j.mrfmmm.2008.10.011; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; Morton LM, 2006, AM J EPIDEMIOL, V163, P197, DOI 10.1093/aje/kwj036; MOULARD B, 1996, J NEUROL SCI S   AUG, P34; Nelson LM, 2000, AM J EPIDEMIOL, V151, P156, DOI 10.1093/oxfordjournals.aje.a010183; O'Toole O, 2008, J NEUROL NEUROSUR PS, V79, P30, DOI 10.1136/jnnp.2007.117788; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; PIERCERUHLAND R, 1981, ANN CLIN RES, V13, P102; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Popat RA, 2007, AMYOTROPH LATERAL SC, V8, P157, DOI 10.1080/17482960601179456; Ryan MAK, 2007, J CLIN EPIDEMIOL, V60, P181, DOI 10.1016/j.jclinepi.2006.05.009; SAVETTIERI G, 1991, NEUROEPIDEMIOLOGY, V10, P242, DOI 10.1159/000110279; Scarmeas N, 2002, NEUROLOGY, V59, P773, DOI 10.1212/WNL.59.5.773; Schmidt S, 2008, NEUROEPIDEMIOLOGY, V30, P191, DOI 10.1159/000126911; Smith RG, 1996, LANCET, V348, P334, DOI 10.1016/S0140-6736(05)64502-3; Song YQ, 2004, ANN INTERN MED, V141, P137, DOI 10.7326/0003-4819-141-2-200407200-00013; Sorenson EJ, 2002, NEUROLOGY, V59, P280, DOI 10.1212/WNL.59.2.280; Tartaglia MC, 2007, ARCH NEUROL-CHICAGO, V64, P232, DOI 10.1001/archneur.64.2.232; Traynor BJ, 1999, NEUROLOGY, V52, P504, DOI 10.1212/WNL.52.3.504; van Es MA, 2009, NAT GENET, V41, P1083, DOI 10.1038/ng.442; Wahner AD, 2007, NEUROLOGY, V69, P1836, DOI 10.1212/01.wnl.0000279519.99344.ad; Weisskopf MG, 2004, AM J EPIDEMIOL, V160, P26, DOI 10.1093/aje/kwh179; Weisskopf MG, 2005, NEUROLOGY, V64, P32, DOI 10.1212/01.WNL.0000148649.17706.D9; Zoccolella S, 2008, J NEUROL NEUROSUR PS, V79, P33, DOI 10.1136/jnnp.2007.118018	71	83	83	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	APR 15	2010	291	1-2					22	29		10.1016/j.jns.2010.01.011			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	582UG	WOS:000276624200005	20129626	Green Accepted			2022-02-06	
J	Hartikainen, KM; Waljas, M; Isoviita, T; Dastidar, P; Liimatainen, S; Solbakk, AK; Ogawa, KH; Soimakallio, S; Ylinen, A; Ohman, J				Hartikainen, Kaisa M.; Waljas, Minna; Isoviita, Tuulia; Dastidar, Prasun; Liimatainen, Suvi; Solbakk, Anne-Kristin; Ogawa, Keith H.; Soimakallio, Seppo; Ylinen, Aarne; Ohman, Juha			Persistent symptoms in mild to moderate traumatic brain injury associated with executive dysfunction	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Executive function; Mild traumatic brain injury; Postconcussion syndrome; Head injury; Diffusion tensor imaging; Neuropsychological assessment; Frontal lobes; Mesencephalon; Cognitive performance; Reaction time	ATTENTION; STIMULI; SEVERITY; LESIONS; MEMORY	In order to improve detection of subtle cognitive dysfunction and to shed light on the etiology of persistent symptoms after mild-to-moderate traumatic brain injury (TBI), we employed an experimental executive reaction time (RT) test, standardized neuropsychological tests, and diffusion tensor imaging (DTI). The Executive RT-Test, an Executive Composite Score from standardized neuropsychological tests, and DTI-indices in the midbrain differentiated between patients with persistent symptoms from those fully recovered after mild-to-moderate TBI. We suggest that persistent symptoms in mild-to-moderate TBI may reflect disrupted fronto-striatal network involved in executive functioning, and the Executive RT-Test provides an objective and novel method to detect it.	[Hartikainen, Kaisa M.; Liimatainen, Suvi] Tampere Univ Hosp, Dept Neurol, Tampere 33521, Finland; [Hartikainen, Kaisa M.; Isoviita, Tuulia] Tampere Univ, Fac Med, Dept Physiol, FIN-33101 Tampere, Finland; [Waljas, Minna; Ohman, Juha] Tampere Univ Hosp, Dept Neurosurg, Tampere 33521, Finland; [Dastidar, Prasun; Soimakallio, Seppo] Tampere Univ Hosp, Dept Radiol, Tampere 33521, Finland; [Solbakk, Anne-Kristin] Univ Oslo, Rikshosp, Div Clin Neurosci, Oslo Univ Hosp,Dept Neuropsychiat & Psychosomat M, N-0027 Oslo, Norway; [Ogawa, Keith H.] St Marys Coll Calif, John Magaddino Neurosci Lab, Moraga, CA USA; [Ylinen, Aarne] Finnish Assoc People Phys Disabil, Kapyla Rehabilitat Ctr Synapsia, Helsinki, Finland		Hartikainen, KM (corresponding author), Tampere Univ Hosp, Dept Neurol, BO 2000, Tampere 33521, Finland.	kaisa.hartikainen@pshp.fi		Hartikainen, Kaisa/0000-0001-7278-9635; Ohman, Juha/0000-0002-6592-1367			Adair JC, 1996, NEUROLOGY, V46, P842; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; Brown G.K., 1996, BDI 2 BECK DEPRESSIO; *CANTAB, 2004, CAMBR NEUR AUT TEST; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; Fan J, 2005, NEUROIMAGE, V26, P471, DOI 10.1016/j.neuroimage.2005.02.004; GOLDBERG E, 1989, CORTEX, V25, P687, DOI 10.1016/S0010-9452(89)80029-2; Hanna-Pladdy B, 2007, J Neurol Phys Ther, V31, P119; Hartikainen K., 2003, DETECTION CHANGE EVE, P99, DOI DOI 10.1007/978-1-4615-0294-4; Hartikainen KA, 2001, BRAIN COGNITION, V47, P339; Hartikainen KM, 2007, NEUROREPORT, V18, P1929, DOI 10.1097/WNR.0b013e3282f1ca18; Hartikainen KM, 2000, NEUROPSYCHOLOGIA, V38, P1576, DOI 10.1016/S0028-3932(00)00072-5; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; McCullagh S, 2003, J NEUROL NEUROSUR PS, V74, P39, DOI 10.1136/jnnp.74.1.39; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Morrow LA, 2002, CLIN NEUROPSYCHOL, V16, P373, DOI 10.1076/clin.16.3.373.13850; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Picton TW, 2007, CEREB CORTEX, V17, P826, DOI 10.1093/cercor/bhk031; Posner MI, 1998, ATTENTIVE BRAIN, P401; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Rosen HJ, 2002, NEUROLOGY, V58, P1608, DOI 10.1212/WNL.58.11.1608; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; SCHNIDER A, 1999, SCI PRACT NEUROPSYCH, P487; Smith EE, 1999, SCIENCE, V283, P1657, DOI 10.1126/science.283.5408.1657; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; SOLBAKK AK, 2001, THESIS U OSLO OSLO; SOLBAKK AK, 2000, J CLIN EXPT NEUROPSY, V22, P1; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Tsanadis J, 2008, CLIN NEUROPSYCHOL, V22, P1080, DOI 10.1080/13854040701796928; Turner C, 2004, ACCIDENT ANAL PREV, V36, P93, DOI 10.1016/S0001-4575(02)00131-8; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vuilleumier P, 2001, NEUROREPORT, V12, P1119, DOI 10.1097/00001756-200105080-00014; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54	50	83	83	0	19	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2010	32	7					767	774	PII 919572123	10.1080/13803390903521000			8	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	631WB	WOS:000280380200010	20198531				2022-02-06	
J	Chastain, CA; Oyoyo, UE; Zipperman, M; Joo, E; Ashwal, S; Shutter, LA; Tong, KA				Chastain, Cody A.; Oyoyo, Udochukwu E.; Zipperman, Michelle; Joo, Elliot; Ashwal, Stephen; Shutter, Lori A.; Tong, Karen A.			Predicting Outcomes of Traumatic Brain Injury by Imaging Modality and Injury Distribution	JOURNAL OF NEUROTRAUMA			English	Article						brain regions; CT; FLAIR; MRI; outcomes; SWI; TBI; T2	DIFFUSE AXONAL INJURY; WHITE-MATTER INJURY; CLOSED-HEAD INJURY; STEM LESIONS; CLINICAL-APPLICATIONS; COMPUTED-TOMOGRAPHY; MR; CT; VENOGRAPHY; CLASSIFICATION	Early prediction of outcomes after traumatic brain injury (TBI) is often difficult. To improve prognostic accuracy soon after trauma, we compared different radiological modalities and anatomical injury distribution in a group of adult TBI patients. The four methods studied were computed tomography (CT), magnetic resonance imaging (MRI) with T2-weighted imaging (T2WI), fluid-attenuated inversion recovery (FLAIR) imaging, and susceptibility weighted imaging (SWI). The objective of this study was to identify which modality and anatomic model best predict outcome. The patient population consisted of 38 adults admitted between February 2001 and May 2003. Early CT, T2WI, FLAIR, and SWI were obtained for each patient as well as a Glasgow Outcome Score (GOS) between 0.1 and 22 months (mean 9.2 months) after injury. Using a semi-automated computer method, intraparenchymal lesions were traced, measured, and converted to lesion volumes based on slice thickness and pixel size. Lesions were assigned to zones and regions. Outcomes were dichotomized into good (GOS 4-5) and poor (GOS 1-3) outcome groups. Brain injury detected by imaging was analyzed by median total lesion volume, median volume per lesion, and median number of lesions per outcome group. T2WI and FLAIR imaging most consistently discriminated between good and poor outcomes by median total lesion volume, median volume per lesion, and median number of lesions. In addition, T2WI and FLAIR imaging most consistently discriminated between good and poor outcomes by zonal distribution. While SWI rarely discriminated by outcome, it was very sensitive to intraparenchymal injury and its optimal use in evaluating TBI is unclear. SWI and other new imaging modalities should be further studied to fully evaluate their prognostic utility in TBI evaluation.	[Oyoyo, Udochukwu E.; Tong, Karen A.] Loma Linda Univ, Med Ctr, Dept Radiol, Div Neuroradiol, Loma Linda, CA 92354 USA; [Joo, Elliot] Loma Linda Univ, Med Ctr, Dept Med, Loma Linda, CA 92354 USA; [Chastain, Cody A.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; [Zipperman, Michelle] Univ So Calif, Keck Sch Med, Dept Radiol, Los Angeles, CA 90033 USA; [Ashwal, Stephen] Loma Linda Univ, Childrens Hosp, Div Child Neurol, Dept Pediat, Loma Linda, CA 92354 USA; [Shutter, Lori A.] Univ Cincinnati, Dept Neurosurg, Cincinnati, OH USA; [Shutter, Lori A.] Univ Cincinnati, Dept Neurol, Cincinnati, OH USA		Tong, KA (corresponding author), Loma Linda Univ, Med Ctr, Dept Radiol, Div Neuroradiol, 11234 Anderson St, Loma Linda, CA 92354 USA.	ktong@.llu.edu	Shutter, Lori A/G-2957-2013	Shutter, Lori/0000-0002-1390-0628			Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Bhatoe HS, 1999, ACTA NEUROCHIR, V141, P515, DOI 10.1007/s007010050333; CHO ZH, 1992, MAGNET RESON MED, V28, P25, DOI 10.1002/mrm.1910280104; de la Plata CM, 2007, J NEUROTRAUM, V24, P591, DOI 10.1089/neu.2006.0214; Eder HG, 2000, CHILD NERV SYST, V16, P21, DOI 10.1007/s003810050005; Firsching R, 2002, NEUROL RES, V24, P145, DOI 10.1179/016164102101199684; Firsching R, 2001, ACTA NEUROCHIR, V143, P263; Gerber DJ, 2004, BRAIN INJURY, V18, P1083, DOI 10.1080/02699050410001672341; HASHIMOTO T, 1993, NEUROSURG REV, V16, P291, DOI 10.1007/BF00383839; Hoelper BM, 2000, ACTA NEUROCHIR SUPPL, V76, P21; Hou DJ, 2007, J NEUROTRAUM, V24, P1558, DOI 10.1089/neu.2007.0339; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; JENNETT B, 1975, LANCET, V1, P480; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; KIDO DK, 1992, RADIOLOGY, V182, P777, DOI 10.1148/radiology.182.3.1535893; King JT, 2005, J NEUROTRAUM, V22, P947, DOI 10.1089/neu.2005.22.947; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Langlois J. A., 2006, TRAUMATIC BRAIN INJU, P1; Lee BCP, 1999, AM J NEURORADIOL, V20, P1239; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Ogawa T, 1992, Acta Neurochir Suppl (Wien), V55, P8; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Scheid R, 2007, J NEUROTRAUM, V24, P1811, DOI 10.1089/neu.2007.0382; Sehgal V, 2005, J MAGN RESON IMAGING, V22, P439, DOI 10.1002/jmri.20404; Shen YM, 2007, MAGN RESON IMAGING, V25, P219, DOI 10.1016/j.mri.2006.09.018; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sigmund GA, 2007, PEDIATR NEUROL, V36, P217, DOI 10.1016/j.pediatrneurol.2007.01.003; Tong KA, 2008, AM J NEURORADIOL, V29, P9, DOI 10.3174/ajnr.A0786; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; TSAI FY, 1980, J COMPUT ASSIST TOMO, V4, P291, DOI 10.1097/00004728-198006000-00002; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; Wedekind C, 2002, BRIT J NEUROSURG, V16, P256, DOI 10.1080/02688690220148842; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208	46	83	89	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2009	26	8					1183	1196		10.1089/neu.2008.0650			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	479AF	WOS:000268629900002	19317591				2022-02-06	
J	Sakowitz, OW; Kiening, KL; Krajewski, KL; Sarrafzadeh, AS; Fabricius, M; Strong, AJ; Unterberg, AW; Dreier, JP				Sakowitz, Oliver W.; Kiening, Karl L.; Krajewski, Kara L.; Sarrafzadeh, Asita S.; Fabricius, Martin; Strong, Anthony J.; Unterberg, Andreas W.; Dreier, Jens P.			Preliminary Evidence That Ketamine Inhibits Spreading Depolarizations in Acute Human Brain Injury	STROKE			English	Article						electrocorticography; intracerebral hemorrhage; NMDA receptor antagonists; spreading depression; traumatic brain injury	DEPRESSION; RAT	Background and Purpose-Spreading depolarizations, characterized by large propagating, slow potential changes, have been demonstrated with electrocorticography in patients with cerebral hemorrhage and ischemic stroke. Whereas spreading depolarizations are harmless under normal conditions in animals, they cause or augment damage in the ischemic brain. A fraction of spreading depolarizations is abolished by N-methyl-D-aspartate receptor antagonists. Summary of Case-In 2 patients with severe acute brain injury (traumatic and spontaneous intracranial hemorrhage), spreading depolarizations were inhibited by the noncompetitive N-methyl-D-aspartate receptor antagonist ketamine. This restored electrocorticographic activity. Conclusions-These anecdotal electrocorticographic findings suggest that ketamine has an inhibitory effect on spreading depolarizations in humans. This is of potential interest for future neuroprotective trials. (Stroke. 2009; 40: e519-e522.)	[Sakowitz, Oliver W.; Kiening, Karl L.; Krajewski, Kara L.; Unterberg, Andreas W.] Univ Heidelberg, Dept Neurosurg, D-69120 Heidelberg, Germany; [Sarrafzadeh, Asita S.] Charite Univ Med Berlin, Dept Neurosurg, D-13353 Berlin, Germany; [Fabricius, Martin] Univ Copenhagen, Glostrup Hosp, Dept Clin Neurophysiol, Copenhagen, Denmark; [Strong, Anthony J.] Kings Coll London, Dept Clin Neurosci, London WC2R 2LS, England; [Dreier, Jens P.] Charite Univ Med Berlin, Dept Neurol, D-13353 Berlin, Germany; [Dreier, Jens P.] Charite Univ Med Berlin, Ctr Stroke Res, D-13353 Berlin, Germany		Sakowitz, OW (corresponding author), Univ Heidelberg, Dept Neurosurg, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	oliver.sakowitz@med.uni-heidelberg.de	Krajewski, Kara/ABH-2587-2020	Sakowitz, Oliver/0000-0003-3248-6335; Dreier, Jens/0000-0001-7459-2828	"ZNS-Hannelore Kohl Stiftung" [2004006]; Wilhelm Sander Foundation [2002.028.1]; Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [SFB-507A1, DFG DR 323/3-1, 323/5-1]; BMBF Berlin Neuroimaging CenterFederal Ministry of Education & Research (BMBF) [01GI9902/4]; Center for Stroke Research [01 EO 0801]; Kompetenznetz Schlaganfall	O.W.S. received grant support through "ZNS-Hannelore Kohl Stiftung" (#2004006) and the Medical Faculty of the University of Heidelberg ("Young Investigator Award"). J.P.D. was supported by the Wilhelm Sander Foundation (2002.028.1), Deutsche Forschungsgemeinschaft (SFB-507A1, DFG DR 323/3-1, 323/5-1), BMBF Berlin Neuroimaging Center (01GI9902/4)/Center for Stroke Research (01 EO 0801), and Kompetenznetz Schlaganfall.	Dohmen C, 2008, ANN NEUROL, V63, P720, DOI 10.1002/ana.21390; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; HERNANDEZCACERES J, 1987, BRAIN RES, V437, P360, DOI 10.1016/0006-8993(87)91652-0; Himmelseher S, 2005, ANESTH ANALG, V101, P524, DOI 10.1213/01.ANE.0000160585.43587.5B; IIJIMA T, 1992, J CEREBR BLOOD F MET, V12, P727, DOI 10.1038/jcbfm.1992.103; Kaube H, 2000, NEUROLOGY, V55, P139, DOI 10.1212/WNL.55.1.139; LEAO AAP, 1947, J NEUROPHYSIOL, V10, P409, DOI 10.1152/jn.1947.10.6.409; MARRANNES R, 1988, BRAIN RES, V457, P226, DOI 10.1016/0006-8993(88)90690-7; NEDERGAARD M, 1993, J CEREBR BLOOD F MET, V13, P568, DOI 10.1038/jcbfm.1993.74; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09	10	83	85	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	AUG	2009	40	8					E519	E522		10.1161/STROKEAHA.109.549303			4	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	475UN	WOS:000268387000049	19520992	Bronze			2022-02-06	
J	Gubern, C; Hurtado, O; Rodriguez, R; Morales, JR; Romera, VG; Moro, MA; Lizasoain, I; Serena, J; Mallolas, J				Gubern, Carme; Hurtado, Olivia; Rodriguez, Rocio; Morales, Jesus R.; Romera, Victor G.; Moro, Maria A.; Lizasoain, Ignacio; Serena, Joaquin; Mallolas, Judith			Validation of housekeeping genes for quantitative real-time PCR in in-vivo and in-vitro models of cerebral ischaemia	BMC MOLECULAR BIOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; RT-PCR; EXPERIMENTAL STROKE; ARTERY OCCLUSION; DISEASE-MODELS; ANIMAL-MODEL; RAT-BRAIN; EXPRESSION; NORMALIZATION; NEUROPROTECTION	Background: Studies of gene expression in experimental cerebral ischaemia models can contribute to understanding the pathophysiology of brain ischaemia and to identifying prognostic markers and potential therapeutic targets. The normalization of relative qRT-PCR data using a suitable reference gene is a crucial prerequisite for obtaining reliable conclusions. No validated housekeeping genes have been reported for the relative quantification of the mRNA expression profile activated in in-vitro ischaemic conditions, whereas for the in-vivo model different reference genes have been used. The present study aims to determine the expression stability of ten housekeeping genes (Gapdh, beta 2m, Hprt, Ppia, Rpl13a, Oaz1, 18S rRNA, Gusb, Ywhaz and Sdha) to establish their suitability as control genes for in-vitro and in-vivo cerebral ischaemia models. Results: The expression stability of the candidate reference genes was evaluated using the 2(-Delta CT) method and ANOVA followed by Dunnett's test. For the in-vitro model using primary cultures of rat astrocytes, all genes analysed except for Rpl13a and Sdha were found to have significantly different levels of mRNA expression. These different levels were also found in the case of the in-vivo model of pMCAO in rats except for Hprt, Sdha and Ywhaz mRNA, where the expression did not vary. Sdha and Ywhaz were identified by geNorm and NormFinder as the two most stable genes. Conclusion: We have validated endogenous control genes for qRT-PCR analysis of gene expression in in-vitro and in-vivo cerebral ischaemia models. For normalization purposes, Rpl13a and Sdha are found to be the most suitable genes for the in-vitro model and Sdha and Ywhaz for the in-vivo model. Genes previously used as housekeeping genes for the in-vivo model in the literature were not validated as good control genes in the present study, showing the need for careful evaluation for each new experimental setup.	[Gubern, Carme; Rodriguez, Rocio; Romera, Victor G.; Serena, Joaquin; Mallolas, Judith] Hosp Girona Dr Josep Trueta, Fundacio Privada, Inst Invest Biomed Girona Dr Josep Trueta IDIBGi, Serv Neurol, Girona, Spain; [Hurtado, Olivia; Morales, Jesus R.; Moro, Maria A.; Lizasoain, Ignacio] Univ Complutense Madrid, Fac Med, Dept Farmacol, Madrid, Spain		Mallolas, J (corresponding author), Hosp Girona Dr Josep Trueta, Fundacio Privada, Inst Invest Biomed Girona Dr Josep Trueta IDIBGi, Serv Neurol, Girona, Spain.	cgubern.girona.ics@gencat.cat; olhurtad@med.ucm.es; rociorodriguez.girona.ics@gencat.cat; jrmorales@med.ucm.es; vgromera@gmail.com; neurona@med.ucm.es; ignacio.lizasoain@med.ucm.es; jserena.girona.ics@gencat.cat; jmallolas.girona.ics@gencat.cat	Lizasoain, Ignacio/K-9844-2014; Gubern-Merida, Carme/ABA-1934-2021; Moro, Maria Angeles/K-6396-2014; HURTADO, OLIVIA/E-7248-2012	Lizasoain, Ignacio/0000-0002-6028-7379; Gubern-Merida, Carme/0000-0001-8378-4477; Moro, Maria Angeles/0000-0003-1010-8237; HURTADO, OLIVIA/0000-0001-5735-7092	Spanish Ministry of Science and InnovationSpanish Government; European Regional Development Fund (ERDF)European Commission [CIT 090100-2005-15, CIT 090100-2007-43, CIT 090000-2008-11]; Institut de Salud Carlos III (ISCIII)Instituto de Salud Carlos III [FIS-PI070322, RD06/0026/0005, RD07/0026/2002]; Generalitat de CatalunyaGeneralitat de CatalunyaGeneral Electric [RDITSCON07-1-0006]; Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR)Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR) [2007 BE-100293]	This work was partially supported by the Spanish Ministry of Science and Innovation and the European Regional Development Fund (ERDF) PROFIT grant nos. CIT 090100-2005-15, CIT 090100-2007-43, CIT 090000-2008-11 (J. Mallolas and I. Lizasoain), Spanish Ministry of Science and Innovation, Institut de Salud Carlos III (ISCIII) grant nos. FIS-PI070322 (J. Mallolas), ISCIII retics-RENEVAS-RD06/0026/0005 (MA. Moro) and RD07/0026/2002 (J. Serena) and the Centre d'Innovacio i Desenvolupament Empresarial (CIDEM) of the Generalitat de Catalunya (grant no. RDITSCON07-1-0006). C. Gubern was recipient of a BE grant no. 2007 BE-100293 from the Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR).	Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496; Bond BC, 2002, MOL BRAIN RES, V106, P101, DOI 10.1016/S0169-328X(02)00417-5; Bonefeld BE, 2008, SYNAPSE, V62, P302, DOI 10.1002/syn.20496; BRINT S, 1988, J CEREBR BLOOD F MET, V8, P474, DOI 10.1038/jcbfm.1988.88; Buga AM, 2008, J CELL MOL MED, V12, P2731, DOI 10.1111/j.1582-4934.2008.00252.x; Candelario-Jalil E, 2008, CURR PHARM DESIGN, V14, P1401, DOI 10.2174/138161208784480216; Caso JR, 2007, CIRCULATION, V115, P1599, DOI 10.1161/CIRCULATIONAHA.106.603431; CHEN J, 1995, NEUROREPORT, V6, P394, DOI 10.1097/00001756-199501000-00040; Cook NL, 2009, J NEUROSCI RES, V87, P34, DOI 10.1002/jnr.21846; Coulson DTR, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-46; de Jonge HJM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000898; Derks NM, 2008, NEUROSCIENCE, V156, P305, DOI 10.1016/j.neuroscience.2008.07.047; Dheda K, 2004, BIOTECHNIQUES, V37, P112, DOI 10.2144/04371RR03; Dheda K, 2005, ANAL BIOCHEM, V344, P141, DOI 10.1016/j.ab.2005.05.022; Dirnagl U, 2003, TRENDS NEUROSCI, V26, P248, DOI 10.1016/S0166-2236(03)00071-7; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; Harrison DC, 2000, MOL BRAIN RES, V75, P143, DOI 10.1016/S0169-328X(99)00305-8; Hurtado O, 2008, NEUROBIOL DIS, V29, P123, DOI 10.1016/j.nbd.2007.08.004; Hurtado O, 2005, NEUROBIOL DIS, V18, P336, DOI 10.1016/j.nbd.2004.10.006; Keyvani K, 2002, J CEREBR BLOOD F MET, V22, P153, DOI 10.1097/00004647-200202000-00003; Krieger DW, 2004, STROKE, V35, P1482, DOI 10.1161/01.STR.0000126118.44249.5c; Langnaese K, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-53; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mallolas J, 2006, J EXP MED, V203, P711, DOI 10.1084/jem.20051979; Matsushita K, 1998, NEUROSCIENCE, V83, P439, DOI 10.1016/S0306-4522(97)00391-6; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; McNeill RE, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-107; Medhurst AD, 2000, J NEUROSCI METH, V98, P9, DOI 10.1016/S0165-0270(00)00178-3; Meldgaard M, 2006, J NEUROSCI METH, V156, P101, DOI 10.1016/j.jneumeth.2006.02.008; Morales JR, 2008, CIRCULATION, V118, P1450, DOI 10.1161/CIRCULATIONAHA.108.782300; Rhinn H, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-62; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; Schwarz DA, 2002, MOL BRAIN RES, V101, P12, DOI 10.1016/S0169-328X(02)00135-3; Sobrado M, 2009, J NEUROSCI, V29, P3875, DOI 10.1523/JNEUROSCI.5529-08.2009; Splegler M, 2007, J NEUROPATH EXP NEUR, V66, P481, DOI 10.1097/01.jnen.0000263875.22306.3c; Suzuki T, 2000, BIOTECHNIQUES, V29, P332, DOI 10.2144/00292rv02; TAMURA A, 1981, J CEREBR BLOOD F MET, V1, P53, DOI 10.1038/jcbfm.1981.6; TAMURA A, 1981, J CEREBR BLOOD F MET, V1, P61, DOI 10.1038/jcbfm.1981.7; Tanic N, 2007, J MOL NEUROSCI, V32, P38, DOI 10.1007/s12031-007-0006-7; Thellin O, 1999, J BIOTECHNOL, V75, P291, DOI 10.1016/S0168-1656(99)00163-7; Tian YF, 2007, ACTA ANAESTH SCAND, V51, P158, DOI 10.1111/j.1399-6576.2006.01161.x; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034	42	83	84	0	21	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2199			BMC MOL BIOL	BMC Mol. Biol.	JUN 16	2009	10								57	10.1186/1471-2199-10-57			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	469VC	WOS:000267927800001		Green Published, hybrid			2022-02-06	
J	Raskin, SA				Raskin, Sarah A.			Memory for Intentions Screening Test: Psychometric Properties and Clinical Evidence	BRAIN IMPAIRMENT			English	Article						prospective memory; memory for intentions	PERFORMED TASKS; BRAIN-INJURY; HIV; IMPAIRMENT; PREDICTORS; INFECTION; PEOPLE	As he field of prospective memory (ProM) research has expanded, recognition of the need to make a clinical diagnosis of ProM difficulties has also increased. In addition, there is increasing interest in understanding in more detail the ways in which ProM deficits differ in populations with different underlying neurological dysfunctions. While questionnaires, naturalistic studies and laboratory studies have all been invaluable in furthering our understanding of ProM, until recently there has not been a standardised clinical measure. The Memory for Intentions Screening Test (MIST) was designed to be a relatively brief clinical measure of ProM in clinical populations. The MIST allows for comparisons of performance with event-based and time-based cues. The MIST also has some items with a short (2-minute) and some with a long (15-minute) delay period. Finally, the MIST contains items that require a verbal response as well as items that require an action response. The MIST has now been used in studies of normal ageing as well as a range of clinical populations, including individuals with traumatic brain injury, individuals with HIV infection and individuals with schizophrenia. The psychometric properties of the MIST have been found to be acceptable. Data from each of the clinical populations that have been administered the MIST demonstrate good specificity and sensitivity of the measure as well as the ability to begin to make comparisons about different patterns of performance between disease types.	[Raskin, Sarah A.] Trinity Coll, Dept Psychol, Hartford, CT 06106 USA; [Raskin, Sarah A.] Trinity Coll, Neurosci Program, Hartford, CT 06106 USA		Raskin, SA (corresponding author), Trinity Coll, Dept Psychol, 300 Summit St, Hartford, CT 06106 USA.	sarah.raskin@trincoll.edu	Raskin, Sarah/T-1420-2019	Raskin, Sarah/0000-0002-4310-4278			BASSO MR, 2008, INT NEUR SOC M WAIK; Carey CL, 2006, J CLIN EXP NEUROPSYC, V28, P536, DOI 10.1080/13803390590949494; COCKBURN J, 1994, BRIT J PSYCHOL, V85, P273, DOI 10.1111/j.2044-8295.1994.tb02523.x; COCKBURN J, 1996, PROSPECTIVE MEMORY T; CONTARDO C, RELATIONSHIP P UNPUB; DELISI L, 2006, THESIS E WASHINGTON; EDWARDS C, 2009, COGN NEUR SOC M SAN; Einstein, 2002, PSYCHOL BEITR, V44, P303, DOI [10.1037/0012-1649.44.2.612, DOI 10.1037/0012-1649.44.2.612]; Ellis J., 1996, PROSPECTIVE MEMORY T; ENGELKAMP J, 1994, PSYCHOL RES-PSYCH FO, V57, P47, DOI 10.1007/BF00452995; Fleming J, 2008, J INT NEUROPSYCH SOC, V14, P823, DOI 10.1017/S1355617708080971; Ghaleb H., 2008, COGN NEUR SOC M SAN; GOSHKE T, 1993, J EXPT PSYCHOL LEARN, V19, P1211; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Hicks JL, 2000, J EXP PSYCHOL LEARN, V26, P1160, DOI 10.1037/0278-7393.26.5.1160; KARANTZOULIS S, 2008, 36 ANN M INT NEUR SO; KARANTZOULIS S, 2007, 35 ANN M INT NEUR SO; KORIAT A, 1990, MEM COGNITION, V18, P568, DOI 10.3758/BF03197099; MAYE J, 2008, NE UND GRAD ORG NEUR; MEACHAM JA, 1982, MEMORY OBSERVED REME; MOSCOVITCH M, 2008, PROSPECTIVE MEMORY C; Pearce R, 2000, THESIS TRINITY COLL; Phillips L.H., 2008, Prospective Memory: Cognitive, Neuroscience, Developmental, and Applied; RASKIN S, 2001, INT NEUR SOC BOST MA; RASKIN S, 2004, COGN NEUR SOC SAN FR; RASKIN S, 2003, ANN M INT NEUR SOC H; Raskin S, 2004, J INT NEUROPSYCHO S1, V10, P110, DOI DOI 10.1017/S1355617704040019; RASKIN S, 1998, COGN NEUR SOC SAN FR; Schaefer EG, 1998, MEM COGNITION, V26, P644, DOI 10.3758/BF03211384; SETHNA J, 2001, COGN NEUR SOC M SAN; TROSTER A, 2008, INT NEUR SOC M BUEN; TWAMLEY E, 2007, SCHIZOPHRENIA RES, V10; Uttl B, 2001, CONSCIOUS COGN, V10, P451, DOI 10.1006/ccog.2001.0505; Wilson B.A., 1985, RIVERMEAD BEHAV MEMO; Woods SP, 2008, CLIN NEUROPSYCHOL, V22, P864, DOI 10.1080/13854040701595999; Woods SP, 2008, ARCH CLIN NEUROPSYCH, V23, P257, DOI 10.1016/j.acn.2007.12.006; Woods SP, 2008, NEUROPSYCHOLOGY, V22, P110, DOI 10.1037/0894-4105.22.1.110; Woods SP, 2007, ARCH CLIN NEUROPSYCH, V22, P187, DOI 10.1016/j.acn.2006.12.006; Woods SP, 2007, SCHIZOPHR RES, V90, P344, DOI 10.1016/j.schres.2006.11.005	39	83	83	1	16	AUSTRALIAN ACAD PRESS	BOWEN HILLS	32 JEAYS ST, BOWEN HILLS, QLD 4006, AUSTRALIA	1443-9646			BRAIN IMPAIR	Brain Impair.	MAY	2009	10	1					23	33		10.1375/brim.10.1.23			11	Clinical Neurology; Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	443CQ	WOS:000265888200005					2022-02-06	
J	Turner, GR; Levine, B				Turner, Gary R.; Levine, Brian			Augmented neural activity during executive control processing following diffuse axonal injury	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; WORKING-MEMORY PERFORMANCE; PREFRONTAL CORTEX; FMRI DATA; MRI; NEUROPATHOLOGY; MANIPULATION; ACTIVATION; RECOVERY; DEFICITS	Background: Deficits in working memory are commonly observed after traumatic brain injury (TBI), with executive control processes preferentially impacted relative to storage and rehearsal. Previous activation functional neuroimaging investigations of working memory in patients with TBI have reported altered functional recruitment, but methodologic issues including sample heterogeneity (e. g., variability in injury mechanism, severity, neuropathology or chronicity), underspecified definitions of "working memory," and behavioral differences between TBI and control groups have hindered interpretation of these changes. Methods: Executive control processing in working memory was explicitly engaged during fMRI in a sample of carefully selected chronic-stage, moderate-to-severe TBI patients with diffuse axonal injury (DAI) but without focal lesions. Results: Despite equivalent task performance, we observed a pattern of greater recruitment of interhemispheric and intrahemispheric regions of prefrontal cortex (PFC) and posterior cortices in our DAI sample. Enhanced activations were recorded in the left dorsolateral PFC (middle frontal gyrus), right ventrolateral PFC (inferior frontal gyrus), bilateral posterior parietal cortices, and left temporo-occipital junction. Region-of-interest analyses confirmed that these effects were robust across individual patients and could not be attributed to load factors or slowed speed of processing. Conclusions: Augmented functional recruitment in the context of normal behavioral performance may be a neural marker of capacity or efficiency limits that can affect functional outcome after traumatic brain injury with diffuse injury.	[Turner, Gary R.; Levine, Brian] Baycrest Ctr Geriatr Care, Rotman Res Inst, Toronto, ON M6A 2E1, Canada; [Turner, Gary R.; Levine, Brian] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; [Levine, Brian] Univ Toronto, Dept Med Neurol, Toronto, ON, Canada		Levine, B (corresponding author), Baycrest Ctr Geriatr Care, Rotman Res Inst, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	blevine@rotman-baycrest.on.ca	Levine, Brian/O-2725-2019; Levine, Brian/G-4328-2010	Levine, Brian/0000-0003-4343-811X; Levine, Brian/0000-0003-4343-811X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042385] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD42385-01] Funding Source: Medline		Baddeley A.D., 1986, WORKING MEMORY; Chen AJW, 2006, J HEAD TRAUMA REHAB, V21, P107, DOI 10.1097/00001199-200603000-00004; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; COURVILLE CB, 1937, PATHOLOGY CENTRAL 4; Cox RW, 1997, NMR BIOMED, V10, P171, DOI 10.1002/(SICI)1099-1492(199706/08)10:4/5<171::AID-NBM453>3.0.CO;2-L; Craik FI., 1986, HUMAN MEMORY COGNITI, V5, P409; Curtis CE, 2003, TRENDS COGN SCI, V7, P415, DOI 10.1016/S1364-6613(03)00197-9; D'Esposito M, 1999, BRAIN COGNITION, V41, P66, DOI 10.1006/brcg.1999.1096; D'Esposito M, 2006, J INT NEUROPSYCH SOC, V12, P248, DOI 10.1017/S1355617706060322; FUJIWARA E, NEUROPSYCHO IN PRESS; Goldman-Rakic P.S., 2011, COMPR PHYSIOL, P373, DOI DOI 10.1002/CPHY.CP010509; Hillary FG, 2006, HUM BRAIN MAPP, V27, P837, DOI 10.1002/hbm.20226; Kane MJ, 2004, J EXP PSYCHOL GEN, V133, P189, DOI 10.1037/0096-3445.133.2.189; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Levine B., 2002, PRINCIPLES FRONTAL L, P448; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Newsome MR, 2007, CORTEX, V43, P95, DOI 10.1016/S0010-9452(08)70448-9; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Petrides M, 1999, EUR J NEUROSCI, V11, P1011, DOI 10.1046/j.1460-9568.1999.00518.x; PETRIDES M, 1982, NEUROPSYCHOLOGIA, V20, P249, DOI 10.1016/0028-3932(82)90100-2; Postle BR, 1999, P NATL ACAD SCI USA, V96, P12959, DOI 10.1073/pnas.96.22.12959; Postle BR, 2006, NEUROSCIENCE, V139, P23, DOI 10.1016/j.neuroscience.2005.06.005; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; TEASDALE G, 1974, LANCET, V2, P81; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Wager TD, 2003, COGN AFFECT BEHAV NE, V3, P255, DOI 10.3758/CABN.3.4.255; Zachary R. A., 1986, SHIPLEY I LIVING SCA	31	83	83	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	SEP 9	2008	71	11					812	818		10.1212/01.wnl.0000325640.18235.1c			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	345ZU	WOS:000259039000007	18779509	Green Published			2022-02-06	
J	Flint, AC; Manley, GT; Gean, AD; Hemphill, JC; Rosenthal, G				Flint, Alexander C.; Manley, Geoffrey T.; Gean, Alisa D.; Hemphill, J. Claude, III; Rosenthal, Guy			Post-operative expansion of hemorrhagic contusions after unilateral decompressive hemicraniectomy in severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; clinical outcomes; clinical trial; decompressive hemicraniectomy; hemorrhagic contusions; hypothermia; subarachnoid hemorrhage	ACUTE INTRACEREBRAL HEMORRHAGE; PREDICTS HEMATOMA EXPANSION; INTRA-CEREBRAL HEMATOMAS; SEVERE HEAD TRAUMA; PROGNOSTIC VALUE; PERFUSION-CT; PROGRESSION; EXTRAVASATION; CRANIECTOMY; CONTRAST	Decompressive hemicraniectomy is commonly performed in patients with traumatic brain injury (TBI) with diffuse brain swelling or refractory raised intracranial pressure. Expansion of hemorrhagic contusions in TBI patients is common, but its frequency following decompressive hemicraniectomy has not been well established. The aim of this retrospective study was to determine the rate of hemorrhagic contusion expansion following unilateral hemicraniectomy in severe TBI, to identify factors associated with contusion expansion, and to examine whether contusion expansion is associated with worsened clinical outcomes. Computed tomography (CT) scans of 40 consecutive patients with non-penetrating TBI who underwent decompressive hemicraniectomy were analyzed. Hemorrhagic contusion volumes were measured on initial, last pre-operative, and first post-operative CT scans. Mortality and 6-month Glasgow Outcome Scale (GOS) score were recorded. Hemorrhagic contusions of any size were present on the initial head CT scan in 48% of patients, but hemorrhagic contusions with a total volume of >5 cc were present in only 10%. New or expanded hemorrhagic contusions of >= 5 cc were observed after hemicraniectomy in 58% of patients. The mean volume of increased hemorrhage among these patients was 37.1 +/- 36.3 cc. The Rotterdam CT score on the initial head CT was strongly associated with the occurrence and the total volume of expanded hemorrhagic contusions following decompressive hemicraniectomy. Expanded hemorrhagic contusion volume greater than 20 cc after hemicraniectomy was strongly associated with mortality and poor 6-month GOS even after controlling for age and initial Glasgow Coma Scale (GCS) score. Expansion of hemorrhagic contusions is common after decompressive hemicraniectomy following severe TBI. The volume of hemorrhagic contusion expansion following hemicraniectomy is strongly associated with mortality and poor outcome. Severity of initial CT findings may predict the risk of contusion expansion following hemicraniectomy, thereby identifying a subgroup of patients who might benefit from therapies aimed at augmenting the coagulation system.	[Flint, Alexander C.; Hemphill, J. Claude, III] Univ Calif San Francisco, Dept Neurol, Neurovasc & Neurocrit Care Serv, San Francisco, CA 94143 USA; [Manley, Geoffrey T.; Rosenthal, Guy] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Gean, Alisa D.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA; [Flint, Alexander C.; Manley, Geoffrey T.; Gean, Alisa D.; Hemphill, J. Claude, III; Rosenthal, Guy] Univ Calif San Francisco, USCF Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA		Manley, GT (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, 1001 Potrero Ave, San Francisco, CA 94110 USA.	manleyg@neurosurg.ucsf.edu	Hemphill, Claude/AAY-5630-2021; Demchuk, Andrew M/E-1103-2012	Hemphill, Claude/0000-0003-4019-7525; Demchuk, Andrew M/0000-0002-4930-7789; Flint, Alexander/0000-0002-3721-2694			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Becker KJ, 1999, STROKE, V30, P2025, DOI 10.1161/01.STR.30.10.2025; BROWN FD, 1978, J NEUROSURG, V48, P1019, DOI 10.3171/jns.1978.48.6.1019; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; Coplin WM, 2001, NEUROL RES, V23, P277, DOI 10.1179/016164101101198433; DIAZ FG, 1979, J NEUROSURG, V50, P217, DOI 10.3171/jns.1979.50.2.0217; Givner A, 2002, J PEDIATR SURG, V37, P381, DOI 10.1053/jpsu.2002.30825; Goldstein JN, 2007, NEUROLOGY, V68, P889, DOI 10.1212/01.wnl.0000257087.22852.21; GUDEMAN SK, 1979, NEUROSURGERY, V5, P309, DOI 10.1227/00006123-197909000-00002; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; MAYER SA, 2007, 16 EUR STROK C GLASG; MERINODEVILLASANTE J, 1976, AM J ROENTGENOL, V126, P765, DOI 10.2214/ajr.126.4.765; MERTOL T, 1991, British Journal of Neurosurgery, V5, P491, DOI 10.3109/02688699108998478; MURRAY L, 2007, 13 INT S INTR PRESS; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Smith JS, 2007, J TRAUMA, V63, P75, DOI 10.1097/01.ta.0000245991.42871.87; SOLONIUK D, 1986, J TRAUMA, V26, P787, DOI 10.1097/00005373-198609000-00003; Wada R, 2007, STROKE, V38, P1257, DOI 10.1161/01.STR.0000259633.59404.f3; Wintermark M, 2006, J NEURORADIOLOGY, V33, P27, DOI 10.1016/S0150-9861(06)77225-X; Wintermark M, 2004, RADIOLOGY, V232, P211, DOI 10.1148/radiol.2321030824; YOUNG HA, 1984, NEUROSURGERY, V14, P22, DOI 10.1227/00006123-198401000-00006	28	83	90	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2008	25	5					503	512		10.1089/neu.2007.0442			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	303PY	WOS:000256054100007	18346002				2022-02-06	
J	Covassin, T; Stearne, D; Elbin, R				Covassin, Tracey; Stearne, David; Elbin, Robert, III			Concussion history and postconcussion neurocognitive performance and symptoms in collegiate athletes	JOURNAL OF ATHLETIC TRAINING			English	Article						mild traumatic brain injury; ImPACT; memory; reaction time	SPORTS-RELATED CONCUSSION; SCHOOL FOOTBALL PLAYERS; RECURRENT CONCUSSION; CONTACT SPORTS; HEAD-INJURY; MANAGEMENT; RECOVERY; ASSOCIATION; STATEMENT; TRENDS	Context: Athletes are at an inherent risk for sustaining concussions. Research examining the long-term consequences of sport-related concussion has been inconsistent in demonstrating lingering neurocognitive decrements that may be associated with a previous history of concussion. Objective: To determine the relationship between concussion history and postconcussion neurocognitive performance and symptoms in collegiate athletes. Design: Repeated-measures design. Setting: Multi-center analysis of collegiate athletes. Patients or Other Participants: Fifty-seven concussed collegiate athletes (36 without concussion history, 21 with a history of 2 or more concussions). Intervention(s): All subjects were administered an Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) neurocognitive test battery, which measures verbal memory, visual memory, reaction time, and visual processing speed and 22 concussion symptoms. Main Outcome Measure(s): Subjects who sustained a concussion were administered 2 follow-up tests at days 1 and 5 postinjury. Independent variables were history of concussion (no history of concussion, 2 or more concussions) and time (baseline, day 1 postconcussion, or day 5 postconcussion). Results: A within-subjects effect (time) on ImPACT performance (P < .001), a between-subjects multivariate effect of group (P < .001), and a group-by-time interaction (P = .034) were noted. Athletes with a concussion history performed significantly worse on verbal memory (P = .01) and reaction time (P = .023) at day 5 postconcussion compared with athletes who did not report a previous concussion. No significant group differences were seen at day 5 postinjury on visual memory (P = .167), processing speed (P = .179), or total concussion symptoms (P = .87). Conclusions: Concussed collegiate athletes with a history of 2 or more concussions took longer to recover verbal memory and reaction time than athletes without a history of concussion.	[Covassin, Tracey; Stearne, David; Elbin, Robert, III] Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA		Covassin, T (corresponding author), Michigan State Univ, Dept Kinesiol, 105 IM Sport Circle, E Lansing, MI 48824 USA.	covassin@msu.edu					Autti T, 1997, LANCET, V349, P1144, DOI 10.1016/S0140-6736(05)63019-X; BECKER DP, 1987, PHYSL BASIS MODERN S, P763; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Gaetz M, 2000, BRAIN INJURY, V14, P1077; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2000, NEUROLOGIC ATHLETIC, P80; GRONWALL D, 1974, LANCET, V2, P605; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2004, NEUROSURGERY, V55, P891, DOI 10.1227/01.NEU.0000143800.49798.19; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kelly JP, 1997, NEUROLOGY, V48, P581; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Tegner Y, 1996, BRIT J SPORT MED, V30, P251, DOI 10.1136/bjsm.30.3.251; THOMASSEN A, 1979, ACTA NEUROL SCAND, V60, P352, DOI 10.1111/j.1600-0404.1979.tb07661.x; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	35	83	84	1	36	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	MAR-APR	2008	43	2					119	124		10.4085/1062-6050-43.2.119			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	293TX	WOS:000255359200002	18345335	Green Published			2022-02-06	
J	Schirmer-Mikalsen, K; Vik, A; Gisvold, SE; Skandsen, T; Hynne, H; Klepstad, P				Schirmer-Mikalsen, K.; Vik, A.; Gisvold, S. E.; Skandsen, T.; Hynne, H.; Klepstad, P.			Severe head injury: control of physiological variables, organ failure and complications in the intensive care unit	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						severe head injury; secondary brain injury; control of physiological variables; intensive care; outcome; pneumonia	CEREBRAL PERFUSION-PRESSURE; TRAUMATIC BRAIN-INJURY; MARKED NEUROPROTECTIVE EFFICACY; SECONDARY ISCHEMIC INSULTS; COLLOID ONCOTIC PRESSURE; INTRACRANIAL-PRESSURE; VOLUME REGULATION; ALBUMIN THERAPY; LUND CONCEPT; BLOOD-FLOW	Background: In patients with severe head injury, control of physiological variables is important to avoid intracranial hypertension and secondary injury to the brain. The aims of this retrospective study were to evaluate deviations of physiological variables and the incidence of extracranial complications in patients with severe head injury. We also studied if these deviations could be related to outcome. Patients and methods: One hundred and thirty-three patients were included during a 5-year period (1998-2002). Deviations from treatment goals for the following physiological variables were studied: blood pressure, haemoglobin, blood sugar, serum sodium, serum albumin and temperature. Extra cerebral organ complications were also recorded as well as outcome at 6 months. Results: The median age was 32 years (range; 1-88 years). Median Glasgow Coma Scale (GCS) before intubation was 6 (range; 3-14). The frequencies of severe deviations from the desired values of the physiological variables for at least one treatment day were: hypotensive episodes (systolic BP < 90 mmHg) - 20%, anaemia (hgb < 8 g/dL) - 22%, blood glucose > 10 mmol/1 - 26%, serum sodium concentration < 130 mmol/1 - 10%, serum albumin < 25 g/l(-1) - 31% and hyperthermia > 39 degrees C - 24%. Pneumonia was diagnosed in 71% and Acute Lung Injury (ALI)/Adult Respiratory Distress Syndrome (ARDS) in 26% of the patients. Other complications such as severe sepsis (6%), renal failure (1.5%), a coagulation disorder (6%) and liver failure (one patient) were infrequent. Age, GCS, hypotension during the first day of treatment, elevated blood sugar and low albumin predicted an unfavourable outcome. Conclusions: Deviations of key physiological variables and pulmonary complications were frequent in patients suffering from severe head injury. During intensive care treatment, hypotension, elevated blood sugar and hypoalbuminemia are possible independent predictors of an unfavourable outcome.	St Olav Uni Hosp, Dept Anaesthesia & Acute Med, Trondheim, Norway; St Olavs Univ Hosp, Dept Neurosurg, Trondheim, Norway; St Olavs Univ Hosp, Dept Phys Med & Rehabil, Trondheim, Norway; Norwegian Univ Sci & Technol, Fac Med, Dept Circulat & Med Imaging, Trondheim, Norway; Norwegian Univ Sci & Technol, Fac Med, Dept Neurosci, Trondheim, Norway		Schirmer-Mikalsen, K (corresponding author), St Olav Uni Hosp, Dept Anaesthesia & Acute Med, Trondheim, Norway.	kari.schirmer@stolav.no	Skandsen, Toril/P-6767-2014	Skandsen, Toril/0000-0001-5495-9338			Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Belayev L, 1998, STROKE, V29, P2587, DOI 10.1161/01.STR.29.12.2587; Belayev L, 2001, STROKE, V32, P553, DOI 10.1161/01.STR.32.2.553; Bronchard G, 2004, ANESTHESIOLOGY, V100, P234, DOI 10.1097/00000542-200402000-00009; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Cherian L, 1998, J NEUROTRAUM, V15, P307, DOI 10.1089/neu.1998.15.307; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Clayton TJ, 2004, BRIT J ANAESTH, V93, P761, DOI 10.1093/bja/aeh249; Drummond JC, 1998, ANESTHESIOLOGY, V88, P993, DOI 10.1097/00000542-199804000-00020; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; Elf K, 2005, NEUROSURGERY, V56, P962, DOI 10.1227/01.NEU.0000158317.00603.40; Gisvold SE, 2001, ACTA ANAESTH SCAND, V45, P399, DOI 10.1034/j.1399-6576.2001.045004399.x; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; HAKAMATA Y, 1995, STROKE, V26, P2149, DOI 10.1161/01.STR.26.11.2149; HARRISON MJG, 1981, LANCET, V2, P114, DOI 10.1016/S0140-6736(81)90298-1; Haynes GR, 2003, EUR J ANAESTH, V20, P771, DOI 10.1097/00003643-200310000-00003; Janssens U, 2000, INTENS CARE MED, V26, P1037, DOI 10.1007/s001340051316; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; KAIEDA R, 1989, ANESTHESIOLOGY, V71, P554, DOI 10.1097/00000542-198910000-00013; Kongstad L, 1999, ACTA ANAESTH SCAND, V43, P501, DOI 10.1034/j.1399-6576.1999.430503.x; LANIER WL, 1987, ANESTHESIOLOGY, V66, P39, DOI 10.1097/00000542-198701000-00008; Leonard K, 2006, SOC SCI MED, V63, P2330, DOI 10.1016/j.socscimed.2006.06.003; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; Portella G, 2005, ACTA NEUROCHIR, V147, P707, DOI 10.1007/s00701-005-0537-z; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; Schoon P, 2002, ACT NEUR S, V81, P285; Stover JF, 1998, EUR J CLIN PHARMACOL, V54, P529, DOI 10.1007/s002280050508; THOMAS DJ, 1977, LANCET, V2, P941, DOI 10.1016/S0140-6736(77)90885-6; ZHUANG J, 1995, CRIT CARE MED, V23, P140, DOI 10.1097/00003246-199501000-00023; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	40	83	92	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	OCT	2007	51	9					1194	1201		10.1111/j.1399-6576.2007.01372.x			8	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	209GE	WOS:000249376200012	17711565				2022-02-06	
J	Li, L; Lu, J; Tay, SSW; Moochhala, SM; He, BP				Li, Lu; Lu, Jia; Tay, Samuel Sam Wah; Moochhala, Shabbir M.; He, Bei Ping			The function of microglia, either neuroprotection or neurotoxicity, is determined by the equilibrium among factors released from activated microglia in vitro	BRAIN RESEARCH			English	Article						2,5-hexanedione; dual function; microglia; neurodegeneration; neurotoxicity; neuroprotection	CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE; SPINAL-CORD; 2,5-HEXANEDIONE-INDUCED CHANGES; ALZHEIMERS-DISEASE; NEURONAL DAMAGE; MOTOR-NEURONS; UP-REGULATION; EXPRESSION; BRAIN	Opposing functions of activated microglia, namely neuroprotection or neurotrophy versus neurodestruction or neurotoxicity, have been observed in a number of experimental models of neurotrauma and neurodegenerative diseases. However, the mechanism(s) involved in the determination of which function activated microglia execute under a given set of conditions still remains to be elucidated. Our current in vitro study has revealed that a neuroprotective/neurotrophic or a neurodestructive/neurotoxic microglial function may be configured by the equilibrium among various microglial factors released into the microenvironment. When NSC-34 neurons were treated with lower concentrations of lipopolysaccharide-stimulated BV-2 microglial conditioned medium (LPS-BVCM), viability of the NSC-34 neurons increased, outgrowth of neuronal processes was promoted, and the formation of 2,5-hexanedione-induced aggregates was prevented. However, when NSC-34 neurons were treated with higher concentrations of the same LPS-BVCM, neuronal viability was reduced, apoptosis was induced and outgrowth of neuronal processes was prevented. Measurement of the cytokines tumor necrotic factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), and IL-6 in the LPS-BVCM has shown that the upregulation in expression for each cytokine varied both temporally and quantitatively. It is postulated that an alteration in the concentration of the LPS-BVCM might significantly affect the functional balance of microglial factors in the microenvironment with a resultant different microglial function. (C) 2007 Elsevier B.V. All rights reserved.	Natl Univ Singapore, Dept Anat, Yong Loo Lin Sch Med, Singapore 117597, Singapore; DSO Natl Labs, Def Med & Environm Res Inst, Singapore, Singapore		He, BP (corresponding author), Natl Univ Singapore, Dept Anat, Yong Loo Lin Sch Med, MD10,4 Med Dr, Singapore 117597, Singapore.	anthebp@nus.edu.sg		MOOCHHALA, SHABBIR/0000-0003-4521-3192			Bissonnette CJ, 2004, NEUROSCI LETT, V361, P40, DOI 10.1016/j.neulet.2004.01.005; Brown GC, 2003, MOL NEUROBIOL, V27, P325, DOI 10.1385/MN:27:3:325; CASHMAN NR, 1992, DEV DYNAM, V194, P209, DOI 10.1002/aja.1001940306; COFFEY PJ, 1990, NEUROSCIENCE, V35, P121, DOI 10.1016/0306-4522(90)90126-O; DICKSON DW, 1993, GLIA, V7, P75, DOI 10.1002/glia.440070113; DURHAM HD, 1993, NEUROTOXICOLOGY, V14, P387; Ehrlich LC, 1998, J IMMUNOL, V160, P1944; Eriksson C, 2000, CYTOKINE, V12, P423, DOI 10.1006/cyto.1999.0582; Gibbons HM, 2006, BRAIN RES, V1084, P1, DOI 10.1016/j.brainres.2006.02.032; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GRAHAM DG, 1995, CRIT REV TOXICOL, V25, P91, DOI 10.3109/10408449509021609; Hao AJ, 2002, NEUROSCIENCE, V112, P889, DOI 10.1016/S0306-4522(02)00144-6; Hao AJ, 2001, NEUROREPORT, V12, P1391, DOI 10.1097/00001756-200105250-00020; Hartley CL, 1997, NEUROPATH APPL NEURO, V23, P364; He BP, 1997, EXP NEUROL, V146, P587, DOI 10.1006/exnr.1997.6561; He BP, 2002, J NEUROIMMUNOL, V128, P31, DOI 10.1016/S0165-5728(02)00141-8; Isaksson J, 1999, J NEUROTRAUM, V16, P165, DOI 10.1089/neu.1999.16.165; Johnson AB, 2006, J NEUROIMMUNOL, V174, P82, DOI 10.1016/j.jneuroim.2006.01.019; Kim SU, 2005, J NEUROSCI RES, V81, P302, DOI 10.1002/jnr.20562; Kitamura Y, 2004, J PHARMACOL SCI, V94, P203, DOI 10.1254/jphs.94.203; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LoPachin RM, 2005, NEUROTOXICOLOGY, V26, P229, DOI 10.1016/j.neuro.2004.09.007; LoPachin RM, 2004, TOXICOL APPL PHARM, V198, P61, DOI 10.1016/j.taap.2004.03.002; Lunemann A, 2006, GLIA, V53, P412, DOI 10.1002/glia.20301; Marron TU, 2005, J NEUROCHEM, V92, P10, DOI 10.1111/j.1471-4159.2004.02836.x; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; MERRILL JE, 1993, J IMMUNOL, V151, P2132; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; NAGATA K, 1993, J NEUROSCI RES, V34, P357, DOI 10.1002/jnr.490340313; Nakajima K, 2001, J NEUROSCI RES, V65, P322, DOI 10.1002/jnr.1157; Neumann J, 2006, FASEB J, V20, P714, DOI 10.1096/fj.05-4882fje; PROBERT L, 1995, P NATL ACAD SCI USA, V92, P11294, DOI 10.1073/pnas.92.24.11294; RAINE CS, 1994, J NEUROPATH EXP NEUR, V53, P328, DOI 10.1097/00005072-199407000-00002; Roy A, 2006, J BIOL CHEM, V281, P14971, DOI 10.1074/jbc.M600236200; Schmuck G, 1996, TOXICOL IND HEALTH, V12, P683, DOI 10.1177/074823379601200507; Shrikant P, 1996, J IMMUNOL, V157, P892; Thomas DM, 2005, FASEB J, V19, P515, DOI 10.1096/fj.05-4873fje; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Wen WY, 2006, NEUROSCI RES, V55, P87, DOI 10.1016/j.neures.2006.02.004; YAO JB, 1992, BRAIN RES, V591, P88, DOI 10.1016/0006-8993(92)90981-E	40	83	86	1	10	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 23	2007	1159						8	17		10.1016/j.brainres.2007.04.066			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	198GD	WOS:000248614100002	17572395				2022-02-06	
J	Ariza, M; Pueyo, R; Matarin, MD; Junque, C; Mataro, M; Clemente, I; Moral, P; Poca, MA; Garnacho, A; Sahuquillo, J				Ariza, M.; Pueyo, R.; Matarin, M. del M.; Junque, C.; Mataro, M.; Clemente, I.; Moral, P.; Poca, M. A.; Garnacho, A.; Sahuquillo, J.			Influence of APOE polymorphism on cognitive and behavioural outcome in moderate and severe traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							APOLIPOPROTEIN-E; HEAD-INJURY; ALZHEIMERS-DISEASE; RECOVERY; GENOTYPE; REHABILITATION; ASSOCIATION; EPSILON-4	Aim: To analyse the influence of apolipoprotein (APOE) is an element of 4 status on the cognitive and behavioural functions usually impaired after moderate and severe traumatic brain injury (TBI). Methods: In all, 77 patients with TBI selected from 140 consecutive admissions were genotyped for APOE. Each patient was subjected to neuropsychological and neurobehavioural assessment at least 6 months after injury. Results: Performance of participants carrying the is an element of 4 allele was notably worse on verbal memory (Auditory Verbal Learning Test), motor speed, fine motor coordination, visual scanning, attention and mental flexibility (Grooved Pegboard, Symbol Digit Modalities Test and part B of the Trail Making Test) and showed considerably more neurobehavioural disturbances (Neurobehavioral Rating Scale Revised) than the group without the is an element of 4 allele. Conclusions: In particular, performance on neuropsychological tasks that are presumed to be related to temporal lobe, frontal lobe and white matter integrity is worse in patients with the APOE is an element of 4 allele than in those without it. More neurobehavioural disturbances are observed in APOE is an element of 4 carriers than in APOE is an element of 2 and is an element of 3 carriers.	Univ Barcelona, Dept Psiquiatria & Psicobiol Clin, Barcelona 08035, Spain; IDIBAPS, Barcelona, Spain; Univ Barcelona, Dept Biol Anim, Barcelona 08035, Spain; Vall Hebron Univ Hosp, Dept Neurosurg, Barcelona, Spain; Vall Hebron Univ Hosp, Neurotraumatol Intens Care Unit, Barcelona, Spain		Ariza, M (corresponding author), Univ Barcelona, Dept Psiquiatria & Psicobiol Clin, Passeig Vall Hebron,171, Barcelona 08035, Spain.	marizago7@docd4.ub.edu	Moral, Pedro/K-9587-2014; Sahuquillo, Juan/B-3577-2008; Poca, Maria A./B-8475-2008; Ariza, Mar/F-2754-2019; Clemente, I Concepcion/H-5399-2013; Benito, Roser Pueyo/G-3433-2011; Garnacho, Angel/A-9309-2013; Junque, Carme/B-4400-2011; Matarin, Mar/F-1771-2016; Mataro, Maria/B-4524-2011	Moral, Pedro/0000-0001-5072-5892; Sahuquillo, Juan/0000-0003-0713-5875; Poca, Maria A./0000-0002-3831-0536; Clemente, I Concepcion/0000-0003-0728-0925; Benito, Roser Pueyo/0000-0002-8230-8409; Junque, Carme/0000-0002-6381-3063; Matarin, Mar/0000-0002-4717-5735; Mataro, Maria/0000-0002-9946-2656; Ariza, Mar/0000-0003-1020-6945			Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gennarelli, 1998, Semin Clin Neuropsychiatry, V3, P160; Horsburgh K, 2000, NEUROBIOL AGING, V21, P245, DOI 10.1016/S0197-4580(00)00097-X; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Mitrushina MN, 1999, HDB NORMATIVE DATA N; Rey A., 1959, TEST COPIE REPROD ME; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Teasdale TW, 2000, NEUROPSYCHOL REHABIL, V10, P151, DOI 10.1080/096020100389228; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K	20	83	88	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	OCT	2006	77	10					1191	1193		10.1136/jnnp.2005.085167			3	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	084LX	WOS:000240535500019	16614010	Green Published			2022-02-06	
J	Newman, MB; Willing, AE; Manresa, JJ; Sanberg, CD; Sanberg, PR				Newman, Mary B.; Willing, Alison E.; Manresa, John J.; Sanberg, Cyndy Davis; Sanberg, Paul R.			Cytokines produced by cultured human umbilical cord blood (HUCB) cells: Implications for brain repair	EXPERIMENTAL NEUROLOGY			English	Article						human umbilical cord blood; chemokines; cytokines; MCP-1; migration; IL-8; IL-6; IL-1 alpha; IL-10	MESSENGER-RNA EXPRESSION; C-KIT LIGAND; MAST-CELLS; TNF-ALPHA; PERIPHERAL-BLOOD; PROGENITOR CELLS; BONE-MARROW; STEM-CELLS; MIGRATION; IL-8	The potential therapeutic benefits from human umbilical cord blood (HUCB) cells for the treatment of injuries, diseases, and neurodegencration are becoming increasingly recognized. The transplantation or infusion of cord blood cells in various animal models, such as ischemia/stroke, traumatic brain injury, myocardial infarction, Parkinson's disease, and amyotropic lateral sclerosis, has resulted in amelioration of behavioral deficits, and with some diseases, a prolonged lifespan decreased neuropathology. Previously, we reported the migration of HUCB cells to ischemic brain supernatant (tissue extracts) is time-dependent, and the expression of specific chemokines responds to this migration pattern. The mechanism(s) responsible for these effects are unknown. The expression of cytokines and chemokines produced by HUCB cells (under various culturing conditions) was investigated in this study. IL-8, MCP-1, and IL-1 alpha were consistently expressed by the HUCB mononuclear cells regardless of the culture condition. These results provide insights to factors that may be partially responsible for the functional improvements seen in the animal models of injury investigating the therapeutic use of HUCB cells. (c) 2006 Elsevier Inc. All rights reserved.	Univ S Florida, Coll Med, Ctr Excellence Aging & Brain Repair, Tampa, FL 33612 USA; Coll Arts & Sci, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Neurosurg, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Psychol, Tampa, FL 33612 USA; Saneron CCEL Therapeut Inc, Temple Terrace, FL 33617 USA		Newman, MB (corresponding author), Rush Univ, Med Ctr, Dept Pharmacol, Cohn Res Bldg,Suite 406,1735 W Harrison St,Room 4, Chicago, IL 60612 USA.	mnewman@rush.edu	Willing, Alison/I-4946-2012; Willing, Alison/AAP-7759-2021				Berner R, 2000, EUR J PEDIATR, V159, P205, DOI 10.1007/s004310050051; Brass LM, 2006, EXP NEUROL, V199, P16, DOI 10.1016/j.expneurol.2006.03.009; Broxmeyer HE, 1999, ANN NY ACAD SCI, V872, P142, DOI 10.1111/j.1749-6632.1999.tb08460.x; Chen S, 2001, METALL MATER TRANS B, V32, P11, DOI 10.1007/s11663-001-0002-1; Chen SH, 2006, EXP NEUROL, V199, P67, DOI 10.1016/j.expneurol.2005.11.015; COHEN SB, 2000, CORD BLOOD CHARACTER; Dollner H, 2001, BIOL NEONATE, V80, P41, DOI 10.1159/000047118; DVORAK AM, 1993, J LEUKOCYTE BIOL, V54, P465, DOI 10.1002/jlb.54.5.465; DVORAK AM, 1993, EUR J CELL BIOL, V62, P422; English D, 2006, EXP NEUROL, V199, P10, DOI 10.1016/j.expneurol.2006.03.005; Garbuzova-Davis S, 2003, J HEMATOTH STEM CELL, V12, P255, DOI 10.1089/152581603322022990; Ha Y, 2001, NEUROREPORT, V12, P3523, DOI 10.1097/00001756-200111160-00030; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; KASAHARA T, 1991, IMMUNOLOGY, V74, P60; Kim JS, 1996, J NEUROL SCI, V137, P69, DOI 10.1016/0022-510X(95)00338-3; Kostulas N, 1999, STROKE, V30, P2174, DOI 10.1161/01.STR.30.10.2174; Krueger M, 2001, BIOL NEONATE, V80, P118, DOI 10.1159/000047130; Kushi H, 2003, ACTA NEUROCHIR SUPPL, V86, P347; Lee Y, 2002, BLOOD, V99, P4307, DOI 10.1182/blood.V99.12.4307; Lin TJ, 2000, J IMMUNOL, V165, P211, DOI 10.4049/jimmunol.165.1.211; Lin TJ, 2001, INT ARCH ALLERGY IMM, V124, P142, DOI 10.1159/000053693; Lu L, 1996, CRIT REV ONCOL HEMAT, V22, P61, DOI 10.1016/1040-8428(96)88370-3; Lund BT, 2004, J NEUROIMMUNOL, V155, P161, DOI 10.1016/j.jneuroim.2004.06.008; Mirshahi F, 2000, THROMB RES, V99, P587, DOI 10.1016/S0049-3848(00)00292-9; Newman MB, 2005, STEM CELLS DEV, V14, P576, DOI 10.1089/scd.2005.14.576; Qi XY, 2003, JPN HEART J, V44, P451, DOI 10.1536/jhj.44.451; Ramos CDL, 2003, CYTOKINE, V21, P214, DOI 10.1016/S1043-4666(03)00050-4; Salvucci O, 2004, J LEUKOCYTE BIOL, V76, P217, DOI 10.1189/jlb.1203609; Sanchez-Ramos JR, 2001, EXP NEUROL, V171, P109, DOI 10.1006/exnr.2001.7748; Senaris R, 1997, ENDOCRINOLOGY, V138, P4501, DOI 10.1210/en.138.10.4501; Vendrame M, 2004, STROKE, V35, P2390, DOI 10.1161/01.STR.0000141681.06735.9b; Vendrame M, 2005, STEM CELLS DEV, V14, P595, DOI 10.1089/scd.2005.14.595; Vendrame M, 2006, EXP NEUROL, V199, P191, DOI 10.1016/j.expneurol.2006.03.017; Wang Ji Ming, 1996, Methods (Orlando), V10, P135, DOI 10.1006/meth.1996.0087; Widera D, 2004, EUR J CELL BIOL, V83, P381, DOI 10.1078/0171-9335-00403; Willing AE, 2003, J NEUROSCI RES, V73, P296, DOI 10.1002/jnr.10659; Willing AE, 2003, CELL TRANSPLANT, V12, P449, DOI 10.3727/000000003108746885; Yang YY, 2004, ATHEROSCLEROSIS, V174, P207, DOI 10.1016/j.atherosclerosis.2004.01.024; Yong K, 1999, BRIT J HAEMATOL, V107, P441, DOI 10.1046/j.1365-2141.1999.01714.x; Yoshimura T, 1996, HUMAN CYTOKINES HDB, VII, P198; Zigova T, 2002, CELL TRANSPLANT, V11, P265	41	83	92	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAY	2006	199	1					201	208		10.1016/j.expneurol.2006.04.001			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	060KI	WOS:000238800700022	16730351				2022-02-06	
J	Gurkoff, GG; Giza, CC; Hovda, DA				Gurkoff, GG; Giza, CC; Hovda, DA			Lateral fluid percussion injury in the developing rat causes an acute, mild behavioral dysfunction in the absence of significant cell death	BRAIN RESEARCH			English	Article						cell death; dysfunction; hippocampus; Morris water maze; stereology; traumatic brain injury	TRAUMATIC BRAIN-INJURY; UNBIASED STEREOLOGICAL ESTIMATION; CONTROLLED CORTICAL IMPACT; LONG-TERM POTENTIATION; CEREBRAL-CORTEX; HEAD-INJURY; STATUS EPILEPTICUS; IMMATURE RAT; ENRICHED ENVIRONMENT; GLUCOSE-UTILIZATION	Lateral fluid percussion injury (LFP), a model of mild-moderate concussion, leads to the temporary loss of the capacity for experience-dependent plasticity in developing rats. To determine if this injury-induced loss in capacity for plasticity is due to cell death, we conducted stereological measurements within the cerebral cortex and CA3 of the hippocampus 2 weeks following mild, moderate or severe LFP in the post-natal day 19 (P19) rat. Results indicated that there was no significant change in the absolute number of neurons, regardless of injury severity, in either the ipsilateral cortex (sham = 10.6 +/- 1.7, mild = 11.5 +/- 2.1, moderate = 10.0 +/- 1.0, severe = 10.9 +/- 1.3 million neurons) or CA3 region of the hippocampus (sham = 251 +/- 38, mild = 289 +/- 2, moderate = 245 +/- 48, severe = 255 +/- 62 thousand neurons). Even though there was no evidence of a significant degree of injury-induced cell death, animals exhibited cognitive deficits as revealed in a Morris water maze task (MWM). The MWM results indicated that regardless of injury severity, P19-injured rats exhibited a significant increase in escape latency compared to age-matched shams (injury by day; P < 0.001) and a significant increase in the number of trials needed to reach criterion (P < 0.05). Analysis of a probe trial one week post-MWM training, however, indicated that there was no deficit in storage or recall of the learned behavior as analyzed by platform hits (sham = 2.9 +/- 0.37, mild = 2.0 +/- 0.40, moderate = 1 +/- 0, severe 2.8 +/- 0.62) or percent time spent in, or immediately surrounding, the platform area (sham 13.5 +/- 1.71, mild = 10.8 +/- 2.32, moderate = 12.7 +/- 0, severe = 13.5 +/- 1.69). Taken together, these results indicate that while LFP in P19-injured animals does not lead to significant cell death, it does generate acute, mild deficits in MWM performance. (C) 2006 Elsevier B.V. All rights reserved.	Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Dept Surg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Div Pediat Neurol, Dept Pediat, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med & Mol Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Brain Injury Res Ctr, Los Angeles, CA 90095 USA		Gurkoff, GG (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Dept Surg, Mail Code 703919,Room 18-228 NPI, Los Angeles, CA 90095 USA.	ggurkoff@ucla.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS02197, NS27544] Funding Source: Medline		Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; DIAMOND MC, 1972, J NEUROBIOL, V3, P47, DOI 10.1002/neu.480030105; DIAMOND MC, 1966, J COMP NEUROL, V128, P117, DOI 10.1002/cne.901280110; DIAMOND MC, 1964, J COMP NEUROL, V123, P111, DOI 10.1002/cne.901230110; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Giza CC, 2002, J NEUROTRAUM, V19, P387, DOI 10.1089/08977150252932352; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; GREENSPAN AI, 1994, PEDIATRICS, V94, P425; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HAYES RL, 1995, J NEUROTRAUM, V12, P933, DOI 10.1089/neu.1995.12.933; Hellmich HL, 2005, BRAIN RES, V1044, P144, DOI 10.1016/j.brainres.2005.02.054; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; HOVDA DA, 1990, ACT NEUR S, V51, P331; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KRAUS JF, 1990, NEUROSURGERY, V27, P334; LE HM, 1995, J NEUROTRAUM, V12, P129; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Narkilahti S, 2005, NEUROSCIENCE, V131, P887, DOI 10.1016/j.neuroscience.2004.12.013; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Posmantur RM, 2000, EXP NEUROL, V161, P15, DOI 10.1006/exnr.1999.7244; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; ROSENZWEIG MR, 1962, J COMP PHYSIOL PSYCH, V55, P429, DOI 10.1037/h0041137; RUDY JW, 1987, BEHAV NEUROSCI, V101, P62, DOI 10.1037/0735-7044.101.1.62; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Sanders MJ, 2001, BRAIN RES, V904, P141, DOI 10.1016/S0006-8993(01)02424-6; Sankar R, 1998, J NEUROSCI, V18, P8382; Sankar R, 1997, EPILEPSY RES, V28, P129, DOI 10.1016/S0920-1211(97)00040-5; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Shetty AK, 2004, J NEUROSCI RES, V78, P520, DOI 10.1002/jnr.20302; Skoglund TS, 1996, J NEUROSCI METH, V70, P201, DOI 10.1016/S0165-0270(96)00119-7; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Thompson K, 1998, NEUROSCIENCE, V82, P337; Thompson K, 1997, DEV BRAIN RES, V100, P1, DOI 10.1016/S0165-3806(96)00209-X; WEST MJ, 1990, J COMP NEUROL, V296, P1, DOI 10.1002/cne.902960102; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	73	83	86	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 10	2006	1077						24	36		10.1016/j.brainres.2006.01.011			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	030TZ	WOS:000236659000004	16490184				2022-02-06	
J	Walker, WC; Seel, RT; Curtiss, G; Warden, DL				Walker, WC; Seel, RT; Curtiss, G; Warden, DL			Headache after moderate and severe traumatic brain injury: A longitudinal analysis	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	63rd Annual Meeting of the American-Academy-of-Physical-Medicine-and-Rehabilitation	NOV 20-24, 2002	ORLANDO, FL	Amer Acad Phys Med & Rehabil		anxiety; brain injuries; depression; headache; rehabilitation	HAMILTON RATING-SCALE; BECK DEPRESSION INVENTORY; POSTTRAUMATIC HEADACHE; CHRONIC PAIN; EPIDEMIOLOGY; DISABILITY; COMPLAINTS; VALIDITY; ANXIETY; STATES	Objectives: To measure longitudinally headache (HA) after moderate and severe traumatic brain injury (TBI) and to examine potential association with demographic, injury, and psychologic factors. Design: Cohort study. Setting: Four Veterans Administration rehabilitation facilities (Minneapolis, Palo Alto, Richmond, Tampa) within the Defense and Veterans Brain Injury Center. Participants: Consecutive patients (military or veteran beneficiaries) with moderate or severe TBI (N = 109) who during acute rehabilitation consented to data collection and who completed 6- and 12-month follow-up evaluations. Interventions: Not applicable. Main Outcome Measures: HA frequency, location, type, and incapacitation levels measured during prospective neurologic assessments. Results: Nearly 38% (41/109) of patients had acute post-traumatic headache (PTHA) symptoms; most often in a frontal location (20/41), most often of daily frequency (31/41), and showing no relation to injury severity, emotional, or demographic variables. Postacutely, PTHA symptom severity declined within the group. Better individual improvement was associated with less anxiety and depression at 6-month follow-up. Almost all subjects (21/22) with PTHA symptoms that persisted into the 6-month follow-up period reported symptoms again at 12-month follow-up. Conclusions: PTHA severity in this sample of persons with moderate and severe TBI showed a pattern of improvement that leveled off by 6 months posthospitalization.	Hunter Holmes McGuire Vet Affairs Med Ctr, Richmond, VA USA; Crawford Res Inst, Sheperd Ctr, Atlanta, GA USA; James A Haley Vet Hosp, Tampa, FL 33612 USA; Univ S Florida, Dept Psychiat & Behav Med, Tampa, FL USA; Def & Vet Brain Injury Ctr, Washington, DC USA; Walter Reed Army Med Ctr, Washington, DC 20307 USA; Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA		Walker, WC (corresponding author), MCV Campus,POB 980661, Richmond, VA 23298 USA.	wc.walker@mail2.vcu.edu	Curtiss, Glenn/ABB-5566-2020; Walker, William C/N-3162-2014				Alfano Dennis P, 1990, Clin Neuropsychol, V4, P69, DOI 10.1080/13854049008401498; Annoni J M, 1992, Disabil Rehabil, V14, P23; BARNAT MR, 1986, HEADACHE, V26, P271, DOI 10.1111/j.1526-4610.1986.hed2606271.x; BECH P, 1975, ACTA PSYCHIAT SCAND, V51, P161, DOI 10.1111/j.1600-0447.1975.tb00002.x; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BROWN C, 1995, PSYCHOL ASSESSMENT, V7, P59; *COMM ACCR REH FAC, 2002, STAND MAN INT GUID M; COOLIGAN R, 1994, J CLIN PSYCHOL, V50, P168; Couch JR, 2001, HEADACHE, V41, P559, DOI 10.1046/j.1526-4610.2001.041006559.x; De Benedittis G, 1983, J Neurosurg Sci, V27, P177; GASS CS, 1991, J CLIN PSYCHOL, V47, P253, DOI 10.1002/1097-4679(199103)47:2<253::AID-JCLP2270470210>3.0.CO;2-A; GOLDSTEIN J, 1991, MED CLIN N AM, V75, P641, DOI 10.1016/S0025-7125(16)30439-4; Guy W., 1976, CLIN GLOBAL IMPRESSI; Hagen C., 1972, LEVELS COGNITIVE FUN; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50, DOI 10.1111/j.2044-8341.1959.tb00467.x; HAMMEN CL, 1980, J CONSULT CLIN PSYCH, V48, P126, DOI 10.1037/0022-006X.48.1.126; Hillier SL, 1997, BRAIN INJURY, V11, P661; Hines ME, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P375; Jacobson L, 2001, BONICAS MANAGEMENT P; JENSEN OK, 1990, CEPHALALGIA, V10, P285, DOI 10.1046/j.1468-2982.1990.1006285.x; JONES JH, 1992, ARCH PHYS MED REHAB, V73, P145; KNESEVICH JW, 1977, BRIT J PSYCHIAT, V131, P49, DOI 10.1192/bjp.131.1.49; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; MOWBRAY RM, 1972, PSYCHOL MED, V2, P272, DOI 10.1017/S0033291700042574; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Packard RC, 1999, J HEAD TRAUMA REHAB, V14, P9, DOI 10.1097/00001199-199902000-00004; PORTER JH, 1986, STAT APPL BEHAV SCI; RAMOSBRIEVA JA, 1988, J PSYCHIAT RES, V22, P21, DOI 10.1016/0022-3956(88)90024-6; RASMUSSEN BK, 1991, J CLIN EPIDEMIOL, V44, P1147, DOI 10.1016/0895-4356(91)90147-2; Rasmussen BK, 2001, CEPHALALGIA, V21, P774, DOI 10.1046/j.1468-2982.2001.00248.x; REHM LP, 1985, J PSYCHIAT RES, V19, P31, DOI 10.1016/0022-3956(85)90066-4; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RISKIND JH, 1987, J NERV MENT DIS, V175, P474, DOI 10.1097/00005053-198708000-00005; Salazar AM, 2000, J HEAD TRAUMA REHAB, V15, P1081, DOI 10.1097/00001199-200010000-00002; SALAZAR AM, 1999, BRAIN INJ SOURCE, V3, P8; STEWART WF, 1994, NEUROLOGY, V44, P24; TSUSHIMA WT, 1993, HEADACHE, V33, P139, DOI 10.1111/j.1526-4610.1993.hed3303139.x; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; YAMAGUCHI M, 1992, HEADACHE, V32, P427, DOI 10.1111/j.1526-4610.1992.hed3209427.x; ZIEGLER VE, 1978, BIOL PSYCHIAT, V13, P119; [No title captured]; 1988, CEPHALGIA, V8, P1	44	83	83	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2005	86	9					1793	1800		10.1016/j.apmr.2004.12.042			8	Rehabilitation; Sport Sciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	962QM	WOS:000231747300014	16181945				2022-02-06	
J	Hart, T; Whyte, J; Kim, J; Vaccaro, M				Hart, T; Whyte, J; Kim, J; Vaccaro, M			Executive function and self-awareness of "real-world" behavior and attention deficits following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						executive function; observational rating scales; self-awareness; traumatic brain njury	COGNITIVE-FAILURES-QUESTIONNAIRE; VERBAL FLUENCY TASKS; CLOSED-HEAD-INJURY; IMPAIRED AWARENESS; INDIVIDUAL-DIFFERENCES; FRONTAL-LOBE; CONSCIOUSNESS; REHABILITATION; DISTURBANCES; DYSFUNCTION	Objective: To investigate the relationship between executive function and awareness of real-world behavioral and attentional dysfunction in persons with moderate and severe traumatic brain injury (TBI) and uninjured controls. Design: Observational 2-group study. Participants: Thirty-six persons with moderate to severe TBI and residual cognitive deficits, recruited from therapy programs and the community, and 30 uninjured control participants of similar age, education, gender, and race. Measures: Eight clinical measures of executive function were combined in a composite score, the Executive Composite (EC). Awareness of behavioral and attentional lapses in everyday life was estimated using Self and Significant Other (SO) ratings on the Dysexecutive (DEX) Questionnaire and the Cognitive Failures Questionnaire (CFQ). Results: Participants with TBI scored significantly worse on the EC than control participants and exhibited impaired self-awareness (ISA) compared to controls. Control participants agreed closely with their SOs on both the DEX and CFQ scales, whereas the SOs of TBI participants reported significantly greater degrees of difficulty on both scales than was endorsed by participants with TBI. Low-EC scorers within the TBI group had significantly worse ISA than controls, lending support to the hypothesis that executive function is related to ISA in chronic, moderate to severe TBI. Executive function and discrepancy scores demonstrated a modest but statistically significant association across the sample. Conclusion: Although executive function was associated with ISA in this sample, further research is needed to determine whether executive function deficits contribute in a causal fashion to ISA, and which of the cognitive operations within executive function are responsible for supporting self-awareness.	Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Moss Rehabil Res Inst, Elkins Pk, PA USA; Jefferson Med Coll, Dept Rehabil Med, Philadelphia, PA 19107 USA		Hart, T (corresponding author), Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.	thart@einstein.edu	Kim, Junghoon John/I-6702-2019; Kim, Junghoon/A-6669-2012	Kim, Junghoon John/0000-0001-5729-8993; Whyte, John/0000-0002-4381-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039163] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS39163] Funding Source: Medline		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Baddeley A, 1998, J INT NEUROPSYCH SOC, V4, P523, DOI 10.1017/S135561779800513X; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Benton AL, 1994, MULTILINGUAL APHASIA; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; BROWN J, 1958, Q J EXP PSYCHOL, V10, P12, DOI 10.1080/17470215808416249; Burgess P, 1996, BEHAV ASSESSMENT DYS; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; Hart T, 2004, ARCH PHYS MED REHAB, V85, P1450, DOI 10.1016/j.apmr.2004.01.030; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; Hart T, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P133; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Jones GV, 2003, APPL COGNITIVE PSYCH, V17, P861, DOI 10.1002/acp.935; KIM J, IN PRESS J INT NEURO; Kruger J, 1999, J PERS SOC PSYCHOL, V77, P1121, DOI 10.1037/0022-3514.77.6.1121; Kruger J, 2004, PERS SOC PSYCHOL B, V30, P328, DOI 10.1177/0146167203259932; Larson GE, 1997, BRIT J PSYCHOL, V88, P29, DOI 10.1111/j.2044-8295.1997.tb02618.x; Lee GP, 1997, CLIN NEUROPSYCHOL, V11, P59, DOI 10.1080/13854049708407030; LEVINE B, 1995, J CLIN EXP NEUROPSYC, V17, P740, DOI 10.1080/01688639508405164; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Malec JF, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199706000-00002; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MEIRAN N, 1994, PERS INDIV DIFFER, V17, P727, DOI 10.1016/0191-8869(94)90042-6; Newman AC, 2000, BRAIN INJURY, V14, P333; Ownsworth TL, 2002, BRAIN INJURY, V16, P291, DOI 10.1080/02699050110103986; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; PETRIDES M, 1982, NEUROPSYCHOLOGIA, V20, P249, DOI 10.1016/0028-3932(82)90100-2; Prigatano GP, 2003, NEUROPSYCHOL REHABIL, V13, P13, DOI 10.1080/09602010244000282; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; Prigozhin L, 1996, FREE BOUNDARY PROBLE, V10, P2; Randolph C., 1993, NEUROPSYCHOLOGY, V7, P82, DOI [10.1037/0894-4105.7.1.82, DOI 10.1037/0894-4105.7.1.82]; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; REGARD M, 1982, PERCEPT MOTOR SKILL, V55, P839, DOI 10.2466/pms.1982.55.3.839; Reitan R, 1985, HALSTEAD REITAN NEUR; Royall DR, 2002, J NEUROPSYCH CLIN N, V14, P377, DOI 10.1176/appi.neuropsych.14.4.377; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; Stuss DT, 2004, BRAIN COGNITION, V55, P69, DOI 10.1016/s0278-2626(03)00271-9; TEASDALE G, 1974, LANCET, V2, P81; Trenerry MR, 1989, STROOP NEUROPSYCHOLO; Troyer AK, 2000, J CLIN EXP NEUROPSYC, V22, P370, DOI 10.1076/1380-3395(200006)22:3;1-V;FT370; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; Wagle AC, 1999, COMPR PSYCHIAT, V40, P478, DOI 10.1016/S0010-440X(99)90093-7; Wallace JC, 2003, J BUS PSYCHOL, V17, P503, DOI 10.1023/A:1023452218225; Wechsler D., 1997, WECHSLER MEMORY SCAL; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3	56	83	84	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2005	20	4					333	347		10.1097/00001199-200507000-00005			15	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	941MV	WOS:000230219800005	16030440				2022-02-06	
J	Suehiro, E; Fujisawa, H; Akimura, T; Ishihara, H; Kajiwara, K; Kato, S; Fujii, M; Yamashita, S; Maekawa, T; Suzuki, M				Suehiro, E; Fujisawa, H; Akimura, T; Ishihara, H; Kajiwara, K; Kato, S; Fujii, M; Yamashita, S; Maekawa, T; Suzuki, M			Increased matrix metalloproteinase-9 in blood in association with activation of interleukin-6 after traumatic brain injury: Influence of hypothermic therapy	JOURNAL OF NEUROTRAUMA			English	Article						blood-brain barrier; hypothermia; interleukin-6; matrix metalloproteinase-9; traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; MATRIX METALLOPROTEINASES; CYCLOSPORINE-A; RAT; EXPRESSION; BARRIER; TRANSCRIPTION; INHIBITION; ASTROCYTES; MICROGLIA	Recent experimental data have shown that levels of matrix metalloproteinase-9 (MMP-9) increase after traumatic brain injury (TBI), degrading components of the basal lamina disrupting the blood-brain barrier. However, the post-traumatic secretion patterns of MMP-9 in humans are unknown. We measured the concentration of MMP-9 in plasma after TBI at the same time as the concentration of interleukin-6 (IL-6) in serum. Levels of MMP-9 and IL-6 in systemic arterial and jugular venous blood from seven patients with TBI were measured on days 0 and 1 post-injury. All patients underwent hypothermia at 32-35 degreesC as soon as possible after admission. Before induction of hypothermia, levels of MMP-9 in arterial and internal jugular venous blood exceeded the normal range. Higher MMP-9 levels were detected in internal jugular venous blood than in arterial blood. After hypothermia had been induced, MMP-9 levels in arterial blood and internal jugular venous blood decreased significantly, to within the normal range. In addition to these changes, a significant correlation was seen between levels of MMP-9 and IL-6 in internal jugular venous blood during the investigation period. These results indicate that MMP-9 is elevated in patients with acute TBI, and may play an important role in traumatic brain damage. The elevation of MMP-9 is associated with inflammatory events following TBI. Hypothermic intervention may suppress the elevation of MMP-9 with suppression of the inflammatory response, affording neuroprotection in TBI.	Yamaguchi Univ, Sch Med, Dept Neurosurg, Ube, Yamaguchi 7558505, Japan; Yamaguchi Univ, Sch Med, Adv Med Emergency & Crit Care Ctr, Ube, Yamaguchi 7558505, Japan		Suehiro, E (corresponding author), Yamaguchi Univ, Sch Med, Dept Neurosurg, 1-1-1 Minamikogushi, Ube, Yamaguchi 7558505, Japan.	suehiro-nsu@umin.ac.jp	Suehiro, Eiichi/I-5852-2019				Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; Gasche Y, 1999, J CEREBR BLOOD F MET, V19, P1020, DOI 10.1097/00004647-199909000-00010; GOTTSCHALL PE, 1995, J NEUROSCI RES, V42, P335, DOI 10.1002/jnr.490420307; GOTTSCHALL PE, 1995, J NEUROCHEM, V64, P1513; Harkness KA, 2000, BRAIN, V123, P698, DOI 10.1093/brain/123.4.698; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Morita-Fujimura Y, 2000, J CEREBR BLOOD F MET, V20, P130, DOI 10.1097/00004647-200001000-00017; Mun-Bryce S, 1998, J CEREBR BLOOD F MET, V18, P1163, DOI 10.1097/00004647-199811000-00001; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Petty MA, 2002, PROG NEUROBIOL, V68, P311, DOI 10.1016/S0301-0082(02)00128-4; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rosenberg GA, 1996, J CEREBR BLOOD F MET, V16, P360, DOI 10.1097/00004647-199605000-00002; Rosenberg GA, 1997, NEUROLOGY, V48, P921, DOI 10.1212/WNL.48.4.921; Rosenberg GA, 2001, BRAIN RES, V893, P104, DOI 10.1016/S0006-8993(00)03294-7; Schumann G, 1999, J NEUROCHEM, V73, P2009; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Yamamoto T, 2002, NEUROL RES, V24, P789, DOI 10.1179/016164102101200906; Zawadzka M, 2003, MOL CELL NEUROSCI, V22, P202, DOI 10.1016/S1044-7431(03)00036-8; Zhang ZG, 2001, BRAIN RES, V912, P181, DOI 10.1016/S0006-8993(01)02735-4	25	83	90	0	3	MARY ANN LIEBERT INC	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2004	21	12					1706	1711		10.1089/0897715042664957			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	877FY	WOS:000225554400002	15684762				2022-02-06	
J	Hammond, FM; Grattan, KD; Sasser, H; Corrigan, JD; Rosenthal, M; Bushnik, T; Shull, W				Hammond, FM; Grattan, KD; Sasser, H; Corrigan, JD; Rosenthal, M; Bushnik, T; Shull, W			Five years after traumatic brain injury: A study of individual outcomes and predictors of change in function	NEUROREHABILITATION			English	Article						brain injury; outcome; function; disability rating scale; prediction; employment	DISABILITY RATING-SCALE; SEVERE HEAD-INJURY; SYSTEMATIC BIAS; FOLLOW-UP; RECOVERY; VALIDITY; MODERATE; RETURN; WORK; COMA	Objective: Study functional changes between one and five years after traumatic brain injury (TBI). Design: Prospective cohort. Setting and participants: TBI Model Systems National Database subjects using cohort with complete one and five year data (n = 301). Main outcome measures: Disability Rating Scale (DRS) Level of Functioning and Employability Items. Results: On Level of Functioning, 53 (18%) individuals improved, 228 (76%) stayed the same, and 20 (7%) worsened by more than one point from Year 1 to Year 5. On Employability, 50 (17%) individuals improved, 237 (79%) stayed the same, and 14 (5%) worsened by greater than one point. Level of Functioning improvement was predicted by FIM(TM)-Motor, FIM(TM)-Cognitive, Rey Auditory Verbal Learning Test, Symbol Digit Modalities Test (written and oral), and Wechsler Adult Intelligence Scale-Revised Block Design, and worsening predicted by Symbol Digit Modalities Test (written and oral). Improvement in Employability was predicted by race, while Glasgow Coma Scale Eye Opening was predictive of worsening. Conclusions: Although the majority did not demonstrate meaningful change on the DRS items from year 1 to 5, some individuals made dramatic gains and a minority declined. There are demographic and functional indicators present at one-year post-injury that may be predictive of subsequent change.	Carolinas HealthCare Syst, Charlotte Inst Rehabil, Dept Phys Med & Rehabil, Charlotte, NC 28203 USA; Carolinas HealthCare Syst, R Stuart Dickson Inst Hlth Studies, Charlotte, NC USA; Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA; Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, San Jose, CA 95128 USA; Univ Penn, Dept Rehabil Med, Philadelphia, PA 19104 USA		Hammond, FM (corresponding author), Carolinas HealthCare Syst, Charlotte Inst Rehabil, Dept Phys Med & Rehabil, 1100 Blythe Blvd, Charlotte, NC 28203 USA.	Flora.hammond@carolinashealthcare.org	Corrigan, John D./E-2921-2011	Bushnik, Tamara/0000-0003-3328-257X			COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; ELIASON MR, 1984, PHYS THER, V64, P1357, DOI 10.1093/ptj/64.9.1357; FRYER LJ, 1987, J HEAD TRAUMA REHAB, V2, P51, DOI DOI 10.1097/00001199-198709000-00007; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; HAMMOND F, 2000, ARCH PHYS MED REHAB, V81, P1268; HAMMOND F, 2000, ARCH PHYS MED REHAB, V81, P1259; Hammond FM, 2001, J HEAD TRAUMA REHAB, V16, P318, DOI 10.1097/00001199-200108000-00003; HEATON RK, 1981, COMPREHENSIVE NORMS; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; Lezak MD., 1983, NEUROPSYCHOLOGICAL A, V2nd ed.; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; NOVACK TA, 1991, J HEAD TRAUMA REHAB, V6, P69, DOI DOI 10.1097/00001199-199112000-00014; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Olver JH, 1995, CURR OPIN NEUROL, V8, P443, DOI 10.1097/00019052-199512000-00008; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; *SAS I INC, 1995, SAS FUND PROGR APPR; Shiozaki T, 2001, J NEUROTRAUM, V18, P665, DOI 10.1089/089771501750357618; Smith A., 1982, SYMBOL DIGIT MODALIT; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Wechsler D., 1981, WECHSLER INTELLIGENC, V3rd; WIERCISIEWSKI D, 2000, ARCH PHYS MED REHAB, V81, P1628; Zafonte RD, 1996, NEUROREHABILITATION, V6, P19, DOI 10.3233/NRE-1996-6104; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P456, DOI 10.1097/00002060-199611000-00011; 1998, TRAUMATIC BRAIN INJU	42	83	85	0	11	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2004	19	1					25	35					11	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	777KA	WOS:000189176500004	14988585				2022-02-06	
J	Pickett, W; Simpson, K; Walker, J; Brison, RJ				Pickett, W; Simpson, K; Walker, J; Brison, RJ			Traumatic spinal cord injury in Ontario, Canada	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						spinal cord injury; neurotrauma; blunt trauma; hospital admissions; injury surveillance; prevention; Canada	NATIONWIDE EPIDEMIOLOGIC SURVEY; UNITED-STATES; LIFE SATISFACTION; REGION; HEALTH; COUNTY; JAPAN; HEAD	Background. Few population-based analyses of spinal cord injuries exist from which to base Canadian prevention initiatives. This study aimed to calculate rates of traumatic spinal cord injury for the province of Ontario and describe these injuries by several epidemiologic parameters. Methods. Two thousand three hundred eighty-five hospital admissions were studied for April 1, 1994, through March 319 1999. Results. Annual age-standardized rates declined from a maximum of 46.2 hospitalizations per 1 million population (95% confidence interval, 42.1-50.3) to 37.2 per 1 million (95% confidence interval, 33.8-41.0). Male rates declined over the study period, whereas female rates remained stable. Leading external causes included unintentional falls (1,030 of 2,385 [43.2%]), especially among the elderly, and transport injuries (1,021 of 2,385 [42.8%]), especially among those aged less than 40 years. Intentional injuries were most commonly seen among those aged 20 to 39 years (48 of 86 [55.8%]). Misclassification of some elder fall cases as spinal cord injuries is a methodologic concern. Conclusion. The results indicate the relative importance of several external causes of injury and are useful in establishing rational priorities for prevention.	Queens Univ, Dept Emergency Med, Kingston, ON, Canada; Queens Univ, Dept Community Hlth & Epidemiol, Kingston, ON, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada; W Pk Healthcare Ctr, Clin Evaluat & Res Unit, Toronto, ON, Canada		Pickett, W (corresponding author), Kingston Gen Hosp, Dept Emergency Med, Angada 3,76 Stuart St, Kingston, ON K7L 2V7, Canada.	pickettW@post.queensu.ca					ACTON PA, 1993, ARCH PHYS MED REHAB, V74, P1035, DOI 10.1016/0003-9993(93)90058-I; Anderson GM, 1997, MED CARE, V35, pOS93, DOI 10.1097/00005650-199710001-00012; ANDREWS LG, 1979, PARAPLEGIA, V17, P442, DOI 10.1038/sc.1979.87; AO JDY, 1993, PARAPLEGIA, V31, P759; BO BK, 1995, SPINAL CORD INJURY C, P21; Botterell E H, 1975, Can J Neurol Sci, V2, P361; BRACKEN MB, 1981, AM J EPIDEMIOL, V113, P615, DOI 10.1093/oxfordjournals.aje.a113140; BRESLOW NE, 1987, IARC SCI PUBL, V82, P52; Burke DA, 2001, SPINAL CORD, V39, P274, DOI 10.1038/sj.sc.3101158; BURNEY RE, 1993, ARCH SURG-CHICAGO, V128, P596; *CAN I HLTH INF, 2001, ONT TRAUM REG 2001 R; *CAN I HLTH INF, 1999, SPIN CORD INJ ADM ON; *CAND I HLTH INF, 2001, NEUR HOSP ONT 1998 9; *CAND PAR ASS, 2000, CPA 2000 ANN REP; Cantella D, 1999, Crit Care Nurs Q, V22, P14; Carriere KC, 2000, HEALTH SERV RES, V35, P467; DANESH JN, 1991, NEW ZEAL MED J, V104, P295; DeVivo M, 1995, SPINAL CORD INJURY C, P234; DeVivo MJ, 1997, SPINAL CORD, V35, P809, DOI 10.1038/sj.sc.3100501; Dunnum L, 1990, J Neurosci Nurs, V22, P43; FINE PR, 1979, PARAPLEGIA, V17, P237, DOI 10.1038/sc.1979.47; GRIFFIN MR, 1985, AM J EPIDEMIOL, V121, P884, DOI 10.1093/oxfordjournals.aje.a114058; Hartkopp A, 1997, SPINAL CORD, V35, P76, DOI 10.1038/sj.sc.3100351; Hoque MF, 1999, SPINAL CORD, V37, P858, DOI 10.1038/sj.sc.3100938; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; Karamehmetoglu SS, 1997, SPINAL CORD, V35, P531, DOI 10.1038/sj.sc.3100404; KRAMER CF, 1995, J TRAUMA, V39, P935, DOI 10.1097/00005373-199511000-00019; KRAUS JF, 1980, J NEUROSURG, V53, pS3; Krause JS, 2000, SPINAL CORD, V38, P77, DOI 10.1038/sj.sc.3100961; LAN C, 1993, PARAPLEGIA, V31, P398, DOI 10.1038/sc.1993.66; LASFARGUES JE, 1995, PARAPLEGIA, V33, P62, DOI 10.1038/sc.1995.16; Maharaj JC, 1996, SPINAL CORD, V34, P549, DOI 10.1038/sc.1996.99; Martins F, 1998, SPINAL CORD, V36, P574, DOI 10.1038/sj.sc.3100657; McColl MA, 1997, SPINAL CORD, V35, P818, DOI 10.1038/sj.sc.3100546; Miller T.R., 1995, DATABOOK NONFATAL IN; MINAIRE P, 1978, PARAPLEGIA, V16, P76, DOI 10.1038/sc.1978.13; NOBUNGA AI, 2002, ARCH PHYS MED REHAB, V80, P1372; Otom AS, 1997, SPINAL CORD, V35, P253, DOI 10.1038/sj.sc.3100402; Pajareya K, 1996, SPINAL CORD, V34, P608, DOI 10.1038/sc.1996.108; Post MWM, 1998, ARCH PHYS MED REHAB, V79, P395, DOI 10.1016/S0003-9993(98)90139-3; PRICE C, 1994, AM J EPIDEMIOL, V139, P37, DOI 10.1093/oxfordjournals.aje.a116933; Richards JS, 1999, ARCH PHYS MED REHAB, V80, P1501; SHINGU H, 1995, PARAPLEGIA, V33, P183, DOI 10.1038/sc.1995.42; SHINGU H, 1994, PARAPLEGIA, V32, P3, DOI 10.1038/sc.1994.2; SILBERSTEIN B, 1995, PARAPLEGIA, V33, P322, DOI 10.1038/sc.1995.72; *SMARTR, 1999, EC BURD UN INJ ONT; SOOPRAMANIEN A, 1994, PARAPLEGIA, V32, P715, DOI 10.1038/sc.1994.116; *STAT CAN, 2000, 91213 STAT CAN; STOVER SL, 1987, PARAPLEGIA, V25, P225, DOI 10.1038/sc.1987.40; Sullivan J, 1999, Crit Care Nurs Q, V22, P80; Surkin J, 2000, SPINE, V25, P716, DOI 10.1097/00007632-200003150-00011; Tarazi F, 1999, AM J SPORT MED, V27, P177, DOI 10.1177/03635465990270021101; TATOR CH, 1993, SURG NEUROL, V40, P207, DOI 10.1016/0090-3019(93)90069-D; Tator CH, 2000, CAN MED ASSOC J, V162, P787; THURMAN DJ, 1994, PARAPLEGIA, V32, P665, DOI 10.1038/sc.1994.107; Tyroch AH, 1997, ARCH SURG-CHICAGO, V132, P778; van Asbeck FWA, 2000, SPINAL CORD, V38, P420, DOI 10.1038/sj.sc.3101003; World Health Organization, 1985, INT CLASS DIS; Yeo JD, 1998, SPINAL CORD, V36, P329, DOI 10.1038/sj.sc.3100628	59	83	87	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2003	55	6					1070	1076		10.1097/01.TA.0000034228.18541.D1			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	758TL	WOS:000187666200012	14676653				2022-02-06	
J	Zweckberger, K; Stoffel, M; Baethmann, A; Plesnila, N				Zweckberger, K; Stoffel, M; Baethmann, A; Plesnila, N			Effect of decompression craniotomy on increase of contusion volume and functional outcome after controlled cortical impact in mice	JOURNAL OF NEUROTRAUMA			English	Article						craniotomy; functional outcome; intracranial pressure; neuroprotection; traumatic brain injury	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; INTRACRANIAL-PRESSURE; SURGICAL DECOMPRESSION; MANAGEMENT; CRANIECTOMY; HALOTHANE; RABBITS; MOUSE; EDEMA	If, how, and when decompressive craniotomy should be used for the treatment of increased intracranial pressure after traumatic brain injury are widely discussed clinical subjects. Despite the large number of clinical studies addressing this issue, experimental evidence of a beneficial or detrimental role of decompressive craniotomy after brain trauma is sparse. Therefore, we investigated the influence of craniotomy on intracranial pressure, contusion volume, and functional outcome in a model of traumatic brain injury in mice. Male C57/B16 mice were craniotomized above the right parietal cortex and were subjected to controlled cortical impact injury. In control mice, the craniotomy was closed immediately after trauma, whereas in treated animals the craniotomy was left open. In control mice intracranial pressure (ICP) increased to a.maximum of 23.7 +/- 3.1 mm Hg 6 h after trauma (p < 0.001),while in craniotomized animals; no ICP increase was observed. Twenty-four hours after trauma, the point in time of maximal lesion expansion, contusion volume in craniotomized mice was 40% smaller as compared to controls (18.3 +/- 2.0 vs. 30.2 +/- 3.5 mm(3), p < 0.04). Furthermore, craniotomized mice showed significantly improved motor function in a beam walking task (p < 0.04) and faster recovery of body weight after trauma (p < 0.02). Our results demonstrate that craniotomy blunts post-traumatic ICP increase, significantly reduces secondary brain damage and improves functional outcome after experimental TBI. Careful clinical evaluation of craniotomy as a therapeutic option after TBI in man may therefore be indicated.	Univ Munich, Klinikum Grosshadern, Inst Surg Res, D-8000 Munich, Germany; Univ Bonn, Dept Neurosurg, D-5300 Bonn, Germany		Plesnila, N (corresponding author), Univ Munich, Klinikum Grosshadern, Inst Surg Res, D-8000 Munich, Germany.	plesnila@icf.med.uni-muenchen.de	Plesnila, Nikolaus/T-7522-2019				BAETHMAN A, 1978, NEUROSURG REV, V1, P85; Burkert W, 1989, Zentralbl Neurochir, V50, P106; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; CUNITZ G, 1976, ANAESTHESIST, V25, P323; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; GAAB M, 1979, CHILD BRAIN, V5, P484; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Hans P, 1980, Acta Anaesthesiol Belg, V31 Suppl, P49; JENNETT B, 1980, J NEUROL NEUROSUR PS, V43, P289, DOI 10.1136/jnnp.43.4.289; Kocher T., 1901, HIRNERSCHUTTERUNG HI, V3, P262; Liu H, 2002, J NEUROTRAUM, V19, P327, DOI 10.1089/089771502753594891; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MOODY RA, 1968, J NEUROSURG, V29, P586, DOI 10.3171/jns.1968.29.6.0586; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Ogawa M, 1974, Med J Osaka Univ, V25, P73; Piek Jurgen, 2002, Curr Opin Crit Care, V8, P134, DOI 10.1097/00075198-200204000-00008; RINALDI A, 1990, ACT NEUR S, V51, P394; SCHELLER MS, 1987, ANESTHESIOLOGY, V67, P507, DOI 10.1097/00000542-198710000-00011; The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P537; Wilberger J, 1991, Neurosurg Clin N Am, V2, P341; ZORNOW MH, 1992, ANESTH ANALG, V75, P232	23	83	85	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2003	20	12					1307	1314		10.1089/089771503322686102			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	756XH	WOS:000187510700003	14748979				2022-02-06	
J	WoldeMussie, E; Yoles, E; Schwartz, M; Ruiz, G; Wheeler, LA				WoldeMussie, E; Yoles, E; Schwartz, M; Ruiz, G; Wheeler, LA			Neuroprotective effect of memantine in different retinal injury models in rats	JOURNAL OF GLAUCOMA			English	Article						chronic ocular hypertension; ganglion cells; memantine; neuroprotection; optic nerve	NMDA-RECEPTOR ANTAGONIST; CHANNEL BLOCKER MEMANTINE; TRAUMATIC BRAIN INJURY; OPTIC-NERVE CRUSH; GANGLION-CELLS; GLUTAMATE NEUROTOXICITY; PARKINSONS-DISEASE; VITREOUS BODY; ISCHEMIA; GLAUCOMA	Purpose: To evaluate the neuroprotective effect of memantine, an NMDA receptor channel blocker, in two retinal ganglion cell (RGC) injury models in rats. Methods: Neuroprotective effect of memantine was tested in partial optic nerve injury and chronic ocular hypertensive models. In the optic nerve injury model, memantine (0.1 - 30 mg/kg) was injected intraperitoneally immediately after injury. Two weeks later, optic nerve function was determined by measuring compound action potential and surviving RGC was determined by retrograde labeling with dextran tetramethyl rhodamine. Chronic ocular hypertension was attained by laser photocoagulation of episcleral and limbal veins. Memantine (5 or 10 mg/kg) was administered continuously each day with an osmotic pump, either immediately after or 10 days after first laser photocoagulation, for 3 weeks, after which RGC survival was determined. Results: Two weeks after partial optic nerve injury, there was approximate to80% reduction in RGC number. Memantine (5 mg/kg) caused a twofold increase in compound action potential amplitude and a 1.7-fold increase in survival of RGCs, respectively. In the chronic ocular hypertension model there was 37% decrease in RGCS after 3 weeks of elevated intraocular pressure. Memantine (10 mg/kg daily) reduced ganglion cell loss to 12% when applied immediately after first laser photocoagulation, and prevented any further loss when applied 10 days after first laser photocoagulation. Conclusion: The protective effect of memantine suggests that excessive stimulation of NMDA receptors by glutamate is involved in causing cell damage in these RGC injury models.	Allergan Pharmaceut Inc, Dept Sci Biol, Irvine, CA USA; Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel		WoldeMussie, E (corresponding author), Allergan Pharmaceut Inc, Dept Sci Biol, 2525 Dupont Dr, Irvine, CA USA.	WoldeMussieLiz@allergan.com					ABUELASRAR AM, 1992, INVEST OPHTH VIS SCI, V33, P3463; Block F, 1996, NEUROSCI LETT, V208, P41, DOI 10.1016/0304-3940(96)12545-3; BORMANN J, 1989, EUR J PHARMACOL, V166, P591, DOI 10.1016/0014-2999(89)90385-3; Brooks DE, 1997, AM J VET RES, V58, P864; Chaudhary P, 1998, BRAIN RES, V792, P154, DOI 10.1016/S0006-8993(98)00212-1; Chen HSV, 1998, NEUROSCIENCE, V86, P1121, DOI 10.1016/S0306-4522(98)00163-8; CHEN HSV, 1992, J NEUROSCI, V12, P4427; Chen HSV, 1997, J PHYSIOL-LONDON, V499, P27, DOI 10.1113/jphysiol.1997.sp021909; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Danysz W, 2002, CURR PHARM DESIGN, V8, P835, DOI 10.2174/1381612024607117; Donello JE, 2001, J PHARMACOL EXP THER, V296, P216; Dresser R, 2000, SCIENCE, V289, P869; Dreyer EB, 1996, ARCH OPHTHALMOL-CHIC, V114, P299, DOI 10.1001/archopht.1996.01100130295012; Dreyer EB, 1997, CLIN NEUROSCI, V4, P270; FREESE A, 1990, BRAIN RES, V521, P254, DOI 10.1016/0006-8993(90)91550-Z; GORTELMEYER R, 1992, ARZNEIMITTEL-FORSCH, V42-2, P904; Jain KK, 2000, EXPERT OPIN INV DRUG, V9, P1397, DOI 10.1517/13543784.9.6.1397; Jones MW, 2002, SEIZURE-EUR J EPILEP, V11, P104, DOI 10.1053/seiz.2002.0589; Kornhuber J, 1997, BIOL PSYCHIAT, V41, P135, DOI 10.1016/S0006-3223(96)00047-9; KORNHUBER J, 1995, NEUROSCI LETT, V195, P137, DOI 10.1016/0304-3940(95)11785-U; Kreutz MR, 1999, RESTOR NEUROL NEUROS, V14, P127; Lagreze WA, 1998, INVEST OPHTH VIS SCI, V39, P1063; Lam TT, 1997, J OCUL PHARMACOL TH, V13, P129, DOI 10.1089/jop.1997.13.129; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LOUZADAJUNIOR P, 1992, J NEUROCHEM, V59, P358, DOI 10.1111/j.1471-4159.1992.tb08912.x; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; Melton ST, 1997, ANN PHARMACOTHER, V31, P457, DOI 10.1177/106002809703100413; Neufeld AH, 1999, SURV OPHTHALMOL, V43, pS129, DOI 10.1016/S0039-6257(99)00010-7; Neufeld AH, 1999, P NATL ACAD SCI USA, V96, P9944, DOI 10.1073/pnas.96.17.9944; Nikolajsen L, 2000, ANESTH ANALG, V91, P960, DOI 10.1097/00000539-200010000-00036; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; Osborne NN, 1999, VISUAL NEUROSCI, V16, P45, DOI 10.1017/S0952523899161017; Parsons CG, 1999, NEUROPHARMACOLOGY, V38, P735, DOI 10.1016/S0028-3908(99)00019-2; PARSONS CG, 1995, NEUROPHARMACOLOGY, V34, P1239, DOI 10.1016/0028-3908(95)00092-K; Pease ME, 2000, INVEST OPHTH VIS SCI, V41, P764; RABEY JM, 1992, J NEURAL TRANSM-PARK, V4, P277, DOI 10.1007/BF02260076; Rao VLR, 2001, BRAIN RES, V911, P96; RIEDERER P, 1991, LANCET, V338, P1022, DOI 10.1016/0140-6736(91)91888-2; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Schmitt U, 1996, J NEUROTRAUM, V13, P791, DOI 10.1089/neu.1996.13.791; Solberg Y, 1997, INVEST OPHTH VIS SCI, V38, P1380; Stieg PE, 1999, EUR J PHARMACOL, V375, P115, DOI 10.1016/S0014-2999(99)00214-9; Sucher N J, 1990, Neuroreport, V1, P29, DOI 10.1097/00001756-199009000-00009; Vorwerk CK, 1996, INVEST OPHTH VIS SCI, V37, P1618; Wilkinson D, 2001, INT J CLIN PRACT, V55, P129; WoldeMussie E, 2001, INVEST OPHTH VIS SCI, V42, P2849; Yoles E, 1996, J NEUROTRAUM, V13, P49, DOI 10.1089/neu.1996.13.49; Yoles E, 1999, INVEST OPHTH VIS SCI, V40, P65; Yoles E, 1997, J NEUROTRAUM, V14, P665, DOI 10.1089/neu.1997.14.665; Yoles E, 1998, ARCH OPHTHALMOL-CHIC, V116, P906, DOI 10.1001/archopht.116.7.906	51	83	87	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1057-0829	1536-481X		J GLAUCOMA	J. Glaucoma	DEC	2002	11	6					474	480		10.1097/00061198-200212000-00003			7	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Ophthalmology	628UV	WOS:000180015700003	12483089				2022-02-06	
J	Donders, J; Hoffman, NA				Donders, J; Hoffman, NA			Gender differences in learning and memory after pediatric traumatic brain injury	NEUROPSYCHOLOGY			English	Article							SEX-DIFFERENCES; HEAD-INJURY; READING-DISABILITY; CHILDREN; RECOVERY; LATERALIZATION; ADOLESCENTS; PERFORMANCE; DAMAGE; MILD	Thirty boys and 30 girls who sustained a traumatic brain injury (TBI) were evaluated within I year postinjury with the California Verbal Learning Test-Children's Version (CVLT-C; D. C. Delis, J. H. Kramer, E. Kaplan, & B. A. Ober, 1994). Boys had statistically significantly lower performance on the CVLT-C than girls in the absence of statistically significant group differences on various demographic and neurological variables. Although the effect size for this difference was modest (eta(2) = .09), gender accounted for a statistically significant amount of the variance (5%) in CVLT-C scores in addition to effects of injury severity and age. It is concluded that male gender is associated with an increased risk for retrieval deficits after pediatric TBI, possibly because of reduced speed or efficiency of information processing.	Mary Free Bed Hosp, Psychol Serv, Grand Rapids, MI 49503 USA; Rehabil Ctr, Grand Rapids, MI USA		Donders, J (corresponding author), Mary Free Bed Hosp, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.	jdonders@mfbrc.com					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Anderson VA, 2000, BRAIN INJURY, V14, P679; Badian NA, 1999, J LEARN DISABIL, V32, P138, DOI 10.1177/002221949903200204; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; BERNEY J, 1994, CHILD NERV SYST, V10, P517, DOI 10.1007/BF00335074; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; BJORKLUND DF, 1997, DEV MEMORY CHILDHOOD, P00201; BRYDEN MP, 1994, BRAIN COGNITION, V26, P103, DOI 10.1006/brcg.1994.1045; Cernak I, 1999, BRAIN INJURY, V13, P1005; Ciccetti D., 1984, VINELAND ADAPTIVE BE; Delis DC., 1994, CALIFORNIA VERBAL LE; Dennis M, 2000, BRAIN COGNITION, V42, P102, DOI 10.1006/brcg.1999.1174; Dennis M, 2000, SCI PRACT NEUROPSYCH, P3; Donders J, 1999, DEV NEUROPSYCHOL, V15, P395, DOI 10.1080/87565649909540757; Donders J, 1997, ASSESSMENT, V4, P107, DOI 10.1177/107319119700400114; DONDERS J, 1998, HDB PEDIAT PSYCHOL P, V2, P166; DONDERS J, 1995, ASSESSMENT, V2, P219; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Farmer JE, 1999, DEV NEUROPSYCHOL, V15, P269, DOI 10.1080/87565649909540749; Flannery KA, 2000, J INT NEUROPSYCH SOC, V6, P433, DOI 10.1017/S1355617700644016; GESCHWIND N, 1985, ARCH NEUROL-CHICAGO, V42, P428, DOI 10.1001/archneur.1985.04060050026008; GRUMBACH MM, 1998, WILLIAMS TXB ENDOCRI, P1509; Hiscock M, 1999, J CLIN EXP NEUROPSYC, V21, P17, DOI 10.1076/jcen.21.1.17.944; Hoffman N, 2000, ARCH CLIN NEUROPSYCH, V15, P47, DOI 10.1016/S0887-6177(98)00156-5; Hostler SL, 1999, J HEAD TRAUMA REHAB, V14, P384, DOI 10.1097/00001199-199908000-00007; HUGDAHL K, 1990, NEUROPSYCHOLOGIA, V28, P673, DOI 10.1016/0028-3932(90)90122-5; Kolb B, 2000, DEV NEUROPSYCHOL, V18, P423, DOI 10.1207/S1532694208Kolb; Kolk A, 2000, J CHILD NEUROL, V15, P581, DOI 10.1177/088307380001500903; Kramer JH, 1997, NEUROPSYCHOLOGY, V11, P577, DOI 10.1037/0894-4105.11.4.577; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Levin HS, 2000, J CLIN EXP NEUROPSYC, V22, P1, DOI 10.1076/1380-3395(200002)22:1;1-8;FT001; MADIGAN KA, 1997, STUDENTS ACQUIRED BR, P123; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; MCGLONE J, 1977, BRAIN, V100, P775, DOI 10.1093/brain/100.4.775; MCGLONE J, 1980, BEHAV BRAIN SCI, V3, P215, DOI 10.1017/S0140525X00004398; Meyer GJ, 2001, AM PSYCHOL, V56, P128, DOI 10.1037//0003-066X.56.2.128; Meyers J. E., 1996, REY COMPLEX FIGURE T; Meyers JE., 1995, REY COMPLEX FIGURE T; MILLER LJ, IN PRESS REHABILITAT; MURPHY KR, 1998, STAT POWER ANAL; PAPERO PH, 1993, NEUROPSYCHOL REHABIL, V3, P321, DOI 10.1080/09602019308401445; RAZ S, 1995, DEV PSYCHOL, V31, P958, DOI 10.1037/0012-1649.31.6.958; RAZ S, 1994, PSYCHOBIOLOGY, V22, P244; Reiter EO, 1998, WILLIAMS TXB ENDOCRI, P1427; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Sheslow D., 1990, WIDE RANGE ASSESSMEN; SHURTLEFF HA, 1995, J HEAD TRAUMA REHAB, V10, P64, DOI 10.1097/00001199-199510000-00008; SNOW WG, 1985, J CONSULT CLIN PSYCH, V53, P940, DOI 10.1037/0022-006X.53.6.940; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; SUCHING L, 1994, BRAIN INJURY, V8, P571; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2000, NEUROPSYCHOLOGY, V14, P509, DOI 10.1037/0894-4105.14.4.509; TEASDALE G, 1974, LANCET, V2, P81; Tremont G, 1999, CHILD NEUROPSYCHOL, V5, P104, DOI 10.1076/chin.5.2.104.3166; van den Burg W, 1999, ARCH CLIN NEUROPSYCH, V14, P545, DOI 10.1016/S0887-6177(98)00042-0; WABER DP, 1992, J CLIN ONCOL, V10, P810, DOI 10.1200/JCO.1992.10.5.810; WABER DP, 1990, J PEDIATR PSYCHOL, V15, P105, DOI 10.1093/jpepsy/15.1.105; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; Welsh TN, 2001, NEUROPSYCHOLOGIA, V39, P25, DOI 10.1016/S0028-3932(00)00094-4; Willcutt EG, 2000, J LEARN DISABIL, V33, P179, DOI 10.1177/002221940003300206; Woodward H, 1999, J HEAD TRAUMA REHAB, V14, P351, DOI 10.1097/00001199-199908000-00004; Woodward H, 1998, APPL NEUROPSYCHOL, V5, P113, DOI 10.1207/s15324826an0503_1; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; YLVISAKER M, 1994, ED DIMENSIONS ACQUIR, P121	67	83	84	0	7	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	OCT	2002	16	4					491	499		10.1037//0894-4105.16.4.491			9	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	601HR	WOS:000178440800005	12382988				2022-02-06	
J	Schatz, P; Browndyke, J				Schatz, P; Browndyke, J			Applications of computer-based neuropsychological assessment	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						assessment; computer; concussion; evaluation; Internet; neuropsychology; symptom validity	TRAUMATIC BRAIN-INJURY; SYMPTOM VALIDITY TEST; COGNITIVE ASSESSMENT; TEST-PERFORMANCE; CATEGORY TEST; TESTS; SPORTS; TECHNOLOGY; CONCUSSION; STANDARD	Objectives: To present current applications of computer-based neuropsychological assessment, including the assessment of sports-related concussion, symptom validity testing, and the remote administration of tests through the Internet. Problem areas: If computer-based assessment benefits are to become popularized, a few issues will need to be addressed: the development of psychometric data based on comparisons with long-standing empirically sound test measures; additional validation of measures by parties not involved in their commercial development; increased focus on ecological validity; exploration of the usefulness of remote data storage and automated posting to databases; and improved documentation of specific computer hardware and software used in experimental methods. Conclusions: Beyond ease of administration and data collection, computer-based assessment offers benefits over paper-and-pencil measures in the form of millisecond tinting accuracy, reliable and randomized presentation of stimuli over multiple trials and repeat administrations, and unobtrusive measurement of cognitive skills and response times during all aspects of the assessment process.	St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA		Schatz, P (corresponding author), St Josephs Univ, Dept Psychol, 5600 City Ave,222 Post Hall, Philadelphia, PA 19131 USA.	pschatz@sju.edu	Browndyke, Jeffrey/AAE-7292-2021	Browndyke, Jeffrey/0000-0002-8573-7073; Schatz, Philip/0000-0002-6222-6545			ALLEN LM, 1997, CARB MANUAL COMPUTER; *AM PSYCH ASS, 1986, GUID COMP BAS TESTS; Ball C, 1997, J Telemed Telecare, V3, P126, DOI 10.1258/1357633971931020; Ball C, 1999, J TELEMED TELECARE, V5, P253, DOI 10.1258/1357633991933819; Ball C, 1998, J TELEMED TELECARE, V4, P36, DOI 10.1258/1357633981931362; Barak A, 1999, APPL PREV PSYCHOL, V8, P231, DOI 10.1016/S0962-1849(05)80038-1; Barth JT, 1989, MILD HEAD INJURY; BARTRAM D, 1984, J OCCUP PSYCHOL, V57, P221, DOI 10.1111/j.2044-8325.1984.tb00164.x; BEAUMONT JG, 1975, J CLIN PSYCHOL, V31, P458, DOI 10.1002/1097-4679(197507)31:3<458::AID-JCLP2270310320>3.0.CO;2-I; BENNETT RE, 1999, ED MEASUREMENT I FAL, P5; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; BROOKS J, 1998, EPIDEMIOLOGY PREVENT; Browndyke JN, 1999, ARCH CLIN NEUROPSYCH, V14, P26, DOI 10.1093/arclin/14.1.26; BROWNDYKE JN, 2001, REMOTE NEUROPSYCHOLO; BURKE MJ, 1987, PROF PSYCHOL-RES PR, V18, P42, DOI 10.1037/0735-7028.18.1.42; Campbell KA, 1999, ASSESSMENT, V6, P21, DOI 10.1177/107319119900600103; Choca J., 1992, CLIN NEUROPSYCHOL, V6, P9, DOI [10.1080/13854049208404112, DOI 10.1080/13854049208404112]; CHOCA J, 1987, CATEGORY TEST COMPUT; CHUTE DL, 1996, POWER LAB; Coffin RJ, 1999, COMPUT HUM BEHAV, V15, P549, DOI 10.1016/S0747-5632(99)00036-9; *COGST LTD, 1999, COGSP; COHEN J, 1993, BEHAV RES METH INSTR, V25, P257, DOI 10.3758/BF03204507; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; COLLINS M, 2001, 21 ANN C NAT AC NEUR; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; COONS WH, 1956, ONTARIO PSYCHOL ASS, V12, P33; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; ELWOOD DL, 1972, J CONSULT CLIN PSYCH, V38, P9, DOI 10.1037/h0032416; Epstein J, 2001, COMPUT HUM BEHAV, V17, P295, DOI 10.1016/S0747-5632(01)00004-8; Erlanger D, 2001, J ATHL TRAINING, V36, P280; ERLANGER DM, IN PRESS ARCH CLIN N; Erlanger DM, 1999, CONCUSSION RESOLUTIO; Etcoff LM, 1996, NEUROPSYCHOL REV, V6, P171, DOI 10.1007/BF01874896; Feldstein SN, 1999, CLIN NEUROPSYCHOL, V13, P303, DOI 10.1076/clin.13.3.303.1744; Fortuny LA, 1996, CLIN NEUROPSYCHOL, V10, P419, DOI 10.1080/13854049608406702; FRENCH CC, 1987, BRIT J CLIN PSYCHOL, V26, P267, DOI 10.1111/j.2044-8260.1987.tb01360.x; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; GREEN P, 2000, WORD MEMORY TEST; Grote CL, 2000, J CLIN EXP NEUROPSYC, V22, P709, DOI 10.1076/jcen.22.6.709.958; Guilmette T J, 1990, Arch Clin Neuropsychol, V5, P373, DOI 10.1016/0887-6177(90)90016-I; Gur RC, 2001, NEUROPSYCHOPHARMACOL, V25, P766, DOI 10.1016/S0893-133X(01)00278-0; Gur RC, 2000, BRAIN LANG, V74, P157, DOI 10.1006/brln.2000.2325; Gutierrez JM, 1998, CRIT ISS NE, P81; HARTLAGE LC, 1980, INT J CLIN NEUROPSYC, V2, P200; Heaton R., 1991, HRB COMPREHENSIVE NO; HEATON R K, 1981, Journal of Clinical Neuropsychology, V3, P121, DOI 10.1080/01688638108403118; Heaton RK, 1999, WISCONSIN CARD SORTI; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; HONAKER LM, 1988, CLIN PSYCHOL REV, V8, P561, DOI 10.1016/0272-7358(88)90081-5; Horowitz T, 1997, ARCH CLIN NEUROPSYCH, V12, P338, DOI 10.1093/arclin/12.4.338a; Iverson G L, 2001, Appl Neuropsychol, V8, P167, DOI 10.1207/S15324826AN0803_6; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; *JARV B MED, 2002, DIRECTRT; Jerome LW, 2000, AM PSYCHOL, V55, P407, DOI [10.1037/0003-066X.55.4.407, 10.1037//0003-066X.55.4.407]; JOHNSON DF, 1980, J APPL PSYCHOL, V65, P357, DOI 10.1037/0021-9010.65.3.357; KANE RL, 1992, NEUROPSYCHOL REV, V3, P1, DOI 10.1007/BF01108787; KELLER FF, 1998, CARF SORT VER 1 0 CO; Lee JH, 2000, ALZ DIS ASSOC DIS, V14, P94, DOI 10.1097/00002093-200004000-00007; LeesHaley PR, 1996, ARCH CLIN NEUROPSYCH, V11, P45, DOI 10.1016/0887-6177(95)00011-9; Lovell M, 2000, IMPACT IMMEDIATE POS; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Matthews E, 1991, GLOBAL BIOGEOCHEM CY, V5, P3, DOI 10.1029/90GB02311; MCCRAE M, 1997, STANDARDIZED ASSESSM; McMinn MR, 1999, PROF PSYCHOL-RES PR, V30, P165, DOI 10.1037/0735-7028.30.2.165; MEAD AD, 1993, PSYCHOL BULL, V114, P449, DOI 10.1037/0033-2909.114.3.449; Mercer WN, 1997, CLIN NEUROPSYCHOL, V11, P174, DOI 10.1080/13854049708407047; MILLER DC, 1993, COMPUTERIZED VERSION; Montani C, 1997, J Telemed Telecare, V3, P140, DOI 10.1258/1357633971931048; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Newburger Eric, 2001, CURRENT POPULATION R; PANKRATZ L, 1983, PERCEPT MOTOR SKILL, V57, P367, DOI 10.2466/pms.1983.57.2.367; REED AV, 1979, BEHAV RES METH INSTR, V11, P572, DOI 10.3758/BF03201384; Reeves DL., 1997, NEUROPSYCHOLOGY HDB, V1, P423; Rosen LarryD., 1992, MEASURING TECHNOPHOB; Rosen LD, 1996, PROF PSYCHOL-RES PR, V27, P635, DOI 10.1037/0735-7028.27.6.635; Schatz P, 1999, ARCH CLIN NEUROPSYCH, V14, P747; Schatz P, 1999, ARCH CLIN NEUROPSYCH, V14, P159, DOI 10.1093/arclin/14.1.159; Schatz P, 2001, ARCH CLIN NEUROPSYCH, V16, P746; Schultheis MT, 2001, REHABIL PSYCHOL, V46, P296, DOI 10.1037/0090-5550.46.3.296; Schultheis MT, 1999, ARCH CLIN NEUROPSYCH, V14, P794; Slick DJ, 2000, J CLIN EXP NEUROPSYC, V22, P569, DOI 10.1076/1380-3395(200010)22:5;1-9;FT569; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 1995, VICTORIA SYMPTOM VAL; SPACE LG, 1975, BEHAV RES METH INSTR, V7, P191, DOI 10.3758/BF03201323; SPACE LG, 1981, BEHAV RES METH INSTR, V13, P595, DOI 10.3758/BF03202072; Strauss E, 1999, CLIN NEUROPSYCHOL, V13, P420, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT420; Sturges JW, 1998, PROF PSYCHOL-RES PR, V29, P183, DOI 10.1037/0735-7028.29.2.183; Tien Allen Y., 1996, Kaohsiung Journal of Medical Sciences, V12, P479; VINCENT KR, 1980, J CLIN PSYCHOL, V36, P437, DOI 10.1002/jclp.6120360209; WALKER NW, 1985, J SCHOOL PSYCHOL, V23, P51, DOI 10.1016/0022-4405(85)90034-2; WATERFALL RC, 1979, J AUDIOV MEDIA MED, V2, P21, DOI 10.3109/17453057909153878; WESTALL RF, 1989, BEHAV RES METH INSTR, V21, P540, DOI 10.3758/BF03202886; WILSON SL, 1991, MICROCOMPUTERS CLIN, P79; Wolfson, 1993, HALSTEAD REITAN NEUR	99	83	91	0	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	2002	17	5					395	410		10.1097/00001199-200210000-00003			16	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	610DD	WOS:000178944700003	12802251	Green Submitted			2022-02-06	
J	Levine, B; Cabeza, R; McIntosh, AR; Black, SE; Grady, CL; Stuss, DT				Levine, B; Cabeza, R; McIntosh, AR; Black, SE; Grady, CL; Stuss, DT			Functional reorganisation of memory after traumatic brain injury: a study with (H2O)-O-15 positron emission tomography	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							CLOSED-HEAD-INJURY; INDUCED AXONAL INJURY; EPISODIC MEMORY; ALZHEIMERS-DISEASE; PREFRONTAL CORTEX; WORKING-MEMORY; TECHNETIUM-99M-HMPAO SPECT; COMPUTERIZED-TOMOGRAPHY; PET; RETRIEVAL	Objective: To study the effects of moderate to severe traumatic brain injury (TBI) on the functional neuroanatomy supporting memory retrieval. Methods: Subjects were six patients who had sustained a moderate to severe TBI about four years before scanning and had since made a good recovery. Eleven healthy young adults matched to the patients for age and education served as controls. An established (H2O)-O-15 positron emission tomography paradigm was used to elicit brain activations in response to memory retrieval. TBI patients' patterns of brain activation were compared statistically with those of control subjects. Both group and individual case data were analysed. Results: Both TBI patients and controls engaged frontal, temporal, and parietal regions known to be involved in memory retrieval, yet the TBI patients showed relative increases in frontal, anterior cingulate, and occipital activity. The hemispheric asymmetry characteristic of controls was attenuated in patients with TBI. Reduced activation was noted in the right dorsomedial thalamus. Although local aspects of this pattern were affected by the presence of focal lesions and performance differences, the overall pattern was reliable across patients and comparable to functional neuroimaging results reported for normal aging, Alzheimer's disease, and other patients with TBI. Conclusions: The TBI patients performed memory tasks using altered functional neuroanatomical networks. These changes are probably the result of diffuse axonal injury and may reflect either cortical disinhibition attributable to disconnection or compensation for inefficient mnemonic processes.	Baycrest Ctr Geriatr Care, Rotman Res Inst, Toronto, ON M6E 3A5, Canada; Univ Toronto, Dept Psychol, Toronto, ON, Canada; Univ Toronto, Dept Med Neurol, Toronto, ON, Canada; Duke Univ, Ctr Cognit Sci, Durham, NC USA		Levine, B (corresponding author), Baycrest Ctr Geriatr Care, Rotman Res Inst, 3560 Bathurst St, Toronto, ON M6E 3A5, Canada.		Black, Sandra E./C-7294-2011; Levine, Brian/G-4328-2010; McIntosh, Anthony R/G-4955-2011; Levine, Brian/O-2725-2019	Levine, Brian/0000-0003-4343-811X; Levine, Brian/0000-0003-4343-811X; McIntosh, Anthony/0000-0002-1784-5662; Black, Sandra/0000-0001-7093-8289			ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Altrocchi PH, 1996, NEUROLOGY, V46, P278; Backman L, 1999, NEUROLOGY, V52, P1861, DOI 10.1212/WNL.52.9.1861; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barch DM, 1997, NEUROPSYCHOLOGIA, V35, P1373, DOI 10.1016/S0028-3932(97)00072-9; Becker JT, 1996, NEUROLOGY, V46, P692, DOI 10.1212/WNL.46.3.692; Bookheimer SY, 2000, NEW ENGL J MED, V343, P450, DOI 10.1056/NEJM200008173430701; Buckner RL, 1996, P NATL ACAD SCI USA, V93, P1249, DOI 10.1073/pnas.93.3.1249; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Cabeza R, 1997, J NEUROSCI, V17, P391; Cabeza R, 1997, J COGNITIVE NEUROSCI, V9, P254, DOI 10.1162/jocn.1997.9.2.254; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; DEsposito M, 1997, NEUROIMAGE, V6, P113, DOI 10.1006/nimg.1997.0281; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DUARA R, 1992, J CEREBR BLOOD F MET, V12, P927, DOI 10.1038/jcbfm.1992.129; Dupont S, 2000, BRAIN, V123, P1722, DOI 10.1093/brain/123.8.1722; Duzel E, 1999, P NATL ACAD SCI USA, V96, P1794, DOI 10.1073/pnas.96.4.1794; Engelien A, 1995, BRAIN, V118, P1395, DOI 10.1093/brain/118.6.1395; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; GRADY CL, 1995, SCIENCE, V269, P218, DOI 10.1126/science.7618082; GRAY BG, 1992, J NUCL MED, V33, P52; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Henson RNA, 1999, BRAIN, V122, P1367, DOI 10.1093/brain/122.7.1367; ICHISE M, 1994, J NUCL MED, V35, P217; Kapur S, 1996, COGNITIVE BRAIN RES, V4, P243, DOI 10.1016/S0926-6410(96)00058-4; KAPUR S, 1994, NEUROREPORT, V5, P2193, DOI 10.1097/00001756-199410270-00051; Kirkby BS, 1996, NEUROPSYCHOLOGIA, V34, P689; KURTZKE JF, 1982, NEUROLOGY, V32, P1207, DOI 10.1212/WNL.32.11.1207; Labbe C, 1996, ALZ DIS ASSOC DIS, V10, P141, DOI 10.1097/00002093-199601030-00005; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; Lepage M, 2000, P NATL ACAD SCI USA, V97, P506, DOI 10.1073/pnas.97.1.506; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Levin HS., 1982, NEUROBEHAVIORAL CONS; Levine B, 1998, BRAIN, V121, P1951, DOI 10.1093/brain/121.10.1951; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; Levine B., 2002, PRINCIPLES FRONTAL L, P448; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI DOI 10.1097/00001199-198709000-00009; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; *NAT CTR INJ PREV, 1999, TRAUM BRAIN INJ US R; Nolde SF, 1998, NEUROREPORT, V9, P3509, DOI 10.1097/00001756-199810260-00032; Nyberg L, 1996, PSYCHON B REV, V3, P135, DOI 10.3758/BF03212412; Nyberg L, 1998, BEHAV BRAIN RES, V90, P107, DOI 10.1016/S0166-4328(97)00094-6; Ogawa T, 1992, Acta Neurochir Suppl (Wien), V55, P8; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Price CJ, 1999, HUM BRAIN MAPP, V8, P102, DOI 10.1002/(SICI)1097-0193(1999)8:2/3<102::AID-HBM6>3.0.CO;2-J; Reuter-Lorenz PA, 2000, J COGNITIVE NEUROSCI, V12, P174, DOI 10.1162/089892900561814; Ricker JH, 2001, J CLIN EXP NEUROPSYC, V23, P196, DOI 10.1076/jcen.23.2.196.1204; Ricker JH, 2000, J HEAD TRAUMA REHAB, V15, P859, DOI 10.1097/00001199-200004000-00007; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STUSS DT, 1988, BRAIN COGNITION, V8, P348, DOI 10.1016/0278-2626(88)90059-0; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Talairach J., 1988, COPLANAR STEREOTAXIC; TEASDALE G, 1974, LANCET, V2, P81; TERAYAMA Y, 1991, J CEREBR BLOOD F MET, V11, P852, DOI 10.1038/jcbfm.1991.145; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2016, DOI 10.1073/pnas.91.6.2016; Wechsler D, 1985, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; WEILLER C, 1995, ANN NEUROL, V37, P723, DOI 10.1002/ana.410370605; Woodard JL, 1998, NEUROPSYCHOLOGY, V12, P491, DOI 10.1037/0894-4105.12.4.491	70	83	83	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	AUG	2002	73	2					173	181		10.1136/jnnp.73.2.173			9	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	577KK	WOS:000177059900017	12122177	Green Published, Bronze			2022-02-06	
J	Rice, AC; Zsoldos, R; Chen, T; Wilson, MS; Alessandri, B; Hamm, RJ; Bullock, MR				Rice, AC; Zsoldos, R; Chen, T; Wilson, MS; Alessandri, B; Hamm, RJ; Bullock, MR			Lactate administration attenuates cognitive deficits following traumatic brain injury	BRAIN RESEARCH			English	Article						Morris water maze; lateral fluid percussion injury	FLUID-PERCUSSION MODEL; HIPPOCAMPAL-LESIONS; GLUCOSE; RAT; NEURONS; GLIA; IMPAIRMENT; IMPACT; TISSUE	Moderately head injured patients often suffer long term neurological sequelae. There is no therapy for brain trauma and current treatments aim only to minimize secondary damage. These secondary effects we often triggered by the inability to re-establish ionic homeostasis after injury, due to large energy demands. Recent reports have demonstrated that neurons are capable of utilizing lactate as an energy source, thus this report examines the usefulness of lactate administration in the attenuation of behavioural deficits following a moderate brain injury. Lactate infusion (i.v.) was started 30 min after lateral fluid percussion injury and continued for 3 h. Cognitive deficits were determined using the Morris water maze. Lactate infused injured animals demonstrated significantly less cognitive deficits than saline infused injured animals. Thus, lactate infusion attenuated the cognitive deficits normally observed in this model, and therefore may provide moderately head injured patients with a treatment to help ameliorate the sequelae. (C) 2002 Elsevier Science B.V. All rights reserved.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Psychol, Richmond, VA 23298 USA		Rice, AC (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, Richmond, VA 23298 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, P50NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587] Funding Source: Medline		Alvarez-Maubecin V, 2000, J NEUROSCI, V20, P4091; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; Chen T, 2000, BRAIN RES, V861, P281, DOI 10.1016/S0006-8993(00)01992-2; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hilton G, 1994, Orthop Nurs, V13, P25, DOI 10.1097/00006416-199407000-00006; IZUMI Y, 1994, NEUROREPORT, V5, P617, DOI 10.1097/00001756-199401000-00021; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Larrabee MG, 1996, J NEUROCHEM, V67, P1726; LARRABEE MG, 1995, J NEUROCHEM, V64, P1734; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MOSER E, 1993, J NEUROSCI, V13, P3916; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Schousboe A, 1997, GLIA, V21, P99; Schurr A, 1998, DEV NEUROSCI-BASEL, V20, P348, DOI 10.1159/000017330; Schurr A, 1999, J NEUROSCI, V19, P34, DOI 10.1523/JNEUROSCI.19-01-00034.1999; Schurr A, 1997, BRAIN RES, V744, P105, DOI 10.1016/S0006-8993(96)01106-7; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Tsacopoulos M, 1996, J NEUROSCI, V16, P877	23	83	84	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	FEB 22	2002	928	1-2					156	159	PII S0006-8993(01)03299-1	10.1016/S0006-8993(01)03299-1			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	530TJ	WOS:000174374800017	11844482				2022-02-06	
J	Keep, M; Elmer, E; Fong, KSK; Csiszar, K				Keep, M; Elmer, E; Fong, KSK; Csiszar, K			Intrathecal cyclosporin prolongs survival of late-stage ALS mice	BRAIN RESEARCH			English	Article						amyotrophic lateral sclerosis; neurodegeneration; SOD1-G93A transgenic mice; mitochondrial permeability transition; intrathecal cyclosporin A; neuroprotection	TRAUMATIC BRAIN INJURY; TRANSGENIC-MOUSE MODEL; MITOCHONDRIAL PERMEABILITY TRANSITION; SUPEROXIDE-DISMUTASE; OXIDATIVE DAMAGE; AXONAL DAMAGE; ANIMAL-MODEL; CYTOCHROME-C; SCLEROSIS; PROTEIN	Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by upper and lower motor neuron death with ascending paralysis leading to death. In a transgenic mouse model of ALS (SOD1-G93A) weakness appears at 3 months of age, and because of progressive paralysis leads to death by 5 months. Cyclosporin A (CsA) is well known, for its extracerebral effect, as an immunosuppressant in organ transplantation. When able to access the brain, CsA is an effective neuroprotective agent mainly due to its protection of mitochondria through inhibition of the mitochondrial permeability transition. CsA does not cross the intact blood-brain barrier and was in the present study delivered to the brain through an infusion into the lateral cerebral ventricle. Injections started at the onset of late disease when weakness of the hindlimbs was apparent. CsA treatment prolonged the survival of ALS transgenic mice as compared to vehicle-treated controls. This finding implicates mitochondrial function in ALS and may have significance for human disease. (C) 2001 Elsevier Science B.V. All rights reserved.	Univ Hawaii, Pacific Biomed Res Ctr, Lab Matrix Pathobiol, Honolulu, HI 96822 USA; Univ Lund Hosp, Wallenburg Neurosci Ctr, Expt Brain Res Lab, SE-22185 Lund, Sweden; Maas BiolAB LLC, Honolulu, HI 96817 USA		Keep, M (corresponding author), Univ Hawaii, Pacific Biomed Res Ctr, Lab Matrix Pathobiol, 1960 East West Rd, Honolulu, HI 96822 USA.		Elmer, Eskil/F-9341-2014	Elmer, Eskil/0000-0001-7901-1826			Andrus PK, 1998, J NEUROCHEM, V71, P2041; APPEL SH, 1988, ARCH NEUROL-CHICAGO, V45, P381, DOI 10.1001/archneur.1988.00520280027011; BEGLEY DJ, 1990, J NEUROCHEM, V55, P1222, DOI 10.1111/j.1471-4159.1990.tb03128.x; Bogdanov MB, 1998, J NEUROCHEM, V71, P1321; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; CRAPO JD, 1992, P NATL ACAD SCI USA, V89, P10405, DOI 10.1073/pnas.89.21.10405; Cudkowicz ME, 1997, ANN NEUROL, V41, P210, DOI 10.1002/ana.410410212; DALCANTO MC, 1995, BRAIN RES, V676, P25, DOI 10.1016/0006-8993(95)00063-V; Dugan LL, 1997, P NATL ACAD SCI USA, V94, P9434, DOI 10.1073/pnas.94.17.9434; Ferrante RJ, 1997, J NEUROCHEM, V69, P2064; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Gurney ME, 1996, ANN NEUROL, V39, P147, DOI 10.1002/ana.410390203; Gurney ME, 1997, J NEUROL, V244, pS15, DOI 10.1007/BF03160575; GURNEY ME, 1994, NEW ENGL J MED, V331, P1721, DOI 10.1056/NEJM199412223312516; HIRANO A, 1967, ARCH NEUROL-CHICAGO, V16, P232, DOI 10.1001/archneur.1967.00470210008002; Hottinger AF, 1997, EUR J NEUROSCI, V9, P1548, DOI 10.1111/j.1460-9568.1997.tb01511.x; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568; Kong JM, 1998, J NEUROSCI, V18, P3241; Kostic V, 1997, SCIENCE, V277, P559, DOI 10.1126/science.277.5325.559; Kristal BS, 1997, J NEUROCHEM, V69, P524; Kuroda S, 1999, BRAIN RES, V835, P148, DOI 10.1016/S0006-8993(99)01535-8; LAD RP, 1991, MOL BRAIN RES, V9, P239, DOI 10.1016/0169-328X(91)90007-K; Lee JP, 1999, P NATL ACAD SCI USA, V96, P3251, DOI 10.1073/pnas.96.6.3251; Lemasters JJ, 1999, AM J PHYSIOL-GASTR L, V276, pG1, DOI 10.1152/ajpgi.1999.276.1.G1; LENSMEYER GL, 1991, J ANAL TOXICOL, V15, P110, DOI 10.1093/jat/15.3.110; Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; Liu DX, 1999, FASEB J, V13, P2318, DOI 10.1096/fasebj.13.15.2318; Martin LJ, 2000, INT J MOL MED, V5, P3; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Miller RG, 1998, WESTERN J MED, V168, P262; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pedersen WA, 1999, BRAIN RES, V833, P117, DOI 10.1016/S0006-8993(99)01471-7; PREHN JHM, 1994, P NATL ACAD SCI USA, V91, P12599, DOI 10.1073/pnas.91.26.12599; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; TINDALL RSA, 1992, J AUTOIMMUN, V5, P301, DOI 10.1016/0896-8411(92)90048-U; Tsuji A, 1998, THER DRUG MONIT, V20, P588, DOI 10.1097/00007691-199810000-00024; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; WILLIAMS DB, 1991, MAYO CLIN PROC, V66, P54, DOI 10.1016/S0025-6196(12)61175-6; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3	47	83	86	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAR 16	2001	894	2					327	331		10.1016/S0006-8993(01)02012-1			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	411WA	WOS:000167521200022	11251210				2022-02-06	
J	Salim, A; Velmahos, GC; Jindal, A; Chan, L; Vassiliu, P; Belzberg, H; Asensio, J; Demetriades, D				Salim, A; Velmahos, GC; Jindal, A; Chan, L; Vassiliu, P; Belzberg, H; Asensio, J; Demetriades, D			Clinically significant blunt cardiac trauma: Role of serum troponin levels combined with electrocardiographic findings	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	60th Annual Meeting of the American-Association-for-the-Surgery-of Trauma	OCT 11-15, 2000	SAN ANTONIO, TEXAS	Amer Assoc Surg Trauma		blunt cardiac trauma; blunt myocardial injury; troponin; electrocardiography; echocardiography; cardiac complications	SUSPECTED MYOCARDIAL CONTUSION; CHEST TRAUMA; INJURY; DIAGNOSIS; ECHOCARDIOGRAPHY; INFARCTION	Background: The true importance of blunt cardiac trauma (BCT) Is related to the cardiac complications arising from it. Diagnostic tests that can predict accurately if such complications will develop or not may allow early and aggressive monitoring or early discharge. We investigated the role of two simple and convenient tests, serum cardiac troponin I (cTnI) and electrocardiogram (ECG), when used to identify patients at risk of cardiac complications after BCT. Methods: Over a 10-month period, 115 patients with evidence of significant blunt thoracic trauma were prospectively followed to identify the presence of clinically significant BCT (Sig-BCT), defined as cardiogenic shock, arrhythmias requiring treatment, or structural cardiac abnormalities directly related to the cardiac trauma. An ECG was obtained at admission and at 8 hours. Cardiac troponin I was measured at admission, at 4 hours, and at 8 hours. Transthoracic echocardiography was performed when clinically indicated, The sensitivity, specificity, and positive and negative predictive values of ECG and cTnI to identify Sig-BCT were calculated, Clinical risk factors for Sig-BCT were examined by univariate and multivariate analysis. Results: Nineteen patients (16.5%) were diagnosed with Sig-BCT and, in 18 of them, symptoms presented within 24 hours of admission. Abnormal electrocardiographic findings were detected in 58 patients (50%) and elevated cTnI levels in 27 (23.5%), Electrocardiography and cTnI had positive predictive values of 28% and 48% and negative predictive values of 95% and 93%, respectively. However, when both tests were abnormal (positive) or normal (negative), the positive and negative predictive values increased to 62% and 100%, respectively. Other independent risk factors for Sig-BCT were head injury, spinal injury, history of preexisting cardiac disease, and a chest Abbreviated Injury Score greater than 2. Conclusion: The combination of ECG and cTnI identifies reliably the presence or absence of Sig-BCT, Patients with an abnormal ECG and cTnI need close monitoring for at least 24 hours. Patients with a normal admission ECG and cTnI can be safely discharged in the absence of other injuries.	LAC & USC, Med Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA USA; Univ So Calif, Keck Sch Med, Dept Biostat, Los Angeles, CA USA		Salim, A (corresponding author), LAC & USC, Med Ctr, 1200 N State St,Room 9900, Los Angeles, CA 90033 USA.			Vassiliu, Panteleimon/0000-0002-5859-7917			ADAMS JE, 1993, CIRCULATION, V88, P101, DOI 10.1161/01.CIR.88.1.101; Adams JE, 1996, AM HEART J, V131, P308, DOI 10.1016/S0002-8703(96)90359-2; ADAMS JE, 1993, CIRCULATION, V88, P750, DOI 10.1161/01.CIR.88.2.750; BEDOR GS, 1992, CLIN CHEM, V11, P2203; Bertinchant JP, 2000, J TRAUMA, V48, P924, DOI 10.1097/00005373-200005000-00018; BIFFL WL, 1994, AM J SURG, V169, P523; Christensen M A, 1993, Am J Crit Care, V2, P28; DUBROW TJ, 1989, SURGERY, V106, P262; EISENACH JC, 1986, ANESTHESIOLOGY, V64, P364, DOI 10.1097/00000542-198603000-00011; FEGHALI NT, 1995, CHEST, V108, P1673, DOI 10.1378/chest.108.6.1673; Ferjani M, 1997, CHEST, V111, P427, DOI 10.1378/chest.111.2.427; FILDES JJ, 1995, AM SURGEON, V61, P832; FLISS JL, 1973, STAT METHODS RATES P; FOIL MB, 1990, AM J SURG, V160, P638, DOI 10.1016/S0002-9610(05)80764-0; FRAZEE RC, 1986, J TRAUMA, V26, P510, DOI 10.1097/00005373-198606000-00004; Fulda GJ, 1997, J TRAUMA, V43, P304, DOI 10.1097/00005373-199708000-00016; GODBE D, 1992, ARCH SURG-CHICAGO, V127, P888; HEALEY MA, 1990, J TRAUMA, V30, P137, DOI 10.1097/00005373-199002000-00002; HELM M, 1998, TRAUMA CARE A, V8, P50; ILLIG KA, 1991, AM J SURG, V162, P537, DOI 10.1016/0002-9610(91)90105-M; KARALIS DG, 1994, J TRAUMA, V36, P53, DOI 10.1097/00005373-199401000-00008; KATUS HA, 1991, CIRCULATION, V83, P902, DOI 10.1161/01.CIR.83.3.902; KING RM, 1983, J TRAUMA, V23, P610, DOI 10.1097/00005373-198307000-00011; LARUE C, 1993, CLIN CHEM, V39, P972; Maenza RL, 1996, AM J EMERG MED, V14, P237, DOI 10.1016/S0735-6757(96)90165-5; Mair J, 1996, CLIN CHIM ACTA, V245, P19, DOI 10.1016/0009-8981(95)06168-1; MATTOX KL, 1992, J TRAUMA, V33, P649; MILLER FA, 1982, AM J CARDIOL, V50, P1022, DOI 10.1016/0002-9149(82)90412-X; Newman PG, 1999, NEW HORIZ-SCI PRACT, V7, P26; Ognibene A, 1998, CLIN CHEM, V44, P889; RuDusky BM, 1997, CHEST, V112, P858, DOI 10.1378/chest.112.3.858-a; TENZER ML, 1985, J TRAUMA, V25, P620, DOI 10.1097/00005373-198507000-00008; Weiss RL, 1996, CHEST, V109, P73, DOI 10.1378/chest.109.1.73; WISNER DH, 1990, ANN SURG, V212, P82, DOI 10.1097/00000658-199007000-00011	34	83	94	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2001	50	2					237	242		10.1097/00005373-200102000-00008			6	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	404WL	WOS:000167125000014	11242287				2022-02-06	
J	Levin, HS; Song, J; Ewing-Cobbs, L; Chapman, SB; Mendelsohn, D				Levin, HS; Song, J; Ewing-Cobbs, L; Chapman, SB; Mendelsohn, D			Word fluency in relation to severity of closed head injury, associated frontal brain lesions, and age at injury in children	NEUROPSYCHOLOGIA			English	Article						word fluency; closed head injury; children; frontal lesions; neuroplasticity	VERBAL FLUENCY; PREFRONTAL CORTEX; LOBE; RECOVERY; SEQUELAE; APHASIA; PERFORMANCE; MATURATION; DISCOURSE; TESTS	Effects of closed head injury (CHI) severity, focal brain lesions, and age at injury on word fluency (WF) were studied longitudinally in 122 children (78 severe, 44 mild); 112 CHI patients (68 severe, 44 mild CHI) and 104 uninjured normal controls participated in a cross-sectional study. WF was measured by asking the child to generate as many words as possible beginning with a designated letter within 60 s, repeated for three letters. Intellectual ability, receptive vocabulary, narrative discourse,and word list recall were also measured. Results of the cross-sectional study showed a significant group effect with poorer WF in severe CHI than mild CHI and control groups. Growth curve analysts of longitudinal data revealed an interaction of age, follow-up interval, and CHI severity as WF recovery was slower after severe CHI in younger children as compared to seven CHI in older children or mild CHI in younger children. An interaction of left frontal lesion with age and interval indicated a more adverse effect on WF in older children. Right frontal lesion effect was nonsignificant and did not interact with age. Correlations of WF with receptive vocabulary, word list recall, and narrative discourse were moderate and weak with estimated intellectual ability. Differences in focal lesion effects after traumatic versus nontraumatic brain injury in children, the contribution of diffuse white matter injury, reduced opportunity for language development, and functional commitment of left frontal region at time of CHI were discussed. (C) 2000 Elsevier Science Ltd. All rights reserved.	Baylor Coll Med, Dept Phys Med & Rehabil, MSC, Houston, TX 77003 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77003 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77003 USA; Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77225 USA; Univ Texas, Callier Ctr Commun Disorders, Dallas, TX 75235 USA; Univ Texas, SW Med Sch, Dept Radiol, Div Neuroradiol, Dallas, TX 75235 USA		Levin, HS (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, MSC, 1 Baylor Plaza,ST1144, Houston, TX 77003 USA.	hlevin@bcm.tmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		Bates E, 1997, DEV NEUROPSYCHOL, V13, P275, DOI 10.1080/87565649709540682; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; BENTON AL, 1993, MANUAL MULTILINGUAL; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; BRYK AS, 1987, PSYCHOL BULL, V101, P147, DOI 10.1037/0033-2909.101.1.147; Buckner RL, 1996, P NATL ACAD SCI USA, V93, P1249, DOI 10.1073/pnas.93.3.1249; CHAPMAN SB, 1995, J HEAD TRAUMA REHAB, V10, P36, DOI 10.1097/00001199-199510000-00006; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; CHUGANI HT, 1987, ANN NEUROL, V22, P487, DOI 10.1002/ana.410220408; Crowe SF, 1998, J CLIN EXP NEUROPSYC, V20, P391, DOI 10.1076/jcen.20.3.391.810; CUENOD CA, 1995, NEUROLOGY, V45, P1821, DOI 10.1212/WNL.45.10.1821; DAMASIO HC, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P92; Delis D, 1994, MANUAL CALIFORNIA VE; DIGGLE P, 1994, J R STAT SOC C-APPL, V43, P49; Dunn LM., 1981, PEABODY PICTURE VOCA; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FELDMAN HM, 1992, BRAIN LANG, V42, P89, DOI 10.1016/0093-934X(92)90058-M; FRANCIS DJ, 1991, J CONSULT CLIN PSYCH, V59, P27, DOI 10.1037/0022-006X.59.1.27; FRITH CD, 1991, P ROY SOC B-BIOL SCI, V244, P241, DOI 10.1098/rspb.1991.0077; GADDES WH, 1975, BRAIN LANG, V2, P257, DOI 10.1016/S0093-934X(75)80070-8; GAIDOLFI E, 1980, ITAL J NEUROL SCI, V1, P65; Gaillard WD, 2000, NEUROLOGY, V54, P180, DOI 10.1212/WNL.54.1.180; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; HECAEN H, 1976, BRAIN LANG, V3, P114, DOI 10.1016/0093-934X(76)90009-2; Huttenlocher PR, 1997, J COMP NEUROL, V387, P167, DOI 10.1002/(SICI)1096-9861(19971020)387:2<167::AID-CNE1>3.0.CO;2-Z; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; Levin HS, 1996, ARCH NEUROL-CHICAGO, V53, P88, DOI 10.1001/archneur.1996.00550010108024; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; LITTLE RC, 1996, SAS SYSTEM MIXED MOD; McIntosh TK, 1996, LAB INVEST, V74, P315; MICELI G, 1981, Journal of Clinical Neuropsychology, V3, P53, DOI 10.1080/01688638108403113; MILNER B, 1964, FRONTAL GRANULAR COR, P65; Mitrushina MN, 1999, HDB NORMATIVE DATA N; PAPANICOLAOU AC, 1988, ARCH NEUROL-CHICAGO, V45, P1025, DOI 10.1001/archneur.1988.00520330117020; Paus T, 1999, SCIENCE, V283, P1908, DOI 10.1126/science.283.5409.1908; PERRET E, 1974, NEUROPSYCHOLOGIA, V12, P323, DOI 10.1016/0028-3932(74)90047-5; Phelps EA, 1997, NEUROREPORT, V8, P561, DOI 10.1097/00001756-199701200-00036; RAMIER AM, 1970, REV NEUROL, V123, P17; REGARD M, 1982, PERCEPT MOTOR SKILL, V55, P839, DOI 10.2466/pms.1982.55.3.839; Rueckert L, 1994, J Neuroimaging, V4, P67; RUTTER CM, 1994, STAT MED, V13, P1211, DOI 10.1002/sim.4780131204; Sowell ER, 1999, NAT NEUROSCI, V2, P859, DOI 10.1038/13154; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); TEASDALE G, 1974, LANCET, V2, P81; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; Troxel AB, 1998, STAT MED, V17, P653, DOI 10.1002/(SICI)1097-0258(19980315/15)17:5/7<653::AID-SIM812>3.3.CO;2-D; Troyer AK, 1997, NEUROPSYCHOLOGY, V11, P138, DOI 10.1037/0894-4105.11.1.138; Warburton E, 1999, J NEUROL NEUROSUR PS, V66, P155, DOI 10.1136/jnnp.66.2.155; Wechsler D., 1974, WISCR MANUAL WECHSLE; WEILLER C, 1995, ANN NEUROL, V37, P723, DOI 10.1002/ana.410370605; Yakovlev PI, 1967, REGIONAL DEV BRAIN E, P3	57	83	84	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia		2001	39	2					122	131		10.1016/S0028-3932(00)00111-1			10	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	386HK	WOS:000166054800003	11163370				2022-02-06	
J	Wallesch, CW; Curio, N; Galazky, I; Jost, S; Synowitz, H				Wallesch, CW; Curio, N; Galazky, I; Jost, S; Synowitz, H			The neuropsychology of blunt head injury in the early postacute stage: Effects of focal lesions and diffuse axonal injury	JOURNAL OF NEUROTRAUMA			English	Article						contusion; diffuse axonal injury; neuropsychology; traumatic brain injury	FRONTAL-LOBE; TRAUMA; TOMOGRAPHY; COMA	This investigation evaluated the neuropsychological symptoms in the early posttraumatic period following blunt head injury and their correlation to routine imaging data in a consecutive series of TBI patients (Magdeburg Neurotrauma Databank). Of 135 consecutive patients, 68 could be assessed neuropsychologically 8-21 days after trauma. In 61 patients, routine clinical CT data were sufficient for neuroradiological analysis focusing on the presence or absence of CT signs of diffuse axonal injury (DAI) or focal traumatic injury. In these patients, the initial GCS score was significantly correlated with the presence of DAI but not with focal pathology. The presence of DAI was correlated with behavioral and cognitive symptoms of frontal lobe dysfunction, especially in interference tasks (Go/NoGO and Stroop reaction times) and semantic fluency. The presence of local frontal or temporal traumatic lesions was associated with deficits in concept formation, fluency tasks and behavioral symptoms, but not with increased interference. Patients with frontal contusions were impaired in a task of visuomotor planning and performance (Block design). Our data indicate that both traumatic DAI and focal lesions result in frontal lobe symptoms. We conclude that, even in clinically "mild" TBI, brain imaging should be used to identify patients with substantial brain damage. These should be assessed neuropsychologically for possible posttraumatic cognitive or behavioral impairment. In consideration of its easy accessibility, the refined use of the CT is considered a promising and valid tool for patient stratification. The application of MRI and biochemical markers may further improve prognostic predictions.	Otto Von Guericke Univ, Dept Neurol, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Dept Neuropsychol, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Dept Neurosurg, D-39120 Magdeburg, Germany		Wallesch, CW (corresponding author), Otto Von Guericke Univ, Dept Neurol, Leipziger Str 44, D-39120 Magdeburg, Germany.	wallesch@medizin.uni-magdeburg.de					ETTLIN T, 1999, SCI PRACT NEUROPSYCH, P233; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1994, HEAD INJURY, P137; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GURDJIAN ES, 1976, J TRAUMA, V16, P35, DOI 10.1097/00005373-197601000-00005; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KESSLER J, 1988, DEMENZTEST; KRAMER J, 1977, KURZE ANLEITUNG KRAM; Lee TT, 1998, ACTA NEUROCHIR, V140, P41, DOI 10.1007/s007010050055; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Masdeu J C, 1994, J Neuroimaging, V4, P177; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; OSWALD WD, 1995, NURNBERGER ALTERSINV; PERRET E, 1974, NEUROPSYCHOLOGIA, V12, P323, DOI 10.1016/0028-3932(74)90047-5; PETRIDES M, 1986, J NEUROSCI, V6, P2054; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; REGARD M, 1982, PERCEPT MOTOR SKILL, V55, P839, DOI 10.2466/pms.1982.55.3.839; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; TEASDALE G, 1974, LANCET, V2, P81; WALLESCH CW, 1983, ARCH PSYCHIAT NERVEN, V233, P279, DOI 10.1007/BF00345798; Wechsler, 1997, WECHSLER ADULT INTEL; ZIMMERMANN P, 1993, NEUROPSYCHOLOGISCHE	27	83	85	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2001	18	1					11	20		10.1089/089771501750055730			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	390EU	WOS:000166283400002	11200246				2022-02-06	
J	Satake, K; Matsuyama, Y; Kamiya, M; Kawakami, H; Iwata, H; Adachi, K; Kiuchi, K				Satake, K; Matsuyama, Y; Kamiya, M; Kawakami, H; Iwata, H; Adachi, K; Kiuchi, K			Up-regulation of glial cell line-derived neurotrophic factor (GDNF) following traumatic spinal cord injury	NEUROREPORT			English	Article						glial cell line-derived neurotrophic factor; macrophage; microglia; rat; spinal cord injury; weight drop technique	FACTOR EXPRESSION; RAT; BRAIN; LOCALIZATION; ASTROCYTES; STRIATUM; CNS	We investigated the temporal and spatial expression patterns of the GDNF gene after subjecting rats to an acute contusion injury of the spinal cord using the weight drop technique. Reverse transcriptase-polymerase chain reaction (RT-PCR) revealed that GDNF transcription in the spinal cord began to increase within 30 min after injury and peaked within 3 h. Immunohistochemical analysis showed GDNF immunoreactivity to be present mainly in microglia and macrophages 1 day after injury,but not in neurons or astrocytes. This immediate upregulation of GDNF gene expression may be a component of an inflammatory process and probably exerts a protective effect on neurons following spinal cord injury (SCI). NeuroReport 11:3877-3881 (C) 2000 Lippincott Williams & Wilkins.	Nagoya Univ, Sch Med, Dept Orthopaed Surg, Nagoya, Aichi 4668550, Japan; RIKEN, Biomimet Control Res Program, Lab Genes Motor Syst, Moriyama Ku, Nagoya, Aichi 4630003, Japan; Gifu Univ, Fac Engn, Dept Biomol Sci, Gifu 5011193, Japan		Kiuchi, K (corresponding author), Nagoya Univ, Sch Med, Dept Orthopaed Surg, Nagoya, Aichi 4668550, Japan.						Allen AR., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Amar AP, 1999, NEUROSURGERY, V44, P1027, DOI 10.1097/00006123-199905000-00052; Appel E, 1997, NEUROREPORT, V8, P3309, DOI 10.1097/00001756-199710200-00023; Batchelor PE, 1999, J NEUROSCI, V19, P1708; Bizon JL, 1999, J COMP NEUROL, V408, P283; DOHRMANN GJ, 1971, J NEUROSURG, V35, P263, DOI 10.3171/jns.1971.35.3.0263; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; Holstege JC, 1998, NEUROREPORT, V9, P2893, DOI 10.1097/00001756-199808240-00039; Ikeda T, 1999, INT J DEV NEUROSCI, V17, P681, DOI 10.1016/S0736-5748(99)00057-X; Lazarov-Spiegler O, 1998, MOL MED TODAY, V4, P337, DOI 10.1016/S1357-4310(98)01298-2; Lee MY, 1998, NEUROSCI LETT, V255, P79, DOI 10.1016/S0304-3940(98)00710-1; Liberatore GT, 1997, NEUROREPORT, V8, P3097, DOI 10.1097/00001756-199709290-00018; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LIN LFH, 1996, NEURAL NOTES, V11, P3; OBRIEN MF, 1994, SPINE, V19, P2321, DOI 10.1097/00007632-199410150-00012; Pan WH, 1997, EXP NEUROL, V146, P367, DOI 10.1006/exnr.1997.6533; Pochon NAM, 1997, EUR J NEUROSCI, V9, P463, DOI 10.1111/j.1460-9568.1997.tb01623.x; POPOVICH PG, 1993, J NEUROTRAUM, V10, P37, DOI 10.1089/neu.1993.10.37; Sakurai M, 1999, NEUROSCI LETT, V276, P123, DOI 10.1016/S0304-3940(99)00804-6; SCHAAR DG, 1993, EXP NEUROL, V124, P368, DOI 10.1006/exnr.1993.1207; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; Trupp M, 1997, J NEUROSCI, V17, P3554; Verity AN, 1999, J NEUROSCI RES, V55, P187, DOI 10.1002/(SICI)1097-4547(19990115)55:2<187::AID-JNR6>3.3.CO;2-K	23	83	96	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-4965	1473-558X		NEUROREPORT	Neuroreport	NOV 27	2000	11	17					3877	3881		10.1097/00001756-200011270-00054			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	378DM	WOS:000165569800049	11117507				2022-02-06	
J	Gaetz, M; Weinberg, H				Gaetz, M; Weinberg, H			Electrophysiological indices of persistent post-concussion symptoms	BRAIN INJURY			English	Article							MILD HEAD-INJURY; AUDITORY EVOKED-POTENTIALS; TRAUMATIC BRAIN INJURY; AXONAL INJURY; NEUROFILAMENT SUBUNITS; STEM RESPONSES; P300; HYPOTHESIS; SPECTRUM; P-300	Mild head injuries (MHI) including concussion were once considered transient alterations of function that resulted in no long-term structural or functional effects. This opinion has changed somewhat in recent years, based on the scientific evidence and popular cases in the media that suggest MHI can result in damage that can, in some cases, lead to long-term cognitive sequelae. Purpose and methods: An EP/ERP assessment battery is presented as a method for detecting changes in brain function that form the organic basis of persistent post-concussion symptoms (PCS). The primary focus of the paper was directed towards using this battery to determine whether or not brain function in individuals with persistent PCS was different than responses of individuals that comprised a normative database. Results: Visual and auditory ERPs and visual EPs were beyond a 2.5 standard deviation normal limit in young and older groups of individuals with persistent post-concussion symptoms. Conclusions: Evidence of changes in brain function in individuals with persistent post-concussion symptoms is consistent with the position that the post-concussion syndrome has a substantial biological, as opposed to a psychological, basis.	Simon Fraser Univ, Fac Sci Appl, Sch Kinesiol, Brain Behav Lab, Burnaby, BC V5A 1S6, Canada		Gaetz, M (corresponding author), Simon Fraser Univ, Fac Sci Appl, Sch Kinesiol, Brain Behav Lab, Burnaby, BC V5A 1S6, Canada.	gaetz@sfu.ca					Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Barth JT, 1996, CLIN ELECTROENCEPHAL, V27, P183; BENNA P, 1982, ITAL J NEUROL SCI, V3, P281, DOI 10.1007/BF02043575; BERNAD PG, 1988, CLIN ELECTROENCEPHAL, V19, P174; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; BOHNEN NJ, 1995, J NEUROL REHABIL, V9, P33; CREMONAMETEYARD SL, 1994, BRAIN INJURY, V8, P541, DOI 10.3109/02699059409151006; DEADWYLER SA, 1987, CRC CR REV CL NEUROB, V2, P335; DESALLES AAF, 1987, J NEUROSURG, V66, P102, DOI 10.3171/jns.1987.66.1.0102; Drake M E Jr, 1996, Electromyogr Clin Neurophysiol, V36, P457; DRAKE ME, 1987, CLIN EVOKED POTENTIA, V5, P19; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; ETTLIN TM, 1992, J NEUROL NEUROSUR PS, V55, P943, DOI 10.1136/jnnp.55.10.943; Freed S, 1997, BRAIN INJURY, V11, P25, DOI 10.1080/026990597123782; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GFELLER JD, 1994, HEADACHE, V34, P503, DOI 10.1111/j.1526-4610.1994.hed3409503.x; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; *GUID 9 GUID EV PO, 1994, J CLIN NEUROPHYSIOL, V11, P40; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P353; HALGREN E, 1980, SCIENCE, V210, P803, DOI 10.1126/science.7434000; JOHNSON R, 1988, BRAIN, V111, P1517, DOI 10.1093/brain/111.6.1517; Kelly JP, 1997, NEUROLOGY, V48, P581; Keren O, 1998, J HEAD TRAUMA REHAB, V13, P15; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; KNIGHT RT, 1989, BRAIN RES, V502, P109, DOI 10.1016/0006-8993(89)90466-6; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LHERMITTE F, 1985, ARCH NEUROL-CHICAGO, V42, P567, DOI 10.1001/archneur.1985.04060060069011; MARSH NV, 1995, BRAIN INJURY, V9, P553, DOI 10.3109/02699059509008214; MCCARTHY G, 1982, NEUR ABSTR, V8, P976; MCCLELLAND RJ, 1994, J ROY SOC MED, V87, P508; MILLIS SR, 1994, J CLIN PSYCHOL, V50, P601, DOI 10.1002/1097-4679(199407)50:4<601::AID-JCLP2270500417>3.0.CO;2-9; Misulis K. E., 1994, SPEHLMANNS EVOKED PO; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; NOSEWORTHY JH, 1981, ARCH NEUROL-CHICAGO, V38, P275, DOI 10.1001/archneur.1981.00510050041004; ONOFRJ M, 1991, ACTA NEUROL SCAND, V83, P273, DOI 10.1111/j.1600-0404.1991.tb04700.x; PAPATHANASOPOULOS P, 1994, EUR NEUROL, V34, P268, DOI 10.1159/000117054; PARKINSON D, 1992, MED HYPOTHESES, V37, P37, DOI 10.1016/0306-9877(92)90010-A; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; PICTON TW, 1974, ELECTROEN CLIN NEURO, V36, P179, DOI 10.1016/0013-4694(74)90155-2; PICTON TW, 1994, CURR OPIN NEUROBIOL, V4, P256, DOI 10.1016/0959-4388(94)90082-5; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; Regan, 1989, HUMAN BRAIN ELECTROP; RIZZO PA, 1983, NEUROPSYCHOBIOLOGY, V9, P78, DOI 10.1159/000117941; RIZZO PA, 1978, ELECTROEN CLIN NEURO, V45, P281, DOI 10.1016/0013-4694(78)90012-3; ROTTEVEEL J, 1990, EVOKED POTENTIAL MAN, P79; ROWE MJ, 1980, ARCH NEUROL-CHICAGO, V37, P679, DOI 10.1001/archneur.1980.00500600027002; Sangal RB, 1996, BIOL PSYCHIAT, V39, P305, DOI 10.1016/0006-3223(95)00447-5; SCHOENHUBER R, 1986, NEUROSURGERY, V19, P532, DOI 10.1227/00006123-198610000-00006; SCHOENHUBER R, 1985, EVOKED POTENTIALS NE, P237; SQUIRES NK, 1983, TUTORIALS EVENT RELA; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; VANBOXTEL GJM, 1994, BIOL PSYCHOL, V38, P37, DOI 10.1016/0301-0511(94)90048-5; WATSON MR, 1995, BRIT J PSYCHIAT, V167, P514, DOI 10.1192/bjp.167.4.514; Weight DG, 1998, PSYCHIAT CLIN N AM, V21, P609, DOI 10.1016/S0193-953X(05)70026-5; WERNER RA, 1991, ARCH PHYS MED REHAB, V72, P31; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; WOOD C C, 1985, Society for Neuroscience Abstracts, V11, P879; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; [No title captured], DOI DOI 10.1037/0894-4105.5.4.253	64	83	84	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2000	14	9					815	832					18	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	357YT	WOS:000089530300005	11030455				2022-02-06	
J	Agrawal, SK; Nashmi, R; Fehlings, MG				Agrawal, SK; Nashmi, R; Fehlings, MG			Role of L- and N-type calcium channels in the pathophysiology of traumatic spinal cord white matter injury	NEUROSCIENCE			English	Article						rat; conotoxin; calcium channels; glia; astrocytes; oligodendrocytes	CENTRAL-NERVOUS-SYSTEM; RAT OPTIC-NERVE; CA2+ CHANNEL; GLIAL-CELLS; GLUTAMATE RECEPTORS; ANOXIC INJURY; NA+-CA2+ EXCHANGER; SECONDARY INJURY; CALPAIN-I; AXONS	Recent work has suggested a potential role for voltage-gated Ca2+ channels in the pathophysiology of anoxic central nervous system whits matter injury. To examine the relevance of these findings to neurotrauma, we conducted electrophysiological studies with inorganic Ca2+ channels blockers and L- and N-subtype-specific calcium channel antagonists in an in vitro model of spinal cord injury. Confocal immunohistochemistry was used to examine for localization of L- and N-type calcium channels in spinal cord white matter tracts. A 30-mm length of dorsal column was isolated from the spinal cord of adult rats, pinned in an in vitro recording chamber and injured with a modified clip (2 g closing force) for 15 s. The functional integrity of the dorsal column was monitored electrophysiologically by quantitatively measuring the compound action potential at two points with glass microelectrodes. The compound action potential decreased to 71.4 +/- 2.0% of control (P < 0.05) after spinal cord injury. Removal of extracellular Ca2+ promoted significantly greater recovery of compound action potential amplitude (86.3 +/- 7.6% of control; P < 0.05) after injury. Partial blockade of voltage-gated Ca2+ channels with cobalt (20 mu M) or cadmium (200 mu M) conferred improvement in compound action potential amplitude. Application of the L-type Ca2+ channel blockers diltiazem (50 mu M) or verapamil (90 mu M), and the N-type antagonist omega-conotoxin GVIA (1 mu M), significantly enhanced the recovery of compound action potential amplitude postinjury. Go-application of the L-type antagonist diltiazem with the N-type blocker omega-conotoxin GVIA showed significantly greater (P < 0.05) improvement in compound action potential amplitude than application of either drug alone. Confocal immunohistochemistry with double labelling for glial fibrillary acidic protein, GalC and NF200 demonstrated L- and N-type Ca2+ channels on astrocytes and oligodendrocytes, but not axons, in spinal cord white matter. In conclusion, the injurious effects of Ca2+ in traumatic central nervous system white matter injury appear to be partially mediated by voltage-gated Ca2+ channels. The presence of L- and N-type Ca2+ channels on periaxonal astrocytes and oligodendrocytes suggests a role for these cells in post-traumatic axonal conduction failure. (C) 2000 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Toronto Western Res Inst, Div Cell & Mol Biol, Toronto, ON, Canada; Univ Toronto, Univ Hlth Network, Div Neurosurg, Toronto, ON M5T 2S8, Canada		Fehlings, MG (corresponding author), Toronto Western Res Inst, Div Cell & Mol Biol, Toronto, ON, Canada.			Nashmi, Raad/0000-0001-6596-2620; Fehlings, Michael/0000-0002-5722-6364			Agrawal SK, 1998, J NEUROTRAUM, V15, P929, DOI 10.1089/neu.1998.15.929; Agrawal SK, 1996, J NEUROSCI, V16, P545; Agrawal SK, 1997, J NEUROSCI, V17, P1055; BALENTINE JD, 1977, ANN NEUROL, V2, P520, DOI 10.1002/ana.410020612; BARRES BA, 1990, NEURON, V4, P507, DOI 10.1016/0896-6273(90)90109-S; BARRES BA, 1989, J NEUROSCI, V9, P3169; BARRES BA, 1990, NEURON, V5, P527, DOI 10.1016/0896-6273(90)90091-S; BARRES BA, 1988, GLIA, V1, P10, DOI 10.1002/glia.440010104; Bengtsson F, 1990, CEREBRAL ISCHEMIA RE, P215; BERGER T, 1992, EUR J NEUROSCI, V4, P1271, DOI 10.1111/j.1460-9568.1992.tb00153.x; BORGES K, 1995, J NEUROSCI RES, V40, P591, DOI 10.1002/jnr.490400504; CATTERALL WA, 1992, TRENDS PHARMACOL SCI, V13, P256, DOI 10.1016/0165-6147(92)90079-L; CHIU SY, 1994, GLIA, V11, P191, DOI 10.1002/glia.440110213; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; Fehlings MG, 1997, J NEUROSCI METH, V71, P215, DOI 10.1016/S0165-0270(96)00147-1; FEHLINGS MG, 1989, J NEUROSURG, V71, P403, DOI 10.3171/jns.1989.71.3.0403; Fern R, 1998, J NEUROSCI, V18, P7232; FERN R, 1995, J NEUROPHYSIOL, V74, P369, DOI 10.1152/jn.1995.74.1.369; GEAN PW, 1991, BRAIN RES, V560, P306, DOI 10.1016/0006-8993(91)91248-Y; HAPPEL RD, 1981, BRAIN RES, V211, P476, DOI 10.1016/0006-8993(81)90976-8; Hille B., 1992, IONIC CHANNELS EXCIT, V2nd; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.ne.17.030194.002151; Huguenard JR, 1996, ANNU REV PHYSIOL, V58, P329, DOI 10.1146/annurev.ph.58.030196.001553; Huh KH, 1999, J BIOL CHEM, V274, P151, DOI 10.1074/jbc.274.1.151; Imaizumi T, 1999, BRAIN RES, V817, P84, DOI 10.1016/S0006-8993(98)01214-1; KRIEGLER S, 1993, J NEUROSCI, V13, P4229, DOI 10.1523/jneurosci.13-10-04229.1993; LACINOVA L, 1995, J PHARMACOL EXP THER, V274, P54; LEVITAN ES, 1995, J BIOL CHEM, V270, P6036, DOI 10.1074/jbc.270.11.6036; LEVRAM V, 1995, J NEUROSCI, V15, P2628; LEVRAM V, 1987, BIOPHYS J, V52, P571, DOI 10.1016/S0006-3495(87)83246-0; LEVRAM V, 1986, P NATL ACAD SCI USA, V83, P6651, DOI 10.1073/pnas.83.17.6651; Li S, 1999, J Neurosci, V19, pRC16; Li SX, 2000, J NEUROSCI, V20, P1190, DOI 10.1523/JNEUROSCI.20-03-01190.2000; LUNDY PM, 1994, BRAIN RES, V643, P204, DOI 10.1016/0006-8993(94)90026-4; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; MACVICAR BA, 1984, SCIENCE, V226, P1345, DOI 10.1126/science.6095454; Marrero H, 1996, GLIA, V16, P285; MAUBECIN VA, 1995, J NEUROCHEM, V64, P2544; OJCIUS DM, 1991, EXP CELL RES, V197, P43, DOI 10.1016/0014-4827(91)90477-C; Philippi M, 1996, GLIA, V17, P72; REGAN RF, 1991, NEUROSCIENCE, V43, P585, DOI 10.1016/0306-4522(91)90317-H; SATO K, 1993, BIOCHEM BIOPH RES CO, V194, P1292, DOI 10.1006/bbrc.1993.1964; Schumacher PA, 1999, NEUROSCIENCE, V91, P733, DOI 10.1016/S0306-4522(98)00552-1; Siesjo BK, 1996, ADV NEUROL, V71, P209; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; Smirnov SV, 1998, EUR J PHARMACOL, V360, P81, DOI 10.1016/S0014-2999(98)00656-6; STYS PK, 1990, NEUROSCI LETT, V115, P293, DOI 10.1016/0304-3940(90)90471-K; Stys PK, 1998, J CEREBR BLOOD F MET, V18, P2, DOI 10.1097/00004647-199801000-00002; STYS PK, 1992, J NEUROSCI, V12, P430; Sun BB, 1999, J NEUROSCI, V19, P5185; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Theriault E., 1994, Society for Neuroscience Abstracts, V20, P1071; Tymianski M, 1996, NEUROSURGERY, V38, P1176; VERKHRATSKY AN, 1990, NEUROSCI LETT, V112, P194, DOI 10.1016/0304-3940(90)90202-K; VONBLANKENFELD G, 1992, EUR J NEUROSCI, V4, P1035; Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792; WAXMAN SG, 1993, ANN NEUROL, V33, P121, DOI 10.1002/ana.410330202; WERTH JL, 1994, J NEUROSCI, V14, P348	58	83	85	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2000	99	1					179	188		10.1016/S0306-4522(00)00165-2			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	343GA	WOS:000088692300017	10924962				2022-02-06	
J	Schnuelle, P; Lorenz, D; Mueller, A; Trede, M; van der Woude, FJ				Schnuelle, P; Lorenz, D; Mueller, A; Trede, M; van der Woude, FJ			Donor catecholamine use reduces acute allograft rejection and improves graft survival after cadaveric renal transplantation	KIDNEY INTERNATIONAL			English	Article						kidney transplantation; acute rejection; brain death; catecholamines; graft survival	ENDOTHELIAL ADHESION MOLECULES; TUMOR-NECROSIS-FACTOR; BRAIN-DEAD PATIENTS; KIDNEY-TRANSPLANTS; LIVER GRAFT; DOPAMINE; EXPRESSION; CYTOKINES; INJURY; INFLAMMATION	Background Epidemiological data implicate that renal transplants from living unrelated donors result in superior survival rates as compared with cadaveric grafts, despite a higher degree of human lymphocyte antigen (HLA) mismatching. We undertook a center-based case control study to identify donor-specific determinants affecting early outcome in cadaveric transplantation. Methods. The study database consisted of 152 consecutive cadaveric renal transplants performed at our center between June 1989 and September 1998. Of these, 24 patients received a retransplant. Donor kidneys were allocated on the basis of prospective HLA matching according to the Eurotransplant rules of organ sharing. Immunosuppressive therapy consisted of a cyclosporine-based triple-drug regimen. In 67 recipients, at least one acute rejection episode occurred during the first month after transplantation. They were taken as cases, and the remaining 85 patients were the controls. Stepwise logistic regression was done on donor-specific explanatory variables obtained from standardized Eurotransplant Necrokidney reports. In a secondary evaluation, the impact on graft survival in long-term follow-up was further measured by applying a Cox regression model. The mean follow-up of all transplant recipients was 3.8 years (SD 2.7 years). Results. Donor age [odds ratio (OR) 1.05; 95% CI, 1.02 to 1.08], traumatic brain injury as cause of death (OR 2.75; 95% CI, 1.16 to 6.52), and mismatch on HLA-DR (OR 3.0; 95% CI, 1.47 to 6.12) were associated with an increased risk of acute rejection, whereas donor use of dopamine (OR 0.22; 95% CI, 0.09 to 0.51) and/or noradrenaline (OR 0.24; 95% CI, 0.10 to 0.60) independently resulted in a significant beneficial effect. In the multivariate Cox regression analysis, both donor treatment with dopamine (HR 0.44; 95% CI, 0.22 to 0.84) and noradrenaline (HR 0.30; 95% CI, 0.10 to 0.87) remained a significant predictor of superior graft survival in long-term follow-up. Conclusions. Our data strongly suggest that the use of catecholamines in postmortal organ donors during intensive care results in immunomodulating effects and improves graft survival in long-term follow-up. These findings may at least partially be explained by down-regulating effects of adrenergic substances on the expression of adhesion molecules (VCAM, E-selectin) in the vessel walls of the graft.	Univ Hosp Mannheim, Med Clin Nephrol Endocrinol 5, D-68167 Mannheim, Germany; Univ Hosp Mannheim, Surg Clin, D-68167 Mannheim, Germany; Heidelberg Univ, Fac Med, D-6800 Mannheim, Germany		Schnuelle, P (corresponding author), Univ Hosp Mannheim, Med Clin Nephrol Endocrinol 5, Thedor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.	schnuell@rumms.uni-mannheim.de					AGODOA LY, 1995, AM J KIDNEY DIS, V25, P119, DOI 10.1016/0272-6386(95)90638-X; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Betz A. Lorris, 1996, Keio Journal of Medicine, V45, P230; CARLOS TM, 1994, BLOOD, V84, P2068; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; CARMELLINI M, 1994, TRANSPLANT P, V26, P2626; CECKA JM, 1992, TRANSPLANTATION, V53, P59, DOI 10.1097/00007890-199201000-00011; CECKA JM, 1994, CLIN TRANSPLANT, V8, P324; DUSTIN ML, 1986, J IMMUNOL, V137, P245; FERGUSON CJ, 1990, NEPHROL DIAL TRANSPL, V5, P816, DOI 10.1093/ndt/5.9.816; FERGUSON R, 1994, CLIN TRANSPLANT, V8, P328; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; Fortenberry JD, 1997, CRIT CARE MED, V25, P303, DOI 10.1097/00003246-199702000-00019; GRUNDMANN R, 1982, KLIN WOCHENSCHR, V60, P193, DOI 10.1007/BF01715586; HALLORAN PF, 1988, TRANSPLANTATION, V46, P223, DOI 10.1097/00007890-198808000-00007; HAUG CE, 1993, TRANSPLANTATION, V55, P766, DOI 10.1097/00007890-199304000-00016; Hourmant M, 1996, TRANSPLANTATION, V62, P1565, DOI 10.1097/00007890-199612150-00006; KADIEVA VS, 1993, ANESTH ANALG, V76, P362; Kim JS, 1996, J NEUROL SCI, V137, P69, DOI 10.1016/0022-510X(95)00338-3; Lehtonen SRK, 1997, TRANSPLANTATION, V64, P103, DOI 10.1097/00007890-199707150-00019; MALLICK NP, 1995, AM J KIDNEY DIS, V25, P176, DOI 10.1016/0272-6386(95)90642-8; MANAKA D, 1992, TRANSPLANTATION, V53, P545, DOI 10.1097/00007890-199203000-00010; Marcen R, 1998, TRANSPLANTATION, V66, P461, DOI 10.1097/00007890-199808270-00008; Marshall R, 1996, SURGERY, V120, P663, DOI 10.1016/S0039-6060(96)80014-6; MASSY ZA, 1995, KIDNEY INT, V48, pS85; NAKATANI T, 1991, INTENS CARE MED, V17, P103, DOI 10.1007/BF01691432; O'Brien E A, 1996, J Transpl Coord, V6, P215; Ojo AO, 1997, TRANSPLANTATION, V63, P968, DOI 10.1097/00007890-199704150-00011; OPELZ G, 1992, TRANSPLANT P, V24, P2342; PIENAAR H, 1990, TRANSPLANTATION, V50, P580, DOI 10.1097/00007890-199010000-00010; POBER JS, 1993, J IMMUNOL, V150, P5114; POBER JS, 1986, J IMMUNOL, V136, P1680; SANDBERG J, 1992, TRANSPLANT P, V24, P357; Shoskes DA, 1998, TRANSPLANTATION, V66, P1697, DOI 10.1097/00007890-199812270-00022; Stanimirovic DB, 1997, ACT NEUR S, V70, P12; SUTHERLAND FR, 1993, CAN J SURG, V36, P141; TAKEMOTO S, 1992, NEW ENGL J MED, V327, P834, DOI 10.1056/NEJM199209173271202; Terasaki PI, 1997, CLIN TRANSPLANT, V11, P366; TERASAKI PI, 1995, NEW ENGL J MED, V333, P333, DOI 10.1056/NEJM199508103330601; VANSAASE JLCM, 1995, TRANSPLANTATION, V59, P1280, DOI 10.1097/00007890-199505150-00010; WALASZEWSKI J, 1988, TRANSPLANT P, V20, P913; YAMAOKA Y, 1990, TRANSPLANT INT, V3, P78, DOI 10.1007/BF00336208	42	83	90	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0085-2538	1523-1755		KIDNEY INT	Kidney Int.	AUG	1999	56	2					738	746		10.1046/j.1523-1755.1999.00567.x			9	Urology & Nephrology	Science Citation Index Expanded (SCI-EXPANDED)	Urology & Nephrology	219HE	WOS:000081601200041	10432416	Bronze			2022-02-06	
J	McKinney, JS; Willoughby, KA; Liang, S; Ellis, EF				McKinney, JS; Willoughby, KA; Liang, S; Ellis, EF			Stretch-induced injury of cultured neuronal, glial, and endothelial cells - Effect of Polyethylene glycol-conjugated superoxide dismutase	STROKE			English	Article						brain injuries; cerebral blood flow; free radicals	CEREBRAL BLOOD-FLOW; INDUCED BRAIN EDEMA; ACUTE HYPERTENSION; ARTERIOLAR ABNORMALITIES; RADICAL FORMATION; ARACHIDONIC-ACID; RATS; PERMEABILITY; GENERATION; MECHANISM	Background nod Purpose There is abundant evidence that after in vivo traumatic brain injury, oxygen radicals contribute to changes in cerebrovascular structure and function; however, the cellular source of these oxygen radicals is not clear. The purpose of these experiments was to use a newly developed in vitro tissue culture model to elucidate the effect of strain, or stretch, on neuronal, glial, and endothelial cells and to determine the effect of the free radical scavenger polyethylene glycol-conjugated superoxide dismutase (PEG-SOD; pegorgotein, Dismutec) on the response of each cell type to trauma. Methods Rat brain astrocytes, neuronal plus glial cells, and aortic endothelial cells were grown in cell culture wells with 2-mm-thick silastic membrane bottoms. A controllable, 50-millisecond pressure pulse was used Co transiently deform the silastic membrane and thus stretch the cells. injury was assessed by quantifying the number of cells that took up the normally cell-impermeable dye propidium iodide. Some cultures were pretreated with 100 to 300 U/mL PEG-SOD. Results increasing degrees of deformation produced increased cell injury in astrocytes, neuronal plus glial cultures, and aortic endothelial cells. By 24 hours after injury, all cultures showed evidence of repair as demonstrated by cells regaining their capacity to exclude propidium iodide. Compared with astrocytes or neuronal plus glial cultures, endothelial cells were much more resistant to stretch-induced injury and more quickly regained their capacity to exclude propidium iodide. PEG-SOD had no effect on the neuronal or glial response to injury but reduced immediate posttraumatic endothelial cell dye uptake by 51%. Conclusions These studies further document the utility of the model for studying cell injury and repair and further support the vascular endothelial cell as a site of free radical generation and radical-mediated injury. On the assumption that like aortic endothelial cells, stretch-injured cerebral endothelial cells also produce oxygen radicals, our results further suggest the endothelial cell as a site of therapeutic action of fl ee radical scavengers after traumatic brain injury.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,RICHMOND,VA 23284						NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-27214] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027214] Funding Source: NIH RePORTER		AMRUTHESH SC, 1993, J NEUROCHEM, V61, P150, DOI 10.1111/j.1471-4159.1993.tb03550.x; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; CHAN PH, 1988, J NEUROCHEM, V50, P1185, DOI 10.1111/j.1471-4159.1988.tb10591.x; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; CHAN PH, 1984, NEUROLOGY, V34, P315, DOI 10.1212/WNL.34.3.315; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Hall ED, 1993, IRON CENTRAL NERVOUS, P173; HE YY, 1993, AM J PHYSIOL, V265, pH252, DOI 10.1152/ajpheart.1993.265.1.H252; KAMITANI T, 1985, CIRC RES, V57, P545, DOI 10.1161/01.RES.57.4.545; KIRSCH JR, 1993, PEDIATR RES, V34, P530, DOI 10.1203/00006450-199310000-00030; KONTOS HA, 1981, AM J PHYSIOL, V240, pH511, DOI 10.1152/ajpheart.1981.240.4.H511; LAMB RG, 1995, J NEUROTRAUM, V12, P969; LAURINDO FRM, 1994, CIRC RES, V74, P700, DOI 10.1161/01.RES.74.4.700; MUIR JK, 1995, J NEUROTRAUM, V12, P179, DOI 10.1089/neu.1995.12.179; OURY TD, 1993, J BIOL CHEM, V268, P15394; RAYTCH RE, 1987, SURGERY, V102, P122; ROSEN GM, 1984, P NATL ACAD SCI-BIOL, V81, P7269, DOI 10.1073/pnas.81.23.7269; ROSENBLUM WI, 1995, AM J PHYSIOL-HEART C, V268, pH512, DOI 10.1152/ajpheart.1995.268.1.H512; Santilli S M, 1991, Ann Vasc Surg, V5, P429, DOI 10.1007/BF02133047; SCHLEIEN CL, 1994, STROKE, V25, P1830, DOI 10.1161/01.STR.25.9.1830; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767, DOI 10.1152/jn.1995.74.6.2767; TRUELOVE D, 1994, FREE RADICAL BIO MED, V17, P445, DOI 10.1016/0891-5849(94)90171-6; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; WEI EP, 1985, CIRC RES, V57, P781, DOI 10.1161/01.RES.57.5.781; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOSHIDA K, 1992, J NEUROTRAUM, V9, P85, DOI 10.1089/neu.1992.9.85; ZHANG XM, 1991, STROKE, V22, P489, DOI 10.1161/01.STR.22.4.489; ZHANG XM, 1990, AM J PHYSIOL, V259, pH497, DOI 10.1152/ajpheart.1990.259.2.H497; ZWEIER JL, 1988, P NATL ACAD SCI USA, V85, P4046, DOI 10.1073/pnas.85.11.4046	31	83	84	0	8	AMER HEART ASSOC	DALLAS	7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596	0039-2499			STROKE	Stroke	MAY	1996	27	5					934	940		10.1161/01.STR.27.5.934			7	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	UJ685	WOS:A1996UJ68500025	8623116				2022-02-06	
J	DeKosky, ST; Styren, SD; OMalley, ME; Goss, JR; Kochanek, P; Marion, D; Evans, CH; Robbins, PD				DeKosky, ST; Styren, SD; OMalley, ME; Goss, JR; Kochanek, P; Marion, D; Evans, CH; Robbins, PD			Interleukin-1 receptor antagonist suppresses neurotrophin response in injured rat brain	ANNALS OF NEUROLOGY			English	Article							NERVE GROWTH-FACTOR; SEVERE HEAD-INJURIES; AMINO-ACIDS; EXPRESSION; INCREASES; PROTEIN; IL-1; STIMULATION; FIBROBLASTS; ASTROCYTES	Traumatic brain injury (TBI) induces astrocytic and microglial activation and proliferation and augmented production of the cytokine interleukin-1 beta (IL-1 beta) and nerve growth factor (NGF). The increase in NGF temporally follows the increase in IL-1 beta, suggesting that the IL-1 beta up-regulation after trauma directly induces the increase in NGF. We examined the effect of IL-1 receptor antagonist protein (IL-1ra) on microglial proliferation and NGF production in rat cortex, following two different models of TBI. Rabbit fibroblasts infected with a retroviral vector containing the human IL-1ra gene were implanted into the wound cavity immediately following a cortical stab wound or 6 hours after a weight drop-induced trauma. Both microglial proliferation and NGF up-regulation were decreased significantly in animals receiving IL-1ra-expressing cells compared with animals receiving naive (untransfected) fibroblasts. These data demonstrate that the increase in NGF after central nervous system trauma is directly mediated through IL-1 beta and that blocking IL-1 beta following brain injury leads to suppression of an NGF-mediated reparative response. Such blockade of inflammation, however, may prove to be of significant therapeutic benefit in human brain injury and other inflammatory states.	UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,WESTERN PSYCHIAT INST & CLIN,PITTSBURGH,PA 15213; UNIV PITTSBURGH,SCH MED,DEPT NEUROL,WESTERN PSYCHIAT INST & CLIN,PITTSBURGH,PA 15213; UNIV PITTSBURGH,SCH MED,DEPT NEUROBIOL,WESTERN PSYCHIAT INST & CLIN,PITTSBURGH,PA 15213; UNIV PITTSBURGH,SCH MED,DEPT NEUROSURG,WESTERN PSYCHIAT INST & CLIN,PITTSBURGH,PA 15213; UNIV PITTSBURGH,SCH MED,DEPT ORTHOPED SURG,WESTERN PSYCHIAT INST & CLIN,PITTSBURGH,PA 15213; SAFAR CTR RESUSCITAT RES,PITTSBURGH,PA		DeKosky, ST (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT PSYCHIAT,WESTERN PSYCHIAT INST & CLIN,3811 OHARA ST,PITTSBURGH,PA 15213, USA.		Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; DeKosky, Steven/0000-0003-3743-2758	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P01DK044935] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, P20NS030318, P01NS030318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005133] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG05133] Funding Source: Medline; NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK44935] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline		BANDARA G, 1993, P NATL ACAD SCI USA, V90, P10764, DOI 10.1073/pnas.90.22.10764; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; CASTELLANO B, 1991, J HISTOCHEM CYTOCHEM, V39, P561, DOI 10.1177/39.5.1707903; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DEKOSKY ST, 1994, J NEUROTRAUMA, V11, P106; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GIULIAN D, 1988, J NEUROSCI, V8, P709; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; JOHNSON EM, 1988, TRENDS NEUROSCI, V11, P299, DOI 10.1016/0166-2236(88)90090-2; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KOCH AE, 1992, CLIN IMMUNOL IMMUNOP, V65, P23, DOI 10.1016/0090-1229(92)90243-H; Kochanek P, 1991, J NEUROTRAUM, V8, P19, DOI 10.1089/neu.1991.8.19; KRZESICKI RF, 1993, J IMMUNOL, V150, P4008; LEE SC, 1993, J IMMUNOL, V150, P2659; LINDHOLM D, 1988, J BIOL CHEM, V263, P16348; Lindholm D, 1990, Neuroreport, V1, P9; LOREZ H, 1989, NEUROSCI LETT, V98, P339, DOI 10.1016/0304-3940(89)90425-4; MANEV H, 1990, FASEB J, V4, P2789, DOI 10.1096/fasebj.4.10.2165013; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MERRILL JE, 1991, DEV NEUROSCI, V14, P1; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; PAN ZH, 1993, J NEUROCHEM, V61, P1713, DOI 10.1111/j.1471-4159.1993.tb09808.x; RESNICK DK, 1994, NEUROSURGERY, V34, P252, DOI 10.1227/00006123-199402000-00007; Roitt I. M., 1993, IMMUNOLOGY; ROTHWELL NJ, 1993, NEUROSCI BIOBEHAV R, V17, P217, DOI 10.1016/S0149-7634(05)80152-6; SPRANGER M, 1990, EUR J NEUROSCI, V2, P69, DOI 10.1111/j.1460-9568.1990.tb00382.x; STOCKMAN BJ, 1992, BIOCHEMISTRY-US, V31, P5237, DOI 10.1021/bi00138a001; STYREN SD, 1995, EXP NEUROL, V131, P165, DOI 10.1016/0014-4886(95)90038-1; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Tuszynski M H, 1994, Neurobiol Dis, V1, P67, DOI 10.1006/nbdi.1994.0009	38	83	87	1	4	LITTLE BROWN CO	BOSTON	34 BEACON STREET, BOSTON, MA 02108-1493	0364-5134			ANN NEUROL	Ann. Neurol.	JAN	1996	39	1					123	127		10.1002/ana.410390118			5	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	TT880	WOS:A1996TT88000017	8572657				2022-02-06	
J	CORRIGAN, JD; DEMING, R				CORRIGAN, JD; DEMING, R			PSYCHOMETRIC CHARACTERISTICS OF THE COMMUNITY INTEGRATION QUESTIONNAIRE - REPLICATION AND EXTENSION	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article								Psychometric characteristics of the Community Integration Questionnaire (CIQ) were replicated and extended. Retrospective CIQs assessing premorbid functioning were completed at inpatient admission for 461 patients with traumatic brain injury (TBI) or disabilities resulting from other injuries. Data were collected at follow-up from 217 persons. The total score was normally distributed, with premorbid scores showing a slight negative skew. Significant mean differences for premorbid versus follow-up samples were evident for the total score and all three subscales, except TBI home integration. Age and gender had minimal effects on total and subscale scores. Overall, results supported the utility of the CIQ as a measure of handicap following TBI. Problems in the distribution of the productivity subscale suggested that it should not be used independently of the total score. Findings also suggested that retrospective assessment may be a useful method for collecting comparative data and that the CIQ can be used to measure integration in populations other than TBI.	OHIO STATE UNIV,MED CTR,COLUMBUS,OH 43210		CORRIGAN, JD (corresponding author), OHIO STATE UNIV,DEPT PHYS MED & REHABIL,COLUMBUS,OH 43210, USA.		Corrigan, John D./E-2921-2011				Carmines E.G., 1979, RELIABILITY VALIDITY; RIMEL RW, 1990, REHABILITATION ADULT; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; WILLER BS, 1993, BRAIN INJURY REHABIL; World Health Organization, 1980, INT CLASS IMP DIS HA	7	83	83	0	3	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	1995	10	4					41	53		10.1097/00001199-199508000-00005			13	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	RN010	WOS:A1995RN01000005					2022-02-06	
J	Schwartz, MF; Montgomery, MW; FitzpatrickDeSalme, EJ; Ochipa, C; Coslett, HB; Mayer, NH				Schwartz, MF; Montgomery, MW; FitzpatrickDeSalme, EJ; Ochipa, C; Coslett, HB; Mayer, NH			Analysis of a disorder of everyday action	COGNITIVE NEUROPSYCHOLOGY			English	Article							POSITRON EMISSION TOMOGRAPHY; FRONTAL-LOBE DAMAGE; OBJECT RECOGNITION; ALZHEIMERS-DISEASE; IDEATIONAL APRAXIA; SEMANTIC MEMORY; OPTIC APHASIA; IMPAIRMENTS; AGNOSIA; CORTEX	We present a patient, JK, who developed a profound disturbance of routine action production subsequent to closed head injury. Part I of the study describes the disorder as it was expressed in tasks of everyday living. JK demonstrated the features of frontal apraxia, including extreme vulnerability to object substitution and object misuse. In Part II we carried out a neuropsychological assessment targeted at JK's recognition and understanding of objects and implements. This assessment showed a surprising preservation of low- and high-level vision, as well as semantic knowledge relevant to everyday tasks. It also revealed some areas of weakness, notably in access to semantic memory and gesture recall. It is widely accepted that everyday action tasks are planned and executed automatically, that is, with minimal involvement of executive control processes. JK's defects in the areas of semantic memory and gesture recall may have compromised the automaticity of his action planning, but this alone cannot account for his flagrant everyday-action disorder. We speculate, without direct evidence, that the executive control processes (supervisory attention/working memory) that support non-automatic action planning might also have been compromised in JK. If so, it suggests a new account of frontal apraxia, which rests on a combination of deficits: (1) disruption of the fast, automatic retrieval of information from memory stores relevant to action planning; and (2) pathological depletion of executive resources necessary to plan and execute routine behaviour when automaticity fails.	TEMPLE UNIV,SCH MED,PHILADELPHIA,PA 19122; JAMES A HALEY VET HOSP,TAMPA,FL 33612		Schwartz, MF (corresponding author), MOSS REHABIL RES INST,1200 W TABOR RD,PHILADELPHIA,PA 19141, USA.						Allport A., 1987, PERSPECTIVES PERCEPT; BAARS BJ, 1992, EXPT SLIPS HUMAN ERR; Baddeley A.D., 1994, NEUROPSYCHOLOGY, V8, P485, DOI [10.1037/0894-4105.8.4.485, DOI 10.1037/0894-4105.8.4.485]; BAYLIS GC, 1987, J NEUROSCI, V7, P330; Benson D.F., 1986, FRONTAL LOBES; BIEDERMAN I, 1993, UNPUB HIGH LEVEL OBJ; CANAVAN AGM, 1985, J NEUROL NEUROSUR PS, V48, P1049, DOI 10.1136/jnnp.48.10.1049; CHERTKOW H, 1989, BRAIN LANG, V36, P420, DOI 10.1016/0093-934X(89)90078-3; CHERTKOW H, 1990, MODULAR DEFICITS ALZ; CICERONE KD, 1992, NEUROREHABILITATION, V2, P12, DOI DOI 10.3233/NRE-1992-2304; COSLETT HB, 1989, BRAIN, V112, P1091, DOI 10.1093/brain/112.4.1091; DERENZI E, 1988, BRAIN, V111, P1173, DOI 10.1093/brain/111.5.1173; DERENZI E, 1986, CORTEX, V22, P171, DOI 10.1016/S0010-9452(86)80041-7; DERENZI E, 1968, NEUROPSYCHOLOGIA, V6, P41, DOI 10.1016/0028-3932(68)90037-7; FARAH MJ, 1990, VISUAL AGNOSIA; Fuster JM, 1989, PREFRONTAL CORTEX, V2nd; GOLDMANRAKIC PS, 1987, HDB PHYSL NERVOUS SY, V5; GROSS CG, 1992, PHILOS T ROY SOC B, V335, P3, DOI 10.1098/rstb.1992.0001; HAXBY JV, 1991, P NATL ACAD SCI USA, V88, P1621, DOI 10.1073/pnas.88.5.1621; HUMPHREYS GW, 1984, Q J EXP PSYCHOL-A, V36, P385, DOI 10.1080/14640748408402169; Kaplan E, 1983, BOSTON NAMING TEST; KIMBERG DY, 1993, J EXP PSYCHOL GEN, V122, P411, DOI 10.1037/0096-3445.122.4.411; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEHMKUHL G, 1981, CORTEX, V17, P153, DOI 10.1016/S0010-9452(81)80017-2; LIEPMANN H, 1905, TRANSLATIONS LIEPMAN; Luria A.R., 1966, HIGHER CORTICAL FUNC; Luria AR, 1973, PSYCHOPHYSIOLOGY FRO; MACKAY DG, 1985, NEUROPSYCHOLOGICAL S; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MATTSON ME, 1992, EXPT SLIPS HUMAN ERR; MAYER NH, 1990, NEUROPSYCHOLOGY EVER; NORMAN DA, 1981, PSYCHOL REV, V88, P1, DOI 10.1037/0033-295X.88.1.1; NORMAN DA, 1986, CONSCIOUSNESS SELF R, V0004; OCHIPA C, 1989, ANN NEUROL, V25, P190, DOI 10.1002/ana.410250214; OCHIPA C, 1992, BRAIN, V115, P1061, DOI 10.1093/brain/115.4.1061; POECK K, 1980, CORTEX, V16, P273, DOI 10.1016/S0010-9452(80)80062-1; Poeck K., 1985, NEUROPSYCHOLOGICAL S; Prigatano G. P., 1991, AWARENESS DEFICIT BR; RAPCSAK SZ, 1993, BRAIN COGNITION, V23, P181, DOI 10.1006/brcg.1993.1054; Reason J., 1982, ABSENT MINDED PSYCHO; Reason J., 1990, HUMAN ERROR INTERNET, DOI DOI 10.1017/CBO9781139062367; Reason J. T., 1984, VARIETIES ATTENTION; REASON JT, 1979, ASPECTS CONSCIOUSNES, V1; Reed Edward S., 1992, Ecological Psychology, V4, P129, DOI 10.1207/s15326969eco0403_1; RIDDOCH MJ, 1987, COGN NEUROPSYCHOL, V4, P131, DOI 10.1080/02643298708252038; Rothi L. J. G., 1991, FLORIDA APRAXIA BATT; ROTHI LJG, 1991, COGN NEUROPSYCHOL, V8, P443, DOI 10.1080/02643299108253382; ROTHI LJG, 1991, UNPUB FLORIDA APRAXI; ROY EA, 1982, NORMALITY PATHOLOGY; ROY EA, 1983, MEMORY CONTROL ACTIO; Roy EA, 1985, NEUROPSYCHOLOGICAL S; SAFFRAN A, 1994, ATTENTION PERFORMANC, V15; Schwartz M. F., 1993, J HEAD TRAUMA REHAB, V8, P59, DOI [10.1097/00001199-199303000-00007, DOI 10.1097/00001199-199303000-00007]; SCHWARTZ MF, 1991, COGN NEUROPSYCHOL, V8, P381, DOI 10.1080/02643299108253379; SCHWARTZ MF, 1990, MODULAR DEFICITS ALZ; SERGENT J, 1992, BRAIN, V115, P15, DOI 10.1093/brain/115.1.15; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Shallice T., 1988, NEUROPSYCHOLOGY MENT; SIRIGU A, 1991, BRAIN, V114, P2555, DOI 10.1093/brain/114.6.2555; UNGERLEIDER LG, 1982, ANAL VISUAL BEHAVIOU; Warrington E. K, 1984, MANUAL RECOGNITION M; WARRINGTON EK, 1978, PERCEPTION, V7, P695, DOI 10.1068/p070695; WARRINGTON EK, 1982, PHILOS T ROY SOC B, V298, P15, DOI 10.1098/rstb.1982.0069; WARRINGTON EK, 1975, Q J EXP PSYCHOL, V27, P635, DOI 10.1080/14640747508400525; WHYTE J, 1993, REHABILITATION MED P; [No title captured]; [No title captured]	68	83	83	0	6	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE, EAST SUSSEX, ENGLAND BN3 2FA	0264-3294			COGNITIVE NEUROPSYCH	Cogn. Neuropsychol.		1995	12	8					863	892		10.1080/02643299508251406			32	Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	TM093	WOS:A1995TM09300005					2022-02-06	
J	LEACH, LR; FRANK, RG; BOUMAN, DE; FARMER, J				LEACH, LR; FRANK, RG; BOUMAN, DE; FARMER, J			FAMILY FUNCTIONING, SOCIAL SUPPORT AND DEPRESSION AFTER TRAUMATIC BRAIN INJURY	BRAIN INJURY			English	Article							RATING-SCALE; HEAD-INJURY; PERSONALITY	Functional outcome after traumatic brain injury (TBI) is thought to be dependent upon effective social support and avoidance of depressive episodes. Research indicates that post-injury changes often occur in the family's functioning, hence impacting the family's ability to provide the needed social support. Social support, in turn, has been hypothesized to work as a buffer between significant life event and levels of depressive symptoms. Thus poor social support after a TBI, due to changes in family functioning, could result in depressive episodes for the person with a TBI. This paper empirically examines this question by investigating whether social support is predictive of depression in persons who have sustained a TBI. Thirty-nine persons who had sustained TBI were interviewed to assess their family functioning, perceived social support, and current depressive symptomatology. The results showed that the effective use of problem-solving and behavioural coping strategies by the family in response to TBI was significantly related to lower levels of depression in the person who sustained the TBI. However, perceived social support was not predictive of depression.	UNIV MISSOURI,DEPT PHYS MED & REHABIL,2R01 RUSK REHABILITAT CTR,COLUMBIA,MO 65212; UNIV MISSOURI,DEPT PSYCHOL,COLUMBIA,MO 65201								BARRERA M, 1990, J SOCIAL PERSONAL RE, V71, P541; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BROOKS N, 1984, CLOSED HEAD INJURY P, P123; CASSEL J, 1974, INT J HEALTH SERV, V4, P471, DOI 10.2190/WF7X-Y1L0-BFKH-9QU2; CLEARY PD, 1982, J HEALTH SOC BEHAV, V23, P159, DOI 10.2307/2136512; COYNE JC, 1976, PSYCHIATRY, V39, P28, DOI 10.1080/00332747.1976.11023874; ELLIOTT TR, 1990, REHABIL PSYCHOL, V35, P111; ENDICOTT J, 1981, ARCH GEN PSYCHIAT, V38, P98; Florian V, 1991, NEUROPSYCHOLOGY, V5, P267, DOI DOI 10.1037/0894-4105.5.4.267; FRANK R G, 1990, Brain Injury, V4, P289, DOI 10.3109/02699059009026179; HOLAHAN CJ, 1986, J PERS SOC PSYCHOL, V51, P389, DOI 10.1037/0022-3514.51.2.389; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KAPLAN SP, 1990, REHABIL COUNS BULL, V34, P16; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; MCCUBBIN HI, 1985, FAMILY INVENTORIES I, P143; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; PIERCE GR, 1986, MAY W PSYCHOL ASS CO; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; SARASON IG, 1983, J PERS SOC PSYCHOL, V44, P127, DOI 10.1037/0022-3514.44.1.127; STRACK S, 1983, J PERS SOC PSYCHOL, V44, P798, DOI 10.1037/0022-3514.44.4.798; THOMSEN IV, 1974, SCANDINAVIAN J REHAB, V6, P189; WHYBROW PC, 1984, MOOD DISORDERS NEW P; WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742; WORTMAN CB, 1989, J CONSULT CLIN PSYCH, V57, P349, DOI 10.1037/0022-006X.57.3.349	25	83	83	0	7	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	OCT	1994	8	7					599	606		10.3109/02699059409151012			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	PH426	WOS:A1994PH42600003	7804296				2022-02-06	
J	WROBLEWSKI, BA; LEARY, JM; PHELAN, AM; WHYTE, J; MANNING, K				WROBLEWSKI, BA; LEARY, JM; PHELAN, AM; WHYTE, J; MANNING, K			METHYLPHENIDATE AND SEIZURE FREQUENCY IN BRAIN INJURED PATIENTS WITH SEIZURE DISORDERS	JOURNAL OF CLINICAL PSYCHIATRY			English	Article								Background: Psychostimulant drugs such as methylphenidate are increasingly being used in patients with traumatic brain injury or other brain injuries for a variety of cognitive and behavioral problems. However, there is some reluctance among clinicians and family members to use methylphenidate in brain injured patients because of warnings of seizure occurrence, which are prominently reported by the product labeling included in the Physicians' Desk Reference. Method: We retrospectively studied the use of methylphenidate in 30 consecutive patients with active seizure disorders. We compared the seizure frequency in the 3 months before and after methylphenidate with the seizure frequency during methylphenidate treatment, using the Wilcoxon signed-rank test. Results: Overall, the findings demonstrated a trend toward a lesser incidence of seizures in patients during methylphenidate treatment. Only 4 patients had greater seizure frequency during methylphenidate treatment, and 3 of these 4 were receiving tricyclic antidepressants. Conclusion: Methylphenidate can be safely used in brain injured patients, even those at high risk for seizures, as it was associated with a trend toward reduction (rather than increase) in seizure frequency in this population.	TUFTS UNIV,SCH MED,DEPT REHABIL MED,BOSTON,MA 02111; MASSACHUSETTS COLL PHARM & ALLIED HLTH SCI,BOSTON,MA; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT PHYS MED & REHABIL,PHILADELPHIA,PA 19140; MOSS REHABIL HOSP,DRUCKER BRAIN INJURY CTR,PHILADELPHIA,PA 19141		WROBLEWSKI, BA (corresponding author), GREENERY REHABIL CTR,99 CHESTNUT HILL AVE,BOSTON,MA 02135, USA.			Whyte, John/0000-0002-4381-1474			APPLEBY JG, 1985, J S C MED ASS, V5, P281; CRISOSTOMO EA, 1988, ANN NEUROL, V23, P94, DOI 10.1002/ana.410230117; Evans R. W., 1987, J HEAD TRAUMA REHAB, V2, P29; EVANS RW, 1986, J NERV MENT DIS, V175, P106; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FELDMAN H, 1989, AM J DIS CHILD, V143, P1081, DOI 10.1001/archpedi.1989.02150210117030; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; LIPPER S, 1976, J NERV MENT DIS, V162, P366, DOI 10.1097/00005053-197605000-00008; LIVINGSTON S, 1975, JAMA-J AM MED ASSOC, V233, P278, DOI 10.1001/jama.233.3.278; LIVINGSTON S, 1948, J PEDIATR, V32, P490, DOI 10.1016/S0022-3476(48)80169-1; MALKMUS D, 1980, REHABILITATION HEAD; Parmelee D X, 1987, Brain Inj, V1, P41, DOI 10.3109/02699058709034443; Weinberg R M, 1987, Brain Inj, V1, P57, DOI 10.3109/02699058709034445; WROBLEWSKI BA, 1990, J CLIN PSYCHOPHARM, V10, P124, DOI 10.1097/00004714-199004000-00009; 1991, MED EC	16	83	84	0	3	PHYSICIANS POSTGRADUATE PRESS	MEMPHIS	P O BOX 240008, MEMPHIS, TN 38124	0160-6689			J CLIN PSYCHIAT	J. Clin. Psychiatry	MAR	1992	53	3					86	89					4	Psychology, Clinical; Psychiatry	Social Science Citation Index (SSCI); Science Citation Index Expanded (SCI-EXPANDED)	Psychology; Psychiatry	HM911	WOS:A1992HM91100003	1548250				2022-02-06	
J	CRUZ, J; MINER, ME; ALLEN, SJ; ALVES, WM; GENNARELLI, TA				CRUZ, J; MINER, ME; ALLEN, SJ; ALVES, WM; GENNARELLI, TA			CONTINUOUS MONITORING OF CEREBRAL OXYGENATION IN ACUTE BRAIN INJURY - ASSESSMENT OF CEREBRAL HEMODYNAMIC RESERVE	NEUROSURGERY			English	Article						ARTERIOJUGULAR OXYGEN DIFFERENCE; COMA; FIBEROPTIC MONITORING; HEAD INJURY; HEMODYNAMIC RESERVE; HYPERVENTILATION; INTRACRANIAL PRESSURE	BLOOD-FLOW; COMATOSE PATIENTS; INTRACRANIAL-PRESSURE; HEAD-INJURY; MANNITOL; METABOLISM	A new index of cerebral hemodynamics, cerebral hemodynamic reserve (CHR), was evaluated in 12 comatose adults with severe, acute, traumatic, diffuse swelling of the brain, who underwent continuous monitoring with a fiberoptic catheter of the saturation difference in arteriojugular oxyhemoglobin. CHR was assessed as the ratio of changes in global cerebral oxygen extraction to changes in cerebral perfusion pressure (CPP) as a result of spontaneous increases in intracranial pressure (ICP). During the course of hyperventilation (Pco2 in the range of 20 mm Hg) for ICP control below 20 mm Hg, 34 observations were made over the initial 48 hours postinjury. Despite normal CPP, in 25 of the observations (73.5%), ICP elevations to the range of 20 mm Hg were associated with compromised CHR, as evidenced by decreases in jugular oxygenation directly attributed to the ICP increases. In the remaining nine observations (26.5%), CHR was preserved, as evidenced by no changes or increases in jugular oxygenation when ICP increased. The CHR improved on the second day, suggesting an improved tolerance of the cerebral hemodynamics to ICP increases. Before the ICP elevations, in most of the observations, the global cerebral blood flow was estimated as being optimally decreased (by hypocapnia), in relation to cerebral oxygen consumption. This was reflected by the occurrence of baseline normalized cerebral oxygen extraction. It is concluded that in this group of patients, under circumstances of profound hyperventilation, ICP elevations within the normal CPP range may result in decreased cerebral oxygenation, even when the normal CPP would imply otherwise. It is suggested that CHR assessment may provide information regarding the status of intracranial "tightness," insofar as cerebral circulation and oxygenation are concerned.	UNIV PENN,SCH MED,DIV NEUROSURG,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,CTR HEAD INJURY,PHILADELPHIA,PA 19104; OHIO STATE UNIV,SCH MED,DIV NEUROL SURG,COLUMBUS,OH 43210; UNIV TEXAS,SCH MED,DEPT ANESTHESIOL,HOUSTON,TX 77025						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, P50NS008803] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-08803-19] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R 49/CCR303687-02] Funding Source: Medline		BRODERSEN P, 1974, J NEUROL NEUROSUR PS, V37, P384, DOI 10.1136/jnnp.37.4.384; BROWN FD, 1979, J NEUROSURG, V50, P423, DOI 10.3171/jns.1979.50.4.0423; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; BURKE AM, 1981, J NEUROSURG, V55, P550, DOI 10.3171/jns.1981.55.4.0550; Cruz J, 1988, Acta Neurochir Suppl (Wien), V42, P35; CRUZ J, 1985, CRIT CARE MED, V13, P284, DOI 10.1097/00003246-198504000-00047; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; CRUZ J, 1986, NEUROTRAUMA TREATMEN, P55; CRUZ J, 1984, 52ND ANN M AM ASS NE; Gibbs EL, 1942, J BIOL CHEM, V144, P325; GRUBB RL, 1975, J NEUROSURG, V43, P385, DOI 10.3171/jns.1975.43.4.0385; LASSEN NA, 1966, LANCET, V2, P1113, DOI 10.1016/S0140-6736(66)92199-4; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Rappaport Z H, 1981, Prog Neurol Surg, V10, P1, DOI 10.1159/000384765; ROBERTSON CS, 1991, J NEUROSURG, V74, P43, DOI 10.3171/jns.1991.74.1.0043; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; SHALIT MN, 1972, NEUROLOGY, V22, P155, DOI 10.1212/WNL.22.2.155; TABADDOR K, 1972, J TRAUMA, V12, P1053, DOI 10.1097/00005373-197212000-00006; TEASDALE G, 1974, LANCET, V2, P81	19	83	83	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	NOV	1991	29	5					743	749		10.1227/00006123-199111000-00017			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	GL761	WOS:A1991GL76100017	1961406				2022-02-06	
J	BENZEL, EC; DAY, WT; KESTERSON, L; WILLIS, BK; KESSLER, CW; MODLING, D; HADDEN, TA				BENZEL, EC; DAY, WT; KESTERSON, L; WILLIS, BK; KESSLER, CW; MODLING, D; HADDEN, TA			CIVILIAN CRANIOCEREBRAL GUNSHOT WOUNDS	NEUROSURGERY			English	Article						CRANIOCEREBRAL GUNSHOT WOUND; GUNSHOT WOUND; PENETRATING CRANIOCEREBRAL INJURIES	CEREBRAL MISSILE INJURY; TRAUMATIC ANEURYSM; HEAD-INJURY; BRAIN; PERSPECTIVE; MANAGEMENT; FRAGMENTS; MORTALITY; DEATHS	Experience with 120 patients who incurred a gunshot wound to the head with dural penetration is presented. All of the patients were managed by a standard resuscitation protocol and assigned a clinical grade based on their level of consciousness both at the time of presentation and at 2 to 4 months after injury. Fifty patients (42%) underwent surgery. Twenty-eight patients (23%) had a good recovery, 19 (16%) were moderately disabled, 6 (5%) were severely disabled, and 67 (56%) died. All patients who were alert and awake with a normal or near normal neurological examination at the time of admission survived with a good outcome. All but 4 patients who were comatose at the time of admission died. Nine patients, however, who were not comatose at the time of admission died from potentially preventable causes. In 3 of these patients, a more aggressive diagnostic approach (including cerebral angiography) may have altered their ultimate outcome. An expeditious approach to the trauma victim with a comprehensive management scheme after injury may have altered the course in the remainder of these patients.	LOUISIANA STATE UNIV, SCH MED, DIV NEUROSURG, SHREVEPORT, LA 71105 USA		BENZEL, EC (corresponding author), UNIV NEW MEXICO, SCH MED, DIV NEUROSURG, ALBUQUERQUE, NM 87131 USA.						ACOSTA C, 1972, J NEUROSURG, V36, P531, DOI 10.3171/jns.1972.36.5.0531; ASARI S, 1977, J NEUROSURG, V46, P795, DOI 10.3171/jns.1977.46.6.0795; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; CAREY ME, 1989, J NEUROSURG, V71, P754, DOI 10.3171/jns.1989.71.5.0754; CLARK WC, 1986, J NEUROSURG, V65, P9, DOI 10.3171/jns.1986.65.1.0009; COOPER PR, 1979, NEUROSURGERY, V4, P373, DOI 10.1227/00006123-197905000-00001; CROCKARD HA, 1977, J NEUROSURG, V46, P784, DOI 10.3171/jns.1977.46.6.0784; CROCKARD HA, 1977, J NEUROSURG, V46, P776, DOI 10.3171/jns.1977.46.6.0776; Cushing H, 1918, BRIT J SURG, V5, P558; Cushing H, 1918, Br Med J, V1, P221; HUBSCHMANN O, 1979, NEUROSURGERY, V5, P285; JAGGER J, 1986, JAMA-J AM MED ASSOC, V255, P3143, DOI 10.1001/jama.255.22.3143; JENNETT B, 1975, LANCET, V1, P480; KAUFMAN HH, 1980, NEUROSURGERY, V6, P181, DOI 10.1227/00006123-198002000-00011; KAUFMAN HH, 1986, NEUROSURGERY, V18, P689, DOI 10.1227/00006123-198606000-00002; KIRKPATRICK JB, 1978, J NEUROSURG, V49, P185, DOI 10.3171/jns.1978.49.2.0185; LILLARD PL, 1978, SURG NEUROL, V9, P79; MEIROWSKY AM, 1982, J NEUROSURG, V57, P617, DOI 10.3171/jns.1982.57.5.0617; NAGIB MG, 1986, NEUROSURGERY, V18, P533, DOI 10.1227/00006123-198605000-00003; ORNATO JP, 1985, J TRAUMA, V25, P575, DOI 10.1097/00005373-198507000-00001; RAHIMIZADEH A, 1987, ACTA NEUROCHIR, V84, P93, DOI 10.1007/BF01418831; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; RISH BL, 1980, J NEUROSURG, V53, P772, DOI 10.3171/jns.1980.53.6.0772; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; TEASDALE G, 1974, LANCET, V2, P81; WEST CGH, 1981, SURG NEUROL, V16, P145, DOI 10.1016/0090-3019(81)90117-8	26	83	84	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUL	1991	29	1					67	72		10.1227/00006123-199107000-00011			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	FT164	WOS:A1991FT16400011	1870690				2022-02-06	
J	LEVIN, HS				LEVIN, HS			MEMORY DEFICIT AFTER CLOSED-HEAD INJURY	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article											LEVIN, HS (corresponding author), UNIV TEXAS,MED BRANCH,JOHN SEALY HOSP 9 112,DIV NEUROSURG,GALVESTON,TX 77550, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ALBERT MS, 1979, ARCH NEUROL-CHICAGO, V36, P211, DOI 10.1001/archneur.1979.00500400065010; ARTIOLA I, 1980, J NEUROL NEUROSUR PS, V43, P377; BENTON AL, 1964, J NERV MENT DIS, V139, P110, DOI 10.1097/00005053-196408000-00003; BRODIE B, 1854, PSYCHOL ENQUIRIES; BROOKS D N, 1975, Cortex, V11, P329; BROOKS DN, 1976, NEUROPSYCHOLOGIA, V14, P111, DOI 10.1016/0028-3932(76)90012-9; BROOKS DN, 1974, J NEUROL NEUROSUR PS, V37, P794, DOI 10.1136/jnnp.37.7.794; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; Butters N., 1980, ALCOHOLIC KORSAKOFFS; COHEN NJ, 1980, SCIENCE, V210, P207, DOI 10.1126/science.7414331; CORKIN S, 1968, NEUROPSYCHOLOGIA, V6, P255, DOI 10.1016/0028-3932(68)90024-9; CRAIK FIM, 1972, J VERB LEARN VERB BE, V11, P671, DOI 10.1016/S0022-5371(72)80001-X; CROSSON B, 1984, J CLIN NEUROPSYCHOL, V6, P287, DOI 10.1080/01688638408401219; CROVITZ HF, 1979, CORTEX, V15, P225, DOI 10.1016/S0010-9452(79)80027-1; DANIEL WF, 1987, CORTEX, V23, P169, DOI 10.1016/S0010-9452(87)80030-8; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; EISENBERG HM, UNPUB J NEUROSURGERY; ESLINGER PJ, 1986, J NEUROSCI, V6, P3006; EWERT J, 1989, ARCH NEUROL-CHICAGO, V46, P911, DOI 10.1001/archneur.1989.00520440105027; FREEDMAN M, 1986, BRAIN COGNITION, V5, P108, DOI 10.1016/0278-2626(86)90063-1; GLASGOW RE, 1977, J CLIN PSYCHOL, V33, P1049, DOI 10.1002/1097-4679(197710)33:4<1049::AID-JCLP2270330429>3.0.CO;2-V; GLISKY EL, 1986, NEUROPSYCHOLOGIA, V24, P313, DOI 10.1016/0028-3932(86)90017-5; GLISKY EL, 1988, NEUROPSYCHOLOGIA, V26, P173, DOI 10.1016/0028-3932(88)90041-3; GOLDSTEIN FC, IN PRESS CORTEX; GOLDSTEIN FC, IN PRESS J CLIN EXPT; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; GRONWALL D, 1974, LANCET, V2, P605; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; Harris J E, 1981, Int Rehabil Med, V3, P206; HASHER L, 1979, J EXP PSYCHOL GEN, V108, P356, DOI 10.1037/0096-3445.108.3.356; HIGH WM, IN PRESS J CLIN EXPT; HIRST W, 1982, PSYCHOL BULL, V91, P435, DOI 10.1037/0033-2909.91.3.435; JENNETT WB, 1969, SPECIAL PUBLICATION, V4; KOVNER R, 1983, J CLIN NEUROPSYCHOL, V5, P65, DOI 10.1080/01688638308401151; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P14, DOI 10.1136/jnnp.51.1.14; LEVIN HS, 1985, J NEUROL NEUROSUR PS, V48, P556, DOI 10.1136/jnnp.48.6.556; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LEVIN HS, 1983, CORTEX, V19, P427, DOI 10.1016/S0010-9452(83)80025-2; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1985, ARCH NEUROL-CHICAGO, V42, P963, DOI 10.1001/archneur.1985.04060090045012; LEVIN HS, 1988, BRAIN COGNITION, V7, P283, DOI 10.1016/0278-2626(88)90003-6; LEVIN HS, 1981, BRAIN LANG, V12, P360, DOI 10.1016/0093-934X(81)90025-0; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Levin HS., 1982, NEUROBEHAVIORAL CONS; LEVIN HS, UNPUB J NEUROSURGERY; LEVIN HS, 1979, J NEUROSURG, V50, P42; MARTONE M, 1984, ARCH NEUROL-CHICAGO, V41, P965, DOI 10.1001/archneur.1984.04050200071020; MILNER B, 1968, NEUROPSYCHOLOGIA, V6, P215, DOI 10.1016/0028-3932(68)90021-3; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PAPANICOLAOU AC, 1984, NEUROSURGERY, V14, P676, DOI 10.1227/00006123-198406000-00005; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Ribot T., 1882, DISEASES MEMORY ESSA; RICHARDSON JTE, 1979, BRIT J SOC CLIN PSYC, V18, P319, DOI 10.1111/j.2044-8260.1979.tb00342.x; RUFF RM, UNPUB J NEUROSURGERY; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUSSELL WR, 1946, BRAIN, V69, P183; SCHACTER DL, 1977, CORTEX, V8, P150; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SHIMAMURA AP, 1984, J EXP PSYCHOL GEN, V113, P556, DOI 10.1037/0096-3445.113.4.556; SQUIRE LR, 1981, J NEUROSCI, V1, P635; SQUIRE LR, 1982, J EXP PSYCHOL LEARN, V8, P560, DOI 10.1037/0278-7393.8.6.560; SQUIRE LR, 1975, J EXPT PSYCHOL HUMAN, V1, P50, DOI DOI 10.1037/0278-7393.1.1.50; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P164; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1977, SCAND J REHABIL MED, V9, P73; TWEEDY JR, 1987, J CLIN EXP NEUROPSYC, V9, P19; WEINGARTNER H, 1983, SCIENCE, V221, P380, DOI 10.1126/science.6867715; Weinstein E.A., 1955, DENIAL ILLNESS SYMBO; WILSON B, CLIN MANAGEMENT MEMO; Wilson BA., 1985, RIVERMEAD BEHAVIOURA; ZATORRE RJ, 1983, BRAIN COGNITION, V2, P331, DOI 10.1016/0278-2626(83)90017-9; [No title captured]; [No title captured]	82	83	84	0	7	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JAN	1990	12	1					129	153		10.1080/01688639008400960			25	Psychology, Clinical; Clinical Neurology; Psychology	Social Science Citation Index (SSCI); Science Citation Index Expanded (SCI-EXPANDED)	Psychology; Neurosciences & Neurology	CK557	WOS:A1990CK55700466	2406280				2022-02-06	
J	OMMAYA, AK; ROCKOFF, SD; BALDWIN, M				OMMAYA, AK; ROCKOFF, SD; BALDWIN, M			EXPERIMENTAL CONCUSSION - FIRST REPORT	JOURNAL OF NEUROSURGERY			English	Article																	Cannon WB, 1901, AM J PHYSIOL, V6, P91; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DENNYBROWN D, 1945, PHYSIOL REV, V25, P296, DOI 10.1152/physrev.1945.25.2.296; DOW RS, 1945, J NEUROPHYSIOL, V8, P161; EVANS FG, 1961, BIOMECHANICAL STUDIE, V9, P192; FOLTZ EL, 1953, J NEUROSURG, V10, P342, DOI 10.3171/jns.1953.10.4.0342; FRIEDE RL, 1961, ARCH NEUROL-CHICAGO, V4, P449, DOI 10.1001/archneur.1961.00450100097012; GROAT R, 1950, J NEUROPATH EXP NEUR, V9, P150, DOI 10.1097/00005072-195004000-00003; GROAT RA, 1945, J NEUROSURG, V2, P26, DOI 10.3171/jns.1945.2.1.0026; Gurdjian ES, 1944, J NEUROSURG, V1, P393, DOI 10.3171/jns.1944.1.6.0393; GURDJIAN ES, 1943, SURG GYNECOL OBSTET, V76, P623; GURDJIAN ES, 1961, BIOMECHANICAL STUDIE, V9, P192; HADDAD B. F., 1955, NEUROLOGY, V5, P798; Holbourn AHS, 1943, LANCET, V2, P438; HOLLISTER NR, 1958, 58 WADC TECH REP WRI; Jakob A., 1912, HISTOL HISTOPATH ARB, V5, P182; JOHNSON T, WORKS FAMOUS CHIRURG, P350; KLATZO I, 1958, J NEUROPATH EXP NEUR, V17, P548, DOI 10.1097/00005072-195810000-00002; KRUEGER TP, 1963, AMER J ROENTGENOL RA, V90, P506; LITTRE, 1905, HIST ACAD SCI PARIS, P54; MEYER JS, 1955, ELECTROEN CLIN NEURO, V7, P529, DOI 10.1016/0013-4694(55)90078-X; Miller GG, 1927, ARCH SURG-CHICAGO, V14, P891, DOI 10.1001/archsurg.1927.01130160100005; MOORE GE, 1953, DIAGNOSIS LOCALIZATI, V23, P221; OMMAYA A K, 1963, Med Ann Dist Columbia, V32, P18; OMMAYA AK, 1963, MED ANN DC, V32, P38; ROCKOFF SD, IN PRESS; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; SCHMAUS H, 1890, VIRCHOWS ARCH PATH A, V122, P326; SCHMAUS H, 1890, VIRCHOWS ARCH PATH A, V122, P470; Scott WW, 1940, ARCH NEURO PSYCHIATR, V43, P270, DOI 10.1001/archneurpsyc.1940.02280020078006; STRICH SJ, 1961, LANCET, V2, P443; SYMONDS C, 1962, LANCET, V1, P1; Symonds CP, 1928, BRIT MED J, V1928, P829, DOI 10.1136/bmj.2.3540.829; TEDESCHI CG, 1945, ARCH NEURO PSYCHIATR, V53, P333, DOI 10.1001/archneurpsyc.1945.02300050007002; Walker AE, 1944, J NEUROSURG, V1, P103, DOI 10.3171/jns.1944.1.2.0103; WARD JW, 1948, SCIENCE, V107, P349, DOI 10.1126/science.107.2779.349; White JC, 1943, ANN SURG, V119, P619, DOI 10.1097/00000658-194310000-00010; Williams D, 1941, BRAIN, V64, P223, DOI 10.1093/brain/64.4.223; Windle W. F., 1944, SURG GYNECOL AND OBSTET, V79, P561; WINDLE WF, 1945, ANAT REC, V93, P201, DOI 10.1002/ar.1090930210; WINDLE WF, 1948, ANAT REC, V100, P725; WITKOWSKI L, 1877, VIRCHOWS ARCH, V69, P498; ZIMMERMAN FT, 1947, ARCH NEURO PSYCHIATR, V57, P521, DOI 10.1001/archneurpsyc.1947.02300280015001	44	83	83	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.		1964	21	4					249	+		10.3171/jns.1964.21.4.0249			1	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	6091B	WOS:A19646091B00011	14152540				2022-02-06	
J	Scott, G; Zetterberg, H; Jolly, A; Cole, JH; De Simoni, S; Jenkins, PO; Feeney, C; Owen, DR; Lingford-Hughes, A; Howes, O; Patel, MC; Goldstone, AP; Gunn, RN; Blennow, K; Matthews, PM; Sharp, DJ				Scott, Gregory; Zetterberg, Henrik; Jolly, Amy; Cole, James H.; De Simoni, Sara; Jenkins, Peter O.; Feeney, Claire; Owen, David R.; Lingford-Hughes, Anne; Howes, Oliver; Patel, Maneesh C.; Goldstone, Anthony P.; Gunn, Roger N.; Blennow, Kaj; Matthews, Paul M.; Sharp, David J.			Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration	BRAIN			English	Article						traumatic brain injury; microglia; minocycline; neurodegeneration; positron emission tomography	NEUROFILAMENT LIGHT PROTEIN; RHESUS-MONKEY; SPINAL-CORD; INJURY; BINDING; SINGLE; PET; INFLAMMATION; BIOMARKER; EFFICACY	Survivors of a traumatic brain injury can deteriorate years later, developing brain atrophy and dementia. Traumatic brain injury triggers chronic microglial activation, but it is unclear whether this is harmful or beneficial. A successful chronic-phase treatment for traumatic brain injury might be to target microglia. In experimental models, the antibiotic minocycline inhibits microglial activation. We investigated the effect of minocycline on microglial activation and neurodegeneration using PET, MRI, and measurement of the axonal protein neurofilament light in plasma. Microglial activation was assessed using C-11-PBR28 PET. The relationships of microglial activation to measures of brain injury, and the effects of minocycline on disease progression, were assessed using structural and diffusion MRI, plasma neurofilament light, and cognitive assessment. Fifteen patients at least 6 months after a moderate-to-severe traumatic brain injury received either minocycline 100 mg orally twice daily or no drug, for 12 weeks. At baseline, C-11-PBR28 binding in patients was increased compared to controls in cerebral white matter and thalamus, and plasma neurofilament light levels were elevated. MRI measures of white matter damage were highest in areas of greater C-11-PBR28 binding. Minocycline reduced 11 C-PBR28 binding (mean Delta white matter binding = -23.30%, 95% confidence interval -40.9 to -5.64%, P = 0.018), but increased plasma neurofilament light levels. Faster rates of brain atrophy were found in patients with higher baseline neurofilament light levels. In this experimental medicine study, minocycline after traumatic brain injury reduced chronic microglial activation while increasing a marker of neurodegeneration. These findings suggest that microglial activation has a reparative effect in the chronic phase of traumatic brain injury.	[Scott, Gregory; Jolly, Amy; Cole, James H.; De Simoni, Sara; Jenkins, Peter O.; Feeney, Claire; Owen, David R.; Lingford-Hughes, Anne; Howes, Oliver; Goldstone, Anthony P.; Matthews, Paul M.; Sharp, David J.] Imperial Coll London, Div Brain Sci, Dept Med, London, England; [Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Molndal, Sweden; [Zetterberg, Henrik; Blennow, Kaj] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden; [Zetterberg, Henrik] UCL Inst Neurol, Dept Mol Neurosci, London, England; [Patel, Maneesh C.] Imperial Coll Healthcare NHS Trust, Charing Cross Hosp, London, England; [Gunn, Roger N.] Imanova Ltd, London, England		Sharp, DJ (corresponding author), Imperial Coll London, Hammersmith Hosp, Computat Cognit & Clin Neuroimaging Lab, 3rd Floor,Burlington Danes Bldg,Du Cane Rd, London W12 0NN, England.	david.sharp@imperial.ac.uk	Cole, James H/I-5197-2019; Sharp, David J/A-2119-2013; Howes, Oliver/E-7156-2010	Cole, James H/0000-0003-1908-5588; Howes, Oliver/0000-0002-2928-1972; Gunn, Roger/0000-0003-1181-5769; Owen, David/0000-0002-1198-7563; Goldstone, Anthony/0000-0001-8179-7071; Scott, Gregory/0000-0001-8063-5871; Lingford-Hughes, Anne/0000-0003-4512-3453; Jolly, Amy/0000-0002-7413-9772	Wellcome Trust-GlaxoSmithKline Translational Medicine Training Programme; UK National Institute for Health Research (NIHR)National Institute for Health Research (NIHR); MS Society of Great Britain; Progressive MS Alliance; Medical Research Council (MRC)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); GlaxoSmithKlineGlaxoSmithKline; Imperial College Healthcare Trust Biomedical Research Centre; Swedish Research CouncilSwedish Research CouncilEuropean Commission; Knut and Alice Wallenberg FoundationKnut & Alice Wallenberg Foundation; VINNOVAVinnova; Torsten Soderberg foundation; NIHRNational Institute for Health Research (NIHR); MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0900897, MR/L022141/1, MR/N026063/1, G0700995, MR/N026934/1, MR/N008219/1] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0700995, MC_U120097115, 1116129, MR/L022141/1, G0900897, MR/N026934/1, MR/N008219/1, MR/N026063/1, MR/K501013/1] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-011-048, NF-SI-0514-10022] Funding Source: researchfish	G.S. was supported by a clinical research fellowship awarded in the Wellcome Trust-GlaxoSmithKline Translational Medicine Training Programme. D.R.O. is supported by the UK National Institute for Health Research (NIHR). P.M.M. has research support from the MS Society of Great Britain, the Progressive MS Alliance, the Medical Research Council (MRC) and GlaxoSmithKline and personal support from the Edmund J. Safra Foundation and from Lily Safra. D.J.S. currently holds a National Institute of Health Research Professorship -RP-011-048. K.B. currently holds the Torsten Soderberg Professorship in Medicine. H.Z. is a Wallenberg Academy Fellow. This work was supported by the Imperial College Healthcare Trust Biomedical Research Centre, the Swedish Research Council, the Knut and Alice Wallenberg Foundation, VINNOVA and the Torsten Soderberg foundation. This paper presents independent research funded by the NIHR and carried out at the NIHR/Wellcome Trust Imperial Clinical Research Facility. The views expressed are those of the author(s) and not necessarily those of the NIHR, the NHS or the Department of Health.	Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; Ashburner J, 2013, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00197; Bacioglu M, 2016, NEURON, V91, P494, DOI 10.1016/j.neuron.2016.07.007; Bacioglu M, 2016, NEURON, V91, P56, DOI 10.1016/j.neuron.2016.05.018; Casha S, 2012, BRAIN, V135, P1224, DOI 10.1093/brain/aws072; Cole JH, 2015, ANN NEUROL, V77, P571, DOI 10.1002/ana.24367; Faden AI, 2015, NEUROTHERAPEUTICS, V12, P143, DOI 10.1007/s13311-014-0319-5; Fischl B, 2012, NEUROIMAGE, V62, P774, DOI 10.1016/j.neuroimage.2012.01.021; Gaiottino J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075091; Garrido-Mesa N, 2013, BRIT J PHARMACOL, V169, P337, DOI 10.1111/bph.12139; Garrido-Mesa N, 2013, PHARMACOL RES, V67, P18, DOI 10.1016/j.phrs.2012.10.006; Gentleman SM, 2013, NEUROPATH APPL NEURO, V39, P45, DOI 10.1111/nan.12017; Gisslen M, 2016, EBIOMEDICINE, V3, P135, DOI 10.1016/j.ebiom.2015.11.036; Gordon PH, 2007, LANCET NEUROL, V6, P1045, DOI 10.1016/S1474-4422(07)70270-3; Hansson O, 2017, NEUROLOGY, V88, P930, DOI 10.1212/WNL.0000000000003680; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Jucaite A, 2015, BRAIN, V138, P2687, DOI 10.1093/brain/awv184; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kuhle J, 2016, CLIN CHEM LAB MED, V54, P1655, DOI 10.1515/cclm-2015-1195; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Lampl Y, 2007, NEUROLOGY, V69, P1404, DOI 10.1212/01.wnl.0000277487.04281.db; Ljungqvist J, 2017, J NEUROTRAUM, V34, P1124, DOI 10.1089/neu.2016.4496; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; LOGAN J, 1990, J CEREBR BLOOD F MET, V10, P740, DOI 10.1038/jcbfm.1990.127; Loggia ML, 2015, BRAIN, V138, P604, DOI 10.1093/brain/awu377; Lu CH, 2015, NEUROLOGY, V84, P2247, DOI 10.1212/WNL.0000000000001642; Maas AIR, 2004, ACT NEUR S, V89, P113; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Nagamoto-Combs K, 2007, J NEUROTRAUM, V24, P1719, DOI 10.1089/neu.2007.0377; Nagamoto-Combs K, 2010, J NEUROTRAUM, V27, P565, DOI 10.1089/neu.2009.0966; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Owen DR, 2014, J CEREBR BLOOD F MET, V34, P989, DOI 10.1038/jcbfm.2014.46; Owen DR, 2012, J CEREBR BLOOD F MET, V32, P1, DOI 10.1038/jcbfm.2011.147; Plane JM, 2010, ARCH NEUROL-CHICAGO, V67, P1442, DOI 10.1001/archneurol.2010.191; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ransohoff RM, 2016, NAT NEUROSCI, V19, P987, DOI 10.1038/nn.4338; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Sandiego CM, 2015, P NATL ACAD SCI USA, V112, P12468, DOI 10.1073/pnas.1511003112; Shahim P, 2016, SCI REP-UK, V6, DOI 10.1038/srep36791; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Siopi E, 2011, J NEUROTRAUM, V28, P2135, DOI 10.1089/neu.2010.1738; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Srivastava MVP, 2012, NEUROL INDIA, V60, P23, DOI 10.4103/0028-3886.93584; Thelin EP, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00351; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Zhang H, 2007, IEEE T MED IMAGING, V26, P1585, DOI 10.1109/TMI.2007.906784	52	82	82	0	11	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	FEB	2018	141		2				459	471		10.1093/brain/awx339			13	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FV0AI	WOS:000424217900020	29272357	Green Published, hybrid			2022-02-06	
J	Vavilala, MS; Kernic, MA; Wang, J; Kannan, N; Mink, RB; Wainwright, MS; Groner, JI; Bell, MJ; Giza, CC; Zatzick, DF; Ellenbogen, RG; Boyle, LN; Mitchell, PH; Rivara, FP				Vavilala, Monica S.; Kernic, Mary A.; Wang, Jin; Kannan, Nithya; Mink, Richard B.; Wainwright, Mark S.; Groner, Jonathan I.; Bell, Michael J.; Giza, Christopher C.; Zatzick, Douglas F.; Ellenbogen, Richard G.; Boyle, Linda Ng; Mitchell, Pamela H.; Rivara, Frederick P.		Pediat Guideline Adherence	Acute Care Clinical Indicators Associated With Discharge Outcomes in Children With Severe Traumatic Brain Injury	CRITICAL CARE MEDICINE			English	Article						brain injury; indicators; injury; outcomes; pediatrics; trauma	HEAD-INJURY; HYPOTENSION; HYPOXIA; MORTALITY; MODERATE; CENTERS; TRIALS	Objective: The effect of the 2003 severe pediatric traumatic brain injury (TBI) guidelines on outcomes has not been examined. We aimed to develop a set of acute care guideline-influenced clinical indicators of adherence and tested the relationship between these indicators during the first 72 hours after hospital admission and discharge outcomes. Design: Retrospective multicenter cohort study. Setting: Five regional pediatric trauma centers affiliated with academic medical centers. Patients: Children under 18 years with severe traumatic brain injury (admission Glasgow Coma Scale score <= 8, International Classification of Diseases, 9th Edition, diagnosis codes of 800.0-801.9, 803.0-804.9, 850.0-854.1, 959.01, 950.1-950.3, 995.55, maximum head abbreviated Injury Severity Score >= 3) who received tracheal intubation for at least 48 hours in the ICU between 2007 and 2011 were examined. Interventions: None. Measurements and Main Results: Total percent adherence to the clinical indicators across all treatment locations (prehospital, emergency department, operating room, and ICU) during the first 72 hours after admission to study center were determined. Main outcomes were discharge survival and Glasgow Outcome Scale score. Total adherence rate across all locations and all centers ranged from 68% to 78%. Clinical indicators of adherence were associated with survival (adjusted hazard ratios, 0.94; 95% CI, 0.91-0.96). Three indicators were associated with survival: absence of prehospital hypoxia (adjusted hazard ratios, 0.20; 95% CI, 0.08-0.46), early ICU start of nutrition (adjusted hazard ratios, 0.06; 95% CI, 0.01-0.26), and ICU Paco(2) more than 30 mm Hg in the absence of radiographic or clinical signs of cerebral herniation (adjusted hazard ratios, 0.22; 95% CI, 0.06-0.8). Clinical indicators of adherence were associated with favorable Glasgow Outcome Scale among survivors (adjusted hazard ratios, 0.99; 95% CI, 0.98-0.99). Three indicators were associated with favorable discharge Glasgow Outcome Scale: all operating room cerebral perfusion pressure more than 40 mm Hg (adjusted relative risk, 0.61; 95% CI, 0.58-0.64), all ICU cerebral perfusion pressure more than 40 mm Hg (adjusted relative risk, 0.73; 95% CI, 0.63-0.84), and no surgery (any type; adjusted relative risk, 0.68; 95% CI, 0.53-0.86). Conclusions: Acute care clinical indicators of adherence to the Pediatric Guidelines were associated with significantly higher discharge survival and improved discharge Glasgow Outcome Scale. Some indicators were protective, regardless of treatment location, suggesting the need for an interdisciplinary approach to the care of children with severe traumatic brain injury.	[Vavilala, Monica S.; Kannan, Nithya] Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA; [Vavilala, Monica S.; Kannan, Nithya] Univ Washington, Dept Pain Med, Seattle, WA 98195 USA; [Vavilala, Monica S.; Wang, Jin; Rivara, Frederick P.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Vavilala, Monica S.; Ellenbogen, Richard G.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Vavilala, Monica S.; Ellenbogen, Richard G.] Univ Washington, Dept Global Hlth Med, Seattle, WA 98195 USA; [Kernic, Mary A.; Rivara, Frederick P.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Mink, Richard B.] Harbor UCLA, Dept Pediat, Torrance, CA USA; [Mink, Richard B.] Los Angeles BioMed Res Inst, Torrance, CA USA; [Wainwright, Mark S.] Ann & Robert H Lurie Childrens Hosp Chicago, Dept Pediat, Chicago, IL USA; [Groner, Jonathan I.] Ohio State Univ, Coll Med, Dept Surg, Columbus, OH 43210 USA; [Bell, Michael J.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA; [Giza, Christopher C.] Univ Calif Los Angeles, Mattel Childrens Hosp, Dept Neurosurg, Los Angeles, CA USA; [Giza, Christopher C.] Univ Calif Los Angeles, Mattel Childrens Hosp, Div Pediat Neurol, Los Angeles, CA USA; [Zatzick, Douglas F.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Boyle, Linda Ng] Univ Washington, Dept Ind & Syst Engn, Seattle, WA 98195 USA; [Mitchell, Pamela H.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA; Univ Washington, Harborview Med Ctr, Lead & Data Coordinating Ctr, Seattle, WA 98104 USA; Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA; Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL USA; Harbor UCLA Med Ctr, Torrance, CA 90509 USA; Nationwide Childrens Hosp, Columbus, OH USA		Vavilala, MS (corresponding author), Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA.	vavilala@u.washington.edu			National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institutes of Neurological Diseases and Stroke (NINDS) [R01 NS072308-03]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); National Institute of Alcohol Abuse and Alcoholism (NIAAA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); National Institute of Justice (NIJ); Joseph Drown Foundation; NCAA; Paul Allen Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072308] Funding Source: NIH RePORTER	Dr. Vavilala received support for article research from the National Institutes of Health (NIH). She received support for this work including design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript from the National Institutes of Neurological Diseases and Stroke (NINDS) (R01 NS072308-03). Her institution received grant support from the NIH. Dr. Kernic is employed by the University of Washington (receives salary support for work on grants as principal investigator or co-investigator) and received support for article research from the NIH. Her institution received grant support from the NINDS, the National Institute of Alcohol Abuse and Alcoholism (NIAAA), and National Institute of Justice (NIJ) (Dr. Kernic is principal investigator on two federal grants-NIAAA and NIJ-in an area unrelated to the NINDS grant that supported the work to produce this manuscript). Dr. Kannan received support for article research from the NIH. Her institution received grant support from the NIH. Dr. Mink received support for travel from American Academy of Pediatrics Section on Critical Care and received support for article research from the NIH. He and his institution received grant support from the NIH. Dr. Wainwright received support for article research from the NIH. His institution received grant support from the NINDS. Dr. Groner received support for article research from the NIH. His institution received grant support from the NIH (grant title: Implementation Science to Increase Use of Evidence Based Pediatric Brain Injury Guidelines [PEGASUS Study]-multicenter study). Dr. Bell received support for article research from the NIH. His institution received grant support from the NINDS. Dr. Giza consulted for the California State Athletic Commission (received support for attending and traveling to California State Athletic Commission meetings); provides expert testimony for medicolegal cases; lectured for the Medical Education Speakers Network and various institutions; received royalties from Blackwell Publishing (book: Neurological Differential Diagnosis); received support for travel from National Collegiate Athletic Association (NCAA), Major League Soccer, National Football League, and the Ontario Neurotrauma Foundation (serves on advisory board or as consulted and receives support for travel); and received support for article research from the NIH. His institution received grant support from the NIH, Joseph Drown Foundation, and NCAA (research grants). Dr. Ellenbogen is employed by the University of Washington, received grant support from the Paul Allen Foundation, and received royalties from Elsevier. Dr. Boyle received support for article research from the NIH. Her institution received grant support from the NIH. Dr. Mitchell received support for article research from the NIH. Her institution received grant support from the NIH. Dr. Rivara received support for article research from NIH. Her institution received grant support from NIH. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS72; Altman D.G., 1990, PRACTICAL STAT MED R; Buck CJ, 2010, INT CLASSIFICATION D; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Doig GS, 2013, JAMA-J AM MED ASSOC, V309, P2130, DOI 10.1001/jama.2013.5124; Faul M, 2010, TRAUMATIC BRAIN INJU; Fleiss JH., 1981, STAT METHODS RATES P; Franschman G, 2009, RESUSCITATION, V80, P1147, DOI 10.1016/j.resuscitation.2009.06.029; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; JENNETT B, 1976, LANCET, V1, P1031; Kernic MA, 2013, J NEUROTRAUM, V30, P1129, DOI 10.1089/neu.2012.2716; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Kouznetsov E, 2012, PEDIATR NEUROSURG, V48, P1, DOI 10.1159/000340068; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; National Institutes of Health ( NIH), NINDS COMM DAT EL WE; Peppercorn JM, 2004, LANCET, V363, P263, DOI 10.1016/S0140-6736(03)15383-4; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Pollack MM, 2013, PEDIATR CRIT CARE ME, V14, P1; Pronovost PJ, 2004, J CRIT CARE, V19, P158, DOI 10.1016/j.jcrc.2004.07.003; Rivara FP, 2011, PEDIATRICS, V128, pE1129, DOI 10.1542/peds.2011-0840; Rogers E., 1995, DIFFUSION INNOVATION, V4th edn.; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P64, DOI 10.1007/s00508-006-0765-0; Samant UB, 2008, J NEUROTRAUM, V25, P495, DOI 10.1089/neu.2007.0491; Sills MR, 2005, ARCH PEDIAT ADOL MED, V159, P665, DOI 10.1001/archpedi.159.7.665; *STATACORP LP, 2009, STAT STAT SOFTW COMP; Zebrack M, 2009, PEDIATRICS, V124, P56, DOI 10.1542/peds.2008-1006; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	31	82	82	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	OCT	2014	42	10					2258	2266		10.1097/CCM.0000000000000507			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AP7BC	WOS:000342231500014	25083982	Green Accepted			2022-02-06	
J	Lagarde, E; Salmi, LR; Holm, LW; Contrand, B; Masson, F; Ribereau-Gayon, R; Laborey, M; Cassidy, JD				Lagarde, Emmanuel; Salmi, Louis-Rachid; Holm, Lena W.; Contrand, Benjamin; Masson, Francoise; Ribereau-Gayon, Regis; Laborey, Magali; Cassidy, J. David			Association of Symptoms Following Mild Traumatic Brain Injury With Posttraumatic Stress Disorder vs Postconcussion Syndrome	JAMA PSYCHIATRY			English	Article							HEAD-INJURY; CONCUSSION SYMPTOMS; PTSD; AFGHANISTAN; PERCEPTION; SEQUELAE; COHORT; IRAQ	IMPORTANCE A proportion of patients experience long-lasting symptoms following mild traumatic brain injury (MTBI). The postconcussion syndrome (PCS), included in the DSM-IV, has been proposed to describe this condition. Because these symptoms are subjective and common to other conditions, there is controversy whether PCS deserves to be identified as a diagnostic syndrome. OBJECTIVE To assess whether persistent symptoms 3 months following head injury are specific to MTBI or whether they are better described as part of posttraumatic stress disorder (PTSD). DESIGN, SETTING, AND PARTICIPANTS We conducted a prospective cohort study of injured patients recruited at the adult emergency department of the University Hospital of Bordeaux from December 4, 2007, to February 25, 2009. MAIN OUTCOMES AND MEASURES At 3-month follow-up, we compared the prevalence and risk factors for PCS and PTSD. Multiple correspondence analyses were used to assess clustering of symptoms and their associations with the type of injury. RESULTS We included 534 patients with head injury and 827 control patients with other nonhead injuries. Three months following the trauma, 21.2% of head-injured and 16.3% of nonhead-injured patients fulfilled the DSM-IV diagnosis of PCS; 8.8% of head-injured patients fulfilled the diagnostic criteria for PTSD compared with 2.2% of control patients. In multivariate analysis, MTBI was a predictor of PTSD (odds ratio, 4.47; 95% CI, 2.38-8.40) but not of PCS (odds ratio, 1.13; 95% CI, 0.82-1.55). Correspondence analysis suggested that symptoms considered part of PCS behave similarly to PTSD symptoms in the hyperarousal dimension. None of these 22 symptoms showed any pattern of clustering, and no clear proximity with head or nonhead injury status could be found. CONCLUSIONS AND RELEVANCE Persistent subjective symptoms frequently reported 3 months after MTBI are not specific enough to be identified as a unique PCS and should be considered part of the hyperarousal dimension of PTSD.	[Lagarde, Emmanuel; Salmi, Louis-Rachid; Contrand, Benjamin; Masson, Francoise; Ribereau-Gayon, Regis; Laborey, Magali] INSERM, ISPED, Ctr INSERM Epidemiol Biostat U897, Equipe Prevent & Prise Charge Traumatismes, F-33000 Bordeaux, France; [Lagarde, Emmanuel; Salmi, Louis-Rachid; Contrand, Benjamin; Laborey, Magali] Univ Bordeaux, ISPED, Ctr INSERM Epidemiol Biostat U897, F-33000 Bordeaux, France; [Salmi, Louis-Rachid] CHU Bordeaux, Pole Sante Publ, Serv Informat Med, F-33000 Bordeaux, France; [Holm, Lena W.] Karolinska Inst, Inst Environm Med, Div Epidemiol, S-10401 Stockholm, Sweden; [Masson, Francoise] CHU Bordeaux, Pole Anesthesie Reanimat, F-33000 Bordeaux, France; [Ribereau-Gayon, Regis] CHU Bordeaux, Pole Med, F-33000 Bordeaux, France; [Cassidy, J. David] Univ Southern Denmark, Fac Hlth, Inst Sports Sci & Clin Biomech, Odense, Denmark; [Cassidy, J. David] Univ Toronto, Univ Hlth Network, Toronto Western Res Inst, Div Hlth Care & Outcomes Res, Toronto, ON M5S 1A1, Canada; [Cassidy, J. David] Univ Toronto, Dalla Lana Sch Publ Hlth, Div Epidemiol, Toronto, ON M5S 1A1, Canada; [Cassidy, J. David] Univ Toronto, Inst Hlth Policy Management & Evaluat, Fac Med, Toronto, ON M5S 1A1, Canada		Lagarde, E (corresponding author), Univ Bordeaux, INSERM Res Ctr U897, 146 Rue Leo Saignat,CS61292, F-33076 Bordeaux, France.	emmanuel.lagarde@isped.u-bordeaux2.fr	Regis, RIBEREAU-GAYON/U-5423-2019; contrand, benjamin/T-1994-2019; Salmi, Louis-Rachid/T-1982-2019; Lagarde, Emmanuel/F-7132-2013	Lagarde, Emmanuel/0000-0001-8031-7400	INSERMInstitut National de la Sante et de la Recherche Medicale (Inserm)European Commission; REUNICA Group; Bordeaux University Hospital	This study was funded by INSERM, the REUNICA Group, and Bordeaux University Hospital (PHRC 2007).	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Asmundson GJG, 2004, J TRAUMA STRESS, V17, P467, DOI 10.1007/s10960-004-5795-7; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BRAMER G R, 1988, World Health Statistics Quarterly, V41, P32; Brooks BL, 2014, ARCH CLIN NEUROPSYCH, V29, P186, DOI 10.1093/arclin/act083; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Davis CH, 2002, AM J PHYS MED REHAB, V81, P609, DOI 10.1097/00002060-200208000-00009; de Leon MB, 2009, ARCH PHYS MED REHAB, V90, P956, DOI 10.1016/j.apmr.2008.12.016; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Friedland JF, 2001, J NERV MENT DIS, V189, P426, DOI 10.1097/00005053-200107000-00003; King DW, 1998, PSYCHOL ASSESSMENT, V10, P90, DOI 10.1037/1040-3590.10.2.90; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Laborey M, 2014, J HEAD TRAUMA REHAB, V29, pE28, DOI 10.1097/HTR.0b013e318280f896; Lange RT, 2010, ARCH CLIN NEUROPSYCH, V25, P442, DOI 10.1093/arclin/acq031; McLean SA, 2009, AM J EMERG MED, V27, P182, DOI 10.1016/j.ajem.2008.01.054; Pietrzak RH, 2009, AM J PSYCHIAT, V166, P726, DOI 10.1176/appi.ajp.2009.09010032; Rona RJ, 2012, J HEAD TRAUMA REHAB, V27, P33, DOI 10.1097/HTR.0b013e318212f814; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Stovner LJ, 2009, EUR J NEUROL, V16, P112, DOI 10.1111/j.1468-1331.2008.02363.x; World Health Organization, 1992, INT STAT CLASS DIS 1; Zongo D, 2012, ANN EMERG MED, V59, P209, DOI 10.1016/j.annemergmed.2011.07.027	28	82	84	1	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-622X	2168-6238		JAMA PSYCHIAT	JAMA Psychiatry	SEP	2014	71	9					1032	1040		10.1001/jamapsychiatry.2014.666			9	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	AP0SV	WOS:000341775300009	25029015	Bronze			2022-02-06	
J	Hudson, AE; Calderon, DP; Pfaff, DW; Proekt, A				Hudson, Andrew E.; Calderon, Diany Paola; Pfaff, Donald W.; Proekt, Alex			Recovery of consciousness is mediated by a network of discrete metastable activity states	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						anesthesia; state transitions; spectral analysis; emergence	TRAUMATIC BRAIN-INJURY; GENERAL-ANESTHESIA; MOLECULAR TARGETS; SLEEP; SUPPRESSION; DYNAMICS; AROUSAL; ELECTROENCEPHALOGRAM; POTENTIALS; MECHANISMS	It is not clear how, after a large perturbation, the brain explores the vast space of potential neuronal activity states to recover those compatible with consciousness. Here, we analyze recovery from pharmacologically induced coma to show that neuronal activity en route to consciousness is confined to a low-dimensional subspace. In this subspace, neuronal activity forms discrete metastable states persistent on the scale of minutes. The network of transitions that links these metastable states is structured such that some states form hubs that connect groups of otherwise disconnected states. Although many paths through the network are possible, to ultimately enter the activity state compatible with consciousness, the brain must first pass through these hubs in an orderly fashion. This organization of metastable states, along with dramatic dimensionality reduction, significantly simplifies the task of sampling the parameter space to recover the state consistent with wakefulness on a physiologically relevant timescale.	[Hudson, Andrew E.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Anesthesiol & Perioperat Med, Los Angeles, CA 90095 USA; [Calderon, Diany Paola; Pfaff, Donald W.; Proekt, Alex] Rockefeller Univ, Neurobiol & Behav Lab, New York, NY 10065 USA; [Proekt, Alex] Weill Cornell Med Coll, Dept Anesthesiol, New York, NY 10021 USA		Pfaff, DW (corresponding author), Rockefeller Univ, Neurobiol & Behav Lab, New York, NY 10065 USA.	pfaff@rockefeller.edu; proekt@gmail.com	Hudson, Andrew/B-6152-2016	Hudson, Andrew/0000-0001-7292-5406; Proekt, Alexander/0000-0002-9272-5337	Foundation for Anesthesia Education and Research grant [K08 (GM106144-01)]; American Association of University Women International Fellowship; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K08GM106144] Funding Source: NIH RePORTER	This work was supported by a Foundation for Anesthesia Education and Research grant and K08 (GM106144-01) awarded to A.P. and an American Association of University Women International Fellowship awarded to D.P.C.	Alkire MT, 2008, SCIENCE, V322, P876, DOI 10.1126/science.1149213; Alkire MT, 2007, ANESTHESIOLOGY, V107, P264, DOI 10.1097/01.anes.0000270741.33766.24; Brown EN, 2010, NEW ENGL J MED, V363, P2638, DOI 10.1056/NEJMra0808281; Clement EA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002004; Destexhe A, 1999, J NEUROSCI, V19, P4595, DOI 10.1523/jneurosci.19-11-04595.1999; Doyle PG, 2000, CARUS MATH MONOGRAPH, V22, P1; Franks NP, 2008, NAT REV NEUROSCI, V9, P370, DOI 10.1038/nrn2372; Friedman EB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011903; Gervasoni D, 2004, J NEUROSCI, V24, P11137, DOI 10.1523/JNEUROSCI.3524-04.2004; Gibbs FA, 1937, ARCH INTERN MED, V60, P154, DOI 10.1001/archinte.1937.00180010159012; Jones EG, 1998, NEUROSCIENCE, V85, P331, DOI 10.1016/S0306-4522(97)00581-2; Kelz MB, 2008, P NATL ACAD SCI USA, V105, P1309, DOI 10.1073/pnas.0707146105; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; Langsjo JW, 2012, J NEUROSCI, V32, P4935, DOI 10.1523/JNEUROSCI.4962-11.2012; LEVINTHAL C, 1968, J CHIM PHYS PCB, V65, P44, DOI 10.1051/jcp/1968650044; Lioudyno MI, 2013, J NEUROSCI, V33, P16310, DOI 10.1523/JNEUROSCI.0344-13.2013; Nunez P. L., 2006, ELECT FIELDS BRAIN N; OHTAHARA S, 1987, BRAIN DEV-JPN, V9, P371, DOI 10.1016/S0387-7604(87)80110-9; Percival D.B., 1993, SPECTRAL ANAL PHYS A; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2008, ANN NY ACAD SCI, V1129, P105, DOI 10.1196/annals.1417.029; Stecker MM, 2001, ANN THORAC SURG, V71, P14, DOI 10.1016/S0003-4975(00)01592-7; STERIADE M, 1990, ELECTROEN CLIN NEURO, V76, P481, DOI 10.1016/0013-4694(90)90001-Z; STERIADE M, 1993, J NEUROSCI, V13, P3252, DOI 10.1523/jneurosci.13-08-03252.1993; Stratmann G, 2009, ANESTH ANALG, V109, P801, DOI 10.1213/ane.0b013e3181aff364; Strogatz S.H., 1994, NONLINEAR DYNAMICS C, P123; SWANK RL, 1949, J NEUROPHYSIOL, V12, P137, DOI 10.1152/jn.1949.12.2.137; Thomke F, 2002, J CLIN NEUROPHYSIOL, V19, P24; TUCKWELL HC, 1989, STOCHASTIC PROCESSES; Victor JD, 2011, P NATL ACAD SCI USA, V108, P15631, DOI 10.1073/pnas.1012168108; Whitlock EL, 2011, ANESTHESIOLOGY, V115, P1209, DOI 10.1097/ALN.0b013e3182395dcb	31	82	82	0	8	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	JUN 24	2014	111	25					9283	9288		10.1073/pnas.1408296111			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AJ5WJ	WOS:000337760600065	24927558	Green Published, Bronze			2022-02-06	
J	Martin, KD; Franz, B; Kirsch, M; Polanski, W; von der Hagen, M; Schackert, G; Sobottka, SB				Martin, K. Daniel; Franz, Benjamin; Kirsch, Matthias; Polanski, Witold; von der Hagen, Maja; Schackert, Gabriele; Sobottka, Stephan B.			Autologous bone flap cranioplasty following decompressive craniectomy is combined with a high complication rate in pediatric traumatic brain injury patients	ACTA NEUROCHIRURGICA			English	Article						Bone flap resorption; Autologous bone flap cranioplasty; Pediatric traumatic brain injury; Decompressive craniectomy	SEVERE HEAD-INJURY; SINKING SKIN FLAP; INTRACRANIAL HYPERTENSION; CLINICAL ARTICLE; HINGE CRANIOTOMY; CHILDREN	Decompressive craniectomy (DC) is a last treatment option of refractory intracranial hypertension in traumatic brain injury (TBI) patients. Replacement of the autologous bone flap is the preferred method to cover the cranial defect after brain swelling has subsided. Long term outcomes and complications after replacement of the autologous bone flap in pediatric patients were studied in comparison to young, healthy adults. Medical records of 27 pediatric patients who underwent DC and subsequent replacement of the bone flap between 1998 and 2011 were reviewed retrospectively. Patients were divided into two age groups (group 1: 18 children < 15 years; group 2:9 adolescents 15-18 years). For comparative reasons, a young adult control group of 39 patients between 18 and 30 years was additionally evaluated. With 81.8 % resorption of the bone flap, this was the major complication in young children. In up to 54.4 % of patients, a surgical revision of the osteolytic bone flap became necessary. However, in some pediatric patients, the osteolysis resolved spontaneously and further operations were not required. Probable enabling factors for bone flap resorption were young age (0-7 years), size of craniectomy, permanent shunt placement, and extent of dural opening/duraplasty. Other complications were bone flap infections, loosening of the re-inserted bone flap, and postoperative hematomas. There is an unacceptably high complication rate after reimplantation of the autologous bone following DC in pediatric TBI patients, especially in young children up to seven years of age. Artificial or synthetic cranioplasties may be considered as alternatives to initial bone flap reimplantation in the growing child. Despite the fact that DC is an effective treatment in TBI with persistent intracranial hypertension, it is important to realize that DC is not only combined with replacement of the autologous bone flap but also with a high rate of additional complications especially in pediatric patients.	[Martin, K. Daniel; Franz, Benjamin; Kirsch, Matthias; Polanski, Witold; Schackert, Gabriele; Sobottka, Stephan B.] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Neurol Surg, D-01307 Dresden, Germany; [von der Hagen, Maja] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Childrens Hosp, Dept Paediat Neurol, D-01307 Dresden, Germany		Martin, KD (corresponding author), Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Neurol Surg, Fetscherstr 74, D-01307 Dresden, Germany.	hippocampus@dr-daniel-martin.com	Polanski, Witold H/C-9657-2010; Kirsch, Matthias/F-2824-2014; Polanski, Witold/C-9657-2010	Polanski, Witold H/0000-0002-9214-150X; Polanski, Witold/0000-0002-6603-5375			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Aydin S, 2011, J NEUROSCI RURAL PRA, V2, P162, DOI 10.4103/0976-3147.83584; Bao YH, 2010, J NEUROTRAUM, V27, P341, DOI 10.1089/neu.2009.1040; Bowers CA, 2013, J NEUROSURG-PEDIATR, V11, P526, DOI 10.3171/2013.1.PEDS12483; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; FODSTAD H, 1984, ACTA NEUROCHIR, V70, P21, DOI 10.1007/BF01406039; Frassanito P, 2012, ACTA NEUROCHIR, V154, P927, DOI 10.1007/s00701-011-1253-5; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; GRUBER R, 1988, Z KINDERCHIR, V43, P375; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Jagannathan J, 2007, J NEUROSURG, V106, P268, DOI 10.3171/ped.2007.106.4.268; JENNETT B, 1975, LANCET, V1, P480; Josan VA, 2006, CHILD NERV SYST, V22, P1268, DOI 10.1007/s00381-006-0064-0; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Kenning TJ, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0960; Li LM, 2010, ANESTH ANALG, V111, P736, DOI 10.1213/ANE.0b013e3181e75cd1; Suarez EP, 2011, J TRAUMA, V71, P133, DOI 10.1097/TA.0b013e318211071f; Piedra MP, 2012, J NEUROSURG-PEDIATR, V10, P268, DOI 10.3171/2012.6.PEDS1268; Sakamoto S, 2006, CLIN NEUROL NEUROSUR, V108, P583, DOI 10.1016/j.clineuro.2005.03.012; Schmidt JH, 2007, J NEUROSURG, V107, P678, DOI 10.3171/JNS-07/09/0678; Schorl M, 2009, CENT EUR NEUROSURG, V70, P68, DOI 10.1055/s-0028-1093355; Shoakazemi A, 2009, NEUROSURGERY, V65, P505, DOI 10.1227/01.NEU.0000350870.69891.86; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Wen L, 2007, J CRANIOFAC SURG, V18, P526, DOI 10.1097/scs.0b013e3180534348; Winkler PA, 2000, J NEUROSURG, V93, P53, DOI 10.3171/jns.2000.93.1.0053; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470; Yang Xue-Jun, 2003, Chin J Traumatol, V6, P99	30	82	83	0	11	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	APR	2014	156	4					813	824		10.1007/s00701-014-2021-0			12	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	AD3GV	WOS:000333127200028	24532225				2022-02-06	
J	Hicks, R; Giacino, J; Harrison-Felix, C; Manley, G; Valadka, A; Wilde, EA				Hicks, Ramona; Giacino, Joseph; Harrison-Felix, Cynthia; Manley, Geoffrey; Valadka, Alex; Wilde, Elisabeth A.			Progress in Developing Common Data Elements for Traumatic Brain Injury Research: Version Two - The End of the Beginning	JOURNAL OF NEUROTRAUMA			English	Article						acute; chronic; collaboration; concussion; data standardization; epidemiology; rehabilitation	WORKING GROUP; PEDIATRIC CONSIDERATIONS; PSYCHOLOGICAL HEALTH; CLINICAL-ASSESSMENT; OUTCOME MEASURES; RECOMMENDATIONS; DEMOGRAPHICS; BIOSPECIMENS; SCORE	To accelerate data sharing and research on traumatic brain injury (TBI), several federal agencies have been collaborating to support the development and implementation of common data elements (CDEs). The first recommendations for CDEs were made in 2010, and were well suited for hospital-based studies of acute TBI in adults. To broaden the utility of the TBI CDEs, experts were asked to update the recommendations to make them relevant to all ages, levels of injury severity, and phases of recovery. The second version of the TBI CDEs (v.2) was organized around four major study types: 1) epidemiological research; 2) studies on acute, hospitalized patients; 3) studies of the rehabilitation for moderate/severe TBI; and 4) mild TBI/concussion research. Given the heterogeneity of TBI, only a small set of core CDEs were found to be relevant across all study types. However, within groups, a much larger set of highly relevant CDEs were identified, and these were called basic CDEs. In addition, an expanded number of supplemental CDEs were specified and recommended for use depending upon the study goals. Version 2 provides a rich data dictionary for TBI research with about 900 CDEs. Many of the CDEs overlap across the study types, which will facilitate comparisons and meta-analysis across studies. Further modifications of the CDEs should be based on evaluation of their usefulness following implementation across a range of studies.	[Hicks, Ramona] NINDS, Bethesda, MD 20892 USA; [Giacino, Joseph] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA; [Harrison-Felix, Cynthia] Craig Hosp, Dept Phys Med & Rehabil, Englewood, CO USA; [Harrison-Felix, Cynthia] Univ Colorado, Dept Phys Med & Rehabil, Denver, CO 80202 USA; [Manley, Geoffrey] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Valadka, Alex] Seton Brain & Spine Inst, Austin, TX USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Wilde, Elisabeth A.] Michael E DeBakey VA Med Ctr, Houston, TX USA		Hicks, R (corresponding author), NINDS, NIH, 6001 Execut Blvd,Room 2206, Bethesda, MD 20892 USA.	hicksra@mail.nih.gov	Giacino, Joseph/AAF-1952-2021	Giacino, Joseph/0000-0002-7916-9698			Adelson PD, 2012, J NEUROTRAUM, V29, P639, DOI 10.1089/neu.2011.1952; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Berger RP, 2012, J NEUROTRAUM, V29, P672, DOI 10.1089/neu.2011.1861; Carrillo MC, 2012, ALZHEIMERS DEMENT, V8, P337, DOI 10.1016/j.jalz.2012.04.007; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Duhaime AC, 2012, J NEUROTRAUM, V29, P629, DOI 10.1089/neu.2011.1927; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Federal Interagency TBI Research (FITBIR) Informatics System, 2013, FED INT TBI RES FITB; Finster M, 2005, ANESTHESIOLOGY, V102, P855, DOI 10.1097/00000542-200504000-00022; Gerring JP, 2012, J NEUROTRAUM, V29, P621, DOI 10.1089/neu.2011.2234; Gershon RC, 2012, QUAL LIFE RES, V21, P475, DOI 10.1007/s11136-011-9958-8; Gershon RC, 2010, LANCET NEUROL, V9, P138, DOI 10.1016/S1474-4422(09)70335-7; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Hunter JV, 2012, J NEUROTRAUM, V29, P654, DOI 10.1089/neu.2011.1906; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; Miller AC, 2012, J NEUROTRAUM, V29, P634, DOI 10.1089/neu.2011.1932; National Institute of Neurological Disorders and Stroke, 2013, NINDS COMM DAT EL TR; National Institute of Neurological Disorders and Stroke, 2013, NINDS COMM DAT EL; National Research Council, 2011, PREC MED BUILD KNOWL; Steiner LA, 2006, BRIT J ANAESTH, V97, P26, DOI 10.1093/bja/ael110; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034; Whyte J, 2010, ARCH PHYS MED REHAB, V91, P1692, DOI 10.1016/j.apmr.2010.06.031; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	26	82	82	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2013	30	22					1852	1861		10.1089/neu.2013.2938			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	243PH	WOS:000326328400003	23725058	Green Published			2022-02-06	
J	Gibson, S; Nigrovic, LE; O'Brien, M; Meehan, WP				Gibson, Sarah; Nigrovic, Lise E.; O'Brien, Michael; Meehan, William P., III			The effect of recommending cognitive rest on recovery from sport-related concussion	BRAIN INJURY			English	Article						Sport-related concussion; cognitive rest; mild traumatic brain injury	HIGH-SCHOOL; PERFORMANCE; MANAGEMENT; SYMPTOMS	Objective: To determine whether recommending cognitive rest to athletes after a sport-related concussion affects time to symptom resolution. Methods: A retrospective cohort study was conducted of 184 patients who presented to a sports concussion clinic in an academic medical centre between 1 November 2007 and 31 July 2009. The effect of recommending cognitive rest on symptom duration (days) was measured after adjusting for age, gender, initial PCSS score, history of amnesia, history of loss of consciousness and number of previous concussions. Using multivariate logistic regression, independent predictors of prolonged symptoms were identified, defined as >30 days. Results: Of the 135 study patients with complete medical records, 85 (63%) had cognitive rest recommended. Of those, 79 (59%) had prolonged symptoms. In the multivariate analysis, only initial PCSS score was associated with the duration of concussion symptoms (adjusted odds ratio (AOR) = 1.03; 95% CI = 1.01-1.05). The recommendation for cognitive rest was not significantly associated with time to concussion symptom resolution (AOR 0.5; 95% CI = 0.18-1.37). Conclusions: Given the limited evidence regarding the effects of cognitive rest on recovery from concussion, recommendations of prolonged periods of cognitive rest, particularly absences from school, should be approached cautiously.	[Gibson, Sarah] Meli Orthoped, Ft Lauderdale, FL USA; [Nigrovic, Lise E.; Meehan, William P., III] Childrens Hosp, Dept Med, Div Emergency Med, Boston, MA 02115 USA; [O'Brien, Michael; Meehan, William P., III] Childrens Hosp, Div Sports Med, Sports Concuss Clin, Dept Orthoped, Boston, MA 02115 USA; [Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Meehan, William P., III] Childrens Hosp, Brain Injury Ctr, Boston, MA 02115 USA		Meehan, WP (corresponding author), Childrens Hosp, Div Sports Med, Sports Concuss Clin, 319 Longwood Ave,Floor 6, Boston, MA 02115 USA.	william.meehan@childrens.harvard.edu		Nigrovic, Lise/0000-0002-6369-3997	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 HD040128-06A1]; Hood Children's Research Grant; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER	Supported by NIH grant T32 HD040128-06A1 (WPM III) and Hood Children's Research Grant (LEN). The authors report no conflicts of interest.	Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; McGrath N, 2010, J ATHL TRAINING, V45, P492, DOI 10.4085/1062-6050-45.5.492; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Meehan WP, 2011, AM J SPORTS MED; Moonie S, 2008, J SCHOOL HEALTH, V78, P140, DOI 10.1111/j.1746-1561.2007.00276.x	12	82	82	0	26	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	2013	27	7-8					839	842		10.3109/02699052.2013.775494			4	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	169UO	WOS:000320806200010	23758286				2022-02-06	
J	Walcott, BP; Kwon, CS; Sheth, SA; Fehnel, CR; Koffie, RM; Asaad, WF; Nahed, BV; Coumans, JV				Walcott, Brian P.; Kwon, Churl-Su; Sheth, Sameer A.; Fehnel, Corey R.; Koffie, Robert M.; Asaad, Wael F.; Nahed, Brian V.; Coumans, Jean-Valery			Predictors of cranioplasty complications in stroke and trauma patients Clinical article	JOURNAL OF NEUROSURGERY			English	Article						cranioplasty; trauma; infection; complication; stroke; decompressive; craniectomy; traumatic brain injury; vascular disorders	RESISTANT STAPHYLOCOCCUS-AUREUS; CEREBRAL-ARTERY INFARCTION; INTENSIVE-CARE UNITS; DECOMPRESSIVE CRANIECTOMY; RISK-FACTORS; WOUND-INFECTION; ISCHEMIC-STROKE; BRAIN-INJURY; CONTROLLED-TRIAL; CARDIAC-SURGERY	Object. Decompressive craniectomy mandates subsequent cranioplasty. Complications of cranioplasty may be independent of the initial craniectomy, or they may be contingent upon the craniectomy. Authors of this study aimed to identify surgery- and patient-specific risk factors related to the development of surgical site infection and other complications following cranioplasty. Methods. A consecutive cohort of patients of all ages and both sexes who had undergone cranioplasty following craniectomy for stroke or trauma at a single institution in the period from May 2004 to May 2012 was retrospectively established. Patients who had undergone craniectomy for infectious lesions or neoplasia were excluded. A logistic regression analysis was performed to model and predict determinants related to infection following cranioplasty. Results. Two hundred thirty-nine patients met the study criteria. The overall rate of complication following cranioplasty was 23.85% (57 patients). Complications included, predominantly, surgical site infection, hydrocephalus, and new-onset seizures. Logistic regression analysis identified previous reoperation (OR 3.25, 95% CI 1.30-8.11, p = 0.01) and therapeutic indication for stroke (OR 2.45, 95% CI 1.11-5.39, p = 0.03) as significantly associated with the development of cranioplasty infection. Patient age, location of cranioplasty, presence of an intracranial device, bone flap preservation method, cranioplasty material, booking method, and time interval > 90 days between initial craniectomy and cranioplasty were not predictive of the development of cranioplasty infection. Conclusions. Cranioplasty complications are common. Cranioplasty infection rates are, predicted by reoperation following craniectomy and therapeutic indication (stroke). These variables may be associated with patient-centered risk factors that increase cranioplasty infection risk. (http://thejns.org/doi/abs/10.3171/2013.1.JNS121626)	[Walcott, Brian P.; Kwon, Churl-Su; Sheth, Sameer A.; Koffie, Robert M.; Nahed, Brian V.; Coumans, Jean-Valery] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA; [Walcott, Brian P.; Kwon, Churl-Su; Sheth, Sameer A.; Koffie, Robert M.; Nahed, Brian V.; Coumans, Jean-Valery] Harvard Univ, Sch Med, Boston, MA USA; [Fehnel, Corey R.] Brown Univ, Dept Neurol, Alpert Med Sch, Providence, RI 02912 USA; [Fehnel, Corey R.] Rhode Isl Hosp, Providence, RI USA; [Asaad, Wael F.] Dept Neurosurg, Providence, RI USA; [Asaad, Wael F.] Brown Inst Brain Sci, Providence, RI USA		Walcott, BP (corresponding author), Massachusetts Gen Hosp, 55 Fruit St,White Bldg Room 502, Boston, MA 02114 USA.	walcott.brian@mgh.harvard.edu	Asaad, Wael/I-8485-2012; Nahed, Brian/E-4239-2014	Asaad, Wael/0000-0003-4406-9096; Nahed, Brian/0000-0001-8537-106X; Fehnel, Corey/0000-0003-1726-5809			Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Cepeda JA, 2005, LANCET, V365, P295, DOI 10.1016/S0140-6736(05)17783-6; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Chiang HY, 2011, J NEUROSURG, V114, P1746, DOI 10.3171/2011.1.JNS10782; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Engelman DT, 1999, J THORAC CARDIOV SUR, V118, P866, DOI 10.1016/S0022-5223(99)70056-5; Folsom AR, 1999, DIABETES CARE, V22, P1077, DOI 10.2337/diacare.22.7.1077; Furnary AP, 1999, ANN THORAC SURG, V67, P352, DOI 10.1016/S0003-4975(99)00014-4; Gillitzer R, 2001, J LEUKOCYTE BIOL, V69, P513; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Grau AJ, 2001, STROKE, V32, P2559, DOI 10.1161/hs1101.098524; Greene K A, 1991, J Arthroplasty, V6, P321, DOI 10.1016/S0883-5403(06)80183-X; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; HORAN TC, 1992, INFECT CONT HOSP EP, V13, P606; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Klein JD, 1996, ORTHOP CLIN N AM, V27, P33; Kuo JR, 2004, J CLIN NEUROSCI, V11, P486, DOI 10.1016/j.jocn.2003.06.005; Levitt MR, 2011, NEUROSURGERY, V69, pE773, DOI 10.1227/NEU.0b013e31821964ba; Lucet JC, 2005, INTENS CARE MED, V31, P1051, DOI 10.1007/s00134-005-2679-0; Mann G, 2000, CEREBROVASC DIS, V10, P380, DOI 10.1159/000016094; Marion DW, 2006, NEUROSURGERY, V58, P655; NAGACHINTA T, 1987, J INFECT DIS, V156, P967, DOI 10.1093/infdis/156.6.967; Nakamura K, 2005, NUTRITION, V21, P639, DOI 10.1016/j.nut.2005.03.001; O'Neill PA, 1998, STROKE, V29, P1480; O'Sullivan NP, 2000, J HOSP INFECT, V45, P206, DOI 10.1053/jhin.2000.0759; Russell L, 2001, Br J Nurs, V10, pS44; SACCO RL, 1995, NEUROLOGY, V45, pS10; Sakamoto S, 2006, CLIN NEUROL NEUROSUR, V108, P583, DOI 10.1016/j.clineuro.2005.03.012; Sanan A, 1997, NEUROSURGERY, V40, P588, DOI 10.1097/00006123-199703000-00033; Schuss P, 2012, J NEUROTRAUM, V29, P1090, DOI 10.1089/neu.2011.2176; SEGAL DH, 1994, NEUROSURGERY, V34, P729, DOI 10.1227/00006123-199404000-00024; Shiono Y, 2012, SPINE, V37, P523, DOI 10.1097/BRS.0b013e318224d7b2; Simard JM, 2011, CURR TREAT OPTION NE, V13, P217, DOI 10.1007/s11940-010-0110-9; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Smith ER, 2002, NEUROSURGERY, V51, P117, DOI 10.1097/00006123-200207000-00018; Smithard DG, 1996, STROKE, V27, P1200, DOI 10.1161/01.STR.27.7.1200; Sorensen LT, 2003, ANN SURG, V238, P1, DOI 10.1097/01.SLA.0000074980.39700.31; Suk SH, 2003, STROKE, V34, P1586, DOI 10.1161/01.STR.0000075294.98582.2F; Tabachnick B.G., 2001, USING MULTIVARIATE S; Timmons SD, 2011, NEW ENGL J MED, V365, P373, DOI 10.1056/NEJMc1106421; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; von Baum H, 2002, INFECT CONT HOSP EP, V23, P511, DOI 10.1086/502098; Walcott BP, 2012, J NEUROTRAUM, V29, P1879, DOI 10.1089/neu.2012.2382; Walcott BP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029193; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37; Wen L, 2007, J CRANIOFAC SURG, V18, P526, DOI 10.1097/scs.0b013e3180534348; Wukich DK, 2010, J BONE JOINT SURG AM, V92A, P287, DOI 10.2106/JBJS.I.00080; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470; Yoshida K, 1996, J NEUROL NEUROSUR PS, V61, P166, DOI 10.1136/jnnp.61.2.166; Zerr KJ, 1997, ANN THORAC SURG, V63, P356	51	82	87	0	10	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2013	118	4					757	762		10.3171/2013.1.JNS121626			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	114BT	WOS:000316715700012	23394335				2022-02-06	
J	Xuan, WJ; Vatansever, F; Huang, LY; Wu, QH; Xuan, Y; Dai, TH; Ando, T; Xu, T; Huang, YY; Hamblin, MR				Xuan, Weijun; Vatansever, Fatma; Huang, Liyi; Wu, Qiuhe; Xuan, Yi; Dai, Tianhong; Ando, Takahiro; Xu, Tao; Huang, Ying-Ying; Hamblin, Michael R.			Transcranial Low-Level Laser Therapy Improves Neurological Performance in Traumatic Brain Injury in Mice: Effect of Treatment Repetition Regimen	PLOS ONE			English	Article							BIPHASIC DOSE-RESPONSE; ACUTE ISCHEMIC-STROKE; LIGHT THERAPY; FLUORO-JADE; ADULT BRAIN; NEURONAL DEGENERATION; SUBVENTRICULAR ZONE; STEM-CELLS; DEFICITS; NEUROGENESIS	Low-level laser (light) therapy (LLLT) has been clinically applied around the world for a spectrum of disorders requiring healing, regeneration and prevention of tissue death. One area that is attracting growing interest in this scope is the use of transcranial LLLT to treat stroke and traumatic brain injury (TBI). We developed a mouse model of severe TBI induced by controlled cortical impact and explored the effect of different treatment schedules. Adult male BALB/c mice were divided into 3 broad groups (a) sham-TBI sham-treatment, (b) real-TBI sham-treatment, and (c) real-TBI active-treatment. Mice received active-treatment (transcranial LLLT by continuous wave 810 nm laser, 25 mW/cm(2), 18 J/cm(2), spot diameter 1 cm) while sham-treatment was immobilization only, delivered either as a single treatment at 4 hours post TBI, as 3 daily treatments commencing at 4 hours post TBI or as 14 daily treatments. Mice were sacrificed at 0, 4, 7, 14 and 28 days post-TBI for histology or histomorphometry, and injected with bromodeoxyuridine (BrdU) at days 21-27 to allow identification of proliferating cells. Mice with severe TBI treated with 1-laser Tx (and to a greater extent 3-laser Tx) had significant improvements in neurological severity score (NSS), and wire-grip and motion test (WGMT). However 14-laser Tx provided no benefit over TBI-sham control. Mice receiving 1-and 3-laser Tx had smaller lesion size at 28-days (although the size increased over 4 weeks in all TBI-groups) and less Fluoro-Jade staining for degenerating neurons (at 14 days) than in TBI control and 14-laser Tx groups. There were more BrdU-positive cells in the lesion in 1-and 3-laser groups suggesting LLLT may increase neurogenesis. Transcranial NIR laser may provide benefit in cases of acute TBI provided the optimum treatment regimen is employed.	[Xuan, Weijun; Vatansever, Fatma; Huang, Liyi; Wu, Qiuhe; Xuan, Yi; Dai, Tianhong; Ando, Takahiro; Xu, Tao; Huang, Ying-Ying; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; [Xuan, Weijun; Vatansever, Fatma; Huang, Liyi; Wu, Qiuhe; Dai, Tianhong; Xu, Tao; Huang, Ying-Ying; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; [Xuan, Weijun] Tradit Chinese Med Univ Guangxi, Dept Otolaryngol, Nanning, Peoples R China; [Huang, Liyi] Guangxi Med Univ, Affiliated Coll & Hosp 1, Dept Infect Dis, Nanning, Peoples R China; [Wu, Qiuhe] Jinan Ctr Hosp, Dept Burn, Jinan, Peoples R China; [Xuan, Yi] Tufts Univ, Sch Engn, Medford, MA USA; [Ando, Takahiro] Keio Univ, Dept Elect & Elect Engn, Kohoku Ku, Yokohama, Kanagawa 223, Japan; [Xu, Tao] Shanghai Jiao Tong Univ, Lab Anesthesiol, Shanghai 200030, Peoples R China; [Huang, Ying-Ying] Guangxi Med Univ, Aesthet & Plast Ctr, Nanning, Peoples R China; [Hamblin, Michael R.] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA USA		Hamblin, MR (corresponding author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.	hamblin@helix.mgh.harvard.edu	Ando, Takahiro/R-8374-2019; Huang, Ying-ying/G-3153-2011; Dai, Tianhong/P-5961-2018; Hamblin, Michael R/H-2758-2019; Huang, yingying/J-7329-2012; Ando, Takahiro/H-5209-2019	Huang, Ying-ying/0000-0003-3066-6981; Dai, Tianhong/0000-0001-8960-8896; Hamblin, Michael R/0000-0001-6431-4605; Huang, yingying/0000-0002-4038-0277; Xu, Tao/0000-0001-5868-4079	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AI050875]; Center for Integration of Medicine and Innovative Technology [DAMD17-02-2-0006]; CDMRP Program in TBI [W81XWH-09-1-0514]; Air Force Office of Scientific Research Military Photomedicine Program [FA9550-11-1-0331]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI050875] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [10J04881] Funding Source: KAKEN	NIH grant R01AI050875, Center for Integration of Medicine and Innovative Technology (DAMD17-02-2-0006), CDMRP Program in TBI (W81XWH-09-1-0514) and Air Force Office of Scientific Research Military Photomedicine Program (FA9550-11-1-0331). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ando T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026212; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Barker JM, 2011, EUR J NEUROSCI, V34, P963, DOI 10.1111/j.1460-9568.2011.07823.x; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Chen ACH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022453; Chung H, 2012, ANN BIOMED ENG, V40, P516, DOI 10.1007/s10439-011-0454-7; Davis Philip J., 2007, METHODS NUMERICAL IN; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; Feeser VR, 2011, J NEUROIMMUNOL, V237, P4, DOI 10.1016/j.jneuroim.2011.06.007; Frenette AJ, 2012, J NEUROTRAUM, V29, P1, DOI 10.1089/neu.2011.1812; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; Heile Anna, 2011, Dialogues Clin Neurosci, V13, P279; Huang YY, 2012, J BIOPHOTONICS, V5, P827, DOI 10.1002/jbio.201200077; Huang YY, 2011, DOSE-RESPONSE, V9, P602, DOI 10.2203/dose-response.11-009.Hamblin; Huang YY, 2009, DOSE-RESPONSE, V7, P358, DOI 10.2203/dose-response.09-027.Hamblin; Karonen JO, 1999, STROKE, V30, P1583, DOI 10.1161/01.STR.30.8.1583; KARU T, 1995, J PHOTOCH PHOTOBIO B, V27, P219, DOI 10.1016/1011-1344(94)07078-3; Karu TI, 2005, LASER SURG MED, V36, P307, DOI 10.1002/lsm.20148; Khuman J, 2012, J NEUROTRAUM, V29, P408, DOI 10.1089/neu.2010.1745; Kokaia Z, 2006, CEREB CORTEX, V16, pI162, DOI 10.1093/cercor/bhj174; Kuo JR, 2011, J TRAUMA, V71, pE87, DOI 10.1097/TA.0b013e31820932e2; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lampl Yair, 2007, Expert Rev Neurother, V7, P961, DOI 10.1586/14737175.7.8.961; Lapchak PA, 2004, STROKE, V35, P1985, DOI 10.1161/01.STR.0000131808.69640.b7; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Ling GSF, 2011, CURR OPIN ANESTHESIO, V24, P124, DOI 10.1097/ACO.0b013e32834458da; Ling GSF, 2005, NEUROCRIT CARE, V2, P75, DOI 10.1385/NCC:2:1:075; Lulic D, 2011, NEUROSURGERY, V68, P1172, DOI 10.1227/NEU.0b013e31820c6cdc; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; McIntosh TK, 1996, EUR J ANAESTH, V13, P291, DOI 10.1046/j.1365-2346.1996.00981.x; Muller CJ, 2009, EXP NEUROL, V219, P284, DOI 10.1016/j.expneurol.2009.05.035; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P443, DOI 10.1089/pho.2011.9908; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P351, DOI 10.1089/pho.2010.2814; Nichol AD, 2011, LANCET NEUROL, V10, P405, DOI 10.1016/S1474-4422(11)70085-0; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Oron A, 2012, J NEUROTRAUM, V29, P401, DOI 10.1089/neu.2011.2062; Pascual JL, 2011, J TRAUMA, V70, P535, DOI 10.1097/TA.0b013e31820b59de; Quirk BJ, 2012, PHOTOMED LASER SURG, V30, P523, DOI 10.1089/pho.2012.3261; Salman H, 2004, J NEUROTRAUM, V21, P283, DOI 10.1089/089771504322972077; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; Sharma SK, 2011, LASER SURG MED, V43, P851, DOI 10.1002/lsm.21100; Stemer Andrew B, 2010, Curr Cardiol Rep, V12, P29, DOI 10.1007/s11886-009-0071-3; Streeter J, 2004, MITOCHONDRION, V4, P569, DOI 10.1016/j.mito.2004.07.037; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Wu QH, 2012, LASER SURG MED, V44, P218, DOI 10.1002/lsm.22003; Xiong Y, 2010, DISCOV MED, V10, P434; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zhang RL, 2008, NEUROPHARMACOLOGY, V55, P345, DOI 10.1016/j.neuropharm.2008.05.027; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547	55	82	86	0	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 7	2013	8	1							e53454	10.1371/journal.pone.0053454			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	069IS	WOS:000313429100069	23308226	Green Published, Green Submitted, gold			2022-02-06	
J	Schuss, P; Vatter, H; Oszvald, A; Marquardt, G; Imohl, L; Seifert, V; Guresir, E				Schuss, Patrick; Vatter, Hartmut; Oszvald, Agi; Marquardt, Gerhard; Imoehl, Lioba; Seifert, Volker; Gueresir, Erdem			Bone Flap Resorption: Risk Factors for the Development of a Long-Term Complication following Cranioplasty after Decompressive Craniectomy	JOURNAL OF NEUROTRAUMA			English	Article						BFR; cranioplasty; complications; DC	MIDDLE CEREBRAL-ARTERY; SUBARACHNOID HEMORRHAGE; DURA-MATER; INFARCTION; CHILDREN; IMMATURE; GRAFTS; DESIGN; INJURY	Aseptic bone flap resorption (BFR) is a known long-term complication after cranioplasty (CP). We analyzed our institutional data in order to identify risk factors for BFR. From October 1999 to April 2012, 254 patients underwent CP after decompressive craniectomy (DC) at our institution, and had a long-term follow-up period of >1 year after CP (range 12146 months). Overall, BFR occurred in 10 of 254 patients as a long-term complication after CP (4%). BFR developed more often in patients aged <= 18 years (p = 0.008), in patients who previously underwent DC for traumatic brain injury (p = 0.04), and in patients with multiple fractures within the reinserted bone flap (p = 0.002). Furthermore, BFR developed significantly more often in patients who underwent cranioplasty <= 2 months after DC (p = 0.008), as well as in patients with wound healing disturbance or abscess as an early complication after the CP procedure (p = 0.01). The multivariate analysis of the present data identified the presence of multiple fractures within the bone flap (p = 0.002, OR 10.3, 95% CI 2.4-43.8), wound infection after CP (p = 0.003, OR 12.3, 95% CI 2.3-65.3), and cranioplasty performed <= 2 months after DC (p = 0.01, OR 6.3, 95% CI 1.5-26.3) as independent risk factors for the development of BFR after CP in a large series with long-term follow-up. This might influence future surgical decision making, especially in patients fulfilling high risk criteria for developing BFR.	[Schuss, Patrick; Vatter, Hartmut; Oszvald, Agi; Marquardt, Gerhard; Imoehl, Lioba; Seifert, Volker; Gueresir, Erdem] Goethe Univ Frankfurt, Dept Neurosurg, D-60528 Frankfurt, Germany		Schuss, P (corresponding author), Goethe Univ Frankfurt, Dept Neurosurg, Schleusenweg 2-16, D-60528 Frankfurt, Germany.	patrick.schuss@med.uni-frankfurt.de	Schuss, Patrick/ABC-6469-2020; Guresir, Erdem/AAL-4484-2020; Guresir, Erdem/AAV-7224-2021	Schuss, Patrick/0000-0002-5806-2576; Guresir, Erdem/0000-0001-8319-0847; Guresir, Agi/0000-0003-1492-5461			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Elsalanty ME, 2009, CRANIOMAX TRAUM REC, V2, P125, DOI 10.1055/s-0029-1215875; Eppley BL, 2002, PLAST RECONSTR SURG, V109, P864, DOI 10.1097/00006534-200203000-00005; EPPLEY BL, 1990, PLAST RECONSTR SURG, V86, P1085, DOI 10.1097/00006534-199012000-00006; Fong KD, 2003, PLAST RECONSTR SURG, V112, P1312, DOI 10.1097/01.PRS.0000079860.14734.D6; Frassanito P, 2012, ACTA NEUROCHIR, V154, P927, DOI 10.1007/s00701-011-1253-5; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; Greenwald JA, 2000, PLAST RECONSTR SURG, V105, P1382, DOI 10.1097/00006534-200004040-00018; Guresir E, 2009, J NEUROL NEUROSUR PS, V80, P799, DOI 10.1136/jnnp.2008.155630; Guresir E, 2012, NEUROSURGERY, V70, P881, DOI 10.1227/NEU.0b013e318237a6a6; Guresir E, 2011, J NEUROSURG, V114, P954, DOI 10.3171/2009.12.JNS091065; Guresir E, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0954; Heino TJ, 2002, J CELL BIOCHEM, V85, P185, DOI 10.1002/jcb.10109; Honeybul S, 2010, J CLIN NEUROSCI, V17, P430, DOI 10.1016/j.jocn.2009.09.007; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Kriegel RJ, 2007, ZBL NEUROCHIR, V68, P182, DOI 10.1055/s-2007-985857; Marion DW, 2006, NEUROSURGERY, V58, P655; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Roberson J B, 1997, J Craniomaxillofac Trauma, V3, P8; Schuss P, 2012, J NEUROTRAUM, V29, P1090, DOI 10.1089/neu.2011.2176; Stevenson S, 1997, J BONE JOINT SURG AM, V79A, P1; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Vaananen K, 2005, ADV DRUG DELIVER REV, V57, P959, DOI 10.1016/j.addr.2004.12.018; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4	28	82	83	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2013	30	2					91	95		10.1089/neu.2012.2542			5	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	069NT	WOS:000313444000004	22970998				2022-02-06	
J	Evans, KN; Forsberg, JA; Potter, BK; Hawksworth, JS; Brown, TS; Andersen, R; Dunne, JR; Tadaki, D; Elster, EA				Evans, Korboi N.; Forsberg, Jonathan A.; Potter, Benjamin K.; Hawksworth, Jason S.; Brown, Trevor S.; Andersen, Romney; Dunne, James R.; Tadaki, Douglas; Elster, Eric A.			Inflammatory Cytokine and Chemokine Expression is Associated With Heterotopic Ossification in High-Energy Penetrating War Injuries	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						inflammatory cytokines and chemokines; heterotopic ossification; high energy way injuries	TRAUMATIC BRAIN-INJURY; BONE-FORMATION; RISK-FACTORS; SPINAL-CORD; DIFFERENTIATION; OSTEOBLASTS; PREVALENCE; CELLS; INTERLEUKIN-6; INDOMETHACIN	Objective: Heterotopic ossification (HO) develops frequently after modern high-energy penetrating war injuries. The purpose of this prospective study was to identify and characterize the unique cytokine and chemokine profile associated with the development of HO as it pertained to the systemic inflammatory response after penetrating combat-related trauma. Methods: Patients with high-energy penetrating extremity wounds were prospectively enrolled. Surgical debridement along with the use of a pulse lavage and vacuum-assisted-closure device was performed every 48-72 hours until definitive wound closure. Wound bed tissue biopsy, wound effluent, and serum were collected before each debridement. Effluent and serum were analyzed for 22 relevant cytokines and chemokines. Tissue was analyzed quantitatively for bacterial colonization. Correlations between specific wound and patient characteristics were also analyzed. The primary clinical outcome measure was the formation of HO as confirmed by radiographs at a minimum of 2 months of follow-up. Results: Thirty-six penetrating extremity war wounds in 24 patients were investigated. The observed rate of HO in the study population was 38%. Of the 36 wounds, 13 (36%) demonstrated HO at a minimum follow-up of 2 months. An elevated injury severity score was associated with the development of HO (P = 0.006). Wound characteristics that correlated with the development of HO included impaired healing (P = 0.005) and bacterial colonization (P < 0.001). Both serum (interleukin-6, interleukin-10, and MCP-1) and wound effluent (IP-10 and MIP-1 alpha) cytokine and chemokine bioprofiles were individually associated and suggestive of the development of HO (P < 0.05). Conclusions: A severe systemic and wound-specific inflammatory state as evident by elevated levels of inflammatory cytokines, elevated injury severity score, and bacterial wound colonization is associated with the development of HO. These findings suggest that the development of HO in traumatic combat-related wounds is associated with a hyper-inflammatory systemic response to injury.	[Evans, Korboi N.; Hawksworth, Jason S.; Elster, Eric A.] USN, Regenerat Med Dept, Med Res Ctr, Silver Spring, MD 20910 USA; [Evans, Korboi N.; Forsberg, Jonathan A.; Potter, Benjamin K.; Brown, Trevor S.; Andersen, Romney; Tadaki, Douglas] Walter Reed Natl Mil Med Ctr, Integrated Dept Orthoped & Rehabil, Bethesda, MD USA; [Evans, Korboi N.; Forsberg, Jonathan A.; Potter, Benjamin K.; Andersen, Romney; Dunne, James R.; Elster, Eric A.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Hawksworth, Jason S.; Dunne, James R.; Elster, Eric A.] Walter Reed Natl Mil Med Ctr, Integrated Dept Surg, Bethesda, MD USA		Elster, EA (corresponding author), USN, Regenerat Med Dept, Med Res Ctr, Silver Spring, MD 20910 USA.	eric.elster@med.navy.mil	Brown, Trevor/K-4703-2012; Brown, Trevor/F-7392-2015; Elster, Eric/ABG-6091-2021; Potter, Benjamin/U-1769-2019	Brown, Trevor/0000-0001-7042-785X; Brown, Trevor/0000-0001-7042-785X; Elster, Eric/0000-0002-0981-2748; Potter, MD, Benjamin K./0000-0002-8771-0317	US Navy Bureau of Medicine and Surgery under the Medical Development Program [PE 0604771N];  [601153N.4508.5180.A0508]	Supported by the US Navy Bureau of Medicine and Surgery under the Medical Development Program (PE 0604771N). This work was funded by work unit number: 601153N.4508.5180.A0508 and approved by the National Naval Medical Center Institutional Review Board in compliance with all Federal regulations governing the protection of human subjects. The NNMC IRB number is NNMC>2005.0069, and the protocol title is "The Use of Vacuum Assisted Wound Closure Device in treating Extremity Wounds."	Andermahr J, 2006, J NEUROTRAUM, V23, P708, DOI 10.1089/neu.2006.23.708; Billings PC, 2008, J BONE MINER RES, V23, P305, DOI 10.1359/JBMR.071030; Board TN, 2007, J BONE JOINT SURG BR, V89B, P434, DOI 10.1302/0301-620X.89B4.18845; Bosse A, 1997, Veroff Pathol, V146, P1; Boyd JI, 2004, CLIN ORTHOP RELAT R, P13, DOI 10.1097/01.blo.0000144859.73074.45; BROOKER AF, 1973, J BONE JOINT SURG AM, VA 55, P1629, DOI 10.2106/00004623-197355080-00006; Burd TA, 2001, J BONE JOINT SURG AM, V83A, P1783, DOI 10.2106/00004623-200112000-00003; Carano RAD, 2003, DRUG DISCOV TODAY, V8, P980, DOI 10.1016/S1359-6446(03)02866-6; Chandrasenan Jeevan, 2008, J Shoulder Elbow Surg, V17, pe15, DOI 10.1016/j.jse.2007.06.018; Claes L, 2002, J ORTHOP RES, V20, P1099, DOI 10.1016/S0736-0266(02)00044-X; Diefenderfer DL, 2003, J BONE JOINT SURG AM, V85A, P19, DOI 10.2106/00004623-200300003-00005; Erices A, 2002, EXP CELL RES, V280, P24, DOI 10.1006/excr.2002.5627; Forsberg JA, 2008, J BONE JOINT SURG AM, V90A, P580, DOI 10.2106/JBJS.G.00265; Forsberg JA, 2009, J BONE JOINT SURG AM, V91A, P1084, DOI 10.2106/JBJS.H.00792; Franchimont N, 2005, BONE, V37, P601, DOI 10.1016/j.bone.2005.06.002; GARLAND DE, 1988, CLIN ORTHOP RELAT R, P86; Gautschi OP, 2007, J NEUROTRAUM, V24, P154, DOI 10.1089/neu.2006.0166; GREENHALGH DG, 1987, SURGERY, V102, P306; Hawksworth JS, 2009, ANN SURG, V250, P1002, DOI 10.1097/SLA.0b013e3181b248d9; Jacobs S, 2008, J PLAST RECONSTR AES; Kaplan FS, 2004, J AM ACAD ORTHOP SUR, V12, P116, DOI 10.5435/00124635-200403000-00007; Kirt NT, 1942, JAMA-J AM MED ASSOC, P120; LARSON JM, 1981, RHEUMATOL REHABIL, V20, P193, DOI 10.1093/rheumatology/20.4.193; Melamed E, 2002, AM J PHYS MED REHAB, V81, P670, DOI 10.1097/00002060-200209000-00006; Moore KD, 1998, J BONE JOINT SURG BR, V80B, P259, DOI 10.1302/0301-620X.80B2.8157; Olmsted-Davis E, 2007, AM J PATHOL, V170, P620, DOI 10.2353/ajpath.2007.060692; Otis GA., 1883, THE MEDICAL AND SURG, V1883, P880; Posner LJ, 1997, BONE, V21, P321, DOI 10.1016/S8756-3282(97)00154-3; Potter Benjamin K, 2006, J Am Acad Orthop Surg, V14, pS188; Potter BK, 2007, J BONE JOINT SURG AM, V89A, P476, DOI 10.2106/JBJS.F.00412; RIFAS L, 1989, CONNECT TISSUE RES, V23, P163, DOI 10.3109/03008208909002416; Sears BW, 2009, J AM ACAD ORTHOP SUR, V17, P255, DOI 10.5435/00124635-200904000-00006; Shapiro F, 2008, EUR CELLS MATER, V15, P53, DOI 10.22203/eCM.v015a05; Sharp JG, 2005, CLIN ORTHOP RELAT R, P52, DOI 10.1097/01.blo.0000165733.64757.f2; Simonsen LL, 2007, INJURY, V38, P1146, DOI 10.1016/j.injury.2007.03.019; Taguchi Y, 1998, P ASSOC AM PHYSICIAN, V110, P559; Thornton FJ, 1997, SHOCK, V8, P391, DOI 10.1097/00024382-199712000-00001; Waydhas C, 1996, J TRAUMA, V40, P624, DOI 10.1097/00005373-199604000-00018; Webb Lawrence X, 2002, J Am Acad Orthop Surg, V10, P303	39	82	88	1	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0890-5339			J ORTHOP TRAUMA	J. Orthop. Trauma	NOV	2012	26	11					E204	E213		10.1097/BOT.0b013e31825d60a5			10	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	028WR	WOS:000310456200002	22588530				2022-02-06	
J	Rincon, F; Ghosh, S; Dey, S; Maltenfort, M; Vibbert, M; Urtecho, J; McBride, W; Moussouttas, M; Bell, R; Ratliff, JK; Jallo, J				Rincon, Fred; Ghosh, Sayantani; Dey, Saugat; Maltenfort, Mitchell; Vibbert, Matthew; Urtecho, Jacqueline; McBride, William; Moussouttas, Michael; Bell, Rodney; Ratliff, John K.; Jallo, Jack			Impact of Acute Lung Injury and Acute Respiratory Distress Syndrome After Traumatic Brain Injury in the United States	NEUROSURGERY			English	Article						Administrative database; Epidemiology; Hypoxia; International Classification of Diseases; Nationwide Inpatient Sample; Outcome; Respiratory failure	PULMONARY-ARTERY; WEDGE PRESSURE; HEAD-INJURY; MORTALITY; EPIDEMIOLOGY; OUTCOMES; SEPSIS; ARDS; DEFINITIONS; SEVERITY	BACKGROUND: Traumatic brain injury (TBI) is a major cause of disability, morbidity, and mortality. The effect of the acute respiratory distress syndrome and acute lung injury (ARDS/ALI) on in-hospital mortality after TBI remains controversial. OBJECTIVE: To determine the epidemiology of ARDS/ALI, the prevalence of risk factors, and impact on in-hospital mortality after TBI in the United States. METHODS: Retrospective cohort study of admissions of adult patients >18 years with a diagnosis of TBI and ARDS/ALI from 1988 to 2008 identified through the Nationwide Inpatient Sample. RESULTS: During the 20-year study period, the prevalence of ARDS/ALI increased from 2% (95% confidence interval [CI], 2.1%-2.4%) in 1988 to 22% (95% CI, 21%-22%) in 2008 (P < .001). ARDS/ALI was more common in younger age; males; white race; later year of admission; in conjunction with comorbidities such as congestive heart failure, hypertension, chronic obstructive pulmonary disease, chronic renal and liver failure, sepsis, multiorgan dysfunction; and nonrural, medium/large hospitals, located in the Midwest, South, and West continental US location. Mortality after TBI decreased from 13% (95% CI, 12%-14%) in 1988 to 9% (95% CI, 9%-10%) in 2008 (P < .001). ARDS/ALI-related mortality after TBI decreased from 33% (95% CI, 33%-34%) in 1988 to 28% (95% CI, 28%-29%) in 2008 (P < .001). Predictors of in-hospital mortality after TBI were older age, male sex, white race, cancer, chronic kidney disease, hypertension, chronic liver disease, congestive heart failure, ARDS/ALI, and organ dysfunctions. CONCLUSION: Our analysis demonstrates that ARDS/ALI is common after TBI. Despite an overall reduction of in-hospital mortality, ARDS/ALI carries a higher risk of in-hospital death after TBI.	[Rincon, Fred; Vibbert, Matthew; Urtecho, Jacqueline; McBride, William; Moussouttas, Michael; Bell, Rodney] Thomas Jefferson Univ, Dept Neurol, Div Crit Care, Philadelphia, PA 19107 USA; [Rincon, Fred; Ghosh, Sayantani; Dey, Saugat; Vibbert, Matthew; Urtecho, Jacqueline; Bell, Rodney; Jallo, Jack] Thomas Jefferson Univ, Dept Neurosurg, Div Neurotrauma, Philadelphia, PA 19107 USA; [Maltenfort, Mitchell] Rothman Inst, Dept Biostat, Philadelphia, PA USA; [McBride, William; Moussouttas, Michael; Bell, Rodney] Thomas Jefferson Univ, Div Cerebrovasc Dis, Philadelphia, PA 19107 USA; [Ratliff, John K.] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA		Rincon, F (corresponding author), Thomas Jefferson Univ, Dept Neurol Surg, 909 Walnut St,3rd Floor, Philadelphia, PA 19107 USA.	fred.rincon@jefferson.edu	Dey, Saugat/ABI-5969-2020	Dey, Saugat/0000-0003-4128-3337; Rincon, Fred/0000-0002-8510-118X; Jallo, Jack/0000-0002-5512-1729			Adams DL, 2002, J NATL MED ASSOC, V94, P430; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; [Anonymous], NATL IMPATIENT SAMPL; ASHBAUGH DG, 1967, LANCET, V2, P319; Bateman BT, 2010, ANESTHESIOLOGY, V112, P917, DOI 10.1097/ALN.0b013e3181cea3d0; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Bersten AD, 2002, AM J RESP CRIT CARE, V165, P443, DOI 10.1164/ajrccm.165.4.2101124; Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337; Branas CC, 2005, JAMA-J AM MED ASSOC, V293, P2626, DOI 10.1001/jama.293.21.2626; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Brun-Buisson C, 2004, INTENS CARE MED, V30, P51, DOI 10.1007/s00134-003-2022-6; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cedeno Arturo, 2002, P R Health Sci J, V21, P305; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Erickson SE, 2009, CRIT CARE MED, V37, P1, DOI 10.1097/CCM.0b013e31819292ea; Ferguson ND, 2005, CRIT CARE MED, V33, P2228, DOI 10.1097/01.CCM.0000181529.08630.49; Ferguson ND, 2002, INTENS CARE MED, V28, P1073, DOI 10.1007/s00134-002-1354-y; FIFE D, 1987, AM J PUBLIC HEALTH, V77, P810, DOI 10.2105/AJPH.77.7.810; Forfia PR, 2005, J AM COLL CARDIOL, V45, P1667, DOI 10.1016/j.jacc.2005.01.046; Goss CH, 2003, CRIT CARE MED, V31, P1607, DOI 10.1097/01.CCM.0000063475.65751.1D; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Howard AE, 2004, AM J CRIT CARE, V13, P59, DOI 10.4037/ajcc2004.13.1.59; Hudson LD, 1999, CHEST, V116, p74S, DOI 10.1378/chest.116.suppl_1.74S-a; Johnston CJ, 2003, CHEST, V124, P653, DOI 10.1378/chest.124.2.653; LEWANDOWSKI K, 1995, AM J RESP CRIT CARE, V151, P1121; Luhr OR, 1999, AM J RESP CRIT CARE, V159, P1849, DOI 10.1164/ajrccm.159.6.9808136; Luhr OR, 2000, INTENS CARE MED, V26, P508, DOI 10.1007/s001340051197; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; Mikkelsen ME, 2012, AM J RESP CRIT CARE, V185, P1307, DOI 10.1164/rccm.201111-2025OC; Moss M, 2000, CRIT CARE MED, V28, P2187, DOI 10.1097/00003246-200007000-00001; Phua J, 2008, CRIT CARE MED, V36, P2912, DOI 10.1097/CCM.0b013e31817d20bd; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Rana R, 2006, CRIT CARE MED, V34, P1941, DOI 10.1097/01.CCM.0000220492.15645.47; Reynolds, 1998, Crit Care, V2, P29, DOI 10.1186/cc121; Richard C, 2011, CURR OPIN CRIT CARE, V17, P296, DOI 10.1097/MCC.0b013e3283466b85; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Rubenfeld GD, 1999, CHEST, V116, P1347, DOI 10.1378/chest.116.5.1347; Rubenfeld GD, 2007, CHEST, V131, P554, DOI 10.1378/chest.06-1976; Ryb GE, 2010, J NATL MED ASSOC, V102, P865, DOI 10.1016/S0027-9684(15)30700-8; Salim A, 2008, INJURY, V39, P30, DOI 10.1016/j.injury.2007.06.015; Silverboard H, 2005, J TRAUMA, V59, P717, DOI 10.1097/01.ta.0000174919.35240.21; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; Stanley RM, 2012, PEDIATRICS, V129, pE24, DOI 10.1542/peds.2011-2074; THOMSEN GE, 1995, AM J RESP CRIT CARE, V152, P965, DOI 10.1164/ajrccm.152.3.7663811; Tiesman H, 2007, J NEUROTRAUM, V24, P1189, DOI 10.1089/neu.2006.0196; Villar J, 1999, INTENS CARE MED, V25, P930, DOI 10.1007/s001340050984; VILLAR J, 1989, AM REV RESPIR DIS, V140, P814, DOI 10.1164/ajrccm/140.3.814; Wheeler AP, 2006, NEW ENGL J MED, V354, P2213; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	49	82	86	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	OCT	2012	71	4					795	803		10.1227/NEU.0b013e3182672ae5			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	010TO	WOS:000309117200027	22855028				2022-02-06	
J	Spitz, G; Ponsford, JL; Rudzki, D; Maller, JJ				Spitz, Gershon; Ponsford, Jennie L.; Rudzki, Dion; Maller, Jerome J.			Association Between Cognitive Performance and Functional Outcome Following Traumatic Brain Injury: A Longitudinal Multilevel Examination	NEUROPSYCHOLOGY			English	Article						TBI; cognition; functional outcome	SEVERE HEAD-INJURY; RECOVERY; PRODUCTIVITY; REHABILITATION; PREDICTORS; INTEGRATION; SEVERITY; BATTERY; RETURN; TBI	Objective: Individuals' cognitive abilities predict functional outcomes following traumatic brain injury (TBI). However, it is not known to what extent concurrent cognitive abilities affect the magnitude or the rate of functional recovery. The current study modeled the progression of functional outcome as it related to background, injury severity, and cognitive variables over the first year postinjury. Method: This study comprised 111 individuals with moderate-to-severe TBI assessed on average at 3, 6, and 13 months postinjury. In addition, 79 healthy controls were assessed at a single time point. Each assessment consisted of an administration of a neuropsychological battery-comprising measures of memory, information processing speed, and executive functions-as well as an administration of the Mayo-Portland Adaptability Inventory to examine functional outcomes. Results: Older age, lower levels of education, and greater days of posttraumatic amnesia were associated with poorer functional outcomes. The addition of cognitive variables resulted in better models than simply considering background and injury severity variables. However, the results showed that the model comprising executive functions best characterized the progression of functional outcomes. Conclusions: The findings indicate that consideration of cognitive ability, rather than reliance on demographic and injury severity variables, provide a more accurate representation of functional outcome over the first year postinjury. In addition, the results suggest that specific cognitive domains, particularly executive functions, are likely to have the strongest effect on functional outcomes.	[Spitz, Gershon; Ponsford, Jennie L.] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [Spitz, Gershon; Ponsford, Jennie L.] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Maller, Jerome J.] Monash Univ, Cent Clin Sch, Melbourne, Vic 3004, Australia; [Maller, Jerome J.] Alfred Hosp, Monash Alfred Psychiat Res Ctr, Melbourne, Vic, Australia		Spitz, G (corresponding author), Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia.	Gershon.Spitz@monash.edu	Maller, Jerome J/H-4963-2014; Spitz, Gershon/H-7755-2014	Maller, Jerome J/0000-0003-4685-1508; Spitz, Gershon/0000-0002-7810-1480			Atchison TB, 2004, CLIN NEUROPSYCHOL, V18, P249, DOI 10.1080/13854040490501475; BECKER B, 1975, J CLIN PSYCHOL, V31, P307, DOI 10.1002/1097-4679(197504)31:2<307::AID-JCLP2270310231>3.0.CO;2-Y; Benton AL, 1994, MULTILINGUAL APHASIA; Bercaw EL, 2011, CLIN NEUROPSYCHOL, V25, P72, DOI 10.1080/13854046.2010.532813; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Burgess P, 1996, BEHAV ASSESSMENT DYS; Christensen BK, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2008.10.002; Chu BC, 2007, J CLIN EXP NEUROPSYC, V29, P617, DOI 10.1080/13803390600878893; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; DRUDGE OW, 1984, J CLIN PSYCHOL, V40, P259, DOI 10.1002/1097-4679(198401)40:1<259::AID-JCLP2270400149>3.0.CO;2-C; Fitzmaurice G.M., 2004, APPL LONGITUDINAL AN, Ved; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS51, DOI 10.1016/j.apmr.2008.09.552; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS16, DOI 10.1016/j.apmr.2008.09.551; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Hanks RA, 2008, ARCH PHYS MED REHAB, V89, P950, DOI 10.1016/j.apmr.2008.01.011; Johnson JB, 2004, TRENDS ECOL EVOL, V19, P101, DOI 10.1016/j.tree.2003.10.013; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Malec J. F., 1994, J HEAD TRAUMA REHAB, V9, P1, DOI [10. 1097/ 00001199- 199412000- 00003, DOI 10.1097/00001199-199412000-00003]; MANDLEBERG IA, 1976, J NEUROL NEUROSUR PS, V39, P1001, DOI 10.1136/jnnp.39.10.1001; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; Millis S R, 1994, Int J Neurosci, V79, P165; Novack TA, 2000, BRAIN INJURY, V14, P987; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Reitan R, 1988, HALSTEAD REITAN NEUR; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Singer J, 2003, APPL LONGITUDINAL DA APPL LONGITUDINAL DA, DOI [10.1093/acprof:oso/ 9780195152968.003.0001, DOI 10.1093/ACPROF:OSO/9780195152968.003.0001]; Smith A., 1982, SYMBOL DIGIT MODALIT; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wong PP, 2001, BRAIN INJURY, V15, P519, DOI 10.1080/02699050010005995; [No title captured]	39	82	85	0	33	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105			NEUROPSYCHOLOGY	Neuropsychology	SEP	2012	26	5					604	612		10.1037/a0029239			9	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	994ME	WOS:000307934100006	22799747				2022-02-06	
J	Swick, D; Honzel, N; Larsen, J; Ashley, V; Justus, T				Swick, Diane; Honzel, Nikki; Larsen, Jary; Ashley, Victoria; Justus, Timothy			Impaired Response Inhibition in Veterans with Post-Traumatic Stress Disorder and Mild Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						PTSD; TBI; Go/NoGo; Executive control; Inhibitory control; Impulsivity	INFERIOR FRONTAL GYRUS; PSYCHOMETRIC PROPERTIES; EXECUTIVE FUNCTION; PREFRONTAL CORTEX; WAR VETERANS; RISK-FACTORS; NO-GO; PTSD; PERFORMANCE; SYMPTOMS	Combat veterans with post-traumatic stress disorder (PTSD) can show impairments in executive control and increases in impulsivity. The current study examined the effects of PTSD on motor response inhibition, a key cognitive control function. A Go/NoGo task was administered to veterans with a diagnosis of PTSD based on semi-structured clinical interview using DSM-IV criteria (n=40) and age-matched control veterans (n=33). Participants also completed questionnaires to assess self-reported levels of PTSD and depressive symptoms. Performance measures from the patients (error rates and reaction times) were compared to those from controls. PTSD patients showed a significant deficit in response inhibition, committing more errors on NoGo trials than controls. Higher levels of PTSD and depressive symptoms were associated with higher error rates. Of the three symptom clusters, re-experiencing was the strongest predictor of performance. Because the co-morbidity of mild traumatic brain injury (mTBI) and PTSD was high in this population, secondary analyses compared veterans with PTSD+mTBI (n=30) to veterans with PTSD only (n=10). Although preliminary, results indicated the two patient groups did not differ on any measure (p>.88). Since cognitive impairments could hinder the effectiveness of standard PTSD therapies, incorporating treatments that strengthen executive functions might be considered in the future. (JINS, 2012, 18, 917-926)	Vet Affairs No Calif Hlth Care Syst, Res Serv, Martinez, CA USA; Univ Calif Davis, Dept Neurol, Davis, CA 95616 USA		Swick, D (corresponding author), VA No Calif Hlth Care Syst, Res Serv 151, 150 Muir Rd, Martinez, CA 94553 USA.	swicklab@gmail.com			U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-08-2-0086]; VA Merit Review grantUS Department of Veterans Affairs	We thank Dr. Andrew Kayser for patient referrals, Dr. Juliana Baldo for providing WTAR data, Timothy Heron for statistical advice, and all participants for taking part in the study. This work was supported by the U.S. Army Medical Research and Materiel Command under W81XWH-08-2-0086 and a VA Merit Review grant. The authors declare that they have no conflicts of interest. The information in this manuscript and the manuscript itself has never been published either electronically or in print. The contents do not represent the views of the Department of Veterans Affairs or the United States Government.	Aron AR, 2003, NAT NEUROSCI, V6, P115, DOI 10.1038/nn1003; Aupperle RL, 2012, NEUROPHARMACOLOGY, V62, P686, DOI 10.1016/j.neuropharm.2011.02.008; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Botvinick MM, 2004, TRENDS COGN SCI, V8, P539, DOI 10.1016/j.tics.2004.10.003; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Chambers CD, 2009, NEUROSCI BIOBEHAV R, V33, P631, DOI 10.1016/j.neubiorev.2008.08.016; Cloitre M, 2002, GENDER PTSD, P117; Dimou A, 2011, J PANCREAS, V12, P1; Donohoe G, 2006, J INT NEUROPSYCH SOC, V12, P901, DOI 10.1017/S135561770606108X; Etkin A, 2007, AM J PSYCHIAT, V164, P1476, DOI 10.1176/appi.ajp.2007.07030504; Falconer E, 2008, J PSYCHIATR NEUROSCI, V33, P413; Fan J, 2005, NEUROIMAGE, V26, P471, DOI 10.1016/j.neuroimage.2005.02.004; Fisher T, 2011, CLIN NEUROPHYSIOL, V122, P2390, DOI 10.1016/j.clinph.2011.05.010; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Gordon SN, 2011, CLIN NEUROPSYCHOL, V25, P337, DOI 10.1080/13854046.2010.550634; Hamner M B, 1999, Depress Anxiety, V9, P1; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Iversen AC, 2008, PSYCHOL MED, V38, P511, DOI 10.1017/S0033291708002778; Jakupcak M, 2009, J TRAUMA STRESS, V22, P303, DOI 10.1002/jts.20423; Koso M, 2006, EUR PSYCHIAT, V21, P167, DOI 10.1016/j.eurpsy.2005.06.004; Kroes MCW, 2011, J PSYCHIATR NEUROSCI, V36, P256, DOI 10.1503/jpn.100077; Larson GE, 2009, MIL MED, V174, P737, DOI 10.7205/MILMED-D-02-0308; Leskin LP, 2007, NEUROPSYCHOLOGY, V21, P275, DOI 10.1037/0894-4105.21.3.275; Lew HL, 2010, NEUROREHABILITATION, V26, P271, DOI 10.3233/NRE-2010-0562; Li CSR, 2006, J NEUROSCI, V26, P186, DOI 10.1523/JNEUROSCI.3741-05.2006; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Mcnab F, 2008, NEUROPSYCHOLOGIA, V46, P2668, DOI 10.1016/j.neuropsychologia.2008.04.023; MCNALLY RJ, 1990, J ABNORM PSYCHOL, V99, P398, DOI 10.1037/0021-843X.99.4.398; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Morey RA, 2008, PSYCHIAT RES-NEUROIM, V162, P59, DOI 10.1016/j.pscychresns.2007.07.007; Mostofsky SH, 2008, J COGNITIVE NEUROSCI, V20, P751, DOI 10.1162/jocn.2008.20500; Nee DE, 2007, COGN AFFECT BEHAV NE, V7, P1, DOI 10.3758/CABN.7.1.1; Nelson LA, 2009, J HEAD TRAUMA REHAB, V24, P32, DOI 10.1097/HTR.0b013e3181957016; Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1; PETRIDES M, 1986, J NEUROSCI, V6, P2054; Picton TW, 2007, CEREB CORTEX, V17, P826, DOI 10.1093/cercor/bhk031; Qureshi SU, 2011, J NEUROPSYCH CLIN N, V23, P16, DOI 10.1176/appi.neuropsych.23.1.16; Rauch SL, 2003, NEUROREPORT, V14, P913, DOI 10.1097/01.wnr.0000071767.24455.10; Rentrop M, 2008, PSYCHOPATHOLOGY, V41, P50, DOI 10.1159/000110626; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Romesser J, 2011, MIL MED, V176, P246, DOI 10.7205/MILMED-D-10-00056; Shin LM, 2006, ANN NY ACAD SCI, V1071, P67, DOI 10.1196/annals.1364.007; Sigford B, 2009, NEW ENGL J MED, V361, P536, DOI 10.1056/NEJMc096180; Simmons AN, 2012, NEUROPHARMACOLOGY, V62, P598, DOI 10.1016/j.neuropharm.2011.03.016; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Swick D, 2002, P NATL ACAD SCI USA, V99, P16354, DOI 10.1073/pnas.252521499; Swick D, 2011, NEUROIMAGE, V56, P1655, DOI 10.1016/j.neuroimage.2011.02.070; Swick D, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-102; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Vasterling JJ, 2009, J INT NEUROPSYCH SOC, V15, P826, DOI 10.1017/S1355617709990683; Vasterling JJ, 1998, NEUROPSYCHOLOGY, V12, P125, DOI 10.1037/0894-4105.12.1.125; VRANA SR, 1995, J ANXIETY DISORD, V9, P515, DOI 10.1016/0887-6185(95)00028-M; Weathers F.W., 1994, PTSD CHECKLIST MILIT; WechslerD, 2001, WECHSLER TEST ADULT; Whyte J, 2006, NEUROPSYCHOLOGIA, V44, P2007, DOI 10.1016/j.neuropsychologia.2006.02.012; Woodward SH, 2006, BIOL PSYCHIAT, V59, P582, DOI 10.1016/j.biopsych.2005.07.033; Wu JH, 2010, NEUROSCI LETT, V486, P117, DOI 10.1016/j.neulet.2010.07.040; Zheng D, 2008, J COGNITIVE NEUROSCI, V20, P1434, DOI 10.1162/jocn.2008.20100	69	82	84	1	41	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2012	18	5					917	926		10.1017/S1355617712000458			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	999KB	WOS:000308309100014	22595028				2022-02-06	
J	Papa, L; Stiell, IG; Clement, CM; Pawlowicz, A; Wolfram, A; Braga, C; Draviam, S; Wells, GA				Papa, Linda; Stiell, Ian G.; Clement, Catherine M.; Pawlowicz, Artur; Wolfram, Andrew; Braga, Carolina; Draviam, Sameer; Wells, George A.			Performance of the Canadian CT Head Rule and the New Orleans Criteria for Predicting Any Traumatic Intracranial Injury on Computed Tomography in a United States Level I Trauma Center	ACADEMIC EMERGENCY MEDICINE			English	Article							BRAIN-INJURY; RADIATION-EXPOSURE; CANCER-RISKS; MANAGEMENT	Objectives: This study compared the clinical performance of the Canadian CT Head Rule (CCHR) and the New Orleans Criteria (NOC) for detecting any traumatic intracranial lesion on computed tomography (CT) in patients with a Glasgow Coma Scale (GCS) score of 15. Also assessed were ability to detect patients with clinically important brain injury and patients requiring neurosurgical intervention. Additionally, the performance of the CCHR was assessed in a larger cohort of those presenting with GCS of 13 to 15. Methods: This prospective cohort study was conducted in a U.S. Level I trauma center and enrolled a consecutive sample of mildly head-injured adults who presented to the emergency department (ED) with witnessed loss of consciousness, disorientation or amnesia, and GCS 13 to 15. The rules were compared in the group of patients with GCS 15. The primary outcome was prediction of any traumatic intracranial injury on CT. Secondary outcomes included clinically important brain injury on CT and need for neurosurgical intervention. Results: Among the 431 enrolled patients, 314 patients (73%) had a GCS of 15, and 22 of the 314 (7%) had evidence of a traumatic intracranial lesion on CT. There were 11 of 314 (3.5%) who had clinically important brain injury, and 3 of 314 (1.0%) required neurosurgical intervention. The NOC and CCHR both had 100% sensitivity (95% confidence interval [CI] = 82% to 100%), but the CCHR was more specific for detecting any traumatic intracranial lesion on CT, with a specificity of 36.3% (95% CI = 31% to 42%) versus 10.2% (95% CI = 7% to 14%) for NOC. For clinically important brain lesions, the CCHR and the NOC had similar sensitivity (both 100%; 95% CI = 68% to 100%), but the specificity was 35% (95% CI = 30% to 41%) for CCHR and 9.9% (95% CI = 7% to 14%) for NOC. When the rules were compared for predicting need for neurosurgical intervention, the sensitivity was equivalent at 100% (95% CI = 31% to 100%) but the CCHR had a higher specificity at 80.7% (95% CI = 76% to 85%) versus 9.6% (95% CI = 7% to 14%) for NOC. Among all 431 patients with a GCS score 13 to 15, the CCHR had sensitivities of 100% (95% CI = 84% to 100%) for 27 patients with clinically important brain injury and 100% (95% CI = 46% to 100%) for five patients requiring neurosurgical intervention. Conclusions: In a U.S. sample of mildly head-injured patients, the CCHR and the NOC had equivalently high sensitivities for detecting any traumatic intracranial lesion on CT, clinically important brain injury, and neurosurgical intervention, but the CCHR was more specific. A larger cohort will be needed to validate these findings.	[Papa, Linda; Braga, Carolina; Draviam, Sameer] Orlando Reg Med Ctr Inc, Dept Emergency Med, Orlando, FL USA; [Stiell, Ian G.] Univ Ottawa, Dept Emergency Med, Ottawa, ON, Canada; [Wells, George A.] Ottawa Hlth Res Inst, Dept Epidemiol & Community Med, Ottawa, ON, Canada; [Pawlowicz, Artur] Univ Cent Florida, Coll Med, Orlando, FL 32816 USA; [Wolfram, Andrew] Univ Penn, Philadelphia, PA 19104 USA		Papa, L (corresponding author), Orlando Reg Med Ctr Inc, Dept Emergency Med, Orlando, FL USA.	lpstat@aol.com		Stiell, Ian/0000-0002-2583-6408	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS057676] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS057676] Funding Source: NIH RePORTER		Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; de Gonzalez AB, 2009, ARCH INTERN MED, V169, P2071, DOI 10.1001/archinternmed.2009.440; Faul M, TRAUMATIC BRAIN INJU; Fayngersh V, 2009, LUNG, V187, P143, DOI 10.1007/s00408-009-9143-9; Fleiss J.L., 1981, STAT METHODS RATES P; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; Hall EJ, 2008, BRIT J RADIOL, V81, P362, DOI 10.1259/bjr/01948454; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Heilbrun Marta E, 2005, J Am Coll Radiol, V2, P889, DOI 10.1016/j.jacr.2005.06.013; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; Mettler FA, 2008, HEALTH PHYS, V95, P502, DOI 10.1097/01.HP.0000326333.42287.a2; Mower WR, 2005, J TRAUMA, V59, P954, DOI 10.1097/01.ta.0000187813.79047.42; Rosengren David, 2004, Emerg Med Australas, V16, P195, DOI 10.1111/j.1742-6723.2004.00563.x; Schwartz DT, 2008, WEST J EMERG MED, V9, P120; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; STEIN SC, 1993, ANN EMERG MED, V22, P1193, DOI 10.1016/S0196-0644(05)80989-8; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Stein SC, 2006, J TRAUMA, V61, P558, DOI 10.1097/01.ta.0000233766.60315.5e; Stein SC, 2009, ANN EMERG MED, V53, P180, DOI 10.1016/j.annemergmed.2008.01.002; Stiell I.G., 2000, ACAD EMERG MED, V7, P572; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 1997, ANN EMERG MED, V30, P14, DOI 10.1016/S0196-0644(97)70104-5; Stiell IG, 2001, ANN EMERG MED, V38, P160, DOI 10.1067/mem.2001.116796; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; WARDLAW JM, 2004, HEALTH TECHNOL ASSES, V8, pR9	29	82	82	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	JAN	2012	19	1					2	10		10.1111/j.1553-2712.2011.01247.x			9	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	877CT	WOS:000299155200001	22251188	Green Accepted			2022-02-06	
J	Li, M; Li, F; Luo, CX; Shan, YA; Zhang, LJ; Qian, ZM; Zhu, G; Lin, JK; Feng, H				Li, Mei; Li, Fei; Luo, Chunxia; Shan, Youan; Zhang, Lijun; Qian, Zhongming; Zhu, Gang; Lin, Jiangkai; Feng, Hua			Immediate Splenectomy Decreases Mortality and Improves Cognitive Function of Rats After Severe Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; Splenectomy; Mortality; Cognitive function; Brain edema	EXPERIMENTAL STROKE; HEAD-INJURY; INFLAMMATION; NEURODEGENERATION; INTERLEUKIN-1; EPIDEMIOLOGY; OUTCOMES; EDEMA	Background: Traumatic brain injury (TBI) is a major health problem all over the world. It frequently causes a considerable social burden because of its high incidence of death and long-term disability, especially in the case of severe TBI. Recent studies revealed that the spleen might contribute to secondary brain injury after ischemia or intracerebral hemorrhage. The purpose of this study was to evaluate the significance of the spleen in traumatic brain edema after severe TBI. Methods: We established a severe TBI model with rats and performed splenectomy to observe the mortality, brain water content, cognitive function (water maze), and cytokines levels, including interleukin (IL)-1 beta, tumor necrosis factor-alpha (TNF-alpha), IL-6, and IL-10, in the blood plasma (enzyme-linked immunosorbent assay) and their mRNA expression levels in injured brain tissue (quantitative reverse transcriptase-polymerase chain reaction). Results: The immediate splenectomy after TBI significantly decreased the death rate from 35.42% to 14.89% and eliminated the brain water content of the injured brain, especially at days 2 and 3. The Morris water maze assessment showed an improved spatial reference memory in rats that underwent both TBI and splenectomy when compared with those in the TBI group, 4 weeks later. Splenectomy reduced the IL-1 beta, TNF-alpha, and IL-6 contents in the blood serum after TBI, and the mRNA expression levels of IL-1 beta, TNF-alpha, and IL-6 in the ipsilateral brain tissue also decreased. Conclusions: Our study demonstrates that splenectomy has a protective effect on rats with severe TBI by inhibiting proinflammatory cytokines, including IL-1 beta, TNF-alpha, and IL-6, both systematically and locally in the injured brain, hence leading to a decreased mortality and improved cognitive function.	[Li, Mei; Li, Fei; Luo, Chunxia; Shan, Youan; Zhang, Lijun; Zhu, Gang; Lin, Jiangkai; Feng, Hua] Third Mil Med Univ, Southwest Hosp, Dept Neurosurg, Chongqing 400038, Peoples R China; [Qian, Zhongming] Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Kowloon, Hong Kong, Peoples R China		Feng, H (corresponding author), Third Mil Med Univ, Southwest Hosp, Dept Neurosurg, Chongqing 400038, Peoples R China.	fenghua8888@yahoo.com.cn	Feng, Hua/AAX-4121-2021; Li, Ming/G-3911-2015; Jiang, Rui/P-8022-2015; Jiang, Rui/F-9719-2013	Feng, Hua/0000-0003-4489-9217; Li, Ming/0000-0002-8545-0726; 	Health Sector Public Welfare fund of China [200802017]	Supported by Health Sector Public Welfare fund of China grant 200802017.	Abbott NJ, 2000, CELL MOL NEUROBIOL, V20, P131, DOI 10.1023/A:1007074420772; Ajmo CT, 2008, J NEUROSCI RES, V86, P2227, DOI 10.1002/jnr.21661; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Chamorro A, 2007, STROKE, V38, P1097, DOI 10.1161/01.STR.0000258346.68966.9d; Chu K, 2004, J CEREBR BLOOD F MET, V24, P926, DOI 10.1097/01.WCB.0000130866.25040.7D; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Gendron A, 2002, BRAIN RES, V955, P85, DOI 10.1016/S0006-8993(02)03368-1; Guseva MV, 2008, J NEUROTRAUM, V25, P975, DOI 10.1089/neu.2008.0516; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Hurn PD, 2007, J CEREBR BLOOD F MET, V27, P1798, DOI 10.1038/sj.jcbfm.9600482; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; Lee ST, 2008, BRAIN, V131, P616, DOI 10.1093/brain/awm306; Lee ST, 2010, BRAIN RES, V1309, P164, DOI 10.1016/j.brainres.2009.10.076; Liu BY, 2008, NEUROL RES, V30, P594, DOI 10.1179/174313208X310296; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Marshall L F, 2000, Clin Neurosurg, V46, P105; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Nujaimin U, 2009, ASIAN J SURG, V32, P157, DOI 10.1016/S1015-9584(09)60387-0; Offner H, 2006, J IMMUNOL, V176, P6523, DOI 10.4049/jimmunol.176.11.6523; Petroni G, 2010, J TRAUMA, V68, P564, DOI 10.1097/TA.0b013e3181ce1eed; Pinteaux E, 2009, CYTOKINE, V45, P1, DOI 10.1016/j.cyto.2008.10.008; Subramanian S, 2009, STROKE, V40, P2539, DOI 10.1161/STROKEAHA.108.543991; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S	27	82	87	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	2011	71	1					141	147		10.1097/TA.0b013e3181f30fc9			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	790RR	WOS:000292607400034	21248654				2022-02-06	
J	Bhardwaj, G; Chowdhury, V; Jacobs, MB; Moran, KT; Martin, FJ; Coroneo, MT				Bhardwaj, Gaurav; Chowdhury, Vivek; Jacobs, Mark B.; Moran, Kieran T.; Martin, Frank J.; Coroneo, Minas T.			A Systematic Review of the Diagnostic Accuracy of Ocular Signs in Pediatric Abusive Head Trauma	OPHTHALMOLOGY			English	Article							SHAKEN BABY SYNDROME; PERIMACULAR RETINAL FOLDS; SUSPECTED CHILD-ABUSE; YOUNG-CHILDREN; BRAIN-INJURY; SUBDURAL-HEMATOMA; INTRACRANIAL HEMORRHAGE; OPHTHALMOLOGIC FINDINGS; NONACCIDENTAL INJURY; INFANTS	Topic: To review systematically the diagnostic accuracy of various ocular signs for pediatric abusive head trauma (AHT). Clinical Relevance: Intraocular hemorrhages (IOH), perimacular retinal folds, traumatic retinoschisis and optic nerve sheath hemorrhages have been reported as cardinal signs of AHT. The evidence base supporting the accuracy of this interpretation, however, has not been systematically reviewed. Methods: A systematic keyword search of MEDLINE, EMBASE, and Evidence-Based Medicine Reviews was conducted for original studies reporting ocular findings in AHT. Articles were graded using a checklist for systematic reviews of diagnostic accuracy. Results: The initial search yielded 971 articles, of which 55 relevant studies were graded, and 20 studies met inclusion criteria and were included in the review. The overall sensitivity of IOH for AHT was 75% and their specificity was 94%. Intraretinal hemorrhage at the posterior pole was the most common finding, although extensive, bilateral, and multilayered IOH were the most specific for AHT. Optic nerve sheath hemorrhages had a sensitivity and specificity for AHT of 72% and 71%, respectively. Traumatic retinoschisis and perimacular retinal folds were reported in 8% and 14% of AHT, respectively, but were not reported in other conditions. Conclusions: Prospective, consecutive studies confirm that IOH in infants-particularly bilateral, extensive, and multilayered-are highly specific for AHT. Optic nerve sheath hemorrhages are significantly more common in AHT than in other conditions, in autopsy studies. Traumatic retinoschisis and perimacular folds are present in a minority of AHT, but rarely seen in other conditions.	[Martin, Frank J.] Univ Sydney, Fac Med, Sydney, NSW 2006, Australia; [Martin, Frank J.] Childrens Hosp Westmead, Dept Ophthalmol, Westmead, NSW, Australia; [Moran, Kieran T.] Sydney Childrens Hosp, Child Protect Unit, Randwick, NSW, Australia; [Chowdhury, Vivek; Jacobs, Mark B.; Martin, Frank J.; Coroneo, Minas T.] Sydney Childrens Hosp, Dept Ophthalmol, Randwick, NSW, Australia; [Bhardwaj, Gaurav; Jacobs, Mark B.; Moran, Kieran T.; Coroneo, Minas T.] Univ New S Wales, Fac Med, Randwick, NSW, Australia		Bhardwaj, G (corresponding author), Prince Wales Hosp, Dept Ophthalmol, 2nd Floor,S Wing,Edmund Blacket Bldg, Randwick, NSW 2031, Australia.	gauravb23@gmail.com	Coroneo, Minas/AAJ-4600-2020				Arlotti SA, 2007, J AAPOS, V11, P175, DOI 10.1016/j.jaapos.2006.09.023; Atwal GS, 1998, FORENSIC SCI INT, V96, P215, DOI 10.1016/S0379-0738(98)00126-1; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Bechtel K, 2004, PEDIATRICS, V114, P165, DOI 10.1542/peds.114.1.165; Betz P, 1996, FORENSIC SCI INT, V78, P71, DOI 10.1016/0379-0738(95)01866-2; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; BINEBAUM G, 2009, AAPOS, V13, P268; Binenbaum G, 2009, J AAPOS, V13, P268, DOI 10.1016/j.jaapos.2009.03.005; Biousse V, 2002, AM J OPHTHALMOL, V133, P249, DOI 10.1016/S0002-9394(01)01366-6; Biron D, 2005, CHILD ABUSE NEGLECT, V29, P1347, DOI 10.1016/j.chiabu.2005.05.003; Biron DL, 2007, J PAEDIATR CHILD H, V43, P60, DOI 10.1111/j.1440-1754.2007.01004.x; Bonnier C, 2003, PEDIATRICS, V112, P808, DOI 10.1542/peds.112.4.808; BUDENZ DL, 1994, OPHTHALMOLOGY, V101, P559; BUYS YM, 1992, OPHTHALMOLOGY, V99, P1718; CANTANI A, 1990, Pediatric Emergency Care, V6, P271, DOI 10.1097/00006565-199012000-00005; CHEAH IGS, 1994, ANN TROP PAEDIATR, V14, P325, DOI 10.1080/02724936.1994.11747737; Dashti SR, 1999, PEDIATR NEUROSURG, V31, P302, DOI 10.1159/000028880; DiScala C, 2000, ARCH PEDIAT ADOL MED, V154, P16; Donohoe M, 2003, AM J FOREN MED PATH, V24, P239, DOI 10.1097/01.paf.0000083635.85457.97; Drack AV, 1999, AM J OPHTHALMOL, V128, P340, DOI 10.1016/S0002-9394(99)00147-6; DUHAIME AC, 1992, PEDIATRICS, V90, P179; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; EISENBREY AB, 1979, CHILD BRAIN, V5, P40; ELNER SG, 1990, ARCH OPHTHALMOL-CHIC, V108, P1094, DOI 10.1001/archopht.1990.01070100050033; Emerson MV, 2007, OPHTHALMOLOGY, V114, P1384, DOI 10.1016/j.ophtha.2007.04.015; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Feldman KW, 2001, PEDIATRICS, V108, P636, DOI 10.1542/peds.108.3.636; Fishman CD, 1998, J PEDIAT OPHTH STRAB, V35, P22; FRANK Y, 1985, DEV MED CHILD NEUROL, V27, P312; Fujiwara T, 2008, PEDIATRICS, V122, pE841, DOI 10.1542/peds.2008-0387; Fung ELW, 2002, PEDIATR INT, V44, P37, DOI 10.1046/j.1442-200X.2002.01500.x; Ganesh A, 2004, OPHTHALMOLOGY, V111, P1428, DOI 10.1016/j.ophtha.2003.10.028; GAYNON MW, 1988, AM J OPHTHALMOL, V106, P423, DOI 10.1016/0002-9394(88)90877-X; Geddes JF, 2003, NEUROPATH APPL NEURO, V29, P14, DOI 10.1046/j.1365-2990.2003.00434.x; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Ghahreman A, 2005, J NEUROSURG, V103, P213, DOI 10.3171/ped.2005.103.3.0213; GIANGIACOMO J, 1988, OPHTHALMOLOGY, V95, P295; Gilles EE, 2003, J PEDIATR-US, V143, P494, DOI 10.1067/S0022-3476(03)00416-5; GILLILAND MGF, 1993, AM J FOREN MED PATH, V14, P187, DOI 10.1097/00000433-199309000-00003; Gleckman AM, 2000, ARCH PATHOL LAB MED, V124, P251; Gnanaraj L, 2007, EYE, V21, P5, DOI 10.1038/sj.eye.6702174; Golden N, 2005, J CLIN NEUROSCI, V12, P235, DOI 10.1016/j.jocn.2004.11.001; GOLDSTEIN B, 1993, CRIT CARE MED, V21, P1328, DOI 10.1097/00003246-199309000-00016; Graupman P, 2006, J NEUROSURG, V104, P245, DOI 10.3171/ped.2006.104.4.245; Green MA, 1996, BRIT J OPHTHALMOL, V80, P282, DOI 10.1136/bjo.80.4.282; Greenes DS, 1998, ANN EMERG MED, V32, P680, DOI 10.1016/S0196-0644(98)70067-8; GREENWALD MJ, 1986, OPHTHALMOLOGY, V93, P618; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; Han D P, 1990, J Pediatr Ophthalmol Strabismus, V27, P299; HARCOURT B, 1971, BMJ-BRIT MED J, V3, P398, DOI 10.1136/bmj.3.5771.398; HENDELES S, 1985, CHILD CARE HLTH DEV, V11, P345, DOI 10.1111/j.1365-2214.1985.tb00475.x; HOLLOWAY M, 1994, MED J AUSTRALIA, V160, P786, DOI 10.5694/j.1326-5377.1994.tb125947.x; Hoskote A, 2002, CHILD NERV SYST, V18, P311, DOI 10.1007/s00381-002-0616-x; JACOBI G, 1986, MONATSSCHR KINDERH, V134, P307; Jayawant S, 2007, ARCH DIS CHILD, V92, P343, DOI 10.1136/adc.2005.084988; Kafil-Hussain NA, 2000, J PEDIAT OPHTH STRAB, V37, P289; Kapoor S, 1997, PEDIATR EMERG CARE, V13, P183, DOI 10.1097/00006565-199706000-00002; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; KEITHAHN MAZ, 1993, OPHTHALMOLOGY, V100, P1187; KIFFNEY GT, 1964, ARCH OPHTHALMOL-CHIC, V72, P231; King WJ, 2003, CAN MED ASSOC J, V168, P155; Kivlin JD, 2008, ARCH OPHTHALMOL-CHIC, V126, P800, DOI 10.1001/archopht.126.6.800; Kivlin JD, 2000, OPHTHALMOLOGY, V107, P1246, DOI 10.1016/S0161-6420(00)00161-5; LAMBERT SR, 1986, ARCH OPHTHALMOL-CHIC, V104, P1509; Lantz PE, 2004, BRIT MED J, V328, P754, DOI 10.1136/bmj.328.7442.754; Laskey AL, 2004, J PEDIATR-US, V144, P719, DOI 10.1016/j.jpeds.2004.02.023; Leestma JE, 2005, AM J FOREN MED PATH, V26, P199, DOI 10.1097/01.paf.0000164228.79784.5a; LEVIN AV, 1999, RECENT ADV PAEDIAT, V17, P151; Loh JK, 2002, SURG NEUROL, V58, P218, DOI 10.1016/S0090-3019(02)00830-3; LUDWIG S, 1984, ANN EMERG MED, V13, P104, DOI 10.1016/S0196-0644(84)80571-5; Lueder GT, 2006, ARCH OPHTHALMOL-CHIC, V124, P1782, DOI 10.1001/archopht.124.12.1782; LUERSSEN TG, 1991, CONC PED N, V11, P87; Makoroff KL, 2005, PEDIATR RADIOL, V35, P668, DOI 10.1007/s00247-005-1441-7; Marshall DH, 2001, CAN J OPHTHALMOL, V36, P377, DOI 10.1016/S0008-4182(01)80081-8; MASSICOTTE SJ, 1991, OPHTHALMOLOGY, V98, P1124; McCabe CF, 2000, ARCH OPHTHALMOL-CHIC, V118, P373, DOI 10.1001/archopht.118.3.373; Mills M, 1998, J AAPOS, V2, P67, DOI 10.1016/S1091-8531(98)90066-0; Morad Y, 2004, J AAPOS, V8, P521, DOI 10.1016/j.jaapos.2004.07.009; Morad Y, 2004, J AAPOS, V8, P445, DOI 10.1016/j.jaapos.2004.06.007; Morad Y, 2003, J PEDIATR-US, V142, P431, DOI 10.1067/mpd.2003.161; Morad Y, 2002, AM J OPHTHALMOL, V134, P354, DOI 10.1016/S0002-9394(02)01628-8; Morris MW, 2000, PEDIATRICS, V105, P549, DOI 10.1542/peds.105.3.549; MUNGER CE, 1993, AM J FOREN MED PATH, V14, P193, DOI 10.1097/00000433-199309000-00004; MUSHIN AS, 1971, BRIT MED J, V3, P402, DOI 10.1136/bmj.3.5771.402; Naidoo S, 2000, CHILD ABUSE NEGLECT, V24, P521, DOI 10.1016/S0145-2134(00)00114-9; Nassogne MC, 2002, CHILD NERV SYST, V18, P729, DOI 10.1007/s00381-002-0630-z; Pierre-Kahn V, 2003, OPHTHALMOLOGY, V110, P1718, DOI 10.1016/S0161-6420(03)00581-5; RAO N, 1988, FORENSIC SCI INT, V39, P293, DOI 10.1016/0379-0738(88)90133-8; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; RIFFENBURGH R, 2005, CLIN SURG OPHTHALMOL, V23, P178; RIFFENBURGH RS, 1991, OPHTHALMOLOGY, V98, P1519; Rubin DM, 2003, PEDIATRICS, V111, P1382, DOI 10.1542/peds.111.6.1382; Schmidt US, 1997, KLIN MONATSBL AUGENH, V211, P354, DOI 10.1055/s-2008-1035147; SMITH SM, 1974, BMJ-BRIT MED J, V3, P666, DOI 10.1136/bmj.3.5932.666; Sun DTF, 2006, CHILD NERV SYST, V22, P593, DOI 10.1007/s00381-006-0094-7; Talvik I, 2006, ACTA PAEDIATR, V95, P799, DOI 10.1080/08035250500464923; Togioka BM, 2009, J EMERG MED, V37, P98, DOI 10.1016/j.jemermed.2008.06.022; Tung GA, 2006, PEDIATRICS, V118, P626, DOI 10.1542/peds.2006-0130; Tzioumi D, 1998, CHILD ABUSE NEGLECT, V22, P1105, DOI 10.1016/S0145-2134(98)00093-3; Vinchon M, 2005, J NEUROSURG, V102, P380, DOI 10.3171/ped.2005.102.4.0380; Vinchon M, 2004, PRESSE MED, V33, P1174, DOI 10.1016/S0755-4982(04)98886-0; Watts P, 2008, EYE, V22, P1514, DOI 10.1038/eye.2008.224; Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25; WILKINSON WS, 1989, ARCH OPHTHALMOL-CHIC, V107, P1472, DOI 10.1001/archopht.1989.01070020546037; Wygnanski-Jaffe T, 2006, AM J OPHTHALMOL, V142, P233, DOI 10.1016/j.ajo.2006.03.038	106	82	82	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0161-6420	1549-4713		OPHTHALMOLOGY	Ophthalmology	MAY	2010	117	5					983	U186		10.1016/j.ophtha.2009.09.040			27	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Ophthalmology	590XM	WOS:000277261800020	20347153				2022-02-06	
J	Cole, JT; Mitala, CM; Kundu, S; Verma, A; Elkind, JA; Nissim, I; Cohen, AS				Cole, Jeffrey T.; Mitala, Christina M.; Kundu, Suhali; Verma, Ajay; Elkind, Jaclynn A.; Nissim, Itzhak; Cohen, Akiva S.			Dietary branched chain amino acids ameliorate injury-induced cognitive impairment	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						branched chain amino acids; cognitive impairment; hippocampus; tramautic brain injury	TRAUMATIC BRAIN-INJURY; CONDITIONED FEAR; AMINOTRANSFERASE; METABOLISM; RECOVERY; LEUCINE	Neurological dysfunction caused by traumatic brain injury results in profound changes in net synaptic efficacy, leading to impaired cognition. Because excitability is directly controlled by the balance of excitatory and inhibitory activity, underlying mechanisms causing these changes were investigated using lateral fluid percussion brain injury in mice. Although injury-induced shifts in net synaptic efficacy were not accompanied by changes in hippocampal glutamate and GABA levels, significant reductions were seen in the concentration of branched chain amino acids (BCAAs), which are key precursors to de novo glutamate synthesis. Dietary consumption of BCAAs restored hippocampal BCAA concentrations to normal, reversed injury-induced shifts in net synaptic efficacy, and led to reinstatement of cognitive performance after concussive brain injury. All brain-injured mice that consumed BCAAs demonstrated cognitive improvement with a simultaneous restoration in net synaptic efficacy. Posttraumatic changes in the expression of cytosolic branched chain aminotransferase, branched chain ketoacid dehydrogenase, glutamate dehydrogenase, and glutamic acid decarboxylase support a perturbation of BCAA and neurotransmitter metabolism. Ex vivo application of BCAAs to hippocampal slices from injured animals restored post-traumatic regional shifts in net synaptic efficacy as measured by field excitatory postsynaptic potentials. These results suggest that dietary BCAA intervention could promote cognitive improvement by restoring hippocampal function after a traumatic brain injury.	[Cole, Jeffrey T.; Mitala, Christina M.; Kundu, Suhali; Cohen, Akiva S.] Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA; [Nissim, Itzhak] Childrens Hosp Philadelphia, Div Child Dev, Philadelphia, PA 19104 USA; [Verma, Ajay] Uniformed Serv Univ Hlth Sci, Dept Neurol & Neurosci, Bethesda, MD 20814 USA; [Elkind, Jaclynn A.; Cohen, Akiva S.] Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; [Nissim, Itzhak; Cohen, Akiva S.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; [Nissim, Itzhak] Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; [Cohen, Akiva S.] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA		Cohen, AS (corresponding author), Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA.	cohena@email.chop.edu			National Institutes of Health/National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [RO1HD059288]; National Institutes of Health/National Institute of Diabetes and Digestive and Kidney DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [RO1DK053761, 5T32NS043126-07]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD059288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK053761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS069629, T32NS043126] Funding Source: NIH RePORTER	The authors are indebted to Ilana Nissim for determination of amino acids levels by HPLC and to Yevgeny Daikhin for measurement of <SUP>15</SUP>N-labeled metabolites at the GC-MS Core. We thank Drs. M.J. Schell, M. B. Robinson, and M. Yudkoff for many helpful and insightful discussions, and Drs. R. G. Kalb and D. Dinges for critiquing earlier drafts of this manuscript. This work was supported by National Institutes of Health/National Institute of Child Health and Human Development grant RO1HD059288 (A. S. C.), and by National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases grants RO1DK053761 (I.N.) and 5T32NS043126-07 (C. M. M). This work is dedicated to Maimon M. Cohen, whose suggestions were instrumental in planting the seeds for this line of investigation.	Aquilani R, 2005, ARCH PHYS MED REHAB, V86, P1729, DOI 10.1016/j.apmr.2005.03.022; Aquilani R, 2008, ARCH PHYS MED REHAB, V89, P1642, DOI 10.1016/j.apmr.2008.02.023; Bartolucci EJ, 2007, IEEE IND APPL MAG, V13, P24, DOI 10.1109/MIA.2007.322272; BOGEN IL, 2008, J NEUROCHEM, V106, P1515; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; De Bandt JP, 2006, J NUTR, V136, p308S, DOI 10.1093/jn/136.1.308S; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; FANELLI FR, 1986, GUT, V27, P111, DOI 10.1136/gut.27.Suppl_1.111; GRADY MS, 1995, ANESTHETIC MANAGEMEN, P87; Lifshitz J, 2007, BEHAV BRAIN RES, V177, P347, DOI 10.1016/j.bbr.2006.11.014; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; McKenna MC, 2000, NEUROCHEM INT, V37, P229, DOI 10.1016/S0197-0186(00)00042-5; Mikics E, 2006, BEHAV PHARMACOL, V17, P223; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Richardson MA, 2004, J CLIN PSYCHIAT, V65, P92; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sakai R, 2004, J NEUROCHEM, V88, P612, DOI 10.1111/j.1471-4159.2004.02179.x; Sato S, 2005, HEPATOL RES, V31, P232, DOI 10.1016/j.hepres.2005.01.009; SOLTESZ I, 1995, NEURON, V14, P1273, DOI 10.1016/0896-6273(95)90274-0; Sweatt AJ, 2004, J COMP NEUROL, V477, P360, DOI 10.1002/cne.20200; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; WALSER M, 1984, CLIN SCI, V66, P1; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Yee BK, 2004, EUR J NEUROSCI, V20, P1928, DOI 10.1111/j.1460-9568.2004.03642.x	27	82	84	0	9	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	JAN 5	2010	107	1					366	371		10.1073/pnas.0910280107			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	543FX	WOS:000273559200064	19995960	Green Published, Bronze			2022-02-06	
J	Smith, RM; Conn, AKT				Smith, R. Malcolm; Conn, Alasdair K. T.			Prehospital care - Scoop and run or stay and play?	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Prehospital Care; "Scoop and run"; "Stay and play"	TRAUMATIC BRAIN-INJURY; LIFE-SUPPORT; HEAD-INJURY; INTUBATION	Improved training and expertise has enabled emergency medical personnel to provide advanced levels of care at the scene of trauma. While this could be expected to improve the outcome from major injury, current data does not support this. Indeed, prehospital interventions beyond the BLS level have not been shown to be effective and in many cases have proven to be detrimental to patient outcome. It is better to "scoop and run" than "stay and play". Current data relates to the urban environment where transport times to trauma centres are short and where it appears better to simply rapidly transport the patient to hospital than attempt major interventions at the scene. There may be more need for advanced techniques in the rural environment or where transport times are prolonged and certainly a need for more studies into subsets of patients who may benefit from interventions in the field.	[Smith, R. Malcolm] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Orthopaed Trauma Serv, Boston, MA 02114 USA		Smith, RM (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Orthopaed Trauma Serv, 55 Fruit St,WACC 5-525, Boston, MA 02114 USA.	rmsmith@partners.org					Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; Cornwell EE, 2000, ARCH SURG-CHICAGO, V135, P315, DOI 10.1001/archsurg.135.3.315; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Isenberg DL, 2005, PREHOSPITAL DISASTER, V20, P265, DOI 10.1017/S1049023X0000265X; Liberman M, 2003, ANN SURG, V237, P153, DOI 10.1097/00000658-200302000-00001; Liberman M, 2000, J TRAUMA, V49, P584, DOI 10.1097/00005373-200010000-00003; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Novak L, 1999, J TRAUMA, V47, P834, DOI 10.1097/00005373-199911000-00003; Stiell IG, 2008, CAN MED ASSOC J, V178, P1141, DOI 10.1503/cmaj.071154	9	82	84	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	NOV	2009	40						S23	S26		10.1016/j.injury.2009.10.033			4	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	534YI	WOS:000272933100004	19895949				2022-02-06	
J	Mammis, A; Mclntosh, TK; Maniker, AH				Mammis, Antonios; Mclntosh, Tracy K.; Maniker, Allen H.			Erythropoietin as a neuroprotective agent in traumatic brain injury Review	SURGICAL NEUROLOGY			English	Article						Erythropoietin; Traumatic brain injury; Apoptosis; Neuroprotection; Neurosurgery	INCREASED EXPRESSION; NEURONAL APOPTOSIS; CEREBRAL-ISCHEMIA; CORTICAL-NEURONS; ACTIVATION; MODEL; RATS	Background: In the United States, TBI remains a major cause of morbidity and mortality in children and young adults. A total of 1.5 million Americans experience head trauma every year, and the yearly economic cost of this exceeds $56 billion. The magnitude of this problem has generated a great deal of interest in elucidating the complex molecular mechanism underlying cell death and dysfunction after TBI and in the development of neuroprotective agents that will reduce morbidity and mortality. Methods: A review of recent literature on EPO, TBI, and apoptosis is conducted with analysis of pathophysiologic mechanisms of TBI. In addition, animal experiments and clinical trials pertaining to mechanisms of cell death in TBI and EPO as a neuroprotective agent are reviewed. Conclusion: The literature and evidence for EPO as a potent inhibitor of apoptosis and promising therapeutic agent in a variety of neurological insults, including trauma, are mounting. With the recent interest in clinical trials of EPO in human stroke, it is both timely and Prudent to consider the use of this pharmaceutical avenue in TBI in man, (C) 2009 Elsevier Inc. All rights reserved.	[Mammis, Antonios; Mclntosh, Tracy K.; Maniker, Allen H.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurosurg, Newark, NJ 07103 USA		Mammis, A (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurosurg, 185 S Orange Ave, Newark, NJ 07103 USA.	mammisan@umdnj.edu		Mammis, Antonios/0000-0003-0892-9888			Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Baciu I, 2000, Rom J Physiol, V37, P3; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chen G, 2007, NEUROSCI LETT, V425, P177, DOI 10.1016/j.neulet.2007.08.022; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Dressler J, 2007, INT J LEGAL MED, V121, P365, DOI 10.1007/s00414-006-0126-6; Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200; Erbayraktar S, 2003, P NATL ACAD SCI USA, V100, P6741, DOI 10.1073/pnas.1031753100; Fisher JW, 2003, EXP BIOL MED, V228, P1; Ghezzi P, 2004, CELL DEATH DIFFER, V11, pS37, DOI 10.1038/sj.cdd.4401450; Graham D.I., 1996, NEUROTRAUMA, P43; Grasso G, 2007, BRAIN RES, V1182, P99, DOI 10.1016/j.brainres.2007.08.078; Hasselblatt M, 2006, J NEUROSURG ANESTH, V18, P132, DOI 10.1097/00008506-200604000-00007; Junk AK, 2002, P NATL ACAD SCI USA, V99, P10659, DOI 10.1073/pnas.152321399; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Larner SF, 2005, J NEUROCHEM, V94, P97, DOI 10.1111/j.1471-4159.2005.03172.x; Larner SF, 2004, J NEUROCHEM, V88, P78, DOI 10.1046/j.1471-4159.2003.02141.x; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liao ZB, 2008, EUR J NEUROL, V15, P140, DOI 10.1111/j.1468-1331.2007.02013.x; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Luo Chun, 2002, Chin J Traumatol, V5, P299; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; Marti HH, 2004, J EXP BIOL, V207, P3233, DOI 10.1242/jeb.01049; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; *NAT CTR INJ PREV, 2001, INJ FACT BOOK 2001 2, P1; Noguchi CT, 2007, CRIT REV ONCOL HEMAT, V64, P159, DOI 10.1016/j.critrevonc.2007.03.001; O'Dell DM, 2000, J NEUROSCI, V20, P4821; Ozisik PA, 2007, SURG NEUROL, V68, P547, DOI 10.1016/j.surneu.2007.01.030; Ozturk E, 2005, PROG NEURO-PSYCHOPH, V29, P920, DOI 10.1016/j.pnpbp.2005.04.028; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Savitz SI, 1998, NEUROSURGERY, V42, P555, DOI 10.1097/00006123-199803000-00026; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Verdonck O, 2007, J CEREBR BLOOD F MET, V27, P1369, DOI 10.1038/sj.jcbfm.9600443; Villa P, 2007, J CEREBR BLOOD F MET, V27, P552, DOI 10.1038/sj.jcbfm.9600370; Wen TC, 2002, J NEUROSCI RES, V67, P795, DOI 10.1002/jnr.10166; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhang XP, 2003, FASEB J, V17, P1367, DOI 10.1096/fj.02-1067fje	44	82	88	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0090-3019			SURG NEUROL	Surg. Neurol.	MAY	2009	71	5					527	531		10.1016/j.surneu.2008.02.040			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	439VR	WOS:000265656000005	18789503				2022-02-06	
J	Fujita, T; Tozaki-Saitoh, H; Inoue, K				Fujita, Takumi; Tozaki-Saitoh, Hidetoshi; Inoue, Kazuhide			P2Y(1) Receptor Signaling Enhances Neuroprotection by Astrocytes Against Oxidative Stress via IL-6 Release in Hippocampal Cultures	GLIA			English	Article						adenosine triphosphate; cell survival; cytokines; cytoprotection; hippocampus	NECROSIS-FACTOR-ALPHA; FRESHLY ISOLATED ASTROCYTES; SPINAL-CORD-INJURY; ALZHEIMERS-DISEASE; PC12 CELLS; HYDROGEN-PEROXIDE; GROWTH-FACTOR; SYNAPTIC-TRANSMISSION; GLUTAMATE EXOCYTOSIS; INTERLEUKIN-6 IL-6	Cell survival is a critical issue in the onset and progression of neurodegenerative diseases and following pathological events including ischemia and traumatic brain injury. Oxidative stress is the main cause of cell damage in such pathological conditions. Here, we report that adenosine 5'-triphosphate (ATP) protects hippocampal astrocytes from hydrogen peroxide (H2O2)-evoked oxidative injury in astrocyte monocultures. The effect of ATP was prevented by a selective antagonist of or siRNAs against P2Y(1)R. Interestingly, in astrocyte-neuron cocultures, ATP also produced neuroprotective effects against H2O2-evoked neuronal cell death, whereas ATP did not produce any neuroprotective effects in monocultures. The ATP-induced neuroprotection in cocultures was completely inhibited by silencing of astrocytic P2Y(1)R expression, indicating that ATP acts on astrocytes and enhances their neuroprotective functions by activating P2Y(1)R. Furthermore, this neuroprotective effect was mimicked by applying conditioned medium from astrocytes that had been stimulated by ATP, implying an involvement of diffusible factors from astrocytes. We found that, in both purified astrocyte cultures and astrocyte-neuronal cocultures, ATP and the P2Y(1)R agonist 2-methylthioadenosine 5' diphosphate (2MeSADP) induced the release of interleukin-6 (IL-6), but this did not occur in neuron monocultures. Moreover, exogenous IL-6 produced a neuroprotective effect, and the neuroprotection induced by P2Y(1)R-stimulated astrocytes was prevented in the presence of an anti-IL-6 antibody. Taken together, these results suggest that P2Y(1)R-stimulated astrocytes protect against neuronal damage induced by oxidative stress, and that IL-6 is a crucial signaling molecule released from astrocytes. Thus, activation of P2Y(1)R in astrocytes may rescue neurons from secondary cell death under pathological conditions. (C) 2008 Wiley-Liss, Inc.	[Inoue, Kazuhide] Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Mol & Syst Pharmacol, Higashi Ku, Fukuoka 8128582, Japan		Inoue, K (corresponding author), Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Mol & Syst Pharmacol, Higashi Ku, 3-1-1 Maidashi Collabostn 11-Rm 410, Fukuoka 8128582, Japan.	inoue@phar.kyushu-u.ac.jp		, hidetoshi/0000-0003-0423-2143	Ministry of Education, Science, Sports and Culture of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)	Grant sponsor: Ministry of Education, Science, Sports and Culture of Japan.	Abbracchio MP, 1999, PROG BRAIN RES, V120, P333; Abe K, 1996, J NEUROCHEM, V67, P2074; AGARDH CD, 1991, INT J DEV NEUROSCI, V9, P127, DOI 10.1016/0736-5748(91)90003-5; Aihara H, 2002, BRAIN RES, V952, P31, DOI 10.1016/S0006-8993(02)03185-2; Amadio S, 2002, NEUROPHARMACOLOGY, V42, P489, DOI 10.1016/S0028-3908(01)00197-6; Arthur DB, 2007, J NEUROCHEM, V100, P1257, DOI 10.1111/j.1471-4159.2006.04305.x; Arthur DB, 2006, J NEUROSCI, V26, P3798, DOI 10.1523/JNEUROSCI.5338-05.2006; BANKER GA, 1980, SCIENCE, V209, P809, DOI 10.1126/science.7403847; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Belliveau DJ, 2006, J BIOL CHEM, V281, P20920, DOI 10.1074/jbc.M600026200; Benjelloun N, 1998, CELL MOL BIOL, V44, P579; Bennett GC, 2003, BRIT J PHARMACOL, V139, P279, DOI 10.1038/sj.bjp.0705242; BENVENISTE EN, 1990, J NEUROIMMUNOL, V30, P201, DOI 10.1016/0165-5728(90)90104-U; Bezzi P, 2001, CURR OPIN NEUROBIOL, V11, P387, DOI 10.1016/S0959-4388(00)00223-3; Bissonnette CJ, 2004, NEUROSCI LETT, V361, P40, DOI 10.1016/j.neulet.2004.01.005; Bowser DN, 2004, J NEUROSCI, V24, P8606, DOI 10.1523/JNEUROSCI.2660-04.2004; Burnstock G, 2004, CURR TOP MED CHEM, V4, P793, DOI 10.2174/1568026043451014; Burnstock G, 2007, PHYSIOL REV, V87, P659, DOI 10.1152/physrev.00043.2006; Carlson NG, 1999, J IMMUNOL, V163, P3963; Chen WC, 1998, GLIA, V22, P360, DOI 10.1002/(SICI)1098-1136(199804)22:4<360::AID-GLIA5>3.0.CO;2-7; Cheung KK, 2003, DEV DYNAM, V228, P254, DOI 10.1002/dvdy.10378; Cuajungco MP, 2000, J BIOL CHEM, V275, P19439, DOI 10.1074/jbc.C000165200; D'Ambrosi N, 2001, NEUROSCIENCE, V108, P527, DOI 10.1016/S0306-4522(01)00431-6; delaMonte SM, 1997, J NEUROL SCI, V152, P73, DOI 10.1016/S0022-510X(97)00131-7; Desagher S, 1996, J NEUROSCI, V16, P2553; Domercq M, 2006, J BIOL CHEM, V281, P30684, DOI 10.1074/jbc.M606429200; Fiebich BL, 2005, NEUROCHEM INT, V46, P501, DOI 10.1016/j.neuint.2004.11.009; Fiebich BL, 1996, J NEUROCHEM, V66, P1426; Fields RD, 2006, NAT REV NEUROSCI, V7, P423, DOI 10.1038/nrn1928; Franke H, 1999, GLIA, V28, P190, DOI 10.1002/(SICI)1098-1136(199912)28:3<190::AID-GLIA3>3.3.CO;2-S; Franke H, 2006, PHARMACOL THERAPEUT, V109, P297, DOI 10.1016/j.pharmthera.2005.06.002; FUKUDA J, 1983, J NEUROSCI METH, V8, P295, DOI 10.1016/0165-0270(83)90042-0; Giffard RG, 2005, GLIA, V50, P299, DOI 10.1002/glia.20167; Guthrie PB, 1999, J NEUROSCI, V19, P520, DOI 10.1523/jneurosci.19-02-00520.1999; Heine C, 2006, NEUROSCIENCE, V138, P303, DOI 10.1016/j.neuroscience.2005.11.056; Herpers BL, 1999, NEUROREPORT, V10, P2647, DOI 10.1097/00001756-199908200-00038; Hirota H, 1996, J EXP MED, V183, P2627, DOI 10.1084/jem.183.6.2627; Inoue K, 1999, PROG BRAIN RES, V120, P193; Jourdain P, 2007, NAT NEUROSCI, V10, P331, DOI 10.1038/nn1849; Kawamura M, 2004, J NEUROSCI, V24, P10835, DOI 10.1523/JNEUROSCI.3028-04.2004; Khakh BS, 2001, NAT REV NEUROSCI, V2, P165, DOI 10.1038/35058521; Koizumi S, 2003, P NATL ACAD SCI USA, V100, P11023, DOI 10.1073/pnas.1834448100; Koizumi Schuichi, 2004, Nihon Yakurigaku Zasshi, V123, P389; Lin JHC, 2007, DEV BIOL, V302, P356, DOI 10.1016/j.ydbio.2006.09.017; Liu JSH, 2000, J NEUROSCI, V20, P5292, DOI 10.1523/JNEUROSCI.20-14-05292.2000; Loddick SA, 1998, J CEREBR BLOOD F MET, V18, P176, DOI 10.1097/00004647-199802000-00008; Matsuda S, 1996, NEUROSCI LETT, V204, P109, DOI 10.1016/0304-3940(96)12340-5; Mattson MP, 1997, BRAIN RES REV, V23, P47, DOI 10.1016/S0165-0173(96)00014-8; MATTSON MP, 1990, INT J DEV NEUROSCI, V8, P399, DOI 10.1016/0736-5748(90)90073-B; Mattson MP, 1996, NEUROBIOL AGING, V17, P485, DOI 10.1016/0197-4580(96)00016-4; Moran-Jimenez MJ, 2000, MOL BRAIN RES, V78, P50, DOI 10.1016/S0169-328X(00)00067-X; Nakajima A, 2002, FREE RADICAL BIO MED, V32, P1324, DOI 10.1016/S0891-5849(02)00845-6; Neary JT, 2004, NEUROCHEM RES, V29, P2037, DOI 10.1007/s11064-004-6876-y; Neary JT, 1996, TRENDS NEUROSCI, V19, P13, DOI 10.1016/0166-2236(96)81861-3; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NORRIS JG, 1994, J IMMUNOL, V152, P841; Novak I, 2003, NEWS PHYSIOL SCI, V18, P12, DOI 10.1152/nips.01409.2002; Pavelko KD, 2003, J NEUROSCI, V23, P481, DOI 10.1523/JNEUROSCI.23-02-00481.2003; PEARCE B, 1994, BRAIN RES, V660, P329, DOI 10.1016/0006-8993(94)91307-2; Peng YP, 2005, NEUROSCI LETT, V374, P192, DOI 10.1016/j.neulet.2004.10.069; Penkowa M, 2000, GLIA, V32, P271, DOI 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5; Petito CK, 1998, J NEUROPATH EXP NEUR, V57, P231, DOI 10.1097/00005072-199803000-00004; Pizzi M, 2004, MOL CELL NEUROSCI, V25, P301, DOI 10.1016/j.mcn.2003.10.022; Pousset F, 1999, GLIA, V26, P12, DOI 10.1002/(SICI)1098-1136(199903)26:1<12::AID-GLIA2>3.0.CO;2-S; Ralevic V, 1998, PHARMACOL REV, V50, P413; Rathbone MP, 1999, PROG NEUROBIOL, V59, P663, DOI 10.1016/S0301-0082(99)00017-9; Ryu JK, 2002, NEUROREPORT, V13, P1611, DOI 10.1097/00001756-200209160-00008; Shinozaki Y, 2005, GLIA, V49, P288, DOI 10.1002/glia.20118; Tabner BJ, 2002, FREE RADICAL BIO MED, V32, P1076, DOI 10.1016/S0891-5849(02)00801-8; Tabner Brian J., 2001, Current Topics in Medicinal Chemistry, V1, P507, DOI 10.2174/1568026013394822; Takuma K, 2004, PROG NEUROBIOL, V72, P111, DOI 10.1016/j.pneurobio.2004.02.001; Tanaka J, 1999, GLIA, V28, P85, DOI 10.1002/(SICI)1098-1136(199911)28:2<85::AID-GLIA1>3.0.CO;2-Y; TWENTYMAN PR, 1987, BRIT J CANCER, V56, P279, DOI 10.1038/bjc.1987.190; Van Wagoner NJ, 1999, J NEUROSCI, V19, P5236; Van Wagoner NJ, 1999, J NEUROIMMUNOL, V100, P124, DOI 10.1016/S0165-5728(99)00187-3; Volonte C, 2003, CNS NEUROL DISORD-DR, V2, P403, DOI 10.2174/1568007033482643; Volterra A, 2005, NAT REV NEUROSCI, V6, P626, DOI 10.1038/nrn1722; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; Yamada K, 1997, BRAIN RES BULL, V43, P573, DOI 10.1016/S0361-9230(96)00336-X; YAMADA M, 1994, BRAIN RES, V643, P173, DOI 10.1016/0006-8993(94)90023-X; Zhu YZ, 2004, DEV BRAIN RES, V148, P77, DOI 10.1016/j.devbrainres.2003.10.014; Zhu YZ, 2001, J NEUROCHEM, V77, P530, DOI 10.1046/j.1471-4159.2001.00241.x	82	82	84	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	FEB	2009	57	3					244	257		10.1002/glia.20749			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	392BF	WOS:000262277200002	18756525				2022-02-06	
J	Jin, W; Wang, HD; Yan, W; Zhu, L; Hu, ZG; Ding, YS; Tang, K				Jin, Wei; Wang, Handong; Yan, Wei; Zhu, Lin; Hu, Zhigang; Ding, Yasuo; Tang, Ke			Role of Nrf2 in Protection against Traumatic Brain Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						inflammation; nuclear factor erythroid 2-related factor 2; oxidative stress; traumatic brain injury	CEREBRAL-ISCHEMIA; ENHANCES SUSCEPTIBILITY; NRF2-DEFICIENT MICE; OXIDATIVE STRESS; IN-VIVO; EXPRESSION; PATHWAY; ANTIOXIDANTS; INDUCTION; REDUCTASE	Previous studies have shown that nuclear factor erythroid 2-related factor 2 (Nrf2) plays a unique role in many physiological stress processes. The present study investigated the role of Nrf2 in modulating traumatic brain injury (TBI)-induced secondary brain injury. Wild-type Nrf2 (+/+) and Nrf2 (-/-)-deficient mice were subjected to a moderately severe weight-drop impact head injury. The absence of Nrf2 function in mice resulted in exacerbated brain injury as shown by the increased severity of neurological deficit, apoptosis, and brain edema at 24 h after TBI. This exacerbation of brain injury in Nrf2-deficient mice was associated with increased mRNA and protein expression of inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), and interleukin-6 (IL-6), and with decreased mRNA expression and enzymatic activity of antioxidant and detoxifying enzymes including NAD(P) H: quinone oxidoreductase 1 (NQO1) and glutathione S-transferase alpha-1 (GST-alpha 1), compared with their wild-type counterparts after TBI. In combination, these results suggest that Nrf2 plays an important role in protecting TBI-induced secondary brain injury, possibly by regulating inflammatory cytokines and inducing antioxidant and detoxifying enzymes.	[Jin, Wei; Wang, Handong; Zhu, Lin; Hu, Zhigang; Ding, Yasuo; Tang, Ke] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu Prov, Peoples R China; [Yan, Wei] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou 310003, Zhejiang, Peoples R China		Wang, HD (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu Prov, Peoples R China.	hdwang_jw@yahoo.com.cn		Yan, Wei/0000-0002-1123-0835	Jinling Hospital of Nanjing, China	This work was supported by grants from Jinling Hospital of Nanjing, China. The authors would like to thank Dr. Bo Wu and Dr. Geng-bao Feng for technical assistance.	Bayir H, 2006, DEV NEUROSCI-BASEL, V28, P420, DOI 10.1159/000094168; Beaumont A, 2002, ACT NEUR S, V81, P217; BENSON AM, 1980, P NATL ACAD SCI-BIOL, V77, P5216, DOI 10.1073/pnas.77.9.5216; Bramlett HM, 1999, J NEUROTRAUM, V16, P1035, DOI 10.1089/neu.1999.16.1035; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; Chen XL, 2004, CURR PHARM DESIGN, V10, P879, DOI 10.2174/1381612043452901; Chesnut Randall M., 1997, Emergency Medicine Clinics of North America, V15, P581, DOI 10.1016/S0733-8627(05)70319-9; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Hellal F, 2004, NEUROSCI LETT, V357, P21, DOI 10.1016/j.neulet.2003.12.036; Hutchison JS, 2001, J NEUROTRAUM, V18, P1333, DOI 10.1089/08977150152725632; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jain AK, 2005, J BIOL CHEM, V280, P29158, DOI 10.1074/jbc.M502083200; Kelly VP, 2000, CANCER RES, V60, P957; Khor TO, 2006, CANCER RES, V66, P11580, DOI 10.1158/0008-5472.CAN-06-3562; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Laxton AW, 2001, NEUROREPORT, V12, P1045, DOI 10.1097/00001756-200104170-00036; Lee JM, 2005, FASEB J, V19, P1061, DOI 10.1096/fj.04-2591hyp; Lee JM, 2004, J BIOCHEM MOL BIOL, V37, P139; Lee JM, 2003, J BIOL CHEM, V278, P37948, DOI 10.1074/jbc.M305204200; Mikrogianakis A, 2007, J NEUROTRAUM, V24, P338, DOI 10.1089/neu.2006.003615; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Naga KK, 2007, NEUROL RES, V29, P877, DOI 10.1179/016164107X181842; Osburn WO, 2007, INT J CANCER, V121, P1883, DOI 10.1002/ijc.22943; Osburn WO, 2006, ARCH BIOCHEM BIOPHYS, V454, P7, DOI 10.1016/j.abb.2006.08.005; Owuor ED, 2002, BIOCHEM PHARMACOL, V64, P765, DOI 10.1016/S0006-2952(02)01137-1; Park HK, 1999, CRIT REV NEUROSURG, V9, P44, DOI 10.1007/s003290050108; Ramsey CP, 2007, J NEUROPATH EXP NEUR, V66, P75, DOI 10.1097/nen.0b013e31802d6da9; Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538; Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146; RIINK A, 1995, AM J PATHOL, V147, P1575; Shah ZA, 2007, NEUROSCIENCE, V147, P53, DOI 10.1016/j.neuroscience.2007.02.066; Shih AY, 2005, J NEUROSCI, V25, P10321, DOI 10.1523/JNEUROSCI.4014-05.2005; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Smeyne M, 2007, P NATL ACAD SCI USA, V104, P1977, DOI 10.1073/pnas.0610978104; Stringer JL, 2004, J COMP NEUROL, V471, P289, DOI 10.1002/cne.20048; Thimmulappa RK, 2006, J CLIN INVEST, V116, P984, DOI 10.1172/JCI25790; van Muiswinkel FL, 2005, CNS NEUROL DISORD-DR, V4, P267, DOI 10.2174/1568007054038238; Wang JA, 2007, FREE RADICAL BIO MED, V43, P408, DOI 10.1016/j.freeradbiomed.2007.04.020; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649	45	82	87	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2009	26	1					131	139		10.1089/neu.2008.0655			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	409OW	WOS:000263516700011	19125683				2022-02-06	
J	Till, C; Colella, B; Verwegen, J; Green, RE				Till, Christine; Colella, Brenda; Verwegen, Joel; Green, Robin E.			Postrecovery Cognitive Decline in Adults With Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Cognition; Follow-up studies; Neuropsychological tests; Recovery of function; Rehabilitation	SEVERE HEAD-INJURY; NEUROPSYCHOLOGICAL RECOVERY; INFLAMMATORY RESPONSE; ALZHEIMER-DISEASE; AGED BRAIN; FOLLOW-UP; PLASTICITY; MEMORY; REHABILITATION; PERFORMANCE	Objective: To assess prospectively the degree of postrecovery long-term cognitive decline after moderate to severe traumatic brain injury (TBI). Design: Observational cohort. Setting: Inpatient rehabilitation hospital. Participants: Adults (N=33) with moderate and severe TB I from a well characterized sample with low attrition: Interventions: Not applicable. Main Outcome Measures: Recovery of functioning was ascertained through repeat neuropsychological assessments over the first 5 years postinjury. Cognitive decline from a baseline of 12 months postinjury to a follow-up evaluation conducted on average +/- SD 2.1 +/- 0.99 years later. Change was calculated using the reliable change index (RCI) for 12 neuropsychological tests commonly used in the assessment of TBI. Results: At the group level, negligible changes in cognitive function were observed over tune. However, application of the RCI using 90% confidence intervals showed statistically significant cognitive decline on at least 2 neuropsychological measures in 27.3% of study participants. Decline was most commonly observed on a test of verbal fluency and the delayed recall portion of a test of verbal list learning (Rey Auditory Verbal Learning Test), although substantial variability existed across patients. Decline was significantly correlated with hours of therapy received at 5 months postinjury (P<.02). Conclusions: Consistent with a small number of previous studies, cognitive deterioration may follow an initial period of recovery. Overall, the pattern of decline across tests varied across individuals. Possible mechanisms of decline are discussed. Further research is needed to understand the stability of this finding and its functional implications.	[Till, Christine; Verwegen, Joel; Green, Robin E.] Toronto Rehabil Inst, Toronto, ON, Canada; [Green, Robin E.] Univ Toronto, Dept Rehabil Sci, Toronto, ON, Canada		Till, C (corresponding author), York Univ, Dept Psychol, 4700 Keele St, N York, ON M3J 1P3, Canada.	ctill@yorku.ca	Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146; Green, Robin/0000-0001-9451-3963; Till, Christine/0000-0001-5030-3155	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [MOP-67072]; Physicians' Services Incorporated [05-50]; Ontario Mental Health Foundation.	Supported by the Canadian Institutes of Health Research (grant no. MOP-67072), Physicians' Services Incorporated (grant no. 05-50), and the Ontario Mental Health Foundation.	Basso MR, 2001, CLIN NEUROPSYCHOL, V15, P471, DOI 10.1076/clin.15.4.471.1883; Bayona Nestor A, 2005, Top Stroke Rehabil, V12, P27; Beck A. T., 1996, MANUAL BECK DEPRESSI, VII; Beck AT, 1993, BECK ANXIETY INVENTO; Benton A., 1978, MULTILINGUAL APHASIA; Bigler ED, 1996, BRAIN INJURY, V10, P197, DOI 10.1080/026990596124511; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Brooks D N, 1979, Int Rehabil Med, V1, P166; Burton CL, 2002, CLIN NEUROPSYCHOL, V16, P264, DOI 10.1076/clin.16.3.264.13854; BUTTERS N, 1985, J CLIN EXP NEUROPSYC, V7, P181, DOI 10.1080/01688638508401252; Chu BC, 2007, J CLIN EXP NEUROPSYC, V29, P617, DOI 10.1080/13803390600878893; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Cohen J., 1983, APPL MULTIPLE REGRES; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; Dancause N, 2006, J NEUROPHYSIOL, V96, P3506, DOI 10.1152/jn.00792.2006; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Ferrer E, 2004, PSYCHOL AGING, V19, P243, DOI 10.1037/0882-7974.19.2.243; FRANCIS DJ, 1991, J CONSULT CLIN PSYCH, V59, P27, DOI 10.1037/0022-006X.59.1.27; Frost SB, 2003, J NEUROPHYSIOL, V89, P3205, DOI 10.1152/jn.01143.2002; GEFFEN GM, 1994, ARCH CLIN NEUROPSYCH, V9, P303, DOI 10.1016/0887-6177(94)90018-3; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Heaton RK, 1992, COMPREHENSIVE NORMS; Helzner EP, 2007, ARCH NEUROL-CHICAGO, V64, P1749, DOI 10.1001/archneur.64.12.1749; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hinkebein JH, 2003, BRAIN INJURY, V17, P1035, DOI 10.1080/0269905031000110490; HOLLINGSHEAD AB, 1975, 4 FACTORS SOCIAL STA; Isoniemi H, 2006, J NEUROTRAUM, V23, P1600, DOI 10.1089/neu.2006.23.1600; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Jones AS, 2007, J STUD ALCOHOL DRUGS, V68, P266, DOI 10.15288/jsad.2007.68.266; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Kim H, 2006, CAN J NEUROL SCI, V33, P48, DOI 10.1017/S0317167100004686; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Lange RT, 2007, NEUROPSYCHOLOGY, V21, P590, DOI 10.1037/0894-4105.21.5.590; Levine AJ, 2004, CLIN NEUROPSYCHOL, V18, P373, DOI 10.1080/1385404049052420; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Mahncke HW, 2006, PROG BRAIN RES, V157, P81, DOI 10.1016/S0079-6123(06)57006-2; Mahncke HW, 2006, P NATL ACAD SCI USA, V103, P12523, DOI 10.1073/pnas.0605194103; MANDLEBERG IA, 1976, J NEUROL NEUROSUR PS, V39, P1001, DOI 10.1136/jnnp.39.10.1001; Mateer CA, 2000, BRAIN COGNITION, V42, P106, DOI 10.1006/brcg.1999.1175; Mauri M, 2006, FUNCT NEUROL, V21, P223; Millis S R, 1994, Int J Neurosci, V79, P165; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Morey, 1991, PERSONALITY ASSESSME; Novack TA, 2000, BRAIN INJURY, V14, P987; Nudo Randolph J, 2006, NeuroRx, V3, P420; Nudo RJ, 2007, STROKE, V38, P840, DOI 10.1161/01.STR.0000247943.12887.d2; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Petcu EB, 2008, GERONTOLOGY, V54, P6, DOI 10.1159/000112845; Popa-Wagner A, 2007, CURR NEUROVASC RES, V4, P216; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; RUFF RM, 1991, J NEUROSURG, V75, pS50, DOI 10.3171/sup.1991.75.1s.0s50; Salmond CH, 2006, NEUROPSYCHOLOGIA, V44, P1995, DOI 10.1016/j.neuropsychologia.2006.03.013; SALTHOUSE TA, 1991, PSYCHOL AGING, V6, P118, DOI 10.1037/0882-7974.6.1.118; Sander AM, 2001, J HEAD TRAUMA REHAB, V16, P356, DOI 10.1097/00001199-200108000-00006; Sankoh AJ, 1997, STAT MED, V16, P2529, DOI 10.1002/(SICI)1097-0258(19971130)16:22<2529::AID-SIM692>3.0.CO;2-J; Sawrie S M, 1996, J Int Neuropsychol Soc, V2, P556; Scarmeas Nikolaos, 2004, Curr Neurol Neurosci Rep, V4, P374, DOI 10.1007/s11910-004-0084-7; Schmidt M., 1996, REY AUDITORY VERBAL; Schmidt OI, 2007, ORTHOPADE, V36, P248, DOI 10.1007/s00132-007-1061-z; Smith A., 1982, SYMBOL DIGIT MODALIT; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Spreen O., 1989, CLIN NEUROPSYCHOL, V3, P129, DOI [10.1080/13854048908403285, DOI 10.1080/13854048908403285]; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; TEASDALE G, 1974, LANCET, V2, P81; Tombough T., 1996, TEST MEMORY MALINGER; TURNER GR, NEUROPSYCHO IN PRESS; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Wechsler D., 2011, WECHSLER ABBREVIATED; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WechslerD, 2001, WECHSLER TEST ADULT; Whiteneck GG, 2004, J HEAD TRAUMA REHAB, V19, P191, DOI 10.1097/00001199-200405000-00001; Wilson RS, 2007, NEUROLOGY, V69, P1911, DOI 10.1212/01.wnl.0000271087.67782.cb; WONT PP, 2001, BRAIN INJURY, V15, P519; Yager JY, 2006, BEHAV BRAIN RES, V173, P171, DOI 10.1016/j.bbr.2006.06.019	83	82	88	0	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2008	89	12		2			S25	S34		10.1016/j.apmr.2008.07.004			10	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	388DB	WOS:000261999400004	19081438				2022-02-06	
J	Schreiber, S; Barkai, G; Gur-Hartman, T; Peles, E; Tov, N; Dolberg, OT; Pick, CG				Schreiber, Shaul; Barkai, Gabriel; Gur-Hartman, Tamar; Peles, Einat; Tov, Naveh; Dolberg, Ornah T.; Pick, Chaim G.			Long-lasting sleep patterns of adult patients with minor traumatic brain injury (mTBI) and non-mTBI subjects	SLEEP MEDICINE			English	Article						adults; minor traumatic brain injury (mTBI); multiple sleep latency test (MSLT); polysomnography (PSG)	HEAD-INJURY; COGNITIVE IMPAIRMENT; MEMORY CONSOLIDATION; PHASE SYNDROME; DISTURBANCES; COMPLAINTS; RECOVERY; INSOMNIA; MICE; REM	Background: Sleep disturbance is a common subjective complaint of minor traumatic brain-injured (mTBI) patients, but little is known about the characteristics of sleep disturbance in adults years after the injury. Methods: Polysomnographic (PSG) and multiple sleep latency test (MSLT) records of 26 mTBI adult patients with normal brain computerized tomography and negative encephalographic studies, no past history of CNS pathology, no premorbid or present major psychiatric diagnosis, and no sleep apnea syndrome were compared to a matched group of apparently healthy individuals (controls). Results: Sleep patterns were disturbed in the mTBI patients. Their sleep architecture was altered, with significantly higher light-sleep non-rapid eye movement (NREM) stage 2 scores compared to controls (54.5 +/- 13.4% vs. 46.6 +/- 10.40/0, respectively, p = 0.03) and significantly lower REM sleep scores (21.2 +/- 18.4% vs. 25.4 +/- 4.5%, respectively, p = 0.05). The MSLT findings documented significant excessive daytime episodes of falling asleep. Conclusions: Sleep disturbances of adult patients with chronic mTBI may manifest characteristic alterations in both timing and architecture of their sleep patterns. Sleep lab evaluations may help identify subgroups of mTBI patients who would probably benefit from treatment. (C) 2007 Elsevier B.V. All rights reserved.	[Schreiber, Shaul; Barkai, Gabriel; Dolberg, Ornah T.] Tel Aviv Sourasky Med Ctr, Dept Psychiat, IL-64239 Tel Aviv, Israel; [Schreiber, Shaul; Barkai, Gabriel; Dolberg, Ornah T.] Tel Aviv Univ, Sackler Fac Med, IL-64239 Tel Aviv, Israel; [Schreiber, Shaul; Barkai, Gabriel; Dolberg, Ornah T.] Neuropsychol Unit Treatment & Rehabil, Tel Aviv, Israel; [Schreiber, Shaul; Barkai, Gabriel; Dolberg, Ornah T.] Neuropsychol Unit Treatment & Rehabil, Jerusalem, Israel; [Gur-Hartman, Tamar; Pick, Chaim G.] Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Peles, Einat] Tel Aviv Sourasky Med Ctr, Dr Miriam & Sheldon G Adelson Clin Drug Abuse Tre, IL-64239 Tel Aviv, Israel; [Tov, Naveh] Bnai Zion Med Ctr, Dept Internal Med C, Haifa, Israel		Schreiber, S (corresponding author), Tel Aviv Sourasky Med Ctr, Dept Psychiat, IL-64239 Tel Aviv, Israel.	Shaldsch@tasmc.health.gov.il	Pick, Chaim/D-4789-2009; Schreiber, Shaul/E-5821-2010; Sanguansri, Luz/B-6630-2011	Schreiber, Shaul/0000-0002-2189-0693; Sanguansri, Luz/0000-0003-1908-7604			ALEXANDRIA VA, 2005, BRAIN INJ FACTS; Antoniadis EA, 2000, BEHAV BRAIN RES, V114, P219, DOI 10.1016/S0166-4328(00)00290-4; ARMITAGE R, 1995, SLEEP, V18, P334, DOI 10.1093/sleep/18.5.334; AUTRET A, 1990, PRESSE MED, V19, P1833; Autret A, 2001, NEUROPHYSIOL CLIN, V31, P356, DOI 10.1016/S0987-7053(01)00282-9; BEETAR J, 1996, AM J PHYS MED REHABI, V75, P63; Bonnet MH, 2003, SLEEP MED REV, V7, P297, DOI 10.1053/smrv.2001.0245; CARSKADON MA, 1986, SLEEP, V9, P519, DOI 10.1093/sleep/9.4.519; Carskadon MA, 1994, PRINCIPLES PRACTICE; *CDCP, 2001, TRAUM BRAI INJ US RE; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; CZEISLER CA, 1980, SCIENCE, V210, P1264, DOI 10.1126/science.7434029; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Finset A, 1999, PSYCHOSOM MED, V61, P576, DOI 10.1097/00006842-199907000-00024; Francisco GE, 1996, AM J PHYS MED REHAB, V75, P63, DOI 10.1097/00002060-199601000-00016; GEORGE B, 1981, NEUROCHIRURGIE, V27, P35; Guilleminault C, 2000, NEUROLOGY, V54, P653, DOI 10.1212/WNL.54.3.653; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; KAUFMAN DM, 1995, CLIN NEUROLOGY PSYCH; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; LENARD HG, 1970, ACTA PAEDIATR SCAND, V59, P565, DOI 10.1111/j.1651-2227.1970.tb16809.x; Maeda M, 1995, Rinsho Shinkeigaku, V35, P811; Maquet P, 2001, SCIENCE, V294, P1048, DOI 10.1126/science.1062856; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Nagtegaal JE, 1997, FUNCT NEUROL, V12, P345; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; PATTEN SB, 1992, J AM ACAD CHILD PSY, V31, P100, DOI 10.1097/00004583-199201000-00015; PELED R, 1999, HAREFUAH, V137, P432; Perlis ML, 1997, PERCEPT MOTOR SKILL, V84, P595, DOI 10.2466/pms.1997.84.2.595; PRIGATANO GP, 1982, J NEUROL NEUROSUR PS, V45, P78, DOI 10.1136/jnnp.45.1.78; RECHTSCHALTEN A, 1968, NIH PUBLICATION, V204; REGESTEIN QR, 1995, AM J PSYCHIAT, V152, P602; RON S, 1980, ELECTROEN CLIN NEURO, V48, P432, DOI 10.1016/0013-4694(80)90135-2; Rosenthal L, 2005, SLEEP MED, V6, P485, DOI 10.1016/j.sleep.2005.05.012; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; SCHREIBER S, 1998, J NEUROPSYCHIATRY CL, V9, P640; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; Siegel JM, 2001, SCIENCE, V294, P1058, DOI 10.1126/science.1063049; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; TRONCOSO JC, 1996, HEAD INJURY POSTCONC; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Vertes RP, 2004, NEURON, V44, P135, DOI 10.1016/j.neuron.2004.08.034; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	48	82	83	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1389-9457	1878-5506		SLEEP MED	Sleep Med.	JUL	2008	9	5					481	487		10.1016/j.sleep.2007.04.014			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	330BA	WOS:000257913100004	17638592				2022-02-06	
J	Field, S; Treleaven, J; Jull, G				Field, Sandra; Treleaven, Julia; Jull, Gwendolen			Standing balance: A comparison between idiopathic and whiplash-induced neck pain	MANUAL THERAPY			English	Article						balance; whiplash; neck pain; proprioception; wavelet analysis; RMS	SUSPECTED CERVICAL ORIGIN; POSTURAL CONTROL; DYNAMIC POSTUROGRAPHY; PERSISTENT WHIPLASH; VESTIBULAR LOSS; MILD HEAD; STABILITY; DISORDERS; INJURY; DIZZINESS	Disturbances of balance have been found both in patients with whiplash-associated disorders and idiopathic neck pain. This study directly compared balance between these groups to determine if neck pain precipitated by trauma resulted in greater or different balance impairments. The study was a comparative, observational design. Thirty subjects with whiplash, 30 with idiopathic neck pain and 30 healthy controls, took part in the study. Subjects performed balance tests in comfortable, narrow and tandem stances. Balance disturbances (sway energy and/or root mean squared (RMS) amplitude) were evident in several tests between subjects with neck pain and controls. Direct comparison between the neck pain groups revealed that the whiplash group had significantly greater sway energy and RMS amplitude than the idiopathic group in comfortable stance tests on a soft surface (F > 4.4, p < 0.04). Further, the whiplash group had greater RMS, but significantly less sway energy than the idiopathic group in most narrow stance tests in the anterior posterior direction F > 5.8, p < 0.02). Both neck pain groups were also significantly less able to complete the eyes closed, tandem test compared to control subjects. In conclusion, the study has found that balance deficits exist in both subjects with whiplash-associated disorders and idiopathic neck pain compared to controls; however, differences in balance strategies may exist between the neck pain groups. Overall, subjects who have experienced trauma appear to have greater balance disturbances. (c) 2007 Elsevier Ltd. All rights reserved.	[Field, Sandra; Treleaven, Julia; Jull, Gwendolen] Univ Queensland, Sch Hlth & Rehabil Sci, Div Physiotherapy, Brisbane, Qld 4072, Australia		Treleaven, J (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Div Physiotherapy, Brisbane, Qld 4072, Australia.	j.treleaven@uq.edu.au	Treleaven, Julia/N-1379-2019; Treleaven, Julia M/F-8734-2010; Jull, Gwendolen/F-4233-2010	Treleaven, Julia/0000-0002-6258-3972; Treleaven, Julia M/0000-0002-6258-3972; Jull, Gwendolen/0000-0003-2670-1318			Ageberg Eva, 2002, J Electromyogr Kinesiol, V12, P205, DOI 10.1016/S1050-6411(02)00022-6; Allum JHJ, 2001, GAIT POSTURE, V14, P217, DOI 10.1016/S0966-6362(01)00142-4; ALUND M, 1991, ACTA OTO-LARYNGOL, P601; Alund M, 1993, J Vestib Res, V3, P383; Bove M, 2002, J NEUROPHYSIOL, V88, P2232, DOI 10.1152/jn.00198.2002; CHESTER JB, 1991, SPINE, V16, P716, DOI 10.1097/00007632-199107000-00004; Courtine G, 2003, NEUROREPORT, V14, P2365, DOI 10.1097/00001756-200312190-00015; Dault MC, 2001, GAIT POSTURE, V14, P248, DOI 10.1016/S0966-6362(01)00130-8; DEJONG PI, 1977, ANN NEUROL, P240; DELLAVOLPE R, 2005, GAIT POSTURE    1124; El-Kahky AM, 2000, ACTA OTO-LARYNGOL, V120, P508, DOI 10.1080/000164800750046018; Fattori B, 1996, ACUPUNCTURE ELECTRO, V21, P207, DOI 10.3727/036012996816356861; FISCHER AJEM, 1995, J NEUROL SCI, V132, P35, DOI 10.1016/0022-510X(95)00118-L; Gosselin G, 2004, CLIN BIOMECH, V19, P473, DOI 10.1016/j.clinbiomech.2004.02.001; Heikkila H, 1996, SCAND J REHABIL MED, V28, P133; HINOKI M, 1975, ACTA OTOLARYNGOL STO, V419, P9; HORAK FB, 1990, EXP BRAIN RES, V82, P167; Huskisson EE, 1983, VISUAL ANALOGUE SCAL, P33; Ishikawa K, 1998, ACTA OTO-LARYNGOL, P6; KARLBERG M, 1995, ACTA OTO-LARYNGOL, P440; Karlberg M, 1996, ARCH PHYS MED REHAB, V77, P874, DOI 10.1016/S0003-9993(96)90273-7; Karlberg M, 1996, J VESTIBUL RES-EQUIL, V6, P37; Kavounoudias A, 1999, EXP BRAIN RES, V124, P80, DOI 10.1007/s002210050602; Koskimies K, 1997, ACTA OTO-LARYNGOL, P95; Kristjansson E, 2003, CLIN REHABIL, V17, P768, DOI 10.1191/0269215503cr676oa; Le Pera D, 2001, CLIN NEUROPHYSIOL, V112, P1633, DOI 10.1016/S1388-2457(01)00631-9; Lekhel H, 1998, GAIT POSTURE, V7, P228, DOI 10.1016/S0966-6362(98)00012-5; MALLINSON AI, 1996, J MUSCULOSKELET PAIN, V4, P105, DOI DOI 10.1300/J094V04N04_10; MARTEAU T, 1992, BR J CLIN PSYCHOL, V3, P301; McIlroy WE, 1997, CLIN BIOMECH, V12, P66, DOI 10.1016/S0268-0033(96)00040-X; McPartland JM, 1997, J MANIP PHYSIOL THER, V20, P24; Michaelson P, 2003, J REHABIL MED, V35, P229, DOI 10.1080/16501970306093; NASHNER LM, 1990, NEUROL CLIN, V8, P331, DOI 10.1016/S0733-8619(18)30359-1; Persson L, 1996, J VESTIBUL RES-EQUIL, V6, P439; Peterson BW, 2004, PROG BRAIN RES, V143, P369, DOI 10.1016/S0079-6123(03)43035-5; Prieto TE, 1996, IEEE T BIO-MED ENG, V43, P956, DOI 10.1109/10.532130; Pyykko I, 1989, Acta Otolaryngol Suppl, V468, P175; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rocchi L, 2004, MED BIOL ENG COMPUT, V42, P71, DOI 10.1007/BF02351013; Rocchi L, 2002, J NEUROL NEUROSUR PS, V73, P267, DOI 10.1136/jnnp.73.3.267; RUBIN AM, 1995, AM J OTOL, V16, P216; Schieppati M, 2003, NEUROSCIENCE, V121, P277, DOI 10.1016/S0306-4522(03)00439-1; SCOTT D, 2005, CLIN J PAIN, V21; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; Sjostrom H, 2003, SPINE, V28, P1725, DOI 10.1097/00007632-200308010-00018; Speers RA, 1998, GAIT POSTURE, V7, P207, DOI 10.1016/S0966-6362(98)00006-X; SPITZER WO, 1995, SPINE S8, V20, P1, DOI DOI 10.1097/00007632-199504151-00001; Thunberg J, 2001, PAIN, V91, P15, DOI 10.1016/S0304-3959(00)00415-2; Tjell C, 2003, J WHIPLASH ASS DISOR, V1, P9; Treleaven J, 2005, J REHABIL MED, V37, P224, DOI 10.1080/16501970510027989; Treleaven J, 2005, GAIT POSTURE, V21, P395, DOI 10.1016/j.gaitpost.2004.04.008; TRELEAVEN J, IN PRESS ARCH PHYS M; Vernon H, 1996, J MUSCULOSKELET PAIN, V4, P95, DOI DOI 10.1300/J094V04N04_; Wenngren BI, 1998, NEUROSCI RES, V32, P119, DOI 10.1016/S0168-0102(98)00074-1	54	82	87	1	15	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1356-689X			MANUAL THER	Man. Ther.	JUN	2008	13	3					183	191		10.1016/j.math.2006.12.005			9	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation	303AV	WOS:000256012600002	17306599				2022-02-06	
J	Hanks, RA; Millis, SR; Ricker, JH; Giacino, JT; Nakese-Richardson, R; Frol, AB; Novack, TA; Kalmar, K; Sherer, M; Gordon, WA				Hanks, Robin A.; Millis, Scott R.; Ricker, Joseph H.; Giacino, Joseph T.; Nakese-Richardson, Risa; Frol, Alan B.; Novack, Toln A.; Kalmar, Kathleen; Sherer, Mark; Gordon, Wayne A.			The predictive validity of a brief inpatient neuropsychologic battery for persons with traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; neuropsychological tests; outcomes assessment (health care); psychometrics; rehabilitation	DISABILITY RATING-SCALE; SEVERE HEAD TRAUMA; GALVESTON ORIENTATION; AMNESIA TEST; PRODUCTIVITY; COMA; SUPERVISION; 1-YEAR	Objective: To examine the predictive validity of a brief neuropsychologic test battery consisting of the Galveston Orientation and Amnesia Test, the California Verbal Learning, Test-II, Trail-Making Test (TMT), Symbol Digit Modalities Test, grooved pegboard, phonemic and categorical word generation tasks, the Wechsler Test of Adult Reading (WTAR). and the Wisconsin Card Sorting Test-64 relative to functional outcome at I year in person, with traumatic brain injury. Design: Inception cohort Study. Follow-Lip period of 12 months. Setting: Seven Traumatic Brain Injury Model System centers. Neuropsychologic testing was conducted during the acute inpatient rehabilitation stay and functional outcome measures were obtained at 1-year outpatient follow-up. Participants: Adults (N = 174) who met criteria for admission to inpatient brain injury rehabilitation. Interventions: Not applicable. Main Outcome Measures: FIM instrument. Disability Rating Scale, Supervision Rating Scale. Satisfaction With Life Scale (SWLS), and Glasgow Outcome Scale-Extended. Results: Multiple regression analyses revealed that performance on the neuropsychologic test battery was predictive of outcome at I year postinjury for all outcome measures, except FIM motor scores and the SWLS. Cognitive performance Using this battery Was found to predict 1-year outcomes above and beyond functional variables and injury severity variables collected during inpatient rehabilitation, thereby indicating incremental validity for this test battery. Individual tests that were found to be significant predictors of 1-year outcomes included the WTAR and TMT part B. Conclusions: These findings support the clinical utility and ecological validity of this battery with respect to level of disability, functional independence. and supervision required.	[Hanks, Robin A.; Millis, Scott R.] Rehabil Inst Michigan, Detroit, MI 48201 USA; [Hanks, Robin A.; Millis, Scott R.] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA; [Ricker, Joseph H.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA; [Giacino, Joseph T.; Kalmar, Kathleen] JFK Med Ctr, JFK Johnson Rehabil Inst, Edison, NJ USA; [Giacino, Joseph T.; Kalmar, Kathleen] JFK Med Ctr, New Jersey Neurosci Inst, Edison, NJ USA; [Nakese-Richardson, Risa] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; [Nakese-Richardson, Risa] Methodist Rehabil Ctr, Jackson, MS USA; [Frol, Alan B.] Baylor Inst Rehabil, Dept Phys Med & Rehabil, Dallas, TX USA; [Novack, Toln A.] Spain Rehabil Ctr, Birmingham, AL USA; [Sherer, Mark] Mem Hermann TIRR, Houston, TX USA; [Gordon, Wayne A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA		Hanks, RA (corresponding author), Rehabil Inst Michigan, 261 Mack Blvd, Detroit, MI 48201 USA.	rhanks@med.wayne.edu	Giacino, Joseph/AAF-1952-2021	Giacino, Joseph/0000-0002-7916-9698; Ricker, Joseph/0000-0003-3415-991X	National Insulate on Disability and Rehabilitation Research [H133A020501, H133A020502, H133A020509, H133A020514, H133A020515, H133A020518, H133A020526]	Supported by the National Insulate on Disability and Rehabilitation Research (grant nos. H133A020501 H133A020502. H133A020509. H133A020514, H133A020515, H133A020518. H133A020526).	Atchison TB, 2004, CLIN NEUROPSYCHOL, V18, P249, DOI 10.1080/13854040490501475; Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; DELIS DC, 2000, CALIFORNIA VERBAL LE; DELIS DC, 2001, DELISKAPLAN EXECUTIV; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Farmer JE, 2002, DEV NEUROPSYCHOL, V22, P455, DOI 10.1207/S15326942DN2202_2; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Hart T, 2003, ARCH PHYS MED REHAB, V84, P221, DOI 10.1053/apmr.2003.50023; Heaton R., 2000, WISCONSIN CARD SORTI; Heaton R. K., 2004, REVISED COMPREHENSIV; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Neese LE, 2000, BRAIN INJURY, V14, P719; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; Paradee CV, 2005, CLIN NEUROPSYCHOL, V19, P55, DOI 10.1080/13854040490524173; Pastorek NJ, 2004, J INT NEUROPSYCH SOC, V10, P807, DOI 10.1017/S1355617704106012; Rappaport M, 2005, NEUROPSYCHOL REHABIL, V15, P442, DOI 10.1080/09602010443000335; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reitan R.M., 1993, HALSTEADREITAN NEURO; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; RUFF RM, 1992, PERCEPT MOTOR SKILL, V75, P1311, DOI 10.2466/PMS.75.8.1311-1319; Schiff ND, 2006, J NEUROTRAUM, V23, P1436, DOI 10.1089/neu.2006.23.1436; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Smith A., 1982, SYMBOL DIGIT MODALIT; Taylor HG, 2004, DEV NEUROPSYCHOL, V25, P199, DOI 10.1207/s15326942dn2501&2_11; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	32	82	84	0	12	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2008	89	5					950	957		10.1016/j.apmr.2008.01.011			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	341ST	WOS:000258735900022	18452745				2022-02-06	
J	Whalen, MJ; Dalkara, T; You, ZR; Qiu, JH; Bermpohl, D; Mehta, N; Suter, B; Bhide, PG; Lo, EH; Ericsson, M; Moskowitz, MA				Whalen, Michael J.; Dalkara, Turgay; You, Zerong; Qiu, Jianhua; Bermpohl, Daniela; Mehta, Niyati; Suter, Bernhard; Bhide, Pradeep G.; Lo, Eng H.; Ericsson, Maria; Moskowitz, Michael A.			Acute plasmalemma permeability and protracted clearance of injured cells after controlled cortical impact in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						apoptosis; mice; necrosis; plasmalemma; propidium iodide; traumatic brain injury	TRAUMATIC BRAIN-INJURY; DEATH MECHANISMS; HEAD-INJURY; RATS; INHIBITOR; APOPTOSIS; NECROSIS; CULTURES; NEURONS; MOUSE	Cell death after traumatic brain injury (TBI) evolves over days to weeks. Despite advances in understanding biochemical mechanisms that contribute to posttraumatic brain cell death, the time course of cell injury, death, and removal remains incompletely characterized in experimental TBI models. In a mouse controlled cortical impact (CCI) model, plasmalemma permeability to propidium iodide (PI) was an early and persistent feature of posttraumatic cellular injury in cortex and hippocampus. In cortical and hippocampal brain regions known to be vulnerable to traumatic cell death, the number of PI + cells peaked early after CCI, and increased with increasing injury severity in hippocampus but not cortex (P < 0.05). Propidium iodide labeling correlated strongly with hematoxylin and eosin staining in injured cells (r = 0.99, P < 0.001), suggesting that plasmalemma damage portends fatal cellular injury. Using PI pulse labeling to identify and follow the fate of a cohort of injured cells, we found that many PI + cells recovered plasmalemma integrity by 24 h and were terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling negative, but nonetheless disappeared from injured brain by 7 days. Propidium iodide-positive cells in dentate gyrus showed significant ultrastructural damage, including plasmalemma and nuclear membrane damage or overt membrane loss, in all cells when examined by laser capture microdissection and transmission electron microscopy 1 to 24 h after CCI. The data suggest that plasmalemma damage is a fundamental marker of cellular injury after CCI; some injured cells might have an extended window for potential rescue by neuroprotective strategies.	[Whalen, Michael J.; Dalkara, Turgay; You, Zerong; Qiu, Jianhua; Bermpohl, Daniela; Mehta, Niyati; Suter, Bernhard; Bhide, Pradeep G.; Lo, Eng H.; Moskowitz, Michael A.] Massachusetts Gen Hosp, Dept Pediat Crit Care Med, Ctr Neurosci, Charlestown, MA 02129 USA; [Whalen, Michael J.; You, Zerong] Massachusetts Gen Hosp, Dept Pediat, Charlestown, MA 02129 USA; [Whalen, Michael J.; Qiu, Jianhua; Bermpohl, Daniela; Lo, Eng H.; Moskowitz, Michael A.] Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA 02129 USA; [Suter, Bernhard; Bhide, Pradeep G.; Lo, Eng H.; Moskowitz, Michael A.] Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA; [Ericsson, Maria] Harvard Univ, Sch Med, Electron Microscopy Facil, Boston, MA USA		Whalen, MJ (corresponding author), Massachusetts Gen Hosp, Dept Pediat Crit Care Med, Ctr Neurosci, 149 13th St, Charlestown, MA 02129 USA.	MWhalen@Partners.org	Moskowitz, Michael A/D-9916-2011	Bhide, Pradeep/0000-0003-4236-9415; Dalkara, Turgay/0000-0003-3943-7819	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS043426, R01NS047447, R01NS053560, R01NS037074, P30NS045776] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA020796] Funding Source: NIH RePORTER; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 DA020796, R01 DA020796-03] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS037074, R01 NS053560, R01 NS043426, R01 NS 37074, R01 NS047447-03, P30 NS045776-06A17807, R01 NS 047447, P30 NS 45776, R01 NS 53560, P30 NS045776, R01 NS043426-05, R01 NS047447] Funding Source: Medline		BERMPOHL D, 2007, IN PRESS J CEREB BLO; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Castejon O. J., 2004, Journal of Submicroscopic Cytology and Pathology, V36, P167; Castejon O. J., 2004, Journal of Submicroscopic Cytology and Pathology, V36, P273; Cevik IU, 2003, CELL DEATH DIFFER, V10, P928, DOI 10.1038/sj.cdd.4401250; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Festjens N, 2006, BBA-BIOENERGETICS, V1757, P1371, DOI 10.1016/j.bbabio.2006.06.014; GALLYAS F, 1992, ACTA NEUROPATHOL, V83, P499, DOI 10.1007/BF00310026; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hamabe W, 2003, J PHARMACOL EXP THER, V307, P205, DOI 10.1124/jpet.103.053033; Hannay HJ, 1999, J NEUROTRAUM, V16, P1103, DOI 10.1089/neu.1999.16.1103; Kelly KJ, 2003, AM J PHYSIOL-CELL PH, V284, pC1309, DOI 10.1152/ajpcell.00353.2002; Knoblach SM, 2004, J CEREBR BLOOD F MET, V24, P1119, DOI 10.1097/01.WCB.0000138664.17682.32; Kristensen BW, 2003, BRAIN RES, V964, P264, DOI 10.1016/S0006-8993(02)04080-5; Matsumoto Y, 2004, STROKE, V35, P185, DOI 10.1161/01.STR.0000106910.42815.C2; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; RINK A, 1995, AM J PATHOL, V147, P1575; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Saelens X, 2005, J CELL BIOL, V168, P545, DOI 10.1083/jcb.200407162; Serbest G, 2006, FASEB J, V20, P308, DOI 10.1096/fj.05-4024fje; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Toth Z, 1997, J NEUROSCI, V17, P8106; Unal-Cevik I, 2004, STROKE, V35, P2189, DOI 10.1161/01.STR.0000136149.81831.c5; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x	34	82	82	2	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	2008	28	3					490	505		10.1038/sj.jcbfm.9600544			16	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	266DA	WOS:000253410400007	17713463	Green Accepted, Bronze			2022-02-06	
J	Buz, S; Zipfel, B; Mulahasanovic, S; Pasic, M; Weng, Y; Hetzer, R				Buz, Semih; Zipfel, Burkhart; Mulahasanovic, Sead; Pasic, Miralem; Weng, Yuguo; Hetzer, Roland			Conventional surgical repair and endovascular treatment of acute traumatic aortic rupture	EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY			English	Article; Proceedings Paper	20th Annual Meeting of the European-Association-for-Cardio-Thoracic-Surgery/14th Annual Meeting of the European-Society-of-Thoracic-Surgeons	SEP 10-13, 2006	Stockholm, SWEDEN	European Assoc Cardio Thorac Surg, European Soc Thorac Surg		traumatic aortic rupture; conventional surgery; endovascular stent graft	THORACIC AORTA; DELAYED TREATMENT; INJURIES; MANAGEMENT; MORTALITY	Objective: Endoluminal aortic stent grafting offers a potentially less invasive alternative to open chest surgery, especially in patients with polytrauma. We compare the results of conventional surgical repair and endovascular treatment of traumatic aortic rupture. Methods: Retrospectively, 74 patients with acute traumatic aortic rupture were analyzed. Most of the patients had a rupture limited to the isthmus, and severe associated injuries. Thirty-five patients (6 female, 29 mate, mean age 36 years) underwent surgical repair. Two patients were operated upon without cardiopulmonary bypass. In 39 patients (5 female, 34 mate, mean age 36 years) thoracic endografts were implanted. The delay between trauma and treatment was comparable in the two groups. Results: Hospital mortality was 20% (7 of 35 patients) in the surgical group and 7.7% (3 of 39 patients) in the endovascular group. The most common cause of death in the surgical group was brain death in severe traumatic patients. Ten surgical complications occurred in 5 patients: respiratory insufficiency (n = 3), pulmonary infection (n = 2), recurrent nerve palsy In = 2), repeat thoracotomy (n = 2), and compartment syndrome (n = 1). No patient in this group had paraplegia. Except for one case, which required conversion to conventional surgery, stent-graft implantation was successful in all cases, without peri-interventional complications or procedure-induced paraplegia. In 9 patients the left subclavian artery was covered with the device. Two patients underwent surgical repair 15 days and 4 months after endografting because of injury of the aortic wall by the stent and development of a spurious aneurysm, respectively. Conclusions: In the treatment of traumatic thoracic aortic rupture, the early outcome of patients treated with endovascular stent grafts appears to be better than that with conventional surgical repair. The new technique allows safe and successful repair of this life-threatening injury in the early phase of trauma management. How far this potential benefit is sustained in the tong term remains unclear at present. (c) 2007 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.	[Buz, Semih; Zipfel, Burkhart; Mulahasanovic, Sead; Pasic, Miralem; Weng, Yuguo; Hetzer, Roland] Deutsch Herzzentrum Berlin, Dept Cardiothorac & Vasc Surg, D-13353 Berlin, Germany		Buz, S (corresponding author), Deutsch Herzzentrum Berlin, Dept Cardiothorac & Vasc Surg, Augustburger Pl 1, D-13353 Berlin, Germany.	buz@dhzb.de					Amabile P, 2004, J VASC SURG, V40, P873, DOI 10.1016/j.jvs.2004.08.053; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Fabian TC, 1997, J TRAUMA, V42, P374, DOI 10.1097/00005373-199703000-00003; Grabenwoger M, 2003, EUR J CARDIO-THORAC, V23, P788, DOI 10.1016/S1010-7940(03)00075-7; HETZER R, 2000, TSCHERNE UNFALLCHIRU, V2, P159; Holmes JH, 2002, ANN THORAC SURG, V73, P1149, DOI 10.1016/S0003-4975(01)03585-8; Hoornweg LL, 2006, J VASC SURG, V43, P1096, DOI 10.1016/j.jvs.2006.01.034; Hunt JP, 1996, J TRAUMA, V40, P547, DOI 10.1097/00005373-199604000-00005; Idu MM, 2005, J ENDOVASC THER, V12, P503, DOI 10.1583/04-1515R.1; Jahromi AS, 2001, J VASC SURG, V34, P1029, DOI 10.1067/mva.2001.120036; Jamieson WRE, 2002, AM J SURG, V183, P571, DOI 10.1016/S0002-9610(02)00851-6; Kuhne CA, 2005, UNFALLCHIRURG, V108, P279, DOI 10.1007/s00113-004-0890-z; Langanay T, 2002, EUR J CARDIO-THORAC, V21, P282, DOI 10.1016/S1010-7940(01)01133-2; MAGGISANO R, 1995, ANN VASC SURG, V9, P44, DOI 10.1007/BF02015316; Nicolosi AC, 1996, ANN THORAC SURG, V61, P875, DOI 10.1016/0003-4975(95)01136-6; Ott MC, 2004, J TRAUMA, V56, P565, DOI 10.1097/01.TA.0000114061.69699.A3; PARMLEY LF, 1958, CIRCULATION, V17, P1086, DOI 10.1161/01.CIR.17.6.1086; PATE JW, 1995, WORLD J SURG, V19, P119, DOI 10.1007/BF00316994; Pierangeli A, 2000, CARDIOVASC SURG, V8, P280, DOI 10.1016/S0967-2109(00)00015-6; Rousseau H, 2005, J THORAC CARDIOV SUR, V129, P1050, DOI 10.1016/j.jtcvs.2004.12.023; Rousseau H, 1999, CIRCULATION, V99, P498, DOI 10.1161/01.CIR.99.4.498; SMITH RS, 1986, AM J SURG, V152, P660, DOI 10.1016/0002-9610(86)90444-7; VONOPPELL UO, 1994, ANN THORAC SURG, V58, P585, DOI 10.1016/0003-4975(94)92270-5; ZIPFEL B, 1999, THORAC CARDIOVASC S1, V43, P260; Zipfel B, 2007, ANN THORAC SURG, V83, P441, DOI 10.1016/j.athoracsur.2006.09.036	25	82	89	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1010-7940	1873-734X		EUR J CARDIO-THORAC	Eur. J. Cardio-Thorac. Surg.	FEB	2008	33	2					143	149		10.1016/j.ejcts.2007.10.017			7	Cardiac & Cardiovascular Systems; Respiratory System; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Cardiovascular System & Cardiology; Respiratory System; Surgery	270XC	WOS:000253752500002	18065235	Bronze			2022-02-06	
J	Hergenroeder, G; Redell, JB; Moore, AN; Dubinsky, WP; Funk, RT; Crommett, J; Clifton, GL; Levine, R; Valadka, A; Dash, PK				Hergenroeder, Georgene; Redell, John B.; Moore, Anthony N.; Dubinsky, William P.; Funk, Robert T.; Crommett, John; Clifton, Guy L.; Levine, Robert; Valadka, Alex; Dash, Pramod K.			Identification of serum biomarkers in brain-injured adults: Potential for predicting elevated intracranial pressure	JOURNAL OF NEUROTRAUMA			English	Article						biomarker; c-reactive protein; intracranial pressure; retinol binding protein 4; secondary pathology; serum amyloid protein A	CEREBROSPINAL-FLUID; PROTEIN BIOMARKERS; CANCER-DETECTION; HEAD-INJURY; MARKERS; PLASMA; HYPERTENSION; CHILDREN; DAMAGE; CHROMATOGRAPHY	Brain injury biornarkers may have clinical utility in stratifying injury severity level, predicting adverse secondary events or outcomes, and monitoring the effectiveness of therapeutic interventions. As a biomarker source, serum offers several advantages over cerebrospinal fluid (CSF), including ease of accessibility and reduced risk to the patient. We screened pooled serum samples obtained from 11 severely injured traumatic brain injury (TBI) patients (Glasgow Coma Scale [GCS] <= 8) and 11 age-, sex- and race-matched volunteers. Two time points-41.5 +/- 4.9 h and 66.3 +/- 6.6 h post-injury-were chosen for the initial screening analysis. Samples were immunodepleted for 12 highly abundant serum proteins, and then labeled with mass-balanced isobaric tags (iTRAQ), and analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Identification and quantification of 2455 iTRAQ-labeled peptides that mapped to 160 proteins revealed 31 candidate biomarkers whose serum abundance was altered after injury. Changes in three candidate biomarkers (serum amyloid A, [SAA], c-reactive protein [CRP], retinol binding protein 4 [RBP4]) were verified using independent TBI and healthy volunteer serum samples. Receiver operating characteristic (ROC) curve analysis of CRP and SAA indicated they were robust indicators of injury even at very acute time points. Analysis of serum RBP4 levels at 24-36 h post-injury indicates it may predict subsequent increases in intracranial pressure (ICP) with a sensitivity of 86% and specificity of 88% at 11.6 mu g/mL [n = 7, ICP < 20 mm Hg; n = 8, ICP > 25 mm Hg). Our results support the use of serum as a source for discovery of TBI biomarkers, and indicate that serum biomarkers may have utility for predicting secondary pathologies (e.g., elevated ICP) associated with TBI.	[Redell, John B.; Moore, Anthony N.; Dash, Pramod K.] Univ Texas Houston, Sch Med, Dept Neurobiol & Anat, Houston, TX 77225 USA; [Hergenroeder, Georgene; Funk, Robert T.; Crommett, John; Clifton, Guy L.; Levine, Robert; Valadka, Alex; Dash, Pramod K.] Univ Texas Houston, Sch Med, Vivian L Smith Ctr Neurol Res, Houston, TX 77225 USA; [Hergenroeder, Georgene; Funk, Robert T.; Crommett, John; Clifton, Guy L.; Levine, Robert; Valadka, Alex; Dash, Pramod K.] Univ Texas Houston, Sch Med, Dept Neurosurg, Houston, TX 77225 USA; [Dubinsky, William P.] Univ Texas Houston, Sch Med, Dept Integrat Biol, Houston, TX 77225 USA		Dash, PK (corresponding author), Univ Texas Houston, Sch Med, Dept Neurobiol & Anat, POB 20708, Houston, TX 77225 USA.	p.dash@uth.tmc.edu		Hergenroeder, Georgene/0000-0002-6170-2191; Dash, Pramod/0000-0001-6746-1002	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01-RR02558] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH072933] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS049160, NS35457] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH072933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035457, R01NS049160] Funding Source: NIH RePORTER		Anderson NL, 2002, MOL CELL PROTEOMICS, V1, P845, DOI 10.1074/mcp.R200007-MCP200; Bazarian JJ, 2006, BRAIN INJURY, V20, P759, DOI 10.1080/02699050500488207; Beers SR, 2007, J NEUROTRAUM, V24, P97, DOI 10.1089/neu.2006.0055; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2002, J NEUROTRAUM, V19, P1405, DOI 10.1089/089771502320914633; Boehm AM, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-214; Borovecki F, 2005, P NATL ACAD SCI USA, V102, P11023, DOI 10.1073/pnas.0504921102; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Eastham JA, 2005, NAT CLIN PRACT UROL, V2, P482, DOI 10.1038/ncpuro0321; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Haqqani AS, 2007, J NEUROTRAUM, V24, P54, DOI 10.1089/neu.2006.0079; Haskins WE, 2005, J NEUROTRAUM, V22, P629, DOI 10.1089/neu.2005.22.629; Hlatky R, 2005, NEUROSURGERY, V57, P917, DOI 10.1227/01.NEU.0000180025.43747.fc; Hlatky R, 2004, NEUROCRIT CARE, V1, P69, DOI 10.1385/NCC:1:1:69; Hlatky R, 2002, J NEUROSURG, V97, P1054, DOI 10.3171/jns.2002.97.5.1054; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kalsotra A, 2007, J CEREBR BLOOD F MET, V27, P963, DOI 10.1038/sj.jcbfm.9600396; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kratz A, 2002, AM J CLIN PATHOL, V118, P856, DOI 10.1092/BTWQ5YMYVQ67QK9L; Lachmann HJ, 2007, NEW ENGL J MED, V356, P2361, DOI 10.1056/NEJMoa070265; Lai YC, 2006, DEV NEUROSCI-BASEL, V28, P336, DOI 10.1159/000094159; Liotta LA, 2006, J CLIN INVEST, V116, P26, DOI 10.1172/JCI27467; Maier B, 2005, J NEUROTRAUM, V22, P822, DOI 10.1089/neu.2005.22.822; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pieper R, 2003, PROTEOMICS, V3, P422, DOI 10.1002/pmic.200390057; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Posadas EM, 2004, CURR OPIN ONCOL, V16, P478, DOI 10.1097/00001622-200409000-00012; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; Shore PM, 2007, J NEUROTRAUM, V24, P75, DOI 10.1089/neu.2006.0062; Shore PM, 2004, J NEUROTRAUM, V21, P1113; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Taracha E, 2006, CLIN CHEM LAB MED, V44, P1446, DOI 10.1515/CCLM.2006.263; TEASDALE G, 1974, LANCET, V2, P81; Troyer DA, 2004, DIS MARKERS, V20, P117, DOI 10.1155/2004/509276; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603; Wulfkuhle JD, 2003, NAT REV CANCER, V3, P267, DOI 10.1038/nrc1043; Yocum AK, 2005, J PROTEOME RES, V4, P1722, DOI 10.1021/pr0501721; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7; ZWEIG MH, 1993, CLIN CHEM, V39, P561	48	82	90	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2008	25	2					79	93		10.1089/neu.2007.0386			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	266RZ	WOS:000253456000001	18260791				2022-02-06	
J	Ylvisaker, M; McPherson, K; Kayes, N; Pellett, E				Ylvisaker, Mark; McPherson, Kathryn; Kayes, Nicola; Pellett, Ellen			Metaphoric identity mapping: Facilitating goal setting and engagement in rehabilitation after traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Traumatic brain injury; Rehabilitation; Identity; Goal setting; Self-regulation	SELF-REGULATION; QUALITATIVE RESEARCH; HEALTH-CARE; MOTIVATION; PEOPLE; PERSPECTIVES; NARRATIVES; CLINICIAN; ARTHRITIS	Difficulty re-establishing an organised and compelling sense of personal identity has increasingly been identified as a critical theme in outcome studies of individuals with severe traumatic brain injury (TBI) and a serious obstacle to active engagement in rehabilitation. There exists little empirical support for approaches to identity reconstruction that address common impairments associated with TBI. Similarly, there is as yet little empirical support for theoretically sound approaches to promoting engagement in goal setting for this population. This article has two purposes. First, theory and procedures associated with metaphoric identity mapping are discussed in relation to goal setting in TBI rehabilitation. Second, the results of a qualitative pilot study are presented. The study explored metaphoric identity mapping as a facilitator of personally meaningful goal setting with five individuals with significant disability many years after their injury. Drawing on principles of grounded theory, the investigators extracted data from semi-structured interviews with clients and clinicians, from focus groups with the clinicians, and from observation of client-clinician interaction. Analysis of the data yielded five general themes concerning the use of this approach: All clients and clinicians found identity mapping to be an acceptable process and also useful for deriving meaningful rehabilitation goals. Both clients and clinicians saw client-centred goals as important. Cognitive impairments posed obstacles to this goal-setting intervention and mandated creative compensations. And finally, identity-related goal setting appeared to require a "mind shift" for some clinicians and demanded clinical skills not uniformly distributed among rehabilitation professionals.	[Ylvisaker, Mark] Coll St Rose, Albany, NY USA; [McPherson, Kathryn; Kayes, Nicola] AUT Univ, Hlth & Rehabil Res Ctr, Auckland, New Zealand; [Pellett, Ellen] Pellett & Associates, Oakville, ON, Canada		Ylvisaker, M (corresponding author), 1171 Van Antwerp Rd, Schenectady, NY 12309 USA.	ylvisakm@mail.strose.edu		McPherson, Kathryn/0000-0003-1240-8882; McPherson, Kath/0000-0003-0487-8497			Barnard PJ, 1985, PROGR PSYCHOL LANGUA, P197; Biderman D, 2006, INT J PSYCHOL, V41, P355, DOI 10.1080/00207590500345963; Boekaerts M., 1998, RES DIALOGUE LEARNIN, V1, P13, DOI [10.1016/S0959-4752(98)00008-5, DOI 10.1016/S0959-4752(98)00008-5]; Bruner Jerome, 2002, MAKING STORIES LAW L; BULGREN JA, 2006, TEACHING ADOLESCENTS, P79; Carver C.S., 1998, SELF REGULATION BEHA; Deci EL, 2000, PSYCHOL INQ, V11, P227, DOI 10.1207/S15327965PLI1104_01; Denzin N.K., 2000, HDB QUALITATIVE RES; Emmons RA, 1996, STRIVING AND FEELING, P79; Epston, 1990, NARRATIVE MEANS THER; Fitzsimons G.M., 2004, HDB SELF REGULATION, P151; Grafman G., 2002, PRINCIPLES FRONTAL L, P292; Hart T, 2006, J HEAD TRAUMA REHAB, V21, P142, DOI 10.1097/00001199-200603000-00007; Heller W, 2006, J REHABIL, V72, P44; HERMANS HJM, 1992, AM PSYCHOL, V47, P23, DOI 10.1037/0003-066X.47.1.23; Hill H, 1999, BRAIN INJURY, V13, P839, DOI 10.1080/026990599121043; Johansson U, 2006, AM J OCCUP THER, V60, P60, DOI 10.5014/ajot.60.1.60; Judd D, 2005, BRAIN INJURY, V19, P437, DOI 10.1080/02699050400010994; Kelly AE, 2000, PSYCHOL BULL, V126, P475, DOI 10.1037//0033-2909.126.4.475; KIRESUK TJ, 1968, COMMUNITY MENT HLT J, V4, P443, DOI 10.1007/BF01530764; Klinger L, 2005, J OCCUP SCI, V12, P9, DOI 10.1080/14427591.2005.9686543; Kovarsky Dana, 2007, Commun Med, V4, P53, DOI 10.1515/CAM.2007.029; Lakoff G, 2008, METAPHORS WE LIVE; Lakoff G.., 1999, PHILOS FLESH EMBODIE; Levack WMM, 2006, BRAIN INJURY, V20, P1439, DOI 10.1080/02699050601118422; Levack WMM, 2006, CLIN REHABIL, V20, P739, DOI 10.1177/0269215506070791; Levack WMM, 2006, DISABIL REHABIL, V28, P741, DOI 10.1080/09638280500265961; Levine B, 1999, NEUROCASE, V5, P263, DOI 10.1080/13554799908402731; Locke E.A., 1990, THEORY GOAL SETTING; Maclean N, 2000, SOC SCI MED, V50, P495; Mallinson T, 1996, AM J OCCUP THER, V50, P338, DOI 10.5014/ajot.50.5.338; MARKUS H, 1987, ANNU REV PSYCHOL, V38, P299, DOI 10.1146/annurev.ps.38.020187.001503; MARKUS H, 1986, AM PSYCHOL, V41, P954, DOI 10.1037/0003-066X.41.9.954; Mays N, 2000, BMJ-BRIT MED J, V320, P50, DOI 10.1136/bmj.320.7226.50; MAYS N, 1996, QUALITATIVE RES HLTH; McMullin R. E., 2000, NEW HDB COGNITIVE TH; McPherson KM, 2004, DISABIL REHABIL, V26, P988, DOI 10.1080/09638280410001702414; McPherson KM, 2001, DISABIL REHABIL, V23, P706; Medical Research Council, 2000, FRAM DEV EV RCTS COM; MORRIS SD, 2004, J COGN REHABIL, V22, P15; Nippold M., 1998, LATER LANGUAGE DEV S; Nochi M, 2000, SOC SCI MED, V51, P1795, DOI 10.1016/S0277-9536(00)00111-8; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; Patton M.Q., 1990, QUALITATIVE EVALUATI; Patton MQ, 1999, HEALTH SERV RES, V34, P1189; Perna R. B., 2004, J COGNITIVE REHABILI, V22, P10; Petrella L, 2005, BRAIN INJURY, V19, P643, DOI 10.1080/02699050410001671874; Pinker S., 2007, STUFF THOUGHT LANGUA; Pope C, 2000, BMJ-BRIT MED J, V320, P114, DOI 10.1136/bmj.320.7227.114; Prigatano G. P., 1991, AWARENESS DEFICIT BR; ROGERS C, 1974, AM PSYCHOL, V2, P358; Ryan RM, 2000, AM PSYCHOL, V55, P68, DOI 10.1037/0003-066X.55.1.68; Siegert R, 2004, DISABIL REHABIL, V26, P1, DOI 10.1080/09638280410001644932; Siegert RJ, 2004, DISABIL REHABIL, V26, P1175, DOI 10.1080/09638280410001724834; Strauss A., 1998, BASICS QUALITATIVE R, V2nd Edition; Stuss DT, 2000, MEMORY, CONSCIOUSNESS, AND THE BRAIN, P215; TEASDALE G, 1974, LANCET, V2, P81; Teasdale J. D., 1993, AFFECT COGNITION CHA; TEASDALE JD, 1997, TRANSFORMATION MEANI, P141; Unruh Anita M, 2004, Can J Occup Ther, V71, P290; Unruh Anita M, 2002, Can J Occup Ther, V69, P5; Vickery CD, 2005, BRAIN INJURY, V19, P657, DOI 10.1080/02699050400005218; Wade DT, 1998, CLIN REHABIL, V12, P273, DOI 10.1191/026921598678166365; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yeates G, 2007, NEUROPSYCHOL REHABIL, V17, P151, DOI 10.1080/09602010600696423; Ylvisaker M., 2000, BRAIN IMPAIR, V1, P12, DOI [DOI 10.1375/BRIM.1.1.12, 10.1375/brim.1.1.12]; YLVISAKER M, 2007, BRAIN IMPAIR, V8, P1	67	82	85	1	19	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2008	18	5-6					713	741		10.1080/09602010802201832			29	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	360PQ	WOS:000260070200001	18629719				2022-02-06	
J	Langevoort, G; Myklebust, G; Dvorak, J; Junge, A				Langevoort, G.; Myklebust, G.; Dvorak, J.; Junge, A.			Handball injuries during major international tournaments	SCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE IN SPORTS			English	Article						team handball; sports injury; incidence rate; international tournaments	CRUCIATE LIGAMENT INJURIES; YOUNG FEMALE PLAYERS; TEAM HANDBALL; PREVENTION; SPORTS; INTERVENTION; RISK	Background. Several authors have analyzed the incidence of handball injuries in amateur players but information of handball injury in top-level players is very limited. The aim of the study was to analyze the incidence, circumstances and characteristics of handball injuries during major international tournaments. Methods: Injuries during six international handball tournaments were analyzed, using an established injury report system. The physicians of all participating teams were asked to report all injuries after each match on a standardized injury report form. The response rate was on average 87%. Results: The incidence of injury was on average 108 injuries/1000 player hours (95% confidence interval (0): 98-117) or 1.5 injuries/ match (95% CI: 1.4-1.6). The injuries affected most frequently the lower extremity (42%), followed by injuries of the head (23%), upper extremity (18%) and trunk (14%). The most frequent diagnosis was contusion of head (14%) or ankle sprain (8%). The majority of injuries were caused by contact with another player. The incidence of time loss injuries was on average 27/1000 player hours (95% CI: 2232), and significantly higher in men than in women. Conclusion: Preventive program proven effective should be implemented. Fair Play is an essential aspect of injury prevention. Therefore, close cooperation with the referees is also necessary to make handball a safer sport.	IHF, Bern, Switzerland; OSTRC, Oslo, Norway; NIMI, Norwegian Inst Sports Med, Oslo, Norway; F MARC, Zurich, Switzerland; Schulthess Klin, Zurich, Switzerland		Junge, A (corresponding author), Schulthess Klin, Lengghalde 2, CH-8008 Zurich, Switzerland.	Astrid.Junge@kws.ch					Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Asembo JM, 1998, E AFR MED J, V75, P113; BACKX FJG, 1991, AM J SPORT MED, V19, P124, DOI 10.1177/036354659101900206; Caraffa A, 1996, Knee Surg Sports Traumatol Arthrosc, V4, P19, DOI 10.1007/BF01565992; FULLE RCW, 2005, BR J SPORTS MED S1, V39, pI3; Hewett TE, 1999, AM J SPORT MED, V27, P699, DOI 10.1177/03635465990270060301; Junge A, 2006, AM J SPORT MED, V34, P565, DOI 10.1177/0363546505281807; JUNGE A, 2002, AM J SPORTS MED, V32, P23; Junge A, 2004, AM J SPORT MED, V32, p80S, DOI 10.1177/0363546503261245; Leidinger A, 1990, Sportverletz Sportschaden, V4, P65, DOI 10.1055/s-2007-993600; Mandelbaum BR, 2005, AM J SPORT MED, V33, P1003, DOI 10.1177/0363546504272261; Myklebust G, 1998, SCAND J MED SCI SPOR, V8, P149, DOI 10.1111/j.1600-0838.1998.tb00185.x; Myklebust G, 2003, CLIN J SPORT MED, V13, P71, DOI 10.1097/00042752-200303000-00002; Myklebust G, 1997, SCAND J MED SCI SPOR, V7, P289, DOI 10.1111/j.1600-0838.1997.tb00155.x; NIELSEN AB, 1988, INT J SPORTS MED, V9, P341, DOI 10.1055/s-2007-1025037; Oehlert K, 2004, SPORTVERLETZ SPORTSC, V18, P80, DOI 10.1055/s-2004-813031; Olsen OE, 2005, BRIT MED J, V330, P449, DOI 10.1136/bmj.38330.632801.8F; Olsen OE, 2003, SCAND J MED SCI SPOR, V13, P299, DOI 10.1034/j.1600-0838.2003.00329.x; Petersen W, 2002, SPORTVERLETZ SPORTSC, V16, P122, DOI 10.1055/s-2002-34753; Reckling C, 2003, SPORTVERLETZ SPORTSC, V17, P112; Seil R, 1997, Sportverletz Sportschaden, V11, P58, DOI 10.1055/s-2007-993367; Seil R, 1998, AM J SPORT MED, V26, P681, DOI 10.1177/03635465980260051401; Wedderkopp N, 1999, SCAND J MED SCI SPOR, V9, P41; Wedderkopp N, 2003, SCAND J MED SCI SPOR, V13, P371, DOI 10.1046/j.1600-0838.2003.00336.x; Wedderkopp N, 1997, SCAND J MED SCI SPOR, V7, P342; Yde J, 1990, Br J Sports Med, V24, P51; Yoon YS, 2004, AM J SPORT MED, V32, p36S, DOI 10.1177/0095399703258781	27	82	87	1	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0905-7188	1600-0838		SCAND J MED SCI SPOR	Scand. J. Med. Sci. Sports	AUG	2007	17	4					400	407		10.1111/j.1600-0838.2006.00587.x			8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	196KW	WOS:000248481300015	17038157				2022-02-06	
J	Mechoulam, R; Shohami, E				Mechoulam, R.; Shohami, E.			Endocannabinoids and traumatic brain injury	MOLECULAR NEUROBIOLOGY			English	Article						2-AG; blood-brain barrier; brain endothelial cells; cannabinoids; cytokines; endocannabinoids; NF-kappa B; TNF-alpha; vasodilation	CLOSED-HEAD-INJURY; FACTOR-KAPPA-B; CANNABINOID CB2 RECEPTOR; NEUROPROTECTIVE ACTIONS; DEXANABINOL HU-211; MESSENGER-RNA; CELL-DEATH; ALPHA; TARGET; INHIBITOR	In response to traumatic brain injury, there is local and transient accumulation of 2-AG at the site of injury, peaking at 4 h and sustained up to at least 24 h. Neuroprotection exerted by exogenous 2-AG suggests that the formation of 2-AG may serve as a molecular regulator of pathophysiological events, attenuating the brain damage. Inhibition of this protective effect by SR-141716A, a CB1 cannabinoid receptor antagonist, and the lack of effect of 2-AG in CB1 knockout mice suggest that 2-AG and the CB1 receptor may be important in the pathophysiology of traumatic brain injury. 2-AG exerts its neuroprotective effect after traumatic brain injury, at least in part, by inhibition of NF-kappa B transactivation. 2-AG also inhibits, at an early stage (2-4 h), the expression of the main proinflammatory cytokines, TNF-alpha, IL-6, and IL-1 beta, and is accompanied by reduction of BBB permeability. Moreover, the CB1, CB2, and TRVP1 receptors are expressed on microvascular endothelial cells, and their activation by 2-AG counteracts endothelin (ET-1)-induced cerebral microvascular responses (namely, Ca2+ mobilization and cytoskeleton rearrangement). This suggests that the functional interaction between 2-AG and ET-1 may provide a potential alternative pathway for abrogating ET-1-inducible vasoconstriction after brain injury and play a role in the neuroprotective effects exerted by 2-AG, as a potent vasodilator.	Hebrew Univ Jerusalem, Fac Med, Dept Med Chem & Nat Prod, IL-91010 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel		Mechoulam, R (corresponding author), Hebrew Univ Jerusalem, Fac Med, Dept Med Chem & Nat Prod, IL-91010 Jerusalem, Israel.	mechou@cc.huji.ac.il					Ashton JC, 2007, CURR NEUROPHARMACOL, V5, P73, DOI 10.2174/157015907780866884; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Ben-Shabat S, 1998, EUR J PHARMACOL, V353, P23, DOI 10.1016/S0014-2999(98)00392-6; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Chen Y, 2000, CIRC RES, V87, P323, DOI 10.1161/01.RES.87.4.323; Chen YQ, 2000, J PHARMACOL EXP THER, V293, P807; DIMARZO V, 2006, J ENDOCRINOL INVES S, V29, P15; Fernandez-Ruiz J, 2005, MIL DRUG TH, P79; Fernandez-Ruiz J, 2007, TRENDS PHARMACOL SCI, V28, P39, DOI 10.1016/j.tips.2006.11.001; Gallily R, 2000, EUR J PHARMACOL, V406, pR5, DOI 10.1016/S0014-2999(00)00653-1; Hampson AJ, 1998, P NATL ACAD SCI USA, V95, P8268, DOI 10.1073/pnas.95.14.8268; Hansen HH, 2001, J NEUROCHEM, V78, P1415, DOI 10.1046/j.1471-4159.2001.00542.x; Hansen HS, 2002, PHARMACOL THERAPEUT, V95, P119, DOI 10.1016/S0163-7258(02)00251-6; Hanus L, 1999, P NATL ACAD SCI USA, V96, P14228, DOI 10.1073/pnas.96.25.14228; Herring AC, 1999, J PHARMACOL EXP THER, V291, P1156; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Leker RR, 2003, STROKE, V34, P2000, DOI 10.1161/01.STR.0000079817.68944.1E; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Mackie K, 2006, ANNU REV PHARMACOL, V46, P101, DOI 10.1146/annurev.pharmtox.46.120604.141254; Malek S, 2001, J BIOL CHEM, V276, P45225, DOI 10.1074/jbc.M105865200; Marsicano G, 2006, J Endocrinol Invest, V29, P27; McCarron RM, 2006, J PHYSIOL PHARMACOL, V57, P133; MCCARRON RM, 2003, ACTA NEUROCHIR SUPP, V86, P871; Mechoulam R, 2002, TRENDS MOL MED, V8, P58, DOI 10.1016/S1471-4914(02)02276-1; Milman G, 2006, P NATL ACAD SCI USA, V103, P2428, DOI 10.1073/pnas.0510676103; Molina-Holgado F, 2003, J NEUROSCI, V23, P6470; Mori T, 2002, J NEUROTRAUM, V19, P1411, DOI 10.1089/089771502320914642; Moro MA, 2003, NEUROSIGNALS, V12, P53, DOI 10.1159/000071814; Nagayama T, 1999, J NEUROSCI, V19, P2987; Pacher P, 2006, PHARMACOL REV, V58, P389, DOI 10.1124/pr.58.3.2; Panikashvili D, 2006, NEUROBIOL DIS, V22, P257, DOI 10.1016/j.nbd.2005.11.004; Panikashvili D, 2005, J CEREBR BLOOD F MET, V25, P477, DOI 10.1038/sj.jcbfm.9600047; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Parmentier-Batteur S, 2002, J NEUROSCI, V22, P9771, DOI 10.1523/jneurosci.22-22-09771.2002; PIOMELLI D, 2005, CURR OPIN INVEST DR, V6, P622; Sancho R, 2003, MOL PHARMACOL, V63, P429, DOI 10.1124/mol.63.2.429; Shohami E, 2000, DRUG DEVELOP RES, V50, P211, DOI 10.1002/1098-2299(200007/08)50:3/4<211::AID-DDR3>3.0.CO;2-G; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SOFIA RD, 1974, LIFE SCI, V15, P251; Trembovler V, 1999, J INTERF CYTOK RES, V19, P791, DOI 10.1089/107999099313640; van der Stelt M, 2002, MOL NEUROBIOL, V26, P317, DOI 10.1385/MN:26:2-3:317; Vollgraf U, 1999, J NEUROCHEM, V73, P2501, DOI 10.1046/j.1471-4159.1999.0732501.x; von Gertten C, 2003, J NEUROSCI RES, V73, P803, DOI 10.1002/jnr.10729; Walter L, 2004, BRIT J PHARMACOL, V141, P775, DOI 10.1038/sj.bjp.0705667; Zimmer A, 1999, P NATL ACAD SCI USA, V96, P5780, DOI 10.1073/pnas.96.10.5780; Zingarelli B, 2003, CRIT CARE MED, V31, pS105, DOI 10.1097/00003246-200301001-00015	49	82	82	0	6	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	AUG	2007	36	1					68	74		10.1007/s12035-007-8008-6			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	219XI	WOS:000250121100008	17952651				2022-02-06	
J	Shapira, M; Licht, A; Milman, A; Pick, CG; Shohami, E; Eldar-Finkelman, H				Shapira, Moran; Licht, Avital; Milman, Anat; Pick, Chaim G.; Shohami, Esther; Eldar-Finkelman, Hagit			Role of glycogen synthase kinase-3 beta in early depressive behavior induced by mild traumatic brain injury	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article							GLYCOGEN-SYNTHASE KINASE-3; CLOSED-HEAD INJURY; FOCAL CEREBRAL-ISCHEMIA; BETA-CATENIN; HIPPOCAMPAL VOLUME; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; PRIMARY NEURONS; RAT-BRAIN; PROTEIN	Traumatic brain injury (TBI) is a triggering event for a set of pathophysiological changes and concomitant depressive behavior. Glycogen synthase kinase-3 (GSK-3) is a potent in vivo regulator of cell apoptosis and, in addition, is implicated in depressive behavior. In this study, we investigated the role of GSK-3 in the physiological model of mild TBI (mTBI) at both the cellular and behavior levels. mTBI resulted in increased phosphorylation of inhibitory site serine(9) of GSK-3 beta, which coincided with increased serine(473) phosphorylation of its upstream kinase PKB and accumulation of its downstream target beta-catenin in the hippocampus. mTBI induced a depressive behavior which was evident as early as 24 h post-injury. Pretreatment with GSK-3 inhibitors, lithium, or L803-mts prevented mTBI-induced depression. We suggest that mTBI elicits a pro-survival cascade of PKB/GSK-3 beta/ beta-catenin as part of a rehabilitation program. Furthermore, the use of selective GSK-3 inhibitors may have therapeutic benefits in treatment conditions associated with brain injury. (c) 2007 Elsevier Inc. All rights reserved.	Tel Aviv Univ, Sackler Sch Med, Dept Mol Human Genet & Biochem, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Anat, IL-69978 Tel Aviv, Israel; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel		Eldar-Finkelman, H (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Mol Human Genet & Biochem, IL-69978 Tel Aviv, Israel.	heldar@post.tau.ac.il	Eldar-Finkelman, Hagit/AAF-8329-2019; Pick, Chaim/D-4789-2009	Eldar-Finkelman, Hagit/0000-0002-8460-9686; Milman, Anat/0000-0002-8551-4101			Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Atkins CM, 2006, J CEREBR BLOOD F MET, V26, P1507, DOI 10.1038/sj.jcbfm.9600301; Bamji SX, 2006, J CELL BIOL, V174, P289, DOI 10.1083/jcb.200601087; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chen G, 1999, J NEUROCHEM, V72, P1327, DOI 10.1046/j.1471-4159.2000.0721327.x; Chen HM, 2004, SER REMOTE SENS, V3, P3, DOI 10.1142/9789812702630_0001; CHEN S, IN PRESS J CEREB BLO; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Chen X, 2005, NEUROSCIENCE, V135, P11, DOI 10.1016/j.neuroscience.2005.05.041; Chenn A, 2002, SCIENCE, V297, P365, DOI 10.1126/science.1074192; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; Clark RSB, 1997, J NEUROSCI, V17, P9172; Cole AR, 2004, J BIOL CHEM, V279, P50176, DOI 10.1074/jbc.C400412200; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cross DAE, 2001, J NEUROCHEM, V77, P94, DOI 10.1046/j.1471-4159.2001.t01-1-00251.x; Friguls B, 2001, NEUROREPORT, V12, P3381, DOI 10.1097/00001756-200110290-00046; Gould TD, 2004, INT J NEUROPSYCHOPH, V7, P387, DOI 10.1017/S1461145704004535; Hongisto V, 2003, MOL CELL BIOL, V23, P6027, DOI 10.1128/MCB.23.17.6027-6036.2003; Hye A, 2005, NEUROSCI LETT, V373, P1, DOI 10.1016/j.neulet.2004.10.031; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Kaidanovich-Beilin O, 2004, BIOL PSYCHIAT, V55, P781, DOI 10.1016/j.biopsych.2004.01.008; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Kilic E, 2006, FASEB J, V20, P1185, DOI 10.1096/fj.05-4829fje; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kuan CY, 2003, P NATL ACAD SCI USA, V100, P15184, DOI 10.1073/pnas.2336254100; Larner SF, 2005, J NEUROCHEM, V94, P97, DOI 10.1111/j.1471-4159.2005.03172.x; Leker RR, 2002, ACTA NEUROCHIR SUPPL, V83, P49; Leuner B, 2004, J NEUROSCI, V24, P7477, DOI 10.1523/JNEUROSCI.0204-04.2004; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; Li XH, 2005, J NEUROCHEM, V92, P701, DOI 10.1111/j.1471-4159.2004.02898.x; Li XH, 2002, BIPOLAR DISORD, V4, P137, DOI 10.1034/j.1399-5618.2002.40201.x; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; MacQueen GM, 2003, P NATL ACAD SCI USA, V100, P1387, DOI 10.1073/pnas.0337481100; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; MOCCHETTI I, 1995, J NEUROTRAUM, V12, P853, DOI 10.1089/neu.1995.12.853; Neary JT, 2005, J NEUROTRAUM, V22, P491, DOI 10.1089/neu.2005.22.491; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; O'Brien WT, 2004, J NEUROSCI, V24, P6791, DOI 10.1523/JNEUROSCI.4753-03.2004; Otani N, 2002, J NEUROTRAUM, V19, P1587, DOI 10.1089/089771502762300247; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Plotkin B, 2003, J PHARMACOL EXP THER, V305, P974, DOI 10.1124/jpet.102.047381; PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0; RINK A, 1995, AM J PATHOL, V147, P1575; Robinson R G, 1992, Clin Neuropharmacol, V15 Suppl 1 Pt A, p638A; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Sheline YI, 2003, AM J PSYCHIAT, V160, P1516, DOI 10.1176/appi.ajp.160.8.1516; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Starkstein SE, 2002, NEUROREHABILITATION, V17, P105; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; WOODGETT JR, 1984, BIOCHIM BIOPHYS ACTA, V788, P339, DOI 10.1016/0167-4838(84)90047-5; Yano S, 2001, J CEREBR BLOOD F MET, V21, P351, DOI 10.1097/00004647-200104000-00004; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Yu X, 2003, NAT NEUROSCI, V6, P1169, DOI 10.1038/nn1132; Zhang XP, 2006, J CEREBR BLOOD F MET, V26, P915, DOI 10.1038/sj.jcbfm.9600238; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208	61	82	86	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431	1095-9327		MOL CELL NEUROSCI	Mol. Cell. Neurosci.	APR	2007	34	4					571	577		10.1016/j.mcn.2006.12.006			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	156NK	WOS:000245656000007	17289399				2022-02-06	
J	Tsubokawa, T; Jadhav, V; Solaroglu, I; Shiokawa, Y; Konishi, Y; Zhang, JH				Tsubokawa, Tamiji; Jadhav, Vikram; Solaroglu, Ihsan; Shiokawa, Yoshiaki; Konishi, Yoshifumi; Zhang, John H.			Lecithinized superoxide dismutase improves outcomes and attenuates focal cerebral ischemic injury via antiapoptotic mechanisms in rats	STROKE			English	Article						cerebral ischemia; lecithinized superoxide dismutase; neuronal apoptosis; oxidative stress	SPINAL-CORD INJURY; TRAUMATIC BRAIN-INJURY; HYPERBARIC-OXYGEN; OXIDATIVE STRESS; TRANSGENIC MICE; CYTOCHROME-C; ACTIVATION; MODEL; APOPTOSIS; RELEASE	Background and Purpose - Recent studies have shown the antiapoptotic neuroprotective effects of lecithinized superoxide dismutase (PC-SOD) in different forms of brain injury. We tested the effects of PC-SOD in focal cerebral ischemia in the rat middle cerebral artery occlusion model (MCAO). Methods - Adult male Sprague-Dawley rats were treated with PC-SOD (0.3, 1.0, and 3.0 mg/kg) administered intravenously after 90 minutes of occlusion (beginning of reperfusion). Physiological parameters, neurological score, and infarct volume were assessed at 24 and 72 hours in 3 groups of animals: sham-operated (n = 18), MCAO treated with vehicle (n=26), and MCAO treated with PC-SOD (n=37). Oxidative stress was evaluated by malondialdehyde assay, and the apoptotic mechanisms were studied by Western blotting. Results - PC-SOD treatment significantly reduced infarct volume and improved neurological scores at different time points compared with the vehicle-treated group. PC-SOD treatment decreased malondialdehyde levels, cytochrome c, and cleaved caspase 3 expression and increased mitochondrial Bcl-2 expression. Conclusions - Inhibition of oxidative stress with PC-SOD treatment improves outcomes after focal cerebral ischemia. This neuroprotective effect is likely exerted by antiapoptotic mechanisms.	Loma Linda Univ, Sch Med, Dept Physiol & Pharmacol, Loma Linda, CA 92354 USA; Loma Linda Univ, Sch Med, Dept Neurosurg, Loma Linda, CA 92354 USA; Loma Linda Univ, Sch Med, Dept Anesthesiol, Loma Linda, CA 92354 USA; Kyorin Univ, Sch Med, Tokyo, Japan		Zhang, JH (corresponding author), Loma Linda Univ, Med Ctr, Div Neurosurg, 11234 Anderson St,Rm 2562B, Loma Linda, CA 92354 USA.	johnzhang3910@yahoo.com	Solaroglu, Ihsan/ABF-7606-2020; Solaroglu, Ihsan/ABE-8816-2020; tao, li/G-7956-2011	Solaroglu, Ihsan/0000-0002-9472-1735; 	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD43120] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS45694, NS43338] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD043120] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045694, R01NS043338] Funding Source: NIH RePORTER		Calvert JW, 2003, J APPL PHYSIOL, V95, P2072, DOI 10.1152/japplphysiol.00630.2003; Chan PH, 2004, STROKE, V35, P2748, DOI 10.1161/01.STR.0000143325.25610.ac; CHAN PH, 1995, J NEUROTRAUM, V12, P815, DOI 10.1089/neu.1995.12.815; Chikawa T, 2001, J NEUROTRAUM, V18, P93, DOI 10.1089/089771501750055802; Fujimura M, 2000, J NEUROSCI, V20, P2817; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Hori Y, 1997, JPN J PHARMACOL, V74, P99, DOI 10.1254/jjp.74.99; IGARASHI R, 1994, J PHARMACOL EXP THER, V271, P1672; IGARASHI R, 1992, J PHARMACOL EXP THER, V262, P1214; IMAIZUMI S, 1990, STROKE, V21, P1312, DOI 10.1161/01.STR.21.9.1312; Koo DDH, 2001, KIDNEY INT, V60, P786, DOI 10.1046/j.1523-1755.2001.060002786.x; Kusaka I, 2004, AM J PHYSIOL-HEART C, V286, pH2442, DOI 10.1152/ajpheart.01169.2003; LIU TH, 1989, AM J PHYSIOL, V256, pH589, DOI 10.1152/ajpheart.1989.256.2.H589; MEHTA JL, 1990, J CARDIOVASC PHARM, V16, P112, DOI 10.1097/00005344-199007000-00016; Nakauchi K, 1996, J NEUROTRAUM, V13, P573, DOI 10.1089/neu.1996.13.573; Noshita N, 2003, STROKE, V34, P1513, DOI 10.1161/01.STR.0000072986.46924.F4; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P557, DOI 10.1097/00004647-200105000-00010; Saito A, 2003, J NEUROSCI, V23, P1710; Shimmura S, 2003, AM J OPHTHALMOL, V135, P613, DOI 10.1016/S0002-9394(02)02151-7; Takenaga M, 2006, J CONTROL RELEASE, V110, P283, DOI 10.1016/j.jconrel.2005.10.022; Tsubokawa T, 2006, STROKE, V37, P1888, DOI 10.1161/01.STR.0000227259.15506.24; Yin DL, 2003, J CEREBR BLOOD F MET, V23, P855, DOI 10.1097/01.WCB.0000073946.29308.55; Yunoki M, 1997, J NEUROTRAUM, V14, P739, DOI 10.1089/neu.1997.14.739; Yunoki M, 2003, SURG NEUROL, V59, P156, DOI 10.1016/S0090-3019(02)01040-6	24	82	89	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	MAR	2007	38	3					1057	1062		10.1161/01.STR.0000257978.70312.1d			6	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	140DB	WOS:000244482500046	17272760	Bronze			2022-02-06	
J	Darrow, KN; Maison, SF; Liberman, MC				Darrow, Keith N.; Maison, Stephane F.; Liberman, M. Charles			Selective removal of lateral olivocochlear efferents increases vulnerability to acute acoustic injury	JOURNAL OF NEUROPHYSIOLOGY			English	Article							GUINEA-PIG COCHLEA; INDUCED HEARING-LOSS; NICOTINIC ACETYLCHOLINE-RECEPTORS; AUDITORY-NERVE ACTIVITY; HAIR CELL AFFERENTS; MIDDLE-EAR MUSCLES; BRAIN-STEM; SUPERIOR OLIVE; ELECTRICAL-STIMULATION; INFERIOR COLLICULUS	Cochlear sensory cells and neurons receive efferent feedback from the olivocochlear (OC) system. The myelinated medial component of the OC system and its effects on outer hair cells (OHCs) have been implicated in protection from acoustic injury. The unmyelinated lateral (L) OC fibers target ipsilateral cochlear nerve dendrites and pharmacological studies suggest the LOC's dopaminergic component may protect these dendrites from excitotoxic effects of acoustic overexposure. Here, we explore LOC function in vivo by selective stereotaxic destruction of LOC cell bodies in mouse. Lesion success in removing the LOC, and sparing the medial (M) OC, was assessed by histological analysis of brain stem sections and cochlear whole mounts. Auditory brain stem responses (ABRs), a neural-based metric, and distortion product otoacoustic emissions (DPOAEs), an OHC-based metric, were measured in control and surgical mice. In cases where the LOC was at least partially destroyed, there were increases in suprathreshold neural responses that were frequency- and level-independent and not attributable to OHC-based effects. These interaural response asymmetries were not found in controls or in cases where the lesion missed the LOC. In LOC-lesion cases, after exposure to a traumatic stimulus, temporary threshold shifts were greater in the ipsilateral ear, but only when measured in the neural response; OHC-based measurements were always bilaterally symmetric, suggesting OHC vulnerability was unaffected. Interaural asymmetries in threshold shift were not found in either unlesioned controls or in cases that missed the LOC. These findings suggest that the LOC modulates cochlear nerve excitability and protects the cochlea from neural damage in acute acoustic injury.	Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA USA; Harvard Univ, Div Hlth Sci & Technol, Program Speech & Hearing Biosci & Technol, Cambridge, MA USA; MIT, Cambridge, MA USA		Liberman, MC (corresponding author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, 243 Charles St, Boston, MA 02114 USA.	Charles_Liberman@meei.harvard.edu			NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [P30DC005209, T32DC000038, R01DC000188] Funding Source: NIH RePORTER; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [P30 DC 05209, T32 DC000038, P30 DC005209, R01 DC 00188, R01 DC000188, T32 DC 0038] Funding Source: Medline		ADAMS JC, 1995, J COMP NEUROL, V361, P645, DOI 10.1002/cne.903610408; Arnold T, 1998, HEARING RES, V125, P147, DOI 10.1016/S0378-5955(98)00144-0; Bailey GP, 2000, J NEUROSCI, V20, P5163; Bao JX, 2005, J NEUROSCI, V25, P3041, DOI 10.1523/JNEUROSCI.5277-04.2005; BROWN MC, 1987, J COMP NEUROL, V260, P605, DOI 10.1002/cne.902600412; BROWN MC, 1993, J COMP NEUROL, V337, P600, DOI 10.1002/cne.903370406; CAMPBELL JP, 1988, HEARING RES, V35, P271, DOI 10.1016/0378-5955(88)90124-4; CODY AR, 1985, NATURE, V315, P662, DOI 10.1038/315662a0; Cooper NP, 2003, J PHYSIOL-LONDON, V548, P307, DOI 10.1113/jphysiol.2003.039081; Dajas-Bailador F, 2004, TRENDS PHARMACOL SCI, V25, P317, DOI 10.1016/j.tips.2004.04.006; DALDIN C, 1995, HEARING RES, V90, P202, DOI 10.1016/0378-5955(95)00167-5; Darrow KN, 2006, J COMP NEUROL, V498, P403, DOI 10.1002/cne.21050; DARROW KN, IN PRESS NAT NEUROSC; EYBALIN M, 1993, PHYSIOL REV, V73, P309, DOI 10.1152/physrev.1993.73.2.309; FELIX D, 1992, HEARING RES, V64, P1, DOI 10.1016/0378-5955(92)90163-H; Franklin K.B., 1997, MOUSE BRAIN STEREOTA; Groff JA, 2003, J NEUROPHYSIOL, V90, P3178, DOI 10.1152/jn.00537.2003; Guinan JJ, 1996, COCHLEA, P435, DOI DOI 10.1007/978-1-4612-0757-3_8; HANDROCK M, 1982, ARCH OTO-RHINO-LARYN, V234, P191, DOI 10.1007/BF00453630; HENDERSON D, 1994, HEARING RES, V74, P22, DOI 10.1016/0378-5955(94)90172-4; Kelly JB, 1998, HEARING RES, V116, P43, DOI 10.1016/S0378-5955(97)00195-0; Kirk EC, 2003, JARO-J ASSOC RES OTO, V4, P445, DOI 10.1007/s10162-002-3013-y; Kujawa SG, 1997, J NEUROPHYSIOL, V78, P3095, DOI 10.1152/jn.1997.78.6.3095; Le Prell CG, 2005, JARO-J ASSOC RES OTO, V6, P48, DOI 10.1007/s10162-004-5009-2; Le Prell CG, 2004, J ACOUST SOC AM, V116, P1044, DOI 10.1121/1.1772395; Le Prell CG, 2003, JARO-J ASSOC RES OTO, V4, P276, DOI 10.1007/s10162-002-3018-6; Liberman M. C., 1982, NEW PERSPECTIVES NOI, P105; LIBERMAN MC, 1990, J COMP NEUROL, V301, P443, DOI 10.1002/cne.903010309; LIBERMAN MC, 1990, HEARING RES, V49, P209, DOI 10.1016/0378-5955(90)90105-X; Liberman MC, 1997, AUDIT NEUROSCI, V3, P255; LIBERMAN MC, 1984, HEARING RES, V16, P55, DOI 10.1016/0378-5955(84)90025-X; Maison SF, 2002, J NEUROSCI, V22, P10838; Maison SF, 2000, J NEUROSCI, V20, P4701, DOI 10.1523/JNEUROSCI.20-12-04701.2000; Maison SF, 2003, J NEUROPHYSIOL, V90, P2941, DOI 10.1152/jn.00596.2003; Maison SF, 2003, J COMP NEUROL, V455, P406, DOI 10.1002/cne.10490; Mills DM, 2003, J ACOUST SOC AM, V113, P914, DOI 10.1121/1.1535942; Mulders WHAM, 2004, HEARING RES, V187, P122, DOI 10.1016/S0378-5955(03)00308-3; Muller M, 2005, HEARING RES, V202, P63, DOI 10.1016/j.heares.2004.08.011; Murugasu E, 1996, J NEUROSCI, V16, P325; Oestreicher E, 1997, HEARING RES, V107, P46, DOI 10.1016/S0378-5955(97)00023-3; OSEN KK, 1969, BRAIN RES, V16, P165, DOI 10.1016/0006-8993(69)90092-4; PUEL JL, 1994, J COMP NEUROL, V341, P241, DOI 10.1002/cne.903410209; Puel JL, 1998, NEUROREPORT, V9, P2109, DOI 10.1097/00001756-199806220-00037; RAJAN R, 1988, J NEUROPHYSIOL, V60, P549, DOI 10.1152/jn.1988.60.2.549; REITER ER, 1995, J NEUROPHYSIOL, V73, P506, DOI 10.1152/jn.1995.73.2.506; ROBERTSON D, 1983, HEARING RES, V9, P263, DOI 10.1016/0378-5955(83)90031-X; Ruel J, 2001, EUR J NEUROSCI, V14, P977, DOI 10.1046/j.0953-816x.2001.01721.x; RYAN AF, 1994, HEARING RES, V72, P23, DOI 10.1016/0378-5955(94)90201-1; SAHLEY TL, 1991, HEARING RES, V55, P133, DOI 10.1016/0378-5955(91)90099-U; SHIBAYAMA H, 1990, Acta Anatomica Nipponica, V65, P120; Walsh EJ, 1998, J NEUROSCI, V18, P3859; Wang Y, 2002, JARO, V3, P248, DOI 10.1007/s101620020028; Warr WB, 1997, HEARING RES, V108, P89, DOI 10.1016/S0378-5955(97)00044-0; WINTER IM, 1990, HEARING RES, V45, P191, DOI 10.1016/0378-5955(90)90120-E; Zheng XY, 1999, J COMP NEUROL, V406, P72	55	82	83	0	5	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3077			J NEUROPHYSIOL	J. Neurophysiol.	FEB	2007	97	2					1775	1785		10.1152/jn.00955.2006			11	Neurosciences; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Physiology	134NQ	WOS:000244090500071	17093118	Green Accepted			2022-02-06	
J	Patel, AV; Mihalik, JP; Notebaert, AJ; Guskiewicz, KM; Prentice, WE				Patel, Akshay V.; Mihalik, Jason P.; Notebaert, Andrew J.; Guskiewicz, Kevin M.; Prentice, William E.			Neuropsychological performance, postural stability, and symptoms after dehydration	JOURNAL OF ATHLETIC TRAINING			English	Article						cognition; balance; mild traumatic brain injury	COLLEGIATE FOOTBALL PLAYERS; CEREBRAL CONCUSSION; NCAA CONCUSSION; BRAIN-INJURY; HEAT-STRESS; EXERCISE; VASOPRESSIN; HYDRATION; SPORT; RATS	Context: Dehydration and concussion are common in athletic performance. Some experts have speculated that dehydration may negatively influence performance on tests commonly used for concussion assessment. Objective: To determine how the signs and symptoms, neuropsychological performance, and postural stability are affected by dehydration. Design: Repeated-measures design assessing subjects in the euhydrated and dehydrated conditions. Setting: Sports Medicine Research Laboratory. Patients or Other Participants: Twenty-four healthy, male recreational athletes participated in the study. Intervention(s): Subjects participated in 2 counterbalanced sessions (euhydrated and dehydrated) separated by at least 7 days. Subjects were dehydrated using fluid restriction and an exercise task. No direct intervention was provided for the euhydrated condition. Main Outcome Measure(s): We used the Standardized Assessment of Concussion to test mental status, the Automated Neuropsychological Assessment Metrics (ANAM) to evaluate neuropsychological performance, the NeuroCom Sensory Organization Test and Balance Error Scoring System to test postural stability, the Graded Symptom Checklist to assess symptom presence and severity in our participants, and urine specific gravity and body mass to determine hydration status. Results: No differences were noted for the Standardized Assessment of Concussion, total Balance Error Scoring System errors, composite Sensory Organization Test, and composite ANAM scores between conditions. Subjects in the dehydrated condition had significant deterioration in visual memory (t(23) = 2.130, P <.001) and fatigue measures (t(23) = -7.880, P <.001) as assessed by ANAM. The dehydrated condition resulted in subjects reporting a significantly higher number (t23 = -8.585, P <.001) and severity (t(23) = -7.673, P <.001) of symptoms than the euhydrated subjects on the Graded Symptom Checklist. Conclusions: Our results suggest that moderate dehydration (-2.5 +/- 0.63%) significantly influenced the self-report of symptoms commonly associated with concussion. Dehydration resulted in a deterioration of visual memory and increases in the self-report of fatigue. Despite these findings, dehydration did not affect other neuropsychological and postural stability objective testing measures for concussion.	Univ N Carolina, Sports Med Res Lab, Fetzer Gymnasium, Chapel Hill, NC 27599 USA		Guskiewicz, KM (corresponding author), Univ N Carolina, Sports Med Res Lab, Fetzer Gymnasium, CB 8700,South Rd, Chapel Hill, NC 27599 USA.	gus@email.unc.edu		Guskiewicz, Kevin/0000-0002-8682-2130; Mihalik, Jason/0000-0001-6085-8322			ARMSTRONG L E, 1987, Annals of Sports Medicine, V3, P182; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Casa DJ, 2000, J ATHL TRAINING, V35, P212; Cian C, 2001, INT J PSYCHOPHYSIOL, V42, P243, DOI 10.1016/S0167-8760(01)00142-8; Davranche K, 2004, J SPORT SCI, V22, P419, DOI 10.1080/02640410410001675289; Derave W, 1998, ERGONOMICS, V41, P782, DOI 10.1080/001401398186630; ELSABBAN F, 1995, INT J BIOMETEOROL, V38, P92, DOI 10.1007/BF01270666; ENGLAND AC, 1982, ANN INTERN MED, V97, P196, DOI 10.7326/0003-4819-97-2-196; Gauchard GC, 2002, INT J NEUROSCI, V112, P1191, DOI 10.1080/00207450290026157; Giza CC, 2001, J ATHL TRAINING, V36, P228; GOPINATHAN PM, 1988, ARCH ENVIRON HEALTH, V43, P15, DOI 10.1080/00039896.1988.9934367; GROSS PM, 1985, BRAIN RES, V330, P329, DOI 10.1016/0006-8993(85)90693-6; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; GUSKIEWICZ KM, 1997, MED SCI SPORTS EXERC, V29, P213; KARVONEN MJ, 1957, ANN MED EXP BIOL FEN, V35, P307; KOOB GF, 1989, BRAIN RES BULL, V23, P359, DOI 10.1016/0361-9230(89)90222-0; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maroon Joseph C, 2002, Clin Neurosurg, V49, P319; McArdle WD., 2001, EXERCISE PHYSL ENERG; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2001, J ATHL TRAINING, V36, P274; McEwen B. B., 2004, ADV PHARMACOL, V50, p[531, 655], DOI DOI 10.1016/S1054-3589(04)50001-7; PACKARD MG, 1985, REGUL PEPTIDES, V11, P51, DOI 10.1016/0167-0115(85)90031-X; PARDINI D, 2004, 2 INT S CONC SPORT N; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Reghunandanan V., 1998, Indian Journal of Experimental Biology, V36, P635; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Shirreffs SM, 2004, BRIT J NUTR, V91, P951, DOI 10.1079/BJN20041149; Szinnai G, 2005, AM J PHYSIOL-REG I, V289, pR275, DOI 10.1152/ajpregu.00501.2004; Tomporowski PD, 2003, ACTA PSYCHOL, V112, P297, DOI 10.1016/S0001-6918(02)00134-8	37	82	84	0	22	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JAN-MAR	2007	42	1					66	75					10	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	158BS	WOS:000245766500012	17597946				2022-02-06	
J	Savaskan, NE; Rocha, L; Kotter, MR; Baer, A; Lubec, G; van Meeteren, LA; Kishi, Y; Aoki, J; Moolenaar, WH; Nitsch, R; Brauer, AU				Savaskan, N. E.; Rocha, L.; Kotter, M. R.; Baer, A.; Lubec, G.; van Meeteren, L. A.; Kishi, Y.; Aoki, J.; Moolenaar, W. H.; Nitsch, R.; Braeuer, A. U.			Autotaxin (NPP-2) in the brain: cell type-specific expression and regulation during development and after neurotrauma	CELLULAR AND MOLECULAR LIFE SCIENCES			English	Article						LPA signaling; S1P; axonal growth and regeneration; hippocampus; brain development; G protein-coupled receptors; myelination; oligodendrocyte precursor cells	NUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE FAMILY; LYSOPHOSPHATIDIC ACID PRODUCTION; LYSOPHOSPHOLIPASE-D; RAT-BRAIN; PHOSPHODIESTERASE-I; CEREBROSPINAL-FLUID; CEREBRAL-ISCHEMIA; CATALYTIC SITE; LPA RECEPTORS; IDENTIFICATION	Autotaxin is a secreted cell motility-stimulating exo-phosphodiesterase with lysophospholipase D activity that generates bioactive lysophosphatidic acid. Lysophosphatidic acid has been implicated in various neural cell functions such as neurite remodeling, demyelination, survival and inhibition of axon growth. Here, we report on the in vivo expression of autotaxin in the brain during development and following neurotrauma. We found that autotaxin is expressed in the proliferating subventricular and choroid plexus epithelium during embryonic development. After birth, autotaxin is mainly found in white matter areas in the central nervous system. In the adult brain, autotaxin is solely expressed in leptomeningeal cells and oligodendrocyte precursor cells. Following neurotrauma, autotaxin is strongly up-regulated in reactive astrocytes adjacent to the lesion. The present study revealed the cellular distribution of autotaxin in the developing and lesioned brain and implies a function of autotaxin in oligodendrocyte precursor cells and brain injuries.	Netherlands Canc Inst, Div Cellular Biochem, Amsterdam, Netherlands; Charite Univ Med Berlin, Ctr Anat, Inst Cell Biol & Neurobiol, D-10115 Berlin, Germany; Med Univ Vienna, AKH, BrainProt Neuroprotect Neuroregenerat Lab, Dept Neurosurg, Vienna, Austria; Univ Tokyo, Grad Sch Pharmaceut Sci, PRESTO, Japan Sci & Technol Agcy, Tokyo, Japan		Savaskan, NE (corresponding author), Netherlands Canc Inst, Div Cellular Biochem, Plesmanlaan 121, Amsterdam, Netherlands.	n.savaskan@nki.nl; anja.braeuer@charite.de	Brauer, Anja/N-3692-2019; Messier, Claude/A-2322-2008; Nitsch, Robert/AAI-9129-2021; Braeuer, Anja/K-8339-2013; van Meeteren, Laurens/A-9890-2008; Savaskan, Nicolai/D-2923-2018	Messier, Claude/0000-0002-4791-1763; van Meeteren, Laurens/0000-0001-9885-0668; Savaskan, Nicolai/0000-0003-1348-094X; Kotter, Mark/0000-0001-5145-7199; Lubec, Gert/0000-0002-6333-9461; Aoki, Junken/0000-0001-9435-1896			Acarin L, 2001, STROKE, V32, P2394, DOI 10.1161/hs1001.097243; Anliker B, 2004, J BIOL CHEM, V279, P20555, DOI 10.1074/jbc.R400013200; Aoki J, 2004, SEMIN CELL DEV BIOL, V15, P477, DOI 10.1016/j.semcdb.2004.05.001; Bachner D, 1999, MECH DEVELOP, V84, P121, DOI 10.1016/S0925-4773(99)00048-9; Baumforth KRN, 2005, BLOOD, V106, P2138, DOI 10.1182/blood-2005-02-0471; Bollen M, 2000, CRIT REV BIOCHEM MOL, V35, P393, DOI 10.1080/10409230091169249; Brauer AU, 2004, FEBS LETT, V563, P41, DOI 10.1016/S0014-5793(04)00244-3; Brauer AU, 2003, NEUROSCIENCE, V121, P111, DOI 10.1016/S0306-4522(03)00336-1; Clair T, 2003, CANCER RES, V63, P5446; Colognato H, 2004, J CELL BIOL, V167, P365, DOI 10.1083/jcb.200404076; Corcoran DL, 2005, GENOME RES, V15, P840, DOI 10.1101/gr.2952005; DAS AK, 1989, LIPIDS, V24, P329, DOI 10.1007/BF02535172; Dawson J, 2003, J NEUROCHEM, V87, P947, DOI 10.1046/j.1471-4159.2003.02056.x; Dehn D, 2006, GLIA, V53, P491, DOI 10.1002/glia.20307; Dennis J, 2005, J NEUROSCI RES, V82, P737, DOI 10.1002/jnr.20686; Duan RD, 2003, J BIOL CHEM, V278, P38528, DOI 10.1074/jbc.M305437200; Fox MA, 2004, MOL CELL NEUROSCI, V27, P140, DOI 10.1016/j.mcn.2004.06.002; Fox MA, 2003, MOL CELL NEUROSCI, V23, P507, DOI 10.1016/S1044-7431(03)00073-3; Fukushima N, 2000, DEV BIOL, V228, P6, DOI 10.1006/dbio.2000.9930; Fukushima N, 2001, PROSTAG OTH LIPID M, V64, P21, DOI 10.1016/S0090-6980(01)00105-8; Fuss B, 1997, J NEUROSCI, V17, P9095; Gijsbers R, 2003, FEBS LETT, V538, P60, DOI 10.1016/S0014-5793(03)00133-9; Goding JW, 1998, IMMUNOL REV, V161, P11, DOI 10.1111/j.1600-065X.1998.tb01568.x; Goding JW, 2003, BBA-MOL BASIS DIS, V1638, P1, DOI 10.1016/S0925-4439(03)00058-9; Hama K, 2004, J BIOL CHEM, V279, P17634, DOI 10.1074/jbc.M313927200; Hama K, 2002, FEBS LETT, V523, P187, DOI 10.1016/S0014-5793(02)02976-9; Hammack BN, 2004, MULT SCLER, V10, P245, DOI 10.1191/1352458504ms1023oa; Holtsberg FW, 1998, J NEUROCHEM, V70, P66; Inoue M, 2004, NAT MED, V10, P712, DOI 10.1038/nm1060; Ishii I, 2004, ANNU REV BIOCHEM, V73, P321, DOI 10.1146/annurev.biochem.73.011303.073731; Jansen S, 2005, J CELL SCI, V118, P3081, DOI 10.1242/jcs.02438; Kingsbury MA, 2003, NAT NEUROSCI, V6, P1292, DOI 10.1038/nn1157; KINOUCHI H, 1990, MOL CHEM NEUROPATHOL, V12, P215, DOI 10.1007/BF03159946; Kishi Y, 2006, J BIOL CHEM, V281, P17492, DOI 10.1074/jbc.M601803200; Koh E, 2003, CANCER RES, V63, P2042; Koike S, 2006, GENES CELLS, V11, P133, DOI 10.1111/j.1365-2443.2006.00924.x; Kusaka S, 1998, J PHYSIOL-LONDON, V506, P445, DOI 10.1111/j.1469-7793.1998.445bw.x; Lee HY, 1996, J BIOL CHEM, V271, P24408, DOI 10.1074/jbc.271.40.24408; Lee HY, 2002, FEBS LETT, V515, P137, DOI 10.1016/S0014-5793(02)02457-2; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Meier S, 2004, CELL MOL LIFE SCI, V61, P1082, DOI 10.1007/s00018-004-3469-5; Meier S, 2003, FASEB J, V17, P1153, DOI 10.1096/fj.02-0453fje; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; Nam SW, 2000, ONCOGENE, V19, P241, DOI 10.1038/sj.onc.1203263; NARITA M, 1994, J BIOL CHEM, V269, P28235; Ness JK, 2005, GLIA, V50, P321, DOI 10.1002/glia.20206; Ohe Y, 2003, BIOCHEM BIOPH RES CO, V308, P719, DOI 10.1016/S0006-291X(03)01454-2; PAXINOS G, 1985, J NEUROSCI METH, V13, P139, DOI 10.1016/0165-0270(85)90026-3; Ramakers GJA, 1998, EXP CELL RES, V245, P252, DOI 10.1006/excr.1998.4224; REYNOLDS R, 1988, DEVELOPMENT, V102, P409; Sakagami H, 2005, J BIOL CHEM, V280, P23084, DOI 10.1074/jbc.M413438200; Sato K, 2005, J NEUROCHEM, V92, P904, DOI 10.1111/j.1471-4159.2004.02933.x; Sayas CL, 1999, J BIOL CHEM, V274, P37046, DOI 10.1074/jbc.274.52.37046; Schilling T, 2004, J PHYSIOL-LONDON, V557, P105, DOI 10.1113/jphysiol.2004.060632; Siess W, 1999, P NATL ACAD SCI USA, V96, P6931, DOI 10.1073/pnas.96.12.6931; Stefan C, 2005, TRENDS BIOCHEM SCI, V30, P542, DOI 10.1016/j.tibs.2005.08.005; Stefan C, 1999, BBA-MOL CELL RES, V1450, P45, DOI 10.1016/S0167-4889(99)00031-2; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; Sugiura T, 1999, BBA-MOL CELL BIOL L, V1440, P194, DOI 10.1016/S1388-1981(99)00127-4; Sugiura T, 2002, J LIPID RES, V43, P2049, DOI 10.1194/jlr.M200242-JLR200; Sun GY, 2004, J NEUROCHEM, V88, P40; Tanaka M, 2006, J BIOL CHEM, V281, P25822, DOI 10.1074/jbc.M605142200; TIGYI G, 1995, AM J PHYSIOL-HEART C, V268, pH2048, DOI 10.1152/ajpheart.1995.268.5.H2048; Tigyi G, 2003, PROG LIPID RES, V42, P498, DOI 10.1016/S0163-7827(03)00035-3; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; Tokumura A, 1999, LIFE SCI, V65, P245, DOI 10.1016/S0024-3205(99)00243-X; TOKUMURA A, 1986, BIOCHIM BIOPHYS ACTA, V875, P31; Umemura K, 2006, NEUROSCI LETT, V400, P97, DOI 10.1016/j.neulet.2006.02.008; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; van Meeteren LA, 2005, J BIOL CHEM, V280, P21155, DOI 10.1074/jbc.M413183200; van Meeteren LA, 2006, MOL CELL BIOL, V26, P5015, DOI 10.1128/MCB.02419-05; Weiner JA, 1998, J COMP NEUROL, V398, P587; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Wu VW, 1998, J NEUROCHEM, V71, P749; Xie Y, 2002, CHIN J INORG CHEM, V18, P1; Xu Y, 1995, CLIN CANCER RES, V1, P1223	77	82	84	0	4	BIRKHAUSER VERLAG AG	BASEL	VIADUKSTRASSE 40-44, PO BOX 133, CH-4010 BASEL, SWITZERLAND	1420-682X			CELL MOL LIFE SCI	Cell. Mol. Life Sci.	JAN	2007	64	2					230	243		10.1007/s00018-006-6412-0			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	128IF	WOS:000243650700013	17192809				2022-02-06	
J	Jones, K; Sharp, C; Mangram, AJ; Dunn, EL				Jones, Kory; Sharp, Collin; Mangram, Alicia J.; Dunn, Ernest L.			The effects of preinjury clopidogrel use on older trauma patients with head injuries	AMERICAN JOURNAL OF SURGERY			English	Article; Proceedings Paper	58th Annual Meeting of the Southwestern-Surgical-Congress	APR 03-07, 2006	Kauai, HI	SW Surg Congress		clopidogrel; trauma; head injury	INTRACRANIAL HEMORRHAGE; ELDERLY-PATIENTS; WARFARIN USE; MORTALITY; OUTCOMES	Background: This Study was designed to determine whether or not older trauma patients on clopidogrel have an increased risk of morbidity and mortality. Methods: A retrospective review was performed on all trauma patients >= 50 years of age between January 1, 2002, and August 31, 2005. The charts of those patients who had documented preinjury use of clopidogrel were further reviewed. A control group of patients with no history of clopidogrel use was matched for age, sex, mechanism of injury, and injury severity score. Results: During this time period, there were 1,020 trauma patients >= 50 years of age admitted, 43 of which had documented preinjury clopiclogrel use (P). A higher percentage of patients in the P group underwent cranial Surgery, had episodes of rebleeds, and required transfusions of blood products than in the control group. The mortality and length of stay were comparable in both groups. Conclusion: This study indicates that the preinjury use of clopidogrel may cause significant morbidity in patients with closed-head injuries. Further studies are needed to suggest specific treatment modalities. (c) 2006 Excerpta Medica Inc. All rights reserved.	Med Educ Dept, Dept Surg, Methodist Hlth Syst, Dallas, TX 75203 USA		Dunn, EL (corresponding author), Med Educ Dept, Dept Surg, Methodist Hlth Syst, 1441 N Beckley Ave, Dallas, TX 75203 USA.	bertaturner@mhd.com					ABUHAJIR M, 1999, ANESTHESIOL CLIN N A, V17, P749; Ferrera PC, 1999, AM J EMERG MED, V17, P154, DOI 10.1016/S0735-6757(99)90050-5; Gallagher SF, 2003, AM J SURG, V185, P131, DOI 10.1016/S0002-9610(02)01208-4; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Kennedy DM, 2000, J TRAUMA, V48, P451, DOI 10.1097/00005373-200003000-00012; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; SCHWAB CW, 1992, ARCH SURG-CHICAGO, V127, P701; Spektor S, 2003, J NEUROSURG, V99, P661, DOI 10.3171/jns.2003.99.4.0661; STEIN J, 1995, ARCH PHYS MED REHAB, V76, P840, DOI 10.1016/S0003-9993(95)80549-4	10	82	84	0	1	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9610	1879-1883		AM J SURG	Am. J. Surg.	DEC	2006	192	6					743	745		10.1016/j.amjsurg.2006.08.037			3	Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Surgery	118FS	WOS:000242928400015	17161086				2022-02-06	
J	Ashman, TA; Gordon, WA; Cantor, JB; Hibbard, MR				Ashman, Teresa A.; Gordon, Wayne A.; Cantor, Joshua B.; Hibbard, Mary R.			Neurobehavioral consequences of traumatic brain injury	MOUNT SINAI JOURNAL OF MEDICINE			English	Article						traumatic brain injury; neuropsychiatry; rehabilitation; axis I disorders; psychiatric disorders	MILD HEAD-INJURY; UNITED-STATES; PSYCHIATRIC-DISORDERS; FOLLOW-UP; AXIS-I; COGNITIVE REHABILITATION; POSTCONCUSSION SYNDROME; NATURAL-HISTORY; SILENT EPIDEMIC; DEPRESSION	At least 1.4 million people die, or receive hospital or emergency care every year in the United States as a result of traumatic brain injury (TBI). Many more are treated in other settings or receive no treatment at all. Thus TBI is often unidentified, with subsequent cognitive, behavioral, emotional and physical sequelae that are not linked to the injury. Yet, over 5.3 million Americans live with TBI-related disabilities that interfere with their overall performance and social roles within the community. The pathophysiolog and consequences of TBI are discussed, as are functional changes and psychiatric manifestations after TBI. Finally, implications and recommendations for clinical practice are reviewed, including the importance of screening for TBI.	CUNY Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA		Ashman, TA (corresponding author), CUNY Mt Sinai Sch Med, Dept Rehabil Med, Box 1240,1 Gustave L Levy Pl, New York, NY 10029 USA.	teresa.ashman@mssm.edu	Ashman, Teresa/B-1621-2013				Alexander, 1997, Semin Clin Neuropsychiatry, V2, P177; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Arciniegas DB, 2000, CURRENT TREATMENT OP, V2, P169; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Bigler ED, 2003, ARCH CLIN NEUROPSYCH, V18, P595; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; Bordini EJ, 2002, NEUROREHABILITATION, V17, P93; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Brown CG, 2003, GEOTIMES, V48, P4; Brown M, 1999, MT SINAI J MED, V66, P160; Bryant RA, 2000, BRAIN INJURY, V14, P175, DOI 10.1080/026990500120826; Burg JS, 1996, J CLIN PSYCHOL MED S, V3, P243, DOI 10.1007/BF01993910; Callahan CD, 1999, J HEAD TRAUMA REHAB, V14, P581, DOI 10.1097/00001199-199912000-00006; Cantor JB, 2005, J HEAD TRAUMA REHAB, V20, P527, DOI 10.1097/00001199-200511000-00005; *CDCP, FACTS TRAUM BRAIN IN; Chan RCK, 2000, BRAIN INJURY, V14, P227, DOI 10.1080/026990500120709; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Deb S, 1999, AM J PSYCHIAT, V156, P374; DIJKERS M, ARCH PHYS MED REH S2, V85, pS21; DIKMEN S, 1989, J NEUROL NEUROSUR PS, V49, P1227; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Feinstein A, 2000, CAN J PUBLIC HEALTH, V91, P325, DOI 10.1007/BF03404799; Fortin S, 2003, CORTEX, V39, P273, DOI 10.1016/S0010-9452(08)70109-6; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Gordon WR, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199812000-00006; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Holtzer R, 2000, BRAIN INJURY, V14, P959, DOI 10.1080/02699050050191904; Hoofien D, 2001, BRAIN INJURY, V15, P189; JENNETT B, 1990, REHABILITATION ADULT, P3; Jorge R, 2003, INT REV PSYCHIATR, V15, P317, DOI 10.1080/09540260310001606700; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Marr A, 2002, CENTRAL NERVOUS SYST; Mateer CA, 2005, J HEAD TRAUMA REHAB, V20, P62, DOI 10.1097/00001199-200501000-00007; MAYOU R, 1993, BRIT MED J, V307, P646; Mayou RA, 2000, BRIT J PSYCHIAT, V177, P540, DOI 10.1192/bjp.177.6.540; McAllister TW, 1997, COMMUNITY MENT HLT J, V33, P341, DOI 10.1023/A:1025055426260; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McDermott S, 2005, DISABIL REHABIL, V27, P117, DOI 10.1080/09638280400007380; McGuire LM, 1998, BRAIN INJURY, V12, P207, DOI 10.1080/026990598122683; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Nicholson K, 2004, J HEAD TRAUMA REHAB, V19, P2, DOI 10.1097/00001199-200401000-00002; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; Olver John, 2005, Aust Fam Physician, V34, P269; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Patterson C M, 1998, J Ark Med Soc, V95, P109; Potter DD, 2001, NEUROPSYCHOLOGIA, V39, P1464, DOI 10.1016/S0028-3932(01)00057-4; Rao V, 2002, PSYCHIAT CLIN N AM, V25, P43, DOI 10.1016/S0193-953X(03)00052-2; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; RIMEL RW, 1995, NEUROSURGERY, P221; Schootman M, 2000, BRAIN INJURY, V14, P373; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2005, J NERV MENT DIS, V193, P680, DOI 10.1097/01.nmd.0000180743.65943.c8; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Thaxton L, 2002, J HEAD TRAUMA REHAB, V17, P335, DOI 10.1097/00001199-200208000-00007; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Warriner Erin M, 2006, Curr Psychiatry Rep, V8, P73, DOI 10.1007/s11920-006-0083-2; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Wehman P, 2003, ARCH PHYS MED REHAB, V84, P192, DOI 10.1053/apmr.2003.50027; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011	85	82	85	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0027-2507	1931-7581		MT SINAI J MED	Mt. Sinai J. Med.	NOV	2006	73	7					999	1005					7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	116BB	WOS:000242776400010	17195886				2022-02-06	
J	Baguley, IJ; Heriseanu, RE; Felmingham, KL; Cameron, ID				Baguley, Ian J.; Heriseanu, Roxana E.; Felmingham, Kim L.; Cameron, Ian D.			Dysautonomia and heart rate variability following severe traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; dysautonomia; heart rate variability	SPECTRAL-ANALYSIS; DIENCEPHALIC SEIZURES; CIRCADIAN-RHYTHM; DEATH	Primary objective: To investigate disconnection theories postulated as the cause of dysautonomia following severe traumatic brain injury (TBI) through analysis of heart rate variability (HRV). Methods and procedures: Data were collected on age-matched subjects with and without dysautonomia ( eight subjects in each group) and 16 non-injured controls. Data included injury details, continuous electrocardiograph recordings and rehabilitation outcome. Main outcomes and results: The TBI group revealed significant differences in HRV parameters both compared to controls and between dysautonomic and non-dysautonomic subjects. Additionally, HRV parameters for dysautonomic subjects showed evidence of an uncoupling of the normal relationship between heart rate and sympathetic/parasympathetic balance. HRV changes persisted for the dysautonomia group for a mean of 14 months post-injury. Conclusions: Dysautonomic subjects revealed prolonged uncoupling of heart rate and HRV parameters compared to non-dysautonomic subjects and controls. These findings represent direct	Westmead Hosp, Brain Injury Rehabil Serv, Westmead, NSW 2145, Australia; Univ Sydney, Rehabil Studies Unit, Sydney, NSW 2006, Australia		Baguley, IJ (corresponding author), Westmead Hosp, Brain Injury Rehabil Serv, POB 533, Westmead, NSW 2145, Australia.	ianb@biru.wsahs.nsw.gov.au	Baguley, Ian/AAM-5828-2021; Baguley, Ian J/K-6878-2013	Baguley, Ian J/0000-0001-5650-3705			ADINOFF B, 1992, PSYCHIAT RES, V41, P89, DOI 10.1016/0165-1781(92)90101-8; ALIMELKKILA T, 1991, ACTA ANAESTH SCAND, V35, P436, DOI 10.1111/j.1399-6576.1991.tb03324.x; Baguley I, 2000, BRAIN INJURY, V14, P505; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Baguley IJ, 2004, BRAIN INJURY, V18, P409, DOI 10.1080/02699050310001645775; BAGULEY IJ, 2005, BRAIN INJURY S1, V19, P84; Baillard C, 2002, CRIT CARE MED, V30, P306, DOI 10.1097/00003246-200202000-00007; BEKHEIT S, 1990, AM HEART J, V119, P79, DOI 10.1016/S0002-8703(05)80085-7; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; BULLARD DE, 1987, ANN NEUROL, V21, P609, DOI 10.1002/ana.410210617; Camm AJ, 1996, CIRCULATION, V93, P1043; COUMEL P, 1991, EUR HEART J, V12, P412, DOI 10.1093/oxfordjournals.eurheartj.a059910; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Goldsmith RL, 2000, CORONARY ARTERY DIS, V11, P129, DOI 10.1097/00019501-200003000-00007; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287, DOI 10.1152/ajpregu.1998.275.4.R1287; GUZZETTI S, 1994, AM J PHYSIOL, V266, pH1112, DOI 10.1152/ajpheart.1994.266.3.H1112; HALLIWILL JR, 1992, AM J PHYSIOL, V262, pH1719, DOI 10.1152/ajpheart.1992.262.6.H1719; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; HUIKURI HV, 1990, AM J CARDIOL, V65, P391, DOI 10.1016/0002-9149(90)90308-N; Keller C, 1993, J Neurosci Nurs, V25, P349; King ML, 1997, BRAIN INJURY, V11, P445; Korpelainen JT, 1997, STROKE, V28, P2150, DOI 10.1161/01.STR.28.11.2150; Meglic B, 2001, CEREBROVASC DIS, V11, P2, DOI 10.1159/000047605; Novak V, 1995, Clin Auton Res, V5, P24, DOI 10.1007/BF01845495; Ori Z, 1992, Cardiol Clin, V10, P499; PRANZATELLI MR, 1991, J CHILD NEUROL, V6, P115, DOI 10.1177/088307389100600204; Rapenne T, 2001, J NEUROSURG ANESTH, V13, P260, DOI 10.1097/00008506-200107000-00016; Rossitch E Jr, 1988, Br J Neurosurg, V2, P471, DOI 10.3109/02688698809029601; SINGER DH, 1988, J ELECTROCARDIOL, V21, pS46, DOI 10.1016/0022-0736(88)90055-6; STRUM S, 2004, POST HEAD INJURY AUT; Thorley RR, 2001, ARCH PHYS MED REHAB, V82, P246, DOI 10.1053/apmr.2001.18698; Vanravenswaaijarts CMA, 1993, ANN INTERN MED, V118, P436, DOI 10.7326/0003-4819-118-6-199303150-00008; Winchell RJ, 1997, J TRAUMA, V43, P927, DOI 10.1097/00005373-199712000-00010	34	82	85	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2006	20	4					437	444		10.1080/02699050600664715			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	045GN	WOS:000237730700008	16716989				2022-02-06	
J	Havet-Thomassin, V; Allain, P; Etcharry-Bouyx, F; Le Gall, D				Havet-Thomassin, V; Allain, P; Etcharry-Bouyx, F; Le Gall, D			What about theory of mind after severe brain injury?	BRAIN INJURY			English	Article; Proceedings Paper	Conference on Day of Spring	JUN 04-05, 2004	Angers, FRANCE			traumatic brain injury; theory of mind; executive functions; social cognition	CLOSED-HEAD INJURY; ASPERGER-SYNDROME; SOCIAL COGNITION; NORMAL ADULTS; AUTISM; IMPAIRMENTS; ATTRIBUTION; SCHIZOPHRENIA; DISTURBANCE; INTENTIONS	Background: Behavioural changes are often reported after a severe traumatic brain injury (TBI). These changes are usually a greater burden for relatives than physical or cognitive impairments. This study investigated social cognition in TBI patients using two theory of mind (TOM) tasks. Method: The performances of 17 patients with severe TBI and 17 matched controls were compared on two tasks designed to investigate understanding of other people's mental states: The 'Reading the Mind in the Eyes' test (RME) and the 'Character Intention Task' (CIT). TBI patients and controls were also given several executive function tasks. Results: Compared to healthy controls, patients were impaired in most executive tests and in both TOM tasks. No relationship was found between TOM and executive measures. This is consistent with Rowe's position, who suggested an independence between executive functioning and social cognition. These data suggest that TBI patients may have specific social intelligence disturbances. Conclusion: Future work should employ additional tests of TOM and behavioural ratings and recruit more patients in order to complete analysis.	Ctr Hosp Univ Angers, Dept Psychol, Angers, France		Le Gall, D (corresponding author), Ctr Hosp Univ Angers, Dept Neurol, Unite Neuropsychol, 4 Rue Larrey, F-49933 Angers 01, France.	neuropsychologie@chu-angers.fr		ALLAIN, Philiooe/0000-0003-0668-0986			Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; Allain P, 1999, J CLIN EXP NEUROPSYC, V21, P643, DOI 10.1076/jcen.21.5.643.871; Baron-Cohen S, 1999, EUR J NEUROSCI, V11, P1891, DOI 10.1046/j.1460-9568.1999.00621.x; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; Baron-Cohen S., 1995, MINDBLINDNESS ESSAY; BARONCOHEN S, 1994, BRIT J PSYCHIAT, V165, P640, DOI 10.1192/bjp.165.5.640; BARONCOHEN S, 1986, BRIT J DEV PSYCHOL, V4, P113, DOI 10.1111/j.2044-835X.1986.tb01003.x; BaronCohen S, 1997, J CHILD PSYCHOL PSYC, V38, P813, DOI 10.1111/j.1469-7610.1997.tb01599.x; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Bird CM, 2004, BRAIN, V127, P914, DOI 10.1093/brain/awh108; Blair RJR, 2000, BRAIN, V123, P1122, DOI 10.1093/brain/123.6.1122; Brunet E, 2000, NEUROIMAGE, V11, P157, DOI 10.1006/nimg.1999.0525; Brunet Eric, 2003, Cogn Neuropsychiatry, V8, P129, DOI 10.1080/13546800244000256; Channon S, 2000, NEUROPSYCHOLOGIA, V38, P1006, DOI 10.1016/S0028-3932(99)00154-2; Cicerone KD, 1997, ARCH CLIN NEUROPSYCH, V12, P173, DOI 10.1016/S0887-6177(96)00022-4; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; FONTAINE A, 1995, NEUROPSYCHOLOGIE TRA, P13; Frith C. D., 1996, COGNITIVE NEUROPSYCH; Happe F, 2001, NEUROPSYCHOLOGIA, V39, P83, DOI 10.1016/S0028-3932(00)00093-2; Happe F, 1999, COGNITION, V70, P211, DOI 10.1016/S0010-0277(99)00005-0; HUGHES C, 1993, DEV PSYCHOL, V29, P498, DOI 10.1037/0012-1649.29.3.498; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; LEGALL D, 1987, NEUROPSY, V4, P257; LEVIN HS, 1995, J NEUROTRAUM, V12, P601, DOI 10.1089/neu.1995.12.601; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; PERNER J, 2000, UNDERSTANDING OTHER, P155; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rowe AD, 2001, BRAIN, V124, P600, DOI 10.1093/brain/124.3.600; Russell TA, 2000, AM J PSYCHIAT, V157, P2040, DOI 10.1176/appi.ajp.157.12.2040; Sarfati Y, 1997, SCHIZOPHR RES, V25, P199, DOI 10.1016/S0920-9964(97)00025-X; Shallice T, 2001, BRAIN, V124, P247, DOI 10.1093/brain/124.2.247; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss DT, 2001, BRAIN, V124, P279, DOI 10.1093/brain/124.2.279; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; TEASDALE G, 1974, LANCET, V2, P81; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; Wellman H. M., 1990, CHILDS THEORY MIND; Wilson BA, 1998, NEUROPSYCHOL REHABIL, V8, P213, DOI 10.1080/713755570	44	82	84	0	22	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2006	20	1					83	91		10.1080/02699050500340655			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Rehabilitation	001AQ	WOS:000234505000009	16403703				2022-02-06	
J	Compagnone, C; Murray, GD; Teasdale, GM; Maas, AIR; Esposito, D; Princi, P; D'Avella, D; Servadei, F				Compagnone, C; Murray, GD; Teasdale, GM; Maas, AIR; Esposito, D; Princi, P; D'Avella, D; Servadei, F			The management of patients with intradural post-traumatic mass lesions: A multicenter survey of current approaches to surgical management in 729 patients coordinated by the european brain injury consortium	NEUROSURGERY			English	Article						decompressive cranietomy; intradural mass lesions; surgical management; traumatic brain injury	ACUTE SUBDURAL-HEMATOMA; DECOMPRESSIVE CRANIECTOMY; CONSERVATIVE TREATMENT; EXTRADURAL HEMATOMA; HEAD-INJURY; EVACUATION; HEMORRHAGE; MORTALITY; TRIAL; SCAN	OBJECTIVE: Controversy exists about the indications and timing for surgery in head injured patients with an intradural mass lesion. The aim of this study was to survey contemporary approaches to the treatment of head injured patients with an intradural lesion, placing a particular focus on the utilization of decompressive craniectomy. METHODS: A prospective international survey was conducted over a 3-month period in 67 centers from 24 countries on the neurosurgical management of head injured patients with an intradural mass lesion and/or radiological signs of raised intracranial pressure. Information was obtained about demographic, clinical, and radiological features; surgical management, and mortality at discharge. RESULTS: Over the period of the study, data were collected about 729 patients consecutively admitted to one of the participating centers. The survey included 397 patients with a severe head injury (Glasgow Coma Scale [GCS] 3-8), 155 with a moderate head injury (GCS 9-12) and 143 patients with a mild head injury (GCS 13-15). An operation was performed on 502 patients (69%). Emergency surgery (<24 h) was most frequently performed on 502 patients (69%). Emergency surgery (<24 h) was most frequently performed for patients with an extracerebral mass lesions (subdural hematomas) whereas delayed surgery was most frequently performed for an intracerebral hematoma or contusion. Decompressive craniectomy was performed in a substantial number of patients, either during an emergency procedure (n = 134, 33%) or a delayed procedure (n = 47, 31%). The decompressive procedure was nearly always combined with evacuation of a mass lesion. The size of the decompression was however considered too small in 25% of cases. CONCLUSION: The results provide a contemporary picture of neurosurgical surgical approaches to the management of head injured with an intradural mass lesion and/or signs of raised intracranial pressure in some Neurosurgical Units across the world. The relative benefits of early versus delayed surgery in patients with intraparenchymal lesions and on the indications, technique and benefits of decompressive craniectomy could be topics for future head injury research.	Osped Gen Provinciale M Bufalini, WHO, Neurotrauma Collaborating Ctr, I-47023 Cesena, Italy; Osped Gen Provinciale M Bufalini, Div Neurosurg, I-47023 Cesena, Italy; Univ Edinburgh, Sch Med, Div Community Hlth Sci, Edinburgh, Midlothian, Scotland; So Gen Hosp, Inst Neurol Sci, Div Neurosci, Glasgow G51 4TF, Lanark, Scotland; Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands; Univ Mississippi, Dept Neurosurg, Jackson, MS 39216 USA; CNR, Messina, Italy; Univ Messina, Neurosurg Clin, Messina, Italy		Servadei, F (corresponding author), Osped Gen Provinciale M Bufalini, WHO, Neurotrauma Collaborating Ctr, I-47023 Cesena, Italy.	francoservadei@libero.it	; Maas, Andrew I.R./C-5584-2013; Alfieri, Alex/B-5936-2013; Sahuquillo, Juan/B-3577-2008	Splavski, Bruno/0000-0002-4483-9364; Servadei, Franco/0000-0002-3595-3464; Maas, Andrew I.R./0000-0003-1612-1264; D'AVELLA, Domenico/0000-0001-9077-412X; Alfieri, Alex/0000-0002-0209-4114; Sahuquillo, Juan/0000-0003-0713-5875; Compagnone, Christian/0000-0001-9951-5503; Murray, Gordon/0000-0001-9866-4734			Breasted J., 1930, E SMITH SURG PAPYRUS; BRICOLO AP, 1984, NEUROSURGERY, V14, P8, DOI 10.1227/00006123-198401000-00003; BULLOCK R, 1989, SURG NEUROL, V32, P181, DOI 10.1016/0090-3019(89)90176-6; Bullock RM, 2000, J NEUROTRAUM, V17, P449; CHESNUT R, 1999, TRAUMATIC BRAIN INJU, P81; Cooper P R, 1976, Surg Neurol, V5, P25; CROCE MA, 1994, J TRAUMA, V36, P820, DOI 10.1097/00005373-199406000-00012; Csokay A, 2002, SURG NEUROL, V57, P126, DOI 10.1016/S0090-3019(01)00686-3; DECARPI B, TRACTATUS PERUTILIS; DOE J, 1940, B MED LIBR ASSOC, V28, P165; FRENCH BN, 1977, SURG NEUROL, V7, P171; GRAHAM DI, 1971, LANCET, V1, P265; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; HAMILTON M, 1992, AM J NEURORADIOL, V13, P853; HOUNDFIELD GN, 1973, BRIT J RADIOL, V46, P1016, DOI 10.1259/0007-1285-46-552-1016; Hutchinson PJ, 2005, ACTA NEUROCHIR, V147, P1, DOI 10.1007/s00701-004-0400-7; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MENDELOW AD, 1979, BRIT MED J, V1, P1240, DOI 10.1136/bmj.1.6173.1240; Mendelow AD, 2005, LANCET, V365, P387; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Piek Jurgen, 2002, Curr Opin Crit Care, V8, P134, DOI 10.1097/00075198-200204000-00008; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Procaccio F, 2000, J Neurosurg Sci, V44, P1; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; Servadei F, 2000, NEUROSURGERY, V46, P70, DOI 10.1093/neurosurgery/46.1.70; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; WONG CW, 1995, ACTA NEUROCHIR, V135, P38, DOI 10.1007/BF02307412	33	82	90	0	15	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	DEC	2005	57	6					1183	1191					9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	991PQ	WOS:000233826300036	16331166				2022-02-06	
J	Yurkewicz, L; Weaver, J; Bullock, MR; Marshall, LF				Yurkewicz, L; Weaver, J; Bullock, MR; Marshall, LF			The effect of the selective NMDA receptor antagonist traxprodil in the treatment of traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						neuroprotectant; NMDA receptor antagonist; traumatic brain injury	REGIONAL CEREBRAL EDEMA; ACUTE SUBDURAL-HEMATOMA; GLASGOW OUTCOME SCALE; SEVERE HEAD-INJURY; GLUTAMATE NEUROTOXICITY; CLINICAL-TRIALS; CP-101,606; RAT; ASPARTATE; DAMAGE	Traumatic brain injury (TBI) remains a major public health problem, and there is a great medical need for a pharmacological treatment that could improve long-term outcome. The excitatory neurotransmitter, glutamate, has been implicated in processes leading to neurodegeneration. Traxo- prodil (CP-101,606) is a novel and potent glutamate receptor antagonist that is highly selective for the NR2B subunit of the NMDA receptor; it has been shown to be neuroprotective in animal models of brain injury and ischemia. A randomized, double-blind, placebo-controlled study was therefore conducted to assess the efficacy and safety of a 72-h infusion of traxoprodil compared to placebo in subjects with computed tomography scan evidence of severe TBI (GCS 4-8). A total of 404 males and non-pregnant females, aged 16-70, were treated within 8 h of injury. At baseline, subjects were stratified by motor score severity. The results showed that a greater proportion of the traxoprodil-treated subjects had a favorable outcome on the dichotomized Glasgow Outcome Scale (dGOS) at 6 months (delta 5.5%, OR 1.3, p = 0.21, 95% Cl: [0.85, 2.06]) and at last visit (delta 7.5%, OR 1.47, p = 0.07, 95% CI:[0.97, 2.25]). The mortality rate with traxoprodil treatment was 7% less than with placebo treatment (OR 1.45, p = 0.08, 95% CI: [0.96, 2.18]). Differences between treatment groups were more pronounced in the severest subset (delta 11.8% for the dGOS at last visit and delta 16.6% for mortality). Traxoprodil was well tolerated. Although these results are intriguing, no definitive claim of efficacy can be made for traxoprodil for the treatment of severe TBI.	Pfizer, Global Res & Dev, CNS, Groton, CT 06340 USA; Pfizer Global Res & Dev, Groton, CT USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, Richmond, VA 23298 USA; Univ Calif San Diego, Ctr Med, Neurosurg Serv, San Diego, CA 92103 USA		Yurkewicz, L (corresponding author), Pfizer, Global Res & Dev, CNS, Eastern Point Rd, Groton, CT 06340 USA.	lorraine.yurkewicz@pfizer.com					*AANS, 1996, J NEUROTRAUM, V13, P640; Agresti A., 1990, CATEGORICAL DATA ANA; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bullock MR, 1999, ANN NY ACAD SCI, V890, P51, DOI 10.1111/j.1749-6632.1999.tb07980.x; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CASAGRANDE JT, 1978, BIOMETRICS, V34, P483, DOI 10.2307/2530613; CHEN MH, 1991, J NEUROSURG, V74, P944, DOI 10.3171/jns.1991.74.6.0944; CHENARD BL, 1995, J MED CHEM, V38, P3138, DOI 10.1021/jm00016a017; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1987, J NEUROSCI, V7, P357; CHOI SC, 1995, CONTROL CLIN TRIALS, V16, P164, DOI 10.1016/0197-2456(94)00112-G; Di X, 1997, STROKE, V28, P2244, DOI 10.1161/01.STR.28.11.2244; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; Faden AI, 2001, ARCH NEUROL-CHICAGO, V58, P1553, DOI 10.1001/archneur.58.10.1553; Farin A, 2003, J NEUROSURG, V98, P32, DOI 10.3171/jns.2003.98.1.0032; FOSTER AC, 1988, J NEUROSCI, V8, P4745; Kemp JA, 2002, NAT NEUROSCI, V5, P1039, DOI 10.1038/nn936; KOCH GG, 1988, BIOPHARMACEUTICAL ST, P418; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Maas AIR, 2000, CNS DRUGS, V13, P139, DOI 10.2165/00023210-200013020-00007; MARAGOS WF, 1987, TRENDS NEUROSCI, V10, P65, DOI 10.1016/0166-2236(87)90025-7; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; Menniti F, 1997, EUR J PHARMACOL, V331, P117, DOI 10.1016/S0014-2999(97)10092-9; Menniti Frank S., 1998, CNS Drug Reviews, V4, P307, DOI 10.1111/j.1527-3458.1998.tb00073.x; Menniti FS, 2000, NEUROPHARMACOLOGY, V39, P1147, DOI 10.1016/S0028-3908(99)00211-7; Merchant RE, 1999, ANN NY ACAD SCI, V890, P42, DOI 10.1111/j.1749-6632.1999.tb07979.x; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Okiyama K, 1998, BRAIN RES, V792, P291, DOI 10.1016/S0006-8993(98)00158-9; Okiyama K, 1997, J NEUROTRAUM, V14, P211, DOI 10.1089/neu.1997.14.211; Teng E L, 1994, Int Psychogeriatr, V6, P45, DOI 10.1017/S1041610294001602; *TRAUM COM DAT BAN, 1987, MAN OP; Tsuchida E, 1997, J NEUROTRAUM, V14, P409, DOI 10.1089/neu.1997.14.409; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; WOLF AL, 1993, J NEUROSURG, V78, P54, DOI 10.3171/jns.1993.78.1.0054	35	82	87	0	10	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2005	22	12					1428	1443		10.1089/neu.2005.22.1428			16	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	000EA	WOS:000234442500006	16379581				2022-02-06	
J	Schuster, R; Waxman, K; Sanchez, B; Becerra, S; Chung, R; Conner, S; Jones, T				Schuster, R; Waxman, K; Sanchez, B; Becerra, S; Chung, R; Conner, S; Jones, T			Magnetic resonance imaging is not needed to clear cervical spines in blunt trauma patients with normal computed tomographic results and no motor deficits	ARCHIVES OF SURGERY			English	Article; Proceedings Paper	76th Annual Meeting of the Pacific-Coast-Surgical-Association	FEB 19-20, 2005	Dana Point, CA	Pacific Coast Surg Assoc			RADIOGRAPHY; INJURY; FRACTURES	Hypothesis: Trauma patients with normal motor examination results and normal cervical spine helical computed tomographic (CT) scans with sagittal reconstructions do not have significant cervical spine injury. Design: Prospectively collected registry data. Setting: Level 11 community-based trauma center Patients: All patients admitted to the trauma service from January 1, 1999, to December 31, 2003. Main Outcome Measures: Injury detected by CT and/or magnetic resonance imaging (MRI) of the cervical spine. Neurologic examination and need for surgery were secondary outcomes. Results: During the study period, 2854 trauma patients were admitted, of whom 91.2% had blunt trauma. Of these patients, 56.2% had a closed head injury. One hundred patients had cervical spine and/or spinal cord injuries. Eighty-five patients had a cervical spine injury diagnosed by CT. Fifteen patients had admission neurologic deficits not seen on CT, and 7 of these patients had nonbony abnormalities on MRI. Ninety-three patients had a normal admission motor examination result, a CT result negative for trauma, and persistent cervical spine pain, and were examined with MRI. All MRI examination results were negative for clinically significant injury. Seventeen patients had MRIs that showed degenerative disc disease, and 6 had spinal canal stenosis secondary to ossification. Twelve comatose patients (Glasgow Coma Scale score, < 9), moving all 4 extremities on arrival, with normal CT results of the cervical spine, were examined with MRI. All of these MRI examination results were negative for injury. None of the patients experienced neurologic deterioration. No patient required operative management of spinal injury. Conclusion: Blunt trauma patients with normal motor examination results and normal CT results of the cervical spine do not require further radiologic examination before clearing the cervical spine.	Santa Barbara Cottage Hosp, Dept Surg Educ, Santa Barbara, CA 93102 USA; Santa Barbara Cottage Hosp, Dept Surg, Santa Barbara, CA 93102 USA; Santa Barbara Cottage Hosp, Dept Neurosurg, Santa Barbara, CA 93102 USA		Waxman, K (corresponding author), Santa Barbara Cottage Hosp, Dept Surg Educ, POB 689, Santa Barbara, CA 93102 USA.	kwaxman@sbch.org					Albrecht RM, 2003, AM SURGEON, V69, P261; Barba CA, 2001, J TRAUMA, V51, P652, DOI 10.1097/00005373-200110000-00005; Berne JD, 1999, J TRAUMA, V47, P896, DOI 10.1097/00005373-199911000-00014; Besman A, 2003, AM SURGEON, V69, P1010; BOROCK EC, 1991, J TRAUMA, V31, P1001, DOI 10.1097/00005373-199107000-00021; Crim JR, 2001, SEMIN ULTRASOUND CT, V22, P283, DOI 10.1016/S0887-2171(01)90023-X; Diaz JJ, 2003, J TRAUMA, V55, P658, DOI 10.1097/01.TA.0000088120.99247.4A; Hanson JA, 2002, AM J ROENTGENOL, V178, P1261, DOI 10.2214/ajr.178.5.1781261; Hoffman JR, 1998, ANN EMERG MED, V32, P461, DOI 10.1016/S0196-0644(98)70176-3; Hoffman JR, 2000, NEW ENGL J MED, V343, P94, DOI 10.1056/NEJM200007133430203; Horn EM, 2004, J NEUROSURG-SPINE, V1, P39, DOI 10.3171/spi.2004.1.1.0039; MARION D, DETERMINATION CERVIC; Pasquale M, 1998, J TRAUMA, V44, P941, DOI 10.1097/00005373-199806000-00001; RAVICHANDRAN G, 1982, BRIT MED J, V284, P953, DOI 10.1136/bmj.284.6320.953; ROBERGE RJ, 1988, J TRAUMA, V28, P784, DOI 10.1097/00005373-198806000-00010; SANCHEZ B, IN PRESS J TRAUMA; Schenarts PJ, 2001, J TRAUMA, V51, P663, DOI 10.1097/00005373-200110000-00007; Weisskopf M, 2001, EUR SPINE J, V10, P250, DOI 10.1007/s005860000208; WOODRING JH, 1993, J TRAUMA, V34, P32, DOI 10.1097/00005373-199301000-00006	19	82	83	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0004-0010	1538-3644		ARCH SURG-CHICAGO	Arch. Surg.	AUG	2005	140	8					762	765		10.1001/archsurg.140.8.762			4	Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Surgery	951RM	WOS:000230948300013	16103286	Bronze			2022-02-06	
J	Jorge, RE; Starkstein, SE; Arndt, S; Moser, D; Crespo-Facorro, B; Robinson, RG				Jorge, RE; Starkstein, SE; Arndt, S; Moser, D; Crespo-Facorro, B; Robinson, RG			Alcohol misuse and mood disorders following traumatic brain injury	ARCHIVES OF GENERAL PSYCHIATRY			English	Article							STRUCTURED CLINICAL INTERVIEW; SEROTONIN TRANSPORTER; ANTERIOR CINGULATE; SUBSTANCE-ABUSE; PREFRONTAL CORTEX; ACUTE PREDICTORS; DRUG-ADDICTION; FRONTAL-CORTEX; POLYMORPHISMS; DEPRESSION	Context: Alcohol abuse and/or dependence (AA/D) and mood disturbance are co-occurring conditions among patients who have had a traumatic brain injury (TBI). However, the relationship between these disorders has not been extensively studied. Objective: To examine the relationship of AA/D and post-TBI mood disorders and the effect of these conditions on psychosocial outcome. Design: Prospective, case-control surveillance study conducted during the first year following trauma. Settings: University hospital level I trauma centers and specialized rehabilitation units. Patients: One hundred fifty-eight TBI patients with closed head injury with and without a history of AA/D. Methods: We prospectively compared psychiatric, neuropsychological, and psychosocial outcomes among the patients, who were evaluated at baseline and at 3, 6, and 12 months after trauma. Psychiatric diagnosis was made using a structured clinical interview and DSM-IV criteria. Neuropsychological testing results and quantitative magnetic resonance images were obtained at the 3-month follow-up. Results: A history of AA/D was significantly more frequent among patients who developed mood disorders during the first year following TBI. There was also a significantly higher frequency of mood disorders among patients with alcohol abuse relapse. Patients with a history of AA/D had significantly reduced frontal gray matter volumes than did patients without a history of alcohol abuse. in addition, patients who resumed alcohol abuse had decreased medial frontal gray matter volumes and impaired performance in executive tasks. Both AA/D and mood disorders following TBI were associated with a poor vocational outcome. Conclusions: Previous alcohol abuse increases the risk of developing mood disorders after TBI, and emotional disturbance, in turn, increases the risk of alcohol abuse relapse. Alcohol's neurotoxic effects and TBI likely interact to produce greater disruption of the neural circuits that modulate reward, mood, and executive function. Patients with a history of AA/D who also developed mood disorders following TBI had major difficulties resuming a productive life.	Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA; Univ Western Australia, Sch Psychiat & Clin Neurosci, Perth, WA 6009, Australia		Jorge, RE (corresponding author), 500 Newton Rd, Iowa City, IA 52242 USA.	ricardo-jorge@uiowa.edu	Arndt, Stephan/A-6976-2013; Robinson, Robert/AAF-6191-2021; Crespo-Facorro, BENEDICTO/AAY-2238-2021	Arndt, Stephan/0000-0003-0783-8204; Crespo-Facorro, BENEDICTO/0000-0003-0033-7132; Moser, David/0000-0003-4102-5266	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH-40355, MH-53592, MH-52879] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH052879, R01MH053592, R01MH040355] Funding Source: NIH RePORTER		Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; ANDREASEN NC, 1994, P NATL ACAD SCI USA, V91, P93, DOI 10.1073/pnas.91.1.93; ANDREASEN NC, 1992, J NEUROPSYCH CLIN N, V4, P125; Andreasen NC, 1996, J COMPUT ASSIST TOMO, V20, P98, DOI 10.1097/00004728-199601000-00018; ANDREASEN NC, 1993, J NEUROPSYCH CLIN N, V5, P121; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Benton AL, 1994, MULTILINGUAL APHASIA; Berns GS, 1997, SCIENCE, V276, P1272, DOI 10.1126/science.276.5316.1272; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Bombardier CH, 2002, ARCH PHYS MED REHAB, V83, P1765, DOI 10.1053/apmr.2002.36085; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; Cherner M, 2001, ARCH PHYS MED REHAB, V82, P780, DOI 10.1053/apmr.2001.23263; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; COHEN G, 1992, PSYCHIAT RES-NEUROIM, V45, P33, DOI 10.1016/0925-4927(92)90012-S; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Crespo-Facorro B, 1999, NEUROIMAGE, V10, P500, DOI 10.1006/nimg.1999.0489; Davidson RJ, 2002, BIOL PSYCHIAT, V51, P68, DOI 10.1016/S0006-3223(01)01328-2; Davidson RJ, 2003, AM J PSYCHIAT, V160, P64, DOI 10.1176/appi.ajp.160.1.64; Davidson RJ, 2002, BIOL PSYCHIAT, V52, P478, DOI 10.1016/S0006-3223(02)01458-0; Dawson DR, 2004, BRAIN INJURY, V18, P221, DOI 10.1080/02699050310001617406; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Drevets WC, 2001, CURR OPIN NEUROBIOL, V11, P240, DOI 10.1016/S0959-4388(00)00203-8; Drevets WC, 2002, EUR NEUROPSYCHOPHARM, V12, P527, DOI 10.1016/S0924-977X(02)00102-5; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gerra G, 2004, AM J MED GENET B, V126B, P37, DOI 10.1002/ajmg.b.20111; Gilman S, 1998, ANN NEUROL, V44, P326, DOI 10.1002/ana.410440307; Golden CJ, 1978, STROOP COLOR WORD TE; Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642; Gorwood P, 2000, BIOL PSYCHIAT, V48, P259, DOI 10.1016/S0006-3223(00)00840-4; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Harris G, 1999, J COMPUT ASSIST TOMO, V23, P144, DOI 10.1097/00004728-199901000-00030; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Heinz A, 2003, MOL PSYCHIATR, V8, P231, DOI 10.1038/sj.mp.4001214; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hill EM, 2002, PSYCHIAT GENET, V12, P143, DOI 10.1097/00041444-200209000-00005; Hinson JM, 2002, COGN AFFECT BEHAV NE, V2, P341, DOI 10.3758/CABN.2.4.341; Johnson PA, 2003, J NEUROPSYCH CLIN N, V15, P397, DOI 10.1176/appi.neuropsych.15.4.397; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kaplan E, 1983, BOSTON NAMING TEST; KAUFMAN AS, 1999, ESSENTIALS WAIS 3 AS, V8; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; Kolakowsky-Hayner S, 2002, BRAIN INJURY, V16, P583, DOI 10.1080/02699050110119475; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Lakatos K, 2003, MOL PSYCHIATR, V8, P90, DOI 10.1038/sj.mp.4001212; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Lezak MD., 1983, NEUROPSYCHOLOGICAL A, V2nd ed.; Magnotta VA, 1999, RADIOLOGY, V211, P781, DOI 10.1148/radiology.211.3.r99ma07781; Magnotta VA, 1999, CEREB CORTEX, V9, P151, DOI 10.1093/cercor/9.2.151; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; Morgan D, 2002, NAT NEUROSCI, V5, P169, DOI 10.1038/nn798; Patkar AA, 2002, PSYCHIAT RES, V110, P103, DOI 10.1016/S0165-1781(02)00098-7; Peoples LL, 2002, SCIENCE, V296, P1623, DOI 10.1126/science.1072997; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; REITAN RM, 1971, PERCEPT MOTOR SKILL, V33, P575, DOI 10.2466/pms.1971.33.2.575; Ridderinkhof KR, 2002, SCIENCE, V298, P2209, DOI 10.1126/science.1076929; ROBINSON RG, 1981, ANN NEUROL, V9, P447, DOI 10.1002/ana.410090506; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P138, DOI 10.1016/S0003-9993(97)90254-9; Shidara M, 2002, SCIENCE, V296, P1709, DOI 10.1126/science.1069504; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624; Starr L B, 1982, Soc Work Res Abstr, V18, P28; STARR LB, 1983, EXP AGING RES, V9, P101, DOI 10.1080/03610738308258434; Szabo Z, 2004, BIOL PSYCHIAT, V55, P766, DOI 10.1016/j.biopsych.2003.11.023; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Turner AP, 2003, ARCH PHYS MED REHAB, V84, P358, DOI 10.1053/apmr.2003.50107; Volkow ND, 2002, NEUROBIOL LEARN MEM, V78, P610, DOI 10.1006/nlme.2002.4099; Volkow ND, 2003, J CLIN INVEST, V111, P1444, DOI 10.1172/JCI200318533; Wager TD, 2004, SCIENCE, V303, P1162, DOI 10.1126/science.1093065; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604; WILLIAMS JBW, 1992, ARCH GEN PSYCHIAT, V49, P630; WING JK, 1990, ARCH GEN PSYCHIAT, V47, P589; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013	80	82	84	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0003-990X	1538-3636		ARCH GEN PSYCHIAT	Arch. Gen. Psychiatry	JUL	2005	62	7					742	749		10.1001/archpsyc.62.7.742			8	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	943KJ	WOS:000230352100007	15997015	Bronze			2022-02-06	
J	Kraus, MF; Smith, GS; Butters, M; Donnell, AJ; Dixon, E; Yilong, C; Marion, D				Kraus, MF; Smith, GS; Butters, M; Donnell, AJ; Dixon, E; Yilong, C; Marion, D			Effects of the dopaminergic agent and NMDA receptor antagonist amantadine on cognitive function, cerebral glucose metabolism and D2 receptor availability in chronic traumatic brain injury: A study using positron emission tomography (PET)	BRAIN INJURY			English	Article; Proceedings Paper	9th Annual Meeting of the Organization-for-Human-Brain-Mapping	JUN 18-22, 2003	New York, NY	Org Human Brain Mapping		amantadine; traumatic brain injury; frontal lobes; executive function; positron emission tomography; dopamine	PREFRONTAL CORTEX; MILD; MEMANTINE; PERFUSION; RELEASE	Primary objective: This study was performed to assess effects of amantadine (AMH), a dopaminergic agent and NMDA antagonist, on chronic traumatic brain injury (TBI). The primary hypotheses were that amantadine treatment would result in executive function improvement and increased activity in pre-frontal cortex. Research design: An open-label design was used. Methods: Twenty-two subjects underwent neuropsychological testing pre- and post-12 week treatment. Six subjects also underwent PET scanning. Intervention: Amantadine 400 mg was administered per day. Results: Significant improvements on tests of executive function were observed with treatment. Analysis of PET data demonstrated a significant increase in left pre- frontal cortex glucose metabolism. There was a significant positive correlation between executive domain scores and left pre- frontal glucose metabolism. Conclusions: This is the first known study to assess amantadine in chronic TBI using PET and the data are consistent with the hypotheses. The conduction of further studies is warranted.	Univ Illinois, Dept Psychiat, Ctr Cognit Med, Chicago, IL 60612 USA; N Shore Long Isl Jewish Hlth Syst, Zucker Hillside Hosp, New York, NY USA; N Shore Long Isl Jewish Hlth Syst, Ctr Neurosci, N Shore Long Isl Jewish Res Inst, New York, NY USA; Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA USA; Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA USA; Boston Univ, Med Ctr, Dept Neurol Surg, Boston, MA USA		Kraus, MF (corresponding author), Univ Illinois, Dept Psychiat, Ctr Cognit Med, 912 S Wood St,Suite 235,MC 913, Chicago, IL 60612 USA.	mkraus@psych.uic.edu	Butters, Meryl/AAR-2863-2021		PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [100849] Funding Source: Medline		Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Abu-Judeh HH, 1998, J NUCL MED, V39, P1357; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Andersson Stein, 1992, Tidsskrift for den Norske Laegeforening, V112, P2070; AOKI FY, 1988, CLIN PHARMACOKINET, V14, P35, DOI 10.2165/00003088-198814010-00003; Baldo JV, 2001, J INT NEUROPSYCH SOC, V7, P586, DOI 10.1017/S1355617701755063; Benton A., 1994, CONTRIBUTIONS NEUROP; Benton AL, 1994, MULTILINGUAL APHASIA; Blanpied TA, 1997, J NEUROPHYSIOL, V77, P309, DOI 10.1152/jn.1997.77.1.309; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; CHUGANI HT, 1991, J NUCL MED, V32, P23; Conners C. K., 2000, CONNERS CONTINUOUS P; Deep P, 1999, SYNAPSE, V34, P313, DOI 10.1002/(SICI)1098-2396(19991215)34:4<313::AID-SYN7>3.0.CO;2-1; Delis D.C., 2000, CALIFORNIA VERBAL LE; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Eker C, 2000, BRAIN INJURY, V14, P605; FRISTON KJ, 1995, J CEREBR BLOOD F MET, V15, P361, DOI 10.1038/jcbfm.1995.45; GIANUTSOS G, 1985, EUR J PHARMACOL, V110, P357, DOI 10.1016/0014-2999(85)90564-3; GOLDMAN PS, 1971, EXP NEUROL, V32, P366, DOI 10.1016/0014-4886(71)90005-7; Gronwall D, 1989, MILD HEAD INJURY, P153; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; HERRMANN EC, 1960, P SOC EXP BIOL MED, V103, P625, DOI 10.3181/00379727-103-25617; Hesselink MB, 1999, J NEURAL TRANSM, V106, P803, DOI 10.1007/s007020050201; Hoofien D, 2001, BRAIN INJURY, V15, P189; Kegeles LS, 2002, SYNAPSE, V43, P19, DOI 10.1002/syn.10010; KRAUS JF, 1998, REHABILITATION ADULT, P3; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Logan J, 2001, J CEREBR BLOOD F MET, V21, P307, DOI 10.1097/00004647-200103000-00014; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Moresco RM, 2002, J NEURAL TRANSM, V109, P1265, DOI 10.1007/s00702-002-0694-7; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; Passler MA, 1985, DEV NEUROPSYCHOL, V1, P349, DOI 10.1080/87565648509540320; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; SCHWAB RS, 1969, J AMER MED ASSOC, V208, P1168, DOI 10.1001/jama.208.7.1168; Smith GS, 1998, NEUROPSYCHOPHARMACOL, V18, P18; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; *WAR DEP, 1944, ARM IND TEST BATT; Winblad B, 1999, INT J GERIATR PSYCH, V14, P135, DOI 10.1002/(SICI)1099-1166(199902)14:2<135::AID-GPS906>3.0.CO;2-0; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009	45	82	86	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2005	19	7					471	479		10.1080/02699050400025059			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Rehabilitation	933IQ	WOS:000229622500001	16134735				2022-02-06	
J	Ozdemir, D; Uysal, N; Gonenc, S; Acikgoz, O; Sonmez, A; Topcu, A; Ozdemir, N; Duman, M; Semin, I; Ozkan, H				Ozdemir, D; Uysal, N; Gonenc, S; Acikgoz, O; Sonmez, A; Topcu, A; Ozdemir, N; Duman, M; Semin, I; Ozkan, H			Effect of melatonin on brain oxidative damage induced by traumatic brain injury in immature rats	PHYSIOLOGICAL RESEARCH			English	Article						traumatic brain injury (TBI); immature rat; lipid peroxidation; superoxide dismutase (SOD); glutathione peroxidase (GPx); melatonin	INDUCED LIPID-PEROXIDATION; EXPERIMENTAL HEAD TRAUMA; GLUTATHIONE-PEROXIDASE; SUPEROXIDE-DISMUTASE; FREE-RADICALS; DNA-DAMAGE; IN-VITRO; STRESS; PROTECTS; CHILDREN	Progressive compromise of antioxidant defenses and free radical-mediated lipid peroxidation, which is one of the major mechanisms of secondary traumatic brain injury (TBI), has also been reported in pediatric head trauma. In the present study, we aimed to demonstrate the effect of melatonin, which is a potent free radical scavenger, on brain oxidative damage in 7-day-old rat pups subjected to contusion injury. Whereas TBI significantly increased thiobarbituric acid reactive substances (TBARS) levels, there was no compensatory increase in the antioxidant enzymes such as superoxide dismutase (SOD) and glutathione peroxidase (GPx) 24 hours after TBI in 7-day-old rats. Melatonin administered as a single dose of 5 mg/kg prevented the increase in TBARS levels in both non-traumatized and traumatized brain hemispheres. In conclusion, melatonin protects against oxidative damage induced by TBI in the immature brain.	Dokuz Eylul Univ, Sch Med, Dept Pediat, Inciralti, Turkey; Dokuz Eylul Univ, Sch Med, Dept Physiol, Inciralti, Turkey; Ataturk Training & Res Hosp, Dept Neurosurg, Izmir, Turkey		Ozkan, H (corresponding author), Dokuz Eylul Univ, Sch Med, Dept Pediat, TR-35340 Izmir, Turkey.	hasan.ozkan@deu.edu.tr		Uysal, Nazan/0000-0002-2348-7427; ACIKGOZ, OSMAN/0000-0003-1444-5847; Ozkan, Hasan/0000-0003-2542-7441; Semin, Ilgi/0000-0001-8747-5145; Duman, Murat/0000-0001-6767-5748			Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Buonocore G, 2002, PEDIATR RES, V52, P46, DOI 10.1203/01.PDR.0000016664.46604.01; Buonocore G, 2001, BIOL NEONATE, V79, P180; CARRILLO MC, 1991, LIFE SCI, V48, P517, DOI 10.1016/0024-3205(91)90466-O; Cirak B, 1999, PEDIATR NEUROSURG, V31, P298, DOI 10.1159/000028879; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Cuzzocrea S, 2001, EUR J PHARMACOL, V426, P1, DOI 10.1016/S0014-2999(01)01175-X; DELMASBEAUVIEUX MC, 1995, CLIN BIOCHEM, V28, P163, DOI 10.1016/0009-9120(94)00071-3; EVANS PH, 1993, BRIT MED BULL, V49, P577, DOI 10.1093/oxfordjournals.bmb.a072632; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; Garcia JJ, 1997, FEBS LETT, V408, P297, DOI 10.1016/S0014-5793(97)00447-X; Gilad E, 1997, LIFE SCI, V60, pPL169, DOI 10.1016/S0024-3205(97)00008-8; HAGEMAN JJ, 1992, CHEM-BIOL INTERACT, V82, P243, DOI 10.1016/0009-2797(92)90001-2; Kabuto H, 1998, EPILEPSIA, V39, P237, DOI 10.1111/j.1528-1157.1998.tb01367.x; Kasprzak HA, 2001, J NEUROTRAUM, V18, P793, DOI 10.1089/089771501316919157; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; MELCHIORRI D, 1995, FASEB J, V9, P1205, DOI 10.1096/fasebj.9.12.7672513; Okatani Y, 2000, J PINEAL RES, V28, P89, DOI 10.1034/j.1600-079X.2001.280204.x; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Pekarkova I, 2001, PHYSIOL RES, V50, P595; REHNCRONA S, 1980, J NEUROCHEM, V34, P1630, DOI 10.1111/j.1471-4159.1980.tb11254.x; Reiter RJ, 2000, BIOL SIGNAL RECEPT, V9, P160; Reiter RJ, 2000, J BIOMED SCI, V7, P444, DOI 10.1159/000025480; REITERRJ, 1998, PROG NEUROBIOL, V56, P359; Rodriguez C, 2004, J PINEAL RES, V36, P1, DOI 10.1046/j.1600-079X.2003.00092.x; Rogerio F, 2002, BRAIN RES, V926, P33, DOI 10.1016/S0006-8993(01)03286-3; SEWERYNEK E, 1995, FREE RADICAL BIO MED, V19, P903, DOI 10.1016/0891-5849(95)00101-3; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Solar P, 1999, Cesk Fysiol, V48, P27; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; Tan DX, 2000, FREE RADICAL BIO MED, V29, P1177, DOI 10.1016/S0891-5849(00)00435-4; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Undeger U, 2004, EXP TOXICOL PATHOL, V55, P379, DOI 10.1078/0940-2993-00332; Ustun ME, 2001, J TRAUMA, V51, P22, DOI 10.1097/00005373-200107000-00004; Ustun ME, 2001, J NEUROSURG ANESTH, V13, P227; Wakatsuki A, 1999, J PINEAL RES, V26, P147, DOI 10.1111/j.1600-079X.1999.tb00576.x; Wakatsuki A, 2001, J PINEAL RES, V31, P167, DOI 10.1034/j.1600-079x.2001.310211.x; Wakatsuki A, 2001, J PINEAL RES, V30, P22, DOI 10.1034/j.1600-079X.2001.300103.x; WATANABE N, 1986, CLIN CHEM, V32, P1551; Yamamoto H, 1996, J PINEAL RES, V21, P108, DOI 10.1111/j.1600-079X.1996.tb00277.x; Yamamoto HA, 2002, TOXICOLOGY, V179, P29, DOI 10.1016/S0300-483X(02)00244-5	44	82	87	1	14	ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY	PRAGUE 4	VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC	0862-8408	1802-9973		PHYSIOL RES	Physiol. Res.		2005	54	6					631	637					7	Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Physiology	000RV	WOS:000234481000008	15720160				2022-02-06	
J	Shutter, L; Tong, KA; Holshouser, BA				Shutter, L; Tong, KA; Holshouser, BA			Proton MRS in acute traumatic brain injury: Role for glutamate/glutamine and choline for outcome prediction	JOURNAL OF NEUROTRAUMA			English	Article						diffuse axonal injury; glutamate; glutamine; proton magnetic resonance spectroscopy; traumatic brain injury	MAGNETIC-RESONANCE-SPECTROSCOPY; SEVERE HEAD-INJURY; SOMATOSENSORY-EVOKED POTENTIALS; METABOLISM; GLUTAMATE; CREATINE; SPECTRA; TREE	Proton magnetic resonance spectroscopy (MRS) is being used to evaluate individuals with acute traumatic brain injury and several studies have shown that changes in certain brain metabolites (N-acetylaspartate, choline) are associated with poor neurologic outcomes. The majority of previous MRS studies have been obtained relatively late after injury and none have examined the role of glutamate/glutamine (Glx). We conducted a prospective MRS study of 42 severely injured adults to measure quantitative metabolite changes early (7 days) after injury in normal appearing brain. We used these findings to predict long-term neurologic outcome and to determine if MRS data alone or in combination with clinical outcome variables provided better prediction of long-term outcomes. We found that glutamate/glutamine (Glx) and choline (Cho) were significantly elevated in occipital gray and parietal white matter early after injury in patients with poor long-term (6-12-month) outcomes. Glx and Cho ratios predicted long-term outcome with 94% accuracy and when combined with the motor Glasgow Coma Scale score provided the highest predictive accuracy (97%). Somatosensory evoked potentials were not as accurate as MRS data in predicting outcome. Elevated Glx and Cho are more sensitive indicators of injury and predictors of poor outcome when spectroscopy is done early after injury. This may be a reflection of early excitotoxic injury (i.e., elevated Glx) and of injury associated with membrane disruption (i.e., increased Cho) secondary to diffuse axonal injury.	Loma Linda Univ, Med Ctr, Loma Linda, CA 92354 USA; Loma Linda Univ, Med Ctr, Dept Radiol, Loma Linda, CA 92350 USA; Univ Cincinnati, Med Ctr, Dept Neurosurg, Cincinnati, OH 45221 USA		Holshouser, BA (corresponding author), Loma Linda Univ, Med Ctr, MRI-B624,12354 Anderson St, Loma Linda, CA 92354 USA.	bholshouser@ahs.llumc.edu	Shutter, Lori A/G-2957-2013	Shutter, Lori/0000-0002-1390-0628			Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; BECA J, 1995, J PEDIATR-US, V126, P44, DOI 10.1016/S0022-3476(95)70498-1; Brain Trauma Foundation American Association of Neurological Surgeons Joint Section on Neurotrauma and Critical Care, 2000, GUID MAN SEV HEAD IN; Brewer GJ, 2000, J NEUROCHEM, V74, P1968, DOI 10.1046/j.1471-4159.2000.0741968.x; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; Brustovetsky N, 2001, J NEUROCHEM, V76, P425, DOI 10.1046/j.1471-4159.2001.00052.x; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; Fisher SK, 2002, J NEUROCHEM, V82, P736, DOI 10.1046/j.1471-4159.2002.01041.x; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; GUTLING E, 1993, ELECTROEN CLIN NEURO, V88, P369, DOI 10.1016/0168-5597(93)90013-F; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MOULTON RJ, 1994, CLIN INVEST MED, V17, P187; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; PohlmannEden B, 1997, INTENS CARE MED, V23, P301, DOI 10.1007/s001340050332; Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Shutter LA, 2000, PROGNOSIS NEUROLOGIC, P335	31	82	93	1	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2004	21	12					1693	1705		10.1089/neu.2004.21.1693			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	877FY	WOS:000225554400001	15684761				2022-02-06	
J	Lu, DY; Mahmood, A; Goussev, A; Schallert, T; Qu, CS; Zhang, ZG; Li, Y; Lu, M; Chopp, M				Lu, DY; Mahmood, A; Goussev, A; Schallert, T; Qu, CS; Zhang, ZG; Li, Y; Lu, M; Chopp, M			Atorvastatin reduction of intravascular thrombosis, increase in cerebral microvascular patency and integrity, and enhancement of spatial learning in rats subjected to traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; atorvastatin; vascular injury; spatial memory; rat	CONTROLLED CORTICAL IMPACT; ENDOTHELIAL NITRIC-OXIDE; HEAD-INJURY; STATINS; ISCHEMIA; STROKE; MICE; INHIBITOR; SYNTHASE; PROTECTS	Object. Atorvastatin, a beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor, has pleiotropic effects, such as promoting angiogenesis, increasing fibrinolysis, and reducing inflammatory responses, and has shown promise in enhancing recovery in animals with traumatic brain injury (TBI) and stroke. The authors tested the effect of atorvastatin on vascular changes after TBI. Methods. Male Wistar rats subjected to controlled cortical impact injury were perfused at different time points with fluorescein isothiocyanate (FITC)-conjugated dextran 1 minute before being killed. Spatial memory function had been measured using a Morris Water Maze test at various points before and after TBI. The temporal profile of intravascular thrombosis and vascular changes was measured on brain tissue sections by using a microcomputer imaging device and a laser confocal microscopy. The study revealed the following results. 1) Vessels in the lesion boundary zone and hippocampal CA3 region showed a variety of damage, morphological alterations, reduced perfusion, and intraluminal microthrombin formation. 2) Atorvastatin enhanced FITC-dextran perfusion of vessels and reduced intravascular coagulation. 3) Atorvastatin promoted the restoration of spatial memory function. Conclusions. These results indicated that atorvastatin warrants investigation as a potential therapeutic drug for TBI.	Henry Ford Hlth Sci Ctr, Dept Neurosurg, Detroit, MI USA; Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI USA; Henry Ford Hlth Sci Ctr, Dept Biostat, Detroit, MI USA; Univ Texas, Dept Psychol, Austin, TX 78712 USA; Univ Texas, Inst Neurosci, Austin, TX 78712 USA; Oakland Univ, Dept Phys, Rochester, MI USA		Chopp, M (corresponding author), Henry Ford Hosp, Dept Neurol, 2799 W Grand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS40225] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [P01 42345] Funding Source: Medline		Aktas O, 2003, J EXP MED, V197, P725, DOI 10.1084/jem.20021425; Amin-Hanjani S, 2001, STROKE, V32, P980, DOI 10.1161/01.STR.32.4.980; Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; Biros MH., 1998, EMERGENCY MED CONCEP, P416; Bocan Thomas M A, 2002, Curr Opin Investig Drugs, V3, P1312; Brouet A, 2001, CIRC RES, V89, P866, DOI 10.1161/hh2201.100319; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Cominacini L, 2003, J AM COLL CARDIOL, V41, P499, DOI 10.1016/S0735-1097(02)02811-5; Dalla Nora E, 2003, J ENDOCRINOL INVEST, V26, P73, DOI 10.1007/BF03345126; Day LB, 1999, BEHAV NEUROSCI, V113, P914, DOI 10.1037/0735-7044.113.5.914; Day LB, 1996, BEHAV NEUROSCI, V110, P998; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Eberlein M, 2001, BRIT J PHARMACOL, V133, P1172, DOI 10.1038/sj.bjp.0704173; Eto M, 2003, ENDOTHELIUM-J ENDOTH, V10, P35, DOI 10.1080/10623320303359; Friedrich DH, 2000, ACTA NEUROCHIR SUPPL, V76, P257; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Gennarelli TA, 1997, NEUROSCIENTIST, V3, P73, DOI 10.1177/107385849700300117; Golding EA, 2003, J CEREBR BLOOD F MET, V23, P210, DOI 10.1097/01.WCB.0000044739.64940.B5; Gryglewski RJ, 2001, ANN NY ACAD SCI, V947, P229; Honjo M, 2002, ARCH OPHTHALMOL-CHIC, V120, P1707; KAUFMAN HH, 1980, NEUROSURGERY, V7, P445, DOI 10.1227/00006123-198011000-00003; Kitching AR, 1997, J EXP MED, V185, P963, DOI 10.1084/jem.185.5.963; Lattimore SU, 2003, STROKE, V34, pE55, DOI 10.1161/01.STR.0000073789.12120.F3; Laufs U, 2000, STROKE, V31, P2442, DOI 10.1161/01.STR.31.10.2442; Laufs U, 2003, EUR J CLIN PHARMACOL, V58, P719, DOI 10.1007/s00228-002-0556-0; Laufs U, 2002, BRAIN RES, V942, P23, DOI 10.1016/S0006-8993(02)02649-5; Laurer HL., 2000, EUR J TRAUMA, V26, P95, DOI [10.1007/s000680050007, DOI 10.1007/S000680050007]; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mason JC, 2003, CLIN SCI, V105, P251, DOI 10.1042/CS20030148; Mason JC, 2002, CIRC RES, V91, P696, DOI 10.1161/01.RES.0000038151.57577.19; MINER ME, 1985, NEUROSURGERY, P1666; Mital S, 2000, AM J PHYSIOL-HEART C, V279, pH2649, DOI 10.1152/ajpheart.2000.279.6.H2649; Ohyama H, 2001, BRAIN RES, V902, P264, DOI 10.1016/S0006-8993(01)02354-X; PLOPLIS VA, 1995, CIRCULATION, V92, P2585, DOI 10.1161/01.CIR.92.9.2585; Shovman O, 2002, IMMUNOL RES, V25, P271, DOI 10.1385/IR:25:3:271; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sparks D L, 2002, J Nutr Health Aging, V6, P324; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Stumpf C, 2003, CLIN SCI, V105, P45, DOI 10.1042/CS20020359; Yamada K, 1999, BRIT J PHARMACOL, V126, P235, DOI 10.1038/sj.bjp.0702309; Yokota H, 2002, J NEUROTRAUM, V19, P1007, DOI 10.1089/089771502760341929; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Zhang ZG, 1999, J NEUROSCI, V19, P10898, DOI 10.1523/JNEUROSCI.19-24-10898.1999	46	82	82	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2004	101	5					813	821		10.3171/jns.2004.101.5.0813			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	873UL	WOS:000225306500013	15540920				2022-02-06	
J	Cornwell, EE; Chang, DC; Phillips, J; Campbell, KA				Cornwell, EE; Chang, DC; Phillips, J; Campbell, KA			Enhanced trauma program commitment at a level I trauma center - Effect on the process and outcome of care	ARCHIVES OF SURGERY			English	Article; Proceedings Paper	74th Annual Meeting of the Pacific-Coast-Surgical-Association	FEB 16-18, 2003	MONTEREY, CALIFORNIA	Pacific Coast Surg Assoc			SEVERELY INJURED PATIENTS; HOUSE; SURGEONS; IMPACT; QUALITY; COST	Hypothesis: With advances in surgical care, the occurrences of major adverse outcomes have become a rare event. The effect of a surgical service can be more comprehensively evaluated by following the Donabedian model, looking at the triad of structure, process, and outcome. It is hypothesized that the implementation of a focused program commitment at a trauma center is associated with improvements in process of care and patient outcomes. Design: Evaluation of prospectively collected information in a trauma registry for the 3-year periods immediately before (1995-1997) and after (1999-2001) the implementation (in 1998) of the full-time trauma. service. Setting: Level I university-affiliated trauma center. Patients: Patients meeting criteria for major trauma. Intervention: The implementation of a full-time trauma service, featuring 24-hour in-house attending coverage, dedicated trauma admitting unit, regular trauma core curriculum, regular multidisciplinary quality assurance meetings, and state designation for level I status. Main Outcome Measures: Process of care measures, including time in the emergency department (ED) and trauma "bypass" hours (ie, time spent in the trauma resuscitation area). Outcome measures, including lengths of stay, overall mortality and mortality, excluding ED deaths. Results: The total number of patients with major trauma increased from 2240 (1995-1997) to 2513 (1999-2001). The average time in the ED for patients going to the operating room, intensive care unit, and observation wards all decreased significantly (84 vs 52 minutes, 197 vs 118 minutes, and 300 vs 140 minutes, respectively; all with P < .01). The number of hours that the trauma center was closed owing to ED overcrowding also decreased significantly, from 56 to 2.7 hours per month (P < .01). After excluding ED deaths, there was a trend on bivariate analyses toward lower overall mortality rates (4.5% vs 3.4%, P = .07) and mortality rates among patients with severe head injury (23.8% vs 17.2%, P = .07). On further analyses with multiple logistic regression, controlling for age, Injury Severity Score, Abbreviated Injury Score (for a head injury) I and admission blood pressure, the later period is associated with a 31% decrease in overall odds of death (P = .047) and a 42% decrease in odds of death among patients with severe head injury (an Abbreviated Injury Score, greater than or equal to3; P = .03). Conclusion: The implementation of a full-time trauma service is associated with improved timeliness of triage and therapeutic interventions and improved patient outcomes.	Johns Hopkins Univ, Sch Med, Div Trauma, Dept Surg, Baltimore, MD 21218 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA		Cornwell, EE (corresponding author), Johns Hopkins Univ Hosp, 600 N Wolfe St,Osler 625, Baltimore, MD 21287 USA.						[Anonymous], 1999, RES OPT CAR INJ PAT; Cohen MM, 1999, J TRAUMA, V46, P1114, DOI 10.1097/00005373-199906000-00028; Demarest GAB, 1999, J TRAUMA, V46, P535, DOI 10.1097/00005373-199904000-00001; DEMETRIADES D, 1995, ARCH SURG-CHICAGO, V130, P216; Dodek P, 2000, AM J MED QUAL, V15, P3, DOI 10.1177/106286060001500102; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; Fulda GJ, 2002, J TRAUMA, V53, P494, DOI 10.1097/00005373-200209000-00017; Luchette F, 1997, J TRAUMA, V42, P490, DOI 10.1097/00005373-199703000-00017; Porter JM, 2001, AM SURGEON, V67, P611; ROGERS FB, 1993, J TRAUMA, V34, P871, DOI 10.1097/00005373-199306000-00019; THOMPSON CT, 1992, J TRAUMA, V32, P336, DOI 10.1097/00005373-199203000-00011	11	82	88	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0004-0010			ARCH SURG-CHICAGO	Arch. Surg.	AUG	2003	138	8					838	842		10.1001/archsurg.138.8.838			5	Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Surgery	709HB	WOS:000184618800005	12912741	Bronze			2022-02-06	
J	Valera, EM; Berenbaum, H				Valera, EM; Berenbaum, H			Brain injury in battered women	JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY			English	Article; Proceedings Paper	Annual Meeting of the International-Society-for-Traumatic-Stress-Studies	DEC 06-09, 2001	NEW ORLEANS, LOUISIANA	Int Soc Traumat Stress Studies			MINOR HEAD-INJURY; POSTTRAUMATIC-STRESS-DISORDER; VIOLENCE; RELIABILITY; CONCUSSION; DEPRESSION; SYMPTOMS; SCALES	The goals of the present study were to examine (a) whether battered women in a sample of both shelter and nonshelter women are sustaining brain injuries from their partners and (b) if so, whether such brain injuries are associated with partner abuse severity, cognitive functioning, or psychopathology. Ninety-nine battered women were assessed using neuropsychological, psychopathology, and abuse history measures. Almost three quarters of the sample sustained at least I partner-related brain injury and half sustained multiple partner-related brain injuries. Further, in a subset of women (n = 57), brain injury severity was negatively associated with measures of memory, learning, and cognitive flexibility and was positively associated with partner abuse severity, general distress, anhedonic depression, worry, anxious arousal, and posttraurnatic stress disorder symptomatology.	Univ Illinois, Dept Psychol, Urbana, IL 61801 USA		Valera, EM (corresponding author), Massachusetts Gen Hosp, Dept Pathol, Bldg 149,9th Floor E,13th St, Charlestown, MA 02129 USA.				NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [1 F31 MH11763-01A2] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [F31MH011763] Funding Source: NIH RePORTER		Adjutant General's Office, 1944, ARM IND TEST BATT MA; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; Bremner JD, 1999, BIOL PSYCHIAT, V45, P797, DOI 10.1016/S0006-3223(99)00009-8; BROWN R, 1992, JAMA-J AM MED ASSOC, V267, P3184; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; Campbell JC, 1997, PSYCHIAT CLIN N AM, V20, P353, DOI 10.1016/S0193-953X(05)70317-8; CASCARDI M, 1992, J FAM VIOLENCE, V7, P249, DOI 10.1007/BF00994617; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; CLARK LA, 1991, J ABNORM PSYCHOL, V100, P316, DOI 10.1037/0021-843X.100.3.316; COHEN J, 1987, STAT POWER ANAL BEHA; Committee on Mild Traumatic Brain Injury and American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P48; DELIS D, 1987, CALIFORNIA VERBAL LE; Delis DC, 1988, CLIN NEUROPSYCHOL, V2, P188, DOI DOI 10.1080/13854048808520100; Diaz-Olavarrieta C, 1999, ARCH NEUROL-CHICAGO, V56, P681, DOI 10.1001/archneur.56.6.681; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dutton MA, 1992, EMPOWERING HEALING B; First MB, 1995, STRUCTURED CLIN INTE; GENNARELLI TA, 1981, ACTA NEUROPATHOL B S, V7, P26; Goodman LA, 1993, APPL PREV PSYCHOL, V2, P79, DOI [10.1016/S0962-1849(05)80114-3, DOI 10.1016/S0962-1849(05)80114-3]; GRONWALL D, 1975, LANCET, V2, P995; Harway M, 1994, SPOUSE ABUSE ASSESSI; Hawley DA, 2001, J EMERG MED, V21, P317, DOI 10.1016/S0736-4679(01)00401-2; HOUSKAMP BM, 1991, J INTERPERS VIOLENCE, V6, P367, DOI 10.1177/088626091006003008; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Koss M. P., 1994, NO SAFE HAVEN MALE V, P69; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEZAK MD, 1982, 5 EUR C INT NEUR SOC; MARSHALL LL, 1992, J FAM VIOLENCE, V7, P103, DOI 10.1007/BF00978700; MATARAZZO JD, 1984, J CLIN NEUROPSYCHOL, V6, P351, DOI 10.1080/01688638408401227; Mayberg H, 2001, FRONTAL-SUBCORTICAL CIRCUITS IN PSYCHIATRIC AND NEUROLOGICAL DISORDERS, P177; McGrath E., 1990, WOMEN DEPRESSION RIS; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; MEYER TJ, 1990, BEHAV RES THER, V28, P487, DOI 10.1016/0005-7967(90)90135-6; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROURKE SB, 1996, NEUROPSYCHOLOGICAL A, P379; RUFF RM, 1987, DEV NEUROPSYCHOL, V3, P37, DOI 10.1080/87565648709540362; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; SMITH DJ, 2001, J EMERG MED, V21, P223; Straus M, 1990, PHYSICAL VIOLENCE AM; STRAUS MA, 1979, J MARRIAGE FAM, V41, P75, DOI 10.2307/351733; Vitanza S, 1995, Violence Vict, V10, P23; WALKER LEA, 1994, ABUSED WOMAN SURVIVO; WARSHAW C, 2001, PSYCHOL ASPECTS WOME, P477; Wechsler D., 1981, WAIS R MANUAL; YOUNGJOHN JR, 1992, CLIN NEUROPSYCHOL, V6, P276, DOI DOI 10.1080/13854049208404129; [No title captured], DOI DOI 10.1037/0894-4105.5.4.253	53	82	82	0	12	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0022-006X			J CONSULT CLIN PSYCH	J. Consult. Clin. Psychol.	AUG	2003	71	4					797	804		10.1037/0022-006X.71.4.797			8	Psychology, Clinical	Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Social Science Citation Index (SSCI)	Psychology	703QM	WOS:000184292500018	12924684				2022-02-06	
J	Wagner, AK; Kline, AE; Sokoloski, J; Zafonte, RD; Capulong, E; Dixon, CE				Wagner, AK; Kline, AE; Sokoloski, J; Zafonte, RD; Capulong, E; Dixon, CE			Intervention with environmental enrichment after experimental brain trauma enhances cognitive recovery in male but not female rats	NEUROSCIENCE LETTERS			English	Article						environmental enrichment; traumatic brain injury; controlled cortical impact; gender; cognitive recovery; spatial memory	INJURY; PROGESTERONE; EXPRESSION; ESTROGEN; CORTEX	Environmental enrichment (EE) has been repeatedly shown to affect multiple aspects of brain function, and is known to enhance cognitive recovery after experimental traumatic brain injury (TBI) in males. However, the impact of gender on how EE affects behavioral performance after experimental TBI have not been studied. Male and normally cycling female Sprague-Dawley rats underwent controlled cortical impact injury or sham surgery and then were placed in either a standard or enriched housing environment. Motor function was assessed both pre-injury and for the first 5 days after injury. Spatial memory was assessed beginning 14 days after injury. Placement in an EE after TBI enhanced spatial memory performance in male but not female rats. EE did not impact motor performance in this setting. These findings have gender specific implications for how to approach and evaluate treatments and interventions after TBI. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.	Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA		Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Kaufmann Bldg,Suite 201, Pittsburgh, PA 15213 USA.	wagnerak@msx.upmc.edu					Berchtold NC, 2001, EUR J NEUROSCI, V14, P1992, DOI 10.1046/j.0953-816x.2001.01825.x; Bland ST, 2000, STROKE, V31, P1144, DOI 10.1161/01.STR.31.5.1144; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; BRYAN JM, 2001, J NEUROTRAUM, V18, P1129; BUTCHER RL, 1974, ENDOCRINOLOGY, V94, P1704, DOI 10.1210/endo-94-6-1704; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Ickes BR, 2000, EXP NEUROL, V164, P45, DOI 10.1006/exnr.2000.7415; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; KOLB B, 1995, BEHAV NEUROSCI, V109, P285, DOI 10.1037/0735-7044.109.2.285; Kolb B, 1998, NEUROSCI BIOBEHAV R, V22, P143, DOI 10.1016/S0149-7634(97)00008-0; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Pham TM, 1999, NEUROSCIENCE, V94, P279, DOI 10.1016/S0306-4522(99)00316-4; Rampon C, 2000, P NATL ACAD SCI USA, V97, P12880, DOI 10.1073/pnas.97.23.12880; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Teskey GC, 1999, CEREB CORTEX, V9, P675, DOI 10.1093/cercor/9.7.675; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Winterfeld KT, 1998, J NEUROSCI RES, V52, P201, DOI 10.1002/(SICI)1097-4547(19980415)52:2<201::AID-JNR8>3.0.CO;2-E	20	82	85	0	9	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	DEC 16	2002	334	3					165	168	PII S0304-3940(02)01103-5	10.1016/S0304-3940(02)01103-5			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	624MK	WOS:000179763300006	12453621				2022-02-06	
J	Stuart, MJ; Smith, AM; Malo-Ortiguera, SA; Fischer, TL; Larson, DR				Stuart, MJ; Smith, AM; Malo-Ortiguera, SA; Fischer, TL; Larson, DR			A comparison of facial protection and the incidence of head, neck, and facial injuries in junior A hockey players - A function of individual playing time	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article; Proceedings Paper	AOSSM-NHL Team Physician Meeting on Sports Medicine and Hockey: A Summit for the NHL and Beyond	AUG, 2001	TORONTO, CANADA				ICE HOCKEY; FACE MASKS; HELMETS	A cohort of 282 elite amateur ice hockey players were analyzed to 1) record the number, type, location, and severity of head, neck, and facial injuries sustained during games; 2) examine the relationship between injuries and the type of facial protection (none, partial, or full) according to individual playing time; and 3) determine whether full or partial facial protection is associated with an increased incidence of concussions, eye injuries, and neck injuries. Fifty-two injuries (158.9 per 1000 player-game hours) occurred in players wearing no facial protection, 45 (73.5 per 1000 player-game hours) in players wearing partial facial protection (half shield), and 16 (23.2 per 1000 player-game hours) In players wearing full facial protection (full cage or shield). Players wearing no protection were injured at a rate more than twice that of players wearing partial protection and almost seven times higher than those wearing full protection. Concussions occurred in four players wearing no protection, five players wearing partial protection, and two players wearing full protection; these differences were not significant. The risk of eye injury was 4.7 times greater for players wearing no protection compared with those wearing partial protection. No eye or neck injuries occurred in players wearing full protection. This study demonstrates that both full and partial facial protection significantly reduce injuries to the eye and face without increasing neck injuries and concussions.	Mayo Clin & Mayo Fdn, Dept Orthoped, Rochester, MN 55905 USA		Stuart, MJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Orthoped, 200 1st St SW, Rochester, MN 55905 USA.						BEMARD D, 1993, ASTM STP, V112, P44; Benson BW, 1999, JAMA-J AM MED ASSOC, V282, P2328, DOI 10.1001/jama.282.24.2328; GIBLERT WD, 2000, ASTM STP, V1341, P291; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; LAPRADE RF, 1995, AM J SPORT MED, V23, P773, DOI 10.1177/036354659502300624; LINDENFELD TN, 1998, AM J SPORTS MED S1, V16, pS69; LORENTZON R, 1988, AM J SPORT MED, V16, P392, DOI 10.1177/036354658801600415; Mair SD, 1996, AM J SPORT MED, V24, P137, DOI 10.1177/036354659602400203; MARCOTTE G, 1993, ASTM STP, V1212, P103, DOI DOI 10.1520/STP13128S; MURRAY TM, 1995, PEDIATRICS, V95, P419; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Pless IB, 2000, CAN MED ASSOC J, V162, P792; PSHBY T, 1993, ASTM STP, V1212, P159; REYNEN PD, 1994, AM J SPORT MED, V22, P167, DOI 10.1177/036354659402200203; Rice SG, 2000, AM SOC TEST MATER, V1341, P3, DOI 10.1520/STP15223S; Roberts WO, 1996, ARCH PEDIAT ADOL MED, V150, P140, DOI 10.1001/archpedi.1996.02170270022003; Sim FH., 1989, J MUSCULOSKELET MED, V6, P15; Smith AM, 1997, AM J SPORT MED, V25, P500, DOI 10.1177/036354659702500413; Smith AM, 2000, AM SOC TEST MATER, V1341, P199, DOI 10.1520/STP15240S; STUART MJ, 1995, MAYO CLIN PROC, V70, P350, DOI 10.4065/70.4.350; STUART MJ, 1995, AM J SPORT MED, V23, P458, DOI 10.1177/036354659502300415; Stuart MJ, 2000, AM SOC TEST MATER, V1341, P19, DOI 10.1520/STP15224S; Tator CH, 1997, CLIN J SPORT MED, V7, P17, DOI 10.1097/00042752-199701000-00004; WALSH S, 1989, ASTM STP, V1050, P55	25	82	82	1	14	AMER ORTHOPAEDIC SOC SPORT MED	WALTHAM	230 CALVARY STREET, WALTHAM, MA 02154 USA	0363-5465			AM J SPORT MED	Am. J. Sports Med.	JAN-FEB	2002	30	1					39	44		10.1177/03635465020300012001			6	Orthopedics; Sport Sciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	512XX	WOS:000173349800007	11798994				2022-02-06	
J	Felmingham, KL; Baguley, IJ; Crooks, J				Felmingham, KL; Baguley, IJ; Crooks, J			A comparison of acute and postdischarge predictors of employment 2 years after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; employment; forecasting; rehabilitation	HEAD-INJURY; SCALE; RETURN; WORK; VALIDATION; ABUSE; COMA	Objective: To examine whether adding postdischarge psychosocial predictors to premorbid and injury-related variables improved the capacity to predict employment 2 years after rehabilitation for traumatic brain injury (TBI). Design: Data were collected prospectively at 6 and 24 months after discharge from rehabilitation. Logistic regression analyses examined predictors of employment status. Setting: Inpatient and community TBI rehabilitation service attached to a major Australian teaching hospital. Participants: Fifty-five patients with TBI, aged 16 or older, who were consecutively admitted to a brain injury unit with complete longitudinal data and who agreed to participate in the study. Intervention: Measured injury severity (Glasgow Coma Scale scores, posttraumatic amnesia): functional independence (Functional Assessment Measure cognitive subscale) at admission and discharge from rehabilitation; self-report of employment (premorbid, postdischarge): postdischarge psychosocial status at 6 months and 2 years (Community Integration Questionnaire, General Health Questionnaire, Trauma Complaints List, Overt Aggression Scale. Alcohol Use Disorders Inventory Test, Satisfaction with Life Scale). Main Outcome Measures: Employment status (employed, unemployed) was used to reflect vocational outcome. Predictor variables comprised premorbid work status, injury-related variables (age, injury severity). and postdischarge variables (employ ment, community integration, psychologic, cognitive status). Results: Adding postdischarge predictors to premorbid and acute variables significantly improved the ability to predict work status 2 years after rehabilitation. Age at the time of injury, premorbid employment status, work status, and psychologic distress 6 months postdischarge were significant predictors of employment. Conclusions: It is important to consider postdischarge psychologic well-being. in conjunction with premorbid and acute factors, in vocational interventions after TBI.	Westmead Hosp, Brain Injury Unit, Brain Injury Rehabil Serv, Westmead, NSW 2145, Australia		Felmingham, KL (corresponding author), Westmead Hosp, Brain Injury Unit, Brain Injury Rehabil Serv, Westmead, NSW 2145, Australia.		Baguley, Ian J/K-6878-2013; Baguley, Ian/AAM-5828-2021	Baguley, Ian J/0000-0001-5650-3705; 			Baguley IJ, 1997, ARCH PHYS MED REHAB, V78, P1248, DOI 10.1016/S0003-9993(97)90339-7; BOHN MJ, 1995, J STUD ALCOHOL, V56, P423, DOI 10.15288/jsa.1995.56.423; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CORRIGAN J D, 1992, Brain Injury, V6, P155, DOI 10.3109/02699059209029653; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Goldberg D., 1972, DETECTION PSYCHIAT I; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Gurka JA, 1999, J HEAD TRAUMA REHAB, V14, P247, DOI 10.1097/00001199-199906000-00005; Hall K, 1992, NEUROREHABILITATION, V2, P98, DOI DOI 10.3233/NRE-1992-2410; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; Stuss D. T., 1992, J HEAD TRAUMA REHAB, V7, P40; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; TEASDALE G, 1974, LANCET, V2, P81; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35	29	82	82	0	10	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2001	82	4					435	439		10.1053/apmr.2001.21985			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	419GC	WOS:000167940100002	11295001				2022-02-06	
J	Mauler, F; Fahrig, T; Horvath, E; Jork, R				Mauler, F; Fahrig, T; Horvath, E; Jork, R			Inhibition of evoked glutamate release by the neuroprotective 5-HT1A receptor agonist BAY x 3702 in vitro and in vivo	BRAIN RESEARCH			English	Article						BAY x 3702; glutamate release; ischemia; middle cerebral artery occlusion; microdialysis	BAY X 3702; CEREBRAL-ARTERY OCCLUSION; EXCITATORY AMINO-ACIDS; ISCHEMIC BRAIN-DAMAGE; EXTRACELLULAR GLUTAMATE; NMDA ANTAGONIST; RAT STRIATUM; SEROTONIN; HYPOTHERMIA; METABOLITES	Brain ischemia provoked by stroke or traumatic brain injury induces a massive increase in neurotransmitter release, in particular of the excitotoxin glutamate. Glutamate triggers a cascade of events finally leading to widespread neuronal cell damage and death. The aminomethylchroman derivative BAY x 3702 is a novel neuroprotectant which shows pronounced beneficial effects in various animal models of ischemic brain injury. As shown previously BAY x 3702 binds to 5-HT1A receptors of different species in subnanomolar range and is characterized as a full receptor agonist. In this study we investigated the influence of BAY x 3702 on potassium-evoked glutamate release in vitro and ischemia-induced glutamate release in vivo. In rat hippocampal slices BAY x 3702 inhibited evoked glutamate release in a dose-dependent manner (IC50 = 1 muM). This effect was blocked by the selective 5-HT1A receptor antagonist WAY 100635, indicating that BAY x 3702 specifically acts via 5-HT1A receptors. In vivo, release of endogenous aspartate and glutamate was measured in the cortex of rats by microdialysis before and after onset of permanent middle cerebral artery occlusion. Single dose administration of BAY x 3702 (1 mug/kg or 10 mug/kg i.v.) immediately after occlusion reduced the increase and total release of extracellular glutumate by about 50% compared to non-treated animals, whereas the extracellular aspartate levels were not significantly affected. Inhibition of glutamate release may therefore contribute to the pronounced neuroprotective efficacy of BAY x 3702 in various animal models of ischemic brain damage. (C) 2001 Elsevier Science B.V. All rights reserved.	Bayer AG, PHR CNS, D-42096 Wuppertal, Germany		Mauler, F (corresponding author), Bayer AG, PHR CNS, Aprather Weg 18a, D-42096 Wuppertal, Germany.	frank.mauler.fm@buyer-ag.de					Alessandri B, 1999, BRAIN RES, V845, P232, DOI 10.1016/S0006-8993(99)01948-4; BAKER AJ, 1991, J NEUROCHEM, V57, P1370, DOI 10.1111/j.1471-4159.1991.tb08303.x; Barnes NM, 1999, NEUROPHARMACOLOGY, V38, P1083, DOI 10.1016/S0028-3908(99)00010-6; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Boxer PA, 1997, DRUG DISCOV TODAY, V2, P219, DOI 10.1016/S1359-6446(97)01045-3; BULLOCK R, 1995, STROKE, V26, P2187, DOI 10.1161/01.STR.26.11.2187; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; BUTCHER SP, 1990, STROKE, V21, P1727, DOI 10.1161/01.STR.21.12.1727; CHEN J, 1995, BRAIN RES, V699, P121, DOI 10.1016/0006-8993(95)00868-Q; COLINO A, 1987, NATURE, V328, P73, DOI 10.1038/328073a0; DAMSMA G, 1990, J NEUROCHEM, V54, P801, DOI 10.1111/j.1471-4159.1990.tb02322.x; DAVIES MF, 1987, BRAIN RES, V423, P347, DOI 10.1016/0006-8993(87)90861-4; De Keyser J, 1999, TRENDS NEUROSCI, V22, P535, DOI 10.1016/S0166-2236(99)01463-0; De Vry J, 1998, J PHARMACOL EXP THER, V284, P1082; De Vry J, 1998, EUR J PHARMACOL, V357, P1, DOI 10.1016/S0014-2999(98)00503-2; De Vry Jean, 1997, Drugs of the Future, V22, P341; GLOBUS MYT, 1988, J NEUROCHEM, V51, P1455, DOI 10.1111/j.1471-4159.1988.tb01111.x; GRAHAM JL, 1994, BRIT J PHARMACOL, V112, pU141; GRAHAM SH, 1993, J CEREBR BLOOD F MET, V13, P88, DOI 10.1038/jcbfm.1993.11; HAGBERG H, 1985, J CEREBR BLOOD F MET, V5, P413, DOI 10.1038/jcbfm.1985.56; HARRINGTON CR, 1990, ANAL BIOCHEM, V186, P285, DOI 10.1016/0003-2697(90)90081-J; HILLERED L, 1989, J CEREBR BLOOD F MET, V9, P607, DOI 10.1038/jcbfm.1989.87; Horvath E., 1997, Society for Neuroscience Abstracts, V23, P1923; HORVATH E, 1998, J NEUROTRAUM, V14, P800; Huh PW, 2000, J NEUROSURG, V92, P91, DOI 10.3171/jns.2000.92.1.0091; Kornhuber J, 1997, BIOL PSYCHIAT, V41, P135, DOI 10.1016/S0006-3223(96)00047-9; Koyama T, 1999, NEUROSCI LETT, V265, P33, DOI 10.1016/S0304-3940(99)00200-1; Lees KR, 1997, NEUROLOGY, V49, pS66, DOI 10.1212/WNL.49.5_Suppl_4.S66; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; MELDRUM BS, 1992, BRAIN RES, V593, P1, DOI 10.1016/0006-8993(92)91254-C; MITANI A, 1991, NEUROSCIENCE, V42, P661, DOI 10.1016/0306-4522(91)90035-M; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; PAXINOS G, 1982, RAT BRAIN STEREOTACT; PERUCHE B, 1994, J NEURAL TRANSM-PARK, V8, P73, DOI 10.1007/BF02250918; PREHN JHM, 1993, BRAIN RES, V630, P10, DOI 10.1016/0006-8993(93)90636-2; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Seki Y, 1999, STROKE, V30, P433, DOI 10.1161/01.STR.30.2.433; Shimada F, 1999, EUR J PHARMACOL, V386, P263, DOI 10.1016/S0014-2999(99)00735-9; SHIMIZU H, 1993, BRAIN RES, V605, P33, DOI 10.1016/0006-8993(93)91353-T; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; Suchanek B, 1998, EUR J PHARMACOL, V355, P95, DOI 10.1016/S0014-2999(98)00469-5; TAKAGI K, 1993, J CEREBR BLOOD F MET, V13, P575, DOI 10.1038/jcbfm.1993.75; WAHL F, 1994, J NEUROCHEM, V63, P1003; Whitaker-Azmitia PM, 1999, NEUROPSYCHOPHARMACOL, V21, pS2, DOI 10.1016/S0893-133X(99)00031-7; Yenari MA, 1998, CLIN NEUROPHARMACOL, V21, P28	45	82	84	1	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 5	2001	888	1					150	157		10.1016/S0006-8993(00)03074-2			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	392TB	WOS:000166427700016	11146061				2022-02-06	
J	Ben Arzi, N; Solomon, Z; Dekel, R				Ben Arzi, N; Solomon, Z; Dekel, R			Secondary traumatization among wives of PTSD and post-concussion casualties: distress, caregiver burden and psychological separation	BRAIN INJURY			English	Article							POSTTRAUMATIC-STRESS-DISORDER; MALE VIETNAM VETERANS; INDIVIDUATION; VALIDATION; INJURY; SCL-90; TRAUMA	This study has two aims. First, it assesses the implication of husbands' post-traumatic stress disorder (PTSD) and post-concussion syndrome (PC) on their wives' sense of burden and emotional distress. The second aim was to examine the implication of the women's separation-individuation on their adjustment. Sixty women participated in study: 20 women married to war veterans diagnosed as suffering to PTSD, 20 women married to war veterans suffering from PC, and 20 women married to healthy controls. Data was collected using self report questionnaires assessing psychiatric symptomatology, caregiver burden and psychological separation-individuation. Results indicate that women from both research groups suffer from higher levels of burden and distress than controls. The level of separation-individuation was found to be correlated to levels of burden and distress. The complex implications of living with a traumatized spouse are discussed.	Tel Aviv Univ, Bob Shapell Sch Social Work, IL-69978 Tel Aviv, Israel; Bar Ilan Univ, Sch Social Work, Ramat Gan, Israel		Solomon, Z (corresponding author), Tel Aviv Univ, Bob Shapell Sch Social Work, IL-69978 Tel Aviv, Israel.	solomon@post.tau.ac.il					BERROL S, 1992, PHYSICAL MED REHABIL; Blos P., 1979, ADOLESCENT PASSAGE; Bowen M., 1978, FAMILY THERAPY CLIN; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Coughlan K, 1987, J Psychosoc Nurs Ment Health Serv, V25, P25; Danieli Y., 1982, STRESS ANXIETY, P405; DEKEL R, IN PRESS J TRAUMATIC; DEROGATIS LR, 1977, J CLIN PSYCHOL, V33, P981, DOI 10.1002/1097-4679(197710)33:4<981::AID-JCLP2270330412>3.0.CO;2-0; DEROGATIS LR, 1976, BRIT J PSYCHIAT, V128, P280, DOI 10.1192/bjp.128.3.280; DEROGATIS RL, 1977, SCL90R MANUAL, V1; DICKS HV, 1967, MARITAL TENSIONS; Figley CR., 1983, STRESS FAMILY, P3; FIGLEY CR, 1986, TRAUMA ITS WAKE, V2, P39; Florian V, 1991, NEUROPSYCHOLOGY, V5, P267, DOI DOI 10.1037/0894-4105.5.4.267; HOFFMAN JA, 1987, J COUNS PSYCHOL, V34, P157; Horowitz MJ, 1986, STRESS RESPONSE SYND; JORDAN BK, 1992, J CONSULT CLIN PSYCH, V60, P916, DOI 10.1037/0022-006X.60.6.916; KARPEL M, 1976, FAM PROCESS, V15, P65, DOI 10.1111/j.1545-5300.1976.00065.x; KAY T, 1992, PHYSICAL MED REHABIL; LEVINSON OJ, 1979, SEASONS MANS LIFE; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LYONS JA, 1986, ANN CONV AM PSYCH AS; Mahler MS., 1975, PSYCHOL BIRTH HUMAN; MALONEY LJ, 1988, SMITH COLL STUD SOC, V58, P122, DOI 10.1080/00377318809516639; Marks NF, 1996, FAM RELAT, V45, P27, DOI 10.2307/584767; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; McAllister Thomas W., 1994, P357; MERIKANGAS KR, 1983, ARCH GEN PSYCHIAT, V40, P795; NOVAK M, 1989, GERONTOLOGIST, V29, P798, DOI 10.1093/geront/29.6.798; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; OSHANICK GJ, 1994, NEUROPSYCHIATRY TRAU, P163; Riggs DS, 1998, J TRAUMA STRESS, V11, P87, DOI 10.1023/A:1024409200155; ROSENBAUM M, 1987, J CONSULT CLIN PSYCH, V44, P881; ROSENHECK R, 1985, HOSP COMMUNITY PSYCH, V36, P538; ROSENHECK R, 1986, FAM PROCESS, V25, P559, DOI 10.1111/j.1545-5300.1986.00559.x; SABATELLI RM, 1985, ADOLESCENCE, V20, P619; SBOODONE R, 1995, BRAIN INJURY, V9, P405; SCHAUBEN LJ, 1995, PSYCHOL WOMEN QUART, V19, P49, DOI 10.1111/j.1471-6402.1995.tb00278.x; Schulz R., 1991, FAMILY CAREGIVING CH; SHEAN C, 1987, FAM RELAT, V36, P55; SOLOMON Z, 1992, FAM PROCESS, V31, P289, DOI 10.1111/j.1545-5300.1992.00289.x; SOLOMON Z, 1992, J MARRIAGE FAM, V54, P316, DOI 10.2307/353063; Solomon Z., 1993, COMBAT STRESS REACTI; SUTHERLAND JD, 1980, J AM PSYCHOANAL ASS, V28, P829, DOI 10.1177/000306518002800404; Taylor Craig A., 1994, P81; TOUR A, 1992, THESIS BAR ILAN U; Verbosky S J, 1988, Issues Ment Health Nurs, V9, P95, DOI 10.3109/01612848809140912; WILLIAMS CM, 1980, POST TRAUMATIC STRES, P79	48	82	82	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2000	14	8					725	736					12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	342XT	WOS:000088672000006	10969891				2022-02-06	
J	Minard, G; Kudsk, KA; Melton, S; Patton, JH; Tolley, EA				Minard, G; Kudsk, KA; Melton, S; Patton, JH; Tolley, EA			Early versus delayed feeding with an immune-enhancing diet in patients with severe head injuries	JOURNAL OF PARENTERAL AND ENTERAL NUTRITION			English	Article; Proceedings Paper	22nd Clinical Congress of the American-Society-of-Parenteral-and-Enteral-Nutrition	JAN 18-21, 1998	ORLANDO, FL	Amer Soc Parenteral & Enteral Nutr			MAJOR ABDOMINAL-TRAUMA; ENTERAL NUTRITION; SEPTIC COMPLICATIONS; CANCER-PATIENTS; ARGININE; BENEFITS; OMEGA-3-FATTY-ACIDS; PNEUMONIA; MORBIDITY; RNA	Background: Although early enteral feeding clearly reduces septic morbidity after blunt and penetrating trauma, data for head-injured patients are conflicting. This study examines the effects of early us delayed enteral feedings on outcome in patients with severe closed-head injuries with a Glasgow Coma Scale (GCS) score greater than 3 and less than 11. Methods: Thirty patients were prospectively randomized to receive an immune-enhancing diet (Impact with fiber) early (initiated < 72 hours after trauma) delivered via an endoscopically placed nasoenteric tube (Stay-Put)or late (administered after gastric ileus resolved). This formula was continued for 14 days or until the patient tolerated oral feeding. Goal rate of nutrition was 21 nonprotein cal/kg/d and 0.3 g N/kg/d. Results: Two patients in the early group were excluded due to inability to place the tube, and one patient in the late group died before 72 hours. Five of the remaining 27 died, 1 in the early group and 4 in the late group. There were no significant differences between the groups in length of stay, intensive care unit (ICU) days, significant infection, or GCS score. However, major infection correlated inversely with admission GCS score (R = -0.6, p <.003). Time to reach a GCS score of 14 was significantly longer in patients with significant infections compared with those without (p <.02). Conclusions: No difference in length of stay or infectious complications is shown in patients with severe closed-head injury when they are given early us delayed feeding using an immune-enhancing formula. Severity of the head injury is closely associated with significant infection.	Univ Tennessee, Dept Surg, Memphis, TN USA; Univ Tennessee, Dept Biostat & Epidemiol, Memphis, TN USA		Minard, G (corresponding author), 956 Court Ave,Suite E228, Memphis, TN 38163 USA.	gminard@utmem.edu					BORZOTTA AP, 1994, J TRAUMA, V37, P459, DOI 10.1097/00005373-199409000-00022; Braga M, 1996, EUR J SURG, V162, P105; CERRA FB, 1991, NUTRITION, V7, P193; DALY JM, 1992, SURGERY, V112, P56; DALY JM, 1995, ANN SURG, V221, P327, DOI 10.1097/00000658-199504000-00002; FELICIANO D V, 1991, Contemporary Surgery, V39, P30; GOTTSCHLICH MM, 1990, JPEN-PARENTER ENTER, V14, P225, DOI 10.1177/0148607190014003225; GRAHM TW, 1989, NEUROSURGERY, V25, P729, DOI 10.1227/00006123-198911000-00007; HSIEH AHH, 1992, AM REV RESPIR DIS, V146, P290, DOI 10.1164/ajrccm/146.2.290; KEMEN M, 1995, CRIT CARE MED, V23, P652, DOI 10.1097/00003246-199504000-00012; KUDSK KA, 1992, ANN SURG, V215, P503, DOI 10.1097/00000658-199205000-00013; Kudsk KA, 1996, ANN SURG, V224, P531, DOI 10.1097/00000658-199610000-00011; Mendez C, 1997, J TRAUMA, V42, P933, DOI 10.1097/00005373-199705000-00026; Mendez C, 1996, SHOCK, V6, P7, DOI 10.1097/00024382-199607000-00003; MOORE EE, 1986, J TRAUMA, V26, P874, DOI 10.1097/00005373-198610000-00003; MOORE FA, 1989, J TRAUMA, V29, P916, DOI 10.1097/00005373-198907000-00003; MOORE FA, 1992, ANN SURG, V216, P172, DOI 10.1097/00000658-199208000-00008; MOORE FA, 1994, J TRAUMA, V37, P607, DOI 10.1097/00005373-199410000-00014; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; QUATTROCCHI KB, 1992, J NEUROTRAUM, V9, P1, DOI 10.1089/neu.1992.9.1; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; RODRIGUEZ JL, 1991, J TRAUMA, V31, P907, DOI 10.1097/00005373-199107000-00005; Schilling J, 1996, NUTRITION, V12, P423, DOI 10.1016/S0899-9007(96)00096-2; TRICE S, 1997, NUTR CLIN PRACT, V12, P114; Woratyla S P, 1995, Conn Med, V59, P643; YOUNG B, 1987, J NEUROSURG, V67, P668, DOI 10.3171/jns.1987.67.5.0668	26	82	93	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0148-6071	1941-2444		JPEN-PARENTER ENTER	J. Parenter. Enter. Nutr.	MAY-JUN	2000	24	3					145	149		10.1177/0148607100024003145			5	Nutrition & Dietetics	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Nutrition & Dietetics	355MK	WOS:000089389300003	10850938				2022-02-06	
J	Lundqvist, A; Gerdle, B; Ronnberg, J				Lundqvist, A; Gerdle, B; Ronnberg, J			Neuropsychological aspects of driving after a stroke - in the simulator and on the road	APPLIED COGNITIVE PSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; CEREBRAL-DAMAGE; AGE-DIFFERENCES; BRAIN-DAMAGE; PERFORMANCE; OPERATIONS; CONCUSSION; BEHAVIOR; DRIVERS; SPEED	Thirty patients with stroke and 30 matched controls participated in the study (mean age 68 years, mean interval since stroke onset 8.6 months). The patients performed significantly worse on cognitive and attentional processing measured by a neuropsychological test battery. The patients had significantly greater difficulty in allocating processing resources to a secondary information processing task during driving in an advanced simulator. The patients performed worse driving in real traffic, and had less driving skill; fifty per cent did not pass the driving test. The neuropsychological test battery showed a pattern with three factors: (1) attentional processing (2) executive capacity, and (3) cognitive processing. Regression models based on simulator driving variables and neuropsychological test variables respectively, overall classified correctly in 85% and 83% of the cases with respect to driving skill. Decreased cognitive and attentional processing were suggested + to be associated with an overall speed impairment. Copyright (C) 2000 John Wiley & Sons, Ltd.	Linkoping Univ, Fac Hlth Sci, Dept Rehabil Med, S-58185 Linkoping, Sweden; Pain & Rehabil Ctr, Linkoping, Sweden; Linkoping Univ, Dept Educ & Psychol, S-58185 Linkoping, Sweden		Lundqvist, A (corresponding author), Linkoping Univ, Fac Hlth Sci, Dept Rehabil Med, S-58185 Linkoping, Sweden.		Ronnberg, Jerker/AAW-5049-2021	Gerdle, Bjorn/0000-0002-4316-1264; Ronnberg, Jerker/0000-0001-7311-9959			ALM H, 1995, ACCIDENT ANAL PREV, V27, P707, DOI 10.1016/0001-4575(95)00026-V; ALM H, 1989, V1017; BADDELEY A, 1985, J MEM LANG, V24, P119, DOI 10.1016/0749-596X(85)90019-1; Baddeley A. D., 1990, HUMAN MEMORY THEORY, P67; BINDER LM, 1978, REHABIL PSYCHOL, P65; BROOKE MM, 1992, AM J PHYS MED REHAB, V71, P177, DOI 10.1097/00002060-199206000-00009; Brouwer W H, 1994, Disabil Rehabil, V16, P149; CHRISTIE N, 1996, 207 TRL TRANSP ROAD; CRAIK FIM, 1987, J EXP PSYCHOL LEARN, V13, P474, DOI 10.1037/0278-7393.13.3.474; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; ENGUM SG, 1989, COGNITIVE REHABILITA, V7, P22; Filley C. M., 1995, NEUROPSYCHIATRY COMP, P913; Fox G K, 1992, Disabil Rehabil, V14, P140; GALSKI T, 1990, AM J OCCUP THER, V44, P709, DOI 10.5014/ajot.44.8.709; GALSKI T, 1992, AM J OCCUP THER, V46, P324, DOI 10.5014/ajot.46.4.324; Galski T, 1997, AM J OCCUP THER, V51, P352, DOI 10.5014/ajot.51.5.352; GOUVIER WD, 1989, ARCH PHYS MED REHAB, V70, P745; GREENWOOD P, 1991, DEV NEUROPSYCHOL, V7, P421, DOI 10.1080/87565649109540502; GRONWALL D, 1974, LANCET, V2, P605; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; GRUBERBALDINI AL, 1991, HDB PSYCHOL AGING, P276; HAKAMIESBLOMQVI.L, 1996, J INT ASS TRAFFIC SA, V20, P91; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JOHANSSON K, 1997, THESIS KAROLINSKA I; KNAPP TR, 1989, WESTERN J NURS RES, V11, P635; LEVANDER S, 1988, 11 U TRONDH DEP PSYC; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Lincoln N., 1992, CLIN REHABIL, V6, P275, DOI DOI 10.1177/026921559200600402; Loong J.W.K., 1990, WISCONSIN CARD SORTI; Lundberg C, 1998, ACCIDENT ANAL PREV, V30, P371, DOI 10.1016/S0001-4575(97)00111-5; Lundqvist A, 1997, APPL NEUROPSYCHOL, V4, P220, DOI 10.1207/s15324826an0404_3; Mazer BL, 1998, ARCH PHYS MED REHAB, V79, P743, DOI 10.1016/S0003-9993(98)90350-1; McDowd JM, 1990, HDB PSYCHOL AGING, P222, DOI [10.1016/b978-0-12-101280-9.50019-x, DOI 10.1016/B978-0-12-101280-9.50019-X]; Michon J. A., 1985, HUMAN BEHAV TRAFFIC, P485, DOI [DOI 10.1007/978-1-4613-2173-6_19, 10.1007/978-1-4613-2173-6_19]; MICHON JA, 1979, WORKSH TRAFF RES CTR; NESTOR PG, 1989, DEV NEUROPSYCHOL, V5, P141, DOI 10.1080/87565648909540429; NILSSON L, 1995, V2006 DRIVE EMMIS; Nordmark S., 1988, VTI DRIVING SIMULATO; NORUSIS MJ, 1993, SPSS WIND; NOURI EM, 1987, INT DISABILITY STUDI, V9, P110; PRIDDY D A, 1990, Brain Injury, V4, P267, DOI 10.3109/02699059009026176; RANNEY TA, 1994, ACCIDENT ANAL PREV, V26, P733, DOI 10.1016/0001-4575(94)90051-5; RONNBERG J, 1989, J SPEECH HEAR RES, V32, P725, DOI 10.1044/jshr.3204.725; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; SMITH GJ, 1986, MANUAL CWT SERIALT F; *SPSS INC, 1986, SPSS STAT PACK SOC S; STOKX LC, 1986, J CLIN EXP NEUROPSYC, V8, P421, DOI 10.1080/01688638608401332; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; SUNDET K, 1995, SCAND J PSYCHOL, V36, P47, DOI 10.1111/j.1467-9450.1995.tb00967.x; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; VANZOMEREN AH, 1988, ARCH PHYS MED REHAB, V69, P90; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; *VVFS, 1996, VAGV FOR MED KRAV IN; WELFORD AT, 1989, DEV NEUROPSYCHOL, V5, P261, DOI 10.1080/87565648909540436; WIEBERS DO, 1997, HDB STROKE, P43; Wilson T, 1983, Int Rehabil Med, V5, P170; Zomeren A.V., 1992, HDB NEUROPSYCHOLOGIC, P241, DOI [10.4324/9780429490316-12, DOI 10.4324/9780429490316-12]	60	82	83	0	4	JOHN WILEY & SONS LTD	W SUSSEX	BAFFINS LANE CHICHESTER, W SUSSEX PO19 1UD, ENGLAND	0888-4080			APPL COGNITIVE PSYCH	Appl. Cogn. Psychol.	MAR-APR	2000	14	2					135	150		10.1002/(SICI)1099-0720(200003/04)14:2<135::AID-ACP628>3.0.CO;2-S			16	Psychology, Experimental	Social Science Citation Index (SSCI)	Psychology	301FQ	WOS:000086299900003					2022-02-06	
J	Graham, DI; Raghupathi, R; Saatman, KE; Meaney, D; McIntosh, TK				Graham, DI; Raghupathi, R; Saatman, KE; Meaney, D; McIntosh, TK			Tissue tears in the white matter after lateral fluid percussion brain injury in the rat: relevance to human brain injury	ACTA NEUROPATHOLOGICA			English	Article						rat; lateral fluid percussion; tissue tears; traumatic brain injury	AMYLOID PRECURSOR PROTEIN; DIFFUSE AXONAL INJURY; FOCAL CEREBRAL-ISCHEMIA; HEAD-INJURY; RADIOPATHOLOGIC FEATURES; TRAUMATIC LESIONS; DAMAGE; MR; MILD; IMMEDIATE	A characteristic feature of severe diffuse axonal injury in man is radiological evidence of the "shearing injury triad" represented by lesions, sometimes haemorrhagic, in the corpus callosum, deep white matter and the rostral brain stem. With the exception of studies carried out on the non-human primate, such lesions have not been replicated to date in the multiple and diverse rodent laboratory models of traumatic brain injury. The present report describes tissue tears in the white matter, particularly in the fimbria of Sprague-Dawley rats killed 12, 24, and 48 h and 7 days after lateral fluid percussion brain injury of moderate severity (2.1-2.4 atm). The lesions were most easily seen at 24 h when they appeared as foci of tissue rarefaction in which there were a few polymorphonuclear leucocytes. At the margins of these lesions, large amounts of accumulated amyloid precursor protein (APP) were found in axonal swellings and bulbs. By 1 week post-injury, there was macrophage infiltration with marked astrocytosis and early scar formation. This lesion is considered to be due to severe defomation of white matter and this is the first time that it has been identified reproducibly in a rodent model of head injury under controlled conditions.	Univ Glasgow, Dept Neuropathol, Inst Neurol Sci, So Gen Hosp NHS Trust, Glasgow G51 4TF, Lanark, Scotland; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA		Graham, DI (corresponding author), Univ Glasgow, Dept Neuropathol, Inst Neurol Sci, So Gen Hosp NHS Trust, Glasgow G51 4TF, Lanark, Scotland.	D.Graham@clinmed.gla.ac.uk		Meaney, David/0000-0002-0954-4122	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS26818, P50-NS-08803] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P50NS008803] Funding Source: NIH RePORTER		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BLUMBERGS PC, 1994, ZENTRALBL NEUROCHIR, V52, P89; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; GEAN AD, 1994, IMAGING HEAD TRAUMA, P207; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1987, P 31 STAPP CAR CRASH, P48; Gennarelli TA, 1993, HEAD INJURY, P137; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Graham DI, 1997, GREENFIELDS NEUROPAT, P197; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; KALARIA RN, 1993, NEUROREPORT, V4, P211, DOI 10.1097/00001756-199302000-00025; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; OSBORNE KA, 1987, J NEUROL NEUROSUR PS, V50, P402, DOI 10.1136/jnnp.50.4.402; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pileri SA, 1997, J PATHOL, V183, P116; PILZ P, 1982, J NEUROL NEUROSUR PS, V45, P422, DOI 10.1136/jnnp.45.5.422; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SIMPSON DA, 1989, J TRAUMA, V29, P1519, DOI 10.1097/00005373-198911000-00011; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Soares HD, 1995, J NEUROSCI, V15, P8223; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; STRICH SJ, 1970, J CLIN PATHOL S4, V23, P166; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; Yam PS, 1998, J NEUROTRAUM, V15, P441, DOI 10.1089/neu.1998.15.441; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393; ZIMMERMAN RA, 1986, AM J NEURORADIOL, V7, P757; [No title captured]	57	82	82	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	FEB	2000	99	2					117	124		10.1007/PL00007414			8	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	275TA	WOS:000084835200005	10672317				2022-02-06	
J	Sanderson, KL; Raghupathi, R; Saatman, KE; Martin, D; Miller, G; McIntosh, TK				Sanderson, KL; Raghupathi, R; Saatman, KE; Martin, D; Miller, G; McIntosh, TK			Interleukin-1 receptor antagonist attenuates regional neuronal cell death and cognitive dysfunction after experimental brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						traumatic brain injury; cytokines; interleukins; histopathology; behavior; fluid-percussion	LONG-TERM POTENTIATION; FOCAL CEREBRAL-ISCHEMIA; RAT-BRAIN; INDUCE OVEREXPRESSION; ADENOVIRAL VECTOR; MESSENGER-RNA; HEAD-INJURY; EXPRESSION; DAMAGE; HIPPOCAMPUS	The effect of systemic administration of human recombinant interleukin-l receptor antagonist (rhIL-lra) on behavioral outcome and histopathologic damage after lateral fluid-percussion brain injury of moderate severity was evaluated. In study 1, brain-injured Sprague Dawley rats received timed subcutaneous injections beginnings 15 minutes after injury of either 100 mg/kg rhIL-lra (high dose, total dose = 1900 mg/kg), 10 mg/kg rhiIL-lra (low dose, total dose = 190 mg/kg), or vehicle over 7 days. No effect of low-dose rhIL-lra was observed in study 1. High-dose rhIL-lra significantly attenuated posttraumatic neuronal loss in the injured hippocampal CA, region (P < 0.05), dentate hilus (P < 0.05), and cortex (P < 0.05) but impaired recovery of motor function at 7 days after trauma (P < 0.05). In study 2, rats were pretrained to learn a visuospatial task in a Morris water maze, subjected to fluid- percussion brain injury or sham treatment, and randomly assigned to receive multiple subcutaneous injections at timed intervals of 100 mg/kg rhIL-lra (total dose = 900 mg/kg) or vehicle over 42 hours, followed by continuous infusion of a lower concentration of rhIL-lra (20 mg/kg/day, total dose = 100 mg/kg), or vehicle for 5 days using subcutaneously implanted osmotic minipumps, Postinjury administration of rhIL-Ira significantly attenuated cognitive deficits compared with vehicle-treated animals at 42 hours (P < 0.05) but did not affect motor function at 48 hours, 1 week, and 2 weeks. These results suggest that inhibitors of cytokine pathways may be therapeutically useful for the treatment of brain trauma.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Amgen Inc, Dept Pharmacol, Thousand Oaks, CA 91320 USA		McIntosh, TK (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P50NS008803] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NS08803, R01-NS26818] Funding Source: Medline		ALBRIGHT AL, 1984, J NEUROSURG, V60, P481, DOI 10.3171/jns.1984.60.3.0481; BELAYEV L, 1998, J NEUROTRAUM, V15, P858; BELLINGER FP, 1993, BRAIN RES, V628, P227, DOI 10.1016/0006-8993(93)90959-Q; BETZ AL, 1995, J CEREBR BLOOD F MET, V15, P547, DOI 10.1038/jcbfm.1995.68; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; CARMANKRZAN M, 1991, J NEUROCHEM, V56, P636, DOI 10.1111/j.1471-4159.1991.tb08197.x; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; GARCIA JH, 1995, AM J PATHOL, V147, P1477; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3; GUTIERREZ EG, 1994, J NEUROIMMUNOL, V55, P153, DOI 10.1016/0165-5728(94)90005-1; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; KADOYA C, 1995, STROKE, V26, P1035, DOI 10.1161/01.STR.26.6.1035; Lee SC, 1995, BRAIN BEHAV IMMUN, V9, P345, DOI 10.1006/brbi.1995.1032; Loddick SA, 1996, J CEREBR BLOOD F MET, V16, P932, DOI 10.1097/00004647-199609000-00017; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MARTIN D, 1994, EXP NEUROL, V130, P362, DOI 10.1006/exnr.1994.1215; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Murray CA, 1998, J NEUROSCI, V18, P2974; PELLMAR TC, 1991, NEUROSCIENCE, V44, P353, DOI 10.1016/0306-4522(91)90060-2; Pierce JES, 1996, J NEUROSCI, V16, P1083; Relton JK, 1996, EXP NEUROL, V138, P206, DOI 10.1006/exnr.1996.0059; RINK A, 1995, AM J PATHOL, V147, P1575; Rothwell NJ, 1998, NEUROSCIENTIST, V4, P195, DOI 10.1177/107385849800400315; ROTHWELL NJ, 1993, CEREBROVAS BRAIN MET, V5, P178; Scripter JL, 1997, EXP NEUROL, V145, P329, DOI 10.1006/exnr.1997.6470; Sheng JG, 1996, NEUROBIOL AGING, V17, P761; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SINSON G, 1995, J NEUROCHEM, V65, P2209; SMITH DH, 1993, J NEUROSCI, V13, P5383, DOI 10.1523/JNEUROSCI.13-12-05383.1993; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Stroemer RP, 1998, J CEREBR BLOOD F MET, V18, P833, DOI 10.1097/00004647-199808000-00003; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; YAMASHIRO K, 1995, HUM PATHOL, V26, P67, DOI 10.1016/0046-8177(95)90116-7; Yang GY, 1998, J CEREBR BLOOD F MET, V18, P840, DOI 10.1097/00004647-199808000-00004; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375	43	82	83	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	OCT	1999	19	10					1118	1125		10.1097/00004647-199910000-00008			8	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	276NH	WOS:000084883900008	10532636	Bronze			2022-02-06	
J	McDonald, S				McDonald, S			Exploring the process of inference generation in sarcasm: A review of normal and clinical studies	BRAIN AND LANGUAGE			English	Article							RIGHT-HEMISPHERE DAMAGE; CLOSED-HEAD-INJURY; AUTISTIC-CHILD; IRONY; MIND; BRAIN; KNOWLEDGE; PRETENSE; REQUESTS; DEFICITS	This article evaluates two theoretical accounts of how sarcasm is understood; the traditional model, which asserts that listeners derive a counterfactual inference from the sarcastic comment, and relevance theory, which asserts that listeners recognize sarcasm as a scornful echo of a previous assertion. Evidence from normal speakers provides only partial support for both theories. Evidence from brain-injured populations suggests that aspects of the pragmatic process can be arrested in ways not predicted by either theory. It is concluded that sarcasm is more effortful to process than nonsarcastic comments and that inferences about the facts of the situation and the mental state of the speaker (e.g., attitudes, knowledge, and intentions) are important to comprehending sarcasm. It is questioned whether inferences about mental state are relatively more difficult for brain-injured subjects and, if so, whether this is a continuum of difficulty or reflects reliance upon different cognitive processes. (C) 1999 Academic Press.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia		McDonald, S (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094			Bara BG, 1997, BRAIN LANG, V59, P7, DOI 10.1006/brln.1997.1812; BARONCOHEN S, 1992, J CHILD PSYCHOL PSYC, V33, P1141, DOI 10.1111/j.1469-7610.1992.tb00934.x; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; BENOWITZ LI, 1990, NEUROPSYCHOLOGIA, V28, P231, DOI 10.1016/0028-3932(90)90017-I; Brown P., 1978, POLITENESS SOME UNIV; CLARK HH, 1984, J EXP PSYCHOL GEN, V113, P121, DOI 10.1037/0096-3445.113.1.121; CLARK HH, 1980, COGNITION, V8, P111, DOI 10.1016/0010-0277(80)90009-8; CROSSON B, 1987, CLIN NEUROPSYCHOL, V1, P335, DOI DOI 10.1080/13854048708520069; DELIS DC, 1983, CORTEX, V19, P43, DOI 10.1016/S0010-9452(83)80049-5; DEWS S, 1995, METAPHOR SYMB ACT, V10, P3, DOI 10.1207/s15327868ms1001_2; EISENMAJER R, 1991, BRIT J DEV PSYCHOL, V9, P351, DOI 10.1111/j.2044-835X.1991.tb00882.x; EPPEL ML, 1983, J GENET PSYCHOL, V143, P143, DOI 10.1080/00221325.1983.10533544; FLANAGAN S, 1997, P 21 ANN BRAIN IMP C; FLANAGAN S, 1995, TREATMENT ISSUES LON; FOLDI NS, 1987, BRAIN LANG, V31, P88, DOI 10.1016/0093-934X(87)90062-9; Frith U., 1989, AUTISM EXPLAINING EN; GIBBS RW, 1995, DISCOURSE PROCESS, V20, P187, DOI 10.1080/01638539509544937; GIBBS RW, 1991, J PRAGMATICS, V16, P523, DOI 10.1016/0378-2166(91)90101-3; GIBBS RW, 1986, ACTA PSYCHOL, V62, P41, DOI 10.1016/0001-6918(86)90004-1; GIBBS RW, 1986, J EXP PSYCHOL GEN, V115, P3, DOI 10.1037/0096-3445.115.1.3; GIORA R, 1995, DISCOURSE PROCESS, V19, P239, DOI 10.1080/01638539509544916; GORDON D, 1975, SYNTAX SEMANTICS SPE, V3; GRICE H, 1975, SYNTAX SEMANTICS SPE, V3; GRICE HP, 1978, SYNTAX SEMANTICS PRA, V9; Happe F, 1996, NEUROREPORT, V8, P197, DOI 10.1097/00001756-199612200-00040; HAPPE FGE, 1993, COGNITION, V48, P101, DOI 10.1016/0010-0277(93)90026-R; HAVERKATE H, 1990, J PRAGMATICS, V14, P77, DOI 10.1016/0378-2166(90)90065-L; Jorgensen J, 1996, J PRAGMATICS, V26, P613, DOI 10.1016/0378-2166(95)00067-4; JORGENSEN J, 1984, J EXP PSYCHOL GEN, V113, P112, DOI 10.1037/0096-3445.113.1.112; KAPLAN JA, 1990, BRAIN LANG, V38, P315, DOI 10.1016/0093-934X(90)90117-Y; KRUEZ RJ, 1989, J EXPT PSYCHOL GEN, V118, P374; Leech Geoffrey, 1983, PRINCIPALS PRAGMATIC; LEEKAM SR, 1991, COGNITION, V40, P203, DOI 10.1016/0010-0277(91)90025-Y; LESLIE AM, 1994, COGNITION, V50, P211, DOI 10.1016/0010-0277(94)90029-9; LEVINE MJ, 1993, BRAIN INJURY, V7, P153, DOI 10.3109/02699059309008169; Levinson Stephen., 1983, PRAGMATICS; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LUCARIELLO J, 1994, J EXP PSYCHOL GEN, V123, P129, DOI 10.1037/0096-3445.123.2.129; MARSH DT, 1981, J GENET PSYCHOL, V138, P37, DOI 10.1080/00221325.1981.10532840; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; MILTON SB, 1986, CLIN NEUROPSYCHOLOGY; NEWMAN D, 1986, DEV REV, V6, P122, DOI 10.1016/0273-2297(86)90008-0; Ozonoff S, 1996, BRAIN LANG, V52, P411, DOI 10.1006/brln.1996.0022; OZONOFF S, 1994, J CHILD PSYCHOL PSYC, V35, P1015, DOI 10.1111/j.1469-7610.1994.tb01807.x; PREMINGER A, 1974, PRINCETON ENCY POETR; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; RUMSEY JM, 1985, J AUTISM DEV DISORD, V20, P581; SANTORO J, 1994, BRAIN INJURY, V8, P265, DOI 10.3109/02699059409150978; SAVER JL, 1991, NEUROPSYCHOLOGIA, V29, P1241, DOI 10.1016/0028-3932(91)90037-9; SEARLE JR, 1975, SYNTAX SEMANTICS SPE, V3; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SIEGAL M, 1991, COGNITION, V38, P1, DOI 10.1016/0010-0277(91)90020-5; Siegal M, 1996, BRAIN LANG, V53, P40, DOI 10.1006/brln.1996.0035; Slugoski B. R., 1988, J LANG SOCIAL PSYCHO, V7, P102, DOI DOI 10.1177/0261927X8800700202; SPERBER D, 1984, J EXP PSYCHOL GEN, V113, P130, DOI 10.1037/0096-3445.113.1.130; SPERBER D, 1987, BEHAV BRAIN SCI, V10, P697, DOI 10.1017/S0140525X00055345; Sperber D., 1981, RADICAL PRAGMATICS; SPIERS MV, 1994, BRAIN INJURY, V8, P463, DOI 10.3109/02699059409150998; SULLIVAN K, 1995, BRIT J DEV PSYCHOL, V13, P191, DOI 10.1111/j.2044-835X.1995.tb00673.x; TAGERFLUSBERG H, 1995, APPL PSYCHOLINGUIST, V16, P241, DOI 10.1017/S0142716400007281; TOMPKINS CA, 1985, BRAIN LANG, V24, P185, DOI 10.1016/0093-934X(85)90130-0; Van Horn K R, 1992, Brain Inj, V6, P15, DOI 10.3109/02699059209008118; Walsh KW., 1991, UNDERSTANDING BRAIN; WAPNER W, 1981, BRAIN LANG, V14, P15, DOI 10.1016/0093-934X(81)90061-4; WILLIAMS JP, 1984, J EXP PSYCHOL GEN, V113, P127, DOI 10.1037/0096-3445.113.1.127; Wilson D., 1986, RELEVANCE COMMUNICAT; Winner E, 1998, BRAIN LANG, V62, P89, DOI 10.1006/brln.1997.1889; WINNER E, 1991, BRIT J DEV PSYCHOL, V9, P257, DOI 10.1111/j.2044-835X.1991.tb00875.x; [No title captured]	71	82	84	1	19	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X			BRAIN LANG	Brain Lang.	JUL	1999	68	3					486	506		10.1006/brln.1999.2124			21	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	226TE	WOS:000082037100007	10441190				2022-02-06	
J	Hart, T; Giovannetti, T; Montgomery, MW; Schwartz, MF				Hart, T; Giovannetti, T; Montgomery, MW; Schwartz, MF			Awareness of errors in naturalistic action after traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						deficit awareness; error detection; traumatic brain injury	HEAD-INJURY; DEFICITS	A prospective study was performed to develop a method for assessing "on-line" error detection and correction during performance of naturalistic action, to determine whether traumatic brain injury (TBI) affects error detection and correction, and to compare actual task performance with verbal self-ratings of performance. Participants included 18 persons who had sustained severe TBI from 34 to 186 days prior to study and who were comparable to controls in their rate of naturalistic action error, along with 18 control subjects chosen to be demographically comparable to subjects with TDI. Subjects performed two different tests of naturalistic action in which they completed everyday activities leg, wrapping a gift, making toast) at different levels of complexity, as manipulated by the addition of distractor objects, the number of tasks that had to be completed per trial, and other demands on planning and working memory. Using a specially developed coding system, each error on these tasks was scored as to whether the subject corrected it and whether the subject otherwise demonstrated awareness of the error. Error scores were also compared to subjects' responses to a questionnaire in which the) rated their own performance on the most challenging level of the naturalistic action test. In general, subjects with TDI corrected and showed awareness of proportionally fewer of their errors when compared to controls. Qualitative patterns for some error types also differed between groups. Despite making more errors than control subjects on the most challenging task, subjects with TBI did not rate themselves as performing more poorly with respect to its cognitive demands. However, for subjects with TBI, the number of errors was correlated with performance ratings on certain questionnaire items. This study showed that error detection and correction can be reliably measured during naturalistic action and appear to be impaired in severe TBI even when the base rate of error is controlled. TBI may affect error detection and correction by reducing, or impairing the allocation of, attentional resources needed for the simultaneous execution and monitoring of routine action.	Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; MossRehab Hosp, Drucker Brain Injury Ctr, Philadelphia, PA USA; Drexel Univ, Philadelphia, PA 19104 USA; Temple Univ, Sch Med, Dept Phys Med & Rehabil, Philadelphia, PA 19122 USA		Hart, T (corresponding author), Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.		Giovannetti, Tania/H-3491-2019	Giovannetti, Tania/0000-0001-5661-152X	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS31824] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS031824] Funding Source: NIH RePORTER		ADAMS JA, 1973, J MOTOR BEHAV, V5, P217, DOI 10.1080/00222895.1973.10734968; ALLWOOD CM, 1984, COGNITIVE SCI, V8, P413, DOI 10.1016/S0364-0213(84)80009-9; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; [Anonymous], 1993, GUID UN DAT SET MED; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Buxbaum LJ, 1997, COGNITIVE NEUROPSYCH, V14, P219, DOI 10.1080/026432997381565; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Crisp R, 1992, Aust Occup Ther J, V39, P15, DOI 10.1111/j.1440-1630.1992.tb01730.x; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fleming JM, 1996, BRAIN INJURY, V10, P1; Frith C. D., 1992, Journal of Psychopharmacology, V6, P436, DOI 10.1177/026988119200600314; Gasquoine P., 1992, NEUROPSYCHOLOGY, V6, P187, DOI [10.1037/0894-4105.6.3.187., DOI 10.1037/0894-4105.6.3.187, https://doi.org/10.1037/0894-4105.6.3.187]; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; PRIGATANO GP, 1986, CLIN NEUROPSYCHOLOGY; RABBITT, 1967, ACTA PSYCHOL, V27, P131, DOI 10.1016/0001-6918(67)90053-4; RABBITT PMA, 1966, J EXP PSYCHOL, V71, P264, DOI 10.1037/h0022853; RANSEEN JD, 1990, INT J CLIN NEUROPSYC, V12, P29; SALTHOUSE TA, 1986, PSYCHOL BULL, V99, P303, DOI 10.1037/0033-2909.99.3.303; Schmidt R., 1987, PERSPECTIVES PERCEPT; SCHMIDT RA, 1972, J MOTOR BEHAV, V4, P143, DOI 10.1080/00222895.1972.10734930; Schwartz MF, 1998, NEUROPSYCHOLOGY, V12, P13, DOI 10.1037/0894-4105.12.1.13; SCHWARTZ MF, IN PRESS NEUROPSYCHO; SELLEN AJ, 1992, EXPT SLIPS HUMAN ERR; SHAFFER LH, 1969, Q J EXP PSYCHOL, V21, P209, DOI 10.1080/14640746908400215; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Woods D.D., 1984, I CHEM ENG S SERIES, P21	32	82	82	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1998	13	5					16	28		10.1097/00001199-199810000-00004			13	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	175UU	WOS:000079114600004	9753532				2022-02-06	
J	Okonkwo, DO; Pettus, EH; Moroi, J; Povlishock, JT				Okonkwo, DO; Pettus, EH; Moroi, J; Povlishock, JT			Alteration of the neurofilament side arm and its relation to neurofilament compaction occurring with traumatic axonal injury	BRAIN RESEARCH			English	Article						traumatic brain injury; cat; cytoskeleton; neurofilament; phosphorylation; calcium	BRAIN INJURY; AXOLEMMAL PERMEABILITY; PHOSPHORYLATION; CALIBER	Traumatic injury evokes two characteristic forms of focal axonal injury, one of which involves focal perturbation of axolemmal permeability associated with rapid compaction of the underlying axonal neurofilament lattice and microtubular loss. In this process, the neurofilament sidearms have been the subject of intense scrutiny in relation to their role in this NF compaction, with the suggestion that the sidearms, thought to maintain interfilament distance, are proteolytically cleaved and degraded at the time of injury. The current communication addresses the fate of the NF sidearms in such injured axons. Adult cats were subjected to moderate/severe fluid percussion brain injury after intrathecal administration of horseradish peroxidase (HRP). This tracer, excluded by the intact axolemma of uninjured axons, was used to recognize injured axons via HRP intra-axonal uptake/flooding with HRP. Animals were perfused and processed for light microscopic and electron microscopic study of both HRP-containing and non-HRP containing axons from the same field. HRP-containing axons consistently displayed evidence of traumatically-induced (NF) cytoskeletal collapse. Electron micrographs of HRP-containing axons as well as uninjured, non-HRP-containing axons from the same fields were videographically captured, digitized, enlarged and analysed for NF sidearm length and NF density. HRP-containing axons were found to have increased NF density. Surprisingly, this increased NF density occurred despite the retention of the NF sidearms, which now, however, were reduced in height in comparison to the non-HRP-containing uninjured axons. These observations are not consistent with previously published reports suggesting that overt proteolytic degradation of sidearms was responsible for NF compaction. Based on our findings, we suggest that the NF compaction associated with traumatically-induced axolemmal permeability changes may have its genesis in more subtle sidearm modification, perhaps involving a change in phosphorylation state. (C) 1998 Elsevier Science B.V.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA		Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Box 980 709, Richmond, VA 23298 USA.						BALENTINE JD, 1988, J NEUROPATH EXP NEUR, V47, P77, DOI 10.1097/00005072-198803000-00001; BALENTINE JD, 1985, CENTRAL NERVOUS SYST, P455; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; HALL GF, 1996, J COMP NEUROL, V353, P39; ISHIZAKI Y, 1994, J NEUROSCI, V14, P3934; KAMAKURA K, 1985, J NEUROSCI RES, V13, P391, DOI 10.1002/jnr.490130306; Kampfl A, 1996, J NEUROCHEM, V67, P1575; MCHALE MK, 1995, J COMP NEUROL, V353, P25, DOI 10.1002/cne.903530105; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; NIXON RA, 1994, J CELL BIOL, V126, P1031, DOI 10.1083/jcb.126.4.1031; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Povlishock JT, 1996, ACT NEUR S, V66, P81; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; STYS PK, 1991, ANN NEUROL, V30, P375, DOI 10.1002/ana.410300309; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520	17	82	82	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	FEB 16	1998	784	1-2					1	6		10.1016/S0006-8993(97)01075-5			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZC505	WOS:000072586800001	9518527				2022-02-06	
J	Sherer, M; Meyers, CA; Bergloff, P				Sherer, M; Meyers, CA; Bergloff, P			Efficacy of postacute brain injury rehabilitation for patients with primary malignant brain tumors	CANCER			English	Article; Proceedings Paper	3rd World Congress on Psycho-Oncology	OCT 04-06, 1996	NEW YORK, NY			brain tumor; rehabilitation; independence; productivity; cognitive deficits		BACKGROUND. Patients with primary malignant brain tumors (PMBT) often have neurobehavioral deficits due to the tumor, subsequent surgery, and therapies that interfere with their ability to live independently or work. Previous studies have shown that such patients generally have a progressive decline in functioning from diagnosis to death. Consequently, PMBT patients have not been considered good candidates for rehabilitation services. The current study is a preliminary, retrospective investigation of the effectiveness of postacute brain injury rehabilitation methods, originally developed for traumatic brain injury survivors, in a sample of patients with PMBT. METHODS. The subjects were 13 patients with a history of surgical resection of PMBT and subsequent radiation and chemotherapy. There were 8 males and 5 females with a mean age of 34.3 +/- 10.0 years and a mean educational level of 15.1 +/- 1.7 years. Mean time from tumor diagnosis to the commencement of rehabilitation was 75.4 +/- 87.9 months. All patients had cognitive deficits documented with neuropsychologic tests. Patients received an average of 2.6 +/- 1.9 months of postacute brain injury rehabilitation. RESULTS. Six patients had increased independence during the time from the start of rehabilitation to discharge, six were unchanged, and one patient had decreased independence. Eight patients had increased productivity during the same time period, four were unchanged, and one had decreased productivity. Treatment gains were maintained at follow-up 8.0 +/- 7.6 months after discharge. CONCLUSIONS. The results of the current study offer preliminary support for the effectiveness of postacute brain injury rehabilitation in the management of PMBT patients. Although additional investigation is needed, such treatment appears to be an attractive, relatively low cost option for these patients. (C) 1997 American Cancer Society.	BAYLOR COLL MED,DEPT PHYS MED & REHABIL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT NEUROONCOL,HOUSTON,TX		Sherer, M (corresponding author), TIRR,CHALLENGE PROGRAM,DEPT NEUROPSYCHOL,4007 EE BELLAIRE BLVD,HOUSTON,TX 77025, USA.						AIKEN RD, 1994, SEMIN ONCOL, V21, P273; ANDERSON SW, 1990, ARCH NEUROL-CHICAGO, V47, P397, DOI 10.1001/archneur.1990.00530040039017; Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; BERGLOFF P, IN PRESS ARCH CLIN N; *CENTR BRAIN TUM R, 1995, 1 CENTR BRAIN TURM B; DESMEULES M, 1992, J NATL CANCER I, V84, P442, DOI 10.1093/jnci/84.6.442; FOBAIR P, 1990, BRAIN TUM C LIV RES; HIGH WM, 1997, J INT NEUROPSYCHOL S, V3, P5; HOCHBERG FH, 1980, NEUROLOGY, V30, P172, DOI 10.1212/WNL.30.2.172; KREUTZER J, 1991, COGNITIVE REHABILITA; LEVIN VA, 1993, CANC PRINCIPLES PRAC, P1679; LIEBERMAN AN, 1982, NEUROSURGERY, V10, P50; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Meyers CA, 1996, CANC NERVOUS SYSTEM, P449; Meyers Christina A., 1993, Cancer Bulletin (Houston), V45, P362; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Radhakrishnan K., 1994, BRAIN TUMORS COMPREH, P1; SACHSENHEIMER W, 1992, J NEURO-ONCOL, V13, P177; Scheibel RS, 1996, J NEURO-ONCOL, V30, P61; SHERER M, 1997, J INT NEUROPSYCH SOC, V3, P75; Weitzner MA, 1996, BAILLIERE CLIN NEUR, V5, P425	21	82	82	0	1	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012	0008-543X			CANCER	Cancer	JUL 15	1997	80	2					250	257		10.1002/(SICI)1097-0142(19970715)80:2<250::AID-CNCR13>3.3.CO;2-T			8	Oncology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Oncology	XJ016	WOS:A1997XJ01600013	9217038	Bronze			2022-02-06	
J	Corrigan, JD; Bogner, JA; Mysiw, WJ; Clinchot, D; Fugate, L				Corrigan, JD; Bogner, JA; Mysiw, WJ; Clinchot, D; Fugate, L			Systematic bias in outcome studies of persons with traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							SEVERE HEAD-INJURY; COMMUNITY INTEGRATION QUESTIONNAIRE; SUBSTANCE-ABUSE; FOLLOW-UP; 1-YEAR; REHABILITATION; RECOVERY; SCALE; COMA	Objective: (1) Examine systematic biases created by subjects lost at 1-year follow-up in samples of persons with traumatic brain injury; (2) identify potential threats to generalization of outcomes data. Design: A consecutive sample of admissions to acute rehabilitation studied 1 year following discharge. Setting: An inpatient brain injury rehabilitation unit in a large, academic medical center. Subjects: Eighty-eight patients with primary diagnosis of traumatic brain injury. Main Outcome Measures: Subjects were considered lost to follow-up when phone calls, mail, clinic visits, and assistance from family failed to allow contact 1 year after discharge from acute rehabilitation. Potential effects of the biased follow-up sample were examined for seven suboptimal outcomes. Results: A total of 38.6% of subjects were lost to follow-up. Subjects intoxicated at time of injury and those with history of substance abuse were more likely to be lost. Among subjects followed, the likelihood of working or being in school I year after discharge was significantly less for those intoxicated at time of injury and those with a history of substance abuse. Conclusions: Systematic bias in longitudinal studies may result from subjects with substance use problems being lost to follow-up. Population estimates for return to work or school will be overestimated if those lost who have substance use problems resemble those followed. (C) 1997 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	OHIO STATE UNIV,DEPT PHYS MED & REHABIL,COLUMBUS,OH 43210				Mysiw, Walter/E-3724-2011; Corrigan, John D./E-2921-2011	Clinchot, Daniel/0000-0002-2810-7227			ANSELL BJ, 1989, W NEURO SENSORY STIM; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; CICCHETTI DV, 1994, J CLIN EXP NEUROPSYC, V16, P339, DOI 10.1080/01688639408402644; CORRIGAN JD, 1985, ARCH PHYS MED REHAB, V66, P626; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P29; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; CORRIGAN JD, 1996, FUNCTIONAL ASSESSMEN; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DIKMEN S, 1995, J HEAD TRAUMA REHAB, V10, P74, DOI 10.1097/00001199-199502000-00008; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRANCIS DJ, 1994, NEUROPSYCHOL REV, V4, P199, DOI 10.1007/BF01874892; Granger C. V., 1986, TOP GERIATR REHABIL, V1, P59, DOI DOI 10.1097/00013614-198604000-00007; JOHNSTON MV, 1994, ARCH PHYS MED REHAB, V75, pSC2; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Marmarou A., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI [10.1097/00001199-199009000-00006, DOI 10.1097/00001199-199009000-00006]; MCCUBBIN H, 1987, FAMILY ASSESSMENT IN, P203; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Reitan R, 1985, HALSTEAD REITAN NEUR; ROSENTHAL M, 1996, TRAUM BRAIN INJ MOD; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; SPETTELL CM, 1991, ARCH PHYS MED REHAB, V72, P320; *SUNY BUFF, 1993, UN DAT SYST MED REH; TEASDALE G, 1974, LANCET, V2, P81; Thomsen I V, 1987, Brain Inj, V1, P131, DOI 10.3109/02699058709034452; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B., 1993, BRAIN INJURY REHABIL, P355; [No title captured], DOI DOI 10.1037/0894-4105.7.3.296; [No title captured]	42	82	82	0	7	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	1997	78	2					132	137		10.1016/S0003-9993(97)90253-7			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	WH072	WOS:A1997WH07200004	9041892				2022-02-06	
J	Lobato, RD; Gomez, PA; Alday, R; Rivas, JJ; Dominguez, J; Cabrera, A; Turanzas, FS; Benitez, A; Rivero, B				Lobato, RD; Gomez, PA; Alday, R; Rivas, JJ; Dominguez, J; Cabrera, A; Turanzas, FS; Benitez, A; Rivero, B			Sequential computerized tomography changes and related final outcome in severe head injury patients	ACTA NEUROCHIRURGICA			English	Article						head injury; computerized tomography; intracranial haematoma; intracranial pressure	LESION; COMA	The authors analysed the serial computerized tomography (CT) findings in a large series of severely head injured patients in order to assess the variability in gross intracranial pathology through the acute posttraumatic period and determine the most common patterns of CT change. A second aim was to compare the prognostic significance of the different CT diagnostic categories used in the study (Traumatic Coma Data Bank CT pathological classification) when gleaned either from the initial (postadmission) or the control CT scans, and determine the extent to which having a second CT scan provides more prognostic information than only one scan. 92 patients (13.3% of the total population) died soon after injury. Of the 587 who survived long enough to have at least one control CT scan 23.6% developed new diffuse brain swelling, and 20.9% new focal mass lesions most of which had to be evacuated. The relative risk for requiring a delayed operation as related to the diagnostic category established by using the initial CT scans was by decreasing order: diffuse injury IV (30.7%), diffuse injury III (30.5%), non evacuated mass (20%), evacuated mass (20.2%), diffuse injury II (12.1%), and diffuse injury I (8.6%). Overall, 51.2% of the patients developed significant CT changes (for worse or better) occurring either spontaneously or following surgery, and their final outcomes were more closely related to the control than to the initial CT diagnoses. In fact, the final outcome was more accurately predicted by using the control CT scans (81.2% of the cases) than by using the initial CT scans (71.5% of the cases only). Since the majority of relevant CT changes developed within 48 hours after injury a pathological categorization made by using an early control CT scan seems to be most useful for prognostic purposes. Prognosis associated with the CT pathological categories used in the study was similar independently of the moment of the acute posttraumatic period at which diagnoses were made.	UNIV COMPLUTENSE MADRID,FAC MED,E-28040 MADRID,SPAIN		Lobato, RD (corresponding author), HOSP 12 OCTUBRE,NEUROSURG SERV,CARRETERA ANDALUCIA,KM 54,E-28041 MADRID,SPAIN.		Gomez, Pedro/N-5051-2019	Gomez, Pedro/0000-0002-4185-5238			BULLOCK R, 1990, J NEUROSURG, V72, P9, DOI 10.3171/jns.1990.72.1.0009; BULLOCK R, 1989, SURG NEUROL, V322, P181; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; COOPER PR, 1979, NEUROSURGERY, V5, P566, DOI 10.1227/00006123-197911000-00004; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; JENNETT B, 1975, LANCET, V1, P480; KOBAYASHI S, 1983, SURG NEUROL, V20, P25, DOI 10.1016/0090-3019(83)90101-5; LOBATO RD, 1988, J NEUROSURG, V68, P417, DOI 10.3171/jns.1988.68.3.0417; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; LOBATO RD, 1988, J NEUROSURG, V68, P48, DOI 10.3171/jns.1988.68.1.0048; LOBTO RD, 1986, J NEUROSURG, V65, P784; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; ROBERSON FC, 1979, SURG NEUROL, V12, P161; SAUTREAUX JL, 1982, NEUROCHIRURGIE, V28, P263; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; TEASDALE E, 1984, J NEUROL NEUROSUR PS, V47, P600, DOI 10.1136/jnnp.47.6.600; TEASDALE G, 1974, LANCET, V2, P81; TURAZZI S, 1987, ACTA NEUROCHIR, V85, P87, DOI 10.1007/BF01456103; VANDONGEN KJ, 1983, J NEUROSURG, V59, P951, DOI 10.3171/jns.1983.59.6.0951	22	82	84	0	3	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1997	139	5					385	391		10.1007/BF01808871			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	XC750	WOS:A1997XC75000001	9204105				2022-02-06	
J	Jacobs, A; Put, E; Ingels, M; Put, T; Bossuyt, A				Jacobs, A; Put, E; Ingels, M; Put, T; Bossuyt, A			One-year follow-up of technetium-99m-HMPAO SPECT in mild head injury	JOURNAL OF NUCLEAR MEDICINE			English	Article						regional cerebral blood flow; SPECT; mild head injury; technetium-99m-HMPAO	TRAUMATIC BRAIN INJURY; CEREBRAL BLOOD-FLOW; COMPUTED-TOMOGRAPHY; BEHAVIORAL SEQUELAE; CT; MRI	We evaluated the predictive capacity of Tc-99m-HMPAO SPECT for clinical outcome during a follow-up period of 12 mo after mild head injury. Methods: We prospectively evaluated 136 patients with mild head injury who underwent initial SPECT imaging (SPECTO) within 4 wk after the trauma. Re-evaluations were made 2.9-3.3 mo (T3mo), 5.7-6.3 mo (T6mo) and 11.9-12.6 mo (T12mo) postinjury. All patients with an abnormal SPECT underwent a repeat study at the subsequent time of evaluation. Patients with a previously normal SPECT scan did not undergo a repeat study. Clinical reassessments (GUN) were performed as long as the earlier study had been positive or until patients were completely asymptomatic. Results: During all follow-up evaluations, SPECT had a high sensitivity and negative predictive value, increasing from 91% and 89%, respectively, at T3mo to 100% at T6mo and at T12mo. Clinical normalization occurred earlier than scintigraphic normalization. However, at 12 mo postinjury, we observed considerable improvement in the specificity and positive predictive value of SPECT (85% and 83%, respectively). The persistent lesions on the SPECT scan were related to their severity and to localization in the frontal cortex. Conclusion: A normal Tc-99m-HMPAO SPECT scan is a reliable tool in the exclusion of clinical sequelae of mild head injury. At 12 mo postinjury, a positive SPECT study is also a reliable predictor for clinical outcome.	ST FRANCISKUS HOSP,DEPT NEUROSURG,HEUSDEN ZOLDER,BELGIUM; FREE UNIV BRUSSELS HOSP,DEPT NUCL MED,JETTE,BELGIUM		Jacobs, A (corresponding author), VIRGA JESSE HOSP,DEPT NUCL MED,STADSOMVAART 11,B-3500 HASSELT,BELGIUM.						ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; ELSON LM, 1994, SEMIN NEUROL, V14, P8, DOI 10.1055/s-2008-1041053; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GRAY BG, 1992, J NUCL MED, V33, P52; ICHISE M, 1994, J NUCL MED, V35, P217; JACOBS A, 1994, J NUCL MED, V35, P942; JACOBS A, 1993, NUCL MED COMMUN, V14, P702, DOI 10.1097/00006231-199308000-00011; KIDO DK, 1992, RADIOLOGY, V182, P777, DOI 10.1148/radiology.182.3.1535893; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; MOHANTY SK, 1991, J TRAUMA, V31, P801, DOI 10.1097/00005373-199106000-00010; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; REID RH, 1990, ACTA NEUROCHIR S, V51, P283; REIDERGROSWASSER I, 1993, AM J ROENTGENOL, V160, P147, DOI 10.2214/ajr.160.1.8416613; ROPER SN, 1991, J NUCL MED, V32, P1684; RUTHERFORD WH, 1977, LANCET, V1, P1; STEIN SC, 1991, ANN EMERG MED, V20, P1286, DOI 10.1016/S0196-0644(05)81066-2; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TIKOFSKY RS, 1994, J NUCL MED, V35, P947	18	82	85	0	0	SOC NUCLEAR MEDICINE INC	RESTON	1850 SAMUEL MORSE DR, RESTON, VA 22090-5316	0161-5505			J NUCL MED	J. Nucl. Med.	OCT	1996	37	10					1605	1609					5	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	VL581	WOS:A1996VL58100014	8862291				2022-02-06	
J	Prigatano, GP				Prigatano, GP			Behavioral limitations TBI patients tend to underestimate: A replication and extension to patients with lateralized cerebral dysfunction	CLINICAL NEUROPSYCHOLOGIST			English	Article							TRAUMATIC BRAIN INJURY; ANOSOGNOSIA; AWARENESS; LESIONS	Patients with moderate to severe traumatic brain injury (TBI), as well as patients with lateralized cerebral dysfunction, completed the Patient Competency Rating Scale (PCRS) along with a neuropsychological control group. Relatives or significant others for each patient also rated the patient's abilities on the PCRS. A previous finding that TBT patients overestimate social interaction and emotional control skills was replicated. Patients with right versus left hemisphere lesions also tended to show this same pattern, while the neuropsychological control group did not. Brain dysfunction may increase the tendency to overstate certain behavioral characteristics irrespective of the location of the lesion. Nonneurological factors, however, may also contribute to this phenomenon. In this regard, it may be useful to distinguish between impaired self-awareness versus denial of disability after brain injury.			Prigatano, GP (corresponding author), ST JOSEPHS HOSP,BARROW NEUROL INST,350 W THOMAS RD,PHOENIX,AZ 85013, USA.						ADAMS KM, 1985, J CLIN EXP NEUROPSYC, V7, P445, DOI 10.1080/01688638508401276; BENYISHAY Y, 1990, REHABILITATION ADULT, P393; BROWN DSO, 1992, ARCH PHYS MED REHAB, V73, P758; Feher EP., 1991, ANOSOGNOSIA ALZHEIME, V4, P136; Fleming J., 1995, BRIT J OCCUPATIONAL, V58, P55, DOI [https://doi.org/10.1177/030802269505800204, DOI 10.1177/030802269505800204]; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; LORD FM, 1969, PSYCHOL BULL, V72, P336, DOI 10.1037/h0028108; LORD FM, 1967, PSYCHOL BULL, V68, P304, DOI 10.1037/h0025105; Mesulam M., 1985, PRINCIPLES BEHAV NEU; MIZUNO M, 1991, Keio Journal of Medicine, V40, P221; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; PRIGATANO GP, 1995, 10 ANN M SECT NEUR B; PRIGATANO GP, 1995, MANUAL BNI SCREEN HI, P2; PRIGATANO GP, IN PRESS NEUROPSYCHO; REITAN RM, 1994, CLIN NEUROPSYCHOL, V8, P193, DOI 10.1080/13854049408401557; REITAN RM, 1955, UNPUB MANUAL ADM NEU; ROBINSON RG, 1985, CRC CR REV CL NEUROB, V1, P285; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; SQUIRE LR, 1988, J CLIN EXPT NEUROPSC, V10, P737; STARKSTEIN SE, 1992, STROKE, V23, P1446, DOI 10.1161/01.STR.23.10.1446; STARKSTEIN SE, 1993, NEUROPSY NEUROPSY BE, V6, P43; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; VILKKI J, 1991, CORTEX, V27, P203, DOI 10.1016/S0010-9452(13)80124-4; Weinstein E.A., 1955, DENIAL ILLNESS SYMBO; WEINSTEIN EA, IN PRESS NEUROPSYCHI; [No title captured]	32	82	83	0	7	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	MAY	1996	10	2					191	201		10.1080/13854049608406680			11	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	UM880	WOS:A1996UM88000009					2022-02-06	
J	Taneda, M; Kataoka, K; Akai, F; Asai, T; Sakata, I				Taneda, M; Kataoka, K; Akai, F; Asai, T; Sakata, I			Traumatic subarachnoid hemorrhage as a predictable indicator of delayed ischemic symptoms	JOURNAL OF NEUROSURGERY			English	Article						cerebral ischemia; vasospasm; subarachnoid hemorrhage; head injury; delayed ischemic deficit	CEREBRAL BLOOD-FLOW; TRANSCRANIAL DOPPLER ULTRASOUND; HEAD-INJURY; ANGIOGRAPHIC FINDINGS; ARTERIAL SPASM; VASOSPASM; COMA	This report provides findings of an investigation of the influence of traumatic subarachnoid hemorrhage on the development of delayed cerebral ischemia caused by vasospasm. The authors prospectively studied 130 patients with closed-head trauma, who exhibited subarachnoid blood on admission computerized tomography (CT) scans. Ten (7.7%) of these patients developed delayed ischemic symptoms between Days 4 and 16 after the head injury. They consisted of three (3.0%) of 101 patients with small amounts of subarachnoid blood and seven (24.1%) of 29 patients with massive quanti ties of subarachnoid blood on admission CT scans. In each of the 10 patients, severe vasospasm was demonstrated by angiography performed soon after development of ischemic symptoms. There was a close correlation between the main site of the subarachnoid blood and the location of severe vasospasm. In seven of the patients, follow-up CT scans showed development of focal ischemic areas in the cerebral territories corresponding to the vasospastic arteries. These results demonstrate that traumatic subarachnoid hemorrhage, especially if massive, is a predictable indicator of delayed ischemic symptoms.	KINKI UNIV,SCH MED,CRIT CARE MED CTR,SAYAMA,OSAKA 589,JAPAN		Taneda, M (corresponding author), KINKI UNIV,SCH MED,DEPT NEUROSURG,377-2 OHNO HIGASHI,SAYAMA,OSAKA 589,JAPAN.						ARSENI C, 1971, ACTA NEUROCHIR, V24, P25, DOI 10.1007/BF01403138; ARUTIUNOV AI, 1974, J NEUROSURG, V40, P459, DOI 10.3171/jns.1974.40.4.0459; CHAN KH, 1992, NEUROSURGERY, V30, P697; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; FREIDENFELT H, 1963, ACTA RADIOL DIAGN, V1, P278, DOI 10.1177/028418516300100221; JENNETT B, 1975, LANCET, V1, P480; KASSELL NF, 1984, J NEUROSURG, V61, P225, DOI 10.3171/jns.1984.61.2.0225; KISTLER JP, 1983, NEUROLOGY, V33, P424, DOI 10.1212/WNL.33.4.424; Kostron H, 1985, Neurochirurgia (Stuttg), V28 Suppl 1, P103; LEWIN W, 1968, BRIT J SURG, V55, P321, DOI 10.1002/bjs.1800550502; MACPHERSON P, 1978, J NEUROL NEUROSUR PS, V41, P122, DOI 10.1136/jnnp.41.2.122; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; Newell D W, 1992, Clin Neurosurg, V39, P348; PASQUALIN A, 1986, NEUROSURGERY, V15, P855; SEILER RW, 1986, J NEUROSURG, V64, P594, DOI 10.3171/jns.1986.64.4.0594; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; SYMON L, 1967, J NEUROL NEUROSUR PS, V30, P497, DOI 10.1136/jnnp.30.6.497; TANEDA M, 1982, J NEUROSURG, V57, P622, DOI 10.3171/jns.1982.57.5.0622; TEASDALE G, 1974, LANCET, V2, P81; VARDIMAN AB, 1995, AM J NEURORADIOL, V16, P319; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; WEIR B, 1978, J NEUROSURG, V48, P173, DOI 10.3171/jns.1978.48.2.0173; Wilkins R H, 1977, Clin Neurosurg, V24, P185; WILKINS RH, 1970, J NEUROSURG, V32, P626, DOI 10.3171/jns.1970.32.6.0626; WILKINS RH, 1980, CEREBRAL ARTERIAL SP, P472; YOSHIHARA M, 1995, J NEUROSURG, V82, P386, DOI 10.3171/jns.1995.82.3.0386	28	82	89	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	MAY	1996	84	5					762	768		10.3171/jns.1996.84.5.0762			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	UG540	WOS:A1996UG54000008	8622149				2022-02-06	
J	SINSON, G; VODDI, M; MCINTOSH, TK				SINSON, G; VODDI, M; MCINTOSH, TK			NERVE GROWTH-FACTOR ADMINISTRATION ATTENUATES COGNITIVE BUT NOT NEUROBEHAVIORAL MOTOR DYSFUNCTION OR HIPPOCAMPAL CELL LOSS FOLLOWING FLUID-PERCUSSION BRAIN INJURY IN RATS	JOURNAL OF NEUROCHEMISTRY			English	Article						FLUID-PERCUSSION INJURY; NERVE GROWTH FACTOR; NEUROTROPHIN; COGNITIVE DYSFUNCTION; TRAUMATIC BRAIN INJURY	NEURONAL DEATH; EXCITOTOXIC LESIONS; CHOLINERGIC NEURONS; FACTOR INFUSION; SEPTAL NEURONS; ADULT-RATS; NGF; TRANSPLANTATION; AMELIORATION; REGENERATION	Lateral fluid-percussion brain injury in rats results in cognitive deficits, motor dysfunction, and selective hippocampal cell loss. Neurotrophic factors have been shown to have potential therapeutic applications in neurodegenerative diseases, and nerve growth factor (NGF) has been shown to be neuroprotective in models of excitotoxicity. This study evaluated the neuroprotective efficacy of intracerebral NGF infusion after traumatic brain injury. Male Sprague-Dawley rats received lateral fluid-percussion brain injury of moderate severity (2.1-2.3 atm). A miniosmotic pump was implanted 24 h after injury to infuse NGF (n = 34) or vehicle (n = 16) directly into the region of maximal cortical injury. Infusions of NGF continued until the animal was killed at 72 h, 1 week, or 2 weeks after injury. Animals were evaluated for cognitive dysfunction (Morris Water Maze) and regional neuronal cell loss (Nissl staining) at each of the three time points. Animals surviving for 1 or 2 weeks were also evaluated for neurobehavioral motor function. Although an improvement in memory scores was not observed at 72 h after injury, animals receiving NGF infusions showed significantly improved memory scores when tested at 1 or 2 weeks after injury compared with injured animals receiving vehicle infusions (p < 0.05). Motor scores and CA3 hippocampal cell loss were not significantly different in any group of NGF-treated animals when compared with controls. These data suggest that NGF administration, in the acute, posttraumatic period following fluid-percussion brain injury, may have potential in improving posttraumatic cognitive deficits.	UNIV PENN,SCH MED,DIV NEUROSURG,PHILADELPHIA,PA 19104						NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS08803, NS26818] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, P50NS008803, R55NS026818, R01NS026818] Funding Source: NIH RePORTER		Charles V., 1994, Society for Neuroscience Abstracts, V20, P1103; CHENG B, 1991, NEURON, V7, P1031, DOI 10.1016/0896-6273(91)90347-3; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DACEY RG, 1993, HEAD INJURY, P159; DEKKER AJ, 1994, NEUROSCIENCE, V60, P299, DOI 10.1016/0306-4522(94)90244-5; DEKKER AJ, 1994, BRAIN RES, V639, P149, DOI 10.1016/0006-8993(94)91775-2; FISCHER W, 1987, NATURE, V329, P65, DOI 10.1038/329065a0; FRIDEN PM, 1993, SCIENCE, V259, P373, DOI 10.1126/science.8420006; FRIM DM, 1993, NEUROREPORT, V4, P367, DOI 10.1097/00001756-199304000-00006; FRIM DM, 1993, J NEUROSURG, V78, P267, DOI 10.3171/jns.1993.78.2.0267; GAROFALO L, 1992, P NATL ACAD SCI USA, V89, P2639, DOI 10.1073/pnas.89.7.2639; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; HAGG T, 1990, J NEUROSCI, V10, P3087; HAGG T, 1993, EXP NEUROL, V119, P37, DOI 10.1006/exnr.1993.1005; HAGG T, 1990, EXP NEUROL, V109, P153, DOI 10.1016/0014-4886(90)90069-5; HAGG T, 1988, EXP NEUROL, V101, P303, DOI 10.1016/0014-4886(88)90013-1; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOFFMAN D, 1993, EXP NEUROL, V122, P100, DOI 10.1006/exnr.1993.1111; KAWAJA MD, 1992, J NEUROSCI, V12, P2849; KOLIATSOS VE, 1990, J NEUROSCI, V10, P3801, DOI 10.1523/JNEUROSCI.10-12-03801.1990; KORSCHING S, 1993, J NEUROSCI, V13, P2739; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LEVIMONTALCINI R, 1953, J EXP ZOOL, V123, P233, DOI 10.1002/jez.1401230203; MANESS LM, 1994, NEUROSCI BIOBEHAV R, V18, P143, DOI 10.1016/0149-7634(94)90043-4; MARKOWSKA AL, 1994, J NEUROSCI, V14, P4815; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P373, DOI 10.1089/neu.1993.10.373; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; OKIYAMA K, 1992, J NEUROSURG, V77, P605; PATTERSON SL, 1993, BRAIN RES, V605, P43, DOI 10.1016/0006-8993(93)91354-U; Pierce J. E. S., 1994, Society for Neuroscience Abstracts, V20, P196; PIERCE JES, 1993, BRAIN RES, V624, P199, DOI 10.1016/0006-8993(93)90078-2; ROSENBERG MB, 1988, SCIENCE, V242, P1575, DOI 10.1126/science.3201248; SALVANT JB, 1994, J NEUROTRAUM, V12, P139; SCHUMACHER JM, 1991, NEUROSCIENCE, V45, P561, DOI 10.1016/0306-4522(91)90271-O; SHIGENO T, 1991, J NEUROSCI, V11, P2914; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SMITH DH, 1993, J NEUROSCI, V13, P5383, DOI 10.1523/JNEUROSCI.13-12-05383.1993; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Soares Holly D., 1992, Society for Neuroscience Abstracts, V18, P174; TUSZYNSKI MH, 1990, J NEUROSCI, V10, P3604; VINK R, 1990, J NEUROSCI, V10, P3524; WAYNE DB, 1990, DEV BIOL, V138, P473, DOI 10.1016/0012-1606(90)90213-3; WHITTEMORE SR, 1991, J NEUROSCI RES, V28, P156, DOI 10.1002/jnr.490280203; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231; WINN SR, 1994, P NATL ACAD SCI USA, V91, P2324, DOI 10.1073/pnas.91.6.2324; YUNSHAO H, 1992, Brain Research, V586, P27	51	82	82	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.	NOV	1995	65	5					2209	2216					8	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	TA742	WOS:A1995TA74200037	7595509				2022-02-06	
J	PRALL, JA; WINSTON, KR; BRENNAN, R				PRALL, JA; WINSTON, KR; BRENNAN, R			SEVERE SNOWBOARDING INJURIES	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article								Thirty-seven consecutive patients with severe snowboard-related injuries (defined by referral to a Level I trauma centre) were reviewed. The type and mechanism of each injury were examined and found to be similar to those reported for skiers. Mild closed head injuries were common (54 per cent). Head and abdominal injuries were move common among snowboarders than skiers, but chest and skeletal injuries were rare. There were no deaths. Serious snowboarding injury rates were similar to those for serious skiing injuries. The incidence of snowboarding injuries sufficiently severe to require tertiary referral was estimated at 0.03 injuries/1000 snowboarder days. Similar to reports of minor snowboarding injury, these data indicate that injury patterns in more serious snowboarding accidents are quite different from those of serious downhill skiing accidents. Injured snowboarders suffer splenic injuries more often and chest and spinal injuries less often than do skiers, and should be evaluated for blunt injuries with these statistical differences in mind.	UNIV COLORADO,HLTH SCI CTR,DEPT SURG,DIV NEUROSURG,DENVER,CO 80262									0	82	82	0	1	BUTTERWORTH-HEINEMANN LTD	OXFORD	LINACRE HOUSE JORDAN HILL, OXFORD, OXON, ENGLAND OX2 8DP	0020-1383			INJURY	Inj.-Int. J. Care Inj.	OCT	1995	26	8					539	542		10.1016/0020-1383(95)00085-N			4	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	RZ593	WOS:A1995RZ59300009	8550144				2022-02-06	
J	Nelson, LD; Temkin, NR; Dikmen, S; Barber, J; Giacino, JT; Yuh, E; Levin, HS; McCrea, MA; Stein, MB; Mukherjee, P; Okonkwo, DO; Diaz-Arrastia, R; Manley, GT; Adeoye, O; Badjatia, N; Boase, K; Bodien, Y; Bullock, MR; Chesnut, R; Corrigan, JD; Crawford, K; Duhaime, AC; Ellenbogen, R; Feeser, VR; Ferguson, A; Foreman, B; Gardner, R; Gaudette, E; Gonzalez, L; Gopinath, S; Gullapalli, R; Hemphill, JC; Hotz, G; Jain, S; Korley, F; Kramer, J; Kreitzer, N; Lindsell, C; Machamer, J; Madden, C; Martin, A; McAllister, T; Merchant, R; Noel, F; Palacios, E; Perl, D; Puccio, A; Rabinowitz, M; Robertson, CS; Rosand, J; Sander, A; Satris, G; Schnyer, D; Seabury, S; Sherer, M; Taylor, S; Toga, A; Valadka, A; Vassar, MJ; Vespa, P; Wang, K; Yue, JK; Zafonte, R				Nelson, Lindsay D.; Temkin, Nancy R.; Dikmen, Sureyya; Barber, Jason; Giacino, Joseph T.; Yuh, Esther; Levin, Harvey S.; McCrea, Michael A.; Stein, Murray B.; Mukherjee, Pratik; Okonkwo, David O.; Diaz-Arrastia, Ramon; Manley, Geoffrey T.; Adeoye, Opeolu; Badjatia, Neeraj; Boase, Kim; Bodien, Yelena; Bullock, M. Ross; Chesnut, Randall; Corrigan, John D.; Crawford, Karen; Duhaime, Ann-Christine; Ellenbogen, Richard; Feeser, V. Raman; Ferguson, Adam; Foreman, Brandon; Gardner, Raquel; Gaudette, Etienne; Gonzalez, Luis; Gopinath, Shankar; Gullapalli, Rao; Hemphill, J. Claude; Hotz, Gillian; Jain, Sonia; Korley, Frederick; Kramer, Joel; Kreitzer, Natalie; Lindsell, Chris; Machamer, Joan; Madden, Christopher; Martin, Alastair; McAllister, Thomas; Merchant, Randall; Noel, Florence; Palacios, Eva; Perl, Daniel; Puccio, Ava; Rabinowitz, Miri; Robertson, Claudia S.; Rosand, Jonathan; Sander, Angelle; Satris, Gabriela; Schnyer, David; Seabury, Seth; Sherer, Mark; Taylor, Sabrina; Toga, Arthur; Valadka, Alex; Vassar, Mary J.; Vespa, Paul; Wang, Kevin; Yue, John K.; Zafonte, Ross		TRACK-TBI Investigators	Recovery After Mild Traumatic Brain Injury in Patients Presenting to US Level I Trauma Centers: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Study	JAMA NEUROLOGY			English	Article							POSTTRAUMATIC-STRESS-DISORDER; COMMON DATA ELEMENTS; LONG-TERM OUTCOMES; SEVERE HEAD-INJURY; EARLY INTERVENTION; UNITED-STATES; MODERATE; RECOMMENDATIONS; CONCUSSION; DISABILITY	Key PointsQuestionHow common are persistent, injury-related functional limitations following mild traumatic brain injury vs orthopedic trauma? FindingsIn this cohort study of 1154 patients with mild traumatic brain injury and 299 patients with orthopedic trauma serving as controls, 53% of participants with mild traumatic brain injury reported impairment 12 months postinjury vs 38% of those with orthopedic trauma. Patients with intracranial abnormalities had the poorest outcomes; however, patients without abnormalities also reported problems at 12 months. MeaningMany patients who present to level I trauma centers with mild traumatic brain injury experience difficulties at 12 months postinjury, suggesting that this injury is not always benign; better follow-up and treatment appear to be needed. ImportanceMost traumatic brain injuries (TBIs) are classified as mild (mTBI) based on admission Glasgow Coma Scale (GCS) scores of 13 to 15. The prevalence of persistent functional limitations for these patients is unclear. ObjectivesTo characterize the natural history of recovery of daily function following mTBI vs peripheral orthopedic traumatic injury in the first 12 months postinjury using data from the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) study, and, using clinical computed tomographic (CT) scans, examine whether the presence (CT+) or absence (CT-) of acute intracranial findings in the mTBI group was associated with outcomes. Design, Setting, and ParticipantsTRACK-TBI, a cohort study of patients with mTBI presenting to US level I trauma centers, enrolled patients from February 26, 2014, to August 8, 2018, and followed up for 12 months. A total of 1453 patients at 11 level I trauma center emergency departments or inpatient units met inclusion criteria (ie, mTBI [n=1154] or peripheral orthopedic traumatic injury [n=299]) and were enrolled within 24 hours of injury; mTBI participants had admission GCS scores of 13 to 15 and clinical head CT scans. Patients with peripheral orthopedic trauma injury served as the control (OTC) group. ExposuresParticipants with mTBI or OTC. Main Outcomes and MeasuresThe Glasgow Outcome Scale Extended (GOSE) scale score, reflecting injury-related functional limitations across broad life domains at 2 weeks and 3, 6, and 12 months postinjury was the primary outcome. The possible score range of the GOSE score is 1 (dead) to 8 (upper good recovery), with a score less than 8 indicating some degree of functional impairment. ResultsOf the 1453 participants, 953 (65.6%) were men; mean (SD) age was 40.9 (17.1) years in the mTBI group and 40.9 (15.4) years in the OTC group. Most participants (mTBI, 87%; OTC, 93%) reported functional limitations (GOSE <8) at 2 weeks postinjury. At 12 months, the percentage of mTBI participants reporting functional limitations was 53% (95% CI, 49%-56%) vs 38% (95% CI, 30%-45%) for OTCs. A higher percentage of CT+ patients reported impairment (61%) compared with the mTBI CT- group (49%; relative risk [RR], 1.24; 95% CI, 1.08-1.43) and a higher percentage in the mTBI CT-group compared with the OTC group (RR, 1.28; 95% CI, 1.02-1.60). Conclusions and RelevanceMost patients with mTBI presenting to US level I trauma centers report persistent, injury-related life difficulties at 1 year postinjury, suggesting the need for more systematic follow-up of patients with mTBI to provide treatments and reduce the risk of chronic problems after mTBI. This cohort study examines the physical and neuropsychological outcomes in patients with mild traumatic brain injury up to 12 months after presentation.	[Nelson, Lindsay D.; McCrea, Michael A.] Med Coll Wisconsin, 8701 W Watertown Plank Rd, Milwaukee, WI 53226 USA; [Temkin, Nancy R.; Dikmen, Sureyya; Barber, Jason] Univ Washington, Seattle, WA 98195 USA; [Giacino, Joseph T.] Harvard Med Sch, Spaulding Rehabil Hosp, Boston, MA 02115 USA; [Giacino, Joseph T.; Bodien, Yelena; Rosand, Jonathan] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Yuh, Esther; Mukherjee, Pratik; Manley, Geoffrey T.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Levin, Harvey S.] Baylor Coll Med, Houston, TX 77030 USA; [Stein, Murray B.; Adeoye, Opeolu; Foreman, Brandon; Kreitzer, Natalie] Univ Calif San Diego, La Jolla, CA 92093 USA; [Stein, Murray B.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA; [Okonkwo, David O.] Univ Pittsburgh, Pittsburgh, PA USA; [Diaz-Arrastia, Ramon] Univ Penn, Philadelphia, PA 19104 USA; [Badjatia, Neeraj; Gullapalli, Rao] Univ Maryland, College Pk, MD 20742 USA; [Boase, Kim; Machamer, Joan] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Bullock, M. Ross; Hotz, Gillian] Univ Miami, Coral Gables, FL 33124 USA; [Chesnut, Randall; Ellenbogen, Richard] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Corrigan, John D.] Ohio State Univ, Columbus, OH 43210 USA; [Crawford, Karen; Gaudette, Etienne; Seabury, Seth; Toga, Arthur] Univ Southern Calif, Los Angeles, CA USA; [Duhaime, Ann-Christine] MassGen Hosp Children, Boston, MA USA; [Feeser, V. Raman] Virginia Commonwealth Univ, Dept Emergency Med, Richmond, VA 23284 USA; [Ferguson, Adam; Taylor, Sabrina; Vassar, Mary J.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Gardner, Raquel; Hemphill, J. Claude; Kramer, Joel] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Gonzalez, Luis; Sherer, Mark] TIRR Mem Hermann, Houston, TX USA; [Gopinath, Shankar] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Korley, Frederick] Univ Michigan, Sch Med, Dept Emergency Med, Ann Arbor, MI USA; [Lindsell, Chris] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA; [Madden, Christopher] UT Southwestern Med Ctr, Dept Neurol Surg, Dallas, TX USA; [Martin, Alastair; Palacios, Eva] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA; [McAllister, Thomas] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA; [Merchant, Randall] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23284 USA; [Noel, Florence] Baylor Coll Med, Duncan L Inst Clin & Translat Res, Houston, TX 77030 USA; [Perl, Daniel] Uniformed Serv Univ Hlth Sci, Dept Pathol, Bethesda, MD USA; [Puccio, Ava] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA USA; [Rabinowitz, Miri] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Robertson, Claudia S.; Sander, Angelle] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Satris, Gabriela; Vassar, Mary J.; Yue, John K.] Zuckerberg San Francisco Gen Hosp & Trauma Ctr, Brain & Spinal Cord Injury Ctr, San Francisco, CA USA; [Schnyer, David] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Valadka, Alex] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23284 USA; [Vespa, Paul] Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA; [Wang, Kevin] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; [Zafonte, Ross] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA 02115 USA		Nelson, LD (corresponding author), Med Coll Wisconsin, 8701 W Watertown Plank Rd, Milwaukee, WI 53226 USA.	linelson@mcw.edu	Hemphill, Claude/AAY-5630-2021; Badjatia, Neeraj/AAS-4855-2021; Giacino, Joseph/AAF-1952-2021; Schnyer, David/ABD-6372-2021; Yue, John/P-1348-2015	Hemphill, Claude/0000-0003-4019-7525; Giacino, Joseph/0000-0002-7916-9698; Schnyer, David/0000-0002-7472-2853; Ferguson, Adam/0000-0001-7102-1608; Wang, Kevin/0000-0002-9343-6473; Yue, John/0000-0001-9694-7722; Badjatia, Neeraj/0000-0003-1509-9034; Bodien, Yelena/0000-0003-4858-2903	US NIH-NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01 NS1365885]; US DoD TBI Endpoints Development Initiative grant [W81XWH-14-2-0176]; OneMind; NeuroTrauma Sciences LLC; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS047996] Funding Source: NIH RePORTER	The study was funded by US NIH-NINDS grant U01 NS1365885, OneMind, NeuroTrauma Sciences LLC, and US DoD TBI Endpoints Development Initiative grant W81XWH-14-2-0176.	Al Sayegh A, 2010, J NEUROL NEUROSUR PS, V81, P1128, DOI 10.1136/jnnp.2008.170092; Altman DG., 1991, PRACTICAL STAT MED R; Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Bay E, 2011, J HEAD TRAUMA REHAB, V26, P355, DOI 10.1097/HTR.0b013e3181f20146; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Broshek DK, 2015, BRAIN INJURY, V29, P228, DOI 10.3109/02699052.2014.974674; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Derogatis L.R., 2001, BRIEF SYMPTOM INVENT; DeRoon-Cassini TA, 2010, REHABIL PSYCHOL, V55, P1, DOI 10.1037/a0018601; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dikmen S, 2017, J NEUROTRAUM, V34, P1524, DOI 10.1089/neu.2016.4618; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Hoffman JM, 2012, ARCH PHYS MED REHAB, V93, P287, DOI 10.1016/j.apmr.2011.08.041; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kristman Vicki L, 2014, Arch Phys Med Rehabil, V95, pS265, DOI 10.1016/j.apmr.2013.04.026; Levin HS, 2012, J NEUROSURG, V116, P706; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; McCaffrey DF, 2004, PSYCHOL METHODS, V9, P403, DOI 10.1037/1082-989X.9.4.403; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Nelson LD, 2018, J NEUROTRAUM, V35, P249, DOI 10.1089/neu.2017.4988; Nelson LD, 2016, NEUROLOGY, V86, P1856, DOI 10.1212/WNL.0000000000002679; Nelson LD, 2016, J INT NEUROPSYCH SOC, V22, P24, DOI 10.1017/S1355617715001101; Nelson LD, 2013, NEUROPSYCHOL REV, V23, P285, DOI 10.1007/s11065-013-9240-7; Palermo TM, 2010, PAIN, V148, P387, DOI 10.1016/j.pain.2009.10.004; Pampallona S, 2004, ARCH GEN PSYCHIAT, V61, P714, DOI 10.1001/archpsyc.61.7.714; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; REITAN RM, 1971, PERCEPT MOTOR SKILL, V33, P575, DOI 10.2466/pms.1971.33.2.575; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Roden-Foreman K, 2017, J ORTHOP TRAUMA, V31, pE275, DOI 10.1097/BOT.0000000000000884; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Schadel S, 2019, MEAS SCI TECHNOL, V30, DOI 10.1088/1361-6501/ab1501; Schmidt M., 1996, REY AUDITORY VERBAL; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Seabury SA, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.0210; Sosin DM, 1996, BRAIN INJURY, V10, P47; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Wang KK, 2018, EXPERT REV MOL DIAGN, V18, P165, DOI 10.1080/14737159.2018.1428089; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th Edn; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	66	81	81	5	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	SEP	2019	76	9					1049	1059		10.1001/jamaneurol.2019.1313			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	IZ2CY	WOS:000486895500009	31157856	Green Published, Bronze	Y	N	2022-02-06	
J	Kochanek, PM; Tasker, RC; Carney, N; Totten, AM; Adelson, PD; Selden, NR; Davis-O'Reilly, C; Hart, EL; Bell, MJ; Bratton, SL; Grant, GA; Kissoon, N; Reuter-Rice, KE; Vavilala, MS; Wainwright, MS				Kochanek, Patrick M.; Tasker, Robert C.; Carney, Nancy; Totten, Annette M.; Adelson, P. David; Selden, Nathan R.; Davis-O'Reilly, Cynthia; Hart, Erica L.; Bell, Michael J.; Bratton, Susan L.; Grant, Gerald A.; Kissoon, Niranjan; Reuter-Rice, Karin E.; Vavilala, Monica S.; Wainwright, Mark S.			Guidelines for the Management of Pediatric Severe Traumatic Brain Injury, Third Edition: Update of the Brain Trauma Foundation Guidelines	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						critical care; evidence-based medicine; guidelines; pediatrics; systematic review; traumatic brain injury	SEVERE HEAD-INJURY; CEREBRAL PERFUSION-PRESSURE; EARLY DECOMPRESSIVE CRANIECTOMY; REFRACTORY INTRACRANIAL HYPERTENSION; COMMON DATA ELEMENTS; CEREBROSPINAL-FLUID DRAINAGE; SINGLE-CENTER EXPERIENCE; TIGHT GLYCEMIC CONTROL; LENGTH-OF-STAY; HYPERTONIC SALINE	This document was endorsed by the American Association of Neurological Surgeons/Congress of Neurological Surgeons. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the U.S. Army Contracting Command, Aberdeen Proving Ground, Natick Contracting Division, Stanford University, or the Brain Trauma Foundation. The information contained in the Guidelines for the Management of Pediatric Severe Traumatic Brain Injury reflects the current state of knowledge at the time of publication. The Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, and other collaborating organizations are not engaged in rendering professional medical services and assume no responsibility for patient outcomes resulting from application of these general recommendations in specific patient circumstances. Accordingly, the Brain Trauma Foundation, American Association of Neurological Surgeons, and Congress of Neurological Surgeons consider adherence to these clinical practice guidelines will not necessarily assure a successful medical outcome. The information contained in these guidelines reflects published scientific evidence at the time of completion of the guidelines and cannot anticipate subsequent findings and/or additional evidence, and therefore should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same result. Medical advice and decisions are appropriately made only by a competent and licensed physician who must make decisions in light of all the facts and circumstances in each individual and particular case and on the basis of availability of resources and expertise. Guidelines are not intended to supplant physician judgment with respect to particular patients or special clinical situations and are not a substitute for physician-patient consultation. Accordingly, the Brain Trauma Foundation, American Association of Neurological Surgeons, and Congress of Neurological Surgeons consider adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in light of each patient's individual circumstances.	[Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Crit Care Med, Pittsburgh, PA 15260 USA; [Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Pediat Bioengn & Clin & Translat Sci, Pittsburgh, PA 15260 USA; [Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Tasker, Robert C.] Harvard Med Sch, Boston Childrens Hosp, Dept Neurol, Boston, MA 02115 USA; [Tasker, Robert C.] Harvard Med Sch, Boston Childrens Hosp, Dept Anesthesiol Crit Care & Pain Med, Boston, MA 02115 USA; [Carney, Nancy; Totten, Annette M.; Davis-O'Reilly, Cynthia; Hart, Erica L.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Pacif Northwest Evidence Based Practice Ctr, Portland, OR 97201 USA; [Adelson, P. David] Phoenix Childrens Hosp, Pediat Neurosci, Phoenix, AZ USA; [Adelson, P. David] Phoenix Childrens Hosp, Pediat Neurosurg, Phoenix, AZ USA; [Adelson, P. David] Phoenix Childrens Hosp, BARROW Neurol Inst, Phoenix, AZ USA; [Selden, Nathan R.] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR USA; [Bell, Michael J.] Childrens Natl Med Ctr, Crit Care Med, Washington, DC 20010 USA; [Bratton, Susan L.] Univ Utah, Pediat, Salt Lake City, UT USA; [Grant, Gerald A.] Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA; [Kissoon, Niranjan] Univ British Columbia, British Columbias Childrens Hosp, Dept Pediat, Child & Family Res Inst, Vancouver, BC, Canada; [Reuter-Rice, Karin E.] Duke Univ, Dept Pediat, Sch Med, Sch Nursing,Div Pediat Crit Care Med, Durham, NC 27706 USA; [Vavilala, Monica S.] Univ Washington, Strateg Affairs Anesthesiol & Pain Med, Seattle, WA 98195 USA; [Vavilala, Monica S.] Univ Washington, Pediat, Seattle, WA 98195 USA; [Vavilala, Monica S.] Univ Washington, HIPRC, Seattle, WA 98195 USA; [Wainwright, Mark S.] Univ Washington, Seattle Childrens Hosp, Div Pediat Neurol, Seattle, WA 98195 USA		Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Crit Care Med, Pittsburgh, PA 15260 USA.; Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA.; Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Pediat Bioengn & Clin & Translat Sci, Pittsburgh, PA 15260 USA.; Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Kissoon, Niranjan/AAC-6140-2021	Totten, Annette/0000-0002-9100-8678; Reuter-Rice, Karin/0000-0003-1501-8994; Kissoon, Niranjan/0000-0001-8847-9973			Adamo MA, 2009, J NEUROSURG-PEDIATR, V3, P334, DOI 10.3171/2008.12.PEDS08310; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS53; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS19; Adelson PD, 2013, LANCET NEUROL, V12, P546, DOI 10.1016/S1474-4422(13)70077-2; Adelson PD, 2012, J NEUROTRAUM, V29, P639, DOI 10.1089/neu.2011.1952; Adelson PD, 2011, CHILD NERV SYST, V27, P1465, DOI 10.1007/s00381-011-1476-z; Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Agus MSD, 2017, NEW ENGL J MED, V376, P729, DOI 10.1056/NEJMoa1612348; Agus MSD, 2012, NEW ENGL J MED, V367, P1208, DOI 10.1056/NEJMoa1206044; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Alkhoury F, 2014, JAMA SURG, V149, P544, DOI 10.1001/jamasurg.2013.4329; Allen BB, 2014, PEDIATR CRIT CARE ME, V15, P62, DOI 10.1097/PCC.0b013e3182a556ea; Annane D, 2017, INTENS CARE MED, V43, P1751, DOI 10.1007/s00134-017-4919-5; ARJAMAA O, 1992, ACTA PHYSIOL SCAND, V144, P113, DOI 10.1111/j.1748-1716.1992.tb09275.x; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Bailey BM, 2012, J TRAUMA ACUTE CARE, V72, P263, DOI 10.1097/TA.0b013e31822a9512; BALDWIN HZ, 1992, PEDIATR NEUROSURG, V17, P115, DOI 10.1159/000120579; Bar-Joseph G, 2009, J NEUROSURG-PEDIATR, V4, P40, DOI 10.3171/2009.1.PEDS08319; Barlow KM, 1999, DEV MED CHILD NEUROL, V41, P220, DOI 10.1017/S0012162299000481; Barthelemy EJ, 2016, WORLD NEUROSURG, V88, P411, DOI 10.1016/j.wneu.2015.12.044; BARZILAY Z, 1988, INTENS CARE MED, V14, P417, DOI 10.1007/BF00262899; Bata SC, 2014, ANZ J SURG, V84, P438, DOI 10.1111/ans.12582; Beca J, 2015, CRIT CARE MED, V43, P1458, DOI 10.1097/CCM.0000000000000947; Becker DP, 1972, INTRACRANIAL PRESSUR, P309; Bell MJ, 2017, CHILD NERV SYST, V33, P1663, DOI 10.1007/s00381-017-3530-y; Bell MJ, 2013, PEDIATR CRIT CARE ME, V14, P811, DOI 10.1097/PCC.0b013e3182975e2f; Bennett TD, 2017, JAMA PEDIATR, V171, P965, DOI 10.1001/jamapediatrics.2017.2127; Bennett TD, 2012, ARCH PEDIAT ADOL MED, V166, P641, DOI 10.1001/archpediatrics.2012.322; Bennett TD, 2012, CRIT CARE MED, V40, P208, DOI 10.1097/CCM.0b013e31822e9d31; Berger RP, 2012, J NEUROTRAUM, V29, P672, DOI 10.1089/neu.2011.1861; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; Bourdages M, 2010, PEDIATR CRIT CARE ME, V11, P408, DOI 10.1097/PCC.0b013e3181c51dea; Bramwell KJ, 2006, PEDIATR EMERG CARE, V22, P90, DOI 10.1097/01.pec.0000199563.64264.3a; Briassoulis G, 2006, PEDIATR CRIT CARE ME, V7, P56, DOI 10.1097/01.PCC.0000192339.44871.26; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1979, CHILD BRAIN, V5, P174; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chaiwat O, 2009, J NEUROTRAUM, V26, P657, DOI 10.1089/neu.2008.0770; Chambers IR, 2000, BRIT J NEUROSURG, V14, P424; Chambers IR, 2001, J NEUROSURG, V94, P412, DOI 10.3171/jns.2001.94.3.0412; Chen HI, 2008, NEUROSURGERY, V63, P880, DOI 10.1227/01.NEU.0000327882.10629.06; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Chin KH, 2015, PEDIATR CRIT CARE ME, V16, P352, DOI 10.1097/PCC.0000000000000344; Cho DY, 1995, PEDIATR NEUROSURG, V23, P192, DOI 10.1159/000120958; Chung MG, 2016, PEDIATR CRIT CARE ME, V17, P150, DOI 10.1097/PCC.0000000000000588; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cottenceau V, 2011, J NEUROTRAUM, V28, P2003, DOI 10.1089/neu.2011.1929; Crompton E, 2017, CRIT CARE MED, V45, pE1091, DOI 10.1097/CCM.0000000000002565; Crompton EM, 2017, CRIT CARE MED, V45, P575, DOI 10.1097/CCM.0000000000002205; Cruz J, 2002, NEUROSURGERY, V50, P774, DOI 10.1097/00006123-200204000-00017; Csokay A, 2012, CHILD NERV SYST, V28, P441, DOI 10.1007/s00381-011-1661-0; Curry R, 2008, PEDIATR CRIT CARE ME, V9, P141, DOI 10.1097/PCC.0B013e318166870e; de Andrade AF, 2011, ARQ NEURO-PSIQUIAT, V69, P79, DOI 10.1590/S0004-282X2011000100016; Dean NP, 2007, J NEUROSURG, V107, P387, DOI 10.3171/PED-07/11/387; DEBRAY JM, 1993, CHILD NERV SYST, V9, P220, DOI 10.1007/BF00303573; DeKosky ST, 2017, BRAIN INJURY, V31, P1177, DOI 10.1080/02699052.2017.1312528; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; Desgranges FP, 2014, CHILD NERV SYST, V30, P1393, DOI 10.1007/s00381-014-2417-4; Dietrich WD, 2010, NEUROTHERAPEUTICS, V7, P43, DOI 10.1016/j.nurt.2009.10.015; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; Duhaime AC, 2012, J NEUROTRAUM, V29, P629, DOI 10.1089/neu.2011.1927; Edwards P, 2005, LANCET, V365, P1957; Elkon B, 2014, PEDIATR CRIT CARE ME, V15, P623, DOI 10.1097/PCC.0000000000000170; Empey PE, 2013, CRIT CARE MED, V41, P2379, DOI 10.1097/CCM.0b013e318292316c; ESPARZA J, 1985, CHILD NERV SYST, V1, P109, DOI 10.1007/BF00706691; FANCONI S, 1988, INTENS CARE MED, V14, P163; FEIG PU, 1977, NEW ENGL J MED, V297, P1444, DOI 10.1056/NEJM197712292972608; Felmet K, 2003, PEDIATRICS, V112, P1002, DOI 10.1542/peds.112.4.1002; Ferguson NM, 2016, PEDIATR CRIT CARE ME, V17, P444, DOI 10.1097/PCC.0000000000000709; Figaji AA, 2006, SAMJ S AFR MED J, V96, P969; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; Figaji AA, 2010, NEUROCRIT CARE, V12, P430, DOI 10.1007/s12028-010-9344-3; Figaji AA, 2009, CHILD NERV SYST, V25, P1325, DOI 10.1007/s00381-009-0822-x; Figg RE, 2006, PEDIATR SURG INT, V22, P215, DOI 10.1007/s00383-005-1560-0; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; Fivez T, 2016, NEW ENGL J MED, V374, P1111, DOI 10.1056/NEJMoa1514762; Friess SH, 2012, CRIT CARE RES PRACT, V2012, DOI 10.1155/2012/361310; Garbutt JM, 2013, CLIN PEDIATR, V52, P1014, DOI 10.1177/0009922813504823; Gibbison B, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1659-4; Gonda DD, 2013, PEDIATR CRIT CARE ME, V14, P610, DOI 10.1097/PCC.0b013e318291772b; Grinkeviciute DE, 2008, MEDICINA-LITHUANIA, V44, P119, DOI 10.3390/medicina44020015; Guerra SD, 2010, J PEDIAT-BRAZIL, V86, P73, DOI 10.2223/JPED.1960; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1303, DOI 10.1016/j.jclinepi.2011.04.014; Hejazi N, 2002, EUR J PEDIATR, V161, P99, DOI 10.1007/s00431-001-0864-x; HENDRICK EB, 1959, ARCH SURG-CHICAGO, V79, P362; Herman ST, 2015, J CLIN NEUROPHYSIOL, V32, P87, DOI 10.1097/WNP.0000000000000166; Hollingworth W, 2007, PEDIATR CRIT CARE ME, V8, P348, DOI 10.1097/01.PCC.0000270837.66217.3B; Holmes GL, 2005, PEDIATR NEUROL, V33, P1, DOI 10.1016/j.pediatrneurol.2004.12.003; Honeybul S, 2018, CURR OPIN CRIT CARE, V24, P97, DOI 10.1097/MCC.0000000000000481; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Hutchison JS, 2010, DEV NEUROSCI-BASEL, V32, P406, DOI 10.1159/000323260; Jacobi J, 2012, CRIT CARE MED, V40, P3251, DOI 10.1097/CCM.0b013e3182653269; Jagannathan J, 2008, J NEUROSURG-PEDIATR, V2, P240, DOI 10.3171/PED.2008.2.10.240; Jagannathan J, 2007, J NEUROSURG, V106, P268, DOI 10.3171/ped.2007.106.4.268; JAMES HE, 1980, ACTA NEUROCHIR, V51, P161, DOI 10.1007/BF01406742; JAMES HE, 1977, ACTA NEUROCHIR, V36, P189, DOI 10.1007/BF01405391; Jehan F, 2017, J TRAUMA ACUTE CARE, V83, P1148, DOI 10.1097/TA.0000000000001658; Jha RM, 2017, LANCET NEUROL, V16, P578, DOI 10.1016/S1474-4422(17)30225-9; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Josan VA, 2006, CHILD NERV SYST, V22, P1268, DOI 10.1007/s00381-006-0064-0; KAIEDA R, 1989, NEUROSURGERY, V24, P671, DOI 10.1227/00006123-198905000-00003; KAISER G, 1984, NEUROPEDIATRICS, V15, P68, DOI 10.1055/s-2008-1052344; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Kapapa T, 2010, J CHILD NEUROL, V25, P274, DOI 10.1177/0883073809332699; KASOFF SS, 1988, PEDIATR NEUROSCI, V14, P241, DOI 10.1159/000120397; KASSELL NF, 1980, NEUROSURGERY, V7, P598, DOI 10.1227/00006123-198012000-00011; Kasselman LJ, 2007, J VASC RES, V44, P283, DOI 10.1159/000101450; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; Keenan Heather T, 2005, Pediatr Crit Care Med, V6, P537, DOI 10.1097/01.PCC.0000164638.44600.67; Kerr ME, 1999, CRIT CARE MED, V27, P2776, DOI 10.1097/00003246-199912000-00028; Khan SA, 2014, CHILD NERV SYST, V30, P277, DOI 10.1007/s00381-013-2225-2; Klein P, 2012, ARCH NEUROL-CHICAGO, V69, P1290, DOI 10.1001/archneurol.2012.445; KLOTI J, 1987, CHILD NERV SYST, V3, P103, DOI 10.1007/BF00271134; Kochanek PM, 2019, PEDIATR CRIT CARE ME, V20, P269, DOI 10.1097/PCC.0000000000001737; Kochanek PM, 2015, CRIT CARE MED, V43, P1544, DOI 10.1097/CCM.0000000000001041; Kochanek PM, 2015, SEMIN NEUROL, V35, P83, DOI 10.1055/s-0035-1544237; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Koenig MA, 2008, NEUROLOGY, V70, P1023, DOI 10.1212/01.wnl.0000304042.05557.60; Kolias AG, 2016, BRIT J NEUROSURG, V30, P246, DOI 10.3109/02688697.2016.1159655; Kurz JE, 2016, PEDIATR CRIT CARE ME, V17, P649, DOI 10.1097/PCC.0000000000000765; Kurzbuch AR, 2015, NEUROSURG REV, V38, P629, DOI 10.1007/s10143-015-0626-2; Lescot T, 2006, CRIT CARE MED, V34, P3029, DOI 10.1097/01.CCM.0000243797.42346.64; LEVI L, 1991, BRIT J NEUROSURG, V5, P617, DOI 10.3109/02688699109002885; LEVY DI, 1995, J NEUROSURG, V83, P453, DOI 10.3171/jns.1995.83.3.0453; LEWIS RJ, 1993, ANN EMERG MED, V22, P1114, DOI 10.1016/S0196-0644(05)80974-6; Li H, 2009, J NEUROTRAUM, V26, P1905, DOI [10.1089/neu.2008.0828, 10.1089/neu.2008-0828]; Liesemer K, 2014, PEDIATR CRIT CARE ME, V15, P554, DOI 10.1097/PCC.0000000000000150; Liesemer K, 2011, J NEUROTRAUM, V28, P755, DOI 10.1089/neu.2010.1518; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Macrae D, 2014, NEW ENGL J MED, V370, P107, DOI 10.1056/NEJMoa1302564; Malakouti A, 2012, PEDIATR CRIT CARE ME, V13, pE18, DOI 10.1097/PCC.0b013e31820aba1f; Mangat HS, 2015, J NEUROSURG, V122, P202, DOI 10.3171/2014.10.JNS132545; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Martinon C, 2011, PEDIATR CRIT CARE ME, V12, P65, DOI 10.1097/PCC.0b013e3181e2a244; MAXWELL RE, 1971, J NEUROSURG, V34, P477, DOI 10.3171/jns.1971.34.4.0477; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; McManus ML, 1998, ANESTHESIOLOGY, V88, P1586, DOI 10.1097/00000542-199806000-00023; Mehta A, 2010, DEV NEUROSCI-BASEL, V32, P413, DOI 10.1159/000316804; Mellion SA, 2013, PEDIATR CRIT CARE ME, V14, P239, DOI 10.1097/PCC.0b013e318271c3b2; Messing-Junger AM, 2003, ZBL NEUROCHIR, V64, P171; Mhanna MJ, 2015, J NEUROSURG PEDIAT, V16, P1; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Minardi C, 2012, CURR DRUG TARGETS, V13, P936, DOI 10.2174/138945012800675740; Morris KP, 2006, INTENS CARE MED, V32, P1606, DOI 10.1007/s00134-006-0285-4; Morton SC, 2018, AHRQ PUBLICATION; MOSS GS, 1988, AM J SURG, V155, P425, DOI 10.1016/S0002-9610(88)80106-5; Mtaweh H, 2014, PEDIATR CRIT CARE ME, V15, P242, DOI 10.1097/PCC.0000000000000041; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; MUIZELAAR JP, 1988, J NEUROSURG, V69, P923, DOI 10.3171/jns.1988.69.6.0923; Nagai M, 2017, WORLD NEUROSURG, V100, P224, DOI 10.1016/j.wneu.2016.12.134; NAKAYAMA SI, 1985, J SURG RES, V38, P180, DOI 10.1016/0022-4804(85)90025-3; Narotam PK, 2006, J PEDIATR SURG, V41, P505, DOI 10.1016/j.jpedsurg.2005.11.069; Natale JE, 2000, CRIT CARE MED, V28, P2608, DOI 10.1097/00003246-200007000-00071; Oluigbo CO, 2012, J NEUROSURG-PEDIATR, V9, P125, DOI 10.3171/2011.11.PEDS09449; PAPPIUS HM, 1969, ARCH NEUROL-CHICAGO, V20, P207, DOI 10.1001/archneur.1969.00480080107013; Pearl PL, 2013, EPILEPSIA, V54, pe135, DOI 10.1111/epi.12326; Pechmann A, 2015, NEUROPEDIATRICS, V46, P5, DOI 10.1055/s-0034-1393707; Perez SE, 2011, J TRAUMA, V71, P133; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; PFENNINGER J, 1983, INTENS CARE MED, V9, P13, DOI 10.1007/BF01693699; Pfenninger J, 2002, SWISS MED WKLY, V132, P116; PIATT JH, 1984, NEUROSURGERY, V15, P427, DOI 10.1227/00006123-198409000-00023; Piper BJ, 2015, ANAESTH INTENS CARE, V43, P204, DOI 10.1177/0310057X1504300210; PITLICK WH, 1982, CLIN PHARMACOL THER, V31, P466, DOI 10.1038/clpt.1982.61; PITTMAN T, 1989, PEDIATR NEUROSCI, V15, P13, DOI 10.1159/000120433; Polderman KH, 2004, INTENS CARE MED, V30, P556, DOI 10.1007/s00134-003-2152-x; Polderman KH, 2003, CRIT CARE MED, V31, P584, DOI 10.1097/01.CCM.0000050287.68977.84; Prabhakaran P, 2004, J NEUROSURG, V100, P454, DOI 10.3171/ped.2004.100.5.0454; Prasad GL, 2015, CHILD NERV SYST, V31, P269, DOI 10.1007/s00381-014-2529-x; Prasad GL, 2015, BRAIN INJURY, V29, P1; Qureshi AI, 2000, CRIT CARE MED, V28, P1556, DOI 10.1097/00003246-200005000-00049; Qureshi AI, 2000, CRIT CARE MED, V28, P3301, DOI 10.1097/00003246-200009000-00032; Ragan DK, 2012, PEDIATR RES, V71, P199, DOI 10.1038/pr.2011.31; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; Roumeliotis N, 2016, CHILD NERV SYST, V32, P2363, DOI 10.1007/s00381-016-3231-y; Rubiano AM, 2009, ULUS TRAVMA ACIL CER, V15, P28; Ruf B, 2003, CRIT CARE, V7, pR133, DOI 10.1186/cc2361; Rutigliano D, 2006, J PEDIATR SURG, V41, P83, DOI 10.1016/j.jpedsurg.2005.10.010; Sakurai A, 2012, J NEUROTRAUM, V29, P313, DOI 10.1089/neu.2011.2152; Salonia R, 2010, J NEUROTRAUM, V27, P1819, DOI 10.1089/neu.2010.1402; Schoon P, 2002, ACT NEUR S, V81, P285; Segal S, 2001, INTENS CARE MED, V27, P236, DOI 10.1007/s001340000717; SHAPIRO K, 1982, J NEUROSURG, V56, P819, DOI 10.3171/jns.1982.56.6.0819; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; Shein SL, 2016, PEDIATR CRIT CARE ME, V17, P236, DOI 10.1097/PCC.0000000000000610; Shore PM, 2004, J NEUROTRAUM, V21, P1113; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; Skoglund TS, 2006, J NEUROTRAUM, V23, P1502, DOI 10.1089/neu.2006.23.1502; Srinivasan Vijay, 2012, J Diabetes Sci Technol, V6, P37; Stein DM, 2011, J TRAUMA, V71, P364, DOI 10.1097/TA.0b013e31822820da; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Steiner LA, 2006, BRIT J ANAESTH, V97, P26, DOI 10.1093/bja/ael110; Stiefel MF, 2006, J NEUROSURG, V105, P281, DOI 10.3171/ped.2006.105.4.281; Stippler M, 2012, J NEUROSURG-PEDIATR, V10, P383, DOI 10.3171/2012.8.PEDS12165; Su E, 2012, NEUROCRIT CARE, V17, P401, DOI 10.1007/s12028-012-9767-0; Taha AA, 2011, J NEUROSCI NURS, V43, P291, DOI 10.1097/JNN.0b013e318234e9b2; Tapper Julius, 2017, Surg Neurol Int, V8, P141, DOI 10.4103/sni.sni_453_16; Tasker RC, 2017, CRIT CARE MED, V45, pE1091, DOI 10.1097/CCM.0000000000002526; Tasker RC, 2017, PEDIATR CRIT CARE ME, V18, P355, DOI 10.1097/PCC.0000000000001098; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P521; Thomale UW, 2010, CHILD NERV SYST, V26, P1563, DOI 10.1007/s00381-010-1103-4; Tilford JM, 2001, CRIT CARE MED, V29, P1056, DOI 10.1097/00003246-200105000-00037; Tilford JM, 2005, CRIT CARE MED, V33, P2074, DOI 10.1097/01.CCM.0000171839.65687.F5; Tume LN, 2011, NURS CRIT CARE, V16, P77, DOI 10.1111/j.1478-5153.2010.00412.x; van Beek AHEA, 2008, J CEREBR BLOOD F MET, V28, P1071, DOI 10.1038/jcbfm.2008.13; Vavilala MS, 2014, CRIT CARE MED, V42, P2258, DOI 10.1097/CCM.0000000000000507; Vavilala MS, 2003, J NEUROSURG ANESTH, V15, P307, DOI 10.1097/00008506-200310000-00003; Vlasselaers D, 2009, LANCET, V373, P547, DOI 10.1016/S0140-6736(09)60044-1; Wahlstrom MR, 2005, INTENS CARE MED, V31, P832, DOI 10.1007/s00134-005-2632-2; Webster DL, 2015, J CRIT CARE, V30, P1267, DOI 10.1016/j.jcrc.2015.07.022; Weed LH, 1919, AM J PHYSIOL, V48, P512, DOI 10.1152/ajplegacy.1919.48.4.512; WEISS MH, 1970, J NEUROSURG, V32, P452, DOI 10.3171/jns.1970.32.4.0452; Welch TP, 2016, CRIT CARE MED, V44, P809, DOI 10.1097/CCM.0000000000001558; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011; WISE B L, 1961, Surg Forum, V12, P398; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478; YABLON SA, 1993, ARCH PHYS MED REHAB, V74, P983; Yue JK, 2017, J NEUROSURG SCI, DOI 10.23736/S0390-5616.17.04003-6; Zwienenberg M, 1999, J NEUROTRAUM, V16, P937, DOI 10.1089/neu.1999.16.937	235	81	82	4	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	MAR	2019	20	3		1			S1	S82		10.1097/PCC.0000000000001735			82	Critical Care Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Pediatrics	IQ4HT	WOS:000480712400001	30829890	Bronze	Y	N	2022-02-06	
J	Chen, SB; Ye, JF; Chen, XR; Shi, JN; Wu, WH; Lin, WP; Lin, WB; Li, YS; Fu, HD; Li, S				Chen, Shoubo; Ye, Jingfang; Chen, Xiangrong; Shi, Jinnan; Wu, Wenhua; Lin, Wenping; Lin, Weibin; Li, Yasong; Fu, Huangde; Li, Shun			Valproic acid attenuates traumatic spinal cord injury-induced inflammation via STAT1 and NF-kappa B pathway dependent of HDAC3	JOURNAL OF NEUROINFLAMMATION			English	Article						Spinal cord injury; Valproic acid; HDAC3; Microglia; Inflammatory; STAT1; NF-kappa B pathway	BRAIN-INJURY; ACTIVATION; INHIBITION; MICROGLIA; CELLS; POLARIZATION; ACETYLATION; EXPRESSION; AUTOPHAGY; RELEASE	Background: Microglial polarization with M1/M2 phenotype shifts and the subsequent neuroinflammatory responses are vital contributing factors for spinal cord injury (SCI)-induced secondary injury. Nuclear factor-kappa B (NF-kappa B) is considered the central transcription factor of inflammatory mediators, which plays a crucial role in microglial activation. Lysine acetylation of STAT1 seems necessary for NF-kappa B pathway activity, as it is regulated by histone deacetylases (HDACs). There have been no studies that have explained if HDAC inhibition by valproic acid (VPA) affects the NF-kappa B pathway via acetylation of STAT1 dependent of HDAC activity in the microglia-mediated central inflammation following SCI. We investigated the potential molecular mechanisms that focus on the phenotypic transition of microglia and the STAT1-mediated NF-kappa B acetylation after a VPA treatment. Methods: The Basso-Beattie-Bresnahan locomotion scale, the inclined plane test, the blood-spinal cord barrier, and Nissl staining were employed to determine the neuroprotective effects of VPA treatment after SCI. Assessment of microglia polarization and pro-inflammatory markers, such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-1 beta, IL-6, and interferon (INF)-gamma was used to evaluate the neuroinflammatory responses and the anti-inflammatory effects of VPA treatment. Immunofluorescent staining and Western blot analysis were used to detect HDAC3 nuclear translocation, activity, and NF-kappa B signaling pathway activation to evaluate the effects of VPA treatment. The impact of STAT1 acetylation on NF-kappa B pathway and the interaction between STAT1 and NF-kappa B were assessed to evaluate anti-inflammation effects of VPA treatment and also whether these effects were dependent on a STAT1/NF-kappa B pathway to gain further insight into the mechanisms underlying the development of the neuroinflammatory response after SCI. Results: The results showed that the VPA treatment promoted the phenotypic shift of microglia from M1 to M2 phenotype and inhibited microglial activation, thus reducing the SCI-induced inflammatory factors. The VPA treatment upregulation of the acetylation of STAT1/NF-kappa B pathway was likely caused by the HDAC3 translocation to the nucleus and activity. These results indicated that the treatment with the VPA suppressed the expression and the activity of HDAC3 and enhanced STAT1, as well as NF-kappa B p65 acetylation following a SCI. The acetylation status of NF-kappa B p65 and the complex with NF-kappa B p65 and STAT1 inhibited the NF-kappa B p65 transcriptional activity and attenuated the microglia-mediated central inflammatory response following SCI. Conclusions: These results suggested that the VPA treatment attenuated the inflammatory response by modulating microglia polarization through STAT1-mediated acetylation of the NF-kappa B pathway, dependent of HDAC3 activity. These effects led to neuroprotective effects following SCI.	[Chen, Shoubo; Shi, Jinnan; Wu, Wenhua; Lin, Wenping] Fujian Med Univ, Affiliated Hosp 2, Dept Orthopaed, Quanzhou 362000, Fujian, Peoples R China; [Ye, Jingfang] Quanzhou Med Coll, Dept Nursing Fac, Quanzhou 362000, Fujian, Peoples R China; [Chen, Xiangrong; Lin, Weibin; Li, Yasong] Fujian Med Univ, Affiliated Hosp 2, Dept Neurosurg, Quanzhou 362000, Fujian, Peoples R China; [Fu, Huangde] YouJiang Med Univ Nationalities, Affiliated Hosp, Dept Neurosurg, Baise 533000, Guangxi Provinc, Peoples R China; [Li, Shun] North Sichuan Med Coll, Affiliated Hosp, Dept Neurosurg, Nanchong 637000, Sichuan, Peoples R China		Chen, XR (corresponding author), Fujian Med Univ, Affiliated Hosp 2, Dept Neurosurg, Quanzhou 362000, Fujian, Peoples R China.; Li, S (corresponding author), North Sichuan Med Coll, Affiliated Hosp, Dept Neurosurg, Nanchong 637000, Sichuan, Peoples R China.	xiangrong_chen281@126.com	zhang, chuengji/AAD-4591-2020		funds for Fujian Province Scientific and Technological Foundation [2060402]; Fujian Province Scientific Foundation [2017J01183]	This work was supported by grants from the funds for Fujian Province Scientific and Technological Foundation (No. 2060402) from Dr. Xiangrong Chen and Fujian Province Scientific Foundation (No. 2017J01183) from Dr. Shoubo Chen.	Bambakidis T, 2016, J NEUROTRAUM, V33, P1514, DOI 10.1089/neu.2015.4163; Chen S, 2014, NEUROCHEM RES, V39, P1621, DOI 10.1007/s11064-014-1241-2; Chen XR, 2017, J NEUROINFLAMM, V14, DOI [10.1186/s12974-017-0917-3, 10.1186/s12974-018-1151-3]; Chi JH, 2017, EUR J PHARMACOL, V796, P101, DOI 10.1016/j.ejphar.2016.12.026; Chu TC, 2015, REGEN MED, V10, P193, DOI [10.2217/RME.14.86, 10.2217/rme.14.86]; Cui XL, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.270; Deng ZT, 2017, INT J NANOMED, V12, P3617, DOI 10.2147/IJN.S124661; Fang P, 2014, MOL NEUROBIOL, V49, P472, DOI 10.1007/s12035-013-8533-4; He XX, 2017, RES VET SCI, V112, P7, DOI 10.1016/j.rvsc.2016.12.011; He ZL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08052-4; Ji MM, 2015, AUTOPHAGY, V11, P2160, DOI 10.1080/15548627.2015.1082024; Jiang J, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00363; Jiang XJ, 2017, NEUROCHEM RES, V42, P3245, DOI 10.1007/s11064-017-2361-2; Kim WH, 2017, PHARMACOL REP, V69, P1030, DOI 10.1016/j.pharep.2017.04.006; Kramer OH, 2006, GENE DEV, V20, P473, DOI 10.1101/gad.364306; Kuboyama T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08535-4; Kumar H, 2017, MOL NEUROBIOL, V54, P3578, DOI 10.1007/s12035-016-9910-6; Kumar P, 2017, AM J PHYSIOL-RENAL, V313, pF781, DOI 10.1152/ajprenal.00166.2017; Lan KC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12285-8; Lee JY, 2014, J NEUROTRAUM, V31, P582, DOI 10.1089/neu.2013.3146; Leus NGJ, 2016, CURR OPIN CHEM BIOL, V33, P160, DOI 10.1016/j.cbpa.2016.06.019; Leus NGJ, 2016, BIOCHEM PHARMACOL, V108, P58, DOI 10.1016/j.bcp.2016.03.010; Li HT, 2016, MOL NEUROBIOL, V53, P4073, DOI 10.1007/s12035-015-9327-7; Li ZM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020315; Liu G, 2017, CELL MOL NEUROBIOL, V37, P843, DOI 10.1007/s10571-016-0422-8; Nakazawa H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170391; Park SY, 2014, MOL NUTR FOOD RES, V58, P738, DOI 10.1002/mnfr.201300445; Penas C, 2011, NEUROSCIENCE, V178, P33, DOI 10.1016/j.neuroscience.2011.01.012; Raible DJ, 2015, EXP NEUROL, V271, P445, DOI 10.1016/j.expneurol.2015.07.001; Sinkovics JG, 2015, INT J ONCOL, V47, P1211, DOI 10.3892/ijo.2015.3102; Song JW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00553-6; Su ZD, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4338; Suda S, 2015, BRAIN RES, V1606, P1, DOI 10.1016/j.brainres.2015.02.013; Wang CG, 2018, J CELL MOL MED, V22, P1148, DOI 10.1111/jcmm.13368; Wang GH, 2015, P NATL ACAD SCI USA, V112, P2853, DOI 10.1073/pnas.1501441112; Wilson CB, 2014, BEHAV BRAIN RES, V268, P72, DOI 10.1016/j.bbr.2014.03.029; Xu HZ, 2017, NEURAL PLAST, V2017, DOI 10.1155/2017/5405104; Xu Q, 2015, J MOL NEUROSCI, V55, P289, DOI 10.1007/s12031-014-0320-9; Yi HB, 2016, INT IMMUNOPHARMACOL, V36, P199, DOI 10.1016/j.intimp.2016.04.032; Zendedel A, 2018, MOL NEUROBIOL, V55, P1364, DOI 10.1007/s12035-017-0400-2; Zhang Q, 2016, MOL NEUROBIOL, V53, P662, DOI 10.1007/s12035-014-9035-8; Zhang XS, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.292	42	81	86	1	22	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	MAY 18	2018	15								150	10.1186/s12974-018-1193-6			14	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	GH0WJ	WOS:000433122600001	29776446	Green Published, gold			2022-02-06	
J	Cai, W; Yang, T; Liu, H; Han, LJ; Zhang, K; Hu, XM; Zhang, XJ; Yin, KJ; Gao, YQ; Bennett, MVL; Leak, RK; Chen, J				Cai, Wei; Yang, Tuo; Liu, Huan; Han, Lijuan; Zhang, Kai; Hu, Xiaoming; Zhang, Xuejing; Yin, Ke-Jie; Gao, Yanqin; Bennett, Michael V. L.; Leak, Rehana K.; Chen, Jun			Peroxisome proliferator-activated receptor gamma (PPAR gamma): A master gatekeeper in CNS injury and repair	PROGRESS IN NEUROBIOLOGY			English	Article						Thiazolidinedione; Nrf2; Stroke; Traumatic brain injury; Inflammation; Remyelination	BLOOD-BRAIN-BARRIER; SPINAL-CORD-INJURY; INSULIN-RESISTANCE INTERVENTION; PIOGLITAZONE CLINICAL-TRIAL; MICROGLIA/MACROPHAGE POLARIZATION DYNAMICS; EXPERIMENTAL INTRACEREBRAL HEMORRHAGE; ADULT HIPPOCAMPAL NEUROGENESIS; VASCULAR COGNITIVE IMPAIRMENT; TYPE-2 DIABETES-MELLITUS; OBSERVATIONAL FOLLOW-UP	Peroxisome proliferator-activated receptor gamma (PPAR gamma) is a widely expressed ligand-modulated transcription factor that governs the expression of genes involved in inflammation, redox equilibrium, trophic factor production, insulin sensitivity, and the metabolism of lipids and glucose. Synthetic PPAR gamma agonists (e.g. thiazolidinediones) are used to treat Type II diabetes and have the potential to limit the risk of developing brain injuries such as stroke by mitigating the influence of comorbidities. If brain injury develops, PPAR gamma serves as a master gatekeeper of cytoprotective stress responses, improving the chances of cellular survival and recovery of homeostatic equilibrium. In the acute injury phase, PPAR gamma directly restricts tissue damage by inhibiting the NFKI3 pathway to mitigate inflammation and stimulating the Nrf2/ARE axis to neutralize oxidative stress. During the chronic phase of acute brain injuries, PPAR gamma activation in injured cells culminates in the repair of gray and white matter, preservation of the blood brain barrier, reconstruction of the neurovascular unit, resolution of inflammation, and long-term functional recovery. Thus, PPAR gamma lies at the apex of cell fate decisions and exerts profound effects on the chronic progression of acute injury conditions. Here, we review the therapeutic potential of PPAR gamma in stroke and brain trauma and highlight the novel role of PPAR gamma in long-term tissue repair. We describe its structure and function and identify the genes that it targets. PPAR gamma regulation of inflammation, metabolism, cell fate (proliferation/differentiation/maturation/survival), and many other processes also has relevance to other neurological diseases. Therefore, PPAR gamma is an attractive target for therapies against a number of progressive neurological disorders. (C) 2018 Elsevier Ltd. All rights reserved.	[Cai, Wei; Yang, Tuo; Liu, Huan; Han, Lijuan; Zhang, Kai; Hu, Xiaoming; Zhang, Xuejing; Yin, Ke-Jie; Chen, Jun] Univ Pittsburgh, Pittsburgh Inst Brain Disorders & Recovery, Pittsburgh, PA 15213 USA; [Cai, Wei; Yang, Tuo; Liu, Huan; Han, Lijuan; Zhang, Kai; Hu, Xiaoming; Zhang, Xuejing; Yin, Ke-Jie; Chen, Jun] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA; [Gao, Yanqin; Chen, Jun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China; [Gao, Yanqin; Chen, Jun] Fudan Univ, Inst Brain Sci, Shanghai 200032, Peoples R China; [Bennett, Michael V. L.] Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, Bronx, NY 10461 USA; [Leak, Rehana K.] Duquesne Univ, Sch Pharm, Div Pharmaceut Sci, Pittsburgh, PA 15282 USA; [Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA		Chen, J (corresponding author), Univ Pittsburgh, Sch Med, Pittsburgh Inst Brain Disorders & Recovery, Pittsburgh, PA 15213 USA.; Leak, RK (corresponding author), Duquesne Univ, Grad Sch Pharmaceut Sci, Pittsburgh, PA 15282 USA.	leakr@duq.edu; chenj2@upmc.edu	Yang, Tuo/J-5620-2019; Leak, Rehana K/I-2607-2019; Zhang, Xuejing/J-8857-2018	Leak, Rehana K/0000-0003-2817-7417; Zhang, Xuejing/0000-0003-2994-5502	National Institutes of Health/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS095029, NS095671, NS045048, NS092618, R15NS093539]; VA Merit Review awardsUS Department of Veterans Affairs [I01BX003377, 1I01BX002495]; Chinese Natural Science FoundationNational Natural Science Foundation of China (NSFC) [81529002, 81371306, 81571285]; VA Senior Research Career Scientist Award; Richard King Mellon Endowed Chair; UPMC Endowed Professorship; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS086820, R01NS092618, R01NS095671, R01NS091175, R01NS095029, R01NS045048, R15NS093539] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX003377, I01BX002495] Funding Source: NIH RePORTER	W.C. and T.Y. contributed equally to this article. This work was supported by National Institutes of Health/NINDS grants NS095029 (to J.C., R.K.L., and M.V.L.B.), NS095671 (to J.C.), NS045048 (to J.C.), NS092618 (to X.H.), and R15NS093539 (to R.K.L.), the VA Merit Review awards (I01BX003377 and 1I01BX002495 to J.C.), and grants from the Chinese Natural Science Foundation grants 81529002, 81371306, and 81571285, and (to Y.G. and J.C.). J.C. is a recipient of the VA Senior Research Career Scientist Award, and the Richard King Mellon Endowed Chair and UPMC Endowed Professorship.	Abou Kheir W, 2005, J CELL SCI, V118, P5369, DOI 10.1242/jcs.02638; Abraham HMA, 2016, J CEREBR BLOOD F MET, V36, P132, DOI 10.1038/jcbfm.2015.121; Agostini M, 2006, CELL METAB, V4, P303, DOI 10.1016/j.cmet.2006.09.003; Ahmadian M, 2013, NAT MED, V19, P557, DOI 10.1038/nm.3159; Ait-Oufella H, 2011, ARTERIOSCL THROM VAS, V31, P969, DOI 10.1161/ATVBAHA.110.207415; Aktas O, 2007, ARCH NEUROL-CHICAGO, V64, P185, DOI 10.1001/archneur.64.2.185; Allahtavakoli M, 2009, BRAIN RES, V1271, P121, DOI 10.1016/j.brainres.2009.03.040; ANDERSON CL, 1990, J EXP MED, V171, P1333, DOI 10.1084/jem.171.4.1333; Aoun P, 2003, INVEST OPHTH VIS SCI, V44, P2999, DOI 10.1167/iovs.02-1060; Appel S, 2005, BLOOD, V106, P3888, DOI 10.1182/blood-2004-12-4709; Arbo BD, 2016, PROG NEUROBIOL, V144, P27, DOI 10.1016/j.pneurobio.2016.03.010; Armstrong RC, 2016, NEUROPHARMACOLOGY, V110, P654, DOI 10.1016/j.neuropharm.2015.04.029; Armstrong RC, 2016, EXP NEUROL, V275, P328, DOI 10.1016/j.expneurol.2015.02.011; Aronowski J, 2011, STROKE, V42, P1781, DOI 10.1161/STROKEAHA.110.596718; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Asano T, 1999, CRIT REV NEUROSURG, V9, P303, DOI 10.1007/s003290050147; Aspelund A, 2015, J EXP MED, V212, P991, DOI 10.1084/jem.20142290; Attwell D, 2016, J CEREBR BLOOD F MET, V36, P451, DOI 10.1177/0271678X15610340; Auclair M, 2013, ARTERIOSCL THROM VAS, V33, P829, DOI 10.1161/ATVBAHA.112.300962; Azoulay L, 2010, PHARMACOEPIDEM DR S, V19, P343, DOI 10.1002/pds.1883; Bach RG, 2013, CIRCULATION, V128, P785, DOI 10.1161/CIRCULATIONAHA.112.000678; Bagshaw SM, 2008, RENAL FAILURE, V30, P581, DOI 10.1080/08860220802134649; Ballesteros I, 2014, J LEUKOCYTE BIOL, V95, P587, DOI 10.1189/jlb.0613326; Barnabe-Heider F, 2010, CELL STEM CELL, V7, P470, DOI 10.1016/j.stem.2010.07.014; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Bath PM, 2016, INT J STROKE, V11, P741, DOI 10.1177/1747493016660099; Bauer S, 2005, NEUROSCIENCE, V130, P75, DOI 10.1016/j.neuroscience.2004.08.047; Baylis C, 2003, J PHARMACOL EXP THER, V307, P854, DOI 10.1124/jpet.103.055616; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Benarroch EE, 2009, NEUROLOGY, V72, P1779, DOI 10.1212/WNL.0b013e3181a6b123; Berg RMG, 2011, J CEREBR BLOOD F MET, V31, P1532, DOI 10.1038/jcbfm.2011.48; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Bernardo A, 2000, EUR J NEUROSCI, V12, P2215, DOI 10.1046/j.1460-9568.2000.00110.x; Bernardo A, 2009, J NEUROPATH EXP NEUR, V68, P797, DOI 10.1097/NEN.0b013e3181aba2c1; Bernier PJ, 2002, P NATL ACAD SCI USA, V99, P11464, DOI 10.1073/pnas.172403999; Bevers MB, 2017, J CEREBR BLOOD F MET, V37, P2577, DOI 10.1177/0271678X16671730; Beyer AM, 2008, HYPERTENSION, V51, P867, DOI 10.1161/HYPERTENSIONAHA.107.103648; Bhatt DL, 2007, AM HEART J, V154, P137, DOI 10.1016/j.ahj.2007.03.029; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; BLAKEMORE WF, 1974, NATURE, V249, P577, DOI 10.1038/249577a0; Blanco M, 2005, STROKE, V36, P1189, DOI 10.1161/01.STR.0000166054.55993.e5; Boekhoff TMA, 2012, J NEUROTRAUM, V29, P1000, DOI 10.1089/neu.2011.1821; BORHANI NO, 1965, AM J PUBLIC HEALTH N, V55, P673, DOI 10.2105/AJPH.55.5.673; Braissant O, 1998, ENDOCRINOLOGY, V139, P2748, DOI 10.1210/en.139.6.2748; Bruemmer D, 2003, CIRC RES, V93, pE38, DOI 10.1161/01.RES.0000088344.15288.E6; Bruemmer D, 2003, EUR J PHARMACOL, V466, P225, DOI 10.1016/S0014-2999(03)01556-5; Butt AM, 2006, GLIA, V54, P666, DOI 10.1002/glia.20424; Canton J, 2013, NAT REV IMMUNOL, V13, P621, DOI 10.1038/nri3515; Carroll WM, 1998, BRAIN, V121, P293, DOI 10.1093/brain/121.2.293; Carson MJ, 2006, IMMUNOL REV, V213, P48, DOI 10.1111/j.1600-065X.2006.00441.x; Chaitanya GV, 2011, BRAIN PATHOL, V21, P16, DOI 10.1111/j.1750-3639.2010.00426.x; Chang CZ, 2015, J VASC RES, V52, P12, DOI 10.1159/000381099; Chang KL, 2015, SCI REP-UK, V5, DOI 10.1038/srep09000; Charbonnel B, 2004, DIABETES CARE, V27, P1647, DOI 10.2337/diacare.27.7.1647; Chen H, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.544; Chen QW, 2017, TRANSL STROKE RES, V8, P362, DOI 10.1007/s12975-017-0521-y; Chen S, 2014, PROG NEUROBIOL, V115, P64, DOI 10.1016/j.pneurobio.2013.09.002; Chen YC, 2012, MOL NEUROBIOL, V46, P114, DOI 10.1007/s12035-012-8259-8; Chen Z, 2001, ARTERIOSCL THROM VAS, V21, P372, DOI 10.1161/01.ATV.21.3.372; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; Ching J, 2015, ONCOTARGET, V6, P21301, DOI 10.18632/oncotarget.4019; Chistiakov DA, 2016, J CELL MOL MED, V20, P17, DOI 10.1111/jcmm.12689; Cho HY, 2010, AM J RESP CRIT CARE, V182, P170, DOI 10.1164/rccm.200907-1047OC; Choi JH, 2011, NATURE, V477, P477, DOI 10.1038/nature10383; Choi JH, 2010, NATURE, V466, P451, DOI 10.1038/nature09291; Choi YS, 2008, GLIA, V56, P791, DOI 10.1002/glia.20653; Chu K, 2006, BRAIN RES, V1093, P208, DOI 10.1016/j.brainres.2006.03.114; Chung BH, 2005, AM J TRANSPLANT, V5, P1856, DOI 10.1111/j.1600-6143.2005.00979.x; Cipolletta D, 2012, NATURE, V486, P549, DOI 10.1038/nature11132; Clark RB, 2000, J IMMUNOL, V164, P1364, DOI 10.4049/jimmunol.164.3.1364; CLARK RK, 1993, BRAIN RES BULL, V31, P565, DOI 10.1016/0361-9230(93)90124-T; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Clarkson BD, 2012, ADV EXP MED BIOL, V946, P309, DOI 10.1007/978-1-4614-0106-3_18; Clarner T, 2012, GLIA, V60, P1468, DOI 10.1002/glia.22367; Clelland CD, 2009, SCIENCE, V325, P210, DOI 10.1126/science.1173215; Collino M, 2006, EUR J PHARMACOL, V530, P70, DOI 10.1016/j.ejphar.2005.11.049; Compe E, 2005, MOL CELL BIOL, V25, P6065, DOI 10.1128/MCB.25.14.6065-6076.2005; Conti AC, 1998, J NEUROSCI, V18, P5663; Cullingford TE, 1998, J NEUROCHEM, V70, P1366; Culman J, 2007, TRENDS PHARMACOL SCI, V28, P244, DOI 10.1016/j.tips.2007.03.004; Cunard R, 2004, J IMMUNOL, V172, P7530, DOI 10.4049/jimmunol.172.12.7530; Curb JD, 2004, AM J EPIDEMIOL, V160, P150, DOI 10.1093/aje/kwh177; da Rocha  LF, 2013, PPAR RES, V2013, DOI 10.1155/2013/519724; Dawson MRL, 2003, MOL CELL NEUROSCI, V24, P476, DOI 10.1016/S1044-7431(03)00210-0; Dayer AG, 2005, J CELL BIOL, V168, P415, DOI 10.1083/jcb.200407053; De Nuccio C, 2011, J NEUROPATH EXP NEUR, V70, P900, DOI 10.1097/NEN.0b013e3182309ab1; de Wit NM, 2017, NEUROBIOL DIS, V107, P57, DOI 10.1016/j.nbd.2016.09.015; Dekkers JF, 2012, TRENDS MOL MED, V18, P283, DOI 10.1016/j.molmed.2012.03.004; Delerive P, 2000, FEBS LETT, V471, P34, DOI 10.1016/S0014-5793(00)01364-8; Dello Russo C, 2003, J BIOL CHEM, V278, P5828, DOI 10.1074/jbc.M208132200; Desmond DW, 2002, CEREBROVASC DIS, V13, P53, DOI 10.1159/000049151; Dhawan V., 2014, STUDIES RESP DISORDE, P27; Di Sanzo M, 2017, CURR PHARM BIOTECHNO, V18, P194, DOI 10.2174/1389201018666170224105600; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Doetsch F, 1997, J NEUROSCI, V17, P5046; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; Dormandy JA, 2005, LANCET, V366, P1279, DOI 10.1016/S0140-6736(05)67528-9; Duan HM, 2016, SCI CHINA LIFE SCI, V59, P1313, DOI 10.1007/s11427-016-0205-2; Duan SZ, 2008, CIRC RES, V102, P283, DOI 10.1161/CIRCRESAHA.107.164384; Duarte JV, 2015, J CEREBR BLOOD F MET, V35, P1671, DOI 10.1038/jcbfm.2015.106; Dustin ML, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.MCHD-0034-2016; Duvanel CB, 2003, J NEUROSCI RES, V71, P246, DOI 10.1002/jnr.10471; Elbrecht A, 1996, BIOCHEM BIOPH RES CO, V224, P431, DOI 10.1006/bbrc.1996.1044; Elder CP, 2004, SPINAL CORD, V42, P711, DOI 10.1038/sj.sc.3101652; Elmelund M, 2017, NEUROUROL URODYNAM, V36, P1607, DOI 10.1002/nau.23163; Elting JW, 2000, J NEUROL SCI, V181, P104, DOI 10.1016/S0022-510X(00)00442-1; Erdmann E, 2016, DIABETES OBES METAB, V18, P266, DOI 10.1111/dom.12608; Erdmann E, 2014, DIABETES OBES METAB, V16, P63, DOI 10.1111/dom.12180; Erdmann E, 2010, J DIABETES, V2, P212, DOI 10.1111/j.1753-0407.2010.00082.x; Ericsson H, 2004, DRUG METAB DISPOS, V32, P923; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; Fadok VA, 1998, J IMMUNOL, V161, P6250; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Fancy SPJ, 2004, MOL CELL NEUROSCI, V27, P247, DOI 10.1016/j.mcn.2004.06.015; Fang H, 2014, J IMMUNOL, V192, P5984, DOI 10.4049/jimmunol.1400054; Faveeuw C, 2000, FEBS LETT, V486, P261, DOI 10.1016/S0014-5793(00)02319-X; FDA, 2015, FDA DRUG SAF COMM FD; FDA, 2013, FDA DRUG SAF COMM FD; FEDDERSEN RM, 1989, BIOTECHNIQUES, V7, P44; Feinstein DL, 2002, ANN NEUROL, V51, P694, DOI 10.1002/ana.10206; Ferguson LB, 2014, NEUROPHARMACOLOGY, V86, P397, DOI 10.1016/j.neuropharm.2014.06.024; Finch ER, 2017, BLOOD, V129, P1802, DOI 10.1182/blood-2016-08-736405; Floyd ZE, 2008, METABOLISM, V57, pS32, DOI 10.1016/j.metabol.2008.04.006; Flygt J, 2013, EUR J NEUROSCI, V38, P2153, DOI 10.1111/ejn.12179; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Frankel HL, 1998, SPINAL CORD, V36, P266, DOI 10.1038/sj.sc.3100638; Franklin RJM, 2008, NAT REV NEUROSCI, V9, P839, DOI 10.1038/nrn2480; Freeman SA, 2014, IMMUNOL REV, V262, P193, DOI 10.1111/imr.12212; Funfschilling U, 2012, NATURE, V485, P517, DOI 10.1038/nature11007; GAETANI P, 1990, STROKE, V21, P328, DOI 10.1161/01.STR.21.2.328; Galeffi F, 2016, J CEREBR BLOOD F MET, V36, P696, DOI 10.1177/0271678X15624699; Gan Y, 2014, P NATL ACAD SCI USA, V111, P2704, DOI 10.1073/pnas.1315943111; Garcia-Bueno B, 2007, NEUROPSYCHOPHARMACOL, V32, P1251, DOI 10.1038/sj.npp.1301252; Gelderblom M, 2009, STROKE, V40, P1849, DOI 10.1161/STROKEAHA.108.534503; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Genovese T, 2008, SHOCK, V30, P142, DOI 10.1097/SHK.0b013e31815dd381; Gensert JM, 1997, NEURON, V19, P197, DOI 10.1016/S0896-6273(00)80359-1; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Gillespie W, 2011, INDIAN J BIOCHEM BIO, V48, P73; Girnun GD, 2002, MOL ENDOCRINOL, V16, P2793, DOI 10.1210/me.2002-0020; Glass CK, 2006, NAT REV IMMUNOL, V6, P44, DOI 10.1038/nri1748; Gold M, 2010, DEMENT GERIATR COGN, V30, P131, DOI 10.1159/000318845; Gong C, 2000, BRAIN RES, V871, P57, DOI 10.1016/S0006-8993(00)02427-6; Gosset P, 2001, EUR J IMMUNOL, V31, P2857, DOI 10.1002/1521-4141(2001010)31:10<2857::AID-IMMU2857>3.0.CO;2-X; Gough PJ, 2006, J CLIN INVEST, V116, P59, DOI 10.1172/JCI25074; Goverman J, 2009, NAT REV IMMUNOL, V9, P393, DOI 10.1038/nri2550; Graham DJ, 2010, JAMA-J AM MED ASSOC, V304, P411, DOI 10.1001/jama.2010.920; Grau AJ, 2010, NAT REV NEUROL, V6, P681, DOI 10.1038/nrneurol.2010.163; Greene M. E., 1995, Gene Expression, V4, P281; Greenhalgh AD, 2014, J NEUROSCI, V34, P6316, DOI 10.1523/JNEUROSCI.4912-13.2014; Griggs RB, 2015, PAIN, V156, P469, DOI 10.1097/01.j.pain.0000460333.79127.be; Grommes C, 2013, CANCER CHEMOTH PHARM, V71, P929, DOI 10.1007/s00280-013-2084-2; GROVES AK, 1993, NATURE, V362, P453, DOI 10.1038/362453a0; Grygiel-Gorniak B, 2014, NUTR J, V13, DOI 10.1186/1475-2891-13-17; Guan LQM, 2000, PLANT J, V22, P87, DOI 10.1046/j.1365-313x.2000.00723.x; Guan YF, 1997, AM J PHYSIOL-RENAL, V273, pF1013, DOI 10.1152/ajprenal.1997.273.6.F1013; Habib ZA, 2009, PHARMACOEPIDEM DR S, V18, P437, DOI 10.1002/pds.1722; Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012; Halabi CM, 2008, CELL METAB, V7, P215, DOI 10.1016/j.cmet.2007.12.008; Hamblin M, 2009, ANTIOXID REDOX SIGN, V11, P1415, DOI [10.1089/ars.2008.2280, 10.1089/ARS.2008.2280]; Hamming AM, 2016, J CEREBR BLOOD F MET, V36, P1224, DOI 10.1177/0271678X15619189; Han LJ, 2015, STROKE, V46, P2628, DOI 10.1161/STROKEAHA.115.010091; HARRISON B M, 1975, Proceedings of the Australian Association of Neurologists, V12, P117; HAWKINS CP, 1991, BRAIN, V114, P801, DOI 10.1093/brain/114.2.801; He F, 2008, OBESITY, V16, P1735, DOI 10.1038/oby.2008.269; Heinaniemi M, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-7-r147; Heneka MT, 1999, J NEUROIMMUNOL, V100, P156, DOI 10.1016/S0165-5728(99)00192-7; Henson PM, 2006, TRENDS IMMUNOL, V27, P244, DOI 10.1016/j.it.2006.03.005; Heppner FL, 2015, NAT REV NEUROSCI, V16, P358, DOI 10.1038/nrn3880; Hesp ZC, 2015, J NEUROSCI, V35, P1274, DOI 10.1523/JNEUROSCI.2568-14.2015; Hickenbottom SL, 1999, STROKE, V30, P2472, DOI 10.1161/01.STR.30.11.2472; Hills NK, 2014, NEUROLOGY, V83, P890, DOI 10.1212/WNL.0000000000000752; Hills NK, 2012, ANN NEUROL, V72, P850, DOI 10.1002/ana.23688; Hind WH, 2015, BRIT J PHARMACOL, V172, P3015, DOI 10.1111/bph.13106; Home PD, 2009, LANCET, V373, P2125, DOI 10.1016/S0140-6736(09)60953-3; Hovelmeyer N, 2005, J IMMUNOL, V175, P5875, DOI 10.4049/jimmunol.175.9.5875; HOWARD G, 1995, STROKE, V26, P1153, DOI 10.1161/01.STR.26.7.1153; Hsiao FY, 2009, DRUG SAFETY, V32, P675, DOI 10.2165/00002018-200932080-00006; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Huria T, 2015, J CEREBR BLOOD F MET, V35, P543, DOI 10.1038/jcbfm.2014.227; HUSAIN J, 1995, BRAIN RES, V698, P86, DOI 10.1016/0006-8993(95)00832-B; Huxley RR, 2011, CIRCULATION, V124, P2056, DOI 10.1161/CIRCULATIONAHA.111.028373; Iankova I, 2006, MOL ENDOCRINOL, V20, P1494, DOI 10.1210/me.2005-0222; Ibrahim WNW, 2013, TOXICOL APPL PHARM, V269, P51, DOI 10.1016/j.taap.2013.03.003; Ikeda Y, 2000, J BIOL CHEM, V275, P33142, DOI 10.1074/jbc.M002319200; Imamoto E, 2004, BIOFACTORS, V20, P37, DOI 10.1002/biof.5520200104; Inzucchi SE, 2016, J DIABETES, V8, P607, DOI 10.1111/1753-0407.12399; Irvine KA, 2008, BRAIN, V131, P1464, DOI 10.1093/brain/awn080; Cuartero MI, 2013, STROKE, V44, P3498, DOI 10.1161/STROKEAHA.113.002470; Ishii T, 2004, CIRC RES, V94, P609, DOI 10.1161/01.RES.0000119171.44657.45; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Iwai S, 2008, DRUG DISCOV THER, V2, P353; Izawa Y, 2009, BRAIN RES, V1305, P64, DOI 10.1016/j.brainres.2009.09.098; Jackson SM, 1999, ARTERIOSCL THROM VAS, V19, P2094, DOI 10.1161/01.ATV.19.9.2094; Jana M, 2012, J BIOL CHEM, V287, P34134, DOI 10.1074/jbc.M112.398552; Janani C, 2015, DIABETES METAB SYND, V9, P46, DOI 10.1016/j.dsx.2014.09.015; Jeffery ND, 1997, BRAIN, V120, P27, DOI 10.1093/brain/120.1.27; Jennewein C, 2008, J IMMUNOL, V181, P5646, DOI 10.4049/jimmunol.181.8.5646; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Jia HB, 2013, NEUROSCI LETT, V543, P130, DOI 10.1016/j.neulet.2013.03.046; Jiang XY, 2016, TRANSL STROKE RES, V7, P548, DOI 10.1007/s12975-016-0502-6; Jin KL, 2010, P NATL ACAD SCI USA, V107, P7993, DOI 10.1073/pnas.1000154107; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; Jin WN, 2017, J CEREBR BLOOD F MET, V37, P2224, DOI 10.1177/0271678X17694185; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Johnstone JT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080975; Jordan JE, 1999, CARDIOVASC RES, V43, P860, DOI 10.1016/S0008-6363(99)00187-X; Joseph MJE, 2016, TRANSL STROKE RES, V7, P192, DOI 10.1007/s12975-015-0445-3; Jurkunas UV, 2010, AM J PATHOL, V177, P2278, DOI 10.2353/ajpath.2010.100279; Juurlink BHJ, 1997, NEUROSCI BIOBEHAV R, V21, P151, DOI 10.1016/S0149-7634(96)00005-X; Kanakasabai S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050500; Kane CJM, 2011, BRAIN BEHAV IMMUN, V25, pS137, DOI 10.1016/j.bbi.2011.02.016; Kapadia R, 2008, FRONT BIOSCI-LANDMRK, V13, P1813, DOI 10.2741/2802; Kaplan JM, 2005, SHOCK, V24, P59, DOI 10.1097/01.shk.0000167108.88376.f2; Katzan I, 2007, NAT CLIN PRACT NEURO, V3, P486, DOI 10.1038/ncpneuro0562; Kaundal RK, 2010, DRUG NEWS PERSPECT, V23, P241, DOI 10.1358/dnp.2010.23.4.1437710; Kawabori M, 2015, CURR MED CHEM, V22, P1258, DOI 10.2174/0929867322666150209154036; Kernan WN, 2016, NEW ENGL J MED, V374, P1321, DOI 10.1056/NEJMoa1506930; Khandoudi N, 2002, DIABETES, V51, P1507, DOI 10.2337/diabetes.51.5.1507; Kielian T, 2008, J IMMUNOL, V180, P5004, DOI 10.4049/jimmunol.180.7.5004; Kim TH, 2013, YONSEI MED J, V54, P545, DOI 10.3349/ymj.2013.54.3.545; Kivisakk P, 2009, ANN NEUROL, V65, P457, DOI 10.1002/ana.21379; Klopfleisch S, 2008, J NEUROSCI, V28, P13609, DOI 10.1523/JNEUROSCI.2765-08.2008; Klotz L, 2009, J EXP MED, V206, P2079, DOI 10.1084/jem.20082771; Koenigsknecht-Talboo J, 2005, J NEUROSCI, V25, P8240, DOI 10.1523/JNEUROSCI.1808-05.2005; Koizumi S, 2007, NATURE, V446, P1091, DOI 10.1038/nature05704; Kokoeva MV, 2005, SCIENCE, V310, P679, DOI 10.1126/science.1115360; Krueger M, 2015, J CEREBR BLOOD F MET, V35, P292, DOI 10.1038/jcbfm.2014.199; Kumari R, 2010, J CEREBR BLOOD F MET, V30, P352, DOI 10.1038/jcbfm.2009.221; Lai TW, 2014, PROG NEUROBIOL, V115, P157, DOI 10.1016/j.pneurobio.2013.11.006; Lalloyer F, 2010, ARTERIOSCL THROM VAS, V30, P894, DOI 10.1161/ATVBAHA.108.179689; Lan LF, 2015, CNS NEUROSCI THER, V21, P410, DOI 10.1111/cns.12374; Lee J, 2007, NEUROCHEM RES, V32, P635, DOI 10.1007/s11064-006-9138-3; Lee TM, 2003, AM J PHYSIOL-HEART C, V285, pH1650, DOI 10.1152/ajpheart.00407.2002; Lee YJ, 2012, NATURE, V487, P443, DOI 10.1038/nature11314; Lee-Liu D, 2013, GENESIS, V51, P529, DOI 10.1002/dvg.22406; Leesnitzer LM, 2002, BIOCHEMISTRY-US, V41, P6640, DOI 10.1021/bi0159581; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Leisewitz AV, 2008, J CELL PHYSIOL, V217, P367, DOI 10.1002/jcp.21509; Lemay DG, 2006, J LIPID RES, V47, P1583, DOI 10.1194/jlr.M500504-JLR200; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; Li XW, 2015, AM J PATHOL, V185, P230, DOI 10.1016/j.ajpath.2014.09.016; Li XG, 2013, J INT MED RES, V41, P153, DOI 10.1177/0300060513476601; Liebetanz D, 2006, EXP NEUROL, V202, P217, DOI 10.1016/j.expneurol.2006.05.032; Liesz A, 2015, J NEUROSCI, V35, P583, DOI 10.1523/JNEUROSCI.2439-14.2015; Lin TN, 2006, ARTERIOSCL THROM VAS, V26, P481, DOI 10.1161/01.ATV.0000201933.53964.5b; Lin WS, 2005, J CELL BIOL, V169, P603, DOI 10.1083/jcb.200502086; Lindvall O., 2015, COLD SPRING HARB PER, V7; Liu H, 2016, BIOCHEM BIOPH RES CO, V472, P648, DOI 10.1016/j.bbrc.2016.03.003; Liu HR, 2004, CARDIOVASC RES, V62, P135, DOI 10.1016/j.cardiores.2003.12.027; Liu J, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010693.pub3; Liu SH, 2010, CELL MOL LIFE SCI, V67, P1465, DOI 10.1007/s00018-009-0255-4; Lo Verme J, 2005, MOL PHARMACOL, V67, P15, DOI 10.1124/mol.104.006353; Losy J, 2005, FOLIA NEUROPATHOL, V43, P97; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Lu CJ, 2013, CEREBROVASC DIS, V36, P145, DOI 10.1159/000353679; Luna-Medina R, 2005, J BIOL CHEM, V280, P21453, DOI 10.1074/jbc.M414390200; Luo YM, 2006, J NEUROCHEM, V97, P435, DOI 10.1111/j.1471-4159.2006.03758.x; Luzzati F, 2006, J NEUROSCI, V26, P609, DOI 10.1523/JNEUROSCI.4371-05.2006; Lygate CA, 2003, CARDIOVASC RES, V58, P632, DOI 10.1016/S0008-6363(03)00289-X; Mahaffey KW, 2013, AM HEART J, V166, P240, DOI 10.1016/j.ahj.2013.05.004; Majai G, 2007, EUR J IMMUNOL, V37, P1343, DOI 10.1002/eji.200636398; Mandai K, 1997, NEUROSCIENCE, V77, P849, DOI 10.1016/S0306-4522(97)00517-4; Mandrekar-Colucci S, 2013, ASN NEURO, V5, DOI 10.1042/AN20130030; Marklund N, 2001, J NEUROTRAUM, V18, P1217, DOI 10.1089/089771501317095250; Marx N, 2000, J IMMUNOL, V164, P6503, DOI 10.4049/jimmunol.164.12.6503; Masuda T, 2007, NEUROSCI LETT, V425, P114, DOI 10.1016/j.neulet.2007.08.039; Matute C, 2007, J ANAT, V210, P693, DOI 10.1111/j.1469-7580.2007.00733.x; MCGUIRE EJ, 1981, J UROLOGY, V126, P205, DOI 10.1016/S0022-5347(17)54449-3; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; McTigue DM, 2007, EXP NEUROL, V205, P396, DOI 10.1016/j.expneurol.2007.02.009; McTigue DM, 2008, PPAR RES, V2008, DOI 10.1155/2008/517162; Meletis K, 2008, PLOS BIOL, V6, P1494, DOI 10.1371/journal.pbio.0060182; Meng B, 2011, J INT MED RES, V39, P805, DOI 10.1177/147323001103900313; Michalik L, 2006, J CLIN INVEST, V116, P598, DOI 10.1172/JCI27958; Mierzwa AJ, 2015, J NEUROPATH EXP NEUR, V74, P218, DOI 10.1097/NEN.0000000000000165; Migaud M, 2010, EUR J NEUROSCI, V32, P2042, DOI 10.1111/j.1460-9568.2010.07521.x; Min LJ, 2012, HYPERTENSION, V59, P1079, DOI 10.1161/HYPERTENSIONAHA.112.192401; Ming XD, 2015, LIFE SCI, V136, P36, DOI 10.1016/j.lfs.2015.06.015; Miron VE, 2007, GLIA, V55, P130, DOI 10.1002/glia.20441; Miron VE, 2009, AM J PATHOL, V174, P1880, DOI 10.2353/ajpath.2009.080947; Molina-Holgado E, 2010, J NEUROCHEM, V114, P1277, DOI 10.1111/j.1471-4159.2010.06849.x; Molshatzki N, 2011, CEREBROVASC DIS, V31, P271, DOI 10.1159/000322155; Moreno S, 2004, NEUROSCIENCE, V123, P131, DOI 10.1016/j.neuroscience.2003.08.064; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Mozaffarian D, 2016, CIRCULATION, V133, pE38, DOI 10.1161/CIR.0000000000000350; Mracsko E, 2014, J NEUROSCI, V34, P16784, DOI 10.1523/JNEUROSCI.1867-14.2014; Mughal MM, 2011, EXPERT REV CARDIOVAS, V9, P1315, DOI [10.1586/erc.11.120, 10.1586/ERC.11.120]; Mukohda Masashi, 2016, Am J Physiol Heart Circ Physiol, V310, pH39, DOI 10.1152/ajpheart.00490.2015; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; NAKAYAMA H, 1994, ARCH PHYS MED REHAB, V75, P394, DOI 10.1016/0003-9993(94)90161-9; Nathan DM, 2009, DIABETES CARE, V32, P193, DOI 10.2337/dc08-9025; Neschen S, 2007, DIABETES, V56, P1034, DOI 10.2337/db06-1206; Neumann J, 2008, J NEUROSCI, V28, P5965, DOI 10.1523/JNEUROSCI.0060-08.2008; Ni W, 2016, STROKE, V47, P505, DOI 10.1161/STROKEAHA.115.010920; Niino M, 2001, J NEUROIMMUNOL, V116, P40, DOI 10.1016/S0165-5728(01)00285-5; Nissen SE, 2010, ARCH INTERN MED, V170, P1191, DOI 10.1001/archinternmed.2010.207; Okada T, 2006, DIABETES, V55, P1666, DOI 10.2337/db05-1285; Ormerod BK, 2013, BRAIN BEHAV IMMUN, V29, P28, DOI 10.1016/j.bbi.2012.10.017; Ott A, 1999, NEUROLOGY, V53, P1937, DOI 10.1212/WNL.53.9.1937; Ou ZS, 2006, BRAIN RES, V1096, P196, DOI 10.1016/j.brainres.2006.04.062; Ouyang YB, 2014, ADV NEUROBIOL, V11, P171, DOI 10.1007/978-3-319-08894-5_9; Owens J, 1997, NUCL MED COMMUN, V18, P149, DOI 10.1097/00006231-199702000-00010; Oyinbo CA, 2011, ACTA NEUROBIOL EXP, V71, P281; Padilla J., 2000, J IMMUNOL, V165; Paintlia AS, 2010, GLIA, V58, P1669, DOI 10.1002/glia.21039; Paintlia AS, 2008, MOL PHARMACOL, V73, P1381, DOI 10.1124/mol.107.044230; Paintlia AS, 2005, FASEB J, V19, P1407, DOI 10.1096/fj.05-3861com; Pan HC, 2013, EUR J IMMUNOL, V43, P2854, DOI 10.1002/eji.201343301; Pang Y, 2005, J NEUROSCI RES, V80, P226, DOI 10.1002/jnr.20450; Pantoni L, 1996, STROKE, V27, P1641, DOI 10.1161/01.STR.27.9.1641; Park BV, 2015, CELL MOL IMMUNOL, V12, P533, DOI 10.1038/cmi.2015.21; Park EJ, 2003, J BIOL CHEM, V278, P14747, DOI 10.1074/jbc.M210819200; Park EY, 2004, CANCER RES, V64, P3701, DOI 10.1158/0008-5472.CAN-03-3924; Park KS, 2004, EXP CELL RES, V297, P424, DOI 10.1016/j.yexcr.2004.03.034; Pasceri V, 2000, CIRCULATION, V101, P235, DOI 10.1161/01.CIR.101.3.235; Pascual G, 2005, NATURE, V437, P759, DOI 10.1038/nature03988; Patel Anita R, 2013, Int J Physiol Pathophysiol Pharmacol, V5, P73; Patel PC, 2008, MOL BIOL CELL, V19, P4628, DOI 10.1091/mbc.E08-02-0223; Patel SN, 2004, J INFECT DIS, V189, P204, DOI 10.1086/380764; Paterniti I, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-20; Pedersen WA, 2006, EXP NEUROL, V199, P265, DOI 10.1016/j.expneurol.2006.01.018; Pennypacker KR, 2015, J CEREBR BLOOD F MET, V35, P186, DOI 10.1038/jcbfm.2014.212; Piantadosi CA, 1996, STROKE, V27, P327, DOI 10.1161/01.STR.27.2.327; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Pierce AA, 2010, J NEUROSCI, V30, P723, DOI 10.1523/JNEUROSCI.2479-09.2010; Pittet JF, 2002, J TRAUMA, V52, P611, DOI 10.1097/00005373-200204000-00001; Polvani S, 2012, PPAR RES, V2012, DOI 10.1155/2012/641087; Pourcet B, 2010, J BIOL CHEM, V285, P5983, DOI 10.1074/jbc.M109.078311; Puyal J, 2013, PROG NEUROBIOL, V105, P24, DOI 10.1016/j.pneurobio.2013.03.002; Qi L, 2010, INT J CLIN EXP MED, V3, P283; Quinones-Hinojosa A, 2006, J COMP NEUROL, V494, P415, DOI 10.1002/cne.20798; Qureshi AI, 2009, LANCET, V373, P1632, DOI 10.1016/S0140-6736(09)60371-8; Qureshi AI, 2001, NEW ENGL J MED, V344, P1450, DOI 10.1056/NEJM200105103441907; Qureshi Al, 2017, J CEREB BLOOD FLOW M; Ramirez-Amaya V, 2006, J NEUROSCI, V26, P12237, DOI 10.1523/JNEUROSCI.2195-06.2006; RANDALL RD, 1992, J NEUROSCI, V12, P1882; Redondo-Castro E, 2013, EUR J NEUROSCI, V38, P3786, DOI 10.1111/ejn.12382; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Riyahi TY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027311; Robinson MB, 1998, NEUROCHEM INT, V33, P479, DOI 10.1016/S0197-0186(98)00055-2; Rohatagi S, 2008, J CLIN PHARMACOL, V48, P1420, DOI 10.1177/0091270008323260; Rolland M, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005547; Romera C, 2007, J CEREBR BLOOD F MET, V27, P1327, DOI 10.1038/sj.jcbfm.9600438; Rosenberg GA, 2016, J CEREBR BLOOD F MET, V36, P4, DOI 10.1177/0271678X15609542; Rosenberg GA, 2009, STROKE, V40, pS20, DOI 10.1161/STROKEAHA.108.533133; ROSENBLUTH J, 1966, J CELL BIOL, V28, P73, DOI 10.1083/jcb.28.1.73; ROSS GD, 1992, J LEUKOCYTE BIOL, V51, P109, DOI 10.1002/jlb.51.2.109; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Roth AD, 2003, J NEUROSCI RES, V72, P425, DOI 10.1002/jnr.10596; Rotshenker S, 2003, J MOL NEUROSCI, V21, P65, DOI 10.1385/JMN:21:1:65; Rotshenker S, 2009, J MOL NEUROSCI, V39, P99, DOI 10.1007/s12031-009-9186-7; Rowat A, 2014, INT J STROKE, V9, P633, DOI 10.1111/ijs.12264; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817; Salehi A, 2017, J CEREBR BLOOD F MET, V37, P2320, DOI 10.1177/0271678X17701460; Salter MG, 2005, NATURE, V438, P1167, DOI 10.1038/nature04301; Saluja I, 2001, GLIA, V33, P191, DOI 10.1002/1098-1136(200103)33:3<191::AID-GLIA1018>3.0.CO;2-M; Samaha FF, 2006, ARTERIOSCL THROM VAS, V26, P624, DOI 10.1161/01.ATV.0000200136.56716.30; Sarafidis PA, 2006, AM J HYPERTENS, V19, P646, DOI 10.1016/j.amjhyper.2005.12.017; Sarafidis PA, 2010, AM J KIDNEY DIS, V55, P835, DOI 10.1053/j.ajkd.2009.11.013; Sasaki Makoto, 2005, BMC Physiol, V5, P3, DOI 10.1186/1472-6793-5-3; Sauer S, 2015, TRENDS PHARMACOL SCI, V36, P688, DOI 10.1016/j.tips.2015.06.010; Scheen AJ, 2012, DIABETES RES CLIN PR, V98, P175, DOI 10.1016/j.diabres.2012.09.001; Schilling M, 2005, EXP NEUROL, V196, P290, DOI 10.1016/j.expneurol.2005.08.004; Schirmer-Mikalsen K, 2007, ACTA ANAESTH SCAND, V51, P1194, DOI 10.1111/j.1399-6576.2007.01372.x; Schousboe A, 2005, NEUROTOX RES, V8, P221, DOI 10.1007/BF03033975; Schulz MK, 2000, J NEUROSURG, V93, P808, DOI 10.3171/jns.2000.93.5.0808; Semple RK, 2006, J CLIN INVEST, V116, P581, DOI 10.1172/JCI28003; Seri B, 2001, J NEUROSCI, V21, P7153, DOI 10.1523/JNEUROSCI.21-18-07153.2001; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Sharma SK, 2016, J THORAC DIS, V8, P1406, DOI 10.21037/jtd.2016.05.22; Shattil SJ, 2010, NAT REV MOL CELL BIO, V11, P288, DOI 10.1038/nrm2871; Shaya Fadia T, 2009, P T, V34, P490; Shen JF, 2008, J CEREBR BLOOD F MET, V28, P1460, DOI 10.1038/jcbfm.2008.37; Shereen A, 2011, J CEREBR BLOOD F MET, V31, P1155, DOI 10.1038/jcbfm.2010.212; Shevach EM, 2006, IMMUNOL REV, V212, P60, DOI 10.1111/j.0105-2896.2006.00415.x; Shevach EM, 2009, IMMUNITY, V30, P636, DOI 10.1016/j.immuni.2009.04.010; Shi H, 2015, EXP NEUROL, V272, P17, DOI 10.1016/j.expneurol.2015.03.017; Shi YJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10523; Shi YJ, 2016, TRANSL STROKE RES, V7, P89, DOI 10.1007/s12975-016-0447-9; Shih AY, 2005, J BIOL CHEM, V280, P22925, DOI 10.1074/jbc.M414635200; Shiomi T, 2002, CIRCULATION, V106, P3126, DOI 10.1161/01.CIR.0000039346.31538.2C; Siddiqui AM, 2006, CRIT CARE MED, V34, P1874, DOI 10.1097/01.CCM.0000221921.71300.BF; Sidell RJ, 2002, DIABETES, V51, P1110, DOI 10.2337/diabetes.51.4.1110; Sim FJ, 2002, J NEUROSCI, V22, P2451, DOI 10.1523/JNEUROSCI.22-07-02451.2002; Sim FJ, 2008, GLIA, V56, P954, DOI 10.1002/glia.20669; SIMONI J, 1990, BIOMATER ARTIF CELL, V18, P189, DOI 10.3109/10731199009117301; SMITH KJ, 1979, NATURE, V280, P395, DOI 10.1038/280395a0; Soares HD, 1995, J NEUROSCI, V15, P8223; Staessen JA, 2003, JAMA-J AM MED ASSOC, V289, P2420, DOI 10.1001/jama.289.18.2420; Stephen RL, 2004, CANCER RES, V64, P3162, DOI 10.1158/0008-5472.CAN-03-2760; Storer PD, 2005, J NEUROSCI RES, V80, P66, DOI 10.1002/jnr.20413; STREILEIN JW, 1995, SCIENCE, V270, P1158, DOI 10.1126/science.270.5239.1158; Sugawara A, 2001, ENDOCRINOLOGY, V142, P3125, DOI 10.1210/en.142.7.3125; Sullivan GM, 2013, J NEUROPATH EXP NEUR, V72, P1106, DOI 10.1097/NEN.0000000000000009; Sundararajan S, 2004, DRUG NEWS PERSPECT, V17, P229, DOI 10.1358/dnp.2004.17.4.829049; Taheri M, 2015, PHARMACOL REP, V67, P1103, DOI 10.1016/j.pharep.2015.04.011; Takeuchi H, 2006, J BIOL CHEM, V281, P21362, DOI 10.1074/jbc.M600504200; Tanaka R, 2015, J ATHEROSCLER THROMB, V22, P1305, DOI 10.5551/jat.30007; Tang Y, 2016, MOL NEUROBIOL, V53, P1181, DOI 10.1007/s12035-014-9070-5; Tekkok SB, 2001, J NEUROSCI, V21, P4237, DOI 10.1523/JNEUROSCI.21-12-04237.2001; Terasaki Y, 2014, CURR MED CHEM, V21, P2035, DOI 10.2174/0929867321666131228223400; Tesfamariam B, 2007, VASC PHARMACOL, V46, P229, DOI 10.1016/j.vph.2006.11.005; Thal SC, 2008, J NEUROTRAUM, V25, P785, DOI 10.1089/neu.2007.0497; Thal SC, 2014, ARCH MED RES, V45, P698, DOI 10.1016/j.arcmed.2014.11.006; Thal SC, 2011, J NEUROTRAUM, V28, P983, DOI 10.1089/neu.2010.1685; Tholance Y, 2015, ACS CHEM NEUROSCI, V6, P1902, DOI 10.1021/acschemneuro.5b00299; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Tripathi R, 2007, GLIA, V55, P698, DOI 10.1002/glia.20491; Tsai YS, 2009, P NATL ACAD SCI USA, V106, P19084, DOI 10.1073/pnas.0909657106; Trang T, 2011, NEURON GLIA BIOL, V7, P99, DOI 10.1017/S1740925X12000087; TYMIANSKI M, 1993, BRAIN RES, V607, P319, DOI 10.1016/0006-8993(93)91523-U; Urra X, 2009, CURR MOL MED, V9, P195, DOI 10.2174/156652409787581574; Uruno A, 2011, J MOL ENDOCRINOL, V46, P37, DOI 10.1677/JME-10-0088; Vallarino C, 2013, CLIN DRUG INVEST, V33, P621, DOI 10.1007/s40261-013-0106-9; Vanasse A, 2009, DIABETES VASC DIS RE, V6, P87, DOI 10.1177/1479164109336047; Vattulainen-Collanus S, 2016, J CELL SCI, V129, P693, DOI 10.1242/jcs.169011; Venkatesan C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-32; Verrier E, 2004, CIRC RES, V94, P1515, DOI 10.1161/01.RES.0000130527.92537.06; Victor NA, 2006, EUR J NEUROSCI, V24, P1653, DOI 10.1111/j.1460-9568.2006.05037.x; Viola HM, 2013, CLIN EXP PHARMACOL P, V40, P295, DOI 10.1111/1440-1681.12072; Viscoli CM, 2014, AM HEART J, V168, P823, DOI 10.1016/j.ahj.2014.07.016; Von Knethen A, 2001, FASEB J, V15, P535, DOI 10.1096/fj.00-0187com; Wada K, 2006, J BIOL CHEM, V281, P12673, DOI 10.1074/jbc.M513786200; Wahl LM, 1997, TRANSPL IMMUNOL, V5, P173, DOI 10.1016/S0966-3274(97)80033-0; Waite KJ, 2001, J BIOL CHEM, V276, P7062, DOI 10.1074/jbc.M007894200; Wang CY, 2014, ANTIOXID REDOX SIGN, V21, P2208, DOI 10.1089/ars.2014.5845; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang HE, 2010, INT J HEALTH GEOGR, V9, DOI 10.1186/1476-072X-9-9; Wang J, 2005, STROKE, V36, P613, DOI 10.1161/01.STR.0000155729.12931.8f; Wang J, 2003, ANN NEUROL, V54, P655, DOI 10.1002/ana.10750; Wang NP, 2002, J BIOL CHEM, V277, P34176, DOI 10.1074/jbc.M203436200; Wang SH, 2009, MOL CELL ENDOCRINOL, V307, P176, DOI 10.1016/j.mce.2009.02.012; Wang XM, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0038932, 10.1371/journal.pone.0052707, 10.1371/journal.pone.0045036, 10.1371/journal.pone.0047429, 10.1371/journal.pone.0036663, 10.1371/journal.pone.0052082, 10.1371/journal.pone.0040857, 10.1371/journal.pone.0040711, 10.1371/journal.pone.0045939, 10.1371/journal.pone.0045380, 10.1371/journal.pone.0040084]; Wang YL, 2002, J BIOL CHEM, V277, P31781, DOI 10.1074/jbc.M204279200; Wang YD, 2017, J MOL NEUROSCI, V62, P199, DOI 10.1007/s12031-017-0931-z; Wang YT, 2012, CURR DRUG TARGETS, V13, P166, DOI 10.2174/138945012799201603; Wang Y, 2016, PROG NEUROBIOL, V141, P45, DOI [10.1016/j.pneurobio.2016.04.00, 10.1016/j.pneurobio.2016.04.005]; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Warden A, 2016, SCI REP-UK, V6, DOI 10.1038/srep27618; Wardyn JD, 2015, BIOCHEM SOC T, V43, P621, DOI 10.1042/BST20150014; Wartenberg KE, 2011, STROKE RES TREAT, V2011, DOI 10.4061/2011/830614; Wasserman JK, 2008, EXP NEUROL, V214, P266, DOI 10.1016/j.expneurol.2008.08.010; Wayman NS, 2002, FASEB J, V16, P1027, DOI 10.1096/fj.01-0793com; Weiss N, 2009, BBA-BIOMEMBRANES, V1788, P842, DOI 10.1016/j.bbamem.2008.10.022; Wilcox R, 2007, STROKE, V38, P865, DOI 10.1161/01.STR.0000257974.06317.49; Willmot M, 2004, HYPERTENSION, V43, P18, DOI 10.1161/01.HYP.0000105052.65787.35; Wilson HM, 2010, J CELL MOL MED, V14, P2055, DOI 10.1111/j.1582-4934.2010.01121.x; Winkelmayer WC, 2008, ARCH INTERN MED, V168, P2368, DOI 10.1001/archinte.168.21.2368; Wohlfert EA, 2007, J IMMUNOL, V178, P4129, DOI 10.4049/jimmunol.178.7.4129; Wolinski P, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/727189; Woo MS, 2016, J BIOL CHEM, V291, P23654, DOI 10.1074/jbc.M116.750018; Wu GF, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0287-3; Wu JS, 2016, MOL NEUROBIOL, V53, P3626, DOI 10.1007/s12035-015-9294-z; Wu JS, 2009, CIRCULATION, V119, P1124, DOI 10.1161/CIRCULATIONAHA.108.812537; Xiang ZM, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-18; Xu R., 2016, J NEUROSURG, P1; Xu Y, 2003, DIABETES, V52, P1187, DOI 10.2337/diabetes.52.5.1187; Xu Y, 2005, EXP NEUROL, V192, P251, DOI 10.1016/j.expneurol.2004.12.021; Xue MZ, 2000, NEUROSCI LETT, V283, P230, DOI 10.1016/S0304-3940(00)00971-X; Ya JC, 2015, MOL MED REP, V12, P6591, DOI 10.3892/mmr.2015.4292; Yamanaka M, 2012, J NEUROSCI, V32, P17321, DOI 10.1523/JNEUROSCI.1569-12.2012; Yamashita D, 2004, GENES CELLS, V9, P1017, DOI 10.1111/j.1365-2443.2004.00786.x; Yang HC, 2009, J AM SOC NEPHROL, V20, P2380, DOI 10.1681/ASN.2008111138; Yang JC, 2009, CLIN SCI, V116, P17, DOI 10.1042/CS20070462; Yang T, 2016, SPR SER TRANSL STROK, P377, DOI 10.1007/978-3-319-32337-4_18; Yang T, 2017, AGEING RES REV, V34, P15, DOI 10.1016/j.arr.2016.09.007; Yang TX, 1999, AM J PHYSIOL-RENAL, V277, pF966, DOI 10.1152/ajprenal.1999.277.6.F966; Yessoufou A, 2010, SWISS MED WKLY, V140, P4, DOI 10.4414/smw.2010.13071; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Yilmaz G, 2008, NEUROL RES, V30, P783, DOI 10.1179/174313208X341085; Yin KJ, 2014, NEUROCHEM INT, V77, P9, DOI 10.1016/j.neuint.2014.03.013; Yin KJ, 2013, BRAIN, V136, P1274, DOI 10.1093/brain/awt002; Yin KJ, 2010, J NEUROSCI, V30, P6398, DOI 10.1523/JNEUROSCI.0780-10.2010; Yoo HY, 1999, GENE, V234, P87, DOI 10.1016/S0378-1119(99)00176-6; Yoshihara D, 2011, AM J PHYSIOL-RENAL, V300, pF465, DOI 10.1152/ajprenal.00460.2010; Yoshii H, 2014, J ATHEROSCLER THROMB, V21, P563; Yu Y, 2015, HYPERTENSION, V66, P403, DOI 10.1161/HYPERTENSIONAHA.115.05726; Yue TL, 2001, CIRCULATION, V104, P2588, DOI 10.1161/hc4601.099403; Zelko IN, 2002, FREE RADICAL BIO MED, V33, P337, DOI 10.1016/S0891-5849(02)00905-X; Zhang MJ, 2013, PROG NEUROBIOL, V100, P30, DOI 10.1016/j.pneurobio.2012.09.003; Zhang Q, 2010, NEUROL RES, V32, P852, DOI 10.1179/016164110X12556180206112; Zhang X, 2004, BLOOD, V104, P3276, DOI 10.1182/blood-2004-02-0664; Zhang YM, 2004, J NEUROSCI, V24, P10616, DOI 10.1523/JNEUROSCI.2469-04.2004; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369; Zhang ZG, 2002, TRENDS CARDIOVAS MED, V12, P62, DOI 10.1016/S1050-1738(01)00149-9; Zhao XR, 2015, CNS NEUROSCI THER, V21, P357, DOI 10.1111/cns.12350; Zhao XR, 2007, ANN NEUROL, V61, P352, DOI 10.1002/ana.21097; Zhao XR, 2006, J CEREBR BLOOD F MET, V26, P811, DOI 10.1038/sj.jcbfm.9600233; Zhao XR, 2015, J NEUROCHEM, V133, P144, DOI 10.1111/jnc.12974; Zhao XR, 2009, J NEUROSCI, V29, P6186, DOI 10.1523/JNEUROSCI.5857-08.2009; Zhao XR, 2009, STROKE, V40, pS92, DOI 10.1161/STROKEAHA.108.533158; Zhao ZQ, 2004, EXP NEUROL, V190, P356, DOI 10.1016/j.expneurol.2004.06.015; Zhao X., 2014, IMMUNOLOGICAL MECH T, P301; Zhou K, 2017, J CEREBR BLOOD F MET, V37, P967, DOI 10.1177/0271678X16648712; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921; Vincent ZA, 2007, BBA-MOL CELL BIOL L, V1771, P915, DOI 10.1016/j.bbalip.2007.01.007; Zuhayra M, 2011, NEUROPATH APPL NEURO, V37, P738, DOI 10.1111/j.1365-2990.2011.01169.x; Zuo YQ, 2012, NEPHROL DIAL TRANSPL, V27, P174, DOI 10.1093/ndt/gfr240	506	81	85	0	33	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0301-0082	1873-5118		PROG NEUROBIOL	Prog. Neurobiol.	APR-MAY	2018	163				SI		27	58		10.1016/j.pneurobio.2017.10.002			32	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GK5OM	WOS:000436224400003	29032144	Green Accepted			2022-02-06	
J	Nordstrom, A; Nordstrom, P				Nordstrom, Anna; Nordstrom, Peter			Traumatic brain injury and the risk of dementia diagnosis: A nationwide cohort study	PLOS MEDICINE			English	Article							ALZHEIMERS-DISEASE; HEAD-INJURY; OLDER-ADULTS; IMPAIRMENT; ONSET; AGE	Background Traumatic brain injury (TBI) has been associated with dementia. The questions of whether the risk of dementia decreases over time after TBI, whether it is similar for different TBI types, and whether it is influenced by familial aggregation are not well studied. Methods and findings The cohort considered for inclusion comprised all individuals in Sweden aged >= 50 years on December 31, 2005 (n = 3,329,360). Diagnoses of dementia and TBI were tracked through nationwide databases from 1964 until December 31, 2012. In a first cohort, individuals diagnosed with TBI (n = 164,334) were matched with up to two controls. A second cohort consisted of subjects diagnosed with dementia during follow-up (n = 136,233) matched with up to two controls. A third cohort consisted of 46,970 full sibling pairs with discordant TBI status. During a mean follow-up period of 15.3 (range, 0-49) years, 21,963 individuals in the first cohort (6.3% with TBI, 3.6% without TBI) were diagnosed with dementia (adjusted odds ratio [OR], 1.81; 95% confidence interval [CI], 1.75-1.86). The association was strongest in the first year after TBI (OR, 3.52; 95% CI, 3.23-3.84), but the risk remained significant > 30 years (OR, 1.25; 95% CI, 1.11-1.41). Single mild TBI showed a weaker association with dementia (OR, 1.63; 95% CI, 1.57-1.70) than did more severe TBI (OR, 2.06; 95% CI, 1.95-2.19) and multiple TBIs (OR, 2.81; 95% CI, 2.51-3.15). These results were in general confirmed in the nested case-control cohort. TBI was also associated with an increased risk of dementia diagnosis in sibling pairs with discordant TBI status (OR, 1.89; 95% CI, 1.62- 2.21). A main limitation of the present study is the observational design. Thus, no causal inferences can be made based on the associations found. Conclusions The risk of dementia diagnosis decreased over time after TBI, but it was still evident > 30 years after the trauma. The association was stronger for more severe TBI and multiple TBIs, and it persisted after adjustment for familial factors.	[Nordstrom, Anna] Umea Univ, Dept Publ Hlth & Clin Med, Environm Med, Umea, Sweden; [Nordstrom, Anna] UiT Arctic Univ Norway, Sch Sports Sci, Tromso, Norway; [Nordstrom, Peter] Umea Univ, Dept Community Med & Rehabil, Geriatr Med, Umea, Sweden		Nordstrom, P (corresponding author), Umea Univ, Dept Community Med & Rehabil, Geriatr Med, Umea, Sweden.	peter.nordstrom@umu.se	Nordstrom, Anna/O-2504-2018; Nordstrom, Anna/F-2238-2010	Nordstrom, Anna/0000-0003-3534-456X; Nordstrom, Anna/0000-0003-3534-456X	Swedish Research CouncilSwedish Research CouncilEuropean Commission [2016-02584]	The present study was funded by the Swedish Research Council (https://www.vr.se, grant number 2016-02584). The funding body had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Carroll LJ, 2004, J REHABIL MED, V84; Crane PK, 2016, JAMA NEUROL, V73, P1062, DOI 10.1001/jamaneurol.2016.1948; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FRIEDLAND RP, 1988, ANN NEUROL, V24, P782, DOI 10.1002/ana.410240613; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Jellinger K A, 2001, BMC Neurol, V1, P3, DOI 10.1186/1471-2377-1-3; Launer LJ, 1999, NEUROLOGY, V52, P78, DOI 10.1212/WNL.52.1.78; Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062422; Li W, 2016, J NEUROL, V263, P1280, DOI 10.1007/s00415-016-8093-4; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; MOLGAARD CA, 1990, NEUROEPIDEMIOLOGY, V9, P233, DOI 10.1159/000110778; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nordstrom A, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f723; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Raj R, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002316; Rapoport M, 2008, J NEUROPSYCH CLIN N, V20, P68, DOI 10.1176/jnp.2008.20.1.68; Royston P, 2002, STAT MED, V21, P2175, DOI 10.1002/sim.1203; Salib E, 1997, INT J GERIATR PSYCH, V12, P363, DOI 10.1002/(SICI)1099-1166(199703)12:3<363::AID-GPS515>3.0.CO;2-F; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; van Doorn C, 2003, J AM GERIATR SOC, V51, P1213, DOI 10.1046/j.1532-5415.2003.51404.x; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554	25	81	81	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1549-1676			PLOS MED	PLos Med.	JAN	2018	15	1							e1002496	10.1371/journal.pmed.1002496			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU4JC	WOS:000423818400017	29381704	Green Published, gold			2022-02-06	
J	Gattringer, T; Pinter, D; Enzinger, C; Seifert-Held, T; Kneihsl, M; Fandler, S; Pichler, A; Barro, C; Grobke, S; Voortman, M; Pirpamer, L; Hofer, E; Ropele, S; Schmidt, R; Kuhle, J; Fazekas, F; Khalil, M				Gattringer, Thomas; Pinter, Daniela; Enzinger, Christian; Seifert-Held, Thomas; Kneihsl, Markus; Fandler, Simon; Pichler, Alexander; Barro, Christian; Grobke, Svenya; Voortman, Margarete; Pirpamer, Lukas; Hofer, Edith; Ropele, Stefan; Schmidt, Reinhold; Kuhle, Jens; Fazekas, Franz; Khalil, Michael			Serum neurofilament light is sensitive to active cerebral small vessel disease	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; WHITE-MATTER LESIONS; MULTIPLE-SCLEROSIS; NEURODEGENERATION; BIOMARKERS; PROTEIN; STROKE; BLOOD; CHAIN	Objective: To explore whether serum neurofilament light chain protein (NfL) levels are increased in patients with MRI-confirmed recent small subcortical infarcts (RSSI) compared to healthy controls and to determine the subsequent course and determinants of NfL levels in a longitudinal manner. Methods: In a prospectively collected group of symptomatic patients with an RSSI (n = 79, mean age 61 6 11 years, 67% male), we analyzed brain MRI and serum NfL using a Single Molecule Array (Simoa) assay at baseline and at 3 and 15 months after stroke. Community-dwelling healthy age-and sex-matched individuals with comparable severity of MRI white matter hyperintensities (WMH) (n = 53) served as controls. Results: Patients with an RSSI had higher NfL baseline levels compared to controls (73.45 vs 34.59 pg/mL, p < 0.0001), and they were increasingly higher with the time from stroke symptom onset to blood sampling (median 4 days, range 1-11 days, r(s) < 0.51, p < 0.0001). NfL levels remained increased at the 3-month follow-up but returned to normal at 15 months after stroke. NfL levels were associated with RSSI size and baselineWMH severity and were especially high in patients with new, clinically silent cerebral small vessel disease (CSVD)-related lesions at followup. Conclusions: Serum NfL is increased in patients with an RSSI and the occurrence of new CSVDrelated MRI lesions, even when clinically silent. This suggests NfL as a blood biomarker for active CSVD.	[Gattringer, Thomas; Pinter, Daniela; Enzinger, Christian; Seifert-Held, Thomas; Kneihsl, Markus; Fandler, Simon; Pichler, Alexander; Voortman, Margarete; Pirpamer, Lukas; Hofer, Edith; Ropele, Stefan; Schmidt, Reinhold; Fazekas, Franz; Khalil, Michael] Med Univ Graz, Dept Neurol, Graz, Austria; [Enzinger, Christian] Med Univ Graz, Div Neuroradiol Vasc & Intervent Radiol, Graz, Austria; [Hofer, Edith] Med Univ Graz, Inst Med Informat Stat & Documentat, Graz, Austria; [Barro, Christian; Grobke, Svenya; Kuhle, Jens] Univ Basel, Univ Basel Hosp, Neurol Clin & Policlin, Dept Med, Basel, Switzerland; [Barro, Christian; Grobke, Svenya; Kuhle, Jens] Univ Basel, Univ Basel Hosp, Neurol Clin & Policlin, Dept Biomed, Basel, Switzerland; [Barro, Christian; Grobke, Svenya; Kuhle, Jens] Univ Basel, Univ Basel Hosp, Neurol Clin & Policlin, Dept Clin Res, Basel, Switzerland		Gattringer, T (corresponding author), Med Univ Graz, Dept Neurol, Graz, Austria.	thomas.gattringer@medunigraz.at	Fandler-Hofler, Simon/AAL-9956-2020; Schmidt, Reinhold/E-1137-2014; Barro, Christian/AAO-3567-2021	Fandler-Hofler, Simon/0000-0001-9043-0378; Barro, Christian/0000-0002-7795-7383; Gattringer, Thomas/0000-0002-6065-6576; Khalil, Michael/0000-0002-5350-3328; Pinter, Daniela/0000-0003-3138-5225	Austrian Science FundAustrian Science Fund (FWF) [T690-B23]	Daniela Pinter receives funding from the Austrian Science Fund: T690-B23.	Benjamin P, 2016, J CEREBR BLOOD F MET, V36, P228, DOI 10.1038/jcbfm.2015.113; Byrne LM, 2017, LANCET NEUROL, V16, P601, DOI 10.1016/S1474-4422(17)30124-2; Conklin J, 2014, ANN NEUROL, V76, P899, DOI 10.1002/ana.24285; Debette S, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3666; FAZEKAS F, 1987, AM J ROENTGENOL, V149, P351, DOI 10.2214/ajr.149.2.351; Fazekas F, 2013, NEUROLOGY, V81, P1914, DOI 10.1212/01.wnl.0000436611.28210.ec; Gaiottino J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075091; Gunnarsson M, 2011, ANN NEUROL, V69, P83, DOI 10.1002/ana.22247; Jonsson M, 2010, EUR J NEUROL, V17, P377, DOI 10.1111/j.1468-1331.2009.02808.x; Kim KW, 2008, BIOL PSYCHIAT, V64, P273, DOI 10.1016/j.biopsych.2008.03.024; Kolominsky-Rabas PL, 2001, STROKE, V32, P2735, DOI 10.1161/hs1201.100209; Kuhle J, 2016, CLIN CHEM LAB MED, V54, P1655, DOI 10.1515/cclm-2015-1195; Kuhle J, 2015, NEUROLOGY, V84, P1639, DOI 10.1212/WNL.0000000000001491; Kuhle J, 2015, J NEUROL NEUROSUR PS, V86, P273, DOI 10.1136/jnnp-2013-307454; Kuhle J, 2013, MULT SCLER J, V19, P1597, DOI 10.1177/1352458513482374; Mattsson N, 2017, JAMA NEUROL, V74, P557, DOI 10.1001/jamaneurol.2016.6117; Norgren N, 2002, HYBRIDOMA HYBRIDOM, V21, P53, DOI 10.1089/15368590252917647; Pirpamer L, 2016, NEUROBIOL AGING, V43, P149, DOI 10.1016/j.neurobiolaging.2016.04.002; Schmidt R, 2005, ANN NEUROL, V58, P610, DOI 10.1002/ana.20630; Shahim P, 2017, NEUROLOGY, V88, P1788, DOI 10.1212/WNL.0000000000003912; Shahim P, 2016, SCI REP-UK, V6, DOI 10.1038/srep36791; Steinacker P, 2017, NEUROLOGY, V88, P961, DOI 10.1212/WNL.0000000000003688; Teunissen CE, 2009, NEUROLOGY, V73, P1914, DOI 10.1212/WNL.0b013e3181c47cc2; Teunissen CE, 2012, MULT SCLER J, V18, P552, DOI 10.1177/1352458512443092; Traenka C, 2015, CEREBROVASC DIS, V40, P222, DOI 10.1159/000440774; Vilar-Bergua A, 2016, J CEREBR BLOOD F MET, V36, P55, DOI 10.1038/jcbfm.2015.68; Wardlaw JM, 2013, LANCET NEUROL, V12, P822, DOI 10.1016/S1474-4422(13)70124-8; Weydt P, 2016, ANN NEUROL, V79, P152, DOI 10.1002/ana.24552; Yan J, 2009, J NEUROIMMUNOL, V206, P112, DOI 10.1016/j.jneuroim.2008.11.001	29	81	81	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	NOV 14	2017	89	20					2108	2114		10.1212/WNL.0000000000004645			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FP5RA	WOS:000417676500014	29046363	Green Published			2022-02-06	
J	Press, JN; Rowson, S				Press, Jaclyn N.; Rowson, Steven			Quantifying Head Impact Exposure in Collegiate Women's Soccer	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; gender; frequency; sensor; acceleration; football	ACCELERATION MEASUREMENT; NECK INJURIES; BRAIN-INJURY; FOOTBALL; CONCUSSION; BALL; PLAYERS; HOCKEY; RISK	Objective:The aim of this study was to quantify head impact exposure for a collegiate women's soccer team over the course of the 2014 season.Design:Observational and prospective study.Setting:Virginia Tech women's soccer games and practices.Participants:Twenty-six collegiate level women's soccer players with a mean player age of 19 1.Interventions:Participating players were instrumented with head impact sensors for biomechanical analysis. Video recordings of each event were used to manually verify each impact sustained.Main Outcome Measures:Head impact counts by player position and impact situation.Results:The sensors collected data from a total of 17865 accelerative events, 8999 of which were classified as head impacts. Of these, a total of 1703 impacts were positively identified (19% of total real impacts recorded by sensor), 90% of which were associated with heading the ball. The average number of impacts per player per practice or game was 1.86 +/- 1.42. Exposure to head impact varied by player position.Conclusions:Head impact exposure was quantified through 2 different methods, which illustrated the challenges associated with autonomously collecting acceleration data with head impact sensors. Users of head impact data must exercise caution when interpreting on-field head impact sensor data.	[Press, Jaclyn N.; Rowson, Steven] Virginia Tech, Dept Biomed Engn & Mech, Blacksburg, VA USA		Rowson, S (corresponding author), 343 Kelly Hall,325 Stanger St, Blacksburg, VA 24061 USA.	rowson@vt.edu	Rowson, Steven/B-1270-2012	Rowson, Steven/0000-0002-3227-0596			Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Daniel RW, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4027872; Delany JS, 2002, CLIN J SPORT MED, V12, P8; Duma SM, 2014, CONCUSSIONS ATHLETIC, P115; Duma SM, 2009, IEEE ENG MED BIO, P1123, DOI 10.1109/IEMBS.2009.5333423; Fuller CW, 2005, BRIT J SPORT MED, V39, pI3, DOI 10.1136/bjsm.2005.018937; Funk JR, 2011, ANN BIOMED ENG, V39, P766, DOI 10.1007/s10439-010-0183-3; Guskiewicz KM, 2002, AM J SPORT MED, V30, P630; Hanlon E, 2010, J APPL BIOMECH, V26, P424, DOI 10.1123/jab.26.4.424; Hanlon EM, 2012, MED SCI SPORT EXER, V44, P1102, DOI 10.1249/MSS.0b013e3182444d7d; Janda David H, 2002, Inj Control Saf Promot, V9, P25, DOI 10.1076/icsp.9.1.25.3324; Kunz M, 2007, FIFA MAGAZINE, P6; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; Naunheim RS, 2003, ACAD EMERG MED, V10, P85, DOI 10.1197/aemj.10.1.85; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Queen RM, 2003, MED SCI SPORT EXER, V35, P2069, DOI 10.1249/01.MSS.0000099081.20125.A5; Rowson B, 2015, ANN BIOMED ENG, V43, P2429, DOI 10.1007/s10439-015-1278-7; Rowson S, 2014, J NEUROSURG, V120, P919, DOI 10.3171/2014.1.JNS13916; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2012, ANN BIOMED ENG, V40, P2512, DOI 10.1007/s10439-012-0660-y; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; Young TJ, 2014, CLIN J SPORT MED, V24, P416, DOI 10.1097/JSM.0000000000000055	27	81	81	1	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAR	2017	27	2					104	110		10.1097/JSM.0000000000000313			7	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	EM8PJ	WOS:000395573100003	26978008				2022-02-06	
J	Slobounov, SM; Walter, A; Breiter, HC; Zhu, DC; Bai, XX; Bream, T; Seidenberg, P; Mao, XL; Johnson, B; Talavage, TM				Slobounov, Semyon M.; Walter, Alexa; Breiter, Hans C.; Zhu, David C.; Bai, Xiaoxiao; Bream, Tim; Seidenberg, Peter; Mao, Xianglun; Johnson, Brian; Talavage, Thomas M.			The effect of repetitive subconcussive collisions on brain integrity in collegiate football players over a single football season: A multi-modal neuroimaging study	NEUROIMAGE-CLINICAL			English	Article						Subconcussive; Repetitive impacts; Football; MRI; Accelerometers	HIGH-SCHOOL FOOTBALL; DEFAULT-MODE NETWORK; CHRONIC TRAUMATIC ENCEPHALOPATHY; PHYSICAL STRESS TEST; RESTING-STATE FMRI; FUNCTIONAL CONNECTIVITY; PROFESSIONAL FOOTBALL; HEAD IMPACTS; CONCUSSED INDIVIDUALS; SOCCER PLAYERS	The cumulative effect of repetitive subconcussive collisions on the structural and functional integrity of the brain remains largely unknown. Athletes in collision sports, like football, experience a large number of impacts across a single season of play. The majority of these impacts, however, are generally overlooked, and their long-term consequences remain poorly understood. This study sought to examine the effects of repetitive collisions across a single competitive season in NCAA Football Bowl Subdivision athletes using advanced neuroimaging approaches. Players were evaluated before and after the season using multiple MRI sequences, including T1 weighted imaging, diffusion tensor imaging (DTI), arterial spin labeling (ASL), resting-state functional MRI (rsfMRI), and susceptibility weighted imaging (SWI). While no significant differences were found between pre- and post-season for DTI metrics or cortical volumes, seed-based analysis of rs-fMRI revealed significant (p < 0.05) changes in functional connections to right isthmus of the cingulate cortex (ICC), left ICC, and left hippocampus. ASL data revealed significant (p < 0.05) increases in global cerebral blood flow (CBF), with a specific regional increase in right postcentral gyrus. SWI data revealed that 44% of the players exhibited outlier rates (p < 0.05) of regional decreases in SWI signal. Of key interest, athletes in whom changes in rs-fMRI, CBF and SWI were observed were more likely to have experienced high G impacts on a daily basis. These findings are indicative of potential pathophysiological changes in brain integrity arising from only a single season of participation in the NCAA Football Bowl Subdivision, even in the absence of clinical symptoms or a diagnosis of concussion. Whether these changes reflect compensatory adaptation to cumulative head impacts or more lasting alteration of brain integrity remains to be further explored.	[Slobounov, Semyon M.] Penn State Univ, Dept Kinesiol, Concuss Neuroimaging Consortium, University Pk, PA 16802 USA; [Walter, Alexa; Johnson, Brian] Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA; [Breiter, Hans C.] Northwestern Univ, Dept Psychiat & Behav Sci, Concuss Neuroimaging Consortium, Evanston, IL 60208 USA; [Zhu, David C.] Michigan State Univ, Dept Radiol & Psychol, Concuss Neuroimaging Consortium, E Lansing, MI 48824 USA; [Bai, Xiaoxiao] Penn State Univ, Social Life & Engn Sci Imaging Ctr, University Pk, PA 16802 USA; [Bream, Tim; Seidenberg, Peter] Penn State Univ, Athlet Dept, University Pk, PA 16802 USA; [Mao, Xianglun] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA; [Talavage, Thomas M.] Purdue Univ, Sch Elect & Comp Engn, Concuss Neuroimaging Consortium, W Lafayette, IN 47907 USA		Walter, A (corresponding author), 25 Recreat Hall, University Pk, PA 16802 USA.	sms18@psu.edu; aow5128@psu.edu; h-breiter@northwestern.edu; David.Zhu@radiology.msu.edu; xxb4@psu.edu; htb2@psu.edu; pseidenberg@hmc.psu.edu; mao48@purdue.edu; bdj5039@psu.edu; tmt@purdue.edu		Talavage, Thomas/0000-0003-4977-6398	Dr. Slobounov's lab	This project was entirely internally funded by Dr. Slobounov's lab. We would like to express special thanks to Dr. Josef Pfeuffer, Siemens Healthcare, Erlangen for providing us with the advanced 3D ASL WIP package. We would like to thank Penn State football players for their time and efforts participating in this study. We also would like to thank Katie Finelli for recruitment and logistics and Madeleine Scaramuzzo for collecting the accelerometer data.	Abbas K., 2015, BIOM ENG SOC 2015 AN; Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; Abbas K, 2015, DEV NEUROPSYCHOL, V40, P51, DOI 10.1080/87565641.2014.990455; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Bartnik-Olson BL, 2014, J NEUROTRAUM, V31, P1497, DOI 10.1089/neu.2013.3213; Bauer JA, 2001, J SPORT SCI, V19, P171, DOI 10.1080/026404101750095312; Baugh CM, 2015, J NEUROTRAUM, V32, P314, DOI 10.1089/neu.2014.3582; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Breedlove KM., 2014, ATHL TRAIN SPORTS HL, V6, P1; Broglio SP, 2012, EXERC SPORT SCI REV, V40, P138, DOI 10.1097/JES.0b013e3182524273; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Chun IY, 2015, DEV NEUROPSYCHOL, V40, P92, DOI 10.1080/87565641.2015.1020945; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Cummiskey B., 2016, THESIS, P2015; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Giza Christopher C, 2014, Continuum (Minneap Minn), V20, P1545, DOI 10.1212/01.CON.0000458975.78766.11; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; Haacke EM, 2009, J MAGN RESON IMAGING, V29, P537, DOI 10.1002/jmri.21676; Hobbs JG, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15617; Houck Z, 2016, AM J SPORT MED, V44, P2269, DOI 10.1177/0363546516645070; Johnson B, 2014, J NEUROTRAUM, V31, P1907, DOI 10.1089/neu.2014.3415; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kerr ZY, 2015, AM J SPORT MED, V43, P1134, DOI 10.1177/0363546515570622; Koerte IK, 2016, J NEUROTRAUM, V33, P346, DOI 10.1089/neu.2015.3880; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Lehman EJ, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt188; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Mayer AR, 2015, J NEUROTRAUM, V32, P1759, DOI 10.1089/neu.2014.3833; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McCuen E, 2015, J BIOMECH, V48, P3720, DOI 10.1016/j.jbiomech.2015.08.003; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meier TB, 2016, J NEUROTRAUM, V33, P330, DOI 10.1089/neu.2015.3919; Merchant-Borna K, 2016, ANN BIOMED ENG, V44, P3679, DOI 10.1007/s10439-016-1680-9; Mittal S, 2009, AM J NEURORADIOL, V30, P232, DOI 10.3174/ajnr.A1461; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Narayana PA, 2015, NEUROIMAGE-CLIN, V7, P87, DOI 10.1016/j.nicl.2014.07.010; Nauman EA, 2015, DEV NEUROPSYCHOL, V40, P85, DOI 10.1080/87565641.2015.1016161; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Obler LK, 2010, BRAIN LANG, V113, P113, DOI [10.1016/j.bandl.2010.03.001, 10.1016/j.band1.2010.03.001]; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Poole VN, 2015, DEV NEUROPSYCHOL, V40, P12, DOI 10.1080/87565641.2014.984810; Poole VN, 2014, DEV NEUROPSYCHOL, V39, P459, DOI 10.1080/87565641.2014.940619; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Robinson ME, 2015, DEV NEUROPSYCHOL, V40, P74, DOI 10.1080/87565641.2015.1012204; Shuttleworth-Edwards AB, 2008, J CLIN EXP NEUROPSYC, V30, P870, DOI 10.1080/13803390701846914; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Svaldi D. O, 2016, BRAIN IMAGING BEHAV, P1; Svaldi DO, 2015, DEV NEUROPSYCHOL, V40, P80, DOI 10.1080/87565641.2014.973959; Talavage TM, 2016, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00273; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Velarde F, 1992, J NEUROTRAUM, V9; Wang Y, 2016, J NEUROTRAUM, V33, P1227, DOI 10.1089/neu.2015.4072; Ward B. D., 2000, SIMULTANEOUS INFEREN; Yeo BTT, 2011, J NEUROPHYSIOL, V106, P1125, DOI 10.1152/jn.00338.2011; Zagorchev L, 2016, J NEUROTRAUM, V33, P29, DOI 10.1089/neu.2014.3831; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhang K, 2012, J NEUROTRAUM, V29, P756, DOI 10.1089/neu.2011.2125; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413	70	81	81	2	12	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2017	14						708	718		10.1016/j.nicl.2017.03.006			11	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	FB2OY	WOS:000405984300076	28393012	Green Published, gold			2022-02-06	
J	Lee, JH; Wei, ZZ; Cao, WY; Won, S; Gu, XH; Winter, M; Dix, TA; Wei, L; Yu, SP				Lee, Jin Hwan; Wei, Zheng Z.; Cao, Wenyuan; Won, Soonmi; Gu, Xiaohuan; Winter, Megan; Dix, Thomas A.; Wei, Ling; Yu, Shan Ping			Regulation of therapeutic hypothermia on inflammatory cytokines, microglia polarization, migration and functional recovery after ischemic stroke in mice	NEUROBIOLOGY OF DISEASE			English	Article						Stroke; Hypothermia; Neurotensin receptor agonist; HPI-201; Inflammation; M1/M2 polarization; Microglia migration; Functional recovery	TRAUMATIC BRAIN-INJURY; PHARMACOLOGICALLY INDUCED HYPOTHERMIA; TRANSIENT CEREBRAL-ISCHEMIA; MILD HYPOTHERMIA; ARTERY-OCCLUSION; CARDIAC-ARREST; POSTISCHEMIC HYPOTHERMIA; MODERATE HYPOTHERMIA; INFARCT SIZE; FOCAL MODEL	Stroke is a leading threat to human life and health in the US and around the globe, while very few effective treatments are available for stroke patients. Preclinical and clinical studies have shown that therapeutic hypothermia (TH) is a potential treatment for stroke. Using novel neurotensin receptor 1 (NTR1) agonists, we have demonstrated pharmacologically induced hypothermia and protective effects against brain damages after ischemic stroke, hemorrhage stroke, and traumatic brain injury (TBI) in rodent models. To further characterize the mechanism of TH-induced brain protection, we examined the effect of TH (at +/- 33 degrees C for 6 h) induced by the NTR1 agonist HPI-201 or physical (ice/cold air) cooling on inflammatory responses after ischemic stroke in mice and oxygen glucose deprivation (OGD) in cortical neuronal cultures. Seven days after focal cortical ischemia, microglia activation in the penumbra reached a peak level, which was significantly attenuated by TH treatments commenced 30 min after stroke. The TH treatment decreased the expression of M1 type reactive factors including tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta, IL-12, IL-23, and inducible nitric oxide synthase (iNOS) measured by RT-PCR and Western blot analyses. Meanwhile, TH treatments increased the expression of M2 type reactive factors including IL-10, Fizz1, Ym1, and arginase-1. In the ischemic brain and in cortical neuronal/BV2 microglia cultures subjected to OGD, TH attenuated the expression of monocyte chemoattractant protein -1 (MCP-1) and macrophage inflammatory protein-1 alpha(MIP-1 alpha), two key chemokines in the regulation of microglia activation and infiltration. Consistently, physical cooling during OGD significantly decreased microglia migration 16 h after OGD. Finally, TH improved functional recovery at 1, 3, and 7 days after stroke. This study reveals the first evidence for hypothermia mediated regulation on inflammatory factor expression, microglia polarization, migration and indicates that the anti-inflammatory effect is an important mechanism underlying the brain protective effects of a TH therapy. (C) 2016 Elsevier Inc. All rights reserved.	[Lee, Jin Hwan; Wei, Zheng Z.; Cao, Wenyuan; Won, Soonmi; Gu, Xiaohuan; Winter, Megan; Wei, Ling; Yu, Shan Ping] Emory Univ, Sch Med, Dept Anesthesiol, Atlanta, GA 30322 USA; [Wei, Ling] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; [Lee, Jin Hwan; Wei, Zheng Z.; Gu, Xiaohuan; Yu, Shan Ping] Atlanta Vet Affairs Med Ctr, Ctr Visual & Neurocognit Rehabil, Atlanta, GA 30033 USA; [Dix, Thomas A.] JT Pharmaceut, Mt Pleasant, SC 29464 USA; [Dix, Thomas A.] Med Univ South Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29401 USA		Yu, SP (corresponding author), Emory Univ, Sch Med, 101 Woodruff Circle,WMR Bldg,Suite 620, Atlanta, GA 30322 USA.	spyu@emory.edu	Wei, Zheng Zachory/I-2109-2019	Wei, Zheng Zachory/0000-0001-7682-9286	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS073378, NS075338, NS085568, NS091585]; VA National Merit grant [RX000666]; American Heart Association Postdoctoral FellowshipAmerican Heart Association [14P0ST20130024, 15POST25680013, 15POST25710112]; NIH S10 grant [1S10 RR025679 01]; O. Wayne Rollins Endowed Chair fund; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR025679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS091585, R41NS073378, R21NS075338, R42NS073378, R44NS073378, R01NS085568] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000666] Funding Source: NIH RePORTER	This work was supported by the NIH grants NS073378, (TD/SPY), NS075338, (LW/SPY), NS085568, (LW), NS091585, (LW) a VA National Merit grant RX000666 (SPY), and American Heart Association Postdoctoral Fellowship, 14P0ST20130024, (SW), 15POST25680013, (JHL), and 15POST25710112, (ZZW). We also acknowledge the Emory Electron Microscope Core supported by NIH S10 grant (1S10 RR025679 01). This study was also supported by the O. Wayne Rollins Endowed Chair fund to SPY.	Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Chen DD, 2015, ASN NEURO, V7, DOI 10.1177/1759091415605114; Choi KE, 2012, FASEB J, V26, P2799, DOI 10.1096/fj.11-201822; Colbourne F, 1999, J CEREBR BLOOD F MET, V19, P742, DOI 10.1097/00004647-199907000-00003; Colbourne F, 2000, J CEREBR BLOOD F MET, V20, P1702, DOI 10.1097/00004647-200012000-00009; Dae MW, 2003, STROKE, V34, P734, DOI 10.1161/01.STR.0000057461.56040.FE; Davis MJ, 2013, MBIO, V4, DOI 10.1128/mBio.00264-13; Dietrich WD, 2010, NEUROTHERAPEUTICS, V7, P43, DOI 10.1016/j.nurt.2009.10.015; Doyle KP, 2008, NEUROPHARMACOLOGY, V55, P310, DOI 10.1016/j.neuropharm.2008.01.005; Fantegrossi WE, 2005, PHARMACOL BIOCHEM BE, V80, P341, DOI 10.1016/j.pbb.2004.12.005; Flugel A, 2001, J CEREBR BLOOD F MET, V21, P69; Frink M, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/762840; Gao JL, 2016, CELL TRANSPLANT, V25, P1863, DOI 10.3727/096368916X691150; Gelderblom M, 2012, J CEREBR BLOOD F MET, V32, P835, DOI 10.1038/jcbfm.2011.189; Geurts M, 2014, CRIT CARE MED, V42, P231, DOI 10.1097/CCM.0b013e3182a276e8; Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80; Gordon R, 2016, NEUROBIOL DIS, V93, P96, DOI 10.1016/j.nbd.2016.04.008; Gu XH, 2015, EXP NEUROL, V267, P135, DOI 10.1016/j.expneurol.2015.02.029; Guillemette A, 2012, EUR J PAIN, V16, P473, DOI 10.1016/j.ejpain.2011.07.008; Hadden MK, 2005, NEUROPHARMACOLOGY, V49, P1149, DOI 10.1016/j.neuropharm.2005.06.010; Herz J, 2014, NEUROBIOL DIS, V62, P456, DOI 10.1016/j.nbd.2013.10.022; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Huang J, 2006, SURG NEUROL, V66, P232, DOI 10.1016/j.surneu.2005.12.028; Hughes PM, 2002, J CEREBR BLOOD F MET, V22, P308, DOI 10.1097/00004647-200203000-00008; Jiang M. Q, 2016, BRAIN PATHOL; Karaszewski B, 2013, J CEREBR BLOOD F MET, V33, P1083, DOI 10.1038/jcbfm.2013.52; Katz LM, 2004, BRAIN RES, V1017, P85, DOI 10.1016/j.brainres.2004.05.020; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Krieger DW, 2004, STROKE, V35, P1482, DOI 10.1161/01.STR.0000126118.44249.5c; Lee JH, 2016, STROKE, V47, P1907, DOI 10.1161/STROKEAHA.116.013061; Lee JH, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0575-x; Lee JH, 2014, J NEUROTRAUM, V31, P1417, DOI 10.1089/neu.2013.3251; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Lyden PD, 2014, INT J STROKE, V9, P117, DOI 10.1111/ijs.12151; MacLellan CL, 2009, J NEUROTRAUM, V26, P313, DOI 10.1089/neu.2008.0580; Maier CM, 2001, J NEUROSURG, V94, P90, DOI 10.3171/jns.2001.94.1.0090; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; Marion D, 2009, J NEUROTRAUM, V26, P455, DOI 10.1089/neu.2008.0582; Markarian GZ, 1996, NEUROSURGERY, V38, P542; Mechanic JA, 2009, EUR NEUROPSYCHOPHARM, V19, P466, DOI 10.1016/j.euroneuro.2009.01.004; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Murphy Sherry L, 2013, Natl Vital Stat Rep, V61, P1; Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Oddo M, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1294-5; Ogle ME, 2012, NEUROBIOL DIS, V45, P733, DOI 10.1016/j.nbd.2011.10.020; Orwig KS, 2009, J MED CHEM, V52, P1803, DOI 10.1021/jm801072v; Pan J, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0270-3; Perez-de Puig I, 2013, J CEREBR BLOOD F MET, V33, P1955, DOI 10.1038/jcbfm.2013.155; Phipps MS, 2011, STROKE, V42, P3357, DOI 10.1161/STROKEAHA.111.621425; PIIRONEN IL, 2014, STROKE, V45, P486, DOI DOI 10.1161/STROKEAHA.111.621425; Polderman KH, 2015, CRIT CARE MED, V43, P2191, DOI 10.1097/CCM.0000000000001158; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; Ransohoff RM, 2012, J CLIN INVEST, V122, P1164, DOI 10.1172/JCI58644; Rappert A, 2004, J NEUROSCI, V24, P8500, DOI 10.1523/JNEUROSCI.2451-04.2004; Schwab S, 1998, ACT NEUR S, V71, P131; Shobha N, 2011, CEREBROVASC DIS, V31, P223, DOI 10.1159/000321893; Skuljec J, 2011, CELL IMMUNOL, V270, P164, DOI 10.1016/j.cellimm.2011.05.001; Sladojevic N, 2014, NEUROBIOL DIS, V67, P57, DOI 10.1016/j.nbd.2014.03.010; Steele AD, 2007, P NATL ACAD SCI USA, V104, P1983, DOI 10.1073/pnas.0610779104; Stewart CR, 2010, PEDIATR CRIT CARE ME, V11, P109, DOI 10.1097/PCC.0b013e3181b01042; Su YY, 2016, STROKE, V47, P457, DOI 10.1161/STROKEAHA.115.009789; Subramaniam A, 2015, THER HYPOTHERMIA TEM, V5, P13, DOI 10.1089/ther.2014.0019; Sugerman NT, 2009, J NEUROTRAUM, V26, P371, DOI 10.1089/neu.2008.0588; Takami S, 2001, J CEREBR BLOOD F MET, V21, P1430, DOI 10.1097/00004647-200112000-00007; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; van der Worp HB, 2007, BRAIN, V130, P3063, DOI 10.1093/brain/awm083; van der Worp HB, 2010, J CEREBR BLOOD F MET, V30, P1079, DOI 10.1038/jcbfm.2010.44; Vila N, 2000, STROKE, V31, P2325, DOI 10.1161/01.STR.31.10.2325; Wan YH, 2014, J STROKE CEREBROVASC, V23, P2736, DOI 10.1016/j.jstrokecerebrovasdis.2014.06.017; Wang HK, 2008, J NEUROSCI, V28, P1721, DOI 10.1523/JNEUROSCI.4973-07.2008; Webster CM, 2009, NEUROBIOL DIS, V33, P301, DOI 10.1016/j.nbd.2008.11.001; WEI L, 1995, STROKE, V26, P1459, DOI 10.1161/01.STR.26.8.1459; Wei S, 2013, NEUROSCIENCE, V252, P489, DOI 10.1016/j.neuroscience.2013.07.052; Won S, 2015, BRAIN BEHAV IMMUN, V49, P267, DOI 10.1016/j.bbi.2015.06.007; Xiao GG, 2013, EMERG MED J, V30, P91, DOI 10.1136/emermed-2012-201120; Xiong XX, 2011, STROKE, V42, P2026, DOI 10.1161/STROKEAHA.110.593772; Yenari MA, 2010, NEUROTHERAPEUTICS, V7, P378, DOI 10.1016/j.nurt.2010.07.005; Yoshino H, 1997, BRAIN RES, V767, P81, DOI 10.1016/S0006-8993(97)00616-1; ZHANG ZG, 1993, J NEUROL SCI, V117, P240, DOI 10.1016/0022-510X(93)90179-3; Zhu W, 2008, STROKE, V39, P1254, DOI 10.1161/STROKEAHA.107.500801	81	81	87	3	31	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	DEC	2016	96						248	260		10.1016/j.nbd.2016.09.013			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EC3WX	WOS:000388058900023	27659107	Green Accepted			2022-02-06	
J	Bar-Kochba, E; Scimone, MT; Estrada, JB; Franck, C				Bar-Kochba, Eyal; Scimone, Mark T.; Estrada, Jonathan B.; Franck, Christian			Strain and rate-dependent neuronal injury in a 3D in vitro compression model of traumatic brain injury	SCIENTIFIC REPORTS			English	Article							MECHANICAL STRETCH; AMYLOID-BETA; CULTURE; MICROTUBULES; DEFORMATION; ACTIVATION; VIABILITY; CASPASE-3; BREAKING; AXONS	In the United States over 1.7 million cases of traumatic brain injury are reported yearly, but predictive correlation of cellular injury to impact tissue strain is still lacking, particularly for neuronal injury resulting from compression. Given the prevalence of compressive deformations in most blunt head trauma, this information is critically important for the development of future mitigation and diagnosis strategies. Using a 3D in vitro neuronal compression model, we investigated the role of impact strain and strain rate on neuronal lifetime, viability, and pathomorphology. We find that strain magnitude and rate have profound, yet distinctively different effects on the injury pathology. While strain magnitude affects the time of neuronal death, strain rate influences the pathomorphology and extent of population injury. Cellular injury is not initiated through localized deformation of the cytoskeleton but rather driven by excess strain on the entire cell. Furthermore we find that, mechanoporation, one of the key pathological trigger mechanisms in stretch and shear neuronal injuries, was not observed under compression.	[Bar-Kochba, Eyal; Scimone, Mark T.; Estrada, Jonathan B.; Franck, Christian] Brown Univ, Sch Engn, Providence, RI 02912 USA		Franck, C (corresponding author), Brown Univ, Sch Engn, Providence, RI 02912 USA.	franck@brown.edu	Estrada, Jonathan/ABC-3088-2020	Estrada, Jonathan/0000-0003-1083-4597; Scimone, Mark/0000-0003-0123-3765	RI Science and Technology Council; Haythornthwaite Research Initiation Grant; Office of Naval ResearchOffice of Naval Research; National Science FoundationNational Science Foundation (NSF); Graduate Assistance in Areas of National Need (GAANN) fellowship from the Brown University Institute for Molecular and Nanoscale Innovation	The authors acknowledge Molly Boutin and Alana Levine for helpful discussions, and Jennet Toyjanova for her input on early protocol development. Gratefully acknowledge financial support from the RI Science and Technology Council, a Haythornthwaite Research Initiation Grant, and the Office of Naval Research (Dr. Timothy Bentley). E.B.-K. acknowledges support from a National Science Foundation Graduate Research Fellowship. J.B.E. acknowledges support from a Graduate Assistance in Areas of National Need (GAANN) fellowship from the Brown University Institute for Molecular and Nanoscale Innovation.	Ahmadzadeh H, 2014, BIOPHYS J, V106, P1123, DOI 10.1016/j.bpj.2014.01.024; Ahmed WW, 2014, SCI REP-UK, V4, DOI 10.1038/srep04481; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Bar-Kochba E, 2015, EXP MECH, V55, P261, DOI 10.1007/s11340-014-9874-2; Berthiaume F., 2014, METHODS BIOENGINEERI; Botev ZI, 2010, ANN STAT, V38, P2916, DOI 10.1214/10-AOS799; Bratosin D, 2005, CYTOM PART A, V66A, P78, DOI 10.1002/cyto.a.20152; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Cullen DK, 2007, ANN BIOMED ENG, V35, P835, DOI 10.1007/s10439-007-9292-z; Cullen DK, 2006, J NEUROTRAUM, V23, P1304, DOI 10.1089/neu.2006.23.1304; Cullen DK, 2011, J NEUROTRAUM, V28, P2219, DOI 10.1089/neu.2011.1841; Di Pietro V, 2010, J NEUROTRAUM, V27, P349, DOI 10.1089/neu.2009.1095; Dingle YTL, 2015, TISSUE ENG PART C-ME, V21, P1274, DOI [10.1089/ten.tec.2015.0135, 10.1089/ten.TEC.2015.0135]; Dubreuil CI, 2006, EXP NEUROL, V198, P361, DOI 10.1016/j.expneurol.2005.12.002; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Estrada JB, 2015, J APPL MECH-T ASME, V82, DOI 10.1115/1.4030821; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Faul M, 2010, INJURY PREV, V16, pA268, DOI 10.1136/ip.2010.029215.951; Fratzl P., 2008, COLLAGEN STRUCTURE M; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Garland P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047552; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Hemphill MA, 2015, NEURON, V85, P1177, DOI 10.1016/j.neuron.2015.02.041; Hemphill MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022899; Henry SJ, 2014, INTEGR BIOL-UK, V6, P348, DOI 10.1039/c3ib40225h; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kilinc D, 2008, EXP NEUROL, V212, P422, DOI 10.1016/j.expneurol.2008.04.025; Kraft RH, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002619; LaPlaca MC, 2005, J BIOMECH, V38, P1093, DOI 10.1016/j.jbiomech.2004.05.032; LaPlaca MC, 1997, ANN BIOMED ENG, V25, P665, DOI 10.1007/BF02684844; Lusardi TA, 2004, J NEUROTRAUM, V21, P61, DOI 10.1089/089771504772695959; Mao HJ, 2010, J NEUROTRAUM, V27, P877, DOI 10.1089/neu.2008.0616; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Morse JD, 2014, ANN BIOMED ENG, V42, P2501, DOI 10.1007/s10439-014-1091-8; Nyein MK, 2010, P NATL ACAD SCI USA, V107, P20703, DOI 10.1073/pnas.1014786107; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pervin F, 2009, J BIOMECH, V42, P731, DOI 10.1016/j.jbiomech.2009.01.023; Pfister BJ, 2003, ANN BIOMED ENG, V31, P589, DOI 10.1114/1.1566445; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Prevedel R, 2014, NAT METHODS, V11, P727, DOI [10.1038/NMETH.2964, 10.1038/nmeth.2964]; Rajagopalan J, 2010, BIOPHYS J, V99, P3208, DOI 10.1016/j.bpj.2010.09.029; Rousseeuw PJ, 1999, TECHNOMETRICS, V41, P212, DOI 10.2307/1270566; ROUSSEEUW PJ, 1984, J AM STAT ASSOC, V79, P871, DOI 10.2307/2288718; Saif T., 2010, MRS P, V1274; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Siechen S, 2009, P NATL ACAD SCI USA, V106, P12611, DOI 10.1073/pnas.0901867106; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Toyjanova J, 2015, J BIOL CHEM, V290, P3752, DOI 10.1074/jbc.M114.619643; Young L, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00089; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	58	81	81	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	AUG 2	2016	6								30550	10.1038/srep30550			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DS2SB	WOS:000380632800002	27480807	Green Published, gold			2022-02-06	
J	Akbar, M; Essa, MM; Daradkeh, G; Abdelmegeed, MA; Choi, Y; Mahmood, L; Song, BJ				Akbar, Mohammed; Essa, Musthafa Mohamed; Daradkeh, Ghazi; Abdelmegeed, Mohamed A.; Choi, Youngshim; Mahmood, Lubna; Song, Byoung-Joon			Mitochondrial dysfunction and cell death in neurodegenerative diseases through nitroxidative stress	BRAIN RESEARCH			English	Article						Oxidative stress; Mitochondrial dysfunction; Neuronal cell death; Neurodegenerative diseases; Post-translational protein modifications; Antioxidants; Translational research	NITRIC-OXIDE SYNTHASE; TRAUMATIC BRAIN-INJURY; DEPENDENT NEUROPROTECTIVE PROTEIN; MILD COGNITIVE IMPAIRMENT; TRANSGENIC MOUSE MODEL; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; AMYLOID-BETA; PARKINSONS-DISEASE; S-NITROSYLATION	Mitochondria are important for providing cellular energy ATP through the oxidative phosphorylation pathway. They are also critical in regulating many cellular functions including the fatty acid oxidation, the metabolism of glutamate and urea, the anti-oxidant defense, and the apoptosis pathway. Mitochondria are an important source of reactive oxygen species leaked from the electron transport chain while they are susceptible to oxidative damage, leading to mitochondrial dysfunction and tissue injury. In fact, impaired mitochondrial function is commonly observed in many types of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease, alcoholic dementia, brain ischemia-reperfusion related injury, and others, although many of these neurological disorders have unique etiological factors. Mitochondrial dysfunction under many pathological conditions is likely to be promoted by increased nitroxidative stress, which can stimulate post-translational modifications (PTMs) of mitochondrial proteins and/or oxidative damage to mitochondrial DNA and lipids. Furthermore, recent studies have demonstrated that various antioxidants, including naturally occurring flavonoids and polyphenols as well as synthetic compounds, can block the formation of reactive oxygen and/or nitrogen species, and thus ultimately prevent the PTMs of many proteins with improved disease conditions. Therefore, the present review is aimed to describe the recent research developments in the molecular mechanisms for mitochondrial dysfunction and tissue injury in neurodegenerative diseases and discuss translational research opportunities. Published by Elsevier B.V.	[Akbar, Mohammed; Abdelmegeed, Mohamed A.; Choi, Youngshim; Song, Byoung-Joon] NIAAA, Sect Mol Pharmacol & Toxicol, Lab Membrane Biochem & Biophys, NIH, Bethesda, MD USA; [Essa, Musthafa Mohamed; Daradkeh, Ghazi] Sultan Qaboos Univ, Coll Agr & Marine Sci, Dept Food Sci & Nutr, Muscat, Oman; [Essa, Musthafa Mohamed] Sultan Qaboos Univ, Ageing & Dementia Res Grp, Muscat, Oman; [Mahmood, Lubna] Qatar Univ, Dept Nutr Sci, Muscat, Qatar		Akbar, M; Song, BJ (corresponding author), NIAAA, Sect Mol Pharmacol & Toxicol, Lab Membrane Biochem & Biophys, NIH, Bethesda, MD USA.; Essa, MM (corresponding author), Sultan Qaboos Univ, Coll Agr & Marine Sci, Dept Food Sci & Nutr, Muscat, Oman.		Daradkeh, Ghazi/AAG-7759-2020; Essa, Mohamed/AAX-2596-2020	Musthafa Mohamed, Essa/0000-0001-7505-9785	National Institute on Alcohol Abuse and AlcoholismUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Research Council, Oman [RC/AGR/FOOD/11/01]; Sultan Qaboos University, Oman [IG/AGR/FOOD/14/01]; KRIBB Research Initiative Program (Korean Biomedical Scientist Fellowship Program), Korea Research Institute of Bioscience and Biotechnology, Republic of Korea; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [ZIAAA000036] Funding Source: NIH RePORTER	The work is supported by the Intramural Program Fund of the National Institute on Alcohol Abuse and Alcoholism. The authors (MME and GD) also highly appreciate the research supports from the Research Council, Oman (RC/AGR/FOOD/11/01 to MME) and the internal grant (IG/AGR/FOOD/14/01) from Sultan Qaboos University, Oman. Youngshim Choi is supported by the KRIBB Research Initiative Program (Korean Biomedical Scientist Fellowship Program), Korea Research Institute of Bioscience and Biotechnology, Republic of Korea.	Abdelmegeed MA, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/149627; Abdelmegeed MA, 2013, FREE RADICAL BIO MED, V60, P211, DOI 10.1016/j.freeradbiomed.2013.02.018; Abdelmegeed MA, 2010, BIOCHEM PHARMACOL, V79, P57, DOI 10.1016/j.bcp.2009.07.016; Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Adwan L, 2014, NEUROPHARMACOLOGY, V79, P596, DOI 10.1016/j.neuropharm.2014.01.009; Agrawal R., 2015, J CEREB BLOOD FLOW M, V2015, P1; Akter K, 2011, BRIT J CLIN PHARMACO, V71, P365, DOI 10.1111/j.1365-2125.2010.03830.x; Al-Mansoori KM, 2013, CURR ALZHEIMER RES, V10, P559; Alano CC, 2004, J BIOL CHEM, V279, P18895, DOI 10.1074/jbc.M313329200; Alano CC, 2010, J NEUROSCI, V30, P2967, DOI 10.1523/JNEUROSCI.5552-09.2010; Alzheimer's Association, 2014, ALZHEIMERS DEMENT, V10; Antoniou X, 2011, J ALZHEIMERS DIS, V24, P633, DOI 10.3233/JAD-2011-091567; Aoyama K, 2013, INT J MOL SCI, V14, P21021, DOI 10.3390/ijms141021021; Ashrafi G, 2013, CELL DEATH DIFFER, V20, P31, DOI 10.1038/cdd.2012.81; Ashrafi G, 2014, J CELL BIOL, V206, P655, DOI 10.1083/jcb.201401070; Auburger G, 2014, PROG MOL BIOL TRANSL, V127, P155, DOI 10.1016/B978-0-12-394625-6.00006-4; Bahari-Javan S, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00160; Barbero-Camps E, 2014, AM J PATHOL, V184, P2066, DOI 10.1016/j.ajpath.2014.03.014; Barr Taura L, 2007, J Neurosci Nurs, V39, P278; Bastidas AC, 2013, BIOCHEMISTRY-US, V52, P6368, DOI 10.1021/bi400575k; Besson VC, 2009, BRIT J PHARMACOL, V157, P695, DOI 10.1111/j.1476-5381.2009.00229.x; Bihaqi SW, 2013, NEUROTOXICOLOGY, V39, P95, DOI 10.1016/j.neuro.2013.07.010; Bishop P, 2014, J BIOL CHEM, V289, P36140, DOI 10.1074/jbc.M114.557124; Borutaite V, 2013, FEBS J, V280, P4999, DOI 10.1111/febs.12353; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; Bozyczko-Coyne D, 2001, J NEUROCHEM, V77, P849, DOI 10.1046/j.1471-4159.2001.00294.x; Brown GC, 2010, NITRIC OXIDE-BIOL CH, V23, P153, DOI 10.1016/j.niox.2010.06.001; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Bunevicius A, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/634598; Butterfield DA, 2007, BRAIN RES, V1148, P243, DOI 10.1016/j.brainres.2007.02.084; Butterfield DA, 2014, BIOCHEM J, V463, P177, DOI 10.1042/BJ20140772; Butterfield DA, 2010, J ALZHEIMERS DIS, V20, P369, DOI 10.3233/JAD-2010-1375; Byun K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104699; Byun K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037917; Calabrese V, 2012, BBA-MOL BASIS DIS, V1822, P753, DOI 10.1016/j.bbadis.2011.11.002; Calon F, 2007, PROSTAG LEUKOTR ESS, V77, P287, DOI 10.1016/j.plefa.2007.10.019; Chang HC, 2014, J AGR FOOD CHEM, V62, P3466, DOI 10.1021/jf403286w; Chaturvedi RK, 2013, FREE RADICAL BIO MED, V63, P1, DOI 10.1016/j.freeradbiomed.2013.03.018; Chen CY, 2005, BIOCHEM BIOPH RES CO, V331, P993, DOI 10.1016/j.bbrc.2005.03.237; Chen F, 2004, CURR DRUG TARGETS, V5, P503, DOI 10.2174/1389450043345236; Chen HC, 2007, CELL, V130, P548, DOI 10.1016/j.cell.2007.06.026; Cho DH, 2009, SCIENCE, V324, P102, DOI 10.1126/science.1171091; Choi BR, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2013.147; Chung KKK, 2010, NITRIC OXIDE-BIOL CH, V22, P290, DOI 10.1016/j.niox.2010.02.002; Chung KKK, 2004, SCIENCE, V304, P1328, DOI 10.1126/science.1093891; Ciccone S, 2013, INT J MOL SCI, V14, P2388, DOI 10.3390/ijms14022388; Cookson MR, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a009415; Correia SC, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00138; Costa C, 2010, EXP NEUROL, V221, P217, DOI 10.1016/j.expneurol.2009.11.002; Dai ZL, 2013, BIOFACTORS, V39, P383, DOI 10.1002/biof.1099; Dashdorj A, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-178; de la Monte SM, 2014, BIOCHEM PHARMACOL, V88, P548, DOI 10.1016/j.bcp.2013.12.012; de la Monte SM, 2009, J ALZHEIMERS DIS, V17, P817, DOI 10.3233/JAD-2009-1098; de Vries RLA, 2013, MOL CELL NEUROSCI, V55, P37, DOI 10.1016/j.mcn.2012.07.008; Dexter DT, 2013, FREE RADICAL BIO MED, V62, P132, DOI 10.1016/j.freeradbiomed.2013.01.018; Dias V, 2013, J PARKINSON DIS, V3, P461, DOI 10.3233/JPD-130230; Dickey AS, 2011, J NEUROSCI, V31, P15716, DOI 10.1523/JNEUROSCI.3159-11.2011; DuBoff B, 2013, TRENDS NEUROSCI, V36, P325, DOI 10.1016/j.tins.2013.03.002; Eliasson MJL, 1999, J NEUROSCI, V19, P5910, DOI 10.1523/JNEUROSCI.19-14-05910.1999; Ergin V, 2013, AGING DIS, V4, P276, DOI 10.14336/AD.2013.0400276; Essa MM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120964; Ezoulin MJM, 2005, NEUROSCI LETT, V389, P61, DOI 10.1016/j.neulet.2005.07.026; Faller P, 2013, INORG CHEM, V52, P12193, DOI 10.1021/ic4003059; Fang JG, 2007, P NATL ACAD SCI USA, V104, P18742, DOI 10.1073/pnas.0705904104; Ferramosca A, 2013, BBA-MOL CELL RES, V1833, P494, DOI 10.1016/j.bbamcr.2012.11.014; Ferraris D, 2013, FUTURE MED CHEM, V5, P1923, DOI [10.4155/fmc.13.150, 10.4155/FMC.13.150]; Fischer A, 2014, NEUROPHARMACOLOGY, V80, P95, DOI 10.1016/j.neuropharm.2014.01.038; Fitzmaurice AG, 2013, P NATL ACAD SCI USA, V110, P636, DOI 10.1073/pnas.1220399110; Folmes CDL, 2010, PROTEOME SCI, V8, DOI 10.1186/1477-5956-8-38; Forlenza OV, 2011, J PSYCHIATR RES, V45, P220, DOI 10.1016/j.jpsychires.2010.06.002; Franco MC, 2013, P NATL ACAD SCI USA, V110, pE1102, DOI 10.1073/pnas.1215177110; Gacar N, 2011, PHARMACOL BIOCHEM BE, V99, P316, DOI 10.1016/j.pbb.2011.05.017; Galter D, 2003, NEUROBIOL DIS, V14, P637, DOI 10.1016/j.nbd.2003.09.001; Garcia-Bonilla L, 2014, J IMMUNOL, V193, P2531, DOI 10.4049/jimmunol.1400918; Garcia-Escudero V, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/162152; Gebriel M, 2014, J NEUROSCI RES, V92, P104, DOI 10.1002/jnr.23297; Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Goldstein DS, 2015, J NEUROCHEM, V133, P14, DOI 10.1111/jnc.13042; Goncalves M, 2015, CLIN CHIM ACTA, V438, P342, DOI 10.1016/j.cca.2014.09.011; Gould N, 2013, J BIOL CHEM, V288, P26473, DOI 10.1074/jbc.R113.460261; Gozes I, 2004, J MOL NEUROSCI, V24, P67, DOI 10.1385/JMN:24:1:067; Gozes I, 2003, J MOL NEUROSCI, V20, P315, DOI 10.1385/JMN:20:3:315; Grimm S, 2011, FREE RADICAL RES, V45, P73, DOI 10.3109/10715762.2010.512040; Guedes-Dias P, 2013, BBA-MOL BASIS DIS, V1832, P1345, DOI 10.1016/j.bbadis.2013.04.005; Han SH, 2009, J CLIN NEUROL, V5, P120, DOI 10.3988/jcn.2009.5.3.120; Hanawa N, 2008, J BIOL CHEM, V283, P13565, DOI 10.1074/jbc.M708916200; Hanna RA, 2012, J BIOL CHEM, V287, P19094, DOI 10.1074/jbc.M111.322933; Hara MR, 2006, P NATL ACAD SCI USA, V103, P3887, DOI 10.1073/pnas.0511321103; Harris C, 2002, J NEUROCHEM, V83, P992, DOI 10.1046/j.1471-4159.2002.01219.x; Haskin J, 2013, HUM MOL GENET, V22, P2083, DOI 10.1093/hmg/ddt058; Hidding U, 2002, BIOCHEM PHARMACOL, V64, P781, DOI 10.1016/S0006-2952(02)01139-5; Hoang T, 2009, FREE RADICAL BIO MED, V47, P1049, DOI 10.1016/j.freeradbiomed.2009.07.013; Hsieh HL, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/484613; Huang HF, 2012, CNS NEUROSCI THER, V18, P811, DOI 10.1111/j.1755-5949.2012.00380.x; Ilvesmaki T, 2014, BRAIN, V137, P1876, DOI 10.1093/brain/awu095; Jang S, 2015, REDOX BIOL, V6, P552, DOI 10.1016/j.redox.2015.09.040; Jauslin ML, 2003, FASEB J, V17, P1972, DOI 10.1096/fj.03-0240fje; Jimenez S, 2011, J BIOL CHEM, V286, P18414, DOI 10.1074/jbc.M110.209718; Jin HJ, 2014, J BIOL CHEM, V289, P34743, DOI 10.1074/jbc.M114.576702; Jo J, 2011, NAT NEUROSCI, V14, P545, DOI 10.1038/nn.2785; Johri A, 2012, J PHARMACOL EXP THER, V342, P619, DOI 10.1124/jpet.112.192138; Jope RS, 2007, NEUROCHEM RES, V32, P577, DOI 10.1007/s11064-006-9128-5; Kalonia H, 2010, NEUROTOXICOLOGY, V31, P195, DOI 10.1016/j.neuro.2009.12.008; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kanamaru T, 2015, NEUROSCI LETT, V587, P126, DOI 10.1016/j.neulet.2014.12.033; Karababa A, 2014, METAB BRAIN DIS, V29, P975, DOI 10.1007/s11011-013-9454-7; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kijima K, 2005, HUM GENET, V116, P23, DOI 10.1007/s00439-004-1199-2; Kilinc M, 2010, NEUROBIOL DIS, V40, P293, DOI 10.1016/j.nbd.2010.06.003; Kim BJ, 2006, J BIOL CHEM, V281, P21256, DOI 10.1074/jbc.M510644200; Klein JA, 2003, J CLIN INVEST, V111, P785, DOI 10.1172/JCI200318182; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; Kopeikina KJ, 2011, AM J PATHOL, V179, P2071, DOI 10.1016/j.ajpath.2011.07.004; Kumar A, 2015, MOL NEUROBIOL; Kumar A, 2014, FREE RADICAL BIO MED, V73, P51, DOI 10.1016/j.freeradbiomed.2014.04.014; Kunwar A., 2011, J MED ALLIED SCI, V1, P53; Kurauchi Y, 2012, BRIT J PHARMACOL, V166, P1151, DOI 10.1111/j.1476-5381.2012.01833.x; Kwak YD, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-49; LaFerla FM, 2007, NAT REV NEUROSCI, V8, P499, DOI 10.1038/nrn2168; Lazo-Gomez R, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00243; Lee JM, 2004, J BIOCHEM MOL BIOL, V37, P139; Lee Y, 2015, J NEUROSCI RES, V93, P755, DOI 10.1002/jnr.23544; Li HY, 2014, NUTRITION, V30, P337, DOI 10.1016/j.nut.2013.08.021; Li J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033860; Liang JM, 2013, J INT MED RES, V41, P618, DOI 10.1177/0300060513476587; Liberatore GT, 1999, NAT MED, V5, P1403; Lipton P, 2013, TRANSL STROKE RES, V4, P672, DOI 10.1007/s12975-013-0301-2; Liu GX, 2014, J CLIN INVEST, V124, P3032, DOI 10.1172/JCI72176; Liu XY, 2015, J NEUROCHEM, V133, P187, DOI 10.1111/jnc.13069; Liu Y, 2014, BEHAV BRAIN RES, V267, P178, DOI 10.1016/j.bbr.2014.02.040; Lozano L, 2014, EXP GERONTOL, V58, P198, DOI 10.1016/j.exger.2014.08.008; Lu P, 2014, J NEUROSCI, V34, P15975, DOI 10.1523/JNEUROSCI.2499-14.2014; Maggio DM, 2012, J NEUROTRAUM, V29, P2244, DOI 10.1089/neu.2012.2371; Mailloux RJ, 2011, FREE RADICAL BIO MED, V51, P1106, DOI 10.1016/j.freeradbiomed.2011.06.022; Malinski T, 2007, J ALZHEIMERS DIS, V11, P207; Malkus KA, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-24; Manczak M, 2012, HUM MOL GENET, V21, P2538, DOI 10.1093/hmg/dds072; Mandel SA, 2008, J ALZHEIMERS DIS, V15, P211; Martin E, 2005, J NEUROSCI RES, V79, P240, DOI 10.1002/jnr.20293; McCormack D, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/575482; McCoy MK, 2012, ANTIOXID REDOX SIGN, V16, P869, DOI [10.1089/ars.2011.4019, 10.1089/ars.2011.4074]; McNeilly AD, 2012, DIABETOLOGIA, V55, P3061, DOI 10.1007/s00125-012-2686-y; Medeiros R, 2007, J NEUROSCI, V27, P5394, DOI 10.1523/JNEUROSCI.5047-06.2007; Miquel E, 2014, FREE RADICAL BIO MED, V70, P204, DOI 10.1016/j.freeradbiomed.2014.02.019; Mkhikian H, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1333; Mondragon-Rodriguez S, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/940603; Moon KH, 2008, GASTROENTEROLOGY, V135, P1344, DOI 10.1053/j.gastro.2008.06.048; Moon KH, 2006, HEPATOLOGY, V44, P1218, DOI 10.1002/hep.21372; Moon KH, 2010, FREE RADICAL BIO MED, V48, P391, DOI 10.1016/j.freeradbiomed.2009.11.008; Morrison CD, 2010, J NEUROCHEM, V114, P1581, DOI 10.1111/j.1471-4159.2010.06865.x; Mota SI, 2015, BBA-MOL BASIS DIS, V1852, P1428, DOI 10.1016/j.bbadis.2015.03.015; Naoi M, 2010, CURR PHARM DESIGN, V16, P2799, DOI 10.2174/138161210793176527; Narayan PJ, 2015, NEUROBIOL DIS, V74, P281, DOI 10.1016/j.nbd.2014.11.023; Narendra DP, 2011, ANTIOXID REDOX SIGN, V14, P1929, DOI 10.1089/ars.2010.3799; Nataraj J., 2015, NUTR NEUROSCI, P1; Nathan C, 2005, J EXP MED, V202, P1163, DOI 10.1084/jem.20051529; Navarro A, 2008, ADV DRUG DELIVER REV, V60, P1534, DOI 10.1016/j.addr.2008.05.002; Navarro A, 2009, J BIOENERG BIOMEMBR, V41, P517, DOI 10.1007/s10863-009-9250-6; Ng LF, 2014, FREE RADICAL BIO MED, V71, P390, DOI 10.1016/j.freeradbiomed.2014.03.003; Nijboer CH, 2013, NEUROBIOL DIS, V54, P432, DOI 10.1016/j.nbd.2013.01.017; Nistico R, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00063; Nobunaga M, 2014, NEUROCHEM INT, V78, P61, DOI 10.1016/j.neuint.2014.09.002; Novak I, 2010, EMBO REP, V11, P45, DOI 10.1038/embor.2009.256; Nuzzo D, 2015, CURR ALZHEIMER RES, V12, P723, DOI 10.2174/1567205012666150710115506; Ohsawa I, 2008, J NEUROSCI, V28, P6239, DOI 10.1523/JNEUROSCI.4956-07.2008; Oikawa S, 2014, FREE RADICAL RES, V48, P694, DOI 10.3109/10715762.2014.901509; Okatsu K, 2012, BIOCHEM BIOPH RES CO, V428, P197, DOI 10.1016/j.bbrc.2012.10.041; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Ortman JMVV, 2014, AGING NATION OLDER P; Pan J, 2009, NEUROCHEM INT, V54, P418, DOI 10.1016/j.neuint.2009.01.013; Park SY, 2013, NEUROTOXICOLOGY, V38, P115, DOI 10.1016/j.neuro.2013.07.004; Pattaroni C, 2013, MOL NEUROBIOL, V47, P740, DOI 10.1007/s12035-012-8376-4; Pena-Altamira LE, 2013, CURR PHARM DESIGN, V19, P5085, DOI 10.2174/13816128113199990355; Pickrell AM, 2015, NEURON, V85, P257, DOI 10.1016/j.neuron.2014.12.007; Pickrell AM, 2011, J NEUROSCI, V31, P9895, DOI 10.1523/JNEUROSCI.6223-10.2011; Placido AI, 2014, BBA-MOL BASIS DIS, V1842, P1444, DOI 10.1016/j.bbadis.2014.05.003; Proitsi P, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001713; Puschmann A, 2013, PARKINSONISM RELAT D, V19, P407, DOI 10.1016/j.parkreldis.2013.01.020; Qi X, 2013, J CELL SCI, V126, P789, DOI 10.1242/jcs.114439; Qu MH, 2016, CURR TOP MED CHEM, V16, P558, DOI 10.2174/1568026615666150813144437; Quintana FJ, 2006, ANN NY ACAD SCI, V1070, P500, DOI 10.1196/annals.1317.069; Rajan KB, 2014, ALZ DIS ASSOC DIS, V28, P134, DOI 10.1097/WAD.0000000000000013; Rege SD, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/419092; Ren JW, 2011, NEUROCHEM RES, V36, P2352, DOI 10.1007/s11064-011-0561-8; Rhee S G, 2000, Sci STKE, V2000, ppe1; Ribas V, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00151; Rodrigo R, 2013, CNS NEUROL DISORD-DR, V12, P698; Rohrer JD, 2012, BBA-MOL BASIS DIS, V1822, P325, DOI 10.1016/j.bbadis.2011.07.014; Ron D, 2013, CURR TOP BEHAV NEURO, V13, P87, DOI 10.1007/7854_2011_161; Sadigh-Eteghad S, 2012, NEUROSCIENCES, V17, P321; Sanderson TH, 2015, NEUROSCIENCE, V301, P71, DOI 10.1016/j.neuroscience.2015.05.078; Sanderson TH, 2015, MOL CELL NEUROSCI, V64, P116, DOI 10.1016/j.mcn.2014.12.007; Schedin-Weiss S, 2014, FEBS J, V281, P46, DOI 10.1111/febs.12590; Schildknecht S, 2013, J NEUROCHEM, V125, P491, DOI 10.1111/jnc.12226; Schmid AW, 2013, MOL CELL PROTEOMICS, V12, P3543, DOI 10.1074/mcp.R113.032730; Schroeter H, 2003, BIOCHEM J, V372, P359, DOI 10.1042/BJ20030201; Schroeter H, 2007, J NEUROCHEM, V101, P1596, DOI 10.1111/j.1471-4159.2006.04434.x; Scorziello A, 2013, J CELL SCI, V126, P5566, DOI 10.1242/jcs.129668; Sekigawa A, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/817807; Sha YG, 2012, BBA-GEN SUBJECTS, V1820, P701, DOI 10.1016/j.bbagen.2011.05.008; Shah SA, 2015, MOL NEUROBIOL, V51, P1278, DOI 10.1007/s12035-014-8805-7; Shahani N, 2012, BBA-GEN SUBJECTS, V1820, P736, DOI 10.1016/j.bbagen.2011.07.010; Shahpasandzadeh H, 2014, J BIOL CHEM, V289, P31224, DOI 10.1074/jbc.M114.559237; Singhal NK, 2013, MOL CELL BIOCHEM, V384, P47, DOI 10.1007/s11010-013-1780-x; Slavin JL, 2012, ADV NUTR, V3, P506, DOI 10.3945/an.112.002154; Smith RAJ, 2010, ANN NY ACAD SCI, V1201, P96, DOI 10.1111/j.1749-6632.2010.05627.x; Son Y, 2013, METHOD ENZYMOL, V528, P27, DOI 10.1016/B978-0-12-405881-1.00002-1; Son Yong, 2011, J Signal Transduct, V2011, P792639, DOI 10.1155/2011/792639; Song Byoung-Joon, 2015, Adv Pharmacol, V74, P303, DOI 10.1016/bs.apha.2015.04.002; Song BJ, 2014, REDOX BIOL, V3, P109, DOI 10.1016/j.redox.2014.10.004; Song BJ, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/781050; Song BJ, 2011, J PROTEOMICS, V74, P2691, DOI 10.1016/j.jprot.2011.05.013; Song BJ, 2010, METHOD ENZYMOL, V473, P251, DOI 10.1016/S0076-6879(10)73013-5; Soustiel JF, 2007, NEUROL RES, V29, P654, DOI 10.1179/016164107X240017; Spruss A, 2011, ANTIOXID REDOX SIGN, V14, P2121, DOI 10.1089/ars.2010.3263; Subash S, 2015, NUTRITION, V31, P223, DOI 10.1016/j.nut.2014.06.004; Subash S, 2014, NEURAL REGEN RES, V9, P1557, DOI 10.4103/1673-5374.139483; Subash S, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/546357; Subramaniam S, 2010, FEBS J, V277, P22, DOI 10.1111/j.1742-4658.2009.07367.x; Sultana R, 2013, FREE RADICAL BIO MED, V62, P157, DOI 10.1016/j.freeradbiomed.2012.09.027; Sultana R, 2013, J ALZHEIMERS DIS, V33, pS243, DOI [10.3233/JAD-2012-129018, 10.3233/978-1-61499-154-0-243]; Sun J, 2014, BRAIN RES, V1589, P126, DOI 10.1016/j.brainres.2014.09.039; Sun KH, 2009, MOL BIOL CELL, V20, P4611, DOI 10.1091/mbc.E09-05-0433; Syntichaki P, 2002, NATURE, V419, P939, DOI 10.1038/nature01108; Tajuddin NF, 2013, ALCOHOL, V47, P39, DOI 10.1016/j.alcohol.2012.09.003; Tan EP, 2014, J BIOL CHEM, V289, P14719, DOI 10.1074/jbc.M113.525790; Tanaka A, 2010, J CELL BIOL, V191, P1367, DOI 10.1083/jcb.201007013; Tapias V, 2014, NEUROBIOL AGING, V35, P1162, DOI 10.1016/j.neurobiolaging.2013.10.077; Tepper K, 2014, J BIOL CHEM, V289, P34389, DOI 10.1074/jbc.M114.611368; Tolkovsky AM, 2009, BBA-MOL CELL RES, V1793, P1508, DOI 10.1016/j.bbamcr.2009.03.002; Tradewell ML, 2012, HUM MOL GENET, V21, P136, DOI 10.1093/hmg/ddr448; Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963; Upreti VV, 2011, PROTEOMICS, V11, P202, DOI 10.1002/pmic.201000203; Vauzour D, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/914273; Vepsalainen S, 2013, J NUTR BIOCHEM, V24, P360, DOI 10.1016/j.jnutbio.2012.07.006; Verma R, 2009, NEUROCHEM INT, V55, P369, DOI 10.1016/j.neuint.2009.04.001; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Vina J, 2010, J ALZHEIMERS DIS, V20, pS527, DOI 10.3233/JAD-2010-100501; Wagner GR, 2012, HUM MOL GENET, V21, P2688, DOI 10.1093/hmg/dds095; Walker AK, 2010, BRAIN, V133, P105, DOI 10.1093/brain/awp267; Waly MI, 2011, ALCOHOL CLIN EXP RES, V35, P277, DOI 10.1111/j.1530-0277.2010.01343.x; Wang DM, 2014, CELL MOL NEUROBIOL, V34, P1209, DOI 10.1007/s10571-014-0098-x; Wang JZ, 2013, J ALZHEIMERS DIS, V33, pS123, DOI 10.3233/JAD-2012-129031; Wang W, 2015, INT J STROKE, V10, P1261, DOI 10.1111/ijs.12560; Wang WY, 2004, NEUROSCI RES, V48, P195, DOI 10.1016/j.neures.2003.10.012; Wang XN, 2011, CELL, V147, P893, DOI 10.1016/j.cell.2011.10.018; Weinberg F, 2009, ANN NY ACAD SCI, V1177, P66, DOI 10.1111/j.1749-6632.2009.05039.x; Weinreb O, 2012, CURR DRUG TARGETS, V13, P483, DOI 10.2174/138945012799499794; Wey MCY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031522; Win S, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.522; Win S, 2011, J BIOL CHEM, V286, P35071, DOI 10.1074/jbc.M111.276089; Winklhofer KF, 2014, TRENDS CELL BIOL, V24, P332, DOI 10.1016/j.tcb.2014.01.001; Winterbourn CC, 2008, NAT CHEM BIOL, V4, P278, DOI 10.1038/nchembio.85; Wirth M, 2014, J NEUROSCI, V34, P8612, DOI 10.1523/JNEUROSCI.4612-13.2014; Wu WW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132499; Xie YC, 2014, TOXICOL APPL PHARM, V279, P266, DOI 10.1016/j.taap.2014.05.010; Xu K, 2008, ADV EXP MED BIOL, V614, P379, DOI 10.1007/978-0-387-74911-2_42; YANG S, 2013, BIOMED RES INT, V2013, DOI DOI 10.1155/2013/215798; Yarza R, 2016, FRONT PHARMACOL, V6, DOI [10.3389/fphys.2015.00321, 10.3389/fphar.2015.00321]; Yin F, 2013, BIOCHEM SOC T, V41, P101, DOI 10.1042/BST20120260; Yin L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117546; Zhang F, 2013, NEUROCHEM INT, V62, P1055, DOI 10.1016/j.neuint.2013.03.016; Zhang HY, 2012, ACTA PHARMACOL SIN, V33, P1170, DOI 10.1038/aps.2012.128; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zhang J, 2010, AUTOPHAGY, V6, P405, DOI 10.4161/auto.6.3.11245; Zhu YP, 2014, J BIOL CHEM, V289, P34472, DOI 10.1074/jbc.R114.601351; Zhu ZH, 2015, BRAIN RES, V1620, P17, DOI 10.1016/j.brainres.2015.05.011	270	81	88	4	52	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	APR 15	2016	1637						34	55		10.1016/j.brainres.2016.02.016			22	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DK0NY	WOS:000374610700004	26883165	Green Accepted			2022-02-06	
J	Olson, DM; Stutzman, S; Saju, C; Wilson, M; Zhao, WD; Aiyagari, V				Olson, DaiWai M.; Stutzman, Sonja; Saju, Ciji; Wilson, Margaret; Zhao, Weidan; Aiyagari, Venkatesh			Interrater Reliability of Pupillary Assessments	NEUROCRITICAL CARE			English	Article						Pupillometry; Interrater reliability; Neurological illness; Traumatic brain injury; Pupil assessment	GLASGOW COMA SCALE; SEVERE HEAD-INJURY; DILATED PUPILS; INFRARED PUPILLOMETRY; ANISOCORIA; PREDICTION; REACTIVITY; HERNIATION; AGREEMENT; TRAUMA	Background Subjective scoring of pupil reactivity is a fundamental element of the neurological examination for which the pupillometer provides an objective measure. Methods This single-blinded observational study examined interrater reliability of pupil exam findings between two practitioners and between practitioners and a pupillometer. Results From 2329 paired assessments, the interrater reliability between practitioners was only moderate for pupil size (k = 0.54), shape (k = 0.62), and reactivity (k = 0.40). Only 33.3 % of pupils scored as non-reactive by practitioners were scored as non-reactive by pupillometry. Conclusions Despite the strong emphasis placed on the traditional pupil examination, especially for patients with a neurological illness, there is limited interrater reliability for subjective scoring of pupillary assessments. Thus, the use of automated pupillometers should be examined as a potential method to increase the reliability of measuring of pupil reactivity.	[Olson, DaiWai M.; Stutzman, Sonja; Saju, Ciji; Wilson, Margaret; Zhao, Weidan; Aiyagari, Venkatesh] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Aiyagari, Venkatesh] Univ Texas SW Med Ctr Dallas, Dept Neurol Surg, 5323 Harry Hines Blvd, Dallas, TX 75390 USA		Olson, DM (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	daiwai.olson@utsouthwestern.edu	Olson, DaiWai/I-5932-2019	Olson, DaiWai/0000-0002-9280-078X; Aiyagari, Venkatesh/0000-0001-8139-3819			AANN, 2010, AANN COR CURR NEUR N, P21; ANDREWS BT, 1991, NEUROSURGERY, V29, P227, DOI 10.1227/00006123-199108000-00010; Blumenfeld H., 2002, NEUROANATOMY CLIN CA; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Campbell WW, 2005, DEJONGS NEUROLOGIC E; Chen Jeff W, 2011, Surg Neurol Int, V2, P82, DOI 10.4103/2152-7806.82248; Chen YJ, 2013, INVEST OPHTH VIS SCI, V54, P2951, DOI 10.1167/iovs.12-10916; CHESNUT RM, 1994, NEUROSURGERY, V34, P840, DOI 10.1227/00006123-199405000-00008; Chesnut RM, 1994, NEUROSURGERY, V34, P845; Clusmann H, 2001, J NEUROL NEUROSUR PS, V71, P175, DOI 10.1136/jnnp.71.2.175; Du R, 2005, NEUROSURGERY, V57, P198, DOI 10.1227/01.NEU.0000163425.79170.CB; Fountas KN, 2006, NEUROCRIT CARE, V5, P55, DOI 10.1385/NCC:5:1:55; GOEBERT HW, 1970, SURG CLIN N AM, V50, P427; Greenberg M, 2006, HDB NEUROSURGERY; Gwet KL, 2010, INTERRATER RALIABILI; Kramer CL, 2014, NEUROCRIT CARE, V21, P309, DOI 10.1007/s12028-014-9988-5; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Majdan M, 2015, J NEUROTRAUM, V32, P101, DOI 10.1089/neu.2014.3438; Manley GT, 2002, J NEUROSURG ANESTH, V14, P223, DOI 10.1097/00008506-200207000-00009; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; Meeker Michele, 2005, J Neurosci Nurs, V37, P34; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Posner JB., 1980, DIAGNOSIS STUPOR COM, V3; Rebolleda G, 2013, ARCH SOC ESP OFTALMO, V88, P125, DOI [10.1016/j.oftal.2013.02.014, DOI 10.1016/J.0FTAL.2013.02.014]; Ritter AM, 1999, NEUROSURGERY, V44, P941, DOI 10.1097/00006123-199905000-00005; SAKAS DE, 1995, J NEUROSURG, V82, P961, DOI 10.3171/jns.1995.82.6.0961; Schallenberg M, 2010, J REFRACT SURG, V26, P134, DOI 10.3928/1081597X-20100121-09; Song Z, 2012, CLIN NEUROL NEUROSUR, V114, P634, DOI 10.1016/j.clineuro.2011.12.029; Tien HC, 2006, J TRAUMA, V60, P274, DOI 10.1097/01.ta.0000197177.13379.f4; Viera AJ, 2005, FAM MED, V37, P360; Wilson S F, 1988, J Neurosci Nurs, V20, P189; Witting MD, 2003, ANN EMERG MED, V41, P832, DOI 10.1067/mem.2003.193; Zafar SF, 2014, J CRIT CARE, V29, P599, DOI 10.1016/j.jcrc.2014.01.012	34	81	83	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2016	24	2					251	257		10.1007/s12028-015-0182-1			7	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	DJ3JN	WOS:000374101200014	26381281				2022-02-06	
J	Wasserman, EB; Kerr, ZY; Zuckerman, SL; Covassin, T				Wasserman, Erin B.; Kerr, Zachary Y.; Zuckerman, Scott L.; Covassin, Tracey			Epidemiology of Sports-Related Concussions in National Collegiate Athletic Association Athletes From 2009-2010 to 2013-2014: Symptom Prevalence, Symptom Resolution Time, and Return-to-Play Time	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						head injuries; concussions; epidemiology; collegiate athletics	STATES HIGH-SCHOOL; NEUROCOGNITIVE PERFORMANCE; FOOTBALL PLAYERS; NCAA CONCUSSION; SEX-DIFFERENCES; RECOVERY-TIME; IMPACT; AGE; METAANALYSIS; SEVERITY	Background: Limited data exist among collegiate student-athletes on the epidemiology of sports-related concussion (SRC) outcomes, such as symptoms, symptom resolution time, and return-to-play time. Purpose: This study used the National Collegiate Athletic Association (NCAA) Injury Surveillance Program (ISP) to describe the epidemiology of SRC outcomes in 25 collegiate sports. Study Design: Descriptive epidemiology study. Methods: SRC data from the NCAA ISP during the 2009-2010 to 2013-2014 academic years were analyzed regarding symptoms, time to resolution of symptoms, and time to return to play. Findings were also stratified by sex in sex-comparable sports (ie, ice hockey, soccer, basketball, lacrosse, baseball/softball) and whether SRCs were reported as recurrent. Results: Of the 1670 concussions reported during the 2009-2010 to 2013-2014 academic years, an average (SD) of 5.29 +/- 2.94 concussion symptoms were reported, with the most common being headache (92.2%) and dizziness (68.9%). Most concussions had symptoms resolve within 1 week (60.1%); however, 6.2% had a symptom resolution time of over 4 weeks. Additionally, 8.9% of concussions required over 4 weeks before return to play. The proportion of SRCs that required at least 1 week before return to play increased from 42.7% in 2009-2010 to 70.2% in 2013-2014 (linear trend, P < .001). Within sex-comparable sports analyses, the average number of symptoms and symptom resolution time did not differ by sex. However, a larger proportion of concussions in male athletes included amnesia and disorientation; a larger proportion of concussions in female athletes included headache, excess drowsiness, and nausea/vomiting. A total of 151 SRCs (9.0%) were reported as recurrent. The average number of symptoms reported with recurrent SRCs (5.99 +/- 3.43) was greater than that of nonrecurrent SRCs (5.22 +/- 2.88; P = .01). A greater proportion of recurrent SRCs also resulted in a long symptom resolution time (14.6% vs 5.4%, respectively; P < .001) and long return-to-play time (21.2% vs 7.7%, respectively; P < .001) compared with nonrecurrent SRCs. Conclusion: Trends in return-to-play time may indicate changing concussion management practices in which team medical staff members withhold players from participation longer to ensure symptom resolution. Concussion symptoms may differ by sex and recurrence. Future research should continue to examine the trends and discrepancies in symptom resolution time and return-to-play time.	[Wasserman, Erin B.] Univ Rochester, Sch Med & Dent, Dept Publ Hlth Sci, Rochester, NY USA; [Wasserman, Erin B.] Univ N Carolina, Matthew A Gfeller Sport Related Traumat Brain Inj, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Wasserman, Erin B.; Kerr, Zachary Y.; Zuckerman, Scott L.; Covassin, Tracey] Datalys Ctr Sports Injury Res & Prevent Inc, Indianapolis, IN 46202 USA; [Zuckerman, Scott L.] Vanderbilt Univ, Sch Med, Vanderbilt Sports Concuss Ctr, Dept Neurol Surg, Nashville, TN 37212 USA; [Covassin, Tracey] Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA		Kerr, ZY (corresponding author), Datalys Ctr Sports Injury Res & Prevent Inc, 401 W Michigan St,Suite 500, Indianapolis, IN 46202 USA.	zkerr@datalyscenter.org		Kerr, Zachary/0000-0003-1423-1259; Wasserman, Erin/0000-0001-5957-5878			Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS210, DOI 10.1016/j.apmr.2013.06.035; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; Chrisman SP, 2013, BRAIN INJURY, V27, P1, DOI 10.3109/02699052.2012.722251; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Covassin T, 2013, AM J SPORT MED, V41, P2885, DOI 10.1177/0363546513499230; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Dougan BK, 2014, J INT NEUROPSYCH SOC, V20, P64, DOI 10.1017/S1355617712001464; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Kerr ZY, 2014, PEDIATRICS, V134, P489, DOI 10.1542/peds.2014-0770; Kerr ZY, 2014, J ATHL TRAINING, V49, P552, DOI 10.4085/1062-6050-49.3.58; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Mayers LB, 2013, J NEUROPSYCH CLIN N, V25, P115, DOI 10.1176/appi.neuropsych.11120374; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P268, DOI 10.1136/bjsports-2013-092247; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKeon JMM, 2013, J ATHL TRAINING, V48, P836, DOI 10.4085/1062-6050-48.6.17; National Collegiate Athletic Association, CONC GUID DIAGN MAN; National Collegiate Athletic Association, STUD ATHL PART 1981; Pellman EJ, 2005, NEUROSURGERY, V56, P79, DOI 10.1227/01.NEU.0000150180.16552.8D; Williams RM, 2015, SPORTS MED, V45, P893, DOI 10.1007/s40279-015-0325-8	32	81	81	0	38	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	JAN	2016	44	1					226	233		10.1177/0363546515610537			8	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	DA2GU	WOS:000367614100035	26546304				2022-02-06	
J	Baratz, R; Tweedie, D; Wang, JY; Rubovitch, V; Luo, WM; Hoffer, BJ; Greig, NH; Pick, CG				Baratz, Renana; Tweedie, David; Wang, Jia-Yi; Rubovitch, Vardit; Luo, Weiming; Hoffer, Barry J.; Greig, Nigel H.; Pick, Chaim G.			Transiently lowering tumor necrosis factor-alpha synthesis ameliorates neuronal cell loss and cognitive impairments induced by minimal traumatic brain injury in mice	JOURNAL OF NEUROINFLAMMATION			English	Article							CLOSED-HEAD INJURY; CONTROLLED CORTICAL IMPACT; TNF-ALPHA; SIGNAL-TRANSDUCTION; SYNTHESIS INHIBITOR; DENTATE GYRUS; HIPPOCAMPAL NEUROGENESIS; SYNAPTIC PLASTICITY; FACTOR RECEPTORS; GENE-EXPRESSION	Background: The treatment of traumatic brain injury (TBI) represents an unmet medical need, as no effective pharmacological treatment currently exists. The development of such a treatment requires a fundamental understanding of the pathophysiological mechanisms that underpin the sequelae resulting from TBI, particularly the ensuing neuronal cell death and cognitive impairments. Tumor necrosis factor-alpha (TNF-alpha) is a cytokine that is a master regulator of systemic and neuroinflammatory processes. TNF-alpha levels are reported to become rapidly elevated post TBI and, potentially, can lead to secondary neuronal damage. Methods: To elucidate the role of TNF-alpha in TBI, particularly as a drug target, the present study evaluated (i) time-dependent TNF-alpha levels and (ii) markers of apoptosis and gliosis within the brain and related these to behavioral measures of 'well being' and cognition in a mouse closed head 50 g weight drop mild TBI (mTBI) model in the presence and absence of post-treatment with an experimental TNF-alpha synthesis inhibitor, 3,6'-dithiothalidomide. Results: mTBI elevated brain TNF-alpha levels, which peaked at 12 h post injury and returned to baseline by 18 h. This was accompanied by a neuronal loss and an increase in astrocyte number (evaluated by neuronal nuclei (NeuN) and glial fibrillary acidic protein (GFAP) immunostaining), as well as an elevation in the apoptotic death marker BH3-interacting domain death agonist (BID) at 72 h. Selective impairments in measures of cognition, evaluated by novel object recognition and passive avoidance paradigms - without changes in well being, were evident at 7 days after injury. A single systemic treatment with the TNF-alpha synthesis inhibitor 3,6'-dithiothalidomide 1 h post injury prevented the mTBI-induced TNF-alpha elevation and fully ameliorated the neuronal loss (NeuN), elevations in astrocyte number (GFAP) and BID, and cognitive impairments. Cognitive impairments evident at 7 days after injury were prevented by treatment as late as 12 h post mTBI but were not reversed when treatment was delayed until 18 h. Conclusions: These results implicate that TNF-alpha in mTBI induced secondary brain damage and indicate that pharmacologically limiting the generation of TNF-alpha post mTBI may mitigate such damage, defining a time-dependent window of up to 12 h to achieve this reversal.	[Baratz, Renana; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Tweedie, David; Luo, Weiming; Greig, Nigel H.] NIA, Drug Design & Dev Sect, Translat Gerontol Branch, Intramural Res Program,NIH, Baltimore, MD 21224 USA; [Wang, Jia-Yi] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei, Taiwan; [Hoffer, Barry J.] Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH USA		Greig, NH (corresponding author), NIA, Drug Design & Dev Sect, Translat Gerontol Branch, Intramural Res Program,NIH, BRC Room 05C220,251 Bayview Blvd, Baltimore, MD 21224 USA.	greign@grc.nia.nih.gov		Wang, Jia-Yi/0000-0002-9106-3351	Intramural Research Program, National Institute on Aging, NIH, Baltimore, USA; Tel-Aviv University, Tel-Aviv, Israel; Ministry of Science and Technology, TaiwanMinistry of Science and Technology, Taiwan [MOST103-2321-B-038-002]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000994, ZIAAG000311] Funding Source: NIH RePORTER	This study was supported in part by the Intramural Research Program, National Institute on Aging, NIH, Baltimore, USA; by Tel-Aviv University, Tel-Aviv, Israel; and by a grant from the Ministry of Science and Technology, Taiwan (MOST103-2321-B-038-002 to JY Wang). None of the authors have any competing interests in the manuscript.	Ali MS, 2013, J CEREBR BLOOD F MET, V33, P1564, DOI 10.1038/jcbfm.2013.109; Amaral DG, 2007, PROG BRAIN RES, V163, P3, DOI 10.1016/S0079-6123(07)63001-5; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Becker RE, 2014, NAT REV DRUG DISCOV, V13, P157, DOI 10.1038/nrd3842-c2; Belarbi K, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-23; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Bussey TJ, 2008, LEARN MEMORY, V15, P516, DOI 10.1101/lm.987808; CDER U, 2005, GUID IND EST MAX SAF; Chio CC, 2010, J NEUROCHEM, V115, P921, DOI 10.1111/j.1471-4159.2010.06969.x; Clark IA, 2010, PHARMACOL THERAPEUT, V128, P519, DOI 10.1016/j.pharmthera.2010.08.007; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; DELLU F, 1992, BRAIN RES, V588, P132, DOI 10.1016/0006-8993(92)91352-F; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Dix SL, 1999, BEHAV BRAIN RES, V99, P191, DOI 10.1016/S0166-4328(98)00079-5; Edut S, 2011, PSYCHOPHARMACOLOGY, V214, P877, DOI 10.1007/s00213-010-2098-y; Faul M, 2010, TRAUMATIC BRAIN INJU; Finnie JW, 2013, J CLIN NEUROSCI, V20, P1759, DOI 10.1016/j.jocn.2013.03.010; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; Fontaine V, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-07-j0001.2002; Frankola KA, 2011, CNS NEUROL DISORD-DR, V10, P391; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Gabbita SP, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-99; Gardner RC, 2014, JAMA NEUROL; Genovese T, 2008, SHOCK, V30, P231, DOI 10.1097/shk.0b013e318162d290; Ghajar J, 2008, NEUROREHAB NEURAL RE, V22, P217, DOI 10.1177/1545968308315600; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; Greig NH, 2014, ALZHEIMERS DEMENT, V10, pS62, DOI 10.1016/j.jalz.2013.12.011; Grell M, 1998, P NATL ACAD SCI USA, V95, P570, DOI 10.1073/pnas.95.2.570; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Grell M, 1996, J INFLAMM, V47, P8; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Han XD, 2011, J NEUROTRAUM, V28, P995, DOI 10.1089/neu.2010.1563; Hogg S, 1996, PHARMACOL BIOCHEM BE, V54, P21, DOI 10.1016/0091-3057(95)02126-4; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Ignatowski TA, 2014, CNS DRUGS, V28, P679, DOI 10.1007/s40263-014-0174-2; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Israelsson C, 2009, J NEUROTRAUM, V26, P1307, DOI [10.1089/neu.2008.0676, 10.1089/neu.2008-0676]; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Koopmans GC, 2009, EXP NEUROL, V216, P490, DOI 10.1016/j.expneurol.2009.01.005; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Lee CJ, 2007, SPINAL CORD, V45, P149, DOI 10.1038/sj.sc.3101931; Li JX, 2013, ADV IMMUNOL, V119, P135, DOI 10.1016/B978-0-12-407707-2.00005-9; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Longhi L, 2008, ACTA NEUROCHIR SUPPL, V102, P409, DOI 10.1007/978-3-211-85578-2_80; Longhi L, 2013, J CEREBR BLOOD F MET, V33, P1182, DOI 10.1038/jcbfm.2013.65; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Mahony C, 2013, P NATL ACAD SCI USA, V110, P12703, DOI 10.1073/pnas.1307684110; Marchetti L, 2004, J BIOL CHEM, V279, P32869, DOI 10.1074/jbc.M311766200; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Messier C, 1997, NEUROBIOL LEARN MEM, V67, P172, DOI 10.1006/nlme.1996.3755; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morris GP, 2013, NEUROBIOL LEARN MEM, V105, P40, DOI 10.1016/j.nlm.2013.07.002; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Park KM, 2010, CELL SIGNAL, V22, P977, DOI 10.1016/j.cellsig.2010.01.010; Peredeny JV, 2013, FRONT NEURAL CIRCUIT, V7, DOI 10.3389/fncir.2013.00017; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Russo I, 2012, J NEUROCHEM, V122, P1181, DOI 10.1111/j.1471-4159.2012.07846.x; Ryu WHA, 2009, CAN J NEUROL SCI, V36, P429, DOI 10.1017/S0317167100007745; Saab BJ, 2009, NEURON, V63, P643, DOI 10.1016/j.neuron.2009.08.014; Santello M, 2012, TRENDS NEUROSCI, V35, P638, DOI 10.1016/j.tins.2012.06.001; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Starke RM, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-77; Stoica BA, 2009, NEUROTOX RES, V16, P221, DOI 10.1007/s12640-009-9050-0; Stoll G, 2002, ADV EXP MED BIOL, V513, P87; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tobinick E, 2012, CNS DRUGS, V26, P1051, DOI 10.1007/s40263-012-0013-2; Tuttolomondo A, 2014, DRUG DES DEV THER, V8, P2221, DOI 10.2147/DDDT.S67655; Tuttolomondo A, 2008, CURR PHARM DESIGN, V14, P3574, DOI 10.2174/138161208786848739; Tweedie D, 2007, CURR ALZHEIMER RES, V4, P378, DOI 10.2174/156720507781788873; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Tweedie D, 2013, EXP NEUROL, V239, P170, DOI 10.1016/j.expneurol.2012.10.001; Tweedie D, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-106; Vargesson N, 2013, P NATL ACAD SCI USA, V110, pE4820, DOI 10.1073/pnas.1318475110; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wakade C, 2010, J NEUROSURG, V113, P1195, DOI 10.3171/2010.3.JNS091212; Wallister TW, 2008, WORLD PSYCHIATRY, V7, P3; Yang JS, 2010, J NEUROTRAUM, V27, P1037, DOI 10.1089/neu.2009.1229; Yang LB, 2002, J NEUROSCI, V22, P3025, DOI 10.1523/JNEUROSCI.22-08-03025.2002; Yoon JS, 2013, J NEUROSCI RES, V91, P671, DOI 10.1002/jnr.23190; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zhu XX, 2003, J MED CHEM, V46, P5222, DOI 10.1021/jm030152f; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	102	81	83	0	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	MAR 7	2015	12								45	10.1186/s12974-015-0237-4			14	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	CD3FQ	WOS:000350963800001	25879458	Green Published, gold			2022-02-06	
J	Naci, L; Cusack, R; Anello, M; Owen, AM				Naci, Lorina; Cusack, Rhodri; Anello, Mimma; Owen, Adrian M.			A common neural code for similar conscious experiences in different individuals	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						fMRI; brain injury; disorders of consciousness	INDEPENDENT COMPONENT ANALYSIS; TRAUMATIC BRAIN-INJURY; SUSTAINED ATTENTION; DETECTING AWARENESS; EXECUTIVE FUNCTIONS; DISORDERS; STATE; INTELLIGENCE; PERFORMANCE; LESIONS	The interpretation of human consciousness from brain activity, without recourse to speech or action, is one of the most provoking and challenging frontiers of modern neuroscience. We asked whether there is a common neural code that underpins similar conscious experiences, which could be used to decode these experiences in the absence of behavior. To this end, we used richly evocative stimulation (an engaging movie) portraying real-world events to elicit a similar conscious experience in different people. Common neural correlates of conscious experience were quantified and related to measurable, quantitative and qualitative, executive components of the movie through two additional behavioral investigations. The movie's executive demands drove synchronized brain activity across healthy participants' frontal and parietal cortices in regions known to support executive function. Moreover, the timing of activity in these regions was predicted by participants' highly similar qualitative experience of the movie's moment-to-moment executive demands, suggesting that synchronization of activity across participants underpinned their similar experience. Thus we demonstrate, for the first time to our knowledge, that a neural index based on executive function reliably predicted every healthy individual's similar conscious experience in response to real-world events unfolding over time. This approach provided strong evidence for the conscious experience of a brain-injured patient, who had remained entirely behaviorally nonresponsive for 16 y. The patient's executive engagement and moment-to-moment perception of the movie content were highly similar to that of every healthy participant. These findings shed light on the common basis of human consciousness and enable the interpretation of conscious experience in the absence of behavior.	[Naci, Lorina; Cusack, Rhodri; Owen, Adrian M.] Univ Western Ontario, Brain & Mind Inst, Dept Psychol, London, ON N6A 5B7, Canada; [Anello, Mimma] Univ Western Ontario, Schulich Sch Med & Dent, London, ON N6A 5B7, Canada		Naci, L (corresponding author), Univ Western Ontario, Brain & Mind Inst, Dept Psychol, London, ON N6A 5B7, Canada.	lorina.clare@gmail.com	Williams, Jackie/B-3495-2015; Cusack, Rhodri/A-2231-2010; Owen, Adrian M/B-4997-2015	Cusack, Rhodri/0000-0002-5234-7415; Naci, Lorina/0000-0001-9630-3978	Canada Excellence Research Chairs programCanada Research Chairs	We are grateful to Leah Sinai for her help with the first movie experiment. This research was supported by the Canada Excellence Research Chairs program.	ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Barbey AK, 2012, BRAIN, V135, P1154, DOI 10.1093/brain/aws021; Bardin JC, 2012, ARCH NEUROL-CHICAGO, V69, P176, DOI 10.1001/archneurol.2011.892; Beckmann CF, 2005, NEUROIMAGE, V25, P294, DOI 10.1016/j.neuroimage.2004.10.043; Beckmann CF, 2004, IEEE T MED IMAGING, V23, P137, DOI 10.1109/TMI.2003.822821; Boly M, 2011, SCIENCE, V332, P858, DOI 10.1126/science.1202043; Calhoun VD, 2009, NEUROIMAGE, V45, pS163, DOI 10.1016/j.neuroimage.2008.10.057; Casali AG, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006294; Chennu S, 2013, NEUROIMAGE-CLIN, V3, P450, DOI 10.1016/j.nicl.2013.10.008; Chung CSY, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008391.pub2; Coleman MR, 2009, BRAIN, V132, P2541, DOI 10.1093/brain/awp183; Collette F, 2005, COGNITIVE BRAIN RES, V24, P237, DOI 10.1016/j.cogbrainres.2005.01.023; Cruse D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049933; Cruse D, 2011, LANCET, V378, P2088, DOI 10.1016/S0140-6736(11)61224-5; Datta Avijit, 2007, Comput Intell Neurosci, P93968, DOI 10.1155/2007/93968; Davis MH, 2007, P NATL ACAD SCI USA, V104, P16032, DOI 10.1073/pnas.0701309104; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; Duncan J, 2010, TRENDS COGN SCI, V14, P172, DOI 10.1016/j.tics.2010.01.004; Elliott R, 2003, BRIT MED BULL, V65, P49, DOI 10.1093/bmb/65.1.49; Fernandez-Espejo D, 2013, NAT REV NEUROSCI, V14, P801, DOI 10.1038/nrn3608; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Hampshire A, 2006, CEREB CORTEX, V16, P1679, DOI 10.1093/cercor/bhj116; Hasson U, 2004, SCIENCE, V303, P1634, DOI 10.1126/science.1089506; Hasson U, 2008, PROJECTIONS, V2, P1, DOI 10.3167/proj.2008.020102; Hasson U, 2010, TRENDS COGN SCI, V14, P40, DOI 10.1016/j.tics.2009.10.011; Kamitani Y, 2005, NAT NEUROSCI, V8, P679, DOI 10.1038/nn1444; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Mizuno K, 2012, NEUROPSYCHOLOGIA, V50, P1998, DOI 10.1016/j.neuropsychologia.2012.04.025; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Naci L, 2013, JAMA NEUROL, V70, P1235, DOI 10.1001/jamaneurol.2013.3686; Naci L, 2013, J NEUROSCI, V33, P9385, DOI 10.1523/JNEUROSCI.5577-12.2013; Naci L, 2012, ANN NEUROL, V72, P312, DOI 10.1002/ana.23656; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; OWEN AM, 1990, NEUROPSYCHOLOGIA, V28, P1021, DOI 10.1016/0028-3932(90)90137-D; Owen AM, CONSCIOUSNE IN PRESS; Plum F, 1966, DIAGNOSIS STUPOR COM; Ptak R, 2012, NEUROSCIENTIST, V18, P502, DOI 10.1177/1073858411409051; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Sauseng P, 2005, INT J PSYCHOPHYSIOL, V57, P97, DOI 10.1016/j.ijpsycho.2005.03.018; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Soon CS, 2008, NAT NEUROSCI, V11, P543, DOI 10.1038/nn.2112; Vilkki J, 1996, NEUROPSYCHOLOGIA, V34, P1051, DOI 10.1016/0028-3932(96)00028-0; Whyte J, 2006, NEUROPSYCHOLOGIA, V44, P2007, DOI 10.1016/j.neuropsychologia.2006.02.012; Woolgar A, 2010, P NATL ACAD SCI USA, V107, P14899, DOI 10.1073/pnas.1007928107	46	81	82	0	16	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	SEP 30	2014	111	39					14277	14282		10.1073/pnas.1407007111			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AP8SW	WOS:000342350200062	25225384	Bronze, Green Published			2022-02-06	
J	Hillary, FG; Rajtmajer, SM; Roman, CA; Medaglia, JD; Slocomb-Dluzen, JE; Calhoun, VD; Good, DC; Wylie, GR				Hillary, Frank G.; Rajtmajer, Sarah M.; Roman, Cristina A.; Medaglia, John D.; Slocomb-Dluzen, Julia E.; Calhoun, Vincent D.; Good, David C.; Wylie, Glenn R.			The Rich Get Richer: Brain Injury Elicits Hyperconnectivity in Core Subnetworks	PLOS ONE			English	Article							INDEPENDENT COMPONENT ANALYSIS; WORKING-MEMORY DYSFUNCTION; GRAPH-THEORETICAL ANALYSIS; FUNCTIONAL MRI DATA; DEFAULT MODE; LOW-FREQUENCY; CONNECTIVITY; NETWORKS; DEFICITS; MILD	There remains much unknown about how large-scale neural networks accommodate neurological disruption, such as moderate and severe traumatic brain injury (TBI). A primary goal in this study was to examine the alterations in network topology occurring during the first year of recovery following TBI. To do so we examined 21 individuals with moderate and severe TBI at 3 and 6 months after resolution of posttraumatic amnesia and 15 age- and education-matched healthy adults using functional MRI and graph theoretical analyses. There were two central hypotheses in this study: 1) physical disruption results in increased functional connectivity, or hyperconnectivity, and 2) hyperconnectivity occurs in regions typically observed to be the most highly connected cortical hubs, or the "rich club". The current findings generally support the hyperconnectivity hypothesis showing that during the first year of recovery after TBI, neural networks show increased connectivity, and this change is disproportionately represented in brain regions belonging to the brain's core subnetworks. The selective increases in connectivity observed here are consistent with the preferential attachment model underlying scale-free network development. This study is the largest of its kind and provides the unique opportunity to examine how neural systems adapt to significant neurological disruption during the first year after injury.	[Hillary, Frank G.; Roman, Cristina A.; Medaglia, John D.] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA; [Rajtmajer, Sarah M.] Penn State Univ, Dept Math, University Pk, PA 16802 USA; [Slocomb-Dluzen, Julia E.; Good, David C.] Hershey Med Ctr, Dept Neurol, Hershey, PA USA; [Calhoun, Vincent D.] Mind Res Network, Albuquerque, NM USA; [Wylie, Glenn R.] Kessler Fdn Res Ctr, W Orange, NJ USA		Hillary, FG (corresponding author), Penn State Univ, Dept Psychol, University Pk, PA 16802 USA.	fhillary@psu.edu; gwylie@kesslerfoundation.org	Hillary, Frank/AAN-8622-2021		New Jersey Commission for Brain Injury Research [09.001.BIR1]; Social Sciences Research Institute at Pennsylvania State University in University Park, Pennsylvania	This work was funded in part by the New Jersey Commission for Brain Injury Research (09.001.BIR1) and the Social Sciences Research Institute at Pennsylvania State University in University Park, Pennsylvania. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abou-Elseoud A, 2010, HUM BRAIN MAPP, V31, P1207, DOI 10.1002/hbm.20929; Achard S, 2006, J NEUROSCI, V26, P63, DOI 10.1523/JNEUROSCI.3874-05.2006; Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; Allen EA, 2012, NEUROIMAGE, V59, P4141, DOI 10.1016/j.neuroimage.2011.10.010; Allen EA, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00002; Army Individual Test Battery, 1990, MAN DIR SCOR; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Bassett DS, 2011, P NATL ACAD SCI USA, V108, P7641, DOI 10.1073/pnas.1018985108; Benedict RHB, 2008, MULT SCLER J, V14, P940, DOI 10.1177/1352458508090923; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Bouilleret V, 2009, J NEUROTRAUM, V26, P1999, DOI 10.1089/neu.2009.0943; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Caeyenberghs K, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00726; Caeyenberghs K, 2012, BRAIN, V135, P1293, DOI 10.1093/brain/aws048; Calhoun VD, 2001, HUM BRAIN MAPP, V13, P43, DOI 10.1002/hbm.1024; Calhoun VD, 2001, HUM BRAIN MAPP, V14, P140, DOI 10.1002/hbm.1048; Calhoun Vince D, 1800, IEEE Rev Biomed Eng, V5, P60, DOI 10.1109/RBME.2012.2211076; Calhoun VD, 2009, NEUROIMAGE, V45, pS163, DOI 10.1016/j.neuroimage.2008.10.057; Castellanos NP, 2011, NEUROIMAGE, V55, P1189, DOI 10.1016/j.neuroimage.2010.12.046; Castellanos NP, 2010, BRAIN, V133, P2365, DOI 10.1093/brain/awq174; Cayley A, 1875, BER DTSCH CHEM GES, V8, P1056; Cole MW, 2010, NEUROIMAGE, V49, P3132, DOI 10.1016/j.neuroimage.2009.11.001; Craig AD, 2009, NAT REV NEUROSCI, V10, P59, DOI 10.1038/nrn2555; DeLuca J, 2000, ARCH PHYS MED REHAB, V81, P1327, DOI 10.1053/apmr.2000.9390; Di Perri C, 2013, NEUROLOGY, V81, P1417, DOI 10.1212/WNL.0b013e3182a43b78; Du Y, 2014, P ORG HUM BRAIN MAPP; English SW, 2013, NEUROCRIT CARE, V18, P131, DOI 10.1007/s12028-012-9748-3; Erhardt EB, 2011, HUM BRAIN MAPP, V32, P2075, DOI 10.1002/hbm.21170; Fujiwara E, 2008, NEUROPSYCHOLOGIA, V46, P461, DOI 10.1016/j.neuropsychologia.2007.08.027; GAZZANIGA MS, 1984, BRAIN, V107, P145, DOI 10.1093/brain/107.1.145; GAZZANIGA MS, 1979, BRAIN, V102, P805, DOI 10.1093/brain/102.4.805; Harriger L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046497; Hilgetag CC, 2000, PHILOS T ROY SOC B, V355, P91, DOI 10.1098/rstb.2000.0551; Hillary FG, 2007, CLIN NEUROPSYCHOL, V21, P58, DOI 10.1080/13854040601064542; Hillary FG, 2011, INT J PSYCHOPHYSIOL, V82, P115, DOI 10.1016/j.ijpsycho.2011.03.011; Hillary FG, 2014, NEUROPSYCHOLOGY; Hillary FG, 2008, J INT NEUROPSYCH SOC, V14, P526, DOI 10.1017/S1355617708080788; Hillary FG, 2006, HUM BRAIN MAPP, V27, P837, DOI 10.1002/hbm.20226; Hillary FG, 2011, BRAIN, V134, P1555, DOI 10.1093/brain/awr043; Hillary FG, 2010, BRAIN IMAGING BEHAV, V4, P141, DOI 10.1007/s11682-010-9094-z; JENSEN AR, 1966, ACTA PSYCHOL, V25, P36, DOI 10.1016/0001-6918(66)90004-7; Jimenez N, 2013, PEDIATRICS, V131, pE1850, DOI 10.1542/peds.2012-3354; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Jourdan C, 2013, BRAIN INJURY, V27, P1000, DOI 10.3109/02699052.2013.794971; Kelly RE, 2010, J NEUROSCI METH, V189, P233, DOI 10.1016/j.jneumeth.2010.03.028; KIRCHNER WK, 1958, J EXP PSYCHOL, V55, P352, DOI 10.1037/h0043688; Kiviniemi V, 2009, HUM BRAIN MAPP, V30, P3865, DOI 10.1002/hbm.20813; Kouloulas EJ, 2013, INT J REHABIL RES, V36, P260, DOI 10.1097/MRR.0b013e32835fd99a; Leech R, 2012, J NEUROSCI, V32, P215, DOI 10.1523/JNEUROSCI.3689-11.2012; Liang X, 2013, P NATL ACAD SCI USA, V110, P1929, DOI 10.1073/pnas.1214900110; Lin QH, 2010, HUM BRAIN MAPP, V31, P1076, DOI 10.1002/hbm.20919; Liu YR, 2010, J NUCL MED, V51, P1788, DOI 10.2967/jnumed.110.078626; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Mantini D, 2011, J NEUROSCI, V31, P12954, DOI 10.1523/JNEUROSCI.2318-11.2011; Mazaika P K., 2009, HUMAN BRAIN MAPPING; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McCauley SR, 2013, J NEUROTRAUM, V30, P1506, DOI 10.1089/neu.2013.2925; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Medaglia JD, 2012, HUM BRAIN MAPP, V33, P979, DOI 10.1002/hbm.21264; Micheloyannis S, 2006, NEUROSCI LETT, V402, P273, DOI 10.1016/j.neulet.2006.04.006; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Palacios EM, 2013, JAMA NEUROL, P1; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Pouratian Nader, 2003, Neurosurg Focus, V15, pE2; Radford K, 2013, BRAIN INJURY, V27, P507, DOI 10.3109/02699052.2013.766929; Reitan R, 1985, HALSTEAD REITAN NEUR; Scott J., 2000, SOCIAL NETWORK ANAL; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Sheline YI, 2013, BIOL PSYCHIAT, V74, P340, DOI 10.1016/j.biopsych.2012.11.028; Shimamura M, 2005, NEUROSCIENCE, V131, P87, DOI 10.1016/j.neuroscience.2004.10.041; Shultz SR, 2013, EPILEPSIA, V54, P1240, DOI 10.1111/epi.12223; Sidlauskaite J, 2014, NEUROIMAGE; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Sporns O, 2011, ANN NY ACAD SCI, V1224, P109, DOI 10.1111/j.1749-6632.2010.05888.x; Stam CJ, 2007, CEREB CORTEX, V17, P92, DOI 10.1093/cercor/bhj127; Stam CJ, 2004, NEUROSCI LETT, V355, P25, DOI 10.1016/j.neulet.2003.10.063; Stibick DL, 2001, J NEUROTRAUM, V18, P303, DOI 10.1089/08977150151070955; Strigel RM, 2005, AM J NEURORADIOL, V26, P578; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Sylvester J, 1878, NATURE, V17, P284, DOI [10.1038/017284a0, DOI 10.1038/017284A0]; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; TEASDALE G, 1974, LANCET, V2, P81; Trenerry MR, 1989, PROFESSIONAL MANUAL; Turner GR, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00009; Vakhtin AA, 2013, BRAIN INJURY, V27, P1304, DOI 10.3109/02699052.2013.823561; van den Heuvel MP, 2012, P NATL ACAD SCI USA, V109, P11372, DOI 10.1073/pnas.1203593109; Vul E, 2012, NEUROIMAGE, V62, P945, DOI 10.1016/j.neuroimage.2012.01.027; Walker WC, 2013, CEPHALALGIA, V33, P998, DOI 10.1177/0333102413482197; Wechsler D, 1997, ADM SCORING MANUAL; Wu HM, 2004, NEUROSURGERY, V55, P1306, DOI 10.1227/01.NEU.0000143028.08719.42; Xu JS, 2013, NEUROIMAGE, V79, P62, DOI 10.1016/j.neuroimage.2013.04.038; Ystad Martin A, 2009, BMC Med Imaging, V9, P17, DOI 10.1186/1471-2342-9-17; Yu QB, 2013, SCHIZOPHR RES, V143, P165, DOI 10.1016/j.schres.2012.11.001; Yu QB, 2011, FRONT SYST NEUROSCI, V5, DOI [10.3389/fnsys.2011.00007, 10.3389/fnsys.2011.00103]	97	81	81	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2014	9	8							e104021	10.1371/journal.pone.0104021			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AO0QT	WOS:000341017000024	25121760	Green Published, Green Submitted, gold			2022-02-06	
J	Depreitere, B; Guiza, F; Van den Berghe, G; Schuhmann, MU; Maier, G; Piper, I; Meyfroidt, G				Depreitere, Bart; Gueiza, Fabian; Van den Berghe, Greet; Schuhmann, Martin U.; Maier, Gottlieb; Piper, Ian; Meyfroidt, Geert			Pressure autoregulation monitoring and cerebral perfusion pressure target recommendation in patients with severe traumatic brain injury based on minute-by-minute monitoring data Clinical article	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; cerebral perfusion pressure; autoregulation; intracranial pressure	CEREBROVASCULAR AUTOREGULATION; INTRACRANIAL-PRESSURE; REACTIVITY; VALIDATION	Object. In severe traumatic brain injury, a universal target for cerebral perfusion pressure (CPP) has been abandoned. Attempts to identify a dynamic CPP target based on the patient's cerebrovascular autoregulatory capacity have been promising so far. Bedside monitoring of pressure autoregulatory capacity has become possible by a number of methods, Czosnyka's pressure reactivity index (PRx) being the most frequently used. The PRx is calculated as the moving correlation coefficient between 40 consecutive 5-second averages of intracranial pressure (ICP) and mean arterial blood pressure (MABP) values. Plotting PRx against CPP produces a U-shaped curve in roughly two-thirds of monitoring time, with the bottom of this curve representing a CPP range corresponding with optimal autoregulatory capacity (CPPopt). In retrospective series, keeping CPP close to CPPopt corresponded with better outcomes. Monitoring of PRx requires high-frequency signal processing. The aim of the present study is to investigate how the processing of the information on cerebrovascular pressure reactivity that can be obtained from routine minute-by-minute ICP and MABP data can be enhanced to enable CPPopt recommendations that do not differ from those obtained by the PRx method, show the same associations with outcome, and can be generated in more than two-thirds of monitoring time. Methods. The low-frequency autoregulation index (LAx) was defined as the moving minute-by-minute ICP/MABP correlation coefficient calculated over time intervals varying from 3 to 120 minutes. The CPPopt calculation was based on LAx-CPP plots and done for time windows between 1 and 24 hours and for each LAx type. The resulting matrix of CPPopts were then averaged in a weighted manner, with the weight based on the goodness of fit of a U-shape and the lower value of the LAx corresponding to the U-bottom, to result in a final CPPopt recommendation. The association between actual CPP/CPPopt and outcome was assessed in the multicenter Brain Monitoring with Information Technology Research Group (BrainIT) database (n = 180). In the Leuven-Tubingen database (60-Hz waveform data, n = 21), LAx- and PRx-based CPPopts were compared. Results. In the BrainIT database, CPPopt recommendations were generated in 95% of monitoring time. Actual CPP being close to LAx-based CPPopt was associated with increased survival. In a multivariate model using the Corticosteroid Randomization After Significant Head Injury (CRASH) model as covariates, the average absolute difference between actual CPP and CPPopt was independently associated with increased mortality. In the high-frequency data set no significant difference was observed between PRx-based and LAx-based CPPopts. The new method issued a CPPopt recommendation in 97% of monitoring time, as opposed to 44% for PRx-based CPPopt. Conclusions. Minute-by-minute ICP/MABP data contain relevant information for autoregulation monitoring. In this study, the authors' new method based on minute-by-minute data resolution allowed for CPPopt calculation in nearly the entire monitoring time. This will facilitate the use of pressure reactivity monitoring in all ICUs.	[Depreitere, Bart; Gueiza, Fabian; Van den Berghe, Greet; Meyfroidt, Geert] Univ Hosp Leuven, B-3000 Louvain, Belgium; [Schuhmann, Martin U.; Maier, Gottlieb] Univ Klinikum Tubingen, Neurochirurg Klin, Tubingen, Germany; [Piper, Ian] So Gen Hosp, Glasgow G51 4TF, Lanark, Scotland		Depreitere, B (corresponding author), Univ Hosp Leuven, Herestr 49, B-3000 Louvain, Belgium.	bart.depreitere@uzleuven.be	Depreitere, Bart/AAA-9846-2020; Van den Berghe, Greet/J-6788-2018	Depreitere, Bart/0000-0002-7458-0648; Van den Berghe, Greet/0000-0002-5320-1362; Guiza, Fabian/0000-0001-7026-0957	Foundation for Scientific Research Flanders (Fonds voor Wetenschappelijk Onderzoek Vlaanderen, FWO) [G. 0904.11]; FWOFWO [1846113N]; Flemish GovernmentEuropean Commission [METH/08/07]; European Framework Programma [FP5-QLRI-2000-00454, QLG-2002-00160, FP7-IST-2007-217049]	The present study was supported by the Foundation for Scientific Research Flanders (Fonds voor Wetenschappelijk Onderzoek Vlaanderen, FWO) (Research project G. 0904.11). Geert Meyfroidt receives funding from FWO as senior clinical investigator (1846113N). Greet Van den Berghe receives long-term structural research financing via the Methusalem program funded by the Flemish Government (METH/08/07). BrainIT data collection was supported by The European Framework Programma (FP5-QLRI-2000-00454, QLG-2002-00160, and FP7-IST-2007-217049). The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.	AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; Guiza F, 2013, CRIT CARE MED, V41, P554, DOI 10.1097/CCM.0b013e3182742d0a; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Jaeger M, 2006, CRIT CARE MED, V34, P1783, DOI 10.1097/01.CCM.0000218413.51546.9E; Johnson U, 2011, NEUROSURGERY, V68, P714, DOI 10.1227/NEU.0b013e3182077313; Kellie George, 1824, Trans Med Chir Soc Edinb, V1, P84; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; Lodi CA, 1998, AM J PHYSIOL-HEART C, V274, pH1729, DOI 10.1152/ajpheart.1998.274.5.H1729; Monro A., 1783, OBSERVATIONS STRUCTU; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Piper I, 2003, ACTA NEUROCHIR, V145, P615, DOI 10.1007/s00701-003-0066-6; Ragauskas A, 2005, ACTA NEUROCHIR SUPPL, V95, P367; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; Santos E, 2011, ACTA NEUROCHIR, V153, P2189, DOI 10.1007/s00701-011-1148-5; Shaw M, 2008, ACTA NEUROCHIR SUPPL, V102, P217, DOI 10.1007/978-3-211-85578-2_42; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Sviri GE, 2009, J NEUROSURG, V111, P695, DOI 10.3171/2008.10.17686; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; Ursino M, 2010, ANN BIOMED ENG, V38, P955, DOI 10.1007/s10439-010-9923-7; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	27	81	83	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	2014	120	6					1451	1457		10.3171/2014.3.JNS131500			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	AH7ZA	WOS:000336352700022	24745709				2022-02-06	
J	Morey, RA; Haswell, CC; Selgrade, ES; Massoglia, D; Liu, CL; Weiner, J; Marx, CE; Cernak, I; McCarthy, G				Morey, Rajendra A.; Haswell, Courtney C.; Selgrade, Elizabeth S.; Massoglia, Dino; Liu, Chunlei; Weiner, Jonathan; Marx, Christine E.; Cernak, Ibolja; McCarthy, Gregory		MIRECC Work Grp	Effects of Chronic Mild Traumatic Brain Injury on White Matter Integrity in Iraq and Afghanistan War Veterans	HUMAN BRAIN MAPPING			English	Article						mild traumatic brain injury; high angular resolution diffusion imaging; white matter; crossing fibers; posttraumatic stress disorder	POSTTRAUMATIC-STRESS-DISORDER; MULTIPLE FIBER ORIENTATIONS; DIFFUSION-TENSOR; COGNITIVE IMPAIRMENT; AXONAL INJURY; OUTCOMES; TESTS; ABNORMALITIES; UNCERTAINTY; DEPENDENCE	Mild traumatic brain injury (TBI) is a common source of morbidity from the wars in Iraq and Afghanistan. With no overt lesions on structural MRI, diagnosis of chronic mild TBI in military veterans relies on obtaining an accurate history and assessment of behavioral symptoms that are also associated with frequent comorbid disorders, particularly posttraumatic stress disorder (PTSD) and depression. Military veterans from Iraq and Afghanistan with mild TBI (n = 30) with comorbid PTSD and depression and non-TBI participants from primary (n = 42) and confirmatory (n = 28) control groups were assessed with high angular resolution diffusion imaging (HARDI). White matter-specific registration followed by whole-brain voxelwise analysis of crossing fibers provided separate partial volume fractions reflecting the integrity of primary fibers and secondary (crossing) fibers. Loss of white matter integrity in primary fibers (P < 0.05; corrected) was associated with chronic mild TBI in a widely distributed pattern of major fiber bundles and smaller peripheral tracts including the corpus callosum (genu, body, and splenium), forceps minor, forceps major, superior and posterior corona radiata, internal capsule, superior longitudinal fasciculus, and others. Distributed loss of white matter integrity correlated with duration of loss of consciousness and most notably with feeling dazed or confused, but not diagnosis of PTSD or depressive symptoms. This widespread spatial extent of white matter damage has typically been reported in moderate to severe TBI. The diffuse loss of white matter integrity appears consistent with systemic mechanisms of damage shared by blast- and impact-related mild TBI that involves a cascade of inflammatory and neurochemical events. Hum Brain Mapp 34:2986-2999, 2013. (c) 2012 Wiley Periodicals, Inc.	[Morey, Rajendra A.; Haswell, Courtney C.; Selgrade, Elizabeth S.; Liu, Chunlei] Duke Univ, Med Ctr, Duke UNC Brain Imaging & Anal Ctr, Durham, NC USA; [Morey, Rajendra A.; Marx, Christine E.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA; [Morey, Rajendra A.; Haswell, Courtney C.; Selgrade, Elizabeth S.; Weiner, Jonathan; Marx, Christine E.; McCarthy, Gregory] Durham VA Med Ctr, Mental Illness Res Educ & Clin Ctr Post Deploymen, Durham, NC 27705 USA; [Massoglia, Dino] Duke Univ, Med Ctr, Div Neuroradiol, Durham, NC USA; [Cernak, Ibolja] Johns Hopkins Univ, Appl Phys Lab, Natl Secur Technol Dept, Laurel, MD USA; [McCarthy, Gregory] Yale Univ, Dept Psychol, New Haven, CT 06520 USA		Morey, RA (corresponding author), Durham VA Med Ctr, 508 Fulton St,Bldg 5, Durham, NC 27705 USA.	morey@biac.duke.edu	Morey, Rajendra A/P-3079-2018	Morey, Rajendra A/0000-0002-6517-6969; Ibolja, Cernak/0000-0003-3214-698X; Liu, Chunlei/0000-0001-8816-4832	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23 MH073091]; Department of Veterans Affairs, Mental Illness Research Education and Clinical Center Grant for Post-Deployment Mental Health; Department of Veterans Health Affairs, from Rehabilitation Research and Development (RRD) [RX000389-01]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R00EB007182] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH073091] Funding Source: NIH RePORTER	Contract grant sponsor: National Institutes of Health; Contract grant number: K23 MH073091; Contract grant sponsor: Department of Veterans Affairs, Mental Illness Research Education and Clinical Center Grant for Post-Deployment Mental Health; Contract grant sponsor: Department of Veterans Health Affairs, from Rehabilitation Research and Development (RR & D); Contract grant number: RX000389-01.	ABOITIZ F, 1992, BRAIN RES, V598, P143, DOI 10.1016/0006-8993(92)90178-C; Anderson MJ, 2001, AUST NZ J STAT, V43, P75, DOI 10.1111/1467-842X.00156; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Dedert EA, 2009, J PSYCHIATR RES, V43, P830, DOI 10.1016/j.jpsychires.2009.01.004; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Hayes JP, 2011, NEUROCASE; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hosey T, 2005, MAGN RESON MED, V54, P1480, DOI 10.1002/mrm.20723; Hsu JL, 2008, NEUROIMAGE, V39, P566, DOI 10.1016/j.neuroimage.2007.09.017; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Ivins BJ, 2003, J TRAUMA, V55, P617, DOI 10.1097/01.TA.0000052368.97573.D4; Jbabdi S, 2010, NEUROIMAGE, V49, P247, DOI 10.1016/j.neuroimage.2009.08.039; Jones DK, 2003, MAGN RESON MED, V49, P7, DOI 10.1002/mrm.10331; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.0.CO;2-Q; Kanaan R, 2009, BRIT J PSYCHIAT, V194, P236, DOI 10.1192/bjp.bp.108.054320; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KENNEDY PE, 1995, J BUS ECON STAT, V13, P85, DOI 10.2307/1392523; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Madden DJ, 2004, NEUROIMAGE, V21, P1174, DOI 10.1016/j.neuroimage.2003.11.004; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Moore DF, 2009, 6 ANN WORLD C BRAIN; Mori S, 2005, MRI ATLAS HUMAN WHIT; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P1390, DOI 10.1176/appi.ajp.161.8.1390; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Scholz J, 2009, NAT NEUROSCI, V12, P1370, DOI 10.1038/nn.2412; Schuff N, 2011, NEUROIMAGE, V54, pS62, DOI 10.1016/j.neuroimage.2010.05.024; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Sponheim S, 2011, NEUROIMAGE IN PRESS; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tuch DS, 2002, MAGNET RESON MED, V48, P577, DOI 10.1002/mrm.10268; Versace A, 2008, ARCH GEN PSYCHIAT, V65, P1041, DOI 10.1001/archpsyc.65.9.1041; Weber JT, 2007, PROG BRAIN RES, V161, P253, DOI 10.1016/S0079-6123(06)61018-2; Xu JS, 2010, NEUROPSYCHOPHARMACOL, V35, P1541, DOI 10.1038/npp.2010.25; Yang FPG, 2011, P INT SOC MAGN RES I; Yeh PH, 2009, PSYCHIAT RES-NEUROIM, V173, P22, DOI 10.1016/j.pscychresns.2008.07.012; Zhuang L, 2010, NEUROIMAGE, V53, P16, DOI 10.1016/j.neuroimage.2010.05.068	61	81	81	0	33	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	NOV	2013	34	11					2986	2999		10.1002/hbm.22117			14	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	295FG	WOS:000330101400020	22706988	Green Accepted, Green Published, Green Submitted			2022-02-06	
J	Tanaka, Y; Matsuwaki, T; Yamanouchi, K; Nishihara, M				Tanaka, Y.; Matsuwaki, T.; Yamanouchi, K.; Nishihara, M.			INCREASED LYSOSOMAL BIOGENESIS IN ACTIVATED MICROGLIA AND EXACERBATED NEURONAL DAMAGE AFTER TRAUMATIC BRAIN INJURY IN PROGRANULIN-DEFICIENT MICE	NEUROSCIENCE			English	Article						progranulin; traumatic brain injury; microglia; lysosome	FRONTOTEMPORAL LOBAR DEGENERATION; HOST-DEFENSE; GRANULIN; PROTEIN; GENE; PRECURSOR; INFLAMMATION; MODEL; NEURODEGENERATION; NEUROPROTECTION	Progranulin (PGRN) is known to play a role in the pathogenesis of neurodegenerative diseases. Recently, it has been demonstrated that patients with the homozygous mutation in the GRN gene present with neuronal ceroid lipofuscinosis, and there is growing evidence that PGRN is related to lysosomal function. In the present study, we investigated the possible role of PGRN in the lysosomes of activated microglia in the cerebral cortex after traumatic brain injury (TBI). We showed that the mouse GRN gene has two possible coordinated lysosomal expression and regulation (CLEAR) sequences that bind to transcription factor EB (TFEB), a master regulator of lysosomal genes. PGRN was colocalized with Lamp1, a lysosomal marker, and Lamp1-positive areas in GRN-deficient (KO) mice were significantly expanded compared with wild-type (WT) mice after TBI. Expression of all the lysosome-related genes examined in KO mice was significantly higher than that in WT mice. The number of activated microglia with TFEB localized to the nucleus was also significantly increased in KO as compared with WT mice. Since the TFEB translocation is regulated by the mammalian target of rapamycin complex 1 (mTORC1) activity in the lysosome, we compared ribosomal S6 kinase 1 (S6K1) phosphorylation that reflects mTORC1 activity. S6K1 phosphorylation in KO mice was significantly lower than that in WT mice. In addition, the number of nissl-positive and fluoro-jade B-positive cells around the injury was significantly decreased and increased, respectively, in KO as compared with WT mice. These results suggest that PGRN localized in the lysosome is involved in the activation of mTORC1, and its deficiency leads to increased TFEB nuclear translocation with a resultant increase in lysosomal biogenesis in activated microglia and exacerbated neuronal damage in the cerebral cortex after TBI. (c) 2013 IBRO. Published by Elsevier Ltd. All rights reserved.	[Tanaka, Y.; Matsuwaki, T.; Yamanouchi, K.; Nishihara, M.] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Physiol, Bunkyo Ku, Tokyo 1138657, Japan		Nishihara, M (corresponding author), Grad Sch Agr & Life Sci, Dept Vet Physiol, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	amnishi@mail.ecc.u-tokyo.ac.jp	Yamanouchi, Keitaro/R-5003-2019	Tanaka, Yoshinori/0000-0003-1428-0683	JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [23228004, 24-7548]	This work was supported in part by JSPS KAKENHI Grant Number 23228004 to MN, and 24-7548 to YT	Ahmed Z, 2010, AM J PATHOL, V177, P311, DOI 10.2353/ajpath.2010.090915; Arai T, 2006, BIOCHEM BIOPH RES CO, V351, P602, DOI 10.1016/j.bbrc.2006.10.093; Asakura R, 2011, NEUROREPORT, V22, P881, DOI 10.1097/WNR.0b013e32834bf4ca; BABA T, 1993, MOL REPROD DEV, V34, P233, DOI 10.1002/mrd.1080340302; Baker M, 2006, NATURE, V442, P916, DOI 10.1038/nature05016; Barrachina M, 2006, NEUROPATH APPL NEURO, V32, P505, DOI 10.1111/j.1365-2990.2006.00756.x; Bateman A, 2009, BIOESSAYS, V31, P1245, DOI 10.1002/bies.200900086; BHANDARI V, 1992, P NATL ACAD SCI USA, V89, P1715, DOI 10.1073/pnas.89.5.1715; Brouwers N, 2008, NEUROLOGY, V71, P656, DOI 10.1212/01.wnl.0000319688.89790.7a; Carecchio M, 2009, J NEUROL SCI, V287, P291, DOI 10.1016/j.jns.2009.07.011; Ceccariglia S, 2011, NEUROSCIENCE, V174, P160, DOI 10.1016/j.neuroscience.2010.11.024; Cenik B, 2012, J BIOL CHEM, V287, P32298, DOI 10.1074/jbc.R112.399170; Chen HJ, 2012, REV NEUROSCIENCE, V23, P279, DOI 10.1515/revneuro-2012-0001; Chiba S, 2007, J REPROD DEVELOP, V53, P297, DOI 10.1262/jrd.18108; Conus S, 2008, BIOCHEM PHARMACOL, V76, P1374, DOI 10.1016/j.bcp.2008.07.041; Cortini F, 2008, EUR J NEUROL, V15, P1111, DOI 10.1111/j.1468-1331.2008.02266.x; Cruts M, 2006, NATURE, V442, P920, DOI 10.1038/nature05017; Daniel R, 2000, J HISTOCHEM CYTOCHEM, V48, P999, DOI 10.1177/002215540004800713; Daniel R, 2003, DEV DYNAM, V227, P593, DOI 10.1002/dvdy.10341; Ghoshal N, 2012, NEUROBIOL DIS, V45, P395, DOI 10.1016/j.nbd.2011.08.029; Hadano S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009805; Hiesberger T, 1998, EMBO J, V17, P4617, DOI 10.1093/emboj/17.16.4617; Hu FH, 2010, NEURON, V68, P654, DOI 10.1016/j.neuron.2010.09.034; Jalanko A, 2009, BBA-MOL CELL RES, V1793, P697, DOI 10.1016/j.bbamcr.2008.11.004; Kayasuga Y, 2007, BEHAV BRAIN RES, V185, P110, DOI 10.1016/j.bbr.2007.07.020; Kessenbrock K, 2008, J CLIN INVEST, V118, P2438, DOI 10.1172/JCI34694; Khurana V, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001026; Kim S, 2007, J NEUROCHEM, V103, P2640, DOI 10.1111/j.1471-4159.2007.04995.x; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Leibinger M, 2012, NEUROBIOL DIS, V46, P314, DOI 10.1016/j.nbd.2012.01.004; Malik M, 2011, NEUROCHEM RES, V36, P754, DOI 10.1007/s11064-010-0395-9; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; McCormack R, 2013, J INNATE IMMUN, V5, P185, DOI 10.1159/000345249; Murray PD, 1998, J NEUROSCI, V18, P7306; Nedachi T, 2011, NEUROSCIENCE, V185, P106, DOI 10.1016/j.neuroscience.2011.04.037; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; Ohmi K, 2003, P NATL ACAD SCI USA, V100, P1902, DOI 10.1073/pnas.252784899; Palmieri M, 2011, HUM MOL GENET, V20, P3852, DOI 10.1093/hmg/ddr306; Park B, 2011, IMMUNITY, V34, P505, DOI 10.1016/j.immuni.2011.01.018; Pena-Llopis S, 2011, CELL CYCLE, V10, P3987, DOI 10.4161/cc.10.23.18251; Petkau TL, 2010, J COMP NEUROL, V518, P3931, DOI 10.1002/cne.22430; Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Selvaraj S, 2012, J CLIN INVEST, V122, P1354, DOI 10.1172/JCI61332; Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32; Sleegers K, 2008, NEUROLOGY, V71, P253, DOI 10.1212/01.wnl.0000289191.54852.75; Smith KR, 2012, AM J HUM GENET, V90, P1102, DOI 10.1016/j.ajhg.2012.04.021; Song L, 2011, J LIPID RES, V52, P1542, DOI 10.1194/jlr.M015412; Surace MJ, 2012, CELL MOL LIFE SCI, V69, P2409, DOI 10.1007/s00018-012-1015-4; Suzuki M, 1998, NEUROSCI LETT, V242, P127, DOI 10.1016/S0304-3940(98)00008-1; Tanaka Y, 2013, NEUROSCIENCE, V231, P49, DOI 10.1016/j.neuroscience.2012.11.032; Tao J, 2012, BRAIN RES, V1436, P130, DOI 10.1016/j.brainres.2011.11.063; Thurner L, 2013, J AUTOIMMUN, V42, P29, DOI 10.1016/j.jaut.2012.10.003; Veerhuis R, 2011, MOL IMMUNOL, V48, P1592, DOI 10.1016/j.molimm.2011.04.003; Wang IF, 2012, P NATL ACAD SCI USA, V109, P15024, DOI 10.1073/pnas.1206362109; Wils H, 2012, J PATHOL, V228, P67, DOI 10.1002/path.4043; Xu J, 2011, IET SIGNAL PROCESS, V5, P16, DOI 10.1049/iet-spr.2009.0284; Yin FF, 2010, J EXP MED, V207, P117, DOI 10.1084/jem.20091568; You ZR, 2007, J CEREBR BLOOD F MET, V27, P1954, DOI 10.1038/sj.jcbfm.9600497; Zhu J, 2002, CELL, V111, P867, DOI 10.1016/S0092-8674(02)01141-8	61	81	82	0	12	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	OCT 10	2013	250						8	19		10.1016/j.neuroscience.2013.06.049			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	223YC	WOS:000324847400002	23830905				2022-02-06	
J	Bramoweth, AD; Germain, A				Bramoweth, Adam D.; Germain, Anne			Deployment-Related Insomnia in Military Personnel and Veterans	CURRENT PSYCHIATRY REPORTS			English	Article						Insomnia; Comorbid insomnia; Military personnel; Veterans; PTSD; Depression; Anxiety; Traumatic brain injury; Suicide; Psychotherapy; Pharmacotherapy; Sleep disorders; Psychiatry	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; BRIEF BEHAVIORAL TREATMENT; ADVERSE CHILDHOOD EXPERIENCES; SLEEP DISTURBANCES; COMBAT VETERANS; CHRONIC NIGHTMARES; SERVICE MEMBERS; DEPRESSION; IRAQ	Insomnia is a prevalent disorder that greatly impacts military personnel, especially those deployed in support of combat efforts. Deployment-related stressors like combat exposure, mild traumatic brain injury (mTBI) irregular sleep-wake schedules, and adjustment to the return home all contribute to insomnia. However, insomnia can also exacerbate the deployment experience and is a risk factor for traumatic stress reactions such as PTSD, depression, and suicide. Military personnel with mTBI are significantly impacted by insomnia; the majority experience sleep disruption and this can impede recovery and rehabilitation. As more service members return home from deployment, treatment is vital to reduce the impact of insomnia. Preliminary outcome data, showing positive results for reduction of sleep disruption, has been found with treatments such as combined cognitive behavioral treatment of insomnia (CBTI) and imagery rehearsal therapy (IRT), preference-based interventions, as well as efforts to broadly disseminate CBTI. The recent literature on the impact and treatment of deployment-related insomnia is reviewed.	[Bramoweth, Adam D.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA 15206 USA; [Bramoweth, Adam D.; Germain, Anne] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA; [Germain, Anne] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA		Germain, A (corresponding author), Univ Pittsburgh, Sch Med, Dept Psychiat, 3811 OHara St,Sterling Plaza 239, Pittsburgh, PA 15213 USA.	adam.bramoweth@va.gov; germax@upmc.edu	Bramoweth, Adam/ABB-6789-2020	Bramoweth, Adam/0000-0002-3535-0292	VISN 4 Mental Illness Research, Education and Clinical Center (MIRECC), VA Pittsburgh Healthcare System; Congressionally Directed Medical Research ProgramUnited States Department of Defense [PT073961 W81XWH-08-1-0637, PR054093-W81XWH-07-PTSD-IIRA]; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH080696]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R34MH080696] Funding Source: NIH RePORTER	Dr. Bramoweth's work is supported by resources and funding from the VISN 4 Mental Illness Research, Education and Clinical Center (MIRECC, Director: D. Oslin; Pittsburgh Site Director: G. Haas), VA Pittsburgh Healthcare System. Dr. Germain's work is supported by the Congressionally Directed Medical Research Program (PT073961 W81XWH-08-1-0637; PR054093-W81XWH-07-PTSD-IIRA) and the National Institute of Mental Health (MH080696). The contents do not represent the views of the Department of Veterans Affairs, Department of Defense, or the United States Government.	Agargun MY, 1997, J CLIN PSYCHIAT, V58, P249; Baglioni C, 2011, J AFFECT DISORDERS, V135, P10, DOI 10.1016/j.jad.2011.01.011; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Bernert RA, 2005, SLEEP, V28, P1135, DOI 10.1093/sleep/28.9.1135; Bootzin RR, 1972, P AM PSYCHOL ASS, V7, P395; Bryan CJ, 2013, SLEEP, V36, P941, DOI 10.5665/sleep.2730; Bryan CJ, 2010, MIL MED, V175, P713, DOI 10.7205/MILMED-D-09-00248; Bryant RA, 2010, SLEEP, V33, P69, DOI 10.1093/sleep/33.1.69; Buysse DJ, 2011, ARCH INTERN MED, V171, P887, DOI 10.1001/archinternmed.2010.535; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Collen J, 2012, CHEST, V142, P622, DOI 10.1378/chest.11-1603; Cozza S. J., 2004, IRAQ WAR CLIN GUIDE; Edinger JD, 2001, SLEEP MED, V2, P493, DOI 10.1016/S1389-9457(01)00078-8; Epstein DR, 2013, REHABIL NURS, V38, P120, DOI 10.1002/rnj.67; Epstein DR, 2012, J REHABIL RES DEV, V49, P867, DOI 10.1682/JRRD.2011.06.0114; FAWCETT J, 1990, AM J PSYCHIAT, V147, P1189; Germain A, 2006, J CLIN SLEEP MED, V2, P403; Germain A, 2007, BEHAV RES THER, V45, P627, DOI 10.1016/j.brat.2006.04.009; Germain A, 2013, AM J PSYCHIAT, V170, P372, DOI 10.1176/appi.ajp.2012.12040432; Germain A, 2012, J PSYCHOSOM RES, V72, P89, DOI 10.1016/j.jpsychores.2011.11.010; Harvey AG, 2001, CLIN PSYCHOL REV, V21, P1037, DOI 10.1016/S0272-7358(00)00083-0; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hughes J, 2013, BEHAV SLEEP MED, V11, P258, DOI 10.1080/15402002.2012.683903; Insana SP, 2012, BIOL PSYCHOL, V89, P570, DOI 10.1016/j.biopsycho.2012.01.001; Karlin BE, 2013, J CONSULT CLIN PSYCH; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Kontos AP, 2013, J NEUROTRAUM, V30, P680, DOI 10.1089/neu.2012.2506; Koren D, 2002, AM J PSYCHIAT, V159, P855, DOI 10.1176/appi.ajp.159.5.855; KRAKOW B, 1995, BEHAV RES THER, V33, P837, DOI 10.1016/0005-7967(95)00009-M; Krakow B, 2001, JAMA-J AM MED ASSOC, V286, P537, DOI 10.1001/jama.286.5.537; Lande RG, 2013, COMPLEMENT THER MED, V21, P8, DOI 10.1016/j.ctim.2012.11.007; Lavie P, 2001, NEW ENGL J MED, V345, P1825, DOI 10.1056/NEJMra012893; LeardMann CA, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-437; Makley MJ, 2008, NEUROREHAB NEURAL RE, V22, P341, DOI 10.1177/1545968308315598; Manber R, 2012, J CLIN SLEEP MED, V8, P209, DOI 10.5664/jcsm.1786; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; McLay RN, 2010, MIL MED, V175, P759, DOI 10.7205/MILMED-D-10-00193; MELLMAN TA, 1995, AM J PSYCHIAT, V152, P1659; Nappi CM, 2010, BEHAV THER, V41, P237, DOI 10.1016/j.beth.2009.03.003; Neylan TC, 1998, AM J PSYCHIAT, V155, P929, DOI 10.1176/ajp.155.7.929; Ohayon MM, 2002, SLEEP MED REV, V6, P97, DOI 10.1053/smrv.2002.0186; Pigeon WR, 2012, AM J PUBLIC HEALTH, V102, pS93, DOI 10.2105/AJPH.2011.300470; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; Reissig CJ, 2009, DRUG ALCOHOL DEPEN, V99, P1, DOI 10.1016/j.drugalcdep.2008.08.001; Roane BM, 2008, SLEEP, V31, P1351; Roehrs T, 2008, SLEEP MED REV, V12, P153, DOI 10.1016/j.smrv.2007.07.004; Roth T, 2011, BIOL PSYCHIAT, V69, P592, DOI 10.1016/j.biopsych.2010.10.023; Sareen J, 2013, PSYCHOL MED, V43, P73, DOI 10.1017/S003329171200102X; Smith MT, 2004, SLEEP MED REV, V8, P119, DOI 10.1016/S1087-0792(03)00044-3; Spielman A., 1991, CASE STUDIES INSOMNI, P1, DOI DOI 10.1007/978-1-4757-9586-8_1; SPIELMAN AJ, 1987, SLEEP, V10, P45; Tanielian T, 2008, RAND CORPORATION MON; Taylor DJ, 2005, SLEEP, V28, P1457, DOI 10.1093/sleep/28.11.1457; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Toblin Robin L., 2012, Morbidity and Mortality Weekly Report, V61, P895; Troxel WM, 2012, BEHAV SLEEP MED, V10, P266, DOI 10.1080/15402002.2011.607200; Ulmer CS, 2011, J CLIN SLEEP MED, V7, P57; van Liempt S, 2013, DEPRESS ANXIETY, V30, P469, DOI 10.1002/da.22054; Wallace DM, 2011, SLEEP MED, V12, P850, DOI 10.1016/j.sleep.2011.06.004; Weathers F.W., 1993, PTSD CHECKLIST RELIA; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Worthington AD, 2006, BRAIN INJURY, V20, P327, DOI 10.1080/02699050500488249; Wright KM, 2011, J CLIN PSYCHOL, V67, P1240, DOI 10.1002/jclp.20845	65	81	83	0	21	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1523-3812			CURR PSYCHIAT REP	Curr. Psychiatry Rep.	OCT	2013	15	10							401	10.1007/s11920-013-0401-4			8	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	224JI	WOS:000324880100003	24005883	Green Accepted			2022-02-06	
J	Bryant, RA; O'Donnell, ML; Creamer, M; McFarlane, AC; Silove, D				Bryant, Richard A.; O'Donnell, Meaghan L.; Creamer, Mark; McFarlane, Alexander C.; Silove, Derrick			A Multisite Analysis of the Fluctuating Course of Posttraumatic Stress Disorder	JAMA PSYCHIATRY			English	Article							DELAYED-ONSET PTSD; MOTOR-VEHICLE ACCIDENTS; TRAUMATIC BRAIN-INJURY; FOLLOW-UP; CONDITIONED FEAR; IMMEDIATE-ONSET; HEART-RATE; EXTINCTION; PREDICTORS; SURVIVORS	IMPORTANCE Delayed-onset posttraumatic stress disorder (PTSD) accounts for approximately 25% of PTSD cases. Current models do not adequately explain the delayed increases in PTSD symptoms after trauma exposure. OBJECTIVE To test the roles of initial psychiatric reactions, mild traumatic brain injury (MTBI), and ongoing stressors on delayed-onset PTSD. DESIGN, SETTING, AND PARTICIPANTS In this prospective cohort study, patients were selected from recent admissions to 4 major trauma hospitals across Australia. A total of 1084 traumatically injured patients were assessed during hospital admission from April 1, 2004, through February 28, 2006, and 785 (72.4%) were followed up at 3, 12, and 24 months after injury. MAIN OUTCOME AND MEASURE Severity of PTSD was determined at each assessment with the Clinician-Administered PTSD Scale. RESULTS Of those who met PTSD criteria at 24 months, 44.1% reported no PTSD at 3 months and 55.9% had subsyndromal or full PTSD. In those who displayed subsyndromal or full PTSD at 3 months, PTSD severity at 24 months was predicted by prior psychiatric disorder, initial PTSD symptom severity, and type of injury. In those who displayed no PTSD at 3 months, PTSD severity at 24 months was predicted by initial PTSD symptom severity, MTBI, length of hospitalization, and the number of stressful events experienced between 3 and 24 months. CONCLUSIONS AND RELEVANCE These data highlight the complex trajectories of PTSD symptoms over time. This study also points to the roles of ongoing stress and MTBI in delayed cases of PTSD and suggests the potential of ongoing stress to compound initial stress reactions and lead to a delayed increase in PTSD symptom severity. This study also provides initial evidence that MTBI increases the risk of delayed PTSD symptoms, particularly in those with no acute symptoms.	[Bryant, Richard A.] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; [Bryant, Richard A.] Univ Sydney, Brain Dynam Ctr, Sydney, NSW, Australia; [Bryant, Richard A.] Westmead Millennium Inst, Sydney, NSW, Australia; [O'Donnell, Meaghan L.] Univ Melbourne, Australian Ctr Posttraumat Mental Hlth, Natl Trauma Res Inst, Dept Psychiat, Melbourne, Vic, Australia; [Creamer, Mark] Univ Melbourne, Australian Ctr Posttraumat Mental Hlth, Dept Psychiat, Melbourne, Vic, Australia; [McFarlane, Alexander C.] Ctr Mil & Veteran Hlth, Brisbane, Qld, Australia; [Silove, Derrick] Univ New S Wales, Sch Psychiat, Sydney, NSW 2052, Australia		Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	r.bryant@unsw.edu.au	Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X; O'Donnell, Meaghan/0000-0003-4349-0022	National Health and Medical Research Council ProgramNational Health and Medical Research Council of Australia [568970]; Victorian Trauma Foundation [V-11]; National Health and Medical Research Council Australian Clinical Research FellowshipNational Health and Medical Research Council of Australia [359284]	This research was supported by grant 568970 from the National Health and Medical Research Council Program (Drs Byrant, Silove, McFarlane, and Creamer), Victorian Trauma Foundation grant V-11 (Drs Creamer and O'Donnell), and National Health and Medical Research Council Australian Clinical Research Fellowship grant 359284 (Drs Creamer and O'Donnell).	American Psychiatric Association, 1994, DIAGNOSTIC AND STATI; Andrews B, 2007, AM J PSYCHIAT, V164, P1319, DOI 10.1176/appi.ajp.2007.06091491; Andrews B, 2009, J ABNORM PSYCHOL, V118, P767, DOI 10.1037/a0017203; [Anonymous], 2004, AM J PSYCHIAT, V161, P1321; Berninger A, 2010, AM J IND MED, V53, P1177, DOI 10.1002/ajim.20894; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Blanchard EB, 1996, BEHAV RES THER, V34, P775, DOI 10.1016/0005-7967(96)00038-1; Boscarino JA, 2009, SOC PSYCH PSYCH EPID, V44, P887, DOI 10.1007/s00127-009-0011-y; Bouton ME, 2004, LEARN MEMORY, V11, P485, DOI 10.1101/lm.78804; Bouton ME, 2002, BIOL PSYCHIAT, V52, P976, DOI 10.1016/S0006-3223(02)01546-9; BRESLAU N, 1995, AM J PSYCHIAT, V152, P529; Brewin CR, 2010, PSYCHOL REV, V117, P210, DOI 10.1037/a0018113; BRUGHA T, 1985, PSYCHOL MED, V15, P189, DOI 10.1017/S003329170002105X; Bryant RA, 2003, BIOL PSYCHIAT, V53, P789, DOI 10.1016/S0006-3223(02)01895-4; Bryant RA, 2002, AUST NZ J PSYCHIAT, V36, P205, DOI 10.1046/j.1440-1614.2002.01009.x; Bryant RA, 2008, ARCH GEN PSYCHIAT, V65, P659, DOI 10.1001/archpsyc.65.6.659; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Bryant RA, 2011, J CLIN PSYCHIAT, V72, P233, DOI 10.4088/JCP.09r05072blu; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Bryant RA, 2008, J CLIN PSYCHIAT, V69, P1694, DOI 10.4088/JCP.v69n1104; Buckley TC, 1996, J ABNORM PSYCHOL, V105, P617, DOI 10.1037/0021-843X.105.4.617; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Carty J, 2006, J AFFECT DISORDERS, V90, P257, DOI 10.1016/j.jad.2005.11.011; Clohessy S, 1999, BRIT J CLIN PSYCHOL, V38, P251, DOI 10.1348/014466599162836; Ehlers A, 2000, BEHAV RES THER, V38, P319, DOI 10.1016/S0005-7967(99)00123-0; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; Freedman SA, 1999, BRIT J PSYCHIAT, V174, P353, DOI 10.1192/bjp.174.4.353; Gillies ML, 2003, J TRAUMA STRESS, V16, P523, DOI 10.1023/A:1025774915005; Gray MJ, 2004, J CONSULT CLIN PSYCH, V72, P909, DOI 10.1037/0022-006X.72.5.909; GREEN MM, 1993, MED J AUSTRALIA, V159, P529, DOI 10.5694/j.1326-5377.1993.tb138006.x; Griffin MG, 2008, J TRAUMA STRESS, V21, P91, DOI 10.1002/jts.20300; Harvey AG, 2001, J TRAUMA STRESS, V14, P277, DOI 10.1023/A:1011108816888; Hermans D, 2005, BEHAV RES THER, V43, P533, DOI 10.1016/j.brat.2004.03.013; Hobfoll SE, 2006, J TRAUMA STRESS, V19, P867, DOI 10.1002/jts.20166; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Horesh D, 2011, SOC PSYCH PSYCH EPID, V46, P863, DOI 10.1007/s00127-010-0255-6; Kessler RC, 2008, MOL PSYCHIATR, V13, P374, DOI 10.1038/sj.mp.4002119; King DW, 1996, J CONSULT CLIN PSYCH, V64, P520, DOI 10.1037/0022-006X.64.3.520; LaBar KS, 2005, BEHAV NEUROSCI, V119, P677, DOI 10.1037/0735-7044.119.3.677; Mayou R, 1997, PSYCHOSOM MED, V59, P578, DOI 10.1097/00006842-199711000-00004; McFarlane AC, 2010, WORLD PSYCHIATRY, V9, P3; Milad MR, 2006, BIOL PSYCHOL, V73, P61, DOI 10.1016/j.biopsycho.2006.01.008; Monroe SM, 2008, ANNU REV CLIN PSYCHO, V4, P33, DOI 10.1146/annurev.clinpsy.4.022007.141207; Norrholm SD, 2006, LEARN MEMORY, V13, P681, DOI 10.1101/lm.393906; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Ruzich MJ, 2005, AM J GERIAT PSYCHIAT, V13, P424, DOI 10.1176/appi.ajgp.13.5.424; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Shalev AY, 1998, ARCH GEN PSYCHIAT, V55, P553, DOI 10.1001/archpsyc.55.6.553; Shalev AY, 2000, J CLIN PSYCHIAT, V61, P33; Shalev AY, 2000, AM J PSYCHIAT, V157, P255, DOI 10.1176/appi.ajp.157.2.255; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Smid GE, 2012, PSYCHOL MED, V42, P1675, DOI 10.1017/S0033291711002765; Smid GE, 2009, J CLIN PSYCHIAT, V70, P1572, DOI 10.4088/JCP.08r04484; SOLOMON Z, 1991, J COMMUNITY PSYCHOL, V19, P231, DOI 10.1002/1520-6629(199107)19:3<231::AID-JCOP2290190304>3.0.CO;2-C; SOLOMON Z, 1989, PSYCHIATRY, V52, P428, DOI 10.1080/00332747.1989.11024467; Stam R, 2007, NEUROSCI BIOBEHAV R, V31, P530, DOI 10.1016/j.neubiorev.2006.11.010; Stam R, 2007, NEUROSCI BIOBEHAV R, V31, P558, DOI 10.1016/j.neubiorev.2007.01.001; Tsai KY, 2007, J PSYCHIATR RES, V41, P90, DOI 10.1016/j.jpsychires.2005.10.004; Wolfe J, 1999, J CONSULT CLIN PSYCH, V67, P520, DOI 10.1037/0022-006X.67.4.520; Yehuda R, 1998, BIOL PSYCHIAT, V44, P1305, DOI 10.1016/S0006-3223(98)00276-5	60	81	81	0	31	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-622X	2168-6238		JAMA PSYCHIAT	JAMA Psychiatry	AUG	2013	70	8					839	846		10.1001/jamapsychiatry.2013.1137			8	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	197EW	WOS:000322833600010	23784521	Bronze			2022-02-06	
J	Resch, J; Driscoll, A; McCaffrey, N; Brown, C; Ferrara, MS; Macciocchi, S; Baumgartner, T; Walpert, K				Resch, Jacob; Driscoll, Aoife; McCaffrey, Noel; Brown, Cathleen; Ferrara, Michael S.; Macciocchi, Stephen; Baumgartner, Ted; Walpert, Kimberly			ImPact Test-Retest Reliability: Reliably Unreliable?	JOURNAL OF ATHLETIC TRAINING			English	Article						intraclass correlation; concussions; mild traumatic brain injuries; neuropsychological testing; athletes	INTERNATIONAL-CONFERENCE; AGREEMENT STATEMENT; CONCUSSION; SPORT; SENSITIVITY; MANAGEMENT	Context: Computerized neuropsychological testing is commonly used in the assessment and management of sport-related concussion. Even though computerized testing is widespread, psychometric evidence for test-retest reliability is somewhat limited. Additional evidence for test-retest reliability is needed to optimize clinical decision making after concussion. Objective: To document test-retest reliability for a commercially available computerized neuropsychological test battery (ImPACT) using 2 different clinically relevant time intervals. Design: Cross-sectional study. Setting: Two research laboratories. Patients or Other Participants: Group 1 (n = 46) consisted of 25 men and 21 women (age = 22.4 +/- 1.89 years). Group 2 (n = 45) consisted of 17 men and 28 women (age = 20.9 +/- 1.72 years). Intervention(s): Both groups completed ImPACT forms 1, 2, and 3, which were delivered sequentially either at 1-week intervals (group 1) or at baseline, day 45, and day 50 (group 2). Group 2 also completed the Green Word Memory Test (WMT) as a measure of effort. Main Outcome Measures: Intraclass correlation coefficients (ICCs) were calculated for the composite scores of ImPACT between time points. Repeated-measures analysis of variance was used to evaluate changes in ImPACT and WMT results over time. Results: The ICC values for group 1 ranged from 0.26 to 0.88 for the 4 ImPACT composite scores. The ICC values for group 2 ranged from 0.37 to 0.76. In group 1, ImPACT classified 37.0% and 46.0% of healthy participants as impaired at time points 2 and 3, respectively. In group 2, ImPACT classified 22.2% and 28.9% of healthy participants as impaired at time points 2 and 3, respectively. Conclusions: We found variable test-retest reliability for ImPACT metrics. Visual motor speed and reaction time demonstrated greater reliability than verbal and visual memory. Our current data support a multifaceted approach to concussion assessment using clinical examinations, symptom reports, cognitive testing, and balance assessment.	[Resch, Jacob] Univ Texas Arlington, Arlington, TX 76102 USA; [Driscoll, Aoife; McCaffrey, Noel] Dublin City Univ, Dublin 9, Ireland; [Brown, Cathleen; Ferrara, Michael S.; Baumgartner, Ted] Univ Georgia, Athens, GA 30602 USA; [Macciocchi, Stephen] Shepherd Ctr, Atlanta, GA USA; [Walpert, Kimberly] Georgia Neurol Surg, Athens, Greece		Resch, J (corresponding author), Univ Texas Arlington, Box 19259,113 Maverick Act Ctr, Arlington, TX 76102 USA.	resch@uta.edu	Brown, Cathleen/A-6626-2013	Brown, Cathleen/0000-0002-3414-7938; Resch, Jacob/0000-0001-6031-3197			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Baumgartner TA, 2007, MEASUREMENT EVALUATI; Baumgatner T., 2001, MEAS PHYS EDUC EXERC, V5, P179, DOI [10.1207/S15327841MPEE0503_4, DOI 10.1207/S15327841MPEE0503_4]; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Brown CN, 2007, J ATHL TRAINING, V42, P515; Cernich AN, 2007, ARCH CLIN NEUROPSYCH, V22, pS39, DOI 10.1016/j.acn.2006.10.004; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Green P., 2005, GREENS WORD MEMORY T, Vrev. ed.; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Lovell M, 2007, IMPACT 2007 6 0 CLIN; Lovell M.R, 2007, IMPACT 2007 6 0 SOFT; Maxwell S. E., 2003, DESIGNING EXPT ANAL; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McGraw KO, 1996, PSYCHOL METHODS, V1, P30, DOI 10.1037/1082-989X.1.4.390; Pedhazu EJ, 1991, MEASUREMENT DESIGN A; Portney LG, 1993, FDN CLIN RES APPL PR, V3rd; Randolph C, 2005, J ATHL TRAINING, V40, P139; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	25	81	81	0	21	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL-AUG	2013	48	4					506	511		10.4085/1062-6050-48.3.09			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	211GX	WOS:000323895400010	23724770	Green Published			2022-02-06	
J	Mohan, K; Kecova, H; Hernandez-Merino, E; Kardon, RH; Harper, MM				Mohan, Kabhilan; Kecova, Helga; Hernandez-Merino, Elena; Kardon, Randy H.; Harper, Matthew M.			Retinal Ganglion Cell Damage in an Experimental Rodent Model of Blast-Mediated Traumatic Brain Injury	INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE			English	Article						traumatic brain injury; traumatic optic neuropathy; pattern electroretinography; blast injury	AMYLOID PRECURSOR PROTEIN; VISUAL FUNCTION; AXONAL INJURY; MOUSE RETINA; HEAD-INJURY; MILD; EYE	PURPOSE. To evaluate retina and optic nerve damage following experimental blast injury. METHODS. Healthy adult mice were exposed to an overpressure blast wave using a custom-built blast chamber. The effects of blast exposure on retina and optic nerve function and structure were evaluated using the pattern electroretinogram (pERG), spectral domain optical coherence tomography (OCT), and the chromatic pupil light reflex. RESULTS. Assessment of the pupil response to light demonstrated decreased maximum pupil constriction diameter in blast-injured mice using red light or blue light stimuli 24 hours after injury compared with baseline in the eye exposed to direct blast injury. A decrease in the pupil light reflex was not observed chronically following blast exposure. We observed a biphasic pERG decrease with the acute injury recovering by 24 hours postblast and the chronic injury appearing at 4 months postblast injury. Furthermore, at 3 months following injury, a significant decrease in the retinal nerve fiber layer was observed using OCT compared with controls. Histologic analysis of the retina and optic nerve revealed punctate regions of reduced cellularity in the ganglion cell layer and damage to optic nerves. Additionally, a significant upregulation of proteins associated with oxidative stress was observed acutely following blast exposure compared with control mice. CONCLUSIONS. Our study demonstrates that decrements in retinal ganglion cell responses can be detected after blast injury using noninvasive functional and structural tests. These objective responses may serve as surrogate tests for higher CNS functions following traumatic brain injury that are difficult to quantify.	[Mohan, Kabhilan; Kardon, Randy H.; Harper, Matthew M.] Ctr Prevent & Treatment Visual Loss, Iowa City Vet Adm, Iowa City, IA 52242 USA; [Mohan, Kabhilan] Iowa State Univ, Dept Biomed Sci, Ames, IA USA; [Kecova, Helga; Hernandez-Merino, Elena] Iowa State Univ, Dept Vet Clin Sci, Ames, IA USA; [Kardon, Randy H.] Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA USA		Harper, MM (corresponding author), Ctr Prevent & Treatment Visual Loss, Dept Vet Affairs, 601 Highway 6 W, Iowa City, IA 52242 USA.	kabhilan@gmail.com; matthew.harper@va.gov		Harper, Matthew/0000-0003-3395-2406; Kardon, Randy/0000-0002-3173-7123	Department of Veterans AffairsUS Department of Veterans Affairs; Veterans Health AdministrationUS Department of Veterans Affairs; Office of Research and Development; Rehabilitation Research and Development Center for Prevention and Treatment of Visual Loss; Rehabilitation Research and Development Career Development Award; RRD Merit Study Award [1I01RX000427-01]; Iowa State University T32 National Institutes of Health Fellowship awardsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Iowa State University Biotechnology Fund; Veterans AffairsUS Department of Veterans Affairs [I01RX000427] Funding Source: NIH RePORTER	Supported by the Department of Veterans Affairs; Veterans Health Administration; Office of Research and Development; Rehabilitation Research and Development Center for Prevention and Treatment of Visual Loss; a Rehabilitation Research and Development Career Development Award (MMH); an RRD Merit Study Award (1I01RX000427-01); Iowa State University T32 National Institutes of Health Fellowship awards; and The Iowa State University Biotechnology Fund. The authors alone are responsible for the content and writing of the paper.	[Anonymous], 2006, CLIN PRACT GUID REC; Bach M, 2006, INVEST OPHTH VIS SCI, V47, P4881, DOI 10.1167/iovs.05-0875; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Cernak I, 2000, J NEUROTRAUM, V17, P53, DOI 10.1089/neu.2000.17.53; Cockerham GC, 2011, NEW ENGL J MED, V364, P2172, DOI 10.1056/NEJMc1010683; Cockerham GC, 2009, J REHABIL RES DEV, V46, P811, DOI 10.1682/JRRD.2008.08.0109; CONNOLLY SE, 1988, MICROVASC RES, V36, P275, DOI 10.1016/0026-2862(88)90028-3; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Dougherty AL, 2011, BRAIN INJURY, V25, P8, DOI 10.3109/02699052.2010.536195; Du T, 2005, BRAIN INJURY, V19, P1125, DOI 10.1080/02699050500149817; Freed S, 1997, BRAIN INJURY, V11, P25, DOI 10.1080/026990597123782; Gaetz M, 2000, BRAIN INJURY, V14, P815; Goldstein L.E., 2012, SCI TRANSL MED, V4; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Green W, 2010, J REHABIL RES DEV, V47, P183, DOI 10.1682/JRRD.2009.04.0041; Hines-Beard J, 2012, EXP EYE RES, V99, P63, DOI 10.1016/j.exer.2012.03.013; Kardon R, 2011, OPHTHALMOLOGY, V118, P376, DOI 10.1016/j.ophtha.2010.06.033; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kretschmer WB, 2011, J ORAL MAXIL SURG, V69, P861, DOI 10.1016/j.joms.2010.05.024; Kuehn R, 2011, J NEUROTRAUM, V28, P2155, DOI 10.1089/neu.2010.1532; Lachapelle J, 2008, BRAIN INJURY, V22, P265, DOI 10.1080/02699050801938983; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2005, J REHABIL RES DEV, V42, P29, DOI 10.1682/JRRD.2004.05.0056; Lew HL, 2004, AM J PHYS MED REHAB, V83, P428, DOI 10.1097/00002060-200406000-00004; Lew HL, 2003, AM J PHYS MED REHAB, V82, P53, DOI [10.1097/00002060-200301000-00009, 10.1097/01.PHM.0000043771.90606.81]; Mohan K, 2012, VET OPHTHALMOL, V15, P94, DOI 10.1111/j.1463-5224.2012.01034.x; RAPPAPORT M, 1990, CLIN ELECTROENCEPHAL, V21, P188, DOI 10.1177/155005949002100406; Risling M, 2002, FOIR0757SE SWED DEF, P1; SOTA, 2008, STAT ART 9 TRAUM BRA; Wang JQ, 2011, J NEUROTRAUM, V28, P1185, DOI 10.1089/neu.2011.1756; Zunic Gordana, 2005, Vojnosanit Pregl, V62, P273, DOI 10.2298/VSP0504273Z	32	81	81	0	12	ASSOC RESEARCH VISION OPHTHALMOLOGY INC	ROCKVILLE	12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA	0146-0404			INVEST OPHTH VIS SCI	Invest. Ophthalmol. Vis. Sci.	MAY	2013	54	5					3440	3450		10.1167/iovs.12-11522			11	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Ophthalmology	173YC	WOS:000321118300042	23620426	Green Published			2022-02-06	
J	Yutthakasemsunt, S; Kittiwatanagul, W; Piyavechvirat, P; Thinkamrop, B; Phuenpathom, N; Lumbiganon, P				Yutthakasemsunt, Surakrant; Kittiwatanagul, Warawut; Piyavechvirat, Parnumas; Thinkamrop, Bandit; Phuenpathom, Nakornchai; Lumbiganon, Pisake			Tranexamic acid for patients with traumatic brain injury: a randomized, double-blinded, placebo-controlled trial	BMC EMERGENCY MEDICINE			English	Article						Traumatic brain injury; Adults; Moderately severe TBI; Intracranial haemorrhage; Progressive haemorrhage; Delayed haemorrhage; Expanding haemorrhage; Antifibrinolytic agent; Tranexamic acid; Randomized controlled trial; Human; Placebo	HEAD TRAUMA; HEMORRHAGE; COAGULOPATHY; PROGRESSION; PREDICTORS	Background: Traumatic brain injury (TBI) is commonly accompanied by intracranial bleeding which can worsen after hospital admission. Tranexamic acid (TXA) has been shown to reduce bleeding in elective surgery and there is evidence that short courses of TXA can reduce rebleeding in spontaneous intracranial haemorrhage. We aimed to determine the effectiveness and safety of TXA in preventing progressive intracranial haemorrhage in TBI. Methods: This is a double blinded, placebo controlled randomized trial. We enrolled 238 patients older than 16 years with moderate to severe TBI (post-resuscitation Glasgow Coma Scale (GCS) 4 to 12) who had a computerized tomography (CT) brain scan within eight hours of injury and in whom there was no immediate indication for surgery. We excluded patients if they had a coagulopathy or a serum creatinine over than 2.0 milligrams%. The treatment was a single dose of 2 grams of TXA in addition to other standard treatments. The primary outcome was progressive intracranial haemorrhage (PIH) which was defined as an intracranial haemorrhage seen on the second CT scan that was not seen on the first CT scan, or an intracranial haemorrhage seen on the first scan that had expanded by 25% or more on any dimension (height, length, or width) on the second scan. Results: Progressive intracranial haemorrhage was present in 21 (18%) of 120 patients allocated to TXA and in 32 (27%) of 118 patients allocated to placebo. The difference was not statistically significant [RR = 0.65 (95% CI 0.40 to 1.05)]. There were no significant difference in the risk of death from all causes in patients allocated to TXA compared with placebo [RR = 0.69 (95% CI 0.35 to 1.39)] and the risk of unfavourable outcome on the Glasgow Outcome Scale [RR = 0.76 (95% CI 0.46 to 1.27)]. There was no evidence of increased risk of thromboembolic events in those patients allocated to TXA. Conclusions: TXA may reduce PIH in patients with TBI; however, the difference was not statistically significant in this trial. Large clinical trials are needed to confirm and to assess the effect of TXA on death or disability after TBI.	[Yutthakasemsunt, Surakrant; Kittiwatanagul, Warawut; Piyavechvirat, Parnumas] Khon Kaen Hosp, Surg Unit, Khon Kaen, Thailand; [Thinkamrop, Bandit] Kaen Univ, Dept Biostat & Demog, Fac Publ Hlth, Khon Kaen, Thailand; [Phuenpathom, Nakornchai] Prince Songkla Univ, Dept Surg, Fac Med, Hat Yai, Songkla, Thailand; [Lumbiganon, Pisake] Khon Kaen Univ, Dept Obstet & Gynaecol, Fac Med, Khon Kaen, Thailand		Yutthakasemsunt, S (corresponding author), Khon Kaen Hosp, Surg Unit, Khon Kaen, Thailand.	surakrant@gmail.com	Lumbiganon, Pisake/E-8634-2010	Lumbiganon, Pisake/0000-0001-9372-0071	Khon Kaen hospital (KKH); Thailand research fundThailand Research Fund (TRF); Faculty of medicine, Khon Kaen University (KKU), Thailand	We thank Khon Kaen hospital (KKH), the Thailand research fund, the Faculty of medicine, Khon Kaen University (KKU), Thailand. We thank Ian Roberts from London School of Hygiene & Tropical Medicine (LSHTM) for advice on the protocol and the manuscript. We also thank the patients and relatives involved in the trial and the staffs who cared for them.	Brohi K, 2007, CURR OPIN CRIT CARE, V13, P680, DOI 10.1097/MCC.0b013e3282f1e78f; BROWN FD, 1978, J NEUROSURG, V48, P1019, DOI 10.3171/jns.1978.48.6.1019; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bullock MR, 2006, NEUROSURGERY, V58, pS1; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Cohen TI, 1996, NEUROTRAUMA, P689; DIAZ FG, 1979, J NEUROSURG, V50, P217, DOI 10.3171/jns.1979.50.2.0217; Dunn CJ, 1999, DRUGS, V57, P1005, DOI 10.2165/00003495-199957060-00017; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; GUDEMAN SK, 1979, NEUROSURGERY, V5, P309, DOI 10.1227/00006123-197909000-00002; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Henry DA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001886.pub2; Hillman J, 2002, J NEUROSURG, V97, P771, DOI 10.3171/jns.2002.97.4.0771; MERINODEVILLASANTE J, 1976, AM J ROENTGENOL, V126, P765, DOI 10.2214/ajr.126.4.765; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Perel P, 2009, BMC EMERG MED, V9, DOI 10.1186/1471-227X-9-15; Perel P, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007877.pub2; ROCKSWOLD GL, 1987, NEUROSURGERY, V21, P51, DOI 10.1227/00006123-198707000-00010; Roos YB, 2003, COCHRANE DB SYST REV, V2, DOI [DOI 10.1002/14651858.CD001245, 10.1002/14651858.CD001245]; Sanus GZ, 2004, NEUROSURG QUART, V14, P97, DOI 10.1097/01.wnq.0000127718.06183.12; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; White CL, 2009, J TRAUMA, V67, P508, DOI 10.1097/TA.0b013e3181b2519f; Yadav YR, 2006, NEUROL INDIA, V54, P377, DOI 10.4103/0028-3886.28109; YAMAKI T, 1990, ACTA NEUROCHIR, V103, P112, DOI 10.1007/BF01407516; Yutthakasemsunt S, 2006, J TRAUMA, V25, P53	27	81	84	1	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-227X			BMC EMERG MED	BMC Emerg. Med.		2013	13								20	10.1186/1471-227X-13-20			7	Emergency Medicine	Emerging Sources Citation Index (ESCI)	Emergency Medicine	V55DA	WOS:000210472100020	24267513	Green Published, gold			2022-02-06	
J	Choi, BY; Jang, BG; Kim, JH; Lee, BE; Sohn, M; Song, HK; Suh, SW				Choi, Bo Yong; Jang, Bong Geom; Kim, Jin Hee; Lee, Bo Eun; Sohn, Min; Song, Hong Ki; Suh, Sang Won			Prevention of traumatic brain injury-induced neuronal death by inhibition of NADPH oxidase activation	BRAIN RESEARCH			English	Article						Traumatic brain injury; Apocynin; Hippocampus; NADPH oxidase; Microglia; Reactive oxygen species; Blood-brain barrier disruption	POLY(ADP-RIBOSE) POLYMERASE; NEUTROPHIL ACCUMULATION; CEREBRAL-ISCHEMIA; OXIDATIVE STRESS; APOCYNIN; ZINC; SUPEROXIDE; RATS; HYPERTHERMIA; REPERFUSION	The present study aimed to evaluate the therapeutic potential of apocynin, an NADPH oxidase assembly inhibitor, on traumatic brain injury. Rat traumatic brain injury (TBI) was performed using a weight drop model. Apocynin (100 mg/kg) was injected into the intraperitoneal space 15 min before TBI. Reactive oxygen species (ROS) in the hippocampal CA3 pyramidal neurons were detected by dihydroethidium (dHEt) at 3 h after TBI. Oxidative injury was detected by 4-hydroxy-2-nonenal (4HNE) at 6 h after TBI. Blood-brain barrier disruption was detected by IgG extravasation and neuronal death was evaluated with Fluoro Jade-B staining 24h after TBI. Microglia activation was detected by CD11b immunohistochemistry in the hippocampus at 1 week after TBI. ROS production was inhibited by apocynin administration in the hippocampal CA3 pyramidal neurons. This pre-treatment with apocynin decreased the blood-brain barrier disruption, the number of degenerating neurons in the hippocampal CA3 region and microglial activation after TBI. The present study indicates that apocynin pre-treatment prevents TBI-induced ROS production, thus decreasing BBB disruption, neuronal death and microglial activation. Therefore, the present study suggests that inhibition of NADPH oxidase by apocynin may have a high therapeutic potential to reduce traumatic brain injury-induced neuronal death. (C) 2012 Elsevier B.V. All rights reserved.	[Choi, Bo Yong; Jang, Bong Geom; Kim, Jin Hee; Lee, Bo Eun; Suh, Sang Won] Hallym Univ, Coll Med, Dept Physiol, 1 Okcheon Dong,39 Hallymdaehak Gil, Chunchon 200702, South Korea; [Suh, Sang Won] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Suh, Sang Won] Vet Affairs Med Ctr, San Francisco, CA 94121 USA; [Sohn, Min] Inha Univ, Dept Nursing, Inchon, South Korea; [Song, Hong Ki] Hallym Univ, Coll Med, Dept Neurol, Chunchon 200702, South Korea		Suh, SW (corresponding author), Hallym Univ, Coll Med, Dept Physiol, 1 Okcheon Dong,39 Hallymdaehak Gil, Chunchon 200702, South Korea.	hksong0@paran.com; swsuh@hallym.ac.kr		SOHN, MIN/0000-0003-4021-2051; Choi, Bo Young/0000-0002-9579-3503	Korea Healthcare technology RAMP;D Project, Ministry of Health AMP; Welfare, Republic of Korea [A120202]	This study was supported by a grant of the Korea Healthcare technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A120202). Sang Won Suh, MD, PhD is the person whom takes full responsibility for the manuscript and its originality. The authors thank Aaron M. Hamby, University of California, Berkeley, for help with preparing the manuscript and Ms, Tae Yul Kim for schematic illustration.	Brennan AM, 2009, NAT NEUROSCI, V12, P857, DOI 10.1038/nn.2334; Cai AL, 2006, EUR J NEUROSCI, V24, P2169, DOI 10.1111/j.1460-9568.2006.05110.x; Carbonell WS, 1999, ANN NY ACAD SCI, V890, P287, DOI 10.1111/j.1749-6632.1999.tb08005.x; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; DeCoursey TE, 2005, CELL MOL LIFE SCI, V62, P2173, DOI 10.1007/s00018-005-5177-1; Groemping Y, 2005, BIOCHEM J, V386, P401, DOI 10.1042/BJ20041835; Hart B A, 1992, Biotechnol Ther, V3, P119; Hayashi T, 2005, DIABETES OBES METAB, V7, P334, DOI 10.1111/j.1463-1326.2004.00393.x; Hoane MR, 2006, BRAIN RES, V1125, P185, DOI 10.1016/j.brainres.2006.10.019; Inamasu J, 2000, J NEUROIMMUNOL, V109, P66, DOI 10.1016/S0165-5728(00)00211-3; Kauppinen TM, 2008, J NEUROSCI, V28, P5827, DOI 10.1523/JNEUROSCI.1236-08.2008; Kauppinen UM, 2005, J IMMUNOL, V174, P2288, DOI 10.4049/jimmunol.174.4.2288; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mabuchi T, 2000, STROKE, V31, P1735, DOI 10.1161/01.STR.31.7.1735; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; Murakami K, 1998, BRAIN RES, V780, P304, DOI 10.1016/S0006-8993(97)01217-1; Parikh S, 2007, INT ANESTHESIOL CLIN, V45, P119, DOI 10.1097/AIA.0b013e318078cfe7; Peters EA, 2001, FREE RADICAL BIO MED, V31, P1442, DOI 10.1016/S0891-5849(01)00725-0; RUTH RE, 1988, ACTA NEUROPATHOL, V76, P380, DOI 10.1007/BF00686975; Schroeter M, 1997, STROKE, V28, P382, DOI 10.1161/01.STR.28.2.382; Singh P, 2003, NEUROL INDIA, V51, P215; STOLK J, 1994, AM J RESP CELL MOL, V11, P95, DOI 10.1165/ajrcmb.11.1.8018341; Suh SW, 2008, J CEREBR BLOOD F MET, V28, P1697, DOI 10.1038/jcbfm.2008.61; Suh SW, 2007, J CLIN INVEST, V117, P910, DOI 10.1172/JCI30077; Suh SW, 2008, ANN NEUROL, V64, P654, DOI 10.1002/ana.21511; Suh SW, 2006, J CEREBR BLOOD F MET, V26, P161, DOI 10.1038/sj.jcbfm.9600176; Suh SW, 2003, J NEUROSCI, V23, P10681; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Tang XN, 2008, NEUROSCIENCE, V154, P556, DOI 10.1016/j.neuroscience.2008.03.090; Tang XAN, 2010, J NEUROSCI METH, V190, P240, DOI 10.1016/j.jneumeth.2010.05.004; Thompson HJ, 2005, J CEREBR BLOOD F MET, V25, P163, DOI 10.1038/sj.jcbfm.9600008; Van den Worm E, 2001, EUR J PHARMACOL, V433, P225, DOI 10.1016/S0014-2999(01)01516-3; Wang Q, 2006, BRAIN RES, V1090, P182, DOI 10.1016/j.brainres.2006.03.060; Weight DG, 1998, PSYCHIAT CLIN N AM, V21, P609, DOI 10.1016/S0193-953X(05)70026-5; Yenari MA, 2006, STROKE, V37, P1087, DOI 10.1161/01.STR.0000206281.77178.ac; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504	41	81	82	0	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	OCT 24	2012	1481						49	58		10.1016/j.brainres.2012.08.032			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	114AE	WOS:000316711100004	22975130				2022-02-06	
J	Zhao, YB; Luo, P; Guo, QD; Li, SZ; Zhang, L; Zhao, MM; Xu, HX; Yang, YF; Poon, WS; Fei, Z				Zhao, Yongbo; Luo, Peng; Guo, Qindong; Li, Sanzhong; Zhang, Lei; Zhao, Mingming; Xu, Haoxiang; Yang, Yuefan; Poon, Waisang; Fei, Zhou			Interactions between SIRT1 and MAPK/ERK regulate neuronal apoptosis induced by traumatic brain injury in vitro and in vivo	EXPERIMENTAL NEUROLOGY			English	Article						SIRT1; ERK; Salermide; Traumatic brain injury; Apoptosis	RAT CORTICAL-NEURONS; CLOSED-HEAD INJURY; CELL-DEATH; HISTONE DEACETYLASE; GLUCOSE DEPRIVATION; OXIDATIVE TOXICITY; KINASE; SIRTUINS; PROTECTS; NEUROPROTECTION	Traumatic brain injury (TBI) is a serious insult that frequently leads to neurological dysfunction or death. Silent information regulator family protein 1 (SIRT1), as the founding member of nicotinamide adenine dinucleotide (NAD)-dependent deacetylases, has recently been demonstrated to have neuroprotective effect in several models of neurodegenerative diseases. The present study attempts to determine whether SIRT1 has a neuroprotective effect in the model of TBI, and further to investigate the possible regulatory mechanism of neuron death. Thus, we employ transection model in vitro and weight-drop model in vivo to mimic the insults of TBI. The study shows that the expressions of SIRT1, phosphorylation extracellular signal-regulated kinase (p-ERK) and cleaved Caspase-3 are induced after trauma injury in vitro or in vivo. Furthermore, inhibiting SIRT1 by pharmacological inhibitor salermide or SIRT1 siRNA significantly promotes apoptotic neuron death and reduces ERK1/2 activation induced by mechanical injury in vitro and in vivo. Inhibition of ERK1/2 activation with PD98059 or U0126 (two mitogen activated protein kinase kinase inhibitors) in vitro and in vivo significantly attenuates the SIRT1 and cleaved Caspase-3 expression to protect neuron against TBI-induced apoptosis. These results reveal that SIRT1 plays a neuroprotective effect against neuronal apoptosis induced by TBI. The interactions between SIRT1 and MAPK/ERK pathway regulate neuronal apoptosis induced by mechanical trauma injury in vitro and in vivo. (c) 2012 Elsevier Inc. All rights reserved.	[Poon, Waisang] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Div Neurosurg, Shatin Nt, Hong Kong, Peoples R China; [Zhao, Yongbo; Luo, Peng; Guo, Qindong; Li, Sanzhong; Zhang, Lei; Zhao, Mingming; Xu, Haoxiang; Yang, Yuefan; Fei, Zhou] Fourth Mil Med Univ, Xijing Hosp, Inst Neurosurg, Xian 710032, Shaanxi Provinc, Peoples R China; [Zhao, Yongbo] 323th Hosp PLA, Dept Neurosurg, Xian 710032, Shaanxi Provinc, Peoples R China		Poon, WS (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Div Neurosurg, Shatin Nt, Hong Kong, Peoples R China.	wpoon@cuhk.edu.hk; zhoufei@fmmu.edu.cn	Poon, Wai Sang/F-1558-2011; Yang, Yuefan/AAJ-9136-2020	Luo, Peng/0000-0003-0746-939X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30670796, 30930093]; 863 High-Tech ProjectNational High Technology Research and Development Program of China [2009AA02Z419]	We would like to give our thanks to Wenbo Liu, Tao Chen, Ning Su, Yihui Ma, Kai Wang, Kai Huo, Junli Huo, Juan Li, Xiaoyan Chen, and Yufen Shi for technical assistance. The work was supported by the National Natural Science Foundation of China (No. 30670796 and No. 30930093) and the 863 High-Tech Project (2009AA02Z419).	Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Chen Da-qing, 2007, Chin J Traumatol, V10, P105; Chen J, 2005, J BIOL CHEM, V280, P40364, DOI 10.1074/jbc.M509329200; Chen T, 2011, NEUROSCIENCE, V183, P203, DOI 10.1016/j.neuroscience.2011.03.038; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Chong ZZ, 2008, CURR NEUROVASC RES, V5, P159, DOI 10.2174/156720208785425666; Chong ZZ, 2005, CURR NEUROVASC RES, V2, P271, DOI 10.2174/156720205774322584; Della-Morte D, 2009, NEUROSCIENCE, V159, P993, DOI 10.1016/j.neuroscience.2009.01.017; Fei Z, 2005, NEUROSCI LETT, V380, P280, DOI 10.1016/j.neulet.2005.01.063; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Fukunaga K, 1998, MOL NEUROBIOL, V16, P79, DOI 10.1007/BF02740604; Gan L, 2008, NEURON, V58, P10, DOI 10.1016/j.neuron.2008.03.015; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; Guerra B, 2004, J NEUROCHEM, V91, P99, DOI 10.1111/j.1471-4159.2004.02695.x; Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506; Hisahara S, 2008, P NATL ACAD SCI USA, V105, P15599, DOI 10.1073/pnas.0800612105; Huang TT, 2009, J NEUROTRAUM, V26, P1535, DOI [10.1089/neu.2008.0743, 10.1089/neu.2008-0743]; Irving EA, 2002, J CEREBR BLOOD F MET, V22, P631, DOI 10.1097/00004647-200206000-00001; Jin QH, 2007, J CELL PHYSIOL, V213, P88, DOI 10.1002/jcp.21091; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kim EJ, 2007, MOL CELL, V28, P277, DOI 10.1016/j.molcel.2007.08.030; Kuroki Y, 2001, EUR J NEUROSCI, V13, P472, DOI 10.1046/j.0953-816x.2000.01409.x; Lara E, 2009, ONCOGENE, V28, P781, DOI 10.1038/onc.2008.436; Lesuisse C, 2002, J CEREBR BLOOD F MET, V22, P935, DOI 10.1097/00004647-200208000-00005; Li Y, 2008, CELL METAB, V8, P38, DOI 10.1016/j.cmet.2008.05.004; Liu D, 2009, NEUROMOL MED, V11, P28, DOI 10.1007/s12017-009-8058-1; Luo P, 2012, FREE RADICAL RES, V46, P766, DOI 10.3109/10715762.2012.678340; Luo Y, 2006, J BIOL CHEM, V281, P16436, DOI 10.1074/jbc.M512430200; Ma YH, 2011, BRAIN RES BULL, V86, P441, DOI 10.1016/j.brainresbull.2011.07.007; Michishita E, 2005, MOL BIOL CELL, V16, P4623, DOI 10.1091/mbc.E05-01-0033; Milne JC, 2008, CURR OPIN CHEM BIOL, V12, P11, DOI 10.1016/j.cbpa.2008.01.019; Morris KC, 2011, J CEREBR BLOOD F MET, V31, P1003, DOI 10.1038/jcbfm.2010.229; Outeiro TF, 2008, BBA-MOL BASIS DIS, V1782, P363, DOI 10.1016/j.bbadis.2008.02.010; Parker JA, 2005, NAT GENET, V37, P349, DOI 10.1038/ng1534; Peck B, 2010, MOL CANCER THER, V9, P844, DOI 10.1158/1535-7163.MCT-09-0971; Pfister JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004090; Ramadori G, 2008, J NEUROSCI, V28, P9989, DOI 10.1523/JNEUROSCI.3257-08.2008; Raval AP, 2006, J CEREBR BLOOD F MET, V26, P1141, DOI 10.1038/sj.jcbfm.9600262; Sakamoto J, 2004, FEBS LETT, V556, P281, DOI 10.1016/S0014-5793(03)01444-3; Saunders LR, 2007, ONCOGENE, V26, P5489, DOI 10.1038/sj.onc.1210616; Shindler KS, 2007, INVEST OPHTH VIS SCI, V48, P3602, DOI 10.1167/iovs.07-0131; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; Subramaniam S, 2006, NEUROSCIENCE, V138, P1055, DOI 10.1016/j.neuroscience.2005.12.013; Subramaniam S, 2010, FEBS J, V277, P22, DOI 10.1111/j.1742-4658.2009.07367.x; Sun C, 2007, CELL METAB, V6, P307, DOI 10.1016/j.cmet.2007.08.014; Tanno M, 2007, J BIOL CHEM, V282, P6823, DOI 10.1074/jbc.M609554200; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Wang J, 2011, NEUROSCI LETT, V503, P250, DOI 10.1016/j.neulet.2011.08.047; Wang L, 2009, EUR J PHARMACOL, V609, P40, DOI 10.1016/j.ejphar.2009.03.033; Wang SP, 2008, STROKE, V39, P2587, DOI 10.1161/STROKEAHA.107.509158; Zhang HP, 2010, ANESTH ANALG, V111, P506, DOI 10.1213/ANE.0b013e3181e45519; Zhang J, 2007, J BIOL CHEM, V282, P34356, DOI 10.1074/jbc.M706644200; Zhang W, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002429; Zhen HN, 2005, CANCER-AM CANCER SOC, V104, P2775, DOI 10.1002/cncr.21490	57	81	86	0	25	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2012	237	2					489	498		10.1016/j.expneurol.2012.07.004			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	009OJ	WOS:000309034800027	22828134				2022-02-06	
J	Farbota, KD; Bendlin, BB; Alexander, AL; Rowley, HA; Dempsey, RJ; Johnson, SC				Farbota, Kimberly D.; Bendlin, Barbara B.; Alexander, Andrew L.; Rowley, Howard A.; Dempsey, Robert J.; Johnson, Sterling C.			Longitudinal diffusion tensor imaging and neuropsychological correlates in traumatic brain injury patients	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						traumatic brain injury; diffusion tensor imaging; longitudinal; neuropsychology; recovery; DTI; TBI	CORPUS-CALLOSUM MICROSTRUCTURE; WHITE-MATTER INTEGRITY; AXONAL INJURY; DAMAGE; MODEL; MRI; ADOLESCENTS; ACTIVATION; PLASTICITY; FASCICULUS	Traumatic brain injury (TBI) often involves focal cortical injury and white matter (WM) damage that can be measured shortly after injury. Additionally, slowly evolving WM change can be observed but there is a paucity of research on the duration and spatial pattern of long-term changes several years post-injury. The current study utilized diffusion tensor imaging to identify regional WM changes in 12 TBI patients and nine healthy controls at three time points over a four year period. Neuropsychological testing was also administered to each participant at each time point. Results indicate that TBI patients exhibit longitudinal changes to WM indexed by reductions in fractional anisotropy (FA) in the corpus callosum, as well as FA increases in bilateral regions of the superior longitudinal fasciculus (SLF) and portions of the optic radiation (OR). FA changes appear to be driven by changes in radial (not axial) diffusivity, suggesting that observed longitudinal FA changes may be related to changes in myelin rather than to axons. Neuropsychological correlations indicate that regional FA values in the corpus callosum and sagittal stratum (SS) correlate with performance on finger tapping and visuomotor speed tasks (respectively) in TBI patients, and that longitudinal increases in FA in the SS, SLF, and OR correlate with improved performance on the visuomotor speed (SS) task as well as a derived measure of cognitive control (SLF, OR). The results of this study showing progressive WM deterioration for several years post-injury contribute to a growing literature supporting the hypothesis that TBI should be viewed not as an isolated incident but as a prolonged disease state. The observations of long-term neurological and functional improvement provide evidence that some ameliorative change may be occurring concurrently with progressive degeneration.	[Farbota, Kimberly D.; Bendlin, Barbara B.; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI USA; [Farbota, Kimberly D.] Univ Wisconsin, Neurosci Training Program, Madison, WI 53705 USA; [Bendlin, Barbara B.; Johnson, Sterling C.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI 53705 USA; [Alexander, Andrew L.] Univ Wisconsin, Dept Med Phys, Sch Med & Publ Hlth, Madison, WI 53705 USA; [Rowley, Howard A.] Univ Wisconsin, Dept Radiol, Sch Med & Publ Hlth, Madison, WI 53705 USA; [Dempsey, Robert J.] Univ Wisconsin, Dept Neurol Surg, Sch Med & Publ Hlth, Madison, WI 53705 USA		Johnson, SC (corresponding author), Univ Wisconsin, William S Middleton Mem VA Hosp, Dept Med, 2500 Overlook Terrace, Madison, WI 53705 USA.	scj@medicine.wisc.edu		Bendlin, Barbara/0000-0002-0580-9875	Department of Veterans AffairsUS Department of Veterans Affairs; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [MH65723, AG000213]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD003352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH065723] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG000213] Funding Source: NIH RePORTER	This study was supported by a Merit Review Grant from the Department of Veterans Affairs, the NIH MH65723 (SCJ), NIH AG000213 and by the facilities and resources of the William S. Middleton Memorial Veterans Hospital. The assistance of Lisa Newman, Amy Hawley, Donald McLaren, and Erik Kastman is greatly appreciated. We would also like to acknowledge the support of researchers and staff at the Waisman Center , University of Wisconsin, Madison, where MR imaging took place . Finally, we thank all the patients who took part in this study . The contents of this report do not necessarily represent the views of the Department of Veterans Affairs or the United States Government.	Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 1996, BRAIN INJURY, V10, P197, DOI 10.1080/026990596124511; Blizzard CA, 2011, CEREB CORTEX, V21, P281, DOI 10.1093/cercor/bhq091; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Caeyenberghs K, 2011, J NEUROTRAUM, V28, P897, DOI 10.1089/neu.2010.1721; Caeyenberghs K, 2011, NEUROREHAB NEURAL RE, V25, P492, DOI 10.1177/1545968310394870; Chan JHM, 2003, NEURORADIOLOGY, V45, P34, DOI 10.1007/s00234-002-0891-y; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Field AS, 2003, AM J NEURORADIOL, V24, P1461; Filippi CG, 2001, AM J NEURORADIOL, V22, P277; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; Frye RE, 2010, DEV MED CHILD NEUROL, V52, P760, DOI 10.1111/j.1469-8749.2010.03633.x; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Hao XJ, 2013, HUM BRAIN MAPP, V34, P253, DOI 10.1002/hbm.21440; Karlsgodt KH, 2008, BIOL PSYCHIAT, V63, P512, DOI 10.1016/j.biopsych.2007.06.017; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Kiraly MA, 2007, THESCIENTIFICWORLDJO, V7, P1768, DOI 10.1100/tsw.2007.269; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2010, J HEAD TRAUMA REHAB, V25, P31, DOI 10.1097/HTR.0b013e3181bff331; Le Bihan D, 1991, Magn Reson Q, V7, P1; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Li J, 2011, EUR J NEUROSCI, V33, P933, DOI 10.1111/j.1460-9568.2010.07573.x; Lin MR, 2010, ARCH PHYS MED REHAB, V91, P474, DOI 10.1016/j.apmr.2009.10.031; Ljungqvist J, 2011, BRAIN INJURY, V25, P370, DOI 10.3109/02699052.2011.558038; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Makris N, 2005, CEREB CORTEX, V15, P854, DOI 10.1093/cercor/bhh186; Malec JF, 2010, ARCH PHYS MED REHAB, V91, P1087, DOI 10.1016/j.apmr.2010.04.002; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Matsukawa H, 2011, ACTA NEUROCHIR, V153, P1687, DOI 10.1007/s00701-011-1002-9; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Muetzel RL, 2008, NEUROIMAGE, V39, P1918, DOI 10.1016/j.neuroimage.2007.10.018; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Povlishock J T, 2000, Clin Neurosurg, V46, P113; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Staudt M, 2010, SEMIN PERINATOL, V34, P87, DOI 10.1053/j.semperi.2009.10.009; Tasker RC, 2010, DEV NEUROSCI-BASEL, V32, P374, DOI 10.1159/000316806; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Wang JY, 2011, NEUROLOGY, V77, P818, DOI 10.1212/WNL.0b013e31822c61d7; Wheeler-Kingshott CAM, 2009, MAGN RESON MED, V61, P1255, DOI 10.1002/mrm.21965; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Xie MQ, 2010, J NEUROPATH EXP NEUR, V69, P704, DOI 10.1097/NEN.0b013e3181e3de90; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208	58	81	82	0	16	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	JUN 19	2012	6								160	10.3389/fnhum.2012.00160			15	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	965SK	WOS:000305787400001	22723773	Green Published, gold			2022-02-06	
J	Anderson, E; Kian, EM				Anderson, Eric; Kian, Edward M.			Examining Media Contestation of Masculinity and Head Trauma in the National Football League	MEN AND MASCULINITIES			English	Article						media; sports; violence; health; hegemonic masculinity	INCLUSIVE MASCULINITY; WOMENS SPORTS; COVERAGE	American football has long been central to the construction of masculinity in the United States. Of the multiple masculine scripts promoting professional players' hegemonic masculine status, sacrificing one's body for the sake of sporting glory is a key tenet. Sport journalists have traditionally used their media platform to reify this social script, an act which simultaneously promotes their own masculine capital. However, this article investigates a crack in this hegemonic system. Through a media analysis of the reporting on Aaron Rodgers' self-withdrawal (after hitting his head) from an important National Football League (NFL) game, we argue that increasing cultural awareness as to the devastating effects of concussions, in the form of chronic traumatic encephalopathy, combined with a softening of American masculinity is beginning to permit some prominent players to distance themselves from the self-sacrifice component of sporting masculinity. Concerning concussions, we conclude major sport media are beginning to support the notion of health over a masculine warrior narrative.	[Anderson, Eric] Univ Winchester, Winchester SO22 4NR, NR, England; [Kian, Edward M.] Univ Cent Florida, Dept Sport & Exercise Sci, Orlando, FL 32816 USA		Anderson, E (corresponding author), Univ Winchester, Sparkford Rd, Winchester SO22 4NR, NR, England.	ericandersonphd@aol.com					Adams A, 2011, J HOMOSEXUAL, V58, P579, DOI 10.1080/00918369.2011.563654; Adams A, 2010, J LANG SOC PSYCHOL, V29, P278, DOI 10.1177/0261927X10368833; Anderson E, 2005, SOCIOL PERSPECT, V48, P337, DOI 10.1525/sop.2005.48.3.337; Anderson E, 2009, ROUTL RES GEND SOC, P1; Anderson E, 2008, SEX ROLES, V58, P104, DOI 10.1007/s11199-007-9337-7; Anderson E, 2010, J GENDER STUD, V19, P249, DOI 10.1080/09589236.2010.494341; [Anonymous], 2010, ESPN INTERNET   1216; [Anonymous], 2010, ESPN INTERNET   1019; [Anonymous], 2010, FOXSPORTS COM   1216; Battista J., 2010, NY TIMES        1020; Bouchette E., 2009, PITTSBURGH POST 0324; Bouchette E., 2010, PITTSBURGH POST 1019; Brown S., 2010, PITTSBURGH TRIB 1116; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Connell R.W., 1995, MASCULINITIES; Creswell JW, 2003, RES DESIGN QUANTITAT; Deggans, 2011, ST PETERSBURG T 0207; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Duncan M. C., 2006, HDB SPORTS MEDIA, P231; Florio M., 2010, PRO FOOTBALL TA 1216; Glasser B., 1967, DISCOVERY GROUNDED T; Gramsci A., 1971, SELECTIONS PRISON NO; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Hardin M, 2005, JOURNALISM MASS COMM, V82, P62, DOI 10.1177/107769900508200105; Hardin Marie, 2006, CRITICAL STUDIES MAS, V23, P332; Hargreaves J., 1994, SPORTING FEMALES CRI; Ibson J., 2002, PICTURING MEN CENTUR; Keown T., 2010, ESPN INTERNET   0204; Kian E.M., 2009, INT J SPORT COMMUN, V2, P185, DOI 10.1123/ijsc.2.2.185; Kian EM, 2011, J HOMOSEXUAL, V58, P680, DOI 10.1080/00918369.2011.563672; Kian EM, 2008, SOCIOL SPORT J, V25, P223, DOI 10.1123/ssj.25.2.223; Kian EM, 2009, J BROADCAST ELECTRON, V53, P477, DOI 10.1080/08838150903102519; Kian Edward (Ted) M., 2007, SMART J, V4, P5; Kuypers J.A., 2002, PRESS BIAS POLITICS; Lapchick RA, 2011, 2010 11 ASS PRESS SP; McCormack M, 2011, SOCIOL PERSPECT, V54, P83, DOI 10.1525/sop.2011.54.1.83; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McDonough W., 1999, NFL CENTURY; McIntosh AS, 2009, MED SCI SPORT EXER, V41, P306, DOI 10.1249/MSS.0b013e3181864bee; McKee Alan, 2001, METRO, V127, P138; Messner M. A., 2002, TAKING FIELD WOMEN M; Messner Michael A., 1992, POWER PLAY SPORTS PR; Nylund D, 2004, J SPORT SOC ISSUES, V28, P136, DOI 10.1177/0193723504264409; O'Brien J., 2004, LAMBERT MAN MIDDLE O; Pedersen P. M., 2002, International Review for the Sociology of Sport, V37, P303, DOI 10.1177/1012690202037004895; Pronger B., 1990, ARENA MASCULINITY SP; Sanderson A. R., 2002, Journal of Sports Economics, V3, P204, DOI 10.1177/152700250200300206; Schwarz A., 2011, NY TIMES        0502; Schwarz A., 2010, NY TIMES        0204; Schwarz A., 2011, NY TIMES        0204; Shea D., 2010, WALL STREET J T 0426; Smith M. D., 2011, PRO FOOTBALL TA 0419; Smith S., 2009, CNNHEALTH COM   0127; SPARKES A, 1992, RES PHYS ED SPORT EX, P271; TRUJILLO N, 1991, CRIT STUD MASS COMM, V8, P290, DOI 10.1080/15295039109366799; Tuchman G., 1978, HEARTH HOME IMAGES W, P3; TURNER BA, 1981, QUAL QUANT, V15, P225; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viera M., 2010, NY TIMES        1217; Vincent J., 2002, International Review for the Sociology of Sport, V37, P319, DOI 10.1177/101269020203700312; Vincent J, 2004, SOCIOL SPORT J, V21, P435, DOI 10.1123/ssj.21.4.435; Vincent J., 2008, INT J SPORT COMMUNIC, V1, P78, DOI DOI 10.1123/ijsc.1.1.78; [No title captured]	63	81	81	3	44	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1097-184X	1552-6828		MEN MASC	Men Masc.	JUN	2012	15	2					152	173		10.1177/1097184X11430127			22	Sociology	Social Science Citation Index (SSCI)	Sociology	952UO	WOS:000304818700004					2022-02-06	
J	Anderson, V; Godfrey, C; Rosenfeld, JV; Catroppa, C				Anderson, Vicki; Godfrey, Celia; Rosenfeld, Jeffrey V.; Catroppa, Cathy			10 years outcome from childhood traumatic brain injury	INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE			English	Article						Traumatic brain injury; Children; Recovery of function; Long term adolescence	HEAD-INJURY; PSYCHOSOCIAL OUTCOMES; INTELLECTUAL ABILITY; FUNCTIONAL RECOVERY; TERM; CHILDREN; PREDICTORS; PLASTICITY; MEMORY; SKILLS	Childhood traumatic brain injury (TBI) is a common, acquired disability, which has significant implications for subsequent development, and for later quality of life. To date few studies have documented outcomes in these children into adolescence, when academic, social and personal demands increase. The objective of this study was to document functional outcomes at 10 years post-injury, and to identify predictors of outcome including injury, socio-demographic and pre-injury characteristics. The study employed consecutive recruitment to a prospective, longitudinal study. Children with a diagnosis of TBI between 2 and 12 years were initially recruited and divided according to injury severity (mild, moderate, severe). The sample was reviewed at 10 years post-injury and intellectual, adaptive, executive and social domains were investigated. Results indicated that, at 10 years post child TBI, survivors' functional abilities fell overall within the low average to average range regardless of injury severity, suggesting no extreme impairments at a group level for any of the domains under investigation. Significant group differences were identified, though, for adaptive abilities and for speed of processing, with more severe injury associated with poorer performances in each instance. Further, a similar trend was identified for measures of intellectual ability and executive functions. Individual rates of impairment were considerably higher than population expectations across all severity groups for these domains. Although rates of social impairment were also elevated, they were less related to injury factors, suggesting that cognitive/adaptive outcomes and social consequences of TBI may have different bases. (C) 2011 Published by Elsevier Ltd on behalf of ISDN.	[Anderson, Vicki; Godfrey, Celia; Catroppa, Cathy] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Anderson, Vicki; Catroppa, Cathy] Royal Childrens Hosp, Parkville, Vic 3052, Australia; [Anderson, Vicki; Catroppa, Cathy] Univ Melbourne, Melbourne, Vic 3010, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Melbourne, Vic 3004, Australia; [Rosenfeld, Jeffrey V.] Alfred Hosp, Melbourne, Vic, Australia		Anderson, V (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	vicki.anderson@rch.org.au; celia.godfrey@mcri.edu.au; J.Rosenfeld@alfred.org.au; cathy.catroppa@mcri.edu.au	Catroppa, Cathy/AAX-9458-2021; Rosenfeld, Jeffrey V/B-7249-2011	Catroppa, Cathy/0000-0002-9750-0436; 	Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia; Victorian Government OIS	This research was supported by a grant to the authors from the Australian National Health and Medical Research Council, and by the Victorian Government OIS Scheme.	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson V., 2009, PEDIATRICS, V124, p[6, 1064]; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Anderson V, 2010, J NEUROTRAUM, V27, P863, DOI 10.1089/neu.2009.1169; Anderson V, 2009, J HEAD TRAUMA REHAB, V24, P303, DOI 10.1097/HTR.0b013e3181ada830; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; Bayreuther J, 2009, ARCH DIS CHILDHOOD-E, V94, P37, DOI 10.1136/adc.2007.132787; Belsky J, 2011, J CHILD PSYCHOL PSYC, V52, P409, DOI 10.1111/j.1469-7610.2010.02281.x; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Casey BJ, 2000, BIOL PSYCHOL, V54, P241, DOI 10.1016/S0301-0511(00)00058-2; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; Catroppa C, 2007, CHILD NEUROPSYCHOL, V13, P240, DOI 10.1080/09297040600837362; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Ciccetti D., 1984, VINELAND ADAPTIVE BE; Crowe L, 2009, J PAEDIATR CHILD H, V45, P346, DOI 10.1111/j.1440-1754.2009.01499.x; Daniel A., 1983, POWER PRIVILEGE PRES; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gioia GA IP, 2000, BEHAV RATING INVENTO; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Greenham M., 2010, FRONT HUM NEUROSCI, V4; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hoofien D, 2001, BRAIN INJURY, V15, P189; Jonsson CA, 2004, BRAIN INJURY, V18, P921, DOI 10.1080/02699050410001671900; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Kraus JF., 1995, TRAUMATIC HEAD INJUR, P117; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; Maller JJ, 2007, HIPPOCAMPUS, V17, P1023, DOI 10.1002/hipo.20339; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Mitra B, 2007, J PAEDIATR CHILD H, V43, P154, DOI 10.1111/j.1440-1754.2007.01035.x; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; Noller P, 1988, ICPS FAMILY FU UNPUB; Nybo T, 2004, J INT NEUROPSYCH SOC, V10, P719, DOI 10.1017/S1355617704105109; Nybo T, 1999, BRAIN INJURY, V13, P759; Oakland T, 2008, PRACT RESOUR MENT, P1; Rosema S., J NEUROTRAU IN PRESS; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 2003, REHABIL PSYCHOL, V48, P227, DOI 10.1037/0090-5550.48.4.227; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D., 1997, MANUAL WECHSLER ADUL; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; [No title captured]; [No title captured]	57	81	81	2	31	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0736-5748	1873-474X		INT J DEV NEUROSCI	Int. J. Dev. Neurosci.	MAY	2012	30	3			SI		217	224		10.1016/j.ijdevneu.2011.09.008			8	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	936XH	WOS:000303622800007	22100364				2022-02-06	
J	Caeyenberghs, K; Leemans, A; Heitger, MH; Leunissen, I; Dhollander, T; Sunaert, S; Dupont, P; Swinnen, SP				Caeyenberghs, Karen; Leemans, Alexander; Heitger, Marcus H.; Leunissen, Inge; Dhollander, Thijs; Sunaert, Stefan; Dupont, Patrick; Swinnen, Stephan P.			Graph analysis of functional brain networks for cognitive control of action in traumatic brain injury	BRAIN			English	Article						traumatic brain injury; cognitive control; functional MRI; task switching; functional network	PREFRONTAL CORTEX; WHITE-MATTER; INTRINSIC CONNECTIONS; NORMATIVE DATA; NEURAL BASIS; HEAD-INJURY; MOTOR AREA; MOVEMENT; COORDINATION; ACTIVATION	Patients with traumatic brain injury show clear impairments in behavioural flexibility and inhibition that often persist beyond the time of injury, affecting independent living and psychosocial functioning. Functional magnetic resonance imaging studies have shown that patients with traumatic brain injury typically show increased and more broadly dispersed frontal and parietal activity during performance of cognitive control tasks. We constructed binary and weighted functional networks and calculated their topological properties using a graph theoretical approach. Twenty-three adults with traumatic brain injury and 26 age-matched controls were instructed to switch between coordination modes while making spatially and temporally coupled circular motions with joysticks during event-related functional magnetic resonance imaging. Results demonstrated that switching performance was significantly lower in patients with traumatic brain injury compared with control subjects. Furthermore, although brain networks of both groups exhibited economical small-world topology, altered functional connectivity was demonstrated in patients with traumatic brain injury. In particular, compared with controls, patients with traumatic brain injury showed increased connectivity degree and strength, and higher values of local efficiency, suggesting adaptive mechanisms in this group. Finally, the degree of increased connectivity was significantly correlated with poorer switching task performance and more severe brain injury. We conclude that analysing the functional brain network connectivity provides new insights into understanding cognitive control changes following brain injury.	[Caeyenberghs, Karen; Heitger, Marcus H.; Leunissen, Inge; Swinnen, Stephan P.] Biomed Sci Grp, Dept Kinesiol, Movement Control & Neuroplast Res Grp, B-3000 Louvain, Belgium; [Leemans, Alexander] Univ Med Ctr Utrecht, Image Sci Inst, NL-3564 CX Utrecht, Netherlands; [Dhollander, Thijs] Ctr Proc Speech & Images, ESAT PSI, Dept Elect Engn ESAT, Sci Engn & Technol Grp, B-3000 Louvain, Belgium; [Sunaert, Stefan] Biomed Sci Grp, Dept Imaging & Pathol, B-3000 Louvain, Belgium; [Dupont, Patrick] Biomed Sci Grp, Dept Neurosci, Res Grp Expt Neurol, Lab Cognit Neurol, B-3000 Louvain, Belgium		Caeyenberghs, K (corresponding author), Katholieke Univ Leuven, Grp Biomed Sci, Res Ctr Motor Control & Neuroplast, Lab Motor Control, B-3001 Heverlee, Belgium.	Karen.Caeyenberghs@faber.kuleuven.be	Leemans, Alexander/A-1784-2011; Dupont, Patrick/B-8044-2009	Leemans, Alexander/0000-0002-9306-6126; Dupont, Patrick/0000-0003-1980-2540; Dhollander, Thijs/0000-0003-3088-3636; Leunissen, Inge/0000-0002-3977-3620; Caeyenberghs, Karen/0000-0001-7009-6843	Research Foundation - Flanders (FWO)FWO [G.0482.010, G.A114.11]; Belgian federal government [P6/29]	Support for this study was provided through a grant from the Research Program of the Research Foundation - Flanders (FWO) (Levenslijn G.0482.010 and G.A114.11) and Grant P6/29 from the Interuniversity Attraction Poles program of the Belgian federal government. Caeyenberghs K. is funded by a postdoctoral fellowship of the Research Foundation - Flanders (FWO).	Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Bamiou DE, 2003, BRAIN RES REV, V42, P143, DOI 10.1016/S0165-0173(03)00172-3; BARBAS H, 1989, J COMP NEUROL, V286, P353, DOI 10.1002/cne.902860306; Bartolomei F, 2006, ANN NEUROL, V59, P128, DOI 10.1002/ana.20710; Bartolomei F, 2006, CLIN NEUROPHYSIOL, V117, P2039, DOI 10.1016/j.clinph.2006.05.018; Bosma I, 2008, J NEURO-ONCOL, V88, P77, DOI 10.1007/s11060-008-9535-3; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Cao C, 2010, IEEE T NEUR SYS REH, V18, P11, DOI 10.1109/TNSRE.2009.2027704; Castellanos NP, 2011, NEUROIMAGE, V55, P1189, DOI 10.1016/j.neuroimage.2010.12.046; Castellanos NP, 2010, BRAIN, V133, P2365, DOI 10.1093/brain/awq174; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Corbetta M, 2008, NEURON, V58, P306, DOI 10.1016/j.neuron.2008.04.017; Coxon JP, 2010, CEREB CORTEX, V20, P2368, DOI 10.1093/cercor/bhp306; Crinion J, 2007, NEUROIMAGE, V37, P866, DOI 10.1016/j.neuroimage.2007.04.065; Fallani FD, 2007, BRAIN TOPOGR, V19, P125, DOI 10.1007/s10548-007-0019-0; Debaere F, 2001, NEUROIMAGE, V14, P947, DOI 10.1006/nimg.2001.0892; Debaere F, 2004, NEUROPSYCHOLOGIA, V42, P855, DOI 10.1016/j.neuropsychologia.2003.12.010; DEIBER MP, 1991, EXP BRAIN RES, V84, P393; DESROSIERS J, 1995, DISABIL REHABIL, V17, P217, DOI 10.3109/09638289509166638; DESROSIERS J, 1995, ARCH PHYS MED REHAB, V76, P1125, DOI 10.1016/S0003-9993(95)80120-0; Dosenbach NUF, 2006, NEURON, V50, P799, DOI 10.1016/j.neuron.2006.04.031; Duann JR, 2009, J NEUROSCI, V29, P10171, DOI 10.1523/JNEUROSCI.1300-09.2009; DUM RP, 1991, J NEUROSCI, V11, P667; Ehrsson HH, 2002, J NEUROSCI, V22, P5074, DOI 10.1523/JNEUROSCI.22-12-05074.2002; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Garth J, 1997, Pediatr Rehabil, V1, P99; Goble DJ, 2011, HUM BRAIN MAPP, P22; Godefroy O, 2003, J NEUROL, V250, P1, DOI 10.1007/s00415-003-0918-2; GOLDMANRAKIC PS, 1982, SCIENCE, V216, P755, DOI 10.1126/science.6177037; Guye M, 2010, MAGN RESON MATER PHY, V23, P409, DOI 10.1007/s10334-010-0205-z; Hampson M, 2002, HUM BRAIN MAPP, V15, P247, DOI 10.1002/hbm.10022; Heuninckx S, 2005, J NEUROSCI, V25, P6787, DOI 10.1523/JNEUROSCI.1263-05.2005; Hillary FG, 2002, J HEAD TRAUMA REHAB, V17, P411, DOI 10.1097/00001199-200210000-00004; Hillary FG, 2008, J INT NEUROPSYCH SOC, V14, P526, DOI 10.1017/S1355617708080788; Hillary FG, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00024; Iturria-Medina Y, 2008, NEUROIMAGE, V40, P1064, DOI 10.1016/j.neuroimage.2007.10.060; KELSO JAS, 1995, CHAOS, V5, P64, DOI 10.1063/1.166087; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Kim YH, 2009, NEUROREHAB NEURAL RE, V23, P468, DOI 10.1177/1545968308328728; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Larson MJ, 2006, J CLIN EXP NEUROPSYC, V28, P968, DOI 10.1080/13803390600646860; Latora V, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.198701; Lee L, 2006, NEUROIMAGE, V30, P1243, DOI 10.1016/j.neuroimage.2005.11.007; Leunissen I., 2012, HUM BRAIN MAPP, DOI 10.1002/hbm.21508; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Levin HS, 2004, J CLIN EXP NEUROPSYC, V26, P589, DOI 10.1080/13803390490504434; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Lewis PA, 2004, NEUROPSYCHOLOGIA, V42, P1301, DOI 10.1016/j.neuropsychologia.2004.03.001; Liu Y, 2008, BRAIN, V131, P945, DOI 10.1093/brain/awn018; Mecklinger A, 1999, J CLIN EXP NEUROPSYC, V21, P606, DOI 10.1076/jcen.21.5.606.873; Medaglia JD, 2011, HUM BRAIN MAPP; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Miller EK, 2000, NAT REV NEUROSCI, V1, P59, DOI 10.1038/35036228; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Newsome MR, 2008, NEUROPSYCHOLOGY, V22, P419, DOI 10.1037/0894-4105.22.4.419; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; PANDYA DN, 1990, PROG BRAIN RES, V85, P63; Park BS, 2009, APPL NEUROPSYCHOL, V16, P1, DOI 10.1080/09084280802636371; Perlstein WM, 2006, NEUROPSYCHOLOGIA, V44, P260, DOI 10.1016/j.neuropsychologia.2005.05.009; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Petrides M, 1999, EUR J NEUROSCI, V11, P1011, DOI 10.1046/j.1460-9568.1999.00518.x; Picard N, 2001, CURR OPIN NEUROBIOL, V11, P663, DOI 10.1016/S0959-4388(01)00266-5; Platel H, 1997, BRAIN, V120, P229, DOI 10.1093/brain/120.2.229; Powell KB, 2004, J CHILD NEUROL, V19, P785, DOI 10.1177/08830738040190100801; Puttemans V, 2005, J NEUROSCI, V25, P4270, DOI 10.1523/JNEUROSCI.3866-04.2005; Rees L, 2007, BRAIN INJURY, V21, P161, DOI 10.1080/02699050701201813; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Sadato N, 1997, J NEUROSCI, V17, P9667; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Salvador R, 2005, PHILOS T R SOC B, V360, P937, DOI 10.1098/rstb.2005.1645; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Schroeter ML, 2007, NEUROPSYCHOLOGIA, V45, P3149, DOI 10.1016/j.neuropsychologia.2007.07.004; SELTZER B, 1989, J COMP NEUROL, V290, P451, DOI 10.1002/cne.902900402; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2011, NEUROIMAGE, V54, P875, DOI 10.1016/j.neuroimage.2010.08.063; Stam CJ, 2010, J NEUROL SCI, V289, P128, DOI 10.1016/j.jns.2009.08.028; Stephen KM, 1999, EXP BRAIN RES, V128, P243, DOI 10.1007/s002210050844; TEASDALE G, 1974, LANCET, V2, P81; Thaut MH, 2003, ANN NY ACAD SCI, V999, P364, DOI 10.1196/annals.1284.044; Thoenissen D, 2002, J NEUROSCI, V22, P9024; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Toni I, 1999, CEREB CORTEX, V9, P35, DOI 10.1093/cercor/9.1.35; Tsirka V, 2011, INT J PSYCHOPHYSIOL, V79, P89, DOI 10.1016/j.ijpsycho.2010.09.006; van Wijk BCM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013701; Verhagen L, 2008, J NEUROSCI, V28, P4726, DOI 10.1523/JNEUROSCI.0057-08.2008; Wenderoth N, 2009, J NEUROPHYSIOL, V102, P302, DOI 10.1152/jn.91090.2008; Zalesky A, 2010, NEUROIMAGE, V53, P1197, DOI 10.1016/j.neuroimage.2010.06.041	92	81	87	2	23	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	APR	2012	135		4				1293	1307		10.1093/brain/aws048			15	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	927ZH	WOS:000302948700031	22427332	Bronze			2022-02-06	
J	Echemendia, RJ; Bruce, JM; Bailey, CM; Sanders, JF; Arnett, P; Vargas, G				Echemendia, Ruben J.; Bruce, Jared M.; Bailey, Christopher M.; Sanders, James Forrest; Arnett, Peter; Vargas, Gray			The Utility of Post-Concussion Neuropsychological Data in Identifying Cognitive Change Following Sports-Related MTBI in the Absence of Baseline Data	CLINICAL NEUROPSYCHOLOGIST			English	Article						Concussion; MTBI; Neuropsychological testing; Baseline evaluation	TEST-RETEST RELIABILITY; TRAUMATIC BRAIN-INJURY; PERFORMANCE; IMPACT; PSYCHOTHERAPY; REGRESSION; DEFICITS	Neuropsychological tests have become commonplace in the assessment of sports-related concussion. Typically, post-injury test data are compared to pre-injury "baselines.'' Baseline testing can be expensive and logistically challenging, yet the usefulness of neuropsychological baseline testing has not been tested empirically. This paper examines the extent to which baseline testing is useful for detecting neurocognitive deficits following sports concussion in a college-age population. A total of 223 collegiate athletes from multiple sports who sustained concussions and had both baseline and post-injury testing using Immediate Post-concussion Assessment and Cognitive Testing (ImPACT) were included in the study. Reliable change (RC) in scores was determined by two approaches, the Jacobson and Truax (JT) and the Gulliksen-Lord-Novick (GLN) methods. The 90% confidence interval was used for both. Classification using these methods was compared to standard normative methods that compared post-concussion performance to baseline population means. Agreement between reliable change and normative methods was examined using Cohen's Kappa scores to determine whether post-injury scores alone could identify reliable cognitive decline. Mean time from concussion to post-injury testing was 3.40 days. The percentage of athletes who declined when using the JT method was similar to the percentage that would be expected to decline due to chance alone. Although the GLN and JT methods demonstrated moderate to substantial agreement, the GLN method consistently identified more cognitively compromised athletes than the JT method. Post-injury scores alone identified a significant majority of athletes with a reliable decline on ImPACT. Although preliminary and in need of replication across age groups and instruments, these findings suggest that the majority of collegiate athletes who experience clinically meaningful post-concussion cognitive decline can be identified without baseline data.	[Echemendia, Ruben J.] Psychol & Neurobehav Associates, State Coll, PA USA; [Echemendia, Ruben J.; Bruce, Jared M.] Univ Missouri, Dept Psychol, Kansas City, MO 64110 USA; [Bailey, Christopher M.] Case Western Reserve Univ, Sch Med, Dept Neurol, Neurol Inst, Cleveland, OH 44106 USA; [Sanders, James Forrest] Womack Army Med Ctr, Dept Behav Med, Ft Bragg, NC USA; [Arnett, Peter; Vargas, Gray] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA		Echemendia, RJ (corresponding author), 204 E Calder Way,Ste 205, State Coll, PA 16801 USA.	rechemendia@comcast.net	Echemendia, Ruben/R-6939-2019	Echemendia, Ruben/0000-0001-6116-8462			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Barth JT, 1989, MILD HEAD INJURY; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Bruce JM, 2003, NEUROPSYCHOLOGY, V17, P622, DOI 10.1037/0894-4105.17.4.622; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Comper P, 2010, BRAIN INJURY, V24, P1257, DOI 10.3109/02699052.2010.506854; Echemendia RJ, 2009, BRIT J SPORT MED, V43, pI32, DOI 10.1136/bjsm.2009.058164; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Echemendia RJ, 2010, B NATL ACAD NEUROPSY, V25, P5; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Heaton RK, 1991, COMPREHENSIVE NORMS; HSU LM, 1989, BEHAV ASSESS, V11, P459; Hsu LM, 1999, J CONSULT CLIN PSYCH, V67, P594, DOI 10.1037/0022-006X.67.4.594; HSU LM, 1995, J CONSULT CLIN PSYCH, V63, P141, DOI 10.1037/0022-006X.63.1.141; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; LOVELL M, 2002, IMPACT VERSION 2 0 C; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Mayers LB, 2012, J CLIN EXP NEUROPSYC, V34, P235, DOI 10.1080/13803395.2011.630655; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mild Traumatic Brain Injury Committee, 1993, J HEAD TRAUMA REHAB, V8, P86; NCAA, 2011, 2011 12 SPORTS MED H; Pascrell B., 2011, REP PASCRELL SEN MEN; Rabinowitz AR, 2012, J INT NEUROPSYCH SOC, V18, P139, DOI 10.1017/S1355617711001275; Randolph C, 2005, J ATHL TRAINING, V40, P139; Randolph C, 2009, J INT NEUROPSYCH SOC, V15, P512, DOI 10.1017/S135561770909064X; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Stern R. A., 2011, PHYS MED REHABILITAT, V3, P1265; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	41	81	83	0	15	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2012	26	7					1077	1091		10.1080/13854046.2012.721006			15	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	027DE	WOS:000310331200002	23003560				2022-02-06	
J	Gavett, BE; Cantu, RC; Shenton, M; Lin, AP; Nowinski, CJ; McKee, AC; Stern, RA				Gavett, Brandon E.; Cantu, Robert C.; Shenton, Martha; Lin, Alexander P.; Nowinski, Christopher J.; McKee, Ann C.; Stern, Robert A.			Clinical appraisal of chronic traumatic encephalopathy: current perspectives and future directions	CURRENT OPINION IN NEUROLOGY			English	Article						biomarkers; chronic traumatic encephalopathy; concussion; dementia; traumatic brain injury	MAGNETIC-RESONANCE SPECTROSCOPY; PROFESSIONAL FOOTBALL PLAYERS; LIST LEARNING TEST; BRAIN-INJURY; ALZHEIMERS-DISEASE; HEAD-INJURY; NEUROPSYCHOLOGICAL PERFORMANCE; OLFACTORY DYSFUNCTION; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION	Purpose of review There are currently no consensus-based clinical diagnostic criteria for chronic traumatic encephalopathy (CTE). This review provides an update on recent literature pertaining to clinically relevant procedures that - presently or in the future - may be useful for the in-vivo detection, characterization, and/or prediction of CTE. Recent findings Preliminary evidence about the clinical manifestations of CTE has been accumulating via post-mortem medical record review and interviews of friends or family members of individuals with neuropathologically documented CTE. This evidence suggests that CTE is manifested clinically by changes in cognition (especially memory and executive functioning, with dementia later in the disease course), mood (especially, depression, apathy, and suicidality), personality and behavior (especially poor impulse control and behavioral disinhibition), and movement (including parkinsonism and signs of motor neuron disease). At the present time, evidence regarding CTE has not been confirmed in a prospective study of a cohort at risk for CTE. Summary On the basis of recent research in the fields of dementia and traumatic brain injury, several in-vivo procedures (including neurological examination, neuropsychological assessment, neuroimaging techniques, and blood and cerebrospinal fluid biomarkers) each have the potential to contribute unique information about the manifestations of CTE, including clinical and preclinical stages. More research is needed to develop a set of consensus diagnostic criteria that provide a reliable and valid indicator of neuropathologically verified CTE. Until such criteria are developed, the clinical assessment of CTE should be informed by modern research that is of relevance to traumatic brain injury and neurodegenerative diseases.	[Stern, Robert A.] Boston Univ, Sch Med, Ctr Study Traumat Encephalopathy, Boston, MA 02118 USA; [Shenton, Martha; Lin, Alexander P.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; [McKee, Ann C.] Vet Affairs Boston Healthcare Syst, Boston, MA USA; [Gavett, Brandon E.] Univ Colorado, Dept Psychol, Colorado Springs, CO 80933 USA		Stern, RA (corresponding author), Boston Univ, Sch Med, Ctr Study Traumat Encephalopathy, 72 E Concord St,B-7380, Boston, MA 02118 USA.	bobstern@bu.edu	, Bob/ABA-8507-2020; Shenton, Martha/V-8780-2019	Stern, Robert/0000-0002-5008-077X; Gavett, Brandon/0000-0003-1938-1854	Boston University Alzheimer's Disease Center NIA [P30 AG13846]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS078337]; VA Biorepository [CSP 501]; Department of Veterans AffairsUS Department of Veterans Affairs; Sports Legacy Institute; National Operating Committee on Standards for Athletic Equipment; National Football League; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846] Funding Source: NIH RePORTER	The study was supported by the Boston University Alzheimer's Disease Center NIA P30 AG13846, supplement 0572063345-5; NIH R01NS078337; the VA Biorepository (CSP 501), funded by the Department of Veterans Affairs; the Sports Legacy Institute; the National Operating Committee on Standards for Athletic Equipment; and by an un-restricted gift from the National Football League.	Amen DG, 2011, J NEUROPSYCH CLIN N, V23, P98, DOI 10.1176/appi.neuropsych.23.1.98; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Brown W S, 1982, Bull Los Angeles Neurol Soc, V47, P91; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Cimatti M, 2006, J Neurosurg Sci, V50, P83; Colbert CA, 2010, RADIOLOGY, V256, P898, DOI 10.1148/radiol.10091842; Collet S, 2009, B-ENT, P97; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; DONCHIN E, 1981, PSYCHOPHYSIOLOGY, V18, P493, DOI 10.1111/j.1469-8986.1981.tb01815.x; DONCHIN E, 1988, BEHAV BRAIN SCI, V11, P357, DOI 10.1017/S0140525X00058027; Fodero-Tavoletti MT, 2011, BRAIN, V134, P1089, DOI 10.1093/brain/awr038; Galvin JE, 2011, NEUROLOGY, V76, P1797, DOI 10.1212/WNL.0b013e31821ccc83; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gavett BE, 2010, J INT NEUROPSYCH SOC, V16, P651, DOI 10.1017/S1355617710000421; Gavett BE, 2009, J INT NEUROPSYCH SOC, V15, P121, DOI 10.1017/S1355617708090176; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hampel H, 2010, EXP GERONTOL, V45, P30, DOI 10.1016/j.exger.2009.10.010; Haschke M, 2007, CLIN CHEM, V53, P489, DOI 10.1373/clinchem.2006.078972; Haxel BR, 2008, J HEAD TRAUMA REHAB, V23, P407, DOI 10.1097/01.HTR.0000341437.59627.ec; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; HOMBERG V, 1986, ELECTROEN CLIN NEURO, V63, P552, DOI 10.1016/0013-4694(86)90143-4; Immonen RJ, 2009, NEUROIMAGE, V45, P1, DOI 10.1016/j.neuroimage.2008.11.022; Jagust WJ, 2009, NEUROLOGY, V73, P1193, DOI 10.1212/WNL.0b013e3181bc010c; Jones DK, 2000, NEUROSURGERY, V47, P306, DOI 10.1097/00006123-200008000-00008; KRAMER AF, 1988, BIOL PSYCHOL, V26, P231, DOI 10.1016/0301-0511(88)90022-1; Lin A.P, 2010, NEUROCHEMICAL CHANGE; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; ODONNELL BF, 1987, BIOL PSYCHOL, V24, P23, DOI 10.1016/0301-0511(87)90097-4; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; POLICH J, 1986, ELECTROEN CLIN NEURO, V63, P138, DOI 10.1016/0013-4694(86)90007-6; POLICH J, 1987, ELECTROEN CLIN NEURO, V68, P311, DOI 10.1016/0168-5597(87)90052-9; Prabhu SP, 2011, CLIN SPORT MED, V30, P103, DOI 10.1016/j.csm.2010.09.003; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Sandford AA, 2006, INT J PEDIATR OTORHI, V70, P1015, DOI 10.1016/j.ijporl.2005.10.013; Seeley WW, 2009, NEURON, V62, P42, DOI 10.1016/j.neuron.2009.03.024; Shaw LM, 2009, ANN NEUROL, V65, P403, DOI 10.1002/ana.21610; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Sperling RA, 2010, NEUROMOL MED, V12, P27, DOI 10.1007/s12017-009-8109-7; Stern RA, 2011, WILEY-BL HB BEHAV SC, P369; Talavage TM, 2010, J NEUROTRAUMA; Theriault M, 2011, J CLIN EXP NEUROPSYC, V33, P30, DOI 10.1080/13803391003772873; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vemuri P, 2009, NEUROLOGY, V73, P294, DOI 10.1212/WNL.0b013e3181af79fb; Vent J, 2010, BRAIN RES, V1320, P1, DOI 10.1016/j.brainres.2010.01.007; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Wu AP, 2008, AM J RHINOL, V22, P606, DOI 10.2500/ajr.2008.22.3238; Zhou J, 2010, BRAIN, V133, P1352, DOI 10.1093/brain/awq075; [No title captured]	61	81	81	1	48	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2011	24	6					525	531		10.1097/WCO.0b013e32834cd477			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	845VC	WOS:000296850900002	22045219				2022-02-06	
J	Kan, LX; Lounev, VY; Pignolo, RJ; Duan, LH; Liu, YJ; Stock, SR; McGuire, TL; Lu, B; Gerard, NP; Shore, EM; Kaplan, FS; Kessler, JA				Kan, Lixin; Lounev, Vitali Y.; Pignolo, Robert J.; Duan, Lishu; Liu, Yijie; Stock, Stuart R.; McGuire, Tammy L.; Lu, Bao; Gerard, Norma P.; Shore, Eileen M.; Kaplan, Frederick S.; Kessler, John A.			Substance P Signaling Mediates BMP-Dependent Heterotopic Ossification	JOURNAL OF CELLULAR BIOCHEMISTRY			English	Article						HETEROTOPIC OSSIFICATION (HO); FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP); BONE MORPHOGENETIC PROTEIN (BMP); SUBSTANCE P (SP); TACHYKININ RECEPTOR 1 (NK1R); NK1R ANTAGONIST; MAST CELLS	TACHYKININ NK1 RECEPTOR; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; DORSAL-ROOT GANGLION; MAST-CELLS; NEUROGENIC INFLAMMATION; IMMUNE INTERACTIONS; MESSENGER-RNA; NK-1 RECEPTOR; SPINAL-CORD	Heterotopic ossification (HO) is a disabling condition associated with neurologic injury, inflammation, and overactive bone morphogenetic protein (BMP) signaling. The inductive factors involved in lesion formation are unknown. We found that the expression of the neuro-inflammatory factor Substance P (SP) is dramatically increased in early lesional tissue in patients who have either fibrodysplasia ossificans progressiva (FOP) or acquired HO, and in three independent mouse models of HO. In Nse-BMP4, a mouse model of HO, robust HO forms in response to tissue injury; however, null mutations of the preprotachykinin (PPT) gene encoding SP prevent HO. Importantly, ablation of SP+ sensory neurons, treatment with an antagonist of SP receptor NK1r, deletion of NK1r gene, or genetic down-regulation of NK1r-expressing mast cells also profoundly inhibit injury-induced HO. These observations establish a potent neuro-inflammatory induction and amplification circuit for BMP-dependent HO lesion formation, and identify novel molecular targets for prevention of HO. J. Cell. Biochem. 112: 2759-2772, 2011. (C) 2011 Wiley-Liss, Inc.	[Kan, Lixin; Duan, Lishu; Liu, Yijie; McGuire, Tammy L.; Kessler, John A.] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA; [Lounev, Vitali Y.; Pignolo, Robert J.; Shore, Eileen M.; Kaplan, Frederick S.] Univ Penn, Dept Orthopaed Surg, Perelman Sch Med, Philadelphia, PA 19104 USA; [Lounev, Vitali Y.; Pignolo, Robert J.; Shore, Eileen M.; Kaplan, Frederick S.] Univ Penn, Ctr Res FOP & Related Disorders, Perelman Sch Med, Philadelphia, PA 19104 USA; [Stock, Stuart R.] Northwestern Univ, Feinberg Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA; [Pignolo, Robert J.; Kaplan, Frederick S.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Lu, Bao; Gerard, Norma P.] Childrens Hosp, Boston, MA 02215 USA; [Shore, Eileen M.] Univ Penn, Dept Genet, Perelman Sch Med, Philadelphia, PA 19104 USA		Kan, LX (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Neurol, Ward Bldg 10-233,303 E Chicago Ave, Chicago, IL 60611 USA.	l-kan@northwestern.edu	kan, lixin/I-6665-2013		Center for Research in FOP and Related Disorders; International FOP Association; Ian Cali Endowment; Weldon Family Endowment; Penn Center for Musculoskeletal Disorders; Rita Allen Foundation; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-AR041916, NS20013, NS20778]; Center for Research in FOP and Related Disorders of The University of Pennsylvania School of Medicine; Center for Research in FOP and Related Disorders at The Perelman School of Medicine of The University of Pennsylvania; Orthopaedic Molecular Medicine; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U54CA151880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01AR041916] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020013, R01NS020778] Funding Source: NIH RePORTER	Grant sponsor: Center for Research in FOP and Related Disorders; Grant sponsor: International FOP Association; Grant sponsor: Ian Cali Endowment; Grant sponsor: Weldon Family Endowment; Grant sponsor: Penn Center for Musculoskeletal Disorders; Grant sponsor: The Isaac & Rose Nassau Professorship of Orthopaedic Molecular Medicine; Grant sponsor: Rita Allen Foundation; Grant sponsor: NIH; Grant numbers: R01-AR041916, NS20013, NS20778.; We appreciate the help from many members of the Kessler lab, the assistance provided by CCM Animal Health Technicians in the acquisition of digital radiographs, and the professional help provided by Dr. Xiao-Qi Wang of Department of Dermatology, Northwestern University. We thank Dr. Mary Ann Keenan and Dr. John Esterhai in the Department of Orthopaedic Surgery, University of Pennsylvania, for samples of acquired HO. LK was supported in part by grants to from The Center for Research in FOP and Related Disorders of The University of Pennsylvania School of Medicine. JAK was supported by NIH grants NS20013 and NS20778. This work was also supported in part by the Center for Research in FOP and Related Disorders at The Perelman School of Medicine of The University of Pennsylvania, the International FOP Association, the Ian Cali Endowment, the Weldon Family Endowment, the Penn Center for Musculoskeletal Disorders, The Isaac & Rose Nassau Professorship of Orthopaedic Molecular Medicine and by grants from the Rita Allen Foundation and the NIH (R01-AR041916) to FSK and EMS. Author contributions: LK: conception and design, collection and assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript; SRS, RJP, EMS, and FSK: provision of study material, technical advice, data analysis, and manuscript editing, VYL, LD, YL, and TM: collection and/or assembly of data; BL and NPG: provision of study material; JAK: data analysis, manuscript editing, approval of manuscript.	Allison SJ, 2009, J BONE MINER RES, V24, P294, DOI 10.1359/JBMR.081013; Andoh T, 1996, MOL BRAIN RES, V35, P329, DOI 10.1016/0169-328X(95)00244-M; BARBUT D, 1981, BRAIN RES, V205, P289, DOI 10.1016/0006-8993(81)90340-1; BARR AJ, 1993, BRIT J PHARMACOL, V108, P223, DOI 10.1111/j.1476-5381.1993.tb13466.x; Bergstrom J, 2006, J ORTHOP RES, V24, P1193, DOI 10.1002/jor.20132; Bozic CR, 1996, SCIENCE, V273, P1722, DOI 10.1126/science.273.5282.1722; Cao YQ, 1998, NATURE, V392, P390, DOI 10.1038/32897; Castagliuolo I, 1998, J CLIN INVEST, V101, P1547, DOI 10.1172/JCI2039; Castagliuolo I, 1997, P NATL ACAD SCI USA, V94, P4788, DOI 10.1073/pnas.94.9.4788; Cullen N, 2009, J HEAD TRAUMA REHAB, V24, P69, DOI 10.1097/HTR.0b013e31819a8fcc; Czura CJ, 2005, J INTERN MED, V257, P156, DOI 10.1111/j.1365-2796.2004.01442.x; Datar P, 2004, CURR TOP MED CHEM, V4, P75, DOI 10.2174/1568026043451636; Donkin JJ, 2007, PROG BRAIN RES, V161, P97, DOI 10.1016/S0079-6123(06)61007-8; Donkin JJ, 2009, J CEREBR BLOOD F MET, V29, P1388, DOI 10.1038/jcbfm.2009.63; DUTTLINGER R, 1993, DEVELOPMENT, V118, P705; Edoff K, 1997, ANAT EMBRYOL, V195, P531, DOI 10.1007/s004290050073; Folgueras AR, 2009, P NATL ACAD SCI USA, V106, P16451, DOI 10.1073/pnas.0908507106; Forsberg Jonathan Agner, 2010, J Surg Orthop Adv, V19, P54; FORSSPETTER S, 1990, NEURON, V5, P187, DOI 10.1016/0896-6273(90)90308-3; Freeman TA, 2010, FIBROGENESIS TISSUE, V3, DOI 10.1186/1755-1536-3-17; Gannon FH, 2001, HUM PATHOL, V32, P842, DOI 10.1053/hupa.2001.26464; Goto T, 1998, CELL TISSUE RES, V293, P87, DOI 10.1007/s004410051100; Goto T, 2002, MICROSC RES TECHNIQ, V58, P91, DOI 10.1002/jemt.10123; Goto Tetsuya, 2001, Medical Electron Microscopy, V34, P77; HARMAR A, 1982, BRAIN RES, V231, P379, DOI 10.1016/0006-8993(82)90374-2; HEDBERG A, 1995, ANAT EMBRYOL, V192, P247; HOLZERPETSCHE U, 1995, BRIT J PHARMACOL, V115, P486, DOI 10.1111/j.1476-5381.1995.tb16359.x; Hong HS, 2009, NAT MED, V15, P425, DOI 10.1038/nm.1909; KAKU Y, 1993, J CEREBR BLOOD F MET, V13, P402, DOI 10.1038/jcbfm.1993.54; Kan LX, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/309287; Kan LX, 2009, STEM CELLS, V27, P150, DOI 10.1634/stemcells.2008-0576; Kan LX, 2004, AM J PATHOL, V165, P1107, DOI 10.1016/S0002-9440(10)63372-X; Kaplan FS, 2008, J BONE MINER METAB, V26, P521, DOI 10.1007/s00774-008-0879-8; Kaplan FS, 2007, J BONE JOINT SURG AM, V89A, P347, DOI 10.2106/JBJS.F.00472; Kennedy PGE, 1997, P NATL ACAD SCI USA, V94, P4167, DOI 10.1073/pnas.94.8.4167; Kulka M, 2008, IMMUNOLOGY, V123, P398, DOI 10.1111/j.1365-2567.2007.02705.x; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; Lerner U. H., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P154; Li JA, 2010, J ORTHOP RES, V28, P1643, DOI 10.1002/jor.21169; Madsen JE, 1998, CLIN ORTHOP RELAT R, P230; Malin SA, 2007, NAT PROTOC, V2, P152, DOI 10.1038/nprot.2006.461; MANTYH PW, 1991, ANN NY ACAD SCI, V632, P263, DOI 10.1111/j.1749-6632.1991.tb33114.x; Marques-Deak A, 2005, MOL PSYCHIATR, V10, P239, DOI 10.1038/sj.mp.4001643; MCGILLIS JP, 1987, FED PROC, V46, P196; Medici D, 2010, NAT MED, V16, P1400, DOI 10.1038/nm.2252; Millward-Sadler SJ, 2003, ARTHRITIS RHEUM, V48, P146, DOI 10.1002/art.10711; MOUSSAOUI SM, 1993, BRIT J PHARMACOL, V109, P259, DOI 10.1111/j.1476-5381.1993.tb13562.x; Mukhopadhyay A, 2009, DEVELOPMENT, V136, P2633, DOI 10.1242/dev.034439; NAGY JI, 1981, NEUROSCIENCE, V6, P1923, DOI 10.1016/0306-4522(81)90032-4; NAKAYA Y, 1994, J COMP NEUROL, V347, P249, DOI 10.1002/cne.903470208; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; NAUKKARINEN A, 1994, INT J DERMATOL, V33, P361, DOI 10.1111/j.1365-4362.1994.tb01069.x; Nelson DA, 2004, FRONT BIOSCI-LANDMRK, V9, P2166, DOI 10.2741/1372; OCHS S, 1978, J NEUROBIOL, V9, P465, DOI 10.1002/neu.480090606; Okada T, 1999, INFLAMM RES, V48, P274, DOI 10.1007/s000110050459; PAULSON JC, 1975, ANN NY ACAD SCI, V253, P517, DOI 10.1111/j.1749-6632.1975.tb19225.x; Pinto FM, 2004, EUR J PHARMACOL, V494, P233, DOI 10.1016/j.ejphar.2004.05.016; Quartara L, 1998, NEUROPEPTIDES, V32, P1, DOI 10.1016/S0143-4179(98)90015-4; REINSHAGEN M, 1994, GASTROENTEROLOGY, V106, P1208, DOI 10.1016/0016-5085(94)90011-6; Rowley D A, 1980, Contemp Top Immunobiol, V9, P205; Saban R, 2002, AM J PHYSIOL-RENAL, V283, pF616, DOI 10.1152/ajprenal.00096.2002; Salisbury E, 2010, CRIT REV EUKAR GENE, V20, P313, DOI 10.1615/CritRevEukarGeneExpr.v20.i4.30; Savastano S, 1994, Acta Neurol (Napoli), V16, P206; SAWYER JR, 1991, CALCIFIED TISSUE INT, V49, P208, DOI 10.1007/BF02556120; SHARMA HS, 1990, NEUROSCIENCE, V38, P205, DOI 10.1016/0306-4522(90)90386-I; SHEPHEARD SL, 1993, BRIT J PHARMACOL, V108, P11, DOI 10.1111/j.1476-5381.1993.tb13432.x; Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783; Stock SR, 2004, J STRUCT BIOL, V147, P185, DOI 10.1016/j.jsb.2004.03.003; Sugimoto T, 1998, BRAIN RES, V807, P147, DOI 10.1016/S0006-8993(98)00788-4; Suzuki A, 2004, BIOL PHARM BULL, V27, P1891, DOI 10.1248/bpb.27.1891; Thornton E, 2010, MOLECULES, V15, P6598, DOI 10.3390/molecules15096598; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Wang LP, 2009, BONE, V45, P309, DOI 10.1016/j.bone.2009.04.203; YANO H, 1989, J CLIN INVEST, V84, P1276, DOI 10.1172/JCI114295; Yu PB, 2008, NAT MED, V14, P1363, DOI 10.1038/nm.1888; Zubrzycka M, 2000, Endocr Regul, V34, P195	76	81	86	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0730-2312	1097-4644		J CELL BIOCHEM	J. Cell. Biochem.	OCT	2011	112	10					2759	2772		10.1002/jcb.23259			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	829YP	WOS:000295623300014	21748788	Green Accepted			2022-02-06	
J	Nigrovic, LE; Schunk, JE; Foerster, A; Cooper, A; Miskin, M; Atabaki, SM; Hoyle, J; Dayan, PS; Holmes, JF; Kuppermann, N				Nigrovic, Lise E.; Schunk, Jeff E.; Foerster, Adele; Cooper, Arthur; Miskin, Michelle; Atabaki, Shireen M.; Hoyle, John; Dayan, Peter S.; Holmes, James F.; Kuppermann, Nathan		Pediat Emergency Care Appl Res Net	The Effect of Observation on Cranial Computed Tomography Utilization for Children After Blunt Head Trauma	PEDIATRICS			English	Article						traumatic brain injury; computed tomography; clinical observation	CT; INJURY	OBJECTIVE: Children with minor blunt head trauma often are observed in the emergency department before a decision is made regarding computed tomography use. We studied the impact of this clinical strategy on computed tomography use and outcomes. METHODS: We performed a subanalysis of a prospective multicenter observational study of children with minor blunt head trauma. Clinicians completed case report forms indicating whether the child was observed before making a decision regarding computed tomography. We defined clinically important traumatic brain injury as an intracranial injury resulting in death, neurosurgical intervention, intubation for longer than 24 hours, or hospital admission for 2 nights or longer. To compare computed tomography rates between children observed and those not observed before a decision was made regarding computed tomography use, we used a generalized estimating equation model to control for hospital clustering and patient characteristics. RESULTS: Of 42 412 children enrolled in the study, clinicians noted if the patient was observed before making a decision on computed tomography in 40 113 (95%). Of these, 5433 (14%) children were observed. The computed tomography use rate was lower in those observed than in those not observed (31.1% vs 35.0%; difference: -3.9% [95% confidence interval: -5.3 to -2.6]), but the rate of clinically important traumatic brain injury was similar (0.75% vs 0.87%; difference: -0.1% [95% confidence interval: -0.4 to 0.1]). After adjustment for hospital and patient characteristics, the difference in the computed tomography use rate remained significant (adjusted odds ratio for obtaining a computed tomography in the observed group: 0.53 [95% confidence interval: 0.43-0.66]). CONCLUSIONS: Clinical observation was associated with reduced computed tomography use among children with minor blunt head trauma and may be an effective strategy to reduce computed tomography use. Pediatrics 2011; 127:1067-1073	[Nigrovic, Lise E.] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Emergency Med, Boston, MA 02115 USA; [Schunk, Jeff E.] Primary Childrens Med Ctr, Dept Pediat, Salt Lake City, UT 84103 USA; [Schunk, Jeff E.; Miskin, Michelle] Univ Utah, Sch Med, Salt Lake City, UT USA; [Foerster, Adele] Holy Cross Hosp, Silver Spring, MD USA; [Cooper, Arthur] Columbia Univ Coll Phys & Surg, Harlem Hosp Med Ctr, Dept Surg, New York, NY 10032 USA; [Dayan, Peter S.] Columbia Univ Coll Phys & Surg, Morgan Stanley Childrens Hosp New York Presbyteri, Dept Pediat, New York, NY 10032 USA; [Atabaki, Shireen M.] George Washington Univ, Sch Med, Dept Pediat, Childrens Natl Med Ctr, Washington, DC 20052 USA; [Atabaki, Shireen M.] George Washington Univ, Sch Med, Dept Emergency Med, Childrens Natl Med Ctr, Washington, DC USA; [Hoyle, John] Michigan State Univ, Sch Med, Helen DeVos Childrens Hosp, Div Emergency Med, Grand Rapids, MI USA; [Holmes, James F.; Kuppermann, Nathan] Univ Calif Davis, Davis Sch Med, Davis Med Ctr, Dept Emergency Med, Davis, CA 95616 USA; [Kuppermann, Nathan] Univ Calif Davis, Davis Sch Med, Davis Med Ctr, Dept Pediat, Davis, CA 95616 USA		Nigrovic, LE (corresponding author), Harvard Univ, Sch Med, Childrens Hosp Boston, Div Emergency Med, 300 Longwood Ave, Boston, MA 02115 USA.	lise.nigrovic@childrens.harvard.edu		Nigrovic, Lise/0000-0002-6369-3997	Health Resources and Services Administration/Maternal and Child Health Bureau, Division of Research, Training, and EducationUnited States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA); Emergency Medical Services of Children Program [R40MC02461]; Health Resources and Services Administration/Maternal and Child Health BureauUnited States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA) [U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008]	This work was supported by a grant from the Health Resources and Services Administration/Maternal and Child Health Bureau, Division of Research, Training, and Education, and the Emergency Medical Services of Children Program (R40MC02461). The PECARN is supported by cooperative agreements U03MC00001, U03MC00003, U03MC00006, U03MC00007, and U03MC00008 from the Emergency Medical Services of Children Program of the Health Resources and Services Administration/Maternal and Child Health Bureau.	Beaudin M, 2007, J PEDIATR SURG, V42, P849, DOI 10.1016/j.jpedsurg.2006.12.038; Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; DAVIS RL, 1994, ANN EMERG MED, V24, P640, DOI 10.1016/S0196-0644(94)70273-X; Frush DP, 2008, NEW ENGL J MED, V358, P851; Frush DP, 2008, PEDIATR RADIOL, V38, pS629, DOI 10.1007/s00247-008-1006-7; Hamilton M, 2010, PEDIATRICS, V126, pE33, DOI 10.1542/peds.2009-0692; Hillman BJ, 2010, NEW ENGL J MED, V363, P4, DOI 10.1056/NEJMp1003173; Klassen TP, 2000, ACAD EMERG MED, V7, P739, DOI 10.1111/j.1553-2712.2000.tb02260.x; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; McCollough CH, 2009, RADIOL CLIN N AM, V47, P27, DOI 10.1016/j.rcl.2008.10.006; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; Reilly BM, 2006, ANN INTERN MED, V144, P201, DOI 10.7326/0003-4819-144-3-200602070-00009; SCHUTZMAN SA, 1993, ANN EMERG MED, V22, P535, DOI 10.1016/S0196-0644(05)81938-9; Shrimpton PC, 1998, BRIT J RADIOL, V71, P1, DOI 10.1259/bjr.71.841.9534691; Smith-Bindman R, 2010, NEW ENGL J MED, V363, P1, DOI 10.1056/NEJMp1002530; SNOEK JW, 1984, BRAIN, V107, P15, DOI 10.1093/brain/107.1.15; Varnholt H, 2008, NEW ENGL J MED, V358, P852	22	81	83	0	3	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JUN	2011	127	6					1067	1073		10.1542/peds.2010-3373			7	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	771GV	WOS:000291146100047	21555498				2022-02-06	
J	Schatz, P; Moser, RS; Covassin, T; Karpf, R				Schatz, Philip; Moser, Rosemarie Scolaro; Covassin, Tracey; Karpf, Robin			Early Indicators of Enduring Symptoms in High School Athletes With Multiple Previous Concussions	NEUROSURGERY			English	Article						Concussion symptoms; Long-term effects; Post-Concussion Symptom Scale; Postconcussion syndrome	CHRONIC TRAUMATIC ENCEPHALOPATHY; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; RISK; RECOVERY; PLAY	BACKGROUND: Despite recent findings of cognitive, emotional, physical, and behavioral symptomatology in retired professional athletes with a history of multiple concussions, there is little systematic research examining these symptoms in high school athletes with a history of concussion. OBJECTIVE: To identify cognitive, emotional, and physical symptoms at baseline in nonconcussed high school athletes based on concussion history. METHODS: A multicenter sample of 616 high school athletes who completed baseline evaluations were assigned to groups based on history of concussion (none, 1, 2, or more previous concussions). The Post-Concussion Symptom Scale was administered as part of a computerized neuropsychological test battery during athletes' preseason baseline evaluations. Cross-sectional analyses were used to examine symptoms reported at the time of baseline neuropsychological testing. RESULTS: High school athletes with a history of 2 or more concussions showed significantly higher ratings of concussion-related symptoms (cognitive, physical, sleep difficulties) than athletes with a history of one or no previous concussions. CONCLUSION: It appears that youth athletes who sustain multiple concussions experience a variety of subtle effects, which may be possible precursors of the future onset of concussion-related difficulties.	[Schatz, Philip] St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA; [Schatz, Philip; Moser, Rosemarie Scolaro] Int Brain Res Fdn, Edison, NJ USA; [Moser, Rosemarie Scolaro] RSM Psychol Ctr LLC, Sports Concuss Ctr New Jersey, Lawrenceville, NJ USA; [Covassin, Tracey] Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA; [Karpf, Robin] Lawrenceville Sch, Lawrenceville, NJ USA		Schatz, P (corresponding author), St Josephs Univ, Dept Psychol, 222 Post Hall, Philadelphia, PA 19131 USA.	pschatz@sju.edu		Schatz, Philip/0000-0002-6222-6545			Center BUAsD, 2010, SEL CSTE CAS 18 YEAR; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Moser RS, 2007, PROF PSYCHOL-RES PR, V38, P699, DOI 10.1037/0735-7028.38.6.699; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Olian C, 2009, STUDY LINKS CONCUSSI; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pardini D., 2004, BR J SPORTS MED, V38, P661; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Schwarz A, 2008, NY TIMES        0924; Schwarz A, 2010, NFL DON 1 MILL DOLL; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	26	81	81	0	31	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUN	2011	68	6					1562	1567		10.1227/NEU.0b013e31820e382e			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Surgery	760CK	WOS:000290299700049	21258259	Bronze			2022-02-06	
J	Ye, R; Zhang, X; Kong, X; Han, J; Yang, Q; Zhang, Y; Chen, Y; Li, P; Liu, J; Shi, M; Xiong, L; Zhao, G				Ye, R.; Zhang, X.; Kong, X.; Han, J.; Yang, Q.; Zhang, Y.; Chen, Y.; Li, P.; Liu, J.; Shi, M.; Xiong, L.; Zhao, G.			GINSENOSIDE Rd ATTENUATES MITOCHONDRIAL DYSFUNCTION AND SEQUENTIAL APOPTOSIS AFTER TRANSIENT FOCAL ISCHEMIA	NEUROSCIENCE			English	Article						ginsenoside Rd; neuroprotection; mitochondria; stroke	CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; RAT-BRAIN; NEURONAL APOPTOSIS; REPERFUSION INJURY; HYPERBARIC-OXYGEN; ACUTE STROKE; ADULT RATS; MODEL; NEUROPROTECTION	We previously found that ginsenoside Rd (Rd), one of the major active ingredients in Panax ginseng, protects neuronal cells from hydrogen peroxide and oxygen-glucose deprivation, an in vitro model of cerebral ischemia. In this study, we examined the protective effects of Rd in an animal model of focal cerebral ischemia. Rats administered with Rd or vehicle were subjected to transient middle cerebral artery occlusion (MCAO). Rd (50 mg/kg) significantly reduced the infarct volume by 52.8%. This reduction of injury volume was associated with an improvement in neurological function and was sustained for at least 2 weeks after the induction of ischemia. To evaluate the underlying mechanisms of Rd against stroke, brain tissues were assayed for mitochondrial enzyme activities, mitochondrial membrane potential (MMP), production of reactive oxygen species (ROS), energy metabolites, and apoptosis. Rd markedly protected mitochondria as indicated by preserved respiratory chain complex activities and aconitase activity, lowered mitochondrial hydrogen peroxide production, and hyperpolarized MMP. Microdialysis results illustrated that Rd significantly decreased the accumulation of lactate, the end product of anaerobic glycolysis, and increased pyruvate, the end product of aerobic glycolysis, hence inducing a lower lactate/pyruvate ratio. Additionally, in vitro studies further exhibited that Rd protected isolated mitochondria from calcium-induced damage by attenuating mitochondrial swelling, preserving MMP and decreasing ROS production. Moreover, Rd treatment reduced mitochondrial release of cytochrome c (CytoC) and apoptosis-inducing factor (AIF), thereby minimizing mitochondria-mediated apoptosis following ischemia. In conclusion, these findings demonstrated that Rd exerts neuroprotective effects in transient focal ischemia, which may involve an integrated process of the mitochondrial protection, energy restoration and inhibition of apoptosis. (c) 2011 IBRO. Published by Elsevier Ltd. All rights reserved.	[Ye, R.; Zhang, X.; Han, J.; Zhang, Y.; Liu, J.; Shi, M.; Zhao, G.] Fourth Mil Med Univ, Xijing Hosp, Dept Neurol, Xian 710032, Peoples R China; [Kong, X.] Fourth Mil Med Univ, Coll Stomatol, Xian 710032, Peoples R China; [Yang, Q.; Chen, Y.; Xiong, L.] Fourth Mil Med Univ, Dept Anaesthesiol, Xijing Hosp, Xian 710032, Peoples R China; [Li, P.] Fourth Mil Med Univ, Xijing Hosp, Dept Orthoped, Xian 710032, Peoples R China		Zhao, G (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Neurol, Xian 710032, Peoples R China.	zhaogang@fmmu.edu.cn	Shi, Ming/B-7829-2012		National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81073094]	This study was supported in part by the National Natural Science Foundation of China (Grant No. 81073094). The authors are grateful to Dongyun Feng and Shiquan Wang for their excellent technical assistance with Western blot and MCAO model experiments.	Ashwal S, 1998, STROKE, V29, P1037, DOI 10.1161/01.STR.29.5.1037; Badr AE, 2001, BRAIN RES, V916, P85, DOI 10.1016/S0006-8993(01)02867-0; Barrientos A, 1998, J BIOL CHEM, V273, P14210, DOI 10.1074/jbc.273.23.14210; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Clark RSB, 2007, J CEREBR BLOOD F MET, V27, P316, DOI 10.1038/sj.jcbfm.9600338; Dave KR, 2008, J NEUROSCI, V28, P4172, DOI 10.1523/JNEUROSCI.5471-07.2008; DERYCK M, 1989, STROKE, V20, P1383, DOI 10.1161/01.STR.20.10.1383; ESTORNELL E, 1993, FEBS LETT, V332, P127, DOI 10.1016/0014-5793(93)80498-J; Gao YQ, 2010, STROKE, V41, P166, DOI 10.1161/STROKEAHA.109.561852; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Gardner PR, 2002, METHOD ENZYMOL, V349, P9, DOI 10.1016/S0076-6879(02)49317-2; Ginsberg MD, 2008, NEUROPHARMACOLOGY, V55, P363, DOI 10.1016/j.neuropharm.2007.12.007; Gropen TI, 2006, NEUROLOGY, V67, P88, DOI 10.1212/01.wnl.0000223622.13641.6d; Guan YY, 2006, EUR J PHARMACOL, V548, P129, DOI 10.1016/j.ejphar.2006.08.001; Halestrap AP, 1998, BBA-BIOENERGETICS, V1366, P79, DOI 10.1016/S0005-2728(98)00122-4; Head E, 2009, EXP NEUROL, V220, P171, DOI 10.1016/j.expneurol.2009.08.014; ISAYAMA K, 1991, STROKE, V22, P1394, DOI 10.1161/01.STR.22.11.1394; KRAHENBUHL S, 1991, J BIOL CHEM, V266, P20998; Li JS, 2008, BRAIN RES, V1210, P223, DOI 10.1016/j.brainres.2008.03.007; Li XY, 2010, CLIN EXP PHARMACOL P, V37, P199, DOI 10.1111/j.1440-1681.2009.05286.x; Lian XY, 2005, ANN NEUROL, V57, P642, DOI 10.1002/ana.20450; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Liu X, 2009, EUR J NEUROL, V16, P569, DOI 10.1111/j.1468-1331.2009.02534.x; Liu ZQ, 2003, J AGR FOOD CHEM, V51, P2555, DOI 10.1021/jf026228i; LU Y, 2009, CHIN J NEUROSURG DIS, V8, P496; Mackensen GB, 2001, J NEUROSCI, V21, P4582, DOI 10.1523/JNEUROSCI.21-13-04582.2001; Morin C, 2002, NEUROSCIENCE, V115, P415, DOI 10.1016/S0306-4522(02)00416-5; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; Sacco RL, 2007, LANCET, V369, P331, DOI 10.1016/S0140-6736(07)60155-X; Savitz SI, 2007, ANN NEUROL, V61, P396, DOI 10.1002/ana.21127; Schabitz WR, 2003, STROKE, V34, P745, DOI 10.1161/01.STR.0000057814.70180.17; Shen H, 2009, FASEB J, V23, P1958, DOI 10.1096/fj.08-123281; Sims NR, 2010, BBA-MOL BASIS DIS, V1802, P80, DOI 10.1016/j.bbadis.2009.09.003; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sutherland BA, 2004, FASEB J, V18, P258, DOI 10.1096/fj.04-2806fje; Tang W., 1992, CHINESE DRUGS PLANT; Vosler PS, 2009, STROKE, V40, P3149, DOI 10.1161/STROKEAHA.108.543769; Wang Q, 2008, ANESTHESIOLOGY, V108, P1071, DOI 10.1097/ALN.0b013e318173f66b; Wang Q, 2009, STROKE, V40, P2157, DOI 10.1161/STROKEAHA.108.541490; WHARTON DC, 1967, METHOD ENZYMOL, V55, P328; Yang F, 2010, J NEUROSCI RES, V88, P519, DOI 10.1002/jnr.22224; Yang L, 2007, J CHROMATOGR B, V854, P77, DOI 10.1016/j.jchromb.2007.04.014; Ye RD, 2008, BIOL PHARM BULL, V31, P1923, DOI 10.1248/bpb.31.1923; Ye RD, 2009, NEUROSCI RES, V64, P306, DOI 10.1016/j.neures.2009.03.016; YUAN L, 2010, CHIN J NEUROSURG DIS, V9, P254; Zeng X, 2010, J CLIN PHARMACOL, V50, P285, DOI 10.1177/0091270009344334; Zheng CY, 2008, J NEUROSCI RES, V86, P2432, DOI 10.1002/jnr.21681	51	81	93	1	22	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	MAR 31	2011	178						169	180		10.1016/j.neuroscience.2011.01.007			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	736WK	WOS:000288525500017	21219973				2022-02-06	
S	Friedman, J		Gadoth, N; Gobel, HH		Friedman, Joseph			Why Is the Nervous System Vulnerable to Oxidative Stress?	OXIDATIVE STRESS AND FREE RADICAL DAMAGE IN NEUROLOGY	Oxidative Stress in Applied Basic Research and Clinical Practice		English	Article; Book Chapter						Neuron; Microglia; Mitochondria; ROS; OS; NO; O-2 consumption; PUFA; Excitoxicity; Ca2+; Iron; NADPH oxidase; Auto-oxidation; Neurotransmitters; Antioxidants; BBB	BRAIN; DISEASE; RAT; NEURODEGENERATION; NEUROTOXICITY; CALCIUM; NEURONS; CELLS; ACID; IRON	The nervous system is especially vulnerable to reactive oxygen species (ROS)-mediated injury for the following reasons. (1) High oxygen consumption of the brain for high energy needs, that is, high O-2 consumption, results in excessive ROS produced. (2) Neuronal membranes are rich in polyunsaturated fatty acids (PUPA), which are particularly vulnerable to free radical attack. (3) The ratio of membrane surface area to cytoplasmic volume is high. (4) Specialized neuronal conduction and synaptic transmission activity depend on efficient membrane function. (5) Extended axonal morphology is prone to peripheral injury. (6) Neuronal anatomic network is vulnerable to disruptions. (7) The excitotoxic glutamate is the major effector that causes oxidative stress (OS). (8) The high Ca2+ traffic across neuronal membranes and interference of ion transport increase intracellular Ca2+, often leading to OS. (9) Auto-oxidation of neurotransmitters can generate O-2 and quinones that reduce glutathione. (10) Iron is formed throughout the brain, and brain damage readily releases iron ions capable of catalyzing free radical reactions. (11) Antioxidant defense mechanisms are modest, in particular, low levels of catalase, glutathione peroxidase, and vitamin E. (12) ROS directly downregulate proteins of tight junctions and indirectly activate matrix metalloproteinases (AMP) that contribute to open the blood brain barrier (BBB). (13) Activated microglia produce ROS and cytokines in a perpetual process. (14) Cytochrome P450 produces ROS. (15) Loss of trophic support can activate NADPH oxidase, which increases ROS. (16) The presence of hemoglobin within the neural tissues secondary to spontaneous, iatrogenic, or traumatic causes is neurotoxic. Heme and iron are released and promote ROS. (17) Neuronal mitochondria generate O-2. (18) The interaction of NO with superoxide can be implicated also in neuronal degeneration. (19) Neuronal cells are nonreplicating and thus are sensitive to ROS. In comparison with other organs, the neuronal network may be especially vulnerable to ROS-mediated injury because of the following anatomic, physiological, and biochemical properties of the brain.			Friedman, J (corresponding author), Weizmann Sci Pk, Ness Ziona, Israel.	dr.josephfriedman@gmail.com					Alayash AI, 2004, NAT REV DRUG DISCOV, V3, P152, DOI 10.1038/nrd1307; Ameijeiras A.H., 2004, NEUROCHEM INT, V45, P103; Asaeda M, 2005, NEUROSCI LETT, V373, P222, DOI 10.1016/j.neulet.2004.10.008; Carey J., 2002, BRAIN FACTS PRIMER B; Chen CT, 2008, PROSTAG LEUKOTR ESS, V79, P85, DOI 10.1016/j.plefa.2008.09.003; Chen-Roetling J, 2009, NEUROPHARMACOLOGY, V56, P922, DOI 10.1016/j.neuropharm.2009.01.022; Devi SA, 2009, THESCIENTIFICWORLDJO, V9, P366, DOI 10.1100/tsw.2009.46; Duncan Andrew J., 2005, Molecular Aspects of Medicine, V26, P67, DOI 10.1016/j.mam.2004.09.004; Dyall SC, 2008, NEUROMOL MED, V10, P219, DOI 10.1007/s12017-008-8036-z; Fishel ML, 2007, MUTAT RES-FUND MOL M, V614, P24, DOI 10.1016/j.mrfmmm.2006.06.007; Gonzalez A, 2002, CELL SIGNAL, V14, P153, DOI 10.1016/S0898-6568(01)00247-9; Halliwell B, 2006, J NEUROCHEM, V97, P1634, DOI 10.1111/j.1471-4159.2006.03907.x; Hider RC, 2008, BIOCHEM SOC T, V36, P1304, DOI 10.1042/BST0361304; Howard LA, 2003, BRIT J PHARMACOL, V138, P1376, DOI 10.1038/sj.bjp.0705146; Kim GW, 2003, J NEUROSCI, V23, P8733; Kudin AP, 2005, BIOMED PHARMACOTHER, V59, P163, DOI 10.1016/j.biopha.2005.03.012; Mailly F, 1999, J NEUROCHEM, V73, P1181, DOI 10.1046/j.1471-4159.1999.0731181.x; Miksys S, 2004, DRUG METAB REV, V36, P313, DOI 10.1081/DMR-120034149; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Phillis JW, 2003, NEUROCHEM INT, V43, P461, DOI 10.1016/S0197-0186(03)00035-4; Phumala N, 2003, FREE RADICAL RES, V37, P129, DOI 10.1080/1071576031000060607; Pun PBL, 2009, FREE RADICAL RES, V43, P348, DOI 10.1080/10715760902751902; Puntambekar P, 2005, J NEUROCHEM, V95, P1689, DOI 10.1111/j.1471-4159.2005.03518.x; Sanchez-Carbente MR, 2005, CELL DEATH DIFFER, V12, P279, DOI 10.1038/sj.cdd.4401560; Spencer JPE, 1998, J NEUROCHEM, V71, P2112; Stankiewicz JM, 2009, CURR OPIN CLIN NUTR, V12, P22, DOI 10.1097/MCO.0b013e32831ba07c; Troadec JD, 2001, J NEUROCHEM, V79, P200, DOI 10.1046/j.1471-4159.2001.00556.x; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Vannucci RC, 2001, DEV BRAIN RES, V126, P117, DOI 10.1016/S0165-3806(00)00135-8	29	81	84	4	4	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES	2197-7224	2197-7232	978-1-60327-513-2	OXID STRESS APPL BAS	Oxid. Stress Appl. Basic Res. Clin. Pract.		2011							19	27		10.1007/978-1-60327-514-9_2	10.1007/978-1-60327-514-9		9	Biochemical Research Methods; Neurosciences	Book Citation Index – Science (BKCI-S)	Biochemistry & Molecular Biology; Neurosciences & Neurology	BSM94	WOS:000284978600002					2022-02-06	
J	Chio, CC; Lin, JW; Chang, MW; Wang, CC; Kuo, JR; Yang, CZ; Chang, CP				Chio, Chung-Ching; Lin, Jia-Wei; Chang, Ming-Wen; Wang, Che-Chuan; Kuo, Jinn-Rung; Yang, Chung-Zhing; Chang, Ching-Ping			Therapeutic evaluation of etanercept in a model of traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						apoptosis; etanercept; inflammation; traumatic brain injury; tumor necrosis factor-alpha	NECROSIS-FACTOR-ALPHA; PERISPINAL ETANERCEPT; CEREBRAL-ISCHEMIA; INTERLEUKIN-10; INFLAMMATION; IL-10; NEUROGENESIS; REGENERATION; ENDOTOXEMIA; OUTGROWTH	P>Antagonism of tumor necrosis factor-alpha with etanercept has proved to be effective in the treatment of spinal cord injury and centrally endotoxin-induced brain injury. However, etanercept may offer promise as therapy for traumatic brain injury (TBI). In this study, anesthetized rats, immediately after the onset of TBI, were divided into two major groups and given the vehicle solution (1 mL/kg of body weight) or etanercept (5 mg/kg of body weight) intraperitoneally once per 12 h for consecutive 3 days. Etanercept caused attenuation of TBI-induced cerebral ischemia (e.g., increased cellular levels of glutamate and lactate-to-pyruvate ratio), damage (e.g., increased cellular levels of glycerol) and contusion and motor and cognitive function deficits. TBI-induced neuronal apoptosis (e.g., increased numbers of terminal deoxynucleotidyl transferase alpha UTP nick-end labeling and neuronal-specific nuclear protein double-positive cells), glial apoptosis (e.g., increased numbers of terminal deoxynucleotidyl transferase alpha UTP nick-end labeling and glial fibrillary acidic protein double-positive cells), astrocytic (e.g., increased numbers of glial fibrillary acidic protein positive cells) and microglial (e.g., increased numbers of ionized calcium-binding adapter molecule 1-positive cells) activation and activated inflammation (e.g., increased levels of tumor necrosis factor-alpha, interleukin-1 beta and interleukin-6) were all significantly reduced by etanercept treatment. These findings suggest that etanercept may improve outcomes of TBI by penetrating into the cerebrospinal fluid in rats.	[Kuo, Jinn-Rung; Yang, Chung-Zhing; Chang, Ching-Ping] So Taiwan Univ, Dept Biotechnol, Tainan, Taiwan; [Chio, Chung-Ching; Wang, Che-Chuan; Kuo, Jinn-Rung] Chi Mei Med Ctr, Dept Surg, Tainan, Taiwan; [Lin, Jia-Wei] Taipei Med Univ, Dept Neurosurg, Shuang Ho Hosp, Taipei, Taiwan; [Lin, Jia-Wei] Taipei Med Univ, Grad Inst Clin Med, Taipei, Taiwan; [Chang, Ming-Wen] So Taiwan Univ, Dept Elect Engn, Tainan, Taiwan		Chang, CP (corresponding author), So Taiwan Univ, Dept Biotechnol, Tainan, Taiwan.	jessica@mail.stut.edu.tw		Chang, Ching-Ping/0000-0003-0890-9414	National Science Council of the Republic of ChinaMinistry of Science and Technology, Taiwan [NSC 98-2314-B-218 -001 -MY2, NSC 99-2314-B-384 -004 -MY3, DOH99-TD-B-111-003]	This study was funded in part by the National Science Council of the Republic of China (Grant Nos. NSC 98-2314-B-218 -001 -MY2 and NSC 99-2314-B-384 -004 -MY3, and DOH99-TD-B-111-003, Center of Excellence for Clinical Trial and Research in Neuroscience.	Aden U, 2010, BRAIN BEHAV IMMUN, V24, P747, DOI 10.1016/j.bbi.2009.10.010; Banks WA, 2004, CURR PHARM DESIGN, V10, P1365, DOI 10.2174/1381612043384862; BERG DJ, 1995, J CLIN INVEST, V96, P2339, DOI 10.1172/JCI118290; BULLOCK R, 1995, STROKE, V26, P2187, DOI 10.1161/01.STR.26.11.2187; Campbell SJ, 2007, J NEUROCHEM, V103, P2245, DOI 10.1111/j.1471-4159.2007.04928.x; Cartmell T, 2003, J PHYSIOL-LONDON, V549, P653, DOI 10.1113/jphysiol.2002.037291; Chang MW, 2008, J NEUROSCI METH, V168, P186, DOI 10.1016/j.jneumeth.2007.09.013; Chen SH, 2009, CRIT CARE MED, V37, P3097, DOI 10.1097/CCM.0b013e3181bc7986; Chio CC, 2007, SHOCK, V28, P284, DOI 10.1097/SHK.0b013e3180311e60; Chou YT, 2003, SHOCK, V19, P388, DOI 10.1097/00024382-200304000-00016; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; Francis J, 2004, AM J PHYSIOL-HEART C, V286, pH2264, DOI 10.1152/ajpheart.01072.2003; Genovese T, 2006, J PHARMACOL EXP THER, V316, P1006, DOI 10.1124/jpet.105.097188; Hailer NP, 2005, EUR J NEUROSCI, V21, P2347, DOI 10.1111/j.1460-9568.2005.04067.x; Hoehn BD, 2005, STROKE, V36, P2718, DOI 10.1161/01.STR.0000190020.30282.cc; Jiang Y, 2008, NEUROBIOL DIS, V32, P125, DOI 10.1016/j.nbd.2008.06.017; Kato K, 2010, J NEUROSCI RES, V88, P360, DOI 10.1002/jnr.22202; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Kuo JR, 2007, RESUSCITATION, V75, P506, DOI 10.1016/j.resuscitation.2007.05.011; Larsson K, 2005, SPINE, V30, P621, DOI 10.1097/01.brs.0000155410.48700.9e; Leon LR, 1999, AM J PHYSIOL-REG I, V276, pR81, DOI 10.1152/ajpregu.1999.276.1.R81; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; MARCHANT A, 1994, EUR J IMMUNOL, V24, P1167, DOI 10.1002/eji.1830240524; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; Neumann H, 2002, J NEUROSCI, V22, P854, DOI 10.1523/JNEUROSCI.22-03-00854.2002; Nilsson OG, 1996, ACT NEUR S, V67, P45; Paxinos G., 1982, RAT BRAIN STEREOTAXI, V1st ed.; Rasmussen M, 2005, ACTA ANAESTH SCAND, V49, P341, DOI 10.1111/j.1399-6576.2005.00647.x; Rennick DM, 1997, J LEUKOCYTE BIOL, V61, P389, DOI 10.1002/jlb.61.4.389; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; STANDIFORD TJ, 1995, J IMMUNOL, V155, P2222; Tobinick E, 2010, EXPERT REV NEUROTHER, V10, P985, DOI 10.1586/ERN.10.52; Tobinick EL, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-2; vanderPoll T, 1997, J INFECT DIS, V175, P118, DOI 10.1093/infdis/175.1.118; Wang Q, 2001, AM J PHYSIOL-REG I, V281, pR1013, DOI 10.1152/ajpregu.2001.281.3.R1013; Wang Y, 1997, J NEUROSCI, V17, P4341; Zhou ZG, 2009, J NEUROCHEM, V110, P1617, DOI 10.1111/j.1471-4159.2009.06263.x	39	81	83	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	NOV	2010	115	4					921	929		10.1111/j.1471-4159.2010.06969.x			9	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	669UF	WOS:000283375000012	20796174	Bronze			2022-02-06	
J	Newcombe, VFJ; Williams, GB; Scoffings, D; Cross, J; Carpenter, TA; Pickard, JD; Menon, DK				Newcombe, Virginia F. J.; Williams, Guy B.; Scoffings, Daniel; Cross, Justin; Carpenter, T. Adrian; Pickard, John D.; Menon, David K.			Aetiological differences in neuroanatomy of the vegetative state: insights from diffusion tensor imaging and functional implications	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; HYPOXIC-ISCHEMIC ENCEPHALOPATHY; COMA RECOVERY SCALE; CLOSED-HEAD INJURY; AXONAL INJURY; MR-IMAGES; METHYLPHENIDATE; NEUROPATHOLOGY; CONSCIOUSNESS; COMPREHENSION	Background An improved in vivo understanding of variations in neuropathology in the vegetative state (VS) may aid diagnosis, improve prognostication and help refine the selection of patients for particular treatment regimes. The authors have used diffusion tensor imaging (DTI) to characterise the extent and location of white matter loss in VS secondary to traumatic brain injury (TBI) and ischaemicehypoxic injury. Methods Twelve patients with VS (seven TBI, five ischaemic/hypoxic injuries) underwent MRI including DTI at a minimum of 3 months postinjury. Mean apparent diffusion coefficient, fractional anisotropy and eigenvalues were obtained for whole-brain grey and white matter, the pons, thalamus, ventral midbrain, dorsal midbrain and the corpus callosum. DTI measures of supratentorial damage were compared with a summed measure from the JFK modified Coma Recovery Scale (CRS-R) and with a three-point scale of functional magnetic resonance imaging (fMRI) response to an auditory paradigm to assess whether residual integrity of supratentorial white matter connectivity correlated with cortical processing. Results Conventional radiological approaches did not detect lesions in regions where quantitative DTI demonstrated abnormalities. There was evidence of marked, broadly similar, abnormalities in the supratentorial grey-and white-matter compartments from both aetiologies. In contrast, discordant findings were found in the infratentorial compartment, with DTI abnormalities in the brainstem confined to the TBI group. Supratentorial DTI abnormalities correlated with the CRS-R as well as responses to an fMRI paradigm that detected convert cognitive processing. Conclusions DTI may help to characterise differences in patients in VS. These findings may have implications for response to therapies, and should be taken into account in trials of interventions aimed at arousal in VS.	[Newcombe, Virginia F. J.; Menon, David K.] Univ Cambridge, Univ Div Anaesthesia, Cambridge CB2 2QQ, England; [Newcombe, Virginia F. J.; Williams, Guy B.; Carpenter, T. Adrian; Pickard, John D.; Menon, David K.] Univ Cambridge, Dept Clin Neurosci, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England; [Scoffings, Daniel; Cross, Justin] Univ Cambridge, Dept Radiol, Addenbrookes Hosp, Cambridge CB2 2QQ, England; [Pickard, John D.] Univ Cambridge, Acad Neurosurg Unit, Dept Clin Neurosci, Cambridge CB2 2QQ, England		Newcombe, VFJ (corresponding author), Univ Cambridge, Univ Div Anaesthesia, Addenbrookes Hosp, Box 93,Hills Rd, Cambridge CB2 2QQ, England.	vfjn2@wbic.cam.ac.uk	Scoffings, Daniel/AAA-1649-2022	Newcombe, Virginia/0000-0001-6044-9035	UK Department of Health; Gates Cambridge Trust; NIHR Cambridge Biomedical Research CentreNational Institute for Health Research (NIHR); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0001237, G0600986] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327, ACF-2009-14-007] Funding Source: researchfish; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0600986, G0001237, G9439390] Funding Source: UKRI	This research was supported by: UK National Institute of Health Research Biomedical Research Centre at Cambridge Technology Platform funding provided by the UK Department of Health. VFJN was supported by the Gates Cambridge Trust and an Overseas Research Studentship. JC and DS are supported by the NIHR Cambridge Biomedical Research Centre.	Adams JH, 1999, J CLIN PATHOL, V52, P804, DOI 10.1136/jcp.52.11.804; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Ammermann H, 2007, J NEUROL SCI, V260, P65, DOI 10.1016/j.jns.2007.03.026; AUER RN, 2008, HYPOXIA RELATED COND, pCH2; Coleman MR, 2009, BRAIN, V132, P2541, DOI 10.1093/brain/awp183; Coleman MR, 2007, BRAIN, V130, P2494, DOI 10.1093/brain/awm170; Els T, 2004, ACTA NEUROL SCAND, V110, P361, DOI 10.1111/j.1600-0404.2004.00342.x; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Giacino JT, 2006, ARCH PHYS MED REHAB, V87, pS67, DOI 10.1016/j.apmr.2006.07.272; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Greer DM, 2006, SEMIN NEUROL, V26, P373, DOI 10.1055/s-2006-948317; Holmes CJ, 1998, J COMPUT ASSIST TOMO, V22, P324, DOI 10.1097/00004728-199803000-00032; Juengling FD, 2005, J NEUROL SCI, V228, P179, DOI 10.1016/j.jns.2004.11.052; Kalmar K, 2005, NEUROPSYCHOL REHABIL, V15, P454, DOI 10.1080/09602010443000425; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; Kawahara H, 2000, J NEUROL SCI, V181, P73, DOI 10.1016/S0022-510X(00)00433-0; Kim YH, 2006, CLIN REHABIL, V20, P24, DOI 10.1191/0269215506cr927oa; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; KINNEY HC, 1994, NEW ENGL J MED, V330, P1469, DOI 10.1056/NEJM199405263302101; Leonard BE, 2004, HUM PSYCHOPHARM CLIN, V19, P151, DOI 10.1002/hup.579; McKinney AM, 2004, AM J NEURORADIOL, V25, P1659; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Oehmichen M, 1999, INT J LEGAL MED, V112, P261, DOI 10.1007/s004140050246; Owen AM, 2007, ARCH NEUROL-CHICAGO, V64, P1098, DOI 10.1001/archneur.64.8.1098; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Pavlovskaya M, 2007, BRAIN INJURY, V21, P489, DOI 10.1080/02699050701311117; Rodd JM, 2005, CEREB CORTEX, V15, P1261, DOI 10.1093/cercor/bhi009; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2002, BRAIN, V125, P1210, DOI 10.1093/brain/awf131; Sherbondy A, 2005, IEEE T VIS COMPUT GR, V11, P419, DOI 10.1109/TVCG.2005.59; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Teitelman E, 2001, AM J PSYCHIAT, V158, P1341, DOI 10.1176/ajp.158.8.1341; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Ward P, 2006, PEDIATRICS, V117, pE619, DOI 10.1542/peds.2005-0545; Wijdicks EFM, 2001, AM J NEURORADIOL, V22, P1561; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013; Yasokawa YT, 2007, J NEUROTRAUM, V24, P163, DOI 10.1089/neu.2006.0073; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424; ANAL SOFTWARE SYSTEM; FMRIBS DIFFSUION TOO; VTK CISG REGISTRATIO	43	81	86	0	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	2010	81	5					552	561		10.1136/jnnp.2009.196246			10	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	594MM	WOS:000277541800022	20460593	Bronze			2022-02-06	
J	Govind, V; Gold, S; Kaliannan, K; Saigal, G; Falcone, S; Arheart, KL; Harris, L; Jagid, J; Maudsley, AA				Govind, Varan; Gold, Stuart; Kaliannan, Krithica; Saigal, Gaurav; Falcone, Steven; Arheart, Kristopher L.; Harris, Leo; Jagid, Jonathan; Maudsley, Andrew A.			Whole-Brain Proton MR Spectroscopic Imaging of Mild-to-Moderate Traumatic Brain Injury and Correlation with Neuropsychological Deficits	JOURNAL OF NEUROTRAUMA			English	Article						brain; magnetic resonance spectroscopic imaging; magnetic resonance spectroscopy; neuropsychological test; traumatic brain injury	MAGNETIC-RESONANCE-SPECTROSCOPY; DIFFUSE AXONAL INJURY; HEAD-INJURY; IN-VIVO; LIPID-SYNTHESIS; ACETYL GROUPS; H-1 MRS; SEVERITY; CT; ABNORMALITIES	Changes in the distribution of the magnetic resonance (MR)-observable brain metabolites N-acetyl aspartate (NAA), total choline (Cho), and total creatine (Cre), following mild-to-moderate closed-head traumatic brain injury (mTBI) were evaluated using volumetric proton MR spectroscopic imaging (MRSI). Studies were carried out during the subacute time period following injury, and associations of metabolite indices with neuropsychological test (NPT) results were evaluated. Twenty-nine subjects with mTBI and Glasgow Coma Scale (GCS) scores of 10-15 were included. Differences in individual metabolite and metabolite ratio distributions relative to those of age-matched control subjects were evaluated, as well as analyses by hemispheric lobes and tissue types. Primary findings included a widespread decrease of NAA and NAA/Cre, and increases of Cho and Cho/NAA, within all lobes of the TBI subject group, and with the largest differences seen in white matter. Examination of the association between all of the metabolite measures and the NPT scores found the strongest negative correlations to occur in the frontal lobe and for Cho/NAA. No significant correlations were found between any of the MRSI or NPT measures and the GCS. These results demonstrate that significant and widespread alterations of brain metabolites occur as a result of mild-to-moderate TBI, and that these measures correlate with measures of cognitive performance.	[Govind, Varan; Kaliannan, Krithica; Saigal, Gaurav; Falcone, Steven; Harris, Leo; Maudsley, Andrew A.] Univ Miami, Sch Med, Dept Radiol, Profess Arts Ctr, Miami, FL 33136 USA; [Harris, Leo; Jagid, Jonathan] Univ Miami, Sch Med, Dept Neurosurg, Miami, FL 33136 USA; [Gold, Stuart] Univ Miami, Sch Med, Dept Neurol, Miami, FL 33136 USA; [Arheart, Kristopher L.] Univ Miami, Sch Med, Dept Epidemiol, Miami, FL 33136 USA		Govind, V (corresponding author), Univ Miami, Sch Med, Dept Radiol, Profess Arts Ctr, 1150 NW 14th St,Suite 713, Miami, FL 33136 USA.	VGovind@med.miami.edu		Maudsley, Andrew/0000-0001-7653-3063; Govind, Varan/0000-0002-1205-5194	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS055107, R01EB000822]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB000822] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055107] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health grants R01NS055107 and R01EB000822. The authors thank Sulaiman Sheriff for his help in creating the figures.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Baldo JV, 2001, J INT NEUROPSYCH SOC, V7, P586, DOI 10.1017/S1355617701755063; Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Benton AL, 1994, MULTILINGUAL APHASIA; Bigler ED, 2003, ARCH CLIN NEUROPSYCH, V18, P595; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P227, DOI 10.1016/S0887-6177(00)00081-0; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; BURRI R, 1991, DEV NEUROSCI-BASEL, V13, P403, DOI 10.1159/000112191; Carpentier A, 2006, J NEUROTRAUM, V23, P674, DOI 10.1089/neu.2006.23.674; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cecil KM, 1998, J NEUROCHEM, V70, P2038; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Chakraborty G, 2001, J NEUROCHEM, V78, P736, DOI 10.1046/j.1471-4159.2001.00456.x; Collins DL, 1998, IEEE T MED IMAGING, V17, P463, DOI 10.1109/42.712135; Dautry W, 2000, J CEREBR BLOOD F MET, V20, P789, DOI 10.1097/00004647-200005000-00005; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Frost JA, 1999, BRAIN, V122, P199, DOI 10.1093/brain/122.2.199; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; Gasparovic C, 2001, J NEUROTRAUM, V18, P241, DOI 10.1089/08977150151070856; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GOLDBERG E, 1994, J NEUROPSYCH CLIN N, V6, P371; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Govindaraju V, 2000, NMR BIOMED, V13, P129, DOI 10.1002/1099-1492(200005)13:3<129::AID-NBM619>3.0.CO;2-V; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Holshouser BA, 2006, J MAGN RESON IMAGING, V24, P33, DOI 10.1002/jmri.20607; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Jones NR, 1998, J CLIN NEUROSCI, V5, P73, DOI 10.1016/S0967-5868(98)90207-7; Kirov I, 2007, BRAIN INJURY, V21, P1147, DOI 10.1080/02699050701630383; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Kwok FY, 2008, BRAIN INJURY, V22, P740, DOI 10.1080/02699050802336989; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Macmillan CSA, 2002, ACTA NEUROCHIR, V144, P853, DOI 10.1007/s00701-002-0966-x; Marino S, 2007, J NEUROL NEUROSUR PS, V78, P501, DOI 10.1136/jnnp.2006.099796; Maudsley AA, 2006, NMR BIOMED, V19, P492, DOI 10.1002/nbm.1025; Maudsley AA, 2009, MAGN RESON MED, V61, P548, DOI 10.1002/mrm.21875; MAUDSLEY AA, 2009, NMR BIOMED, V22, P1; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Reitan RM, 1985, HALSTEADREITAN NEURO; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Signoretti S, 2002, ACT NEUR S, V81, P373; Signoretti S, 2010, MOL CELL BIOCHEM, V333, P269, DOI 10.1007/s11010-009-0228-9; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Stroobant N, 2009, BEHAV BRAIN RES, V199, P190, DOI 10.1016/j.bbr.2008.11.040; Uzan M, 2003, J NEUROL NEUROSUR PS, V74, P33, DOI 10.1136/jnnp.74.1.33; Wechsler D., 2002, WAIS 3 WMS 3 TECHNIC; Wechsler D., 1997, WECHSLER MEMORY SCAL; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391	62	81	85	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2010	27	3					483	496		10.1089/neu.2009.1159			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	575PJ	WOS:000276079100003	20201668	Green Published			2022-02-06	
J	Iverson, GL; Brooks, BL; Ashton, VL; Lange, RT				Iverson, Grant L.; Brooks, Brian L.; Ashton, V. Lynn; Lange, Rael T.			Interview Versus Questionnaire Symptom Reporting in People With the Postconcussion Syndrome	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						mild traumatic brain injury; open-ended interview; postconcussion syndrome; recall bias	TRAUMATIC BRAIN-INJURY; POST-CONCUSSION SYNDROME; EMOTIONAL RISK-FACTORS; COMPLAINT BASE RATES; MILD HEAD-INJURY; COGNITIVE PERFORMANCE; DIAGNOSIS THREAT; SELF-REPORT; EXPECTATION; NOCEBO	Objective: To compare spontaneous, interview-based, postconcussion symptom reporting to endorsement of symptoms on a standardized questionnaire. Participants: Sixty-one patients referred to a concussion clinic following mild traumatic brain injury. Procedure: Patients recalled their current symptoms and problems via open-ended interview and then completed a structured postconcussion checklist. Main Outcome Measures: Open-ended interview and the British Columbia Postconcussion Symptom Inventory (BC-PSI). Results: On average, patients endorsed 3.3 symptoms (SD = 1.9) during open-ended interview and 9.1 symptoms (SD = 3.2) on the BC-PSI (P < .001). Approximately 44% endorsed 4 or more symptoms during interview compared with 92% on the BC-PSI. The percentage of patients endorsing items on the BC-PSI compared with interview was significantly greater on all 13 items. It was common for patients to endorse symptoms as moderate-severe on the BC-PSI, despite not spontaneously reporting those symptoms during the interview. Conclusions: Clinicians need to be cautious when interpreting questionnaires and be aware of the possibility of nonspecific symptom endorsement, symptom overendorsement, symptom expectations influencing symptom endorsement, and the nocebo effect.	[Iverson, Grant L.] Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2A1, Canada; [Iverson, Grant L.; Lange, Rael T.] British Columbia Mental Hlth & Addict Serv, Vancouver, BC, Canada; [Ashton, V. Lynn] Coquitlam & Royal Columbian Hosp, Fraser Hlth Concuss Clin, New Westminster, BC, Canada; [Brooks, Brian L.] Univ Calgary, Calgary, AB T2N 1N4, Canada		Iverson, GL (corresponding author), Univ British Columbia, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada.	giverson@interchange.ubc.ca		Iverson, Grant/0000-0001-7348-9570	University of British Columbia Behavioural Research Ethics Board	This research was granted ethical clearance by the University of British Columbia Behavioural Research Ethics Board.	Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; Bootzin RR, 2005, J CLIN PSYCHOL, V61, P871, DOI 10.1002/jclp.20131; Bowling A, 2005, J PUBLIC HEALTH-UK, V27, P281, DOI 10.1093/pubmed/fdi031; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Davis CH, 2002, AM J PHYS MED REHAB, V81, P609, DOI 10.1097/00002060-200208000-00009; DUNN JT, 1995, J CLIN PSYCHOL, V51, P577, DOI 10.1002/1097-4679(199507)51:4<577::AID-JCLP2270510418>3.0.CO;2-E; Evans RW, 2003, HEADACHE, V43, P1113, DOI 10.1046/j.1526-4610.2003.03216.x; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; Hahn RA, 1997, PREV MED, V26, P607, DOI 10.1006/pmed.1996.0124; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Hilsabeck RC, 1998, J CLIN EXP NEUROPSYC, V20, P328, DOI 10.1076/jcen.20.3.328.813; Homsi J, 2006, SUPPORT CARE CANCER, V14, P444, DOI 10.1007/s00520-005-0009-2; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2004, STUD NEUROPSYCHOL DE, P323; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; KENNEDY W P, 1961, Med World, V95, P203; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; MCCAULEY SR, 2007, J CLIN EXP NEUROPSYC, V30, P1; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Nolin P, 2006, BRAIN INJURY, V20, P1147, DOI 10.1080/02699050601049247; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Ryder AG, 2008, J ABNORM PSYCHOL, V117, P300, DOI 10.1037/0021-843X.117.2.300; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Stapleton E, 2008, J LARYNGOL OTOL, V122, P139, DOI 10.1017/S0022215107009073; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Tsanadis J, 2008, CLIN NEUROPSYCHOL, V22, P1080, DOI 10.1080/13854040701796928; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; World Health Organization, 2004, ICD 10 INT STAT CLAS	55	81	82	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2010	25	1					23	30		10.1097/HTR.0b013e3181b4b6ab			8	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	550XC	WOS:000274165800004	19680134				2022-02-06	
J	Hoffman, AN; Cheng, JP; Zafonte, RD; Kline, AE				Hoffman, Ann N.; Cheng, Jeffrey P.; Zafonte, Ross D.; Kline, Anthony E.			Administration of haloperidol and risperidone after neurobehavioral testing hinders the recovery of traumatic brain injury-induced deficits	LIFE SCIENCES			English	Article						Antipsychotics; Brain injury; Functional recovery; Water maze	CONTROLLED CORTICAL IMPACT; WATER MAZE PERFORMANCE; RAT FRONTAL-CORTEX; ISCHEMIA IN-VIVO; ATYPICAL ANTIPSYCHOTICS; SIGMA(1) RECEPTOR; WORKING-MEMORY; DOPAMINERGIC TRANSMISSION; METHYLPHENIDATE TREATMENT; CHOLINERGIC MARKERS	Aims: Agitation and aggression are common behavioral sequelae of traumatic brain injury (TBI). The management of these symptoms is critical for effective patient care and therefore antipsychotics are routinely administered even though the benefits vs. risks of this approach on functional outcome after TBI are unclear. A recent study from our group revealed that both haloperidol and risperidone impaired recovery when administered prior to testing. However, the results may have been confounded by drug-induced sedation. Hence, the current study reevaluated the behavioral effects of haloperidol and risperidone when provided after daily testing, thus circumventing the potential sedative effect. Main methods: Fifty-four isoflurane-anesthetized mate rats received a cortical impact or sham injury and then were randomly assigned to three TBI and three sham groups that received haloperidol (0.5 mg/kg), risperidone (0.45 nng/kg), or vehicle (1.0 mL/kg). Treatments began 24 h after surgery and were administered (i.p.) every day thereafter for 19 days. Motor and cognitive function was assessed on post-operative days 1-5 and 14-19, respectively. Hippocampal CA(1)/CA(3) neurons and cortical lesion volume were quantified at 3 weeks. Key findings: Only risperidone delayed motor recovery, but both antipsychotics impaired spatial learning relative to vehicle (p<0.05). Neither swim speed nor histological outcomes were affected. No differences were observed between the haloperidol and risperidone groups in any task. Significance: These data support our previous finding that chronic haloperidol and risperidone hinder the recovery of TBI-induced deficits, and augment those data by demonstrating that the effects are not mediated by drug-induced sedation. (C) 2008 Elsevier Inc. All rights reserved.	[Kline, Anthony E.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Hoffman, Ann N.; Cheng, Jeffrey P.; Kline, Anthony E.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15213 USA; [Zafonte, Ross D.] Harvard Univ, Sch Med, Boston, MA 02144 USA; [Zafonte, Ross D.] Spaulding Rehabil Hosp, Boston, MA 02114 USA; [Zafonte, Ross D.] Massachusetts Gen Hosp, Boston, MA 02114 USA		Kline, AE (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu		Cheng, Jeffrey/0000-0001-8285-3207	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD046700]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069620] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD046700] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005] Funding Source: NIH RePORTER	This work was supported, in part, by NIH grant HD046700 (AEK).	Cheng JP, 2007, NEUROSCI LETT, V416, P165, DOI 10.1016/j.neulet.2007.02.006; Didriksen M, 2006, EUR J PHARMACOL, V542, P108, DOI 10.1016/j.ejphar.2006.05.021; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dunn-Meynell AA, 1998, BRAIN RES, V800, P245, DOI 10.1016/S0006-8993(98)00524-1; Elovic EP, 2008, J HEAD TRAUMA REHAB, V23, P132, DOI 10.1097/01.HTR.0000314532.07530.e5; Elovic EP, 2003, J HEAD TRAUMA REHAB, V18, P177, DOI 10.1097/00001199-200303000-00008; Espallergues J, 2007, BRIT J PHARMACOL, V152, P267, DOI 10.1038/sj.bjp.0707386; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1993, J NEURAL TRANSP PLAS, V4, P199, DOI 10.1155/NP.1993.199; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Gemperle AY, 2003, PSYCHOPHARMACOLOGY, V169, P354, DOI 10.1007/s00213-003-1459-1; Goldstein LB, 2002, NEUROREHAB NEURAL RE, V16, P321, DOI 10.1177/154596830201600402; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hoffman AN, 2008, NEUROSCI LETT, V431, P226, DOI 10.1016/j.neulet.2007.11.042; Karl T, 2006, BEHAV BRAIN RES, V171, P286, DOI 10.1016/j.bbr.2006.04.004; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2001, HEAD TRAUMA, P65; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Kline AE, 2007, CRIT CARE MED, V35, P919, DOI 10.1097/01.CCM.0000256722.88854.C0; Kobayashi T, 1996, J PHARMACOL EXP THER, V279, P106; Kobayashi T, 1997, NEUROCHEM RES, V22, P1105, DOI 10.1023/A:1027361101419; Li M, 2007, NEUROPSYCHOPHARMACOL, V32, P263, DOI 10.1038/sj.npp.1301110; Lombard LA, 2005, AM J PHYS MED REHAB, V84, P797, DOI 10.1097/01.phm.0000179438.22235.08; Massucci JL, 2004, NEUROSCI LETT, V372, P127, DOI 10.1016/j.neulet.2004.09.026; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Mysiw WJ, 1997, ARCH PHYS MED REHAB, V78, P213, DOI 10.1016/S0003-9993(97)90266-5; Naiker DV, 2006, EUR J PHARMACOL, V540, P87, DOI 10.1016/j.ejphar.2006.04.048; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Rosengarten H, 2002, PROG NEURO-PSYCHOPH, V26, P1047, DOI 10.1016/S0278-5846(02)00221-X; Sandel ME, 1996, ARCH PHYS MED REHAB, V77, P617, DOI 10.1016/S0003-9993(96)90306-8; Schotte A, 1996, PSYCHOPHARMACOLOGY, V124, P57, DOI 10.1007/BF02245606; SCHOTTE A, 1993, BRAIN RES, V631, P191, DOI 10.1016/0006-8993(93)91535-Z; Skarsfeldt T, 1996, PSYCHOPHARMACOLOGY, V124, P126, DOI 10.1007/BF02245612; Terry AV, 2006, J PHARMACOL EXP THER, V318, P709, DOI 10.1124/jpet.105.099218; Terry AV, 2002, PSYCHOPHARMACOLOGY, V164, P360, DOI 10.1007/s00213-002-1230-z; Terry AV, 2003, NEUROPSYCHOPHARMACOL, V28, P300, DOI 10.1038/sj.npp.1300039; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Wilson MS, 2003, AM J PHYS MED REHAB, V82, P871, DOI 10.1097/01.PHM.0000091982.33232.CB; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009; Yulug B, 2006, BRAIN RES BULL, V69, P656, DOI 10.1016/j.brainresbull.2006.03.017; Yulug B, 2006, BRAIN RES BULL, V71, P296, DOI 10.1016/j.brainresbull.2006.09.018; Zhao CS, 2005, BEHAV BRAIN RES, V158, P211, DOI 10.1016/j.bbr.2004.09.001	48	81	82	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0024-3205			LIFE SCI	Life Sci.	OCT 24	2008	83	17-18					602	607		10.1016/j.lfs.2008.08.007			6	Medicine, Research & Experimental; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine; Pharmacology & Pharmacy	365JJ	WOS:000260401700004	18801378	Green Accepted			2022-02-06	
J	Bab, I; Ofek, O; Tam, J; Rehnelt, J; Zimmer, A				Bab, I.; Ofek, O.; Tam, J.; Rehnelt, J.; Zimmer, A.			Endocannabinoids and the regulation of bone metabolism	JOURNAL OF NEUROENDOCRINOLOGY			English	Article; Proceedings Paper	Workshop on Endocannabinoids in Endocrinology, Metabolism and Cardiovascular Diseases, Scientific Background and Clinical Perspectives	JUL, 2007	Padua, ITALY			bone remodelling; endocannabinoid system; sympathtic nervous system; single nucleotide polymorphism; osteoporosis	COMPONENT LINKAGE ANALYSIS; CANNABINOID RECEPTOR; MINERAL DENSITY; BRAIN-INJURY; GENE; CB2; EXPRESSION; FRACTURE; CELLS; MASS	In mammals, including humans, bone metabolism is manifested as an ongoing modelling/remodelling process whereby the bone mineralised matrix is being continuously renewed. Recently, the main components of the endocannabinoid system have been reported in the skeleton. Osteoblasts, the bone forming cells, and other cells of the osteoblastic lineage, as well as osteoclasts, the bone resorbing cells, and their precursors, synthesise the endocannabinoids anandamide and 2-arachidonoylglycerol (2-AG). CB1 cannabinoid receptors are present in sympathetic nerve terminals in close proximity to osteoblasts. Activation of these CB1 receptors by elevated bone 2-AG levels communicates brain-to-bone signals as exemplified by traumatic brain injury-induced stimulation of bone formation. In this process, the retrograde CB1 signalling inhibits noradernaline release and alleviates the tonic sympathetic restrain of bone formation. CB2 receptors are expressed by osteoblasts and osteoclasts. Their activation stimulates bone formation and suppresses bone resorption. CB2-deficient mice display a markedly accelerated age-related bone loss. Ovariectomy-induced bone loss can be both prevented and rescued by a CB2 specific agonist. Hence, synthetic CB2 ligands, which are stable and orally available, provide a basis for developing novel anti-osteoporotic therapies, free of psychotropic effects. The CNR2 gene (encoding CB2) in women is associated with low bone mineral density, offering an assay for identifying females at risk of developing osteoporosis.	[Bab, I.; Ofek, O.; Tam, J.] Hebrew Univ Jerusalem, Bone Lab, IL-91120 Jerusalem, Israel; [Rehnelt, J.; Zimmer, A.] Univ Bonn, Inst Mol Psychiat, D-5300 Bonn, Germany		Bab, I (corresponding author), Hebrew Univ Jerusalem, Bone Lab, POB 12272, IL-91120 Jerusalem, Israel.	babi@cc.huji.ac.il	Zimmer, Andreas/B-8357-2009				Abe E, 2003, CELL, V115, P151, DOI 10.1016/S0092-8674(03)00771-2; Alexander JM, 2001, J BONE MINER RES, V16, P1665, DOI 10.1359/jbmr.2001.16.9.1665; Amor S, 2005, J NEUROIMMUNOL, V165, P1, DOI 10.1016/j.jneuroim.2005.04.010; Araujo AN, 2004, EUR J ORTHODONT, V26, P515, DOI 10.1093/ejo/26.5.515; BAB I, 2005, CANNABINOIDS THERAPE, P201; Bab IA, 2007, ANN NY ACAD SCI, V1116, P414, DOI 10.1196/annals.1402.014; Baldock PA, 2002, J CLIN INVEST, V109, P915, DOI 10.1172/JCI14588; Boes M, 2006, J BONE JOINT SURG AM, V88A, P738, DOI 10.2106/JBJS.D.02648; Correa F, 2005, BRIT J PHARMACOL, V145, P441, DOI 10.1038/sj.bjp.0706215; Devoto M, 2005, EUR J HUM GENET, V13, P781, DOI 10.1038/sj.ejhg.5201411; Devoto M, 1998, EUR J HUM GENET, V6, P151, DOI 10.1038/sj.ejhg.5200169; Devoto M, 2001, HUM MOL GENET, V10, P2447, DOI 10.1093/hmg/10.21.2447; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; Donahue Seth W., 2006, Critical Reviews in Biomedical Engineering, V34, P215; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; FORD L, 2007, P 17 ANN S INT CANN, P60; George KL, 2008, J CELL PHYSIOL, V214, P714, DOI 10.1002/jcp.21263; Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435; Hanus L, 1999, P NATL ACAD SCI USA, V96, P14228, DOI 10.1073/pnas.96.25.14228; Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255; Karsak M, 2005, HUM MOL GENET, V14, P3389, DOI 10.1093/hmg/ddi370; Karsenty G, 2001, Novartis Found Symp, V232, P6; Lanyon LE, 1996, BONE, V18, pS37, DOI 10.1016/8756-3282(95)00378-9; Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401; Leung D, 2006, BIOCHEMISTRY-US, V45, P4720, DOI 10.1021/bi060163l; McCaw EA, 2004, EUR J BIOCHEM, V271, P4909, DOI 10.1111/j.1432-1033.2004.04460.x; Melamed E, 2002, AM J PHYS MED REHAB, V81, P670, DOI 10.1097/00002060-200209000-00006; Monteleone P, 2005, NEUROPSYCHOPHARMACOL, V30, P1216, DOI 10.1038/sj.npp.1300695; Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103; ORZEL JA, 1985, J NUCL MED, V26, P125; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; PARFITT AM, 1987, BONE, V8, pS1; Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301-472X(99)00061-2; Sato S, 2007, NAT MED, V13, P1234, DOI 10.1038/nm1640; Scutt A, 2007, CALCIFIED TISSUE INT, V80, P50, DOI 10.1007/s00223-006-0171-7; Seeman E, 2003, ENDOCRIN METAB CLIN, V32, P25, DOI 10.1016/S0889-8529(02)00078-6; Sun L, 2006, CELL, V125, P247, DOI 10.1016/j.cell.2006.01.051; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Tam J, 2008, FASEB J, V22, P285, DOI 10.1096/fj.06-7957com; Tam J, 2006, MOL PHARMACOL, V70, P786, DOI 10.1124/mol.106.026435; Wildburger R, 1998, J ENDOCRINOL INVEST, V21, P78, DOI 10.1007/BF03350319; Yamada Y, 2007, INT J MOL MED, V19, P791; Yirmiya R, 2006, P NATL ACAD SCI USA, V103, P16876, DOI 10.1073/pnas.0604234103; Zhang PW, 2004, MOL PSYCHIATR, V9, P916, DOI 10.1038/sj.mp.4001560; ZHANG RW, 1995, CALCIFIED TISSUE INT, V56, P283, DOI 10.1007/BF00318048; ZHOU H, 1994, J BONE MINER RES, V9, P1489; Zimmer A, 1999, P NATL ACAD SCI USA, V96, P5780, DOI 10.1073/pnas.96.10.5780	47	81	85	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-8194	1365-2826		J NEUROENDOCRINOL	J. Neuroendocrinol.	MAY	2008	20			1			69	74		10.1111/j.1365-2826.2008.01675.x			6	Endocrinology & Metabolism; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Endocrinology & Metabolism; Neurosciences & Neurology	289NI	WOS:000255060800013	18426503	Bronze			2022-02-06	
J	Mascia, L; Sakr, Y; Pasero, D; Payen, D; Reinhart, K; Vincent, JL				Mascia, Luciana; Sakr, Yasser; Pasero, Daniela; Payen, Didier; Reinhart, Konrad; Vincent, Jean-Louis		SOAP Investigators	Extracranial complications in patients with acute brain injury: a post-hoc analysis of the SOAP study	INTENSIVE CARE MEDICINE			English	Article						sepsis; acute respiratory distress syndrome; brain injury; stroke	SEVERE HEAD-INJURY; NEUROGENIC PULMONARY-EDEMA; ANEURYSMAL SUBARACHNOID HEMORRHAGE; INTENSIVE-CARE UNITS; ACUTE LUNG INJURY; ORGAN DYSFUNCTION; MEDICAL COMPLICATIONS; CONSENSUS CONFERENCE; MULTICENTER; SCORE	Objective: To assess the incidence and severity of nonneurological organ dysfunction and its effect on outcome in acute neurological patients in an international cohort observational study. Design and setting: Analysis of database from the observational Sepsis Occurrence in Acutely Ill Patients (SOAP) study in 198 intensive care units (ICUs) in 24 European countries. Patients: All adult patients admitted to the participating ICUs between 1 and 15 May 2002. Of the 3,147 patients in the SOAP database 373 (12%) were admitted with a neurological diagnosis, including 154 (41%) with traumatic brain injury and 186 (50%) with cerebrovascular accident. Measurements and results: Patients were followed until death, hospital discharge, or for 60 days. Neurological patients were younger and had a higher incidence of trauma and fewer comorbidities than nonneurological patients. Neurological patients developed ICU-acquired sepsis and respiratory failure more frequently than the other patients. ICU and hospital mortality rates were higher and ICU length of stay longer in neurological than in nonneurological patients. Multivariate logistic analysis showed that, in addition to the Glasgow Coma Score (GCS) and the presence of nontraumatic brain injury, cardiovascular failure, hepatic failure, and ALI/ARDS were the only factors independently associated with a higher risk of death in the ICU in patients with a neurological diagnosis. Conclusions: Although neurological patients were younger and had fewer comorbidities, they developed ICU-acquired sepsis and respiratory failure more frequently than other patients. Efforts should be oriented to reduce cardiovascular, hepatic, and respiratory complications.	[Mascia, Luciana; Pasero, Daniela] Univ Turin, Osped S Giovanni Battista, Dept Anesthesiol & Intens Care, I-10126 Turin, Italy; [Sakr, Yasser; Reinhart, Konrad] Univ Jena, Dept Anesthesiol & Intens Care, Jena, Germany; [Payen, Didier] CHU Lariboisiere, Dept Anesthesiol & Intens Care, Paris, France; [Vincent, Jean-Louis] Free Univ Brussels, Erasme Hosp, Dept Intens Care, B-1050 Brussels, Belgium		Mascia, L (corresponding author), Univ Turin, Osped S Giovanni Battista, Dept Anesthesiol & Intens Care, Corso Dogliotti 14, I-10126 Turin, Italy.	luciana.mascia@unito.it	pasero, daniela cristina/ABF-4731-2021; mascia, Luciana/L-3039-2018; Sakr, Yasser/D-9802-2013; Sierra, Rafael/I-3441-2015	Sierra, Rafael/0000-0002-6021-396X; Vincent, Jean-Louis/0000-0001-6011-6951			BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; Bratton SL, 1997, NEUROSURGERY, V40, P707, DOI 10.1097/00006123-199704000-00009; Brienza N, 2006, INTENS CARE MED, V32, P267, DOI 10.1007/s00134-005-0023-3; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Chen HI, 1995, BIOL SIGNAL, V4, P186; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Gruber A, 1999, CRIT CARE MED, V27, P505, DOI 10.1097/00003246-199903000-00026; Harbrecht BG, 2002, J TRAUMA, V53, P517, DOI 10.1097/00005373-200209000-00020; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; *INT STUD UNR INTR, 1998, NEW ENGL J MED, V339, P1275; KIKUCHI T, 1995, NEUROL RES, V17, P106, DOI 10.1080/01616412.1995.11740296; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Lennihan L, 2000, STROKE, V31, P383, DOI 10.1161/01.STR.31.2.383; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; McKeating EG, 1997, BRIT J ANAESTH, V78, P520, DOI 10.1093/bja/78.5.520; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROGERS FB, 1995, J TRAUMA, V39, P860, DOI 10.1097/00005373-199511000-00009; ROSENWASSER RH, 1995, NEUROSURGERY, V37, P872, DOI 10.1227/00006123-199511000-00004; SOLENSKI NJ, 1995, CRIT CARE MED, V23, P1007, DOI 10.1097/00003246-199506000-00004; TEASDALE G, 1974, LANCET, V2, P81; TOUHO H, 1989, NEUROSURGERY, V25, P762, DOI 10.1227/00006123-198911000-00011; Tracey KJ, 2007, J CLIN INVEST, V117, P289, DOI 10.1172/JCI30555; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Vincent JL, 2006, CRIT CARE MED, V34, P344, DOI 10.1097/01.CCM.0000194725.48928.3A; Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35; Yildirim E, 2004, EUR J CARDIO-THORAC, V25, P523, DOI 10.1016/j.ejcts.2003.12.021; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	31	81	85	0	2	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	APR	2008	34	4					720	727		10.1007/s00134-007-0974-7			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	278BV	WOS:000254259400018	18175107				2022-02-06	
J	Narayan, RK; Maas, AIR; Marshall, LF; Servadei, F; Skolnick, BE; Tillinger, MN				Narayan, Raj K.; Maas, Andrew I. R.; Marshall, Lawrence F.; Servadei, Franco; Skolnick, Brett E.; Tillinger, Michael N.		rFVIIa Traumatic ICH Study Grp	Recombinant factor VIIA in traumatic intracerebral hemorrhage: Results of a dose-escalation clinical trial	NEUROSURGERY			English	Article						clinical trial; deep vein thrombosis; intracerebral hemorrhage; lesion expansion; recombinant factor VIIa; thromboembolic complications; traumatic brain injury	DEEP VENOUS THROMBOSIS; ACTIVATED FACTOR-VII; SEVERE HEAD-INJURY; BRAIN-INJURY; SUBARACHNOID HEMORRHAGE; TIME-COURSE; MANAGEMENT; CT; THROMBOEMBOLISM; COAGULOPATHY	OBJECTIVE: Intracerebral hemorrhages, whether spontaneous or traumatic (tICH), often expand, and an association has been described between hemorrhage expansion and worse clinical outcomes. Recombinant factor VIIa (rFVIIa) is a hemostatic agent that has been shown to limit hemorrhage expansion and which, therefore, could potentially reduce morbidity and mortality in tICH. This first prospective, randomized, placebo-controlled, dose-escalation study evaluated the safety and preliminary effectiveness of rFVIIa to limit tICH progression. METHODS: Patients were enrolled if they had tICH lesions of at least 2 ml on a baseline computed tomographic scan obtained within 6 hours of injury. rFVIIa or placebo was administered within 2.5 hours of the baseline computed tomographic scan but no later than 7 hours after injury. Computed tomographic scans were repeated at 24 and 72 hours. Five escalating dose tiers were evaluated (40, 80, 120, 160, and 200 mu g/kg rFVIIa). Clinical evaluations and adverse events were recorded until Day 15. RESULTS: No significant differences were detected in mortality rate or number and type of adverse events among treatment groups. Asymptomatic deep vein thrombosis, detected on routinely performed ultrasound at Day 3, was observed more frequently in the combined rFVIIa treatment group (placebo, 3%; rFVIIa, 8%; not significant). A nonsignificant trend for rFVIIa dose-response to limit tICH volume increase was observed (placebo, 21.0 ml; rFVIIa, 10.1 ml). CONCLUSION: In this first prospective study of rFVIIa in tICH, there appeared to be less hematoma progression in rFVIIa-treated patients (80-200 mu g/kg) compared with that seen in placebo treated patients. The potential significance of this biological effect on clinical outcomes and the significance of the somewhat higher incidence of ultrasound-detected deep vein thromboses in the rFVIIa-treated group need to be examined in a larger prospective randomized clinical trial.	[Narayan, Raj K.] Univ Cincinnati, Dept Neurosurg, Cincinnati, OH USA; [Maas, Andrew I. R.] Erasmus MC, Rotterdam, Netherlands; [Marshall, Lawrence F.] Univ Calif San Diego, Dept Neurosurg, San Diego, CA 92103 USA; [Servadei, Franco] Osped Maggiore Parma, Parma, Italy; [Skolnick, Brett E.; Tillinger, Michael N.] Novo Nordisk AS, Princeton, NJ USA		Narayan, RK (corresponding author), Univ Cincinnati, Univ Hosp, Inst Neurosci, Dept Neurosurg, 231 Albert Sabin Way,POB 670515, Cincinnati, OH 45267 USA.	raj.narayan@uc.edu	Maas, Andrew IR/C-5584-2013	Maas, Andrew IR/0000-0003-1612-1264; Servadei, Franco/0000-0002-3595-3464			Andrews E James Jr, 2005, Ultrasound Q, V21, P213, DOI 10.1097/01.ruq.0000187024.54319.19; Anonymous, 2006, Morbidity and Mortality Weekly Report, V55, P201; [Anonymous], 1997, ICH HARM TRIP GUID G; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Brott T, 1997, STROKE, V28, P1, DOI 10.1161/01.STR.28.1.1; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Carlile MC, 2006, J HEAD TRAUMA REHAB, V21, P483, DOI 10.1097/00001199-200611000-00003; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; Crowther MA, 2005, J CRIT CARE, V20, P334, DOI 10.1016/j.jcrc.2005.09.011; Davis SM, 2006, NEUROLOGY, V66, P1175, DOI 10.1212/01.wnl.0000208408.98482.99; Denson K, 2007, AM J SURG, V193, P380, DOI 10.1016/j.amjsurg.2006.12.004; Fainardi E, 2004, ACTA NEUROCHIR, V146, P257, DOI 10.1007/s00701-003-0207-y; FUJITSU K, 1990, J NEUROSURG, V73, P518, DOI 10.3171/jns.1990.73.4.0518; Geerts WH, 2004, CHEST, V126, p338S, DOI 10.1378/chest.126.3_suppl.338S; Hawryluk GWJ, 2006, J NEUROSURG, V105, P859, DOI 10.3171/jns.2006.105.6.859; Karadimov D, 2003, J NEUROSURG ANESTH, V15, P330, DOI 10.1097/00008506-200310000-00008; King BS, 2000, SURG CLIN N AM, V80, P855, DOI 10.1016/S0039-6109(05)70100-6; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Kurtoglu M, 2004, WORLD J SURG, V28, P807, DOI 10.1007/s00268-004-7295-6; Levy JH, 2006, TRANSFUSION, V46, P919, DOI 10.1111/j.1537-2995.2006.00824.x; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Marion DW, 2006, NEUROSURGERY, V58, P655; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; MERINODEVILLASANTE J, 1976, AM J ROENTGENOL, V126, P765, DOI 10.2214/ajr.126.4.765; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pathak A, 2005, Neurol India, V53, P178; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Servadei F, 2000, NEUROSURGERY, V46, P70, DOI 10.1093/neurosurgery/46.1.70; Siddique MS, 2002, J NEUROSURG, V96, P86, DOI 10.3171/jns.2002.96.1.0086; Siegel LJ, 2004, ANESTHESIOLOGY, V100, P441, DOI 10.1097/00000542-200402000-00037; Stawicki SP, 2005, AM SURGEON, V71, P387; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thomas GOR, 2007, J TRAUMA, V62, P564, DOI 10.1097/TA.0b013e318031afc2; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wittebole X, 2005, J ELECTROCARDIOL, V38, P77, DOI 10.1016/j.jelectrocard.2004.09.004; World Medical Association General Assembly, 2004, J Int Bioethique, V15, P124; YAMAKI T, 1990, ACTA NEUROCHIR, V103, P112, DOI 10.1007/BF01407516; Zaaroor M, 2004, SEMIN HEMATOL, V41, P175, DOI 10.1053/j.seminhematol.2003.11.033	45	81	87	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	APR	2008	62	4					776	786		10.1227/01.NEU.0000297095.04013.C4			11	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	294TR	WOS:000255429300014	18496183				2022-02-06	
J	Morel, N; Morel, O; Petit, L; Hugel, B; Cochard, JF; Freyssinet, JM; Sztark, F; Dabadie, P				Morel, Nicolas; Morel, Olivier; Petit, Laurent; Hugel, Benedicte; Cochard, Jean-Francois; Freyssinet, Jean-Marie; Sztark, Francois; Dabadie, Philippe			Generation of procoagulant microparticles in cerebrospinal fluid and peripheral blood after traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	Joint 12th Annual Meeting of the European-Society-of-Anaesthesiologists (ESA) and European-Academy-of-Anaesthesiology (EAA) (EUROANAESTHESIA)	JUN 05-08, 2004	Lisbon, PORTUGAL	European Soc Anaesthesiol, European Acad Anaesthesiol		microparticles; apoptosis; traumatic brain injury	PROGRAMMED CELL-DEATH; TISSUE FACTOR; ENDOTHELIAL-CELLS; MEMBRANE MICROPARTICLES; HEAD-INJURY; IN-VITRO; APOPTOSIS; DYSFUNCTION; ACTIVATION; THROMBIN	Background: Traumatic brain injury (TBI) can induce cell damage. Procoagulant microparticles (MPs) are reliable markers of cell stimulation. The aim of this study was to investigate the generation of procoagulant MPs in the cerebrospinal fluid (CSF) and plasma of patients with severe TBI. Material: CSF and plasma MPs of 16 patients with severe TBI were quantified by functional prothrombinase assay (i) on the day of the trauma, (ii) during a 10-day follow-up and compared with control samples. The cellular origin of NIP was determined after capture with specific antibodies. Results: The CSF and plasma of patients with severe TBI revealed a significantly increased generation of MP compared with control samples on the day of the trauma (CSF: 4.5 +/- 1.8 vs. 0.83 +/- 0.28 nanomolar PhtdSer equivalent; p = 0.01 and plasma 4.1 +/- 3.7 vs. 2.3 +/- 0.19 nanomolar PhtdSer equivalent; p = 0.02). Procoagulant MPs were mainly of platelet and endothelial origin in CSF. MPs decreased significantly in the CSF 10 days after TBI. In CSF, a sustained generation of procoagulant MP was evidenced in two patients presenting a poor clinical outcome. In the blood flow, elevated amounts of procoagulant MEN were detected in three patients presenting disseminated intravascular coagulopathy during the follow-up. Conclusion: Procoagulant MP testifying to platelet and endothelial activation are produced in the CSF and in the plasma after severe TBI. A sustained generation of procoagulant MP in the CSF could contribute to a poor clinical outcome.	[Morel, Nicolas; Dabadie, Philippe] Hop Pellegrin, Dept Urgences, Serv Reanimat Urgences, F-33076 Bordeaux, France; [Morel, Olivier; Hugel, Benedicte; Freyssinet, Jean-Marie] Univ Strasbourg, Fac Med, Inst Immunol Hematol, F-67085 Strasbourg, France; [Morel, Olivier; Hugel, Benedicte; Freyssinet, Jean-Marie] INSERM, U770, F-94272 Le Kremlin Bicetre, France; [Morel, Olivier; Hugel, Benedicte; Freyssinet, Jean-Marie] Univ Paris Sud 11, Fac Med, F-94272 Le Kremlin Bicetre, France; [Petit, Laurent; Cochard, Jean-Francois; Sztark, Francois] Hop Pellegrin, Serv Reanim Chirurg, F-33076 Bordeaux, France; [Morel, Olivier] Hop Hautepierre, Dept Cardiol, F-67000 Strasbourg, France		Morel, N (corresponding author), Serv Urgences Adultes, Place Amelie Raba Leon, F-33076 Bordeaux, France.	nicolas.morel@chu-bordeaux.fr	Freyssinet, Jean-Marie/G-2719-2013	LAURENT, PETIT/0000-0003-1530-5678			Abbott NJ, 2000, CELL MOL NEUROBIOL, V20, P131, DOI 10.1023/A:1007074420772; Aras O, 2004, BLOOD, V103, P4545, DOI 10.1182/blood-2003-03-0713; Aupeix K, 1997, J CLIN INVEST, V99, P1546, DOI 10.1172/JCI119317; Barry OP, 1997, J CLIN INVEST, V99, P2118, DOI 10.1172/JCI119385; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bombeli T, 1999, BLOOD, V93, P3831, DOI 10.1182/blood.V93.11.3831; Bombeli T, 1997, BLOOD, V89, P2429, DOI 10.1182/blood.V89.7.2429; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Combes V, 1999, J CLIN INVEST, V104, P93, DOI 10.1172/JCI4985; DacharyPrigent J, 1996, SEMIN THROMB HEMOST, V22, P157, DOI 10.1055/s-2007-999004; Dempsey RJ, 2003, J NEUROSURG, V98, P867, DOI 10.3171/jns.2003.98.4.0867; Falati S, 2003, J EXP MED, V197, P1585, DOI 10.1084/jem.20021868; Gando S, 1997, CRIT CARE MED, V25, P1820, DOI 10.1097/00003246-199711000-00019; Gando S, 1999, J TRAUMA, V46, P1070, DOI 10.1097/00005373-199906000-00018; Geisbert TW, 2003, J INFECT DIS, V188, P1618, DOI 10.1086/379724; Giesen PLA, 1999, P NATL ACAD SCI USA, V96, P2311, DOI 10.1073/pnas.96.5.2311; Guettier-Sigrist S, 2002, MUSCLE NERVE, V25, P700, DOI 10.1002/mus.10081; Harter L, 2001, J NEUROIMMUNOL, V121, P76, DOI 10.1016/S0165-5728(01)00409-X; Ikegami K, 1998, J TRAUMA, V44, P789, DOI 10.1097/00005373-199805000-00008; Jacoby RC, 2001, J TRAUMA, V51, P639, DOI 10.1097/00005373-200110000-00003; Jy W, 2004, J THROMB HAEMOST, V2, P1842, DOI 10.1111/j.1538-7836.2004.00936.x; Mallat Z, 1999, CIRCULATION, V99, P348, DOI 10.1161/01.CIR.99.3.348; Martin SJ, 1996, J BIOL CHEM, V271, P28753, DOI 10.1074/jbc.271.46.28753; Molino M, 1997, J BIOL CHEM, V272, P11133; Morel O, 2004, THROMB HAEMOSTASIS, V91, P345, DOI 10.1160/TH03-05-0294; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; Ng I., 1999, Annals Academy of Medicine Singapore, V28, P363; Ogura H, 2001, J TRAUMA, V50, P801, DOI 10.1097/00005373-200105000-00005; Osterud B, 2006, SEMIN THROMB HEMOST, V32, P11, DOI 10.1055/s-2006-933336; Osterud B, 2001, SEMIN THROMB HEMOST, V27, P605, DOI 10.1055/s-2001-18866; RINK A, 1995, AM J PATHOL, V147, P1575; Sapet C, 2006, BLOOD, V108, P1868, DOI 10.1182/blood-2006-04-014175; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; *SFAR SRLF, 2002, 22 C CONS COAG INTR; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Taubman MB, 1999, THROMB HAEMOSTASIS, V82, P801; UNTERBERG A, 1984, J CEREBR BLOOD F MET, V4, P574, DOI 10.1038/jcbfm.1984.82	38	81	88	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2008	64	3					698	704		10.1097/TA.0b013e31816493ad			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	274JE	WOS:000253996800028	18332810				2022-02-06	
J	Yeo, JE; Kang, SK				Yeo, Jee Eun; Kang, Soo Kyung			Selenium effectively inhibits ROS-mediated apoptotic neural precursor cell death in vitro and in vivo in traumatic brain injury	BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE			English	Article						brain trauma; hydrogen peroxide; neuroprotection; oxidation; sodium selenite	MAMMALIAN THIOREDOXIN REDUCTASE; SPINAL-CORD-INJURY; PARKINSONS-DISEASE; LIPID-PEROXIDATION; SIGNAL-TRANSDUCTION; RADICAL HYPOTHESIS; OXIDATIVE STRESS; MITOCHONDRIA; BCL-2; INDUCTION	This study was designed to investigate possible prevention of apoptotic cell death by selenium, an antioxidant, using cultured brain-derived neural progenitor cells (NPCs) and an experimental mouse brain trauma (BT) model. We tested some of the neuroprotective effects of sodium selenite in NPC cells by monitoring thioredoxin reductase (TR) expression, optimum H2O2 removal, and consequent inhibition of pro-apoptotic events including cytochrome c release and caspase 3 and 9 activation. Analysis of key apoptotic regulators during H2O2-induced apoptosis of NPCs showed that selenite blocks the activation of c-jun N-terminal protein kinase (JNK)/P38 mitogen-activated protein kinase (MAPK), and Akt survival protein. Moreover, selenite activates p44/42 MAPK and inhibits the downregulation of Bcl2 in selenite-treated NPC cells. For in vivo experiments, the effects of selenite on H2O2 neurotoxicity were tested using several biochemical and morphologic markers. Here we show that selenite potentially inhibits H2O2-induced apoptosis of NPCs and in traumatic brain injury. This in vivo protective function was also associated with inhibition of H2O2-induced reactive oxygen species (ROS) generation, cytochrome c release and caspase 3 and 9 activation. Our data show that the protective function of selenite through attenuation of secondary pathological events most likely results from its comprehensive effects that block apoptotic cell death, resulting in the maintenance of functional neurons and in inhibition of astrogliosis. The finding that selenite administration prevents secondary pathological events in an animal model of traumatic brain injury, as well as its efficacy, may provide novel drug targets for treating brain trauma. (c) 2007 Elsevier B.V. All rights reserved.	[Yeo, Jee Eun; Kang, Soo Kyung] Pusan Natl Univ, Sch Med, Dept Physiol, Pusan 602739, South Korea		Kang, SK (corresponding author), Pusan Natl Univ, Sch Med, Dept Physiol, 1-10 Ami Dong, Pusan 602739, South Korea.	skkang@pusan.ac.kr					Anderson CNG, 1999, J NEUROSCI, V19, P664; ARMAN D, 1993, FREE RADICALS AGING, P205; BELLAVITE P, 1988, FREE RADICAL BIO MED, V4, P225, DOI 10.1016/0891-5849(88)90044-5; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Bruce-Keller AJ, 1998, J NEUROCHEM, V70, P31; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Cornett CR, 1998, NEUROTOXICOLOGY, V19, P339; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; DEXTER DT, 1989, J NEUROCHEM, V52, P1830, DOI 10.1111/j.1471-4159.1989.tb07264.x; DEXTER DT, 1989, J NEUROCHEM, V52, P381, DOI 10.1111/j.1471-4159.1989.tb09133.x; Facchinetti F, 1998, CELL MOL NEUROBIOL, V18, P667, DOI 10.1023/A:1020221919154; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; GIULIAN D, 1993, J NEUROSCI, V13, P29; HALLIWELL B, 1992, FEBS LETT, V307, P108, DOI 10.1016/0014-5793(92)80911-Y; HALLIWELL B, 1984, LANCET, V1, P1396; Imam SZ, 1999, BRAIN RES, V818, P575, DOI 10.1016/S0006-8993(98)01311-0; ITOH N, 1993, J IMMUNOL, V151, P621; Jones LL, 2003, EXP NEUROL, V182, P399, DOI 10.1016/S0014-4886(03)00087-6; Jurynec MJ, 2003, MOL CELL NEUROSCI, V23, P69, DOI 10.1016/S1044-7431(03)00019-8; Kang SK, 2006, STEM CELLS DEV, V15, P165, DOI 10.1089/scd.2006.15.165; Kim TS, 2002, BIOCHEM BIOPH RES CO, V294, P1130, DOI 10.1016/S0006-291X(02)00612-5; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Lee SR, 2000, P NATL ACAD SCI USA, V97, P2521, DOI 10.1073/pnas.050579797; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LIU X, 1996, CELL, V86, P145; Marcocci L, 1997, BIOFACTORS, V6, P351, DOI 10.1002/biof.5520060305; Murphy MP, 2000, ADV DRUG DELIVER REV, V41, P235, DOI 10.1016/S0169-409X(99)00069-1; Nakahara S, 1999, J NEUROPATH EXP NEUR, V58, P442, DOI 10.1097/00005072-199905000-00003; OLANOW CW, 1993, TRENDS NEUROSCI, V16, P439, DOI 10.1016/0166-2236(93)90070-3; OLANOW CW, 1992, ANN NEUROL, V32, pS2, DOI 10.1002/ana.410320703; Ozawa H, 1999, NEUROSCI LETT, V262, P57, DOI 10.1016/S0304-3940(99)00034-8; Ragusa RJ, 1997, NEUROMUSCULAR DISORD, V7, P379, DOI 10.1016/S0960-8966(97)00096-5; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RICHTER C, 1993, TOXICOL LETT, V67, P119, DOI 10.1016/0378-4274(93)90050-8; RICHTER C, 1991, CHEM-BIOL INTERACT, V77, P1, DOI 10.1016/0009-2797(91)90002-O; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; Sagara Y, 1998, NEUROTOXICOLOGY, V19, P339; Sarker KP, 2003, J NEUROCHEM, V87, P1345, DOI 10.1046/j.1471-4159.2003.02096.x; SCHEID MP, 2003, EXP NEUROL, V166, P115; Shamloo M, 1999, NEUROSCIENCE, V93, P81, DOI 10.1016/S0306-4522(99)00137-2; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; Svensson B, 1998, J NEUROSCI RES, V52, P453, DOI 10.1002/(SICI)1097-4547(19980515)52:4<453::AID-JNR9>3.0.CO;2-8; TAN S, 1995, J NEUROCHEM, V71, P95; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yakovlev Alexander G, 2004, NeuroRx, V1, P5, DOI 10.1602/neurorx.1.1.5; YU BP, 1994, PHYSIOL REV, V74, P139, DOI 10.1152/physrev.1994.74.1.139	46	81	87	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0925-4439			BBA-MOL BASIS DIS	Biochim. Biophys. Acta-Mol. Basis Dis.	DEC	2007	1772	11-12					1199	1210		10.1016/j.bbadis.2007.09.004			12	Biochemistry & Molecular Biology; Biophysics; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics; Cell Biology	249OR	WOS:000252238800003	17997286	Bronze			2022-02-06	
J	Rehni, AK; Singh, N; Jaggi, AS; Singh, M				Rehni, Ashish K.; Singh, Nirmal; Jaggi, Arnteshwar S.; Singh, Manjeet			Amniotic fluid derived stem cells ameliorate focal cerebral ischaemia-reperfusion injury induced behavioural deficits in mice	BEHAVIOURAL BRAIN RESEARCH			English	Article						stem cells; amniotic fluid; sources; cerebral ischaemia	REDUCES INFARCT SIZE; CLOSED-HEAD INJURY; ARTERY OCCLUSION; BRAIN; MODEL; MOTOR; TRANSPLANTATION; REGENERATION; ANTIOXIDANTS; RECEPTORS	The present study has been designed to investigate the effect of amniotic fluid derived stem cells on focal cerebral ischaemia-reperfusion injury induced behavioural deficits in mice. Middle cerebral artery occlusion of 60 min followed by reperfusion for 7 days was employed in present study to produce ischaemia and reperfusion induced cerebral injury in mice. Assessment of cognitive behaviour was done using elevated plus maze. Assessment of neurological severity score was employed to assess motor, sensory, reflex, and balance tests in a composite manner. Adhesive-removal somatosensory test was employed to evaluate somatosensory deficit. Partial occlusion of middle cerebral artery markedly impaired memory, motor coordination, sensorimotor ability and somatosensory functions as inferred from the results of elevated plus-maze test, adhesive-removal test and neurological severity score test. Intracerebroventricular administration of amniotic fluid derived stem cells/embryonic neuronal stem cells significantly reversed the focal cerebral ischaemia-reperfus ion induced behavioural deficit measured in terms of loss of short-term memory, motor coordination, sensorimotor ability and somatosensory functions. Therefore, it may be concluded that stem cells derived from amniotic fluid exert beneficial effect on the ischaemic brain to an extent comparable to the neuroprotective effect of embryonic neuronal stem cells. (C) 2007 Elsevier B.V. All rights reserved.	Punjabi Univ, Dept Pharmaceut Sci & Drug Res, Patiala 147002, Punjab, India		Singh, N (corresponding author), Punjabi Univ, Dept Pharmaceut Sci & Drug Res, Patiala 147002, Punjab, India.	ashishkrehni@yahoo.co.in; nirmalresearch@gmail.com	Singh, Nouratan/N-9377-2017; Singh, Nirmal/ABA-2264-2020; Rehni, Ashish/AAR-9908-2021	Singh, Nouratan/0000-0002-8063-8375; 			Assady S, 2001, DIABETES, V50, P1691, DOI 10.2337/diabetes.50.8.1691; Baker K, 1998, J PHARMACOL EXP THER, V284, P215; Bhardwaj Anish, 2003, Curr Cardiol Rep, V5, P160, DOI 10.1007/s11886-003-0085-1; BORLONGAN CV, 1995, BRAIN RES, V676, P231, DOI 10.1016/0006-8993(95)00150-O; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chenard BL, 1999, CURR PHARM DESIGN, V5, P381; Dahlke MH, 2003, J HEPATOL, V39, P365, DOI 10.1016/S0168-8278(03)00264-2; DHINGRA D, 2003, INDIAN J PHARM, V91, P361; Dobkin B H, 1991, Clin Geriatr Med, V7, P507; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Fischer G, 1997, J PHARMACOL EXP THER, V283, P1285; GERMANO AF, 1994, J NEUROTRAUM, V11, P345, DOI 10.1089/neu.1994.11.345; Gupta R, 2003, PHARMACOL RES, V48, P209, DOI 10.1016/S1043-6618(03)00102-6; HALEY TJ, 1957, BRIT J PHARM CHEMOTH, V12, P12, DOI 10.1111/j.1476-5381.1957.tb01354.x; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; in 'tAnker PS, 2003, BLOOD, V102, P1548, DOI 10.1182/blood-2003-04-1291; ITOH J, 1990, PSYCHOPHARMACOLOGY, V101, P27, DOI 10.1007/BF02253713; JENKINS LW, 1981, ACTA NEUROPATHOL, V55, P205, DOI 10.1007/BF00691320; Jeong SW, 2003, STROKE, V34, P2258, DOI 10.1161/01.STR.0000083698.20199.1F; Johansson BB, 1996, STROKE, V27, P324, DOI 10.1161/01.STR.27.2.324; Mooney Chris, 2005, REPUBLICAN WAR SCI; Park KI, 2000, YONSEI MED J, V41, P825, DOI 10.3349/ymj.2000.41.6.825; Polgar S, 2003, BRAIN RES BULL, V60, P1, DOI 10.1016/S0361-9230(03)00017-0; Prusa AR, 2003, HUM REPROD, V18, P1489, DOI 10.1093/humrep/deg279; Reddy DS, 1998, BRAIN RES, V799, P215, DOI 10.1016/S0006-8993(98)00419-3; Rehni AK, 2007, PHARMACOL REP, V59, P192; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; *ROYAL COLL PHYS, 2004, NAT CLIN GUID STOK, P31; Savitz Sean I, 2004, NeuroRx, V1, P406; Sawamoto K, 2006, SCIENCE, V311, P629, DOI 10.1126/science.1119133; Schabitz WR, 1997, J CEREBR BLOOD F MET, V17, P500, DOI 10.1097/00004647-199705000-00003; Schallert T, 1997, ADV NEUROL, V73, P229; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Singh N, 1998, PHARMACOLOGY, V56, P46, DOI 10.1159/000028181; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Tsai MS, 2006, BIOL REPROD, V74, P545, DOI 10.1095/biolreprod.105.046029; Vasudevan M, 2006, PHYTOMEDICINE, V13, P677, DOI 10.1016/j.phymed.2006.01.007; Warner DS, 2004, J EXP BIOL, V207, P3221, DOI 10.1242/jeb.01022; WELSH FA, 1987, J NEUROCHEM, V49, P846, DOI 10.1111/j.1471-4159.1987.tb00971.x; WHISNANT JP, 1984, STROKE, V15, P160, DOI 10.1161/01.STR.15.1.160; Wise PM, 2001, BRAIN RES REV, V37, P313, DOI 10.1016/S0165-0173(01)00136-9; Wojcik C, 2004, STROKE, V35, P1506, DOI 10.1161/01.STR.0000126891.93919.4e; World Health Organization, 1978, CER DIS CLIN RES CLA, V43; Yamashita K, 1997, METAB BRAIN DIS, V12, P271, DOI 10.1007/BF02674671; Yan J, 2006, STEM CELLS, V24, P1976, DOI 10.1634/stemcells.2005-0518; Zhang L, 2000, J NEUROL SCI, V174, P141, DOI 10.1016/S0022-510X(00)00268-9	47	81	84	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	OCT 1	2007	183	1					95	100		10.1016/j.bbr.2007.05.028			6	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	211GA	WOS:000249511100012	17619060				2022-02-06	
J	Keenan, HT; Hooper, SR; Wetherington, CE; Nocera, M; Runyan, DK				Keenan, Heather T.; Hooper, Stephen R.; Wetherington, Crista E.; Nocera, Maryalice; Runyan, Desmond K.			Neurodevelopmental consequences of early traumatic brain injury in 3-year-old children	PEDIATRICS			English	Article						abuse; traumatic brain injury; shaken baby syndrome; injury; developmental disabilities	YOUNG-CHILDREN; ENVIRONMENTAL RISK; SCORES; OUTCOMES	OBJECTIVES. The purpose of this work was to determine cognitive and adaptive behavioral outcomes of children with traumatic brain injury acquired before age 2 years and to compare outcomes between inflicted versus noninflicted brain injury. PATIENTS AND METHODS. All North Carolina children hospitalized in an ICU for a traumatic brain injury before age 2 years between the years 2000 and 2001 were eligible for study entry. A total of 112 surviving children were prospectively identified, 52 ( 46%) of whom had complete follow- up. Thirty- one control children were recruited from preschool settings. Control subjects were chosen to be demographically similar to case subjects. Child measures of cognition and adaptive behavior at age 3 years were measured and compared between children with and without traumatic brain injury and children with inflicted and noninflicted traumatic brain injury. RESULTS. Sixty percent of injured children were > 1 SD below normal on cognitive testing. Forty percent of injured children scored > 1 SD below normal on adaptive behavior testing. Children with inflicted traumatic brain injury performed more poorly on tests of cognition and adaptive behavior. Glasgow Coma Scale >= 13, absence of seizures, income above twice the poverty guidelines, and high social capital were associated with improved outcomes. Injured children had lower scores than uninjured control children after adjustment for socioeconomic status. CONCLUSIONS. Very young children with mild- to- severe traumatic brain injury as measured by the Glasgow Coma Scale are at risk for global cognitive deficits more than a year after the time of injury. Inflicted brain injury is associated with more severe injury and worse outcomes. This is less optimistic than findings in this same cohort 1 year after injury. Family characteristics seem to play a role in recovery after injury.	Univ Utah, Dept Pediat, Salt Lake City, UT USA; Univ N Carolina, Clin Ctr Study Dev & Learning, Dept Psychiat, Chapel Hill, NC USA; Univ N Carolina, Sch Educ, Chapel Hill, NC 27599 USA; Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC USA; Univ N Carolina, Dept Social Med, Chapel Hill, NC USA; Univ N Carolina, Dept Pediat, Chapel Hill, NC USA		Keenan, HT (corresponding author), 295 Chipeta Way,POB 581289, Salt Lake City, UT 84158 USA.	heather.keenan@hsc.utah.edu	Hooper, Stephen/X-8171-2019; Runyan, Desmond/S-3974-2016	Runyan, Desmond/0000-0001-5571-9029	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23 HD041040-01A2, K23 HD041040-05, K23 HD041040] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD041040] Funding Source: NIH RePORTER		Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; AYLWARD GP, 1992, J DEV BEHAV PEDIATR, V13, P222; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Braveman PA, 2005, JAMA-J AM MED ASSOC, V294, P2879, DOI 10.1001/jama.294.22.2879; COLEMAN JS, 1988, AM J SOCIOL, V94, pS95, DOI 10.1086/228943; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Hill, 1996, SCALES INDEPENDENT B; Keenan HT, 2006, PEDIATRICS, V117, P1291, DOI 10.1542/peds.2005-1883; Keenan HT, 2006, PEDIATRICS, V117, P317, DOI 10.1542/peds.2005-0979; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; King WJ, 2003, CAN MED ASSOC J, V168, P155; Langlois J. A., 2000, TRAUMATIC BRAIN INJU; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Mullen E.M., 1995, MULLEN SCALES EARLY; Newgard CD, 2004, ACAD EMERG MED, V11, P953, DOI 10.1197/j.aem.2004.02.530; NICHOLS DG, 1996, GOLDEN HOUR HDB ADV; POLITZ K, CONSUMERS GUIDE GETT; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; Runyan DK, 1998, PEDIATRICS, V101, P12, DOI 10.1542/peds.101.1.12; SAMEROFF AJ, 1987, PEDIATRICS, V79, P343; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2000, DEV NEUROPSYCHOL, V17, P289, DOI 10.1207/S15326942DN1703_2; TEASDALE G, 1974, LANCET, V2, P81; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617	27	81	81	0	14	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	MAR	2007	119	3					E616	E623		10.1542/peds.2006-2313			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	141LK	WOS:000244579800057	17332181	Green Accepted, Green Submitted			2022-02-06	
J	Arango-Lasprilla, JC; Rosenthal, M; Deluca, J; Komaroff, E; Sherer, M; Cifu, D; Hanks, R				Arango-Lasprilla, Juan Carlos; Rosenthal, Mitchell; Deluca, John; Komaroff, Eugene; Sherer, Mark; Cifu, David; Hanks, Robin			Traumatic brain injury and functional outcomes: Does minority status matter?	BRAIN INJURY			English	Article						functional outcomes; TBI; minority status	SCALE; HEALTH; IMPACT; RACE	Objectives: ( 1) to determine differences between minorities vs. non- minorities on demographic, injury and rehabilitation characteristics and functional outcomes at admission, discharge and 1- year post- injury and ( 2) to examine differences in functional outcome at 1- year post- injury among ( African- Americans, Hispanics and Whites). Design: Retrospective study. Setting: Longitudinal data were extracted from the TBI Model Systems database. Participants: 4929 individuals with moderate- to- severe TBI ( 3354 Whites vs. 1575 Minorities: 1207 African- Americans and 368 Hispanics) hospitalized between 1989 - 2004. Main outcome measures: Functional outcomes at 1- year post- injury ( Disability Rating Scale, Functional Independence Measure, Glasgow Outcome Scale- Extended and Community Integration Questionnaire). Results: At discharge and 1- year post- injury, minorities had poorer functional outcomes compared with Caucasians on all measures. After controlling for sociodemographic, injury and functional characteristics at admission, Hispanics and AfricanAmericans still showed worse functional outcomes at 1- year post- injury compared with Whites on the DRS, FIM and CIQ. There were no significant differences between African Americans and Hispanics. Conclusions: Minorities had significantly reduced long- term functional outcome after rehabilitation relative to Whites. It is imperative that rehabilitation professionals' consider factors related to poorer long- term functional outcome and work to improve the quality of life of minorities with TBI.	Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA; Univ Med & Dent New Jersey, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; Univ Mississippi, Med Ctr, Methodist Rehabil Ctr, Jackson, MS 39216 USA; Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23284 USA; Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA		Arango-Lasprilla, JC (corresponding author), Virginia Commonwealth Univ W Hosp, Dept Phys Med & Rehabil, 3rd Floor,Room 3-102,1200 E Broad St, Richmond, VA 23298 USA.	jcarangolasp@vcu.edu		Cifu, David/0000-0003-1600-9387	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007522] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD07522-05, T32 HD007522-05] Funding Source: Medline		Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; Brown SA, 2004, APPL NEUROPSYCHOL, V11, P54, DOI 10.1207/s15324826an1101_7; Burnett DM, 2000, BRAIN INJURY, V14, P713; Burnett DM, 2003, ARCH PHYS MED REHAB, V84, P263, DOI 10.1053/apmr.2003.50091; Finkelstein E., 2006, INCIDENCE EC BURDEN; Hanks RA, 2003, ARCH PHYS MED REHAB, V84, P249, DOI 10.1053/apmr.2003.50096; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; Hosmer D, 1989, APPL LOGISTIC REGRES; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Rosenthal M, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P49, DOI 10.1037/10361-003; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; *STAT U NEW YORK B, 1997, GUID UN DAT SET MED; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; *TRAUM BRAIN INJ N, 2005, TRAUM BRAIN INJ MOD; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; [No title captured]	24	81	81	2	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	7					701	708		10.1080/02699050701481597			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	192LX	WOS:000248204400006	17653944				2022-02-06	
J	O'Keeffe, F; Dockree, P; Moloney, P; Carton, S; Robertson, IH				O'Keeffe, Fiadhnait; Dockree, Paul; Moloney, Pauline; Carton, Simone; Robertson, Ian H.			Awareness of deficits in traumatic brain injury: A multidimensional approach to assessing metacognitive knowledge and online-awareness	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						impaired self-awareness; traumatic brain injury; neuropsychological deficits; error-monitoring; executive functions; behavior	IMPAIRED SELF-AWARENESS; SUSTAINED ATTENTION; BEHAVIORAL LIMITATIONS; EXECUTIVE FUNCTION; SIGNIFICANT OTHERS; REHABILITATION; PERFORMANCE; QUESTIONNAIRE; DISTURBANCES; PERCEPTIONS	Recent models of impaired awareness in brain injury draw a distinction between metacognitive knowledge of difficulties and online awareness of errors (emergent and anticipatory). We examined performance of 31 Traumatic Brain Injury (TBI) participants and 31 healthy controls using a three-strand approach to assessing awareness. Metacognitive knowledge was assessed with an awareness interview and discrepancy scores on three questionnaires-Patient Competency Rating Scale, Frontal Systems Behavioral Scale and the Cognitive Failures Questionnaire. Online Emergent Awareness was assessed using an online error-monitoring task while participants performed tasks of sustained attention. Online anticipatory awareness was examined using prediction performance on two cognitive tasks. Results indicated that the TBI Low Self-Awareness (SA) group and High SA group did not differ in terms of severity, chronicity or standard neuropsychological tasks but those with Low SA were more likely to exhibit disinhibition, interpersonal problems and more difficulties in total competency. Sustained attention abilities were associated with both types of online awareness (emergent and anticipatory). There was a strong, relationship between online emergent and online anticipatory awareness. Metacognitive knowledge did not correlate with the other two measures. This study highlights the necessity in adopting a multidimensional approach to assessing the multifaceted phenomenon of awareness of deficits.	Trinity Coll Dublin, Inst Neurosci, Dublin 2, Ireland; Trinity Coll Dublin, Dept Psychol, Dublin 2, Ireland; Natl Rehabilitat Hosp, Dept Clin Neuropsychol, Dublin, Ireland		Robertson, IH (corresponding author), Trinity Coll Dublin, Inst Neurosci, Dublin 2, Ireland.	iroberts@tcd.ie		Robertson, Ian H/0000-0001-8637-561X			Abreu BC, 2001, ARCH PHYS MED REHAB, V82, P49, DOI 10.1053/apmr.2001.9167; ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Boone KB, 1999, J INT NEUROPSYCH SOC, V5, P616, DOI 10.1017/S1355617799577047; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Coben RA, 1995, ARCH CLIN NEUROPSYCH, V10, P309; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [DOI 10.1097/00001199-198909000-00008, 10.1097/00001199-198909000-00008]; Dockree PM, 2006, EXP BRAIN RES, V168, P218, DOI 10.1007/s00221-005-0079-x; Dubois B, 2000, NEUROLOGY, V55, P1621, DOI 10.1212/WNL.55.11.1621; Enderby P M, 1987, Int Rehabil Med, V8, P166; Fischer S, 2004, BRAIN INJURY, V18, P547, DOI 10.1080/02699050310001645793; Fischer S, 2004, J INT NEUROPSYCH SOC, V10, P190, DOI 10.1017/S1355617704102051; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; Fleming JM, 1996, BRAIN INJURY, V10, P1; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Gauggel S, 2002, J CLIN EXP NEUROPSYC, V24, P1070, DOI 10.1076/jcen.24.8.1070.8377; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P285, DOI 10.1097/00001199-200507000-00001; Hoofien D, 2004, J CLIN EXP NEUROPSYC, V26, P278, DOI 10.1076/jcen.26.2.278.28084; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; Malec JF, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199706000-00002; Malloy PF., 2002, FRONTAL SYSTEMS BEHA; Manly T, 2003, NEUROCASE, V9, P340, DOI 10.1076/neur.9.4.340.15553; Markova IS, 2001, PSYCHOPATHOLOGY, V34, P245, DOI 10.1159/000049317; McAvinue L, 2005, NEUROPSYCHOL REHABIL, V15, P569, DOI 10.1080/09602010443000119; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MEHRABIAN A, 1972, J PERS, V40, P525, DOI 10.1111/j.1467-6494.1972.tb00078.x; Nelson H.E., 1991, NATL ADULT READING T, V2nd ed.; Nelson H.E., 1982, NATL ADULT READING T; Noe E, 2005, J NEUROL, V252, P168, DOI 10.1007/s00415-005-0625-2; O'Keeffe FM, 2004, COGNITIVE BRAIN RES, V22, P101, DOI 10.1016/j.cogbrainres.2004.07.012; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Ownsworth TL, 2000, CLIN NEUROPSYCHOL, V14, P76, DOI 10.1076/1385-4046(200002)14:1;1-8;FT076; Ownsworth TL, 2002, BRAIN INJURY, V16, P291, DOI 10.1080/02699050110103986; OWNSWORTH TL, IN PRESS NEUROPSYCHO; Prigatano G., 1999, PRINCIPLES NEUROPSYC, P265; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1997, NEUROPSY NEUROPSY BE, V10, P135; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; PRIGATANO GP, 1986, NUROPSYCHOLOGICAL RE; Robertson I H, 1996, J Int Neuropsychol Soc, V2, P525; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Sawchyn JM, 2005, J HEAD TRAUMA REHAB, V20, P301, DOI 10.1097/00001199-200507000-00003; SCHACTER DL, 1990, J CLIN EXP NEUROPSYC, V12, P155, DOI 10.1080/01688639008400962; Schmitz TW, 2006, NEUROPSYCHOLOGIA, V44, P762, DOI 10.1016/j.neuropsychologia.2005.07.012; Sherer M, 2005, J HEAD TRAUMA REHAB, V20, P287, DOI 10.1097/00001199-200507000-00002; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Sohlberg MM, 1998, J HEAD TRAUMA REHAB, V13, P62, DOI 10.1097/00001199-199810000-00008; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Spreen O., 1969, NEUROSENSORY CTR COM; STUSS D, 2001, FRONTAL LOBES NEUROP; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; WALKER D, 2003, THESIS U READING REA; Wallace CA, 2000, BRAIN INJURY, V14, P549; WECHSLER D, 1998, WECHSLER MEMORY SCAL, V3; Wise K, 2005, BRAIN INJURY, V19, P765, DOI 10.1080/0269905050019977; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	68	81	81	0	11	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2007	13	1					38	49		10.1017/S1355617707070075			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	127PO	WOS:000243599000005	17166302	Green Published			2022-02-06	
J	Greve, KW; Bianchini, KJ; Doane, BM				Greve, Kevin W.; Bianchini, Kevin J.; Doane, Bridget M.			Classification accuracy of the test of memory malingering in traumatic brain injury: Results of a known-groups analysis	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							ADULT INTELLIGENCE SCALE; CARD SORTING TEST; NEUROCOGNITIVE DYSFUNCTION; COGNITIVELY INTACT; NORMATIVE DATA; TOMM; VALIDATION; PERFORMANCE; DEPRESSION	This study used a known-groups design to determine the classification accuracy of the Test of Memory Malingering (Tombaugh, 1996, 1997) in detecting cognitive malingering in traumatic brain injury (TBI). Forty-one of 161 TBI patients met Slick, Sherman, and Iverson (1999) criteria for Malingered Neurocognitive Dysfunction. Twenty-two no-incentive memory disorder patients were also included. The original cutoffs (< 45) for Trial 2 and Retention demonstrated excellent specificity (less than a 5% false positive error rate) and impressive sensitivity (greater than 45%). However, these cutoffs are actually conservative in the context of mild TBI. Over 90% of the non-MND mild TBI sample scored 48 or higher on the Retention Trial and none scored less than 46 while 60% of the MND patients claiming mild TBI were detected at those levels. Trial 1 also demonstrated excellent classification accuracy. Application of these data to clinical practice is discussed.	Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; Jefferson Neurobehav Grp, Metairie, LA USA		Greve, KW (corresponding author), Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P461, DOI 10.1076/clin.15.4.461.1890; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; BINDER LM, 1993, PORTLAND DIGIT RECOG; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Delis DC, 1987, CALIFORNIA VERBAL LE; Etherton JL, 2005, ARCH CLIN NEUROPSYCH, V20, P375, DOI 10.1016/j.acn.2004.09.007; Gansler DA, 1996, ARCH CLIN NEUROPSYCH, V11, P393, DOI 10.1016/0887-6177(96)83889-3; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Gouvier WD, 1998, CRIT ISS NE, P55; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2006, ARCH CLIN NEUROPSYCH, V21, P117, DOI 10.1016/j.acn.2005.06.009; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Greve KW, 2003, ARCH CLIN NEUROPSYCH, V18, P245, DOI 10.1016/S0887-6177(02)00137-3; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; Heaton SK, 1993, WISCONSIN CARD SORTI; HENNEKENS CH, 1987, EPIDEMIOLOGY MED; Kaemmer, 1989, MMPI 2 MANUAL ADM SC; KAGEHIRO DK, 1990, PSYCHOL SCI, V1, P194, DOI 10.1111/j.1467-9280.1990.tb00197.x; KIERNAN RJ, 1983, NEUROBEHAVIORAL COGN; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; LEESHALEY PR, 2003, J FORENSIC NEUROPSYC, V3, P167, DOI DOI 10.1300/J151V03N01_01; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Millis S. R., 2004, PRINCIPLES PRACTICE, P1077; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Rogers R., 1997, CLIN ASSESSMENT MALI, P398; Slick DJ, 2004, ARCH CLIN NEUROPSYCH, V19, P465, DOI 10.1016/j.acn.2003.04.001; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Weinborn M, 2003, J CLIN EXP NEUROPSYC, V25, P979, DOI 10.1076/jcen.25.7.979.16481; [No title captured]	44	81	81	0	7	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	OCT	2006	28	7					1176	1190		10.1080/13803390500263550			15	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	064KV	WOS:000239089300009	16840243				2022-02-06	
J	Carlson, AP; Schermer, CR; Lu, SW				Carlson, Andrew P.; Schermer, Carol R.; Lu, Stephen W.			Retrospective evaluation of anemia and transfusion in traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	64th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 22-24, 2005	Atlanta, GA	Amer Assoc Surg Trauma			AUTOLOGOUS BLOOD-TRANSFUSION; SECONDARY SYSTEMIC INSULTS; SEVERE HEAD-INJURY; CEREBRAL HEMODYNAMICS; CANCER-SURGERY; NATURAL-KILLER; MANAGEMENT; HYPOXIA; CARE; METABOLISM	Background: Despite clear evidence in critical care that blood transfusion has an adverse impact on outcome, neurosurgical textbooks still recommend transfusion of patients with traumatic brain injury (TBI) to a hematocrit (HCT) of 30%. There is little empirical evidence to support this practice. The current study addresses transfusion requirements in TBI in terms of neurologic outcome. Methods: Retrospective record review of patients with severe TBI. Outcome measures were Glasgow Coma Scale score (GCS), Glasgow Outcome Score (GOS), and Ranchos Los Amigos Score (RLA) at hospital discharge (D/C); and GOS and Functional Independence Measures at follow-up. Association of outcomes with the number of days the HCT < 30% and lowest measured HCT were evaluated. Results: In all, 169 patients reviewed; 150 with D/C outcome data and 72 with long-term follow-up data. Univariate analysis showed that lowest measured HCT was associated with lower D/C GCS, D/C GOS, and RLA scores. Linear regression showed that more days with HCT < 30% were associated with improved neurologic outcomes measured by GOS (R-2 = 0.424, p < 0.001), GCS (R-2 = 0.381, p < 0.001) and RLA (R-2 = 0.392,p < 0.001) scores on D/C. Both transfusion and lowest measured HCT were significantly associated with all lower outcome scores on D/C. Additional factors with adverse impact on outcome were head Abbreviated Injury Score (AIS), Injury Severity Score, hyperglycemia, and hypotension. Long-term outcomes were only significantly associated with head AIS. Conclusions: Patients with severe TBI should not have a different transfusion threshold than other critical care patients. Prospective studies are needed to evaluate the effects of anemia in TBI.	Univ New Mexico, Dept Surg, Albuquerque, NM 87131 USA; Univ New Mexico, Dept Neurosurg, Albuquerque, NM 87131 USA; Loyola Univ, Chicago Stritch Sch Med, Maywood, IL 60153 USA		Lu, SW (corresponding author), Univ New Mexico, Dept Surg, MSC 10 5610, Albuquerque, NM 87131 USA.	swlu@salud.unm.edu	Carlson, Andrew P/B-4369-2012	Carlson, Andrew P/0000-0003-2189-3699			Bedell Eric, 2002, Anesthesiol Clin North Am, V20, P417, DOI 10.1016/S0889-8537(01)00010-4; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; CARREL M, 1994, ANN FR ANESTH, V13, P326, DOI 10.1016/S0750-7658(94)80041-3; CZER LSC, 1978, SURG GYNECOL OBSTET, V147, P363; Gibson JB, 2002, SHOCK, V17, P234, DOI 10.1097/00024382-200203000-00013; Goodnough LT, 2003, CRIT CARE MED, V31, pS678, DOI 10.1097/01.CCM.0000100124.50579.D9; Hebert PC, 2001, CRIT CARE MED, V29, P227, DOI 10.1097/00003246-200102000-00001; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; HEISS MM, 1993, LANCET, V342, P1328, DOI 10.1016/0140-6736(93)92247-Q; Heiss MM, 1997, VOX SANG, V73, P237, DOI 10.1046/j.1423-0410.1997.7340237.x; JENSEN LS, 1992, BRIT J SURG, V79, P513, DOI 10.1002/bjs.1800790613; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Lee EJ, 1999, J NEUROL SCI, V164, P117, DOI 10.1016/S0022-510X(99)00068-4; Lee EJ, 2001, J NEUROL SCI, V190, P3, DOI 10.1016/S0022-510X(01)00567-6; Marescal C, 1998, ANN FR ANESTH, V17, P234, DOI 10.1016/S0750-7658(98)80005-1; MARIK PE, 1993, JAMA-J AM MED ASSOC, V269, P3024, DOI 10.1001/jama.269.23.3024; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Offner PJ, 2002, ARCH SURG-CHICAGO, V137, P711, DOI 10.1001/archsurg.137.6.711; OPELZ G, 1973, TRANSPLANT P, V5, P253; OPELZ G, 1976, TRANSPLANTATION, V22, P380, DOI 10.1097/00007890-197610000-00010; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Winn HR, 2004, YOUMANS NEUROLOGICAL, V5	23	81	88	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2006	61	3					567	571		10.1097/01.ta.0000231768.44727.a2			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	084YL	WOS:000240570200013	16966988				2022-02-06	
J	Root, JC; Robbins, RN; Chang, L; Van Gorp, WG				Root, James C.; Robbins, Reuben N.; Chang, Luke; Van Gorp, Wilfred G.			Detection of inadequate effort on the California Verbal Learning Test-Second edition: Forced Choice Recognition and Critical Item Analysis	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						malingering; neuropsychological tests; memory; forensic; assessment; neuropsychology	MEMORY MALINGERING TOMM; TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL EVALUATION; HEAD-INJURY; PERFORMANCE; PREDICTORS; DEFICITS; INTERNET; RATES	The Forced Choice Recognition (FCR) and the Critical Item Analysis (CIA) indices of the California Verbal Learning Test-II (CVLT II) have been identified by the CVLT-II test developers as potentially useful, brief screening indicators of effort in neuropsychological assessment. This retrospective study analyzes performance on these measures in three groups: (1) clinically referred individuals; (2) forensically referred individuals not suspected of inadequate effort; and (3) forensically referred individuals whose performance on freestanding tests of effort suggested inadequate effort. Performances on FCR were analyzed for their relation to actual memory impairment and with regard to concrete and abstract distractor endorsement. FCR and CIA performances were analyzed for agreement with formal tests of inadequate effort and their test characteristics. Incremental validity was assessed by hierarchical logistic regression with previously identified indices for detection of inadequate effort on the CVLT. Results indicate that (1) FCR and CIA performances are not related to decreased memory performance; (2) FCR and CIA indices exhibit higher specificity and lower sensitivity, with higher positive predictive value than negative predictive value; and (3) FCR and CIA indices exhibit modest incremental validity with previously identified indices. Implications for use of FCR and CIA indices in inadequate effort detection are discussed.	Cornell Univ, Weill Med Coll, Dept Psychiat, New York, NY 10021 USA; Fordham Univ, Dept Psychol, Bronx, NY 10458 USA; New Sch Social Res, Dept Psychol, New York, NY USA; Columbia Univ, Dept Psychiat, New York, NY USA		Root, JC (corresponding author), Cornell Univ, Weill Med Coll, Dept Psychiat, 1300 York Ave,F1302, New York, NY 10021 USA.	jcr2003@med.cornell.edu	Robbins, Reuben/AAI-7146-2021	Robbins, Reuben/0000-0003-0774-2245; Chang, Luke/0000-0002-6621-8120; CHANG, LUKE/0000-0002-7177-4711			ARNETT PA, 1995, CLIN NEUROPSYCHOL, V9, P17, DOI 10.1080/13854049508402052; Ashendorf L, 2003, CLIN NEUROPSYCHOL, V17, P255, DOI 10.1076/clin.17.2.255.16502; Bauer L, 2006, ARCH CLIN NEUROPSYCH, V21, P121, DOI 10.1016/j.acn.2005.06.010; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; Cohen J., 2013, STAT POWER ANAL BEHA; Coleman RD, 1998, J CLIN EXP NEUROPSYC, V20, P201, DOI 10.1076/jcen.20.2.201.1164; CONDER R, 1992, COMPUTERIZED ASSESSM; Connor D. J., 1997, AM AC NEUR BOST; Delis D.C., 2000, CALIFORNIA VERBAL LE; Delis DC, 1987, CALIFORNIA VERBAL LE; Frederick R. I., 1997, VALIDITY INDICATOR P; Frederick RI, 1994, NEUROPSYCHOLOGY, V8, P118, DOI 10.1037/0894-4105.8.1.118; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Green P., 1996, WORD MEMORY TEST USE; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Lee G. P., 1992, PSYCHOL ASSESSMENT, V4, P43, DOI DOI 10.1037/1040-3590.4.1.43; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Rosenfeld B, 2000, ARCH CLIN NEUROPSYCH, V15, P349, DOI 10.1016/S0887-6177(99)00025-6; Royston P, 2006, STAT MED, V25, P127, DOI 10.1002/sim.2331; Ruiz MA, 2002, PROF PSYCHOL-RES PR, V33, P294, DOI 10.1037//0735-7028.33.3.294; SCHRETLEN DJ, 1988, CLIN PSYCHOL REV, V8, P451, DOI 10.1016/0272-7358(88)90074-8; Sweet JJ, 2000, ARCH CLIN NEUROPSYCH, V15, P105, DOI 10.1016/S0887-6177(98)00153-X; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Vallabhajosula B, 2001, J AM ACAD PSYCHIATRY, V29, P207	31	81	82	1	8	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2006	12	5					688	696		10.1017/S1355617706060838			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	081ZE	WOS:000240355300011	16961950	Green Published			2022-02-06	
J	Leinhase, I; Schmidt, OI; Thurman, JM; Hossini, AM; Rozanski, M; Taha, ME; Scheffler, A; John, T; Smith, WR; Holers, VM; Stahel, PF				Leinhase, Iris; Schmidt, Oliver I.; Thurman, Joshua M.; Hossini, Amir M.; Rozanski, Michal; Taha, Mohy E.; Scheffler, Alice; John, Thilo; Smith, Wade R.; Holers, V. Michael; Stahel, Philip F.			Pharmacological complement inhibition at the C3 convertase level promotes neuronal survival, neuroprotective intracerebral gene expression, and neurological outcome after traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article; Proceedings Paper	Annual Meeting of the German-Society-for-Trauma-Surgery	OCT 19-22, 2005	Berlin, GERMANY	German Soc Trauma Soc		complement; traumatic brain injury; neuroinflammation; neurodegeneration; gene expression	CLOSED-HEAD INJURY; CENTRAL-NERVOUS-SYSTEM; C5A RECEPTOR; AXONAL INJURY; CRRY-IG; MICE; PROTEIN; ACTIVATION; REGULATOR; DEMYELINATION	The complement system represents an important mediator of neuroinflammation in traumatic brain injury. We have previously shown that transgenic mice with central nervous system-targeted overexpression of Crry, a potent murine complement inhibitor at the level of C3 convertases, are protected from complement-mediated neuropathological sequelae in brain-injured mice. This knowledge was expanded in the present study to a pharmacological approach by the use of a recombinant Crry molecule (termed Crry-Ig) which was recently made available in a chimeric form fused to the non-complement fixing mouse IgG1 Fc region. In a standardized model of closed head injury in mice, the systemic injection of I mg Crry-Ig at I h and 24 h after trauma resulted in a significant neurological improvement for up to 7 days, as compared to vehicle-injected control mice (P < 0.05, repeated measures ANOVA). Furthermore, the extensive neuronal destruction seen in the hippocampal CA3/CA4 sublayers in head-injured mice with vehicle injection only was shown to be preserved - to a similar extent as in "sbam"-operated mice - by the posttraumatic injection of Crry-Ig. Real-time RT-PCR analysis revealed that the post-treatment with Crry-Ig resulted in a significant up-regulation of candidate neuroprotective genes in the injured hemisphere (Bcl-2, C1-Inh, CD55, CD59), as compared to the vehicle control group (P < 0.01, unpaired Student's t test). Increased intracerebral Bcl-2 expression by Crry-Ig treatment was furthermore confirmed at the protein level by Western blot analysis. These data suggest that pharmacological complement inhibition represents a promising approach for attenuation of neuroinflammation and secondary neurodegeneration after head injury. (c) 2006 Elsevier Inc. All rights reserved.	Univ Berlin, Med Sch, Dept Trauma & Reconstruct Surg, D-12200 Berlin, Germany; Univ Colorado, Hlth Sci Ctr, Div Rheumatol, Dept Med, Denver, CO 80309 USA; Univ Colorado, Denver Hlth Med Ctr, Dept Orthoped, Denver, CO 80309 USA		Stahel, PF (corresponding author), Univ Berlin, Med Sch, Dept Trauma & Reconstruct Surg, Campus Benjamin Franklin,Hindenburgdamm 30, D-12200 Berlin, Germany.	pfstahel@aol.com			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [K08DK064790] Funding Source: NIH RePORTER; NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [K08 DK064790-02] Funding Source: Medline		Alexander JJ, 2003, BBA-MOL BASIS DIS, V1639, P169, DOI 10.1016/j.bbadis.2003.09.005; Baalasubramanian S, 2004, J IMMUNOL, V173, P3684, DOI 10.4049/jimmunol.173.6.3684; Barnum SR, 1999, MOL MED, V5, P569, DOI 10.1007/BF03402070; Bayir H, 2003, CRIT CARE MED, V31, pS112, DOI 10.1097/01.CCM.0000042464.46603.0E; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; D'Ambrosio AL, 2001, MOL MED, V7, P367, DOI 10.1007/BF03402183; Davoust N, 1999, GLIA, V27, P162, DOI 10.1002/(SICI)1098-1136(199908)27:2<162::AID-GLIA6>3.0.CO;2-K; Du LH, 2005, ONCOGENE, V24, P107, DOI 10.1038/sj.onc.1208189; Elf K, 2003, EUR J TRAUMA, V29, P74; Farkas I, 1998, J PHYSIOL-LONDON, V507, P679, DOI 10.1111/j.1469-7793.1998.679bs.x; Fecker LF, 2005, J INVEST DERMATOL, V124, P221, DOI 10.1111/j.0022-202X.2004.23572.x; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; FOLEY S, 1993, EUR J IMMUNOL, V23, P1381, DOI 10.1002/eji.1830230630; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; Harris CL, 2002, BIOCHEM SOC T, V30, P1019, DOI 10.1042/bst0301019; Hicks RR, 2002, J NEUROTRAUM, V19, P705, DOI 10.1089/08977150260139093; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kulkarni AP, 2004, ANN NY ACAD SCI, V1035, P147, DOI 10.1196/annals.1332.010; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Max JE, 2001, J NEUROPSYCH CLIN N, V13, P161, DOI 10.1176/appi.neuropsych.13.2.161; McArthur DL, 2004, BRAIN PATHOL, V14, P185, DOI 10.1111/j.1750-3639.2004.tb00052.x; Mead RJ, 2004, LAB INVEST, V84, P21, DOI 10.1038/labinvest.3700015; Mead RJ, 2002, J IMMUNOL, V168, P458, DOI 10.4049/jimmunol.168.1.458; Minghetti L, 2005, CURR OPIN NEUROL, V18, P315, DOI 10.1097/01.wco.0000169752.54191.97; Mizuno M., 2004, Current Drug Targets - Inflammation and Allergy, V3, P87, DOI 10.2174/1568010043483890; Molina H, 2002, CELL MOL LIFE SCI, V59, P220, DOI 10.1007/s00018-002-8418-6; Morgan BP, 2005, XENOTRANSPLANTATION, V12, P258, DOI 10.1111/j.1399-3089.2005.00237.x; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Qu CS, 2005, J NEUROSURG, V103, P695, DOI 10.3171/jns.2005.103.4.0695; Quigg RJ, 1998, J IMMUNOL, V160, P4553; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Reed AR, 2002, SAMJ S AFR MED J, V92, P221; Rehrig S, 2001, J IMMUNOL, V167, P5921, DOI 10.4049/jimmunol.167.10.5921; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; Rus H, 2005, ANN MED, V37, P97, DOI 10.1080/07853890510007278; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Schmidt O.I., 2004, EUR J TRAUMA, V30, P135, DOI DOI 10.1007/S00068-004-1394-9; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schmidt OI, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-13; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; Shacka JJ, 2005, CNS NEUROL DISORD-DR, V4, P25, DOI 10.2174/1568007053005127; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Singhrao SK, 1999, LAB INVEST, V79, P1247; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Stahel PF, 2000, J NEUROIMMUNOL, V109, P164, DOI 10.1016/S0165-5728(00)00304-0; Strauss KI, 2004, NEUROTOX RES, V6, P333, DOI 10.1007/BF03033444; Thurman JM, 2005, MOL IMMUNOL, V42, P87, DOI 10.1016/j.molimm.2004.07.043; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; van Beek J, 2005, J IMMUNOL, V174, P2353, DOI 10.4049/jimmunol.174.4.2353; Van Beek J, 2003, ANN NY ACAD SCI, V992, P56; WALDMEIER PC, 2003, BIOL PSYCHIAT, V27, P303; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496	60	81	83	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	JUN	2006	199	2					454	464		10.1016/j.expneurol.2006.01.033			11	Neurosciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	063DB	WOS:000238995200026	16545803				2022-02-06	
J	Fuller, CW; Junge, A; Dvorak, J				Fuller, CW; Junge, A; Dvorak, J			A six year prospective study of the incidence and causes of head and neck injuries in international football	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							PROFESSIONAL FOOTBALL; ANKLE INJURIES; BRAIN-INJURY; SOCCER; MECHANISMS; CONCUSSION; RISK	Objective: To identify those risk factors that have the greatest impact on the incidence of head and neck injuries in international football. Method: A case-control study of players sustaining head and neck injuries during 20 FIFA tournaments (men and women) from 1998 to 2004. Video recordings of incidents were used to identify a range of parameters associated with the incidents. Team physicians provided medical reports describing the nature of each injury. chi(2) tests (p <= 0.01) and 95% confidence intervals were used to assess differences in distribution and incidence of injury, respectively. Results: In total, 248 head and neck injuries were recorded of which 163 were identified and analysed on video sequences. The commonest injuries were contusions (53%), lacerations (20%), and concussions (11%). The incidence of all head and neck injuries was 12.5/1000 player hours (men 12.8, women 11.5) and 3.7 for lost-time injuries (men 3.5, women 4.1). The commonest causes of injury involved aerial challenges (55%) and the use of the upper extremity (33%) or head (30%). The unfair use of the upper extremity was significantly more likely to cause an injury than any other player action. Only one injury (a neck muscle strain) occurred as a result of heading the ball throughout the 20 tournaments equivalent to 0.05 injuries/ 1000 player hours. Conclusions: Players' actions most likely to cause a head or neck injury were the use of the upper extremity or the head but in the majority of cases these challenges were deemed to be fair and within the laws of the game.	Univ Leicester, Scarman Ctr, Leicester, Leics, England; Schulthess Clin, Zurich, Switzerland		Fuller, CW (corresponding author), Univ Leicester, Scarman Ctr, Leicester, Leics, England.	cwf2@le.ac.uk					Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Andersen TE, 2003, BRIT J SPORT MED, V37, P226, DOI 10.1136/bjsm.37.3.226; Andersen TE, 2004, AM J SPORT MED, V32, p69S, DOI 10.1177/0363546503262023; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; DEMETRIADES AK, 2003, BRIT J SPORT MED, V30, P289; Dvorak J, 2000, AM J SPORT MED, V28, pS3; ETTLINGER CF, 1995, AM J SPORT MED, V23, P531, DOI 10.1177/036354659502300503; FAUDE O, IN PRESS AM J SPORTS; *FIFA, 2004, REP STAT FIFA TOURN; *FOOTB ASS, 2004, RUL ASS LAWS GAM SEA; Fuller CW, 2004, AM J SPORT MED, V32, p17S, DOI 10.1177/0363546503261249; Fuller CW, 2004, AM J SPORT MED, V32, p43S, DOI 10.1177/0363546503261248; Fuller CW, 2004, AM J SPORT MED, V32, p28S, DOI 10.1177/0363546503261247; Fuller CW, 1997, SAFETY SCI, V27, P115; Giza E, 2003, AM J SPORT MED, V31, P550, DOI 10.1177/03635465030310041201; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Hawkins RD, 1998, BRIT J SPORT MED, V32, P326, DOI 10.1136/bjsm.32.4.326; Hawkins RD, 1996, BRIT J SPORT MED, V30, P165, DOI 10.1136/bjsm.30.2.165; Hawkins RD, 1999, BRIT J SPORT MED, V33, P196, DOI 10.1136/bjsm.33.3.196; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Junge A, 2004, AM J SPORT MED, V32, p80S, DOI 10.1177/0363546503261245; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Lewin G., 1989, PHYSIOTHERAPY, V75, P601, DOI [10.1016/S0031-9406(10)62366-8, DOI 10.1016/S0031-9406(10)62366-8]; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrory PR, 2003, BRIT MED J, V327, P351, DOI 10.1136/bmj.327.7411.351; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Putukian Margot, 2004, Curr Sports Med Rep, V3, P9; Rahnama N, 2002, BRIT J SPORT MED, V36, P354, DOI 10.1136/bjsm.36.5.354; Rutherford A, 2003, NEUROPSYCHOL REV, V13, P153, DOI 10.1023/A:1025525613477; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; Wilson B D, 1999, J Sci Med Sport, V2, P153, DOI 10.1016/S1440-2440(99)80195-9; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401	38	81	82	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2005	39			1			I3	I9		10.1136/bjsm.2005.018937			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	954KI	WOS:000231153600002	16046353	Green Published, Bronze			2022-02-06	
J	Johnston, MV; Goverover, Y; Dijkers, M				Johnston, MV; Goverover, Y; Dijkers, M			Community activities and individuals' satisfaction with them: Quality of life in the first year after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; outcome assessment (health care); program evaluation; quality of life; rehabilitation	SELF-IDENTIFIED GOALS; SYSTEMATIC BIAS; REHABILITATION; OUTCOMES; ACHIEVEMENT; INTEGRATION; MODELS; ADULTS; TBI	Objective: To investigate the relations between community activities and satisfaction with these activities, desires to change them. and global life satisfaction. Design: Interview Study with follow-up 1 month after rehabilitation discharge and 12 months postinjury. Setting: Community. Participants: One hundred sixty-two individuals hospitalized with mostly moderate-to-severe traumatic brain injury. About 90% were reached (mostly by phone) 1 month after rehabilitation discharge: 84.6%, at 12 months postinjury. Interventions: Not applicable. Main Outcome Measures: Community Integration Questionnaire-2. augmented by individuals' ratings of satisfaction or dissatisfaction with and desire to change each activity; and the Satisfaction With Life Scale. Results: Although significant correlations were found for some items. most correlations between activities and ratings of Global quality of life (QOL) were low and nonsignificant. Individuals reported that they were satisfied with most of their community activities, but there were exceptions (eg, paid work). Correlations between activity-specific satisfaction and General life satisfaction were Generally weak and nonsignificant. Dissatisfaction with an activity correlated strongly with desire to change the activity, but general life satisfaction did not con-elate With desire to change activities. Conclusions: The lack of association between frequency of activities and subjective appraisals of them is a challenge to outcomes measurement and has implications for the targeting of rehabilitative interventions and evaluation of their worth. More research is needed to understand how individualizing functional objectives might maximize the effects of rehabilitation on the QOL of persons served.	Kessler Med Rehabil Res & Educ Corp, W Orange, NJ 07052 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; Mt Sinai Sch Med, New York, NY USA		Johnston, MV (corresponding author), Kessler Med Rehabil Res & Educ Corp, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.		Heinemann, Allen W/K-6283-2012	Heinemann, Allen W/0000-0003-2782-7326; Dijkers, Marcel/0000-0002-8362-5596			BANJA J, 1994, ARCH PHYS MED REHABI; Batavia A I, 1992, Disabil Rehabil, V14, P156; Bowling A., 1997, MEASURING HLTH REV Q; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Brown M, 2000, BRAIN INJURY, V14, P5, DOI 10.1080/026990500120899; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; *COMM ACCR REH FAC, 2003, MED REH STAND MAN; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Cox WM, 2003, J ADDICT DIS, V22, P93, DOI 10.1300/J069v22n01_07; DePalma J A, 2001, Crit Care Nurs Q, V23, P42; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers M, 1999, AM J PHYS MED REHAB, V78, P286, DOI 10.1097/00002060-199905000-00022; Dijkers MP, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50241; Felce D, 2000, BEHAVIORAL OBSERVATION, P159; FERRANS CE, 1992, RES NURS HLTH, V15, P19; FUHRER MJ, 1994, AM J PHYS MED REHAB, V73, P358, DOI 10.1097/00002060-199409000-00010; FUHRER MJ, 1987, REAHBILITATION OUTCO; FUHRER MJ, 1997, ASSESSING MED REHABI; GILL TM, 1994, JAMA-J AM MED ASSOC, V272, P619, DOI 10.1001/jama.272.8.619; GORDON WA, 1999, REHABILITATION ADULT, P312; Granger CV, 1998, ARCH PHYS MED REHAB, V79, P235, DOI 10.1016/S0003-9993(98)90000-4; Granger CV, 2000, AM J PHYS MED REHAB, V79, P197, DOI 10.1097/00002060-200003000-00015; Granger CV, 1984, FUNCTIONAL ASSESSMEN; Granger CV, 2000, PHYS MED REHABILITAT, P151; Heinemann AW, 2002, ARCH PHYS MED REHAB, V83, P1052, DOI 10.1053/apmr.2002.34283; Hoofien D, 2001, BRAIN INJURY, V15, P189; Institute of Medicine Committee on Quality of Health Care in America, 2001, CROSS QUAL CHASM NEW; Johnson M.L., 1997, ASSESSING MED REHABI, P1; JOHNSTON M V, 1991, Brain Injury, V5, P155, DOI 10.3109/02699059109008086; Johnston Mark, 2002, J Spinal Cord Med, V25, P11; Johnston MV, 2002, ARCH PHYS MED REHAB, V83, pS26, DOI 10.1053/apmr.2002.37100; JOYCE BM, 1994, AM J PHYS MED REHAB, V73, P10, DOI 10.1097/00002060-199473010-00003; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kreuter M, 1998, SPINAL CORD, V36, P252, DOI 10.1038/sj.sc.3100592; LAMAN H, 1994, DISABIL REHABIL, V16, P198, DOI 10.3109/09638289409166613; LOW M, 1990, CAN J OCCUP THER, V57, P82; MCCOLL MA, 2001, MEASURING OCCUPATION, P215; McNeny R., 1999, REHABILITATION ADULT, P242; Murawski M M, 1996, Med Interface, V9, P54; Patrick DL, 1993, HLTH STATUS HLTH POL; Pavot W., 1993, PSYCHOL ASSESSMENT, V52, P164, DOI DOI 10.1037/1040-3590.5.2.164; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Schwartz CE, 2000, ADAPTATION CHANGING; Seibert PS, 2002, BRAIN INJURY, V16, P837, DOI 10.1080/02699050210131939; SIEGEL S, 1998, NONPARAMETRIC STAT B; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Stineman MG, 2000, SCAND J REHABIL MED, V32, P143; Stineman MG, 2003, ARCH PHYS MED REHAB, V84, pS15, DOI 10.1053/apmr.2003.50242; Trombly CA, 1998, AM J OCCUP THER, V52, P810, DOI 10.5014/ajot.52.10.810; Trombly CA, 2002, AM J OCCUP THER, V56, P489, DOI 10.5014/ajot.56.5.489; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; World Health Organization, 2007, INT CLASS FUNCT DIS	55	81	85	0	8	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2005	86	4					735	745		10.1016/j.apmr.2004.10.031			11	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	914ON	WOS:000228237300019	15827926				2022-02-06	
J	Larsson, A; Wilhelmsson, U; Pekna, M; Pekny, M				Larsson, A; Wilhelmsson, U; Pekna, M; Pekny, M			Increased cell proliferation and neurogenesis in the hippocampal dentate gyrus of old GFAP(-/-)Vim(-/-) mice	NEUROCHEMICAL RESEARCH			English	Article						neurogenesis; dentate gyrus; hippocampus; astrocytes; intermediate filaments; glial fibrillary acidic protein; vimentin	FIBRILLARY ACIDIC PROTEIN; NEURAL STEM-CELLS; CENTRAL-NERVOUS-SYSTEM; ADULT-RAT; REACTIVE ASTROCYTES; GLIAL REACTION; MOUSE-BRAIN; VIMENTIN; NEURONS; REGENERATION	In response to central nervous system (CNS) injury, and more discretely so also during aging, astrocytes become reactive and increase their expression of the intermediate. lament proteins glial fibrillary acidic protein (GFAP) and vimentin. Studies of mice deficient in astrocytic intermediate. laments have provided insights into the function of reactive gliosis. Recently we demonstrated robust integration of retinal transplants (1) and increased post-traumatic synaptic regeneration (2) in GFAP(-/-) Vim(-/-) mice, suggesting that modulation of astrocyte activity affects the permissiveness of the CNS environment for regeneration. Neurogenesis in the adult mammalian CNS is restricted to essentially two regions, the hippocampus and the subventricular zone. Here, we assessed neurogenesis in the hippocampus of 18-month-old GFAP(-/-) Vim(-/-) mice. In the granular layer of the dentate gyrus, cell proliferation/survival was 34% higher and neurogenesis 36% higher in GFAP(-/-) Vim(-/-) mice than in wildtype controls. These findings suggest that the adult hippocampal neurogenesis in healthy old mice can be increased by modulating astrocyte reactivity.	Univ Gothenburg, Dept Med Biochem, Sahlgrenska Acad, S-40530 Gothenburg, Sweden		Pekny, M (corresponding author), Univ Gothenburg, Dept Med Biochem, Sahlgrenska Acad, Box 440, S-40530 Gothenburg, Sweden.	Milos.Pekny@medkem.gu.se	Pekna, Marcela/AAM-3261-2021; Pekna, Marcela/AAM-3249-2021	Pekna, Marcela/0000-0003-2734-8237; Pekna, Marcela/0000-0003-2734-8237; Wilhelmsson, Ulrika/0000-0003-3227-2687			Amenta F, 1998, MICROSC RES TECHNIQ, V43, P29, DOI 10.1002/(SICI)1097-0029(19981001)43:1<29::AID-JEMT5>3.0.CO;2-H; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; David JP, 1997, NEUROSCI LETT, V235, P53, DOI 10.1016/S0304-3940(97)00708-8; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Eliasson C, 1999, J BIOL CHEM, V274, P23996, DOI 10.1074/jbc.274.34.23996; Emsley JG, 2004, TRENDS NEUROSCI, V27, P238, DOI 10.1016/j.tins.2004.02.008; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; GOSS JR, 1991, NEUROBIOL AGING, V12, P165, DOI 10.1016/0197-4580(91)90056-P; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; Imura T, 2003, J NEUROSCI, V23, P2824; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Kinouchi R, 2003, NAT NEUROSCI, V6, P863, DOI 10.1038/nn1088; KOHAMA SG, 1995, NEUROBIOL AGING, V16, P59, DOI 10.1016/0197-4580(95)80008-F; Kurimoto Y, 2001, NEUROSCI LETT, V306, P57, DOI 10.1016/S0304-3940(01)01857-2; Lane EB, 2004, METHOD CELL BIOL, V78, P229; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; Menet V, 2003, P NATL ACAD SCI USA, V100, P8999, DOI 10.1073/pnas.1533187100; Mirich JM, 2002, J COMP NEUROL, V454, P361, DOI 10.1002/cne.10426; Nishida A, 2000, INVEST OPHTH VIS SCI, V41, P4268; Noctor SC, 2001, NATURE, V409, P714, DOI 10.1038/35055553; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; Pekny M, 2004, TRENDS NEUROSCI, V27, P243, DOI 10.1016/j.tins.2004.01.012; PEKNY M, 2004, IN PRESS J PATHOL, V204; Privat A, 2003, GLIA, V43, P91, DOI 10.1002/glia.10249; Quinlan R, 2004, TRENDS NEUROSCI, V27, P241, DOI 10.1016/j.tins.2004.02.009; Rakic P, 2002, J NEUROSCI, V22, P614, DOI 10.1523/JNEUROSCI.22-03-00614.2002; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Shi YH, 2004, NATURE, V427, P78, DOI 10.1038/nature02211; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; Unger JW, 1998, MICROSC RES TECHNIQ, V43, P24, DOI 10.1002/(SICI)1097-0029(19981001)43:1<24::AID-JEMT4>3.0.CO;2-P; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004	34	81	87	1	5	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	NOV	2004	29	11					2069	2073		10.1007/s11064-004-6880-2			5	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	876ZS	WOS:000225538200014	15662841				2022-02-06	
J	Holloway, AC; Keene, JL; Noakes, DG; Moccia, RD				Holloway, AC; Keene, JL; Noakes, DG; Moccia, RD			Effects of clove oil and MS-222 on blood hormone profiles in rainbow trout Oncorhynchus mykiss, Walbaum	AQUACULTURE RESEARCH			English	Article						clove oil; eugenol; MS-222; anaesthesia; blood plasma; hormones; trout	CATFISH ICTALURUS-PUNCTATUS; TRICAINE METHANESULFONATE; ANESTHESIA; EUGENOL; FISH; RESPONSES; EFFICACY; RECOVERY; SALMON; STRESS	Clove oil has been demonstrated to be an effective, inexpensive anaesthetic and euthanizing agent for a number of fish species, including rainbow trout, used in aquaculture and fisheries research. However, the potential for clove oil to cause perturbations in important plasma hormone concentrations has not been investigated. The effect of anaesthesia and euthanasia in trout with eugenol (the active ingredient in clove oil) on plasma cortisol, glucose, growth hormone (GH) and two thyroid hormones [tri-iodothyronine (T-3) and thyroxine (T-4)] was compared with tricaine methanesulfonate (MS-222) anaesthesia, and stunning by cranial concussion in two experiments. Effects on blood chemistry were different when comparing the particular anaesthetic method being used. Stunning fish significantly increased plasma cortisol and glucose levels (both P<0.05), while euthanizing fish using either clove oil or MS-222 had no effect on these hormone levels. In contrast, the levels of GH, T-3 and T-4 hormones were unaffected regardless of whether fish were euthanized by stunning, MS-222 or clove oil. Variation in effects between hormones were observed using clove oil eugenol. In fish sampled 10 min after anaesthetizing with 150 mg L-1 of eugenol, cortisol levels were significantly decreased (P<0.03), while there were no differences in either glucose or GH levels. Tri-iodothyronine and T-4 also showed significantly elevated levels (P<0.05) after 10-min exposure to eugenol. These results highlight the importance of investigating the potential effects of any new anaesthetic or euthanizing compounds on blood plasma parameters, prior to using them in a research setting, or when comparing results to other studies which have utilized alternative anaesthetic compounds.	Univ Guelph, Aquaculture Ctr, Dept Anim & Poultry Sci, Guelph, ON N1G 2W1, Canada; Univ Guelph, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada; Univ Guelph, Axelrod Inst Ichthyol, Dept Zool, Guelph, ON N1G 2W1, Canada		Moccia, RD (corresponding author), Univ Guelph, Aquaculture Ctr, Dept Anim & Poultry Sci, Guelph, ON N1G 2W1, Canada.	Rmoccia@uoguelph.ca					Bernstein PS, 1997, AM J OPHTHALMOL, V124, P843, DOI 10.1016/S0002-9394(14)71705-2; Chanseau M, 2002, B FR PECHE PISCIC, P579, DOI 10.1051/kmae:2002054; Curtis E K, 1990, Bull Hist Dent, V38, P9; Davidson GW, 2000, J WORLD AQUACULT SOC, V31, P105, DOI 10.1111/j.1749-7345.2000.tb00704.x; *DEP HLTH SOC SEC, 1993, BRIT PHARM; ENDO T, 1972, B JPN SOC SCI FISH, V38, P761; FARBRIDGE KJ, 1991, GEN COMP ENDOCR, V83, P7, DOI 10.1016/0016-6480(91)90100-K; FISCHER IU, 1990, XENOBIOTICA, V20, P209, DOI 10.3109/00498259009047156; Food and Drug Administration (FDA), 2002, GUID IND STAT CLOV O; GINGERICH WH, 1989, GEN COMP ENDOCR, V73, P390, DOI 10.1016/0016-6480(89)90196-2; HARRINGTON AJ, 1991, LIPIDS, V26, P774, DOI 10.1007/BF02535630; HIKASA Y, 1986, JPN J VET SCI, V48, P341; Houston AH, 1997, T AM FISH SOC, V126, P879, DOI 10.1577/1548-8659(1997)126&lt;0879:RATCHV&gt;2.3.CO;2; JOLLY DW, 1972, VET REC, V91, P424, DOI 10.1136/vr.91.18.424; Keene JL, 1998, AQUAC RES, V29, P89, DOI 10.1111/j.1365-2109.1998.tb01113.x; LIU EH, 1977, ANAL BIOCHEM, V79, P597, DOI 10.1016/0003-2697(77)90439-0; MARKING LL, 1985, FISHERIES, V10, P2, DOI 10.1577/1548-8446(1985)010<0002:ABANIF>2.0.CO;2; MAURA A, 1989, MUTAT RES, V227, P125, DOI 10.1016/0165-7992(89)90008-0; McFARLAND WILLIAM N., 1959, PUBL INST MARINE SCI, V6, P23; MILLER EC, 1983, CANCER RES, V43, P1124; PRINCE A, 2000, N AM J FISH MANAGE, V20, P1019; Small BC, 2003, AQUACULTURE, V218, P177, DOI 10.1016/S0044-8486(02)00302-2; Soto CG, 1995, AQUACULTURE, V136, P149, DOI 10.1016/0044-8486(95)01051-3; Summerfelt R.C., 1990, P213; Taylor PW, 1999, N AM J AQUACULT, V61, P150, DOI 10.1577/1548-8454(1999)061<0150:COAAAF>2.0.CO;2; Wagner E, 2002, AQUACULTURE, V211, P353, DOI 10.1016/S0044-8486(01)00878-X; Wagner GN, 2003, AQUAC RES, V34, P1139, DOI 10.1046/j.1365-2109.2003.00916.x; Waterstrat PR, 1999, J WORLD AQUACULT SOC, V30, P250, DOI 10.1111/j.1749-7345.1999.tb00872.x; Woody CA, 2002, J FISH BIOL, V60, P340, DOI 10.1006/jfbi.2001.1842	29	81	87	0	33	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1355-557X	1365-2109		AQUAC RES	Aquac. Res.	SEP 10	2004	35	11					1025	1030		10.1111/j.1365-2109.2004.01108.x			6	Fisheries	Science Citation Index Expanded (SCI-EXPANDED)	Fisheries	845ZF	WOS:000223283500002					2022-02-06	
J	Kashluba, S; Paniak, C; Reynolds, S; Toller-Lobe, G; Nagy, J				Kashluba, S; Paniak, C; Reynolds, S; Toller-Lobe, G; Nagy, J			A longitudinal, controlled study of patient complaints following treated mild traumatic brain injury	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						mild traumatic brain injury; longitudinal	POST-CONCUSSION SYMPTOMS; MINOR HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; RANDOMIZED-TRIAL; LONG; PEOPLE	This study provided 3-month follow-up data to a previous paper that compared symptom complaints of patients with mild traumatic brain injury (MTBI) with those of non-injured control participants within 1 month of injury. The 110 MTBI patients and 118 control participants were group-matched on age, gender, education level, and socioeconomic status. As a group, MTBI patients no longer endorsed significantly more symptoms (M = 14.09, S.D. = 10.77) than did the control group (M = 12.56, S.D. = 8.46, P = .232). Only 3 of the 43 queried symptoms were endorsed by significantly more (Bonferroni-corrected P < .00116) MTBI patients than controls. Using the same Bonferroni-corrected criteria, 10 of the 43 symptoms were endorsed at a significantly higher severity level by MTBI patients. Overall, the treated MTBI group's symptom complaints diminished from baseline to 3 months post-injury, with relatively few differences remaining between the two groups. (C) 2003 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Glenrose Rehabil Hosp, Edmonton, AB T5G 0B7, Canada; Univ Alberta, Edmonton, AB, Canada		Paniak, C (corresponding author), Glenrose Rehabil Hosp, 10230-111 Ave, Edmonton, AB T5G 0B7, Canada.	cpaniak@cha.ab.ca					Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BLISHEN BR, 1987, CAN REV SOC ANTHROP, V24, P465; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; KRAUS JF, 1989, MILD HEAD INJURY, P8; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Paniak C, 2000, BRAIN INJURY, V14, P219; PANIAK C, 1992, DISS ABSTR INT, V52, P6093; PANIAK CE, 1992, ARCH CLIN NEUROPSYCH, V7, P529, DOI 10.1016/0887-6177(92)90143-B; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Reynolds S, 2003, J HEAD TRAUMA REHAB, V18, P139, DOI 10.1097/00001199-200303000-00005; Santa Maria MP, 2001, ARCH CLIN NEUROPSYCH, V16, P133; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631	34	81	81	0	7	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	SEP	2004	19	6					805	816		10.1016/j.acn.2003.09.005			12	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	847SF	WOS:000223414500008	15288333	Bronze			2022-02-06	
J	Scheuer, ML; Wilson, SB				Scheuer, ML; Wilson, SB			Data analysis for continuous EEG monitoring in the ICU: Seeing the forest and the trees	JOURNAL OF CLINICAL NEUROPHYSIOLOGY			English	Article						electroencephalography; continuous; quantitative; ICU; seizure; detection	INTENSIVE-CARE-UNIT; NONCONVULSIVE STATUS EPILEPTICUS; CEREBRAL FUNCTION MONITOR; TRAUMATIC BRAIN-INJURY; SEIZURE DETECTION; BISPECTRAL ANALYSIS; CRITICALLY-ILL; NEURAL-NETWORK; ANESTHESIA; DEVICE	Continuous EEG monitoring (CEEG) is a powerful tool for evaluating cerebral function in obtunded and comatose critically ill patients. The ongoing analysis of CEEG data is a major task because of the volume of data generated during monitoring and the need for near real-time interpretation of a patient's EEG patterns. Advances in digital EEG data acquisition, computer processing, data transmission, and data display have made CEEG monitoring in the intensive care unit technically feasible. A variety of quantitative EEG tools such as Fourier analysis and amplitude-integrated EEG, and other methods of data analysis Such as computerized seizure detection, increasingly allow for focused review of EEG epochs of potential interest. These tools reduce the tremendous time burdens that accompany analysis of the complete CEEG data stream, and allow bedside personnel and nonexpert staff to potentially recognize significant EEG changes in a timely fashion. This article uses literature review and clinical case examples to illustrate techniques for the display and analysis of intensive care unit CEEG recordings. Areas requiring further research and development are discussed.	Persyst Dev Corp, Prescott, AZ USA; Univ Pittsburgh, Epilepsy Ctr, Pittsburgh, PA USA		Scheuer, ML (corresponding author), Dept Neurol, Suite 811,Kaufmann Med Bldg,3471 5th Ave, Pittsburgh, PA 15213 USA.	scheuer@pitt.edu					Bruhn J, 2000, J Clin Monit Comput, V16, P593, DOI 10.1023/A:1012216600170; Bullock TH, 1997, ELECTROEN CLIN NEURO, V103, P661, DOI 10.1016/S0013-4694(97)00087-4; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; CLAASSEN J, IN PRESS CLIN NEUROP; DeLorenzo RJ, 1998, EPILEPSIA, V39, P833, DOI 10.1111/j.1528-1157.1998.tb01177.x; Epstein CM, 2003, CLIN NEUROPHYSIOL, V114, P1974, DOI 10.1016/S1388-2457(03)00168-8; Gabor AJ, 1998, ELECTROEN CLIN NEURO, V107, P27, DOI 10.1016/S0013-4694(98)00043-1; Hagihira S, 2001, ANESTH ANALG, V93, P966, DOI 10.1097/00000539-200110000-00032; Hirsch LJ, 2004, EPILEPSIA, V45, P109, DOI 10.1111/j.0013-9580.2004.38103.x; Jeleazcov C, 2003, BIOMED TECH, V48, P269, DOI 10.1515/bmte.2003.48.10.269; Jordan KG, 1999, J CLIN NEUROPHYSIOL, V16, P14, DOI 10.1097/00004691-199901000-00002; Jordan KG, 1999, J CLIN NEUROPHYSIOL, V16, P332, DOI 10.1097/00004691-199907000-00005; Leistritz L, 1999, J CLIN MONIT COMPUT, V15, P357, DOI 10.1023/A:1009990629797; MAYNARD D, 1969, ELECTROEN CLIN NEURO, V27, P672; MAYNARD D, 1969, BRIT MED J, V4, P545, DOI 10.1136/bmj.4.5682.545-a; MAYNARD DE, 1984, ANAESTHESIA, V39, P678, DOI 10.1111/j.1365-2044.1984.tb06477.x; Miller A, 2004, BRIT J ANAESTH, V92, P8, DOI 10.1093/bja/aeh003; Nikias C. L., 1993, HIGHER ORDER SPECTRA, V1st; NING T, 1993, IEEE T BIO-MED ENG, V40, P870, DOI 10.1109/10.245607; Ortolani O, 2002, BRIT J ANAESTH, V88, P644, DOI 10.1093/bja/88.5.644; PAURI F, 1992, ELECTROEN CLIN NEURO, V82, P1, DOI 10.1016/0013-4694(92)90175-H; Procaccio F, 2001, Curr Opin Crit Care, V7, P74, DOI 10.1097/00075198-200104000-00004; Rampil IJ, 1998, ANESTHESIOLOGY, V89, P980, DOI 10.1097/00000542-199810000-00023; Rennie JM, 2004, ARCH DIS CHILD-FETAL, V89, pF37, DOI 10.1136/fn.89.1.F37; Salinsky MC, 1997, ELECTROEN CLIN NEURO, V103, P445, DOI 10.1016/S0013-4694(97)00025-4; Sarkela Mika, 2002, J Clin Monit Comput, V17, P125, DOI 10.1023/A:1016393904439; Scheuer ML, 2002, EPILEPSIA, V43, P114, DOI 10.1046/j.1528-1157.43.s.3.7.x; SEBEL PS, 1983, BRIT J ANAESTH, V55, P1265, DOI 10.1093/bja/55.12.1265; Sleigh JW, 2001, BRIT J ANAESTH, V86, P50, DOI 10.1093/bja/86.1.50; Takeichi T, 2002, CLIN TRANSPLANT, V16, P273, DOI 10.1034/j.1399-0012.2002.01138.x; ter Horst H, 2004, PEDIATR RES, V55, P1026, DOI 10.1203/01.pdr.0000127019.52562.8c; Toet MC, 2002, PEDIATRICS, V109, P772, DOI 10.1542/peds.109.5.772; Tufte E., 2001, VISUAL DISPLAY QUANT; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 1997, ELECTROEN CLIN NEURO, V103, P607, DOI 10.1016/S0013-4694(97)00071-0; Vespa PM, 2002, J NEUROSURG, V97, P84, DOI 10.3171/jns.2002.97.1.0084; Vespa PM, 1999, J CLIN NEUROPHYSIOL, V16, P1, DOI 10.1097/00004691-199901000-00001; Wilson SB, 2004, CLIN NEUROPHYSIOL, V115, P2280, DOI 10.1016/j.clinph.2004.05.018; Wilson SB, 2003, CLIN NEUROPHYSIOL, V114, P2156, DOI 10.1016/S1388-2457(03)00212-8	39	81	82	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0736-0258			J CLIN NEUROPHYSIOL	J. Clin. Neurophysiol.	SEP-OCT	2004	21	5					353	378					26	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	878TO	WOS:000225670000006	15592009				2022-02-06	
J	Rovlias, A; Kotsou, S				Rovlias, A; Kotsou, S			Classification and regression tree for prediction of outcome after severe head injury using simple clinical and laboratory variables	JOURNAL OF NEUROTRAUMA			English	Article						head injury; prediction tree; prognosis	TRAUMATIC SUBARACHNOID HEMORRHAGE; SECONDARY BRAIN INJURY; COMPUTERIZED-TOMOGRAPHY; BLOOD-FLOW; HYPERGLYCEMIA; DAMAGE; LEUKOCYTES; PROGNOSIS; ADMISSION; SYSTEM	Many previous studies have constructed several predictive models for outcome after severe head injury, but these have often used expensive, time consuming, or highly specialized measurements. The goal of this study was to develop a simple, easy to use a model involving only variables that are rapidly and easily achievable in daily routine practice. To this end, a classification and regression tree (CART) technique was employed in the analysis of data from 345 patients with isolated severe brain injury who were admitted to Asclepeion General Hospital of Athens from January, 1993, to December, 2000. A total of 16 prognostic indicators were examined to predict neurological outcome at 6 months after head injury. Our results indicated that Glasgow Coma Scale was the best predictor of outcome. With regard to the other data, not only the most widely examined variables such as age, pupillary reactivity, or computed tomographic findings proved again to be strong predictors, but less commonly applied parameters, indirectly associated with brain damage, such as hyperglycemia and leukocytosis, were found to correlate significantly with prognosis too. The overall cross-validated predictive accuracy of CART model for these data was 86.84%, with a cross-validated relative error of 0.308. All variables included in this tree have been shown previously to be related to outcome. Methodologically, however, CART is quite different from the more commonly used statistical methods, with the primary benefit of illustrating the important prognostic variables as related to outcome. This technique may prove useful in developing new therapeutic strategies and approaches for patients with severe brain injury.	Asclepeion Gen Hosp, Dept Neurosurg, Athens, Greece		Rovlias, A (corresponding author), 55 Erasinidou St, Athens 17237, Greece.	ealex@tee.gr					AUER LM, 1980, ACTA NEUROCHIR, V52, P225, DOI 10.1007/BF01402078; Bednar MM, 1997, NEUROL RES, V19, P588; Breiman L., 1984, CLASSIFICATION REGRE; Chesnut R M, 1995, New Horiz, V3, P366; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; COCHRANE CG, 1966, J EXP MED, V124, P733, DOI 10.1084/jem.124.4.733; DESALLES AAF, 1987, NEUROSURGERY, V21, P45, DOI 10.1227/00006123-198707000-00009; Dings J, 1996, ACTA NEUROCHIR, V138, P425, DOI 10.1007/BF01420305; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FANTONE JC, 1982, AM J PATHOL, V107, P397; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; HALLENBECK JM, 1986, STROKE, V17, P246, DOI 10.1161/01.STR.17.2.246; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; JENNETT B, 1975, LANCET, V1, P480; Kakarieka A, 1997, NEUROL RES, V19, P230, DOI 10.1080/01616412.1997.11740804; KESKIL S, 1994, ACTA NEUROCHIR, V131, P211, DOI 10.1007/BF01808615; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; LOKKEBERG AR, 1984, J NEUROSURG, V61, P254, DOI 10.3171/jns.1984.61.2.0254; MARGULIES DR, 1994, AM SURGEON, V60, P387; MARMAROU A, 1991, J NEUROSURG S, V75, P59; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MISSORI P, 1997, CLIN NEUROLOGY NEU S, V99, pS79; MOULTON RJ, 1994, CLIN INVEST MED, V17, P187; NORDBY HK, 1985, ACTA NEUROCHIR, V76, P131, DOI 10.1007/BF01418475; PFENNINGER EG, 1991, ACTA ANAESTH SCAND, V35, P148, DOI 10.1111/j.1399-6576.1991.tb03263.x; Raabe A, 2000, NEUROSURG REV, V23, P136, DOI 10.1007/PL00011944; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Rovlias A, 2001, SURG NEUROL, V55, P190, DOI 10.1016/S0090-3019(01)00414-1; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; SIEGEL JH, 1995, J NEUROTRAUM, V12, P579, DOI 10.1089/neu.1995.12.579; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Steinberg D., 1995, CART TREE STRUCTURED; STEINBERG D, 1997, CART CLASSIFICATION; Takanashi Y, 2001, No To Shinkei, V53, P61; TEMKIN NR, 1995, J NEUROSURG, V82, P764, DOI 10.3171/jns.1995.82.5.0764; VOLMER DG, 1991, J NEUROSURG S, V75, pS37; Yang SY, 1995, SURG NEUROL, V44, P373, DOI 10.1016/0090-3019(96)80243-6; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014	45	81	83	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2004	21	7					886	893		10.1089/0897715041526249			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	842AE	WOS:000222973800006	15307901				2022-02-06	
J	Brennan, DM; Georgeadis, AC; Baron, CR; Barker, LM				Brennan, DM; Georgeadis, AC; Baron, CR; Barker, LM			The effect of videoconference-based telerehabilitation on story retelling performance by brain-injured subjects and its implications for remote speech-language therapy	TELEMEDICINE JOURNAL AND E-HEALTH			English	Article							APHASIA; DISORDERS; ADULTS	This paper presents results from a study conducted at the Rehabilitation Engineering Research Center (RERC) on Telerehabilitation at the National Rehabilitation Hospital. The study was designed to measure performance by brain-injured subjects, with medical diagnoses of stroke or traumatic brain injury, on a standardized Speech-Language Pathology evaluation conducted in both face-to-face and videoconference-based telerehabilitation settings. The Story Retelling Procedure (SRP), which measures connected language production and comprehension of spoken narratives, was administered to each subject in both settings. The primary objectives of this study were to: (1) compare communication as measured by the SRP between experimental settings, and (2) determine if subject variables (such as age, education, technology experience or gender) had an effect on performance differences between settings. The rationale was that any difference in this aspect of performance must be identified and characterized before this mode of intervention can be used clinically. Across all subjects (n=40), no significant difference (p>0.05) was found between SRP performance measured in the two settings. Additionally, variables including age, education, technology experience, and gender did not significantly affect the difference between performance in the two settings. Overall, subjects reported a high level of acceptance of videoconferencing with 34 subjects responding "yes," 4 responding "no," and 2 responding "maybe" when asked if they would use videoconferencing again to talk to a clinician. Results of this study confirm the potential for SLP treatment using videoconferencing and indicate a need for continued research in the field.	Natl Rehabil Hosp, Rehabil Engn Res Ctr Telerehabil, Washington, DC 20010 USA; Natl Rehabil Hosp, Speech Language Pathol Serv, Washington, DC 20010 USA		Brennan, DM (corresponding author), Natl Rehabil Hosp, Rehabil Engn Res Ctr Telerehabil, 102 Irving St NW, Washington, DC 20010 USA.	david.m.brennan@medstar.net					Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brookshire R. H., 1993, DISCOURSE COMPREHENS; Czaja SJ, 1998, J GERONTOL B-PSYCHOL, V53, pP329, DOI 10.1093/geronb/53B.5.P329; Doyle PJ, 1998, APHASIOLOGY, V12, P561, DOI 10.1080/02687039808249558; Doyle PJ, 2000, APHASIOLOGY, V14, P537, DOI 10.1080/026870300401306; Duffy JR, 1997, MAYO CLIN PROC, V72, P1116, DOI 10.4065/72.12.1116; DYCK JL, 1994, J EDUC COMPUT RES, V10, P239, DOI 10.2190/E79U-VCRC-EL4E-HRYV; Kully D, 2000, J TELEMED TELECARE, V6, P39, DOI 10.1258/1357633001935509; MARQUIE JC, 1994, APPL ERGON, V25, P130, DOI 10.1016/0003-6870(94)90011-6; MATEER CM, 1987, J HEAD TRAUMA REHAB, V2, P79; McCullough A, 2001, INT J LANG COMM DIS, V36, P321, DOI 10.3109/13682820109177905; McNeil MR, 2002, APHASIOLOGY, V16, P815, DOI 10.1080/02687030244000284; McNeil MR, 2001, APHASIOLOGY, V15, P991, DOI 10.1080/02687040143000348; NICHOLAS LE, 1995, J SPEECH HEAR RES, V38, P146, DOI 10.1044/jshr.3801.145; NICHOLAS LE, 1993, J SPEECH HEAR RES, V36, P338, DOI 10.1044/jshr.3602.338; SCHOENLE P, 2001, P 4 WORLD C BRAIN IN, P55; Schopp L, 2000, TELEMED TODAY, V8, P33; Vaughn G R, 1976, ASHA, V18, P13; Wertz R. T., 1987, CLIN APHASIOLOGY, V17, P117; WERTZ RT, 1992, APHASIOLOGY, V6, P195, DOI 10.1080/02687039208248591	20	81	83	0	24	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1530-5627	1556-3669		TELEMED J E-HEALTH	Telemed. J. e-Health	SUM	2004	10	2					147	154		10.1089/1530562041641237			8	Health Care Sciences & Services	Science Citation Index Expanded (SCI-EXPANDED)	Health Care Sciences & Services	845MM	WOS:000223248400006	15319044				2022-02-06	
J	Falsig, J; Latta, M; Leist, M				Falsig, J; Latta, M; Leist, M			Defined inflammatory states in astrocyte cultures: correlation with susceptibility towards CD95-driven apoptosis	JOURNAL OF NEUROCHEMISTRY			English	Article						apoptosis; astrocyte; CD95; inflammation; nitric oxide; p38	NITRIC-OXIDE SYNTHASE; ACTIVATED PROTEIN-KINASE; HUMAN FETAL ASTROCYTES; CENTRAL-NERVOUS-SYSTEM; TRANSIENT GLOBAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; PROGRAMMED CELL-DEATH; NECROSIS-FACTOR-ALPHA; HUMAN GLIOMA-CELLS; FAS LIGAND CD95L	A complete cytokine mix (CCM) or its individual components tumour necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interferon-gamma (IFN-gamma) were used to switch resting murine astrocytes to reactive states. The transformation process was characterized by differential up-regulation of interleukin-6 (IL-6), cyclooxygenase-2 (COX-2) and inducible nitric oxide synthetase (iNOS) mRNA and protein and a subsequent release of prostaglandin E2, nitric oxide (NO) and IL-6. Both CD95L and anti-CD95 antibodies triggered caspase activation followed by apoptotic death in fully pro-inflammatory astrocytes, whereas resting cells were totally resistant. Two other death-inducing ligands, TNF and TNF-related apoptosis-inducing ligand (TRAIL) did not induce apoptosis in reactive astrocytes. The switch in astrocyte sensitivity was accompanied by up-regulation of caspase-8 and CD95 as well as the capacity to recruit Fas-associated death domain (FADD) to the activated death receptor complex. Neither CD95-mediated death, nor other inflammatory parameters were affected by inhibition of iNOS or COX, respectively. Accordingly, IFN-gamma was absolutely essential for up-regulation of iNOS, but not for the switch in apoptosis sensitivity. In contrast, p38 kinase activity was identified as an important controller of both the inflammatory reaction and apoptosis both in astrocytes stimulated with CCM and in glia exposed to TNF and IL-1 only.	H Lundbeck & Co AS, Mol Dis Biol, DK-2500 Valby, Denmark; Univ Konstanz, D-7750 Constance, Germany		Falsig, J (corresponding author), H Lundbeck & Co AS, Mol Dis Biol, Ottiliavej 9, DK-2500 Valby, Denmark.		Leist, Marcel/D-2133-2010	Leist, Marcel/0000-0002-3778-8693			Barone FC, 2001, MED RES REV, V21, P129, DOI 10.1002/1098-1128(200103)21:2<129::AID-MED1003>3.0.CO;2-H; Becher B, 1998, NEUROSCIENCE, V84, P627, DOI 10.1016/S0306-4522(97)00455-7; Bechmann I, 2000, GLIA, V32, P25, DOI 10.1002/1098-1136(200010)32:1<25::AID-GLIA30>3.0.CO;2-Y; Bechmann I, 1999, GLIA, V27, P62, DOI 10.1002/(SICI)1098-1136(199907)27:1<62::AID-GLIA7>3.0.CO;2-S; Bechmann I, 2002, J NEUROIMMUNOL, V132, P60, DOI 10.1016/S0165-5728(02)00311-9; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bonetti B, 1997, ANN NEUROL, V42, P74, DOI 10.1002/ana.410420113; Bordin S, 2003, J IMMUNOL, V170, P667, DOI 10.4049/jimmunol.170.2.667; Bowman CC, 2003, GLIA, V43, P281, DOI 10.1002/glia.10256; Cheema ZF, 1999, J NEUROSCI, V19, P1754; Chen JJ, 1998, SCIENCE, V282, P1714, DOI 10.1126/science.282.5394.1714; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Choi C, 1999, J IMMUNOL, V162, P1889; Choi C, 2002, J NEURO-ONCOL, V56, P13, DOI 10.1023/A:1014467626314; Choi C, 2001, CANCER RES, V61, P3084; CHUNG IY, 1990, J IMMUNOL, V144, P2999; Ciccarelli R, 2001, INT J DEV NEUROSCI, V19, P395, DOI 10.1016/S0736-5748(00)00084-8; DaSilva J, 1997, J BIOL CHEM, V272, P28373, DOI 10.1074/jbc.272.45.28373; Davidson WF, 2002, J IMMUNOL, V169, P6218, DOI 10.4049/jimmunol.169.11.6218; delaMonte SM, 1997, J NEUROL SCI, V152, P73, DOI 10.1016/S0022-510X(97)00131-7; Desbarats J, 2003, NAT CELL BIOL, V5, P118, DOI 10.1038/ncb916; Dong YS, 2001, GLIA, V36, P180, DOI 10.1002/glia.1107; Dorf ME, 2000, J NEUROIMMUNOL, V111, P109, DOI 10.1016/S0165-5728(00)00371-4; DSouza SD, 1996, J EXP MED, V184, P2361, DOI 10.1084/jem.184.6.2361; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; ENDOH M, 1994, BRAIN RES, V651, P92, DOI 10.1016/0006-8993(94)90683-1; Ferrer I, 2001, ACTA NEUROPATHOL, V102, P121; Franz G, 2002, J CEREBR BLOOD F MET, V22, P951, DOI 10.1097/00004647-200208000-00006; French LE, 1996, J CELL BIOL, V133, P335, DOI 10.1083/jcb.133.2.335; Harrrison M, 1998, FEBS LETT, V435, P207, DOI 10.1016/S0014-5793(98)01051-5; Hensley K, 1999, J NEUROCHEM, V72, P2053, DOI 10.1046/j.1471-4159.1999.0722053.x; Hentze H, 2001, BIOCHEM BIOPH RES CO, V283, P1111, DOI 10.1006/bbrc.2001.4918; Hirst WD, 1999, MOL CELL NEUROSCI, V13, P57, DOI 10.1006/mcne.1998.0731; Hou ST, 2002, J BIOL CHEM, V277, P48764, DOI 10.1074/jbc.M206336200; Hua LWL, 2002, J NEUROIMMUNOL, V126, P180, DOI 10.1016/S0165-5728(02)00055-3; Kohji T, 2000, J NEUROIMMUNOL, V106, P165, DOI 10.1016/S0165-5728(00)00238-1; Lee SJ, 2000, J IMMUNOL, V164, P1277, DOI 10.4049/jimmunol.164.3.1277; Lehnardt S, 2002, J NEUROSCI, V22, P2478, DOI 10.1523/JNEUROSCI.22-07-02478.2002; LEITHAUSER F, 1993, LAB INVEST, V69, P415; Li GL, 2000, ACTA NEUROPATHOL, V100, P75, DOI 10.1007/s004010051195; Loihl AK, 1999, BRAIN RES, V830, P155, DOI 10.1016/S0006-8993(99)01388-8; MAEDA Y, 1994, J EXP MED, V180, P2297, DOI 10.1084/jem.180.6.2297; Malipiero U, 1997, EUR J IMMUNOL, V27, P3151, DOI 10.1002/eji.1830271211; Martin-Villalba A, 2001, CELL DEATH DIFFER, V8, P679, DOI 10.1038/sj.cdd.4400882; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Maslinska D, 1999, FOLIA NEUROPATHOL, V37, P75; MATSUYAMA T, 1994, BRAIN RES, V657, P342, DOI 10.1016/0006-8993(94)90989-X; Mezosi E, 2002, J CLIN ENDOCR METAB, V87, P4264, DOI 10.1210/jc.2002-020111; Minagar A, 2002, J NEUROL SCI, V202, P13, DOI 10.1016/S0022-510X(02)00207-1; Molina-Holgado E, 2000, BRIT J PHARMACOL, V131, P152, DOI 10.1038/sj.bjp.0703557; MOLINAHOLGADO F, 1995, GLIA, V15, P167, DOI 10.1002/glia.440150209; Moreau G, 2001, BLOOD, V97, P3069, DOI 10.1182/blood.V97.10.3069; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OrtizArduan A, 1996, AM J PHYSIOL-RENAL, V271, pF1193; Piao CS, 2002, MOL BRAIN RES, V107, P137, DOI 10.1016/S0169-328X(02)00456-4; Quirk SM, 2000, BIOL REPROD, V63, P49, DOI 10.1095/biolreprod63.1.49; Raoul C, 2002, NEURON, V35, P1067, DOI 10.1016/S0896-6273(02)00905-4; Raoul C, 1999, J CELL BIOL, V147, P1049, DOI 10.1083/jcb.147.5.1049; RENSINGEHL A, 1995, EUR J IMMUNOL, V25, P2253, DOI 10.1002/eji.1830250821; Riccioli A, 2000, J IMMUNOL, V165, P743, DOI 10.4049/jimmunol.165.2.743; Saas P, 1999, J IMMUNOL, V162, P2326; Saas P, 2002, NEUROREPORT, V13, P1921, DOI 10.1097/00001756-200210280-00018; Scaffidi C, 1999, METHODS, V17, P287, DOI 10.1006/meth.1999.0742; Shin DH, 2002, J NEUROIMMUNOL, V123, P50, DOI 10.1016/S0165-5728(01)00478-7; SIMMONS ML, 1992, J NEUROCHEM, V59, P897, DOI 10.1111/j.1471-4159.1992.tb08328.x; Sola C, 2002, EUR J NEUROSCI, V16, P1275, DOI 10.1046/j.1460-9568.2002.02199.x; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Terrazzino S, 2002, J NEUROIMMUNOL, V124, P45, DOI 10.1016/S0165-5728(02)00013-9; Van Landeghem FKH, 2002, PEDIATR RES, V51, P129, DOI 10.1203/00006450-200202000-00003; Weinstein DE, 1997, CURRENT PROTOCOLS NE; Wosik K, 2001, GLIA, V33, P217, DOI 10.1002/1098-1136(200103)33:3<217::AID-GLIA1020>3.0.CO;2-W	71	81	82	0	1	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0022-3042			J NEUROCHEM	J. Neurochem.	JAN	2004	88	1					181	193		10.1046/j.1471-4159.2003.02144.x			13	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	753YJ	WOS:000187275700019	14675162				2022-02-06	
J	Glaesser, J; Neuner, F; Lutgehetmann, R; Schmidt, R; Elbert, T				Glaesser, Judith; Neuner, Frank; Luetgehetmann, Ralph; Schmidt, Roger; Elbert, Thomas			Posttraumatic Stress Disorder in patients with traumatic brain injury	BMC PSYCHIATRY			English	Article								Background: Severe traumatic stressors such as war, rape, or life-threatening accidents can result in a debilitating psychopathological development conceptualised as Posttraumatic Stress Disorder (PTSD). Pathological memory formation during an alarm response may set the precondition for PTSD to occur. If true, a lack of memory formation by extended unconsciousness in the course of the traumatic experience should preclude PTSD. Methods: 46 patients from a neurological rehabilitation clinic were examined by means of questionnaires and structured clinical interviews. All patients had suffered a TBI due to an accident, but varied with respect to falling unconscious during the traumatic event. Results: 27% of the sub-sample who were not unconscious for an extended period but only 3% (1 of 31 patients) who were unconscious for more than 12 hours as a result of the accident were diagnosed as having current PTSD (P < .02). Furthermore, intrusive memories proved to be far more frequent in patients who had not been unconscious. This was also the case for other reexperiencing symptoms and for psychological distress and physiological reactivity to reminders of the traumatic event. Conclusion: TBI and PTSD are not mutually exclusive. However, victims of accidents are unlikely to develop a PTSD if the impact to the head had resulted in an extended period of unconsciousness.	[Glaesser, Judith; Neuner, Frank; Elbert, Thomas] Univ Konstanz, Dept Psychol, D-78457 Constance, Germany; [Neuner, Frank; Elbert, Thomas] Vivo, Cupramontana, Italy; [Luetgehetmann, Ralph; Schmidt, Roger] Kliniken Schmieder, D-78464 Constance, Germany		Glaesser, J (corresponding author), Univ Konstanz, Dept Psychol, D-78457 Constance, Germany.	Judith.Glaesser@uni-konstanz.de; Frank.Neuner@uni-konstanz.de; r.luetgehetmann@t-online.de; r.Schmidt@kliniken-schmieder.de; Thomas.Elbert@vivo.org	Elbert, Thomas/C-8556-2009	Elbert, Thomas/0000-0003-1332-4939; Glaesser, Judith/0000-0002-6173-3596	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG); Lurija-Institute	Supported by the Deutsche Forschungsgemeinschaft and the Lurija-Institute. We thank Christina J. Robert for editorial assistance and helpful comments on the ms.	American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; BONTKE CF, 1996, J HEAD TRAUMA REHAB, V11, P95, DOI DOI 10.1097/00001199-199602000-00011; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; Elbert T, 2002, NATURE, V419, P883, DOI 10.1038/419883a; Foa E. B., 1995, POSTTRAUMATIC STRESS; Freeman HL, 1999, BRIT J PSYCHIAT, V174, P79, DOI 10.1192/bjp.174.1.79b; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; Gunkel S, 1999, TRAUMA KONFLIKT ZUGA, P48; Harting C., 2000, WECHSLER GEDACHTNIST; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; Joseph S, 1999, J TRAUMA STRESS, V12, P437, DOI 10.1023/A:1024762919372; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; LAYTON BS, 1995, CLIN NEUROPSYCHOL, V9, P2, DOI 10.1080/13854049508402050; Maes M, 2000, EUR ARCH PSY CLIN N, V250, P156, DOI 10.1007/s004060070034; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; Neuner F, PSYCHOL TRAUMA UNPUB; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; STEIL R, 1997, POSTTRAUMATISCHE INT; Wittchen H.-U., 1997, STRUKTURIERTES KLIN	21	81	84	0	6	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-244X			BMC PSYCHIATRY	BMC Psychiatry		2004	4								5	10.1186/1471-244X-4-5			6	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Psychiatry	V22MU	WOS:000208280100005	15113439				2022-02-06	
J	Lusardi, TA; Wolf, JA; Putt, ME; Smith, DH; Meaney, DF				Lusardi, TA; Wolf, JA; Putt, ME; Smith, DH; Meaney, DF			Effect of acute calcium influx after mechanical stretch injury in vitro on the viability of hippocampal neurons	JOURNAL OF NEUROTRAUMA			English	Article						calcium; cell death; cell mechanics; hippocampus; neuron; traumatic brain injury	INTRACELLULAR FREE CALCIUM; METHYL-D-ASPARTATE; TRAUMATIC INJURY; BRAIN-INJURY; CULTURED ASTROCYTES; CORTICAL-NEURONS; NMDA RECEPTORS; CELL-DEATH; MODEL; HEAD	We use a new in vitro model to examine the effect of mechanical deformation on neurons. We examined acute changes in cytosolic calcium concentrations ([Ca2+](i)) caused by a rapid stretch of cultured hippocampal neurons, using mechanical loading conditions that mimic brain deformations during trauma. We found that stretch-injury of neurons induces a strain-dependent increase in [Ca2+](i). Remarkably, the extent of this calcium response exceeded the levels initiated by chemical toxicity with NMDA (100 muM) or glutamate (5 mM) exposure. Propidium iodide labeling at 24 h following stretch showed neuronal death occurred only at the most severe level of mechanical injury. Although NMDA-induced toxicity could be inhibited in calcium free media or by treatment with MK-801, stretch-induced neuronal death was not similarly reduced with either treatment. Unexpectedly, reduction of the acute stretch-induced calcium transient with calcium-free media or MK-801 resulted in an increase in neuronal death at lower stretch levels. These data suggest that mechanical stretch can initiate calcium influx in hippocampal neurons, but substantially modulating the early calcium flux from the extracellular space or through the NMDA channel does not provide an effective means for improving neuronal survival.	Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA		Meaney, DF (corresponding author), Univ Penn, Dept Bioengn, 3320 Smith Walk,Room 120,Hayden Hall, Philadelphia, PA 19104 USA.	dmeaney@seas.upenn.edu	smith, douglas/A-1321-2007; Wolf, John A/A-1034-2007	Wolf, John A/0000-0002-6950-2303; Meaney, David/0000-0002-0954-4122; Lusardi, Theresa/0000-0003-0699-5662	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K08AG021527] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG21527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35712] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [41699] Funding Source: Medline; ODCDC CDC HHS [R49/CCR 312712] Funding Source: Medline		AbdelHamid KM, 1997, J NEUROSCI, V17, P3538; Ahmed SM, 2002, J NEUROTRAUM, V19, P1619, DOI 10.1089/089771502762300274; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.0741951.x; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; Citron BA, 1997, NEUROSCI LETT, V230, P25, DOI 10.1016/S0304-3940(97)00468-0; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Floyd CL, 2001, GLIA, V33, P12, DOI 10.1002/1098-1136(20010101)33:1<12::AID-GLIA1002>3.0.CO;2-V; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hasbani MJ, 2001, NEUROREPORT, V12, P2731, DOI 10.1097/00001756-200108280-00028; Hyrc K, 1997, J NEUROSCI, V17, P6669; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kiedrowski L, 1999, MOL PHARMACOL, V56, P619, DOI 10.1124/mol.56.3.619; King AI, 2000, ANNU REV BIOMED ENG, V2, P55, DOI 10.1146/annurev.bioeng.2.1.55; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; KUTNER MH, 1996, APPL LINEAR STAT MOD; Lamb RG, 1997, J NEUROCHEM, V68, P1904; LaPlaca MC, 1997, ANN BIOMED ENG, V25, P665, DOI 10.1007/BF02684844; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Leski ML, 1999, BRAIN RES, V828, P27, DOI 10.1016/S0006-8993(99)01270-6; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; McCulloch CE, 2001, GENERALIZED LINEAR M; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Ripley B.D., 1999, MODERN APPL STAT S P; ROTHMAN SM, 1995, TRENDS NEUROSCI, V18, P57; Rzigalinski BA, 1997, J NEUROCHEM, V68, P289; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Sapolsky RM, 2001, J NEUROCHEM, V76, P1601, DOI 10.1046/j.1471-4159.2001.00203.x; Sattler R, 1998, J NEUROCHEM, V71, P2349; Sattler R, 2000, J NEUROSCI, V20, P22, DOI 10.1523/JNEUROSCI.20-01-00022.2000; Shi R, 2000, NEUROSCIENCE, V98, P157, DOI 10.1016/S0306-4522(00)00096-8; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; Smith DH, 1999, J NEUROSCI, V19, P4263; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632, DOI 10.1152/jn.1997.77.2.632; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767, DOI 10.1152/jn.1995.74.6.2767; Vergun O, 2001, J PHYSIOL-LONDON, V531, P147, DOI 10.1111/j.1469-7793.2001.0147j.x; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; White BC, 2000, J NEUROL SCI, V179, P1, DOI 10.1016/S0022-510X(00)00386-5; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yuan Q, 1998, SPINE, V23, P1677, DOI 10.1097/00007632-199808010-00012; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921; ZHOU C, 1994, STAPP CAR CRASH C SO	60	81	82	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2004	21	1					61	72		10.1089/089771504772695959			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	766GU	WOS:000188368700007	14987466				2022-02-06	
J	Haydel, MJ; Shembekar, AD				Haydel, MJ; Shembekar, AD			Prediction of intracranial injury in children aged five years and older with loss of consciousness after minor head injury due to nontrivial mechanisms	ANNALS OF EMERGENCY MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; COMPUTED-TOMOGRAPHY; PEDIATRIC-PATIENTS; NEUROLOGIC EXAMINATION; CLINICAL INDICATORS; EPIDURAL HEMATOMAS; SKULL FRACTURE; CT-SCANS; MILD; MANAGEMENT	Study objective: Indications for computed tomography (CT) in children with minor head injury remain controversial. The objective of this preliminary study is to determine whether a clinical decision rule developed for adults could be used in children aged 5 years and older. Methods: A prospective questionnaire was completed on all patients who were aged 5 to 17 years with major mechanisms of injury resulting in minor head injury (defined as normal Glasgow Coma Scale or modified coma scale in infants, plus normal brief neurologic examination) and loss of consciousness. The questionnaire documented 6 clinical variables: headache, emesis, intoxication, seizure, short-term memory deficits, and physical evidence of trauma above the clavicles. CT was obtained for all patients, findings were compared with the results of the questionnaires, and the sensitivity and specificity of the decision rule were determined. Results: Throughout a 30-month period, 175 patients were enrolled, with a mean age of 12.8 years. Fourteen (8%) patients had intracranial injury or depressed skull fracture on CT. The presence of any of the 6 criteria was significantly associated with an abnormal CT scan result (P<.05) and was 100% (95% confidence interval 73% to 100%) sensitive for identifying patients with intracranial injury. Conclusion: In this preliminary study, CT use in pediatric patients with minor head injury could have been safely reduced by 23% by using a clinical decision rule previously validated in adults.	Louisiana State Univ, Hlth Sci Ctr, Sect Emergency Med, New Orleans, LA USA		Haydel, MJ (corresponding author), Charity Hosp, Emergency Med Off, 13th Floor,1532 Tulane Ave, New Orleans, LA 70112 USA.	micellehaydel@yahoo.com					Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Abu-Judeh HH, 1999, NUCL MED COMMUN, V20, P505, DOI 10.1097/00006231-199906000-00003; Aitken ME, 1998, ARCH PEDIAT ADOL MED, V152, P1176; *AM COLL SURG COMM, 1999, ADV TRAUM LIF SUPP; Bejjani GK, 1996, PEDIATR NEUROSURG, V25, P302, DOI 10.1159/000121144; Bergman DA, 1999, PEDIATRICS, V104, P1407; BONADIO WA, 1989, AM J DIS CHILD, V143, P194, DOI 10.1001/archpedi.1989.02150140084025; Cook L S, 1994, Acad Emerg Med, V1, P227; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; DAVIES RL, 1995, PEDIATRICS, V95, P345; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; DUUS BR, 1993, BRIT J SURG, V80, P988, DOI 10.1002/bjs.1800800817; Greenes DS, 1997, ANN EMERG MED, V30, P253, DOI 10.1016/S0196-0644(97)70158-6; Greenes DS, 2001, PEDIATR EMERG CARE, V17, P88, DOI 10.1097/00006565-200104000-00002; Greenes DS, 1999, PEDIATRICS, V104, P861, DOI 10.1542/peds.104.4.861; Gruskin KD, 1999, ARCH PEDIAT ADOL MED, V153, P15; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Herrera EJ, 2000, CHILD NERV SYST, V16, P585, DOI 10.1007/s003810000340; Homer CJ, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e78; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI [10.1067/mem.2002.125782, 10.1016/j.jen.2008.12.010]; KNUCKEY NW, 1989, J NEUROSURG, V70, P392, DOI 10.3171/jns.1989.70.3.0392; LEE ST, 1992, J NEUROSURG, V76, P435, DOI 10.3171/jns.1992.76.3.0435; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; Lloyd DA, 1997, LANCET, V349, P821, DOI 10.1016/S0140-6736(96)09356-7; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; Murshid WR, 1998, ACTA NEUROCHIR, V140, P56, DOI 10.1007/s007010050058; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; Nee PA, 1999, J NEUROL NEUROSUR PS, V66, P470, DOI 10.1136/jnnp.66.4.470; Pretto Flores L, 2000, J Neurosurg Sci, V44, P77; Quayle KS, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e11; Quayle KS, 1999, PEDIATR CLIN N AM, V46, P1189, DOI 10.1016/S0031-3955(05)70182-6; RAMUNDO ML, 1995, PEDIATR EMERG CARE, V11, P1, DOI 10.1097/00006565-199502000-00001; REINUS WR, 1993, ANN EMERG MED, V22, P1148, DOI 10.1016/S0196-0644(05)80981-3; Riesgo P, 1997, SURG NEUROL, V48, P226, DOI 10.1016/S0090-3019(97)00194-8; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983; Schutzman SA, 2001, ANN EMERG MED, V37, P65, DOI 10.1067/mem.2001.109440; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Shane SA, 1997, PEDIATR EMERG CARE, V13, P198, DOI 10.1097/00006565-199706000-00006; Simon B, 2001, J TRAUMA, V51, P231, DOI 10.1097/00005373-200108000-00004; Sinha M, 2001, J TRAUMA, V50, P308, DOI 10.1097/00005373-200102000-00018; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Stiell IG, 2001, ANN EMERG MED, V38, P160, DOI 10.1067/mem.2001.116796; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Summers L E, 2001, J La State Med Soc, V153, P81; Vogelbaum MA, 1998, PEDIATR NEUROSURG, V29, P96, DOI 10.1159/000028697; Wang MY, 2000, NEUROSURGERY, V46, P1093, DOI 10.1097/00006123-200005000-00014; Zahari M., 1996, Singapore Medical Journal, V37, P285	50	81	82	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	OCT	2003	42	4					507	514		10.1067/S0196-0644(03)00512-2			8	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	729CC	WOS:000185752700007	14520321				2022-02-06	
J	Wetzel, M; Rosenberg, GA; Cunningham, LA				Wetzel, M; Rosenberg, GA; Cunningham, LA			Tissue inhibitor of metalloproteinases-3 and matrix metalloproteinase-3 regulate neuronal sensitivity to doxorubicin-induced apoptosis	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						Fas/CD95/APO-1; neuronal apoptosis; Sheddases; Wistar rats	TRAUMATIC BRAIN INJURY; FAS LIGAND; CELL-DEATH; TNF-ALPHA; RAT-BRAIN; RHEUMATOID-ARTHRITIS; EXTRACELLULAR-MATRIX; REPERFUSION INJURY; IN-VITRO; TIMP-3	Metalloproteinase activity at the cell surface influences cellular sensitivity to extrinsic death vs. survival signals in a variety of cell types, through proteolytic shedding of cell surface signalling molecules. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a unique natural metalloproteinase inhibitor that plays a pro-apoptotic role through its ability to inhibit metalloproteinases that proteolytically cleave death receptors and their ligands from the cell surface. To study the convergence of metalloproteinase activity and death receptor signalling in neurons, we established an in vitro model of neuronal apoptosis utilizing the chemotherapeutic drug, doxorubicin (Dox). Primary cultures established from embryonic rat cerebral cortices displayed robust and selective neuronal apoptosis in response to Dox, an effect that was dependent on the activation of the death receptor, Fas. We demonstrate that both TIMP-3 and matrix metalloproteinase-3 (MMP-3) are constitutively expressed by primary cortical neurons in culture, and selectively modulated Fas-mediated neuronal apoptosis induced by Dox. Metalloproteinase inhibition by TIMP-3 was found to be necessary for Dox-induced neuronal death, whereas addition of active MMP-3 markedly attenuated apoptosis and diminished Fas-Fas ligand interaction at the cell surface. These observations implicate a physiological role for the balance of TIMP-3 and MMP-3 activity at the neuronal surface in regulating death receptor sensitivity. The convergence of metalloproteinase activity and death receptor signalling at the cell surface may influence neuronal cell death vs. survival decisions.	Univ New Mexico, Sch Med, Hlth Sci Ctr, Dept Neurosci, Albuquerque, NM 87131 USA; Univ New Mexico, Sch Med, Hlth Sci Ctr, Dept Neurol, Albuquerque, NM 87131 USA		Cunningham, LA (corresponding author), Univ New Mexico, Sch Med, Hlth Sci Ctr, Dept Neurosci, Albuquerque, NM 87131 USA.	leeanna@salud.unm.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21169, NS38655] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021169, R01NS038655] Funding Source: NIH RePORTER		Ahonen M, 1998, CANCER RES, V58, P2310; APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; Bechmann I, 1999, GLIA, V27, P62, DOI 10.1002/(SICI)1098-1136(199907)27:1<62::AID-GLIA7>3.0.CO;2-S; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bernassola F, 1999, CELL DEATH DIFFER, V6, P652, DOI 10.1038/sj.cdd.4400537; Bond M, 2002, J BIOL CHEM, V277, P13787, DOI 10.1074/jbc.M111507200; Bond M, 2000, J BIOL CHEM, V275, P41358, DOI 10.1074/jbc.M007929200; Borland G, 1999, J BIOL CHEM, V274, P2810, DOI 10.1074/jbc.274.5.2810; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Butler GS, 1999, J BIOL CHEM, V274, P10846, DOI 10.1074/jbc.274.16.10846; Cai ZW, 2000, PEDIATR RES, V47, P64, DOI 10.1203/00006450-200001000-00013; Cheema ZF, 1999, J NEUROSCI, V19, P1754; DSouza SD, 1996, J EXP MED, V184, P2361, DOI 10.1084/jem.184.6.2361; Farbman AI, 1999, J COMP NEUROL, V414, P306, DOI 10.1002/(SICI)1096-9861(19991122)414:3<306::AID-CNE2>3.0.CO;2-#; Felderhoff-Mueser U, 2000, BRAIN PATHOL, V10, P17; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Fulda S, 1997, CANCER RES, V57, P3823; Garden GA, 2002, J NEUROSCI, V22, P4015, DOI 10.1523/JNEUROSCI.22-10-04015.2002; George SJ, 2000, CIRCULATION, V101, P296, DOI 10.1161/01.CIR.101.3.296; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Hansen HP, 2000, J IMMUNOL, V165, P6703, DOI 10.4049/jimmunol.165.12.6703; Hargreaves PG, 1998, BRIT J HAEMATOL, V101, P694, DOI 10.1046/j.1365-2141.1998.00754.x; HERTZ E, 1993, DISSECTION TISSUE CU, P183; HOUSLEY TJ, 1993, J BIOL CHEM, V268, P4481; Jaworski DM, 2000, J NEUROSCI RES, V61, P396, DOI 10.1002/1097-4547(20000815)61:4<396::AID-JNR6>3.0.CO;2-S; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Linseman DA, 2002, J BIOL CHEM, V277, P24546, DOI 10.1074/jbc.M201098200; Martin-Villalba A, 2001, CELL DEATH DIFFER, V8, P679, DOI 10.1038/sj.cdd.4400882; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Matsuno H, 2001, J RHEUMATOL, V28, P22; Matsushita K, 2000, J NEUROSCI, V20, P6879, DOI 10.1523/JNEUROSCI.20-18-06879.2000; Matsushita N, 2002, CLIN EXP IMMUNOL, V130, P156, DOI 10.1046/j.1365-2249.2002.01963.x; Mitsiades N, 2001, CANCER RES, V61, P577; Morishima Y, 2001, J NEUROSCI, V21, P7551, DOI 10.1523/JNEUROSCI.21-19-07551.2001; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Nadeau S, 1999, J NEUROPATH EXP NEUR, V58, P61, DOI 10.1097/00005072-199901000-00008; Nath D, 2001, J CELL SCI, V114, P1213; NISHIMURA T, 1995, BRAIN RES, V695, P137, DOI 10.1016/0006-8993(95)00699-Q; OKADA Y, 1987, J RHEUMATOL, V14, P41; Oliver GW, 1997, ANAL BIOCHEM, V244, P161, DOI 10.1006/abio.1996.9895; OSBORN M, 1981, COLD SPRING HARB SYM, V46, P413, DOI 10.1101/SQB.1982.046.01.040; Pan TL, 1999, CLIN EXP IMMUNOL, V118, P180; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; Qiu JH, 2002, J NEUROSCI, V22, P3504; Raoul C, 2000, CURR OPIN NEUROBIOL, V10, P111, DOI 10.1016/S0959-4388(99)00055-0; Rose S, 2000, AM J GASTROENTEROL, V95, P1; Rosenberg GA, 2001, BRAIN RES, V893, P104, DOI 10.1016/S0006-8993(00)03294-7; Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; Venters HD, 2000, TRENDS NEUROSCI, V23, P175, DOI 10.1016/S0166-2236(99)01533-7; Wallace JA, 2002, J CEREBR BLOOD F MET, V22, P1303, DOI 10.1097/01.WCB.0000040943.89393.c1; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang JD, 1997, J INTERF CYTOK RES, V17, P369, DOI 10.1089/jir.1997.17.369; Yeow KM, 2002, MATRIX BIOL, V21, P75, DOI 10.1016/S0945-053X(01)00180-9; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200	61	81	84	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	SEP	2003	18	5					1050	1060		10.1046/j.1460-9568.2003.02838.x			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	719EK	WOS:000185190500004	12956705				2022-02-06	
J	Lu, DY; Mahmood, A; Zhang, RL; Li, Y; Chopp, M				Lu, DY; Mahmood, A; Zhang, RL; Li, Y; Chopp, M			Upregulation of neurogenesis and reduction in functional deficits following administration of DETA/NONOate, a nitric oxide donor, after traumatic brain injury in rats	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; neurogenesis; DETA/NONOate; nitric oxide donor; rat	NEURAL STEM-CELLS; ZONE NEURONAL PRECURSORS; SUBVENTRICULAR ZONE; DENTATE GYRUS; HIPPOCAMPAL NEUROGENESIS; GENE-EXPRESSION; CORTICAL DAMAGE; ADULT-RAT; SYNTHASE; MOUSE	Object. Neurogenesis, which is upregulated by neural injury in the adult mammalian brain, may be involved in the repair of the injured brain and functional recovery. Therefore, the authors sought to identify agents that can enhance neurogenesis after brain injury, and they report that (Z)-1-[N-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate (DETA/NONOate), a nitric oxide donor, upregulates neurogenesis and reduces functional deficits after traumatic brain injury (TBI) in rats. Methods. The agent DETA/NONOate (0.4 mg/kg) was injected intraperitoneally into 16 rats daily for 7 days, starting I day after TBI induced by controlled cortical impact. Bromodeoxyuridine (100 mg/kg) was also injected intraperitoneally daily for 14 days after TBI to label the newly generated cells in the brain. A neurological functional evaluation was pet-formed in all rats and the animals were killed at 14 or 42 days postinjury. Immunohistochemical staining was used to identify proliferating cells. Conclusions. Compared with control rats, the proliferation, survival, migration and differentiation of neural progenitor cells were all significantly enhanced in the hippocampus, subventricular zone, striatum, corpus callosum, and the boundary zone of the injured cortex, as well as in the contralateral hemisphere in rats with TBI that received DETA/NONOate treatment. Neurological functional outcomes in the DETA/NONOate-treated group were also significantly improved compared with the untreated group. These data indicate that DETA/NONOate may be useful in the treatment of TBI.	Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA; Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI USA; Oakland Univ, Dept Phys, Rochester, MN USA; Henry Ford Hlth Sci Ctr, Dept Neurosurg, Detroit, MI USA		Chopp, M (corresponding author), Henry Ford Hosp, Dept Neurol, 2799 W Grand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042259] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 42259] Funding Source: Medline; OAPP OPHS HHS [PPG NS 23393] Funding Source: Medline		Alvarez-Buylla A, 2002, BRAIN RES BULL, V57, P751, DOI 10.1016/S0361-9230(01)00770-5; Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Anderson MF, 2002, DEV BRAIN RES, V134, P115; BARTH TM, 1990, J NEUROSCI, V10, P3449; BARTH TM, 1987, EXP NEUROL, V95, P661, DOI 10.1016/0014-4886(87)90307-4; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; BARTLETT PF, 1982, P NATL ACAD SCI-BIOL, V79, P2722, DOI 10.1073/pnas.79.8.2722; BEDARD A, 2001, SOC NEUROSCI, V248, P8; Bengzon J, 1997, P NATL ACAD SCI USA, V94, P10432, DOI 10.1073/pnas.94.19.10432; BREDT DS, 1994, NEURON, V13, P301, DOI 10.1016/0896-6273(94)90348-4; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; Cameron HA, 1999, NAT NEUROSCI, V2, P894, DOI 10.1038/13197; Cameron HA, 1998, NEUROSCIENCE, V82, P349; Castillo J, 2000, STROKE, V31, P852, DOI 10.1161/01.STR.31.4.852; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHAPIN JK, 1984, J COMP NEUROL, V229, P199, DOI 10.1002/cne.902290206; Chen S, 2001, METALL MATER TRANS B, V32, P11, DOI 10.1007/s11663-001-0002-1; Craig CG, 1996, J NEUROSCI, V16, P2649; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; DE CR, 1995, J CLIN INVEST, V96, P60; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; Ding MZ, 1997, J NEUROIMMUNOL, V77, P99, DOI 10.1016/S0165-5728(97)00065-9; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Doetsch F, 1996, P NATL ACAD SCI USA, V93, P14895, DOI 10.1073/pnas.93.25.14895; Durante W, 1997, CIRC RES, V80, P557, DOI 10.1161/01.RES.80.4.557; Eigenthaler M, 1999, Rev Physiol Biochem Pharmacol, V135, P173, DOI 10.1007/BFb0033673; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; GIUILI G, 1994, DEV BRAIN RES, V81, P269, DOI 10.1016/0165-3806(94)90313-1; Gould E, 2000, BIOL PSYCHIAT, V48, P715, DOI 10.1016/S0006-3223(00)01021-0; Gould E, 2002, J NEUROSCI, V22, P619, DOI 10.1523/JNEUROSCI.22-03-00619.2002; Gould E, 1999, BIOL PSYCHIAT, V46, P1472, DOI 10.1016/S0006-3223(99)00247-4; Gould E, 2001, P NATL ACAD SCI USA, V98, P10910, DOI 10.1073/pnas.181354698; HABY C, 1994, J NEUROCHEM, V62, P496; Hua Y, 2002, STROKE, V33, P2478, DOI 10.1161/01.STR.0000032302.91894.0F; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; Iadecola C, 1997, J NEUROSCI, V17, P9157; Idriss SD, 1999, J BIOL CHEM, V274, P9489, DOI 10.1074/jbc.274.14.9489; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Keilhoff G, 1996, NEUROSCIENCE, V75, P1193, DOI 10.1016/0306-4522(96)00330-2; Kempermann G, 2000, Prog Brain Res, V127, P35; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kirschenbaum B, 1999, J NEUROSCI, V19, P2171; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; LEVISON SW, 1993, DEVELOPMENT, V119, P611; Lim DA, 1997, P NATL ACAD SCI USA, V94, P14832, DOI 10.1073/pnas.94.26.14832; LINDEN R, 1994, NEUROSCIENCE, V58, P671, DOI 10.1016/0306-4522(94)90447-2; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Liu JL, 1998, J NEUROSCI, V18, P7768; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; Lu DY, 2002, CELL TRANSPLANT, V11, P275; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Madsen TM, 2000, BIOL PSYCHIAT, V47, P1043, DOI 10.1016/S0006-3223(00)00228-6; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Moreno-Lopez B, 2000, BRAIN RES, V869, P244, DOI 10.1016/S0006-8993(00)02474-4; MORSHEAD CM, 1992, J NEUROSCI, V12, P249; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; OKUSKY YP, J NEUROSCI, V20, P8435; Parent JM, 1997, J NEUROSCI, V17, P3727; Paxinos G, 1995, RAT NERVOUS SYSTEM; Peterson DA, 2002, CURR OPIN PHARMACOL, V2, P34, DOI 10.1016/S1471-4892(01)00118-7; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; REH T, 1982, J COMP NEUROL, V211, P276, DOI 10.1002/cne.902110306; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; ROSKAMS AJ, 1994, NEURON, V13, P289; Santacana M, 1998, DEV BRAIN RES, V111, P205, DOI 10.1016/S0165-3806(98)00140-0; Scheffler B, 1999, TRENDS NEUROSCI, V22, P348, DOI 10.1016/S0166-2236(99)01416-2; Schmanke TD, 1996, J NEUROTRAUM, V13, P293, DOI 10.1089/neu.1996.13.293; Scott D E, 1997, Va Med Q, V124, P249; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Stys PK, 1998, J CEREBR BLOOD F MET, V18, P2, DOI 10.1097/00004647-199801000-00002; Tanapat P, 1999, J NEUROSCI, V19, P5792, DOI 10.1523/JNEUROSCI.19-14-05792.1999; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858; Vallieres L, 2002, J NEUROSCI, V22, P486, DOI 10.1523/JNEUROSCI.22-02-00486.2002; YAGINUMA H, 1994, PROG NEUROBIOL, V44, P249, DOI 10.1016/0301-0082(94)90041-8; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0; Zhang RL, 2001, ANN NEUROL, V50, P602, DOI 10.1002/ana.1249; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8	84	81	85	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	2003	99	2					351	361		10.3171/jns.2003.99.2.0351			11	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	707TN	WOS:000184526100028	12924710				2022-02-06	
J	Kupina, NC; Detloff, MR; Bobrowski, WF; Snyder, BJ; Hall, ED				Kupina, NC; Detloff, MR; Bobrowski, WF; Snyder, BJ; Hall, ED			Cytoskeletal protein degradation and neurodegeneration evolves differently in males and females following experimental head injury	EXPERIMENTAL NEUROLOGY			English	Article						traumatic brain injury; gender difference; cytoskeleton; calpain; neurofilament; spectrin	TRAUMATIC BRAIN INJURY; PRIMARY CORTICAL-NEURONS; CEREBRAL BLOOD-FLOW; HIPPOCAMPAL-NEURONS; OXIDATIVE STRESS; NEUROBLASTOMA-CELLS; ESTRADIOL PROTECTS; GLUTAMATE TOXICITY; GENDER DIFFERENCES; ALPHA-SPECTRIN	The resulting neuropathological degeneration that occurs following a traumatic brain injury (TBI) is a consequence of both immediate and secondary neurochemical sequelae. Proteolysis of cytoskeletal proteins, triggered by calcium-mediated events, is believed to be a particularly significant contributor to TBI-induced neuronal death. To date, efforts to associate cytoskeletal degradation and neurodegeneration in TBI have been primarily qualitative or semiquantitative. The objectives of this study were (1) to quantitatively describe, over a posttraumatic time course, the relationship and mechanisms of cytoskeletal degradation (Western blot) and neurodegeneration (silver staining) in male and female mice following a moderately severe weight-drop impact-acceleration head injury; (2) to evaluate gender differences in the response to TBI; and (3) to examine the potential therapeutic window for future pharmacological treatment strategies. In male and female mice, we report a close correlation in the time courses of neurofilament M protein degradation and alpha-spectrin breakdown products (SBDP 150 and 145) with the peak magnitude of neurodegeneration, as quantified by silver staining. Evidence from the increased patterns of SBDPs suggests that both calpain and caspase-3 are involved. In general, males incurred peak protein degradation and neurodegeneration within 3 days after injury, while in females this did not occur until 14 days. The neuroprotective effects of estrogen are believed to be key factors in the superior outcome of female vs male mice following TBI. In mice, the therapeutic window of opportunity for pharmacological intervention aimed at limiting cytoskeletal degradation might be as much as 24 h following injury. Evidence of a protracted time course of cytoskeletal degradation, especially in females, suggests a potential for an extended treatment-duration following TBI. (C) 2003 Elsevier Science (USA). All rights reserved.	Pfizer Global Res & Dev, Ann Arbor Labs, CNS Pharmacol, Ann Arbor, MI 48105 USA; Pfizer Global Res & Dev, Ann Arbor Labs, DSE, Ann Arbor, MI 48105 USA		Hall, ED (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res ctr, 232 Hlth Sci Res Bldg, Lexington, KY 40536 USA.		Hall, Edward D/F-8930-2013				Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Azcoitia I, 1999, J NEUROSCI RES, V58, P815, DOI 10.1002/(SICI)1097-4547(19991215)58:6<815::AID-JNR8>3.0.CO;2-R; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Bartus RT, 1997, NEUROSCIENTIST, V3, P314, DOI 10.1177/107385849700300513; Behl C, 1997, MOL PHARMACOL, V51, P535, DOI 10.1124/mol.51.4.535; BEHL C, 1995, BIOCHEM BIOPH RES CO, V216, P473, DOI 10.1006/bbrc.1995.2647; BERRY K, 1975, J NEUROL SCI, V25, P75, DOI 10.1016/0022-510X(75)90188-4; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; COTTIN P, 1991, BIOCHIM BIOPHYS ACTA, V1079, P139, DOI 10.1016/0167-4838(91)90118-J; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; Dubal DB, 1999, J NEUROSCI, V19, P6385; FERRIS DC, 1995, NEUROREPORT, V6, P1485, DOI 10.1097/00001756-199507310-00005; Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; Goodman YD, 1996, J NEUROCHEM, V66, P1836; GOULD E, 1990, J NEUROSCI, V10, P1286; GRAFE MR, 1980, J NEUROPATH EXP NEUR, V39, P555, DOI 10.1097/00005072-198009000-00005; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Green PS, 1996, NEUROSCI LETT, V218, P165, DOI 10.1016/S0304-3940(96)13148-7; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Hall E.D., 1995, CENTRAL NERVOUS SYST, P213; HALL ED, 1991, J CEREBR BLOOD F MET, V11, P292, DOI 10.1038/jcbfm.1991.61; HALL ED, 1998, CEREBROVASC DIS, P710; HARRIS AS, 1988, J NEUROSCI, V8, P2640; HAYASHI T, 1992, P NATL ACAD SCI USA, V89, P11259, DOI 10.1073/pnas.89.23.11259; HURN PD, 1995, J CEREBR BLOOD F MET, V15, P666, DOI 10.1038/jcbfm.1995.82; Ikonomidou C, 2000, SCIENCE, V287, P1056, DOI 10.1126/science.287.5455.1056; KAMAKURA K, 1985, J NEUROSCI RES, V13, P391, DOI 10.1002/jnr.490130306; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; KANNEL WB, 1994, HEART INCIDENCE PREV; Kassell NF, 1996, J NEUROSURG, V84, P221, DOI 10.3171/jns.1996.84.2.0221; KONTOS HA, 1989, CHEM-BIOL INTERACT, V72, P229, DOI 10.1016/0009-2797(89)90001-X; KumeKick J, 1996, BRAIN RES, V738, P8, DOI 10.1016/0006-8993(96)00744-5; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; MacManus JP, 1997, J CEREBR BLOOD F MET, V17, P815, DOI 10.1038/aj.jcbfm.9590266; McIntosh TK, 1997, NEUROSCIENTIST, V3, P169, DOI 10.1177/107385849700300310; McIntosh TK, 1996, LAB INVEST, V74, P315; MENDELSON ME, 1994, CURR OPIN CARDIOL, V9, P619, DOI 10.1097/00001573-199409000-00018; MIKKOLA T, 1995, J CLIN ENDOCR METAB, V80, P1832, DOI 10.1210/jc.80.6.1832; Moosmann B, 1999, P NATL ACAD SCI USA, V96, P8867, DOI 10.1073/pnas.96.16.8867; MORSE JK, 1986, EXP NEUROL, V94, P649, DOI 10.1016/0014-4886(86)90244-X; Murphy DD, 1998, P NATL ACAD SCI USA, V95, P11412, DOI 10.1073/pnas.95.19.11412; PAYAN HM, 1977, STROKE, V8, P194, DOI 10.1161/01.STR.8.2.194; Pelligrino DA, 1998, NEUROREPORT, V9, P3285, DOI 10.1097/00001756-199810050-00026; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; REGAN RF, 1997, BRAIN RES, V764, P130; RINK A, 1995, AM J PATHOL, V147, P1575; ROOF RL, 1993, BEHAV BRAIN RES, V57, P47, DOI 10.1016/0166-4328(93)90060-4; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; ROOF RL, 1994, NEUROTRAUMA, V11, P124; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; SAATMAN KE, 1996, P NATL ACAD SCI, V93; SAATMAN KE, 1996, J NEUROPATH EXP NEUR, V55, P852; SADOSHIMA S, 1988, BRAIN RES, V454, P238, DOI 10.1016/0006-8993(88)90823-2; Shi J, 1997, EXP BRAIN RES, V117, P200, DOI 10.1007/s002210050216; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; Singer CA, 1999, J NEUROSCI, V19, P2455; Singer CA, 1998, NEUROREPORT, V9, P2565, DOI 10.1097/00001756-199808030-00025; Singer CA, 1996, NEUROSCI LETT, V212, P13, DOI 10.1016/0304-3940(96)12760-9; SINGH M, 1995, ENDOCRINOLOGY, V136, P2320, DOI 10.1210/en.136.5.2320; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; VERITY MA, 1992, NEUROTOXICOLOGY, V13, P139; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; Wise PM, 2001, ENDOCRINOLOGY, V142, P969, DOI 10.1210/en.142.3.969; WOOLLEY CS, 1992, J NEUROSCI, V12, P2549; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YAMAMOTO T, 1986, BRAIN RES, V374, P419, DOI 10.1016/0006-8993(86)90442-7; YUEN PW, 1996, EXPERT OPIN INV DRUG, V5, P1291; ZHANG A, 1992, BRIT J PHARMACOL, V105, P305, DOI 10.1111/j.1476-5381.1992.tb14250.x; Zhang YQ, 1998, BRAIN RES, V784, P321, DOI 10.1016/S0006-8993(97)00502-7; Zheng JQ, 2001, J NEUROSCI, V21, P9291, DOI 10.1523/JNEUROSCI.21-23-09291.2001; [No title captured]	79	81	85	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	MAR	2003	180	1					55	72		10.1016/S0014-4886(02)00048-1			18	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	663UR	WOS:000182025100006	12668149				2022-02-06	
J	Hergan, K; Schaefer, PW; Sorensen, AG; Gonzalez, RG; Huisman, TAGM				Hergan, K; Schaefer, PW; Sorensen, AG; Gonzalez, RG; Huisman, TAGM			Diffusion-weighted MRI in diffuse axonal injury of the brain	EUROPEAN RADIOLOGY			English	Article						diffusion-weighted imaging; diffuse axonal injury; brain injury	HEAD-INJURY; EDEMA; TRAUMA	The goal of this study was to identify and describe the different types and patterns of tissue injury which are encountered by diffusion-weighted imaging (DWI) in diffuse axonal injury (DAI) of the brain. The DWI data sets of 98 patients who suffered from a closed-head injury were retrospectively evaluated. Medical records were reviewed to rule out pre-existing neurological diseases. Lesions were studied for their DWI signal characteristics and lesion size or extension. Traumatic lesions were classified into three categories depending on their signal characteristica on DWI and apparent diffusion coefficient (ADC) maps: type 1, DWI- and ADC-hyperintense most likely representing lesions with vasogenic edema; type 2, DWI-hyperintense, ADC-hypointense indicating cytotoxic edema; type 3, central hemorrhagic lesion surrounded by an area of increased diffusion. According to the size and extent of lesions, injury was classified into three groups: group A, focal injury; group B, regional/confluent injury; and group C, extensive/diffuse injury. Our study showed that diffusion-weighted imaging differentiates between lesions with decreased and increased diffusion in patients with DAI. Different degrees of tissue injury extent were noticed. Future prospective studies should study if this additional information can be used as a predictor of injury reversibility, final outcome and prognosis.	Massachusetts Gen Hosp, Dept Radiol, Neuroradiol Sect, Boston, MA 02129 USA; Massachusetts Gen Hosp, MGH NMR Ctr, Boston, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02129 USA; LKH Feldkirch, Dept Radiol, Feldkirch, Austria		Huisman, TAGM (corresponding author), Massachusetts Gen Hosp, Dept Radiol, Neuroradiol Sect, Bldg 149,13th St,Mailcode 149-2301, Boston, MA 02129 USA.	thierry@nmr.mgh.harvard.edu	Schaefer, Pamela/AAA-1323-2019				ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Anderson CV, 1996, J NEUROTRAUM, V13, P59, DOI 10.1089/neu.1996.13.59; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; GEAN AD, 1994, IMAGING HEAD TRAUMA, P217; GENNARELLI TA, 1991, J EMERGENCY MED, V11, P5; Gonzalez RG, 1999, RADIOLOGY, V210, P155, DOI 10.1148/radiology.210.1.r99ja02155; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Kawamata T, 2000, ACTA NEUROCHIR SUPPL, V76, P9; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; MARION DW, 1999, TRAUMATIC BRAIN INJU, P31; Marmarou A, 2000, ACT NEUR S, V76, P349; Nakahara M, 2001, ACTA RADIOL, V42, P365, DOI 10.1080/028418501127346990; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Schaefer PW, 2000, RADIOLOGY, V217, P331, DOI 10.1148/radiology.217.2.r00nv24331; STRICH SJ, 1961, LANCET, V2, P443; Suh DY, 2001, NEUROSURGERY, V49, P309, DOI 10.1097/00006123-200108000-00011; Takayama H, 2000, CLIN NEUROL NEUROSUR, V102, P135, DOI 10.1016/S0303-8467(00)00079-2; Unterberg AW, 1997, ACT NEUR S, V70, P106	20	81	90	1	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0938-7994	1432-1084		EUR RADIOL	Eur. Radiol.	OCT	2002	12	10					2536	+		10.1007/s00330-002-1333-2			6	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	606EG	WOS:000178720500018	12271396				2022-02-06	
J	Cattelani, R; Tanzi, F; Lombardi, F; Mazzucchi, A				Cattelani, R; Tanzi, F; Lombardi, F; Mazzucchi, A			Competitive re-employment after severe traumatic brain injury: clinical, cognitive and behavioural predictive variables	BRAIN INJURY			English	Article							VOCATIONAL-REHABILITATION; HEAD-INJURY; FOLLOW-UP; WORK; RETURN; OUTCOMES	Primary objective: To contribute to the identification of relationships between the return to pre-trauma competitive activities at the final discharge from rehabilitation facilities, and neuroanatomical, neuropsychological and behavioural data collected at different phases of the recovery from a traumatic brain injury (TBI). Methods and procedures: Thirty-five severe TBI subjects were retrospectively selected from 228 consecutive admissions over a 3-year period, according to pre-morbid, clinical and demographic characteristics matching the established selection criteria, and submitted to comprehensive neurophysiological, intellectual, cognitive and behavioural examinations carried out at different stages of the recovery (acute, subacute and chronic phases). Experimental interventions: Barthel Activity of Daily Living (BADL) index, Wechsler Adult Intelligence Scale-Revised (WAIS-R), checklists aimed to detect cognitive and behavioural dysfunction, Main outcomes and results: TBI subjects successfully re-employed obtained significantly better scores on length of coma and PTA, intellectual status, cognitive functioning and behavioural competence. Other specific measures of injury severity (CT-scan abnormalities, GCS score level, BADL index) resulted as being unrelated to the resumption of pre-trauma competitive activities. Conclusions: Findings seem to confirm the opinion that a significant relationship exists between the initial TBI severity level, especially as indicated by the duration of coma and PTA, and eventual return to work at the final discharge from facilities.	Univ Parma, Ist Neurol, Dept Neurol, I-43100 Parma, Italy; S Sebastiano Hosp Correggio, Reggio Emilia, Italy; Cardinal Ferrari Rehabil Ctr Fontanellato, Parma, Italy		Cattelani, R (corresponding author), Univ Parma, Ist Neurol, Dept Neurol, Str Quartiere 4, I-43100 Parma, Italy.			LOMBARDI, Francesco/0000-0002-7184-6391			Abrams D., 1993, J HEAD TRAUMA REHAB, V8, P59; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P45; Burke W H, 1988, Brain Inj, V2, P313, DOI 10.3109/02699058809150902; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FABIANO RJ, 1995, REHABIL PSYCHOL, V40, P223, DOI 10.1037/0090-5550.40.3.223; FRASER RT, 1995, NEUROREHABILITATION, V5, P39, DOI 10.3233/NRE-1995-5104; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Gurka JA, 1999, J HEAD TRAUMA REHAB, V14, P247, DOI 10.1097/00001199-199906000-00005; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Johnstone B, 1999, J HEAD TRAUMA REHAB, V14, P220, DOI 10.1097/00001199-199906000-00003; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; Laicardi C, 1997, WAIS R CONTRIBUTO TA; MAHONEY F I, 1965, Md State Med J, V14, P61; Marshall LF, 1991, J NEUROSURG S, V75, P14; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Sander AM, 1997, J HEAD TRAUMA REHAB, V12, P28, DOI 10.1097/00001199-199710000-00004; Wechsler, 1997, WECHSLER ADULT INTEL; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047	33	81	84	0	8	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK,, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	2002	16	1					51	64		10.1080/02699050110088821			14	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	515BM	WOS:000173475600005	11796099				2022-02-06	
J	de la Torre, JC				de la Torre, J. C.			Alzheimer's disease: How does it start?	JOURNAL OF ALZHEIMERS DISEASE			English	Article							NITRIC-OXIDE SYNTHASE; CEREBRAL-BLOOD-FLOW; ENDOTHELIAL GROWTH-FACTOR; MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; E EPSILON-4 ALLELE; FACTOR-KAPPA-B; VASCULAR DEMENTIA; APOLIPOPROTEIN-E; RISK-FACTORS	Presently, non-genetic Alzheimer's disease (AD) is wrongly classified as a neurodegenerative disorder. When vascular lesions are present, AD is considered to be a vascular dementia. However, compelling evidence indicates that (AD) is a vascular disorder with neurodegenerative consequences. There is an urgent clinical need to ascertain the true cause of this dementia. In this review, evidence indicating that AD is a vascular disorder comes from a number of different disciplines including studies in epidemiology, pharmacology, neuroimaging, clinical medicine, pathology, physiology and experimental research. This collective evidence also addresses many previously puzzling questions regarding: i) past and present treatment failures in AD, ii) strange association of AD risk factors with many vascular-related disorders, iii) parallel lesions, clinical symptoms risk factors and potentially interchangeable treatments present in AD and vascular dementia, iv) historical difficulty in finding neurodegenerative markers to detect AD pre-clinivally, and, v) paradoxical pathophysiologic events preceding AD neurodegenerative changes. Re-classifying AD as a vascular disorder would very likely improve the chances of finding a useful treatment for this disorder because clinical study designs could focus on more realistic and relevant pathologic targets than is presently practiced. A short summary of potential new research lines that may provide novel therapy in the treatment and management of AD is discussed.	UCSD Neuropathol Div, Escondido, CA 92026 USA		de la Torre, JC (corresponding author), UCSD Neuropathol Div, 1363 Shinly,Suite 100, Escondido, CA 92026 USA.	jdelator@nctimes.net			Alzheimer's AssociationAlzheimer's Association	This research was supported by an Investigator-Initiated Research Grant from the Alzheimer's Association.	Abdollahian NP, 1998, CYTOCHROME OXIDASE IN NEURONAL METABOLISM AND ALZHEIMER'S DISEASE, P233; Aguero-Torres H, 2000, ANN NY ACAD SCI, V903, P547, DOI 10.1111/j.1749-6632.2000.tb06412.x; Ajmani RS, 2000, NEUROBIOL AGING, V21, P257, DOI 10.1016/S0197-4580(00)00118-4; Aliev G, 2002, BRAIN PATHOL, V12, P21; Ansell B, 2002, ADV THER, V19, P61, DOI 10.1007/BF02850055; Arnaiz E, 2001, NEUROREPORT, V12, P851, DOI 10.1097/00001756-200103260-00045; Azzi A, 2002, FEBS LETT, V519, P8, DOI 10.1016/S0014-5793(02)02706-0; BANAI S, 1994, CIRCULATION, V89, P2183, DOI 10.1161/01.CIR.89.5.2183; Barber R, 1999, J NEUROL NEUROSUR PS, V67, P66, DOI 10.1136/jnnp.67.1.66; Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114; Bayorh MA, 2001, CLIN EXP HYPERTENS, V23, P611, DOI 10.1081/CEH-100107391; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Blackwell TS, 1996, J IMMUNOL, V157, P1630; Blass JP, 2001, J NEUROSCI RES, V66, P851, DOI 10.1002/jnr.10087; Bonetta L, 2002, NAT MED, V8, P541, DOI 10.1038/nm0602-541a; Bots ML, 1998, HAEMOSTASIS, V28, P216; Bowler JV, 1997, ARCH NEUROL-CHICAGO, V54, P697, DOI 10.1001/archneur.1997.00550180021007; Bowler JV, 1998, J NEUROL NEUROSUR PS, V64, P18, DOI 10.1136/jnnp.64.1.18; Boyer M, 2000, J VASC SURG, V31, P181, DOI 10.1016/S0741-5214(00)70080-2; Bozoki A, 2001, ARCH NEUROL-CHICAGO, V58, P411, DOI 10.1001/archneur.58.3.411; Breteler MMB, 2000, NEUROBIOL AGING, V21, P153, DOI 10.1016/S0197-4580(99)00110-4; Breteler MMB, 2000, ANN NY ACAD SCI, V903, P457, DOI 10.1111/j.1749-6632.2000.tb06399.x; Breteler MMB, 1998, HAEMOSTASIS, V28, P167; Buee L, 1997, ANN NY ACAD SCI, V826, P7, DOI 10.1111/j.1749-6632.1997.tb48457.x; BUEE L, 1994, ACTA NEUROPATHOL, V87, P469; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; Callahan A, 2001, AM J CARDIOL, V88, p33J; Cameron NE, 1997, EUR J PHARMACOL, V319, P239, DOI 10.1016/S0014-2999(96)00844-8; Chen Y, 1999, J CEREBR BLOOD F MET, V19, P133, DOI 10.1097/00004647-199902000-00003; Cheung F, 1999, BIOCHEM PHARMACOL, V58, P1665, DOI 10.1016/S0006-2952(99)00255-5; Chui HC, 2000, ARCH NEUROL-CHICAGO, V57, P191, DOI 10.1001/archneur.57.2.191; Claus JJ, 1998, NEUROBIOL AGING, V19, P57, DOI 10.1016/S0197-4580(98)00004-9; Colquhoun David M, 2002, Aust Fam Physician, V31, P25; Colton CA, 2002, ANN NY ACAD SCI, V962, P212, DOI 10.1111/j.1749-6632.2002.tb04070.x; Davies MJ, 2001, AM J CARDIOL, V88, p2F; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; Davis DG, 1999, J NEUROPATH EXP NEUR, V58, P376, DOI 10.1097/00005072-199904000-00008; Davis JN, 1997, TRENDS NEUROSCI, V20, P558; de la Torre J.C., 1997, ANN NY ACAD SCI, V826, P1; de la Torre J.C., 2002, ANN NY ACAD SCI, V977, P1; de la Torre JC, 1999, ACTA NEUROPATHOL, V98, P1, DOI 10.1007/s004010051044; de la Torre JC, 2002, STROKE, V33, P1152, DOI 10.1161/01.STR.0000014421.15948.67; de la Torre JC, 2000, BRAIN RES REV, V34, P119, DOI 10.1016/S0165-0173(00)00043-6; de la Torre JC, 2000, NEUROBIOL AGING, V21, P331, DOI 10.1016/S0197-4580(00)00111-1; de Leon MJ, 2001, P NATL ACAD SCI USA, V98, P10966, DOI 10.1073/pnas.191044198; De Santi S, 2001, NEUROBIOL AGING, V22, P529, DOI 10.1016/S0197-4580(01)00230-5; DeJong GI, 1997, ANN NY ACAD SCI, V826, P56; Deklunder G, 1998, STROKE, V29, P1821, DOI 10.1161/01.STR.29.9.1821; DELAMONTE SM, 2001, PATHOLOGY AGING HUMA, P123; delaTorre JC, 1997, NEUROSCI LETT, V223, P165, DOI 10.1016/S0304-3940(97)13421-8; delaTorre JC, 1997, ANN NY ACAD SCI, V826, P75; DELATORRE JC, 1993, NEUROL RES, V15, P146; DELATORRE JC, 1992, BRAIN RES, V582, P186, DOI 10.1016/0006-8993(92)90132-S; DELATORRE JC, 1994, NEUROSCI BIOBEHAV R, V18, P397, DOI 10.1016/0149-7634(94)90052-3; DELATORRE JC, 2000, NEUROBIOL AGING, V21, P153; Delles C, 2002, KIDNEY INT, V61, P1462, DOI 10.1046/j.1523-1755.2002.00260.x; Desideri G, 2002, J CLIN ENDOCR METAB, V87, P2940, DOI 10.1210/jc.87.6.2940; Devanand DP, 1996, ARCH GEN PSYCHIAT, V53, P175; DIAZARRASTIA R, 1998, ARCH NEUROL-CHICAGO, V55, P1; Dickson DW, 2001, CLIN GERIATR MED, V17, P209, DOI 10.1016/S0749-0690(05)70066-5; Dobrucki L W, 2001, Med Sci Monit, V7, P622; Doggrell SA, 2001, EXPERT OPIN INV DRUG, V10, P1755, DOI 10.1517/13543784.10.9.1755; DUARA R, 1992, J CEREBR BLOOD F MET, V12, P927, DOI 10.1038/jcbfm.1992.129; Elwood PC, 2002, AGE AGEING, V31, P43, DOI 10.1093/ageing/31.1.43; Erkinjuntti T, 2002, LANCET, V359, P1283, DOI 10.1016/S0140-6736(02)08267-3; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; FISCHER VW, 1990, ACTA NEUROPATHOL, V79, P672, DOI 10.1007/BF00294246; Gainotti G, 1998, ALZ DIS ASSOC DIS, V12, P152, DOI 10.1097/00002093-199809000-00006; Ganz P, 2002, AM J CARDIOL, V90, p11F, DOI 10.1016/S0002-9149(01)02218-4; Geerlings MI, 2000, BRIT J PSYCHIAT, V176, P568, DOI 10.1192/bjp.176.6.568; Goldsmith H.S., ANN NY ACAD IN PRESS; Goldsmith HS, 2001, NEUROL RES, V23, P555, DOI 10.1179/016164101101198893; GRAVES AB, 1991, INT J EPIDEMIOL, V20, pS48, DOI 10.1093/ije/20.Supplement_2.S48; Grosser Nina, 2002, Nitric Oxide, V6, P396; Groves WC, 2000, J NEUROPSYCH CLIN N, V12, P305, DOI 10.1176/appi.neuropsych.12.3.305; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Guo Z, 1997, BIOMED PHARMACOTHER, V51, P68, DOI 10.1016/S0753-3322(97)87729-3; Halliwell B, 1997, FEBS LETT, V411, P157, DOI 10.1016/S0014-5793(97)00469-9; Hamilton CA, 2001, HYPERTENSION, V37, P529, DOI 10.1161/01.HYP.37.2.529; Harman D, 2002, ANN NY ACAD SCI, V959, P384, DOI 10.1111/j.1749-6632.2002.tb02109.x; HATAKE K, 1990, STROKE, V21, P1039, DOI 10.1161/01.STR.21.7.1039; Hatanpaa K, 1996, ANN NEUROL, V40, P411, DOI 10.1002/ana.410400310; Heymes C, 2000, BRIT J PHARMACOL, V131, P804, DOI 10.1038/sj.bjp.0703632; Higashi Y, 1997, HYPERTENSION, V30, P252, DOI 10.1161/01.HYP.30.2.252; Hofman A, 1997, LANCET, V349, P151, DOI 10.1016/S0140-6736(96)09328-2; Holmes C, 1999, BRIT J PSYCHIAT, V174, P45, DOI 10.1192/bjp.174.1.45; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Ihara M, 2001, J CEREBR BLOOD F MET, V21, P828, DOI 10.1097/00004647-200107000-00008; Imaoka Y, 1999, J CARDIOVASC PHARM, V33, P756, DOI 10.1097/00005344-199905000-00012; Inoue M, 1996, ANN NY ACAD SCI, V786, P224, DOI 10.1111/j.1749-6632.1996.tb39065.x; Jendroska K, 1997, Ann N Y Acad Sci, V826, P401, DOI 10.1111/j.1749-6632.1997.tb48492.x; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Johnson KA, 1998, NEUROLOGY, V50, P1563, DOI 10.1212/WNL.50.6.1563; Johnson KA, 2000, NEUROBIOL AGING, V21, P289, DOI 10.1016/S0197-4580(00)00137-8; Jones AM, 1997, NUCL MED COMMUN, V18, P662, DOI 10.1097/00006231-199707000-00011; Joosten E, 2001, CLIN CHEM LAB MED, V39, P717, DOI 10.1515/CCLM.2001.119; Joscowicz A., 2002, NITRIC OXIDE-BIOL CH, V6, P408; Kalaria RN, 1999, ALZ DIS ASSOC DIS, V13, pS115, DOI 10.1097/00002093-199912003-00017; Kalaria RN, 1998, MOL BRAIN RES, V62, P101, DOI 10.1016/S0169-328X(98)00190-9; KALARIA RN, 1995, NEUROREPORT, V6, P477, DOI 10.1097/00001756-199502000-00018; Kalaria RN, 2000, ANN NY ACAD SCI, V903, P1; Kalinowski L, 2002, CIRCULATION, V105, P933, DOI 10.1161/hc0802.104283; Kalmijn S, 1999, AM J EPIDEMIOL, V150, P283, DOI 10.1093/oxfordjournals.aje.a010000; Kalmijn S, 1997, ANN NEUROL, V42, P776, DOI 10.1002/ana.410420514; Kang ES, 2001, FREE RADICAL RES, V35, P341, DOI 10.1080/10715760100300871; KAO CH, 1993, NUCL MED COMMUN, V14, P47, DOI 10.1097/00006231-199301000-00010; Kauser Katalin, 2002, Nitric Oxide, V6, P409; Kawabata A, 1996, BRIT J PHARMACOL, V119, P346, DOI 10.1111/j.1476-5381.1996.tb15992.x; Kawabata A, 1996, BRIT J PHARMACOL, V117, P236, DOI 10.1111/j.1476-5381.1996.tb15181.x; Kilander L, 1998, STROKE, V29, P1816, DOI 10.1161/01.STR.29.9.1816; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Kogure D, 2000, J NUCL MED, V41, P1155; Korczyn A., ANN NY ACAD IN PRESS; KUBES P, 1993, FASEB J, V7, P1293, DOI 10.1096/fasebj.7.13.8405815; KUBES P, 1992, AM J PHYSIOL, V262, pH611, DOI 10.1152/ajpheart.1992.262.2.H611; KUNG CF, 1995, HYPERTENSION, V25, P194, DOI 10.1161/01.HYP.25.2.194; Laham RJ, 2002, J AM COLL CARDIOL, V39, P1, DOI 10.1016/S0735-1097(01)01691-6; Lederman R.J., 2002, J GERONTOL B-PSYCHOL, V359, P2048; Lee TJF, 2000, J BIOMED SCI, V7, P16; Li D, 2001, J Cardiovasc Pharmacol Ther, V6, P155, DOI 10.1177/107424840100600207; Liaudet L, 2000, P NATL ACAD SCI USA, V97, P10203, DOI 10.1073/pnas.170226797; Losordo DW, 1998, CIRCULATION, V98, P2800, DOI 10.1161/01.CIR.98.25.2800; Luth HJ, 2001, BRAIN RES, V913, P57, DOI 10.1016/S0006-8993(01)02758-5; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Malek AM, 1999, NEUROSURGERY, V45, P334, DOI 10.1097/00006123-199908000-00028; MANCARDI GL, 1980, ACTA NEUROPATHOL, V49, P79, DOI 10.1007/BF00692225; Martin TR, 2000, DEMENT GERIATR COGN, V11, P239, DOI 10.1159/000017245; Matz RL, 2000, BRIT J PHARMACOL, V131, P303, DOI 10.1038/sj.bjp.0703568; Maxwell AJ, 2002, NITRIC OXIDE-BIOL CH, V6, P101, DOI 10.1006/niox.2001.0394; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Meyer JS, 2000, NEUROBIOL AGING, V21, P161, DOI 10.1016/S0197-4580(00)00136-6; Miyakawa T, 1997, ANN NY ACAD SCI, V826, P25, DOI 10.1111/j.1749-6632.1997.tb48458.x; Morris JC, 2000, NEUROL CLIN, V18, P773, DOI 10.1016/S0733-8619(05)70225-5; Morris JC, 2001, ARCH NEUROL-CHICAGO, V58, P397, DOI 10.1001/archneur.58.3.397; Morrison R.A., LOW BLOOD PRESSURE S; Mueller XM, 1999, SCHWEIZ MED WSCHR, V129, P1889; Munzel T, 2001, CIRCULATION, V104, P1571, DOI 10.1161/hc3801.095585; Napoli C, 2001, NITRIC OXIDE-BIOL CH, V5, P88, DOI 10.1006/niox.2001.0337; Neve RL, 1998, TRENDS NEUROSCI, V21, P15, DOI 10.1016/S0166-2236(97)01168-5; NIU XF, 1994, CIRC RES, V74, P1133, DOI 10.1161/01.RES.74.6.1133; Notkola IL, 1998, NEUROEPIDEMIOLOGY, V17, P14, DOI 10.1159/000026149; Nunomura A, 2000, J NEUROPATH EXP NEUR, V59, P1011, DOI 10.1093/jnen/59.11.1011; OHKURA T, 1994, ENDOCR J, V41, P361, DOI 10.1507/endocrj.41.361; Okamura N, 2000, Nihon Ronen Igakkai Zasshi, V37, P974; Ott A, 1997, STROKE, V28, P316, DOI 10.1161/01.STR.28.2.316; Ott A, 1999, NEUROLOGY, V53, P1937, DOI 10.1212/WNL.53.9.1937; Ott A, 1998, LANCET, V351, P1840, DOI 10.1016/S0140-6736(97)07541-7; Ott A, 1996, DIABETOLOGIA, V39, P1392, DOI 10.1007/s001250050588; OTT A, 1995, BRIT MED J, V310, P970, DOI 10.1136/bmj.310.6985.970; Ouchi Y, 1998, J NUCL MED, V39, P198; Pacher P, 2002, BRIT J PHARMACOL, V135, P1347, DOI 10.1038/sj.bjp.0704627; Pacher P, 2002, DIABETES, V51, P514, DOI 10.2337/diabetes.51.2.514; Pappas B A, 1997, Ann N Y Acad Sci, V826, P498, DOI 10.1111/j.1749-6632.1997.tb48512.x; Parnetti L, 2000, NEUROLOGY, V54, P735, DOI 10.1212/WNL.54.3.735; Passant U, 1997, INT J GERIATR PSYCH, V12, P395, DOI 10.1002/(SICI)1099-1166(199703)12:3<395::AID-GPS527>3.3.CO;2-R; Pecher P, 2000, ANN THORAC SURG, V69, P1414, DOI 10.1016/S0003-4975(00)01162-0; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; POSTIGLIONE A, 1991, PHARMACOL RES, V23, P241, DOI 10.1016/S1043-6618(05)80083-0; Ransmayr G, 1998, J NEURAL TRANSM-SUPP, P79; Reuter U, 2002, ANN NEUROL, V51, P507, DOI 10.1002/ana.10159; Rodriguez G, 2000, PSYCHIAT RES-NEUROIM, V100, P65, DOI 10.1016/S0925-4927(00)00071-8; Rodriguez-Martinez MA, 1998, BRIT J PHARMACOL, V123, P113, DOI 10.1038/sj.bjp.0701595; Roman G, 2001, INT J CLIN PRACT, P9; Rosendorff C, 2002, J HUM HYPERTENS, V16, pS26, DOI 10.1038/sj.jhh.1001337; Sata M, 2001, FASEB J, V15, P2530, DOI 10.1096/fj.01-0415fje; Scheltens Philip, 2000, Current Opinion in Neurology, V13, P391, DOI 10.1097/00019052-200008000-00005; Schini-Kerth VB, 1999, TRANSFUS CLIN BIOL, V6, P355, DOI 10.1016/S1246-7820(00)88980-6; Schumacher B, 1998, CIRCULATION, V97, P645, DOI 10.1161/01.CIR.97.7.645; Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613; Shah Y, 2000, GERIATRICS, V55, P62; Singh N, 2002, CLIN SCI, V102, P595, DOI 10.1042/CS20010262; Skoog I, 1999, ALZ DIS ASSOC DIS, V13, pS106, DOI 10.1097/00002093-199912003-00016; Smith MA, 2002, LANCET, V359, P1864, DOI 10.1016/S0140-6736(02)08695-6; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813; Solerte SB, 2000, NEUROBIOL AGING, V21, P271, DOI 10.1016/S0197-4580(00)00105-6; Solerte SB, 1998, NEUROBIOL AGING, V19, P191, DOI 10.1016/S0197-4580(98)00050-5; Szabo C, 1997, J CLIN INVEST, V100, P723, DOI 10.1172/JCI119585; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; TADDEI S, 1995, CIRCULATION, V91, P1981, DOI 10.1161/01.CIR.91.7.1981; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; Tanaka K, 2000, NEUROCHEM RES, V25, P313, DOI 10.1023/A:1007544124794; Tanaka K, 1998, J NEUROSCI METH, V84, P63, DOI 10.1016/S0165-0270(98)00092-2; Tanaka M, 2002, J NEUROIMAGING, V12, P112, DOI 10.1111/j.1552-6569.2002.tb00106.x; Tarkowski E, 1999, J CLIN IMMUNOL, V19, P223, DOI 10.1023/A:1020568013953; Terry RD, 1996, J NEUROPATH EXP NEUR, V55, P1023, DOI 10.1097/00005072-199655100-00001; Thomas T, 1998, NEUROREPORT, V9, P2595, DOI 10.1097/00001756-199808030-00031; Thomas T, 2000, NEUROBIOL AGING, V21, P343, DOI 10.1016/S0197-4580(00)00100-7; TSUCHIYA M, 1993, EXP BRAIN RES, V95, P1; Tsurumi Y, 1996, CIRCULATION, V94, P3281, DOI 10.1161/01.CIR.94.12.3281; Tyas SL, 2001, INT J EPIDEMIOL, V30, P590, DOI 10.1093/ije/30.3.590; Urbich C, 2002, CIRC RES, V90, P737, DOI 10.1161/01.RES.0000014081.30867.F8; van der Loo B, 2000, J EXP MED, V192, P1731, DOI 10.1084/jem.192.12.1731; Vanderploeg RD, 2001, J INT NEUROPSYCH SOC, V7, P563, DOI 10.1017/S135561770175504X; VANDUIJN CM, 1995, BMJ-BRIT MED J, V310, P627, DOI 10.1136/bmj.310.6980.627; Vaughan CJ, 2001, CNS DRUGS, V15, P589, DOI 10.2165/00023210-200115080-00002; Wallin A, 1998, DEMENT GERIATR COGN, V9, P30, DOI 10.1159/000051187; Walter DH, 2002, CIRCULATION, V105, P3017, DOI 10.1161/01.CIR.0000018166.84319.55; Waring SC, 1999, NEUROLOGY, V52, P965, DOI 10.1212/WNL.52.5.965; Wentzel C, 2000, NEUROEPIDEMIOLOGY, V19, P186, DOI 10.1159/000026254; Wissink MJB, 2000, J CONTROL RELEASE, V64, P103, DOI 10.1016/S0168-3659(99)00145-5; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Wong A, 2001, EUR J NEUROSCI, V14, P1961, DOI 10.1046/j.0953-816x.2001.01820.x; Zhang JG, 2001, INT J GERIATR PSYCH, V16, P438, DOI 10.1002/gps.330; Zhang QX, 1997, J SURG RES, V67, P147, DOI 10.1006/jsre.1996.4983	205	81	82	0	6	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877	1875-8908		J ALZHEIMERS DIS	J. Alzheimers Dis.		2002	4	6					497	512		10.3233/jad-2002-4606			16	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	V24ZH	WOS:000208447800006	12515901				2022-02-06	
J	Siessegger, M; Mischkowski, RA; Schneider, BT; Krug, B; Klesper, B; Zoller, JE				Siessegger, M; Mischkowski, RA; Schneider, BT; Krug, B; Klesper, B; Zoller, JE			Image guided surgical navigation for removal of foreign bodies in the head and neck	JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY			English	Article							INTRAOPERATIVE NAVIGATION; GUNSHOT WOUNDS; BODY	Introduction: The removal of foreign bodies in the head and neck area is often a surgical challenge due to a combination of difficult access and a close anatomical relationship of the foreign body to vital structures. Recent developments in computer-assisted surgery (CAS) have brought major improvements to the operating rooms for maxillofacial surgeons. The purpose of this paper is to report our experience in computer assisted removal of foreign bodies from the head and neck area, based on various clinical cases. Patients: Computer assisted removal of foreign bodies from the head and neck area was performed in 11 patients. Three patients sustained gun shot wounds with remaining projectiles or fragments in the soft tissue. In six cases, objects related to a preceding surgical intervention were removed. Two patients presented with dislocated teeth in the facial or cervical soft tissues after 3rd molar surgery. Method: For surgical planning and intra-operative navigation, a computer based image guided surgery system (VectorVision(2(R)), BrainLab) was used. Results: In 10 of 11 cases the foreign bodies could be removed without major complications by a minimal invasive manner. More than 40 % of surgery time could be saved compared to similar interventions operated upon using conventional methods. Conclusion: In our opinion, the use of a computer based image guided surgical system is of great benefit when removing foreign bodies from the head and neck area. The minimally invasive access helps to prevent major complications such as injury to vital structures and allows a quicker operation. (C) 2001 European Association for Cranio-Maxillofacial Surgery.	Univ Cologne, Dept Maxillofacial Surg, D-50937 Cologne, Germany; Univ Cologne, Dept Radiol, D-50937 Cologne, Germany		Siessegger, M (corresponding author), Univ Cologne, Dept Maxillofacial Surg, Kerpener Str 62, D-50937 Cologne, Germany.		Krug, Kathrin Barbara/ABA-5087-2020				Amirjamshidi A, 1997, SURG NEUROL, V47, P331, DOI 10.1016/S0090-3019(96)00357-6; Balbani APS, 1998, INT J PEDIATR OTORHI, V46, P37, DOI 10.1016/S0165-5876(98)00118-9; Coales UF, 1999, J LARYNGOL OTOL, V113, P683, DOI 10.1017/S0022215100144858; Enislidis G, 1997, BRIT J ORAL MAX SURG, V35, P271, DOI 10.1016/S0266-4356(97)90046-2; Gonul E, 1999, MINIM INVAS NEUROSUR, V42, P207, DOI 10.1055/s-2008-1053401; Gumprecht HK, 1999, NEUROSURGERY, V44, P97, DOI 10.1097/00006123-199901000-00056; HASSFELD S, 1995, INT J ORAL MAX SURG, V24, P111; Hyckel P, 1999, Mund Kiefer Gesichtschir, V3, P102, DOI 10.1007/s100060050106; Potapov AA, 1996, J CRANIOFAC SURG, V7, P224, DOI 10.1097/00001665-199605000-00011; Reiss M, 1998, SCHWEIZ RUNDSCH MED, V87, P832; Wenzel M., 1994, Ophthalmologe, V91, P31; Winkler D, 2000, INT CONGR SER, V1214, P161; Yetiser S, 1998, MIL MED, V163, P346, DOI 10.1093/milmed/163.5.346	13	81	86	0	1	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1010-5182			J CRANIO MAXILL SURG	J. Cranio-MaxilloFac. Surg.	DEC	2001	29	6					321	325		10.1054/jcms.2001.0254			5	Dentistry, Oral Surgery & Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Dentistry, Oral Surgery & Medicine; Surgery	516CW	WOS:000173535100001	11777348				2022-02-06	
J	Sarrafzadeh, AS; Peltonen, EE; Kaisers, U; Kuchler, I; Lanksch, WR; Unterberg, AW				Sarrafzadeh, AS; Peltonen, EE; Kaisers, U; Kuchler, I; Lanksch, WR; Unterberg, AW			Secondary insults in severe head injury - Do multiply injured patients do worse?	CRITICAL CARE MEDICINE			English	Article						cerebral hypoxia; head injury; multiple injuries; polytrauma; outcome; secondary insults	BRAIN-TISSUE PO2; CEREBRAL OXYGENATION; TRAUMA; SATURATION; MANAGEMENT; FRACTURE	Objectives: To study the occurrence of secondary insults and the influence of extracranial injuries on cerebral oxygenation and outcome in patients with closed severe head injury (Glasgow Coma Scale score less than or equal to8). Design: Two-year prospective, clinical study. Setting: Two intensive care units in a level III trauma center. Patients: We studied 119 patients. Eighty patients had severe head injury and were divided into two categories: "isolated" severe head injury patients (n = 36, Injury Severity Score < 30), and severe head injury patients with associated extracranial injuries (n = 44, injury Severity Score > 29). Thirty-nine patients with extracranial injuries and no head injury served as the control group. Interventions: After patients were admitted to the intensive care unit, we began continuous multimodal cerebral monitoring of intracranial pressure, mean arterial blood pressure, cerebral perfusion pressure, end-tidal Co-2, brain tissue Po-2 (Licox), jugular bulb oxyhemoglobin saturation in severe head injury patients, and mean arterial blood pressure in the control group. Targets of management included intracranial pressure < 20 mm Hg, cerebral perfusion pressure > 60 mm Hg, Paco(2) > 30 mm Hg, control of cerebral oxygenation, and delayed surgery for non-life-threatening extracranial lesions. Measurements and Main Results: Data were analyzed for critical thresholds. The occurrence of secondary insults (intracranial pressure > 20 mm Hg, mean arterial blood pressure < 70 mm Hg, cerebral perfusion pressure < 60 mm Hg, end-tidal Co-2 <30 torr, brain tissue Po-2 <less than>10 torr, jugular bulb oxyhemoglobin saturation < 50%) was comparable in patients with isolated severe head injury and those with severe head injury with associated extracranial lesions (Abbreviated Injury Scale score less than or equal to5). The duration of intracranial hypertension and arterial hypotension significantly correlated with an unfavorable outcome, independent of the Injury Severity Score. In patients with severe head injury, 1-yr outcome was 29% dead or vegetative, 17% severely disabled, and 54% moderate or good outcome. This was similar to patients with severe head injury and extracranial injuries (31% dead or vegetative, 14% severely disabled, and 56% moderate or goad outcome) and was independent of the Injury Severity Score. Patients with no head injury had less secondary insults (mean arterial blood pressure < 70 mm Hg, p < .01) and a better outcome compared with both severe head injury groups (P < .044). Conclusions: In patients with severe head injury who have targeted management including intracranial pressure- and cerebral perfusion pressure-guided therapy and delayed surgery for extracranial lesions, the occurrence of secondary insults in the intensive care unit and long-term neurological outcome were comparable and independent of the presence of extracranial lesions (Abbreviated Injury Severity level less than or equal to5). A severe head injury is still a major contributor predicting an unfavorable outcome in multiply injured patients.	Humboldt Univ, Dept Neurosurg, D-13353 Berlin, Germany; Humboldt Univ, Dept Anesthesiol & Intens Care Med, D-13353 Berlin, Germany; Humboldt Univ, Inst Biometr, Fac Med, D-13353 Berlin, Germany		Sarrafzadeh, AS (corresponding author), Humboldt Univ, Dept Neurosurg, Charite CampusVirchow Med Ctr,Augustenburger Pl 1, D-13353 Berlin, Germany.	asita.sarrafzadeh@charite.de					*ABBR INJ SCAL, 1990, REV PLAIN; ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bardt TF, 1998, ACT NEUR S, V71, P153; Bardt TF, 1998, ACTA NEUROCHIR, V140, P357, DOI 10.1007/s007010050109; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Bullock MR, 1996, J NEUROTRAUM, V13, P647; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; DEARDEN NM, 1993, ACTA NEUROCHIR, P91; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GLENN JN, 1973, J TRAUMA, V13, P958, DOI 10.1097/00005373-197311000-00004; GOBIET W, 1995, ZBL CHIR, V120, P544; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Jaicks RR, 1997, J TRAUMA, V42, P1, DOI 10.1097/00005373-199701000-00001; JENNETT B, 1975, LANCET, V1, P480; Jennett B., 1991, NIMODIPINE PHARM CLI, P225; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McKee MD, 1997, J TRAUMA, V42, P1041, DOI 10.1097/00005373-199706000-00009; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; ROBERTSON C, 1993, ACTA NEUROCHIR, P98; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; TEASDALE G, 1974, LANCET, V2, P81; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; Unterberg AW, 1997, J TRAUMA, V42, pS32, DOI 10.1097/00005373-199705001-00006; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; WELKERLING H, 1991, ZBL CHIR, V116, P1263	32	81	87	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUN	2001	29	6					1116	1123		10.1097/00003246-200106000-00004			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	442BY	WOS:000169266400003	11395585				2022-02-06	
J	Adamchik, Y; Frantseva, MV; Weisspapir, M; Carlen, PL; Velazquez, JLP				Adamchik, Y; Frantseva, MV; Weisspapir, M; Carlen, PL; Velazquez, JLP			Methods to induce primary and secondary traumatic damage in organotypic hippocampal slice cultures	BRAIN RESEARCH PROTOCOLS			English	Article						trauma; organotypic hippocampal culture; hypothermia; cell death; propidium iodide		Organotypic brain slice cultures have been used in a variety of studies on neurodegenerative processes [K.M. Abdel-Hamid, M. Tymianski, Mechanisms and effects of intracellular calcium buffering on neuronal survival in organotypic hippocampal cultures exposed to anoxia/aglycemia or to excitotoxins, J. Neurosci. 17, 1997, pp. 3538-3553; D.W. Newell, A. Earth, V. Papermaster, A.T. Malouf, Glutamate and non-glutamate receptor mediated toxicity caused by oxygen and glucose deprivation in organotypic hippocampal cultures, J. Neurosci. 15, 1995, pp. 7702-7711; J.L. Perez Velazquez, M.V. Frantseva, P.L. Carlen, In vitro ischemia promotes glutamate mediated free radical generation and intracellular calcium accumulation in pyramidal neurons of cultured hippocampal:slices, J. Neurosci. 23, 1997, pp. 9085-9094; L. Stoppini, L.A. Buchs, D. Muller, A simple method for organotypic cultures of nervous tissue, J. Neurosci. Methods 37, 1991, pp. 173-182, R.C. Tasker, J.T. Coyle, J.J. Vornov, The regional vulnerability to hypoglycemia induced neurotoxicity in organotypic hippocampal culture: protection by early tetrodotoxin or delayed MK 801, J. Neurosci. 12, 1992, pp. 4298-4308.]. We describe two methods to induce traumatic cell damage in hippocampal organotypic cultures. Primary trauma injury was achieved by rolling a stainless steel cylinder (0.9 g) on the organotypic slices. Secondary injury was followed after dropping a weight (0.137 g) on a localised area of the organotypic slice, from a height of 2 mm. The time course and extent of cell death were determined by measuring the fluorescence of the viability indicator propidium iodide (PI) at several time points after the injury. The initial localised impact damage spread 24 and 67 h after injury, cell death being 25% and 54%, respectively, when slices were kept at 37 degrees C. To validate these methods as models to assess neuroprotective strategies, similar insults were applied to slices at relatively low temperatures (30 degrees C), which is known to be neuroprotective [F.C. Barone, G.Z. Feuerstein, R.F. White, Brain cooling during transient focal ischaemia provides complete neuroprotection, Neurosci. Biobehav. Rev. 1, 1997, pp. 31-44; V.M. Bruno, M.P. Goldberg, L.L. Dugan, R.G. Giffard, D.W. Choi, Neuroprotective effect of hypothermia in cortical cultures exposed to oxygen glucose deprivation or excitatory aminoacids, J. Neurochem. 4, 1994, pp. 387-392; G.C. Newman, H. Qi, F.E. Hospod, K. Grundhmann, Preservation of hippocampal brain slices with in vivo or in vitro hypothermia, Brain Res. 1, 1992, pp. 159-163; J.Y. Yager, J. Asseline, Effect of mild hypothermia on cerebral energy metabolism during the evolution of hypoxic ischaemic brain damage in the immature rat, Stroke, 5, 1996, pp. 919-925.]. Low temperature incubation significantly reduced cell death, now being 9% at 24 h and 14% at 67 h. Our results show that these models of moderate mechanical trauma using organotypic slice cultures can be used to study neurodegeneration and neuroprotective strategies. (C) 2000 Elsevier Science B.V. All rights reserved.	Univ Toronto, Toronto Western Hosp, Playfair Neurosci Unit, Dept Med Neurol, Toronto, ON M5T 2S8, Canada		Velazquez, JLP (corresponding author), Univ Toronto, Toronto Western Hosp, Playfair Neurosci Unit, Dept Med Neurol, McL 12-413,399 Bathurst St, Toronto, ON M5T 2S8, Canada.			Carlen, Peter/0000-0002-3339-8102			AbdelHamid KM, 1997, J NEUROSCI, V17, P3538; Barone FC, 1997, NEUROSCI BIOBEHAV R, V21, P31, DOI 10.1016/0149-7634(95)00080-1; BRUNO VM, 1994, J NEUROCHEM, V4, P387; Frantseva MV, 1999, J NEUROSCI METH, V89, P25, DOI 10.1016/S0165-0270(99)00030-8; JENNETT B, 1980, TRENDS NEUROSCI, V3, P1; NEWELL DW, 1995, J NEUROSCI, V15, P7702; NEWMAN GC, 1992, BRAIN RES, V575, P159, DOI 10.1016/0006-8993(92)90438-F; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; TASKER RC, 1992, J NEUROSCI, V12, P4298; Velazquez JLP, 1997, J NEUROSCI, V17, P9085; VORNOV JJ, 1991, EXP NEUROL, V114, P112; Yager JY, 1996, STROKE, V27, P919, DOI 10.1161/01.STR.27.5.919	12	81	86	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1385-299X			BRAIN RES PROTOC	Brain Res. Protoc.	APR	2000	5	2					153	158		10.1016/S1385-299X(00)00007-6			6	Biochemical Research Methods; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	311VV	WOS:000086907300006	10775835				2022-02-06	
J	McCracken, E; Hunter, AJ; Patel, S; Graham, DI; Dewar, D				McCracken, E; Hunter, AJ; Patel, S; Graham, DI; Dewar, D			Calpain activation and cytoskeletal protein breakdown in the corpus callosum of head-injured patients	JOURNAL OF NEUROTRAUMA			English	Article						axonal damage; human; head injury; calpain; cytoskeleton	AMYLOID PRECURSOR PROTEIN; TRAUMATIC BRAIN INJURY; DIFFUSE AXONAL INJURY; FOCAL CEREBRAL-ISCHEMIA; RAT-BRAIN; NEUROFILAMENT SUBUNITS; WHITE-MATTER; BETA-APP; CALCIUM; DAMAGE	Calpain-mediated breakdown of the cytoskeleton has been proposed to contribute to brain damage resulting from head injury, We examined the corpus callosum from patients who died after a blunt head injury in order to determine if there was evidence of these pathophysiological events in a midline myelinated commissure that is susceptible to damage after human head injury. Western blotting revealed marked reductions in the levels of neurofilament triplet proteins 200 and 68kDa in the corpus callosum of head-injured patients compared with control subjects, Neurofilament 200kDa levels were significantly reduced as detected by either phosphorylation-dependent or -independent antibodies, In contrast, there were minimal changes in the levels of beta-tubulin or the microtubule-associated protein, tau, in the head-injured patients, although amyloid precursor protein immunostaining demonstrated axonal damage in 9 of the 10 patients, The inactive 80kDa and active 76kDa subunits of mu-calpain were present in control subjects and head-injured patients, However, there was a significant increase in the levels of calpain-mediated spectrin breakdown products in head-injured patients compared with the control subjects, The results demonstrate that following human blunt head injury, there is a significant degradation of neurofilament proteins and increased levels of calpain-mediated spectrin breakdown products within the corpus callosum, Therefore, our data support the hypothesis that calpain-mediated breakdown of the cytoskeleton may contribute to axonal damage after head injury.	Univ Glasgow, Wellcome Surg Inst, Glasgow, Lanark, Scotland; Univ Glasgow, Hugh Fraser Labs, Glasgow, Lanark, Scotland; SmithKline Beecham Pharmaceut, Neurosci Res, Harlow CM19 5AD, Essex, England; Univ Glasgow, Dept Neuropathol, Glasgow, Lanark, Scotland		McCracken, E (corresponding author), Univ Glasgow, Wellcome Surg Inst, Garscube Estate, Glasgow, Lanark, Scotland.				Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Bartus RT, 1998, BRAIN RES, V790, P1, DOI 10.1016/S0006-8993(97)01414-5; BARTUS RT, 1995, J CEREBR BLOOD F MET, V15, P969, DOI 10.1038/jcbfm.1995.123; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; DEWAR D, 1995, BRAIN RES, V684, P70, DOI 10.1016/0006-8993(95)00417-O; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FTIZPATRICK MO, 1997, J CEREB BLOOD FLO S1, V17, pS415; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GOLDSTEIN ME, 1987, J NEUROIMMUNOL, V14, P149, DOI 10.1016/0165-5728(87)90049-X; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; GRAHAM DI, 1987, NEUROPATH APPL NEURO, V13, P209, DOI 10.1111/j.1365-2990.1987.tb00184.x; Graham DI, 1996, NEUROPATH APPL NEURO, V22, P505, DOI 10.1111/j.1365-2990.1996.tb01125.x; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Graham DI, 1997, GREENFIELDS NEUROPAT, P197; HAMAKUBO T, 1986, J NEUROSCI, V6, P3103, DOI 10.1523/jneurosci.06-11-03103.1986; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; Jendroska K, 1997, Ann N Y Acad Sci, V826, P401, DOI 10.1111/j.1749-6632.1997.tb48492.x; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI ZH, 1995, BRAIN RES, V697, P112; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; MASLIAH E, 1990, J NEUROSCI, V10, P2113; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; OGHAMI T, 1992, NEUROSCI LETT, V136, P75; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; PANT HC, 1988, BIOCHEM J, V256, P665, DOI 10.1042/bj2560665; PERLMUTTER LS, 1990, J COMP NEUROL, V296, P269, DOI 10.1002/cne.902960207; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SCHLAEPFER WW, 1987, J NEUROPATH EXP NEUR, V46, P117, DOI 10.1097/00005072-198703000-00001; SHAPIRA Y, 1989, Neurological Research, V11, P169; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; SUENAGA T, 1994, ACTA NEUROPATHOL, V87, P450; SZENDREI GI, 1993, J NEUROSCI RES, V34, P243, DOI 10.1002/jnr.490340212; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Yam PS, 1997, BRAIN RES, V760, P150, DOI 10.1016/S0006-8993(97)00290-4; Yam PS, 1998, J NEUROTRAUM, V15, P441, DOI 10.1089/neu.1998.15.441	64	81	83	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	1999	16	9					749	761		10.1089/neu.1999.16.749			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	241EL	WOS:000082869700001	10521135				2022-02-06	
J	Park, NW; Moscovitch, M; Robertson, IH				Park, NW; Moscovitch, M; Robertson, IH			Divided attention impairments after traumatic brain injury	NEUROPSYCHOLOGIA			English	Article						working memory; controlled processes; central executive; traumatic brain injury; component process model; meta-analysis	CLOSED-HEAD-INJURY; ADULT AGE-DIFFERENCES; WORKING-MEMORY; VERBAL FLUENCY; REACTION-TIME; FRONTAL-LOBE; PERFORMANCE; RECOVERY; DEFICITS; DYSFUNCTION	This research investigated whether people with severe traumatic brain injury (TBI) are impaired on divided attention tasks requiring working memory. In experiment 1, a severe TBI and control group performed two tasks requiring working memory separately and concurrently. Results showed that the TBI group had impaired divided attention when performing the two tasks concurrently, although the two groups did not differ in performance when these tasks were performed separately. Experiment 2 showed that performance on the paced auditory serial addition task improved with increases in the intertrial interval for both TBI and control groups. A meta-analysis showed that TBIs are impaired on divided attention when the tasks require controlled processing, but not when the tasks can be carried out relatively automatically. (C) 1999 Elsevier Science Ltd. All rights reserved.	Baycrest Ctr Geriatr Care, Dept Psychol, Toronto, ON M6A 2E1, Canada; Baycrest Ctr Geriatr Care, Kunin Lunenfeld Appl Res Unit, Toronto, ON M6A 2E1, Canada; Univ Toronto, Erindale Coll, Dept Psychol, Rotman Res Inst, Toronto, ON M5S 1A1, Canada; MRC, Cognit & Brain Sci Unit, Cambridge, England; Baycrest Ctr Geriatr Care, Rotman Res Unit, Toronto, ON M6A 2E1, Canada		Park, NW (corresponding author), Baycrest Ctr Geriatr Care, Dept Psychol, 3560 Bathurst St,Suite 4W-02, Toronto, ON M6A 2E1, Canada.	npark@credit.erin.utoronto.ca		Robertson, Ian H/0000-0001-8637-561X			BADDELEY A, 1992, SCIENCE, V255, P556, DOI 10.1126/science.1736359; Baddeley A.D., 1974, RECENT ADV LEARNING, V8; Baddeley A.D., 1986, WORKING MEMORY; Baddeley A.D., 1997, HUMAN MEMORY THEORY; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; BROOKS DN, 1987, NEUROBEHAVIORAL RECO, P57; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; Craik F.I.M., 1992, HDB AGING COGNITION, P51; Craik FI., 1986, HUMAN MEMORY COGNITI, V5, P409; Craik FIM, 1996, J EXP PSYCHOL GEN, V125, P159, DOI 10.1037/0096-3445.125.2.159; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; DOBBS AR, 1989, PSYCHOL AGING, V4, P500, DOI 10.1037/0882-7974.4.4.500; Gentilini M., 1989, MILD HEAD INJURY; GOLDSTEIN FC, 1990, J CLIN EXP NEUROPSYC, V12, P286, DOI 10.1080/01688639008400975; Gronwall D, 1974, PSYCHOL EFFECTS CONC; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HEDGES LV, 1982, PSYCHOL BULL, V92, P490, DOI 10.1037/0033-2909.92.2.490; Hedges LV., 1981, J EDUC STAT, V6, P107, DOI [10.3102/10769986006002107, DOI 10.2307/1164588]; HYDE TS, 1969, J EXP PSYCHOL, V82, P472, DOI 10.1037/h0028372; JACOBY LL, 1991, J MEM LANG, V30, P513, DOI 10.1016/0749-596X(91)90025-F; JACOBY LL, 1993, J EXP PSYCHOL GEN, V122, P139, DOI 10.1037/0096-3445.122.2.139; KRAUS JF, 1989, MILD HEAD INJURY; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; LOESS H, 1967, J VERB LEARN VERB BE, V6, P455, DOI 10.1016/S0022-5371(67)80001-X; LORSBACH TC, 1990, AM J PSYCHOL, V103, P21, DOI 10.2307/1423257; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MCKINLAY WW, 1983, J NEUROL NEUROSUR PS, V46, P1084, DOI 10.1136/jnnp.46.12.1084; MELAMED S, 1985, SCAND J REHABIL MED, P16; Miller E, 1970, Cortex, V6, P121; Milner B., 1964, FRONTAL GRANULAR COR, P313; MOSCOVITCH M, 1992, J COGNITIVE NEUROSCI, V4, P257, DOI 10.1162/jocn.1992.4.3.257; Moscovitch M., 1994, NEUROPSYCHOLOGY, V8, P524; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Ponsford JL, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; SchmitterEdgecombe M, 1996, NEUROPSYCHOLOGY, V10, P155; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Stuss DT, 1988, CLIN NEUROPSYCHOL, V2, P246, DOI [DOI 10.1080/13854048808520107, 10.1080/13854048808520107]; TOTH JP, 1996, APA S COGN NEUR APPL; Troyer AK, 1997, NEUROPSYCHOLOGY, V11, P138, DOI 10.1037/0894-4105.11.1.138; Troyer AK, 1998, NEUROPSYCHOLOGIA, V36, P499, DOI 10.1016/S0028-3932(97)00152-8; Tulving E., 1972, ORG MEMORY, P381; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; Winocur G., 1992, HDB AGING COGNITION, P315; [No title captured]	56	81	82	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	SEP	1999	37	10					1119	1133		10.1016/S0028-3932(99)00034-2			15	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	235BG	WOS:000082518400003	10509834				2022-02-06	
J	Wojtys, EM; Hovda, D; Landry, G; Boland, A; Lovell, M; McCrea, M; Minkoff, J				Wojtys, EM; Hovda, D; Landry, G; Boland, A; Lovell, M; McCrea, M; Minkoff, J			Concussion in sports	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article							CEREBRAL BLOOD-FLOW; TRAUMATIC BRAIN INJURY; HEAD-INJURY; STANDARDIZED ASSESSMENT; GLUCOSE-UTILIZATION; CONTACT-SPORTS; 2ND IMPACT; RAT-BRAIN; GUIDELINES; CALCIUM		AOSSM Concuss Workshop Grp, Rosemont, IL USA		Wojtys, EM (corresponding author), Univ Michigan, POB 363, Ann Arbor, MI 48106 USA.						ACKERMANN RF, 1989, J CEREBR BLOOD F MET, V9, P774, DOI 10.1038/jcbfm.1989.111; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Barth JT, 1989, MILD HEAD INJURY, P257; BENTON A, 1978, MNULTILINGUAL APHASI; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Brandt J, 1991, CLIN NEUROPSYCHOL, V5, P125, DOI [10.1080/13854049108403297, DOI 10.1080/13854049108403297]; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P172; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; *COL MED SOC, 1991, GUID MAN CONC SPORTS; COSGROVE JW, 1987, EXP GERONTOL, V22, P187, DOI 10.1016/0531-5565(87)90039-8; Doberstein C., 1992, Society for Neuroscience Abstracts, V18, P175; DOBERSTEIN CE, 1993, ANN EMERG MED, V22, P993, DOI 10.1016/S0196-0644(05)82740-4; EVANS RW, 1994, SEMIN NEUROL, V14, P32, DOI 10.1055/s-2008-1041056; FALLGREN B, 1993, J AUTONOM NERV SYST, V44, P151, DOI 10.1016/0165-1838(93)90027-R; FICK DS, 1995, POSTGRAD MED, V97, P53, DOI 10.1080/00325481.1995.11945958; Golden CJ, 1978, STROOP COLOR WORD TE; GOLIGORSKY MS, 1995, AM J PHYSIOL-RENAL, V268, pF251, DOI 10.1152/ajprenal.1995.268.2.F251; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; HARDER DR, 1987, CIRC RES, V60, P102, DOI 10.1161/01.RES.60.1.102; HOVDA DA, 1992, ROLE OF NEUROTRANSMITTERS IN BRAIN INJURY, P327; HOVDA DA, 1990, ACT NEUR S, V51, P331; HOVDA DA, 1995, J NEUROSURG A, V376; HOVDA DA, 1993, INTRACRANIAL PRESSUR, V8, P469; HOVDA DA, 1995, NEUROTRAUMA, P1459; JACEWICZ M, 1990, J CEREBR BLOOD F MET, V10, P903, DOI 10.1038/jcbfm.1990.147; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENKINS LW, 1996, MECH SECONDARY BRAIN, P273; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KELLY J, 1995, CURRENT THERAPY SPOR; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; KLOVE H, 1974, CLIN NEUROPSYCHOLOGY; LANDRY G, 1994, P MILD BRAIN INJ SUM; LEBLANC KE, 1994, AM FAM PHYSICIAN, V50, P801; LEE SM, 1995, J CEREB BLOOD FLOW M, V15, P722; LIFSHITZ J, 1995, J NEUROTRAUM, V12, P129; LO EH, 1991, NEUROSCI LETT, V131, P17, DOI 10.1016/0304-3940(91)90327-P; LO EH, 1991, J CEREBR BLOOD F MET, V11, P803, DOI 10.1038/jcbfm.1991.138; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; MCCREA M, 1997, MANUAL ADM SCORING I; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; MCQUILLEN JB, 1988, AM J FOREN MED PATH, V9, P12, DOI 10.1097/00000433-198803000-00004; MUIZELAAR JP, 1989, TXB HEAD INJURY, P221; Parkinson D, 1996, SURG NEUROL, V45, P459, DOI 10.1016/0090-3019(95)00210-3; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; ROSEN P, 1998, EMERGENCY MED; SAKURADA O, 1978, AM J PHYSIOL, V234, pH59, DOI 10.1152/ajpheart.1978.234.1.H59; SALMAN E, 1995, J NEUROTRAUM, V12, P141; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Smith A., 1982, SYMBOL DIGIT MODALIT; STEINBERG GK, 1991, NEUROSCI LETT, V133, P225, DOI 10.1016/0304-3940(91)90575-E; SUTTON RL, 1994, ACTA NEUROCHIR, P446; TABRIZCHI R, 1994, ARCH INT PHARMACOD T, V328, P26; TAKENAKA T, 1993, CIRC RES, V73, P743, DOI 10.1161/01.RES.73.4.743; WALKER AE, 1994, J NEUROSURG, V81, P493, DOI 10.3171/jns.1994.81.3.0493; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D., 1997, WECHSLER MEMORY SCAL, VIII; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YAMAKAMI I, 1990, J NEUROTRAUM, V7, P101; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	73	81	82	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	SEP-OCT	1999	27	5					676	687		10.1177/03635465990270052401			12	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	236ML	WOS:000082603300023	10496590				2022-02-06	
J	Nakaguchi, H; Fujimaki, T; Ueki, K; Takahashi, M; Yoshida, H; Kirino, T				Nakaguchi, H; Fujimaki, T; Ueki, K; Takahashi, M; Yoshida, H; Kirino, T			Snowboard head injury: Prospective study in Chino, Nagano, for two seasons from 1995 to 1997	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						head injury; snowboard; ski; occipital impact		Background: The popularity of snowboarding has been growing rapidly throughout the world. To date, however, the risk of head injury associated with this relatively new winter sport, especially in comparison with alpine skiing, has not been well analyzed, This study was conducted to assess the risk of head injury in snowboarding and to elucidate its features in comparison with skiing head injury. Methods: We prospectively analyzed 301 cases of head injuries related to snowboarding or skiing experienced from December of 1995 to May of 1997 at our institution, which is located close to the most popular skiing areas in Japan. Of those injuries, 143 cases were snowboard related and 158 cases were ski related. In addition to appropriate medical evaluation and medical care, detailed examination was performed on every patient to determine various factors, including ses, age, skill level, cause and mechanism of the accident, and the side of impact to the head. The data are statistically analyzed to elucidate unique features of snowboard head injury. Results: During the study period, 2.2 million snowboarders and 4.2 million skiers visited the five skiing facilities that are covered hg our hospital. Thus, the incidence of head injury was 6.5 per 100,000, visits for snowboarders and 3.8 per 100,000 visits for skiers. Beginning snowboarders more frequently sustained head injuries compared with beginning skiers (60 of 142 vs. 48 of 154, p = 0.022), Likewise, frequent causes of snowboarding head injuries were fall during jumping (43 of 139 vs. 2 of 147, p < 0.0001), falling backward (67 of 127 vs. 49 of 147, p = 0.001)! and occipital impact (67 of 126 vs, 49 Of 147).,More importantly, there were nine major head injury cases (6.3%) in snowboard head injuries in contrast to only two such cases found in skiing head injuries (1.3%). Of II major head injury cases, 10 were caused by occipital impact. Conclusion: These results indicate that snowboarders sl particularly beginners, are at higher risk for head injury, frequently involving occipital impact, and could lead to more major head injuries. We propose that measures should be taken to protect the head, especially the occiput, in snowboarding.	Tokyo Univ Hosp, Dept Neurosurg, Bunkyo Ku, Tokyo 113, Japan; Suwa Cent Hosp, Dept Neurosurg, Nagano, Japan; Suwa Cent Hosp, Dept Orthoped, Nagano, Japan		Kirino, T (corresponding author), Tokyo Univ Hosp, Dept Neurosurg, Bunkyo Ku, Hongo 7-3-1, Tokyo 113, Japan.						ABU LR, 1991, CMAJ, V145, P1097; Berghold F, 1991, Schweiz Z Sportmed, V39, P13; BIASCA N, 1995, UNFALLCHIRURG, V98, P33; Binet M H, 1994, Schweiz Z Med Traumatol, P21; BLADIN C, 1995, SPORTS MED, V19, P358, DOI 10.2165/00007256-199519050-00005; BLADIN C, 1993, AM J SPORT MED, V21, P701, DOI 10.1177/036354659302100511; BLANKMAN E, 1987, POWDER, V15, P95; CALLE SC, 1995, J PEDIATR SURG, V30, P791, DOI 10.1016/0022-3468(95)90749-1; Chow TK, 1996, J TRAUMA, V41, P321, DOI 10.1097/00005373-199608000-00021; Pigozzi F, 1997, ORTHOPEDICS, V20, P505; PINO EC, 1989, AM J SPORT MED, V17, P778, DOI 10.1177/036354658901700610; PRALL JA, 1995, INJURY, V26, P539, DOI 10.1016/0020-1383(95)00085-N; Sacco DE, 1998, J TRAUMA, V44, P654, DOI 10.1097/00005373-199804000-00016; SUMI Y, 1997, CLIN SPORTS MED, V14, P207; Zollinger H, 1994, Sportverletz Sportschaden, V8, P31, DOI 10.1055/s-2007-993450	15	81	81	1	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	1999	46	6					1066	1069		10.1097/00005373-199906000-00017			4	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	205BR	WOS:000080801900021	10372627				2022-02-06	
J	Kinsella, G; Ong, B; Murtagh, D; Prior, M; Sawyer, M				Kinsella, G; Ong, B; Murtagh, D; Prior, M; Sawyer, M			The role of the family for behavioral outcome in children and adolescents following traumatic brain injury	JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY			English	Article							CLOSED HEAD-INJURY; ACADEMIC-PERFORMANCE; ASSESSMENT DEVICE; PREDICTORS; VALIDITY; SEVERITY; DISTURBANCES; RELIABILITY; CHILDHOOD; SEQUELAE	This study assessed the behavioral outcome of 51 children with traumatic brain injury (TBT) up to 2 years following injury. Children with severe injuries, but not those with mild or moderate injuries, were reported by parents to have a greater incidence of behavior problems following TBI. Regression analyses indicated that the presence of a partner for the primary caregiver of the child and the acute emotional reaction of the parent to the injury were both predictive of child behavioral outcome, although not by 2-year follow-up. These findings suggest that parental coping resources may impact on the development of child behavioral sequelae following TBI, emphasizing the role of the family in the child's response and the importance of supportive intervention.	La Trobe Univ, Sch Psychol Sci, Bundoora, Vic 3083, Australia; Royal Childrens Hosp, Melbourne, Vic, Australia; Adelaide Childrens Hosp Inc, Adelaide, SA 5006, Australia		Kinsella, G (corresponding author), La Trobe Univ, Sch Psychol Sci, Bundoora, Vic 3083, Australia.		Kinsella, Glynda/O-6347-2017; Murtagh, Donal/F-8694-2011	Kinsella, Glynda/0000-0002-5859-0934; Murtagh, Donal/0000-0003-1539-3559			Achenbach T, 1983, MANUAL CHILD BEHAV C; ACHENBACH TM, 1986, MANUAL TEACHER VERSI; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; BARRY P, 1992, Brain Injury, V6, P229, DOI 10.3109/02699059209029664; BASSON MD, 1991, J TRAUMA, V31, P1363, DOI 10.1097/00005373-199110000-00008; BURVENICH C, 1983, VET RES COMMUN, V7, P237, DOI 10.1007/BF02228626; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; CHEUNG P, 1994, SOC PSYCH PSYCH EPID, V29, P95; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; DALBY PR, 1991, DEV NEUROPSYCHOL, V7, P35, DOI 10.1080/87565649109540476; Daniel A., 1983, POWER PRIVILEGE PRES; DONDERS J, 1992, J ABNORM CHILD PSYCH, V20, P233, DOI 10.1007/BF00916690; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Fletcher J M, 1991, Brain Inj, V5, P337, DOI 10.3109/02699059109008106; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1987, NEUROBEHAVIOURAL REC, P270; Goldberg D., 1988, USERS GUIDE GEN HLTH; Goldberg D., 1978, MANUAL GEN HLTH QUES; GOLDSTEIN FC, 1995, HDB MEMORY DISORDERS, P187; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Kabacoff R.I., 1990, J FAM PSYCHOL, V3, P431, DOI [10.1037/h0080547, DOI 10.1037/H0080547]; Kehle TJ, 1996, J LEARN DISABIL, V29, P633, DOI 10.1177/002221949602900607; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Levin HS., 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; MCGUIRE TL, 1986, J HEAD TRAUMA REHAB, V1, P1; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; ODDY M, 1993, NEUROPSYCHOL REHABIL, V3, P301, DOI 10.1080/09602019308401444; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; PRIOER M, 1994, AUST PSYCHOL, V29, P116, DOI 10.1080/00050069408257334; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; ROMANSCLARKSON SE, 1989, AUST NZ J PSYCHIAT, V23, P187, DOI 10.3109/00048678909062135; RUTTER M, 1982, Journal of Clinical Neuropsychology, V4, P91, DOI 10.1080/01688638208401121; SAWYER MG, 1988, J MARITAL FAM THER, V14, P287, DOI 10.1111/j.1752-0606.1988.tb00748.x; TEASDALE G, 1974, LANCET, V2, P81; TOMPKINS CA, 1990, BRAIN COGNITION, V13, P86, DOI 10.1016/0278-2626(90)90042-M; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; [No title captured]	44	81	81	0	12	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0022-006X			J CONSULT CLIN PSYCH	J. Consult. Clin. Psychol.	FEB	1999	67	1					116	123		10.1037/0022-006X.67.1.116			8	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	164GK	WOS:000078454700013	10028215				2022-02-06	
J	Herrmann, M; Curio, N; Jost, S; Wunderlich, MT; Synowitz, H; Wallesch, CW				Herrmann, M; Curio, N; Jost, S; Wunderlich, MT; Synowitz, H; Wallesch, CW			Protein S-100B and neuron specific enolase as early neurobiochemical markers of the severity of traumatic brain injury	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						NSE; protein S-100B; traumatic brain injury; outcome	CALCIUM-BINDING PROTEINS; MINOR HEAD-INJURY; DAMAGE; INFARCTION; FAMILY	The present study aimed at the predictive value of early release patterns of protein S-100B and neuron specific enolase (NSE) in patients with traumatic brain injury. We investigated 69 patients who were admitted to the Department of Neurosurgery following traumatic brain injury. Both NSE and S-100B serum concentrations during the first three days after admission were highly and significantly correlated with Glasgow Coma and Coma Remission Scale scores at the respective blood sampling times as well as 2 weeks later. Signs of intracranial pathology as evaluated by CCT or MRI scans showed no association with NSE or S-100B release patterns. Our data support the hypothesis that NSE and protein S-100B are useful and sensitive neurobiochemical markers for the early clinical outcome of traumatic brain injury.	Otto Von Guericke Univ, Div Neuropsychol & Behav Neurol, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Dept Neurol, Magdeburg, Germany; Otto Von Guericke Univ, Dept Neurosurg, Magdeburg, Germany		Herrmann, M (corresponding author), Otto Von Guericke Univ, Div Neuropsychol & Behav Neurol, Leipziger Str 44, D-39120 Magdeburg, Germany.		Herrmann, Manfred/H-3931-2011	Herrmann, Manfred/0000-0003-1872-8406			Buttner T, 1997, STROKE, V28, P1961, DOI 10.1161/01.STR.28.10.1961; CUNNINGHAM RT, 1991, EUR J CLIN INVEST, V21, P497, DOI 10.1111/j.1365-2362.1991.tb01401.x; DONATO R, 1991, CELL CALCIUM, V12, P713, DOI 10.1016/0143-4160(91)90040-L; FANO G, 1995, PROG NEUROBIOL, V46, P71, DOI 10.1016/0301-0082(94)00062-M; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GRILL M, 1998, PHARMACOPSYCHIATRY, V31, pR18; HATFIELD RH, 1992, BRAIN RES, V577, P249, DOI 10.1016/0006-8993(92)90280-M; Heierhorst J, 1996, NATURE, V380, P636, DOI 10.1038/380636a0; Ilg EC, 1996, INT J CANCER, V68, P325, DOI 10.1002/(SICI)1097-0215(19961104)68:3<325::AID-IJC10>3.3.CO;2-0; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; Johnsson P, 1996, J CARDIOTHOR VASC AN, V10, P120, DOI 10.1016/S1053-0770(96)80187-X; KAHN HJ, 1991, MODERN PATHOL, V4, P698; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; POTTS BC, 1995, NATURE STRUCTURAL BI, V9, P790; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/0968-0004(96)10020-7; SCHONLE PW, 1995, NEUROL REHABIL, V2, P87; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; TEASDALE G, 1974, LANCET, V2, P81; Thatcher RW, 1997, J NEUROTRAUM, V14, P1, DOI 10.1089/neu.1997.14.1; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Westaby S, 1996, ANN THORAC SURG, V61, P88, DOI 10.1016/0003-4975(95)00904-3; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Yang QE, 1996, DEV BRAIN RES, V91, P181, DOI 10.1016/0165-3806(95)00180-8; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	26	81	82	0	2	IOS PRESS	AMSTERDAM	VAN DIEMENSTRAAT 94, 1013 CN AMSTERDAM, NETHERLANDS	0922-6028			RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		1999	14	2-3					109	114					6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	183XN	WOS:000079579700005					2022-02-06	
J	Dietrich, WD; Alonso, O; Busto, R; Prado, R; Zhao, WZ; Dewanjee, MK; Ginsberg, MD				Dietrich, WD; Alonso, O; Busto, R; Prado, R; Zhao, WZ; Dewanjee, MK; Ginsberg, MD			Posttraumatic cerebral ischemia after fluid percussion brain injury: An autoradiographic and histopathological study in rats	NEUROSURGERY			English	Article						cerebral blood flow; histopathology; ischemia; platelets; traumatic brain injury; vasoactive substances	DISSEMINATED INTRAVASCULAR COAGULATION; ACUTE SUBDURAL-HEMATOMA; ACUTE HEAD-INJURY; BLOOD-FLOW; SUBARACHNOID HEMORRHAGE; PLATELET ACCUMULATION; DAMAGE; MODEL; TRAUMA; METABOLISM	OBJECTIVES: Mild-to-moderate reductions in local cerebral blood flow (lCBF) have been reported to occur in rats after moderate (1.7-2.2 atm) fluid percussion brain injury. The purpose of this study was to determine whether evidence for severe ischemia (i.e., mean lCBF < 0.25 ml/g/min) could be demonstrated after severe brain injury. In addition, patterns of indium-labeled platelet accumulation and histopathological outcome were correlated with the hemodynamic alterations. METHODS: Sprague-Dawley rats (n = 23), anesthetized with halothane and maintained on a 70:30 mixture of nitrous oxide:oxygen and 0.5% halothane, underwent normothermic (37 degrees C) parasagittal fluid percussion brain injury (2.4-2.6 atm). Indium-111-tropolone-labeled platelets were injected 30 minutes before traumatic brain injury (TBI), while C-14-iodoantipyrine was infused 30 minutes after trauma for lCBF determination. Sham-operated animals (n = 8) underwent similar surgical procedures but were not injured. For histopathological analysis, traumatized rats (n = 5) were perfusion-fixed 3 days after TBI. RESULTS: In autoradiographic images of indium-labeled platelets, abnormal platelet accumulation that was most pronounced overlying the pial surface was commonly associated with severe reductions in lCBF within underlying cortical regions 30 minutes after TBI. For example, within the lateral parietal cortex, lCBF was significantly reduced from 1.67 +/- 0.11 ml/g per minute (mean +/- standard error of the mean) in sham-operated animals to 0.23 +/- 0.03 ml/g per minute within the traumatized group. In addition to focal severe ischemia, moderate reductions in lCBF were detected throughout the traumatized hemisphere, including the frontal and occipital cortices, hippocampus, thalamus, and striatum. Mild decreases in lCBF were also observed throughout the contralateral cerebral cortex. At 3 days after severe TBI, histopathology demonstrated intracerebral and subarachnoid hemorrhage associated with cerebral contusion and selective neuronal necrosis. CONCLUSION: These data indicate that multiple cerebrovascular abnormalities, including subarachnoid hemorrhage, focal platelet accumulation, and severe ischemia, are important early events in the pathogenesis of cortical contusion formation after TBI. Injury severity is expected to be a critical factor in determining what therapeutic strategies are attempted in the clinical setting.	Univ Miami, Sch Med, Dept Neurol D45, Neurotrauma Dis Res Ctr, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Neurol Surg, Cerebrovasc Dis Res Ctr, Miami, FL 33101 USA		Dietrich, WD (corresponding author), Univ Miami, Sch Med, Dept Neurol D45, Neurotrauma Dis Res Ctr, POB 016960, Miami, FL 33101 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027127, P01NS005820, P50NS030291, P50NS005820] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30291, NS27127, NS05820] Funding Source: Medline		Adams JH, 1982, RECENT ADV NEUROPATH, P165; ASTRUP J, 1977, STROKE, V8, P51, DOI 10.1161/01.STR.8.1.51; BACK T, 1995, J CEREBR BLOOD F MET, V15, P566, DOI 10.1038/jcbfm.1995.70; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOLANDER HG, 1989, STROKE, V20, P930, DOI 10.1161/01.STR.20.7.930; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; Busto R, 1997, J NEUROTRAUM, V14, P35, DOI 10.1089/neu.1997.14.35; CHEN MH, 1991, J NEUROSURG, V74, P944, DOI 10.3171/jns.1991.74.6.0944; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEWANJEE MK, 1983, MAYO CLIN PROC, V58, P307; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DEWITT DS, 1996, NEW HORIZ, V3, P376; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DRAYER BP, 1975, JAMA-J AM MED ASSOC, V231, P174, DOI 10.1001/jama.231.2.174; ELLIS EF, 1977, STROKE, V8, P480, DOI 10.1161/01.STR.8.4.480; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859, DOI 10.1152/ajpheart.1997.272.6.H2859; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HEISS WD, 1983, ANN NEUROL, V14, P294, DOI 10.1002/ana.410140307; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; HUBER A, 1993, INT J LEGAL MED, V106, P152, DOI 10.1007/BF01225238; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; KEIMOWITZ RM, 1973, J NEUROSURG, V39, P178, DOI 10.3171/jns.1973.39.2.0178; Lee KR, 1996, J NEUROSURG, V84, P91, DOI 10.3171/jns.1996.84.1.0091; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; OBRENOVITCH TP, 1985, STROKE, V16, P224, DOI 10.1161/01.STR.16.2.224; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Perri BR, 1997, J NEUROTRAUM, V14, P15, DOI 10.1089/neu.1997.14.15; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; ROBERTSON CS, 1992, J NEUROTRAUM, V9, pS349; SAKURADA O, 1978, AM J PHYSIOL, V234, pH59, DOI 10.1152/ajpheart.1978.234.1.H59; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SOLOMON RA, 1985, STROKE, V16, P58, DOI 10.1161/01.STR.16.1.58; Stagliano NE, 1997, J CEREBR BLOOD F MET, V17, P1182, DOI 10.1097/00004647-199711000-00007; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; THOMPSON JA, 1984, STROKE, V15, P1021, DOI 10.1161/01.STR.15.6.1021; TORNHEIM PA, 1984, J NEUROSURG, V60, P473, DOI 10.3171/jns.1984.60.3.0473; TORNHEIM PA, 1981, J NEUROSURG, V55, P407, DOI 10.3171/jns.1981.55.3.0407; TYSON GW, 1984, ANN NEUROL, V15, P559, DOI 10.1002/ana.410150608; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YANG GY, 1994, J NEUROSURG, V81, P93, DOI 10.3171/jns.1994.81.1.0093; Young W, 1988, J Neurotrauma, V5, P219, DOI 10.1089/neu.1988.5.219; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; ZILLES K, 1985, CORTES RAT STEREOTAX; Zuccarello M, 1996, J NEUROSURG, V84, P503, DOI 10.3171/jns.1996.84.3.0503	67	81	82	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	SEP	1998	43	3					585	593		10.1097/00006123-199809000-00105			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	114NC	WOS:000075614700094	9733314				2022-02-06	
J	Durkin, MS; Olsen, S; Barlow, B; Virella, A; Connolly, ES				Durkin, MS; Olsen, S; Barlow, B; Virella, A; Connolly, ES			The epidemiology of urban pediatric neurological trauma: Evaluation of, and implications for, injury prevention programs	NEUROSURGERY			English	Article						epidemiology; infant; neurological; pediatric; trauma	HEAD-INJURY; UNITED-STATES; BRAIN INJURY; POPULATION; NEIGHBORHOODS; COMMUNITY; TRENDS; COUNTY	OBJECTIVE: To describe the incidence and causes of pediatric]lead, spinal cord, and peripheral nerve injuries in an urban setting and to assess the implications of these data for injury prevention programs. METHODS: Pediatric deaths and hospital admissions secondary to neurological trauma included in the Northern Manhattan Injury Surveillance System from 1983 to 1932 were linked to census counts to compute incidence rates. Rates before the implementation of a nonspecific injury prevention program were compared with rates after the implementation, and rates for die target population were compared to rates for the control population, Rates were analyzed on the basis of the cause of injury as well as the age, gender, and neighborhood income level of the injured, RESULTS: The incidence of neurological injuries resulting in hospitalization or death was 155 incidents per 100,000 population per year; the mortality rate was 6 people per 100,000 population per year. Neurological injuries represented 18% of all pediatric injuries and accounted for 23% of all traumatic deaths. Spinal cord and peripheral nerve injuries were relatively rare (5%) compared to head injuries (95%). Minor head injuries, including isolated cranial fractures, minor concussions (<7 h loss of consciousness), and unspecified minor head injuries, accounted for the majority of neurological injuries (76%), whereas severe head injuries, including severe concussion (>1 h loss of consciousness), cerebral laceration/contusion, intracerebral hemorrhage, and unspecified major injuries, were less common (18% of all neurological injuries). Boys were move often affected than girls at every age, and this preference increased with age. Children younger than 1 year showed the highest incidence of both major and minor injuries, One- to 4-year olds showed the lowest rates, with steady increases thereafter. Traffic accidents and falls were the leading causes (38 and 34%, respectively), and assaults were the next leading causes (12%). Among children admitted to surveillance system hospitals, falls were most common in children younger than 4 years, pedestrian motor vehicle accidents were most common in late childhood, and assaults were most common in early adolescence. Case:fatality rates were 5 to 7% for all age groups except 5- to 12-year-olds, for whom the case:fatality rate was 1.9%. Residence in a low-income neighborhood was associated with an increased risk of injury (rate ratio, 1.71; confidence interval, 95%, 1.54, 1.89). The average hospitalization cost per injury was $8502. Medicaid (54%) and other government sources (5%) covered the majority of expenses, including indirect reimbursement of usually uncollected self-pay billing (19%). Although injury incidence rates fell in both the control and intervention cohorts during implementation of a nonspecific injury prevention program, targeted age and population groups demonstrated greater relative reductions in injuries than nontargeted ones, suggesting a positive effect. CONCLUSIONS: Deaths and hospital admissions secondary to pediatric neurological trauma represent a significant public health problem, with the majority of the direct cost being born by government agencies. Future efforts to prevent neurological trauma in children who live in inner cities should focus on families with low incomes and provide novel education programs regarding infant abuse, infant neglect, and infant injury avoidance. Age-appropriate school-based programs should also be developed to address traffic safety and conflict resolution.	Columbia Univ Coll Phys & Surg, Harlem Hosp Ctr, Div Pediat & Pediat Surg, New York, NY 10032 USA; Columbia Univ, Sch Publ Hlth, New York State Psychiat Inst, Gertrude H Sergievsky Ctr,Fac Med,Div Epidemiol, New York, NY USA; Columbia Univ, Sch Publ Hlth, New York State Psychiat Inst, Gertrude H Sergievsky Ctr,Fac Med,Dept Neurosurg, New York, NY USA; Columbia Univ, Sch Publ Hlth, New York State Psychiat Inst, Gertrude H Sergievsky Ctr,Fac Med,Dept Pediat, New York, NY USA		Connolly, ES (corresponding author), Columbia Univ Coll Phys & Surg, Dept Neurol Surg, Neurol Inst, Room 204,710 W 168th St, New York, NY 10032 USA.		Durkin, Maureen/B-7834-2015		PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR 202585, R48/CCR 205055] Funding Source: Medline		ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; CHIU WT, 1993, J TRAUMA, V35, P206, DOI 10.1097/00005373-199308000-00006; COOPER K D, 1983, Neuroepidemiology, V2, P70, DOI 10.1159/000110512; DAVIDSON LL, 1994, AM J PUBLIC HEALTH, V84, P580, DOI 10.2105/AJPH.84.4.580; DURKIN MS, 1994, AM J PUBLIC HEALTH, V84, P587, DOI 10.2105/AJPH.84.4.587; EDNA TH, 1984, SCAND J SOC MED, V12, P7, DOI 10.1177/140349488401200103; FIFE D, 1986, AM J PUBLIC HEALTH, V76, P773, DOI 10.2105/AJPH.76.7.773; Fleiss J.L., 1981, STAT METHODS RATES P; HARRISON CL, 1991, PARAPLEGIA, V29, P233, DOI 10.1038/sc.1991.34; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; Kempe A, 1997, PEDIATRICS, V99, P338, DOI 10.1542/peds.99.3.338; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KRAUS JF, 1987, PEDIATRICS, V79, P501; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LEE LH, 1992, CHIN MED J TAPIEI, V50, P219; LEVI L, 1990, NEUROEPIDEMIOLOGY, V9, P278, DOI 10.1159/000110784; LEVY ML, 1993, NEUROSURGERY, V33, P1018; NESTVOLD K, 1988, NEUROEPIDEMIOLOGY, V7, P134, DOI 10.1159/000110147; PARKINSON D, 1985, CAN J SURG, V28, P79; Servadei F, 1985, J Neurosurg Sci, V29, P297; Singh GK, 1996, AM J PUBLIC HEALTH, V86, P505, DOI 10.2105/AJPH.86.4.505; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; *US DEP COMM, 1981, 1980 CENS; *US DEP COMM, 1992, 1990 CENS; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; WOLTER KM, 1991, SCIENCE, V253, P12, DOI 10.1126/science.253.5015.12; Wong Pauline P., 1993, Brain Injury, V7, P283, DOI 10.3109/02699059309034955; WOODWARD A, 1984, MED J AUSTRALIA, V141, P13, DOI 10.5694/j.1326-5377.1984.tb132660.x	30	81	84	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0148-396X			NEUROSURGERY	Neurosurgery	FEB	1998	42	2					300	310		10.1097/00006123-199802000-00052			11	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	YV348	WOS:000071814200019	9482180				2022-02-06	
J	Sander, AM; High, WM; Hannay, HJ; Sherer, M				Sander, AM; High, WM; Hannay, HJ; Sherer, M			Predictors of psychological health in caregivers of patients with closed head injury	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; DISABILITY RATING-SCALE; ALZHEIMERS PATIENTS; COPING STRATEGIES; RELATIVES VIEW; SOCIAL SUPPORT; FAMILY; BURDEN; STRESS; RECOVERY	The purpose of the current study was to investigate the contribution of coping strategies, subjective burden, and social support to psychological health in caregivers. The sample included 69 primary caregivers of patients with severe closed head injuries. There were three groups of caregivers: acute (0-6 months post-injury); intermediate (6 months-1.5 years); and long-term (> 1.5 years). All had participated in rehabilitation. Caregivers completed an interview and series of questionnaires, including the Ways of Coping Questionnaire, Social Support Questionnaire, Subjective Burden Measure, and General Health Questionnaire. The Disability Rating Scale was completed by staff to assess patients' level of functioning at the time of caregivers' assessment. ANOVA revealed no between-group differences in coping style or social support. Multiple regression revealed that greater use of emotion-focused coping was associated with greater emotional distress. Coping style contributed to a greater proportion of the variance in caregivers' psychological health than did patients' level of functioning. Increased satisfaction with social support was associated with less emotional distress. The full model, including group, caregiver gender, emotion-focused coping, social support, patient level of recovery, burden, and the burden x coping interaction accounted for over half of the variance in psychological health. Results support a multidimensional model for explaining caregivers' adjustment.	BAYLOR COLL MED,DEPT PHYS MED & REHABIL,HOUSTON,TX 77030; INST REHABIL & RES,BRAIN INJURY RES CTR,HOUSTON,TX 77025; UNIV HOUSTON,DEPT PSYCHOL,HOUSTON,TX 77204; BAYLOR COLL MED,DEPT NEUROSURG,HOUSTON,TX 77030		Sander, AM (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHYS MED & REHABIL,MCV BOX 980542,RICHMOND,VA 23298, USA.			Hannay, H. Julia/0000-0001-7023-912X			ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/0090-5550.39.1.29; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CHWALISZ K, 1992, REHABIL PSYCHOL, V37, P189, DOI 10.1037/h0079103; DILLEHAY RC, 1990, INT J AGING HUM DEV, V30, P263, DOI 10.2190/2P3J-A9AH-HHF4-00RG; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; FOLKMAN S, 1988, MANUAL WAYS COPING; Goldberg DP, 1972, DETECTION PSYCHIATRI; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Graffi S, 1989, J APPLIED SOCIAL SCI, V13, P293; HALEY WE, 1987, PSYCHOL AGING, V2, P323, DOI 10.1037/0882-7974.2.4.323; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KOSCIULEK JF, 1994, REHABIL COUNS BULL, V37, P244; KOSCIULEK JF, 1993, J REHABIL, V59, P40; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; KREUTZER JS, 1994, BRAIN INJURY, V8, P187; LAZARUS RS, 1988, STRESS APPRAISAL COP; Levin HS., 1982, NEUROBEHAVIORAL CONS; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; MCCUBBIN HI, 1979, J MARRIAGE FAM, V41, P237, DOI 10.2307/351693; MCCUBBIN HI, 1983, SOCIAL STRESS FAMILY, P00007, DOI DOI 10.1300/J002V06N01_02; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; PRATT CC, 1985, FAM RELAT, V34, P27, DOI 10.2307/583754; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SARASON IG, 1983, J PERS SOC PSYCHOL, V44, P127, DOI 10.1037/0022-3514.44.1.127; STEPHENS MAP, 1988, PSYCHOL AGING, V3, P208, DOI 10.1037/0882-7974.3.2.208; Tarter S B, 1990, Arch Clin Neuropsychol, V5, P15; White N E, 1992, West J Nurs Res, V14, P211, DOI 10.1177/019394599201400208; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649	40	81	82	0	6	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	APR	1997	11	4					235	249		10.1080/026990597123548			15	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	WQ736	WOS:A1997WQ73600001	9134198				2022-02-06	
J	Bellamy, R; Safar, P; Tisherman, SA; Basford, R; Bruttig, SP; Capone, A; Dubick, MA; Ernster, L; Hattler, BG; Hochachka, P; Klain, M; Kochanek, PM; Kofke, WA; Lancaster, JR; McGowan, FX; Oeltgen, PR; Severinghaus, JW; Taylor, MJ; Zar, H				Bellamy, R; Safar, P; Tisherman, SA; Basford, R; Bruttig, SP; Capone, A; Dubick, MA; Ernster, L; Hattler, BG; Hochachka, P; Klain, M; Kochanek, PM; Kofke, WA; Lancaster, JR; McGowan, FX; Oeltgen, PR; Severinghaus, JW; Taylor, MJ; Zar, H			Suspended animation for delayed resuscitation	CRITICAL CARE MEDICINE			English	Article; Proceedings Paper	International Resuscitation Research Conference (IRRC 94)	MAY 07-09, 1994	PITTSBURGH, PA			cerebral anoxia; cardiopulmonary resuscitation; hypothermia; ischemia; exsanguination; suspended animation; cardiac arrest; preservation; hibernation; cardiopulmonary bypass	AUTOPERFUSION MULTIORGAN PREPARATION; HYPOTHERMIC CIRCULATORY ARREST; HIBERNATION INDUCTION TRIGGER; NITRIC-OXIDE; REPERFUSION INJURY; HEMORRHAGIC-SHOCK; PARTIAL EPILEPSY; CARDIAC-ARREST; MAJOR ORGANS; ISCHEMIA	Suspended animation is defined as the therapeutic induction of a state of tolerance to temporary complete systemic ischemia, i.e., protection-preservation of the whole organism during prolonged circulatory arrest (greater than or equal to 1 hr), followed by resuscitation to survival without brain damage. The objectives of suspended animation include: a) helping to save victims of temporarily uncontrollable (internal) traumatic (e.g., combat casualties) or nontraumatic (e.g., ruptured aortic aneurysm) exsanguination, without severe brain trauma, by enabling evacuation and resuscitative surgery during circulatory arrest, followed by delayed resuscitation; b) helping to save some nontraumatic cases of sudden death, seemingly unresuscitable before definitive repair; and c) enabling selected (elective) surgical procedures to be performed which are only feasible during a state of no blood flow. In the discussion session, investigators with suspended animation relevant research interests brainstorm on present knowledge, future research potentials, and the advisability of a major research effort concerning this subject. The following topics are addressed: the epidemiologic facts of sudden death in combat casualties, which require a totally new resuscitative approach; the limits and potentials of reanimation research; complete reversibility of circulatory arrest of 1 hr in dogs under profound hypothermia (<10 degrees C), induced and reversed by portable cardiopulmonary bypass; the need for a still elusive pharmacologic or chemical induction of suspended animation in the field; asanguinous profound hypothermic low-flow with cardiopulmonary bypass; electric anesthesia; opiate therapy; lessons learned from hypoxia tolerant vertebrate animals, hibernators, and freeze tolerant animals (cryobiology); myocardial preservation during open heart surgery; organ preservation for transplantation; and reperfusion reoxygenation injury in vital organs, including the roles of nitric oxide and free radicals; and how cells (particularly cerebral neurons) die after transient prolonged ischemia and reperfusion. The majority of authors believe that seeking a breakthrough in suspended animation is not utopian, that ongoing communication between relevant research groups is indicated, and that a coordinated multicenter research effort, basic and applied, on suspended animation is justified.	UNIV PITTSBURGH, SAFAR CTR RESUSCITAT RES, PITTSBURGH, PA 15260 USA; PONTCTOC CANYON ESTATES, TUCSON, AZ 85718 USA; USA, MED RES & MAT COMMAND, SGRD PLB, FREDERICK, MD 21702 USA; SGRD USMT, HOUSTON, TX 78234 USA; UNIV STOCKHOLM, ARRHENIUS LAB, DEPT BIOCHEM, S-10691 STOCKHOLM, SWEDEN; UNIV PITTSBURGH, MED CTR, DEPT SURG, PITTSBURGH, PA 15213 USA; UNIV BRITISH COLUMBIA, DEPT ZOOL & SPORTS MED, VANCOUVER, BC V5Z 1M9, CANADA; UNIV PITTSBURGH, MED CTR, DEPT ANESTHESIOL & NEUROSURG, PITTSBURGH, PA 15260 USA; LOUISIANA STATE UNIV, MED CTR, NEW ORLEANS, LA 70112 USA; UNIV PITTSBURGH, CHILDRENS HOSP PITTSBURGH, DEPT ANESTHESIOL, CCM, PITTSBURGH, PA 15213 USA; VET ADM MED CTR, LEXINGTON, KY 40511 USA; UNIV CALIF SAN FRANCISCO, DEPT ANESTHESIOL, SAN FRANCISCO, CA 94143 USA; ALLEGHENY GEN HOSP, PITTSBURGH, PA 15212 USA		Bellamy, R (corresponding author), WALTER REED ARMY MED CTR, BORDEN INST, BLDG 11, ROOM 1-117, 6825 16TH ST NW, WASHINGTON, DC 20307 USA.		Tisherman, Samuel A./AAK-9377-2020; Kochanek, Patrick M/D-2371-2015	Tisherman, Samuel A./0000-0003-3810-3729; Kochanek, Patrick M/0000-0002-2627-913X; Oeltgen, Peter/0000-0002-4416-5099			ADLER L, 1994, ANESTHESIOLOGY, V81, pA917; ADLER MW, 1980, LIFE SCI, V26, P497, DOI 10.1016/0024-3205(80)90312-4; ANANEV MG, 1960, ANESTHESIOLOGY, V21, P215, DOI 10.1097/00000542-196003000-00013; ARNOLD K, 1978, MIL MED, V143, P161; BAILES JE, 1991, J NEUROSURG, V74, P781, DOI 10.3171/jns.1991.74.5.0781; BAKER CC, 1986, ANN EMERG MED, V15, P1389, DOI 10.1016/S0196-0644(86)80921-0; BAKER SP, 1982, J TRAUMA, V22, P187; BARNES BM, 1989, SCIENCE, V244, P1593, DOI 10.1126/science.2740905; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; Beecher HK, 1949, RESUSCITATION ANESTH; BELLAMY RF, 1986, ANN EMERG MED, V15, P1384, DOI 10.1016/S0196-0644(86)80920-9; BELLAMY RF, 1984, MIL MED, V149, P55; Bellamy RF, 1988, ADV TRAUMA, V3, P163; BELLINGER DC, 1991, PEDIATRICS, V87, P701; BOVERIS A, 1980, P NATL ACAD SCI-BIOL, V77, P347, DOI 10.1073/pnas.77.1.347; CAPONE A, 1995, RESUSCITATION, V29, P143, DOI 10.1016/0300-9572(95)00829-I; CAPONE A, IN PRESS J TRAUMA; CAPONE A, 1995, ACAD EMERG MED, V2, P363; CAPONE AC, 1995, J AM COLL SURGEONS, V180, P49; CASCINO GD, 1993, J CLIN NEUROPHYSIOL, V10, P520, DOI 10.1097/00004691-199310000-00010; CHIEN S, 1994, J THORAC CARDIOV SUR, V107, P964; CHIEN S, 1989, ANN THORAC SURG, V47, P860, DOI 10.1016/0003-4975(89)90021-0; CHIEN S, 1993, XANTHUS INTELLIGENCE, P1; CHIEN S, 1993, 73RD ANN M AM ASS TR; CHIEN SF, 1991, J THORAC CARDIOV SUR, V102, P224; CONNOLLY JE, 1965, ANN SURG, V162, P373, DOI 10.1097/00000658-196510000-00014; DAWE AR, 1969, SCIENCE, V163, P298, DOI 10.1126/science.163.3864.298; DAWE AR, 1971, CRYOBIOLOGY, V8, P302, DOI 10.1016/0011-2240(71)90058-7; DREW CE, 1959, LANCET, V1, P748; ERNSTER L, 1988, CRIT CARE MED, V16, P947, DOI 10.1097/00003246-198810000-00005; FINKEL MS, 1993, AM J CARDIOL, V71, P1231, DOI 10.1016/0002-9149(93)90654-U; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; FINKEL MS, 1993, J IMMUNOL IMMUNOPHAR, V13, P1; FINKEL MS, 1994, MYOCARDIAL VIABILITY; FLACH VA, 1958, ANAESTHESIST, V7, P180; FRERICHS KU, 1994, J CEREBR BLOOD F MET, V14, P193, DOI 10.1038/jcbfm.1994.26; Fry FE, 1947, PUBL ONTARIO FISH RE, V68, P1; GADDIS GM, 1994, ANN EMERG MED, V23, P75, DOI 10.1016/S0196-0644(94)70012-5; GRANGER DN, 1981, GASTROENTEROLOGY, V81, P22; Haglund H, 1971, Methods Biochem Anal, V19, P1; HARDY JD, 1961, JAMA-J AM MED ASSOC, V175, P599, DOI 10.1001/jama.1961.63040070001013; HERIN RA, 1994, UST P S EL FORT COLL, P22; HJALMARSSON SG, 1975, SCI TOOLS, V22, P35; HOCHOCHKA PW, 1993, SURVIVING HYPOXIA; HORTON ND, 1995, TOXICOLOGIST, V15; JENNINGS RB, 1990, CIRCULATION, V82, P2; KEARSE LA, 1993, ELECTROEN CLIN NEURO, V87, P374, DOI 10.1016/0013-4694(93)90150-T; KERWIN JF, IN PRESS J MED CHEM; KIM SH, 1995, ACAD EMERG MED, V2, P364; KIRIMLI B, 1968, ACTA ANAESTH SCAND, VS, P183; KIRIMLI B, 1969, SURG GYNECOL OBSTETR, V129, P89; KLAIN M, 1989, CARDIOVASCULAR SCI T, P318; Kofke W. A., 1993, Society for Neuroscience Abstracts, V19, P1159; Kofke W. A., 1994, J NEUROSURG ANESTH, V6, P323; KOFKE WA, 1992, ANESTH ANALG, V75, P953; KOFKE WA, 1994, ANESTHESIOLOGY, V81, pA820; KOFKE WA, 1994, J NEUROSURG ANESTH, V6, P322; KRUMAN II, 1986, COMP BIOCHEM PHYS B, V83, P173, DOI 10.1016/0305-0491(86)90349-4; LABORIT H, 1954, PRACTICE HIBERNATION; LITTARRU GP, 1993, CLIN INVESTIGATOR, V71, P587; LUTZ PL, 1994, BRAIN OXYGEN CAUSES; LYMAN CP, 1981, SCIENCE, V212, P668, DOI 10.1126/science.7221552; MALINSKI T, 1993, J CEREBR BLOOD F MET, V13, P355, DOI 10.1038/jcbfm.1993.48; MARSHALL HP, IN PRESS J TRAUMA; MCGOWAN FX, 1994, J THORAC CARDIOV SUR, V108, P772; MYERS RD, 1981, BRAIN RES BULL, V7, P691, DOI 10.1016/0361-9230(81)90120-9; NILEKANI SP, 1990, FED PROC, V4, P854; NUSSLER AK, 1993, BIOCHEM BIOPH RES CO, V194, P826, DOI 10.1006/bbrc.1993.1896; OELTGEN PR, 1988, LIFE SCI, V43, P1565, DOI 10.1016/0024-3205(88)90406-7; OELTGEN PR, 1978, PREP BIOCHEM, V8, P171, DOI 10.1080/00327487808069058; OELTGEN PR, 1982, PHARMACOL BIOCHEM BE, V17, P1271, DOI 10.1016/0091-3057(82)90132-0; OELTGEN PR, 1987, LIFE SCI, V41, P2115, DOI 10.1016/0024-3205(87)90529-7; OELTGEN PR, 1995, FASEB J, V9, pA642; OELTGEN PR, 1981, HIBERNATION OTHER AD, P139; OHKADO A, 1994, J THORAC CARDIOV SUR, V108, P762; ORDOG GJ, 1994, J TRAUMA, V36, P106, DOI 10.1097/00005373-199401000-00017; OUGHTERSON AW, 1962, WOUND BALLISTICS; PEGG DE, 1981, ORGAN PRESERVATION T, P31; POZZATI R, 1986, SCIENCE, V84, P232; PRETTO EA, 1991, CRIT CARE MED, V19, P1188, DOI 10.1097/00003246-199109000-00016; RADI R, 1993, BIOCHEM J, V290, P51, DOI 10.1042/bj2900051; RIEDESEL ML, 1980, FED PROC, V39, P2959; SAFAR P, 1990, AM J EMERG MED, V8, P55, DOI 10.1016/0735-6757(90)90298-E; SAFAR P, 1993, ANN EMERG MED, V22, P324, DOI 10.1016/S0196-0644(05)80463-9; SAFAR P, 1988, CRIT CARE MED, V16, P919; SAFAR P, 1995, CARDIAC ARREST, pCH49; SCHOLANDER PF, 1962, HARVEY LECT, P93; SCIAMANNA MA, 1993, ARCH BIOCHEM BIOPHYS, V305, P215, DOI 10.1006/abbi.1993.1414; SHORT CE, 1964, J AM VET MED ASSOC, V145, P1104; SMITH RH, 1967, ANESTH ANAL CURR RES, V46, P109; SNEAD OC, 1981, NEUROPHARMACOLOGY, V21, P299; SNYDER J, 1966, COMMUNICATION    JAN; STOREY KB, 1987, J BIOL CHEM, V262, P1670; SU TP, 1988, FASEB J, V2, pA1074; SUSSMAN MS, 1990, METHOD ENZYMOL, V186, P711; TAKAORI M, 1967, J AMER MED ASSOC, V199, P297, DOI 10.1001/jama.199.5.297; TAKEUCHI K, IN PRESS CIRCULATION; Taylor M J, 1994, ASAIO J, V40, pM351, DOI 10.1097/00002480-199407000-00022; Taylor M. J., 1994, Cryobiology, V31, P592; TAYLOR MJ, 1995, CIRCULATION, V91, P431, DOI 10.1161/01.CIR.91.2.431; TAYLOR MJ, IN PRESS ADV LOW TEM, V3; TEMPELHOFF R, 1992, J NEUROSURG, V77, P201, DOI 10.3171/jns.1992.77.2.0201; THIEMERMANN C, 1993, P NATL ACAD SCI USA, V90, P267, DOI 10.1073/pnas.90.1.267; TISHERMAN S, 1992, Anesthesiology (Hagerstown), V77, pA285, DOI 10.1097/00000542-199209001-00285; TISHERMAN S, 1994, RESUSCITATION, V28, pS14; TISHERMAN S, 1994, RESUSCITATION, V28, pS5; TISHERMAN SA, 1991, J TRAUMA, V31, P1051, DOI 10.1097/00005373-199131080-00002; TISHERMAN SA, 1990, J TRAUMA, V30, P836, DOI 10.1097/00005373-199007000-00014; TISHERMAN SA, 1990, ACTA ANAESTH SCAND, V34, P63, DOI 10.1111/j.1399-6576.1990.tb03224.x; TISHERMAN SA, 1991, CRIT CARE MED, V19, pS89; TISHERMAN SA, 1989, ANN EMERG MED, V18, P460; TRAVIS J, 1973, CLIN CHIM ACTA, V49, P49, DOI 10.1016/0009-8981(73)90341-0; TURBES CC, 1994, 1ST P S EL FORT COLL, P52; TURKER MS, 1988, CELL BIOL TOXICOL, V4, P211, DOI 10.1007/BF00119247; Wang L. C. H., 1978, STRATEGIES COLD NATU, P109; WOLFE RR, 1982, 30TH ANN C MASS SPEC; YANG GY, 1994, STROKE, V25, P165, DOI 10.1161/01.STR.25.1.165; ZAJTCHUK R, 1995, MIL MED, V160, P1; ZAR H, 1994, FASEB J, V8, pA128; 1970, EVALUATION WOUND DAT, V3; EXERCEPTA MED INT C, V136; 1970, EVALUATION WOUND DAT, V1; 1985, ABBREVIATED INJURY S	123	81	82	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	1996	24	2		S			S24	S47					24	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	TW260	WOS:A1996TW26000004	8608704				2022-02-06	
J	YANG, K; MU, XS; XUE, JJ; WHITSON, J; SALMINEN, A; DIXON, CE; LIU, PK; HAYES, RL				YANG, K; MU, XS; XUE, JJ; WHITSON, J; SALMINEN, A; DIXON, CE; LIU, PK; HAYES, RL			INCREASED EXPRESSION OF C-FOS MESSENGER-RNA AND AP-1 TRANSCRIPTION FACTORS AFTER CORTICAL IMPACT INJURY IN RATS	BRAIN RESEARCH			English	Article						IMMEDIATE EARLY GENE EXPRESSION; C-FOS; AP-1 TRANSCRIPTION FACTOR; IN SITU HYBRIDIZATION; RT-PCR; BRAIN TRAUMA	TRAUMATIC BRAIN INJURY; NERVE GROWTH-FACTOR; CEREBELLAR GRANULE CELLS; MESSENGER-RNA; INSITU HYBRIDIZATION; PRIMARY CULTURES; PC12 CELLS; HIPPOCAMPUS; INDUCTION; JUN	Levels of c-fos mRNA and AP-1 transcription factors co-expression were measured in a controlled lateral cortical impact model of traumatic brain injury (TBI) in rats. Ipsilateral cerebral cortex and bilateral hippocampal c-fos mRNA increases were revealed by in situ hybridization after lateral cortical impact injury. Based on regional in situ hybridization data, we employed semi-quantitative RT-PCR methods to study the temporal profile of changes in the ipsilateral cortex at the site of injury. We found that TBI produces transient increases of c-fos mRNP; expression in the ipsilateral cerebral cortex at 5 min postinjury, which peaks at 1 h postinjury and subsides by 1 day postinjury. Gel shift nuclear protein binding assays showed that AP-1 transcription factor binding was robustly increased in injured cerebral cortex at 1 h, 3 h, 5 h and 1 day after injury. These data indicate that TBI can produce significant increases in c-fos expression and subsequent upregulation of the AP-1 transcription factors. Thus, AP-1 transcription factors modulation of downstream gene expression may be an important component of pathophysiological responses to TBT.	UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,HOUSTON,TX 77030; BAYLOR COLL MED,DIV RESTORAT NEUROL & HUMAN NEUROBIOL,HOUSTON,TX 77030						NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21458, P01 NS3199801] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458, P01NS031998] Funding Source: NIH RePORTER		AN G, 1993, ANN NEUROL, V33, P457, DOI 10.1002/ana.410330508; CELI FS, 1993, NUCLEIC ACIDS RES, V21, P1047, DOI 10.1093/nar/21.4.1047; CHAN RKW, 1993, J NEUROSCI, V13, P5126, DOI 10.1523/JNEUROSCI.13-12-05126.1993; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DASH PK, 1993, 23RD ANN M SOC NEUR; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DRAGUNOW M, 1987, NEUROSCI LETT, V82, P157, DOI 10.1016/0304-3940(87)90121-2; DRAGUNOW M, 1988, BRAIN RES, V455, P295, DOI 10.1016/0006-8993(88)90088-1; DRAGUNOW M, 1987, NATURE, V329, P441, DOI 10.1038/329441a0; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HENGERER B, 1990, P NATL ACAD SCI USA, V87, P3899, DOI 10.1073/pnas.87.10.3899; HUGHES P, 1993, NEUROSCI LETT, V150, P122, DOI 10.1016/0304-3940(93)90122-2; KAMINSKA B, 1993, NEUROSCI LETT, V153, P189, DOI 10.1016/0304-3940(93)90319-G; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LYETH B G, 1991, Society for Neuroscience Abstracts, V17, P165; MACHIDA CM, 1989, NEURON, V2, P1587, DOI 10.1016/0896-6273(89)90047-0; MORGAN JI, 1991, TRENDS PHARMACOL SCI, V12, P343, DOI 10.1016/0165-6147(91)90594-I; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MORGAN PF, 1991, NEUROREPORT, V2, P251, DOI 10.1097/00001756-199105000-00009; PENNYPACKER KR, 1994, J NEUROSCI, V14, P3998; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; ROBINSON SE, 1990, BRAIN RES, V511, P141, DOI 10.1016/0006-8993(90)90233-2; RUZDIJIC S, 1993, BRAIN RES, V69, P230; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SONNENBERG JL, 1989, NEURON, V3, P359, DOI 10.1016/0896-6273(89)90260-2; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; SZEKELY AM, 1989, MOL PHARMACOL, V35, P401; SZEKELY AM, 1987, NEUROPHARMACOLOGY, V26, P1779, DOI 10.1016/0028-3908(87)90132-8; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TURNER R, 1989, SCIENCE, V243, P1659; YANG K, 1993, 23RD ANN M SOC NEUR; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287; ZHENG M, 1988, MOL BRAIN RES, V3, P133, DOI 10.1016/0169-328X(88)90058-7	43	81	98	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	NOV 21	1994	664	1-2					141	147		10.1016/0006-8993(94)91964-X			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PR431	WOS:A1994PR43100019	7895023				2022-02-06	
J	LEONARD, JR; MARIS, DO; GRADY, MS				LEONARD, JR; MARIS, DO; GRADY, MS			FLUID PERCUSSION INJURY CAUSES LOSS OF FOREBRAIN CHOLINE-ACETYLTRANSFERASE AND NERVE GROWTH-FACTOR RECEPTOR IMMUNOREACTIVE CELLS IN THE RAT	JOURNAL OF NEUROTRAUMA			English	Article							TRAUMATIC BRAIN INJURY; FIMBRIA-FORNIX TRANSECTION; BASAL FOREBRAIN; ALZHEIMERS-DISEASE; MEDIAL SEPTUM; HIPPOCAMPAL-FORMATION; RETROGRADE TRANSPORT; SUPEROXIDE-DISMUTASE; NUCLEUS BASALIS; DIAGONAL BAND	Memory dysfunction is a common sequela of human traumatic brain injury (TBI). Cholinergic forebrain neurons are recognized for their role in memory. We tested the hypothesis that forebrain cholinergic neurons are vulnerable to fluid percussion injury (FPI), a model of human TBI. Rodents were subjected to a moderate parasagittal FPI, sham injury, or fimbria/fornix axotomy and then killed 10 days after the procedure. Additional animals underwent FPI or sham injury and were killed 7, 14, and 28 days after the procedure. Neurons in the medial septal nucleus and vertical limb of the nucleus of the diagonal band of Broca were identified and quantitated using choline acetyltransferase (ChAT) and low affinity nerve growth factor receptor (NGF-R) immunohistochemistry. Our results showed a significant decrease in ChAT (17% +/- 5%) and NGF-R (24% +/- 8%) immunoreactive cells in FPI animals killed after 10 days when compared to sham-injured animals. Animals undergoing fimbria/fornix axotomy showed a greater reduction in ChAT (53% +/- 13%) and NGF-R (55% +/- 5%) immunoreactive cells 10 days postaxotomy. The number of ChAT and NGF-R immunoreactive neurons was reduced at all time points. However, statistical significance was present 10 and 14 days postinjury for ChAT immunoreactive neurons and 10 days only for NGF-R immunoreactive neurons. These studies have shown that FPI produces transient loss of ChAT and NGF-R immunoreactive neurons.	UNIV WASHINGTON,HARBORVIEW MED CTR,DEPT NEUROL SURG,SEATTLE,WA 98104						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001371] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 01371] Funding Source: Medline		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; AMARAL DG, 1985, J COMP NEUROL, V240, P37, DOI 10.1002/cne.902400104; ARENDT T, 1985, NEUROSCIENCE, V14, P1, DOI 10.1016/0306-4522(85)90160-5; ARMSTRONG DM, 1991, J COMP NEUROL, V304, P596, DOI 10.1002/cne.903040407; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; DAVIES P, 1976, LANCET, V2, P1403; DAWBARN D, 1988, BRAIN RES, V440, P185, DOI 10.1016/0006-8993(88)91175-4; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; GAGE FH, 1988, J COMP NEUROL, V269, P147, DOI 10.1002/cne.902690112; GAGE FH, 1986, NEUROSCIENCE, V19, P241, DOI 10.1016/0306-4522(86)90018-7; GNAHN H, 1983, DEV BRAIN RES, V9, P45, DOI 10.1016/0165-3806(83)90107-4; GORMAN LK, 1993, BRAIN RES, V614, P29, DOI 10.1016/0006-8993(93)91014-J; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HARRELL LE, 1987, BEHAV NEUROSCI, V101, P644, DOI 10.1037/0735-7044.101.5.644; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; JOHNSON EM, 1987, J NEUROSCI, V7, P923; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATAYAMA Y, 1990, ACT NEUR S, V51, P271; KINJO N, 1989, NEUROSCI RES, V7, P154, DOI 10.1016/0168-0102(89)90055-2; KOLIATOS VE, 1991, EXP NEUROL, V112, P116; Kraus JF, 1987, HEAD INJURY, V2, P1; LEVASSEUR JE, 1989, J NEUROSURG, V71, P573, DOI 10.3171/jns.1989.71.4.0573; Levin H., 1987, HEAD INJURY, P442; LEWIS PR, 1967, BRAIN, V90, P521, DOI 10.1093/brain/90.3.521; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MARTIN LJ, 1993, J NEUROSCI, V13, P2249; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MESULAM MM, 1983, NEUROSCIENCE, V10, P1185, DOI 10.1016/0306-4522(83)90108-2; MORSE JK, 1993, J NEUROSCI, V13, P4146; MUIZELAAR JP, 1993, ANN EMERG MED, V22, P1014, DOI 10.1016/S0196-0644(05)82744-1; OBRIEN TS, 1990, BRAIN RES, V508, P249, DOI 10.1016/0006-8993(90)90403-X; Povlishock J T, 1992, Hum Cell, V5, P345; SANADA T, 1993, J NEUROTRAUM, V10, P65, DOI 10.1089/neu.1993.10.65; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SEILER M, 1984, BRAIN RES, V300, P33, DOI 10.1016/0006-8993(84)91338-6; SENUT MC, 1990, NEUROSCI LETT, V113, P12, DOI 10.1016/0304-3940(90)90486-S; SENUT MC, 1989, NEUROSCIENCE, V30, P385, DOI 10.1016/0306-4522(89)90260-1; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOFRONIEW MV, 1987, BRAIN RES, V411, P310, DOI 10.1016/0006-8993(87)91084-5; TUSZYNSKI MH, 1990, BRAIN RES, V508, P241, DOI 10.1016/0006-8993(90)90402-W; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	50	81	83	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	1994	11	4					379	392		10.1089/neu.1994.11.379			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	PG289	WOS:A1994PG28900004	7837279				2022-02-06	
J	NELL, V; BROWN, DSO				NELL, V; BROWN, DSO			EPIDEMIOLOGY OF TRAUMATIC BRAIN INJURY IN JOHANNESBURG .2. MORBIDITY, MORTALITY AND ETIOLOGY	SOCIAL SCIENCE & MEDICINE			English	Article						EPIDEMIOLOGY; TRAUMATIC BRAIN INJURY; MORBIDITY; MORTALITY; ETIOLOGY; JOHANNESBURG	HEAD				NELL, V (corresponding author), UNIV S AFRICA,HLTH PSYCHOL UNIT,POB 392,PRETORIA,SOUTH AFRICA.						ANDERSON DW, 1980, J NEUROSURG, V53, pS32; ARMITAGE P, 1971, STATISTICAL METHODS; AUSTIN RL, 1983, J CRIM JUST, V11, P93, DOI 10.1016/0047-2352(83)90045-4; AUSTIN RL, 1987, J CRIM JUST, V15, P437, DOI 10.1016/0047-2352(87)90001-8; BAKER SP, 1985, INJURY FACT BOOK; BOND MR, 1976, SCAND J REHABIL MED, V8, P127; BRADSHAW D, 1987, REV S AFRICAN MORTAL; Bulhan H.A., 1985, FRANTZ FANON PSYCHOL; BULHAN HA, 1981, RACE CLASS, V23, P25, DOI 10.1177/030639688102300102; BULHAN HA, 1979, RACE CLASS, V20, P243; BUTCHART RA, 1991, SA MED J, V79, P472; Joffe J.M., 1984, READINGS PRIMARY PRE; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; Morton RF, 1979, STUDY GUIDE EPIDEMIO; NELL V, 1989, CRITICAL HLTH, V28, P44; RIMEL RW, 1983, REHABILITATION BRAIN; SANDERCOCK P, 1989, J NEUROL NEUROSUR PS, V52, P817, DOI 10.1136/jnnp.52.7.817	18	81	85	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0277-9536			SOC SCI MED	Soc. Sci. Med.		1991	33	3					289	296		10.1016/0277-9536(91)90363-H			8	Public, Environmental & Occupational Health; Social Sciences, Biomedical	Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health; Biomedical Social Sciences	GA785	WOS:A1991GA78500008	1925693				2022-02-06	
J	LEVIN, HS; GROSSMAN, RG; KELLY, PJ				LEVIN, HS; GROSSMAN, RG; KELLY, PJ			APHASIC DISORDER IN PATIENTS WITH CLOSED HEAD-INJURY	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article									UNIV TEXAS,MED BRANCH,DIV NEUROSURG,GALVESTON,TX 77550								AKBAROVA NA, 1972, ZH NEVOPATOLOGII PSI, V11, P1641; Bender L, 1938, VISUAL MOTOR GESTALT; Benton A. L., 1959, RIGHT LEFT DISCRIMIN; Benton A.L., 1967, CORTEX, V3, P32, DOI [10.1016/s0010-9452(67)80005-4, DOI 10.1016/S0010-9452(67)80005-4]; BENTON AL, 1964, J NERV MENT DIS, V139, P110, DOI 10.1097/00005053-196408000-00003; BROOKS DN, 1974, J NEUROL NEUROSUR PS, V37, P794, DOI 10.1136/jnnp.37.7.794; HEILMAN KM, 1971, J NEUROL NEUROSUR PS, V34, P265, DOI 10.1136/jnnp.34.3.265; LEVIN HS, 1975, J PSYCHOL, V91, P223, DOI 10.1080/00223980.1975.9923946; LEVIN HS, 1976, CORTEX, V12, P175, DOI 10.1016/S0010-9452(76)80021-4; MORSIER GD, 1973, PSYCHIAT CLIN, V6, P226, DOI 10.1159/000283277; SPREEN O, 1966, MANUAL NEUROSENSORY; Van Allen MW, 1968, CORTEX, V93, P38, DOI [10.1016/S0010-9452(68)80018-8, DOI 10.1016/S0010-9452(68)80018, 10.1016/S0010-9452(68)80018]	12	81	81	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry		1976	39	11					1062	1070		10.1136/jnnp.39.11.1062			9	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Surgery	CP283	WOS:A1976CP28300004	1011017	Bronze, Green Published			2022-02-06	
J	Alosco, ML; Mez, J; Tripodis, Y; Kiernan, PT; Abdolmohammadi, B; Murphy, L; Kowall, NW; Stein, TD; Huber, BR; Goldstein, LE; Cantu, RC; Katz, DI; Chaisson, CE; Martin, B; Solomon, TM; McClean, MD; Daneshvar, DH; Nowinski, CJ; Stern, RA; McKee, AC				Alosco, Michael L.; Mez, Jesse; Tripodis, Yorghos; Kiernan, Patrick T.; Abdolmohammadi, Bobak; Murphy, Lauren; Kowall, Neil W.; Stein, Thor D.; Huber, Bertrand Russell; Goldstein, Lee E.; Cantu, Robert C.; Katz, Douglas I.; Chaisson, Christine E.; Martin, Brett; Solomon, Todd M.; McClean, Michael D.; Daneshvar, Daniel H.; Nowinski, Christopher J.; Stern, Robert A.; McKee, Ann C.			Age of first exposure to tackle football and chronic traumatic encephalopathy	ANNALS OF NEUROLOGY			English	Article							21ST-CENTURY BRAIN BANKING; HEAD IMPACT EXPOSURE; HIGH-SCHOOL FOOTBALL; WHITE-MATTER; COGNITIVE RESERVE; LATER-LIFE; CHILDREN; ADOLESCENCE; CONCUSSION; MATURATION	ObjectiveTo examine the effect of age of first exposure to tackle football on chronic traumatic encephalopathy (CTE) pathological severity and age of neurobehavioral symptom onset in tackle football players with neuropathologically confirmed CTE. MethodsThe sample included 246 tackle football players who donated their brains for neuropathological examination. Two hundred eleven were diagnosed with CTE (126 of 211 were without comorbid neurodegenerative diseases), and 35 were without CTE. Informant interviews ascertained age of first exposure and age of cognitive and behavioral/mood symptom onset. ResultsAnalyses accounted for decade and duration of play. Age of exposure was not associated with CTE pathological severity, or Alzheimer's disease or Lewy body pathology. In the 211 participants with CTE, every 1 year younger participants began to play tackle football predicted earlier reported cognitive symptom onset by 2.44 years (p<0.0001) and behavioral/mood symptoms by 2.50 years (p<0.0001). Age of exposure before 12 predicted earlier cognitive (p<0.0001) and behavioral/mood (p<0.0001) symptom onset by 13.39 and 13.28 years, respectively. In participants with dementia, younger age of exposure corresponded to earlier functional impairment onset. Similar effects were observed in the 126 CTE-only participants. Effect sizes were comparable in participants without CTE. InterpretationIn this sample of deceased tackle football players, younger age of exposure to tackle football was not associated with CTE pathological severity, but predicted earlier neurobehavioral symptom onset. Youth exposure to tackle football may reduce resiliency to late-life neuropathology. These findings may not generalize to the broader tackle football population, and informant-report may have affected the accuracy of the estimated effects. Ann Neurol 2018;83:886-901	[Alosco, Michael L.; Mez, Jesse; Tripodis, Yorghos; Kiernan, Patrick T.; Abdolmohammadi, Bobak; Murphy, Lauren; Kowall, Neil W.; Stein, Thor D.; Huber, Bertrand Russell; Goldstein, Lee E.; Cantu, Robert C.; Katz, Douglas I.; Chaisson, Christine E.; Martin, Brett; Solomon, Todd M.; Daneshvar, Daniel H.; Nowinski, Christopher J.; Stern, Robert A.; McKee, Ann C.] Boston Univ, Sch Med, Dept Neurol, Alzheimers Dis & CTE Ctr, Boston, MA 02118 USA; [Tripodis, Yorghos] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Kiernan, Patrick T.] Midwestern Univ, Arizona Coll Osteopath Med, Glendale, AZ USA; [Kowall, Neil W.; Stein, Thor D.; Goldstein, Lee E.; McKee, Ann C.] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; [Kowall, Neil W.; Stein, Thor D.; Goldstein, Lee E.; McKee, Ann C.] Boston Univ, Sch Med, Dept Lab Med, Boston, MA 02118 USA; [Kowall, Neil W.; Stein, Thor D.; Huber, Bertrand Russell; McKee, Ann C.] US Dept Vet Affairs, VA Boston Healthcare Syst, Boston, MA USA; [Stein, Thor D.; McKee, Ann C.] US Dept Vet Affairs, Med Ctr, Bedford, MA USA; [Goldstein, Lee E.] Boston Univ, Sch Med, Dept Psychiat, Ophthalmol, Boston, MA 02118 USA; [Goldstein, Lee E.] Boston Univ, Coll Engn, Dept Biomed Engn, Boston, MA 02215 USA; [Goldstein, Lee E.] Boston Univ, Coll Engn, Dept Elect Engn, Boston, MA 02215 USA; [Goldstein, Lee E.] Boston Univ, Coll Engn, Dept Comp Engn, Boston, MA 02215 USA; [Cantu, Robert C.; Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Cantu, Robert C.; Nowinski, Christopher J.] Concuss Legacy Fdn, Boston, MA USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Boston, MA USA; [Katz, Douglas I.] Braintree Rehabil Hosp, Braintree, MA USA; [Chaisson, Christine E.; Martin, Brett] Boston Univ, Sch Publ Hlth, Data Coordinating Ctr, Boston, MA USA; [McClean, Michael D.] Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA; [Daneshvar, Daniel H.] Stanford Univ, Dept Orthopaed, Stanford, CA 94305 USA; [Stern, Robert A.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA		McKee, AC (corresponding author), Boston Univ, Sch Med, Dept Neurol, 72 East Concord St,B7800, Boston, MA 02118 USA.	amckee@bu.edu	, Bob/ABA-8507-2020; Kowall, Neil/M-5378-2019	Kowall, Neil/0000-0002-6624-0213; Tripodis, Yorghos/0000-0003-2190-7608	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1U01NS086659-01, U01NS093334, R01NS078337, R56NS078337]; Department of DefenseUnited States Department of Defense [W81XWH-13-2-0064]; Department of Veterans AffairsUS Department of Veterans Affairs; Veterans Affairs Biorepository [CSP 501]; National Institute of Aging Boston University Alzheimer's Disease Center [P30AG13846, 0572063345-5]; Department of Defense Peer Reviewed Alzheimer's Research Program (DoD-PRARP) [13267017]; National Institute of Aging Boston University Framingham Heart Study [R01AG1649]; National Operating Committee on Standards for Athletic Equipment; Concussion Legacy Foundation; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [F32NS096803, K23 AG046377]; Boston University Alzheimer's Disease Center [AG013846]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086659, K23NS102399, U01NS093334, F32NS096803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K23AG046377, RF1AG057902, R01AG062348, P30AG013846] Funding Source: NIH RePORTER	This work was supported by the National Institute of Neurological Disorders and Stroke (1U01NS086659-01, U01NS093334, R01NS078337, and R56NS078337), Department of Defense (W81XWH-13-2-0064), Department of Veterans Affairs, the Veterans Affairs Biorepository (CSP 501), the National Institute of Aging Boston University Alzheimer's Disease Center (P30AG13846; supplement 0572063345-5), Department of Defense Peer Reviewed Alzheimer's Research Program (DoD-PRARP #13267017), the National Institute of Aging Boston University Framingham Heart Study (R01AG1649), and the National Operating Committee on Standards for Athletic Equipment and the Concussion Legacy Foundation. This work was also supported by unrestricted gifts from the Andlinger Foundation, the WWE, and the NFL. Michael L. Alosco and research reported in this publication is supported by the National Institutes of Health under grant number F32NS096803 and a Pilot Grant from the Boston University Alzheimer's Disease Center (AG013846). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Jesse Mez is supported by the National Institutes of Health under grant number K23 AG046377. Funding sources did not have restrictions on the design and conduct of the study, collection, management, analysis, and interpretation of data, or the preparation, review, or approval of the manuscript, or decision to submit the manuscript for publication.	Alosco ML, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.197; Alosco ML, 2017, J NEUROPSYCH CLIN N, V29, P6, DOI 10.1176/appi.neuropsych.16030043; Angrist JD, 1996, J AM STAT ASSOC, V91, P444, DOI 10.2307/2291629; Bahrami N, 2016, RADIOLOGY, V281, P919, DOI 10.1148/radiol.2016160564; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Borenstein AR, 2006, ALZ DIS ASSOC DIS, V20, P63, DOI 10.1097/01.wad.0000201854.62116.d7; Caviness VS, 1996, CEREB CORTEX, V6, P726, DOI 10.1093/cercor/6.5.726; Cherry JD, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0382-8; CHUGANI HT, 1987, ANN NEUROL, V22, P487, DOI 10.1002/ana.410220408; Cole SR, 2010, INT J EPIDEMIOL, V39, P417, DOI 10.1093/ije/dyp334; Courchesne E, 2000, RADIOLOGY, V216, P672, DOI 10.1148/radiology.216.3.r00au37672; Deshpande SK, 2017, JAMA NEUROL, V74, P909, DOI 10.1001/jamaneurol.2017.1317; Epstein HT, 1999, BRAIN DEV-JPN, V21, P535, DOI 10.1016/S0387-7604(99)00066-2; Esopenko C, 2017, J NEUROL NEUROSUR PS, V88, P512, DOI 10.1136/jnnp-2016-315260; Giedd JN, 2008, J ADOLESCENT HEALTH, V42, P335, DOI 10.1016/j.jadohealth.2008.01.007; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gogtay N, 2010, BRAIN COGNITION, V72, P6, DOI 10.1016/j.bandc.2009.08.009; Haneuse S, 2009, NEUROEPIDEMIOLOGY, V32, P229, DOI 10.1159/000197389; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Klingberg T, 1999, NEUROREPORT, V10, P2817, DOI 10.1097/00001756-199909090-00022; Lebel C, 2008, NEUROIMAGE, V40, P1044, DOI 10.1016/j.neuroimage.2007.12.053; Marek S, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002328; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McMillan TM, 2017, J NEUROL NEUROSUR PS, V88, P505, DOI 10.1136/jnnp-2016-314279; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Mez J, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0148-8; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Munce TA, 2015, MED SCI SPORT EXER, V47, P1567, DOI 10.1249/MSS.0000000000000591; Ng TSC, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt239; Schultz V, 2018, J NEUROTRAUM, V35, P278, DOI 10.1089/neu.2017.5145; Shaw P, 2006, NATURE, V440, P676, DOI 10.1038/nature04513; Shaw P, 2008, J NEUROSCI, V28, P3586, DOI 10.1523/JNEUROSCI.5309-07.2008; Sherman LE, 2014, DEV COGN NEUROS-NETH, V10, P148, DOI 10.1016/j.dcn.2014.08.002; Snook L, 2005, NEUROIMAGE, V26, P1164, DOI 10.1016/j.neuroimage.2005.03.016; Solomon GS, 2016, AM J SPORT MED, V44, P1106, DOI 10.1177/0363546515626164; Stamm JM, 2015, J NEUROTRAUM, V32, P1768, DOI 10.1089/neu.2014.3822; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stern Y, 2012, LANCET NEUROL, V11, P1006, DOI 10.1016/S1474-4422(12)70191-6; Tagge CA, 2018, BRAIN, V141, P422, DOI 10.1093/brain/awx350; THATCHER RW, 1991, DEV NEUROPSYCHOL, V7, P397, DOI 10.1080/87565649109540500; Uematsu A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046970; Vonsattel JPG, 2008, CELL TISSUE BANK, V9, P247, DOI 10.1007/s10561-008-9079-y; Vonsattel JPG, 2008, ACTA NEUROPATHOL, V115, P509, DOI 10.1007/s00401-007-0311-9; Winship C, 1999, ANNU REV SOCIOL, V25, P659, DOI 10.1146/annurev.soc.25.1.659	47	80	80	5	30	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	MAY	2018	83	5					886	901		10.1002/ana.25245			16	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GK7QH	WOS:000436402600003	29710395	Bronze, Green Accepted			2022-02-06	
J	Zhang, L; Wang, HD; Fan, YW; Gao, YY; Li, X; Hu, ZG; Ding, K; Wang, YJ; Wang, XL				Zhang, Li; Wang, Handong; Fan, Youwu; Gao, Yongyue; Li, Xiang; Hu, Zhigang; Ding, Ke; Wang, Yujie; Wang, Xiaoliang			Fucoxanthin provides neuroprotection in models of traumatic brain injury via the Nrf2-ARE and Nrf2-autophagy pathways	SCIENTIFIC REPORTS			English	Article							OXIDATIVE STRESS; IN-VITRO; NEURONAL APOPTOSIS; AUTOPHAGY; ANTIOXIDANT; EXPRESSION; DAMAGE; MICE; ACTIVATION; SYSTEM	Fucoxanthin is abundant in seaweed and is considered as a powerful antioxidant. It has been proposed to possess anti-cancer, anti-obesity and anti-diabetes effects. However, its roles in brain injury models have not been fully understood. The objective of this study was to investigate the neuroprotection of fucoxanthin in models of traumatic brain injury (TBI) and the role of the nuclear factor erythroid 2-related factor 2 (Nrf2)-antioxidant-response element (ARE) and Nrf2-autophagy pathways in the putative neuroprotection. We found that fucoxanthin alleviated TBI-induced secondary brain injury, including neurological deficits, cerebral edema, brain lesion and neuronal apoptosis. Moreover, the upregulation of malondialdehyde (MDA) and the activity of glutathione peroxidase (GPx) were reversed by fucoxanthin treatment. Furthermore, our in vitro studies demonstrated that fucoxanthin increased the neuron survival and reduced the reactive oxygen species (ROS) level. In addition, fucoxanthin activated the Nrf2-ARE pathway and autophagy both in vivo and in vitro, which was proven by the results of immunohistochemistry, western blot and electrophoretic mobility shift assay (EMSA). However, fucoxanthin failed to provide neuroprotection and activated autophagy following TBI in Nrf2/mice. In conclusion, our studies indicated that fucoxanthin provided neuroprotective effects in models of TBI, potentially via regulation of the Nrf2-ARE and Nrf2-autophagy pathways.	[Zhang, Li; Wang, Handong; Fan, Youwu; Gao, Yongyue; Li, Xiang; Hu, Zhigang; Ding, Ke; Wang, Yujie; Wang, Xiaoliang] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China		Wang, HD (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China.	njhdwang@hotmail.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81672503, 81401026]; Key Medical Subjects of Jiangsu Province [X4200722]	This work was supported by Grants from the National Natural Science Foundation of China (No. 81672503 and 81401026) and the Key Medical Subjects of Jiangsu Province (no. X4200722).	Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Brooks JC, 2013, ARCH PHYS MED REHAB, V94, P2203, DOI 10.1016/j.apmr.2013.07.005; Chen G, 2011, J NEUROSCI RES, V89, P515, DOI 10.1002/jnr.22577; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; de Vries HE, 2008, FREE RADICAL BIO MED, V45, P1375, DOI 10.1016/j.freeradbiomed.2008.09.001; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Dogan A, 1997, J NEUROSURG, V87, P921, DOI 10.3171/jns.1997.87.6.0921; Fan WL, 2010, AUTOPHAGY, V6, P614, DOI 10.4161/auto.6.5.12189; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Gammone MA, 2015, MAR DRUGS, V13, P2196, DOI 10.3390/md13042196; GEACINTOV NE, 1984, BIOPHYS CHEM, V20, P121, DOI 10.1016/0301-4622(84)80012-5; Hatic H, 2012, J NEUROTRAUM, V29, P1188, DOI 10.1089/neu.2011.1806; Jin W, 2011, INJURY, V42, P714, DOI 10.1016/j.injury.2011.03.009; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Larsen KB, 2010, AUTOPHAGY, V6, P784, DOI 10.4161/auto.6.6.12510; Lei S, 2014, ASN NEURO, V6, DOI 10.1177/1759091414558417; Li LL, 2015, CELL MOL NEUROBIOL, V35, P615, DOI 10.1007/s10571-015-0166-x; Lin JJ, 2016, MAR DRUGS, V14, DOI 10.3390/md14040067; Liu CL, 2011, J AGR FOOD CHEM, V59, P11344, DOI 10.1021/jf2029785; Liu Y, 2016, INT J OPHTHALMOL-CHI, V9, P9, DOI 10.18240/ijo.2016.01.02; Liu YX, 2016, J AGR FOOD CHEM, V64, P416, DOI 10.1021/acs.jafc.5b05436; Mao L, 2012, J TRAUMA ACUTE CARE, V72, P189, DOI 10.1097/TA.0b013e31821bf541; Noda NN, 2008, GENES CELLS, V13, P1211, DOI 10.1111/j.1365-2443.2008.01238.x; Ovey IS, 2015, NEUROSCIENCE, V284, P225, DOI 10.1016/j.neuroscience.2014.09.078; Pajares M, 2016, AUTOPHAGY, V12, P1902, DOI 10.1080/15548627.2016.1208889; Puissant A, 2012, AM J CANCER RES, V2, P397; Rodriguez KJ, 2013, J DERMATOL SCI, V72, P304, DOI 10.1016/j.jdermsci.2013.08.004; Sauzeau V, 2003, J BIOL CHEM, V278, P9472, DOI 10.1074/jbc.M212776200; Sugawara T, 2002, J NUTR, V132, P946, DOI 10.1093/jn/132.5.946; Villeneuve NF, 2010, ANTIOXID REDOX SIGN, V13, P1699, DOI 10.1089/ars.2010.3211; Wang JA, 2007, FREE RADICAL BIO MED, V43, P408, DOI 10.1016/j.freeradbiomed.2007.04.020; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wu KC, 2012, TOXICOL APPL PHARM, V263, P14, DOI 10.1016/j.taap.2012.05.017; Xu JG, 2014, BRAIN RES, V1582, P237, DOI 10.1016/j.brainres.2014.07.042; Xu JG, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/187873; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Yan W, 2009, J TRAUMA, V66, P1431, DOI 10.1097/TA.0b013e318180f5c7; Yan XJ, 1999, BIOSCI BIOTECH BIOCH, V63, P605, DOI 10.1271/bbb.63.605; Zhang HL, 2011, NEUROSCIENCE, V176, P381, DOI 10.1016/j.neuroscience.2010.12.029; Zhang Lijuan, 2016, Zhongguo Zhen Jiu, V36, P131; Zhang Yan-Bo, 2008, Neurosci Bull, V24, P143, DOI 10.1007/s12264-008-1108-0; Zhao YB, 2012, EXP NEUROL, V237, P489, DOI 10.1016/j.expneurol.2012.07.004; Zheng J, 2014, MAR DRUGS, V12, P4214, DOI 10.3390/md12074214	43	80	84	2	27	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	2045-2322			SCI REP-UK	Sci Rep	APR 21	2017	7								46763	10.1038/srep46763			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET0UU	WOS:000399980400001	28429775	gold, Green Published			2022-02-06	
J	Nelson, LD; Tarima, S; LaRoche, AA; Hammeke, TA; Barr, WB; Guskiewicz, K; Randolph, C; McCrea, MA				Nelson, Lindsay D.; Tarima, Sergey; LaRoche, Ashley A.; Hammeke, Thomas A.; Barr, William B.; Guskiewicz, Kevin; Randolph, Christopher; McCrea, Michael A.			Preinjury somatization symptoms contribute to clinical recovery after sport-related concussion	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; MINOR HEAD-INJURY; PROLONGED RECOVERY; MENTAL-DISORDERS; HIGH-SCHOOL; PREDICTORS; SEVERITY	Objective:To determine the degree to which preinjury and acute postinjury psychosocial and injury-related variables predict symptom duration following sport-related concussion.Methods:A total of 2,055 high school and collegiate athletes completed preseason evaluations. Concussed athletes (n = 127) repeated assessments serially (<24 hours and days 8, 15, and 45) postinjury. Cox proportional hazard modeling was used to predict concussive symptom duration (in days). Predictors considered included demographic and history variables; baseline psychological, neurocognitive, and balance functioning; acute injury characteristics; and postinjury clinical measures.Results:Preinjury somatic symptom score (Brief Symptom Inventory-18 somatization scale) was the strongest premorbid predictor of symptom duration. Acute (24-hour) postconcussive symptom burden (Sport Concussion Assessment Tool-3 symptom severity) was the best injury-related predictor of recovery. These 2 predictors were moderately correlated (r = 0.51). Path analyses indicated that the relationship between preinjury somatization symptoms and symptom recovery was mediated by postinjury concussive symptoms.Conclusions:Preinjury somatization symptoms contribute to reported postconcussive symptom recovery via their influence on acute postconcussive symptoms. The findings highlight the relevance of premorbid psychological factors in postconcussive recovery, even in a healthy athlete sample relatively free of psychopathology or medical comorbidities. Future research should elucidate the neurobiopsychosocial mechanisms that explain the role of this individual difference variable in outcome following concussive injury.	[Nelson, Lindsay D.; LaRoche, Ashley A.; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Nelson, Lindsay D.; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Tarima, Sergey] Med Coll Wisconsin, Div Biostat, Inst Hlth & Soc, Milwaukee, WI 53226 USA; [Hammeke, Thomas A.] Med Coll Wisconsin, Dept Psychiat & Behav Med, Milwaukee, WI 53226 USA; [Barr, William B.] NYU, Dept Neurol, Sch Med, New York, NY 10016 USA; [Guskiewicz, Kevin] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Randolph, Christopher] Loyola Univ, Med Ctr, Dept Neurol, 2160 S 1st Ave, Maywood, IL 60153 USA		Nelson, LD (corresponding author), Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA.; Nelson, LD (corresponding author), Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA.	linelson@mcw.edu		Barr, William/0000-0001-7711-7758; LaRoche, Ashley/0000-0003-0197-0853	US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-12-1-0004]; Clinical and Translational Science Institute [1UL1-RR031973 [-01]]; NIH National Center for Advancing Translational Sciences [8UL1TR000055]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000055] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR031973] Funding Source: NIH RePORTER	Supported by the US Army Medical Research and Materiel Command (award W81XWH-12-1-0004), the Clinical and Translational Science Institute (grant 1UL1-RR031973 [-01]), and the NIH National Center for Advancing Translational Sciences (grant 8UL1TR000055). Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army. The manuscript's contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.	[Anonymous], 2003, GREENS MED SYMPT VAL; Broshek DK, 2015, BRAIN INJURY, V29, P228, DOI 10.3109/02699052.2014.974674; Browning M, 2011, PSYCHOSOM MED, V73, P173, DOI 10.1097/PSY.0b013e31820824f6; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Derogatis L.R., 2001, BRIEF SYMPTOM INVENT; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dimsdale JE, 2013, J PSYCHOSOM RES, V75, P223, DOI 10.1016/j.jpsychores.2013.06.033; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Helmick K, 2006, DEFENSE VETERANS BRA, P1; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Iacobucci D, 2012, J CONSUM PSYCHOL, V22, P582, DOI 10.1016/j.jcps.2012.03.006; Insel T, 2010, AM J PSYCHIAT, V167, P748, DOI 10.1176/appi.ajp.2010.09091379; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Krueger RF, 1999, ARCH GEN PSYCHIAT, V56, P921, DOI 10.1001/archpsyc.56.10.921; LaRoche AA, 2016, CLIN J SPORT MED, V26, P33, DOI 10.1097/JSM.0000000000000192; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MacFarlane MP, 2015, BRAIN INJURY, V29, P139, DOI 10.3109/02699052.2014.965208; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2015, BRAIN INJURY, V29, P276, DOI 10.3109/02699052.2014.965216; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Nelson LD, 2016, J INT NEUROPSYCH SOC, V22, P24, DOI 10.1017/S1355617715001101; Nelson LD, 2015, AM J SPORT MED, V43, P2018, DOI 10.1177/0363546515587714; Nelson LD, 2013, NEUROPSYCHOL REV, V23, P285, DOI 10.1007/s11065-013-9240-7; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Tsao JW, 2014, NEUROLOGY, V83, P2196, DOI 10.1212/WNL.0000000000001086; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; WechslerD, 2001, WECHSLER TEST ADULT; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Widiger TA, 2005, J ABNORM PSYCHOL, V114, P494, DOI 10.1037/0021-843X.114.4.494; Wood RL, 2011, BRAIN INJURY, V25, P1296, DOI 10.3109/02699052.2011.624569; Yuh Esther L, 2014, Neurosurgery, V75 Suppl 4, pS50, DOI 10.1227/NEU.0000000000000491	39	80	80	2	28	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	MAY 17	2016	86	20					1856	1863		10.1212/WNL.0000000000002679			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DN0US	WOS:000376782000006	27164666	Green Published			2022-02-06	
J	Tulsky, DS; Kisala, PA; Victorson, D; Carlozzi, N; Bushnik, T; Sherer, M; Choi, SW; Heinemann, AW; Chiaravalloti, N; Sander, AM; Englander, J; Hanks, R; Kolakowsky-Hayner, S; Roth, E; Gershon, R; Rosenthal, M; Cella, D				Tulsky, David S.; Kisala, Pamela A.; Victorson, David; Carlozzi, Noelle; Bushnik, Tamara; Sherer, Mark; Choi, Seung W.; Heinemann, Allen W.; Chiaravalloti, Nancy; Sander, Angelle M.; Englander, Jeffrey; Hanks, Robin; Kolakowsky-Hayner, Stephanie; Roth, Elliot; Gershon, Richard; Rosenthal, Mitchell; Cella, David			TBI-QOL: Development and Calibration of Item Banks to Measure Patient Reported Outcomes Following Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						common data elements; clinical research; health-related quality of life; item response theory; patient-reported outcomes; quality of life; traumatic brain injury	QUALITY-OF-LIFE; COMPUTERIZED ADAPTIVE ASSESSMENT; INFORMATION-SYSTEM PROMIS; RESPONSE THEORY; REHABILITATION-MEDICINE; SHORT-FORMS; HEALTH; ISSUES; SCALE; RECOMMENDATIONS	Objective: To use a patient-centered approach or participatory action research design combined with advanced psychometrics to develop a comprehensive patient-reported outcomes (PRO) measurement system specifically for individuals with traumatic brain injury (TBI). This TBI Quality-of-Life (TBI-QOL) measurement system expands the work of other large PRO measurement initiatives, that is, the Patient-Reported Outcomes Measurement Information System and the Neurology Quality-of-Life measurement initiative. Setting: Five TBI Model Systems centers across the United States. Participants: Adults with TBI. Design: Classical and modern test development methodologies were used. Qualitative input was obtained from individuals with TBI, TBI clinicians, and caregivers of individuals with TBI through multiple methods, including focus groups, individual interviews, patient consultation, and cognitive debriefing interviews. Item pools were field tested in a large multisite sample (n = 675) and calibrated using item response theory methods. Main Outcomes Measures: Twenty-two TBI-QOL item banks/scales. Results: The TBI-QOL consists of 20 independent calibrated item banks and 2 uncalibrated scales that measure physical, emotional, cognitive, and social aspects of health-related quality of life. Conclusions: The TBI-QOL measurement system has potential as a common data element in TBI research and to enhance collection of health-related quality-of-life and PRO data in rehabilitation research and clinical settings.	[Tulsky, David S.; Kisala, Pamela A.] Univ Delaware, Coll Hlth Sci, Dept Phys Therapy, STAR Hlth Sci Complex,540 S Coll Ave, Newark, DE 19713 USA; [Tulsky, David S.; Chiaravalloti, Nancy; Rosenthal, Mitchell] Kessler Fdn Res Ctr, W Orange, NJ USA; [Bushnik, Tamara] NYU, Langone Med Ctr, New York, NY USA; [Victorson, David; Heinemann, Allen W.; Roth, Elliot; Gershon, Richard; Cella, David] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Carlozzi, Noelle] Univ Michigan, Sch Med, Ann Arbor, MI USA; [Sherer, Mark; Sander, Angelle M.] TIRR Mem Hermann, Houston, TX USA; [Choi, Seung W.] McGraw Hill Educ CTB, Monterey, CA USA; [Heinemann, Allen W.; Roth, Elliot] Rehabil Inst Chicago, Chicago, IL 60611 USA; [Chiaravalloti, Nancy] Rutgers NJ Univ, Med Ctr, Newark, NJ USA; [Sander, Angelle M.] Baylor Coll Med, Houston, TX 77030 USA; [Englander, Jeffrey; Kolakowsky-Hayner, Stephanie] Santa Clara Valley Med Ctr, Santa Clara, CA USA; [Hanks, Robin] Wayne State Univ, Sch Med, Detroit, MI USA		Tulsky, DS (corresponding author), Univ Delaware, Coll Hlth Sci, Dept Phys Therapy, STAR Hlth Sci Complex,540 S Coll Ave, Newark, DE 19713 USA.	dtulsky@udel.edu	Heinemann, Allen W./AAI-2790-2021; Kolakowsky-Hayner, Stephanie A./I-9858-2019	Heinemann, Allen W./0000-0003-2782-7326; Kolakowsky-Hayner, Stephanie A./0000-0002-6228-9909; Bushnik, Tamara/0000-0003-3328-257X; Tulsky, David/0000-0002-4335-4509	National Institute on Disability and Rehabilitation Research [H133G070138, H133A070037, H133A070043, H133A080045, H133A080044, H133A70038]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U2CCA186878] Funding Source: NIH RePORTER	This study was supported by grant nos. H133G070138, H133A070037, H133A070043, H133A080045, H133A080044, and H133A70038 from the National Institute on Disability and Rehabilitation Research.	Bjorner JB, 2007, QUAL LIFE RES, V16, P95, DOI 10.1007/s11136-007-9168-6; Bode RK, 2003, ARCH PHYS MED REHAB, V84, pS52, DOI 10.1053/apmr.2003.50247; Bottari C, 2007, J HEAD TRAUMA REHAB, V22, P26, DOI 10.1097/00001199-200701000-00003; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Carlozzi NE, 2011, ARCH PHYS MED REHAB, V92, pS52, DOI 10.1016/j.apmr.2010.12.046; Cella D F, 1995, Oncology (Williston Park), V9, P47; Cella D, 2007, QUAL LIFE RES, V16, P133, DOI 10.1007/s11136-007-9204-6; Cella D, 2011, ARCH PHYS MED REHAB, V92, pS28, DOI 10.1016/j.apmr.2011.01.025; Cella D, 2010, J CLIN EPIDEMIOL, V63, P1179, DOI 10.1016/j.jclinepi.2010.04.011; Choi SW, 2011, J STAT SOFTW, V39, P1; DeWitt EM, 2011, J CLIN EPIDEMIOL, V64, P794, DOI 10.1016/j.jclinepi.2010.10.012; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Eremenco SL, 2005, EVAL HEALTH PROF, V28, P212, DOI 10.1177/0163278705275342; Fries JF, 2009, J RHEUMATOL, V36, P2061, DOI 10.3899/jrheum.090358; Fries JF, 2005, CLIN EXP RHEUMATOL, V23, pS53; Gershon R, 2010, QUAL LIFE RES, V19, P677, DOI 10.1007/s11136-010-9634-4; Gershon RC, 2012, QUAL LIFE RES, V21, P475, DOI 10.1007/s11136-011-9958-8; Hays RD, 2009, QUAL LIFE RES, V18, P873, DOI 10.1007/s11136-009-9496-9; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Kisala Pamela A, 2010, J Appl Meas, V11, P315; Lai JS, 2011, ARCH PHYS MED REHAB, V92, pS20, DOI 10.1016/j.apmr.2010.08.033; Lie HH, 2010, J CLIN EPIDEMIOL, V63, P1169, DOI 10.1016/j.jclinepi.2009.11.021; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; MESSICK S, 1995, AM PSYCHOL, V50, P741, DOI 10.1037/0003-066X.50.9.741; MESSICK S, 1980, AM PSYCHOL, V35, P1012, DOI 10.1037/0003-066X.35.11.1012; Orlando M, 2003, APPL PSYCH MEAS, V27, P289, DOI 10.1177/0146621603027004004; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; PROMIS, 2012, PROMIS INSTR DEV PSY; Quatrano LA, 2011, ARCH PHYS MED REHAB, V92, pS7, DOI 10.1016/j.apmr.2010.08.032; Reeve BB, 2007, QUAL LIFE RES, V16, P175, DOI 10.1007/s11136-007-9190-8; Reeve BB, 2007, QUAL LIFE RES, V16, P1, DOI 10.1007/s11136-007-9220-6; REISE SP, 1990, J EDUC MEAS, V27, P133, DOI 10.1111/j.1745-3984.1990.tb00738.x; Rosenthal M, 2007, HDB REHABILITATION P, P49; Samejima F, 1996, HDB MODERN ITEM RESP, P85; Sherer M., 2005, FORENSIC NEUROPSYCHO, P237; Steinberg L, 1996, PSYCHOL METHODS, V1, P81, DOI 10.1037/1082-989X.1.1.81; STOCKING ML, 1983, APPL PSYCH MEAS, V7, P201, DOI 10.1177/014662168300700208; Thissen D, 2007, QUAL LIFE RES, V16, P109, DOI 10.1007/s11136-007-9169-5; Tulsky DS, 2011, ARCH PHYS MED REHAB, V92, pS1, DOI 10.1016/j.apmr.2011.07.202; Varni JW, 2010, J PAIN, V11, P1109, DOI 10.1016/j.jpain.2010.02.005; Velozo CA, 2012, ARCH PHYS MED REHAB, V93, pS154, DOI 10.1016/j.apmr.2012.06.001; Whiteneck GG, 2011, ARCH PHYS MED REHAB, V92, P542, DOI 10.1016/j.apmr.2010.08.002; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Whyte J, 2005, PHYS MED REHABILITAT, P1677; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Yeatts KB, 2010, J ASTHMA, V47, P295, DOI 10.3109/02770900903426997	49	80	80	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2016	31	1					40	51		10.1097/HTR.0000000000000131			12	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	DK9CN	WOS:000375228000013	25931184	Green Published			2022-02-06	
J	Krajcova, A; Waldauf, P; Andel, M; Duska, F				Krajcova, Adela; Waldauf, Petr; Andel, Michal; Duska, Frantisek			Propofol infusion syndrome: a structured review of experimental studies and 153 published case reports	CRITICAL CARE			English	Article							RAT-LIVER MITOCHONDRIA; FATTY-ACID OXIDATION; GENERAL ANESTHETIC 2,6-DIISOPROPYLPHENOL; FATAL MYOCARDIAL FAILURE; CRITICALLY-ILL ADULTS; INTENSIVE-CARE-UNIT; METABOLIC-ACIDOSIS; LACTIC-ACIDOSIS; MECHANICAL VENTILATION; OVERLOAD SYNDROME	Introduction: Propofol infusion syndrome (PRIS) is a rare, but potentially lethal adverse effect of a commonly used drug. We aimed to review and correlate experimental and clinical data about this syndrome. Methods: We searched for all case reports published between 1990 and 2014 and for all experimental studies on PRIS pathophysiology. We analysed the relationship between signs of PRIS and the rate and duration of propofol infusion causing PRIS. By multivariate logistic regression we looked at the risk factors for mortality. Results: Knowledge about PRIS keeps evolving. Compared to earlier case reports in the literature, recently published cases describe older patients developing PRIS at lower doses of propofol, in whom arrhythmia, hypertriglyceridaemia and fever are less frequently seen, with survival more likely. We found that propofol infusion rate and duration, the presence of traumatic brain injury and fever are factors independently associated with mortality in reported cases of PRIS (area under receiver operator curve = 0.85). Similar patterns of exposure to propofol (in terms of time and concentration) are reported in clinical cases and experimental models of PRIS. Cardiac failure and metabolic acidosis occur early in a dose-dependent manner, while arrhythmia, other electrocardiographic changes and rhabdomyolysis appear more frequently after prolonged propofol infusions, irrespective of dose. Conclusion: PRIS can develop with propofol infusion <4 mg/kg per hour and its diagnosis may be challenging as some of its typical features (hypertriglyceridaemia, fever, hepatomegaly, heart failure) are often (>95 %) missing and others (arrhythmia, electrocardiographic changes) occur late.	[Krajcova, Adela; Andel, Michal; Duska, Frantisek] Charles Univ Prague, Lab Metab & Bioenerget, Fac Med 3, Prague, Czech Republic; [Krajcova, Adela; Andel, Michal] Charles Univ Prague, Ctr Res Diabet Metab & Nutr, Fac Med 3, Prague, Czech Republic; [Waldauf, Petr; Duska, Frantisek] Charles Univ Prague, Dept Anaesthesiol & Intens Care, Fac Med 3, Prague, Czech Republic; [Duska, Frantisek] Nottingham Univ Hosp NHS Trust, Adult Intens Care Unit, Nottingham, England		Krajcova, A (corresponding author), Charles Univ Prague, Lab Metab & Bioenerget, Fac Med 3, Prague, Czech Republic.	adela.krajcova@seznam.cz	Krajcova, Adela/AAM-6645-2020; Andel, Michal/E-4305-2012; Waldauf, Petr/K-6785-2017	Waldauf, Petr/0000-0003-4668-5837; Krajcova, Adela/0000-0002-9859-960X	grant SVV;  [GAUK 270915];  [PRVOUK P31]	We thank Dr. Dale Gardiner and Dr. Tom Munford for valuable comments. Supported by grant GAUK 270915 Mitochondrial pathogenesis of propofol infusion syndrome in an in vitro model of human skeletal muscle and by grants PRVOUK P31 and SVV 2015.	Adolph M., 2009, GER MED SCI, V7, pDoc22; Ahlen K, 2006, EUR J ANAESTH, V23, P990, DOI 10.1017/S0265021506001281; BARCLAY K, 1992, BRIT MED J, V305, P953, DOI 10.1136/bmj.305.6859.953; Baumeister FAM, 2004, NEUROPEDIATRICS, V35, P250, DOI 10.1055/s-2004-820992; BODD E, 1992, TIDSSKR NOR LAEGEFOR, V112, P1636; BRANCA D, 1991, ARCH BIOCHEM BIOPHYS, V290, P517, DOI 10.1016/0003-9861(91)90575-4; BRANCA D, 1991, BIOCHEM PHARMACOL, V42, P87, DOI 10.1016/0006-2952(91)90684-W; BRANCA D, 1995, COMP BIOCHEM PHYS C, V110, P41, DOI 10.1016/0742-8413(94)00078-O; BRAY RJ, 1995, ANAESTHESIA, V50, P94, DOI 10.1111/j.1365-2044.1995.tb04544.x; Bray RJ, 1998, PAEDIATR ANAESTH, V8, P491; Burow BK, 2004, ANESTHESIOLOGY, V101, P239, DOI 10.1097/00000542-200407000-00035; Chukwuemeka A, 2006, ANAESTH INTENS CARE, V34, P651, DOI 10.1177/0310057X0603400503; Commissioner COT, MEDWATCH FDA SAF INF; Cray SH, 1998, CRIT CARE MED, V26, P2087, DOI 10.1097/00003246-199812000-00046; Cree MG, 2008, AM J PHYSIOL-ENDOC M, V294, pE1, DOI 10.1152/ajpendo.00562.2007; Cremer OL, 2001, LANCET, V357, P117, DOI 10.1016/S0140-6736(00)03547-9; Fong JJ, 2008, CRIT CARE MED, V36, P2281, DOI 10.1097/CCM.0b013e318180c1eb; Fraser GL, 2013, CRIT CARE MED, V41, pS30, DOI 10.1097/CCM.0b013e3182a16898; Gura KM, 2010, NUTR CLIN PRACT, V25, P399, DOI 10.1177/0884533610373770; Haase R, 2005, J NEUROSURG ANESTH, V17, P122, DOI 10.1097/01.ana.0000161267.63160.13; Hanna JP, 1998, NEUROLOGY, V50, P301, DOI 10.1212/WNL.50.1.301; HEYMAN MB, 1981, AM J DIS CHILD, V135, P628, DOI 10.1001/archpedi.1981.02130310034012; Holzki J, 2004, PEDIATR ANESTH, V14, P265, DOI 10.1046/j.1460-9592.2003.01179.x; Jiang W, 2012, ACTA PHARMACOL SIN, V33, P27, DOI 10.1038/aps.2011.155; Jouven X, 2001, CIRCULATION, V104, P756, DOI 10.1161/hc3201.094151; Kill C, 2003, PAEDIATR ANAESTH, V13, P823, DOI 10.1046/j.1460-9592.2003.01114.x; KIRKPATRICK M, 1992, BRIT MED J, V305, P1223, DOI 10.1136/bmj.305.6863.1223-a; Koch M, 2004, INTENS CARE MED, V30, P522, DOI 10.1007/s00134-003-2130-3; Lee SK, 2012, CELL SIGNAL, V24, P2329, DOI 10.1016/j.cellsig.2012.07.022; Lin MC, 2012, TOXICOL APPL PHARM, V265, P253, DOI 10.1016/j.taap.2012.08.013; Linko R, 2014, J BURN CARE RES, V35, pE364, DOI 10.1097/BCR.0000000000000053; Lonardo NW, 2014, AM J RESP CRIT CARE, V189, P1383, DOI 10.1164/rccm.201312-2291OC; Marinella MA, 1996, CHEST, V109, P292, DOI 10.1378/chest.109.1.292; Mehta N, 1999, LANCET, V354, P866, DOI 10.1016/S0140-6736(05)75936-5; Neubauer S, 2007, NEW ENGL J MED, V356, P1140, DOI 10.1056/NEJMra063052; Notisfra Bivirkningsnaenet, 1990, UGESKRIFT LAEGER, V152, P1176; PARKE TJ, 1992, BRIT MED J, V305, P613, DOI 10.1136/bmj.305.6854.613; Perrier ND, 2000, CRIT CARE MED, V28, P3071, DOI 10.1097/00003246-200008000-00066; Richter S, 2012, Herzschrittmacherther Elektrophysiol, V23, P56, DOI 10.1007/s00399-011-0156-8; Rigoulet M, 1996, EUR J BIOCHEM, V241, P280; Rinaido P, ACYLCARNITINE PROFIL; Roberts RJ, 2009, CRIT CARE, V13, DOI 10.1186/cc8145; Romero C, 2008, REV MED CHILE, V136, P88, DOI /S0034-98872008000100011; ROTTENBERG H, 1983, P NATL ACAD SCI-BIOL, V80, P3313, DOI 10.1073/pnas.80.11.3313; Schenkman KA, 2000, CRIT CARE MED, V28, P172, DOI 10.1097/00003246-200001000-00028; Schroeppel TJ, 2014, INJURY, V45, P245, DOI 10.1016/j.injury.2013.05.004; STANLEY CA, 2006, INBORN METABOLIC DIS, P175; Stelow EB, 2000, CLIN CHEM, V46, P577; STRICKLAND RA, 1995, CRIT CARE MED, V23, P405, DOI 10.1097/00003246-199502000-00029; Terrone G, 2014, NEUROLOGY, V82, pE1, DOI 10.1212/01.wnl.0000438217.31437.72; Tiwari R., US ANESTHESIA DRUGS; Tong Xian-xiang, 2010, Sichuan Da Xue Xue Bao Yi Xue Ban, V41, P1021; U.S. Food and Drug Administration MedWatch, 2001, 2001 SAF AL DRUGS BI; U.S. Food snd Drug Administration, 2007, DET VIEW SAF LAB CHA; Vanlander AV, 2015, ANESTHESIOLOGY, V122, P343, DOI 10.1097/ALN.0000000000000484; Westhout FD, 2007, J NEUROSURG, V106, P139, DOI 10.3171/ped.2007.106.2.139; Withington DE, 2004, PEDIATR ANESTH, V14, P505, DOI 10.1111/j.1460-9592.2004.01299.x; Wolf A, 2001, LANCET, V357, P606, DOI 10.1016/S0140-6736(00)04064-2; Wolf AR, 2004, PEDIATR ANESTH, V14, P435, DOI 10.1111/j.1460-9592.2004.01332.x; Ypsilantis P, 2007, ANESTH ANALG, V105, P155, DOI 10.1213/01.ane.0000265544.44948.0b	60	80	82	0	17	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	NOV 12	2015	19								398	10.1186/s13054-015-1112-5			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CV8RZ	WOS:000364556700001	26558513	Green Published, gold			2022-02-06	
J	Goldshmit, Y; Kanner, S; Zacs, M; Frisca, F; Pinto, AR; Currie, PD; Pinkas-Kramarski, R				Goldshmit, Yona; Kanner, Sivan; Zacs, Maria; Frisca, Frisca; Pinto, Alexander R.; Currie, Peter D.; Pinkas-Kramarski, Ronit			Rapamycin increases neuronal survival, reduces inflammation and astrocyte proliferation after spinal cord injury	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article						Rapamycin; Spinal cord injury; Akt; Inflammation; Astrogliosis; Neuronal survival	UP-REGULATION; CEREBRAL-ISCHEMIA; PROTEIN-KINASE; AUTOPHAGY; INHIBITION; PATHWAY; TARGET; REGENERATION; IMPROVEMENT; ACTIVATION	Spinal cord injury (SCI) frequently leads to a permanent functional impairment as a result of the initial injury followed by secondary injury mechanism, which is characterised by increased inflammation, glial scarring and neuronal cell death. Finding drugs that may reduce inflammatory cell invasion and activation to reduce glial scarring and increase neuronal survival is of major importance for improving the outcome after SCI. In the present study, we examined the effect of rapamycin, an mTORC1 inhibitor and an inducer of autophagy, on recovery from spinal cord injury. Autophagy, a process that facilitates the degradation of cytoplasmic proteins, is also important for maintenance of neuronal homeostasis and plays a major role in neurodegeneration after neurotrauma. We examined rapamycin effects on the inflammatory response, glial scar formation, neuronal survival and regeneration in vivo using spinal cord hemisection model in mice, and in vitro using primary cortical neurons and human astrocytes. We show that a single injection of rapamycin, inhibited p62/SQSTM1, a marker of autophagy, inhibited mTORC1 downstream effector p70S6K, reduced macrophage/neutrophil infiltration into the lesion site, microglia activation and secretion of TNF alpha. Rapamycin inhibited astrocyte proliferation and reduced the number of GFAP expressing cells at the lesion site. Finally, it increased neuronal survival and axonogenesis towards the lesion site. Our study shows that rapamycin treatment increased significantly p-Akt levels at the lesion site following SCI. Similarly, rapamycin treatment of neurons and astrocytes induced p-Akt elevation under stress conditions. Together, these findings indicate that rapamycin is a promising candidate for treatment of acute SCI condition and may be a useful therapeutic agent. (C) 2015 Elsevier Inc. All rights reserved.	[Goldshmit, Yona; Kanner, Sivan; Zacs, Maria; Pinkas-Kramarski, Ronit] Tel Aviv Univ, Dept Neurobiol, IL-69978 Ramat Aviv, Israel; [Goldshmit, Yona; Frisca, Frisca; Pinto, Alexander R.; Currie, Peter D.] Monash Univ, Australian Regenerat Med Inst, Clayton, Vic 3800, Australia; [Frisca, Frisca] Univ Melbourne, Dept Ophthalmol, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic, Australia		Goldshmit, Y (corresponding author), Tel Aviv Univ, Dept Neurobiol, IL-69978 Ramat Aviv, Israel.	yona.goldshmit@monash.edu; lironit@post.tau.ac.il	Pinto, Alexander/AAF-5556-2021	Pinto, Alexander/0000-0001-6421-4970; Pinkas-Kramarski, Ronit/0000-0002-1000-369X; Currie, Peter/0000-0001-8874-8862	Ministry of Aliyah and Immigrant Absorption [00050001000]; Ministry of Defence for Medical Research [00340051000]	This work was supported by the Ministry of Aliyah and Immigrant Absorption no. 00050001000, and by the Ministry of Defence for Medical Research no. 00340051000, Israel (to YG).	Angliker Nico, 2013, Bioarchitecture, V3, P113, DOI 10.4161/bioa.26497; Beattie MS, 2004, TRENDS MOL MED, V10, P580, DOI 10.1016/j.molmed.2004.10.006; Berger Z, 2006, HUM MOL GENET, V15, P433, DOI 10.1093/hmg/ddi458; Carloni S, 2008, NEUROBIOL DIS, V32, P329, DOI 10.1016/j.nbd.2008.07.022; Chen HC, 2013, J SURG RES, V179, pE203, DOI 10.1016/j.jss.2012.02.023; Cicora F, 2010, TRANSPL P, V42, P365, DOI 10.1016/j.transproceed.2009.11.013; Codeluppi S, 2009, J NEUROSCI, V29, P1093, DOI 10.1523/JNEUROSCI.4103-08.2009; Das F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109608; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Erlich S, 2006, AUTOPHAGY, V2, P49, DOI 10.4161/auto.2156; Goldshmit Y, 2004, J NEUROSCI, V24, P10064, DOI 10.1523/JNEUROSCI.2981-04.2004; Goldshmit Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024636; Gregory EN, 2013, J NEUROSCI RES, V91, P300, DOI 10.1002/jnr.23144; Herzog N, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/5/056008; Hu LY, 2010, NEUROSCIENCE, V169, P1046, DOI 10.1016/j.neuroscience.2010.05.046; Kamada Y, 2003, CURR TOP MICROBIOL, V279, P73; Kanno H, 2011, SPINE, V36, pE1427, DOI 10.1097/BRS.0b013e3182028c3a; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011; Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Pinto AR, 2013, J IMMUNOL METHODS, V393, P74, DOI 10.1016/j.jim.2013.03.012; Puyal J, 2009, ANN NEUROL, V66, P378, DOI 10.1002/ana.21714; Rami A, 2008, NEUROBIOL DIS, V29, P132, DOI 10.1016/j.nbd.2007.08.005; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Reggiori F, 2002, EUKARYOT CELL, V1, P11, DOI 10.1128/EC.01.1.11-21.2002; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Smith CM, 2011, NEUROBIOL DIS, V43, P52, DOI 10.1016/j.nbd.2010.09.014; Song Y, 2015, J BIOCHEM MOL TOXIC, V29, P29, DOI 10.1002/jbt.21603; Tachibana T, 2005, J THORAC CARDIOV SUR, V129, P123, DOI 10.1016/j.jtcvs.2004.04.047; Tang PF, 2014, MOL NEUROBIOL, V49, P276, DOI 10.1007/s12035-013-8518-3; Vignot S, 2005, ANN ONCOL, V16, P525, DOI 10.1093/annonc/mdi113; Wang CW, 2003, MOL MED, V9, P65, DOI 10.1007/BF03402040; Xie LK, 2014, J IMMUNOL, V192, P6009, DOI 10.4049/jimmunol.1303492	35	80	84	2	21	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431	1095-9327		MOL CELL NEUROSCI	Mol. Cell. Neurosci.	SEP	2015	68						82	91		10.1016/j.mcn.2015.04.006			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CU2MO	WOS:000363357800008	25936601				2022-02-06	
J	Acosta, SA; Tajiri, N; de la Pena, I; Bastawrous, M; Sanberg, PR; Kaneko, Y; Borlongan, CV				Acosta, Sandra A.; Tajiri, Naoki; de la Pena, Ike; Bastawrous, Marina; Sanberg, Paul R.; Kaneko, Yuji; Borlongan, Cesar V.			Alpha-Synuclein as a Pathological Link Between Chronic Traumatic Brain Injury and Parkinson's Disease	JOURNAL OF CELLULAR PHYSIOLOGY			English	Article							IN-VIVO; EXPRESSION; MICE; NEURODEGENERATION; PATHOPHYSIOLOGY; OLIGOMERIZATION; ENCEPHALOPATHY; CONSEQUENCES; DEFICITS; RELEASE	The long-term consequences of traumatic brain injury (TBI) are closely associated with the development of histopathological deficits. Notably, TBI may predispose long-term survivors to age-related neurodegenerative diseases, such as Parkinson's disease (PD), which is characterized by a gradual degeneration of the nigrostriatal dopaminergic neurons. However, preclinical studies on the pathophysiological changes in substantia nigra (SN) after chronic TBI are lacking. In the present in vivo study, we examined the pathological link between PD-associated dopaminergic neuronal loss and chronic TBI. Sixty days post-TBI, rats were euthanized and brain tissues harvested. Immunostaining was performed using tyrosine hydroxylase (TH), an enzyme required for the synthesis of dopamine in neurons, -synuclein, a presynaptic protein that plays a role in synaptic vesicle recycling, and major histocompatibility complex II (MHCII), a protein found in antigen presenting cells such as inflammatory microglia cells, all key players in PD pathology. Unbiased stereology analyses revealed significant decrease of TH-positive expression in the surviving dopaminergic neurons of the SN pars compacta (SNpc) relative to sham control. In parallel, increased -synuclein accumulation was detected in the ipsilateral SN compared to the contralateral SN in TBI animals or sham control. In addition, exacerbation of MHCII+ cells was recognized in the SN and cerebral peduncle ipsilateral to injury relative to contralateral side and sham control. These results suggest -synuclein as a pathological link between chronic effects of TBI and PD symptoms as evidenced by significant overexpression and abnormal accumulation of -synuclein in inflammation-infiltrated SN of rats exposed to chronic TBI. J. Cell. Physiol. 230: 1024-1032, 2015. (c) 2014 The Authors. Journal of Cellular Physiology Published by Wiley Periodicals, Inc.	[Acosta, Sandra A.; Tajiri, Naoki; de la Pena, Ike; Bastawrous, Marina; Sanberg, Paul R.; Kaneko, Yuji; Borlongan, Cesar V.] Univ S Florida, Coll Med, Ctr Excellence Aging & Brain Repair, Dept Neurosurg & Brain Repair, Tampa, FL 33612 USA; [Sanberg, Paul R.] Univ S Florida, Off Res & Innovat, Tampa, FL 33612 USA		Borlongan, CV (corresponding author), Univ S Florida, Coll Med, Ctr Excellence Aging & Brain Repair, Dept Neurosurg & Brain Repair, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.	cborlong@health.usf.edu		dela Pena, Ike/0000-0003-2046-522X	National Institutes of Health, National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS071956-01]; Department of DefenseUnited States Department of Defense [W81XWH-11-1-0634]; James and Esther King Foundation for Biomedical Research Program; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS071956] Funding Source: NIH RePORTER	Contract grant sponsor: National Institutes of Health, National Institute of Neurological Disorders and Stroke;; Contract grant number: 1R01NS071956-01.; Contract grant sponsor: Department of Defense;; Contract grant number: W81XWH-11-1-0634.; Contract grant sponsor: James and Esther King Foundation for Biomedical Research Program.	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Amstrong RA, 2003, HISTOPATHOLOGY, V42, P521; Armstrong RA, 2014, J NEURAL TRANSM, V121, P171, DOI 10.1007/s00702-013-1084-z; Auluck PK, 2010, ANNU REV CELL DEV BI, V26, P211, DOI 10.1146/annurev.cellbio.042308.113313; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Burre J, 2010, SCIENCE, V329, P1663, DOI 10.1126/science.1195227; Chandra S, 2004, P NATL ACAD SCI USA, V101, P14966, DOI 10.1073/pnas.0406283101; Chaudhuri KR, 2006, LANCET NEUROL, V5, P235, DOI 10.1016/S1474-4422(06)70373-8; Chauhan NB, 2014, RESTOR NEUROL NEUROS, V32, P337, DOI 10.3233/RNN-130354; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 2000, ANN NY ACAD SCI, V920, P42; Danzer KM, 2011, FASEB J, V25, P326, DOI 10.1096/fj.10-164624; Emmanouilidou E, 2010, J NEUROSCI, V30, P6838, DOI 10.1523/JNEUROSCI.5699-09.2010; Ettenhofer ML, 2009, J CLIN EXP NEUROPSYC, V31, P363, DOI 10.1080/13803390802175270; Fabrizio KS, 2010, NURS CLIN N AM, V45, P569, DOI 10.1016/j.cnur.2010.06.003; Faul M, 2010, TRAUMATIC BRAIN INJU; Gaugler MN, 2012, ACTA NEUROPATHOL, V123, P653, DOI 10.1007/s00401-012-0963-y; Glover LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033646; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Hutson CB, 2011, J NEUROTRAUM, V28, P1783, DOI 10.1089/neu.2010.1723; Jankovic J, 2008, J NEUROL NEUROSUR PS, V79, P368, DOI 10.1136/jnnp.2007.131045; Jannetta PJ, 2011, NEUROL INT, V3, P24, DOI 10.4081/ni.2011.e7; Karantzoulis S, 2013, NEUROPSYCHOL REV, V23, P350, DOI 10.1007/s11065-013-9243-4; Klein C, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a008888; Kokjohn TA, 2013, J NEUROTRAUM, V30, P981, DOI 10.1089/neu.2012.2699; Levin B, 2014, NEUROCRIT CARE, V20, P334, DOI 10.1007/s12028-013-9931-1; Matsuda W, 2003, J NEUROL NEUROSUR PS, V74, P1571, DOI 10.1136/jnnp.74.11.1571; MAYHEW TM, 1991, EXP PHYSIOL, V76, P639, DOI 10.1113/expphysiol.1991.sp003533; Mondello S, 2013, NEUROLOGY, V80, P1662, DOI 10.1212/WNL.0b013e3182904d43; Nemani VM, 2010, NEURON, V65, P66, DOI 10.1016/j.neuron.2009.12.023; Ozen LJ, 2012, ARCH CLIN NEUROPSYCH, V27, P85, DOI 10.1093/arclin/acr087; Paxinos G., 2005, RAT BRAIN STEREOTAXI, V400; Prins M, 2013, DIS MODEL MECH, V6, P1307, DOI 10.1242/dmm.011585; Protter D, 2012, PARKINSONS DIS-US, V2012, DOI 10.1155/2012/829207; Rodrigues TM, 2014, DRUG AGING, V31, P239, DOI 10.1007/s40266-014-0160-x; Saing T, 2012, J NEUROTRAUM, V29, P1054, DOI 10.1089/neu.2011.1957; Sato H, 2013, REV NEUROSCIENCE, V24, P115, DOI 10.1515/revneuro-2012-0071; Shahaduzzaman M, 2013, MED HYPOTHESES, V81, P675, DOI 10.1016/j.mehy.2013.07.025; Siebert H, 2010, J NEUROCHEM, V114, P1007, DOI 10.1111/j.1471-4159.2010.06832.x; Smith C, 2013, NEUROPATH APPL NEURO, V39, P35, DOI 10.1111/nan.12006; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stefanis L, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a009399; Su E, 2010, DEV NEUROSCI-BASEL, V32, P385, DOI 10.1159/000321342; Su LHJ, 2010, DIS MODEL MECH, V3, P194, DOI 10.1242/dmm.004267; Tajiri N, 2014, J NEUROSCI, V34, P313, DOI 10.1523/JNEUROSCI.2425-13.2014; Ulusoy A, 2013, MOL NEUROBIOL, V47, P484, DOI 10.1007/s12035-012-8329-y; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Wagner AK, 2011, J CEREBR BLOOD F MET, V31, P1886, DOI 10.1038/jcbfm.2011.31; Wakabayashi K, 2007, NEUROPATHOLOGY, V27, P494, DOI 10.1111/j.1440-1789.2007.00803.x; Wan OW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038545; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wong JC, 2013, CRIT REV CL LAB SCI, V50, P103, DOI 10.3109/10408363.2013.844678; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yu S, 2004, NEUROSCI LETT, V367, P34, DOI 10.1016/j.neulet.2004.05.118; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067	59	80	80	0	56	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9541	1097-4652		J CELL PHYSIOL	J. Cell. Physiol.	MAY	2015	230	5					1024	1032		10.1002/jcp.24830			9	Cell Biology; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Physiology	CB0FL	WOS:000349301000007	25251017	Green Published, hybrid			2022-02-06	
J	Ling, H; Hardy, J; Zetterberg, H				Ling, Helen; Hardy, John; Zetterberg, Henrik			Neurological consequences of traumatic brain injuries in sports	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article						Chronic traumatic encephalopathy; Dementia pugilistica; Tau; Concussion; Traumatic brain injury; TDP-43	COLLEGIATE FOOTBALL PLAYERS; AMYLOID PRECURSOR PROTEIN; HEAD-INJURY; ALZHEIMERS-DISEASE; PROFESSIONAL FOOTBALL; INTERNATIONAL-CONFERENCE; POSTCONCUSSION SYNDROME; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION; CEREBROSPINAL-FLUID	Traumatic brain injury (TBI) is common in boxing and other contact sports. The long term irreversible and progressive aftermath of TBI in boxers depicted as punch drunk syndrome was described almost a century ago and is now widely referred as chronic traumatic encephalopathy (CTE). The short term sequelae of acute brain injury including subdural haematoma and catastrophic brain injury may lead to death, whereas mild TBI, or concussion, causes functional disturbance and axonal injury rather than gross structural brain damage. Following concussion, symptoms such as dizziness, nausea, reduced attention, amnesia and headache tend to develop acutely but usually resolve within a week or two. Severe concussion can also lead to loss of consciousness. Despite the transient nature of the clinical symptoms, functional neuroimaging, electrophysiological, neuropsychological and neurochemical assessments indicate that the disturbance of concussion takes over a month to return to baseline and neuropathological evaluation shows that concussion-induced axonopathy may persist for years. The developing brains in children and adolescents are more susceptible to concussion than adult brain. The mechanism by which acute TBI may lead to the neurodegenerative process of CTE associated with tau hyperphosphorylation and the development of neurofibrillary tangles (NFTs) remains speculative. Focal tau-positive NFTs and neurites in close proximity to focal axonal injury and foci of microhaemorrhage and the predilection of CTE-tau pathology for perivascular and subcortical regions suggest that acute TBI-related axonal injury, loss of microvascular integrity, breach of the blood brain barrier, resulting inflammatory cascade and microglia and astrocyte activation are likely to be the basis of the mechanistic link of TBI and CTE. This article provides an overview of the acute and long-term neurological consequences of TBI in sports. Clinical, neuropathological and the possible pathophysiological mechanisms are discussed. This article is part of a Special Issue entitled 'Traumatic Brain Injury'. (C) 2015 The Authors. Published by Elsevier Inc.	[Ling, Helen; Hardy, John; Zetterberg, Henrik] UCL Inst Neurol, Reta Lila Weston Inst Neurol Studies, London WC1N 1PJ, England; [Ling, Helen; Hardy, John; Zetterberg, Henrik] UCL Inst Neurol, Queen Sq Brain Bank Neurol Disorders, London WC1N 1PJ, England; [Zetterberg, Henrik] Univ Gothenburg, Sahlgrenska Univ Hosp, Sahlgrenska Acad, Clin Neurochem Lab,Inst Neurosci & Physiol, SE-43180 Molndal, Sweden		Ling, H (corresponding author), UCL Inst Neurol, Reta Lila Weston Inst Neurol Studies, 1 Wakefield St, London WC1N 1PJ, England.	h.ling@ucl.ac.uk; j.hardy@ucl.ac.uk; henrik.zetterberg@clinchem.gu.se	Meijer, Anna/K-5118-2016; Hardy, John/C-2451-2009	Hardy, John/0000-0002-3122-0423	Corticobasal Degeneration Solutions Research Grant; Swedish Research CouncilSwedish Research CouncilEuropean Commission; Alzheimer's AssociationAlzheimer's Association; Swedish State Support for Clinical Research; Knut and Alice Wallenberg FoundationKnut & Alice Wallenberg Foundation; Leonard Wolfson Experimental Neurology Centre	Helen Ling is employed by UCL Institute of Neurology and is funded by the Corticobasal Degeneration Solutions Research Grant. Henrik Zetterberg is a Wallenberg Academy Fellow and receives research support from the Swedish Research Council, Alzheimer's Association, Swedish State Support for Clinical Research and the Knut and Alice Wallenberg Foundation. We gratefully acknowledge the support of the Leonard Wolfson Experimental Neurology Centre.	Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Baird LC, 2010, NEUROSURGERY, V67, P1444, DOI 10.1227/NEU.0b013e3181e5e2cd; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chio A, 2005, BRAIN, V128, P472, DOI 10.1093/brain/awh373; Chio A, 2009, AMYOTROPH LATERAL SC, V10, P205, DOI 10.1080/17482960902721634; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Cottler LB, 2011, DRUG ALCOHOL DEPEN, V116, P188, DOI 10.1016/j.drugalcdep.2010.12.003; Critchley M, 1949, PUNCH DRUNK SYNDROME; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; FOSTER JB, 1976, LANCET, V1, P981; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Gartland S, 2001, BRIT J SPORT MED, V35, P308, DOI 10.1136/bjsm.35.5.308; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Gosselin N, 2011, J NEUROTRAUM, V28, P329, DOI 10.1089/neu.2010.1493; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; GUTERMAN A, 1987, SPORTS MED, V4, P194, DOI 10.2165/00007256-198704030-00004; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Koh JO, 2004, CLIN J SPORT MED, V14, P72, DOI 10.1097/00042752-200403000-00004; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Kors EE, 2001, ANN NEUROL, V49, P753, DOI 10.1002/ana.1031; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Ling H, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-24; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Logan SM, 2001, J ATHL TRAINING, V36, P433; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Lucke-Wold BP, 2014, J NEUROTRAUM, V31, P1129, DOI 10.1089/neu.2013.3303; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; MCQUILLEN JB, 1988, AM J FOREN MED PATH, V9, P12, DOI 10.1097/00000433-198803000-00004; Miele VJ, 2004, MED SCI SPORT EXER, V36, P1852, DOI 10.1249/01.MSS.0000145470.16938.7A; Millspaugh JA, 1937, US NAVAL MED B, V35, P297; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Morales R, 2009, CNS NEUROL DISORD-DR, V8, P363, DOI 10.2174/187152709789541998; Mori T, 2006, ACTA NEUROCHIR SUPPL, V96, P40; Mueller F, 2009, CATASTROPHIC FOOTBAL; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Ohhashi G, 2002, BRIT J SPORT MED, V36, P346, DOI 10.1136/bjsm.36.5.346; Okawa Y, 2003, FEBS LETT, V535, P183, DOI 10.1016/S0014-5793(02)03883-8; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Osnato M, 1927, ARCH NEURO PSYCHIATR, V18, P181, DOI 10.1001/archneurpsyc.1927.02210020025002; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Ramage SN, 2005, NEUROPATH APPL NEURO, V31, P439, DOI 10.1111/j.1365-2990.2005.00670.x; Roberts AH, 1969, BRAIN DAMAGE BOXERS; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Smits M, 2009, HUM BRAIN MAPP, V30, P2789, DOI 10.1002/hbm.20709; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; STRICEVIC MV, 1983, AM J SPORT MED, V11, P320, DOI 10.1177/036354658301100507; Svinth J.R., 2011, J COMBAT SPORT, P1; Tanriverdi F, 2007, CLIN ENDOCRINOL, V66, P360, DOI 10.1111/j.1365-2265.2006.02737.x; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; Unterharnscheidt F, 1995, Rev Neurol, V23, P661; Victoroff J, 2013, NEUROREHABILITATION, V32, P211, DOI 10.3233/NRE-130839; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029; Wilcox BJ, 2014, J BIOMECH, V47, P109, DOI 10.1016/j.jbiomech.2013.10.004; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; Zazryn TR, 2003, BRIT J SPORT MED, V37, P448, DOI 10.1136/bjsm.37.5.448; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7; Zetterberg H, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2007.037143; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489	104	80	82	3	93	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431	1095-9327		MOL CELL NEUROSCI	Mol. Cell. Neurosci.	MAY	2015	66		B		SI		114	122		10.1016/j.mcn.2015.03.012			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CK7FT	WOS:000356398900007	25770439	hybrid, Green Published			2022-02-06	
J	Hijazi, N; Abu Fanne, R; Abramovitch, R; Yarovoi, S; Higazi, M; Abdeen, S; Basheer, M; Maraga, E; Cines, DB; Higazi, AAR				Hijazi, Nuha; Abu Fanne, Rami; Abramovitch, Rinat; Yarovoi, Serge; Higazi, Muhamed; Abdeen, Suhair; Basheer, Maamon; Maraga, Emad; Cines, Douglas B.; Higazi, Abd Al-Roof			Endogenous plasminogen activators mediate progressive intracerebral hemorrhage after traumatic brain injury in mice	BLOOD			English	Article							CLOSED-HEAD INJURY; RECOMMENDED RESEARCH PRIORITIES; LYS HUMAN-PLASMINOGEN; TRANEXAMIC ACID; NERVOUS-SYSTEM; KNOWLEDGE GAPS; NATIVE GLU; TISSUE; RECEPTOR; BINDING	Persistent intracerebral hemorrhage (ICH) is amajor cause of death and disability after traumatic brain injury (TBI) for which no medical treatment is available. Delayed bleeding is often ascribed to consumptive coagulopathy initiated by exposed brain tissue factor. We examined an alternative hypothesis, namely, that marked release of tissue-type plasminogen activator (tPA) followed by delayed synthesis and release of urokinase plasminogen activator (uPA) from injured brain leads to posttraumatic bleeding by causing premature clot lysis. Using a murine model of severe TBI, we found that ICH is reduced in tPA(-/-) and uPA(-/-) mice but increased in PAI-1(-/-) mice compared with wild-type (WT) mice. tPA(-/-), but not uPA(-/-), mice developed a systemic coagulopathy post-TBI. Tranexamic acid inhibited ICH expansion in uPA(-/-) mice but not in tPA(-/-) mice. Catalytically inactive tPA-S 481 A inhibited plasminogen activation by tPA and uPA, attenuated ICH, lowered plasma D-dimers, lessened thrombocytopenia, and improved neurologic outcome in WT, tPA(-/-), anduPA(-/-) mice. ICH expansion was also inhibited by tPA-S 481 A in WT mice anticoagulated with warfarin. These data demonstrate that protracted endogenous fibrinolysis induced by TBI is primarily responsible for persistent ICH and post-TBI coagulopathy in this model and offer a novel approach to interrupt bleeding.	[Hijazi, Nuha; Abu Fanne, Rami; Higazi, Muhamed; Abdeen, Suhair; Basheer, Maamon; Maraga, Emad; Higazi, Abd Al-Roof] Hebrew Univ Jerusalem, Dept Clin Biochem, Hadassah Med Ctr, Jerusalem, Israel; [Abramovitch, Rinat] Hebrew Univ Jerusalem, MRI MRS Lab, Human Biol Res Ctr, Dept Med Biophys,Hadassah Med Ctr, Jerusalem, Israel; [Yarovoi, Serge; Cines, Douglas B.; Higazi, Abd Al-Roof] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA		Higazi, AAR (corresponding author), Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, 513A Stellar Chance,422 Curie Blvd, Philadelphia, PA 19104 USA.	higazi@mail.med.upenn.edu		Cines, Douglas/0000-0001-5986-504X	National Institutes of Health National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS080014]; National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [PO1 HL076406, HL82545]; Israeli Science FoundationIsrael Science Foundation [930/04]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL123912, T32HL007971, P01HL076406] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS080014] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health National Institute of Neurological Disorders and Stroke grant R21 NS080014 and National Heart, Lung, and Blood Institute grants PO1 HL076406 and HL82545; and the Israeli Science Foundation grant 930/04.	Abu Fanne R, 2011, AM J PHYSIOL-REG I, V301, pR668, DOI 10.1152/ajpregu.00058.2011; Akkawi S, 2006, AM J PHYSIOL-HEART C, V291, pH1351, DOI 10.1152/ajpheart.01042.2005; Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; Armstead WM, 2008, BRAIN RES, V1231, P121, DOI 10.1016/j.brainres.2008.06.115; Armstead WM, 2005, DEV BRAIN RES, V156, P139, DOI 10.1016/j.devbraines.2005.02.012; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Boto GR, 2006, J NEUROL NEUROSUR PS, V77, P1054, DOI 10.1136/jnnp.2005.087056; Chang CF, 2011, AM J PATHOL, V178, P1749, DOI 10.1016/j.ajpath.2010.12.023; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chitlur M, 2011, HAEMOPHILIA, V17, P532, DOI 10.1111/j.1365-2516.2010.02451.x; Day SM, 2003, CIRCULATION, V107, P2601, DOI 10.1161/01.CIR.0000066910.02844.D0; Engstrom M, 2005, J NEUROTRAUM, V22, P291, DOI 10.1089/neu.2005.22.291; Fan ZQ, 1998, BLOOD, V91, P1987, DOI 10.1182/blood.V91.6.1987.1987_1987_1998; Fanne Rami Abu, 2011, J Neurosurg, V114, P85, DOI 10.3171/2010.4.JNS10263; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Higazi AA, 1998, BLOOD, V92, P2075, DOI 10.1182/blood.V92.6.2075.418k08_2075_2083; HIGAZI AAR, 1995, J BIOL CHEM, V270, P9472, DOI 10.1074/jbc.270.16.9472; Higazi AAR, 1996, J BIOL CHEM, V271, P17650, DOI 10.1074/jbc.271.30.17650; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Hultman K, 2014, J THROMB HAEMOST, V12, P701, DOI 10.1111/jth.12553; Klak M, 2010, SCAND J INFECT DIS, V42, P351, DOI 10.3109/00365540903510690; LIU JN, 1991, J CLIN INVEST, V88, P2012, DOI 10.1172/JCI115528; Maiya R, 2009, P NATL ACAD SCI USA, V106, P1983, DOI 10.1073/pnas.0812491106; Markus G, 1996, FIBRINOLYSIS, V10, P75, DOI 10.1016/S0268-9499(96)80082-8; MARKUS G, 1978, J BIOL CHEM, V253, P733; MARKUS G, 1979, J BIOL CHEM, V254, P1211; Morowski M, 2013, BLOOD, V121, P4938, DOI 10.1182/blood-2012-10-461459; Nagai N, 1999, CIRCULATION, V99, P2440, DOI 10.1161/01.CIR.99.18.2440; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Nassar T, 2004, BLOOD, V103, P897, DOI 10.1182/blood-2003-05-1685; Nassar T, 2011, AM J PHYSIOL-LUNG C, V301, pL307, DOI 10.1152/ajplung.00429.2010; Nicole O, 2001, NAT MED, V7, P59, DOI 10.1038/83358; Norris EH, 2007, P NATL ACAD SCI USA, V104, P13473, DOI 10.1073/pnas.0705848104; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Pawlak R, 2003, NAT NEUROSCI, V6, P168, DOI 10.1038/nn998; Pusateri AE, 2013, SHOCK, V39, P121, DOI 10.1097/SHK.0b013e318280409a; Reade MC, 2013, SHOCK, V40, P160, DOI 10.1097/SHK.0b013e31829ab240; Roberts I, 2011, LANCET, V377, P1096, DOI 10.1016/S0140-6736(11)60278-X; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; Shliom O, 2000, J BIOL CHEM, V275, P24304, DOI 10.1074/jbc.M002024200; Silva MMCG, 2012, J THROMB HAEMOST, V10, P2354, DOI 10.1111/j.1538-7836.2012.04925.x; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; VIOLAND BN, 1978, J BIOL CHEM, V253, P5395; Wu H, 2011, J CEREBR BLOOD F MET, V31, P1243, DOI 10.1038/jcbfm.2010.209; Yepes M, 2004, EXP BIOL MED, V229, P1097, DOI 10.1177/153537020422901103; Yepes M, 2004, TRENDS CARDIOVAS MED, V14, P173, DOI 10.1016/j.tcm.2004.03.004	50	80	81	0	9	AMER SOC HEMATOLOGY	WASHINGTON	2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA	0006-4971	1528-0020		BLOOD	Blood	APR 16	2015	125	16					2558	2567		10.1182/blood-2014-08-588442			10	Hematology	Science Citation Index Expanded (SCI-EXPANDED)	Hematology	CI4VK	WOS:000354751700017	25673638	Green Published, Bronze			2022-02-06	
J	Kuhle, J; Gaiottino, J; Leppert, D; Petzold, A; Bestwick, JP; Malaspina, A; Lu, CH; Dobson, R; Disanto, G; Norgren, N; Nissim, A; Kappos, L; Hurlbert, J; Yong, VW; Giovannoni, G; Casha, S				Kuhle, Jens; Gaiottino, Johanna; Leppert, David; Petzold, Axel; Bestwick, Jonathan P.; Malaspina, Andrea; Lu, Ching-Hua; Dobson, Ruth; Disanto, Giulio; Norgren, Niklas; Nissim, Ahuva; Kappos, Ludwig; Hurlbert, John; Yong, V. Wee; Giovannoni, Gavin; Casha, Steven			Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; NF-H; CEREBROSPINAL-FLUID; AXONAL INJURY; MINOCYCLINE; RECOVERY; PHOSPHOFORMS; DEGENERATION; MARKERS; TRIALS	Background Neurofilaments (Nf) are major structural proteins that occur exclusively in neurons. In spinal cord injury (SCI), the severity of disease is quantified by clinical measures that have limited sensitivity and reliability, and no blood-based biomarker has been established to further stratify the degree of injury. We aimed to examine a serum-based NfL immunoassay as predictor of the clinical outcome in SCI. Methods Longitudinal measurement of serum NfL was performed in patients with central cord syndrome (CCS, n=4), motor-incomplete SCI (iSCI, n=10), motor-complete SCI (cSCI, n=13) and healthy controls (HC, n=67), and correlated with clinical severity, neurological outcome, and neuroprotective effect of the drug minocycline. Results Baseline NfL levels were higher in iSCI (21 pg/mL) and cSCI (70 pg/mL) than in HC (5 pg/mL, p=0.006 and p<0.001) and CCS (6 pg/mL, p=0.025 and p=0.010). Levels increased over time (p<0.001) and remained higher in cSCI versus iSCI (p=0.011) and than in CCS (p<0.001). NfL levels correlated with American Spinal Injury Association (ASIA) motor score at baseline (r=-0.53, p=0.004) and after 24 h (r=-0.69, p<0.001) and 3-12-month motor outcome (baseline NfL: r=-0.43, p=0.026 and 24 h NfL: r=-0.72, p<0.001). Minocycline treatment showed decreased NfL levels in the subgroup of cSCI patients. Conclusions Serum NfL concentrations in SCI patients show a close correlation with acute severity and neurological outcome. Our data provide evidence that serum NfL is of prognostic value in SCI patients for the first time. Further, blood NfL levels may qualify as drug response markers in SCI.	[Kuhle, Jens; Gaiottino, Johanna; Malaspina, Andrea; Lu, Ching-Hua; Dobson, Ruth; Disanto, Giulio; Giovannoni, Gavin] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, London, England; [Kuhle, Jens; Leppert, David; Kappos, Ludwig] Univ Basel Hosp, CH-4031 Basel, Switzerland; [Petzold, Axel] UCL Inst Neurol, Dept Mol Neurosci, London, England; [Bestwick, Jonathan P.] Queen Mary Univ London, Barts & London Sch Med & Dent, Wolfson Inst Prevent Med, London, England; [Malaspina, Andrea] North East London & Essex Reg MND Care Ctr, London, England; [Norgren, Niklas] UmanDiagnostics, Umea, Sweden; [Nissim, Ahuva] Queen Mary Univ London, John Vane Sci Ctr, London, England; [Hurlbert, John; Yong, V. Wee; Casha, Steven] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada; [Hurlbert, John; Yong, V. Wee; Casha, Steven] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada		Kuhle, J (corresponding author), Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, 4 Newark St, London, England.	j.kuhle@qmul.ac.uk	Petzold, Axel/C-1090-2009	Petzold, Axel/0000-0002-0344-9749	GenzymeSanofi-AventisGenzyme Corporation; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MR/J002747/1] Funding Source: researchfish; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MR/J002747/1] Funding Source: UKRI	This study was supported by an unrestricted grant from Genzyme and institutional funding. The study sponsors had no involvement in the study design; in the collection, analysis and interpretation of the data; in the writing of the report; and in the decision to submit the paper for publication.	Casha S, 2012, BRAIN, V135, P1224, DOI 10.1093/brain/aws072; Charlifue SB, 2004, J SPINAL CORD MED, V27, P151; Courtine G, 2007, NAT MED, V13, P561, DOI 10.1038/nm1595; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DITUNNO JF, 1994, PARAPLEGIA, V32, P70, DOI 10.1038/sc.1994.13; Fawcett JW, 2007, SPINAL CORD, V45, P190, DOI 10.1038/sj.sc.3102007; Fawcett JW, 2006, CLIN MED, V6, P598, DOI 10.7861/clinmedicine.6-6-598; Fehlings MG, 2005, INJURY, V36, P113, DOI 10.1016/j.injury.2005.06.022; Festoff BW, 2006, J NEUROCHEM, V97, P1314, DOI 10.1111/j.1471-4159.2006.03799.x; Gaiottino J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075091; Geisler FH, 2001, SPINE, V26, pS87, DOI 10.1097/00007632-200112151-00015; Guez M, 2003, J NEUROTRAUM, V20, P853, DOI 10.1089/089771503322385782; Harrop James S, 2006, Spine J, V6, p198S, DOI 10.1016/j.spinee.2006.04.006; Hayakawa K, 2012, SPINAL CORD, V50, P493, DOI 10.1038/sc.2011.184; Kuhle Jens, 2011, Expert Opin Med Diagn, V5, P333, DOI 10.1517/17530059.2011.578624; Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007; Kwon BK, 2011, CLIN CHEM LAB MED, V49, P425, DOI 10.1515/CCLM.2011.068; Lee SM, 2003, J NEUROTRAUM, V20, P1017, DOI 10.1089/089771503770195867; Maier IC, 2006, PHILOS T R SOC B, V361, P1611, DOI 10.1098/rstb.2006.1890; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Petzold A, 2003, J IMMUNOL METHODS, V278, P179, DOI 10.1016/S0022-1759(03)00189-3; Petzold A, 2011, BRAIN, V134, P464, DOI 10.1093/brain/awq360; Popovic N, 2002, ANN NEUROL, V51, P215, DOI 10.1002/ana.10092; Sadowsky C, 2002, DISABIL REHABIL, V24, P680, DOI 10.1080/09638280110110640; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Tator CH, 2006, NEUROSURGERY, V59, P957, DOI 10.1227/01.NEU.0000245591.16087.89; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Ueno T, 2011, SPINAL CORD, V49, P333, DOI 10.1038/sc.2010.116; Wells JEA, 2003, BRAIN, V126, P1628, DOI 10.1093/brain/awg178; Yong VW, 2004, LANCET NEUROL, V3, P744, DOI 10.1016/S1474-4422(04)00937-8; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	33	80	82	1	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAR	2015	86	3					273	279		10.1136/jnnp-2013-307454			7	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	CB6EX	WOS:000349720800008					2022-02-06	
J	Yuan, Y; Zha, H; Rangarajan, P; Ling, EA; Wu, CY				Yuan, Yun; Zha, Hao; Rangarajan, Parakalan; Ling, Eng-Ang; Wu, Chunyun			Anti-inflammatory effects of Edaravone and Scutellarin in activated microglia in experimentally induced ischemia injury in rats and in BV-2 microglia	BMC NEUROSCIENCE			English	Article						Activated microglia; Cerebral ischemia; Edaravone; Scutellarin; Anti-inflammation	FOCAL CEREBRAL-ISCHEMIA; TUMOR-NECROSIS-FACTOR; TRAUMATIC BRAIN-INJURY; FREE-RADICAL SCAVENGER; INFLAMMATORY CELLS; HYDROGEN-PEROXIDE; AMEBOID MICROGLIA; ARTERY OCCLUSION; FACTOR-ALPHA; SPINAL-CORD	Background: In response to cerebral ischemia, activated microglia release excessive inflammatory mediators which contribute to neuronal damage. Therefore, inhibition of microglial over-activation could be a therapeutic strategy to alleviate various microglia-mediated neuroinflammation. This study was aimed to elucidate the anti-inflammatory effects of Scutellarin and Edaravone given either singly, or in combination in activated microglia in rats subjected to middle cerebral artery occlusion (MCAO), and in lipopolysaccharide (LPS)-induced BV-2 microglia. Expression of proinflammatory cytokines, including tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), and inducible nitric oxide synthase (iNOS) was assessed by immunofluorescence staining and Western blot. Reactive oxygen species (ROS) and nitric oxide (NO) levels were determined by flow cytometry and fluorescence microscopy, respectively. Results: In vivo, both Edaravone and Scutellarin markedly reduced the infarct cerebral tissue area with the latter drug being more effective with the dosage used; furthermore, when used in combination the reduction was more substantial. Remarkably, a greater diminution in distribution of activated microglia was observed with the combined drug treatment which also attenuated the immunoexpression of TNF-alpha, IL-1 beta and iNOS to a greater extent as compared to the drugs given separately. In vitro, both drugs suppressed upregulated expression of inflammatory cytokines, iNOS, NO and ROS in LPS-induced BV-2 cells. Furthermore, Edaravone and Scutellarin in combination cumulatively diminished the expression levels of the inflammatory mediators being most pronounced for TNF-alpha as evidenced by Western blot. Conclusion: The results suggest that Edaravone and Scutellarin effectively suppressed the inflammatory responses in activated microglia, with Scutellarin being more efficacious within the dosage range used. Moreover, when both drugs were used in combination, the infarct tissue area was reduced more extensively; also, microglia-mediated inflammatory mediators notably TNF-alpha expression was decreased cumulatively.	[Yuan, Yun; Zha, Hao; Wu, Chunyun] Kunming Med Univ, Dept Anat & Histol Embryol, Fac Basic Med Sci, Kunming 650500, Peoples R China; [Yuan, Yun; Rangarajan, Parakalan; Ling, Eng-Ang] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore 117597, Singapore		Ling, EA (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Blk MD10,4 Med Dr, Singapore 117597, Singapore.	antlea@nus.edu.sg; wuchunyunkm@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31260254]; Applied Basic Research Program of Yunnan Province [2011FB243]; National University of SingaporeNational University of Singapore [R-180-000-140-592]	This project is supported by National Natural Science Foundation of China [Project number 31260254, CY Wu], Applied Basic Research Program of Yunnan Province [Project number 2011FB243, CY Wu] and National University of Singapore [Project number R-180-000-140-592 E-A Ling].	ABE K, 1988, STROKE, V19, P480, DOI 10.1161/01.STR.19.4.480; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Bohacek I, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-191; Cao Q, 2010, J NEUROSCI RES, V88, P2701, DOI 10.1002/jnr.22429; Cao Q, 2008, GLIA, V56, P1224, DOI 10.1002/glia.20692; Ceulemans AG, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-60; Chen XY, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/432623; Czeh M, 2011, DEV NEUROSCI-BASEL, V33, P199, DOI 10.1159/000328989; Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961; Dohi K, 2006, J NEUROTRAUM, V23, P1591, DOI 10.1089/neu.2006.23.1591; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; Guillot-Sestier MV, 2013, CNS NEUROL DISORD-DR, V12, P593; Hong H, 2004, LIFE SCI, V74, P2959, DOI 10.1016/j.lfs.2003.09.074; Hosomi N, 2005, J CEREBR BLOOD F MET, V25, P959, DOI 10.1038/sj.jcbfm.9600086; Itoh T, 2010, NEUROCHEM RES, V35, P348, DOI 10.1007/s11064-009-0061-2; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; Kaur C, 2009, PROG NEUROBIOL, V87, P264, DOI 10.1016/j.pneurobio.2009.01.003; Kaur C, 2008, CURR MED CHEM, V15, P3068, DOI 10.2174/092986708786848640; Lalancette-Hebert M, 2009, BRAIN, V132, P940, DOI 10.1093/brain/awn345; Lambertsen KL, 2012, J CEREBR BLOOD F MET, V32, P1677, DOI 10.1038/jcbfm.2012.88; Lambertsen KL, 2009, J NEUROSCI, V29, P1319, DOI 10.1523/JNEUROSCI.5505-08.2009; Lehnardt S, 2007, J NEUROIMMUNOL, V190, P28, DOI 10.1016/j.jneuroim.2007.07.023; Ling E A, 2001, Prog Brain Res, V132, P61; Liu H, 2005, PHARMACOL RES, V51, P205, DOI 10.1016/j.phrs.2004.09.001; Luo P, 2008, YAKUGAKU ZASSHI, V128, P1293, DOI 10.1248/yakushi.128.1293; Ma JY, 2008, J ASIAN NAT PROD RES, V10, P1147, DOI 10.1080/10286020802361255; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; Neumann H, 2009, BRAIN, V132, P288, DOI 10.1093/brain/awn109; Pantoni L, 1998, ARTERIOSCL THROM VAS, V18, P503, DOI 10.1161/01.ATV.18.4.503; Patel Anita R, 2013, Int J Physiol Pathophysiol Pharmacol, V5, P73; Pettigrew LC, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-47; Politis M, 2011, HUM BRAIN MAPP, V32, P258, DOI 10.1002/hbm.21008; Qian L, 2010, J NEURAL TRANSM, V117, P971, DOI 10.1007/s00702-010-0428-1; Sivakumar V, 2010, GLIA, V58, P507, DOI 10.1002/glia.20940; Tang H, 2014, PHARMACOL BIOCHEM BE, V118, P51, DOI 10.1016/j.pbb.2014.01.003; Uno M, 2005, FREE RADICAL BIO MED, V39, P1109, DOI 10.1016/j.freeradbiomed.2005.06.001; Vidal PM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.466; Wang GH, 2011, J NEUROTRAUM, V28, P2123, DOI 10.1089/neu.2011.1939; Wang S, 2011, NEUROSCIENCE, V185, P150, DOI 10.1016/j.neuroscience.2011.04.005; Wu CY, 2013, MOL CELL BIOCHEM, V382, P47, DOI 10.1007/s11010-013-1717-4; Wu YP, 1997, EXP BRAIN RES, V115, P129, DOI 10.1007/PL00005672; Yao LL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078439; Zgavc T, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-105; Zhang HF, 2009, PLANTA MED, V75, P121, DOI 10.1055/s-0028-1088368; Zhang N, 2005, STROKE, V36, P2220, DOI 10.1161/01.STR.0000182241.07096.06; Zhang P, 2012, NEUROSCIENCE, V201, P297, DOI 10.1016/j.neuroscience.2011.11.005; Ziegler G, 2007, BIOCHEM BIOPH RES CO, V359, P574, DOI 10.1016/j.bbrc.2007.05.157; Ziegler G, 2011, J CEREBR BLOOD F MET, V31, P757, DOI 10.1038/jcbfm.2010.161	48	80	90	1	24	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2202			BMC NEUROSCI	BMC Neurosci.	NOV 22	2014	15								125	10.1186/s12868-014-0125-3			21	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AU9SK	WOS:000345934800001	25416145	Green Published, gold			2022-02-06	
J	Tremblay, S; Henry, LC; Bedetti, C; Larson-Dupuis, C; Gagnon, JF; Evans, AC; Theoret, H; Lassonde, M; De Beaumont, L				Tremblay, Sebastien; Henry, Luke C.; Bedetti, Christophe; Larson-Dupuis, Camille; Gagnon, Jean-Francois; Evans, Alan C.; Theoret, Hugo; Lassonde, Maryse; De Beaumont, Louis			Diffuse white matter tract abnormalities in clinically normal ageing retired athletes with a history of sports-related concussions	BRAIN			English	Article						sports-related concussions; ageing; white matter; neuropsychology	TRAUMATIC BRAIN-INJURY; MILD COGNITIVE IMPAIRMENT; TENSOR IMAGING FINDINGS; AXONAL INJURY; ALZHEIMERS-DISEASE; LONG-TERM; IN-VIVO; DEPRESSIVE SYMPTOMS; PROFESSIONAL BOXERS; PREFRONTAL GRAY	Sports-related concussions have been shown to lead to persistent subclinical anomalies of the motor and cognitive systems in young asymptomatic athletes. In advancing age, these latent alterations correlate with detectable motor and cognitive function decline. Until now, the interacting effects of concussions and the normal ageing process on white matter tract integrity remain unknown. Here we used a tract-based spatial statistical method to uncover potential white matter tissue damage in 15 retired athletes with a history of concussions, free of comorbid medical conditions. We also investigated potential associations between white matter integrity and declines in cognitive and motor functions. Compared to an age-and education-matched control group of 15 retired athletes without concussions, former athletes with concussions exhibited widespread white matter anomalies along many major association, interhemispheric, and projection tracts. Group contrasts revealed decreases in fractional anisotropy, as well as increases in mean and radial diffusivity measures in the concussed group. These differences were primarily apparent in fronto-parietal networks as well as in the frontal aspect of the corpus callosum. The white matter anomalies uncovered in concussed athletes were significantly associated with a decline in episodic memory and lateral ventricle expansion. Finally, the expected association between frontal white matter integrity and motor learning found in former non-concussed athletes was absent in concussed participants. Together, these results show that advancing age in retired athletes presenting with a history of sports-related concussions is linked to diffuse white matter abnormalities that are consistent with the effects of traumatic axonal injury and exacerbated demyelination. These changes in white matter integrity might explain the cognitive and motor function declines documented in this population.	[Tremblay, Sebastien] McGill Univ, Montreal Neurol Inst, Integrated Program Neurosci, Montreal, PQ, Canada; [Henry, Luke C.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA; [Bedetti, Christophe; Larson-Dupuis, Camille; Gagnon, Jean-Francois; De Beaumont, Louis] Hop Sacre Coeur, Montreal Res Ctr, Montreal, PQ, Canada; [Larson-Dupuis, Camille; Theoret, Hugo; Lassonde, Maryse] Univ Montreal, Dept Psychol, Montreal, PQ, Canada; [Gagnon, Jean-Francois] Univ Quebec, Dept Psychol, Montreal, PQ, Canada; [Evans, Alan C.] McGill Univ, McConnell Brain Imaging Ctr, Montreal, PQ, Canada; [Evans, Alan C.] Montreal Neurol Inst, Montreal, PQ, Canada; [Theoret, Hugo; Lassonde, Maryse] Univ Montreal, Ctr Rech Neuropsychol & Cognit, Montreal, PQ, Canada; [De Beaumont, Louis] Univ Quebec Trois Rivieres, Dept Psychol, Trois Rivieres, PQ GA9 5H7, Canada		De Beaumont, L (corresponding author), Univ Quebec Trois Rivieres, Dept Psychol, Trois Rivieres, PQ GA9 5H7, Canada.	louis.debeaumont@uqtr.ca	Evans, Alan C/B-2373-2013; Meijer, Anna/K-5118-2016	Evans, Alan C/0000-0003-3841-6098; Theoret, Hugo/0000-0002-7458-8797	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Natural Sciences and Engineering Research Council of Canada (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC); NSERC Alexander Graham Bell Canada Graduate Scholarship	This work was supported by grants to H.T., M.L., and L.D.B. from the Canadian Institutes of Health Research (CIHR) and the Natural Sciences and Engineering Research Council of Canada (NSERC). The NSERC Alexander Graham Bell Canada Graduate Scholarship supported S.T.	Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Ardekani S, 2007, MAGN RESON IMAGING, V25, P154, DOI 10.1016/j.mri.2006.09.045; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Basser PJ, 2002, NMR BIOMED, V15, P456, DOI 10.1002/nbm.783; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bennett IJ, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2010.03.017; Bennett IJ, 2010, HUM BRAIN MAPP, V31, P378, DOI 10.1002/hbm.20872; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Broglio SP, 2012, EXERC SPORT SCI REV, V40, P138, DOI 10.1097/JES.0b013e3182524273; Burzynska AZ, 2010, NEUROIMAGE, V49, P2104, DOI 10.1016/j.neuroimage.2009.09.041; Chamard E, 2013, BRAIN INJURY, V27, P1038, DOI 10.3109/02699052.2013.794968; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; Chua TC, 2008, CURR OPIN NEUROL, V21, P83, DOI 10.1097/WCO.0b013e3282f4594b; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Davis SW, 2009, NEUROIMAGE, V46, P530, DOI 10.1016/j.neuroimage.2009.01.068; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-109; De Beaumont L, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12278; De Beaumont L, 2012, CEREB CORTEX, V22, P112, DOI 10.1093/cercor/bhr096; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Didehbani N, 2013, ARCH CLIN NEUROPSYCH, V28, P418, DOI 10.1093/arclin/act028; Fjell AM, 2013, NEUROBIOL AGING, V34, P2239, DOI 10.1016/j.neurobiolaging.2013.04.006; Fjell AM, 2009, CEREB CORTEX, V19, P2001, DOI 10.1093/cercor/bhn232; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; World Medical Association, 2013, JAMA, V310, P2191, DOI 10.1001/jama.2013.281053; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786; Grieve SM, 2007, AM J NEURORADIOL, V28, P226; Gunning-Dixon FM, 2009, INT J GERIATR PSYCH, V24, P109, DOI 10.1002/gps.2087; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074; Liu JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059440; Lyttelton O, 2007, NEUROIMAGE, V34, P1535, DOI 10.1016/j.neuroimage.2006.10.041; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Madden DJ, 2009, NEUROPSYCHOL REV, V19, P415, DOI 10.1007/s11065-009-9113-2; Malloy P, 2007, CLIN NEUROPSYCHOL, V21, P73, DOI 10.1080/13854040500263583; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Marner L, 2003, J COMP NEUROL, V462, P144, DOI 10.1002/cne.10714; Masliah E, 2006, ALZHEIMER'S DISEASE: A CENTURY OF SCIENTIFIC AND CLINICAL RESEARCH, P91; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Monti JM, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00041; Moretti L, 2012, LANCET NEUROL, V11, P1103, DOI 10.1016/S1474-4422(12)70226-0; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Nir TM, 2013, NEUROIMAGE-CLIN, V3, P180, DOI 10.1016/j.nicl.2013.07.006; Patenaude B, 2011, NEUROIMAGE, V56, P907, DOI 10.1016/j.neuroimage.2011.02.046; Pearce AJ, 2014, J NEUROTRAUM, V31, P1139, DOI 10.1089/neu.2013.3219; Peters A, 2002, J NEUROCYTOL, V31, P581, DOI 10.1023/A:1025731309829; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; Petersen RC, 2005, NEW ENGL J MED, V352, P2379, DOI 10.1056/NEJMoa050151; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Raz N, 1997, CEREB CORTEX, V7, P268, DOI 10.1093/cercor/7.3.268; Raz N, 2006, NEUROSCI BIOBEHAV R, V30, P730, DOI 10.1016/j.neubiorev.2006.07.001; Salat DH, 2005, NEUROBIOL AGING, V26, P1215, DOI 10.1016/j.neurobiolaging.2004.09.017; Salat DH, 1999, ARCH NEUROL-CHICAGO, V56, P338, DOI 10.1001/archneur.56.3.338; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Smith SM, 2002, NEUROIMAGE, V17, P479, DOI 10.1006/nimg.2002.1040; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Strain J, 2013, NEUROLOGY, V81, P25, DOI 10.1212/WNL.0b013e318299ccf8; Stricker NH, 2013, J INT NEUROPSYCH SOC, V19, P925, DOI 10.1017/S1355617713000660; Sullivan EV, 2006, CEREB CORTEX, V16, P1030, DOI 10.1093/cercor/bhj045; Sun SW, 2006, NEUROIMAGE, V32, P1195, DOI 10.1016/j.neuroimage.2006.04.212; Tisserand DJ, 2002, NEUROIMAGE, V17, P657, DOI 10.1006/nimg.2002.1173; Tremblay S, 2014, CLIN NEUROPHYSIOL, V125, P1371, DOI 10.1016/j.clinph.2013.11.040; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Virji-Babul N, 2013, PEDIATR NEUROL, V48, P24, DOI 10.1016/j.pediatrneurol.2012.09.005; Wang PN, 2014, HUM BRAIN MAPP, V35, P1529, DOI 10.1002/hbm.22271; Wiest-Daessle N, 2008, LECT NOTES COMPUT SC, V5242, P171, DOI 10.1007/978-3-540-85990-1_21; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhang L, 2006, AM J NEURORADIOL, V27, P2000; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52; Zhang Y, 2007, NEUROLOGY, V68, P13, DOI 10.1212/01.wnl.0000250326.77323.01; Zhang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066367	96	80	80	2	43	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	NOV	2014	137		11				2997	3011		10.1093/brain/awu236			15	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AX2GG	WOS:000346760900022	25186429	Green Published, Bronze			2022-02-06	
J	Yin, TC; Britt, JK; De Jesus-Cortes, H; Lu, Y; Genova, RM; Khan, MZ; Voorhees, JR; Shao, JQ; Katzman, AC; Huntington, PJ; Wassink, C; McDaniel, L; Newell, EA; Dutca, LM; Naidoo, J; Cui, HX; Bassuk, AG; Harper, MM; McKnight, SL; Ready, JM; Pieper, AA				Yin, Terry C.; Britt, Jeremiah K.; De Jesus-Cortes, Hector; Lu, Yuan; Genova, Rachel M.; Khan, Michael Z.; Voorhees, Jaymie R.; Shao, Jianqiang; Katzman, Aaron C.; Huntington, Paula J.; Wassink, Cassie; McDaniel, Latisha; Newell, Elizabeth A.; Dutca, Laura M.; Naidoo, Jacinth; Cui, Huxing; Bassuk, Alexander G.; Harper, Matthew M.; McKnight, Steven L.; Ready, Joseph M.; Pieper, Andrew A.			P7C3 Neuroprotective Chemicals Block Axonal Degeneration and Preserve Function after Traumatic Brain Injury	CELL REPORTS			English	Article							MOUSE MODEL; AMINOPROPYL CARBAZOLES; EFFICACY; BIOSYNTHESIS; DISCOVERY; ISCHEMIA	The P7C3 class of neuroprotective aminopropyl carbazoles has been shown to block neuronal cell death in models of neurodegeneration. We now show that P7C3 molecules additionally preserve axonal integrity after injury, before neuronal cell death occurs, in a rodent model of blast-mediated traumatic brain injury (TBI). This protective quality may be linked to the ability of P7C3 molecules to activate nicotinamide phosphoribosyltransferase, the rate-limiting enzyme in nicotinamide adenine dinucleotide salvage. Initiation of daily treatment with our recently reported lead agent, P7C3-S243, 1 day after blast-mediated TBI blocks axonal degeneration and preserves normal synaptic activity, learning and memory, and motor coordination in mice. We additionally report persistent neurologic deficits and acquisition of an anxiety-like phenotype in untreated animals 8 months after blast exposure. Optimized variants of P7C3 thus offer hope for identifying neuroprotective agents for conditions involving axonal damage, neuronal cell death, or both, such as occurs in TBI.	[Yin, Terry C.; Britt, Jeremiah K.; De Jesus-Cortes, Hector; Lu, Yuan; Genova, Rachel M.; Khan, Michael Z.; Voorhees, Jaymie R.; Katzman, Aaron C.; Wassink, Cassie; McDaniel, Latisha; Cui, Huxing; Pieper, Andrew A.] Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA; [Newell, Elizabeth A.; Bassuk, Alexander G.] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; [Bassuk, Alexander G.; Pieper, Andrew A.] Univ Iowa, Dept Neurol, Iowa City, IA 52242 USA; [Bassuk, Alexander G.] Univ Iowa, Dept Pediat Neurol, Iowa City, IA 52242 USA; [Voorhees, Jaymie R.; Pieper, Andrew A.] Univ Iowa, Interdisciplinary Grad Program Human Toxicol, Iowa City, IA 52242 USA; [Shao, Jianqiang] Univ Iowa, Cent Microscopy Facil, Iowa City, IA 52242 USA; [Voorhees, Jaymie R.; Dutca, Laura M.; Harper, Matthew M.; Pieper, Andrew A.] Univ Iowa, Dept Ophthalmol & Visual Sci, Dept Vet Affairs Ctr Prevent & Treatment Visual L, Iowa City, IA 52242 USA; [Huntington, Paula J.; Naidoo, Jacinth; McKnight, Steven L.; Ready, Joseph M.] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA; [De Jesus-Cortes, Hector] Univ Texas SW Med Ctr Dallas, Grad Program Neurosci, Dallas, TX 75390 USA		Pieper, AA (corresponding author), Univ Iowa, Dept Psychiat, 200 Hawkins Dr, Iowa City, IA 52242 USA.	andrew-pieper@uiowa.edu	Britt, Jeremiah/L-9441-2015; Pieper, Andrew A/R-5552-2016; De Jesus-Cortes, Hector/ABC-9091-2020	Britt, Jeremiah/0000-0003-4010-662X; De Jesus-Cortes, Hector/0000-0001-6983-6963; Newell, Elizabeth/0000-0002-1476-033X; Bassuk, Alexander/0000-0002-4067-2157; Cui, Huxing/0000-0002-8627-8534; Pieper, Andrew/0000-0001-6299-6577; Harper, Matthew/0000-0003-3395-2406	NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [5-RO1-MH087986]; Welch FoundationThe Welch Foundation [I-1612]; Edward N. and Della C. Thome Memorial Foundation; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R21MH100086-01, 5R01NS064159-05]; Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service (Center for the Treatment and Prevention of Visual Loss, RR&D Career Development Award and Merit Award) [RX000427]; National Science Foundation Graduate Research FellowshipNational Science Foundation (NSF); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH100086, R01MH087986] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS064159] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000427] Funding Source: NIH RePORTER	We thank Mike Welsh and Randy Kardon for advice and encouragement and Noelle Williams for pharmacologic studies. Medical illustration was provided by Teresa A. Ruggle (Department of Internal Medicine Design Center, University of Iowa Hospitals and Clinics) and Victor Powell (Medical Media, Iowa City VA Health Care System). The work was funded by a grant awarded to A.A.P. and S.L.M. from the NIMH (5-RO1-MH087986); grant awards from the Welch Foundation (I-1612) and the Edward N. and Della C. Thome Memorial Foundation to J.M.R.; unrestricted funds provided to S.L.M. by an anonymous donor; NIH grants 1R21MH100086-01 and 5R01NS064159-05 to A.G.B.; the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service (Center for the Treatment and Prevention of Visual Loss, RR&D Career Development Award [to M.M.H.] and Merit Award RX000427); and a National Science Foundation Graduate Research Fellowship to H.D.J.-C.	Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Blaya MO, 2014, J NEUROTRAUM, V31, P476, DOI [10.1089/NEU.2013.3135, 10.1089/neu.2013.3135]; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Coleman PD, 2003, NEUROBIOL AGING, V24, P1023, DOI 10.1016/j.neurobiolaging.2003.09.001; De Jesus-Cortes H, 2012, P NATL ACAD SCI USA, V109, P17010, DOI 10.1073/pnas.1213956109; Fischer LR, 2004, EXP NEUROL, V185, P232, DOI 10.1016/j.expneurol.2003.10.004; Goldstein L.E., 2012, SCI TRANSL MED, V4; Gunawardena S, 2005, ARCH NEUROL-CHICAGO, V62, P46, DOI 10.1001/archneur.62.1.46; Hawkins BT, 2006, J NEUROSCI METH, V151, P262, DOI 10.1016/j.jneumeth.2005.08.006; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Li H, 2001, J NEUROSCI, V21, P8473, DOI 10.1523/JNEUROSCI.21-21-08473.2001; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; LUNN ER, 1989, EUR J NEUROSCI, V1, P27, DOI 10.1111/j.1460-9568.1989.tb00771.x; Luo LQ, 2005, ANNU REV NEUROSCI, V28, P127, DOI 10.1146/annurev.neuro.28.061604.135632; Luong TN, 2011, JOVE-J VIS EXP, DOI 10.3791/2376; MacMillan KS, 2011, J AM CHEM SOC, V133, P1428, DOI 10.1021/ja108211m; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Mohan K, 2013, INVEST OPHTH VIS SCI, V54, P3440, DOI 10.1167/iovs.12-11522; Naidoo J, 2014, J MED CHEM, V57, P3746, DOI 10.1021/jm401919s; Naidoo J, 2013, TETRAHEDRON LETT, V54, P4429, DOI 10.1016/j.tetlet.2013.06.024; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Northington FJ, 2001, NEUROBIOL DIS, V8, P207, DOI 10.1006/nbdi.2000.0371; Pieper A.A., 2014, CHEM SOC REV; Pieper AA, 2010, CELL, V142, P39, DOI 10.1016/j.cell.2010.06.018; PREISS J, 1958, J BIOL CHEM, V233, P488; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; Sasaki Y, 2006, J NEUROSCI, V26, P8484, DOI 10.1523/JNEUROSCI.2320-06.2006; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Tesla R, 2012, P NATL ACAD SCI USA, V109, P17016, DOI 10.1073/pnas.1213960109; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; Walker AK, 2014, MOL PSYCHIAT; Wang G, 2014, CELL, V158, P1324, DOI 10.1016/j.cell.2014.07.040; Wang J, 2005, J CELL BIOL, V170, P349, DOI 10.1083/jcb.200504028; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9; Xu P, 2013, P NATL ACAD SCI USA, V110, P10759, DOI 10.1073/pnas.1308195110; Yan TT, 2010, NEUROCHEM INT, V56, P529, DOI 10.1016/j.neuint.2010.01.013	36	80	80	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	2211-1247			CELL REP	Cell Reports	SEP 25	2014	8	6					1731	1740		10.1016/j.celrep.2014.08.030			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	AR9BZ	WOS:000343867400015	25220467	Green Accepted, gold			2022-02-06	
J	Brines, M; Dunne, AN; van Velzen, M; Proto, PL; Ostenson, CG; Kirk, RI; Petropoulos, IN; Javed, S; Malik, RA; Cerami, A; Dahan, A				Brines, Michael; Dunne, Ann N.; van Velzen, Monique; Proto, Paolo L.; Ostenson, Claes-Goran; Kirk, Rita I.; Petropoulos, Ioannis N.; Javed, Saad; Malik, Rayaz A.; Cerami, Anthony; Dahan, Albert			ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes	MOLECULAR MEDICINE			English	Article							CORNEAL CONFOCAL MICROSCOPY; TRAUMATIC BRAIN-INJURY; LONG-TERM RELIEF; TERTIARY STRUCTURE; TISSUE PROTECTION; HEMORRHAGIC-SHOCK; MIMETIC PEPTIDE; PAIN; SARCOIDOSIS; RECEPTOR	Although erythropoietin ameliorates experimental type 2 diabetes with neuropathy, serious side effects limit its potential clinical use. ARA 290, a nonhematopoietic peptide designed from the structure of erythropoietin, interacts selectively with the innate repair receptor that mediates tissue protection. ARA 290 has shown efficacy in preclinical and clinical studies of metabolic control and neuropathy. To evaluate the potential activity of ARA 290 in type 2 diabetes and painful neuropathy, subjects were enrolled in this phase 2 study. ARA 290 (4 mg) or placebo were self-administered subcutaneously daily for 28 d and the subjects followed for an additional month without further treatment. No potential safety issues were identified. Subjects receiving ARA 290 exhibited an improvement in hemoglobin A(1c) (Hb A(1c)) and lipid profiles throughout the 56 d observation period. Neuropathic symptoms as assessed by the PainDetect questionnaire improved significantly in the ARA 290 group. Mean corneal nerve fiber density (CNFD) was reduced significantly compared with normal controls and subjects with a mean CNFD >1 standard deviation from normal showed a significant increase in CNFD compared with no change in the placebo group. These observations suggest that ARA 290 may benefit both metabolic control and neuropathy in subjects with type 2 diabetes and deserves continued clinical evaluation.	[Brines, Michael; Dunne, Ann N.; Kirk, Rita I.; Cerami, Anthony] Araim Pharmaceut, Tarrytown, NY 10591 USA; [van Velzen, Monique; Proto, Paolo L.; Dahan, Albert] Leiden Univ, Med Ctr, Dept Anesthesiol, Leiden, Netherlands; [Ostenson, Claes-Goran] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden; [Petropoulos, Ioannis N.; Javed, Saad; Malik, Rayaz A.] Manchester Acad Hlth Sci Ctr, Inst Human Dev, Ctr Diabet & Endocrinol, Manchester, Lancs, England; [Petropoulos, Ioannis N.; Malik, Rayaz A.] Qatar Fdn, Weill Cornell Med Coll Qatar, Doha, Qatar		Brines, M (corresponding author), Araim Pharmaceut, 580 White Plains Rd,Suite 210, Tarrytown, NY 10591 USA.	mbrines@araimpharma.com	van Velzen, Monique/H-7697-2019; Proto, Paolo/AAB-8940-2021; Malik, Rayaz/H-9231-2019; Brinesd, Michael/AAE-6072-2020	van Velzen, Monique/0000-0002-0289-6432; Proto, Paolo/0000-0001-9820-6274; Malik, Rayaz/0000-0002-7188-8903; Brines, Michael/0000-0003-4151-4449	Dutch government [FES0908]; Dutch government (Swedish Research Council, ALF); Dutch government (Swedish Diabetes Association)	This work was supported in part by a grant from the Dutch government to the Netherlands Institute for Regenerative Medicine (NIRM, grant no. FES0908, the Swedish Research Council, ALF, and the Swedish Diabetes Association). The authors thank Ferdinand C Breedveld and Geertrui Betgen for invaluable assistance, as well as the subjects and their families for agreeing to participate in this trial.	Ahmet I, 2013, J PHARMACOL EXP THER, V345, P446, DOI 10.1124/jpet.113.202945; Ahmet I, 2011, MOL MED, V17, P194, DOI 10.2119/molmed.2010.00235; Baron R, 2013, P 4 INT C NEUR PAIN; Baron R, 2009, PAIN; Bohr S, 2013, P NATL ACAD SCI USA, V110, P3513, DOI 10.1073/pnas.1214099110; Bouhassira D, 2004, PAIN, V108, P248, DOI 10.1016/j.pain.2003.12.024; Brines M, 2008, J INTERN MED, V264, P405, DOI 10.1111/j.1365-2796.2008.02024.x; Brines M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/pnas.0406491101; Brines M, 2008, P NATL ACAD SCI USA, V105, P10925, DOI 10.1073/pnas.0805594105; Brines M, 2012, MOL MED, V18, P486, DOI 10.2119/molmed.2011.00414; Collino M, 2014, BRIT J PHARMACOL, V171, P5802, DOI 10.1111/bph.12888; Corwin HL, 2007, NEW ENGL J MED, V357, P965, DOI 10.1056/NEJMoa071533; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; Dahan A, 2013, MOL MED, V19, P334, DOI 10.2119/molmed.2013.00122; Dejager S, 2012, VASC HEALTH RISK MAN, V8, P339, DOI 10.2147/VHRM.S31758; Drent M, 2012, EUR RESPIR J, V40, P255, DOI 10.1183/09031936.00002512; Freynhagen R, 2006, CURR MED RES OPIN, V22, P1911, DOI 10.1185/030079906X132488; Hays R D, 1993, Health Econ, V2, P217, DOI 10.1002/hec.4730020305; Heij L, 2012, MOL MED, V18, P1430, DOI 10.2119/molmed.2012.00332; Hoeijmakers JG, 2012, NAT REV NEUROL, V8, P369, DOI 10.1038/nrneurol.2012.97; Hoitsma E, 2011, RESP MED, V105, P95, DOI 10.1016/j.rmed.2010.09.014; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; McVicar CM, 2011, DIABETES, V60, P2995, DOI 10.2337/db11-0026; Menichella DM, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-42; Muller C, 2013, DIABETOLOGIA, V56, pS268; Navarro JF, 2005, NEPHROL DIAL TRANSPL, V20, P2601, DOI 10.1093/ndt/gfi155; Niesters M, 2013, EXPERT OPIN ORPHAN D, V1, P77, DOI 10.1517/21678707.2013.719289; Ortmann KLM, 2014, BRAIN BEHAV IMMUN, V41, P144, DOI 10.1016/j.bbi.2014.05.009; Patel NSA, 2011, MOL MED, V17, P883, DOI 10.2119/molmed.2011.00053; Petropoulos IN, 2014, INVEST OPHTH VIS SCI, V55, P2071, DOI 10.1167/iovs.13-13787; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Robertson CS, 2013, J NEUROTRAUM, V30, P765, DOI 10.1089/neu.2012.2431; Robertson CS, 2012, J NEUROTRAUM, V29, P1156, DOI 10.1089/neu.2011.1827; Rolke R, 2006, PAIN, V123, P231, DOI 10.1016/j.pain.2006.01.041; Rolke R, 2006, EUR J PAIN, V10, P77, DOI 10.1016/j.ejpain.2005.02.003; Schmidt RE, 2011, EXP NEUROL, V232, P126, DOI 10.1016/j.expneurol.2011.05.025; Swartjes M, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-13; Swartjes M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071326; Swartjes M, 2011, ANESTHESIOLOGY, V115, P1084, DOI 10.1097/ALN.0b013e31822fcefd; Tavakoli M, 2011, DIABETIC MED, V28, P1261, DOI 10.1111/j.1464-5491.2011.03372.x; Tavakoli M, 2013, DIABETES, V62, P254, DOI 10.2337/db12-0574; Tavakoli M, 2011, JOVE-J VIS EXP, DOI 10.3791/2194; Troosters T, 1999, EUR RESPIR J, V14, P270, DOI 10.1034/j.1399-3003.1999.14b06.x; Woo M, 2014, DIABETES, V63, P2229, DOI 10.2337/db14-0566	44	80	81	0	4	FEINSTEIN INST MED RES	MANHASSET	350 COMMUNITY DR, MANHASSET, NY 11030 USA	1076-1551	1528-3658		MOL MED	Mol. Med.	JUL-DEC	2014	20						658	666		10.2119/molmed.2014.00215			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	CE3SV	WOS:000351749900005	25387363	gold, Green Published			2022-02-06	
J	Murray, N; Salvatore, A; Powell, D; Reed-Jones, R				Murray, Nicholas; Salvatore, Anthony; Powell, Douglas; Reed-Jones, Rebecca			Reliability and Validity Evidence of Multiple Balance Assessments in Athletes With a Concussion	JOURNAL OF ATHLETIC TRAINING			English	Article						Clinical Test of Sensory Organization and Balance; Sensory Organization Test; Balance Error Scoring System; Romberg test; Wii Fit; sensitivity; specificity	COLLEGIATE FOOTBALL PLAYERS; SENSORY ORGANIZATION TEST; TEST-RETEST RELIABILITY; STATES HIGH-SCHOOL; MILD HEAD-INJURY; POSTURAL STABILITY; INTERNATIONAL-CONFERENCE; STANDING BALANCE; SPORT; MANAGEMENT	Context: An estimated 300 000 sport-related concussion injuries occur in the United States annually. Approximately 30% of individuals with concussions experience balance disturbances. Common methods of balance assessment include the Clinical Test of Sensory Organization and Balance (CTSIB), the Sensory Organization Test (SOT), the Balance Error Scoring System (BESS), and the Romberg test; however, the National Collegiate Athletic Association recommended the Wii Fit as an alternative measure of balance in athletes with a concussion. A central concern regarding the implementation of the Wii Fit is whether it is reliable and valid for measuring balance disturbance in athletes with concussion. Objective: To examine the reliability and validity evidence for the CTSIB, SOT, BESS, Romberg test, and Wii Fit for detecting balance disturbance in athletes with a concussion. Data Sources: Literature considered for review included publications with reliability and validity data for the assessments of balance (CTSIB, SOT, BESS, Romberg test, and Wii Fit) from PubMed, PsycINFO, and CINAHL. Data Extraction: We identified 63 relevant articles for consideration in the review. Of the 63 articles, 28 were considered appropriate for inclusion and 35 were excluded. Data Synthesis: No current reliability or validity information supports the use of the CTSIB, SOT, Romberg test, or Wii Fit for balance assessment in athletes with a concussion. The BESS demonstrated moderate to high reliability (interclass correlation coefficient = 0.87) and low to moderate validity (sensitivity = 34%, specificity = 87%). However, the Romberg test and Wii Fit have been shown to be reliable tools in the assessment of balance in Parkinson patients. Conclusions: The BESS can evaluate balance problems after a concussion. However, it lacks the ability to detect balance problems after the third day of recovery. Further investigation is needed to establish the use of the CTSIB, SOT, Romberg test, and Wii Fit for assessing balance in athletes with concussions.	[Murray, Nicholas] Georgia So Univ, Dept Hlth & Kinesiol, Statesboro, GA 30460 USA; [Salvatore, Anthony] Univ Texas El Paso, El Paso, TX 79902 USA; [Powell, Douglas] Campbell Univ, Buies Creek, NC 27506 USA; [Reed-Jones, Rebecca] Univ Prince Edward Isl, Charlottetown, PE C1A 4P3, Canada		Murray, N (corresponding author), Georgia So Univ, Dept Hlth & Kinesiol, POB 8076, Statesboro, GA 30460 USA.	nmurray@georgiasouthern.edu	Reed-Jones, Rebecca/L-2021-2019	Reed-Jones, Rebecca/0000-0002-2128-2671			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Clark RA, 2010, GAIT POSTURE, V31, P307, DOI 10.1016/j.gaitpost.2009.11.012; FORDSMITH CD, 1995, ARCH PHYS MED REHAB, V76, P77, DOI 10.1016/S0003-9993(95)80047-6; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Holmes JD, 2013, CLIN REHABIL, V27, P361, DOI 10.1177/0269215512458684; Howley E. T., 2012, FITNESS PROFESSIONAL; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; Jacobson GP, 2011, EAR HEARING, V32, pE1, DOI 10.1097/AUD.0b013e31822802bb; Kandel ER, 2000, PRINCIPLES NEURAL SC, P810; Khasnis A, 2003, J Postgrad Med, V49, P169; Lanska DJ, 2000, NEUROLOGY, V55, P1201, DOI 10.1212/WNL.55.8.1201; Liberati Alessandro, 2009, J Clin Epidemiol, V62, pe1, DOI 10.1016/j.jclinepi.2009.06.006; Looney MA, 2006, MEASUREMENT THEORY P, P297; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2013, J SCI MED SPORT, V16, P178, DOI 10.1016/j.jsams.2013.02.009; Michalski A, 2012, GAIT POSTURE, V36, P449, DOI 10.1016/j.gaitpost.2012.04.005; NCAA Publications, 2010, NCAA SPORTS MED HDB; Reed-Jones RJ, 2012, GAIT POSTURE, V36, P430, DOI 10.1016/j.gaitpost.2012.03.027; Riemann BL, 2000, J ATHL TRAINING, V35, P19; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Steffen T, 2008, PHYS THER, V88, P733, DOI 10.2522/ptj.20070214; Whitney SL, 1998, AM J OCCUP THER, V52, P666, DOI 10.5014/ajot.52.8.666; Wikstrom EA, 2012, J ATHL TRAINING, V47, P306, DOI 10.4085/1062-6050-47.3.16; Wrisley DM, 2007, ARCH PHYS MED REHAB, V88, P1049, DOI 10.1016/j.apmr.2007.05.003; Yamada M, 2011, GERIATR NURS, V32, P188, DOI 10.1016/j.gerinurse.2011.02.002	35	80	81	2	32	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL-AUG	2014	49	4					540	549		10.4085/1062-6050-49.3.32			10	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	AQ4LO	WOS:000342768700014	24933431	Green Published			2022-02-06	
J	Sabaz, M; Simpson, GK; Walker, AJ; Rogers, JM; Gillis, I; Strettles, B				Sabaz, Mark; Simpson, Grahame K.; Walker, Alexandra J.; Rogers, Jeffrey M.; Gillis, Inika; Strettles, Barbara			Prevalence, Comorbidities, and Correlates of Challenging Behavior Among Community-Dwelling Adults With Severe Traumatic Brain Injury: A Multicenter Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						challenging behavior; participation; prevalence; psychiatric disorders; support needs; traumatic brain injury	NEUROBEHAVIORAL REHABILITATION SERVICE; CLOSED HEAD-INJURY; AGGRESSIVE-BEHAVIOR; SCALE; APATHY; PERSONALITY; AGITATION; PROGRAM; PEOPLE; IMPACT	Objective: Investigate the prevalence, comorbidities, and correlates of challenging behaviors among clients of the New South Wales Brain Injury Rehabilitation Program. Setting: All community-based rehabilitation services of the statewide program. Participants: Five hundred seven active clients with severe traumatic brain injury. Design: Prospective multicenter study. Main Measures: Eighty-eight clinicians from the 11 services rated clients on the Overt Behaviour Scale, Disability Rating Scale, Sydney Psychosocial Reintegration Scale-2, Care and Needs Scale, and Health of the Nation Outcome Scale-Acquired Brain Injury. Results: Overall prevalence rate of challenging behaviors was 54%. Inappropriate social behavior (33.3%), aggression (31.9%), and adynamia (23.1%) were the 3 most common individual behaviors, with 35.5% of the sample displaying more than 1 challenging behavior. Significant associations were found between increasing levels of challenging behavior and longer duration of posttraumatic amnesia, increasing functional disability, greater restrictions in participation, increased support needs, and greater degrees of psychiatric disturbance, respectively (P < 0.004). Multivariate binomial logistic regression found that premorbid alcohol abuse, postinjury restrictions in participation, and higher levels of postinjury psychiatric disturbance were independent predictors of challenging behavior. Conclusions: Challenging behaviors are widespread among community-dwelling adults with severe traumatic brain injury. Services need to deliver integrated anger management, social skills, and motivational treatments.	[Sabaz, Mark; Simpson, Grahame K.] Liverpool Hosp, Liverpool Brain Injury Rehabil Unit, Sydney, NSW 1871, Australia; [Simpson, Grahame K.] Univ Sydney, Sydney Sch Med, Rehabil Studies Unit, Sydney, NSW 2006, Australia; [Walker, Alexandra J.] Australian Catholic Univ, Westmead Hosp, Westmead Brain Injury Rehabil Unit, Sydney, NSW, Australia; [Rogers, Jeffrey M.] Univ New S Wales, Fac Med, Sch Psychiat, Sydney, NSW, Australia; [Gillis, Inika] Univ New S Wales, Fac Med, Black Dog Inst, Sydney, NSW, Australia; [Strettles, Barbara] Agcy Clin Innovat, Sydney, NSW, Australia		Sabaz, M (corresponding author), Liverpool Hosp, Liverpool Brain Injury Rehabil Unit, Locked Bag 7279 Liverpool BC, Sydney, NSW 1871, Australia.	mark.sabaz@sswahs.nsw.gov.au	Simpson, Grahame K/W-1074-2019	Simpson, Grahame K/0000-0001-8156-9060; Rogers, Jeffrey M/0000-0002-0320-969X	New South Wales Agency for Clinical Innovation	The New South Wales Agency for Clinical Innovation funded the project. Dr Sabaz, Dr Rogers, and Ms Gillis were employed by the Agency for Clinical Innovation when working on the project. The authors thank Natalie Pride, Dr Adeline Hodgkinson, Suzanne Benson, Naomi Brookes, Matthew Dowton, Marion Fisher, Kate O'Reilly, Vicki Solomon, and Maysaa Daher.	Alderman N, 2002, BRAIN INJURY, V16, P469, DOI 10.1080/02699050110118458; Alderman N, 1997, BRAIN INJURY, V11, P503, DOI 10.1080/713802182; Alderman N, 2007, BRAIN INJURY, V21, P891, DOI 10.1080/02699050701543560; Andersson S, 1999, BRAIN INJURY, V13, P393, DOI 10.1080/026990599121458; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Belanger HG, 2008, ARCH PHYS MED REHAB, V89, P244, DOI 10.1016/j.apmr.2007.08.145; Brain Injury Rehabilitation Directorate, 2010, NSW BRAIN INJ REH PR; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; Coetzer R., 2001, PSYCHIATR BULL, V25, P421, DOI [https://doi.org/10.1192/pb.25.11.421, DOI 10.1192/PB.25.11.421]; Colantonio A, 2010, BRAIN IMPAIR, V11, P31, DOI 10.1375/brim.11.1.31; Dickens G L, 2001, J Psychiatr Ment Health Nurs, V8, P543, DOI 10.1046/j.1351-0126.2001.00426.x; Emerson E., 2001, CHALLENGING BEHAV AN; ESLINGER PJ, 1995, NEUROREHABILITATION, V5, P161, DOI 10.3233/NRE-1995-5206; Feeney TJ, 2001, J HEAD TRAUMA REHAB, V16, P61, DOI 10.1097/00001199-200102000-00008; Fleminger S, 2005, PSYCHIATR BULL, V29, P53, DOI 10.1192/pb.29.2.53; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Greve KW, 2001, BRAIN INJURY, V15, P255; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Johnson R., 1996, CLIN REHABIL, V10, P173, DOI [DOI 10.1177/026921559601000215, 10.1177/026921559601000215]; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Kelly G, 2006, BRAIN INJURY, V20, P307, DOI 10.1080/02699050500488074; Kelly G., 2004, BRAIN IMPAIR, V5, DOI [10.1375/brim.5.1.42.35398, DOI 10.1375/brim.5.1.42.35398]; Kelly G, 2008, BRAIN INJURY, V22, P457, DOI 10.1080/02699050802060647; Kim SH, 1999, J NERV MENT DIS, V187, P327, DOI 10.1097/00005053-199906000-00001; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lane-Brown A, 2010, J HEAD TRAUMA REHAB, V25, P459, DOI 10.1097/HTR.0b013e3181d98e1d; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; RAO N, 1985, ARCH PHYS MED REHAB, V66, P30; Rao V, 2009, J NEUROPSYCH CLIN N, V21, P420, DOI 10.1176/appi.neuropsych.21.4.420; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SABHESAN S, 1989, ARCH SEX BEHAV, V18, P349, DOI 10.1007/BF01541953; Simpson G, 2001, J HEAD TRAUMA REHAB, V16, P556, DOI 10.1097/00001199-200112000-00004; Simpson G, 1999, J HEAD TRAUMA REHAB, V14, P567, DOI 10.1097/00001199-199912000-00005; Tate RL, 2004, BRAIN INJURY, V18, P445, DOI 10.1080/02699050310001641183; Tate RL, 2003, STUD NEUROPSYCHOL DE, P137; Tate RL, 2011, J REHABIL MED, V43, P609, DOI 10.2340/16501977-0829; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; van Reekum R, 2005, J NEUROPSYCH CLIN N, V17, P7, DOI 10.1176/appi.neuropsych.17.1.7; Walker AJ, 2010, BRAIN INJURY, V24, P517, DOI 10.3109/02699051003601721; Wood RL, 2001, NEUROBEHAVIOURAL DIS, P1; Wood RL, 2006, J NEUROPSYCH CLIN N, V18, P333, DOI 10.1176/appi.neuropsych.18.3.333; Worthington AD, 2006, BRAIN INJURY, V20, P947, DOI 10.1080/02699050600888314	46	80	80	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2014	29	2					E19	E30		10.1097/HTR.0b013e31828dc590			12	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AH9ZH	WOS:000336504600003	23640541				2022-02-06	
J	Angelakis, E; Liouta, E; Andreadis, N; Korfias, S; Ktonas, P; Stranjalis, G; Sakas, DE				Angelakis, Efthymios; Liouta, Evangelia; Andreadis, Nikos; Korfias, Stephanos; Ktonas, Periklis; Stranjalis, George; Sakas, Damianos E.			Transcranial Direct Current Stimulation Effects in Disorders of Consciousness	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Deep brain stimulation; Persistent vegetative state; Rehabilitation; tDCS	PERSISTENT VEGETATIVE STATE; MOTOR CORTEX; INTRATHECAL BACLOFEN; BRAIN POLARIZATION; EVOKED POTENTIALS; PREFRONTAL CORTEX; DC STIMULATION; MODULATION; TDCS; WAKEFULNESS	Objective: To assess the efficacy of transcranial direct current stimulation (tDCS) on improving consciousness in patients with persistent unresponsive wakefulness syndrome (UWS) (previously termed persistent vegetative state [PVS]) or in a minimally conscious state (MCS). Design: Prospective, case series trial with follow-up at 12 months. Setting: General and research hospital. Participants: Inpatients in a PVS/UWS or MCS (N=10; 7 men, 3 women; age range, 19-62y; etiology: traumatic brain injury, n=5; anoxia, n=4; postoperative infarct, n=1; duration of PVS/UWS or MCS range, 6mo-10y). No participant withdrew because of adverse effects. Intervention: All patients received sham tDCS for 20 minutes per day, 5 days per week, for 1 week, and real tDCS for 20 minutes per day, 5 days per week, for 2 weeks. An anodal electrode was placed over the left primary sensorimotor cortex or the left dorsolateral prefrontal cortex, with cathodal stimulation over the right eyebrow. One patient in an MCS received a second round of 10 tDCS sessions 3 months after initial participation. Main Outcome Measure: JFK Coma Recovery Scale-Revised. Results: All patients in an MCS showed clinical improvement immediately after treatment. The patient who received a second round of tDCS 3 months after initial participation showed further improvement and emergence into consciousness after stimulation, with no change between treatments. One patient who was in an MCS for <1 year before treatment (postoperative infarct) showed further improvement and emergence into consciousness at 12-month follow-up. No patient showed improvement before stimulation. No patient in a PVS/UWS showed immediate improvement after stimulation, but 1 patient who was in a PVS/UWS for 6 years before treatment showed improvement and change of status to an MCS at 12-month follow-up. Conclusions: tDCS seems promising for the rehabilitation of patients with severe disorders of consciousness. Severity and duration of pathology may be related to the degree of tDCS' beneficial effects. (C) 2014 by the American Congress of Rehabilitation Medicine	[Angelakis, Efthymios; Liouta, Evangelia; Andreadis, Nikos; Korfias, Stephanos; Ktonas, Periklis; Stranjalis, George; Sakas, Damianos E.] Hellen Ctr Neurosurg Res Prof Petros Kokkalis, GR-10675 Athens, Greece; [Angelakis, Efthymios; Liouta, Evangelia; Korfias, Stephanos; Stranjalis, George; Sakas, Damianos E.] Natl & Kapodistrian Univ Athens, Sch Med, Dept Neurosurg, Evangelismos Hosp, Athens 11528, Greece		Angelakis, E (corresponding author), Hellen Ctr Neurosurg Res Prof Petros Kokkalis, 3 Ploutarchou Str, GR-10675 Athens, Greece.	eaggelak@med.uoa.gr			European CommissionEuropean CommissionEuropean Commission Joint Research Centre [222079]; Hellenic Center for Neurosurgical Research "Prof. Petros Kokkalis"	Supported in part by the HIVE project (http://hive-eu.org), a Future and Emerging Technologies program within the 7th Framework Programme for Research of the European Commission (grant no. 222079) and the Hellenic Center for Neurosurgical Research "Prof. Petros Kokkalis."	Accornero N, 2007, EXP BRAIN RES, V178, P261, DOI 10.1007/s00221-006-0733-y; Anaclet C, 2009, J NEUROSCI, V29, P14423, DOI 10.1523/JNEUROSCI.2604-09.2009; ANDREWS K, 1993, BRIT MED J, V306, P1597, DOI 10.1136/bmj.306.6892.1597; Antal A, 2001, NEUROREPORT, V12, P3553, DOI 10.1097/00001756-200111160-00036; Antal A, 2008, CLIN J PAIN, V24, P56, DOI 10.1097/AJP.0b013e318157233b; Ardolino G, 2005, J PHYSIOL-LONDON, V568, P653, DOI 10.1113/jphysiol.2005.088310; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Baudewig J, 2001, MAGN RESON MED, V45, P196, DOI 10.1002/1522-2594(200102)45:2<196::AID-MRM1026>3.0.CO;2-1; BINDMAN LJ, 1964, J PHYSIOL-LONDON, V172, P369, DOI 10.1113/jphysiol.1964.sp007425; Boggio PS, 2008, INT J NEUROPSYCHOPH, V11, P249, DOI 10.1017/S1461145707007833; Boggio PS, 2007, RESTOR NEUROL NEUROS, V25, P123; Boggio PS, 2006, J NEUROL SCI, V249, P31, DOI 10.1016/j.jns.2006.05.062; Bruno MA, 2012, J NEUROL, V259, P1087, DOI 10.1007/s00415-011-6303-7; Childs NL, 1996, BRIT MED J, V313, P944; Clark VP, 2011, NEUROSCI LETT, V500, P67, DOI 10.1016/j.neulet.2011.05.244; CREUTZFELDT O, 1962, EXP NEUROL, V5, P436, DOI 10.1016/0014-4886(62)90056-0; Dell'Osso B, 2012, EUR PSYCHIAT, V27, P513, DOI 10.1016/j.eurpsy.2011.02.008; Floel A, 2008, J COGNITIVE NEUROSCI, V20, P1415, DOI 10.1162/jocn.2008.20098; Frank E, 2010, BRAIN STIMUL, V3, P58, DOI 10.1016/j.brs.2009.04.002; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; Furubayashi T, 2008, EXP BRAIN RES, V185, P279, DOI 10.1007/s00221-007-1149-z; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Hummel F, 2005, BRAIN, V128, P490, DOI 10.1093/brain/awh369; Hummel FC, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-73; Iyer MB, 2005, NEUROLOGY, V64, P872, DOI 10.1212/01.WNL.0000152986.07469.E9; JENNETT B, 1972, LANCET, V1, P734; Keeser D, 2011, NEUROIMAGE, V55, P644, DOI 10.1016/j.neuroimage.2010.12.004; Kincses TZ, 2004, NEUROPSYCHOLOGIA, V42, P113, DOI 10.1016/S0028-3932(03)00124-6; Kwon YH, 2008, NEUROSCI LETT, V435, P56, DOI 10.1016/j.neulet.2008.02.012; Lang N, 2005, EUR J NEUROSCI, V22, P495, DOI 10.1111/j.1460-9568.2005.04233.x; Lang N, 2007, INVEST OPHTH VIS SCI, V48, P5782, DOI 10.1167/iovs.07-0706; Laureys S, 2006, J CLIN INVEST, V116, P1823, DOI 10.1172/JCI29172; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Leon-Carrion J, 2012, BRAIN RES, V1476, P22, DOI 10.1016/j.brainres.2012.03.055; Lin JS, 2011, CELL MOL LIFE SCI, V68, P2499, DOI 10.1007/s00018-011-0631-8; Marshall L, 2004, J NEUROSCI, V24, P9985, DOI 10.1523/JNEUROSCI.2725-04.2004; Monti A, 2008, J NEUROL NEUROSUR PS, V79, P451, DOI 10.1136/jnnp.2007.135277; Nakamura-Palacios EM, 2012, INT J NEUROPSYCHOPH, V15, P601, DOI 10.1017/S1461145711001040; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; Ohn SH, 2008, NEUROREPORT, V19, P43, DOI 10.1097/WNR.0b013e3282f2adfd; Palm U, 2008, BRAIN STIMUL, V1, P241; PURPURA DP, 1965, J NEUROPHYSIOL, V28, P166, DOI 10.1152/jn.1965.28.1.166; Quartarone A, 2004, NEUROREPORT, V15, P1287, DOI 10.1097/01.wnr.0000127637.22805.7c; Sara M, 2009, ARCH PHYS MED REHAB, V90, P1245, DOI 10.1016/j.apmr.2009.01.012; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Silva S, 2010, NEUROLOGY, V74, P313, DOI 10.1212/WNL.0b013e3181cbcd96; Stempien L, 2000, AM J PHYS MED REHAB, V79, P536, DOI 10.1097/00002060-200011000-00010; Terney D, 2008, J PAIN SYMPTOM MANAG, V36, P79, DOI 10.1016/j.jpainsymman.2007.08.014; Vanhaudenhuyse A, 2011, J COGNITIVE NEUROSCI, V23, P570, DOI 10.1162/jocn.2010.21488; Vines BW, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-103; Vines BW, 2006, NEUROREPORT, V17, P671, DOI 10.1097/00001756-200604240-00023; Yamamoto T, 2005, NEUROPSYCHOL REHABIL, V15, P406, DOI 10.1080/09602010443000353; Zheng X, 2011, NEUROIMAGE, V58, P26, DOI 10.1016/j.neuroimage.2011.06.018	54	80	97	0	30	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2014	95	2					283	289		10.1016/j.apmr.2013.09.002			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	AA2LW	WOS:000330927100011	24035769				2022-02-06	
J	Soble, JR; Silva, MA; Vanderploeg, RD; Curtiss, G; Belanger, HG; Donnell, AJ; Scott, SG				Soble, Jason R.; Silva, Marc A.; Vanderploeg, Rodney D.; Curtiss, Glenn; Belanger, Heather G.; Donnell, Alison J.; Scott, Steven G.			Normative Data for the Neurobehavioral Symptom Inventory (NSI) and Post-Concussion Symptom Profiles Among TBI, PTSD, and Nonclinical Samples	CLINICAL NEUROPSYCHOLOGIST			English	Article						Neurobehavioral Symptom Inventory; Normative data; Post-Concussion Syndrome; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; POSTCONCUSSIVE SYMPTOMS; HEAD-INJURY; METAANALYSIS; VETERANS; IRAQ; ASSOCIATIONS; EQUIVALENCE; VALIDATION	The Neurobehavioral Symptom Inventory (NSI) is a self-report measure of symptoms commonly associated with Post-Concussion Syndrome (PCS) that may emerge after mild traumatic brain injury (mTBI). Despite frequent clinical use, no NSI norms have been developed. Thus, the main objective of this study was to establish NSI normative data using the four NSI factors (i.e., vestibular, somatic, cognitive, and affective) identified by Vanderploeg, Silva, et al. (2014) among nonclinical epidemiological samples of deployed and non-deployed Florida National Guard members as well as a reference sample of Guard members with combat-related mTBI. In addition, NSI subscale profile patterns were compared across four distinct subgroups (i.e., non-deployed-nonclinical, deployed-nonclinical, deployed-mTBI, and deployed-PTSD). The deployed-nonclinical group endorsed greater PCS symptom severity than the non-deployed group, and the mTBI group uniformly endorsed more symptoms than both nonclinical groups. However, the PTSD group endorsed higher symptom severity relative to the other three subgroups. As such, this highlights the non-specificity of PCS symptoms and suggests that PTSD is associated with higher symptom endorsement than mTBI.	[Soble, Jason R.; Silva, Marc A.; Vanderploeg, Rodney D.; Curtiss, Glenn; Belanger, Heather G.; Donnell, Alison J.] James A Haley Vet Hosp, Mental Hlth & Behav Sci Serv, Tampa, FL 33612 USA; [Soble, Jason R.; Vanderploeg, Rodney D.; Curtiss, Glenn; Belanger, Heather G.] Univ S Florida, Dept Psychiat & Behav Neurosci, Tampa, FL USA; [Vanderploeg, Rodney D.; Belanger, Heather G.; Scott, Steven G.] James A Haley Vet Hosp, Hlth Serv Res & Dev HSR&D, Rehabil Res & Dev RR&D Ctr Excellence Maximizing, Tampa, FL 33612 USA; [Vanderploeg, Rodney D.; Belanger, Heather G.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; [Vanderploeg, Rodney D.; Belanger, Heather G.; Donnell, Alison J.; Scott, Steven G.] Def & Vet Brain Injury Ctr, Tampa, FL USA; [Scott, Steven G.] James A Haley Vet Hosp, Phys Med & Rehabil Serv, Tampa, FL 33612 USA; [Scott, Steven G.] Univ S Florida, Dept Internal Med, Tampa, FL 33612 USA		Vanderploeg, RD (corresponding author), James A Haley Vet Hosp, Psychol Serv 116B, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	Rodney.Vanderploeg@va.gov	Silva, Marc A./J-1874-2019; Curtiss, Glenn/ABB-5566-2020	Silva, Marc A./0000-0002-3879-6054; 	Department of Veterans Affairs, Veterans Health Administration (VHA)US Department of Veterans Affairs; Defense and Veterans Brain Injury Center (DVBIC)US Department of Veterans Affairs; VA Grant SDR HSRD [08-411]; TBI Screening Instruments; VA HSRD Grant [CCN 06-164]; James A. Haley Veterans' HospitalUS Department of Veterans Affairs; HSR&D/RR&D Center of Excellence	This research was supported by the Department of Veterans Affairs, Veterans Health Administration (VHA), and Defense and Veterans Brain Injury Center (DVBIC), and by VA Grant SDR HSR&D #08-411, TBI Screening Instruments, processed to Rodney D. Vanderploeg, and VA HSR&D Grant CCN 06-164 processed to Steven G. Scott. Further support was provided by James A. Haley Veterans' Hospital, and its HSR&D/RR&D Center of Excellence, and the Defense and Veterans Brain Injury Center (DVBIC).	American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5, DOI [10.1176/appi.books.9780890425596.dsm02, 10.1176/appi.books.9780890425596]; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Donnell AJ, 2012, CLIN NEUROPSYCHOL, V26, P1092, DOI 10.1080/13854046.2012.713984; Elhai JD, 2011, J ANXIETY DISORD, V25, P404, DOI 10.1016/j.janxdis.2010.11.003; Faul M, 2010, TRAUMATIC BRAIN INJU; Finger MS, 1999, PSYCHOL ASSESSMENT, V11, P58, DOI 10.1037/1040-3590.11.1.58; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Granacher R. P., 2008, TRAUMATIC BRAIN INJU, VSecond; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King PR, 2012, J REHABIL RES DEV, V49, P879, DOI 10.1682/JRRD.2011.03.0051; Kroenke K, 2002, PSYCHIAT ANN, V32, P509, DOI 10.3928/0048-5713-20020901-06; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meterko M, 2012, J HEAD TRAUMA REHAB, V27, P55, DOI 10.1097/HTR.0b013e318230fb17; National Center for PTSD, 2012, US PTSD CHECKL PCL; Nunnally J.C., 1994, PSYCHOMETRIC THEORY, V3; Ramchand R, 2010, J TRAUMA STRESS, V23, P59, DOI 10.1002/jts.20486; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Schmitz N, 1999, PSYCHIAT RES, V87, P217, DOI 10.1016/S0165-1781(99)00060-8; Schmitz N, 2000, ACTA PSYCHIAT SCAND, V102, P147, DOI 10.1034/j.1600-0447.2000.102002147.x; Schulenberg SE, 2001, CURR PSYCHOL, V20, P216, DOI 10.1007/s12144-001-1008-1; Silva MA, 2013, CLIN NEUROPSYCHOL, V27, P601; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; STEER RA, 1993, J PERS ASSESS, V60, P532, DOI 10.1207/s15327752jpa6003_10; Trahan D. E., 1997, BEAUMONT POSTCONCUSS; Traub RE., 1994, RELIABILITY SOCIAL S; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vanderploeg RD, 2015, J HEAD TRAUMA REHAB, V30, P1, DOI 10.1097/HTR.0000000000000009; Vanderploeg RD, 2014, J HEAD TRAUMA REHAB, V29, P1, DOI 10.1097/HTR.0b013e318281966e; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Weathers F.W., 1993, ANN CONV INT SOC TRA; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; World Health Organization, 1992, ICD 10 CLASSIFICATIO	52	80	80	0	13	TAYLOR & FRANCIS INC	PHILADELPHIA	530 CHESTNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2014	28	4			SI		614	632		10.1080/13854046.2014.894576			19	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	AM8PH	WOS:000340138900006	24625213				2022-02-06	
J	Tang, YH; Cai, BB; Yuan, FL; He, XS; Lin, XJ; Wang, JX; Wang, YT; Yang, GY				Tang, Yaohui; Cai, Beibei; Yuan, Falei; He, Xiaosong; Lin, Xiaojie; Wang, Jixian; Wang, Yongting; Yang, Guo-Yuan			Melatonin Pretreatment Improves the Survival and Function of Transplanted Mesenchymal Stem Cells After Focal Cerebral Ischemia	CELL TRANSPLANTATION			English	Article						Melatonin; Mesenchymal stem cells (MSCs); Ischemia; Survival; Angiogenesis	MARROW STROMAL CELLS; TRAUMATIC BRAIN-INJURY; INFARCTED MYOCARDIUM; RAT-BRAIN; STROKE; ANGIOGENESIS; MODEL; REPERFUSION; RECOVERY; THERAPY	Mesenchymal stem cell (MSC) transplantation has been shown to be beneficial in treating cerebral ischemia. However, such benefit is limited by the low survival of transplanted MSCs in an ischemic microenvironment. Previous studies showed that melatonin pretreatment can increase MSC survival in the ischemic kidney. However, whether it will improve MSC survival in cerebral ischemia is unknown. Our study examined the effect of melatonin pretreatment on MSCs under ischemia-related conditions in vitro and after transplantation into ischemic rat brain. Results showed that melatonin pretreatment greatly increased survival of MSCs in vitro and reduced their apoptosis after transplantation into ischemic brain. Melatonin-treated MSCs (MT-MSCs) further reduced brain infarction and improved neurobehavioral outcomes. Angiogenesis, neurogenesis, and the expression of vascular endothelial growth factor (VEGF) were greatly increased in the MT-MSC-treated rats. Melatonin treatment increased the level of p-ERK1/2 in MSCs, which can be blocked by the melatonin receptor antagonist luzindole. ERK phosphorylation inhibitor U0126 completely reversed the protective effects of melatonin, suggesting that melatonin improves MSC survival and function through activating the ERK1/2 signaling pathway. Thus, stem cells pretreated by melatonin may represent a feasible approach for improving the beneficial effects of stem cell therapy for cerebral ischemia.	[Tang, Yaohui; Cai, Beibei; Yuan, Falei; He, Xiaosong; Lin, Xiaojie; Wang, Yongting; Yang, Guo-Yuan] Med X Res Inst, Neurosci & Neuroengn Res Ctr, Shanghai, Peoples R China; [Tang, Yaohui; Cai, Beibei; Yuan, Falei; He, Xiaosong; Lin, Xiaojie; Wang, Yongting; Yang, Guo-Yuan] Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai 200030, Peoples R China; [Wang, Jixian; Yang, Guo-Yuan] Shanghai Jiao Tong Univ, Sch Med, Shanghai Ruijin Hosp, Shanghai 200030, Peoples R China		Yang, GY (corresponding author), Shanghai Jiao Tong Univ, Neurosci & Neuroengn Res Ctr, Med X Res Inst, 1954 Hua Shan Rd, Shanghai 200030, Peoples R China.	yongting.wang@gmail.com; gyyang0626@gmail.com	Tang, Yaohui/AAE-9746-2019; Wang, Yongting/C-2916-2014	Tang, Yaohui/0000-0002-9603-2650; 	Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81070939, 81100868]; National Basic Research Program of China (973 Program)National Basic Research Program of China [2011CB504405]; Science and Technology Commission of Shanghai MunicipalityScience & Technology Commission of Shanghai Municipality (STCSM) [10JC1408100]; KC Wong Foundation	This study was supported by research Natural Science Foundation of China (81070939 and 81100868), National Basic Research Program of China (973 Program 2011CB504405), the Science and Technology Commission of Shanghai Municipality (10JC1408100), and KC Wong Foundation (G.Y.Y.). We thank Dr Richard E Keep from the University of Michigan and Tiffany Dai from the University of California Berkeley for their valuable discussion and kind editorial assistance. The authors declare no conflicts of interest.	Arendt J, 2000, NEW ENGL J MED, V343, P1114, DOI 10.1056/NEJM200010123431510; Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; Barbash IM, 2003, CIRCULATION, V108, P863, DOI 10.1161/01.CIR.0000084828.50310.6A; BORLONGAN CV, 1995, J NEUROSCI, V15, P5372; BOSSI P, 1995, CANCER RES, V55, P5049; Cervantes M, 2008, J PINEAL RES, V45, P1, DOI 10.1111/j.1600-079X.2007.00551.x; Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D; Cheung RTF, 2003, J PINEAL RES, V34, P153, DOI 10.1034/j.1600-079X.2003.00034.x; Edalatmanesh MA, 2011, NEUROL RES, V33, P913, DOI 10.1179/1743132811Y.0000000036; England TJ, 2012, STROKE, V43, P405, DOI 10.1161/STROKEAHA.111.636449; Fan YF, 2010, ANN NEUROL, V67, P488, DOI 10.1002/ana.21919; Folkerth RD, 2000, J NEURO-ONCOL, V50, P165, DOI 10.1023/A:1006499824379; Fraser SE, 1996, METHOD CELL BIOL, V51, P147, DOI 10.1016/S0091-679X(08)60627-5; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Harris AL, 1996, BREAST CANCER RES TR, V38, P97, DOI 10.1007/BF01803788; Henrich D, 2009, TISSUE ENG PART C-ME, V15, P551, DOI [10.1089/ten.tec.2008.0385, 10.1089/ten.TEC.2008.0385]; Jin KL, 2011, BRAIN RES, V1374, P56, DOI 10.1016/j.brainres.2010.12.037; Khakoo AY, 2006, J EXP MED, V203, P1235, DOI 10.1084/jem.20051921; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; Maharaj DS, 2007, BIOSCIENCE REP, V27, P299, DOI 10.1007/s10540-007-9052-1; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Makkar RR, 2012, LANCET, V379, P895, DOI 10.1016/S0140-6736(12)60195-0; Mias C, 2008, STEM CELLS, V26, P1749, DOI 10.1634/stemcells.2007-1000; Moriya T, 2007, J PINEAL RES, V42, P411, DOI 10.1111/j.1600-079X.2007.00435.x; Muller-Ehmsen J, 2002, J MOL CELL CARDIOL, V34, P107, DOI 10.1006/jmcc.2001.1491; Niles LP, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-41; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Penn MS, 2012, CIRC RES, V110, P304, DOI 10.1161/CIRCRESAHA.111.253427; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Radio NM, 2006, J PINEAL RES, V40, P332, DOI 10.1111/j.1600-079X.2006.00318.x; Reiter RJ, 2003, CARDIOVASC RES, V58, P10, DOI 10.1016/S0008-6363(02)00827-1; Reiter RJ, 2010, ANN MED, V42, P276, DOI 10.3109/07853890903485748; Roh JK, 2008, CURR STEM CELL RES T, V3, P185, DOI 10.2174/157488808785740352; Tambara K, 2003, CIRCULATION, V108, P259, DOI 10.1161/01.cir.0000087430.17543.b8; Theus MH, 2008, EXP NEUROL, V210, P656, DOI 10.1016/j.expneurol.2007.12.020; Wechsler LR, 2009, STROKE, V40, pS149, DOI 10.1161/STROKEAHA.108.533208; Wei L, 2012, NEUROBIOL DIS, V46, P635, DOI 10.1016/j.nbd.2012.03.002; Wesseling P, 1997, J NEURO-ONCOL, V32, P253, DOI 10.1023/A:1005746320099; Williams AR, 2011, CIRC RES, V109, P923, DOI 10.1161/CIRCRESAHA.111.243147; Wislet-Gendebien S, 2005, STEM CELLS, V23, P392, DOI 10.1634/stemcells.2004-0149; Yang Guo-Yuan, 2003, Angiogenesis, V6, P151, DOI 10.1023/B:AGEN.0000011803.56605.78; YANG GY, 1994, STROKE, V25, P1658, DOI 10.1161/01.STR.25.8.1658; Zhang L, 2011, STROKE, V42, P1437, DOI 10.1161/STROKEAHA.110.593129; Zhang LM, 2010, J PINEAL RES, V49, P364, DOI 10.1111/j.1600-079X.2010.00803.x; Zlokovic BV, 2011, NAT REV NEUROSCI, V12, P723, DOI 10.1038/nrn3114	46	80	84	1	21	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0963-6897	1555-3892		CELL TRANSPLANT	Cell Transplant.		2014	23	10					1279	1291		10.3727/096368913X667510			13	Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Research & Experimental Medicine; Transplantation	AR1YW	WOS:000343381500010	23635511				2022-02-06	
J	Harris, K; Armstrong, SP; Campos-Pires, R; Kiru, L; Franks, NP; Dickinson, R				Harris, Katie; Armstrong, Scott P.; Campos-Pires, Rita; Kiru, Louise; Franks, Nicholas P.; Dickinson, Robert			Neuroprotection against Traumatic Brain Injury by Xenon, but Not Argon, Is Mediated by Inhibition at the N-Methyl-D-Aspartate Receptor Glycine Site	ANESTHESIOLOGY			English	Article							HIPPOCAMPAL SLICE CULTURES; IN-VITRO MODEL; INHALATIONAL GENERAL-ANESTHETICS; CEREBRAL-ARTERY OCCLUSION; COMPETITIVE-INHIBITION; HYPOXIA-ISCHEMIA; ORGANOTYPIC CULTURES; INTRACELLULAR CA2+; NEONATAL ASPHYXIA; NEURONAL INJURY	Background: Xenon, the inert anesthetic gas, is neuroprotective in models of brain injury. The authors investigate the neuroprotective mechanisms of the inert gases such as xenon, argon, krypton, neon, and helium in an in vitro model of traumatic brain injury. Methods: The authors use an in vitro model using mouse organotypic hippocampal brain slices, subjected to a focal mechanical trauma, with injury quantified by propidium iodide fluorescence. Patch clamp electrophysiology is used to investigate the effect of the inert gases on N-methyl-d-aspartate receptors and TREK-1 channels, two molecular targets likely to play a role in neuroprotection. Results: Xenon (50%) and, to a lesser extent, argon (50%) are neuroprotective against traumatic injury when applied after injury (xenon 431% protection at 72h after injury [N = 104]; argon 30 +/- 6% protection [N = 44]; mean +/- SEM). Helium, neon, and krypton are devoid of neuroprotective effect. Xenon (50%) prevents development of secondary injury up to 48h after trauma. Argon (50%) attenuates secondary injury, but is less effective than xenon (xenon 50 +/- 5% reduction in secondary injury at 72h after injury [N = 104]; argon 34 +/- 8% reduction [N = 44]; mean +/- SEM). Glycine reverses the neuroprotective effect of xenon, but not argon, consistent with competitive inhibition at the N-methyl-d-aspartate receptor glycine site mediating xenon neuroprotection against traumatic brain injury. Xenon inhibits N-methyl-d-aspartate receptors and activates TREK-1 channels, whereas argon, krypton, neon, and helium have no effect on these ion channels. Conclusions: Xenon neuroprotection against traumatic brain injury can be reversed by increasing the glycine concentration, consistent with inhibition at the N-methyl-d-aspartate receptor glycine site playing a significant role in xenon neuroprotection. Argon and xenon do not act via the same mechanism.	[Harris, Katie; Armstrong, Scott P.; Campos-Pires, Rita; Kiru, Louise; Franks, Nicholas P.; Dickinson, Robert] Univ London Imperial Coll Sci Technol & Med, Anaesthet Pain Med & Intens Care Sect, Dept Surg & Canc, London SW7 2AZ, England		Dickinson, R (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sir Ernst Chain Bldg, London SW7 2AZ, England.	r.dickinson@imperial.ac.uk		Franks, Nicholas/0000-0003-4874-4212	European Society for Anaesthesiology, Brussels, Belgium; Royal College of Anaesthetists, London, United Kingdom; Westminster Medical School Research Trust, London, United Kingdom; Medical Research Council, London, United KingdomUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Fundacao para a Ciencia e a Tecnologia, Lisbon, PortugalPortuguese Foundation for Science and Technology; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [1247958] Funding Source: researchfish	Support was provided by the European Society for Anaesthesiology, Brussels, Belgium; The Royal College of Anaesthetists, London, United Kingdom; and Westminster Medical School Research Trust, London, United Kingdom. Katie Harris is the recipient of a studentship from the Westminster Medical School Research Trust, London, United Kingdom. Scott Armstrong is the recipient of a studentship from the Medical Research Council, London, United Kingdom. Dr. Campos-Pires is the recipient of a doctoral training award from the Fundacao para a Ciencia e a Tecnologia, Lisbon, Portugal. Professor Franks has a financial interest in the use of xenon as a neuroprotectant, through an agreement with Air Products and Chemicals, Inc., Allentown, Pennsylvania.	Adamchik Y, 2000, BRAIN RES PROTOC, V5, P153, DOI 10.1016/S1385-299X(00)00007-6; Adembri C, 2004, J NEUROTRAUM, V21, P1103, DOI 10.1089/0897715041651079; Armstrong SP, 2012, ANESTHESIOLOGY, V117, P38, DOI 10.1097/ALN.0b013e31825ada2e; BAHR BA, 1995, J NEUROSCI RES, V42, P294, DOI 10.1002/jnr.490420303; Banks P, 2010, BRIT J ANAESTH, V104, P526; Banks P, 2010, ANESTHESIOLOGY, V112, P614, DOI 10.1097/ALN.0b013e3181cea398; Berger AJ, 1998, J NEUROPHYSIOL, V80, P3336, DOI 10.1152/jn.1998.80.6.3336; Bickler PE, 2012, ANESTHESIOLOGY, V117, P280, DOI 10.1097/ALN.0b013e318260a7b9; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Coburn M, 2008, CRIT CARE MED, V36, P588, DOI 10.1097/01.CCM.0B013E3181611F8A6; Crain SM, 1998, METHODS, V16, P228, DOI 10.1006/meth.1998.0681; David HN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030934; David HN, 2009, J CEREBR BLOOD F MET, V29, P1159, DOI 10.1038/jcbfm.2009.40; de Sousa SLM, 2000, ANESTHESIOLOGY, V92, P1055, DOI 10.1097/00000542-200004000-00024; Dickinson R, 2007, ANESTHESIOLOGY, V107, P756, DOI 10.1097/01.anes.0000287061.77674.71; Dickinson R, 2010, CRIT CARE, V14, DOI 10.1186/cc9051; Dingley J, 2006, STROKE, V37, P501, DOI 10.1161/01.STR.0000198867.31134.ac; Dopico JG, 2006, NEUROPHARMACOLOGY, V50, P548, DOI 10.1016/j.neuropharm.2005.10.014; Downie DL, 1996, BRIT J PHARMACOL, V118, P493, DOI 10.1111/j.1476-5381.1996.tb15430.x; Dyker AG, 1999, STROKE, V30, P986, DOI 10.1161/01.STR.30.5.986; Fahlenkamp AV, 2012, EUR J PHARMACOL, V674, P104, DOI 10.1016/j.ejphar.2011.10.045; Finley M, 2004, BRAIN RES, V1001, P125, DOI 10.1016/j.brainres.2003.12.009; Franks NP, 1998, NATURE, V396, P324, DOI 10.1038/24525; Frantseva M, 2002, PROG BRAIN RES, V137, P171; Frantseva MV, 2002, J CEREBR BLOOD F MET, V22, P453, DOI 10.1097/00004647-200204000-00009; Fries M, 2008, CRIT CARE MED, V36, P2420, DOI 10.1097/CCM.0b013e3181802874; Gray JJ, 2005, ANESTHESIOLOGY, V102, P606, DOI 10.1097/00000542-200503000-00020; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Gruss M, 2004, MOL PHARMACOL, V65, P443, DOI 10.1124/mol.65.2.443; Head BP, 2007, CURR OPIN ANESTHESIO, V20, P395, DOI 10.1097/ACO.0b013e3282efa69d; Hemmings HC, 2008, ANESTHESIOLOGY, V109, P954, DOI 10.1097/ALN.0b013e31818d4964; Heurteaux C, 2004, EMBO J, V23, P2684, DOI 10.1038/sj.emboj.7600234; Homi HM, 2003, ANESTHESIOLOGY, V99, P876, DOI 10.1097/00000542-200310000-00020; Jawad N, 2009, NEUROSCI LETT, V460, P232, DOI 10.1016/j.neulet.2009.05.069; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Ling GSF, 2008, NEUROL CLIN, V26, P409, DOI 10.1016/j.ncl.2008.02.001; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loetscher PD, 2009, CRIT CARE, V13, DOI 10.1186/cc8214; Ma D, 2002, BRIT J ANAESTH, V89, P739, DOI 10.1093/bja/aef258; Ma DQ, 2005, ANN NEUROL, V58, P182, DOI 10.1002/ana.20547; MACKLIS JD, 1990, J NEUROSCI METH, V31, P43, DOI 10.1016/0165-0270(90)90007-3; Montero M, 2007, BRAIN RES, V1177, P124, DOI 10.1016/j.brainres.2007.08.038; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Oei GTML, 2010, ANESTHESIOLOGY, V112, P1503, DOI 10.1097/ALN.0b013e3181d9cb5e; Pan Y, 2007, EXP NEUROL, V205, P587, DOI 10.1016/j.expneurol.2007.03.023; Patel P, 2004, ANESTHESIOLOGY, V100, P1049, DOI 10.1097/00000542-200405000-00003; Preckel B, 2002, BRIT J ANAESTH, V88, P264, DOI 10.1093/bja/88.2.264; Preckel B, 2006, ANESTHESIOLOGY, V105, P187, DOI 10.1097/00000542-200607000-00029; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ryang YM, 2011, CRIT CARE MED, V39, P1448, DOI 10.1097/CCM.0b013e31821209be; Sanders RD, 2003, BRIT J ANAESTH, V91, P709, DOI 10.1093/bja/aeg232; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Sheng SP, 2012, ANESTHESIOLOGY, V117, P1262, DOI 10.1097/ALN.0b013e3182746b81; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Sullivan BL, 2002, ANESTHESIOLOGY, V96, P189, DOI 10.1097/00000542-200201000-00033; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Teasdale GM, 1998, NEUROSURGERY, V43, P1373, DOI 10.1097/00006123-199812000-00068; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1007/BF03206568; Turtzo LC, 2013, NMR BIOMED, V26, P468, DOI 10.1002/nbm.2886; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; Warner DS, 2004, ANESTH ANALG, V99, P1208, DOI 10.1213/01.ANE.0000139930.04010.0D; White CL, 2009, J TRAUMA, V67, P508, DOI 10.1097/TA.0b013e3181b2519f; Wilhelm S, 2002, ANESTHESIOLOGY, V96, P1485, DOI 10.1097/00000542-200206000-00031; Yarin YM, 2005, HEARING RES, V201, P1, DOI 10.1016/j.heares.2004.09.015; Zhuang L, 2012, CRIT CARE MED, V40, P1724, DOI 10.1097/CCM.0b013e3182452164	68	80	83	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	NOV	2013	119	5					1137	1148		10.1097/ALN.0b013e3182a2a265			12	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	290ZS	WOS:000329797900021	23867231				2022-02-06	
J	Bailey, DM; Jones, DW; Sinnott, A; Brugniaux, JV; New, KJ; Hodson, D; Marley, CJ; Smirl, JD; Ogoh, S; Ainslie, PN				Bailey, Damian M.; Jones, Daniel W.; Sinnott, Andrew; Brugniaux, Julien V.; New, Karl J.; Hodson, Danielle; Marley, Christopher J.; Smirl, Jonathan D.; Ogoh, Shigehiko; Ainslie, Philip N.			Impaired cerebral haemodynamic function associated with chronic traumatic brain injury in professional boxers	CLINICAL SCIENCE			English	Article						boxing; cerebrovascular reactivity; chronic traumatic brain injury; cortical oxygenation; dynamic cerebral autoregulation	INITIAL ORTHOSTATIC HYPOTENSION; ACUTE MOUNTAIN-SICKNESS; BLOOD-FLOW; TRANSCRANIAL DOPPLER; HEAD-INJURY; AUTOREGULATION; HUMANS; EXERCISE; OSCILLATIONS; HYPERTENSION	The present study examined to what extent professional boxing compromises cerebral haemodynamic function and its association with CTBI (chronic traumatic brain injury). A total of 12 male professional boxers were compared with 12 age-, gender- and physical fitness-matched non-boxing controls. We assessed dCA (dynamic cerebral autoregulation; thigh-cuff technique and transfer function analysis), CVRco(2) (cerebrovascular reactivity to changes in CO2: 5% CO2 and controlled hyperventilation), orthostatic tolerance (supine to standing) and neurocognitive function (psychometric tests). Blood flow velocity in the middle cerebral artery (transcranial Doppler ultrasound), mean arterial blood pressure (finger photoplethysmography), end-tidal CO2 (capnography) and cortical oxyhaemoglobin concentration (near-IR spectroscopy) were continuously measured. Boxers were characterized by fronto-temporal neurocognitive dysfunction and impaired dCA as indicated by a lower rate of regulation and autoregulatory index (P < 0.05 compared with controls). Likewise, CVRco(2) was also reduced resulting in a lower CVRco(2) range (P < 0.05 compared with controls). The latter was most marked in boxers with the highest CTBI scores and correlated against the volume and intensity of sparring during training (r = -0.84, P < 0.05). These impairments coincided with more marked orthostatic hypotension, cerebral hypoperfusion and corresponding cortical de-oxygenation during orthostatic stress (P < 0.05 compared with controls). In conclusion, these findings provide the first comprehensive evidence for chronically impaired cerebral haemodynamic function in active boxers due to the mechanical trauma incurred by repetitive, sub-concussive head impact incurred during sparring training. This may help explain why CTBI is a progressive disease that manifests beyond the active boxing career.	[Bailey, Damian M.; Jones, Daniel W.; Sinnott, Andrew; Brugniaux, Julien V.; New, Karl J.; Hodson, Danielle; Marley, Christopher J.] Univ Glamorgan, Fac Hlth Sci & Sport, Neurovasc Res Lab, Pontypridd CF37 1DL, M Glam, Wales; [Bailey, Damian M.] Aix Marseille Univ, Inst Chim Radicalaire, CNRS UMR 7273, Marseille, France; [Smirl, Jonathan D.; Ainslie, Philip N.] Univ British Columbia Okanagan, Sch Hlth & Exercise Sci, Kelowna, BC, Canada; [Ogoh, Shigehiko] Toyo Univ, Dept Biomed Engn, Saitama, Japan		Bailey, DM (corresponding author), Univ Glamorgan, Fac Hlth Sci & Sport, Neurovasc Res Lab, Pontypridd CF37 1DL, M Glam, Wales.	dbailey1@glam.ac.uk	Bailey, Damian Miles/AAQ-1840-2020; Marley, Chris/J-3119-2019	Marley, Chris/0000-0002-6757-6448; Ogoh, Shigehiko/0000-0001-5297-6468; Brugniaux, Julien/0000-0001-8076-9861; Smirl, Jonathan/0000-0003-1054-0038	J.P.R. Williams Research Fellowships	This study was funded in part by J.P.R. Williams Research Fellowships (awarded to D.M.B. to support D.H. and C.J.M.).	AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; Ainslie PN, 2009, AM J PHYSIOL-REG I, V296, pR1473, DOI 10.1152/ajpregu.91008.2008; Aries MJH, 2010, STROKE, V41, P2697, DOI 10.1161/STROKEAHA.110.594168; Bailey DM, 2009, J PHYSIOL-LONDON, V587, P73, DOI 10.1113/jphysiol.2008.159855; Bailey DM, 2011, EXP PHYSIOL, V96, P1196, DOI 10.1113/expphysiol.2011.060178; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Colier WNJM, 1997, CLIN PHYSIOL, V17, P83; DELPY DT, 1988, PHYS MED BIOL, V33, P1433, DOI 10.1088/0031-9155/33/12/008; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Fadel PJ, 2003, AM J PHYSIOL-HEART C, V284, pH735, DOI 10.1152/ajpheart.00246.2002; Graham MR, 2011, INT J IMMUNOPATH PH, V24, P119, DOI 10.1177/039463201102400114; Hamner JW, 2004, J PHYSIOL-LONDON, V559, P965, DOI 10.1113/jphysiol.2004.066969; Hasiloglu ZI, 2011, AM J NEURORADIOL, V32, P99, DOI 10.3174/ajnr.A2250; Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298; Houtman S, 1999, CLIN PHYSIOL, V19, P169; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; jordan B. D., 1999, J NEUROIMAGING, V9, P59; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Jordan BD, 1996, PHYSICIAN SPORTSMED, V24, P87, DOI 10.3810/psm.1996.05.1358; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kallenberg K, 2007, J CEREBR BLOOD F MET, V27, P1064, DOI 10.1038/sj.jcbfm.9600404; KONTOS HA, 1978, AM J PHYSIOL, V234, pH371, DOI 10.1152/ajpheart.1978.234.4.H371; Lang EW, 2003, CRIT CARE MED, V31, P267, DOI 10.1097/00003246-200301000-00042; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LASSEN NA, 1959, PHYSIOL REV, V39, P183, DOI 10.1152/physrev.1959.39.2.183; LAUTT WW, 1989, MICROVASC RES, V37, P230, DOI 10.1016/0026-2862(89)90040-X; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Mahony PJ, 2000, STROKE, V31, P476, DOI 10.1161/01.STR.31.2.476; McCrory P, 2004, LANCET NEUROL, V3, P435, DOI 10.1016/S1474-4422(04)00810-5; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Newell DW, 1996, NEUROSURGERY, V39, P35, DOI 10.1097/00006123-199607000-00008; Ogoh S, 2003, J PHYSIOL-LONDON, V550, P317, DOI 10.1113/jphysiol.2003.041517; Provenzano FA, 2010, NUCL MED COMMUN, V31, P952, DOI 10.1097/MNM.0b013e32833e37c4; Rey A., 1942, J EXP PSYCHOL, V28, P286; Rodriguez G, 1998, ITAL J NEUROL SCI, V19, P367, DOI 10.1007/BF02341784; RODRIGUEZ G, 1983, LANCET, V2, P858; Rossen R, 1943, ARCH NEURO PSYCHIATR, V50, P510; Stojsih S, 2010, BRIT J SPORT MED, V44, P725, DOI 10.1136/bjsm.2008.052845; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Taylor JA, 1998, CIRCULATION, V98, P547, DOI 10.1161/01.CIR.98.6.547; Thomas KN, 2009, J APPL PHYSIOL, V107, P506, DOI 10.1152/japplphysiol.91650.2008; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; Trites R. L., 1977, NEUROPSYCHOLOGICAL T; Tzeng YC, 2010, HYPERTENSION, V56, P268, DOI 10.1161/HYPERTENSIONAHA.110.152066; Unterharnscheidt F, 2003, BOXING MED ASPECTS; VANDERZEE P, 1992, ADV EXP MED BIOL, V316, P143; Wechsler D., 1989, WAIS R MANUAL; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; Wieling W, 1997, CLIN AUTONOMIC DISOR, P73; Wieling W, 2007, CLIN SCI, V112, P157, DOI 10.1042/CS20060091; Williams JR, 2008, B WORLD HEALTH ORGAN, V86, P650, DOI 10.2471/BLT.08.050955; Willie CK, 2011, J NEUROSCI METH, V196, P221, DOI 10.1016/j.jneumeth.2011.01.011; Zazryn T, 2007, SPORTS MED, V37, P467, DOI 10.2165/00007256-200737060-00001; Zhang R, 1998, AM J PHYSIOL-HEART C, V274, pH233, DOI 10.1152/ajpheart.1998.274.1.H233; Zhang R, 2002, CIRCULATION, V106, P1814, DOI 10.1161/01.CIR.0000031798.07790.FE	56	80	80	3	27	PORTLAND PRESS LTD	LONDON	CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND	0143-5221	1470-8736		CLIN SCI	Clin. Sci.	FEB	2013	124	3-4					177	189		10.1042/CS20120259			13	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	078FC	WOS:000314083000005	22913765				2022-02-06	
J	Toth, A; Kovacs, N; Perlaki, G; Orsi, G; Aradi, M; Komaromy, H; Ezer, E; Bukovics, P; Farkas, O; Janszky, J; Doczi, T; Buki, A; Schwarcz, A				Toth, Arnold; Kovacs, Noemi; Perlaki, Gabor; Orsi, Gergely; Aradi, Mihaly; Komaromy, Hedvig; Ezer, Erzsebet; Bukovics, Peter; Farkas, Orsolya; Janszky, Jozsef; Doczi, Tamas; Buki, Andras; Schwarcz, Attila			Multi-Modal Magnetic Resonance Imaging in the Acute and Sub-Acute Phase of Mild Traumatic Brain Injury: Can We See the Difference?	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; axonal injury; brain edema; MRI; recovery	HUMAN CEREBRAL-CORTEX; SURFACE-BASED ANALYSIS; DIFFUSE AXONAL INJURY; HEAD-INJURY; GEOMETRICALLY ACCURATE; LONGITUDINAL CHANGES; CORPUS-CALLOSUM; TENSOR; MR; MODERATE	Advanced magnetic resonance imaging (MRI) methods were shown to be able to detect the subtle structural consequences of mild traumatic brain injury (mTBI). The objective of this study was to investigate the acute structural alterations and recovery after mTBI, using diffusion tensor imaging (DTI) to reveal axonal pathology, volumetric analysis, and susceptibility weighted imaging (SWI) to detect microhemorrhage. Fourteen patients with mTBI who had computed tomography with negative results underwent MRI within 3 days and 1 month after injury. High resolution T1-weighted imaging, DTI, and SWI, were performed at both time points. A control group of 14 matched volunteers were also examined following the same imaging protocol and time interval. Tract-Based Spatial Statistics (TBSS) were performed on DTI data to reveal group differences. T1-weighted images were fed into Freesurfer volumetric analysis. TBSS showed fractional anisotropy (FA) to be significantly (corrected p < 0.05) lower, and mean diffusivity (MD) to be higher in the mTBI group in several white matter tracts (FA = 40,737; MD = 39,078 voxels) compared with controls at 72 hours after injury and still 1month later for FA. Longitudinal analysis revealed significant change (i.e., normalization) of FA and MD over 1 month dominantly in the left hemisphere (FA = 3408; MD = 7450 voxels). A significant (p < 0.05) decrease in cortical volumes (mean 1%) and increase in ventricular volumes (mean 3.4%) appeared at 1 month after injury in the mTBI group. SWI did not reveal microhemorrhage in our patients. Our findings present dynamic micro- and macrostructural changes occurring in the acute to sub-acute phase in mTBI, in very mildly injured patients lacking microhemorrhage detectable by SWI. These results underscore the importance of strictly defined image acquisition time points when performing MRI studies on patients with mTBI.	[Toth, Arnold; Perlaki, Gabor; Orsi, Gergely; Janszky, Jozsef] Univ Pecs, Dept Neurol, H-7623 Pecs, Hungary; [Kovacs, Noemi; Ezer, Erzsebet; Bukovics, Peter; Doczi, Tamas; Buki, Andras; Schwarcz, Attila] Univ Pecs, Dept Neurosurg, H-7623 Pecs, Hungary; [Perlaki, Gabor; Orsi, Gergely; Aradi, Mihaly; Komaromy, Hedvig] Pecs Diagnost Ctr, Pecs, Hungary; [Farkas, Orsolya] Univ Pecs, Dept Radiol, H-7623 Pecs, Hungary; [Perlaki, Gabor; Orsi, Gergely; Bukovics, Peter; Janszky, Jozsef; Doczi, Tamas; Buki, Andras; Schwarcz, Attila] MTA PTE Clin Neurosci MR Res Grp, Pecs, Hungary		Toth, A (corresponding author), Univ Pecs, Dept Neurol, Ret U 2, H-7623 Pecs, Hungary.	prsarn@gmail.com	Bukovics, Peter/A-6019-2009; Doczi, Tamas/C-5750-2009		Developing Competitiveness of Universities in the South Transdanubian Region [SROP-4.2.1.B-10/2/KONV-2010- 0002]; Bolyai Scholarship of the Hungarian Academy of Science; OTKA PDOrszagos Tudomanyos Kutatasi Alapprogramok (OTKA) [72240]	This work was supported by Developing Competitiveness of Universities in the South Transdanubian Region (SROP-4.2.1.B-10/2/KONV-2010- 0002), J.J., A.S. was supported by the Bolyai Scholarship of the Hungarian Academy of Science. P.B. was supported by OTKA PD 72240. The Institutional Review Board protocol is U. Pecs, Medical Center IRB Project #00003108.	Akiyama Y, 2009, NEUROL MED-CHIR, V49, P97, DOI 10.2176/nmc.49.97; Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bartsch A.J., 2004, 10 INT C FUNCT MAPP; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Bullmore ET, 1999, IEEE T MED IMAGING, V18, P32, DOI 10.1109/42.750253; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Colbert CA, 2010, RADIOLOGY, V256, P898, DOI 10.1148/radiol.10091842; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; DALE AM, 1993, J COGNITIVE NEUROSCI, V5, P162, DOI 10.1162/jocn.1993.5.2.162; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; Han X, 2006, NEUROIMAGE, V32, P180, DOI 10.1016/j.neuroimage.2006.02.051; Hasiloglu ZI, 2011, AM J NEURORADIOL, V32, P99, DOI 10.3174/ajnr.A2250; Heiervang E, 2006, NEUROIMAGE, V33, P867, DOI 10.1016/j.neuroimage.2006.07.037; Henry-Feugeas MC, 2000, BRAIN INJURY, V14, P597; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Liang LX, 1999, AM J NEURORADIOL, V20, P1527; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Marmarou A, 2007, NEUROSURG FOCUS, P22; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCauley SR, 2010, DEV NEUROPSYCHOL, V35, P318, DOI 10.1080/87565641003696866; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Mittal S, 2009, AM J NEURORADIOL, V30, P232, DOI 10.3174/ajnr.A1461; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Peled S, 2007, IEEE T MED IMAGING, V26, P1448, DOI 10.1109/TMI.2007.906787; Rosenblum WI, 2007, J NEUROPATH EXP NEUR, V66, P771, DOI 10.1097/nen.0b013e3181461965; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032; Segonne F, 2007, IEEE T MED IMAGING, V26, P518, DOI 10.1109/TMI.2006.887364; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; Smith SM, 2002, NEUROIMAGE, V17, P479, DOI 10.1006/nimg.2002.1040; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Steen RG, 2007, AM J NEURORADIOL, V28, P1119, DOI 10.3174/ajnr.A0537; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vos SB, 2012, NEUROIMAGE, V59, P2208, DOI 10.1016/j.neuroimage.2011.09.086; Wang JY, 2011, NEUROLOGY, V77, P818, DOI 10.1212/WNL.0b013e31822c61d7; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	68	80	82	1	27	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2013	30	1					2	10		10.1089/neu.2012.2486			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	061GU	WOS:000312837300002	22905918	Green Accepted			2022-02-06	
J	Sparvero, LJ; Amoscato, AA; Dixon, CE; Long, JB; Kochanek, PM; Pitt, BR; Bayir, H; Kagan, VE				Sparvero, Louis J.; Amoscato, Andrew A.; Dixon, C. Edward; Long, Joseph B.; Kochanek, Patrick M.; Pitt, Bruce R.; Bayir, Huelya; Kagan, Valerian E.			Mapping of phospholipids by MALDI imaging (MALDI-MSI): realities and expectations	CHEMISTRY AND PHYSICS OF LIPIDS			English	Article						Lipidomics; MALDI imaging; Traumatic brain injury; Acute lung injury; Lipid peroxidation; Docosahexaenoic acid	LASER-DESORPTION-IONIZATION; MASS-SPECTROMETRIC CHARACTERIZATION; TRAUMATIC BRAIN-INJURY; OXIDATIVE LIPIDOMICS; ELECTROSPRAY-IONIZATION; STRUCTURAL-CHARACTERIZATION; SHOTGUN LIPIDOMICS; MOUSE MODEL; MATRIX; CARDIOLIPIN	Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) has emerged as a novel powerful MS methodology that has the ability to generate both molecular and spatial information within a tissue section. Application of this technology as a new type of biochemical lipid microscopy may lead to new discoveries of the lipid metabolism and biomarkers associated with area-specific alterations or damage under stress/disease conditions such as traumatic brain injury or acute lung injury, among others. However there are limitations in the range of what it can detect as compared with liquid chromatography-MS (LC-MS) of a lipid extract from a tissue section. The goal of the current work was to critically consider remarkable new opportunities along with the limitations and approaches for further improvements of MALDI-MSI. Based on our experimental data and assessments, improvements of the spectral and spatial resolution, sensitivity and specificity towards low abundance species of lipids are proposed. This is followed by a review of the current literature, including methodologies that other laboratories have used to overcome these challenges. (C) 2012 Elsevier Ireland Ltd. All rights reserved.	[Sparvero, Louis J.; Amoscato, Andrew A.; Bayir, Huelya; Kagan, Valerian E.] Ctr Free Rad & Antioxidant Hlth, Pittsburgh, PA 15213 USA; [Dixon, C. Edward; Kochanek, Patrick M.; Bayir, Huelya] Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Sparvero, Louis J.; Amoscato, Andrew A.; Pitt, Bruce R.; Bayir, Huelya; Kagan, Valerian E.] Dept Environm & Occupat Hlth, Pittsburgh, PA 15213 USA; [Kochanek, Patrick M.; Bayir, Huelya] Dept Crit Care Med, Pittsburgh, PA 15213 USA; [Dixon, C. Edward] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15213 USA; [Long, Joseph B.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Silver Spring, MD 21910 USA		Sparvero, LJ (corresponding author), Univ Pittsburgh, Dept Environm & Occupat Hlth, Ctr Free Rad & Antioxidant Hlth, 100 Technol Dr,Suite 350, Pittsburgh, PA 15219 USA.	ljs39@pitt.edu; amoscatoaa@upmc.edu; dixoec@upmc.edu; joseph.long@us.army.mil; kochanekpm@ccm.upmc.edu; brucep@pitt.edu; bayihx@ccm.upmc.edu; kagan@pitt.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Amoscato, Andrew/0000-0002-1340-9150; Kagan, Valerian E./0000-0002-7245-1885	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U19AI068021, HL70755, HL094488, ES020693, ES021068, NS076511]; Cancer Center Support Grant (CCSG) [P30 CA047904]; NIOSHUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH) [OH008282]; US ArmyUnited States Department of Defense [W81XWH-09-2-0187]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA047904] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL094488, R01HL070755, R37HL065697] Funding Source: NIH RePORTER; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTHUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH) [R01OH008282] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [U19AI068021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01ES020693, R21ES021068] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS076511, P01NS030318, P50NS030318, R01NS061817] Funding Source: NIH RePORTER	This study was supported in part by grants from NIH (U19AI068021, HL70755, HL094488, ES020693, ES021068, and NS076511); Cancer Center Support Grant (CCSG) P30 CA047904; NIOSH (OH008282) and the US Army (W81XWH-09-2-0187).	Aerni HR, 2006, ANAL CHEM, V78, P827, DOI 10.1021/ac051534r; Aizikov K, 2011, REV SCI INSTRUM, V82, DOI 10.1063/1.3594099; Angel PM, 2012, ANAL CHEM, V84, P1557, DOI 10.1021/ac202383m; Axelsen PH, 2010, J LIPID RES, V51, P660, DOI [10.1194/jlr.d001750, 10.1194/jlr.D001750]; Bayir H, 2007, ANN NEUROL, V62, P154, DOI 10.1002/ana.21168; Belayev L, 2009, STROKE, V40, P3121, DOI 10.1161/STROKEAHA.109.555979; Benabdellah F, 2010, ANAL BIOANAL CHEM, V396, P151, DOI 10.1007/s00216-009-3031-2; Bernhard W, 1997, AM J RESP CELL MOL, V17, P41, DOI 10.1165/ajrcmb.17.1.2594; Berry KAZ, 2011, CHEM REV, V111, P6491, DOI 10.1021/cr200280p; Berry KAZ, 2011, J LIPID RES, V52, P1551, DOI 10.1194/jlr.M015750; Boggio KJ, 2011, EXPERT REV PROTEOMIC, V8, P591, DOI [10.1586/EPR.11.53, 10.1586/epr.11.53]; Bouschen W, 2010, RAPID COMMUN MASS SP, V24, P355, DOI 10.1002/rcm.4401; Brunelle A, 2009, ANAL BIOANAL CHEM, V393, P31, DOI 10.1007/s00216-008-2367-3; Burnum KE, 2009, J LIPID RES, V50, P2290, DOI 10.1194/jlr.M900100-JLR200; Carter CL, 2011, J AM SOC MASS SPECTR, V22, P1991, DOI 10.1007/s13361-011-0227-4; Chaurand P, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.O110.004259; Crossman L, 2006, RAPID COMMUN MASS SP, V20, P284, DOI 10.1002/rcm.2259; Debois D, 2009, ANAL CHEM, V81, P2823, DOI 10.1021/ac900045m; Deininger SO, 2011, ANAL BIOANAL CHEM, V401, P167, DOI 10.1007/s00216-011-4929-z; Delvolve AM, 2011, J MASS SPECTROM, V46, P1046, DOI 10.1002/jms.1986; Delvolve AM, 2011, ANAL METHODS-UK, V3, P1729, DOI 10.1039/c1ay05107e; Domingues MRM, 2008, CHEM PHYS LIPIDS, V156, P1, DOI 10.1016/j.chemphyslip.2008.07.003; Eberlin LS, 2011, ANAL CHEM, V83, P8366, DOI 10.1021/ac202016x; Eberlin LS, 2011, BBA-MOL CELL BIOL L, V1811, P946, DOI 10.1016/j.bbalip.2011.05.006; Eibisch M, 2011, RAPID COMMUN MASS SP, V25, P2619, DOI 10.1002/rcm.5161; Fernandez JA, 2011, ANAL BIOANAL CHEM, V401, P29, DOI 10.1007/s00216-011-4696-x; Fernandez-Lima FA, 2011, ANAL CHEM, V83, P8448, DOI 10.1021/ac201481r; Fletcher JS, 2011, MASS SPECTROM REV, V30, P142, DOI 10.1002/mas.20275; Fuchs B, 2011, CHEM PHYS LIPIDS, V164, P782, DOI 10.1016/j.chemphyslip.2011.09.006; Fuchs B, 2010, PROG LIPID RES, V49, P450, DOI 10.1016/j.plipres.2010.07.001; Garrett TJ, 2007, INT J MASS SPECTROM, V260, P166, DOI 10.1016/j.ijms.2006.09.019; Garrett TJ, 2010, METHODS MOL BIOL, V656, P209, DOI 10.1007/978-1-60761-746-4_12; Girotti AW, 1998, J LIPID RES, V39, P1529; Goodwin RJA, 2011, RAPID COMMUN MASS SP, V25, P969, DOI 10.1002/rcm.4939; Goto-Inoue N, 2011, BBA-MOL CELL BIOL L, V1811, P961, DOI 10.1016/j.bbalip.2011.03.004; Greving MP, 2011, ANAL CHEM, V83, P2, DOI 10.1021/ac101565f; Gross J.H., 2011, MASS SPECTROMETRY; Grove KJ, 2011, J AM SOC MASS SPECTR, V22, P192, DOI 10.1007/s13361-010-0013-8; Guichardant M, 2011, CHEM PHYS LIPIDS, V164, P544, DOI 10.1016/j.chemphyslip.2011.05.002; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Han XL, 2007, FRONT BIOSCI, V12, P2601, DOI 10.2741/2258; Han XL, 2012, MASS SPECTROM REV, V31, P134, DOI 10.1002/mas.20342; Hankin JA, 2007, J AM SOC MASS SPECTR, V18, P1646, DOI 10.1016/j.jasms.2007.06.010; Hankin JA, 2011, J AM SOC MASS SPECTR, V22, P1014, DOI 10.1007/s13361-011-0122-z; Hankin JA, 2010, ANAL CHEM, V82, P8476, DOI 10.1021/ac101079v; Hayasaka T, 2008, RAPID COMMUN MASS SP, V22, P3415, DOI 10.1002/rcm.3751; Hayasaka T, 2010, J AM SOC MASS SPECTR, V21, P1446, DOI 10.1016/j.jasms.2010.04.005; Hsu FF, 2005, J AM SOC MASS SPECTR, V16, P1510, DOI 10.1016/j.jasms.2005.04.018; Jackson SN, 2007, J MASS SPECTROM, V42, P1093, DOI 10.1002/jms.1245; Jackson SN, 2007, J AM SOC MASS SPECTR, V18, P17, DOI 10.1016/j.jasms.2006.08.015; Jackson SN, 2008, J AM SOC MASS SPECTR, V19, P1655, DOI 10.1016/j.jasms.2008.07.005; Jackson SN, 2005, ANAL CHEM, V77, P4523, DOI 10.1021/ac050276v; Johanson RA, 2007, ANAL BIOCHEM, V362, P155, DOI 10.1016/j.ab.2006.12.026; JOHNSON KJ, 1981, J CLIN INVEST, V67, P983, DOI 10.1172/JCI110149; Jurchen JC, 2005, J AM SOC MASS SPECTR, V16, P1654, DOI 10.1016/j.jasms.2005.06.006; Kagan VE, 2005, NAT CHEM BIOL, V1, P223, DOI 10.1038/nchembio727; Kaneko Y, 2011, EXP MOL PATHOL, V91, P614, DOI 10.1016/j.yexmp.2011.07.002; Kertesz V, 2010, J MASS SPECTROM, V45, P252, DOI 10.1002/jms.1709; Kiebish MA, 2008, J LIPID RES, V49, P2545, DOI 10.1194/jlr.M800319-JLR200; Kim J, 2011, J LIPID RES, V52, P125, DOI 10.1194/jlr.M010520; Kim Y, 2010, EXP MOL MED, V42, P1, DOI 10.3858/emm.2010.42.1.001; Kiss A, 2011, ANAL BIOANAL CHEM, V399, P2623, DOI 10.1007/s00216-010-4644-1; Koeniger SL, 2011, RAPID COMMUN MASS SP, V25, P503, DOI 10.1002/rcm.4891; Koizumi S, 2010, NEUROSCIENCE, V168, P219, DOI 10.1016/j.neuroscience.2010.03.056; Korytowski W, 2011, J BIOL CHEM, V286, P26334, DOI 10.1074/jbc.M110.188516; Lagarrigue M, 2012, BIOL REPROD, V86, DOI 10.1095/biolreprod.111.094896; Landgraf RR, 2011, RAPID COMMUN MASS SP, V25, P3178, DOI 10.1002/rcm.5189; Landgraf RR, 2009, ANAL CHEM, V81, P8488, DOI 10.1021/ac901387u; Liu W, 2011, FREE RADICAL BIO MED, V50, P166, DOI 10.1016/j.freeradbiomed.2010.10.709; Lobasso S, 2010, LIPIDS, V45, P593, DOI 10.1007/s11745-010-3432-1; Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200; Milasinovic S, 2012, ANAL CHEM, V84, P3945, DOI 10.1021/ac300557a; Minkler PE, 2010, J LIPID RES, V51, P856, DOI 10.1194/jlr.D002857; Murphy RC, 2011, BBA-MOL CELL BIOL L, V1811, P776, DOI 10.1016/j.bbalip.2011.06.019; Murphy RC, 2011, BBA-MOL CELL BIOL L, V1811, P970, DOI 10.1016/j.bbalip.2011.04.012; Murphy RC, 2009, J LIPID RES, V50, pS317, DOI 10.1194/jlr.R800051-JLR200; Niemoller TD, 2010, PROSTAG OTH LIPID M, V91, P85, DOI 10.1016/j.prostaglandins.2009.09.005; Northen TR, 2007, NATURE, V449, P1033, DOI 10.1038/nature06195; Passarelli MK, 2011, BBA-MOL CELL BIOL L, V1811, P976, DOI 10.1016/j.bbalip.2011.05.007; Picariello G, 2009, J AGR FOOD CHEM, V57, P5391, DOI 10.1021/jf9008795; Puolitaival SM, 2008, J AM SOC MASS SPECTR, V19, P882, DOI 10.1016/j.jasms.2008.02.013; Ramrakhiani L, 2011, APPL BIOCHEM BIOTECH, V164, P991, DOI 10.1007/s12010-011-9190-6; Samhan-Arias A.K., 2012, BIOCH BIOPHYSICA ACT; Scherer M, 2010, ANAL CHEM, V82, P8794, DOI 10.1021/ac1021826; Schiller J, 2002, ANAL BIOCHEM, V309, P311, DOI 10.1016/S0003-2697(02)00308-1; Schuhmann K, 2011, ANAL CHEM, V83, P5480, DOI 10.1021/ac102505f; Shevchenko A, 2010, NAT REV MOL CELL BIO, V11, P593, DOI 10.1038/nrm2934; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Sparvero L.J., 2011, SOC TOX 50 ANN M WAS; Sparvero LJ, 2010, J NEUROCHEM, V115, P1322, DOI 10.1111/j.1471-4159.2010.07055.x; Spraggins JM, 2011, J AM SOC MASS SPECTR, V22, P1022, DOI 10.1007/s13361-011-0121-0; Stegemann C, 2011, CIRC-CARDIOVASC GENE, V4, P232, DOI 10.1161/CIRCGENETICS.110.959098; Stubiger G, 2007, ANAL CHEM, V79, P3206, DOI 10.1021/ac062236c; Sun G, 2008, ANAL CHEM, V80, P7576, DOI 10.1021/ac801200w; Sun G, 2007, ANAL CHEM, V79, P6629, DOI 10.1021/ac070843+; Teuber K, 2010, CHEM PHYS LIPIDS, V163, P552, DOI 10.1016/j.chemphyslip.2010.04.005; Thomas A, 2012, ANAL CHEM, V84, P2048, DOI 10.1021/ac2033547; Touboul D, 2011, BIOCHIMIE, V93, P113, DOI 10.1016/j.biochi.2010.05.013; Tyurin VA, 2008, METHOD ENZYMOL, V442, P375, DOI [10.1017/S0076-6879(08)01419-5, 10.1016/S0076-6879(08)01419-5]; Tyurin VA, 2010, METHODS MOL BIOL, V610, P353, DOI 10.1007/978-1-60327-029-8_21; Tyurin VA, 2009, J CHROMATOGR B, V877, P2863, DOI 10.1016/j.jchromb.2009.03.007; Tyurin VA, 2008, J NEUROCHEM, V107, P1614, DOI 10.1111/j.1471-4159.2008.05728.x; Tyurina YY, 2011, ACS NANO, V5, P7342, DOI 10.1021/nn202201j; Tyurina YY, 2010, AM J PHYSIOL-LUNG C, V299, pL73, DOI 10.1152/ajplung.00035.2010; Urban PL, 2011, ANAL CHEM, V83, P3918, DOI 10.1021/ac200481j; Vaishnav RA, 2010, J NEUROTRAUM, V27, P1311, DOI 10.1089/neu.2009.1172; Valko M, 2005, CURR MED CHEM, V12, P1161, DOI 10.2174/0929867053764635; van Hove ERA, 2010, J CHROMATOGR A, V1217, P3946, DOI 10.1016/j.chroma.2010.01.033; Vidova V, 2010, J LIPID RES, V51, P2295, DOI 10.1194/jlr.M005488; Vidova V, 2010, ANAL CHEM, V82, P4994, DOI 10.1021/ac100661h; Wang HYJ, 2007, J AM SOC MASS SPECTR, V18, P567, DOI 10.1016/j.jasms.2006.10.023; Wang HYJ, 2010, RAPID COMMUN MASS SP, V24, P2057, DOI 10.1002/rcm.4620; Wang HYJ, 2008, INT J MASS SPECTROM, V278, P143, DOI 10.1016/j.ijms.2008.04.005; Weber LWD, 2003, CRIT REV TOXICOL, V33, P105, DOI 10.1080/713611034; Whitehead SN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020808; Woods AS, 2010, METHODS MOL BIOL, V656, P99, DOI 10.1007/978-1-60761-746-4_5; Yang JH, 2011, ANAL CHEM, V83, P5728, DOI 10.1021/ac200998a; Yin HY, 2011, CHEM REV, V111, P5944, DOI 10.1021/cr200084z; Zhang JR, 1996, J NEUROCHEM, V66, P355	120	80	82	2	98	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0009-3084	1873-2941		CHEM PHYS LIPIDS	Chem. Phys. Lipids	JUL	2012	165	5					545	562		10.1016/j.chemphyslip.2012.06.001			18	Biochemistry & Molecular Biology; Biophysics	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics	004KX	WOS:000308681700006	22692104	Green Accepted			2022-02-06	
J	Hillary, FG; Slocomb, J; Hills, EC; Fitzpatrick, NM; Medaglia, JD; Wang, J; Good, DC; Wylie, GR				Hillary, F. G.; Slocomb, J.; Hills, E. C.; Fitzpatrick, N. M.; Medaglia, J. D.; Wang, J.; Good, D. C.; Wylie, G. R.			Changes in resting connectivity during recovery from severe traumatic brain injury	INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY			English	Article						Resting connectivity; Plasticity; Reorganization; Longitudinal; TBI	WORKING-MEMORY LOAD; CEREBRAL-BLOOD-FLOW; FUNCTIONAL CONNECTIVITY; DEFAULT-MODE; COGNITIVE-CONTROL; PREFRONTAL CORTEX; BIPOLAR DISORDER; AXONAL INJURY; MOTOR CORTEX; SEVERE TBI	In the present study we investigate neural network changes after moderate and severe traumatic brain injury (TBI) through the use of resting state functional connectivity (RSFC) methods. Using blood oxygen level dependent functional MRI, we examined RSFC at 3 and 6 months following resolution of posttraumatic amnesia. The goal of this study was to examine how regional off-task connectivity changes during a critical period of recovery from significant neurological disruption. This was achieved by examining regional changes in the intrinsic, or "resting", BOLD fMRI signal in separate networks: 1) regions linked to goal-directed (or external-state) networks and 2) default mode (or internal-state) networks. Findings here demonstrate significantly increased resting connectivity internal-state networks in the TBI sample during the first 6 months following recovery. The most consistent finding was increased connectivity in both internal and external state networks to the insula and medial temporal regions during recovery. These findings were dissociable from repeat measurements in a matched healthy control sample. (C) 2011 Elsevier B.V. All rights reserved.	[Hillary, F. G.; Medaglia, J. D.] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA; [Hillary, F. G.; Slocomb, J.; Fitzpatrick, N. M.; Good, D. C.] Hershey Med Ctr, Dept Neurol, Hershey, PA USA; [Wang, J.] Hershey Med Ctr, Dept Radiol, Hershey, PA USA; [Hills, E. C.] Hershey Med Ctr, Dept Phys Med & Rehabil, Hershey, PA USA; [Wylie, G. R.] Kessler Fdn Res Ctr, W Orange, NJ 07052 USA		Hillary, FG (corresponding author), Penn State Univ, Dept Psychol, University Pk, PA 16802 USA.	fhillary@psu.edu; gwylie@kesslerfoundation.org	Hillary, Frank/AAN-8622-2021				Beaupre MG, 2005, J CROSS CULT PSYCHOL, V36, P355, DOI 10.1177/0022022104273656; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Biswal BB, 2010, P NATL ACAD SCI USA, V107, P4734, DOI 10.1073/pnas.0911855107; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Camchong J, 2011, SCHIZOPHRENIA BULL, V37, P640, DOI 10.1093/schbul/sbp131; Carter AR, 2010, ANN NEUROL, V67, P365, DOI 10.1002/ana.21905; Chepenik LG, 2010, PSYCHIAT RES-NEUROIM, V182, P207, DOI 10.1016/j.pscychresns.2010.04.002; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cole MW, 2010, NEUROIMAGE, V49, P3132, DOI 10.1016/j.neuroimage.2009.11.001; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Craig AD, 2009, NAT REV NEUROSCI, V10, P59, DOI 10.1038/nrn2555; Di Martino A, 2008, CEREB CORTEX, V18, P2735, DOI 10.1093/cercor/bhn041; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Fox MD, 2007, NEURON, V56, P171, DOI 10.1016/j.neuron.2007.08.023; Fujiwara E, 2008, NEUROPSYCHOLOGIA, V46, P461, DOI 10.1016/j.neuropsychologia.2007.08.027; Glahn DC, 2002, NEUROIMAGE, V17, P201, DOI 10.1006/nimg.2002.1161; Greicius MD, 2004, J COGNITIVE NEUROSCI, V16, P1484, DOI 10.1162/0898929042568532; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Hamilton J.P., 2010, MOL PSYCHIAT; Hampson M, 2002, HUM BRAIN MAPP, V15, P247, DOI 10.1002/hbm.10022; Hampson M, 2010, MAGN RESON IMAGING, V28, P1051, DOI 10.1016/j.mri.2010.03.021; Hillary FG, 2002, BRAIN INJURY, V16, P729, DOI 10.1080/02699050110119844; Hillary FG, 2008, J INT NEUROPSYCH SOC, V14, P526, DOI 10.1017/S1355617708080788; Hillary FG, 2011, BRAIN, V134, P1555, DOI 10.1093/brain/awr043; Hillary FG, 2010, BRAIN IMAGING BEHAV, V4, P141, DOI 10.1007/s11682-010-9094-z; Kelly AMC, 2008, NEUROIMAGE, V39, P527, DOI 10.1016/j.neuroimage.2007.08.008; Kelly C, 2009, J NEUROSCI, V29, P7364, DOI 10.1523/JNEUROSCI.0810-09.2009; Kim J, 2010, J NEUROTRAUM, V27, P1399, DOI 10.1089/neu.2009.1215; Koch W, 2010, NEUROIMAGE, V51, P280, DOI 10.1016/j.neuroimage.2009.12.008; Kurth F, 2010, BRAIN STRUCT FUNCT, V214, P519, DOI 10.1007/s00429-010-0255-z; Larson MJ, 2007, J INT NEUROPSYCH SOC, V13, P961, DOI 10.1017/S1355617707071305; Larson MJ, 2006, J CLIN EXP NEUROPSYC, V28, P968, DOI 10.1080/13803390600646860; LOWE MJ, 1997, HUMAN BRAIN MAPPING, V5, pS194, DOI DOI 10.1002/(SICI)1097-0193(1997)5:3<LESSTHAN>194::AID-HBM4<GREATERTHAN>3.0.CO;2-Z; Ma N, 2011, PLOS ONE, V26; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Medaglia J.D., 2011, HUM BRAIN MAPP   APR; Mennes M, 2010, NEUROIMAGE, V50, P1690, DOI 10.1016/j.neuroimage.2010.01.002; Menon V, 2010, BRAIN STRUCT FUNCT, V214, P655, DOI 10.1007/s00429-010-0262-0; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Murphy K, 2009, NEUROIMAGE, V44, P893, DOI 10.1016/j.neuroimage.2008.09.036; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Newsome MR, 2007, CORTEX, V43, P95, DOI 10.1016/S0010-9452(08)70448-9; Ongur D, 2010, PSYCHIAT RES-NEUROIM, V183, P59, DOI 10.1016/j.pscychresns.2010.04.008; Pagulayan KF, 2006, ARCH PHYS MED REHAB, V87, P611, DOI 10.1016/j.apmr.2006.01.018; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Price CJ, 2006, J MAGN RESON IMAGING, V23, P816, DOI 10.1002/jmri.20580; Price CJ, 2002, NEUROCASE, V8, P345, DOI 10.1076/neur.8.4.345.16186; Pyka M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007198; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Ralchle ME, 2007, NEUROIMAGE, V37, P1083, DOI 10.1016/j.neuroimage.2007.02.041; Rocca MA, 2010, NEUROLOGY, V74, P1252, DOI 10.1212/WNL.0b013e3181d9ed91; Rotarska-Jagiela A, 2010, SCHIZOPHR RES, V117, P21, DOI 10.1016/j.schres.2010.01.001; Sanchez-Carrion R, 2008, J NEUROTRAUM, V25, P479, DOI 10.1089/neu.2007.0417; Sanchez-Carrion R, 2008, NEUROIMAGE, V43, P421, DOI 10.1016/j.neuroimage.2008.08.003; Scheibel RS, 2009, J NEUROTRAUM, V26, P1447, DOI 10.1089/neu.2008.0736; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Sheline YI, 2010, P NATL ACAD SCI USA, V107, P11020, DOI 10.1073/pnas.1000446107; Skudlarski P, 2010, BIOL PSYCHIAT, V68, P61, DOI 10.1016/j.biopsych.2010.03.035; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Spreng RN, 2010, NEUROIMAGE, V53, P303, DOI 10.1016/j.neuroimage.2010.06.016; Sumowski JF, 2010, BRAIN, V133, P362, DOI 10.1093/brain/awp307; TEASDALE G, 1974, LANCET, V2, P81; Van Dijk KRA, 2010, J NEUROPHYSIOL, V103, P297, DOI 10.1152/jn.00783.2009; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Wager TD, 2003, COGN AFFECT BEHAV NE, V3, P255, DOI 10.3758/CABN.3.4.255; Whyte J., 1998, REHABILITATION MED P; Wu HM, 2004, NEUROSURGERY, V55, P1306, DOI 10.1227/01.NEU.0000143028.08719.42; Xiong J., 1998, P INT SOC MAGN RES M, P201; Xiong JH, 1999, HUM BRAIN MAPP, V8, P151, DOI 10.1002/(SICI)1097-0193(1999)8:2/3<151::AID-HBM13>3.0.CO;2-5; Zhou Bing, 2010, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V35, P17, DOI 10.3969/j.issn.1672-7347.2010.01.003; Zhou J, 2010, BRAIN, V133, P1352, DOI 10.1093/brain/awq075; Zou QH, 2009, NEUROIMAGE, V48, P515, DOI 10.1016/j.neuroimage.2009.07.006	75	80	80	0	20	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-8760	1872-7697		INT J PSYCHOPHYSIOL	Int. J. Psychophysiol.	OCT	2011	82	1			SI		115	123		10.1016/j.ijpsycho.2011.03.011			9	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology; Physiology	859PZ	WOS:000297889600013	21473890				2022-02-06	
J	Signoretti, S; Lazzarino, G; Tavazzi, B; Vagnozzi, R				Signoretti, Stefano; Lazzarino, Giuseppe; Tavazzi, Barbara; Vagnozzi, Roberto			The Pathophysiology of Concussion	PM&R			English	Article							TRAUMATIC BRAIN-INJURY; EXCITATORY AMINO-ACIDS; REPETITIVE HEAD-INJURY; N-ACETYLASPARTATE; TEMPORAL WINDOW; MITOCHONDRIAL DYSFUNCTION; OXIDATIVE STRESS; INTERNATIONAL-CONFERENCE; GLUCOSE-UTILIZATION; LIPID-PEROXIDATION	Concussion is defined as a biomechanically induced brain injury characterized by the absence of gross anatomic lesions. Early and late clinical symptoms, including impairments of memory and attention, headache, and alteration of mental status, are the result of neuronal dysfunction mostly caused by functional rather than structural abnormalities. The mechanical insult initiates a complex cascade of metabolic events leading to perturbation of delicate neuronal homeostatic balances. Starting from neurotoxicity, energetic metabolism disturbance caused by the initial mitochondrial dysfunction seems to be the main biochemical explanation for most postconcussive signs and symptoms. Furthermore, concussed cells enter a peculiar state of vulnerability, and if a second concussion is sustained while they are in this state, they may be irreversibly damaged by the occurrence of swelling. This condition of concussion-induced brain vulnerability is the basic pathophysiology of the second impact syndrome. N-acetylaspartate, a brain-specific compound representative of neuronal metabolic wellness, is proving a valid surrogate marker of the post-traumatic biochemical damage, and its utility in monitoring the recovery of the aforementioned "functional" disturbance as a concussion marker is emerging, because it is easily detectable through proton magnetic resonance spectroscopy. PM R 2011;3:S359-S368	[Vagnozzi, Roberto] Univ Roma Tor Vergata, Dept Neurosci, I-00133 Rome, Italy; [Signoretti, Stefano] San Camillo Hosp, Dept Neurosci Head & Neck Surg, Div Neurosurg, Rome, Italy; [Lazzarino, Giuseppe] Univ Catania, Dept Biol Geol & Environm Sci, Div Biochem & Mol Biol, Catania, Italy; [Tavazzi, Barbara] Univ Cattolica Sacro Cuore, Inst Biochem & Clin Biochem, Rome, Italy		Vagnozzi, R (corresponding author), Univ Roma Tor Vergata, Dept Neurosci, Via Montpellier 1, I-00133 Rome, Italy.	vagnozzi@uniroma2.it	TAVAZZI, BARBARA/AAB-9830-2019; Signoretti, stefano/AAL-5631-2020; lazzarino, giuseppe/K-2277-2015	TAVAZZI, BARBARA/0000-0001-8743-0895; Signoretti, stefano/0000-0002-8086-1622; lazzarino, giuseppe/0000-0002-5917-7279			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barkhoudarian G, CLIN SPORTS MED, V30, P33; Baslow MH, 2006, DRUG NEWS PERSPECT, V19, P145, DOI 10.1358/dnp.2006.19.3.985930; Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Bigler ED, 2003, ARCH CLIN NEUROPSYCH, V18, P595; Bowen Anne Phelan, 2003, J Emerg Nurs, V29, P287, DOI 10.1067/men.2003.90; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; CANTU RC, 2000, NEUROLOGIC ATHLETIC, P132; Cantu RC, 2010, J NEUROTRAUM, V27, P1557, DOI 10.1089/neu.2010.1334; Cobb Sarah, 2004, J Sch Nurs, V20, P262; de Kruijk JR, 2001, BRAIN INJURY, V15, P99, DOI 10.1080/026990501458335; Di Pietro V, 2010, J NEUROTRAUM, V27, P349, DOI 10.1089/neu.2009.1095; DOBERSTEIN CE, 1993, ANN EMERG MED, V22, P993, DOI 10.1016/S0196-0644(05)82740-4; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Fabbri A, 2010, INJURY, V41, P913, DOI 10.1016/j.injury.2010.03.002; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Giza CC, 2001, J ATHL TRAINING, V36, P228; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HARFORD S, 1975, BIOCHEM J, V151, P455, DOI 10.1042/bj1510455; HOVDA DA, 1983, INTRACRANIAL PRESSUR, V8, P469; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; JANERO DR, 1993, AM J PHYSIOL, V264, pC1401; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Kelly J., 1997, MMWR-MORBID MORTAL W, V46, P224; Khodorov B, 1996, FEBS LETT, V393, P135, DOI 10.1016/0014-5793(96)00873-3; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; LAUTIER D, 1994, BBA-MOL CELL RES, V1221, P215, DOI 10.1016/0167-4889(94)90243-7; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; Lloyd DA, 1997, LANCET, V349, P821, DOI 10.1016/S0140-6736(96)09356-7; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; MORGAN WA, 1995, BIOCHEM PHARMACOL, V49, P1179, DOI 10.1016/0006-2952(95)00034-W; Mori T, 2006, ACTA NEUROCHIR SUPPL, V96, P40; Nanavaty UB, 2002, EXP LUNG RES, V28, P591, DOI 10.1080/01902140260426715; Nicholls DG, 1998, BBA-BIOENERGETICS, V1366, P97, DOI 10.1016/S0005-2728(98)00123-6; Nojiri H, 2006, J BIOL CHEM, V281, P33789, DOI 10.1074/jbc.M602118200; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Pacher P, 2002, J AM COLL CARDIOL, V40, P1006, DOI 10.1016/S0735-1097(02)02062-4; PALOZZA P, 1992, FREE RADICAL BIO MED, V13, P127, DOI 10.1016/0891-5849(92)90074-Q; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schinder AF, 1996, J NEUROSCI, V16, P6125; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Signoretti S, 2008, J NEUROSURG, V108, P42, DOI 10.3171/JNS/2008/108/01/0042; Solaroglu I, 2005, J CLIN NEUROSCI, V12, P273, DOI 10.1016/j.jocn.2004.12.002; SUNAMI, 1989, NEUROSURG REV, V12, P400; SWANN IJ, 1981, INJURY, V12, P274, DOI 10.1016/0020-1383(81)90200-X; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TAHERI PA, 1993, ARCH SURG-CHICAGO, V128, P289; Tavazzi B, 1998, FREE RADICAL RES, V28, P25, DOI 10.3109/10715769809097873; Tavazzi B, 2000, ANAL BIOCHEM, V277, P104, DOI 10.1006/abio.1999.4386; Tavazzi B, 2000, FREE RADICAL RES, V33, P1, DOI 10.1080/10715760000300561; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; THIES RL, 1991, ARCH BIOCHEM BIOPHYS, V286, P353, DOI 10.1016/0003-9861(91)90051-J; TRUCKENMILLER ME, 1985, J NEUROCHEM, V45, P1658, DOI 10.1111/j.1471-4159.1985.tb07240.x; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; van der Naalt J, 2001, J CLIN EXP NEUROPSYC, V23, P837, DOI 10.1076/jcen.23.6.837.1018; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Walilko TJ, 2005, BRIT J SPORT MED, V39, P710, DOI 10.1136/bjsm.2004.014126; Wu AG, 2010, NEUROREHAB NEURAL RE, V24, P290, DOI 10.1177/1545968309348318; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yates D, 2007, BMJ-BRIT MED J, V335, P719, DOI 10.1136/bmj.39331.702951.47; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	89	80	80	1	46	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	OCT	2011	3	10		3			S359	S368		10.1016/j.pmrj.2011.07.018			10	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	966YK	WOS:000305873100003	22035678				2022-02-06	
J	Wang, Y; Wei, YL; Oguntayo, S; Wilkins, W; Arun, P; Valiyaveettil, M; Song, J; Long, JB; Nambiar, MP				Wang, Ying; Wei, Yanling; Oguntayo, Samuel; Wilkins, William; Arun, Peethambaran; Valiyaveettil, Manojkumar; Song, Jian; Long, Joseph B.; Nambiar, Madhusoodana P.			Tightly Coupled Repetitive Blast-Induced Traumatic Brain Injury: Development and Characterization in Mice	JOURNAL OF NEUROTRAUMA			English	Article						blast exposure; neurobehavioral; neurobiological effects; neuropathology; traumatic brain injury	ADULT-RAT BRAIN; CENTRAL-NERVOUS-SYSTEM; LASTING IMPULSE NOISE; HEAD-INJURY; INTRACRANIAL-PRESSURE; OXIDATIVE STRESS; INDUCED NEUROTRAUMA; COGNITIVE FUNCTION; EXPLOSIVE BLAST; AXONAL INJURY	A mouse model of repeated blast exposure was developed using a compressed air-driven shock tube, to study the increase in severity of traumatic brain injury (bTBI) after multiple blast exposures. Isoflurane anesthetized C57BL/6J mice were exposed to 13.9, 20.6, and 25 psi single blast overpressure (BOP1) and allowed to recover for 5 days. BOP1 at 20.6 psi showed a mortality rate of 2% and this pressure was used for three repeated blast exposures (BOP3) with 1 and 30 min intervals. Overall mortality rate in BOP3 was increased to 20%. After blast exposure, righting reflex time and body-weight loss were significantly higher in BOP3 animals compared to BOP1 animals. At 4 h, brain edema was significantly increased in BOP3 animals compared to sham controls. Reactive oxygen species in the cortex were increased significantly in BOP1 and BOP3 animals. Neuropathological analysis of the cerebellum and cerebral cortex showed dense silver precipitates in BOP3 animals, indicating the presence of diffuse axonal injury. Fluoro-Jade B staining showed increased intensity in the cortex of BOP3 animals indicating neurodegeneration. Rota Rod behavioral test showed a significant decrease in performance at 10 rpm following BOP1 or BOP3 at 2 h post-blast, which gradually recovered during the 5 days. At 20 rpm, the latency to fall was significantly decreased in both BOP1 and BOP3 animals and it did not recover in the majority of the animals through 5 days of testing. These data suggest that repeated blast exposures lead to increased impairment severity in multiple neurological parameters of TBI in mice.	[Wang, Ying; Wei, Yanling; Oguntayo, Samuel; Wilkins, William; Arun, Peethambaran; Valiyaveettil, Manojkumar; Song, Jian; Long, Joseph B.; Nambiar, Madhusoodana P.] Walter Reed Army Inst Res, Blast Induced Neurotrauma Branch, Ctr Mil Psychiat & Neurosci, Silver Spring, MD 20910 USA		Nambiar, MP (corresponding author), Walter Reed Army Inst Res, Blast Induced Neurotrauma Branch, Ctr Mil Psychiat & Neurosci, Silver Spring, MD 20910 USA.	Madhusoodana.nambiar@us.army.mil	Wilkins, William/B-5476-2011				Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Bauman RA, 1997, TOXICOLOGY, V121, P65, DOI 10.1016/S0300-483X(97)03656-1; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Bell M.K., 2008, MIL MED, V173, pv; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Blennow K, 2011, ACTA NEUROL SCAND, V123, P245, DOI 10.1111/j.1600-0404.2010.01408.x; Cantu RC, 2010, J NEUROTRAUM, V27, P1557, DOI 10.1089/neu.2010.1334; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Chen YC, 2009, J NEUROTRAUM, V26, P861, DOI 10.1089/neu.2008.0645; Connell S, 2011, J MED SYST, V35, P765, DOI 10.1007/s10916-010-9464-5; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; Courtney MW, 2011, NEUROIMAGE, V54, pS55, DOI 10.1016/j.neuroimage.2010.05.025; Courtney MW, 2010, REV SCI INSTRUM, V81, DOI 10.1063/1.3518970; Cripps N P, 1999, J R Nav Med Serv, V85, P13; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Elsayed NM, 2007, TOXICOL SCI, V95, P289, DOI 10.1093/toxsci/kfl138; Fabrizio KS, 2010, NURS CLIN N AM, V45, P569, DOI 10.1016/j.cnur.2010.06.003; Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; French LM, 2010, ANN NY ACAD SCI, V1208, P38, DOI 10.1111/j.1749-6632.2010.05696.x; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; GARTH RJN, 1994, J LARYNGOL OTOL, V108, P925, DOI 10.1017/S0022215100128555; Gorbunov NV, 1997, AM J PHYSIOL-LUNG C, V272, pL320, DOI 10.1152/ajplung.1997.272.2.L320; Guy R J, 1998, J R Nav Med Serv, V84, P79; Hoane MR, 2006, BRAIN RES, V1125, P185, DOI 10.1016/j.brainres.2006.10.019; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Kato K, 2007, J NEUROSURG, V106, P667, DOI 10.3171/jns.2007.106.4.667; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; Khil'ko V A, 1997, Zh Vopr Neirokhir Im N N Burdenko, P35; Kocsis JD, 2009, J REHABIL RES DEV, V46, P667, DOI 10.1682/JRRD.2008.08.0100; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Leibovici D, 1996, J TRAUMA, V41, P1030, DOI 10.1097/00005373-199612000-00015; Leonardi AD, 2011, J NEUROTRAUM, V28, P85, DOI 10.1089/neu.2010.1324; Lew HL, 2009, J REHABIL RES DEV, V46, P819, DOI 10.1682/JRRD.2008.09.0129; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Ling GSF, 2011, CURR OPIN ANESTHESIO, V24, P124, DOI 10.1097/ACO.0b013e32834458da; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Matthews S, 2011, PSYCHIAT RES-NEUROIM, V191, P76, DOI 10.1016/j.pscychresns.2010.09.013; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; MAZURKIEWICZKWILECKI IM, 1980, PHARMACOL BIOCHEM BE, V12, P35, DOI 10.1016/0091-3057(80)90412-8; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mellor S G, 1988, Br J Hosp Med, V39, P536; Mori T, 2006, ACTA NEUROCHIR SUPPL, V96, P40; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Nakagawa A, 2008, ACTA NEUROCHIR SUPPL, V102, P421, DOI 10.1007/978-3-211-85578-2_82; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Owen-Smith M, 1982, Nurs Times, V78, P49; Park E, 2011, J NEUROTRAUM, V28, P343, DOI 10.1089/neu.2009.1050; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; PRATT H, 1985, AUDIOLOGY, V24, P297; Pun Pamela B L, 2011, Front Neurol, V2, P19, DOI 10.3389/fneur.2011.00019; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; RICHMOND DR, 1991, SCAND AUDIOL, P49; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Ritenour AE, 2008, CRIT CARE MED, V36, pS311, DOI 10.1097/CCM.0b013e31817e2a8c; Roberto M, 1989, Ann Otol Rhinol Laryngol Suppl, V140, P23; Saljo A, 2002, J NEUROTRAUM, V19, P985, DOI 10.1089/089771502320317131; Saljo A, 2002, J NEUROTRAUM, V19, P379, DOI 10.1089/089771502753594945; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Saljo A, 2010, J NEUROTRAUM, V27, P383, DOI 10.1089/neu.2009.1053; Saljo Annette, 2001, Pathophysiology, V8, P105, DOI 10.1016/S0928-4680(01)00067-0; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Saunders LL, 2009, BRAIN INJURY, V23, P866, DOI 10.1080/02699050903283213; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Scott SG, 2006, J AM OSTEOPATH ASSOC, V106, P265; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Snell FI, 2010, J PSYCHOSOC NURS MEN, V48, P22, DOI [10.3928/02793695-20100107-01, 10.3928/02793695-20100108-02]; SUNESON A, 1990, J TRAUMA, V30, P295, DOI 10.1097/00005373-199003000-00007; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vink R, 2003, ACT NEUR S, V86, P257; Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9; Xydakis MS, 2008, NEW ENGL J MED, V358, P2177, DOI 10.1056/NEJMc086083; Yang ZH, 1996, J TRAUMA, V40, pS81, DOI 10.1097/00005373-199603001-00019; YLIKOSKI ME, 1994, SCAND J WORK ENV HEA, V20, P93, DOI 10.5271/sjweh.1415	89	80	80	1	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2011	28	10					2171	2183		10.1089/neu.2011.1990			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	839OX	WOS:000296378500017	21770761				2022-02-06	
J	Hutson, CB; Lazo, CR; Mortazavi, F; Giza, CC; Hovda, D; Chesselet, MF				Hutson, Che Brown; Lazo, Carlos R.; Mortazavi, Farzad; Giza, Christopher C.; Hovda, David; Chesselet, Marie-Francoise			Traumatic Brain Injury in Adult Rats Causes Progressive Nigrostriatal Dopaminergic Cell Loss and Enhanced Vulnerability to the Pesticide Paraquat	JOURNAL OF NEUROTRAUMA			English	Article						alpha-synuclein; lateral fluid percussion; microglia; paraquat; Parkinson's disease; traumatic brain injury	LIPOPOLYSACCHARIDE-INDUCED NEUROTOXICITY; INTRACEREBRAL INFLAMMATORY RESPONSE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ENVIRONMENTAL RISK-FACTORS; NIGRA PARS COMPACTA; PARKINSONS-DISEASE; SUBSTANTIA-NIGRA; MICROGLIAL ACTIVATION; AXONAL INJURY; COMPLEX-I	Parkinson's disease (PD) is a neurodegenerative disorder characterized by the loss of nigrostriatal dopaminergic neurons and the accumulation of alpha-synuclein. Both traumatic brain injury (TBI) and pesticides are risk factors for PD, but whether TBI causes nigrostriatal dopaminergic cell loss in experimental models and whether it acts synergistically with pesticides is unknown. We have examined the acute and long-term effects of TBI and exposure to low doses of the pesticide paraquat, separately and in combination, on nigrostriatal dopaminergic neurons in adult male rats. In an acute study, rats received moderate TBI by lateral fluid percussion (LFP) injury, were injected with saline or paraquat (10 mg/kg IP) 3 and 6 days after LFP, were sacrificed 5 days later, and their brains processed for immunohistochemistry. TBI alone increased microglial activation in the substantia nigra, and caused a 15% loss of dopaminergic neurons ipsilaterally. Paraquat increased the TBI effect, causing a 30% bilateral loss of dopaminergic neurons, reduced striatal tyrosine hydroxylase (TH) immunoreactivity more than TBI alone, and induced alpha-synuclein accumulation in the substantia nigra pars compacta. In a long-term study, rats received moderate LFP, were injected with saline or paraquat at 21 and 22 weeks post-injury, and were sacrificed 4 weeks later. At 26 weeks post injury, TBI alone induced a 30% bilateral loss of dopaminergic neurons that was not exacerbated by paraquat. These data suggest that TBI is sufficient to induce a progressive degeneration of nigrostriatal dopaminergic neurons. Furthermore, TBI and pesticide exposure, when occurring within a defined time frame, could combine to increase the PD risk.	[Chesselet, Marie-Francoise] Univ Calif Los Angeles, David Geffen Sch Med, Reed Neurol Res Ctr, Dept Neurobiol, Los Angeles, CA 90095 USA; [Hutson, Che Brown; Lazo, Carlos R.; Mortazavi, Farzad; Chesselet, Marie-Francoise] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; [Giza, Christopher C.; Hovda, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Hovda, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; [Giza, Christopher C.] Univ Calif Los Angeles, Mattel Childrens Hosp, Div Pediat Neurol, Los Angeles, CA 90095 USA		Chesselet, MF (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Reed Neurol Res Ctr, Dept Neurobiol, B114 710 Westwood Plaza, Los Angeles, CA 90095 USA.	mchesselet@mednet.ucla.edu	Mortazavi, Farzad/AAI-8136-2021	Mortazavi, Farzad/0000-0002-1911-5428	UC TSRTP; APA; The Michael J. Fox Foundation for Parkinson's Research; UCLA BIRC;  [1 F31 NS51163-011];  [U54 ES12078];  [P01 ES016732];  [P50 NS38367];  [NS027544];  [NS057420];  [NS02197]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [U54ES012078, P01ES016732] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS051163, R01NS027544, P50NS038367, K02NS057420] Funding Source: NIH RePORTER	This work was supported by a UC TSR&TP student fellowship, and 1 F31 NS51163-011 (C.B.H.); an APA minority fellowship (C.R.L.); grants U54 ES12078, P01 ES016732, and P50 NS38367 (M.F.C.); grant NS027544 (D.H.); grants NS057420 and NS02197 (C.C.G.); The Michael J. Fox Foundation for Parkinson's Research (F.M.); and UCLA BIRC.	Aghaloo T, 2006, AM J PATHOL, V169, P903, DOI 10.2353/ajpath.2006.051210; Albers DS, 1999, NEUROSCIENCE, V89, P209, DOI 10.1016/S0306-4522(98)00328-5; Arimoto T, 2003, NEUROBIOL DIS, V12, P35, DOI 10.1016/S0969-9961(02)00017-7; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Berman SB, 1999, J NEUROCHEM, V73, P1127, DOI 10.1046/j.1471-4159.1999.0731127.x; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; BHARUCHA NE, 1986, NEUROLOGY, V36, P284, DOI 10.1212/WNL.36.2.284; Bonneh-Barkay D, 2005, ANTIOXID REDOX SIGN, V7, P649, DOI 10.1089/ars.2005.7.649; Bonneh-Barkay D, 2005, MOL BRAIN RES, V134, P52, DOI 10.1016/j.molbrainres.2004.11.005; Bower JH, 1999, NEUROLOGY, V52, P1214, DOI 10.1212/WNL.52.6.1214; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Braak H, 2006, MOVEMENT DISORD, V21, P2042, DOI 10.1002/mds.21065; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Bramlett HM, 1999, J NEUROTRAUM, V16, P1035, DOI 10.1089/neu.1999.16.1035; Carvey PM, 2003, FRONT BIOSCI-LANDMRK, V8, pS826, DOI 10.2741/1158; Chan JHM, 2003, NEURORADIOLOGY, V45, P34, DOI 10.1007/s00234-002-0891-y; Chen HL, 2003, ARCH NEUROL-CHICAGO, V60, P1059, DOI 10.1001/archneur.60.8.1059; Church AJ, 2005, J NEUROTRAUM, V22, P277, DOI 10.1089/neu.2005.22.277; Cicchetti F, 2005, NEUROBIOL DIS, V20, P360, DOI 10.1016/j.nbd.2005.03.018; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Cocheme HM, 2008, J BIOL CHEM, V283, P1786, DOI 10.1074/jbc.M708597200; Conti AC, 1998, J NEUROSCI, V18, P5663; Costello S, 2009, AM J EPIDEMIOL, V169, P919, DOI 10.1093/aje/kwp006; Cruz-Muros I, 2007, EXP NEUROL, V204, P147, DOI 10.1016/j.expneurol.2006.10.004; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DOBERSTEIN CE, 1993, ANN EMERG MED, V22, P993, DOI 10.1016/S0196-0644(05)82740-4; Farrer M, 2001, HUM MOL GENET, V10, P1847, DOI 10.1093/hmg/10.17.1847; Fernagut PO, 2007, SYNAPSE, V61, P991, DOI 10.1002/syn.20456; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Gao HM, 2003, FASEB J, V17, P1957, DOI 10.1096/fj.03-0203fje; Gao HM, 2003, J NEUROSCI, V23, P1228, DOI 10.1523/JNEUROSCI.23-04-01228.2003; Gayle DA, 2002, DEV BRAIN RES, V133, P27, DOI 10.1016/S0165-3806(01)00315-7; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Gerhard A, 2006, NEUROBIOL DIS, V21, P404, DOI 10.1016/j.nbd.2005.08.002; GERMAN DC, 1992, ANN NY ACAD SCI, V648, P42, DOI 10.1111/j.1749-6632.1992.tb24523.x; Gerstenfeld LC, 2003, J BONE MINER RES, V18, P1584, DOI 10.1359/jbmr.2003.18.9.1584; Giannoudis PV, 1999, J BONE JOINT SURG BR, V81B, P356, DOI 10.1302/0301-620X.81B2.8988; Giza CC, 2002, J NEUROTRAUM, V19, P387, DOI 10.1089/08977150252932352; Giza CC, 2001, J ATHL TRAINING, V36, P228; GIZA RC, 2000, NEUROLOGIC ATHLETIC, P80; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Goralski KB, 2004, TOXICOL APPL PHARM, V196, P381, DOI 10.1016/j.taap.2003.12.022; GRAHAM DG, 1978, MOL PHARMACOL, V14, P633; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Greenamyre JT, 1999, BIOCHEM SOC SYMP, V66, P85, DOI 10.1042/bss0660085; GRIESBACH GS, 2002, J NEUROTRAUM, V19, P1276; Hartings JA, 2009, J NEUROTRAUM, V26, P1857, DOI [10.1089/neu.2009.0961, 10.1089/neu.2009-0961]; HERTZMAN C, 1990, AM J IND MED, V17, P349, DOI 10.1002/ajim.4700170307; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Hutchison JS, 2001, J NEUROTRAUM, V18, P1333, DOI 10.1089/08977150152725632; Imamura K, 2003, ACTA NEUROPATHOL, V106, P518, DOI 10.1007/s00401-003-0766-2; Ip EY, 2003, J CEREBR BLOOD F MET, V23, P900, DOI 10.1097/01.WCB.0000076702.71231.F2; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENKINS LW, 1986, MECHANISMS SECONDARY, P273; Kalfas I H, 2001, Neurosurg Focus, V10, pE1; Kim JS, 2003, BIOCHEM BIOPH RES CO, V304, P463, DOI 10.1016/S0006-291X(03)00618-1; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kosinski CM, 1998, NEUROSCIENCE, V86, P783, DOI 10.1016/S0306-4522(97)00654-4; Kuter K, 2007, BRAIN RES, V1155, P196, DOI 10.1016/j.brainres.2007.04.018; Langlois JA, 2006, TRAUMATIC BRAIN INJU; LANGSTON JW, 1990, NEUROLOGY, V40, P70; Law MM, 1996, SHOCK, V6, P213, DOI 10.1097/00024382-199609000-00010; Li FQ, 2004, J NEUROIMMUNOL, V148, P24, DOI 10.1016/j.jneuroim.2003.10.054; Li XY, 2009, J CLIN NEUROSCI, V16, P614, DOI 10.1016/j.jocn.2008.08.005; Liang CL, 1996, NEURODEGENERATION, V5, P313, DOI 10.1006/neur.1996.0042; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Liou HH, 1997, NEUROLOGY, V48, P1583, DOI 10.1212/WNL.48.6.1583; Liu B, 2000, J PHARMACOL EXP THER, V295, P125; Liu YX, 2003, J PHARMACOL EXP THER, V305, P212, DOI 10.1124/jpet.102.043166; Lu XH, 2009, J NEUROSCI, V29, P1962, DOI 10.1523/JNEUROSCI.5351-08.2009; MA SY, 1995, NEUROPATH APPL NEURO, V21, P341, DOI 10.1111/j.1365-2990.1995.tb01068.x; Maeda T, 2005, J NEUROTRAUM, V22, P763, DOI 10.1089/neu.2005.22.763; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Mazzeo AT, 2009, EXP NEUROL, V218, P363, DOI 10.1016/j.expneurol.2009.05.026; McCormack AL, 2002, NEUROBIOL DIS, V10, P119, DOI 10.1006/nbdi.2002.0507; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Meurers BH, 2009, NEUROBIOL DIS, V33, P182, DOI 10.1016/j.nbd.2008.10.001; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Miyazaki I, 2009, NEUROCHEM RES, V34, P698, DOI 10.1007/s11064-008-9843-1; MIZUNO Y, 1989, BIOCHEM BIOPH RES CO, V163, P1450, DOI 10.1016/0006-291X(89)91141-8; Mouton PR, 2002, J MICROSC-OXFORD, V206, P54, DOI 10.1046/j.1365-2818.2002.01006.x; NICKLAS WJ, 1985, LIFE SCI, V36, P2503, DOI 10.1016/0024-3205(85)90146-8; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Oorschot DE, 1996, J COMP NEUROL, V366, P580, DOI 10.1002/(SICI)1096-9861(19960318)366:4<580::AID-CNE3>3.0.CO;2-0; Ossowska K, 2005, EUR J NEUROSCI, V22, P1294, DOI 10.1111/j.1460-9568.2005.04301.x; PAKKENBERG B, 1991, J NEUROL NEUROSUR PS, V54, P30, DOI 10.1136/jnnp.54.1.30; PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606; Petrovic V M, 1986, Free Radic Res Commun, V1, P305, DOI 10.3109/10715768609080969; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Prensa L, 2001, J NEUROSCI, V21, P7247, DOI 10.1523/JNEUROSCI.21-18-07247.2001; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; Purisai MG, 2007, NEUROBIOL DIS, V25, P392, DOI 10.1016/j.nbd.2006.10.008; Qin LY, 2007, GLIA, V55, P453, DOI 10.1002/glia.20467; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Roberts RC, 2002, SYNAPSE, V45, P78, DOI 10.1002/syn.10081; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Rub U, 2002, J NEUROL S3, V249, DOI DOI 10.1007/S00415-002-1301-4; Rudow G, 2008, ACTA NEUROPATHOL, V115, P461, DOI 10.1007/s00401-008-0352-8; Rugbjerg K, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2494; Saint-Pierre M, 2006, J NEUROCHEM, V98, P760, DOI 10.1111/j.1471-4159.2006.03923.x; SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0; SEMCHUK KM, 1992, NEUROLOGY, V42, P1328, DOI 10.1212/WNL.42.7.1328; Sherer TB, 2003, EXP NEUROL, V179, P9, DOI 10.1006/exnr.2002.8072; Sherer TB, 2002, J NEUROSCI, V22, P7006; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Soares HD, 1995, J NEUROSCI, V15, P8223; Stokely ME, 2008, J NEUROTRAUM, V25, P52, DOI 10.1089/neu.2007.0397; Stokes AH, 1999, J NEUROSCI RES, V55, P659, DOI 10.1002/(SICI)1097-4547(19990315)55:6<659::AID-JNR1>3.0.CO;2-C; Sulzer D, 2007, TRENDS NEUROSCI, V30, P244, DOI 10.1016/j.tins.2007.03.009; Suzuki T, 2004, J NEUROTRAUM, V21, P842, DOI 10.1089/0897715041526186; Taya K, 2010, J NEUROTRAUM, V27, P229, DOI 10.1089/neu.2009.0933; Taylor CA, 1999, AM J MED GENET, V88, P742, DOI 10.1002/(SICI)1096-8628(19991215)88:6<742::AID-AJMG29>3.0.CO;2-#; Thiruchelvam M, 2003, EUR J NEUROSCI, V18, P589, DOI 10.1046/j.1460-9568.2003.02781.x; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Thompson HJ, 2005, J CEREBR BLOOD F MET, V25, P163, DOI 10.1038/sj.jcbfm.9600008; Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wahner AD, 2007, NEUROLOGY, V69, P1836, DOI 10.1212/01.wnl.0000279519.99344.ad; Wahner AD, 2007, ARCH NEUROL-CHICAGO, V64, P836, DOI 10.1001/archneur.64.6.836; Wang TG, 2004, J PHARMACOL EXP THER, V308, P975, DOI 10.1124/jpet.103.059683; Werneck ALD, 1999, ARQ NEURO-PSIQUIAT, V57, P347, DOI 10.1590/S0004-282X1999000300001; West MJ, 2002, PROG BRAIN RES, V135, P43; Wu XF, 2005, ANTIOXID REDOX SIGN, V7, P654, DOI 10.1089/ars.2005.7.654; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496	138	80	81	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2011	28	9					1783	1801		10.1089/neu.2010.1723			19	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	821AK	WOS:000294947000011	21644813	Green Published			2022-02-06	
J	Ryang, YM; Fahlenkamp, AV; Rossaint, R; Wesp, D; Loetscher, PD; Beyer, C; Coburn, M				Ryang, Yu-Mi; Fahlenkamp, Astrid V.; Rossaint, Rolf; Wesp, Dominik; Loetscher, Philip D.; Beyer, Cordian; Coburn, Mark			Neuroprotective effects of argon in an in vivo model of transient middle cerebral artery occlusion in rats	CRITICAL CARE MEDICINE			English	Article						argon; neuroprotection; middle cerebral artery occlusion	TRAUMATIC BRAIN-INJURY; VITRO MODEL; ISCHEMIA; XENON; REPERFUSION; ANESTHESIA; NEURONS; STROKE; GASES	Objective: The neuroprotective effects of the noble gas xenon are well known. Argon, in contrast to xenon, is abundant, inexpensive, and therefore widely applicable. In this study, we analyzed the possible neuroprotective role of argon in an in vivo rat model of acute focal cerebral ischemia. Design: Controlled laboratory study. Setting: Academic research laboratory. Subjects: Male adult Sprague-Dawley rats. Interventions: Twenty-two rats underwent 2 hrs of transient middle cerebral artery occlusion using the endoluminal thread model. One hr after transient middle cerebral artery occlusion induction, spontaneously breathing rats received either 50 vol % argon/50 vol % O-2 (argon group, n = 11) or 50 vol % N-2/50 vol % O-2 (control group, n = 11) for 1 hr through a face mask. Twenty-four hrs after reperfusion, rats were neurologically and behaviorally tested and euthanized. Rat brains were stained with 2,3,5-triphenyltetrazolium chloride and infarct volumes determined by planimetry. Measurements and Main Results: After 2 hrs of transient middle cerebral artery occlusion in the rat, we found in the argon group a significant reduction in the overall (p = .004) and after subdivision in the cortical (p = .007) and the basal ganglia (p = .02) infarct volumes. Argon treatment resulted in a significant improvement of the composite adverse outcome (p = .034). However, there was no advantage in acute survival 24 hrs after transient middle cerebral artery occlusion (p = .361). Conclusion: We were able to demonstrate argon's neuroprotective effects in an in vivo experimental rat model of acute focal cerebral ischemia. Animals breathing spontaneously 50 vol % argon 1 hr after induction of transient middle cerebral artery occlusion for 1 hr by face mask showed significantly reduced infarct volumes and composite adverse outcomes. (Crit Care Med 2011; 39: 1448-1453)	[Ryang, Yu-Mi] Hosp Tech Univ Munich, Dept Neurosurg, Klinikum Rechts Isar, Munich, Germany; [Ryang, Yu-Mi; Wesp, Dominik] Univ Hosp RWTH Aachen, Dept Neurosurg, Aachen, Germany; [Fahlenkamp, Astrid V.; Rossaint, Rolf; Loetscher, Philip D.; Coburn, Mark] Univ Hosp RWTH Aachen, Dept Anesthesiol, Aachen, Germany; [Fahlenkamp, Astrid V.; Beyer, Cordian] Rhein Westfal TH Aachen, Fac Med, Inst Neuroanat, Aachen, Germany		Ryang, YM (corresponding author), Hosp Tech Univ Munich, Dept Neurosurg, Klinikum Rechts Isar, Munich, Germany.	mcoburn@ukaachen.de	Ryang, Yu-Mi/Q-8373-2016	Ryang, Yu-Mi/0000-0002-9045-5038; Coburn, Mark/0000-0002-7930-0270	Medical Faculty of the RWTH Aachen, Aachen	This research was conducted with funding by the Rotationsprogramm of the Medical Faculty of the RWTH Aachen, Aachen.	Abraini JH, 2003, ANESTH ANALG, V96, P746, DOI 10.1213/01.ANE.0000050282.14291.38; ASCHER P, 1987, TRENDS NEUROL SCI, V10, P8; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Belayev L, 2003, STROKE, V34, P758, DOI 10.1161/01.STR.0000056169.45365.15; Bickler PE, 2003, ANESTH ANALG, V97, P564, DOI 10.1213/01.ANE.0000068880.82739.7B; Chopp M, 2008, ACTA NEUROCHIR SUPPL, V105, P79; Coburn M, 2008, CRIT CARE MED, V36, P588, DOI 10.1097/01.CCM.0B013E3181611F8A6; David HN, 2008, FASEB J, V22, P1275, DOI 10.1096/fj.07-9420com; Dickinson R, 2010, CRIT CARE, V14, DOI 10.1186/cc9051; DIEMER NH, 1993, PROG BRAIN RES, V96, P105; Franks NP, 2008, NAT REV NEUROSCI, V9, P370, DOI 10.1038/nrn2372; Galeffi F, 2000, J NEUROCHEM, V75, P1242, DOI 10.1046/j.1471-4159.2000.0751242.x; Jawad N, 2009, NEUROSCI LETT, V460, P232, DOI 10.1016/j.neulet.2009.05.069; Koizumi J, 1986, JPN J STROKE, V8, P1, DOI DOI 10.3995/JSTROKE.8.1; Kramer M, 2010, J NEUROSCI METH, V187, P84, DOI 10.1016/j.jneumeth.2009.12.020; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Loetscher PD, 2009, CRIT CARE, V13, DOI 10.1186/cc8214; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Ma D, 2002, BRIT J ANAESTH, V89, P739, DOI 10.1093/bja/aef258; Moustafa RR, 2008, BRIT J PHARMACOL, V153, pS44, DOI 10.1038/sj.bjp.0707530; PAVLOV BN, 1997, HIGH PRESSURE BIOL M, P133; Preckel B, 2000, ANESTH ANALG, V91, P1327, DOI 10.1097/00000539-200012000-00003; Sanders RD, 2010, CRIT CARE, V14, DOI 10.1186/cc8847; Schwartz-Bloom RD, 2000, NEUROSCIENCE, V98, P471, DOI 10.1016/S0306-4522(00)00144-5; Sosin DM, 1996, BRAIN INJURY, V10, P47; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Xu J, 2008, NEUROPHARMACOLOGY, V54, P1029, DOI 10.1016/j.neuropharm.2008.01.014; Zausinger S, 2000, BRAIN RES, V863, P94, DOI 10.1016/S0006-8993(00)02100-4; Zhang F, 2007, NEUROSCIENCE, V150, P938, DOI 10.1016/j.neuroscience.2007.09.070	30	80	82	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUN	2011	39	6					1448	1453		10.1097/CCM.0b013e31821209be			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	765NM	WOS:000290715000031	21336110				2022-02-06	
J	Belanger, HG; Proctor-Weber, Z; Kretzmer, T; Kim, M; French, LM; Vanderploeg, RD				Belanger, Heather G.; Proctor-Weber, Zoe; Kretzmer, Tracy; Kim, Michelle; French, Louis M.; Vanderploeg, Rodney D.			Symptom Complaints Following Reports of Blast Versus Non-Blast Mild TBI: Does Mechanism of Injury Matter?	CLINICAL NEUROPSYCHOLOGIST			English	Article						TBI; Mild TBI; Post-traumatic stress disorder; Post-concussion syndrome; Blast	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSIVE SYMPTOMS; NEUROPSYCHOLOGICAL PERFORMANCE; COGNITIVE DEFICITS; WAR VETERANS; HEAD-INJURY; IRAQ; AFGHANISTAN; CONCUSSION	Patients with a reported history of mild traumatic brain injury (mild TBI) due to blast (n = 298) or non-blast (n = 92) mechanisms were asked to complete the Neurobehavioral Symptom Inventory (NSI) and the Post-traumatic Stress Disorder Checklist (PCL). Mechanism of injury did not account for a significant amount of variance in post-concussion symptom reporting overall, nor did severity of mild TBI (i.e., brief loss of consciousness versus only an alteration of consciousness). Symptom reporting was greater in those injured more than 1 month ago compared to those injured less than 1 month ago and in those reporting higher levels versus lower levels of PTSD symptoms. When examining specific symptoms, the only symptom that significantly varied between groups was hearing difficulty (with the blast-injured group reporting more severe difficulty with hearing). Findings suggest that greater symptom reporting is most strongly related to emotional distress.	[Belanger, Heather G.; Kretzmer, Tracy; Kim, Michelle; Vanderploeg, Rodney D.] James A Haley VA, Dept Mental Hlth & Behav Sci, Tampa, FL USA; [Belanger, Heather G.; Vanderploeg, Rodney D.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychiat, Tampa, FL USA; [Proctor-Weber, Zoe] Bay Pines VA Healthcare Syst, Dept Mental Hlth & Behav Sci, Bay Pines, FL USA; [Belanger, Heather G.; French, Louis M.; Vanderploeg, Rodney D.] Def & Vet Brain Injury Ctr, Washington, DC USA; [French, Louis M.] Walter Reed Army Med Ctr, Dept Orthoped & Rehabil, Washington, DC 20307 USA; [French, Louis M.] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA		Belanger, HG (corresponding author), James A Haley Vet Hosp, Psychol Serv 116B, Tampa, FL 33612 USA.	Heather.Belanger@va.gov	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604	Department of Veterans AffairsUS Department of Veterans Affairs; Veterans Health Administration (VHA)US Department of Veterans Affairs; Defense and Veterans Brain Injury Center (DVBIC)US Department of Veterans Affairs; James A. Haley Veterans HospitalUS Department of Veterans Affairs	The research reported here was supported by the Department of Veterans Affairs, Veterans Health Administration (VHA), and the Defense and Veterans Brain Injury Center (DVBIC). Further support was provided by the James A. Haley Veterans Hospital. The views expressed herein are those of the authors and do not necessarily reflect the views or the official policy of the Department of Army, Department of Defense, Department of Veterans Affairs, or U.S. Government.	Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; Binder LM, 1999, ARCH CLIN NEUROPSYCH, V14, P531, DOI 10.1016/S0887-6177(98)00047-X; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; French L., 2008, J SPECIAL OPERATIONS, V8, P68; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lindem K, 2003, J PSYCHOPATHOL BEHAV, V25, P121, DOI 10.1023/A:1023347016334; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Mora AG, 2009, J TRAUMA, V66, pS178, DOI 10.1097/TA.0b013e31819ce2d6; Nageris Ben I., 2008, Journal of Basic and Clinical Physiology and Pharmacology, V19, P185; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Schell T.L., 2008, SURVEY INDIVIDUALS P; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Spencer RJ, 2010, J REHABIL RES DEV, V47, P521, DOI 10.1682/JRRD.2009.11.0181; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Van Dyke SA, 2010, ARCH CLIN NEUROPSYCH, V25, P634, DOI 10.1093/arclin/acq063; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Weathers F.W., 1993, 9 ANN C ISTSS; Weathers FW, 1991, PCL C DSM 4; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Xydakis MS, 2007, NEW ENGL J MED, V357, P830, DOI 10.1056/NEJMc076071	45	80	80	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2011	25	5					702	715		10.1080/13854046.2011.566892			14	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	882JE	WOS:000299559000002	21512958				2022-02-06	
J	Mills, JD; Bailes, JE; Sedney, CL; Hutchins, H; Sears, B				Mills, James D.; Bailes, Julian E.; Sedney, Cara L.; Hutchins, Heather; Sears, Barry			Omega-3 fatty acid supplementation and reduction of traumatic axonal injury in a rodent head injury model Laboratory investigation	JOURNAL OF NEUROSURGERY			English	Article						omega-3 fatty acids; traumatic brain injury; amyloid precursor protein; dietary supplementation	POLYUNSATURATED FATTY-ACIDS; NEURONAL CELL-DEATH; SPINAL-CORD-INJURY; BRAIN-INJURY; OXIDATIVE STRESS; RAT HIPPOCAMPUS; APOPTOSIS; INFLAMMATION; DYSFUNCTION; FAILURE	Object. Traumatic brain injury remains the most common cause of death in persons under 45 years of age in the Western world. Recent evidence from animal studies suggests that supplementation with omega-3 fatty acid (O3FA) (particularly eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) improves functional outcomes following focal neural injury. The purpose of this study is to determine the benefits of O3FA supplementation following diffuse axonal injury in rats. Methods. Forty adult male Sprague-Dawley rats were used. Three groups of 10 rats were subjected to an impact acceleration injury and the remaining group underwent a sham-injury procedure (surgery, but no impact injury). Two of the groups subjected to the injury were supplemented with 10 or 40 mg/kg/day of O3FA; the third injured group served as an unsupplemented control group. The sham-injured rats likewise received no O3FA supplementation. Serum fatty acid levels were determined from the isolated plasma phospholipids prior to the injury and at the end of the 30 days of supplementation. After the animals had been killed, immunohistochemical analysis of brainstem white matter tracts was performed to assess the presence of beta-amyloid precursor protein (APP), a marker of axonal injury. Immunohistochemical analyses of axonal injury mechanisms including analysis for caspase-3, a marker of apoptosis; RMO-14, a marker of neurofilament compaction; and cytochrome c, a marker of mitochondrial injury- were performed. Results. Dietary supplementation with a fish oil concentrate rich in EPA and DHA for 30 days resulted in significant increases in O3FA serum levels: 11.6% +/- 4.9% over initial levels in the 10 mg/kg/day group and 30.7% +/- 3.6% in the 40 mg/kg/day group. Immunohistochemical analysis revealed significantly (p<0.05) decreased numbers of APP-positive axons in animals receiving O3FA supplementation: 7.7 +/- 14.4 axons per mm(2) in the 10 mg/kg/day group and 6.2 +/- 11.4 axons per mm2 in the 40 mg/kg/day group, versus 182.2 +/- 44.6 axons per mm2 in unsupplemented animals. Sham-injured animals had 4.1 +/- 1.3 APP-positive axons per mm(2). Similarly, immunohistochemical analysis of caspase-3 expression demonstrated significant (p<0.05) reduction in animals receiving O3FA supplementation, 18.5 +/- 28.3 axons per mm2 in the 10 mg/kg/day group and 13.8 +/- 18.9 axons per mm(2) in the 40 mg/kg/day group, versus 129.3 +/- 49.1 axons per mm(2) in unsupplemented animals. Conclusions. Dietary supplementation with a fish oil concentrate rich in the O3FAs EPA and DHA increases serum levels of these same fatty acids in a dose-response effect. Omega-3 fatty acid supplementation significantly reduces the number of APP-positive axons at 30 days postinjury to levels similar to those in uninjured animals. Omega-3 fatty acids are safe, affordable, and readily available worldwide to potentially reduce the burden of traumatic brain injury. (DOI: 10.3171/2010.5.JNS08914)	[Mills, James D.] W Virginia Univ, Hlth Sci Ctr, Dept Neurosurg, Sch Med, Morgantown, WV 26506 USA; [Hutchins, Heather; Sears, Barry] Inflammat Res Fdn, Marblehead, MA USA		Mills, JD (corresponding author), W Virginia Univ, Hlth Sci Ctr, Dept Neurosurg, Sch Med, POB 9183, Morgantown, WV 26506 USA.	jmills@hsc.wvu.edu		Sedney, Cara/0000-0003-1290-7083			Bazan NG, 2005, BRAIN PATHOL, V15, P159; Blondeau N, 2002, NEUROSCIENCE, V109, P231, DOI 10.1016/S0306-4522(01)00473-0; Buki A, 2000, J NEUROSCI, V20, P2825; Calder PC, 2003, BRAZ J MED BIOL RES, V36, P433, DOI 10.1590/S0100-879X2003000400004; Calderon F, 2004, J NEUROCHEM, V90, P979, DOI 10.1111/j.1471-4159.2004.02520.x; Cao DH, 2004, PHARMACOL BIOCHEM BE, V79, P651, DOI 10.1016/j.pbb.2004.09.016; Danthi SJ, 2005, BIOCHEM BIOPH RES CO, V327, P485, DOI 10.1016/j.bbrc.2004.12.033; Doppenberg EMR, 1997, ANN NY ACAD SCI, V825, P305, DOI 10.1111/j.1749-6632.1997.tb48441.x; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Emsley R, 2003, CNS DRUGS, V17, P1081, DOI 10.2165/00023210-200317150-00003; Hogyes E, 2003, NEUROSCIENCE, V119, P999, DOI 10.1016/S0306-4522(03)00198-2; HOLUB BJ, 1987, METHOD ENZYMOL, V141, P234; Jump DB, 2002, CURR OPIN LIPIDOL, V13, P155, DOI 10.1097/00041433-200204000-00007; Lang-Lazdunski L, 2003, J VASC SURG, V38, P564, DOI 10.1016/S0741-5214(03)00473-7; Lauritzen I, 2000, EMBO J, V19, P1784, DOI 10.1093/emboj/19.8.1784; Lonergan PE, 2004, J NEUROCHEM, V91, P20, DOI 10.1111/j.1471-4159.2004.02689.x; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mills JD, 2003, J BIOMED OPT, V8, P347, DOI 10.1117/1.1584443; Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101; MURPHY EJ, 1994, MOL CHEM NEUROPATHOL, V23, P13, DOI 10.1007/BF02858504; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; NEEDLEMAN P, 1979, P NATL ACAD SCI USA, V76, P944, DOI 10.1073/pnas.76.2.944; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Roberts L, 2008, J AM COLL SURGEONS, V207, P276, DOI 10.1016/j.jamcollsurg.2008.02.015; Sarsimaz M, 2003, NEUROSCI RES COMMUN, V33, P114, DOI 10.1002/nrc.10087; Schlanger S, 2002, EPILEPSIA, V43, P103, DOI 10.1046/j.1528-1157.2002.13601.x; Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877; Songur A, 2004, PROG NEURO-PSYCHOPH, V28, P693, DOI 10.1016/j.pnpbp.2004.05.006; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang XY, 2003, J AM SOC NEPHROL, V14, p729A; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Xu GY, 2004, EXP NEUROL, V187, P329, DOI 10.1016/j.expneurol.2004.01.029	38	80	85	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	2011	114	1					77	84		10.3171/2010.5.JNS08914			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	699NG	WOS:000285669500019	20635852				2022-02-06	
J	Zatzick, DF; Rivara, FP; Jurkovich, GJ; Hoge, CW; Wang, J; Fan, MY; Russo, J; Trusz, SG; Nathens, A; Mackenzie, EJ				Zatzick, Douglas F.; Rivara, Frederick P.; Jurkovich, Gregory J.; Hoge, Charles W.; Wang, Jin; Fan, Ming-Yu; Russo, Joan; Trusz, Sarah Geiss; Nathens, Avery; Mackenzie, Ellen J.			Multisite Investigation of Traumatic Brain Injuries, Posttraumatic Stress Disorder, and Self-reported Health and Cognitive Impairments	ARCHIVES OF GENERAL PSYCHIATRY			English	Article							QUALITY-OF-LIFE; FUNCTIONAL OUTCOMES; NEUROPSYCHOLOGICAL OUTCOMES; PSYCHOMETRIC PROPERTIES; PTSD CHECKLIST; SYMPTOMS; RISK; CHILDREN; IRAQ; DEPRESSION	Context: Few large-scale, multisite investigations have assessed the development of posttraumatic stress disorder (PTSD) symptoms and health outcomes across the spectrum of patients with mild, moderate, and severe traumatic brain injury (TBI). Objectives: To understand the risk of developing PTSD symptoms and to assess the impact of PTSD on the development of health and cognitive impairments across the full spectrum of TBI severity. Design: Multisite US prospective cohort study. Setting: Eighteen level I trauma centers and 51 non-trauma center hospitals. Patients: A total of 3047 (weighted n=10 372) survivors of multiple traumatic injuries between the ages of 18 and 84 years. Main Outcome Measures: Severity of TBI was categorized from chart-abstracted International Classification of Diseases, Ninth Revision, Clinical Modification codes. Symptoms consistent with a DSM-IV diagnosis of PTSD were assessed with the PTSD Checklist 12 months after injury. Self-reported outcome assessment included the 8 Medical Outcomes Study 36-Item Short Form Health Survey health status domains and a 4-item assessment of cognitive function at telephone interviews 3 and 12 months after injury. Results: At the time of injury hospitalization, 20.5% of patients had severe TBI, 11.7% moderate TBI, 12.9% mild TBI, and 54.9% no TBI. Patients with severe (relative risk, 0.72; 95% confidence interval, 0.58-0.90) and moderate (0.63; 0.44-0.89) TBI, but not mild TBI (0.83; 0.61-1.13), demonstrated a significantly diminished risk of PTSD symptoms relative to patients without TBI. Across TBI categories, in adjusted analyses patients with PTSD demonstrated an increased risk of health status and cognitive impairments when compared with patients without PTSD. Conclusions: More severe TBI was associated with a diminished risk of PTSD. Regardless of TBI severity, injured patients with PTSD demonstrated the greatest impairments in self-reported health and cognitive function. Treatment programs for patients with the full spectrum of TBI severity should integrate intervention approaches targeting PTSD.	[Zatzick, Douglas F.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Hoge, Charles W.] Walter Reed Army Inst Res, Silver Spring, MD USA; [Nathens, Avery] Univ Toronto, Dept Surg, Toronto, ON, Canada; [Mackenzie, Ellen J.] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Injury Res & Policy, Baltimore, MD USA		Zatzick, DF (corresponding author), Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Harborview Injury Prevent & Res Ctr, Campus Box 359911,325 9th Ave, Seattle, WA 98104 USA.	dzatzick@u.washington.edu			National Center for Injury Prevention and ControlUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CCR316840]; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01/AG20361]; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01/MH073613, K24/MH086814]; Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K24MH086814, R01MH073613] Funding Source: NIH RePORTER	This work was funded by grant R49/CCR316840 from the National Center for Injury Prevention and Control and the Centers for Disease Control and Prevention, grant R01/AG20361 from the National Institute on Aging, and grants R01/MH073613 and K24/MH086814 from the National Institute of Mental Health.	[Anonymous], 1990, ABBR INJ SCAL 1990 R; *ASS ADV AUT MED C, 2008, ABBR INJ SCAL 2005 U; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Bryant RA, 2001, J NERV MENT DIS, V189, P109, DOI 10.1097/00005053-200102000-00006; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Bryant RA, 2009, J INT NEUROPSYCH SOC, V15, P862, DOI 10.1017/S1355617709990671; BUTLER JA, 2001, CENTRAL NERVOUS SYST; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Civil ID, 1985, ABBREVIATED INJURY S; Corrigan JD, 2008, JAMA-J AM MED ASSOC, V300, P720, DOI 10.1001/jama.300.6.720; Engel C. C., 1999, STRATEGIES PROTECT H, P173; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Friedman MJ, 2004, NEW ENGL J MED, V351, P75, DOI 10.1056/NEJMe048129; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Glaesser J, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-5; Glynn SM, 2007, J TRAUMA, V62, P410, DOI 10.1097/01.ta.0000231556.05899.b0; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; Harvey AG, 2003, J INT NEUROPSYCH SOC, V9, P663, DOI 10.1017/S1355617703940069; Hatcher MB, 2009, BRIT J HEALTH PSYCH, V14, P541, DOI 10.1348/135910708X373445; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; Hiott DW, 2002, NEUROREHABILITATION, V17, P345; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Holbrook TL, 2005, J TRAUMA, V59, P1126, DOI 10.1097/01.ta.0000196433.61423.f2; Holbrook TL, 1999, J TRAUMA, V46, P765, DOI 10.1097/00005373-199905000-00003; Holbrook TL, 2007, J TRAUMA, V62, P577, DOI 10.1097/TA.0b013e318031aa97; Joseph S, 1999, J TRAUMA STRESS, V12, P437, DOI 10.1023/A:1024762919372; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Koren D, 2006, CNS SPECTRUMS, V11, P616, DOI 10.1017/S1092852900013675; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Love B, 1987, J Burn Care Rehabil, V8, P280, DOI 10.1097/00004630-198707000-00008; Lude P, 2005, SPINAL CORD, V43, P102, DOI 10.1038/sj.sc.3101688; MacGregor AJ, 2009, INJURY, V40, P1004, DOI 10.1016/j.injury.2009.04.006; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; MacKenzie EJ, 2007, J TRAUMA, V63, pS54, DOI 10.1097/TA.0b013e31815acb09; Magaziner J, 1997, AM J EPIDEMIOL, V146, P418, DOI 10.1093/oxfordjournals.aje.a009295; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; McNett Molly, 2007, J Neurosci Nurs, V39, P68; Meredith JW, 2002, J TRAUMA, V53, P621, DOI 10.1097/00005373-200210000-00001; Michaels AJ, 1999, J TRAUMA, V47, P460, DOI 10.1097/00005373-199909000-00005; Mora AG, 2009, J TRAUMA, V66, pS178, DOI 10.1097/TA.0b013e31819ce2d6; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; National Institute of Neurological Disorders and Stroke, 2002, NIH PUBL, V02-158; O'Donnell ML, 2008, J CONSULT CLIN PSYCH, V76, P923, DOI 10.1037/a0012918; O'Donnell ML, 2005, J TRAUMA, V59, P1328, DOI 10.1097/01.ta.0000197621.94561.4e; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; *PC CAR AM RET WOU, 2007, SERV SUPP SIMPL REP; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Ramchand R, 2008, J CONSULT CLIN PSYCH, V76, P668, DOI 10.1037/0022-006X.76.4.668; Rothman KJ, 1998, MODERN EPIDEMIOLOGY; Rubin D.B., 1987, MULTIPLE IMPUTATION; Ruggiero KJ, 2006, J TRAUMA STRESS, V19, P699, DOI 10.1002/jts.20141; Ruggiero KJ, 2003, J TRAUMA STRESS, V16, P495, DOI 10.1023/A:1025714729117; Rusch MD, 2000, PLAST RECONSTR SURG, V106, P1451, DOI 10.1097/00006534-200012000-00001; Saxe GN, 2005, AM J PSYCHIAT, V162, P1299; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schnurr PP, 2007, JAMA-J AM MED ASSOC, V297, P820, DOI 10.1001/jama.297.8.820; Schnurr PP, 2009, CLIN PSYCHOL REV, V29, P727, DOI 10.1016/j.cpr.2009.08.006; Schnyder U, 2001, AM J PSYCHIAT, V158, P594, DOI 10.1176/appi.ajp.158.4.594; Shalev AY, 1996, AM J PSYCHIAT, V153, P219; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Sneeuw KCA, 1997, MED CARE, V35, P490, DOI 10.1097/00005650-199705000-00006; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Stoddard FJ, 2006, J AM ACAD CHILD PSY, V45, P87, DOI 10.1097/01.chi.0000184934.71917.3a; Stoddard FJ, 2001, J AM ACAD CHILD PSY, V40, P1128, DOI 10.1097/00004583-200110000-00007; TABER KH, 2009, J NEUROPSYCH CLIN N, V21, pR4; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ., 1995, GUIDELINES SURVEILLA; Ursano RJ., 2004, PRACTICE GUIDELINE T; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vasa RA, 2004, BIOL PSYCHIAT, V55, P208, DOI 10.1016/S0006-3223(03)00708-X; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Wade AL, 2007, J TRAUMA, V63, P836, DOI 10.1097/01.ta.0000251453.54663.66; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Ware J.E., 1993, SF 36 HLTH SURVEY MA; Weathers FW, 1991, PTSD CHECKLIST CIVIL; Williams WH, 2002, J TRAUMA STRESS, V15, P397, DOI 10.1023/A:1020185325026; Winston FK, 2003, JAMA-J AM MED ASSOC, V290, P643, DOI 10.1001/jama.290.5.643; Zatzick D, 2004, ARCH GEN PSYCHIAT, V61, P498, DOI 10.1001/archpsyc.61.5.498; Zatzick DF, 1997, AM J PSYCHIAT, V154, P1690, DOI 10.1176/ajp.154.12.1690; Zatzick DF, 2002, ARCH SURG-CHICAGO, V137, P200, DOI 10.1001/archsurg.137.2.200; Zatzick D, 2008, ANN SURG, V248, P429, DOI 10.1097/SLA.0b013e318185a6b8; Zatzick DF, 2008, ARCH PEDIAT ADOL MED, V162, P642, DOI 10.1001/archpedi.162.7.642; Zatzick DF, 2007, PSYCHOL MED, V37, P1469, DOI 10.1017/S0033291707000943; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; ZHENG WB, 2006, C P IEEE ENG MED BIO, V1, P1052; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	102	80	80	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0003-990X	1538-3636		ARCH GEN PSYCHIAT	Arch. Gen. Psychiatry	DEC	2010	67	12					1291	1300		10.1001/archgenpsychiatry.2010.158			10	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	690NO	WOS:000285011700013	21135329	Green Accepted, Bronze			2022-02-06	
J	Manley, GT; Diaz-Arrastia, R; Brophy, M; Engel, D; Goodman, C; Gwinn, K; Veenstra, TD; Ling, G; Ottens, AK; Tortella, F; Hayes, RL				Manley, Geoffrey T.; Diaz-Arrastia, Ramon; Brophy, Mary; Engel, Doortje; Goodman, Clay; Gwinn, Katrina; Veenstra, Timothy D.; Ling, Geoffrey; Ottens, Andrew K.; Tortella, Frank; Hayes, Ronald L.			Common Data Elements for Traumatic Brain Injury: Recommendations From the Biospecimens and Biomarkers Working Group	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Biological Markers; Brain Injuries; Rehabilitation	HUMAN CEREBROSPINAL-FLUID; GENOTYPE; POLYMORPHISM; ASSOCIATION; PROTEOMICS; PROTEINS; EVENTS; APOE	Recent advances in genomics, proteomics, and biotechnology have provided unprecedented opportunities for translational research and personalized medicine. Human biospecimens and biofluids represent an important resource from which molecular data can be generated to detect and classify injury and to identify molecular mechanisms and therapeutic targets. To date, there has been considerable variability in biospecimen and biofluid collection, storage, and processing in traumatic brain injury (TBI) studies. To realize the full potential of this important resource, standardization and adoption of best practice guidelines are required to insure the quality and consistency of these specimens. The aim of the Biospecimens and Biomarkers Working Group was to provide recommendations for core data elements for TBI research and develop best practice guidelines to standardize the quality and accessibility of these specimens. Consensus recommendations were developed through interactions with focus groups and input from stakeholders participating in the interagency workshop on Standardization of Data Collection in TBI and Psychological Health held in Washington, DC, in March 2009. With the adoption of these standards and best practices, future investigators will be able to obtain data across multiple studies with reduced costs and effort and accelerate the progress of genomic, proteomic, and metabolomic research in TBI.	[Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94110 USA; [Diaz-Arrastia, Ramon] Univ Texas SW Med Sch, Dallas, TX USA; [Brophy, Mary] Dept Vet Affairs Cooperat Studies Program, Boston, MA USA; [Engel, Doortje] Univ Heidelberg Hosp, Heidelberg, Germany; [Goodman, Clay; Gwinn, Katrina] Baylor Coll Med, Houston, TX 77030 USA; [Veenstra, Timothy D.] NCI, Sci Applicat Int Corp Frederick Inc, Frederick, MD 21701 USA; [Ling, Geoffrey] Uniformed Serv Univ Hlth Sci, Bethesda, MD USA; [Tortella, Frank] Walter Reed Army Inst Res, Silver Spring, MD USA; [Ottens, Andrew K.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA USA; [Ottens, Andrew K.] Virginia Commonwealth Univ, Dept Biochem, Richmond, VA USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Alachua, FL USA		Manley, GT (corresponding author), Univ Calif San Francisco, Dept Neurosurg, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA.	manleyg@neurosurg.ucsf.edu	Gwinn, Katrina A/C-2508-2009; Ottens, Andrew/K-3352-2012	Ottens, Andrew/0000-0002-2118-3796; Diaz-Arrastia, Ramon/0000-0001-6051-3594; Gwinn, Katrina/0000-0002-8277-651X			Bergquist J, 2002, MASS SPECTROM REV, V21, P2, DOI 10.1002/mas.10016; BLENNOW K, 1993, EUR NEUROL, V33, P126, DOI 10.1159/000116918; Carrette O, 2005, PROTEOMICS, V5, P3060, DOI 10.1002/pmic.200402039; de Frias CM, 2005, J COGNITIVE NEUROSCI, V17, P1018, DOI 10.1162/0898929054475136; Diaz-Arrastia R, 2006, J HEAD TRAUMA REHAB, V21, P361, DOI 10.1097/00001199-200607000-00007; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; Eiseman E., 2003, CASE STUDIES EXISTIN; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GOOSSENS W, 1991, CLIN LAB HAEMATOL, V13, P291; Hadjigeorgiou GM, 2005, NEUROLOGY, V65, P1077, DOI 10.1212/01.wnl.0000178890.93795.0e; Hesse C, 2000, NEUROCHEM RES, V25, P511, DOI 10.1023/A:1007516210548; Huhmer AF, 2006, DIS MARKERS, V22, P3; *INT SOC BIOL ENV, 2005, CELL PRESERV TECHNOL, V3, P5; Isoniemi H, 2006, J NEUROTRAUM, V23, P1600, DOI 10.1089/neu.2006.23.1600; Lipsky RH, 2005, J NEUROPSYCH CLIN N, V17, P465, DOI 10.1176/appi.neuropsych.17.4.465; Maurer MH, 2010, MASS SPECTROM REV, V29, P17, DOI 10.1002/mas.20213; Organisation for Economic Co-operation and Development, 2007, OECD BEST PRACT GUID; Ottens AK, 2007, PROG BRAIN RES, V161, P401, DOI 10.1016/S0079-6123(06)61029-7; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Prieto DA, 2008, EXPERT REV PROTEOMIC, V5, P283, DOI 10.1586/14789450.5.2.283; Schrohl AS, 2008, MOL CELL PROTEOMICS, V7, P2061, DOI 10.1074/mcp.R800010-MCP200; Shore PM, 2004, J NEUROTRAUM, V21, P1113; Shores KS, 2007, J PROTEOME RES, V6, P3739, DOI 10.1021/pr070293w; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Teunissen CE, 2009, NEUROLOGY, V73, P1914, DOI 10.1212/WNL.0b013e3181c47cc2; *US DEP HHS NIH, 2007, NIH PUB; Vanderstichele H, 2000, AMYLOID, V7, P245, DOI 10.3109/13506120009146438; Wagner AK, 2007, J NEUROSURG, V106, P538, DOI 10.3171/jns.2007.106.4.538; Xie PX, 2009, ARCH GEN PSYCHIAT, V66, P1201, DOI 10.1001/archgenpsychiatry.2009.153; Zhang J, 2007, PROTEOM CLIN APPL, V1, P805, DOI 10.1002/prca.200700081; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489	31	80	80	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2010	91	11					1667	1672		10.1016/j.apmr.2010.05.018			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	681UQ	WOS:000284346400006	21044710	Green Published			2022-02-06	
J	Arabi, YM; Haddad, S; Tamim, HM; Al-Dawood, A; Al-Qahtani, S; Ferayan, A; Al-Abdulmughni, I; Al-Oweis, J; Rugaan, A				Arabi, Yaseen M.; Haddad, Samir; Tamim, Hani M.; Al-Dawood, Abdulaziz; Al-Qahtani, Saad; Ferayan, Ahmad; Al-Abdulmughni, Ibrahim; Al-Oweis, Jalal; Rugaan, Asia			Mortality reduction after implementing a clinical practice guidelines-based management protocol for severe traumatic brain injury	JOURNAL OF CRITICAL CARE			English	Article						Guidelines; Mortality; Protocol; Severe Head Injury; Trauma; Traumatic Brain Injury	SEVERE HEAD-INJURY; ROAD TRAFFIC ACCIDENTS; INTRACRANIAL-PRESSURE; UNITED-STATES; CRITICAL-CARE; SAUDI-ARABIA; EPIDEMIOLOGY; DEATH; DISABILITY; COMATOSE	Introduction: The objective of this study was to examine the effect of implementing a clinical practice guidelines based management protocol on the outcome of patients with severe traumatic brain injury (TBI). Methods: We carried out a pre-post guideline implementation study using previously collected data in the Intensive Care Unit (ICU). All patients older than 12 years with severe TBI, defined as a Glasgow Coma Scale score of 8 or less, from March 1999 to January 2001 (control group) and from February 2001 to December 2006 (protocol group) were identified and included in this study. Patients in the protocol group were managed using a clinical practice guidelines based management protocol, derived from the guidelines published by the Brain Trauma Foundation. Primary outcome was hospital mortality, whereas the secondary outcome was ICU mortality. To assess whether the ICU protocol might have led to an increase in the number of surviving patients with severe disability, we examined the association of the protocol use and the need for tracheostomies, mechanical ventilation duration, and ICU and hospital length of stay (LOS) among survivors. Results: During the study period, a total of 434 patients met the inclusion criteria. After adjustment for several prognostic factors, the use of protocol was independently associated with a significant reduction in hospital and ICU mortality (odds ratio, 0.45; 95% confidence interval, 0.24-0.86; and odds ratio, 0.47; 95% confidence interval, 0.23-0.96, respectively). The use of the protocol was not associated with an increase in the need for tracheostomies, mechanical ventilation duration, ICU LOS, and hospital LOS.	[Arabi, Yaseen M.; Haddad, Samir; Al-Dawood, Abdulaziz; Al-Qahtani, Saad; Al-Abdulmughni, Ibrahim; Al-Oweis, Jalal; Rugaan, Asia] King Abdul Aziz Med City, Dept Intens Care, Riyadh 11426, Saudi Arabia; [Arabi, Yaseen M.; Tamim, Hani M.; Al-Dawood, Abdulaziz; Al-Qahtani, Saad] King Saud Bin Abdulaziz Univ Hlth Sci, Riyadh 11426, Saudi Arabia; [Ferayan, Ahmad] King Abdualziz Med City, Div Neurosurg, Dept Surg, Riyadh 11426, Saudi Arabia		Arabi, YM (corresponding author), King Saud Bin Abdulaziz Univ Hlth Sci, King Fahad Natl Guard Hosp, Dept Intens Care, Riyadh, Saudi Arabia.	arabi@ngha.med.sa		Alowais, Jalal/0000-0003-3103-2622; Arabi, Yaseen/0000-0001-5735-6241			Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; [Anonymous], 2007, J NEUROTRAUMA S1, V24, pS1, DOI DOI 10.1089/NEU.2006.0209; Ansari S, 2000, PUBLIC HEALTH, V114, P37, DOI 10.1016/S0033-3506(00)00306-1; Arabi Y, 2006, CRIT CARE MED, V34, P605, DOI 10.1097/01.CCM.0000203947.60552.DD; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Cremer OL, 2008, EUR J ANAESTH, V25, P87, DOI 10.1017/S0265021507003237; Demetriades D, 1998, J AM COLL SURGEONS, V187, P373, DOI 10.1016/S1072-7515(98)00209-9; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Engberg A, 1995, Acta Neurol Scand Suppl, V164, P1; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Haddad SH, 2007, ANAESTH INTENS CARE, V35, P393, DOI 10.1177/0310057X0703500313; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Mauritz W, 2008, INTENS CARE MED, V34, P1208, DOI 10.1007/s00134-008-1079-7; Meyer AA, 1998, J TRAUMA, V44, P1, DOI 10.1097/00005373-199801000-00001; Rappaport M, 2005, NEUROPSYCHOL REHABIL, V15, P442, DOI 10.1080/09602010443000335; REGEL G, 1995, J TRAUMA, V38, P70, DOI 10.1097/00005373-199501000-00020; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; SHANKS NJ, 1994, PUBLIC HEALTH, V108, P27, DOI 10.1016/S0033-3506(05)80032-0; Sinuff T, 2008, CRIT CARE MED, V36, P1049, DOI 10.1097/CCM.0b013e31816a01ec; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Steiner LA, 2004, CRIT CARE MED, V32, P1049, DOI 10.1097/01.CCM.0000120054.32845.A6; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Vukic M, 1999, ACTA NEUROCHIR, V141, P1203, DOI 10.1007/s007010050419; Wilkins IA, 2001, ANAESTHESIA, V56, P350, DOI 10.1046/j.1365-2044.2001.01708.x	29	80	85	0	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441	1557-8615		J CRIT CARE	J. Crit. Care	JUN	2010	25	2					190	195		10.1016/j.jcrc.2009.05.004			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	609EM	WOS:000278638200004	19592201				2022-02-06	
J	Perlbarg, V; Puybasset, L; Tollard, E; Lehericy, S; Benali, H; Galanaud, D				Perlbarg, Vincent; Puybasset, Louis; Tollard, Eleonore; Lehericy, Stephane; Benali, Habib; Galanaud, Damien			Relation Between Brain Lesion Location and Clinical Outcome in Patients with Severe Traumatic Brain Injury: A Diffusion Tensor Imaging Study Using Voxel-Based Approaches	HUMAN BRAIN MAPPING			English	Article						traumatic brain injury; clinical outcome; diffusion tensor imaging; tract-based spatial statistics	WHITE-MATTER INJURY; AXONAL INJURY; ANISOTROPY	The early prediction of consciousness recovery from traumatic brain injury (TBI) is crucial to make decisions about the appropriate use of prolonged intensive care. Diffusion tensor imaging (DTI) has been proposed as a biomarker of white matter injury that could be used in a classification purpose. Instead of region-of-interest-based approach, we applied voxel-based approaches (voxel-based DTI and tract-based spatial statistics) on 30 patients with TBI to identify, without any prior, the brain regions that were specifically damaged in unfavorable 1-year outcome group compared to the favorable one. DTI were acquired at mean 23 days (5-53 days) and two DTI-derived indices, fractional anisotropy (FA) and apparent diffusion coefficient (ADC), were tested. Our results showed that (1) ADC is not a relevant biomarker for early 1-year outcome prognosis; (2) FA measured in inferior longitudinal fasciculus, in cerebral peduncle, in posterior limb of the internal capsule, and in posterior corpus callosum is specifically decreased in unfavorable outcome group compare to the favorable one; (3) a linear discriminant analysis using the FA measured in these four regions showed good classification performance (sensitivity = 86% and specificity = 86%). These findings confirm the relevance of the use of DTI as biomarkers for consciousness recovery after TBI and support the possible use of these biomarkers for early classification of patients. Hum Brain Mapp 30:3924-3933, 2009. (C) 2009 Wiley-Liss, Inc.	[Perlbarg, Vincent] Univ Paris 06, INSERM, UMRS 678, Lab Imagerie Fonctionnelle, F-75634 Paris 13, France; [Perlbarg, Vincent; Benali, Habib] UPMC Univ Paris 06, UMRS 678, Lab Imagerie Fonctionnelle, Paris, France; [Puybasset, Louis] UPMC Univ Paris 06, Pitie Salpetriere Hosp, AP HP, Surg Neurointens Care Unit, Paris, France; [Tollard, Eleonore] UPMC Univ Paris 06, Pitie Salpetriere Hosp, AP HP, Dept Neuroradiol, Paris, France; [Lehericy, Stephane; Galanaud, Damien] Univ Hosp Rouen, Dept Radiol, Rouen, France; [Lehericy, Stephane] UPMC Univ Paris 06, CENIR, Paris, France		Perlbarg, V (corresponding author), Univ Paris 06, INSERM, UMRS 678, Lab Imagerie Fonctionnelle, 91 Blvd Hop, F-75634 Paris 13, France.	vperlbar@imed.jussieu.fr					Albrecht J, 2007, J NEUROL NEUROSUR PS, V78, P964, DOI 10.1136/jnnp.2006.112987; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Chan JHM, 2003, NEURORADIOLOGY, V45, P34, DOI 10.1007/s00234-002-0891-y; Coles JP, 2007, BRIT J ANAESTH, V99, P49, DOI 10.1093/bja/aem141; GIACINO JT, 1995, J HEAD TRAUMA REHAB, V10, P40; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; Hou DJ, 2007, J NEUROTRAUM, V24, P1558, DOI 10.1089/neu.2007.0339; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Jones DK, 2005, NEUROIMAGE, V26, P546, DOI 10.1016/j.neuroimage.2005.02.013; Kumar R, 2008, J MAGN RESON IMAGING, V27, P1061, DOI 10.1002/jmri.21342; Lescot T, 2008, CURR OPIN CRIT CARE, V14, P129, DOI 10.1097/MCC.0b013e3282f63c51; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Parvizi J, 2001, COGNITION, V79, P135, DOI 10.1016/S0010-0277(00)00127-X; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Thivard L, 2007, J NEUROL NEUROSUR PS, V78, P889, DOI 10.1136/jnnp.2006.101758; Weiss GA, 2007, CURR OPIN CHEM BIOL, V11, P241, DOI 10.1016/j.cbpa.2007.05.022; Weiss N, 2008, J NEUROL, V255, P217, DOI 10.1007/s00415-008-0658-4	24	80	82	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	DEC	2009	30	12					3924	3933		10.1002/hbm.20817			10	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	530IW	WOS:000272584000007	19507154	Green Submitted, Green Published			2022-02-06	
J	Zhang, ZQ; Larner, SF; Liu, MC; Zheng, WR; Hayes, RL; Wang, KKW				Zhang, Zhiqun; Larner, Stephen F.; Liu, Ming Cheng; Zheng, Wenrong; Hayes, Ronald L.; Wang, Kevin K. W.			Multiple alphaII-spectrin breakdown products distinguish calpain and caspase dominated necrotic and apoptotic cell death pathways	APOPTOSIS			English	Article						alpha II-spectrin; Breakdown product; Calpain; Caspase; Apoptosis; Oncosis; Necrosis; Proteolysis; Biomarker	TRAUMATIC BRAIN-INJURY; II-SPECTRIN; NEUROBLASTOMA-CELLS; PROTEASE ACTIVATION; NEURONAL APOPTOSIS; CYTOLYTIC PORE; NEONATAL-RATS; PC12 CELLS; IN-VIVO; NECROSIS	Apoptosis and oncotic necrosis in neuronal and glial cells have been documented in many neurological diseases. Distinguishing between these two major types of cell death in different neurological diseases is needed in order to better reveal the injury mechanisms so as to open up opportunities for therapy development. Accumulating evidence suggests apoptosis and oncosis epitomize the extreme ends of a broad spectrum of morphological and biochemical events. Biochemical markers that can distinguish between the calpain and caspase dominated types of cell death would help in this process. In this study, three chemical agents, maitotoxin (MTX), staurosporine (STS) and thylenediaminetetraacetic acid (EDTA), were used to induce different types of cell death in PC12 neuronal-like cells. MTX-induced necrosis, as determined by the increased levels of calpain-specific cleaved fragments of spectrin by antibodies specific to the calpain-cleaved 150 kDa alpha II-spectrin breakdown product (SBDP150) and 145 kDa alpha II-spectrin breakdown product (SBDP145). In this paradigm, there were no detectable SBDP150i and SBDP120 fragments as determined by antibodies specific to the caspase-cleaved specific fragments similar to those seen in the EDTA-mediated apoptotic PC-12 cells. In contrast to the calpain specific MTX necrosis treatment and the caspase EDTA apoptotic treatment is the STS treatment which induced both proteases as shown by the increase in all the SBDP fragments. Furthermore, compared to SBDP150, SBDP145 appears to be a more specific and sensitive biomarker for calpain activation. Taken together, our results suggested calpains and caspases which dominate the two major types of cell death could be independently discriminated by specifically examining the multiple alpha II-spectrin cleavage breakdown products.	[Zhang, Zhiqun; Larner, Stephen F.; Liu, Ming Cheng; Zheng, Wenrong; Hayes, Ronald L.; Wang, Kevin K. W.] Banyan Biomarkers Inc, Ctr Innovat Res, Alachua, FL 32615 USA		Zhang, ZQ (corresponding author), Banyan Biomarkers Inc, Ctr Innovat Res, 12085 Res Dr, Alachua, FL 32615 USA.	zqzhang@banyanbio.com; kwang@banyanbio.com		Wang, Kevin/0000-0002-9343-6473	Department of DefenseUnited States Department of Defense [DAMMED-03-1-0066]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS049175-01-A1, R01 NS051431]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049175, R01NS051431] Funding Source: NIH RePORTER	We wish to thank Meghan O'Donoghue for her technical assistance. This work was supported by the Department of Defense grant DAMMED-03-1-0066, National Institutes of Health grants R01 NS049175-01-A1 and R01 NS051431. K. K. W. Wang and R. L. Hayes own stock of Banyan Biomarkers Inc., and may benefit financially as a result of the outcome of this research or the work reported in this publication.	Abud HE, 2004, CELL DEATH DIFFER, V11, P788, DOI 10.1038/sj.cdd.4401402; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Behl C, 2000, J NEURAL TRANSM, V107, P1325, DOI 10.1007/s007020070021; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; Bouvry D, 2006, AM J RESP CELL MOL, V35, P519, DOI 10.1165/rcmb.2005-0478OC; Cardali S, 2006, J Neurosurg Sci, V50, P25; Castillo MR, 1998, NEUROSCIENCE, V86, P1133, DOI 10.1016/S0306-4522(98)00070-0; Chiesa R, 1998, J NEUROCHEM, V70, P1474; Clark RSB, 1997, J NEUROSCI, V17, P9172; Criddle DN, 2007, CELL DEATH DIFFER, V14, P1285, DOI 10.1038/sj.cdd.4402150; Das A, 2008, J PINEAL RES, V45, P117, DOI 10.1111/j.1600-079X.2008.00582.x; Del Rio P, 2008, NEUROCHEM RES, V33, P1475, DOI 10.1007/s11064-008-9612-1; Deshmukh M, 2000, CELL DEATH DIFFER, V7, P250, DOI 10.1038/sj.cdd.4400641; Dutta S, 2002, BIOL CHEM, V383, P785, DOI 10.1515/BC.2002.082; FARBER E, 1994, MODERN PATHOL, V7, P605; Friedman LM, 1998, FUNDAMENTALS CLIN TR; Fukiage C, 1997, BBA-MOL BASIS DIS, V1361, P304, DOI 10.1016/S0925-4439(97)00043-4; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Huh GY, 2001, NEUROSCI LETT, V316, P41, DOI 10.1016/S0304-3940(01)02371-0; Kawamura M, 2005, BRAIN RES, V1037, P59, DOI 10.1016/j.brainres.2004.12.050; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kim YJ, 2002, J DENT RES, V81, P788, DOI 10.1177/154405910208101113; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; Koumura A, 2008, NEUROSCIENCE, V157, P309, DOI 10.1016/j.neuroscience.2008.09.007; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Lecoeur H, 2001, CYTOMETRY, V44, P65, DOI 10.1002/1097-0320(20010501)44:1<65::AID-CYTO1083>3.0.CO;2-Q; Levin S, 1998, TOXICOL SCI, V41, P155; Lewis SB, 2007, J NEUROSURG, V107, P792, DOI 10.3171/JNS-07/10/0792; Li C, 2002, P NATL ACAD SCI USA, V99, P9830, DOI 10.1073/pnas.152571899; Lockshin RA, 2004, ONCOGENE, V23, P2766, DOI 10.1038/sj.onc.1207514; MAJNO G, 1995, AM J PATHOL, V146, P3; McGinnis KM, 1999, J NEUROCHEM, V72, P1853, DOI 10.1046/j.1471-4159.1999.0721853.x; Meary F, 2007, J BIOL CHEM, V282, P14226, DOI 10.1074/jbc.M700028200; MEUCCI O, 1992, J NEUROCHEM, V59, P679, DOI 10.1111/j.1471-4159.1992.tb09422.x; Muller GJ, 2004, BRAIN PATHOL, V14, P415; Nath R, 2000, NEUROCHEM INT, V36, P119, DOI 10.1016/S0197-0186(99)00112-6; NATH R, 1925, BIOCHEM BIOPH RES CO, V274, P16; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Povlishock JT, 2001, HEAD TRAUMA, P281; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rathmell JC, 1999, ANNU REV IMMUNOL, V17, P781, DOI 10.1146/annurev.immunol.17.1.781; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; RIEDERER BM, 1986, J CELL BIOL, V102, P2088, DOI 10.1083/jcb.102.6.2088; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Rotter B, 2004, BIOCHEM J, V378, P161, DOI 10.1042/BJ20030955; Sakabe I, 1998, CELL STRUCT FUNCT, V23, P95, DOI 10.1247/csf.23.95; SCHILLING WP, 2002, AM J PHYSIOL, V277, pC755; SCHILLING WP, 2002, AM J PHYSIOL, V277, pC766; Seo SR, 2009, EXP MOL MED, V41, P269, DOI 10.3858/emm.2009.41.4.030; Serper A, 2001, J Oral Sci, V43, P233; Short DM, 2007, PROTEOMICS, V7, P3085, DOI 10.1002/pmic.200600964; SOERGEL DG, 1992, MOL PHARMACOL, V41, P487; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Tamada Y, 2005, BRAIN RES, V1050, P148, DOI 10.1016/j.brainres.2005.05.048; Van Cruchten S, 2002, ANAT HISTOL EMBRYOL, V31, P214, DOI 10.1046/j.1439-0264.2002.00398.x; Vanderklish PW, 2000, INT J EXP PATHOL, V81, P323, DOI 10.1111/j.1365-2613.2000.00169.x; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang KKW, 1996, ARCH BIOCHEM BIOPHYS, V331, P208, DOI 10.1006/abbi.1996.0300; Wang Y, 2008, J CELL PHYSIOL, V215, P676, DOI 10.1002/jcp.21350; Zhang XD, 2004, MOL CANCER THER, V3, P187; Zhang Z, 2006, CELL MOL BIOL LETT, V11, P12, DOI 10.2478/s11658-006-0002-x	67	80	82	0	7	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	1360-8185	1573-675X		APOPTOSIS	Apoptosis	NOV	2009	14	11					1289	1298		10.1007/s10495-009-0405-z			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	503MX	WOS:000270540800004	19771521				2022-02-06	
J	Amorini, AM; Petzold, A; Tavazzi, B; Eikelenboom, J; Keir, G; Belli, A; Giovannoni, G; Di Preto, V; Polman, C; D'Urso, S; Vagnozzi, R; Uitdehaag, B; Lazzarino, G				Amorini, Angela M.; Petzold, Axel; Tavazzi, Barbara; Eikelenboom, Judith; Keir, Geoffrey; Belli, Antonio; Giovannoni, Gavin; Di Preto, Valentina; Polman, Chris; D'Urso, Serafina; Vagnozzi, Roberto; Uitdehaag, Bernard; Lazzarino, Giuseppe			Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients	CLINICAL BIOCHEMISTRY			English	Article						Multiple sclerosis; Uric acid; Purine compounds; Cerebrospinal fluid; Serum; HPLC; Energy metabolism; Oxidative stress; Nitrosative stress	TRAUMATIC BRAIN-INJURY; CEREBROSPINAL-FLUID; MITOCHONDRIAL DYSFUNCTION; OXIDATIVE STRESS; LIPID-PEROXIDATION; NITROSATIVE STRESS; CYCLOSPORINE-A; ENERGY-STATE; HYPOXANTHINE; XANTHINE	Objectives: In this study, the concentrations of uric acid, purine profile and creatinine in samples of cerebrospinal fluid and serum of multiple sclerosis (MS) patients were measured by HPLC and compared with corresponding values recorded in patients Without MS (cerebrospinal fluid) and healthy subjects (serum). Design and methods: All samples were deproteinized with ultrafiltration (which ensures minimal sample manipulation and efficient protein removal) and then assayed for the synchronous HPLC separation of uric acid, hypoxanthine, xanthine, inosine, adenosine, guanosine and creatinine. Results: The values of all compounds assayed were significantly higher in both biological fluids of MS patients with respect to values measured in controls. In particular, serum hypoxanthine, xanthine, uric acid and sum of oxypurines were, respectively, 3.17, 3.11, 1.23 and 1.27-fold higher in these patients than corresponding values recorded in controls (p < 0.001). Conclusions: Differently from what previously reported, we here demonstrate that all purine compounds, including uric acid, are elevated in biological fluids of MS patients. Reinforced by the trend observed for creatinine, this corroborates the notion of sustained purine catabolism, possibly due to imbalance in ATP homeostasis, under these pathological conditions. These results cast doubt oil the hypothesis that uric acid is depleted in MS because of increased oxidative stress, rather suggesting that this disease causes a generalized increase in purine catabolism. As observed in other pathological states, uric acid, purine compounds and creatinine, can be considered markers of metabolic energy imbalance rather than of reactive oxygen species, even in MS. (c) 2009 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.	[D'Urso, Serafina; Lazzarino, Giuseppe] Univ Catania, Biochem Lab, Dept Chem Sci, I-95125 Catania, Italy; [Amorini, Angela M.; Tavazzi, Barbara; Di Preto, Valentina] Catholic Univ Rome Sacro Cuore, Inst Biochem & Clin Biochem, Rome, Italy; [Petzold, Axel; Keir, Geoffrey] UCL, Inst Neurol, Neuroimmunol & CSF Unit, Dept Neuroinflammat, London, England; [Eikelenboom, Judith; Polman, Chris; Uitdehaag, Bernard] Univ Amsterdam, Dept Neurol, VU Med Ctr, Amsterdam, Netherlands; [Belli, Antonio] Univ Southampton, Div Clin Neurosci, Southampton, Hants, England; [Giovannoni, Gavin] Royal London Hosp, Dept Neurol, London E1 1BB, England; [Vagnozzi, Roberto] Univ Roma Tor Vergata, Dept Neurosci, Rome, Italy		Lazzarino, G (corresponding author), Univ Catania, Biochem Lab, Dept Chem Sci, Viale A Dorio 6, I-95125 Catania, Italy.	lazzarig@unict.it	Petzold, Axel/C-1090-2009; Belli, Antonio/I-3799-2015; TAVAZZI, BARBARA/AAB-9830-2019; lazzarino, giuseppe/K-2277-2015	Petzold, Axel/0000-0002-0344-9749; Belli, Antonio/0000-0002-3211-9933; TAVAZZI, BARBARA/0000-0001-8743-0895; Di Pietro, Valentina/0000-0001-9430-4723; lazzarino, giuseppe/0000-0002-5917-7279; AMORINI, Angela Maria/0000-0003-3525-9955	Catania University, of Catholic University of Rome;  [MIUR - PRIN 2007JBHZ5F]	This work has been supported in part by research funds of Catania University, of Catholic University of Rome "Sacro Cuore", and by MIUR - PRIN 2007JBHZ5F grant,	Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; Besler HT, 2003, NUTR NEUROSCI, V6, P189, DOI 10.1080/1028415031000115945; Bizzozero OA, 2005, J NEUROSCI RES, V81, P687, DOI 10.1002/jnr.20587; CADOUXHUDSON TAD, 1991, J NEUROL NEUROSUR PS, V54, P1004, DOI 10.1136/jnnp.54.11.1004; Calabrese V, 2002, J NEUROSCI RES, V70, P580, DOI 10.1002/jnr.10408; Carlson NG, 2006, CNS DRUGS, V20, P433, DOI 10.2165/00023210-200620060-00001; Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010; Cristofori L, 2005, CLIN BIOCHEM, V38, P97, DOI 10.1016/j.clinbiochem.2004.09.013; Cristofori L, 2001, J INVEST MED, V49, P450, DOI 10.2310/6650.2001.33790; Czauderna M, 1997, J CHROMATOGR B, V704, P89, DOI 10.1016/S0378-4347(97)00459-3; Drulovic J, 2001, J NEUROL, V248, P121, DOI 10.1007/s004150170246; Dutta R, 2006, ANN NEUROL, V59, P478, DOI 10.1002/ana.20736; GIARDINA B, 1993, AM J CARDIOL, V71, P788, DOI 10.1016/0002-9149(93)90825-W; Gu Z, 2005, CELL DEATH DIFFER, V12, P1202, DOI 10.1038/sj.cdd.4401705; Guerrero AL, 2008, EUR J NEUROL, V15, P394, DOI 10.1111/j.1468-1331.2008.02087.x; Hao Q, 2005, J ALZHEIMERS DIS, V8, P161; Hartmann S, 2006, CLIN CHEM, V52, P1127, DOI 10.1373/clinchem.2005.058842; Jolivalt CG, 2003, J NEUROIMMUNOL, V138, P56, DOI 10.1016/S0165-5728(03)00097-3; Koch M, 2006, NEUROL RES, V28, P316, DOI 10.1179/016164106X98215; KOJIMA T, 1987, CLIN CHEM, V33, P2052; Kuracka L, 1996, CLIN CHEM, V42, P756; la Marca G, 2006, J MASS SPECTROM, V41, P1442, DOI 10.1002/jms.1115; Lazzarino G, 2003, ANAL BIOCHEM, V322, P51, DOI 10.1016/j.ab.2003.07.013; LAZZARINO G, 1994, CIRCULATION, V90, P291, DOI 10.1161/01.CIR.90.1.291; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; Mancuso M, 2006, J ALZHEIMERS DIS, V10, P59; Mastrocola R, 2005, J ENDOCRINOL, V187, P37, DOI 10.1677/joe.1.06269; Minniti G, 1998, ADV EXP MED BIOL, V431, P843; MOSERT JP, 2005, J NEUROL SCI, V231, P41; NIKLASSON F, 1983, CLIN CHEM, V29, P1543; Noiri E, 2001, AM J PHYSIOL-RENAL, V281, pF948, DOI 10.1152/ajprenal.0071.2001; Petzold A, 2006, MULT SCLER J, V12, P325, DOI 10.1191/135248505ms1277oa; Qi XP, 2006, J BIOL CHEM, V281, P31950, DOI 10.1074/jbc.M603717200; Ramsaransing GSM, 2005, EUR J NEUROL, V12, P514, DOI 10.1111/j.1468-1331.2005.01009.x; Rejdak K, 2004, NEUROLOGY, V63, P1439; Rentzos M, 2006, CLIN NEUROL NEUROSUR, V108, P527, DOI 10.1016/j.clineuro.2005.08.004; Roxburgh RHSR, 2005, NEUROLOGY, V64, P1144, DOI 10.1212/01.WNL.0000156155.19270.F8; SHARMA KR, 1995, MUSCLE NERVE, V18, P1403, DOI 10.1002/mus.880181210; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Sotgiu S, 2002, NEUROL SCI, V23, P183, DOI 10.1007/s100720200059; Squadrito GL, 2000, ARCH BIOCHEM BIOPHYS, V376, P333, DOI 10.1006/abbi.2000.1721; Stover JF, 1997, NEUROSCI LETT, V238, P25, DOI 10.1016/S0304-3940(97)00840-9; Tavazzi B, 2005, CLIN BIOCHEM, V38, P997, DOI 10.1016/j.clinbiochem.2005.08.002; Taylor NF, 2006, DISABIL REHABIL, V28, P1119, DOI 10.1080/09638280500531834; Vagnozzi R, 1997, EXP BRAIN RES, V117, P411, DOI 10.1007/s002210050235; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Vidotto C, 2003, CLIN CHIM ACTA, V335, P27, DOI 10.1016/S0009-8981(03)00291-2	48	80	81	0	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0009-9120	1873-2933		CLIN BIOCHEM	Clin. Biochem.	JUL	2009	42	10-11					1001	1006		10.1016/j.clinbiochem.2009.03.020			6	Medical Laboratory Technology	Science Citation Index Expanded (SCI-EXPANDED)	Medical Laboratory Technology	461NN	WOS:000267274300011	19341721				2022-02-06	
J	Nelson, LA; Yoash-Gantz, RE; Pickett, TC; Campbell, TA				Nelson, Lonnie A.; Yoash-Gantz, Ruth E.; Pickett, Treven C.; Campbell, Thomas A.			Relationship Between Processing Speed and Executive Functioning Performance Among OEF/OIF Veterans: Implications for Postdeployment Rehabilitation	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						neuropsychology; processing speed; psychiatric; PTSD; rehabilitation; Stroop; TBI	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE REHABILITATION; DEPRESSION; SOLDIERS; MEMORY; TRAIL; TESTS; TRIAL	Background: Comorbid mild traumatic brain injury (mTBI) with posttraumatic stress disorder (PTSD) is a common clinical presentation among troops returning from Operation Enduring Freedom and Operation Iraqi Freedom (OEF/OIF). This study examined processing speed and executive functioning in a sample of OEF/OIF veterans who had sustained mTBI, a subset of whom also had comorbid PTSD. Methods: Fifty-three OEF/OIF veterans with a history of mTBI completed Wechsler Adult Intelligence Scale-III Symbol Search and Digit Symbol-Coding subscales, Stroop Word, color and color-word trials, and Trail Making Test, Parts A and B as part of a comprehensive neuropsychological test battery. Results: Excluding from analysis those who scored poorly on effort testing, multiple regression showed that measures of processing speed accounted for 43% of the variance in performance on the Trail Making Test, Part B and 50% of the variance in performance on the Stroop task. Significant differences in processing speed and executive functioning were found on the basis of presence of comorbid PTSD. Stroop Color (F = 9.27, df = 52, P < .004) and Stroop Color Word (F = 7.19, df = 52, P < .01) scores differed significantly between the groups. Those having comorbid PTSD (+TBI/+PTSD) scored significantly poorer than the mTBI-only group (+TBI/-PTSD). Implications for treatment of the comorbid conditions are discussed.	[Yoash-Gantz, Ruth E.] Hefner VA Med Ctr, Salisbury, NC 28144 USA; [Nelson, Lonnie A.; Pickett, Treven C.; Campbell, Thomas A.] Hunter Holmes McGuire Dept Vet Affairs Med Ctr, Mental Hlth Serv, Richmond, VA USA; [Nelson, Lonnie A.; Pickett, Treven C.] Def & Vet Brain Injury Ctr, Richmond, VA USA; [Yoash-Gantz, Ruth E.; Pickett, Treven C.] VISN6, MIRECC, Richmond, NC USA; [Pickett, Treven C.] Virginia Commonwealth Univ, Sch Med, Dept Phys Med & Rehabil, Richmond, NC USA; [Yoash-Gantz, Ruth E.] Wake Forest Univ, Bowman Gray Sch Med, Dept Psychiat & Behav Sci, Winston Salem, NC USA		Yoash-Gantz, RE (corresponding author), Hefner VA Med Ctr, Mental Hlth & Behav Sci 11M-2,1601 Brenner Ave, Salisbury, NC 28144 USA.	ruth.yoash-gantz@va.gov					Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Bryant RA, 2008, ARCH GEN PSYCHIAT, V65, P659, DOI 10.1001/archpsyc.65.6.659; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; BURNAM MA, 2008, INVISIBLE WOUNDS WAR, P3; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone K, 2006, J COGNITIVE NEUROSCI, V18, P1212, DOI 10.1162/jocn.2006.18.7.1212; Demakis GJ, 2004, J CLIN EXP NEUROPSYC, V26, P441, DOI 10.1080/13803390490510149; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Everly George S Jr, 2003, Int J Emerg Ment Health, V5, P179; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Golden CJ, 1978, STROOP COLOR WORD TE; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jaycox, 2008, INVISIBLE WOUNDS WAR, P3; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; Michel J A, 2006, Eura Medicophys, V42, P59; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P581, DOI 10.1080/13803390500434474; Ravnkilde B, 2002, J CLIN EXP NEUROPSYC, V24, P534, DOI 10.1076/jcen.24.4.534.1033; Reitan R. M, 1985, HALLSTED REITAN NEUR; Resick PA, 2008, J CONSULT CLIN PSYCH, V76, P243, DOI 10.1037/0022-006X.76.2.243; Ruffolo LF, 2000, CLIN NEUROPSYCHOL, V14, P223, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT223; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Stuss DT, 2001, NEUROPSYCHOLOGIA, V39, P771, DOI 10.1016/S0028-3932(01)00013-6; SUSAN D, 2002, J CLIN PSYCHOL, V58, P947; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird	32	80	80	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2009	24	1					32	40		10.1097/HTR.0b013e3181957016			9	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	427GT	WOS:000264768500006	19158594				2022-02-06	
J	Angst, MS; Clark, JD; Carvalho, B; Tingle, M; Schmelz, M; Yeomans, DC				Angst, M. S.; Clark, J. D.; Carvalho, B.; Tingle, M.; Schmelz, M.; Yeomans, D. C.			Cytokine profile in human skin in response to experimental inflammation, noxious stimulation, and administration of a COX-inhibitor: A microdialysis study	PAIN			English	Article						Microdialysis; Skin; Human; Ultraviolet B; Sunburn; Inflammation; Cytokines; Interleukins; Chemokines; Nerve Growth Factor; Cyclooxygenase Inhibitor; lbuprofen; Hyperalgesia; Heat; Mechanical; Analgesia; Anti-hyperalgesia; Anti-inflammatory	NERVE GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; OPIOID AGONIST REMIFENTANIL; TRAUMATIC BRAIN-INJURY; GENE-RELATED PEPTIDE; PAIN SYNDROME TYPE-1; BEAD ARRAY ASSAYS; ULTRAVIOLET-B; IN-VIVO; PROINFLAMMATORY CYTOKINES	Animal studies have documented a critical role for cytokines in cell signaling events underlying inflammation and pain associated with tissue injury. While clinical reports indicate an important role of cytokines in inflammatory pain, methodological limitations have made systematic human studies difficult. This study examined the utility of a human in vivo bioassay combining rnicrodialysis with multiplex immunoassay techniques for measuring cytokine arrays in tissue. The first experiment measured cytokines in interstitial fluid collected from non-inflamed and experimentally inflamed skin (UVB). The effects of noxious heat on cytokine release were also assessed. The second experiment examined whether anti-hyperalgesic effects of the COX-inhibitor ibuprofen were associated with decreased tissue levels of the pro-inflammatory cytokines IL-1 beta and IL-6. In the first experiment, inflammation significantly increased IL-1 beta, IL-6, IL-8, IL-10, G-CSF, and MIP-1 beta. Noxious heat but not experimental inflammation significantly increased IL-7 and IL-13. In the second experiment, an oral dose of 400 and 800 mg ibuprofen produced similar anti-hyperalgesic effects Suggesting a ceiling effect. Tissue levels of IL-1 beta and IL-6 were not affected after the 400 mg dose but decreased significantly (44 +/- 32% and 38 +/- 13%) after the 800 mg dose. These results Support the utility of explored method for tracking cytokines in human tissue and suggest that anti-hyperalgesic and anti-inflammatory effects of ibuprofen are at least partially dissociated. The data further suggest that high clinical doses of ibuprofen exert anti-inflammatory effects by down-regulating tissue cytokine levels. Explored human bioassay is a promising tool for studying the pathology and pharmacology of inflammatory and chronic pain conditions. (C) 2008 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.	[Angst, M. S.; Clark, J. D.; Carvalho, B.; Tingle, M.; Yeomans, D. C.] Stanford Univ, Sch Med, Dept Anesthesia, Stanford, CA 94305 USA; [Clark, J. D.] Vet Affiairs Palo Alto Hlth Care Syst, Dept Anesthesia, Palo Alto, CA 94304 USA; [Schmelz, M.] Univ Heidelberg, Dept Anesthesiol, D-6800 Mannheim, Germany		Angst, MS (corresponding author), Stanford Univ, Sch Med, Dept Anesthesia, 300 Pasteur Dr, Stanford, CA 94305 USA.	ang@stanford.edu	Schmelz, Martin/A-9327-2013	Schmelz, Martin/0000-0002-9736-7241			Angst MS, 2004, ANESTHESIOLOGY, V101, P744, DOI 10.1097/00000542-200409000-00024; Angst MS, 2003, PAIN, V106, P49, DOI 10.1016/S0304-3959(03)00276-8; Angst MS, 2000, ANESTHESIOLOGY, V92, P312, DOI 10.1097/00000542-200002000-00011; Averbeck M, 2006, EXP DERMATOL, V15, P447, DOI 10.1111/j.0906-6705.2006.00429.x; AVGERINOS A, 1990, CHIRALITY, V2, P249, DOI 10.1002/chir.530020410; Bahlmann L, 2004, INTENS CARE MED, V30, P889, DOI 10.1007/s00134-004-2199-3; Basu S, 2005, P NATL ACAD SCI USA, V102, P5120, DOI 10.1073/pnas.0407780102; Bessler H, 2006, NEUROSCI LETT, V404, P154, DOI 10.1016/j.neulet.2006.05.030; Biedermann T, 2004, J INVEST DERM SYMP P, V9, P5, DOI 10.1111/j.1087-0024.2004.00829.x; Bowman PD, 1997, AM J PHYSIOL-CELL PH, V272, pC1988, DOI 10.1152/ajpcell.1997.272.6.C1988; Buvanendran A, 2006, ANESTHESIOLOGY, V104, P403, DOI 10.1097/00000542-200603000-00005; Cataisson C, 2006, J CLIN INVEST, V116, P2757, DOI 10.1172/JCI27514; Clark JD, 2006, ANESTHESIOLOGY, V104, P1274, DOI 10.1097/00000542-200606000-00024; Clingen PH, 2001, BRIT J DERMATOL, V145, P54, DOI 10.1046/j.1365-2133.2001.04281.x; Clough GF, 2007, J INVEST DERMATOL, V127, P2799, DOI 10.1038/sj.jid.5700930; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; CUNHA FQ, 1992, BRIT J PHARMACOL, V107, P660, DOI 10.1111/j.1476-5381.1992.tb14503.x; Cunha FQ, 1999, BRIT J PHARMACOL, V126, P45, DOI 10.1038/sj.bjp.0702266; Dallos A, 2006, NEUROPEPTIDES, V40, P251, DOI 10.1016/j.npep.2006.06.002; Denda M, 2007, J INVEST DERMATOL, V127, P654, DOI 10.1038/sj.jid.5700590; Di Nuzzo S, 1998, J INVEST DERMATOL, V110, P978, DOI 10.1046/j.1523-1747.1998.00220.x; DIMARCO E, 1991, J BIOL CHEM, V266, P21718; Elshal MF, 2006, METHODS, V38, P317, DOI 10.1016/j.ymeth.2005.11.010; ENK CD, 1995, J IMMUNOL, V154, P4851; Fang Y, 2007, BRIT J DERMATOL, V157, P458, DOI 10.1111/j.1365-2133.2007.07979.x; Feldmeyer L, 2007, CURR BIOL, V17, P1140, DOI 10.1016/j.cub.2007.05.074; FERREIRA SH, 1979, PROSTAGLANDINS, V18, P179, DOI 10.1016/0090-6980(79)90103-5; FERREIRA SH, 1988, NATURE, V334, P698, DOI 10.1038/334698a0; FITZPATRICK TB, 1988, ARCH DERMATOL, V124, P869, DOI 10.1001/archderm.124.6.869; Flodgren GM, 2006, EUR J APPL PHYSIOL, V97, P557, DOI 10.1007/s00421-006-0216-7; FUKUOKA H, 1994, BRAIN RES, V657, P133, DOI 10.1016/0006-8993(94)90960-1; HAWK JLM, 1988, BRIT J DERMATOL, V118, P27, DOI 10.1111/j.1365-2133.1988.tb01746.x; Heijmans-Antonissen C, 2006, MEDIAT INFLAMM, V2006, DOI 10.1155/MI/2006/28398; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; Hino R, 2007, BRIT J DERMATOL, V156, P830, DOI 10.1111/j.1365-2133.2007.07774.x; Holzheimer R G, 2000, Eur J Med Res, V5, P347; Imokawa G, 1996, BIOCHEM J, V313, P625, DOI 10.1042/bj3130625; Inaoka M, 2006, EXP DERMATOL, V15, P981, DOI 10.1111/j.1600-0625.2006.00505.x; Joussen AM, 2002, FASEB J, V16, P438, DOI 10.1096/fj.01-0707fje; Kang JS, 2007, J INVEST DERMATOL, V127, P698, DOI 10.1038/sj.jid.5700572; KANG KF, 1994, J IMMUNOL, V153, P5256; Khan SS, 2004, CYTOM PART B-CLIN CY, V61B, P35, DOI 10.1002/cyto.b.20021; KILO S, 1995, PAIN, V62, P187, DOI 10.1016/0304-3959(94)00265-G; Li WH, 2007, J INVEST DERMATOL, V127, P2328, DOI 10.1038/sj.jid.5700880; Lindenlaub T, 2003, ACTA NEUROPATHOL, V105, P593, DOI 10.1007/s00401-003-0689-y; LONNROTH P, 1987, AM J PHYSIOL, V253, pE228, DOI 10.1152/ajpendo.1987.253.2.E228; Lorenzetti BB, 2001, EUR CYTOKINE NETW, V12, P260; Lotsch J, 2003, PAIN, V102, P151, DOI 10.1016/S0304-3959(02)00349-4; LOTZ M, 1994, J UROLOGY, V152, P869, DOI 10.1016/S0022-5347(17)32594-6; Munnikes RJM, 2005, MEDIAT INFLAMM, P366, DOI 10.1155/MI.2005.366; Murdolo G, 2007, J CLIN ENDOCR METAB, V92, P2688, DOI 10.1210/jc.2006-2814; Obreja O, 2005, BRAIN, V128, P1634, DOI 10.1093/brain/awh490; Opree A, 2000, J NEUROSCI, V20, P6289, DOI 10.1523/JNEUROSCI.20-16-06289.2000; POOLE S, 1995, BRIT J PHARMACOL, V115, P684, DOI 10.1111/j.1476-5381.1995.tb14987.x; Purwar R, 2006, J INVEST DERMATOL, V126, P1043, DOI 10.1038/sj.jid.5700085; Rosenbloom AJ, 2006, J IMMUNOL METHODS, V309, P55, DOI 10.1016/j.jim.2005.11.013; Saade NE, 2000, BRIT J PHARMACOL, V131, P1317, DOI 10.1038/sj.bjp.0703699; Salemi S, 2003, J RHEUMATOL, V30, P146; Samuelsson A, 2006, CRIT CARE, V10, DOI 10.1186/cc5124; Sandqvist M, 2006, EUR J CLIN INVEST, V36, P383, DOI 10.1111/j.1365-2362.2006.01647.x; Sauerstein K, 2000, J PHYSIOL-LONDON, V529, P803, DOI 10.1111/j.1469-7793.2000.00803.x; Saunders CIM, 2007, MOL IMMUNOL, V44, P1429, DOI 10.1016/j.molimm.2006.04.027; Schmelz M, 1999, CLIN EXP ALLERGY, V29, P695; Shah JP, 2005, J APPL PHYSIOL, V99, P1977, DOI 10.1152/japplphysiol.00419.2005; Silva MA, 2005, TRANSPLANTATION, V79, P828, DOI 10.1097/01.TP.0000153156.38617.97; Sommer C, 2004, NEUROSCI LETT, V361, P184, DOI 10.1016/j.neulet.2003.12.007; Sopasakis VR, 2004, OBES RES, V12, P454, DOI 10.1038/oby.2004.51; Strickland I, 1997, J INVEST DERMATOL, V108, P763, DOI 10.1111/1523-1747.ep12292156; Takahashi T, 1998, ORAL SURG ORAL MED O, V85, P135, DOI 10.1016/S1079-2104(98)90415-2; Terui T, 2001, ACTA DERM-VENEREOL, V81, P8, DOI 10.1080/000155501750208100; Teunissen MBM, 2002, J IMMUNOL, V168, P3732, DOI 10.4049/jimmunol.168.8.3732; TRON VA, 1990, J CLIN INVEST, V85, P1085, DOI 10.1172/JCI114539; Verdant CL, 2006, ANN SURG, V244, P994, DOI 10.1097/01.sla.0000225092.45734.e6; Verri WA, 2006, PHARMACOL THERAPEUT, V112, P116, DOI 10.1016/j.pharmthera.2006.04.001; Waelgaard L, 2006, SCAND J IMMUNOL, V64, P345, DOI 10.1111/j.1365-3083.2006.01826.x; Wagner LA, 1999, EUR J IMMUNOL, V29, P2530, DOI 10.1002/(SICI)1521-4141(199908)29:08<2530::AID-IMMU2530>3.0.CO;2-2; Wang Y, 1997, BIOCHEM BIOPH RES CO, V239, P676, DOI 10.1006/bbrc.1997.7533; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Wu CR, 2007, ANESTHESIOLOGY, V107, P128, DOI 10.1097/01.anes.0000267512.08619.bd; Yamaki K, 2005, INT J IMMUNOPATH PH, V18, P133, DOI 10.1177/039463200501800114	80	80	81	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0304-3959			PAIN	Pain	SEP 30	2008	139	1					15	27		10.1016/j.pain.2008.02.028			13	Anesthesiology; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; Neurosciences & Neurology	361WV	WOS:000260159200003	18396374				2022-02-06	
J	Arias, RL; Sung, MLA; Vasylyev, D; Zhang, MY; Albinson, K; Kubek, K; Kagan, N; Beyer, C; Lin, Q; Dwyer, JM; Zaleska, MM; Bowlby, MR; Dunlop, J; Monaghan, M				Arias, Robert L.; Sung, Mei-Li A.; Vasylyev, Dmytro; Zhang, Mei-Yi; Albinson, Kristin; Kubek, Katie; Kagan, Natasha; Beyer, Chad; Lin, Qian; Dwyer, Jason M.; Zaleska, Margaret M.; Bowlby, Mark R.; Dunlop, John; Monaghan, Michael			Amiloride is neuroprotective in an MPTP model of Parkinson's disease	NEUROBIOLOGY OF DISEASE			English	Article						MPTP; amiloride; psalmotoxin; substantia nigra; Parkinson's disease; dopamine transporter; tyrosine hydroxylase; ASIC	SENSING ION CHANNELS; TRAUMATIC BRAIN-INJURY; GATED CATION CHANNELS; CEREBRAL BLOOD-FLOW; MICROGLIAL ACTIVATION; INDUCED NEUROTOXICITY; MOUSE MODEL; TNF-ALPHA; ISCHEMIA; CAFFEINE	The diuretic amiloride has recently proven neuroprotective in models of cerebral ischemia, a property attributable to the drug's inhibition of central acid-sensing ion channels (ASICs). Given that Parkinson's disease (PD), like ischemia, is associated with cerebral lactic acidosis, we tested amiloride in the MPTP-treated mouse, a model of PD also manifesting lactic acidosis. Amiloride was found to protect substantia nigra (SNc) neurons from MPTP-induced degeneration, as determined by attenuated reductions in striatal tyrosine hydroxylase (TH) and dopamine transporter (DAT) immunohistochemistry, as well as smaller declines in striatal DAT radioligand binding and dopamine levels. More significantly, amiloride also preserved dopaminergic cell bodies in the SNc. Administration of psalmotoxin venom (PcTX), an ASIC1a blocker, resulted in a much more modest effect, attenuating only the deficits in striatal DAT binding and dopamine. These findings represent the first experimental evidence of a potential role for ASICs in the pathogenesis of Parkinson's disease. (C) 2008 Elsevier Inc. All rights reserved.	[Arias, Robert L.; Sung, Mei-Li A.; Vasylyev, Dmytro; Zhang, Mei-Yi; Albinson, Kristin; Kubek, Katie; Kagan, Natasha; Beyer, Chad; Lin, Qian; Dwyer, Jason M.; Zaleska, Margaret M.; Bowlby, Mark R.; Dunlop, John; Monaghan, Michael] Wyeth Discovery Neurosci, Princeton, NJ USA		Arias, RL (corresponding author), Wyeth Neurosci, CN-8000 1513, Princeton, NJ 08543 USA.	ariasr@wyeth.com					Abeliovich A, 2006, J NEUROCHEM, V99, P1062, DOI 10.1111/j.1471-4159.2006.04102.x; Alfinito PD, 2003, J NEUROSCI, V23, P10982; Ascherio A, 2001, ANN NEUROL, V50, P56, DOI 10.1002/ana.1052; Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769; Bove Jordi, 2005, NeuroRx, V2, P484, DOI 10.1602/neurorx.2.3.484; BOWEN BC, 1995, AM J NEURORADIOL, V16, P61; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; BROUILLET E, 1993, NEUROREPORT, V4, P387, DOI 10.1097/00001756-199304000-00011; Chen JF, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-10-j0001.2001; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Escoubas P, 2003, PROTEIN SCI, V12, P1332, DOI 10.1110/ps.0307003; Fahn S, 2003, ANN NY ACAD SCI, V991, P1, DOI 10.1111/j.1749-6632.2003.tb07458.x; Ferger B, 2004, J NEUROCHEM, V89, P822, DOI 10.1111/j.1471-4159.2004.02399.x; Friese MA, 2007, NAT MED, V13, P1483, DOI 10.1038/nm1668; GARRITSEN A, 1990, BIOCHEM PHARMACOL, V40, P827, DOI 10.1016/0006-2952(90)90323-D; Gupta AK, 2004, J NEUROTRAUM, V21, P678, DOI 10.1089/0897715041269722; Haddad JJ, 2002, AM J RESP CELL MOL, V26, P114, DOI 10.1165/ajrcmb.26.1.4657; Horisberger JD, 1998, CURR OPIN CELL BIOL, V10, P443, DOI 10.1016/S0955-0674(98)80056-2; Immke DC, 2001, NAT NEUROSCI, V4, P869, DOI 10.1038/nn0901-869; INAMURA K, 1988, J CEREBR BLOOD F MET, V8, P375, DOI 10.1038/jcbfm.1988.73; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Joch M, 2007, MOL BIOL CELL, V18, P3105, DOI 10.1091/mbc.E05-11-1027; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; Koga K, 2006, EUR J NEUROSCI, V23, P1077, DOI 10.1111/j.1460-9568.2006.04610.x; Krishtal O, 2003, TRENDS NEUROSCI, V26, P477, DOI 10.1016/S0166-2236(03)00210-8; Kristian T, 2004, CELL CALCIUM, V36, P221, DOI 10.1016/j.ceca.2004.02.016; Lang AE, 2004, LANCET NEUROL, V3, P309, DOI 10.1016/S1474-4422(04)00740-9; Lee VMY, 2006, NEURON, V52, P33, DOI 10.1016/j.neuron.2006.09.026; Mandemakers W, 2007, J CELL SCI, V120, P1707, DOI 10.1242/jcs.03443; MARTONE R, 2005, DRUG DISCOV TODAY TH, V2, P299; Mccoy MK, 2006, J NEUROSCI, V26, P9365, DOI 10.1523/JNEUROSCI.1504-06.2006; Moore DJ, 2005, ANNU REV NEUROSCI, V28, P57, DOI 10.1146/annurev.neuro.28.061604.135718; Murray TK, 2003, J PHARMACOL EXP THER, V306, P752, DOI 10.1124/jpet.103.049445; Neuhoff H, 2002, J NEUROSCI, V22, P1290, DOI 10.1523/JNEUROSCI.22-04-01290.2002; Paxinos G., 2008, MOUSE BRAIN STEREOTA; Picloplichko VI, 2006, P NATL ACAD SCI USA, V103, P11376, DOI 10.1073/pnas.0600768103; Pignataro G, 2007, BRAIN, V130, P151, DOI 10.1093/brain/awl325; Ross GW, 2000, JAMA-J AM MED ASSOC, V283, P2674, DOI 10.1001/jama.283.20.2674; Schwarzschild MA, 2006, TRENDS NEUROSCI, V29, P647, DOI 10.1016/j.tins.2006.09.004; Shen J, 2004, NEURON, V43, P301, DOI 10.1016/j.neuron.2004.07.012; Siesjo BK, 1996, ADV NEUROL, V71, P209; SMITH ML, 1987, J CEREB BLOOD FLO S1, V7, pS76; Sriram K, 2006, FASEB J, V20, P670, DOI 10.1096/fj.05-5106com; Teismann P, 2001, SYNAPSE, V39, P167, DOI 10.1002/1098-2396(200102)39:2<167::AID-SYN8>3.0.CO;2-U; TOMLINSON FH, 1993, STROKE, V24, P435, DOI 10.1161/01.STR.24.3.435; Veselovsky NS, 1996, PFLUG ARCH EUR J PHY, V432, P351, DOI 10.1007/s004240050143; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6; Wemmie JA, 2003, J NEUROSCI, V23, P5496; Wemmie JA, 2006, TRENDS NEUROSCI, V29, P578, DOI 10.1016/j.tins.2006.06.014; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Xiong ZG, 2006, J MEMBRANE BIOL, V209, P59, DOI 10.1007/s00232-005-0840-x; Xiong ZG, 2004, CELL, V118, P687, DOI 10.1016/j.cell.2004.08.026; Xu K, 2002, NEUROSCI LETT, V322, P13, DOI 10.1016/S0304-3940(02)00069-1; Yao H, 2004, CELL CALCIUM, V36, P247, DOI 10.1016/j.ceca.2004.02.013; Yermolaieva O, 2004, P NATL ACAD SCI USA, V101, P6752, DOI 10.1073/pnas.0308636100; Zygun DA, 2004, NEUROSURGERY, V55, P877, DOI 10.1227/01.NEU.0000137658.14906.E4	58	80	84	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	SEP	2008	31	3					334	341		10.1016/j.nbd.2008.05.008			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	343NY	WOS:000258862000006	18606547				2022-02-06	
J	Andrews, PJD; Citerio, G; Longhi, L; Polderman, K; Sahuquillo, J; Vajkoczy, P				Andrews, Peter J. D.; Citerio, Giuseppe; Longhi, Luca; Polderman, Kees; Sahuquillo, Juan; Vajkoczy, Peter		NICEM Section European Soc Intensi	NICEM consensus on neurological monitoring in acute neurological disease	INTENSIVE CARE MEDICINE			English	Article						intracranial pressure monitoring; cerebral perfusion pressure; brain tissue oxygenation; microdialysis	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; CEREBRAL PERFUSION-PRESSURE; TISSUE OXYGEN-TENSION; INTRACRANIAL-PRESSURE; MICRODIALYSIS; CARE; AUTOREGULATION; EXPERIENCE	This manuscript summarises the consensus on neuromonitoring in neuro-intensive care promoted and organised by the Neuro-Intensive Care and Emergency Medicine (NICEM) Section of the European Society of Intensive Care Medicine (ESICM). It is expected that continuous monitoring using multi-modal techniques will help to overcome the limitations of each individual method and will provide a better diagnosis. More specific treatment can then be applied; however, it remains to be determined which combination of parameters is optimal. The questions discussed and addressed in this manuscript are: (1) Who should have ICP monitoring and for how long? (2) What ICP technologies are available and what are their relative advantages/disadvantages? (3) Should CPP monitoring and autoregulation testing be used? (4) When should brain tissue oxygen tension (PbrO(2)) be monitored? (5) Should structurally normal or abnormal tissue be monitored with PbrO(2)? (6) Should microdialysis be considered in complex cases? It is hoped that this document will prove useful to clinicians working in NICU and also to those developing specialist NICU services within their hospital practice.	[Andrews, Peter J. D.] Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland; [Citerio, Giuseppe] San Gerardo Hosp, Dept Perioperat Med & Intens Care, Neuroanesthesia & Neurosurg Intens Care Unit, Monza, Italy; [Longhi, Luca] Univ Milan, Osped Maggiore Policlin, Fdn IRCCS, Dept Anaesthesia & Crit Care Med,Neurosurg Intens, Milan, Italy; [Polderman, Kees] Univ Utrecht, Med Ctr, Dept Intens Care, Utrecht, Netherlands; [Sahuquillo, Juan] Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Div Neurosurg, E-08193 Barcelona, Spain; [Vajkoczy, Peter] Charite, Dept Neurosurg, D-13353 Berlin, Germany		Andrews, PJD (corresponding author), Western Gen Hosp, Crewe Rd S, Edinburgh EH4 2XU, Midlothian, Scotland.	p.andrews@ed.ac.uk	Citerio, Giuseppe/B-1839-2015; Polderman, Kees H/K-3623-2012; Sahuquillo, Juan/B-3577-2008; Viani, Rafael/V-1196-2018; Longhi, Luca/AAF-9903-2021	Citerio, Giuseppe/0000-0002-5374-3161; Sahuquillo, Juan/0000-0003-0713-5875; Longhi, Luca/0000-0001-9894-8788			Andrews PJD, 2004, INTENS CARE MED, V30, P1730, DOI 10.1007/s00134-004-2376-4; Bardt TF, 1998, ACT NEUR S, V71, P153; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; *BRAIN TRAUM FDN, 2007, J NEUROTRAUMA S1, V24, pS55, DOI DOI 10.1089/NEU.2007.9988; *BRAIN TRAUM FDN, 2007, J NEUROTRAUMA S1, V24, pS45; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Brain Trauma Foundation: American association of Neurological surgeons, 2007, J NEUROTRAUMA S1, V24, pS59; Chaurasia CS, 2007, J CLIN PHARMACOL, V47, P589, DOI 10.1177/0091270006299091; Citerio G, 2004, INTENS CARE MED, V30, P1882, DOI 10.1007/s00134-004-2377-3; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Czosnyka M, 2006, ACTA NEUROCHIR SUPPL, V96, P114; Czosnyka M, 2000, ACT NEUR S, V76, P483; Czosnyka M, 1996, NEUROSURGERY, V38, P219, DOI 10.1097/00006123-199601000-00053; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Diringer MN, 2004, CRIT CARE MED, V32, P1489, DOI 10.1097/01.CCM.0000129484.61912.84; Fergusen S, 2007, NEUROSURGERY, V60, P658, DOI 10.1227/01.NEU.0000255396.23280.31; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gupta AK, 2002, J NEUROSURG, V96, P263, DOI 10.3171/jns.2002.96.2.0263; Hoelper BM, 2003, NEUROSURGERY, V52, P970, DOI 10.1227/01.NEU.0000053033.98317.A3; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Jaeger M, 2006, CRIT CARE MED, V34, P1783, DOI 10.1097/01.CCM.0000218413.51546.9E; Kett-White R, 2002, NEUROSURGERY, V50, P1213, DOI 10.1097/00006123-200206000-00008; Kett-White R, 2002, J NEUROSURG, V96, P1013, DOI 10.3171/jns.2002.96.6.1013; Koskinen LOD, 2005, NEUROSURGERY, V56, P693, DOI 10.1227/01.NEU.0000156609.95596.24; Longhi L, 2007, INTENS CARE MED, V33, P2136, DOI 10.1007/s00134-007-0845-2; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; MAAS AIR, 1993, ACTA NEUROCHIR, P50; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Morgalla MH, 1999, J MED ENG TECHNOL, V23, P144; Nortje J, 2006, BRIT J ANAESTH, V97, P95, DOI 10.1093/bja/ael137; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Scheufler KM, 2002, ANESTH ANALG, V95, P1042, DOI 10.1097/00000539-200210000-00046; SIGGAARDANDERSEN O, 1995, ACTA ANAESTH SCAND, V39, P137; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Stocchetti N, 1998, ACT NEUR S, V71, P162; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van den Brink WA, 1998, ACT NEUR S, V71, P190; van Hulst RA, 2002, INTENS CARE MED, V28, P68, DOI 10.1007/s00134-001-1157-6; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; ZAUNER A, 1995, NEUROSURGERY, V37, P1168, DOI 10.1227/00006123-199512000-00017; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	50	80	84	1	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	AUG	2008	34	8					1362	1370		10.1007/s00134-008-1103-y			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	330IH	WOS:000257933700003	18398598				2022-02-06	
J	Hou, SP; Duale, H; Cameron, AA; Abshire, SM; Lyttle, TS; Rabchevsky, AG				Hou, Shaoping; Duale, Hanad; Cameron, Adrian A.; Abshire, Sarah M.; Lyttle, Travis S.; Rabchevsky, Alexander G.			Plasticity of lumbosacral propriospinal neurons is associated with the development of autonomic dysreflexia after thoracic spinal cord transection	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						dorsal gray commissure; dorsal commissural nucleus; neuronal tracers; c-Fos; hypertension; stereology; colorectal distension	SYMPATHETIC PREGANGLIONIC NEURONS; PHASEOLUS-VULGARIS-LEUKOAGGLUTININ; GLUTAMATE-IMMUNOREACTIVE SYNAPSES; DORSAL COMMISSURAL NUCLEUS; TRAUMATIC BRAIN-INJURY; C-FOS PROTEIN; CYTOARCHITECTONIC ORGANIZATION; COMPRESSION INJURY; CORRELATED NEURONS; PRIMARY AFFERENTS	Complete thoracic (T) spinal cord injury (SCI) above the T6 level typically results in autonomic dysreflexia, an abnormal hypertensive condition commonly triggered by nociceptive stimuli below the level of SCI. Overexpression of nerve growth factor in the lumbosacral spinal cord induces profuse sprouting of nociceptive pelvic visceral afferent fibers that correlates with increased hypertension in response to noxious colorectal distension. After complete T4 SCI, we evaluated the plasticity of propriospinal neurons conveying visceral input rostrally to thoracic sympathetic preganglionic neurons. The anterograde tracer biotinylated dextran amine (BDA) was injected into the lumbosacral dorsal gray commissure (DGC) of injured/nontransected rats immediately after injury (acute) or 2 weeks later (delayed). At 1 or 2 weeks after delayed or acute injections, respectively, a higher density (P < 0.05) of BDA(+) fibers was found in thoracic dorsal gray matter of injured vs. nontransected spinal cords. For corroboration, fast blue (FB) or cholera toxin subunit beta (CTb) was injected into the T9 dorsal horns 2 weeks postinjury/nontransection. After 1 week transport, more retrogradely labeled (P G 0.05) DGC propriospinal neurons (T13-S1) were quantified in injured vs. nontransected cords. We also monitored immediate early gene c-fos expression following colorectal distension and found increased (P < 0.01) c-Fos(+) cell numbers throughout the DGC after injury. Collectively, these results imply that, in conjunction with local primary afferent fiber plasticity, injury-induced sprouting of DGC neurons may be a key constituent in relaying visceral sensory input to sympathetic preganglionic neurons that elicit autonomic dysreflexia after high thoracic SCI.	[Hou, Shaoping; Duale, Hanad; Cameron, Adrian A.; Abshire, Sarah M.; Lyttle, Travis S.; Rabchevsky, Alexander G.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Hou, Shaoping; Duale, Hanad; Rabchevsky, Alexander G.] Univ Kentucky, Dept Physiol, Lexington, KY 40536 USA		Rabchevsky, AG (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, B471,Biomed & Biol Sci Res Bldg,741 S Limestone S, Lexington, KY 40536 USA.	agrab@uky.edu	Rabchevsky, Alexander/AAQ-2451-2021	Rabchevsky, Alexander/0000-0002-1991-0915	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30 NS051220, R01 NS049901-01, R01 NS049901] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049901, P30NS051220] Funding Source: NIH RePORTER		ABERCROMBIE M, 1946, J ANAT, V80, P37; AlChaer ED, 1996, J NEUROPHYSIOL, V76, P2675, DOI 10.1152/jn.1996.76.4.2675; ANDERSON CR, 1994, J NEUROSCI METH, V53, P137, DOI 10.1016/0165-0270(94)90170-8; BACON SJ, 1988, J AUTONOM NERV SYST, V24, P97, DOI 10.1016/0165-1838(88)90140-3; Brown A, 2004, EXP NEUROL, V188, P115, DOI 10.1016/j.expneurol.2004.03.017; Cameron AA, 2006, J NEUROSCI, V26, P2923, DOI 10.1523/JNEUROSCI.4390-05.2006; Chau D, 2000, J NEUROPHYSIOL, V83, P2699, DOI 10.1152/jn.2000.83.5.2699; CHUNG KS, 1983, J COMP NEUROL, V217, P47, DOI 10.1002/cne.902170105; CUELLO AC, 1984, J HISTOCHEM CYTOCHEM, V32, P947, DOI 10.1177/32.9.6086744; DAMPNEY RAL, 1994, PHYSIOL REV, V74, P323, DOI 10.1152/physrev.1994.74.2.323; DEBIASI S, 1988, P NATL ACAD SCI USA, V85, P7820; Diaz-Ruiz A, 2007, NEUROCHEM RES, V32, P57, DOI 10.1007/s11064-006-9225-5; DIETZ GW, 1980, J BIOL CHEM, V255, P612; DRAGUNOW M, 1989, J NEUROSCI METH, V29, P261, DOI 10.1016/0165-0270(89)90150-7; Grider MH, 2006, J NEUROSCI METH, V155, P172, DOI 10.1016/j.jneumeth.2005.12.021; Guillery RW, 2002, J COMP NEUROL, V447, P1, DOI 10.1002/cne.10221; HANCOCK MB, 1979, J COMP NEUROL, V183, P65, DOI 10.1002/cne.901830106; Hirshberg RM, 1996, PAIN, V67, P291, DOI 10.1016/0304-3959(96)03127-2; HOLETS V, 1982, NEUROSCIENCE, V7, P1155, DOI 10.1016/0306-4522(82)91123-X; HOSOYA Y, 1994, EXP BRAIN RES, V98, P21; Karlsson AK, 1999, SPINAL CORD, V37, P383, DOI 10.1038/sj.sc.3100867; KRASSIOUKOV AV, 1995, AM J PHYSIOL-HEART C, V268, pH2077, DOI 10.1152/ajpheart.1995.268.5.H2077; Krassioukov AV, 2002, J NEUROTRAUM, V19, P1521, DOI 10.1089/089771502762300193; Krassioukov AV, 1996, NEUROSCIENCE, V70, P211, DOI 10.1016/0306-4522(95)00294-S; Kratskin IL, 1997, BRAIN RES BULL, V44, P199, DOI 10.1016/S0361-9230(97)00092-0; Krenz NR, 1998, NEUROSCIENCE, V85, P443, DOI 10.1016/S0306-4522(97)00622-2; Krenz NR, 1998, NEUROSCI LETT, V243, P61, DOI 10.1016/S0304-3940(98)00101-3; Landrum LM, 2002, NEUROSCIENCE, V110, P569, DOI 10.1016/S0306-4522(01)00548-6; LINDAN R, 1980, PARAPLEGIA, V18, P285, DOI 10.1038/sc.1980.51; Llewellyn-Smith IJ, 1998, J AUTONOM NERV SYST, V71, P96, DOI 10.1016/S0165-1838(98)00069-1; LLEWELLYNSMITH IJ, 1992, BRAIN RES, V581, P67, DOI 10.1016/0006-8993(92)90345-A; Lu Y, 2001, J COMP NEUROL, V437, P156, DOI 10.1002/cne.1276; Marsh DR, 2002, J NEUROTRAUM, V19, P1531, DOI 10.1089/089771502762300201; MASSON RL, 1991, J COMP NEUROL, V307, P120, DOI 10.1002/cne.903070111; Matsushita M, 1998, EXP BRAIN RES, V119, P356, DOI 10.1007/s002210050351; Mayorov DN, 2001, J NEUROTRAUM, V18, P727, DOI 10.1089/089771501750357663; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; MINSON JB, 1994, BRAIN RES, V646, P44, DOI 10.1016/0006-8993(94)90056-6; MOLANDER C, 1989, J COMP NEUROL, V289, P375, DOI 10.1002/cne.902890303; MOLANDER C, 1984, J COMP NEUROL, V230, P133, DOI 10.1002/cne.902300112; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; NESS TJ, 1987, J NEUROPHYSIOL, V57, P1867, DOI 10.1152/jn.1987.57.6.1867; Novikov LN, 2001, J NEUROSCI METH, V112, P145, DOI 10.1016/S0165-0270(01)00461-7; Pan B, 2007, AM J PHYSIOL-REG I, V293, pR178, DOI 10.1152/ajpregu.00044.2007; Pan BH, 2005, J NEUROTRAUM, V22, P1399, DOI 10.1089/neu.2005.22.1399; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; PASCUAL JI, 1993, J UROLOGY, V150, P500, DOI 10.1016/S0022-5347(17)35535-0; Petko M, 2000, J COMP NEUROL, V422, P312, DOI 10.1002/(SICI)1096-9861(20000626)422:2<312::AID-CNE11>3.0.CO;2-A; Preston GA, 1996, MOL CELL BIOL, V16, P211; Rabchevsky AG, 2006, PROG BRAIN RES, V152, P265, DOI 10.1016/S0079-6123(05)52017-X; Rabchevsky AG, 2007, GLIA, V55, P831, DOI 10.1002/glia.20508; Rodriguez MJ, 2005, J NEUROCHEM, V95, P651, DOI 10.1111/j.1471-4159.2005.03394.x; ROMAGNANO MA, 1987, J COMP NEUROL, V266, P319, DOI 10.1002/cne.902660303; SAGAR SM, 1988, SCIENCE, V240, P1328, DOI 10.1126/science.3131879; Schwartz-Bloom RD, 2001, J NEUROCHEM, V77, P353, DOI 10.1046/j.1471-4159.2001.00274.x; Seki Y, 2008, J COMP NEUROL, V506, P93, DOI 10.1002/cne.21528; SNOW JC, 1978, PARAPLEGIA, V15, P327, DOI 10.1038/sc.1977.49; Steward O., 2007, NEURON, V38, P187, DOI DOI 10.1016/J.NEURON.2007.04.004; Steward O, 2007, NEURON, V54, P191, DOI 10.1016/j.neuron.2007.04.004; Sun D, 2007, J COMP NEUROL, V505, P92, DOI 10.1002/cne.21478; Tang XR, 2003, BRAIN RES, V976, P185, DOI 10.1016/S0006-8993(03)02601-5; THOR KB, 1994, NEUROREPORT, V5, P1673, DOI 10.1097/00001756-199408150-00033; TODD AJ, 1989, NEUROSCIENCE, V31, P799, DOI 10.1016/0306-4522(89)90442-9; Vizzard MA, 2000, AM J PHYSIOL-REG I, V279, pR295, DOI 10.1152/ajpregu.2000.279.1.R295; Wang CC, 1999, J COMP NEUROL, V415, P341, DOI 10.1002/(SICI)1096-9861(19991220)415:3<341::AID-CNE3>3.0.CO;2-7; Weaver LC, 2001, J NEUROTRAUM, V18, P1107, DOI 10.1089/08977150152693782; Weaver LC, 1997, NEUROSCIENCE, V81, P535, DOI 10.1016/S0306-4522(97)00151-6; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Whisler RL, 1997, CELL IMMUNOL, V175, P41, DOI 10.1006/cimm.1996.1048; Xu YJ, 2006, BRAIN RES, V1087, P175, DOI 10.1016/j.brainres.2006.03.003; Yaici ED, 2002, INT J IMPOT RES, V14, P151, DOI 10.1038/sj.ijir.3900809; Yaici ED, 2002, NEUROSCIENCE, V114, P945, DOI 10.1016/S0306-4522(02)00367-6; Ye Y, 2000, J COMP NEUROL, V420, P127	73	80	81	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9967	1096-9861		J COMP NEUROL	J. Comp. Neurol.	AUG 1	2008	509	4					382	399		10.1002/cne.21771			18	Neurosciences; Zoology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Zoology	323XS	WOS:000257482400004	18512692	Green Accepted			2022-02-06	
J	Turegano-Fuentes, F; Caba-Doussoux, P; Jover-Navalon, JM; Martin-Perez, E; Fernandez-Luengas, D; Diez-Valladares, L; Perez-Diaz, D; Yuste-Garcia, P; Labajo, HG; Rios-Blanco, R; Hernando-Trancho, F; Nisa, FGM; Sanz-Sanchez, M; Garcia-Fuentes, C; Martinez-Virto, A; Leon-Baltasar, JL; Vazquez-Estevez, J				Turegano-Fuentes, Fernando; Caba-Doussoux, P.; Jover-Navalon, J. M.; Martin-Perez, E.; Fernandez-Luengas, D.; Diez-Valladares, L.; Perez-Diaz, D.; Yuste-Garcia, P.; Guadalajara Labajo, H.; Rios-Blanco, R.; Hernando-Trancho, F.; Garcia-Moreno Nisa, F.; Sanz-Sanchez, M.; Garcia-Fuentes, C.; Martinez-Virto, A.; Leon-Baltasar, J. L.; Vazquez-Estevez, J.			Injury patterns from major urban terrorist bombings in trains: The madrid experience	WORLD JOURNAL OF SURGERY			English	Article							BLAST; EXPLOSION; TRAUMA	Background Terrorist urban mass casualty incidents (MCI) in the last 3 years have targeted commuter trains at rush hour, producing large numbers of casualties. Civilian care providers are usually not familiar with the types of blast injuries sustained by victims of these MCI. Methods We focus on the injury patterns sustained by casualties of the Madrid, 11 March 2004, terrorist bombings, at the seven hospitals that received most victims. Data were gathered of casualties who had injuries other than superficial bruises, transient hearing loss from barotrauma without eardrum perforation, and/or emotional shock. The degree of severity in critical patients was assessed with the ISS. Results The bombings resulted in 177 immediate fatalities, 9 early deaths, and 5 late deaths. Most survivors had noncritical injuries, but 72 (14%) of 512 casualties assessed had an Injury Severity Score (ISS) > 15. The critical mortality rate was of 19.5%. The most frequently injured body regions were the head-neck and face. Almost 50% of casualties had ear-drum perforation, and 60% of them were bilateral. There were 43 documented cases of blast lung injury, with a survival rate of 88.3%. Maxillofacial and open long-bone fractures were most prevalent. Gustillo's grade III of severity predominated in tibia-fibular and humeral fractures. Upper thoracic fractures (D1-6 segment) represented 65% of all vertebral fractures and were associated with severe blast to the torso. Severe burns were uncommon. Eye injuries were frequent, although most were of a mild-to-moderate severity. Abdominal visceral lesions were present in 25 (5%) patients. A multidisciplinary approach was necessary in most operated patients, and orthopedic trauma procedures accounted for 50% of the caseload in the first 24 h. Conclusions Ninety-three percent of the fatalities of the Madrid trains terrorist bombings were immediate, and most survivors had noncritical injuries. Closed doors increased the immediate fatality rate in the trains. Severely wounded casualties presented specific patterns of injuries, some of them life-threatening and unusual in other types of trauma mechanisms. Ear-lobe amputations and upper thoracic spine fractures were markers of critical injuries.	[Turegano-Fuentes, Fernando; Perez-Diaz, D.; Sanz-Sanchez, M.; Vazquez-Estevez, J.] Hosp Gen Gregorio Maranon, Dept Gen Surg, Madrid 28040, Spain; [Caba-Doussoux, P.; Yuste-Garcia, P.; Garcia-Fuentes, C.; Leon-Baltasar, J. L.] Hosp 12 Octubre, E-28041 Madrid, Spain; [Jover-Navalon, J. M.; Rios-Blanco, R.] Hosp Getafe, Madrid, Spain; [Martin-Perez, E.] Hosp Princesa, Madrid, Spain; [Fernandez-Luengas, D.; Guadalajara Labajo, H.; Martinez-Virto, A.] Hosp La Paz, Madrid, Spain; [Diez-Valladares, L.; Hernando-Trancho, F.] Hosp Clin Madrid, Madrid, Spain; [Garcia-Moreno Nisa, F.] Hosp Ramon & Cajal, E-28034 Madrid, Spain		Turegano-Fuentes, F (corresponding author), Hosp Gen Gregorio Maranon, Dept Gen Surg, Plaza Ciudad Viena 6, Madrid 28040, Spain.	fturegano.hgugm@salud.madrid.org; pedrocabado@gmail.com; josemjover@aecirujanos.es; elemartin203@aecirujanos.es; dfernandezl.hulp@salud.madrid.org; lidiez@hotmail.com; lolaperezdiaz@hotmail.com; pyuste.hdoc@salud.madrid.org; h.guadalajara@yahoo.es; raquelriosblanco@yahoo.es; fhtrancho@hotmail.com; plpunisa@mixmail.com; mersanz@mundofree.com; cgarciaf.hdoc@salud.madrid.org; ammvirto@yahoo.es; jleonb@terra.es; jvazqueze.hgugm@salud.madrid.org	MARTIN-PEREZ, ELENA/ABC-5039-2020; PEREZ, ELENA MARTIN/D-5735-2018; nisa, francisca f garcia-moreno/J-3906-2015; Luengas, David Fernandez/ABD-2527-2020	MARTIN-PEREZ, ELENA/0000-0002-4933-738X; PEREZ, ELENA MARTIN/0000-0002-4933-738X; nisa, francisca f garcia-moreno/0000-0001-5360-0577; Guadalajara, Hector/0000-0001-6297-9347; garcia-moreno nisa, francisca/0000-0002-2194-4647			Almogy G, 2006, J AM COLL SURGEONS, V202, P313, DOI 10.1016/j.jamcollsurg.2005.10.011; Almogy G, 2004, ANN SURG, V239, P295, DOI 10.1097/01.sla.0000114014.63423.55; Aschkenasy-Steuer G, 2005, CRIT CARE, V9, P490, DOI 10.1186/cc3762; Avidan V, 2005, AM J SURG, V190, P927, DOI 10.1016/j.amjsurg.2005.08.022; Aylwin CJ, 2006, LANCET, V368, P2219, DOI 10.1016/S0140-6736(06)69896-6; Born CT, 2005, SCAND J SURG, V94, P279, DOI 10.1177/145749690509400406; Cooper G J, 1989, J R Army Med Corps, V135, P58; Cushman JG, 2003, J TRAUMA, V54, P147, DOI 10.1097/00005373-200301000-00018; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Einav S, 2006, ANN SURG, V243, P533, DOI 10.1097/01.sla.0000206417.58432.48; ELKHOURY GY, 1993, AM J ROENTGENOL, V160, P95, DOI 10.2214/ajr.160.1.8416656; Frykberg ER, 2002, J TRAUMA, V53, P201, DOI 10.1097/00005373-200208000-00001; GUSTILO RB, 1976, J BONE JOINT SURG AM, V58, P453, DOI 10.2106/00004623-197658040-00004; Gutierrez de Ceballos J Peral, 2005, Crit Care Med, V33, pS107, DOI 10.1097/01.CCM.0000151072.17826.72; Hamilton-Farrell M, 2004, INJURY, V35, P359, DOI 10.1016/j.injury.2003.08.020; KATZ E, 1989, ANN SURG, V209, P484, DOI 10.1097/00000658-198904000-00016; KIRSCHENBAUM L, 2001, CRIT CARE MED, V33, pS48; Koizumi Munehisa, 2002, Spine (Phila Pa 1976), V27, pE467, DOI 10.1097/00007632-200211010-00020; Kuhn F, 1996, OPHTHALMOLOGY, V103, P240; Leibovici D, 1996, J TRAUMA, V41, P1030, DOI 10.1097/00005373-199612000-00015; Lockey DJ, 2005, RESUSCITATION, V66, pIX, DOI 10.1016/j.resuscitation.2005.07.005; MELLOR SG, 1992, WORLD J SURG, V16, P893, DOI 10.1007/BF02066988; Miguel-Tobal JJ, 2006, J TRAUMA STRESS, V19, P69, DOI 10.1002/jts.20091; Peleg K, 2003, AM J EMERG MED, V21, P258, DOI 10.1016/S0735-6757(03)00043-3; Peleg K, 2004, ANN SURG, V239, P311, DOI 10.1097/01.sla.0000114012.84732.be; Pizov R, 1999, CHEST, V115, P165, DOI 10.1378/chest.115.1.165; Stein M, 2005, SCAND J SURG, V94, P286, DOI 10.1177/145749690509400407; Stein M, 1999, SURG CLIN N AM, V79, P1537, DOI 10.1016/S0039-6109(05)70091-8; Wong JML, 2006, J TRAUMA, V60, P402, DOI 10.1097/01.ta.0000203715.31280.65; ZWIMPFER TJ, 1990, J NEUROSURG, V72, P894, DOI 10.3171/jns.1990.72.6.0894	30	80	84	0	2	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0364-2313	1432-2323		WORLD J SURG	World J.Surg.	JUN	2008	32	6					1168	1175		10.1007/s00268-008-9557-1			8	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	303JN	WOS:000256036900033	18365272				2022-02-06	
J	Benton, RL; Maddie, MA; Minnillo, DR; Hagg, T; Whittemore, SR				Benton, Richard L.; Maddie, Melissa A.; Minnillo, Danielle R.; Hagg, Theo; Whittemore, Scott R.			Griffonia simplicifolia isolectin B4 identifies a specific subpopulation of angiogenic blood vessels following contusive spinal cord injury in the adult mouse	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						neovascularization; lectin; microvascular; endothelial; tight junction; adaptive angiogenesis	BRAIN-BARRIER BREAKDOWN; TIGHT JUNCTION PROTEINS; ENDOTHELIAL-CELLS; LESION DEVELOPMENT; NERVOUS-SYSTEM; LECTIN-BINDING; RAT; EXPRESSION; LOCALIZATION; SURFACE	After traumatic spinal cord injury (SCI), disruption and plasticity of the microvasculature within injured spinal tissue contribute to the pathological cascades associated with the evolution of both primary and secondary injury. Conversely, preserved vascular function most likely results in tissue sparing and subsequent functional recovery. It has been difficult to identify subclasses of damaged or regenerating blood vessels at the cellular level. Here, adult mice received a single intravenous injection of the Griffonia simplicifolia isolectin B4 (1134) at 1-28 days following a moderate thoracic (T9) contusion. Vascular binding of 1134 was maximally observed 7 days following injury, a time associated with multiple pathologic aspects of the intrinsic adaptive angiogenesis, with numbers of 1134 vascular profiles decreasing by 21 days postinjury. Quantitative assessment of 1134 binding shows that it occurs within the evolving lesion epicenter, with affected vessels expressing a temporally specific dysfunctional tight junctional phenotype as assessed by occludin, claudin-5, and ZO-1 immunoreactivities. Taken together, these results demonstrate that intravascular lectin delivery following SCI is a useful approach not only for observing the functional status of neovascular formation but also for definitively identifying specific subpopulations of reactive spinal microvascular elements. J. Comp. Neurol. 507:1031-1052, 2008. (c) 2007 Wiley-Liss, Inc.	[Benton, Richard L.; Maddie, Melissa A.; Minnillo, Danielle R.; Hagg, Theo; Whittemore, Scott R.] Univ Louisville, Sch Med, Kentucky Spinal Cord Injury Res Ctr, Louisville, KY 40292 USA; [Maddie, Melissa A.; Hagg, Theo] Univ Louisville, Sch Med, Dept Neurol Surg, Louisville, KY 40292 USA; [Benton, Richard L.; Whittemore, Scott R.] Univ Louisville, Sch Med, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA; [Minnillo, Danielle R.] Univ Louisville, Sch Med, Summer Res Scholar Program, Louisville, KY 40292 USA; [Hagg, Theo] Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA		Whittemore, SR (corresponding author), Univ Louisville, Sch Med, Kentucky Spinal Cord Injury Res Ctr, 511 S Floyd St,MDR 616, Louisville, KY 40292 USA.	swhittemore@louisville.edu			NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR015576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045734] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20 RR015576, RR15576, P20 RR015576-09] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS045734-04, NS045734, R01 NS045734] Funding Source: Medline		Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Alliot F, 1999, J NEUROSCI RES, V58, P367; ALROY J, 1987, HISTOCHEMISTRY, V86, P603, DOI 10.1007/BF00489554; Balding P, 1975, Z Immunitatsforsch Exp Klin Immunol, V145, P156; Bao F, 2005, J NEUROCHEM, V94, P1361, DOI 10.1111/j.1471-4159.2005.03280.x; Bazzoni G, 2004, PHYSIOL REV, V84, P869, DOI 10.1152/physrev.00035.2003; BELLONI PN, 1988, J CELL PHYSIOL, V136, P398, DOI 10.1002/jcp.1041360303; Bolton SJ, 1998, NEUROSCIENCE, V86, P1245, DOI 10.1016/S0306-4522(98)00058-X; BRABEC RK, 1980, P NATL ACAD SCI-BIOL, V77, P477, DOI 10.1073/pnas.77.1.477; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; CASELLA GT, 2006, IN PRESS EXP NEUROL; Casella GTB, 2002, EXP NEUROL, V173, P63, DOI 10.1006/exnr.2001.7827; Chan-Ling T, 2004, AM J PATHOL, V165, P1301, DOI 10.1016/S0002-9440(10)63389-5; Chi L, 2007, NEUROSCIENCE, V144, P991, DOI 10.1016/j.neuroscience.2006.09.064; Debbage PL, 1998, J HISTOCHEM CYTOCHEM, V46, P627, DOI 10.1177/002215549804600508; Dobrogowska DH, 2004, J MOL HISTOL, V35, P529, DOI 10.1007/s10735-004-1318-3; Edsbagge J, 2005, DEVELOPMENT, V132, P1085, DOI 10.1242/dev.01643; FATEHI MI, 1987, BRAIN RES, V415, P30, DOI 10.1016/0006-8993(87)90266-6; Franz S, 2006, CYTOM PART A, V69A, P230, DOI 10.1002/cyto.a.20206; Fujiki M, 1996, J COMP NEUROL, V371, P469; GALILI U, 1988, J BIOL CHEM, V263, P17755; Ge SJ, 2006, J NEUROIMMUNOL, V177, P209, DOI 10.1016/j.jneuroim.2006.05.012; Glaser J, 2004, J NEUROSCI RES, V77, P701, DOI 10.1002/jnr.20204; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; Hamm S, 2004, CELL TISSUE RES, V315, P157, DOI 10.1007/s00441-003-0825-y; Han HS, 2005, CURR NEUROVASC RES, V2, P409, DOI 10.2174/156720205774962647; HAYES CE, 1974, J BIOL CHEM, V249, P1904; Hirasawa T, 2005, J NEUROSCI RES, V81, P357, DOI 10.1002/jnr.20480; Hsu JYC, 2006, J NEUROSCI, V26, P9841, DOI 10.1523/JNEUROSCI.1993-06.2006; Hughes S, 2000, MICROCIRCULATION, V7, P317, DOI 10.1038/sj.mn.7300119; Hughes S, 2006, NEUROBIOL AGING, V27, P1838, DOI 10.1016/j.neurobiolaging.2005.10.021; Iruela-Arispe ML, 1999, MICROCIRCULATION, V6, P127, DOI 10.1080/713773947; Jaeger CB, 1997, EXP NEUROL, V144, P381, DOI 10.1006/exnr.1996.6405; Jakovcevski I, 2007, J NEUROSCI, V27, P7222, DOI 10.1523/JNEUROSCI.0739-07.2007; Jilani SM, 2003, J HISTOCHEM CYTOCHEM, V51, P597, DOI 10.1177/002215540305100505; Kigerl KA, 2006, J COMP NEUROL, V494, P578, DOI 10.1002/cne.20827; Kokovay E, 2006, J CEREBR BLOOD F MET, V26, P545, DOI 10.1038/sj.jcbfm.9600214; KOYANAGI I, 1993, NEUROSURGERY, V33, P285, DOI 10.1227/00006123-199308000-00016; LAITINEN L, 1987, HISTOCHEM J, V19, P225, DOI 10.1007/BF01680633; Lippoldt A, 2000, BRAIN RES, V885, P251, DOI 10.1016/S0006-8993(00)02954-1; Lowe JB, 2003, CURR OPIN CELL BIOL, V15, P531, DOI 10.1016/j.ceb.2003.08.002; Loy DN, 2002, J COMP NEUROL, V445, P308, DOI 10.1002/cne.10168; Ma MH, 2001, EXP NEUROL, V169, P239, DOI 10.1006/exnr.2001.7679; Mark KS, 2002, AM J PHYSIOL-HEART C, V282, pH1485, DOI 10.1152/ajpheart.00645.2001; Mautes AEM, 2000, PHYS THER, V80, P673, DOI 10.1093/ptj/80.7.673; Mazzetti S, 2004, EUR J HISTOCHEM, V48, P423; McEwen BS, 2004, EUR J PHARMACOL, V490, P13, DOI 10.1016/j.ejphar.2004.02.041; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; MORIOKA T, 1993, J COMP NEUROL, V327, P123, DOI 10.1002/cne.903270110; NAG S, 1984, ACTA NEUROPATHOL, V63, P276, DOI 10.1007/BF00687333; Nico B, 1998, ANAT EMBRYOL, V197, P305, DOI 10.1007/s004290050140; Nico B, 2000, DEV BRAIN RES, V119, P231, DOI 10.1016/S0165-3806(99)00177-7; Niethammer AG, 2002, NAT MED, V8, P1369, DOI 10.1038/nm794; NISHIDA S, 1986, HISTOL HISTOPATHOL, V1, P69; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; Noble LJ, 1996, J COMP NEUROL, V376, P542; NOBLE LJ, 1989, BRAIN RES, V482, P57, DOI 10.1016/0006-8993(89)90542-8; NOBLE LJ, 1985, EXP NEUROL, V88, P135, DOI 10.1016/0014-4886(85)90119-0; NOBLE LJ, 1989, EXP NEUROL, V103, P34, DOI 10.1016/0014-4886(89)90182-9; Noguera-Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355; Oatway MA, 2005, J NEUROSCI, V25, P637, DOI 10.1523/JNEUROSCI.3960-04.2005; PAPAIOANNOU VE, 1993, LAB ANIM SCI, V43, P189; Pardridge WM, 2007, DRUG DISCOV TODAY, V12, P54, DOI 10.1016/j.drudis.2006.10.013; Perdiki M, 1998, ACTA NEUROPATHOL, V96, P8, DOI 10.1007/s004010050854; PETERS BP, 1979, EXP CELL RES, V120, P321, DOI 10.1016/0014-4827(79)90392-6; PONDER BAJ, 1983, DEV BIOL, V96, P535, DOI 10.1016/0012-1606(83)90191-4; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Raub TJ, 1996, AM J PHYSIOL-CELL PH, V271, pC495, DOI 10.1152/ajpcell.1996.271.2.C495; Richter MW, 2005, J NEUROSCI, V25, P10700, DOI 10.1523/JNEUROSCI.3632-05.2005; Sennino B, 2007, CANCER RES, V67, P7358, DOI 10.1158/0008-5472.CAN-07-0293; Stamatovic SM, 2005, J CEREBR BLOOD F MET, V25, P593, DOI 10.1038/sj.jcbfm.9600055; STREIT WJ, 1985, J HISTOCHEM CYTOCHEM, V33, P1042, DOI 10.1177/33.10.4045182; Thurston G, 1996, AM J PHYSIOL-HEART C, V271, pH2547, DOI 10.1152/ajpheart.1996.271.6.H2547; Vinores SA, 2003, DEV BRAIN RES, V140, P169, DOI 10.1016/S0165-3806(02)00581-3; Vischer UM, 2006, J THROMB HAEMOST, V4, P1186, DOI 10.1111/j.1538-7836.2006.01949.x; Vorbrodt AW, 2003, BRAIN RES REV, V42, P221, DOI 10.1016/S0165-0173(03)00177-2; VORBRODT AW, 1986, DEV BRAIN RES, V29, P69, DOI 10.1016/0165-3806(86)90083-0; VORBRODT AW, 1986, ACTA NEUROPATHOL, V70, P103, DOI 10.1007/BF00691427; Whetstone WD, 2003, J NEUROSCI RES, V74, P227, DOI 10.1002/jnr.10759; Willis CL, 2004, GLIA, V48, P1, DOI 10.1002/glia.20049; Wolburg H, 2003, ACTA NEUROPATHOL, V105, P586, DOI 10.1007/s00401-003-0688-z; Yamauchi T, 2004, J NEUROTRAUM, V21, P1017, DOI 10.1089/0897715041651042	82	80	81	2	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9967	1096-9861		J COMP NEUROL	J. Comp. Neurol.	MAR 1	2008	507	1					1031	1052		10.1002/cne.21570			22	Neurosciences; Zoology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Zoology	253MT	WOS:000252523000002	18092342	Green Accepted			2022-02-06	
J	Baguley, IJ				Baguley, Ian J.			The excitatory : inhibitory ratio model (EIR model): An integrative explanation of acute autonomic overactivity syndromes	MEDICAL HYPOTHESES			English	Article							TRAUMATIC BRAIN-INJURY; INTRATHECAL BACLOFEN; DYSAUTONOMIA; MANAGEMENT; DYSREFLEXIA; DYSFUNCTION; MECHANISMS; SPASTICITY; HYPERTENSION; ORGANIZATION	Numerous medical conditions present with acute and severe autonomic and muscular overactivity. These syndromes include Neuroleptic Malignant Syndrome, Serotonin Syndrome, Dysautonomia (or paroxysmal sympathetic storms) following acquired brain injury, Autonomic Dysreflexia, Parkinsonian-Hyperpyrexia Syndrome, Malignant Catatonia, intrathecal baclofen withdrawal, Malignant Hyperthermia, Stiff Man Syndrome and Irukandji Syndrome. In their worst forms, each of these syndromes are relatively rare, are treated by different medical specialties and show widely varying pathophysiology. Most are considered to be medical emergencies and share significant mortality rates. Previous authors have noted similarities between some of these conditions, prompting the suggestion that a single common mechanism may underlie their clinical presentation. However, the development of such an integrative model has not occurred. This paper presents a short review of the clinical syndromes, grouped by the location of pathology and mechanism of action. From this background, an integrative framework termed the excitatory: inhibitory ratio (EIR) model is presented. The EIR model consists of two inter-retated networks operating at spinal and brainstem levels. The model is evaluated against pre-clinical scientific research, known pathways, each disorder's pathophysiology (where this is known) and variable severity, and used to explain the reasons behind the efficacy of current treatment regimes. Circumstantial evidence for an expanded aetiology for Malignant Hyperthermia is provided and generic treatment strategies for a number of other conditions are suggested. Finally, minor modifications to this model provide a basis to begin to explain less severe, regional "overlap" syndromes. (C) 2007 Elsevier Ltd. All rights reserved.	Westmead Hosp, Brain Injury Rehabil Serv, Wentworthville, NSW 2145, Australia		Baguley, IJ (corresponding author), Westmead Hosp, Brain Injury Rehabil Serv, POB 533, Wentworthville, NSW 2145, Australia.	ianb@biru.wsahs.nsw.gov.au	Baguley, Ian J/K-6878-2013; Baguley, Ian/AAM-5828-2021	Baguley, Ian J/0000-0001-5650-3705; 			Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Baguley IJ, 2005, BRAIN INJURY, V19, P545, DOI 10.1080/02699050400025075; Baguley IJ, 2004, BRAIN INJURY, V18, P409, DOI 10.1080/02699050310001645775; BAGULEY IJ, 2006, BRAIN INJ; Barwood S, 2000, DEV MED CHILD NEUROL, V42, P116, DOI 10.1017/S0012162200000220; BAUGLEY IJ, 2007, J NEUROL NEUROSURG P; Becker R, 2000, J CLIN NEUROSCI, V7, P316, DOI 10.1054/jocn.1999.0227; BENARROCH EE, 1993, MAYO CLIN PROC, V68, P988, DOI 10.1016/S0025-6196(12)62272-1; Bensmail D, 2006, NEUROLOGY, V67, P1432, DOI 10.1212/01.wnl.0000239827.38036.23; Boyer EW, 2005, NEW ENGL J MED, V352, P1112, DOI 10.1056/NEJMra041867; CAMPAGNOLO DI, AUTONOMIC DYSREFLEXI; Cervero F, 1996, PAIN, V68, P13, DOI 10.1016/S0304-3959(96)03165-X; Coffey RJ, 2002, ARCH PHYS MED REHAB, V83, P735, DOI 10.1053/apmr.2002.32820; Cuny E, 2001, BRAIN INJURY, V15, P917, DOI 10.1080/02699050110065277; Do D, 2000, J NEUROL NEUROSUR PS, V69, P832, DOI 10.1136/jnnp.69.6.832; Elliott S, 2006, SPINAL CORD, V44, P386, DOI 10.1038/sj.sc.3101847; Ener RA, 2003, PAIN MED, V4, P63, DOI 10.1046/j.1526-4637.2003.03005.x; Fenner PJ, 2002, MED J AUSTRALIA, V177, P362, DOI 10.5694/j.1326-5377.2002.tb04838.x; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; Green LB, 1999, ARCH PHYS MED REHAB, V80, P1600, DOI 10.1016/S0003-9993(99)90337-4; Guillaume D, 2005, ARCH PHYS MED REHAB, V86, P2165, DOI 10.1016/j.apmr.2005.05.018; Isbister GK, 2005, CLIN NEUROPHARMACOL, V28, P205, DOI 10.1097/01.wnf.0000177642.89888.85; Kipps CM, 2005, MOVEMENT DISORD, V20, P322, DOI 10.1002/mds.20325; KROIN JS, 1993, J NEUROSURG, V79, P544, DOI 10.3171/jns.1993.79.4.0544; Linderoth B, 1999, NEUROMODULATION, V2, P150, DOI 10.1046/j.1525-1403.1999.00150.x; Macrokanis CJ, 2004, MED J AUSTRALIA, V181, P699, DOI 10.5694/j.1326-5377.2004.tb06527.x; McCarthy E Jane, 2004, AACN Clin Issues, V15, P231, DOI 10.1097/00044067-200404000-00009; Meinck HM, 2002, MOVEMENT DISORD, V17, P853, DOI 10.1002/mds.10279; Mohammed Imran, 2004, BMC Clin Pharmacol, V4, P6, DOI 10.1186/1472-6904-4-6; MOULTON RJ, 2001, J BIOCH, V354, P597; Onofrj M, 2005, NEUROLOGY, V64, P1162, DOI 10.1212/01.WNL.0000157058.17871.7B; Ouardouz M, 2003, NEURON, V40, P53, DOI 10.1016/j.neuron.2003.08.016; PHILBRICK KL, 1994, J NEUROPSYCH CLIN N, V6, P1; PRANZATELLI MR, 1991, J CHILD NEUROL, V6, P115, DOI 10.1177/088307389100600204; Price DD, 2000, SCIENCE, V288, P1769, DOI 10.1126/science.288.5472.1769; Priebe MM, 1997, SPINAL CORD, V35, P171, DOI 10.1038/sj.sc.3100366; Rabchevsky AG, 2006, PROG BRAIN RES, V152, P265, DOI 10.1016/S0079-6123(05)52017-X; Rossitch E Jr, 1988, Br J Neurosurg, V2, P471, DOI 10.3109/02688698809029601; Russo RN, 2000, J PAEDIATR CHILD H, V36, P283, DOI 10.1046/j.1440-1754.2000.00485.x; SANDEL ME, 1986, ARCH PHYS MED REHAB, V67, P469; Sandrini G, 2005, PROG NEUROBIOL, V77, P353, DOI 10.1016/j.pneurobio.2005.11.003; SIDDALL PJ, 1998, NEURAL BLOCKADE CLIN; SOLOMON GE, 1973, J PEDIATR-US, V83, P277, DOI 10.1016/S0022-3476(73)80492-5; Sutton KG, 2002, BRIT J PHARMACOL, V135, P257, DOI 10.1038/sj.bjp.0704439; TALMAN WT, 1988, ARCH NEUROL-CHICAGO, V45, P1037, DOI 10.1001/archneur.1988.00520330129022; Teasell RW, 2000, ARCH PHYS MED REHAB, V81, P506, DOI 10.1053/mr.2000.3848; Thorley RR, 2001, ARCH PHYS MED REHAB, V82, P246, DOI 10.1053/apmr.2001.18698; Van Hilten BJ, 2000, NEW ENGL J MED, V343, P625, DOI 10.1056/NEJM200008313430905; Weaver LC, 2006, PROG BRAIN RES, V152, P245, DOI 10.1016/S0079-6123(05)52016-8; Wilkowsky D, 1999, SSA J-J SEMICOND SAF, V13, P12; Winkel KD, 2005, CLIN EXP PHARMACOL P, V32, P777, DOI 10.1111/j.1440-1681.2005.04258.x; Wissel J, 2000, J PAIN SYMPTOM MANAG, V20, P44, DOI 10.1016/S0885-3924(00)00146-9; Wrathall JR, 2003, NAT MED, V9, P1347, DOI 10.1038/nm1103-1347	54	80	87	0	3	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0306-9877	1532-2777		MED HYPOTHESES	Med. Hypotheses		2008	70	1					26	35		10.1016/j.mehy.2007.04.037			10	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	245IU	WOS:000251929100007	17583440				2022-02-06	
J	Matsumoto, H; Kumon, Y; Watanabe, H; Ohnishi, T; Shudou, M; Ii, C; Takahashi, H; Imai, Y; Tanaka, J				Matsumoto, Hiroaki; Kumon, Yoshiaki; Watanabe, Hideaki; Ohnishi, Takanori; Shudou, Masachika; Ii, Chisato; Takahashi, Hisaaki; Imai, Yoshinori; Tanaka, Junya			Antibodies to CD11b, CD68, and lectin label neutrophils rather than microglia in traumatic and ischemic brain lesions	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						MCAO; stab wound; microglia; macrophage; Iba1; NO; proinflammatory cytokines	CEREBRAL-ARTERY OCCLUSION; NITRIC-OXIDE SYNTHASE; SPINAL-CORD-INJURY; NG2 PROTEOGLYCAN; FOCAL ISCHEMIA; CELLS; EXPRESSION; REPERFUSION; CORTEX; OLIGODENDROCYTES	Resident quiescent microglia have been thought to respond rapidly to various pathologic events in the brain by proliferating and producing many bioactive substances, including proinflammatory cytokines and nitric oxide (NO). In this study, we investigated the reaction of microglia in traumatic and ischemic lesions caused by stab wounds and the transient 90-min occlusion of middle cerebral artery in a mature rat brain. Although many lba1(+) resident microglia underwent apoptotic degeneration in the lesion core within 24 hr after the onset of the brain insult as revealed by TUNEL staining, numerous small, round, isolectin B4(+)/CD11b(+)/CD68(+) cells were localized in the lesion core. These small, round cells with diameters of 7-9 mu m and polymorph nuclei expressed neutrophil-specific elastase, alkaline phosphatase, and platelet-activating factor receptor. Accordingly, they were not activated microglia but neutrophils. Immunohistochemical staining with antibodies to inducible NO synthase (iNOS) showed that most iNOS(+) cells were neutrophils. The results from spatial and kinetic analyses using RT-PCR and immunoblotting were consistent with the immunohistochemical observations. These results suggest the necessity of reevaluating the traditional view on the roles of activated microglia in severe neuropathologic events. Note that the traditional microglial markers isolectin B4, CD11b, and CD68 are not specific for microglia, particularly in a pathologic brain. (c) 2007 Wiley-Liss, Inc.	Ehime Univ, Grad Sch Med, Dept Mol & Cellular Physiol, Toon, Ehime 7910295, Japan; Ehime Univ, Grad Sch Med, Dept Neurosurg, Toon, Ehime 7910295, Japan; Ehime Univ, Integrated Ctr Sci, Toon, Ehime 7910295, Japan		Tanaka, J (corresponding author), Ehime Univ, Grad Sch Med, Dept Mol & Cellular Physiol, Toon, Ehime 7910295, Japan.	jtanaka@in.ehime-u.ac.jp	Tanaka, Junya/Y-1033-2019	Tanaka, Junya/0000-0003-1056-5948			BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BARONE FC, 1992, STROKE, V23, P1337, DOI 10.1161/01.STR.23.9.1337; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Beray-Berthat V, 2003, BRAIN RES, V987, P32, DOI 10.1016/S0006-8993(03)03224-4; Bu J, 2001, GLIA, V34, P296, DOI 10.1002/glia.1063; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Gibson CL, 2005, GLIA, V50, P417, DOI 10.1002/glia.20143; Gowing G, 2006, GLIA, V53, P331, DOI 10.1002/glia.20288; Hashimoto H, 1999, ACTA NEUROPATHOL, V98, P603, DOI 10.1007/s004010051125; Heppner FL, 2005, NAT MED, V11, P146, DOI 10.1038/nm1177; HWANG SB, 1988, J BIOL CHEM, V263, P3225; Iadecola C, 1997, J NEUROSCI, V17, P9157; Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112; Ito D, 2001, STROKE, V32, P1208, DOI 10.1161/01.STR.32.5.1208; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; Jones LL, 2002, J NEUROSCI, V22, P2792, DOI 10.1523/JNEUROSCI.22-07-02792.2002; Kato H, 1996, BRAIN RES, V734, P203, DOI 10.1016/0006-8993(96)00636-1; Kitamura Y, 1996, GLIA, V18, P233, DOI 10.1002/(SICI)1098-1136(199611)18:3<233::AID-GLIA7>3.0.CO;2-#; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kuwabara Y, 2003, J NEUROSCI RES, V73, P22, DOI 10.1002/jnr.10637; LING EA, 1993, GLIA, V7, P9, DOI 10.1002/glia.440070105; Mobberley-Schuman PS, 2005, INFECT IMMUN, V73, P7317, DOI 10.1128/IAI.73.11.7317-7323.2005; Mori K, 2002, NEUROPHARMACOLOGY, V43, P1026, DOI 10.1016/S0028-3908(02)00211-3; MORIOKA T, 1991, J CEREBR BLOOD F MET, V11, P966, DOI 10.1038/jcbfm.1991.162; Nakajima K., 2005, NEUROGLIA, V2, P443; Neudenberger J, 2006, BRIT J HAEMATOL, V133, P337, DOI 10.1111/j.1365-2141.2006.06013.x; Paietta E, 1998, BRIT J HAEMATOL, V100, P265, DOI 10.1046/j.1365-2141.1998.00561.x; PERSSON L, 1976, VIRCHOWS ARCH B, V22, P21; SAITO N, 1991, AM J PATHOL, V139, P1053; Schroeter M, 1997, STROKE, V28, P382, DOI 10.1161/01.STR.28.2.382; Shibano M, 1999, AM J HEMATOL, V60, P12, DOI 10.1002/(SICI)1096-8652(199901)60:1<12::AID-AJH3>3.0.CO;2-P; Shimakura A, 2000, BRAIN RES, V858, P55, DOI 10.1016/S0006-8993(99)02431-2; Simard AR, 2006, NEURON, V49, P489, DOI 10.1016/j.neuron.2006.01.022; Strbian D, 2006, J CEREBR BLOOD F MET, V26, P605, DOI 10.1038/sj.jcbfm.9600228; Streit W. J., 2005, NEUROGLIA, P60; Sugishita H, 2001, J NEUROSCI RES, V64, P392, DOI 10.1002/jnr.1090; Tanaka J, 1997, GLIA, V19, P286; Tanaka J, 1996, EXP NEUROL, V137, P367, DOI 10.1006/exnr.1996.0038; Tanaka R, 2003, NEUROSCIENCE, V117, P531, DOI 10.1016/S0306-4522(02)00954-5; Wang Y, 2007, EXP NEUROL, V203, P168, DOI 10.1016/j.expneurol.2006.08.006; Weston RM, 2007, J CEREBR BLOOD F MET, V27, P100, DOI 10.1038/sj.jcbfm.9600324; Wu CT, 2003, HEPATOLOGY, V38, P1018, DOI 10.1053/jhep.2003.50407; Yokoyama A, 2006, GLIA, V53, P754, DOI 10.1002/glia.20332; Yokoyama A, 2004, GLIA, V45, P96, DOI 10.1002/glia.10306; Zai LJ, 2005, GLIA, V50, P247, DOI 10.1002/glia.20176; Zhang ZG, 1997, BRAIN RES, V744, P189, DOI 10.1016/S0006-8993(96)01085-2	46	80	82	1	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	APR	2007	85	5					994	1009		10.1002/jnr.21198			16	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	157NK	WOS:000245726700008	17265469				2022-02-06	
J	Korfias, S; Stranjalis, G; Boviatsis, E; Psachoulia, C; Jullien, G; Gregson, B; Mendelow, AD; Sakas, DE				Korfias, Stefanos; Stranjalis, George; Boviatsis, Efstathios; Psachoulia, Christina; Jullien, Gerard; Gregson, Barbara; Mendelow, A. David; Sakas, Damianos E.			Serum S-100B protein monitoring in patients with severe traumatic brain injury	INTENSIVE CARE MEDICINE			English	Article						S-100B protein; severe traumatic brain injury; traumatic brain injury; outcome	SEVERE HEAD-INJURY; COMPUTERIZED-TOMOGRAPHY; PREDICTOR; PATHOLOGY; PRESSURE; MARKER	Objective: S-100B protein is a promising marker of injury severity and outcome after head injury. We examined the relationship between serum S-100B concentrations and injury severity, clinical course, survival, and treatment efficacy after severe traumatic brain injury (TBI). Design and setting: Prospective observational study in a neurosurgical intensive care unit. Patients and participants: 102 adult patients with severe TBI, admitted between June 2001 and November 2003 (30 months). Interventions: Serum S-100B levels were measured by immunoluminometric technique on admission and every 24 h thereafter for a maximum of 7 days. Measurements and results: Initial S-100B levels were significantly related to pupillary status, computed tomography severity1, and 1-month survival. Cox's proportional hazard regression analysis showed that initial S-100B was an independent predictor of 1-month survival, in the presence of dilated pupils, and with increased age. Subjects with initial levels above 1 g/l had a nearly threefold increased probability of death within 1 month. Serum S-100B alteration indicated neurological improvement or deterioration. Finally, surgical treatment reduced S-100B levels. Conclusions: Serum S-100B protein reflects injury severity and improves prediction of outcome after severe TBI. S-100B may also have a role in assessing the efficacy of treatment after severe TBI.	Univ Newcastle Upon Tyne, Newcastle Gen Hosp, Dept Neurosurg, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Univ Athens, Evangelismos Gen Hosp, Dept Neurosurg, Athens 10676, Greece; Evangelismos Gen Hosp, Dept Biochem, Athens 10676, Greece		Korfias, S (corresponding author), Univ Newcastle Upon Tyne, Newcastle Gen Hosp, Dept Neurosurg, Westgate Rd, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.	Stefanos.Korfias@NUTH.NHS.UK	Mendelow, Alexander/AAW-2878-2021	Gregson, Barbara/0000-0003-4868-9137			*AM ASS NEUR SURG, 2000, J NEUROTRAUM, V17, P463; Bullock MR, 1996, J NEUROTRAUM, V13, P661; Dimopoulou I, 2003, NEUROLOGY, V60, P947, DOI 10.1212/01.WNL.0000049931.77887.7F; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; MARSHAK DR, 1990, PROG BRAIN RES, V86, P169; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McKeating EG, 1998, ACT NEUR S, V71, P117; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Raabe A, 1999, J NEUROSURG, V91, P875, DOI 10.3171/jns.1999.91.5.0875; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/0968-0004(96)10020-7; Stranjalis G, 2004, J NEUROTRAUM, V21, P1070, DOI 10.1089/0897715041651088; TEASDALE G, 1975, LANCET, V1, P480; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026	18	80	84	0	1	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	FEB	2007	33	2					255	260		10.1007/s00134-006-0463-4			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	133QA	WOS:000244026200008	17143637				2022-02-06	
J	Ptito, A; Chen, JK; Johnston, KM				Ptito, Alain; Chen, Jen-Kai; Johnston, Karen M.			Contributions of functional Magnetic Resonance Imaging (fMRI) to sport concussion evaluation	NEUROREHABILITATION			English	Article						concussion; functional Magnetic Resonance Imaging (fMRI); post-concussive symptoms depression	TRAUMATIC BRAIN-INJURY; WORKING-MEMORY; ELECTROPHYSIOLOGICAL EVIDENCE; FRONTAL-CORTEX; HEAD-INJURY; DEPRESSION; PERFORMANCE; IMPAIRMENT; GUIDELINES; SYMPTOMS	Mild traumatic brain injury (mTBI) in contact sport is a problem of such magnitude that improved approaches to diagnosis, investigation and management are urgent. Concussion has traditionally been described as a transient, fully reversible, cerebral dysfunction. However, this seemingly 'mild' injury sometimes results in long-lasting and disabling post-concussion symptoms (PCS) and abnormal neuropsychological profiles characteristic of frontal and/or temporal lobe dysfunction. At present, the pathological changes following concussion remain unclear, but it is now widely accepted that concussion results mainly in functional disturbance rather than structural damage. Therefore, functional imaging techniques can help in demonstrating brain abnormalities undetectable by structural imaging methods. This paper will review the use of functional magnetic resonance imaging (fMRI) in studies of concussion. Our existing and ongoing fMRI studies will be described as examples to highlight the potential and contribution of this non-invasive functional neuroimaging technique in the assessment of sports-related concussion and its management.	McGill Univ, Montreal Neurol Inst, Neuropsychol Dept, Cognit Neurosci Unit, Montreal, PQ H3A 2B4, Canada; Univ Toronto, Concuss Clin Neurorehabil Program, Toronto Rehabil Div Neurosurg, Toronto, ON, Canada		Ptito, A (corresponding author), McGill Univ, Montreal Neurol Inst, Neuropsychol Dept, Cognit Neurosci Unit, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.	alain.ptito@mcgill.ca					ANDERSON SD, 1995, CAN J DIAGN, V12, P77; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Aubry Mark, 2002, Phys Sportsmed, V30, P57, DOI 10.3810/psm.2002.02.176; Cantu R, 2004, LANCET NEUROL, V3, P437; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chen JK, 2004, CLIN J SPORT MED, V14, P379; CHEN JK, 2006, SEVERITY DEPRESSION; CHEN JK, IN PRESS ARCH GEN PS; CHEN JK, 2007, IN PRESS J NEUROL NE; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Drevets WC, 1999, ANN NY ACAD SCI, V877, P614, DOI 10.1111/j.1749-6632.1999.tb09292.x; Duncan J, 2000, TRENDS NEUROSCI, V23, P475, DOI 10.1016/S0166-2236(00)01633-7; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gould RL, 2003, NEUROIMAGE, V20, P1006, DOI 10.1016/S1053-8119(03)00365-3; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; HEINZE HJ, 1992, NEUROPSYCHOLOGIA, V30, P495, DOI 10.1016/0028-3932(92)90054-P; Honey CR, 1998, CLIN J SPORT MED, V8, P43, DOI 10.1097/00042752-199801000-00010; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Johnston KM, 2000, CLIN J SPORT MED, V10, P209; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Liotti M, 2000, BIOL PSYCHIAT, V48, P30, DOI 10.1016/S0006-3223(00)00874-X; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; *NIH, 1998, NAT I HLTH CONS STAT, V15; PETRIDES M, 1982, NEUROPSYCHOLOGIA, V20, P249, DOI 10.1016/0028-3932(82)90100-2; Petrides M, 1995, ANN NY ACAD SCI, V769, P85, DOI 10.1111/j.1749-6632.1995.tb38133.x; PETRIDES M, 1991, P ROY SOC B-BIOL SCI, V246, P293, DOI 10.1098/rspb.1991.0157; PETRIDES M, 1995, J NEUROSCI, V15, P359; Petrides M, 1994, HDB NEUROPSYCHOLOGY, V9, P59; PIKE GB, 2000, PAIN IMAGING PROGR P, V18; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Rose EJ, 2006, NEUROIMAGE, V29, P203, DOI 10.1016/j.neuroimage.2005.07.002; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092	53	80	80	1	16	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2007	22	3					217	227					11	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	216NM	WOS:000249884800008	17917172				2022-02-06	
J	Shao, CX; Roberts, KN; Markesbery, WR; Scheff, SW; Lovell, MA				Shao, ChangXing; Roberts, Kelly N.; Markesbery, William R.; Scheff, Stephen W.; Lovell, Mark A.			Oxidative stress in head trauma in aging	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						acrolein; glutathione peroxidase; glutathione reductase; glutathione transferase; 4-hydroxynonenal; traumatic brain injury; superoxide dismutase	ANTIOXIDANT ENZYME-ACTIVITY; LIPID-PEROXIDATION PRODUCT; CONTROLLED CORTICAL IMPACT; BRAIN-INJURY; GLUTATHIONE-PEROXIDASE; SUPEROXIDE DISMUTASES; IMPAIRED MITOCHONDRIAL; HYDROXYL RADICALS; TIME-COURSE; HIPPOCAMPAL	Oxidative damage is proposed as a key mediator of exacerbated morphological responses and deficits in behavioral recovery in aged subjects with traumatic brain injury (TBI). In the present study, we show exacerbated loss of tissue in middle aged (12 months) and aged (22 months) Fisher-344 rats compared to young animals (3 months) subjected to moderate TBI. Analysis of 4-hydroxynonenal (4-HNE) and acrolein, neurotoxic by-products of lipid peroxidation, shows significant (P < 0.05) age-dependent increases in ipsilateral (IP) hippocampus 1 and 7 days post injury. In IP cortex, 4-HNE was significantly elevated 1 day post injury in all age groups, and both 4-HNE and acrolein were elevated in middle aged and aged animals 7 days post injury. Comparison of antioxidant enzyme activities shows significant (P < 0.05) age-dependent decreases of manganese superoxide dismutase in IP hippocampus and cortex 1 and 7 days post injury. Glutathione reductase activity also showed an age-dependent decrease. Overall, our data show increased levels of oxidative damage, diminished antioxidant capacities, and increased tissue loss in TBI in aging. (c) 2006 Elsevier Inc. All rights reserved.	Univ Kentucky, Dept Chem, Lexington, KY 40536 USA; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA		Lovell, MA (corresponding author), 135 Sanders Brown Bldg,800 S,Limestone St, Lexington, KY 40536 USA.	malove2@email.uky.edu			NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG21981] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG021981] Funding Source: NIH RePORTER		Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Baldwin SA, 1996, GLIA, V16, P266; Baldwin SA, 1998, J NEUROSURG, V88, P874, DOI 10.3171/jns.1998.88.5.0874; Baud O, 2004, J NEUROSCI, V24, P1531, DOI 10.1523/JNEUROSCI.3989-03.2004; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BIROS M, 1998, HEAD TRAUMA; Camandola S, 2000, J NEUROCHEM, V74, P159, DOI 10.1046/j.1471-4159.2000.0740159.x; Cooper P., 1985, DELAYED BRAIN INJURY, P217; DeKosky ST, 2004, J NEUROTRAUM, V21, P491, DOI 10.1089/089771504774129838; Engle MR, 2004, TOXICOL APPL PHARM, V194, P296, DOI 10.1016/j.taap.2003.10.001; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1991, J NEUROSURG, V75, P916, DOI 10.3171/jns.1991.75.6.0916; Ho YS, 1997, J BIOL CHEM, V272, P16644, DOI 10.1074/jbc.272.26.16644; Hoane MR, 2004, BEHAV BRAIN RES, V153, P189, DOI 10.1016/j.bbr.2003.11.012; Hoffman SW, 1996, J NEUROSCI METH, V68, P133; Hsiang JNK, 1997, ACTA NEUROCHIR, V139, P464, DOI 10.1007/BF01808884; Inci S, 1998, NEUROSURGERY, V43, P330, DOI 10.1097/00006123-199808000-00095; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Liu YH, 2003, CHEM RES TOXICOL, V16, P1589, DOI 10.1021/tx034160a; Long Y, 2003, J NEUROSCI RES, V71, P710, DOI 10.1002/jnr.10524; Lovell MA, 1997, NEUROBIOL AGING, V18, P457, DOI 10.1016/S0197-4580(97)00108-5; LOVELL MA, 1995, NEUROLOGY, V45, P1594, DOI 10.1212/WNL.45.8.1594; Lovell MA, 2001, NEUROBIOL AGING, V22, P187, DOI 10.1016/S0197-4580(00)00235-9; Maier CM, 2002, NEUROSCIENTIST, V8, P323, DOI 10.1177/107385840200800408; Matsushita M, 1997, J COMP NEUROL, V377, P251, DOI 10.1002/(SICI)1096-9861(19970113)377:2<251::AID-CNE7>3.0.CO;2-2; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Maughan PH, 2000, J NEUROTRAUM, V17, P1141, DOI 10.1089/neu.2000.17.1141; McCall J M, 1987, Acta Anaesthesiol Belg, V38, P373; Medina-Navarro R, 2004, HUM EXP TOXICOL, V23, P101, DOI 10.1191/0960327104ht416oa; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; MISRA HP, 1972, J BIOL CHEM, V247, P3170; MIZUNO Y, 1984, EXP NEUROL, V84, P58, DOI 10.1016/0014-4886(84)90006-2; Nishio S, 1997, ACT NEUR S, V70, P84; Okado-Matsumoto A, 2001, J BIOL CHEM, V276, P38388, DOI 10.1074/jbc.M105395200; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; RICCI G, 1994, ANAL BIOCHEM, V218, P463, DOI 10.1006/abio.1994.1209; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; Shetty AK, 2004, J NEUROSCI RES, V78, P520, DOI 10.1002/jnr.20302; SIESJO BK, 1995, J NEUROTRAUM, V12, P943, DOI 10.1089/neu.1995.12.943; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Springer JE, 1997, J NEUROCHEM, V68, P2469; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; TATOR C, 1994, ISCHEMIA SECONDARY N; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Uchida K, 1998, J BIOL CHEM, V273, P16058, DOI 10.1074/jbc.273.26.16058; Valentine JS, 1998, CURR OPIN CHEM BIOL, V2, P253, DOI 10.1016/S1367-5931(98)80067-7; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wang H, 2003, J NEUROCHEM, V87, P1527, DOI 10.1046/j.1471-4159.2003.02123.x; Xie CS, 2001, FREE RADICAL BIO MED, V31, P73, DOI 10.1016/S0891-5849(01)00553-6	64	80	83	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	JUL 1	2006	41	1					77	85		10.1016/j.freeradbiomed.2006.03.007			9	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism	058LV	WOS:000238667400009	16781455				2022-02-06	
J	Maxwell, WL; MacKinnon, MA; Smith, DH; McIntosh, TK; Graham, DI				Maxwell, William L.; MacKinnon, Mary Anne; Smith, Douglas H.; McIntosh, Tracy K.; Graham, David I.			Thalamic nuclei after human blunt head injury	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						blunt head injury; glia; intralaminar nuclei; thalamus	TRAUMATIC BRAIN-INJURY; UNBIASED STEREOLOGICAL ESTIMATION; CELL LOSS; NEURONS; MODERATE; INTRALAMINAR; MEDIODORSAL; RESPONSES; DISEASE; NUMBER	Paraffin-embedded blocks from the thalamus of 9 control patients, 9 moderately disabled, 12 severely disabled, and 10 vegetative head-injured patients assessed using the Glasgow Outcome Scale and identified from the Department of Neuropathology archive. Neurons, astrocytes, macrophages, and activated microglia were differentiated by Luxol fast blue/cresyl violet, GFAP, CD68, and CR3/43 staining and stereological techniques used to estimate cell number in a 28-mu m-thick coronal section. Counts were made in subnuclei of the mediodorsal, lateral posterior, and ventral posterior nuclei, the intralaminar nuclei, and the related internal lamina. Neuronal loss occurred from mediodorsal parvocellularis, rostral center medial, central lateral and paracentral nuclei in moderately disabled patients; and from mediodorsal magnocellularis, caudal center medial, rhomboid, and parafascicular nuclei in severely disabled patients; and all of the above and the centre median nucleus in vegetative patients. Neuronal loss occurred primarily from cognitive and executive function nuclei, a lesser loss from somatosensory nuclei and the least loss from limbic motor nuclei. There was an increase in the number of reactive astrocytes, activated microglia, and macrophages with increasing severity of injury. The study provides novel quantitative evidence for differential neuronal loss, with survival after human head injury, from thalamic nuclei associated with different aspects of cortical activation.	Univ Penn, Dept Neurosurg, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; So Gen Hosp, Acad Unit Neuropathol, Glasgow G51 4TF, Lanark, Scotland; Univ Glasgow, IBLS, Div Neurosci & Biomed Syst, Dept Anat, Glasgow, Lanark, Scotland		Maxwell, WL (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Thomson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	wmaxwell@bio.gla.ac.uk	smith, douglas/A-1321-2007		NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG12527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38104, NS08803] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS038104, P01NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG012527] Funding Source: NIH RePORTER		Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Benes FM, 2001, TRENDS NEUROSCI, V24, P11, DOI 10.1016/S0166-2236(00)01660-X; CAMMERMEYER JAN, 1961, ACTA NEUROPATHOL, V1, P245; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Henderson JM, 2000, ANN NEUROL, V47, P345, DOI 10.1002/1531-8249(200003)47:3<345::AID-ANA10>3.0.CO;2-V; Henderson JM, 2000, BRAIN, V123, P1410, DOI 10.1093/brain/123.7.1410; HIRAI T, 1989, BRAIN RES REV, V14, P1, DOI 10.1016/0165-0173(89)90007-6; Howard C.V., 1998, UNBIASED STEREOLOGY, V1; JENNETT B, 1975, LANCET, V1, P480; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Kemether EM, 2003, ARCH GEN PSYCHIAT, V60, P983, DOI 10.1001/archpsyc.60.9.983; KLUVER H, 1953, J NEUROPATH EXP NEUR, V12, P400; Koshinaga M, 2000, J NEUROTRAUM, V17, P185, DOI 10.1089/neu.2000.17.185; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; Morel A, 1997, J COMP NEUROL, V387, P588, DOI 10.1002/(SICI)1096-9861(19971103)387:4<588::AID-CNE8>3.0.CO;2-Z; Mouton P. R., 2002, PRINCIPLES PRACTICES; Nakamura Y, 2002, BIOL PHARM BULL, V25, P945, DOI 10.1248/bpb.25.945; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; PAKKENBERG B, 1992, SCHIZOPHR RES, V7, P95, DOI 10.1016/0920-9964(92)90038-7; Parent M, 2005, J COMP NEUROL, V481, P127, DOI 10.1002/cne.20348; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Popken GJ, 2000, P NATL ACAD SCI USA, V97, P9276, DOI 10.1073/pnas.150243397; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Stark AK, 2004, AM J PSYCHIAT, V161, P882, DOI 10.1176/appi.ajp.161.5.882; Van der Werf YD, 1999, J NEUROL NEUROSUR PS, V66, P36; Van der Werf YD, 2002, BRAIN RES REV, V39, P107, DOI 10.1016/S0165-0173(02)00181-9; WEST MJ, 1990, J COMP NEUROL, V296, P1, DOI 10.1002/cne.902960102; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; WILLIAMS RW, 1988, J COMP NEUROL, V278, P344, DOI 10.1002/cne.902780305; Wilson S, 2004, J NEUROTRAUM, V21, P239, DOI 10.1089/089771504322972031; XUEREB JH, 1991, BRAIN, V114, P1363	36	80	81	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAY	2006	65	5					478	488		10.1097/01.jnen.0000229241.28619.75			11	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	100TO	WOS:000241692000006	16772871	Bronze			2022-02-06	
J	Davis, DP; Douglas, DJ; Smith, W; Sise, MJ; Vilke, GM; Holbrook, TL; Kennedy, F; Eastman, AB; Velky, T; Hoyt, DB				Davis, DP; Douglas, DJ; Smith, W; Sise, MJ; Vilke, GM; Holbrook, TL; Kennedy, F; Eastman, AB; Velky, T; Hoyt, DB			Traumatic brain injury outcomes in pre- and post-menopausal females versus age-matched males	JOURNAL OF NEUROTRAUMA			English	Article						estrogen; gender; head trauma; menopause; outcomes; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; NECROSIS-FACTOR-ALPHA; GENDER-DIFFERENCES; SEX-DIFFERENCES; LIPID-PEROXIDATION; HYPOGONADOTROPIC HYPOGONADISM; PROGESTERONE PROTECTS; ESTROUS-CYCLE; HEAD TRAUMA; CELL-DEATH	Gender differences in outcomes from major trauma have been described previously, and exogenous female hormone administration appears to be neuroprotective following traumatic brain injury (TBI). This analysis explored outcomes in pre- and post-menopausal females versus age-matched males. A total of 13,437 patients (n = 3,178 females, it = 10,259 males) with moderate-to-severe TBI (head AIS >= 3) were identified from our county trauma registry. Overall mortality was similar between males and females (22% for both). Logistic regression was used to compare gender outcome differences, with a separate analysis performed for premenopausal (<50 years) versus postmenopausal (>= 50 years) patients, and after stratification by decade of life. No statistically significant difference in outcomes was observed for pre-menopausal females versus males (odds ratio [OR] 1.06; 95% confidence interval [CI] 0.83, 1.35; p = 0.633), but outcomes were significantly better in postmenopausal females versus males (OR 0.63, 95% CI 0.48-0.81, p < 0.001) after adjusting for age, mechanism of injury, Glasgow Coma Scale (GCS), hypotension (SBP <= 90 min Hg), head Abbreviated Injury Score (AIS), and Injury Severity Score (ISS). Stratification by decade of life revealed the gender survival differential inflection point to occur between ages 40-49 (OR 1.06, 95% CI 0.66-1.71, p = 0.798) and ages 50-59 (OR 0.38, 95% CI 0.20-0.74, p = 0.005). In addition, Revised Trauma Score and Injury Severity Score (TRISS) was used to calculate probability of survival (PS); all patients were then stratified by decade of life, and males and females were compared with regard to mean survival differential (outcome PS). The identical pattern of improved outcomes in post-menopausal but not pre-menopausal females versus age-matched males was observed. These data suggest that endogenous female sex hormone production is not neuroprotective.	Univ Calif San Diego, San Diego Emergency Med, Dept Emergency Med, San Diego, CA 92103 USA; Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA; Scripps Mercy Hosp, San Diego, CA USA; San Diego Cty EMS, San Diego, CA USA; Univ Calif San Diego, Div Trauma, San Diego, CA 92103 USA; Sharp Mem Hosp & Rehabil Ctr, San Diego, CA USA; Scripps Mem Hosp, San Diego, CA USA; Palomar Hosp, Escondido, CA USA		Davis, DP (corresponding author), Univ Calif San Diego, San Diego Emergency Med, Dept Emergency Med, 200 W Arbor Dr, San Diego, CA 92103 USA.	davismd@cox.net					Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; BARRON WM, 1986, AM J PHYSIOL, V250, pE352, DOI 10.1152/ajpendo.1986.250.4.E352; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Bujas M, 1997, BRAIN RES BULL, V43, P411, DOI 10.1016/S0361-9230(97)00027-0; Cannon JG, 1998, ANN NY ACAD SCI, V856, P234, DOI 10.1111/j.1749-6632.1998.tb08330.x; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; DAVISON JM, 1984, AM J PHYSIOL, V246, pF105, DOI 10.1152/ajprenal.1984.246.1.F105; Dimopoulou I, 2004, INTENS CARE MED, V30, P1051, DOI 10.1007/s00134-004-2257-x; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Donders J, 2004, ASSESSMENT, V11, P275, DOI 10.1177/1073191104268914; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Farin A, 2004, ACT NEUR S, V89, P101; FLEISCHER AS, 1978, J NEUROSURG, V49, P650, DOI 10.3171/jns.1978.49.5.0650; Gannon CJ, 2002, J AM COLL SURGEONS, V195, P11, DOI 10.1016/S1072-7515(02)01187-0; Garcia EF, 2003, P W PHARMACOL SOC, V46, P54; Gerring JP, 2002, J AM ACAD CHILD PSY, V41, P157, DOI 10.1097/00004583-200202000-00009; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Grachev ID, 2000, NEUROIMAGE, V11, P554, DOI 10.1006/nimg.2000.0557; Green PS, 2000, INT J DEV NEUROSCI, V18, P347, DOI 10.1016/S0736-5748(00)00017-4; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Harukuni I, 2001, BRAIN RES, V900, P137, DOI 10.1016/S0006-8993(01)02278-8; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Holbrook TL, 2004, J TRAUMA, V56, P284, DOI 10.1097/01.TA.0000109758.75406.F8; Jones F S, 1998, N C Med J, V59, P191; Kadyan V, 2004, AM J PHYS MED REHAB, V83, P747, DOI 10.1097/01.PHM.0000140790.30468.F4; Kaldi I, 2004, EUR J OPHTHALMOL, V14, P306, DOI 10.5301/EJO.2008.1363; KIMURA D, 1995, HORM BEHAV, V29, P312, DOI 10.1006/hbeh.1995.1022; Kimura D, 1996, CURR OPIN NEUROBIOL, V6, P259, DOI 10.1016/S0959-4388(96)80081-X; Kimura D, 2003, PSYCHOL REP, V93, P263, DOI 10.2466/PR0.93.5.263-264; Kimura D, 2002, PSYCHOL REP, V91, P1137, DOI 10.2466/PR0.91.7.1137-1142; KIMURA D, 1992, SCI AM, V267, P119; KIMURA D, 1984, PROG BRAIN RES, V61, P423; KIMURA D, 1983, CAN J PSYCHOL, V37, P19, DOI 10.1037/h0080696; Knoferl MW, 2003, CELL IMMUNOL, V222, P27, DOI 10.1016/S0008-8749(03)00081-9; KOSTELJANETZ M, 1981, ACTA NEUROL SCAND, V63, P169; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Landgren BM, 2004, J CLIN ENDOCR METAB, V89, P2763, DOI 10.1210/jc.2003-030824; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; McCauley LD, 1995, J PHARMACOL EXP THER, V275, P1412; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCullough LD, 2003, J NEUROSCI, V23, P8701; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; Murphy SJ, 2000, STROKE, V31, P1173, DOI 10.1161/01.STR.31.5.1173; Murphy SJ, 2002, J CEREBR BLOOD F MET, V22, P1181, DOI 10.1097/01.WCB.0000037990.07114.07; Nunez JL, 2003, ENDOCRINOLOGY, V144, P2350, DOI 10.1210/en.2002-220840; OVTSCHAROFF W, 1992, J COMP NEUROL, V323, P299, DOI 10.1002/cne.903230212; RIVIER C, 1990, ENDOCRINOLOGY, V127, P849; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Russell SH, 2001, J NEUROENDOCRINOL, V13, P296, DOI 10.1046/j.1365-2826.2001.00632.x; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; SPINEDI E, 1992, ENDOCRINOLOGY, V131, P2430, DOI 10.1210/en.131.5.2430; SPRATT DI, 1992, J CLIN ENDOCR METAB, V75, P1562, DOI 10.1210/jc.75.6.1562; STACHENFELD N.S., 1998, AM J PHYSIOL, V274, P187; Suzuki T, 2004, J NEUROTRAUM, V21, P842, DOI 10.1089/0897715041526186; TABIBZADEH S, 1994, HUM REPROD, V9, P947, DOI 10.1093/oxfordjournals.humrep.a138621; Theas S, 2000, ENDOCRINE, V12, P249, DOI 10.1385/ENDO:12:3:249; Vedder H, 1999, J NEUROCHEM, V72, P2531, DOI 10.1046/j.1471-4159.1999.0722531.x; Veliskova J, 2001, ANN NEUROL, V50, P596, DOI 10.1002/ana.1248; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; WILSON MA, 1992, BRAIN RES BULL, V29, P165, DOI 10.1016/0361-9230(92)90022-P; Wilson MA, 1997, LIFE SCI, V60, P1679, DOI 10.1016/S0024-3205(97)00110-0; WOOLF PD, 1986, CLIN ENDOCRINOL, V25, P265, DOI 10.1111/j.1365-2265.1986.tb01691.x	74	80	80	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2006	23	2					140	148		10.1089/neu.2006.23.140			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	020HX	WOS:000235900600003	16503798				2022-02-06	
J	Manley, GT; Rosenthal, G; Lam, M; Morabito, D; Yan, DH; Derugin, N; Bollen, A; Knudson, MM; Panter, SS				Manley, GT; Rosenthal, G; Lam, M; Morabito, D; Yan, DH; Derugin, N; Bollen, A; Knudson, MM; Panter, SS			Controlled cortical impact in swine: Pathophysiology and biomechanics	JOURNAL OF NEUROTRAUMA			English	Article						CCI; head injury; TBI model; neuromonitoring	TRAUMATIC BRAIN-INJURY; FLUID-PERCUSSION; RAT; MILD; PIGS; HIPPOCAMPUS; PROTEIN; MARKER; CORTEX; GLIA	Investigations of the basic pathological, cellular, and molecular mechanisms of traumatic brain injury (TBI) over the past two decades have been carried out primarily in rodents. Unfortunately, these studies have not translated into improved outcome in patients with TBI. To better model human TBI, a swine model of controlled cortical impact (CCI) was developed. A CCI device was used to generate a focal lesion in 23 anesthetized male Yorkshire swine. In 10 swine, CCI parameters of velocity and dwell time were varied to achieve a consistent injury (3.5 m/sec, 400 msec, respectively). In 13 swine, depth of depression was varied from 9 to 12 mm. Physiological data, including heart rate (HR), mean arterial blood pressure (MAP), intracranial pressure (ICP), and cerebral perfusion pressure (CPP), were collected for 10 h after injury. Following injury, ICP and HR increased above baseline values in all swine, with a more pronounced elevation in animals impacted to a depth of depression of 12 mm. An 11-mm depth of depression was found to most closely mimic pathological features of human TBI with edema, infiltration of inflammatory cells, pericapillary hemorrhage, and petechial hemorrhages in the white matter. Injury to a depth of depression of 12 mm resulted in cortical laceration obscuring these features. Immunohistological staining with Neu-N, MAP-2, and Fluoro Jade B revealed evidence of degenerating neurons, axonal disruption, and impending cell death. These results indicate that the swine model of CCI results in a defined and reproducible injury with pathological features similar to human TBI. Physiological parameters after injury are readily monitored in a setting mimicking conditions of an intensive care unit, establishing a more clinically relevant experimental model for future investigations.	Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94110 USA		Manley, GT (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 1001 Potrero Ave,Bldg 1,Rm 101, San Francisco, CA 94110 USA.	manley@itsa.ucsf.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49, CCR903697] Funding Source: Medline		Alessandri B, 2003, J NEUROTRAUM, V20, P1293, DOI 10.1089/089771503322686094; BASS NH, 1971, J COMP NEUROL, V143, P481, DOI 10.1002/cne.901430405; Bonde C, 2002, NEUROSCI LETT, V327, P49, DOI 10.1016/S0304-3940(02)00382-8; Brodhun M, 2001, ACTA NEUROPATHOL, V101, P424; Dawson DA, 1996, J CEREBR BLOOD F MET, V16, P170, DOI 10.1097/00004647-199601000-00020; DIXON C E, 1988, Journal of Neurotrauma, V5, P91, DOI 10.1089/neu.1988.5.91; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; FREIDE VR, 1954, ACTA ANAT, V20, P290; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; GRAHAM DI, 2002, GREENFIELDS NEUROPAT, V1, P823; Grate LL, 2003, J NEUROSCI METH, V123, P201, DOI 10.1016/S0165-0270(02)00361-8; HANNON JP, 1990, LAB ANIM SCI, V40, P293; HAWKINS A, 1957, SCIENCE, V126, P76, DOI 10.1126/science.126.3263.76; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; King DR, 2004, SURGERY, V136, P355, DOI 10.1016/j.surg.2004.05.011; KITAGAWA K, 1989, NEUROSCIENCE, V2, P401; KRAUS JF, 1994, SEMIN NEUROL, V14, P1, DOI 10.1055/s-2008-1041052; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5	28	80	83	0	11	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2006	23	2					128	139		10.1089/neu.2006.23.128			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	020HX	WOS:000235900600002	16503797				2022-02-06	
J	Yilmazlar, S; Arslan, E; Kocaeli, H; Dogan, S; Aksoy, K; Korfali, E; Doygun, M				Yilmazlar, S; Arslan, E; Kocaeli, H; Dogan, S; Aksoy, K; Korfali, E; Doygun, M			Cerebrospinal fluid leakage complicating skull base fractures: analysis of 81 cases	NEUROSURGICAL REVIEW			English	Article						cerebrospinal fluid leakage; skull base fracture; complication	TEMPORAL BONE-FRACTURES; SEVERE HEAD-INJURY; PROPHYLACTIC ANTIBIOTICS; MANAGEMENT; RHINORRHEA; FISTULAS; METAANALYSIS; DIAGNOSIS; ANTERIOR	The aim of this study was to evaluate the results of conservative and surgical management options for traumatic cerebrospinal fluid (CSF) leakage complicating skull base fractures. The subjects were 81 patients who were treated between 1996 and 2003 for CSF leaks that had persisted for 24 h or longer after head injury. For each case the medical records were reviewed, and the data collected were as follows: demographic features, clinical and radiological findings, management options, complications and outcome scores. Analysis was done with patients grouped according to Glasgow coma scale (GCS) score at admission (<= 8 vs >8), and findings for three treatment methods (conservative, CSF drainage, surgery) were evaluated. In 32 cases (39.5%), the CSF leakage resolved spontaneously, and the mean hospital stay for these patients was 14 +/- 11 days. Twenty-four patients (29.6%) were treated by CSF drainage, and seven of these individuals ultimately required surgery to close the leak. Hospital stay was 17 +/- 7 days. Twenty-five patients (30.9%) underwent surgery as the initial treatment step, and the mean hospital stay for these individuals was 15 +/- 9 days. The large majority (74.2%) of patients with admission GCS scores <= 8 had poor outcomes. Compared with this group, a greater proportion of the CSF leaks in the patients with admission GCS scores >8 resolved spontaneously. The factors that had a critical influence on outcome in this series were level of consciousness on admission and presence of additional intracranial pathology associated with CSF leakage within cases of traumatic CSF fistulae due to skull base fractures. Treatment decisions should be dictated by the severity of neurological decline during the emergency period and the presence/absence of associated intracranial lesions. The timing for surgery and CSF drainage procedures must be decided with great care and with a clear strategy. The authors offer a treatment algorithm.	Uludag Univ, Sch Med, Dept Neurosurg, TR-16059 Gorukle, Bursa, Turkey		Yilmazlar, S (corresponding author), Uludag Univ, Sch Med, Dept Neurosurg, TR-16059 Gorukle, Bursa, Turkey.	selsus@uludag.edu.tr	, selcuk/AAH-5070-2021	, selcuk/0000-0003-3633-7919			AARABI B, 1992, Ear Nose and Throat Journal, V71, P300; BECKHARDT RN, 1991, OTOLARYNG HEAD NECK, V104, P425, DOI 10.1177/019459989110400402; Brodie HA, 1997, ARCH OTOLARYNGOL, V123, P749; Brodie HA, 1997, AM J OTOL, V18, P188; CALCATERRA TC, 1985, OTOLARYNG CLIN N AM, V18, P99; CLEMENZA JW, 1995, J ORAL MAXIL SURG, V53, P1004, DOI 10.1016/0278-2391(95)90114-0; CONSTANTINO PD, 1998, HEAD NECK SURG OTOLA, P1848; COOPER PW, 1982, J OTOLARYNGOL, V11, P319; Dagi T F, 1983, Am J Emerg Med, V1, P295, DOI 10.1016/0735-6757(83)90109-2; DALY D T, 1992, Ear Nose and Throat Journal, V71, P311; DEMETRIADES D, 1992, INJURY, V23, P377, DOI 10.1016/0020-1383(92)90011-G; HELLING TS, 1988, J TRAUMA, V28, P1575, DOI 10.1097/00005373-198811000-00009; HUBBARD JL, 1985, NEUROSURGERY, V16, P314, DOI 10.1227/00006123-198503000-00006; JENNETT B, 1980, J NEUROL NEUROSUR PS, V43, P289, DOI 10.1136/jnnp.43.4.289; Lanza DC, 1996, LARYNGOSCOPE, V106, P1119, DOI 10.1097/00005537-199609000-00015; LAUN A, 1982, ACTA NEUROCHIR, V60, P215, DOI 10.1007/BF01406308; Lee D, 1998, LARYNGOSCOPE, V108, P816, DOI 10.1097/00005537-199806000-00008; LEECH PJ, 1973, LANCET, V1, P1013; Loew F, 1984, Adv Tech Stand Neurosurg, V11, P169; MARENTETTE LJ, 1991, OTOLARYNG CLIN N AM, V24, P151; Marion D W, 1991, Neurosurg Clin N Am, V2, P411; MCGUIRT WF, 1995, LARYNGOSCOPE, V105, P359, DOI 10.1288/00005537-199504000-00003; PARK JI, 1983, LARYNGOSCOPE, V93, P1294; Villalobos T, 1998, CLIN INFECT DIS, V27, P364, DOI 10.1086/514666; ZLAB M K, 1992, Ear Nose and Throat Journal, V71, P314	25	80	85	0	11	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5607	1437-2320		NEUROSURG REV	Neurosurg. Rev.	JAN	2006	29	1					64	71		10.1007/s10143-005-0396-3			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	986QU	WOS:000233465600014	15937689				2022-02-06	
J	Zygun, DA; Zuege, DJ; Boiteau, PJE; Loupland, KB; Henderson, EA; Kortbeek, JB; Doig, CJ				Zygun, David A.; Zuege, Danny J.; Boiteau, Paul J. E.; Loupland, Kevin B.; Henderson, Elizabeth A.; Kortbeek, John B.; Doig, Christopher J.			Ventilator-associated pneumonia in severe traumatic brain injury	NEUROCRITICAL CARE			English	Article						craniocerebral trauma; pneumonia; multiple organ failure; treatment outcome; critical care	ORGAN DYSFUNCTION; HEAD-INJURY; STAPHYLOCOCCUS-AUREUS; NOSOCOMIAL PNEUMONIA; RISK-FACTORS; COMPLICATIONS; COLONIZATION; CARE; MODERATE; OUTCOMES	Introduction: Pneumonia is an important cause of morbidity following severe traumatic brain injury (TBI). However, previous studies have been limited by inclusion of specific patient subgroups or by selection bias. The primary objective of this study was to describe the incidence, risk factors for, and outcome of ventilator-associated pneumonia in an unselected population-based cohort of patients with severe TBI. An additional goal was to define the relationship of ventilator-associated pneumonia (VAP) with nonneurological organ dysfunction. Methods: A prospective, observational cohort study was performed at Foothills Medical Centre, the sole adult tertiary-care trauma center servicing southern Alberta. All patients with severe TBI requiring ventilation for more than 48 hours between May 1, 2000 and December 30, 2002 were included. Results: A total of 60 patients (45%) acquired VAP for an incidence density of 42.7/1000 ventilator days. Patients with polytrauma were at higher risk (risk ratio 1.7,95% confidence interval, 0.9-3.1) for development of VAP than those with isolated head injury. Development of VAP was associated with a significantly greater degree of nonneurological organ system dysfunction. Although VAP was not associated with increased hospital mortality, patients who developed VAP had a longer duration of mechanical ventilation (15 versus 8 days, p < 0.0001), longer intensive care unit (17 versus 9 days, p < 0.0001) and hospital (60 versus 28 days, p = 0.003) lengths of stay, and more often required tracheostomy (35 versus 18%, p = 0.003). Conclusions: VAP occurs frequently and is associated with significant morbidity in requests to: patients with severe TBI.	Univ Calgary, Dept Crit Care Med, Calgary, AB T2N 1N4, Canada; Univ Calgary, Dept Clin Neurosci, Calgary, AB T2N 1N4, Canada; Univ Calgary, Dept Med, Calgary, AB T2N 1N4, Canada; Univ Calgary, Dept Surg, Calgary, AB T2N 1N4, Canada; Univ Calgary, Dept Community Hlth Sci, Calgary, AB T2N 1N4, Canada		Zygun, DA (corresponding author), Foothills Med Ctr, Room EG23,1403-29 St NW, Calgary, AB T2N 2T9, Canada.	david.zygun@calgaryhealthregion.ca	Zuege, Danny J./L-5368-2017; Doig, Christopher/AAC-7949-2020; Kortbeek, John B/AAO-5298-2020	Zuege, Danny J./0000-0003-2033-5847; Doig, Christopher/0000-0002-8576-9139; Laupland, kevin/0000-0002-1205-5354			Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Artigas AT, 2001, CRIT CARE MED, V29, P304, DOI 10.1097/00003246-200102000-00015; Berrouane Y, 1998, J HOSP INFECT, V40, P275, DOI 10.1016/S0195-6701(98)90303-6; Bronchard G, 2004, ANESTHESIOLOGY, V100, P234, DOI 10.1097/00000542-200402000-00009; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Campbell W, 1999, CRIT CARE MED, V27, P798, DOI 10.1097/00003246-199904000-00039; Cazzadori A, 1997, RESP MED, V91, P193, DOI 10.1016/S0954-6111(97)90038-X; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Doig CJ, 2004, CRIT CARE MED, V32, P384, DOI 10.1097/01.CCM.0000108881.14082.10; Eggimann P, 2003, INTENS CARE MED, V29, P2086, DOI 10.1007/s00134-003-1991-9; EMORI TG, 1991, AM J INFECT CONTROL, V19, P19, DOI 10.1016/0196-6553(91)90157-8; Ewig S, 1999, AM J RESP CRIT CARE, V159, P188, DOI 10.1164/ajrccm.159.1.9803097; Friedman JA, 2003, NEUROSURGERY, V52, P1025, DOI 10.1227/01.NEU.0000058222.59289.F1; HSIEH AHH, 1992, AM REV RESPIR DIS, V146, P290, DOI 10.1164/ajrccm/146.2.290; Kerwin AJ, 2000, J TRAUMA, V48, P878, DOI 10.1097/00005373-200005000-00011; Kollef MH, 1999, NEW ENGL J MED, V340, P627, DOI 10.1056/NEJM199902253400807; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Laupland KB, 2003, CLIN INFECT DIS, V37, P933, DOI 10.1086/377735; Leone M, 2002, CRIT CARE MED, V30, P1741, DOI 10.1097/00003246-200208000-00011; MACKENZIE EJ, 1988, J TRAUMA, V28, P281, DOI 10.1097/00005373-198803000-00003; Masson F, 1997, J CLIN EPIDEMIOL, V50, P595, DOI 10.1016/S0895-4356(97)00012-7; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Mostafa G, 2002, J TRAUMA, V53, P430, DOI 10.1097/00005373-200209000-00006; Napolitano LM, 2002, J TRAUMA, V53, P434; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Rello J, 2002, CHEST, V122, P656, DOI 10.1378/chest.122.2.656; RELLO J, 1992, EUR RESPIR J, V5, P1249; RODRIGUEZ JL, 1991, J TRAUMA, V31, P907, DOI 10.1097/00005373-199107000-00005; Sirvent JM, 2000, INTENS CARE MED, V26, P1369, DOI 10.1007/s001340000611; Sirvent JM, 1997, AM J RESP CRIT CARE, V155, P1729, DOI 10.1164/ajrccm.155.5.9154884; SNOW WG, 1988, CAN J SURG, V31, P191; Solomon S, 2003, AM J INFECT CONTROL, V31, P481; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P479, DOI DOI 10.1089/NEU.2000.17.479; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1; Warren DK, 2003, CRIT CARE MED, V31, P1312, DOI 10.1097/01.CCM.0000063087.93157.06; Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35; Wehler M, 2003, CRIT CARE MED, V31, P1094, DOI 10.1097/01.CCM.0000059642.97686.8B; Wong Pauline P., 1993, Brain Injury, V7, P283, DOI 10.3109/02699059309034955; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54; Zygun DA, 2005, CAN J NEUROL SCI, V32, P87, DOI 10.1017/S0317167100016930; ZYGUN DA, 2005, IN PRESS CRIT CARE M	45	80	84	0	11	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care		2006	5	2					108	114		10.1385/NCC:5:2:108			7	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	098ZN	WOS:000241562400006	17099256	Green Published			2022-02-06	
J	Killam, C; Cautin, RL; Santucci, AC				Killam, C; Cautin, RL; Santucci, AC			Assessing the enduring residual neuropsychological effects of head trauma in college athletes who participate in contact sports	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						concussion; memory; Postconcussion Syndrome Checklist; processing speed; Repeatable Battery for the Assessment of Neuropsychological Status; stroop task	MILD BRAIN INJURY; REPEATABLE BATTERY; POSTCONCUSSION SYMPTOMS; FOOTBALL PLAYERS; HIGH-SCHOOL; CONCUSSION; RECOVERY; VALIDITY; SCHIZOPHRENIA; IMPAIRMENT	The present study examined the enduring residual neuropsychological effects of head trauma in college athletes using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Postconcussion Syndrome Checklist, and the Stroop task. Based on a brief self-report concussion history survey, male and female athletes who participated in ice hockey, field hockey, lacrosse, and/or soccer were assigned to one of three concussion-history conditions: Non-concussed, Non-recent concussed (i.e., more than 2 years since last concussion), or Recent concussed (i.e., 2 years or less since last concussion). A fourth group of subjects consisting of non-concussed/non-athletes served in the control condition. Group differences emerged on the RBANS when immediate memory, delayed memory, and total scores were analyzed. Specifically, recent concussed athletes and, surprisingly, non-concussed athletes scored lower than control subjects in the two memory domains, whereas all three athlete groups had lower total RBANS scores than those of control subjects. Moreover, recent concussed athletes not only had lower immediate memory scores than control subjects, but also were impaired relative to non-recent concussed athlete subjects in this memory domain. No group differences were detected on the Stroop task or on the Postconcussion Syndrome Checklist. Interestingly, however, the severity of the Postconcussion Syndrome Checklist scores for the two athlete-concussed groups, taken in aggregate, correlated negatively with RBANS scores for attention (r= -.65) and delayed memory (r= -.61), and with the total RBANS score (r = -.59). In recent concussed athletes, lower in contact sports may produce sub-clinical cognitive impairments in the absence of a diagnosable concussion presumably resulting from the cumulative consequences produced by multiple mild head trauma delayed memory scores correlated with more severe Postconcussion Symptom Checklist scores (r = -.90), while more severe/higher number of concussions correlated with increased processing speed on the Stroop interference task (r =.90). These findings indicate that recent head injury produces alterations in neuropsychological function, especially that of memory, that resolve with time. More provocatively, the data also suggest that participation in contact sports may produce sub-clinical cognitive impairments in the absence of a diagnosable concussion presumably resulting from the cumulative consequences produced by multiple mild head trauma. (c) 2005 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Manhattanville Coll, Dept Psychol, Purchase, NY 10577 USA		Santucci, AC (corresponding author), Manhattanville Coll, Dept Psychol, 2900 Purchase St, Purchase, NY 10577 USA.	santuccia@mville.edu					*AM AC NEUR, 1997, PRACT PAR MAN CONC S; Beatty WW, 2003, ARCH CLIN NEUROPSYCH, V18, P509, DOI 10.1016/S0887-6177(02)00148-8; BIRDSONG WH, 1992, J OCCUP ENVIRON MED, V34, P940; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gold JM, 1999, AM J PSYCHIAT, V156, P1944; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hinton-Bayre AD, 2002, NEUROLOGY, V59, P1068, DOI 10.1212/WNL.59.7.1068; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McKeever CK, 2003, APPL NEUROPSYCHOL, V10, P4, DOI 10.1207/S15324826AN1001_2; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Randolph C, 1998, J CLIN EXP NEUROPSYC, V20, P310, DOI 10.1076/jcen.20.3.310.823; Randolph C., 1998, REPEATABLE BATTERY A; Rutherford A, 2003, NEUROPSYCHOL REV, V13, P153, DOI 10.1023/A:1025525613477; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Wilk CM, 2002, AM J PSYCHIAT, V159, P838, DOI 10.1176/appi.ajp.159.5.838; ZHOU YL, 1995, PHYSIOL BEHAV, V57, P1107, DOI 10.1016/0031-9384(95)00019-F	31	80	81	1	17	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JUL	2005	20	5					599	611		10.1016/j.acn.2005.02.001			13	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	942EY	WOS:000230266900004	15939185	Bronze			2022-02-06	
J	Levin, HS; McCauley, SR; Josic, CP; Boake, C; Brown, SA; Goodman, HS; Merritt, SG; Brundage, SI				Levin, HS; McCauley, SR; Josic, CP; Boake, C; Brown, SA; Goodman, HS; Merritt, SG; Brundage, SI			Predicting depression following mild traumatic brain injury	ARCHIVES OF GENERAL PSYCHIATRY			English	Article							MINOR HEAD-INJURY; MAJOR DEPRESSION; COMMUNITY SAMPLE; PSYCHIATRIC-DISORDERS; MOOD DISORDERS; UNITED-STATES; SYMPTOMS; PREVALENCE; SCALE; RELIABILITY	Context: Minimizing negative consequences of major depression following traumatic brain injury is an important public health objective. Identifying high-risk patients and referring them for treatment could reduce morbidity and loss of productivity. Objective: To develop a model for early screening of patients at risk for major depressive episode at 3 months after traumatic brain injury. Design: Prediction model using receiver operating characteristic curve. Setting: Level I trauma center in a major metropolitan area. Participants: Prospective cohort of 129 adults with mild traumatic brain injury. Main Outcome Measures: Center for Epiderniologic Studies Depression Scale score and current major depressive episode module of the Structured Clinical Interview for the DSM-IV. Results: A prediction model including higher I-week Center for Epiderniologic Studies Depression Scale score, older age, and computed tomographic scans of intracranial lesions yielded 93% sensitivity and 62% specificity. Conclusion: This study supports the feasibility of identifying patients with mild traumatic brain injury who are at high risk for developing major depressive episode by 3 months' postinjury, which could facilitate selective referral for potential treatment and reduction of negative outcomes.	Baylor Coll Med, Cognit Neurosci Lab, Phys Med & Rehabil Alliance, Houston, TX 77030 USA; Univ Texas, Sch Med, Houston, TX USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA; Baylor Coll Med, Dept Surg, Houston, TX 77030 USA		Levin, HS (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Phys Med & Rehabil Alliance, 6560 Fannin St,Suite 1144, Houston, TX 77030 USA.	hlevin@bcm.tmc.edu			ODCDC CDC HHS [R49/CCR612707] Funding Source: Medline		American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; BEEKMAN ATF, 1997, TIJDSCHRIFT PSYCHIAT, V0039; BLAZER DG, 1994, AM J PSYCHIAT, V151, P979; BOAKE C, IN PRESS NEUROSURGER; BOYD JH, 1982, ARCH GEN PSYCHIAT, V39, P1195; Cocco KM, 1998, PSYCHOL ASSESSMENT, V10, P408, DOI 10.1037/1040-3590.10.4.408; *COMM INJ SCAL, 1990, ABBR INJ SCAL; DAVIDSON H, 1994, J GERONTOL, V49, pP159, DOI 10.1093/geronj/49.4.P159; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Deb S, 1999, AM J PSYCHIAT, V156, P374; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; First M.B., 1996, STRUCTURED CLIN INTE; GOLDING JM, 1991, J CLIN PSYCHOL, V47, P61, DOI 10.1002/1097-4679(199101)47:1<61::AID-JCLP2270470110>3.0.CO;2-E; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; GUTH PE, 2000, DISS ABSTR INT, V51, P1803; Haarasilta L, 2001, PSYCHOL MED, V31, P1169, DOI 10.1017/S0033291701004573; HIMMELFARB S, 1983, J GERONTOL, V38, P333, DOI 10.1093/geronj/38.3.333; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Iwata N, 2002, PSYCHIAT RES, V110, P281, DOI 10.1016/S0165-1781(02)00102-6; Jonas BS, 2003, SOC PSYCH PSYCH EPID, V38, P618, DOI 10.1007/s00127-003-0682-8; Jorge R, 2003, INT REV PSYCHIATR, V15, P317, DOI 10.1080/09540260310001606700; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Maisto SA, 2000, PSYCHOL ASSESSMENT, V12, P186, DOI 10.1037/1040-3590.12.2.186; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; MYERS JK, 1980, AM J PSYCHIAT, V137, P1081; MYERS JK, 1984, ARCH GEN PSYCHIAT, V41, P959; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; REGIER DA, 1988, ARCH GEN PSYCHIAT, V45, P977; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROBERTS RE, 1980, PSYCHIAT RES, V2, P125, DOI 10.1016/0165-1781(80)90069-4; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; *SAS I INC, 2001, STAT AN SOFTW WIND C; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; Schopp LH, 2001, J CLIN PSYCHOL MED S, V8, P181, DOI 10.1023/A:1011369620254; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; SHINAR D, 1986, STROKE, V17, P241, DOI 10.1161/01.STR.17.2.241; TEASDALE G, 1974, LANCET, V2, P81; VERA M, 1991, AM J EPIDEMIOL, V134, P502, DOI 10.1093/oxfordjournals.aje.a116122; WEISSMAN MM, 1977, AM J EPIDEMIOL, V106, P203, DOI 10.1093/oxfordjournals.aje.a112455; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	52	80	80	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0003-990X			ARCH GEN PSYCHIAT	Arch. Gen. Psychiatry	MAY	2005	62	5					523	528		10.1001/archpsyc.62.5.523			6	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	923JG	WOS:000228905600008	15867105	Bronze			2022-02-06	
J	Togher, L; McDonald, S; Code, C; Grant, S				Togher, L; McDonald, S; Code, C; Grant, S			Training communication partners of people with traumatic brain injury: A randomised controlled trial	APHASIOLOGY			English	Article							SOCIAL-SKILLS; HEAD-INJURY; APHASIA; CONVERSATION; DISCOURSE; ADULTS; REHABILITATION; INDIVIDUALS; IMPAIRMENT; VOLUNTEERS	Background : Communication disorders after traumatic brain injury (TBI) are difficult to modify due to the cognitive limitation imposed by frontal lobe damage. As an alternative approach, this paper describes a training programme designed to improve communication partners' responsiveness to people with TBI during routine service inquiries with a community agency. Aims : To evaluate the effectiveness of a training programme aimed at improving the communication of police officers during service encounters with people with TBI. Methods & Procedures : A total of 20 police officers were randomly assigned to two groups (training or control). Prior to the 6-week training programme, participants with TBI made a routine telephone inquiry to the police officers. Training focused on specific aspects of telephone inquiries previously documented to be aberrant in service encounters of people with TBI. Following the training programme, police subjects received another telephone service inquiry. Service encounters were transcribed and analysed using generic structure potential analysis. Outcome & Results : Comparison of pre- and post-training measures indicated that trained police had learned strategies to successfully establish the nature of the inquiry, provide a clear answer to the inquiry, and ensure appropriate leave taking, resulting in more efficient, focused interactions in the post-training telephone calls. People with TBI also altered their communication in the post-training calls, with reduced episodes of unrelated utterances and an increased proportion of the interaction devoted to completing the service encounter. This appeared to be in response to the communicative options they were given. Conclusions : This study demonstrates the efficacy of an approach based on training communication partners rather than people with TBI themselves. Training communication partners led to the provision of appropriate feedback, support, and structure of everyday interactions. Service encounters account for a significant amount of everyday communication exchanges, therefore training service providers has the potential to have a significant impact on the communicative effectiveness of people with TBI.	Univ Sydney, Fac Hlth Sci, Sch Commun Sci & Disorders, Lidcombe, NSW 2199, Australia; Univ NSW, Kensington, NSW, Australia; Univ Sydney, Sydney, NSW 2006, Australia; Univ Exeter, Exeter EX4 4QJ, Devon, England; Hanse Inst Adv Study, Delmenhorst, Germany		Togher, L (corresponding author), Univ Sydney, Fac Hlth Sci, Sch Commun Sci & Disorders, POB 170, Lidcombe, NSW 2199, Australia.	l.togher@fhs.usyd.edu.au	Togher, Leanne/AAC-7083-2019; Code, Chris/F-4259-2010; McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094; Togher, Leanne/0000-0002-4518-6748			Boles L, 1998, J COMMUN DISORD, V31, P261, DOI 10.1016/S0021-9924(98)00005-7; Booth S, 1999, INT J LANG COMM DIS, V34, P291, DOI 10.1080/136828299247423; Booth S, 1999, APHASIOLOGY, V13, P283, DOI 10.1080/026870399402109; Bourgeois M., 2001, AUGMENTATIVE ALTERNA, V17, P196, DOI DOI 10.1080/714043383; BRAUNLINGMCMORROW D, 1986, J REHABIL, V52, P39; BRENNAN M, 1994, CLEAR TALK POLICE RE; BROTHERTON FA, 1988, ARCH PHYS MED REHAB, V69, P827; Burgio LD, 2001, GERONTOLOGIST, V41, P449, DOI 10.1093/geront/41.4.449; Byng S., 2000, ACQUIRED NEUROLOGICA; Carnevale GJ, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199602000-00005; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; Coelho CA, 1996, J SPEECH HEAR RES, V39, pS5, DOI 10.1044/jshr.3905.s5; Cohen J., 2013, STAT POWER ANAL BEHA; Duffy, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; EGGINS S, 1997, ANAL CONVERSATION; FLANAGAN S, 1995, BRAIN INJURY, V9, P321, DOI 10.3109/02699059509005773; Frattali C M, 1993, Disabil Rehabil, V15, P1; GAJAR A, 1984, J APPL BEHAV ANAL, V17, P353, DOI 10.1901/jaba.1984.17-353; Godfrey HPD, 2000, APHASIOLOGY, V14, P433, DOI 10.1080/026870300401441; Halliday M., 2004, INTRO FUNCTIONAL GRA; Hartley L. L, 1995, COGNITIVE COMMUNICAT; Hasan Ruqaiya, 1985, LANGUAGE CONTEXT TEX; HELFFENSTEIN DA, 1982, INT J CLIN NEUROPSYC, V4, P139; Holland D, 1998, BRAIN INJURY, V12, P993, DOI 10.1080/026990598121918; Hopper T, 2002, APHASIOLOGY, V16, P745, DOI 10.1080/02687030244000059; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JOHNSON DA, 1987, BRIT J CLIN PSYCHOL, V26, P289, DOI 10.1111/j.2044-8260.1987.tb01362.x; Kagan A, 2001, J SPEECH LANG HEAR R, V44, P624, DOI 10.1044/1092-4388(2001/051); LEWIS FD, 1988, BEHAV THER, V19, P203, DOI 10.1016/S0005-7894(88)80043-1; Lock S, 2001, INT J LANG COMM DIS, V36, P25, DOI 10.3109/13682820109177853; Luiselli JK, 2000, INT J OFFENDER THER, V44, P647, DOI 10.1177/0306624X00446002; Lyon JG, 1997, APHASIOLOGY, V11, P693, DOI 10.1080/02687039708249416; MARSH NV, 1999, BRAIN DAM B, P175; Martin J. R., 1992, ENGLISH TEXT SYSTEM; McDonald S, 1998, BRAIN LANG, V61, P88, DOI 10.1006/brln.1997.1846; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MCDONALD S, 2003, PSYCHOL INTERACTION, V13, P47; MCDONALD S, 1999, COMMUNICATION DISORD; MENTIS M, 1991, J SPEECH HEAR RES, V34, P583, DOI 10.1044/jshr.3403.583; NEWHOFF M, 1981, CLIN APHASIOLOGY, V11, P234; *NHIF, 1989, ED MAN WHAT ED NEED; OLVER J, 2001, 6 ANN BRAIN INJ REH; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Pound C., 2000, APHASIA THERAPIES LI; Poynton C., 1985, LANGUAGE GENDER MAKI; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; Ripich D. N., 1999, CLIN GERONTOLOGIST, V21, P37, DOI DOI 10.1300/J018V21N01; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Schiffrin Deborah, 1987, DISCOURSE MARKERS; SCHLOSS PJ, 1985, APPL RES MENT RETARD, V6, P269, DOI 10.1016/0270-3092(85)90001-3; SIMMONS N, 1987, CLIN APHASIOLOGY, V17, P106; Simmons-Mackie N, 1999, APHASIOLOGY, V13, P807, DOI 10.1080/026870399401894; SMITH L, 1986, B COLLEGE SPEECH THE, V409, P10; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; STRATTON MC, 1994, BRAIN INJURY, V8, P631, DOI 10.3109/02699059409151016; Szekeres Shirley F., 1992, Seminars in Speech and Language, V13, P293, DOI 10.1055/s-2008-1064204; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 1999, APHASIOLOGY, V13, P709, DOI 10.1080/026870399401821; Togher L, 1998, APHASIOLOGY, V12, P755, DOI 10.1080/02687039808249571; Togher L, 1997, APHASIOLOGY, V11, P491, DOI 10.1080/02687039708248486; Togher L, 1996, DISABIL REHABIL, V18, P559, DOI 10.3109/09638289609166317; Wilkinson IAG, 1998, READ RES QUART, V33, P144, DOI 10.1598/RRQ.33.2.1; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183; World Health Organization, 2001, INT CLASSIFICATION F; Worrall L, 2000, APHASIOLOGY, V14, P911, DOI 10.1080/02687030050127711; Worrall L. E., 2000, NEUROGENIC COMMUNICA, P162; Ylvisaker M. E., 1998, TRAUMATIC BRAIN INJU; YVISAKER M, 1993, STAFF DEV CLIN INTER, P57	70	80	84	1	21	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0268-7038	1464-5041		APHASIOLOGY	Aphasiology	APR	2004	18	4					313	335		10.1080/02687030344000535			23	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	814FG	WOS:000220960000002					2022-02-06	
J	Cuevas, P; Carceller, F; Garcia-Gomez, I; Yan, M; Dujovny, M				Cuevas, P; Carceller, F; Garcia-Gomez, I; Yan, M; Dujovny, M			Bone marrow stromal cell implantation for peripheral nerve repair	NEUROLOGICAL RESEARCH			English	Article						sciatic nerve transection; bone marrow stromal cells; cellular therapy; regeneration	TRAUMATIC BRAIN INJURY; STEM-CELLS; RATS; TRANSPLANTATION; REGENERATION; RECOVERY; STROKE	Cell therapy using bone marrow stromal cells is a new promising therapy for regenerative medicine. Previous studies demonstrated that local bone marrow stromal cells implantation in the distal stump of transected sciatic nerve of rats promotes early functional recovery. The purpose of this study was to expand on the preliminary research by investigating the long-term efficacy of bone marrow stromal cells using the same experimental setting. Functional test and histological studies demonstrate that bone marrow stromal cell-treated rats exhibit significant improvement on a walking tract test at day 180 after surgery compared with control rats. Taken together, these data suggest that bone marrow stromal cell therapy is a safe and effective strategy for peripheral nerve injuries.	Univ Alcala de Henares, Serv Histol, Dept Invest, Hosp Univ Ramon & Cajal, E-28034 Madrid, Spain; Wayne State Univ, Dept Neurosurg, Detroit, MI USA; Hosp Jingxi, Beijing, Peoples R China		Cuevas, P (corresponding author), Univ Alcala de Henares, Serv Histol, Dept Invest, Hosp Univ Ramon & Cajal, E-28034 Madrid, Spain.	pedro.cuevas@hrc.es					Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Cuevas P, 2002, NEUROL RES, V24, P634, DOI 10.1179/016164102101200564; CUEVAS P, 2003, CELULAS TRONCALES HU, P63; Dezawa M, 2001, EUR J NEUROSCI, V14, P1771, DOI 10.1046/j.0953-816x.2001.01814.x; Dijkstra JR, 2000, J NEUROSCI METH, V96, P89, DOI 10.1016/S0165-0270(99)00174-0; Korbling M, 2003, BONE MARROW TRANSPL, V32, pS23, DOI 10.1038/sj.bmt.1703939; Li Y, 2001, NEUROSCI LETT, V316, P67, DOI 10.1016/S0304-3940(01)02384-9; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Siminiak T, 2003, CIRCULATION, V108, P1167, DOI 10.1161/01.CIR.0000086628.42652.8D; Varejao ASP, 2001, J NEUROSCI METH, V108, P1, DOI 10.1016/S0165-0270(01)00378-8; Wakitani S, 2003, RHEUMATOLOGY, V42, P162, DOI 10.1093/rheumatology/keg024; WALL PD, 1979, PAIN, V7, P103, DOI 10.1016/0304-3959(79)90002-2	18	80	91	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	MAR	2004	26	2					230	232		10.1179/016164104225013897			3	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	809BS	WOS:000220612800015	15072644				2022-02-06	
J	Azouvi, P; Couillet, J; Leclercq, M; Martin, Y; Asloun, S; Rousseaux, M				Azouvi, P; Couillet, J; Leclercq, M; Martin, Y; Asloun, S; Rousseaux, M			Divided attention and mental effort after severe traumatic brain injury	NEUROPSYCHOLOGIA			English	Article						divided attention; central executive; working memory; executive functions; traumatic brain injury	CLOSED-HEAD INJURY; DUAL-TASK PERFORMANCE; RANDOM NUMBER GENERATION; WORKING-MEMORY; DEFICITS; IMPAIRMENTS; TESTS	The aim of this study was to assess dual-task performance in TBI patients, under different experimental conditions, with or without explicit emphasis on one of two tasks. Results were compared with measurement of the subjective mental effort required to perform each task. Forty-three severe TBI patients at the subacute or chronic phase performed two tasks under single- and dual-task conditions: (a) random generation; (b) visual go-no go reaction time task. Three dual-task conditions were given, requiring either to consider both tasks as equally important or to focus preferentially on one of them. Patients were compared to matched controls. Subjective mental effort was rated on a visual analogic scale. TBI patients showed a disproportionate increase in reaction time in the go-no go task under the dual-task condition. However, they were just as able as controls to adapt performance to the specific instructions about the task to be emphasised. Patients reported significantly higher subjective mental effort, but the variation of mental effort according to task condition was similar to that of controls. These results suggest that the divided attention deficit of TBI patients is related to a reduction in available processing resources rather than an impairment of strategic processes responsible for attentional allocation and switching. The higher level of subjective mental effort may explain why TBI patients frequently complain of mental fatigue, although this subjective complaint seems to be relatively independent of cognitive impairment. (C) 2004 Elsevier Ltd. All rights reserved.	Univ Versailles St Quentin, Hop Raymond Poincare, Fac Med Paris Ile France Quest, Serv Reeducat Neurol, F-92380 Garches, France; Ctr Neurol William Lennox, Louvain, Belgium; Ctr Reeducat Espoir, Lille Hellemmes, France; Hop Swynghedauw, Serv Reeducat Neurol, Lille, France		Azouvi, P (corresponding author), Univ Versailles St Quentin, Hop Raymond Poincare, Fac Med Paris Ile France Quest, Serv Reeducat Neurol, F-92380 Garches, France.	philippe.azouvi@rpc.ap-hop-paris.fr					Adcock RA, 2000, P NATL ACAD SCI USA, V97, P3567, DOI 10.1073/pnas.060588897; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; Baddeley A.D., 1986, WORKING MEMORY; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brouwer W, 2001, BRAIN COGNITION, V46, P54, DOI 10.1016/S0278-2626(01)80033-6; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; Brouwer WH, 2002, J HEAD TRAUMA REHAB, V17, P1, DOI 10.1097/00001199-200202000-00003; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; CHATFIELD C, 1984, ANAL TIME SERIES; Collette F, 2002, NEUROSCI BIOBEHAV R, V26, P105, DOI 10.1016/S0149-7634(01)00063-X; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; EVANS FJ, 1978, B PSYCHONOMIC SOC, V12, P35; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Herath P, 2001, CEREB CORTEX, V11, P796, DOI 10.1093/cercor/11.9.796; KENDALL MG, 1973, TIMES SERIES; Klingberg T, 1998, CEREB CORTEX, V8, P593, DOI 10.1093/cercor/8.7.593; Koechlin E, 1999, NATURE, V399, P148, DOI 10.1038/20178; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; Leclercq M, 2002, APPLIED NEUROPSYCHOLOGY OF ATTENTION: THEORY DIAGNOSIS AND REHABILITATION, P257; LECLERCQ M, 1990, NORMALISATION 3 EPRE; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Riese H, 1999, NEUROPSYCHOL REHABIL, V9, P189, DOI 10.1080/713755600; ROSENBERG S, 1990, PSYCHOL MED, V20, P953, DOI 10.1017/S0033291700036643; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Vilkki J, 1996, NEUROPSYCHOLOGIA, V34, P1051, DOI 10.1016/0028-3932(96)00028-0; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; WITHAAR FK, 2000, THESIS RIJSKUNIVERSI	39	80	83	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia		2004	42	9					1260	1268		10.1016/j.neuropsychologia.2004.01.001			9	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	834NN	WOS:000222417900012	15178177				2022-02-06	
J	Hattori, N; Huang, SC; Wu, HM; Yeh, E; Glenn, TC; Vespa, PM; McArthur, D; Phelps, ME; Hovda, DA; Bergsneider, M				Hattori, N; Huang, SC; Wu, HM; Yeh, E; Glenn, TC; Vespa, PM; McArthur, D; Phelps, ME; Hovda, DA; Bergsneider, M			Correlation of regional metabolic rates of glucose with Glasgow coma scale after traumatic brain injury	JOURNAL OF NUCLEAR MEDICINE			English	Article						PET; cerebral glucose metabolism; concussion; coma; head injury; diffuse axonal injury	POSITRON-EMISSION-TOMOGRAPHY; CEREBRAL BLOOD-FLOW; DIFFUSE AXONAL INJURY; FDG LUMPED CONSTANT; SEVERE HEAD-INJURY; TIME UPTAKE DATA; GRAPHICAL EVALUATION; PRACTICAL SCALE; HUMANS; CONSCIOUSNESS	After traumatic brain injury (TBI), subcortical white matter damage may induce a functional disconnection leading to a dissociation of regional cerebral metabolic rate of glucose (CMRglc) between the cerebral cortex and deeper brain regions. Therefore, thalamic and brain stem CMRglc may have a closer correlation than does the cerebral cortex with depth of coma after TBI. Methods: Eleven adult healthy volunteers and 23 adult patients with TBI (median initial Glasgow Coma Scale score [GCSini], 8) underwent F-18-FDG PET within 5 d after injury. The CMRglc of cortical areas (remote from hemorrhagic lesions), striatum, thalamus, brain stem, cerebellar cortex, and whole brain was compared with severity of injury and the level of consciousness evaluated using GCSini and the Glasgow Coma Scale score at the time of PET (GCSpet). Results: The regional CMRglc of the brain stem is relatively unaffected by the TBI. Compared with healthy volunteers, TBI patients exhibited significantly depressed CMRglc in the striatum (3.9 +/- 1.3 vs. 5.1 +/- 0.9 mg/100 g/min, P < 0.05) and thalamus (3.1 +/- 1.0 vs. 4.3 +/- 0.9 mg/100 g/min, P < 0.05). CMRglc levels were not statistically lower in the cerebellum (2.9 +/- 0.8 vs. 3.5 +/- 0.8 mg/100 g/min, P = NS) and brain stem (2.5 +/- 0.5 vs. 2.6 +/- 0.5 mg/100 g/min, P NS). However, compared between comatose and noncomatose patients, ClVlRg1c values in the thalamus (2.7 +/- 0.7 vs. 3.6 +/-1.2 mg/100 g/min, P < 0.05), brain stem (2.2 +/- 0.4 vs. 2.8 +/- 0.5 mg/100 g/min, P < 0.01), and cerebellar cortex (2.6 +/- 0.5 vs. 3.4 +/- 1.0 mg/100 g/min, P < 0.05) were significantly lower in comatose patients. When individual values of regional ClVlRglc were plotted against posttraumatic level of consciousness, ClVlRglc values for the thalamus, brain stem, and cerebellum significantly correlated with the level of consciousness at the time of PET (r = 0.58, P < 0.01; r = 0.66, P < 0.01; r = 0.64, P < 0.01, respectively). CT or MRI findings were normal for the analyzed structures except for 3 patients with diffuse axonal injury of the brain stem. The presence of shear injury was associated with poor GCSini (P < 0.05.) but was not related to GCSpet and brain stem CMRglc. Conclusion: A PET investigation using F-18 FDG demonstrated a significant difference in glucose metabolism in the thalamus, brain stem, and cerebellum between comatose and noncomatose patients acutely after TBI. The metabolic rate of glucose in these regions significantly correlated with the level of consciousness at the time of PET.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, David Geffen Sch Med, US DOE, Ctr Mol Med, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, David Geffen Sch Med, Brain Injury Res Ctr, Div Neurosurg, Los Angeles, CA 90024 USA		Hattori, N (corresponding author), Box 956948, Los Angeles, CA 90095 USA.	nhattori@mednet.ucla.edu	Hattori, Naoya/G-2298-2012; Hattori, Naoya/AAR-6405-2020	Glenn, Thomas/0000-0003-4273-3408	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [30308] Funding Source: Medline		ALKIRE MT, 1995, ANESTHESIOLOGY, V82, P393, DOI 10.1097/00000542-199502000-00010; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Braun AR, 1997, BRAIN, V120, P1173, DOI 10.1093/brain/120.7.1173; Fiset P, 1999, J NEUROSCI, V19, P5506; FOSTER NL, 1987, J CEREBR BLOOD F MET, V7, P415, DOI 10.1038/jcbfm.1987.84; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Graham MM, 2002, J NUCL MED, V43, P1157; Hasselbalch SG, 1998, J CEREBR BLOOD F MET, V18, P154, DOI 10.1097/00004647-199802000-00005; Hasselbalch SG, 2001, J CEREBR BLOOD F MET, V21, P995, DOI 10.1097/00004647-200108000-00012; HATTORI N, 2002, J NEUROTRAUM, V19, P1273; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1984, SCIENCE, V223, P301, DOI 10.1126/science.6701514; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; HUANG SC, 1980, AM J PHYSIOL, V238, pE69, DOI 10.1152/ajpendo.1980.238.1.E69; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Ichimi K, 1999, NEUROL RES, V21, P579, DOI 10.1080/01616412.1999.11740980; ICHISE M, 1994, J NUCL MED, V35, P217; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; LIN KP, 1994, IEEE T NUCL SCI, V41, P2850, DOI 10.1109/23.340657; LLOYD KG, 1977, BRAIN RES, V127, P269, DOI 10.1016/0006-8993(77)90540-6; LONDON ED, 1990, ARCH GEN PSYCHIAT, V47, P73; McIntosh TK, 1996, LAB INVEST, V74, P315; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; NOLTE J, 1999, HUMAN BRAIN INTRO FU, P260; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; PATLAK CS, 1985, J CEREBR BLOOD F MET, V5, P584, DOI 10.1038/jcbfm.1985.87; PATLAK CS, 1983, J CEREBR BLOOD F MET, V3, P1, DOI 10.1038/jcbfm.1983.1; PHELPS ME, 1979, ANN NEUROL, V6, P371, DOI 10.1002/ana.410060502; POWELL MJD, 1964, COMPUT J, V7, P155, DOI 10.1093/comjnl/7.2.155; Press W. H., 1992, NUMERICAL RECIPES C, P394; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; TEASDALE G, 1974, LANCET, V2, P81; TENJIN H, 1990, NEUROSURGERY, V26, P971, DOI 10.1227/00006123-199006000-00009; WU HM, 2001, J CEREB BLOOD FLOW S, V21, pS180; Yamaki T, 1996, J NUCL MED, V37, P1166	44	80	87	0	7	SOC NUCLEAR MEDICINE INC	RESTON	1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA	0161-5505	1535-5667		J NUCL MED	J. Nucl. Med.	NOV	2003	44	11					1709	1716					8	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	741YV	WOS:000186488700010	14602850				2022-02-06	
J	Mattiasson, G; Friberg, H; Hansson, M; Elmer, E; Wieloch, T				Mattiasson, G; Friberg, H; Hansson, M; Elmer, E; Wieloch, T			Flow cytometric analysis of mitochondria from CA1 and CA3 regions of rat hippocampus reveals differences in permeability transition pore activation	JOURNAL OF NEUROCHEMISTRY			English	Article						cell death; flow cytometry; hippocampus; mitochondria; permeability transition; reactive oxygen species	TRANSIENT FOREBRAIN ISCHEMIA; TRAUMATIC BRAIN-INJURY; MOUSE-LIVER MITOCHONDRIA; SINGLE ORGANELLE LEVEL; CYCLOSPORINE-A; UNCOUPLING PROTEIN-2; CEREBRAL-ISCHEMIA; OXIDATIVE STRESS; CELL-DEATH; CYTOCHROME-C	Mitochondria are important in the pathophysiology of several neurodegenerative diseases, and mitochondrial production of reactive oxygen species (ROS), membrane depolarization, permeability changes and release of apoptogenic proteins are involved in these processes. Following brain insults, cell death often occurs in discrete regions of the brain, such as the subregions of the hippocampus. To analyse mitochondrial structure and function in such subregions, only small amounts of mitochondria are available. We developed a protocol for flow cytometric analysis of very small samples of isolated brain mitochondria, and analysed mitochondrial swelling and formation of ROS in mitochondria from the CA1 and CA3 regions of the hippocampus. Calcium-induced mitochondrial swelling was measured, and fluorescent probes were used to selectively stain mitochondria ( nonyl acridine orange), to measure membrane potential (tetramethylrhodamine-methylester, 1,1', 3,3,3',3'-hexamethylindodicarbocyanine-iodide) and to measure production of ROS (2',7'-dichlorodihydrofluorescein-diacetate). We found that formation of ROS and mitochondrial permeability transition pore activation were higher in mitochondria from the CA1 than from the CA3 region, and propose that differences in mitochondrial properties partly underlie the selective vulnerability of the CA1 region to brain insults. We also conclude that flow cytometry is a useful tool to analyse the role of mitochondria in cell death processes.	Lund Univ, Wallenberg Neurosci Ctr, Expt Brain Res Lab, SE-22184 Lund, Sweden		Mattiasson, G (corresponding author), Lund Univ, Wallenberg Neurosci Ctr, Expt Brain Res Lab, BMC A13, SE-22184 Lund, Sweden.	Gustav.Mattiasson@Expbr.lu.se	Elmer, Eskil/F-9341-2014; Hansson, Magnus/G-4486-2014	Elmer, Eskil/0000-0001-7901-1826; Hansson, Magnus/0000-0002-0201-0638; Wieloch, Tadeusz/0000-0002-7669-2520			Anderson MF, 2000, BRAIN RES PROTOC, V5, P95, DOI 10.1016/S1385-299X(99)00060-4; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Bernardi P, 1998, BIOFACTORS, V8, P273, DOI 10.1002/biof.5520080315; Bindokas VP, 1996, J NEUROSCI, V16, P1324; Casteilla L, 2001, IUBMB LIFE, V52, P181, DOI 10.1080/15216540152845984; Chen J, 1998, J NEUROSCI, V18, P4914; CHEN LB, 1989, METHOD CELL BIOL, V29, P103; CONNERN CP, 1994, BIOCHEM J, V302, P321, DOI 10.1042/bj3020321; Cossarizza A, 1996, EXP CELL RES, V222, P84, DOI 10.1006/excr.1996.0011; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Cunningham R E, 1999, Methods Mol Biol, V115, P249; DYKENS JA, 1994, J NEUROCHEM, V63, P584; Elmer E, 1998, NEUROSCIENCE, V83, P351, DOI 10.1016/S0306-4522(97)00387-4; Fiskum G, 1999, J CEREBR BLOOD F MET, V19, P351, DOI 10.1097/00004647-199904000-00001; Friberg H, 1999, J NEUROCHEM, V72, P2488, DOI 10.1046/j.1471-4159.1999.0722488.x; Friberg H, 2002, NEUROSCI LETT, V334, P111, DOI 10.1016/S0304-3940(02)01116-3; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Greenamyre JT, 1999, BIOCHEM SOC SYMP, V66, P85, DOI 10.1042/bss0660085; GRIFFITHS EJ, 1995, BIOCHEM J, V307, P93, DOI 10.1042/bj3070093; Gylys KH, 2000, J NEUROSCI RES, V61, P186, DOI 10.1002/1097-4547(20000715)61:2<186::AID-JNR9>3.0.CO;2-X; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Halestrap AP, 1998, BBA-BIOENERGETICS, V1366, P79, DOI 10.1016/S0005-2728(98)00122-4; Hansson MJ, 2003, BRAIN RES, V960, P99, DOI 10.1016/S0006-8993(02)03798-8; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; ITO U, 1975, ACTA NEUROPATHOL, V32, P209, DOI 10.1007/BF00696570; Jacobson J, 2002, J NEUROCHEM, V82, P224, DOI 10.1046/j.1471-4159.2002.00945.x; Jaroszeski MJ, 1999, MOL BIOTECHNOL, V11, P37, DOI 10.1007/BF02789175; KATO H, 1995, J CEREBR BLOOD F MET, V15, P60, DOI 10.1038/jcbfm.1995.7; KNIGHT VA, 1981, BIOCHIM BIOPHYS ACTA, V637, P146, DOI 10.1016/0005-2728(81)90220-6; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; LAPIDUS RG, 1994, J BIOL CHEM, V269, P18931; Lenaz G, 2001, IUBMB LIFE, V52, P159, DOI 10.1080/15216540152845957; LOPEZMEDIAVILLA C, 1992, EXP CELL RES, V203, P134, DOI 10.1016/0014-4827(92)90048-D; LOPEZMEDIAVILLA C, 1995, BBA-BIOENERGETICS, V1232, P27, DOI 10.1016/0005-2728(95)00105-8; LOPEZMEDIAVILLA C, 1989, FEBS LETT, V254, P115, DOI 10.1016/0014-5793(89)81020-8; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; MATEOS A, 1995, ALCOHOL CLIN EXP RES, V19, P1327, DOI 10.1111/j.1530-0277.1995.tb01620.x; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Medina JM, 2002, FEBS LETT, V510, P127, DOI 10.1016/S0014-5793(01)03260-4; Metivier D, 1998, IMMUNOL LETT, V61, P157, DOI 10.1016/S0165-2478(98)00013-3; Murphy AN, 1999, J CEREBR BLOOD F MET, V19, P231, DOI 10.1097/00004647-199903000-00001; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; OCONNOR JE, 1988, CELL TISSUE KINET, V21, P331, DOI 10.1111/j.1365-2184.1988.tb00791.x; OCONNOR JE, 1988, BIOCHEM BIOPH RES CO, V151, P568, DOI 10.1016/0006-291X(88)90632-8; Ouyang YB, 1999, J CEREBR BLOOD F MET, V19, P1126, DOI 10.1097/00004647-199910000-00009; PETIT JM, 1994, EUR J BIOCHEM, V220, P871, DOI 10.1111/j.1432-1033.1994.tb18690.x; PETIT PX, 1990, EUR J BIOCHEM, V194, P389, DOI 10.1111/j.1432-1033.1990.tb15632.x; Piccotti L, 2002, J BIOL CHEM, V277, P12075, DOI 10.1074/jbc.M200029200; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Richard D, 2001, BIOCHEM SOC T, V29, P812, DOI 10.1042/0300-5127:0290812; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Salvioli S, 2000, CYTOMETRY, V40, P189, DOI 10.1002/1097-0320(20000701)40:3<189::AID-CYTO3>3.0.CO;2-6; Shapiro HM, 2000, METHODS, V21, P271, DOI 10.1006/meth.2000.1007; SIMS NR, 1991, J NEUROCHEM, V56, P1836, DOI 10.1111/j.1471-4159.1991.tb03438.x; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Swift LM, 2000, AM J PHYSIOL-HEART C, V278, pH982, DOI 10.1152/ajpheart.2000.278.3.H982; Teranishi M, 2000, EXP MOL PATHOL, V68, P104, DOI 10.1006/exmp.1999.2288; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; VegaNunez E, 1997, ENDOCRINOLOGY, V138, P3771, DOI 10.1210/en.138.9.3771; Votyakova TV, 2001, J NEUROCHEM, V79, P266, DOI 10.1046/j.1471-4159.2001.00548.x; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	66	80	84	2	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	OCT	2003	87	2					532	544		10.1046/j.1471-4159.2003.02026.x			13	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	726JN	WOS:000185596100026	14511130				2022-02-06	
J	Figaji, AA; Fieggen, AG; Peter, JC				Figaji, AA; Fieggen, AG; Peter, JC			Early decompressive craniotomy in children with severe traumatic brain injury	CHILDS NERVOUS SYSTEM			English	Article						decompressive craniectomy; decompressive craniotomy; acute deterioration; raised intracranial pressure	SEVERE HEAD-INJURIES; CEREBRAL EDEMA; INTRACRANIAL HYPERTENSION; HEMISPHERIC INFARCTION; SURGICAL DECOMPRESSION; CRANIECTOMY; PRESSURE; MANAGEMENT; SURGERY; CONSCIOUSNESS	Introduction. Decompressive craniectomy remains a controversial procedure in the treatment of raised intracranial pressure (ICP) associated with post-traumatic brain swelling. Although there are a number of studies in adults published in the literature on this topic, most commonly as a salvage procedure in the treatment of refractory raised ICP, there are few that investigate it primarily in children with head injuries. Aim. Our aim was to report the experience with decompressive craniotomy in children with severe traumatic brain injury (TBI) at the Red Cross Children's' hospital. Methods. This study reports five patients in whom decompressive craniectomy or craniotomy with duraplasty was used as an early, aggressive treatment of raised ICP causing secondary acute neurological deterioration after head injury. The rationale was to save the patient from acute cerebral herniation and to prevent exposure to a prolonged course of intracranial hypertension. Results. All patients benefited from the procedure, demonstrating control of ICP, radiological improvement and neurological recovery. Long-term follow-up was available, with outcome assessed at a minimum of 14 months after injury. Discussion. The early approach to the use of decompressive craniotomy in the treatment of severe traumatic brain injury (TBI) with secondary deterioration due to raised ICP is emphasised. A favourable outcome was achieved in all of the cases presented. The potential benefit of decompressive craniectomy/craniotomy in the management of children with severe TBI is discussed.	Univ Cape Town, Div Paediat Neurosci Neurosurg, Sch Child & Adolescent Hlth, ZA-7700 Rondebosch, South Africa; Red Cross Childrens Hosp, ZA-7700 Rondebosch, South Africa		Figaji, AA (corresponding author), Univ Cape Town, Div Paediat Neurosci Neurosurg, Sch Child & Adolescent Hlth, Klipfontein Rd, ZA-7700 Rondebosch, South Africa.	afigaji@uctgsh1.uct.ac.za	Fieggen, Anthony Graham/AAT-6510-2021	Fieggen, Anthony Graham/0000-0001-6541-8377; Figaji, Anthony/0000-0002-3357-6490			ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Alexander E, 1987, Br J Neurosurg, V1, P427, DOI 10.3109/02688698708999632; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Carter BS, 1997, NEUROSURGERY, V40, P1168, DOI 10.1097/00006123-199706000-00010; Cho DY, 1995, PEDIATR NEUROSURG, V23, P192, DOI 10.1159/000120958; CLARK K, 1968, J NEUROSURG, V29, P367, DOI 10.3171/jns.1968.29.4.0367; Cooper P R, 1976, Surg Neurol, V5, P25; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Cruz J, 1996, J NEUROSURG, V85, P758, DOI 10.3171/jns.1996.85.5.0758; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; Doerfler A, 1996, J NEUROSURG, V85, P853, DOI 10.3171/jns.1996.85.5.0853; FORSTING M, 1995, STROKE, V26, P259, DOI 10.1161/01.STR.26.2.259; GAAB M, 1979, CHILD BRAIN, V5, P484; GAAB MR, 1990, ACT NEUR S, V51, P326; GOWER DJ, 1988, NEUROSURGERY, V23, P417, DOI 10.1227/00006123-198810000-00002; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; HASE U, 1978, ACTA NEUROCHIR, V45, P1, DOI 10.1007/BF01774379; HATASHITA S, 1985, STROKE, V16, P661, DOI 10.1161/01.STR.16.4.661; HATASHITA S, 1987, J NEUROSURG, V67, P573, DOI 10.3171/jns.1987.67.4.0573; Hieu PD, 1996, CHILD NERV SYST, V12, P270; JENNETT B, 1975, LANCET, V1, P480; Johnson DL, 1998, PEDIATR NEUROSURG, V28, P167, DOI 10.1159/000028643; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; KERR FWL, 1968, MAYO CLIN PROC, V43, P852; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Meyer P, 1999, CHILD NERV SYST, V15, P732, DOI 10.1007/s003810050462; MOODY RA, 1968, J NEUROSURG, V29, P586, DOI 10.3171/jns.1968.29.6.0586; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; Pillai S, 2001, PEDIATR NEUROSURG, V34, P98, DOI 10.1159/000056002; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; POPLE IK, 1995, PEDIATR NEUROSURG, V23, P64, DOI 10.1159/000120938; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; Rekate Harold L., 2001, Child's Nervous System, V17, P632, DOI 10.1007/s003810100487; RENGACHARY SS, 1981, NEUROSURGERY, V8, P321, DOI 10.1227/00006123-198103000-00004; RIEKE K, 1995, CRIT CARE MED, V23, P1576, DOI 10.1097/00003246-199509000-00019; RINALDI A, 1990, ACT NEUR S, V51, P394; ROPPER AH, 1986, NEW ENGL J MED, V314, P953, DOI 10.1056/NEJM198604103141504; ROSS DA, 1989, J NEUROSURG, V71, P498, DOI 10.3171/jns.1989.71.4.0498; SHAPIRO K, 1982, J NEUROSURG, V56, P819, DOI 10.3171/jns.1982.56.6.0819; SHAPIRO K, 1985, J NEUROSURG, V63, P76, DOI 10.3171/jns.1985.63.1.0076; Simma B, 2002, INTENS CARE MED, V28, P1000, DOI 10.1007/s00134-002-1333-3; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; VANDONGEN KJ, 1983, J NEUROSURG, V59, P951, DOI 10.3171/jns.1983.59.6.0951; VENES JL, 1975, J NEUROSURG, V42, P429, DOI 10.3171/jns.1975.42.4.0429; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953	53	80	83	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	SEP	2003	19	9					666	673		10.1007/s00381-003-0804-3			8	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	717MW	WOS:000185094500005	12908115				2022-02-06	
J	Schuhmann, MU; Stiller, D; Skardelly, M; Bernarding, J; Klinge, PM; Samii, A; Samii, M; Brinker, T				Schuhmann, MU; Stiller, D; Skardelly, M; Bernarding, J; Klinge, PM; Samii, A; Samii, M; Brinker, T			Metabolic changes in the vicinity of brain contusions: a proton magnetic resonance spectroscopy and histology study	JOURNAL OF NEUROTRAUMA			English	Article						brain contusion; gliosis; LCModel; mitochondrial failure; neuronal loss; proton magnetic resonance spectroscopy; traumatic brain injury	CONTROLLED CORTICAL IMPACT; RAT-BRAIN; IN-VIVO; MR SPECTROSCOPY; AXONAL INJURY; H-1 MRS; GLUCOSE-UTILIZATION; N-ACETYLASPARTATE; FOCAL ISCHEMIA; ADULT-RATS	Proton MR spectroscopy (H-1-MRS) has been previously used to monitor metabolic changes in areas of diffuse brain injury. We studied metabolism in the close vicinity of experimental traumatic brain contusions and remote on the contralateral side from 1h to 28d post-injury. Changes of creatine and phosphocreatine (Cr&PCr), N-acetylaspartate (NAA), choline (Cho), inositol (Ino), taurine (Tau), glutamate (Glu), and lactate (Lac) were assessed and compared to neuronal, glial and inflammatory changes in histology. In the pericontusional zone Cr&PCr, NAA, and Glu decreased immediately after trauma by -35%, -60%, and -37%, respectively, related to primary cell disintegration and secondary perturbations as reflected in histology. These metabolites partially recovered at 7d (-15%, -37%, and -21% respectively), in parallel to indicators of repair in immunhistochemistry. Control levels were not regained at 28d, in correlation to a decrease of viable neurons. Cho and Ino, initially lowered by -26% and -31% respectively, increased at 7d by +74% and 31%, reflecting glial activation and proliferation. The signal including the lactate resonance increased by >1000% with a maximum at 7d, possibly related to energy failure, inflammation and glial activation. A partial contribution of lipids to this signal cannot be fully excluded. The contralateral side showed mild astroglial activation in histology, but no changes in H-1-MRS. The study demonstrates the feasibility of volume selective H-1-MRS using the LCModel (Linear Combination of Model in vitro spectra of metabolites solutions) to monitor metabolic changes close to focal traumatic lesions and suggests how metabolic alterations can be differentiated in cause.	Wayne State Univ, Childrens Hosp Michigan, Sch Med, Dept Pediat Neurosurg, Detroit, MI 48202 USA; Hannover Med Sch, Dept Neurosurg, D-3000 Hannover, Germany; Boehringer Ingelheim KG, Pharma, In Vivo MR Lab, CNS Res Div, Ingelheim, Germany; Univ Hosp Benjamin Franklin, Inst Med Informat, Berlin, Germany; Int Neurosci Inst, Hannover, Germany; Nordstadt Hosp, Dept Neurosurg, Hannover, Germany		Schuhmann, MU (corresponding author), Univ Klinikum Leipzig, Klin & Poliklin Neurochirurg, Liebigstr 20, D-04103 Leipzig, Germany.	mschuh@gmx.de	Skardelly, Marco/AAF-8680-2021				Alessandri B, 2000, NEUROL RES, V22, P705; Barkovich AJ, 1999, AM J NEURORADIOL, V20, P1399; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; Berry I, 1986, Acta Radiol Suppl, V369, P338; Bouzier AK, 2000, J NEUROCHEM, V75, P480, DOI 10.1046/j.1471-4159.2000.0750480.x; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Brooks WM, 1999, J RHEUMATOL, V26, P81; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Cecil KM, 1998, J NEUROCHEM, V70, P2038; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Chadi G, 1998, BRAZ J MED BIOL RES, V31, P231, DOI 10.1590/S0100-879X1998000200007; Chang L, 1999, J MAGN RESON IMAGING, V10, P521, DOI 10.1002/(SICI)1522-2586(199910)10:4<521::AID-JMRI4>3.3.CO;2-0; Chang L, 1999, NEUROLOGY, V53, P782, DOI 10.1212/WNL.53.4.782; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; CHEN S, 2002, J NEUROTRAUM, V19, P1282; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DAMOISEAUX JGMC, 1994, IMMUNOLOGY, V83, P140; DESTEFANO N, 1995, MAGN RESON MED, V34, P721; Dhillon HS, 1999, J NEUROTRAUM, V16, P455, DOI 10.1089/neu.1999.16.455; ERECINSKA M, 1990, PROG NEUROBIOL, V35, P245, DOI 10.1016/0301-0082(90)90013-7; ERECINSKA M, 1988, J NEUROCHEM, V51, P892, DOI 10.1111/j.1471-4159.1988.tb01826.x; Fortuna S, 1997, NEUROCHEM INT, V31, P563, DOI 10.1016/S0197-0186(97)00005-3; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gasparovic C, 2001, J NEUROTRAUM, V18, P241, DOI 10.1089/08977150151070856; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kroppenstedt SN, 1998, J NEUROTRAUM, V15, P191, DOI 10.1089/neu.1998.15.191; KUGLER P, 1989, BIOMED RES-TOKYO, V10, P251; KUGLER P, 1988, HISTOCHEMISTRY, V90, P99, DOI 10.1007/BF00500974; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LOPEZVILLEGAS D, 1995, MAGNET RESON MED, V34, P32, DOI 10.1002/mrm.1910340107; Magistretti P J, 2000, Rev Med Suisse Romande, V120, P739; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; McBride DQ, 1995, SURG NEUROL, V44, P137, DOI 10.1016/0090-3019(95)00139-5; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MIYAKE M, 1981, J NEUROCHEM, V37, P1064, DOI 10.1111/j.1471-4159.1981.tb04500.x; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; PETROFF OAC, 1992, NEUROLOGY, V42, P1349, DOI 10.1212/WNL.42.7.1349; Pfeuffer J, 1999, J MAGN RESON, V141, P104, DOI 10.1006/jmre.1999.1895; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Planas AM, 1997, PROG NEUROBIOL, V51, P607, DOI 10.1016/S0301-0082(97)00004-X; POLLOCK JS, 1995, HISTOCHEM J, V27, P738; Portella G, 2000, ACT NEUR S, V76, P273; Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Reilly JF, 1996, EXP NEUROL, V140, P139, DOI 10.1006/exnr.1996.0124; ROSS B, 1994, MAGN RESON QUART, V10, P191; Ross BD, 1998, NEUROIMAG CLIN N AM, V8, P809; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rubin Y, 1997, J NEUROTRAUM, V14, P441, DOI 10.1089/neu.1997.14.441; SCHIFFER D, 1986, BRAIN RES, V374, P110, DOI 10.1016/0006-8993(86)90399-9; SCHROETER M, 1995, EXP BRAIN RES, V106, P1; Schuhmann MU, 2002, ACT NEUR S, V81, P209; Schuhmann MU, 2002, ACTA NEUROCHIR SUPPL, V81, P213; Schuhmann MU, 2000, ACTA NEUROCHIR SUPPL, V76, P3; Schurr A, 1999, J NEUROSCI, V19, P34, DOI 10.1523/JNEUROSCI.19-01-00034.1999; Schurr A, 2002, INT J MOL MED, V10, P131, DOI 10.3892/ijmm.10.2.131; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; Sorensen JC, 1996, EXP BRAIN RES, V112, P203; Stroop R, 1998, ACT NEUR S, V71, P303; TAKAMI K, 1992, EXP BRAIN RES, V90, P1; TAKAMIYA Y, 1988, DEV BRAIN RES, V38, P201, DOI 10.1016/0165-3806(88)90045-4; TALLAN HH, 1956, J BIOL CHEM, V219, P257; vanderToorn A, 1995, NMR BIOMED, V8, P245; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; VINK R, 1988, MAGNET RESON MED, V7, P95, DOI 10.1002/mrm.1910070111; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; Watson, 1998, RAT BRAIN STEREOTACT	79	80	82	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2003	20	8					725	743		10.1089/089771503767869962			19	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	712BU	WOS:000184777000004	12965052				2022-02-06	
J	Buki, A; Farkas, O; Doczi, T; Povlishock, JT				Buki, A; Farkas, O; Doczi, T; Povlishock, JT			Preinjury administration of the calpain inhibitor MDL-28170 attenuates traumatically induced axonal injury	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; calpain; MDL-28170; spectrin; traumatic brain injury	EXPERIMENTAL BRAIN-INJURY; CYCLOSPORINE-A; POSTTRAUMATIC HYPOTHERMIA; NEUROFILAMENT COMPACTION; SPECTRIN PROTEOLYSIS; DAMAGE; MODEL; BREAKDOWN; ACTIVATION; ANTIBODIES	Traumatic brain injury (TBI) evokes diffuse (traumatic) axonal injury (TAI), which contributes to morbidity and mortality. Damaged axons display progressive alterations gradually evolving to axonal disconnection. In severe TAI, the tensile forces of injury lead to a focal influx of Ca2+, initiating a series of proteolytic processes wherein the cysteine proteases, calpain and caspase modify the axonal cytoskeleton, causing irreversible damage over time postinjury. Although several studies have demonstrated that the systemic administration of calpain inhibitors reduces the extent of ischemic and traumatic contusional injury a direct beneficial effect on TAI has not been established to date. The current study was initiated to address this issue in an impact acceleration rat-TBI model in order to provide further evidence on the contribution of calpain-mediated proteolytic processes in the pathogenesis of TAI, while further supporting the utility of calpain-inhibitors. A single tail vein bolus injection of 30 mg/kg MDL-28170 was administered to Wistar rats 30 min preinjury. After injury the rats were allowed to survive 120 min when they were perfused with aldehydes. Brains were processed for immunohistochemical localization of damaged axonal profiles displaying either amyloid precursor protein (APP)- or RMO-14-immunoreactivity (IR), both considered markers of specific features of TAL Digital data acquisition and statistical analysis demonstrated that preinjury administration of MDL-28170 significantly reduced the mean number of damaged RMO-14- as well as APP-IR axonal profiles in the brainstem fiber tracts analyzed. These results further underscore the role of calpain-mediated proteolytic processes in the pathogenesis of DAI and support the potential use of cell permeable calpain-inhibitors as a rational therapeutic approach in TBI.	Virginia Commonwealth Univ, VCU Neurosci Ctr, Dept Anat & Neurobiol, Richmond, VA 23298 USA; Univ Pecs, Fac Med, Dept Neurosurg, Pecs, Hungary		Povlishock, JT (corresponding author), Virginia Commonwealth Univ, VCU Neurosci Ctr, Dept Anat & Neurobiol, Med Coll Virginia Campus,POB 980709,1101 E Marsha, Richmond, VA 23298 USA.	jpovlish@hsc.vcu.edu	Doczi, Tamas/C-5750-2009; Buki, Andras/B-1960-2010		FIC NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [1-R03-TW0131302A1] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS20193] Funding Source: Medline; FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [R03TW001313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Banik NL, 1998, ANN NY ACAD SCI, V844, P131, DOI 10.1111/j.1749-6632.1998.tb08228.x; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; HONG SC, 1994, STROKE, V25, P663, DOI 10.1161/01.STR.25.3.663; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Lee KS, 1997, ANN NY ACAD SCI, V825, P95, DOI 10.1111/j.1749-6632.1997.tb48419.x; LEE VMY, 1987, J NEUROSCI, V7, P3474; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; Meaney DF, 2001, J NEUROSURG, V95, P1108; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001	43	80	84	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2003	20	3					261	268		10.1089/089771503321532842			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	661GU	WOS:000181883500004	12820680				2022-02-06	
J	Sherer, M; Hart, T; Nick, TG				Sherer, M; Hart, T; Nick, TG			Measurement of impaired self-awareness after traumatic brain injury: a comparison of the patient competency rating scale and the awareness questionnaire	BRAIN INJURY			English	Article							BEHAVIORAL LIMITATIONS; REHABILITATION; DISABILITY; DEFICITS; RECOVERY; OUTCOMES	Primary objective: To compare the Patient Competency Rating Scale (PCRS) and the Awareness Questionnaire (AQ) in the measurement of impaired self-awareness (ISA) in persons with traumatic brain injury (TBI). Research design: Prospective cohort of patients seen for inpatient rehabilitation following TBI. Procedures: Measures of self-awareness were collected at resolution of post-traumatic amnesia and outcomes (rated employability) were collected at discharge from inpatient rehabilitation. Outcomes and results: Subjects were 129 persons with TBI. Measures from the PCRS and AQ showed moderate correlations. Models using as predictors patient/clinician discrepancies for the PCRS and the AQ performed comparably in predicting employability (Nagelkerke R-2=0.22 and 0.20, respectively). Conclusions: The PCRS and AQ showed only moderate correlations, but performed comparably as measures of ISA after TBI. Patient/clinician discrepancies appeared to be more valid measures of ISA early after TBI than patient/family discrepancies. Preliminary cutting points for severity of ISA were presented for the two scales.	Methodist Rehabil Ctr, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; Moss Rehabil Res Inst, Philadelphia, PA USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Rehabil Med, Philadelphia, PA 19107 USA		Sherer, M (corresponding author), Methodist Rehabil Ctr, 1350 E Woodrow Wilson, Jackson, MS 39216 USA.	marks@mmrcrehab.org					BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; HAMILTON BB, 1987, REHABILITATION OUTCO, P135; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; Levin H S, 1991, Neurosurg Clin N Am, V2, P457; MALEC J, 1990, J HEAD TRAUMA REHAB, V5, P60; Malec JF, 2000, REHABIL PSYCHOL, V45, P227, DOI 10.1037/0090-5550.45.3.227; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1997, NEUROPSY NEUROPSY BE, V10, P135; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; SHERER M, IN PRESS ARCH PHYSIC; TEASDALE G, 1974, LANCET, V2, P81; Wallace CA, 2000, BRAIN INJURY, V14, P549; Whyte J, 2001, ARCH PHYS MED REHAB, V82, P1355, DOI 10.1053/apmr.2001.26091	31	80	82	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2003	17	1					25	37		10.1080/0269905021000010113			13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	633LK	WOS:000180284600002	12519645				2022-02-06	
J	Petzold, A; Green, AJE; Keir, G; Fairley, S; Kitchen, N; Smith, M; Thompson, EJ				Petzold, A; Green, AJE; Keir, G; Fairley, S; Kitchen, N; Smith, M; Thompson, EJ			Role of serum S100B as an early predictor of high intracranial pressure and mortality in brain injury: A pilot study	CRITICAL CARE MEDICINE			English	Article; Proceedings Paper	10th Meeting of the European-Society-of-Neurology	JUN 18-22, 2000	JERUSALEM, ISRAEL	European Soc Neurol		acute brain injury; traumatic brain injury; serum; S100B; intracranial pressure; surrogate marker; subarachnoid hemorrhage; intracranial hemorrhage; Glasgow Coma Scale	NEUROBIOCHEMICAL MARKERS; CEREBROSPINAL-FLUID; HEAD-INJURY; PROTEIN; DAMAGE; RELEASE; S-100; CALCIUM; INFARCTION; SURGERY	Objective: To investigate whether serum S100B is suitable as a sensitive biomarker for early prediction of increased intracranial pressure and mortality rates after brain injury. Design: A prospective, longitudinal study. Setting: Neurosurgical intensive care unit. Patients: Twenty-one patients with acute brain injury and 13 healthy controls. Interventions. None. Measurements and Main Results: We assessed Glasgow Coma Scale score and pupil reaction on admission and quantified serum S100B (in-house enzyme-linked immunosorbent assay) and intracranial pressure on admission and the subsequent 6 days. Serum S100B concentrations on admission and day 1 were significantly higher in patients with fatal outcome (p <.05, p <.01, respectively), with a sensitivity of 100% and a specificity of 75-83%. Patients with high serum S100B on admission had an eight-fold and on day 1 a 12-fold increased relative risk of a fatal outcome. Subsequent serum S100B values predicted the development of high intracranial pressure in patients with traumatic brain injury (p <.01). Patients with high intracranial pressure on day 5 had an 11-fold and on day 6 a nine-fold increased risk of fatal outcome. Conclusions: Serum S100B is a sensitive biomarker for early prediction of the development of high intracranial pressure and fatal outcome following acute brain injury. Monitoring S100B concentrations could contribute to early detection of patients at risk of secondary increases in intracranial pressure and subsequent mortality. This would allow earlier targeting of therapy in selected patients.	Inst Neurol, Dept Neuroimmunol, London WC1N 3BG, England; UCL Natl Hosp Neurol & Neurosurg, Surg Intens Care Unit, London WC1N 3BG, England; Natl CJD Surveillance Unit, Edinburgh, Midlothian, Scotland		Petzold, A (corresponding author), Inst Neurol, Dept Neuroimmunol, Queen Sq, London WC1N 3BG, England.	a.petzold@ion.ucl.ac.uk	Green, Alison/O-7356-2019; Smith, Martin/B-2616-2009; Petzold, Axel/C-1090-2009	Petzold, Axel/0000-0002-0344-9749			Ali MS, 2000, BRIT J ANAESTH, V85, P287, DOI 10.1093/bja/85.2.287; AURELL A, 1991, STROKE, V22, P1254, DOI 10.1161/01.STR.22.10.1254; BARGER SW, 1992, J BIOL CHEM, V267, P9689; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Blomquist S, 1997, J CARDIOTHOR VASC AN, V11, P699, DOI 10.1016/S1053-0770(97)90160-9; Cody R P, 1997, APPL STAT SAS PROGRA; Coplin WM, 2001, NEUROL RES, V23, P277, DOI 10.1179/016164101101198433; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; FURLAN A, 1994, SPECIAL ASPECTS TREA, P579; Gazzolo D, 2001, CLIN CHEM, V47, P1836; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GREEN A, 1999, THESIS U COLL LONDON; Green AJE, 1997, NEUROSCI LETT, V235, P5, DOI 10.1016/S0304-3940(97)00701-5; Green AJE, 1997, J IMMUNOL METHODS, V205, P35, DOI 10.1016/S0022-1759(97)00050-1; HALLER JA, 1983, JAMA-J AM MED ASSOC, V249, P47, DOI 10.1001/jama.249.1.47; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Holtkamp M, 2001, J NEUROL NEUROSUR PS, V70, P226, DOI 10.1136/jnnp.70.2.226; Koura SS, 1998, ACT NEUR S, V71, P244; McKeating EG, 1998, ACT NEUR S, V71, P117; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Otto M, 1998, BRIT MED J, V316, P577, DOI 10.1136/bmj.316.7131.577; PETZOLD A, IN PRESS BRAIN RES B; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Reinert M, 2000, J NEUROSURG, V93, P800, DOI 10.3171/jns.2000.93.5.0800; RIEKE K, 1995, CRIT CARE MED, V23, P1576, DOI 10.1097/00003246-199509000-00019; Rothoerl RD, 1999, BRAIN INJURY, V13, P387; Schwab S, 1997, NEUROLOGY, V48, P412, DOI 10.1212/WNL.48.2.412; Scotto C, 1998, MOL CELL BIOL, V18, P4272, DOI 10.1128/MCB.18.7.4272; SELINFREUND RH, 1991, P NATL ACAD SCI USA, V88, P3554, DOI 10.1073/pnas.88.9.3554; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; TEASDALE G, 1974, LANCET, V2, P81; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190	37	80	83	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	DEC	2002	30	12					2705	2710		10.1097/00003246-200212000-00015			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	633AP	WOS:000180257300015	12483062				2022-02-06	
J	Vespa, PM; Boscardin, WJ; Hovda, DA; McArthur, DL; Nuwer, MR; Martin, NA; Nenov, V; Glenn, TC; Bergsneider, M; Kelly, DF; Becker, DP				Vespa, PM; Boscardin, WJ; Hovda, DA; McArthur, DL; Nuwer, MR; Martin, NA; Nenov, V; Glenn, TC; Bergsneider, M; Kelly, DF; Becker, DP			Early and persistent impaired percent alpha variability on continuous electroencephalography monitoring as predictive of poor outcome after traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; neurosurgery intensive care unit; percentage of alpha variability; secondary insult; prognosis	SEVERE HEAD-INJURY; CEREBRAL BLOOD-FLOW; SOMATOSENSORY-EVOKED-POTENTIALS; COMPRESSED SPECTRAL ARRAY; STATUS-EPILEPTICUS; PROGNOSTIC VALUE; COMA; EEG; SCALE; VASOSPASM	Object. Early prediction Of Outcomes in patients after they suffer traumatic brain injury (TBI) is often nonspecific and based on initial imaging and clinical findings alone, without direct physiological testing. Improved outcome prediction is desirable for ethical, social. and financial reasons. The goal of this Study was to determine the usefulness of continuous electroencephalography (EEG) monitoring in determining prognosis early after TBI. while the patient is in the intensive care unit. Methods. The authors hypothesized that the reduced percentage of alpha variability (PAV) in continuous EEG tracings indicates a poor prognosis. Prospective continuous EEG monitoring was performed in 89 consecutive patients with moderate to severe TBI (Glasgow Coma Scale [GCS] Scores 3-12) from 0 to 10 days after injury. The PAV was calculated daily, and the time course and trends of the PAV were analyzed in comparison with the patient's Glasgow Outcome Scale (GOS) score at the time of discharge. In patients with GCS scores of 8 or lower, a PAV value of 0.1 or lower is highly predictive of a poor outcome or death (positive predictive value 86%). The determinant PAV value was obtained by Day 3 after injury. Persistent PAV values of 0.1 or lower over several days or worsening of the PAV to a Value of 0.1 or lower indicated a high likelihood of poor Outcome (GOS Scores 1 and 2). In comparison with the combination of traditional initial clinical indicators of outcome (GCS score, pupillary response to light, patient age, results of computerized tomography scanning, and early hypotension or hypoxemia), the early PAV value during the initial 3 days after injury independently improved prognostic ability (P < 0.01). Conclusions. Continuous EEG monitoring performed with particular attention paid to the PAV is a sensitive and specific method of prognosis that can indicate Outcomes in patients with moderate to severe TBI within 3 days postinjury.	Univ Calif Los Angeles, Sch Med, Div Neurosurg, Dept Neurol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Div Neurosurg, Dept Med & Mol Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Biostat, Sch Publ Hlth, Los Angeles, CA 90095 USA		Vespa, PM (corresponding author), Univ Calif Los Angeles, Sch Med, Div Neurosurg, Dept Neurol, 10833 LeConte Ave,CHS 18-218, Los Angeles, CA 90095 USA.	Pvespa@mednet.ucla.edu	McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314; Martin, Neil/0000-0002-6565-4131; Glenn, Thomas/0000-0003-4273-3408			Alster Jason, 1993, Brain Injury, V7, P191, DOI 10.3109/02699059309029672; BERGAMASCO B, 1968, ELECTROEN CLIN NEURO, V24, P374, DOI 10.1016/0013-4694(68)90198-3; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BICKFORD RG, 1973, AUTOMATION CLIN ELEC, P56; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Breiman L., 1984, CLASSIFICATION REGRE; BRICOLO A, 1978, ELECTROEN CLIN NEURO, V45, P211, DOI 10.1016/0013-4694(78)90005-6; CHAN KH, 1993, NEUROSURGERY, V32, P547, DOI 10.1227/00006123-199304000-00009; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CUSUMANO S, 1992, ELECTROEN CLIN NEURO, V84, P499, DOI 10.1016/0168-5597(92)90039-E; EVANS BM, 1995, J NEUROL NEUROSUR PS, V59, P17, DOI 10.1136/jnnp.59.1.17; FACCO E, 1986, CHILD NERV SYST, V2, P67; GUTLING E, 1994, ELECTROEN CLIN NEURO, V92, P568, DOI 10.1016/0168-5597(94)90141-4; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HILZ MJ, 1991, INTENS CARE MED, V17, P87, DOI 10.1007/BF01691429; HULIHAN JF, 1994, NEUROLOGY, V44, P758, DOI 10.1212/WNL.44.4.758; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; Jaitly R, 1997, J CLIN NEUROPHYSIOL, V14, P326, DOI 10.1097/00004691-199707000-00005; JENNETT B, 1975, LANCET, V1, P480; JENNETT WB, 1960, J NEUROL NEUROSUR PS, V23, P295, DOI 10.1136/jnnp.23.4.295; JUDSON JA, 1990, CRIT CARE MED, V18, P363, DOI 10.1097/00003246-199004000-00003; KARNAZE DS, 1982, NEUROLOGY, V32, P289, DOI 10.1212/WNL.32.3.289; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; KIDO DK, 1992, RADIOLOGY, V182, P777, DOI 10.1148/radiology.182.3.1535893; KRIEGER D, 1995, CRIT CARE MED, V23, P1123, DOI 10.1097/00003246-199506000-00020; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVY ML, 1994, NEUROSURGERY, V35, P77, DOI 10.1227/00006123-199407000-00012; Littell R.C., 1996, SAS SYSTEM MIXED MOD; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; Lowenstein DH, 1998, NEW ENGL J MED, V338, P970, DOI 10.1056/NEJM199804023381407; LOWENSTEIN DH, 1993, NEUROLOGY, V43, P483, DOI 10.1212/WNL.43.3_Part_1.483; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Miller J D, 1994, Neurosurg Clin N Am, V5, P661; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; RAEGRANT AD, 1991, ELECTROEN CLIN NEURO, V79, P349, DOI 10.1016/0013-4694(91)90199-E; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; RUMPL E, 1979, ELECTROEN CLIN NEURO, V46, P487, DOI 10.1016/0013-4694(79)90002-6; Steudel W I, 1979, Acta Neurochir Suppl (Wien), V28, P40; SYNEK VM, 1988, J CLIN NEUROPHYSIOL, V5, P161, DOI 10.1097/00004691-198804000-00003; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 1997, ELECTROEN CLIN NEURO, V103, P607, DOI 10.1016/S0013-4694(97)00071-0; YAFFE K, 1993, NEUROLOGY, V43, P895, DOI 10.1212/WNL.43.5.895; YOUNG GB, 1994, ELECTROEN CLIN NEURO, V91, P93, DOI 10.1016/0013-4694(94)90030-2	56	80	87	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUL	2002	97	1					84	92		10.3171/jns.2002.97.1.0084			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	570NU	WOS:000176665000013	12134937				2022-02-06	
J	Jamieson, WRE; Janusz, MT; Gudas, VM; Burr, LH; Fradet, GJ; Henderson, C				Jamieson, WRE; Janusz, MT; Gudas, VM; Burr, LH; Fradet, GJ; Henderson, C			Traumatic rupture of the thoracic aorta: third decade of experience	AMERICAN JOURNAL OF SURGERY			English	Article; Proceedings Paper	88th Annual Meeting of the North-Pacific-Surgical-Association	NOV 09-10, 2001	VICTORIA, CANADA	N Pacific Surg Assoc		traumatic aortic injury; heparinless cardiopulmonary bypass	METAANALYSIS; CIRCULATION; PARAPLEGIA; DIAGNOSIS; MORTALITY; REPAIR; BYPASS; TEARS; PUMP	Background: Traumatic rupture of the thoracic aorta is a relatively common injury of deceleration accidents, usually high-speed motor vehicle accidents. Spinal cord injury has been a well-documented complication of surgical management. The use of nonheparnized partial bypass with a centrifugal pump was evaluated for protection against spinal cord injury and reduction of risk of associated injuries. Methods: From 1989 to 1999, the third decade of the authors' experience, traumatic rupture was diagnosed in 58 patients (male 46 and female 12; mean age 39.9 years, range 17 to 85). Associated injuries were documented in 98.3% (57 patients). In all, 45 patients (77.6%) had the opportunity for definitive surgical management; 42 (93.3%) were managed with partial cardiopulmonary bypass, 35 without the use of heparin. Full cardiopulmonary bypass was utilized in 1 patient while 2 had repair without cardiopulmonary bypass support. Thirteen patients did not have the opportunity for definitive surgical management, 1 death on arrival, 8 (61.5%) suspected, and 4 (30.8%) diagnosed. Results: There were 6 deaths in the surgical group, 5 in nonheparinized patients. The causes were intraoperative hypovolemia (2), anoxic brain death after intraoperative cardiac arrest (1), sepsis (1), and adult respiratory distress syndrome (1). The other was in the simple aortic cross-clamp group from intraoperative pulmonary compromise. There was one spinal cord injury, paraparesis in 1 of the 2 patients managed without bypass support. The total hospital stay ranged from 8 to 112 days, primarily owing to management of associated injuries. Of the 13 patients who did not have the opportunity for definitive surgical management, 5 had unsuccessful emergency thoracotomy and 3 survived the hospital course without surgery. Of the total population, the overall mortality was 27.6%, whereas the mortality of the potentially operable patients was 25.8%. Of the surgical group, the intraoperative mortality was 6.7% and 30-day mortality was 13.3%. Conclusions: Spinal cord injury was prevented by the use of partial cardiopulmonary bypass. Nonheparinized bypass was likely to be a contributory factor to lack of mortality directly related to associated injuries. (C) 2002 Excerpta Medica, Inc. All rights reserved.	Univ British Columbia, St Pauls Hosp, Dept Surg, Vancouver, BC V6Z 1Y6, Canada		Jamieson, WRE (corresponding author), Univ British Columbia, St Pauls Hosp, Dept Surg, 331-332 Burrard Bldg,1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.						Duke BJ, 1997, J TRAUMA, V42, P1135, DOI 10.1097/00005373-199706000-00026; Fishman JE, 2000, J THORAC IMAG, V15, P97, DOI 10.1097/00005382-200004000-00004; Franchello A, 1997, INT SURG, V82, P79; Gammie JS, 1998, ANN THORAC SURG, V66, P1295, DOI 10.1016/S0003-4975(98)00778-4; Glock Y, 1996, Rev Esp Cardiol, V49 Suppl 4, P100; HESS PJ, 1989, ANN THORAC SURG, V48, P6, DOI 10.1016/0003-4975(89)90167-7; HILLS MW, 1994, AUST NZ J SURG, P64312; JAMIESON WRE, 1996, SURG TECHNOL INT, P305; JANUSZ MT, 1994, AM J SURG, V167, P501, DOI 10.1016/0002-9610(94)90244-5; KODALI S, 1991, CIRCULATION, V84, P11140; MAGGISANO R, 1995, ANN VASC SURG, V9, P44, DOI 10.1007/BF02015316; Mengozzi E, 2000, Radiol Med, V100, P139; OLIVIER HF, 1984, ANN THORAC SURG, V38, P586, DOI 10.1016/S0003-4975(10)62315-6; PATE JW, 1995, ANN THORAC SURG, V59, P90, DOI 10.1016/0003-4975(94)00719-N; VONOPPELL UO, 1994, J CARDIAC SURG, V9, P685; VONOPPELL UO, 1994, ANN THORAC SURG, V58, P585, DOI 10.1016/0003-4975(94)92270-5; VONOPPELL UO, 1991, S AFR MED J, V79, P595; Wicky S, 1998, EUR RADIOL, V8, P828, DOI 10.1007/s003300050480	18	80	85	1	2	EXCERPTA MEDICA INC	NEW YORK	650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA	0002-9610			AM J SURG	Am. J. Surg.	MAY	2002	183	5					571	575	PII S0002-9610(02)00851-6	10.1016/S0002-9610(02)00851-6			5	Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Surgery	557EG	WOS:000175894700018	12034396				2022-02-06	
J	Port, A; Willmott, C; Charlton, J				Port, A; Willmott, C; Charlton, J			Self-awareness following traumatic brain injury and implications for rehabilitation	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; CLOSE RELATIVES; DEFICITS; MEMORY; QUESTIONNAIRE; COMPLAINTS; ADULTS	Primary objective: Many studies investigating self-awareness following traumatic brain injury (TBI) have been conducted more than 2 years post-injury, thereby providing limited information regarding the implications of insight for rehabilitation. The present study aimed to investigate awareness of deficits in a group of patients who were less than 2 years post-injury and still involved in rehabilitation. Research design: Thirty patients with a history of moderate or severe TBI and their significant other (SO) were studied in a cross-sectional analysis. A sub-group also participated in an interdisciplinary Memory Group at the Bethesda Rehabilitation Centre. Methods and procedures: Level of insight was measured by the degree of agreement between self and significant other (SO) report on the Awareness of Deficit questionnaire (ADQ), assessing various domains of daily functioning. Results: There was substantial agreement between patients and their SO, although the patients with TBI were less likely to acknowledge executive problems. Interestingly, both groups reported only low-to-moderate levels of difficulty. Conclusions: The data indicate that SO's awareness may also be limited in the early recovery stages. A sub-group of the patients obtained benefit from participation in the Memory Group in a rehabilitation setting.	Epworth Med Fdn, Dept Psychol, Bethesda Rehabil Ctr, Richmond, Vic 3121, Australia; Deakin Univ, Melbourne, Vic, Australia; Monash Univ, Melbourne, Vic 3004, Australia; Deakin Univ, Burwood, Australia		Willmott, C (corresponding author), Epworth Med Fdn, Dept Psychol, Bethesda Rehabil Ctr, 89 Bridge Rd, Richmond, Vic 3121, Australia.	cathyw@epworth.org.au	Willmott, Catherine/AAA-5105-2019	Willmott, Catherine/0000-0001-8517-9035; Charlton, Judith/0000-0002-5990-2151			ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Burgess P, 1996, BEHAV ASSESSMENT DYS; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [DOI 10.1097/00001199-198909000-00008, 10.1097/00001199-198909000-00008]; ELSASS L, 1991, THESIS LA TROBE U ME; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fleming JM, 1996, BRAIN INJURY, V10, P1; FLEMMING, 1999, P 21 ANN BRAIN IMP C; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Heilbronner R L, 1989, Brain Inj, V3, P387, DOI 10.3109/02699058909004562; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; Hillier SL, 1997, BRAIN INJURY, V11, P525, DOI 10.1080/713802189; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; McWilliams S, 1991, BRIT J OCCUPATIONAL, V54, P246; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ponsford J, 1999, NEUROPSYCHOL REHABIL, V9, P517, DOI 10.1080/096020199389563; Prigatano G. P., 1991, AWARENESS DEFICIT BR; PRIGATANO GP, 1995, J HEAD TRAUMA REHAB, V10, P87; SANTORO J, 1994, BRAIN INJURY, V8, P265, DOI 10.3109/02699059409150978; Santos ME, 1998, BRAIN INJURY, V12, P759, DOI 10.1080/026990598122151; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; SHEERER M, 1996, J INT NEUROPSYCH SOC, V2, P17; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; Stuss D., 1991, AWARENESS DEFICIT BR, P63; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; Wallace CA, 2000, BRAIN INJURY, V14, P549	40	80	81	2	14	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2002	16	4					277	289		10.1080/02699050110103274			13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	541CM	WOS:000174967700001	11953000				2022-02-06	
J	Shaw, GJ; Jauch, EC; Zemlan, FP				Shaw, GJ; Jauch, EC; Zemlan, FP			Serum cleaved tau protein levels and clinical outcome in adult patients with closed head injury	ANNALS OF EMERGENCY MEDICINE			English	Article							S-100; DAMAGE	Study objective: Intracranial injuries (ICI) are associated with high mortality and morbidity. Unfortunately, tools for diagnosis and risk stratification of ICIs are limited in the emergency department setting. We determine the relationship between the presence or absence of a detectable cleaved serum tau protein (tau(C)), ICI, and outcome at hospital discharge in adults with closed head injuries (CHI). Methods: This was a prospective pilot study of adult patients with CHI presenting to the ED of an urban Level I trauma center. Patients presenting within 10 hours of a CHI who underwent a head computed tomographic (CT) scan were eligible. A blood sample was collected at presentation and the tau(C) level was measured. Initial Glasgow Coma Scale scores and demographic information were recorded. A chart review was performed to determine outcome and final readings on the initial head CT scan. Results: Patients were dichotomized to 1 of 2 groups, those with an ICI (n = 17) and those with an isolated skull fracture or no CT abnormality (NICI) (n = 11). The 2 groups were similar in regard to demographic composition, mechanism of injury, and coexisting injuries. A tau(C) level of more than 0 was associated with an increased chance of an ICI on the initial head CT scan (odds ratio 11.25; 95% confidence interval [CI] 1.17 to 108.4) and a greater chance of poor outcome, defined as death while in hospital or transfer to a nursing home at hospital discharge (odds ratio 8.17; 95% Cl 1.42 to 47). Conclusion: A tau(C) level of more than 0 is associated with a greater chance of intracranial injury and poor outcome in patients with CHI.	Univ Cincinnati, Coll Med, Dept Emergency Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45267 USA		Shaw, GJ (corresponding author), Univ Cincinnati, Coll Med, Dept Emergency Med, 231 Albet Sabin Way, Cincinnati, OH 45267 USA.	shawge@acmail.uc.edu		Jauch, Edward/0000-0002-3533-4364			BERNSTEIN D, 1998, SOC NEUR ANN M NOV L; Fridriksson T, 2000, ACAD EMERG MED, V7, P816, DOI 10.1111/j.1553-2712.2000.tb02276.x; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; Zemlan F. P., 2000, Journal of Neurotrauma, V17, P946; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x	10	80	83	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	MAR	2002	39	3					254	257		10.1067/mem.2002.121214			4	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	529PV	WOS:000174308500006	11867977				2022-02-06	
J	Markgraf, CG; Clifton, GL; Moody, MR				Markgraf, CG; Clifton, GL; Moody, MR			Treatment window for hypothermia in brain injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; impact injury; edema; hypothermia; rat	CONTROLLED CORTICAL IMPACT; SEVERE HEAD-INJURY; POSTTRAUMATIC HYPOTHERMIA; MODERATE HYPOTHERMIA; INTRACRANIAL HYPERTENSION; MILD HYPOTHERMIA; RAT; MODEL; GLUTAMATE; PRESSURE	Object. The goal of this study was to evaluate the therapeutic window for hypothermia treatment following experimental brain injury by measuring edema formation and functional outcome. Methods. Traumatic brain injury (TBI) was produced in anesthetized rats by using cortical impact injury. Edema was measured in the ipsilateral and contralateral hemispheres by subtracting dry weight from wet weight, and neurological function was assessed using a battery of behavioral tests 24 hours after TBI In injured rats, it was found that brain water levels were elevated at I hour postinjury, compared with those in sham-injured control animals, and that edema peaked at 24 hours and remained elevated for 4 days. Hypothermia (3 hours at 30 degreesC) induced either immediately after TBI or 60 minutes after TBI significantly reduced early neurological deficits. Delay of treatment by 90 or 120 minutes postinjury did not result in this neurological protection. Immediate administration of hypothermia also significantly decreased the peak magnitude of edema at 24 hours and 48 hours postinjury, compared with that in normothermic injured control animals. When delayed by 90 minutes, hypothermia did not affect the pattern of edema formation. Conclusions. When hypothermia was administered immediately or 60 minutes after TBI, injured rats showed an improvement in functional outcome and a decrease in edema. Delayed hypothermia treatment had no effect on functional outcome or on edema.	Univ Texas, Hlth Sci Ctr, Dept Neurosurg, Houston, TX USA; Univ Texas, Hlth Sci Ctr, Vivian L Smith Fdn Neurol Res, Houston, TX USA		Markgraf, CG (corresponding author), Schering Plough Corp, POB 32,144 Route 94, Lafayette, NJ 07848 USA.						BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; BETZ A L, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P133; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; CLASEN RA, 1968, ARCH NEUROL-CHICAGO, V19, P472, DOI 10.1001/archneur.1968.00480050042004; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1991, J NEUROSCI METH, V39, P253; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; GREEN EJ, 1992, BRAIN RES, V580, P197, DOI 10.1016/0006-8993(92)90945-6; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Kaibara T, 1999, J NEUROSURG, V90, P339, DOI 10.3171/jns.1999.90.2.0339; Kawai N, 2000, J NEUROTRAUM, V17, P193, DOI 10.1089/neu.2000.17.193; LASKOWSKI EJ, 1960, NEUROLOGY, V10, P499, DOI 10.1212/WNL.10.5.499; Markgraf CG, 2001, J NEUROTRAUM, V18, P175, DOI 10.1089/08977150150502604; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; Poca MA, 1998, ACT NEUR S, V71, P27; ROSOMOFF HL, 1960, SURG GYNECOL OBSTET, V110, P27; Sakamoto KI, 1997, J NEUROTRAUM, V14, P349, DOI 10.1089/neu.1997.14.349; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003	25	80	84	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	DEC	2001	95	6					979	983		10.3171/jns.2001.95.6.0979			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	499HA	WOS:000172564600010	11765843				2022-02-06	
J	Takasu, A; Saitoh, D; Kaneko, N; Sakamoto, T; Okada, Y				Takasu, A; Saitoh, D; Kaneko, N; Sakamoto, T; Okada, Y			Hyperthermia: is it an ominous sign after cardiac arrest?	RESUSCITATION			English	Article						hyperthermia; cardiac arrest; brain death	GASTRIC CONTENTS; HYPOTHERMIA; ISCHEMIA; RESUSCITATION; ASPIRATION; INJURY	Objective: To clarify the clinical characteristics of hyperthermia at an early stage after resuscitation from cardiac arrest (CA). Materials and methods: We reviewed the medical records of 43 adult patients with non-traumatic out-of-hospital CA, who survived for longer than 24 h after admission to our intensive care unit (ICU) between January, 1995, and December, 1998. The patients were divided into two groups: a clinical brain death (CBD) group (n = 23) and a non-CBD group (n = 20), and various factors relating to hyperthermia were compared between the two groups. Results: The mean value of peak axillary temperatures within 72 h of admission was 39.8 +/- 0.9 degreesC for the CBD group, which was significantly greater than 38.3 +/- 0.6 degreesC for the non-CBD group (P < 0.0001). The time of occurrence of the peak axillary temperature was at 19 +/- 16 h of admission in the CBD group and 20 +/- 18 h in the non-CBD group (not significantly different). There were no significant differences in risk factors relating to the occurrence of hyperthermia. between the two groups, except for the number of patients who received epinephrine at ICU. In 23 patients with a peak axillary temperature of greater than or equal to 39 degreesC during the first 72 h of hospitalization, brain death was diagnosed in 20 patients, whereas only 3 of 20 patients having a peak axillary temperature of < 39 degreesC developed brain death (odds ratio, 37.8; 95% confidence interval, 6.72-212.2). Conclusion: Hyperthermia at an early stage after resuscitation from CA may be associated with the outcome of brain death. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.	Natl Def Med Coll, Dept Traumatol & Crit Care Med, Tokorozawa, Saitama 3598513, Japan		Takasu, A (corresponding author), Natl Def Med Coll, Dept Traumatol & Crit Care Med, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan.			Takasu, Akira/0000-0003-3430-0119			Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; BYNUM LJ, 1976, AM REV RESPIR DIS, V114, P1129; Coimbra C, 1996, STROKE, V27, P1578, DOI 10.1161/01.STR.27.9.1578; FELDBERG W, 1964, J PHYSIOL-LONDON, V173, P226, DOI 10.1113/jphysiol.1964.sp007454; FELDBERG W, 1963, NATURE, V200, P1325, DOI 10.1038/2001325a0; GUSTAFSON I, 1992, RESUSCITATION, V24, P245, DOI 10.1016/0300-9572(92)90185-F; HINDFELT B, 1976, ACTA NEUROL SCAND, V53, P72, DOI 10.1111/j.1600-0404.1976.tb04326.x; LANDAY MJ, 1978, AM J ROENTGENOL, V131, P587, DOI 10.2214/ajr.131.4.587; MINAMISAWA H, 1990, ANN NEUROL, V28, P26, DOI 10.1002/ana.410280107; TAKINO M, 1991, INTENS CARE MED, V17, P419, DOI 10.1007/BF01720680; TRUOG RD, 1992, CRIT CARE MED, V20, P1705, DOI 10.1097/00003246-199212000-00018; WASS CT, 1995, ANESTHESIOLOGY, V83, P325, DOI 10.1097/00000542-199508000-00013; Yanagawa Y, 1998, RESUSCITATION, V39, P61, DOI 10.1016/S0300-9572(98)00118-X	15	80	86	1	2	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0300-9572			RESUSCITATION	Resuscitation	JUN	2001	49	3					273	277		10.1016/S0300-9572(00)00360-9			5	Critical Care Medicine; Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine	456EY	WOS:000170071200008	11719121				2022-02-06	
J	Dikmen, S; Machamer, J; Miller, B; Doctor, J; Temkin, N				Dikmen, S; Machamer, J; Miller, B; Doctor, J; Temkin, N			Functional status examination: A new instrument for assessing outcome in traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						functional status; measurement development; outcome assessment; psychometric properties; psychosocial; quality of life; traumatic brain injury	HEAD-INJURY; POSTTRAUMATIC SEIZURES; SCALE; COMA	The Functional Status Examination (FSE) is a new measure designed to evaluate change in activities of everyday life as a function of an event or illness, including traumatic brain injury. The measure covers physical, social, and psychological domains. The FSE is based on a structured interview and includes levels of functioning that accommodate the full spectrum of possible outcomes, from death through recovery to preinjury functioning. Based on 133 prospectively studied patients with moderate to severe traumatic brain injury, the FSE has favorable psychometric properties including good test-retest reliability (r = 0.80) and close correspondence of assessments provided by the patient and their significant other (SO; r = 0.80). The FSE correlated significantly with each of three severity indices with closest relationships occurring between the FSE assessed by the SO and posttraumatic amnesia (r = 0.76). The FSE assessed by the SO was significantly (p < 0.05) more closely related to each severity index than the Glasgow Outcome Scale (GOS) or Sickness Impact Profile and, for two of the three indices, than the SF-36. All measures showed significant change from 1 to 6 months after injury with the FSE showing the largest effect sizes. The FSE is significantly related to important constructs such as family burden, SO depression, and sacrifices the family makes, as well as overall indices of recovery and satisfaction with level of functioning. The latter relationships are significantly stronger than for the GOS. The FSE has demonstrated good reliability, validity, and sensitivity, and appears to be a promising instrument for monitoring recovery and assessing functional status in clinical trials.	Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA		Dikmen, S (corresponding author), Univ Washington, Dept Rehabil Med, Box 356490, Seattle, WA 98195 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD033677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD33677] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS19643] Funding Source: Medline		BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; CHOI SC, 1977, BIOMETRIKA, V64, P645, DOI 10.1093/biomet/64.3.645; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; COMSTOCK GW, 1976, PSYCHOL MED, V6, P551, DOI 10.1017/S0033291700018171; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; DEYO RA, 1984, CONTROL CLIN TRIALS, V5, P223, DOI 10.1016/0197-2456(84)90026-6; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hamilton BB, 1987, REHABILITATION OUTCO, P137; JENNETT B, 1975, LANCET, V1, P480; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; Patrick DL, 1993, HLTH STATUS HLTH POL; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; TEMKIN NR, 1989, MED CARE, V27, pS44, DOI 10.1097/00005650-198903001-00004; TERI L, 1997, J GERONTOL B-PSYCHOL, V52, P159, DOI DOI 10.1093/GER0NB/52B.4.P159; Ware J.E., 1993, SF 36 HLTH SURVEY MA; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; World Health Organization, 1993, INT CLASS IMP DIS HA; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649	29	80	80	0	8	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2001	18	2					127	140		10.1089/08977150150502578			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	402PW	WOS:000166998200002	11229707				2022-02-06	
J	Hansen, HH; Ikonomidou, C; Bittigau, P; Hansen, SH; Hansen, HS				Hansen, HH; Ikonomidou, C; Bittigau, P; Hansen, SH; Hansen, HS			Accumulation of the anandamide precursor and other N-acylethanolamine phospholipids in infant rat models of in vivo necrotic and apoptotic neuronal death	JOURNAL OF NEUROCHEMISTRY			English	Article						anandamide; apoptosis; excitotoxicity; N-acyl-phosphatidylethanolamine; necrosis; neurodegeneration	ENDOGENOUS CANNABINOID PRECURSOR; HIPPOCAMPAL-NEURONS; CORTICAL-NEURONS; CELL-DEATH; BRAIN; RECEPTOR; NEURODEGENERATION; CALCIUM; ACYLPHOSPHATIDYLETHANOLAMINE; NEUROTOXICITY	It has been demonstrated that the endogenous cannabinoid receptor ligand, anandamide, and other N-acylethanolamines (NAEs), accumulate during neuronal injury in vitro, a process that may be linked to the neuroprotective effects of NAEs. The crucial step for generation of NAEs is the synthesis of the corresponding precursors, N-acylethanolamine phospholipids (NAPEs). However, it is unknown whether this, key event for NAE formation is regulated differently in the context of insults causing necrotic or apoptotic neuronal death. To address this question, we monitored a range of cortical NAPE species in three infant rat models of in vivo neurodegeneration: (i) necrosis caused by intrastriatal injection of NMDA (25 nmol); (ii) apoptosis induced by systemic administration of the NMDA-receptor antagonist (+)MK-801 (3 x 0.5 mg/kg, i.p.); and (iii) apoptosis following focal necrosis triggered by concussive head trauma. A marked increase of all NAPE species was observed in both hemispheres 4 and 24 h after NMDA-induced injury, with a relatively larger increase in N-stearoyl-containing NAPE species. Thus, the percentage of the anandamide precursor fell from 1.1 to 0.5 mol %. In contrast, administration of (+)MK-801 did not alter cortical NAPE levels. Concussion head trauma resulted in a similar but less pronounced upregulation of NAPE levels at both 4 and 24 h as compared to NMDA injections. Increased levels of NAPE 24 h post-trauma possibly reflect that necrosis is still ongoing at this time point. Consequently, our data suggest that excitotoxic necrotic mechanisms of neurodegeneration, as opposed to apoptotic neurodegeneration, have a profound effect on in vivo NAE precursor homeostasis.	Royal Danish Sch Pharm, Dept Pharmacol, DK-2100 Copenhagen, Denmark; Humboldt Univ, Charite Virchow Clin, Dept Paediat Neurol, Berlin, Germany; Royal Danish Sch Pharm, Dept Analyt & Pharmaceut Chem, DK-2100 Copenhagen, Denmark		Hansen, HS (corresponding author), Royal Danish Sch Pharm, Dept Pharmacol, 2 Univ Pk, DK-2100 Copenhagen, Denmark.	hsh@dfh.dk	Hansen, Steen Honore/A-5179-2011	Hansen, Harald S./0000-0001-7360-7418			Ameri A, 1999, BRIT J PHARMACOL, V126, P1831, DOI 10.1038/sj.bjp.0702478; Berrendero F, 1999, SYNAPSE, V33, P181, DOI 10.1002/(SICI)1098-2396(19990901)33:3<181::AID-SYN3>3.0.CO;2-R; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Cadas H, 1996, J NEUROSCI, V16, P3934; Cadas H, 1997, J NEUROSCI, V17, P1226; CAMPAGNE MV, 1995, EUR J NEUROSCI, V7, P1627; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; diMarzo V, 1996, BIOCHEM J, V316, P977, DOI 10.1042/bj3160977; Gwag BJ, 1999, NEUROSCIENCE, V90, P1339, DOI 10.1016/S0306-4522(98)00508-9; Hansen HH, 2000, J NEUROCHEM, V75, P861, DOI 10.1046/j.1471-4159.2000.0750861.x; Hansen HH, 1999, J MASS SPECTROM, V34, P761, DOI 10.1002/(SICI)1096-9888(199907)34:7<761::AID-JMS832>3.0.CO;2-R; Hansen HS, 1999, LIPIDS, V34, pS327, DOI 10.1007/BF02562333; HANSEN HS, 1995, BBA-LIPID LIPID MET, V1258, P303, DOI 10.1016/0005-2760(95)00134-X; Hansen HS, 1998, BIOCHEM PHARMACOL, V55, P719, DOI 10.1016/S0006-2952(97)00396-1; Hansen HS, 1997, J NEUROCHEM, V69, P753; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; IKONOMIDOU C, 1989, J NEUROSCI, V9, P2809; Ikonomidou C, 1996, METAB BRAIN DIS, V11, P125, DOI 10.1007/BF02069500; Ishimaru MJ, 1999, J COMP NEUROL, V408, P461; Kempe K, 1996, J BIOL CHEM, V271, P17287, DOI 10.1074/jbc.271.29.17287; KOCH RA, 1994, J NEUROSCI, V14, P2585; Kondo S, 1998, ARCH BIOCHEM BIOPHYS, V354, P303, DOI 10.1006/abbi.1998.0688; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Lipton SA, 1998, NEUROSCIENTIST, V4, P345, DOI 10.1177/107385849800400516; MACKIE K, 1995, J NEUROSCI, V15, P6552; Modi I, 1995, TRENDS PHARMACOL SCI, V16, P356; Moesgaard B, 1999, J LIPID RES, V40, P515; Moesgaard B, 2000, J LIPID RES, V41, P985; MUNIR M, 1993, BRAIN RES, V616, P163, DOI 10.1016/0006-8993(93)90205-2; Nagayama T, 1999, J NEUROSCI, V19, P2987; NATARAJAN V, 1986, BIOCHIM BIOPHYS ACTA, V878, P32, DOI 10.1016/0005-2760(86)90341-3; OJICIUS DM, 1991, EXP CELL RES, V197, P43; Petersen G, 1999, FEBS LETT, V455, P41, DOI 10.1016/S0014-5793(99)00861-3; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Richardson JD, 1998, J NEUROSCI, V18, P451; SCHMID HHO, 1990, PROG LIPID RES, V29, P1, DOI 10.1016/0163-7827(90)90004-5; Shen MX, 1998, MOL PHARMACOL, V54, P459, DOI 10.1124/mol.54.3.459; Skaper SD, 1996, P NATL ACAD SCI USA, V93, P3984, DOI 10.1073/pnas.93.9.3984; Sugiura T, 1996, EUR J BIOCHEM, V240, P53, DOI 10.1111/j.1432-1033.1996.0053h.x	40	80	84	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JAN	2001	76	1					39	46		10.1046/j.1471-4159.2001.00006.x			8	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	388AE	WOS:000166154600005	11145976	Bronze			2022-02-06	
J	Grote, CL; Kooker, EK; Garron, DC; Nyenhuis, DL; Smith, CA; Mattingly, ML				Grote, CL; Kooker, EK; Garron, DC; Nyenhuis, DL; Smith, CA; Mattingly, ML			Performance of compensation seeking and non-compensation seeking samples on the Victoria Symptom Validity Test: Cross-validation and extension of a standardization study	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article								Previous research suggests that the Victoria Symptom Validity Test (VSVT) is effective in confirming or disconfirming the validity of a patient's reported cognitive impairments. We sought to cross-validate the Findings of the VSVT standardization study, and to determine cut-off scores that are most efficient in discriminating our samples of compensation-seeking patients, primarily with mild traumatic brain injury (CS; n = 53), and non-compensation seeking patients with intractable seizures (NCS; n = 30). All patients in the NCS sample scored in the "valid" range on the VSVT difficult memory items, compared to only 58.5% of the CS sample. We also identified VSVT measures and cut-off scores maximally efficient in discriminating these samples. This study confirms previous research that non-compensation seeking patients do well on the VSVT, but that many compensation seeking patients perform poorly on this measure.	Rush Presbyterian St Lukes Med Ctr, Dept Psychol, Chicago, IL 60612 USA; Cornell Univ, Weill Med Coll, New York, NY USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA		Grote, CL (corresponding author), Rush Presbyterian St Lukes Med Ctr, Dept Psychol, 1653 W Congress Pkwy, Chicago, IL 60612 USA.	cgrote@rush.edu					BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Guilmette TJ, 1996, PERCEPT MOTOR SKILL, V83, P1007, DOI 10.2466/pms.1996.83.3.1007; GUILMETTE TJ, 1993, CLIN NEUROPSYCHOL, V7, P59, DOI 10.1080/13854049308401888; MARTIN RC, 1993, J CLIN EXP NEUROPSYC, V15, P867, DOI 10.1080/01688639308402604; Perrine K, 1999, NEUROLOGY, V53, pS39; PRIGATANO GP, 1993, J CLIN EXP NEUROPSYC, V15, P537, DOI 10.1080/01688639308402577; *PSYCH CORP, 1997, WAIS 3 WMS 3 TECHN M; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; ROSE FE, 1995, CLIN NEUROPSYCHOL, V9, P124, DOI 10.1080/13854049508401594; Rose FE, 1998, ARCH CLIN NEUROPSYCH, V13, P349, DOI 10.1016/S0887-6177(97)00025-5; Slick D.J., 1997, VICTORIA SYMPTOM VAL; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Sweet JJ, 1999, STUD NEUROPSYCHOL DE, P255; Wechsler D., 1981, WAIS R MANUAL WECHSL; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593	16	80	80	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	DEC	2000	22	6					709	719		10.1076/jcen.22.6.709.958			11	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	403QT	WOS:000167054500001	11320430				2022-02-06	
J	Fee, D; Grzybicki, D; Dobbs, M; Ihyer, S; Clotfelter, J; Macvilay, S; Hart, MN; Sandor, M; Fabry, Z				Fee, D; Grzybicki, D; Dobbs, M; Ihyer, S; Clotfelter, J; Macvilay, S; Hart, MN; Sandor, M; Fabry, Z			Interleukin 6 promotes vasculogenesis of murine brain microvessel endothelial cells	CYTOKINE			English	Article						cytokine; brain injury; development; growth factor; vascularization	MYELIN OLIGODENDROCYTE GLYCOPROTEIN; AUTOIMMUNE ENCEPHALOMYELITIS; IN-VITRO; IL-6-DEFICIENT MICE; TIE2 RECEPTOR; GROWTH-FACTOR; ANGIOGENESIS; CYTOKINES; EXPRESSION; GP130	Interleukin 6 (IL-6) is a cytokine that acts on a wide range of tissues influencing cell growth and differentiation. Here we show that IL-6 plays a role in the early vascular development (vasculogenesis) in the central nervous system (CNS). We report that IL-6 induces the proliferation of brain microvascular endothelial cells in vitro. Furthermore, IL-6 significantly accelerates the formation of tube-like structures by these cells in Matrigel basement matrix. Moreover, IL-6 mRNA is expressed in vivo in two physiological conditions in which vascularization in the CNS is important: (1) during normal brain development, (2) during the healing process of a traumatic brain injury. Expression of IL-6 mRNA coincides with the expression of vascular endothelial growth factor (VEGF) mRNA in the developing brain with decreasing expression following birth. However, IL-6 mRNA can be detected in the healing adult murine brain tissue by in situ hybridization coinciding with the period of intense tissue reorganization. The transient upregulation of IL-6 mRNA during normal brain development and at brain injury site and the effect of IL-6 on in vitro vasculogenesis suggest that IL-6 may play a role in normal physiology of vascularization in the CNS, (C) 2000 Academic Press.	Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Neurol, Madison, WI 53706 USA; Duquesne Univ, Sch Hlth Sci, Pittsburgh, PA 15219 USA; Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA		Fabry, Z (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, 1300 Univ Ave, Madison, WI 53706 USA.	zfabry@facstaff.wisc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS24621] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS024621] Funding Source: NIH RePORTER		AUERBACH R, 1991, INT J RADIAT BIOL, V60, P1, DOI 10.1080/09553009114551401; BERNAD A, 1994, IMMUNITY, V1, P725, DOI 10.1016/S1074-7613(94)80014-6; Betz UAK, 1998, J EXP MED, V188, P1955, DOI 10.1084/jem.188.10.1955; Campbell IL, 1998, ANN NY ACAD SCI, V840, P83, DOI 10.1111/j.1749-6632.1998.tb09552.x; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DEBAULT KE, 1980, ADV EXP MED BIOL, V131, P69; DEBAULT LE, 1980, SCIENCE, V207, P653, DOI 10.1126/science.6101511; DEBAULT LE, 1981, IN VITRO CELL DEV B, V17, P480; Eugster HP, 1998, EUR J IMMUNOL, V28, P2178, DOI 10.1002/(SICI)1521-4141(199807)28:07<2178::AID-IMMU2178>3.0.CO;2-D; FABRY Z, 1993, J NEUROIMMUNOL, V47, P23, DOI 10.1016/0165-5728(93)90281-3; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Folkman J, 1985, Important Adv Oncol, P42; Folkman J, 1997, EXS, V79, P1; FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277; Fukushi J, 1998, BIOCHEM BIOPH RES CO, V250, P444, DOI 10.1006/bbrc.1998.9334; GAMBLE JR, 1993, J CELL BIOL, V121, P931, DOI 10.1083/jcb.121.4.931; Giraudo E, 1996, J IMMUNOL, V157, P2618; HART MN, 1987, J NEUROPATH EXP NEUR, V46, P141, DOI 10.1097/00005072-198703000-00003; IruelaArispe ML, 1997, THROMB HAEMOSTASIS, V78, P672; Klein MA, 1997, GLIA, V19, P227, DOI 10.1002/(SICI)1098-1136(199703)19:3<227::AID-GLIA5>3.0.CO;2-W; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Kumar R, 1998, INT J ONCOL, V12, P749; Loganadane LD, 1997, CYTOKINE, V9, P740, DOI 10.1006/cyto.1997.0229; Mendel I, 1998, EUR J IMMUNOL, V28, P1727, DOI 10.1002/(SICI)1521-4141(199805)28:05<1727::AID-IMMU1727>3.0.CO;2-#; MOORE SA, 1990, J NEUROCHEM, V55, P391, DOI 10.1111/j.1471-4159.1990.tb04150.x; MOORE SA, 1988, AM J PHYSIOL, V254, pC37, DOI 10.1152/ajpcell.1988.254.1.C37; MOTRO B, 1990, P NATL ACAD SCI USA, V87, P3092, DOI 10.1073/pnas.87.8.3092; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Okuda Y, 1998, INT IMMUNOL, V10, P703, DOI 10.1093/intimm/10.5.703; PETZELBAUER P, 1995, CYTOKINE, V7, P267, DOI 10.1006/cyto.1995.0031; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; ROBINSON RA, 1986, BRAIN RES, V384, P114, DOI 10.1016/0006-8993(86)91226-6; Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9; SAHAGUN G, 1989, AM J PATHOL, V134, P1227; Sambrook J., 1989, MOL CLONING LAB MANU; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Takashima S, 1996, J BIOL CHEM, V271, P24901, DOI 10.1074/jbc.271.40.24901; Vallieres L, 1997, J NEUROCHEM, V69, P1668, DOI 10.1046/j.1471-4159.1997.69041668.x; Volpert OV, 1998, J EXP MED, V188, P1039, DOI 10.1084/jem.188.6.1039; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407; Zhao BY, 1998, J NEUROSCI RES, V52, P7, DOI 10.1002/(SICI)1097-4547(19980401)52:1<7::AID-JNR2>3.0.CO;2-I	44	80	87	0	3	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	1043-4666	1096-0023		CYTOKINE	Cytokine	JUN	2000	12	6					655	665		10.1006/cyto.1999.0599			11	Biochemistry & Molecular Biology; Cell Biology; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Immunology	321YC	WOS:000087482100014	10843741				2022-02-06	
J	Weber, JT; Rzigalinski, BA; Willoughby, KA; Moore, SF; Ellis, EF				Weber, JT; Rzigalinski, BA; Willoughby, KA; Moore, SF; Ellis, EF			Alterations in calcium-mediated signal transduction after traumatic injury of cortical neurons	CELL CALCIUM			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; EXPERIMENTAL BRAIN INJURY; STRETCH-INDUCED INJURY; GLUTAMATE RECEPTORS; DELAYED DEPOLARIZATION; NMDA-RECEPTORS; CELLS; MODULATION; ASTROCYTES; FURA-2	Calcium influx and elevation of intracellular free calcium ([Ca2+](i)), with subsequent activation of degradative enzymes, is hypothesized to cause cell injury and death after traumatic brain injury. We examined the effects of mild-to-severe stretch-induced traumatic injury on [Ca2+](i) dynamics in cortical neurons cultured on silastic membranes. [Ca2+](i) was rapidly elevated after injury, however, the increase was transient with neuronal [Ca2+](i) returning to basal levels by 3 h after injury, except in the most severely injured cells. Despite a return of [Ca2+](i) to basal levels, there were persistent alterations in calcium-mediated signal transduction through 24 h after injury. [Ca2+](i) elevation in response to glutamate or NMDA was enhanced after injury. We also found novel alterations in intracellular calcium store-mediated signaling. Neuronal calcium stores failed to respond to a stimulus 15 min after injury and exhibited potentiated responses to stimuli at 3 and 24 h post-injury. Thus, changes in calcium-mediated cellular signaling may contribute to the pathology that is observed after traumatic brain injury. (C) Harcourt Publishers Ltd 1999.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA		Ellis, EF (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, POB 980613, Richmond, VA 23298 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027214] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-27214] Funding Source: Medline		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRUNO V, 1995, NEUROPHARMACOLOGY, V34, P1089, DOI 10.1016/0028-3908(95)00077-J; Casado M, 1998, J PHYSIOL-LONDON, V513, P317, DOI 10.1111/j.1469-7793.1998.317bb.x; Choi S, 1996, J NEUROSCI, V16, P36; DELAHUNTY TM, 1992, BRAIN RES, V594, P307, DOI 10.1016/0006-8993(92)91140-A; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAROOQUI AA, 1994, J NEUROSCI RES, V38, P6, DOI 10.1002/jnr.490380103; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FLOYD CL, 1998, J NEUROTRAUM, V15, P869; FRANDSEN A, 1991, J NEUROCHEM, V56, P1075, DOI 10.1111/j.1471-4159.1991.tb02031.x; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146; Kaftan EJ, 1997, J GEN PHYSIOL, V110, P529, DOI 10.1085/jgp.110.5.529; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; KOSTYUK P, 1994, NEUROSCIENCE, V63, P381, DOI 10.1016/0306-4522(94)90537-1; Lamb RG, 1997, J NEUROCHEM, V68, P1904; LEI SHZ, 1992, BRAIN RES, V598, P196, DOI 10.1016/0006-8993(92)90183-A; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCINTOSH TK, 1992, J NEUROTRAUM, V9, pS201; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; Mukhin AG, 1997, NEUROREPORT, V8, P2561, DOI 10.1097/00001756-199707280-00028; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Ozawa S, 1998, PROG NEUROBIOL, V54, P581, DOI 10.1016/S0301-0082(97)00085-3; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Picard L, 1998, CELL CALCIUM, V23, P339, DOI 10.1016/S0143-4160(98)90029-X; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; PRASAD MR, 1994, J NEUROCHEM, V63, P773; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; Rahman S, 1996, BRIT J PHARMACOL, V117, P675, DOI 10.1111/j.1476-5381.1996.tb15243.x; ROE MW, 1990, CELL CALCIUM, V11, P63, DOI 10.1016/0143-4160(90)90060-8; Rzigalinski BA, 1997, J NEUROCHEM, V68, P289; Rzigalinski BA, 1999, J BIOL CHEM, V274, P175, DOI 10.1074/jbc.274.1.175; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; RZIGALINSKI BA, 1998, J NEUROTRAUM, V15, P894; Schreiber D., 1995, P 1995 INT RES C BIO, P233; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632, DOI 10.1152/jn.1997.77.2.632; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767, DOI 10.1152/jn.1995.74.6.2767; THASTRUP O, 1994, AGENTS ACTIONS, V43, P187, DOI 10.1007/BF01986687; TRUMP BF, 1995, FASEB J, V9, P219, DOI 10.1096/fasebj.9.2.7781924; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; WILLIAMS DA, 1990, CELL CALCIUM, V11, P75, DOI 10.1016/0143-4160(90)90061-X; YOUNG W, 1992, J NEUROTRAUMA S1, V9, P9; Yu SP, 1997, J PHYSIOL-LONDON, V499, P721, DOI 10.1113/jphysiol.1997.sp021964; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	51	80	82	0	1	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0143-4160			CELL CALCIUM	Cell Calcium	DEC	1999	26	6					289	299		10.1054/ceca.1999.0082			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	273RN	WOS:000084721100006	10668567				2022-02-06	
J	Marmarou, A; Nichols, J; Burgess, J; Newell, D; Troha, J; Burnham, D; Pitts, L				Marmarou, A; Nichols, J; Burgess, J; Newell, D; Troha, J; Burnham, D; Pitts, L		Amer Brain Injury Consortium Study Grp	Effects of the bradykinin antagonist Bradycor (TM) (deltibant, CP-1027) in severe traumatic brain injury: Results of a multi-center, randomized, placebo-controlled trial	JOURNAL OF NEUROTRAUMA			English	Article						bradycor; bradykinin; brain trauma; clinical trial; head injury	KALLIKREIN-KININ SYSTEM; SEVERE HEAD-INJURY; HUMAN NEUTROPHILS; CLINICAL-TRIALS; EDEMA; MEDIATOR; TISSUE; PERMEABILITY; INHIBITION; RECEPTORS	A phase II prospective, randomized, double blind clinical trial of Bradycor(TM), a bradykinin antagonist, was conducted at 31 centers within North America in severely brain injured patients, Patients of Glasgow Coma Score (GCS) 3-8 (n = 139) with at least one reactive pupil were randomized to receive either Bradycor, 3 mu g/kg/min or placebo as a continuous intravenous infusion for 5 days, with the infusion beginning within 12 h of the injury, The primary objective was to assess the efficacy of a continuous infusion of Bradycor (3.0 mc/kg/min) in preventing elevation of intracranial pressure (ICP), Other efficacy measures included the effect of Bradycor on the Therapy Intensity Level (TIL), mortality, and functional outcome. A secondary objective was to evaluate the safety of Bradycor in patients with severe brain injury, Randomization was carried out according to a computer generated randomization list. Patients were followed for the first 14 days of hospitalization with long-term outcome assessed at 3 and 6 months after injury. During the infusion and while the ICP monitor was in place, ICP measurements were recorded hourly along with blood pressure and heart rate. A modified version of the TIL was used to record therapeutic interventions hourly, while the ICP was being monitored. Outcome was assessed at 3 and 6 months after injury using the Glasgow Outcome Score (GOS). Bradycor was well tolerated in this patient population, and no adverse events were attributable to the compound, Although positive trends were seen for both ICP and Tn, in the Bradycor group, these differences analyzed on a daily basis were not significant. However a mixed model of variance which included treatment, day, treatment by day interaction, age and GCS revealed that the percentage time ICP of >15 mm Hg on days 4 and 5 was significantly lower in the Bradycor group compared to placebo (p = 0.035). There were fewer deaths in the Bradycor group, which had a 28-day all cause mortality of 20% versus 27% on placebo. Patients treated with Bradycor showed a 10.3% improvement in favorable outcome at 3 months and a 12% improvement in dichotomized GOS at 6 months (p = 0.26). The consistent positive trends seen in ICP, TIL, neuropsychological tests, and, most importantly, 3- and 6-month GOS provide supportive evidence that a bradykinin antagonist may play a neuroprotective role in severe brain injury.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA; Provenant St Anthonys Cent, Denver, CO USA; Fairfax Hosp, Alexandria, VA USA; Univ Washington, Sch Med, Seattle, WA USA; Cortech Inc, Denver, CO USA; SmithKline Beecham Pharmaceut, Collegeville, PA USA; Univ Calif San Francisco, Med Ctr, San Francisco, CA 94143 USA		Marmarou, A (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, POB 980508, Richmond, VA 23298 USA.	Marmarou@abic.vcu.edu					BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Bhoola KD, 1996, IMMUNOPHARMACOLOGY, V33, P247, DOI 10.1016/0162-3109(96)00067-7; Carl VS, 1996, IMMUNOPHARMACOLOGY, V33, P325, DOI 10.1016/0162-3109(96)00055-0; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Choi S C, 1997, J Biopharm Stat, V7, P533; CHOI SC, 1985, CONTROL CLIN TRIALS, V6, P280, DOI 10.1016/0197-2456(85)90104-7; CHOI SC, 1989, BIOMETRICS, V45, P317, DOI 10.2307/2532056; COCHRANE CG, 1973, J EXP MED, V138, P1564, DOI 10.1084/jem.138.6.1564; ELLIS EF, 1989, J NEUROSURG, V71, P437, DOI 10.3171/jns.1989.71.3.0437; ELLIS EF, 1987, STROKE, V18, P792, DOI 10.1161/01.STR.18.4.792; FIGUEROA CD, 1989, BRIT J HAEMATOL, V72, P321, DOI 10.1111/j.1365-2141.1989.tb07711.x; FIGUEROA CD, 1992, BLOOD, V79, P754; FRANCEL PC, 1992, J NEUROTRAUM, V9, pS27; GALLIN JI, 1988, INFLAMMATION BASIC P, P493; Griffin J H, 1979, Adv Exp Med Biol, V120B, P39; HALLENBECK JM, 1977, NEUROLOGY, V27, P3, DOI 10.1212/WNL.27.1.3; HENDERSON L, 1992, AGENTS ACTIONS S, V1, P590; HSU CY, 1994, NEUROBIOLOGY CENTRAL, P145; Kaplan A P, 1978, Prog Hemost Thromb, V4, P127; Kaplan A P, 1983, Adv Exp Med Biol, V156, P45; KAPLAN AP, 1987, BLOOD, V70, P1; KAPLAN AP, 1972, J EXP MED, V135, P81, DOI 10.1084/jem.135.1.81; Kochanek PM, 1997, SHOCK, SEPSIS AND ORGAN FAILURE, P197; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; MAIERHAUFF K, 1984, J NEUROSURG, V61, P97, DOI 10.3171/jns.1984.61.1.0097; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; Marmarou A, 1996, ACT NEUR S, V66, P118; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MASET AL, 1986, INTRACRANIAL PRESSUR, V6, P647; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Narotam PK, 1998, ACTA NEUROCHIR, V140, P793, DOI 10.1007/s007010050181; Phillis J. W., 1993, REGULATION CEREBRAL, P315; TEASDALE G, 1974, LANCET, V2, P81; UNTERBERG A, 1986, J NEUROSURG, V64, P269, DOI 10.3171/jns.1986.64.2.0269; UNTERBERG A, 1984, J NEUROSURG, V61, P87, DOI 10.3171/jns.1984.61.1.0087; WAHL M, 1983, J CEREBR BLOOD F MET, V3, P231, DOI 10.1038/jcbfm.1983.31; WAHL M, 1988, J CEREBR BLOOD F MET, V8, P621, DOI 10.1038/jcbfm.1988.109; Wahl M, 1996, IMMUNOPHARMACOLOGY, V33, P257, DOI 10.1016/0162-3109(96)00068-9; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; WEISS SJ, 1989, NEW ENGL J MED, V320, P365	41	80	81	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	1999	16	6					431	444		10.1089/neu.1999.16.431			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	206LD	WOS:000080879800001	10391361				2022-02-06	
J	Stone, JR; Walker, SA; Povlishock, JT				Stone, JR; Walker, SA; Povlishock, JT			The visualization of a new class of traumatically injured axons through the use of a modified method of microwave antigen retrieval	ACTA NEUROPATHOLOGICA			English	Article						amyloid precursor protein immunoreactivity axonal injury; microwave antigen retrieval; traumatic brain injury; ultrastructure	AMYLOID PRECURSOR PROTEIN; DIFFUSE BRAIN INJURY; CLOSED-HEAD INJURY; ULTRASTRUCTURAL-LOCALIZATION; NEUROFILAMENT SUBUNITS; AXOLEMMAL PERMEABILITY; TISSUE-SECTIONS; BETA-APP; RAT; DAMAGE	Antibodies to the amyloid precursor proteins (APP) have become routine markers for detecting traumatically induced axonal injury (AI) in animals and man. Unfortunately, the techniques used to visualize these proteins are not compatible with routine electron microscopic (EM) analysis. In the current communication, we describe a method for the ultrastructural visualization of antibodies to APP and, using this method, we identify a previously unrecognized population of traumatically injured axons. Rats were subjected to an impact acceleration traumatic brain injury and allowed to survive 30 min to 3h postinjury. The animals were then perfused, their brains sectioned on a vibratome and the sections prepared for immunocytochemistry using a computer-controlled microwave capable of temperature regulation. The use of temperature-controlled microwave energy unmasked APP antigenic epitopes without sacrificing ultrastructural detail. The APP antibody was found in two distinct populations of reactive axons that differed in size, morphology, location, and temporal progression. Comparable to previous descriptions, one population showed traumatically related reactive changes that led to swelling and disconnection. The other population, however, revealed unanticipated changes reflected in nodal and paranodal swelling of small continuous fibers that showed no evidence of disconnection during the time periods assessed. These studies provide new insight into the complexity of the pathobiology of AI, while describing a novel approach for enhancing APP immunoreactivity at the EM level.	Virginia Commonwealth Univ, Div Neurosurg, Med Coll Virginia, Richmond, VA USA; Virginia Commonwealth Univ, Dept Anat, Med Coll Virginia, Richmond, VA 23298 USA		Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Dept Anat, Med Coll Virginia, 1101 E Marshall St,POB 980709, Richmond, VA 23298 USA.	jpovlishock@gems.vcu.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS20193] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER		AbouHamden A, 1997, J NEUROTRAUM, V14, P699, DOI 10.1089/neu.1997.14.699; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Ahlgren S, 1996, ACTA NEUROPATHOL, V92, P49, DOI 10.1007/s004010050488; BENOWITZ LI, 1989, EXP NEUROL, V106, P237, DOI 10.1016/0014-4886(89)90156-8; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GIBERSON RT, 1995, MICROSC RES TECHNIQ, V32, P246, DOI 10.1002/jemt.1070320307; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; IGARASHI H, 1994, APMIS, V102, P295, DOI 10.1111/j.1699-0463.1994.tb04879.x; KAWAI M, 1992, AM J PATHOL, V140, P947; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Lewis SB, 1996, J NEUROTRAUM, V13, P505, DOI 10.1089/neu.1996.13.505; LI GL, 1995, J NEUROTRAUM, V12, P269, DOI 10.1089/neu.1995.12.269; LOGIN GR, 1994, PROG HISTOCHEM CYTOC, V27, P1; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCGEER PL, 1992, J NEUROSCI RES, V31, P428, DOI 10.1002/jnr.490310305; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; NEVIN NC, 1967, J NEUROPATH EXP NEUR, V26, P77, DOI 10.1097/00005072-196701000-00006; Ochs S, 1996, NEUROSCIENCE, V70, P1081, DOI 10.1016/0306-4522(95)00390-8; OCHS S, 1994, NEUROSCIENCE, V61, P361, DOI 10.1016/0306-4522(94)90237-2; PALACIOS G, 1992, MOL BRAIN RES, V15, P195, DOI 10.1016/0169-328X(92)90109-O; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pierce JES, 1996, J NEUROSCI, V16, P1083; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Povlishock JT, 1996, ACT NEUR S, V66, P81; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; SHERRIFF FE, 1994, NEUROREPORT, V5, P1085, DOI 10.1097/00001756-199405000-00016; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; SHIGEMATSU K, 1992, BRAIN RES, V592, P353, DOI 10.1016/0006-8993(92)91697-D; STRICH SJ, 1967, J NEUROL NEUROSUR PS, P163; Suurmeyer AJH, 1993, APPL IMMUNOHISTO M M, V1, P143; VANEZIS P, 1987, FORENSIC SCI INT, V35, P1, DOI 10.1016/0379-0738(87)90018-1; WASIELEWSKI R, 1994, HISTOCHEMISTRY, V102, P165; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YAMAGUCHI H, 1992, ACTA NEUROPATHOL, V85, P15, DOI 10.1007/BF00304629; YAMAGUCHI H, 1994, GERONTOLOGY, V40, P65; YAMAZAKI T, 1993, VIRCHOWS ARCH B, V63, P173, DOI 10.1007/BF02899258; Yamazaki T, 1996, J CELL SCI, V109, P999	53	80	80	0	3	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	APR	1999	97	4					335	345		10.1007/s004010050996			11	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	176XG	WOS:000079176900004	10208272				2022-02-06	
S	Huang, TT; Carlson, EJ; Raineri, M; Gillespie, AM; Kozy, H; Epstein, CJ		Blass, JP; McDowell, FH		Huang, TT; Carlson, EJ; Raineri, M; Gillespie, AM; Kozy, H; Epstein, CJ			The use of transgenic and mutant mice to study oxygen free radical metabolism	OXIDATIVE/ENERGY METABOLISM IN NEURODEGENERATIVE DISORDERS	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	Conference on Oxidative/Energy Metabolism in Neurodegenerative Disorders	MAR 19-22, 1999	NEW YORK, NY	New York Acad Sci, Winifred Masterson Burke Med Res Inst Inc, NIA, NIH, MitoKor, Amer Fed Aging Res, Warner Lambert Co, Parke Davis Pharmaceut Res			CUZN-SUPEROXIDE-DISMUTASE; FOCAL CEREBRAL-ISCHEMIA; HSP70 MESSENGER-RNA; PERINATAL HYPOXIA-ISCHEMIA; TRAUMATIC BRAIN INJURY; MU-OPIOID RECEPTORS; METHYLENEDIOXYMETHAMPHETAMINE MDMA; NEUROMUSCULAR-JUNCTION; DEFICIENT MICE; DOWNS-SYNDROME	To distinguish the role of Mn superoxide dismutase (MnSOD) from that of cytoplasmic CuZn superoxide dismutase (CuZnSOD), the mouse MnSOD gene (Sod2) mas inactivated by homologous recombination. Sod2 -/- mice on a CD1 (outbred) genetic background die within the first 10 days of life (mean, 5.4 days) with a complex phenotype that includes dilated cardiomyopathy, accumulation of lipid in liver and skeletal muscle, metabolic acidosis and ketosis, and a severe reduction in succinate dehydrogenase (complex II) and aconitase (a TCA cycle enzyme) activities in the heart and, to a lesser extent, in other organs. These findings indicate that MnSOD is required to maintain the integrity of mitochondrial enzymes susceptible to direct inactivation by superoxide. On the other hand, Lebovitz et al. reported an independently derived MnSod null mouse (Sod2tmlLeb) on a mixed C57BL/6 and 129Sv background with a different phenotype. Because a difference in genetic background is the most likely explanation for the phenotypic differences, the two mutant lines were crossed into different genetic backgrounds for further analyses. To study the phenotype of Sod2tmlLeb mice CD1 background, the Sod2tmlLeb mice were crossed to CD1 for two generations before the -/+ mice were intercrossed to generate -/- mice. The life span distribution of CD1<Sod2-/->Leb was shifted to the left, indicating a shortened life span on the CD1 background. Furthermore, the CD1<Sod2-/->Leb mice develop metabolic acidosis at an early stage as was observed with CD1<Sod2-/->Cje. When Sod2tmlCje was placed on C57BL/6J (B6) background, the -/- mice were found to die either during midgestation or within the first 4 days after birth. However, when the B6<Sod2-/+>Cje mere crossed with DBA/2J (D2) for the generation of B6D2F2<Sod2-/->Cje mice, an entirely different phenotype, similar to that described by Lebovitz et at, was observed. The F2 Sod -/- mice were able to survive up to 18 days, and the animals that Lived for more than 15 days displayed neurological abnormalities including ataxia and seizures. Their hearts were not as severely affected as were those of the CD1 mice, and neurological degeneration rather than heart defect appears to be the cause of death.	Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA		Epstein, CJ (corresponding author), Univ Calif San Francisco, Dept Pediat, 531 Parnassus,U585L, San Francisco, CA 94143 USA.	cepst@itsa.ucsf.edu			NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG008938, R01AG016998, R03AG015151] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG-16998, AG-15151, AG-08938] Funding Source: Medline		Andrews AM, 1996, MOL PHARMACOL, V50, P1511; AVRAHAM KB, 1991, J NEUROCYTOL, V20, P208, DOI 10.1007/BF01186993; AVRAHAM KB, 1988, CELL, V54, P823, DOI 10.1016/S0092-8674(88)91153-1; BEAL MF, 1995, J NEUROCHEM, V65, P919; CADET JL, 1995, SYNAPSE, V21, P169, DOI 10.1002/syn.890210210; CADET JL, 1994, BRAIN RES, V655, P259, DOI 10.1016/0006-8993(94)91624-1; CADET JL, 1994, J NEUROCHEM, V62, P380; CHAN PH, 1993, NEUROREPORT, V5, P293, DOI 10.1097/00001756-199312000-00028; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; Chan PH, 1998, J NEUROSCI, V18, P8292, DOI 10.1523/jneurosci.18-20-08292.1998; Chen ZY, 1998, J MOL CELL CARDIOL, V30, P2281, DOI 10.1006/jmcc.1998.0789; Ditelberg JS, 1996, PEDIATR RES, V39, P204, DOI 10.1203/00006450-199602000-00003; ELMER GI, 1995, EUR J PHARMACOL, V283, P227, DOI 10.1016/0014-2999(95)00365-R; Elmer GI, 1996, BEHAV PHARMACOL, V7, P628; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; Friedlich A. L., 1993, Society for Neuroscience Abstracts, V19, P1036; Fullerton HJ, 1998, ANN NEUROL, V44, P357, DOI 10.1002/ana.410440311; GARDNER PR, 1994, P NATL ACAD SCI USA, V91, P12248, DOI 10.1073/pnas.91.25.12248; HIRATA H, 1995, BRAIN RES, V677, P345, DOI 10.1016/0006-8993(95)00218-F; Hirata H, 1996, BRAIN RES, V714, P95, DOI 10.1016/0006-8993(95)01502-7; Ho YS, 1998, AM J RESP CELL MOL, V18, P538, DOI 10.1165/ajrcmb.18.4.2959; Huang TT, 1997, ARCH BIOCHEM BIOPHYS, V344, P424, DOI 10.1006/abbi.1997.0237; Huang TT, 1998, AGE, V21, P83, DOI 10.1007/s11357-998-0011-y; HUANG TT, 1999, IN PRESS J GERONTOL; KAMII H, 1994, BRAIN RES, V662, P240, DOI 10.1016/0006-8993(94)90818-4; KAMII H, 1994, J CEREBR BLOOD F MET, V14, P478, DOI 10.1038/jcbfm.1994.59; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; Klivenyi P, 1998, NEUROBIOL DIS, V5, P253, DOI 10.1006/nbdi.1998.0191; Kondo T, 1997, J NEUROSCI, V17, P4180; Kondo T, 1997, J CEREBR BLOOD F MET, V17, P241, DOI 10.1097/00004647-199703000-00001; Kondo T, 1996, BRAIN RES, V737, P321, DOI 10.1016/0006-8993(96)00949-3; KUJIRAI K, 1994, SYNAPSE, V17, P76, DOI 10.1002/syn.890170203; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Li YB, 1998, BRAIN RES, V814, P164, DOI 10.1016/S0006-8993(98)01082-8; Melov S, 1999, P NATL ACAD SCI USA, V96, P846, DOI 10.1073/pnas.96.3.846; Mena MA, 1997, J NEUROCHEM, V69, P21; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; MIKAWA S, 1995, MOL BRAIN RES, V33, P288, DOI 10.1016/0169-328X(95)00146-J; Murakami K, 1998, J NEUROSCI, V18, P205; Murakami K, 1997, STROKE, V28, P1797, DOI 10.1161/01.STR.28.9.1797; NAKAO N, 1995, NAT MED, V1, P226, DOI 10.1038/nm0395-226; PRZEDBORSKI S, 1992, J NEUROSCI, V12, P1658; Przedborski S, 1996, J NEUROCHEM, V67, P1383; Raber J, 1996, VIROLOGY, V226, P362, DOI 10.1006/viro.1996.0664; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; ROBERTS JR, 1994, J BIOL CHEM, V269, P17841; Roberts JR, 1996, J BIOL CHEM, V271, P24604, DOI 10.1074/jbc.271.40.24604; Rozmahel R, 1996, NAT GENET, V12, P280, DOI 10.1038/ng0396-280; SanchezRamos JR, 1997, J NEUROCHEM, V68, P58; Sun JT, 1999, MOL CELL BIOL, V19, P216; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Van Remmen H, 1999, ARCH BIOCHEM BIOPHYS, V363, P91, DOI 10.1006/abbi.1998.1060; Williams MD, 1998, J BIOL CHEM, V273, P28510, DOI 10.1074/jbc.273.43.28510; YANG GY, 1994, STROKE, V25, P165, DOI 10.1161/01.STR.25.1.165; Yen HC, 1999, ARCH BIOCHEM BIOPHYS, V362, P59, DOI 10.1006/abbi.1998.1011; ZHANG Y, 1990, J BIOL CHEM, V265, P16330	57	80	82	0	3	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-209-6	ANN NY ACAD SCI	Ann.NY Acad.Sci.		1999	893						95	112		10.1111/j.1749-6632.1999.tb07820.x			18	Biochemistry & Molecular Biology; Endocrinology & Metabolism; Multidisciplinary Sciences; Neurosciences; Ornithology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism; Science & Technology - Other Topics; Neurosciences & Neurology; Zoology	BP50E	WOS:000085330600009	10672232				2022-02-06	
J	Serio, CD; Kreutzer, JS; Witol, AD				Serio, CD; Kreutzer, JS; Witol, AD			Family needs after traumatic brain injury: A factor analytic study of the Family Needs Questionnaire	BRAIN INJURY			English	Article							CRITICALLY ILL PATIENTS; HEAD-INJURY; RELATIVES	The present investigation examined the empirical and theoretical validity of an instrument developed to assess family members' perceptions of needs following the brain injury of a relative. The Family Needs Questionnaire (FNQ) consists of 40 items reflecting commonly reported family needs. The development of the items was based on the literature describing family reactions to brain injury and other medical disabilities. A principal-components factor analysis was executed based on the FNQ responses of 178 family members. A six-factor solution was selection as the best fit for the data, yielding the following independent subscales: (1) Need for Health Information; (2) Need for Emotional Support; (3) Need for Instrumental Support; (4) Need for Professional Support; (5) Need for a Support Network; and (6) Need for Involvement with Care. Further analysis indicated at least adequate internal reliability for each scale. Overall, the measure appears to offer unique information relevant to family members' needs after brain injury.	VIRGINIA COMMONWEALTH UNIV MED COLL VIRGINIA,DEPT PHYS MED & REHABIL,RICHMOND,VA; VIRGINIA COMMONWEALTH UNIV MED COLL VIRGINIA,DIV NEUROL SURG,RICHMOND,VA								Campbell C H, 1988, Rehabil Nurs, V13, P320; CAMPLAIR P, 1989, 13 ANN POSTG COURS R; CATTELL RB, 1966, MULTIVAR BEHAV RES, V1, P245, DOI 10.1207/s15327906mbr0102_10; Comrey A. L., 1973, 1 COURSE FACTOR ANAL; Engli M, 1993, J Neurosci Nurs, V25, P78; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KAISER HF, 1958, PSYCHOMETRIKA, V23, P187, DOI 10.1007/BF02289233; Kozloff R., 1987, J HEAD TRAUMA REHAB, V2, P14, DOI [DOI 10.1097/00001199-198709000-00004, 10.1097/00001199-198709000-00004]; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; Kreutzer JS, 1990, COMMUNITY INTEGRATIO; LESKE JS, 1986, HEART LUNG, V15, P189; LEZAK M, 1978, J CLIN PSYCHIAT, V39, P111; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Mathis M, 1984, J Neurosurg Nurs, V16, P36; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; MOLTER NC, 1979, HEART LUNG, V8, P332; NORRIS LO, 1986, HEART LUNG, V15, P194; Nunnally JC., 1978, PSYCHOMETRIC THEORY, V2; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Panting A, 1972, REHABILITATION, V38, P33; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; Tabachnick B. G., 1989, USING MULTIVARIATE S	23	80	81	0	10	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JAN	1997	11	1					1	9		10.1080/026990597123764			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	WB723	WOS:A1997WB72300001	9012547				2022-02-06	
J	Douglas, JM; Spellacy, FJ				Douglas, JM; Spellacy, FJ			Indicators of long-term family functioning following severe traumatic brain injury in adults	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; ALCOHOLIC PATIENTS; LIFE EVENTS; RELATIVES; DEPRESSION; REHABILITATION; ENVIRONMENT; BEHAVIOR; CHILDREN; RECOVERY	This study investigated the degree of association between four sets of predictor variables (demographic, injury-related, patient functioning, and caregiver functioning variables) and the criterion variable of long-term family functioning following severe traumatic brain injury (TBI). Thirty families participated in the study and a minimum of 3.5 years had elapsed since the time of injury. The mean length of post-traumatic amnesia (PTA) for the brain-injured individuals was 92.4 days. Data collection took place in the family home and both the brain-injured family members and primary caregivers were involved. Standard regression analyses revealed that two sets of variables accounted for a significant amount of variance in long-term family functioning. The largest amount of variance, 55% (44% adjusted), was accounted for by the caregivers' self-report variables which measured caregivers' depression, social support, and coping as well as caregivers' perceptions of patient competency. Overall, measures of severity of injury (PTA), residual neurobehavioural function, and adequacy of social support for caregivers proved to be reliable and significant indicators of family functioning. These findings are discussed with respect to their implications for service delivery and long-term provision of support for caregivers of severely brain-injured individuals living with their families.	UNIV VICTORIA, DEPT PSYCHOL, VICTORIA, BC, CANADA		Douglas, JM (corresponding author), LA TROBE UNIV, SCH COMMUN DISORDERS, BUNDOORA, VIC 3083, AUSTRALIA.		Douglas, Jacinta M/C-2380-2009	Douglas, Jacinta/0000-0003-0940-6624			ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/0090-5550.39.1.29; BARNETT PA, 1988, PSYCHOL BULL, V104, P97, DOI 10.1037/0033-2909.104.1.97; Billings A G, 1981, J Behav Med, V4, P139, DOI 10.1007/BF00844267; BILLINGS AG, 1984, J PERS SOC PSYCHOL, V46, P877, DOI 10.1037/0022-3514.46.4.877; BLUMENTHAL MD, 1975, ARCH GEN PSYCHIAT, V32, P985; Bond M R, 1975, Ciba Found Symp, P141; BROMET EJ, 1984, ACTA PSYCHIAT SCAND, V69, P197, DOI 10.1111/j.1600-0447.1984.tb02487.x; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CARROLL BJ, 1973, ARCH GEN PSYCHIAT, V28, P361; CORRIGAN J D, 1990, Brain Injury, V4, P215, DOI 10.3109/02699059009026170; DOUGLAS JM, 1990, P BIENN C NZ SPEECH, P24; Ensel W., 1986, SOCIAL SUPPORT LIFE, P129; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; FINNEY JW, 1980, J CONSULT CLIN PSYCH, V48, P17, DOI 10.1037/0022-006X.48.1.17; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; FRANK RG, 1994, BRAIN INJURY, V8, P193, DOI 10.3109/02699059409150972; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LEI H, 1980, J PSYCHOSOM RES, V24, P57, DOI 10.1016/0022-3999(80)90054-9; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; Lin N., 1986, SOCIAL SUPPORT LIFE; Liss M, 1990, Int J Rehabil Res, V13, P309, DOI 10.1097/00004356-199012000-00004; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; LUNGHI ME, 1977, BRIT J PSYCHIAT, V130, P598, DOI 10.1192/bjp.130.6.598; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MOORE A, 1993, BRAIN INJURY, V7, P247, DOI 10.3109/02699059309029677; Moos R.H., 1981, FAMILY ENV SCALE MAN; MOOS RH, 1979, J STUD ALCOHOL, V40, P78, DOI 10.15288/jsa.1979.40.78; MOOS RH, 1981, J STUD ALCOHOL, V42, P383, DOI 10.15288/jsa.1981.42.383; MOOS RH, 1988, HLTH DAILY LIVING MA; Nelson H. E., 1991, NATIONAL ADULT READI; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; ODDY M, 1984, CLOSED HEAD INJURY P, P108; PESSAR LF, 1993, BRAIN INJURY, V7, P231, DOI 10.3109/02699059309029675; PETERS L C, 1992, Brain Injury, V6, P461, DOI 10.3109/02699059209008141; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; Rehm LP, 1988, BEHAV ASSESSMENT PRA, P313; RESNICK C, 1993, SOC WORK HEALTH CARE, V18, P49, DOI 10.1300/J010v18n02_03; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; RIVARA JB, 1993, ARCH PHYSICAL MED RE, V74, P1947; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; ROSS CE, 1979, J HEALTH SOC BEHAV, V20, P166, DOI 10.2307/2136437; SARASON IG, 1985, PSYCHOSOM MED, V47, P156, DOI 10.1097/00006842-198503000-00007; SCHAEFER C, 1981, Journal of Behavioral Medicine, V4, P381, DOI 10.1007/BF00846149; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SINES JO, 1984, J PERS ASSESS, V48, P6, DOI 10.1207/s15327752jpa4801_2; SPIEGEL D, 1983, FAM PROCESS, V22, P537, DOI 10.1111/j.1545-5300.1983.00537.x; Tausig M., 1986, SOCIAL SUPPORT LIFE, P71; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; Willer B., 1990, CANADIAN J REHABILIT, V3, P167; ZUNG WW, 1974, MEASUREMENT DEPRESSI; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008; [No title captured]	66	80	80	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	1996	10	11					819	839		10.1080/026990596123936			21	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	VM779	WOS:A1996VM77900004	8905160				2022-02-06	
J	Kimura, H; Meaney, DF; McGowan, JC; Grossman, RI; Lenkinski, RE; Ross, DT; McIntosh, TK; Gennarelli, TA; Smith, DH				Kimura, H; Meaney, DF; McGowan, JC; Grossman, RI; Lenkinski, RE; Ross, DT; McIntosh, TK; Gennarelli, TA; Smith, DH			Magnetization transfer imaging of diffuse axonal injury following experimental brain injury in the pig: Characterization by magnetization transfer ratio with histopathologic correlation	JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY			English	Article						animal studies; brain, wounds and injuries; magnetization transfer; magnetization imaging	HEAD-INJURY; CLINICAL-APPLICATIONS; MR; TRAUMA; CT	Purpose: Our goal was to evaluate the use of the magnetization transfer ratio (MTR) in the detection of diffuse axonal injury (DAI) resulting from traumatic brain injury in a swine model, Method: DAI was created by applying a nonimpact, coronal plane, rotational acceleration to the heads of miniature swine (n = 4). GE imaging was performed with and without off-resonance MT saturation. Histologic correlation of axonal injury with MRI was performed 7 days postinjury, Thirty-one subcortical white matter regions and 10 deep white matter regions were selected for the direct comparison of histologic data and MTR measurements, Results: Nineteen of 41 examined locations exhibited histologic evidence of axonal injury, The mean MTR in regions with axonal damage was significantly less than in regions without axonal damage. These changes were observed both in regions demonstrating high signal intensity on T2-weighted images (T2WI) (p < 0.0001, n = 6) and in regions with no signal intensity change on T2WI (p < 0.05, n = 13). Conclusion: These results suggest that the measurement of MTR may have the potential for evaluating axonal damage in DAI following traumatic brain injury even when conventional T2WI does not demonstrate the lesion.	UNIV PENN,SCH MED,HOSP UNIV PENN,DEPT RADIOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,HOSP UNIV PENN,DEPT BIOENGN,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,HOSP UNIV PENN,DIV NEUROSURG,PHILADELPHIA,PA 19104				Lenkinski, Robert/F-9045-2014; smith, douglas/A-1321-2007	Meaney, David/0000-0002-0954-4122; Lenkinski, Robert/0000-0001-7371-5048	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, P50NS008803] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 08803] Funding Source: Medline		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1984, GREENFIELDS NEUROPAT, P85; ATLAS SW, 1988, RADIOLOGY, V168, P803, DOI 10.1148/radiology.168.3.3406410; BALABAN R S, 1992, Magnetic Resonance Quarterly, V8, P116; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; Bullock Ross, 1993, Journal of Emergency Medicine, V11, P23; CROOKS DA, 1991, J PATHOL, V165, P5, DOI 10.1002/path.1711650103; DOUSSET V, 1992, RADIOLOGY, V182, P483, DOI 10.1148/radiology.182.2.1732968; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GENTILE NT, 1993, ANN EMERG MED, V22, P1028, DOI 10.1016/S0196-0644(05)82746-5; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1991, MAGNETIC RESONANCE I, P439; GOMORI JM, 1993, AM J NEURORADIOL, V14, P871; GROSSMAN RI, 1994, RADIOGRAPHICS, V14, P279, DOI 10.1148/radiographics.14.2.8190954; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; *MAGN RES MED, 1991, TECHN MAGN TRANSF IM, P175; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; NG HK, 1994, CLIN NEUROL NEUROSUR, V96, P24, DOI 10.1016/0303-8467(94)90025-6; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SHREIBER DI, 1995, J NEUROTRAUM, V12, P689; WOLFF SD, 1989, MAGNET RESON MED, V10, P135, DOI 10.1002/mrm.1910100113	29	80	83	0	4	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0363-8715			J COMPUT ASSIST TOMO	J. Comput. Assist. Tomogr.	JUL-AUG	1996	20	4					540	546		10.1097/00004728-199607000-00007			7	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	UY664	WOS:A1996UY66400007	8708052				2022-02-06	
J	Conway, MA; Tacchi, PC				Conway, MA; Tacchi, PC			Motivated confabulation	NEUROCASE			English	Article							MEMORIES; REALITY; RETRIEVAL; SELF	OP, a 73-year-old woman, suffered a closed head injury that caused bilateral damage to the temporal and frontal lobes. She had impaired access to episodic and semantic knowledge, showed some deficits in visual processing, performed at floor on tests of frontal lobe function, and was in the severely impaired range on tests of autobiographical memory. However, OP's most striking memory disturbance was that she confabulated. Her confabulated memories provided a basis for explanations of the behaviour of others towards her since her accident and in this respect were motivated confabulations. It is argued that OP has suffered an impairment to executive functions and, as a consequence, can no longer discriminate mental representations of wishes and imaginings from memories of actual experiences.	UNIV BRISTOL, DEPT PSYCHOL, BRISTOL BS8 1TN, AVON, ENGLAND								ANDERSON SJ, 1993, J EXP PSYCHOL LEARN, V19, P1178, DOI 10.1037/0278-7393.19.5.1178; Baddeley A. D., 1990, AUTOBIOGRAPHICAL MEM; BADDELEY AD, 1986, AUTOBIOGRAPHICAL MEM, P225; BADDELEY AD, 1994, SPEED CAPACITY LANGU; BADDELEY AD, 1992, DOORS PEOPLE; Benson D.F., 1986, FRONTAL LOBES; Burgess PW, 1996, MEMORY, V4, P359, DOI 10.1080/096582196388906; CATTEL RB, 1986, HDB 16 PERSONALITY F; Conway M.A., 1990, AUTOBIOGRAPHICAL MEM; Conway M.A., 1996, REMEMBERING OUR STUD, P67, DOI [10.1017/CBO9780511527913.003, DOI 10.1017/CBO9780511527913.003]; CONWAY MA, 1987, MEM COGNITION, V15, P119, DOI 10.3758/BF03197023; CONWAY MA, 1992, NATO ADV SCI INST SE, V65, P167; CONWAY MA, 1996, J EXPT PSYCHOL GEN, V125, P1; CONWAY MA, 1993, HDB NEUROPSYCHOLOGY, P175; Conway Martin A., 1993, P103; DALLABARBA G, 1993, COGN NEUROPSYCHOL, V10, P1; DALLABARBA G, 1995, BROKEN MEMORIES CASE, P101; DAMASIO AR, 1989, COGNITION, V33, P25, DOI 10.1016/0010-0277(89)90005-X; Downes J. J., 1995, BROKEN MEMORIES CASE, P115; ERICSSON KA, 1995, PSYCHOL REV, V102, P211, DOI 10.1037/0033-295X.102.2.211; HIGGINS ET, 1987, PSYCHOL REV, V94, P319, DOI 10.1037/0033-295X.94.3.319; Howard D, 1992, PYRAMIDS PALM TREES; Johnson M.K., 1996, BASIC APPL MEMORY RE, V1, P295; JOHNSON MK, 1993, PSYCHOL BULL, V114, P3, DOI 10.1037/0033-2909.114.1.3; JOHNSON MK, 1981, PSYCHOL REV, V88, P67, DOI 10.1037/0033-295X.88.1.67; Johnson-Laird P.N., 1983, MENTAL MODELS; KAHNEMAN D, 1986, PSYCHOL REV, V93, P136, DOI 10.1037/0033-295X.93.2.136; Kopelman MD, 1995, NEUROCASE, V1, P71, DOI 10.1080/13554799508402348; KOPELMAN MD, 1987, J NEUROL NEUROSUR PS, V50, P1482, DOI 10.1136/jnnp.50.11.1482; Kopelman MD, 1995, BROKEN MEMORIES CASE, P137; LINDSAY DS, 1994, APPL COGNITIVE PSYCH, V8, P281, DOI 10.1002/acp.2350080403; LOFTUS EF, 1993, AM PSYCHOL, V48, P518, DOI 10.1037/0003-066X.48.5.518; MARKUS H, 1986, AM PSYCHOL, V41, P954, DOI 10.1037/0003-066X.41.9.954; MARSHALL JC, 1995, CORTEX, V31, P183, DOI 10.1016/S0010-9452(13)80116-5; Mayes A R, 1994, Memory, V2, P183, DOI 10.1080/09658219408258944; Moscovitch M., 1989, VARIETIES MEMORY CON, P133; Nelson H. E., 1991, NATIONAL ADULT READI; Norman D., 1980, ATTENTION ACTION WIL; OCONNOR M, 1992, J CLIN EXP NEUROPSYC, V14, P159, DOI 10.1080/01688639208402821; OGDEN JA, 1993, NEUROPSYCHOLOGIA, V31, P571, DOI 10.1016/0028-3932(93)90053-3; Papagno C, 1996, NEUROCASE, V2, P111; Riddoch M. J., 1993, BIRMINGHAM OBJECT RE; Robinson J.A., 1986, AUTOBIOGRAPHICAL MEM, VVol. 325, P19, DOI [10.1017/CBO9780511558313.005, DOI 10.1017/CBO9780511558313.005]; ROBINSON JA, 1992, NATO ADV SCI INST SE, V65, P223; ROSS M, 1989, PSYCHOL REV, V96, P341, DOI 10.1037/0033-295X.96.2.341; Rubin D. C., 1986, AUTOBIOGRAPHICAL MEM; SCHACTER DL, 1996, IN PRESS PSYCHIAT AN; SCHACTER DL, 1995, MEMORY DISTORTION MI; SHALLICE T, 1982, PHILOS T ROY SOC LON, pB298; Shallice T., 1988, NEUROPSYCHOLOGY MENT; STEVENS M, 1979, B BRIT PSYCHOL SOC, V32, P211; STRAUMAN TJ, 1990, J PERS SOC PSYCHOL, V59, P869, DOI 10.1037/0022-3514.59.5.869; Talland G.A., 1965, DERANGED MEMORY; TULVING E, 1985, CAN PSYCHOL, V26, P1, DOI 10.1037/h0080017; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; Williams J.M.G., 1996, REMEMBERING OUR STUD, P244, DOI DOI 10.1017/CBO9780511527913.010; WILLIAMS MD, 1981, COGNITIVE SCI, V5, P87, DOI 10.1207/s15516709cog0502_1; Wilson BA, 1991, RIVERMEAD BEHAV MEMO	59	80	81	0	5	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND	1355-4794			NEUROCASE	Neurocase		1996	2	4					325	338					14	Clinical Neurology; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	VL519	WOS:A1996VL51900003					2022-02-06	
J	Johnstone, B; Callahan, CD; Kapila, CJ; Bouman, DE				Johnstone, B; Callahan, CD; Kapila, CJ; Bouman, DE			The comparability of the WRAT-R reading test and NAART as estimates of premorbid intelligence in neurologically impaired patients	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article							WAIS-R	A study by Wiens, Bryan, and Crossen (1993) suggests the Wide Range Achievement Test-Revised (WRAT-R) Reading subtest and North American Adult Reading Test (NAART) are adequate predictors of Wechsler Adult Intelligence Scale-Revised (WAIS-R) IQ scores for a normal population. Although it is common practice to use reading scores to estimate premorbid IQ in clinical populations, the WRAT-R and NAART have not been compared using individuals with brain dysfunction The current study cross-validated the Wiens et al. (1993) study using neurologically impaired populations: traumatic brain injury (n = 118), dementia (n = 37), and other neurologic impairments (n = 77). The results were generally consistent across all three groups: (a) the WRAT-R and NAART were equivalent and accurate estimates of average VIQ levels; (b) the WRAT-R and NAART were equivalent but underestimates of higher intelligence ranges: and (c) the WRAT-R is a more accurate estimate for lower VIQ ranges, although both are overestimates. This third finding is in contrast to Wiens et al.'s (1993) results that suggest the WRAT-R is an accurate estimate of lower Ie ranges for normals. It is concluded that the WRAT-R is the preferred measure of premorbid verbal intelligence for psychometric and clinical reasons.	UNIV MISSOURI,SCH MED,COLUMBIA,MO; MEM MED CTR,DEPT PSYCHOL,SPRINGFIELD,IL 62781; DRAKE CTR,DEPT PSYCHOL,CINCINNATI,OH					Johnstone, Brick/0000-0001-8845-9649			BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; BERRY DTR, 1994, ARCH CLIN NEUROPSYCH, V9, P239, DOI 10.1016/0887-6177(94)90029-9; BUTTERS N, 1990, J CLIN EXP NEUROPSYC, V12, P963, DOI 10.1080/01688639008401035; Christensen H., 1991, J CONSULT CLIN PSYCH, V3, P147, DOI DOI 10.1037/1040-3590.3.2.147; Crawford J. R., 1992, HDB NEUROPSYCHOLOGIC; JSTAK S, 1984, WRAT R WIDE RANGE AC; KARAKEN DA, 1995, ARCH CLIN NEUROPSYCH, V10, P147; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Nelson H. E, 1982, NATIONAL ADULT READI; Spreen O., 1989, CLIN NEUROPSYCHOL, V3, P129, DOI [10.1080/13854048908403285, DOI 10.1080/13854048908403285]; Stebbins Glenn T, 1990, Clin Neuropsychol, V4, P18, DOI 10.1080/13854049008401493; Wechsler, 1997, WECHSLER ADULT INTEL; WIENS AN, 1993, CLIN NEUROPSYCHOL, V7, P70, DOI 10.1080/13854049308401889	14	80	81	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.		1996	11	6					513	519		10.1016/0887-6177(96)82330-4			7	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	VF792	WOS:A1996VF79200005	14588456	Bronze			2022-02-06	
J	WUDEL, JH; MORRIS, JA; YATES, K; WILSON, A; BASS, SM				WUDEL, JH; MORRIS, JA; YATES, K; WILSON, A; BASS, SM			MASSIVE TRANSFUSION - OUTCOME IN BLUNT TRAUMA PATIENTS	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	20TH ANNUAL MEETING OF THE WESTERN TRAUMA ASSOC	FEB 26-MAR 02, 1990	CRESTED BUTTE, CO	W TRAUMA ASSOC			BLOOD TRANSFUSIONS; GERIATRIC-PATIENTS; MAJOR TRAUMA; INJURY; COAGULATION; HEMOSTASIS; CARE	Over a 54-month period 6,142 patients were consecutively admitted to our Level I trauma center. Ninety-two blunt trauma patients required massive transfusion (MT) of 20 or more units of packed red blood cells (range, 20-126). Eighty-two per cent of all transfused blood was given within 24 hours of admission. Forty-eight patients (52%) were long-term survivors. Twenty-six patients died (28%) within 24 hours and 21 of these exsanguinated. Eighteen patients died > 24 hours: nine (50%) died from multiple organ failure, and nine (50%) died from severe closed head injury (CHI). Clinical predictors of increased mortality were: shock on admission, closed head injury, and age. Forty-three survivors were followed for a mean of 2.5 years (range, 1-5 years). No patient died during followup. All patients were home at 1 year; only four patients required continued medical assistance. Thirty-two patients (74%) returned to work. We conclude that: 1) blunt and penetrating trauma patients receiving MT have similar survival rates of 50%; 2) shock, closed head injury, and age predict increased mortality but do not preclude survival; 3) long-term outcome in blunt patients requiring MT is excellent. Post-discharge death is rare and 3/4 of the survivors return to work, justifying the high cost of acute care.	VANDERBILT UNIV,SCH MED,DIV TRAUMA,2100 PIERCE AVE,NASHVILLE,TN 37212				Woolley, Tom/D-8110-2012	Woolley, Tom/0000-0001-9957-6453			BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; CHAMPION HR, 1989, AM J PUBLIC HEALTH, V79, P1278, DOI 10.2105/AJPH.79.9.1278; COLLINS JA, 1974, SURGERY, V75, P274; COUNTS RB, 1979, ANN SURG, V190, P91, DOI 10.1097/00000658-197907000-00020; FELICIANO DV, 1981, J TRAUMA, V21, P285, DOI 10.1097/00005373-198104000-00005; FINELLI FC, 1989, J TRAUMA, V29, P541, DOI 10.1097/00005373-198905000-00001; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; Harke H, 1980, Bibl Haematol, P179; HARRIGAN C, 1989, J TRAUMA, V29, P1416, DOI 10.1097/00005373-198910000-00020; HARRIGAN C, 1982, AM SURGEON, V48, P393; KASHUK JL, 1982, J TRAUMA, V22, P672, DOI 10.1097/00005373-198208000-00004; MARTIN DJ, 1985, ANN SURG, V202, P505, DOI 10.1097/00000658-198510000-00010; MILLER RD, 1971, ANN SURG, V174, P794, DOI 10.1097/00000658-197111000-00010; MORRIS JA, 1990, J TRAUMA, V30, P1476, DOI 10.1097/00005373-199012000-00006; PHILLIPS TF, 1987, J TRAUMA, V27, P903, DOI 10.1097/00005373-198708000-00010; SIEGEL J H, 1989, Journal of Trauma, V29, P1731; STONE HH, 1983, AM SURGEON, V5, P532; STRING T, 1971, ARCH SURG-CHICAGO, V102, P406; WEST HC, 1989, SOUTHERN MED J, V82, P186, DOI 10.1097/00007611-198902000-00010; WILSON RF, 1971, J TRAUM, V11, P275, DOI 10.1097/00005373-197104000-00001; 1971, JAMA-J AM MED ASSOC, V215, P277	22	80	82	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	1991	31	1					1	7		10.1097/00005373-199101000-00001			7	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	EU220	WOS:A1991EU22000001	1986111				2022-02-06	
J	DeWitt, DS; Kong, DL; Lyeth, BG; Jenkins, LW; Hayes, RL; Wooten, ED; Prough, DS				DeWitt, Douglas S.; Kong, Daniel L.; Lyeth, Bruce G.; Jenkins, Larry W.; Hayes, Ronald L.; Wooten, Esther D.; Prough, Donald S.			Experimental Traumatic Brain Injury Elevates Brain Prostaglandin E-2 and Thromboxane B-2 Levels in Rats	JOURNAL OF NEUROTRAUMA			English	Article							CEREBRAL-BLOOD-FLOW; FLUID-PERCUSSION MODEL; ARACHIDONIC-ACID; ADRENERGIC TRANSMISSION; SYNTHETASE INHIBITION; SMOOTH-MUSCLE; FREE-RADICALS; CYCLOOXYGENASE; PROSTACYCLIN; EICOSANOIDS	Prostaglandin E-2 (PGE(2)) and thromboxane B-2 (TxB(2)) levels were measured in rats following experimental traumatic brain injury. Rats (n = 36) were prepared for fluid percussion brain injury under pentobarbital anesthesia. Twenty-four hours later, rats were lightly anesthetized using methoxyflurane, injured (2.3 atm), and killed 5 or 15 min later. Twelve of the rats died before and are not included in the analyses. The following groups were used for data analysis: group I (n = 6) were sham-injured rats prepared for injury but not injured: group II (n = 6) were injured and killed 5 min later; group III (n = 12) were injured and killed 15 min posttrauma. Thirty seconds prior to sacrifice by decapitation into liquid nitrogen, all rats were injected with indomethacin (3 mg/kg, intravenously [IV]) to prevent postmortem PG synthesis. After sacrifice, brains were removed, weighed, and homogenized in a small quantity of phosphate buffer with indomethacin (50 ug/ml). PGE(2) and TxB(2) levels were determined using double-label radioimmunoassays. Posttraumatic convulsions were observed in 5 of 12 rats in group III and these rats were analyzed separately. PGE(2) and TxB(2) levels increased significantly (p < 0.05) in both hemisphere and brainstem 5 min posttrauma. Fifteen minutes after injury, both PGE(2) and TxB(2) levels remained elevated but the levels were lower than at 5 min in the rats that did not exhibit posttraumatic seizures. This decrease in PG levels at 15 min was not observed in the rats that had seizures after injury and both PGE(2) and TxB(2) levels remained high in hemispheres and brainstem. Thus, fluid percussion brain injury results in substantial elevations in PGE(2) and TxB(2) levels and posttraumatic seizures exacerbate the observed increases.	[DeWitt, Douglas S.; Kong, Daniel L.; Wooten, Esther D.; Prough, Donald S.] Bowman Gray Sch Med, Dept Anesthesia, Winston Salem, NC 27103 USA; [Lyeth, Bruce G.; Jenkins, Larry W.; Hayes, Ronald L.] Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA		DeWitt, DS (corresponding author), Bowman Gray Sch Med, Dept Anesthesia, 300 S Hawthorne Rd, Winston Salem, NC 27103 USA.		Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X; Lyeth, Bruce/0000-0003-4811-1474	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 19355, NS 19550]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019355, R01NS019550] Funding Source: NIH RePORTER	The authors thank Ms. Jacqui Gunter and Mr. Larry Olneac for their expert technical assistance. We also thank Ms. Susan Margitic for her editorial comments and Ms. Vicky Cranfill and Ms. Debra Richards for their help in typing this manuscript. This research was funded by grants NS 19355 and NS 19550 from the NIH.	ALTURA BM, 1976, FED PROC, V35, P2360; BIRKLE DL, 1987, J NEUROCHEM, V48, P1768, DOI 10.1111/j.1471-4159.1987.tb05735.x; BRITTAIN RT, 1985, CIRCULATION, V72, P1208, DOI 10.1161/01.CIR.72.6.1208; DEGEORGE JJ, 1986, J BIOL CHEM, V261, P3428; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; DEMOPOULOS HB, 1973, FED PROC, V32, P1903; DEMPSEY RJ, 1986, J NEUROSURG, V64, P118, DOI 10.3171/jns.1986.64.1.0118; DeWitt D.S., 1988, SOC NEUR ABSTR, V14, P691; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DUBOCOVICH ML, 1975, J PHYSIOL-LONDON, V251, P737, DOI 10.1113/jphysiol.1975.sp011119; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; ELLIS EF, 1977, STROKE, V8, P480, DOI 10.1161/01.STR.8.4.480; FLAMM ES, 1978, STROKE, V9, P445, DOI 10.1161/01.STR.9.5.445; FOLCO GC, 1977, PROSTAG OTH LIPID M, V13, P893, DOI 10.1016/0090-6980(77)90218-0; Frame M.H., 1976, ADV PROSTAGLANDIN TH; GARCIASZABO RR, 1983, CIRC RES, V53, P214, DOI 10.1161/01.RES.53.2.214; GREENBERG RP, 1981, SURG FORUM, V32, P492; GRICE SC, 1987, STROKE, V18, P787, DOI 10.1161/01.STR.18.4.787; HAGEN AA, 1979, STROKE, V10, P306, DOI 10.1161/01.STR.10.3.306; HALES CA, 1981, J CLIN INVEST, V68, P497, DOI 10.1172/JCI110281; HAMAMDZIC M, 1977, AM J PHYSIOL, V232, pE201, DOI 10.1152/ajpendo.1977.232.2.E201; Hayes R L, 1986, Cent Nerv Syst Trauma, V3, P163; Hayes R.L., 1987, J CEREB BLOOD FLO S1, V7, pS636; HAYES RL, 1984, SCIENCE, V223, P301, DOI 10.1126/science.6701514; HEDQVIST P, 1970, LIFE SCI, V9, P269, DOI 10.1016/0024-3205(70)90028-7; HORTON EW, 1964, BRIT J PHARM CHEMOTH, V22, P189, DOI 10.1111/j.1476-5381.1964.tb01558.x; Hutlemeirer P.C., 1982, CIRC RES, V50, P688; KATOAKA K, 1967, SCIENCE, V157, P1187, DOI 10.1126/science.157.3793.1187; KELLER M, 1985, NEUROCHEM INT, V7, P655, DOI 10.1016/0197-0186(85)90063-4; KEMPSKI O, 1987, STROKE, V18, P111, DOI 10.1161/01.STR.18.1.111; KOCHANEK PM, 1987, STROKE, V18, P634, DOI 10.1161/01.STR.18.3.634; Kontos H.A., 1980, CEREBRAL MICROVASCUL; KONTOS HA, 1985, CIRC RES, V57, P142, DOI 10.1161/01.RES.57.1.142; KONTOS HA, 1981, FED PROC, V40, P2326; KONTOS HA, 1980, SCIENCE, V209, P1242, DOI 10.1126/science.7403881; KONTOS HA, 1984, CIRC RES, V55, P295, DOI 10.1161/01.RES.55.3.295; Langfitt T W, 1981, Prog Neurol Surg, V10, P14, DOI 10.1159/000384767; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; MACKENZIE ET, 1976, AM J PHYSIOL, V231, P483, DOI 10.1152/ajplegacy.1976.231.2.483; MALIK KU, 1975, CIRC RES, V36, P599, DOI 10.1161/01.RES.36.5.599; MCCOSH EJ, 1976, PROSTAGLANDINS, V12, P471, DOI 10.1016/0090-6980(76)90028-9; MENT LR, 1986, J NEUROSURG, V65, P851, DOI 10.3171/jns.1986.65.6.0851; MONCADA S, 1979, NEW ENGL J MED, V300, P1142, DOI 10.1056/NEJM197905173002006; MOSKOWITZ MA, 1981, STROKE, V12, P696; MOUFARRIJ NA, 1984, J NEUROSURG, V61, P1107, DOI 10.3171/jns.1984.61.6.1107; MURPHY S, 1985, NEUROSCI LETT, V61, P61, DOI 10.1016/0304-3940(85)90401-X; Nilsson B., 1977, J NEUROSURG, V47; PAPPIUS HM, 1983, NEUROCHEM RES, V8, P63, DOI 10.1007/BF00965654; Pickard J.D, 1987, J CEREB BLOOD FLOW M, V1, P361; PICKARD JD, 1977, EUR J PHARMACOL, V43, P343, DOI 10.1016/0014-2999(77)90040-1; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; PROUGH DS, 1986, STROKE, V17, P1272, DOI 10.1161/01.STR.17.6.1272; REICHMAN M, 1987, J NEUROCHEM, V49, P1216, DOI 10.1111/j.1471-4159.1987.tb10013.x; ROSNER MJ, 1985, CENTRAL NERVOUS SYST, P405; SAEEDABDELHALIM M, 1980, J NEUROCHEM, V34, P1331, DOI 10.1111/j.1471-4159.1980.tb09980.x; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; WOLFE LS, 1982, J NEUROCHEM, V38, P1, DOI 10.1111/j.1471-4159.1982.tb10847.x; WOLFE LS, 1976, BIOCHEM BIOPH RES CO, V70, P907, DOI 10.1016/0006-291X(76)90677-X; Wonders T.R., 1987, T AM SOC ART INT ORG, V276, P276; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YAMAKAMI I, 1987, Society for Neuroscience Abstracts, V13, P1501; YUAN X Q, 1988, Anesthesiology (Hagerstown), V69, pA538, DOI 10.1097/00000542-198809010-00538	68	80	80	1	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma		1988	5	4					303	U72		10.1089/neu.1988.5.303			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	V21VO	WOS:000208235300004	3249309				2022-02-06	
J	VINK, R; MCINTOSH, TK; DEMEDIUK, P; FADEN, AI				VINK, R; MCINTOSH, TK; DEMEDIUK, P; FADEN, AI			DECREASE IN TOTAL AND FREE MAGNESIUM CONCENTRATION FOLLOWING TRAUMATIC BRAIN INJURY IN RATS	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS			English	Article									VET ADM MED CTR,SAN FRANCISCO,CA 94121		VINK, R (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT NEUROL,CTR NEURAL INJURY,SAN FRANCISCO,CA 94143, USA.		Vink, Robert/J-7351-2012; Vink, Robert/S-5616-2019	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [902269] Funding Source: Medline		BECKER GL, 1980, BIOCHIM BIOPHYS ACTA, V591, P234, DOI 10.1016/0005-2728(80)90155-3; CHOI DW, 1987, J NEUROSCI, V7, P369; COOPER PR, 1985, NIH CENTRAL NERVOUS, P217; CORKEY BE, 1986, J BIOL CHEM, V261, P2567; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; FADEN AI, 1986, ARCH NEUROL-CHICAGO, V43, P501, DOI 10.1001/archneur.1986.00520050073026; GARFINKEL L, 1985, Magnesium, V4, P60; GUPTA RK, 1984, ANNU REV BIOPHYS BIO, V13, P221; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KUSHMERICK MJ, 1986, J BIOL CHEM, V261, P4420; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; MALLOY CR, 1986, BIOCHIM BIOPHYS ACTA, V885, P1, DOI 10.1016/0167-4889(86)90032-7; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; NILSSON B, 1985, NIH CENTRAL NERVOUS, P425; PRICHARD JW, 1986, ANNU REV NEUROSCI, V9, P61; ROSNER MJ, 1984, J NEUROSURG, V60, P961, DOI 10.3171/jns.1984.60.5.0961; SIESJO BK, 1985, NIH CENTRAL NERVOUS, P513; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1987, IN PRESS MAGN RESON; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617	20	80	80	1	2	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495	0006-291X			BIOCHEM BIOPH RES CO	Biochem. Biophys. Res. Commun.	DEC 16	1987	149	2					594	599		10.1016/0006-291X(87)90409-8			6	Biochemistry & Molecular Biology; Biophysics	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics	L2618	WOS:A1987L261800041	3426591				2022-02-06	
J	LEE, KF; WAGNER, LK; LEE, YE; SUH, JH; LEE, SR				LEE, KF; WAGNER, LK; LEE, YE; SUH, JH; LEE, SR			THE IMPACT-ABSORBING EFFECTS OF FACIAL FRACTURES IN CLOSED-HEAD INJURIES - AN ANALYSIS OF 210 PATIENTS	JOURNAL OF NEUROSURGERY			English	Article									UNIV TEXAS,HLTH SCI CTR,DEPT OPHTHALMOL,HOUSTON,TX 77030; YONSEI UNIV,MED CTR,SEOUL,SOUTH KOREA; HANYANG UNIV,MED CTR,DEPT RADIOL,SEOUL,SOUTH KOREA		LEE, KF (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT RADIOL,6431 FANNIN,HOUSTON,TX 77030, USA.						BRANTZAWADZKI MN, 1982, AM J ROENTGENOL, V138, P477, DOI 10.2214/ajr.138.3.477; COOPER PR, 1979, NEUROSURGERY, V5, P566, DOI 10.1227/00006123-197911000-00004; CRUSE CW, 1980, J TRAUMA, V20, P551, DOI 10.1097/00005373-198007000-00003; DOLAN KD, 1978, SEMIN ROENTGENOL, V13, P37, DOI 10.1016/S0037-198X(78)80017-0; DOLAN KD, 1984, RADIOGRAPHICS, V4, P576; FRENCH BN, 1977, SURG NEUROL, V7, P171; GENTRY LR, 1983, AM J ROENTGENOL, V140, P533, DOI 10.2214/ajr.140.3.533; GENTRY LR, 1983, AM J ROENTGENOL, V140, P523, DOI 10.2214/ajr.140.3.523; Halazonetis J A, 1968, Br J Oral Surg, V6, P37, DOI 10.1016/S0007-117X(68)80025-3; HARRIS JH, 1984, CRC CR REV DIAGN IM, V21, P105; HUELKE DF, 1969, J ORAL SURG, V27, P451; JENNETT B, 1975, LANCET, V1, P480; KISHORE PRS, 1981, AM J ROENTGENOL, V137, P829, DOI 10.2214/ajr.137.4.829; KISHORE PRS, 1981, AM J NEURORADIOL, V2, P307; Le Fort R, 1972, PLAST RECONSTR SURG, V50, P600; LEE KF, 1984, PROGR CRITICAL CARE, V1, P80; LEE KF, 1984, PROGR CRITICAL CARE, V1, P97; LIPPER MH, 1985, AM J ROENTGENOL, V144, P483, DOI 10.2214/ajr.144.3.483; LUCE EA, 1979, PLAST RECONSTR SURG, V63, P26, DOI 10.1097/00006534-197901000-00005; MATRAS H, 1980, J MAXILLOFAC SURG, V8, P52, DOI 10.1016/S0301-0503(80)80072-5; MCCOY FJ, 1962, PLAST RECONSTR SURG, V29, P381; Murray J F, 1975, Clin Plast Surg, V2, P131; Nahum A M, 1975, Clin Plast Surg, V2, P59; NAKAMURA T, 1973, ARCH OTOLARYNGOL, V97, P288; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; SALEM JE, 1968, ORAL SURG ORAL MED O, V26, P390, DOI 10.1016/0030-4220(68)90412-X; SCHULTZ R C, 1970, Review of Surgery, V27, P394; SCHULTZ RC, 1977, SURG CLIN N AM, V57, P987; Swearingen John, 1965, TOLERANCES HUMAN FAC; TEASDALE G, 1974, LANCET, V2, P81	30	80	81	1	3	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	APR	1987	66	4					542	547		10.3171/jns.1987.66.4.0542			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	G6498	WOS:A1987G649800009	3559719				2022-02-06	
J	Benabid, AL; Costecalde, T; Eliseyev, A; Charvet, G; Verney, A; Karakas, S; Foerster, M; Lambert, A; Moriniere, B; Abroug, N; Schaeffer, MC; Moly, A; Sauter-Starace, F; Ratel, D; Moro, C; Torres-Martinez, N; Langar, ML; Oddoux, M; Polosan, M; Pezzani, S; Auboiroux, V; Aksenova, T; Mestais, C; Chabardes, S				Benabid, Alim Louis; Costecalde, Thomas; Eliseyev, Andrey; Charvet, Guillaume; Verney, Alexandre; Karakas, Serpil; Foerster, Michael; Lambert, Aurelien; Moriniere, Boris; Abroug, Neil; Schaeffer, Marie-Caroline; Moly, Alexandre; Sauter-Starace, Fabien; Ratel, David; Moro, Cecile; Torres-Martinez, Napoleon; Langar, Lilia; Oddoux, Manuela; Polosan, Mircea; Pezzani, Stephane; Auboiroux, Vincent; Aksenova, Tetiana; Mestais, Corinne; Chabardes, Stephan			An exoskeleton controlled by an epidural wireless brain-machine interface in a tetraplegic patient: a proof-of-concept demonstration	LANCET NEUROLOGY			English	Article							CORTICAL CONTROL; MOTOR; RESTORATION; MOVEMENT	Background Approximately 20% of traumatic cervical spinal cord injuries result in tetraplegia. Neuroprosthetics are being developed to manage this condition and thus improve the lives of patients. We aimed to test the feasibility of a semi-invasive technique that uses brain signals to drive an exoskeleton. Methods We recruited two participants at Clinatec research centre, associated with Grenoble University Hospital, Grenoble, France, into our ongoing clinical trial. Inclusion criteria were age 18-45 years, stability of neurological deficits, a need for additional mobility expressed by the patient, ambulatory or hospitalised monitoring, registration in the French social security system, and signed informed consent. The exclusion criteria were previous brain surgery, anticoagulant treatments, neuropsychological sequelae, depression, substance dependence or misuse, and contraindications to magnetoencephalography (MEG), EEG, or MRI. One participant was excluded because of a technical problem with the implants. The remaining participant was a 28-year-old man, who had tetraplegia following a C4-C5 spinal cord injury. Two bilateral wireless epidural recorders, each with 64 electrodes, were implanted over the upper limb sensorimotor areas of the brain. Epidural electrocorticographic (ECoG) signals were processed online by an adaptive decoding algorithm to send commands to effectors (virtual avatar or exoskeleton). Throughout the 24 months of the study, the patient did various mental tasks to progressively increase the number of degrees of freedom. Findings Between June 12,2017, and July 21,2019, the patient cortically controlled a programme that simulated walking and made bimanual, multi-joint, upper-limb movements with eight degrees of freedom during various reach-andtouch tasks and wrist rotations, using a virtual avatar at home (64.0% [SD 5.1] success) or an exoskeleton in the laboratory (70.9% [11.6] success). Compared with rnicroelectrodes, epidural ECoG is semi-invasive and has similar efficiency. The decoding models were reusable for up to approximately 7 weeks without recalibration. Interpretation These results showed long-term (24-month) activation of a four-limb neuroprosthetic exoskeleton by a complete brain-machine interface system using continuous, online epidural ECoG to decode brain activity in a tetraplegic patient. Up to eight degrees of freedom could be simultaneously controlled using a unique model, which was reusable without recalibration for up to about 7 weeks. Copyright (C) 2019 Elsevier Ltd. All rights reserved.	[Benabid, Alim Louis; Costecalde, Thomas; Eliseyev, Andrey; Charvet, Guillaume; Verney, Alexandre; Karakas, Serpil; Foerster, Michael; Lambert, Aurelien; Moriniere, Boris; Abroug, Neil; Schaeffer, Marie-Caroline; Moly, Alexandre; Sauter-Starace, Fabien; Ratel, David; Moro, Cecile; Torres-Martinez, Napoleon; Langar, Lilia; Oddoux, Manuela; Pezzani, Stephane; Auboiroux, Vincent; Aksenova, Tetiana; Mestais, Corinne; Chabardes, Stephan] Univ Grenoble, Clinatec, LETI, CEA, MINATEC Campus, F-38000 Grenoble, France; [Benabid, Alim Louis; Langar, Lilia; Oddoux, Manuela; Polosan, Mircea; Pezzani, Stephane; Chabardes, Stephan] CHU Grenoble Alpes, Grenoble, France; [Verney, Alexandre; Moriniere, Boris; Abroug, Neil] CEA, LIST, DIASI, SRI, Gif Sur Yvette, France		Benabid, AL (corresponding author), Univ Grenoble, Clinatec, LETI, CEA, MINATEC Campus, F-38000 Grenoble, France.	alimlouis@sfr.fr	SAUTER-STARACE, Fabien/AAY-9542-2020; Torres, Napoleon R/H-6182-2015; Eliseyev, Andrey/I-1434-2019	Torres, Napoleon R/0000-0003-3067-4172; CHARVET, Guillaume/0000-0003-4938-9419; Aksenova, Tetiana/0000-0003-4007-2343; Eliseyev, Andrey/0000-0002-0312-889X	CEAFrench Atomic Energy Commission; French Ministry of Health [PHRC-15-15-0124]; Fondation Motrice; Fondation Nanosciences; Institut Carnot; Fonds de Dotation Clinatec	CLINATEC is a Laboratory of CEA-Grenoble and has statutory links with the University Hospital of Grenoble (CHUGA) and with University Grenoble Alpes (UGA). This study was funded by CEA (recurrent funding) and the French Ministry of Health (Grant PHRC-15-15-0124), Fondation Motrice, Fondation Nanosciences, Institut Carnot, Fonds de Dotation Clinatec. Fondation Philanthropique Edmond J Safra is a major founding institution of the Clinatec Edmond J Safra Biomedical Research Center. We thank Maighed Gallagher Gambarelly for English language editing.	Ajiboye AB, 2017, LANCET, V389, P1821, DOI 10.1016/S0140-6736(17)30601-3; Bouton CE, 2016, NATURE, V533, P247, DOI 10.1038/nature17435; Capogrosso M, 2016, NATURE, V539, P284, DOI 10.1038/nature20118; Donati ARC, 2016, SCI REP-UK, V6, DOI 10.1038/srep30383; Eliseyev A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16579-9; Eliseyev A, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/4/046012; Elnady AM, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00168; Felton EA, 2007, J NEUROSURG, V106, P495, DOI 10.3171/jns.2007.106.3.495; Friggeri A., 2006, INFLUENCE TYPE NIVEA; Frolov AA, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00400; Hatsopoulos NG, 2011, NEURON, V72, P477, DOI 10.1016/j.neuron.2011.10.020; Hochberg LR, 2012, NATURE, V485, P372, DOI 10.1038/nature11076; Kennedy PR, 1998, NEUROREPORT, V9, P1707, DOI 10.1097/00001756-199806010-00007; Kennefick M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113563; Mestais CS, 2015, IEEE T NEUR SYS REH, V23, P10, DOI 10.1109/TNSRE.2014.2333541; Milekovic T, 2018, J NEUROPHYSIOL, V120, P343, DOI 10.1152/jn.00493.2017; Moriniere B, 2015, IEEE INT C INT ROBOT, P5333, DOI 10.1109/IROS.2015.7354130; Mushahwar VK, 2006, IEEE T NEUR SYS REH, V14, P198, DOI 10.1109/TNSRE.2006.875532; Pfurtscheller G, 2000, NEUROSCI LETT, V292, P211, DOI 10.1016/S0304-3940(00)01471-3; Rose J., 2006, HUMAN WALKING, V3; Roux FE, 2003, NEUROSURGERY, V53, P1342, DOI 10.1227/01.NEU.0000093424.71086.8F; Sauter-Starace F, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00847; Schaeffer Marie-Caroline, 2016, J Physiol Paris, V110, P348, DOI 10.1016/j.jphysparis.2017.03.002; Simeral JD, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/2/025027; Skelsey P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075892; Sussillo D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13749; Taylor DM, 2002, SCIENCE, V296, P1829, DOI 10.1126/science.1070291; Vansteensel MJ, 2016, NEW ENGL J MED, V375, P2060, DOI 10.1056/NEJMoa1608085; Wang W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055344; Wodlinger B, 2015, J NEURAL ENG, V12, DOI 10.1088/1741-2560/12/1/016011; Yousry TA, 1997, BRAIN, V120, P141, DOI 10.1093/brain/120.1.141	31	79	82	17	55	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2019	18	12					1112	1122		10.1016/S1474-4422(19)30321-7			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	JM0CO	WOS:000495892200017	31587955				2022-02-06	
J	Tanaka, Y; Suzuki, G; Matsuwaki, T; Hosokawa, M; Serrano, G; Beach, TG; Yamanouchi, K; Hasegawa, M; Nishihara, M				Tanaka, Yoshinori; Suzuki, Genjiro; Matsuwaki, Takashi; Hosokawa, Masato; Serrano, Geidy; Beach, Thomas G.; Yamanouchi, Keitaro; Hasegawa, Masato; Nishihara, Masugi			Progranulin regulates lysosomal function and biogenesis through acidification of lysosomes	HUMAN MOLECULAR GENETICS			English	Article							FRONTOTEMPORAL LOBAR DEGENERATION; AMYOTROPHIC-LATERAL-SCLEROSIS; TRAUMATIC BRAIN-INJURY; ACTIVATED MICROGLIA; DEFICIENT MICE; KNOCKOUT MICE; CATHEPSIN-D; TDP-43; GENE; MUTATIONS	Progranulin (PGRN) haploinsufficiency resulting from loss-of-function mutations in the PGRN gene causes frontotemporal lobar degeneration accompanied by TDP-43 accumulation, and patients with homozygous mutations in the PGRN gene present with neuronal ceroid lipofuscinosis. Although it remains unknown why PGRN deficiency causes neurodegenerative diseases, there is increasing evidence that PGRN is implicated in lysosomal functions. Here, we show PGRN is a secretory lysosomal protein that regulates lysosomal function and biogenesis by controlling the acidification of lysosomes. PGRN gene expression and protein levels increased concomitantly with the increase of lysosomal biogenesis induced by lysosome alkalizers or serum starvation. Down-regulation or insufficiency of PGRN led to the increased lysosomal gene expression and protein levels, while PGRN overexpression led to the decreased lysosomal gene expression and protein levels. In particular, the level of mature cathepsin D (CTSDmat) dramatically changed depending upon PGRN levels. The acidification of lysosomes was facilitated in cells transfected with PGRN. Then, this caused degradation of CTSDmat by cathepsin B. Secreted PGRN is incorporated into cells via sortilin or cation-independent mannose 6-phosphate receptor, and facilitated the acidification of lysosomes and degradation of CTSDmat. Moreover, the change of PGRN levels led to a cell-type-specific increase of insoluble TDP-43. In the brain tissue of FTLD-TDP patients with PGRN deficiency, CTSD and phosphorylated TDP-43 accumulated in neurons. Our study provides new insights into the physiological function of PGRN and the role of PGRN insufficiency in the pathogenesis of neurodegenerative diseases.	[Tanaka, Yoshinori; Suzuki, Genjiro; Hosokawa, Masato; Hasegawa, Masato] Tokyo Metropolitan Inst Med Sci, Dept Dementia & Higher Brain Funct, Dementia Res Project, Setagaya Ku, 2-1-6 Kamikitazawa, Tokyo 1568506, Japan; [Tanaka, Yoshinori; Matsuwaki, Takashi; Yamanouchi, Keitaro; Nishihara, Masugi] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Physiol, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan; [Serrano, Geidy; Beach, Thomas G.] Banner Sun Hlth Res Inst, Civin Lab Neuropathol, 10515 West Santa Fe Dr, Sun City, AZ 85351 USA		Nishihara, M (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Physiol, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	amnishi@mail.ecc.u-tokyo.ac.jp	Yamanouchi, Keitaro/R-5003-2019	Hosokawa, Masato/0000-0003-2377-9232; Tanaka, Yoshinori/0000-0003-1428-0683	Japan Society for the Promotion of Science KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP15K18370, JP14J03307, JP23228004, JP15H02356]; Ministry of Education, Culture, Sports, Science and Technology KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP26117005, JP23240050]; Ministry of Health, Labour and WelfareMinistry of Health, Labour and Welfare, Japan [12946221]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [14J03307, 16K21650] Funding Source: KAKEN	This work was supported by Japan Society for the Promotion of Science KAKENHI [Grant Numbers JP15K18370, JP14J03307 to Y.T., JP23228004 to M.N., JP15H02356 to M.H.]; Ministry of Education, Culture, Sports, Science and Technology KAKENHI [Grant Numbers JP26117005, JP23240050 to M.H.]; and Ministry of Health, Labour and Welfare [Grant ID Number 12946221 to M.H.].	Ahmed Z, 2010, AM J PATHOL, V177, P311, DOI 10.2353/ajpath.2010.090915; Arai T, 2006, BIOCHEM BIOPH RES CO, V351, P602, DOI 10.1016/j.bbrc.2006.10.093; Baker M, 2006, NATURE, V442, P916, DOI 10.1038/nature05016; Beach TG, 2015, NEUROPATHOLOGY, V35, P354, DOI 10.1111/neup.12189; Benussi L, 2016, NEUROBIOL AGING, V40, P41, DOI 10.1016/j.neurobiolaging.2016.01.001; Birdsill AC, 2011, CELL TISSUE BANK, V12, P311, DOI 10.1007/s10561-010-9210-8; Breton S, 2013, PHYSIOLOGY, V28, P318, DOI 10.1152/physiol.00007.2013; CONNER GE, 1989, BIOCHEM J, V263, P601, DOI 10.1042/bj2630601; Cruts M, 2006, NATURE, V442, P920, DOI 10.1038/nature05017; Farmery MR, 2003, J BIOL CHEM, V278, P24277, DOI 10.1074/jbc.M211992200; GIESELMANN V, 1985, J BIOL CHEM, V260, P3215; Gotzl JK, 2014, ACTA NEUROPATHOL, V127, P845, DOI 10.1007/s00401-014-1262-6; Gowrishankar S, 2015, P NATL ACAD SCI USA, V112, pE3699, DOI 10.1073/pnas.1510329112; Han JY, 2010, CHEM REV, V110, P2709, DOI 10.1021/cr900249z; Hasegawa M, 2008, ANN NEUROL, V64, P60, DOI 10.1002/ana.21425; He ZH, 2002, CANCER RES, V62, P5590; Hu FH, 2010, NEURON, V68, P654, DOI 10.1016/j.neuron.2010.09.034; Inukai Y, 2008, FEBS LETT, V582, P2899, DOI 10.1016/j.febslet.2008.07.027; Kayasuga Y, 2007, BEHAV BRAIN RES, V185, P110, DOI 10.1016/j.bbr.2007.07.020; Kessenbrock K, 2008, J CLIN INVEST, V118, P2438, DOI 10.1172/JCI34694; KHOURI HE, 1991, BIOCHEM J, V275, P751, DOI 10.1042/bj2750751; Lee AY, 1998, NAT STRUCT BIOL, V5, P866, DOI 10.1038/2306; Lu YY, 2013, J BIOL CHEM, V288, P24247, DOI 10.1074/jbc.M113.484253; Luciani F, 2004, JNCI-J NATL CANCER I, V96, P1702, DOI 10.1093/jnci/djh305; Lui HS, 2016, CELL, V165, P921, DOI 10.1016/j.cell.2016.04.001; Mackenzie IRA, 2006, BRAIN, V129, P3081, DOI 10.1093/brain/awl271; Mindell JA, 2012, ANNU REV PHYSIOL, V74, P69, DOI 10.1146/annurev-physiol-012110-142317; Nakamichi K, 2006, NEUROSCI LETT, V407, P205, DOI 10.1016/j.neulet.2006.08.044; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Palmieri M, 2011, HUM MOL GENET, V20, P3852, DOI 10.1093/hmg/ddr306; Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447; Sargeant TJ, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00011; Saura J, 2003, GLIA, V44, P183, DOI 10.1002/glia.10274; Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32; Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592; Smith KR, 2012, AM J HUM GENET, V90, P1102, DOI 10.1016/j.ajhg.2012.04.021; Suzuki M, 1998, NEUROSCI LETT, V242, P127, DOI 10.1016/S0304-3940(98)00008-1; Takenouchi T, 2005, BBA-GEN SUBJECTS, V1726, P177, DOI 10.1016/j.bbagen.2005.08.001; Tanaka Y, 2013, NEUROSCIENCE, V250, P8, DOI 10.1016/j.neuroscience.2013.06.049; Tanaka Y, 2013, NEUROSCIENCE, V231, P49, DOI 10.1016/j.neuroscience.2012.11.032; Tanaka Y, 2016, PRION, V10, P283, DOI 10.1080/19336896.2016.1207033; Tanaka Y, 2016, HUM MOL GENET, V25, P1420, DOI 10.1093/hmg/ddw024; Tanaka Y, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0078-x; Wang K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131789; Wils H, 2012, J PATHOL, V228, P67, DOI 10.1002/path.4043; Zhou XL, 2015, J CELL BIOL, V210, P991, DOI 10.1083/jcb.201502029	46	79	79	0	10	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0964-6906	1460-2083		HUM MOL GENET	Hum. Mol. Genet.	MAR 1	2017	26	5					969	988		10.1093/hmg/ddx011			20	Biochemistry & Molecular Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Genetics & Heredity	EQ3UZ	WOS:000398000100011	28073925	Bronze			2022-02-06	
J	Wan, S; Cheng, YY; Jin, H; Guo, DW; Hua, Y; Keep, RF; Xi, GH				Wan, Shu; Cheng, Yingying; Jin, Hang; Guo, Dewei; Hua, Ya; Keep, Richard F.; Xi, Guohua			Microglia Activation and Polarization After Intracerebral Hemorrhage in Mice: the Role of Protease-Activated Receptor-1	TRANSLATIONAL STROKE RESEARCH			English	Article						Cerebral hemorrhage; Microglia; Mouse; Protease-activated receptor-1	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; MICROGLIA/MACROPHAGE POLARIZATION; ALTERNATIVE ACTIVATION; ADULT MICROGLIA; CELL-DEATH; MACROPHAGES; THROMBIN; INFLAMMATION; MECHANISMS	Polarized microglia play a dual (beneficial/detrimental) role in neurological diseases. However, the status and the factors that modulate microglia polarization in intracerebral hemorrhage (ICH) remain unclear. In the present study, we investigated the role of protease-activated receptor-1 (PAR-1, a thrombin receptor) in ICH-induced microglia polarization in mice. Male wild-type (WT) and PAR-1 knockout (PAR-1 KO) mice received an infusion of 30-mu L autologous blood or saline into the right basal ganglia. Mice were euthanized at different time points and the brains were used for Western blotting and immunohistochemistry. Some mice had magnetic resonance imaging. We found that ICH induced microglia activation and polarization. M1 phenotypic markers were markedly increased and reached a peak as early as 4 h, remained high at 3 days and decreased 7 days after ICH. M2 phenotypic markers were upregulated later than M1 markers reaching a peak at day 1 and declining by day 7 after ICH. PAR-1 was upregulated after ICH and expressed in the neurons and microglia. ICH induced less brain swelling and neuronal death in PAR-1 KO mice, and this was associated with less M1 polarization and reduced proinflammatory cytokine levels in the brain. In conclusion, these results suggest that polarized microglia occur dynamically after ICH and that PAR-1 plays a role in the microglia activation and polarization.	[Wan, Shu; Cheng, Yingying; Jin, Hang; Guo, Dewei; Hua, Ya; Keep, Richard F.; Xi, Guohua] Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA; [Wan, Shu] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Neurosurg, Hangzhou, Zhejiang, Peoples R China; [Cheng, Yingying; Jin, Hang] Jilin Univ, Sch Med, Affiliated Hosp 1, Dept Neurol, Changchun, Peoples R China; [Xi, Guohua] Univ Michigan, Room5018 BSRB,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA		Xi, GH (corresponding author), Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA.; Xi, GH (corresponding author), Univ Michigan, Room5018 BSRB,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	guohuaxi@umich.edu		Keep, Richard/0000-0001-6441-5334	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-073595, NS-079157, NS-084049, NS-090925, NS-091545, NS-096917]; 973 ProgramNational Basic Research Program of China [2014CB541600]; National Natural Science Foundation of China (NSFC)National Natural Science Foundation of China (NSFC) [81371336, 81400942, 81400945]; Natural Science Foundation of Zhejiang Province (ZJNSF)Natural Science Foundation of Zhejiang Province [LY13H090005]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS091545, R21NS084049, R01NS073595, R01NS090925, R01NS096917, R01NS079157] Funding Source: NIH RePORTER	This study was supported by grants NS-073595, NS-079157, NS-084049, NS-090925, NS-091545 and NS-096917 from the National Institutes of Health (NIH), 973 Program-2014CB541600, and by grants 81371336, 81400942, 81400945 from National Natural Science Foundation of China (NSFC) and grants LY13H090005 from Natural Science Foundation of Zhejiang Province (ZJNSF). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, NSFC, and ZJNSF.	Adams MN, 2011, PHARMACOL THERAPEUT, V130, P248, DOI 10.1016/j.pharmthera.2011.01.003; Cheng YY, 2014, TRANSL STROKE RES, V5, P472, DOI 10.1007/s12975-013-0288-8; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Cunningham LA, 2005, GLIA, V50, P329, DOI 10.1002/glia.20169; Durafourt BA, 2012, GLIA, V60, P717, DOI 10.1002/glia.22298; Eyo UB, 2013, NEURAL PLAST, V2013, DOI 10.1155/2013/456857; Gieseler F, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-86; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Goerdt S, 1999, PATHOBIOLOGY, V67, P222, DOI 10.1159/000028096; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Junge CE, 2003, P NATL ACAD SCI USA, V100, P13019, DOI 10.1073/pnas.2235594100; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Keep RF, 2012, LANCET NEUROL, V11, P720, DOI 10.1016/S1474-4422(12)70104-7; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Lawrence T, 2011, NAT REV IMMUNOL, V11, P750, DOI 10.1038/nri3088; Luo W, 2007, BRAIN RES REV, V56, P331, DOI 10.1016/j.brainresrev.2007.08.002; Mantovani A, 2013, J PATHOL, V229, P176, DOI 10.1002/path.4133; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; McLaughlin JN, 2007, P NATL ACAD SCI USA, V104, P5662, DOI 10.1073/pnas.0700763104; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Nakamura T, 2004, J NEUROSURG, V100, P672, DOI 10.3171/jns.2004.100.4.0672; Ni W, 2016, STROKE, V47, P505, DOI 10.1161/STROKEAHA.115.010920; Okauchi M, 2009, BRAIN RES, V1249, P229, DOI 10.1016/j.brainres.2008.10.035; Perego C, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-174; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Storer PD, 2005, J NEUROIMMUNOL, V161, P113, DOI 10.1016/j.jneuroim.2004.12.015; Taylor RA, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/746068; van Rossum D, 2004, METAB BRAIN DIS, V19, P393, DOI 10.1023/B:MEBR.0000043984.73063.d8; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang JA, 2010, PROG NEUROBIOL, V92, P463, DOI 10.1016/j.pneurobio.2010.08.001; Wasserman JK, 2007, BRAIN RES, V1180, P140, DOI 10.1016/j.brainres.2007.08.058; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Xi GH, 1999, STROKE, V30, P1247, DOI 10.1161/01.STR.30.6.1247; Xi GH, 2003, J NEUROCHEM, V84, P3, DOI 10.1046/j.1471-4159.2003.01268.x; Xi GH, 2014, PROG NEUROBIOL, V115, P45, DOI 10.1016/j.pneurobio.2013.09.007; Xue MZ, 2009, STROKE, V40, P2199, DOI 10.1161/STROKEAHA.108.540393; Xue MZ, 2000, NEUROSCI LETT, V283, P230, DOI 10.1016/S0304-3940(00)00971-X; Yabluchanskiy A, 2010, INT J NEUROSCI, V120, P765, DOI 10.3109/00207454.2010.523129; Zhao H, 2015, TRANSL STROKE RES, V6, P407, DOI 10.1007/s12975-015-0428-4; Zheng MZ, 2015, TRANSL STROKE RES, V6, P215, DOI 10.1007/s12975-015-0388-8; Zhou Y, 2014, PROG NEUROBIOL, V115, P25, DOI 10.1016/j.pneurobio.2013.11.003	46	79	80	3	35	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1868-4483	1868-601X		TRANSL STROKE RES	Transl. Stroke Res.	DEC	2016	7	6					478	487		10.1007/s12975-016-0472-8			10	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EA1VJ	WOS:000386379800004	27206851	Green Accepted			2022-02-06	
J	Harrison, EB; Hochfelder, CG; Lamberty, BG; Meays, BM; Morsey, BM; Kelso, ML; Fox, HS; Yelamanchili, SV				Harrison, Emily B.; Hochfelder, Colleen G.; Lamberty, Benjamin G.; Meays, Brittney M.; Morsey, Brenda M.; Kelso, Matthew L.; Fox, Howard S.; Yelamanchili, Sowmya V.			Traumatic brain injury increases levels of miR-21 in extracellular vesicles: implications for neuroinflammation	FEBS OPEN BIO			English	Article						controlled cortical impact; exosomes; microglia; microRNA; neuroinflammation; secondary injury	SPINAL-CORD-INJURY; MICRORNA EXPRESSION; IMMUNE-RESPONSES; INFLAMMATORY RESPONSE; MESSENGER-RNAS; UP-REGULATION; CELL-DEATH; RECEPTOR 7; RATS; NEURONS	Traumatic brain injury (TBI) is an important health concern and effective treatment strategies remain elusive. Understanding the complex multicellular response to TBI may provide new avenues for intervention. In the context of TBI, cell-cell communication is critical. One relatively unexplored form of cell-cell communication in TBI is extracellular vesicles (EVs). These membrane-bound vesicles can carry many different types of cargo between cells. Recently, miRNA in EVs have been shown to mediate neuroinflammation and neuronal injury. To explore the role of EV-associated miRNA in TBI, we isolated EVs from the brain of injured mice and controls, purified RNA from brain EVs, and performed miRNA sequencing. We found that the expression of miR-212 decreased, while miR-21, miR-146, miR-7a, and miR-7b were significantly increased with injury, with miR-21 showing the largest change between conditions. The expression of miR-21 in the brain was primarily localized to neurons near the lesion site. Interestingly, adjacent to these miR-21-expressing neurons were activated microglia. The concurrent increase in miR-21 in EVs with the elevation of miR-21 in neurons, suggests that miR-21 is secreted from neurons as potential EV cargo. Thus, this study reveals a new potential mechanism of cell-cell communication not previously described in TBI.	[Harrison, Emily B.; Hochfelder, Colleen G.; Lamberty, Benjamin G.; Meays, Brittney M.; Morsey, Brenda M.; Fox, Howard S.; Yelamanchili, Sowmya V.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, 985800 Nebraska Med Ctr, Omaha, NE 68198 USA; [Kelso, Matthew L.] Univ Nebraska Med Ctr, Dept Cellular & Integrat Physiol, Omaha, NE USA; [Hochfelder, Colleen G.] Albert Einstein Coll Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA; [Kelso, Matthew L.] Medpace Reference Labs, 5365 Medpace Way, Cincinnati, OH USA		Yelamanchili, SV (corresponding author), Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, 985800 Nebraska Med Ctr, Omaha, NE 68198 USA.	syelamanchili@unmc.edu	Harrison, Emily B./AAW-1826-2021	Harrison, Emily B./0000-0002-6934-3875	Nebraska Research Initiative Grant; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P30GM106397] Funding Source: NIH RePORTER	This work was supported by a Nebraska Research Initiative Grant.	Alexander M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8321; Bellingham SA, 2012, NUCLEIC ACIDS RES, V40, P10937, DOI 10.1093/nar/gks832; Bergman P, 2013, J IMMUNOL, V190, P4066, DOI 10.4049/jimmunol.1200728; Bhalala OG, 2013, NAT REV NEUROL, V9, P328, DOI 10.1038/nrneurol.2013.67; Bhalala OG, 2012, J NEUROSCI, V32, P17935, DOI 10.1523/JNEUROSCI.3860-12.2012; Boldin MP, 2011, J EXP MED, V208, P1189, DOI 10.1084/jem.20101823; Buller B, 2010, FEBS J, V277, P4299, DOI 10.1111/j.1742-4658.2010.07818.x; Chaudhuri AD, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00160; Choi DC, 2014, J NEUROSCI, V34, P12725, DOI 10.1523/JNEUROSCI.0985-14.2014; Choudhury NR, 2013, GENE DEV, V27, P24, DOI 10.1101/gad.199190.112; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Crozat K, 2004, P NATL ACAD SCI USA, V101, P6835, DOI 10.1073/pnas.0401347101; Fabbri M, 2012, P NATL ACAD SCI USA, V109, pE2110, DOI 10.1073/pnas.1209414109; Faden AI, 2016, BRIT J PHARMACOL, V173, P681, DOI 10.1111/bph.13179; Finnie JW, 2013, INFLAMMOPHARMACOLOGY, V21, P309, DOI 10.1007/s10787-012-0164-2; Forsbach A, 2008, J IMMUNOL, V180, P3729, DOI 10.4049/jimmunol.180.6.3729; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; Hu G, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.114; Hu ZH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039357; Kim AH, 2010, SCHIZOPHR RES, V124, P183, DOI 10.1016/j.schres.2010.07.002; Kraft-Terry SD, 2009, NEURON, V64, P133, DOI 10.1016/j.neuron.2009.09.042; Kuo CY, 2015, INT J ENV RES PUB HE, V12, P4116, DOI 10.3390/ijerph120404116; Lagraoui Mouna, 2012, Front Neurol, V3, P155, DOI 10.3389/fneur.2012.00155; Lehmann SM, 2012, NAT NEUROSCI, V15, P827, DOI 10.1038/nn.3113; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Lescher J, 2012, J NEUROIMMUNOL, V246, P27, DOI 10.1016/j.jneuroim.2012.02.012; Liu HY, 2015, EXP NEUROL, V269, P202, DOI 10.1016/j.expneurol.2015.04.011; Liu L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103948; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; Meissner L, 2016, J NEUROTRAUM, V33, P713, DOI 10.1089/neu.2015.4077; Mittelbrunn M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1285; Montalban E, 2014, NEUROMOL MED, V16, P415, DOI 10.1007/s12017-014-8292-z; Montecalvo A, 2012, BLOOD, V119, P756, DOI 10.1182/blood-2011-02-338004; O'Connor C, 2003, J NEUROTRAUM, V20, P985, DOI 10.1089/089771503770195830; Patz S, 2013, J NEUROTRAUM, V30, P1232, DOI 10.1089/neu.2012.2596; Perez-Gonzalez R, 2012, J BIOL CHEM, V287, P43108, DOI 10.1074/jbc.M112.404467; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Sakai A, 2013, BIOCHEM BIOPH RES CO, V435, P176, DOI 10.1016/j.bbrc.2013.04.089; Sandhir R, 2014, NEUROCHEM INT, V78, P117, DOI 10.1016/j.neuint.2014.09.009; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Strickland IT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023423; Sun TY, 2014, J HUAZHONG U SCI-MED, V34, P548, DOI 10.1007/s11596-014-1313-1; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Tang Y, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-92; Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Wanet A, 2012, NUCLEIC ACIDS RES, V40, P4742, DOI 10.1093/nar/gks151; Wang WX, 2011, ACTA NEUROPATHOL, V121, P193, DOI 10.1007/s00401-010-0756-0; WHITTEMORE ER, 1993, BRAIN RES, V621, P59, DOI 10.1016/0006-8993(93)90297-Z; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wright DW, 2013, MMWR-MORBID MORTAL W, V62, P549; Yelamanchili SV, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.56; Yelamanchili SV, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005032; Yelamanchili SV, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-52; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhang L, 2012, GLIA, V60, P1888, DOI 10.1002/glia.22404; Zhang ZP, 2010, INT J BIOCHEM CELL B, V42, P367, DOI 10.1016/j.biocel.2009.11.023	60	79	82	1	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2211-5463			FEBS OPEN BIO	FEBS Open Bio	AUG	2016	6	8					835	846		10.1002/2211-5463.12092			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	DS8RC	WOS:000381049500005	27516962	gold, Green Published, Green Submitted			2022-02-06	
J	Puvenna, V; Engeler, M; Banjara, M; Brennan, C; Schreiber, P; Dadas, A; Bahrami, A; Solanki, J; Bandyopadhyay, A; Morris, JK; Bernick, C; Ghosh, C; Rapp, E; Bazarian, JJ; Janigro, D				Puvenna, Vikram; Engeler, Madeline; Banjara, Manoj; Brennan, Chanda; Schreiber, Peter; Dadas, Aaron; Bahrami, Ashkon; Solanki, Jesal; Bandyopadhyay, Anasua; Morris, Jacqueline K.; Bernick, Charles; Ghosh, Chaitali; Rapp, Edward; Bazarian, Jeffrey J.; Janigro, Damir			Is phosphorylated tau unique to chronic traumatic encephalopathy? Phosphorylated tau in epileptic brain and chronic traumatic encephalopathy	BRAIN RESEARCH			English	Article						American football; Cognitive decline; Traumatic brain injury; Blood-brain barrier; Serum markers	INJURY	Repetitive traumatic brain injury (rTBI) is one of the major risk factors for the abnormal deposition of phosphorylated tau (PT) in the brain and chronic traumatic encephalopathy (CTE). CTE and temporal lobe epilepsy (TLE) affect the limbic system, but no comparative studies on PT distribution in TLE and CTE are available. It is also unclear whether PT pathology results from repeated head hits (rTBI). These gaps prevent a thorough understanding of the pathogenesis and clinical significance of PT, limiting our ability to develop preventative and therapeutic interventions. We quantified PT in TLE and CTE to unveil whether a history of rTBI is a prerequisite for PT accumulation in the brain. Six postmortem CTE (mean 73.3 years) and age matched control samples were compared to 19 surgically resected TLE brain specimens (4 months-58 years; mean 27.6 years). No history of TBI was present in TLE or control; all CTE patients had a history of rTBI. TLE and GTE brain displayed increased levels of PT as revealed by immunohistochemistry. No age-dependent changes were noted, as PT was present as early as 4 months after birth. In TLE and GTE, cortical neurons, perivascular regions around penetrating pial vessels and meninges were immunopositive for PT; white matter tracts also displayed robust expression of extracellular PT organized in bundles parallel to venules. Microscopically, there were extensive tau-immunoreactive neuronal, astrocytic and degenerating neurites throughout the brain. In GTE perivascular tangles were most prominent. Overall, significant differences in staining intensities were found between GTE and control (P<0.01) but not between GTE and TLE (P=0.08). pS199 tau analysis showed that GTE had the most high molecular weight tangle-associated tau, whereas epileptic brain contained low molecular weight tau. Tau deposition may not be specific to rTBI since TLE recapitulated most of the pathological features of GTE. (C) 2015 Elsevier B.V. All rights reserved.	[Rapp, Edward; Janigro, Damir] Flocel Inc, Cleveland, OH 44103 USA; [Puvenna, Vikram; Engeler, Madeline; Banjara, Manoj; Brennan, Chanda; Schreiber, Peter; Dadas, Aaron; Bahrami, Ashkon; Solanki, Jesal; Bandyopadhyay, Anasua; Ghosh, Chaitali; Janigro, Damir] Cerebrovasc Res, Cleveland, OH USA; [Puvenna, Vikram; Banjara, Manoj; Brennan, Chanda; Ghosh, Chaitali] Cleveland Clin, Lerner Coll Med, Dept Biomed Engn & Mol Med, Cleveland, OH 44106 USA; [Schreiber, Peter] Univ Pittsburgh, Pittsburgh, PA USA; [Dadas, Aaron; Solanki, Jesal] Ohio State Univ, Columbus, OH 43210 USA; [Engeler, Madeline] Brandeis Univ, Waltham, MA USA; [Bandyopadhyay, Anasua] Emory Univ, Atlanta, GA 30322 USA; [Bazarian, Jeffrey J.] Univ Rochester, Med Ctr, Rochester, NY 14627 USA; [Bahrami, Ashkon] Baldwin Wallace Univ, Dept Biol, Berea, OH USA; [Bernick, Charles] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Las Vegas, NV USA		Janigro, D (corresponding author), Flocel Inc, Cleveland, OH 44103 USA.	djanigro@flocel.com		Ghosh, Chaitali/0000-0003-4078-0278; Morris, Jacqueline/0000-0002-3515-0821	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS078307, R01NS43284, R41MH093302, R21NS077236, R42MH093302, UH3TR000491, R21HD057256]; American Heart AssociationAmerican Heart Association [13SDG13950015]; Brain Behavior Research FoundationNARSAD; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD057256] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UH2TR000491, UH3TR000491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R42MH093302, R41MH093302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS043284, R01NS078307, R21NS077236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health [R01NS078307, R01NS43284, R41MH093302, R21NS077236, R42MH093302, UH3TR000491 and R21HD057256] to DJ and a Scientist Development Grant from the American Heart Association [13SDG13950015] and a Brain Behavior Research Foundation Grant to CG.	Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Devos SL, 2013, J NEUROSCI, V33, P12887, DOI 10.1523/JNEUROSCI.2107-13.2013; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hazrati LN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00222; Iliff JJ, 2013, J NEUROSCI, V33, P18190, DOI 10.1523/JNEUROSCI.1592-13.2013; Iliff JJ, 2013, J CLIN INVEST, V123, P1299, DOI 10.1172/JCI67677; Janigro D, 2012, EPILEPSIA, V53, P26, DOI 10.1111/j.1528-1167.2012.03472.x; Mandelkow E.-M., 2012, COLD SPRING HARB PER, V2; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mez J, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0407-7; Morris M, 2011, NEURON, V70, P410, DOI 10.1016/j.neuron.2011.04.009; Peskind ER, 2013, J CLIN PSYCHIAT, V74, P180, DOI 10.4088/JCP.12011co1c; Porzig R, 2007, BIOCHEM BIOPH RES CO, V358, P644, DOI 10.1016/j.bbrc.2007.04.187; Sahara N, 2014, J ALZHEIMERS DIS, V40, pS91, DOI 10.3233/JAD-132429; Schubert M, 2004, P NATL ACAD SCI USA, V101, P3100, DOI 10.1073/pnas.0308724101; Sen A, 2007, EPILEPSIA, V48, P1447, DOI 10.1111/j.1528-1167.2007.01107.x; Sengupta A, 1998, ARCH BIOCHEM BIOPHYS, V357, P299, DOI 10.1006/abbi.1998.0813; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Thom M, 2011, BRAIN, V134, P2969, DOI 10.1093/brain/awr209	21	79	80	0	23	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 1	2016	1630						225	240		10.1016/j.brainres.2015.11.007			16	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CZ4YU	WOS:000367109900021	26556772	Green Accepted			2022-02-06	
J	Kabaria, S; Choi, DC; Chaudhuri, AD; Jain, MR; Li, H; Junn, E				Kabaria, Sayan; Choi, Doo Chul; Chaudhuri, Amrita Datta; Jain, Mohit Raja; Li, Hong; Junn, Eunsung			MicroRNA-7 activates Nrf2 pathway by targeting Keap1 expression	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						MicroRNA-7; Keap1; Nrf2; MPP; Oxidative stress; Parkinson's disease	1-METHYL-4-PHENYLPYRIDINIUM-INDUCED CELL-DEATH; TRAUMATIC BRAIN-INJURY; HEME OXYGENASE-1 HO-1; OXIDATIVE STRESS; NEURODEGENERATIVE DISEASES; PARKINSONS-DISEASE; NEURONAL SURVIVAL; PROTECTS; GENE; INDUCTION	Nuclear factor E2-related factor 2 (Nrf2) is a key transcription factor that regulates the expression of a number of antioxidant and detoxifying genes that provide cellular protection against various stressors including reactive oxygen species (ROS). Nrf2 activity is tightly regulated by a cytoplasmic inhibitory protein called Kelch-like ECH-associated protein 1 (Keap1). The mechanism that controls Keap1 expression, however, remains poorly understood. In the present study, we demonstrate that microRNA-7 (miR-7), which is highly expressed in the brain, represses Keap1 expression by targeting the 3'-untranslated region (UTR) of its mRNA in human neuroblastoma cells, SH-SY5Y. Subsequently, this event results in an increased Nrf2 activity, as evidenced by an increase in the expression of its transcriptional targets, heme oxygenase 1 (HO-1) and glutamate-cysteine ligase modifier subunit (GCLM), and an enhanced nuclear localization of Nrf2. In addition, miR-7 decreases the intracellular hydroperoxides level and increases the level of reduced form of glutathione, indicative of oxidative stress relief. We also demonstrate that targeted repression of Keap1 and activation of Nrf2 pathway, in part, underlies the protective effects of miR-7 against 1-methyl-4-phenylpyridinium (MPP+)-induced toxicity in SH-SY5Y and differentiated human neural progenitor cells, ReNcell VM. These findings point to a new mechanism by which miR-7 exerts cytoprotective effects by regulating the Nrf2 pathway. (C) 2015 Elsevier Inc. All rights reserved.	[Kabaria, Sayan; Choi, Doo Chul; Chaudhuri, Amrita Datta; Junn, Eunsung] Rutgers Robert Wood Johnson Med Sch, Dept Neurol, Ctr Neurodegenerat & Neuroimmunol Dis, Piscataway, NJ 08854 USA; [Jain, Mohit Raja; Li, Hong] Rutgers New Jersey Med Sch, Ctr Adv Prote Res, Newark, NJ 07103 USA		Junn, E (corresponding author), Rutgers Robert Wood Johnson Med Sch, Dept Neurol, 683 Hoes Lane West,Room 185, Piscataway, NJ 08854 USA.	junneu@rwjms.rutgers.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS070898, P30NS046593]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS046593, R01NS070898] Funding Source: NIH RePORTER	This work was supported by NIH grant NS070898 (E.J), and in part by NIH grant P30NS046593 (H.L).	Ahmad AS, 2006, NEUROSCIENCE, V141, P1703, DOI 10.1016/j.neuroscience.2006.05.035; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P377, DOI 10.1007/s004010000202; Bilen J, 2006, MOL CELL, V24, P157, DOI 10.1016/j.molcel.2006.07.030; Bogdanov M, 2008, BRAIN, V131, P389, DOI 10.1093/brain/awm304; Boudreau RL, 2014, NEURON, V81, P294, DOI 10.1016/j.neuron.2013.10.062; Cao TT, 2005, J NEUROCHEM, V95, P406, DOI 10.1111/j.1471-4159.2005.03377.x; Chaudhuri AD, 2015, J BIOL CHEM, V290, P12425, DOI 10.1074/jbc.M114.625962; Chen HL, 2010, BIOCHEM BIOPH RES CO, V394, P921, DOI 10.1016/j.bbrc.2010.03.076; Chen PC, 2009, P NATL ACAD SCI USA, V106, P2933, DOI 10.1073/pnas.0813361106; Choi DC, 2014, J NEUROSCI, V34, P12725, DOI 10.1523/JNEUROSCI.0985-14.2014; Donato R, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-36; Eacker SM, 2009, NAT REV NEUROSCI, V10, P837, DOI 10.1038/nrn2726; Eades G, 2011, J BIOL CHEM, V286, P40725, DOI 10.1074/jbc.M111.275495; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; Gorrini C, 2013, J EXP MED, V210, P1529, DOI 10.1084/jem.20121337; Hara H, 2006, J NEUROSCI RES, V84, P860, DOI 10.1002/jnr.20974; He CH, 2001, J BIOL CHEM, V276, P20858, DOI 10.1074/jbc.M101198200; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Huang E, 2005, J NEUROSCI RES, V80, P268, DOI 10.1002/jnr.20444; Hwang YP, 2008, FEBS LETT, V582, P2655, DOI 10.1016/j.febslet.2008.06.045; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074; Jakel RJ, 2007, BRAIN RES, V1144, P192, DOI 10.1016/j.brainres.2007.01.131; Jeyapaul J, 2000, BIOCHEM PHARMACOL, V59, P1433, DOI 10.1016/S0006-2952(00)00256-2; Junn E, 2012, PHARMACOL THERAPEUT, V133, P142, DOI 10.1016/j.pharmthera.2011.10.002; Junn E, 2009, P NATL ACAD SCI USA, V106, P13052, DOI 10.1073/pnas.0906277106; Kalyanaraman B, 2012, FREE RADICAL BIO MED, V52, P1, DOI 10.1016/j.freeradbiomed.2011.09.030; Kim J, 2007, SCIENCE, V317, P1220, DOI 10.1126/science.1140481; Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lee JM, 2003, J BIOL CHEM, V278, P37948, DOI 10.1074/jbc.M305204200; Lin Y, 2007, J CEREBR BLOOD F MET, V27, P1010, DOI 10.1038/sj.jcbfm.9600412; Liu GH, 2008, BBA-MOL CELL RES, V1783, P713, DOI 10.1016/j.bbamcr.2008.01.002; MacKenzie EL, 2008, FREE RADICAL BIO MED, V44, P1762, DOI 10.1016/j.freeradbiomed.2008.01.031; Maines MD, 1998, J NEUROCHEM, V70, P2057; Meijering E, 2004, CYTOM PART A, V58A, P167, DOI 10.1002/cyto.a.20022; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Motohashi H, 2004, P NATL ACAD SCI USA, V101, P6379, DOI 10.1073/pnas.0305902101; Narasimhan M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051111; Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200; Ramsey CP, 2007, J NEUROPATH EXP NEUR, V66, P75, DOI 10.1097/nen.0b013e31802d6da9; Rehmsmeier M, 2004, RNA, V10, P1507, DOI 10.1261/rna.5248604; Satoh T, 2009, BIOCHEM BIOPH RES CO, V380, P298, DOI 10.1016/j.bbrc.2009.01.063; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Stokes AH, 1999, J NEUROSCI RES, V55, P659, DOI 10.1002/(SICI)1097-4547(19990315)55:6<659::AID-JNR1>3.0.CO;2-C; Uttara B, 2009, CURR NEUROPHARMACOL, V7, P65, DOI 10.2174/157015909787602823; Wruck CJ, 2007, J NEURAL TRANSM-SUPP, P57; Yu MA, 2011, CELL SIGNAL, V23, P883, DOI 10.1016/j.cellsig.2011.01.014; Zhang JY, 2006, MOL CELL BIOL, V26, P7942, DOI 10.1128/MCB.00700-06; Zielonka J, 2012, CHEM RES TOXICOL, V25, P1793, DOI 10.1021/tx300164j	50	79	84	5	24	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	DEC	2015	89						548	556		10.1016/j.freeradbiomed.2015.09.010			9	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism	CY4CI	WOS:000366355800050	26453926	Green Accepted			2022-02-06	
J	McKinlay, A; Corrigan, J; Horwood, LJ; Fergusson, DM				McKinlay, Audrey; Corrigan, J.; Horwood, L. J.; Fergusson, D. M.			Substance Abuse and Criminal Activities Following Traumatic Brain Injury in Childhood, Adolescence, and Early Adulthood	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						adolescence; birth cohort; childhood; criminal activities; longitudinal; substance abuse; traumatic brain injury; young adult	NEUROPSYCHOLOGICAL FUNCTION; PSYCHOSOCIAL OUTCOMES; MENTAL-DISORDERS; HEAD-INJURY; CHILDREN; PREVALENCE; RISK; ASSOCIATION; SYMPTOMS	Objective: Use a longitudinal birth cohort to evaluate the association of traumatic brain injury at ages 0 to 5, 6 to 15, and 16 to 21 years with drug and alcohol abuse and engagement in criminal activities. Main Measures: Follow-up over 21 to 25 years using self-report of drug and alcohol use, arrests, and violent and property offenses. Outcomes were assessed for 2 levels of severity (inpatient, hospitalized; outpatient, seen by general practitioner or at emergency department). Participants: Members of the Christchurch Health and Development Study, a longitudinal birth cohort. Setting: Christchurch, New Zealand. Results: Adjusted for child and family factors, compared with noninjured individuals, inpatients injured at 0 to 5 years or 16 to 21 years were more likely to have symptoms consistent with drug dependence. All inpatient groups had increased risk of arrest, with the age groups of 0 to 5 and 6 to 15 years more likely to be involved in violent offenses and the age group of 0 to 5 years more likely to engage in property offenses. Outpatient group had an increased risk of violent offenses for first injury 0 to 5 years, arrests and property offenses for injury 6 to 15 years, and increased risk of arrests and violent offenses for injury 16 to 21 years of age. However, when alcohol dependence and drug dependence were added as an additional covariate, traumatic brain injury was no longer associated with criminal behavior for the age group of 0 to 5 years. Conclusions: Traumatic brain injury is associated with increased criminal behavior and may represent a risk factor for offending. However, early substance use is a mediating factor for those injured early in life.	[McKinlay, Audrey] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [McKinlay, Audrey] Univ Canterbury, Dept Psychol, Christchurch 1, New Zealand; [Corrigan, J.] Ohio State Univ, Med Ctr, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Horwood, L. J.; Fergusson, D. M.] Univ Otago, Christchurch Hlth & Dev Study, Christchurch, New Zealand		McKinlay, A (corresponding author), Univ Melbourne, Melbourne Sch Psychol Sci, Melbourne, Vic 3010, Australia.	audrey.mckinlay@unimelb.edu.au		McKinlay, Audrey/0000-0001-9846-8514; Horwood, L./0000-0003-4881-1956	Health Research Council/Accident Compensation Corporation of New Zealand	Dr McKinlay was supported by a postdoctoral fellowship from the Health Research Council/Accident Compensation Corporation of New Zealand.	Davies RC, 2012, J HEAD TRAUMA REHAB, V27, pE21, DOI 10.1097/HTR.0b013e31825360da; ELLEY WB, 1976, NEW ZEAL J EDUC STUD, V11, P25; ELLIOTT DS, 1989, NATO ADV SCI I D-BEH, V50, P155; Ferguson PL, 2012, J HEAD TRAUMA REHAB, V27, pE11, DOI 10.1097/HTR.0b013e31824e5f47; Fergusson DM, 1998, J EMOT BEHAV DISORD, V6, P2, DOI 10.1177/106342669800600101; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Gerring JP, 2012, J NEUROTRAUM, V29, P621, DOI 10.1089/neu.2011.2234; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hessen E, 2006, SCAND J PSYCHOL, V47, P245, DOI 10.1111/j.1467-9450.2006.00514.x; Mena JH, 2011, J TRAUMA, V71, P1185, DOI 10.1097/TA.0b013e31823321f8; Luukkainen S, 2012, PSYCHIAT RES, V200, P767, DOI 10.1016/j.psychres.2012.04.018; Maruschak, 2009, PARENTS PRISON THEIR; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Max JE, 1997, J AM ACAD CHILD PSY, V36, P404, DOI 10.1097/00004583-199703000-00020; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; McKinlay A, 2010, INJURY PREV, V16, P31, DOI 10.1136/ip.2009.022483; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P22, DOI 10.1111/j.1365-2214.2009.00947.x; McKinlay A, 2003, BRAIN INJ S1, V17, P39; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; MOFFITT TE, 1988, AUST NZ J CRIMINOL, V21, P227, DOI 10.1177/000486588802100405; Shiroma EJ, 2012, J CORRECT HEALTH CAR, V16, P273, DOI DOI 10.1177/1078345810378253; Shiroma EJ, 2012, J HEAD TRAUMA REHAB, V27, pE1, DOI 10.1097/HTR.0b013e3182571c14; Shiroma Eric J, 2010, J Correct Health Care, V16, P147, DOI 10.1177/1078345809356538; Slade EP, 2008, DRUG ALCOHOL DEPEN, V95, P1, DOI 10.1016/j.drugalcdep.2007.11.019; Tiihonen J, 1997, AM J PSYCHIAT, V154, P840; Timonen M, 2002, PSYCHIAT RES, V113, P217, DOI 10.1016/S0165-1781(02)00269-X; WHITE HR, 1989, J STUD ALCOHOL, V50, P30, DOI 10.15288/jsa.1989.50.30; WHO, 1993, COMP INT DIAGN INT C; Wilde EA, 2012, NEUROREHABILITATION, V31, P245, DOI 10.3233/NRE-2012-0794; Williams H, 2010, TLS-TIMES LIT SUPPL, P20; Williams WH, 2010, BRAIN INJURY, V24, P1184, DOI 10.3109/02699052.2010.495697; Wilson JJ, 2001, CHILD PSYCHIAT HUM D, V31, P297, DOI 10.1023/A:1010234422719; Winqvist S, 2006, J ADOLESCENT HEALTH, V39	36	79	79	0	27	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2014	29	6					498	506		10.1097/HTR.0000000000000001			9	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AT7LI	WOS:000345117800010	24263173				2022-02-06	
J	Bartnik-Olson, BL; Holshouser, B; Wang, H; Grube, M; Tong, K; Wong, V; Ashwal, S				Bartnik-Olson, Brenda L.; Holshouser, Barbara; Wang, Harrison; Grube, Matthew; Tong, Karen; Wong, Valarie; Ashwal, Stephen			Impaired Neurovascular Unit Function Contributes to Persistent Symptoms after Concussion: A Pilot Study	JOURNAL OF NEUROTRAUMA			English	Article						cerebral blood flow; concussion; metabolism; MRI; pediatric; white matter integrity	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; CEREBRAL-BLOOD-FLOW; POSTTRAUMATIC HEADACHE; WHITE-MATTER; POSTCONCUSSION SYNDROME; PATHOPHYSIOLOGY; AUTOREGULATION; PERSPECTIVE; REPAIR	Research shows that approximately 14% of school age children with mild traumatic brain injury (TBI) including sports-related concussions (SRCs) remain symptomatic three months after injury. Advanced imaging studies early after injury have shown evidence of axonal damage, reduced N-acetyl aspartate (NAA) and impaired cerebral blood flow (CBF) in individuals with mild TBI. This study was undertaken to determine whether these techniques can provide valuable information in pediatric SRC patients with persistent post-concussive symptoms. Fifteen pediatric subjects ages 8 to 17 years with persistent post-concussive symptoms were evaluated using perfusion-weighted imaging (PWI), three-dimensional (3D) magnetic resonance spectroscopic imaging, and diffusion tensor imaging (DTI) three to 12 months post-SRC. Data were compared with 15 demographically similar (age, gender, and body mass index) controls. In the bilateral thalami, SRC patients showed reduced CBF (p=0.02 and p=0.02) and relative cerebral blood volume (CBV; p=0.05 and p=0.03), compared with controls. NAA/creatine (Cr) and NAA/choline (Cho) ratios were reduced in the corpus callosum (p=0.003; p=0.05) and parietal white matter (p<0.001; p=0.006) of SRC subjects, compared with controls. Significant differences in DTI metrics differentiated patients with cognitive symptoms, compared with those without cognitive symptoms and controls. Advanced imaging methods detect a spectrum of injury including impaired axonal function, neuronal metabolism and perfusion, suggesting involvement of the neurovascular unit in the presence of persistent symptoms in pediatric SRC patients.	[Bartnik-Olson, Brenda L.; Holshouser, Barbara; Wang, Harrison; Grube, Matthew; Tong, Karen] Loma Linda Univ, Dept Radiol, Sch Med, Loma Linda, CA 92354 USA; [Wong, Valarie; Ashwal, Stephen] Loma Linda Univ, Dept Pediat, Sch Med, Loma Linda, CA 92354 USA		Bartnik-Olson, BL (corresponding author), Loma Linda Univ, Dept Radiol, 11234 Anderson St,Room B623, Loma Linda, CA 92354 USA.	bbartnik@llu.edu	Meijer, Anna/K-5118-2016	Bartnik-Olson, Brenda/0000-0002-1137-9437			Arai K, 2011, J CHILD NEUROL, V26, P1193, DOI 10.1177/0883073811408610; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Becelewski Janusz, 2003, Neurol Neurochir Pol, V37, P339; Blume H, 2012, CURR OPIN PEDIATR, V24, P724, DOI 10.1097/MOP.0b013e328359e4cc; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Choe MC, 2012, CURR OPIN PEDIATR, V24, P689, DOI 10.1097/MOP.0b013e32835a1a44; del Zoppo GJ, 2010, J INTERN MED, V267, P156, DOI 10.1111/j.1365-2796.2009.02199.x; del Zoppo GJ, 2012, ANN NY ACAD SCI, V1268, P127, DOI 10.1111/j.1749-6632.2012.06686.x; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Faul M, 2010, TRAUMATIC BRAIN INJU; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Khurana VG, 2012, J CLIN NEUROSCI, V19, P1, DOI 10.1016/j.jocn.2011.08.002; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kuczynski A, 2013, DEV MED CHILD NEUROL, V55, P636, DOI 10.1111/dmcn.12152; Lecrux C, 2011, ACTA PHYSIOL, V203, P47, DOI 10.1111/j.1748-1716.2011.02256.x; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Maxwell WL, 2012, INT J DEV NEUROSCI, V30, P167, DOI 10.1016/j.ijdevneu.2011.12.008; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Messe A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065470; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Pop V, 2011, TRANSL STROKE RES, V2, P533, DOI 10.1007/s12975-011-0126-9; Raichle M., 1998, ANN NY ACAD SCI, V19, P373; Sarmento E, 2009, HEADACHE, V49, P1345, DOI 10.1111/j.1526-4610.2009.01494.x; Schwarzmaier SM, 2010, J NEUROTRAUM, V27, P121, DOI 10.1089/neu.2009.1114; Seifert TD, 2010, CURR PAIN HEADACHE R, V14, P292, DOI 10.1007/s11916-010-0117-7; Shrey DW, 2011, PHYS MED REH CLIN N, V22, P577, DOI 10.1016/j.pmr.2011.08.002; Solomon S, 2009, HEADACHE, V49, P1112, DOI 10.1111/j.1526-4610.2009.01462.x; Steiner J, 2004, NITRIC OXIDE-BIOL CH, V10, P162, DOI 10.1016/j.niox.2004.03.005; Strebel S, 1997, SURG NEUROL, V47, P128, DOI 10.1016/S0090-3019(96)00459-4; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Vavilala Monica S, 2004, Pediatr Crit Care Med, V5, P257, DOI 10.1097/01.PCC.0000123545.69133.C3; Virji-Babul N, 2013, PEDIATR NEUROL, V48, P24, DOI 10.1016/j.pediatrneurol.2012.09.005; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Xing CH, 2012, NEUROL RES, V34, P325, DOI 10.1179/1743132812Y.0000000019; Zhou YX, 2014, J MAGN RESON IMAGING, V39, P1558, DOI 10.1002/jmri.24310	50	79	79	0	23	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP 1	2014	31	17					1497	1506		10.1089/neu.2013.3213			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AO7GO	WOS:000341520700004	24735414				2022-02-06	
J	Lei, BL; Mace, B; Dawson, HN; Warner, DS; Laskowitz, DT; James, ML				Lei, Beilei; Mace, Brian; Dawson, Hana N.; Warner, David S.; Laskowitz, Daniel T.; James, Michael L.			Anti-Inflammatory Effects of Progesterone in Lipopolysaccharide-Stimulated BV-2 Microglia	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; NF-KAPPA-B; NITRIC-OXIDE SYNTHASE; TUMOR-NECROSIS-FACTOR; CEREBRAL-ARTERY OCCLUSION; PRIMARY GLIAL CULTURES; INTRACEREBRAL HEMORRHAGE; RATS; EXPRESSION; ISCHEMIA	Female sex is associated with improved outcome in experimental brain injury models, such as traumatic brain injury, ischemic stroke, and intracerebral hemorrhage. This implies female gonadal steroids may be neuroprotective. A mechanism for this may involve modulation of post-injury neuroinflammation. As the resident immunomodulatory cells in central nervous system, microglia are activated during acute brain injury and produce inflammatory mediators which contribute to secondary injury including proinflammatory cytokines, and nitric oxide (NO) and prostaglandin E-2 (PGE(2)), mediated by inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2), respectively. We hypothesized that female gonadal steroids reduce microglia mediated neuroinflammation. In this study, the progesterone's effects on tumor necrosis factor alpha (TNF-alpha), iNOS, and COX-2 expression were investigated in lipopolysaccharide (LPS)-stimulated BV-2 microglia. Further, investigation included nuclear factor kappa B (NF-kappa B) and mitogen activated protein kinase (MAPK) pathways. LPS (30 ng/ml) upregulated TNF-alpha, iNOS, and COX-2 protein expression in BV-2 cells. Progesterone pretreatment attenuated LPS-stimulated TNF-alpha, iNOS, and COX-2 expression in a dose-dependent fashion. Progesterone suppressed LPS-induced NF-kappa B activation by decreasing inhibitory kappa B alpha and NF-kappa B p65 phosphorylation and p65 nuclear translocation. Progesterone decreased LPS-mediated phosphorylation of p38, c-Jun N-terminal kinase and extracellular regulated kinase MAPKs. These progesterone effects were inhibited by its antagonist mifepristone. In conclusion, progesterone exhibits pleiotropic anti-inflammatory effects in LPS-stimulated BV-2 microglia by down-regulating proinflammatory mediators corresponding to suppression of NF-kappa B and MAPK activation. This suggests progesterone may be used as a potential neurotherapeutic to treat inflammatory components of acute brain injury.	[Lei, Beilei; Warner, David S.; Laskowitz, Daniel T.; James, Michael L.] Duke Univ, Med Ctr, Multidisciplinary Neuroprotect Labs, Durham, NC 27708 USA; [Lei, Beilei; Warner, David S.; Laskowitz, Daniel T.; James, Michael L.] Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; [Mace, Brian; Dawson, Hana N.; Laskowitz, Daniel T.; James, Michael L.] Duke Univ, Med Ctr, Dept Neurol, Durham, NC USA; [Warner, David S.; Laskowitz, Daniel T.] Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA		James, ML (corresponding author), Duke Univ, Med Ctr, Multidisciplinary Neuroprotect Labs, Durham, NC 27708 USA.	Michael.james@duke.edu	James, Michael L./AAJ-5592-2020	James, Michael L./0000-0002-8715-5210; Mace, Brian/0000-0002-5478-6227	American Heart Association-Scientist Development GrantAmerican Heart Association	This work was supported by American Heart Association-Scientist Development Grant (MLJ). The funders had no role in study design, data collection and analysis, decision to publish, or prearation of the manuscript.	Bachstetter AD, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-79; Bhat NR, 2002, J BIOL CHEM, V277, P29584, DOI 10.1074/jbc.M204994200; Bhat NR, 1998, J NEUROSCI, V18, P1633; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; BOCCHINI V, 1992, J NEUROSCI RES, V31, P616, DOI 10.1002/jnr.490310405; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; Burguillos MA, 2011, NATURE, V472, P319, DOI 10.1038/nature09788; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; DAcquisto F, 1997, FEBS LETT, V418, P175, DOI 10.1016/S0014-5793(97)01377-X; Dang J, 2011, BRAIN BEHAV IMMUN, V25, P715, DOI 10.1016/j.bbi.2011.01.013; Floden AM, 2006, J NEUROSCI, V26, P4644, DOI 10.1523/JNEUROSCI.4822-05.2006; Gibson CL, 2011, BRAIN, V134, P2125, DOI 10.1093/brain/awr132; Gomes-Leal W, 2012, BRAIN BEHAV, V2, P345, DOI 10.1002/brb3.51; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; Hardy DB, 2008, MOL ENDOCRINOL, V22, P1812, DOI 10.1210/me.2007-0443; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hehlgans T, 2005, IMMUNOLOGY, V115, P1, DOI 10.1111/j.1365-2567.2005.02143.x; Henn A, 2009, ALTEX-ALTERN TIEREXP, V26, P83; Ishrat T, 2009, BRAIN RES, V1257, P94, DOI 10.1016/j.brainres.2008.12.048; Jang BC, 2005, CELL SIGNAL, V17, P625, DOI 10.1016/j.cellsig.2004.10.001; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; Lei BL, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-103; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Mani S, 2008, ENDOCRINOLOGY, V149, P2750, DOI 10.1210/en.2008-0097; Mani SK, 2012, FRONT ENDOCRINOL, V3, P7, DOI [10.3389/fendo.2012.00007, DOI 10.3389/FENDO.2012.00007]; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; Morali G, 2005, NEUROSCI LETT, V382, P286, DOI 10.1016/j.neulet.2005.03.066; NELSON JF, 1992, ENDOCRINOLOGY, V130, P805, DOI 10.1210/en.130.2.805; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Ridder DA, 2009, NEUROSCIENCE, V158, P995, DOI 10.1016/j.neuroscience.2008.07.007; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Singh M, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00159; Singh M, 2013, HORM BEHAV, V63, P284, DOI 10.1016/j.yhbeh.2012.06.003; Taylor RA, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/746068; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641; Vallee M, 1997, P NATL ACAD SCI USA, V94, P14865, DOI 10.1073/pnas.94.26.14865; Waetzig V, 2005, GLIA, V50, P235, DOI 10.1002/glia.20173; Wagner CK, 2006, FRONT NEUROENDOCRIN, V27, P340, DOI 10.1016/j.yfrne.2006.07.003; Wang Z, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/848309; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yan F, 2013, NEUROSCI LETT, V543, P163, DOI 10.1016/j.neulet.2013.03.005; Zhang P, 1998, NEUROCHEM RES, V23, P219, DOI 10.1023/A:1022489127107; Zhao XR, 2007, J NEUROCHEM, V101, P652, DOI 10.1111/j.1471-4159.2006.04414.x; Zhou ZG, 2010, PAIN, V151, P296, DOI 10.1016/j.pain.2010.06.017; Zhu Y, 2008, COMP BIOCHEM PHYS C, V148, P381, DOI 10.1016/j.cbpc.2008.05.019	52	79	85	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2014	9	7							e103969	10.1371/journal.pone.0103969			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM6EF	WOS:000339954800102	25080336	Green Published, Green Submitted, gold			2022-02-06	
J	Uteshev, VV				Uteshev, Victor V.			The therapeutic promise of positive allosteric modulation of nicotinic receptors	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						Positive allosteric modulator; Nicotinic acetylcholine receptor; PNU-120596; Choline; Cerebral ischemia; Analgesia	ACETYLCHOLINE-RECEPTOR; COMPARATIVE PHARMACOLOGY; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; COGNITIVE FUNCTION; ALPHA-7 RECEPTORS; BINDING-SITES; BRAIN-TISSUE; AGONIST; CHOLINE	In the central nervous system, deficits in cholinergic neurotransmission correlate with decreased attention and cognitive impairment, while stimulation of neuronal nicotinic acetylcholine receptors improves attention, cognitive performance and neuronal resistance to injury as well as produces robust analgesic and anti-inflammatory effects. The rational basis for the therapeutic use of orthosteric agonists and positive allosteric modulators (PAMs) of nicotinic receptors arises from the finding that functional nicotinic receptors are ubiquitously expressed in neuronal and non-neuronal tissues including brain regions highly vulnerable to traumatic and ischemic types of injury (e g, cortex and hippocampus). Moreover, functional nicotinic receptors do not vanish in age-, disease- and trauma-related neuropathologies, but their expression and/or activation levels decline in a subunit- and brain region-specific manner. Therefore, augmenting the endogenous cholinergic tone by nicotinic agents is possible and may offset neurological impairments associated with cholinergic hypofunction. Importantly, because neuronal damage elevates extracellular levels of choline (a selective agonist of alpha 7 nicotinic acetylcholine receptors) near the site of injury, alpha 7-PAM-based treatments may augment pathology-activated alpha 7-dependent auto-therapies where and when they are most needed (i.e., in the penumbra, post-injury). Thus, nicotinic-PAM-based treatments are expected to augment the endogenous cholinergic tone in a spatially and temporally restricted manner creating the potential for differential efficacy and improved, safety as compared to exogenous orthosteric nicotinic agonists that activate nicotinic receptors indiscriminately. In this review, I will summarize the existing trends in therapeutic applications of nicotinic PAMs. (C) 2014 Elsevier B.V. All rights reserved.	Univ North Texas Hlth Sci Ctr, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA		Uteshev, VV (corresponding author), Univ North Texas Hlth Sci Ctr, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA.	Victor.Uteshev@unthsc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DK082625]; Rainwater Charitable Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK082625] Funding Source: NIH RePORTER	I thank Dr. John Dani and Dr. Daniel McGehee for productive discussions and criticism. I thank Dr. Imad Damaj for helpful suggestions. This study was supported by the NIH grant DK082625 and a grant from the Rainwater Charitable Foundation to VU.	Akaike A, 2010, J MOL NEUROSCI, V40, P211, DOI 10.1007/s12031-009-9236-1; Alkondon M, 1997, EUR J NEUROSCI, V9, P2734, DOI 10.1111/j.1460-9568.1997.tb01702.x; ARENDASH GW, 1995, BRAIN RES, V674, P252, DOI 10.1016/0006-8993(94)01449-R; BADIO B, 1994, MOL PHARMACOL, V45, P563; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; Bencherif M, 2011, CELL MOL LIFE SCI, V68, P931, DOI 10.1007/s00018-010-0525-1; Cabrera SM, 2006, BEHAV NEUROSCI, V120, P298, DOI 10.1037/0735-7044.120.2.298; Callahan PM, 2013, NEUROPHARMACOLOGY, V67, P201, DOI 10.1016/j.neuropharm.2012.10.019; Damaj MI, 2000, NEUROPHARMACOLOGY, V39, P2785, DOI 10.1016/S0028-3908(00)00139-8; del Barrio L, 2011, TOXICOL SCI, V123, P193, DOI 10.1093/toxsci/kfr163; Dinklo T, 2011, J PHARMACOL EXP THER, V336, P560, DOI 10.1124/jpet.110.173245; DJURICIC B, 1991, J CEREBR BLOOD F MET, V11, P308, DOI 10.1038/jcbfm.1991.63; Egea J, 2007, NEUROSCIENCE, V145, P866, DOI 10.1016/j.neuroscience.2006.12.036; Faghih R, 2009, J MED CHEM, V52, P3377, DOI 10.1021/jm9003818; Feuerbach D, 2009, NEUROPHARMACOLOGY, V56, P254, DOI 10.1016/j.neuropharm.2008.08.025; FREEDMAN R, 1995, BIOL PSYCHIAT, V38, P22, DOI 10.1016/0006-3223(94)00252-X; Freedman R, 2008, AM J PSYCHIAT, V165, P1040, DOI 10.1176/appi.ajp.2008.07071135; Freitas K, 2013, BRIT J PHARMACOL, V169, P567, DOI 10.1111/j.1476-5381.2012.02226.x; Freitas K, 2013, J PHARMACOL EXP THER, V344, P264, DOI 10.1124/jpet.112.197871; Gasull T, 2000, J BIOL CHEM, V275, P18350, DOI 10.1074/jbc.M910468199; GERZANICH V, 1995, MOL PHARMACOL, V48, P774; Guan ZZ, 2000, J NEUROCHEM, V74, P237, DOI 10.1046/j.1471-4159.2000.0740237.x; Gusev AG, 2010, J PHARMACOL EXP THER, V332, P588, DOI 10.1124/jpet.109.162099; Guseva MV, 2008, J NEUROTRAUM, V25, P975, DOI 10.1089/neu.2008.0516; Harris JG, 2004, NEUROPSYCHOPHARMACOL, V29, P1378, DOI 10.1038/sj.npp.1300450; Hu M, 2009, BRIT J PHARMACOL, V158, P1857, DOI 10.1111/j.1476-5381.2009.00474.x; Hurst RS, 2005, J NEUROSCI, V25, P4396, DOI 10.1523/JNEUROSCI.5269-04.2005; JANOWSKY DS, 1974, PSYCHOSOM MED, V36, P248, DOI 10.1097/00006842-197405000-00008; Kalappa BI, 2013, EUR J PHARMACOL, V718, P226, DOI 10.1016/j.ejphar.2013.08.027; Kalappa BI, 2013, BRIT J PHARMACOL, V169, P1862, DOI 10.1111/bph.12247; Kalappa BI, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013964; Kaneko S, 1997, BRAIN RES, V765, P135, DOI 10.1016/S0006-8993(97)00556-8; Kelso ML, 2012, CURR DRUG TARGETS, V13, P631, DOI 10.2174/138945012800398964; Kem WR, 2000, BEHAV BRAIN RES, V113, P169, DOI 10.1016/S0166-4328(00)00211-4; Kiewert C, 2010, BRAIN RES, V1312, P101, DOI 10.1016/j.brainres.2009.11.068; Kitagawa H, 2003, NEUROPSYCHOPHARMACOL, V28, P542, DOI 10.1038/sj.npp.1300028; Lee CH, 2011, BIOCHEM PHARMACOL, V82, P959, DOI 10.1016/j.bcp.2011.06.044; Lendvai B, 2013, BRAIN RES BULL, V93, P86, DOI 10.1016/j.brainresbull.2012.11.003; Leonard S, 2000, EUR J PHARMACOL, V393, P237, DOI 10.1016/S0014-2999(00)00035-2; Levin ED, 2006, PSYCHOPHARMACOLOGY, V184, P523, DOI 10.1007/s00213-005-0164-7; Li YX, 1999, BRAIN RES, V830, P218, DOI 10.1016/S0006-8993(99)01372-4; McLean SL, 2012, J PSYCHOPHARMACOL, V26, P1265, DOI 10.1177/0269881111431747; Medhurst SJ, 2008, J PAIN, V9, P580, DOI 10.1016/j.jpain.2008.01.336; Munro G, 2012, BRIT J PHARMACOL, V167, P421, DOI 10.1111/j.1476-5381.2012.02003.x; Newhouse PA, 2004, CURR OPIN PHARMACOL, V4, P36, DOI 10.1016/j.coph.2003.11.001; Ng HJ, 2007, P NATL ACAD SCI USA, V104, P8059, DOI 10.1073/pnas.0701321104; Nirogi R, 2013, EUR J PHARMACOL, V712, P22, DOI 10.1016/j.ejphar.2013.04.021; NORDBERG A, 1986, NEUROSCI LETT, V72, P115, DOI 10.1016/0304-3940(86)90629-4; Olincy A, 2006, ARCH GEN PSYCHIAT, V63, P630, DOI 10.1001/archpsyc.63.6.630; Papke RL, 1996, NEUROSCI LETT, V213, P201; Papke RL, 2002, BRIT J PHARMACOL, V137, P49, DOI 10.1038/sj.bjp.0704833; Parada E., 2013, ANTIOXID REDOX SIGNA; PERRY EK, 1995, NEUROSCIENCE, V64, P385, DOI 10.1016/0306-4522(94)00410-7; PETERSEN RC, 1977, PSYCHOPHARMACOLOGY, V52, P283, DOI 10.1007/BF00426713; QIAN CG, 1993, EUR J PHARMACOL, V250, pR13; Rao AM, 2000, J NEUROCHEM, V75, P2528, DOI 10.1046/j.1471-4159.2000.0752528.x; Rode F, 2012, BRAIN RES, V1458, P67, DOI 10.1016/j.brainres.2012.03.064; Roncarati R, 2009, J PHARMACOL EXP THER, V329, P459, DOI 10.1124/jpet.108.150094; Rowbotham MC, 2009, PAIN, V146, P245, DOI 10.1016/j.pain.2009.06.013; Shimohama S, 1998, BRAIN RES, V779, P359, DOI 10.1016/S0006-8993(97)00194-7; Shimohama S, 2009, BIOL PHARM BULL, V32, P332, DOI 10.1248/bpb.32.332; Sun F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073581; Takeuchi H, 2009, J NEUROSCI RES, V87, P576, DOI 10.1002/jnr.21869; Thomsen MS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027014; Umana IC, 2013, BIOCHEM PHARMACOL, V86, P1208, DOI 10.1016/j.bcp.2013.08.001; Uteshev VV, 2003, J NEUROPHYSIOL, V89, P1797, DOI 10.1152/jn.00943.2002; Verbois SL, 2003, NEUROSCIENCE, V119, P1199, DOI 10.1016/S0306-4522(03)00206-9; Wallace TL, 2011, BIOCHEM PHARMACOL, V82, P891, DOI 10.1016/j.bcp.2011.06.034; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; White SH, 2012, J NEUROPHYSIOL, V107, P2083, DOI 10.1152/jn.00701.2011; Yang JS, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002612; Zhu CZ, 2011, BIOCHEM PHARMACOL, V82, P967, DOI 10.1016/j.bcp.2011.05.007	72	79	82	0	22	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	MAR 15	2014	727						181	185		10.1016/j.ejphar.2014.01.072			5	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	AC8EY	WOS:000332767500023	24530419	Green Accepted			2022-02-06	
J	Han, K; Mac Donald, CL; Johnson, AM; Barnes, Y; Wierzechowski, L; Zonies, D; Oh, J; Flaherty, S; Fang, R; Raichle, ME; Brody, DL				Han, Kihwan; Mac Donald, Christine L.; Johnson, Ann M.; Barnes, Yolanda; Wierzechowski, Linda; Zonies, David; Oh, John; Flaherty, Stephen; Fang, Raymond; Raichle, Marcus E.; Brody, David L.			Disrupted modular organization of resting-state cortical functional connectivity in US military personnel following concussive 'mild' blast-related traumatic brain injury	NEUROIMAGE			English	Article						Functional connectivity; Traumatic brain injury; Graph theory; Modularity; Functional magnetic resonance imaging (fMRI); Blast injury	DEFAULT MODE NETWORK; HUMAN CEREBRAL-CORTEX; GRAPH-THEORETICAL ANALYSIS; SURFACE-BASED ANALYSIS; SMALL-WORLD NETWORKS; GLOBAL SIGNAL; HEAD MOTION; FMRI; SEGMENTATION; ACTIVATION	Blast-related traumatic brain injury (TBI) has been one of the "signature injuries" of the wars in Iraq and Afghanistan. However, neuroimaging studies in concussive 'mild' blast-related TBI have been challenging due to the absence of abnormalities in computed tomography or conventional magnetic resonance imaging (MRI) and the heterogeneity of the blast-related injury mechanisms. The goal of this study was to address these challenges utilizing single-subject, module-based graph theoretic analysis of resting-state functional MRI (fMRI) data. We acquired 20 min of resting-state fMRI in 63 U.S. military personnel clinically diagnosed with concussive blast-related TBI and 21 U.S. military controls who had blast exposures but no diagnosis of TBI. All subjects underwent an initial scan within 90 days post-injury and 65 subjects underwent a follow-up scan 6 to 12 months later. A second independent cohort of 40 U.S. military personnel with concussive blast-related TBI served as a validation dataset The second independent cohort underwent an initial scan within 30 days post-injury. 75% of the scans were of good quality, with exclusions primarily due to excessive subject motion. Network analysis of the subset of these subjects in the first cohort with good quality scans revealed spatially localized reductions in the participation coefficient, a measure of between-module connectivity, in the TBI patients relative to the controls at the time of the initial scan. These group differences were less prominent on the follow-up scans. The 15 brain areas with the most prominent reductions in the participation coefficient were next used as regions of interest (ROIs) for single-subject analyses. In the first TBI cohort, more subjects than would be expected by chance (27/47 versus 2/47 expected, p < 0.0001) had 3 or more brain regions with abnormally low between-module connectivity relative to the controls on the initial scans. On the follow-up scans, more subjects than expected by chance (5/37, p = 0.044) but fewer subjects than on the initial scans had 3 or more brain regions with abnormally low between-module connectivity. Analysis of the second TBI cohort validation dataset with no free parameters provided a partial replication; again more subjects than expected by chance (8/31, p = 0.006) had 3 or more brain regions with abnormally low between-module connectivity on the initial scans, but the numbers were not significant (2/27, p = 0.276) on the follow-up scans. A single-subject, multivariate analysis by probabilistic principal component analysis of the between-module connectivity in the 15 identified ROIs, showed that 31/47 subjects in the first TBI cohort were found to be abnormal relative to the controls on the initial scans. In the second TB! cohort, 9/31 patients were found to be abnormal in identical multivariate analysis with no free parameters. Again, there were not substantial differences on the follow-up scans. Taken together, these results indicate that single-subject, module-based graph theoretic analysis of resting-state fMRI provides potentially useful information for concussive blast-related TBI if high quality scans can be obtained. The underlying biological mechanisms and consequences of disrupted between-module connectivity are unknown, thus further studies are required. (C) 2013 Elsevier Inc. All rights reserved.	[Han, Kihwan; Mac Donald, Christine L.; Raichle, Marcus E.; Brody, David L.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Johnson, Ann M.] Washington Univ, Sch Med, Ctr Clin Studies, St Louis, MO 63110 USA; [Barnes, Yolanda; Wierzechowski, Linda; Zonies, David; Oh, John; Flaherty, Stephen; Fang, Raymond] Landstuhl Reg Med Ctr, Dept Trauma & Crit Care, Landstuhl, Germany; [Raichle, Marcus E.] Washington Univ, Sch Med, Dept Radiol, St Louis, MO 63110 USA; [Raichle, Marcus E.] Washington Univ, Sch Med, Dept Neurobiol, St Louis, MO 63110 USA; [Raichle, Marcus E.] Washington Univ, Sch Med, Dept Biomed Engn, St Louis, MO 63110 USA; [Raichle, Marcus E.] Washington Univ, Sch Med, Dept Psychol, St Louis, MO 63110 USA		Brody, DL (corresponding author), Washington Univ, Dept Neurol, 660 South Euclid Ave,Box 8111, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu	Oh, John/AAS-9557-2020; Zonies, David/B-6497-2011; Han, Kihwan/I-1984-2019	Oh, John/0000-0001-9010-0627; Han, Kihwan/0000-0002-4574-7306	Department of Defense CDMRPUnited States Department of Defense [PT075299, PT090444]; Washington University Center for High Performance Computing [NCRR 1S10RR022984-01A1]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR022984] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS062529] Funding Source: NIH RePORTER	First of all, we would like to thank all participants, their families, the commanding officers and the clinical care providers that supported this study. Our thanks also go to Dr. Nico U. Dosenbach, Dr. Steven E. Petersen and Dr. Abraham Z. Snyder for their helpful comments. This work has been supported by Department of Defense CDMRP grants PT075299 and PT090444 to DLB. We also would like to thank the facilities of the Washington University Center for High Performance Computing, which were partially provided through grant NCRR 1S10RR022984-01A1 for providing computational resource for conducting this study. Finally, we would like to thank the two anonymous reviewers for their comments which substantially improved this manuscript.	Achard S, 2006, J NEUROSCI, V26, P63, DOI 10.1523/JNEUROSCI.3874-05.2006; Anderson JS, 2011, HUM BRAIN MAPP, V32, P919, DOI 10.1002/hbm.21079; Arenivas A., 2012, BRAIN IMAGING BEHAV, V13, P1; Argall BD, 2006, HUM BRAIN MAPP, V27, P14, DOI 10.1002/hbm.20158; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Blondel VD, 2008, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2008/10/P10008; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Braun U, 2012, NEUROIMAGE, V59, P1404, DOI 10.1016/j.neuroimage.2011.08.044; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Caeyenberghs K, 2012, BRAIN, V135, P1293, DOI 10.1093/brain/aws048; Casscells S.W., 2007, TRAUMATIC BRAIN INJU; Castellanos NP, 2011, NEUROIMAGE, V55, P1189, DOI 10.1016/j.neuroimage.2010.12.046; Castellanos NP, 2010, BRAIN, V133, P2365, DOI 10.1093/brain/awq174; Chai XQJ, 2012, NEUROIMAGE, V59, P1420, DOI 10.1016/j.neuroimage.2011.08.048; Chang C, 2009, NEUROIMAGE, V47, P1448, DOI 10.1016/j.neuroimage.2009.05.012; Chen ZJ, 2008, CEREB CORTEX, V18, P2374, DOI 10.1093/cercor/bhn003; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; DALE AM, 1993, J COGNITIVE NEUROSCI, V5, P162, DOI 10.1162/jocn.1993.5.2.162; de Haan W, 2012, NEUROIMAGE, V59, P3085, DOI 10.1016/j.neuroimage.2011.11.055; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; Dempsey Kenneth E, 2009, J Trauma Nurs, V16, P6, DOI 10.1097/01.JTN.0000348063.41099.a7; Destrieux C, 2010, NEUROIMAGE, V53, P1, DOI 10.1016/j.neuroimage.2010.06.010; Domsch S, 2013, MAGN RESON IMAGING, V31, P201, DOI 10.1016/j.mri.2012.06.020; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; EVANS AC, 1993, NUCLEAR SCIENCE SYMPOSIUM & MEDICAL IMAGING CONFERENCE, VOLS 1-3, P1813, DOI 10.1109/NSSMIC.1993.373602; Finkel MF, 2006, J NEUROL SCI, V249, P63, DOI 10.1016/j.jns.2006.06.005; Fischl B, 1999, HUM BRAIN MAPP, V8, P272, DOI 10.1002/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fortunato S, 2010, PHYS REP, V486, P75, DOI 10.1016/j.physrep.2009.11.002; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Fox MD, 2009, J NEUROPHYSIOL, V101, P3270, DOI 10.1152/jn.90777.2008; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Guimera R, 2005, NATURE, V433, P895, DOI 10.1038/nature03288; Gujar N, 2010, J COGNITIVE NEUROSCI, V22, P1637, DOI 10.1162/jocn.2009.21331; Hagler DJ, 2006, NEUROIMAGE, V33, P1093, DOI 10.1016/j.neuroimage.2006.07.036; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Hayasaka S, 2010, NEUROIMAGE, V50, P499, DOI 10.1016/j.neuroimage.2009.12.051; He Y, 2007, CEREB CORTEX, V17, P2407, DOI 10.1093/cercor/bhl149; He Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005226; Honey CJ, 2009, P NATL ACAD SCI USA, V106, P2035, DOI 10.1073/pnas.0811168106; Horovitz SG, 2009, P NATL ACAD SCI USA, V106, P11376, DOI 10.1073/pnas.0901435106; Jacobs A, 1996, J NUCL MED, V37, P1605; Jo HJ, 2008, NEUROIMAGE, V40, P1077, DOI 10.1016/j.neuroimage.2007.12.036; Jo HJ, 2007, NEUROIMAGE, V34, P550, DOI 10.1016/j.neuroimage.2006.09.047; Johnson B, 2012, NEUROSCI LETT, V509, P5, DOI 10.1016/j.neulet.2011.11.013; Johnstone T, 2006, HUM BRAIN MAPP, V27, P779, DOI 10.1002/hbm.20219; Jovicich J, 2006, NEUROIMAGE, V30, P436, DOI 10.1016/j.neuroimage.2005.09.046; Kasahara M, 2010, NEUROLOGY, V75, P168, DOI 10.1212/WNL.0b013e3181e7ca58; Larson-Prior LJ, 2009, P NATL ACAD SCI USA, V106, P4489, DOI 10.1073/pnas.0900924106; Latora V, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.198701; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Liang X, 2013, P NATL ACAD SCI USA, V110, P1929, DOI 10.1073/pnas.1214900110; Liao YH, 2012, NEUROSCI LETT, V522, P36, DOI 10.1016/j.neulet.2012.06.009; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Lowe MJ, 1998, NEUROIMAGE, V7, P119, DOI 10.1006/nimg.1997.0315; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Meunier David, 2009, Front Neuroinform, V3, P37, DOI 10.3389/neuro.11.037.2009; Meunier D, 2009, NEUROIMAGE, V44, P715, DOI 10.1016/j.neuroimage.2008.09.062; Micheloyannis S, 2006, SCHIZOPHR RES, V87, P60, DOI 10.1016/j.schres.2006.06.028; Minka T.P, 2000, ADV NEURAL INF PROCE, DOI DOI 10.1126/SCIENCE.1164015; Murphy K, 2009, NEUROIMAGE, V44, P893, DOI 10.1016/j.neuroimage.2008.09.036; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Newman MEJ, 2004, PHYS REV E, V69, DOI 10.1103/PhysRevE.69.026113; Newman MEJ, 2004, PHYS REV E, V69, DOI 10.1103/PhysRevE.69.066133; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Ojemann JG, 1997, NEUROIMAGE, V6, P156, DOI 10.1006/nimg.1997.0289; Okie S, 2006, NEW ENGL J MED, V355, P2609, DOI 10.1056/NEJMp068235; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Ponten SC, 2007, CLIN NEUROPHYSIOL, V118, P918, DOI 10.1016/j.clinph.2006.12.002; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Power JD, 2011, NEURON, V72, P665, DOI 10.1016/j.neuron.2011.09.006; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Rombouts SARB, 2003, NEUROIMAGE, V20, P1236, DOI 10.1016/S1053-8119(03)00386-0; Rosvall M, 2008, P NATL ACAD SCI USA, V105, P1118, DOI 10.1073/pnas.0706851105; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Saad ZS, 2012, BRAIN CONNECT, V2, P25, DOI 10.1089/brain.2012.0080; Saad ZS, 2004, 2004 2ND IEEE INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING: MACRO TO NANO, VOLS 1 and 2, P1510; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Salvador R, 2005, CEREB CORTEX, V15, P1332, DOI 10.1093/cercor/bhi016; Satterthwaite TD, 2012, NEUROIMAGE, V60, P623, DOI 10.1016/j.neuroimage.2011.12.063; Scheibel RS, 2012, J INT NEUROPSYCH SOC, V18, P89, DOI 10.1017/S1355617711001433; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Stam CJ, 2007, CEREB CORTEX, V17, P92, DOI 10.1093/cercor/bhj127; Stork R. O, 2001, PATTERN CLASSIFICATI; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Tucholka A, 2012, NEUROIMAGE, V63, P1443, DOI 10.1016/j.neuroimage.2012.06.019; Valencia M, 2009, CHAOS, V19, DOI 10.1063/1.3129783; van den Heuvel MP, 2008, NEUROIMAGE, V43, P528, DOI 10.1016/j.neuroimage.2008.08.010; Van Dijk KRA, 2012, NEUROIMAGE, V59, P431, DOI 10.1016/j.neuroimage.2011.07.044; Van Dijk KRA, 2010, J NEUROPHYSIOL, V103, P297, DOI 10.1152/jn.00783.2009; Van Essen DC, 2007, NEUROIMAGE, V37, P1050, DOI 10.1016/j.neuroimage.2007.02.021; van Wingen GA, 2012, P NATL ACAD SCI USA, V109, P15508, DOI 10.1073/pnas.1206330109; Vincent JL, 2008, J NEUROPHYSIOL, V100, P3328, DOI 10.1152/jn.90355.2008; Wang JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021976; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Wig GS, 2011, ANN NY ACAD SCI, V1224, P126, DOI 10.1111/j.1749-6632.2010.05947.x; Yeo BTT, 2011, J NEUROPHYSIOL, V106, P1125, DOI 10.1152/jn.00338.2011; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578; Zhang DY, 2008, J NEUROPHYSIOL, V100, P1740, DOI 10.1152/jn.90463.2008	118	79	81	0	30	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	JAN 1	2014	84						76	96		10.1016/j.neuroimage.2013.08.017			21	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	278DF	WOS:000328868600008	23968735	Green Accepted			2022-02-06	
J	Hadass, O; Tomlinson, BN; Gooyit, M; Chen, SY; Purdy, JJ; Walker, JM; Zhang, CY; Giritharan, AB; Purnell, W; Robinson, CR; Shin, D; Schroeder, VA; Suckow, MA; Simonyi, A; Sun, GY; Mobashery, S; Cui, JK; Chang, M; Gu, ZZ				Hadass, Orr; Tomlinson, Brittany N.; Gooyit, Major; Chen, Shanyan; Purdy, Justin J.; Walker, Jennifer M.; Zhang, Chunyang; Giritharan, Andrew B.; Purnell, Whitley; Robinson, Christopher R., II; Shin, Dmitriy; Schroeder, Valerie A.; Suckow, Mark A.; Simonyi, Agnes; Sun, Grace Y.; Mobashery, Shahriar; Cui, Jiankun; Chang, Mayland; Gu, Zezong			Selective Inhibition of Matrix Metalloproteinase-9 Attenuates Secondary Damage Resulting from Severe Traumatic Brain Injury	PLOS ONE			English	Article							MATRIX METALLOPROTEINASES; GELATINASE INHIBITOR; KNOCK-OUT; BLOOD; DEGRADATION; EXPRESSION; NEURODEGENERATION; ACTIVATION; MICROGLIA; MECHANISM	Traumatic brain injury (TBI) is a leading cause of death and long-term disability. Following the initial insult, severe TBI progresses to a secondary injury phase associated with biochemical and cellular changes. The secondary injury is thought to be responsible for the development of many of the neurological deficits observed after TBI and also provides a window of opportunity for therapeutic intervention. Matrix metalloproteinase-9 (MMP-9 or gelatinase B) expression is elevated in neurological diseases and its activation is an important factor in detrimental outcomes including excitotoxicity, mitochondrial dysfunction and apoptosis, and increases in inflammatory responses and astrogliosis. In this study, we used an experimental mouse model of TBI to examine the role of MMP-9 and the therapeutic potential of SB-3CT, a mechanism-based gelatinase selective inhibitor, in ameliorating the secondary injury. We observed that activation of MMP-9 occurred within one day following TBI, and remained elevated for 7 days after the initial insult. SB-3CT effectively attenuated MMP-9 activity, reduced brain lesion volumes and prevented neuronal loss and dendritic degeneration. Pharmacokinetic studies revealed that SB-3CT and its active metabolite, p-OH SB-3CT, were rapidly absorbed and distributed to the brain. Moreover, SB-3CT treatment mitigated microglial activation and astrogliosis after TBI. Importantly, SB-3CT treatment improved long-term neurobehavioral outcomes, including sensorimotor function, and hippocampus-associated spatial learning and memory. These results demonstrate that MMP-9 is a key target for therapy to attenuate secondary injury cascades and that this class of mechanism-based gelatinase inhibitor-with such desirable pharmacokinetic properties-holds considerable promise as a potential pharmacological treatment of TBI.	[Hadass, Orr; Tomlinson, Brittany N.; Chen, Shanyan; Purdy, Justin J.; Zhang, Chunyang; Giritharan, Andrew B.; Purnell, Whitley; Robinson, Christopher R., II; Shin, Dmitriy; Cui, Jiankun; Gu, Zezong] Univ Missouri, Sch Med, Dept Pathol & Anat Sci, Columbia, MO USA; [Simonyi, Agnes; Sun, Grace Y.] Univ Missouri, Sch Med, Dept Biochem, Columbia, MO USA; [Hadass, Orr; Tomlinson, Brittany N.; Chen, Shanyan; Purdy, Justin J.; Zhang, Chunyang; Giritharan, Andrew B.; Purnell, Whitley; Robinson, Christopher R., II; Simonyi, Agnes; Sun, Grace Y.; Cui, Jiankun; Gu, Zezong] Univ Missouri, Sch Med, Ctr Translat Neurosci, Columbia, MO USA; [Hadass, Orr; Tomlinson, Brittany N.] Univ Missouri, MS Pathol Program, Grad Sch, Columbia, MO USA; [Chen, Shanyan] Univ Missouri, Interdisciplinary Neurosci Program, Grad Sch, Columbia, MO USA; [Walker, Jennifer M.] Univ Missouri, Dept Psychol Sci, Columbia, MO USA; [Gooyit, Major; Mobashery, Shahriar; Chang, Mayland] Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; [Schroeder, Valerie A.; Suckow, Mark A.] Univ Notre Dame, Freimann Life Sci Ctr, Notre Dame, IN 46556 USA; [Schroeder, Valerie A.; Suckow, Mark A.] Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA		Chang, M (corresponding author), Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA.	mchang@nd.edu; guze@health.missouri.edu	Suckow, Mark/C-2696-2014	Suckow, Mark/0000-0001-7317-697X; Shin, Dmitriy/0000-0002-5571-9384	Mizzou Advantage; Department of Pathology and Anatomical Sciences; ICATS; NFL Charities Foundation; Indiana Department of Health Spinal Cord and Brain Fund; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [GM075762]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM075762] Funding Source: NIH RePORTER	This work was supported in part by funding from Mizzou Advantage, the Department of Pathology and Anatomical Sciences (to ZG) and ICATS Fellowship (to JP) at the University of Missouri; the NFL Charities Foundation and the Indiana Department of Health Spinal Cord and Brain Fund (to MC and ZG) and National Institutes of Health Training Grant GM075762 (to MG). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bell RD, 2012, NATURE, V485, P512, DOI 10.1038/nature11087; Bell RD, 2010, NEURON, V68, P409, DOI 10.1016/j.neuron.2010.09.043; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Brown S, 2000, J AM CHEM SOC, V122, P6799, DOI 10.1021/ja001461n; Buss A, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-17; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; Cui JK, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-21; del Zoppo GJ, 2007, STROKE, V38, P646, DOI 10.1161/01.STR.0000254477.34231.cb; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Forbes C, 2009, CHEM BIOL DRUG DES, V74, P527, DOI 10.1111/j.1747-0285.2009.00881.x; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Garden GA, 2002, J NEUROSCI, V22, P4015, DOI 10.1523/JNEUROSCI.22-10-04015.2002; Gooyit M, 2012, ACS CHEM NEUROSCI, V3, P730, DOI 10.1021/cn300062w; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Gu ZZ, 2005, J NEUROSCI, V25, P6401, DOI 10.1523/JNEUROSCI.1563-05.2005; Guo ZD, 2010, NEUROL RES, V32, P715, DOI 10.1179/016164109X12478302362491; Helton R, 2005, J NEUROSCI, V25, P4099, DOI 10.1523/JNEUROSCI.4555-04.2005; Horstmann S, 2003, STROKE, V34, P2165, DOI 10.1161/01.STR.0000088062.86084.F2; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kettenmann H, 2007, NATURE, V446, P987, DOI 10.1038/nature05713; Kim GW, 2003, J NEUROSCI, V23, P8733; Lam CK, 2010, NATURE, V465, P478, DOI 10.1038/nature09001; Lee M, 2007, CHEM BIOL DRUG DES, V70, P371, DOI 10.1111/j.1747-0285.2007.00577.x; Lee M, 2009, CHEM BIOL DRUG DES, V73, P189, DOI 10.1111/j.1747-0285.2008.00750.x; Liu HQ, 2011, EXP NEUROL, V231, P236, DOI 10.1016/j.expneurol.2011.06.015; Liu J, 2012, J NEUROSCI, V32, P3044, DOI 10.1523/JNEUROSCI.6409-11.2012; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Montaner J, 2001, STROKE, V32, P2762, DOI 10.1161/hs1201.99512; Mott JD, 2004, CURR OPIN CELL BIOL, V16, P558, DOI 10.1016/j.ceb.2004.07.010; Noble LJ, 2002, J NEUROSCI, V22, P7526; Pardridge WM, 2007, DRUG DISCOV TODAY, V12, P54, DOI 10.1016/j.drudis.2006.10.013; Pardridge William M, 2005, NeuroRx, V2, P3; Qiu LB, 2011, TOXICOLOGY, V285, P31, DOI 10.1016/j.tox.2011.03.019; Rosenberg GA, 2009, LANCET NEUROL, V8, P205, DOI 10.1016/S1474-4422(09)70016-X; Sheng WW, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-121; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Switzer JA, 2011, STROKE, V42, P2633, DOI 10.1161/STROKEAHA.111.618215; Toth M, 2000, J BIOL CHEM, V275, P41415, DOI 10.1074/jbc.M006871200; Walker JM, 2011, BEHAV BRAIN RES, V222, P169, DOI 10.1016/j.bbr.2011.03.049; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Yagi Y, 2008, DIAGN PATHOL, V3, DOI 10.1186/1746-1596-3-S1-S12; Yong VW, 2005, NAT REV NEUROSCI, V6, P931, DOI 10.1038/nrn1807; Yu F, 2008, J NEUROTRAUM, V25, P184, DOI 10.1089/neu.2007.0438; Zhang HQ, 2010, NEUROSCIENTIST, V16, P156, DOI 10.1177/1073858409355830; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Zhao BQ, 2006, NAT MED, V12, P441, DOI 10.1038/nm1387	48	79	84	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 23	2013	8	10							e76904	10.1371/journal.pone.0076904			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	239PE	WOS:000326037000028	24194849	Green Published, Green Submitted, gold			2022-02-06	
J	Dahm, J; Wong, DN; Ponsford, J				Dahm, Jane; Wong, Dana; Ponsford, Jennie			Validity of the Depression Anxiety Stress Scales in assessing depression and anxiety following traumatic brain injury	JOURNAL OF AFFECTIVE DISORDERS			English	Article						Brain injury; Assessment; Anxiety; Depression; Depression Anxiety Stress Scales; Hospital Anxiety and Depression Scale	LARGE NONCLINICAL SAMPLE; HOSPITAL ANXIETY; PSYCHIATRIC-DISORDERS; EMOTIONAL STATUS; NORMATIVE DATA; DIAGNOSIS; DASS-21; VERSION	Background: Anxiety and depression following traumatic brain injury (TBI) are associated with poorer outcomes. A brief self-report questionnaire would assist in identifying those at risk, however validity of such measures is complicated by confounding symptoms of the injury. This study investigated the validity of the Depression Anxiety Stress Scales (DASS) and Hospital Anxiety and Depression Scale (HADS), in screening for clinical diagnoses of anxiety and mood disorders following TBI. Methods: One hundred and twenty-three participants with mild to severe TBI were interviewed using the SCID (Axis I) and completed the DASS and HADS. Results: The DASS, DASS21 and HADS scales demonstrated validity compared with SOD diagnoses of anxiety and mood disorders as measured by Area Under ROC Curve, sensitivity and specificity. Validity of the DASS depression scale benefited from items reflecting symptoms of devaluation of life, self-deprecation, and hopelessness that are not present on the HADS. Validity of the HADS anxiety scale benefited from items reflecting symptoms of tension and worry that are measured separately for the DASS on the stress scale. Limitations: Participants were predominantly drawn from a rehabilitation centre which may limit the extent to which results can be generalized. Scores for the DASS21 were derived from the DASS rather than being administered separately. Conclusions: The DASS, DASS21 and RADS demonstrated validity as screening measures of anxiety and mood disorders in this TBI sample. The findings support use of these sell report questionnaires for individuals with TBI to identify those who should be referred for clinical diagnostic follow-up. (C) 2013 Elsevier B.V. All rights reserved.	[Dahm, Jane; Wong, Dana; Ponsford, Jennie] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [Ponsford, Jennie] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Ponsford, Jennie] Natl Trauma Res Inst, Melbourne, Vic, Australia		Wong, DN (corresponding author), Monash Univ, Sch Psychol & Psychiat, Clayton Campus,Wellington Rd,Bldg 17, Clayton, Vic 3800, Australia.	dana.wong@monash.edu	Wong, Dana/AAD-3410-2020	Wong, Dana/0000-0001-9619-1929	Transport Accident Commission (TAC)	This research was supported by funding from the Transport Accident Commission (TAC).	Al-Adawi S, 2007, BRAIN INJURY, V21, P385, DOI 10.1080/02699050701311059; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Andrew MJ, 2000, J PSYCHOSOM RES, V48, P537, DOI 10.1016/S0022-3999(00)00089-1; Antony MM, 1998, PSYCHOL ASSESSMENT, V10, P176, DOI 10.1037/1040-3590.10.2.176; Crawford JR, 2003, BRIT J CLIN PSYCHOL, V42, P111, DOI 10.1348/014466503321903544; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; First M., 1995, STRUCTURED CLIN INTE, V9, P92; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Gould KR, 2011, J HEAD TRAUMA REHAB, V26, P79, DOI 10.1097/HTR.0b013e3182036799; Henry JD, 2005, BRIT J CLIN PSYCHOL, V44, P227, DOI 10.1348/014466505X29657; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Lovibond SH., 1995, MANUAL DEPRESSION AN, V2nd; McMillan TM, 2001, BRAIN INJURY, V15, P39, DOI 10.1080/02699050118030; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Ownsworth T, 2008, BRAIN INJURY, V22, P858, DOI 10.1080/02699050802446697; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Seel RT, 2010, J HEAD TRAUMA REHAB, V25, P99, DOI 10.1097/HTR.0b013e3181ce3966; Snaith R., 1994, HOSP ANXIETY DEPRESS; Sukantarat KT, 2007, ANAESTHESIA, V62, P239, DOI 10.1111/j.1365-2044.2006.04948.x; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Wood BM, 2010, PAIN MED, V11, P1780, DOI 10.1111/j.1526-4637.2010.01005.x; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	23	79	80	5	45	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0327			J AFFECT DISORDERS	J. Affect. Disord.	OCT	2013	151	1					392	396		10.1016/j.jad.2013.06.011			5	Clinical Neurology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	213FE	WOS:000324039500054	23830002				2022-02-06	
J	Castro, M; Paleti, R; Bhat, CR				Castro, Marisol; Paleti, Rajesh; Bhat, Chandra R.			A spatial generalized ordered response model to examine highway crash injury severity	ACCIDENT ANALYSIS AND PREVENTION			English	Article						Highway crash injury severity; Generalized ordered response model; Unobserved heterogeneity; Spatial dependence; Composite marginal likelihood; Spatial econometrics	STATISTICAL-ANALYSIS; MULTINOMIAL LOGIT; SINGLE-VEHICLE; DRIVER-INJURY; PROBIT; ACCIDENTS	This paper proposes a flexible econometric structure for injury severity analysis at the level of individual crashes that recognizes the ordinal nature of injury severity categories, allows unobserved heterogeneity in the effects of contributing factors, as well as accommodates spatial dependencies in the injury severity levels experienced in crashes that occur close to one another in space. The modeling framework is applied to analyze the injury severity sustained in crashes occurring on highway road segments in Austin, Texas. The sample is drawn from the Texas Department of Transportation (TxDOT) crash incident files from 2009 and includes a variety of crash characteristics, highway design attributes, driver and vehicle characteristics, and environmental factors. The results from our analysis underscore the value of our proposed model for data fit purposes as well as to accurately estimate variable effects. The most important determinants of injury severity on highways, according to our results, are (1) whether any vehicle occupant is ejected, (2) whether collision type is head-on, (3) whether any vehicle involved in the crash overturned, (4) whether any vehicle occupant is unrestrained by a seat-belt, and (5) whether a commercial truck is involved. (C) 2012 Elsevier Ltd. All rights reserved.	[Castro, Marisol; Paleti, Rajesh; Bhat, Chandra R.] Univ Texas Austin, Dept Civil Architectural & Environm Engn, Austin, TX 78712 USA		Bhat, CR (corresponding author), Univ Texas Austin, Dept Civil Architectural & Environm Engn, 301 E Dean Keeton St Stop C1761, Austin, TX 78712 USA.	m.castro@utexas.edu; rajeshp@mail.utexas.edu; bhat@mail.utexas.edu	Bhat, Chandra/AAC-6965-2019; Bhat, Chandra R/B-3952-2013	Bhat, Chandra/0000-0002-0715-8121; Bhat, Chandra R/0000-0002-0715-8121			Allen R. G., 1998, FAO Irrigation and Drainage Paper; Amoros E, 2006, ACCIDENT ANAL PREV, V38, P627, DOI 10.1016/j.aap.2005.11.006; Anastasopoulos PC, 2011, ACCIDENT ANAL PREV, V43, P1140, DOI 10.1016/j.aap.2010.12.024; Bagdadi O, 2013, ACCIDENT ANAL PREV, V50, P167, DOI 10.1016/j.aap.2012.04.007; Bhat CR, 2010, ADV ECONOMETRICS, V26, P65, DOI 10.1108/S0731-9053(2010)0000026007; Bhat CR, 2011, TRANSPORT RES B-METH, V45, P923, DOI 10.1016/j.trb.2011.04.005; Chen F, 2011, ACCIDENT ANAL PREV, V43, P1677, DOI 10.1016/j.aap.2011.03.026; Christoforou Z, 2010, ACCIDENT ANAL PREV, V42, P1606, DOI 10.1016/j.aap.2010.03.019; Das A, 2009, J SAFETY RES, V40, P317, DOI 10.1016/j.jsr.2009.05.003; Dissanayake S., 2006, J TRANSPORTATION RES, V45, P87; Dupont E, 2010, ACCIDENT ANAL PREV, V42, P645, DOI 10.1016/j.aap.2009.10.011; Eluru N, 2008, ACCIDENT ANAL PREV, V40, P1033, DOI 10.1016/j.aap.2007.11.010; Eluru N, 2007, ACCIDENT ANAL PREV, V39, P1037, DOI 10.1016/j.aap.2007.02.001; Eluru N, 2010, TRANSPORT RES REC, P1, DOI 10.3141/2165-01; Franzese R. J., 2008, OXFORD HDB POLITICAL, P570; Fu V., 1998, STATA TECHNICAL B, V44, P27; GODAMBE VP, 1960, ANN MATH STAT, V31, P1208, DOI 10.1214/aoms/1177705693; Greene W.H., 2009, MODELING ORDERED CHO; Haleem K, 2010, J SAFETY RES, V41, P347, DOI 10.1016/j.jsr.2010.04.006; Helai H, 2008, ACCIDENT ANAL PREV, V40, P45, DOI 10.1016/j.aap.2007.04.002; Hu Jingwen, 2005, Annu Proc Assoc Adv Automot Med, V49, P119; Hu W, 2010, ACCIDENT ANAL PREV, V42, P1697, DOI 10.1016/j.aap.2010.04.009; JANSSEN W, 1994, ACCIDENT ANAL PREV, V26, P249, DOI 10.1016/0001-4575(94)90095-7; Jung SY, 2010, ACCIDENT ANAL PREV, V42, P213, DOI 10.1016/j.aap.2009.07.020; Kermanshah M., 2011, TRANSPORTATION RES J, V1, P35; Khorashadi A, 2005, ACCIDENT ANAL PREV, V37, P910, DOI 10.1016/j.aap.2005.04.009; Lee J, 2002, ACCIDENT ANAL PREV, V34, P149, DOI 10.1016/S0001-4575(01)00009-4; LeSage J, 2009, STAT TEXTB MONOGR, P1; Lindsay BG, 1988, CONT MATH, V80, P221; Liu Z., 2011, P TRANSP RES BOARD 9; Lord D, 2010, TRANSPORT RES A-POL, V44, P291, DOI 10.1016/j.tra.2010.02.001; Ma ZL, 2009, IEEE INT VEH SYM, P983, DOI 10.1109/IVS.2009.5164414; Malyshkina NV, 2009, ACCIDENT ANAL PREV, V41, P829, DOI 10.1016/j.aap.2009.04.006; Milton JC, 2008, ACCIDENT ANAL PREV, V40, P260, DOI 10.1016/j.aap.2007.06.006; Molenberghs G, 2005, SPR S STAT; Moore DN, 2011, ACCIDENT ANAL PREV, V43, P621, DOI 10.1016/j.aap.2010.09.015; Muller G, 2005, J COMPUT GRAPH STAT, V14, P320, DOI 10.1198/106186005X48687; Murphy SL, 2012, NATL VITAL STAT REPO, V60; National Highway Traffic Safety Administration (NHTSA), 2012, 811552 NHTSA DOT HS; National Highway Traffic Safety Administration (NHTSA), 2011, 811402 NHTSA DOT HS; Mujalli RO, 2011, J SAFETY RES, V42, P317, DOI 10.1016/j.jsr.2011.06.010; Paleti R, 2010, ACCIDENT ANAL PREV, V42, P1839, DOI 10.1016/j.aap.2010.05.005; Patil S, 2012, ACCIDENT ANAL PREV, V45, P646, DOI 10.1016/j.aap.2011.09.034; Petridou E, 2000, EUR J EPIDEMIOL, V16, P819, DOI 10.1023/A:1007649804201; Quddus MA, 2010, J TRANSP ENG, V136, P424, DOI 10.1061/(ASCE)TE.1943-5436.0000044; Rana TA, 2010, TRANSPORT RES REC, P75, DOI 10.3141/2147-10; Rifaat SM, 2011, ACCIDENT ANAL PREV, V43, P276, DOI 10.1016/j.aap.2010.08.024; Savolainen P, 2007, ACCIDENT ANAL PREV, V39, P955, DOI 10.1016/j.aap.2006.12.016; Savolainen PT, 2011, ACCIDENT ANAL PREV, V43, P1666, DOI 10.1016/j.aap.2011.03.025; Schneider I.V., 2009, TRANSPORT RES REC, V2102, P85, DOI DOI 10.3141/2102-11; Shankar V, 1996, J SAFETY RES, V27, P183, DOI 10.1016/0022-4375(96)00010-2; Srinivasan KK, 2002, TRANSPORT RES REC, P132, DOI 10.3141/1784-17; Ulfarsson GF, 2004, ACCIDENT ANAL PREV, V36, P135, DOI 10.1016/S0001-4575(02)00135-5; Varin C, 2011, STAT SINICA, V21, P5; Varin C, 2010, BIOSTATISTICS, V11, P127, DOI 10.1093/biostatistics/kxp042; Varin C, 2009, ECONOMET REV, V28, P170, DOI 10.1080/07474930802388009; Wang XS, 2008, ACCIDENT ANAL PREV, V40, P1674, DOI 10.1016/j.aap.2008.06.001; Wang YG, 2011, PERIOD POLYTECH-CIV, V55, P191, DOI 10.3311/pp.ci.2011-2.11; Wang ZY, 2009, TRANSP RES RECORD, P43, DOI 10.3141/2102-06; Williams R, 2006, STATA J, V6, P58, DOI 10.1177/1536867X0600600104; Winston C, 2006, J RISK UNCERTAINTY, V32, P83, DOI 10.1007/s11166-006-8288-7; Xie YC, 2009, J TRANSP ENG, V135, P18, DOI 10.1061/(ASCE)0733-947X(2009)135:1(18); Xu XM, 2011, J STAT PLAN INFER, V141, P3047, DOI 10.1016/j.jspi.2011.03.026; Yamamoto T, 2008, ACCIDENT ANAL PREV, V40, P1320, DOI 10.1016/j.aap.2007.10.016; Yan XP, 2011, ACCIDENT ANAL PREV, V43, P1751, DOI 10.1016/j.aap.2011.04.006; Ye F, 2011, TRANSPORT RES REC, P51, DOI 10.3141/2241-06; Zhang Y, 2011, PROCEDIA ENGINEER, V21, P178, DOI 10.1016/j.proeng.2011.11.2002; Zhao YS, 2005, CAN J STAT, V33, P335, DOI 10.1002/cjs.5540330303; Zhu XY, 2011, ACCIDENT ANAL PREV, V43, P49, DOI 10.1016/j.aap.2010.07.007	69	79	79	1	41	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575	1879-2057		ACCIDENT ANAL PREV	Accid. Anal. Prev.	MAR 28	2013	52						188	203		10.1016/j.aap.2012.12.009			16	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Social Science Citation Index (SSCI)	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	124DN	WOS:000317444100022	23333845	Green Submitted			2022-02-06	
J	Elbogen, EB; Johnson, SC; Newton, VM; Straits-Troster, K; Vasterling, JJ; Wagner, HR; Beckham, JC				Elbogen, Eric B.; Johnson, Sally C.; Newton, Virginia M.; Straits-Troster, Kristy; Vasterling, Jennifer J.; Wagner, H. Ryan; Beckham, Jean C.			Criminal Justice Involvement, Trauma, and Negative Affect in Iraq and Afghanistan War Era Veterans	JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY			English	Article						veterans; criminal arrest; posttraumatic stress disorder; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH; SUBSTANCE USE; VIOLENCE; RISK; AGGRESSION; SYMPTOMS; BEHAVIOR; SCALE; ABUSE	Objective: Although criminal behavior in veterans has been cited as a growing problem, little is known about why some veterans are at increased risk for arrest. Theories of criminal behavior postulate that people who have been exposed to stressful environments or traumatic events and who report negative affect such as anger and irritability are at increased risk of antisocial conduct. Method: We hypothesized veterans with posttraumatic stress disorder (FTSD) or traumatic brain injury (TBI) who report anger/irritability would show higher rates of criminal arrests. To test this, we examined data in a national survey of N = 1,388 Iraq and Afghanistan war era veterans. Results: We found that 9% of respondents reported arrests since returning home from military service. Most arrests were associated with nonviolent criminal behavior resulting in incarceration for less than 2 weeks. Unadjusted bivariate analyses revealed that veterans with probable PTSD or TBI who reported anger/irritability were more likely to be arrested than were other veterans. In multivariate analyses, arrests were found to be significantly related to younger age, male gender, having witnessed family violence, prior history of arrest, alcohol/drug misuse, and PTSD with high anger/irritability but were not significantly related to combat exposure or TBI. Conclusions: Findings show that a subset of veterans with PTSD and negative affect may be at increased risk of criminal arrest. Because arrests were more strongly linked to substance abuse and criminal history, clinicians should also consider non-PTSD factors when evaluating and treating veterans with criminal justice involvement.	[Elbogen, Eric B.] Univ N Carolina, Sch Med, Forens Psychiat Program & Clin, Dept Psychiat, Chapel Hill, NC 27599 USA; [Elbogen, Eric B.; Newton, Virginia M.; Straits-Troster, Kristy; Wagner, H. Ryan; Beckham, Jean C.] Vet Affairs Midatlantic Mental Illness Res Educ &, Durham, NC USA; [Straits-Troster, Kristy; Wagner, H. Ryan; Beckham, Jean C.] Duke Univ, Med Ctr, Durham, NC 27706 USA; [Vasterling, Jennifer J.] Vet Affairs Boston Healthcare Syst, Psychol Serv, Boston, MA USA; [Vasterling, Jennifer J.] Vet Affairs Boston Healthcare Syst, Vet Affairs Natl Ctr Posttraumat Stress Disorder, Boston, MA USA; [Vasterling, Jennifer J.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02215 USA		Elbogen, EB (corresponding author), Univ N Carolina, Sch Med, Forens Psychiat Program & Clin, Dept Psychiat, CB 7167, Chapel Hill, NC 27599 USA.	eric.elbogen@unc.edu			NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH080988, R01 MH080988] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH080988] Funding Source: NIH RePORTER		AGNEW R, 1992, CRIMINOLOGY, V30, P475, DOI 10.1111/j.1745-9125.1992.tb01113.x; Beckham JC, 2008, MIL MED, V173, P448, DOI 10.7205/MILMED.173.5.448; Bosworth H. B., 2005, J TRAUMA PRACTICE, V3, P1, DOI DOI 10.1300/J189V03N03_01; Bradley KA, 1998, J GEN INTERN MED, V13, P379, DOI 10.1046/j.1525-1497.1998.00118.x; Burt SA, 2009, AGGRESSIVE BEHAV, V35, P453, DOI 10.1002/ab.20324; Davidson JRT, 1997, PSYCHOL MED, V27, P153, DOI 10.1017/S0033291796004229; Day Andrew, 2003, Crim Behav Ment Health, V13, P45, DOI 10.1002/cbm.530; Defense Manpower Data Center, 2010, FY2009 ANN DEM PROF; Dillman D.A., 2009, INTERNET MAIL MIXED, V3rd ed.; Elbogen EB, 2009, ARCH GEN PSYCHIAT, V66, P152, DOI 10.1001/archgenpsychiatry.2008.537; FARRINGTON DP, 1973, J CRIM LAW CRIM, V64, P99, DOI 10.2307/1142661; Forbes D, 2008, J TRAUMA STRESS, V21, P142, DOI 10.1002/jts.20315; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Greenberg GA, 2009, PSYCHIAT QUART, V80, P41, DOI 10.1007/s11126-009-9092-8; Institute of Medicine, 2010, RET HOM IR AFGH PREL; King D. W., 2003, MANUAL DEPLOYMENT RI; Kroner DG, 2005, PERS INDIV DIFFER, V38, P413, DOI 10.1016/j.paid.2004.04.019; Maschi T, 2008, YOUTH VIOLENCE JUV J, V6, P136, DOI 10.1177/1541204007305527; Mason WA, 2009, SUBST USE MISUSE, V44, P1142, DOI 10.1080/10826080802495211; McCoy K, 2010, CLIN PSYCHOL REV, V30, P317, DOI 10.1016/j.cpr.2009.12.006; McDonald SD, 2009, J ANXIETY DISORD, V23, P247, DOI 10.1016/j.janxdis.2008.07.007; National Association of Drug Court Professionals, 2011, JUST VETS NAT CLEAR; Nieves K., 2000, J OFFENDER REHABIL, V30, P133, DOI DOI 10.1300/J076V30N03_07; Pandiani JA, 2003, LAW HUMAN BEHAV, V27, P289, DOI 10.1023/A:1023483807731; Roberton T, 2012, AGGRESS VIOLENT BEH, V17, P72, DOI 10.1016/j.avb.2011.09.006; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Russell R. T., 2009, N E J CRIM CIV CONF, V35, P357; Savarese VW, 2001, J TRAUMA STRESS, V14, P717, DOI 10.1023/A:1013038021175; Saxon AJ, 2001, PSYCHIATR SERV, V52, P959, DOI 10.1176/appi.ps.52.7.959; Schubert CA, 2011, J AM ACAD CHILD PSY, V50, P925, DOI 10.1016/j.jaac.2011.06.006; SHAW DM, 1987, COMPR PSYCHIAT, V28, P403, DOI 10.1016/0010-440X(87)90057-5; Skeem JL, 2011, LAW HUMAN BEHAV, V35, P110, DOI 10.1007/s10979-010-9223-7; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3; Taft CT, 2007, J ABNORM PSYCHOL, V116, P498, DOI 10.1037/0021-843X.116.3.498; Tanielian T., 2008, INVISIBLE WOUNDS WAR; U.S. Bureau of Justice Statistics, 2007, VET STAT FED PRIS 20; Vogt D, 2011, J ABNORM PSYCHOL, V120, P797, DOI 10.1037/a0023452	37	79	79	0	36	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0022-006X	1939-2117		J CONSULT CLIN PSYCH	J. Consult. Clin. Psychol.	DEC	2012	80	6					1097	1102		10.1037/a0029967			6	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	047DI	WOS:000311817500013	23025247	Green Accepted, Green Submitted			2022-02-06	
J	Covassin, T; Elbin, RJ; Sarmiento, K				Covassin, Tracey; Elbin, R. J.; Sarmiento, Kelly			Educating Coaches About Concussion in Sports: Evaluation of the CDC's "Heads Up: Concussion in Youth Sports" Initiative	JOURNAL OF SCHOOL HEALTH			English	Article						concussions; youth coaches; CDC Heads Up	2ND IMPACT; EPIDEMIOLOGY	BACKGROUND: Concussions remain a serious public health concern. It is important that persons involved in youth sports, particularly coaches, be made aware and educated on the signs and symptoms of concussion. This study assessed the perceptions of youth sport coaches who have received the Centers for Disease Control and Prevention's (CDC's) Heads Up: Concussion in Youth Sports materials in preventing, recognizing, and responding to concussions. METHODS: A 22-item survey was developed with questions pertaining to demographics, awareness of sports-related concussion, and the usefulness of the CDC's "Heads Up: Concussion in Youth Sports'' initiative and materials. A total of 340 youth sport coaches completed the survey, for a response rate of 34.0%. RESULTS: All youth sport coaches reported having the "Heads Up'' materials for approximately 6 months before completing the survey. Seventy-seven percent of youth sports coaches reported being better able to identify athletes who may have a concussion, with 50% reported having learned something new about concussion after reviewing the materials. Sixty-three percent of youth sport coaches viewed concussions as being more serious, while 72% of coaches reporting that they are now educating others on concussion. CONCLUSION: The "Heads Up'' materials demonstrated that youth sports coaches' were able to appropriately prevent, recognize, and respond to sports-related concussions after reviewing the materials. Future studies should concentrate on evaluating the impact of concussion policies, laws and media coverage on coaches' awareness and prevention, recognition, and response to concussions using a rigorous design including a control group.	[Covassin, Tracey] Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA; [Elbin, R. J.] Univ Pittsburgh, Sch Med, Dept Orthopaed Surg, UPMC Sports Med Concuss Program, Pittsburgh, PA 15261 USA; [Sarmiento, Kelly] Ctr Dis Control & Prevent, Div Injury Response, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA		Covassin, T (corresponding author), Michigan State Univ, Dept Kinesiol, 105 IM Sport Circle, E Lansing, MI 48824 USA.	covassin@msu.edu; rje13@pitt.edu; egz8@cdc.gov					Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; CANTU RC, 1992, PHYSICIAN SPORTSMED, V20, P55, DOI 10.1080/00913847.1992.11947483; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140, DOI 10.1097/JSM.0b013e31803212ae; National Center for Injury Prevention and Control, 2007, HEADS CONC HIGH SCH; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538	13	79	79	0	26	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-4391	1746-1561		J SCHOOL HEALTH	J. Sch. Health	MAY	2012	82	5					233	238		10.1111/j.1746-1561.2012.00692.x			6	Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health	923NI	WOS:000302625600005	22494094				2022-02-06	
J	Bryan, CJ; Clemans, TA; Hernandez, AM				Bryan, Craig J.; Clemans, Tracy A.; Hernandez, Ann Marie			Perceived burdensomeness, fearlessness of death, and suicidality among deployed military personnel	PERSONALITY AND INDIVIDUAL DIFFERENCES			English	Article						Suicide; Military; Interpersonal-psychological theory; Perceived burdensomeness; Acquired capability	INTERPERSONAL-PSYCHOLOGICAL THEORY; ACQUIRED CAPABILITY; BEHAVIOR; TESTS	The interpersonal-psychological theory of suicide posits that the interaction of three elements is required for lethal suicidal behaviors: the perception that one is a burden on others, the perception that one does not belong, and fearlessness about death combined with high pain tolerance (termed "acquired capability" for suicide). Although an ever expanding research base supports the theory, very limited data exist supporting the theory among military personnel, a group that has experienced a rapid increase in suicides during the past several years. The current study tests the interpersonal-psychological theory in two clinical samples of military personnel while deployed to Iraq: those seeking treatment for mild traumatic brain injury, and those seeking outpatient mental health treatment. In both samples, perceived burdensomeness and acquired capability were significantly associated with suicidality, as was their interaction term. Results partially support the interpersonal-psychological theory of suicide, and indicate that perceptions of burdensomeness combined with fearlessness about death are associated with increased suicidality among deployed military personnel. (C) 2011 Elsevier Ltd. All rights reserved.	[Bryan, Craig J.; Clemans, Tracy A.; Hernandez, Ann Marie] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA; [Bryan, Craig J.] Univ Utah, Natl Ctr Vet Studies, Salt Lake City, UT 84112 USA		Bryan, CJ (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, 7550 IH-10 W,Suite 1325, San Antonio, TX 78229 USA.	bryanc3@uthscsa.edu		Clemans, Tracy/0000-0001-5994-1508; Bryan, Craig/0000-0002-9714-0733			Anestis M., 2009, J MENTAL HLTH COUNSE, V31, P60, DOI DOI 10.17744/MEHC.31.1.U394H1470; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Blount T. H., 2010, CONV ASS BEH COGN TH; Brenner L.A., 2008, J MENTAL HEALTH COUN, V30, P211, DOI [10.17744/mehc.30.3.n6418tm72231j606, DOI 10.17744/MEHC.30.3.N6418TM72231J606]; Bryan C. J., 2010, J CLIN PSYCHOL, V15, P5, DOI [10.1002/jcIp.20726, DOI 10.1002/JCIP.20726]; Bryan CJ, 2006, J CLIN PSYCHOL, V62, P185, DOI 10.1002/jclp.20222; Bryan CJ, 2011, SUICIDE LIFE-THREAT, V41, P126, DOI 10.1111/j.1943-278X.2011.00023.x; Bryan CJ, 2010, J CLIN PSYCHOL, V66, P1044, DOI 10.1002/jclp.20703; Bryan CJ, 2010, PERS INDIV DIFFER, V48, P347, DOI 10.1016/j.paid.2009.10.023; deCatanzaro D, 1995, ETHOL SOCIOBIOL, V16, P385, DOI 10.1016/0162-3095(95)00055-0; Defense and Veterans Brain Injury Center, 2007, MIL AC CONC EV; Department of Defense Task Force on the Prevention of Suicide by Members of the Armed Forces, 2010, CHALL PROM STRENGTH; Headquarters Department of the Army, 2010, ARM HLTH PROM RISK R; Joiner T.E., 2005, WHY PEOPLE DIE SUICI; Joiner TE, 2009, J ABNORM PSYCHOL, V118, P634, DOI 10.1037/a0016500; Kang HK, 2008, JAMA-J AM MED ASSOC, V300, P652, DOI 10.1001/jama.300.6.652; Kopta SM, 2002, PSYCHOTHER RES, V12, P413, DOI 10.1093/ptr/12.4.413; LINEHAN MM, 1983, J CONSULT CLIN PSYCH, V51, P276, DOI 10.1037/0022-006X.51.2.276; Nademin E, 2008, ARCH SUICIDE RES, V12, P309, DOI 10.1080/13811110802324847; Nock MK, 2006, PSYCHIAT RES, V144, P65, DOI 10.1016/j.psychres.2006.05.010; Orbach I, 1997, J CONSULT CLIN PSYCH, V65, P646, DOI 10.1037/0022-006X.65.4.646; Osman A, 2001, ASSESSMENT, V8, P443, DOI 10.1177/107319110100800409; Ritchie EC, 2003, MIL MED, V168, P177, DOI 10.1093/milmed/168.3.177; Rudd MD., 2001, TREAT MAN PRACTITION; Selby EA, 2010, CLIN PSYCHOL REV, V30, P298, DOI 10.1016/j.cpr.2009.12.004; Tanielian T., 2008, INVISIBLE WOUNDS WAR; TROUT DL, 1980, SUICIDE LIFE-THREAT, V10, P10; Van Orden K.A., PSYCHOL ASS IN PRESS; Van Orden KA, 2008, J CONSULT CLIN PSYCH, V76, P72, DOI 10.1037/0022-006X.76.1.72; Van Orden KA, 2006, COGNITIVE THER RES, V30, P457, DOI 10.1007/s10608-006-9057-2; Weathers F.W., 1993, ANN CONV INT SOC TRA; WOZNICA JG, 1990, J PEDIATR PSYCHOL, V15, P789, DOI 10.1093/jpepsy/15.6.789	32	79	81	0	12	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0191-8869			PERS INDIV DIFFER	Pers. Individ. Differ.	FEB	2012	52	3					374	379		10.1016/j.paid.2011.10.045			6	Psychology, Social	Social Science Citation Index (SSCI)	Psychology	884ND	WOS:000299713900025					2022-02-06	
J	Lange, RT; Pancholi, S; Bhagwat, A; Anderson-Barnes, V; French, LM				Lange, Rael T.; Pancholi, Sonal; Bhagwat, Aditya; Anderson-Barnes, Victoria; French, Louis M.			Influence of poor effort on neuropsychological test performance in US military personnel following mild traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Mild traumatic brain injury; Neuropsychological testing; Poor effort; Military; Service members	SYMPTOM VALIDITY TEST; POSTTRAUMATIC-STRESS-DISORDER; SELF-REPORTED SYMPTOMS; COMPENSATION-SEEKING; COMBAT VETERANS; RESPONSE BIAS; LITIGATION STATUS; TEST FAILURE; BASE RATES; EXAGGERATION	The purpose of this study was to examine the influence of poor effort on neuropsychological test performance in military personnel following mild traumatic brain injury (MTBI). Participants were 143 U. S. service members who sustained a TBI, divided into three groups based on injury severity and performance on the Word Memory Test and four embedded markers of poor effort: MTBI-pass (n = 87), MTBI-fail (n = 21), and STBI-pass (n = 35; where STBI denotes severe TBI). Patients were evaluated at the Walter Reed Army Medical Center on average 3.9 months (SD = 3.4) post injury. The majority of the sample was Caucasian (84.6%), was male (93.0%), and had 12+ years of education (96.5%). Measures included the Personality Assessment Inventory (PAI) and 13 common neurocognitive measures. Patients in the MTBI-fail group performed worse on the majority of neurocognitive measures, followed by the Severe TBI-Pass group and the MTBI-pass group. Using a criterion of three or more low scores <10th percentile, the MTBI-fail group had the greatest rate of impairment (76.2%), followed by the Severe TBI-Pass group (34.3%) and MTBI-pass group (16.1%). On the PAI, the MTBI-fail group had higher scores on the majority of clinical scales (p < .05). There were a greater number of elevated scales (e. g., 5 or more elevated mild or higher) in the MTBI-fail group (71.4%) than in the MTBI-pass group (32.2%) and Severe TBI-Pass group (17.1%). Effort testing is an important component of postacute neuropsychological evaluations following combat-related MTBI. Those who fail effort testing are likely to be misdiagnosed as having severe cognitive impairment, and their symptom reporting is likely to be inaccurate.	[Lange, Rael T.; Pancholi, Sonal; Bhagwat, Aditya; French, Louis M.] Def & Vet Brain Injury Ctr, Bethesda, MD 20852 USA; [Lange, Rael T.; Bhagwat, Aditya; French, Louis M.] Walter Reed Natl Mil Med Ctr, Dept Orthopaed & Rehabil, Bethesda, MD USA; [Lange, Rael T.] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; [Pancholi, Sonal] Ft Belvoir Community Hosp, Ft Belvoir, VA USA; [Bhagwat, Aditya] United States Publ Hlth Serv, Bethesda, MD USA; [Anderson-Barnes, Victoria] Penn State Univ, Dept Psychol, State Coll, PA USA; [French, Louis M.] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA		Lange, RT (corresponding author), Def & Vet Brain Injury Ctr, 11300 Rockville Pike,Suite 1100, Bethesda, MD 20852 USA.	rlange@dvbic.org	french, louis/AAB-2083-2020	Merritt, Victoria/0000-0001-5683-4168; french, louis/0000-0002-9451-0604			Ardolf BR, 2007, CLIN NEUROPSYCHOL, V21, P899, DOI 10.1080/13825580600966391; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Boone KB, 1999, CLIN NEUROPSYCHOL, V13, P414; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cohen J., 2013, STAT POWER ANAL BEHA; Conners K., 2002, CONNERS CONTINUOUS P; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; Defense and Veterans Brain Injury Center, 2010, TBI NUMB; Delis D.C., 2000, CALIFORNIA VERBAL LE; DeViva JC, 2003, J TRAUMA STRESS, V16, P503, DOI 10.1023/A:1025766713188; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Dobscha SK, 2009, PAIN MED, V10, P1200, DOI 10.1111/j.1526-4637.2009.00721.x; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Fox DD, 2011, CLIN NEUROPSYCHOL, V25, P488, DOI 10.1080/13854046.2011.554443; Frueh BC, 2000, CLIN PSYCHOL REV, V20, P853, DOI 10.1016/S0272-7358(99)00015-X; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Gervais RO, 2008, CLIN NEUROPSYCHOL, V22, P1061, DOI 10.1080/13854040701756930; Gold PB, 1999, J NERV MENT DIS, V187, P680, DOI 10.1097/00005053-199911000-00005; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P, 2007, PHYS MED REHABILITAT, V18, pvi; Green P., 2003, GREENS WORD MEMORY T; Green Paul, 2007, Phys Med Rehabil Clin N Am, V18, P43, DOI 10.1016/j.pmr.2006.11.002; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; Haggerty KA, 2007, CLIN NEUROPSYCHOL, V21, P917, DOI 10.1080/13854040600899724; Heaton R. K., 2004, REVISED COMPREHENSIV; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Henry GK, 2009, CLIN NEUROPSYCHOL, V23, P153, DOI 10.1080/13854040801969524; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson G.L., 2007, BRAIN INJURY MED PRI, P333; Iverson GL, 2002, CLIN NEUROPSYCHOL, V16, P398, DOI 10.1076/clin.16.3.398.13861; Iverson GL, 2011, LITTLE BLACK BOOK OF NEUROPSYCHOLOGY: A SYNDROME-BASED APPROACH, P697, DOI 10.1007/978-0-387-76978-3_22; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kim N, 2010, ARCH CLIN NEUROPSYCH, V25, P420, DOI 10.1093/arclin/acq040; Lange RT, 2010, J CLIN EXP NEUROPSYC, V32, P961, DOI 10.1080/13803391003645657; Larrabee G.J., 2005, FORENSIC NEUROPSYCHO; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P395, DOI 10.1076/clin.17.3.395.18087; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Meyers JE, 2011, ARCH CLIN NEUROPSYCH, V26, P8, DOI 10.1093/arclin/acq083; Mitrushina MN, 1999, HDB NORMATIVE DATA N; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Morey, 1991, PERSONALITY ASSESSME; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P380, DOI 10.1080/13803390903066881; Ramchand R, 2010, J TRAUMA STRESS, V23, P59, DOI 10.1002/jts.20486; Reitan RM, 1992, TRAIL MAKING TEST MA; Root JC, 2006, J INT NEUROPSYCH SOC, V12, P688, DOI 10.1017/S1355617706060838; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Smith DW, 1996, PSYCHOL ASSESSMENT, V8, P3, DOI 10.1037/1040-3590.8.1.3; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Stevens A, 2008, PSYCHIAT RES, V157, P191, DOI 10.1016/j.psychres.2007.01.003; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; Suhr J, 2008, ARCH CLIN NEUROPSYCH, V23, P521, DOI 10.1016/j.acn.2008.05.003; Sumanti M, 2006, CLIN NEUROPSYCHOL, V20, P754, DOI 10.1080/13854040500428467; Tsanadis J, 2007, J INT NEUROPSYCH SOC, V13, P196; Tsanadis J, 2008, CLIN NEUROPSYCHOL, V22, P1080, DOI 10.1080/13854040701796928; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; West LK, 2011, J NEUROPSYCHOL, V5, P114, DOI 10.1348/174866410X521434; Whitney KA, 2010, APPL NEUROPSYCHOL, V17, P196, DOI 10.1080/09084282.2010.499787; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P145, DOI 10.1093/arclin/acp020; Wygant DB, 2007, ARCH CLIN NEUROPSYCH, V22, P489, DOI 10.1016/j.acn.2007.01.027	69	79	79	0	16	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2012	34	5					453	466		10.1080/13803395.2011.648175			14	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	936AA	WOS:000303562100002	22273465				2022-02-06	
J	Prevost, TP; Jin, G; de Moya, MA; Alam, HB; Suresh, S; Socrate, S				Prevost, Thibault P.; Jin, Guang; de Moya, Marc A.; Alam, Hasan B.; Suresh, Subra; Socrate, Simona			Dynamic mechanical response of brain tissue in indentation in vivo, in situ and in vitro	ACTA BIOMATERIALIA			English	Article						Brain indentation; Porcine; Viscoelasticity; Constitutive properties; Brain injury	MAGNETIC-RESONANCE ELASTOGRAPHY; VISCOELASTIC PROPERTIES; DURA-MATER; BEHAVIOR; SHEAR; BIOMECHANICS; INJURY; DEFORMATION; COMPRESSION; ELASTICITY	Characterizing the dynamic mechanical properties of brain tissue is deemed important for developing a comprehensive knowledge of the mechanisms underlying brain injury. The results gathered to date on the tissue properties have been mostly obtained in vitro. Learning how these results might differ quantitatively from those encountered in vivo is a critical step towards the development of biofidelic brain models. The present study provides novel and unique experimental results on, and insights into, brain biorheology in vivo, in situ and in vitro, at large deformations, in the quasi-static and dynamic regimes. The nonlinear dynamic response of the cerebral cortex was measured in indentation on the exposed frontal and parietal lobes of anesthetized porcine subjects. Load-unload cycles were applied to the tissue surface at sinusoidal frequencies of 10, 1, 0.1 and 0.01 Hz. Ramp-relaxation tests were also conducted to assess the tissue viscoelastic behavior at longer times. After euthanasia, the indentation test sequences were repeated in situ on the exposed cortex maintained in its native configuration within the cranium. Mixed gray and white matter samples were subsequently excised from the superior cortex to be subjected to identical indentation test segments in vitro within 6-7 h post mortem. The main response features (e.g. nonlinearities, rate dependencies, hysteresis and conditioning) were measured and contrasted in vivo, in situ and in vitro. The indentation response was found to be significantly stiffer in situ than in vivo. The consistent, quantitative set of mechanical measurements thereby collected provides a preliminary experimental database, which may be used to support the development of constitutive models for the study of mechanically mediated pathways leading to traumatic brain injury. (C) 2011 Acts Materialia Inc. Published by Elsevier Ltd. All rights reserved.	[Socrate, Simona] MIT, Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA; [Prevost, Thibault P.; Suresh, Subra] MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA; [Jin, Guang; de Moya, Marc A.; Alam, Hasan B.] Massachusetts Gen Hosp, Dept Surg, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02114 USA		Socrate, S (corresponding author), MIT, Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA.	ssocrate@mit.edu	Suresh, Subra/B-8289-2008	Suresh, Subra/0000-0002-6223-6831	US Army Research Office; Joint Improvised Explosive Devices Defeat Organization [W911NF-07-1-0035]; US Army Medical Research Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [GRANTT00521959]; MIT Institute for Soldier Nanotechnologies [W911NF-07-D-0004]; Ecole Nationale des Ponts et Chaussees (Universite Paris-Est, France); Singapore-MIT Alliance (SMA); Interdisciplinary Research Group on Infectious Diseases at the Singapore-MIT Alliance for Research and Technology (SMART)	This work was supported by the US Army Research Office and Joint Improvised Explosive Devices Defeat Organization, under Contract No. W911NF-07-1-0035; the US Army Medical Research Material Command GRANTT00521959 (to HBA); the MIT Institute for Soldier Nanotechnologies, under contract number W911NF-07-D-0004; Ecole Nationale des Ponts et Chaussees (Universite Paris-Est, France); the Computational Systems Biology Programme of the Singapore-MIT Alliance (SMA); and the Interdisciplinary Research Group on Infectious Diseases at the Singapore-MIT Alliance for Research and Technology (SMART). The authors are grateful to Dr. Asha Balakrishnan for designing the testing frame used in the in vivo experiments.	Atay SM, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2899575; Balakrishnan A, 2008, EXP MECH, V48, P549, DOI 10.1007/s11340-007-9087-z; BALAKRISHNAN A, 2007, THESIS MIT; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Bernick KB, 2011, ACTA BIOMATER, V7, P1210, DOI 10.1016/j.actbio.2010.10.018; Bilston LE, 1997, BIORHEOLOGY, V34, P377, DOI 10.1016/S0006-355X(98)00022-5; Cheng S, 2007, J BIOMECH, V40, P117, DOI 10.1016/j.jbiomech.2005.11.004; Coats B, 2006, J BIOMECH, V39, P2521, DOI 10.1016/j.jbiomech.2005.07.020; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Crowe LM, 2010, EMERG MED AUSTRALAS, V22, P56, DOI 10.1111/j.1742-6723.2009.01249.x; Darvish KK, 2001, MED ENG PHYS, V23, P633, DOI 10.1016/S1350-4533(01)00101-1; Franceschini G, 2006, J MECH PHYS SOLIDS, V54, P2592, DOI 10.1016/j.jmps.2006.05.004; Garo A, 2007, BIORHEOLOGY, V44, P51; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Gefen A, 2001, CLIN BIOMECH, V16, P921, DOI 10.1016/S0268-0033(01)00074-2; Green MA, 2008, NMR BIOMED, V21, P755, DOI 10.1002/nbm.1254; Hamhaber U, 2007, ACTA BIOMATER, V3, P127, DOI 10.1016/j.actbio.2006.08.007; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Hrapko M, 2006, BIORHEOLOGY, V43, P623; Hrapko M, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2907746; Hrapko M, 2008, BIORHEOLOGY, V45, P663, DOI 10.3233/BIR-2008-0512; Kerdok AE, 2006, J BIOMECH, V39, P2221, DOI 10.1016/j.jbiomech.2005.07.005; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; LAIFOOK SJ, 1976, J APPL PHYSIOL, V40, P508, DOI 10.1152/jappl.1976.40.4.508; Li LP, 2006, CLIN BIOMECH, V21, P420, DOI 10.1016/j.clinbiomech.2005.12.010; Lu YB, 2006, P NATL ACAD SCI USA, V103, P17759, DOI 10.1073/pnas.0606150103; Maikos JT, 2008, J NEUROTRAUM, V25, P38, DOI 10.1089/neu.2007.0348; Manley GT, 2006, J NEUROTRAUM, V23, P128, DOI 10.1089/neu.2006.23.128; McCracken PJ, 2005, MAGN RESON MED, V53, P628, DOI 10.1002/mrm.20388; MCCRORY P, 2005, BRIT J SPORT MED, V39, P158; McElhaney JH, 1973, PERSPECTIVES BIOMEDI, P215, DOI DOI 10.1007/978-1-349-01604-4_34; MCGARVEY KA, 1984, BIOMATERIALS, V5, P109, DOI 10.1016/0142-9612(84)90011-5; METZ H, 1970, J BIOMECH, V3, P453, DOI 10.1016/0021-9290(70)90017-5; Miga MI, 2000, J BIOMECH ENG-T ASME, V122, P354, DOI 10.1115/1.1288207; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; Miller K, 2000, J BIOMECH, V33, P1369, DOI 10.1016/S0021-9290(00)00120-2; MUTHUPILLAI R, 1995, SCIENCE, V269, P1854, DOI 10.1126/science.7569924; Nicolle Stephane, 2004, Stapp Car Crash J, V48, P239; Pervin F, 2009, J BIOMECH, V42, P731, DOI 10.1016/j.jbiomech.2009.01.023; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Prevost TP, 2011, ACTA BIOMATER, V7, P83, DOI 10.1016/j.actbio.2010.06.035; Runza M, 1999, ANESTH ANALG, V88, P1317, DOI 10.1097/00000539-199906000-00022; SCHETTINI A, 1988, AM J PHYSIOL, V255, P799; Schiavone P, 2009, MED IMAGE ANAL, V13, P673, DOI 10.1016/j.media.2009.04.001; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; Tamura A, 2007, J BIOMECH SCI ENG, V2, P115, DOI [10.1299/jbse.2.115, DOI 10.1299/JBSE.2.115]; Tamura A, 2008, J BIOMECH SCI ENG, V3, P263, DOI DOI 10.1299/JBSE.3.263; van Dommelen JAW, 2010, J MECH BEHAV BIOMED, V3, P158, DOI 10.1016/j.jmbbm.2009.09.001; Vannah WM, 1996, J REHABIL RES DEV, V33, P239; Velardi F, 2006, BIOMECH MODEL MECHAN, V5, P53, DOI 10.1007/s10237-005-0007-9; Xu L, 2007, ACTA RADIOL, V48, P327, DOI 10.1080/02841850701199967; Zheng YP, 1999, J REHABIL RES DEV, V36, P71	54	79	80	1	53	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1742-7061			ACTA BIOMATER	Acta Biomater.	DEC	2011	7	12					4090	4101		10.1016/j.actbio.2011.06.032			12	Engineering, Biomedical; Materials Science, Biomaterials	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Materials Science	853OV	WOS:000297436500001	21742064				2022-02-06	
J	Brenner, DJ; Shuryak, I; Einstein, AJ				Brenner, David J.; Shuryak, Igor; Einstein, Andrew J.			Impact of Reduced Patient Life Expectancy on Potential Cancer Risks from Radiologic Imaging	RADIOLOGY			English	Article							LONG-TERM SURVIVAL; TRAUMATIC BRAIN-INJURY; COMPUTED-TOMOGRAPHY; RADIATION-EXPOSURE; CORONARY-ANGIOGRAPHY; COLORECTAL-CANCER; UNITED-STATES; LUNG-CANCER; FOLLOW-UP; CT	Purpose: To quantify the effect of reduced life expectancy on cancer risk by comparing estimated lifetime risks of lung cancer attributable to radiation from commonly used computed tomographic (CT) examinations in patients with and those without cancer or cardiac disease. Materials and Methods: With the use of clinically determined life tables, reductions in radiation-attributable lung cancer risks were estimated for coronary CT angiographic examinations in patients with multivessel coronary artery disease who underwent coronary artery bypass graft (CABG) surgery and for surveillance CT examinations in patients treated for colon cancer. Statistical uncertainties were estimated for the risk ratios in patients who underwent CABG surgery and patients with colon cancer versus the general population. Results: Patients with decreased life expectancy had decreased radiation-associated cancer risks. For example, for a 70-year-old patient with colon cancer, the estimated reduction in lifetime radiation-associated lung cancer risk was approximately 92% for stage IV disease, versus 8% for stage 0 or I disease. For a patient who had been treated with CABG surgery, the estimated reduction in lifetime radiation-associated lung cancer risk was approximately 57% for a 55-year-old patient, versus 12% for a 75-year-old patient. Conclusion: The importance of radiation exposure in determining optimal imaging usage is much reduced for patients with markedly reduced life expectancies: Imaging justification and optimization criteria for patients with substantially reduced life expectancies should not necessarily be the same as for those with normal life expectancies.	[Brenner, David J.; Shuryak, Igor] Columbia Univ, Coll Phys & Surg, Med Ctr, Ctr Radiol Res, New York, NY 10032 USA; [Einstein, Andrew J.] Columbia Univ, Coll Phys & Surg, Med Ctr, Dept Med, New York, NY 10032 USA; [Einstein, Andrew J.] Columbia Univ, Coll Phys & Surg, Med Ctr, Dept Radiol, New York, NY 10032 USA		Brenner, DJ (corresponding author), Columbia Univ, Coll Phys & Surg, Med Ctr, Ctr Radiol Res, 630 W 168th St,VC 11-235, New York, NY 10032 USA.	djb3@columbia.edu			Spectrum Dynamics; GE HealthcareGeneral ElectricGE Healthcare; Toshiba America Medical Systems; INVIA	D.J.B. No potential conflicts of interest to disclose. I. S. No potential conflicts of interest to disclose. A.J.E. Financial activities related to the present article: none to disclose. Financial activities not related to the present article: is a consultant for the International Atomic Energy Agency; has grants or grants pending from Spectrum Dynamics and GE Healthcare; receives travel, accommodations, and/or meeting expenses from Toshiba America Medical Systems and INVIA. Other relationships: none to disclose.	Angel E, 2009, AM J ROENTGENOL, V193, P1340, DOI 10.2214/AJR.09.2886; Arias Elizabeth, 2002, Natl Vital Stat Rep, V51, P1; BEIR, 2006, HLTH RISKS EXP LOW L; Boysen G, 2009, NEUROEPIDEMIOLOGY, V33, P254, DOI 10.1159/000229780; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2005, GASTROENTEROLOGY, V129, P328, DOI 10.1053/j.gastro.2005.05.021; Brenner DJ, 2004, RADIOLOGY, V231, P440, DOI 10.1148/radiol.2312030880; Brenner DJ, 2004, RADIOLOGY, V232, P735, DOI 10.1148/radiol.2323031095; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Capewell S, 2006, HEART, V92, P1563, DOI 10.1136/hrt.2005.085399; Chau I, 2004, J CLIN ONCOL, V22, P1420, DOI 10.1200/JCO.2004.05.041; de Gonzalez AB, 2008, J MED SCREEN, V15, P153, DOI 10.1258/jms.2008.008052; de Gonzalez AB, 2010, CIRCULATION, V122, P2403, DOI 10.1161/CIRCULATIONAHA.110.941625; de Gonzalez AB, 2009, ARCH INTERN MED, V169, P2071, DOI 10.1001/archinternmed.2009.440; Desch CE, 2005, J CLIN ONCOL, V23, P8512, DOI 10.1200/JCO.2005.04.0063; Einstein AJ, 2007, JAMA-J AM MED ASSOC, V298, P317, DOI 10.1001/jama.298.3.317; Ellison Lany F, 2006, Health Rep, V17, P19; Fujii K, 2007, BRIT J RADIOL, V80, P657, DOI 10.1259/bjr/97260522; Gao GQ, 2006, ANN THORAC SURG, V82, P806, DOI 10.1016/j.athoracsur.2006.04.032; Gatsonis CA, 2011, RADIOLOGY, V258, P243, DOI 10.1148/radiol.10091808; Goske MJ, 2008, AM J ROENTGENOL, V190, P273, DOI 10.2214/AJR.07.3526; Gustafsson F, 2004, EUR HEART J, V25, P1711, DOI 10.1016/j.ehj.2004.07.007; Hall EJ, 2008, BRIT J RADIOL, V81, P362, DOI 10.1259/bjr/01948454; Hamon M, 2008, RADIOLOGY, V247, P679, DOI 10.1148/radiol.2473071132; HORNER MJ, 1975, SEER CANC STAT REV; Kim KP, 2009, ARCH INTERN MED, V169, P1188, DOI 10.1001/archinternmed.2009.162; LEW EA, 1987, T SOC ACTUARIES, V39, P107; Madonna M B, 1997, Semin Pediatr Surg, V6, P105; MAILLIE HD, 1994, HEALTH PHYS, V66, P615, DOI 10.1097/00004032-199406000-00001; Merrill RM, 2000, ANN EPIDEMIOL, V10, P88, DOI 10.1016/S1047-2797(99)00051-4; Mettler FA, 2009, RADIOLOGY, V253, P520, DOI 10.1148/radiol.2532082010; *NAT COUNC RAD PRO, 1997, 126 NAT COUNC RAD PR; *NAT CTR HLTH STAT, 1975, US DEC LIF TABL 1969, V2; Pena BMG, 2004, PEDIATRICS, V113, P24, DOI 10.1542/peds.113.1.24; REYNOLDS S, 2010, NCI CANC B, V7, P8; Shuryak I, 2010, JNCI-J NATL CANCER I, V102, P1628, DOI 10.1093/jnci/djq346; Smith-Bindman R, 2009, ARCH INTERN MED, V169, P2078, DOI 10.1001/archinternmed.2009.427; Smolarz K, 1998, NUKLEARMED, V37, P286; Stein SC, 2009, ANN EMERG MED, V53, P180, DOI 10.1016/j.annemergmed.2008.01.002; van Domburg RT, 2009, EUR HEART J, V30, P453, DOI 10.1093/eurheartj/ehn530; WARD KC, 2007, NIH PUB; Weustink AC, 2009, JACC-CARDIOVASC IMAG, V2, P816, DOI 10.1016/j.jcmg.2009.02.010	43	79	83	0	1	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	OCT	2011	261	1					193	198		10.1148/radiol.11102452			6	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	822IW	WOS:000295039000021	21771956				2022-02-06	
J	Baratz, R; Tweedie, D; Rubovitch, V; Luo, WM; Yoon, JS; Hoffer, BJ; Greig, NH; Pick, CG				Baratz, Renana; Tweedie, David; Rubovitch, Vardit; Luo, Weiming; Yoon, Jeong Seon; Hoffer, Barry J.; Greig, Nigel H.; Pick, Chaim G.			Tumor necrosis factor-alpha synthesis inhibitor, 3,6 '-dithiothalidomide, reverses behavioral impairments induced by minimal traumatic brain injury in mice	JOURNAL OF NEUROCHEMISTRY			English	Article						etanercept; neuroinflammation; thalidomide; thiothalidomide; TNF-alpha; traumatic brain injury	CLOSED-HEAD INJURY; CELL-DEATH MECHANISMS; TNF-ALPHA; MESSENGER-RNA; COGNITIVE DEFICITS; FACTOR RECEPTORS; RAT-BRAIN; THALIDOMIDE; MEMORY; SEQUELAE	Mild traumatic brain injury (mTBI) patients do not show clear structural brain defects and, in general, do not require hospitalization, but frequently suffer from long-lasting cognitive, behavioral and emotional difficulties. Although there is no current effective treatment or cure for mTBI, tumor necrosis factor-alpha (TNF-alpha), a cytokine fundamental in the systemic inflammatory process, represents a potential drug target. TNF-alpha levels increase after mTBI and may induce or exacerbate secondary damage to brain tissue. The present study evaluated the efficacy of the experimental TNF-alpha synthesis inhibitor, 3,6'-dithiothalidomide, on recovery of mice from mTBI in a closed head weight-drop model that induces an acute elevation in brain TNF-alpha and an impairment in cognitive performance, as assessed by the Y-maze, by novel object recognition and by passive avoidance paradigms at 72 h and 7 days after injury. These impairments were fully ameliorated in mice that received a one time administration of 3,6'-dithiothalidomide at either a low (28 mg/kg) or high (56 mg/kg) dose provided either 1 h prior to injury, or at 1 or 12 h post-injury. Together, these results implicate TNF-alpha as a drug target for mTBI and suggests that 3,6'-dithiothalidomide may act as a neuroprotective drug to minimize impairment.	[Greig, Nigel H.] NIA, Drug Design & Dev Sect, Neurosci Lab, Intramural Res Program,NIH, Baltimore, MD 21224 USA; [Baratz, Renana; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Hoffer, Barry J.] Natl Inst Drug Abuse, Cellular Neurobiol Branch, Intramural Res Program, NIH, Baltimore, MD USA; [Hoffer, Barry J.] Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH USA		Greig, NH (corresponding author), NIA, Drug Design & Dev Sect, Neurosci Lab, Intramural Res Program,NIH, BRC Room 05C220,251 Bayview Blvd, Baltimore, MD 21224 USA.	greign@grc.nia.nih.gov			Sackler School of Medicine, Tel-Aviv University; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); National Institute on Drug Abuse, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA); NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000311] Funding Source: NIH RePORTER	This research was supported in part by the Sackler School of Medicine, Tel-Aviv University, and the Intramural Research Programs of both the National Institute on Aging and National Institute on Drug Abuse, National Institutes of Health. This work was performed in partial fulfillment of the requirements for a Ph.D. degree of Renana Baratz, Sackler Faculty of Medicine, Tel Aviv University, Israel.	Andersson M, 2006, ANN RHEUM DIS, V65, P1237, DOI 10.1136/ard.2006.055194; Aragon-Ching JB, 2007, RECENT PAT ANTI-CANC, V2, P167, DOI 10.2174/157489207780832478; Baratz R, 2010, J NEUROTRAUM, V27, P555, DOI 10.1089/neu.2009.0891; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; DELLU F, 1992, BRAIN RES, V588, P132, DOI 10.1016/0006-8993(92)91352-F; Dix SL, 1999, BEHAV BRAIN RES, V99, P191, DOI 10.1016/S0166-4328(98)00079-5; Edut S, 2011, PSYCHOPHARMACOLOGY, V214, P877, DOI 10.1007/s00213-010-2098-y; Esposito E, 2009, CURR MED CHEM, V16, P3152, DOI 10.2174/092986709788803024; Frank-Cannon TC, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-47; Frankola KA, 2011, CNS NEUROL DISORD-DR, V10, P391; Garner Jeff, 2007, Anesthesiol Clin, V25, P147; Ghajar J, 2008, NEUROREHAB NEURAL RE, V22, P217, DOI 10.1177/1545968308315600; Greig NH, 2004, ACTA NEUROBIOL EXP, V64, P1; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Hyakkoku K, 2009, NEUROSCIENCE, V159, P760, DOI 10.1016/j.neuroscience.2008.12.043; Israelsson C, 2009, J NEUROTRAUM, V26, P1307, DOI [10.1089/neu.2008.0676, 10.1089/neu.2008-0676]; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Khera TK, 2010, PROG RETIN EYE RES, V29, P610, DOI 10.1016/j.preteyeres.2010.08.003; Kiraly MA, 2007, THESCIENTIFICWORLDJO, V7, P1768, DOI 10.1100/tsw.2007.269; Knight R, 2005, SEMIN ONCOL, V32, pS24, DOI 10.1053/j.seminoncol.2005.06.018; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Koopmans GC, 2009, EXP NEUROL, V216, P490, DOI 10.1016/j.expneurol.2009.01.005; Lecca D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003579; Lee CJ, 2007, SPINAL CORD, V45, P149, DOI 10.1038/sj.sc.3101931; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Luo WM, 2008, SYNTHESIS-STUTTGART, P3415, DOI 10.1055/s-0028-1083179; McTighe SM, 2010, SCIENCE, V330, P1408, DOI 10.1126/science.1194780; Melchert M, 2007, INT J BIOCHEM CELL B, V39, P1489, DOI 10.1016/j.biocel.2007.01.022; Messier C, 1997, NEUROBIOL LEARN MEM, V67, P172, DOI 10.1006/nlme.1996.3755; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; MOREIRA AL, 1993, J EXP MED, V177, P1675, DOI 10.1084/jem.177.6.1675; Pan WH, 2003, EXP BRAIN RES, V149, P195, DOI 10.1007/s00221-002-1355-7; Patil CS, 2008, MOL THER, V16, P1657, DOI 10.1038/mt.2008.163; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Reale M, 2009, MINI-REV MED CHEM, V9, P1229, DOI 10.2174/138955709789055199; Reyes-Alva HJ, 2009, ACTA NEUROBIOL EXP, V69, P494; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; SAMPAIO EP, 1991, J EXP MED, V173, P699, DOI 10.1084/jem.173.3.699; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shannon EJ, 1996, IMMUNOPHARM IMMUNOT, V18, P59, DOI 10.3109/08923979609007110; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stamou P, 2010, CURR DIR AUTOIMMUN, V11, P61, DOI 10.1159/000289197; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; Tadesse A, 2006, IMMUNOPHARM IMMUNOT, V28, P431, DOI 10.1080/08923970600928023; Tansey MG, 2010, NEUROBIOL DIS, V37, P491, DOI 10.1016/j.nbd.2009.12.004; Tansey MG, 2009, DRUG DISCOV TODAY, V14, P1082, DOI 10.1016/j.drudis.2009.10.002; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Taylor PC, 2010, CURR OPIN PHARMACOL, V10, P308, DOI 10.1016/j.coph.2010.01.005; Teo SK, 2004, CLIN PHARMACOKINET, V43, P311, DOI 10.2165/00003088-200443050-00004; Tobinick E, 2010, EXPERT REV NEUROTHER, V10, P985, DOI 10.1586/ERN.10.52; TWEEDIE D, OPEN BIOCH IN PRESS; Tweedie D, 2007, CURR ALZHEIMER RES, V4, P378, DOI 10.2174/156720507781788873; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Tweedie D, 2009, J NEUROSCI METH, V183, P182, DOI 10.1016/j.jneumeth.2009.06.034; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Yan YP, 2009, BRAIN RES, V1288, P116, DOI 10.1016/j.brainres.2009.06.073; Yang JS, 2010, J NEUROTRAUM, V27, P1037, DOI 10.1089/neu.2009.1229; Zhou QH, 2011, DRUG METAB DISPOS, V39, P71, DOI 10.1124/dmd.110.036012; Zhu XX, 2003, J MED CHEM, V46, P5222, DOI 10.1021/jm030152f; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	71	79	79	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	SEP	2011	118	6					1032	1042		10.1111/j.1471-4159.2011.07377.x			11	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	820JB	WOS:000294900600009	21740439	Bronze, Green Accepted			2022-02-06	
J	Novakovic-Agopian, T; Chen, AJW; Rome, S; Abrams, G; Castelli, H; Rossi, A; McKim, R; Hills, N; D'Esposito, M				Novakovic-Agopian, Tatjana; Chen, Anthony J. -W.; Rome, Scott; Abrams, Gary; Castelli, Holli; Rossi, Annemarie; McKim, Ryan; Hills, Nancy; D'Esposito, Mark			Rehabilitation of Executive Functioning With Training in Attention Regulation Applied to Individually Defined Goals: A Pilot Study Bridging Theory, Assessment, and Treatment	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						attention regulation training; brain injury; cognitive rehabilitation; executive control; functional performance; metacognitive training	TRAUMATIC BRAIN-INJURY; COGNITIVE REHABILITATION; FRONTAL-LOBE; INTELLIGENCE; MANAGEMENT; BEHAVIOR; DEFICITS; STROKE	Objective: To assess feasibility and effects of training in goal-oriented attentional self-regulation for patients with brain injury and chronic executive dysfunction. Participants: Sixteen individuals with chronic brain injury and mild to moderate executive dysfunction. Design: Participants were divided into 2 groups: one group completed goal-oriented attentional self-regulation training during the first 5 weeks, followed by a brief (2-hour) educational instruction session as a control midway through the second 5 weeks; the other group participated in reverse order. Measures: Neuropsychological and functional performance assessed at baseline and at weeks 5 and 10. Results: Participants found training in goal-oriented attentional self-regulation engaging, incorporated some trained strategies into daily life, and reported subjective improvements in personal functioning. At week 5, participants who completed goals training significantly improved on tests of attention and executive function and had fewer functional task failures, while performance did not change after educational instruction. At week 10, participants who crossed over from educational instruction to goals training also significantly improved on attention and executive function tests. Participants who crossed from goals training to educational instruction maintained their week 5 gains. Conclusions: Training in goal-oriented attentional self-regulation is theoretically driven and feasible in a research setting. Pilot results suggest improvements in cognitive and functional domains targeted by the intervention.	[Novakovic-Agopian, Tatjana; Chen, Anthony J. -W.; Abrams, Gary; Rossi, Annemarie; McKim, Ryan] Vet Adm Med Ctr, San Francisco, CA 94121 USA; [Novakovic-Agopian, Tatjana; Chen, Anthony J. -W.; D'Esposito, Mark] Vet Adm No Calif Hlth Care Syst, Martinez, CA USA; [Novakovic-Agopian, Tatjana; Rome, Scott; Castelli, Holli; Rossi, Annemarie] Calif Pacific Reg Rehabil Ctr, San Francisco, CA USA; [Novakovic-Agopian, Tatjana; Chen, Anthony J. -W.; Abrams, Gary; Hills, Nancy] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Chen, Anthony J. -W.; D'Esposito, Mark] Univ Calif Berkeley, Berkeley, CA 94720 USA		Novakovic-Agopian, T (corresponding author), SFVA Med Ctr, 4150 Clement St,Mail Code 127, San Francisco, CA 94121 USA.	tna@cns-site.com			Office of Research and Development Rehabilitation R&D Service Department of Veterans AffairsUS Department of Veterans Affairs; California Pacific Medical Center Foundation	This material is based upon the work supported by the Office of Research and Development Rehabilitation R&D Service Department of Veterans Affairs, and the California Pacific Medical Center Foundation.	Benedict, 2001, HOPKINS VERBAL LEARN; BENEDICT R, 1997, BRIEF VISUOSPATIALME; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Chen AJW, 2006, J HEAD TRAUMA REHAB, V21, P107, DOI 10.1097/00001199-200603000-00004; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; D'Esposito M, 2006, PROG BRAIN RES, V157, P123, DOI 10.1016/S0079-6123(06)57008-6; Delis DC., 2001, DELIS KAPLAN EXECUTI; DESPOSITO M, 2006, NEURAL REHABILITATIO, P475; Dewar BK, 2009, NEUROPSYCHOL REHABIL, V19, P383, DOI 10.1080/09602010802278152; DUNCAN J, 1995, NEUROPSYCHOLOGIA, V33, P261, DOI 10.1016/0028-3932(94)00124-8; Duncan J, 1996, COGNITIVE PSYCHOL, V30, P257, DOI 10.1006/cogp.1996.0008; DZURILLA TJ, 1971, J ABNORM PSYCHOL, V78, P107, DOI 10.1037/h0031360; Evans J, 2005, EFFECTIVENESS REHABI, P247; Evans JJ, 2001, BRAIN DAM B, P209; Fischer S, 2004, BRAIN INJURY, V18, P547, DOI 10.1080/02699050310001645793; Hart T, 2009, NEUROPSYCHOL REHABIL, V19, P824, DOI 10.1080/09602010902995945; Heaton RK, 2004, COMPREHENSIVE NORMS; Hecaen H., 1978, HUMAN NEUROPSYCHOLOG; Hyndman D, 2003, DISABIL REHABIL, V25, P817, DOI 10.1080/0963828031000122221; Kabat-Zinn J., 1990, FULL CATASTROPHE LIV; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Levine B., 2008, COGNITIVE NEUROREHAB, V2nd, P464, DOI [10.1017/CBO9781316529898.033, DOI 10.1017/CBO9781316529898.033]; Levine B, 2007, J INT NEUROPSYCH SOC, V13, P143, DOI 10.1017/S1355617707070178; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; Miller BT, 2005, NEURON, V48, P535, DOI 10.1016/j.neuron.2005.11.002; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Miotto EC, 2009, NEUROPSYCHOL REHABIL, V19, P517, DOI 10.1080/09602010802332108; Nezu CM., 2007, SOLVING LIFES PROBLE; Novakovic-Agopian T, 1999, ARCH CLIN NEUROPSYCH, V14, P640, DOI 10.1016/S0887-6177(99)80044-4; Ozdemir F, 2001, AM J PHYS MED REHAB, V80, P410, DOI 10.1097/00002060-200106000-00003; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; Prigatano GP, 1999, ARCH PHYS MED REHAB, V80, P77, DOI 10.1016/S0003-9993(99)90311-8; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Robertson I., 1996, GOAL MANAGEMENT TRAI; Schweizer TA, 2008, NEUROREHAB NEURAL RE, V22, P72, DOI 10.1177/1545968307305303; Sohlberg McKay Moore, 2005, Seminars in Speech and Language, V26, P268, DOI 10.1055/s-2005-922105; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; Sohlberg MM, 2003, J MED SPEECH-LANG PA, V11, pXIX; Stuss DT, 1988, CLIN NEUROPSYCHOL, V2, P246, DOI [DOI 10.1080/13854048808520107, 10.1080/13854048808520107]; TATEMICHI TK, 1994, J NEUROL NEUROSUR PS, V57, P202, DOI 10.1136/jnnp.57.2.202; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wilson BA, 2008, ANNU REV CLIN PSYCHO, V4, P141, DOI 10.1146/annurev.clinpsy.4.022007.141212	46	79	79	2	39	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2011	26	5					325	338		10.1097/HTR.0b013e3181f1ead2			14	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	814VO	WOS:000294485500001	21169860				2022-02-06	
J	Zanelli, S; Buck, M; Fairchild, K				Zanelli, S.; Buck, M.; Fairchild, K.			Physiologic and pharmacologic considerations for hypothermia therapy in neonates	JOURNAL OF PERINATOLOGY			English	Article						hypothermia; hypoxic-ischemic encephalopathy; neonate; pharmacologic effect; physiology effect; rewarming	WHOLE-BODY HYPOTHERMIA; HYPOXIC-ISCHEMIC ENCEPHALOPATHY; MILD SYSTEMIC HYPOTHERMIA; CEREBRAL-BLOOD-FLOW; SEVERE HEAD-INJURY; CARDIOPULMONARY BYPASS; MODERATE HYPOTHERMIA; CYTOKINE PRODUCTION; PLATELET-AGGREGATION; ASPHYXIATED INFANTS	With mounting evidence that hypothermia is neuroprotective in newborns with hypoxic-ischemic encephalopathy (HIE), an increasing number of centers are offering this therapy. Hypothermia is associated with a wide range of physiologic changes affecting every organ system, and awareness of these effects is essential for optimum patient management. Lowering the core temperature also alters pharmacokinetic and pharmacodynamic properties of medications commonly used in asphyxiated neonates, necessitating close attention to drug efficacy and side effects. Rewarming introduces additional risks and challenges as the hypothermia-associated physiologic and pharmacologic changes are reversed. In this review we provide an organ system-based assessment of physiologic changes associated with hypothermia. We also summarize evidence from randomized controlled trials showing lack of serious adverse effects of moderate hypothermia therapy in term and near-term newborns with moderate-to-severe HIE. Finally, we review the effects of hypothermia on drug metabolism and clearance based on studies in animal models and human adults, and limited data from neonates. Journal of Perinatology (2011) 31, 377-386; doi:10.1038/jp.2010.146; published online 23 December 2010	[Zanelli, S.; Buck, M.; Fairchild, K.] Univ Virginia, Dept Pediat, Charlottesville, VA 22903 USA; [Buck, M.] Univ Virginia, Dept Pharm, Charlottesville, VA 22903 USA		Zanelli, S (corresponding author), Univ Virginia, Dept Pediat, Box 800386, Charlottesville, VA 22903 USA.	sz5d@virginia.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD051609] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08 HD051609] Funding Source: Medline		AKRIOTIS V, 1985, J LEUKOCYTE BIOL, V37, P51, DOI 10.1002/jlb.37.1.51; Alderson P, 2004, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001048.pub2, DOI 10.1002/14651858.CD001048.PUB2]; Alston Theodore A, 2004, Int Anesthesiol Clin, V42, P73, DOI 10.1097/00004311-200404240-00008; Ancora G, 2009, BRAIN DEV-JPN, V31, P442, DOI 10.1016/j.braindev.2008.06.003; Arpino PA, 2008, PHARMACOTHERAPY, V28, P102, DOI 10.1592/phco.28.1.102; Azzopardi D, 2008, BMC PEDIATR, V8, DOI 10.1186/1471-2431-8-17; Azzopardi D, 2000, PEDIATRICS, V106, P684, DOI 10.1542/peds.106.4.684; Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Bacher A, 2005, INTENS CARE MED, V31, P24, DOI 10.1007/s00134-004-2369-3; Battin M, 2004, PEDIATRICS, V114, P1369, DOI 10.1542/peds.2004-1695; Battin MR, 2009, PEDIATRICS, V123, P1031, DOI 10.1542/peds.2008-1610; BENUMOF JL, 1977, J APPL PHYSIOL, V42, P56, DOI 10.1152/jappl.1977.42.1.56; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bhagat H, 2006, J CLIN NEUROSCI, V13, P953, DOI 10.1016/j.jocn.2005.09.018; Bisson Jamie, 2006, Nurs Crit Care, V11, P232, DOI 10.1111/j.1478-5153.2006.00177.x; BODIS J, 1984, Acta Paediatrica Hungarica, V25, P343; Boldt J, 1996, ANN THORAC SURG, V62, P130, DOI 10.1016/0003-4975(96)00239-1; Burnsed J, 2011, J CLIN NEUROPHYSIOL, V28, P10, DOI 10.1097/WNP.0b013e318205134b; Caldwell JE, 2000, ANESTHESIOLOGY, V92, P84, DOI 10.1097/00000542-200001000-00018; Chakkarapani E, 2009, ACTA PAEDIATR, V98, P1844, DOI 10.1111/j.1651-2227.2009.01470.x; CLARDY CW, 1985, PEDIATR INFECT DIS J, V4, P379, DOI 10.1097/00006454-198507000-00009; Cochran A, 2003, J TRAUMA, V55, P1035, DOI 10.1097/01.TA.0000031175.96507.48; CURRY DL, 1970, ENDOCRINOLOGY, V87, P750, DOI 10.1210/endo-87-4-750; Doherty DR, 2009, CIRCULATION, V119, P1492, DOI 10.1161/CIRCULATIONAHA.108.791384; Eicher DJ, 2005, PEDIATR NEUROL, V32, P18, DOI 10.1016/j.pediatrneurol.2004.06.015; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; Fairchild K, 2010, J PERINATOL, V30, P324, DOI 10.1038/jp.2009.168; Fairchild KD, 2000, J INTERF CYTOK RES, V20, P1049, DOI 10.1089/107999000750053708; Filippi L, 2009, EPILEPSIA, V50, P2355, DOI 10.1111/j.1528-1167.2009.02302.x; Frank SM, 2003, CLIN SCI, V104, P503, DOI 10.1042/CS20020256; FRANK SM, 1993, ANESTHESIOLOGY, V78, P468, DOI 10.1097/00000542-199303000-00010; FRANK SM, 1995, ANESTHESIOLOGY, V82, P83, DOI 10.1097/00000542-199501000-00012; Fritz HG, 2005, ANESTH ANALG, V100, P996, DOI 10.1213/01.ANE.0000146517.17910.54; Fukuoka N, 2004, RESUSCITATION, V60, P225, DOI 10.1016/j.resuscitation.2003.09.017; GAMBASSI G, 1994, CARDIOVASC RES, V28, P391, DOI 10.1093/cvr/28.3.391; Gebauer CM, 2006, PEDIATRICS, V117, P843, DOI 10.1542/peds.2004-1587; Gerrits LC, 2005, PEDIATR RES, V57, P342, DOI 10.1203/01.PDR.0000150801.61188.5F; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; GREELEY WJ, 1989, CIRCULATION, V80, P209; Grether JK, 1997, JAMA-J AM MED ASSOC, V278, P207, DOI 10.1001/jama.278.3.207; Groenendaal F, 2009, PEDIATRICS, V123, P170, DOI 10.1542/peds.2008-1955; Groenendaal F, 2009, EARLY HUM DEV, V85, P73, DOI 10.1016/j.earlhumdev.2008.11.006; Guignard JP, 1997, ACTA PAEDIATR, V86, P1040, DOI 10.1111/j.1651-2227.1997.tb14802.x; Hall MW, 2002, AM J HEMATOL, V69, P45, DOI 10.1002/ajh.10018; Hallberg B, 2010, ACTA PAEDIATR, V99, P531, DOI 10.1111/j.1651-2227.2009.01653.x; Hallberg B, 2009, ACTA PAEDIATR, V98, P942, DOI 10.1111/j.1651-2227.2009.01303.x; Heinius G, 2002, J SURG RES, V108, P7, DOI 10.1006/jsre.2002.6470; HELMAN A, 1984, ENDOCRINOLOGY, V115, P1722, DOI 10.1210/endo-115-5-1722; Holzer M, 2002, NEW ENGL J MED, V346, P549; Horan M, 2007, EARLY HUM DEV, V83, P217, DOI 10.1016/j.earlhumdev.2006.05.016; Horan M, 2007, EARLY HUM DEV, V83, P69, DOI 10.1016/j.earlhumdev.2006.05.004; Horan MR, 2004, J PEDIATR-US, V144, P301, DOI 10.1016/j.jpeds.2003.11.034; Horn A, 2009, PEDIATRICS, V123, pE1090, DOI 10.1542/peds.2007-3766; Iida Y, 2001, THER DRUG MONIT, V23, P192, DOI 10.1097/00007691-200106000-00002; Inder TE, 2004, J PEDIATR-US, V145, P835, DOI 10.1016/j.jpeds.2004.07.034; Iyer P, 1996, CRIT CARE MED, V24, P507, DOI 10.1097/00003246-199603000-00023; Jacobs SE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub3; KADAR D, 1982, CAN ANAESTH SOC J, V29, P16, DOI 10.1007/BF03007942; Karlsson M, 2008, PEDIATR RES, V64, P74, DOI 10.1203/PDR.0b013e318174efdd; Kawamura S, 2000, ACTA NEUROCHIR, V142, P1117, DOI 10.1007/s007010070039; Keller E, 2000, Neurosurg Focus, V8, pe4; Kimura A, 2002, CRIT CARE MED, V30, P1499, DOI 10.1097/00003246-200207000-00017; KOCHS E, 1995, J NEUROSURG ANESTH, V7, P222, DOI 10.1097/00008506-199507000-00022; KOREN G, 1985, CRIT CARE MED, V13, P844, DOI 10.1097/00003246-198510000-00014; KOREN G, 1987, EUR J CLIN PHARMACOL, V32, P373, DOI 10.1007/BF00543972; Kuwagata Y, 1999, J TRAUMA, V47, P666, DOI 10.1097/00005373-199910000-00010; Laptook A, 2008, PEDIATRICS, V122, P491, DOI 10.1542/peds.2007-1673; Laptook AR, 2002, CLIN PERINATOL, V29, P623, DOI 10.1016/S0095-5108(02)00057-X; Liu X, 2009, PEDIATRICS, V124, P310, DOI 10.1542/peds.2008-2942; MACNAB AJ, 1990, CRIT CARE MED, V18, P1066, DOI 10.1097/00003246-199010000-00003; Mattu A, 2002, AM J EMERG MED, V20, P314, DOI 10.1053/ajem.2002.32633; McGowan JE, 2006, CLIN PERINATOL, V33, P183, DOI 10.1016/j.clp.2005.11.007; Meek JH, 1999, ARCH DIS CHILD-FETAL, V81, pF110, DOI 10.1136/fn.81.2.F110; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; MICHENFELDER JD, 1968, ANESTHESIOLOGY, V29, P1107, DOI 10.1097/00000542-196811000-00005; Ohri SK, 1997, ANN THORAC SURG, V64, P163, DOI 10.1016/S0003-4975(97)00290-7; OKADA M, 1984, J ELECTROCARDIOL, V17, P123, DOI 10.1016/S0022-0736(84)81085-7; Parikh NA, 2009, J PERINATOL, V29, P143, DOI 10.1038/jp.2008.184; Polderman KH, 2009, CRIT CARE MED, V37, P1101, DOI 10.1097/CCM.0b013e3181962ad5; Polderman KH, 2001, J NEUROSURG, V94, P697, DOI 10.3171/jns.2001.94.5.0697; POULOS ND, 1991, J TRAUMA, V31, P996, DOI 10.1097/00005373-199107000-00020; Powell RW, 1999, J PEDIATR SURG, V34, P193, DOI 10.1016/S0022-3468(99)90255-5; PUIG MM, 1987, BRIT J ANAESTH, V59, P1459, DOI 10.1093/bja/59.11.1459; Roelfsema V, 2005, EXP PHYSIOL, V90, P545, DOI 10.1113/expphysiol.2005.030320; Roelfsema V, 2005, J SOC GYNECOL INVEST, V12, P232, DOI 10.1016/j.jsgi.2005.01.025; ROHRER MJ, 1992, CRIT CARE MED, V20, P1402, DOI 10.1097/00003246-199210000-00007; Roka A, 2008, PEDIATRICS, V121, pE844, DOI 10.1542/peds.2007-1987; Roka A, 2007, ACTA PAEDIATR, V96, P1118, DOI 10.1111/j.1651-2227.2007.00361.x; Royl G, 2008, NEUROIMAGE, V40, P1523, DOI 10.1016/j.neuroimage.2008.01.041; Rutherford MA, 2005, PEDIATRICS, V116, P1001, DOI 10.1542/peds.2005-0328; Rutherford M, 2010, LANCET NEUROL, V9, P39, DOI 10.1016/S1474-4422(09)70295-9; Sakoh M, 2003, AM J PHYSIOL-HEART C, V285, pH17, DOI 10.1152/ajpheart.01112.2002; Salman H, 2000, ACTA PHYSIOL SCAND, V168, P431; Sarkar S, 2009, J PERINATOL, V29, P558, DOI 10.1038/jp.2009.37; Satas S, 2000, BIOL NEONATE, V77, P50; Saur J, 2008, IN VIVO, V22, P143; Shah PS, 2007, ARCH PEDIAT ADOL MED, V161, P951, DOI 10.1001/archpedi.161.10.951; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Shankaran S, 2008, PEDIATRICS, V122, pE791, DOI 10.1542/peds.2008-0456; Speziale G, 2000, J CARDIOVASC SURG, V41, P819; STAYER SA, 1994, ANESTH ANALG, V79, P834; Thoren A, 2001, ANESTH ANALG, V92, P5, DOI 10.1097/00000539-200101000-00003; Thoresen M, 2001, PEDIATR RES, V50, P405, DOI 10.1203/00006450-200109000-00017; Thoresen M, 2000, PEDIATRICS, V106, P92, DOI 10.1542/peds.106.1.92; Thoresen M, 2003, PAS, P137; Thoresen M, 2010, PEDIATRICS, V126, pE131, DOI 10.1542/peds.2009-2938; Thoresen M, 2008, CLIN PERINATOL, V35, P749, DOI 10.1016/j.clp.2008.07.018; Toet MC, 2006, PEDIATRICS, V117, P333, DOI 10.1542/peds.2005-0987; Tooley JR, 2003, ANN NEUROL, V53, P65, DOI 10.1002/ana.10402; Tortorici MA, 2007, CRIT CARE MED, V35, P2196, DOI 10.1097/01.CCM.0000281517.97507.6E; VALERI CR, 1987, ANN SURG, V205, P175, DOI 10.1097/00000658-198702000-00012; VANBEL F, 1993, PEDIATRICS, V92, P365; Watts DD, 1998, J TRAUMA, V44, P846, DOI 10.1097/00005373-199805000-00017; Wyatt JS, 2007, PEDIATRICS, V119, P912, DOI 10.1542/peds.2006-2839; Xavier RG, 2007, THROMB HAEMOSTASIS, V98, P1266, DOI 10.1160/TH07-03-0189; Zhou WH, 2010, J PEDIATR-US, V157, P367, DOI 10.1016/j.jpeds.2010.03.030	116	79	82	3	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0743-8346	1476-5543		J PERINATOL	J. Perinatol.	JUN	2011	31	6					377	386		10.1038/jp.2010.146			10	Obstetrics & Gynecology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Obstetrics & Gynecology; Pediatrics	769NX	WOS:000291024300001	21183927	Bronze, Green Accepted			2022-02-06	
J	Meehan, WP				Meehan, William P., III			Medical Therapies for Concussion	CLINICS IN SPORTS MEDICINE			English	Article						Concussion; Mild traumatic brain injury; Head injury; Trauma; Injury; Sports	TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; RANDOMIZED CONTROLLED-TRIAL; SCHOOL FOOTBALL PLAYERS; POSTTRAUMATIC HEADACHE; EARLY INTERVENTION; ATTENTION DEFICITS; AMANTADINE; METHYLPHENIDATE; RECOVERY	Clinicians who manage sport-related concussions have excellent guidelines by which most injuries can be managed. Because sport-related concussions typically resolve within a short time frame, most can be managed with physical and cognitive rest alone. However, clinicians who specialize in the assessment and management of this diagnosis encounter patients with prolonged recovery courses, persistent symptoms, and significant deficits in cognitive functioning. These patients require more involved therapy, which may include additional education, academic accommodations, physical therapy, cognitive rehabilitation, and medication. This article reviews the main medical therapies for the management of concussive brain injury.	[Meehan, William P., III] Childrens Hosp Boston, Sports Concuss Clin, Div Sports Med, Dept Orthoped, Boston, MA 02115 USA; [Meehan, William P., III] Childrens Hosp Boston, Dept Med, Div Emergency Med, Boston, MA 02115 USA		Meehan, WP (corresponding author), Childrens Hosp Boston, Sports Concuss Clin, Div Sports Med, Dept Orthoped, 319 Longwood Ave, Boston, MA 02115 USA.	william.meehan@childrens.harvard.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 HD040128-06A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER	This manuscript was supported by the National Institutes of Health through a T32 Award to Dr Meehan (T32 HD040128-06A1).	[Anonymous], 2003, J NEUROPSYCH CLIN N, V15, P383, DOI 10.1176/appi.neuropsych.15.3.383; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Beers SR, 2005, J HEAD TRAUMA REHAB, V20, P450, DOI 10.1097/00001199-200509000-00006; Chew E, 2009, J REHABIL RES DEV, V46, P851, DOI 10.1682/JRRD.2008.09.0120; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Couch JR, 2001, HEADACHE, V41, P559, DOI 10.1046/j.1526-4610.2001.041006559.x; DINAN TG, 1992, ACTA PSYCHIAT SCAND, V85, P292, DOI 10.1111/j.1600-0447.1992.tb01472.x; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; Ganong W.F., 1999, REV MED PHYSL; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Green LB, 2004, AM J PHYS MED REHAB, V83, P893, DOI 10.1097/01.PHM.0000143400.15346.C8; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; Ho MR, 1997, ARCH CLIN NEUROPSYCH, V12, P1; Horsfield SA, 2002, INT J PSYCHIAT MED, V32, P337, DOI 10.2190/KQ48-XT0L-2H14-5UMV; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; Kaye NS, 2003, J NEUROPSYCHIATRY CL, V15, P383; Kraus MF, 2005, BRAIN INJURY, V19, P471, DOI 10.1080/02699050400025059; LABEL L S, 1991, Neurology, V41, P247; Lane Judy C., 2002, Curr Treat Options Neurol, V4, P89, DOI 10.1007/s11940-002-0007-3; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Lee LK, 2007, PEDIATR EMERG CARE, V23, P580, DOI 10.1097/PEC.0b013e31813444ea; Lenaerts Marc E, 2004, Curr Treat Options Neurol, V6, P507, DOI 10.1007/s11940-004-0008-5; Leone H, 2005, J CLIN PHARM THER, V30, P101, DOI 10.1111/j.1365-2710.2005.00628.x; LEVIN HS, 1991, J NEUROL SCI, V103, pS39; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Maldonado MD, 2007, J PINEAL RES, V42, P1, DOI 10.1111/j.1600-079X.2006.00376.x; Masanic CA, 2001, ARCH PHYS MED REHAB, V82, P896, DOI 10.1053/apmr.2001.23833; MCBEATH JG, 1994, HEADACHE, V34, P148, DOI 10.1111/j.1526-4610.1994.hed3403148.x; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; MITTENBERG W, 1994, BRAIN INJURY, V8, P429, DOI 10.3109/02699059409150994; Morey CE, 2003, BRAIN INJURY, V17, P809, DOI 10.1080/0269905031000088586; Napolitano E, 2005, MED SCI MONITOR, V11, pRA212; Packard RC, 1999, J HEAD TRAUMA REHAB, V14, P9, DOI 10.1097/00001199-199902000-00004; Packard RC, 2000, HEADACHE, V40, P736, DOI 10.1046/j.1526-4610.2000.00128.x; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; Reddy CC, 2004, BRAIN INJURY PROFESS, V4, P24; Salazar AM, 2002, J NEUROL NEUROSUR PS, V73, P239, DOI 10.1136/jnnp.73.3.239; Samantaray S, 2009, J PINEAL RES, V47, P134, DOI 10.1111/j.1600-079X.2009.00703.x; SARAN A, 1988, INT J PSYCHIAT MED, V18, P75, DOI 10.2190/15AH-JB7Q-U94T-JEAF; Sawyer E, 2008, ANN PHARMACOTHER, V42, P247, DOI 10.1345/aph.1K284; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schneider WN, 1999, BRAIN INJURY, V13, P863; Siddall ORM, 2005, ANN PHARMACOTHER, V39, P1309, DOI 10.1345/aph.1E637; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Silver JM, 2009, BRAIN INJURY, V23, P123, DOI 10.1080/02699050802649696; Sivan M, 2010, CLIN REHABIL, V24, P110, DOI 10.1177/0269215509343234; Tenovuo O, 2005, PROG NEURO-PSYCHOPH, V29, P61, DOI 10.1016/j.pnpbp.2004.10.006; Tenovuo O, 2006, CURR OPIN NEUROL, V19, P528, DOI 10.1097/WCO.0b013e328010944f; Tsaousides T, 2009, MT SINAI J MED, V76, P173, DOI 10.1002/msj.20099; TYLER GS, 1980, HEADACHE, V20, P213, DOI 10.1111/j.1526-4610.1980.hed2004213.x; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Walker W, 2004, BRAIN INJURY, V18, P739, DOI 10.1080/02699050310001646224; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; WEISS HD, 1991, HEADACHE, V31, P451, DOI 10.1111/j.1526-4610.1991.hed3107451.x; Whelan F J, 2000, Ann Clin Psychiatry, V12, P131; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Williams SE, 1998, J HEAD TRAUMA REHAB, V13, P73, DOI 10.1097/00001199-199806000-00007; Williams SE, 2007, BRAIN INJURY, V21, P885, DOI 10.1080/02699050701553213; Zafonte RD, 1996, NEUROREHABILITATION, V7, P189, DOI 10.3233/NRE-1996-7304; Zafonte R, 2009, J NEUROTRAUM, V26, P2207, DOI 10.1089/neu.2009.1015; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014	84	79	79	3	36	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-5919	1556-228X		CLIN SPORT MED	Clin. Sports Med.	JAN	2011	30	1					115	+		10.1016/j.csm.2010.08.003			11	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	691XR	WOS:000285114800011	21074086	Green Accepted			2022-02-06	
J	Roozenbeek, B; Lingsma, HF; Perel, P; Edwards, P; Roberts, I; Murray, GD; Maas, AIR; Steyerberg, EW				Roozenbeek, Bob; Lingsma, Hester F.; Perel, Pablo; Edwards, Phil; Roberts, Ian; Murray, Gordon D.; Maas, Andrew I. R.; Steyerberg, Ewout W.		IMPACT Int Mission Prognosis Clin; CRASH Corticosteroid Randomisation	The added value of ordinal analysis in clinical trials: an example in traumatic brain injury	CRITICAL CARE			English	Article							RANDOMIZED CONTROLLED-TRIALS; NEUROPROTECTIVE AGENTS; OUTCOME SCALES; ACUTE STROKE; HEAD-INJURY; EFFICACY; DESIGN	Introduction: In clinical trials, ordinal outcome measures are often dichotomized into two categories. In traumatic brain injury (TBI) the 5-point Glasgow outcome scale (GOS) is collapsed into unfavourable versus favourable outcome. Simulation studies have shown that exploiting the ordinal nature of the GOS increases chances of detecting treatment effects. The objective of this study is to quantify the benefits of ordinal analysis in the real-life situation of a large TBI trial. Methods: We used data from the CRASH trial that investigated the efficacy of corticosteroids in TBI patients (n = 9,554). We applied two techniques for ordinal analysis: proportional odds analysis and the sliding dichotomy approach, where the GOS is dichotomized at different cut-offs according to baseline prognostic risk. These approaches were compared to dichotomous analysis. The information density in each analysis was indicated by a Wald statistic. All analyses were adjusted for baseline characteristics. Results: Dichotomous analysis of the six-month GOS showed a non-significant treatment effect (OR = 1.09, 95% CI 0.98 to 1.21, P = 0.096). Ordinal analysis with proportional odds regression or sliding dichotomy showed highly statistically significant treatment effects (OR 1.15, 95% CI 1.06 to 1.25, P = 0.0007 and 1.19, 95% CI 1.08 to 1.30, P = 0.0002), with 2.05-fold and 2.56-fold higher information density compared to the dichotomous approach respectively. Conclusions: Analysis of the CRASH trial data confirmed that ordinal analysis of outcome substantially increases statistical power. We expect these results to hold for other fields of critical care medicine that use ordinal outcome measures and recommend that future trials adopt ordinal analyses. This will permit detection of smaller treatment effects.	[Roozenbeek, Bob; Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, B-2650 Edegem, Belgium; [Roozenbeek, Bob; Lingsma, Hester F.; Steyerberg, Ewout W.] Erasmus MC, Dept Publ Hlth, NL-3000 CA Rotterdam, Netherlands; [Edwards, Phil; Roberts, Ian] Univ London London Sch Hyg & Trop Med, Epidemiol & Populat Hlth Dept, London WC1E 7HT, England; [Murray, Gordon D.] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland		Roozenbeek, B (corresponding author), Univ Antwerp Hosp, Dept Neurosurg, Wilrijkstr 10, B-2650 Edegem, Belgium.	b.roozenbeek@erasmusmc.nl	Abdullah, J/C-2828-2011; Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Abdullah, J/0000-0002-0258-7410; Maas, Andrew IR/0000-0003-1612-1264; /0000-0002-2342-301X; Murray, Gordon/0000-0001-9866-4734; Edwards, Phil/0000-0003-4431-8822; Steyerberg, Ewout/0000-0002-7787-0122	US National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS-042691]; UK Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC); MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0800803] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0800803] Funding Source: researchfish; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER	This study was performed as a part of the IMPACT Study in collaboration with the MRC CRASH Trial Collaborators. The IMPACT study was funded by the US National Institutes of Health (Clinical Trial Design and Analysis in TBI Project: R01 NS-042691). The CRASH trial was funded by the UK Medical Research Council.	Aberegg Scott K, 2010, Crit Care, V14, pR77, DOI 10.1186/cc8990; Altman DG, 2006, BRIT MED J, V332, P1080, DOI 10.1136/bmj.332.7549.1080; Bath PMW, 2007, STROKE, V38, P1911, DOI 10.1161/STROKEAHA.106.474080; den Hertog HM, 2009, LANCET NEUROL, V8, P434, DOI 10.1016/S1474-4422(09)70051-1; Edwards P, 2005, LANCET, V365, P1957; Hernandez AV, 2006, J NEUROTRAUM, V23, P1295, DOI 10.1089/neu.2006.23.1295; Lees KR, 2006, NEW ENGL J MED, V354, P588, DOI 10.1056/NEJMoa052980; Lees KR, 2000, LANCET, V355, P1949, DOI 10.1016/S0140-6736(00)02326-6; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; MAHONEY F I, 1965, Md State Med J, V14, P61; McHugh GS, 2010, CLIN TRIALS, V7, P44, DOI 10.1177/1740774509356580; Mendelow AD, 2005, LANCET, V365, P387; Murray GD, 2005, J NEUROTRAUM, V22, P511, DOI 10.1089/neu.2005.22.511; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; RANKIN J, 1957, Scott Med J, V2, P200; Roozenbeek B, 2009, CRIT CARE MED, V37, P2683, DOI 10.1097/CCM.0b013e3181ab85ec; Saver JL, 2007, STROKE, V38, P3055, DOI 10.1161/STROKEAHA.107.488536; Senn S, 2009, STAT MED, V28, P3189, DOI 10.1002/sim.3603; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x; SHANNON CE, 1948, BELL SYST TECH J, V27, P623, DOI 10.1002/j.1538-7305.1948.tb00917.x; Steyerberg EW, 2000, AM HEART J, V139, P745, DOI 10.1016/S0002-8703(00)90001-2; Valenta Z, 2006, STAT MED, V25, P4227, DOI 10.1002/sim.2678	28	79	80	1	9	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2011	15	3							R127	10.1186/cc10240			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832JB	WOS:000295799700009	21586148	Green Published, Green Accepted, gold			2022-02-06	
J	Kim, DH; Ko, IG; Kim, BK; Kim, TW; Kim, SE; Shin, MS; Kim, CJ; Kim, H; Kim, KM; Baek, SS				Kim, Dong-Hyun; Ko, Il-Gyu; Kim, Bo-Kyun; Kim, Tae-Woon; Kim, Sung-Eun; Shin, Mal-Soon; Kim, Chang-Ju; Kim, Hong; Kim, Kyeong-Mi; Baek, Seung-Soo			Treadmill exercise inhibits traumatic brain injury-induced hippocampal apoptosis	PHYSIOLOGY & BEHAVIOR			English	Article						Traumatic brain injury; Treadmill exercise; Short term memory; Apoptosis; Hippocampus	PROGRAMMED CELL-DEATH; COGNITIVE IMPAIRMENT; BCL-2 FAMILY; RATS; EXPRESSION; ISCHEMIA; DISEASE; MEMORY; BAX; MITOCHONDRIA	Traumatic brain injury (TBI) occurs when an outside force impacts the brain The main problem associated with TBI is neuronal cell death of the brain and the outcome of TBI ranges from complete recovery to permanent disability and sometimes death Physical exercise is known to ameliorate neurologic impairment induced by various brain insults In the present study we investigated the effects of treadmill exercise on short-term memory and apoptosis in the hippocampus following TBI in rats TBI was induced by an electromagnetic-controlled cortical impact The rats in the exercise group were forced to run on a treadmill for 30 min once daily for 10 consecutive days beginning 2 days after induction of TBI For the current study a step-down avoidance task terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay Western blot for Bcl 2 and Bax and immunohistochemistry for caspase-3 were conducted The present results revealed that TBI impaired short term memory and increased DNA fragmentation and caspase-3 expression in the hippocampus Induction of TBI also enhanced expression of pro-apoptotic factor Bax protein and suppressed expression of anti-apoptotic factor Bcl-2 protein in the hippocampus Treadmill exercise alleviated short term memory impairment and decreased DNA fragmentation and caspase-3 expression in the hippocampus In addition treadmill exercise remarkably suppressed expression of Bax protein and slightly increased expression of Bcl 2 protein in TBI-induced rats The present study showed that treadmill exercise might overcome TBI-induced apoptotic neuronal cell death thus facilitating recovery following TBI Published by Elsevier Inc	[Baek, Seung-Soo] Sang Myung Univ, Dept Phys Educ, Coll Arts & Phys Educ, Seoul 110743, South Korea; [Kim, Dong-Hyun; Ko, Il-Gyu; Kim, Bo-Kyun; Kim, Tae-Woon; Kim, Sung-Eun; Shin, Mal-Soon; Kim, Chang-Ju] Kyung Hee Univ, Dept Physiol, Coll Med, Seoul 130701, South Korea; [Kim, Dong-Hyun; Kim, Tae-Woon] Sungkyunkwan Univ, Sch Sport Sci, Kyonggi Do 440746, South Korea; [Kim, Hong] Daegu Haany Univ, Dept Oriental Sports Med, Coll Hlth & Therapy, Gyeongbuk 712715, South Korea; [Kim, Kyeong-Mi] Inje Univ, Dept Occupat Therapy, Gyeongnam 621749, South Korea		Baek, SS (corresponding author), Sang Myung Univ, Dept Phys Educ, Coll Arts & Phys Educ, 7 Hongji Dong, Seoul 110743, South Korea.		Kim, Dong-Hyun/AAH-3043-2020; Kim, Chang Ju/M-4216-2017	Kim, Chang Ju/0000-0003-4749-5795	Korean GovernmentKorean Government [KRF-2009-332-1-G00090]	This work was supported by the Korea Research Foundation Grant funded by the Korean Government (KRF-2009-332-1-G00090)	Ang ET, 2007, CURR MED CHEM, V14, P2564, DOI 10.2174/092986707782023280; Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Carro E, 2001, J NEUROSCI, V21, P5678, DOI 10.1523/JNEUROSCI.21-15-05678.2001; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Devine JM, 2009, PM&R, V1, P560, DOI 10.1016/j.pmrj.2009.03.015; Ding Q, 2006, NEUROSCIENCE, V140, P823, DOI 10.1016/j.neuroscience.2006.02.084; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Graham SH, 2000, J NEUROTRAUM, V17, P831, DOI 10.1089/neu.2000.17.831; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Greve KW, 2003, ARCH CLIN NEUROPSYCH, V18, P245, DOI 10.1016/S0887-6177(02)00137-3; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Guezennec CY, 1998, INT J SPORTS MED, V19, P323, DOI 10.1055/s-2007-971925; Hassett LM, 2009, J REHABIL MED, V41, P247, DOI 10.2340/16501977-0316; Hu ZG, 2009, BRAIN INJURY, V23, P459, DOI 10.1080/02699050902788469; Jee YS, 2008, NEUROSCI LETT, V443, P188, DOI 10.1016/j.neulet.2008.07.078; Jia F, 2009, J NEUROTRAUM, V26, P243, DOI 10.1089/neu.2008.0670; Ko CH, 2006, HUM MOL GENET, V15, pR271, DOI 10.1093/hmg/ddl207; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; Laurin D, 2001, ARCH NEUROL-CHICAGO, V58, P498, DOI 10.1001/archneur.58.3.498; Masley S, 2009, J CLIN PSYCHOL MED S, V16, P186, DOI 10.1007/s10880-009-9159-6; PINILLA FG, 1998, NEUROSCIENCE, V85, P53; Ploughman M, 2009, STROKE, V40, P1490, DOI 10.1161/STROKEAHA.108.531806; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Sim YJ, 2004, NEUROSCI LETT, V372, P256, DOI 10.1016/j.neulet.2004.09.060; Tehranian R, 2008, J NEUROTRAUM, V25, P755, DOI 10.1089/neu.2007.0441; Teles AVFF, 2008, NEUROSCI LETT, V438, P59, DOI 10.1016/j.neulet.2008.03.062; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tong LQ, 2001, NEUROBIOL DIS, V8, P1046, DOI 10.1006/nbdi.2001.0427; Um HS, 2008, INT J MOL MED, V22, P529, DOI 10.3892/ijmm_00000052; Upadhyay D, 2003, AM J RESP CELL MOL, V29, P180, DOI 10.1165/rcmb.2002-0269OC; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8	39	79	83	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0031-9384			PHYSIOL BEHAV	Physiol. Behav.	DEC 2	2010	101	5					660	665		10.1016/j.physbeh.2010.09.021			6	Psychology, Biological; Behavioral Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Behavioral Sciences	692BK	WOS:000285126300017	20888848				2022-02-06	
J	Mustafa, AG; Singh, IN; Wang, JA; Carrico, KM; Hall, ED				Mustafa, Ayman G.; Singh, Indrapal N.; Wang, Juan; Carrico, Kimberly M.; Hall, Edward D.			Mitochondrial protection after traumatic brain injury by scavenging lipid peroxyl radicals	JOURNAL OF NEUROCHEMISTRY			English	Article						3-nitrotyrosine; 4-hydroxynonenal; lipid peroxidation; mitochondria; traumatic brain injury; U-83836E	PERMEABILITY TRANSITION; OXIDATIVE DAMAGE; IMPAIRS GLUTAMATE; PEROXIDATION; PEROXYNITRITE; DYSFUNCTION; MEMBRANE; CELLS; RAT; ANTIOXIDANT	P>Mitochondrial dysfunction after traumatic brain injury (TBI) is manifested by increased levels of oxidative damage, loss of respiratory functions and diminished ability to buffer cytosolic calcium. This study investigated the detrimental effects of lipid peroxyl radicals (LOO center dot) and lipid peroxidation (LP) in brain mitochondria after TBI by examining the protective effects of U-83836E, a potent and selective scavenger of LOO center dot radicals. Male CF1 mice were subjected to severe controlled cortical impact TBI (CCI-TBI) and treated with either vehicle or U-83836E initiated i.v. at 15 min post-injury. Calcium (Ca++) buffering capacity and respiratory function were measured in isolated cortical mitochondrial samples taken from the ipsilateral hemisphere at 3 and 12 h post-TBI, respectively. In vehicle-treated injured mice, the cortical mitochondrial Ca++ buffering capacity was reduced by 60% at 3 h post-injury (p < 0.001) and the respiratory control ratio was decreased by 27% at 12 h post-TBI, relative to sham, non-injured mice. U-83836E treatment significantly (p < 0.05) preserved Ca++ buffering capacity and attenuated the reduction in respiratory control ratio values. Consistent with the functional effects of U-83836E being as a result of an attenuation of mitochondrial oxidative damage, the compound significantly (p < 0.001) reduced LP-generated 4-hydroxynonenal levels in both cortical homogenates and mitochondria at both 3 and 12 h post-TBI. Unexpectedly, U-83836E also reduced peroxynitrite-generated 3-nitrotyrosine in parallel with the reduction in 4-hydroxynonenal. The results demonstrate that LOO center dot radicals contribute to secondary brain mitochondrial dysfunction after TBI by propagating LP and protein nitrative damage in cellular and mitochondrial membranes.	[Mustafa, Ayman G.; Singh, Indrapal N.; Wang, Juan; Carrico, Kimberly M.; Hall, Edward D.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA		Hall, ED (corresponding author), Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, 741 S Limestone St,BBSRB Room 483, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013	mustafa, ayman/0000-0002-0341-7149	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046566, P30NS051220, P01NS058484] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS046566, P01 NS058484, P30 NS051220] Funding Source: Medline		Alvarez B, 2003, AMINO ACIDS, V25, P295, DOI 10.1007/s00726-003-0018-8; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028; Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; Durmaz R, 2003, CAN J NEUROL SCI, V30, P143, DOI 10.1017/S0317167100053415; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Gadelha FR, 1997, ARCH BIOCHEM BIOPHYS, V345, P243, DOI 10.1006/abbi.1997.0259; GrasbonFrodl EM, 1996, J NEUROCHEM, V67, P1653; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; HALL ED, 1988, J NEUROSURG, V68, P462, DOI 10.3171/jns.1988.68.3.0462; HALL ED, 1991, J PHARMACOL EXP THER, V258, P688; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; HALLIWELL B, 1993, AM J CLIN NUTR, V57, pS724; Halliwell Barry, 1993, American Journal of Clinical Nutrition, V57, p715S, DOI 10.1093/ajcn/57.5.715S; Hansson MJ, 2008, FREE RADICAL BIO MED, V45, P284, DOI 10.1016/j.freeradbiomed.2008.04.021; Jouaville LS, 1998, MOL CELL BIOCHEM, V184, P371, DOI 10.1023/A:1006850121769; Kabadere S, 2004, ACTA NEUROBIOL EXP, V64, P461; Karlsson J, 2002, BRAIN RES, V955, P268, DOI 10.1016/S0006-8993(02)03601-6; Keller JN, 1997, NEUROSCIENCE, V80, P685, DOI 10.1016/S0306-4522(97)00065-1; KIMURA M, 1992, BRIT J PHARMACOL, V107, P488, DOI 10.1111/j.1476-5381.1992.tb12772.x; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Madikians A, 2006, INDIAN J NEUROTRAUM, V3, P9; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; MUNNS PL, 1995, FREE RADICAL BIO MED, V18, P467, DOI 10.1016/0891-5849(94)00163-E; Pedersen WA, 1999, EXP NEUROL, V155, P1, DOI 10.1006/exnr.1998.6890; Racay P, 1997, BIOCHEM MOL BIOL INT, V41, P647; Radi R, 1998, CHEM RES TOXICOL, V11, P720, DOI 10.1021/tx980096z; Rohn TT, 1998, EUR J PHARMACOL, V353, P329, DOI 10.1016/S0014-2999(98)00399-9; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; SHI FL, 1995, FREE RADICAL BIO MED, V19, P349, DOI 10.1016/0891-5849(95)00049-4; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Spiteller G, 2006, FREE RADICAL BIO MED, V41, P362, DOI 10.1016/j.freeradbiomed.2006.03.013; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Sureda FX, 1999, TOXICOL APPL PHARM, V156, P1, DOI 10.1006/taap.1998.8613; Thajeb P, 2006, J CLIN NEUROSCI, V13, P467, DOI 10.1016/j.jocn.2005.05.019; Violi F, 1999, DIABETES-METAB RES, V15, P283, DOI 10.1002/(SICI)1520-7560(199907/08)15:4<283::AID-DMRR42>3.0.CO;2-U; Xiong Y, 1997, J NEUROTRAUM, V14, P907, DOI 10.1089/neu.1997.14.907; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	47	79	82	0	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0022-3042			J NEUROCHEM	J. Neurochem.	JUL	2010	114	1					271	280		10.1111/j.1471-4159.2010.06749.x			10	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	608FA	WOS:000278567100025	20403083	Green Accepted			2022-02-06	
J	Sozda, CN; Hoffman, AN; Olsen, AS; Cheng, JP; Zafonte, RD; Kline, AE				Sozda, Christopher N.; Hoffman, Ann N.; Olsen, Adam S.; Cheng, Jeffrey P.; Zafonte, Ross D.; Kline, Anthony E.			Empirical Comparison of Typical and Atypical Environmental Enrichment Paradigms on Functional and Histological Outcome after Experimental Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						behavior; controlled cortical impact; enrichment; recovery; spatial learning; water maze	FACTOR MESSENGER-RNA; RECEPTOR AGONIST 8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; SPINAL-CORD-INJURY; MORRIS WATER MAZE; COGNITIVE DEFICITS; SPATIAL MEMORY; DENTATE GYRUS; SYNAPTOPHYSIN LEVELS; PHYSICAL-ACTIVITY; TREATMENT REGIMEN	Several studies have shown that housing rats in an enriched environment (EE) after traumatic brain injury (TBI) improves functional and histological outcome. The typical EE includes exploratory, sensory, and social components in cages that are often vastly larger than standard (STD) housing. It is uncertain, however, whether a single or specific component is sufficient to confer these benefits after TBI, or if all, perhaps in an additive or synergistic manner, are necessary. To clarify this ambiguity, anesthetized adult male rats were subjected to either a controlled cortical impact or sham injury, and then were randomly assigned to five different housing paradigms: (1) EE (typical), (2) EE (-social), (3) EE (-stimuli), (4) STD (typical), and (5) STD (+stimuli). Motor and cognitive function were assessed using conventional motor (beam-balance/traversal) and cognitive (spatial learning in a Morris water maze) tests on postoperative days 1-5 and 14-19, respectively, and cortical lesion volume and CA1/CA3 cell loss were quantified at 3 weeks. No significant differences were observed among the sham groups in any comparison and thus their data were pooled (i.e., SHAM). In the TBI groups, typical EE improved beam-balance versus both STD (+stimuli) and EE (-social), it facilitated the acquisition of spatial learning and memory retention versus all other housing conditions (p<0.003), and it reduced lesion volume and CA3 cell loss versus STD (typical) housing. While rats in the three atypical EE conditions exhibited slightly better cognitive performance and histological protection versus the typical STD group, the overall effects were not significant. These data suggest that exposing TBI rats to any of the three components individually may be more advantageous than no enrichment, but only exposure to typical EE yields optimal benefits.	[Kline, Anthony E.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Rehabil Res, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15213 USA; [Zafonte, Ross D.] Harvard Univ, Sch Med, Boston, MA USA; [Zafonte, Ross D.] Spaulding Rehabil Hosp, Boston, MA USA; [Zafonte, Ross D.] Massachusetts Gen Hosp, Boston, MA 02114 USA		Kline, AE (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Rehabil Res, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu		Cheng, Jeffrey/0000-0001-8285-3207; Olsen, Adam/0000-0003-0957-9867	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD046700, NS060005]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD046700] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005] Funding Source: NIH RePORTER	This work was supported, in part, by National Institutes of Health grants HD046700 and NS060005, awarded to A.E.K.	Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; BENNETT EL, 1969, SCIENCE, V163, P825, DOI 10.1126/science.163.3869.825; Berrocal Y, 2007, J NEUROTRAUM, V24, P1761, DOI 10.1089/neu.2007.0327; Briones TL, 2009, J NEUROTRAUM, V26, P613, DOI 10.1089/neu.2008.0707; Bruel-Jungerman E, 2005, EUR J NEUROSCI, V21, P513, DOI 10.1111/j.1460-9568.2005.03875.x; Buchhold B, 2007, RESTOR NEUROL NEUROS, V25, P467; Burke DA, 2007, J AM ASSOC LAB ANIM, V46, P34; Cheng JP, 2008, BEHAV BRAIN RES, V194, P79, DOI 10.1016/j.bbr.2008.06.025; Cracchiolo JR, 2007, NEUROBIOL LEARN MEM, V88, P277, DOI 10.1016/j.nlm.2007.07.007; Dahlqvist P, 2004, EUR J NEUROSCI, V19, P2288, DOI 10.1111/j.0953-816X.2004.03248.x; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Dixon CE, 2003, CRIT CARE MED, V31, P2222, DOI 10.1097/01.CCM.0000080493.04978.73; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Elliott BM, 2005, BEHAV BRAIN RES, V165, P187, DOI 10.1016/j.bbr.2005.06.025; Faherty CJ, 2005, MOL BRAIN RES, V134, P170, DOI 10.1016/j.molbrainres.2004.08.008; FALKENBERG T, 1992, NEUROSCI LETT, V138, P153, DOI 10.1016/0304-3940(92)90494-R; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; Fischer FR, 2007, J SPINAL CORD MED, V30, P147, DOI 10.1080/10790268.2007.11753926; Frick KM, 2003, NEUROBIOL AGING, V24, P615, DOI 10.1016/S0197-4580(02)00138-0; Gabriel AF, 2010, BEHAV BRAIN RES, V208, P90, DOI 10.1016/j.bbr.2009.11.015; Gaulke LJ, 2005, MOL BRAIN RES, V141, P138, DOI 10.1016/j.molbrainres.2005.08.011; GENTILE AM, 1987, BEHAV NEURAL BIOL, V47, P321, DOI 10.1016/S0163-1047(87)90435-3; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; HELD JM, 1985, BEHAV NEUROSCI, V99, P678, DOI 10.1037/0735-7044.99.4.678; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Hoffman AN, 2008, NEUROSCI LETT, V431, P226, DOI 10.1016/j.neulet.2007.11.042; Ickes BR, 2000, EXP NEUROL, V164, P45, DOI 10.1006/exnr.2000.7415; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; Jankowsky JL, 2005, J NEUROSCI, V25, P5217, DOI 10.1523/JNEUROSCI.5080-04.2005; Johansson BB, 1996, EXP NEUROL, V139, P322, DOI 10.1006/exnr.1996.0106; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; Kline AE, 2002, NEUROSCI LETT, V333, P179, DOI 10.1016/S0304-3940(02)01101-1; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kokiko ON, 2007, BRAIN INJURY, V21, P259, DOI 10.1080/02699050701209964; Lambert TJ, 2005, NEUROBIOL LEARN MEM, V83, P206, DOI 10.1016/j.nlm.2004.12.001; Leggio MG, 2005, BEHAV BRAIN RES, V163, P78, DOI 10.1016/j.bbr.2005.04.009; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Nilsson M, 1999, J NEUROBIOL, V39, P569, DOI 10.1002/(SICI)1097-4695(19990615)39:4<569::AID-NEU10>3.0.CO;2-F; Nithianantharajah J, 2004, NEUROBIOL LEARN MEM, V81, P200, DOI 10.1016/j.nlm.2004.02.002; Olson AK, 2006, HIPPOCAMPUS, V16, P250, DOI 10.1002/hipo.20157; Parton A, 2005, CURR OPIN NEUROL, V18, P675, DOI 10.1097/01.wco.0000189872.54245.13; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; ROSE FD, 1987, BEHAV BRAIN RES, V24, P195, DOI 10.1016/0166-4328(87)90057-X; ROSENZWEIG MR, 1978, BRAIN RES, V153, P563, DOI 10.1016/0006-8993(78)90340-2; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schrijver NCA, 2004, BEHAV BRAIN RES, V152, P307, DOI 10.1016/j.bbr.2003.10.016; Torasdotter M, 1998, BEHAV BRAIN RES, V93, P83, DOI 10.1016/S0166-4328(97)00142-3; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001; Zhao LR, 2000, NEUROSCIENCE, V97, P177, DOI 10.1016/S0306-4522(00)00023-3; Zhao LR, 2001, NEUROSCI LETT, V305, P169, DOI 10.1016/S0304-3940(01)01837-7	62	79	81	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2010	27	6					1047	1057		10.1089/neu.2010.1313			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	612VO	WOS:000278933300008	20334496	Green Published			2022-02-06	
J	Halamek, J; Windmiller, JR; Zhou, J; Chuang, MC; Santhosh, P; Strack, G; Arugula, MA; Chinnapareddy, S; Bocharova, V; Wang, J; Katz, E				Halamek, Jan; Windmiller, Joshua Ray; Zhou, Jian; Chuang, Min-Chieh; Santhosh, Padmanabhan; Strack, Guinevere; Arugula, Mary A.; Chinnapareddy, Soujanya; Bocharova, Vera; Wang, Joseph; Katz, Evgeny			Multiplexing of injury codes for the parallel operation of enzyme logic gates	ANALYST			English	Article							TRAUMATIC BRAIN-INJURY; NOISE-REDUCTION; BIOCHEMICAL LOGIC; LACTATE; NOREPINEPHRINE; BIOSENSOR; GLUCOSE; DEHYDROGENASE; BATTLEFIELD; EPINEPHRINE	The development of a highly parallel enzyme logic sensing concept employing a novel encoding scheme for the determination of multiple pathophysiological conditions is reported. The new concept multiplexes a contingent of enzyme-based logic gates to yield a distinct 'injury code' corresponding to a unique pathophysiological state as prescribed by a truth table. The new concept is illustrated using an array of NAND and AND gates to assess the biomedical significance of numerous biomarker inputs including creatine kinase, lactate dehydrogenase, norepinephrine, glutamate, alanine transaminase, lactate, glucose, glutathione disulfide, and glutathione reductase to assess soft-tissue injury, traumatic brain injury, liver injury, abdominal trauma, hemorrhagic shock, and oxidative stress. Under the optimal conditions, physiological and pathological levels of these biomarkers were detected through either optical or electrochemical techniques by monitoring the level of the outputs generated by each of the six logic gates. By establishing a pathologically meaningful threshold for each logic gate, the absorbance and amperometric assays tendered the diagnosis in a digitally encoded 6-bit word, defined as an 'injury code'. This binary 'injury code' enabled the effective discrimination of 64 unique pathological conditions to offer a comprehensive high-fidelity diagnosis of multiple injury conditions. Such processing of relevant biomarker inputs and the subsequent multiplexing of the logic gate outputs to yield a comprehensive 'injury code' offer significant potential for the rapid and reliable assessment of varied and complex forms of injury in circumstances where access to a clinical laboratory is not viable. While the new concept of parallel and multiplexed enzyme logic gates is illustrated here in connection to multi-injury diagnosis, it could be readily extended to a wide range of practical medical, industrial, security and environmental applications.	[Halamek, Jan; Zhou, Jian; Strack, Guinevere; Arugula, Mary A.; Chinnapareddy, Soujanya; Bocharova, Vera; Katz, Evgeny] Clarkson Univ, Dept Chem & Biomol Sci, Potsdam, NY 13699 USA; [Windmiller, Joshua Ray; Chuang, Min-Chieh; Santhosh, Padmanabhan; Wang, Joseph] Univ Calif San Diego, Dept NanoEngn, La Jolla, CA 92093 USA		Wang, J (corresponding author), Clarkson Univ, Dept Chem & Biomol Sci, Potsdam, NY 13699 USA.	josephwang@ucsd.edu; ekatz@clarkson.edu	Wang, Joseph/C-6175-2011; Padmanabhan, Santhosh/A-6930-2009	Padmanabhan, Santhosh/0000-0003-2418-5284	Office of Naval ResearchOffice of Naval Research [N00014-08-1-1202]	This work was supported by the Office of Naval Research (Award #N00014-08-1-1202).	Ahn CH, 2004, P IEEE, V92, P154, DOI 10.1109/JPROC.2003.820548; Bashir R, 2004, ADV DRUG DELIVER REV, V56, P1565, DOI 10.1016/j.addr.2004.03.002; Bhasale A, 1998, FAM PRACT, V15, P308, DOI 10.1093/fampra/15.4.308; Bourner G, 2005, Lab Hematol, V11, P285, DOI 10.1532/LH96.05036; Champion HR, 2003, J TRAUMA, V54, pS13, DOI 10.1097/01.TA.0000057151.02906.27; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; Ettinger A, 1999, ANN THORAC SURG, V68, P2196, DOI 10.1016/S0003-4975(99)00849-8; EYER P, 1986, ANAL BIOCHEM, V153, P57, DOI 10.1016/0003-2697(86)90061-8; Giannoudis PV, 2003, J BONE JOINT SURG BR, V85B, P478, DOI 10.1302/0301-620X.85B4.14217; Katz E, 2010, FOURTH INTERNATIONAL CONFERENCE ON QUANTUM, NANO AND MICRO TECHNOLOGIES: ICQNM 2010, PROCEEDINGS, P1, DOI 10.1109/ICQNM.2010.8; Katz E, 2010, CHEM SOC REV, V39, P1835, DOI 10.1039/b806038j; Keel M, 2005, INJURY, V36, P691, DOI 10.1016/j.injury.2004.12.037; Kline JA, 1997, J MOL CELL CARDIOL, V29, P2465, DOI 10.1006/jmcc.1997.0483; Kratz A, 2004, NEW ENGL J MED, V351, P1548, DOI 10.1056/NEJMcpc049016; KUDSK KA, 1992, ANN SURG, V215, P503, DOI 10.1097/00000658-199205000-00013; Lakstein D, 2003, J TRAUMA, V54, pS221, DOI 10.1097/01.TA.0000047227.33395.49; LANZINO G, 1993, J NEUROSURG, V79, P885, DOI 10.3171/jns.1993.79.6.0885; Ligler FS, 2007, ANAL SCI, V23, P5, DOI 10.2116/analsci.23.5; Ling GSF, 1999, P SOC PHOTO-OPT INS, V3712, P1, DOI 10.1117/12.353012; Manesh KM, 2009, BIOSENS BIOELECTRON, V24, P3569, DOI 10.1016/j.bios.2009.05.019; MANGER WM, 1957, AM J PHYSIOL, V190, P310, DOI 10.1152/ajplegacy.1957.190.2.310; Maynard ND, 1997, CHEST, V111, P180, DOI 10.1378/chest.111.1.180; Melnikov D, 2009, J PHYS CHEM B, V113, P10472, DOI 10.1021/jp904585x; MICHAELI D, 1979, J ROY SOC MED, V72, P370; Moser I, 2002, BIOSENS BIOELECTRON, V17, P297, DOI 10.1016/S0956-5663(01)00298-6; Moser I, 1997, SENSOR ACTUAT B-CHEM, V44, P377, DOI 10.1016/S0925-4005(97)00228-1; OLERUD JE, 1976, ARCH INTERN MED, V136, P692, DOI 10.1001/archinte.136.6.692; Papa Linda, 2008, Expert Opin Med Diagn, V2, P937, DOI 10.1517/17530059.2.8.937; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Pita M, 2009, SENSOR ACTUAT B-CHEM, V139, P631, DOI 10.1016/j.snb.2009.03.001; PRASAD MR, 1994, J NEUROCHEM, V63, P1086; Privman M, 2009, J AM CHEM SOC, V131, P1314, DOI 10.1021/ja8088108; Privman V, 2008, J PHYS CHEM B, V112, P11777, DOI 10.1021/jp802673q; Privman V, 2009, BIOSENS BIOELECTRON, V25, P695, DOI 10.1016/j.bios.2009.08.014; Privman V, 2009, J PHYS CHEM B, V113, P5301, DOI 10.1021/jp810743w; RIGNAULT DP, 1992, WORLD J SURG, V16, P940, DOI 10.1007/BF02066996; ROSENBERG J, 1961, ANN SURG, V154, P611, DOI 10.1097/00000658-196110000-00011; Rossi R, 2002, CLIN CHEM, V48, P742; Scott SG, 2006, J AM OSTEOPATH ASSOC, V106, P265; Sies H, 1997, EXP PHYSIOL, V82, P291, DOI 10.1113/expphysiol.1997.sp004024; SPRULES SD, 1995, ANAL CHIM ACTA, V304, P17, DOI 10.1016/0003-2670(94)00565-4; Strack G, 2008, CHEMBIOCHEM, V9, P1260, DOI 10.1002/cbic.200700762; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tam TK, 2009, SENSOR ACTUAT B-CHEM, V140, P1, DOI 10.1016/j.snb.2009.04.010; Tan KK, 2009, INJURY, V40, P978, DOI 10.1016/j.injury.2009.02.023; Thevenot DR, 2001, BIOSENS BIOELECTRON, V16, P121, DOI 10.1081/AL-100103209; WANG J, 1994, ANAL CHEM, V66, P1007, DOI 10.1021/ac00079a013; Wang J, 2010, ANAL BIOANAL CHEM, V398, P1591, DOI 10.1007/s00216-010-3746-0; Wedmore I, 2006, J TRAUMA, V60, P655, DOI 10.1097/01.ta.0000199392.91772.44; Weinstein T, 2000, NEPHROL DIAL TRANSPL, V15, P883, DOI 10.1093/ndt/15.6.883; Wheeler AP, 1999, NEW ENGL J MED, V340, P207, DOI 10.1056/NEJM199901213400307; Wilson M, 2003, J EMERG MED, V24, P413, DOI 10.1016/S0736-4679(03)00042-8; WINTERBORN RJ, 2003, SURGERY OXFORD, V21, pA240, DOI DOI 10.1383/SURG.21.9.240.16923; Zhou J, 2009, J PHYS CHEM B, V113, P16065, DOI 10.1021/jp9079052; Zink BJ, 1999, BRAIN RES, V837, P1, DOI 10.1016/S0006-8993(99)01646-7	55	79	79	1	24	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND	0003-2654	1364-5528		ANALYST	Analyst		2010	135	9					2249	2259		10.1039/c0an00270d			11	Chemistry, Analytical	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry	639WM	WOS:000281007300008	20617272				2022-02-06	
J	Lange, RT; Iverson, GL; Brooks, BL; Rennison, VLA				Lange, Rael T.; Iverson, Grant L.; Brooks, Brian L.; Rennison, V. Lynn Ashton			Influence of poor effort on self-reported symptoms and neurocognitive test performance following mild traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Postconcussion symptoms; Response bias; Symptom validity testing; Test of Memory Malingering	MEMORY MALINGERING TOMM; RESPONSE BIAS SCALE; MMPI-2 VALIDITY SCALES; SPORTS-RELATED CONCUSSION; COMPLAINT BASE RATES; GOOD OLD DAYS; HEAD-INJURY; POSTCONCUSSION SYNDROME; NEUROPSYCHOLOGICAL TESTS; COGNITIVE PERFORMANCE	When considering a diagnosis of postconcussion syndrome, clinicians must systematically evaluate and eliminate the possible contribution of many differential diagnoses, comorbidities, and factors that may cause or maintain self-reported symptoms long after mild traumatic brain injury (MTBI). One potentially significant contributing factor is symptom exaggeration. The purpose of the study is to examine the influence of poor effort on self-reported symptoms (postconcussion symptoms and cognitive complaints) and neurocognitive test performance following MTBI. The MTBI sample consisted of 63 referrals to a concussion clinic, evaluated within 5 months post injury (M = 2.0, SD = 1.0, range = 0.6-4.6), who were receiving financial compensation from the Workers' Compensation Board. Participants completed the Post-Concussion Scale (PCS), British Columbia Cognitive Complaints Inventory (BC-CCI), selected tests from the Neuropsychological Assessment Battery Screening Module (S-NAB), and the Test of Memory Malingering (TOMM). Participants were divided into two groups based on TOMM performance (15 fail, 48 pass). There were significant main effects and large effect sizes for the PCS (p = .002, d = 0.79) and BC-CCI (p = .011, d = 0.98) total scores. Patients in the TOMM fail group scored higher than those in the TOMM pass group on both measures. Similarly, there were significant main effects and/or large effect sizes on the S-NAB. Patients in the TOMM fail group performed more poorly on the Attention (p = .004, d = 1.26), Memory (p = .006, d = 1.16), and Executive Functioning (p .05, d = 0.70) indexes. These results highlight the importance of considering the influence of poor effort, in conjunction with a growing list of factors that can influence, maintain, and/or mimic the persistent postconcussion syndrome.	[Lange, Rael T.] PHSA Res & Networks, British Columbia Mental Hlth & Addict Serv, Vancouver, BC V5Z 4C2, Canada; [Lange, Rael T.; Iverson, Grant L.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Brooks, Brian L.] Alberta Childrens Prov Gen Hosp, Calgary, AB T2T 5C7, Canada; [Brooks, Brian L.] Univ Calgary, Calgary, AB T2N 1N4, Canada; [Rennison, V. Lynn Ashton] Fraser Hlth Concuss Clin, Coquitlam, BC, Canada; [Rennison, V. Lynn Ashton] Royal Columbian Hosp, New Westminster, BC, Canada		Lange, RT (corresponding author), PHSA Res & Networks, British Columbia Mental Hlth & Addict Serv, Suite 201,601 W Broadway St, Vancouver, BC V5Z 4C2, Canada.	rael.lange@gmail.com		Iverson, Grant/0000-0001-7348-9570			American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Backhaus SL, 2004, CLIN NEUROPSYCHOL, V18, P591, DOI 10.1080/13854040490888558; Bauer L, 2007, ASSESSMENT, V14, P215, DOI 10.1177/1073191106297617; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Boone KB, 1999, CLIN NEUROPSYCHOL, V13, P414; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cohen J., 2013, STAT POWER ANAL BEHA; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; Cook J B, 1972, Scand J Rehabil Med, V4, P27; Crawford JR, 2007, NEUROPSYCHOLOGY, V21, P419, DOI 10.1037/0894-4105.21.4.419; DenBoer JW, 2007, CLIN NEUROPSYCHOL, V21, P943, DOI 10.1080/13854040601020783; Donders J, 2005, CHILD NEUROPSYCHOL, V11, P221, DOI 10.1080/09297040490917298; DUNN JT, 1995, J CLIN PSYCHOL, V51, P577, DOI 10.1002/1097-4679(199507)51:4<577::AID-JCLP2270510418>3.0.CO;2-E; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; Garden N, 2010, NEUROPSYCHOLOGY, V24, P168, DOI 10.1037/a0017431; Gavett BE, 2005, APPL NEUROPSYCHOL, V12, P1, DOI 10.1207/s15324826an1201_1; Gervais RO, 2005, ARCH CLIN NEUROPSYCH, V20, P891; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Gervais RO, 2007, ASSESSMENT, V14, P196, DOI 10.1177/1073191106295861; Gervais RO, 2008, CLIN NEUROPSYCHOL, V22, P1061, DOI 10.1080/13854040701756930; Gierok SD, 2005, ARCH CLIN NEUROPSYCH, V20, P755, DOI 10.1016/j.acn.2005.04.008; Green P, 2007, PHYS MED REHABILITAT, V18, pvi; Green Paul, 2007, Phys Med Rehabil Clin N Am, V18, P43, DOI 10.1016/j.pmr.2006.11.002; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Haggerty KA, 2007, CLIN NEUROPSYCHOL, V21, P917, DOI 10.1080/13854040600899724; Hahn RA, 1997, PREV MED, V26, P607, DOI 10.1006/pmed.1996.0124; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Henry GK, 2009, CLIN NEUROPSYCHOL, V23, P153, DOI 10.1080/13854040801969524; Hill S. K., 2003, J FORENSIC NEUROPSYC, P1, DOI [10.1300/J151v03n03_01, DOI 10.1300/J151V03N03_01]; Horner MD, 2006, INT J NEUROSCI, V116, P1181, DOI 10.1080/00207450500514029; Iverson G. L., 2003, CAN PSYCH ASS HAL NO; Iverson G.L, 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; IVERSON GL, 2003, NAT AC NEUR DALL TX; Iverson GL, 2007, CLIN NEUROPSYCHOL, V21, P532, DOI 10.1080/13854040600611392; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Kaemmer, 1989, MINNESOTA MULTIPHASI; Larrabee G. J., 2008, J INT NEUROPSYCH SOC, V14, P122; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P395, DOI 10.1076/clin.17.3.395.18087; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Locke DEC, 2008, NEUROREHABILITATION, V23, P273; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; McCaffrey R.J., 2003, J FORENSIC NEUROPSYC, V3, P45, DOI [https://doi.org/10.1300/J151v03n03_03, DOI 10.1300/J151V03N03_03]; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; Morey, 1991, PERSONALITY ASSESSME; Nelson NW, 2007, J INT NEUROPSYCH SOC, V13, P440, DOI 10.1017/S1355617707070373; Nelson NW, 2007, J CLIN EXP NEUROPSYC, V29, P67, DOI 10.1080/13803390500488546; O'Bryant SE, 2008, APPL NEUROPSYCHOL, V15, P113, DOI 10.1080/09084280802083921; O'Bryant SE, 2007, CLIN NEUROPSYCHOL, V21, P511, DOI 10.1080/13854040600611368; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Reynolds S, 2003, J HEAD TRAUMA REHAB, V18, P139, DOI 10.1097/00001199-200303000-00005; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruocco AC, 2008, CLIN NEUROPSYCHOL, V22, P547, DOI 10.1080/13854040701336444; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Stern RA, 2003, NEUROPSYCHOLOGICAL A; Stevens A, 2008, PSYCHIAT RES, V157, P191, DOI 10.1016/j.psychres.2007.01.003; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Suhr J, 2008, ARCH CLIN NEUROPSYCH, V23, P521, DOI 10.1016/j.acn.2008.05.003; Sullivan Michael J L, 2002, Pain Res Manag, V7, P120; Sumanti M, 2006, CLIN NEUROPSYCHOL, V20, P754, DOI 10.1080/13854040500428467; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Tsanadis J, 2007, J INT NEUROPSYCH SOC, V13, P196; Tsanadis J, 2008, CLIN NEUROPSYCHOL, V22, P1080, DOI 10.1080/13854040701796928; van Hout MSE, 2003, NEUROTOXICOLOGY, V24, P547, DOI 10.1016/S0161-813X(03)00054-8; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; White T, 2003, NEUROPSYCHOLOGICAL A; Whiteside DM, 2009, CLIN NEUROPSYCHOL, V23, P523, DOI 10.1080/13854040802389169; Whitney KA, 2008, ARCH CLIN NEUROPSYCH, V23, P777, DOI 10.1016/j.acn.2008.09.001; Wygant DB, 2007, ARCH CLIN NEUROPSYCH, V22, P489, DOI 10.1016/j.acn.2007.01.027	90	79	80	0	19	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2010	32	9					961	972	PII 921816386	10.1080/13803391003645657			12	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	676CU	WOS:000283888500006	20437284				2022-02-06	
J	Jastrow, KM; Gonzalez, EA; McGuire, MF; Suliburk, JW; Kozar, RA; Iyengar, S; Motschall, DA; McKinley, BA; Moore, FA; Mercer, DW				Jastrow, Kenneth M., III; Gonzalez, Ernest A.; McGuire, Mary F.; Suliburk, James W.; Kozar, Rosemary A.; Iyengar, Sriram; Motschall, Deborah A.; McKinley, Bruce A.; Moore, Frederick A.; Mercer, David W.			Early Cytokine Production Risk Stratifies Trauma Patients for Multiple Organ Failure	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							INTERFERON-INDUCIBLE PROTEIN-10; CHEMOKINE RECEPTORS; INFLAMMATORY RESPONSE; SHOCK RESUSCITATION; HEMORRHAGIC-SHOCK; SEVERE SEPSIS; PLASMA-LEVELS; EXPRESSION; PATTERNS; SEVERITY	BACKGROUND: Shock is a prime inciting event for postinjury multiple organ failure (MOF), believed to induce a state of injurious systemic inflammation. In animal models of hemorrhagic shock, early (< 24 hours) changes in cytokine production are an index of the systemic inflammatory response syndrome. However, their predictive value in trauma patients remains to be fully elucidated. STUDY DESIGN: In a prospective observational pilot study of > I year at an urban Level I trauma center, serial (every 4 hours) serum cytokine levels were determined during a 24-hour period using multiplex suspension immunoassay in patients with major torso trauma (excluding severe brain injury) who met criteria for standardized shock resuscitation. Temporal cytokine expression was assessed during shock resuscitation in severe trauma patients to predict risk for MOF. MOF was assessed with the Denver score. RESULTS: Of 48 study patients (mean age 39 +/- 3 years, 67% men, 88% blunt mechanism, mean Injury Severity Score 25 +/- 2), MOF developed in 11 (23%). MOF patients had a considerably higher mortality (64% versus 3%) and fewer ICU-free days (3.5 +/- 2 versus 17.8 +/- 1.3 days) compared with non-MOF patients. Traditional predictors of MOF, including age (45 +/- 7 versus 38 +/- 3 years; p = 0.21), Injury Severity Score (26 +/- 3 versus 25 +/- 2; p = 0.67), admission hemoglobin (11.4 +/- 0.9 versus 12.1 +/- 0.5 g/dL; p = 0.22), international normalized ratio (1.6 +/- 0.2 versus 1.4 +/- 0.06; p = 0.17), and base deficit (9.0 +/- 2 versus 7.1 +/- 0.8; p = 0.19), were not significantly different between MOF and non-MOF patients. Statistical analysis identified six candidate predictors of MOF: inducible protein 10, macrophage inflammatory protein-1 beta, interleukin-10, interleukin-6, interleukin-1Ra, and eotaxin. CONCLUSIONS: These data provide insight into cytokine expression during traumatic shock that can enable earlier identification of patients at risk for development of MOF. (J Am Coll Surg 2009;209: 320-331. (C) 2009 by the American College of Surgeons)	[Jastrow, Kenneth M., III; Gonzalez, Ernest A.; Suliburk, James W.; Kozar, Rosemary A.; Motschall, Deborah A.; Mercer, David W.] Univ Texas Med Sch Houston, Dept Surg, Houston, TX 77030 USA; [McGuire, Mary F.; Iyengar, Sriram] Univ Texas Sch Hlth Informat Sci Houston, Houston, TX USA; [McKinley, Bruce A.; Moore, Frederick A.] Methodist Hosp Syst, Dept Surg, Houston, TX USA		Mercer, DW (corresponding author), Univ Texas Med Sch Houston, Dept Surg, 6431 Fannin St,MSB 4-264, Houston, TX 77030 USA.	david.w.mercer@uth.tmc.edu		Suliburk, James/0000-0002-6421-269X	National Institute of General Medical SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM-38529, GM-08792]; National Institutes of Health Clinical Research Feasibility Funds University Clinical Research CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [M01RR002558]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008792, P50GM038529] Funding Source: NIH RePORTER	Supported by National Institute of General Medical Sciences grant Nos. GM-38529 and GM-08792 and National Institutes of Health Clinical Research Feasibility Funds University Clinical Research Center grant No. M01RR002558.	ANGIOLILLO AL, 1995, J EXP MED, V182, P155, DOI 10.1084/jem.182.1.155; Asensio VC, 1999, TRENDS NEUROSCI, V22, P504, DOI 10.1016/S0166-2236(99)01453-8; Baue AE, 1998, SHOCK, V10, P79, DOI 10.1097/00024382-199808000-00001; Berney T, 1999, PANCREAS, V18, P371, DOI 10.1097/00006676-199905000-00007; Bozza FA, 2007, CRIT CARE, V11, DOI 10.1186/cc5783; BROXMEYER HE, 1991, J IMMUNOL, V147, P2586; Chow CC, 2005, SHOCK, V24, P74, DOI 10.1097/01.shk.0000168526.97716.f3; Ciesla DJ, 2005, ARCH SURG-CHICAGO, V140, P432, DOI 10.1001/archsurg.140.5.432; Gabuzda D, 2000, J NEUROVIROL, V6, pS24; Geppert A, 2002, CRIT CARE MED, V30, P1987, DOI 10.1097/00003246-200209000-00007; Glabinski AR, 1999, J NEUROVIROL, V5, P3, DOI 10.3109/13550289909029740; Gonzalez EA, 2007, J TRAUMA, V62, P112, DOI 10.1097/01.ta.0000250497.08101.8b; Hollander M., 1973, NONPARAMETRIC STAT I; Hynninen M, 2003, SHOCK, V20, P1, DOI 10.1097/01.shk.0000068322.08268.b4; Kanegane C, 1998, J LEUKOCYTE BIOL, V64, P384, DOI 10.1002/jlb.64.3.384; Kellum JA, 2007, ARCH INTERN MED, V167, P1655, DOI 10.1001/archinte.167.15.1655; Livaditi O, 2006, CYTOKINE, V36, P283, DOI 10.1016/j.cyto.2007.02.007; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; LUSTER AD, 1987, J EXP MED, V166, P1084, DOI 10.1084/jem.166.4.1084; Mahalingam S, 1999, J VIROL, V73, P1479, DOI 10.1128/JVI.73.2.1479-1491.1999; Maier B, 2007, SHOCK, V28, P668, DOI 10.1097/shk.0b013e318123e64e; Marr AB, 2004, SHOCK, V21, P300, DOI 10.1097/00024382-200404000-00002; Martin C, 1997, CRIT CARE MED, V25, P1813, DOI 10.1097/00003246-199711000-00018; McKinley BA, 2001, J TRAUMA, V50, P415, DOI 10.1097/00005373-200103000-00004; McKinley BA, 2002, J TRAUMA, V53, P825, DOI 10.1097/00005373-200211000-00004; Mennicken F, 1999, TRENDS PHARMACOL SCI, V20, P73, DOI 10.1016/S0165-6147(99)01308-5; MOORE FA, 1991, J TRAUMA, V31, P629, DOI 10.1097/00005373-199105000-00006; MYERS RD, 1993, NEUROCHEM RES, V18, P667, DOI 10.1007/BF00966780; Neidhardt R, 1997, J TRAUMA, V42, P863, DOI 10.1097/00005373-199705000-00017; Oberholzer A, 2005, SHOCK, V23, P488, DOI 10.1097/01.shk.0000163802.46355.59; Oberholzer A, 2000, CRIT CARE MED, V28, pN3, DOI 10.1097/00003246-200004001-00002; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; Rivers EP, 2007, CRIT CARE MED, V35, P2016, DOI 10.1097/01.CCM.0000281637.08984.6E; ROUMEN RMH, 1993, ANN SURG, V218, P769, DOI 10.1097/00000658-199312000-00011; SARRIS AH, 1993, J EXP MED, V178, P1127, DOI 10.1084/jem.178.3.1127; Sauaia A, 1996, WORLD J SURG, V20, P392, DOI 10.1007/s002689900062; Sauaia A, 2009, SHOCK, V31, P438, DOI 10.1097/SHK.0b013e31818ba4c6; Stewart RM, 2007, J TRAUMA, V62, pS47, DOI 10.1097/TA.0b013e31806546ab; STRIETER RM, 1995, BIOCHEM BIOPH RES CO, V210, P51, DOI 10.1006/bbrc.1995.1626; Ulvik A, 2007, CRIT CARE, V11, DOI 10.1186/cc6111; Wunder C, 2004, INFLAMM RES, V53, P158, DOI 10.1007/s00011-003-1239-3; Yamada Y, 1996, BURNS, V22, P587, DOI 10.1016/S0305-4179(96)00052-6	42	79	85	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1072-7515	1879-1190		J AM COLL SURGEONS	J. Am. Coll. Surg.	SEP	2009	209	3					320	331		10.1016/j.jamcollsurg.2009.05.002			12	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	493RH	WOS:000269755100006	19717036				2022-02-06	
J	Greve, KW; Ord, JS; Bianchini, KJ; Curtis, KL				Greve, Kevin W.; Ord, Jonathan S.; Bianchini, Kevin J.; Curtis, Kelly L.			Prevalence of Malingering in Patients With Chronic Pain Referred for Psychologic Evaluation in a Medico-Legal Context	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	35th Annual Meeting of the International-Neuropsychological-Society	FEB 07-10, 2007	Portland, OR	Int Neuropsychol Soc		Chronic disease; Malingering; Pain; Prevalence; Rehabilitation	TRAUMATIC BRAIN-INJURY; VERBAL-LEARNING TEST; NEUROCOGNITIVE DYSFUNCTION; BASE RATES; NEUROPSYCHOLOGICAL EVALUATION; CLASSIFICATION ACCURACY; BELIEVABLE DEFICITS; ACCIDENT NEUROSIS; RESPONSE BIAS; DISABILITY	Prevalence of malingering in patients with chronic pain referred for psychologic evaluation in a medico-legal context. Objective: To provide an empirical estimate of the prevalence of malingered disability in patients with chronic pain who have financial incentive to appear disabled. Design: Retrospective review of cases. Setting: A private neuropsychologic clinic in a southeastern metropolitan area. Participants: Consecutive patients (N=508) referred for psychologic evaluation related to chronic pain over a 10-year period (1995-2005). Interventions: Not applicable. Main Outcome Measures: Prevalence of malingering was examined using 2 published clinical diagnostic systems (Malingered Pain-Related Disability and Malingered Neurocognitive Dysfunction) as well as statistical estimates based on well validated indicators of malingering. Results: The prevalence of malingering in patients with chronic pain with financial incentive is between 20% and 50% depending on the diagnostic system used and the statistical model's underlying assumptions. Some factors associated with the medico-legal context such as the jurisdiction of a workers' compensation claim or attorney representation were associated with slightly higher malingering rates. Conclusions: Malingering is present in a sizable minority of patients with pain seen for potentially compensable injuries. However, not all excess pain-related disability is a result of malingering. It is important not to diagnose malingering reflexively on the basis of limited or unreliable findings. A diagnosis of malingering should be explicitly based on a formal diagnostic system.	[Greve, Kevin W.; Ord, Jonathan S.; Bianchini, Kevin J.; Curtis, Kelly L.] Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; [Greve, Kevin W.; Bianchini, Kevin J.] Jefferson Neurobehav Grp, Metairie, LA USA		Greve, KW (corresponding author), Univ New Orleans Lakefront, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu					Allum JHJ, 1999, J VESTIBUL RES-EQUIL, V9, P223; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Ardolf BR, 2007, CLIN NEUROPSYCHOL, V21, P899, DOI 10.1080/13825580600966391; Artuso A, 2004, Acta Otorhinolaryngol Ital, V24, P8; Bianchini Kevin J, 2005, Spine J, V5, P404, DOI 10.1016/j.spinee.2004.11.016; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1993, PORTLAND DIGIT RECOG; Block A R, 2001, Spine J, V1, P274, DOI 10.1016/S1529-9430(01)00054-7; Block AR, 2003, PSYCHOL SPINE SURG; Bond CF, 2006, PERS SOC PSYCHOL REV, V10, P214, DOI 10.1207/s15327957pspr1003_2; Boone K.B., 2007, ASSESSMENT FEIGNED C; Chafetz MD, 2008, CLIN NEUROPSYCHOL, V22, P529, DOI 10.1080/13854040701346104; Curtis KL, 2006, ASSESSMENT, V13, P46, DOI 10.1177/1073191105285210; DELIS D, 1987, CALIFORNIA VERBAL LE; DELIS DC, 2000, CALIFORNIA VERBAL LE; Etherton Joseph L, 2006, Spine J, V6, P61, DOI 10.1016/j.spinee.2005.05.382; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; FAUST D, 1988, J CONSULT CLIN PSYCH, V56, P578, DOI 10.1037/0022-006X.56.4.578; FAUST D, 1995, NEUROL CLIN, V13, P255, DOI 10.1016/S0733-8619(18)30044-6; Fink P, 2005, PSYCHOSOMATICS, V46, P540, DOI 10.1176/appi.psy.46.6.540; Fink P, 2005, AUST NZ J PSYCHIAT, V39, P772, DOI 10.1080/j.1440-1614.2005.01682.x; Fishbain DA, 1999, CLIN J PAIN, V15, P244, DOI 10.1097/00002508-199912000-00002; Gatchel RJ, 1999, NEUROL CLIN, V17, P149, DOI 10.1016/S0733-8619(05)70119-5; Gianoli G, 2000, OTOLARYNG HEAD NECK, V122, P11, DOI 10.1016/S0194-5998(00)70137-9; Green P., 2005, GREENS WORD MEMORY T, Vrev. ed.; Greiffenstein M F, 1996, J Int Neuropsychol Soc, V2, P477; Greiffenstein M.F., 2007, ASSESSMENT FEIGNED C; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2006, NEUROTOXICOLOGY, V27, P940, DOI 10.1016/j.neuro.2006.06.009; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Grevitt M, 1998, Eur Spine J, V7, P218, DOI 10.1007/s005860050059; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; HENNEKENS CH, 1987, EPIDEMIOLOGY MED; Kaemmer, 1989, MMPI 2 MANUAL ADM SC; Kay NRM, 1998, INJURY, V29, P305, DOI 10.1016/S0020-1383(97)00207-6; Larrabee G.J., 2007, ASSESSMENT MALINGERE; LEAVITT F, 1986, PAIN, V25, P357, DOI 10.1016/0304-3959(86)90239-3; Linton SJ, 2000, SPINE, V25, P1148, DOI 10.1097/00007632-200005010-00017; Mallinson AI, 2005, OTOL NEUROTOL, V26, P686, DOI 10.1097/01.mao.0000169639.48193.fb; MEEHL PE, 1955, PSYCHOL BULL, V52, P194, DOI 10.1037/h0048070; Meyers JE, 2002, ARCH CLIN NEUROPSYCH, V17, P157, DOI 10.1016/S0887-6177(00)00107-4; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; Millis S. R., 2004, PRINCIPLES PRACTICE, P1077; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; PARK SS, 1988, AM REV RESPIR DIS, V138, P1002, DOI 10.1164/ajrccm/138.4.1002; Schapmire D, 2002, J Hand Ther, V15, P242; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Stevens A, 2008, PSYCHIAT RES, V157, P191, DOI 10.1016/j.psychres.2007.01.003; Straus SE., 2005, EVIDENCE BASED MED P, V3rd; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; [No title captured]	57	79	82	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUL	2009	90	7					1117	1126		10.1016/j.apmr.2009.01.018			10	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation; Sport Sciences	470SA	WOS:000267999000007	19577024				2022-02-06	
J	Park, E; Bell, JD; Siddiq, IP; Baker, AJ				Park, Eugene; Bell, Joshua D.; Siddiq, Ishita P.; Baker, Andrew J.			An analysis of regional microvascular loss and recovery following two grades of fluid percussion trauma: a role for hypoxia-inducible factors in traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						FPI; HIF1 alpha; microangiography; microvasculature; PHD2; VEGF	ENDOTHELIAL GROWTH-FACTOR; CEREBRAL-BLOOD-FLOW; CORPUS-CALLOSUM; GENE-EXPRESSION; HEAD TRAUMA; FACTOR VEGF; RAT; VULNERABILITY; CALPONIN; COMPLEX	Secondary hypoxic/ischemic injuries, stemming from reductions in cerebral blood flow are important contributing factors in progressive neuronal dysfunction after brain trauma. A greater preclinical understanding of how brain trauma leads to secondary hypoxia/ischemia is necessary in the development of posttraumatic brain injury (TBI) therapeutics. To this end, we examined the density of microvascular coverage in the injured and contralateral cortical hemispheres using two intensities of fluid percussion trauma in rats. A silicone microangiography technique showed a significant loss in microvascular density in 2 atmosphere (atm) (16.9 +/- 3.8%) and 3 atm (15.7 +/- 1.3%) injured animals relative to sham animals (29.9 +/- 2.5%; P < 0.01). RECA-1 immunohistochemistry indicated that capillary changes involved a reduction in capillary number and diameter. Reduction in microvascular density was shown to be a diffuse phenomenon occurring up to 4mm rostral and caudal to the injury epicenter. Recovery of microvasculature occurred by 2 weeks after injury only in the 2 atm injury group. Expression of HIF1 alpha and increased vascular endothelial growth factor expression were observed in the ipsilateral hippocampus suggesting sufficiently impaired microcirculation resulting in the expression of hypoxic-response proteins. Collectively, the results indicate diffuse and heterogeneous microvascular alterations as well as endogenous expression of neuroprotective and neovascularization pathways after TBI.	[Park, Eugene; Bell, Joshua D.; Siddiq, Ishita P.; Baker, Andrew J.] St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Cara Phelan Ctr Trauma Res, Toronto, ON M5B 1W8, Canada; [Bell, Joshua D.; Siddiq, Ishita P.; Baker, Andrew J.] Univ Toronto, Toronto, ON, Canada		Park, E (corresponding author), St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Cara Phelan Ctr Trauma Res, 30 Bond St,7-086 Bond Wing, Toronto, ON M5B 1W8, Canada.	parke@smh.toronto.on.ca					Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; Berra E, 2006, EMBO REP, V7, P41, DOI 10.1038/sj.embor.7400598; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P471; Chodobski A, 2003, NEUROSCIENCE, V122, P853, DOI 10.1016/j.neuroscience.2003.08.055; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dore-Duffy P, 2007, NEUROL RES, V29, P395, DOI 10.1179/016164107X204729; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; Gora-Kupilas K, 2005, FOLIA NEUROPATHOL, V43, P31; Huh JW, 2008, EXP NEUROL, V213, P84, DOI 10.1016/j.expneurol.2008.05.009; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kreipke CW, 2007, NEUROL RES, V29, P369, DOI 10.1179/016164107X204684; Kreipke CW, 2006, MICROVASC RES, V71, P197, DOI 10.1016/j.mvr.2006.02.002; Lazarovici P, 2006, CURR PHARM DESIGN, V12, P2609, DOI 10.2174/138161206777698738; Lin B, 2001, J NEUROTRAUM, V18, P389, DOI 10.1089/089771501750170958; Longhi L, 2007, INTENS CARE MED, V33, P2136, DOI 10.1007/s00134-007-0845-2; Maeda T, 2005, J NEUROTRAUM, V22, P763, DOI 10.1089/neu.2005.22.763; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Morgan R, 2007, NEUROL RES, V29, P375, DOI 10.1179/016164107X204693; Muellner A, 2003, J NEUROTRAUM, V20, P745, DOI 10.1089/089771503767869971; Park E, 2007, EXP NEUROL, V204, P49, DOI 10.1016/j.expneurol.2006.09.012; Park E, 2006, J NEUROPATH EXP NEUR, V65, P226, DOI 10.1097/01.jnen.0000202888.29705.93; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Petrov T, 2001, NEUROL RES, V23, P139, DOI 10.1179/016164101101198479; Pugh C W, 1999, Adv Nephrol Necker Hosp, V29, P191; Ratcliffe PJ, 1998, J EXP BIOL, V201, P1153; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Shen FX, 2006, STROKE, V37, P2601, DOI 10.1161/01.STR.0000240407.14765.e8; Shen YM, 2007, MAGN RESON IMAGING, V25, P219, DOI 10.1016/j.mri.2006.09.018; Skold MK, 2006, EUR J NEUROSCI, V23, P21, DOI 10.1111/j.1460-9568.2005.04527.x; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Verweij BH, 2007, PROG BRAIN RES, V161, P111, DOI 10.1016/S0079-6123(06)61008-X; Vespa Paul, 2003, Neurosurg Focus, V15, pE4; Wan YQ, 2007, J NEUROSCI RES, V85, P73, DOI 10.1002/jnr.21091; Wu HM, 2004, NEUROSURGERY, V55, P1306, DOI 10.1227/01.NEU.0000143028.08719.42; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	40	79	83	0	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	2009	29	3					575	584		10.1038/jcbfm.2008.151			10	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	412KD	WOS:000263722800013	19088740	Bronze			2022-02-06	
J	Pape, TLB; Rosenow, J; Lewis, G; Ahmed, G; Walker, M; Guernon, A; Roth, H; Patil, V				Pape, Theresa Louise-Bender; Rosenow, Joshua; Lewis, Gwyn; Ahmed, Ghada; Walker, Matthew; Guernon, Ann; Roth, Heidi; Patil, Vijaya			Repetitive transcranial magnetic stimulation-associated neurobehavioral gains during coma recovery	BRAIN STIMULATION			English	Article						neual stimulation; coma; treatment; intervention; traumatic brain injury	MINIMALLY CONSCIOUS STATES; EVENT-RELATED POTENTIALS; EVOKED POTENTIALS; PREFRONTAL CORTEX; VEGETATIVE STATE; ATTENTION; NEUROPATHOLOGY; NETWORKS	Background Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive method to induce changes in cortical neural excitability. This report presents findings from the first participant of a safety and efficacy study that examined a therapeutic rTMS protocol for persons with severe traumatic brain injury (TBI). Objective The primary hypothesis was that there will be no adverse events related to the provision of a 6-week rTMS protocol for persons with severe TBI who remain, at best, in a minimally conscious state for longer than 3 months. The secondary hypothesis was that the rTMS protocol Would induce significant neurobehavioral gains during treatment and that these gains would persist at 6-week follow-up. Methods A 6-week rTMS protocol (30 sessions) was delivered to a 26-year-old man who remained in a vegetative state 287 days after severe TBI. Stimulation was directed over the right dorsolateral prefrontal cortex. Repeated safety measures, neurobehavioral assessments, clinical examinations, and evoked potentials (EP) were obtained at baseline, every fifth rTMS session (weekly), and at a 6-week follow-up. Results There were no adverse events related to the provision of rTMS treatment. A trend toward significant (P = .066) neurobehavioral gains was temporally related to provision of rTMS. Left-sided brain stem auditory EP wave V latencies and waves I to V interpeak latencies improved along with neurobehavioral gains during provision of rTMS, suggesting that improved neural conduction in the pathway Mediated the neurobehavioral improvements. Conclusions Repetitive TMS merits further investigation as a safe therapeutic intervention to after neural activity, to modulate neural activity, and/or to facilitate recovery in persons with disordered consciousness subsequent to severe TBI. (C) 2009 Elsevier Inc. All rights reserved.	[Pape, Theresa Louise-Bender; Patil, Vijaya] Edward Hines Jr VA Hosp, Res Serv, Dept Vet Affairs, Hines, IL 60141 USA; [Pape, Theresa Louise-Bender; Guernon, Ann] Marianjoy Rehabil Hosp, Wheaton, IL USA; [Pape, Theresa Louise-Bender; Lewis, Gwyn; Ahmed, Ghada] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL USA; [Pape, Theresa Louise-Bender] Northwestern Univ, Feinberg Sch Med, Inst Hlth Care Studies, Chicago, IL USA; [Pape, Theresa Louise-Bender; Lewis, Gwyn; Ahmed, Ghada] Northwestern Univ, Feinberg Sch Med, Dept Neurosurg, Chicago, IL USA; [Lewis, Gwyn] AUT Univ, Hlth & Rehabil Res Ctr, Auckland, New Zealand; [Lewis, Gwyn; Roth, Heidi] Rehabil Inst Chicago, Chicago, IL 60611 USA; [Walker, Matthew] Northwestern Univ, Feinberg Sch Med, Dept Radiol, Chicago, IL USA; [Walker, Matthew] NW Mem Hosp, Dept Neuroradiol, Chicago, IL 60611 USA; [Patil, Vijaya] Loyola Univ, Med Ctr, Maywood, IL 60153 USA		Pape, TLB (corresponding author), Edward Hines Jr VA Hosp, Res Serv, Dept Vet Affairs, POB 5000,MC 151H, Hines, IL 60141 USA.	Theresa.Pape@va.gov		Bender Pape, Theresa/0000-0001-7738-5963	Department of Veterans Affairs, Office of Research and Development, Rehabilitation Research and Development ServiceUS Department of Veterans Affairs [B3302K, B4949N]; General Clinical Research Center (GCRC) of Northwestern University Feinberg School of MedicineUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR); National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR-00048]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000048] Funding Source: NIH RePORTER	Funding was provided by the Department of Veterans Affairs, Office of Research and Development, Rehabilitation Research and Development Service through an advanced research career development award (B3302K) and a career development transition award (B4949N). The research described in this article was also supported by the General Clinical Research Center (GCRC) of Northwestern University Feinberg School of Medicine. The GCRC is supported by Grant M01 RR-00048 from the National Center for Research Resources, National Institutes of Health. The Nick Kot Charity, a not-for-profit, also provided an unrestricted grant to support this project. Substantial in-kind contributions from the Departments of Neurosurgery and Physical Medicine and Rehabilitation, of Northwestern University Feinberg School of Medicine, and Marianjoy Rehabilitation Hospital also made this research possible. Additional in-kind contributions from Northwestern Memorial Hospital and the Rehabilitation Institute of Chicago are appreciated.	Adams JH, 1999, J CLIN PATHOL, V52, P804, DOI 10.1136/jcp.52.11.804; Cohen E, 1999, J NEUROL NEUROSUR PS, V67, P129, DOI 10.1136/jnnp.67.1.129; Di Lazzaro V, 2007, CLIN NEUROPHYSIOL, V118, P1193, DOI 10.1016/j.clinph.2007.02.020; Eker C, 2000, BRAIN INJURY, V14, P605; George MS, 2003, NEUROSURG CLIN N AM, V14, P283, DOI 10.1016/S1042-3680(02)00120-1; Giacino J, 2005, J HEAD TRAUMA REHAB, V20, P30, DOI 10.1097/00001199-200501000-00005; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GOLDMANRAKIC PS, 1984, TRENDS NEUROSCI, V7, P419, DOI 10.1016/S0166-2236(84)80146-0; GOLDMANRAKIC PS, 1988, ANNU REV NEUROSCI, V11, P137, DOI 10.1146/annurev.neuro.11.1.137; Harris-Love ML, 2006, ARCH PHYS MED REHAB, V87, pS84, DOI 10.1016/j.apmr.2006.08.330; Hausmann A, 2004, J CLIN PSYCHIAT, V65, P772; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Jorge RE, 2004, BIOL PSYCHIAT, V55, P398, DOI 10.1016/j.biopsych.2003.08.017; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Lew HL, 2006, J HEAD TRAUMA REHAB, V21, P350, DOI 10.1097/00001199-200607000-00006; Lew HL, 2004, AM J PHYS MED REHAB, V83, P210, DOI 10.1097/01.PHM.0000113402.85460.59; Lew HL, 2003, AM J PHYS MED REHAB, V82, P53, DOI [10.1097/00002060-200301000-00009, 10.1097/01.PHM.0000043771.90606.81]; LINACRE M, 1999, WINSTEPS; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; MESULAM MM, 1990, ANN NEUROL, V28, P597, DOI 10.1002/ana.410280502; Muri RM, 1996, J NEUROPHYSIOL, V76, P2102, DOI 10.1152/jn.1996.76.3.2102; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; PAPE T, PHYS MED RE IN PRESS; Pape T, 2006, J HEAD TRAUMA REHAB, V21, P417, DOI 10.1097/00001199-200609000-00025; Pape TLB, 2006, J HEAD TRAUMA REHAB, V21, P437, DOI 10.1097/00001199-200609000-00063; Pape TLB, 2005, J REHABIL RES DEV, V42, P19, DOI 10.1682/JRRD.2004.03.0033; Pape TLB, 2005, J REHABIL RES DEV, V42, P1, DOI 10.1682/JRRD.2004.03.0032; Pascual-Leone A., 2002, HDB TRANSCRANIAL MAG; PascualLeone A, 1996, NEUROLOGY, V46, P499, DOI 10.1212/WNL.46.2.499; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Schiff ND, 2002, BRAIN, V125, P1210, DOI 10.1093/brain/awf131; Thickbroom GW, 2006, CLIN NEUROPHYSIOL, V117, P61, DOI 10.1016/j.clinph.2005.09.010; Wagner M, 2006, J PSYCHIATR RES, V40, P315, DOI 10.1016/j.jpsychires.2005.06.001; Wassermann EM, 1996, ELECTROMYOGR MOTOR C, V101, P412; Wassermann EM, 2001, CLIN NEUROPHYSIOL, V112, P1367, DOI 10.1016/S1388-2457(01)00585-5	38	79	81	1	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1935-861X	1876-4754		BRAIN STIMUL	Brain Stimul.	JAN	2009	2	1					22	35		10.1016/j.brs.2008.09.004			14	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	406OG	WOS:000263304200004	20633400				2022-02-06	
J	Renolleau, S; Fau, S; Charriaut-Marlangue, C				Renolleau, Sylvain; Fau, Sebastien; Charriaut-Marlangue, Christiane			Gender-related differences in apoptotic pathways after neonatal cerebral ischemia	NEUROSCIENTIST			English	Article						female; male; caspase inhibitor; mitochondria; cytochrome c; cell death	TRAUMATIC BRAIN INJURY; Q-VD-OPH; HYPOXIA-ISCHEMIA; CELL-DEATH; RAT-BRAIN; CASPASE-3 ACTIVATION; NITRIC-OXIDE; POLY(ADP-RIBOSE) POLYMERASE; NUCLEAR TRANSLOCATION; MITOCHONDRIAL PATHWAY	Many central nervous system (CNS) diseases display sexual dimorphism, specifically a predilection for one gender or a gender-dependent response to treatment. Exposure to circulating sex steroids is felt to be a chief contributor to this phenomenon. However, CNS diseases of childhood and of the elderly also demonstrate gender predominance and/or sexual dimorphism response to therapies. In this short update, we provide information concerning one of the most interesting new emerging concepts related to the influence of the sex in the pathogenesis of developmental brain injuries leading to different levels of neuroprotection between genders after cerebral hypoxia-ischemia or ischemia.	[Renolleau, Sylvain; Fau, Sebastien; Charriaut-Marlangue, Christiane] Univ Paris 06, F-75252 Paris 05, France; [Renolleau, Sylvain; Fau, Sebastien] Univ Paris 06, Hop Armand Trousseau, Serv Reanimat Neonatale & Pediat, F-75252 Paris 05, France		Charriaut-Marlangue, C (corresponding author), CNRS, UMR 7102, HICD Case 14,9 Quai St Bernard, F-75005 Paris, France.	Christiane.Marlangue@snv.jussieu.fr	, CHARRIAUT-MARLANGUE/H-3249-2019				Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; Benjelloun N, 2003, NEUROPATH APPL NEURO, V29, P350, DOI 10.1046/j.1365-2990.2003.00467.x; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; Bona E, 1998, PEDIATR RES, V43, P738, DOI 10.1203/00006450-199806000-00005; Bramlett Helen M, 2005, Pathophysiology, V12, P17, DOI 10.1016/j.pathophys.2005.02.009; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Carruth LL, 2002, NAT NEUROSCI, V5, P933, DOI 10.1038/nn922; Caserta TM, 2003, APOPTOSIS, V8, P345, DOI 10.1023/A:1024116916932; Chauvier D, 2007, CELL DEATH DIFFER, V14, P387, DOI 10.1038/sj.cdd.4402044; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; Culmsee C, 2005, J NEUROSCI, V25, P10262, DOI 10.1523/JNEUROSCI.2818-05.2005; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Dewing P, 2003, MOL BRAIN RES, V118, P82, DOI 10.1016/S0169-328X(03)00339-5; Dhote VV, 2007, LIFE SCI, V81, P188, DOI 10.1016/j.lfs.2007.05.010; Donders J, 2002, NEUROPSYCHOLOGY, V16, P491, DOI 10.1037//0894-4105.16.4.491; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253, DOI 10.1097/00004647-199811000-00012; Ducrocq S, 2000, J NEUROCHEM, V74, P2504, DOI 10.1046/j.1471-4159.2000.0742504.x; Edwards AD, 2000, PEDIATR RES, V47, P431, DOI 10.1203/00006450-200004000-00003; Edwards D, 2004, J PEDIATR-US, V145, P723, DOI 10.1016/j.jpeds.2004.08.062; Felderhoff-Mueser U, 2002, NEUROBIOL DIS, V11, P231, DOI 10.1006/nbdi.2002.0521; Ferrand-Drake M, 2003, J NEUROCHEM, V85, P1431, DOI 10.1046/j.1471-4159.2003.01794.x; Goel A, 2007, CARDIOVASC RES, V76, P351, DOI 10.1016/j.cardiores.2007.06.029; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hagberg H, 2004, J NEUROCHEM, V90, P1068, DOI 10.1111/j.1471-4159.2004.02547.x; Halestrap AP, 2006, BIOCHEM SOC T, V34, P232, DOI 10.1042/BST0340232; HALL ED, 1991, J CEREBR BLOOD F MET, V11, P292, DOI 10.1038/jcbfm.1991.61; Hawk T, 1998, BRAIN RES, V796, P296, DOI 10.1016/S0006-8993(98)00327-8; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; HURN PD, 1995, J CEREBR BLOOD F MET, V15, P666, DOI 10.1038/jcbfm.1995.82; Hurn PD, 2005, STROKE, V36, P193, DOI 10.1161/01.STR.0000153064.41332.f6; Hurn PD, 2000, J CEREBR BLOOD F MET, V20, P631, DOI 10.1097/00004647-200004000-00001; Igarashi T, 2001, EXP NEUROL, V172, P332, DOI 10.1006/exnr.2001.7820; Joashi UC, 1999, EUR J NEUROSCI, V11, P91, DOI 10.1046/j.1460-9568.1999.00409.x; Joly LM, 2004, J CEREBR BLOOD F MET, V24, P124, DOI 10.1097/01.WCB.0000100061.36077.5F; Joly LM, 2003, PEDIATR RES, V53, P776, DOI 10.1203/01.PDR.0000059751.00465.F6; Jones NM, 2004, J NEUROCHEM, V89, P157, DOI 10.1111/j.1471-4159.2004.02324.x; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; Kondo Y, 1997, NEUROSCI LETT, V238, P45, DOI 10.1016/S0304-3940(97)00847-1; Lesuisse C, 2002, J CEREBR BLOOD F MET, V22, P935, DOI 10.1097/00004647-200208000-00005; Mabley JG, 2005, J PHARMACOL EXP THER, V315, P812, DOI 10.1124/jpet.105.090480; Manabat C, 2003, STROKE, V34, P207, DOI 10.1161/01.STR.0000047101.87575.3C; McCullough LD, 2003, TRENDS ENDOCRIN MET, V14, P228, DOI 10.1016/S1043-2760(03)00076-6; McCullough LD, 2005, J CEREBR BLOOD F MET, V25, P502, DOI 10.1038/sj.jcbfm.9600059; Momoi T, 2004, J CHEM NEUROANAT, V28, P101, DOI 10.1016/j.jchemneu.2004.05.008; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; Murph E, 2007, CARDIOVASC RES, V75, P478, DOI 10.1016/j.cardiores.2007.03.025; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nijboer CHA, 2007, J CEREBR BLOOD F MET, V27, P282, DOI 10.1038/sj.jcbfm.9600342; Northington FJ, 2001, J NEUROSCI, V21, P1931, DOI 10.1523/JNEUROSCI.21-06-01931.2001; Pelligrino DA, 1998, NEUROREPORT, V9, P3285, DOI 10.1097/00001756-199810050-00026; Plesnila N, 2004, J CEREBR BLOOD F MET, V24, P458, DOI 10.1097/00004647-200404000-00011; Renolleau S, 2007, J NEUROCHEM, V100, P1062, DOI 10.1111/j.1471-4159.2006.04269.x; Roth KA, 2001, MENT RETARD DEV D R, V7, P261, DOI 10.1002/mrdd.1036; Rusa R, 1999, STROKE, V30, P1665, DOI 10.1161/01.STR.30.8.1665; Sampei K, 2000, STROKE, V31, P738, DOI 10.1161/01.STR.31.3.738; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Simpkins JW, 1997, J NEUROSURG, V87, P724, DOI 10.3171/jns.1997.87.5.0724; Spierings D, 2005, SCIENCE, V310, P66, DOI 10.1126/science.1117105; Subramanian M, 2007, J IMMUNOL, V179, P2330, DOI 10.4049/jimmunol.179.4.2330; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Toung TJK, 1998, STROKE, V29, P1666, DOI 10.1161/01.STR.29.8.1666; Wang ML, 2003, J THEOR COMPUT CHEM, V2, P351, DOI 10.1142/S0219633603000562; Wang Q, 1999, STROKE, V30, P630, DOI 10.1161/01.STR.30.3.630; Wang XY, 2001, BIOL NEONATE, V79, P172; Weil MD, 1998, JAMA-J AM MED ASSOC, V279, P1474, DOI 10.1001/jama.279.18.1474; Wen TC, 2006, NEUROSCIENCE, V139, P803, DOI 10.1016/j.neuroscience.2006.02.057; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zhang L, 2003, NEUROSCI LETT, V337, P65, DOI 10.1016/S0304-3940(02)01179-5; Zhu CL, 2003, J NEUROCHEM, V86, P306, DOI 10.1046/j.1471-4159.2003.01832.x; Zhu CL, 2006, J NEUROCHEM, V96, P1016, DOI 10.1111/j.1471-4159.2005.03639.x	75	79	79	1	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-8584	1089-4098		NEUROSCIENTIST	Neuroscientist	FEB	2008	14	1					46	52		10.1177/1073858407308889			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	251VL	WOS:000252403600013	17971506				2022-02-06	
J	Kato, T; Nakayama, N; Yasokawa, Y; Okumura, A; Shinoda, J; Iwama, T				Kato, Takayuki; Nakayama, Noriyuki; Yasokawa, Yuto; Okumura, Ayumi; Shinoda, Jun; Iwama, Toru			Statistical image analysis of cerebral glucose metabolism in patients with cognitive impairment following diffuse traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						cognitive function; metabolism; positron emission tomography; traumatic brain injury	CLOSED HEAD-INJURY; ANTERIOR CINGULATE CORTEX; AXONAL INJURY; BLOOD-FLOW; SUSTAINED ATTENTION; FRONTAL-CORTEX; FDG-PET; SPECT; MRI; LOCALIZATION	The aim of this study was to explore the regional cerebral glucose metabolism (rCM) in patients with chronic stage traumatic brain injury (TBI) compared with normal controls. We also investigated the relationship between regional cerebral glucose metabolism and cognitive function. We performed 2-[F-18]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) study using statistical parametric mapping (SPM) analysis in 36 diffuse axonal injury (DAI) patients (mean age +/- SD, 36.3 +/- 9.8 years). At 6 months or more after head injury, all patients underwent FDG-PET study and neuropsychological batteries to assess cognitive function. Thirty healthy, gender-matched control subjects who were comparable in age were also studied. Between the TBI patients and normal controls, group comparisons showed regional metabolic decreases in the bilateral frontal lobes, temporal lobes, thalamus, as well as the right cerebellum in the TBI group. Only full-scale Intelligence Quotient (IQ) (mean +/- SD, 78.5 +/- 11.9) correlated positively with rCM in the right cingulate gyrus and the bilateral medial frontal gyrus. In other examinations, the correlation was not provided. DAI may induce functional disconnection and decreased neuronal activity, and finally lead to diffuse glucose hypometabolism. Low full-scale IQ scores may be related to significantly different underlying cognitive impairment. In supporting cognitive function following TBI, which showed diffuse cerebral metabolic reduction compared with normal controls, medial prefrontal cortex and anterior cingulate cortex may be an important component.	Kizawa Mem Hosp, Chubu Med Ctr Prolonged Traumat Brain Dysfunct, Gifu 5050034, Japan; Gifu Univ, Grad Sch Med, Dept Neurosurg, Gifu, Japan		Kato, T (corresponding author), Kizawa Mem Hosp, Chubu Med Ctr Prolonged Traumat Brain Dysfunct, 630 Shimokobi Kobi-machi,Minokamo City, Gifu 5050034, Japan.	nou-taka@a.email.ne.jp		Iwama, Toru/0000-0002-9426-284X			ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Alavi A, 1989, J Neuropsychiatry Clin Neurosci, V1, pS45; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Casey BJ, 1997, DEV PSYCHOBIOL, V30, P61, DOI 10.1002/(SICI)1098-2302(199701)30:1<61::AID-DEV6>3.0.CO;2-T; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Dehaene S, 1998, P NATL ACAD SCI USA, V95, P14529, DOI 10.1073/pnas.95.24.14529; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gehring WJ, 2001, J NEUROSCI, V21, P9430, DOI 10.1523/JNEUROSCI.21-23-09430.2001; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; Haier RJ, 2004, NEUROIMAGE, V23, P425, DOI 10.1016/j.neuroimage.2004.04.025; Karussis D, 2000, J NEUROL SCI, V172, P25, DOI 10.1016/S0022-510X(99)00267-1; Lewin JS, 1996, J COMPUT ASSIST TOMO, V20, P695, DOI 10.1097/00004728-199609000-00002; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.080523; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; Paus T, 2001, NAT REV NEUROSCI, V2, P417, DOI 10.1038/35077500; Peterson BS, 2000, JAMA-J AM MED ASSOC, V284, P1939, DOI 10.1001/jama.284.15.1939; Petrides M, 1995, ANN NY ACAD SCI, V769, P85, DOI 10.1111/j.1749-6632.1995.tb38133.x; Pinter JD, 2001, AM J PSYCHIAT, V158, P1659, DOI 10.1176/appi.ajp.158.10.1659; Rushton JP, 1995, CAN J EXP PSYCHOL, V49, P562, DOI 10.1037/1196-1961.49.4.562; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Swick D, 2002, NEUROPSYCHOLOGIA, V40, P1240, DOI 10.1016/S0028-3932(01)00226-3; Wilke M, 2003, NEUROIMAGE, V20, P202, DOI 10.1016/S1053-8119(03)00199-X; Yamaki T, 1996, J TRAUMA, V40, P50, DOI 10.1097/00005373-199601000-00010; Zysset S, 2002, NEUROIMAGE, V15, P983, DOI 10.1006/nimg.2001.1008	36	79	83	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2007	24	6					919	926		10.1089/neu.2006.0203			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	184EA	WOS:000247622700001	17600509				2022-02-06	
J	Malec, JF; Testa, JA; Rush, BK; Brown, AW; Moessner, AM				Malec, James F.; Testa, Julie A.; Rush, Beth K.; Brown, Allen W.; Moessner, Anne M.			Self-assessment of impairment, impaired self-awareness, and depression after traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain; injury; depression; impaired self-awareness; rehabilitation	CLOSED-HEAD-INJURY; MAJOR DEPRESSION; SOCIAL SUPPORT; FOLLOW-UP; SCALE; CONSCIOUSNESS; PERSONALITY; RELIABILITY; INVENTORY; COGNITION	Objective: To identify patient features associated with early and late depression after traumatic brain injury (TBI). Participants: 3 clinical trauma groups (mild TBI, moderate-severe TBI, orthopedic injury) and their significant others. Measures: Preinjuiy: age, education, substance abuse, and psychiatric history; Injury severity: classification using Glasgow Coma Scale and cranial CT scan, posttraumatic amnesia; Early impairment: Neurobehavioral Functioning Inventory (NFI), Impaired Self-Awareness (ISA); Social and family support: Multidimensional Scale of Perceived Social Support, Family Assessment Device; Depression: NFI Depression Scale. Method: Regression analyses of predictor variables on early and late measures of depression. Results: Depression rates did not differ among the 3 trauma groups. Preinjury level of education, previous psychiatric history, and perceived level of social support explained a small portion of the variance in depressive symptoms. Patients' self-assessment of their impairment at discharge was most strongly correlated with both early and late depression. ISA was associated with reduced self-report of depressive symptoms. However, when those with ISA were excluded from the analysis, self-assessment of impairment remained strongly associated with depression. Conclusions: Patients' self-assessment of impairment is strongly associated with early and late depression. Presence and severity of TBI does not appear to play a direct role in depression but does appear related to ISA, which serves as a barrier to the development of depression. Focusing on impairment appears to be a cardinal feature of depression in both patients with TBI and an orthopedic trauma group.	Mayo Clin, Generose METBI, Coll Med, Dept Psychiat, Rochester, MN 55905 USA; Mayo Clin, Dept Psychol, Coll Med, Rochester, MN 55905 USA; Mayo Clin, Dept Phys Med & Rehabil, Coll Med, Rochester, MN 55905 USA; Mayo Clin, Dept Nursing, Coll Med, Rochester, MN 55905 USA		Malec, JF (corresponding author), Mayo Clin, Generose METBI, Coll Med, Dept Psychiat, Rochester, MN 55905 USA.	malec.james@mayo.edu		Brown, Allen W./0000-0001-7228-3351			Babin PR, 2003, BRAIN INJURY, V17, P889, DOI 10.1080/0269905031000088595; Beck A.T., 1967, DEPRESSION CAUSES TR; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; Goldstein FC, 1996, NEUROPSYCHOLOGY, V10, P147; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Greenberger D, 1995, MIND MOOD CHANGE YOU; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hoofien D, 2001, BRAIN INJURY, V15, P189; Jorge R, 2002, NEUROREHABILITATION, V17, P311; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; KAZARIAN SS, 1991, J COMMUNITY PSYCHOL, V19, P150, DOI 10.1002/1520-6629(199104)19:2<150::AID-JCOP2290190206>3.0.CO;2-J; KREUTZER J, 1999, NEUROBEHAVIORAL FUNC; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Levin, 1997, Semin Clin Neuropsychiatry, V2, P207; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Malec JF, 2004, REHABIL PSYCHOL, V49, P55, DOI 10.1037/0090-5550.49.1.55; Malec JF, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199706000-00002; Malec JF, 2000, REHABIL PSYCHOL, V45, P227, DOI 10.1037/0090-5550.45.3.227; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Rowland SM, 2005, BRAIN INJURY, V19, P77, DOI 10.1080/02699050410001719988; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; TEASDALE G, 1974, LANCET, V2, P81; Testa JA, 2006, J HEAD TRAUMA REHAB, V21, P236, DOI 10.1097/00001199-200605000-00004; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; Wallace CA, 2000, BRAIN INJURY, V14, P549; ZIMET GD, 1988, J PERS ASSESS, V52, P30, DOI 10.1207/s15327752jpa5201_2; [No title captured]	58	79	80	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2007	22	3					156	166		10.1097/01.HTR.0000271116.12028.af			11	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	174OH	WOS:000246951100002	17510591				2022-02-06	
J	Tashlykov, V; Katz, Y; Gazit, V; Zohar, O; Schreiber, S; Pick, CG				Tashlykov, Vadim; Katz, Yeshayahu; Gazit, Vered; Zohar, Ofer; Schreiber, Shaul; Pick, Chaim G.			Apoptotic changes in the cortex and hippocampus following minimal brain trauma in mice	BRAIN RESEARCH			English	Article						apoptosis; neurodegeneration; traumatic brain injury; mice	CELL-DEATH; TEMPORAL CHARACTERIZATION; HEAD-INJURY; NEURONS; EXPRESSION; GLUTAMATE; PATTERNS; MODEL; RATS; CA3	interpretation of the cellular and molecular pathogenic basis of post-minimal traumatic brain injury is a significant clinical and scientific problem, especially due to the high prevalence of motor vehicle-and other accidents. Pathogenetic brain mechanisms following traumatic impact are usually investigated by using models of severe or moderate trauma. Apoptotic neuronal degeneration after notable brain trauma is a well-known phenomenon, but the source of its activation is not clear, especially after mild, subclinical brain trauma. In the present study, we used a closed head weight-drop model to induce minimal brain injury in mice. Pellets of 5,10,15,20,25 and 30 g were dropped on the right side of mice's head kept under light ether anesthesia. No abnormal behavioral or neurophysiological changes were seen following the head trauma. Morphological assessment was done 72 h after the traumatic impact using TUNEL assay and silver staining. We found gradual increase of TUNEL-positive and silver-impregnated cells number in different cortical and hippocampal regions of both injured and contralateral hemispheres. The threshold of traumatic impact that caused a significant activation was 10-15 g pellets (evident by silver staining), and 15-20 g for apoptosis. The most sensitive zones for trauma were anterior cingulate cortex and CA3 area of hippocampus. No bilateral hemispheric differences were found. Our results demonstrate that even closed head minimal traumatic brain injury can cause diffused neuronal damage and apoptosis. This results correlate well with cognitive and behavioral deficits described for mice suffering similar mTBI and can also explain the wide variety of mental disturbances described for post-concussion syndrome in patients who suffered mild head injury. (c) 2006 Elsevier B.V. All rights reserved.	Tel Aviv Univ, Dept Anat & Anthropol, Sackler Fac Med, IL-69978 Tel Aviv, Israel; Technion Israel Inst Technol, Lab Anesthesia Pain & Neural Res, Bruce Rappaport Fac Med, Haifa, Israel; Chaim Sheba Med Ctr, Dept Neurol, Ramat Gan, Israel; Rambam Med Ctr, Dept Anesthesiol, Haifa, Israel; Johns Hopkins Univ, Blanchette Rockefeller Neurosci Inst, Rockville, MD 20850 USA; Tel Aviv Sourasky Med Ctr, Dept Psychiat, Tel Aviv, Israel		Pick, CG (corresponding author), Tel Aviv Univ, Dept Anat & Anthropol, Sackler Fac Med, IL-69978 Tel Aviv, Israel.	pickc@post.tau.ac.il	Pick, Chaim/D-4789-2009; Schreiber, Shaul/E-5821-2010	Schreiber, Shaul/0000-0002-2189-0693			Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Bernabeu R, 2000, J CEREBR BLOOD F MET, V20, P1669, DOI 10.1097/00004647-200012000-00006; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; Chatfield DA, 2002, BRIT J NEUROSURG, V16, P471, DOI 10.1080/0268869021000030285; Chen JW, 2000, J BIOMED SCI, V7, P459, DOI 10.1007/BF02253361; Hamner M B, 1999, Depress Anxiety, V9, P1; INAGAKI M, 2006, J AFFECT DISORD; Johnson EA, 2005, EXP BRAIN RES, V167, P17, DOI 10.1007/s00221-005-2362-2; LaPlaca MC, 1999, J NEUROCHEM, V73, P205, DOI 10.1046/j.1471-4159.1999.0730205.x; LEDOUX JE, 1990, J NEUROSCI, V10, P1043; Lee I, 2004, HIPPOCAMPUS, V14, P66, DOI 10.1002/hipo.10167; Lu J, 2000, NEUROSCI LETT, V290, P89, DOI 10.1016/S0304-3940(00)01307-0; Lu J, 2003, NEUROPHARMACOLOGY, V44, P253, DOI 10.1016/S0028-3908(02)00380-5; MacDonald AW, 2006, BIOL PSYCHIAT, V60, P1241, DOI 10.1016/j.biopsych.2006.04.041; MAGARINOS AM, 1995, NEUROSCIENCE, V69, P89, DOI 10.1016/0306-4522(95)00259-L; Margulies S, 2000, J CLIN NEUROSCI, V7, P400, DOI 10.1054/jocn.1999.0681; Martin LJ, 2001, J COMP NEUROL, V433, P299, DOI 10.1002/cne.1141; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; NEUHAUS AH, 2006, J PSYCHIAT RES; O'Dell DM, 2000, J NEUROSCI, V20, P4821; Orme-Johnson DW, 2006, NEUROREPORT, V17, P1359, DOI 10.1097/01.wnr.0000233094.67289.a8; Pan WH, 2003, EXP BRAIN RES, V149, P195, DOI 10.1007/s00221-002-1355-7; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; RINK A, 1995, AM J PATHOL, V147, P1575; Runnerstam M, 2001, J NEUROTRAUM, V18, P259, DOI 10.1089/08977150151070892; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; Stadelmann C, 2001, BRAIN PATHOL, V11, P273; SYMONDS C, 1962, LANCET, V1, P1; TWEEDIE D, IN PRESS J NEUROSCIE; ZELMAN FP, 2002, BRAIN RES, V947, P131; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	35	79	82	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 26	2007	1130	1					197	205		10.1016/j.brainres.2006.10.032			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	134GT	WOS:000244072200022	17174280				2022-02-06	
J	Krpan, KM; Levine, B; Stuss, DT; Dawson, DR				Krpan, Katherine M.; Levine, Brian; Stuss, Donald T.; Dawson, Deirdre R.			Executive function and coping at one-year post traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							HUMAN PREFRONTAL CORTEX; SEVERE HEAD-INJURY; LESION LOCATION; DECISION-MAKING; SELF-REGULATION; SCHIZOPHRENIA; DISSOCIATION; PERFORMANCE; STRATEGIES; DAMAGE	The purpose of this study was to examine the relationship between executive function and coping at one-year-post traumatic brain injury (TBI). TBI and matched control groups completed a coping questionnaire and a neuropsychological test series. In the TBI group, better executive performance was related to the use of problem focused coping (considered more adaptive). Conversely, lower executive performance was related to the use of emotion focused coping (considered more maladaptive). Planned hierarchical regression showed that executive function contributed significantly to the use of problem focused coping above and beyond pre-morbid intelligence and injury severity. Implications for cognitive rehabilitation are discussed.	Univ Toronto, Kunin Lunenfeld Appl Res Unit, Toronto, ON M6A 2E1, Canada; Univ Toronto, Rotman Res Inst, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON M5S 1A1, Canada; Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Med Neurol, Toronto, ON M5S 1A1, Canada		Dawson, DR (corresponding author), Univ Toronto, Kunin Lunenfeld Appl Res Unit, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	ddawson@klaru-baycrest.on.ca	Levine, Brian/G-4328-2010; Dawson, Deirdre R/I-8882-2014; Levine, Brian/O-2725-2019	Levine, Brian/0000-0003-4343-811X; Dawson, Deirdre R/0000-0001-7517-6121; Levine, Brian/0000-0003-4343-811X			ANDERSON SW, 2002, HDB NEUROPSYCHOLOGY, V7, P145; [Anonymous], 1999, TRAUMATIC BRAIN INJU; Baddeley A.D., 1986, WORKING MEMORY; Bechara A, 2000, BRAIN, V123, P2189, DOI 10.1093/brain/123.11.2189; Bechara A, 1998, J NEUROSCI, V18, P428; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bechara A, 1997, SCIENCE, V275, P1293, DOI 10.1126/science.275.5304.1293; Benson D.F., 1986, FRONTAL LOBES; BROWN J, 1958, Q J EXP PSYCHOL, V10, P12, DOI 10.1080/17470215808416249; Burgess P. W., 2002, PRINCIPLES FRONTAL L, P557, DOI 10.1093/acprof:oso/9780195134971.003.0033; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; COMALLI PE, 1962, J GENET PSYCHOL, V100, P47, DOI 10.1080/00221325.1962.10533572; COURVILLE CB, 1937, PATHOLOGY CENTRAL NE; CRAIK FIM, 1990, ADV NEUROL, V51, P210; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Dawson D.R., 2004, ARCH PHYS MED REHAB, V85, pE8; Dawson DR, 2006, BRAIN COGNITION, V60, P214; Dawson DR, 2004, BRAIN INJURY, V18, P221, DOI 10.1080/02699050310001617406; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Eisenberg, 1987, NEUROBEHAVIORAL RECO, P215; Finset A, 2000, BRAIN INJURY, V14, P887; Folkman S., 1984, STRESS; Folkman S., 1988, WAYS COPING QUESTION; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jennett B, 1981, MANAGEMENT HEAD INJU; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Levin HS., 1982, NEUROBEHAVIORAL CONS; LEVIN HS, 1991, NEUROSURG CLIN N AM, V2, P217; Levine B, 2005, COGN BEHAV NEUROL, V18, P45, DOI 10.1097/01.wnn.0000152227.13001.c3; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; Levine B., 2002, PRINCIPLES FRONTAL L, P448; LUBUSKO AA, 1994, BRAIN INJURY, V8, P65, DOI 10.3109/02699059409150959; MILIA K, 1995, BRAIN INJURY, V9, P607; Moore A D, 1989, Brain Inj, V3, P171, DOI 10.3109/02699058909004549; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; MOORE AD, 1994, BRAIN INJURY, V7, P193; NEVIN NC, 1967, J NEUROPATH EXP NEUR, V26, P77, DOI 10.1097/00005072-196701000-00006; NICHOLSON IR, 1992, AM J ORTHOPSYCHIAT, V62, P117, DOI 10.1037/h0079307; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Ownsworth T, 2004, NEUROPSYCHOL REHABIL, V14, P535, DOI 10.1080/09602010343000538; Ownsworth TL, 2002, BRAIN INJURY, V16, P291, DOI 10.1080/02699050110103986; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Stuss DT, 2000, NEUROPSYCHOLOGIA, V38, P388, DOI 10.1016/S0028-3932(99)00093-7; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Stuss DT, 2001, PSYCHOL ASSESSMENT, V13, P230, DOI 10.1037//1040-3590.13.2.230; Stuss DT, 1999, NEUROPSYCHOLOGIA, V37, P1005, DOI 10.1016/S0028-3932(98)00158-4; Stuss DT, 2001, NEUROPSYCHOLOGIA, V39, P771, DOI 10.1016/S0028-3932(01)00013-6; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN NR, 1995, J NEUROSURG, V82, P764, DOI 10.3171/jns.1995.82.5.0764; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; vandenBosch RJ, 1997, COMPR PSYCHIAT, V38, P341, DOI 10.1016/S0010-440X(97)90930-5; Wilder-Willis KE, 2002, SCHIZOPHR RES, V55, P259, DOI 10.1016/S0920-9964(01)00211-0; ZACHARY RA, 1982, SHIPLEY I LIVING SCA; 1994, MANUAL DIRCETIONS SC	66	79	79	0	20	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JAN	2007	29	1					36	46		10.1080/13803390500376816			11	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	115XS	WOS:000242767700004	17162720				2022-02-06	
J	Kelley, BJ; Farkas, O; Lifshitz, J; Povlishock, JT				Kelley, BJ; Farkas, O; Lifshitz, J; Povlishock, JT			Traumatic axonal injury in the perisomatic domain triggers ultrarapid secondary axotomy and Wallerian degeneration	EXPERIMENTAL NEUROLOGY			English	Article							OPTIC-NERVE FIBERS; BRAIN-INJURY; STRETCH-INJURY; AXOLEMMAL PERMEABILITY; SPINAL-CORD; MYELIN; DEATH; PIG; PATHOLOGY; EVENTS	Traumatic axonal injury (TAI) arising from diffuse brain injury (DBI) results in focally impaired axonal transport with progressive swelling and delayed disconnection over several hours within brainstem axons. Neocortical DBI-mediated perisomatic axotomy does not result in neuronal death, suggesting that a comparably delayed axotomy progression was responsible for this unanticipated response. To evaluate delayed perisomatic axotomy, the current study was initiated. Rats received intracerebroventricular 10-kDa dextran followed by moderate midline/central fluid percussion injury (FPI) or FPI alone. At 15, 303 60, and 180 min post-injury, light and transmission electron microscopy identified impaired axonal transport via antibodies targeting amyloid precursor protein (APP), while double-label fluorescent microscopy explored concomitant focal, axolemmal alterations via dextran-APP co-localization. At 15 min post-injury. perisomatic TAI was identified with LM within dorsolateral and ventral posterior thalamic nuclei. Using TEM, many sustaining somata and related proximal/distal axonal segments revealed normal ultrastructural detail that was Continuous with focal axonal swellings characterized by cytoskeletal and organelle pathology. In other cases, axotomy was confirmed by loss of axonal continuity distal to the swelling. By 30 min post-injury, perisomatic axotomy predominated. By 60-180 min, somatic, proximal axonal segment, and swelling ultrastructure were comparable to earlier time points although swelling diameter increased. Distal axonal segment ultrastructure now revealed the initial stages of Wallerian degeneration. The site of perisomatic axotomy did not internalize dextran, suggesting that its pathogenesis occurred independent of altered axolemmal permeability. Collectively, this DBI-mediated ultrarapid perisomatic axotomy and its sequelae further illustrate the varied axonal responses to trauma. (C) 2005 Elsevier Inc. All rights reserved.	Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA; Univ Pecs, Fac Med, Dept Neurosurg, Pecs, Hungary		Povlishock, JT (corresponding author), 1101 E Marshal St,Sanger Hall,Room 11-044,POB 980, Richmond, VA 23298 USA.	jtpovlis@vcu.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32HD049343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047463, R01NS045824, T32NS007288] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32 HD049343] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5P30NS047463, NS045824, T32NS007288] Funding Source: Medline		Adams JH, 1992, GREENFIELDS NEUROPAT, P106; Ahmed FAKM, 2001, EXP NEUROL, V167, P451, DOI 10.1006/exnr.2000.7562; Barron KD., 1983, SPINAL CORD RECONSTR, P7; BECERRA JL, 1995, AM J NEURORADIOL, V16, P125; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Buss A, 2004, BRAIN, V127, P34, DOI 10.1093/brain/awh001; CHRISTIAN GD, 1994, J FLOW INJECTION ANA, V11, P2; CONRADI S, 1969, ACTA PHYSIOL SCAND, P65; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Hardman JM, 2002, NEUROIMAG CLIN N AM, V12, P175, DOI 10.1016/S1052-5149(02)00009-6; Kraus J, 1996, NEUROTRAUMA, P13; Kreutzberg Georg W., 1995, P355; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LoPachin RM, 1997, TOXICOL APPL PHARM, V143, P233, DOI 10.1006/taap.1997.8106; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; McNeil PL, 2001, CELL TISSUE RES, V304, P141, DOI 10.1007/s004410000286; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POVISHLOK J, 1996, ACTA NEUROCHIR SUPP, V66, P81; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Smith DH, 1999, J NEUROSCI, V19, P4263; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; STRICH SJ, 1968, J NEUROL NEUROSUR PS, V31, P110, DOI 10.1136/jnnp.31.2.110; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Terasaki M, 1997, J CELL BIOL, V139, P63, DOI 10.1083/jcb.139.1.63; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; [No title captured]	40	79	83	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	APR	2006	198	2					350	360		10.1016/j.expneurol.2005.12.017			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	033RJ	WOS:000236866400008	16448652				2022-02-06	
J	Best, JP; McIntosh, AS; Savage, TN				Best, JP; McIntosh, AS; Savage, TN			Rugby World Cup 2003 injury surveillance project	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article								Objectives: To study match injury patterns and incidence during the Rugby World Cup 2003 (RWC 2003); to compare these patterns and rates with comparative rugby injury data; and to assess differences between teams playing at different levels ( eight finalists v 12 non-finalists). Methods: Data were collected prospectively during the tournament. All injuries were recorded by the 20 participating team physicians. These were submitted to the tournament medical officer. An injury was defined as an event which forced a player either to leave the field or to miss a subsequent game or both. Results: 189 injuries were recorded over 48 matches. This corresponds to 97.9 injuries per 1000 player-hours. Pool matches yielded a higher injury rate than non-pool matches. The 12 non-finalist teams sustained significantly higher injury rates than the eight finalist teams. The player positions open side flanker, inside centre, and number 8 were the most frequently injured positions. There was a low concussion rate, which may reflect under-reporting. The non-finalist teams had a higher rate of recurrent injury. Conclusions: The injury rate was higher than comparative data. Mismatches in the areas of skill, fitness, and the availability of resources for medical care of players may explain these differences.	Univ New S Wales, Sch Safety Sci, Sydney, NSW 2052, Australia; Australian Rugby Union, Sydney, NSW, Australia		McIntosh, AS (corresponding author), Univ New S Wales, Sch Safety Sci, Sydney, NSW 2052, Australia.	a.mcintosh@unsw.edu.au	Savage, Trevor N/C-5709-2019	Savage, Trevor N/0000-0001-6608-8664			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bathgate A, 2002, BRIT J SPORT MED, V36, P265, DOI 10.1136/bjsm.36.4.265; BEST J, 2001, INJURIES 2001 21 RUG; FINCH C, 2002, PREVENTING RUGBY UNI; Garraway WM, 2000, BRIT J SPORT MED, V34, P348, DOI 10.1136/bjsm.34.5.348; Hawkins RD, 1996, BRIT J SPORT MED, V30, P165, DOI 10.1136/bjsm.30.2.165; *INT RUGB BOARD, 2003, INT RUGB BOARD LAW B; Jakoet I, 1998, S AFR MED J, V88, P45; Jones SJ, 2004, BRIT J SPORT MED, V38, P159, DOI 10.1136/bjsm.2002.002584; MCINTOSH AS, 2004, RUGBY UNION INJURY S; MILLAR S, 2003, IRB ANN REPORT; Targett SGR, 1998, CLIN J SPORT MED, V8, P280, DOI 10.1097/00042752-199810000-00005; THOMAS C, 2003, IRB ANN REPORT	13	79	81	0	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	NOV	2005	39	11					812	817		10.1136/bjsm.2004.016402			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	976HJ	WOS:000232723600011	16244189	Green Published, Bronze			2022-02-06	
J	Holmes, JF; Palchak, MJ; MacFarlane, T; Kuppermann, N				Holmes, JF; Palchak, MJ; MacFarlane, T; Kuppermann, N			Performance of the pediatric Glasgow Coma Scale in children with blunt head trauma	ACADEMIC EMERGENCY MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Academic-Emergency-Medicine	MAY, 2003	BOSTON, MA	Soc Acad Emergency Med		Glasgow Coma Scale; children; blunt head trauma	YOUNG-CHILDREN; INJURIES; PROGNOSIS; INFANTS	Objectives: To compare the accuracy of a pediatric Glasgow Coma Scale (GCS) score in preverbal children with blunt head trauma with the standard GCS score in older children. Methods: The authors prospectively enrolled children younger than 18 years with blunt head trauma. Patients were divided into cohorts of those 2 years and younger and those older than 2 years. The authors assigned a pediatric GCS score to the younger cohort and the standard GCS score to the older cohort. Outcomes were 1) traumatic brain injury (TBI) on computed tomography (CT) scan or 2) TBI in need of acute intervention. The authors created and compared receiver operating characteristic (ROC) curves between the age cohorts for the association of GCS scores and TBI. Results: The authors enrolled 2,043 children, and 327 were 2 years and younger. Among these 327, 15 (7.7%; 95% confidence interval [CI] = 4.4% to 12.4%) of 194 who underwent imaging with CT had TBI visible and nine (2.8%; 95% Cl = 1.3% to 5.2%) had TBI needing acute intervention. In children older than 2 years, 83 (7.7%; 95% Cl = 6.2% to 9.5%) of the 1,077 who underwent imaging with CT had TBI visible and 96 (5.6%; 95% Cl = 4.6% to 6.8%) had TBI needing acute intervention. For the pediatric GCS in children 2 years and younger, the area under the ROC curve was 0.72 (95% Cl = 0.56 to 0.87) for TBI on CT scan and 0.97 (95% Cl = 0.94 to 1.00) for TBI needing acute intervention. For the standard GCS in older children, the area under the ROC curve was 0.82 (95% Cl = 0.76 to 0.87) for TBI on CT scan and 0.87 (95% Cl = 0.83 to 0.92) for TBI needing acute intervention. Conclusions: This pediatric GCS for children 2 years and younger compares favorably with the standard GCS in the evaluation of children with blunt head trauma. The pediatric GCS is particularly accurate in evaluating preverbal children with blunt head trauma with regard to the need for acute intervention.	Univ Calif Davis, Med Ctr, Div Emergency Med, Dept Emergency Med,Sch Med, Sacramento, CA 95817 USA; Univ Calif Davis, Sch Med, Dept Pediat, Sacramento, CA 95817 USA		Holmes, JF (corresponding author), Univ Calif Davis, Med Ctr, Div Emergency Med, Dept Emergency Med,Sch Med, 2315 Stockton Blvd,PSSB 2100, Sacramento, CA 95817 USA.	jfholmes@ucdavis.edu					CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Fleiss J.L., 1981, STAT METHODS RATES P; Gedeit R, 2001, Pediatr Rev, V22, P118, DOI 10.1542/pir.22-4-118; JAMES HE, 1986, PEDIATR ANN, V15, P16, DOI 10.3928/0090-4481-19860101-05; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; MORRAY JP, 1984, CRIT CARE MED, V12, P1018, DOI 10.1097/00003246-198412000-00002; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; REILLY PL, 1988, CHILD NERV SYST, V4, P30; SIMPSON D, 1982, LANCET, V2, P450; SIMPSON DA, 1991, CHILD NERV SYST, V7, P183; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; Tatman A, 1997, ARCH DIS CHILD, V77, P519, DOI 10.1136/adc.77.6.519; TEASDALE G, 1974, LANCET, V2, P81; YAGER JY, 1990, AM J DIS CHILD, V144, P1088, DOI 10.1001/archpedi.1990.02150340032019	15	79	81	0	4	HANLEY & BELFUS INC	PHILADELPHIA	210 S 13TH ST, PHILADELPHIA, PA 19107 USA	1069-6563			ACAD EMERG MED	Acad. Emerg. Med.	SEP	2005	12	9					814	819		10.1197/j.aem.2005.04.019			6	Emergency Medicine	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	962GT	WOS:000231719700004	16141014	Bronze			2022-02-06	
J	McDonald, S; Saunders, JC				McDonald, S; Saunders, JC			Differential impairment in recognition of emotion across different media in people with severe traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						emotion perception; traumatic brain injury	FRONTAL-LOBE DAMAGE; MISSILE HEAD-INJURY; LANGUAGE FUNCTIONS; SOCIAL-PERCEPTION; RIGHT-HEMISPHERE; AMYGDALA DAMAGE; NEURAL SYSTEMS; FACIAL EMOTION; EXPRESSION; FACES	Recent evidence suggests that there may be dissociable systems for recognizing emotional expressions from different media including audio and visual channels, and still versus moving displays. In this study, 34 adults with severe traumatic brain injuries (TBI) and 28 adults without brain injuries were assessed for their capacity to recognize emotional expressions from dynamic audiovisual displays, conversational tone alone, moving facial displays, and still photographs. The TBI group were significantly impaired in their interpretation of both audio and audiovisual displays. In addition, eight of the 34 were significantly impaired in their capacity to recognize still facial expressions. In contrast, only one individual was impaired in the recognition of moving visual displays. Information processing speed was not found to play a significant role in producing problems with dynamic emotional expression. Instead the results suggest that visual moving displays may enlist different brain systems to those engaged with still displays, for example, the parietal cortices. Problems with the processing of affective prosody, while present, were not clearly related to other emotion processing problems. While this may attest to the independence of the auditory affective system, it may also reflect problems with the dual demands of listening to conversational meaning and affective tone.	Univ New S Wales, Sch Psychol, Sydney, NSW, Australia		McDonald, S (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW, Australia.	s.mcdonald@unsw.edu.au	McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094			ADAMS JH, 1989, SCOT MED J, V34, P399, DOI 10.1177/003693308903400106; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Adolphs R, 2000, J NEUROSCI, V20, P2683; Adolphs R, 2002, CURR OPIN NEUROBIOL, V12, P169, DOI 10.1016/S0959-4388(02)00301-X; Adolphs R, 2004, J COGNITIVE NEUROSCI, V16, P453, DOI 10.1162/089892904322926782; Adolphs R, 2001, NEUROPSYCHOLOGY, V15, P396, DOI 10.1037//0894-4105.15.3.396; Adolphs R, 2003, BRAIN COGNITION, V52, P61, DOI 10.1016/S0278-2626(03)00009-5; Adolphs R, 1996, J NEUROSCI, V16, P7678; Adolphs R, 1999, PSYCHOL SCI, V10, P167, DOI 10.1111/1467-9280.00126; Adolphs R, 2002, EMOTION, V2, P23, DOI 10.1037/1528-3542.2.1.23; Angrilli A, 1999, NEUROREPORT, V10, P1741, DOI 10.1097/00001756-199906030-00021; BASSILI JN, 1978, J EXP PSYCHOL HUMAN, V4, P373, DOI 10.1037/0096-1523.4.3.373; BOROD JC, 1986, NEUROPSYCHOLOGIA, V24, P169; Borod JC, 1993, NEUROPSYCHOLOGY, V7, P445, DOI DOI 10.1037/0894-4105.7.4.445; Breitenstein C, 1998, BEHAV NEUROL, V11, P29, DOI 10.1155/1998/579029; Broks P, 1998, NEUROPSYCHOLOGIA, V36, P59, DOI 10.1016/S0028-3932(97)00105-X; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Buchanan TW, 2004, BEHAV NEUROSCI, V118, P429, DOI 10.1037/0735-7044.118.2.429; CICONE M, 1980, CORTEX, V16, P145, DOI 10.1016/S0010-9452(80)80029-3; Courville C. B., 1945, PATHOLOGY NERVOUS SY; CROKER V, IN PRESS BRAIN INJUR; Eckman P, 1976, PICTURES FACIAL AFFE; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; HUMPHREYS GW, 1993, NEUROPSYCHOLOGIA, V31, P173, DOI 10.1016/0028-3932(93)90045-2; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; Marquardt TP, 2001, APHASIOLOGY, V15, P1091, DOI 10.1080/02687040143000429; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; McDonald S., 2002, AWARENESS SOCIAL INF; McHugo GJ, 1996, MOTIV EMOTION, V20, P85, DOI 10.1007/BF02253867; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Pearce S, 1998, BRAIN COGNITION, V38, P150, DOI 10.1006/brcg.1998.1018; Phillips ML, 2003, BIOL PSYCHIAT, V54, P504, DOI 10.1016/S0006-3223(03)00168-9; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PRIGATANO GP, 1982, J PERCEPTUAL MOTOR S, V54, P859; Ross ED, 1997, BRAIN LANG, V56, P27, DOI 10.1006/brln.1997.1731; ROSS ED, 1979, ARCH NEUROL-CHICAGO, V36, P144, DOI 10.1001/archneur.1979.00500390062006; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Sprengelmeyer R, 1996, BRAIN, V119, P1647, DOI 10.1093/brain/119.5.1647; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Tranel D, 2002, CORTEX, V38, P589, DOI 10.1016/S0010-9452(08)70024-8; van Zomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; Wertz RT, 1998, J NEUROLINGUIST, V11, P89, DOI 10.1016/S0911-6044(98)00007-4	49	79	81	0	11	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2005	11	4					392	399		10.1017/S1355617705050447			8	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	948UY	WOS:000230742400006	16209419				2022-02-06	
J	Craft, JM; Watterson, DM; Frautschy, SA; Van Eldik, LJ				Craft, JM; Watterson, DM; Frautschy, SA; Van Eldik, LJ			Aminopyridazines inhibit beta-amyloid-induced glial activation and neuronal damage in vivo	NEUROBIOLOGY OF AGING			English	Article						Alzheimer's disease; neuroinflammation; glia; drug discovery; animal model; aminopyridazine; amyloid; hippocampus	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CEREBROSPINAL-FLUID S100B; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; PROTEIN; INFLAMMATION; INTERLEUKIN-1; DISCOVERY; NEUROPATHOLOGY; HEPATOTOXICITY	The critical role of chronic inflammation in disease progression continues to be increasingly appreciated across multiple disease areas, especially in neurodegenerative disorders such as Alzheimer's disease. We report that late intervention with a recently discovered aminopyridazine suppressor of glial activation, developed to inhibit both oxidative and inflammatory cytokine pathways, attenuates human amyloid beta (Abeta)-induced glial activation in a murine model. Peripheral administration of the aminopyridazine MW01-070C, beginning 3 weeks after the start of intracerebroventricular infusion of human Abeta 1-42, decreased the number of activated astrocytes and microglia and the levels of proinflammatory cytokines interleukin-1beta, tumor necrosis factor-a and S 10013 in the hippocampus. Inhibition of neuroinflammation correlated with a decreased neuron loss, restoration towards control levels of synaptic dysfunction biomarkers in the hippocampus, and diminished amyloid plaque deposition. The results from this in vivo chemical biology approach provide a proof of concept that targeting of key glia inflammatory cytokine pathways can suppress Abeta-induced neuroinflammation in vivo, with resultant attenuation of neuronal damage. (C) 2004 Elsevier Inc. All rights reserved.	Northwestern Univ, Feinberg Sch Med, Drug Discovery Program, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Mol Pharmacol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Biol Chem, Chicago, IL 60611 USA; Univ Calif Los Angeles, Dept Med, VAGLAHS Sepulveda GRECC, North Hills, CA USA; Univ Calif Los Angeles, Dept Neurol, North Hills, CA USA		Van Eldik, LJ (corresponding author), Northwestern Univ, Feinberg Sch Med, Drug Discovery Program, Chicago, IL 60611 USA.	vaneldik@northwestern.edu		Watterson, Daniel/0000-0001-7605-5866; Frautschy, Sally A./0000-0003-0194-0363	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32 AG00260, AG21184, AG10685, U01 AG028583, P01 AG021184, AG20243, AG13939, P50 AG016570, R01 AG010685] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R25 GM067071] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS47586] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R25GM067071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047586] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG013939, T32AG000260, R37AG013939, R01AG010685, R01AG020243, P50AG016570, P01AG021184, U01AG028583] Funding Source: NIH RePORTER		Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Chitturi S, 2002, SEMIN LIVER DIS, V22, P169, DOI 10.1055/s-2002-30102; Choi DW, 2002, NAT NEUROSCI, V5, P1023, DOI 10.1038/nn930; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; Ehl C, 2003, INT J MOL MED, V11, P235; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Frautschy SA, 2001, NEUROBIOL AGING, V22, P993, DOI 10.1016/S0197-4580(01)00300-1; Frautschy SA, 1996, NEUROBIOL AGING, V17, P311, DOI 10.1016/0197-4580(95)02073-X; Griffin WST, 1998, BRAIN PATHOL, V8, P65; Jantzen PT, 2002, J NEUROSCI, V22, P2246, DOI 10.1523/JNEUROSCI.22-06-02246.2002; Launer LJ, 2003, JAMA-J AM MED ASSOC, V289, P2865, DOI 10.1001/jama.289.21.2865; Lee WM, 2003, NEW ENGL J MED, V349, P474, DOI 10.1056/NEJMra021844; Li YK, 2003, J NEUROSCI, V23, P1605; Lim GP, 2000, J NEUROSCI, V20, P5709, DOI 10.1523/JNEUROSCI.20-15-05709.2000; Manley PW, 2002, EXPERT OPIN INV DRUG, V11, P1715, DOI 10.1517/13543784.11.12.1715; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Mirzoeva S, 1999, BRAIN RES, V844, P126, DOI 10.1016/S0006-8993(99)01911-3; Mirzoeva S, 2002, J MED CHEM, V45, P563, DOI 10.1021/jm015573g; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Mrak RE, 2001, NEUROBIOL AGING, V22, P915, DOI 10.1016/S0197-4580(01)00293-7; Mrak RE, 2001, NEUROBIOL AGING, V22, P903, DOI 10.1016/S0197-4580(01)00287-1; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Orr CF, 2002, PROG NEUROBIOL, V68, P325, DOI 10.1016/S0301-0082(02)00127-2; Pasinetti GM, 2002, J ALZHEIMERS DIS, V4, P435, DOI 10.3233/JAD-2002-4510; Peskind ER, 2001, NEUROCHEM INT, V39, P409, DOI 10.1016/S0197-0186(01)00048-1; Petzold A, 2003, NEUROSCI LETT, V336, P167, DOI 10.1016/S0304-3940(02)01257-0; Rogers JT, 1999, J BIOL CHEM, V274, P6421, DOI 10.1074/jbc.274.10.6421; Schlaf G, 1998, J IMMUNOL METHODS, V213, P191, DOI 10.1016/S0022-1759(98)00027-1; Scorer CA, 2001, DRUG DISCOV TODAY, V6, P1207, DOI 10.1016/S1359-6446(01)02042-6; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; Van Eldik LJ, 2003, RESTOR NEUROL NEUROS, V21, P97; VANELDIK LJ, 1994, BBA-MOL CELL RES, V1223, P398, DOI 10.1016/0167-4889(94)90101-5; Velentza AV, 2003, BIOORG MED CHEM LETT, V13, P3465, DOI 10.1016/S0960-894X(03)00733-9; Wainwright MS, 2003, P NATL ACAD SCI USA, V100, P6233, DOI 10.1073/pnas.1031595100; Watterson DM, 2002, J MOL NEUROSCI, V19, P89, DOI 10.1007/s12031-002-0016-4; Wermuth CG, 1998, J HETEROCYCLIC CHEM, V35, P1091, DOI 10.1002/jhet.5570350508	36	79	83	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0197-4580	1558-1497		NEUROBIOL AGING	Neurobiol. Aging	NOV-DEC	2004	25	10					1283	1292		10.1016/j.neurobiolaging.2004.01.006			10	Geriatrics & Gerontology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Geriatrics & Gerontology; Neurosciences & Neurology	864UY	WOS:000224659600003	15465624	Green Submitted			2022-02-06	
J	Guilmette, TJ; Paglia, MF				Guilmette, TJ; Paglia, MF			The public's misconceptions about traumatic brain injury: a follow up survey	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-Psychological-Association	AUG, 2002	CHICAGO, IL	Amer Psychol Assoc		traumatic brain injury; public's misconceptions; surveys; TBI plaintiffs	JUROR BIAS; REHABILITATION	Two prior surveys from rural Louisiana, Canada, and New York [Arch. Clin. Neuropsychol. 3 (1988) 331; Arch. Clin. Neuropsychol. 8 (1993) 461] revealed that a high portion of the population endorses misconceptions about the sequelae of traumatic brain injury (TBI). The purpose of this study was to assess the public's perceptions of head trauma in an urban setting in the Northeast region of the country and to compare those results with surveys from other geographical areas conducted 8 and 13 years ago. This study also examined the prevalence of perceptions about TBI that may be relevant to personal injury litigation with TBI plaintiffs. Data were collected at an office of the Department of Motor Vehicles from persons conducting business there. Participants (n = 179) voluntarily completed a 19-item survey covering several facets of brain injury. This sample endorsed misconceptions at a level consistent with previous studies, indicating a comparable lack of knowledge about moderate to severe TBI. With regard to mild TBI, however, our sample generally endorsed fewer misconceptions than previous samples. The public also holds perceptions of TBI that may be relevant to personal injury litigation involving TBI plaintiffs. (C) 2003 National Academy of Neuropsychology. Published by Elsevier Science Ltd. All rights reserved.	So New England Rehabil Ctr, Dept Psychol, Providence, RI 02903 USA; Providence Coll, Providence, RI 02918 USA		Guilmette, TJ (corresponding author), So New England Rehabil Ctr, Dept Psychol, Providence, RI 02903 USA.	tguilmet@providence.edu					Erian M., 1998, AM J FORENSIC PSYCHO, V16, P25; Farmer JE, 1997, REHABIL PSYCHOL, V42, P273; GOODMAN J, 1991, LAW SOC REV, V25, P263, DOI 10.2307/3053799; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P331; Hux K, 1996, LANG SPEECH HEAR SER, V27, P171, DOI 10.1044/0161-1461.2702.171; KASSIN SM, 1983, J RES PERS, V17, P423, DOI 10.1016/0092-6566(83)90070-3; Moran G., 1994, LAW PSYCHOL REV, V18, P309; PETROCELLI RW, 1994, TRAUMATIC BRAIN INJU; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Sommers SR, 2001, PSYCHOL PUBLIC POL L, V7, P201, DOI 10.1037/1076-8971.7.1.201; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; WEIR JA, 1990, J APPL SOC PSYCHOL, V20, P901, DOI 10.1111/j.1559-1816.1990.tb01467.x; WILLER B, 1993, ARCH CLIN NEUROPSYCH, V8, P461, DOI 10.1016/0887-6177(93)90009-P; Wrightsman L., 2002, PSYCHOL LEGAL SYSTEM; Wuensch KL, 2002, J SOC PSYCHOL, V142, P587, DOI 10.1080/00224540209603920	15	79	79	1	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAR	2004	19	2					183	189		10.1016/S0887-6177(03)00025-8			7	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Conference Proceedings Citation Index - Science (CPCI-S)	Psychology	804RD	WOS:000220314900003	15010084	Bronze			2022-02-06	
J	Meeson, AP; Hawke, TJ; Graham, S; Jiang, N; Elterman, J; Hutcheson, K; DiMaio, JM; Gallardo, TD; Garry, DJ				Meeson, AP; Hawke, TJ; Graham, S; Jiang, N; Elterman, J; Hutcheson, K; DiMaio, JM; Gallardo, TD; Garry, DJ			Cellular and molecular regulation of skeletal muscle side population cells	STEM CELLS			English	Article						side population cells; myoblast; Foxk1; skeletal muscle; bone marrow	HEMATOPOIETIC STEM-CELLS; FACTOR 3/FORK HEAD; TRANSPORTER; EXPRESSION; MICE; PROLIFERATION; HOECHST-33342; SPECIFICATION; EFFLUX; FAMILY	Muscle progenitor cells (satellite cells) function in the maintenance and repair of adult skeletal muscle. Side population (SP) cells are enriched in repopulating activity and also reside in adult skeletal muscle. In this study, we observed that Abcg2 is a determinant of the SP cell phenotype. Using reverse transcription polymerase chain reaction and immunohistochemical techniques, we localized Abcg2-expressing cells in the interstitium and in close approximation to the vasculature of adult skeletal muscle. Muscle SP cells are able to differentiate into myotubes and increase in number after cardiotoxin-induced muscle injury. Similar to myogenic progenitor cells, muscle SP cells express Foxk1 and are decreased in number in Foxk1 mutant skeletal muscle. Using emerging technologies, we examine the molecular signature of muscle SP cells from normal, injured, and Foxk1 mutant skeletal muscle to define common and distinct molecular programs. We propose that muscle SP cells are progenitor cells that participate in repair and regeneration of adult skeletal muscle.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75216 USA; Univ Texas, SW Med Ctr, Dept Cardiothorac Surg, Dallas, TX 75216 USA; Univ Texas, SW Med Ctr, Dept Biol Mol, Dallas, TX 75216 USA; Univ Texas, SW Med Ctr, Donald W Reynolds Cardiovasc Res, Dallas, TX 75216 USA		Garry, DJ (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd,NB11 118A, Dallas, TX 75216 USA.	daniel.garry@utsouthwestern.edu		Hawke, Thomas/0000-0003-4974-4820	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01AR047850] Funding Source: NIH RePORTER; NIAMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [AR47850] Funding Source: Medline		Asakura A, 2002, EXP HEMATOL, V30, P1339, DOI 10.1016/S0301-472X(02)00954-2; Asakura A, 2002, J CELL BIOL, V159, P123, DOI 10.1083/jcb.200202092; Benchaouir R, 2004, EXP CELL RES, V294, P254, DOI 10.1016/j.yexcr.2003.11.005; Bunting KD, 2002, STEM CELLS, V20, P11, DOI 10.1002/stem.200011; Conboy IM, 2002, DEV CELL, V3, P397, DOI 10.1016/S1534-5807(02)00254-X; Dou CL, 2000, MOL CELL BIOL, V20, P6201, DOI 10.1128/MCB.20.17.6201-6211.2000; Gaca MDA, 2003, MATRIX BIOL, V22, P229, DOI 10.1016/S0945-053X(03)00017-9; Gallardo TD, 2003, GENESIS, V37, P57, DOI 10.1002/gene.10223; Garry DJ, 2000, P NATL ACAD SCI USA, V97, P5416, DOI 10.1073/pnas.100501197; Garry DJ, 1997, DEV BIOL, V188, P280, DOI 10.1006/dbio.1997.8657; Gerety SS, 2002, DEVELOPMENT, V129, P1397; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Hawke TJ, 2001, J APPL PHYSIOL, V91, P534, DOI 10.1152/jappl.2001.91.2.534; Hawke TJ, 2003, J BIOL CHEM, V278, P4015, DOI 10.1074/jbc.M209200200; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kim I, 2001, FASEB J, V15, P126, DOI [10.1096/fj.01-0556fje, 10.1096/fj.01-0805fje]; Kim M, 2002, CLIN CANCER RES, V8, P22; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; Litman T, 2001, CELL MOL LIFE SCI, V58, P931, DOI 10.1007/PL00000912; Majka SM, 2003, J CLIN INVEST, V111, P71, DOI 10.1172/JCI200316157; Meeson AP, 2001, CIRC RES, V88, P713, DOI 10.1161/hh0701.089753; Motoike T, 2000, GENESIS, V28, P75, DOI 10.1002/1526-968X(200010)28:2<75::AID-GENE50>3.0.CO;2-S; Puri MC, 1999, DEVELOPMENT, V126, P4569; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Rousse S, 1998, ENDOCRINOLOGY, V139, P1487, DOI 10.1210/en.139.4.1487; Scharenberg CW, 2002, BLOOD, V99, P507, DOI 10.1182/blood.V99.2.507; SCHULTZ E, 1994, REV PHYSIOL BIOCH P, V123, P213, DOI 10.1007/BFb0030904; Schwarz DA, 1998, IMMUNITY, V9, P657, DOI 10.1016/S1074-7613(00)80663-9; Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0; Seale P, 2000, DEV BIOL, V218, P115, DOI 10.1006/dbio.1999.9565; Shin D, 2001, DEV BIOL, V230, P139, DOI 10.1006/dbio.2000.9957; Sutton J, 1996, J BIOL CHEM, V271, P23126, DOI 10.1074/jbc.271.38.23126; Ward NL, 2002, SEMIN CELL DEV BIOL, V13, P19, DOI 10.1006/scdb.2001.0288; Winnier GE, 1997, GENE DEV, V11, P926, DOI 10.1101/gad.11.7.926; Wulf GG, 2003, HAEMATOLOGICA, V88, P368; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626; Zhou S, 2002, P NATL ACAD SCI USA, V99, P12339, DOI 10.1073/pnas.192276999; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	43	79	84	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells		2004	22	7					1305	1320		10.1634/stemcells.2004-0077			16	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	879ZY	WOS:000225759300017	15579648				2022-02-06	
J	Vavilala, MS; Bowen, A; Lam, AM; Uffman, JC; Powell, J; Winn, HR; Rivara, FP				Vavilala, MS; Bowen, A; Lam, AM; Uffman, JC; Powell, J; Winn, HR; Rivara, FP			Blood pressure and outcome after severe pediatric traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						head injury; children; blood pressure	HEAD-INJURY; CHILDREN; HYPOTENSION	Background. The relationship between systolic blood pressure and outcome in children after severe traumatic brain injury (TBI) is unclear. We examined the relationship between age-appropriate systolic blood pressure (AASBP) percentile and outcome after severe pediatric TBI. Methods. We examined the association between AASBP percentiles and outcome in 172 children younger than 14 years of age with a Glasgow Coma Scale score < 9. Outcome was evaluated using discharge Glasgow Outcome Scale score. Poor outcome was defined as a Glasgow Outcome Scale score < 4. Results. Poor outcome was associated with AASBP < 75th percentile (odds ratio, 4.2; 95% confidence interval, 2.1-8.3). Patients with systolic blood pressure (SBP) ! 90 turn Hg and AASBP < 75th percentile had a higher odds for poor outcome compared with patients with SBP greater than or equal to 90 mm Hg and AASBP greater than or equal to 75th percentile (odds ratio, 3.5; 95% confidence interval, 1.7-7.3). Conclusion. AASBP < 75th percentile was associated with poor outcome after severe pediatric TBI, even when SBP was greater than or equal to 90 min Hg.	Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA		Vavilala, MS (corresponding author), Harborview Med Ctr, Dept Anesthesiol, 325 9th Ave,Box 359724, Seattle, WA 98104 USA.	vavilala@u.washington.edu					Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; BLUMENTHAL S, 1977, PEDIATRICS, V59, P797; BLUMENTHAL S, 1987, PEDIATRICS, V79, P1; Bouma GJ, 1998, ACT NEUR S, V71, P272; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P471; *BRAIN TRAUM FDN, GUID PREHOSPITAL MAN; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P507; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DESWIET M, 1980, PEDIATRICS, V65, P1028; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; JENNETT B, 1975, LANCET, V1, P480; KOHL YM, 1984, INJURY, V16, P25; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Robertson CS, 2001, ANESTHESIOLOGY, V95, P1513, DOI 10.1097/00000542-200112000-00034; RULEY EJ, 1993, TXB CRITICAL CARE, P602; VASSAR MJ, 1991, ARCH SURG-CHICAGO, V126, P1065; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P13, DOI 10.1097/00008506-200101000-00003; WAGSTYL J, 1987, J PEDIATR SURG, V22, P127, DOI 10.1016/S0022-3468(87)80427-X; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011; Zwienenberg M, 1999, J NEUROTRAUM, V16, P937, DOI 10.1089/neu.1999.16.937	22	79	80	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2003	55	6					1039	1044		10.1097/01.TA.0000101759.23607.57			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	758TL	WOS:000187666200007	14676648				2022-02-06	
J	Uryu, K; Giasson, BI; Longhi, L; Martinez, D; Murray, I; Conte, V; Nakamura, M; Saatman, K; Talbot, K; Horiguchi, T; McIntosh, T; Lee, VMY; Trojanowski, JQ				Uryu, K; Giasson, BI; Longhi, L; Martinez, D; Murray, I; Conte, V; Nakamura, M; Saatman, K; Talbot, K; Horiguchi, T; McIntosh, T; Lee, VMY; Trojanowski, JQ			Age-dependent synuclein pathology following traumatic brain injury in mice	EXPERIMENTAL NEUROLOGY			English	Article						traumatic brain injury; mouse brain; neurodegenerative disease; synuclein	SPORADIC PARKINSONS-DISEASE; CORTICAL LEWY BODIES; A-BETA DEPOSITION; ALPHA-SYNUCLEIN; TRANSGENIC MICE; LIPID-PEROXIDATION; DROSOPHILA MODEL; HEAD TRAUMA; DEMENTIA; BODY	Synucleins (Syn), a family of synaptic proteins, includes alpha-Syn, which plays a pivotal role in Parkinson's disease and related neurodegenerative diseases (synucleinopathics) by forming distinct brain pathologies (Lewy bodies and neurites). Since traumatic brain injury (TBI) is a poorly understood risk factor for Parkinson's disease, we examined the effects of TBI in the young and aged mouse brain on alpha-, beta-, and gamma-Syn. Immunohistochemical analysis showed that brains from sham-injured young and aged mice had normal alpha- and beta-Syn immunoreactivity (lR) in neuropil of cortex, striatum, and hippocampus with little or no gamma-Syn IR. At 1 week post TBI, the aged mouse brain showed a transient increase of alpha- and beta-Syn IR in the neuropil as well as an induction of gamma-Syn IR in subcortical axons. This was associated with strong labeling of striatal axon bundles by antibodies to altered or nitrated epitopes in a-Syn as well as by antibodies to inducible nitric oxide synthase. However, these TBI-induced changes disappeared by 16 weeks post TBI, and altered Syn IR was not seen in young mice subjected to TBI nor in alpha-Syn knockout mice while Western blots confirmed that TBI induced transient alterations of alpha-Syn in the mouse brains. This model of age-dependent TBI-induced transient alterations in alpha-Syn provides an opportunity to examine possible links between TBI and mechanisms of disease in synucleinopathies. (C) 2003 Elsevier Science (USA). All rights reserved.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurosurg, Head Injury Ctr, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Psychiat, Head Injury Ctr, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Inst Aging, Philadelphia, PA 19104 USA		Trojanowski, JQ (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, HUP Maloney 3rd Floor, Philadelphia, PA 19104 USA.		Murray, Ian/O-5983-2015; Longhi, Luca/AAF-9903-2021	Murray, Ian/0000-0003-1196-1360; Longhi, Luca/0000-0001-9894-8788	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, P01NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG009215] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG-09215] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-08803] Funding Source: Medline		Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Arawaka S, 1998, NEUROLOGY, V51, P887, DOI 10.1212/WNL.51.3.887; Arima K, 1998, BRAIN RES, V808, P93, DOI 10.1016/S0006-8993(98)00734-3; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Baba M, 1998, AM J PATHOL, V152, P879; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Braak H, 1999, NEUROSCI LETT, V265, P67, DOI 10.1016/S0304-3940(99)00208-6; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Clark RSB, 2001, J NEUROTRAUM, V18, P675, DOI 10.1089/089771501750357627; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Duda JE, 2002, ANN NEUROL, V52, P205, DOI 10.1002/ana.10279; FACTOR SA, 1991, MOVEMENT DISORD, V6, P225, DOI 10.1002/mds.870060306; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Giasson BI, 2000, J NEUROSCI RES, V59, P528, DOI 10.1002/(SICI)1097-4547(20000215)59:4<528::AID-JNR8>3.0.CO;2-0; Giasson BI, 2001, EXP NEUROL, V172, P354, DOI 10.1006/exnr.2001.7805; HUBBLE JP, 1993, NEUROLOGY, V43, P1693, DOI 10.1212/WNL.43.9.1693; Hurtig HI, 2000, NEUROLOGY, V54, P1916, DOI 10.1212/WNL.54.10.1916; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; Ishihara T, 1999, NEURON, V24, P751, DOI 10.1016/S0896-6273(00)81127-7; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; Liu PK, 2002, ANN NY ACAD SCI, V962, P226, DOI 10.1111/j.1749-6632.2002.tb04071.x; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nakagawa Y, 2000, EXP NEUROL, V163, P244, DOI 10.1006/exnr.2000.7375; NAYERNOURI T, 1985, SURG NEUROL, V24, P263, DOI 10.1016/0090-3019(85)90035-7; Newell KL, 1999, J NEUROPATH EXP NEUR, V58, P1263, DOI 10.1097/00005072-199912000-00007; NORRIS EH, 2003, IN PRESS J BIOL CHEM; Paxinou E, 2001, J NEUROSCI, V21, P8053, DOI 10.1523/JNEUROSCI.21-20-08053.2001; PERRY EK, 1994, NEUROREPORT, V5, P747, DOI 10.1097/00001756-199403000-00002; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Pratico D, 2002, J NEUROCHEM, V80, P894, DOI 10.1046/j.0022-3042.2002.00777.x; Przedborski S, 1998, MOVEMENT DISORD, V13, P35; Romijn HJ, 1999, J HISTOCHEM CYTOCHEM, V47, P229, DOI 10.1177/002215549904700211; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Souza JM, 2000, FEBS LETT, V474, P116, DOI 10.1016/S0014-5793(00)01563-5; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Stefanis L, 2001, J NEUROCHEM, V76, P1165, DOI 10.1046/j.1471-4159.2001.00114.x; STERN MB, 1991, MOVEMENT DISORD, V6, P95, DOI 10.1002/mds.870060202; TANNER CM, 1989, NEUROLOGY, V39, P660, DOI 10.1212/WNL.39.5.660; Tanner CM, 1999, JAMA-J AM MED ASSOC, V281, P341, DOI 10.1001/jama.281.4.341; Trojanowski JQ, 2002, NEUROTOXICOLOGY, V23, P457, DOI 10.1016/S0161-813X(02)00065-7; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002	53	79	80	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	NOV	2003	184	1					214	224		10.1016/S0014-4886(03)00245-0			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	747KZ	WOS:000186804800025	14637093	Green Published			2022-02-06	
J	Smith, C; Graham, DI; Murray, LS; Nicoll, JAR				Smith, C; Graham, DI; Murray, LS; Nicoll, JAR			Tau immunohistochemistry in acute brain injury	NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY			English	Article						Alzheimer's disease; tau; traumatic brain injury	AMYLOID PROTEIN DEPOSITION; HEAD-INJURY; ALZHEIMERS-DISEASE; RISK-FACTORS; BETA; DEMENTIA; TRAUMA; CONSEQUENCE; ADULTHOOD; ONSET	Epidemiological studies have identified a history of head injury as a risk factor for Alzheimer's disease. However, the neuropathological mechanism underlying this relationship is as yet unclear. Neuronal cytoskeletal changes in the form of neurofibrillary tangles and neuropil threads have recently been demonstrated in young men who had sustained repetitive head injury and subsequently died in their 20s. In addition, recent experimental studies have found accumulation of tau within neuronal somata and damaged axons following diffuse brain injury. We hypothesized that tau-immunoreactive tangles may be present in the brains of patients who died after a single acute blunt head injury. A total of 45 cases of fatal head injury were immunostained for tau. They comprised nine groups (n = 5 for each group) separated by age (0-19 years, 20-50 years, 50+ years) and survival time (<24 h, 24 h-1 week, 1 week-1 month) and were compared with age-matched controls. Subtle alterations in tau immunoreactivity, for example, in oligodendrocytes, were present in some head injury cases but not controls. However, neurofibrillary tangles did not appear more prevalent after traumatic brain injury (TBI) when compared with age-matched controls. Although alterations in tau immunoreactivity may occur which warrant further study, neurofibrillary tangles were not more prevalent after a single fatal episode of TBI.	Univ Edinburgh, Western Gen Hosp, Dept Pathol, Neuropathol Lab, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Glasgow, So Gen Hosp, Dept Neuropathol, Glasgow, Lanark, Scotland; Univ Glasgow, Western Infirm, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland; Univ Southampton, Southampton Gen Hosp, Div Clin Neurosci, Southampton, Hants, England		Smith, C (corresponding author), Univ Edinburgh, Western Gen Hosp, Dept Pathol, Neuropathol Lab, Edinburgh EH4 2XU, Midlothian, Scotland.	col.smith@ed.ac.uk	Nicoll, James/I-9253-2017	Nicoll, James/0000-0002-9444-7246			AdleBiassette H, 1996, NEUROBIOL AGING, V17, P415, DOI 10.1016/0197-4580(96)00029-2; Carmel G, 1996, J BIOL CHEM, V271, P32789, DOI 10.1074/jbc.271.51.32789; CORKIN S, 1989, J NEUROSCI, V9, P3876; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; FRATIGLIONI L, 1993, ANN NEUROL, V33, P258, DOI 10.1002/ana.410330306; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Irving EA, 1996, NEUROSCI LETT, V213, P189; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Launer LJ, 1999, NEUROLOGY, V52, P78, DOI 10.1212/WNL.52.1.78; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; MENDEZ MF, 1992, NEUROLOGY, V42, P770, DOI 10.1212/WNL.42.4.770; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; NEWMAN SJ, 1995, RESEARCH ADVANCES IN ALZHEIMER'S DISEASE AND RELATED DISORDERS, P397; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554; Zemlan FP, 1999, J NEUROCHEM, V73, P437; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	28	79	80	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0305-1846	1365-2990		NEUROPATH APPL NEURO	Neuropathol. Appl. Neurobiol.	OCT	2003	29	5					496	502		10.1046/j.1365-2990.2003.00488.x			7	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	774WY	WOS:000189010400008	14507341				2022-02-06	
J	Wennberg, RA; Tator, CH				Wennberg, RA; Tator, CH			National Hockey League reported concussions, 1986-87 to 2001-02	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article							MANAGEMENT; INJURIES; SPORTS	Objectives: To examine the longitudinal media reported rate of concussions in the National Hockey League (NHL) over the period 1986-87 to 2001-02. Methods: All injury reports published in the weekly sports newspaper The Hockey News for the 16 seasons 1986-87 through 200102 were reviewed for reported concussions. The Hockey News reports are based on weekly injury reports released by the NHL, which derive from reports submitted to the league by individual team offices. Results: Adjusted for changes in the number of teams and games per season over the 16 year study period, and expressed as: number of concussions per 1000 games, results by season (starting with 198687) were 4, 8, 7, 7, 5, 5, 7, 7, 6, 8, 13, 20, 30, 27, 30, 25. Comparing each season with the prior season, significant increases were reported in 1997-98 and 1998-99 (p<0.05 and 0.025, respectively), with no change since 1998-99. Conclusions: The reported concussion rate in the NHL during the last five years is more than triple that of the previous decade. Bigger, faster players, new equipment and harder boards and glass have all theoretically increased the risk of concussion in the NHL in recent years. However, the abrupt increase and subsequent plateau in concussion rate since 1997 suggests that increased recognition and reporting may be primarily responsible for the apparent increase in incidence.	Univ Toronto, Toronto Western Hosp, Div Neurol, Univ Hlth Network, Toronto, ON M5T 2S8, Canada; Univ Toronto, Toronto Western Hosp, Div Neurosurg, Univ Hlth Network, Toronto, ON M5T 2S8, Canada		Wennberg, RA (corresponding author), Univ Toronto, Toronto Western Hosp, Div Neurol, Univ Hlth Network, 5W444,399 Bathurst St, Toronto, ON M5T 2S8, Canada.						BIASCA N, 1995, UNFALLCHIRURG, V98, P283; GREENBERG J, 2000, TOTAL HOCKEY OFFICIA, P578; Groger A, 2001, SPORTVERLETZ SPORTSC, V15, P82, DOI 10.1055/s-2001-19047; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; MEEUWISSE W, 2001, BRIT J SPORT MED, V35, P375; Orchard J, 2002, BRIT J SPORT MED, V36, P16, DOI 10.1136/bjsm.36.1.16; Tegner Y, 1996, BRIT J SPORT MED, V30, P251, DOI 10.1136/bjsm.30.3.251; TEGNER Y, 2001, BRIT J SPORT MED, V35, P376	9	79	79	0	13	CANADIAN J NEUROL SCI INC	CALGARY	PO BOX 4220, STATION C EDITORIAL & SUBSCRIPTION SERV, CALGARY, AB T2T 5N1, CANADA	0317-1671			CAN J NEUROL SCI	Can. J. Neurol. Sci.	AUG	2003	30	3					206	209		10.1017/S0317167100002596			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	711AY	WOS:000184716400006	12945942	Bronze			2022-02-06	
J	Chuckowree, JA; Vickers, JC				Chuckowree, JA; Vickers, JC			Cytoskeletal and morphological alterations underlying axonal sprouting after localized transection of cortical neuron Axons in vitro	JOURNAL OF NEUROSCIENCE			English	Article						Alzheimer's disease; axonal sprouting; axonal transection; beta III-tubulin; brain trauma; cortical neuron culture; cytoskeleton; growth cone; microtubules; neurite development; posttraumatic epilepsy; neurofilament; tau; taxol	TRAUMATIC BRAIN INJURY; CENTRAL-NERVOUS-SYSTEM; BETA-TUBULIN ISOTYPE; GROWTH CONE GUIDANCE; ALZHEIMERS-DISEASE; HIPPOCAMPAL-NEURONS; NEUROFILAMENT TRANSPORT; PHYSICAL INJURY; RADIAL GROWTH; ADULT CAT	We examined the cytoskeletal dynamics that characterize neurite sprouting after axonal injury to cortical neurons maintained in culture for several weeks and compared these with initial neurite development. Cultured neocortical neurons, derived from embryonic day 18 rats, were examined at 3 d in vitro (DIV) and at various time points after axotomy at 21 DIV. The postinjury neuritic response was highly dynamic, progressing through an initial phase of retraction, followed by substantial axonal sprouting within 4-6 hr. Postinjury sprouts were motile and slender with expanded growth cone-like end structures. Microtubule markers were localized to sprout shafts and the proximal regions of putative growth cones and filamentous actin was distributed throughout growth cones, whereas neurofilament proteins were restricted to sprout shafts. A similar distribution of cytoskeletal proteins was present in developing neurites at 3 DIV. Exposure of developing and mature, injured cultures to the microtubule stabilizing agent taxol (10 mug/ml) caused growth inhibition, process distension, the transformation of growth cones into bulbous structures, and abnormal neurite directionality. Microtubule and neurofilament segregation occurred after taxol exposure in developing neurites and postinjury sprouts. Exposure to the microtubule destabilizing agent nocodazole (100 mug/ml) resulted in substantial morphological alteration of developing neurons and inhibited neurite growth and postinjury axonal sprouting. Our results indicate that the axons of cortical neurons have an intrinsic ability to sprout after transection, and similar cytoskeletal dynamics underlie neurite development and postinjury axonal sprouting.	Univ Tasmania, Fac Hlth Sci, Discipline Pathol, Hobart, Tas 7000, Australia		Vickers, JC (corresponding author), Univ Tasmania, Fac Hlth Sci, Discipline Pathol, 43 Collins St, Hobart, Tas 7000, Australia.	james.vickers@utas.edu.au	Vickers, James C/J-7464-2014	Vickers, James C/0000-0001-5671-4879; Chuckowree, Jyoti/0000-0002-1245-1402			Adlard PA, 2000, ACTA NEUROPATHOL, V100, P183, DOI 10.1007/s004019900160; Arendt T, 2001, NEUROSCIENCE, V102, P723, DOI 10.1016/S0306-4522(00)00516-9; Bandtlow CE, 2000, GLIA, V29, P175, DOI 10.1002/(SICI)1098-1136(20000115)29:2<175::AID-GLIA11>3.0.CO;2-F; Banks WM, 1998, PROF ENG, V11, P36; BERRY M, 1994, EYE, V8, P245, DOI 10.1038/eye.1994.53; BLACK MM, 1987, J NEUROSCI, V7, P3695; Brandt R, 1998, CELL TISSUE RES, V292, P181, DOI 10.1007/s004410051049; BREWER GJ, 1995, J NEUROSCI RES, V42, P674, DOI 10.1002/jnr.490420510; Brewer GJ, 1997, J NEUROSCI METH, V71, P143, DOI 10.1016/S0165-0270(96)00136-7; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; BURKE WJ, 1994, LIFE SCI, V55, pPL313, DOI 10.1016/0024-3205(94)90074-4; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; Deller T, 1997, PROG NEUROBIOL, V53, P687, DOI 10.1016/S0301-0082(97)00044-0; Dent EW, 2001, J NEUROSCI, V21, P9757, DOI 10.1523/JNEUROSCI.21-24-09757.2001; Dickson TC, 2000, J NEUROTRAUM, V17, P1095, DOI 10.1089/neu.2000.17.1095; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; Fawcett JW, 1997, CELL TISSUE RES, V290, P371, DOI 10.1007/s004410050943; Figueroa-Masot XA, 2001, J NEUROSCI, V21, P4657, DOI 10.1523/JNEUROSCI.21-13-04657.2001; FURUKAWA K, 1995, J NEUROCHEM, V65, P1061; Gallo G, 1998, J NEUROBIOL, V35, P121; Gallo G, 2000, J NEUROBIOL, V44, P159, DOI 10.1002/1097-4695(200008)44:2<159::AID-NEU6>3.0.CO;2-H; GEORGE EB, 1988, CELL MOTIL CYTOSKEL, V9, P48, DOI 10.1002/cm.970090106; Goldberg JL, 2000, NATURE, V403, P369, DOI 10.1038/35000309; Gotaskie G E, 1994, Cancer Pract, V2, P27; HOFFMAN PN, 1984, J CELL BIOL, V99, P705, DOI 10.1083/jcb.99.2.705; HOFFMAN PN, 1987, P NATL ACAD SCI USA, V84, P3472, DOI 10.1073/pnas.84.10.3472; HOFFMAN PN, 1985, J NEUROSCI, V5, P2920; HOFFMAN PN, 1988, P NATL ACAD SCI USA, V85, P4530, DOI 10.1073/pnas.85.12.4530; Jafari SS, 1998, J NEUROTRAUM, V15, P955, DOI 10.1089/neu.1998.15.955; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; Jiang XM, 1996, ACTA NEUROPATHOL, V92, P467, DOI 10.1007/s004010050548; JULIEN JP, 1991, STRUCTURE EXPRESSION, P215; Kalil K, 2000, J NEUROBIOL, V44, P145, DOI 10.1002/1097-4695(200008)44:2<145::AID-NEU5>3.0.CO;2-X; King CE, 2000, ALZHEIMERS REP, V3, P31; King CE, 1997, NEUROREPORT, V8, P1663; King CE, 2001, NEUROPATH APPL NEURO, V27, P115, DOI 10.1046/j.1365-2990.2001.00317.x; Korey CA, 2000, J NEUROBIOL, V44, P184, DOI 10.1002/1097-4695(200008)44:2<184::AID-NEU8>3.0.CO;2-N; LARNER AJ, 1995, SEIZURE, V4, P249, DOI 10.1016/S1059-1311(95)80001-8; LEE MK, 1990, CELL MOTIL CYTOSKEL, V17, P118, DOI 10.1002/cm.970170207; Lee MK, 1996, ANNU REV NEUROSCI, V19, P187, DOI 10.1146/annurev.ne.19.030196.001155; LETOURNEAU PC, 1987, CELL MOTIL CYTOSKEL, V8, P193, DOI 10.1002/cm.970080302; LETOURNEAU PC, 1984, J CELL BIOL, V98, P1355, DOI 10.1083/jcb.98.4.1355; Levavasseur F, 1999, MOL BRAIN RES, V69, P104, DOI 10.1016/S0169-328X(99)00104-7; MASLIAH E, 1992, BRAIN RES, V574, P312, DOI 10.1016/0006-8993(92)90831-S; MASLIAH E, 1991, NEURON, V6, P729, DOI 10.1016/0896-6273(91)90170-5; MATTSON MP, 1992, BRAIN RES, V582, P107, DOI 10.1016/0006-8993(92)90323-2; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCHALE MK, 1995, J COMP NEUROL, V353, P25, DOI 10.1002/cne.903530105; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; MELLER D, 1993, J NEUROL SCI, V117, P164, DOI 10.1016/0022-510X(93)90169-Y; Michaelis ML, 1998, J NEUROCHEM, V70, P1623; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; OKABE S, 1990, NATURE, V343, P479, DOI 10.1038/343479a0; Pastor AM, 2000, J COMP NEUROL, V427, P370, DOI 10.1002/1096-9861(20001120)427:3<370::AID-CNE5>3.0.CO;2-M; PerezEspejo MA, 1996, SURG NEUROL, V46, P350, DOI 10.1016/S0090-3019(96)00200-5; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Qiu J, 2000, GLIA, V29, P166, DOI 10.1002/(SICI)1098-1136(20000115)29:2<166::AID-GLIA10>3.3.CO;2-7; Suter DM, 2000, J NEUROBIOL, V44, P97, DOI 10.1002/1097-4695(200008)44:2<97::AID-NEU2>3.0.CO;2-U; Szebenyi G, 1998, J NEUROSCI, V18, P7930; TANAKA E, 1995, CELL, V83, P171, DOI 10.1016/0092-8674(95)90158-2; Theiss C, 2000, CELL TISSUE RES, V299, P213, DOI 10.1007/s004410050019; Vickers JC, 2000, PROG NEUROBIOL, V60, P139, DOI 10.1016/S0301-0082(99)00023-4; Walker KL, 2001, J NEUROSCI, V21, P9655, DOI 10.1523/JNEUROSCI.21-24-09655.2001; Zhang WD, 2001, J NEUROSCI, V21, P5169, DOI 10.1523/JNEUROSCI.21-14-05169.2001; Zhu QZ, 1997, EXP NEUROL, V148, P299, DOI 10.1006/exnr.1997.6654	67	79	79	0	9	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAY 1	2003	23	9					3715	3725					11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	675MX	WOS:000182700100018	12736342				2022-02-06	
J	Pelinka, LE; Toegel, E; Mauritz, W; Redl, H				Pelinka, LE; Toegel, E; Mauritz, W; Redl, H			Serum S100B: A marker of brain damage in traumatic brain injury with and without multiple trauma	SHOCK			English	Article						traumatic brain injury; secondary brain damage; multiple trauma; S100B	SEVERE HEAD-INJURY; S-100 PROTEIN; CEREBROSPINAL-FLUID; RELEASE; ENOLASE; PLASMA; EXTENT	This prospective clinical study was conducted to determine whether S 100 B is a reliable serum marker for traumatic brain injury (TBI) with and without multiple trauma. Fifty-five trauma patients (Injury Severity Score [ISS] greater than or equal to24 and Glasgow Coma Score [GCS] less than or equal to8) were classified by radiography, computer tomography, ultrasound, and neurology as TBI without multiple trauma (n = 23), TBI with multiple trauma (n = 23), or multiple trauma without TBI (n = 9). S 100 B was measured initially after trauma and daily for a maximum of 21 days. Both survivors and nonsurvivors had markedly increased S 100 B initially. All survivors returned to normal or moderately increased S 100 B levels within the first 48 h after trauma. In contrast, all nonsurvivors; of isolated TBI had S 100 B values that either increased consistently or dropped and then increased again 48 h after the initial increase after trauma. There was no relationship between localization, extent, or severity of TBI and S 100 B. According to receiver operating characteristic curve analysis and calculation of the area under the curve (AUC), S 100 B is equally accurate for mortality prediction at 24, 48, and 72 h after trauma and is most accurate >84 h after trauma. Sensitivity/specificity for mortality prediction are more accurate in TBI without multiple trauma (AUC 0.802-0.971) than in TBI with multiple trauma (AUC 0.693-0.783). Thus, though S 100 B may be a reliable marker of brain damage in TBI without multiple trauma 24 h after trauma and thereafter, it appears to be less reliable in TBI with multiple trauma.	Ludwig Boltzmann Inst Expt & Clin Traumatol, Res Ctr Traumatol, Austrian Workers Compensat Board, A-1200 Vienna, Austria; Lorenz Boehler Trauma Ctr, Austrian Workers Compensat Board, Dept Anesthesiol & Crit Care Med, A-1200 Vienna, Austria		Pelinka, LE (corresponding author), Ludwig Boltzmann Inst Expt & Clin Traumatol, Res Ctr Traumatol, Austrian Workers Compensat Board, Donaueschingenstr 13, A-1200 Vienna, Austria.		Redl, Heinz/AAD-8157-2019	Mauritz, Walter/0000-0001-9043-3712			Abraha HD, 1997, ANN CLIN BIOCHEM, V34, P366, DOI 10.1177/000456329703400405; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; BAKAY RAE, 1983, J NEUROSURG, V58, P27, DOI 10.3171/jns.1983.58.1.0027; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; Chesnut RM, 1997, J TRAUMA, V42, pS4, DOI 10.1097/00005373-199705001-00002; Elting JW, 2000, J NEUROL SCI, V181, P104, DOI 10.1016/S0022-510X(00)00442-1; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; ISOBE T, 1984, J NEUROCHEM, V43, P1494, DOI 10.1111/j.1471-4159.1984.tb05415.x; Kilminster S, 1999, STROKE, V30, P1869, DOI 10.1161/01.STR.30.9.1869; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Raabe A, 2000, NEUROSURG REV, V23, P136, DOI 10.1007/PL00011944; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 1999, J NEUROSURG, V91, P875, DOI 10.3171/jns.1999.91.5.0875; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; RAO CJ, 1978, J NEUROL NEUROSUR PS, V41, P948, DOI 10.1136/jnnp.41.10.948; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Rose S, 2000, SHOCK, V13, P92, DOI 10.1097/00024382-200013020-00002; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Rothoerl RD, 2000, ACTA NEUROCHIR, V142, P199, DOI 10.1007/s007010050024; THOMAS DGT, 1977, LANCET, V1, P113; USUI A, 1989, CLIN CHEM, V35, P1942; Wiesmann M, 1997, ACTA NEUROCHIR, V139, P1155, DOI 10.1007/BF01410976; Wong CH, 1999, ANN THORAC SURG, V67, P1911, DOI 10.1016/S0003-4975(99)00425-7; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	31	79	91	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	MAR	2003	19	3					195	200		10.1097/00024382-200303000-00001			6	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	648UG	WOS:000181168500001	12630517				2022-02-06	
J	Spinella, PC; Dominguez, T; Drott, HR; Huh, J; McCormick, L; Rajendra, A; Argon, J; McIntosh, T; Helfaer, M				Spinella, PC; Dominguez, T; Drott, HR; Huh, J; McCormick, L; Rajendra, A; Argon, J; McIntosh, T; Helfaer, M			S-100 beta protein-serum levels in healthy children and its association with outcome in pediatric traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						brain injuries; prognosis; child; nerve tissue protein S-100; human; Severity of Illness Index	INTENSIVE-CARE-UNIT; CEREBROSPINAL-FLUID; HEAD; SEVERITY; S100; NEURONS; AGE; MORTALITY; APOPTOSIS; RELEASE	Objective., To describe normal serum levels of S-100beta in healthy children and determine whether serum S-100beta levels after traumatic brain injury are associated with outcome. Design., Prospective cohort study. Setting., Urban, tertiary care, children's teaching hospital. Patients., A total of 136 healthy children and 27 children with traumatic brain injury. Methods. Serum S-100beta levels were measured in 136 healthy children. A total of 27 children with traumatic brain injury had S-100beta levels collected within 12 hrs of injury. Other indices of severity of injury measured were admission Glasgow Coma Scale score, and Pediatric Risk of Mortality score at 24 hrs (PRISM 24). Outcome was measured by the Pediatric Cerebral Performance Category (PCPC) score at hospital discharge and 6 months postinjury or at death. Measurements and Main Results. S-100beta levels in healthy children had a mean of 0.3 mug/L (90% confidence interval, 0.03-1.47) and inversely correlated with age, (r = -.32, p < .001). In children with traumatic brain injury, 6-month postinjury outcome inversely correlated with Glasgow Coma Scale score (r = -.47, p = .01) and correlated with PRISM 24 score (r = .83, p < .001) and S-100beta levels (r = .75, p < .001). Six months postinjury, comparing good outcome (PCPC less than or equal to 3, n = 20) vs. poor outcome (PCPC greater than or equal to 4, n = 7), median admission Glasgow Coma Scale scores were 8 (range, 3-15) and 3 (range, 3-7, p = .01), median PRISM 24 scores were 7 (range, 0-19) and 30 (range, 18-35, p < .001), and median S-100beta levels were 0.85 mug/L. (range, 0.08-4.8 mug/L) and 3.6 mug/L (range, 1.4-20 mug/L, p < .001), respectively. A serum S-100beta level of greater than or equal to2.0 mug/L is associated with poor outcome, with a sensitivity of 86% and a specificity of 95%. The area under the receiver operating curve for S-100beta was 0.94 (+/-0.05). Conclusions. Serum S-100beta levels in healthy children have a moderate inverse correlation with age. After traumatic brain injury in children, the acute assessment of serum S-100beta levels seems to be associated with outcome.	Childrens Hosp Philadelphia, Dept Anesthesiol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Crit Care Med, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA		Spinella, PC (corresponding author), Childrens Hosp Philadelphia, Dept Anesthesiol, Philadelphia, PA 19104 USA.						Ahlemeyer B, 2000, BRAIN RES, V858, P121, DOI 10.1016/S0006-8993(99)02438-5; AKTAR JI, 2001, CRIT CARE MED S12, V29, P459; AMWHALIN, 2001, CLIN CHIM ACTA, V304, P57; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Berger Rachel, 2001, Pediatric Research, V49, p157A; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; BHATTACHARYYA A, 1992, J NEUROBIOL, V23, P451, DOI 10.1002/neu.480230410; DIECKMANN RA, 1995, PEDIATRICS, V95, P901; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; FANO G, 1995, PROG NEUROBIOL, V46, P71, DOI 10.1016/0301-0082(94)00062-M; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Fiser DH, 2000, CRIT CARE MED, V28, P1173, DOI 10.1097/00003246-200004000-00043; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Fulle S, 2000, EXP PHYSIOL, V85, P243; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Haglid KG, 1997, BRAIN RES, V753, P196, DOI 10.1016/S0006-8993(96)01463-1; HASLAM RHA, 1996, TXB PEDIAT, P1719; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Hu JR, 1997, J NEUROCHEM, V69, P2294; Iwasaki Y, 1997, J NEUROL SCI, V151, P7, DOI 10.1016/S0022-510X(97)00073-7; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; LESCOHIER I, 1993, PEDIATRICS, V91, P721; Lindberg L, 1998, J THORAC CARDIOV SUR, V116, P281, DOI 10.1016/S0022-5223(98)70128-X; MARIGGIO MA, 1994, NEUROSCIENCE, V60, P29, DOI 10.1016/0306-4522(94)90201-1; Maschmann J, 2000, ACTA PAEDIATR, V89, P553, DOI 10.1080/080352500750027844; McAdory BS, 1998, BRAIN RES, V813, P211, DOI 10.1016/S0006-8993(98)01014-2; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Nagdyman N, 2001, PEDIATR RES, V49, P502, DOI 10.1203/00006450-200104000-00011; Nygaard O, 1997, CLIN CHEM, V43, P541; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; TEPAS JJ, 1990, J PEDIATR SURG, V25, P92, DOI 10.1016/S0022-3468(05)80170-8; UEDA S, 1995, MOL BRAIN RES, V29, P365, DOI 10.1016/0169-328X(94)00269-K; VANELDIK LJ, 1991, BRAIN RES, V542, P280, DOI 10.1016/0006-8993(91)91579-P; Verger K, 2000, BRAIN INJURY, V14, P495; WALKER ML, 1984, CHILD BRAIN, V11, P387; WHITAKERAZMITIA PM, 1990, BRAIN RES, V528, P155, DOI 10.1016/0006-8993(90)90210-3; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026	45	79	79	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAR	2003	31	3					939	945		10.1097/01.CCM.0000053644.16336.52			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	660RP	WOS:000181846800043	12627009				2022-02-06	
J	Roche, NL; Fleming, JM; Shum, DHK				Roche, NL; Fleming, JM; Shum, DHK			Self-awareness of prospective memory failure in adults with traumatic brain injury	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; EVERYDAY MEMORY; PERFORMANCE; DEFICITS; BOOK	The frequency of prospective memory failure in individuals with severe traumatic brain injury (TBI) was investigated by comparison with a non-brain-injured control group. Self-awareness of prospective memory function was also assessed by comparing self-ratings with ratings by significant others. Study participants included 33 individuals with severe TBI and 29 non-brain-injured persons. Each participant nominated a close friend or relative who completed the informant's version of the questionnaire. Participants and their significant others both rated the participants' frequency of prospective memory lapses using the Comprehensive Assessment of Prospective Memory (CAPM). An independent groups design was adopted to compare the TBI and control groups. No significant difference was found between the TBI and control participants' self-ratings of frequency of prospective memory failure, but ratings by significant others were significantly different. The TBI group demonstrated less self-awareness (i.e. underestimated the frequency of prospective memory failure compared to significant others) than the control group.	Univ Queensland, Dept Occupat Therapy, Brisbane, Qld 4072, Australia; Princess Alexandra Hosp, Dept Occupat Therapy, Woolloongabba, Qld, Australia; Griffith Univ, Sch Appl Psychol & Neuropsychol, Nathan, Qld 4111, Australia		Fleming, JM (corresponding author), Univ Queensland, Dept Occupat Therapy, Brisbane, Qld 4072, Australia.		Shum, David/A-3914-2008; Fleming, Jennifer M/B-4436-2011	Shum, David/0000-0002-4810-9262; 			Andrewes DG, 1998, NEUROPSYCHOL REHABIL, V8, P377, DOI 10.1080/713755582; Barco PP, 1991, COGNITIVE REHABILITA, P129; Benson D.F., 1986, FRONTAL LOBES; BOAKE C, 1995, BRAIN INJURY, V9, P273, DOI 10.3109/02699059509008198; BROWN DSO, 1992, ARCH PHYS MED REHAB, V73, P758; BURKE JM, 1994, BRAIN INJURY, V8, P71, DOI 10.3109/02699059409150960; Cockburn J, 1996, J CLIN EXP NEUROPSYC, V18, P304, DOI 10.1080/01688639608408284; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [DOI 10.1097/00001199-198909000-00008, 10.1097/00001199-198909000-00008]; DEATON AV, 1986, REHABIL PSYCHOL, V31, P231, DOI 10.1037//0090-5550.31.4.231; Einstein GO, 1997, PSYCHOL AGING, V12, P479, DOI 10.1037/0882-7974.12.3.479; Fleming JM, 1996, BRAIN INJURY, V10, P1; Fluharty George, 1993, Brain Injury, V7, P85, DOI 10.3109/02699059309008160; FORTUNE N, 1999, DEFINITION INCIDENCE; GLISKY EL, 1996, PROSPECTIVE MEMORY T, P249; GOLDSTEIN LH, 1992, BRIT J CLIN PSYCHOL, V31, P75, DOI 10.1111/j.2044-8260.1992.tb00969.x; GRIEVE J, 2000, NEUROPSYCHOLOGY OCCU, P148; Hannon R, 1995, REHABIL PSYCHOL, V40, P289, DOI 10.1037/0090-5550.40.4.289; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; HERRMANN DJ, 1982, PSYCHOL BULL, V92, P434, DOI 10.1037/0033-2909.92.2.434; Hutchinson J, 1997, TOP LANG DISORD, V18, P45, DOI 10.1097/00011363-199711000-00006; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI DOI 10.1097/00001199-198709000-00009; Maylor E. A., 1993, ADULT INFORMATION PR, P529; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Prigatano GP, 1998, CLIN NEUROPSYCHOL, V12, P56, DOI 10.1076/clin.12.1.56.1721; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; SCHWARTZ AF, 1989, CORTEX, V25, P665, DOI 10.1016/S0010-9452(89)80026-7; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Strong J., 1995, BRIT J OCCUPATIONAL, V58, P55; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; THOMPSON SBN, 1996, BRIT J OCCUPATIONAL, V59, P418; Varney NR., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI [10.1097/00001199-199303000-00005, DOI 10.1097/00001199-199303000-00005]; WAUGH N, 1999, THESIS GRIFFITH U	35	79	81	0	7	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	NOV	2002	16	11					931	945		10.1080/02699050210138581			15	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	609PQ	WOS:000178914500001	12443545				2022-02-06	
J	Levy, AS; Hawkes, AP; Hemminger, LM; Knight, S				Levy, AS; Hawkes, AP; Hemminger, LM; Knight, S			An analysis of head injuries among skiers and snowboarders	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	Annual Meeting of the American-College-of-Surgeons	JUN 10-12, 1999	BRECKENRIDGE, CO	Amer Coll Surg		skiing; snowboarding; traumatic brain injury; head injury; helmets	SKIING INJURIES; CHILDREN	Background. Head injury is the leading cause of death and critical injury in skiing and snowboarding accidents. Methods Data relating to head injuries occurring on the ski slopes were collected from the trauma registry of a Level I trauma center located near a number of ski resorts. Results: From 1982 to 1998, 350 skiers and snowboarders with head injuries were admitted to our Level I trauma center. Most of the injuries were mild, with Glasgow Coma Scale (GCS) scores of 13 to 15 in 81% and simple concussion in 69%. However, 14% of patients had severe brain injuries, with GCS scores of 3 to 8, and the overall mortality rate was 4%. Collision with a tree or other stationary object (skier-tree) was the mechanism of injury in 47% of patients; simple falls in 37%; collision with another skier (skier-skier) in 13%; and major falls in 3%. Skier-tree collision and major falls resulted in a higher percentage of severe injuries, with GCS scores of 3 to 8 in 24% and 20%, respectively, and mean Injury Severity Scores of 14 and 17, respectively. Mortality from skier-tree collision was 7.2%, compared with 1.6% in simple falls and no deaths from skier-skier collision or major falls. The risk of sustaining a head injury was 2.23 times greater for male subjects compared with female subjects, 2.81 times higher for skiers/boarders less than or equal to 35 years of age compared with those > 35 years, and 3.04 times higher for snowboarders compared with skiers. Conclusion. Skier-tree collision was the most common mechanism for head injuries in patients admitted to our Level I trauma center, and resulted in the most severe injuries and the highest mortality rate. Because most traumatic brain injuries treated at our facility resulted from a direct impact mechanism, we believe that the use of helmets can reduce the incidence and severity of head injuries occurring on the ski slopes.	St Anthony Cent Hosp, Trauma Serv, Denver, CO USA		Levy, AS (corresponding author), Intermt Neurosurg & Neurosci, 4101 W Conejos Pl,Suite 225, Denver, CO 80204 USA.						ABULABAN RB, 1991, CAN MED ASSOC J, V145, P1097; BLADIN C, 1995, SPORTS MED, V19, P358, DOI 10.2165/00007256-199519050-00005; BLITZER CM, 1984, AM J SPORT MED, V12, P142, DOI 10.1177/036354658401200210; *COL DEP PUBL HLTH, 2000, RECR FAT COL 1996 19, P35; *COL DEP PUBL HLTH, 1996, REC FAT COL 1993 199, P8; Davidson TM, 1996, WESTERN J MED, V164, P231; Davidson TM, 1996, WESTERN J MED, V164, P310; Dean AG, 1994, EPI INFO VERSION 6 W; Deibert MC, 1998, J BONE JOINT SURG AM, V80A, P25, DOI 10.2106/00004623-199801000-00006; FURRER M, 1995, J TRAUMA, V39, P737, DOI 10.1097/00005373-199510000-00024; Macnab A J, 1996, Inj Prev, V2, P286, DOI 10.1136/ip.2.4.286; MORROW PL, 1988, J TRAUMA, V28, P95, DOI 10.1097/00005373-198801000-00014; MYLES ST, 1992, CAN J SURG, V35, P643; Nakaguchi H, 1999, J TRAUMA, V46, P1066, DOI 10.1097/00005373-199906000-00017; PRALL JA, 1995, INJURY, V26, P539, DOI 10.1016/0020-1383(95)00085-N; Sacco DE, 1998, J TRAUMA, V44, P654, DOI 10.1097/00005373-199804000-00016; Sahlin Y, 1989, Br J Sports Med, V23, P241; SANDEGAARD J, 1991, ASTM STP, V1104, P170; SAS Institute Inc, 1998, STATV; SHERRY E, 1988, MED J AUSTRALIA, V149, P615, DOI 10.5694/j.1326-5377.1988.tb120803.x; Shorter NA, 1996, J TRAUMA, V40, P997, DOI 10.1097/00005373-199606000-00024; Sutherland AG, 1996, INJURY, V27, P423, DOI 10.1016/0020-1383(96)00026-5; TOUGH SC, 1993, AM J FOREN MED PATH, V14, P12, DOI 10.1097/00000433-199303000-00003; *UCHSC COL TRAUM I, 1995, SKI SNOWB INJ, P1; UNGERHOLM S, 1983, INT J SPORTS MED, V4, P236, DOI 10.1055/s-2008-1026041; US Consumer Product Safety Commission, 1999, SKIING HELM EV POT R	26	79	79	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2002	53	4					695	704		10.1097/00005373-200210000-00013			10	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	604JZ	WOS:000178618400017	12394869				2022-02-06	
J	Bernstein, DM				Bernstein, DM			Information processing difficulty long after self-reported concussion	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						mild head injury; P300; information processing	MILD HEAD-INJURY; TRAUMATIC BRAIN INJURY; NEUROPSYCHOLOGICAL DEFICITS; AUDITORY-STIMULI; TASK-DIFFICULTY; P300 LATENCY; ATTENTION; RECOVERY; SYMPTOMS; DETERMINANTS	Recovery of cognitive function after mild head injury (MHI) is thought to be relatively swift and complete. The present study replicates and extends previous work in which university students with self-reported concussion demonstrated reduced P300 amplitude on a set of easy and difficult attention tasks, in addition to performing more poorly than controls on demanding cognitive tasks many years after injury. In the present study, 13 students with self-reported concussion (MHl group: M time since injury = 8 years) and 10 controls were matched for age, sex, education, and a variety of cognitive, physical and emotional complaints. Controls outperformed the MHI group on the Digit Symbol substitution task and on a difficult dual task involving tone discrimination and visual working memory. Additionally, controls exhibited larger P300 amplitudes on both an easy and a difficult auditory discrimination task. A combination of electrophysiological, neuropsychological and self-report indices predicted group membership (MHI vs. control) with 88% accuracy. The present results, coupled with previous work, offer preliminary evidence that the combination of event-related potentials and demanding behavioral measures might reveal long-lasting, subtle cognitive problems associated with MHI. These findings may challenge existing notions of complete recovery after MHI.	Simon Fraser Univ, Burnaby, BC V5A 1S6, Canada		Bernstein, DM (corresponding author), Univ Washington, Dept Psychol, POB 351525, Seattle, WA 98105 USA.	db6@u.washington.edu					ARCIA E, 1994, BRAIN INJURY, V8, P395, DOI 10.3109/02699059409150991; BADDELEY AD, 1998, HUMAN MEMORY THEORY; Bernstein DM, 2000, BRAIN COGNITION, V44, P50, DOI 10.1006/brcg.1999.1209; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Ford MR, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199606000-00004; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gaetz M, 2001, J HEAD TRAUMA REHAB, V16, P386, DOI 10.1097/00001199-200108000-00008; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Granovsky Y, 1998, EVOKED POTENTIAL, V108, P554, DOI 10.1016/S0168-5597(98)00036-7; GRONWALL D, 1975, LANCET, V2, P995; HOCHHAUS L, 1972, PSYCHOL BULL, V77, P375, DOI 10.1037/h0032459; Kahneman D., 1973, ATTENTION EFFORT; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI DOI 10.1097/00001199-198709000-00009; MCCARTHY G, 1981, SCIENCE, V211, P77, DOI 10.1126/science.7444452; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; Pinkston JB, 2000, BRAIN COGNITION, V44, P74; POLICH J, 1986, ELECTROEN CLIN NEURO, V63, P251, DOI 10.1016/0013-4694(86)90093-3; POLICH J, 1987, ELECTROEN CLIN NEURO, V68, P311, DOI 10.1016/0168-5597(87)90052-9; Potter DD, 1999, J PSYCHOPHYSIOL, V13, P173, DOI 10.1027//0269-8803.13.3.173; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; PRITCHARD WS, 1981, PSYCHOL BULL, V89, P506, DOI 10.1037/0033-2909.89.3.506; Reinvang I, 2000, NEUROPSYCHOLOGIA, V38, P995, DOI 10.1016/S0028-3932(99)00153-0; Ryan L M, 1996, Appl Neuropsychol, V3, P49, DOI 10.1207/s15324826an0302_1; Sangal RB, 1996, BIOL PSYCHIAT, V39, P305, DOI 10.1016/0006-3223(95)00447-5; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; Solbakk AK, 2000, J CLIN EXP NEUROPSYC, V22, P743, DOI 10.1076/jcen.22.6.743.953; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; SPSS Inc, SPSS WIND; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TANNER WP, 1954, PSYCHOL REV, V61, P401, DOI 10.1037/h0058700; TEECE JJ, 1993, ELECTROENCEPHALOGRAP, P887; Wechsler, 1997, WECHSLER ADULT INTEL; Wilson GF, 1998, BIOL PSYCHOL, V47, P137, DOI 10.1016/S0301-0511(97)00021-5; WINGFIELD A, 1981, PSYCHOL HUMAN MEMORY	50	79	79	0	19	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2002	8	5					673	682		10.1017/S1355617702801400			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	578FA	WOS:000177105700006	12164676				2022-02-06	
J	Mauler, F; Mittendorf, J; Horvath, E; De Vry, J				Mauler, F; Mittendorf, J; Horvath, E; De Vry, J			Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							DISCRIMINATIVE STIMULUS PROPERTIES; ANTAGONIST SR141716A; HIPPOCAMPAL-NEURONS; RAT-BRAIN; IN-VIVO; CB1; PHARMACOLOGY; ACTIVATION; RELEASE; DELTA-9-TETRAHYDROCANNABINOL	(-)-( R)-3-(2-Hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) is a new high-affinity cannabinoid receptor subtype 1 (CB1 receptor) ligand (K-i = 0.46-1.85 nM; rat brain, human cortex, or recombinant human CB1 receptor), structurally unrelated to any cannabinoid receptor ligand known so far. BAY 38-7271 was characterized as a CB1 receptor agonist in 5-[gamma(35)S]-thiophosphate triethylammonium salt binding assays using rat or human CB1 receptors. In the rat hypothermia assay, BAY 38-7271 induced a dose-dependent reduction in body temperature (minimal effective dose = 6 mug/kg, i.v.); whereas in rats trained to discriminate the CB1/CB2 receptor agonist (-)-cis-3-[2-hydroxy-4(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl) cyclohexanol (CP 55,940; 0.03 mg/kg, i.p.) from vehicle, BAY 38-7271 induced complete generalization (3 mug/kg, i.v.). In both in vivo models, a specific CB1 receptor-mediated mechanism was confirmed by demonstrating that the effects of CP 55,940 and BAY 38-7271 were blocked by pretreatment with the selective CB1 receptor antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamidehydrochloride. In the rat traumatic brain injury model, BAY 38-7271 demonstrated highly potent and efficient neuroprotective properties when administered as a 4- h infusion immediately after induction of subdural hematoma (70% infarct volume reduction at 100 ng/kg/h). Even when applied with a 3-h delay, a significant neuroprotective efficacy could be observed (59% infarct volume reduction at 300 ng/kg/h). The neuroprotective potential of BAY 38-7271 was confirmed in a rat model of focal cerebral ischemia induced by permanent occlusion of the middle cerebral artery. It is concluded that the CB1/CB2 receptor agonist BAY 38-7271 shows pronounced neuroprotective properties that do not result from drug-induced hypothermia and that occur in a dose range devoid of typical cannabinoid-like side effects.	Bayer AG, Business Grp Pharma, CNS Res, D-42096 Wuppertal, Germany; Bayer AG, Business Grp Pharma, Med Chem, D-42096 Wuppertal, Germany		Mauler, F (corresponding author), Bayer AG, Business Grp Pharma, CNS Res, PH-R,Aprather Weg 18A, D-42096 Wuppertal, Germany.						Abood ME, 2001, NEUROSCI LETT, V309, P197, DOI 10.1016/S0304-3940(01)02065-1; Barth F, 1998, EXPERT OPIN THER PAT, V8, P301, DOI 10.1517/13543776.8.3.301; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Boxer PA, 1997, DRUG DISCOV TODAY, V2, P219, DOI 10.1016/S1359-6446(97)01045-3; Burkey TH, 1997, EUR J PHARMACOL, V336, P295, DOI 10.1016/S0014-2999(97)01255-7; Compton DR, 1996, J PHARMACOL EXP THER, V277, P586; De Vry J, 1998, EUR J PHARMACOL, V357, P1, DOI 10.1016/S0014-2999(98)00503-2; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; GAOINI Y, 1964, J AM CHEM SOC, V86, P1646; Gerdeman G, 2001, J NEUROPHYSIOL, V85, P468, DOI 10.1152/jn.2001.85.1.468; Glass M, 1997, NEUROSCIENCE, V77, P299, DOI 10.1016/S0306-4522(96)00428-9; Hampson AJ, 1998, P NATL ACAD SCI USA, V95, P8268, DOI 10.1073/pnas.95.14.8268; Hampson AJ, 2000, ANN NY ACAD SCI, V899, P274, DOI 10.1111/j.1749-6632.2000.tb06193.x; HANUS L, 1993, J MED CHEM, V36, P3032, DOI 10.1021/jm00072a026; Jin KL, 2000, ANN NEUROL, V48, P257, DOI 10.1002/1531-8249(200008)48:2<257::AID-ANA18>3.3.CO;2-G; Joy JE, 1999, MARIJUANA MED ASSESS; KALLMAN MJ, 1984, FED PROC, V43, P952; Kim DJ, 2000, BRAIN RES, V852, P398, DOI 10.1016/S0006-8993(99)02210-6; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Mansbach RS, 1996, PSYCHOPHARMACOLOGY, V124, P315, DOI 10.1007/BF02247436; MARTIN BR, 1991, PHARMACOL BIOCHEM BE, V40, P471, DOI 10.1016/0091-3057(91)90349-7; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; Mauler F, 2001, BRAIN RES, V888, P150, DOI 10.1016/S0006-8993(00)03074-2; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; Mu J, 1999, J PHARMACOL EXP THER, V291, P893; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Nagayama T, 1999, J NEUROSCI, V19, P2987; Paxinos G., 1982, RAT BRAIN STEREOTAXI, V1st ed.; Perio A, 1996, BEHAV PHARMACOL, V7, P65; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; Pertwee RG, 1999, CURR MED CHEM, V6, P635; Petitet F, 1998, LIFE SCI, V63, pPL1, DOI 10.1016/S0024-3205(98)00238-0; Piomelli D, 2000, TRENDS PHARMACOL SCI, V21, P218, DOI 10.1016/S0165-6147(00)01482-6; Prather PL, 2000, MOL PHARMACOL, V57, P1000; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; Shen MX, 1998, MOL PHARMACOL, V54, P459, DOI 10.1124/mol.54.3.459; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; WILEY JL, 1995, J PHARMACOL EXP THER, V275, P1; WILEY JL, 1995, NEUROPHARMACOLOGY, V34, P669, DOI 10.1016/0028-3908(95)00027-4	39	79	81	0	5	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0022-3565			J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	JUL	2002	302	1					359	368	UNSP 4852/990837	10.1124/jpet.302.1.359			10	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	562DW	WOS:000176183000046	12065738				2022-02-06	
J	Max, JE; Fox, PT; Lancaster, JL; Kochunov, P; Mathews, K; Manes, FF; Robertson, BAM; Arndt, S; Robin, DA; Lansing, AE				Max, JE; Fox, PT; Lancaster, JL; Kochunov, P; Mathews, K; Manes, FF; Robertson, BAM; Arndt, S; Robin, DA; Lansing, AE			Putamen lesions and the development of attention-deficit/hyperactivity symptomatology	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						attention-deficit/hyperactivity disorder; childhood stroke; putamen	DEFICIT HYPERACTIVITY DISORDER; FUNCTIONAL MAGNETIC-RESONANCE; CLOSED-HEAD INJURY; SPATIAL NORMALIZATION; HUMAN BRAIN; CHILDREN; RELIABILITY; VALIDITY; GIRLS	Objective: To investigate the association between focal stroke lesions of the putamen and either attention-deficit/hyperactivity disorder or traits of the disorder (ADHD/Traits). Method: Twenty-five children with focal stroke lesions were studied with standardized psychiatric assessments and anatomic brain magnetic resonance imaging. The pattern of lesion overlap in subjects with ADHD/Traits was determined. Results: Fifteen of 25 subjects had ADHD/Traits. The densest area of overlapping lesions (n = 7) in subjects with ADHD/Traits included the posterior ventral putamen. The median lesion volume was 9.7 cm(3), and the distribution was highly skewed. Lesion volume was not associated with ADHD/Traits. Therefore the following analyses focused on the 13 subjects with lesions < 10 cm(3): ADHD/Traits were exhibited in 617 subjects with putamen lesions versus 2/6 with no putamen lesions (Fisher exact test p = .1). Half (4/8) of the subjects with ADHD/Traits had overlapping lesions encompassing the posterior ventral putamen. None of the 5 subjects without ADHD/Traits had lesions in this empirically derived region of interest (Fisher exact test p = .1). Conclusions: Lesions within the dopamine-rich ventral putamen, which is part of the ventral or limbic striatum, tended to increase the risk of ADHD/Traits. ADHD/Traits may therefore be a disinhibition syndrome associated with dysfunction in this cortical-striato-thalamocortical loop.	Univ Calif San Diego, Dept Psychiat, San Diego, CA 92123 USA; Childrens Hosp & Hlth Ctr, San Diego, CA USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA; Univ Iowa, Iowa City, IA USA; Raul Carrea Inst Neurol Res, FLENI, Buenos Aires, DF, Argentina; San Diego State Univ, San Diego, CA 92182 USA		Max, JE (corresponding author), Univ Calif San Diego, Dept Psychiat, 3665 Kearny Villa Rd,Suite 101, San Diego, CA 92123 USA.		Robin, Donald/F-2109-2010; Arndt, Stephan/A-6976-2013; Kochunov, Peter/E-4711-2010; Lancaster, Jack L/F-2994-2010; Fox, Peter/B-4725-2010	Arndt, Stephan/0000-0003-0783-8204; Fox, Peter/0000-0002-0465-2028; mathews, katherine/0000-0003-4160-0435	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [P01MH052176, T32MH018399, P20MH052176] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [5 P02 MH52176-07, T32 MH18399] Funding Source: Medline		AFIFI AK, 1998, TXB PEDIAT NEUROPSYC, P65; American Psychiatric Association, 1987, DIAGN STAT MAN MENT, V3; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; Castellanos FX, 2001, ARCH GEN PSYCHIAT, V58, P289, DOI 10.1001/archpsyc.58.3.289; Castellanos FX, 1997, CLIN PEDIATR, V36, P381, DOI 10.1177/000992289703600702; Castellanos FX, 1996, ARCH GEN PSYCHIAT, V53, P607; De Weerd P, 1999, NAT NEUROSCI, V2, P753, DOI 10.1038/11234; Ebaugh FG, 1923, AM J DIS CHILD, V25, P89; Ernst M, 1997, J AM ACAD CHILD PSY, V36, P1399, DOI 10.1097/00004583-199710000-00022; Filipek PA, 1997, NEUROLOGY, V48, P589, DOI 10.1212/WNL.48.3.589; Gerring J, 2000, BRAIN INJURY, V14, P205; Giroud M, 1997, J NEUROL NEUROSUR PS, V63, P611, DOI 10.1136/jnnp.63.5.611; Heinz A, 1999, SYNAPSE, V32, P71, DOI 10.1002/(SICI)1098-2396(199905)32:2<71::AID-SYN1>3.0.CO;2-Q; Hendren RL, 2000, J AM ACAD CHILD PSY, V39, P815, DOI 10.1097/00004583-200007000-00010; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; HYND GW, 1993, J CHILD NEUROL, V8, P339, DOI 10.1177/088307389300800409; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Kochunov P, 2001, J COMPUT ASSIST TOMO, V25, P805, DOI 10.1097/00004728-200109000-00023; Lancaster JL, 1995, HUM BRAIN MAPP, V3, P209, DOI 10.1002/hbm.460030305; Lancaster JL, 1997, HUM BRAIN MAPP, V5, P238, DOI 10.1002/(SICI)1097-0193(1997)5:4<238::AID-HBM6>3.0.CO;2-4; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Levy F, 1997, J AM ACAD CHILD PSY, V36, P737, DOI 10.1097/00004583-199706000-00009; Lippitz BE, 1999, NEUROSURGERY, V44, P452, DOI 10.1097/00006123-199903000-00005; Max JE, 2002, J AM ACAD CHILD PSY, V41, P555, DOI 10.1097/00004583-200205000-00013; MERJANIAN P M, 1989, Society for Neuroscience Abstracts, V15, P302; Obeso JA, 2000, NEUROLOGY, V55, pS7; OUNSTED C, 1955, LANCET, V2, P303; Paus T, 1996, J COMP NEUROL, V376, P664, DOI 10.1002/(SICI)1096-9861(19961223)376:4<664::AID-CNE12>3.0.CO;2-M; Roach ES, 1995, PEDIAT CEREBROVASCUL, P35; ROACH ES, 1995, PEDIAT CEREBROVASCUL, P121; SZATMARI P, 1989, J CHILD PSYCHOL PSYC, V30, P219, DOI 10.1111/j.1469-7610.1989.tb00236.x; Teicher MH, 2000, NAT MED, V6, P470, DOI 10.1038/74737; *US DHHS, 1994, INT CLASS DIS; Vaidya CJ, 1998, P NATL ACAD SCI USA, V95, P14494, DOI 10.1073/pnas.95.24.14494; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD	36	79	80	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0890-8567			J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	MAY	2002	41	5					563	571		10.1097/00004583-200205000-00014			9	Psychology, Developmental; Pediatrics; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Pediatrics; Psychiatry	544YF	WOS:000175188900014	12014789				2022-02-06	
J	Hopkins, MJ; Dywan, J; Segalowitz, SJ				Hopkins, MJ; Dywan, J; Segalowitz, SJ			Altered electrodermal response to facial expression after closed head injury	BRAIN INJURY			English	Article							FACE PROCESSING IMPAIRMENTS; TRAUMATIC BRAIN-INJURY; AMYGDALA DAMAGE; RECOGNITION; EMOTION; INDIVIDUALS; BEHAVIOR; MILD	The objective was to determine whether diffuse damage to orbital and ventromedial regions of the prefrontal cortex usually associated with moderate-to-severe closed head injury (CHI) would affect the ability to perceive and respond to socially relevant information. Methods: Participants with CHI and age-matched non-injured controls were presented with faces that varied with respect to emotional expression while electrodermal activity (EDA) was monitored. Cognitive and general adaptive functioning was also assessed. Results: CHI was associated with a failure to increase EDA in response to negative facial expressions and with reduced ability to identify negative expressions, especially fear. The groups differed on other signs of orbital/medial prefrontal damage such as anosmia and in general social adaptability and awareness-of-deficit as measured by the Brock Adaptive Functioning Questionnaire. Conclusions: CHI affected the ability to identify and respond to negative facial expression. Addressing these deficits may enhance rehabilitative efforts within the social domain.	Brock Univ, Dept Psychol, St Catharines, ON L2S 3A1, Canada; Ctr Addict & Mental Hlth, Community Support & Res Unit, Toronto, ON, Canada		Dywan, J (corresponding author), Brock Univ, Dept Psychol, St Catharines, ON L2S 3A1, Canada.	jdywan@spartan.ac.brocku.ca					Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Abu-Judeh HH, 1999, NUCL MED COMMUN, V20, P505, DOI 10.1097/00006231-199906000-00003; ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; Adolphs R, 1999, NEUROPSYCHOLOGIA, V37, P1111, DOI 10.1016/S0028-3932(99)00039-1; Adolphs R, 1999, PSYCHOL SCI, V10, P167, DOI 10.1111/1467-9280.00126; ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; Bechara A, 1997, SCIENCE, V275, P1293, DOI 10.1126/science.275.5304.1293; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; Broks P, 1998, NEUROPSYCHOLOGIA, V36, P59, DOI 10.1016/S0028-3932(97)00105-X; Calder AJ, 1996, COGNITIVE NEUROPSYCH, V13, P699, DOI 10.1080/026432996381890; Cattell R. B., 1960, TEST G CULTURE FAIR; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; DAMASIO AR, 1990, BEHAV BRAIN RES, V41, P81, DOI 10.1016/0166-4328(90)90144-4; Damasio AR, 1996, PREFRONTAL CORTEX EX, P36, DOI [10.1093/acprof:oso/9780198524410.003.0004, DOI 10.1093/ACPROF:OSO/9780198524410.003.0004]; DAWSON ME, 1995, PRINCIPLES PSYCHOPHY, P295; Dywan J, 1996, J HEAD TRAUMA REHAB, V11, P79, DOI 10.1097/00001199-199604000-00008; DYWAN J, 1995, J INT NEUROPSYCH SOC, V1, P121; Ekman P., 1976, PICTURES FACIAL AFFE; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; FOWLES DC, 1981, PSYCHOPHYSIOLOGY, V18, P232, DOI 10.1111/j.1469-8986.1981.tb03024.x; Fuster J., 1989, PREFRONTAL CORTEX AN; Greenwald M.K., 1988, INT AFFECTIVE PICTUR; Hamann SB, 1996, NATURE, V379, P497, DOI 10.1038/379497a0; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Kraus Jess F., 1994, P3; KUSHNIRUK A, 1985, SLEEP, V8, P146, DOI 10.1093/sleep/8.2.146; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; LEZAK MD, 1990, TRAUMATIC BRAIN INJU, P365; Ongur D, 2000, CEREB CORTEX, V10, P206, DOI 10.1093/cercor/10.3.206; PORGES SW, 1995, PSYCHOPHYSIOLOGY, V32, P301, DOI 10.1111/j.1469-8986.1995.tb01213.x; Rapcsak SZ, 2000, NEUROLOGY, V54, P575, DOI 10.1212/WNL.54.3.575; Rolls E.T., 1999, BRAIN EMOTION; ROLLS ET, 1998, PREFRONTAL CORTEX EX, P67; SCHNIDER A, 1999, SCI PRACT NEUROPSYCH, P487; Sprengelmeyer R, 1997, COGN NEUROPSYCHOL, V14, P839, DOI 10.1080/026432997381376; Sprengelmeyer R, 1996, BRAIN, V119, P1647, DOI 10.1093/brain/119.5.1647; STAMBROOK M, 1991, J CLIN EXP NEUROPSYC, V13, P521, DOI 10.1080/01688639108401068; STAMBROOK M, 1990, COGNITIVE REHABILITA, V8, P26; Stenberg G, 1998, COGNITION EMOTION, V12, P755, DOI 10.1080/026999398379420; Streit M, 1999, COGNITIVE BRAIN RES, V7, P481, DOI 10.1016/S0926-6410(98)00048-2; Varney NR., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI [10.1097/00001199-199303000-00005, DOI 10.1097/00001199-199303000-00005]; Wechsler D., 1981, WAIS R MANUAL; Young AW, 1996, NEUROPSYCHOLOGIA, V34, P31, DOI 10.1016/0028-3932(95)00062-3; YOUNG AW, 1995, BRAIN, V118, P15, DOI 10.1093/brain/118.1.15; Zahn TP, 1999, NEUROPSYCHOLOGIA, V37, P1227, DOI 10.1016/S0028-3932(99)00020-2	47	79	79	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2002	16	3					245	257		10.1080/02699050110103346			13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	526HP	WOS:000174124800006	11874616				2022-02-06	
J	Flashman, LA; McAllister, TW				Flashman, LA; McAllister, TW			Lack of awareness and its impact in traumatic brain injury	NEUROREHABILITATION			English	Article						unawareness; lack of insight; traumatic brain injury; frontal-parietal circuitry	CLOSED HEAD-INJURY; IMPAIRED AWARENESS; SELF-AWARENESS; RATING-SCALE; REHABILITATION; UNAWARENESS; DEFICITS; INSIGHT; APATHY; SCHIZOPHRENIA	Research suggests that up to 45% severe TBI demonstrate reduced awareness or complete lack of awareness of their deficits. We describe dimensions and distinctions within the concept of lack of awareness -- including whether an individual has knowledge of a specific deficit, the emotional response an individual manifests to a specific deficit, the ability to comprehend the impact or consequences of the deficit on day to day life, and how an individual explains or accounts for any deficits -- and various methods of assessing for lack of awareness in this population. Finally, a review of the literature studying lack of awareness in TBI, its relationship to injury severity, the impact of lack of awareness on outcome, and intervention approaches is presented.	Dartmouth Hitchcock Med Ctr, Dept Psychiat, Neuropsychiat Sect, Dartmouth Med Sch, Lebanon, NH 03756 USA; New Hampshire Hosp, Concord, NH USA		Flashman, LA (corresponding author), Dartmouth Hitchcock Med Ctr, Dept Psychiat, Neuropsychiat Sect, Dartmouth Med Sch, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	Laura.A.Flashman@dartmouth.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS40472-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040472] Funding Source: NIH RePORTER		Alexy WD, 1983, COGNITIVE REHABILITA, V1, P8; ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Andersson S, 1999, BRAIN INJURY, V13, P393, DOI 10.1080/026990599121458; Babinski J, 1914, REV NEUROL, V27; BARIN JJ, 1985, HEAD INJURY REHABILI, P362; Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; Benson D.F., 1986, FRONTAL LOBES; Bergquist Thomas F., 1993, Brain Injury, V7, P275, DOI 10.3109/02699059309029680; Bond M R, 1975, Ciba Found Symp, P141; BROOKS N, 1991, Brain Injury, V5, P103, DOI 10.3109/02699059109008082; Buckley PF, 2001, COMPR PSYCHIAT, V42, P39, DOI 10.1053/comp.2001.16569; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; Chittum WR, 1996, BRAIN INJURY, V10, P763; DEATON AV, 1978, REHABIL PSYCHOL, V31, P231; DEKOSKY ST, 1998, SEMIN CLIN NEUROPSYC, V3, P176; DELUCA J, 1996, MAGAZINE, V4, P14; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FAHY TJ, 1967, LANCET, V2, P475; Feinberg TE, 1997, NEUROCASE, V3, P73, DOI 10.1080/13554799708404037; Flashman, 1998, Semin Clin Neuropsychiatry, V3, P201; FLASHMAN LA, 1997, J NEUROPSYCHIATRY CL, V9, P670; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORD B, 1976, MED J AUSTRALIA, V1, P603, DOI 10.5694/j.1326-5377.1976.tb140904.x; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Freeland J, 1996, MAGAZINE, V4, P32; GENARELLI TA, 1998, SEMINARS CLIN NEUROP, V3, P160; Giacino JT, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199810000-00003; Gordon WR, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199812000-00006; Gray J.M, 1994, CLIN REHABIL, V8, P188, DOI [10.1177/026921559400800302, DOI 10.1177/026921559400800302, DOI 10.1080/09602010902949207]; GROSWASSER Z, 1977, SCAND J REHABIL MED, V9, P147; Heilbronner R L, 1989, Brain Inj, V3, P387, DOI 10.3109/02699058909004562; Heilman K.M., 1991, AWARENESS DEFICIT BR, P53; Herbert CM, 1989, CLIN REHABIL, V3, P125; Hillier SL, 1997, BRAIN INJURY, V11, P525, DOI 10.1080/713802189; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; KENT H, 1999, J HEAD TRAUMA REHAB, V13, P62; Kozloff R., 1987, J HEAD TRAUMA REHAB, V2, P14, DOI [DOI 10.1097/00001199-198709000-00004, 10.1097/00001199-198709000-00004]; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVINE DN, 1990, BRAIN COGNITION, V13, P233, DOI 10.1016/0278-2626(90)90052-P; LYSAKER P, 1994, J NERV MENT DIS, V182, P656, DOI 10.1097/00005053-199411000-00010; LYSAKER P, 1998, ADV PSYCHOSOCIAL TRE, P307; MALEC JF, 1993, BRAIN INJURY, V7, P383, DOI 10.3109/02699059309029682; MARIN RS, 1991, J NEUROPSYCH CLIN N, V3, P243; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MILLER H, 1965, LANCET, V1, P225; Mohamed S, 1999, J NERV MENT DIS, V187, P525, DOI 10.1097/00005053-199909000-00001; Newman AC, 2000, BRAIN INJURY, V14, P333; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; OTA Y, 1969, LATE EFFECTS HEAD IN; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; PRIGATANO GP, 1987, BNI Q, V3, P10; RATTOK J, 1992, NEUROPSYCHOLOGIA, V6, P395, DOI DOI 10.1037/0894-4105.6.4.395; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; SACKEIM HA, 1986, ARCH GEN PSYCHIAT, V43, P553; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Schilder P, 1934, AM J PSYCHIAT, V91, P155, DOI 10.1176/ajp.91.1.155; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Sherer M., 1995, J INT NEUROPSYCH SOC, V1, P163; Smith TE, 2000, SCHIZOPHRENIA BULL, V26, P193, DOI 10.1093/oxfordjournals.schbul.a033439; Sohlberg MM, 1998, J HEAD TRAUMA REHAB, V13, P62, DOI 10.1097/00001199-199810000-00008; Stuss D., 1991, AWARENESS DEFICIT BR, P63; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; Tournois J., 2000, EUR REV APPL PSYCHOL, V50, P219; Trivers R, 2000, ANN NY ACAD SCI, V907, P114; TRUDEL TM, 1996, NEW HAMPSH BRAIN INJ; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; WALKER DE, 1987, J CLIN PSYCHOL, V43, P699, DOI 10.1002/1097-4679(198711)43:6<699::AID-JCLP2270430610>3.0.CO;2-9; WATSON RT, 1981, ARCH NEUROL-CHICAGO, V38, P501, DOI 10.1001/archneur.1981.00510080063009; WATSON RT, 1994, ARCH NEUROL-CHICAGO, V51, P1014, DOI 10.1001/archneur.1994.00540220060015; Weinstein E.A., 1955, DENIAL ILLNESS SYMBO; YOUNG DA, 1993, SCHIZOPHR RES, V10, P117, DOI 10.1016/0920-9964(93)90046-L; Zhou J, 1996, J HEAD TRAUMA REHAB, V11, P51, DOI 10.1097/00001199-199602000-00007	85	79	80	1	11	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2002	17	4					285	296					12	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	636GA	WOS:000180445200003	12547977				2022-02-06	
J	Passler, MA; Riggs, RV				Passler, MA; Riggs, RV			Positive outcomes in traumatic brain injury-vegetative state: Patients treated with bromocriptine	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; vegetative state; minimally conscious state; bromocriptine; rehabilitation	RECOVERY; REHABILITATION; COMA; METHYLPHENIDATE; AROUSAL	Objective: To assess the effects of multidisciplinary rehabilitation interventions and use of bromocriptine on outcome in patients with traumatic brain injury-vegetative state (TBI-VS). Design: Retrospective review of clinical cases. Setting: Free-standing rehabilitation hospital; Acute and extended rehabilitation hospital. Participants: Five consecutive TBI-VS patients, as well as 33 TBI-VS patients and 37 traumatic brain injury-minimally conscious state (TBI-MCS) patients reported in the literature. Interventions: Bromocriptine administration, systematic neuropsychologic testing, sensory stimulation, and traditional comprehensive rehabilitation with physical therapy, occupational therapy, and speech therapy. Main Outcome Measures: Disability Rating Scale (DRS) at 1, 3, 6, and 12 months postinjury and FIM(TM) instrument scores at 1 month and 12 months postinjury, Coma Recovery Scale, and Barry Rehabilitation Inpatient Screening of Cognition. Results: The 5 TBI-VS patients emerged from a VS into a MCS and regained functional status. Their recovery of physical and cognitive functioning, as rated by the DRS, was greater than previously reported in the literature for patients in a VS or MCS at 3, 6, and 12 months postinjury. Conclusion: Bromocriptine administration, systematic neuropsychologic testing, sensory stimulation, a comprehensive rehabilitation program, or a combination of these treatments may enhance functional recovery in this TBI-VS patient group. Further systematic study to quantify the contribution of these variables and to reproduce this data in a larger patient population should be pet-formed.	Healthsouth Rehabil Hosp, Dothan, AL USA		Passler, MA (corresponding author), 335 S St Andrews St, Dothan, AL 36301 USA.						ANSELL BJ, 1989, ARCH PHYS MED REHAB, V70, P104; *ASP CONS C, 1996, WORKGR VEG MIN CONSC; Barrett AM, 1999, ARCH PHYS MED REHAB, V80, P600, DOI 10.1016/S0003-9993(99)90205-8; BARRETT K, 1991, J NEUROL NEUROSUR PS, V54, P718, DOI 10.1136/jnnp.54.8.718; BARRY P, 1989, ARCH PHYS MED REHAB, V70, P902; BARTKOWSKI HM, 1986, J HEAD TRAUMA REHAB, V1, P1; BRADDOM RL, 1996, PHYSICAL MED REHABIL, P1027; BRICOLO A, 1980, J NEUROSURG, V52, P625, DOI 10.3171/jns.1980.52.5.0625; BRICOLO A, 1976, HDB CLIN NEUROLOGY, P699; CARDENAS DD, 1992, PSYCHOPHARMACOLOGIC, P273; CELESIA, 1993, ANN NEUROL, V33, P386; DIRICCO C, 1974, J NEUROSURG SCI, V18, P169; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; GIACINO JT, 1995, J HEAD TRAUMA REHAB, V10, P40; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; Goldstein L B, 1990, Restor Neurol Neurosci, V1, P311, DOI 10.3233/RNN-1990-1501; Lal S, 1988, Brain Inj, V2, P225, DOI 10.3109/02699058809150946; LUCIANA M, 1992, J COGNITIVE NEUROSCI, V4, P58, DOI 10.1162/jocn.1992.4.1.58; MCDOWELL FH, 1991, ARZNEIMITTEL-FORSCH, V41-1, P355; MULLER U, 1994, PROG NEURO-PSYCHOPH, V18, P1103, DOI 10.1016/0278-5846(94)90114-7; ODell MW, 1996, J HEAD TRAUMA REHAB, V11, P61, DOI 10.1097/00001199-199606000-00009; ODell MW, 1996, NEUROREHABILITATION, V6, P45, DOI 10.3233/NRE-1996-6106; ODELL MW, 1996, MED REHABILITATION T, P103; PASSLER MA, 1987, REHABIL PSYCHOL, V32, P215; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Ragnarsson KT, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI DOI 10.1097/00001199-199308020-00003; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reinhard DL, 1996, ARCH PHYS MED REHAB, V77, P80, DOI 10.1016/S0003-9993(96)90225-7; ROSENBERG JH, 1995, NEUROLOGY, V45, P1015; Stanczak DE, 1998, NEUROPSYCHOL REV, V8, P191, DOI 10.1023/A:1021670203013; *STAT U NEW YORK B, 1993, GUID UN DAT SET MED; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; VANWOERKOM TCAM, 1982, EUR NEUROL, V21, P227, DOI 10.1159/000115485; WHYTE J, 1992, ARCH PHYS MED REHAB, V73, P940; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Wilson BA, 1997, J INT NEUROPSYCH SOC, V3, P487, DOI 10.1017/S1355617797004876; Worzniak M, 1997, J FAM PRACTICE, V44, P495; ZASLER N D, 1992, Brain Injury, V6, P1, DOI 10.3109/02699059209008117; Zeman A, 1997, LANCET, V350, P795, DOI 10.1016/S0140-6736(97)06447-7	42	79	83	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2001	82	3					311	315		10.1053/apmr.2001.20831			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	407RG	WOS:000167284100004	11245751				2022-02-06	
J	Levine, B; Dawson, D; Boutet, I; Schwartz, ML; Stuss, DT				Levine, B; Dawson, D; Boutet, I; Schwartz, ML; Stuss, DT			Assessment of strategic self-regulation in traumatic brain injury: Its relationship to injury severity and psychosocial outcome	NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; FRONTAL-LOBE DAMAGE; HUMAN PREFRONTAL CORTEX; POSTTRAUMATIC AMNESIA; EPISODIC MEMORY; WORKING-MEMORY; LESIONS; DYSFUNCTION; ATTENTION; DISSOCIATION	Standard neuropsychological tests administered in a constrained and artificial laboratory environment are often insensitive to the real-life deficits faced by patients with traumatic brain injury (TBI). The Revised Strategy Application Test (R-SAT) creates an unstructured environment in the laboratory in which environmental cues and internal habits oppose the most efficient strategy, thus mimicking the real-life situations that are problematic for patients with TBI. In this study, R-SAT performance was related both to severity of TBI (i.e., depth of coma) sustained 2-3 years earlier and to quality of life outcome as assessed by the Sickness Impact Profile. This relationship held after accounting for variance attributable to TBI-related slowing and inattention. These findings support the validity of the R-SAT and suggest that behavioral correlates of quality of life outcome in TBT can be assessed in the laboratory with unstructured tasks.	Baycrest Ctr Geriatr Care, Rotman Res Inst, Toronto, ON M6A 2E1, Canada; Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Med Neurol, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Occupat Therapy, Toronto, ON M5S 1A1, Canada; Sunnybrook Hlth Sci Ctr, Dept Neurosurg, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada		Levine, B (corresponding author), Baycrest Ctr Geriatr Care, Rotman Res Inst, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	blevine@rotman-baycrest.on.ca	Dawson, Deirdre R/I-8882-2014; Levine, Brian/O-2725-2019; Levine, Brian/G-4328-2010; Boutet, Isabelle/Q-2333-2016	Dawson, Deirdre R/0000-0001-7517-6121; Levine, Brian/0000-0003-4343-811X; Levine, Brian/0000-0003-4343-811X; Boutet, Isabelle/0000-0002-1943-0970			ALEXANDER MP, 1984, NEUROLOGY, V34, P752, DOI 10.1212/WNL.34.6.752; ALEXANDER MP, 1982, PSYCHIATRIC ASPECTS, V2, P219; Army Individual Test Battery, 1944, MAN DIR SCOR; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bechara A, 1998, J NEUROSCI, V18, P428; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Burgess PW, 2000, NEUROPSYCHOLOGIA, V38, P848, DOI 10.1016/S0028-3932(99)00134-7; Burgess PW., 1996, BEHAV ASSESSMENT DYS; COURVILLE CB, 1937, PATHOLOGY CENTRAL 4; DAWSON DR, IN PRESS J NEUROLOGY; Dias R, 1996, NATURE, V380, P69, DOI 10.1038/380069a0; Dias R, 1996, BEHAV NEUROSCI, V110, P872, DOI 10.1037/0735-7044.110.5.872; DIKMEN S, 1996, NEUROPSYCHOLOGICAL A, P552; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Duncan J, 1997, COGNITIVE NEUROPSYCH, V14, P713, DOI 10.1080/026432997381420; DUNCAN J, 1986, COGNITIVE NEUROPSYCH, V3, P271, DOI 10.1080/02643298608253360; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Freedman M, 1998, CEREB CORTEX, V8, P18, DOI 10.1093/cercor/8.1.18; Gansler DA, 1996, BRAIN COGNITION, V30, P194, DOI 10.1006/brcg.1996.0012; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; Goel V, 1997, BRAIN, V120, P1805, DOI 10.1093/brain/120.10.1805; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Harlow J.M., 1993, PUBLICATIONS MASSACH, V4, P274, DOI [DOI 10.1177/0957154X9300401407, https://doi.org/10.1177/0957154X9300401407]; JENKINS A, 1986, LANCET, V2, P445; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KIMBERG DY, 1993, J EXP PSYCHOL GEN, V122, P411, DOI 10.1037/0096-3445.122.4.411; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; Levin H. S., 1994, NEUROPSYCHOLOGY, V87, P171, DOI DOI 10.1037/0894-4105.8.2.171; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1994, J CHILD NEUROL, V9, P81, DOI 10.1177/088307389400900121; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1992, J NEUROTRAUM, V9, pS359; Levine B, 1998, BRAIN, V121, P1951, DOI 10.1093/brain/121.10.1951; Levine B, 2000, MEMORY, CONSCIOUSNESS, AND THE BRAIN, P200; Levine B, 1997, NEUROPSYCHOLOGY, V11, P367, DOI 10.1037/0894-4105.11.3.367; Levine B, 1999, NEUROCASE, V5, P263, DOI 10.1080/13554799908402731; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; Levine B, 1996, CLIN NEUROPSYCHOL, V10, P350; LEVINE B, 1999, UNPUB HLTH ADULTS PE; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MILLER BL, 1993, DEMENTIA, V4, P204, DOI 10.1159/000107324; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; MISHKIN M, 1964, FRONTAL GRANULAR COR, P219; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; ROLLS ET, 1994, J NEUROL NEUROSUR PS, V57, P1518, DOI 10.1136/jnnp.57.12.1518; Rolls ET, 1996, PHILOS T ROY SOC B, V351, P1433, DOI 10.1098/rstb.1996.0128; Rueckert L, 1996, NEUROPSYCHOLOGIA, V34, P953, DOI 10.1016/0028-3932(96)00016-4; Schwartz MF, 1999, NEUROPSYCHOLOGIA, V37, P51; Schwartz MF, 1998, NEUROPSYCHOLOGY, V12, P13, DOI 10.1037/0894-4105.12.1.13; Schwartz ML, 1998, CAN J NEUROL SCI, V25, P108, DOI 10.1017/S0317167100033709; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Sherer M, 1998, NEUROREHABILITATION, V10, P25, DOI 10.3233/NRE-1998-10104; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss D.T., 1994, NEUROPSYCHOLOGY, V8, P355, DOI [https://doi.org/10.1037/0894-4105.8.3.355, DOI 10.1037/0894-4105.8.3.355]; Stuss DT, 2000, NEUROPSYCHOLOGIA, V38, P388, DOI 10.1016/S0028-3932(99)00093-7; Stuss DT, 1998, J INT NEUROPSYCH SOC, V4, P265, DOI 10.1017/S1355617798002653; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Stuss DT, 2000, NEUROLOGY, V54, P1337, DOI 10.1212/WNL.54.6.1337; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D, 1985, WECHSLER ADULT INTEL; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3	73	79	82	0	7	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	OCT	2000	14	4					491	500		10.1037/0894-4105.14.4.491			10	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	363HZ	WOS:000089831000001	11055251				2022-02-06	
J	Csuka, E; Hans, VHJ; Ammann, E; Trentz, O; Kossmann, T; Morganti-Kossmann, MC				Csuka, E; Hans, VHJ; Ammann, E; Trentz, O; Kossmann, T; Morganti-Kossmann, MC			Cell activation and inflammatory response following traumatic axonal injury in the rat	NEUROREPORT			English	Article						astrocytes; experimental; immunohistochemistry; impact-acceleration; inflammation; MHC class II; microglia; rat; traumatic brain injury	DIFFUSE BRAIN INJURY; CEREBROSPINAL-FLUID; MESSENGER-RNA; HEAD-INJURY; ASTROCYTES; MODEL; EXPRESSION	In a rat model of traumatic brain injury cell activation was characterized immunohistochemically from 2 h up to 2 weeks. Reactive astrocytosis became apparent perivascularly and in the grey matter within 4 h after trauma. Increased OX42 immunoreactivity indicated microglial activation in cortex and hippocampus as early as 4 h, whereas up-regulation of MHC class II (OX6) was evident in white matter tracts at 24 h. Although macrophage (EDI) numbers increased in the meninges and perivascularly, brain infiltration appeared marginal. Accumulation of lymphocytes and granulocytes was not observed. Our results show that traumatic axonal injury induces a rapid and sustained glial activation in the absence of leukocyte infiltration. Thus, cell activation following diffuse trauma strongly differs from that found after focal brain damage, awaiting further functional characterization. NeuroReport 11:2587-2590 (C) 2000 Lippincott Williams & Wilkins.	Univ Spital Zurich, Dept Chirurg, Forsch Abt, CH-8091 Zurich, Switzerland; Univ Spital Zurich, Unfallchirurg Klin, CH-8091 Zurich, Switzerland; Univ Kliniken Bonn, Inst Neuropathol, D-53105 Bonn, Germany		Morganti-Kossmann, MC (corresponding author), Univ Spital Zurich, Dept Chirurg, Forsch Abt, Ramistr 100, CH-8091 Zurich, Switzerland.			Morganti-Kossmann, Cristina/0000-0002-0807-2063			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Engel S, 1996, Acta Neurochir Suppl, V66, P89; Engelborghs K, 1998, J NEUROSURG, V89, P796, DOI 10.3171/jns.1998.89.5.0796; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GRAEBER MB, 1988, J NEUROSCI RES, V21, P18, DOI 10.1002/jnr.490210104; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184, DOI 10.1097/00004647-199902000-00010; Hausmann R, 1999, INT J LEGAL MED, V112, P227, DOI 10.1007/s004140050241; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; MORGANTIKOSSMAN.MC, 1995, IMMUNE RESPONSES NER, P159; Neumann H, 1996, EUR J NEUROSCI, V8, P2582, DOI 10.1111/j.1460-9568.1996.tb01552.x; SEKIYA S, 1989, J LEUKOCYTE BIOL, V46, P96, DOI 10.1002/jlb.46.2.96; Soares HD, 1995, J NEUROSCI, V15, P8223; Stahel PF, 1997, MOL BRAIN RES, V50, P205, DOI 10.1016/S0169-328X(97)00189-7; [No title captured]	20	79	82	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-4965			NEUROREPORT	Neuroreport	AUG 3	2000	11	11					2587	2590		10.1097/00001756-200008030-00047			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	340ZY	WOS:000088567600049	10943727				2022-02-06	
J	Clark, RSB; Kochanek, PM; Adelson, PD; Bell, MJ; Carcillo, JA; Chen, M; Wisniewski, SR; Janesko, K; Whalen, MJ; Graham, SH				Clark, RSB; Kochanek, PM; Adelson, PD; Bell, MJ; Carcillo, JA; Chen, M; Wisniewski, SR; Janesko, K; Whalen, MJ; Graham, SH			Increases in bcl-2 protein in cerebrospinal fluid and evidence for programmed cell death in infants and children after severe traumatic brain injury	JOURNAL OF PEDIATRICS			English	Article							SEVERE HEAD-INJURY; BCL-2-DEFICIENT MICE; REGULATING APOPTOSIS; NEURONAL APOPTOSIS; CYTOCHROME-C; EXPRESSION; BAX; SURVIVAL; RAT; OVEREXPRESSION	Objectives: To determine whether bcl-2, a protein that inhibits apoptosis, would be increased in cerebrospinal fluid (CSF) in infants and children after traumatic brain injury (TBI) and to examine the association of bcl-2 concentration with clinical variables. Study design: Bcl-2 was measured in CSF from 23 children (aged 2 months-16 years) with severe TBI and from 19 children without TBI or meningitis (control subjects) by enzyme-linked immunosorbent assay CSF oligonucleosome concentration was also determined as a marker of DNA degradation. Brain samples from 2 patients undergoing emergent decompressive craniectomies were analyzed for bcl-2 with Western blot and for DNA fragmentation with TUNEL (terminal deoxynucleotidyl-transerase mediated biotin-dUTP nick-end labeling). Results: CSF bcl-2 concentrations were increased in patients with TBI versus control subjects (P = .01). Bcl-2 was increased in patients with TBI who survived versus those who died (P = .02). CSF oligonucleosome concentration tended to be increased after TBI (P = .07) and was not associated with bcl-2. Brain tissue samples showed an increase in bcl-2 in patients with TBI versus adult brain bank control samples and evidence of DNA fragmentation within cells with apoptotic morphology Conclusions: Bcl-2 may participate in the regulation of cell, death after TBI in infants and children. The increase in bcl-2 seen in patients who survived is consistent with a protective role for this anti-apoptotic protein after TBI.	Childrens Hosp Pittsburgh, Div Pediat Crit Care, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15213 USA; Childrens Hosp Pittsburgh, Dept Pediat, Pittsburgh, PA 15213 USA; Childrens Hosp Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA; Childrens Hosp Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15213 USA; Childrens Hosp Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; VA Pittsburgh Hlth Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA		Clark, RSB (corresponding author), Childrens Hosp Pittsburgh, Div Pediat Crit Care, Dept Anesthesiol & Crit Care Med, 3705 5th Ave, Pittsburgh, PA 15213 USA.		Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5P30 HD28836] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [KO8 NS01946, R01 NS38620] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD028836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038620, K08NS001946] Funding Source: NIH RePORTER		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bell MJ, 1999, CRIT CARE MED, V27, P493, DOI 10.1097/00003246-199903000-00023; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; BRADBURY MW, 1963, CLIN SCI, V25, P97; Chen J, 1997, J CEREBR BLOOD F MET, V17, P2, DOI 10.1097/00004647-199701000-00002; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Edwards AD, 1996, NEUROPATH APPL NEURO, V22, P494, DOI 10.1111/j.1365-2990.1996.tb01122.x; Graham SH, 1996, RESTOR NEUROL NEUROS, V9, P243, DOI 10.3233/RNN-1996-9407; Hochman A, 1998, J NEUROCHEM, V71, P741; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kitamura Y, 1998, BRAIN RES, V780, P260, DOI 10.1016/S0006-8993(97)01202-X; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Marmarou A, 1997, ACT NEUR S, V70, P68; Mogi M, 1996, NEUROSCI LETT, V215, P137, DOI 10.1016/0304-3940(96)12961-X; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; PorteraCailliau C, 1997, J COMP NEUROL, V378, P88, DOI 10.1002/(SICI)1096-9861(19970203)378:1<88::AID-CNE5>3.0.CO;2-G; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; RINK A, 1995, AM J PATHOL, V147, P1575; ROSNER B, 1984, BIOMETRICS, V40, P1025, DOI 10.2307/2531153; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Ruppel R., 1998, Society for Neuroscience Abstracts, V24, P253; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Tarkowski E, 1999, STROKE, V30, P321, DOI 10.1161/01.STR.30.2.321; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Waters KA, 1999, PEDIATR RES, V45, P166, DOI 10.1203/00006450-199902000-00002; WAXWEILER RJ, 1996, TRAUMATIC BRAIN INJU, P1; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533; 1998, NIH CONSENSUS STATEM	48	79	82	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	AUG	2000	137	2					197	204		10.1067/mpd.2000.106903			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	345TZ	WOS:000088832400013	10931412				2022-02-06	
J	Stover, JF; Schoning, B; Beyer, TF; Woiciechowsky, C; Unterberg, AW				Stover, JF; Schoning, B; Beyer, TF; Woiciechowsky, C; Unterberg, AW			Temporal profile of cerebrospinal fluid glutamate, interleukin-6, and tumor necrosis factor-alpha in relation to brain edema and contusion following controlled cortical impact injury in rats	NEUROSCIENCE LETTERS			English	Article						brain edema; contusion; cytokines; excitotoxicity; traumatic brain injury	CLOSED-HEAD INJURY; TNF-ALPHA; CYTOKINE PRODUCTION; MESSENGER-RNA; EXPRESSION; MICE; IL-6	Traumatic brain injury is associated with release of the excitotoxin glutamate and production of pro-inflammatory cytokines IL-6 and tumor necrosis factor-alpha (TNF-alpha). Following controlled cortical impact injury, cerebrospinal fluid (CSF) glutamate, IL-6, and TNF-alpha concentrations were measured to investigate their relationship to evolving tissue damage. Compared to non-traumatized rats CSF glutamate, IL-6 and TNF-alpha: levels were significantly increased by 8 h after trauma (P < 0.005). Parallel to Increasing brain swelling and contusion CSF glutamate was significantly elevated over time, reaching highest levels by 48 h (33 +/- 4 mu M) while IL-6 and TNF-alpha showed maximum values at 24 h after trauma (42 +/- 7 and 4.7 +/- 1 pg/ml) (P < 0.005). The observed different temporal profile of CSF glutamate, IL-6, and TNF-alpha following focal traumatic brain injury could be of therapeutic importance. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.	Charite Virchow Med Ctr, Dept Neurosurg, D-13353 Berlin, Germany		Stover, JF (corresponding author), Charite Virchow Med Ctr, Dept Neurosurg, Augustenburger Pl 01, D-13353 Berlin, Germany.						Baskaya MK, 2000, J NEUROTRAUM, V17, P93, DOI 10.1089/neu.2000.17.93; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Carlson NG, 1999, J IMMUNOL, V163, P3963; CHIANG CS, 1994, DEV NEUROSCI-BASEL, V16, P212, DOI 10.1159/000112109; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fine SM, 1996, J BIOL CHEM, V271, P15303, DOI 10.1074/jbc.271.26.15303; Galasso JM, 2000, NEUROREPORT, V11, P231, DOI 10.1097/00001756-200002070-00002; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184, DOI 10.1097/00004647-199902000-00010; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Obrenovitch TP, 1997, PROG NEUROBIOL, V51, P39, DOI 10.1016/S0301-0082(96)00049-4; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schiefer J, 1998, J NEUROIMMUNOL, V89, P168, DOI 10.1016/S0165-5728(98)00133-7; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Stover JF, 2000, J NEUROSURG, V92, P853, DOI 10.3171/jns.2000.92.5.0853; Van Wagoner NJ, 1999, J NEUROIMMUNOL, V100, P124, DOI 10.1016/S0165-5728(99)00187-3; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S	20	79	84	0	0	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	JUL 7	2000	288	1					25	28		10.1016/S0304-3940(00)01187-3			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	329PT	WOS:000087916600007	10869807				2022-02-06	
J	Lee, YL; Shih, K; Bao, P; Ghirnikar, RS; Eng, LF				Lee, YL; Shih, K; Bao, P; Ghirnikar, RS; Eng, LF			Cytokine chemokine expression in contused rat spinal cord	NEUROCHEMISTRY INTERNATIONAL			English	Article						cytokines; chemokines; spinal cord injury	MONOCYTE CHEMOATTRACTANT PROTEIN-1; CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; WOUND BRAIN INJURY; MESSENGER-RNA; ASTROCYTE EXPRESSION; GENE-EXPRESSION; INTERLEUKIN-8; MICROGLIA	Spinal cord injury within the first few hours, is complicated by inflammatory mechanisms, including the influx of monocyte/macrophages as well as the activation of resident spinal microglia and astrocytes. Numerous studies have suggested that the initial infiltration of the hematogenous cells may be due to the secretion of cytokines and chemokines in the injured CNS. In order to elucidate which chemotactic factors may be expressed following traumatic spinal cord contusion, the presence of mRNA for a number of cytokines, chemokines and growth factors was examined in contused rat spinal cord by reverse transcriptase-polymerase chain reaction and immunohistochemistry. Spinal injury was accompanied by an increase in glial fibrillary acidic protein mRNA suggesting astrocyte activation and astrogliosis. TNF alpha message levels were upregulated as early as 1 h post injury and returned to baseline levels by 3 days post injury (DPI). By immunocytochemistry, staining for TNF, increased at 1 and 3 dpi and was predominantly diffuse in the necrotic tissue. The chemokines IP-10, MCP-1, and MIP-la were also detected in the injured spinal cord. mRNA levels of IP-10 peaked around 6 h post injury and were upregulated up to 7 dpi. MCP-1 mRNA was detected at 1 h post injury and its levels returned to baseline by 14 dpi. An increase in MCP-I staining was observed from 1 to 7 dpi. The staining was also diffuse in the necrotic tissue and also localized to cells near the site of injury. The presence of aFGF and bFGF was also detected in the injured spinal cord. mRNA for aFGF was detected at 0 time, increased at 6 h post injury, peaked at 3 days, and remained elevated up to 21 days. bFGF mRNA was initially detected at 1 h post injury, increased between 6 h and 3 days, declined thereafter and returned to baseline levels by 21 days. (C) 2000 Elsevier Science Ltd. All rights reserved.	VAPA Hlth Care Syst, Dept Pathol, Palo Alto, CA USA; Stanford Univ, Sch Med, Stanford, CA 94305 USA		Eng, LF (corresponding author), VAPA Hlth Care Syst, Dept Pathol, 3801 Miranda Ave, Palo Alto, CA USA.	Ifeng@leland.stanford.edu					Amichay D, 1996, J IMMUNOL, V157, P4511; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BARNA BP, 1994, J NEUROIMMUNOL, V50, P101, DOI 10.1016/0165-5728(94)90220-8; Berman JW, 1996, J IMMUNOL, V156, P3017; BROSNAN CF, 1993, ADV NEUROL, V59, P349; Eng LF, 1999, J NEUROCHEM, V73, pS194; FURIE MB, 1995, AM J PATHOL, V146, P1287; Ghirnikar RS, 1998, NEUROSCI LETT, V247, P21, DOI 10.1016/S0304-3940(98)00268-7; Ghirnikar RS, 1996, J NEUROSCI RES, V46, P727; GHIRNIKAR RS, 1999, IN PRESS J NEUROSCI; Glabinski AR, 1996, J IMMUNOL, V156, P4363; GODISKA R, 1995, J NEUROIMMUNOL, V58, P167, DOI 10.1016/0165-5728(95)00008-P; HULKOWER K, 1993, J IMMUNOL, V150, P2525; HURWITZ AA, 1995, J NEUROIMMUNOL, V57, P193, DOI 10.1016/0165-5728(95)00011-P; KARPUS WJ, 1995, J IMMUNOL, V155, P5003; KLEIN RM, 1996, SOC NEUR ABSTR, V22, P843; Lee YL, 1997, J NEUROCHEM, V69, pS144; Majumder S, 1996, J NEUROSCI RES, V45, P758, DOI 10.1002/(SICI)1097-4547(19960915)45:6<758::AID-JNR12>3.0.CO;2-S; McTigue DM, 1998, J NEUROSCI RES, V53, P368, DOI 10.1002/(SICI)1097-4547(19980801)53:3<368::AID-JNR11>3.0.CO;2-1; MURPHY GM, 1993, J NEUROSCI RES, V35, P643, DOI 10.1002/jnr.490350607; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; RANSOHOFF RM, 1993, FASEB J, V7, P592, DOI 10.1096/fasebj.7.6.8472896; SHYY YJ, 1993, J CLIN INVEST, V92, P1745, DOI 10.1172/JCI116762; STOECKLE M Y, 1990, New Biologist, V2, P313; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; TANI M, 1994, BRAIN PATHOL, V4, P135, DOI 10.1111/j.1750-3639.1994.tb00824.x; TAUB DD, 1993, J EXP MED, V177, P1809, DOI 10.1084/jem.177.6.1809; VANGURI P, 1994, J IMMUNOL, V152, P1411; VANGURI P, 1995, J NEUROIMMUNOL, V56, P35, DOI 10.1016/0165-5728(94)00131-7; WANG XK, 1995, STROKE, V26, P661, DOI 10.1161/01.STR.26.4.661; WILSON SD, 1990, J EXP MED, V171, P1301, DOI 10.1084/jem.171.4.1301; WRATHALL JR, 1985, EXP NEUROL, V88, P108, DOI 10.1016/0014-4886(85)90117-7	33	79	94	0	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	APR	2000	36	4-5					417	425		10.1016/S0197-0186(99)00133-3			9	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	293RQ	WOS:000085867300016	10733009				2022-02-06	
J	Pike, BR; Zhao, XR; Newcomb, JK; Glenn, CC; Anderson, DK; Hayes, RL				Pike, BR; Zhao, XR; Newcomb, JK; Glenn, CC; Anderson, DK; Hayes, RL			Stretch injury causes calpain and caspase-3 activation and necrotic and apoptotic cell death in septo-hippocampal cell cultures	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; calpain; caspase-3; cell culture; neuron; spectrin (fodrin); traumatic brain injury	TRAUMATIC BRAIN INJURY; MICROTUBULE-ASSOCIATED PROTEIN-2; SPINAL-CORD INJURY; CORTICAL NEURONAL INJURY; CEREBRAL-ISCHEMIA; DNA FRAGMENTATION; DELAYED DEPOLARIZATION; SPECTRIN BREAKDOWN; MECHANICAL INJURY; REACTIVE GLIOSIS	Traumatic brain injury (TBI) results in numerous central and systemic responses that complicate interpretation of the effects of the primary mechanical trauma. For this reason, several in vitro models of mechanical cell injury have recently been developed that allow more precise control over intra- and extracellular environments than is possible in vivo. Although we recently reported that calpain and caspase-3 proteases are activated after TBI in rats, the role of calpain and/or caspase-3 has not been examined in any in vitro model of mechanical cell injury. In this investigation, varying magnitudes of rapid mechanical cell stretch were used to examine processing of the cytoskeletal protein alpha-spectrin (280 kDa) to a signature 145-kDa fragment by calpain and to the apoptotic-linked 120-kDa fragment by caspase-3 in septo-hippocampal cell cultures. Additionally, effects of stretch injury on cell viability and morphology were assayed. One hour after injury, maximal release of cytosolic lactate dehydrogenase and nuclear propidium iodide uptake were associated with peak accumulations of the calpain-specific 145-kDa fragment to alpha-spectrin at each injury level. The acute period of calpain activation (1-6 h) was associated with subpopulations of nuclear morphological alterations that appeared necrotic (hyperchromatism) or apoptotic (condensed, shrunken nuclei). In contrast, caspase-3 processing of alpha-spectrin to the apoptotic-linked 120-kDa fragment was only detected 24 h after moderate, but not mild or severe injury. The period of caspase-3 activation was predominantly associated with nuclear shrinkage, fragmentation, and apoptotic body formation characteristic of apoptosis. Results of this study indicate that rapid mechanical stretch injury to septo-hippocampal cell cultures replicates several important biochemical and morphological alterations commonly observed in vivo brain injury, although important differences were also noted.	Univ Florida, Dept Neurosci, Inst Brain, Ctr Traumat Brain Injury Studies, Gainesville, FL 32610 USA; Univ Texas, Hlth Sci Ctr, Dept Neurosurg, Vivian L Smith Ctr Neurol Res, Houston, TX USA; Univ Florida, Coll Med, Dept Neurol Surg, Gainesville, FL USA; Malcom Randall Vet Affairs Med Ctr, Gainesville, FL USA		Pike, BR (corresponding author), Univ Florida, Dept Neurosci, Inst Brain, Ctr Traumat Brain Injury Studies, 100 S Newell Dr,Box 100244, Gainesville, FL 32610 USA.	pike@ufbi.ufl.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458, F32NS010584] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32-NS10584, R01-NS21458] Funding Source: Medline		Banik NL, 1997, BRAIN RES, V752, P301, DOI 10.1016/S0006-8993(96)01488-6; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; Charriaut-Marlangue C, 1998, BIOMED PHARMACOTHER, V52, P264, DOI 10.1016/S0753-3322(98)80012-7; Chen J, 1998, J NEUROSCI, V18, P4914; CHOI DW, 1987, J NEUROSCI, V7, P357; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; DECAMILLI P, 1984, NEUROSCIENCE, V11, P819, DOI 10.1016/0306-4522(84)90194-5; Eldadah BA, 1996, NUCLEIC ACIDS RES, V24, P4092, DOI 10.1093/nar/24.20.4092; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; FISCHER I, 1991, NEUROCHEM RES, V16, P891, DOI 10.1007/BF00965538; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; Gennarelli T.A., 1985, CENTRAL NERVOUS SYST, P391; GOLDBERG MP, 1988, J PHARMACOL EXP THER, V245, P1081; GROSS GW, 1983, J NEUROSCI, V3, P1979; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; Henkels KM, 1997, CANCER RES, V57, P4488; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; HONG SC, 1994, STROKE, V25, P663, DOI 10.1161/01.STR.25.3.663; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; JOHNSON GVW, 1991, J NEUROCHEM, V56, P1630, DOI 10.1111/j.1471-4159.1991.tb02061.x; JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kato H, 1997, J THORAC CARDIOV SUR, V114, P609, DOI 10.1016/S0022-5223(97)70051-5; Katoh K, 1996, NEUROSCI LETT, V216, P9; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Kitagawa H, 1998, STROKE, V29, P1417, DOI 10.1161/01.STR.29.7.1417; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lamb RG, 1997, J NEUROCHEM, V68, P1904; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; LI ZH, 1995, NEUROCHEM INT, V27, P425, DOI 10.1016/0197-0186(95)00024-3; Linnik MD, 1996, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1996, P33; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XZ, 1997, J NEUROSCI, V17, P5395; LUCAS J H, 1990, Journal of Neurotrauma, V7, P169, DOI 10.1089/neu.1990.7.169; MALHOTRA SK, 1990, CYTOBIOS, V61, P133; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MATESIC DF, 1994, J NEUROCHEM, V63, P1012; MONYER H, 1989, BRAIN RES, V483, P347, DOI 10.1016/0006-8993(89)90179-0; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Morrison B, 1998, ANN BIOMED ENG, V26, P381, DOI 10.1114/1.61; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; MURPHY EJ, 1994, NEUROBIOLOGY CENTRAL, P28; Namura S, 1998, J NEUROSCI, V18, P3659; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; Nath R, 1998, J NEUROCHEM, V71, P186; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; NORTON WT, 1992, NEUROCHEM RES, V17, P877, DOI 10.1007/BF00993263; OCALLAGHAN JP, 1993, ANN NY ACAD SCI, V679, P195, DOI 10.1111/j.1749-6632.1993.tb18299.x; Park JS, 1996, NEUROBIOL DIS, V3, P215, DOI 10.1006/nbdi.1996.0022; Pike BR, 1998, J NEUROSCI RES, V52, P505, DOI 10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.3.CO;2-Y; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Piwocka K, 1999, EXP CELL RES, V249, P299, DOI 10.1006/excr.1999.4480; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/S0006-8993(96)00222-3; PURANAM KL, 1999, CRC METH NEUROSCI S, P129; RINK A, 1995, AM J PATHOL, V147, P1575; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Rzigalinski BA, 1997, J NEUROCHEM, V68, P289; RZIGALINSKI BA, 1998, J NEUROTRAUM, V15, P894; RZIGALINSKI BA, 1996, FASEB J, V10, pA280; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Schmechel D.E., 1999, CRC METH NEUROSCI S, P161; SEUBERT P, 1989, BRAIN RES, V492, P366, DOI 10.1016/0006-8993(89)90921-9; SHEPARD SR, 1991, J SURG RES, V51, P417, DOI 10.1016/0022-4804(91)90144-B; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632, DOI 10.1152/jn.1997.77.2.632; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767, DOI 10.1152/jn.1995.74.6.2767; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; WILLOUGHBY KA, 1998, J NEUROTRAUM, V15, P902; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zhao X, 1999, NEUROCHEM RES, V24, P371, DOI 10.1023/A:1020933616351; ZHAO X, 1998, J NEUROTRAUM, V15, P904	94	79	83	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2000	17	4					283	298		10.1089/neu.2000.17.283			16	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	302LA	WOS:000086365500003	10776913				2022-02-06	
J	Levin, HS; Benavidez, DA; Verger-Maestre, K; Perachio, N; Song, J; Mendelsohn, DB; Fletcher, JM				Levin, HS; Benavidez, DA; Verger-Maestre, K; Perachio, N; Song, J; Mendelsohn, DB; Fletcher, JM			Reduction of corpus callosum growth after severe traumatic brain injury in children	NEUROLOGY			English	Article						corpus callosum; traumatic brain injury; children	DIFFUSE AXONAL INJURY; CLOSED-HEAD-INJURY; COMA; MRI	Objective: To study effects of closed head injury (CHI) severity on development of corpus callosum (CC) in children, using MRI. Background: Vulnerability of CC to diffuse axonal injury has been shown in adults and children by neuropathologic and MRI studies. Given continued development of CC through the second decade, serial MRI could characterize effects of CHI on CC growth in children. Methods: MRI performed at 3 and 36 months after severe (mean age = 10.3 years, n = 25) and mild to moderate (mean age = 9.7 years, n = 28) CHI. Mild to moderate and severe CHI groups did not differ in demographic features. Morphometry of T1-weighted midsagittal CC by two operators with satisfactory interrater reliability yielded uncorrected and corrected CC volume. Results: An interaction of occasion with CW severity was present as CC area decreased from 3 to 36 months in severely injured children and increased in the mild to moderate CHI group. Uncorrected CC area was correlated with acute CHI severity and functional outcome at 36 months postinjury. Conclusions: Morphometric measurement of CC area provides a useful index of diffuse injury, which is related to functional outcome of CHI in children.	Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA; Univ Barcelona, Dept Psychol, E-08007 Barcelona, Spain; Univ Texas, SW Med Sch, Dept Radiol, Dallas, TX 75230 USA; Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77225 USA		Levin, HS (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 1333 Moursund Ave,Room A205, Houston, TX 77030 USA.		Fletcher, Jack/AAX-2931-2020; fletcher, jack/Q-5975-2019		NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01-RR02558] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21889] Funding Source: Medline		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Ciccetti D., 1984, VINELAND ADAPTIVE BE; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GIEDD JN, 1996, DEV BRAIN RES, V91, P274; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; HILLMAN GR, 1991, J COMPUT ASSIST TOMO, V15, P640, DOI 10.1097/00004728-199107000-00021; JENNETT B, 1975, LANCET, V1, P480; JOHNSON SC, 1994, NEUROPSYCHOLOGY, V8, P1; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; LINDENBERG R, 1955, AM J PATHOL, V31, P297; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MENDELSOHN DB, 1992, NEURORADIOLOGY, V34, P384, DOI 10.1007/BF00596495; Pandya DN., 1986, 2 HEMISPHERES ONE BR, P47; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; PUJOL J, 1993, ANN NEUROL, V34, P71, DOI 10.1002/ana.410340113; Rajapakse JC, 1996, BRAIN DEV-JPN, V18, P379, DOI 10.1016/0387-7604(96)00034-4; ROKNE J, 1991, GRAPHICS GEMS, V3, P5; STONE MG, 1986, AM MATH MON, V93, P479, DOI 10.2307/2323479; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; TEASDALE G, 1974, LANCET, V2, P81; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799; Yakovlev PI, 1967, REGIONAL DEV BRAIN E, P3	26	79	80	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	FEB 8	2000	54	3					647	653		10.1212/WNL.54.3.647			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	281KZ	WOS:000085160300020	10680798				2022-02-06	
J	Nakagawa, Y; Nakamura, M; McIntosh, TK; Rodriguez, A; Berlin, JA; Smith, DH; Saatman, KE; Raghupathi, R; Clemens, J; Saido, TC; Schmidt, ML; Lee, VMY; Trojanowski, JQ				Nakagawa, Y; Nakamura, M; McIntosh, TK; Rodriguez, A; Berlin, JA; Smith, DH; Saatman, KE; Raghupathi, R; Clemens, J; Saido, TC; Schmidt, ML; Lee, VMY; Trojanowski, JQ			Traumatic brain injury in young, amyloid-beta peptide overexpressing transgenic mice induces marked ipsilateral hippocampal atrophy and diminished A beta deposition during aging	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						Alzheimer's disease; amyloid plaques; head trauma; neuron degeneration	FAMILIAL ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; HEAD-INJURY; SENILE PLAQUES; CORTICAL IMPACT; MEMORY DEFICITS; AXONAL INJURY; NEURONAL LOSS; EXPRESSION; DEATH	Traumatic brain injury (TBI) is an epigenetic risk factor for Alzheimer's disease (AD). To test the hypothesis that TBI contributes to the onset andior progression of AD-like beta-amyloid peptide (AP) deposits, we studied the long-term effects of TBI in transgenic mice that overexpress human A beta from a mutant A beta precursor protein (APP) minigene driven by a platelet derived (PD) growth factor promoter (PDAPP mice). TBI was induced in 4-month-old PDAPP and wild type (WT) mice by controlled cortical impact (CCI). Because A beta begins to deposit progressively in the PDAPP brain by 6 months, we examined WT and PDAPP mice at 2, 5, and 8 months after TBI or sham treatment (i.e., at 6, 9, and 12 months of age). Hippocampal atrophy in the PDAPP mice was more severe ipsilateral versus contralateral to TBI, and immunohistochemical studies with antibodies to different A beta peptides demonstrated a statistically significant reduction in hippocampus and cingulate cortex A beta deposits ipsilateral versus contralateral to CCI in 9-12 month-old PDAPP mice. Hippocampal atrophy and reduced Ap deposits were not seen in hippocampus or cingulate cortex of sham-injured PDAPP mice or in any WT mice. These data suggest that the vulnerability of brain cells to A beta toxicity increases and that the accumulation of AP deposits decrease in the penumbra of CCI months after TBI. Thus, in addition to providing unique opportunities for elucidating genetic mechanisms of AD, transgenic mice that recapitulate AD pathology also may be relevant animal models for investigating the poorly understood role that TBI and other epigenetic risk factors play in the onset and/or progression of AD. (C) 1999 Wiley-Liss. Inc.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Div Anat Pathol,Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Eli Lilly Inc, Indianapolis, IN 46285 USA; RIKEN, Brain Sci Inst, Proteolyt Neurosci Lab, Wako, Saitama 3510198, Japan		Trojanowski, JQ (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Hosp Univ Penn,Ctr Neurodegenerat Dis Res, Maloney 3rd Floor,3400 Spruce St, Philadelphia, PA 19104 USA.		Saido, Takaomi C/N-5472-2015; smith, douglas/A-1321-2007; Sado, Takaomi/AAN-2759-2021; Raghupathi, Ramesh/AAX-5538-2021	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903; 	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG11542, AG09215] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM34690] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG009215, P01AG011542] Funding Source: NIH RePORTER		ARAI H, 1990, P NATL ACAD SCI USA, V87, P2249, DOI 10.1073/pnas.87.6.2249; Arnold SE, 1998, ARCH GEN PSYCHIAT, V55, P225, DOI 10.1001/archpsyc.55.3.225; BUXBAUM JD, 1993, BIOCHEM BIOPH RES CO, V197, P639, DOI 10.1006/bbrc.1993.2527; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; Cummings BJ, 1996, NEUROBIOL AGING, V17, P921, DOI 10.1016/S0197-4580(96)00170-4; Dickson DW, 1997, J NEUROPATH EXP NEUR, V56, P321, DOI 10.1097/00005072-199704000-00001; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GOEDERT M, 1997, MOL GENETIC BASIS NE, P613; Greenberg BD, 1996, NEUROBIOL AGING, V17, P153, DOI 10.1016/0197-4580(96)00001-2; Guillery RW, 1997, J COMP NEUROL, V386, P2, DOI 10.1002/(SICI)1096-9861(19970915)386:1<2::AID-CNE2>3.0.CO;2-6; Hoffmann R, 1997, BIOCHEMISTRY-US, V36, P8114, DOI 10.1021/bi970380+; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HSIAO KK, 1997, MOL MECH DEMENTIA, P39; Irizarry MC, 1997, J NEUROPATH EXP NEUR, V56, P965, DOI 10.1097/00005072-199709000-00002; Irizarry MC, 1997, J NEUROSCI, V17, P7053; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Iwatsubo T, 1996, AM J PATHOL, V149, P1823; Johnson D, 1997, EDN, V42, P94; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; LEBLANC A, 1997, MOL MECH DEMENTIA, P57; LEE VMY, 1984, J NEUROCHEM, V42, P25, DOI 10.1111/j.1471-4159.1984.tb09692.x; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Loring JF, 1996, NEUROBIOL AGING, V17, P173, DOI 10.1016/0197-4580(95)02076-4; Masliah E, 1996, J NEUROSCI, V16, P5795; MATSUO ES, 1994, NEURON, V13, P989, DOI 10.1016/0896-6273(94)90264-X; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Mayeux R, 1998, NEW ENGL J MED, V338, P506, DOI 10.1056/NEJM199802193380804; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MORRISONBOGORAD M, 1997, MOL GENETIC BASIS NE, P581; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, P28; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; PEARSON BE, 1993, P NATL ACAD SCI USA, V90, P10578, DOI 10.1073/pnas.90.22.10578; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Reaume AG, 1996, J BIOL CHEM, V271, P23380, DOI 10.1074/jbc.271.38.23380; RINK A, 1995, AM J PATHOL, V147, P1575; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROCKENSTEIN EM, 1995, J BIOL CHEM, V270, P28257; Saido TC, 1996, NEUROSCI LETT, V215, P173, DOI 10.1016/S0304-3940(96)12970-0; Saido TC, 1998, NEUROBIOL AGING, V19, pS69, DOI 10.1016/S0197-4580(98)00033-5; SAIDO TC, 1995, NEURON, V14, P1; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schmidt ML, 1998, ACTA NEUROPATHOL, V95, P117, DOI 10.1007/s004010050774; SCHMIDT ML, 1994, FEBS LETT, V344, P69, DOI 10.1016/0014-5793(94)00259-2; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SELKOE DJ, 1997, MOL GENETIC BASIS NE, P601; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Shin RW, 1997, J NEUROSCI, V17, P8187; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P281; YACHNIS AT, 1993, J COMP NEUROL, V334, P356, DOI 10.1002/cne.903340303	63	79	79	1	3	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0021-9967			J COMP NEUROL	J. Comp. Neurol.	AUG 30	1999	411	3					390	398					9	Neurosciences; Zoology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Zoology	221JV	WOS:000081724700003	10413774				2022-02-06	
J	Napieralski, JA; Raghupathi, R; McIntosh, TK				Napieralski, JA; Raghupathi, R; McIntosh, TK			The tumor-suppressor gene, p53, is induced in injured brain regions following experimental traumatic brain injury	MOLECULAR BRAIN RESEARCH			English	Article						p53; cyclin D1; cell cycle; cell death; apoptosis; traumatic brain injury	CYCLIN D1; MESSENGER-RNA; CELL-CYCLE; DENTATE GYRUS; RAT-BRAIN; FOREBRAIN ISCHEMIA; DNA FRAGMENTATION; C-JUN; EXPRESSION; APOPTOSIS	A growing body of evidence suggests that neurons undergo apoptotic cell death following traumatic brain injury (TBI). Since the expression of several tumor suppressor and cell cycle genes have been implicated in neuronal apoptosis, the present study used in situ hybridization (ISH) histochemistry to evaluate the regional and temporal patterns of expression of the mRNAs for the tumor suppressor gene, p53, and the cell cycle gene, cyclin DI, following lateral fluid-percussion (FP) brain injury in the rat. Anesthetized adult male Sprague-Dawley rats (n = 16) were subjected to lateral FP brain injury of moderate severity (2.3-2.7 atm), while sham controls (n = 6) were surgically prepared but did not receive brain injury. Animals were killed by decapitation at 6 h (n = 6 injured and 2 sham), 24 h (n = 6 injured and 2 sham), or 3 days (n = 4 injured and 2 sham), and their brains processed for ISH. Little to no expression of p53 mRNA was observed in sham brains. At 6 h post-injury, p53 mRNA was induced predominantly in cells that are vulnerable to TBI, such as those in the contused cortex, lateral and medial geniculate nuclei of the thalamus, and the CA, and hilar neurons of the hippocampus. Increased p53 mRNA was also detected in hippocampal CA, neurons, cells that are relatively resistant to FP brain injury. Levels of p53 mRNA returned to sham levels in all regions of the injured brain by 24 h. In contrast to p53, cyclin D1 mRNA was detectable in the brains of uninjured animals and was not altered by brain injury. These results suggest that the tumor suppressor gene p53, but not cyclin D1, is upregulated and may participate in molecular response to TBI. (C) 1999 Elsevier Science B.V. All rights reserved.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA		McIntosh, TK (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 105B Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS026818] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NS08803, R01-NS26818] Funding Source: Medline		BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; CHESSELET MF, 1996, IN SITU HYBRIDIZATIO, P79; CHOPP M, 1992, BIOCHEM BIOPH RES CO, V182, P1201, DOI 10.1016/0006-291X(92)91859-O; Clark RSB, 1997, J NEUROSCI, V17, P9172; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; CRUMRINE RC, 1994, J CEREBR BLOOD F MET, V14, P887, DOI 10.1038/jcbfm.1994.119; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; EL DW, 1993, CELL, V75, P817; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; Guegan C, 1997, NEUROREPORT, V8, P1003, DOI 10.1097/00001756-199703030-00037; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hughes PE, 1996, NEUROSCIENCE, V74, P1143, DOI 10.1016/0306-4522(96)00174-1; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JORDAN J, 1996, J NEUROSCI, V17, P1405; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; Li Y, 1997, J NEUROL SCI, V150, P93, DOI 10.1016/S0022-510X(97)00075-0; LI Y, 1994, STROKE, V25, P849, DOI 10.1161/01.STR.25.4.849; Liu W, 1996, NEUROREPORT, V7, P2785, DOI 10.1097/00001756-199611040-00076; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MANEV H, 1994, NEUROREPORT, V5, P2661, DOI 10.1097/00001756-199412000-00064; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MIYASHITA T, 1995, CELL, V80, P293; Morrison RS, 1996, J NEUROSCI, V16, P1337; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OLTVAI ZN, 1993, CELL, V74, P619; PAXINOS G, 1994, RAT BRAIN STEREOTAXI; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Postigo JA, 1998, NEUROSCI LETT, V241, P107, DOI 10.1016/S0304-3940(97)00981-6; Preston GA, 1996, MOL CELL BIOL, V16, P211; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; RAGHUPATHI R, 1997, J CEREB BLOOD FLOW M, V17, pS494; RINK A, 1995, AM J PATHOL, V147, P1575; SAKHI S, 1994, P NATL ACAD SCI USA, V91, P7525, DOI 10.1073/pnas.91.16.7525; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; Wiessner C, 1996, NEUROSCIENCE, V72, P947, DOI 10.1016/0306-4522(95)00601-X; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	48	79	84	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	JUL 23	1999	71	1					78	86		10.1016/S0169-328X(99)00155-2			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	218PB	WOS:000081560000009	10407189				2022-02-06	
J	Collin, GR				Collin, GR			Decreasing catheter colonization through the use of an antiseptic-impregnated catheter - A continuous quality improvement project	CHEST			English	Article						antiseptic-impregnated catheter; bloodstream infection; catheter-related; central venous catheterization; chlorhexidine; colonization; catheter; cost savings; infection; catheter-related infection control; intensive care unit; silver sulfadiazine	PULMONARY-ARTERY CATHETERS; BLOOD-STREAM INFECTION; RANDOMIZED TRIAL; BARRIER PRECAUTIONS; PREVENTION; SEPSIS; COMPLICATIONS; PATHOGENESIS; EPIDEMIOLOGY; MANAGEMENT	Study objectives: To evaluate the use of an antiseptic-impregnated (chlorhexidine and silver sulfadiazine) catheter for the prevention of catheter colonization and catheter-related bloodstream infection (CR-BSI). Then, based on these findings, to implement changes in hospital policy and to assess their effect on a hospital service. Design: Prospective, randomized, controlled (phase I); prospective, concurrent data collection (phase II). Setting: Tertiary referral hospital with level 1 trauma center. Patients: Patients > 12 years of age with central venous catheters placed while they were in the emergency room, neurotrauma ICU, or medical/surgical ICU from May through December, 1995 (phase I). All patients > 12 years of age on the trauma service admitted from November 16, 1996, through November 15, 1997 (phase II). Interventions: Randomization table determined whether the patient would receive an antiseptic-impregnated catheter (AIC) or nonimpregnated catheter (NIC) (phase I). All removed or exchanged catheters were sent for semiquantitative culture. In phase II, only AICs were used; "length of time" and "fever" were discouraged as reasons for catheter exchange or removal; and only the tip was sent for culture. Measurements and results: In phase I, there were 139 catheters placed in 60 patients in the NIC group and 98 catheters placed in 55 patients in the AIC group. Two catheters (2.0/100 catheters) in the AIC group were found to be colonized, compared with 25 (18.0/100 catheters) in the NIC group (p = 0.001). The catheter colonization rates were 2.27/1,000 catheter days (AIC) and 24.68/1,000 catheter days (NIC) (p < 0.001), while the CR-BSI rates were 1.14/1,000 catheter days (AIC) and 3.95/1,000 catheter days (NIC) (p = 0.31). The reason for each catheter removal/exchange was noted, and only "positive blood culture" was statistically significant overall. The tip segment was found to be positive more often than the intracutaneous segment. In phase II, there were 213 AICs place in 101 patients. The colonization rate was 3.8/100 catheters (4.52/1,000 catheter days), and CR-BSI rate was 1.0/100 catheters (0.6/1,000 catheter days). The colonization rate for catheters left in place remained low for catheters left in place < 14 days (1.6/100 catheters). Only 11% of catheters were exchanged/removed for reason of "fever," as compared with 23% in phase I. Conclusions: AICs significantly reduce the rate of central venous catheter colonization. In addition, the apparent protective effects of the catheter over time permit less frequent exchanges or removals of the catheters, decreasing both patient risk and hospital cost.	Carilion Roanoke Mem Hosp, Dept Med Educ, Roanoke, VA 24033 USA		Collin, GR (corresponding author), Carilion Roanoke Mem Hosp, Dept Med Educ, POB 13367, Roanoke, VA 24033 USA.						BALL S, 1995, CRIT CARE MED S, V23, pA250; BOOTH FVM, 1996, CRIT CARE MED S1, V24, pA45; CARLSON R, 1992, ONCOL TIMES, V14, P56; Ciresi DL, 1996, AM SURGEON, V62, P641; Civetta JM, 1996, CRIT CARE MED, V24, P1660, DOI 10.1097/00003246-199610000-00010; CLEMENCE MA, 1993, 33 INT C ANT AG CHEM, P416; DION L, 1988, CRIT CARE MED, V16, P436, DOI 10.1097/00003246-198804000-00154; EVANS M, 1984, ARCH SURG-CHICAGO, V119, P109; FARBER TM, 1992, ARROWGARD ANTISEPTIC; FEINSTEIN AR, 1977, CLIN STAT; FLOWERS RH, 1989, JAMA-J AM MED ASSOC, V261, P878, DOI 10.1001/jama.261.6.878; GARRISON RN, 1994, SURG CLIN N AM, V74, P557, DOI 10.1016/S0039-6109(16)46329-2; GREENFIELD J, 1993, 33 INT C ANT AG CHEM, P415; HEARD SO, 1997, CRIT CARE MED S, V25, pA117; HOFFMANN KK, 1992, JAMA-J AM MED ASSOC, V267, P2072, DOI 10.1001/jama.267.15.2072; JOHNSON A, 1992, J HOSP INFECT, V20, P67, DOI 10.1016/0195-6701(92)90108-X; Kruse J A, 1993, Nutr Clin Pract, V8, P163, DOI 10.1177/0115426593008004163; MAKI DG, 1991, LANCET, V338, P339, DOI 10.1016/0140-6736(91)90479-9; MAKI DG, 1994, INFECT CONT HOSP EP, V15, P227; MAKI DG, 1994, CRIT CARE MED, V22, P1729; Maki DG, 1997, ANN INTERN MED, V127, P257, DOI 10.7326/0003-4819-127-4-199708150-00001; MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301; MAKI DG, 1991, 31ST INT C ANT AG CH, P176; MAKI DG, 1992, HOSP INFECT, P849; MERMEL LA, 1991, AM J MED, V91, pS197, DOI 10.1016/0002-9343(91)90369-9; MERMEL LA, 1994, AM J RESP CRIT CARE, V149, P1020, DOI 10.1164/ajrccm.149.4.8143037; Mimoz O, 1996, CRIT CARE MED, V24, P1818, DOI 10.1097/00003246-199611000-00010; MODAK SM, 1992, COMPLICATIONS SURG, V11, P22; NORWOOD S, 1991, CHEST, V99, P968, DOI 10.1378/chest.99.4.968; Pemberton LB, 1996, ARCH SURG-CHICAGO, V131, P986; PITTET D, 1994, JAMA-J AM MED ASSOC, V271, P1598, DOI 10.1001/jama.271.20.1598; RAAD II, 1992, CLIN INFECT DIS, V15, P197, DOI 10.1093/clinids/15.2.197; RAAD II, 1994, INFECT CONT HOSP EP, V15, P231; *SAS I, 1990, STAT AN SYST US GUID; Segura M, 1996, ANN SURG, V223, P363, DOI 10.1097/00000658-199604000-00004	35	79	85	0	4	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	JUN	1999	115	6					1632	1640		10.1378/chest.115.6.1632			9	Critical Care Medicine; Respiratory System	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Respiratory System	206FX	WOS:000080867600027	10378561				2022-02-06	
J	Heath, DL; Vink, R				Heath, DL; Vink, R			Improved motor outcome in response to magnesium therapy received up to 24 hours after traumatic diffuse axonal brain injury in rats	JOURNAL OF NEUROSURGERY			English	Article						neurotrauma; magnesium sulfate; brain injury; treatment evaluation; therapeutic window; rat	ACUTE MYOCARDIAL-INFARCTION; INTRAVENOUS-MAGNESIUM; HEAD-INJURY; NEURONS; SULFATE; METABOLISM; REDUCTION; DAMAGE; DEATH; MODEL	Object. The goal of this study was to establish the therapeutic window during which delayed therapy with MgSO4 improves neurological motor outcome in rats that have suffered severe traumatic axonal brain injury. Methods. Severe brain injury was induced in male Sprague-Dawley rats by using the impact-acceleration model of severe traumatic diffuse axonal brain injury. Injured animals were subsequently treated with MgSO4 (750 mu mol/kg) infused intramuscularly at 30 minutes or at 8, 12, or 24 hours after trauma and were tested for neurological motor outcome during the following week by using the rotarod test. Injured untreated (control) animals demonstrated highly significant (p < 0.001) neurological motor deficits that were sustained over the 1-week assessment period. Animals treated with MgSO4 at 30 minutes or at 8 or 12 hours postinjury demonstrated significantly improved motor outcomes compared with untreated control animals at all time points (0.001 < p < 0.05). Animals treated with MgSO4 at 24 hours had motor scores that were similar to those of untreated control animals early in the week, but demonstrated a significantly more rapid recovery in function and, by the end of the assessment period, they demonstrated significantly improved motor scores (p < 0.01). Repeated administration of MgSO4 over the 1-week observation period did not further improve outcome. Conclusions. The present results demonstrate that Mg++ plays a neuroprotective role following severe diffuse traumatic axonal brain injury. Moreover, Mg++ therapy significantly improved motor outcome when administered up to 24 hours after injury, with early treatments providing the most significant benefit. Repeated administration beyond 24 hours postinjury did not provide additional neuroprotection.	James Cook Univ N Queensland, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia		Vink, R (corresponding author), James Cook Univ N Queensland, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia.	Robert.Vink@jcu.edu.au	Vink, Robert/S-5616-2019; Vink, Robert/J-7351-2012	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ALTURA B M, 1985, Magnesium, V4, P226; Bara M., 1984, MAGNESIUM, V3, P212; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1989, UPDATE INTENSIVE CAR, V9, P14; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; FuchsBuder T, 1997, J NEUROSURG ANESTH, V9, P324, DOI 10.1097/00008506-199710000-00006; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Heath DL, 1998, SCAND J CLIN LAB INV, V58, P161, DOI 10.1080/00365519850186751; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1998, J NEUROTRAUM, V15, P183, DOI 10.1089/neu.1998.15.183; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; HEATH DL, 1997, CHARACTERISATION NEU; Hoane MR, 1998, BRAIN RES BULL, V45, P45, DOI 10.1016/S0361-9230(97)00288-8; ISERI LT, 1984, AM HEART J, V108, P188, DOI 10.1016/0002-8703(84)90572-6; IZUMI Y, 1991, J CEREBR BLOOD F MET, V11, P1025, DOI 10.1038/jcbfm.1991.170; KASS IS, 1988, ANESTHESIOLOGY, V69, P710, DOI 10.1097/00000542-198811000-00012; KWACK H, 1992, CURR TOP CELL REGUL, V33, P185; Lenkinski R. E., 1995, Journal of Neurotrauma, V12, P351; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCDONALD JW, 1990, NEUROSCI LETT, V109, P234, DOI 10.1016/0304-3940(90)90569-U; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1992, EXCITATORY AMINO ACI, P247; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; MUIR KW, 1995, STROKE, V26, P1183, DOI 10.1161/01.STR.26.7.1183; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; Povlishock J.T., 1994, NEUROBIOLOGY CENTRAL, P109; RAM Z, 1991, STROKE, V22, P922, DOI 10.1161/01.STR.22.7.922; Ritter C, 1996, SCAND J CLIN LAB INV, V56, P275, DOI 10.3109/00365519609088647; ROBERTSON CS, 1986, J NEUROSURG, V64, P633, DOI 10.3171/jns.1986.64.4.0633; ROTHMAN SM, 1983, SCIENCE, V220, P536, DOI 10.1126/science.6836300; SCHANNE FAX, 1993, BIOCHIM BIOPHYS ACTA, V1158, P257, DOI 10.1016/0304-4165(93)90023-2; Schendel DE, 1996, JAMA-J AM MED ASSOC, V276, P1805, DOI 10.1001/jama.276.22.1805; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; TEO KK, 1991, BMJ-BRIT MED J, V303, P1499, DOI 10.1136/bmj.303.6816.1499; TSUDA T, 1991, NEUROSCIENCE, V44, P335, DOI 10.1016/0306-4522(91)90058-V; VINK R, 1993, MOL CHEM NEUROPATHOL, V18, P279, DOI 10.1007/BF03160120; WOODS KL, 1992, LANCET, V339, P1553, DOI 10.1016/0140-6736(92)91828-V; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	43	79	84	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	1999	90	3					504	509		10.3171/jns.1999.90.3.0504			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	170KX	WOS:000078805800010	10067920				2022-02-06	
J	Barnes, MA; Dennis, M; Wilkinson, M				Barnes, MA; Dennis, M; Wilkinson, M			Reading after closed head injury in childhood: Effects on accuracy, fluency, and comprehension	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN INJURY; WORD RECOGNITION; NAMING SPEED; DEVELOPMENTAL DYSLEXIA; CHILDREN; AGE; INFORMATION; SKILLS; ADOLESCENTS; PERFORMANCE	Two studies of reading decoding, reading fluency, and reading comprehension after childhood head injury are reported. Study 1 tested whether age at head injury and the type of contusional brain damage were related to reading outcomes. Fifty-five children with head injuries were tested on measures of word decoding accuracy and reading comprehension. Children who sustained head injuries in the preschool years before basic word decoding skills are acquired or in the early primary grades when decoding skills are being taught, and children with bilateral or left-sided contusions were most at risk for difficulties in acquiring basic word decoding and reading comprehension skills. In particular, children injured before 6 1/2 years of age were most at risk for difficulties in acquiring reading decoding skills in comparison to children injured after this age. Study 2 tested whether deficits in processing speed after head injury are also found in reading. Forty-three head-injured children were matched with controls on a pair-by-pair basis for age, grade, and word decoding accuracy. The children with head injuries were slower at naming words, particularly those with less common orthographic patterns, although the groups did not differ on speeded naming of pronounceable nonwords. Reading fluency in the head-injured group was related to reading comprehension, suggesting that slow word-level processing has negative consequences for text comprehension in these individuals. The results are discussed with respect to how head injuries affect the development of skills yet to be acquired and the further acquisition of those skills that are in a rapid phase of development at time of injury. The results are also discussed with reference to models of how head injury affects speeded processing.	Hosp Sick Children, Dept Psychol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON, Canada		Barnes, MA (corresponding author), Hosp Sick Children, Dept Psychol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	mbarnes@sickkids.on.ca					Adams M.J, 1990, BEGINNING READ; ALAJOUANINE T, 1965, BRAIN, V88, P653, DOI 10.1093/brain/88.4.653; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; BACKMAN J, 1984, J EXP CHILD PSYCHOL, V38, P114, DOI 10.1016/0022-0965(84)90022-5; Barnes MA, 1996, J EXP CHILD PSYCHOL, V61, P216, DOI 10.1006/jecp.1996.0015; BARNES MA, 1992, J PEDIATR PSYCHOL, V17, P445, DOI 10.1093/jpepsy/17.4.445; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; BOWERS PG, 1993, J READING BEHAV, V25, P133, DOI 10.1080/10862969309547807; BOWERS PG, 1991, J EXP CHILD PSYCHOL, V51, P195, DOI 10.1016/0022-0965(91)90032-N; BOWERS PG, 1993, READ WRIT, V5, P69, DOI 10.1007/BF01026919; Bradley L., 1985, RHYME REASON READING; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; BRYANT P, 1990, APPL PSYCHOLINGUIST, V11, P237, DOI 10.1017/S0142716400008870; Carr T.H., 1990, READING ITS DEV COMP; CASEY R, 1986, PEDIATRICS, V78, P497; DENCKLA MB, 1976, NEUROPSYCHOLOGIA, V14, P471, DOI 10.1016/0028-3932(76)90075-0; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; DENNIS M, 1988, MASTER LECT SERIES, V7, P89; DENNIS M, 1990, BRAIN LANG, V39, P203; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FLETCHER JM, 1987, NEUROBEHAVIORAL RECO, P277; FOX B, 1984, J EDUC PSYCHOL, V76, P1059; GOLDSTEIN FC, 1990, J CLIN EXP NEUROPSYC, V12, P286, DOI 10.1080/01688639008400975; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; HASLAM C, 1995, NEUROPSYCHOLOGY, V9, P599, DOI 10.1037/0894-4105.9.4.599; Haut M W, 1990, Arch Clin Neuropsychol, V5, P299, DOI 10.1016/0887-6177(90)90028-N; HAUT MW, 1991, BRAIN COGNITION, V17, P31, DOI 10.1016/0278-2626(91)90064-F; HEBB D. O., 1942, PROC AMER PHIL SOC, V85, P275; Hetherington CR, 1996, BRAIN INJURY, V10, P473, DOI 10.1080/026990596124197; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; LABERGE D, 1974, COGNITIVE PSYCHOL, V6, P293, DOI 10.1016/0010-0285(74)90015-2; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1988, SCANDINAVIAN J REH S, V20, P33; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; LOVETT MW, 1992, HDB NEUROPSYCHOLOGY, V7, P163; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MCKEOWN MG, 1983, J READING BEHAV, V15, P3, DOI 10.1080/10862968309547474; NICOLSON RI, 1990, COGNITION, V35, P159, DOI 10.1016/0010-0277(90)90013-A; Oakhill J., 1988, BECOMING SKILLED REA; Oakhill J, 1993, EDUC PSYCHOL REV, V5, P223, DOI 10.1007/BF01323045; Paris R., 1974, CLIN NEUROPSYCHOLOGY, P179; PERFETTI C., 1985, READING ABILITY; RANKIN JL, 1993, J READING BEHAV, V25, P261, DOI 10.1080/10862969009547817; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; SEGALOWITZ S, 1992, J CLIN EXPT NEUROPSY, V14, P73; SEIDENBERG MS, 1989, PSYCHOL REV, V96, P523, DOI 10.1037/0033-295X.96.4.523; SEIDENBERG MS, 1984, J VERB LEARN VERB BE, V23, P383, DOI 10.1016/S0022-5371(84)90270-6; SHAFFER D, 1980, J AM ACAD CHILD PSY, V19, P592, DOI 10.1016/S0002-7138(09)60964-X; SHINN MR, 1992, SCHOOL PSYCHOL REV, V21, P459; SPRING C, 1988, APPL PSYCHOLINGUIST, V9, P315, DOI 10.1017/S0142716400008031; STANOVICH KE, 1986, READ RES QUART, V21, P360, DOI 10.1598/RRQ.21.4.1; STANOVICH KE, 1984, READ RES QUART, V19, P278, DOI 10.2307/747822; TROMP E, 1991, J CLIN EXP NEUROPSYC, V13, P821, DOI 10.1080/01688639108405100; TUNMER WE, 1985, J EDUC PSYCHOL, V77, P417, DOI 10.1037/0022-0663.77.4.417; van Zomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; WATERS GS, 1985, MEM COGNITION, V13, P557, DOI 10.3758/BF03198326; WATERS GS, 1984, MEM COGNITION, V12, P293, DOI 10.3758/BF03197678; Wechsler D., 1974, WECHSLER INTELLIGENC; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; WOLF M, 1992, BRAIN LANG, V42, P219, DOI 10.1016/0093-934X(92)90099-Z; WOLF M, 1986, CHILD DEV, V57, P988, DOI 10.1111/j.1467-8624.1986.tb00260.x; WOLFF PH, 1990, BRAIN LANG, V39, P556, DOI 10.1016/0093-934X(90)90162-A; Woodcock R.W., 1987, WOODCOCK READING MAS; WOODCOCK RW, 1989, TEST COGNITIVE ABILI; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375; [No title captured]	68	79	79	0	9	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		1999	15	1					1	24		10.1080/87565649909540737			24	Psychology, Developmental; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	165BC	WOS:000078497900001					2022-02-06	
J	Rothweiler, B; Temkin, NR; Dikmen, SS				Rothweiler, B; Temkin, NR; Dikmen, SS			Aging effect on psychosocial outcome in traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							MINOR HEAD-INJURY; OLDER ADULTS; CONSEQUENCES; SURVIVAL; RECOVERY	Objective: To examine the effects of age on outcome in persons with traumatic brain injury. Design: Longitudinal cohort design. Setting: Level I trauma center. Patients: A total of 411 hospitalized subjects with mild to severe traumatic brain injury prospectively studied to 1 year; their age range was 18 to 89 years. Main Outcome Measures: Glasgow Outcome Scale, living situation, and employment. Results: Increasing age is associated with increasing levels of psychosocial limitations, especially in persons 60 years of age and older. Part of the reason is the greater severity of injury sustained by older persons as reflected in longer coma (despite equivalent initial coma depth) and greater numbers of complications and surgeries for subdural hematomas. However, the consequences of traumatic brain injuries appear to worsen with increasing age: at each level of brain injury severity examined, including the milder injuries. Conclusions: Older adults clearly show less complete recovery 1 year after brain injury than younger adults, either because they have reduced reserves with which to tolerate brain injury or because their physiologic status creates a more destructive injury. Glasgow Coma Scale alone may underestimate the severity of brain injury in the aged as well as its associated consequences. Caution is advised in generalizing findings based principally on younger individuals to older adults with traumatic brain injuries. (C) 1998 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA		Dikmen, SS (corresponding author), Univ Washington, Dept Rehabil Med, Rehabil Med Box 356490, Seattle, WA 98195 USA.				AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R01HS006497] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD033677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643] Funding Source: NIH RePORTER; AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [HS06497] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD33677] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 19643] Funding Source: Medline		ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; AMACHER AL, 1987, NEUROSURGERY, V20, P954; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; CHAMPION HR, 1989, AM J PUBLIC HEALTH, V79, P1278, DOI 10.2105/AJPH.79.9.1278; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; GOLDSTEIN FC, 1995, J HEAD TRAUMA REHAB, V10, P57, DOI 10.1097/00001199-199502000-00007; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; JENNETT B, 1975, LANCET, V1, P480; KOTWICA Z, 1992, ACTA NEUROCHIR, V118, P98, DOI 10.1007/BF01401293; Kraus JF, 1987, HEAD INJURY, V2, P1; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Mamelak AN, 1996, J TRAUMA, V41, P91, DOI 10.1097/00005373-199607000-00014; Marascuilo L. A., 1977, NONPARAMETRIC DISTRI; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; MILLER J D, 1989, Neurosurgical Review, V12, P441; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; PUTNAM SH, 1996, NEUROPSYCHOLOGICAL A, P429; Ross A M, 1992, J Neurosci Nurs, V24, P88; ROY CW, 1986, INJURY, V17, P220, DOI 10.1016/0020-1383(86)90222-6; SCHWAB CW, 1992, ARCH SURG-CHICAGO, V127, P701; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; TEASDALE G, 1974, LANCET, V2, P81; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Zar J.H, 1995, BIOSTATISTICAL ANAL; ZWIMPFER TJ, 1993, CRIT CARE CLIN, V9, P727, DOI 10.1016/S0749-0704(18)30166-0	35	79	81	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	1998	79	8					881	887		10.1016/S0003-9993(98)90082-X			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	108MJ	WOS:000075269800001	9710157				2022-02-06	
J	Lewen, A; Hillered, L				Lewen, A; Hillered, L			Involvement of reactive oxygen species in membrane phospholipid breakdown and energy perturbation after traumatic brain injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						drug therapy; free radicals; glucose; glycerol; lactate; microdialysis; rat; traumatic brain injury	FREE FATTY-ACIDS; BUTYL-NITRONE PBN; CEREBRAL BLOOD-FLOW; PRECURSOR PROTEIN IMMUNOREACTIVITY; PHOSPHATIDYLINOSITOL BISPHOSPHATE; SUPEROXIDE PRODUCTION; RESPIRATORY ACTIVITY; ARACHIDONIC-ACID; CORTICAL-NEURONS; REGIONAL LEVELS	Interstitial glycerol may be a useful marker for posttraumatic and postischemic membrane phospholipid (PL) breakdown, Degradation of membrane PLs is thought to be triggered by both calcium and reactive oxygen species (ROS)-mediated mechanisms and to be associated with disturbed energy metabolism. In this study, we investigated the temporal changes of interstitial glycerol, lactate, and glucose after traumatic brain injury in the rat and the effect of pretreatment with the free radical spin trap alpha-phenyl-N-tert-butyl nitrone (PBN; 30 mg/kg i.v.). Microdialysate was sampled continuously in 10-min fractions from 1 h before, until 2 h after a cortical contusion injury produced by the weight-drop technique, The maximal concentration of interstitial glycerol (a ninefold increase) was seen 10-30 min after trauma and subsided during the following 2 h, but remained above base line as compared to sham operated animals, Concomitantly, there was an increase in interstitial lactate (fivefold) and a fall in interstitial glucose, indicating a posttraumatic energy perturbation. PEN treatment significantly attenuated the interstitial accumulation of glycerol and lactate. The results support the concept that ROS are involved in posttraumatic membrane PL breakdown and that PEN improves mitochondrial function after CNS injury. Monitoring of interstitial glycerol with microdialysis may be a valuable tool for studies on membrane PL degradation and the efficacy of neuroprotective drugs in acute CNS injury.	Univ Uppsala Hosp, Dept Neurosci, S-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Neurosurg, S-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Med, S-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Clin Chem, S-75185 Uppsala, Sweden		Lewen, A (corresponding author), Univ Uppsala Hosp, Dept Neurosci, S-75185 Uppsala, Sweden.		Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348			ABE K, 1987, J NEUROCHEM, V48, P503, DOI 10.1111/j.1471-4159.1987.tb04121.x; AGARDH CD, 1981, J CEREBR BLOOD F MET, V1, P267, DOI 10.1038/jcbfm.1981.31; Agranoff Bernard W., 1994, P97; ALTHAUS JS, 1993, MOL CHEM NEUROPATHOL, V20, P147, DOI 10.1007/BF02815368; ANDERSON DK, 1994, NEUROBIOLOGY CENTRAL, P131; AU AM, 1985, J CELL BIOCHEM, V27, P449, DOI 10.1002/jcb.240270413; BAZAN NG, 1971, J NEUROCHEM, V18, P1379, DOI 10.1111/j.1471-4159.1971.tb00002.x; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BENVENISTE H, 1989, J NEUROCHEM, V52, P1667, DOI 10.1111/j.1471-4159.1989.tb07243.x; BERTRAND N, 1992, NEUROSCI LETT, V148, P81, DOI 10.1016/0304-3940(92)90809-L; CARNEY JM, 1991, J MOL NEUROSCI, V3, P47, DOI 10.1007/BF02896848; CHAN PH, 1982, J NEUROCHEM, V38, P525, DOI 10.1111/j.1471-4159.1982.tb08659.x; CHEN GM, 1990, FREE RADICAL RES COM, V9, P317, DOI 10.3109/10715769009145690; CHENG Y, 1994, NEUROCHEM RES, V19, P1557, DOI 10.1007/BF00969006; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; Dhillon HS, 1997, EXP NEUROL, V146, P240, DOI 10.1006/exnr.1997.6524; DHILLON HS, 1995, BRAIN RES, V698, P100, DOI 10.1016/0006-8993(95)00840-M; Farooque M, 1997, J NEUROTRAUM, V14, P469, DOI 10.1089/neu.1997.14.469; FAROOQUI AA, 1994, INT REV NEUROBIOL, V36, P267, DOI 10.1016/S0074-7742(08)60306-2; FOLBERGROVA J, 1995, P NATL ACAD SCI USA, V92, P5057, DOI 10.1073/pnas.92.11.5057; FOSTER KJ, 1978, CLIN CHEM, V24, P1568; GERCKEN G, 1973, PFLUG ARCH EUR J PHY, V344, P207, DOI 10.1007/BF00588461; GERCKEN G, 1969, J NEUROCHEM, V16, P761, DOI 10.1111/j.1471-4159.1969.tb06454.x; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HILLERED L, 1984, J CEREBR BLOOD F MET, V4, P430, DOI 10.1038/jcbfm.1984.62; HILLERED L, 1983, J CEREBR BLOOD F MET, V3, P207, DOI 10.1038/jcbfm.1983.28; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; HILLERED L, 1988, J NEUROSCI RES, V19, P94, DOI 10.1002/jnr.490190113; Hinzen D H, 1970, Pflugers Arch, V318, P119; Homayoun P, 1997, J NEUROCHEM, V69, P199; IKEDA M, 1986, J NEUROCHEM, V47, P123; INANAMI O, 1995, FREE RADICAL RES, V23, P33, DOI 10.3109/10715769509064017; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; KIHARA T, 1995, J NEUROCHEM, V65, P282; KIM DK, 1995, BIOCHEM J, V310, P83, DOI 10.1042/bj3100083; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Kuroda S, 1996, NEUROBIOL DIS, V3, P149, DOI 10.1006/nbdi.1996.0015; KUWASHIMA J, 1976, BRAIN RES, V110, P547, DOI 10.1016/0006-8993(76)90865-9; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; LEWEN A, 1996, J NEUROTRAUM, V13, P600; LLOYD B, 1978, CLIN CHEM, V24, P1724; Lyeth BG, 1996, BRAIN RES, V742, P63, DOI 10.1016/S0006-8993(96)01002-5; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; NAKAHARA I, 1991, J NEUROCHEM, V57, P839, DOI 10.1111/j.1471-4159.1991.tb08227.x; Nemoto E M, 1983, Am J Emerg Med, V1, P175, DOI 10.1016/0735-6757(83)90086-4; NEMOTO EM, 1982, J CEREBR BLOOD F MET, V2, P475, DOI 10.1038/jcbfm.1982.54; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; OTANI H, 1987, CIRCULATION, V76, P161; PASCHEN W, 1986, METAB BRAIN DIS, V1, P37, DOI 10.1007/BF00998475; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; PRASAD MR, 1994, J NEUROCHEM, V63, P1086; PRASAD MR, 1994, J NEUROCHEM, V63, P773; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SIESJO BK, 1992, ADV EXP MED BIOL, V318, P41; SUN DD, 1994, NEUROCHEM RES, V19, P525, DOI 10.1007/BF00967333; SUN DD, 1994, J NEUROCHEM, V62, P1921; TAPIAARANCIBIA L, 1992, EUR J PHARM-MOLEC PH, V225, P253, DOI 10.1016/0922-4106(92)90027-S; Tayag EC, 1996, BRAIN RES, V733, P287, DOI 10.1016/0006-8993(96)00669-5; TURRENS JF, 1991, FREE RADICAL RES COM, V12-3, P681, DOI 10.3109/10715769109145847; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; ZHANG Y, 1993, SURG NEUROL, V39, P297, DOI 10.1016/0090-3019(93)90009-P	73	79	79	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	1998	15	7					521	530		10.1089/neu.1998.15.521			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	ZY374	WOS:000074614700006	9674555				2022-02-06	
J	Townsend, RN; Lheureau, T; Protetch, J; Riemer, B; Simon, D				Townsend, RN; Lheureau, T; Protetch, J; Riemer, B; Simon, D			Timing fracture repair in patients with severe brain injury (Glasgow Coma Scale Score < 9)	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	57th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 24-27, 1997	WAIKOLOA, HI	Amer Assoc Surg Trauma		resuscitation; femur fracture; head injury	SEVERE HEAD-INJURY; FAT-EMBOLISM; INTRACRANIAL-PRESSURE; MULTIPLE TRAUMA; FIXATION; DISABILITY; DEATH	Background: Trauma patients with severe brain injury are at risk of secondary brain injury, Femur fractures, if present, should be repaired when potential causes of secondary brain injury have been corrected. Methods: Sixty-one patients with severe or moderate closed head injury and femur fractures were identified, Patients were divided into groups by time until femur fracture reduction. Results: An inversely proportional trend was demonstrated when comparing time until surgery with the percentage of patients who experienced hypotensive events during surgery, Patients in the 0- to 2-hour group were eight times more likely to become hypotensive during femur repair than patients in the > 24-hour group. Seventy-four percent of patients with intracranial pressure monitoring experienced cerebral perfusion pressure < 70 mm Hg. Conclusions: Operation in similar patients should be done when risks are minimized by adequate resuscitation, Secondary brain injury is more common in early femur repair, Operation delay of 24 hours may be necessary to prevent hypoxia, hypotension, and low cerebral perfusion pressure.	Allegheny Gen Hosp, Pittsburgh, PA 15212 USA; Kaplan Hosp, IL-76100 Rehovot, Israel		Townsend, RN (corresponding author), 420 East North Ave,Suite 304, Pittsburgh, PA 15212 USA.						BECKMAN SB, 1989, AM SURGEON, V55, P356; BEHRMAN SW, 1990, J TRAUMA, V30, P792, DOI 10.1097/00005373-199007000-00005; BONE LB, 1989, J BONE JOINT SURG AM, V71A, P336, DOI 10.2106/00004623-198971030-00004; BROOS PLO, 1987, INJURY, V18, P235, DOI 10.1016/0020-1383(87)90004-0; BURGESS RR, 1993, RESOURCES OPTIMAL CA, P47; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DERLET R W, 1989, Journal of Emergency Medicine, V7, P5; FABIAN TC, 1990, CRIT CARE MED, V18, P42; HENK JD, 1988, J TRAUMA, V28, P383; Jaicks RR, 1997, J TRAUMA, V42, P1, DOI 10.1097/00005373-199701000-00001; JENNETT B, 1975, LANCET, V1, P480; JOHNSON KD, 1985, J TRAUMA, V25, P375, DOI 10.1097/00005373-198505000-00001; KREGOR PJ, 1993, J BONE JOINT SURG AM, V75A, P1774, DOI 10.2106/00004623-199312000-00006; LEVY D, 1990, CLIN ORTHOP RELAT R, V61, P281; PAPE HC, 1993, J TRAUMA, V35, P709, DOI 10.1097/00005373-199311000-00010; PELL ACH, 1993, J BONE JOINT SURG BR, V75, P921, DOI 10.1302/0301-620X.75B6.8245083; PIETROPAOLI JA, 1992, J TRAUMA, V33, P403, DOI 10.1097/00005373-199209000-00011; POOLE GV, 1992, J TRAUMA, V32, P654, DOI 10.1097/00005373-199205000-00019; RISKA EB, 1982, J TRAUMA, V22, P891, DOI 10.1097/00005373-198211000-00001; SEIBEL R, 1985, ANN SURG, V202, P283, DOI 10.1097/00000658-198509000-00003; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; SIEGEL JH, 1993, J TRAUMA, V35, P920, DOI 10.1097/00005373-199312000-00019; SIEGEL JH, 1991, CRIT CARE MED, V19, P1252, DOI 10.1097/00003246-199110000-00007; SMITH JS, 1990, J TRAUMA, V30, P1533, DOI 10.1097/00005373-199012000-00017; SPERRY RJ, 1992, ANESTHESIOLOGY, V77, P416, DOI 10.1097/00000542-199209000-00002; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; WEISNER DH, 1993, ADV TRAUMA CRIT CARE, V8, P183	27	79	79	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	1998	44	6					977	982		10.1097/00005373-199806000-00008			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	ZU123	WOS:000074164600007	9637152				2022-02-06	
J	Taverni, JP; Seliger, G; Lichtman, SW				Taverni, JP; Seliger, G; Lichtman, SW			Donepezil mediated memory improvement in traumatic brain injury during post acute rehabilitation	BRAIN INJURY			English	Article								Memory dysfunction is a recognized and difficult to treat complication of traumatic brain injury (TBI). Since medial-temporal lobe injury is a frequent contributor to memory dysfunction in TBI, it is likely that an acetylcholine deficit contributes to memory dysfunction in this population. Recently, Donepezil, an acetylcholine-esterase inhibitor which has demonstrated a high selectivity for neural Ach-esterase (with minimal side effects), was approved for use in dementia in Alzheimer's patients. Due to its promising results in Alzheimer's patients, and reports in the literature describing the use of physostigmine (an anti-cholinesterase with significant cardiovascular and autonomic side effects) to treat memory deficits in closed head injury, we decided to begin a trial of Donepezil in two patients with TBI who were experiencing long term static memory dysfunction refractory to conventional treatment. Both patients were admitted to our facility for physical and cognitive rehabilitation, and were started on a trial of Donepezil. Modified memory tests and subjective observations by both family and staff pointed to an improvement in memory within three weeks of starting Donepezil. Should these initial results be supported in larger trials, Donepezil may prove to be a valuable tool for the treatment of memory dysfunction in TBI.	Helen Hayes Hosp, Dept Internal Med & Cardiol, W Haverstraw, NY 10993 USA; Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10027 USA; Columbia Univ, Coll Phys & Surg, Dept Phys Med & Rehabil, New York, NY 10027 USA; Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY 10027 USA		Seliger, G (corresponding author), Helen Hayes Hosp, Dept Internal Med & Cardiol, Route 9W, W Haverstraw, NY 10993 USA.						*CTR FUNCT ASS RES, 1990, GUID US UN DAT SET M; DUCHEN LW, 1992, GREENFIELDS NEUROPAT; Gennarelli TA, 1993, HEAD INJURY; GOLDBERG E, 1982, ARCH NEUROL-CHICAGO, V39, P581, DOI 10.1001/archneur.1982.00510210051012; Granger C. V., 1986, TOP GERIATR REHABIL, V1, P59, DOI DOI 10.1097/00013614-198604000-00007; HAMILTON B B, 1991, Archives of Physical Medicine and Rehabilitation, V72, P790; Levin H S, 1986, Cent Nerv Syst Trauma, V3, P333; MAYUEX R, 1995, MERRITTS TXB NEUROLO; RODGERS SL, 1996, DEMENTIA, V7, P293; ROGER SL, 1991, CHOLEMERGINIC BASIS; ROSS JD, 1976, ROSS TEST HIGHER PRO; Weinberg R M, 1987, Brain Inj, V1, P57, DOI 10.3109/02699058709034445; Wilson B.A., 1985, RIVERMEAD BEHAV MEMO	13	79	81	0	5	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	1998	12	1					77	80					4	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	YT347	WOS:000071592500008	9483340				2022-02-06	
J	Prasad, K				Prasad, K			The Glasgow coma scale: A critical appraisal of its clinimetric properties	JOURNAL OF CLINICAL EPIDEMIOLOGY			English	Article						Glasgow Coma Scale; reproducibility of results; sensitivity and specificity; brain injuries; neurological examination	SEVERE HEAD-INJURY; ASSESSING IMPAIRED CONSCIOUSNESS; OBSERVER VARIABILITY; EVOKED-POTENTIALS; TRAUMATIC COMA; INSTRUMENTS; PROGNOSIS; LEVEL; SCORE; SUM	The Glasgow Coma Scale is a commonly used instrument in clinical practice, This article examines the published evidence to assess whether the scale possesses the requisite clinimetric properties. Articles describing and using the scale were located through a MEDLINE search. The clinimetric properties of the scale were appraised using the methodological principles of sensibility, reliability, validity, and responsiveness. The scale has a good sensibility and reliability (intraclass correlation coefficient, 0.8 to 1 for trained users). It has a well established cross sectional construct validity. Its predictive validity in traumatic coma, when combined with age and brainstem reflexes, is good in the generating sample (sensitivity, 79 to 97%; specificity, 84-97%) but has not been tested in an external validation sample. Its longitudinal construct validity has not been studied adequately. Thus, the scale is an established discriminative instrument but its validity as a predictive and an evaluative instrument has not yet been studied adequately.			Prasad, K (corresponding author), ALL INDIA INST MED SCI,CTR NEUROSCI,ROOM 704,7TH FLOOR,NEW DELHI 110029,INDIA.						BAKAY RAE, 1983, J NEUROSURG, V58, P27, DOI 10.3171/jns.1983.58.1.0027; BISHARA SN, 1992, BRAIN INJURY, V4, P373; BORN JD, 1985, NEUROSURGERY, V16, P595, DOI 10.1227/00006123-198505000-00002; BOUZARTH WF, 1978, J NEUROSURG, V49, P477; DEYO RA, 1986, J CHRON DIS, V39, P897, DOI 10.1016/0021-9681(86)90038-X; Feinstein AR, 1987, CLINIMETRICS; FRANKE CL, 1992, J NEUROL NEUROSUR PS, V55, P653, DOI 10.1136/jnnp.55.8.653; GUYATT G, 1987, J CHRON DIS, V40, P171, DOI 10.1016/0021-9681(87)90069-5; Hotelling H, 1933, J EDUC PSYCHOL, V24, P417, DOI 10.1037/h0071325; Hotelling H, 1933, J EDUC PSYCHOL, V24, P498, DOI 10.1037/h0070888; Ingersoll G L, 1987, Crit Care Nurse, V7, P26; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; JAGGER J, 1983, LANCET, V2, P97; JENNETT B, 1979, J NEUROSURG, V50, P271; JENNETT B, 1977, LANCET, V1, P878; KIRSHNER B, 1985, J CHRON DIS, V38, P27, DOI 10.1016/0021-9681(85)90005-0; KOZIOL JA, 1990, J NEUROL, V237, P461, DOI 10.1007/BF00314762; LANGFITT TW, 1982, CLIN NEUR, V29, P353; LEVY DE, 1981, ANN INTERN MED, V94, P293, DOI 10.7326/0003-4819-94-3-293; LINDSAY KW, 1981, J NEUROL NEUROSUR PS, V44, P796, DOI 10.1136/jnnp.44.9.796; LINDSAY KW, 1983, J NEUROSURG, V58, P57, DOI 10.3171/jns.1983.58.1.0057; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MULLIE A, 1988, LANCET, V1, P137; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; ROWLEY G, 1991, LANCET, V337, P535, DOI 10.1016/0140-6736(91)91309-I; SACCO RL, 1990, ARCH NEUROL-CHICAGO, V47, P1181, DOI 10.1001/archneur.1990.00530110035013; STANCZAK DE, 1984, J NEUROSURG, V60, P955, DOI 10.3171/jns.1984.60.5.0955; STARMARK JE, 1988, HUM TOXICOL, V7, P551, DOI 10.1177/096032718800700606; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; Steiner DL, 1989, HLTH MEASUREMENT SCA; SUGIURA K, 1983, NEUROSURGERY, V12, P411, DOI 10.1227/00006123-198304000-00007; TEASDALE G, 1983, LANCET, V2, P678; TEASDALE G, 1978, J NEUROL NEUROSUR PS, V41, P603, DOI 10.1136/jnnp.41.7.603; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81	36	79	83	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0895-4356			J CLIN EPIDEMIOL	J. Clin. Epidemiol.	JUL	1996	49	7					755	763		10.1016/0895-4356(96)00013-3			9	Health Care Sciences & Services; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Health Care Sciences & Services; Public, Environmental & Occupational Health	VA007	WOS:A1996VA00700008	8691225				2022-02-06	
J	Dietrich, WD; Alonso, O; Busto, R; Finklestein, SP				Dietrich, WD; Alonso, O; Busto, R; Finklestein, SP			Posttreatment with intravenous basic fibroblast growth factor reduces histopathological damage following fluid-percussion brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						basic fibroblast growth factor; traumatic brain injury; fluid-percussion; histopathology	FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; MODERATE HYPOTHERMIA; HIPPOCAMPAL-NEURONS; FACTOR PROTECTS; FACTOR BFGF; ADULT-RATS; BLOOD-FLOW; EXCITOTOXICITY; DEGENERATION	The purpose of this study was to determine whether treatment with intravenous basic fibroblast growth factor (bFGF) would protect histopathologically in a rat model of traumatic brain injury (TBI). Twenty-four hours prior to TBI, the fluid-percussion interface was positioned parasagittally over the right cerebral cortex. On the second day, fasted rats were anesthetized with 70% nitrous oxide, 1% halothane, and 30% oxygen. Under controlled physiological conditions and normothermic brain temperature (37-37.5 degrees C), rats were injured with a fluid-percussion pulse ranging from 1.6 to 1.9 atm. Rats were randomized into two groups where either bFGF (45 mu g/kg/h) in vehicle (n = 7) or vehicle alone (n = 7) was infused intravenously for 3 h, beginning 30 min after TBI. Three days later, brains were perfusion-fixed for histopathological assessment and quantitative analysis of contusion volume and numbers of necrotic cortical neurons. In vehicle-treated animals, necrotic neurons were observed throughout the lateral cerebral cortex remote from the impact site. In addition, an intracerebral contusion was present in all rats at the gray-white interface underlying the injured cortical areas. Posttraumatic administration of bFGF significantly reduced the numbers of damaged cortical neuron profiles at several coronal levels and reduced the total number of damaged neurons (696 +/- 148 vs. 1,248 +/- 198, means +/- SEM), p < 0.05, ANOVA). In addition, contusion areas at several coronal levels as well as total contusion volume was significantly reduced (1.13 +/- 0.39 mm(3) vs. 3.18 +/- 0.81 mm(3), p < 0.05). These data demonstrate neuroprotection with intravenous bFGF infusion in the posttraumatic setting.	MASSACHUSETTS GEN HOSP,DEPT NEUROL,CNS GROWTH FACTOR RES LAB,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02129		Dietrich, WD (corresponding author), UNIV MIAMI,SCH MED,DEPT NEUROL D45,NEUROTRAUMA RES CTR,POB 016960,MIAMI,FL 33101, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291, R01NS027127] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-27127, NS-30291] Funding Source: Medline		ANDERSON KJ, 1988, NATURE, V332, P360, DOI 10.1038/332360a0; BAROTTE C, 1989, NEUROSCI LETT, V101, P197, DOI 10.1016/0304-3940(89)90530-2; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COGGESHALL RE, 1996, J COMP NEUROL, V354, P6; CORTEZ SC, 1989, BRAIN RES, V482, P272; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINKLESTEIN SP, 1988, BRAIN RES, V460, P253, DOI 10.1016/0006-8993(88)90370-8; FINKLESTEIN SP, 1993, STROKE S1, V24; FISHER M, 1995, J CEREBR BLOOD F MET, V15, P953, DOI 10.1038/jcbfm.1995.121; FRANK E, 1995, NEUROL RES, V17, P129, DOI 10.1080/01616412.1995.11740300; FREESE A, 1992, BRAIN RES, V575, P351, DOI 10.1016/0006-8993(92)90104-H; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HAYES RL, 1988, J NEUROTRAUM, V5, P287; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; KAWAMATA K, 1996, J CEREB FLOOD FLOW M, V16, P542; KIRSCHNER PB, 1995, J CEREBR BLOOD F MET, V15, P619, DOI 10.1038/jcbfm.1995.76; KOKETSU N, 1994, ANN NEUROL, V35, P451, DOI 10.1002/ana.410350413; LOGAN A, 1992, J NEUROSCI, V12, P3828; MATTSON MP, 1990, INT J DEV NEUROSCI, V8, P399, DOI 10.1016/0736-5748(90)90073-B; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MATTSON MP, 1993, J NEUROSCI, V13, P4575; MATTSON MP, 1989, J NEUROSCI, V9, P3728; MATTSON MP, 1995, CEREBROVASCULAR DIS, P371; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MOCCHETTI I, 1995, J NEUROTRAUM, V12, P853, DOI 10.1089/neu.1995.12.853; NAKATA N, 1993, BRAIN RES, V605, P354, DOI 10.1016/0006-8993(93)91766-L; NIETOSAMPEDRO M, 1988, NEUROSCI LETT, V86, P361, DOI 10.1016/0304-3940(88)90511-3; NOZAKI K, 1993, J CEREBR BLOOD F MET, V13, P221, DOI 10.1038/jcbfm.1993.27; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; ROSENBLATT S, 1994, J CEREBR BLOOD F MET, V14, P70, DOI 10.1038/jcbfm.1994.11; Salzman SK, 1994, NEUROBIOLOGY CENTRAL; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; TATTER SB, 1995, NEUROSCIENTIST, V1, P286; WALICKE PA, 1988, J NEUROSCI, V8, P2618; WANAKA A, 1990, NEURON, V5, P267, DOI 10.1016/0896-6273(90)90164-B; YAMADA K, 1991, J CEREBR BLOOD F MET, V11, P472, DOI 10.1038/jcbfm.1991.90; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; ZILLES KJL, 1985, CORTEX BRAIN STEREOT	49	79	82	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	1996	13	6					309	316		10.1089/neu.1996.13.309			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	UZ052	WOS:A1996UZ05200003	8835798				2022-02-06	
J	Lewen, A; Li, GL; Olsson, Y; Hillered, L				Lewen, A; Li, GL; Olsson, Y; Hillered, L			Changes in microtubule-associated protein 2 and amyloid precursor protein immunoreactivity following traumatic brain injury in rat: Influence of MK-801 treatment	BRAIN RESEARCH			English	Article						microtubule-associated protein 2; beta-amyloid precursor protein; beta-amyloid; MK-801; traumatic brain injury; dendrite; axon	EXCITATORY AMINO-ACIDS; MIDDLE CEREBRAL-ARTERY; FOREBRAIN ISCHEMIA; NERVOUS-SYSTEM; HEAD TRAUMA; PHOSPHORYLATION; HIPPOCAMPUS; CELLS; NMDA; VULNERABILITY	We investigated by immunohistochemistry dendritic and axonal changes occurring in the rat brain after mild focal cortical trauma produced by the weight drop technique. One and 3 days after injury, nerve cell bodies and dendrites in the perimeter of the impact site displayed decreased microtubule-associated protein 2 (MAP2) immunoreactivity. Some dendrites in the immediate adjacent region were more intensely stained and distorted. The dentate hilar region of the hippocampus showed a reduction of immunoreactive nerve cell bodies and dendrites. Twenty-one days after injury the strongly stained cortical dendrites and the reduction of immunoreactivity in the hippocampus remained, whereas the reduced staining in the perimeter of the lesion had normalised. These results indicate that there is a long-lasting disturbed dendritic organisation implicating impaired neurotransmission after this type of mild brain trauma, beta-Amyloid precursor protein (APP) immunohistochemistry revealed numerous stained axons in the ipsilateral subcortical white matter and thalamus indicating local and remote axonal injuries with disturbed axonal transport, Twenty-one days after injury, numerous small immunostained profiles appeared in the neuropil of the cortical impact sire and in the ipsilateral thalamus. The axonal changes indicate disturbed connectivity between the site of the impact and other brain regions, chiefly the thalamus, The presence of beta-amyloid was investigated 21 days after trauma. There were no signs of beta-amyloid depositions in the brain after injury. Finally, we tested if the non-competitive NMDA receptor antagonist dizocilpine maleate (MK-801) could influence the observed MAP2 and APP changes, Pretreatment with this compound did not affect the early MAP2 and APP alterations. Instead, an increased expression of the APP antigen in the thalamus was observed 21 days after trauma in the MK-801-treated animals, The cause of this phenomenon is not known but may be related to a delayed neurotoxic action of MK-801 treatment.	UNIV UPPSALA HOSP,DEPT CLIN CHEM,S-75185 UPPSALA,SWEDEN; UNIV UPPSALA HOSP,NEUROPATHOL LAB,S-75185 UPPSALA,SWEDEN		Lewen, A (corresponding author), UNIV UPPSALA HOSP,DEPT NEUROSURG,S-75185 UPPSALA,SWEDEN.		Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348			BEESON JG, 1994, J COMP NEUROL, V342, P69, DOI 10.1002/cne.903420108; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DECAMILLI P, 1984, NEUROSCIENCE, V11, P819, DOI 10.1016/0306-4522(84)90194-5; DIDIER M, 1990, J NEUROSCI RES, V27, P25, DOI 10.1002/jnr.490270105; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; GEISERT EE, 1990, P NATL ACAD SCI USA, V87, P3967, DOI 10.1073/pnas.87.10.3967; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; HANCOCK MB, 1984, J HISTOCHEM CYTOCHEM, V32, P311, DOI 10.1177/32.3.6198359; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; INUZUKA T, 1990, BRAIN RES, V526, P177, DOI 10.1016/0006-8993(90)90269-H; INUZUKA T, 1990, STROKE, V21, P917, DOI 10.1161/01.STR.21.6.917; ITOH K, 1979, BRAIN RES, V175, P341, DOI 10.1016/0006-8993(79)91013-8; KALARIA RN, 1993, ANN NY ACAD SCI, V695, P190, DOI 10.1111/j.1749-6632.1993.tb23050.x; KITAGAWA K, 1989, NEUROSCIENCE, V31, P401, DOI 10.1016/0306-4522(89)90383-7; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; KOZLOWSKI DA, 1994, RESTOR NEUROL NEUROS, V7, P119, DOI 10.3233/RNN-1994-7207; KUDO T, 1990, STROKE, V21, P1205, DOI 10.1161/01.STR.21.8.1205; LEWEN A, 1995, NEUROREPORT, V6, P35; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYNCH G, 1988, BRAIN RES BULL, V21, P363, DOI 10.1016/0361-9230(88)90148-7; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MATUS A, 1994, TRENDS NEUROSCI, V17, P19, DOI 10.1016/0166-2236(94)90030-2; MIYAZAWA T, 1993, ACTA NEUROPATHOL, V85, P526; NAKAMURA K, 1993, BRAIN RES, V613, P181, DOI 10.1016/0006-8993(93)90898-W; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OLNEY JW, 1991, SCIENCE, V254, P1515, DOI 10.1126/science.1835799; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; REGAN RF, 1994, NEUROBIOLOGY CENTRAL, P173; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; SAKIMURA K, 1995, NATURE, V373, P151, DOI 10.1038/373151a0; SHENG JG, 1994, J NEUROCHEM, V63, P1872; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SHU SY, 1988, NEUROSCI LETT, V85, P169, DOI 10.1016/0304-3940(88)90346-1; Steward O., 1994, NEUROBIOLOGY CENTRAL, P266; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; THEURKAUF WE, 1983, J BIOL CHEM, V258, P7883; THEURKAUF WE, 1982, J CELL BIOL, V95, pA340; VALLEE R, 1980, P NATL ACAD SCI-BIOL, V77, P3206, DOI 10.1073/pnas.77.6.3206; WIGSTROM H, 1986, NEUROSCIENCE, V17, P1105, DOI 10.1016/0306-4522(86)90080-1; YAMAUCHI T, 1982, BIOCHEM BIOPH RES CO, V109, P975, DOI 10.1016/0006-291X(82)92035-6; YANAGIHARA T, 1990, ACTA NEUROPATHOL, V80, P499, DOI 10.1007/BF00294610	51	79	81	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAY 6	1996	719	1-2					161	171		10.1016/0006-8993(96)00081-9			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UP705	WOS:A1996UP70500021	8782876				2022-02-06	
J	GRANGER, CV; DIVAN, N; FIEDLER, RC				GRANGER, CV; DIVAN, N; FIEDLER, RC			FUNCTIONAL ASSESSMENT SCALES - A STUDY OF PERSONS AFTER TRAUMATIC BRAIN INJURY	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						FUNCTIONAL ASSESSMENT; TRAUMATIC BRAIN INJURY; FUNCTIONAL INDEPENDENCE MEASURE; DISABILITY		The purpose of this study was to investigate disability in persons after traumatic brain injury (TBI) by using combinations of functional assessment item, subscale, domain, and full-scale scores to predict (1) the need for assistance in performance of specific physical care tasks measured in minutes of help per day provided by another person in the home and (2) the subject's level of satisfaction with life in general. This study also sought to account for the amount of supervision that persons with TBI may require beyond that needed for physical care tasks. The Functional Independence Measure (FIM) contributed to prediction of subjects' physical care needs. A single-point change in total FIM score was equivalent to an average of about 5 min of help from another person per day. Satisfaction with life in general was predicted mainly by the depression subscale of the Brief Symptom inventory. However, this latter prediction was only true when subjects who required constant supervision were removed from analysis. Thus, the amount of supervision required by persons with TBI is an important variable to study in this population. Three categories of supervision were identified: constant (all of the time), periodic (daily or weekly), or not at all. The need for supervision and physical assistance from another person and a subject's satisfaction with life in general are important standards by which functional assessment instruments may be compared to reflect, in pragmatic terms, the impact of disability on the lives of individuals and on human and economic resources of the community.	SUNY BUFFALO,SCH MED & BIOMED SCI,DEPT REHABIL MED,BUFFALO,NY 14214		GRANGER, CV (corresponding author), SUNY BUFFALO,CTR FUNCT ASSESSMENT RES,232 PARKER HALL,SUNY S CAMPUS,BUFFALO,NY 14214, USA.						BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; COOPER K D, 1983, Neuroepidemiology, V2, P70, DOI 10.1159/000110512; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DEROGATIS LR, 1977, SCL90 CLIN PSYCH RE; DITTMAR SS, 1991, J HEALTHCARE TRAININ, V6, P16; GRANGER CV, 1993, ARCH PHYS MED REHAB, V74, P133; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; HALL KM, J HEAD TRAUMA REHABI; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V48, P1121; MELLERUP E, 1981, ACTA NEUROL SCAND, V64, P130, DOI 10.1111/j.1600-0404.1981.tb05549.x; NELSON EC, 1990, MED CARE, V28, P1111, DOI 10.1097/00005650-199012000-00001; ROSENTHAL M, 1990, REHABILITATION ADULT; THICKMAN M, 1986, TOPICS ACUTE CARE TR, V1, P32; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; WILLER B, 1990, NEUROBEHAVIOURAL SEQ, P19; WRIGHT BD, 1991, BIGSTEPS RASCH MODEL; [No title captured]; 1985, MRD MINIMAL RECORD D; 1994, GUIDE USE UNIFORM DA	21	79	80	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	MAR-APR	1995	74	2					107	113					7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	QU579	WOS:A1995QU57900003	7710723				2022-02-06	
J	WILLIAMS, IM; PICTON, A; FARRELL, A; MEAD, GE; MORTIMER, AJ; MCCOLLUM, CN				WILLIAMS, IM; PICTON, A; FARRELL, A; MEAD, GE; MORTIMER, AJ; MCCOLLUM, CN			LIGHT-REFLECTIVE CEREBRAL OXIMETRY AND JUGULAR BULB VENOUS OXYGEN-SATURATION DURING CAROTID ENDARTERECTOMY	BRITISH JOURNAL OF SURGERY			English	Article								A novel instrument using reflected near-infra-red light spectroscopy to measure cerebral oxygen saturation noninvasively was evaluated during carotid endarterectomy; cerebral perfusion was compared with jugular bulb venous oxygen saturation and transcranial Doppler ultrasonographic measurements. Initially, oximetry sensors with light source-detector separation distances of 10 and 27 mm were positioned over the frontal area, while a cannula positioned in the jugular bulb permitted sampling for jugular bulb venous oxygen saturation. To increase cerebral oxygen saturation sensitivity, modified sensors with light source-detector separation distances of 30 and 40 mm were relocated over the middle cerebral artery territory. The changes in cerebral and jugular bulb venous oxygen saturation, and in peak blood flow velocity before and 30 s after carotid clamping and declamping were recorded. The modified cerebral perfusion system achieved improved correlations between cerebral and jugular bulb venous oxygen saturation changes during carotid clamping and declamping (r=0.92, P<0.001). The correlation between change in cerebral oxygen saturation and the percentage change in peak flow velocity on both cross-clamping and declamping was equally strong (r=0.90, P<0.001). Near-infra-red cerebral spectroscopy reliably detects changes in cerebral oxygen saturation during carotid endarterectomy and may have wide applications in monitoring brain perfusion during neurosurgery and cardiopulmonary bypass surgery, and in closed head injury.	UNIV S MANCHESTER HOSP,DEPT ANAESTHET,MANCHESTER M20 8LR,LANCS,ENGLAND		WILLIAMS, IM (corresponding author), UNIV S MANCHESTER HOSP,DEPT SURG,NELL LANE,MANCHESTER M20 8LR,LANCS,ENGLAND.		Mead, Gillian E/F-7648-2011				ANDREWS PJD, 1991, BRIT J ANAESTH, V67, P553, DOI 10.1093/bja/67.5.553; CLAUSS RH, 1965, NEW ENGL J MED, V273, P1127, DOI 10.1056/NEJM196511182732104; LARSON CP, 1967, SURGERY, V62, P31; LYONS C, 1964, ANN SURG, V160, P561, DOI 10.1097/00000658-196410000-00001; MCCORMICK P, 1990, HOSPIMEDICA      JUL, P39; MCCORMICK PW, 1992, J NEUROSURG, V76, P315, DOI 10.3171/jns.1992.76.2.0315; MCCORMICK PW, 1991, CRIT CARE MED, V19, P89, DOI 10.1097/00003246-199101000-00020; MCCORMICK PW, 1991, STROKE, V22, P597; Mchedlishvili G., 1986, ARTERIAL BEHAVIOR BL, P56; SCHNEIDER PA, 1988, J VASC SURG, V7, P223, DOI 10.1067/mva.1988.avs0070223; WILLIAMS IM, 1994, BRIT J SURG, V81, P960, DOI 10.1002/bjs.1800810711; Williams PL, 1989, GRAYS ANATOMY, P793	12	79	86	0	0	BLACKWELL SCIENCE LTD	OXFORD	OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL	0007-1323			BRIT J SURG	Br. J. Surg.	SEP	1994	81	9					1291	1295		10.1002/bjs.1800810911			5	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	PE376	WOS:A1994PE37600009	7953390				2022-02-06	
J	TRELEAVEN, J; JULL, G; ATKINSON, L				TRELEAVEN, J; JULL, G; ATKINSON, L			CERVICAL MUSCULOSKELETAL DYSFUNCTION IN POST-CONCUSSIONAL HEADACHE	CEPHALALGIA			English	Article						CERVICAL SPINE DYSFUNCTION; PHYSICAL EXAMINATION; POST-CONCUSSIONAL HEADACHE	CERVICOGENIC HEADACHE; SPINE; PAIN	Persistent headache is a common symptom following a minor head injury or concussion, possibly related to simultaneous injury of structures of the cervical spine. This study measured aspects of cervical musculoskeletal function in a group of patients (IZ) with post-concussional headache (PCH) and in a normal control group. The PCH group was distinguished from the control group by the presence of painful upper cervical segmental joint dysfunction, less endurance in the neck flexor muscles and a higher incidence of moderately tight neck musculature. Active range of cervical motion and postural attitude were not significantly different between groups. As upper cervical joint dysfunction is a feature of cervicogenic causes of headache, the results of this study support the inclusion of a precise physical examination of the cervical region in differential diagnosis of patients suffering persistent headache following concussion.	PRINCESS ALEXANDRA HOSP,DEPT NEUROSURG,BRISBANE,QLD 4102,AUSTRALIA		TRELEAVEN, J (corresponding author), UNIV QUEENSLAND,DEPT PHYSIOTHERAPY,BRISBANE,QLD 4072,AUSTRALIA.		Treleaven, Julia M/F-8734-2010; Jull, Gwendolen/F-4233-2010; Treleaven, Julia/N-1379-2019	Treleaven, Julia M/0000-0002-6258-3972; Jull, Gwendolen/0000-0003-2670-1318; Treleaven, Julia/0000-0002-6258-3972			AMEVO B, 1992, SPINE, V7, P748; APPENZELLER O, 1987, WOLFFS HEADACHE OTHE, P291; BOGDUK N, 1986, J NEUROL NEUROSUR PS, V49, P775, DOI 10.1136/jnnp.49.7.775; Bourdillon JF, 1992, SPINAL MANIPULATION; BOVIM G, 1992, PAIN, V49, P315, DOI 10.1016/0304-3959(92)90237-6; BRAAF MM, 1975, J TRAUMA, V15, P441, DOI 10.1097/00005373-197505000-00011; DVORAK JU, 1988, SPINE, V7, P748; Edgar D, 1994, Aust J Physiother, V40, P99, DOI 10.1016/S0004-9514(14)60456-6; EHNI G, 1984, J NEUROSURG, V61, P961, DOI 10.3171/jns.1984.61.5.0961; Evjenth O, 1984, MUSCLE STRETCHING MA, VII; EVJENTH O, 1984, MUSCLE STRECTCHING M, V1; FREDRIKSEN TA, 1987, CEPHALALGIA, V7, P147, DOI 10.1046/j.1468-2982.1987.0702147.x; JAEGER B, 1989, CEPHALALGIA, V9, P157, DOI 10.1046/j.1468-2982.1989.0903157.x; Janda V, 1988, PHYS THERAPY CERVICA, P153; JENSEN OK, 1990, CEPHALALGIA, V10, P241, DOI 10.1046/j.1468-2982.1990.1005241.x; JENSEN OK, 1990, CEPHALALGIA, V109, P295; JULL G, 1988, MED J AUSTRALIA, V148, P233, DOI 10.5694/j.1326-5377.1988.tb99431.x; JULL G, 1994, PHYSICAL THERAPY CER; JULL GA, 1986, MODERN MANUAL THERAP, P315; JULL GA, 1986, MODERN MANUAL THERAP, P322; KELLY RE, 1986, HDB CLIN NEUROLOGY, V4, P383; KERR FW, 1961, EXP NEUROL, V4, P134, DOI 10.1016/0014-4886(61)90036-X; LIDVALL H F, 1974, Acta Neurologica Scandinavica Supplementum, V50, P1; Maitland GD, 1986, VERTEBRAL MANIPULATI; MAYER ET, 1985, CEPHALALGIA, V5, P237, DOI 10.1046/j.1468-2982.1985.0504237.x; MILLER H, 1968, HDB CLIN NEUROLOGY, P178; PFAFFENRATH V, 1987, HEADACHE, V27, P495, DOI 10.1111/j.1526-4610.1987.hed2709495.x; SAKUTA M, 1989, CEPHALALGIA S10, V9, P119; SILVERMAN JL, 1991, ARCH PHYS MED REHAB, V72, P679; SJAASTAD O, 1983, CEPHALALGIA, V3, P249, DOI 10.1046/j.1468-2982.1983.0304249.x; SJAASTAD O, 1992, CLIN NEUROL NEUROSUR, V94, pS147; SJAASTAD O, 1990, HEADACHE, V30, P725, DOI 10.1111/j.1526-4610.1990.hed3011725.x; SPEED WG, 1989, HEADACHE, V29, P643, DOI 10.1111/j.1526-4610.1989.hed2910643.x; TREVOR-JONES R, 1964, S Afr Med J, V38, P392; TRUCCI S, 1986, ARCH PHYS MED REHAB, V67, P225; WATSON DH, 1993, CEPHALALGIA, V13, P272, DOI 10.1046/j.1468-2982.1993.1304272.x; WEISS H, 1991, HEADACHE, V7, P451; YOUDAS JW, 1991, PHYS THER, V71, P98, DOI 10.1093/ptj/71.2.98; 1988, CEPHALALGIA S7, V8, P10; [No title captured]	40	79	80	0	12	SCANDINAVIAN UNIVERSITY PRESS	OSLO	PO BOX 2959 TOYEN, JOURNAL DIVISION CUSTOMER SERVICE, N-0608 OSLO, NORWAY	0333-1024			CEPHALALGIA	Cephalalgia	AUG	1994	14	4					273	279		10.1046/j.1468-2982.1994.1404273.x			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PC322	WOS:A1994PC32200008	7954756				2022-02-06	
J	GRUNDL, PD; BIAGAS, KV; KOCHANEK, PM; SCHIDING, JK; BARMADA, MA; NEMOTO, EM				GRUNDL, PD; BIAGAS, KV; KOCHANEK, PM; SCHIDING, JK; BARMADA, MA; NEMOTO, EM			EARLY CEREBROVASCULATURE RESPONSE TO HEAD-INJURY IN IMMATURE AND MATURE RATS	JOURNAL OF NEUROTRAUMA			English	Article							CEREBRAL BLOOD-FLOW; TRAUMATIC BRAIN INJURY; FREELY MOVING RATS; COMPUTERIZED-TOMOGRAPHY; INTRACRANIAL-PRESSURE; C-14 IODOANTIPYRINE; FREE-RADICALS; EDEMA; CHILDREN; METABOLISM	Clinical studies suggest that children respond to head injury with more pronounced cerebral edema and hyperemia than do adults. We hypothesized that these age-related differences could be demonstrated in an animal model. Anesthetized and ventilated mature (2-3 months) and immature (3.5-4.5 weeks) male Wistar rats were traumatized by weight drop onto the exposed right parietal cortex. Trauma severity was adjusted to keep the ratio of force to brain weight constant. This resulted in an energy delivered to the brain of about 9 x 10(3) ergs. mm(-2).g(-1) brain in both age groups. Percent right hemispheric brain water (%RBW) was measured at 2, 24, 48, and 168 h posttrauma. Infarct area, intracranial pressure (ICP), and C-14-iodoantipyrine autoradiographic local cerebral blood flow (ICBF) were measured at 2 h or 24 h posttrauma. In mature rats, %RBW was unchanged at 2 h, but increased at 24 and 48 h (both p < 0.05). In immature rats, %RBW increased at 2 h and remained elevated at 24 and 48 h (all p < 0.05). Traumatic infarct area as a percent of hemispheric area at 24 h did not differ between age groups. In mature rats, at 2 h posttrauma ICBF was reduced (p < 0.05) in 16 of 17 regions but in only 4 of 17 regions in immature rats. ICBF as a percent of age-matched control values showed a greater reduction in mature vs immature rats in 9 of 16 regions (p < 0.05). ICP increased at 24 h posttrauma in both age groups. In immature rats posttrauma, brain water increased earlier and cerebral hypoperfusion was less marked than in mature rats.	UNIV PITTSBURGH, SCH MED, DEPT PEDIAT, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, SCH MED, DEPT PATHOL, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, SCH MED, DEPT ANESTHESIOL CRIT CARE MED, PITTSBURGH, PA 15261 USA				Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Biagas, Katherine/0000-0002-4669-703X			ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMAN HJ, 1979, BRAIN RES BULL, V4, P575, DOI 10.1016/0361-9230(79)90045-5; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; CHAN PH, 1984, NEUROLOGY, V34, P315, DOI 10.1212/WNL.34.3.315; COLE DJ, 1990, AM J PHYSIOL, V259, pH211, DOI 10.1152/ajpheart.1990.259.1.H211; Donaldson HH, 1931, J COMP NEUROL, V53, P263, DOI 10.1002/cne.900530202; DURWARD QJ, 1983, J NEUROSURG, V59, P803, DOI 10.3171/jns.1983.59.5.0803; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; FEUSTEL PJ, 1987, J SURG RES, V43, P86, DOI 10.1016/0022-4804(87)90051-5; Goldman H, 1991, J NEUROTRAUM, V8, P129, DOI 10.1089/neu.1991.8.129; GUPTA D, 1975, STEROIDS, V25, P33, DOI 10.1016/S0039-128X(75)80005-5; HAMM RJ, 1991, J NEUROSURG, V75, P916, DOI 10.3171/jns.1991.75.6.0916; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; IKEDA Y, 1989, NEUROSURGERY, V24, P679, DOI 10.1227/00006123-198905000-00004; ISSEKUTZ AC, 1984, LAB INVEST, V50, P605; JENKINS HG, 1988, J NEUROCHEM, V51, P1634, DOI 10.1111/j.1471-4159.1988.tb01134.x; Kasapi M., 1992, Society for Neuroscience Abstracts, V18, P1088; KASOFF SS, 1972, J NEUROSURG, V36, P463, DOI 10.3171/jns.1972.36.4.0463; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; KOCHANEK P, 1992, J NEUROTRAUM, V9, P390; Kochanek P, 1991, J NEUROTRAUM, V8, P19, DOI 10.1089/neu.1991.8.19; KRUM JM, 1991, SOC NEUR ABSTR, V17, P329; LEE VWK, 1975, J REPROD FERTIL, V42, P121, DOI 10.1530/jrf.0.0420121; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MCDONALD JW, 1987, EUR J PHARMACOL, V140, P359, DOI 10.1016/0014-2999(87)90295-0; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; NEHLIG A, 1989, J CEREBR BLOOD F MET, V9, P579, DOI 10.1038/jcbfm.1989.83; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; NORTON WT, 1973, J NEUROCHEM, V21, P759, DOI 10.1111/j.1471-4159.1973.tb07520.x; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; OVERGAARD J, 1976, J NEUROSURG, V45, P292, DOI 10.3171/jns.1976.45.3.0292; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; RICHARDS HK, 1987, J CEREBR BLOOD F MET, V7, P124, DOI 10.1038/jcbfm.1987.18; SAKURADA O, 1978, AM J PHYSIOL, V234, pH59, DOI 10.1152/ajpheart.1978.234.1.H59; SAUNDERS ML, 1979, J NEUROSURG, V51, P18, DOI 10.3171/jns.1979.51.1.0018; SCHLEIEN CL, 1991, STROKE, V22, P477, DOI 10.1161/01.STR.22.4.477; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SHAPIRA Y, 1988, J CEREBR BLOOD F MET, V8, P395, DOI 10.1038/jcbfm.1988.75; STREICHE.E, 1965, NEUROLOGY, V15, P833, DOI 10.1212/WNL.15.9.833; SUMI SM, 1968, ACTA NEUROPATHOL, V10, P324, DOI 10.1007/BF00690707; TAMURA A, 1981, J CEREBR BLOOD F MET, V1, P61, DOI 10.1038/jcbfm.1981.7; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; TORNHEIM PA, 1981, J NEUROSURG, V55, P407, DOI 10.3171/jns.1981.55.3.0407; UHL M W, 1990, Critical Care Medicine, V18, pS274; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; UZZELL BP, 1986, J NEUROSURG, V65, P630, DOI 10.3171/jns.1986.65.5.0630; VERHEUL HB, 1993, J CEREB BLOOD FLOW M, V13, pS307; WOOTTON R, 1983, CAN J PHYSIOL PHARM, V61, P595, DOI 10.1139/y83-091; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOSHIDA S, 1983, NEUROLOGY, V33, P166, DOI 10.1212/WNL.33.2.166; YOUNG H, 1992, CRITICAL CARE STATE, V13, P427; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	61	79	80	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	1994	11	2					135	148		10.1089/neu.1994.11.135			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	NR684	WOS:A1994NR68400001	7932794				2022-02-06	
J	FORTUNE, JB; FEUSTEL, PJ; WEIGLE, CGM; POPP, AJ				FORTUNE, JB; FEUSTEL, PJ; WEIGLE, CGM; POPP, AJ			CONTINUOUS MEASUREMENT OF JUGULAR VENOUS OXYGEN-SATURATION IN RESPONSE TO TRANSIENT ELEVATIONS OF BLOOD-PRESSURE IN HEAD-INJURED PATIENTS	JOURNAL OF NEUROSURGERY			English	Article						TRAUMATIC BRAIN INJURY; CEREBRAL BLOOD FLOW; AUTOREGULATION; CEREBRAL PERFUSION PRESSURE; JUGULAR VENOUS OXYGEN SATURATION; OXIMETRY	ACUTE BRAIN INJURY; CEREBRAL HEMODYNAMIC RESERVE; INTERNAL CAROTID-ARTERY; AUTO-REGULATION; FLOW; METABOLISM; HYPERTENSION; MANNITOL; CHILDREN; CBF	Following traumatic brain injury, continuous jugular venous oxygen saturation (SjvO(2)) measurements have been made and used to assess cerebral oxygenation. Transients of SjvO(2) may reflect cerebral blood flow (CBF) changes if measurements are made over a short period of time during which cerebral metabolic rate for oxygen is assumed unchanged. In response to alterations in perfusion pressure, transients of SjvO(2) may indicate the extent to which autoregulation has been preserved after injury. The effect of arterial pressure changes on SjvO(2) was measured in 14 severely head-injured patients (Glasgow Coma Scale score < 8) within 36 hours of injury. Mean arterial blood pressure (MABP), arterial oxygen saturation, and intracranial pressure (ICP) data were also continuously recorded by a computer at the patients' bedside. The reliability of the SjvO(2) oximetry measurements varied among patients, and an average 38% of SjvO(2) measurements were off by more than 6% saturation, necessitating recalibration. During periods of satisfactory catheter performance, 120 instances were found in which MABP was elevated more than 8 torr (mean +/- standard deviation: 32 +/- 13 torr) due to endotracheal suctioning. In 94 of these measurements, there was an associated increase in the ICP of 5 torr or more, averaging 16.6 +/- 10.2 torr. The SjvO(2) was 0.62 +/- 0.10 before the increase in MABP and rose to a peak of 0.77 +/- 0.10 during the maximum MABP elevation, suggesting increased CBF during the transient hypertension. In 34 of 37 instances of persistent blood pressure elevations lasting for more than 10 minutes (mean 16.0 +/- 8.0 minutes), the SjvO(2) elevation persisted (average duration 15.0 +/- 12.4 minutes), suggesting impaired or lost autoregulatory vasoconstriction. The presence or absence of hyperemia was unrelated to the extent of the autoregulation response. Results indicate that SjvO(2) rises with increasing perfusion pressure during and after endotracheal suctioning, suggesting a feeble or absent autoregulatory response following traumatic brain injury.	ALBANY MED CTR, DEPT SURG, DIV NEUROSURG, ALBANY, NY USA; ALBANY MED CTR, DEPT PEDIAT, PEDIAT INTENS CARE SECT, ALBANY, NY USA		FORTUNE, JB (corresponding author), ALBANY MED CTR, DEPT SURG, TRAUMA SURG SECT, ALBANY, NY 12208 USA.		Feustel, Paul/AAW-5157-2021	Feustel, Paul/0000-0002-6963-4349	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [30303] Funding Source: Medline		ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; ANDREWS PJD, 1990, BRIT J ANAESTH, V64, pP393; BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; COLD GE, 1981, ACTA ANAESTH SCAND, V25, P379; Cruz J, 1988, Acta Neurochir Suppl (Wien), V42, P35; CRUZ J, 1991, NEUROSURGERY, V29, P743, DOI 10.1227/00006123-199111000-00017; CRUZ J, 1985, CRIT CARE MED, V13, P284, DOI 10.1097/00003246-198504000-00047; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; CRUZ J, 1992, J TRAUMA, V32, P629, DOI 10.1097/00005373-199205000-00015; CRUZ J, 1992, CRIT CARE MED S, V20, P109; CRUZ J, 1991, J TRAUMA, V31, P1714; CRUZ J, 1986, NEUROTRAUMA TREATMEN, P55; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; FEUSTEL PJ, 1987, J SURG RES, V43, P86, DOI 10.1016/0022-4804(87)90051-5; FEUSTEL PJ, IN PRESS AM REV RESP; FORTUNE JB, 1992, J TRAUMA, V32, P618, DOI 10.1097/00005373-199205000-00014; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; KONTOS HA, 1978, AM J PHYSIOL, V234, pH371, DOI 10.1152/ajpheart.1978.234.4.H371; LEOPOLD PW, 1987, BRIT J SURG, V74, P630, DOI 10.1002/bjs.1800740734; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212	25	79	81	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	1994	80	3					461	468		10.3171/jns.1994.80.3.0461			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	MY483	WOS:A1994MY48300007	8113859				2022-02-06	
J	PONSFORD, JL; KINSELLA, G				PONSFORD, JL; KINSELLA, G			EVALUATION OF A REMEDIAL PROGRAM FOR ATTENTIONAL DEFICITS FOLLOWING CLOSED-HEAD INJURY	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article									BETHESDA HOSP,MELBOURNE,AUSTRALIA; LATROBE UNIV,MELBOURNE,AUSTRALIA				Kinsella, Glynda/O-6347-2017	Kinsella, Glynda/0000-0002-5859-0934			BENYISHAY Y, 1978, REHABILITATION MONOG, V59, P63; BLACK P, 1975, CIBA ELSEVIER S, V34, P65; BROOKS DN, 1984, CLOSED HEAD INJURY P, P44; CONKEY RC, 1938, ARCH PSYCHOL, V33; Gianutsos R, 1981, COMPUTER PROGRAMS CO; Gottman J. M., 1981, TIME SERIES ANAL COM; Gronwall D, 1974, PSYCHOL EFFECTS CONC; LEVIN HS, 1982, NEUROBEHAVIOURAL CON; MALEC J, 1984, COGNITIVE REHABILITA, V2, P18; Miller E, 1970, Cortex, V6, P121; NAYLOR GFK, 1972, NAYLORHARWOOD ADULT; NEWCOMBE F, 1982, INJURY, V14, P111, DOI 10.1016/0020-1383(82)90046-8; OCONNOR M, 1987, NEUROPSYCHOL REHABIL, P260; PONSFORD JL, 1985, 10TH P ANN BRAIN IMP, P17; Posner M.I., 1975, HDB PSYCHOBIOLOGY, P441, DOI [DOI 10.1016/B978-0-12-278656-3.50019-3, 10.3758/BF03333099, DOI 10.3758/BF03333099]; POSNER MI, 1971, PSYCHOL REV, V78, P391, DOI 10.1037/h0031333; PRIBRAM KH, 1975, PSYCHOL REV, V82, P116, DOI 10.1037/h0076780; Ruesch J, 1944, AM J PSYCHIAT, V100, P480, DOI 10.1176/ajp.100.4.480; Schacter DL, 1986, CLIN NEUROPSYCHOLOGY, P257; Smith, 1973, SYMBOL DIGIT MODALIT; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Van Zomeren A. H., 1981, REACTION TIME ATTENT; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WATSON PJ, 1981, J BEHAV THER EXP PSY, V12, P257, DOI 10.1016/0005-7916(81)90055-0; WOOD RL, 1984, 4 S MOD TECHN COGN R; [No title captured]	27	79	79	1	7	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	DEC	1988	10	6					693	708		10.1080/01688638808402808			16	Psychology, Clinical; Clinical Neurology; Psychology	Social Science Citation Index (SSCI); Science Citation Index Expanded (SCI-EXPANDED)	Psychology; Neurosciences & Neurology	R2917	WOS:A1988R291700002	3235646				2022-02-06	
J	Ni, HQ; Yang, S; Siaw-Debrah, F; Hu, JN; Wu, K; He, ZB; Yang, JJ; Pan, SS; Lin, X; Ye, HT; Xu, Z; Wang, F; Jin, KL; Zhuge, QC; Huang, LJ				Ni, Haoqi; Yang, Su; Siaw-Debrah, Felix; Hu, Jiangnan; Wu, Ke; He, Zibin; Yang, Jianjing; Pan, Sishi; Lin, Xiao; Ye, Haotuo; Xu, Zhu; Wang, Fan; Jin, Kunlin; Zhuge, Qichuan; Huang, Lijie			Exosomes Derived From Bone Mesenchymal Stem Cells Ameliorate Early Inflammatory Responses Following Traumatic Brain Injury	FRONTIERS IN NEUROSCIENCE			English	Article						traumatic brain injury; bone mesenchymal stem cells; exosomes; neuroprotection; microglia/macrophage; inflammation	STROMAL CELLS; EXTRACELLULAR VESICLES; FUNCTIONAL RECOVERY; ANIMAL-MODELS; TRANSPLANTATION; REGULATORS; THERAPY	Traumatic brain injury (TBI) is a leading cause of mortality and disability worldwide. Although treatment guidelines have been developed, no best treatment option or medicine for this condition exists. Recently, mesenchymal stem cells (MSCs)-derived exosomes have shown lots of promise for the treatment of brain disorders, with some results highlighting the neuroprotective effects through neurogenesis and angiogenesis after TBI. However, studies focusing on the role of exosomes in the early stages of neuroinflammation post-TBI are not sufficient. In this study, we investigated the role of bone mesenchymal stem cells (BMSCs)-exosomes in attenuating neuroinflammation at an early stage post-TBI and explored the potential regulatory neuroprotective mechanism. We administered 30 vg protein of BMSCsexosomes or an equal volume of phosphate-buffered saline (PBS) via the retro-orbital route into C57BL/6 male mice 15 min after controlled cortical impact (CCI)-induced TBI. The results showed that the administration of BMSCs-exosomes reduced the lesion size and improved the neurobehavioral performance assessed by modified Neurological Severity Score (mNSS) and rotarod test. In addition, BMSCs-exosomes inhibited the expression of proapoptosis protein Bcl-2-associated X protein (BAX) and proinflammation cytokines, tumor necrosis factor-alpha (TNF-alpha) and interleukin (IL)-1 beta, while enhancing the expression of the anti-apoptosis protein B-cell lymphoma 2 (BCL2). Furthermore, BMSCs-exosomes modulated microglia/macrophage polarization by downregulating the expression of inducible nitric oxide synthase (INOS) and upregulating the expression of clusters of differentiation 206 (CD206) and arginase-1 (Arg1). In summary, our result shows that BMSCs-exosomes serve a neuroprotective function by inhibiting early neuroinflammation in TBI mice through modulating the polarization of microglia/macrophages. Further research into this may serve as a potential therapeutic strategy for the future treatment of TBI.	[Ni, Haoqi; Yang, Su; Siaw-Debrah, Felix; Wu, Ke; He, Zibin; Yang, Jianjing; Pan, Sishi; Lin, Xiao; Ye, Haotuo; Xu, Zhu; Wang, Fan; Jin, Kunlin; Zhuge, Qichuan; Huang, Lijie] Wenzhou Med Univ, Affiliated Hosp 1, Zhejiang Prov Key Lab Aging & Neurol Disorder Res, Wenzhou, Peoples R China; [Ni, Haoqi; Yang, Su; Siaw-Debrah, Felix; Wu, Ke; He, Zibin; Yang, Jianjing; Pan, Sishi; Lin, Xiao; Ye, Haotuo; Xu, Zhu; Wang, Fan; Zhuge, Qichuan; Huang, Lijie] Wenzhou Med Univ, Affiliated Hosp 1, Dept Neurosurg, Wenzhou, Peoples R China; [Hu, Jiangnan; Jin, Kunlin] Univ North Texas, Dept Pharmacol & Neurosci, Hlth Sci Ctr, Ft Worth, TX USA		Zhuge, QC; Huang, LJ (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Zhejiang Prov Key Lab Aging & Neurol Disorder Res, Wenzhou, Peoples R China.; Zhuge, QC; Huang, LJ (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Dept Neurosurg, Wenzhou, Peoples R China.	zhugeqichuan@vip.163.com; lijiehuangwy@163.com	Hu, John/AAL-6376-2021; Huang, Lijie/AAD-3489-2022; Hu, Jiangnan/ABB-1329-2021; Hu, Jiangnan/ABD-5635-2021	Su, Yang/0000-0001-8120-6016	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81771262]; Zhejiang Health Science and Technology Project [2016RCA022]; Zhejiang Key Research and Development Project [2017C03027]	The work has been supported by National Natural Science Foundation of China (81771262), Zhejiang Health Science and Technology Project (2016RCA022), and Zhejiang Key Research and Development Project (2017C03027).	Chiu CC, 2016, J NEUROSCI METH, V272, P38, DOI 10.1016/j.jneumeth.2016.06.018; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Cox CS, 2011, NEUROSURGERY, V68, P588, DOI 10.1227/NEU.0b013e318207734c; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Herx LM, 2001, J NEUROPATH EXP NEUR, V60, P961, DOI 10.1093/jnen/60.10.961; Huang JH, 2017, J NEUROTRAUM, V34, P3388, DOI 10.1089/neu.2017.5063; Jeong JO, 2011, CIRC RES, V108, P1340, DOI 10.1161/CIRCRESAHA.110.239848; John GR, 2003, NEUROSCIENTIST, V9, P10, DOI 10.1177/1073858402239587; Kim DK, 2016, P NATL ACAD SCI USA, V113, P170, DOI 10.1073/pnas.1522297113; Lai RC, 2011, REGEN MED, V6, P481, DOI [10.2217/RME.11.35, 10.2217/rme.11.35]; Li Y, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0648-5; Li Y, 2009, NEUROSCI LETT, V456, P120, DOI 10.1016/j.neulet.2008.03.096; Liberto CM, 2004, J NEUROCHEM, V89, P1092, DOI 10.1111/j.1471-4159.2004.02420.x; Lotvall J, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.26913; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Mincheva-Nilsson Lucia, 2016, Curr Protoc Immunol, V115, DOI 10.1002/cpim.17; Miron VE, 2013, NAT NEUROSCI, V16, P1211, DOI 10.1038/nn.3469; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Perez EJ, 2017, J CLIN INVEST, V127, P3114, DOI 10.1172/JCI92300; Rani S, 2015, MOL THER, V23, P812, DOI 10.1038/mt.2015.44; Romine J, 2014, JOVE-J VIS EXP, DOI 10.3791/51781; Stoll G, 2002, ADV EXP MED BIOL, V513, P87; Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043; Vlassov AV, 2012, BBA-GEN SUBJECTS, V1820, P940, DOI 10.1016/j.bbagen.2012.03.017; Walker PA, 2012, SURGERY, V152, P790, DOI 10.1016/j.surg.2012.06.006; Wang GH, 2015, P NATL ACAD SCI USA, V112, P2853, DOI 10.1073/pnas.1501441112; Wen ZY, 2017, BRAIN RES, V1665, P88, DOI 10.1016/j.brainres.2017.04.001; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wiklander OPB, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.26316; Williams AM, 2019, J NEUROTRAUM, V36, P54, DOI 10.1089/neu.2018.5711; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wu H, 2018, MOL PHARMACEUT, V15, P1892, DOI 10.1021/acs.molpharmaceut.8b00059; Xin HQ, 2013, STEM CELLS, V31, P2737, DOI 10.1002/stem.1409; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yang JJ, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00061; Yang YX, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00055; Yardeni T, 2011, LAB ANIMAL, V40, P155, DOI 10.1038/laban0511-155; Zhang H, 2017, BONE MARROW STEM CEL, P81, DOI DOI 10.1007/978-981-10-2929-5_4; Zhang L, 2011, STROKE, V42, P1437, DOI 10.1161/STROKEAHA.110.593129; Zhang YL, 2017, NEUROCHEM INT, V111, P69, DOI 10.1016/j.neuint.2016.08.003; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770; Zhang ZX, 2008, CYTOTHERAPY, V10, P134, DOI 10.1080/14653240701883061	46	78	79	2	29	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-453X			FRONT NEUROSCI-SWITZ	Front. Neurosci.	JAN 24	2019	13								14	10.3389/fnins.2019.00014			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HI8ZM	WOS:000456744500001	30733666	Green Published, gold	Y	N	2022-02-06	
J	Li, Y; Yang, YY; Ren, JL; Xu, F; Chen, FM; Li, A				Li, Ye; Yang, Yuan-Yuan; Ren, Jia-Li; Xu, Feng; Chen, Fa-Ming; Li, Ang			Exosomes secreted by stem cells from human exfoliated deciduous teeth contribute to functional recovery after traumatic brain injury by shifting microglia M1/M2 polarization in rats	STEM CELL RESEARCH & THERAPY			English	Article						Traumatic brain injury; Stem cells from human exfoliated deciduous teeth; Exosomes; Microglia; Neuroinflammation	TISSUES; TRANSPLANTATION; REGENERATION; SCAFFOLDS; VESICLES; THERAPY	Background: Traumatic brain injury (TBI) is one of the major causes of mortality and disability for all ages worldwide. Mesenchymal stem cells (MSCs)-originated exosomes have provided therapeutic effects. However, as an indispensable component of MSCs, whether odontogenic stem cell-generated exosomes could benefit TBI is still unclear. Thus we aimed to explore the potential of stem cells from human exfoliated deciduous teeth-originated exosomes (SHED-Ex) for the management of TBI. Methods: First, a transwell system was used to co-culture activated BV-2 microglia cells with SHED. The secretion levels of neuroinflammatory factors and nitrite were evaluated by enzyme-linked immunosorbent assay (ELISA) and Griess assay. Furthermore, purified SHED-Ex were co-cultured with activated BV-2. ELISA, Griess assay, flow cytometry, immunofluorescence, and qRT-PCR were performed to test the levels of inflammatory factors as well as the microglia phenotype. Finally, SHED and SHED-Ex were locally injected into TBI rat models. Basso, Beattie, and Bresnahan (BBB) scores were chosen to evaluate the motor functional recovery. Histopathology and immunofluorescence were performed to measure the lesion volume and neuroinflammation. Results: As a result, SHED-Ex could reduce neuroinflammation by shifting microglia polarization. The administration of SHED-Ex improves rat motor functional recovery and reduces cortical lesion compared with the control group 2 weeks post-injury (P < 0.05). Conclusions: The current study demonstrates for the first time that SHED-Ex contribute a therapeutic benefit to TBI in rats, at least in part by shifting microglia polarization to reduce neuroinflammation. The use of odontogenic stem cells, and indeed their exosomes, may be expanded for the treatment of TBI or other neurological disorders.	[Li, Ye; Li, Ang] Key Lab Shaanxi Prov Craniofacial Precis Med Res, Xian, Shaanxi, Peoples R China; [Li, Ye; Yang, Yuan-Yuan; Ren, Jia-Li; Li, Ang] Xi An Jiao Tong Univ, Coll Stomatol, Dept Periodontol, Xi Wu Rd 98, Xian 710004, Shaanxi, Peoples R China; [Xu, Feng] Xi An Jiao Tong Univ, Sch Life Sci & Technol, Minist Educ, Key Lab Biomed Informat Engn, Xian, Shaanxi, Peoples R China; [Xu, Feng] Xi An Jiao Tong Univ, BEBC, Xian, Shaanxi, Peoples R China; [Chen, Fa-Ming] Fourth Mil Med Univ, Sch Stomatol, Dept Periodontol, Xian, Shaanxi, Peoples R China		Li, A (corresponding author), Key Lab Shaanxi Prov Craniofacial Precis Med Res, Xian, Shaanxi, Peoples R China.; Li, A (corresponding author), Xi An Jiao Tong Univ, Coll Stomatol, Dept Periodontol, Xi Wu Rd 98, Xian 710004, Shaanxi, Peoples R China.	drliang@mail.xjtu.edu.cn	Li, Ang/AAV-6381-2021; Xu, Feng/H-4468-2011	Xu, Feng/0000-0003-4351-0222; Li, Ang/0000-0001-6720-0785; Li, Ye/0000-0002-1624-8831	Shaanxi Provincial Science and Technology Innovation Project co-ordination of Resources Oriented Industries of Key Technologies Project [2011KTCL03-24]	The current work was supported by Shaanxi Provincial Science and Technology Innovation Project co-ordination of Resources Oriented Industries of Key Technologies Project No. 2011KTCL03-24.	Annibali S, 2014, EUR REV MED PHARMACO, V18, P2863; Arslan F, 2013, STEM CELL RES, V10, P301, DOI 10.1016/j.scr.2013.01.002; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Brites D, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00476; Daltoe FP, 2014, BRAZ ORAL RES, V28, P413, DOI 10.1590/1807-3107BOR-2014.vol28.0037; Dorronsoro A, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt187; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Ferguson SW, 2016, J CONTROL RELEASE, V228, P179, DOI 10.1016/j.jconrel.2016.02.037; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Gu JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052465; Guan J, 2013, BIOMATERIALS, V34, P5937, DOI 10.1016/j.biomaterials.2013.04.047; Harry GJ, 2012, NEUROTOXICOLOGY, V33, P558, DOI 10.1016/j.neuro.2012.03.013; Harting MT, 2009, J SURG RES, V153, P188, DOI 10.1016/j.jss.2008.03.037; Huang GTJ, 2009, J DENT RES, V88, P792, DOI 10.1177/0022034509340867; Jose S, 2015, CELL BIOL INT, V39, P1355, DOI 10.1002/cbin.10516; Kanafi MM, 2013, CYTOTHERAPY, V15, P1228, DOI 10.1016/j.jcyt.2013.05.008; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Ma L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051777; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Marote A, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00231; Miura M, 2003, P NATL ACAD SCI USA, V100, P5807, DOI 10.1073/pnas.0937635100; Nakamura Y, 2015, FEBS LETT, V589, P1257, DOI 10.1016/j.febslet.2015.03.031; Nishino Y, 2011, CYTOTHERAPY, V13, P598, DOI 10.3109/14653249.2010.542462; Oh JY, 2008, STEM CELLS, V26, P1047, DOI 10.1634/stemcells.2007-0737; Rani S, 2015, MOL THER, V23, P812, DOI 10.1038/mt.2015.44; Rosa V, 2013, J DENT RES, V92, P970, DOI 10.1177/0022034513505772; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Tajiri N, 2014, J NEUROSCI, V34, P313, DOI 10.1523/JNEUROSCI.2425-13.2014; Tsai CL, 2015, CORNEA, V34, P1471, DOI 10.1097/ICO.0000000000000532; Turturici G, 2014, AM J PHYSIOL-CELL PH, V306, pC621, DOI 10.1152/ajpcell.00228.2013; Ueda M, 2010, J CRANIOFAC SURG, V21, P1861, DOI 10.1097/SCS.0b013e3181f43f0a; Vakhrushev IV, 2012, B EXP BIOL MED+, V153, P143, DOI 10.1007/s10517-012-1663-2; van Buul GM, 2012, OSTEOARTHR CARTILAGE, V20, P1186, DOI 10.1016/j.joca.2012.06.003; Xiong Y, 2015, EXPERT OPIN INV DRUG, V24, P743, DOI 10.1517/13543784.2015.1021919; Yeh YC, 2015, HISTOPATHOLOGY, V66, P922, DOI 10.1111/his.12468; Yin ZH, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0309-0; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Zomer Anoek, 2010, Commun Integr Biol, V3, P447, DOI 10.4161/cib.3.5.12339	38	78	82	2	26	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1757-6512			STEM CELL RES THER	Stem Cell Res. Ther.	SEP 29	2017	8								198	10.1186/s13287-017-0648-5			11	Cell & Tissue Engineering; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Research & Experimental Medicine	FI7RM	WOS:000412195400002	28962585	Green Published, gold			2022-02-06	
J	Meyfroidt, G; Baguley, IJ; Menon, DK				Meyfroidt, Geert; Baguley, Ian J.; Menon, David K.			Paroxysmal sympathetic hyperactivity: the storm after acute brain injury	LANCET NEUROLOGY			English	Article							ALLEVIATES AUTONOMIC DYSFUNCTION; INTRATHECAL BACLOFEN THERAPY; INTENSIVE-CARE-UNIT; PHARMACOLOGICAL MANAGEMENT; DIAGNOSTIC-CRITERIA; VEGETATIVE STATE; AFFERENT STIMULI; METABOLIC-RATE; DYSAUTONOMIA; OVERRESPONSIVENESS	A substantial minority of patients who survive an acquired brain injury develop a state of sympathetic hyperactivity that can persist for weeks or months, consisting of periodic episodes of increased heart rate and blood pressure, sweating, hyperthermia, and motor posturing, often in response to external stimuli. The unifying term for the syndrome-paroxysmal sympathetic hyperactivity (PSH)-and clear diagnostic criteria defined by expert consensus were only recently established. PSH has predominantly been described after traumatic brain injury (TBI), in which it is associated with worse outcomes. The pathophysiology of the condition is not completely understood, although most researchers consider it to be a disconnection syndrome with paroxysms driven by a loss of inhibitory control over excitatory autonomic centres. Although therapeutic strategies to alleviate sympathetic outbursts have been proposed, their effects on PSH are inconsistent between patients and their influence on outcome is unknown. Combinations of drugs are frequently used and are chosen on the basis of local custom, rather than on objective evidence. New rigorous tools for diagnosis could allow better characterisation of PSH to enable stratification of patients for future therapeutic trials	[Meyfroidt, Geert] Univ Hosp Leuven, Dept Intens Care Med, Leuven, Belgium; [Baguley, Ian J.] Westmead Hosp, Westmead, NSW, Australia; [Menon, David K.] Univ Cambridge, Div Anaesthesia, Cambridge, England		Menon, DK (corresponding author), Addenbrookes Hosp, Box 93, Cambridge CB2 2QQ, England.	dkm13@cam.ac.uk	Baguley, Ian/AAM-5828-2021		Research Foundation, FlandersFWO; National Institute for Healthcare Research (NIHR), UK, through the Acute Brain Injury and Repair theme of the Cambridge NIHR Biomedical Research Centre; NIHR Senior Investigator Award; European UnionEuropean Commission [602150]; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090] Funding Source: researchfish	GM is funded by the Research Foundation, Flanders as senior clinical investigator. DKM is supported by the National Institute for Healthcare Research (NIHR), UK, through the Acute Brain Injury and Repair theme of the Cambridge NIHR Biomedical Research Centre and a NIHR Senior Investigator Award, and is supported by a European Union Framework Program 7 grant (CENTER-TBI; grant agreement no. 602150). The funders had no role in the preparation, editing, or submission of the manuscript.	Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Baguley IJ, 2008, MED HYPOTHESES, V70, P26, DOI 10.1016/j.mehy.2007.04.037; Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; Baguley IJ, 2007, J NEUROL NEUROSUR PS, V78, P539, DOI 10.1136/jnnp.2006.096388; Baguley IJ, 2014, J NEUROTRAUM, V31, P1515, DOI 10.1089/neu.2013.3301; Baguley IJ, 2009, AM J PHYS MED REHAB, V88, P615, DOI 10.1097/PHM.0b013e3181aeab96; Baguley IJ, 2009, ARCH PHYS MED REHAB, V90, P580, DOI 10.1016/j.apmr.2008.10.020; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Baguley IJ, 2004, BRAIN INJURY, V18, P409, DOI 10.1080/02699050310001645775; Baguley IJ, 1999, MAYO CLIN PROC, V74, P105, DOI 10.4065/74.1.105; Becker R, 1999, J NEUROL NEUROSUR PS, V66, P114, DOI 10.1136/jnnp.66.1.114; Becker R, 2000, J CLIN NEUROSCI, V7, P316, DOI 10.1054/jocn.1999.0227; Bhatnagar S, 2016, BRAIN RES, V1640, P164, DOI 10.1016/j.brainres.2016.01.021; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; Bower RS, 2010, NEUROCRIT CARE, V13, P233, DOI 10.1007/s12028-010-9381-y; Brown A, 2012, EXP NEUROL, V235, P133, DOI 10.1016/j.expneurol.2011.11.004; Caldwell SB, 2014, BRAIN INJURY, V28, P370, DOI 10.3109/02699052.2013.865265; Choi HA, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0370-3; CHRISTIN L, 1989, METABOLISM, V38, P439, DOI 10.1016/0026-0495(89)90195-9; Cuny E, 2001, BRAIN INJURY, V15, P917, DOI 10.1080/02699050110065277; Do D, 2000, J NEUROL NEUROSUR PS, V69, P832, DOI 10.1136/jnnp.69.6.832; Dolce G, 2021, J NEUROTRAUM, V38, P1441, DOI 10.1089/neu.2008.0536; Farias-Moeller R, 2015, NEUROCRIT CARE, V23, P380, DOI 10.1007/s12028-015-0124-y; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Fernandez-Ortega JF, 2012, J NEUROTRAUMA; Fernandez-Ortega JF, 2017, J NEUROTRAUM, V34, P109, DOI 10.1089/neu.2015.4364; Fernandez-Ortega JF, 2006, J TRAUMA, V61, P1129, DOI 10.1097/01.ta.0000197634.83217.80; Gao B, 2014, ANN CLIN TRANSL NEUR, V1, P215, DOI 10.1002/acn3.44; Hendricks HT, 2010, EUR J NEUROL, V17, P1172, DOI 10.1111/j.1468-1331.2010.02989.x; Hendricks HT, 2007, CLIN REHABIL, V21, P545, DOI 10.1177/0269215507075260; Hinson HE, 2015, BRAIN INJURY, V29, P455, DOI 10.3109/02699052.2014.995229; Hoarau X, 2012, BRAIN INJURY, V26, P927, DOI 10.3109/02699052.2012.661913; Kirk KA, 2012, DEV MED CHILD NEUROL, V54, P759, DOI 10.1111/j.1469-8749.2012.04322.x; Krach LE, 1997, J NEUROL REHABIL, V11, P41; Laxe S, 2013, BRAIN INJURY, V27, P1383, DOI 10.3109/02699052.2013.823648; Lee S.-C., 2016, SPRINGERPLUS, V5; Levy ER, 2011, J PALLIAT MED, V14, P1355, DOI 10.1089/jpm.2010.0444; Lv LQ, 2011, ARCH PHYS MED REHAB, V92, P1515, DOI 10.1016/j.apmr.2011.01.014; Lv LQ, 2010, J NEUROTRAUM, V27, P1945, DOI 10.1089/neu.2010.1391; Mathew MJ, 2016, ACTA NEUROCHIR, V158, P2047, DOI 10.1007/s00701-016-2934-x; May CC, RECTAL PROPRANOLOL C; Mehta NM, 2008, JPEN-PARENTER ENTER, V32, P281, DOI 10.1177/0148607108316196; Mrkobrada S, 2016, CHILD NERV SYST, V32, P1299, DOI 10.1007/s00381-015-2931-z; Patel MB, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-177; Pattoneri Paolo, 1800, J Clin Hypertens (Greenwich), V7, P734, DOI 10.1111/j.1524-6175.2005.04780.x; Peirs C, 2016, SCIENCE, V354, P578, DOI 10.1126/science.aaf8933; Penfield W, 1929, ARCH NEURO PSYCHIATR, V22, P358, DOI 10.1001/archneurpsyc.1929.02220020174010; Penfield W, 1954, EPILEPSY FUNCTIONAL, P412; Perkes I, 2010, ANN NEUROL, V68, P126, DOI 10.1002/ana.22066; Perkes IE, 2011, BRAIN INJURY, V25, P925, DOI 10.3109/02699052.2011.589797; Pignolo L, 2012, J REHABIL MED, V44, P502, DOI 10.2340/16501977-0981; Pozzi M, 2015, J HEAD TRAUMA REHAB, V30, P357, DOI 10.1097/HTR.0000000000000084; Pozzi M, 2014, J NEUROTRAUM, V31, P1897, DOI 10.1089/neu.2014.3540; Rabinstein AA, 2008, CURR TREAT OPTION N, V10, P151, DOI 10.1007/s11940-008-0016-y; Rabinstein AA, 2007, NEUROL RES, V29, P680, DOI 10.1179/016164107X240071; Samuel S, 2016, J NEUROSCI NURS, V48, P82, DOI 10.1097/JNN.0000000000000207; Schroeppel TJ, 2014, J TRAUMA ACUTE CARE, V76, P504, DOI 10.1097/TA.0000000000000104; Tang JS, 2009, PROG NEUROBIOL, V89, P383, DOI 10.1016/j.pneurobio.2009.10.002; Verma R, 2015, INDIAN J CRIT CARE M, V19, P34, DOI 10.4103/0972-5229.148638; WELLE S, 1991, METABOLISM, V40, P619, DOI 10.1016/0026-0495(91)90053-Y	60	78	86	3	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2017	16	9					721	729		10.1016/S1474-4422(17)30259-4			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FC8ZW	WOS:000407131400013	28816118	Green Submitted			2022-02-06	
J	Vestberg, T; Reinebo, G; Maurex, L; Ingvar, M; Petrovic, P				Vestberg, Torbjorn; Reinebo, Gustaf; Maurex, Liselotte; Ingvar, Martin; Petrovic, Predrag			Core executive functions are associated with success in young elite soccer players	PLOS ONE			English	Article							LATENT VARIABLE ANALYSIS; WORKING-MEMORY; PROGRESSIVE MATRICES; COGNITIVE CONTROL; FUNCTION SYSTEM; LATE CHILDHOOD; SKILLS; ANTICIPATION; INFORMATION; ACQUISITION	Physical capacity and coordination cannot alone predict success in team sports such as soccer. Instead, more focus has been directed towards the importance of cognitive abilities, and it has been suggested that executive functions (EF) are fundamentally important for success in soccer. However, executive functions are going through a steep development from adolescence to adulthood. Moreover, more complex EF involving manipulation of information (higher level EF) develop later than simple executive functions such as those linked to simple working memory capacity (Core EF). The link between EF and success in young soccer players is therefore not obvious. In the present study we investigated whether EF are associated with success in soccer in young elite soccer players. We performed tests measuring core EF (a demanding working memory task involving a variable n-back task; dWM) and higher level EF (Design Fluency test; DF). Color-Word Interference Test and Trail Making Test were performed on an exploratory level as they contain a linguistic element. The lower level EF test (dWM) was taken from CogStateSport computerized concussion testing and the higher level EF test (DF) was from Delis-Kaplan Executive Function System test battery (D-KEFS). In a group of young elite soccer players (n = 30; aged 12-19 years) we show that they perform better than the norm in both the dWM (+0.49 SD) and DF (+0.86 SD). Moreover, we could show that both dWM and DF correlate with the number of goals the players perform during the season. The effect was more prominent for dWM (r=0.437) than for DF (r=0.349), but strongest for a combined measurement (r= 0.550). The effect was still present when we controlled for intelligence, length and age in a partial correlation analysis. Thus, our study suggests that both core and higher level EF may predict success in soccer also in young players.	[Vestberg, Torbjorn; Reinebo, Gustaf; Maurex, Liselotte; Ingvar, Martin; Petrovic, Predrag] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden		Vestberg, T (corresponding author), Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden.	Torbjorn.vestberg@ki.se	Petrovic, Predrag/AAS-6736-2020	Petrovic, Predrag/0000-0002-5536-945X; Ingvar, Martin/0000-0002-9041-5714; Reinebo, Gustaf/0000-0001-8444-8686; Vestberg, Torbjorn/0000-0003-0523-6621	PRIMA Barnoch Vuxenpsykiatri AB; Karolinska InstitutetKarolinska Institutet	TV received funding from PRIMA Barnoch Vuxenpsykiatri AB [http://primapsykiatn.sen page td=237]. PP received funding from the Karolinska Institutet [http://ki.seistart]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABERNETHY B, 1989, CAN J SPORT SCI, V14, P27; Abernethy B, 2001, PERCEPTION, V30, P233, DOI 10.1068/p2872; Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; Barkley RA., 2012, EXECUTIVE FUNCTIONS; Best JR, 2010, CHILD DEV, V81, P1641, DOI 10.1111/j.1467-8624.2010.01499.x; Bunge SA, 2002, NEURON, V33, P301, DOI 10.1016/S0896-6273(01)00583-9; Chan RCK, 2008, ARCH CLIN NEUROPSYCH, V23, P201, DOI 10.1016/j.acn.2007.08.010; Cieslik EC, 2015, NEUROSCI BIOBEHAV R, V48, P22, DOI 10.1016/j.neubiorev.2014.11.003; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Constantinidis C, 2016, NAT REV NEUROSCI, V17, P438, DOI 10.1038/nrn.2016.43; Crone EA, 2006, P NATL ACAD SCI USA, V103, P9315, DOI 10.1073/pnas.0510088103; Davidson MC, 2006, NEUROPSYCHOLOGIA, V44, P2037, DOI 10.1016/j.neuropsychologia.2006.02.006; De Luca CR, 2003, J CLIN EXP NEUROPSYC, V25, P242, DOI 10.1076/jcen.25.2.242.13639; Delis DC., 2001, DELIS KAPLAN EXECUTI; Diamond A, 2013, ANNU REV PSYCHOL, V64, P135, DOI 10.1146/annurev-psych-113011-143750; Farrow D, 2002, J SPORT SCI, V20, P471, DOI 10.1080/02640410252925143; Faubert J, 2013, SCI REP-UK, V3, DOI 10.1038/srep01154; Faubert J, 2012, J CLIN SPORT PSYCHOL, V6, P85, DOI 10.1123/jcsp.6.1.85; Friedman NP, 2008, J EXP PSYCHOL GEN, V137, P201, DOI 10.1037/0096-3445.137.2.201; Friedman NP, 2006, PSYCHOL SCI, V17, P172, DOI 10.1111/j.1467-9280.2006.01681.x; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Goldstein S., 2014, HDB EXECUTIVE FUNCTI; Homack S, 2005, J CLIN EXP NEUROPSYC, V27, P599, DOI 10.1080/13803390490918444; Hopwood MJ, 2011, INT J SPORTS SCI COA, V6, P523, DOI 10.1260/1747-9541.6.4.523; Huijgen BCH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144580; Huizinga M, 2006, NEUROPSYCHOLOGIA, V44, P2017, DOI 10.1016/j.neuropsychologia.2006.01.010; Karbach J, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00390; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; Luciana M, 2005, CHILD DEV, V76, P697, DOI 10.1111/j.1467-8624.2005.00872.x; Luna B, 2004, CHILD DEV, V75, P1357, DOI 10.1111/j.1467-8624.2004.00745.x; Lundgren T, 2016, J CLIN SPOR IN PRESS; Mackintosh NJ, 2005, INTELLIGENCE, V33, P663, DOI 10.1016/j.intell.2005.03.004; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Murgia M, 2014, PSYCHOL SPORT EXERC, V15, P642, DOI 10.1016/j.psychsport.2014.07.009; Parsons B, 2016, CLIN EEG NEUROSCI, V47, P37, DOI 10.1177/1550059414563746; Petrovic P, 2016, FRONT BEHAV NEUROSCI, V10, DOI 10.3389/fnbeh.2016.00070; Pind J, 2003, PERS INDIV DIFFER, V34, P375, DOI 10.1016/S0191-8869(02)00058-2; Raven J, 2000, COGNITIVE PSYCHOL, V41, P1, DOI 10.1006/cogp.1999.0735; Raven J, 1998, MANUAL RAVENS PROGR; Ryu D, 2013, RES Q EXERCISE SPORT, V84, P252, DOI 10.1080/02701367.2013.784843; Savelsbergh GJP, 2010, INT J SPORT PSYCHOL, V41, P24; Shim J, 2005, J MOTOR BEHAV, V37, P164, DOI 10.3200/JMBR.37.2.164-175; Shipstead Z, 2012, PSYCHOL BULL, V138, P628, DOI 10.1037/a0027473; Shunk AW., 2006, APPL NEUROPSYCHOLOGY, V13, P275, DOI [DOI 10.1207/S15324826AN1304_9, DOI 10.1207/S15324826AN1304_]; Stratton G., 2004, YOUTH SOCCER SCI PER; Straume-Naesheim TM, 2005, BRIT J SPORT MED, V39, pI64, DOI 10.1136/bjsm.2005.019620; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Stuss DT, 2011, CURR OPIN NEUROL, V24, P584, DOI 10.1097/WCO.0b013e32834c7eb9; Swanson J, 2005, CAN J SCH PSYCHOL, V20, P117, DOI 10.1177/0829573506295469; Toga AW, 2006, TRENDS NEUROSCI, V29, P148, DOI 10.1016/j.tins.2006.01.007; Verburgh L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091254; Vestberg T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034731; Williams AM, 2005, J SPORT SCI, V23, P637, DOI 10.1080/02640410400021328	53	78	78	5	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 8	2017	12	2							e0170845	10.1371/journal.pone.0170845			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EK1UY	WOS:000393712500016	28178738	gold, Green Published, Green Submitted			2022-02-06	
J	Hickman, RA; Faustin, A; Wisniewski, T				Hickman, Richard A.; Faustin, Arline; Wisniewski, Thomas			Alzheimer Disease and Its Growing Epidemic Risk Factors, Biomarkers, and the Urgent Need for Therapeutics	NEUROLOGIC CLINICS			English	Article						Alzheimer disease; Risk factors; Biomarkers; Epidemiology	TRAUMATIC BRAIN-INJURY; MILD COGNITIVE IMPAIRMENT; AMYLOID-BETA PLAQUES; APOLIPOPROTEIN-E; HEAD-INJURY; A-BETA; DIABETES-MELLITUS; CARDIOVASCULAR-DISEASE; NATIONAL INSTITUTE; GLOBAL PREVALENCE	Alzheimer disease (AD) represents one of the greatest medical challenges of this century; the condition is becoming increasingly prevalent worldwide and no effective treatments have been developed for this terminal disease. Because the disease manifests at a late stage after a long period of clinically silent neurodegeneration, knowledge of the modifiable risk factors and the implementation of biomarkers is crucial in the primary prevention of the disease and presymptomatic detection of AD, respectively. This article discusses the growing epidemic of AD and antecedent risk factors in the disease process. Disease biomarkers are discussed, and the implications that this may have for the treatment of this currently incurable disease.	[Hickman, Richard A.] NYU, Dept Pathol, Sch Med, Alexandria ERSP, 450 East 29th St, New York, NY 10016 USA; [Faustin, Arline; Wisniewski, Thomas] NYU, Dept Pathol, Sch Med, Ctr Cognit Neurol,Alexandria ERSP, 450 East 29th St, New York, NY 10016 USA; [Faustin, Arline; Wisniewski, Thomas] NYU, Dept Neurol, Sch Med, Ctr Cognit Neurol,Alexandria ERSP, 450 East 29th St, New York, NY 10016 USA; [Wisniewski, Thomas] NYU, Dept Psychiat, Sch Med, Ctr Cognit Neurol,Alexandria ERSP, 450 East 29th St, New York, NY 10016 USA		Wisniewski, T (corresponding author), NYU, Dept Neurol, Sch Med, Ctr Cognit Neurol,Alexandria ERSP, 450 East 29th St, New York, NY 10016 USA.	Thomas.wisniewski@nyumc.org	Hickman, Richard/ABG-4042-2021; Wisniewski, Thomas/Q-6525-2019	Hickman, Richard/0000-0002-8329-6083; Wisniewski, Thomas/0000-0002-3379-8966	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG08051, AG20245, NS073502]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS073502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG020245, P30AG008051] Funding Source: NIH RePORTER	NIH: AG08051; AG20245; NS073502.	Abbott RD, 2004, JAMA-J AM MED ASSOC, V292, P1447, DOI 10.1001/jama.292.12.1447; Akbaraly TN, 2009, NEUROLOGY, V73, P854, DOI 10.1212/WNL.0b013e3181b7849b; Alzheimer's Association, 2006, EARL ONS DEM NAT CHA; Alzheimers Assoc, 2015, ALZHEIMERS DEMENT, V11, P332, DOI 10.1016/j.jalz.2015.02.003; [Anonymous], 1997, Neurobiol Aging, V18, pS1; Arvanitakis Z, 2004, ARCH NEUROL-CHICAGO, V61, P661, DOI 10.1001/archneur.61.5.661; BACHMAN DL, 1993, NEUROLOGY, V43, P515, DOI 10.1212/WNL.43.3_Part_1.515; Bayer TA, 1999, MOL PSYCHIATR, V4, P524, DOI 10.1038/sj.mp.4000552; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; Blennow K, 2006, LANCET, V368, P387, DOI 10.1016/S0140-6736(06)69113-7; Bloudek LM, 2011, J ALZHEIMERS DIS, V26, P627, DOI 10.3233/JAD-2011-110458; BRETELER MMB, 1994, BRIT MED J, V308, P1604, DOI 10.1136/bmj.308.6944.1604; Brier MR, 2016, NEUROBIOL AGING, V38, P104, DOI 10.1016/j.neurobiolaging.2015.10.025; Brookmeyer R, 2007, ALZHEIMERS DEMENT, V3, P186, DOI 10.1016/j.jalz.2007.04.381; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bu GJ, 2009, NAT REV NEUROSCI, V10, P333, DOI 10.1038/nrn2620; Carlson MC, 2008, ALZHEIMERS DEMENT, V4, P324, DOI 10.1016/j.jalz.2008.07.002; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; CLINTON J, 1993, NEUROPATH APPL NEURO, V19, P277, DOI 10.1111/j.1365-2990.1993.tb00438.x; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Cribbs DH, 1996, NEUROREPORT, V7, P1773, DOI 10.1097/00001756-199607290-00016; Deane R, 2008, CURR PHARM DESIGN, V14, P1601, DOI 10.2174/138161208784705487; Deary IJ, 2004, PSYCHOL AGING, V19, P367, DOI 10.1037/0882-7974.19.2.367; Di Paolo G, 2011, NAT REV NEUROSCI, V12, P284, DOI 10.1038/nrn3012; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; Edland SD, 2002, ARCH NEUROL-CHICAGO, V59, P1589, DOI 10.1001/archneur.59.10.1589; Eisele YS, 2010, SCIENCE, V330, P980, DOI 10.1126/science.1194516; Engelhart MJ, 2002, NEUROLOGY, V59, P1915, DOI 10.1001/archneur.59.12.1915; Esiri MM, 2007, J PATHOL, V211, P181, DOI 10.1002/path.2089; Esiri MM, 2012, ALZHEIMERS RES THER, V4, DOI 10.1186/alzrt105; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; Fazel S, 2014, JAMA PSYCHIAT, V71, P326, DOI 10.1001/jamapsychiatry.2013.3935; Ferguson PL, 2010, EPILEPSIA, V51, P891, DOI 10.1111/j.1528-1167.2009.02384.x; Ferri CP, 2005, LANCET, V366, P2112, DOI 10.1016/S0140-6736(05)67889-0; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Fratiglioni L, 2004, LANCET NEUROL, V3, P343, DOI 10.1016/S1474-4422(04)00767-7; Fratiglioni L, 2007, J ALZHEIMERS DIS, V12, P11; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Groot C, 2016, AGEING RES REV, V25, P13, DOI 10.1016/j.arr.2015.11.005; Guerreiro R, 2013, NEW ENGL J MED, V368, P117, DOI 10.1056/NEJMoa1211851; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; Hartley D, 2015, ALZHEIMERS DEMENT, V11, P700, DOI 10.1016/j.jalz.2014.10.007; Hebert LE, 2013, NEUROLOGY, V80, P1778, DOI 10.1212/WNL.0b013e31828726f5; Hellstrom-Lindahl E, 2008, NEUROBIOL AGING, V29, P210, DOI 10.1016/j.neurobiolaging.2006.10.010; Hickman SE, 2008, J NEUROSCI, V28, P8354, DOI 10.1523/JNEUROSCI.0616-08.2008; Holtzman DM, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006312; Irwin DJ, 2013, JAMA NEUROL, V70, P462, DOI 10.1001/jamaneurol.2013.1933; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; Jack CR, 2011, ALZHEIMERS DEMENT, V7, P257, DOI 10.1016/j.jalz.2011.03.004; Jack CR, 2010, LANCET NEUROL, V9, P119, DOI 10.1016/S1474-4422(09)70299-6; James OG, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00038; Jaunmuktane Z, 2015, NATURE, V525, P247, DOI 10.1038/nature15369; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2009, J NEUROTRAUM, V26, P1197, DOI [10.1089/neu.2008.0843, 10.1089/neu.2008-0843]; Jonsson T, 2012, NATURE, V488, P96, DOI 10.1038/nature11283; Kalaria RN, 2008, LANCET NEUROL, V7, P812, DOI 10.1016/S1474-4422(08)70169-8; Kalaria RN, 2010, NUTR REV, V68, pS74, DOI 10.1111/j.1753-4887.2010.00352.x; Kalmijn S, 1997, ANN NEUROL, V42, P776, DOI 10.1002/ana.410420514; Karch CM, 2015, BIOL PSYCHIAT, V77, P43, DOI 10.1016/j.biopsych.2014.05.006; Kivipelto M, 2001, NEUROLOGY, V56, P1683, DOI 10.1212/WNL.56.12.1683; Kopits IM, 2011, GENET TEST MOL BIOMA, V15, P871, DOI 10.1089/gtmb.2011.0028; Kuller LH, 1998, STROKE, V29, P388, DOI 10.1161/01.STR.29.2.388; Langa KM, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0118-1; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LAUNER LJ, 1995, JAMA-J AM MED ASSOC, V274, P1846, DOI 10.1001/jama.274.23.1846; Leibson C L, 1997, Ann N Y Acad Sci, V826, P422, DOI 10.1111/j.1749-6632.1997.tb48496.x; Luchsinger JA, 2001, AM J EPIDEMIOL, V154, P635, DOI 10.1093/aje/154.7.635; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Martland H., 1928, JAMA-J AM MED ASSOC, V91, P1103, DOI DOI 10.1001/JAMA.1928.02700150029009; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mattson MP, 2004, TRENDS NEUROSCI, V27, P589, DOI 10.1016/j.tins.2004.08.001; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Nadler Y, 2008, GLIA, V56, P552, DOI 10.1002/glia.20638; Nelson PT, 2012, J NEUROPATH EXP NEUR, V71, P362, DOI 10.1097/NEN.0b013e31825018f7; Neumann PJ, 2012, HEALTH ECON, V21, P238, DOI 10.1002/hec.1704; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Ott A, 1999, NEUROLOGY, V53, P1937, DOI 10.1212/WNL.53.9.1937; OTT A, 1995, BRIT MED J, V310, P970, DOI 10.1136/bmj.310.6985.970; Pierce JES, 1996, J NEUROSCI, V16, P1083; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Potter Huntington, 2012, Int J Alzheimers Dis, V2012, P489428, DOI 10.1155/2012/489428; Prince M, 2015, ALZHEIMERS DIS INT W; Prince M, 2013, ALZHEIMERS DEMENT, V9, P63, DOI 10.1016/j.jalz.2012.11.007; Prusiner SB, 2013, ANNU REV GENET, V47, P601, DOI 10.1146/annurev-genet-110711-155524; Raber J, 2004, NEUROBIOL AGING, V25, P641, DOI 10.1016/j.neurobiolaging.2003.12.023; Rajagopalan P, 2013, NEW ENGL J MED, V369, P1565, DOI 10.1056/NEJMc1306509; Reitz C, 2011, NAT REV NEUROL, V7, P137, DOI [10.1038/nrneurol.2011.2, 10.1101/cshperspect.a006239]; Roberts RO, 2010, J ALZHEIMERS DIS, V21, P853, DOI 10.3233/JAD-2010-091597; Rohn TT, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/860959; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rovio S, 2005, LANCET NEUROL, V4, P705, DOI 10.1016/S1474-4422(05)70198-8; Saito S, 2015, CURR ALZHEIMER RES, V12, P507, DOI 10.2174/1567205012666150530202508; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Spinney L, 2014, NATURE, V510, P26, DOI 10.1038/510026a; Stampfer MJ, 2006, J INTERN MED, V260, P211, DOI 10.1111/j.1365-2796.2006.01687.x; Swan GE, 1998, STROKE, V29, P2334, DOI 10.1161/01.STR.29.11.2334; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; Toledo JB, 2013, ACTA NEUROPATHOL, V126, P659, DOI 10.1007/s00401-013-1151-4; Turner AJ, 2004, ANN NY ACAD SCI, V1035, P1, DOI 10.1196/annals.1332.001; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; Vardarajan BN, 2014, JAMA NEUROL, V71, P315, DOI 10.1001/jamaneurol.2013.5570; Vemuri P, 2010, NEUROLOGY, V75, P143, DOI 10.1212/WNL.0b013e3181e7ca82; Wikler EM, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt206; Wisniewski T, 2015, NEURON, V85, P1162, DOI 10.1016/j.neuron.2014.12.064; Yan P, 2006, J BIOL CHEM, V281, P24566, DOI 10.1074/jbc.M602440200; Yang Z, 2013, NEW ENGL J MED, V369, P489, DOI 10.1056/NEJMc1305541	115	78	86	0	23	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0733-8619	1557-9875		NEUROL CLIN	Neurol. Clin.	NOV	2016	34	4					941	+		10.1016/j.ncl.2016.06.009			14	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	EA3YK	WOS:000386545000010	27720002	Green Accepted			2022-02-06	
J	Talbott, JF; Whetstone, WD; Readdy, WJ; Ferguson, AR; Bresnahan, JC; Saigal, R; Hawryluk, GWJ; Beattie, MS; Mabray, MC; Pan, JZ; Manley, GT; Dhall, SS				Talbott, Jason F.; Whetstone, William D.; Readdy, William J.; Ferguson, Adam R.; Bresnahan, Jacqueline C.; Saigal, Rajiv; Hawryluk, Gregory W. J.; Beattie, Michael S.; Mabray, Marc C.; Pan, Jonathan Z.; Manley, Geoffrey T.; Dhall, Sanjay S.			The Brain and Spinal Injury Center score: a novel, simple, and reproducible method for assessing the severity of acute cervical spinal cord injury with axial T2-weighted MRI findings	JOURNAL OF NEUROSURGERY-SPINE			English	Article						spinal cord injury; MRI; T2; ASIA; contusion; BASIC; trauma	OF-THE-ART; MAGNETIC-RESONANCE; PATHOLOGICAL CORRELATIONS; MOUSE MODEL; TRAUMA; RECOVERY; DEMOGRAPHICS; DAMAGE	OBJECT Previous studies that have evaluated the prognostic value of abnormal changes in signals on T2-weighted MRI scans of an injured spinal cord have focused on the longitudinal extent of this signal abnormality in the sagittal plane. Although the transverse extent of injury and the degree of spared spinal cord white matter have been shown to be important for predicting outcomes in preclinical animal models of spinal cord injury (SCI), surprisingly little is known about the prognostic value of altered T2 relaxivity in humans in the axial plane. METHODS The authors undertook a retrospective chart review of 60 patients who met the inclusion criteria of this study and presented to the authors' Level I trauma center with an acute blunt traumatic cervical SCI. Within 48 hours of admission, all patients underwent MRI examination, which included axial and sagittal T2 images. Neurological symptoms, evaluated with the grades according to the American Spinal Injury Association (ASIA) Impairment Scale (AIS), at the time of admission and at hospital discharge were correlated with MRI findings. Five distinct patterns of intramedullary spinal cord T2 signal abnormality were defined in the axial plane at the injury epicenter. These patterns were assigned ordinal values ranging from 0 to 4, referred to as the Brain and Spinal Injury Center (BASIC) scores, which encompassed the spectrum of SCI severity. RESULTS The BASIC score strongly correlated with neurological symptoms at the time of both hospital admission and discharge. It also distinguished patients initially presenting with complete injury who improved by at least one AIS grade by the time of discharge from those whose injury did not improve. The authors' proposed score was rapid to apply and showed excellent interrater reliability. CONCLUSIONS The authors describe a novel 5-point ordinal MRI score for classifying acute SCIs on the basis of axial T2-weighted imaging. The proposed BASIC score stratifies the SCIs according to the extent of transverse T2 signal abnormality during the acute phase of the injury. The new score improves on current MRI-based prognostic descriptions for SCI by reflecting functionally and anatomically significant patterns of intramedullary T2 signal abnormality in the axial plane.	[Talbott, Jason F.; Mabray, Marc C.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA; [Readdy, William J.; Ferguson, Adam R.; Bresnahan, Jacqueline C.; Saigal, Rajiv; Hawryluk, Gregory W. J.; Beattie, Michael S.; Manley, Geoffrey T.; Dhall, Sanjay S.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Pan, Jonathan Z.] Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA; [Whetstone, William D.] San Francisco Gen Hosp, Dept Emergency Med, San Francisco, CA 94110 USA; [Ferguson, Adam R.; Bresnahan, Jacqueline C.; Saigal, Rajiv; Hawryluk, Gregory W. J.; Beattie, Michael S.; Pan, Jonathan Z.; Manley, Geoffrey T.; Dhall, Sanjay S.] San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA		Dhall, SS (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 505 Parnassus Ave,Rm M-779, San Francisco, CA 94143 USA.	sanjay.dhall@ucsf.edu	Mabray, Marc/AAI-6660-2020	Ferguson, Adam/0000-0001-7102-1608; Mabray, Marc/0000-0001-7355-6833	Department of Defense Congressionally Directed Medical Research Programs award [SC140137]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS067092] Funding Source: NIH RePORTER	Partial support for this study was provided by a Department of Defense Congressionally Directed Medical Research Programs award (SC140137) to Drs. Beattie, Manley, Bresnahan, Whetstone, and Ferguson. Dr. Dhall has received speaker honoraria from DePuy and Globus.	Andreoli Chiara, 2005, Radiol Med, V110, P636; Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; BONDURANT FJ, 1990, SPINE, V15, P161, DOI 10.1097/00007632-199003000-00002; Bozzo A, 2011, J NEUROTRAUM, V28, P1401, DOI 10.1089/neu.2009.1236; BRESNAHAN JC, 1987, EXP NEUROL, V95, P548, DOI 10.1016/0014-4886(87)90299-8; Budde MD, 2008, NMR BIOMED, V21, P589, DOI 10.1002/nbm.1229; Burke DA, 2001, SPINAL CORD, V39, P274, DOI 10.1038/sj.sc.3101158; CHAKERES DW, 1987, AM J NEURORADIOL, V8, P5; Collignon FD, 2002, J NEUROSURG, V96, P29, DOI 10.3171/spi.2002.96.1.0029; Cotler H B, 1988, J Orthop Trauma, V2, P1, DOI 10.1097/00005131-198802000-00001; Flanders AE, 1996, RADIOLOGY, V201, P649, DOI 10.1148/radiology.201.3.8939210; Flanders AE, 1999, AM J NEURORADIOL, V20, P926; GOLDBERG AL, 1988, SKELETAL RADIOL, V17, P89, DOI 10.1007/BF00365133; Gomori J M, 1988, Radiographics, V8, P427; HAYASHI K, 1995, PARAPLEGIA, V33, P212, DOI 10.1038/sc.1995.47; Kelley BJ, 2014, J NEUROTRAUM, V31, P1362, DOI 10.1089/neu.2013.3238; Kim JH, 2007, MAGN RESON MED, V58, P253, DOI 10.1002/mrm.21316; Kim JH, 2010, J NEUROTRAUM, V27, P587, DOI 10.1089/neu.2009.1063; Kulkarni M V, 1988, Radiographics, V8, P1059; KULKARNI MV, 1987, RADIOLOGY, V164, P837, DOI 10.1148/radiology.164.3.3615885; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Loy DN, 2007, J NEUROTRAUM, V24, P979, DOI 10.1089/neu.2006.0253; Machino M, 2011, SPINE, V36, pE1568, DOI 10.1097/BRS.0b013e31821273c0; MARCIELLO MA, 1993, ARCH PHYS MED REHAB, V74, P940; MARTIN D, 1992, NEURORADIOLOGY, V34, P262, DOI 10.1007/BF00588177; Mihai G, 2008, J NEUROTRAUM, V25, P1, DOI 10.1089/neu.2007.0338; Miyanji F, 2007, RADIOLOGY, V243, P820, DOI 10.1148/radiol.2433060583; Nout YS, 2009, CRIT CARE MED, V37, P2160, DOI 10.1097/CCM.0b013e3181a05d41; Pearson K, 1901, PHILOS MAG, V2, P559, DOI 10.1080/14786440109462720; Pouw MH, 2012, SPINAL CORD, V50, P426, DOI 10.1038/sc.2011.168; QUENCER RM, 1992, NEURORADIOLOGY, V34, P85, DOI 10.1007/BF00588148; Ramon S, 1997, SPINAL CORD, V35, P664, DOI 10.1038/sj.sc.3100490; SCHAEFER DM, 1989, SPINE, V14, P1090, DOI 10.1097/00007632-198910000-00011; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Shimada K, 1999, SPINAL CORD, V37, P410, DOI 10.1038/sj.sc.3100858; Spearman C, 1904, AM J PSYCHOL, V15, P201, DOI 10.2307/1412107; Stroman PW, 2014, NEUROIMAGE, V84, P1070, DOI 10.1016/j.neuroimage.2013.04.124; Sun LQ, 2014, SPINAL CORD, V52, P541, DOI 10.1038/sc.2014.60; Thompson C, 2015, J SPINAL CORD MED, V38, P214, DOI 10.1179/2045772314Y.0000000233; Wang MY, 2011, MAGN RESON IMAGING, V29, P365, DOI 10.1016/j.mri.2010.10.016; Wheeler-Kingshott CA, 2014, NEUROIMAGE, V84, P1082, DOI 10.1016/j.neuroimage.2013.07.014; Wilson JR, 2012, J NEUROSURG-SPINE, V17, P11, DOI 10.3171/2012.4.AOSPINE1245	42	78	78	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1547-5654	1547-5646		J NEUROSURG-SPINE	J. Neurosurg.-Spine	OCT	2015	23	4					495	504		10.3171/2015.1.SPINE141033			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	CS1YF	WOS:000361864100016	26161519	Bronze			2022-02-06	
J	Genet, F; Kulina, I; Vaquette, C; Torossian, F; Millard, S; Pettit, AR; Sims, NA; Anginot, A; Guerton, B; Winkler, IG; Barbier, V; Lataillade, JJ; Le Bousse-Kerdiles, MC; Hutmacher, DW; Levesque, JP				Genet, Francois; Kulina, Irina; Vaquette, Cedryck; Torossian, Frederic; Millard, Susan; Pettit, Allison R.; Sims, Natalie A.; Anginot, Adrienne; Guerton, Bernadette; Winkler, Ingrid G.; Barbier, Valerie; Lataillade, Jean-Jacques; Le Bousse-Kerdiles, Marie-Caroline; Hutmacher, Dietmar W.; Levesque, Jean-Pierre			Neurological heterotopic ossification following spinal cord injury is triggered by macrophage-mediated inflammation in muscle	JOURNAL OF PATHOLOGY			English	Article						heterotopic ossification; spinal cord injury; macrophage; inflammation	TRAUMATIC BRAIN-INJURY; RISK-FACTORS; SATELLITE CELLS; STEM-CELLS; PROGRESSIVA; MOUSE; PREVALENCE; DEPLETION; IMPACT; SERUM	Neurological heterotopic ossification (NHO) is the abnormal formation of bone in soft tissues as a consequence of spinal cord or traumatic brain injury. NHO causes pain, ankyloses, vascular and nerve compression and delays rehabilitation in this high-morbidity patient group. The pathological mechanisms leading to NHO remain unknown and consequently there are no therapeutic options to prevent or reduce NHO. Genetically modified mouse models of rare genetic forms of heterotopic ossification (HO) exist, but their relevance to NHO is questionable. Consequently, we developed the first model of spinal cord injury (SCI)-induced NHO in genetically unmodified mice. Formation of NHO, measured by micro-computed tomography, required the combination of both SCI and localized muscular inflammation. Our NHO model faithfully reproduced many clinical features of NHO in SCI patients and both human and mouse NHO tissues contained macrophages. Muscle-derived mesenchymal progenitors underwent osteoblast differentiation in vitro in response to serum from NHO mice without additional exogenous osteogenic stimuli. Substance P was identified as a candidate NHO systemic neuropeptide, as it was significantly elevated in the serum of NHO patients. However, antagonism of substance P receptor in our NHO model only modestly reduced the volume of NHO. In contrast, ablation of phagocytic macrophages with clodronate-loaded liposomes reduced the size of NHO by 90%, supporting the conclusion that NHO is highly dependent on inflammation and phagocytic macrophages in soft tissues. Overall, we have developed the first clinically relevant model of NHO and demonstrated that a combined insult of neurological injury and soft tissue inflammation drives NHO pathophysiology. Copyright (c) 2015 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.	[Genet, Francois; Kulina, Irina; Millard, Susan; Pettit, Allison R.; Winkler, Ingrid G.; Barbier, Valerie; Hutmacher, Dietmar W.; Levesque, Jean-Pierre] Univ Queensland, Mater Res Inst, Blood & Bone Dis Programme, Woolloongabba, Qld 4102, Australia; [Genet, Francois] Hop Raymond Poincare, APHP, Dept Phys Med & Rehabil, CIC IT 1429, Garches, France; [Genet, Francois] Univ Versailles St Quentin Yvelines, END ICAP INSERM U1179, Montigny Le Bretonneux, France; [Kulina, Irina; Levesque, Jean-Pierre] Univ Queensland, Sch Med, Herston, Qld, Australia; [Vaquette, Cedryck] Queensland Univ Technol, Inst Hlth Biomed Innovat, Kelvin Grove, Australia; [Torossian, Frederic; Anginot, Adrienne; Guerton, Bernadette; Lataillade, Jean-Jacques; Le Bousse-Kerdiles, Marie-Caroline] INSERM, U972, Villejuif, France; [Torossian, Frederic; Anginot, Adrienne; Guerton, Bernadette; Le Bousse-Kerdiles, Marie-Caroline] Univ Paris 11, Inst Andre Lwoff, Paris, France; [Sims, Natalie A.] St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; [Lataillade, Jean-Jacques] Ctr Transfus Sanguine Armees, Clamart, France		Levesque, JP (corresponding author), Univ Queensland, Mater Res Inst, Translat Res Inst, Blood & Bone Dis Programme, 37 Kent St, Woolloongabba, Qld 4102, Australia.	jp.levesque@mater.uq.edu.au	Anginot, Adrienne/N-9299-2017; Levesque, Jean-Pierre/C-5426-2011; Pettit, Allison/O-4462-2019; Winkler, Ingrid G/F-3263-2011; Sims, Natalie A/A-7192-2012; Millard, Susan/C-8115-2011; Le Bousse-Kerdiles, Marie-Caroline/Q-4029-2018	Levesque, Jean-Pierre/0000-0002-7299-6025; Pettit, Allison/0000-0003-4707-7892; Winkler, Ingrid G/0000-0001-6026-3572; Sims, Natalie A/0000-0003-1421-8468; Millard, Susan/0000-0003-1738-3362; Le Bousse-Kerdiles, Marie-Caroline/0000-0003-0863-5222; Vaquette, Cedryck/0000-0001-7937-4432; Hutmacher, Dietmar Werner/0000-0001-5678-2134	National Health and Medical Research Council (NHMRC) of AustraliaNational Health and Medical Research Council of Australia [1033736, 1044091]; Mater Foundation; NHMRC Project GrantNational Health and Medical Research Council of Australia; Fondation BNP-Paribas; Assistance Publique - Hopitaux de Paris; Universite de Versailles Saint Quentin; Institut National de la Sante et de la Recherche MedicaleInstitut National de la Sante et de la Recherche Medicale (Inserm); Service de Sante des Armees; Forum for European-Australian Science and Technology Cooperation; IPSENIpsen; MERZ; ALLERGANAbbVieAllergan	IGW and JPL are supported by a Career Development Fellowship (No. 1033736) and a Research Fellowship (No. 1044091), respectively, from the National Health and Medical Research Council (NHMRC) of Australia. This study was supported in part by the Mater Foundation (to JPL), a NHMRC Project Grant (to NAS), Fondation BNP-Paribas (to FG), Assistance Publique - Hopitaux de Paris (to FG), Universite de Versailles Saint Quentin (to FG), Institut National de la Sante et de la Recherche Medicale (to MCLBK), Service de Sante des Armees (to JJL) and travel fellowships from the Forum for European-Australian Science and Technology Cooperation, IPSEN, MERZ and ALLERGAN (to FG).	Alexander KA, 2011, J BONE MINER RES, V26, P1517, DOI 10.1002/jbmr.354; Asakura A, 2001, DIFFERENTIATION, V68, P245, DOI 10.1046/j.1432-0436.2001.680412.x; Aubut JAL, 2011, NEUROREHABILITATION, V28, P151, DOI 10.3233/NRE-2011-0643; Banovac K, 2000, J Spinal Cord Med, V23, P40; BRADLEIGH LH, 1992, ARCH PHYS MED REHAB, V73, P293; Cadosch D, 2010, J BONE JOINT SURG AM, V92A, P645, DOI 10.2106/JBJS.I.00097; Chakkalakal SA, 2012, J BONE MINER RES, V27, P1746, DOI 10.1002/jbmr.1637; Chang MK, 2008, J IMMUNOL, V181, P1232, DOI 10.4049/jimmunol.181.2.1232; Dizdar D, 2013, BRAIN INJURY, V27, P807, DOI 10.3109/02699052.2013.775490; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Forsberg JA, 2009, J BONE JOINT SURG AM, V91A, P1084, DOI 10.2106/JBJS.H.00792; GARRET C, 1991, P NATL ACAD SCI USA, V88, P10208, DOI 10.1073/pnas.88.22.10208; Gautschi OP, 2009, ANZ J SURG, V79, P449, DOI 10.1111/j.1445-2197.2008.04803.x; Genet F, 2009, J BONE JOINT SURG BR, V91B, P1493, DOI 10.1302/0301-620X.91B11.22305; Genet F, 2012, J HEAD TRAUMA REHAB, V27, P443, DOI 10.1097/HTR.0b013e31822b54ba; Genet F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016632; Guihard P, 2012, STEM CELLS, V30, P762, DOI 10.1002/stem.1040; HARAN M, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003321.PUB3; Hruska KA, 2011, ADV CHRONIC KIDNEY D, V18, P98, DOI 10.1053/j.ackd.2011.01.001; Jacobsen RN, 2014, EXP HEMATOL, V42, P547, DOI 10.1016/j.exphem.2014.03.009; Jaovisidha S, 1998, SPINAL CORD, V36, P647, DOI 10.1038/sj.sc.3100701; Kan LX, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/309287; Kan LX, 2004, AM J PATHOL, V165, P1107, DOI 10.1016/S0002-9440(10)63372-X; Mitchell EJ, 2010, J ORTHOP TRAUMA, V24, P530, DOI 10.1097/BOT.0b013e3181ed147b; Mitchell KJ, 2010, NAT CELL BIOL, V12, P257, DOI 10.1038/ncb2025; Montarras D, 2005, SCIENCE, V309, P2064, DOI 10.1126/science.1114758; Muller PA, 2014, CELL, V158, P300, DOI 10.1016/j.cell.2014.04.050; Oishi T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056641; Pirraco RP, 2013, J TISSUE ENG REGEN M, V7, P392, DOI 10.1002/term.535; Raggatt LJ, 2014, AM J PATHOL, V184, P3192, DOI 10.1016/j.ajpath.2014.08.017; Reznik JE, 2014, J MUSCULOSKEL NEURON, V14, P19; RODRIGUEZ GP, 1989, ARCH PHYS MED REHAB, V70, P442, DOI 10.1016/0003-9993(89)90003-8; Salga M, 2015, SKELETAL RADIOL, V44, P233, DOI 10.1007/s00256-014-2003-6; Salisbury E, 2011, J CELL BIOCHEM, V112, P2748, DOI 10.1002/jcb.23225; Schurch B, 1998, SPINAL CORD, V36, P78, DOI 10.1038/sj.sc.3100561; Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783; Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215; STOVER SL, 1991, CLIN ORTHOP RELAT R, P71; van Rooijen N, 2010, METHODS MOL BIOL, V605, P189, DOI 10.1007/978-1-60327-360-2_13; Vanden Bossche L, 2005, J REHABIL MED, V37, P129, DOI 10.1080/16501970510027628; VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83; Wick L, 2005, EUR RADIOL, V15, P1867, DOI 10.1007/s00330-005-2769-y; Winkler IG, 2010, BLOOD, V116, P4815, DOI 10.1182/blood-2009-11-253534	43	78	83	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3417	1096-9896		J PATHOL	J. Pathol.	JUN	2015	236	2					229	240		10.1002/path.4519			12	Oncology; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Pathology	CH8YA	WOS:000354321400011	25712044				2022-02-06	
J	Leddy, JJ; Baker, JG; Merchant, A; Picano, J; Gaile, D; Matuszak, J; Willer, B				Leddy, John J.; Baker, John G.; Merchant, Asim; Picano, John; Gaile, Daniel; Matuszak, Jason; Willer, Barry			Brain or Strain? Symptoms Alone Do Not Distinguish Physiologic Concussion From Cervical/Vestibular Injury	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; cervical; symptoms; vestibular; strain	SPORT-RELATED CONCUSSION; POSTTRAUMATIC HEADACHE; CERVICOGENIC HEADACHE; WHIPLASH; MANAGEMENT; THRESHOLD; DIZZINESS; STATEMENT; DIAGNOSIS; REST	Objective: To compare symptoms in patients with physiologic postconcussion disorder (PCD) versus cervicogenic/vestibular PCD. We hypothesized that most symptoms would not be equivalent. In particular, we hypothesized that cognitive symptoms would be more often associated with physiologic PCD. Design: Retrospective review of symptom reports from patients who completed a 22-item symptom questionnaire. Setting: University-based concussion clinic. Patients: Convenience sample of 128 patients who had symptoms after head injury for more than 3 weeks and who had provocative treadmill exercise testing. Independent Variables: Subjects were classified as either physiologic PCD (abnormal treadmill performance and a normal cervical/vestibular physical examination) or cervicogenic/vestibular PCD (CGV, normal treadmill performance, and an abnormal cervical/vestibular physical examination). Main Outcome Measures: Self-reported symptoms. Univariate and multivariate methods, including t tests, tests of equivalence, a logistic regression model, k-nearest neighbor analysis, multidimensional scaling, and principle components analysis were used to see whether symptoms could distinguish PCD from CGV. Results: None of the statistical methods used to analyze self-reported symptoms was able to adequately distinguish patients with PCD from patients with CGV. Conclusions: Symptoms after head injury, including cognitive symptoms, have traditionally been ascribed to brain injury, but they do not reliably discriminate between physiologic PCD and cervicogenic/vestibular PCD. Clinicians should consider specific testing of exercise tolerance and perform a physical examination of the cervical spine and the vestibular/ocular systems to determine the etiology of postconcussion symptoms.	[Leddy, John J.] SUNY Buffalo, Dept Orthopaed, Buffalo, NY 14214 USA; [Leddy, John J.; Merchant, Asim] SUNY Buffalo, Univ Sports Med, Dept Orthopaed, Buffalo, NY 14214 USA; [Baker, John G.] SUNY Buffalo, Dept Nucl Med & Orthopaed, Buffalo, NY 14214 USA; [Merchant, Asim; Matuszak, Jason] SUNY Buffalo, Dept Family Med, Buffalo, NY 14214 USA; [Picano, John] SUNY Buffalo, Sch Med & Biomed Sci, Buffalo, NY 14214 USA; [Gaile, Daniel] SUNY Buffalo, Dept Biostat, Buffalo, NY 14214 USA; [Willer, Barry] SUNY Buffalo, Dept Psychiat, Buffalo, NY 14214 USA		Leddy, JJ (corresponding author), SUNY Buffalo, Univ Sports Med, 160 Farber Hall, Buffalo, NY 14214 USA.	leddy@buffalo.edu			Robert Rich Family Foundation; Buffalo Sabres Foundation; Program for Understanding Childhood Concussion and Stroke; Ralph C. Wilson Foundation; National Football League Charities	The authors thank the following organizations for financial support of the project described in this article: The Robert Rich Family Foundation, The Buffalo Sabres Foundation, Program for Understanding Childhood Concussion and Stroke, The Ralph C. Wilson Foundation, and the National Football League Charities.	Armstrong B, 2008, SPORTS MED, V38, P101, DOI 10.2165/00007256-200838020-00002; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Barth JT, 2001, J ATHL TRAINING, V36, P253; Bogduk N, 2009, LANCET NEUROL, V8, P959, DOI 10.1016/S1474-4422(09)70209-1; Cooper MT, 2003, CLIN SPORT MED, V22, P427, DOI 10.1016/S0278-5919(02)00110-2; Drottning M, 2002, CEPHALALGIA, V22, P165, DOI 10.1046/j.1468-2982.2002.00315.x; Endo K, 2006, EUR SPINE J, V15, P886, DOI 10.1007/s00586-005-0970-y; Evans RW, 2010, HEADACHE, V50, P716, DOI 10.1111/j.1526-4610.2010.01645.x; Findling O, 2011, GAIT POSTURE, V34, P473, DOI 10.1016/j.gaitpost.2011.06.021; Giza CC, 2001, J ATHL TRAINING, V36, P228; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hynes LM, 2006, BRAIN INJURY, V20, P179, DOI 10.1080/02699050500443707; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Leslie O, 2013, CLIN J SPORT MED, V23, P331, DOI 10.1097/JSM.0b013e318295bbb1; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory P, 2013, BRIT J SPORT MED, V47, P268, DOI 10.1136/bjsports-2013-092247; Obermann M, 2010, HEADACHE, V50, P710, DOI 10.1111/j.1526-4610.2010.01644.x; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; SPITZER WO, 1995, SPINE S8, V20, P1, DOI DOI 10.1097/00007632-199504151-00001; Sturzenegger M, 2008, ACTA NEUROL SCAND, V117, P49, DOI 10.1111/j.1600-0404.2007.00939.x; Taylor AE, 1996, ARCH PHYS MED REHAB, V77, P529, DOI 10.1016/S0003-9993(96)90290-7; Treleaven J, 2011, SPINE, V36, pS211, DOI 10.1097/BRS.0b013e3182387f78; Treleaven J, 2011, MANUAL THER, V16, P252, DOI 10.1016/j.math.2010.11.002; Wellek S., 2010, TESTING STAT HYPOTHE; Whiteside JW, 2006, AM FAM PHYSICIAN, V74, P1357; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Zumsteg D, 2006, CAN J NEUROL SCI, V33, P379, DOI 10.1017/S0317167100005333	37	78	79	0	24	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAY	2015	25	3					237	242		10.1097/JSM.0000000000000128			6	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	CH3EX	WOS:000353911700007	25051194				2022-02-06	
J	Oishi, K; Faria, AV; Hsu, J; Tippett, D; Mori, S; Hillis, AE				Oishi, Kenichi; Faria, Andreia V.; Hsu, John; Tippett, Donna; Mori, Susumu; Hillis, Argye E.			Critical Role of the Right Uncinate Fasciculus in Emotional Empathy	ANNALS OF NEUROLOGY			English	Article							FRONTOTEMPORAL LOBAR DEGENERATION; KLUVER-BUCY-SYNDROME; WHITE-MATTER DAMAGE; ORBITOFRONTAL CORTEX; SOCIAL-BEHAVIOR; BRAIN; DEMENTIA; PAIN; DISEASE; NETWORKS	ObjectiveCommon neurological diseases or injuries that can affect the right hemisphere, including stroke, traumatic brain injury, and frontotemporal dementia, disrupt emotional empathythe ability to share in and make inferences about how other people feel. This impairment negatively impacts social interactions and relationships. Accumulating evidence indicates that emotional empathy depends on coordinated functions of orbitofrontal cortex, anterior insula, anterior cingulate, temporal pole, and amygdala, but few studies have investigated effects of lesions to white matter tracts that connect these structures. We tested the hypothesis that percentage damage to specific white matter tracts connecting these gray matter structures predicts error rate in an emotional empathy task after acute right hemisphere ischemic stroke. MethodsWe used multivariate linear regression with percentage damage to 8 white matter tracts, age, and education as independent variables and error rate on emotional empathy as the dependent variable to test a predictive model of emotional empathy in 30 patients with acute ischemic right hemisphere stroke. ResultsPercentage damage to 8 white matter tracts along with age and education predicted the error rate in emotional empathy, but only percentage damage to the uncinate fasciculus was independently associated with error rate. Participants with right uncinate fasciculus lesions were significantly more impaired than right hemisphere stroke patients without uncinate fasciculus lesions in the emotional empathy task. InterpretationThe right uncinate fasciculus plays an important role in the emotional empathy network. Patients with lesions in this network should be evaluated for empathy, so that deficits can be addressed. ANN NEUROL 2015;77:68-74	[Oishi, Kenichi; Faria, Andreia V.; Hsu, John; Mori, Susumu] Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA; [Tippett, Donna; Hillis, Argye E.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Tippett, Donna; Hillis, Argye E.] Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD USA; [Tippett, Donna] Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA; [Hillis, Argye E.] Johns Hopkins Univ, Dept Cognit Sci, Krieger Sch Arts & Sci, Baltimore, MD 21218 USA		Hillis, AE (corresponding author), Johns Hopkins Univ Hosp, Dept Neurol, Phipps 446,600 North Wolfe St, Baltimore, MD 21287 USA.	argye@JHMI.edu	Oishi, Kenichi/H-1371-2013	Oishi, Kenichi/0000-0002-1200-8611	NIH National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RO1NS47691, R01NS084957]; NIH National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD065955]; Yousem Family Research Fund; American Heart AssociationAmerican Heart Association [12SDG12080169]; NIH National Institute of Biomedical Imaging and BioengineeringUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015909]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD065955] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R03EB014357, P41EB015909] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047691, R01NS084957] Funding Source: NIH RePORTER	This work was supported by the NIH National Institute of Neurological Disorders and Stroke (RO1NS47691, A.E.H.; R01NS084957, S.M.), NIH National Institute of Child Health and Human Development award (R01HD065955, K.O.), Yousem Family Research Fund (K.O.), American Heart Association (12SDG12080169, A.V.F.), and NIH National Institute of Biomedical Imaging and Bioengineering (P41EB015909, S.M.).	Bernhardt BC, 2012, ANNU REV NEUROSCI, V35, P1, DOI 10.1146/annurev-neuro-062111-150536; Borroni B, 2008, REJUV RES, V11, P585, DOI 10.1089/rej.2007.0623; Brunnlieb C, 2013, BRAIN RES, V1499, P29, DOI 10.1016/j.brainres.2013.01.009; Bzdok D, 2012, BRAIN STRUCT FUNCT, V217, P783, DOI 10.1007/s00429-012-0380-y; Chakrabarti B, 2006, SOC NEUROSCI-UK, V1, P364, DOI 10.1080/17470910601041317; Critchley HD, 2009, INT J PSYCHOPHYSIOL, V73, P88, DOI 10.1016/j.ijpsycho.2009.01.012; Decety J, 2011, NEUROPSYCHOLOGIA, V49, P2994, DOI 10.1016/j.neuropsychologia.2011.06.024; Gu XS, 2012, BRAIN, V135, P2726, DOI 10.1093/brain/aws199; Gu XS, 2010, J NEUROSCI, V30, P3739, DOI 10.1523/JNEUROSCI.4844-09.2010; Hetu S, 2012, BRAIN STIMUL, V5, P95, DOI 10.1016/j.brs.2012.03.005; Hillis AE, 2014, BRAIN, V137, P981, DOI 10.1093/brain/awt317; Hurlemann R, 2010, J NEUROSCI, V30, P4999, DOI 10.1523/JNEUROSCI.5538-09.2010; Jabbi M, 2007, NEUROIMAGE, V34, P1744, DOI 10.1016/j.neuroimage.2006.10.032; Kim EJ, 2012, CEREB CORTEX, V22, P251, DOI 10.1093/cercor/bhr004; Kringelbach ML, 2004, PROG NEUROBIOL, V72, P341, DOI 10.1016/j.pneurobio.2004.03.006; Lamm C, 2011, NEUROIMAGE, V54, P2492, DOI 10.1016/j.neuroimage.2010.10.014; LANSKA DJ, 1994, J CHILD NEUROL, V9, P67, DOI 10.1177/088307389400900117; Leigh R, 2013, BRAIN, V136, P2539, DOI 10.1093/brain/awt177; Matsuo K, 2008, NEURORADIOLOGY, V50, P605, DOI 10.1007/s00234-008-0379-5; Max JE, 2012, J AM ACAD CHILD PSY, V51, P1208, DOI 10.1016/j.jaac.2012.08.026; MESULAM MM, 1982, J COMP NEUROL, V212, P1, DOI 10.1002/cne.902120102; Narvid J, 2009, NEUROCASE, V15, P190, DOI 10.1080/13554790802632967; Oishi K, 2009, NEUROIMAGE, V46, P486, DOI 10.1016/j.neuroimage.2009.01.002; Perry RJ, 2001, NEUROCASE, V7, P145, DOI 10.1076/neur.7.2.145.16267; Rankin KP, 2006, BRAIN, V129, P2945, DOI 10.1093/brain/awl254; Rankin KP, 2005, COGN BEHAV NEUROL, V18, P28, DOI 10.1097/01.wnn.0000152225.05377.ab; Ross ED, 2008, BRAIN LANG, V104, P51, DOI 10.1016/j.bandl.2007.04.007; Saito Y, 2009, PEDIATR INT, V51, P736, DOI 10.1111/j.1442-200X.2009.02896.x; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Shamay-Tsoory SG, 2011, NEUROSCIENTIST, V17, P18, DOI 10.1177/1073858410379268; Singer T, 2004, SCIENCE, V303, P1157, DOI 10.1126/science.1093535; Vincent A, 2004, BRAIN, V127, P701, DOI 10.1093/brain/awh077; Viskontas IV, 2007, ANN NY ACAD SCI, V1121, P528, DOI 10.1196/annals.1401.025; Zahn R, 2007, P NATL ACAD SCI USA, V104, P6430, DOI 10.1073/pnas.0607061104; Zahn R, 2009, BRAIN, V132, P604, DOI 10.1093/brain/awn343; Zhang Y, 2009, BRAIN, V132, P2579, DOI 10.1093/brain/awp071	36	78	79	1	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	JAN	2015	77	1					68	74		10.1002/ana.24300			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	AZ7UN	WOS:000348423200008	25377694	hybrid, Green Accepted			2022-02-06	
J	Xiang, HY; Wheeler, KK; Groner, JI; Shi, JX; Haley, KJ				Xiang, Huiyun; Wheeler, Krista Kurz; Groner, Jonathan Ira; Shi, Junxin; Haley, Kathryn Jo			Undertriage of major trauma patients in the US emergency departments	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							CENTER DESIGNATION; GERIATRIC TRAUMA; UNITED-STATES; FIELD TRIAGE; LEVEL I; SURVIVAL ADVANTAGE; AMERICAN-COLLEGE; BRAIN-INJURY; CENTER CARE; CENTERS	Background: There is evidence that regionalized trauma care and appropriate triage of major trauma patients improve patient outcomes. However, the national rate of undertriage and diagnoses of undertriaged patients are unknown. Methods: We used the 2010 Nationwide Emergency Department Sample to estimate the national rate of undertriage, identify the prevalent diagnoses, and conduct a simulation analysis of the capacity increase required for level I and II trauma centers (TCs) to accommodate undertriaged patients. Undertriaged patients were those with major trauma, injury severity score >= 16, who received definitive care at nontrauma centers (NTCs), or level III TCs. The rate of undertriage was calculated with those receiving definitive care at an NTC center or level III center as a fraction of all major trauma patients. Results: The estimated number of major trauma patient discharges in 2010 was 232448. Level of care was known for 197702 major trauma discharges, and 34.0% were undertriaged in emergency departments (EDs). Elderly patients were at a significantly higher risk of being undertriaged. Traumatic brain injury (TBI) was the most common diagnosis, 40.2% of the undertriaged patient diagnoses. To accommodate all undertriaged patients, level I and II TCs nationally would have to increase their capacity by 51.5%. Conclusions: We found that more than one-third of US ED major trauma patients were undertriaged, and more than 40% of undertriaged diagnoses were TBIs. A significant capacity increase at level I and II TCs to accommodate these patients appears not feasible. (C) 2014 Elsevier Inc. All rights reserved.	[Xiang, Huiyun; Wheeler, Krista Kurz; Groner, Jonathan Ira; Shi, Junxin] Nationwide Childrens Hosp, Ctr Injury Res & Policy, Res Inst, Columbus, OH 43205 USA; [Xiang, Huiyun; Groner, Jonathan Ira] Ohio State Univ, Coll Med, Columbus, OH 43210 USA; [Groner, Jonathan Ira; Haley, Kathryn Jo] Nationwide Childrens Hosp, Dept Pediat Surg, Trauma Program, Columbus, OH 43205 USA		Xiang, HY (corresponding author), Nationwide Childrens Hosp, Ctr Injury Res & Policy, Res Inst, 700 Childrens Dr, Columbus, OH 43205 USA.	Huiyun.Xiang@NationwideChildrens.org	Groner, Jonathan/E-3156-2011; Xiang, Huiyun/E-4335-2011		Agency for Healthcare Research and QualityUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [1R03-HS022277]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R03HS022277] Funding Source: NIH RePORTER	Supported by a research grant (Principal investigator: Dr Huiyun Xiang, grant no.: 1R03-HS022277) from the Agency for Healthcare Research and Quality. The authors have no conflicts of interest to report.	American College of Surgeons, 2011, PRER QUEST PRQ; American College of Surgeons Committee on Trauma, 2008, REG TRAUM SYST OPT E; Branas CC, 2005, JAMA-J AM MED ASSOC, V293, P2626, DOI 10.1001/jama.293.21.2626; Calland JF, 2012, J TRAUMA ACUTE CARE, V73, pS345, DOI 10.1097/TA.0b013e318270191f; Celso B, 2006, J TRAUMA, V60, P371, DOI 10.1097/01.ta.0000197916.99629.eb; Centers for Disease Control and Prevention, 2013, NAT CTR INJ PREV CON; Chang DC, 2008, ARCH SURG-CHICAGO, V143, P776, DOI 10.1001/archsurg.143.8.776; Committee on Trauma American College of Surgeons, 2006, RES OPT CAR INJ PAT; Demetriades D, 2006, J AM COLL SURGEONS, V202, P212, DOI 10.1016/j.jamcollsurg.2005.09.027; Demetriades D, 2005, ANN SURG, V242, P512, DOI 10.1097/01.sla.0000184169.73614.09; DuBose JJ, 2008, ARCH SURG-CHICAGO, V143, P1213, DOI 10.1001/archsurg.143.12.1213; Finkelstein EA, 2006, ASS INCIDENCE EC BUR; Gage AM, 2012, J AM COLL SURGEONS, V215, P148, DOI 10.1016/j.jamcollsurg.2012.02.025; Garwe T, 2011, J TRAUMA, V70, P1118, DOI 10.1097/TA.0b013e3181e243b8; Gomez D, 2012, J TRAUMA ACUTE CARE, V73, P1288, DOI 10.1097/TA.0b013e318265cec2; Goodmanson NW, 2012, SURGERY, V152, P668, DOI 10.1016/j.surg.2012.08.017; Haas B, 2009, J AM COLL SURGEONS, V208, P28, DOI 10.1016/j.jamcollsurg.2008.09.004; Hsia RY, 2011, ARCH SURG-CHICAGO, V146, P585, DOI 10.1001/archsurg.2010.311; Kohn MA, 2004, ACAD EMERG MED, V11, P1, DOI 10.1197/S1069-656(03)00578-5; Lehmann R, 2009, ARCH SURG-CHICAGO, V144, P853, DOI 10.1001/archsurg.2009.153; Lehmann R, 2009, AM J SURG, V197, P571, DOI 10.1016/j.amjsurg.2008.12.037; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Mangram AJ, 2012, J TRAUMA ACUTE CARE, V72, P119, DOI 10.1097/TA.0b013e318241f0ba; Mansouri B, 2013, NEUROL SCI, V34, P1933, DOI 10.1007/s10072-013-1410-0; Mohan D, 2013, J TRAUMA ACUTE CARE, V74, P1541, DOI 10.1097/TA.0b013e31828c3f75; Mohan D, 2011, ARCH SURG-CHICAGO, V146, P786, DOI 10.1001/archsurg.2011.43; Nakamura Y, 2012, ANN EMERG MED, V60, P335, DOI 10.1016/j.annemergmed.2012.04.006; Nathens AB, 2004, J TRAUMA, V56, P173, DOI 10.1097/01.TA.0000056159.65396.7C; Newgard CD, 2013, J TRAUMA ACUTE CARE, V74, P1298, DOI 10.1097/TA.0b013e31828b7848; Pracht EE, 2011, J TRAUMA, V71, P69, DOI 10.1097/TA.0b013e31820e82b7; Rivara FP, 2006, J TRAUMA, V61, P949, DOI 10.1097/01.ta.0000219936.72483.6a; Rogers A, 2012, AM SURGEON, V78, P711; Sasser SM, 2012, CTR DIS CONTROL, V61, P1; Scheetz LJ, 2011, PREHOSP EMERG CARE, V15, P83, DOI 10.3109/10903127.2010.514088; Shifflette VK, 2010, J TRAUMA, V69, P88, DOI 10.1097/TA.0b013e3181e291e9; Staudenmayer KL, 2013, J AM COLL SURGEONS, V217, P569, DOI 10.1016/j.jamcollsurg.2013.06.017; Sugerman DE, 2012, J TRAUMA ACUTE CARE, V73, P1491, DOI 10.1097/TA.0b013e3182782675; Tepas JJ, 2000, J TRAUMA, V48, P581, DOI 10.1097/00005373-200004000-00001; Tourtier JP, 2012, J AM COLL SURGEONS, V215, P740, DOI 10.1016/j.jamcollsurg.2012.08.011; Trooskin SZ, 2004, J TRAUMA, V57, P998, DOI 10.1097/01.TA.0000135349.24414.AE; Utter GH, 2006, J TRAUMA, V60, P529, DOI 10.1097/01.ta.0000204022.36214.9e	41	78	78	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	SEP	2014	32	9					997	1004		10.1016/j.ajem.2014.05.038			8	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	AR1AY	WOS:000343312600010	24993680				2022-02-06	
J	Cooney, SJ; Bermudez-Sabogal, SL; Byrnes, KR				Cooney, Sean J.; Bermudez-Sabogal, Sara L.; Byrnes, Kimberly R.			Cellular and temporal expression of NADPH oxidase (NOX) isotypes after brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Animal studies; Models of injury; Oxidative stress; Traumatic brain injury	OXIDATIVE DAMAGE; NITRIC-OXIDE; ACTIVATED MICROGLIA; GENE-EXPRESSION; NEURONAL DEATH; PEROXYNITRITE; INHIBITION; STRESS; RAT; INFLAMMATION	Background: Brain injury results in an increase in the activity of the reactive oxygen species generating NADPH oxidase (NOX) enzymes. Preliminary studies have shown that NOX2, NOX3, and NOX4 are the most prominently expressed NOX isotypes in the brain. However, the cellular and temporal expression profile of these isotypes in the injured and non-injured brain is currently unclear. Methods: Double immunofluorescence for NOX isotypes and brain cell types was performed at acute (24 hours), sub-acute (7 days), and chronic (28 days) time points after controlled cortical impact-induced brain injury or sham-injury in rats. Results: NOX2, NOX3, and NOX4 isotypes were found to be expressed in neurons, astrocytes, and microglia, and this expression was dependent on both cellular source and post-injury time. NOX4 was found in all cell types assessed, while NOX3 was positively identified in neurons only, and NOX2 was identified in microglia and neurons. NOX2 was the most responsive to injury, increasing primarily in microglia in response to injury. Quantitation of this isotype showed a significant increase in NOX2 expression at 24 hours, with reduced expression at 7 days and 28 days post-injury, although expression remained above sham levels at later time points. Cellular confirmation using purified primary or cell line culture demonstrated similar patterns in microglia, astrocytes, and neurons. Further, inhibition of NOX, and more specifically NOX2, reduced pro-inflammatory activity in microglia, demonstrating that NOX is not only up-regulated after stimulation, but may also play a significant role in post-injury neuroinflammation. Conclusions: This study illustrates the expression profiles of NOX isotypes in the brain after injury, and demonstrates that NOX2, and to a lesser extent, NOX4, may be responsible for the majority of oxidative stress observed acutely after traumatic brain injury. These data may provide insight into the design of future therapeutic approaches.	[Cooney, Sean J.; Bermudez-Sabogal, Sara L.; Byrnes, Kimberly R.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA		Byrnes, KR (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	kimberly.byrnes@usuhs.edu		Byrnes, Kimberly/0000-0002-7501-7734	Uniformed Services University Intramural Program; NINDS/NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS073667-01A1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS073667] Funding Source: NIH RePORTER	This work was funded by the Uniformed Services University Intramural Program and the NINDS/NIH (Grant number 1R01NS073667-01A1). The authors would like to thank Ms. Guzal Khayrullina and Ms. Ramona von Leden for technical and editorial assistance.	Ambasta RK, 2004, J BIOL CHEM, V279, P45935, DOI 10.1074/jbc.M406486200; Bao F, 2009, EXP NEUROL, V215, P308, DOI 10.1016/j.expneurol.2008.10.022; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Byrnes KR, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-130; Byrnes KR, 2009, GLIA, V57, P550, DOI 10.1002/glia.20783; Byrnes KR, 2006, GLIA, V53, P420, DOI 10.1002/glia.20295; Carrico KM, 2009, J NEUROTRAUM, V26, P1369, DOI 10.1089/neu.2008-0870; Chen Y, 2007, NAT PROTOC, V2, P1044, DOI 10.1038/nprot.2007.149; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; Choi SH, 2012, J NEUROCHEM, V120, P292, DOI 10.1111/j.1471-4159.2011.07572.x; Cross AR, 2004, BBA-BIOENERGETICS, V1657, P1, DOI 10.1016/j.bbabio.2004.03.008; Csanyi G, 2011, FREE RADICAL BIO MED, V51, P1116, DOI 10.1016/j.freeradbiomed.2011.04.025; Dalgard CL, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00006; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Dugan LL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005518; Faul M, 2010, TRAUMATIC BRAIN INJU; Fischer MT, 2012, BRAIN, V135, P886, DOI 10.1093/brain/aws012; Fleming JC, 2006, BRAIN, V129, P3249, DOI 10.1093/brain/awl296; Ginis I, 1999, AM J PHYSIOL-CELL PH, V276, pC1171, DOI 10.1152/ajpcell.1999.276.5.C1171; Guemez-Gamboa A, 2011, J NEUROPATH EXP NEUR, V70, P1020, DOI 10.1097/NEN.0b013e3182358e4e; Hall ED, 2012, EXP NEUROL, V238, P176, DOI 10.1016/j.expneurol.2012.08.024; Hattori H, 2010, P NATL ACAD SCI USA, V107, P3546, DOI 10.1073/pnas.0914351107; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Jaquet V, 2009, ANTIOXID REDOX SIGN, V11, P2535, DOI 10.1089/ARS.2009.2585; Jiang F, 2011, PHARMACOL REV, V63, P218, DOI 10.1124/pr.110.002980; Jin XM, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0041892, 10.1371/journal.pone.0040637]; Ju KD, 2011, INFLAMM RES, V60, P791, DOI 10.1007/s00011-011-0335-4; Kallenborn-Gerhardt W, 2012, J NEUROSCI, V32, P10136, DOI 10.1523/JNEUROSCI.6227-11.2012; Khanna A, 2013, J NEUROIMMUNOL, V254, P69, DOI 10.1016/j.jneuroim.2012.09.006; Kim D, 2010, P NATL ACAD SCI USA, V107, P14851, DOI 10.1073/pnas.1009926107; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Leto TL, 2009, ANTIOXID REDOX SIGN, V11, P2607, DOI [10.1089/ars.2009.2637, 10.1089/ARS.2009.2637]; Li B, 2008, BRAIN RES, V1226, P199, DOI 10.1016/j.brainres.2008.06.024; Li JR, 2005, P NATL ACAD SCI USA, V102, P9936, DOI 10.1073/pnas.0502552102; Li S, 2011, NEUROSCIENCE, V184, P107, DOI 10.1016/j.neuroscience.2011.04.007; Lin CC, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-35; McCann SK, 2008, J NEUROSCI RES, V86, P2524, DOI 10.1002/jnr.21700; Nakano Y, 2007, BIOCHEM J, V403, P97, DOI 10.1042/BJ20060819; Pajoohesh-Ganji A, 2012, BRAIN RES, V1475, P96, DOI 10.1016/j.brainres.2012.07.058; Pendyala S, 2010, RESP PHYSIOL NEUROBI, V174, P265, DOI 10.1016/j.resp.2010.09.016; Reddy PVB, 2012, NEUROCHEM INT, V61, P807, DOI 10.1016/j.neuint.2011.06.011; Reyes RC, 2012, J NEUROSCI, V32, P12973, DOI 10.1523/JNEUROSCI.1597-12.2012; Savchenko VL, 2013, NEUROTOX RES, V23, P201, DOI 10.1007/s12640-012-9327-6; Simonyi A, 2010, MOL NEUROBIOL, V41, P73, DOI 10.1007/s12035-010-8107-7; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Song SX, 2013, MOL MED REP, V7, P327, DOI 10.3892/mmr.2012.1147; Surace MJ, 2012, CELL MOL LIFE SCI, V69, P2409, DOI 10.1007/s00018-012-1015-4; Takeuchi H, 2005, J BIOL CHEM, V280, P10444, DOI 10.1074/jbc.M413863200; Tang XN, 2008, NEUROSCIENCE, V154, P556, DOI 10.1016/j.neuroscience.2008.03.090; Turtzo LC, 2013, NMR BIOMED, V26, P468, DOI 10.1002/nbm.2886; Vallet P, 2005, NEUROSCIENCE, V132, P233, DOI 10.1016/j.neuroscience.2004.12.038; Vendrov AE, 2010, J BIOL CHEM, V285, P26545, DOI 10.1074/jbc.M110.143917; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029; Wang Q, 2006, BRAIN RES, V1090, P182, DOI 10.1016/j.brainres.2006.03.060; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504	55	78	78	0	11	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	DEC 17	2013	10								155	10.1186/1742-2094-10-155			13	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	282XV	WOS:000329209000001	24344836	Green Published, gold			2022-02-06	
J	Neselius, S; Zetterberg, H; Blennow, K; Randall, J; Wilson, D; Marcusson, J; Brisby, H				Neselius, Sanna; Zetterberg, Henrik; Blennow, Kaj; Randall, Jeffrey; Wilson, David; Marcusson, Jan; Brisby, Helena			Olympic boxing is associated with elevated levels of the neuronal protein tau in plasma	BRAIN INJURY			English	Article						Diffuse axonal injury; head injury; mild brain injury	TRAUMATIC BRAIN-INJURY; FIBRILLARY ACIDIC PROTEIN; CEREBROSPINAL-FLUID; NEUROTROPHIC FACTOR; SERUM; HEAD; S100B; MILD; CONCUSSION; ENCEPHALOPATHY	Objectives: The aim of this study was to investigate if olympic (amateur) boxing is associated with elevation of brain injury biomarkers in peripheral blood compared to controls. Materials and methods: Thirty olympic boxers competing in at least 47 bouts were compared to 25 controls. Blood was collected from the controls at one occasion and from the boxers within 1-6 days after a bout and after a rest period of at least 14 days. Tau concentration in plasma was determined using a novel single molecule ELISA assay and S-100B, glial fibrillary acidic protein, brain-derived neurotrophic factor and amyloid beta 1-42 were determined using standard immunoassays. Results: None of the boxers had been knocked-out during the bout. Plasma-tau was significantly increased in the boxers after a bout compared to controls (mean +/- SD, 2.46 +/- 5.10 vs. 0.79 +/- 0.961 ngL(-1), p = 0.038). The other brain injury markers did not differ between the groups. Plasma-tau decreased significantly in the boxers after a resting period compared to after a bout (p = 0.030). Conclusions: Olympic boxing is associated with elevation of tau in plasma. The repetitive minimal head injury in boxing may lead to axonal injuries that can be diagnosed with a blood test.	[Neselius, Sanna; Brisby, Helena] Sahlgrens Univ Hosp, Dept Orthopaed, S-41345 Gothenburg, Sweden; [Neselius, Sanna; Brisby, Helena] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Gothenburg, Sweden; [Zetterberg, Henrik; Blennow, Kaj] Sahlgrens Univ Hosp, Clin Neurochem Lab, Dept Psychiat & Neurochem, S-41345 Gothenburg, Sweden; [Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Gothenburg, Sweden; [Randall, Jeffrey; Wilson, David] Quanterix Corp, Lexington, MA USA; [Marcusson, Jan] Linkoping Univ Hosp, Dept Geriatr, S-58185 Linkoping, Sweden; [Marcusson, Jan] Linkoping Univ, Inst Clin & Expt Med, S-58183 Linkoping, Sweden		Neselius, S (corresponding author), Sahlgrens Univ Hosp, Dept Orthopaed, S-41345 Gothenburg, Sweden.	sanna.neselius@vgregion.se			Marianne and Marcus Wallenberg Foundation, Sweden; ALF Grants; County Council of Vastra Gotaland, Sweden; Sahlgrenska University Hospital, Gothenburg, Sweden; Gothenburg Medical Society, Sweden; ALF Grants, County Council of Ostergotland, Sweden; The Swedish Research CouncilSwedish Research Council	The authors report no conflicts of interest. This study has been funded by: Marianne and Marcus Wallenberg Foundation, Sweden; ALF Grants, County Council of Vastra Gotaland, Sweden; Sahlgrenska University Hospital, Gothenburg, Sweden; Gothenburg Medical Society, Sweden; ALF Grants, County Council of Ostergotland, Sweden and The Swedish Research Council. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Baird LC, 2010, NEUROSURGERY, V67, P1444, DOI 10.1227/NEU.0b013e3181e5e2cd; Bartsch AJ, 2012, J NEUROSURG, V116, P1070, DOI 10.3171/2011.12.JNS111478; Blennow K, 2006, LANCET, V368, P387, DOI 10.1016/S0140-6736(06)69113-7; Bulut M, 2006, ADV THER, V23, P12, DOI 10.1007/BF02850342; CHARNAS L, 1986, HOSP PRACT, V21, P30; de boussard CN, 2004, BRAIN INJURY, V18, P671, DOI 10.1080/02699050310001646215; Donato R, 2009, BBA-MOL CELL RES, V1793, P1008, DOI 10.1016/j.bbamcr.2008.11.009; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gao X, 2009, J NEUROTRAUM, V26, P1325, DOI [10.1089/neu.2008.0744, 10.1089/neu.2008-0744]; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Graham MR, 2011, INT J IMMUNOPATH PH, V24, P119, DOI 10.1177/039463201102400114; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Jordan BD, 1996, AM J SPORT MED, V24, P704, DOI 10.1177/036354659602400526; KASTE M, 1982, LANCET, V2, P1186; Kavalci C, 2007, AM J EMERG MED, V25, P391, DOI 10.1016/j.ajem.2006.10.008; Kay AD, 2003, J NEUROTRAUM, V20, P943, DOI 10.1089/089771503770195795; Kleindienst A, 2010, ACTA NEUROCHIR SUPPL, V106, P247, DOI 10.1007/978-3-211-98811-4_46; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Korhonen L, 1998, NEUROSCI LETT, V240, P151, DOI 10.1016/S0304-3940(97)00937-3; Kushi H, 2009, J TRAUMA, V66, P298, DOI 10.1097/TA.0b013e3181715dba; Liliang PC, 2010, RESUSCITATION, V81, P1205, DOI 10.1016/j.resuscitation.2010.05.016; Liliang PC, 2010, J SURG RES, V160, P302, DOI 10.1016/j.jss.2008.12.022; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Rissin DM, 2010, NAT BIOTECHNOL, V28, P595, DOI 10.1038/nbt.1641; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wiesmann M, 2010, ACTA NEUROL SCAND, V121, P178, DOI 10.1111/j.1600-0404.2009.01196.x; Zetterberg H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028263; Zetterberg H, 2009, BRAIN INJURY, V23, P723, DOI 10.1080/02699050903120399	40	78	79	0	17	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2013	27	4					425	433		10.3109/02699052.2012.750752			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	117LG	WOS:000316954300007	23473386				2022-02-06	
J	Ahmad, A; Crupi, R; Campolo, M; Genovese, T; Esposito, E; Cuzzocrea, S				Ahmad, Akbar; Crupi, Rosalia; Campolo, Michela; Genovese, Tiziana; Esposito, Emanuela; Cuzzocrea, Salvatore			Absence of TLR4 Reduces Neurovascular Unit and Secondary Inflammatory Process after Traumatic Brain Injury in Mice	PLOS ONE			English	Article							NITRIC-OXIDE-SYNTHASE; TOLL-LIKE RECEPTORS; SPINAL-CORD-INJURY; NF-KAPPA-B; EXPRESSION; NEUROPROTECTION; ACTIVATION; SYSTEM; INHIBITION; RELEASE	Background: Traumatic brain injury (TBI) initiates a neuroinflammatory cascade that contributes to neuronal damage and behavioral impairment. Toll-like receptors (TLRs) are signaling receptors in the innate immune system, although emerging evidence indicates their role in brain injury. We have therefore investigated the role played by TLR4 signaling pathway in the development of mechanisms of secondary inflammatory process in traumatic brain injury (TBI) differ in mice that lack a functional TLR4 signaling pathway. Methods/Principal Findings: Controlled cortical impact injury was performed on TLR4 knockout (KO) mice (C57BL/10ScNJ) and wild-type (WT) mice (C57BL/10ScNJ). TBI outcome was evaluated by determination of infarct volume and assessment of neurological scores. Brains were collected at 24 h after TBI. When compared to WT mice, TLR4 KO mice had lower infarct volumes and better outcomes in neurological and behavioral tests (evaluated by EBST and rotarod test). Mice that lacked TLR4 had minor expression of TBI-induced GFAP, Chymase, Tryptase, IL-1 beta, iNOS, PARP and Nitrotyrosine mediators implicated in brain damage. The translocation of expression of p-JNK, I kappa B-alpha and NF-kappa B pathway were also lower in brains from TLR4 KO mice. When compared to WT mice, resulted in significant augmentation of all the above described parameters. In addition, apoptosis levels in TLR4 KO mice had minor expression of Bax while on the contrary with Bcl-2. Conclusions/Significance: Our results clearly demonstrated that absence of TLR4 reduces the development of neuroinflammation, tissues injury events associated with brain trauma and may play a neuroprotective role in TBI in mice.	[Ahmad, Akbar; Crupi, Rosalia; Campolo, Michela; Genovese, Tiziana; Esposito, Emanuela; Cuzzocrea, Salvatore] Univ Messina, Sch Med, Dept Clin & Expt Med & Pharmacol, Messina, Italy; [Cuzzocrea, Salvatore] Univ Manchester, Manchester, Lancs, England		Cuzzocrea, S (corresponding author), Univ Messina, Sch Med, Dept Clin & Expt Med & Pharmacol, Messina, Italy.	salvator@unime.it	AHMAD, AKBAR/D-6621-2013; Crupi, Rosalia/U-4364-2019; Campolo, Michela/K-6432-2016	AHMAD, AKBAR/0000-0003-4341-0352; Crupi, Rosalia/0000-0002-7629-3132; Cuzzocrea, Salvatore/0000-0001-6131-3690; GENOVESE, Tiziana/0000-0002-3335-7327; Ahmad, Akbar/0000-0003-1841-9670	Department of Clinical and Experimental Medicine and Pharmacology, School of Medicine, Messina, Italy	Funding provided by the Department of Clinical and Experimental Medicine and Pharmacology, School of Medicine, Messina, Italy. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akira S, 2006, CURR TOP MICROBIOL, V311, P1; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Bar-Peled O, 1999, J NEUROSCI RES, V55, P542, DOI 10.1002/(SICI)1097-4547(19990301)55:5<542::AID-JNR2>3.0.CO;2-7; Barcia C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002977; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; Bethea JR, 1998, J NEUROSCI, V18, P3251; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Cao GD, 2002, J NEUROSCI, V22, P5423; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Chvatal A, 2007, J NEUROSCI RES, V85, P260, DOI 10.1002/jnr.21113; Cuzzocrea S, 2001, SHOCK, V16, P51, DOI 10.1097/00024382-200116010-00010; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; Farina C, 2007, TRENDS IMMUNOL, V28, P138, DOI 10.1016/j.it.2007.01.005; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Gahm C, 2006, J NEUROTRAUM, V23, P1343, DOI 10.1089/neu.2006.23.1343; Glezer I, 2007, NEUROSCIENCE, V147, P867, DOI 10.1016/j.neuroscience.2007.02.055; Glezer I, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000310; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Heneka MT, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-22; Hwang D, 2001, FASEB J, V15, P2556, DOI 10.1096/fj.01-0432com; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P378, DOI 10.1038/jcbfm.1995.47; Jin JJ, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-23; Jou I, 2006, AM J PATHOL, V168, P1619, DOI 10.2353/ajpath.2006.050924; Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002; Kielian T, 2006, J NEUROSCI RES, V83, P711, DOI 10.1002/jnr.20767; KOWNATZKI E, 1982, MOL IMMUNOL, V19, P1297, DOI 10.1016/0161-5890(82)90296-6; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; Lee JY, 2005, BIOCHEM PHARMACOL, V70, P1231, DOI 10.1016/j.bcp.2005.07.020; Lehnardt S, 2003, P NATL ACAD SCI USA, V100, P8514, DOI 10.1073/pnas.1432609100; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Mishra BB, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-53; O'Neill LAJ, 2003, BIOCHEM SOC T, V31, P643, DOI 10.1042/bst0310643; Okun E, 2009, BRAIN RES REV, V59, P278, DOI 10.1016/j.brainresrev.2008.09.001; Owens T, 2005, BRAIN RES REV, V48, P178, DOI 10.1016/j.brainresrev.2004.12.007; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Raposo G, 1997, MOL BIOL CELL, V8, P2631, DOI 10.1091/mbc.8.12.2631; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rodriguez JJ, 2009, CELL DEATH DIFFER, V16, P378, DOI 10.1038/cdd.2008.172; Schabitz WR, 1999, STROKE, V30, P427, DOI 10.1161/01.STR.30.2.427; Schomacher M, 2008, BRAIN RES, V1240, P213, DOI 10.1016/j.brainres.2008.09.019; SHEA TB, 1994, BIOTECHNIQUES, V16, P1126; Sirin BH, 2002, ACTA CARDIOL, V57, P279, DOI 10.2143/AC.57.4.2005427; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Tang SC, 2007, P NATL ACAD SCI USA, V104, P13798, DOI 10.1073/pnas.0702553104; Trendelenburg G, 2008, J CEREBR BLOOD F MET, V28, P867, DOI 10.1038/sj.jcbfm.9600609; Vanzani MC, 2005, MEDICINA-BUENOS AIRE, V65, P213; Wilhelmsson U, 2006, P NATL ACAD SCI USA, V103, P17513, DOI 10.1073/pnas.0602841103; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zerfaoui M, 2010, J IMMUNOL, V185, P1894, DOI 10.4049/jimmunol.1000646; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	57	78	85	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2013	8	3							e57208	10.1371/journal.pone.0057208			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121RP	WOS:000317262200001	23555560	gold, Green Submitted, Green Published			2022-02-06	
J	Rojas, JJ; Deniz, BF; Miguel, PM; Diaz, R; Hermel, EES; Achaval, M; Netto, CA; Pereira, LO				Rojas, Joseane Jimenez; Deniz, Bruna Ferrary; Miguel, Patricia Maidana; Diaz, Ramiro; Hermel, Erica do Espirito-Santo; Achaval, Matilde; Netto, Carlos Alexandre; Pereira, Lenir Orlandi			Effects of daily environmental enrichment on behavior and dendritic spine density in hippocampus following neonatal hypoxia-ischemia in the rat	EXPERIMENTAL NEUROLOGY			English	Article						Neonatal hypoxia-ischemia; Environmental enrichment; Dendritic spine density; Behavior; Neuroprotection	POSTERODORSAL MEDIAL AMYGDALA; TRAUMATIC BRAIN-INJURY; LOCOMOTOR-ACTIVITY; COGNITIVE DEFICITS; CEREBRAL-ISCHEMIA; MEMORY DEFICITS; NEURONAL DAMAGE; SEX-DIFFERENCES; FIMBRIA-FORNIX; ESTROUS-CYCLE	Hypoxia-ischemia (HI) is the main cause of mortality in the perinatal period and morbidity, in survivors, which is characterized by neurological disabilities. The immature brain is highly susceptible to hypoxicischemic insult and is responsive to environmental stimuli, such as environmental enrichment (EE). Previous results indicate that EE recovered memory deficits in adult rats without reversing hippocampal atrophy related to HI. The aim of this study was to investigate behavioral performance in the open field and rota-rod apparatuses, in object recognition and inhibitory avoidance tasks, as well as dendritic spine density in the hippocampus, in rats undergoing HI and exposed to EE. Seven-day old male rats were submitted to the HI procedure and divided into 4 groups: control maintained in standard environment (CTSE), controls submitted to EE (CTEE), HI in standard environment (HISE) and HI in EE (HIEE). Behavioral and morphological parameters were evaluated 9 weeks after the environmental stimulation. Results indicate impairment in the object recognition task after HI that was recovered by enrichment; however the aversive memory impairment in the inhibitory avoidance task shown by hypoxic-ischemic rats was independent of the environment condition. Hypoxic-ischemic groups showed more crossing responses during the first minute in the open field, when compared to controls, but no differences were found between experimental groups in the rotarod test. Dendritic spine density in the CA1 subfield of the right hippocampus (ipsilateral to the artery occlusion) was decreased after the HI insult, and increased in enriched controls; interestingly enriched HI rats did not differ from CTSE. In conclusion, EE was effective in recovering declarative memory impairment in object recognition and preserved hippocampal dendritic spine density loss after neonatal HI injury. (c) 2012 Elsevier Inc. All rights reserved.	[Rojas, Joseane Jimenez; Diaz, Ramiro; Hermel, Erica do Espirito-Santo; Achaval, Matilde; Netto, Carlos Alexandre; Pereira, Lenir Orlandi] Univ Fed Rio Grande do Sul, ICBS, Programa Posgrad Neurociencias, BR-90046900 Porto Alegre, RS, Brazil; [Rojas, Joseane Jimenez; Deniz, Bruna Ferrary; Miguel, Patricia Maidana; Diaz, Ramiro; Achaval, Matilde; Pereira, Lenir Orlandi] Univ Fed Rio Grande do Sul, ICBS, Dept Ciencias Morfol, BR-90046900 Porto Alegre, RS, Brazil; [Miguel, Patricia Maidana; Netto, Carlos Alexandre] Univ Fed Rio Grande do Sul, ICBS, Dept Bioquim, BR-90046900 Porto Alegre, RS, Brazil		Pereira, LO (corresponding author), ICBS, Rua Sarmento Leite 500, BR-90050170 Porto Alegre, RS, Brazil.	lenir.orlandi@ufrgs.br	Silva, Lenir/AAN-7475-2020	Pereira, Lenir/0000-0001-5541-0697; Maidana Miguel, Patricia/0000-0001-7427-0159; Netto, Carlos Alexandre/0000-0002-0596-5667	CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); CAPESCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); FAPERGSFundacao de Amparo a Ciencia e Tecnologia do Estado do Rio Grande do Sul (FAPERGS)	We would like to thank the technical assistance given by Ana Paula Maciel Ornaghi. This work was supported by Brazilian funding agencies: CNPq, CAPES and FAPERGS.	Alvarez VA, 2007, ANNU REV NEUROSCI, V30, P79, DOI 10.1146/annurev.neuro.30.051606.094222; Araki H, 1999, PHYSIOL BEHAV, V66, P263, DOI 10.1016/S0031-9384(98)00293-5; Arteni NS, 2010, BEHAV BRAIN RES, V210, P92, DOI 10.1016/j.bbr.2010.02.015; Arteni NS, 2003, BRAIN RES, V973, P171, DOI 10.1016/S0006-8993(03)02436-3; Baker KB, 2004, BEHAV NEUROSCI, V118, P15, DOI 10.1037/0735-7044.118.1.15; Balduini W, 2000, BRAIN RES, V859, P318, DOI 10.1016/S0006-8993(00)01997-1; Benice T., 2005, NEUR 2005 SAT S WASH; Benson DL, 2012, HIPPOCAMPUS, V22, P954, DOI 10.1002/hipo.20872; BERGER TW, 1980, PHYSIOL PSYCHOL, V8, P155; Bezard E, 2003, J NEUROSCI, V23, P10999; Bindu B, 2007, NEUROSCIENCE, V144, P412, DOI 10.1016/j.neuroscience.2006.09.057; Bona E, 1997, PEDIATR RES, V42, P678, DOI 10.1203/00006450-199711000-00021; Brotto LA, 2000, EUR J PHARMACOL, V402, P87, DOI 10.1016/S0014-2999(00)00491-X; Brown CE, 2008, STROKE, V39, P1286, DOI 10.1161/STROKEAHA.107.498238; Brusco J, 2008, NEUROSCI LETT, V438, P346, DOI 10.1016/j.neulet.2008.04.063; Capasso A, 1996, PHYTOTHER RES, V10, P309, DOI 10.1002/(SICI)1099-1573(199606)10:4&lt;309::AID-PTR850&gt;3.0.CO;2-J; Cassel JC, 1998, NEUROBIOL LEARN MEM, V69, P22, DOI 10.1006/nlme.1997.3807; Chavez D.G., 2008, NEUROSCI LETT, V448, P148; Chen JR, 2009, NEUROSCIENCE, V161, P1104, DOI 10.1016/j.neuroscience.2009.04.022; Cheng HW, 1997, EXP NEUROL, V147, P287, DOI 10.1006/exnr.1997.6618; Clark RE, 2005, CURR OPIN NEUROBIOL, V15, P593, DOI 10.1016/j.conb.2005.08.014; COLEMANMESCHES K, 1995, BRAIN RES, V670, P75, DOI 10.1016/0006-8993(94)01272-J; Coutureau E, 2000, EXP BRAIN RES, V131, P381, DOI 10.1007/s002219900301; de Castilhos J, 2006, BRAIN RES BULL, V69, P131, DOI 10.1016/j.brainresbull.2005.11.013; de No RL, 1934, J PSYCHOL NEUROL, V46, P113; de Paula S, 2009, PEDIATR RES, V65, P631, DOI 10.1203/PDR.0b013e31819ed5c8; de Witt BW, 2011, NEUROREHAB NEURAL RE, V25, P343, DOI 10.1177/1545968310390520; Delsing BJP, 2001, PEDIATR NEUROL, V24, P283, DOI 10.1016/S0887-8994(01)00245-4; DIAMOND MC, 1976, J NEUROBIOL, V7, P75, DOI 10.1002/neu.480070108; Diamond MC, 2001, AN ACAD BRAS CIENC, V73, P211, DOI 10.1590/S0001-37652001000200006; Dixon CE, 2003, CRIT CARE MED, V31, P2222, DOI 10.1097/01.CCM.0000080493.04978.73; Dunaevsky A, 1999, P NATL ACAD SCI USA, V96, P13438, DOI 10.1073/pnas.96.23.13438; Fischer M, 1998, NEURON, V20, P847, DOI 10.1016/S0896-6273(00)80467-5; Frick KM, 2003, NEUROBIOL AGING, V24, P615, DOI 10.1016/S0197-4580(02)00138-0; GRAY JA, 1983, NEUROSCI BIOBEHAV R, V7, P119, DOI 10.1016/0149-7634(83)90014-3; GREENOUGH WT, 1973, EXP NEUROL, V41, P371, DOI 10.1016/0014-4886(73)90278-1; Harburger LL, 2007, BEHAV BRAIN RES, V185, P43, DOI 10.1016/j.bbr.2007.07.009; Ikeda T, 2001, BEHAV BRAIN RES, V118, P17, DOI 10.1016/S0166-4328(00)00287-4; Im SH, 2010, NEUROSCIENCE, V169, P259, DOI 10.1016/j.neuroscience.2010.04.038; ITO U, 1975, ACTA NEUROPATHOL, V32, P209, DOI 10.1007/BF00696570; Jadavji NM, 2006, NEUROSCIENCE, V140, P1127, DOI 10.1016/j.neuroscience.2006.03.027; Jankowsky JL, 2005, J NEUROSCI, V25, P5217, DOI 10.1523/JNEUROSCI.5080-04.2005; Jansen EM, 1996, BEHAV BRAIN RES, V78, P189, DOI 10.1016/0166-4328(95)00248-0; Jansen EM, 1996, BRAIN RES, V708, P93, DOI 10.1016/0006-8993(95)01288-5; Johansson BB, 2002, J CEREBR BLOOD F MET, V22, P89, DOI 10.1097/00004647-200201000-00011; Kadam SD, 2009, BEHAV BRAIN RES, V197, P77, DOI 10.1016/j.bbr.2008.08.003; Karasev AV, 2010, B EXP BIOL MED+, V149, P677, DOI 10.1007/s10517-010-1022-0; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kempermann G, 2002, J NEUROSCI, V22, P635, DOI 10.1523/JNEUROSCI.22-03-00635.2002; KIRINO T, 1984, ACTA NEUROPATHOL, V62, P209, DOI 10.1007/BF00691854; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; KOELFEN W, 1995, DEV MED CHILD NEUROL, V37, P204; Kokiko ON, 2007, BRAIN INJURY, V21, P259, DOI 10.1080/02699050701209964; KUROIWA T, 1991, BRAIN RES, V563, P33, DOI 10.1016/0006-8993(91)91511-X; Leggio MG, 2005, BEHAV BRAIN RES, V163, P78, DOI 10.1016/j.bbr.2005.04.009; Leuner B, 2003, J NEUROSCI, V23, P659, DOI 10.1523/JNEUROSCI.23-02-00659.2003; LEVINE S, 1960, AM J PATHOL, V36, P1; Lippman J, 2005, J NEUROBIOL, V64, P47, DOI 10.1002/neu.20149; LIPSKA BK, 1991, PHARMACOL BIOCHEM BE, V40, P181, DOI 10.1016/0091-3057(91)90342-Y; Liu ZY, 2007, STROKE, V38, P146, DOI 10.1161/01.STR.0000251791.64910.cd; Lubics A, 2005, BEHAV BRAIN RES, V157, P157, DOI 10.1016/j.bbr.2004.06.019; Luine VN, 2011, CURR GERONTOL GERIAT, P1, DOI DOI 10.1016/J.NEUROIMAGE.2013.08.017; Marcuzzo S, 2007, NEUROSCI LETT, V424, P16, DOI 10.1016/j.neulet.2007.07.019; Matter AM, 2011, NEUROREHAB NEURAL RE, V25, P558, DOI 10.1177/1545968310397206; MEANEY MJ, 1985, BRAIN RES, V328, P176, DOI 10.1016/0006-8993(85)91340-X; MILESON BE, 1991, NEUROSCI LETT, V128, P71, DOI 10.1016/0304-3940(91)90762-I; Nakamura H, 1999, J NEUROSCI RES, V56, P307; NETTO CA, 1985, BEHAV NEURAL BIOL, V44, P515, DOI 10.1016/S0163-1047(85)91048-9; Nicolelis MAL, 1997, SEMIN NEUROSCI, V9, P24, DOI 10.1006/smns.1997.0103; Nilsson M, 1999, J NEUROBIOL, V39, P569, DOI 10.1002/(SICI)1097-4695(19990615)39:4<569::AID-NEU10>3.0.CO;2-F; Okuda S, 2004, P NATL ACAD SCI USA, V101, P853, DOI 10.1073/pnas.0307803100; Pereira LO, 2007, NEUROBIOL LEARN MEM, V87, P101, DOI 10.1016/j.nlm.2006.07.003; Paxinos G, 2004, RAT BRAIN STEREOTAXI; Pereira LO, 2008, BRAIN RES, V1218, P257, DOI 10.1016/j.brainres.2008.04.010; Pereira LO, 2009, BRAIN RES, V1247, P188, DOI 10.1016/j.brainres.2008.10.017; Pham TM, 2002, PHARMACOL BIOCHEM BE, V73, P167, DOI 10.1016/S0091-3057(02)00783-9; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Rasia-Filho AA, 2004, NEUROSCIENCE, V126, P839, DOI 10.1016/j.neuroscience.2004.04.009; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; Rodrigues AL, 2004, BRAIN RES, V1002, P94, DOI 10.1016/j.brainres.2003.12.020; Ruan YW, 2009, J NEUROSCI RES, V87, P61, DOI 10.1002/jnr.21816; Schlager GW, 2011, EXP NEUROL, V230, P67, DOI 10.1016/j.expneurol.2010.11.021; SHEN Y, 1991, RESTOR NEUROL NEUROS, V3, P11, DOI 10.3233/RNN-1991-3102; Shimada Masahisa, 1997, Acta Anatomica Nipponica, V72, P545; Spandou E, 2005, BRAIN RES, V1045, P22, DOI 10.1016/j.brainres.2005.03.013; Takao K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009460; Ten VS, 2004, STROKE, V35, P2183, DOI 10.1161/01.STR.0000137768.25203.df; Trollmann R, 2009, BRAIN DEV-JPN, V31, P503, DOI 10.1016/j.braindev.2009.03.007; VALLE FP, 1980, B PSYCHONOMIC SOC, V16, P429; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; WANG D, 1990, BRAIN RES, V533, P78, DOI 10.1016/0006-8993(90)91798-L; WIDMAN DR, 1990, PHYSIOL BEHAV, V47, P57, DOI 10.1016/0031-9384(90)90042-3; WOOLLEY CS, 1993, J COMP NEUROL, V336, P293, DOI 10.1002/cne.903360210; WOOLLEY CS, 1990, J NEUROSCI, V10, P4035, DOI 10.1523/JNEUROSCI.10-12-04035.1990; YOUNG RSK, 1986, STROKE, V17, P1313, DOI 10.1161/01.STR.17.6.1313; Ziv NE, 1996, NEURON, V17, P91, DOI 10.1016/S0896-6273(00)80283-4	97	78	86	0	19	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAR	2013	241						25	33		10.1016/j.expneurol.2012.11.026			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	095DV	WOS:000315315800004	23219882	hybrid			2022-02-06	
J	Corrigan, JD; Cuthbert, JP; Whiteneck, GG; Dijkers, MP; Coronado, V; Heinemann, AW; Harrison-Felix, C; Graham, JE				Corrigan, John D.; Cuthbert, Jeffrey P.; Whiteneck, Gale G.; Dijkers, Marcel P.; Coronado, Victor; Heinemann, Allen W.; Harrison-Felix, Cynthia; Graham, James E.			Representativeness of the Traumatic Brain Injury Model Systems National Database	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						craniocerebral trauma; methodology; rehabilitation; traumatic brain injury	FUNCTIONAL INDEPENDENCE MEASURE; INPATIENT REHABILITATION; PROSPECTIVE-PAYMENT; FOLLOW-UP; TBI; HOSPITALIZATION; IMPAIRMENT; DISABILITY; ADULTS	Objective: To determine whether the Traumatic Brain Injury Model Systems National Database (TBIMS-NDB) is representative of individuals aged 16 years and older admitted for acute, inpatient rehabilitation in the United States with a primary diagnosis of traumatic brain injury (TBI). Design: Secondary analysis of existing data sets. Setting: Acute inpatient rehabilitation facilities. Participants: Patients aged 16 years and older with a primary rehabilitation diagnosis of TBI. Main Outcome Measures: Demographic characteristics, functional status, and hospital length of stay. Results: Patients included in the TBIMS-NDB from October 2001 through December 2007 were largely representative of all individuals 16 years and older admitted for rehabilitation in the United States with a primary diagnosis of TBI. The major difference in distribution was age-the TBIMS-NDB cohort did not include as large a proportion of patients older than 65 years as were admitted for rehabilitation with a primary diagnosis of TBI in the United States. Distributional differences for age-related characteristics were observed; however, groups of patients partitioned at aged 65 years differed minimally, especially within the younger than 65 years subset. Regardless of age, the proportion of patients with a rehabilitation stay of 1 to 9 days was larger nationwide. Nationwide admissions showed an age distribution similar to patients discharged alive from acute care with moderate, severe or penetrating TBI. The proportion of patients aged 70 years and older admitted for TBI rehabilitation in the United States increased every year, a trend that was not evident in the general population, TBIMS-NDB or among TBI patients in acute care. Conclusions: These results provide substantial empirical evidence that the TBIMS-NDB is representative of patients receiving inpatient rehabilitation for TBI in the United States. Researchers utilizing the TBIMS-NDB may want to adjust statistically for the lower percentage of patients older than 65 years or those with stays less than 10 days.	[Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Cuthbert, Jeffrey P.; Whiteneck, Gale G.; Harrison-Felix, Cynthia] Craig Hosp, Res Dept, Englewood, CO USA; [Dijkers, Marcel P.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA; [Coronado, Victor] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA; [Heinemann, Allen W.] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; [Heinemann, Allen W.] Rehabil Inst Chicago, Chicago, IL 60611 USA; [Graham, James E.] Univ Texas Med Branch, Div Rehabil Sci, Galveston, TX USA		Corrigan, JD (corresponding author), Ohio State Univ, Dept Phys Med & Rehabil, 480 Med Ctr Dr, Columbus, OH 43210 USA.	corrigan.1@osu.edu	Heinemann, Allen W/K-6283-2012; Heinemann, Allen W./AAI-2790-2021; Corrigan, John D./E-2921-2011	Heinemann, Allen W/0000-0003-2782-7326; Heinemann, Allen W./0000-0003-2782-7326; Dijkers, Marcel/0000-0002-8362-5596	National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services; US Department of EducationUS Department of Education [H133A060038]; TBI Model System Center grants [H133A070022]; Ohio State UniversityOhio State University [H133A070029]; Mount Sinai School of Medicine [H133A070033]; Rehabilitation Institute of Chicago [H133A080045]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD065702] Funding Source: NIH RePORTER	This research was supported by supplemental grant funding to the Traumatic Brain Injury Model Systems National Data and Statistical Center from the National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, US Department of Education (grant no. H133A060038), as well as TBI Model System Center grants to Craig Hospital (H133A070022), Ohio State University (H133A070029), Mount Sinai School of Medicine (H133A070033), and the Rehabilitation Institute of Chicago (H133A080045). However, the contents do not necessarily represent the policy of the Department of Education, and the reader should not assume endorsement by the Federal Government. This article does not reflect the official policy or opinions of the Centers for Disease Control and Prevention (CDC) or the US Department of Health and Human Services (HHS) and does not constitute an endorsement of the individuals or their programs-by CDC, HHS, or other components of the federal government-and none should be inferred. No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit upon the authors or upon any organization with which the authors are associated.	Braddom RL, 2005, ARCH PHYS MED REHAB, V86, P1287, DOI 10.1016/j.apmr.2005.01.004; Center for Medicare & Medicaid Services, INP REH FAC PAT ASS; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P418, DOI 10.1016/j.apmr.2007.01.010; Cuthbert JP, 2011, ARCH PHYS MED REHAB, V92, P721, DOI 10.1016/j.apmr.2010.12.023; Department of Health and Human Services. Centers for Medicare & Medicaid Services. Medicare Program, MED PROGR INP REH FA; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; Dijkers MPJM, 2010, LOW COST NO COST STE; Granger CV, 2007, AM J PHYS MED REHAB, V86, P883, DOI 10.1097/PHM.0b013e318152058a; Granger CV, 2010, AM J PHYS MED REHAB, V89, P265, DOI 10.1097/PHM.0b013e3181d3eb20; Gundling R L, 2001, Healthc Financ Manage, V55, P72; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Mallinson TR, 2008, ARCH PHYS MED REHAB, V89, P2066, DOI 10.1016/j.apmr.2008.05.014; Marr A., 2004, CENTRAL NERVOUS SYST; National Center for Injury Prevention and Control Centers for Disease Control and Prevention, 2010, NAT HOSP DISCH SURV; Pickelsimer EE, 2006, J HEAD TRAUMA REHAB, V21, P491, DOI 10.1097/00001199-200611000-00004; Sarmiento K, 2008, J HEAD TRAUMA REHAB, V23, P164, DOI 10.1097/01.HTR.0000319933.22709.61; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Stineman MG, 2002, ARCH PHYS MED REHAB, V83, P1802, DOI 10.1053/apmr.2002.36067; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; TBI Model Systems National Data and Statistical Center, TRAUM BRAIN INJ MOD; U.S. Census Bureau, 2000, NCEST200901 US CENS; Whiteneck G, 2001, COLORADO TRAUMATIC B	24	78	78	1	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2012	27	6					391	403		10.1097/HTR.0b013e3182238cdd			13	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	039CU	WOS:000311221200010	21897288	Green Accepted			2022-02-06	
J	Bitner, BR; Marcano, DC; Berlin, JM; Fabian, RH; Cherian, L; Culver, JC; Dickinson, ME; Robertson, CS; Pautler, RG; Kent, TA; Tour, JM				Bitner, Brittany R.; Marcano, Daniela C.; Berlin, Jacob M.; Fabian, Roderic H.; Cherian, Leela; Culver, James C.; Dickinson, Mary E.; Robertson, Claudia S.; Pautler, Robia G.; Kent, Thomas A.; Tour, James M.			Antioxidant Carbon Particles Improve Cerebrovascular Dysfunction Following Traumatic Brain Injury	ACS NANO			English	Article						traumatic brain injury; cerebral blood flow; antioxidants; hydrophilic carbon clusters; nanoparticles	IN-VIVO; SUPEROXIDE-DISMUTASE; OXIDE NANOPARTICLES; OXIDATIVE STRESS; GRAPHENE OXIDE; NITRIC-OXIDE; RAT MODEL; CELLS; DRUG; CARBOXYFULLERENES	Injury to the neurovasculature is a feature of brain injury and must be addressed to maximize opportunity for improvement. Cerebrovascular dysfunction, manifested by reduction in cerebral blood flow (CBF), is a key factor that worsens outcome after traumatic brain injury (TBI), most notably under conditions of hypotension. We report here that a new class of antioxidants, poly(ethylene glycol)-functionalized hydrophilic carbon dusters (PEG-HCCs), which are nontoxic carbon particles, rapidly restore CBF in a mild TBI/hypotension/resuscitation rat model when administered during resuscitation-a clinically relevant time point. Along with restoration of CBE, there is a concomitant normalization of superoxide and nitric oxide levels. Given the role of poor CBF in determining outcome, this finding is of major importance for improving patient health under clinically relevant conditions during resuscitative care, and it has direct implications for the current TBI/hypotension war-fighter victims in the Afghanistan and Middle East theaters. The results also have relevancy in other related acute circumstances such as stroke and organ transplantation.	[Bitner, Brittany R.; Dickinson, Mary E.; Pautler, Robia G.; Kent, Thomas A.] Baylor Coll Med, Interdept Program Translat Biol & Mol Med, Houston, TX 77030 USA; [Bitner, Brittany R.; Culver, James C.; Dickinson, Mary E.; Pautler, Robia G.] Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; [Marcano, Daniela C.; Berlin, Jacob M.; Tour, James M.] Rice Univ, Dept Chem, Houston, TX 77005 USA; [Marcano, Daniela C.; Berlin, Jacob M.; Tour, James M.] Rice Univ, Smalley Inst Nanoscale Sci & Technol, Houston, TX 77005 USA; [Fabian, Roderic H.; Cherian, Leela; Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Fabian, Roderic H.; Kent, Thomas A.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Kent, Thomas A.] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA		Kent, TA (corresponding author), Baylor Coll Med, Interdept Program Translat Biol & Mol Med, 1 Baylor Plaza, Houston, TX 77030 USA.	tkent@bcm.edu; tour@rice.edu	Nanozymes, Nanozymes/D-8197-2019	Kent, Thomas/0000-0002-9877-7584; Marcano, Daniela C./0000-0002-3446-8010; Tour, James/0000-0002-8479-9328	Mission Connect Mild Traumatic Brain Injury Consortium; Department of DefenseUnited States Department of Defense [W81XWH-08-2-0141, W81XWH-08-2-0143, W81XWH-08-2-0132]; Alliance for NanoHealth through University of Texas Health Science Center, Houston (Department of Defense) [W8XWH-07-2-0101]; Nanoscale Science and Engineering Initiative of the National Science Foundation under NSF through the NSF Center for Biological and Environmental Nanotechnology [EEC-0647452]; National Science FoundationNational Science Foundation (NSF) [Track 2, 0440525]; BCM DERC [P30DK079638-02]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HL095586]; BCM Cytometry and Cell Sorting Core; NIH (NCRR)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR024574, NIAID AI036211, NCI P30CA125123]; NIH from the National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T32 HL007676]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA125123] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR024574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T32HL007676, R01HL095586] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [P30AI036211] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30DK079638] Funding Source: NIH RePORTER	Funding was provided by the Mission Connect Mild Traumatic Brain Injury Consortium, funded by the Department of Defense: W81XWH-08-2-0141, W81XWH-08-2-0143, and W81XWH-08-2-0132. We also thank the support of the Alliance for NanoHealth through a subcontract from the University of Texas Health Science Center, Houston (Department of Defense: W8XWH-07-2-0101); Nanoscale Science and Engineering Initiative of the National Science Foundation under NSF Award EEC-0647452 for funding through the NSF Center for Biological and Environmental Nanotechnology; the Graduate Fellows in K-12 education at Baylor College of Medicine, funded by the National Science Foundation (Track 2, 0440525); the BCM DERC Pilot and Feasibility Award (P30DK079638-02); NIH R01 HL095586; the BCM Cytometry and Cell Sorting Core with funding from the NIH (NCRR Grant S10RR024574, NIAID AI036211, and NCI P30CA125123); and an NIH Training Grant from the National Heart, Lung, and Blood Institute (T32 HL007676).	Ali SS, 2008, NANOMED-NANOTECHNOL, V4, P283, DOI 10.1016/j.nano.2008.05.003; Ali SS, 2004, FREE RADICAL BIO MED, V37, P1191, DOI 10.1016/j.freeradbiomed.2004.07.002; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Aykin-Burns N, 2009, BIOCHEM J, V418, P29, DOI 10.1042/BJ20081258; Berlin JM, 2010, ACS NANO, V4, P4621, DOI 10.1021/nn100975c; Butcher I, 2007, J NEUROTRAUM, V24, P294, DOI 10.1089/neu.2006.0032; Das M, 2007, BIOMATERIALS, V28, P1918, DOI 10.1016/j.biomaterials.2006.11.036; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Dugan LL, 2001, PARKINSONISM RELAT D, V7, P243, DOI 10.1016/S1353-8020(00)00064-X; Dugan LL, 1997, P NATL ACAD SCI USA, V94, P9434, DOI 10.1073/pnas.94.17.9434; FABIAN RH, 1995, J CEREBR BLOOD F MET, V15, P242, DOI 10.1038/jcbfm.1995.30; Fabian RH, 2008, AM J PHYSIOL-HEART C, V295, pH1809, DOI 10.1152/ajpheart.00301.2007; Girase B, 2012, ADV ENG MATER, V14, pB101, DOI 10.1002/adem.201180028; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; Hampel S, 2008, NANOMEDICINE-UK, V3, P175, DOI 10.2217/17435889.3.2.175; Han D, 2001, BIOCHEM J, V353, P411, DOI 10.1042/0264-6021:3530411; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hirst SM, 2009, SMALL, V5, P2848, DOI 10.1002/smll.200901048; Huang ST, 2008, BIOORGAN MED CHEM, V16, P8619, DOI 10.1016/j.bmc.2008.08.004; KEHRER JP, 1993, CRIT REV TOXICOL, V23, P21, DOI 10.3109/10408449309104073; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Liu Z, 2008, J AM CHEM SOC, V130, P10876, DOI 10.1021/ja803688x; Lo EH, 2008, BRIT J PHARMACOL, V153, pS396, DOI 10.1038/sj.bjp.0707626; Lucente-Schultz RM, 2009, J AM CHEM SOC, V131, P3934, DOI 10.1021/ja805721p; Lv M, 2012, NANOSCALE, V4, P3861, DOI 10.1039/c2nr30407d; Makarova EG, 2012, J NANOSCI NANOTECHNO, V12, P119, DOI 10.1166/jnn.2012.5709; Marcano D. C., J NEUROTRAU IN PRESS; Marklund N, 2001, J CEREBR BLOOD F MET, V21, P1259, DOI 10.1097/00004647-200111000-00002; Martin R, 2010, ACS NANO, V4, P6957, DOI 10.1021/nn1019412; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; Murakami T, 2008, NANOMEDICINE-UK, V3, P453, DOI 10.2217/17435889.3.4.453; Nakamura M, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/46/465102; Navarro JC, 2012, J NEUROTRAUM, V29, P322, DOI 10.1089/neu.2011.1979; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; Quick KL, 2008, NEUROBIOL AGING, V29, P117, DOI 10.1016/j.neurobiolaging.2006.09.014; Sano D, 2012, ACS NANO, V6, P2497, DOI 10.1021/nn204885f; Schubert D, 2006, BIOCHEM BIOPH RES CO, V342, P86, DOI 10.1016/j.bbrc.2006.01.129; Toda N, 2009, PHARMACOL REV, V61, P62, DOI 10.1124/pr.108.000547; Wang XY, 1999, PROG LIPID RES, V38, P309, DOI 10.1016/S0163-7827(99)00008-9; Yudoh K, 2009, INT J NANOMED, V4, P217; Zhang Y, 2010, DRUG DISCOV TODAY, V15, P428, DOI 10.1016/j.drudis.2010.04.005	43	78	78	3	74	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1936-0851	1936-086X		ACS NANO	ACS Nano	SEP	2012	6	9					8007	8014		10.1021/nn302615f			8	Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry; Science & Technology - Other Topics; Materials Science	009QP	WOS:000309040600051	22866916	Green Accepted			2022-02-06	
J	Perel, P; Salman, RAS; Kawahara, T; Morris, Z; Prieto-Merino, D; Roberts, I; Sandercock, P; Shakur, H; Wardlaw, J				Perel, P.; Salman, R. Al-Shahi; Kawahara, T.; Morris, Z.; Prieto-Merino, D.; Roberts, I.; Sandercock, P.; Shakur, H.; Wardlaw, J.			CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage) intracranial bleeding study: the effect of tranexamic acid in traumatic brain injury - a nested, randomised, placebo-controlled trial	HEALTH TECHNOLOGY ASSESSMENT			English	Article							HEMATOMAS; SCALE; CT	Background: Tranexamic acid (TXA) has been shown to reduce blood loss in surgical patients and the risk of death in patients with traumatic bleeding, with no apparent increase in vascular occlusive events. These findings raise the possibility that it might also be effective in traumatic brain injury (TBI). Objective: The Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage Intracranial Bleeding Study (CRASH-2 IBS) was conducted to quantify the effect of an early short course of TXA on intracranial haemorrhage and new focal cerebral ischaemic lesions in patients with TBI. Design: CRASH-2 IBS was a prospective randomised controlled trial nested within the CRASH-2 trial. Randomisation was balanced by centre, with an allocation sequence based on a block size of eight. We used a local pack system that selected the lowest numbered treatment pack from a box containing eight numbered packs. Apart from the pack number, the treatment packs were identical. The pack number was recorded on the entry form, which was sent to the international trial co-ordinating centre in London, UK. Once the treatment pack number was recorded, the patient was included in the trial whether or not the treatment pack was opened or the allocated treatment started. All site investigators and trial co-ordinating centre staff were masked to treatment allocation. Setting: Ten hospitals: (India) Aditya Neuroscience Centre, Sanjivani Hospital, CARE Hospital, Christian Medical College, Medical Trust Hospital, Jeevan Jyoti Hospital and (Colombia) Hospital Universitario San Vicente de Paul, Hospital Pablo Tobon Uribe, Hospital Universitario San Jose de Popayan and Fundacion Valle del Lili. Participants: The trial was conducted in a subset of 270 CRASH-2 trial participants. Patients eligible for inclusion in the CRASH-2 IBS fulfilled the inclusion criteria for the CRASH-2 trial, and also had TBI [Glasgow Coma Scale score of <= 14 and a brain computerised tomography (CT) scan compatible with TBI]. Pregnant women and patients for whom a second brain CT scan was not possible were excluded. Interventions: Participants were randomly allocated to receive either a loading dose of 1g of TXA infused over 10 minutes followed by an intravenous infusion of 1g over 8 hours or matching placebo. Main outcome measure: The primary outcome was the increase in size of intracranial haemorrhage growth between a CT scan at hospital admission and a second scan 24-48 hours later. Results: One hundred and thirty-three patients were allocated to TXA and 137 to placebo, of whom information on the primary (imaging) outcome was available for 123 (92%) and 126 (92%) respectively. The analysis suggested that TXA was likely to be associated with a reduction in haemorrhage growth [adjusted difference -3.8 ml, 95% credibility interval (CrI) -11.5 ml to 3.9 ml], fewer focal ischaemic lesions [adjusted odds ratio (OR) 0.54, 95% CrI 0.20 to 1.46] and fewer deaths (adjusted OR 0.49, 95% CrI 0.22 to 1.06). Conclusions: This was the first randomised controlled study to evaluate the effect of TXA in TBI patients and it found that neither moderate benefits nor moderate harmful effects can be excluded. However, although uncertainty remains, our analyses suggest that TXA administration might improve outcome in TBI patients and provide grounds for evaluating this hypothesis in future research.	[Perel, P.; Kawahara, T.; Prieto-Merino, D.; Roberts, I.; Shakur, H.] London Sch Hyg & Trop Med, London WC1, England; [Salman, R. Al-Shahi; Morris, Z.; Sandercock, P.; Wardlaw, J.] Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland		Perel, P (corresponding author), London Sch Hyg & Trop Med, Keppel St, London WC1, England.	pablo.perel@lshtm.ac.uk	Wardlaw, Joanna M/Y-3456-2019	Wardlaw, Joanna M/0000-0002-9812-6642; Prieto-Merino, David/0000-0001-5001-0061; Shakur-Still, Haleema/0000-0002-6511-109X; Al-Shahi Salman, Rustam/0000-0002-2108-9222	NIHRNational Institute for Health Research (NIHR); MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G108/613, G1002605] Funding Source: UKRI	This project was funded by the NIHR Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 16, No. 13. See the HTA programme website for further project information.	Astrup Jens, 2006, Ugeskr Laeger, V168, P1107; Bayir A, 2006, NEUROL INDIA, V54, P363, DOI 10.4103/0028-3886.28106; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; Edwards P, 2005, LANCET, V365, P1957; Gebel JM, 1998, STROKE, V29, P1799, DOI 10.1161/01.STR.29.9.1799; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Henry DA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001886.pub2; HIJDRA A, 1990, STROKE, V21, P1156, DOI 10.1161/01.STR.21.8.1156; KWAK R, 1983, STROKE, V14, P493, DOI 10.1161/01.STR.14.4.493; Lustenberger T, 2010, J TRAUMA, V69, P1410, DOI 10.1097/TA.0b013e3181cdae81; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Osborn A. G., 2004, DIAGNOSTIC IMAGING B, V1st; Pathak A, 2005, Neurol India, V53, P178; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel P, 2009, BMC EMERG MED, V9, DOI 10.1186/1471-227X-9-15; Perel P, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007877.pub2; Perel P, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-72; PETERSEN OF, 1984, NEURORADIOLOGY, V26, P363, DOI 10.1007/BF00327488; Peto R, 1998, BMJ-BRIT MED J, V317, P1170, DOI 10.1136/bmj.317.7167.1170; Prentice C R, 1980, J Clin Pathol Suppl (R Coll Pathol), V14, P35; Roos YB, 2003, COCHRANE DB SYST REV, V2, DOI [DOI 10.1002/14651858.CD001245, 10.1002/14651858.CD001245]; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Spiegelhalter DJ, 2004, BAYESIAN APPROACHES; Stein SC, 2007, INDIAN J MED RES, V125, P186; Sullivan TP, 1999, AM J NEURORADIOL, V20, P107; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; WARDLAW JM, 1994, AM J NEURORADIOL, V15, P1933; Yadav YR, 2006, NEUROL INDIA, V54, P377, DOI 10.4103/0028-3886.28109	32	78	79	0	9	NIHR JOURNALS LIBRARY	SOUTHAMPTON	UNIV SOUTHAMPTON, EVALUATION, TRIALS & STUDIES COORDINATING CENTRE, ALPHA HOUSE, ENTERPRISE RD, SOUTHAMPTON, SO16 7NS, ENGLAND	1366-5278	2046-4924		HEALTH TECHNOL ASSES	Health Technol. Assess.	MAR	2012	16	13					1	+		10.3310/hta16130			47	Health Care Sciences & Services	Science Citation Index Expanded (SCI-EXPANDED)	Health Care Sciences & Services	932HI	WOS:000303280900001	22417901	Green Accepted, gold			2022-02-06	
J	Blyth, BJ; Farahvar, A; He, H; Nayak, A; Yang, C; Shaw, G; Bazarian, JJ				Blyth, Brian J.; Farahvar, Arash; He, Hua; Nayak, Akshata; Yang, Cui; Shaw, Gerry; Bazarian, Jeffrey J.			Elevated Serum Ubiquitin Carboxy-Terminal Hydrolase L1 Is Associated with Abnormal Blood-Brain Barrier Function after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						area under the receiver operator characteristic curve; biomarkers; blood-brain barrier dysfunction; neurofilament heavy chain; phosphorylated neurofilament heavy chain; traumatic brain injury; ubiquitin carboxy-terminal hydrolase L1	AXONAL INJURY; HEAD-INJURY; NF-H; NEUROLOGICAL DISORDERS; IGG ANALYSES; PGP 9.5; PNF-H; BIOMARKER; PROTEIN; S100B	Serum S100B elevations accurately reflect blood-brain barrier (BBB) damage. Because S100B is also present in peripheral tissues, release of this protein may not be specific to central nervous system (CNS) injury. Ubiquitin C-terminal hydrolase 1 (UCHL1), and phosphorylated neurofilament heavy chain (pNF-H) are found exclusively in neurons, but their relationship to BBB dysfunction has not been determined. The objective of this study was to determine the accuracy of serum UCHL1 and pNF-H as measures of BBB integrity after traumatic brain injury (TBI), to and compare them to S100B. We performed a prospective study of 16 patients with moderate to severe TBI (Glasgow Coma Scale [GCS] score <= 12) and 6 patients with non-traumatic headache who had cerebrospinal fluid (CSF) collected by ventriculostomy or lumbar puncture (LP). Serum and CSF were collected at the time of LP for headache patients and at 12, 24, and 48 h after injury for TBI patients. BBB function was determined by calculating albumin quotients (Q(A)), where Q(A) = [albumin(CSF)]/[albumin(serum)]. S100B, UCHL1, and pNF-H were measured by enzyme-linked immunosorbent assay (ELISA). Pearson's correlation coefficient and area under the receiver operator characteristic (ROC) curve were used to determine relationships between serum markers and Q(A). At 12 hours after TBI, a significant relationship was found between Q(A) and serum UCHL1 concentrations (AUC=0.76; 95% CI 0.55,1.00), and between Q(A) and serum S100B concentrations (AUC=0.794; 95% CI 0.57,1.02). There was no significant relationship found between these markers and Q(A) at other time points, or between pNF-H and Q(A) at any time point. We conclude that serum concentrations of UCHL1 are associated with abnormal BBB status 12 h after moderate to severe TBI. This relationship is similar to that observed between serum S100B and Q(A), despite the fact that S100B may be released from peripheral tissues after multi-trauma. We conclude that peripheral release of S100B after multi-trauma is probably negligible and that UCHL1 may have some utility to monitor BBB disruption following TBI.	[Blyth, Brian J.; Nayak, Akshata; Bazarian, Jeffrey J.] Univ Rochester, Med Ctr, Dept Emergency Med, Rochester, NY 14642 USA; [Blyth, Brian J.; Nayak, Akshata; Bazarian, Jeffrey J.] Univ Rochester, Med Ctr, Ctr Neural Dev & Dis, Rochester, NY 14642 USA; [Farahvar, Arash; Nayak, Akshata; Bazarian, Jeffrey J.] Univ Rochester, Med Ctr, Dept Neurosurg, Rochester, NY 14642 USA; [He, Hua] Univ Rochester, Med Ctr, Dept Biostat & Computat Biol, Rochester, NY 14642 USA; [Nayak, Akshata; Bazarian, Jeffrey J.] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA; [Yang, Cui; Shaw, Gerry] Univ Florida, Coll Med, Dept Neurosci, McKnight Brain Inst, Gainesville, FL 32610 USA		Blyth, BJ (corresponding author), Univ Rochester, Med Ctr, Dept Emergency Med, 601 Elmwood Ave, Rochester, NY 14642 USA.	Brian_Blyth@urmc.rochester.edu	, Gerry/X-2377-2019				Adami C, 2001, GLIA, V33, P131, DOI 10.1002/1098-1136(200102)33:2<131::AID-GLIA1012>3.0.CO;2-D; Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; Anderson RE, 2000, ANN THORAC SURG, V69, P847, DOI 10.1016/S0003-4975(99)01526-X; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Berger J, 2007, NEUROL RES, V29, P610, DOI 10.1179/016164107X172158; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI 10.1089/neu.2008-0738; Boylan K, 2009, J NEUROCHEM, V111, P1182, DOI 10.1111/j.1471-4159.2009.06386.x; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Day INM, 2010, PROG NEUROBIOL, V90, P327, DOI 10.1016/j.pneurobio.2009.10.020; Diomedi-Camassei F, 2005, NEPHROL DIAL TRANSPL, V20, P2714, DOI 10.1093/ndt/gfi124; DORAN JF, 1983, J NEUROCHEM, V40, P1542, DOI 10.1111/j.1471-4159.1983.tb08124.x; DOUGLASESCOBAR M, 2010, PEDIAT RES; Faul M, 2010, TRAUMATIC BRAIN INJU; Flierl MA, 2010, CRIT CARE, V14, DOI 10.1186/cc9035; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Flierl MA, 2009, CRIT CARE, V13, DOI 10.1186/cc7794; Gresle MM, 2008, J NEUROSCI RES, V86, P3548, DOI 10.1002/jnr.21803; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Kobbe P, 2008, J ORTHOP TRAUMA, V22, P385, DOI 10.1097/BOT.0b013e318175dd88; Krizbai IA, 2005, SHOCK, V24, P428, DOI 10.1097/01.shk.0000183389.98519.d3; Lewis SB, 2008, J CEREBR BLOOD F MET, V28, P1261, DOI 10.1038/jcbfm.2008.12; Lewis SB, 2010, J NEUROSCI RES, V88, P1475, DOI 10.1002/jnr.22323; LINK H, 1977, SCAND J CLIN LAB INV, V37, P391, DOI 10.3109/00365517709091497; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pelinka LE, 2003, BRIT J ANAESTH, V91, P595, DOI 10.1093/bja/aeg225; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Reiber H, 2001, CLIN CHIM ACTA, V310, P173, DOI 10.1016/S0009-8981(01)00573-3; REIBER H, 1980, J NEUROL, V224, P89, DOI 10.1007/BF00313347; Ruczinski I, 2003, J COMPUT GRAPH STAT, V12, P475, DOI 10.1198/1061860032238; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; Siman R, 2008, BRAIN RES, V1213, P1, DOI 10.1016/j.brainres.2008.03.034; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; Strong MJ, 2001, J NEUROCHEM, V76, P1315, DOI 10.1046/j.1471-4159.2001.00094.x; Swann K, 2007, BRAIN RES, V1129, P26, DOI 10.1016/j.brainres.2006.10.061; Takami Y, 2007, ARTERIOSCL THROM VAS, V27, P2184, DOI 10.1161/ATVBAHA.107.142505; THOMPSON RJ, 1983, BRAIN RES, V278, P224, DOI 10.1016/0006-8993(83)90241-X; TIBBLING G, 1977, SCAND J CLIN LAB INV, V37, P385, DOI 10.3109/00365517709091496; Vilalta A, 2008, INTENS CARE MED, V34, P1384, DOI 10.1007/s00134-008-1056-1; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Wiesmann M, 1999, BIOL PSYCHIAT, V45, P1508, DOI 10.1016/S0006-3223(98)00217-0; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208	50	78	82	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2011	28	12					2453	2462		10.1089/neu.2010.1653			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	865DS	WOS:000298291600005	21428722				2022-02-06	
J	Labombarda, F; Gonzalez, S; Lima, A; Roig, P; Guennoun, R; Schumacher, M; De Nicola, AF				Labombarda, Florencia; Gonzalez, Susana; Lima, Analia; Roig, Paulina; Guennoun, Rachida; Schumacher, Michael; De Nicola, Alejandro F.			Progesterone attenuates astro- and microgliosis and enhances oligodendrocyte differentiation following spinal cord injury	EXPERIMENTAL NEUROLOGY			English	Article						Progesterone; Spinal cord injury; Astrogliosis; Microgliosis; Oligodendrocytes; Neuroprotection	TRAUMATIC BRAIN-INJURY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MYELIN BASIC-PROTEIN; CELL-PROLIFERATION; NEUROTROPHIC FACTOR; FACTOR EXPRESSION; STEROID-HORMONES; NERVOUS-SYSTEM; SEX STEROIDS; MOUSE MODEL	Reactive gliosis, demyelination and proliferation of NG2+ oligodendrocyte precursor cells (OPC) are common responses to spinal cord injury (SCI). We previously reported that short-term progesterone treatment stimulates OPC proliferation whereas chronic treatment enhances OPC differentiation after SCI. Presently, we further studied the proliferation/differentiation of glial cells involved in inflammation and remyelination in male rats with SCI subjected to acute (3 days) or chronic (21 days) progesterone administration. Rats received several pulses of bromodeoyuridine (BrdU) 48 and 72 h post-SCI, and sacrificed 3 or 21 days post-SCI. Double colocalization of BrdU and specific cell markers showed that 3 days of SCI induced a strong proliferation of S100 beta+ astrocytes, OX-42+ microglia/macrophages and NG2+ cells. At this stage, the intense GFAP+ astrogliosis was BrdU negative. Twenty one days of SCI enhanced maturation of S100 beta+ cells into GFAP+ astrocytes, but decreased the number of CC1+ oligodendrocytes. Progesterone treatment inhibited astrocyte and microglia /macrophage proliferation and activation in the 3-day SCI group, and inhibited activation in the 21-day SCI group. BrdU/NG2 double labeled cells were increased by progesterone at 3 days, indicating a proliferation stimulus, but decreased them at 21 days. However, progesterone-enhancement of CC1+/BrdU+ oligodendrocyte density, suggest differentiation of OPC into mature oligondendrocytes. We conclude that progesterone effects after SCI involves: a) inhibition of astrocyte proliferation and activation; b) anti-inflammatory effects by preventing microglial activation and proliferation, and c) early proliferation of NG2+ progenitors and late remyelination. Thus, progesterone behaves as a glioactive factor favoring remyelination and inhibiting reactive gliosis. (C) 2011 Elsevier Inc. All rights reserved.	[Labombarda, Florencia; Gonzalez, Susana; De Nicola, Alejandro F.] Inst Biol & Med Expt, Lab Neuroendocrine Biochem, RA-1428 Buenos Aires, DF, Argentina; [Labombarda, Florencia; Gonzalez, Susana; Lima, Analia; Roig, Paulina; De Nicola, Alejandro F.] Univ Buenos Aires, Fac Med, Dept Human Biochem, RA-1425 Buenos Aires, DF, Argentina; [Guennoun, Rachida; Schumacher, Michael] INSERM, UMR 788, F-94276 Le Kremlin Bicetre, France; [Guennoun, Rachida; Schumacher, Michael] Univ Paris 11 Steroids Neuroprotect & Neuroregene, F-94276 Le Kremlin Bicetre, France		De Nicola, AF (corresponding author), Inst Biol & Med Expt, Lab Neuroendocrine Biochem, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	alejandrodenicola@gmail.com	Schumacher, Michael/G-3581-2013; Messier, Claude/A-2322-2008; Guennoun, Rachida/F-2420-2011	Schumacher, Michael/0000-0001-6117-5371; Messier, Claude/0000-0002-4791-1763; Guennoun, Rachida/0000-0002-9219-7300	CONICETConsejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) [PIP 5542]; University of Buenos AiresUniversity of Buenos Aires [MO16, M611]; FONCYTFONCyT [01044, 00291]; INSERMInstitut National de la Sante et de la Recherche Medicale (Inserm)European Commission	This work was supported by grants from CONICET (PIP 5542), the University of Buenos Aires (MO16 and M611), FONCYT (PICT 2007 no 01044 and PICT 2006 no 00291) and a Cooperative Program between CONICET and INSERM.	Alonso G, 2005, GLIA, V49, P318, DOI 10.1002/glia.20121; Arevalo M. A., 2009, BIOCHIM BIOPHYS ACTA, V1800, P1106; Arnold S, 2008, J MOL ENDOCRINOL, V41, P289, DOI 10.1677/JME-08-0085; Azcoitia I, 2003, NEUROBIOL AGING, V24, P853, DOI 10.1016/S0197-4580(02)00234-8; Barker JM, 2008, NEUROSCIENCE, V152, P888, DOI 10.1016/j.neuroscience.2007.10.071; Batchelor PE, 2008, J NEUROTRAUM, V25, P1217, DOI 10.1089/neu.2007.0308; Baumann N, 2001, PHYSIOL REV, V81, P871, DOI 10.1152/physrev.2001.81.2.871; Benarroch EE, 2005, MAYO CLIN PROC, V80, P1326, DOI 10.4065/80.10.1326; Bezzi P, 2001, CURR OPIN NEUROBIOL, V11, P387, DOI 10.1016/S0959-4388(00)00223-3; Brambilla R, 2005, J EXP MED, V202, P145, DOI 10.1084/jem.20041918; Brambilla R, 2009, J IMMUNOL, V182, P2628, DOI 10.4049/jimmunol.0802954; Brozzi F, 2009, J BIOL CHEM, V284, P8788, DOI 10.1074/jbc.M805897200; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Coughlan T, 2005, J NEUROCHEM, V93, P932, DOI 10.1111/j.1471-4159.2005.03068.x; Crossin KL, 1997, P NATL ACAD SCI USA, V94, P2687, DOI 10.1073/pnas.94.6.2687; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; De Nicola AF, 2006, J MOL NEUROSCI, V28, P3, DOI 10.1385/JMN:28:1:3; De Nicola AF, 2009, FRONT NEUROENDOCRIN, V30, P173, DOI 10.1016/j.yfrne.2009.03.001; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Djebaili M, 2001, MOL BRAIN RES, V93, P190, DOI 10.1016/S0169-328X(01)00197-8; Drew PD, 2000, J NEUROIMMUNOL, V111, P77, DOI 10.1016/S0165-5728(00)00386-6; Gago N, 2004, J NEUROSCI RES, V78, P770, DOI 10.1002/jnr.20348; Gago N, 2001, GLIA, V36, P295, DOI 10.1002/glia.1117; Garay L, 2008, NEUROIMMUNOMODULAT, V15, P76, DOI 10.1159/000135627; Garay L, 2007, J STEROID BIOCHEM, V107, P228, DOI 10.1016/j.jsbmb.2007.03.040; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; Garcia-Segura LM, 2006, GLIA, V54, P485, DOI 10.1002/glia.20404; Ghoumari AM, 2006, FASEB J, V20, P1377, DOI 10.1096/fj.05-5832com; Ghoumari AM, 2005, NEUROSCIENCE, V135, P47, DOI 10.1016/j.neuroscience.2005.05.023; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Deniselle MCG, 2007, EXP NEUROL, V203, P406, DOI 10.1016/j.expneurol.2006.08.019; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Gonzalez SL, 2009, CELL MOL NEUROBIOL, V29, P27, DOI 10.1007/s10571-008-9291-0; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; Horky LL, 2006, J COMP NEUROL, V498, P525, DOI 10.1002/cne.21065; Hu R, 2010, J NEUROSURG-SPINE, V13, P169, DOI 10.3171/2010.3.SPINE09190; Ibanez C, 2004, NEUROPATH APPL NEURO, V30, P80, DOI 10.1046/j.0305-1846.2003.00515.x; JungTestas I, 1996, J STEROID BIOCHEM, V58, P77, DOI 10.1016/0960-0760(96)00009-X; Kipp M, 2007, J NEUROENDOCRINOL, V19, P819, DOI 10.1111/j.1365-2826.2007.01588.x; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Labombarda F, 2006, ENDOCRINOLOGY, V147, P1847, DOI 10.1210/en.2005-0955; Labombarda F, 2006, J NEUROTRAUM, V23, P181, DOI 10.1089/neu.2006.23.181; Labombarda F, 2010, NEUROSCIENCE, V166, P94, DOI 10.1016/j.neuroscience.2009.12.012; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; Labombarda F, 2000, NEUROSCI LETT, V288, P29, DOI 10.1016/S0304-3940(00)01191-5; Labombarda F, 2000, J STEROID BIOCHEM, V73, P159, DOI 10.1016/S0960-0760(00)00064-9; Labombarda F, 2010, NEUROIMMUNOMODULAT, V17, P146, DOI 10.1159/000258709; Labombarda F, 2009, GLIA, V57, P884, DOI 10.1002/glia.20814; Leonelli E, 2007, NEUROSCIENCE, V144, P1293, DOI 10.1016/j.neuroscience.2006.11.014; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; LING EA, 1990, ANAT EMBRYOL, V182, P481; Lorenz L, 2009, J NEUROENDOCRINOL, V21, P841, DOI 10.1111/j.1365-2826.2009.01903.x; McDonald JW, 2006, J NEUROTRAUM, V23, P345, DOI 10.1089/neu.2006.23.345; McTigue DM, 2001, J NEUROSCI, V21, P3392, DOI 10.1523/JNEUROSCI.21-10-03392.2001; Melcangi RC, 1998, EXP GERONTOL, V33, P827, DOI 10.1016/S0531-5565(98)00020-5; Meyer M, 2010, CELL MOL NEUROBIOL, V30, P123, DOI 10.1007/s10571-009-9437-8; Mitterling KL, 2010, J COMP NEUROL, V518, P2729, DOI 10.1002/cne.22361; Morin-Richaud C, 1998, BRAIN RES, V783, P85, DOI 10.1016/S0006-8993(97)01282-1; Muller E, 2006, NEUROENDOCRINOL LETT, V27, P675; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; OGATA T, 1993, NEUROSCIENCE, V55, P445, DOI 10.1016/0306-4522(93)90513-F; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Rabchevsky AG, 2007, GLIA, V55, P831, DOI 10.1002/glia.20508; Revsin Y, 2005, BRAIN RES, V1038, P22, DOI 10.1016/j.brainres.2004.12.032; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Roglio I, 2008, BRAIN RES REV, V57, P460, DOI 10.1016/j.brainresrev.2007.04.010; Rosenberg LJ, 2005, GLIA, V49, P107, DOI 10.1002/glia.20096; Siegenthaler MM, 2007, J NEUROTRAUM, V24, P1631, DOI 10.1089/neu.2007.0302; Sierra A, 2008, GLIA, V56, P659, DOI 10.1002/glia.20644; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Stein DG, 2005, ANN NY ACAD SCI, V1052, P152, DOI 10.1196/annals.1347.011; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stein DG, 2010, EXPERT OPIN INV DRUG, V19, P847, DOI 10.1517/13543784.2010.489549; Suyama K, 2007, J NEUROTRAUM, V24, P1013, DOI 10.1089/neu.2006.0151; Totoiu MO, 2005, J COMP NEUROL, V486, P373, DOI 10.1002/cne.20517; Trivedi A, 2006, CLIN NEUROSCI RES, V6, P283, DOI 10.1016/j.cnr.2006.09.007; Wang DD, 2008, PROG NEUROBIOL, V86, P342, DOI 10.1016/j.pneurobio.2008.09.015; Waters EM, 2008, J COMP NEUROL, V511, P34, DOI 10.1002/cne.21826; WATSON C, 2009, ANN EMERG MED, V49, P391; Wu JF, 2010, GLIA, V58, P410, DOI 10.1002/glia.20932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Zai LJ, 2005, BRAIN RES, V1052, P147, DOI 10.1016/j.brainres.2005.05.071; Zai LJ, 2005, GLIA, V50, P247, DOI 10.1002/glia.20176	87	78	82	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	SEP	2011	231	1					135	146		10.1016/j.expneurol.2011.06.001			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	810DX	WOS:000294106700016	21704617				2022-02-06	
J	Do, AH; Wang, PT; King, CE; Abiri, A; Nenadic, Z				Do, An H.; Wang, Po T.; King, Christine E.; Abiri, Ahmad; Nenadic, Zoran			Brain-Computer Interface Controlled Functional Electrical Stimulation System for Ankle Movement	JOURNAL OF NEUROENGINEERING AND REHABILITATION			English	Article							INFORMATION DISCRIMINANT-ANALYSIS; FEATURE-EXTRACTION; EEG; MOTOR; COMMUNICATION; TETRAPLEGIA; STROKE; INJURY; BCI; RECOVERY	Background: Many neurological conditions, such as stroke, spinal cord injury, and traumatic brain injury, can cause chronic gait function impairment due to foot-drop. Current physiotherapy techniques provide only a limited degree of motor function recovery in these individuals, and therefore novel therapies are needed. Brain-computer interface (BCI) is a relatively novel technology with a potential to restore, substitute, or augment lost motor behaviors in patients with neurological injuries. Here, we describe the first successful integration of a noninvasive electroencephalogram (EEG)-based BCI with a noninvasive functional electrical stimulation (FES) system that enables the direct brain control of foot dorsiflexion in able-bodied individuals. Methods: A noninvasive EEG-based BCI system was integrated with a noninvasive FES system for foot dorsiflexion. Subjects underwent computer-cued epochs of repetitive foot dorsiflexion and idling while their EEG signals were recorded and stored for offline analysis. The analysis generated a prediction model that allowed EEG data to be analyzed and classified in real time during online BCI operation. The real-time online performance of the integrated BCI-FES system was tested in a group of five able-bodied subjects who used repetitive foot dorsiflexion to elicit BCI-FES mediated dorsiflexion of the contralateral foot. Results: Five able-bodied subjects performed 10 alternations of idling and repetitive foot dorsifiexion to trigger BCI-FES mediated dorsifiexion of the contralateral foot. The epochs of BCI-FES mediated foot dorsifiexion were highly correlated with the epochs of voluntary foot dorsifiexion (correlation coefficient ranged between 0.59 and 0.77) with latencies ranging from 1.4 sec to 3.1 sec. In addition, all subjects achieved a 100% BCI-FES response (no omissions), and one subject had a single false alarm. Conclusions: This study suggests that the integration of a noninvasive BCI with a lower-extremity FES system is feasible. With additional modifications, the proposed BCI-FES system may offer a novel and effective therapy in the neuro-rehabilitation of individuals with lower extremity paralysis due to neurological injuries.	[Do, An H.] Univ Calif Irvine, Dept Neurol, Irvine, CA 92697 USA; [Do, An H.] Long Beach Vet Affairs Med Ctr, Dept Neurol, Long Beach, CA 90822 USA; [Wang, Po T.; King, Christine E.; Nenadic, Zoran] Univ Calif Irvine, Dept Biomed Engn, Irvine, CA 92697 USA; [Abiri, Ahmad; Nenadic, Zoran] Univ Calif Irvine, Dept Elect Engn & Comp Sci, Irvine, CA 92697 USA		Do, AH (corresponding author), Univ Calif Irvine, Dept Neurol, Irvine, CA 92697 USA.	and@uci.edu; znenadic@uci.edu	Wang, Po T./H-4878-2014; Nenadic, Zoran/A-9816-2008; LUO, JINGJING/AAZ-6697-2021; Nenadic, Zoran/P-8772-2019	Wang, Po T./0000-0002-6611-3863; LUO, JINGJING/0000-0002-3222-1276; Nenadic, Zoran/0000-0001-5569-3797	Roman Reed Spinal Cord Injury Research Fund of California [RR10-281]; NIH Roadmap for Medical ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1 RR031985]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR031985] Funding Source: NIH RePORTER	This work was partially supported by the Roman Reed Spinal Cord Injury Research Fund of California (RR10-281).; The scientific review of the project described was supported by Grant Number UL1 RR031985 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. Information on NCRR is available at http://www.ncrr.nih.gov/. Information on Reengineering the Clinical Research Enterprise can be obtained from http://nihroadmap.nih.gov.	Birbaumer N, 1999, NATURE, V398, P297, DOI 10.1038/18581; Birbaumer N, 2006, PSYCHOPHYSIOLOGY, V43, P517, DOI 10.1111/j.1469-8986.2006.00456.x; Daly JJ, 2009, J NEUROL PHYS THER, V33, P203, DOI 10.1097/NPT.0b013e3181c1fc0b; Das K., 2007, C P IEEE ENG MED BIO, P6519; Das K, 2008, PATTERN RECOGN, V41, P1548, DOI 10.1016/j.patcog.2007.10.001; Das K, 2009, PATTERN RECOGN, V42, P857, DOI 10.1016/j.patcog.2008.08.036; Dombovy M, 2011, NEUROREHABILITATION, V17, P443; Green JB, 1999, STROKE, V30, P2659, DOI 10.1161/01.STR.30.12.2659; Hochberg LR, 2006, NATURE, V442, P164, DOI 10.1038/nature04970; Huber P.J., 1981, ROBUST STAT; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P27, DOI 10.1016/S0003-9993(95)80038-7; Kanoh S, 2009, IFMBE PROC, V23, P2264; Kay SM., 1998, FUNDAMENTALS STAT SI; Knutson JS, 2007, ARCH PHYS MED REHAB, V88, P513, DOI 10.1016/j.apmr.2007.01.003; Kohavi R., P 14 INT JOINT C ART, P1137; Krawetz P, 1996, ARCH PHYS MED REHAB, V77, P635, DOI 10.1016/S0003-9993(96)90000-3; Leeb Robert, 2007, Comput Intell Neurosci, P79642, DOI 10.1155/2007/79642; LIBET B, 1983, BRAIN, V106, P623, DOI 10.1093/brain/106.3.623; MAYNARD FM, 1979, J NEUROSURG, V50, P611, DOI 10.3171/jns.1979.50.5.0611; Muller-Putz GR, 2007, BRAIN RES, V1137, P84, DOI 10.1016/j.brainres.2006.12.052; Muller-Putz GR, 2005, NEUROSCI LETT, V382, P169, DOI 10.1016/j.neulet.2005.03.021; NENADIC Z, 2010, SOC NEUR ABSTR, V40, P2946; Nenadic Z, 2007, IEEE T PATTERN ANAL, V29, P1394, DOI 10.1109/TPAMI.2007.1156; Neuper C, 1996, NEUROSCI LETT, V216, P17; Pfurtscheller G, 2003, NEUROSCI LETT, V351, P33, DOI 10.1016/S0304-3940(03)00947-9; PFURTSCHELLER G, 1979, ELECTROEN CLIN NEURO, V46, P138, DOI 10.1016/0013-4694(79)90063-4; REDING MJ, 1988, STROKE, V19, P1354, DOI 10.1161/01.STR.19.11.1354; Scherer R, 2008, IEEE T BIO-MED ENG, V55, P675, DOI 10.1109/TBME.2007.903709; Solis-Escalante T, 2008, J NEUROSCI METH, V175, P148, DOI 10.1016/j.jneumeth.2008.07.019; Townsend G, 2004, IEEE T NEUR SYS REH, V12, P258, DOI 10.1109/TNSRE.2004.827220; Townsend G, 2010, CLIN NEUROPHYSIOL, V121, P1109, DOI 10.1016/j.clinph.2010.01.030; Wang PT, 2011, MED ENG PHYS, V33, P546, DOI 10.1016/j.medengphy.2010.12.008; WATERS RL, 1994, ARCH PHYS MED REHAB, V75, P306, DOI 10.1016/0003-9993(94)90034-5; Williams G, 2009, ARCH PHYS MED REHAB, V90, P587, DOI 10.1016/j.apmr.2008.10.013; Wolpaw JR, 2004, P NATL ACAD SCI USA, V101, P17849, DOI 10.1073/pnas.0403504101; Wolpaw JR, 2002, CLIN NEUROPHYSIOL, V113, P767, DOI 10.1016/S1388-2457(02)00057-3	36	78	86	1	34	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1743-0003			J NEUROENG REHABIL	J. NeuroEng. Rehabil.	AUG 26	2011	8								49	10.1186/1743-0003-8-49			14	Engineering, Biomedical; Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Neurosciences & Neurology; Rehabilitation	832RD	WOS:000295823000001	21867567	Green Published, gold			2022-02-06	
J	Emery, C; Kang, J; Shrier, I; Goulet, C; Hagel, B; Benson, B; Nettel-Aguirre, A; McAllister, J; Meeuwisse, W				Emery, Carolyn; Kang, Jian; Shrier, Ian; Goulet, Claude; Hagel, Brent; Benson, Brian; Nettel-Aguirre, Alberto; McAllister, Jenelle; Meeuwisse, Willem			Risk of injury associated with bodychecking experience among youth hockey players	CANADIAN MEDICAL ASSOCIATION JOURNAL			English	Article							OF-THE-LITERATURE; ICE HOCKEY; BODY CHECKING; SPORT INJURY; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; HIGH-SCHOOLS; CONCUSSION; RATES; PARTICIPATION	Background: In a previous prospective study, the risk of concussion and all injury was more than threefold higher among Pee Wee ice hockey players (ages 11-12 years) in a league that allows bodychecking than among those in a league that does not. We examined whether two years of bodychecking experience in Pee Wee influenced the risk of concussion and other injury among players in a Bantam league (ages 13-14) compared with Bantam players introduced to bodychecking for the first time at age 13. Methods: We conducted a prospective cohort study in volving hockey players aged 13-14 years in the top 30% of divisions of play in their leagues. Sixty-eight teams from the province of Alberta (n = 995), whose players had two years of bodychecking experience in Pee Wee, and 62 teams from the province of Quebec (n = 976), whose players had no bodychecking experience in Pee Wee, participated. We estimated incidence rate ratios (IRRs) for injury and for concussion. Results: There were 272 injuries (51 concussions) among the Bantam hockey players who had bodychecking experience in Pee Wee and 244 injuries (49 concussions) among those without such experience. The adjusted IRRs for game-related injuries and concussion overall be tween players with bodychecking experience in Pee Wee and those without it were as follows: injury overall 0.85 (95% confidence interval [CI] 0.63 to 1.16); concussion overall 0.84 (95% CI 0.48 to 1.48); and injury resulting in more than seven days of time loss (i.e., time between injury and re turn to play) 0.67 (95% CI 0.46 to 0.99). The unadjusted IRR for concussion resulting in more than 10 days of time loss was 0.60 (95% CI 0.26 to 1.41). Interpretation: The risk of injury resulting in more than seven days of time loss from play was reduced by 33% among Bantam hockey players in a league where bodychecking was allowed two years earlier in Pee Wee compared with Bantam players introduced to bodychecking for the first time at age 13. In light of the increased risk of concussion and other injury among Pee Wee players in a league where bodychecking is permitted, policy regarding the age at which hockey players are introduced to bodychecking re quires further consideration.	[Emery, Carolyn; Kang, Jian; Benson, Brian; McAllister, Jenelle; Meeuwisse, Willem] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Jackson Ctr Hlth & Wellness Res, Calgary, AB, Canada; [Goulet, Claude] Univ Laval, Dept Phys Educ, Fac Educ, Quebec City, PQ, Canada; [Shrier, Ian] McGill Univ, Jewish Gen Hosp, Ctr Clin Epidemiol & Community Studies, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; [Emery, Carolyn; Hagel, Brent; Nettel-Aguirre, Alberto] Univ Calgary, Fac Med, Dept Pediat, Calgary, AB, Canada; [Emery, Carolyn; Hagel, Brent; Nettel-Aguirre, Alberto; Meeuwisse, Willem] Univ Calgary, Fac Med, Dept Community Hlth Sci, Calgary, AB, Canada		Emery, C (corresponding author), Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Jackson Ctr Hlth & Wellness Res, Calgary, AB, Canada.	caemery@ucalgary.ca	Nettel-Aguirre, Alberto/ABB-9412-2021; Emery, Carolyn/AAI-2761-2020; Shrier, Ian/AAI-6502-2020; Hagel, Brent/AAK-3319-2020	Shrier, Ian/0000-0001-9914-3498; Nettel-Aguirre, Alberto/0000-0001-6604-0652	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Max Bell Foundation; Alberta Heritage FoundationAlberta Heritage Foundation for Medical Research; Alberta Children's Hospital Foundation; Fonds de la recherche en sante du QuebecFonds de la Recherche en Sante du Quebec; Canadian National Railway Company	This study was funded by the Canadian Institutes of Health Research (CIHR) and the Max Bell Foundation. Carolyn Emery is supported by a Population Health Investigator Award from the Alberta Heritage Foundation, a CIHR New Investigator Award and an Alberta Children's Hospital Foundation Professorship in Pediatric Rehabilitation. Ian Shrier is supported by the Senior Clinician Scientist Program of the Fonds de la recherche en sante du Quebec. Brent Hagel holds the Alberta Children's Hospital Foundation Professorship in Child Health and Wellness, funded through the support of an anonymous donor and the Canadian National Railway Company; he is also supported by a Population Health Investigator Award from the Alberta Heritage Foundation for Medical Research and a CIHR New Investigator Award. The role of the sponsors and funding bodies was to provide financial support for this research and the translation of the findings to all community partners.	Benson B., 2005, CLIN J SPORT MED, V15, P395; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Brunelle JP, 2005, J SCI MED SPORT, V8, P294, DOI 10.1016/S1440-2440(05)80040-4; BRUST JD, 1992, AM J DIS CHILD, V146, P741, DOI 10.1001/archpedi.1992.02160180101026; Emery CA, 2009, PAED CHILD HEALT-CAN, V14, P439, DOI 10.1093/pch/14.7.439; Emery CA, 2006, CLIN J SPORT MED, V16, P20, DOI 10.1097/01.jsm.0000184638.72075.b7; Emery CA, 2003, CLIN J SPORT MED, V13, P256, DOI 10.1097/00042752-200307000-00011; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Emery CA, 2010, INJURY PREV, V16, P113, DOI 10.1136/ip.2009.022764; Emery CA, 2009, CLIN J SPORT MED, V19, P207, DOI 10.1097/JSM.0b013e31819d658e; Fuller CW, 2006, CLIN J SPORT MED, V16, P97, DOI 10.1097/00042752-200603000-00003; Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319; *HOCK CAN, BACKGR CHECK; *HOCK CAN, 2008, ANN REP 2008 HOCK CA; Iverson G, 2007, CLIN J SPORT MED, V17, P31; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Makdissi M, 2009, BRIT J SPORT MED, V43, pI23, DOI 10.1136/bjsm.2009.058206; Marchie A, 2003, CAN MED ASSOC J, V169, P124; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Meeuwisse WH, 1998, CLIN J SPORT MED, V8, P164, DOI 10.1097/00042752-199807000-00003; Roberts WO, 1999, MED SCI SPORT EXER, V31, P46, DOI 10.1097/00005768-199901000-00009; ROY MA, 1989, PHYSICIAN SPORTSMED, V17, P119, DOI 10.1080/00913847.1989.11709735; *US HOCK INC, 2008, ANN REP 2007 08 US H; Warsh JM, 2009, CLIN J SPORT MED, V19, P134, DOI 10.1097/JSM.0b013e3181987783; Willer B, 2005, MED SCI SPORT EXER, V37, P1658, DOI 10.1249/01.mss.0000181839.86170.06	27	78	78	1	17	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 3Y6, CANADA	0820-3946			CAN MED ASSOC J	Can. Med. Assoc. J.	AUG 9	2011	183	11					1249	1256		10.1503/cmaj.101540			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	800SR	WOS:000293387700051	21690221	Green Published, gold			2022-02-06	
J	McMillan, TM; Teasdale, GM; Weir, CJ; Stewart, E				McMillan, T. M.; Teasdale, G. M.; Weir, C. J.; Stewart, E.			Death after head injury: the 13 year outcome of a case control study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; PROSPECTIVE COHORT; YOUNG-PEOPLE; FARE WORSE; MORTALITY; AGE; EPIDEMIOLOGY; POPULATION; DISABILITY; VARIABLES	Background Head injury is common, and the risk of subsequent disability and death is high. Increased risk of death years after injury might be explained by factors associated with, but not a consequence of, the head injury. This unique prospective study investigates mortality over 13 years after injury. Methods A cohort of n=767 with head injury was compared with two case control groups, matched for age, gender and deprivation, and in one control group, matched for duration of hospital admission following (non-head) injury. Results Two-fifths of the head injury cohort had died. The death rate (30.99 per 1000 per year) was much higher than in community controls (13.72 per 1000 per year). More than 1 year after injury, the death rate in younger (15-54 years) adults was much higher than in community controls (17.36 vs 2.36 per 1000 per year) whereas in older adults the difference was more marginal (61.47 vs 42.36). Death rate was elevated after mild and after more severe head injury, including in younger adults after mild head injury (14.82 per 1000 per year mild head injury vs 2.21 community). Female gender and greater deprivation were not associated with increased death rates after head injury. Late after injury, deaths occurred from the same main causes as for the general population. Conclusion Head injury is associated with increased vulnerability to death from a variety of causes for at least 13 years after hospital admission. There is a need to understand how head injury influences mortality, particularly in younger adults and after mild head injury.	[McMillan, T. M.; Stewart, E.] Univ Glasgow, Fac Med, Glasgow G12 0XH, Lanark, Scotland; [Teasdale, G. M.] NHS Qual Improvement Scotland, Glasgow, Lanark, Scotland; [Weir, C. J.] Univ Edinburgh, Ctr Populat Hlth Sci, MRC Hub Trials Methodol Res, Edinburgh, Midlothian, Scotland		McMillan, TM (corresponding author), Univ Glasgow, Gartnavel Royal Hosp, Fac Med, 1055 Great Western Rd, Glasgow G12 0XH, Lanark, Scotland.	t.m.mcmillan@clinmed.gla.ac.uk		Weir, Christopher/0000-0002-6494-4903	Chief Scientist Office [CZG/2/397, K/OPR/2/2/D229]; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0800803] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0800803] Funding Source: researchfish; Chief Scientist Office [CZH/4/674] Funding Source: researchfish	The 13 year follow-up was funded by the Chief Scientist Office (CZG/2/397). The original prospective study was also funded by the Chief Scientist Office (K/OPR/2/2/D229).	Baguley I, 2000, BRAIN INJURY, V14, P505; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; CONROY C, 1988, NEUROEPIDEMIOLOGY, V7, P13, DOI 10.1159/000110131; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Farin A, 2003, J NEUROSURG, V98, P32, DOI 10.3171/jns.2003.98.1.0032; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Gujral IB, 2006, BRAIN INJURY, V20, P283, DOI 10.1080/02699050500488058; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kraus J F, 2000, Neurosurg Focus, V8, pe5; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; McMillan TM, 2007, BRAIN, V130, P2520, DOI 10.1093/brain/awm185; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Pentland B, 2005, J NEUROL NEUROSUR PS, V76, P395, DOI 10.1136/jnnp.2004.037861; *SCOTT EX, 2007, ALL OUR FUT PLANN SC, V3; Scottish Executive, 2006, SCOTT IND MULT DEPR; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tate R, 1997, J HEAD TRAUMA REHAB, V12, P16, DOI 10.1097/00001199-199712000-00003; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246	30	78	78	0	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	AUG	2011	82	8					931	935		10.1136/jnnp.2010.222232			5	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	789TE	WOS:000292538400069	21282727				2022-02-06	
J	Khan, M; Sakakima, H; Dhammu, TS; Shunmugavel, A; Im, YB; Gilg, AG; Singh, AK; Singh, I				Khan, Mushfiquddin; Sakakima, Harutoshi; Dhammu, Tajinder S.; Shunmugavel, Anandakumar; Im, Yeong-Bin; Gilg, Anne G.; Singh, Avtar K.; Singh, Inderjit			S-Nitrosoglutathione reduces oxidative injury and promotes mechanisms of neurorepair following traumatic brain injury in rats	JOURNAL OF NEUROINFLAMMATION			English	Article							FOCAL CEREBRAL-ISCHEMIA; NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; RECEPTOR AGONIST 8-OH-DPAT; CORTICAL IMPACT INJURY; ENDOTHELIAL DYSFUNCTION; PROTECTS BRAIN; TNF-ALPHA; LIQUID-CHROMATOGRAPHY; SYNAPTIC PLASTICITY	Background: Traumatic brain injury (TBI) induces primary and secondary damage in both the endothelium and the brain parenchyma, collectively termed the neurovascular unit. While neurons die quickly by necrosis, a vicious cycle of secondary injury in endothelial cells exacerbates the initial injury in the neurovascular unit following TBI. In activated endothelial cells, excessive superoxide reacts with nitric oxide (NO) to form peroxynitrite. Peroxynitrite has been implicated in blood brain barrier (BBB) leakage, altered metabolic function, and neurobehavioral impairment. S-nitrosoglutathione (GSNO), a nitrosylation-based signaling molecule, was reported not only to reduce brain levels of peroxynitrite and oxidative metabolites but also to improve neurological function in TBI, stroke, and spinal cord injury. Therefore, we investigated whether GSNO promotes the neurorepair process by reducing the levels of peroxynitrite and the degree of oxidative injury. Methods: TBI was induced by controlled cortical impact (CCI) in adult male rats. GSNO or 3-Morpholinosydnonimine (SIN-1) (50 mu g/kg body weight) was administered orally two hours following CCI. The same dose was repeated daily until endpoints. GSNO-treated (GSNO group) or SIN-1-treated (SIN-1 group) injured animals were compared with vehicle-treated injured animals (TBI group) and vehicle-treated sham-operated animals (Sham group) in terms of peroxynitrite, NO, glutathione (GSH), lipid peroxidation, blood brain barrier (BBB) leakage, edema, inflammation, tissue structure, axon/myelin integrity, and neurotrophic factors. Results: SIN-1 treatment of TBI increased whereas GSNO treatment decreased peroxynitrite, lipid peroxides/aldehydes, BBB leakage, inflammation and edema in a short-term treatment (4-48 hours). GSNO also reduced brain infarctions and enhanced the levels of NO and GSH. In a long-term treatment (14 days), GSNO protected axonal integrity, maintained myelin levels, promoted synaptic plasticity, and enhanced the expression of neurotrophic factors. Conclusion: Our findings indicate the participation of peroxynitrite in the pathobiology of TBI. GSNO treatment of TBI not only reduces peroxynitrite but also protects the integrity of the neurovascular unit, indicating that GSNO blunts the deleterious effects of peroxynitrite. A long-term treatment of TBI with the same low dose of GSNO promotes synaptic plasticity and enhances the expression of neurotrophic factors. These results support that GSNO reduces the levels of oxidative metabolites, protects the neurovascular unit, and promotes neurorepair mechanisms in TBI.	[Khan, Mushfiquddin; Sakakima, Harutoshi; Dhammu, Tajinder S.; Shunmugavel, Anandakumar; Im, Yeong-Bin; Gilg, Anne G.; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA; [Singh, Avtar K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA		Singh, I (corresponding author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA.	singhi@musc.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-72511, NS-22576, NS-37766]; Betty L. Beatty Foundation; Guy E. Beatty Foundation; Veteran Administration; NIH National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06 RR018823, C06 RR015455]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06RR018823, C06RR015455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R37NS022576, R01NS072511, R01NS037766, R01NS022576] Funding Source: NIH RePORTER	These studies were supported by grants from National Institutes of Health (NS-72511, NS-22576 and NS-37766), Betty L. Beatty and Guy E. Beatty Foundations, and Veteran Administration merit awards. This work was also supported by the NIH, Grants C06 RR018823 and No C06 RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources. We are grateful to Dr Tom Smith and Dr Melissa A Crofton from the MUSC Writing Center for their valuable editing and correction of the manuscript. We would like to thank Ms Joyce Bryan for procurement of animals and chemicals, and Ms Chara Williams for secretarial assistance.	Aledia AS, 2002, ASAIO J, V48, P526, DOI 10.1097/00002480-200209000-00015; Bayir H, 2007, J NEUROCHEM, V101, P168, DOI 10.1111/j.1471-4159.2006.04353.x; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; Bilgen M, 2005, NEUROREHAB NEURAL RE, V19, P219, DOI 10.1177/1545968305278635; Bryan NS, 2004, P NATL ACAD SCI USA, V101, P4308, DOI 10.1073/pnas.0306706101; Chen JL, 2010, J CEREBR BLOOD F MET, V30, P102, DOI 10.1038/jcbfm.2009.187; Chen XR, 2007, J NEUROTRAUM, V24, P1119, DOI 10.1089/neu.2006.0216; Chen Z, 2011, STROKE, V42, P465, DOI 10.1161/STROKEAHA.110.602755; Cheng JP, 2008, BEHAV BRAIN RES, V194, P79, DOI 10.1016/j.bbr.2008.06.025; Chiueh CC, 1999, FREE RADICAL RES, V31, P641, DOI 10.1080/10715769900301211; Chiueh Chuang C., 2002, Pediatric Research, V51, P414, DOI 10.1203/00006450-200204000-00002; Choi YB, 2000, CELL MOL LIFE SCI, V57, P1535, DOI 10.1007/PL00000638; Chou PCT, 2011, J MAGN RESON IMAGING, V33, P1301, DOI 10.1002/jmri.22574; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Cui X, 2010, STROKE, V41, P2044, DOI 10.1161/STROKEAHA.110.589333; D'Acquisto F, 2001, N-S ARCH PHARMACOL, V364, P157, DOI 10.1007/s002100100435; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Endres M, 2002, ADV EXP MED BIOL, V513, P455; Erwin PA, 2005, J BIOL CHEM, V280, P19888, DOI 10.1074/jbc.M413058200; Fortenberry JD, 2001, INFLAMM RES, V50, P89; Foster MW, 2009, TRENDS MOL MED, V15, P391, DOI 10.1016/j.molmed.2009.06.007; Foster MW, 2003, TRENDS MOL MED, V9, P160, DOI 10.1016/S1471-4914(03)00028-5; Gursoy-Ozdemir Y, 2004, STROKE, V35, P1449, DOI 10.1161/01.STR.0000126044.83777.f4; Hall ED, 1999, ANN NY ACAD SCI, V890, P462, DOI 10.1111/j.1749-6632.1999.tb08025.x; Heiss C, 2006, J AM COLL CARDIOL, V47, P573, DOI 10.1016/j.jacc.2005.06.089; Hoda MN, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-21; Hoffman AN, 2008, LIFE SCI, V83, P602, DOI 10.1016/j.lfs.2008.08.007; Hoffmann J, 2001, J BIOL CHEM, V276, P41383, DOI 10.1074/jbc.M107566200; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Jatana M, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-12; Joca SRL, 2007, NEUROSCI LETT, V421, P72, DOI 10.1016/j.neulet.2007.05.026; Ju TC, 2005, FREE RADICAL BIO MED, V38, P938, DOI 10.1016/j.freeradbiomed.2004.12.019; Kaposzta Z, 2002, CIRCULATION, V106, P3057, DOI 10.1161/01.CIR.0000041251.07332.28; Kaposzta Z, 2002, CIRCULATION, V105, P1480, DOI 10.1161/01.CIR.0000012347.47001.97; Kaposzta Z, 2001, CIRCULATION, V103, P2371; Khan M, 2005, J CEREBR BLOOD F MET, V25, P177, DOI 10.1038/sj.jcbfm.9600012; Khan M, 2004, J NEUROSCI RES, V76, P519, DOI 10.1002/jnr.20087; Khan M, 2007, J NEUROCHEM, V102, P365, DOI 10.1111/j.1471-4159.2007.04526.x; Khan M, 2006, NITRIC OXIDE-BIOL CH, V15, P114, DOI 10.1016/j.niox.2006.01.008; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kluge I, 1997, J NEUROCHEM, V69, P2599; Konorev EA, 1996, BRIT J PHARMACOL, V119, P511, DOI 10.1111/j.1476-5381.1996.tb15701.x; KONOREV EA, 1995, J PHARMACOL EXP THER, V274, P200; Kuzkaya N, 2003, J BIOL CHEM, V278, P22546, DOI 10.1074/jbc.M302227200; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Lima B, 2010, CIRC RES, V106, P633, DOI 10.1161/CIRCRESAHA.109.207381; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; Martinez-Ruiz A, 2004, CARDIOVASC RES, V62, P43, DOI 10.1016/j.cardiores.2004.01.013; MATSUMOTO A, 2011, NITRIC OXIDE; Mohr S, 1997, BIOCHEM BIOPH RES CO, V238, P387, DOI 10.1006/bbrc.1997.7304; Molloy J, 1998, CIRCULATION, V98, P1372, DOI 10.1161/01.CIR.98.14.1372; Nath N, 2010, J NEUROIMMUNE PHARM, V5, P240, DOI 10.1007/s11481-009-9187-x; Neumann P, 2006, AM J PHYSIOL-LUNG C, V290, pL674, DOI 10.1152/ajplung.00391.2005; Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006; Paintlia AS, 2004, J NEUROSCI RES, V77, P63, DOI 10.1002/jnr.20130; Pannu R, 2007, J NEUROCHEM, V101, P182, DOI 10.1111/j.1471-4159.2006.04354.x; Parnham M, 2000, EXPERT OPIN INV DRUG, V9, P607, DOI 10.1517/13543784.9.3.607; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P793; Prasad A, 1999, J AM COLL CARDIOL, V34, P507, DOI 10.1016/S0735-1097(99)00216-8; Prasad R, 2007, GLIA, V55, P65, DOI 10.1002/glia.20436; RADOMSKI MW, 1992, BRIT J PHARMACOL, V107, P745, DOI 10.1111/j.1476-5381.1992.tb14517.x; Rauhala P, 1998, FASEB J, V12, P165, DOI 10.1096/fasebj.12.2.165; Rauhala P, 1996, SYNAPSE, V23, P58, DOI 10.1002/(SICI)1098-2396(199605)23:1<58::AID-SYN7>3.0.CO;2-G; Ravi K, 2004, P NATL ACAD SCI USA, V101, P2619, DOI 10.1073/pnas.0300464101; Recalcati S, 2010, ANTIOXID REDOX SIGN, V13, P1593, DOI 10.1089/ars.2009.2983; Reed TT, 2009, J NEUROSCI RES, V87, P408, DOI 10.1002/jnr.21872; Savidge TC, 2007, GASTROENTEROLOGY, V132, P1344, DOI 10.1053/j.gastro.2007.01.051; Schmidt HHHW, 1996, P NATL ACAD SCI USA, V93, P14492, DOI 10.1073/pnas.93.25.14492; Schonhoff CM, 2006, P NATL ACAD SCI USA, V103, P2404, DOI 10.1073/pnas.0507243103; Schrammel A, 2003, FREE RADICAL BIO MED, V34, P1078, DOI 10.1016/S0891-5849(03)00038-8; Selemidis S, 2007, CARDIOVASC RES, V75, P349, DOI 10.1016/j.cardiores.2007.03.030; Sharma SS, 2004, J NEUROSURG, V101, P669, DOI 10.3171/jns.2004.101.4.0669; Sheng HX, 2011, STROKE, V42, P471, DOI 10.1161/STROKEAHA.110.600569; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Shunmugavel A, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-17; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh SP, 1996, P NATL ACAD SCI USA, V93, P14428, DOI 10.1073/pnas.93.25.14428; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; Stanimirovic DB, 1997, ACT NEUR S, V70, P12; Sydserff SG, 2002, BRIT J PHARMACOL, V135, P103, DOI 10.1038/sj.bjp.0704449; Szabo C, 2007, NAT REV DRUG DISCOV, V6, P662, DOI 10.1038/nrd2222; Szocs K, 2004, GEN PHYSIOL BIOPHYS, V23, P265; Thiyagarajan M, 2004, BRIT J PHARMACOL, V142, P899, DOI 10.1038/sj.bjp.0705811; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Tsikas D, 1999, ANAL BIOCHEM, V273, P32, DOI 10.1006/abio.1999.4209; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wagner AK, 2007, BEHAV BRAIN RES, V181, P200, DOI 10.1016/j.bbr.2007.04.006; WEISSMAN DE, 1988, J NEURO-ONCOL, V6, P339; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu AG, 2010, NEUROREHAB NEURAL RE, V24, P290, DOI 10.1177/1545968309348318; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Yemisci M, 2009, NAT MED, V15, P1031, DOI 10.1038/nm.2022; Zhang Y, 2001, STROKE, V32, P1378, DOI 10.1161/01.STR.32.6.1378	97	78	84	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	JUL 6	2011	8								78	10.1186/1742-2094-8-78			17	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	810UH	WOS:000294152500001	21733162	Green Published, gold			2022-02-06	
J	Mills, JD; Hadley, K; Bailes, JE				Mills, James D.; Hadley, Kevin; Bailes, Julian E.			Dietary Supplementation With the Omega-3 Fatty Acid Docosahexaenoic Acid in Traumatic Brain Injury?	NEUROSURGERY			English	Article						Amyloid precursor protein (APP); Caspase-3 CD68; Docosahexaenoic acid (DHA); Omega-3 fatty acids; Traumatic brain injury	POLYUNSATURATED FATTY-ACIDS; PHOSPHOLIPID DEGRADATION; ISCHEMIC-STROKE; AXONAL INJURY; ANTIPLATELET; DYSFUNCTION; MECHANISMS; STATINS; GROWTH; MODEL	BACKGROUND: Although various strategies for prevention of brain disease have been implemented, no substance has been found to be advantageous for prophylaxis against brain injury. OBJECTIVE: While previous work in our laboratory and others have shown positive effects using the omega-3 fatty acid docosahexaenoic acid (DHA) in post-injury treatment following traumatic and ischemic insults, we wished to test its effects when given prior to injury. We have attempted to measure anatomical, cellular, and behavioral outcomes with a prophylactic administration of DHA. METHODS: Five groups of 16 adult male Sprague-Dawley rats were subjected to an impact acceleration traumatic brain after having received a prior administration of DHA in doses of 3, 12, and 40 mg/kg for 30 days prior. Serum fatty acid levels were determined from isolated plasma phospholipids at baseline and at the end of 30 days supplementation. Following sacrifice 1 week after injury, brainstem white matter tracts underwent fluorescent immunohistochemical processing for labeling of beta amyloid precursor protein (APP), an anatomical marker of brain injury, as well as measurements of CD68 and caspase-3 levels, and water maze testing was used for behavioral assessment. RESULTS: Dietary supplementation with DHA resulted in increased serum DHA levels proportionate with the escalating dosage. Immunohistochemical analysis revealed significantly (P<.05) decreased numbers of APP levels in all groups of animals receiving pre-injury supplementation with DHA of 4, 12, and 40 mg/kg at 13955, 4186, and 2827 axons per mm(3), respectively, vs 37442 in unsupplemented animals, as measured by stereological methodology. Using a selective measuring technique, only the highest dosage group, 40 mg/kg showed significantly (P<.05) decreased numbers of APP positive axons, at 1.15 axons per high power field vs 6.78 in unsupplemented animals. CD-68, caspase-3, and water maze testing all were significantly (P<.05) improved in the high dose group. CONCLUSION: Dietary supplementation with DHA increases serum levels and, if given prior to traumatic brain injury, reduces the injury response, as measured by axonal injury counts, markers for cellular injury and apoptosis, and memory assessment by water maze testing. This uniform response was seen for the highest dosage group, 40 mg/kg given over 30 days prior to injury, but when measured by stereological counting methodology there was a positive response to anatomical injury across low to high doses of DHA. The potential for DHA to provide prophylactic benefit to the brain against traumatic injury appears promising and requires further investigation.	[Mills, James D.; Bailes, Julian E.] W Virginia Univ, Dept Neurosurg, Sch Med, Morgantown, WV 26506 USA; [Hadley, Kevin] Martek Biosci Corp, Columbia, MD USA		Bailes, JE (corresponding author), W Virginia Univ, Dept Neurosurg, Sch Med, POB 9183, Morgantown, WV 26506 USA.	jbailes@hsc.wvu.edu			Martek, Inc.	This research was supported by a grant from Martek, Inc. Dr Bailes is a consultant for Martek, Inc. The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	Babcock AA, 2006, J NEUROSCI, V26, P12826, DOI 10.1523/JNEUROSCI.4937-05.2006; Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; Bazan NG, 2005, BRAIN PATHOL, V15, P159; Belayev L, 2009, STROKE, V40, pE223; Berman DR, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2009.01.020; Blondeau N, 2002, NEUROSCIENCE, V109, P231, DOI 10.1016/S0306-4522(01)00473-0; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Calder PC, 2003, BRAZ J MED BIOL RES, V36, P433, DOI 10.1590/S0100-879X2003000400004; Calderon F, 2004, J NEUROCHEM, V90, P979, DOI 10.1111/j.1471-4159.2004.02520.x; Cao DH, 2004, PHARMACOL BIOCHEM BE, V79, P651, DOI 10.1016/j.pbb.2004.09.016; Choi JS, 2006, NEUROSCI LETT, V409, P187, DOI 10.1016/j.neulet.2006.09.053; Cucchiara B, 2001, J NEUROL SCI, V187, P81, DOI 10.1016/S0022-510X(01)00529-9; Desire L, 2000, J NEUROCHEM, V75, P151, DOI 10.1046/j.1471-4159.2000.0750151.x; Diener HC, 2000, NEUROL CLIN, V18, P343, DOI 10.1016/S0733-8619(05)70196-1; Doraiswamy PM, 2002, CNS DRUGS, V16, P811, DOI 10.2165/00023210-200216120-00003; Freiberg JJ, 2008, JAMA-J AM MED ASSOC, V300, P2142, DOI 10.1001/jama.2008.621; He CW, 2009, P NATL ACAD SCI USA, V106, P11370, DOI 10.1073/pnas.0904835106; Heller AR, 2006, CRIT CARE MED, V34, P972, DOI 10.1097/01.CCM.0000206309.83570.45; Hogyes E, 2003, NEUROSCIENCE, V119, P999, DOI 10.1016/S0306-4522(03)00198-2; Homayoun P, 1997, J NEUROCHEM, V69, P199; Huang WL, 2007, BRAIN, V130, P3004, DOI 10.1093/brain/awm223; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Jump DB, 2002, CURR OPIN LIPIDOL, V13, P155, DOI 10.1097/00041433-200204000-00007; Lauritzen I, 2000, EMBO J, V19, P1784, DOI 10.1093/emboj/19.8.1784; Leys D, 2009, CEREBROVASC DIS, V27, P120, DOI 10.1159/000200449; Li WK, 2009, J NEUROCHEM, V110, P1339, DOI 10.1111/j.1471-4159.2009.06224.x; Lonergan PE, 2004, J NEUROCHEM, V91, P20, DOI 10.1111/j.1471-4159.2004.02689.x; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARTINEZ M, 1992, J PEDIATR-US, V120, pS129, DOI 10.1016/S0022-3476(05)81247-8; Mills JD, 2003, J BIOMED OPT, V8, P347, DOI 10.1117/1.1584443; Mills JD, 2010, J NEUROSURG     0716; Moreira Paula I, 2006, Expert Rev Neurother, V6, P897, DOI 10.1586/14737175.6.6.897; Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101; NEEDLEMAN P, 1979, P NATL ACAD SCI USA, V76, P944, DOI 10.1073/pnas.76.2.944; Pan HC, 2009, J NUTR BIOCHEM, V20, P715, DOI 10.1016/j.jnutbio.2008.06.014; Rajanikant GK, 2007, CURR MED CHEM, V14, P103, DOI 10.2174/092986707779313462; Roberts L, 2008, J AM COLL SURGEONS, V207, P276, DOI 10.1016/j.jamcollsurg.2008.02.015; Salem N, 2001, LIPIDS, V36, P945, DOI 10.1007/s11745-001-0805-6; Shah RS, 2008, BIOMED PHARMACOTHER, V62, P199, DOI 10.1016/j.biopha.2008.02.005; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Vaughan CJ, 1999, STROKE, V30, P1969, DOI 10.1161/01.STR.30.9.1969; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang XY, 2003, J AM SOC NEPHROL, V14, p729A; Wilcock DM, 2008, J ALZHEIMERS DIS, V15, P555; Wolff T, 2009, ANN INTERN MED, V150, P632, DOI 10.7326/0003-4819-150-9-200905050-00010; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313	47	78	80	1	13	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	FEB	2011	68	2					474	481		10.1227/NEU.0b013e3181ff692b			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	703QJ	WOS:000285994300080	21135750				2022-02-06	
J	de la Plata, CDM; Garces, J; Kojori, ES; Grinnan, J; Krishnan, K; Pidikiti, R; Spence, J; Devous, MD; Moore, C; McColl, R; Madden, C; Diaz-Arrastia, R				de la Plata, Carlos D. Marquez; Garces, Juanita; Kojori, Ehsan Shokri; Grinnan, Jack; Krishnan, Kamini; Pidikiti, Rajesh; Spence, Jeffrey; Devous, Michael D., Sr.; Moore, Carol; McColl, Rodderick; Madden, Christopher; Diaz-Arrastia, Ramon			Deficits in Functional Connectivity of Hippocampal and Frontal Lobe Circuits After Traumatic Axonal Injury	ARCHIVES OF NEUROLOGY			English	Article							BLUNT HEAD-INJURY; BRAIN-INJURY; ALZHEIMERS-DISEASE; CORPUS-CALLOSUM; MEMORY DEFICIT; LESIONS; DYSFUNCTION; ATTENTION; SEVERITY; EPILEPSY	Objective: To examine the functional connectivity of hippocampal and selected frontal lobe circuits in patients with traumatic axonal injury (TAI). Design: Observational study. Setting: An inpatient traumatic brain injury unit. Imaging and neurocognitive assessments were conducted in an outpatient research facility. Participants: Twenty-five consecutive patients with brain injuries consistent with TAI and acute subcortical white matter abnormalities were studied as well as 16 healthy volunteers of similar age and sex. Interventions: Echo-planar and high-resolution T1-weighted images were acquired using 3-T scanners. Regions of interest (ROI) were drawn bilaterally for the hippocampus, anterior cingulate cortex (ACC), and dorsolateral prefrontal cortex and were used to extract time series data. Blood oxygenation level-dependent data from each ROI were used as reference functions for correlating with all other brain voxels. Interhemispheric functional connectivity was assessed for each participant by correlating homologous regions using a Pearson correlation coefficient. Patient functional and neurocognitive outcomes were assessed approximately 6 months after injury. Main Outcome Measures: Interhemispheric functional connectivity, spatial patterns of functional connectivity, and associations of connectivity measures with functional and neurocognitive outcomes. Results: Patients showed significantly lower interhemispheric functional connectivity for the hippocampus and ACC. Controls demonstrated stronger and more focused functional connectivity for the hippocampi and ACC, and a more focused recruitment of the default mode network for the dorsolateral prefrontal cortex ROI. The interhemispheric functional connectivity for the hippocampus was correlated with delayed recall of verbal information. Conclusions: Traumatic axonal injury may affect interhemispheric neural activity, as patients with TAI show disrupted interhemispheric functional connectivity. More careful investigation of interhemispheric connectivity is warranted, as it demonstrated a modest association with outcome in chronic TBI.	[Garces, Juanita; Pidikiti, Rajesh; Moore, Carol; Diaz-Arrastia, Ramon] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [de la Plata, Carlos D. Marquez] Univ Texas Dallas, Ctr Brain Hlth, Richardson, TX 75083 USA; [de la Plata, Carlos D. Marquez; Kojori, Ehsan Shokri; Grinnan, Jack; Krishnan, Kamini] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA; [Spence, Jeffrey] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA; [Devous, Michael D., Sr.; McColl, Rodderick] Univ Texas SW Med Ctr Dallas, Dept Radiol Neuroradiol, Dallas, TX 75390 USA; [Madden, Christopher] Univ Texas SW Med Ctr Dallas, Dept Neurol Surg, Dallas, TX 75390 USA		Diaz-Arrastia, R (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	ramon.diaz-arrastia@utsouthwestern.edu	Pidikiti, Rajesh/E-2686-2013	Diaz-Arrastia, Ramon/0000-0001-6051-3594; McColl, Roderick/0000-0001-7022-100X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23 NS060827, R01 HD48179]; Department of EducationUS Department of Education [H133 A020526]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS060827] Funding Source: NIH RePORTER	This study was supported by grants K23 NS060827 (Dr Marquez de la Plata) and R01 HD48179 (Dr Diaz-Arrastia) from the National Institutes of Health and Department of Education grant H133 A020526.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Allen G, 2007, ARCH NEUROL-CHICAGO, V64, P1482, DOI 10.1001/archneur.64.10.1482; AMARAL DG, 1984, J COMP NEUROL, V224, P307, DOI 10.1002/cne.902240302; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Bosma I, 2008, NEURO-ONCOLOGY, V10, P734, DOI 10.1215/15228517-2008-034; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Buckner RL, 2009, J NEUROSCI, V29, P1860, DOI 10.1523/JNEUROSCI.5062-08.2009; Castellanos FX, 2008, BIOL PSYCHIAT, V63, P332, DOI 10.1016/j.biopsych.2007.06.025; Cordes D, 2001, AM J NEURORADIOL, V22, P1326; Damoiseaux JS, 2008, CEREB CORTEX, V18, P1856, DOI 10.1093/cercor/bhm207; de la Plata CM, 2007, J NEUROTRAUM, V24, P591, DOI 10.1089/neu.2006.0214; Delis D.C., 2000, CALIFORNIA VERBAL LE; DODRILL CB, 1978, EPILEPSIA, V19, P611, DOI 10.1111/j.1528-1157.1978.tb05041.x; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Garnett MR, 2001, CURR OPIN NEUROL, V14, P753, DOI 10.1097/00019052-200112000-00012; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GLOOR P, 1993, BRAIN, V116, P1249, DOI 10.1093/brain/116.5.1249; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Greicius M, 2008, CURR OPIN NEUROL, V21, P424, DOI 10.1097/WCO.0b013e328306f2c5; Gupta RK, 2005, EPILEPSIA, V46, P1465, DOI 10.1111/j.1528-1167.2005.01205.x; Hamster K., 1983, MULTILINGUAL APHASIA; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Johnston JM, 2008, J NEUROSCI, V28, P6453, DOI 10.1523/JNEUROSCI.0573-08.2008; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Langlois JA, 2006, TRAUMATIC BRAIN INJU; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; Lowe MJ, 1998, NEUROIMAGE, V7, P119, DOI 10.1006/nimg.1997.0315; MacDonald CL, 2008, NEUROLOGY, V71, P1199, DOI 10.1212/01.wnl.0000327521.69520.7f; Mai JK, 2004, ATLAS HUMAN BRAIN; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; NG HK, 1994, CLIN NEUROL NEUROSUR, V96, P24, DOI 10.1016/0303-8467(94)90025-6; Peltier SJ, 2002, NEUROIMAGE, V16, P985, DOI 10.1006/nimg.2002.1141; Quigley M, 2003, AM J NEURORADIOL, V24, P208; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Song M, 2008, NEUROIMAGE, V41, P1168, DOI 10.1016/j.neuroimage.2008.02.036; Stein T, 2000, AM J NEURORADIOL, V21, P1397; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; van den Heuvel MP, 2009, HUM BRAIN MAPP, V30, P3127, DOI 10.1002/hbm.20737; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Wang L, 2006, NEUROIMAGE, V31, P496, DOI 10.1016/j.neuroimage.2005.12.033; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Ylvisaker Mark, 1996, Seminars in Speech and Language, V17, P217, DOI 10.1055/s-2008-1064100	56	78	79	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	JAN	2011	68	1					74	84		10.1001/archneurol.2010.342			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	704MO	WOS:000286057300010	21220676	Bronze, Green Accepted			2022-02-06	
J	Greuters, S; van den Berg, A; Franschman, G; Viersen, VA; Beishuizen, A; Peerdeman, SM; Boer, C				Greuters, Sjoerd; van den Berg, Annelies; Franschman, Gaby; Viersen, Victor A.; Beishuizen, Albertus; Peerdeman, Saskia M.; Boer, Christa		ALARM-BLEEDING Investigators	Acute and delayed mild coagulopathy are related to outcome in patients with isolated traumatic brain injury	CRITICAL CARE			English	Article							HEAD-INJURY; INTRAVASCULAR COAGULATION; DISORDERS; HYPOPERFUSION; HYPOTHERMIA; HEMOSTASIS; THROMBOSIS; SYSTEM	Introduction: The relationship between isolated traumatic brain injury (TBI) associated coagulopathy and patient prognosis frequently lacks information regarding the time course of coagulation disorders throughout the post-traumatic period. This study was conducted to assess the prevalence and time course of post-traumatic coagulopathy in patients with isolated TBI and the relationship of these hemostatic disorders with outcome. Methods: The local Human Subjects Committee approved the study. We retrospectively studied the medical records of computed tomography (CT)-confirmed isolated TBI patients with an extracranial abbreviated injury scale (AIS) <3 who were primarily referred to a Level 1 trauma centre in Amsterdam (n = 107). Hemostatic parameters including activated partial thromboplastin time (aPTT), prothrombin time (PT), platelet count, hemoglobin, hematocrit, glucose, pH and lactate levels were recorded throughout a 72-hour period as part of a routine standardized follow-up of TBI. Coagulopathy was defined as a aPPT >40 seconds and/or a PTT in International Normalized Ratio (INR) >1.2 and/or a platelet count <120*10(9)/l. Results: Patients were mostly male, aged 48 +/- 20 years with a median injury severity score of 25 (range 20 to 25). Early coagulopathy as diagnosed in the emergency department (ED) occurred in 24% of all patients. The occurrence of TBI-related coagulopathy increased to 54% in the first 24 hours post-trauma. In addition to an increased age and disturbed pupillary reflex, both coagulopathy upon ED arrival and during the first 24 hours post-trauma provided an independent prognostic factor for unfavorable outcome (odds ratio (OR) 3.75 (95% CI 1.07 to 12.51; P = 0.04) and OR 11.61 (2.79 to 48.34); P = 0.003). Conclusions: Our study confirms a high prevalence of early and delayed coagulopathy in patients with isolated TBI, which is strongly associated with an unfavorable outcome. These data support close monitoring of hemostasis after TBI and indicate that correction of coagulation disturbances might need to be considered.	[Greuters, Sjoerd; van den Berg, Annelies; Franschman, Gaby; Viersen, Victor A.; Boer, Christa] Vrije Univ Amsterdam Med Ctr, Inst Cardiovasc Res, Dept Anesthesiol, NL-1081 HV Amsterdam, Netherlands; [Beishuizen, Albertus] Vrije Univ Amsterdam Med Ctr, Inst Cardiovasc Res, Dept Intens Care Med, NL-1081 HV Amsterdam, Netherlands; [Peerdeman, Saskia M.] Vrije Univ Amsterdam Med Ctr, Dept Neurosurg, NL-1081 HV Amsterdam, Netherlands		Greuters, S (corresponding author), Vrije Univ Amsterdam Med Ctr, Inst Cardiovasc Res, Dept Anesthesiol, De Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands.	s.greuters@vumc.nl		Boer, Christa/0000-0002-7781-6951			Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Brohi K, 2008, J TRAUMA, V64, P1211, DOI 10.1097/TA.0b013e318169cd3c; Brown CVR, 2010, J TRAUMA, V68, P348, DOI 10.1097/TA.0b013e3181bbfb6b; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; Cortiana M, 1986, J Neurosurg Sci, V30, P133; Cosgriff N, 1997, J TRAUMA, V42, P857, DOI 10.1097/00005373-199705000-00016; DRAKE TA, 1989, AM J PATHOL, V134, P1087; Engstrom M, 2006, J NEUROSURG ANESTH, V18, P200, DOI 10.1097/01.ana.0000211002.63774.8a; Etemadrezaie H, 2007, CLIN NEUROL NEUROSUR, V109, P166, DOI 10.1016/j.clineuro.2006.09.001; FRANSCHMAN G, 2010, RESUSCITATION; GANDO S, 1992, CRIT CARE MED, V20, P594, DOI 10.1097/00003246-199205000-00009; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; Halpern CH, 2008, J NEUROTRAUM, V25, P997, DOI 10.1089/neu.2008.0548; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Maegele M, 2007, INJURY, V38, P298, DOI 10.1016/j.injury.2006.10.003; McQuay N, 2009, J NEUROSURG, V111, P666, DOI 10.3171/2009.4.JNS081611; Morel N, 2008, J TRAUMA, V64, P698, DOI 10.1097/TA.0b013e31816493ad; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Saggar V, 2009, J NEUROTRAUM, V26, P1665, DOI 10.1089/neu.2008.0799; SLOAN EP, 1989, J TRAUMA, V29, P1647, DOI 10.1097/00005373-198912000-00011; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Taylor FB, 2001, THROMB HAEMOSTASIS, V86, P1327, DOI 10.1055/s-0037-1616068; VANDERSANDE JJ, 1978, J NEUROSURG, V49, P357, DOI 10.3171/jns.1978.49.3.0357; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Zehtabchi S, 2008, RESUSCITATION, V76, P52, DOI 10.1016/j.resuscitation.2007.06.024	31	78	86	1	7	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2011	15	1							R2	10.1186/cc9399			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742RJ	WOS:000288961900002	21208418	Green Published, gold			2022-02-06	
J	Cretchley, J; Gallois, C; Chenery, H; Smith, A				Cretchley, Julia; Gallois, Cindy; Chenery, Helen; Smith, Andrew			Conversations Between Carers and People With Schizophrenia: A Qualitative Analysis Using Leximancer	QUALITATIVE HEALTH RESEARCH			English	Article						caregiving; communication; concept mapping; families, mental health and illness; schizophrenia; technology, use in research	TRAUMATIC BRAIN-INJURY; FAMILY BURDEN; LANGUAGE; COMMUNICATION; HEALTH; ILLNESS; ACCOMMODATION; PERFORMANCE; DISORDERS; DISCOURSE	We examined conversations between people with schizophrenia (PwS) and family or professional carers with whom they interacted frequently. We allocated PwS to one of two communication profiles: Low-activity communicators talked much less than their conversational partners, whereas high-activity communicators talked much more. We used Leximancer text analytics software to analyze the conversations. We found that carers used different strategies to accommodate to the PwS's behavior, depending on the PwS's communication profile and their relationship. These findings indicate that optimal communication strategies depend on the PwS's conversational tendencies and the relationship context. They also suggest new opportunities for qualitative assessment via intelligent text analytics technologies.	[Cretchley, Julia] Univ Queensland, Sch Psychol, St Lucia, Qld 4072, Australia; [Gallois, Cindy] Univ Queensland, Fac Social & Behav Sci, St Lucia, Qld 4072, Australia; [Chenery, Helen] Univ Queensland, Fac Hlth Sci, St Lucia, Qld 4072, Australia; [Smith, Andrew] Univ Queensland, Social Sci Res Inst, St Lucia, Qld 4072, Australia		Cretchley, J (corresponding author), Univ Queensland, Sch Psychol, St Lucia, Qld 4072, Australia.	j.cretchley@uq.edu.au	Gallois, Cindy/F-9546-2014; Chenery, Helen J/F-5194-2010	Gallois, Cindy/0000-0002-7938-7839; 			American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Andreasen N, 1978, SCALE ASSESSMENT THO; Andreasen N.C., 1985, CONTROVERSIES SCHIZO, P199; ANDREASEN NC, 1979, ARCH GEN PSYCHIAT, V36, P1325; ANDREASEN NC, 1982, ARCH GEN PSYCHIAT, V39, P789; ANDREASEN NC, 1986, SCHIZOPHRENIA BULL, V12, P348, DOI 10.1093/schbul/12.3.348; Arkar H, 1997, SOC PSYCH PSYCH EPID, V32, P171; Atkinson M., 1984, STRUCTURES SOCIAL AC, pix; Berglund N, 2003, SOC PSYCH PSYCH EPID, V38, P116, DOI 10.1007/s00127-003-0615-6; BRUGHA TS, 1988, PSYCHOL MED, V18, P443, DOI 10.1017/S0033291700007984; Carr VJ, 2004, SOC PSYCH PSYCH EPID, V39, P78, DOI 10.1007/s00127-004-0703-2; CHAIKA E, 1974, BRAIN LANG, V1, P257, DOI 10.1016/0093-934X(74)90040-6; Cornwall PL, 1996, SOC PSYCH PSYCH EPID, V31, P345, DOI 10.1007/BF00783423; CRAWFORD JR, 1990, BRIT J CLIN PSYCHOL, V29, P239, DOI 10.1111/j.2044-8260.1990.tb00878.x; CREER C, 1974, SCHIZOPHRENIA HOME; Cretchley J, 2010, J CROSS CULT PSYCHOL, V41, P318, DOI 10.1177/0022022110366105; DAVIES S, 1994, SOC PSYCH PSYCH EPID, V29, P241, DOI 10.1007/BF00802045; De la Varre C, 2005, EXPLORING FRONTIERS; Freeman D. S., 1978, FAMILY THERAPY, V5, P277; Gallois C, 2005, LEA COMMUN SER, P231; Gallois C., 2003, 53 ANN C INT COMM AS; Gallois C., 1995, INTERCULTURAL COMMUN, P115; GALLOIS C, 1996, INT J PSYCHOLINGUIST, V12, P193; Gallois Cindy, 2005, THEORIZING INTERCULT, P121; GIBBONS JS, 1984, BRIT J PSYCHIAT, V144, P70, DOI 10.1192/bjp.144.1.70; Giles H., 1991, STUDIES EMOTION SOCI, P1; GRECH MR, 2002, P HUM FACT ERG SOC 4; Hamilton H., 1991, STUDIES EMOTION SOCI, P158; Harwood J., 1993, LANG SCI, V15, P15, DOI [10.1016/0388-0001(93)90003-B, DOI 10.1016/0388-0001(93)90003-B]; Hewett DG, 2009, SOC SCI MED, V69, P1732, DOI 10.1016/j.socscimed.2009.09.048; Jones E, 1999, J LANG SOC PSYCHOL, V18, P123, DOI 10.1177/0261927X99018002001; KAVANAGH DJ, 1992, BRIT J PSYCHIAT, V160, P601, DOI 10.1192/bjp.160.5.601; KAVANAGH S, 1995, SOC PSYCH PSYCH EPID, V30, P206; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; Kuipers E, 1998, OUTCOME AND INNOVATION IN PSYCHOLOGICAL TREATMENT OF SCHIZOPHRENIA, P201; KUIPERS L, 1993, SOC PSYCH PSYCH EPID, V28, P207; LECOURS AR, 1976, BRAIN LANG, V3, P516, DOI 10.1016/0093-934X(76)90046-8; Martin N. J., 2007, RISK MANAGE, V9, P188, DOI DOI 10.1057/PALGRAVE.RM.8250030; McAuliffe D, 2009, ADV MENT HEALTH, V8, P57, DOI 10.5172/jamh.8.1.57; McDonell MG, 2003, FAM PROCESS, V42, P91, DOI 10.1111/j.1545-5300.2003.00091.x; MCGUFFIN P, 1991, ARCH GEN PSYCHIAT, V48, P764; McKenna B, 2007, J LANG POLIT, V6, P377, DOI 10.1075/jlp.6.3.06mck; Meilijson SR, 2004, J SPEECH LANG HEAR R, V47, P695, DOI 10.1044/1092-4388(2004/053); Rochester Sherry, 1979, CRAZY TALK STUDY DIS; Rooney D., MANAGEMENT IN PRESS, V24, P44; Rooney D, 2010, MANAGE COMMUN Q, V24, P44, DOI 10.1177/0893318909351434; Ryan E., 2005, INTERGROUP COMMUNICA; Saavedra J, 2009, QUAL HEALTH RES, V19, P1548, DOI 10.1177/1049732309351110; SCHEGLOFF E, 1973, SEMIOTICA, V4, P289, DOI DOI 10.1515/SEMI.1973.8.4.289; SCHWARTZ S, 1982, BEHAV BRAIN SCI, V5, P579, DOI 10.1017/S0140525X00013650; SMITH AE, 2003, HLT NAACL 2003 HUM L; Smith AE, 2006, BEHAV RES METHODS, V38, P262, DOI 10.3758/BF03192778; Street RL., 2001, NEW HDB LANGUAGE SOC, P541; TARRIER N, 1995, INT J MENT HEALTH, V24, P38, DOI 10.1080/00207411.1995.11449318; THOMAS P, 1990, BRIT J PSYCHIAT, V156, P204, DOI 10.1192/bjp.156.2.204; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 2000, APHASIOLOGY, V14, P365, DOI 10.1080/026870300401414; VELTRO F, 1994, SOC PSYCH PSYCH EPID, V29, P66; Watson B, 1998, HEALTH COMMUN, V10, P343, DOI 10.1207/s15327027hc1004_3; Watson B, 2004, LANGUAGE MATTERS COM, P63; Watson B., 2008, 11 INT C LANG SOC PS; Watson B. M., 1999, INT J APPL LINGUIST, V9, P167, DOI DOI 10.1111/J.1473-4192.1999.TB00170.X; Watson B, 2007, PALGRAVE ADV, P108; Watson M, 2005, LECT NOTES ARTIF INT, V3683, P1232; Williams A., 2001, INTERGENERATIONAL CO, P85; Wrobel J., 1990, LANGUAGE SCHIZOPHREN	66	78	78	1	30	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1049-7323			QUAL HEALTH RES	Qual. Health Res.	DEC	2010	20	12					1611	1628		10.1177/1049732310378297			18	Public, Environmental & Occupational Health; Information Science & Library Science; Social Sciences, Interdisciplinary; Social Sciences, Biomedical	Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health; Information Science & Library Science; Social Sciences - Other Topics; Biomedical Social Sciences	683IO	WOS:000284469700002	20675536				2022-02-06	
J	Xilouri, M; Stefanis, L				Xilouri, Maria; Stefanis, Leonidas			Autophagy in the Central Nervous System: Implications for Neurodegenerative Disorders	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Autophagosome; chaperone-mediated autophagy; LAMP-2A receptor; LC3; macroautophagy; neurodegenerative diseases	CHAPERONE-MEDIATED AUTOPHAGY; INCLUSION-BODY FORMATION; SCRAPIE-RESPONSIVE GENE; TRAUMATIC BRAIN-INJURY; CELL-DEATH PATHWAYS; ALPHA-SYNUCLEIN; PARKINSONS-DISEASE; HUNTINGTONS-DISEASE; UP-REGULATION; PROTEIN-DEGRADATION	The autophagy-lysosomal pathway is a major proteolytic pathway that in mammalian systems mainly comprises of macroautophagy and chaperone-mediated autophagy. The former is relatively non-selective and involves bulk degradation of proteins and organelles, whereas the latter is selective for certain cytosolic proteins. These autophagy pathways are important in development, differentiation, cellular remodeling and survival during nutrient starvation. Autophagy is crucial for neuronal homeostasis and acts as a local housekeeping process, since neurons are post-mitotic cells and require effective protein degradation to prevent accumulation of toxic aggregates. A growing body of evidence now suggests that dysfunction of autophagy causes accumulation of abnormal proteins and/or damaged organelles. Such accumulation has been linked to synaptic dysfunction, cellular stress and neuronal death. Abnormal autophagy may be involved in the pathology of both chronic nervous system disorders, such as proteinopathies (Alzheimer's, Parkinson's, Huntington's disease) and acute brain injuries. Although autophagy is generally beneficial, its aberrant activation may also exert a detrimental role in neurological diseases depending on the environment and the insult, leading to autophagic neuronal death. In this review we summarize the current knowledge regarding the role of autophagy-lysosomal pathway in the central nervous system and discuss the implication of autophagy dysregulation in human neurological diseases and animal models.	[Xilouri, Maria; Stefanis, Leonidas] Acad Athens, Biomed Res Fdn, Div Basic Neurosci, Athens 11527, Greece; [Stefanis, Leonidas] Univ Athens, Sch Med, Dept Neurol 2, GR-11527 Athens, Greece		Xilouri, M (corresponding author), Acad Athens, Biomed Res Fdn, Div Basic Neurosci, 4 Soranou Efesiou St, Athens 11527, Greece.	mxilouri@bioacademy.gr	Stefanis, Leonidas/AAD-7192-2019	Xilouri, Maria/0000-0001-7038-0780			Abou-Sleiman PM, 2006, NAT REV NEUROSCI, V7, P207, DOI 10.1038/nrn1868; Adhami F, 2006, AM J PATHOL, V169, P566, DOI 10.2353/ajpath.2006.051066; Agarraberes FA, 2001, J CELL SCI, V114, P2491; Agarraberes FA, 1997, J CELL BIOL, V137, P825, DOI 10.1083/jcb.137.4.825; Aguib Y, 2009, AUTOPHAGY, V5, P361, DOI 10.4161/auto.5.3.7662; Aguzzi A, 2004, CELL, V116, P313, DOI 10.1016/S0092-8674(03)01031-6; Alegre-Abarrategui J, 2009, AUTOPHAGY, V5, P1208, DOI 10.4161/auto.5.8.9894; Alegre-Abarrategui J, 2009, HUM MOL GENET, V18, P4022, DOI 10.1093/hmg/ddp346; Anderson JP, 2006, J BIOL CHEM, V281, P29739, DOI 10.1074/jbc.M600933200; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; Axe EL, 2008, J CELL BIOL, V182, P685, DOI 10.1083/jcb.200803137; Bandyopadhyay U, 2008, MOL CELL BIOL, V28, P5747, DOI 10.1128/MCB.02070-07; Bates G, 2003, LANCET, V361, P1642, DOI 10.1016/S0140-6736(03)13304-1; Berger Z, 2006, HUM MOL GENET, V15, P433, DOI 10.1093/hmg/ddi458; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Bjorkoy G, 2006, AUTOPHAGY, V2, P138, DOI 10.4161/auto.2.2.2405; Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4; BOELLAARD JW, 1989, ACTA NEUROPATHOL, V78, P410, DOI 10.1007/BF00688178; BOELLAARD JW, 1991, ACTA NEUROPATHOL, V82, P225, DOI 10.1007/BF00294449; Boland B, 2008, J NEUROSCI, V28, P6926, DOI 10.1523/JNEUROSCI.0800-08.2008; Borsello T, 2003, EUR J NEUROSCI, V18, P473, DOI 10.1046/j.1460-9568.2003.02757.x; Canu N, 2005, J NEUROCHEM, V92, P1228, DOI 10.1111/j.1471-4159.2004.02956.x; Cao Y, 2006, J BIOL CHEM, V281, P20483, DOI 10.1074/jbc.M602180200; Carloni S, 2008, NEUROBIOL DIS, V32, P329, DOI 10.1016/j.nbd.2008.07.022; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Cataldo AM, 2000, AM J PATHOL, V157, P277, DOI 10.1016/S0002-9440(10)64538-5; Cataldo AM, 2004, J NEUROPATH EXP NEUR, V63, P821, DOI 10.1093/jnen/63.8.821; CATALDO AM, 1991, P NATL ACAD SCI USA, V88, P10998, DOI 10.1073/pnas.88.24.10998; CATALDO AM, 1995, NEURON, V14, P671, DOI 10.1016/0896-6273(95)90324-0; Chartier-Harlin MC, 2004, LANCET, V364, P1167, DOI 10.1016/S0140-6736(04)17103-1; Cherra SJ, 2008, FUTUR NEUROL, V3, P309, DOI 10.2217/14796708.3.3.309; CHIANG HL, 1988, J BIOL CHEM, V263, P6797; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; Chiba-Falek O, 2006, MOVEMENT DISORD, V21, P1703, DOI 10.1002/mds.21007; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Cuervo AM, 2000, J BIOL CHEM, V275, P31505, DOI 10.1074/jbc.M002102200; Cuervo AM, 2000, TRAFFIC, V1, P570, DOI 10.1034/j.1600-0854.2000.010707.x; Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738; Cuervo AM, 1997, J BIOL CHEM, V272, P5606, DOI 10.1074/jbc.272.9.5606; Cuervo AM, 2003, EMBO J, V22, P47, DOI 10.1093/emboj/cdg002; CUERVO AM, 1995, AM J PHYSIOL-CELL PH, V269, pC1200, DOI 10.1152/ajpcell.1995.269.5.C1200; Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501; Cuervo AM, 2005, AUTOPHAGY, V1, P131, DOI 10.4161/auto.1.3.2017; Dagda RK, 2009, J BIOL CHEM, V284, P13843, DOI 10.1074/jbc.M808515200; Dandoy-Dron F, 2000, MOL BRAIN RES, V76, P173, DOI 10.1016/S0169-328X(00)00028-0; Dandoy-Dron F, 1998, J BIOL CHEM, V273, P7691, DOI 10.1074/jbc.273.13.7691; Darios F, 2003, HUM MOL GENET, V12, P517, DOI 10.1093/hmg/ddg044; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; de Duve C., 1963, LYSOSOMES; DEDUVE C, 1966, ANNU REV PHYSIOL, V28, P435, DOI 10.1146/annurev.ph.28.030166.002251; DETER RL, 1967, J CELL BIOL, V35, pC11, DOI 10.1083/jcb.35.2.C11; DETER RL, 1967, J CELL BIOL, V33, P437, DOI 10.1083/jcb.33.2.437; Di Fonzo A, 2007, NEUROLOGY, V68, P1557, DOI 10.1212/01.wnl.0000260963.08711.08; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; Ding QX, 2003, J NEUROCHEM, V86, P489, DOI 10.1046/j.1471-4159.2003.01885.x; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Dompierre JP, 2007, J NEUROSCI, V27, P3571, DOI 10.1523/JNEUROSCI.0037-07.2007; Dron M, 2005, EUR J NEUROSCI, V22, P133, DOI 10.1111/j.1460-9568.2005.04172.x; Dron M, 1998, J BIOL CHEM, V273, P18015, DOI 10.1074/jbc.273.29.18015; Duncan C, 2010, AUTOPHAGY, V6, P312, DOI 10.4161/auto.6.2.11139; Emmanouilidou E, 2010, NEUROBIOL AGING, V31, P953, DOI 10.1016/j.neurobiolaging.2008.07.008; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Erlich S, 2006, AUTOPHAGY, V2, P49, DOI 10.4161/auto.2156; Ertmer A, 2007, LEUKEMIA, V21, P936, DOI 10.1038/sj.leu.2404606; Ertmer A, 2004, J BIOL CHEM, V279, P41918, DOI 10.1074/jbc.M405652200; Eskelinen EL, 2008, INT REV CEL MOL BIO, V266, P207, DOI 10.1016/S1937-6448(07)66005-5; Eskelinen EL, 2002, MOL BIOL CELL, V13, P3355, DOI 10.1091/mbc.E02-02-0114; Felbor U, 2002, P NATL ACAD SCI USA, V99, P7883, DOI 10.1073/pnas.112632299; Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925; Florez-McClure ML, 2004, J NEUROSCI, V24, P4498, DOI 10.1523/JNEUROSCI.5744-03.2004; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; FORNO LS, 1976, ACTA NEUROPATHOL, V34, P183, DOI 10.1007/BF00688674; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Gasser T, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001148; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Glabe C, 2001, J MOL NEUROSCI, V17, P137, DOI 10.1385/JMN:17:2:137; Gong XM, 2003, NEURON, V38, P33, DOI 10.1016/S0896-6273(03)00191-0; Gonzalez-Polo RA, 2005, J CELL SCI, V118, P3091, DOI 10.1242/jcs.02447; Guimaraes CA, 2003, J BIOL CHEM, V278, P41938, DOI 10.1074/jbc.M306547200; Hall DH, 1997, J NEUROSCI, V17, P1033; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Hars ES, 2007, AUTOPHAGY, V3, P93, DOI 10.4161/auto.3636; HATEM CL, 1995, J CELL SCI, V108, P2093; Hayashi-Nishino M, 2009, NAT CELL BIOL, V11, P1433, DOI 10.1038/ncb1991; Heiseke A, 2009, J NEUROCHEM, V109, P25, DOI 10.1111/j.1471-4159.2009.05906.x; Heitz S, 2010, BRAIN PATHOL, V20, P119, DOI 10.1111/j.1750-3639.2008.00245.x; Heitz S, 2009, AUTOPHAGY, V5, P422, DOI 10.4161/auto.5.3.7882; HIGGINS JJ, 1992, NEUROLOGY, V42, P2286, DOI 10.1212/WNL.42.12.2286; HORNUNG JP, 1989, J COMP NEUROL, V283, P425, DOI 10.1002/cne.902830310; Hosokawa N, 2009, AUTOPHAGY, V5, P973, DOI 10.4161/auto.5.7.9296; Ichimura Y, 2008, J BIOL CHEM, V283, P22847, DOI 10.1074/jbc.M802182200; Ichimura Y, 2008, AUTOPHAGY, V4, P1063, DOI 10.4161/auto.6826; Iwata A, 2005, P NATL ACAD SCI USA, V102, P13135, DOI 10.1073/pnas.0505801102; Iwata A, 2005, J BIOL CHEM, V280, P40282, DOI 10.1074/jbc.M508786200; Iwata J, 2006, J BIOL CHEM, V281, P4035, DOI 10.1074/jbc.M512283200; Jaeger PA, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-16; Jeong H, 2009, CELL, V137, P60, DOI 10.1016/j.cell.2009.03.018; Ji ZS, 2002, J BIOL CHEM, V277, P21821, DOI 10.1074/jbc.M112109200; Jia KL, 2007, AUTOPHAGY, V3, P21, DOI 10.4161/auto.3528; Kabuta T, 2008, J BIOL CHEM, V283, P23731, DOI 10.1074/jbc.M801918200; Kanki T, 2008, J BIOL CHEM, V283, P32386, DOI 10.1074/jbc.M802403200; Kaushik S, 2008, MOL BIOL CELL, V19, P2179, DOI 10.1091/mbc.E07-11-1155; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Kegel KB, 2000, J NEUROSCI, V20, P7268, DOI 10.1523/jneurosci.20-19-07268.2000; Kim YJ, 2006, NEUROBIOL DIS, V22, P346, DOI 10.1016/j.nbd.2005.11.012; Kimura N, 2007, PATHOBIOLOGY, V74, P169, DOI 10.1159/000103376; Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620; Koike M, 2005, AM J PATHOL, V167, P1713, DOI 10.1016/S0002-9440(10)61253-9; Koike M, 2000, J NEUROSCI, V20, P6898, DOI 10.1523/JNEUROSCI.20-18-06898.2000; Koike M, 2008, AM J PATHOL, V172, P454, DOI 10.2353/ajpath.2008.070876; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035; Komatsu M, 2007, P NATL ACAD SCI USA, V104, P14489, DOI 10.1073/pnas.0701311104; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Kon M, 2010, FEBS LETT, V584, P1399, DOI 10.1016/j.febslet.2009.12.025; Korolchuk VI, 2009, MOL CELL, V33, P517, DOI 10.1016/j.molcel.2009.01.021; Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021; Kraft C, 2009, BBA-MOL CELL RES, V1793, P1404, DOI 10.1016/j.bbamcr.2009.02.006; Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Kunchithapautham K, 2007, AUTOPHAGY, V3, P433, DOI 10.4161/auto.4294; Kunchithapautham K, 2007, AUTOPHAGY, V3, P65, DOI 10.4161/auto.3431; Kvam E, 2007, AUTOPHAGY, V3, P85, DOI 10.4161/auto.3586; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Landles C, 2004, EMBO REP, V5, P958, DOI 10.1038/sj.embor.7400250; Larsen KE, 2002, J NEUROSCI, V22, P8951; Lee HJ, 2004, J NEUROSCI, V24, P1888, DOI 10.1523/JNEUROSCI.3809-03.2004; Lee JA, 2007, CURR BIOL, V17, P1561, DOI 10.1016/j.cub.2007.07.029; Lee JY, 2010, EMBO J, V29, P969, DOI 10.1038/emboj.2009.405; Levine B, 2005, CELL, V120, P159, DOI 10.1016/j.cell.2005.01.005; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260; Levy OA, 2009, APOPTOSIS, V14, P478, DOI 10.1007/s10495-008-0309-3; Liao GH, 2007, AM J PATHOL, V171, P962, DOI 10.2353/ajpath.2007.070052; Liberski Pawel P, 2004, Folia Neuropathol, V42 Suppl B, P59; Liberski PP, 2008, FOLIA NEUROPATHOL, V46, P1; Liberski PP, 2004, INT J BIOCHEM CELL B, V36, P2473, DOI 10.1016/j.biocel.2004.04.016; Liberski PP, 2002, ACTA NEUROBIOL EXP, V62, P141; Ling DJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004201; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Mandel S, 2005, ANN NY ACAD SCI, V1053, P356, DOI 10.1196/annals.1344.031; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; Maraganore DM, 2006, JAMA-J AM MED ASSOC, V296, P661, DOI 10.1001/jama.296.6.661; Marazziti D, 2009, FASEB J, V23, P1978, DOI 10.1096/fj.08-121210; Maries E, 2003, NAT REV NEUROSCI, V4, P727, DOI 10.1038/nrn1199; Martinez-Vicente M, 2005, EXP GERONTOL, V40, P622, DOI 10.1016/j.exger.2005.07.005; Martinez-Vicente M, 2008, J CLIN INVEST, V118, P777, DOI 10.1172/JCI32806; Martinez-Vicente M, 2007, LANCET NEUROL, V6, P352, DOI 10.1016/S1474-4422(07)70076-5; Massey AC, 2006, P NATL ACAD SCI USA, V103, P5805, DOI 10.1073/pnas.0507436103; Matsunaga K, 2009, AUTOPHAGY, V5, P876, DOI 10.4161/auto.9098; Matsunaga K, 2009, NAT CELL BIOL, V11, P385, DOI 10.1038/ncb1846; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; Meikle PJ, 1999, JAMA-J AM MED ASSOC, V281, P249, DOI 10.1001/jama.281.3.249; Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782; Menzies FM, 2010, BRAIN, V133, P93, DOI 10.1093/brain/awp292; Mercer CA, 2009, AUTOPHAGY, V5, P649, DOI 10.4161/auto.5.5.8249; Meredith GE, 2002, BRAIN RES, V956, P156, DOI 10.1016/S0006-8993(02)03514-X; Michiorri S, 2010, CELL DEATH DIFFER, V17, P962, DOI 10.1038/cdd.2009.200; Mijaljica D, 2007, AUTOPHAGY, V3, P417, DOI 10.4161/auto.4441; Mitra S, 2009, AUTOPHAGY, V5, P1037, DOI 10.4161/auto.5.7.9291; Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005; Mizushima N, 2005, CELL DEATH DIFFER, V12, P1535, DOI 10.1038/sj.cdd.4401728; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Mizushima N, 2009, METHOD ENZYMOL, V452, P13, DOI 10.1016/S0076-6879(08)03602-1; Mizushima Noboru, 2008, V445, P119, DOI 10.1007/978-1-59745-157-4_7; Mok SWF, 2007, BIOCHEM BIOPH RES CO, V359, P672, DOI 10.1016/j.bbrc.2007.05.163; Montie HL, 2009, HUM MOL GENET, V18, P1937, DOI 10.1093/hmg/ddp115; Mookerjee S, 2009, J NEUROSCI, V29, P15134, DOI 10.1523/JNEUROSCI.4720-09.2009; Moore RC, 1999, J MOL BIOL, V292, P797, DOI 10.1006/jmbi.1999.3108; Moreira PI, 2007, AUTOPHAGY, V3, P614, DOI 10.4161/auto.4872; Moretra PI, 2007, J NEUROPATH EXP NEUR, V66, P525, DOI 10.1097/01.jnen.0000240476.73532.b0; Muchowski PJ, 2002, P NATL ACAD SCI USA, V99, P727, DOI 10.1073/pnas.022628699; Muller O, 2000, J CELL BIOL, V151, P519, DOI 10.1083/jcb.151.3.519; Nagata E, 2004, NEUROREPORT, V15, P1325, DOI 10.1097/01.wnr.0000127073.66692.8f; Nakanishi H, 2001, J NEUROSCI, V21, P7526, DOI 10.1523/JNEUROSCI.21-19-07526.2001; Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125; Nishino I, 2000, NATURE, V406, P906, DOI 10.1038/35022604; Nishiyama J, 2010, J NEUROSCI, V30, P2177, DOI 10.1523/JNEUROSCI.6030-09.2010; NITATORI T, 1995, J NEUROSCI, V15, P1001; Nixon RA, 2005, J NEUROPATH EXP NEUR, V64, P113, DOI 10.1093/jnen/64.2.113; Nixon RA, 2007, J CELL SCI, V120, P4081, DOI 10.1242/jcs.019265; Nussbaum RL, 1997, HUM MOL GENET, V6, P1687, DOI 10.1093/hmg/6.10.1687; Oh JM, 2008, MOL CELL NEUROSCI, V39, P238, DOI 10.1016/j.mcn.2008.07.003; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Pacheco CD, 2007, HUM MOL GENET, V16, P1495, DOI 10.1093/hmg/ddm100; Pal A, 2006, J CELL BIOL, V172, P605, DOI 10.1083/jcb.200509091; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Pandey UB, 2007, NATURE, V447, P859, DOI 10.1038/nature05853; Park J, 2009, DIS MODEL MECH, V2, P336, DOI 10.1242/dmm.003178; Pasquali L, 2008, ANN NY ACAD SCI, V1139, P191, DOI 10.1196/annals.1432.016; Perutz MF, 2001, NATURE, V412, P143, DOI 10.1038/35084141; Petersen A, 2001, HUM MOL GENET, V10, P1243, DOI 10.1093/hmg/10.12.1243; Pickford F, 2008, J CLIN INVEST, V118, P2190, DOI 10.1172/JCI33585; Plowey ED, 2008, J NEUROCHEM, V105, P1048, DOI 10.1111/j.1471-4159.2008.05217.x; POLLANEN MS, 1993, J NEUROPATH EXP NEUR, V52, P183, DOI 10.1097/00005072-199305000-00001; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Qin ZH, 2003, HUM MOL GENET, V12, P3231, DOI 10.1093/hmg/ddg346; Ramirez A, 2006, NAT GENET, V38, P1184, DOI 10.1038/ng1884; Ravikumar B, 2005, NAT GENET, V37, P771, DOI 10.1038/ng1591; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107; Ravikumar B, 2008, J CELL SCI, V121, P1649, DOI 10.1242/jcs.025726; Reed NA, 2006, CURR BIOL, V16, P2166, DOI 10.1016/j.cub.2006.09.014; Rideout HJ, 2004, INT J BIOCHEM CELL B, V36, P2551, DOI 10.1016/j.biocel.2004.05.008; Riedel M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008753; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Rubinszfein DC, 2005, AUTOPHAGY, V1, P11, DOI 10.4161/auto.1.1.1513; Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291; Sadasivan S, 2008, BIOCHEM BIOPH RES CO, V373, P478, DOI 10.1016/j.bbrc.2008.05.031; Sakaguchi S, 1996, NATURE, V380, P528, DOI 10.1038/380528a0; Sakai Y, 2006, BBA-MOL CELL RES, V1763, P1767, DOI 10.1016/j.bbamcr.2006.08.023; Samara C, 2008, CELL DEATH DIFFER, V15, P105, DOI 10.1038/sj.cdd.4402231; Samokhvalov V, 2008, AUTOPHAGY, V4, P1034, DOI 10.4161/auto.6994; Sandberg M, 2007, MOL CELL ENDOCRINOL, V277, P35, DOI 10.1016/j.mce.2007.07.007; Sapp E, 1997, ANN NEUROL, V42, P604, DOI 10.1002/ana.410420411; Sarkar S, 2009, CELL DEATH DIFFER, V16, P46, DOI 10.1038/cdd.2008.110; Sarkar S, 2007, NAT CHEM BIOL, V3, P331, DOI 10.1038/nchembio883; Scarlatti F, 2009, CELL DEATH DIFFER, V16, P12, DOI 10.1038/cdd.2008.101; Schatzl HM, 1997, J VIROL, V71, P8821; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Shacka JJ, 2007, NEUROSCI LETT, V414, P57, DOI 10.1016/j.neulet.2006.12.025; Shacka JJ, 2007, J NEUROSCI, V27, P2081, DOI 10.1523/JNEUROSCI.5577-06.2007; Shibata M, 2006, J BIOL CHEM, V281, P14474, DOI 10.1074/jbc.M600364200; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Sikorska B, 2004, INT J BIOCHEM CELL B, V36, P2563, DOI 10.1016/j.biocel.2004.04.014; Silvestri L, 2005, HUM MOL GENET, V14, P3477, DOI 10.1093/hmg/ddi377; Simon-Sanchez J, 2009, NAT GENET, V41, P1308, DOI 10.1038/ng.487; Simonsen A, 2008, AUTOPHAGY, V4, P176, DOI 10.4161/auto.5269; Simonsen A, 2007, AUTOPHAGY, V3, P499, DOI 10.4161/auto.4604; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Skibinski G, 2005, NAT GENET, V37, P806, DOI 10.1038/ng1609; Skinner PJ, 2001, AM J PATHOL, V159, P905, DOI 10.1016/S0002-9440(10)61766-X; Small SA, 2005, ANN NEUROL, V58, P909, DOI 10.1002/ana.20667; Spencer B, 2009, J NEUROSCI, V29, P13578, DOI 10.1523/JNEUROSCI.4390-09.2009; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Stefanis L, 2001, J NEUROSCI, V21, P9549, DOI 10.1523/JNEUROSCI.21-24-09549.2001; Sugie K, 2005, J NEUROPATH EXP NEUR, V64, P513, DOI 10.1093/jnen/64.6.513; Suzuki K, 2007, FEBS LETT, V581, P2156, DOI 10.1016/j.febslet.2007.01.096; Syntichaki P, 2002, NATURE, V419, P939, DOI 10.1038/nature01108; Tai HC, 2008, NAT REV NEUROSCI, V9, P826, DOI 10.1038/nrn2499; Tamai K, 2008, AM J PATHOL, V173, P1806, DOI 10.2353/ajpath.2008.080684; Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595; Taylor JP, 2002, SCIENCE, V296, P1991, DOI 10.1126/science.1067122; Taylor JP, 2003, HUM MOL GENET, V12, P749, DOI 10.1093/hmg/ddg074; Uryu K, 2006, AM J PATHOL, V168, P947, DOI 10.2353/ajpath.2006.050770; Vellai T, 2009, CELL DEATH DIFFER, V16, P94, DOI 10.1038/cdd.2008.126; Vig PJS, 2009, CEREBELLUM, V8, P231, DOI 10.1007/s12311-009-0125-5; Vogiatzi T, 2008, J BIOL CHEM, V283, P23542, DOI 10.1074/jbc.M801992200; Wadsworth JD, 2003, BRIT MED BULL, V66, P241, DOI 10.1093/bmb/66.1.241; Wang QJ, 2006, J NEUROSCI, V26, P8057, DOI 10.1523/JNEUROSCI.2261-06.2006; Wang Y, 2008, AUTOPHAGY, V4, P214, DOI 10.4161/auto.5369; Wang YP, 2009, HUM MOL GENET, V18, P4153, DOI 10.1093/hmg/ddp367; Wang YJ, 2008, J BIOL CHEM, V283, P4766, DOI 10.1074/jbc.M706666200; Wang Y, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-5; Ward Walter F, 2002, Prog Mol Subcell Biol, V29, P35; Webb JL, 2003, J BIOL CHEM, V278, P25009, DOI 10.1074/jbc.M300227200; Webb JL, 2004, INT J BIOCHEM CELL B, V36, P2541, DOI 10.1016/j.biocel.2004.02.003; Weissmann C, 2004, NAT REV MICROBIOL, V2, P861, DOI 10.1038/nrmicro1025; Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102; Xilouri M, 2008, AUTOPHAGY, V4, P917, DOI 10.4161/auto.6685; Xilouri M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005515; Xu J, 2002, NAT MED, V8, P600, DOI 10.1038/nm0602-600; Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780; Yamada M, 2002, ANN NEUROL, V52, P498, DOI 10.1002/ana.10328; Yan J, 1998, BIOCHEM BIOPH RES CO, V246, P222, DOI 10.1006/bbrc.1998.8546; Yang Q, 2009, SCIENCE, V323, P124, DOI 10.1126/science.1166088; Yankner BA, 1996, NAT MED, V2, P850, DOI 10.1038/nm0896-850; Yao Z, 2009, ANTIOXID REDOX SIGN, V11, P2135, DOI [10.1089/ars.2009.2624, 10.1089/ARS.2009.2624]; Yla-Anttila P, 2009, AUTOPHAGY, V5, P1180; Young JE, 2009, J BIOL CHEM, V284, P2363, DOI 10.1074/jbc.M806088200; Yu WH, 2009, AM J PATHOL, V175, P736, DOI 10.2353/ajpath.2009.080928; Yu WH, 2005, J CELL BIOL, V171, P87, DOI 10.1083/jcb.200505082; Yu WH, 2004, INT J BIOCHEM CELL B, V36, P2531, DOI 10.1016/j.biocel.2004.05.010; Yue ZY, 2009, BBA-MOL CELL RES, V1793, P1496, DOI 10.1016/j.bbamcr.2009.01.016; Yue ZY, 2002, NEURON, V35, P921, DOI 10.1016/S0896-6273(02)00861-9; Yun SW, 2007, J NEUROVIROL, V13, P328, DOI 10.1080/13550280701361516; Zaidi AU, 2001, J NEUROPATH EXP NEUR, V60, P937, DOI 10.1093/jnen/60.10.937; Zhang C, 2008, NAT MED, V14, P959, DOI 10.1038/nm.1851; Zhang Yan-Bo, 2008, Neurosci Bull, V24, P143, DOI 10.1007/s12264-008-1108-0; Zhou X, 2007, P NATL ACAD SCI USA, V104, P5842, DOI 10.1073/pnas.0701402104; Zhu JH, 2003, BRAIN PATHOL, V13, P473; Zuo J, 1997, NATURE, V388, P769, DOI 10.1038/42009	290	78	87	0	16	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets	DEC	2010	9	6					701	719		10.2174/187152710793237421			19	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	685HZ	WOS:000284621100006	20942791				2022-02-06	
J	Hong, YA; Yan, W; Chen, S; Sun, CR; Zhang, JM				Hong, Yuan; Yan, Wei; Chen, Sheng; Sun, Chong-ran; Zhang, Jian-min			The role of Nrf2 signaling in the regulation of antioxidants and detoxifying enzymes after traumatic brain injury in rats and mice	ACTA PHARMACOLOGICA SINICA			English	Article						nuclear factor-erythroid 2-related factor 2; sulforaphane; traumatic brain injury; oxidative stress; heme oxygenase 1; NAD(P) H:quinine oxidoreductase 1; neurological dysfunction	OXIDATIVE STRESS; CEREBRAL-ISCHEMIA; IN-VIVO; ENHANCES SUSCEPTIBILITY; TRANSCRIPTION FACTOR; ALZHEIMERS-DISEASE; LIPID-PEROXIDATION; HERNE OXYGENASE; REACTIVE OXYGEN; NERVOUS-SYSTEM	Aim: To determine whether Nrf2 signaling pathway activation could attenuate oxidative stress and neuronal damage following traumatic brain injury (TBI). Methods: Controlled cortical impact (CCI) injury was performed in Sprague-Dawley rats and Nrf2-knockout or control mice. Sulforaphane (SFN), a potent Nrf2 activator, was used to activate Nrf2. Oxidative stress, lesion volume, neuron degeneration, and neurologic dysfunction were determined using biochemical, histopathological and neuroethologic approaches. Protein and mRNA levels of Nrf2 and the antioxidant enzymes heme oxygenase 1 (HO-1) and NAD(P) H: quinine oxidoreductase 1 (NQO1) were assessed using Western blot analysis and RT-PCR. Results: Activation of Nrf2 by SFN(5 mg/kg, ip) induced the nuclear translocation and activation of Nrf2, which resulted in an up-regulation of Nrf2-dependent antioxidant enzymes and a reduction of oxidative damage after TBI. In accordance with these biochemical changes, SFN also significantly reduced neuronal death, contusion volume, and neurological dysfunction after TBI. Furthermore, Nrf2-knockout mice showed more severe oxidative stress and neurologic deficits after TBI and did not benefit from the effects of SFN. Conclusion: Nrf2 plays a pivotal role in cell defenses against the oxidative stress of TBI. In addition, pharmacological activation of the Nrf2 signaling pathway by small molecule inducers such as SFN attenuated oxidative stress and neuronal damage following TBI.	[Hong, Yuan; Yan, Wei; Chen, Sheng; Sun, Chong-ran; Zhang, Jian-min] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou 310006, Zhejiang, Peoples R China		Zhang, JM (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou 310006, Zhejiang, Peoples R China.	hy0904@live.cn		Yan, Wei/0000-0002-1123-0835	Research Fund for the Doctoral Program of Higher Education of ChinaResearch Fund for the Doctoral Program of Higher Education of China (RFDP)Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP) [0090101120118]; Zhejiang Provincial Natural Science Foundation in China [Y2090098]	This work was funded by the Research Fund for the Doctoral Program of Higher Education of China (Grant No 0090101120118) and Zhejiang Provincial Natural Science Foundation in China (Grant No Y2090098).	Aleksunes LM, 2007, TOXICOL PATHOL, V35, P459, DOI 10.1080/01926230701311344; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Butterfield DA, 2002, FREE RADICAL BIO MED, V32, P1050, DOI 10.1016/S0891-5849(02)00794-3; CADENAS E, 1995, BIOCHEM PHARMACOL, V49, P127, DOI 10.1016/S0006-2952(94)00333-5; Calkins MJ, 2005, P NATL ACAD SCI USA, V102, P244, DOI 10.1073/pnas.0408487101; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen K, 2000, J NEUROCHEM, V75, P304, DOI 10.1046/j.1471-4159.2000.0750304.x; Chen PC, 2009, P NATL ACAD SCI USA, V106, P2933, DOI 10.1073/pnas.0813361106; Chen XR, 2007, J NEUROTRAUM, V24, P1119, DOI 10.1089/neu.2006.0216; Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; Clausen F, 2004, J NEUROTRAUM, V21, P1168, DOI 10.1089/neu.2004.21.1168; Darwish RS, 2007, J TRAUMA, V63, P439, DOI 10.1097/TA.0b013e318069178a; Dash PK, 2009, NEUROSCI LETT, V460, P103, DOI 10.1016/j.neulet.2009.04.028; Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Jin W, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/725174; Ku BM, 2006, NEUROSCI LETT, V405, P168, DOI 10.1016/j.neulet.2006.06.052; Laxton AW, 2001, NEUROREPORT, V12, P1045, DOI 10.1097/00001756-200104170-00036; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; Li YJ, 2008, CLIN IMMUNOL, V128, P366, DOI 10.1016/j.clim.2008.05.005; Lucius R, 1996, BRAIN RES, V743, P56, DOI 10.1016/S0006-8993(96)01029-3; Mancuso C, 2004, ANTIOXID REDOX SIGN, V6, P878, DOI 10.1089/1523086041798097; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Purdom-Dickinson SE, 2007, J MOL CELL CARDIOL, V42, P159, DOI 10.1016/j.yjmcc.2006.09.012; Radjendirane V, 1998, J BIOL CHEM, V273, P7382, DOI 10.1074/jbc.273.13.7382; Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146; Rigg JL, 2005, J HEAD TRAUMA REHAB, V20, P389, DOI 10.1097/00001199-200507000-00010; SantaCruz KS, 2004, NEUROBIOL AGING, V25, P63, DOI 10.1016/S0197-4580(03)00117-9; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Sekhar KR, 2002, ONCOGENE, V21, P6829, DOI 10.1038/sj.onc.1205905; Shih AY, 2005, J NEUROSCI, V25, P10321, DOI 10.1523/JNEUROSCI.4014-05.2005; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Ueda K, 2008, AM J PHYSIOL-GASTR L, V295, pG460, DOI 10.1152/ajpgi.00204.2007; van Horssen J, 2006, FREE RADICAL BIO MED, V41, P311, DOI 10.1016/j.freeradbiomed.2006.04.013; van Muiswinkel FL, 2004, NEUROBIOL AGING, V25, P1253, DOI 10.1016/j.neurobiolaging.2003.12.010; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Yan W, 2009, J TRAUMA, V66, P1431, DOI 10.1097/TA.0b013e318180f5c7; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8; Zhao J, 2006, NEUROSCI LETT, V393, P108, DOI 10.1016/j.neulet.2005.09.065; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649; Zhao J, 2007, J NEUROSCI, V27, P10240, DOI 10.1523/JNEUROSCI.1683-07.2007; Zhao XR, 2007, STROKE, V38, P3280, DOI 10.1161/STROKEAHA.107.486506; Zhu H, 2005, FEBS LETT, V579, P3029, DOI 10.1016/j.febslet.2005.04.058	48	78	85	1	12	ACTA PHARMACOLOGICA SINICA	SHANGHAI	294 TAI-YUAN RD, SHANGHAI, 200031, PEOPLES R CHINA	1671-4083	1745-7254		ACTA PHARMACOL SIN	Acta Pharmacol. Sin.	NOV	2010	31	11					1421	1430		10.1038/aps.2010.101			10	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry; Pharmacology & Pharmacy	678EH	WOS:000284055500003	20953205	Bronze, Green Published			2022-02-06	
J	Xiong, Y; Mahmood, A; Meng, YL; Zhang, YL; Qu, CS; Schallert, T; Chopp, M				Xiong, Ye; Mahmood, Asim; Meng, Yuling; Zhang, Yanlu; Qu, Changsheng; Schallert, Timothy; Chopp, Michael			Delayed administration of erythropoietin reducing hippocampal cell loss, enhancing angiogenesis and neurogenesis, and improving functional outcome following traumatic brain injury in rats: comparison of treatment with single and triple dose	JOURNAL OF NEUROSURGERY			English	Article						angiogenesis; cell proliferation; erythropoietin; neurogenesis; rat; sensorimotor function; spatial learning; traumatic brain injury	SUBVENTRICULAR ZONE; CORTICAL IMPACT; SPATIAL MEMORY; ADULT RATS; STROKE; MICE; NEUROPROTECTION; NEURONS; DAMAGE; EXPRESSION	Object. This efficacy study was designed to investigate traumatic brain injury (TBI) in rats treated with delayed erythropoietin (EPO) administered in a single dose compared with a triple dose. Methods. Young adult male Wistar rats were randomly divided into the following groups: 1) sham group (6 animals); 2) TBI/saline group (6 animals); 3) TBI/EPOx1 group (6 animals); and 4) TBI/EPOx3 group (7 animals). Traumatic brain injury was induced by controlled cortical impact over the left parietal cortex. Erythropoietin (5000 U/kg) or saline was administered intraperitoneally on Day 1 (EPOx1 group) or on Days 1,2, and 3 (EPOx3 group) postinjury. Neurological function was assessed using a modified neurological severity score, foot-fault, and Morris water maze tests. Animals were killed 35 days after injury and brain sections were stained for immunohistochemistry. Results. Compared with the saline treatment, EPO treatment in both the EPOx1 and EPOx3 groups significantly reduced hippocampal cell loss, enhanced angiogenesis and neurogenesis in the injured cortex and hippocampus, and significantly improved neurological functional outcome. The EPOx3 group exhibited significantly improved functional and histological outcomes compared with the EPOx1 group. Conclusions. These data demonstrate that delayed posttraumatic administration of EPO significantly improved histological and long-term functional outcomes in rats after TBI. The triple doses of delayed EPO treatment produced better histological and functional outcomes in rats, although a single dose provided substantial benefits compared with saline treatment. (DOI: 10.3171/2009.9.JNS09844)	[Xiong, Ye; Mahmood, Asim; Meng, Yuling; Zhang, Yanlu; Qu, Changsheng] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA; [Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Schallert, Timothy] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Schallert, Timothy] Univ Texas Austin, Inst Neurosurg, Austin, TX 78712 USA		Xiong, Y (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, E&R Bldg,Room 3096,2799 W Grand Blvd, Detroit, MI 48202 USA.	nsxye@neuro.hfh.edu	Zhang, Yanlu/H-1275-2011	Xiong, Ye/0000-0001-9770-6031	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RO1 NS62002, PO1 NS42345]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS062002, P01NS042345] Funding Source: NIH RePORTER	Support was received from the National Institute of Neurological Disorders and Stroke (grants RO1 NS62002 [to Dr. Xiong.] and PO1 NS42345 [to Drs. Mahmood and Chopp]).	BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Cerami A, 2001, SEMIN HEMATOL, V38, P33, DOI 10.1053/shem.2001.27484; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Davis A E, 2000, Crit Care Nurs Q, V23, P1; Day LB, 1999, BEHAV NEUROSCI, V113, P914, DOI 10.1037/0735-7044.113.5.914; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Goings GE, 2004, BRAIN RES, V996, P213, DOI 10.1016/j.brainres.2003.10.034; Gonzalez FF, 2007, DEV NEUROSCI-BASEL, V29, P321, DOI 10.1159/000105473; Grasso G, 2006, J NEUROSURG-SPINE, V4, P310, DOI 10.3171/spi.2006.4.4.310; Grasso G, 2005, NEUROSURGERY, V56, P821, DOI 10.1227/01.NEU.0000156493.00904.7E; Grasso G, 2007, BRAIN RES, V1182, P99, DOI 10.1016/j.brainres.2007.08.078; Hartley CE, 2008, J NEUROSURG, V109, P708, DOI 10.3171/JNS/2008/109/10/0708; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Liao ZB, 2008, EUR J NEUROL, V15, P140, DOI 10.1111/j.1468-1331.2007.02013.x; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Okutan O, 2008, SURG NEUROL, V70, P498, DOI 10.1016/j.surneu.2007.07.061; Royo NC, 2003, J NEUROPATH EXP NEUR, V62, P801, DOI 10.1093/jnen/62.8.801; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Statler PA, 2007, PEDIATR RES, V61, P671, DOI 10.1203/pdr.0b013e31805341dc; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sundholm-Peters NL, 2005, J NEUROPATH EXP NEUR, V64, P1089, DOI 10.1097/01.jnen.0000190066.13312.8f; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Xiong Y, 2008, BRAIN RES, V1230, P247, DOI 10.1016/j.brainres.2008.06.127; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Zhang RL, 2004, J CEREBR BLOOD F MET, V24, P441, DOI 10.1097/00004647-200404000-00009; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zhang RL, 2004, J NEUROSCI, V24, P5810, DOI 10.1523/JNEUROSCI.1109-04.2004; Zhang RL, 2008, NEUROPHARMACOLOGY, V55, P345, DOI 10.1016/j.neuropharm.2008.05.027; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4	47	78	85	0	10	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	SEP	2010	113	3					598	608		10.3171/2009.9.JNS09844			11	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	641FV	WOS:000281111100025	19817538	Green Accepted			2022-02-06	
J	Leal-Noval, SR; Cayuela, A; Arellano-Orden, V; Marin-Caballos, A; Padilla, V; Ferrandiz-Millon, C; Corcia, Y; Garcia-Alfaro, C; Amaya-Villar, R; Murillo-Cabezas, F				Leal-Noval, Santiago R.; Cayuela, Aurelio; Arellano-Orden, Victoria; Marin-Caballos, Antonio; Padilla, Vicente; Ferrandiz-Millon, Carmen; Corcia, Yael; Garcia-Alfaro, Claudio; Amaya-Villar, Rosario; Murillo-Cabezas, Francisco			Invasive and noninvasive assessment of cerebral oxygenation in patients with severe traumatic brain injury	INTENSIVE CARE MEDICINE			English	Article						Brain hypoxia; Brain tissue oxygen pressure; Cerebral oxygenation; Neurotrauma; NIRS; rSO(2); PbrO(2); Severe traumatic brain injury and transfusion	NEAR-INFRARED SPECTROSCOPY; SEVERE HEAD-INJURY; PERFUSION-PRESSURE; TISSUE PO-2; SATURATION; TENSION; AUTOREGULATION; DESATURATION; HYPOXIA	The aim of this study is to investigate the relationship between invasive brain tissue oxygen pressure (PbrO(2)) and noninvasive regional transcranial oxygen saturation (rSO(2)) in 22 stable patients with severe traumatic brain injury (TBI) during a 16 h period. This was a prospective, observational study carried out in the Neurocritical Care Unit of a level 1 trauma center in a teaching hospital. A total of 41,809 paired records for neuromonitoring variables were analyzed and compared. A direct and independent correlation between rSO(2) and PbrO(2) was confirmed through adjusted [beta coefficient and (95% confidence interval, CI) = 0.36 (0.35-0.37)] and logistic [PbrO(2) a parts per thousand yen15 mmHg, as a dependent variable; adjusted odds ratio (AOR) and (95% CI) = 1.11 (1.10-1.12)] regression analyses. A receiver-operating characteristic (ROC) curve demonstrated that rSO(2) had low accuracy for detecting moderate (PbrO(2) a parts per thousand currency sign15 mmHg) intracerebral hypoxia [area under curve (AUC) = 0.62], with the likelihood ratio for a positive test (LR+) = 1.2 for an optimal cutoff of rSO(2) a parts per thousand currency sign70%. In contrast, the ROC analysis showed that rSO(2) was moderately accurate for detecting severe (PbrO(2) a parts per thousand currency sign12 mmHg) intracerebral hypoxemia (AUC = 0.82; LR+ = 5.3) for an optimal cutoff of rSO(2) a parts per thousand currency sign60%. In patients with severe TBI, PbrO(2) and rSO(2) were directly and significantly related. Severe intracerebral hypoxia was better detected by rSO(2) than was moderate intracerebral hypoxia. However, the diagnostic accuracy of rSO(2) was limited, and this measure should not be considered a substitute for routine PbrO(2) monitoring.	[Leal-Noval, Santiago R.] Hosp Univ Virgen del Rocio, Serv Cuidados Crit & Urgencias, Inst Biomed Sevilla IBIS, Seville 41013, Spain; [Leal-Noval, Santiago R.; Arellano-Orden, Victoria; Marin-Caballos, Antonio; Padilla, Vicente; Ferrandiz-Millon, Carmen; Corcia, Yael; Garcia-Alfaro, Claudio; Amaya-Villar, Rosario; Murillo-Cabezas, Francisco] Hosp Univ Virgen del Rocio, Neuro Crit Care Div, Seville 41013, Spain; [Cayuela, Aurelio] Hosp Univ Virgen del Rocio, Div Stat, Seville 41013, Spain		Leal-Noval, SR (corresponding author), Hosp Univ Virgen del Rocio, Serv Cuidados Crit & Urgencias, Inst Biomed Sevilla IBIS, Avda Manuel Siurot S-N, Seville 41013, Spain.	srleal@telefonica.net	Noval, Santiago/K-4515-2019; Cayuela, Aurelio/AAZ-1294-2020; IBIS, NEUROCRITICOS/C-1805-2016; Murillo-Cabezas, Francisco/AAO-3348-2021; Cayuela, Aurelio/C-6698-2012	Cayuela, Aurelio/0000-0002-4936-9402	Spanish Government funds (Fondo de Investigacion Sanitaria-FIS-Proyecto de Investigacion) [PI 081069]; Consejeria de Salud de la Junta de AndaluciaJunta de Andalucia	Supported by Spanish Government funds (Fondo de Investigacion Sanitaria-FIS-Proyecto de Investigacion: PI 081069) and by Consejeria de Salud de la Junta de Andalucia. Proyecto de Investigacion 0157/2006.	Akobeng AK, 2007, ACTA PAEDIATR, V96, P487, DOI 10.1111/j.1651-2227.2006.00179.x; Andrews PJD, 2008, INTENS CARE MED, V34, P1362, DOI 10.1007/s00134-008-1103-y; Brady KM, 2007, STROKE, V38, P2818, DOI 10.1161/STROKEAHA.107.485706; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS65; Brawanski A, 2002, J CEREBR BLOOD F MET, V22, P605, DOI 10.1097/00004647-200205000-00012; Buchner K, 2000, ZBL NEUROCHIR, V61, P69, DOI 10.1055/s-2000-8262; Casati A, 2005, ANESTH ANALG, V101, P740, DOI 10.1213/01.ane.0000166974.96219.cd; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Dunham CM, 2004, J TRAUMA, V56, P482, DOI 10.1097/01.TA.0000114537.52540.95; Fischer JE, 2003, INTENS CARE MED, V29, P1043, DOI 10.1007/s00134-003-1761-8; Gracias VH, 2004, J TRAUMA, V56, P469, DOI 10.1097/01.TA.0000114274.95423.C0; Kahraman S, 2006, J TRAUMA, V61, P1480, DOI 10.1097/01.ta.0000197616.10279.48; Leal-Noval SR, 2006, INTENS CARE MED, V32, P1733, DOI 10.1007/s00134-006-0376-2; Lewis SB, 1996, CRIT CARE MED, V24, P1334, DOI 10.1097/00003246-199608000-00011; Longhi L, 2007, INTENS CARE MED, V33, P2136, DOI 10.1007/s00134-007-0845-2; Marcin JP, 2007, CRIT CARE MED, V35, P2212, DOI 10.1097/01.CCM.0000281522.70992.EF; Marin-Caballos A, 2005, CRIT CARE, V9, pR670, DOI 10.1186/cc3822; Marin-Caballos AJ, 2008, MED INTENSIVA, V32, P81, DOI 10.1016/S0210-5691(08)70912-4; Matsumoto S, 2009, NEUROLOGY, V72, P1512, DOI 10.1212/WNL.0b013e3181a2e846; McLeod AD, 2003, ANESTH ANALG, V97, P851, DOI 10.1213/01.ANE.0000072541.57132.BA; Nagdyman N, 2008, PEDIATR ANESTH, V18, P160, DOI 10.1111/j.1460-9592.2007.02365.x; Naidech AM, 2008, NEUROCRIT CARE, V9, P326, DOI 10.1007/s12028-008-9077-8; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; Rose JC, 2006, CURR OPIN CRIT CARE, V12, P97, DOI 10.1097/01.ccx.0000216574.26686.e9; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Rothoerl RD, 2002, ACT NEUR S, V81, P311; Shah N, 2000, J NEUROSURG ANESTH, V12, P201, DOI 10.1097/00008506-200007000-00001; Skhirtladze K, 2009, CRIT CARE MED, V37, P471, DOI 10.1097/CCM.0b013e3181953d4c; Smith M, 2009, ANESTH ANALG, V108, P1055, DOI 10.1213/ane.0b013e31819a0301; Steiner LA, 2009, NEUROCRIT CARE, V10, P122, DOI 10.1007/s12028-008-9140-5; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stoneham MD, 2008, ANESTH ANALG, V107, P1670, DOI 10.1213/ane.0b013e318184d6c3; Tobias JD, 2006, EXPERT REV MED DEVIC, V3, P235, DOI 10.1586/17434440.3.2.235; Tobias Joseph D, 2008, J Intensive Care Med, V23, P384, DOI 10.1177/0885066608324380; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Watzman HM, 2000, ANESTHESIOLOGY, V93, P947, DOI 10.1097/00000542-200010000-00012; Yao FSF, 2004, J CARDIOTHOR VASC AN, V18, P552, DOI 10.1053/j.jvca.2004.07.007; Yoshitani K, 2007, ANESTHESIOLOGY, V106, P458, DOI 10.1097/00000542-200703000-00009	40	78	85	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	AUG	2010	36	8					1309	1317		10.1007/s00134-010-1920-7			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	622RP	WOS:000279683400004	20502869				2022-02-06	
J	Liliang, PC; Liang, CL; Weng, HC; Lu, K; Wang, KW; Chen, HJ; Chuang, JH				Liliang, Po-Chou; Liang, Cheng-Loong; Weng, Hui-Ching; Lu, Kang; Wang, Kuo-Wei; Chen, Han-Jung; Chuang, Jiin-Haur			tau Proteins in Serum Predict Outcome After Severe Traumatic Brain Injury	JOURNAL OF SURGICAL RESEARCH			English	Article						tau protein; outcome; traumatic brain injury; ELISA	SEVERE HEAD-INJURY; CEREBROSPINAL-FLUID; NEURONAL DAMAGE; S-100B PROTEIN; CLEAVED-TAU; BIOMARKER; MARKER	Background. The identification of reliable outcome predictors after traumatic brain injury (TBI) is crucial. The objective of our study was to investigate the role of tau protein as a serum marker of TBI. Methods. Thirty-four patients with severe TBI (Glasgow Coma Scale [GCS] score at admission <= 8) were considered. The tau protein level in the blood samples obtained at the time of admission was measured. The outcome was assessed by using the Glasgow Outcome Scale (GOS) at 6 mo post-injury. Demographic, clinical, and laboratory variables were analyzed to study their effect on the outcome. Results. tau Protein levels were higher in the poor outcome group (436.2 +/- 473.6 pg/mL) than in the good outcome group (51.6 +/- 81.5 pg/mL) (P < 0.0001). Univariate analyses demonstrated that poor outcome was significantly associated with a poor GCS score (P = 0.001), higher serum tau protein levels (P < 0.001), abnormal pupil light reflex (P = 0.013), and basal cistern compression on computed tomogram (CT) (P = 0.026). Multivariate analyses revealed that a poor GCS score (P = 0.049) and higher serum tau protein levels (P = 0.043) were independent prognostic factors for poor outcome. The receiver-operating characteristic (ROC) curve demonstrated that a tau protein level >= 114.5 pg/mL yielded 88% sensitivity and 94% specificity for predicting a poor outcome. Conclusions. These results suggest that in addition to GCS; serum tau protein levels may serve as indicators for the prediction of outcome following severe TBI. However; it should be viewed with caution because of the small sample size and wide standard deviations. (C) 2010 Elsevier Inc. All rights reserved.	[Liliang, Po-Chou] I Shou Univ, E Da Hosp, Dept Neurosurg, Yan Chau Shiang 824, Kaohsiung Cty, Taiwan; [Liliang, Po-Chou] Chang Gung Univ, Coll Med, Grad Inst Clin Med Sci, Kaohsiung, Taiwan; [Weng, Hui-Ching] I Shou Univ, Dept Hlth Management, Kaohsiung, Taiwan; [Chuang, Jiin-Haur] Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Surg, Div Pediat Surg, Kaohsiung, Taiwan		Chen, HJ (corresponding author), I Shou Univ, E Da Hosp, Dept Neurosurg, 1 E Da Rd, Yan Chau Shiang 824, Kaohsiung Cty, Taiwan.	ed100172@edah.org.tw			Taiwan National Science CouncilMinistry of Science and Technology, Taiwan [NSC 94-2314-B-214-003, NSC 95-2314-B-214-006]	This work was supported by research grants from the Taiwan National Science Council grant nos. NSC 94-2314-B-214-003 and NSC 95-2314-B-214-006 to PCL.	Bullock RM, 2000, J NEUROTRAUM, V17, P449; Bulut M, 2006, ADV THER, V23, P12, DOI 10.1007/BF02850342; Chlu WT, 2007, J CLIN NEUROSCI, V14, P930, DOI 10.1016/j.jocn.2006.08.004; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Gabbita SP, 2005, J NEUROTRAUM, V22, P83, DOI 10.1089/neu.2005.22.83; Huang SJ, 2007, J CLIN NEUROSCI, V14, P449, DOI 10.1016/j.jocn.2005.12.012; JENNETT B, 1975, LANCET, V1, P480; Johnson GVW, 1997, J NEUROCHEM, V68, P430; Kavalci C, 2007, AM J EMERG MED, V25, P391, DOI 10.1016/j.ajem.2006.10.008; Korfias S, 2007, INTENS CARE MED, V33, P255, DOI 10.1007/s00134-006-0463-4; Lin JW, 2006, SURG NEUROL, V66, pS20, DOI 10.1016/j.surneu.2006.04.005; MARION DW, 1996, NEUROTRAUMA, P767; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Shaw GJ, 2002, ANN EMERG MED, V39, P254, DOI 10.1067/mem.2002.121214; Tsai MD, 2006, SURG NEUROL, V66, pS3, DOI 10.1016/j.surneu.2006.08.046; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Zemlan FP, 2003, NEUROSCIENCE, V121, P399, DOI 10.1016/S0306-4522(03)00459-7; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7; KHB0042KHB0041	23	78	80	0	12	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	MAY 15	2010	160	2					302	307		10.1016/j.jss.2008.12.022			6	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	590VY	WOS:000277257600021	19345376				2022-02-06	
J	Stephens, FL; Mossop, CM; Bell, RS; Tigno, T; Rosner, MK; Kumar, A; Moores, LE; Armonda, RA				Stephens, Frederick L.; Mossop, Correy M.; Bell, Randy S.; Tigno, Teodoro, Jr.; Rosner, Michael K.; Kumar, Anand; Moores, Leon E.; Armonda, Rocco A.			Cranioplasty complications following wartime decompressive craniectomy	NEUROSURGICAL FOCUS			English	Article						cranioplasty; craniectomy; traumatic brain injury	DELAYED CRANIOPLASTY; GRAFT INFECTION; TECHNICAL NOTE; BONE-GRAFTS; SKULL BONE; EXPERIENCE	Object. In support of Operation Iraqi Freedom (OIF) and Operation Enduring Freedom-Afghanistan (OEF-A), military neurosurgeons in the combat theater are faced with the daunting task of stabilizing patients in such a way as to prevent irreversible neurological injury from cerebral edema while simultaneously allowing for prolonged transport stateside (5000-7000 miles). It is in this setting that decompressive craniectomy has become a mainstay of far-forward neurosurgical management of traumatic brain injury (TBI). As such, institutional experience with cranioplasty at the Walter Reed Army Medical Center (WRAMC) and the National Naval Medical Center (NNMC) has expanded concomitantly. Battlefield blast explosions create cavitary injury zones that often extend beyond the border of the exposed surface wound, and this situation has created unique reconstruction challenges not often seen in civilian TBI. The loss of both soft-tissue and skull base support along with the need for cranial vault reconstruction requires a multidisciplinary approach involving neurosurgery, plastics, oral-maxillofacial surgery, and ophthalmology. With this situation in mind, the authors of this paper endeavored to review the cranial reconstruction complications encountered in these combat-related injuries. Methods. A retrospective database review was conducted for all soldiers injured in OIF and OEF-A who had undergone decompressive craniectomy with subsequent cranioplasty between April 2002 and October 2008 at the WRAMC and NNMC. During this time, both facilities received a total of 408 OIF/OEF-A patients with severe head injuries; 188 of these patients underwent decompressive craniectomies in the theater before transfer to the US. Criteria for inclusion in this study consisted of either a closed or a penetrating head injury sustained in combat operations, resulting in the performance of a decompressive craniectomy and subsequent cranioplasty at either the WRAMC or NNMC. Excluded from the study were patients for whom primary demographic data could not be verified. Demographic data, indications for craniectomy, as well as preoperative, intraoperative, and postoperative parameters following cranioplasty, were recorded. Perioperative and postoperative complications were also recorded. Results. One hundred eight patients (male/female ratio 107: 1) met the inclusion criteria for this study, 93 with a penetrating head injury and 15 with a closed head injury. Explosive blast injury was the predominant mechanism of injury, occurring in 72 patients (67%). The average time that elapsed between injury and cranioplasty was 190 days (range 7-546 days). An overall complication rate of 24% was identified. The prevalence of perioperative infection (12%), seizure (7.4%), and extraaxial hematoma formation (7.4%) was noted. Twelve patients (11%) required prosthetic removal because of either extraaxial hematoma formation or infection. Eight of the 13 cases of infection involved cranioplasties performed between 90 and 270 days from the date of injury (p = 0.06). Conclusions. This study represents the largest to date in which cranioplasty and its complications have been evaluated in a trauma population that underwent decompressive craniectomy. The overall complication rate of 24% is consistent with rates reported in the literature (16-34%); however, the perioperative infection rate of 12% is higher than the rates reported in other studies. This difference is likely related to aspects of the initial injury pattern-such as skull base injury, orbitofacial fractures, sinus injuries, persistent fluid collection, and CSF leakage-which can predispose these patients to infection. (DOI: 10.3171/2010.2.FOCUS1026)	[Stephens, Frederick L.] Walter Reed Army Med Ctr, Dept Neurosurg, Washington, DC 20307 USA; Natl Naval Med Ctr, Dept Neurosurg, Bethesda, MD USA		Stephens, FL (corresponding author), Walter Reed Army Med Ctr, Dept Neurosurg, Washington, DC 20307 USA.	frederick.stephens@us.army.mil					CARVI Y, 2006, NEUROL RES, V28, P139, DOI DOI 10.1179/016164106X98008; Cheng YK, 2008, J CLIN NEUROSCI, V15, P1115, DOI 10.1016/j.jocn.2007.09.022; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Grossman N., 2007, Cell and Tissue Banking, V8, P243, DOI 10.1007/s10561-006-9032-x; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Jho DH, 2007, J NEUROSURG, V107, P440, DOI 10.3171/JNS-07/08/0440; Kawaguchi T, 2003, NEUROL MED-CHIR, V43, P320, DOI 10.2176/nmc.43.320; Kriegel RJ, 2007, ZBL NEUROCHIR, V68, P182, DOI 10.1055/s-2007-985857; Liao CC, 2002, J CLIN NEUROSCI, V9, P553, DOI 10.1054/jocn.2002.1116; Marchac D, 2008, J PLAST RECONSTR AES, V61, P744, DOI 10.1016/j.bjps.2007.10.055; Matsuno A, 2006, ACTA NEUROCHIR, V148, P535, DOI 10.1007/s00701-006-0740-6; Moreira-Gonzalez A, 2003, J CRANIOFAC SURG, V14, P144, DOI 10.1097/00001665-200303000-00003; Movassaghi K, 2006, PLAST RECONSTR SURG, V117, P202, DOI 10.1097/01.prs.0000187152.48402.17; Staffa G, 2007, ACTA NEUROCHIR, V149, P161, DOI 10.1007/s00701-006-1078-9; Wen L, 2007, J CRANIOFAC SURG, V18, P526, DOI 10.1097/scs.0b013e3180534348; Wurm G, 2004, SURG NEUROL, V62, P510, DOI 10.1016/j.surneu.2004.01.025	16	78	81	0	8	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	MAY	2010	28	5							E3	10.3171/2010.2.FOCUS1026			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	589ZU	WOS:000277193600003	20568943				2022-02-06	
J	Pesaresi, M; Maschi, O; Giatti, S; Garcia-Segura, LM; Caruso, D; Melcangi, RC				Pesaresi, Marzia; Maschi, Omar; Giatti, Silvia; Garcia-Segura, Luis Miguel; Caruso, Donatella; Melcangi, Roberto Cosimo			Sex differences in neuroactive steroid levels in the nervous system of diabetic and non-diabetic rats	HORMONES AND BEHAVIOR			English	Article						Peripheral nervous system; Central nervous system; Rat; Diabetes; Liquid chromatography-tandem mass spectrometry; Pregnenolone; Progesterone; Testosterone; Dehydroepiandrosterone; Neurosteroids	MESSENGER-RNA EXPRESSION; TRAUMATIC BRAIN-INJURY; GENDER-DIFFERENCES; HIPPOCAMPAL NEUROGENESIS; ALZHEIMERS-DISEASE; NEUROPROTECTIVE AGENTS; COGNITIVE DYSFUNCTION; NEUROPATHY; ALLOPREGNANOLONE; PROGESTERONE	Neuropathy and encephalopathy represent important complications of diabetes. Recent observations obtained in experimental models have suggested that, in male rats, neuroactive steroids are protective agents and that their levels in peripheral (PNS) and central (CNS) nervous system are strongly affected by the disease. It is interesting to highlight that incidence, progression and severity of diabetic neuropathy and diabetic encephalopathy are different in the two sexes. Consequently, it is important to determine the changes in neuroactive steroid levels in the PNS and the CNS of both males and females. To this aim, we have evaluated the levels of neuroactive steroids such as, pregnenolone, progesterone and its metabolites, testosterone and its metabolites, and dehydroepiandrosterone in different CNS regions (i.e., cerebral cortex, cerebellum and spinal cord) and in the sciatic nerve of control and diabetic (i.e., induced by streptozotocin) male and female rats. Data obtained by liquid chromatography-tandem mass spectrometry indicate that the levels of neuroactive steroids show sex and regional differences in control animals. Streptozotocin-induced diabetes resulted in a strong general decrease in neuroactive steroid levels, in both the PNS and the CNS. In addition, the effects of diabetes on neuroactive steroid levels also show sex and regional differences. These findings may have strong implications for the development of new sex-oriented therapies for the treatment of diabetic neuropathy and diabetic encephalopathy, based on the use of neuroactive steroids. (C) 2009 Elsevier Inc. All rights reserved.	[Pesaresi, Marzia; Giatti, Silvia; Melcangi, Roberto Cosimo] Univ Milan, Ctr Excellence Neurodegenerat Dis, Dept Endocrinol Pathophysiol & Appl Biol, I-20133 Milan, Italy; [Maschi, Omar; Caruso, Donatella] Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy; [Garcia-Segura, Luis Miguel] CSIC, Inst Cajal, E-28002 Madrid, Spain		Melcangi, RC (corresponding author), Univ Milan, Ctr Excellence Neurodegenerat Dis, Dept Endocrinol Pathophysiol & Appl Biol, Via Balzaretti 9, I-20133 Milan, Italy.	roberto.melcangi@unimi.it	Giatti, Silvia/G-9334-2016; Melcangi, Roberto Cosimo/AAA-6534-2022; Garcia-Segura, Luis M/U-3711-2017; caruso, donatella/A-3332-2014	Giatti, Silvia/0000-0001-7741-826X; Garcia-Segura, Luis M/0000-0002-2450-2916; caruso, donatella/0000-0003-2115-778X; Maschi, Omar/0000-0002-4879-436X; MELCANGI, COSIMO ROBERTO/0000-0003-0861-8967	University of Milan, Italy [20074SPYCM_002]	The financial support of PRIN (20074SPYCM_002) and PUR from University of Milan, Italy, to R. C. Melcangi is gratefully acknowledged. We wish to thank Dr. Marc J. Tetel for his critical reading of the manuscript.	Aaberg ML, 2008, J DIABETES COMPLICAT, V22, P83, DOI 10.1016/j.jdiacomp.2007.06.009; Albers JW, 1996, NEUROLOGY, V46, P85, DOI 10.1212/WNL.46.1.85; Alvarez EO, 2009, BEHAV BRAIN RES, V198, P224, DOI 10.1016/j.bbr.2008.11.001; Andersen K, 1999, NEUROLOGY, V53, P1992, DOI 10.1212/WNL.53.9.1992; Aragno M, 2002, ENDOCRINOLOGY, V143, P3250, DOI 10.1210/en.2002-220182; Babich VM, 1998, WAVE MOTION, V28, P1, DOI 10.1016/S0165-2125(97)00059-0; Backstrom T, 2005, EUR J PHARMACOL, V512, P15, DOI 10.1016/j.ejphar.2005.01.049; Basit Abdul, 2004, J Coll Physicians Surg Pak, V14, P79; Beauquis J, 2008, EXP NEUROL, V210, P359, DOI 10.1016/j.expneurol.2007.11.009; Beauquis J, 2006, EUR J NEUROSCI, V23, P1539, DOI 10.1111/j.1460-9568.2006.04691.x; Belelli D, 2005, NAT REV NEUROSCI, V6, P565, DOI 10.1038/nrn1703; Bianchi R, 2004, P NATL ACAD SCI USA, V101, P823, DOI 10.1073/pnas.0307823100; Biessels GJ, 2008, LANCET NEUROL, V7, P184, DOI 10.1016/S1474-4422(08)70021-8; Biessels GJ, 2002, EUR J PHARMACOL, V441, P1, DOI 10.1016/S0014-2999(02)01486-3; Biessels GJ, 2005, NEUROBIOL AGING, V26, pS36, DOI 10.1016/j.neurobiolaging.2005.08.015; Biessels GJ, 1999, BRAIN, V122, P757, DOI 10.1093/brain/122.4.757; BILLIAR RB, 1975, BRAIN RES, V94, P99, DOI 10.1016/0006-8993(75)90880-X; BITRAN D, 1991, BRAIN RES, V561, P157, DOI 10.1016/0006-8993(91)90761-J; Booya F, 2005, BMC NEUROL, V5, DOI 10.1186/1471-2377-5-24; Brown RC, 2003, NEUROBIOL AGING, V24, P57, DOI 10.1016/S0197-4580(02)00048-9; Caruso D, 2008, NEUROCHEM INT, V52, P560, DOI 10.1016/j.neuint.2007.06.004; Caruso D, 2008, J MOL NEUROSCI, V34, P249, DOI 10.1007/s12031-007-9029-3; De Nicola AF, 2009, EXP GERONTOL, V44, P34, DOI 10.1016/j.exger.2008.03.005; Durant S, 1998, AUTOIMMUNITY, V28, P249, DOI 10.3109/08916939808995373; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Franzon R, 2005, DIABETES RES CLIN PR, V69, P107, DOI 10.1016/j.diabres.2004.11.010; Fratiglioni L, 1997, NEUROLOGY, V48, P132, DOI 10.1212/WNL.48.1.132; GEE KW, 1988, J PHARMACOL EXP THER, V246, P803; Gispen WH, 2000, TRENDS NEUROSCI, V23, P542, DOI 10.1016/S0166-2236(00)01656-8; Hedstrom H, 2009, PSYCHOPHARMACOLOGY, V203, P85, DOI 10.1007/s00213-008-1372-8; Huang XF, 2000, J BIOL CHEM, V275, P29452, DOI 10.1074/jbc.M000562200; Jacobson AM, 2002, INT REV NEUROBIOL, V51, P455, DOI 10.1016/S0074-7742(02)51013-8; Joseph EK, 2003, NEUROSCIENCE, V120, P907, DOI 10.1016/S0306-4522(03)00400-7; Kamboj SS, 2008, METAB BRAIN DIS, V23, P427, DOI 10.1007/s11011-008-9104-7; Kawashima R, 2007, NEUROCHEM RES, V32, P1002, DOI 10.1007/s11064-006-9260-2; Kaye W, 2008, PHYSIOL BEHAV, V94, P121, DOI 10.1016/j.physbeh.2007.11.037; Kiziltan ME, 2007, J NEUROL SCI, V258, P75, DOI 10.1016/j.jns.2007.02.028; Kiziltan ME, 2008, DIABETES RES CLIN PR, V79, pE17, DOI 10.1016/j.diabres.2007.07.013; Kodl CT, 2008, ENDOCR REV, V29, P494, DOI 10.1210/er.2007-0034; Kohchi C, 1998, BRAIN RES, V801, P233, DOI 10.1016/S0006-8993(98)00585-X; Lauria G, 2005, J PERIPHER NERV SYST, V10, P202, DOI 10.1111/j.1085-9489.2005.0010210.x; Leonelli E, 2007, NEUROSCIENCE, V144, P1293, DOI 10.1016/j.neuroscience.2006.11.014; Lundgren P, 2003, BRAIN RES, V982, P45, DOI 10.1016/S0006-8993(03)02939-1; Marcus SM, 2008, COMPR PSYCHIAT, V49, P238, DOI 10.1016/j.comppsych.2007.06.012; Marx CE, 2006, BIOL PSYCHIAT, V60, P1287, DOI 10.1016/j.biopsych.2006.06.017; Mastrocola R, 2005, J ENDOCRINOL, V187, P37, DOI 10.1677/joe.1.06269; McCall AL, 2002, INT REV NEUROBIOL, V51, P415, DOI 10.1016/S0074-7742(02)51012-6; Meffre D, 2007, ENDOCRINOLOGY, V148, P2505, DOI 10.1210/en.2006-1678; Meffre D, 2007, J STEROID BIOCHEM, V104, P293, DOI 10.1016/j.jsbmb.2007.03.003; Melcangi RC, 2008, CELL MOL LIFE SCI, V65, P777, DOI 10.1007/s00018-007-7403-5; Melcangi RC, 2006, NEUROSCIENCE, V138, P733, DOI 10.1016/j.neuroscience.2005.10.066; MELLON SH, 1993, BRAIN RES, V629, P283, DOI 10.1016/0006-8993(93)91332-M; Meyer L, 2008, NEUROBIOL DIS, V30, P30, DOI 10.1016/j.nbd.2007.12.001; Naik AK, 2008, NEUROSCIENCE, V154, P1539, DOI 10.1016/j.neuroscience.2008.04.061; Niemeier JP, 2007, NEUROPSYCHOL REHABIL, V17, P293, DOI 10.1080/09602010600814729; Nitta A, 2002, NEUROTOXICOL TERATOL, V24, P695, DOI 10.1016/S0892-0362(02)00220-9; Pathirathna S, 2005, PAIN, V117, P326, DOI 10.1016/j.pain.2005.06.019; Pathirathna S, 2005, PAIN, V114, P429, DOI 10.1016/j.pain.2005.01.009; Roglio I, 2007, CELL MOL LIFE SCI, V64, P1158, DOI 10.1007/s00018-007-7002-5; Salonia A, 2006, DIABETES CARE, V29, P312, DOI 10.2337/diacare.29.02.06.dc05-1067; Saravia F, 2004, J NEUROENDOCRINOL, V16, P704, DOI 10.1111/j.1365-2826.2004.01223.x; Saravia FE, 2006, CELL MOL NEUROBIOL, V26, P943, DOI 10.1007/s10571-006-9096-y; Simonds VA, 2003, J AFFECT DISORDERS, V77, P197, DOI 10.1016/S0165-0327(02)00113-1; Steen E, 2005, J ALZHEIMERS DIS, V7, P63, DOI 10.3233/jad-2005-7107; Stranahan AM, 2008, NAT NEUROSCI, V11, P309, DOI 10.1038/nn2055; Sugimoto K, 2000, DIABETES-METAB RES, V16, P408; Tanaka M, 2001, ENDOCR RES, V27, P109, DOI 10.1081/ERC-100107174; van Dam EWCM, 2003, DIABETES CARE, V26, P1812, DOI 10.2337/diacare.26.6.1812; Veiga S, 2006, NEUROSCI LETT, V402, P150, DOI 10.1016/j.neulet.2006.03.058; Vinik AI, 2000, DIABETOLOGIA, V43, P957, DOI 10.1007/s001250051477; Wang MD, 2002, J NEUROSCI, V22, P3366; Watzka M, 1999, J NEUROENDOCRINOL, V11, P901; Weill-Engerer S, 2002, J CLIN ENDOCR METAB, V87, P5138, DOI 10.1210/jc.2002-020878; Yagihashi S, 1997, J Peripher Nerv Syst, V2, P113; Yorek MA, 2002, AM J PHYSIOL-ENDOC M, V283, pE1067, DOI 10.1152/ajpendo.00173.2002; Zhang WJ, 2008, ACTA NEUROL SCAND, V117, P205, DOI 10.1111/j.1600-0404.2007.00928.x	76	78	78	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0018-506X	1095-6867		HORM BEHAV	Horm. Behav.	JAN	2010	57	1			SI		46	55		10.1016/j.yhbeh.2009.04.008			10	Behavioral Sciences; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Endocrinology & Metabolism	549NC	WOS:000274056700006	19422828				2022-02-06	
J	Bryant, RA; Creamer, M; O'Donnell, M; Silove, D; Clark, CR; McFarlane, AC				Bryant, Richard A.; Creamer, Mark; O'Donnell, Meaghan; Silove, Derrick; Clark, C. Richard; McFarlane, Alexander C.			Post-traumatic amnesia and the nature of post-traumatic stress disorder after mild traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Trauma; Memory; Stress; Risk; Intrusions; Anxiety	POSTCONCUSSIVE SYMPTOMS; MEMORIES; MECHANISMS; SEQUELAE; PTSD; IRAQ; TBI	The prevalence and nature of post-traumatic stress disorder (PTSD) following mild traumatic brain injury (MTBI) is controversial because of the apparent paradox of suffering PTSD with impaired memory for the traumatic event. In this study, 1167 survivors of traumatic injury (MTBI: 459, No TBI: 708) were assessed for PTSD symptoms and post-traumatic amnesia during hospitalization, and were subsequently assessed for PTSD 3 months later (N=920). At the follow-up assessment, 90 (9.4%) patients met criteria for PTSD (MTBI: 50, 11.8%; No-TBI: 40, 7.5%); MTBI patients were more likely to develop PTSD than no-TBI patients, after controlling for injury severity (adjusted odds ratio: 1.86; 95% confidence interval, 1.78-2.94). Longer post-traumatic amnesia was associated with less severe intrusive memories at the acute assessment. These findings indicate that PTSD may be more likely following MTBI, however, longer post-traumatic amnesia appears to be protective against selected re-experiencing symptoms. (JINS, 2009, 157 862-867.)	[Bryant, Richard A.] Univ New S Wales, Sch Psychol, Sydney, NSW, Australia; [Creamer, Mark; O'Donnell, Meaghan] Univ Melbourne, Dept Psychiat, Melbourne, Vic, Australia; [Silove, Derrick] Univ New S Wales, Sch Psychiat, Sydney, NSW, Australia; [Clark, C. Richard] Flinders Univ S Australia, Dept Psychol, Adelaide, SA, Australia; [McFarlane, Alexander C.] Univ Adelaide, Dept Psychiat, Adelaide, SA, Australia		Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW, Australia.	r.bryant@unsw.edu.au	Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X; O'Donnell, Meaghan/0000-0003-4349-0022	NHMRCNational Health and Medical Research Council of Australia [300403]; Victorian Trauma Foundation [V-11]; National Health and Medical Research Council Australian Clinical ResearchNational Health and Medical Research Council of Australia [359284]	This study was Supported by an NHMRC Program Grant (300403), a Victorian Trauma Foundation grant (#V-11), and a National Health and Medical Research Council Australian Clinical Research Fellowship (359284).	American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Aziz Mohamed A, 2004, J Psychiatr Pract, V10, P307, DOI 10.1097/00131746-200409000-00004; Blake DD, 1998, CLIN ADM PTSD SCALE; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 1998, APPL COGNITIVE PSYCH, V12, P81, DOI 10.1002/(SICI)1099-0720(199802)12:1<81::AID-ACP507>3.0.CO;2-8; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Bryant RA, 2007, J CONSULT CLIN PSYCH, V75, P812, DOI 10.1037/0022-006X.75.5.812; Castro CA, 2008, J TRAUMA, V64, pS205; CHARNEY DS, 1993, ARCH GEN PSYCHIAT, V50, P294; Conway MA, 2000, PSYCHOL REV, V107, P261, DOI 10.1037//0033-295X.107.2.261; Dunmore E, 2001, BEHAV RES THER, V39, P1063, DOI 10.1016/S0005-7967(00)00088-7; DUNMORE E, 1997, BEHAV COGN PSYCHOTH, V0025, P00147, DOI DOI 10.1017/S135246580001835X; Ehlers A, 2000, BEHAV RES THER, V38, P319, DOI 10.1016/S0005-7967(99)00123-0; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Greenspan AI, 2006, BRAIN INJURY, V20, P733, DOI 10.1080/02699050600773276; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Harvey AG, 2001, J TRAUMA STRESS, V14, P277, DOI 10.1023/A:1011108816888; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lanius RA, 2006, J PSYCHIATR RES, V40, P709, DOI 10.1016/j.jpsychires.2005.07.007; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Lovibond PF, 2002, J EXP PSYCHOL-ANIM B, V28, P3, DOI 10.1037//0097-7403.28.1.3; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; PITMAN RK, 1988, PSYCHIAT ANN, V18, P182, DOI 10.3928/0048-5713-19880301-11; Rauch SL, 1997, ANN NY ACAD SCI, V821, P83, DOI 10.1111/j.1749-6632.1997.tb48271.x; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Southwick SM, 1997, AM J PSYCHIAT, V154, P173; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	36	78	79	0	9	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	NOV	2009	15	6					862	867		10.1017/S1355617709990671			6	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	523ZV	WOS:000272114500006	19703323	Green Published			2022-02-06	
J	Barker-Collo, SL; Feigin, VL; Lawes, CMM; Parag, V; Senior, H; Rodgers, A				Barker-Collo, Suzanne L.; Feigin, Valery L.; Lawes, Carlene M. M.; Parag, Varsha; Senior, Hugh; Rodgers, Anthony			Reducing Attention Deficits After Stroke Using Attention Process Training A Randomized Controlled Trial	STROKE			English	Article						attention; rehabilitation; neuropsychology; randomized clinical trial; stroke	QUALITY-OF-LIFE; COGNITIVE IMPAIRMENT; BRAIN-INJURY; REHABILITATION; ASSOCIATION; PERFORMANCE; COMMUNITY; RECOVERY; EFFICACY; PROGRAM	Background and Purpose-Impaired attention contributes to poor stroke outcomes. Attention process training (APT) reduces attention deficits after traumatic brain injury. There was no evidence for effectiveness of APT in stroke patients. This trial evaluated effectiveness of APT in improving attention and broader outcomes in stroke survivors 6 months after stroke. Methods-Participants in this prospective, single-blinded, randomized, clinical trial were 78 incident stroke survivors admitted over 18 months and identified via neuropsychological assessment as having attention deficit. Participants were randomly allocated to standard care plus up to 30 hours of APT or standard care alone. Both groups were impaired (z <=-2.0) across measures of attention at baseline, with the exception of Paced Auditory Serial Addition Test, which was below average (z <=-1.0). Outcome assessment occurred at 5 weeks and 6 months after randomization. The primary outcome was Integrated Visual Auditory Continuous Performance Test Full-Scale Attention Quotient. Results-APT resulted in a significantly greater (P<0.01) improvement on the primary outcome than standard care. Difference in change on the Cognitive Failures Questionnaire approached significance (P=0.07). Differences on other measures of attention and broader outcomes were not significant. Conclusion-APT is a viable and effective means of improving attention deficits after incident stroke. (Stroke. 2009;40:3293-3298.)	[Barker-Collo, Suzanne L.] Univ Auckland, Dept Psychol, Clin Training Programme, Fac Sci, Auckland, New Zealand; [Feigin, Valery L.] AUT Univ, Natl Res Ctr Stroke Appl Neurosci & Neurorehabil, Fac Hlth & Environm Studies, Auckland, New Zealand; [Lawes, Carlene M. M.; Parag, Varsha] Univ Auckland, Clin Trials Res Unit, Sch Populat Hlth, Fac Med & Hlth Sci, Auckland 1, New Zealand; [Senior, Hugh; Rodgers, Anthony] Univ Sydney, George Inst Int Hlth, Sydney, NSW 2006, Australia		Barker-Collo, SL (corresponding author), Univ Auckland, Dept Psychol, Clin Training Programme, Fac Sci, Tamaki Campus,Private Bag 92019, Auckland, New Zealand.	s.barker-collo@auckland.ac.nz	Senior, Hugh/H-1579-2011; Feigin, Valery/AAF-2313-2019	Feigin, Valery L./0000-0002-6372-1740; Senior, Hugh/0000-0002-7081-2499; Rodgers, Anthony/0000-0003-1282-1896	New Zealand Health Research CouncilHealth Research Council of New Zealand [06/063C, 07/070C]; National Heart Foundation (New Zealand)	This work was supported by the New Zealand Health Research Council (HRC Refs 06/063C and 07/070C). Dr C. M. M. Lawes is supported by a National Heart Foundation (New Zealand) Fellowship.	AHO K, 1980, B WORLD HEALTH ORGAN, V58, P113; BAMFORD JM, 1989, STROKE, V20, P828, DOI 10.1161/01.STR.20.6.828; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Butler RW, 2002, J INT NEUROPSYCH SOC, V8, P115, DOI 10.1017/S1355617701020112; Dorman P, 1998, STROKE, V29, P63, DOI 10.1161/01.STR.29.1.63; Duncan PW, 2005, STROKE, V36, pE100, DOI 10.1161/01.STR.0000180861.54180.FF; GAUTHIER L, 1989, INT J CLIN NEUROPSYC, V11, P49; Goldberg P., 1978, MANUAL GEN HLTH QUES; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hackett ML, 2000, STROKE, V31, P440, DOI 10.1161/01.STR.31.2.440; Harding Karen L, 2003, Altern Med Rev, V8, P319; Hochstenbach J, 1998, J CLIN EXP NEUROPSYC, V20, P503, DOI 10.1076/jcen.20.4.503.1471; Hochstenbach JB, 2001, ARCH PHYS MED REHAB, V82, P1360, DOI 10.1053/apmr.2001.25970; Hyndman D, 2008, J NEUROL NEUROSUR PS, V79, P656, DOI 10.1136/jnnp.2007.125609; Hyndman D, 2003, DISABIL REHABIL, V25, P817, DOI 10.1080/0963828031000122221; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Loetscher T., COCHRANE DB SYST REV, DOI [10.1002/14651858.CD002842, DOI 10.1002/14651858.CD002842]; Lynch JW, 1997, NEW ENGL J MED, V337, P1889, DOI 10.1056/NEJM199712253372606; Mateer CA, 1990, COGNITIVE REHABILITA, P68; Mazer BL, 2003, ARCH PHYS MED REHAB, V84, P541, DOI 10.1053/apmr.2003.50085; McDowd JM, 2003, J GERONTOL B-PSYCHOL, V58, pP45, DOI 10.1093/geronb/58.1.P45; McDowell I., 1996, MEASURING HLTH GUIDE; MORRIS PLP, 1993, AM J PSYCHIAT, V150, P124; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; NYS GMS, 2005, THESIS U UTRECHT NED; Paolucci S, 1996, EUR NEUROL, V36, P385, DOI 10.1159/000117298; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; Park NW, 1999, NEUROPSYCHOL REHABIL, V9, P135, DOI 10.1080/713755595; Patel MD, 2002, J AM GERIATR SOC, V50, P700, DOI 10.1046/j.1532-5415.2002.50165.x; Penkman Louise, 2004, Pediatr Rehabil, V7, P111, DOI 10.1080/13638490310001649417; Robertson IH, 1997, NEUROPSYCHOLOGY, V11, P290, DOI 10.1037/0894-4105.11.2.290; Ruff R. M., 1989, J HEAD TRAUMA REHAB, V4, P20, DOI [10.1097/00001199-198909000-00006, DOI 10.1097/00001199-198909000-00006]; Schmidt R. A., 1988, MOTOR CONTROL LEARNI; Schottke H, 1997, VERHALTENSTHERAPIE, V7, P21, DOI 10.1159/000259005; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; Sohlberg MM, 2001, ATTENTION PROCESS TR; Stapleton T, 2001, CLIN REHABIL, V15, P437, DOI 10.1191/026921501678310243; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Sturm W, 1997, NEUROPSYCHOL REHABIL, V7, P81, DOI 10.1080/713755526; STURM W, 1993, COMPUTER ASSISTED RE; Sturm W, 1991, NEUROPSYCHOL REHABIL, V1, P259, DOI DOI 10.1080/09602019108402258; THOMSON J, 2001, PAY ATTENTION ATTENT; Tinius TP, 2003, ARCH CLIN NEUROPSYCH, V18, P199, DOI 10.1016/S0887-6177(01)00196-2; Turner A., 2000, INTEGRATED VISUAL AU; Williams LS, 1999, NEUROLOGY, V53, P1839, DOI 10.1212/WNL.53.8.1839; Wood R L, 1987, Int Disabil Stud, V9, P149; ZAK ML, 2000, DISS ABSTR INT B, V60, P5799; Zhu L, 1998, STROKE, V29, P2094, DOI 10.1161/01.STR.29.10.2094	49	78	81	0	32	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	OCT	2009	40	10					3293	3298		10.1161/STROKEAHA.109.558239			6	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Cardiovascular System & Cardiology	499NV	WOS:000270229800024	19628801	Bronze			2022-02-06	
J	Smits, M; Dippel, DWJ; Houston, GC; Wielopolski, PA; Koudstaal, PJ; Hunink, MGM; van der Lugt, A				Smits, Marion; Dippel, Diederik W. J.; Houston, Gavin C.; Wielopolski, Piotr A.; Koudstaal, Peter J.; Hunink, M. G. Myriam; van der Lugt, Aad			Postconcussion Syndrome After Minor Head Injury: Brain Activation of Working Memory and Attention	HUMAN BRAIN MAPPING			English	Article						postconcussion syndrome; cognitive impairment; concussion; MRI/fMRI; functional neuroimaging	EVENT-RELATED FMRI; NEUROPSYCHOLOGICAL DEFICITS; COGNITIVE REHABILITATION; FUNCTIONAL MRI; STROOP TASK; MILD; SYMPTOMS; PERFORMANCE; IMPAIRMENT; LOAD	After minor head injury (MHI) postconcussive Symptoms (PCS) Such as memory and attention deficits frequently occur. It has been hypothesised Thai PCS are Caused by microstructural damage to the brain due to shearing injury, which is not detectable with conventional imaging, and may be responsible for a functional deficit. The purpose of this Study was to correlate functional magnetic resonance imaging brain activation of working memory and selective attention with PCS. 21 MHI patients and 12 healthy controls were scanned at 3T. Stimulation paradigms were the n-back and Counting Stroop tasks to engage working memory and selective attention, respectively. Functional data analysis consisted of random effects group analyses, correlating brain activation patterns with the severity of PCS as evaluated with the Rivermead postconcussion symptoms questionnaire. At minimal working memory load, activation was seen in patients with greater severity of PCS in the working memory network. With an increase of working memory load, increase of activation was more pronounced in patients with greater severity of PCS. At high and increased working memory load, activation associated with the severity of PCS was seen in the posterior parietal area, parahippocampal gyrus, and posterior cingulate gyrus. Activation related to selective attention processing was increased with greater severity of PCS. The increased activity in relation to working memory and attention, and the recruitment of brain areas outside the working memory network at high working memory load, may be considered a reflection of the brain's compensatory, response to microstructural injury in patients with PCS. Hum Brain Mapp 30:2789-2803, 2009. (C) 2008 Wiley-Liss, Inc.	[Smits, Marion; Wielopolski, Piotr A.; Hunink, M. G. Myriam; van der Lugt, Aad] Erasmus MC Univ Med Ctr Rotterdam, Dept Radiol, NL-3000 CA Rotterdam, Netherlands; [Dippel, Diederik W. J.; Koudstaal, Peter J.] Erasmus MC Univ Med Ctr Rotterdam, Dept Neurol, NL-3000 CA Rotterdam, Netherlands; [Houston, Gavin C.] GE Healthcare, Appl Sci Lab, Shertogenbosch, Netherlands; [Hunink, M. G. Myriam] Erasmus MC Univ Med Ctr Rotterdam, Dept Epidemiol & Biostat, NL-3000 CA Rotterdam, Netherlands; [Hunink, M. G. Myriam] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA		Smits, M (corresponding author), Erasmus MC Univ Med Ctr Rotterdam, Dept Radiol HS 224, POB 2040, NL-3000 CA Rotterdam, Netherlands.	marion.smits@erasmusmc.nl	Dippel, Diederik/AAJ-2192-2020; Smits, Marion/AAB-3985-2019; Smits, Marion/E-4795-2011	Dippel, Diederik/0000-0002-9234-3515; Smits, Marion/0000-0001-5563-2871; 			Alexander, 1997, Semin Clin Neuropsychiatry, V2, P177; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Ashburner J, 1999, HUM BRAIN MAPP, V7, P254, DOI 10.1002/(SICI)1097-0193(1999)7:4<254::AID-HBM4>3.0.CO;2-G; Association A. P., 1994, DIAGN STAT MAN MENT; Audoin B, 2003, HUM BRAIN MAPP, V20, P51, DOI 10.1002/hbm.10128; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bigler ED, 2003, ARCH CLIN NEUROPSYCH, V18, P595; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BOHNEN N, 1992, ACTA NEUROL SCAND, V85, P116, DOI 10.1111/j.1600-0404.1992.tb04009.x; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; Bordini EJ, 2002, NEUROREHABILITATION, V17, P93; Bush G, 1998, HUM BRAIN MAPP, V6, P270, DOI 10.1002/(SICI)1097-0193(1998)6:4<270::AID-HBM6>3.3.CO;2-H; Calder AJ, 2001, NAT REV NEUROSCI, V2, P352, DOI 10.1038/35072584; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cicerone KD, 2002, CLIN NEUROPSYCHOL, V16, P280, DOI 10.1076/clin.16.3.280.13849; D'Esposito M, 1998, COGNITIVE BRAIN RES, V7, P1, DOI 10.1016/S0926-6410(98)00004-4; D'Esposito M, 2000, EXP BRAIN RES, V133, P3, DOI 10.1007/s002210000395; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DONALDSON DI, 2002, FUNCTIONAL MRI INTRO, P177; Duncan J, 2000, SCIENCE, V289, P457, DOI 10.1126/science.289.5478.457; Egner T, 2005, NEUROIMAGE, V24, P539, DOI 10.1016/j.neuroimage.2004.09.007; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Eyler LT, 2004, PSYCHIAT RES-NEUROIM, V130, P245, DOI 10.1016/j.pscychresns.2004.01.003; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Friston KJ, 1996, MAGNET RESON MED, V35, P346, DOI 10.1002/mrm.1910350312; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Jonides J, 1997, J COGNITIVE NEUROSCI, V9, P462, DOI 10.1162/jocn.1997.9.4.462; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Laatsch LK, 2004, BRAIN INJURY, V18, P957, DOI 10.1080/02699050410001672369; Lange G, 2005, NEUROIMAGE, V26, P513, DOI 10.1016/j.neuroimage.2005.02.011; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Manoach DS, 1997, NEUROREPORT, V8, P545, DOI 10.1097/00001756-199701200-00033; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Newsome MR, 2007, CORTEX, V43, P95, DOI 10.1016/S0010-9452(08)70448-9; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Owen AM, 1998, P NATL ACAD SCI USA, V95, P7721, DOI 10.1073/pnas.95.13.7721; Qin SZ, 2007, NEUROIMAGE, V38, P212, DOI 10.1016/j.neuroimage.2007.07.020; Smith EE, 1998, P NATL ACAD SCI USA, V95, P12061, DOI 10.1073/pnas.95.20.12061; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Strangman G, 2005, AM J PHYS MED REHAB, V84, P62, DOI 10.1097/01.PHM.0000150787.26860.12; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Sweet LH, 2006, HUM BRAIN MAPP, V27, P28, DOI 10.1002/hbm.20163; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Walsh ND, 2007, BIOL PSYCHIAT, V62, P1236, DOI 10.1016/j.biopsych.2006.12.022; World Health Organization, 1993, ICD 10 CLASS MENT BE; Yetkin FZ, 2006, EUR RADIOL, V16, P193, DOI 10.1007/s00330-005-2794-x	59	78	81	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	SEP	2009	30	9					2789	2803		10.1002/hbm.20709			15	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	490OK	WOS:000269510200007	19117278	Green Published			2022-02-06	
J	Fear, NT; Jones, E; Groom, M; Greenberg, N; Hull, L; Hodgetts, TJ; Wessely, S				Fear, N. T.; Jones, E.; Groom, M.; Greenberg, N.; Hull, L.; Hodgetts, T. J.; Wessely, S.			Symptoms of post-concussional syndrome are non-specifically related to mild traumatic brain injury in UK Armed Forces personnel on return from deployment in Iraq: an analysis of self-reported data	PSYCHOLOGICAL MEDICINE			English	Article						Deployment; mild traumatic brain injury; military personnel; post-concussional syndrome; self-reported data	HEALTH SURVEY SF-36; SOMATIC SYMPTOMS; WAR; VALIDITY; DISORDER; FATIGUE	Background. Mild traumatic brain injury (mTBI) is being claimed as the 'signature' injury of the Iraq war, and is believed to be the cause of long-term symptomatic ill health (post-concussional syndrome; PCS) in an unknown proportion of military personnel. Method. We analysed cross-sectional data from a large, randomly selected cohort of UK military personnel deployed to Iraq (n=5869). Two markers of PCS were generated: 'PCS symptoms' (indicating the presence of mTBI-related symptoms: none, 1-2, 3+) and 'PCS symptom severity' (indicating the presence of mTBI-related symptoms at either a moderate or severe level of severity: none, 1-2, 3+). Results. PCS symptoms and PCS symptom severity were associated with self-reported exposure to blast whilst in a combat zone. However, the same symptoms were also associated with other in-theatre exposures such as potential exposure to depleted uranium and aiding the wounded. Strong associations were apparent between having PCS symptoms and other health outcomes, in particular being a post-traumatic stress disorder or General Health Questionnaire case. Conclusions. PCS symptoms are common and some are related to exposures such as blast injury. However, this association is not specific, and the same symptom complex is also related to numerous other risk factors and exposures. Post-deployment screening for PCS and/or mTBI in the absence of contemporaneous recording of exposure is likely to be fraught with hazards.	[Fear, N. T.; Greenberg, N.] Kings Coll London, Acad Ctr Def Mental Hlth, London WC2R 2LS, England; [Jones, E.; Hull, L.; Wessely, S.] Kings Coll London, Kings Ctr Mil Hlth Res, London WC2R 2LS, England; [Groom, M.] Minist Def, Def Med Serv, London, England; [Hodgetts, T. J.] Minist Def, Royal Coll Def Med, Birmingham, W Midlands, England		Fear, NT (corresponding author), Kings Coll London, Weston Educ Ctr, Ctr Def Mental Hlth, 10 Cutcombe Rd, London SE5 9RJ, England.	nicola.fear@iop.kcl.ac.uk	Wessely, Simon C/A-8713-2008; Fear, Nicola/A-1917-2012	Fear, Nicola/0000-0002-5792-2925; greenberg, neil/0000-0003-4550-2971; Jones, Edgar/0000-0002-4610-9584; Wessely, Simon Charles/0000-0002-6743-9929	UK Ministry of Defence	N.T.F. and E.J. are supported by grants from the UK Ministry of Defence. M.G. and T.H. are full-time active service medical officers who have collaborated with the authors on this piece of work. N.G. is a full-time active service medical officer who has been seconded to the ACDMH, although paid from Ministry of Defence funds they were not directed in any way by the Ministry of Defence in relation to this publication. S. W. is Honorary Civilian Consultant Advisor to the British Army.	Babor TF, 2001, AUDIT ALCOHOL USE DI; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Breslow N., 1980, STAT METHODS CANC RE, V1; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; *DEP VET AFF VET H, 2007, VHA DIR 2007 013 SCR; Fear NT, 2007, ADDICTION, V102, P1749, DOI 10.1111/j.1360-0443.2007.01978.x; Goldberg D., 1988, USERS GUIDE GEN HLTH; Goldberg DP, 1997, PSYCHOL MED, V27, P191, DOI 10.1017/S0033291796004242; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Hotopf M, 2006, LANCET, V367, P1731, DOI 10.1016/S0140-6736(06)68662-5; Iversen A, 2006, BRIT MED J, V332, P165, DOI 10.1136/bmj.332.7534.165; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Simon GE, 1999, NEW ENGL J MED, V341, P1329, DOI 10.1056/NEJM199910283411801; Tate AR, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-51; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wessely S, 1996, AM J PSYCHIAT, V153, P1050; Wessely S, 2003, BRIT J PSYCHIAT, V183, P314, DOI 10.1192/bjp.183.4.314; World Health Organization, 1992, ICD 10 CLASSIFICATIO	24	78	78	0	10	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0033-2917	1469-8978		PSYCHOL MED	Psychol. Med.	AUG	2009	39	8					1379	1387		10.1017/S0033291708004595			9	Psychology, Clinical; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Psychiatry	472XC	WOS:000268165300016	18945380				2022-02-06	
J	Friess, SH; Ichord, RN; Ralston, J; Ryall, K; Helfaer, MA; Smith, C; Margulies, SS				Friess, Stuart H.; Ichord, Rebecca N.; Ralston, Jill; Ryall, Karen; Helfaer, Mark A.; Smith, Colin; Margulies, Susan S.			Repeated Traumatic Brain Injury Affects Composite Cognitive Function in Piglets	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; neurobehavioral assessment; pediatric brain injury; traumatic brain injury	CLOSED-HEAD INJURY; COLLEGIATE FOOTBALL PLAYERS; AXONAL INJURY; NEONATAL PIG; RECURRENT CONCUSSION; NCAA CONCUSSION; CHILDREN; RECOVERY; SPORT; CONTROVERSIES	Cumulative effects of repetitive mild head injury in the pediatric population are unknown. We have developed a cognitive composite dysfunction score that correlates white matter injury severity in neonatal piglets with neurobehavioral assessments of executive function, memory, learning, and problem solving. Anesthetized 3- to 5-day-old piglets were subjected to single (n=7), double one day apart (n=7), and double one week apart (n=7) moderate (190 rad/s) rapid non-impact axial rotations of the head and compared to instrumented shams (n=7). Animals experiencing two head rotations one day apart had a significantly higher mortality rate (43%) compared to the other groups and had higher failures rates in visual-based problem solving compared to instrumented shams. White matter injury, assessed by beta-APP staining, was significantly higher in the double one week apart group compared to that with single injury and sham. Worsening performance on cognitive composite score correlated well with increasing severity of white matter axonal injury. In our immature large animal model of TBI, two head rotations produced poorer outcome as assessed by neuropathology and neurobehavioral functional outcomes compared to that with single rotations. More importantly, we have observed an increase in injury severity and mortality when the head rotations occur 24 h apart compared to 7 days apart. These observations have important clinical translation to infants subjected to repeated inflicted head trauma.	[Ralston, Jill; Ryall, Karen; Margulies, Susan S.] Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA; [Friess, Stuart H.; Helfaer, Mark A.] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; [Ichord, Rebecca N.] Childrens Hosp Philadelphia, Dept Neurol, Philadelphia, PA 19104 USA; [Smith, Colin] Western Gen Hosp, Dept Neuropathol, Edinburgh EH4 2XU, Midlothian, Scotland		Margulies, SS (corresponding author), Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, 240 Skirkanich Hall,210 S 33rd St, Philadelphia, PA 19104 USA.	margulie@seas.upenn.edu		Smith, Colin/0000-0002-4507-5132	The Children's Hospital of Philadelphia; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS39679]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039679] Funding Source: NIH RePORTER	These studies were supported by an endowed chair in critical care medicine from The Children's Hospital of Philadelphia (M.A.H.) and an NIH grant (no. R01-NS39679 [S.S.M.]). The authors are grateful to Ahn Truong and Kristin Owens for their assistance in behavior testing and data analysis.	ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Barrow IM, 2006, BRAIN INJURY, V20, P845, DOI 10.1080/02699050600832445; Biasca N, 2007, PROG BRAIN RES, V161, P263, DOI 10.1016/S0079-6123(06)61019-4; Bolhuis JE, 2004, BEHAV BRAIN RES, V152, P351, DOI 10.1016/j.bbr.2003.10.024; De Monte VE, 2005, J CLIN EXP NEUROPSYC, V27, P224, DOI 10.1080/13803390490515766; DeRoss AL, 2002, J TRAUMA, V52, P708, DOI 10.1097/00005373-200204000-00017; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Frei FJ, 1997, ANAESTHESIA, V52, P1056, DOI 10.1111/j.1365-2044.1997.257-az0376.x; Friess SH, 2007, EXP NEUROL, V204, P234, DOI 10.1016/j.expneurol.2006.10.010; Giza CC, 2001, J ATHL TRAINING, V36, P228; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; HOEHNER PJ, 1994, STROKE, V25, P2060, DOI 10.1161/01.STR.25.10.2060; HOEHNER PJ, 1994, STROKE, V25, P2066; Hoyert Donna L, 2006, Natl Vital Stat Rep, V54, P1; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Power T, 2007, BRAIN INJURY, V21, P279, DOI 10.1080/02699050701253095; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Schnadower D, 2007, CURR OPIN PEDIATR, V19, P258, DOI 10.1097/MOP.0b013e3281084e85; Standaert CJ, 2007, ARCH PHYS MED REHAB, V88, P1077, DOI 10.1016/j.apmr.2007.06.002; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Wilkinson AE, 1999, ACTA NEUROPATHOL, V98, P197, DOI 10.1007/s004010051069	35	78	79	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2009	26	7					1111	1121		10.1089/neu.2008.0845			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	470HJ	WOS:000267965500016	19275468	Green Published			2022-02-06	
J	Lo, TP; Cho, KS; Garg, MS; Lynch, MP; Marcillo, AE; Koivisto, DL; Stagg, M; Abril, RM; Patel, S; Dietrich, WD; Pearse, DD				Lo, Thomas Pang, Jr.; Cho, Kyoung-Suok; Garg, Maneesh Sen; Lynch, Michael Patrick; Marcillo, Alexander Eduardo; Koivisto, Denise Leigh; Stagg, Monica; Abril, Rosa Marie; Patel, Samik; Dietrich, W. Dalton; Pearse, Damien Daniel			Systemic Hypothermia Improves Histological and Functional Outcome After Cervical Spinal Cord Contusion in Rats	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						neuroprotection; spinal cord injury; cooling; axon sparing; tissue loss; reticulospinal; forelimb function	TRAUMATIC BRAIN-INJURY; ORTHOGRADE AXONAL-TRANSPORT; OLFACTORY ENSHEATHING GLIA; AMINO-ACID RELEASE; POSTTRAUMATIC HYPOTHERMIA; HISTOPATHOLOGICAL DAMAGE; SCHWANN-CELLS; BLOOD-FLOW; INFLAMMATORY RESPONSE; ISCHEMIA-REPERFUSION	Hypothermia has been employed during the past 30 years as a therapeutic modality for spinal cord injury (SCI) in animal models and in humans. With our newly developed rat cervical model of contusive SCI, we investigated the therapeutic efficacy of transient systemic hypothermia (beginning 5 minutes post-injury for 4 hours, 33 degrees C) with gradual rewarming (1 degrees C per hour) for the preservation of tissue and the prevention of injury-induced functional loss. A moderate cervical displacement SCI was performed in female Fischer rats, and behavior was assessed for 8 weeks. Histologically, the application of hypothermia after SCI resulted in significant increases in normal-appearing white matter (31% increase) and gray matter (38% increase) volumes, greater preservation (four-fold) of neurons immediately rostral and caudal to the injury epicenter, and enhanced sparing of axonal connections from retrogradely traced reticulospinal neurons (127% increase) compared with normothermic controls. Functionally, a faster rate of recovery in open field locomotor ability (BBB score, weeks 1-3) and improved forelimb strength, as measured by both weight-supported hanging (43% increase) and grip strength (25% increase), were obtained after hypothermia. The current study demonstrates that mild systemic hypothermia is effective for retarding tissue damage and reducing neurological deficits following a clinically relevant contusive cervical SCI. J. Comp. Neurol. 514:433-448, 2009. (C) 2009 Wiley-Liss, Inc.	[Pearse, Damien Daniel] Univ Miami, Miller Sch Med, Lois Pope Life Ctr, Miami Project Cure Paralysis, Miami, FL 33101 USA; [Cho, Kyoung-Suok] Catholic Univ Med Coll, Uijongbu St Marys Hosp, Seoul 480130, South Korea; [Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33101 USA; [Dietrich, W. Dalton; Pearse, Damien Daniel] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33101 USA; [Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Cell Biol & Anat, Miami, FL 33101 USA		Pearse, DD (corresponding author), Univ Miami, Miller Sch Med, Lois Pope Life Ctr, Miami Project Cure Paralysis, Locator Code R-48,POB 016960, Miami, FL 33101 USA.	dpearse@miamiproject.med.miami.edu	Pearse, Damien D/D-3176-2011	Pearse, Damien D/0000-0003-1783-221X	Miami Project to Cure Paralysis; Buoniconti Fund; Paralysis Project of America; State of Florida; U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-05-1-006]	Grant sponsor: The Miami Project to Cure Paralysis; Grant sponsor: The Buoniconti Fund; Grant sponsor: The Paralysis Project of America; Grant sponsor: State of Florida; Grant sponsor: U.S. Army Medical Research and Materiel Command; Grant number: W81XWH-05-1-006.	ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; AKRIOTIS V, 1985, J LEUKOCYTE BIOL, V37, P51, DOI 10.1002/jlb.37.1.51; ALBIN MS, 1967, ANESTH ANAL CURR RES, V46, P8; Albin MS, 2000, ANESTHESIOLOGY, V92, P281, DOI 10.1097/00000542-200001000-00048; Amar AP, 1999, NEUROSURGERY, V44, P1027, DOI 10.1097/00006123-199905000-00052; Barakat DJ, 2005, CELL TRANSPLANT, V14, P225, DOI 10.3727/000000005783983106; Basso DM, 2002, RESTOR NEUROL NEUROS, V20, P189; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BERNTMAN L, 1981, ANESTHESIOLOGY, V55, P495, DOI 10.1097/00000542-198111000-00003; BIGGAR WD, 1984, INFECT IMMUN, V46, P857, DOI 10.1128/IAI.46.3.857-859.1984; BRACKEN MB, 1993, J NEUROSURG, V79, P500, DOI 10.3171/jns.1993.79.4.0500; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bricolo A, 1976, Surg Neurol, V6, P101; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; Chatzipanteli K, 2000, J NEUROTRAUM, V17, P321, DOI 10.1089/neu.2000.17.321; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Diener PS, 1998, J NEUROSCI, V18, P763; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dimar JR, 2000, SPINE, V25, P2294, DOI 10.1097/00007632-200009150-00006; DOLAN EJ, 1982, J NEUROSURG, V53, P350; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; DREW T, 1990, J NEUROPHYSIOL, V64, P767, DOI 10.1152/jn.1990.64.3.767; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; Faden AI, 2007, ARCH NEUROL-CHICAGO, V64, P794, DOI 10.1001/archneur.64.6.794; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Ho CH, 2007, ARCH PHYS MED REHAB, V88, pS49, DOI 10.1016/j.apmr.2006.12.001; Inamasu J, 2003, J NEUROL SCI, V209, P55, DOI 10.1016/S0022-510X(02)00463-X; Inamasu J, 2002, ANN EMERG MED, V40, P220, DOI 10.1067/mem.2002.123697; Ishikawa T, 1999, CELL MOL NEUROBIOL, V19, P199, DOI 10.1023/A:1005401926320; Jakeman LB, 2000, J NEUROTRAUM, V17, P299, DOI 10.1089/neu.2000.17.299; JASSEN L, 1989, SPINE, V14, P23; Kakinohana M, 1999, ANESTHESIOLOGY, V90, P789, DOI 10.1097/00000542-199903000-00022; KIDA Y, 1994, SPINE, V19, P341, DOI 10.1097/00007632-199402000-00015; Kil HY, 1996, J CEREBR BLOOD F MET, V16, P100, DOI 10.1097/00004647-199601000-00012; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; KOONS D D, 1972, Cleveland Clinic Quarterly, V39, P109; Kuchner E F, 1976, Surg Neurol, V6, P371; LEWIN M, 1972, EFFECTS STEROIDS EDE, P101; Marsala M, 1997, J NEUROSCI METH, V74, P97, DOI 10.1016/S0165-0270(97)02270-X; MARSALA M, 1994, STROKE, V25, P2038, DOI 10.1161/01.STR.25.10.2038; MARSALA M, 1994, J CEREBR BLOOD F MET, V14, P604, DOI 10.1038/jcbfm.1994.75; MARTINEZARIZALA A, 1992, J NEUROTRAUM, V9, pS497; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; McKenna JE, 1999, J NEUROSCI, V19, P1885; McKenna JE, 2000, J COMP NEUROL, V419, P286, DOI 10.1002/(SICI)1096-9861(20000410)419:3<286::AID-CNE2>3.0.CO;2-3; Meyer O A, 1979, Neurobehav Toxicol, V1, P233; MINAMISAWA H, 1990, J CEREBR BLOOD F MET, V10, P365, DOI 10.1038/jcbfm.1990.66; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Nakashima K, 1996, STROKE, V27, P913, DOI 10.1161/01.STR.27.5.913; PADILLA S, 1986, J NEUROCHEM, V46, P1227, DOI 10.1111/j.1471-4159.1986.tb00642.x; Pearse D, 2001, BRAIN RES, V894, P193, DOI 10.1016/S0006-8993(01)01993-X; Pearse DD, 2007, GLIA, V55, P976, DOI 10.1002/glia.20490; Pearse DD, 2005, J NEUROTRAUM, V22, P680, DOI 10.1089/neu.2005.22.680; Pearse DD, 2004, J NEUROTRAUM, V21, P1223, DOI 10.1089/0897715041953876; Pearse DD, 2004, NAT MED, V10, P610, DOI 10.1038/nm1056; Pearse DD, 2003, J NEUROPATH EXP NEUR, V62, P1096, DOI 10.1093/jnen/62.11.1096; PETERSON BW, 1979, EXP BRAIN RES, V36, P1; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; ROBERTSON CS, 1986, J NEUROSURG, V64, P633, DOI 10.3171/jns.1986.64.4.0633; ROKKAS CK, 1995, J THORAC CARDIOV SUR, V110, P27, DOI 10.1016/S0022-5223(05)80006-6; Schaal SM, 2007, CELL TRANSPLANT, V16, P207, DOI 10.3727/000000007783464768; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; SCHRIMSHER GW, 1993, EXP NEUROL, V120, P264, DOI 10.1006/exnr.1993.1060; SCHRIMSHER GW, 1992, EXP NEUROL, V117, P287, DOI 10.1016/0014-4886(92)90138-G; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; Shibuya S, 2004, SPINAL CORD, V42, P29, DOI 10.1038/sj.sc.3101516; SIEMIONOW M, 1993, J HAND SURG-AM, V18A, P963, DOI 10.1016/0363-5023(93)90384-F; Sipski ML, 2006, NAT CLIN PRACT NEURO, V2, P402, DOI 10.1038/ncpneuro0221; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; TOMLINSON DR, 1984, MED BIOL, V62, P34; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; WEST NR, 1989, J NEUROPATH EXP NEUR, V48, P94, DOI 10.1097/00005072-198901000-00008; Westergren H, 2000, ACTA NEUROCHIR, V142, P567, DOI 10.1007/s007010050471; Westergren H, 1999, SPINAL CORD, V37, P696, DOI 10.1038/sj.sc.3100920; Westergren H, 2001, SPINAL CORD, V39, P74, DOI 10.1038/sj.sc.3101127; WHITELEY SJ, 1985, DIABETOLOGIA, V28, P847, DOI 10.1007/BF00291076; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082; XU XM, 1995, J COMP NEUROL, V351, P145, DOI 10.1002/cne.903510113; Yenari MA, 2006, NEUROCHEM INT, V49, P164, DOI 10.1016/j.neuint.2006.03.016; Yu C. G., 1999, Society for Neuroscience Abstracts, V25, P1443; Yu CG, 2000, J NEUROSURG, V93, P85, DOI 10.3171/spi.2000.93.1.0085; [No title captured]	86	78	79	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9967	1096-9861		J COMP NEUROL	J. Comp. Neurol.	JUN 10	2009	514	5					433	448		10.1002/cne.22014			16	Neurosciences; Zoology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Zoology	437RK	WOS:000265504400002	19350644				2022-02-06	
J	Williams, G; Morris, ME; Schache, A; McCrory, PR				Williams, Gavin; Morris, Meg E.; Schache, Anthony; McCrory, Paul R.			Incidence of Gait Abnormalities After Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Conference of the International-Brain-Injury-Association	APR 09-12, 2008	Lisbon, PORTUGAL	Int Brain Injury Assoc		Biomechanics; Brain injuries; Gait; Rehabilitation	MOBILITY ASSESSMENT-TOOL; BOTULINUM-TOXIN; REHABILITATION; WALKING; ADULTS; ANKLE; FOOT; DISORDERS; INJECTION; VALIDITY	Williams G, Morris ME, Schache A, McCrory PR. Incidence of gait abnormalities after traumatic brain injury. Arch Phys Med Rehabil 2009;90:587-93. Objective: To identify the most common gait abnormalities presenting after traumatic brain injury (TBI) and quantify their incidence rate. Design: Case series. Setting: Biomechanics laboratory. Participants: A convenience sample of 41 people with TBI receiving therapy for gait abnormalities, and a sample of 25 healthy controls. Intervention: Three-dimensional gait analysis. Main Outcome Measures: Spatiotemporal, kinematic, and kinetic data at a self-selected walking speed. Results: People with TBI walked with a significantly slower speed than matched healthy controls. There was a significant difference between groups for cadence, step length, stance time on the affected leg, double support phase, and width of base of support. The most frequently observed biomechanical abnormality was excessive knee flexion at initial foot contact. Other significant gait abnormalities were increased trunk anterior/posterior amplitude of movement, increased anterior pelvic tilt, increased peak pelvic obliquity, reduced peak knee flexion at toe-off, and increased lateral center of mass displacement. Ankle equinovarus at foot-contact occurred infrequently. Conclusions: People with TBI were found to have multijoint gait abnormalities. Many of these abnormalities have not been previously reported in this Population.	[Williams, Gavin] Epworth Med Fdn, Melbourne, Vic, Australia; [Williams, Gavin; McCrory, Paul R.] Univ Melbourne, Sch Physiotherapy, Ctr Hlth Exercise & Sports Med, Melbourne, Vic, Australia; [Schache, Anthony] Univ Melbourne, Sch Mech Engn, Melbourne, Vic, Australia		Williams, G (corresponding author), Epworth Med Fdn, Physiotherapy Dept, 89 Bridge Rd, Richmond, Vic 3121, Australia.	gavin.williams@epworth.org.au	McCrory, Paul/Q-8688-2019; Schache, Anthony G/F-4482-2016	Schache, Anthony G/0000-0002-1041-5213; Williams, Gavin/0000-0003-2758-7473; Morris, Meg/0000-0002-0114-4175; McCrory, Paul/0000-0003-4850-0568			Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; Bracewell RM, 2005, NEUROLOGY, V64, P751, DOI 10.1212/01.WNL.0000151972.37634.33; Cantin JF, 2007, BRAIN INJURY, V21, P327, DOI 10.1080/02699050701209972; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Chua KSG, 2001, BRAIN INJURY, V15, P733, DOI 10.1080/02699050010009775; De Bujanda E, 2003, J REHABIL MED, V35, P259, DOI 10.1080/16501970310012428; DeLuca PA, 1997, J PEDIATR ORTHOPED, V17, P608, DOI 10.1097/00004694-199709000-00007; Esquenazi A, 2004, J HEAD TRAUMA REHAB, V19, P109, DOI 10.1097/00001199-200403000-00004; Fock J, 2004, BRAIN INJURY, V18, P57, DOI 10.1080/0269905031000149498; Fuller DA, 2002, FOOT ANKLE INT, V23, P738, DOI 10.1177/107110070202300810; Gradenigo B, 2002, EURA MEDICOPHYS, V38, P215; Griffin D., 1990, TROPICAL BRYOLOGY, V2, P127; Harrington ME, 2007, J BIOMECH, V40, P595, DOI 10.1016/j.jbiomech.2006.02.003; Hirtz D, 2007, NEUROLOGY, V68, P326, DOI 10.1212/01.wnl.0000252807.38124.a3; Horn TS, 2005, ARCH PHYS MED REHAB, V86, P1127, DOI 10.1016/j.apmr.2004.11.013; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; Kay RM, 2000, CLIN ORTHOP RELAT R, P217; Kerrigan DC, 1996, ARCH PHYS MED REHAB, V77, P645, DOI 10.1016/S0003-9993(96)90002-7; Kerrigan DCC, 1999, J HEAD TRAUMA REHAB, V14, P136, DOI 10.1097/00001199-199904000-00004; Lee LW, 1997, AM J PHYS MED REHAB, V76, P502, DOI 10.1097/00002060-199711000-00013; Liu MQ, 2006, J BIOMECH, V39, P2623, DOI 10.1016/j.jbiomech.2005.08.017; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; Medley A, 2006, BRAIN INJURY, V20, P1403, DOI 10.1080/02699050601082057; Molteni F, 1995, EUR J NEUROL, V2, P61; Niechwiej-Szwedo E, 2007, GAIT POSTURE, V25, P70, DOI 10.1016/j.gaitpost.2006.01.002; Ochi F, 1999, J HEAD TRAUMA REHAB, V14, P105, DOI 10.1097/00001199-199904000-00002; Perry J, 1999, J HEAD TRAUMA REHAB, V14, P116, DOI 10.1097/00001199-199904000-00003; Pohl M, 2006, CLIN REHABIL, V20, P324, DOI 10.1191/0269215506cr951oa; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Schache AG, 2007, GAIT POSTURE, V25, P440, DOI 10.1016/j.gaitpost.2006.05.018; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Thurman D, 1999, TRAUMATIC BRAIN INJU, DOI http://www.cdc.gov/ncipc/tbi/tbi_congress/TBI_in_the_US.PDF; Vallee M, 2006, ARCH PHYS MED REHAB, V87, P806, DOI 10.1016/j.apmr.2006.02.031; Williams G, 2006, ARCH PHYS MED REHAB, V87, P437, DOI 10.1016/j.apmr.2005.10.028; Williams GP, 2005, BRAIN INJURY, V19, P833, DOI 10.1080/02699050500058711	37	78	79	0	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2009	90	4					587	593		10.1016/j.apmr.2008.10.013			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation; Sport Sciences	432TD	WOS:000265156200008	19345773				2022-02-06	
J	Ge, YL; Patel, MB; Chen, Q; Grossman, EJ; Zhang, K; Miles, L; Babb, JS; Reaume, J; Grossman, RI				Ge, Yulin; Patel, Mayur B.; Chen, Qun; Grossman, Elan J.; Zhang, Ke; Miles, Laura; Babb, James S.; Reaume, Joseph; Grossman, Robert I.			Assessment of thalamic perfusion in patients with mild traumatic brain injury by true FISP arterial spin labelling MR imaging at 3T	BRAIN INJURY			English	Article						Mild traumatic brain injury; cerebral blood flow; ischemia; thalamus; magnetic resonance imaging; arterial spin labelling	CEREBRAL-BLOOD-FLOW; CONTROLLED CORTICAL IMPACT; HEAD-INJURY; RATS; ABNORMALITIES; DEFICITS; MODEL	Objective: To assess cerebral blood flow (CBF) changes in patients with mild traumatic brain injury (MTBI) using an arterial spin labelling (ASL) perfusion MRI and to investigate the severity of neuropsychological functional impairment with respect to haemodynamic changes. Materials and methods: Twenty-one patients with MTBI and 20 healthy controls were studied at 3T MR. The median time since the onset of brain injury in patients was 24.6 months. Both patients and controls underwent a traditional consensus battery of neurocognitive tests. ASL was performed using true fast imaging with steady state precession and a flow-sensitive alternating inversion recovery preparation. Regional CBF were measured in both deep and cortical gray matter as well as white matter at the level of basal ganglia. Results: The mean regional CBF was significantly lower in patients with MTBI (45.9 +/- 9.8 ml/100 g min-1) as compared to normal controls (57.1 +/- 8.1 ml/100 g min-1; p = 0.002) in both sides of thalamus. The decrease of thalamic CBF was significantly correlated with several neurocognitive measures including processing and response speed, memory/learning, verbal fluency and executive function in patients. Conclusions: Haemodynamic impairment can occur and persist in patients with MTBI, the extent of which is more severe in thalamic regions and correlate with neurocognitive dysfunction during the extended course of disease.	[Ge, Yulin; Patel, Mayur B.; Chen, Qun; Grossman, Elan J.; Zhang, Ke; Miles, Laura; Babb, James S.; Reaume, Joseph; Grossman, Robert I.] NYU, Sch Med, Ctr Biomed Imaging, Dept Radiol, New York, NY 10016 USA		Ge, YL (corresponding author), NYU, Sch Med, Ctr Biomed Imaging, Dept Radiol, 650 1St Ave,6th Floor,Rm 615, New York, NY 10016 USA.	yulin.ge@med.nyu.edu	Ge, Yulin/D-9060-2019; Ge, Yulin/L-7052-2019	Ge, Yulin/0000-0002-2320-6031; Babb, James/0000-0003-1798-1186	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [2R01NS039135-06A1, 5R01HL069023-04]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL069023] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039135] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (NIH) grant numbers 2R01NS039135-06A1 and 5R01HL069023-04.	Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Bramlett HM, 1999, J NEUROTRAUM, V16, P1035, DOI 10.1089/neu.1999.16.1035; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Buxton RB, 1998, MAGNET RESON MED, V40, P383, DOI 10.1002/mrm.1910400308; Coles Jonathan P, 2004, Curr Opin Crit Care, V10, P120, DOI 10.1097/00075198-200404000-00008; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Erlanger DM, 2002, J HEAD TRAUMA REHAB, V17, P458, DOI 10.1097/00001199-200210000-00007; Forbes ML, 1997, J CEREBR BLOOD F MET, V17, P865, DOI 10.1097/00004647-199708000-00005; Forbes ML, 1997, J CEREBR BLOOD F MET, V17, P1263; GROSSMAN E, 2007, MEASUREMENT DEEP GRA; Ichimi K, 1999, NEUROL RES, V21, P579, DOI 10.1080/01616412.1999.11740980; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; KIM SG, 1995, MAGNET RESON MED, V34, P293, DOI 10.1002/mrm.1910340303; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kochanek PM, 2002, J NEUROTRAUM, V19, P1029, DOI 10.1089/089771502760341947; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; KWONG KK, 1995, MAGNET RESON MED, V34, P878, DOI 10.1002/mrm.1910340613; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Martirosian P, 2004, MAGNET RESON MED, V51, P353, DOI 10.1002/mrm.10709; Nakamizo A, 2002, J CLIN NEUROSCI, V9, P685, DOI 10.1054/jocn.2002.1146; Natale JE, 2002, NEUROSCIENCE, V112, P665, DOI 10.1016/S0306-4522(02)00098-2; OLEARY DDM, 1994, ANNU REV NEUROSCI, V17, P419, DOI 10.1146/annurev.neuro.17.1.419; Rath JF, 2004, ARCH CLIN NEUROPSYCH, V19, P613, DOI 10.1016/j.acn.2003.08.006; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Shim YS, 2008, J NEUROL SCI, V266, P84, DOI 10.1016/j.jns.2007.09.016; Steriade M, 1997, THALAMUS; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Van der Werf YD, 2000, NEUROPSYCHOLOGIA, V38, P613, DOI 10.1016/S0028-3932(99)00104-9; WEISKOFF R, 1992, MAGNETIC RESONANCE I, P125; Yang YH, 1998, MAGNET RESON MED, V39, P825, DOI 10.1002/mrm.1910390520	37	78	82	0	17	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	7-8					666	674	PII 912685630	10.1080/02699050903014899			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	462QL	WOS:000267370600011	19557570	Green Accepted			2022-02-06	
J	Muscara, F; Catroppa, C; Anderson, V				Muscara, Frank; Catroppa, Cathy; Anderson, Vicki			Social problem-solving skills as a mediator between executive function and long-term social outcome following paediatric traumatic brain injury	JOURNAL OF NEUROPSYCHOLOGY			English	Article							SEVERE HEAD-INJURY; CHILDREN; COMPETENCE; ADJUSTMENT; CHILDHOOD; MODELS	There is debate regarding the relationship between executive function and social outcome following paediatric traumatic brain injury (TBI), due to inconsistent findings in the literature. It has been suggested that these contradictory results may reflect the absence of an established mechanism to explain this relationship. Yeates and colleagues (2004) proposed a possible model in which the maturity of social problem-solving skills mediates the relationship between executive function and social outcome. The current study aimed to explore this model and determine whether social problem solving mediates the relationship between executive function and social outcome in a TBI population. The sample consisted of 36 adolescents and young adults who sustained a TBI between 8 and 12 years of age. They ranged between 16 and 22 years of age and were 7-10 years post-injury. Findings indicated that a higher level of executive dysfunction was associated with less sophisticated social problem-solving skills and poorer social outcome. Further, the maturity of social problem-solving skills was found to mediate the relationship between executive function and social outcome in this group.	[Muscara, Frank] Royal Childrens Hosp, Murdoch Childrens Res Inst, Australian Ctr Child Neuropsychol Studies, Melbourne, Vic 3052, Australia; [Muscara, Frank; Catroppa, Cathy; Anderson, Vicki] Univ Melbourne, Melbourne, Vic, Australia		Muscara, F (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Australian Ctr Child Neuropsychol Studies, Flemington Rd, Melbourne, Vic 3052, Australia.	frank.muscara@mcri.edu.au	Catroppa, Cathy/AAX-9458-2021	Catroppa, Cathy/0000-0002-9750-0436			Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Ciccetti D., 1984, VINELAND ADAPTIVE BE; CRICK NR, 1994, PSYCHOL BULL, V115, P74, DOI 10.1037/0033-2909.115.1.74; Daniel A., 1983, POWER PRIVILEGE PRES; DZURILLA TJ, 1998, MANUAL SOCIAL PROBLE; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; Gioia GA IP, 2000, BEHAV RATING INVENTO; Guralnick MJ, 1999, MENT RETARD DEV D R, V5, P21; Harrison P. L., 2003, ADAPTIVE BEHAV ASSES, V2nd; Holmbeck GN, 1997, J CONSULT CLIN PSYCH, V65, P599, DOI 10.1037/0022-006X.65.4.599; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; LEVINE MJ, 1993, BRAIN INJURY, V7, P153, DOI 10.3109/02699059309008169; Manchester D, 2004, BRAIN INJURY, V18, P1067, DOI 10.1080/02699050410001672387; MARSH NV, 1991, J CLIN EXP NEUROPSYC, V13, P729, DOI 10.1080/01688639108401086; McGann W, 1997, BRAIN INJURY, V11, P621, DOI 10.1080/026990597123179; NEWTON A, 1985, BRIT J CLIN PSYCHOL, V24, P225, DOI 10.1111/j.2044-8260.1985.tb00655.x; Rose BM, 2004, J DEV BEHAV PEDIATR, V25, P58, DOI 10.1097/00004703-200402000-00013; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; SELMAN RL, 1986, DEV PSYCHOL, V22, P450, DOI 10.1037/0012-1649.22.4.450; SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; Tabachnick B.G., 2001, USING MULTIVARIATE S; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; Tatham, 1998, MULTIVARIATE DATA AN; Taylor HG, 2000, CHILD DEV, V71, P1495, DOI 10.1111/1467-8624.00242; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Warschausky S, 2003, REHABIL PSYCHOL, V48, P250, DOI 10.1037/0090-5550.48.4.250; Warschausky S, 1997, Pediatr Rehabil, V1, P77; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; WILLIAMS D, 1992, BRAIN COGNITION, V20, P196, DOI 10.1016/0278-2626(92)90069-X; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; [No title captured]; [No title captured]; [No title captured]; [No title captured]	40	78	78	0	23	BRITISH PSYCHOLOGICAL SOC	LEICESTER	ST ANDREWS HOUSE, 48 PRINCESS RD EAST, LEICESTER LE1 7DR, LEICS, ENGLAND	1748-6645			J NEUROPSYCHOL	J. Neuropsychol.	SEP	2008	2						445	461		10.1348/174866407X250820			17	Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	499XI	WOS:000270259700008	19824165				2022-02-06	
J	Hanna, WC; Ferri, LE; Fata, P; Razek, T; Mulder, DS				Hanna, Waeel C.; Ferri, Lorenzo E.; Fata, Paola; Razek, Tarek; Mulder, David S.			The current status of traumatic Diaphragmatic injury: Lessons learned from 105 patients over 13 years	ANNALS OF THORACIC SURGERY			English	Article							THORACOABDOMINAL TRAUMA; PENETRATING INJURIES; BLUNT TRAUMA; RUPTURE; HERNIA	Background. Our understanding of traumatic diaphragmatic injury (TDI) is based primarily on outdated retrospective series. We sought to reexamine present day patterns of diagnosis, associated injuries, predictors of mortality, and long-term outcomes of this condition. Methods. A prospectively entered trauma database from the Montreal General Hospital was reviewed for patients admitted with a TDI from 1993 to 2006. Hospital charts were reviewed, and patient characteristics, mechanism of injury, associated injuries, operative management, and postoperative outcomes were recorded. Logistic regression was used to identify predictors for mortality. Results. Identified were 105 patients with TDI consisting of blunt in 37% and penetrating in 63%. Only 23% of TDI were diagnosed on initial chest roentgenogram. External wounds in penetrating TDI cases were found in the abdomen alone in 19%, in the chest alone in 46%, and in both in 35%, which was associated with intraabdominal organ injury in 83%, 55%, and 87%, respectively. Less than half of patients had a diaphragmatic hernia. Lung, chest wall, and thoracic organ injuries were more common in blunt trauma, but there was no significant difference between abdominal injuries in both mechanisms. Overall mortality from TDI was 18%, and there was no difference between blunt and penetrating injury. In blunt trauma, brain injury and an Injury Severity Score (ISS) exceeding 15 were independently associated with increased death. In penetrating trauma, only an ISS exceeding 15 predicted death. Conclusions. Traumatic diaphragmatic injury remains a challenge to diagnose and treat, primarily due to the presence of associated injuries. The high incidence of intraabdominal organ injury, irrespective of the site of penetrating wound, dictates a transabdominal approach for exploration and repair. Severity of associated injuries (ISS) predicts death.	[Ferri, Lorenzo E.] McGill Univ, Montreal Gen Hosp, Ctr Hlth, Div Thorac Surg, Montreal, PQ H3G 1A4, Canada; McGill Univ, Ctr Hlth, Div Trauma, Montreal, PQ, Canada		Ferri, LE (corresponding author), McGill Univ, Montreal Gen Hosp, Ctr Hlth, Div Thorac Surg, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.	lorenzo.ferri@muhc.mcgill.ca	Hanna, Wael/AAQ-4976-2021				BEAUCHAMP G, 1984, AM J SURG, V148, P292, DOI 10.1016/0002-9610(84)90240-X; BROOS PLO, 1989, INT SURG, V74, P88; DEMETRIADES D, 1988, BRIT J SURG, V75, P824, DOI 10.1002/bjs.1800750834; EPSTEIN LI, 1968, J TRAUM, V8, P19, DOI 10.1097/00005373-196801000-00003; GRIMES OF, 1974, AM J SURG, V128, P175; Murray JA, 1997, J TRAUMA, V43, P624, DOI 10.1097/00005373-199710000-00010; Murray JA, 1998, J AM COLL SURGEONS, V187, P626, DOI 10.1016/S1072-7515(98)00246-4; OCHSNER MG, 1993, J TRAUMA, V34, P704, DOI 10.1097/00005373-199305000-00013; PAYNE JH, 1982, ARCH SURG-CHICAGO, V117, P18; RODRIGUEZMORALES G, 1986, J TRAUMA, V26, P438, DOI 10.1097/00005373-198605000-00005; Rubikas R, 2001, EUR J CARDIO-THORAC, V20, P53, DOI 10.1016/S1010-7940(01)00753-9; SHAH R, 1995, ANN THORAC SURG, V60, P1444, DOI 10.1016/0003-4975(95)00629-Y; WALDSCHMIDT ML, 1980, J TRAUMA, V20, P587; WARD RE, 1981, J TRAUMA, V21, P35, DOI 10.1097/00005373-198101000-00006	14	78	85	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0003-4975			ANN THORAC SURG	Ann. Thorac. Surg.	MAR	2008	85	3					1044	1048		10.1016/j.athoracsur.2007.10.084			5	Cardiac & Cardiovascular Systems; Respiratory System; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology; Respiratory System; Surgery	266MZ	WOS:000253441500036	18291194				2022-02-06	
